PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Taoufiq, Z; Pino, P; Dugas, N; Conti, M; Tefit, M; Mazier, D; Vouldoukis, I				Taoufiq, Zacharie; Pino, Paco; Dugas, Nathalie; Conti, Marc; Tefit, Maurel; Mazier, Dominique; Vouldoukis, Ioannis			Transient supplementation of superoxide dismutase protects endothelial cells against Plasmodium falciparum-induced oxidative stress	MOLECULAR AND BIOCHEMICAL PARASITOLOGY			English	Article						malaria; endothelium; superoxide dismutase; oxidative stress	HUMAN CEREBRAL MALARIA; BLOOD-BRAIN-BARRIER; NITRIC-OXIDE; INFECTED ERYTHROCYTES; IN-VITRO; DEPENDENT MECHANISM; ANTIOXIDANT ENZYMES; INDUCED APOPTOSIS; ADHESION; CYTOADHERENCE	The pathogenesis of cerebral malaria, a major complication of Plasinodium falciparum infection, relies on mechanisms such as cytokine production and cytoadherence of parasitized red blood cells (PRBCs) on microvascular endothelial cells. In this way parasites avoid spleen clearance by sequestration in post-capillary venules of various organs including the brain. Infected erythrocytes adhesion has also been shown to have molecular signaling consequences providing insight on how tissue homeostasis could be comprised by endothelium perturbation. Our previous work demonstrated that PRBCs adhesion to human lung endothelial cells (HLEC) induces caspases activation, oxidative stress and apoptosis. Cytoplasmic Cu/Zn superoxide dismutase (SOD1), which provides the first line of defense against oxidative stress within a cell, is now used as a treatment of numerous diseases including traumatic brain injury and ischemic stroke. In this report, we demonstrated that transient supplementation of SOD1 protects endothelial cells against P falciparun? induced oxidative stress and apoptosis. We also showed a significant decrease in PRBCs cytoadherence through a downregulation of ICAM-1 and an induction of iNOS. Protection of endothelium via antioxidant delivery may constitute a relevant strategy in cerebral malaria treatment. (c) 2006 Elsevier B.V. All rights reserved.	Univ Paris 06, INSERM, UMR511, CHU Pitie Salpetriere, F-75013 Paris, France; VigiCell sarl, F-94240 Le Kremlin Bicetre, France	Taoufiq, Z (corresponding author), Univ Paris 06, INSERM, UMR511, CHU Pitie Salpetriere, 91 Bd Hop, F-75013 Paris, France.	zacharie.taoufiq@etu.upmc.fr; vouldouk@ext.jussieu.fr		Taoufiq, Zacharie/0000-0003-4893-0322			BARET A, 1984, BIOCHEM PHARMACOL, V33, P2755, DOI 10.1016/0006-2952(84)90692-0; Brown H, 1999, NEUROPATH APPL NEURO, V25, P331; Chillemi R, 2004, CLIN CHIM ACTA, V348, P113, DOI 10.1016/j.cccn.2004.05.007; CLARK IA, 1983, INFECT IMMUN, V39, P1; Craig A, 2001, MOL BIOCHEM PARASIT, V115, P129, DOI 10.1016/S0166-6851(01)00275-4; DELAHARPE J, 1985, J IMMUNOL METHODS, V78, P323, DOI 10.1016/0022-1759(85)90089-4; Dugas B, 2003, CYTOKINE, V21, P270, DOI 10.1016/S1043-4666(03)00100-5; Forman Henry Jay, 2001, Molecular Aspects of Medicine, V22, P189; GOODYER ID, 1994, ANN TROP MED PARASIT, V88, P209, DOI 10.1080/00034983.1994.11812859; Hebert MJ, 1998, AM J PATHOL, V152, P523; Hemmer CJ, 2005, INFECT IMMUN, V73, P1764, DOI 10.1128/IAI.73.3.1764-1770.2005; Hollestelle MJ, 2006, BRIT J HAEMATOL, V133, P562, DOI 10.1111/j.1365-2141.2006.06067.x; JADOT G, 1995, CLIN PHARMACOKINET, V28, P17, DOI 10.2165/00003088-199528010-00003; Jin LH, 2001, FREE RADICAL BIO MED, V31, P1509, DOI 10.1016/S0891-5849(01)00734-1; KELNER MJ, 1995, FREE RADICAL BIO MED, V18, P497, DOI 10.1016/0891-5849(94)00167-I; Mazier D, 2000, PARASITE IMMUNOL, V22, P613, DOI 10.1046/j.1365-3024.2000.00342.x; Medana IM, 2006, INT J PARASITOL, V36, P555, DOI 10.1016/j.ijpara.2006.02.004; Muanza K, 1996, RES IMMUNOL, V147, P149, DOI 10.1016/0923-2494(96)83167-1; OCKENHOUSE CF, 1991, J INFECT DIS, V164, P163, DOI 10.1093/infdis/164.1.163; Pino P, 2003, ANN NY ACAD SCI, V1010, P582, DOI 10.1196/annals.1299.109; Pino P, 2004, CELL MICROBIOL, V6, P839, DOI 10.1111/j.1462-5822.2004.00406.x; Pino P, 2003, J INFECT DIS, V187, P1283, DOI 10.1086/373992; ROCKETT KA, 1991, INFECT IMMUN, V59, P3280, DOI 10.1128/IAI.59.9.3280-3283.1991; Schirmer R H, 1987, Free Radic Res Commun, V3, P3, DOI 10.3109/10715768709069763; Schwartz E, 1999, INFLAMMATION, V23, P361; Serirom S, 2003, AM J PATHOL, V162, P1651, DOI 10.1016/S0002-9440(10)64299-X; Szabo C, 2003, TOXICOL LETT, V140, P105, DOI 10.1016/S0378-4274(02)00507-6; Takahashi H, 2000, J DERMATOL SCI, V23, P12, DOI 10.1016/S0923-1811(99)00060-2; Takahashi M, 1996, CYTOKINE, V8, P817, DOI 10.1006/cyto.1996.0109; Taylor AM, 1998, T ROY SOC TROP MED H, V92, P170, DOI 10.1016/S0035-9203(98)90733-7; Vouldoukis I, 2004, J ETHNOPHARMACOL, V94, P67, DOI 10.1016/j.jep.2004.04.023; Vouldoukis I, 2000, MOL MED, V6, P1042, DOI 10.1007/BF03402055; Vouldoukis L, 2004, PHYTOTHER RES, V18, P957, DOI 10.1002/ptr.1542; Wang PH, 1998, P NATL ACAD SCI USA, V95, P4556, DOI 10.1073/pnas.95.8.4556; *WHO, 1997, 94 WHO, V72, P269; Yang YH, 2002, FEBS LETT, V532, P36, DOI 10.1016/S0014-5793(02)03624-4; Yunoki M, 1997, J NEUROTRAUM, V14, P739, DOI 10.1089/neu.1997.14.739	37	25	25	1	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-6851			MOL BIOCHEM PARASIT	Mol. Biochem. Parasitol.	DEC	2006	150	2					166	173		10.1016/j.molbiopara.2006.07.008			8	Biochemistry & Molecular Biology; Parasitology	Biochemistry & Molecular Biology; Parasitology	111TF	WOS:000242476900005	16930739				2021-06-18	
J	Huang, SJ; Hong, WC; Han, YY; Chen, YS; Wen, CS; Tsai, YS; Tu, YK				Huang, Sheng-Jean; Hong, Wei-Chen; Han, Yin-Yi; Chen, Yuan-Sen; Wen, Chung-Shi; Tsai, Yi-Shin; Tu, Yong-Kwang			Clinical outcome of severe head injury using three different ICP and CPP protocol-driven therapies	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						severe head injury; protocol-driven therapy; intracranial hypertension; cerebral perfusion pressure	TRAUMATIC BRAIN-INJURY; CEREBRAL PERFUSION-PRESSURE; RESPIRATORY-DISTRESS-SYNDROME; INTRACRANIAL-PRESSURE; TARGETED THERAPY; PILOT TRIAL; MANAGEMENT; ISCHEMIA	In the past 5 years, cerebral perfusion pressure (CPP) management has become the standard in the treatment of severe bead injuries. Guidelines published in 2000 suggest that CPP should be at least 70 mmHg; however, there is still debate about the optimal CPP. The purpose of the present study was to evaluate the effectiveness of these three widely used therapies: (i) intracranial pressure (ICP) targeted; (ii) CPP-targeted with CPP > 70 mmHg; and (iii) modified CPP-targeted (mCPP) therapy with CPP > 60 mmHg. The clinical procedures, complications and outcomes of patients in the different groups were compared. Data, including patient age, sex, initial Glasgow Coma Scale, ICP, CPP, fluid status, amount of mannitol and vasopressor used, daily fluid intake and output, complications and clinical results, were collected from 213 patients with severe head injuries over a 12-year period. Patients were categorized into three groups (ICP, CPP, mCPP) according to the treatment protocol used. Retrospective data collection was performed by chart review. The mortality rate was 28.6%, 14.3% and 13.5% in the ICP, CPP, and mCPP groups, respectively. Highest intake/output ratio, amount of vasopressor used and pulmonary complications were seen in the CPP patients. The mCPP patients showed the best clinical outcome and lowest complication rate. Although CPP-targeted therapy is the most recommended therapeutic protocol, our data show that patients treated with modified CPP-target therapy with CPP > 60 mmHg have better clinical outcomes and fewer complications. (c) 2006 Elsevier Ltd. All rights reserved.	Natl Taiwan Univ, Div Neurosurg, Coll Med & Hosp, Taipei 10764, Taiwan	Tu, YK (corresponding author), Natl Taiwan Univ, Div Neurosurg, Coll Med & Hosp, 7 Chung Shan S Rd, Taipei 10764, Taiwan.	yktu@ha.mc.ntu.edu.tw		Tu, Yong-kwang/0000-0003-2113-1176; HAN, YIN-YI/0000-0001-8831-7835			BERNARD GR, 1994, J CRIT CARE, V9, P72, DOI 10.1016/0883-9441(94)90033-7; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P559; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P493; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; JENNETT B, 1975, LANCET, V1, P480; Kelly DF, 1999, J NEUROSURG, V90, P1042, DOI 10.3171/jns.1999.90.6.1042; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Klein D G, 1999, Crit Care Nurs Clin North Am, V11, P209; Macmillan CSA, 2001, J NEUROL NEUROSUR PS, V70, P101, DOI 10.1136/jnnp.70.1.101; MAPSTONE TB, 1996, CONT NEUROSURG, V18, P1; Marion DW, 1997, CONT NEUROSURG, V19, P1; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1990, ADV BRAIN RESUSCITAT, P315; Naredi S, 2001, ACTA ANAESTH SCAND, V45, P402, DOI 10.1034/j.1399-6576.2001.045004402.x; Prabhakaran P, 2004, J NEUROSURG, V100, P454, DOI 10.3171/ped.2004.100.5.0454; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1987, NEUROSURGERY, V21, P147, DOI 10.1227/00006123-198708000-00003; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SAHUQUILLO J, 1993, ACTA NEUROCHIR, V122, P204, DOI 10.1007/BF01405530; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; TEASDALE G, 1974, LANCET, V2, P81; 2000, J NEUROTRAUMA, V17, P479	32	25	26	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	OCT	2006	13	8					818	822		10.1016/j.jocn.2005.11.034			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	099LR	WOS:000241596700003	16908157				2021-06-18	
J	Macciocchi, SN; Seel, RT; Alderson, A; Godsall, R				Macciocchi, Stephen N.; Seel, Ronald T.; Alderson, Amy; Godsall, Robert			Victoria Symptom Validity Test performance in acute severe traumatic brain injury: Implications for test interpretation	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						symptom validity; Victoria Symptom Validity Test; traumatic brain injury	MEMORY IMPAIRMENT; TEST-SCORES; VALIDATION	Effort testing has become commonplace in clinical practice. Recent research has shown that performance on effort tests is highly correlated with performance on neuropsychological measures. Clinical application of effort testing is highly dependent on research derived interpretive guidelines. The Victoria Symptom Validity Test (VSVT) is one of many measures currently used in clinical practice. The VSVT has recommended interpretive guidelines published in the test manual, but the samples used in developing interpretive guidelines are small and heterogeneous and concern has been expressed regarding high false negative rates. In this study, a homogeneous sample of acute, severely brain injured persons were used to assess the sensitivity of the VSVT. Results confirmed that acute, severely brain injured persons (N = 71) perform very well on the VSVT. The severe brain injury population is 99% likely to have between 44.1 and 46.8 correct VSVT Combined Score responses. While the VSVT was insensitive to memory dysfunction, the presence of severe visual perceptual (Benton Visual Form Discrimination Score < 21) and verbal fluency (Controlled Oral Word Association Score < 15) deficits predicted poor performance on the VSVT. These results provide further evidence that performance expectations currently incorporated in the VSVT manual interpretative criteria are too conservative. Empirically based alternative criteria for interpreting VSVT Combined Scores in the TBI population are presented. (c) 2006 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Shepherd Ctr, Atlanta, GA USA	Macciocchi, SN (corresponding author), Shepherd Ctr, 2020 Peachtree Rd, Atlanta, GA USA.	stephen_macciocchi@shepherd.org					Beck A. T., 1996, BECK DEPRESSION INVE, VII; Bender SD, 2004, ARCH CLIN NEUROPSYCH, V19, P49, DOI 10.1016/S0887-6177(02)00165-8; Benton A, 1989, MULTILINGUAL APHASIA; Benton A. L., 1994, CONTRIBUTIONS NEUROP; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BOLLER F, 1966, BRAIN, V89, P815, DOI 10.1093/brain/89.4.815; CULLUM CM, 1991, PSYCHOGEMIC FACTORS; DANIEL WW, 1995, BIOSTATISTICS; Green J., 2000, NEUROPSYCHOLOGICAL E; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Grote CL, 2000, J CLIN EXP NEUROPSYC, V22, P709, DOI 10.1076/jcen.22.6.709.958; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lishman W. A., 1997, ORGANIC PSYCHIAT; Lynch W, 2004, J HEAD TRAUMA REHAB, V19, P277, DOI 10.1097/00001199-200405000-00008; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; Pankratz L., 1990, CLIN NEUROPSYCHOL, V4, P379; PERNA RB, 2000, J COGNITIVE REHABILI, V18, P10; PORTER JH, 1986, STAT APPL BEHAV SCI; Portney L., 2015, FDN CLIN RES APPL PR, V3rd ed.; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Rey A, 1964, EXAMEN CLIN PSYCHOL; Slick D. J., 1997, MANUAL VICTORIA SYMP; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Slick DJ, 2003, CLIN NEUROPSYCHOL, V17, P390, DOI 10.1076/clin.17.3.390.18090; Smith A., 1982, SYMBOL DIGIT MODALIT; Spreen O., 1998, COMPENDIUM NEUROPSYC; Tombaugh TN, 1996, TEST MEMORY MALINGER; Wechsler, 1981, WAIS R MANUAL; Wechsler D., 1987, WECHSLER MEMORY SCAL; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]	36	25	25	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2006	21	5					395	404		10.1016/j.acn.2006.06.003			10	Psychology, Clinical; Psychology	Psychology	084AC	WOS:000240502800003	16889930	Bronze			2021-06-18	
J	Sheng, WW; Li, CT; Zhang, WP; Yuan, YM; Hu, H; Fang, SH; Zhang, L; Wei, EQ				Sheng, Wen-Wen; Li, Cheng-Tan; Zhang, Wei-Ping; Yuan, Yu-Mei; Hu, Hua; Fang, San-Hua; Zhang, Lei; Wei, Er-Qing			Distinct roles of CysLT(1) and CysLT(2) receptors in oxygen glucose deprivation-induced PC12 cell death	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						cysteinyl leukotriene receptor; leukotriene; oxygen glucose deprivation; rat pheochromocytoma cells (PC12 cells)	CYSTEINYL LEUKOTRIENE RECEPTOR-1; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; MOLECULAR-CLONING; 5-LIPOXYGENASE; ANTAGONIST; ACTIVATION; EXPRESSION; PROTECTS; ACID	Cysteinyl leukotrienes are involved in ischemic brain injury, and their receptors (CysLT(1) and CysLT(2)) have been cloned. To clarify which subtype mediates the ischemic neuronal injury, we performed permanent transfection to increase CysLT(1) and CysLT(2) receptor expressions in PC12 cells. Oxygen glucose deprivation (OGD)-induced cell death was detected by Hoechst 33258 and propidium iodide fluorescent staining as well as by flow cytometry. OGD induced late phase apoptosis mainly and necrosis minimally. Over-expression of CysLT(1) receptor decreased and over-expression of CysLT2 receptor increased OGD-induced cell death. An agonist LTD4 (10(-7) M) also induced apoptosis, especially in CysLT(2) receptor over-expressing cells. A selective CysLT(1) receptor antagonist montelukast did not affect OGD- induced apoptosis; while non-selective CysLT receptor antagonist Bay u9773 inhibited OGD-induced apoptosis, especially in CysLT(2) receptor over- expressing cells. Thus, CysLT(1) and CysLT(2) receptors play distinct roles in OGD-induced PC12 cell death; CysLT, attenuates while CysLT(2) facilitates the cell death. (c) 2006 Elsevier Inc. All rights reserved.	Zhejiang Univ, Sch Med, Dept Pharmacol, Hangzhou 310031, Peoples R China; Zhejiang Univ, Sch Med, Dept Neurosurg, Affiliated Hosp 2, Hangzhou 310009, Peoples R China	Wei, EQ (corresponding author), Zhejiang Univ, Sch Med, Dept Pharmacol, Hangzhou 310031, Peoples R China.	weieq2001@yahoo.com	Zhang, Lei/F-2603-2011				Arai K, 2001, BRAIN RES, V904, P167, DOI 10.1016/S0006-8993(01)02491-X; Beller TC, 2004, J BIOL CHEM, V279, P46129, DOI 10.1074/jbc.M407057200; Beller TC, 2004, P NATL ACAD SCI USA, V101, P3047, DOI 10.1073/pnas.0400235101; Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; Cao GD, 2004, J NEUROSCI, V24, P6189, DOI 10.1523/JNEUROSCI.1426-04.2004; Ciceri P, 2001, BRIT J PHARMACOL, V133, P1323, DOI 10.1038/sj.bjp.0704189; Ge QF, 2006, J NEUROCHEM, V97, P992, DOI 10.1111/j.1471-4159.2006.03828.x; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Helgadottir A, 2005, AM J HUM GENET, V76, P505, DOI 10.1086/428066; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; Hu H, 2005, ACTA PHARMACOL SIN, V26, P685, DOI 10.1111/j.1745-7254.2005.00092.x; Hui YQ, 2001, J BIOL CHEM, V276, P47489, DOI 10.1074/jbc.M107556200; Jiang XH, 2005, SURF REV LETT, V12, P59, DOI 10.1142/S0218625X05006792; Kanaoka Y, 2004, J IMMUNOL, V173, P1503, DOI 10.4049/jimmunol.173.3.1503; Kumasawa F, 2005, EUR J PHARMACOL, V517, P11, DOI 10.1016/j.ejphar.2005.05.001; Liu Y, 2003, J CELL MOL MED, V7, P49, DOI 10.1111/j.1582-4934.2003.tb00202.x; Martin V, 2001, BIOCHEM PHARMACOL, V62, P1193, DOI 10.1016/S0006-2952(01)00774-2; Mellor EA, 2003, P NATL ACAD SCI USA, V100, P11589, DOI 10.1073/pnas.2034927100; Nothacker HP, 2000, MOL PHARMACOL, V58, P1601; OHTSUKI T, 1995, AM J PHYSIOL-HEART C, V268, pH1249; Perng DW, 2006, AM J RESP CELL MOL, V34, P101, DOI 10.1165/rcmb.2005-0068OC; Rao AM, 1999, NEUROCHEM RES, V24, P1225, DOI 10.1023/A:1020916905312; Shishido Y, 2001, PHARMACOL BIOCHEM BE, V69, P469, DOI 10.1016/S0091-3057(01)00572-X; Song Y, 2004, NEUROREPORT, V15, P2181, DOI 10.1097/00001756-200410050-00007; Tabakman R, 2004, J NEUROSCI RES, V75, P499, DOI 10.1002/jnr.20008; Tomimoto H, 2002, ACTA NEUROPATHOL, V104, P601, DOI 10.1007/s00401-002-0590-0; Yu GL, 2005, BRAIN RES, V1053, P116, DOI 10.1016/j.brainres.2005.06.046; Yu GL, 2005, PHARMACOLOGY, V73, P31, DOI 10.1159/000081072; ZENG LH, 2001, ACTA PHARMACOL SINIC, V36, P148; Zhang WP, 2004, NEUROSCI LETT, V363, P247, DOI 10.1016/j.neulet.2004.03.088; Zhang WP, 2002, ACTA PHARMACOL SIN, V23, P871	31	25	33	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X	1090-2104		BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	JUL 21	2006	346	1					19	25		10.1016/j.bbrc.2006.05.023			7	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	056TX	WOS:000238549100004	16756959				2021-06-18	
J	Gilworth, G; Carey, A; Eyres, S; Sloan, J; Rainford, B; Bodenham, D; Neumann, V; Tennant, A				Gilworth, Gill; Carey, Amy; Eyres, Sophie; Sloan, John; Rainford, Bruce; Bodenham, Debra; Neumann, Vera; Tennant, Alan			Screening for job loss: Development of a work instability scale for traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; work instability	MODERATE HEAD-INJURY; RETURN; EMPLOYMENT; MILD; STABILITY	Objective: The objective of this study was to explore the concept of work instability (a mis-match between an individual's functional and cognitive abilities and the demands of their job) following traumatic brain injury (TBI) and develop a work instability scale specific to this population. Method: Work instability (WI) following TBI was explored through qualitative interviews which were then used to generate items for a work instability scale (WIS). Rasch analysis was used to examine the scaling properties of the TBI-WIS which was then validated against a gold standard of expert vocational assessment by occupational psychologists. Results and conclusion: The resulting measure is a 36 item, self-administered scale which can be scored in three bands indicating low, medium and high risk of job retention problems. The scale meets modern psychometric requirements for measurement and presents an opportunity in routine clinical practice to take positive action to prevent job loss.	Univ Leeds, Acad Unit Musculoskeletal Med & Rehabil Med, Leeds LS2 9LN, W Yorkshire, England; Countess Chester NHS Fdn Trust, Chester, Cheshire, England; Job Ctr Plus Disabil Serv, Dept Work Psychol, Leeds, W Yorkshire, England	Gilworth, G (corresponding author), Univ Leeds, Acad Unit Musculoskeletal Med & Rehabil Med, 36 Clarendon Rd, Leeds LS2 9LN, W Yorkshire, England.	gilworths@aol.com					ANDRICH D, 1978, PSYCHOMETRIKA, V43, P561, DOI 10.1007/BF02293814; Andrich D, 2003, RUMM 2020; BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170; *BRIT SOC REH MED, 2003, REH FOLL ACQ BRAN IN; Buffington ALH, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199710000-00002; CHAMBERLAIN MA, 1995, TRAUMATIC BRAIN INJU; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; ELASHOFF JD, 2000, USER NQUERY ADVISOR; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Gilworth G, 2003, ARTHRIT RHEUM-ARTHR, V49, P349, DOI 10.1002/art.11114; Gilworth G, 2001, RHEUMATOLOGY, V40, P1206, DOI 10.1093/rheumatology/40.11.1206; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Guttman L, 1950, MEASUREMENT PREDICTI, VIV; Hobart J, 2003, J NEUROL NEUROSUR PS, V74, P22; Holland P. W., 1993, DIFFERENTIAL ITEM FU; *HOUS COMM, 2001, HEAD INJ REH; JONG AD, 1987, J PSYCHIAT RES, V21, P137; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Linacre J M, 1999, J Outcome Meas, V3, P103; Linacre JM, 1994, RASCH MEAS T, V7, P28; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; Possl O, 2001, BRAIN INJURY, V15, P15; Rasch G., 1960, PROBABILISTIC MODELS; Richards L., 1999, USING NVIVO QUALITAT; Smith Everett V Jr, 2002, J Appl Meas, V3, P205; Smith R M, 2000, J Appl Meas, V1, P199; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Tennant A, 2004, VALUE HEALTH, V7, pS22, DOI 10.1111/j.1524-4733.2004.7s106.x; TENNANT A, 1991, J EPIDEMIOL COMMUN H, V45, P312, DOI 10.1136/jech.45.4.312; Tennant A, 2004, MED CARE, V42, P37, DOI 10.1097/01.mlr.0000103529.63132.77; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154	35	25	25	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2006	20	8					835	843		10.1080/02699050600832221			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	081ZO	WOS:000240356300006	17060150				2021-06-18	
J	Carney, ML; Ullrich, P; Esselman, P				Carney, ML; Ullrich, P; Esselman, P			Early unplanned transfers from inpatient rehabilitation	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						rehabilitation; complications; prospective payment system; length of stay	MEDICAL REHABILITATION; STROKE REHABILITATION; RISK-FACTORS; COMPLICATIONS; MORTALITY; LENGTH; INJURY; STAY	Objective: To identify characteristics of patients who transfer off inpatient rehabilitation to a surgical or medical unit before completion of their rehabilitation program. Design: A retrospective 9-yr chart review of patients transferred off the rehabilitation unit at a regional level 1 trauma center due to medical complications. Results: Of 3072 patient admissions, 250 (8%) were transferred to an acute medical or surgical unit, and 55 (22%) of those transfers were within 3 days. Of the 250 patients, 33% had traumatic brain injury, 23% had spinal cord injury, 24% had stroke, 2% had amputations, 18% were in other diagnostic groups, and 23% were > 64 yrs of age. When patients transferred early, only 47% were ultimately discharged to home, compared with approximately 72% of all discharges. The most common reasons for early transfer in these patients were infection (22%) and pulmonary complications (14%). Risk factors for early discharge included age of > 64 yrs, spinal cord injury, or amputation. Conclusion: Patients admitted to the inpatient rehabilitation unit who have spinal cord injuries, amputations, or are > 4 yrs old may have more medical/surgical complications. More detailed study of this patient population may help reduce the number of early transfers off the inpatient rehabilitation unit.	Univ Washington, Harborview Med Ctr, Dept Rehabil Med, Seattle, WA 98104 USA	Esselman, P (corresponding author), Univ Washington, Harborview Med Ctr, Dept Rehabil Med, 325 9th Ave,Box 359740, Seattle, WA 98104 USA.						Centers for Medicare & Medicaid Services (CMS) HHS, 2004, Fed Regist, V69, P25752; Chen D, 1999, ARCH PHYS MED REHAB, V80, P1397, DOI 10.1016/S0003-9993(99)90250-2; Davenport RJ, 1996, STROKE, V27, P415, DOI 10.1161/01.STR.27.3.415; Deshpande AA, 1997, ARCH PHYS MED REHAB, V78, P350, DOI 10.1016/S0003-9993(97)90224-0; Deutsch A, 2002, AM J PHYS MED REHAB, V81, P133, DOI 10.1097/00002060-200202000-00010; KIM SR, 2005, AM J PHYS MED REHABI, V84, P199; Lai SM, 1998, NEUROEPIDEMIOLOGY, V17, P21, DOI 10.1159/000026150; Lai SM, 1999, NEUROEPIDEMIOLOGY, V18, P210, DOI 10.1159/000026213; Medicare Payment Advisory Commission, 1999, REP C MED PAYM POL; Ottenbacher KJ, 2004, JAMA-J AM MED ASSOC, V292, P1687, DOI 10.1001/jama.292.14.1687; Ottenbacher KJ, 2000, AM J PUBLIC HEALTH, V90, P1920, DOI 10.2105/AJPH.90.12.1920; Roth EJ, 2001, STROKE, V32, P523, DOI 10.1161/01.STR.32.2.523; SIEGLER EL, 1994, ARCH INTERN MED, V154, P2185, DOI 10.1001/archinte.154.19.2185; SONG KM, 2004, SEATTLE TIMES   0730; Stineman MG, 2003, ARCH PHYS MED REHAB, V84, P712, DOI 10.1016/S0003-9993(03)04850-5; YAP KKP, 2002, SINGAPORE MED J, V43, P470	16	25	26	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	MAY	2006	85	5					453	460		10.1097/01.phm.0000214279.04759.45			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	037QG	WOS:000237161300007	16628154				2021-06-18	
J	Law, AS; Logie, RH; Pearson, DG				Law, AS; Logie, RH; Pearson, DG			The impact of secondary tasks on multitasking in a virtual environment	ACTA PSYCHOLOGICA			English	Article						multitasking; working memory; phonological loop; central executive	TRAUMATIC BRAIN-INJURY; STRATEGY APPLICATION; WORKING-MEMORY; SIMPLIFIED VERSION; RANDOM GENERATION; INNER SPEECH; TOWER; INTERRUPTIONS; BEHAVIOR; DEFICITS	One experiment is described that examined the possible involvement of working memory in the Virtual Errands Test (McGeorge et al. (2001). Using virtual environments in the assessment of executive dysfunction. Presence, 10, 375-383), which requires participants to complete errands within a virtual environment, presented on a computer screen. Time was limited, therefore participants had to swap between tasks (multitask) efficiently to complete the errands. Forty-two undergraduates participated, all attempting the test twice. On one of these occasions they were asked to perform a concurrent task throughout (order of single and dual-task conditions was counterbalanced). The type of secondary task was manipulated between groups. Twenty-one participants were asked to randomly generate months of the year aloud in the dual-task condition, while another 21 were asked to suppress articulation by repeating the word "December". An overall dual-task effect on the Virtual Errands Test was observed, although this was qualified by an interaction with the order of single and dual-task conditions. Analysis of the secondary task data showed a drop in performance (relative to baseline) under dual-task conditions, and that drop was greater for the random generation group than the articulatory suppression group. These data are interpreted as suggesting that the central executive and phonological loop components of working memory are implicated in this test of multitasking. (c) 2005 Elsevier B.V. All rights reserved.	Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland; Univ Edinburgh, PPLS, Edinburgh EH8 9YL, Midlothian, Scotland; Univ Aberdeen, Sch Psychol, Aberdeen, Scotland	Law, AS (corresponding author), Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland.	a.s.law@stir.ac.uk	Logie, Robert H/C-6965-2009; Pearson, David G/C-4908-2008	Law, Anna/0000-0002-0926-1309; Pearson, David/0000-0002-2912-0976; Logie, Robert/0000-0003-4532-9312			Alderman N, 2003, J INT NEUROPSYCH SOC, V9, P31, DOI 10.1017/S1355617703910046; Baddeley A, 2001, J EXP PSYCHOL GEN, V130, P641, DOI 10.1037//0096-3445.130.4.641; Baddeley A, 1996, Q J EXP PSYCHOL-A, V49, P5; Baddeley A, 2000, TRENDS COGN SCI, V4, P417, DOI 10.1016/S1364-6613(00)01538-2; Baddeley A.D., 1999, MODELS WORKING MEMOR, P28, DOI DOI 10.1017/CBO9781139174909.005; Barrouillet P, 2004, J EXP PSYCHOL GEN, V133, P83, DOI 10.1037/0096-3445.133.1.83; Burgess PW, 2000, CONTROL OF COGNITIVE PROCESSES: ATTENTION AND PERFORMANCE XVIII, P465; Burgess PW, 2000, PSYCHOL RES-PSYCH FO, V63, P279, DOI 10.1007/s004269900006; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Chisholm CD, 2000, ACAD EMERG MED, V7, P1239, DOI 10.1111/j.1553-2712.2000.tb00469.x; Crepeau F, 1996, BRAIN COGNITION, V32, P266; Emerson MJ, 2003, J MEM LANG, V48, P148, DOI 10.1016/S0749-596X(02)00511-9; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; Gilhooly K.J., 1999, PSYCHIAT NEUROSCI, V5, P339, DOI [10.1080/135467899393977, DOI 10.1080/135467899393977]; GOLDSTEIN LH, 1993, J NEUROL NEUROSUR PS, V56, P274, DOI 10.1136/jnnp.56.3.274; Goschke T, 2000, CONTROL OF COGNITIVE PROCESSES: ATTENTION AND PERFORMANCE XVIII, P331; Knight C, 2002, NEUROPSYCHOL REHABIL, V12, P231, DOI 10.1080/09602010244000039; Law AS, 2004, ACTA PSYCHOL, V116, P285, DOI 10.1016/j.actpsy.2004.04.003; LAW AS, 2004, THESIS U ABERDEEN; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Logie RH, 2004, NEUROPSYCHOLOGY, V18, P504, DOI 10.1037/0894-4105.18.3.504; McGeorge P, 2001, PRESENCE-TELEOP VIRT, V10, P375, DOI 10.1162/1054746011470235; Miyake A, 2004, ACTA PSYCHOL, V115, P123, DOI 10.1016/j.actpsy.2003.12.004; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Owen AM, 1997, PROG NEUROBIOL, V53, P431, DOI 10.1016/S0301-0082(97)00042-7; Phillips LH, 2003, EUR J COGN PSYCHOL, V15, P291, DOI 10.1080/09541440244000148; Phillips LH, 2001, Q J EXP PSYCHOL-A, V54, P579, DOI 10.1080/02724980042000237; Phillips LH, 1999, MEMORY, V7, P209, DOI 10.1080/741944066; Rohrer D, 2003, PSYCHON B REV, V10, P96, DOI 10.3758/BF03196472; Rohrer D, 1998, MEM COGNITION, V26, P731, DOI 10.3758/BF03211393; SALWAY AFS, 1991, THESIS U ABERDEEN SC; Seshadri S, 2001, MANAGE SCI, V47, P647, DOI 10.1287/mnsc.47.5.647.10481; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Towse JN, 1997, EUR J COGN PSYCHOL, V9, P381, DOI 10.1080/713752566; Towse JN, 1998, BEHAV RES METH INS C, V30, P583, DOI 10.3758/BF03209475; Ward G, 1997, Q J EXP PSYCHOL-A, V50, P49, DOI 10.1080/027249897392224; Wilson B.A., 1997, METHODOLOGY FRONTAL, P239	39	25	25	0	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0001-6918	1873-6297		ACTA PSYCHOL	Acta Psychol.	MAY	2006	122	1					27	44		10.1016/j.actpsy.2005.09.002			18	Psychology, Experimental	Psychology	032YP	WOS:000236813100003	16307711				2021-06-18	
J	Tabish, A; Lone, NA; Afzal, WM; Salam, A				Tabish, A; Lone, NA; Afzal, WM; Salam, A			The incidence and severity of injury in children hospitalised for traumatic brain injury in Kashmir	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						head injury; brain injury; head trauma; brain concussion; brain contusion; subdural hematoma; epidural hematoma; skull fractures; subarachnoid hemorrhage; intracerebral hemorrhage; Glasgow Coma Scale; intracranial pressure	HEAD-INJURY; EPIDEMIOLOGY	A large number of people experience traumatic brain injury each year, often with severe consequences. This is a public health problem that requires ongoing surveillance to follow trends in the incidence, risk factors, causes, and outcomes of these injuries. In 2003, a prospective study of all children below 15 years admitted to hospitals with a diagnosis of head injury was conducted in the Accident Et Emergency Department of Sher-e-Kashmir Institute of Medical Sciences, Srinagar (India) to determine the incidence and severity of accidental head injury among children and the circumstances of injury. The highest incidence of head injury was seen at ages 6-10 years. Head injury rates were higher in mates than in females. The leading causes include falls and motor vehicle accidents. More than 50% falls occurred in the age group of 4-6 years. Ninety per cent patients, who recovered, were discharged within 16-24 h after admission. Lack of supervision, non-implementation of safety measures and poor implementation of traffic rules leads to many injuries. The ability of the health care system to deal with increasing trauma in Jammu Et Kashmir is limited. Nevertheless, prevention can be low cost strategy to overcome this problem. The results of epidemiological studies are affected by factors like demography, geographic region and socioeconomic status. This study emphasizes the need for intensified effort for prevention, minimising risk factors, strict legislative measures, observing traffic rules, implementation of safety measures, establishing appropriate trauma care at district level, adult supervision, and creating awareness. (C) 2006 Elsevier Ltd. All rights reserved.	Sher E Kashmir Inst Med Sci, Dept Accid & Emergency, Srinagar 190001, Jammu & Kashmir, India; Sher E Kashmir Inst Med Sci, Dept Neurosurg, Srinagar 190001, Jammu & Kashmir, India; Sher E Kashmir Inst Med Sci, Dept Internal Med, Srinagar 190001, Jammu & Kashmir, India	Tabish, A (corresponding author), Sher E Kashmir Inst Med Sci, Dept Accid & Emergency, POB 826, Srinagar 190001, Jammu & Kashmir, India.	amintabish@rediff.com					ADESUNKAMNI ARK, 1988, TRAUMA, V44, P506; BAKER SP, 1987, J TRAUMA, V27, P343, DOI 10.1097/00005373-198704000-00001; Dawodu ST, TRAUMATIC BRAIN INJU; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; HAUGH RH, 1995, INT J ORAL MAXILLOF, V24, P409; JENNET B, 1998, ARCH DIS CHILD, V78, P1; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KNUDSON MM, 1992, J TRAUMA, V32, P729, DOI 10.1097/00005373-199206000-00009; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; MAZUREK AJ, 1994, J ACCID EMERG MED, V11, P9; RAMENOFSKY ML, 1984, J TRAUMA, V24, P818, DOI 10.1097/00005373-198409000-00007; Rohana J, 1998, Med J Malaysia, V53, P217; SHANKS NJ, 1994, PUBLIC HEALTH, V108, P27, DOI 10.1016/S0033-3506(05)80032-0; SHOKUNBI T, 1994, W AFR J MED, P1388; SMITH GS, 1991, EPIDEMIOL REV, V13, P228, DOI 10.1093/oxfordjournals.epirev.a036070; TABISH SA, 2004, JIMSA, V17, P9; TABISH SA, 2004, WALNUT TREE INJURY O; TABISH SA, 2000, J INT MED SCI ACAD, V13, P247; Wesson D, 1995, Semin Pediatr Surg, V4, P83	21	25	26	0	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	MAY	2006	37	5					410	415		10.1016/j.injury.2006.01.039			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	037RH	WOS:000237164100008	16569405				2021-06-18	
J	Geddes-Klein, DM; Serbest, G; Mesfin, MN; Cohen, AS; Meaney, DF				Geddes-Klein, DM; Serbest, G; Mesfin, MN; Cohen, AS; Meaney, DF			Pharmacologically induced calcium oscillations protect neurons from increases in cytosolic calcium after trauma	JOURNAL OF NEUROCHEMISTRY			English	Article						calcium oscillations; NMDA; spectrin; traumatic brain injury	NMDA RECEPTOR SUBUNITS; D-ASPARTATE RECEPTORS; VIVO AXONAL INJURY; IN-VITRO MODEL; CORTICAL-NEURONS; MECHANICAL STRETCH; CA2+ OSCILLATIONS; GABA(A) RECEPTOR; ALPHA-ACTININ; BRAIN-INJURY	Increases in cytosolic calcium ([Ca2+](i)) following mechanical injury are often considered a major contributing factor to the cellular sequelae in traumatic brain injury (TBI). However, very little is known on how developmental changes may affect the calcium signaling in mechanically injured neurons. One key feature in the developing brain that may directly impact its sensitivity to stretch is the reduced inhibition which results in spontaneous [Ca2+](i) oscillations. In this study, we examined the mechanism of stretch-induced [Ca2+](i) transients in 18-days in vitro (DIV) neurons exhibiting bicuculline-induced [Ca2+](i) oscillations. We used an in vitro model of mechanical trauma to apply a defined uniaxial strain to cultured cortical neurons and used increases in [Ca2+](i) as a measure of the neuronal response to the stretch insult. We found that stretch-induced increases in [Ca2+](i) in 18-DIV neurons were inhibited by pretreatment with either the NMDA receptor antagonist, APV [D(-)-2-Amino-5-phosphonopentanoic acid], or by depolymerizing the actin cytoskeleton prior to stretch. Blocking synaptic NMDA receptors prior to stretch significantly attenuated most of the [Ca2+](i) transient. In comparison, cultures with pharmacologically induced [Ca2+](i) oscillations showed a substantially reduced [Ca2+](i) peak after stretch. We provide evidence showing that a contributing factor to this mechanical desensitization from induced [Ca2+](i) oscillations is the PKC-mediated uncoupling of NMDA receptors (NMDARs) from spectrin, an actin-associated protein, thereby rendering neurons insensitive to stretch. These results provide novel insights into how the [Ca2+](i) response to stretch is initiated, and how reduced inhibition - a feature of the developing brain - may affect the sensitivity of the immature brain to trauma.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Childrens Hosp Penn, Abramson Res Ctr, Div Neurol, Philadelphia, PA USA; Childrens Hosp Penn, Sch Med, Dept Pediat, Philadelphia, PA USA	Geddes-Klein, DM (corresponding author), Univ Penn, Dept Bioengn, 3320 Smith Walk, Philadelphia, PA 19104 USA.	dmgeddes@seas.upenn.edu		Meaney, David/0000-0002-0954-4122	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 35712, R01 NS045975, R01 NS045975-05] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R01 41699] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035712, R01NS045975] Funding Source: NIH RePORTER		Bacci A, 1999, EUR J NEUROSCI, V11, P389, DOI 10.1046/j.1460-9568.1999.00440.x; Badea T, 2001, J NEUROBIOL, V48, P215, DOI 10.1002/neu.1052; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; *CDC, 1998, TRAUM BRAIN INJ UN S; CHERUBINI E, 1991, TRENDS NEUROSCI, V14, P515, DOI 10.1016/0166-2236(91)90003-D; COFFEY ET, 1993, J BIOL CHEM, V268, P21060; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; Furukawa Y, 2000, NEUROSCIENCE, V96, P385, DOI 10.1016/S0306-4522(99)00553-9; Garaschuk O, 2000, NAT NEUROSCI, V3, P452; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Khazipov R, 2004, EUR J NEUROSCI, V19, P590, DOI 10.1111/j.0953-816X.2003.03152.x; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Krupp JJ, 1999, J NEUROSCI, V19, P1165; LaPlaca MC, 1998, J NEUROSCI RES, V52, P220, DOI 10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B; Leonard AS, 2002, J BIOL CHEM, V277, P48441, DOI 10.1074/jbc.M205164200; Li H, 2002, EUR J NEUROSCI, V16, P2358, DOI 10.1046/j.1460-9568.2002.02419.x; Li JH, 1998, EUR J NEUROSCI, V10, P1704, DOI 10.1046/j.1460-9568.1998.00169.x; Liljelund P, 2000, J NEUROSCI, V20, P7394; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Nabekura J, 2002, J NEUROSCI, V22, P4412, DOI 10.1523/JNEUROSCI.22-11-04412.2002; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Numakawa T, 2002, J BIOL CHEM, V277, P6520, DOI 10.1074/jbc.M109139200; Nunez L, 1996, EUR J NEUROSCI, V8, P192, DOI 10.1111/j.1460-9568.1996.tb01180.x; O'Dell DM, 2000, BRAIN RES, V861, P325, DOI 10.1016/S0006-8993(00)02055-2; Opitz T, 2002, J NEUROPHYSIOL, V88, P2196, DOI 10.1152/jn.00316.2002; PAOLETTI P, 1994, NEURON, V13, P645, DOI 10.1016/0896-6273(94)90032-9; Passafaro M, 1999, NAT NEUROSCI, V2, P1063; Rao VLR, 2001, BRAIN RES, V911, P96; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; Rivera C, 1999, NATURE, V397, P251; ROBINSON HPC, 1993, J NEUROPHYSIOL, V70, P1606; Samii A, 1999, J NEUROTRAUM, V16, P879, DOI 10.1089/neu.1999.16.879; Schulz TW, 2004, J NEUROSCI, V24, P8584, DOI 10.1523/JNEUROSCI.2100-04.2004; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Siniscalchi A, 2005, NEUROCHEM INT, V46, P117, DOI 10.1016/j.neuint.2004.08.001; Smith DH, 1999, J NEUROSCI, V19, P4263; Tingley WG, 1997, J BIOL CHEM, V272, P5157, DOI 10.1074/jbc.272.8.5157; Tovar KR, 1999, J NEUROSCI, V19, P4180; Toyoda H, 2003, J NEUROPHYSIOL, V89, P1353, DOI 10.1152/jn.00721.2002; Tymianski M, 1996, NEUROSURGERY, V38, P1176; vandenPol AN, 1996, J NEUROSCI, V16, P4283; Wang XS, 1997, BRAIN RES, V767, P239, DOI 10.1016/S0006-8993(97)00585-4; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Wechsler A, 1998, EMBO J, V17, P3931, DOI 10.1093/emboj/17.14.3931; Wenzel A, 1997, J NEUROCHEM, V68, P469; Williams ST, 2003, APOPTOSIS, V8, P353, DOI 10.1023/A:1024168901003; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X	56	25	30	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	APR	2006	97	2					462	474		10.1111/j.1471-4159.2006.03761.x			13	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	026GU	WOS:000236328200015	16539664	Bronze			2021-06-18	
J	Ng, I; Lee, KK; Lim, JHG; Wong, HB; Yan, XY				Ng, I.; Lee, K-K.; Lim, J. H. G.; Wong, H-B.; Yan, X-Y.			Investigating gender differences in outcome following severe traumatic brain injury in a predominantly Asian population	BRITISH JOURNAL OF NEUROSURGERY			English	Article						epidemiology; gender difference; outcome; risk factor; TBI	MINOR HEAD-INJURY; SEX-RELATED DIFFERENCES; BLOOD-FLOW; LIPID-PEROXIDATION; MALE-RATS; PROGESTERONE; ESTROGEN; WOMEN; EPIDEMIOLOGY; PREDICTORS	The objective of this study was to investigate if there are possible gender differences in relation to outcome following closed severe traumatic brain injury (TBI) in a predominantly Asian population. A study was conducted using our prospectively maintained TBI database of 672 patients with severe TBI admitted into our neurosurgical intensive care unit. All patients were managed on a standardized protocol in accordance with the Guidelines to the management of severe traumatic brain injury. Glasgow Outcome Score was used to measure the outcome of patients 6 months postinjury. There were 525 males and 147 females, with the latter significantly older than their counterpart. Females had a significantly higher mortality and poorer outcome compared with males. However, this difference was no longer significant when variables ( presence of multiple injuries, postresuscitation pupil abnormalities and Glasgow Coma Score) are controlled for. However, both crude and adjusted odd ratios revealed that females aged 60 and below were significantly more likely to have a poorer outcome.	Natl Inst Neurosci, Dept Neurosurg, Acute Brain Injury Res Lab, Singapore 308433, Singapore; Natl Inst Neurosci, Dept Nursing Adm, Acute Brain Injury Res Lab, Singapore 308433, Singapore; Clin Trials & Epidemiol Res Unit, Singapore, Singapore	Ng, I (corresponding author), Natl Inst Neurosci, Dept Neurosurg, Acute Brain Injury Res Lab, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.	ivan_ng@nni.com.sg					Alkayed NJ, 2001, J NEUROSCI, V21, P7543; APFEL RJ, 1982, PSYCHOTHER PSYCHOSOM, V37, P106, DOI 10.1159/000287560; Asthana S, 2001, NEUROLOGY, V57, P605, DOI 10.1212/WNL.57.4.605; Balestreri M, 2003, J NEUROSURG, V99, P616; Bayir H, 2001, CRIT CARE MED, V29, pA5; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; Czlonkowska A, 2005, CURR PHARM DESIGN, V11, P1017, DOI 10.2174/1381612053381693; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; EDNA TH, 1987, ACTA NEUROCHIR, V85, P40, DOI 10.1007/BF01402368; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; Farlow MR, 1998, NEUROLOGY, V50, P669, DOI 10.1212/WNL.50.3.669; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Gur RC, 1999, J NEUROSCI, V19, P4065; Gur RC, 2002, CEREB CORTEX, V12, P998, DOI 10.1093/cercor/12.9.998; GUR RE, 1990, SCHIZOPHRENIA BULL, V16, P247, DOI 10.1093/schbul/16.2.247; Holroyd-Leduc JM, 2000, STROKE, V31, P1833, DOI 10.1161/01.STR.31.8.1833; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; JENNETT B, 1975, LANCET, V1, P480; Jensen O K, 2001, Ugeskr Laeger, V163, P5029; Kirkness Catherine J, 2004, Biol Res Nurs, V5, P299, DOI 10.1177/1099800404263050; KLAUBER MR, 1981, NEUROSURGERY, V9, P236, DOI 10.1227/00006123-198109000-00003; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; KRAUS JF, 2000, NEUROSURG FOCUS, V8; Krause JS, 2004, ARCH PHYS MED REHAB, V85, P355, DOI 10.1016/S0003-9993(03)00615-4; Lanza GA, 2004, HEART, V90, P595, DOI 10.1136/hrt.2003.026476; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; Morrell MJ, 1999, NEUROLOGY, V53, pS42; Ng I., 1998, Annals Academy of Medicine Singapore, V27, P332; Payami H, 1996, AM J HUM GENET, V58, P803; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; SHIBASAKI H, 1976, NEUROLOGY, V26, P821, DOI 10.1212/WNL.26.9.821; Silberstein SD, 2000, CEPHALALGIA, V20, P148, DOI 10.1046/j.1468-2982.2000.00034.x; SMITH SS, 1991, NEUROSCIENCE, V42, P309, DOI 10.1016/0306-4522(91)90377-Z; Stachenfeld NS, 1999, J APPL PHYSIOL, V86, P1092; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Ward E, 2004, CA-CANCER J CLIN, V54, P78, DOI 10.3322/canjclin.54.2.78; Warkentin S, 1992, Clin Auton Res, V2, P119, DOI 10.1007/BF01819667	51	25	26	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	APR	2006	20	2					73	78		10.1080/02688690600682259			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	050NF	WOS:000238094300001	16753620				2021-06-18	
J	Figg, RE; Stouffer, CW; Vander Kolk, WE; Connors, RH				Figg, RE; Stouffer, CW; Vander Kolk, WE; Connors, RH			Clinical efficacy of serial computed tomographic scanning in pediatric severe traumatic brain injury	PEDIATRIC SURGERY INTERNATIONAL			English	Article						traumatic brain injury; computed tomography; pediatric trauma	CLOSED-HEAD-INJURY; TRANSPORT; CHILDREN; ADOLESCENTS; MORBIDITY	The purpose of this study is to determine whether serial computed tomography (CT) scans of the head lead to operative intervention in pediatric patients with severe traumatic brain injury (TBI). Serial CT scans are those done in addition to the initial CT scan and one follow up CT scan in the first 24-48 h. This study is a retrospective review from January 1990 to December 2003. The hospital course was reviewed for 942 pediatric patients with traumatic brain injuries. Of these, 40 patients were identified who met the following criteria: age less than 18, admission, Glasgow Coma Scale (GCS) <= 8, intra-cranial pressure (ICP) monitoring during hospitalization, no craniotomy at admission, and at least one serial CT scan after the first 48 h. One hundred fifteen serial CT scans were ordered. Eighty-seven were ordered for routine follow up, 24 were ordered for increased ICP, and 4 were ordered for neurologic change. One craniotomy and one burr hole were performed based on serial CT scans ordered for increased ICP. Serial CT scans, beyond the initial and follow-up scans, have a limited role in children with severe TBI. In this series, only serial CT scans ordered for increased ICP (21%) and neurologic deterioration (3%) led to operative interventions. Serial scans ordered for routine follow-up (76%) resulted in no operative interventions.	Med Educ & Res Ctr, MSU Gen Surg Residency, Grand Rapids, MI 49503 USA; Michigan State Univ, Dept Surg, Grand Rapids, MI USA; Spectrum Hlth, Trauma Serv, Grand Rapids, MI 49503 USA; Michigan State Univ, DeVos Childrens Hosp, Dept Pediat Surg, Grand Rapids, MI 49503 USA	Stouffer, CW (corresponding author), Med Educ & Res Ctr, MSU Gen Surg Residency, 221 Michigan NE Suite 200A, Grand Rapids, MI 49503 USA.	Stouff17@yahoo.com					*AM ASS NEUR SURG, 2000, J NEUROTRAUM, V7, P597; *AM COLL SURG COMM, 1997, ADV TRAUM LIF SUPP D; BRAMAN SS, 1987, ANN INTERN MED, V107, P469, DOI 10.7326/0003-4819-107-4-469; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; CHIN LS, 2004, SABISTON TXB SURG, P2152; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; COOPER P, 1993, NEUROSURG CLIN N AM, V3, P659; COPE DN, 1988, ARCH PHYS MED REHAB, V69, P483; Evans A, 1995, Am J Crit Care, V4, P106; Figg RE, 2003, J TRAUMA, V55, P1061, DOI 10.1097/01.TA.0000096712.90133.5C; Gruen JP, 1996, SURG CLIN N AM, V76, P905, DOI 10.1016/S0039-6109(05)70487-4; KANTER RK, 1992, PEDIATRICS, V90, P893; KOBAYASHI S, 1983, SURG NEUROL, V20, P25, DOI 10.1016/0090-3019(83)90101-5; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; MAYER T, 1981, JAMA-J AM MED ASSOC, V245, P719; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; SMITH I, 1990, CRIT CARE MED, V18, P278, DOI 10.1097/00003246-199003000-00006; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038	19	25	27	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0179-0358	1437-9813		PEDIATR SURG INT	Pediatr. Surg. Int.	MAR	2006	22	3					215	218		10.1007/s00383-005-1560-0			4	Pediatrics; Surgery	Pediatrics; Surgery	022CQ	WOS:000236032700002	16328336				2021-06-18	
J	Malec, JF; Moessner, AM				Malec, JF; Moessner, AM			Replicated positive results for the VCC model of vocational intervention after ABI within the social model of disability	BRAIN INJURY			English	Article						vocational rehabilitation; brain injury; disability	TRAUMATIC BRAIN-INJURY; SUPPORTED EMPLOYMENT; OUTCOMES; RETURN; WORK	Primary objective: Replicated evaluation of the Vocational Case Co-ordinator (VCC) Model for vocational rehabilitation after acquired brain injury (ABI). Research design: Referral cohort studied within the social model of disability. Methods and procedures: One hundred and thirty-eight participants with ABI were assisted by a VCC to develop self-directed vocational plans and networks of medical centre and community services. Early intervention, work trials, temporary or long-term supported employment and employer education are fundamental features of the VCC Model. Main outcomes and results: One year after initial placement 80% of participants remained in community-based employment, 56% of the total sample with no support. Better outcomes were associated with earlier intervention but not with initial injury severity. Conclusions: Results replicate original findings of the effectiveness of the VCC Model of vocational rehabilitation after ABI with a different VCC. Implications for social change within the social model of disability are discussed.	Mayo Clin, Coll Med, Generose ME TBI, Rochester, MN 55905 USA	Malec, JF (corresponding author), Mayo Clin, Coll Med, Generose ME TBI, Rochester, MN 55905 USA.	malec.james@mayo.edu					BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Buffington ALH, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199710000-00002; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; CORTHELL DW, 1985, 12 I REH ISS REH TRA; Corthell DW, 1990, TRAUMATIC BRAIN INJU; JOHNSTON M V, 1991, Brain Injury, V5, P155, DOI 10.3109/02699059109008086; MALEC J, 1992, NEUROREHABILITATION, V2, P1; Malec JF, 2002, ARCH PHYS MED REHAB, V83, P1759, DOI 10.1053/apmr.2002.36072; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; Malec JF, 2000, ARCH PHYS MED REHAB, V81, P1007, DOI 10.1053/apmr.2000.6980; Malec JF, 2005, REHABILITATION TRAUM, P176; MENZ FE, 1990, TRAUMATIC BRAIN INJU; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; THOMAS DF, 1993, COMMUNITY BASED EMPL; Union of the Physically Impaired Against Segregation and the Disability Alliance, 1975, FUND PRINC DIS; Wall JR, 1998, BRAIN INJURY, V12, P215; WEHMAN P, 1989, J APPL BEHAV ANAL, V22, P395, DOI 10.1901/jaba.1989.22-395; WEHMAN P, 1993, AM J PHYS MED REHAB, V72, P355; WEHMAN P, 1993, COMMUNITY BASED EMPL; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011	23	25	26	0	7	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAR	2006	20	3					227	236		10.1080/02699050500488124			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	021GT	WOS:000235972400002	16537264				2021-06-18	
J	Wang, XF; Huang, LD; Yu, PP; Hu, JG; Yin, L; Wang, L; Xu, XM; Lu, PH				Wang, XF; Huang, LD; Yu, PP; Hu, JG; Yin, L; Wang, L; Xu, XM; Lu, PH			Upregulation of type I interleukin-1 receptor after traumatic spinal cord injury in adult rats	ACTA NEUROPATHOLOGICA			English	Article						inflammation; spinal cord injury Rat; IL-1; IL-1 receptor	TUMOR-NECROSIS-FACTOR; INDUCED SICKNESS BEHAVIOR; TIME QUANTITATIVE PCR; FACTOR-ALPHA; DEFICIENT MICE; GENE-EXPRESSION; BRAIN-DAMAGE; CELL-DEATH; IL-1-BETA; CYTOKINES	Post-traumatic inflammation response has been implicated in secondary injury mechanisms after spinal cord injury (SCI). Interleukin-1 (IL-1) is a key inflammatory mediator that is increasingly expressed after SCI. The action of IL-1 is mediated through its functional receptor, type I interleukin-1 receptor (IL-1RI). However, whether this receptor is expressed after SCI remains to be elucidated. In the present study, the temporospatial expression of IL-1RI was detected in rats that received a moderate contusive SCI (a 10 g rod dropped at a height of 12.5 mm) at the ninth to tenth thoracic vertebral level using a widely used New York University impact device. Our study demonstrated that IL-1RI was slightly increased at 4 h post-injury compared to the normal or sham-operated controls, reached the peak at 8 h at mRNA level (4.44-fold, P < 0.01) and 1 d at protein level (2.62-fold, P < 0.01). IL-1RI remained at its elevated levels for a relatively long duration (4 h-7 days). Spatially, IL-1RI was observed throughout the entire length of a 10 mm-long cord segment containing the injury epicenter. Colocalization of IL-1RI was found in neurons, oligodendrocytes, astrocytes, and activated microglia. Our results suggest that the elevated expression of IL-1RI after SCI may contribute to posttraumatic inflammation responses of IL-1.	Shanghai Med Univ 2, Dept Neurobiol, Shanghai 200025, Peoples R China; Nantong Univ, Affiliated Hosp, Dept Lab Sci, Nantong 226001, Peoples R China; Univ Louisville, Sch Med, Dept Neurol Surg, Kentucky Spinal Cord Injury Res Ctr, Louisville, KY 40292 USA	Xu, XM (corresponding author), Shanghai Med Univ 2, Dept Neurobiol, 280 S Chong Qing Rd, Shanghai 200025, Peoples R China.	xmxu0001@louisville.edu; peihualua3@yahoo.com.cn	Yu, Panpan/A-4962-2013; Yu, Panpan/M-5718-2019	Xu, Xiao-ming/0000-0002-7229-0081			Albrecht PJ, 2002, EXP NEUROL, V173, P46, DOI 10.1006/exnr.2001.7834; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Basu A, 2005, J CEREBR BLOOD F MET, V25, P17, DOI 10.1038/sj.jcbfm.9600002; Basu A, 2002, J NEUROSCI, V22, P6071; Basu A, 2004, J NEUROSCI RES, V78, P151, DOI 10.1002/jnr.20266; BERKENBOSCH F, 1987, SCIENCE, V238, P524, DOI 10.1126/science.2443979; BESEDOVSKY H, 1986, SCIENCE, V233, P652, DOI 10.1126/science.3014662; Blasi F, 1999, BIOL CHEM, V380, P259, DOI 10.1515/BC.1999.034; Bluthe RM, 2000, EUR J NEUROSCI, V12, P4447, DOI 10.1111/j.1460-9568.2000.01348.x; BOSSU P, 1995, AM J PATHOL, V147, P1852; Boutin H, 2001, J NEUROSCI, V21, P5528; BRENNEMAN DE, 1995, INT J DEV NEUROSCI, V13, P187, DOI 10.1016/0736-5748(95)00014-8; CHUNG IY, 1990, J IMMUNOL, V144, P2999; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; Cremona S, 1998, NEUROSCI LETT, V246, P101, DOI 10.1016/S0304-3940(98)00238-9; Davies CA, 1999, J CEREBR BLOOD F MET, V19, P87, DOI 10.1097/00004647-199901000-00010; Dziegielewska KM, 2000, CELL TISSUE RES, V299, P335; Eriksson C, 1999, NEUROSCIENCE, V93, P915, DOI 10.1016/S0306-4522(99)00178-5; GIULIAN D, 1988, J NEUROSCI, V8, P709; Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; HSU C Y, 1990, Journal of Neurotrauma, V7, P115, DOI 10.1089/neu.1990.7.115; John GR, 2003, NEUROSCIENTIST, V9, P10, DOI 10.1177/1073858402239587; Johnson RW, 1997, COMP BIOCHEM PHYS A, V116, P183, DOI 10.1016/S0300-9629(96)00277-0; Konsman JP, 2002, TRENDS NEUROSCI, V25, P154, DOI 10.1016/S0166-2236(00)02088-9; Labow M, 1997, J IMMUNOL, V159, P2452; LEE SC, 1994, GLIA, V12, P309, DOI 10.1002/glia.440120407; Li CS, 2005, J BIOL CHEM, V280, P26152, DOI 10.1074/jbc.M503262200; Liberto CM, 2004, J NEUROCHEM, V89, P1092, DOI 10.1111/j.1471-4159.2004.02420.x; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loddick SA, 1996, J CEREBR BLOOD F MET, V16, P932, DOI 10.1097/00004647-199609000-00017; Mason JL, 2001, J NEUROSCI, V21, P7046, DOI 10.1523/JNEUROSCI.21-18-07046.2001; Nesic O, 2001, J NEUROTRAUM, V18, P947, DOI 10.1089/089771501750451857; NORRIS JG, 1994, J IMMUNOL, V152, P841; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650; Pan JZ, 2002, J NEUROSCI RES, V68, P315, DOI 10.1002/jnr.10215; Parish CL, 2002, J NEUROSCI, V22, P8034; Parker LC, 2002, BRIT J PHARMACOL, V136, P312, DOI 10.1038/sj.bjp.0704715; Pearson VL, 1999, GLIA, V25, P311, DOI 10.1002/(SICI)1098-1136(19990215)25:4<311::AID-GLIA1>3.0.CO;2-E; Pinteaux E, 2002, J NEUROCHEM, V83, P754, DOI 10.1046/j.1471-4159.2002.01184.x; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; SAPOLSKY R, 1987, SCIENCE, V238, P522, DOI 10.1126/science.2821621; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; Sung CS, 2004, BRAIN RES, V1015, P145, DOI 10.1016/j.brainres.2004.04.068; Vitkovic L, 2000, J NEUROCHEM, V74, P457, DOI 10.1046/j.1471-4159.2000.740457.x; Wang CX, 1997, BRAIN RES, V759, P190, DOI 10.1016/S0006-8993(97)00254-0; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; Yan P, 2003, EXP NEUROL, V183, P286, DOI 10.1016/S0014-4886(03)00135-3; Yan P, 1999, J NEUROSCI, V19, P9355; Yang LQ, 2005, J CLIN NEUROSCI, V12, P276, DOI 10.1016/j.jocn.2004.06.011; Yang LQ, 2004, SPINE, V29, P966, DOI 10.1097/00007632-200405010-00004	53	25	27	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	MAR	2006	111	3					220	228		10.1007/s00401-005-0016-x			9	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	030HA	WOS:000236624000003	16456668				2021-06-18	
J	Zohar, O; Getslev, V; Miller, AL; Schreiber, S; Pick, CG				Zohar, O; Getslev, V; Miller, AL; Schreiber, S; Pick, CG			Morphine protects for head trauma induced cognitive deficits in mice	NEUROSCIENCE LETTERS			English	Article						minimal traumatic brain injury; morphine; Morris water maze; mice	EXPERIMENTAL BRAIN INJURY; RAT; SCOPOLAMINE; IMPAIRMENT; U-50488H; UPDATE	Victims of minor traumatic brain injury (mTBI) can show long lasting cognitive, emotional and concentration difficulties, amnesia, depression, apathy and anxiety. The symptoms are generally known as a post-concussive syndrome without clear morphological brain defects. Endogenous opiates are released after impact to the brain, suggesting they may play a role in TBI pathophysiology. Furthermore, the administration of opiates to the brain of injured animals has been shown to affect the injury, induce cellular changes and also have protective qualities for neurological impairments. Here, we examined the protective properties of the opiate morphine on cognitive performances following minimal brain injury in mice. For this purpose, we have used our non-invasive closed-head weight drop model in mice, which closely mimics real life mTBI and examined mice performance in the Morris water maze. Our procedure did not cause visible structural or neurological damage to the mice. A single morphine injection administrated immediately after the induction of minimal TBI protected the injured mice from cognitive impairment, checked 30, 60 and 90 days post injury. However, mice injected with morphine that were examined 7 days after the injury did not show better performance than the saline injected mice. Our results indicate that morphine has long but not short-term effects on the cognitive ability of brain-injured mice. Although the exact nature of opioid neuroprotection is still unknown, its elucidation may lead to the much-needed treatment for traumatic brain injury. (c) 2005 Elsevier Ireland Ltd. All rights reserved.	Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; Johns Hopkins Univ, Blanchette Rockefeller Neurosci Inst, Rockville, MD 20850 USA; Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Psychiat, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel	Pick, CG (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel.	pickc@post.tau.ac.il	Schreiber, Shaul/E-5821-2010; Pick, Chaim/D-4789-2009	Schreiber, Shaul/0000-0002-2189-0693; 			FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Finset A, 1999, PSYCHOSOM MED, V61, P576, DOI 10.1097/00006842-199907000-00024; HALL ED, 1987, BRAIN RES, V435, P174, DOI 10.1016/0006-8993(87)91599-X; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAYES RL, 1990, J NEUROSURG, V72, P251; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HUDSON CJ, 1991, BRAIN RES, V564, P261, DOI 10.1016/0006-8993(91)91462-A; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; LYETH BG, 1993, BRAIN RES, V617, P69, DOI 10.1016/0006-8993(93)90614-S; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; MORRIS RGM, 1988, J NEUROSCI METH, V11, P47; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; PERRY DC, 1992, MOL CHEM NEUROPATHOL, V16, P95, DOI 10.1007/BF03159963; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	20	25	25	0	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	FEB 20	2006	394	3					239	242		10.1016/j.neulet.2005.10.099			4	Neurosciences	Neurosciences & Neurology	013FT	WOS:000235395900015	16356639				2021-06-18	
J	Bramwell, KJ; Haizlip, J; Pribble, C; VanDerHeyden, TC; Witte, M				Bramwell, KJ; Haizlip, J; Pribble, C; VanDerHeyden, TC; Witte, M			The effect of etomidate on intracranial pressure and systemic blood pressure in pediatric patients with severe traumatic brain injury	PEDIATRIC EMERGENCY CARE			English	Article						etomidate; induction; sedation; intracranial hypertension; intubation	RAPID-SEQUENCE INTUBATION; HEAD-INJURY; ANESTHESIA; INDUCTION	Objective: To evaluate the effects of single-dose etomidate in pediatric patients with intracranial hypertension after severe traumatic brain injury. Methods: Patients admitted to the pediatric intensive care unit with severe traumatic brain injury were enrolled with the informed consent of their guardians. The experimental intervention was a single dose of etomidate 0.3 mg/kg intravenously. This dosage was administered only when enrolled patients had acute elevations of intracranial pressure (ICP) to over 20 mm Hg for over 5 minutes. ICP and mean arterial pressure (MAP) were monitored continuously. ICP and MAP values for 6 consecutive 5-minute intervals after etomidate administration were averaged for all patients and compared with baseline. Results: Eight patients were enrolled. Mean ICP after etomidate administration was significantly lower than baseline ICP for each 5-minute interval (P < 0.05). The mean MAP for all patients increased from baseline during the first 5-minute interval, but this change was not statistically significant. No patient's MAP decreased below baseline at any time point. Conclusions: In pediatric patients with severe traumatic brain injury, single-dose etomidate administration resulted in statistically significant reductions in ICP and improvement in cerebral perfusion pressure without significantly altering MAP.	St Lukes Reg Med Ctr, Boise, ID USA; Univ Utah, Div Pediat Crit Care, Salt Lake City, UT USA; Univ Utah, Div Pediat Crit Care & Pediat Anesthesiol, Dept Pediat, Salt Lake City, UT USA; Cottage Hlth Syst, Santa Barbara, CA USA	Bramwell, KJ (corresponding author), 250 Bobwhite Court 340, Boise, ID 83706 USA.	kbramwell@emidaho.com					Absalom A, 1999, ANAESTHESIA, V54, P861; BINGHAM RM, 1985, BRIT J ANAESTH, V7, P843; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DEARDEN NM, 1985, BRIT J ANAESTH, V57, P361, DOI 10.1093/bja/57.4.361; Dixon CE, 2003, CRIT CARE MED, V31, P2222, DOI 10.1097/01.CCM.0000080493.04978.73; DONMEZ A, 1988, J CARDIOTHOR VASC AN, V12, P182; FRAGEN RJ, 1984, ANESTHESIOLOGY, V61, P652, DOI 10.1097/00000542-198412000-00004; Guldner G, 2003, ACAD EMERG MED, V10, P134, DOI 10.1197/aemj.10.2.134; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; MCDOWELL RH, 1997, J CLIN ANESTH, V7, P273; MODICA PA, 1992, CAN J ANAESTH, V39, P236, DOI 10.1007/BF03008783; MOSS E, 1979, BRIT J ANAESTH, V51, P347, DOI 10.1093/bja/51.4.347; NEWBY DM, 1983, LANCET, V321, P1381; Plewa MC, 1997, AM J EMERG MED, V15, P98, DOI 10.1016/S0735-6757(97)90066-8; RENOU AM, 1978, BRIT J ANAESTH, V50, P1047, DOI 10.1093/bja/50.10.1047; SEBEL PS, 1983, LANCET, V2, P62; Skinner HJ, 1998, ANAESTHESIA, V53, P702, DOI 10.1046/j.1365-2044.1998.396-az0506.x; Smith DC, 2000, J EMERG MED, V18, P13, DOI 10.1016/S0736-4679(99)00154-7; Sokolove PE, 2000, PEDIATR EMERG CARE, V16, P18, DOI 10.1097/00006565-200002000-00005; Tobias J D, 2000, Pediatr Crit Care Med, V1, P100, DOI 10.1097/00130478-200010000-00002; WATT I, 1984, ANAESTHESIA, V39, P973, DOI 10.1111/j.1365-2044.1984.tb08885.x	21	25	27	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	0749-5161			PEDIATR EMERG CARE	Pediatr. Emerg. Care	FEB	2006	22	2					90	93		10.1097/01.pec.0000199563.64264.3a			4	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	014AH	WOS:000235450600002	16481923				2021-06-18	
J	Movsesyan, VA; Faden, AI				Movsesyan, VA; Faden, AI			Neuroprotective effects of selective group II mGluR activation in brain trauma and traumatic neuronal injury	JOURNAL OF NEUROTRAUMA			English	Article						agonist; brain trauma; mGluR; neuronal cell death	METABOTROPIC GLUTAMATE RECEPTORS; SPINAL-CORD INJURY; EXCITATORY AMINO-ACID; RAT HIPPOCAMPAL SLICES; D-ASPARTATE RECEPTORS; IN-VITRO; CELL-DEATH; NMDA RECEPTORS; MOLECULAR CHARACTERIZATION; SIGNAL-TRANSDUCTION	The effects of group II mGluR activation by selective agonist (-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY379268) were examined in a mouse model of controlled cortical impact (CCI)-induced brain injury and in primary neuronal/glial and neuronal cultures subjected to mechanical trauma. Systemic administration of LY379268 to mice at 30 min after CCI significantly improved both motor and cognitive recovery as compared with vehicle-treated control animals. LY379268 also significantly reduced cell death induced by mechanical injury in rat neuronal/glial and neuronal cultures, as measured by lactate dehydrogenase (LDH) release assay. The neuroprotective effect of LY379268 in vitro was abolished by co-administration of the mGluR2/3 antagonist (s)-alpha-ethylglutamic acid (EGLU); however, co-application of selective mGluR3 antagonist beta-N-acetyl-aspartyl-glutamate (NAAG) had no significant influence in the same system. Together, these findings demonstrate the neuroprotective activity of group 11 mGluR activation and underscore the role of the mGluR2 subtype for this effect.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA	Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, 3900 Reservoir Rd NW,Res Bldg,Rm EP 12, Washington, DC 20007 USA.	fadena@georgetown.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD040677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037313] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD040677] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS37313] Funding Source: Medline		ABE T, 1992, J BIOL CHEM, V267, P13361; Allen JW, 1999, J PHARMACOL EXP THER, V290, P112; Allen JW, 2001, EXP NEUROL, V169, P449, DOI 10.1006/exnr.2001.7672; Allen JW, 2000, CELL DEATH DIFFER, V7, P470, DOI 10.1038/sj.cdd.4400678; Anwyl R, 1999, BRAIN RES REV, V29, P83, DOI 10.1016/S0165-0173(98)00050-2; BIRRELL GJ, 1993, NEUROPHARMACOLOGY, V32, P1351, DOI 10.1016/0028-3908(93)90030-7; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; Bond A, 1999, NEUROSCI LETT, V273, P191, DOI 10.1016/S0304-3940(99)00663-1; Bond A, 1998, NEUROREPORT, V9, P1191, DOI 10.1097/00001756-199804200-00042; Bond A, 2000, J PHARMACOL EXP THER, V294, P800; BRUNO V, 1995, EUR J NEUROSCI, V7, P1906, DOI 10.1111/j.1460-9568.1995.tb00712.x; BRUNO V, 1994, EUR J PHARMACOL, V256, P109, DOI 10.1016/0014-2999(94)90624-6; Bruno V, 2000, J NEUROSCI, V20, P6413, DOI 10.1523/JNEUROSCI.20-17-06413.2000; BUISSON A, 1995, NEUROPHARMACOLOGY, V34, P1081, DOI 10.1016/0028-3908(95)00073-F; CHIAMULERA C, 1992, EUR J PHARMACOL, V216, P335, DOI 10.1016/0014-2999(92)90382-E; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; COPANI A, 1995, MOL PHARMACOL, V47, P890; DiIorio P, 1996, J NEUROCHEM, V67, P302; DUVOISIN RM, 1995, J NEUROSCI, V15, P3075; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P355, DOI 10.1097/01.WCB.0000046144.31247.33; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; Faden AI, 2001, EXP NEUROL, V167, P435, DOI 10.1006/exnr.2000.7577; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faden AI, 1997, J NEUROTRAUM, V14, P885, DOI 10.1089/neu.1997.14.885; Ferraguti F, 1999, EUR J NEUROSCI, V11, P2073, DOI 10.1046/j.1460-9568.1999.00626.x; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Henrich-Noack P, 1998, NEUROREPORT, V9, P985, DOI 10.1097/00001756-199804200-00006; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; Iacovelli L, 2002, J NEUROCHEM, V82, P216, DOI 10.1046/j.1471-4159.2002.00929.x; KOH JY, 1991, P NATL ACAD SCI USA, V88, P9431, DOI 10.1073/pnas.88.21.9431; Kornhuber J, 1997, BIOL PSYCHIAT, V41, P135, DOI 10.1016/S0006-3223(96)00047-9; Lea PM, 2005, BRIT J PHARMACOL, V145, P527, DOI 10.1038/sj.bjp.0706219; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MCDONALD JW, 1992, EUR J PHARMACOL, V215, P353, DOI 10.1016/0014-2999(92)90058-C; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; Meli E, 2002, PHARMACOL BIOCHEM BE, V73, P439, DOI 10.1016/S0091-3057(02)00834-1; Mills CD, 2001, J NEUROCHEM, V79, P835, DOI 10.1046/j.1471-4159.2001.00630.x; MINAKAMI R, 1993, BIOCHEM BIOPH RES CO, V194, P622, DOI 10.1006/bbrc.1993.1866; Monn JA, 1999, J MED CHEM, V42, P1027, DOI 10.1021/jm980616n; Movsesyan VA, 2004, J NEUROCHEM, V89, P1528, DOI 10.1111/j.1471-4159.2004.02451.x; Movsesyan VA, 2001, J PHARMACOL EXP THER, V296, P41; Mukhin A, 1996, J NEUROSCI, V16, P6012; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; NAKAJIMA Y, 1993, J BIOL CHEM, V268, P11868; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; O'Leary DM, 2000, BRIT J PHARMACOL, V131, P1429, DOI 10.1038/sj.bjp.0703715; OKAMOTO N, 1994, J BIOL CHEM, V269, P1231; OLNEY JW, 1989, BIOL PSYCHIAT, V26, P505, DOI 10.1016/0006-3223(89)90072-3; OPITZ T, 1994, NEUROPHARMACOLOGY, V33, P715, DOI 10.1016/0028-3908(94)90178-3; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; PIN JP, 1992, P NATL ACAD SCI USA, V89, P10331, DOI 10.1073/pnas.89.21.10331; PIN JP, 1993, CURR DRUGS NEURODEGE, V1, P111; Poli A, 2003, J NEUROSCI, V23, P6023; SACAAN AI, 1992, NEUROSCI LETT, V139, P77, DOI 10.1016/0304-3940(92)90862-2; SAUGSTAD JA, 1994, MOL PHARMACOL, V45, P367; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; Shapiro BK, 2001, MENT RETARD DEV D R, V7, P13, DOI 10.1002/1098-2779(200102)7:1<13::AID-MRDD1003>3.0.CO;2-1; SILIPRANDI R, 1992, EUR J PHARMACOL, V219, P173, DOI 10.1016/0014-2999(92)90598-X; Stover JF, 2003, J NEUROTRAUM, V20, P315, DOI 10.1089/089771503765172273; TANABE Y, 1993, J NEUROSCI, V13, P1372; VIGNES M, 1995, NEUROPHARMACOLOGY, V34, P973, DOI 10.1016/0028-3908(95)00093-L; WATKINS J, 1994, TRENDS PHARMACOL SCI, V15, P333, DOI 10.1016/0165-6147(94)90028-0; Wigmore MA, 1998, BRIT J PHARMACOL, V123, P667, DOI 10.1038/sj.bjp.0701662; WRATHALL JR, 1992, BRAIN RES, V586, P140, DOI 10.1016/0006-8993(92)91384-Q	75	25	26	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2006	23	2					117	127		10.1089/neu.2006.23.117			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	020HX	WOS:000235900600001	16503796				2021-06-18	
S	Chopp, M; Li, Y		Fisher, JP		Chopp, Michael; Li, Yi			Transplantation of bone marrow stromal cells for treatment of central nervous system diseases	TISSUE ENGINEERING	Advances in Experimental Medicine and Biology		English	Article; Proceedings Paper	2nd International Tissue Engineering Conference	MAY 22-27, 2005	Crete, GREECE				FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; STROKE-INDUCED NEUROGENESIS; MESENCHYMAL STEM-CELLS; ARTERY OCCLUSION; PROGENITOR CELLS; RAT-BRAIN; INTRACEREBRAL TRANSPLANTATION; SUBVENTRICULAR ZONE; THERAPEUTIC BENEFIT		Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA; Oakland Univ, Dept Phys, Rochester, MI 48063 USA	Chopp, M (corresponding author), Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045041, P01NS042345] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS045041, P01 NS042345] Funding Source: Medline		Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Chen HI, 2003, SENSOR ACTUAT B-CHEM, V92, P6, DOI 10.1016/S0925-4005(03)00125-4; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen JL, 2004, BRAIN RES, V1005, P21, DOI 10.1016/j.brainres.2003.11.080; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chen XG, 2002, STROKE, V33, P401; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Cohen-Cory S, 2002, SCIENCE, V298, P770, DOI 10.1126/science.1075510; Cramer SC, 2000, TRENDS NEUROSCI, V23, P265, DOI 10.1016/S0166-2236(00)01562-9; Darsalia V, 2005, STROKE, V36, P1790, DOI 10.1161/01.STR.0000173151.36031.be; Dormady SP, 2001, J HEMATOTH STEM CELL, V10, P125, DOI 10.1089/152581601750098372; Duggal N, 1997, BRAIN RES, V768, P1, DOI 10.1016/S0006-8993(97)00588-X; Fields RD, 2002, SCIENCE, V298, P556, DOI 10.1126/science.298.5593.556; Fok-Seang J, 1998, EUR J NEUROSCI, V10, P2400, DOI 10.1046/j.1460-9568.1998.00251.x; FOURNIER GA, 1981, INVEST OPHTH VIS SCI, V21, P351; Frost SB, 2003, J NEUROPHYSIOL, V89, P3205, DOI 10.1152/jn.01143.2002; GAO Q, 2005, IN PRESS NEUROSCIENC; GARCIA JH, 1993, AM J PATHOL, V142, P623; Gourmala NG, 1999, NEUROSCIENCE, V88, P1255, DOI 10.1016/S0306-4522(98)00295-4; Guegan C, 1998, MOL BRAIN RES, V55, P133, DOI 10.1016/S0169-328X(97)00372-0; Hamano K, 2000, CELL TRANSPLANT, V9, P439, DOI 10.1177/096368970000900315; Haynesworth SE, 1996, J CELL PHYSIOL, V166, P585, DOI 10.1002/(SICI)1097-4652(199603)166:3<585::AID-JCP13>3.0.CO;2-6; KELLY JP, 1985, PRINCIPLES NEURAL SC; Kempermann G, 2000, Prog Brain Res, V127, P35; Koc ON, 2000, J CLIN ONCOL, V18, P307, DOI 10.1200/JCO.2000.18.2.307; Koc ON, 2001, BONE MARROW TRANSPL, V27, P235, DOI 10.1038/sj.bmt.1702791; Li Y, 1999, BRAIN RES, V838, P1, DOI 10.1016/S0006-8993(99)01502-4; LI Y, 1992, STROKE, V23, P1292, DOI 10.1161/01.STR.23.9.1292; Li Y, 1998, STROKE, V29, P1972, DOI 10.1161/01.STR.29.9.1972; LI Y, 1994, STROKE, V25, P849, DOI 10.1161/01.STR.25.4.849; Li Y, 2001, NEUROSCI LETT, V316, P67, DOI 10.1016/S0304-3940(01)02384-9; Li Y, 2002, J NEUROL SCI, V193, P137, DOI 10.1016/S0022-510X(01)00657-8; Li Y, 1997, J CEREBR BLOOD F MET, V17, P846, DOI 10.1097/00004647-199708000-00003; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; LI Y, 1995, AM J PATHOL, V146, P1045; Li Y, 2001, CELL TRANSPLANT, V10, P31; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; LICHTENWALNER RJ, 2005, J CEREB BLOOD F 0615; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Lu M, 2003, J NEUROSCI METH, V128, P183, DOI 10.1016/S0165-0270(03)00188-2; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Mandalfino P, 2000, J NEUROL, V247, P691, DOI 10.1007/s004150070112; McIntosh K, 2002, BONE MARROW TRANSPL, V29, pS65; MCKEON RJ, 1995, EXP NEUROL, V136, P32, DOI 10.1006/exnr.1995.1081; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Rohwedel J, 1998, DEV BIOL, V201, P167, DOI 10.1006/dbio.1998.9002; Rossini PM, 2004, RESTOR NEUROL NEUROS, V22, P193; SCHALLERT T, 1982, PHARMACOL BIOCHEM BE, V16, P455, DOI 10.1016/0091-3057(82)90452-X; Seyfried D, 2006, J NEUROSURG, V104, P313, DOI 10.3171/jns.2006.104.2.313; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; Tamada Y, 2000, J OCUL PHARMACOL TH, V16, P271, DOI 10.1089/jop.2000.16.271; THEODOSIS DT, 1999, CONTRIBUTION ASTROCY, P175; Tse WT, 2003, TRANSPLANTATION, V75, P389, DOI 10.1097/01.TP.0000045055.63901.A9; Wang L, 2002, EXP HEMATOL, V30, P831, DOI 10.1016/S0301-472X(02)00829-9; Wang Lei, 2002, Hematology, V7, P113; Yi L, 2005, GLIA, V49, P407, DOI 10.1002/glia.20126; Zhang J, 2004, BRAIN RES, V1030, P19, DOI 10.1016/j.brainres.2004.09.061; ZHANG J, 2005, IN PRESS EXP NEUROL; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0; Zhang QJ, 2002, INT J RF MICROW C E, V12, P2, DOI 10.1002/mmce.10027; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009; Zhang RL, 2003, NEUROSCIENCE, V116, P373, DOI 10.1016/S0306-4522(02)00696-6; Zhang RL, 1997, BRAIN RES, V766, P83, DOI 10.1016/S0006-8993(97)00580-5; ZHANG RL, 1994, NEUROLOGY, V44, P1747, DOI 10.1212/WNL.44.9.1747; Zhang RL, 2004, J NEUROSCI, V24, P5810, DOI 10.1523/JNEUROSCI.1109-04.2004; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8; Zhang ZG, 2004, NEUROIMAGE, V23, P281, DOI 10.1016/j.neuroimage.2004.05.019; Zhang ZG, 1997, J CEREBR BLOOD F MET, V17, P1081, DOI 10.1097/00004647-199710000-00010; ZHANG ZG, 1995, J NEUROL SCI, V128, P22, DOI 10.1016/0022-510X(94)00216-B; Zhang ZG, 2001, J CEREBR BLOOD F MET, V21, P541, DOI 10.1097/00004647-200105000-00008; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460; Zhang ZG, 2002, J CEREBR BLOOD F MET, V22, P379, DOI 10.1097/00004647-200204000-00002	87	25	29	0	6	SPRINGER-VERLAG BERLIN	BERLIN	HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY	0065-2598	2214-8019	0-387-32664-2	ADV EXP MED BIOL	Adv.Exp.Med.Biol.		2006	585						49	64					16	Cell Biology; Engineering, Biomedical; Medicine, Research & Experimental	Cell Biology; Engineering; Research & Experimental Medicine	BFG57	WOS:000241729000004	17120776				2021-06-18	
B	Graber, KD; Prince, DA		Pitkanen, A; Schwartzkroin, PA; Moshe, SL		Graber, Kevin D.; Prince, David A.			Chronic Partial Cortical Isolation	MODELS OF SEIZURES AND EPILEPSY			English	Article; Book Chapter							ISOLATED CEREBRAL-CORTEX; TRAUMATIC BRAIN-INJURY; HUMAN DYSPLASTIC NEOCORTEX; FLUID PERCUSSION INJURY; V PYRAMIDAL NEURONS; IN-VITRO; EPILEPTIFORM DISCHARGES; RAT NEOCORTEX; HEAD TRAUMA; LAYER-V		[Graber, Kevin D.; Prince, David A.] Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA	Graber, KD (corresponding author), Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.						AGHAJANIAN GK, 1989, SYNAPSE, V3, P331, DOI 10.1002/syn.890030406; Andermann E., 1964, EPILEPSIA, V10, P415; ANDERSEN P, 1980, J PHYSIOL-LONDON, V305, P279, DOI 10.1113/jphysiol.1980.sp013363; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Avoli M, 1999, ANN NEUROL, V46, P816, DOI 10.1002/1531-8249(199912)46:6<816::AID-ANA3>3.0.CO;2-O; Benardo LS, 2003, EPILEPSIA, V44, P27, DOI 10.1046/j.1528-1157.44.s10.2.x; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BURNS BD, 1954, J PHYSIOL-LONDON, V125, P427, DOI 10.1113/jphysiol.1954.sp005170; BURNS BD, 1979, PROC R SOC SER B-BIO, V203, P347, DOI 10.1098/rspb.1979.0002; BURNS BD, 1951, J PHYSIOL-LONDON, V112, P156, DOI 10.1113/jphysiol.1951.sp004517; Cajal S. R. Y., 1928, DEGENERATION REGENER, P656; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V61, P747; CHIAIA NL, 1992, DEV BRAIN RES, V66, P244, DOI 10.1016/0165-3806(92)90086-C; CHOW KL, 1964, NEUROPSYCHOLOGIA, V2, P175, DOI 10.1016/0028-3932(64)90003-X; CONNORS BW, 1988, J PHYSIOL-LONDON, V406, P443, DOI 10.1113/jphysiol.1988.sp017390; CONNORS BW, 1984, NATURE, V310, P685, DOI 10.1038/310685a0; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Antuono M, 2004, BRAIN, V127, P1626, DOI 10.1093/brain/awh181; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P735, DOI 10.1113/jphysiol.1991.sp018733; Douglas RJ, 2004, ANNU REV NEUROSCI, V27, P419, DOI 10.1146/annurev.neuro.27.070203.144152; DOW RS, 1962, ELECTROEN CLIN NEURO, V14, P399, DOI 10.1016/0013-4694(62)90116-5; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; DUNCAN JA, 1968, EXP NEUROL, V20, P268, DOI 10.1016/0014-4886(68)90101-5; ECHLIN FA, 1954, T AM NEUROL ASSOC, P75; ECHLIN FA, 1962, NEUROLOGY, V12, P551, DOI 10.1212/WNL.12.8.551; ECHLIN FA, 1963, ARCH NEUROL-CHICAGO, V9, P154, DOI 10.1001/archneur.1963.00460080064009; ECHLIN FA, 1959, ELECTROEN CLIN NEURO, V11, P697, DOI 10.1016/0013-4694(59)90110-5; ECHLIN FRANCIS A., 1961, TRANS AMER NEUROL ASSOC, V86, P209; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; Engel J, 2003, NEUROLOGY, V60, P538, DOI 10.1212/01.WNL.0000055086.35806.2D; ERNFORS P, 1991, NEURON, V7, P165, DOI 10.1016/0896-6273(91)90084-D; FARRANCE ML, 1975, P W PHARMACOL SOC, V18, P51; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Freund TF, 2003, TRENDS NEUROSCI, V26, P489, DOI 10.1016/S0166-2236(03)00227-3; FUKUDA A, 1992, DEV BRAIN RES, V65, P101, DOI 10.1016/0165-3806(92)90013-M; GALVAN M, 1982, BRAIN RES, V241, P75, DOI 10.1016/0006-8993(82)91230-6; GOLDRING S, 1961, J NEUROPHYSIOL, V24, P633; Graber KD, 2004, ANN NEUROL, V55, P860, DOI 10.1002/ana.20124; Graber KD, 1999, EPILEPSIA, V40, P31; Graber KD, 1998, NEUROLOGY, V50, pA140; Graber KD, 1999, ANN NEUROL, V46, P234, DOI 10.1002/1531-8249(199908)46:2<234::AID-ANA13>3.0.CO;2-Q; Graber Kevin D., 2002, Epilepsia, V43, P21; Graber Kevin D., 2003, Epilepsia, V44, P204; GRAFSTEIN B, 1957, ELECTROEN CLIN NEURO, V9, P723, DOI 10.1016/0013-4694(57)90096-2; GREEN JR, 1973, EPILEPSIA, V14, P223, DOI 10.1111/j.1528-1157.1973.tb03959.x; GREEN JR, 1973, EPILEPSIA, V14, P233, DOI 10.1111/j.1528-1157.1973.tb03960.x; GREEN JR, 1970, BRAIN, V93, P57, DOI 10.1093/brain/93.1.57; GREEN JR, 1970, LIFE SCI, V9, P481, DOI 10.1016/0024-3205(70)90203-1; GRUNER JE, 1974, J COMP NEUROL, V154, P1, DOI 10.1002/cne.901540102; GUTNICK MJ, 1982, J NEUROPHYSIOL, V48, P1321; HALPERN LM, 1972, EXPT MODELS EPILEPSY, P197; HAMMOND EJ, 1980, EPILEPSIA, V21, P3, DOI 10.1111/j.1528-1157.1980.tb04039.x; Hernandez TD, 1997, NEUROLOGY, V48, P803, DOI 10.1212/WNL.48.4.803; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762; HWA GGC, 1989, NEUROSCI LETT, V98, P189, DOI 10.1016/0304-3940(89)90508-9; Jin XM, 2005, J NEUROPHYSIOL, V93, P2117, DOI 10.1152/jn.00728.2004; Kharatishvili I, 2003, EPILEPSIA, V44, P36; Kharazia VN, 2001, NEUROSCIENCE, V102, P23, DOI 10.1016/S0306-4522(00)00467-X; KIM HG, 1995, J NEUROPHYSIOL, V74, P1810; KOYAMA I, 1977, CAN J PHYSIOL PHARM, V55, P523, DOI 10.1139/y77-074; KRNJEVIC K, 1970, ELECTROEN CLIN NEURO, V29, P269, DOI 10.1016/0013-4694(70)90139-2; KRNJEVIC K, 1969, J PHYSIOL-LONDON, V203, pP44; LANGE SC, 1980, EPILEPSIA, V21, P251, DOI 10.1111/j.1528-1157.1980.tb04070.x; Li HF, 2005, J NEUROPHYSIOL, V93, P146, DOI 10.1152/jn.00665.2004; Li HF, 2002, J NEUROPHYSIOL, V88, P2, DOI 10.1152/jn.00507.2001; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LUHMANN HJ, 1991, J NEUROPHYSIOL, V65, P247; LUHMANN HJ, 1990, DEV BRAIN RES, V54, P287, DOI 10.1016/0165-3806(90)90152-O; Marco P, 1997, EXP BRAIN RES, V114, P1, DOI 10.1007/PL00005608; MarinPadilla M, 1997, J NEUROPATH EXP NEUR, V56, P219, DOI 10.1097/00005072-199703000-00001; MATSUMOTO H, 1964, EXP NEUROL, V9, P305, DOI 10.1016/0014-4886(64)90026-3; MATTIA D, 1995, NEUROLOGY, V45, P1391, DOI 10.1212/WNL.45.7.1391; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Prince D A, 1965, Epilepsia, V6, P226, DOI 10.1111/j.1528-1157.1965.tb03791.x; Prince D.A., 2000, SOC NEUR ABSTR, V26, P1779; PRINCE DA, 1981, BRAIN RES, V210, P323, DOI 10.1016/0006-8993(81)90905-7; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276; PRINCE DA, 1971, ELECTROEN CLIN NEURO, V31, P469, DOI 10.1016/0013-4694(71)90168-4; PRINCE DA, 1968, EXP NEUROL, V21, P467, DOI 10.1016/0014-4886(68)90066-6; PURPURA DP, 1961, EXP NEUROL, V4, P377, DOI 10.1016/0014-4886(61)90025-5; QIAN N, 1990, P NATL ACAD SCI USA, V87, P8145, DOI 10.1073/pnas.87.20.8145; REIFFENSTEIN RJ, 1972, ELECTROEN CLIN NEURO, V33, P215, DOI 10.1016/0013-4694(72)90048-X; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Salin P, 1995, J NEUROSCI, V15, P8234; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Schauwecker PE, 2000, EXP NEUROL, V161, P139, DOI 10.1006/exnr.1999.7251; Schwartzkroin P A, 1986, Adv Neurol, V44, P991; SCOVILLE WB, 1960, AM J PSYCHIAT, V117, P525, DOI 10.1176/ajp.117.6.525; SHARPLESS SK, 1962, ELECTROEN CLIN NEURO, V14, P244, DOI 10.1016/0013-4694(62)90034-2; Sharpless SK, 1969, BASIC MECH EPILEPSIE, P329; SILVER JM, 1991, ANN NEUROL, V29, P356, DOI 10.1002/ana.410290404; SOMOGYI P, 1985, BRAIN RES, V332, P143, DOI 10.1016/0006-8993(85)90397-X; SPEHLMANN R, 1971, ARCH NEUROL-CHICAGO, V24, P401, DOI 10.1001/archneur.1971.00480350035003; SPEHLMANN R, 1970, ELECTROEN CLIN NEURO, V28, P99; SUZUKI H, 1964, ELECTROEN CLIN NEURO, V17, P405, DOI 10.1016/0013-4694(64)90164-6; Tamas G, 2004, CEREB CORTEX, V14, P823, DOI 10.1093/cercor/bhh051; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; TETZLAFF W, 1991, J NEUROSCI, V11, P2528; Topolnik L, 2003, CEREB CORTEX, V13, P883, DOI 10.1093/cercor/13.8.883; Toth Z, 1997, J NEUROSCI, V17, P8106; Ueda Y, 1998, EXP NEUROL, V153, P123, DOI 10.1006/exnr.1998.6869; WARD AA, 1972, EXPT MODELS EPILEPSY, P13; WILLIAMS RS, 1979, ARCH NEUROL-CHICAGO, V36, P134, DOI 10.1001/archneur.1979.00500390052004; WILLMORE LJ, 1978, SCIENCE, V200, P1501, DOI 10.1126/science.96527; WILLMORE LJ, 1978, ANN NEUROL, V4, P329, DOI 10.1002/ana.410040408; WONG RKS, 1979, SCIENCE, V204, P1228, DOI 10.1126/science.451569; WRIGHT MK, 1954, ELECTROEN CLIN NEURO, V6, P635, DOI 10.1016/0013-4694(54)90090-5; Yang L, 1997, J NEUROPHYSIOL, V78, P2804; Yang L, 1998, NEUROSCI LETT, V257, P33, DOI 10.1016/S0304-3940(98)00798-8; Yang L, 2000, EPILEPSIA, V41, P1507; Zilles K., 1985, CORTEX RAT STEREOTAX	114	25	25	0	0	ELSEVIER ACADEMIC PRESS INC	SAN DIEGO	525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA			978-0-08-045702-4; 978-0-12-088554-1				2006							477	493		10.1016/B978-012088554-1/50040-2			17	Neurosciences	Neurosciences & Neurology	BCT46	WOS:000311355400040					2021-06-18	
J	Hashimoto, K; Okamoto, T; Watanabe, S; Ohashi, M				Hashimoto, K; Okamoto, T; Watanabe, S; Ohashi, M			Effectiveness of a comprehensive day treatment program for rehabilitation of patients with acquired brain injury in Japan	JOURNAL OF REHABILITATION MEDICINE			English	Article						traumatic brain injury; day treatment program; rehabilitation; Japan	HEAD-INJURY	Objective: To assess the effectiveness of a day treatment program with a comprehensive team approach for treating outpatients with acquired brain injury, which is offered by the Kanagawa Rehabilitation Hospital. Design: Non-randomized controlled study. Subjects: Twenty-five program graduates and 12 control patients with acquired brain injury. Methods: A prospective study using 25 brain-injured patients with cognitive dysfunction who were provided with a comprehensive day treatment program at Kanagawa Rehabilitation Hospital. The 25 enrolled patients had treatment sessions lasting 2-4 hours for 2 days a week over a 3-6-month period. Functional Independence Measure/Functional Assessment Measure (FIM/FAM) and the Community Integration Questionnaire (CIQ) were administered before and after the program to compare outcomes between the 25 program participants and the 12 control patients who did not receive the day treatment program. Results: Significant improvements in speech intelligibility, problem solving, memory, attention and social integration scores in the FIM/FAM and scores in social integration and productive activity in the CIQ were evident in the enrolled subjects. In addition, 9 of the 25 patients returned to work or school. Conclusion: These results demonstrate the effectiveness of this program in helping to rehabilitate patients with acquired brain injury.	Jikei Univ, Sch Med, Dept Rehabil Med, Minato Ku, Tokyo 1058461, Japan; Kanagawa Rehabil Hosp, Dept Rehabil Med, Atsugi, Kanagawa, Japan; Tokyo Metropolitan Univ Hlth Sci, Tokyo, Japan	Hashimoto, K (corresponding author), Jikei Univ, Sch Med, Dept Rehabil Med, Minato Ku, 3-25-8 Nishi Shimbashi, Tokyo 1058461, Japan.	keiman@theia.ocn.ne.jp		Hashimoto, Keiji/0000-0003-2412-860X			Armengol CG, 1999, J HEAD TRAUMA REHAB, V14, P233, DOI 10.1097/00001199-199906000-00004; BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; *BUFF GEN HOSP STA, 1992, DAT MAN SERV GUID US; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P151, DOI 10.1053/apmr.2003.50123; Christensen A., 2000, INT HDB NEUROPSYCHOL, P183; COCKBURN JM, 1988, CLIN REHABIL, V2, P315; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HASHIMOTO K, 2003, JPN J REHABIL MED, V40, P699; KATZ RT, 2000, SOGO REHABIL, V28, P115; KIMURA A, 2003, KEIO J MED, V5, P100; King J, 1998, REHABILITATION MED P, P269; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; Klonoff PS, 2000, ARCH PHYS MED REHAB, V81, P1535, DOI 10.1053/apmr.2000.9177; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; Ohashi M., 1990, JPN J REHABIL MED, V27, P399; Ohashi M, 2000, JPN J REHABIL MED, V37, P121; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; WATANABE S, 2003, SOGO RIHABIRITESHON, V31, P669; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Wiseman-Hakes C, 1998, J HEAD TRAUMA REHAB, V13, P23, DOI 10.1097/00001199-199812000-00005	21	25	27	0	2	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	JAN	2006	38	1					20	25		10.1080/16501970510038473			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	005SV	WOS:000234845000004	16548082	DOAJ Gold			2021-06-18	
J	Lai, YC; Stange, C; Wisniewski, SR; Adelson, PD; Janesko-Feldman, KL; Brown, DS; Kochanek, PM; Clark, RSB				Lai, Yichen; Stange, Christopher; Wisniewski, Stephen R.; Adelson, P. David; Janesko-Feldman, Keri L.; Brown, Danielle S.; Kochanek, Patrick M.; Clark, Robert S. B.			Mitochondrial heat shock protein 60 is increased in cerebrospinal fluid following pediatric traumatic brain injury	DEVELOPMENTAL NEUROSCIENCE			English	Article						head injury; mitochondria; heat shock protein 60; stress response	FOCAL CEREBRAL-ISCHEMIA; CYTOCHROME-C; MESSENGER-RNAS; PROTEIN HSP60; CELL-DEATH; DYSFUNCTION; INFANTS; STRESS; INDUCTION; TRANSIENT	Mitochondrial dysfunction occurs after traumatic brain injury (TBI) and contributes significantly to subsequent cell death. Heat shock protein 60 (hsp60) is a predominantly mitochondrial protein with important homeostatic functions. Induction of hsp60 has been demonstrated in cerebral ischemia models, possibly reflecting mitochondrial stress. We measured hsp60 concentration in the cerebrospinal fluid (CSF) of 34 infants and children after severe TBI and of 7 control patients by ELISA. Peak CSF hsp60 concentration was increased in TBI patients versus controls (0.84 ng/ml, range 0-44.59, vs. 0.0 ng/ml, range 0-0.48; p < 0.05). Induction of hsp60 occurred early after the injury. Peak hsp60 concentration was independently associated with the severity of injury, defined as the admission Glasgow Coma Scale score. These data suggest that increased hsp60 in CSF might reflect the severity of early mitochondrial stress or damage after TBI. Copyright (c) 2006 S. Karger AG, Basel.	Univ Pittsburgh, Sch Med, Dept Crit Care Med, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Epidemiol, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Neurol Surg, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Pediat, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA	Clark, RSB (corresponding author), Pediat Crit Care Med, 3705 5th Ave, Pittsburgh, PA 15213 USA.	clarkrs@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015; Adelson, David/W-2083-2019	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860; Lai, Yi-Chen/0000-0002-9450-5506	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD045968] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, R01NS038620] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD045968, T32 HD40686] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS38620, P50 NS30318] Funding Source: Medline		Abe K, 1998, CELL MOL NEUROBIOL, V18, P709, DOI 10.1023/A:1020230220971; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS65; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Cousar JL, 2006, DEV NEUROSCI-BASEL, V28, P342, DOI 10.1159/000094160; Gupta S, 2005, J CELL MOL MED, V9, P51, DOI 10.1111/j.1582-4934.2005.tb00336.x; Hagberg H, 2004, J BIOENERG BIOMEMBR, V36, P369, DOI 10.1023/B:JOBB.0000041770.00567.4f; HALLBERG EM, 1993, MOL CELL BIOL, V13, P3050, DOI 10.1128/MCB.13.5.3050; HAN YY, 2001, MO CL BI CC, V2, P145; Hashiguchi N, 2003, J TRAUMA, V55, P1054, DOI 10.1097/01.TA.0000033252.43742.8B; Izaki K, 2001, MOL BRAIN RES, V88, P14, DOI 10.1016/S0169-328X(01)00012-2; Lai YC, 2004, J NEUROTRAUM, V21, P229, DOI 10.1089/089771504322972022; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Lin KM, 2001, CIRCULATION, V103, P1787, DOI 10.1161/01.CIR.103.13.1787; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; Okubo A, 2000, MOL BRAIN RES, V84, P127, DOI 10.1016/S0169-328X(00)00200-X; Polster BM, 2004, J NEUROCHEM, V90, P1281, DOI 10.1111/j.1471-4159.2004.02572.x; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; SIMS NR, 1987, J NEUROCHEM, V49, P1367, DOI 10.1111/j.1471-4159.1987.tb01001.x; Solenski NJ, 2002, STROKE, V33, P816, DOI 10.1161/hs0302.104541; Soltys BJ, 1996, EXP CELL RES, V222, P16, DOI 10.1006/excr.1996.0003; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Wagstaff MJD, 1996, MOL BRAIN RES, V42, P236, DOI 10.1016/S0169-328X(96)00127-1; Weber F, 1998, NAT STRUCT BIOL, V5, P977, DOI 10.1038/2952; Xiong Y, 2005, J NEUROCHEM, V95, P732, DOI 10.1111/j.1471-4159.2005.03412.x; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x; ZHANG XP, 2001, MO CL BI CC, V2, P199	35	25	26	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2006	28	4-5					336	341		10.1159/000094159			6	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	080ZS	WOS:000240287600010	16943656				2021-06-18	
J	Mottram, L; Donders, J				Mottram, Lisa; Donders, Jacobus			Cluster subtypes on the California verbal learning test-children's version after pediatric traumatic brain injury	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							STRUCTURAL EQUATION ANALYSIS; HEAD-INJURY; WISC-III; STANDARDIZATION SAMPLE; CVLT-C; MEMORY; PERFORMANCE; ADOLESCENTS; FREQUENCY; PATTERNS	The purpose of this study is to determine the presence of profile subtypes on the California Verbal Learning Test-Children's Version (CVLT-C; Delis, Kramer, Kaplan, & Ober, 1994) in 175 children with traumatic brain injury (TBI). Four key z score variables are used in a 2-stage cluster analysis that reveal 4 reliable subtypes. No meaningful differences among the clusters are found on demographic variables. In contrast, statistically significant differences among the 4 clusters in both level and pattern of performance are found on injury severity parameters and the 4 factor index scores from an independent measure of psychometric intelligence (Wechsler Intelligence Scale for Children-Third Edition; Wechsler, 1991). This study concludes that although no unique profile is found on the CVLT-C after TBI in children, performance on this test is affected strongly by injury severity, with a mediating contribution by speed of information processing.	Mary Free Bed Rehabil Hosp, Psychol Serv, Grand Rapids, MI 49503 USA	Donders, J (corresponding author), Mary Free Bed Rehabil Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.	jacobus.donders@maryfreebed.com					BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Bjorklund D. F., 1997, DEV MEMORY CHILDHOOD, P201; BLASHFIELD RK, 1976, PSYCHOL BULL, V83, P377, DOI 10.1037/0033-2909.83.3.377; BOLL T, 1993, CHILDRENS CATEGORY T; CARTER RL, 1989, PSYCHOMETRIKA, V54, P9, DOI 10.1007/BF02294446; Catroppa C, 2003, DEV NEUROPSYCHOL, V23, P359, DOI 10.1207/S15326942DN2303_3; Cohen M.J., 1997, CHILDRENS MEMORY SCA; DELIS D, 1994, CALIFORNIA VERBAL LE; Donders J, 1996, PSYCHOL ASSESSMENT, V8, P312, DOI 10.1037/1040-3590.8.3.312; Donders J, 1999, DEV NEUROPSYCHOL, V15, P395, DOI 10.1080/87565649909540757; Donders J, 1997, CHILD NEUROPSYCHOL, V3, P71, DOI 10.1080/09297049708401369; Donders J, 1999, DEV NEUROPSYCHOL, V16, P163, DOI 10.1207/S15326942DN1602_2; Donders J, 2004, ASSESSMENT, V11, P275, DOI 10.1177/1073191104268914; Donders J, 1996, CHILD NEUROPSYCHOL, V2, P185, DOI 10.1080/09297049608402251; Fuerst DR, 1995, CHILD NEUROPSYCHOL, V1, P38, DOI 10.1080/09297049508401341; Hair JF., 2002, READING UNDERSTANDIN, P147; Holmbeck GN, 2002, J PEDIATR PSYCHOL, V27, P87, DOI 10.1093/jpepsy/27.1.87; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Kail R, 2002, CHILD DEV, V73, P1703, DOI 10.1111/1467-8624.00500; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Levin HS, 2000, J CLIN EXP NEUROPSYC, V22, P1, DOI 10.1076/1380-3395(200002)22:1;1-8;FT001; Meyers J., 1995, REY COMPLEX FIGURE T; Miller LJ, 2003, REHABIL PSYCHOL, V48, P237, DOI 10.1037/0090-5550.48.4.237; MILLIGAN GW, 1980, PSYCHOMETRIKA, V45, P325, DOI 10.1007/BF02293907; MILLIGAN GW, 1985, PSYCHOMETRIKA, V50, P159, DOI 10.1007/BF02294245; MILLIGAN GW, 2003, HDB PSYCHOL RES METH, V2, P165; Mottram L, 2005, PSYCHOL ASSESSMENT, V17, P212, DOI 10.1037/1040-3590.17.2.212; Nesbit-Greene K, 2002, J CLIN EXP NEUROPSYC, V24, P194, DOI 10.1076/jcen.24.2.194.996; Precourt S, 2002, DEV NEUROPSYCHOL, V21, P173, DOI 10.1207/S15326942DN2102_4; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; *SAS I INC, 1990, SAS STAT US GUIDE VE, V1; Saunders CD, 2000, CHILD NEUROPSYCHOL, V6, P129, DOI 10.1076/chin.6.2.129.7057; Schinka JA, 1998, PSYCHOL ASSESSMENT, V10, P171, DOI 10.1037/1040-3590.10.2.171; Sheslow D., 2003, WIDE RANGE ASSESSMEN, V2nd; Sowell ER, 2001, J INT NEUROPSYCH SOC, V7, P312, DOI 10.1017/S135561770173305X; Verger K, 2001, BRAIN INJURY, V15, P211; Wechsler D., 1991, WECHSLER INTELLIGENC; White DA, 2001, NEUROPSYCHOLOGY, V15, P221, DOI 10.1037/0894-4105.15.2.221; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925; Williams J, 2001, CHILD NEUROPSYCHOL, V7, P15, DOI 10.1076/chin.7.1.15.3148; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	43	25	25	0	1	LAWRENCE ERLBAUM ASSOC INC	MAHWAH	10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA	8756-5641			DEV NEUROPSYCHOL	Dev. Neuropsychol.		2006	30	3					865	883		10.1207/s15326942dn3003_6			19	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	113OM	WOS:000242607200006	17083297				2021-06-18	
J	Kennedy, RE; Livingston, L; Riddick, A; Marwitz, JH; Kreutzer, JS; Zasler, ND				Kennedy, RE; Livingston, L; Riddick, A; Marwitz, JH; Kreutzer, JS; Zasler, ND			Evaluation of the neurobehavioral functioning inventory as a depression screening tool after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						depression; screening; structured interview; traumatic brain injury	PSYCHIATRIC-DISORDERS; NATIONAL-INSTITUTE; MAJOR DEPRESSION; INDIVIDUALS; PREVALENCE; DISABILITY; AWARENESS; ADULTS	Objective: To examine the utility of the Neurobehavioral Functioning Inventory (NFI) for diagnosing depression in a rehabilitation setting. Design: In a prospective study, a structured clinical interview (Structured Clinical Interview for DSM-IV-TR) was used to identify DSM-IV-defiried major depressive disorder (MDD) symptoms among patients with traumatic brain injury (TBI). NFI Depression scale items were compared with DSM-IV diagnosis obtained by the Structured Clinical Interview for DSM-IV Axis I Disorders. Setting: Outpatient neuropsychology clinic at a university hospital, private outpatient physical medicine and rehabilitation clinic, and a long-term specialized living assistance program. Participants: Participants consisted of 78 patients with TBI who were at least 3 months postinjury and 18 years of age or older. Main Outcome Measures: Structured Clinical Interview for DSM-IV Axis I Disorders and the NFI. Results: Psychiatric diagnostic interview with the Structured Clinical Interview for DSM-IV Axis I Disorders indicated that 50% of patients with TBI in our sample had at least one of the following in their lifetime: MDD, MDD due to general medical condition, dysthymia, or adjustment disorder with depressed mood. Thirty percent met diagnostic criteria for current MDD with or without general medical condition. Analyses of the NFI items revealed that individuals with depression endorsed greater levels of problems than did those without depression on 14 of the 32 items related to the DSM-IV symptom domains for depression (P < .00156 with Bonferroni correction). In predicting the diagnosis of depression using individual NFI items, the classification rate based on the Random Forests estimate was 83%. Conclusion: Findings indicate that the NFI items differentiated between depressed and non-depressed patients with TBI. Imposing minimal burden on patients and staff, the NFI appears to have good predictive value in diagnosing major depression. In clinical practice and research, the NFI is a potentially valuable screening tool for identifying major depression in persons with TBI.	Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA	Kennedy, RE (corresponding author), Virginia Commonwealth Univ, Dept Psychiat, Box 980032, Richmond, VA 23298 USA.	rkennedy@vcu.edu					Al-Adawi S, 2004, J NEUROPSYCH CLIN N, V16, P435, DOI 10.1176/appi.neuropsych.16.4.435; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Babin PR, 2003, BRAIN INJURY, V17, P889, DOI 10.1080/0269905031000088595; Beck A. T., 1993, BECK DEPRESSION INVE; Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324; Deb S, 1999, AM J PSYCHIAT, V156, P374; Derogatis L R, 1974, Mod Probl Pharmacopsychiatry, V7, P79; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Evans CC, 2005, J HEAD TRAUMA REHAB, V20, P488, DOI 10.1097/00001199-200511000-00002; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDOROFF JP, 1991, AM J PSYCHIAT, V148, P1172; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; First M.B., 1996, STRUCTURED CLIN INTE; FIRST MB, BACKGROUND ARTICLES; FIRST MB, SCID FREQUENTLY ASKE; Gasquoine PG, 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187]; Gaynes BN, 2004, ANN INTERN MED, V140, P822, DOI 10.7326/0003-4819-140-10-200405180-00015; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; KATHOL RG, 1990, AM J PSYCHIAT, V147, P1021; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kreutzer JS., 1999, NEUROBEHAVIORAL FUNC; LEWIS G, 1992, PSYCHOL MED, V22, P465, DOI 10.1017/S0033291700030415; MCDANIEL JS, 2000, PSYCHIAT CARE MED PA, P149; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Sartorius N, 1974, MEASUREMENT CLASSIFI; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Silberstein Morry, 2002, Neurosurg Focus, V13, pecp2, DOI 10.3171/foc.2002.13.1.6; Skodol A, 2000, HDB PSYCHIAT MEASURE, P45; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; TEASDALE G, 1974, LANCET, V2, P81; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Wallace CA, 2000, BRAIN INJURY, V14, P549; World Health Organization, 1993, COMP INT DIAGN INT V; 2004, RANDOM FOREST BREIMA; 2004, R LANGUAGE ENV STAT	46	25	27	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2005	20	6					512	526		10.1097/00001199-200511000-00004			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	986YF	WOS:000233484900004	16304488				2021-06-18	
J	Aboy, M; Marquez, OW; McNames, J; Hornero, R; Trong, T; Goldstein, B				Aboy, M; Marquez, OW; McNames, J; Hornero, R; Trong, T; Goldstein, B			Adaptive modeling and spectral estimation of nonstationary biomedical signals based on Kalman filtering	IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING			English	Article						intracranial pressure; Kalman filter; linear models; spectral estimation; traumatic brain injury		We describe an algorithm to estimate the instantaneous power spectral density (PSD) of nonstationary signals. The algorithm is based on a dual Kalman filter that adaptively generates an estimate of the autoregressive model parameters at each time instant. The algorithm exhibits superior PSD tracking performance in nonstationary signals than classical nonparametric methodologies, and does not assume local stationarity of the data. Furthermore, it provides better time-frequency resolution, and is robust to model mismatches. We demonstrate its usefulness by a sample application involving PSD estimation of intracranial pressure signals (ICP) from patients with traumatic brain injury (TBI).	Oregon Inst Technol, Dept Elect Engn Technol, Portland, OR 97201 USA; Portland State Univ, Dept Elect & Comp Engn, Biomed Signal Proc Lab, Portland, OR 97201 USA; Univ Vigo, Signal Theory & Commun Dept, ETSI Telecomun, Vigo, Spain; Portland State Univ, Portland, OR 97201 USA; Univ Valladolid, Dept Signal Theory & Commun, ETSI Telecomunicac, Valladolid 47011, Spain; Oregon Hlth & Sci Univ, Dept Biomed Engn, OGI Sch Sci & Engn, Portland, OR 97206 USA; Oregon Hlth & Sci Univ, Dept Pediat, Complex Syst Lab, Portland, OR 97201 USA	Aboy, M (corresponding author), Oregon Inst Technol, Dept Elect Engn Technol, Portland, OR 97201 USA.	mateoaboy@ieee.org	Hornero, Roberto/B-5398-2008; Aboy, Mateo/K-4060-2019; Hornero, Roberto/M-5313-2019	Hornero, Roberto/0000-0001-9915-2570; Hornero, Roberto/0000-0001-9915-2570; Aboy, Mateo/0000-0002-5168-4321			BARTLETT MS, 1948, NATURE, V161, P686, DOI 10.1038/161686a0; BURG JP, 1975, THESIS STANFORD U ST; Gelb A., 1974, APPL OPTIMAL ESTIMAT; Grewal M.S., 2001, KALMAN FILTERING THE; Kailath T, 2000, PR H INF SY, pXIX; Kalman RE., 1960, J BASIC ENG, V82, P35, DOI 10.1115/1.3662552; Kay S. M., 1988, MODERN SPECTRAL ESTI; Manolakis D. G., 2000, STAT ADAPTIVE SIGNAL; NELSON AT, 1998, P IEEE INT JOINT C N, V3, P2489; Tukey, 1958, MEASUREMENT POWER SP; Wan EA, 1998, INT CONF ACOUST SPEE, P381, DOI 10.1109/ICASSP.1998.674447; Wan EA, 1997, NEURAL NETWORKS FOR SIGNAL PROCESSING VII, P466, DOI 10.1109/NNSP.1997.622428; WELCH P, 1967, IEEE T AUDIO ELECTOA, V12, P70	13	25	27	0	4	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9294	1558-2531		IEEE T BIO-MED ENG	IEEE Trans. Biomed. Eng.	AUG	2005	52	8					1485	1489		10.1109/TBME.2005.851465			5	Engineering, Biomedical	Engineering	946DW	WOS:000230553500014	16119245				2021-06-18	
J	Spitznagel, MB; Tremont, G				Spitznagel, MB; Tremont, G			Cognitive reserve and anosognosia in questionable and mild dementia	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						cognitive reserve; anosognosia; dementia	MINI-MENTAL-STATE; CLOSED-HEAD INJURY; ALZHEIMERS-DISEASE; MEMORY DECLINE; EDUCATION; AWARENESS; DEFICIT; PERFORMANCE; OCCUPATION	Cognitive reserve (CR) theory posits that the clinical presentation of individuals with the same brain disease varies based upon premorbid variables (e.g., education, occupation, reading ability). Anosognosia (decreased insight regarding one's deficits) is common in dementia and has implications for safety, treatment, and caregiver burden. The current study examined the role of CR in anosognosia in individuals with mild dementia. Participants were individuals diagnosed with questionable or mild dementia (Clinical Dementia Rating 0.5 or 1) after neuropsychological evaluation. Anosognosia was measured by informant-patient discrepancy on the Cognitive Difficulties Scale. High and Low CR groups were created based upon reading performance. Low CR showed greater anosognosia than High CR. Anosognosia was associated with reduced reading performance, even after controlling for global cognitive decline. These findings suggest CR is related to anosognosia in questionable and mild dementia, and have clinical implications for the assessment of awareness in dementia. (c) 2004 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Brown Med Sch, Providence, RI USA; Rhode Isl Hosp, Neuropsychol Program, Providence, RI 02903 USA	Tremont, G (corresponding author), Brown Med Sch, Providence, RI USA.	gtremont@lifespan.org					Alexander GE, 1997, AM J PSYCHIAT, V154, P165; Arkin S, 2001, Am J Alzheimers Dis Other Demen, V16, P211, DOI 10.1177/153331750101600401; Backman L, 1998, SCAND J PSYCHOL, V39, P131, DOI 10.1111/1467-9450.393067; Bland RC, 2001, CAN J PSYCHIAT, V46, P506, DOI 10.1177/070674370104600604; Bowler JV, 1998, J NEUROL NEUROSUR PS, V65, P184, DOI 10.1136/jnnp.65.2.184; COBB JL, 1995, NEUROLOGY, V45, P1707, DOI 10.1212/WNL.45.9.1707; Cotrell V, 1999, ALZ DIS ASSOC DIS, V13, P151, DOI 10.1097/00002093-199907000-00007; Derouesne C, 1999, INT J GERIATR PSYCH, V14, P1019, DOI 10.1002/(SICI)1099-1166(199912)14:12<1019::AID-GPS61>3.0.CO;2-F; Farmer JE, 2002, DEV NEUROPSYCHOL, V22, P455, DOI 10.1207/S15326942DN2202_2; Fioravanti M, 2001, ARCH GERONTOL GERIAT, P127; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gass CS, 1997, J CLIN EXP NEUROPSYC, V19, P290, DOI 10.1080/01688639708403858; Glatt SL, 1996, NEUROEPIDEMIOLOGY, V15, P20, DOI 10.1159/000109885; Jastak S, 1984, WIDE RANGE ACHIEVEME; Johnstone B, 1996, ARCH CLIN NEUROPSYCH, V11, P513, DOI 10.1016/0887-6177(96)82330-4; Lamar M, 2002, J NEUROPSYCH CLIN N, V14, P430, DOI 10.1176/appi.neuropsych.14.4.430; Legendre SA, 2003, J NEUROPSYCH CLIN N, V15, P333, DOI 10.1176/jnp.15.3.333; Manly JJ, 2003, J CLIN EXP NEUROPSYC, V25, P680, DOI 10.1076/jcen.25.5.680.14579; McNair DM, 1984, ASSESSMENT GERIATRIC; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Qiu CX, 2001, ARCH NEUROL-CHICAGO, V58, P2034, DOI 10.1001/archneur.58.12.2034; Richards M, 2003, J CLIN EXP NEUROPSYC, V25, P614, DOI 10.1076/jcen.25.5.614.14581; ROCCA WA, 1990, NEUROLOGY, V40, P626, DOI 10.1212/WNL.40.4.626; Ropacki MT, 2003, ARCH CLIN NEUROPSYCH, V18, P643, DOI 10.1016/S0887-6177(02)00153-1; Sanchez JL, 2002, NEUROPSY NEUROPSY BE, V15, P113, DOI 10.1097/01.WNN.0000016331.45409.7A; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Sawrie SM, 2000, EPILEPSY BEHAV, V1, P106, DOI 10.1006/ebeh.2000.0042; Seltzer B, 1997, GERONTOLOGIST, V37, P20, DOI 10.1093/geront/37.1.20; Seltzer B, 2001, NEUROPSY NEUROPSY BE, V14, P122; Seltzer B, 1995, J CLIN GEROPSYCHOL, V1, P79; Stern RA, 1996, ARCH NEUROL-CHICAGO, V53, P148, DOI 10.1001/archneur.1996.00550020052015; STERN Y, 1995, NEUROLOGY, V45, P55, DOI 10.1212/WNL.45.1.55; STERN Y, 1992, ANN NEUROL, V32, P371, DOI 10.1002/ana.410320311; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Stern Y, 1999, NEUROLOGY, V53, P1942, DOI 10.1212/WNL.53.9.1942; TENG EL, 1987, J CONSULT CLIN PSYCH, V55, P96, DOI 10.1037/0022-006X.55.1.96; van Exel E, 2001, J NEUROL NEUROSUR PS, V71, P29, DOI 10.1136/jnnp.71.1.29; Veenman M. V. J., 1993, INTELLECTUAL ABILITY; Veenman MVJ, 1997, LEARN INSTR, V7, P187, DOI 10.1016/S0959-4752(96)00025-4; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME; Wilson RS, 2000, ARCH NEUROL-CHICAGO, V57, P1718, DOI 10.1001/archneur.57.12.1718; Zanetti O, 1999, J GERONTOL B-PSYCHOL, V54, pP100, DOI 10.1093/geronb/54B.2.P100	42	25	26	1	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUN	2005	20	4					505	515		10.1016/j.acn.2004.11.003			11	Psychology, Clinical; Psychology	Psychology	934DK	WOS:000229686900008	15896563	Bronze			2021-06-18	
J	Stapp, JM; Sjoelund, V; Lassiter, HA; Feldhoff, RC; Feldhoff, PW				Stapp, JM; Sjoelund, V; Lassiter, HA; Feldhoff, RC; Feldhoff, PW			Recombinant rat IL-1 beta and IL-6 synergistically enhance C3 mRNA levels and complement component C3 secretion by H-35 rat hepatoma cells	CYTOKINE			English	Article						complement 3; cytokines; H-35 hepatoma cells; interleukins; rats	TRAUMATIC BRAIN INJURY; LIVER EPITHELIAL-CELLS; ACUTE-PHASE RESPONSE; NEONATAL-RATS; RECEPTOR ANTAGONIST; NECROSIS-FACTOR; GROWTH-FACTOR; TNF-ALPHA; CYTOKINE; INTERLEUKIN-6	Hepatic synthesis of complement component C3 is regulated in part by inflammatory cytokines. Rat models are frequently employed to investigate pathogenic roles of complement and cytokines. However, cytokines obtained from species other than the rat were used in previous studies of cytokine regulation of C3 synthesis in rat hepatocytes or hepatoma cells. It is not known whether these prior reports predict hepatocellular responses evoked by rat cytokines. Therefore, H-35 rat hepatoma cells were employed to measure the effect of recombinant rat IL-1 beta, IL-6, IFN-gamma, and TNF-alpha on C3 protein secretion and C3 mRNA levels quantified by ELISA and quantitative RT-PCR. Compared to untreated control cells, H-35 cells treated with IL-1 beta, IL-6, and IFN-gamma increased C3 secretion approximately 10-, 4-, and 2-fold, respectively. TNF-alpha was toxic, precluding further analysis. IL-1 beta and IL-6 demonstrated synergy with respect to the quantity and rate of increase of C3 mRNA measured and the magnitude of C3 protein secretion. Previous reports using non-rat cytokines did not consistently predict H-35 responses to rat cytokines. Consequently, we recommend the use of rat cytokines in rat models that include analysis of cytokine-mediated events. (c) 2005 Elsevier Ltd. All rights reserved.	Univ Louisville, Dept Pediat, Div Neonatal Med, Sch Med, Louisville, KY 40202 USA; Univ Louisville, Sch Med, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; Univ Louisville, Sch Med, Kosair Childrens Hosp Res Inst, Louisville, KY 40202 USA	Lassiter, HA (corresponding author), Univ Louisville, Dept Pediat, Div Neonatal Med, Sch Med, 571 S Floyd St,Suite 300, Louisville, KY 40202 USA.	hal.lassiter@louisville.edu	Sjoelund, Virginie/E-8432-2012; Sjoelund, Virginie/T-9266-2019	Sjoelund, Virginie/0000-0002-7929-5950			Akita N, 2003, NEUROSURGERY, V52, P395, DOI 10.1227/01.NEU.0000043710.61233.B4; ALPER CA, 1969, SCIENCE, V163, P286, DOI 10.1126/science.163.3864.286; Andrews E, 2003, CYTOKINE, V23, P164, DOI 10.1016/S1043-4666(03)00219-9; ANTHONY R, 1989, EUR J IMMUNOL, V19, P1405, DOI 10.1002/eji.1830190809; BAUMANN H, 1993, J IMMUNOL, V151, P4248; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; CHAVEZCARTAYA RE, 1995, TRANSPLANTATION, V59, P1047, DOI 10.1097/00007890-199504150-00023; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; COEL FS, 1988, COMPLEMENT SYSTEM, P44; COLTEN HR, 1998, HUMAN COMPLEMENT SYS, P217; Cowell RM, 2003, J NEUROSCI, V23, P9459; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; FALUS A, 1990, MOL IMMUNOL, V27, P197, DOI 10.1016/0161-5890(90)90115-G; FALUS A, 1990, IMMUNOL LETT, V24, P227, DOI 10.1016/0165-2478(90)90001-7; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Guiguet M, 1997, ANAL BIOCHEM, V247, P441, DOI 10.1006/abio.1997.2101; Imm MD, 2002, NEUROSCI LETT, V325, P175, DOI 10.1016/S0304-3940(02)00271-9; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; KOJ A, 1995, INT J BIOCHEM CELL B, V27, P39, DOI 10.1016/1357-2725(94)00058-1; Lassiter HA, 1997, PEDIATR RES, V42, P128, DOI 10.1203/00006450-199707000-00020; LASSITER HA, 2000, HEMATOLOGIC PROBLEMS, P343; Ling YL, 2001, WORLD J GASTROENTERO, V7, P667; LININGTON C, 1989, BRAIN, V112, P895, DOI 10.1093/brain/112.4.895; Mead RJ, 2002, J IMMUNOL, V168, P458, DOI 10.4049/jimmunol.168.1.458; Meistrell ME, 1997, SHOCK, V8, P341; Mizuno M, 2000, CLIN EXP IMMUNOL, V119, P368; Nicola N., 1994, GUIDEBOOK CYTOKINES; PERLMUTTER DH, 1988, INFLAMMATION BASIC P, P75; Platel D, 1996, CYTOKINE, V8, P895, DOI 10.1006/cyto.1996.0120; PLATEL D, 1994, EUR CYTOKINE NETW, V5, P405; Silverstein FS, 1997, NEUROCHEM INT, V30, P375, DOI 10.1016/S0197-0186(96)00072-1; Stammberger U, 2000, J THORAC CARDIOV SUR, V120, P1078, DOI 10.1067/mtc.2000.111175; Suffredini AF, 1999, J CLIN IMMUNOL, V19, P203, DOI 10.1023/A:1020563913045; TETI G, 1993, INFECT IMMUN, V61, P227, DOI 10.1128/IAI.61.1.227-235.1993; Vakeva AP, 1998, CIRCULATION, V97, P2259, DOI 10.1161/01.CIR.97.22.2259; Wright MS, 2001, IMMUNOL LETT, V76, P119, DOI 10.1016/S0165-2478(01)00180-8; Xi GH, 2001, STROKE, V32, P162, DOI 10.1161/01.STR.32.1.162	38	25	25	0	1	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	1043-4666	1096-0023		CYTOKINE	Cytokine	APR 21	2005	30	2					78	85		10.1016/j.cyto.2004.12.007			8	Biochemistry & Molecular Biology; Cell Biology; Immunology	Biochemistry & Molecular Biology; Cell Biology; Immunology	917TJ	WOS:000228491800005	15804599				2021-06-18	
J	Edouard, AR; Vanhille, E; Le Moigno, S; Benhamou, D; Mazoit, JX				Edouard, AR; Vanhille, E; Le Moigno, S; Benhamou, D; Mazoit, JX			Non-invasive assessment of cerebral perfusion pressure in brain injured patients with moderate intracranial hypertension	BRITISH JOURNAL OF ANAESTHESIA			English	Article						brain, cerebral perfusion pressure; brain, intracranial pressure; complications, traumatic brain injury; monitoring, jugular venous oxygen saturation; monitoring, transcranial Doppler ultrasonography	CRITICAL CLOSING PRESSURE; ZERO-FLOW PRESSURE; TRANSCRANIAL DOPPLER; HEAD-INJURY; CIRCULATION; ARTERIES; THERAPY; INSULTS	Background. A non-invasive estimation of cerebral perfusion pressure (CPP) using transcranial Doppler sonography was assessed in brain-injured patients by comparing conventional measurements of CPP (difference between mean arterial pressure and intracranial pressure) (CPPm) with the difference between AP(mean) and the critical closing pressure of the cerebral circulation (CPPe). Methods. Twenty adults with bilateral and diffuse brain injuries were included in the study. CPPe was estimated using a formula combining the phasic values of flow velocities and arterial pressure. In group A (n=10) the comparison was repeatedly performed under stable conditions. In group B (n=10) the comparison was performed during a CO2 reactivity test. Covariance analysis was used to assess the relationships. Results. In group A, CPPe and CPPm were correlated (slope, 0.76; intercept, +10.9; 95% CI, -3.5 to +25.4). During the increase in intracranial pressure (group B) (+1.9 (sd 1.5) mm Hg per mm Hg of Pe'(co2)) the relationship persisted (slope, 0.55; intercept, +32.6; 95% CI, +16.3 to +48.9) but the discrepancy between the two variables increased as reflected by the increase in bias and variability. Conclusion. Non-invasive estimation of CPP can be used for brain monitoring of head-injured patients, but the accuracy of the method may depend on the level of intracranial hypertension.	Hop Bicetre, Serv Anesthesie Reanimat, F-94725 Le Kremlin Bicetre, France; Hop Bicetre, UPRES EA 3540, F-94725 Le Kremlin Bicetre, France	Edouard, AR (corresponding author), Hop Bicetre, Serv Anesthesie Reanimat, F-94725 Le Kremlin Bicetre, France.	alain.edouard@bct.ap-hop-paris.fr					Belfort MA, 2000, HYPERTENS PREGNANCY, V19, P331, DOI 10.1081/PRG-100101995; Belfort MA, 1999, AM J OBSTET GYNECOL, V181, P402, DOI 10.1016/S0002-9378(99)70569-7; Benmalek F, 1999, INTENS CARE MED, V25, P399, DOI 10.1007/s001340050865; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Buhre W, 2003, BRIT J ANAESTH, V90, P291, DOI 10.1093/bja/aeg073; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CHAN KH, 1993, NEUROSURGERY, V32, P547; CHESNUT RM, 1997, J TRAUMA S, V42, P4; CIVIL ID, 1988, J TRAUMA, V28, P87, DOI 10.1097/00005373-198801000-00012; CLARK WC, 1989, NEUROSURGERY, V25, P20; Czosnyka M, 1999, J NEUROL NEUROSUR PS, V66, P606, DOI 10.1136/jnnp.66.5.606; De Deyne C S, 2001, Curr Opin Anaesthesiol, V14, P475, DOI 10.1097/00001503-200110000-00003; EVANS DH, 1988, ULTRASOUND MED BIOL, V14, P103, DOI 10.1016/0301-5629(88)90176-7; FESSLER RD, 1993, ANN EMERG MED, V22, P998, DOI 10.1016/S0196-0644(05)82741-6; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Hancock SM, 2003, ANESTH ANALG, V96, P847, DOI 10.1213/01.ANE.0000047273.85729.A7; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Kaups KL, 1998, J TRAUMA, V45, P884, DOI 10.1097/00005373-199811000-00007; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Lewis SB, 2001, NEUROSURGERY, V48, P369, DOI 10.1097/00006123-200102000-00026; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; May AK, 1997, AM SURGEON, V63, P233; Michel E, 1997, J CEREBR BLOOD F MET, V17, P1127, DOI 10.1097/00004647-199710000-00015; PINHEIRO J, 2001, MIXED EFFECTS MODELS, P30; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rosner MJ, 1996, CRIT CARE MED, V24, P1274, DOI 10.1097/00003246-199607000-00040; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Schmidt EA, 2000, ACT NEUR S, V76, P451; *SFAR, 1997, ANN FR ANESTH, V18, P1; Sherman RW, 2002, BRIT J ANAESTH, V89, P687, DOI 10.1093/bja/aef247; Thees C, 2002, ANESTHESIOLOGY, V96, P595, DOI 10.1097/00000542-200203000-00014; Weyland A, 2000, J NEUROSURG ANESTH, V12, P210, DOI 10.1097/00008506-200007000-00002; 2000, J NEUROTRAUMA, V17, P479	34	25	29	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	FEB	2005	94	2					216	221		10.1093/bja/aei034			6	Anesthesiology	Anesthesiology	885WR	WOS:000226188500014	15591334	Bronze			2021-06-18	
J	Mattiasson, G				Mattiasson, G			Analysis of mitochondrial generation and release of reactive oxygen species	CYTOMETRY PART A			English	Article						mitochondria; reactive oxygen species; cell death; second-messenger systems; flow cytometry; oxidation reduction; neurodegenerative diseases; oxidative stress	FLOW-CYTOMETRIC ANALYSIS; TRAUMATIC BRAIN-INJURY; HYDROGEN-PEROXIDE; PERMEABILITY TRANSITION; OXIDATIVE STRESS; UNCOUPLING PROTEIN-2; SUPEROXIDE ANION; HEART-MITOCHONDRIA; REDOX REGULATION; NEURONAL DEATH	Background: Reactive oxygen species (ROS) are mainly produced in mitochondria and are important contributors to many forms of cell death. ROS also function as second messengers within the cell and may constitute a signaling pathway from mitochondria to the cytoplasm and nucleus. The aim of the present study was to develop a protocol to detect changes in intra- and extramitochondrial releases of ROS, which could be used to analyze the role of mitochondria in cell signaling and cell death. Methods: Fluorescence-based assays were used to measure (a) total production of ROS, (b) intramitochondrial ROS, (c) extramitochondrial hydrogen peroxide, and (d) superoxide outside inverted (inside-out) submitochondrial particles. ROS generation in the samples was increased or decreased by the addition of different substrates, enzymes, and inhibitors of the electron transport chain. Results: The individual assays used were sensitive to increased (e.g., after addition of antimycin A; increased signal) and decreased (ROS scavenging; decreased signal) levels of ROS. In combination, the assays provided information about mitochondrial ROS generation and release dynamics from small samples of isolated mitochondria. Conclusions: The combination of fluorescent techniques described is a useful tool to study the role of ROS in cell death and in cellular redox signaling. (C) 2004 Wiley-Liss, Inc.	Lund Univ, Expt Brain Res Lab, Wallenberg Neurosci Ctr, SE-22184 Lund, Sweden	Mattiasson, G (corresponding author), Lund Univ, Expt Brain Res Lab, Wallenberg Neurosci Ctr, BMC A13, SE-22184 Lund, Sweden.						Anderson MF, 2004, NEUROSCI LETT, V354, P163, DOI 10.1016/j.neulet.2003.09.067; Anderson MF, 2000, BRAIN RES PROTOC, V5, P95, DOI 10.1016/S1385-299X(99)00060-4; Arnaiz SL, 1999, NITRIC OXIDE-BIOL CH, V3, P235, DOI 10.1006/niox.1999.0229; BECKMAN JS, 1994, ANN NY ACAD SCI, V738, P69; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; Bergamini CM, 2004, CURR PHARM DESIGN, V10, P1611, DOI 10.2174/1381612043384664; Bindokas VP, 1996, J NEUROSCI, V16, P1324; BOVERIS A, 1984, METHOD ENZYMOL, V105, P429; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CHANCE B, 1979, PHYSIOL REV, V59, P527; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Friberg H, 2002, NEUROSCI LETT, V334, P111, DOI 10.1016/S0304-3940(02)01116-3; FRIDOVICH I, 1986, ARCH BIOCHEM BIOPHYS, V247, P1, DOI 10.1016/0003-9861(86)90526-6; Gardner AM, 1997, FREE RADICAL BIO MED, V22, P73, DOI 10.1016/S0891-5849(96)00235-3; Gunter TE, 2004, J NEUROCHEM, V88, P266, DOI 10.1046/j.1471-4159.2003.02122.x; Hampton MB, 1998, ANN NY ACAD SCI, V854, P328, DOI 10.1111/j.1749-6632.1998.tb09913.x; Han D, 2003, J BIOL CHEM, V278, P5557, DOI 10.1074/jbc.M210269200; Han MJ, 2003, MOL CELLS, V15, P94; Hansson MJ, 2004, J NEUROCHEM, V89, P715, DOI 10.1111/j.1471-4159.2004.02400.x; Hansson MJ, 2003, BRAIN RES, V960, P99, DOI 10.1016/S0006-8993(02)03798-8; KONTOS HA, 1985, CIRC RES, V57, P142, DOI 10.1161/01.RES.57.1.142; Kowaltowski AJ, 1998, ARCH BIOCHEM BIOPHYS, V359, P77, DOI 10.1006/abbi.1998.0870; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; Kroemer G, 2003, BIOCHEM BIOPH RES CO, V304, P433, DOI 10.1016/S0006-291X(03)00614-4; Kudin AP, 2004, J BIOL CHEM, V279, P4127, DOI 10.1074/jbc.M310341200; Kwong LK, 1998, ARCH BIOCHEM BIOPHYS, V350, P118, DOI 10.1006/abbi.1997.0489; Lenaz G, 2001, IUBMB LIFE, V52, P159, DOI 10.1080/15216540152845957; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Lifshitz J, 2003, J NEUROTRAUM, V20, P139, DOI 10.1089/08977150360547062; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Mattiasson G, 2004, CYTOM PART A, V60A, P145, DOI 10.1002/cyto.a.20024; Mattiasson G, 2003, J NEUROCHEM, V87, P532, DOI 10.1046/j.1471-4159.2003.02026.x; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200; Rego AC, 2003, NEUROCHEM RES, V28, P1563, DOI 10.1023/A:1025682611389; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; WHISLER RL, 1995, ARCH BIOCHEM BIOPHYS, V319, P23, DOI 10.1006/abbi.1995.1263	49	25	29	0	4	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0196-4763			CYTOM PART A	Cytom. Part A	DEC	2004	62A	2					89	96		10.1002/cyto.a.20089			8	Biochemical Research Methods; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	878HB	WOS:000225636300003	15517564				2021-06-18	
J	Lachapelle, J; Ouimet, C; Bach, M; Ptito, A; McKerral, M				Lachapelle, J; Ouimet, C; Bach, M; Ptito, A; McKerral, M			Texture segregation in traumatic brain injury - a VEP study	VISION RESEARCH			English	Article						texture segregation; visual evoked potentials; traumatic brain injury; motion; orientation	VISUAL-EVOKED POTENTIALS; HEAD-INJURY; PERCEPTION; MOTION; MILD; ORIENTATION; CORTEX; VISION	Visual evoked potentials (VEPs) were recorded to textures segregated by gradients in orientation or motion. Recordings were obtained in traumatic brain-injured (TBI) subjects and in normal controls. We analyzed both the low-level VEPs (llVEPs) evoked by homogenous stimuli, as well as the components associated with texture segregation (tsVEP) obtained through an appropriate linear combination. Our results suggest that the tsVEP, presumably higher tip in the visual processing chain than the llVEP, is sensitive to TBI and can reveal further information as to the nature of possible information processing deficits after TBI. It could also help quantify cortical damage that is not revealed with more standard clinical tools. (C) 2004 Elsevier Ltd. All rights reserved.	Site Ctr Readaptat Lucie Bruneau, Ctr Rech Interdisciplinaire Readaptat, Montreal, PQ H2H 2N8, Canada; McGill Univ, Dept Neurol Neurosurg, Montreal, PQ H3A 2T5, Canada; Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; Univ Freiburg, Augenklin, Elektrophysiol Lab, D-7800 Freiburg, Germany	McKerral, M (corresponding author), Site Ctr Readaptat Lucie Bruneau, Ctr Rech Interdisciplinaire Readaptat, 2275 Laurier Ave E, Montreal, PQ H2H 2N8, Canada.	mmckerral@videotron.ca	Bach, Michael/A-6637-2010	Bach, Michael/0000-0003-2028-535X	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [42843] Funding Source: Medline		BACH M, 1990, Investigative Ophthalmology and Visual Science, V31, P104; Bach M, 2000, VISION RES, V40, P3559, DOI 10.1016/S0042-6989(00)00195-4; Bach M, 1997, VISION RES, V37, P1409, DOI 10.1016/S0042-6989(96)00322-7; BACH M, 1992, VISION RES, V32, P417, DOI 10.1016/0042-6989(92)90233-9; BACH M, 2000, EP2000 FREIBURG EVOK; BACH M, 2001, 39 INT SOC CLIN EL V; Bertone A, 2003, J COGNITIVE NEUROSCI, V15, P218, DOI 10.1162/089892903321208150; Cohen A H, 1992, J Am Optom Assoc, V63, P530; FRACO RF, 1989, BRIT J OPTOMETRY, V46, P40; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gaetz M, 2001, J HEAD TRAUMA REHAB, V16, P386, DOI 10.1097/00001199-200108000-00008; GIANUTSOS R, 1988, ARCH PHYS MED REHAB, V69, P573; Habak C, 2000, VISION RES, V40, P943, DOI 10.1016/S0042-6989(99)00235-7; Harding GFA, 1996, VISION RES, V36, P3567, DOI 10.1016/0042-6989(96)00125-3; JULESZ B, 1983, BELL SYST TECH J, V62, P1619, DOI 10.1002/j.1538-7305.1983.tb03502.x; Kandil FI, 2003, EUR J NEUROSCI, V18, P2874, DOI 10.1111/j.1460-9568.2003.03022.x; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; LACHAPELLE J, 2002, T ANN ASS RES VISION; LAMME VAF, 1992, VISION RES, V32, P797, DOI 10.1016/0042-6989(92)90022-B; LAMME VAF, 1993, VISUAL NEUROSCI, V10, P781, DOI 10.1017/S0952523800006039; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Marion DW, 1998, NEUROL CLIN, V16, P485, DOI 10.1016/S0733-8619(05)70073-6; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PADULA WV, 1994, BRAIN INJURY, V8, P125, DOI 10.3109/02699059409150964; PAPATHANASOPOULOS P, 1994, EUR NEUROL, V34, P268, DOI 10.1159/000117054; Regan D., 1989, HUMAN BRAIN ELECTROP; RIZZO PA, 1983, NEUROPSYCHOBIOLOGY, V9, P78, DOI 10.1159/000117941; Uzzell B P, 1990, Adv Neurol, V52, P269; Vaina LM, 1996, P ROY SOC B-BIOL SCI, V263, P1225, DOI 10.1098/rspb.1996.0180; Walsh K. W., 1985, UNDERSTANDING BRAIN; WERNER RA, 1991, ARCH PHYS MED REHAB, V72, P31	31	25	25	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0042-6989	1878-5646		VISION RES	Vision Res.	NOV	2004	44	24					2835	2842		10.1016/j.visres.2004.06.007			8	Neurosciences; Ophthalmology; Psychology	Neurosciences & Neurology; Ophthalmology; Psychology	856LL	WOS:000224046600009	15342227	Bronze			2021-06-18	
J	Sheibani, N; Grabowski, EF; Schoenfeld, DA; Whalen, MJ				Sheibani, N; Grabowski, EF; Schoenfeld, DA; Whalen, MJ			Effect of granulocyte colony-stimulating factor on functional and histoplathologic outcome after traumatic brain injury in mice	CRITICAL CARE MEDICINE			English	Article						brain injury; mice; granulocyte colony-stimulating factor; inflammation; Morris water maze; growth factors	INTERLEUKIN-1 RECEPTOR ANTAGONIST; ACUTE INFLAMMATORY RESPONSE; SEVERE HEAD-INJURIES; CEREBRAL BLOOD-FLOW; BARRIER PERMEABILITY; MILD HYPOTHERMIA; ERYTHROPOIETIN; RATS; ISCHEMIA; INFECTIONS	Objective: Granulocyte colony-stimulating factor has been used to reduce the risk of sepsis in patients with traumatic brain injury. However, granulocyte colony-stimulating factor exerts potent pro- and anti-inflammatory effects that could influence secondary injury, and outcome, after traumatic brain injury. Our objective was to determine the effect of granulocyte colony-stimulating factor on histopathologic, motor, and cognitive Design: Experimental study. Setting: Research laboratory at the Massachusetts General Hospital, Boston, MA. Subjects: Forty-eight adult male C57BI/6 mice. Interventions: Mice (8 wks of age, n = 16/group) were administered granulocyte colony-stimulating factor or saline subcutaneously twice per day for 7 days after controlled cortical impact or sham injury (n = 16). Absolute neutrophil counts, motor function, Morris water maze performance, and lesion volume were determined after controlled cortical impact or sham injury. Measurements and Main Results: At the time of controlled cortical impact, body weight, brain and body temperature, and systemic absolute neutrophil counts did not differ between groups. Compared with control, systemic absolute neutrophil count was increased more than ten-fold in granulocyte colony-stimulating factor-treated mice on posttrauma days 2 and 7 (p < .05, repeated-measures analysis of variance) but did not differ between groups by day 14. There. were no differences between groups in tests of motor function or histopathologic outcome. However, compared with control, mice given granulocyte colony-stimulating factor had improved Morris water maze performance after controlled cortical impact (p < .05, repeated-measures analysis of variance) but not sham injury. Conclusions: The data suggest a small beneficial effect of granulocyte colony-stimulating factor on functional outcome after traumatic brain injury in adult mice but do not show differences in histopathology or motor outcome between treated and control groups.	Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Hematol & Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Epidemiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Sheibani, N (corresponding author), Massachusetts Gen Hosp, 149 13th St Room 6403, Charlestown, MA 02129 USA.		Sheibani, Nader/AAG-2379-2020	Sheibani, Nader/0000-0003-2723-9217	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5K08NS41969] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS041969] Funding Source: NIH RePORTER		Aloe L, 1999, BRAIN RES, V840, P125, DOI 10.1016/S0006-8993(99)01748-5; AUBERT A, 1995, BRAIN BEHAV IMMUN, V9, P129, DOI 10.1006/brbi.1995.1013; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; GIBERTINI M, 1995, BRAIN BEHAV IMMUN, V9, P113, DOI 10.1006/brbi.1995.1012; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Hartung T, 1999, CLIN PHARMACOL THER, V66, P415, DOI 10.1053/cp.1999.v66.a101210; HARTUNG T, 1995, BLOOD, V85, P2482, DOI 10.1182/blood.V85.9.2482.bloodjournal8592482; Hartung T, 1998, Curr Opin Hematol, V5, P221, DOI 10.1097/00062752-199805000-00013; Heard SO, 1998, CRIT CARE MED, V26, P748, DOI 10.1097/00003246-199804000-00027; Heard SO, 1999, CRIT CARE MED, V27, P1019, DOI 10.1097/00003246-199905000-00051; HELLING TS, 1988, J TRAUMA, V28, P1575, DOI 10.1097/00005373-198811000-00009; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOYT DB, 1990, J TRAUMA, V30, P759, DOI 10.1097/00005373-199007000-00001; Iida R, 2000, FASEB J, V14, P1023; Ishikawa K, 1999, J TRAUMA, V46, P999, DOI 10.1097/00005373-199906000-00004; Ishikawa K, 2000, J TRAUMA, V49, P912, DOI 10.1097/00005373-200011000-00020; NEUWELT EA, 1982, J NEUROSURG, V56, P254, DOI 10.3171/jns.1982.56.2.0254; Pugh CR, 2001, NEUROSCI BIOBEHAV R, V25, P29, DOI 10.1016/S0149-7634(00)00048-8; Qiu JH, 2002, J NEUROSCI, V22, P3504; QUATTROCCHI K B, 1990, Journal of Neurotrauma, V7, P77, DOI 10.1089/neu.1990.7.77; Sadamoto Y, 1998, BIOCHEM BIOPH RES CO, V253, P26, DOI 10.1006/bbrc.1998.9748; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Schabitz WR, 2003, STROKE, V34, P745, DOI 10.1161/01.STR.0000057814.70180.17; SCHALEN W, 1992, ACTA ANAESTH SCAND, V36, P369, DOI 10.1111/j.1399-6576.1992.tb03483.x; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Six I, 2003, EUR J PHARMACOL, V458, P327, DOI 10.1016/S0014-2999(02)02785-1; Springborg JB, 2002, BRIT J PHARMACOL, V135, P823, DOI 10.1038/sj.bjp.0704521; Squadrito F, 1997, BRIT J PHARMACOL, V120, P333, DOI 10.1038/sj.bjp.0700904; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Whalen MJ, 1999, CRIT CARE MED, V27, P1014, DOI 10.1097/00003246-199905000-00049; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Whalen MJ, 2000, CRIT CARE MED, V28, P3710, DOI 10.1097/00003246-200011000-00029	37	25	26	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	NOV	2004	32	11					2274	2278		10.1097/01.CCM.0000145998.11686.ED			5	Critical Care Medicine	General & Internal Medicine	872MN	WOS:000225211400014	15640641				2021-06-18	
J	Teng, ZP; Chen, J; Chau, LY; Galunic, N; Regan, RF				Teng, ZP; Chen, J; Chau, LY; Galunic, N; Regan, RF			Adenoviral transfer of the heme oxygenase-1 gene protects striatal astrocytes from heme-mediated oxidative injury	NEUROBIOLOGY OF DISEASE			English	Article						free radical; hemoglobin; hemorrhage; iron; mouse; oxidative stress; stroke	EXPERIMENTAL INTRACEREBRAL HEMORRHAGE; TRAUMATIC BRAIN-INJURY; RAT-BRAIN; HEMOGLOBIN TOXICITY; OXIDANT STRESS; HAMSTER FIBROBLASTS; CORTICAL ASTROCYTES; TIN-PROTOPORPHYRIN; IN-VITRO; INDUCTION	Heme oxygenase-1 (HO-1) is induced in the CNS after hemorrhage, and may have an effect on injury to surrounding tissue. Hemin, the preferred substrate of HO, is a neurotoxin that is present in intracranial hematomas. In a prior study, we observed that HO inhibitors increased the vulnerability of cultured cortical astrocytes to heme-mediated oxidative injury. To investigate the effect of HO more specifically, we used an adenoviral vector encoding the human HO-1 gene to specifically increase HO-1 expression. Incubation with 100 MOI of the HO-1 adenovirus (Adv-HHO-1) for 24 h increased both HO-1 protein and HO activity; a control adenovirus lacking the HO-1 gene had no effect. Using a DNA probe that was specific for human HO-1, 80.5 +/- 7.2% of astrocytes were observed to be infected by in situ hybridization. The cell death produced by 30-60 muM hemin was significantly reduced by pretreatment with 100 MOI Adv-HHO-1, as assessed by LDH release, propidium iodide exclusion, and MTT reduction assay. The threefold increase in cell protein oxidation produced by hemin was also attenuated in cultures pretreated with Adv-HHO-1. These results support the hypothesis that HO-1 protects astrocytes from heme-mediated oxidative injury. Specifically increasing astrocytic HO-1 by gene transfer may have a beneficial effect on hemorrhagic CNS injury. (C) 2004 Elsevier Inc. All rights reserved.	Thomas Jefferson Univ, Dept Emergency Med, Philadelphia, PA 19107 USA; Acad Sinica, Inst Biochem Sci, Div Cardiovasc Res, Taipei, Taiwan	Regan, RF (corresponding author), Thomas Jefferson Univ, Dept Emergency Med, 1020 Sansom St,239 Thompson Bldg, Philadelphia, PA 19107 USA.	Raymond.Regan@jefferson.edu	Chau, Lee-Young/N-7659-2018	Chau, Lee-Young/0000-0002-6316-2328	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS042273] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042273] Funding Source: NIH RePORTER		ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; BALLA G, 1992, J BIOL CHEM, V267, P18148; Boehning D, 2003, NEURON, V40, P129, DOI 10.1016/S0896-6273(03)00596-8; Chang EF, 2003, J NEUROSCI, V23, P3689; Chen J, 2004, BIOCHEM BIOPH RES CO, V318, P88, DOI 10.1016/j.bbrc.2004.03.187; Chen K, 2000, J NEUROCHEM, V75, P304, DOI 10.1046/j.1471-4159.2000.0750304.x; daSilva JL, 1996, J LAB CLIN MED, V128, P290, DOI 10.1016/S0022-2143(96)90030-X; Dennery PA, 1997, J BIOL CHEM, V272, P14937, DOI 10.1074/jbc.272.23.14937; Dennery PA, 1998, J CLIN INVEST, V101, P1001, DOI 10.1172/JCI448; Dennery PA, 1996, AM J PHYSIOL-LUNG C, V271, pL672; Dore S, 1999, MOL MED, V5, P656, DOI 10.1007/BF03401984; Dwyer BE, 1998, J NEUROCHEM, V71, P2497; FUKUDA K, 1995, NEUROSCI LETT, V199, P127, DOI 10.1016/0304-3940(95)12042-3; Goldstein L, 2003, J NEUROSCI RES, V73, P113, DOI 10.1002/jnr.10633; GRUNDEMAR L, 1997, TRENDS PHARMACOL SCI, P18; HARRINGTON JP, 1993, INT J BIOCHEM, V25, P661, DOI 10.1016/0020-711X(93)90350-N; Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287; Iyer S, 1998, J BIOL CHEM, V273, P2692, DOI 10.1074/jbc.273.5.2692; Juan SH, 2001, CIRCULATION, V104, P1519, DOI 10.1161/hc3801.095663; Kaizu T, 2003, KIDNEY INT, V63, P1393, DOI 10.1046/j.1523-1755.2003.00882.x; KAJIKAWA H, 1979, Neurologia Medico-Chirurgica, V19, P61, DOI 10.2176/nmc.19.61; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; LETARTE PB, 1993, J NEUROSURG, V79, P252, DOI 10.3171/jns.1993.79.2.0252; LINDEN DJ, 1993, J NEUROPHYSIOL, V70, P2673; LUO D, 1994, EUR J PHARMACOL, P267; MAINES MD, 1988, FASEB J, V2, P2557; Matz P, 1996, BRAIN RES, V713, P211, DOI 10.1016/0006-8993(95)01511-6; Matz PG, 1997, NEUROSURGERY, V40, P152, DOI 10.1097/00006123-199701000-00034; Mautes AEM, 1998, BRAIN RES, V795, P17, DOI 10.1016/S0006-8993(98)00230-3; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; MEFFERT MK, 1994, NEURON, V13, P1225, DOI 10.1016/0896-6273(94)90060-4; NATH KA, 1994, J LAB CLIN MED, V123, P461; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; Nedergaard M, 2003, TRENDS NEUROSCI, V26, P523, DOI 10.1016/j.tins.2003.08.008; NUTTER LM, 1994, J LAB CLIN MED, V123, P506; Panahian N, 1999, J NEUROCHEM, V72, P1187; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Quan S, 2002, J CELL BIOCHEM, V85, P410, DOI 10.1002/jcb.10147; Regan RF, 2000, NEUROSCI LETT, V282, P1, DOI 10.1016/S0304-3940(00)00817-X; Regan RF, 2003, J NEUROTRAUM, V20, P111, DOI 10.1089/08977150360517236; Regan RF, 2002, NEUROSCIENCE, V113, P985, DOI 10.1016/S0306-4522(02)00243-9; REGAN RF, 1993, NEUROSCI LETT, V153, P219, DOI 10.1016/0304-3940(93)90326-G; Rogers B, 2003, FREE RADICAL BIO MED, V35, P872, DOI 10.1016/S0891-5849(03)00431-3; Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3; Salim M, 2001, J BIOL CHEM, V276, P10929, DOI 10.1074/jbc.M010753200; SMITH A, 1993, J BIOL CHEM, V268, P7365; STOCKER R, 1990, FREE RADICAL RES COM, V9, P101, DOI 10.3109/10715769009148577; STOCKER R, 1987, SCIENCE; Suttner DM, 1999, FASEB J, V13, P1800; Takizawa S, 1998, J CEREBR BLOOD F MET, V18, P559, DOI 10.1097/00004647-199805000-00011; TRAKSHEL GM, 1988, ARCH BIOCHEM BIOPHYS, V260, P732, DOI 10.1016/0003-9861(88)90503-6; Turner CP, 1998, J CEREBR BLOOD F MET, V18, P257, DOI 10.1097/00004647-199803000-00004; VANDEPUTTE C, 1994, CELL BIOL TOXICOL, V10, P415, DOI 10.1007/BF00755791; VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607; Wagner KR, 2000, CELL MOL BIOL, V46, P597; Weng YH, 2003, J BIOL CHEM, V278, P50999, DOI 10.1074/jbc.M307644200; Xi GH, 2002, NEUROSURG CLIN N AM, V13, P371, DOI 10.1016/S1042-3680(02)00007-4; Zager RA, 1997, KIDNEY INT, V51, P728, DOI 10.1038/ki.1997.104	58	25	26	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	NOV	2004	17	2					179	187		10.1016/j.nbd.2004.07.009			9	Neurosciences	Neurosciences & Neurology	866EV	WOS:000224757500007	15474356				2021-06-18	
J	Browne, KD; Leoni, MJ; Iwata, A; Chen, XH; Smith, DH				Browne, KD; Leoni, MJ; Iwata, A; Chen, XH; Smith, DH			Acute treatment with MgSO4 attenuates long-term hippocampal tissue loss after brain trauma in the rat	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article							D-ASPARTATE RECEPTORS; CONTROLLED CORTICAL IMPACT; HEAD-INJURY; POSTTRAUMATIC HYPOTHERMIA; COGNITIVE DYSFUNCTION; MAGNESIUM TREATMENT; UNITED-STATES; NEURON DEATH; ATROPHY; MEMORY	Previous studies have shown that magnesium salts and the noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, NPS 1506, attenuated short-term cognitive deficits and histopathological changes associated with traumatic brain injury (TBI). We evaluated the longterm effects of both therapies after brain trauma. Young adult rats were subjected to parasagittal fluid-percussion brain injury and received either MgSO4 (125 mumol/400 g rat; n = 12) 15 min post-injury, NPS 1506 (1.15 mg/kg; n = 12) 15 min and 4 hr post-injury, or vehicle (n = 9) 15 min post-injury. Uninjured animals (sham) received vehicle (n = 10). Learning function in these animals was evaluated using a water maze paradigm 8 months after injury or sham treatment, and the brains were examined for cortical and hippocampal tissue loss. Compared to sham animals, injured vehicle-treated animals displayed a substantial learning dysfunction, indicated by an increased latency to find a hidden platform in the water maze (P < 0.001). No improvements in learning, however, were found for injured animals treated with NPS 1506 or MgSO4. Injury induced >30% loss of tissue in the ipsilateral cortex in vehicle-treated animals that was not reduced in animals treated with either NPS 1506 or MgSO4. Treatment with MgSO4 significantly reduced progressive tissue loss in the hippocampus (P < 0.001). These findings are the first to demonstrate long-term neuroprotection of hippocampal tissue by an acute treatment in a TBI model. These data also show that the previously reported broad efficacy of MgSO4 or NPS 1506 observed shortly after brain trauma could not be detected 8 months post-injury. (C) 2004 Wiley-Liss, Inc.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA	Smith, DH (corresponding author), Univ Penn, Dept Neurosurg, 3320 Smith Walk,105 Hayden Hall, Philadelphia, PA 19104 USA.	smithdou@mail.med.upenn.edu	smith, douglas/A-1321-2007		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, P01NS008803, R01NS038104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K08AG021527] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG21527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38104, NS08803] Funding Source: Medline		Bareyre FM, 2000, J NEUROTRAUM, V17, P1029, DOI 10.1089/neu.2000.17.1029; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Feldman Z, 1996, J NEUROSURG, V85, P131, DOI 10.3171/jns.1996.85.1.0131; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HAYES RL, 1994, SEMIN NEUROL, V14, P25, DOI 10.1055/s-2008-1041055; Hoane MR, 2000, BRAIN RES BULL, V53, P175, DOI 10.1016/S0361-9230(00)00327-0; Kang TC, 2001, J NEUROCYTOL, V30, P945, DOI 10.1023/A:1021832004954; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Leoni MJ, 2000, EXP NEUROL, V166, P442, DOI 10.1006/exnr.2000.7513; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MONAGHAN DT, 1986, P NATL ACAD SCI USA, V83, P7532, DOI 10.1073/pnas.83.19.7532; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mueller AL, 2000, AMINO ACIDS, V19, P177, DOI 10.1007/s007260070047; Muir JK, 1999, EXP NEUROL, V159, P584, DOI 10.1006/exnr.1999.7187; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; OLNEY J, 1987, EUR J PHARMACOL, V141, P357, DOI 10.1016/0014-2999(87)90552-8; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Smith D H, 1995, New Horiz, V3, P562; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Sosin DM, 1996, BRAIN INJURY, V10, P47; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; VALTYSSON J, 1994, ACTA NEUROCHIR, V129, P58, DOI 10.1007/BF01400874; VINK R, 1988, J BIOL CHEM, V263, P757; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	43	25	27	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	SEP 15	2004	77	6					878	883		10.1002/jnr.20215			6	Neurosciences	Neurosciences & Neurology	852DN	WOS:000223735500010	15334605				2021-06-18	
J	Gagnon, I; Swaine, B; Friedman, D; Forget, R				Gagnon, I; Swaine, B; Friedman, D; Forget, R			Visuomotor response time in children with mild traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	Joint Conference of the 79th Annual Meeting American-Congress-of-Rehabilitation-Medicine/9th Annual Meeting of the American-Society-of-Neurorehabilitation	OCT 02-06, 2002	PHILADELPHIA, PA	American Congress Rehabilitat Med, American Soc Neurorehabilitat		mild traumatic brain injury; pediatrics; response time	HEAD-INJURY; ATTENTIONAL DEFICITS; PERCEPTION; PERFORMANCE; CONCUSSION; BALANCE	Objective: Compare the visuomotor response times of children after a mild traumatic brain injury (mTBI) with those of noninjured children matched for age, sex, and premorbid level of physical activity. Design: Prospective cohort study. Setting: Pediatric trauma center. Participants: Thirty-eight children aged 7 to 16 years in each group. Children with mTBI had a mean Glasgow Coma Scale score of 14.8 and were considered normal on a neurological assessment carried out at the time of hospital discharge. Noninjured children were friends of those with mTBI. Intervention: Assessments of response time were conducted at 1, 4, and 12 weeks after mTBI and at corresponding time intervals for the control children. Main Outcome Measures: The response speed subtest of the Bruininks-Oseretsky Test of Motor Proficiency (BOTMP); reaction and movement time for upper and lower extremities, for simple, choice, and reversed choice response time paradigms. Results: Over the assessment period, children with mTBI performed worse than the control group only on the response speed subtest of the BOTMP. The mTBI children however tended to have slower movement times 1 week postinjury for the reversed choice response time paradigm for the lower extremities. Conclusions: Some children with mTBI may have some problems in response time persisting until 12 weeks postinjury Further research is required to better identify and understand the severity of these problems and determine their impact, if any, on participation in physical activities.	Univ Montreal, Fac Med, Ecole Readaptat, Montreal, PQ H3C 3J7, Canada; McGill Univ, Montreal Childrens Hosp, Hlth Ctr, Dept Phys Therapy, Montreal, PQ H3A 2T5, Canada; Inst Readaptat Montreal, Ctr Rehc Interdisciplinaire & Readaptat Montreal, Montreal, PQ, Canada	Gagnon, I (corresponding author), Univ Montreal, Fac Med, Ecole Readaptat, Montreal, PQ H3C 3J7, Canada.	Isabelle.gagnon6@sympaticaca.ca					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Bruininks R. H., 1978, BRUININKS OSERETSKY; CAVANAGH P, 1989, Spatial Vision, V4, P103, DOI 10.1163/156856889X00077; Faubert J, 2002, CAN J EXP PSYCHOL, V56, P164, DOI 10.1037/h0087394; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Gagnon I, 2004, ARCH PHYS MED REHAB, V85, P444, DOI 10.1016/j.apmr.2003.06.014; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; Gagnon I, 2001, J HEAD TRAUMA REHAB, V16, P595, DOI 10.1097/00001199-200112000-00007; Habak C, 2000, VISION RES, V40, P943, DOI 10.1016/S0042-6989(99)00235-7; HARBIN G, 1989, MED SCI SPORT EXER, V21, P258; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Johnson PD, 2002, CLIN J SPORT MED, V12, P12, DOI 10.1097/00042752-200201000-00006; Kelly JP, 1997, NEUROLOGY, V48, P581; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KINOQUEBEC, 2000, ACTIVITE PHYS DETERM; Levin HS, 1996, NEUROTRAUMA, P749; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; MOSS NEG, 1994, CLIN REHABIL, V8, P149; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; SALLIS JF, 1988, AM J EPIDEMIOL, V127, P933, DOI 10.1093/oxfordjournals.aje.a114896; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Schenk T, 1997, NEUROPSYCHOLOGIA, V35, P1289, DOI 10.1016/S0028-3932(97)00004-3; SCHMIDT RA, 1988, MOTOR CONTROL LEARIN; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Sternberg S, 1969, ACTA PSYCHOL, V30, P276, DOI 10.1016/0001-6918(69)90055-9; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; SWAINE B, 2002, ACTA NEURCHIR, V144, pA34; Swaine BR, 2001, J HEAD TRAUMA REHAB, V16, P292, DOI 10.1097/00001199-200106000-00008; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEEREN AH, 1984, CLOSED HEAD INJURY P; Zahn TP, 1999, J CLIN EXP NEUROPSYC, V21, P352, DOI 10.1076/jcen.21.3.352.924	33	25	25	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2004	19	5					391	404		10.1097/00001199-200409000-00004			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	858UB	WOS:000224216300004	15597030				2021-06-18	
J	Deniselle, MCG; Garay, L; Lopez-Costa, JJ; Gonzalez, S; Mougel, A; Guennoun, R; Schumacher, M; De Nicola, AF				Deniselle, MCG; Garay, L; Lopez-Costa, JJ; Gonzalez, S; Mougel, A; Guennoun, R; Schumacher, M; De Nicola, AF			Progesterone treatment reduces NADPH-diaphorase/nitric oxide synthase in Wobbler mouse motoneuron disease	BRAIN RESEARCH			English	Article						progesterone; neuroprotection; Wobbler mouse; nitric oxide synthase; motoneuron disease	TRAUMATIC BRAIN-INJURY; SPINAL-CORD; LIPID-PEROXIDATION; TRANSGENIC MICE; CELLULAR BASIS; MOTOR-NEURONS; GENETIC MODEL; PROTEIN; NEUROPROTECTION; EXPRESSION	Previous work demonstrated that progesterone (PROG) treatment attenuates morphological, molecular and functional abnormalities in the spinal cord of the Wobbler (Wr) mouse, a genetic model of motoneuron degeneration. Wr mice show a marked up-regulation of the nitric oxide synthesizing enzyme (NOS). Since nitric oxide is a highly reactive species, it may play a role in neuropathology of Wr mice. We now studied if PROG neuroprotection involved changes of NOS activity in motoneurons and astrocytes, determined by the nicotinamide adenine dinucleotide phosphate-diaphorase (NADPHD) histochemical reaction. Two and four-month-old Wr mice at the progressive and stabilization stages of the disease, respectively, and their age-matched controls were left untreated or received a single 20-mg PROG pellet for 18 days. PROG reduced the high number of NADPHD-active motoneurons and white matter astrocytes in 2-month-old Wr mice but was unable to change the low number of NADPHD-active motoneurons in 4-month-old Wr mice or astrocytes in this age group. A large number of motoneurons in 2-month-old Wr mice showed a vacuolated phenotype.. which was significantly reverted by PROG treatment. In summary, PROG treatment during the early symptomatic stage of the disease caused a significant reduction of NADPHD-active motoneurons and astrocytes and also reduced vacuolated degenerating cells, suggesting that blockade of NO synthesis and oxidative damage may contribute to steroid neuroprotection. (C) 2004 Elsevier B.V. All rights reserved.	Univ Buenos Aires, Lab Neuroendocrine Biochem, Inst Biol & Med Expt, RA-1428 Buenos Aires, DF, Argentina; Univ Buenos Aires, Dept Human Biochem, Fac Med, RA-1428 Buenos Aires, DF, Argentina; Univ Buenos Aires, Inst Biol Celular & Neurociencias Prof Eduardo De, RA-1053 Buenos Aires, DF, Argentina; Fdn Barcelo, Inst Univ Ciencias Salud, Buenos Aires, DF, Argentina; Hop Bicetre, INSERM, U488, Paris, France	De Nicola, AF (corresponding author), Univ Buenos Aires, Lab Neuroendocrine Biochem, Inst Biol & Med Expt, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	denicola@dna.uba.ar	Guennoun, Rachida/F-2420-2011; Schumacher, Michael/G-3581-2013	Guennoun, Rachida/0000-0002-9219-7300; Schumacher, Michael/0000-0001-6117-5371			Abe K, 1997, J NEUROSCI RES, V48, P63; Azcoitia I, 2003, NEUROBIOL AGING, V24, P853, DOI 10.1016/S0197-4580(02)00234-8; BEAL MF, 1998, BIOCHIM BIOPHYS ACTA, V1366, P217; Boillee S, 2003, MOL NEUROBIOL, V28, P65, DOI 10.1385/MN:28:1:65; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Clowry GJ, 1996, NEUROSCI LETT, V215, P177, DOI 10.1016/0304-3940(96)12971-2; Corvino V, 2003, NEUROCHEM RES, V28, P341, DOI 10.1023/A:1022345720852; Dave KR, 2003, EXP NEUROL, V182, P412, DOI 10.1016/S0014-4886(03)00091-8; Deniselle MCG, 2002, J STEROID BIOCHEM, V83, P199, DOI 10.1016/S0960-0760(02)00262-5; Deniselle MCG, 2002, NEUROBIOL DIS, V11, P457, DOI 10.1006/nbdi.2002.0564; Deniselle MCG, 1999, BRAIN RES, V841, P78, DOI 10.1016/S0006-8993(99)01783-7; Deniselle MCG, 2001, CELL MOL NEUROBIOL, V21, P237, DOI 10.1023/A:1010943104315; Deniselle MCG, 1999, NEUROCHEM RES, V24, P1, DOI 10.1023/A:1020918310281; Desarnaud F, 1998, J NEUROCHEM, V71, P1765; GUANGPING X, 2001, NEUROSCI LETT, V300, P141; Gurney ME, 2000, BIOESSAYS, V22, P297, DOI 10.1002/(SICI)1521-1878(200003)22:3<297::AID-BIES12>3.0.CO;2-I; HALL ED, 1993, CELL MOL NEUROBIOL, V13, P415, DOI 10.1007/BF00711581; HALL ED, 1982, J NEUROSURG, V49, P563; Henderson JT, 1996, J NEUROSCI, V16, P7574; Ikeda K, 1998, J NEUROL SCI, V160, P9, DOI 10.1016/S0022-510X(98)00224-X; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Kong JM, 1998, J NEUROSCI, V18, P3241; Labombarda F, 2003, J NEUROCHEM, V87, P902, DOI 10.1046/j.1471-4159.2003.02055.x; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Labombarda F, 2000, J STEROID BIOCHEM, V73, P159, DOI 10.1016/S0960-0760(00)00064-9; LEHMANN A, 1974, ATLAS STEREOTAXIQUE; Melcangi RC, 2000, PROG NEUROBIOL, V60, P291, DOI 10.1016/S0301-0082(99)00028-3; MITSUMOTO H, 1982, BRAIN, V105, P811, DOI 10.1093/brain/105.4.811; PHUL RK, 2000, LATERAL SCLER OTHER, V4, P259; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; RUPPRECHT R, 1993, NEURON, V11, P523, DOI 10.1016/0896-6273(93)90156-L; Saravia FE, 2001, CELL MOL NEUROBIOL, V21, P15, DOI 10.1023/A:1007165127420; Sasaki S, 2002, ACTA NEUROPATHOL, V103, P421, DOI 10.1007/s00401-001-0484-6; Schumacher M, 2000, J NEUROCYTOL, V29, P307, DOI 10.1023/A:1007152904926; Stein DG, 1998, NEUROSCIENTIST, V4, P435, DOI 10.1177/107385849800400615; Stewart VC, 2002, EUR J NEUROSCI, V15, P458, DOI 10.1046/j.0953-816x.2001.01878.x; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Tsuzaka K, 2001, MUSCLE NERVE, V24, P474, DOI 10.1002/mus.1029; VINCENT SR, 1992, NEUROSCIENCE, V46, P755, DOI 10.1016/0306-4522(92)90184-4; YUNG KKL, 1992, NEUROSCIENCE, V50, P209, DOI 10.1016/0306-4522(92)90393-G	43	25	25	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 16	2004	1014	1-2					71	79		10.1016/j.braines.2004.04.004			9	Neurosciences	Neurosciences & Neurology	838PZ	WOS:000222726700008	15212993				2021-06-18	
J	Donders, J; Minnema, MT				Donders, J; Minnema, MT			Performance discrepancies on the California Verbal Learning Test-Children's Version (CVLT-C) in children with traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						traumatic brain injury; learning; memory; proactive interference; processing speed	HEAD-INJURY; EXECUTIVE FUNCTION; WISC-III; PROACTIVE-INTERFERENCE; FRONTAL-LOBE; MEMORY; FREQUENCY; EPILEPSY; DEFICITS; TERM	One hundred sixty-seven children with traumatic brain injury (TBI), selected from an 8-year series of consecutive referrals to a Midwestern rehabilitation hospital, completed the California Verbal Learning Test-Children's Version (CVLT-C) and the Wechsler Intelligence Scale for Children-Third Edition (WISC-III) within I year after injury. A large proactive interference (PI) effect, defined as performance on the second list that was at least 1.5 standard deviations below that on the 1st one, was statistically significantly more common in this clinical sample (2 1%) than in the CVLT-C standardization sample (11%). Other performance discrepancies, including retroactive interference, rapid forgetting, and retrieval problems, occurred at approximately the same rate in the clinical and standardization samples. Children with anterior cerebral lesions were about 3 times less likely to have a large PI effect than children without such lesions, but the former group performed worse on the first CVLT-C list. The impact of pediatric TBI on a wide range of CVLT-C quantitative variables was mediated by speed of information processing, as assessed by the WISC-III Processing Speed factor index. It is concluded that failure to release from PI is somewhat common, although certainly not universal, in children with TBI. Unlike with adults, anterior cerebral lesions are not associated selectively with an increased risk for PI after pediatric TBI but rather with a reduced efficiency of allocation of cognitive resources. Deficits in speed of information processing appear to be primarily responsible for the learning deficits on the CVLT-C after pediatric TBI.	Mary Free Bed Hosp & Rehabil Ctr, Psychol Serv, Grand Rapids, MI 49503 USA; Calvin Coll, Dept Psychol, Grand Rapids, MI 49506 USA	Donders, J (corresponding author), Mary Free Bed Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.	jdonders@mfbrc.com					DELIS D, 1994, CALIFORNIA VERBAL LE; Donders J, 2001, CHILD NEUROPSYCHOL, V7, P99, DOI 10.1076/chin.7.2.99.3126; Donders J, 1996, CHILD NEUROPSYCHOL, V2, P185, DOI 10.1080/09297049608402251; Donders J, 1999, J INT NEUROPSYCH SOC, V5, P26, DOI 10.1017/S1355617799511041; GERSHBERG FB, 1995, NEUROPSYCHOLOGIA, V13, P1305; Gioia G.A., 2000, BEHAV RATING INVENTO; Hanten G, 2002, CHILD NEUROPSYCHOL, V8, P107, DOI 10.1076/chin.8.2.107.8729; Hoffman N, 2000, ARCH CLIN NEUROPSYCH, V15, P47, DOI 10.1016/S0887-6177(98)00156-5; Kail R, 2002, CHILD DEV, V73, P1703, DOI 10.1111/1467-8624.00500; Levin HS, 2000, J CLIN EXP NEUROPSYC, V22, P1, DOI 10.1076/1380-3395(200002)22:1;1-8;FT001; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; McDonald CR, 2001, ARCH CLIN NEUROPSYCH, V16, P571, DOI 10.1016/S0887-6177(00)00068-8; Miller LJ, 2003, REHABIL PSYCHOL, V48, P237, DOI 10.1037/0090-5550.48.4.237; Numan B, 2000, J CLIN PSYCHOL, V56, P553, DOI 10.1002/(SICI)1097-4679(200004)56:4<553::AID-JCLP8>3.0.CO;2-Q; Precourt S, 2002, DEV NEUROPSYCHOL, V21, P173, DOI 10.1207/S15326942DN2102_4; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Schinka JA, 1998, PSYCHOL ASSESSMENT, V10, P171, DOI 10.1037/1040-3590.10.2.171; SMITH ML, 1995, NEUROPSYCHOLOGIA, V33, P275; Sowell ER, 2001, J INT NEUROPSYCH SOC, V7, P312, DOI 10.1017/S135561770173305X; TEASDALE G, 1974, LANCET, V2, P81; Tremont G, 1999, CHILD NEUROPSYCHOL, V5, P104, DOI 10.1076/chin.5.2.104.3166; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wechsler D., 1991, WECHSLER INTELLIGENC; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; White DA, 2001, NEUROPSYCHOLOGY, V15, P221, DOI 10.1037/0894-4105.15.2.221; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Williams J, 2001, CHILD NEUROPSYCHOL, V7, P15, DOI 10.1076/chin.7.1.15.3148; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	29	25	25	0	6	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2004	10	4					482	488		10.1017/S1355617704104025			7	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	833VA	WOS:000222367200002	15327727				2021-06-18	
J	Larkins, BM; Worrall, LE; Hickson, LM				Larkins, BM; Worrall, LE; Hickson, LM			Stakeholder opinion of functional communication activities following traumatic brain injury	BRAIN INJURY			English	Article								Primary objective : To establish a process whereby assessment of functional communication reflects the authentic communication of the target population. The major functional communication assessments available from the USA may not be as relevant to those who reside elsewhere, nor assessments developed primarily for persons who have had a stroke as relevant for traumatic brain injury rehabilitation. Research design : The investigation used the Nominal Group Technique to elicit free opinion and support individuals who have compromised communication ability. A survey mailed out sampled a larger number of stakeholders to test out differences among groups. Methods and procedures : Five stakeholder groups generated items and the survey determined relative 'importance'. The stakeholder groups in both studies comprised individuals with traumatic brain injury and their families, health professionals, third-party payers, employers, and Maori, the indigenous population of New Zealand. Main outcomes and results : There was no statistically significant difference found between groups for 19 of the 31 items. Only half of the items explicitly appear on a well-known USA functional communication assessment. Conclusions : The present study has implications for whether functional communication assessments are valid across cultures and the type of impairment.	Univ Queensland, Dept Speech Pathol & Audiol, Brisbane, Qld, Australia	Larkins, BM (corresponding author), 3 Brackendale Pl, Christchurch 8004, New Zealand.	brigette@chch.planet.org.nz	Hickson, Louise MH/F-8748-2010; Worrall, Linda/D-2579-2010	Hickson, Louise MH/0000-0001-6832-4173; Worrall, Linda/0000-0002-3283-7038			*AM SPEECH LANG HE, 1990, P2 ASHA; BAKER R, 1995, AUST J AGEING, V14, P81, DOI 10.1111/j.1741-6612.1995.tb00702.x; Delbecq A.L., 1975, GROUP TECHNIQUES PRO; DRESSER A, 1983, ARCH NEUROL-CHICAGO, V29, P111; Fraterrigo TL, 1999, J BIOL INORG CHEM, V4, P183, DOI 10.1007/s007750050303; FRATTALI CM, 1992, APHASIOLOGY, V6, P63, DOI 10.1080/02687039208248577; Goldberg S., 1997, CLIN SKILLS SPEECH L; Hickson L, 1996, EDUC GERONTOL, V22, P257, DOI 10.1080/0360127960220304; Hochberg J., 1987, MULTIPLE COMP PROCED; Larkins B, 1999, ASIA PACIFIC J SPEEC, V4, P183; LARKINS B, 1995, APH S AUSTR BRISB SE; Larkins B., 2000, NEUROGENIC COMMUNICA, P206; MURDOCH B, 1996, INT PERSPECTIVES TRA, P280; Penn C, 2000, NEUROGENIC COMMUNICA, P103; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P18; World Health Organization, 2001, INT CLASS FUNCT DIS; WORRALL L, 1995, TREATMENT APHASIA TH; WORRALL L, 1990, AUSTR J HUMAN COMMUN, V18, P53; YLVISAKER M S, 1990, Seminars in Speech and Language, V11, P215, DOI 10.1055/s-2008-1064254	19	25	27	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2004	18	7					691	706		10.1080/02699050310001617389			16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	821HJ	WOS:000221450700006	15204330				2021-06-18	
J	Meixensberger, J; Renner, C; Simanowski, R; Schmidtke, A; Dings, J; Roosen, K				Meixensberger, J; Renner, C; Simanowski, R; Schmidtke, A; Dings, J; Roosen, K			Influence of cerebral oxygenation following severe head injury on neuropsychological testing	NEUROLOGICAL RESEARCH			English	Article						head injury; brain oxygenation; outcome; neuropsychological deficits	TRAUMATIC BRAIN-INJURY; TISSUE OXYGENATION; BLOOD-FLOW; CBF	Despite recent advances in the management of severe head injury the mortality and morbidity remains high. Intracranial pressure (ICP) and cerebral perfusion pressure (CPP) are crucial parameters for the correct management at the intensive care unit, due to their therapeutic and prognostic importance. In addition, regional brain tissue oxygenation (p(ti)O(2)) seems to be of importance. While different studies demonstrated the impact of cerebral hypoxia on outcome (mortality), no data are available focusing on morbidity (neuropsychological deficits). Therefore, our study is carried out to demonstrate a possible relationship between amount of cerebral oxygenation during acute stage after severe head injury and neuropsychological outcome. Besides ICP and CPP, p(ti)O(2) was monitored in 40 severely head injured patients during the ICU stay from the day of admission until day 10. Monitoring data were stored and amount of hypoxic episodes were calculated. Besides outcome using the Glasgow Outcome Scale neuropsychological testing was performed 2-3 years after injury. Analysing the quality of brain tissue oxygenation, a relationship to the performance in neuropsychological tests could be found. Patients with low brain tissue oxygenation had a worse outcome in neuropsychological testing, especially concerning intelligence and memory. Associated with these deficits patients showed a reduced performance in their profession. Our data suggest a possible predictive value of brain tissue oxygen on morbidity analysing neurocognitive function after head injury. This may implicate monitoring and treatment of cerebral hypoxia.	Univ Leipzig, Dept Neurosurg, Leipzig, Germany; Univ Wurzburg, Dept Neurosurg, Wurzburg, Germany; Univ Wurzburg, Dept Psychiat, Wurzburg, Germany	Meixensberger, J (corresponding author), Univ Klinikum Leipzig, Neurochirurg Klin & Poliklin, Dept Neurosurg, Liebigstr 20, D-04103 Leipzig, Germany.	meix@medizin.uni-leipzig.de		Schmidtke, Armin/0000-0001-5719-9856			Bardt TF, 1998, ACT NEUR S, V71, P153; BECKER DP, 1982, NEUROLOGICAL SURG, P2137; CHOI SC, 1995, NEUROTRAUMA, P779; Cruz J, 2000, J NEUROSURG, V92, P736; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; HASS WK, 1976, HEAD INJURIES, P35; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; Meixensberger J., 1998, Intensivmedizin und Notfallmedizin, V35, P72; MEIXENSBERGER J, 1999, ANASTH INTENSIVMED, V34, P548; OBRIST WD, 1983, INTRACRANIAL PRESSUR, V5, P491; TABADDOR K, 1972, J TRAUMA, V12, P1053, DOI 10.1097/00005373-197212000-00006; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630; UZZELL BP, 1986, INTRACRANIAL PRESSUR, V6, P687; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Vath A, 2001, NEUROL RES, V23, P315, DOI 10.1179/016164101101198677	16	25	25	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUN	2004	26	4					414	417		10.1179/016164104225014094			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	829CP	WOS:000222021400010	15198869				2021-06-18	
J	Heinemann, AW; Corrigan, JD; Moore, D				Heinemann, AW; Corrigan, JD; Moore, D			Case management for traumatic brain injury survivors with alcohol problems	REHABILITATION PSYCHOLOGY			English	Article							COGNITIVE STATUS EXAMINATION; ADDICTION SEVERITY INDEX; HEALTH SURVEY SF-36; SUBSTANCE-ABUSE; VALIDITY; SCALE	Objective: To evaluate a community-based approach to substance abuse using comprehensive case management for persons with traumatic brain injury (TBI). Setting: Two programs that provide case management services (n = 217); a comparison group was recruited that did not receive case management (n = 102). Intervention: Comprehensive case management. Main Outcome Measures: Self-reported substance use, community integration, employment status, health-related quality of life. Results: For those receiving case management, employment at recruitment and early referral were associated with employment 9 months later. Community integration and physical well-being increased for both groups. Earlier program referral was associated with larger gains in physical well-being, employment, and community integration. Conclusions: Case management appears to have beneficial effects for adults with TBI and substance abuse problems in terms of life and family satisfaction as well as to have potential cost savings.	Rehabil Inst Chicago, Ctr Rehabil Outcomes Res, Chicago, IL 60611 USA; Northwestern Univ, Dept Phys Med & Rehabil, Feinberg Sch Med, Chicago, IL 60611 USA; Northwestern Univ, Inst Hlth Serv Res & Policy Studies, Feinberg Sch Med, Chicago, IL 60611 USA; Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; Wright State Univ, Dept Community Hlth, Sch Med, Dayton, OH 45435 USA	Heinemann, AW (corresponding author), Rehabil Inst Chicago, Ctr Rehabil Outcomes Res, 345 E Super St, Chicago, IL 60611 USA.	a-heinemann@northwestern.edu	Heinemann, Allen W./AAI-2790-2021; Heinemann, Allen W/K-6283-2012; Corrigan, John D./E-2921-2011	Heinemann, Allen W./0000-0003-2782-7326; Heinemann, Allen W/0000-0003-2782-7326; 			Ashery R S, 1994, J Case Manag, V3, P179; Blackerby W.F., 1990, J HEAD TRAUMA REHAB, V5, P47; Bode R K, 2001, J Appl Meas, V2, P78; Bode RK, 2000, J HEAD TRAUMA REHAB, V15, P637, DOI 10.1097/00001199-200002000-00004; CARVER MD, 1992, SOC BEHAV PERSONAL, V20, P71, DOI 10.2224/sbp.1992.20.2.71; CORRIGAN JD, 1995, BRAIN INJURY, V9, P221, DOI 10.3109/02699059509008195; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; *CTR OUTC MEAS BRA, 2000, CIQ PROP; Dikmen S. S., 1993, NEUROPSYCHOLOGIA, V7, P296, DOI DOI 10.1037/0894-4105.7.3.296; Doninger NA, 2000, J HEAD TRAUMA REHAB, V15, P683, DOI 10.1097/00001199-200002000-00007; Drake RE, 1996, AM J ORTHOPSYCHIAT, V66, P42, DOI 10.1037/h0080153; Fisher WP., 1992, RASCH MEASUREMENT T, V6, P238; FORD J, 1995, MAGAZINE, V3, P19; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; KIERNAN RJ, 1987, ANN INTERN MED, V107, P481, DOI 10.7326/0003-4819-107-4-481; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; LANGLEY M, 1991, WORK WORTH DOING ADV, P251; LANGLEY M, 1992, NEUROREHABILITATION, V2, P65; LEHMAN AF, 1988, NEW DIRECTIONS MENTA, V40, P67; LINACRE JM, 1999, WINSTEPS PC COMPATIB; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCLELLAN AT, 1985, J NERV MENT DIS, V173, P412, DOI 10.1097/00005053-198507000-00005; *NAT HEAD INJ FDN, 1988, NAT HEAD INJ FDN SUB; *NO CAL NEUR GROUP, 1988, MAN NEUR COGN STAT E; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; Rasch G., 1980, PROBABILISTIC MODELS; Ridgely M S, 1994, J Case Manag, V3, P132; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; SPARADEO F, 1993, STAFF DEV CLIN INTER, P189; SPARADEO FR, 1992, NEUROREHABILITATION, V2, P65; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE., 1993, SF 36 HLTH SURVEY MA; Weisner C, 2000, J SUBST ABUSE TREAT, V19, P103, DOI 10.1016/S0740-5472(99)00103-8; Willenbring M L, 1994, J Case Manag, V3, P150; Willer B., 1993, BRAIN INJURY REHABIL, P355; Wright B. D., 1982, RATING SCALE ANAL RA	40	25	25	0	7	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	MAY	2004	49	2					156	166		10.1037/0090-5550.49.2.156			11	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	819BS	WOS:000221288800010					2021-06-18	
J	Ward, H; Shum, D; Dick, B; McKinlay, L; Baker-Tweney, S				Ward, H; Shum, D; Dick, B; McKinlay, L; Baker-Tweney, S			Interview study of the effects of paediatric traumatic brain injury on memory	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; EXPLICIT MEMORY; POSTTRAUMATIC AMNESIA; CHILDREN; IMPLICIT; DISSOCIATION; ADOLESCENTS; PERFORMANCE	Primary objective : To investigate the effects of traumatic brain injury (TBI) on children's day-to-day memory functioning. Research design : A qualitative, interview-based procedure. Methods and procedures : Thirteen parents of children and adolescents with TBI were interviewed for 2 hours. Data from 12 of the interviews were analysed using content analysis, which involved transcribing notes, sorting information into categories, identifying similarities or differences among the categories and isolating meaningful trends. Main outcomes and results : Over half of the children experienced explicit (past recall) and prospective memory (future intentions) loss, but few experienced implicit memory (e.g. procedural) loss. Further, parents utilized their own interventions in minimizing their children's memory disabilities. Conclusion : Memory loss is common and can impact on everyday living, but is selective in the types of memory affected. Follow-ups are recommended to assess quantitatively, the so-far, little-known effects of paediatric TBI on prospective memory and to examine more closely parent interventions to assess their wider applicability in TBI rehabilitation.	Griffith Univ, Sch Appl Psychol, Brisbane, Qld 4111, Australia; Griffith Univ, Neuropsychol Clin, Brisbane, Qld 4111, Australia; So Cross Univ, Lismore, Australia; Royal Childrens Hosp, Queensland Paediat Reahbil Serv, Brisbane, Qld 4029, Australia	Ward, H (corresponding author), Griffith Univ, Sch Appl Psychol, Brisbane, Qld 4111, Australia.	h.ward@griffith.edu.au	Shum, David/A-3914-2008	Shum, David/0000-0002-4810-9262; McKinlay, Lynne/0000-0002-6677-0628			BADDELEY AD, 1995, HDB MEMORY DISORDERS, P3; BAKERWARD L, 1993, MEMORY EVERYDAY LIFE, P13; BASSETT SS, 1990, J PEDIATR PSYCHOL, V15, P225, DOI 10.1093/jpepsy/15.2.225; Berg B.L., 2001, QUALITATIVE RES METH; BLACKMAN P, 1990, BEHAV ANAL THEORY PR; Brandimonte M., 1996, PROSPECTIVE MEMORY T; Burgess PW, 2001, NEUROPSYCHOLOGIA, V39, P545, DOI 10.1016/S0028-3932(00)00149-4; COCKBURN J, 1996, PROSPECTIVE MEMORY T, P327; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; DAMASIO AR, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P217; Einstein G., 1996, PROSPECTIVE MEMORY T, P115; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; EWINGCOBBS L, 1998, TRAUMATIC BRAIN INJU, P11; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GABRIELI JDE, 1995, PSYCHOL SCI, V6, P76, DOI 10.1111/j.1467-9280.1995.tb00310.x; GLISKY EL, 1987, NEUROPSYCHOLOGIA, V25, P893, DOI 10.1016/0028-3932(87)90094-7; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P501, DOI 10.1037/0278-7393.11.3.501; Graf P, 2001, CONSCIOUS COGN, V10, P437, DOI 10.1006/ccog.2001.0504; HANNAY HJ, 1998, J CLIN EXPT NEUROPSY, V11, P444; JACOBS MP, 1993, NEUROPSYCHOL REHABIL, V3, P341, DOI 10.1080/09602019308401446; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JENNETT WB, 1981, MANAGEMENT HEAD INJU; JENNETT WB, 1969, BRIT J PSYCHIAT, V4, P40; Johnson SC, 2001, J INT NEUROPSYCH SOC, V7, P55, DOI 10.1017/S135561770171106X; Kerns KA, 2000, J INT NEUROPSYCH SOC, V6, P62, DOI 10.1017/S1355617700611074; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, P23; LAZAR JJ, 1997, DISS ABSTR INT B, V57, P5969; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; LEVIN HS, 1989, NEUROSURGERY, V24, P223, DOI 10.1227/00006123-198902000-00011; Locke K., 2001, GROUNDED THEORY MANA; Marlowe WB, 2000, DEV NEUROPSYCHOL, V18, P445, DOI 10.1207/S1532694209Marlowe; Martin G, 1996, BEHAV MODIFICATION W; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; Meier B, 2000, APPL COGNITIVE PSYCH, V14, pS11, DOI 10.1002/acp.768; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; MICHAUD LJ, 1999, REHABILITATION ADULT, P345; MILNER B, 1985, HUM NEUROBIOL, V4, P137; MOSCOVITCH M, 1992, NEUROPSYCHOLOGY MEMO, P5; NISSEN MJ, 1992, NEUROPSYCHOLOGY MEMO, P203; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Passolunghi MC, 1995, INT J BEHAV DEV, V18, P631, DOI 10.1177/016502549501800404; Powell TJ, 1996, DISABIL REHABIL, V18, P231, DOI 10.3109/09638289609166306; Pushkar D, 1997, PSYCHOL AGING, V12, P600, DOI 10.1037/0882-7974.12.4.600; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; SAINTCYR JA, 1992, NEUROPSYCHOLOGY MEMO, P188; Schacter DL, 2000, OXFORD HDB MEMORY, P627; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHIMAMURA AP, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P173; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P149, DOI 10.1076/jcen.21.2.149.929; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Shum D, 1996, J HEAD TRAUMA REHAB, V11, P43, DOI 10.1097/00001199-199604000-00005; SHUM D, 2002, J INT NEUROPSYCH SOC, V8, P160; SILVER BV, 1994, ARCH PHYS MED REHAB, V75, P742; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Slifer KJ, 1996, J HEAD TRAUMA REHAB, V11, P39, DOI 10.1097/00001199-199602000-00006; SNOW JH, 1994, PEDIAT TRAUMATIC BRA; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; SQUIRE LR, 1992, J COGNITIVE NEUROSCI, V4, P232, DOI 10.1162/jocn.1992.4.3.232; SUNDERLAND A, 1996, J GERONTOL, V41, P376; Vakil E, 1996, BRAIN COGNITION, V31, P75, DOI 10.1006/brcg.1996.0026; Ward H, 2002, J CLIN EXP NEUROPSYC, V24, P458, DOI 10.1076/jcen.24.4.458.1032; West RL, 1996, PSYCHOL BULL, V120, P272, DOI 10.1037/0033-2909.120.2.272; Wilson BA, 1996, J HEAD TRAUMA REHAB, V11, P54, DOI 10.1097/00001199-199604000-00006; Winograd E., 1988, PRACTICAL ASPECTS ME, V1, P348; Yakovlev P.I., 1967, RETIONAL DEV BRAIN E, P3; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU, P221; Ylvisaker M., 1998, COLLABORATIVE BRAIN; YLVISAKER M, 1998, TRAUMATIC BRAIN INJU, P181	74	25	25	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2004	18	5					471	495		10.1080/02699050310001646107			25	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	800SS	WOS:000220048600006	15195795				2021-06-18	
J	Brown, M; Gordon, WA				Brown, M; Gordon, WA			Empowerment in measurement: "Muscle," "Voice," and subjective quality of life as a gold standard	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	State of the Science Conference	APR, 2002	Geroge Washington Univ, Washington, DC	Rehabilitat Res & Training Ctr, NIDRR	Geroge Washington Univ	disabled persons; physician-patient relations; quality of life; rehabilitation	TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH PROGRAMS; GOAL-ATTAINMENT; INTERNATIONAL CLASSIFICATION; DISABILITY RESEARCH; REHABILITATION; PARTICIPATION; MODELS; EPIDEMIOLOGY; SATISFACTION	Measurement and assessment, occurring within both research and clinical service contexts, typically involve an imbalance of power between professionals and persons with disabilities. Power is evidenced in who controls decisions about measurement and whose perspective-the subjective values of the measured person or the objective or normative values of the measurer-is given primacy. The consequences of this imbalance are discussed with respect to both sides of the power relationship. For clinicians, evaluators, and researchers, who typically hold most, if not all of the power in measurement, the process may produce data that meet the highest professional standards. However, the utility of such data is limited in addressing many purposes. For research participants and service recipients, who typically have little if any control of measurement, the measurement process may be disempowering, because measures focus on areas of life that may be of little relevance to what they see as important. In effect, both sides lose, to the degree that resulting data are less revealing than would be the case in a more balanced power relationship. Methods are discussed for reducing power imbalances to improve the utility and efficacy of measurement.	Mt Sinai Med Ctr, Dept Rehabil Med, New York, NY 10029 USA	Gordon, WA (corresponding author), Mt Sinai Med Ctr, Dept Rehabil Med, Box 1240,1 Gustave L Levy Pl, New York, NY 10029 USA.	wayne.gordon@mssm.edu					Andrews F. M., 1976, SOCIAL INDICATORS WE; Badley E M, 1987, Int Disabil Stud, V9, P122; Badley E M, 1987, Int Rehabil Med, V8, P118; BADLEY EM, 1995, DISABIL REHABIL, V17, P53, DOI 10.3109/09638289509166628; Bickenbach JE, 1999, SOC SCI MED, V48, P1173, DOI 10.1016/S0277-9536(98)00441-9; BIGELOW DA, 1990, PSYCHOSOC REHABIL, V14, P94; BOYCE W, 1998, CANADIAN J REHABILIT, V12, P85; Brandt E. N., 1997, ENABLING AM ASSESSIN; Brown M, 1999, MT SINAI J MED, V66, P160; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; BUTTERWORTH J, 1997, QUALITY LIFE APPL PE, V2, P59; CALSYN RJ, 1978, COMMUNITY MENT HLT J, V14, P300, DOI 10.1007/BF00778605; CAMPBELL M, 1998, CANADIAN J REHABILIT, V12, P95; Carpenter L, 2001, Can J Occup Ther, V68, P16; Clark M S, 1983, Int Rehabil Med, V5, P41; CLINE DW, 1973, AM J PSYCHIAT, V130, P105, DOI 10.1176/ajp.130.1.105; DEMBO T, 1964, REHABIL LIT, V25, P231; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers M., 2002, QUAL LIFE RES, V11, P672; Donnelly Catherine, 2002, Can J Occup Ther, V69, P84; FERRANS CE, 1985, ADV NURS SCI, V8, P15, DOI 10.1097/00012272-198510000-00005; FLANAGAN JC, 1978, AM PSYCHOL, V33, P138, DOI 10.1037/0003-066X.33.2.138; FLANAGAN JC, 1982, ARCH PHYS MED REHAB, V63, P56; Forbes D A, 1998, J Gerontol Nurs, V24, P34; GORDON WA, 1995, AM PSYCH ASS 103 ANN; GORDON WA, 1998, LIVING LIFE TRAUMATI; HEAVLIN WD, 1982, COMMUNITY MENT HLT J, V18, P230, DOI 10.1007/BF00754339; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; HOLBURN S, 2002, PERSON CENTERED PLAN; JOYCE BM, 1994, AM J PHYS MED REHAB, V73, P10, DOI 10.1097/00002060-199473010-00003; KIRESUK TJ, 1968, COMMUNITY MENT HLT J, V4, P443, DOI 10.1007/BF01530764; KIRESUK TJ, 1982, DRUG INTEL CLIN PHAR, V16, P145, DOI 10.1177/106002808201600210; KROGH K, 1998, CAN J REHABIL, V12; LAFERRIERE L, 1978, AM J COMMUN PSYCHOL, V6, P271, DOI 10.1007/BF00894357; Law M, 1990, Can J Occup Ther, V57, P82; Law M, 1994, Can J Occup Ther, V61, P191; Lehmkuhl D, 1988, TIRR SYMPTOM CHECKLI; MALEC JF, 1991, ARCH PHYS MED REHAB, V72, P138; MALEC JF, 1993, BRAIN INJURY, V7, P383, DOI 10.3109/02699059309029682; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; McColl M A, 2000, Can J Occup Ther, V67, P22; MENCHETTI BM, 1995, PERSON CENTERED PLAN; MOUNT B, 1997, MOVING PERSONAL FUTU; MOUNT B, 1988, ITS NEVER TOO EARLY; NAGI S, 1975, SWITZER MEMORIAL SER, V1; NAGI SZ, 1976, MILBANK FUND Q, V54, P439, DOI 10.2307/3349677; NAGI SZ, 1969, DISABILITY REHABILAT; OTTENBACHER KJ, 1993, AM J OCCUP THER, V47, P349, DOI 10.5014/ajot.47.4.349; POLLOCK N, 1993, AM J OCCUP THER, V47, P298, DOI 10.5014/ajot.47.4.298; Pollock N, 1990, Can J Occup Ther, V57, P77; Ripat J, 2001, Can J Occup Ther, V68, P247; Rushton PW, 2002, ARCH PHYS MED REHAB, V83, P771, DOI 10.1053/apmr.2002.32636; Schalock RL., 2002, HDB QUALITY LIFE HUM; Stucki G, 2002, DISABIL REHABIL, V24, P932, DOI 10.1080/09638280210148594; Toomey M, 1995, Can J Occup Ther, V62, P242; Trombly CA, 2002, AM J OCCUP THER, V56, P489, DOI 10.5014/ajot.56.5.489; vanBalen HGG, 1996, DISABIL REHABIL, V18, P181, DOI 10.3109/09638289609166298; White GW, 2002, REHABIL PSYCHOL, V47, P438, DOI 10.1037//0090-5550.47.4.438; WHITTY RW, 1985, SOFTW MICROSYST, V4, P2, DOI 10.1049/sm.1985.0002; *WHO, 1999, INT CLASSFUNCT DISB; WHYTE WF, 1991, PARTICIPATORY ACTION; WILLER B, 1976, AM J PUBLIC HEALTH, V66, P1197, DOI 10.2105/AJPH.66.12.1197; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; WOOD PH, 1980, MONOGRAPH, V12; WOOD PHN, 1980, WHO CHRON, V34, P376; World Health Organization, 1980, INT CLASS IMP DIS HA; Wressle E, 2002, J REHABIL MED, V34, P5, DOI 10.1080/165019702317242640; Wressle Ewa, 2002, Can J Occup Ther, V69, P40; Zimmerman MA, 1995, AM J COMMUN PSYCHOL, V23, P581, DOI 10.1007/BF02506983	70	25	25	1	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2004	85	4		2			S13	S20		10.1016/j.apmr.2003.08.110			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	812FL	WOS:000220825300003	15083418				2021-06-18	
J	Dix, ES; Esposito, D; Spinosa, F; Olson, N; Chapman, S				Dix, ES; Esposito, D; Spinosa, F; Olson, N; Chapman, S			Implementation of community consultation for waiver of informed consent in emergency research: One institutional review board's experience	JOURNAL OF INVESTIGATIVE MEDICINE			English	Article						waiver of consent; emergency research; community consultation	FOOD	Background: This article describes how one Institutional Review Board (IRB) chose to implement the issue of waiver of consent for a research study involving brain trauma victims brought to an emergency department. Methods: Presentations were conducted in the state of Mississippi among cultural and ethnic groups representative of Mississippi's demographic composition. Individuals from the neurotrauma research team, including neurosurgeons and nurse study coordinators, conducted all of the presentations. One IRB member served as an objective "community liaison" and attended all presentations. This individual administered evaluation forms to attendees that measured their levels of comprehension and acceptance for the use of waiver of consent in the brain trauma study. Results: All of the 137 attendees in 7 community consultation meetings gave their approval for the use of "waiver of consent." Continued community consultations are planned for the duration of the brain trauma study. Conclusion: Based on our experience, we conclude that in collaborating with local IRBs, research teams can successfully develop strategies for obtaining "acceptable community consultations" as required by regulatory mandates. We suggest that standardized community consultation guidelines be developed for obtaining waivers of informed consent in emergency research. Such criteria should form the basis for local IRBs to obtain their respective community consultations.	Univ Mississippi, Med Ctr, Dept Prevent Med, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Neurosurg, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Inst Review Board, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA	Dix, ES (corresponding author), Univ Mississippi, Med Ctr, Dept Prevent Med, 2500 N State St, Jackson, MS 39216 USA.	edix@prevmed.umsmed.edu					*AM MED ASS, E8085 AM MED ASS; [Anonymous], 1996, Fed Regist, V61, P51498; Baren JM, 1999, ACAD EMERG MED, V6, P1210, DOI 10.1111/j.1553-2712.1999.tb00135.x; Biros MH, 1999, ACAD EMERG MED, V6, P1272, DOI 10.1111/j.1553-2712.1999.tb00144.x; Ellis GB, 1996, 9701 OPRR; Kremers MS, 1999, ANN EMERG MED, V33, P224, DOI 10.1016/S0196-0644(99)70399-9; *NAT COMM PROT HUM, 1979, OPRR PUBL; Shah AN, 2003, ANN EMERG MED, V41, P72, DOI 10.1067/mem.2003.14	8	25	26	0	0	B C DECKER INC	HAMILTON	20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA	1081-5589			J INVEST MED	J. Invest. Med.	MAR	2004	52	2					113	116		10.2310/6650.2004.17646			4	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	806EH	WOS:000220416700011	15068227				2021-06-18	
J	Tunblad, K; Ederoth, P; Gardenfors, A; Hammarlund-Udenaes, M; Nordstrom, CH				Tunblad, K; Ederoth, P; Gardenfors, A; Hammarlund-Udenaes, M; Nordstrom, CH			Altered brain exposure of morphine in experimental meningitis studied with microdialysis	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						blood-brain barrier; disease states; drug transport; meningitis; microdialysis; morphine; pharmacokinetics and pig	CEREBRAL PERFUSION-PRESSURE; P-GLYCOPROTEIN; ENERGY-METABOLISM; BARRIER TRANSPORT; IN-VIVO; PERMEABILITY; PERSPECTIVES; EXPRESSION; LIVER; RATS	Background: During pathologic conditions such as meningitis and traumatic brain injury the function of the blood-brain barrier (BBB) is disturbed. In the present study we examined the cerebral pharmacokinetic pattern of morphine in the intact brain and during experimentally induced meningitis using a pig model. Secondly, the use of intracerebral microdialysis as a potential tool for monitoring damage in the BBB by studying the pharmacokinetics of morphine is addressed. Methods: Six pigs were studied under general anaesthesia. One occipital and two frontal microdialysis probes and one pressure transducer were inserted into the brain tissue. Another probe was placed into the jugularis interna. Morphine 1 mg kg(-1) was administered as a 10-min infusion, and morphine concentrations were then measured for 3 h. Meningitis was subsequently induced by injecting lipopolysaccharide into the cisterna magna. When meningitis was established, the morphine experiment was repeated. Results: The unbound area under the concentration-time curve (AUC(u)) ratio of morphine in brain to blood was 0.47 (0.19) during the control period, and 0.95 (0.20) (P<0.001) during meningitis. The increase in the brain/blood AUC(u) ratio during meningitis implies decreased active efflux and increased passive diffusion of morphine over the BBB. The half-life of morphine in brain was longer than in blood during both periods, and was unaffected by meningitis. Conclusion: This study demonstrates that the morphine exposure to the brain is significantly increased during meningitis as compared with the control situation.	Uppsala Univ, Dept Pharmaceut Biosci, Div Pharmacokinet & Drug Therapy, SE-75124 Uppsala, Sweden; Univ Lund Hosp, Dept Anaesthesiol & Intens Care, S-22185 Lund, Sweden; Malmo Univ Hosp, Dept Anaesthesiol & Intens Care, Malmo, Sweden; Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden	Tunblad, K (corresponding author), Uppsala Univ, Dept Pharmaceut Biosci, Div Pharmacokinet & Drug Therapy, POB 591, SE-75124 Uppsala, Sweden.	Karin.Tunblad@farmbio.uu.se					BOJE KMK, 1995, J PHARMACOL EXP THER, V274, P1199; Bouw MR, 1998, PHARMACEUT RES, V15, P1673, DOI 10.1023/A:1011992125204; Bouw MR, 2000, PHARMACEUT RES, V17, P1220, DOI 10.1023/A:1026414713509; Bouw R, 2001, ACTA ANAESTH SCAND, V45, P390, DOI 10.1034/j.1399-6576.2001.045003390.x; BUNGAY PM, 1990, LIFE SCI, V46, P105, DOI 10.1016/0024-3205(90)90043-Q; Childs S, 1996, BBA-GENE STRUCT EXPR, V1307, P205, DOI 10.1016/0167-4781(96)00048-6; DAVIES B, 1993, PHARMACEUT RES, V10, P1093, DOI 10.1023/A:1018943613122; FENSTERMACHER JD, 1984, EDEMA, P383; Gardenfors A, 2002, ACTA NEUROCHIR, V144, P601, DOI 10.1007/s00701-002-0954-1; Gutmann H, 1999, DRUG METAB DISPOS, V27, P937; Hammarlund-Udenaes M, 2000, ADV DRUG DELIVER REV, V45, P283, DOI 10.1016/S0169-409X(00)00109-5; JOEL SP, 1988, J CHROMATOGR-BIOMED, V430, P394, DOI 10.1016/S0378-4347(00)83176-X; King M, 2001, NAT NEUROSCI, V4, P268, DOI 10.1038/85115; Letrent SP, 1999, DRUG METAB DISPOS, V27, P827; MATOS FF, 1992, J NEUROCHEM, V58, P1773, DOI 10.1111/j.1471-4159.1992.tb10053.x; Park WS, 2000, J KOREAN MED SCI, V15, P203, DOI 10.3346/jkms.2000.15.2.203; Piquette-Miller M, 1998, PHARMACEUT RES, V15, P706, DOI 10.1023/A:1011962818051; QUAGLIARELLO V, 1992, NEW ENGL J MED, V327, P864, DOI 10.1056/NEJM199209173271208; QUAGLIARELLO VJ, 1993, CLIN INFECT DIS, V17, P603, DOI 10.1093/clinids/17.4.603; Sawchuk RJ, 2000, ADV DRUG DELIVER REV, V45, P295, DOI 10.1016/S0169-409X(00)00104-6; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Stain-Texier F, 1999, BRIT J PHARMACOL, V128, P917, DOI 10.1038/sj.bjp.0702873; Tunblad K, 2003, PHARMACEUT RES, V20, P618, DOI 10.1023/A:1023250900462; VANBELLE K, 1995, J PHARMACOL EXP THER, V272, P1217; Xie RJ, 1999, BRIT J PHARMACOL, V128, P563, DOI 10.1038/sj.bjp.0702804	26	25	25	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAR	2004	48	3					294	301		10.1111/j.0001-5172.2003.0311.x			8	Anesthesiology	Anesthesiology	803SS	WOS:000220251400005	14982561				2021-06-18	
J	Hellal, F; Bonnefont-Rousselot, D; Croci, N; Palmier, B; Plotkine, M; Marchand-Verrecchia, C				Hellal, F; Bonnefont-Rousselot, D; Croci, N; Palmier, B; Plotkine, M; Marchand-Verrecchia, C			Pattern of cerebral edema and hemorrhage in a mice model of diffuse brain injury	NEUROSCIENCE LETTERS			English	Article						diffuse brain injury; cerebral edema; electrolytes; blood-brain barrier; cerebral hemorrhage; hemoglobin; iron	CLOSED-HEAD INJURY; ATPASE ACTIVITY; BARRIER; HEMOGLOBIN; RATS; CONTUSION; IRON	This study aims to examine the time course of the brain edema formation in relation with blood-brain barrier (BBB) disruption and cerebral hemorrhage in a murine model of diffuse brain injury. Brain water content increased at 1 h post-injury and persisted up to 7 days. This event was associated with electrolyte imbalance such as Na+ increase within 24 h. Prominent Evans blue extravasation was also observed from 1 to 6 h post-injury. Concurrently, hemoglobin increased markedly by 1 h, reached a peak at 4 h and declined progressively within a week in association with a rise of parenchyma iron content between 24 h and 7 days. These results suggest that brain edema is vasogenic and that the hemorrhage process is involved in the BBB disruption and edema, both leading to post-traumatic secondary events. (C) 2003 Elsevier Ireland Ltd. All rights reserved.	Univ Paris 05, Pharmacol Lab, UPRES EA2510, F-75006 Paris, France; Univ Paris 05, Lab Biochim Metab & Clin, UPRES EA 3617, F-75006 Paris, France	Marchand-Verrecchia, C (corresponding author), Univ Paris 05, Pharmacol Lab, UPRES EA2510, 4 Ave Observ, F-75006 Paris, France.	catherine.verrecehia@univ-paris5.fr	Hellal, Farida/E-8533-2013; Rousselot, Bonnefont/U-7434-2019; Hellal, Farida/D-1834-2015; MARCHAND-LEROUX, Catherine/L-7453-2017	Hellal, Farida/0000-0002-9344-1846; MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; Bonnefont-Rousselot, Dominique/0000-0003-4689-9202			Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; CLENDENON NR, 1978, J NEUROSURG, V49, P563, DOI 10.3171/jns.1978.49.4.0563; Ding-Zhou L, 2002, EUR J PHARMACOL, V457, P137, DOI 10.1016/S0014-2999(02)02686-9; Go K G, 1997, Adv Tech Stand Neurosurg, V23, P47; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; Ildan F, 1995, SURG NEUROL, V44, P573; Kawai N, 2001, BRAIN RES, V895, P50, DOI 10.1016/S0006-8993(01)02026-1; Kinoshita K, 2002, J NEUROSURG, V97, P945, DOI 10.3171/jns.2002.97.4.0945; Lee KR, 1996, ACTA NEUROCHIR, V138, P396, DOI 10.1007/BF01420301; Lomnitski L, 2000, EXP TOXICOL PATHOL, V52, P177; MISRA HP, 1972, J BIOL CHEM, V247, P6960; PANTER SS, 1994, METHOD ENZYMOL, V231, P502; Regan RF, 2003, J NEUROTRAUM, V20, P111, DOI 10.1089/08977150360517236; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Xue MZ, 2000, STROKE, V31, P1721, DOI 10.1161/01.STR.31.7.1721	21	25	29	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	FEB 26	2004	357	1					21	24		10.1016/j.neulet.2003.12.036			4	Neurosciences	Neurosciences & Neurology	777HE	WOS:000189169800006	15036604				2021-06-18	
J	Kondratyev, A; Gale, K				Kondratyev, A; Gale, K			Latency to onset of status epilepticus determines molecular mechanisms of seizure-induced cell death	MOLECULAR BRAIN RESEARCH			English	Article						apoptosis; necrosis; neurodegeneration; rhinal cortex; limbic seizures; calpain; caspase-3; DNA fragmentation	TRAUMATIC BRAIN-INJURY; EVOKED LIMBIC SEIZURES; ACID-INDUCED SEIZURES; METHYL-D-ASPARTATE; ALPHA-II-SPECTRIN; NEURONAL DEATH; KAINIC ACID; DNA FRAGMENTATION; CASPASE-3-LIKE PROTEASE; CEREBRAL-ISCHEMIA	The molecular mechanisms mediating degeneration in response to neuronal insults, including damage evoked by prolonged seizure activity, show substantial variability across laboratories and injury models. Here we investigate the extent to which the proportion of cell death occurring by apoptotic vs. necrotic mechanisms may be shifted by changing the temporal parameters of the insult. In initial studies with continuous seizures (status epilepticus, SE), signs of apoptotic degeneration were most clearly observed when SE occurred following a long latency (>86 min) after injection of kainic acid as compared with a short-latency SE (<76 min). Therefore, in this study we directly compared short- with long-latency SE for the expression of molecular markers for apoptosis and necrosis in an especially vulnerable brain region (rhinal cortex). Molecular markers of apoptosis (DNA fragmentation, cleavage of ICAD, an inhibitor of "caspase-activated DNase" (CAD), and prevalence of a caspase-generated fragment of alpha-spectrin) were detected following long-latency SE. Short-latency SE resulted in expression of predominantly necrotic features of cell death, such as "non-ladder" pattern of genomic DNA degradation, prevalence of a calpain-generated alpha-spectrin fragment, and absence of ICAD cleavage. Silver staining revealed no significant difference in the extent and spatial distribution of degeneration between long- or short-latency SE. These data indicate that the latency to onset of SE determines the extent to which apoptotic or necrotic mechanisms contribute to the degeneration following SE. The presence of a long latency period, during which multiple brief seizure episodes may occur, favors the occurrence of apoptotic cell death. It is possible that the absence of such "preconditioning" period in short-latency SE favors predominantly necrotic profile. (C) 2003 Elsevier B.V. All rights reserved.	Georgetown Univ, Dept Pediat, Washington, DC 20057 USA; Georgetown Univ, Dept Pharmacol, Washington, DC 20057 USA	Kondratyev, A (corresponding author), Georgetown Univ, Dept Pediat, W208 Res Bldg,3970 Reservoir Rd Nw, Washington, DC 20057 USA.	kondrata@georgetown.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020576] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH 02040] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 20576] Funding Source: Medline		ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Araki T, 2002, J NEUROSCI RES, V69, P614, DOI 10.1002/jnr.10356; BEDNARSKI E, 1995, BRAIN RES, V694, P147, DOI 10.1016/0006-8993(95)00851-G; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Brown TL, 1999, J BIOL CHEM, V274, P23256, DOI 10.1074/jbc.274.33.23256; Chen J, 1998, J NEUROSCI, V18, P4914; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Colbourne F, 1999, J NEUROSCI, V19, P4200; Covolan L, 2000, EPILEPSY RES, V41, P9, DOI 10.1016/S0920-1211(00)00122-4; de Olmos JS, 1981, NEUROANATOMICAL TRAC, P117; Ebert U, 2002, EPILEPSIA, V43, P86, DOI 10.1046/j.1528-1157.43.s.5.39.x; Faddis BT, 1997, J NEUROSCI, V17, P951; Faherty CJ, 1999, MOL BRAIN RES, V70, P159, DOI 10.1016/S0169-328X(99)00143-6; Fujikawa DG, 2000, NEUROSCIENCE, V98, P41, DOI 10.1016/S0306-4522(00)00085-3; Fujikawa DG, 1999, EUR J NEUROSCI, V11, P1605, DOI 10.1046/j.1460-9568.1999.00573.x; Fujikawa DG, 2000, EPILEPSIA, V41, pS9, DOI 10.1111/j.1528-1157.2000.tb01549.x; Henshall DC, 2000, BRAIN RES, V858, P290, DOI 10.1016/S0006-8993(99)02452-X; Henshall DC, 2000, J NEUROCHEM, V74, P1215; Henshall DC, 2001, NEUROBIOL DIS, V8, P568, DOI 10.1006/nbdi.2001.0415; Kondratyev A, 2000, MOL BRAIN RES, V75, P216, DOI 10.1016/S0169-328X(99)00292-2; Kondratyev A, 2002, NEUROSCI LETT, V319, P145, DOI 10.1016/S0304-3940(02)00004-6; Kondratyev A, 2001, NEUROSCI LETT, V310, P13, DOI 10.1016/S0304-3940(01)02055-9; Kondratyev A, 2001, MOL BRAIN RES, V91, P1, DOI 10.1016/S0169-328X(01)00099-7; Lee P, 2002, EPILEPSIA, V43, P14, DOI 10.1046/j.1528-1157.43.s.6.7.x; Li H, 2000, STROKE, V31, P176, DOI 10.1161/01.STR.31.1.176; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Newcomb JK, 2000, METH MOL B, V144, P219; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; POLLARD H, 1994, NEUROREPORT, V5, P1053, DOI 10.1097/00001756-199405000-00009; PorteraCailliau C, 1997, J COMP NEUROL, V378, P88, DOI 10.1002/(SICI)1096-9861(19970203)378:1<88::AID-CNE5>3.0.CO;2-G; PorteraCailliau C, 1997, J COMP NEUROL, V378, P70; Puig B, 2002, NEUROSCI LETT, V321, P182, DOI 10.1016/S0304-3940(01)02518-6; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Sankar R, 1998, J NEUROSCI, V18, P8382; SCHWOB JE, 1980, NEUROSCIENCE, V5, P991, DOI 10.1016/0306-4522(80)90181-5; Sloviter RS, 1996, J COMP NEUROL, V366, P516, DOI 10.1002/(SICI)1096-9861(19960311)366:3<516::AID-CNE10>3.0.CO;2-N; SPERK G, 1983, NEUROSCIENCE, V10, P1301, DOI 10.1016/0306-4522(83)90113-6; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Yakovlev AG, 2001, J NEUROSCI, V21, P7439; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	43	25	35	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	FEB 5	2004	121	1-2					86	94		10.1016/j.molbrainres.2003.11.005			9	Neurosciences	Neurosciences & Neurology	779VL	WOS:000189322200009	14969739				2021-06-18	
J	Chen, CC; Heinemann, AW; Bode, RK; Granger, CV; Mallinson, T				Chen, CC; Heinemann, AW; Bode, RK; Granger, CV; Mallinson, T			Impact of pediatric rehabilitation services on children's functional outcomes	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						rehabilitation therapy; treatment effectiveness; WeeFIM (R)	TRAUMATIC BRAIN INJURY; INDEPENDENCE MEASURE; DEVELOPMENTAL-DISABILITIES; PERFORMANCE; STABILITY; RELIABILITY; INTENSITY; AGREEMENT; VALIDITY; WEEFIM	OBJECTIVES. Relatively little is known about the treatment effectiveness and functional outcomes of pediatric rehabilitation therapies. This study was conducted to gain knowledge of the type and quantity of inpatient rehabilitation services provided to children who received acute inpatient rehabilitation and compare functional gains by age and diagnosis. METHOD. A retrospective cohort design was used. Records of rehabilitation therapies and functional assessments of 814 pediatric patients who received inpatient rehabilitation during 1996, 1997, and 1998 were collected. The admission and discharge item ratings of the WeeFIM(R) instrument were first transformed into interval-level measures of self-care, mobility, and cognition. Parametric analyses were, used to compare functional gains across impairment groups and to examine the relationship between amount of treatment and functional gains. RESULTS. Occupational therapy and physical therapy were the primary rehabilitation services received by patients across impairment groups (98% and 99%, respectively). A large proportion of children with traumatic brain injuries also received speech therapy (97%) and psychology services (60%). Across domains (self-care, mobility, cognition), the largest gains were made by children who were older than 7 years and had traumatic injuries. Functional gains were significantly related to the amount of discipline-specific treatment received, after controlling for age, impairment, and functional status at admission. CONCLUSION. Rehabilitation therapy provision in pediatric inpatient rehabilitation varies greatly depending on children's age and the nature of the impairment. Systematic reporting of type and quantity of rehabilitation therapies along with functional assessments before and after hospitalization would allow researchers to track functional changes and study the determinants of functional improvement.	NYU, Steinhardt Sch Educ, Dept Occupat Therapy, New York, NY 10012 USA; Inst Rehabil, Ctr Rehabil Outcomes Res, Chicago, IL USA; SUNY Buffalo, Dept Rehabil Med, Buffalo, NY USA; Uniform Data Syst Med Rehabil UDSMR, Amherst, NY USA	Chen, CC (corresponding author), NYU, Steinhardt Sch Educ, Dept Occupat Therapy, 35 W 4 St,11th Floor, New York, NY 10012 USA.	christine.chen@nyu.edu	Mallinson, Trudy/S-7381-2019; Heinemann, Allen W/K-6283-2012; Heinemann, Allen W./AAI-2790-2021	Mallinson, Trudy/0000-0002-4888-5579; Heinemann, Allen W/0000-0003-2782-7326; Heinemann, Allen W./0000-0003-2782-7326			Bonder B, 2001, OCCUP THER J RES, V21, P3, DOI 10.1177/153944920102100101; BOYER MG, 1991, INJURY, V22, P315, DOI 10.1016/0020-1383(91)90014-6; Bundy AC, 2001, OCCUP THER J RES, V21, P276, DOI 10.1177/153944920102100405; Case-Smith J, 1998, AM J OCCUP THER, V52, P788, DOI 10.5014/ajot.52.10.788; Case-Smith J, 2002, AM J OCCUP THER, V56, P17, DOI 10.5014/ajot.56.1.17; Chen CC, 2002, ARCH PHYS MED REHAB, V83, P1514, DOI 10.1053/apmr.2002.35107; Coster W, 1998, AM J OCCUP THER, V52, P337, DOI 10.5014/ajot.52.5.337; COSTER WJ, 1994, AM J OCCUP THER, V48, P211, DOI 10.5014/ajot.48.3.211; COSTER WJ, 1992, INFANT YOUNG CHILD, V4, P11; Daniels LE, 1998, AM J OCCUP THER, V52, P857, DOI 10.5014/ajot.52.10.857; Deutsch A, 1996, CRIT REV PHYS REHABI, V8, P267; DISCALA C, 1992, AM J PHYS MED REHAB, V71, P145, DOI 10.1097/00002060-199206000-00004; Dorval G, 1996, OCCUP THER INT, V3, P241, DOI DOI 10.1002/(ISSN)1557-0703; DUDGEON BJ, 1996, OCCUPATIONAL THERAPY, P777; Fiedler RC, 1998, AM J PHYS MED REHAB, V77, P444, DOI 10.1097/00002060-199809000-00019; Fisher WP., 1992, RASCH MEASUREMENT T, V6, P238; FUHRER MJ, 1997, ASSESSING MED REHABI; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; HALEY SM, 1992, ADM MANUAL PEDIAT EV; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; HEINEMANN AW, 1999, EFFECTIVENESS OCCUPA; Hwang JL, 2002, OTJR-OCCUP PART HEAL, V22, P48, DOI 10.1177/153944920202200202; JOHNSTON MV, 1997, ASSESSING MED REHABI, P1; Kleinbaum D, 1988, APPL REGRESSION ANAL; Law M, 1999, ARCH PHYS MED REHAB, V80, P629, DOI 10.1016/S0003-9993(99)90164-8; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; LINACRE JM, 2001, WINSTEPS COMPUTER PR; LINACRE JM, 2000, USERS GUIDE WINSTEPS; Lollar DJ, 2000, ARCH PHYS MED REHAB, V81, pS46, DOI 10.1053/apmr.2000.20624; MSALL ME, 1994, CLIN PEDIATR, V33, P421, DOI 10.1177/000992289403300708; Ottenbacher KJ, 1999, AM J OCCUP THER, V53, P181, DOI 10.5014/ajot.53.2.181; Ottenbacher KJ, 1996, DEV MED CHILD NEUROL, V38, P907; Ottenbacher KJ, 1997, ARCH PHYS MED REHAB, V78, P1309, DOI 10.1016/S0003-9993(97)90302-6; Ottenbacher KJ, 1999, DEV MED CHILD NEUROL, V41, P186, DOI 10.1017/S0012162299000377; Ottenbacher KJ, 2000, AM J PHYS MED REHAB, V79, P114, DOI 10.1097/00002060-200003000-00002; Ottenbacher KJ, 2000, ARCH PHYS MED REHAB, V81, P1317, DOI 10.1053/apmr.2000.9387; Pedhazur E.J., 1982, MULTIPLE REGRESSION, V2nd ed.; Scheffe H., 1959, ANAL VARIANCE; *SPSS, 2002, SPSS WIND; Swaine BR, 2000, AM J PHYS MED REHAB, V79, P412, DOI 10.1097/00002060-200009000-00002; *UDSMR, 1993, GUID UN DAT SET MED; *UDSMR, 1997, GUID UN DAT SET MED; Vargas S, 1999, AM J OCCUP THER, V53, P189, DOI 10.5014/ajot.53.2.189; Wright BD., 1996, RASCH MEAS T, V8, P472; Yung A, 1999, Pediatr Rehabil, V3, P21	47	25	26	0	4	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490			AM J OCCUP THER	Am. J. Occup. Ther.	JAN-FEB	2004	58	1					44	53		10.5014/ajot.58.1.44			10	Rehabilitation	Rehabilitation	764NG	WOS:000188212500006	14763635				2021-06-18	
J	Ivanhoe, CB; Hartman, ET				Ivanhoe, CB; Hartman, ET			Clinical caveats on medical assessment and treatment of pain after TBI	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						botox; deep venous thrombosis; dysautonomia; fracture; headache; heterotopic ossification; intrathecal baclofen; motor point block; neuropathic pain; shoulder subluxation; spastic dystonia; spasticity	TRAUMATIC BRAIN-INJURY; BOTULINUM-TOXIN-A; INTRATHECAL BACLOFEN; HETEROTOPIC OSSIFICATION; VENOUS THROMBOEMBOLISM; SPASTICITY; MANAGEMENT; PATIENT; DYSAUTONOMIA; SHOULDER	The diagnosis and management of pain in the patient with traumatic brain injury (TBI) can be difficult in light of the limitations imposed by the cognitive, language, and behavioral deficits. With patients in the acute rehabilitation setting, one must be vigilant for the often subtle signs and symptoms of pain. Causes more commonly seen in the population with TBI as a consequence of the injury itself include dysautonomia, neuropathic pain, spasticity, and heterotopic ossification. Headaches may be a consequence of TBI or associated with it for other reasons. Sources of pain associated with TBI include deep venous thrombosis and others. The reader is, reminded that patients with TBI are subject to all the causes of pain that affect the general population.	Baylor Coll Med, Inst Rehabil & Res, Dept Phys Med & Rehabil, Houston, TX USA	Ivanhoe, CB (corresponding author), Baylor Coll Med, Inst Rehabil & Res, Dept Phys Med & Rehabil, Houston, TX USA.	ivanhc@tirr.tmc.edu					ACQUANDRO MA, 1994, ANESTHESIOLOGY, V80, P706; ANDERSEN G, 1995, PAIN, V61, P187, DOI 10.1016/0304-3959(94)00144-4; ANDERSEN JT, 1977, INT UROL NEPHROL, V9, P133, DOI 10.1007/BF02082015; BAGLEY SL, 1979, ORTHOPEDIC REV, V8, P113; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Becker R, 1997, J NEUROL, V244, P160, DOI 10.1007/s004150050067; Beric A, 1998, NEUROL CLIN, V16, P899, DOI 10.1016/S0733-8619(05)70104-3; BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; Bontke C. F., 1993, J HEAD TRAUMA REHAB, V8, P34; BONTKE CF, 1989, PHYS MED REHABIL STA, V3, P43; Bowsher D, 1996, J NEUROL NEUROSUR PS, V61, P62, DOI 10.1136/jnnp.61.1.62; Brashear A, 2002, NEW ENGL J MED, V347, P395, DOI 10.1056/NEJMoa011892; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; DECOURVAL LP, 1990, ARCH PHYS MED REHAB, V71, P673; Galer BS, 1998, NEUROL CLIN, V16, P791, DOI 10.1016/S0733-8619(05)70098-0; GARLAND DE, 1978, CLIN ORTHOP RELAT R, P111; GARLAND DE, 1985, J BONE JOINT SURG AM, V67A, P1261, DOI 10.2106/00004623-198567080-00019; GARLAND DE, 1981, CLIN ORTHOP RELAT R, V155, P162; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Gellman H, 1996, J HEAD TRAUMA REHAB, V11, P23, DOI 10.1097/00001199-199608000-00005; HAMILTON MG, 1994, NEUROSURGERY, V34, P280, DOI 10.1227/00006123-199402000-00012; Hammond FM, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199802000-00007; Hanscom DA, 1987, J HEAD TRAUMA REHAB, V2, P1; Hulstyn M J, 1993, Orthop Rev, V22, P425; Ivanhoe CB, 2002, PAIN MANAGEMENT IN REHABILITATION, P101; Keenan MAE, 1996, J HEAD TRAUMA REHAB, V11, P8, DOI 10.1097/00001199-199608000-00004; KOMAN LA, 1994, J PEDIATR ORTHOPED, V14, P299, DOI 10.1097/01241398-199405000-00005; Lang AM, 2003, ARCH PHYS MED REHAB, V84, pS69, DOI 10.1053/apmr.2003.50121; LEHMKUHL LD, 1990, J HEAD TRAUMA REHAB, V5, P23, DOI DOI 10.1097/00001199-199012000-00005; Martelli MF, 1999, J HEAD TRAUMA REHAB, V14, P49, DOI 10.1097/00001199-199902000-00007; Mellick GA, 1997, ARCH PHYS MED REHAB, V78, P98, DOI 10.1016/S0003-9993(97)90020-4; MENDELSON L, 1975, SCAND J REHABIL MED, V7, P141; Merren MD, 1998, SOUTHERN MED J, V91, P739, DOI 10.1097/00007611-199808000-00007; Merskey n, 1994, CLASSIFICATION CHRON, V2nd, P207; Meythaler JM, 1996, ARCH PHYS MED REHAB, V77, P1, DOI 10.1016/S0003-9993(96)90210-5; Meythaler JM, 1996, ARCH PHYS MED REHAB, V77, P461, DOI 10.1016/S0003-9993(96)90034-9; On AY, 1999, AM J PHYS MED REHAB, V78, P344, DOI 10.1097/00002060-199907000-00010; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; PACKARD RC, 1994, J NEUROPSYCH CLIN N, V6, P229; Pierson SH, 1996, ARCH PHYS MED REHAB, V77, P717, DOI 10.1016/S0003-9993(96)90015-5; RIMEL RW, 1983, REHABILITATION HEAD, P9; Samkoff LM, 1997, NEUROLOGY, V49, P304, DOI 10.1212/WNL.49.1.304; SPIELMAN G, 1983, ARCH PHYS MED REHAB, V64, P539; STRAKOWSKI JA, 2000, PHYSICAL MED REHABIL, P797; Subbarao J V, 1999, J Spinal Cord Med, V22, P273; VANOUWENALLER C, 1986, ARCH PHYS MED REHAB, V67, P23; Welch MJ, 2000, TOXICON, V38, P245, DOI 10.1016/S0041-0101(99)00153-1; Wheeler AH, 2001, J MUSCULOSKELET PAIN, V9, P67, DOI 10.1300/J094v09n01_08; WHYTE J, 1986, J HEAD TRAUMA REHAB, V1, P39; ZUCKERMAN JD, 1991, AM FAM PHYSICIAN, V43, P497; Zuniga RE, 2002, REGION ANESTH PAIN M, V27, P90, DOI 10.1053/rapm.2002.29244	51	25	25	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2004	19	1					29	39		10.1097/00001199-200401000-00004			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	768UT	WOS:000188554000004	14732829				2021-06-18	
J	Lowther, JL; Mayfield, J				Lowther, JL; Mayfield, J			Memory functioning in children with traumatic brain injuries: a TOMAL validity study	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						memory; pediatric; traumatic brain injury	PEDIATRIC HEAD-INJURY; NEUROPSYCHOLOGICAL SEQUELAE; TEST-PERFORMANCE; ADOLESCENTS; DEFICITS	Traumatic brain injury (TBI) leads the causes of death and disability among children and adolescents. Despite the prevalence of TBI among children, few studies have examined memory in children. The purpose of this study was to compare memory functioning, as measured by the Test of Memory and Learning (TOMAL), of children with and without TBI and with moderate and severe TBI to determine if differences existed. Of the 140 participants, 70 had sustained a head trauma and 70 served as controls. The results indicated that, when the TBI and control group were compared, significant differences were found on all of the TOMAL indexes. With the exception of the verbal delayed recall items, significant differences were demonstrated on all the TOMAL subtests. No differences were identified when moderate and severe groups were compared. These findings further the understanding of memory following pediatric TBI, as well as have implications for interventions with this population. (C) 2002 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Texas Womans Univ, Denton, TX 76204 USA; Our Childrens House, Dallas, TX USA	Lowther, JL (corresponding author), 1919 Creek Wood Dr, Arlington, TX 76006 USA.						BASSETT SS, 1990, J PEDIATR PSYCHOL, V15, P225, DOI 10.1093/jpepsy/15.2.225; BIJUR PE, 1990, PEDIATRICS, V86, P337; Boyd T. A., 1988, ASSESSMENT ISSUES CH, P177; CLANG A, 1997, STUDENTS ACQUIRED BR; DONDERS J, 1993, BRAIN INJURY, V7, P431, DOI 10.3109/02699059309029686; Farmer JE, 1999, DEV NEUROPSYCHOL, V15, P269, DOI 10.1080/87565649909540749; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; GAIDOLFI E, 1980, ITAL J NEUROL SCI, V1, P65; Golden C. J., 1987, LURIA NEBRASKA NEURO; GOLDEN CJ, 1985, LURIA NEBRASKA NEURO; GROSS R, 1999, ASPECTS PSYCHOL; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; Halstead WC., 1947, BRAIN INTELLIGENCE Q; HOLIFIELD JE, 1999, DISS ABSTR INT B, V60, P2343; KAUFMAN AS, 1983, KABC KAUFMAN ASSESSM; Kelly M P, 1996, Appl Neuropsychol, V3, P147, DOI 10.1207/s15324826an0303&4_7; Keppel, 1991, DESIGN ANAL RES HDB; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; KRAEMER BR, 1997, STUDENTS ACQUIRED BR, P3; KRAUS JF, 1987, HEAD INJURY, P1; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; LUCAS JA, 1999, CLIN NEUROPSYCHOLOGY, P243; Mayfield JW, 1997, ARCH CLIN NEUROPSYCH, V12, P111, DOI 10.1016/S0887-6177(96)00016-9; MAYFIELD JW, 1998, ANN M NAT AC NEUR WA; *NAT CTR INJ PREV, 2000, EP TRAUM BRAIN INJ U; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Reitan R.M., 1992, NEUROPSYCHOLOGICAL E; Reitan RM., 1985, HALSTEAD REITAN NEUR; Reynolds C. R., 1997, HDB CLIN CHILD NEURO, P296; Reynolds C.R., 1994, TEST MEMORY LEARNING; Reynolds CR, 1996, ARCH CLIN NEUROPSYCH, V11, P29, DOI 10.1016/0887-6177(95)00027-5; RUSSELL EW, 1994, CLIN GUIDE NEUROPSYC, P211; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Sheslow D., 1990, WIDE RANGE ASSESSMEN; Stevens J., 1996, APPL MULTIVARIATE ST; TEASDALE G, 1974, LANCET, V2, P81; THORNDIKE RL, 1988, STANFORD BINET INTEL; Turkstra LS, 1998, J SPEECH LANG HEAR R, V41, P137, DOI 10.1044/jslhr.4101.137; WASSERMAN JD, 1992, UNPUB CLIN GUIDELINE; Wechsler, 1949, WECHSLER INTELLIGENC; Wechsler D., 1974, MANUAL WECHSLER INTE; Wechsler D., 1991, WECHSLER INTELLIGENC; Willcutt EG, 2001, J ABNORM PSYCHOL, V110, P157, DOI 10.1037//0021-843X.1001.1.157; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	50	25	27	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2004	19	1					105	118		10.1016/S0887-6177(02)00222-6			14	Psychology, Clinical; Psychology	Psychology	759MB	WOS:000187740500009	14670383	Bronze			2021-06-18	
J	Kalsotra, A; Turman, CM; Dash, PK; Strobel, HW				Kalsotra, A; Turman, CM; Dash, PK; Strobel, HW			Differential effects of traumatic brain injury on the cytochrome P450 system: A perspective into hepatic and renal drug metabolism	JOURNAL OF NEUROTRAUMA			English	Article						CYP450 drug substrates; inflammation and injury; leukotriene B-4; tissue-specific response	GENE-EXPRESSION; PROTEIN EXPRESSION; MESSENGER-RNA; P450; INFLAMMATION; INDUCTION; LIVER; LIPOPOLYSACCHARIDE; BIOTRANSFORMATION; INTERLEUKIN-6	Traumatic brain injury is known to cause several secondary effects, one of which is altered drug clearance. Given the fact that patients who sustain TBI are subsequently treated with a variety of pharmacological agents for the purpose of either neuroprotection or physiological support, it is imperative to clarify changes in expression and/or activities of enzymes involved in clearing drugs. The mixed function oxidase system, which consists of cytochrome P450 and cytochrome P450 reductase, plays a vital role in phase I drug metabolism. This paper addresses the issue as to what extent TBI affects the levels and activity of various rat CYP450 subfamilies. Our results show that TBI induces tissue-specific and time-dependent alterations. Total hepatic CYP450 content showed a biphasic response with a decrease seen at 24 h followed by an increase at 2 weeks. CYP450 reductase, in contrast, showed an opposite temporal profile. Immunoblot analyses and marker substrate metabolism demonstrated a clear decrease in hepatic CYP1A levels while a significant increase in kidney was seen at both 24 h and 2 weeks. A dramatic induction of CYP3A was evident at 2 weeks in liver, while no changes were noticed in CYP2B or CYP2D subfamilies. CYP4F subfamily showed induction in kidney only. Collectively, the data reveal the differential effects of TBI on hepatic and renal drug metabolism.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA; Univ Texas, Sch Med, Dept Neurobiol & Anat, Vivian L Smith Ctr Neurol Res, Houston, TX 77225 USA	Strobel, HW (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA.	henry.w.strobel@uth.tmc.edu		Kalsotra, Auinash/0000-0002-1011-0006	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R03MH058927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS023327, R01NS035457] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH58927] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35457, P50NS23327] Funding Source: Medline		ABDELRAZZAK Z, 1993, MOL PHARMACOL, V44, P707; ABDELRAZZAK Z, 1995, FEBS LETT, V366, P159, DOI 10.1016/0014-5793(95)00513-9; Anzenbacher P, 2001, CELL MOL LIFE SCI, V58, P737, DOI 10.1007/PL00000897; BARKER CW, 1992, J BIOL CHEM, V267, P8050; BOUCHER BA, 1991, CLIN PHARMACOL THER, V50, P487, DOI 10.1038/clpt.1991.173; Chen YZ, 2002, POSITIVITY, V6, P47, DOI 10.1023/A:1012079817987; Chen ZL, 1999, J NEUROSCI, V19, P9813; Clark MA, 1996, BIOCHEM PHARMACOL, V51, P701, DOI 10.1016/S0006-2952(95)02391-7; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; Crespi CL, 1997, ANAL BIOCHEM, V248, P188, DOI 10.1006/abio.1997.2145; Cui X, 2003, BBA-GEN SUBJECTS, V1619, P325, DOI 10.1016/S0304-4165(02)00491-9; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; DIGNAM JD, 1977, BIOCHEMISTRY-US, V16, P1116, DOI 10.1021/bi00625a014; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fisher AJ, 1999, LANCET, V353, P1412, DOI 10.1016/S0140-6736(99)00494-8; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Geng J, 1998, BRAIN RES, V784, P276, DOI 10.1016/S0006-8993(97)01346-2; GUENGERICH FP, 1979, MOL PHARMACOL, V15, P154; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; HEINEMEYER G, 1986, THER DRUG MONIT, V8, P145, DOI 10.1097/00007691-198606000-00003; Hiroi T, 1998, BBA-GEN SUBJECTS, V1380, P305, DOI 10.1016/S0304-4165(97)00157-8; Kalsotra A, 2002, DRUG METAB DISPOS, V30, P1022, DOI 10.1124/dmd.30.9.1022; Kawashima H, 1997, ARCH BIOCHEM BIOPHYS, V347, P148, DOI 10.1006/abbi.1997.0342; Kikuta Y, 2002, PROSTAG OTH LIPID M, V68-9, P345, DOI 10.1016/S0090-6980(02)00039-4; Kraus MF, 1999, TRAUMATIC BRAIN INJU, P173; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lasker JM, 2000, J BIOL CHEM, V275, P4118, DOI 10.1074/jbc.275.6.4118; LU AYH, 1970, MOL PHARMACOL, V6, P213; Marion D W, 1999, Clin Neurosurg, V45, P184; Mcintosh TK, 1999, TRAUMATIC BRAIN INJU, P39; McKindley DS, 1997, J CLIN PHARMACOL, V37, P129, DOI 10.1002/j.1552-4604.1997.tb04771.x; McKindley DS, 1998, PHARMACOTHERAPY, V18, P759; Morgan ET, 1997, DRUG METAB REV, V29, P1129, DOI 10.3109/03602539709002246; MORGAN ET, 1994, BBA-GENE STRUCT EXPR, V1219, P475, DOI 10.1016/0167-4781(94)90074-4; MORGAN ET, 1991, BIOCHEM PHARMACOL, V42, P51, DOI 10.1016/0006-2952(91)90680-4; Nebert DW, 2002, LANCET, V360, P1155, DOI 10.1016/S0140-6736(02)11203-7; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; Nelson DR, 1999, ARCH BIOCHEM BIOPHYS, V369, P1, DOI 10.1006/abbi.1999.1352; OMARA NB, 1995, CRIT CARE MED, V23, P1418, DOI 10.1097/00003246-199508000-00017; OMURA T, 1964, J BIOL CHEM, V239, P2370; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Poloyac SM, 2001, DRUG METAB DISPOS, V29, P296; Renton KW, 2001, PHARMACOL THERAPEUT, V92, P147, DOI 10.1016/S0163-7258(01)00165-6; Renton KW, 2000, J PHARMACOL EXP THER, V294, P524; SABEL BA, 1986, NATURE, V323, P493, DOI 10.1038/323493a0; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Shimamoto Y, 1998, ARCH TOXICOL, V72, P492, DOI 10.1007/s002040050533; Stresser DM, 2002, DRUG METAB DISPOS, V30, P845, DOI 10.1124/dmd.30.7.845; Strobel Henry W., 1995, P225; Strobel HW, 1997, DRUG METAB REV, V29, P1079, DOI 10.3109/03602539709002244; TOLER SM, 1993, DRUG METAB DISPOS, V21, P1064; Wang HM, 1997, ARCH BIOCHEM BIOPHYS, V344, P365, DOI 10.1006/abbi.1997.0230; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; XU J, 1990, J NEUROCHEM, V55, P907, DOI 10.1111/j.1471-4159.1990.tb04577.x	55	25	25	1	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2003	20	12					1339	1350		10.1089/089771503322686139			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	756XH	WOS:000187510700006	14748982				2021-06-18	
J	Wang, K; Walz, W				Wang, K; Walz, W			Unusual topographical pattern of proximal astrogliosis around a cortical devascularizing lesion	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						GFAP; glial cells; ischemia; reactive astrocyte; S100 beta; vimentin	ADULT-RAT-BRAIN; REACTIVE ASTROCYTES; GLIAL-CELLS; S-100 PROTEIN; HIPPOCAMPUS; INJURY; GFAP; VIMENTIN; EXPRESSION; IMMUNOHISTOCHEMISTRY	Class II vessels were disrupted on the cortical surface of adult rats within a circular 5-mm-diameter area. This consistently resulted in the formation of a conical lesion by day 1, with a cystic cavity forming by day 21. Four markers were used to identify the glial response surrounding the lesion. The antibody used against S100beta marked the largest astrocytic pool in the gray matter of the cerebral cortex; only similar to5% of astrocytes were glial fibrillary acidic protein (GFAP)(+) in control animals. GFAP served as a marker for distal reactive gliosis and vimentin (VIM) for proximal gliosis. Isolectin B4 was used as an additional marker to distinguish VIM+ microglia from astrocytes inside the lesion area. Three immunohisto-chemically distinct areas of reactive astrocytes surrounding the lesion were found within 24 hr of injury and lasted through day 6. The first area, in contrast to focal traumatic injuries, consisted of a 196-mum-thick boundary layer of S100beta(+) cells immediately surrounding the lesion that never expressed GFAP or VIM by day 6. This boundary layer turns into a GFAP(+) glial limitans encasing the cystic cavity by day 21. A second unusual extended area around the base of the lesion reaching partly into the corpus callosum consisted of S100beta(+)/GFAP(+)/VIM+ cells. This region appears to be compatible with the local or proximal gliotic response usually found completely surrounding other focal-type injuries. The proximal response at the base of the lesion developed over the first 3 days in the following sequence: S100beta(+)/GFAP(-)/VIM- to S100beta(+)/GFAP(+)/VIM- to S100beta(+)/GFAP(+)/VIM+. Ninety percent of the astrocytes in this area express VIM. This is very high compared with findings in stab-wound preparations, where only 10% of astrocytes (surrounding entire lesion) are found to be VIM+. A third region, consistent with a remote or distal reactive gliotic response, demonstrated staining for S100beta and had increased GFAP contents throughout the neocortical hemisphere. Cells in this region were never found to be VIM+. Among S100beta(+) cells close to the boundary region, more than 80% expressed detectable GFAP by 2 days after lesioning. S100beta(+) cells 1 mm more laterally (distal to lesion) did not express GFAP to the same level until day 6. Thus, we find three immunohistochemically distinct populations of reactive astrocytes surrounding the focal ischemic lesion. In contrast to the case for stab-wound traumatic injury, the response closest to and surrounding the lesion did not up-regulate GFAP or VIM by day 6. The proximal response was, instead, more remote and only at the base of the lesion, extending partly into the corpus callosum. (C) 2003 Wiley-Liss, Inc.	Univ Saskatchewan, Dept Physiol, Saskatoon, SK S7N 5E5, Canada	Walz, W (corresponding author), Univ Saskatchewan, Dept Physiol, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	walz@sask.usask.ca					Alonso G, 2001, GLIA, V34, P253, DOI 10.1002/glia.1059; Bar T, 1980, VASCULAR SYSTEM CERE; BAUDIER J, 1985, J NEUROCHEM, V44, P76, DOI 10.1111/j.1471-4159.1985.tb07115.x; BIGNAMI A, 1976, NEUROPATH APPL NEURO, V2, P99, DOI 10.1111/j.1365-2990.1976.tb00488.x; Bordey A, 2001, J NEUROPHYSIOL, V85, P1719; Cerutti SM, 2000, CELL BIOL INT, V24, P35, DOI 10.1006/cbir.1999.0451; Chabot Sophie, 2002, P379; CHVATAL A, 1995, EUR J NEUROSCI, V7, P129, DOI 10.1111/j.1460-9568.1995.tb01027.x; Duggal N, 1997, BRAIN RES, V768, P1, DOI 10.1016/S0006-8993(97)00588-X; Fitch MT, 1997, EXP NEUROL, V148, P587, DOI 10.1006/exnr.1997.6701; GONG C, 2002, SOC NEUR ABSTR, V28; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; Hinterkeuser S, 2000, EUR J NEUROSCI, V12, P2087, DOI 10.1046/j.1460-9568.2000.00104.x; ISOBE T, 1983, BIOCHEM INT, V6, P419; Jabs R, 1997, NEUROSCIENCE, V81, P847, DOI 10.1016/S0306-4522(97)00207-8; JANECZKO K, 1993, INT J DEV NEUROSCI, V11, P139, DOI 10.1016/0736-5748(93)90074-N; JANECZKO K, 1994, INT J DEV NEUROSCI, V12, P431, DOI 10.1016/0736-5748(94)90027-2; KITAMURA T, 1987, BRAIN RES, V423, P189, DOI 10.1016/0006-8993(87)90839-0; KRESSIN K, 1995, GLIA, V15, P173, DOI 10.1002/glia.440150210; LAYWELL ED, 1991, ANN NY ACAD SCI, V633, P122; Li WEI, 1998, EUR J NEUROSCI, V10, P2444, DOI 10.1046/j.1460-9568.1998.00253.x; LUDWIN SK, 1976, J COMP NEUROL, V165, P197, DOI 10.1002/cne.901650206; Malhotra Sudarshan K., 1994, Biomedical Letters, V49, P273; Malhotra Sudarshan K., 2002, P17; Martinez G, 1998, INT J DEV NEUROSCI, V16, P519, DOI 10.1016/S0736-5748(98)00035-5; MIYAKE T, 1989, BRAIN RES, V489, P31, DOI 10.1016/0006-8993(89)90005-X; MIYAKE T, 1992, BRAIN RES, V586, P53, DOI 10.1016/0006-8993(92)91370-T; PETITO CK, 1990, J CEREBR BLOOD F MET, V10, P850, DOI 10.1038/jcbfm.1990.141; Savchenko VL, 2000, NEUROSCIENCE, V96, P195, DOI 10.1016/S0306-4522(99)00538-2; SCHIFFER D, 1993, INT J DEV NEUROSCI, V11, P269, DOI 10.1016/0736-5748(93)90085-R; SCHMIDTKASTNER R, 1990, J CHEM NEUROANAT, V3, P179; SCHROETER M, 1995, EXP BRAIN RES, V106, P1; Schwab JM, 2001, J NEUROTRAUM, V18, P377, DOI 10.1089/089771501750170930; SEIFERT G, 1995, EUR J NEUROSCI, V7, P1872, DOI 10.1111/j.1460-9568.1995.tb00708.x; SOFRONIEW MV, 1983, BRAIN RES, V289, P370, DOI 10.1016/0006-8993(83)90045-8; STEINDLER DA, 1993, ANNU REV NEUROSCI, V16, P445, DOI 10.1146/annurev.ne.16.030193.002305; STREIT WJ, 1990, J HISTOCHEM CYTOCHEM, V38, P1683, DOI 10.1177/38.11.2212623; Vazquez-Chona F, 1999, BRAIN RES, V838, P45, DOI 10.1016/S0006-8993(99)01679-0; Vinesi P, 1997, MOL CHEM NEUROPATHOL, V32, P129, DOI 10.1007/BF02815172; Walz W, 1998, NEUROSCI LETT, V257, P127, DOI 10.1016/S0304-3940(98)00813-1; Walz W, 1999, J NEUROSCI RES, V56, P595, DOI 10.1002/(SICI)1097-4547(19990615)56:6<595::AID-JNR5>3.3.CO;2-X; Walz W, 2000, GLIA, V31, P95, DOI 10.1002/1098-1136(200008)31:2<95::AID-GLIA10>3.0.CO;2-6; Yang HY, 1997, EXP NEUROL, V146, P199, DOI 10.1006/exnr.1997.6518; YONG VW, 1996, CYTOKINES CNS DEV DE, P309; Zhou M, 2000, MOL BRAIN RES, V76, P121, DOI 10.1016/S0169-328X(99)00341-1	45	25	27	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	AUG 15	2003	73	4					497	506		10.1002/jnr.10683			10	Neurosciences	Neurosciences & Neurology	707QH	WOS:000184521000008	12898534				2021-06-18	
J	Shohami, E; Yatsiv, I; Alexandrovich, A; Haklai, R; Elad-Sfadia, G; Grossman, R; Biegon, A; Kloog, Y				Shohami, E; Yatsiv, I; Alexandrovich, A; Haklai, R; Elad-Sfadia, G; Grossman, R; Biegon, A; Kloog, Y			The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid exerts long-lasting neuroprotection in a mouse closed head injury model	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						traumatic brain injury; Ras; S-trans; trans-farnesylthiosalicylic acid (FTS); NMDA receptors; neuroprotection	TRAUMATIC BRAIN INJURY; ACTIVATED PROTEIN-KINASE; TRANSCRIPTION FACTOR; NMDA RECEPTORS; MAP KINASE; H-RAS; MICE; PHOSPHORYLATION; PATHWAYS; SUBUNIT	Traumatic brain injury activates N-methyl-(D)-aspartate receptors (NMDAR) inducing activation of the Ras protein (a key regulator of cell growth, survival, and death) and its effectors. Thus, trauma-induced increase in active Ras-GTP might contribute to traumatic brain injury pathology. Based on this hypothesis, a new concept of neuroprotection is proposed, examined here by investigating the effect of the Ras inhibitor S-trans, trans-farnesylthiosalicylic acid (FTS) in a mouse model of closed head injury (CHI). Mice subjected to CHI were treated systemically 1 h later with FrS (5 mg/kg) or vehicle. After I h, Ras-GTP in the contused hemisphere showed a significant (3.8-fold) increase, which was strongly inhibited by FrS (82% inhibition) or by the NMDA-receptor antagonist MK-801 (53%). Both drugs also decreased active (phosphorylated) extracellular signal-regulated kinase. ITS prevented the CHI-induced reduction in NMDAR binding in cortical, striatal, and hippocampal regions, measured by [H-3]-MK-801 autoradiography, and decreased lesion size by 50%. It also reduced CHI-induced neurologic deficits, indicated by the highly significant (P < 0.0001) 60% increase in extent of recovery. Thus, FTS provided long-term neuroprotection after CHI, rescuing NMDAR binding in the contused hemisphere and profoundly reducing neurologic deficits. These findings suggest that nontoxic Ras inhibitors such as FTS may qualify as neuroprotective drugs.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Ctr, Pediat Intens Care Unit, IL-91120 Jerusalem, Israel; Tel Aviv Univ, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Chaim Sheba Med Ctr, Dept Neurosurg, IL-52621 Tel Hashomer, Israel; Lawrence Berkeley Natl Lab, Dept Funct Imaging, Berkeley, CA USA	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il					Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Biegon A, 2002, J NEUROCHEM, V82, P924, DOI 10.1046/j.1471-4159.2002.01050.x; BOWERY NG, 1988, BRIT J PHARMACOL, V93, P944, DOI 10.1111/j.1476-5381.1988.tb11484.x; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; DALAKAS MC, 1995, ANN NEUROL S, V37, P2; Elad-Sfadia G, 2002, J BIOL CHEM, V277, P37169, DOI 10.1074/jbc.M205698200; English JD, 1996, J BIOL CHEM, V271, P24329, DOI 10.1074/jbc.271.40.24329; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Ferrer I, 2002, ACTA NEUROPATHOL, V103, P391, DOI 10.1007/s00401-001-0481-9; Feuerstein GZ, 1998, NEUROIMMUNOMODULAT, V5, P143, DOI 10.1159/000026331; Fukunaga K, 1998, MOL NEUROBIOL, V16, P79, DOI 10.1007/BF02740604; Goebel DJ, 2001, EXP EYE RES, V72, P547, DOI 10.1006/exer.2001.0981; Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d; Jansen B, 1999, J MOL MED-JMM, V77, P792, DOI 10.1007/s001099900052; Kaminska B, 1999, MOL CELL NEUROSCI, V13, P405, DOI 10.1006/mcne.1999.0757; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; Kloog, 1999, Expert Opin Investig Drugs, V8, P2121, DOI 10.1517/13543784.8.12.2121; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Mandell JW, 2001, GLIA, V34, P283, DOI 10.1002/glia.1062; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Niv H, 2002, J CELL BIOL, V157, P865, DOI 10.1083/jcb.200202009; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Paxinos G., 1997, MOUSE BRAIN STEREOTA; Paz A, 2001, ONCOGENE, V20, P7486, DOI 10.1038/sj.onc.1204950; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Rosenblum K, 1997, J NEUROSCI, V17, P5129; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008	39	25	26	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUN	2003	23	6					728	738		10.1097/01.WCB.0000067704.86573.83			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	689JY	WOS:000183489900011	12796721	Bronze			2021-06-18	
J	Ashendorf, L; O'Bryant, SE; McCaffrey, RJ				Ashendorf, L; O'Bryant, SE; McCaffrey, RJ			Specificity of malingering detection strategies in older adults using the CVLT and WCST	CLINICAL NEUROPSYCHOLOGIST			English	Article							VERBAL-LEARNING TEST; CARD SORTING TEST; TRAUMATIC BRAIN-INJURY; PATIENT SAMPLES; HEAD-INJURY; PERFORMANCE	Strategies for the detection of possible malingering have largely taken two forms. First is the development and validation of domain-specific measures of malingering designed specifically for the detection of malingering (e.g., Test Of Memory Malingering, Word Memory Test, and Word Completion Memory Test). The second has been the development and evaluation of performance patterns and cutoff scores applicable to commonly used neuropsychological instruments. Two such instruments that have been examined are the Wisconsin Card Sorting Test (WCST) and the California Verbal Learning Test (CVLT). While several studies propose possible cutoff scores and actuarial judgement strategies for these tests, the specificity of these strategies within older, nonimpaired adults has not been established. Without proper evaluation of potential age-related effects within these strategies, the actual utility of the strategies within suspected malingerers who are older adults is unknown. Therefore, the present study was conducted to evaluate the specificity of the proposed strategies for detecting possible malingering with the WCST and the CVLT in a sample of older, community-dwelling, nonimpaired adults. The results suggest that the currently existing WCST formulas may have limited utility for the detection of malingering with older adults while the CVLT strategies do appear to have potential clinical utility. The potential of these formulas for use with older adults is discussed.	SUNY Albany, Dept Psychol, Albany, NY 12222 USA	Ashendorf, L (corresponding author), SUNY Albany, Dept Psychol, 1400 Washington Ave, Albany, NY 12222 USA.		Ashendorf, Lee/R-7206-2019	O'Bryant, Sid/0000-0003-0582-5266			Axelrod B., 1992, CLIN NEUROPSYCHOL, V6, P16; Ben-Porath Y. S., 1994, PSYCHOL ASSESSMENT, V6, P14; Bernard LC, 1996, ARCH CLIN NEUROPSYCH, V11, P231, DOI 10.1016/0887-6177(95)00025-9; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Coleman RD, 1998, J CLIN EXP NEUROPSYC, V20, P201, DOI 10.1076/jcen.20.2.201.1164; DELIS D, 1987, CALIFORNIA VERBAL LE; DONDERS J, 1999, J FORENSIC NEUROPSYC, V1, P35; Essig SM, 2001, ARCH CLIN NEUROPSYCH, V16, P271, DOI 10.1016/S0887-6177(99)00065-7; FRIDLUND A, 1987, CVLT ADM SCORING SYS; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; Greve KW, 2002, J CLIN EXP NEUROPSYC, V24, P48, DOI 10.1076/jcen.24.1.48.968; HAYES JS, 1999, EVALUATION TREATMENT; Heaton R., 1993, WISCONSIN CARD SORTI; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; MILLIS SR, 1997, CALIFORNIA VERBAL LE; *PSYCH ASS RES, 1993, WISC CARD SORT TEST; Ruiz MA, 2002, PROF PSYCHOL-RES PR, V33, P294, DOI 10.1037//0735-7028.33.3.294; Slick DJ, 2000, J CLIN EXP NEUROPSYC, V22, P569, DOI 10.1076/1380-3395(200010)22:5;1-9;FT569; Suhr JA, 2000, ARCH CLIN NEUROPSYCH, V15, P415, DOI 10.1016/S0887-6177(99)00033-5; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Sweet JJ, 2000, ARCH CLIN NEUROPSYCH, V15, P105, DOI 10.1016/S0887-6177(98)00153-X; Tombaugh TN, 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671	24	25	26	0	5	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	MAY	2003	17	2					255	262		10.1076/clin.17.2.255.16502			8	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	734PF	WOS:000186065200015	13680433				2021-06-18	
J	Binder, LM; Kelly, MP; Villanueva, MR; Winslow, MM				Binder, LM; Kelly, MP; Villanueva, MR; Winslow, MM			Motivation and neuropsychological test performance following mild head injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; DIGIT RECOGNITION TEST; FORCED-CHOICE METHOD; MEMORY TEST; DEFICITS; VALIDITY; IMPAIRMENT; PROSPECTS; AMNESIA; TASK	Effect of motivation on neuropsychological test performance in mild head injury was assessed. Motivation was measured using the Portland Digit Recognition Test. Three groups were compared: (a) mild head injury, financial incentives, good motivation; (b) mild head injury, financial incentives, poor motivation; (c) moderate/severe head injury, good motivation. The neuropsychological battery included measures of sensory function, motor function, attention, intelligence, abstract reasoning, and memory. Mild head injury well motivated patients performed significantly better than the other two groups on some tests. Mild head injury poorly motivated individuals and moderate-severe head injury patients were indistinguishable on many tests. Consistent with previous reports, tactile sensory (finger recognition and Fingertip Number Writing Perception) and recognition memory (Rey Auditory Verbal Learning) tasks were identified as clinically useful measures of poor motivation. On these measures mild head injury well motivated examinees performed no better than moderate-severe patients, with both groups superior to mild head injury poorly motivated examinees. Sensitivity and specificity data are reported. Our measures of tactile sensation and verbal recognition memory were more affected by motivation than by the severity of head injury.	Univ Maryland, Sch Med, Baltimore, MD 21201 USA; So Oregon Neuropsychol Clin LLC, Medford, OR USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA	Binder, LM (corresponding author), 4900 SW Griffith Dr,Suite 244, Beaverton, OR 97005 USA.	PDXLarry@aol.com					ALEXANDER MP, 1987, NEUROBEHAVIORAL RECO, P191; BENTON AL, 1961, ARCH GEN PSYCHIAT, V4, P105; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P461, DOI 10.1076/clin.15.4.461.1890; BINDER LM, 1993, ARCH CLIN NEUROPSYCH, V8, P137, DOI 10.1016/0887-6177(93)90031-U; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; BRANDT J, 1985, ANN NY ACAD SCI, V444, P502, DOI 10.1111/j.1749-6632.1985.tb37625.x; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Dickens S. E., 1992, STRUCTURED INTERVIEW; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Etcoff LM, 1996, NEUROPSYCHOL REV, V6, P171, DOI 10.1007/BF01874896; Frederick R. I., 1991, PSYCHOL ASSESSMENT J, V3, P596, DOI DOI 10.1037/1040-3590.3.4.596; Frederick RI, 1994, NEUROPSYCHOLOGY, V8, P118, DOI 10.1037/0894-4105.8.1.118; Geffen Gina, 1990, Clin Neuropsychol, V4, P45, DOI 10.1080/13854049008401496; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; GREIFFENSTEIN MF, 1994, PSYCHOL ASSESSMENT, V8, P218; GUILMETTE TJ, 1993, CLIN NEUROPSYCHOL, V7, P59, DOI 10.1080/13854049308401888; Halstead WC, 1985, HALSTEAD REITAN NEUR; Heaton R.K., 1991, COMPREHENSIVE NORMS; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Martin J, 2001, J TURBUL, V2, P1; MARTIN RC, 1993, J CLIN EXP NEUROPSYC, V15, P867, DOI 10.1080/01688639308402604; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; MITTENBERG W, 1993, PSYCHOL ASSESSMENT, V5, P34, DOI DOI 10.1037/1040-3590.5.1.34; Orey SA, 2000, ARCH CLIN NEUROPSYCH, V15, P335, DOI 10.1016/S0887-6177(99)00024-4; PRIGATANO GP, 1993, J CLIN EXP NEUROPSYC, V15, P537, DOI 10.1080/01688639308402577; ROSE F, 1995, CLIN NEUROPSYCHOL, V9, P1245; SLICK D, 1994, J CLIN EXP NEUROPSYC, V16, P472, DOI 10.1080/01688639408402657; Spreen O., 1998, COMPENDIUM NEUROPSYC; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; War Department Adjutant General's Office, 1944, ARM IND TEST BATT MA; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WECHSLER D, 1987, WECHSCLER MEMORY SCA; WIGGINS EC, 1988, LAW HUMAN BEHAV, V12, P57, DOI 10.1007/BF01064274; Youngjohn J.R., 1995, ASSESSMENT, V2, DOI [https://doi.org/10.1177/1073191195002003007, DOI 10.1177/1073191195002003007]; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593	42	25	25	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	MAY	2003	25	3					420	430		10.1076/jcen.25.3.420.13806			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	683GX	WOS:000183141200011	12916654				2021-06-18	
J	Karmy-Jones, R; DuBose, R; King, S				Karmy-Jones, R; DuBose, R; King, S			Traumatic rupture of the innominate artery	EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY			English	Article						blunt innominate artery; trauma	AORTIC-ARCH; ENDOVASCULAR REPAIR; BLUNT INJURIES; MANAGEMENT	Objective: Blunt traumatic rupture of the innominate artery is uncommon. We reviewed our experience to correlate the impact of patient stability, presence of associated injuries and location of the injury within the artery with outcome. Methods: A retrospective review was performed of patients admitted between January 1, 1998 and December 17, 2002 with traumatic innominate artery rupture. Injuries were defined as proximal if they were less than or equal to 0.5 cm from the origin, distal if less than or equal to 0.5 cm from the bifurcation and middle if in between. Results: Over the 5-year study period, 66 patients were admitted with aortic or great vessel injury, including eight with blunt innommate artery disruption. Of the blunt innominate injuries, six involved the origin (five repaired by ascending aortic -innominate artery graft followed by over-sewing of the injury site, one by ligation alone), one middle (treated by interposition graft) and one distal (managed with resection and primary anastomosis). Four of the patients with proximal injuries had evidence of active bleeding (large expanding hematoma and/or frank bleeding) requiring control of the injury site prior to reconstruction. All patients had associated injuries (including closed head injury in three and splenic rupture in two). The only mortality occurred in a patient who presented in shock, and suffered tracheal rupture and severe blunt cardiac injury requiring cardiopulmonary bypass. The remaining patients were stable on presentation. Diagnosis was suspected after chest Xray demonstrated widened mediastinum and was confirmed with either angiography or computer tomography scan. There were no complications in the survivors. Neither cardiopulmonary bypass nor aorto-carotid shunting was utilized in these cases. Conclusions: Patients with blunt innommate artery rupture who survive to admission are usually stable and the diagnosis is suggested by initial chest radiograph. The injuries are usually proximal, requiring aortic-distal innominate bypass. Cardiopulmonary bypass is required only if there is evidence of heart failure (either before or after partial occlusion of the aorta) or to manage specific associated injuries. (C) 2003 Elsevier Science B.V. All rights reserved.	Harborview Med Ctr, Dept Surg, Sect Thorac Vasc Surg, Seattle, WA 98104 USA	Karmy-Jones, R (corresponding author), Harborview Med Ctr, Dept Surg, Sect Thorac Vasc Surg, Box 359796,325 9th Ave, Seattle, WA 98104 USA.	karmy@u.washington.edu					Axisa BM, 2000, J ENDOVASC THER, V7, P245, DOI 10.1583/1545-1550(2000)007<0245:EROAIA>2.3.CO;2; Carter YM, 2002, ANN THORAC SURG, V73, P294, DOI 10.1016/S0003-4975(01)02866-1; Chandler TA, 1999, EUR J VASC ENDOVASC, V18, P80, DOI 10.1053/ejvs.1999.0871; Chen MYM, 2001, J TRAUMA, V51, P1166, DOI 10.1097/00005373-200112000-00024; GRAHAM JM, 1982, J TRAUMA, V22, P647, DOI 10.1097/00005373-198208000-00001; Hemmila MR, 1999, J TRAUMA, V46, P505, DOI 10.1097/00005373-199903000-00029; HOFF SJ, 1994, AM SURGEON, V60, P151; JOHNSTON RH, 1993, J VASC SURG, V17, P134, DOI 10.1016/0741-5214(93)90017-G; Keene J J, 2001, J Extra Corpor Technol, V33, P114; KELLY JP, 1985, ANN THORAC SURG, V40, P551, DOI 10.1016/S0003-4975(10)60347-5; LETSOU G, 1989, J TRAUMA, V29, P104, DOI 10.1097/00005373-198901000-00023; McCoy DW, 1997, AM SURGEON, V63, P761; NICHOLLS SC, 2002, THORACIC TRAUMA CRIT, P303; PATE JW, 1993, ANN THORAC SURG, V55, P586, DOI 10.1016/0003-4975(93)90255-G; Pretre R, 1993, Ann Vasc Surg, V7, P470, DOI 10.1007/BF02002132; ROSENBERG JM, 1989, ANN THORAC SURG, V48, P508, DOI 10.1016/S0003-4975(10)66851-8; SHAH PM, 1987, AM J SURG, V154, P202, DOI 10.1016/0002-9610(87)90179-6; Stover S, 2001, AM SURGEON, V67, P757; Weiman DS, 1998, AM SURGEON, V64, P383	19	25	25	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1010-7940	1873-734X		EUR J CARDIO-THORAC	Eur. J. Cardio-Thorac. Surg.	MAY	2003	23	5					782	787		10.1016/S1010-7940(03)00032-0			6	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Cardiovascular System & Cardiology; Respiratory System; Surgery	687TW	WOS:000183393900020	12754033	Bronze			2021-06-18	
J	Muller, M; Bianchi, O; Erulku, S; Stock, C; Schwerdtfeger, K				Muller, M; Bianchi, O; Erulku, S; Stock, C; Schwerdtfeger, K		Homburg Traumatic Brain Injury Grp	Changes in linear dynamics of cerebrovascular system after severe traumatic brain injury	STROKE			English	Article						cerebral circulation; head injury; transfer; ultrasonography, Doppler, transcranial	ARTERIAL BLOOD-PRESSURE; CEREBRAL AUTOREGULATION; FLOW VELOCITY; INTRACRANIAL-PRESSURE; MATHEMATICAL-MODEL; PHASE RELATIONSHIP; OCCLUSIONS; CO2	Background and Purpose - We sought to describe the dynamic changes in the cerebrovascular system after traumatic brain injury by transfer function estimation and coherence. Methods - In 42 healthy volunteers ( mean +/- SD age, 37 +/- 17 years; range, 17 to 65 years), spontaneous fluctuations of middle cerebral artery blood flow velocity and of finger blood pressure ( BP) were simultaneously recorded over a period of 10 minutes under normocapnic and hypocapnic conditions to generate normative spectra of coherence, phase shift, and gain over the frequency range of 0 to 0.25 Hz. Similar recordings were performed in 24 patients with severe traumatic brain injury ( Glasgow Coma Scale score less than or equal to8; mean +/- SD age, 50 +/- 20 years) serially on days 1, 3, 5, and 8 after trauma. Cranial perfusion pressure was kept at >70 mm Hg. Each blood flow velocity/BP recording was related to the presence or absence of middle cerebral artery territory brain parenchyma lesions on cranial CT performed within a close time frame. Results - In controls, hypocapnia decreased coherence (0.0 to 0.20 Hz), increased phase shift ( 0.0 to 0.17 Hz), and decreased gain in the frequency range of 0.0 to 0.11 Hz but increased gain at frequencies of 0.20 to 0.25 Hz ( P < 0.01 for all frequency ranges reported). In patients with traumatic brain injury, 102 investigations were possible. Compared with controls, coherence was increased in the frequency range <0.03 Hz and between 0.13 and 0.25 Hz in both normocapnia and hypocapnia, irrespective of the CT findings. Gain was unchanged in normocapnia and in the absence of a CT lesion. Gain was decreased in hypocapnia at frequencies >0.12 Hz irrespective of the presence/absence of a CT lesion. Phase shift decreased rapidly between 0.06 and 0.13 Hz under hypocapnic conditions and under normocapnic conditions in the presence of a CT lesion ( P < 0.01). Conclusions - Use of spontaneous fluctuations of blood flow velocity and BP to assess the cerebrovascular system dynamically requires consideration of the PaCO2 level. In different conditions, including severe traumatic brain injury, the cerebrovascular system behaves linearly only in parts of the investigated frequency range.	Saarland Univ Hosp, Dept Neurol, D-66421 Homburg, Germany; Univ Saarland, Inst Appl Math, D-6600 Saarbrucken, Germany; Saarland Univ Hosp, Dept Neurosurg, Homburg, Germany	Muller, M (corresponding author), Saarland Univ Hosp, Dept Neurol, Kirrberger Str, D-66421 Homburg, Germany.						BIRCH AA, 1995, STROKE, V26, P834, DOI 10.1161/01.STR.26.5.834; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; DIEHL RR, 1995, STROKE, V26, P1801, DOI 10.1161/01.STR.26.10.1801; Giller CA, 1997, NEUROL RES, V19, P634; GILLER CA, 1990, NEUROSURGERY, V27, P362, DOI 10.1227/00006123-199009000-00004; Hu HH, 1999, J CEREBR BLOOD F MET, V19, P460, DOI 10.1097/00004647-199904000-00012; Hughson RL, 2001, STROKE, V32, P2403, DOI 10.1161/hs1001.097225; Kirkham SK, 2001, PHYSIOL MEAS, V22, P461, DOI 10.1088/0967-3334/22/3/305; Kuo TBJ, 1998, J CEREBR BLOOD F MET, V18, P311, DOI 10.1097/00004647-199803000-00010; Lang EW, 2002, J NEUROL NEUROSUR PS, V72, P583, DOI 10.1136/jnnp.72.5.583; Lang EW, 2001, CRIT CARE MED, V29, P158, DOI 10.1097/00003246-200101000-00031; MITIS GD, 2002, ANN BIOMED ENG, V30, P555; MULLER M, 1995, STROKE, V26, P96, DOI 10.1161/01.STR.26.1.96; NEWELL DW, 1994, STROKE, V25, P793, DOI 10.1161/01.STR.25.4.793; Panerai RB, 1999, PHYSIOL MEAS, V20, P265, DOI 10.1088/0967-3334/20/3/304; Panerai RB, 2002, PHYSIOL MEAS, V23, P59, DOI 10.1088/0967-3334/23/1/306; Panerai RB, 1999, AM J PHYSIOL-HEART C, V277, pH1089; Panerai RB, 2001, AM J PHYSIOL-HEART C, V280, pH2162; Reinhard M, 2001, CLIN PHYSIOL, V21, P229, DOI 10.1046/j.1365-2281.2001.00322.x; RINGELSTEIN EB, 1988, STROKE, V19, P963, DOI 10.1161/01.STR.19.8.963; Strebel SP, 1998, ANESTHESIOLOGY, V89, P67, DOI 10.1097/00000542-199807000-00012; TEASDALE G, 1974, LANCET, V2, P81; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; URSINO M, 1991, ANN BIOMED ENG, V19, P15, DOI 10.1007/BF02368459; WIDDER B, 1986, EUR ARCH PSY CLIN N, V236, P162, DOI 10.1007/BF00380944; Zhang R, 1998, AM J PHYSIOL-HEART C, V274, pH233, DOI 10.1152/ajpheart.1998.274.1.H233	26	25	25	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	MAY	2003	34	5					1197	1202		10.1161/01.STR.0000068409.81859.C5			6	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	673NB	WOS:000182586100019	12677012	Bronze			2021-06-18	
J	Quinones-Hinojosa, A; Malek, JY; Ames, A; Ogilvy, CS; Maynard, KI				Quinones-Hinojosa, A; Malek, JY; Ames, A; Ogilvy, CS; Maynard, KI			Metabolic effects of hypothermia and its neuroprotective effects on the recovery of metabolic and electrophysiological function in the ischemic retina in vitro	NEUROSURGERY			English	Article						cerebral ischemia; energy metabolism; neuroprotection; stroke; temperature-dependent	TRANSIENT FOREBRAIN ISCHEMIA; CEREBRAL ENERGY-METABOLISM; TRAUMATIC BRAIN INJURY; MILD HYPOTHERMIA; FOCAL ISCHEMIA; RABBIT RETINA; MODERATE HYPOTHERMIA; MAGNETIC-RESONANCE; HYPOXIA-ISCHEMIA; HEAD-INJURY	OBJECTIVE: Reduction in energy usage has been investigated as the mechanism by which hypothermia provides protection during ischemia. We describe, experiments using hypothermia in the rabbit retina in Vitro that show a correlation between energy usage and neuroprotection., hypothermia-induced reductions in METHODS: We examined energy metabolism and electrophysiological function under control/nonischemic conditions during I or 2 hours of "ischemia" (induced by, decreasing glucose from 6 to 1 mmol/L and oxygen from,95 to 15%) and during 3 to conditions. Glucose utilization and lactate production 4 hours of "return-to-control", were measured as indices of energy metabolism, and light-evoked compound action potentials were monitored to assess functional recovery. RESULTS: Nonischemic retinas subjected to both mild (33 +/- 0.5degreesC) hypothermia exhibited a decrease of 38% in the rate of glucose utilization and lactate production compared with normothermic retinas (36 +/- 0.5degreesC) (analysis,of variance, P < 0.001). In retinas that were made ischemic, mild or moderate hypothermia further reduced the rates of glucose utilization (18 and 39%, respectively) and lactate production (21 and 28%, respectively) (P < 0.001 for glucose, P < 0.01 for lactate). Retinas that had, been mildly or moderately hypothermic during ischemia exhibited improved recovery of glucose utilization (65 and 57%, respectively) and lactate production (72 and 74%, respectively) compared with normothermic retinas (18% for glucose and 54% for lactate; repeated-measures analysis of variance, P < 0.001). Recovery of compound action potentials for retinas kept at 36, 33, and 30degreesC was 15, 36, and 53%, respectively (repeated-measures analysis of variance, P < 0.001). CONCLUSION: Our studies in an avascular neuronal ischemia de that hypothermia protects against ischemic injury. We interpret the smaller reductions hypothermia energy generation and usage caused by ischemia when the retinas were mic as evidence that hypothermia had reduced energy requirements more than energy production, and we propose that this at least in part explains its protection.	Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neurosurg Serv,Neurophysiol Lab, Boston, MA 02115 USA	Quinones-Hinojosa, A (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave,M-779, San Francisco, CA 94143 USA.	quinones@neurosurg.ucsf.edu		Mayberg, Marc/0000-0002-6718-7143	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-01732] Funding Source: Medline		Adachi K, 1998, EUR J PHARMACOL, V350, P53, DOI 10.1016/S0014-2999(98)00317-3; AGARDH CD, 1992, ACTA NEUROPATHOL, V83, P379, DOI 10.1007/BF00713529; AMES A, 1995, J CEREBR BLOOD F MET, V15, P433, DOI 10.1038/jcbfm.1995.54; AMES A, 1992, J NEUROSCI, V12, P840, DOI 10.1523/jneurosci.12-03-00840.1992; AMES A, 1990, PREPARATIONS VERTEBR, P183; Barone FC, 1997, NEUROSCI BIOBEHAV R, V21, P31, DOI 10.1016/0149-7634(95)00080-1; Berger R, 1998, DEV BRAIN RES, V105, P67, DOI 10.1016/S0165-3806(97)00165-X; BICKLER PE, 1994, ANESTHESIOLOGY, V81, P1461, DOI 10.1097/00000542-199412000-00022; BUCHAN A, 1990, J NEUROSCI, V10, P311; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CHEN H, 1992, J CEREBR BLOOD F MET, V12, P621, DOI 10.1038/jcbfm.1992.86; Clifton G, 2000, J NEUROSURG, V93, P718; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Colbourne F, 1997, MOL NEUROBIOL, V14, P171, DOI 10.1007/BF02740655; Conroy BP, 1998, ANESTHESIOLOGY, V88, P390, DOI 10.1097/00000542-199802000-00018; Edwards AD, 1995, BIOCHEM BIOPH RES CO, V217, P1193, DOI 10.1006/bbrc.1995.2895; Edwards AD, 1996, NEUROPATH APPL NEURO, V22, P494, DOI 10.1111/j.1365-2990.1996.tb01122.x; FABEROWSKI N, 1989, INVEST OPHTH VIS SCI, V30, P2309; FIELD J, 1994, ANESTHESIOLOGY, V7, P117; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; Gupta AK, 2002, BRIT J ANAESTH, V88, P188, DOI 10.1093/bja/88.2.188; HOCHACHKA PW, 1986, SCIENCE, V231, P234, DOI 10.1126/science.2417316; KAMME F, 1995, EUR J NEUROSCI, V7, P2007, DOI 10.1111/j.1460-9568.1995.tb00623.x; Kamme F, 1996, MOL BRAIN RES, V43, P51, DOI 10.1016/S0169-328X(96)00151-9; KARIBE H, 1994, J CEREBR BLOOD F MET, V14, P620, DOI 10.1038/jcbfm.1994.77; KARIBE H, 1994, BRAIN RES, V649, P12, DOI 10.1016/0006-8993(94)91043-X; KOCHS E, 1995, EUR J ANAESTH, V12, P67; LANIER WL, 1995, J NEUROSURG ANESTH, V7, P216, DOI 10.1097/00008506-199507000-00021; LAPTOOK AR, 1995, STROKE, V26, P1240, DOI 10.1161/01.STR.26.7.1240; LAPTOOK AR, 1995, PEDIATR RES, V38, P919, DOI 10.1203/00006450-199512000-00015; LEI BP, 1994, STROKE, V25, P147, DOI 10.1161/01.STR.25.1.147; LIN BW, 1995, STROKE, V26, P1634, DOI 10.1161/01.STR.26.9.1634; LO EH, 1992, STROKE, V23, P889, DOI 10.1161/01.STR.23.6.889; LUST WD, 1989, BRAIN RES, V489, P12; MAHER J, 1993, CEREBROVAS BRAIN MET, V5, P277; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; Maynard K I, 1998, J Stroke Cerebrovasc Dis, V7, P287, DOI 10.1016/S1052-3057(98)80045-1; Maynard KI, 1996, NEUROREPORT, V8, P81, DOI 10.1097/00001756-199612200-00017; Maynard KI, 1998, NEUROSCI LETT, V249, P159, DOI 10.1016/S0304-3940(98)00416-9; Maynard KI, 1998, NEUROREPORT, V9, P4141, DOI 10.1097/00001756-199812210-00026; Maynard KI, 1999, ANN NY ACAD SCI, V890, P240, DOI 10.1111/j.1749-6632.1999.tb07999.x; MAYNARD KI, 1995, NEUROREPORT, V6, P850, DOI 10.1097/00001756-199504190-00006; MICHENFELDER JD, 1970, ANESTHESIOLOGY, V33, P430, DOI 10.1097/00000542-197010000-00013; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; Mori K, 1998, NEUROL RES, V20, P719; Nakashima K, 1996, STROKE, V27, P913, DOI 10.1161/01.STR.27.5.913; Quinones-Hinojosa A, 1999, J NEUROSCI METH, V90, P107, DOI 10.1016/S0165-0270(99)00068-0; Quinones-Hinojosa A., 1998, Society for Neuroscience Abstracts, V24, P1506; QUINONESHINOJOS.A, 1999, AM ASS NEUR SURG ANN; RIDENOUR TR, 1992, STROKE, V23, P733, DOI 10.1161/01.STR.23.5.733; Riepe MW, 1997, STROKE, V28, P2006, DOI 10.1161/01.STR.28.10.2006; ROSOMOFF HL, 1956, J NEUROSURG, V13, P332; Soukup J, 2002, NEUROL RES, V24, P161, DOI 10.1179/016164102101199710; STYS PK, 1992, J CEREBR BLOOD F MET, V12, P977, DOI 10.1038/jcbfm.1992.135; TAYLOR CP, 1993, NEUROSCIENCE, V52, P555, DOI 10.1016/0306-4522(93)90405-5; Taylor DL, 2002, PEDIATR RES, V51, P13, DOI 10.1203/00006450-200201000-00005; Toyoda T, 1996, NEUROSURGERY, V39, P1200, DOI 10.1097/00006123-199612000-00024; WELSH FA, 1990, J CEREBR BLOOD F MET, V10, P557, DOI 10.1038/jcbfm.1990.98; Williams GD, 1997, PEDIATR RES, V42, P700, DOI 10.1203/00006450-199711000-00024; XUE D, 1992, BRAIN RES, V587, P66, DOI 10.1016/0006-8993(92)91428-H; Yager JY, 1996, STROKE, V27, P919, DOI 10.1161/01.STR.27.5.919; ZAGER EL, 1988, J NEUROSURG, V69, P568, DOI 10.3171/jns.1988.69.4.0568; Zeevalk GD, 1996, J PHARMACOL EXP THER, V279, P332; ZORNOW MH, 1995, J NEUROSURG ANESTH, V7, P148, DOI 10.1097/00008506-199504000-00022	71	25	25	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAY	2003	52	5					1178	1186		10.1227/01.NEU.0000057836.64972.A0			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	675CU	WOS:000182676100046	12699563				2021-06-18	
J	Cui, X; Kalsotra, A; Robida, AM; Matzilevich, D; Moore, AN; Boehme, CL; Morgan, ET; Dash, PK; Strobel, HW				Cui, X; Kalsotra, A; Robida, AM; Matzilevich, D; Moore, AN; Boehme, CL; Morgan, ET; Dash, PK; Strobel, HW			Expression of cytochromes P4504F4 and 4F5 in infection and injury models of inflammation	BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS			English	Article; Proceedings Paper	12th International Symposium on Cellular Biology of Cytochrome P450 Regulation	SEP, 2001	LA GRANDE MOTTE, FRANCE			regulation of CYP4F expression; inflammation and P450 expression; brain cytochrome P450 distribution; lipopolysaccharide and CYP4F subfamily expression; CYP4F subfamily expression; CYP4F subfamily suppression by inflammation	B-4 OMEGA-HYDROXYLASE; TRAUMATIC BRAIN-INJURY; CDNA CLONING; RAT-BRAIN; PROTEIN EXPRESSION; MOLECULAR-CLONING; GENE-EXPRESSION; INDUCTION; INTERLEUKIN-6; HEPATOCYTES	Lipopolysaccharide (LPS) treatment of rats suppresses CYP 4174 and 4175 expression by 50 and 40%, respectively, in a direct fashion occurring in the liver. This contention is borne out by essentially parallel dose-dependent changes observed upon treatment of rat hepatocyte cultures with LPS. An alternate avenue of triggering the inflammatory cascade is traumatic brain injury by controlled cortical impact. Such injury brings about a dramatic change in the expression of CYP 4174 and 4F5 mRNA which reaches its greatest effect 24 h after impact compared with sham-operated but uninjured controls. At time points after 24 h the expression of both isoforms increases dramatically reaching highest levels at 2 weeks post-injury. These changes in mRNA expression are mirrored by changes in protein expression. The results are consistent with the notion that immediately after injury, concentrations of leukotriene and prostaglandin mediators are elevated by decreased CYP 4F concentrations. As time after injury increases those conditions reverse. Increased CYP 4F expression leads to diminished concentrations of leukotriene and prostaglandin mediators and then to recovery and repair. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA; Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77225 USA	Strobel, HW (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, POB 20708,6431 Fannin St, Houston, TX 77225 USA.	henry.w.strobel@uth.tmc.edu		Morgan, Edward/0000-0003-4273-2261; Kalsotra, Auinash/0000-0002-1011-0006	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM 46897] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH 58297] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM046897] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH058297] Funding Source: NIH RePORTER		ABDELRAZZAK Z, 1993, MOL PHARMACOL, V44, P707; BARKER CW, 1992, J BIOL CHEM, V267, P8050; BOEHME CL, 2001, J NEUROTOX RES, V3, P329; Bureau F, 2002, J IMMUNOL, V168, P5318, DOI 10.4049/jimmunol.168.10.5318; Bylund J, 1999, BIOCHEM BIOPH RES CO, V261, P169, DOI 10.1006/bbrc.1999.1011; Bylund J, 2001, BIOCHEM BIOPH RES CO, V280, P892, DOI 10.1006/bbrc.2000.4191; CHEN LP, 1993, ARCH BIOCHEM BIOPHYS, V300, P18, DOI 10.1006/abbi.1993.1003; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cui XM, 2000, GENOMICS, V68, P161, DOI 10.1006/geno.2000.6276; Cui XM, 2001, J PHARMACOL EXP THER, V296, P542; DASH PK, 1995, J NEUROSCI, V15, P2030; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FERRARI L, 1993, J PHARMACOL EXP THER, V264, P1012; FUKUDA Y, 1992, BIOCHEM BIOPH RES CO, V184, P960, DOI 10.1016/0006-291X(92)90684-D; Hofbauer R, 2000, MICROVASC RES, V59, P354, DOI 10.1006/mvre.1999.2220; Kawashima H, 1995, BIOCHEM BIOPH RES CO, V217, P1137, DOI 10.1006/bbrc.1995.2887; Kawashima H, 1997, ARCH BIOCHEM BIOPHYS, V347, P148, DOI 10.1006/abbi.1997.0342; Kawashima H, 1996, J BIOL CHEM, V271, P28176, DOI 10.1074/jbc.271.45.28176; Kikuta Y, 2000, ARCH BIOCHEM BIOPHYS, V383, P225, DOI 10.1006/abbi.2000.2078; Kikuta Y, 1999, DNA CELL BIOL, V18, P723, DOI 10.1089/104454999315006; KIKUTA Y, 1994, FEBS LETT, V348, P70, DOI 10.1016/0014-5793(94)00587-7; Kikuta Y, 1998, DNA CELL BIOL, V17, P221, DOI 10.1089/dna.1998.17.221; Kikuta Y, 1999, ARCH BIOCHEM BIOPHYS, V369, P193, DOI 10.1006/abbi.1999.1271; KIKUTA Y, 1993, J BIOL CHEM, V268, P9376; LIDDLE C, 1992, ARCH BIOCHEM BIOPHYS, V298, P159, DOI 10.1016/0003-9861(92)90107-8; Liu SB, 1998, INFECT IMMUN, V66, P5089, DOI 10.1128/IAI.66.11.5089-5098.1998; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; Morgan ET, 1997, DRUG METAB REV, V29, P1129, DOI 10.3109/03602539709002246; MORGAN ET, 1991, BIOCHEM PHARMACOL, V42, P51, DOI 10.1016/0006-2952(91)90680-4; PETERSON TC, 1986, BIOCHEM PHARMACOL, V35, P1491, DOI 10.1016/0006-2952(86)90114-0; Poloyac SM, 2001, DRUG METAB DISPOS, V29, P296; Sabourault C, 1999, BIOCHEM BIOPH RES CO, V258, P155, DOI 10.1006/bbrc.1999.0608; Sewer MB, 1996, DRUG METAB DISPOS, V24, P401; Sewer MB, 1997, J PHARMACOL EXP THER, V280, P1445; Su GL, 1999, J HEPATOL, V31, P435, DOI 10.1016/S0168-8278(99)80034-8; Thomas SC, 1998, FASEB J, V12, P1371; UFKES JG, 1998, BR J EXP PATHOL, V69, P457; WILLIAMS JF, 1991, BIOCHEM BIOPH RES CO, V178, P1049, DOI 10.1016/0006-291X(91)90998-M; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	41	25	26	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0304-4165	1872-8006		BBA-GEN SUBJECTS	Biochim. Biophys. Acta-Gen. Subj.	FEB 17	2003	1619	3					325	331	PII S0304-4165(02)00491-9	10.1016/S0304-4165(02)00491-9			7	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	648FW	WOS:000181140200013	12573492				2021-06-18	
J	Duncan, CC; Kosmidis, MH; Mirsky, AF				Duncan, CC; Kosmidis, MH; Mirsky, AF			Event-related potential assessment of information processing after closed head injury	PSYCHOPHYSIOLOGY			English	Article						closed head injury; information processing; event-related potentials; N200; P300; reaction time	TRAUMATIC BRAIN INJURY; AUDITORY ODDBALL TASK; P300 COMPONENT; REACTION-TIME; DISCRIMINATION TASK; CEREBRAL CONCUSSION; COGNITIVE FUNCTION; VISUAL-ATTENTION; DYSFUNCTION; GENERATORS	We evaluated alterations in information processing after closed head injury as a function of task demands and stimulus modality. Visual and auditory discrimination tasks ere administered to I I survivors of a head injury and 16 matched healthy controls. In auditory tasks. compared with controls the survivors had smaller N100s, smaller and later N200s, a more posterior scalp distribution of N200 and longer P300 and response latencies. Auditors N200 and P300 correlated highly with duration of unconsciousness. In contrast, in visual tasks, only a reduced N200 in the survivors differentiated the groups. Our results indicate that processing of auditory stimuli. including the perception and discrimination Of Stimulus features and the evaluation and categorization of Stimuli, may be impaired after head trauma. Visual sensory processing may be spared but higher-order visual processing involved ill Stimulus classification may be compromised.	Uniformed Serv Univ Hlth Sci, Dept Psychiat, Clin Psychophysiol & Psychopharmacol Lab, Bethesda, MD 20814 USA; NIMH, Sect Clin & Expt Neuropsychol, Bethesda, MD 20892 USA	Kosmidis, MH (corresponding author), MSC 2615,5415 W Cedar Lane,Suite 203B, Bethesda, MD 20892 USA.	connie_duncan@nih.gov	Kosmidis, Mary H/AAN-2104-2021	Kosmidis, Mary/0000-0001-8790-1220	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [Z01MH000509] Funding Source: NIH RePORTER		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1975, HDB CLINICAL NEUROLO, V23, P35; Alexander JE, 1996, INT J PSYCHOPHYSIOL, V21, P189, DOI 10.1016/0167-8760(95)00047-X; Alexander T, 2000, J CURRICULUM STUD, V32, P467, DOI 10.1080/002202700182664; BARRETT G, 1987, ELECTROEN CLIN NEURO, V66, P409, DOI 10.1016/0013-4694(87)90210-0; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; CAMPBELL K, 1986, STUDIES EVENT RELATE, V38, P486; Campbell K. B., 1995, HDB NEUROPSYCHOLOGY, V10, P269; CAMPBELL KB, 1990, ELECTROEN CLIN NEURO, P202; Clark C. R., 1992, Brain Injury, V6, P509, DOI 10.3109/02699059209008148; COOPER R, 1984, EVOKED POTENTIAL, V2, P446; CREMONAMETEYARD SL, 1994, BRAIN INJURY, V8, P541, DOI 10.3109/02699059409151006; Curry S H, 1996, Electroencephalogr Clin Neurophysiol Suppl, V46, P283; Curry S H, 1986, Electroencephalogr Clin Neurophysiol Suppl, V38, P469; CURRY SH, 1980, MOTIVATION MOTOR SEN, P507; DEACON D, 1991, ELECTROEN CLIN NEURO, V78, P133, DOI 10.1016/0013-4694(91)90113-I; DEACON D, 1991, J CLIN EXP NEUROPSYC, V13, P639, DOI 10.1080/01688639108401079; Deacon-Elliott D L, 1987, Electroencephalogr Clin Neurophysiol Suppl, V40, P664; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; DUNCAN CC, 1994, PSYCHOPHYSIOLOGY, V31, P386, DOI 10.1111/j.1469-8986.1994.tb02447.x; DUNCAN CC, 1987, PSYCHOPHARMACOL BULL, V23, P497; DUNCAN CC, 1990, PSYCHIAT WORLD PERSP, V2, P398; DUNCANJOHNSON CC, 1979, PSYCHOPHYSIOLOGY, V16, P53, DOI 10.1111/j.1469-8986.1979.tb01440.x; DUNCANJOHNSON CC, 1981, PSYCHOPHYSIOLOGY, V18, P207; DUNCANJOHNSON CC, 1977, PSYCHOPHYSIOLOGY, V14, P456, DOI 10.1111/j.1469-8986.1977.tb01312.x; DUNCANJOHNSON CC, 1982, BIOL PSYCHOL, V14, P1, DOI 10.1016/0301-0511(82)90016-3; EGAN MF, 1994, SCHIZOPHR RES, V11, P259, DOI 10.1016/0920-9964(94)90020-5; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; Ford MR, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199606000-00004; FRIEDMAN A, 1981, J EXP PSYCHOL HUMAN, V7, P1031, DOI 10.1037/0096-1523.7.5.1031; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; Holbourn AHS, 1943, LANCET, V2, P438; JOHNSON R, 1993, PSYCHOPHYSIOLOGY, V30, P90; JOHNSON R, 1989, PSYCHOPHYSIOLOGY, V26, P651, DOI 10.1111/j.1469-8986.1989.tb03167.x; JOHNSON R, 1989, PSYCHOPHYSIOLOGY, V26, P633, DOI 10.1111/j.1469-8986.1989.tb03165.x; JOHNSON R, 1991, J PSYCHOPHYSIOL, V5, P11; Kayser J, 1998, PSYCHOPHYSIOLOGY, V35, P576, DOI 10.1017/S0048577298970214; Keren O, 1998, J HEAD TRAUMA REHAB, V13, P15; KOSMIDIS MH, 1993, AM M COGN ERP RES NE; LEVIN HS, 1981, BRAIN LANG, V12, P360, DOI 10.1016/0093-934X(81)90025-0; LINDHOLM E, 1985, INT J PSYCHOPHYSIOL, V3, P121, DOI 10.1016/0167-8760(85)90032-7; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MCCARTHY G, 1985, ELECTROEN CLIN NEURO, V62, P203, DOI 10.1016/0168-5597(85)90015-2; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; Montirosso R, 1997, INT J PSYCHOPHYSIOL, V25, P48, DOI 10.1016/S0167-8760(97)85471-2; MUNTE TF, 1994, ARCH NEUROL-CHICAGO, V51, P482, DOI 10.1001/archneur.1994.00540170058017; NAATANE R, 1992, ATTENTION BRAIN FUNC; NAATANEN R, 1990, BEHAV BRAIN SCI, V13, P201, DOI 10.1017/S0140525X00078407; Naatanen R, 1986, Electroencephalogr Clin Neurophysiol Suppl, V38, P169; NAATANEN R, 1987, PSYCHOPHYSIOLOGY, V24, P375, DOI 10.1111/j.1469-8986.1987.tb00311.x; NATIV A, 1994, ARCH PHYS MED REHAB, V75, P1322; NOVAK GP, 1990, ELECTROEN CLIN NEURO, V75, P255, DOI 10.1016/0013-4694(90)90105-S; OLBRICH HM, 1986, SURG NEUROL, V26, P112, DOI 10.1016/0090-3019(86)90362-9; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PAPO I, 1982, ACTA NEUROCHIR, V62, P47, DOI 10.1007/BF01402210; Picton TW, 2000, PSYCHOPHYSIOLOGY, V37, P127, DOI 10.1017/S0048577200000305; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; Pritchard W.S., 1991, ADV PSYCHOPHYSIOLOGY, V4, P43; Reinvang I, 1999, NEUROPSYCHOL REV, V9, P231, DOI 10.1023/A:1021638723486; Reinvang I, 1998, J CLIN EXP NEUROPSYC, V20, P885, DOI 10.1076/jcen.20.6.885.1106; RITTER W, 1979, SCIENCE, V203, P1358, DOI 10.1126/science.424760; RUBENS AB, 1977, ARCH NEUROL-CHICAGO, V34, P750, DOI 10.1001/archneur.1977.00500240038006; RUCHKIN DS, 1995, PSYCHOPHYSIOLOGY, V32, P399, DOI 10.1111/j.1469-8986.1995.tb01223.x; RUGG M, 1986, CEREBRAL PSYCHOPHY S, V38, P273; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; Solbakk AK, 2000, J CLIN EXP NEUROPSYC, V22, P743, DOI 10.1076/jcen.22.6.743.953; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; Spitzer R.L., 1975, SCHEDULE AFFECTIVE D; SQUIRES NK, 1975, ELECTROEN CLIN NEURO, V38, P387, DOI 10.1016/0013-4694(75)90263-1; STRATTON MC, 1994, BRAIN INJURY, V8, P631, DOI 10.3109/02699059409151016; STRICH SJ, 1961, LANCET, V2, P443; STRICH SJ, 1969, LATE EFFECTS HEAD IN, P501; Stuss D. T., 1989, CLIN NEUROPSYCHOL, V3, P145, DOI DOI 10.1080/13854048908403287; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; UNSAL A, 1995, PSYCHOPHYSIOLOGY, V32, P249, DOI 10.1111/j.1469-8986.1995.tb02953.x; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; Watt S, 1999, NEUROPSYCHOLOGY, V13, P338, DOI 10.1037/0894-4105.13.3.338; WERNER RA, 1991, ARCH PHYS MED REHAB, V72, P31; WIRSEN A, 1992, ELECTROEN CLIN NEURO, V84, P127, DOI 10.1016/0168-5597(92)90017-6; WRIGHT MJ, 1994, AUST J PSYCHOL, V46, P63, DOI 10.1080/00049539408259475	92	25	31	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0048-5772	1469-8986		PSYCHOPHYSIOLOGY	Psychophysiology	JAN	2003	40	1					45	59		10.1111/1469-8986.00006			15	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Psychology; Neurosciences & Neurology; Physiology	636KT	WOS:000180455300006	12751803				2021-06-18	
J	Menzel, M; Soukup, J; Henze, D; Clausen, T; Marx, T; Hillman, A; Miko, I; Grond, S; Rieger, A				Menzel, M; Soukup, J; Henze, D; Clausen, T; Marx, T; Hillman, A; Miko, I; Grond, S; Rieger, A			Brain tissue oxygen monitoring for assessment of autoregulation: Preliminary results suggest a new hypothesis	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						brain tissue oxygen; monitoring; autoregulation; cerebral perfusion pressure	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; BLOOD-FLOW-VELOCITY; INTRACRANIAL-PRESSURE; SUBSTRATE DELIVERY; FELINE BRAIN; SATURATION; ISCHEMIA; TENSION; PH	Brain tissue oxygen monitoring (PtiO2 (Neurotrend, Codman, Germany) was employed in addition to standard intracranial pressure (ICP) and cerebral perfusion pressure (CPP) monitoring in seven patients with severe neuronal damage of heterogeneous etiology. The correlation between PtiO2 changes and CPP fluctuations during periods of 30 minutes were analyzed, when CPP was above 70 mmHg and lower than 100 mmHg. A new ratio, the CPP-oxygen-reactivity (COR) index was calculated as COR = Deltap(ti)O(2)%/DeltaCPP%. The patient COR values were compared to those found in the brain of six noninjured anesthetized piglets. The analysis was performed to determine the significance of synchronous fluctuations of CPP and PtiO2, when CPP is above the lower threshold of autoregulation. The correlation between CPP variations and p(ti)O(2) variations was found to be strong (R-mean 0.74 +/- 0.17) in the patients and was weak in the uninjured animals (R-mean = 0.38 +/- 0.43). The CORmean was 2.05 +/- 0.57 in patients and 0.78 +/- 0.6 in the animals. In the injured brain of our patients, we observed an unexpectedly close correlation between PtiO2 and CPP variations when CPP levels were within a therapeutically targeted range (70 to 100 mmHg). In a porcine model, we could not find this relationship in the noninjured brain. We speculate that an increased COR might be indicative for an impaired local pressure autoregulation. The preliminary data suggest that COR values above "I" might be pathologic. However, the reported sample sizes are too small to provide sufficient statistical power to justify inferential statistical analyses. As such, results are presented with descriptive statistics only, and should be regarded as a hypothesis.	Univ Halle Wittenberg, Dept Anesthesiol & Intens Care, D-06097 Halle An Der Saale, Germany; Univ Halle Wittenberg, Dept Neurosurg, D-06097 Halle An Der Saale, Germany; Univ Debrecen, Dept Expt Surg, H-4012 Debrecen, Hungary	Menzel, M (corresponding author), Univ Halle Wittenberg, Dept Anesthesiol & Intens Care, Magdeburger Str 16, D-06097 Halle An Der Saale, Germany.						Al-Rawi PG, 2000, ZBL NEUROCHIR, V61, P74, DOI 10.1055/s-2000-8263; BARZO P, 1993, NEUROSURGERY, V32, P611; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Cruz J, 1988, Acta Neurochir Suppl (Wien), V42, P35; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; Cruz J, 2000, J NEUROSURG, V93, P158; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; CZOSNYKA M, 1994, ACTA NEUROCHIR, P468; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; Gopinath SP, 1999, NEUROSURGERY, V44, P1273, DOI 10.1097/00006123-199906000-00066; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HAUERBERG J, 1993, J NEUROSURG ANESTH, V5, P258; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Hoffman WE, 1996, NEUROL RES, V18, P54, DOI 10.1080/01616412.1996.11740378; JING ZA, 1992, J TRAUMA, V33, P83, DOI 10.1097/00005373-199207000-00016; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; LAPTOOK AR, 1994, PEDIATR RES, V35, P436, DOI 10.1203/00006450-199404000-00010; Lassen N A, 1966, Res Publ Assoc Res Nerv Ment Dis, V41, P205; MAAS AIR, 1993, ACTA NEUROCHIR, P50; Mascia L, 2000, INTENS CARE MED, V26, P202, DOI 10.1007/s001340050046; MATTA BF, 1994, ANESTH ANALG, V79, P745; Meixensberger J, 1998, ACT NEUR S, V71, P260; Menzel M, 2000, ZBL NEUROCHIR, V61, P181, DOI 10.1055/s-2000-15598; Menzel M, 1998, J NEUROTRAUM, V15, P265, DOI 10.1089/neu.1998.15.265; MURR R, 1995, NEUROL RES, V17, P329, DOI 10.1080/01616412.1995.11740338; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; Prat R, 1998, ACT NEUR S, V71, P123; Reinert M, 2000, ACTA NEUROCHIR SUPPL, V76, P439; ROBERTSON CS, 1992, J NEUROTRAUM, V9, pS349; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, NEUROSURG CLIN N AM, V6, P761; Sahuquillo J, 1998, ACT NEUR S, V71, P233; Sarrafzadeh AS, 1998, ACT NEUR S, V71, P186; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; Stocchetti N, 1998, ACT NEUR S, V71, P162; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van den Brink WA, 1998, ACT NEUR S, V71, P190; VanSantbrink EJP, 1997, J CLIN ENDOCR METAB, V82, P3597, DOI 10.1210/jc.82.11.3597; ZAUNER A, 1995, NEUROSURGERY, V37, P1168, DOI 10.1227/00006123-199512000-00017; Zauner A, 1997, NEUROL RES, V19, P265, DOI 10.1080/01616412.1997.11740812; Zhi DS, 1999, SURG NEUROL, V52, P393, DOI 10.1016/S0090-3019(99)00101-9	51	25	26	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JAN	2003	15	1					33	41		10.1097/00008506-200301000-00006			9	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	629UZ	WOS:000180070800006	12499980				2021-06-18	
J	Cannizzaro, MS; Coelho, CA				Cannizzaro, MS; Coelho, CA			Treatment of story grammar following traumatic brain injury: a pilot study	BRAIN INJURY			English	Article							NARRATIVE DISCOURSE; HEAD; CHILDREN	Recent investigations have documented a variety of discourse deficits following traumatic brain injuries (TBI). However, there is a paucity of information relating to the treatment of such deficits. The present study investigated the treatment of discourse production deficits, specifically story grammar ability, in an individual with TBI. Treatment emphasized meta-linguistic comprehension of story grammar structure and the identification and generation of episode components within stories. Over the course of treatment, a marked increase in the number of complete episodes generated by the individual with TBI was noted in story grammar probes. Follow-up probes at 1 and 3 months post-treatment, however, indicated limited carryover and poor generalization of the treatment effects. Findings are interpreted in terms of the individual's chronic cognitive deficits, disruptions in managerial knowledge, and the limitations of treating discourse acontextually.	Univ Connecticut, Dept Commun Sci, Storrs, CT 06269 USA	Cannizzaro, MS (corresponding author), Univ Connecticut, Dept Commun Sci, U10-85,850 Bolton Rd, Storrs, CT 06269 USA.	michael.cannizzaro@uconn.edu					Applebee A., 1978, CHILDS CONCEPT STORY; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; COELHO CA, 1995, APHASIOLOGY, V9, P409, DOI 10.1080/02687039508248707; GLALSKI T, 1998, BRAIN INJURY, V12, P769; GLOSSER G, 1992, J GERONTOL, V47, pP266, DOI 10.1093/geronj/47.4.P266; Grafman J, 1995, ANN NY ACAD SCI, V769, P337, DOI 10.1111/j.1749-6632.1995.tb38149.x; Grafman J., 1993, J HEAD TRAUMA REHAB, V8, P73, DOI DOI 10.1097/00001199-199303000-00008; GRAFMAN J, 1999, SCI PRACT NEUROPSYCH, P321; Grafman J., 1989, INTEGRATING THEORY P, P93; HAGAN C, 1980, REHABILITATION HEAD; Kertesz A., 1982, W APHASIA BATTERY; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LILES BZ, 1993, J SPEECH HEAR RES, V36, P868, DOI 10.1044/jshr.3605.868; MATTIS S, 1976, GERIATRIC PSYCHIATRY; Snow P, 1997, APHASIOLOGY, V11, P947, DOI 10.1080/02687039708249421; Stein N. L., 1979, NEW DIRECTIONS DISCO, V2, P53; Ylvisaker M., 2001, LANGUAGE INTERVENTIO, P745	20	25	26	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2002	16	12					1065	1073		10.1080/02699050210155230			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	617KK	WOS:000179360700005	12487721				2021-06-18	
J	Reiche, W; Komenda, Y; Schick, B; Grunwald, I; Steudel, WI; Reith, W				Reiche, W; Komenda, Y; Schick, B; Grunwald, I; Steudel, WI; Reith, W			MR cisternography after intrathecal Gd-DTPA application	EUROPEAN RADIOLOGY			English	Article						cerebrospinal fluid fistula; intrathecal contrast media administration cisternography; gadolinium DTPA; magnetic resonance imaging	CEREBROSPINAL-FLUID RHINORRHEA; HIGH-RESOLUTION CT; GADOPENTETATE DIMEGLUMINE; GADOLINIUM-DTPA; SUBARACHNOID SPACE; CSF RHINORRHEA; CONTRAST-MEDIA; FISTULA; LOCALIZATION; DIAGNOSIS	The purpose of this study was to establish and to evaluate MR cisternography after intrathecal GdDTPA administration to detect rhinobasal cerebrospinal fluid (CSF) fistulae in patients with suspected CSF rhinorrhoea. Ten patients with suspected CSF rhinorrhoea were examined. The MR cisternography included the following investigation steps: acquisition of nonenhanced fat-suppressed T1-weighted spin-echo (SE) scans of the skull base and the para-nasal sinuses, lumbar puncture with administration of 1 ml Gd-DTPA solute with 4 ml NaCl and performance of MR cisternography with the same fat-suppressed T1-weighted sequences as used initially. In 10 patients with suspected CSF rhinorrhoea Gd-DTPA enhanced MR cisternography detected 5 CSF fistulae. In 3 of 5 CSF leaks were located in the cribriform plate and in 2 of 5 sphenoidal. Whereas 4 of these depicted leaks were confirmed surgically, in 1 case the CSF fistula closed spontaneously. In another case, CSF leakage after severe head injury was clinically highly suspected but ceased prior to MR cisternography with inability to detect the temporary fistula. In the remaining 4 patients with serous rhinorrhoea MR cisternography did not provide any evidences for CSF fistulae. Intrathecal Gd-DTPA injection was tolerated excellently. Clinical and EEG examinations showed no gross behavioural or neurological disturbances and no seizure activity, respectively. The MR cisternography after intrathecal administration of Gd-DTPA represents a safe, promising and minimally invasive method for detection of CSF fistulae. This MR investigation provides excellent depiction of CSF spaces and pinpoints CSF fistulae.	Saarland Univ Clin, Dept Neuroradiol, Radiol Clin, Ctr Skull Base Surg, Homburg, Germany; Saarland Univ Clin, Clin Ear Nose & Throat, Ctr Skull Base Surg, Homburg, Germany; Klinikum Lahr, Inst Radiol, D-77931 Lahr, Germany	Reiche, W (corresponding author), Saarland Univ Clin, Dept Neuroradiol, Radiol Clin, Ctr Skull Base Surg, Homburg, Germany.						ALLARD M, 1987, J NEURORADIOLOGY, V14, P383; CHOW JM, 1989, OTOLARYNG HEAD NECK, V100, P99, DOI 10.1177/019459988910000204; COLQUHOUN IR, 1993, CLIN RADIOL, V47, P403, DOI 10.1016/S0009-9260(05)81061-X; CURNES JT, 1985, RADIOLOGY, V154, P795, DOI 10.1148/radiology.154.3.3881800; DICHIRO G, 1986, RADIOLOGY, V160, P221, DOI 10.1148/radiology.160.1.3715036; DICHIRO G, 1985, RADIOLOGY, V157, P373, DOI 10.1148/radiology.157.2.4048444; Dietrich U, 1993, Zentralbl Neurochir, V54, P24; Eberhardt KEW, 1997, EUR RADIOL, V7, P1485, DOI 10.1007/s003300050321; El Gammal T, 1998, AM J NEURORADIOL, V19, P627; FARRELL VJ, 1993, SURG NEUROL, V40, P378, DOI 10.1016/0090-3019(93)90216-N; Gjuric M, 1998, HNO, V46, P205, DOI 10.1007/s001060050228; Grainger AJ, 2000, CLIN RADIOL, V55, P163, DOI 10.1053/crad.1999.0374; Gupta V, 1997, ACTA RADIOL, V38, P603; Har-El G, 1999, ANN OTO RHINOL LARYN, V108, P323, DOI 10.1177/000348949910800401; HARBURY OL, 1991, AM J NEURORADIOL, V12, P666; Ibarra R, 2000, J MAGN RESON IMAGING, V11, P20, DOI 10.1002/(SICI)1522-2586(200001)11:1<20::AID-JMRI3>3.0.CO;2-6; Jinkins JR, 2002, RADIOLOGY, V222, P555, DOI 10.1148/radiol.2222010249; Jinkins JR, 1999, INVEST RADIOL, V34, P156, DOI 10.1097/00004424-199902000-00009; NIENDORF HP, 1991, MAGNET RESON MED, V22, P222, DOI 10.1002/mrm.1910220212; NIENDORF HP, 1991, INVEST RADIOL, V26, pS221, DOI 10.1097/00004424-199111001-00075; PARIS S, 1999, NEURORADIOLOGY S1, V41, pS46; PIEPGRAS U, 1987, ACTA RADIOL S, V369, P290; Ray DE, 1996, AM J NEURORADIOL, V17, P365; Schick B, 1997, ARCH OTOLARYNGOL, V123, P77; Shetty PG, 1998, AM J NEURORADIOL, V19, P633; Siebner HR, 1997, NEURORADIOLOGY, V39, P418, DOI 10.1007/s002340050436; Simmen D, 1997, LARYNGO RHINO OTOL, V76, P583, DOI 10.1055/s-2007-997485; Skalpe IO, 1998, ACTA RADIOL, V39, P100; Skalpe IO, 1997, INVEST RADIOL, V32, P140, DOI 10.1097/00004424-199703000-00002; Speck U, 1997, NEURORADIOLOGY, V39, P422; Stone JA, 1999, AM J NEURORADIOL, V20, P706; TISHLER S, 1990, AM J NEURORADIOL, V11, P1167; Toney GM, 2001, INVEST RADIOL, V36, P33, DOI 10.1097/00004424-200101000-00005; VERBRUGGEN AM, 1994, EUR J NUCL MED, V21, P261, DOI 10.1007/BF00188676; WEINMANN HJ, 1984, AM J ROENTGENOL, V142, P619, DOI 10.2214/ajr.142.3.619; WEINMANN HJ, 1990, INVEST RADIOL S1, V25, P49; Wenzel R, 2000, NEURORADIOLOGY, V42, P874, DOI 10.1007/s002340000485; Zeng QY, 1999, AM J ROENTGENOL, V173, P1109, DOI 10.2214/ajr.173.4.10511188	38	25	25	0	1	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0938-7994			EUR RADIOL	Eur. Radiol.	DEC	2002	12	12					2943	2949		10.1007/s00330-002-1606-9			7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	627GL	WOS:000179925300014	12439574				2021-06-18	
J	Jang, SH; Han, BS; Chang, YM; Byun, WM; Lee, J; Ahn, SH				Jang, SH; Han, BS; Chang, YM; Byun, WM; Lee, J; Ahn, SH			Functional MRI evidence for motor cortex reorganization adjacent to a lesion in a primary motor cortex	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						functional magnetic resonance imaging; motor recovery; brain injury; motor cortex	HAND AREA; RECOVERY; PLASTICITY; STROKE; LOCALIZATION; GYRUS	Objective: The object of this study was to verify motor cortex reorganization in patients with primary motor cortex injury using functional magnetic resonance imaging. Design: Ten control subjects and two patients with primary motor cortex injury, caused by a traumatic brain injury in patient 1 and meningioma in patient 2, were evaluated. Functional magnetic resonance imaging was performed using the blood oxygenation level-dependent technique at 1.5 T with hand movements. Results: The contralateral primary sensorimotor cortex was activated by unaffected hand movements. However, only the contralateral primary sensory cortex in patient 1 and the premotor area in patient 2 were activated by affected hand movements, which were totally absent in control subjects. Conclusion: We believe that the hand motor function of injured primary motor cortex was shifted into the primary sensory cortex in patient 1 and premotor area in patient 2. In conclusion, this finding may reflect a functional reorganization of the motor area in patients with a primary motor cortex injury.	Yeungnam Univ, Sch Med, Dept Phys Med & Rehabil, Nam Ku, Taegu 705717, South Korea; Yeungnam Univ, Sch Med, Dept Diagnost Radiol, Nam Ku, Taegu 705717, South Korea; Yeungnam Univ, Sch Med, Dept Neurol, Nam Ku, Taegu 705717, South Korea; Kyungpook Natl Univ, Sch Med, Dept Radiol, Taegu, South Korea	Jang, SH (corresponding author), Yeungnam Univ, Sch Med, Dept Phys Med & Rehabil, Nam Ku, 317-1,Daemyungdong, Taegu 705717, South Korea.		Han, Bong Soo/AAL-6704-2020				BANDETTINI PA, 1993, MAGNET RESON MED, V30, P161, DOI 10.1002/mrm.1910300204; Boroojerdi B, 1999, CLIN NEUROPHYSIOL, V110, P699, DOI 10.1016/S1388-2457(98)00027-3; Caramia MD, 1998, NEUROLOGY, V51, P196, DOI 10.1212/WNL.51.1.196; CASTROALAMANCOS MA, 1995, NEUROSCIENCE, V68, P793, DOI 10.1016/0306-4522(95)00178-L; CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112; Cramer SC, 1997, STROKE, V28, P2518, DOI 10.1161/01.STR.28.12.2518; Cramer SC, 2000, STROKE, V31, P668, DOI 10.1161/01.STR.31.3.668; DAVIDOFF RA, 1990, NEUROLOGY, V40, P332; Duffau H, 2000, ANN NEUROL, V47, P132, DOI 10.1002/1531-8249(200001)47:1<132::AID-ANA23>3.3.CO;2-S; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; JANE JA, 1967, J NEUROSURG, V26, P244, DOI 10.3171/jns.1967.26.2.0244; Kawamata T, 1997, P NATL ACAD SCI USA, V94, P8179, DOI 10.1073/pnas.94.15.8179; Nudo RJ, 1999, REV NEUROL, V155, P713; Nudo RJ, 1996, J NEUROPHYSIOL, V75, P2144; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Rossini PM, 1998, NEUROREPORT, V9, P2141, DOI 10.1097/00001756-199806220-00043; Rouiller EM, 1998, EUR J NEUROSCI, V10, P729, DOI 10.1046/j.1460-9568.1998.00075.x; RUSSELL JR, 1961, NEUROLOGY, V11, P96, DOI 10.1212/WNL.11.2.96; Seitz RJ, 1997, ADV NEUROL, V73, P321; SEITZ RJ, 1995, NEUROREPORT, V6, P742, DOI 10.1097/00001756-199503270-00009; Stroemer RP, 1998, STROKE, V29, P2381, DOI 10.1161/01.STR.29.11.2381; STRUPP JP, 1996, NEUROIMAGE, V3, P607; WEILLER C, 1993, ANN NEUROL, V33, P181; YORK DH, 1987, NEUROSURGERY, V20, P70; Yousry TA, 1997, BRAIN, V120, P141, DOI 10.1093/brain/120.1.141	25	25	25	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	NOV	2002	81	11					844	847		10.1097/00002060-200211000-00007			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	607FP	WOS:000178781700007	12394996				2021-06-18	
J	Bergman, MM				Bergman, MM			The benefits of a cognitive orthotic in brain injury rehabilitation	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						assistive technology; brain injury rehabilitation; cognitive orthotic; computers		Background: Properly designed software can be compensatory; and possibly remedial, for people with significant deficits from traumatic brain injury (FBI). objective: This article will provide a historical overview of the use of microcomputers in brain injury rehabilitation. Emphasis will be placed on the evolution of compensatory assistive technology for overcoming cognitive impairments, with theoretical discussion of the design considerations for an effective cognitive orthotic. Conclusions: Discussion win focus on findings and observations made with a particular multifunction cognitive orthotic system to assist people with TBI in the performance of ecologically relevant activities. Additional observations win address the impact of the current US health care environment on technological innovation.	Lankenau Hosp, Wynnewood, PA USA	Bergman, MM (corresponding author), Lankenau Med Off, Bldg E,100 E Lancaster Ave,Suite 564, Wynnewood, PA 19096 USA.						*ALL TECHN ASS, 1994, COMPUTER RESOURCES P; Batchelor J, 1988, J HEAD TRAUMA REHAB, V3, P78, DOI DOI 10.1097/00001199-198809000-00012; Berg H, 1998, BIOELECTROCH BIOENER, V45, P1; Bergman M M, 2000, Appl Neuropsychol, V7, P76, DOI 10.1207/S15324826AN0702_2; Bergman Marilyn M., 1991, NEUROPSYCHOLOGY, V5, P17; BERGMAN MM, 1991, NEUROPSYCHOLOGY, V5, P25; BERGMAN MM, 1997, Patent No. 5601432; BERGMAN MM, 1999, Patent No. 5890905; BERGMAN MM, 1999, Patent No. 5879162; BERGMAN MM, 1991, J HEAD TRAUMA REHAB, V6, P100; BRACY OL, 1983, COGNITIVE REHABILITA, V1, P7; Chute DL, 1988, NEUROPSYCHOLOGY, V2, P41, DOI 10.1037//0894-4105.2.1.41; COLE E, 1987, COGNITIVE REHABILITA, V5, P29; FISHER L, 1989, COGNITIVE APPROACHES; FOWLER R, 1972, REHABILITATION COUNS, V15, P80; FRANZEN M D, 1991, Neuropsychology Review, V2, P29, DOI 10.1007/BF01108846; GIANUTSOS R, 1980, J REHABIL, V46, P36; GLISKY EL, 1995, HDB MEMORY DISORDERS; Gookin D., 1994, WORD WINDOWS 6 DUMMI; GORMAN P, 2003, IN PRESS NEUROREHABI; JONES G, 1979, B BRIT PSYCHOL SOC, V32, P167; KERNER M, 1985, COGNITIVE REHABILITA, V3, P26; KIRSCH NL, 1987, J HEAD TRAUMA REHAB, V2, P77; Levinson R, 1997, J HEAD TRAUMA REHAB, V12, P85, DOI 10.1097/00001199-199704000-00010; LEVINSON R, 1995, P 2 INT C AI PLANN S; LYNCH WJ, 1986, J HEAD TRAUMA REHAB, V1, P77; Lynch WJ., 1983, COGN REHABIL, V1, P19; LYNCH WJ, 1990, J HEAT TRAUMA REHABI, V5, P96; LYNCH WJ, 1992, J HEAD TRAUMA REHAB, V7, P107; MARKS C, 1986, COGNITIVE REHABILITA, V4, P20; Matthews E, 1991, GLOBAL BIOGEOCHEM CY, V5, P3, DOI 10.1029/90GB02311; *MERR WEBST INC, 1989, WEBST 9 NEW COLL DIC; PARENTE R, 1994, NEUROREHABILITATION, V4, P187; PEPITONE P, 1992, HEADLINES        MAY, P26; STOLL C, 1995, SILICONE SNAKE OIL 2; WEINRICH M, 1988, ADV NEUROLOGY; WEINRICH M, 1998, ADV NEUROLOGY; Wilson B, 1984, EVERYDAY MEMORY ACTI, P207; Wilson BA, 1999, REHABIL PSYCHOL, V44, P284, DOI 10.1037/0090-5550.44.3.284	39	25	25	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	2002	17	5					431	445		10.1097/00001199-200210000-00005			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	610DD	WOS:000178944700005	12802253				2021-06-18	
J	Imai, H; McCulloch, J; Graham, DI; Masayasu, H; Macrae, IM				Imai, H; McCulloch, J; Graham, DI; Masayasu, H; Macrae, IM			New method for the quantitative assessment of axonal damage in focal cerebral ischemia	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						white matter; focal ischemia; method; antioxidant; ebselen; amyloid precursor protein	AMYLOID PRECURSOR PROTEIN; CLOSED-HEAD INJURY; WHITE-MATTER; BRAIN INJURY; RAT-BRAIN; SELENOORGANIC COMPOUND; LIPID-PEROXIDATION; ARTERY OCCLUSION; EBSELEN; MODEL	Quantification of damage in both grey and white matter is required for comprehensive assessment of neuroprotective drug efficacy. Although methods for quantification of neuronal perikaryal damage after ischemia are Well established, assessment of axonal damage has been limited. This article describes a new method for quantitation of axonal injury after middle cerebral artery (MCA) occlusion in rats and its application to the study of the antioxidant ebselen. The methodology is based on immunohistochemical detection of amyloid precursor protein (APP) accumulation in deformed, swollen axons in zones of ischemia. Sixty-five axon-rich sites throughout the MCA territory are assessed for the presence (scored 1) or absence (scored 0) of accumulated APP in axonal swellings. Scores for individual sites are summated in predefined neuro-anatomic regions (e.g. corpus callosum), stereotaxic levels, or for a total hemisphere APP score. Both intra-rater and inter-rater reproducibility were high (r = 0.87 and 0.80, respectively). Ebselen (1 mg kg(-1) hr(-1), intravenously) significantly reduced the volume of neuronal perikaryal damage (24%, P < 0.01) and axonal damage (total APP score reduced from 27 [23.9 to 35.1, 95% CI] to 21.5 [18.2 to 23.3], P = 0.002 With ebselen treatment). In conclusion, a robust and generally applicable method is described for assessing pathologic features in myelinated fiber tracts that is sensitive for detection of drug effects on axonal damage.	Univ Glasgow, Wellcome Surg Inst, Glasgow G61 1QH, Lanark, Scotland; Univ Glasgow, Dept Neuropathol, Glasgow G61 1QH, Lanark, Scotland; Daiichi Pharmaceut Co Ltd, Tokyo, Japan	Macrae, IM (corresponding author), Univ Glasgow, Wellcome Surg Inst, Garscube Estate,Bearsden Rd, Glasgow G61 1QH, Lanark, Scotland.						BINDOLI A, 1988, FREE RADICAL BIO MED, V5, P247, DOI 10.1016/0891-5849(88)90018-4; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Boireau A, 1999, ANN NY ACAD SCI, V893, P254, DOI 10.1111/j.1749-6632.1999.tb07830.x; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; BRIERLEY JB, 1987, GREENFIELDS NEUROPAT, P125; COTGREAVE IA, 1989, BIOCHEM PHARMACOL, V38, P649, DOI 10.1016/0006-2952(89)90211-6; De Keyser J, 1999, TRENDS NEUROSCI, V22, P535, DOI 10.1016/S0166-2236(99)01463-0; DEWAR D, 1995, BRAIN RES, V684, P70, DOI 10.1016/0006-8993(95)00417-O; Dewar D, 1999, EUR J PHARMACOL, V375, P41, DOI 10.1016/S0014-2999(99)00280-0; Dietrich WD, 1998, ACTA NEUROPATHOL, V95, P524, DOI 10.1007/s004010050833; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Gentleman SM, 1999, NEUROPATH APPL NEURO, V25, P41; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; HATTORI R, 1994, EUR J PHARM-MOLEC PH, V267, pR1, DOI 10.1016/0922-4106(94)90179-1; He Z, 1999, STROKE, V30, P2743, DOI 10.1161/01.STR.30.12.2743; Heiss WD, 2000, J CEREBR BLOOD F MET, V20, P1276, DOI 10.1097/00004647-200009000-00002; Herin GA, 2001, J NEUROCHEM, V78, P1307, DOI 10.1046/j.1471-4159.2001.00517.x; Imai H, 2001, STROKE, V32, P2149, DOI 10.1161/hs0901.095725; KALARIA RN, 1993, NEUROREPORT, V4, P211, DOI 10.1097/00001756-199302000-00025; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; KOMJATI K, 2001, J CEREB BLOOD FLO S1, V21, pS14; KONIG JFR, 1963, RAT BRAIN STEREOTAXI; Malecki A, 2000, J NEUROCHEM, V74, P2278, DOI 10.1046/j.1471-4159.2000.0742278.x; Mandai K, 1997, NEUROSCIENCE, V77, P849, DOI 10.1016/S0306-4522(97)00517-4; McCracken E, 2000, J CEREBR BLOOD F MET, V20, P1529, DOI 10.1097/00004647-200011000-00002; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; OSBORNE KA, 1987, J NEUROL NEUROSUR PS, V50, P402, DOI 10.1136/jnnp.50.4.402; Parnham M, 2000, EXPERT OPIN INV DRUG, V9, P607, DOI 10.1517/13543784.9.3.607; Paxinos G, 1986, RAT BRAIN STEREOTAXI; Petty MA, 1999, BRAIN RES REV, V31, P58, DOI 10.1016/S0165-0173(99)00025-9; Pierce JES, 1996, J NEUROSCI, V16, P1083; Schabitz WR, 2000, STROKE, V31, P1709, DOI 10.1161/01.STR.31.7.1709; SCHEWE C, 1994, BIOCHEM PHARMACOL, V48, P65, DOI 10.1016/0006-2952(94)90224-0; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SIES H, 1993, FREE RADICAL BIO MED, V14, P313, DOI 10.1016/0891-5849(93)90028-S; Stys PK, 1998, J CEREBR BLOOD F MET, V18, P2, DOI 10.1097/00004647-199801000-00002; Takasago T, 1997, BRIT J PHARMACOL, V122, P1251, DOI 10.1038/sj.bjp.0701426; TAMURA A, 1981, J CEREBR BLOOD F MET, V1, P53, DOI 10.1038/jcbfm.1981.6; Valeriani V, 2000, J CEREBR BLOOD F MET, V20, P765, DOI 10.1097/00004647-200005000-00002; WAKITA H, 1995, STROKE, V26, P1415, DOI 10.1161/01.STR.26.8.1415; Yam PS, 1997, BRAIN RES, V760, P150, DOI 10.1016/S0006-8993(97)00290-4; Yam PS, 1998, BRAIN RES PROTOC, V2, P315, DOI 10.1016/S1385-299X(98)00005-1; Yam PS, 2000, J CEREBR BLOOD F MET, V20, P772, DOI 10.1097/00004647-200005000-00003; Zhao R, 2002, P NATL ACAD SCI USA, V99, P8579, DOI 10.1073/pnas.122061399	46	25	25	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2002	22	9					1080	1089		10.1097/00004647-200209000-00005			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	592CP	WOS:000177919400005	12218413	Bronze			2021-06-18	
J	Vincent, VAM; Robinson, CC; Simsek, D; Murphy, GM				Vincent, VAM; Robinson, CC; Simsek, D; Murphy, GM			Macrophage colony stimulating factor prevents NMDA-induced neuronal death in hippocampal organotypic cultures	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; caspase-3; hippocampus; macrophage colony stimulating factor; neurotoxicity; NMDA	METHYL-D-ASPARTATE; OSTEOPETROTIC OP/OP MICE; MESSENGER-RNA EXPRESSION; NECROSIS-FACTOR-ALPHA; DELAYED CELL-DEATH; ALZHEIMERS-DISEASE; MICROGLIAL CELLS; SLICE CULTURES; IN-VITRO; CASPASE-3 ACTIVATION	Macrophage colony stimulating factor (M-CSF) and its receptor are up-regulated in the brain in Alzheimer's disease (AD), in transgenic mouse models for AD, and experimental models for traumatic and ischemic brain injury. M-CSF induces activation and proliferation of microglial cells and expression of proinflammatory cytokines. We examined the role of M-CSF in excitotoxic neuronal cell death in organotypic hippocampal cultures. NMDA treatment induced neuronal apoptosis and caspase-3 activation in organotypic hippocampal cultures, whereas treatment with M-CSF protected hippocampal neurons from NMDA-induced apoptosis. Caspase-3 activation was inhibited by M-CSF treatment to the same degree as with the caspase inhibitor Z-VAD-FMK. These results suggest that M-CSF has neuroprotective properties through inhibition of caspase-3 that could promote neuronal survival after excitotoxic insult. The role of M-CSF in neurological disease should be reevaluated as a microglial activator with potentially neuroprotective effects.	Stanford Univ, Sch Med, Neurosci Res Labs, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA	Murphy, GM (corresponding author), Stanford Univ, Sch Med, Neurosci Res Labs, Dept Psychiat & Behav Sci, MSLS P-104, Stanford, CA 94305 USA.	gmurphy@leland.stanford.edu					Adamec E, 1999, BRAIN RES, V849, P67, DOI 10.1016/S0006-8993(99)02004-1; AKIYAMA H, 1994, BRAIN RES, V639, P171, DOI 10.1016/0006-8993(94)91779-5; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Ali C, 2000, J CEREBR BLOOD F MET, V20, P956, DOI 10.1097/00004647-200006000-00008; ALOISI F, 1992, J IMMUNOL, V149, P2358; Bachis A, 2001, J NEUROSCI, V21, P3104, DOI 10.1523/JNEUROSCI.21-09-03104.2001; BEREZOVSKAYA O, 1995, INT J DEV NEUROSCI, V13, P285, DOI 10.1016/0736-5748(95)00013-7; Bruccoleri A, 2000, J NEUROSCI RES, V62, P146, DOI 10.1002/1097-4547(20001001)62:1<146::AID-JNR15>3.0.CO;2-L; Bruno V, 2000, EUR J PHARMACOL, V399, P117, DOI 10.1016/S0014-2999(00)00367-8; Carenini S, 2001, J CELL BIOL, V152, P301, DOI 10.1083/jcb.152.2.301; Castellano C, 2001, CURR DRUG TARGETS, V2, P273, DOI 10.2174/1389450013348515; Chen J, 1998, J NEUROSCI, V18, P4914; Czapiga M, 1999, J NEUROSCI RES, V56, P644, DOI 10.1002/(SICI)1097-4547(19990615)56:6<644::AID-JNR10>3.3.CO;2-0; Du YS, 1997, P NATL ACAD SCI USA, V94, P11657, DOI 10.1073/pnas.94.21.11657; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Enari M, 1998, NATURE, V391, P43; Engidawork E, 2001, NEUROSCI LETT, V303, P79, DOI 10.1016/S0304-3940(01)01618-4; Estus S, 1997, J NEUROSCI, V17, P7736; Fedoroff S, 1997, NEUROSCI BIOBEHAV R, V21, P187, DOI 10.1016/S0149-7634(96)00009-7; Gahwiler BH, 1997, TRENDS NEUROSCI, V20, P471, DOI 10.1016/S0166-2236(97)01122-3; GIULIAN D, 1988, J NEUROSCI, V8, P4707; Gorman AM, 1998, NEUROREPORT, V9, pR49, DOI 10.1097/00001756-199807130-00001; Hailer NP, 1996, GLIA, V18, P319, DOI 10.1002/(SICI)1098-1136(199612)18:4<319::AID-GLIA6>3.0.CO;2-S; Hao AJ, 2001, J NEUROSCI RES, V64, P79, DOI 10.1002/jnr.1056; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Harrison DC, 2000, MOL BRAIN RES, V75, P143, DOI 10.1016/S0169-328X(99)00305-8; Hermann DM, 2001, NEUROSCIENCE, V104, P947, DOI 10.1016/S0306-4522(01)00125-7; Heyen JRR, 2000, MOL BRAIN RES, V77, P138, DOI 10.1016/S0169-328X(00)00042-5; Hirashima Y, 1999, BRAIN RES, V849, P109, DOI 10.1016/S0006-8993(99)02009-0; Huppertz B, 1999, ANAT EMBRYOL, V200, P1, DOI 10.1007/s004290050254; Jain KK, 2000, EXPERT OPIN INV DRUG, V9, P1397, DOI 10.1517/13543784.9.6.1397; Kondratyev A, 2000, MOL BRAIN RES, V75, P216, DOI 10.1016/S0169-328X(99)00292-2; Laake JH, 1999, BRAIN RES PROTOC, V4, P173, DOI 10.1016/S1385-299X(99)00021-5; Le DA, 2001, DRUG AGING, V18, P717, DOI 10.2165/00002512-200118100-00001; LEE SC, 1993, J IMMUNOL, V150, P594; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Liu XH, 1999, BRAIN RES, V851, P94, DOI 10.1016/S0006-8993(99)02126-5; Lue LF, 2001, GLIA, V35, P72, DOI 10.1002/glia.1072; Marin N, 2000, MECH AGEING DEV, V119, P63, DOI 10.1016/S0047-6374(00)00172-X; Masumura M, 2000, MOL BRAIN RES, V80, P219, DOI 10.1016/S0169-328X(00)00163-7; MATSUSHIMA GK, 1994, CELL, V78, P645, DOI 10.1016/0092-8674(94)90529-0; Meucci O, 2000, P NATL ACAD SCI USA, V97, P8075, DOI 10.1073/pnas.090017497; Michaelson MD, 1996, DEVELOPMENT, V122, P2661; Mitrasinovic OM, 2001, J BIOL CHEM, V276, P30142, DOI 10.1074/jbc.M104265200; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Murase S, 1998, J NEUROSCI, V18, P10481; Murphy GM, 1998, J BIOL CHEM, V273, P20967, DOI 10.1074/jbc.273.33.20967; Murphy GM, 2000, AM J PATHOL, V157, P895, DOI 10.1016/S0002-9440(10)64603-2; NAITO M, 1991, AM J PATHOL, V139, P657; Namura S, 1998, J NEUROSCI, V18, P3659; Ni BH, 1997, J NEUROSCI, V17, P1561; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NOHAVA K, 1992, EUR J IMMUNOL, V22, P2539, DOI 10.1002/eji.1830221012; RAIVICH G, 1991, J NEUROSCI RES, V30, P682, DOI 10.1002/jnr.490300412; Raivich G, 1998, J COMP NEUROL, V395, P342, DOI 10.1002/(SICI)1096-9861(19980808)395:3<342::AID-CNE6>3.0.CO;2-2; Ray AM, 2000, BRAIN RES, V867, P62, DOI 10.1016/S0006-8993(00)02230-7; Roth KA, 2001, J NEUROPATH EXP NEUR, V60, P829, DOI 10.1093/jnen/60.9.829; Sakahira H, 1998, NATURE, V391, P96; Schmidt-Kastner R, 2000, MOL BRAIN RES, V79, P88, DOI 10.1016/S0169-328X(00)00104-2; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Selznick LA, 1999, J NEUROPATH EXP NEUR, V58, P1020, DOI 10.1097/00005072-199909000-00012; Shimohama S, 2000, APOPTOSIS, V5, P9, DOI 10.1023/A:1009625323388; Spranger M, 1996, NEUROSCIENTIST, V2, P293, DOI 10.1177/107385849600200515; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Su JH, 2001, BRAIN RES, V898, P350, DOI 10.1016/S0006-8993(01)02018-2; Tenneti L, 2000, J NEUROCHEM, V74, P134, DOI 10.1046/j.1471-4159.2000.0740134.x; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Torp R, 1998, NEUROBIOL DIS, V5, P245, DOI 10.1006/nbdi.1998.0201; Velier JJ, 1999, J NEUROSCI, V19, P5932, DOI 10.1523/JNEUROSCI.19-14-05932.1999; Wang YQ, 1999, J NEUROSCI RES, V57, P616, DOI 10.1002/(SICI)1097-4547(19990901)57:5<616::AID-JNR4>3.0.CO;2-E; Wegiel J, 1998, BRAIN RES, V804, P135, DOI 10.1016/S0006-8993(98)00618-0; Wellington CL, 2000, CLIN GENET, V57, P1, DOI 10.1034/j.1399-0004.2000.570101.x; WITMERPACK MD, 1993, J CELL SCI, V104, P1021; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; Zhu Y, 2001, NEUROCHEM INT, V38, P227, DOI 10.1016/S0197-0186(00)00084-X	75	25	27	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	SEP	2002	82	6					1388	1397		10.1046/j.1471-4159.2002.01087.x			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	589YW	WOS:000177790000008	12354286				2021-06-18	
J	Zauner, A; Clausen, T; Alves, OL; Rice, A; Levasseur, J; Young, HF; Bullock, R				Zauner, A; Clausen, T; Alves, OL; Rice, A; Levasseur, J; Young, HF; Bullock, R			Cerebral metabolism after fluid-percussion injury and hypoxia in a feline model	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; hypoxia; cerebral metabolism; brain chemistry; cat	SEVERE HEAD-INJURY; TRAUMATIC BRAIN INJURY; EXCITATORY AMINO-ACIDS; SUBSTRATE DELIVERY; INTRACELLULAR PH; CORTICAL IMPACT; OXYGEN-TENSION; TISSUE OXYGEN; BLOOD-FLOW; ISCHEMIA	Object. Currently, there are no good clinical tools to identify the onset of secondary brain injury and/or hypoxia after traumatic brain injury (TBI). The aim of this study was to evaluate simultaneously early changes of cerebral metabolism, acid-base homeostasis, and oxygenation, as well as their interrelationship after TBI and arterial hypoxia. Methods. Cerebral biochemistry and O-2 supply were measured simultaneously in a feline model of fluid-percussion injury (FPI) and secondary hypoxic injury. After FPI, brain tissue PO, decreased from 33 +/- 5 mm Hg to 10 +/- 4 mm Hg and brain tissue PCO2 increased from 55 +/- 2 mm Hg to 81 +/- 9 mm Hg, whereas cerebral pH fell from 7.1 +/- 0.06 to 6.84 +/- 0.14 (p < 0.05 for all three measures). After 40 minutes of hypoxia, brain tissue PO2 and pH decreased further to 0 mm Hg and 6.48 +/- 0.28, respectively (p < 0.05), whereas brain tissue PCO2, remained high at 83 13 turn Hg. Secondary hypoxic injury caused a drastic increase in cerebral lactate from 513 69 muM/L to 3219 +/- 490 muM/L (p < 0.05). The lactate/glucose ratio increased from 0.7 +/- 0.1 to 9.1 +/- 2 after hypoxia was introduced. The O-2 consumption decreased significantly from 18.5 +/- 1.1 mul/mg/hr to 13.2 +/- 2.1 mul/mg/hr after hypoxia was induced. Conclusions. Cerebral metabolism, O-2 supply, and acid-base balance were severely compromised ultra-early after TBI, and they declined further if arterial hypoxia was present. The complexity of pathophysiological changes and their interactions after TBI might explain why specific therapeutic attempts that are aimed at the normalization of only one component have failed to improve outcome in severely head injured patients.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA	Zauner, A (corresponding author), Univ Calif Los Angeles, Box 951721, Los Angeles, CA 90095 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER		ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; COHEN PJ, 1967, J APPL PHYSIOL, V23, P183; COMBS DJ, 1990, STROKE, V21, P936, DOI 10.1161/01.STR.21.6.936; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Hutchinson PJ, 1999, NEUROL RES, V21, P352, DOI 10.1080/01616412.1999.11740943; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KRAIG RP, 1987, J CEREBR BLOOD F MET, V7, P379, DOI 10.1038/jcbfm.1987.80; Krebs E G, 1972, Curr Top Cell Regul, V5, P99; Krishnappa IK, 1999, J NEUROTRAUM, V16, P213, DOI 10.1089/neu.1999.16.213; KURODA Y, 1992, J NEUROSURG, V76, P471, DOI 10.3171/jns.1992.76.3.0471; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; Murr R, 1996, ACTA NEUROCHIR, V138, P928, DOI 10.1007/BF01411281; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SIESJO BK, 1973, ARCH NEUROL-CHICAGO, V29, P400, DOI 10.1001/archneur.1973.00490300062008; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1973, SCAND J CLIN LAB INV, V32, P97, DOI 10.3109/00365517309084335; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; ZAUNER A, 1995, NEUROSURGERY, V37, P1168, DOI 10.1227/00006123-199512000-00017; Zauner A, 1997, NEUROL RES, V19, P265, DOI 10.1080/01616412.1997.11740812; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	36	25	25	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	2002	97	3					643	649		10.3171/jns.2002.97.3.0643			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	593JA	WOS:000177986400019	12296649				2021-06-18	
J	Franz, G; Beer, R; Intemann, D; Krajewski, T; Reed, JC; Engelhardt, K; Pike, BR; Hayes, RL; Wang, KK; Schmutzhard, E; Kampfl, A				Franz, G; Beer, R; Intemann, D; Krajewski, T; Reed, JC; Engelhardt, K; Pike, BR; Hayes, RL; Wang, KK; Schmutzhard, E; Kampfl, A			Temporal and spatial profile of bid cleavage after experimental traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						apoptosis; bid; caspases; neurons; glia; traumatic brain injury	APOPTOTIC CELL-DEATH; CASPASE ACTIVATION; NEURONAL APOPTOSIS; CEREBRAL-ISCHEMIA; IN-VITRO; EXPRESSION; CALPAIN; RAT; MITOCHONDRIA; PROTEOLYSIS	Apoptosis plays an essential role in the cascade of CNS cell degeneration after traumatic brain injury. However., the underlying mechanisms are poorly understood, The authors examined the temporal profile and cell subtype distribution of the proapoptotic protein Bid from 6 hours to 7 days after cortical impact injury in the rat. Increased protein levels of tBid were seen in the cortex ipsilateral to the injury site from 6 hours to 3 days after trauma. Immunohistologic examinations revealed expression of tBid in neurons, astrocytes, and oligodendrocytes from 6 hours to 3 days after impact injury, and concurrent assessment of DNA damage using TUNEL identified tBid-immunopositive cells with apoptoticlike morphology in the traumatized cortex. Moreover, Bid cleavage and activation of caspase-8 and caspase-9 occurred at similar time points, and in similar brain regions (i.e., cortical layers 2 to 5) after impact injury. In contrast, there was no evidence of caspase-8 or caspase-9 processing or Bid cleavage in the ipsilateral hippocampus, contralateral cortex, and hippocampus up to 7 days after the injury. The results provide the first evidence of Bid cleavage in the traumatized cortex after experimental traumatic brain injury in vivo, and demonstrate that tBid is expressed in neurons and glial cells. Further, findings indicate that cleavage of Bid may be associated with the activation of the initiator caspase-8 and caspase-9. Finally, these data support the hypothesis that cleavage of Bid contributes to the apoptotic degeneration of different CNS cells in the injured cortex.	Univ Innsbruck Hosp, Dept Neurol, A-6020 Innsbruck, Austria; Pfizer Inc, Dept Neurosci Therapeut, Ann Arbor, MI USA; Univ Florida, Everlyn F & William L McKnight Brain Inst, Dept Neurosci, Gainesville, FL USA; Burnham Inst, La Jolla, CA 92037 USA	Kampfl, A (corresponding author), Univ Innsbruck Hosp, Dept Neurol, Anichstr 35, A-6020 Innsbruck, Austria.		Pike, Bruce/K-5562-2014	Pike, Bruce/0000-0001-8924-683X; Wang, Kevin/0000-0002-9343-6473	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36821] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036821] Funding Source: NIH RePORTER		Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Buki A, 2000, J NEUROSCI, V20, P2825; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Conti AC, 1998, J NEUROSCI, V18, P5663; Crompton M, 2000, CURR OPIN CELL BIOL, V12, P414, DOI 10.1016/S0955-0674(00)00110-1; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Faden AI, 1996, JAMA-J AM MED ASSOC, V276, P569, DOI 10.1001/jama.276.7.569; Franz G, 1999, J NEUROCHEM, V73, P1615, DOI 10.1046/j.1471-4159.1999.0731615.x; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Henshall DC, 2001, NEUROBIOL DIS, V8, P568, DOI 10.1006/nbdi.2001.0415; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Krajewska M, 2002, CELL DEATH DIFFER, V9, P145, DOI 10.1038/sj/cdd/4400934; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Neumar RW, 1996, J NEUROCHEM, V66, P421; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; RINK A, 1995, AM J PATHOL, V147, P1575; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SPRINKLE TJ, 1989, CRIT REV NEUROBIOL, V4, P235; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Van de Craen M, 1999, CELL DEATH DIFFER, V6, P1117, DOI 10.1038/sj.cdd.4400589; Viswanath V, 2001, J NEUROSCI, V21, P9519, DOI 10.1523/JNEUROSCI.21-24-09519.2001; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082; Yakovlev AG, 2001, J NEUROSCI, V21, P7439; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; 1989, FEDERAL LAW GAZETTE, P501	39	25	26	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2002	22	8					951	958		10.1097/00004647-200208000-00006			8	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	579PL	WOS:000177187000006	12172380	Bronze			2021-06-18	
J	Herskovits, EH; Gerring, JP; Davatzikos, C; Bryan, RN				Herskovits, EH; Gerring, JP; Davatzikos, C; Bryan, RN			Is the spatial distribution of brain lesions associated with closed-head injury in children predictive of subsequent development of posttraumatic stress disorder?	RADIOLOGY			English	Article						brain, injuries; brain, MR; children, central nervous system	CHILDHOOD SEXUAL ABUSE; POSITRON-EMISSION-TOMOGRAPHY; SCRIPT-DRIVEN IMAGERY; HIPPOCAMPAL VOLUME; BLOOD-FLOW; DATABASE; PTSD; COMORBIDITY; ADOLESCENTS; WOMEN	PURPOSE: To determine whether there is an association between the spatial distributions of lesions detected at magnetic resonance (MR) imaging of the brain in children, adolescents, and young adults after closed-head injury (CHI) and development of the reexperiencing symptoms of posttraumatic stress disorder (PTSD). MATERIALS AND METHODS: Data obtained in 94 subjects without a history of PTSD as determined by parental interview were analyzed. MR images were obtained 3 months after CHI. Lesions were manually delineated and registered to the Talairach coordinate system. Mann-Whitney analysis of lesion distribution and PTSD status at I year (again, as determined by parental interview) was performed, consisting of an analysis of lesion distribution versus the major symptoms of PTSD: reexperiencing, hyperarousal, and avoidance. RESULTS: Of the 94 subjects, 41 met the PTSD reexperiencing criterion and nine met all three PTSD criteria. Subjects who met the reexperiencing criterion had fewer lesions in limbic system structures (eg, the cingulum) on the right than did subjects who did not meet this criterion (Mann-Whitney, P = .003). CONCLUSION: Lesions induced by CHI in the limbic system on the right may inhibit subsequent manifestation of PTSD reexperiencing symptoms in children, adolescents, and young adults. (C) RSNA, 2002.	Johns Hopkins Med Inst, Div Neuroradiol, Baltimore, MD 21287 USA; Johns Hopkins Sch Publ Hlth, Dept Biostat, Baltimore, MD USA; Johns Hopkins Univ Hosp, Dept Psychiat, Baltimore, MD 21205 USA; Hosp Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA	Herskovits, EH (corresponding author), Johns Hopkins Med Inst, Div Neuroradiol, 600 N Wolfe St, Baltimore, MD 21287 USA.			Davatzikos, Christos/0000-0002-1025-8561	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG13743] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG013743] Funding Source: NIH RePORTER		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; Bremner J D, 1999, Semin Clin Neuropsychiatry, V4, P249; Bremner JD, 1999, AM J PSYCHIAT, V156, P1787; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; Bremner JD, 1999, BIOL PSYCHIAT, V45, P806, DOI 10.1016/S0006-3223(98)00297-2; Brodmann K., 1909, VERGLEICHENDE LOKALI; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Davatzikos C, 1997, COMPUT VIS IMAGE UND, V66, P207, DOI 10.1006/cviu.1997.0605; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Gerring JP, 2002, J AM ACAD CHILD PSY, V41, P157, DOI 10.1097/00004583-200202000-00009; Gurvits TV, 1996, BIOL PSYCHIAT, V40, P1091, DOI 10.1016/S0006-3223(96)00229-6; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Herskovits EH, 2000, METHOD INFORM MED, V39, P291; KELLY D, 1973, BRIT J PSYCHIAT, V123, P133, DOI 10.1192/bjp.123.2.133; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Letovsky SI, 1998, AM J NEURORADIOL, V19, P1869; Lipschitz DS, 1999, J AM ACAD CHILD PSY, V38, P385, DOI 10.1097/00004583-199904000-00010; Lucey JV, 1997, BRIT J PSYCHIAT, V171, P346, DOI 10.1192/bjp.171.4.346; Megalooikonomou V, 2000, HUM BRAIN MAPP, V10, P61, DOI 10.1002/(SICI)1097-0193(200006)10:2<61::AID-HBM20>3.0.CO;2-9; Newport DJ, 2000, CURR OPIN NEUROBIOL, V10, P211, DOI 10.1016/S0959-4388(00)00080-5; Nowinski WL, 1997, ELECT CLIN BRAIN ATL; Rauch SL, 1996, ARCH GEN PSYCHIAT, V53, P380; Rauch SL, 2000, BIOL PSYCHIAT, V47, P769, DOI 10.1016/S0006-3223(00)00828-3; Rauch SL, 1997, ANN NY ACAD SCI, V821, P83, DOI 10.1111/j.1749-6632.1997.tb48271.x; Rauch SL., 1998, CNS SPECTRUMS, V3, P30, DOI [10.1017/S1092852900007306, DOI 10.1017/S1092852900007306]; Reich W, 2000, J AM ACAD CHILD PSY, V39, P59, DOI 10.1097/00004583-200001000-00017; SACK WH, 1993, J AM ACAD CHILD PSY, V32, P431, DOI 10.1097/00004583-199303000-00027; Schuff N, 1997, ANN NY ACAD SCI, V821, P516, DOI 10.1111/j.1749-6632.1997.tb48319.x; Shin LM, 1999, AM J PSYCHIAT, V156, P575; Shin LM, 1997, ARCH GEN PSYCHIAT, V54, P233; SLIFER KJ, 1993, J APPL BEHAV ANAL, V26, P469, DOI 10.1901/jaba.1993.26-469; Stein MB, 1997, PSYCHOL MED, V27, P951, DOI 10.1017/S0033291797005242; Stein MB, 1997, ANN NY ACAD SCI, V821, P76, DOI 10.1111/j.1749-6632.1997.tb48270.x; Talairach J., 1988, COPLANAR STEREOTAXIC; Villarreal G, 2001, Semin Clin Neuropsychiatry, V6, P131, DOI 10.1053/scnp.2001.21840; WEINGARTEN SM, 1999, PSYCHOSURGERY; WILSON J T L, 1990, Brain Injury, V4, P349; Zubieta JK, 1999, J PSYCHIAT RES, V33, P259, DOI 10.1016/S0022-3956(98)00060-0	39	25	25	0	0	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	AUG	2002	224	2					345	351		10.1148/radiol.2242011439			7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	576UY	WOS:000177025400009	12147826				2021-06-18	
J	Hicken, BL; Putzke, JD; Novack, T; Sherer, M; Richards, JS				Hicken, BL; Putzke, JD; Novack, T; Sherer, M; Richards, JS			Life satisfaction following spinal cord and traumatic brain injury: A comparative study	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						head injury; life satisfaction; pain; quality of life; spinal cord injury	QUALITY-OF-LIFE; FUNCTIONAL INDEPENDENCE MEASURE; LONG-TERM ADJUSTMENT; WELL-BEING MEASURES; PHYSICAL-DISABILITY; CHRONOLOGICAL AGE; SOCIAL SUPPORT; HEALTH-STATUS; IMPAIRMENT; COMMUNITY	The current study was designed to examine the predictive validity of several factors that are common to spinal cord injury (SCI) and traumatic brain injury (TBI) populations to overall life satisfaction. We examined several demographic and functional predictors (1) within each group separately and (2) using both groups while controlling for unique predictors within groups. Participants included 190 and 57 individuals with SCI and TBI, respectively. To minimize the influence of injury duration, we assessed life satisfaction at I-year postinjury in both groups. Functional disability (Functional Impairment Measure [FIM]) was the only common predictor within groups. For the TBI group, marital status was also a significant predictor of life satisfaction. None of the other predictors examined was significant among the SCI group. After functional disability and marital status were controlled, overall life satisfaction did not differ between groups. Total explained variance in life satisfaction was low in both groups, 9% and 25% in the SCI and TBI groups, respectively. Future directions are discussed.	Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL USA	Richards, JS (corresponding author), Spain Rehabil Ctr, 1717 6th Ave S,Room 529, Birmingham, AL 35233 USA.				NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD07420-10] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007420] Funding Source: NIH RePORTER		BACH JR, 1994, ARCH PHYS MED REHAB, V75, P626, DOI 10.1016/0003-9993(94)90183-X; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; CLAYTON KS, 1994, ARCH PHYS MED REHAB, V75, P633, DOI 10.1016/0003-9993(94)90184-8; Crewe N M, 1992, J Am Paraplegia Soc, V15, P14; CRISP R, 1992, AUST PSYCHOL, V27, P43, DOI 10.1080/00050069208257573; CUSHMAN LA, 1992, PARAPLEGIA, V30, P690, DOI 10.1038/sc.1992.135; DECKER SD, 1985, AM J OCCUP THER, V39, P740, DOI 10.5014/ajot.39.11.740; DIENER E, 1984, PSYCHOL BULL, V95, P542, DOI 10.1037/0033-2909.95.3.542; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers M, 1997, SPINAL CORD, V35, P829, DOI 10.1038/sj.sc.3100571; Dijkers MPJM, 1999, ARCH PHYS MED REHAB, V80, P867, DOI 10.1016/S0003-9993(99)90076-X; Dowler R, 2001, J Spinal Cord Med, V24, P87; FUHRER MJ, 1992, ARCH PHYS MED REHAB, V73, P552; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; HEINEMANN AW, 1995, REHABIL PSYCHOL, V40, P125; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Heinemann AW, 1991, RATING SCALE ANAL FU; KINNEY WB, 1992, ARCH PHYS MED REHAB, V73, P863; Krause JS, 1997, REHABIL PSYCHOL, V42, P287, DOI 10.1037/0090-5550.42.4.287; Krause JS, 1998, REHABIL PSYCHOL, V43, P282, DOI 10.1037/0090-5550.43.4.282; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; MCCOLL MA, 1994, PARAPLEGIA, V32, P261, DOI 10.1038/sc.1994.46; PAVOT W, 1991, J PERS ASSESS, V57, P149, DOI 10.1207/s15327752jpa5701_17; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; PENTLAND W, 1995, PARAPLEGIA, V33, P367, DOI 10.1038/sc.1995.84; Post MWM, 1998, SCAND J REHABIL MED, V30, P23; Post MWM, 1998, ARCH PHYS MED REHAB, V79, P395, DOI 10.1016/S0003-9993(98)90139-3; Post MWM, 1999, PSYCHOL HEALTH, V14, P679, DOI 10.1080/08870449908410757; Putzke JD, 2001, J CLIN PSYCHOL MED S, V8, P101, DOI 10.1023/A:1009555910604; PUTZKE JD, 2000, IN PRESS ARCH PHYS M; PUTZKE JD, 2001, IN PRESS ARCH PHYS M; Rasch G., 1980, PROBABILISTIC MODELS; Richards JS, 1999, ARCH PHYS MED REHAB, V80, P1501; SCHULZ R, 1985, J PERS SOC PSYCHOL, V48, P1162, DOI 10.1037/0022-3514.48.5.1162; Stover S., 1995, SPINAL CORD INJURY C; Vogel LC, 1998, ARCH PHYS MED REHAB, V79, P1496, DOI 10.1016/S0003-9993(98)90409-9; Warren L, 1996, J REHABIL RES DEV, V33, P404; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WHITENECK GG, 1992, PARAPLEGIA, V30, P617, DOI 10.1038/sc.1992.124	44	25	25	0	5	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.	MAY-JUN	2002	39	3					359	365					7	Rehabilitation	Rehabilitation	575NY	WOS:000176955300007	12173756				2021-06-18	
J	Perry, C; Mackay-Sim, A; Feron, F; McGrath, J				Perry, C; Mackay-Sim, A; Feron, F; McGrath, J			The 2000 Ogura Lecture: Olfactory neural cells: An untapped diagnostic and therapeutic resource	LARYNGOSCOPE			English	Article						olfactory neurones; olfactory ensheathing glial cells; paraplegia cure; schizophrenia diagnosis prevention	ENSHEATHING GLIA; REGENERATION	Objective. This is an over-view of the cellular biology of upper nasal mucosal cells that have special characteristics that enable them to be used to diagnose and study congenital neurological diseases and to aid neural repair. Study Design: After mapping the distribution of neural cells in the upper nose, the authors' investigations moved to the use of olfactory neurones to diagnose neurological diseases of development, especially schizophrenia. Olfactory-ensheating glial cells (OEGs) from the cranial cavity promote axonal penetration of the central nervous system and aid spinal cord repair in rodents. The authors sought to isolate these cells from the more accessible upper nasal cavity in rats and in humans and prove they could likewise promote neural regeneration, making these cells suitable for human spinal repair investigations. Methods: The schizophrenia-diagnosis aspect of the study entailed the biopsy of the olfactory areas of 10 schizophrenic patients and 10 control subjects. The tissue samples were sliced and grown in culture medium. The ease of cell attachment to fibronectin (artificial epithelial basement membrane), as well as the mitotic and apoptotic indices, was studied in the presence and absence of dopamine in those cell cultures. The neural repair part of the study entailed a harvesting and insertion of first rat olfactory lamina propria rich in OEGs between cut ends of the spinal cords and then later the microinjection of an OEG-rich suspension into rat spinal cords previously transected by open laminectomy. Further studies were done in which OEG insertion was performed up to 1 month after rat cord transection and also in monkeys. Results: Schizophrenic patients' olfactory tissues do not easily attach to basement membrane compared with control subjects, adding evidence to the theory that cell wall anomalies are part of the schizophrenic "lesion" of neurones. Schizophrenic patient cell cultures had higher mitotic and apoptotic indices compared with control subjects. The addition of dopamine altered these indices enough to allow accurate differentiation of schizophrenics from control patients, leading to, possibly for the first time, an early objective diagnosis of schizophrenia and possible assessment of preventive strategies. OEGs from the nose were shown to be as effective as those from the olfactory bulb in promoting axonal growth across transected spinal cords even when added I month after injury in the rat. These otherwise paraplegic rats grew motor and proprioceptive and fine touch fibers with corresponding behavioral improvement. Conclusions. The tissues of the olfactory mucosa are readily available to the otolaryngologist. Being surface cells, they must regenerate (called "neurogenesis"). Biopsy of this area and amplification of cells in culture gives the scientist a "window to the developing brain," including early diagnosis of schizophrenia. The "Holy Grail" of neurological disease is the cure of traumatic paraplegia and OEGs from the nose promote that repair. The otolaryngologist may become the necessary partner of the neurophysiologist and spinal surgeon to take the laboratory potential of paraplegic cure into the day-to-day realm of clinical reality.	Univ Queensland, Dept Surg, St Lucia, Qld 4067, Australia; Griffith Univ, Ctr Mol Neurobiol, Sch Biomol & Biomed Sci, Nathan, Qld 4111, Australia; Univ Queensland, Dept Psychiat, St Lucia, Qld 4067, Australia	Perry, C (corresponding author), Watkins Med Ctr, 4th Floor,225 Wickham Terrace, Brisbane, Qld 4000, Australia.		McGrath, John J/G-5493-2010; Feron, Francois/A-3947-2010; Mackay-Sim, Alan/C-3431-2008; Feron, Francois/J-5639-2014	McGrath, John J/0000-0002-4792-6068; Mackay-Sim, Alan/0000-0003-4446-5371; 			Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Feron F, 1998, ARCH OTOLARYNGOL, V124, P861, DOI 10.1001/archotol.124.8.861; Feron F, 1999, SCHIZOPHR RES, V40, P211, DOI 10.1016/S0920-9964(99)00055-9; Gogos JA, 2000, CELL, V103, P609, DOI 10.1016/S0092-8674(00)00164-1; Imaizumi T, 1998, J NEUROSCI, V18, P6176; Li Y, 1998, J NEUROSCI, V18, P10514; Lu J, 2001, BRAIN RES, V889, P344, DOI 10.1016/S0006-8993(00)03235-2; Maguire EA, 2000, P NATL ACAD SCI USA, V97, P4398, DOI 10.1073/pnas.070039597; Ramon-Cueto A, 2000, NEURON, V25, P425, DOI 10.1016/S0896-6273(00)80905-8; Ramon-Cueto A, 1998, J NEUROSCI, V18, P3803; RAMONCUETO A, 1994, EXP NEUROL, V127, P232, DOI 10.1006/exnr.1994.1099	11	25	26	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0023-852X			LARYNGOSCOPE	Laryngoscope	APR	2002	112	4					603	607		10.1097/00005537-200204000-00002			5	Medicine, Research & Experimental; Otorhinolaryngology	Research & Experimental Medicine; Otorhinolaryngology	541DU	WOS:000174970600002	12150509				2021-06-18	
J	Liu, H; Goodman, JC; Robertson, CS				Liu, H; Goodman, JC; Robertson, CS			The effects of L-arginine on cerebral hemodynamics after controlled cortical impact injury in the mouse	JOURNAL OF NEUROTRAUMA			English	Article						L-arginine; cerebral hemodynamics; controlled cortical impact injury; intracranial hypertension; mouse; traumatic brain injury	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; RATS; RESPONSES	Traumatic brain injury (TBI) induces vascular changes that may influence neurological outcome by causing the brain to be more susceptible to secondary ischemic insults. In rat models of TBI, L-arginine administration has been shown to restore cerebral blood flow and improve neurological outcome. The purpose of this study was to determine if hypoperfusion occurs in a mouse model of TBI and if L-arginine administration has the same beneficial effects after injury in the mouse. C57BL6 mice were anesthetized with isoflurane, intubated and mechanically ventilated, and underwent a 3-m/sec, 1.5-mm deformation cortical impact injury. Five minutes after injury, L-arginine, 300 mg/kg, or saline were administered. Arterial blood pressure, intracranial pressure, and laser Doppler flow at the impact site were monitored for 3 h after the injury. The cerebral hemodynamic effects of the TBI induced by cortical impact injury were similar to that previously observed in rats. Intracranial hypertension, with ICP peaking at 46 +/- 2 mm Hg, and systemic hypotension both contributed to a reduction in CPP. In addition, LDF decreased significantly at the impact site. L-Arginine administration restored LDF to near baseline levels without increasing ICP. These studies demonstrate that cerebral hemodynamics can be measured in mouse models of TBI. The changes in cerebral hemodynamics are relatively simlar to those see in the rat model of cortical impact injury and suggest an important role for nitric oxide metabolism in the maintenance of cerebral blood flow following TBI.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; W China Univ Med Sci, Univ Hosp 1, Dept Surg, Chengdu, Peoples R China	Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, 6560 Fannin St,944, Houston, TX 77030 USA.	claudiar@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS 38660] Funding Source: Medline		Champion HC, 2000, AM J PHYSIOL-HEART C, V278, pH8; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; DALKARA T, 1995, J CEREBR BLOOD F MET, V15, P631, DOI 10.1038/jcbfm.1995.78; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; LIU H, 2000, J NEUROTRAUM, V17, P945; Lu YC, 1997, MOL CHEM NEUROPATHOL, V30, P125, DOI 10.1007/BF02815154; Michael LH, 1995, AM J PHYSIOL-HEART C, V269, pH2147; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; STATLER KD, 2000, CRIT CARE MED SA53, V28; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WADA K, 1997, J NEUROTRAUM, V14, P760; WU CC, 1995, BRIT J PHARMACOL, V114, P1666, DOI 10.1111/j.1476-5381.1995.tb14955.x	17	25	26	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2002	19	3					327	334		10.1089/089771502753594891			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	534BC	WOS:000174563900004	11939500				2021-06-18	
J	Matsuura, S; Ikegaya, Y; Yamada, MK; Nishiyama, N; Matsuki, N				Matsuura, S; Ikegaya, Y; Yamada, MK; Nishiyama, N; Matsuki, N			Endothelin downregulates the glutamate transporter GLAST in cAMP-differentiated astrocytes in vitro	GLIA			English	Article						endothelin receptor; Na+ -dependent glutamate transporter; astrocyte; glial cell; GLT-1	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN INJURY; PROTEIN-KINASE; GROWTH-FACTOR; RAT-BRAIN; MAP KINASE; ISCHEMIA; EXPRESSION; RECEPTOR; PATHWAY	Endothelin (ET) is a putative pathogenetic mediator associated with brain trauma and ischemia. Because a link between neuronal damage after these injuries and glial Na+-dependent L-glutamate transporter activity has been suggested, we investigated the effect of ET on the glutamate clearance ability of astrocytes. Dibutyryl cyclic adenosine monophosphate (dBcAMP), which is widely used to induce differentiation of cultured astrocytes, markedly increased [H-3]glutamate transport activity in a concentration- and time-dependent manner. In the presence of ET, however, dBcAMP decreased the glutamate uptake. This effect was efficiently prevented by an antagonist of ETB receptor, but not of ETA receptor. ET per se was virtually ineffective. Eadie-Hofstee analysis demonstrated that dBcAMP increased the V-max value of glutamate uptake activity by 43.4% in the absence of ET, but decreased it by 41.41%, in the presence of ET, without apparent changes in the K, value. Accordingly, Western blot analysis indicated that the change in transport activity correlated closely with that in expression level of the glial glutamate transporter GLAST. These results may represent the mechanisms by which ET aggravates trauma- and ischemia-elicited neuronal damage. (C) 2002 Wiley-Liss, Inc.	Univ Tokyo, Grad Sch Pharmaceut Sci, Chem Pharmacol Lab, Bunkyo Ku, Tokyo 1130033, Japan	Ikegaya, Y (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Chem Pharmacol Lab, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Yamada, Maki/U-5251-2019; Yamada, Maki K./A-1573-2015	Yamada, Maki K./0000-0002-1956-6069; Ikegaya, Yuji/0000-0003-2260-8191			AGNATI LF, 1991, ITAL J NEUROL SCI, V12, P49; BARONE FC, 1994, J CEREBR BLOOD F MET, V14, P337, DOI 10.1038/jcbfm.1994.41; BARONE FC, 1995, J CARDIOVASC PHAR S3, V26, P404; BIAN LG, 1994, NEUROSCI LETT, V174, P47, DOI 10.1016/0304-3940(94)90115-5; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; Cazaubon S, 1997, J NEUROSCI, V17, P6203; Gartshore G, 1997, EXP NEUROL, V147, P353, DOI 10.1006/exnr.1997.6635; Hama H, 1997, J NEUROSCI RES, V47, P590, DOI 10.1002/(SICI)1097-4547(19970315)47:6<590::AID-JNR4>3.0.CO;2-8; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Hoffmann R, 1999, EMBO J, V18, P893, DOI 10.1093/emboj/18.4.893; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HORI S, 1992, ENDOCRINOLOGY, V130, P1885, DOI 10.1210/en.130.4.1885; KASUYA Y, 1994, BIOCHEM BIOPH RES CO, V204, P1325, DOI 10.1006/bbrc.1994.2608; Koyama Y, 1999, GLIA, V26, P268, DOI 10.1002/(SICI)1098-1136(199905)26:3<268::AID-GLIA8>3.0.CO;2-G; Kurino M, 1996, J NEUROCHEM, V67, P2246; LIUZZI FJ, 1987, SCIENCE, V237, P642, DOI 10.1126/science.3603044; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARIA BL, 1989, J NEURO-ONCOL, V7, P329, DOI 10.1007/BF02147090; Pearson VL, 1999, GLIA, V25, P311, DOI 10.1002/(SICI)1098-1136(19990215)25:4<311::AID-GLIA1>3.0.CO;2-E; Pedram A, 1998, J BIOL CHEM, V273, P13966, DOI 10.1074/jbc.273.22.13966; Pfister LA, 2000, ANN NEUROL, V47, P329, DOI 10.1002/1531-8249(200003)47:3<329::AID-ANA8>3.3.CO;2-I; Pluta RM, 1997, J NEUROSURG, V87, P287, DOI 10.3171/jns.1997.87.2.0287; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; RUBANYI GM, 1994, PHARMACOL REV, V46, P328; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Schlag BD, 1998, MOL PHARMACOL, V53, P355; Schubert P, 1997, ANN NY ACAD SCI, V825, P1, DOI 10.1111/j.1749-6632.1997.tb48409.x; Suzuki K, 2001, J CELL SCI, V114, P3717; Swanson RA, 1997, J NEUROSCI, V17, P932; TAKIGAWA M, 1995, EUR J BIOCHEM, V228, P102, DOI 10.1111/j.1432-1033.1995.0102o.x; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Tatlisumak T, 1998, STROKE, V29, P850, DOI 10.1161/01.STR.29.4.850; Toulmond S, 1996, TRENDS NEUROSCI, V19, P409; Uesugi M, 1996, BRAIN RES, V728, P255, DOI 10.1016/S0006-8993(96)00524-0; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Watase K, 1998, EUR J NEUROSCI, V10, P976, DOI 10.1046/j.1460-9568.1998.00108.x; WILLETTE RN, 1993, LIFE SCI, V52, P35, DOI 10.1016/0024-3205(93)90286-C; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240; Yin KJ, 1998, ANAT RECORD, V251, P9, DOI 10.1002/(SICI)1097-0185(199805)251:1<9::AID-AR3>3.0.CO;2-X	40	25	25	0	1	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0894-1491			GLIA	Glia	FEB	2002	37	2					178	182		10.1002/glia.10020			5	Neurosciences	Neurosciences & Neurology	517DZ	WOS:000173597000008	11754215				2021-06-18	
J	Gontkovsky, ST; McDonald, NB; Clark, PG; Ruwe, WD				Gontkovsky, ST; McDonald, NB; Clark, PG; Ruwe, WD			Current directions in computer-assisted cognitive rehabilitation	NEUROREHABILITATION			English	Article						brain injury; cognitive rehabilitation; computers; neuropsychology; neurorehabilitation	TRAUMATIC BRAIN INJURY; NEUROPSYCHOLOGICAL REHABILITATION	Technological advances over the past decade have given rise to the development of multiple computer-assisted cognitive rehabilitation programs. While results of investigations examining the efficacy of such techniques have been mixed, a positive trend for utilization of these procedures has been demonstrated. This review provides a discussion of the progression of research in this area, from anecdotal studies to controlled empirical investigations. Methodological shortcomings are examined and directions for future research in computer-assisted cognitive rehabilitation suggested.	INTEGRIS Jim Thorpe Rehabil Ctr, Oklahoma City, OK USA	Gontkovsky, ST (corresponding author), Methodist Rehabil Ctr, Neuropsychol Dept, 1350 E Woodrow Wilson, Jackson, MS 39216 USA.						Batchelor J, 1988, J HEAD TRAUMA REHAB, V3, P78, DOI DOI 10.1097/00001199-198809000-00012; BERROL S, 1990, ARCH NEUROL-CHICAGO, V47, P219, DOI 10.1001/archneur.1990.00530020127025; Bracy O.D., 1999, COGN TECHNOL, V4, P19; BRACY OL, 1983, COGNITIVE REHABILITA, V1, P7; Brett A W, 1998, Pediatr Rehabil, V2, P27; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Chen SHA, 1997, BRAIN INJURY, V11, P197; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Ethier M, 1989, CANADIAN J REHABILIT, V2, P223; ETHIER M, 1989, CANADIAN J REHABILIT, V3, P7; FINLEY G, 1987, P AM ASSOC CANC RES, V28, P180; GOLDEN CJ, 1992, NEUROPSYCHOLOGICAL A; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; Ho MR, 1997, ARCH CLIN NEUROPSYCH, V12, P1; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Mazmanian Paul E., 1993, Brain Injury, V7, P319, DOI 10.3109/02699059309034958; MCGUIRE BE, 1990, IRISH J PSYCHOL, V11, P299, DOI 10.1080/03033910.1990.10557810; MCLELLAN DL, 1991, CLIN NEUROLOGY, P768; MESSERLY C, 1986, VOLTA REV, V88, P66; MIDDLETON DK, 1991, PERCEPT MOTOR SKILL, V72, P527, DOI 10.2466/PMS.72.2.527-530; Pierce SM, 2001, J HEAD TRAUMA REHAB, V16, P406, DOI 10.1097/00001199-200108000-00009; Reitan R. M., 1996, NEUROPSYCHOLOGICAL A, P3; REITAN RM, 1983, ANN M AM PSYCH ASS A; Robertson I, 1988, Brain Inj, V2, P151, DOI 10.3109/02699058809150939; ROBERTSON IH, 1990, ARCH PHYS MED REHAB, V71, P663; ROSS FL, 1991, AM J OCCUPATIONAL TH, V46, P314; SBORDONE RJ, 1986, PSYCHOTHERAPY PRIVAT, V4, P51; Sena D. A., 1986, ARCH CLIN NEUROPSYCH, V1, P74; SKILBECK C, 1991, MICROCOMPUTERS CLIN, P95; STORY TB, 1988, J HEAD TRAUMA REHAB, V3, P45; THOMASS BA, 1994, EUR J COMMUN, V9, P25, DOI 10.1177/0267323194009001002; Wilson B, 1988, BEHAV INATTENTION TE; Wilson BA, 1997, J INT NEUROPSYCH SOC, V3, P487, DOI 10.1017/S1355617797004876; Wood R L, 1987, Int Disabil Stud, V9, P149	35	25	25	0	2	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2002	17	3					195	199					5	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	611AJ	WOS:000178994000003	12237499				2021-06-18	
J	Petridou, E; Sibert, J; Dedoukou, X; Skalkidis, I; Trichopoulos, D				Petridou, E; Sibert, J; Dedoukou, X; Skalkidis, I; Trichopoulos, D			Injuries in public and private playgrounds: the relative contribution of structural, equipment and human factors	ACTA PAEDIATRICA			English	Article						case control; childhood injury; playground equipment; public versus private playground	CHILD-CARE-CENTERS; RISK; EPIDEMIOLOGY; SURFACES; FALLS	The aim of this case-control Study was to identify and quantify risk factors of injuries in playgrounds, where children spend an increasing amount of time in developed Countries. The study took place in Greater Athens during 1999. A continuous Emergency Departments Injury Surveillance System (EDISS) of hospitals that cover about 30% of the children's time at risk in Greater Athens identified 777 injuries in public and private playgrounds out of a total of 17 497 injuries. Public playgrounds differ from private ones, because the former generally have more equipment. usually of greater height, with less resilient surfaces. and supervision relies mainly on parents or guardians. Patterns of type of playground use were assessed in a sample of 294 children from the same study base who served as a control group in a hierarchical case-control design. The annual incidence of playground injuries in Greater Athens vas about 7 in 1000 among boys and 4 in 1000 among girls, with a 2.2 times higher risk for an injury in public than in private playgrounds (95% confidence interval 1.61-3.07). Children in public vs private playgrounds had a statistically significant eight times higher odds for concussion and six times higher for open wounds, whereas the odds for long bone fractures were four and for other fractures two; swings, slides and seesaws were the types of equipment most frequently associated with injuries. It was further shown that supervision of children was suboptimal (<60%) in both public and private playgrounds. and children in private playgrounds sustained an unduly high frequency of sprain/ dislocation injuries (odds ratio 1.75) because they were encouraged to play bare-footed. Conclusion: Close to 50%, of playground injuries could be prevented by structural and equipment changes. while further reduction could be accomplished through simple measures including closer supervision and encouraging children to wear proper shoes and use, whenever necessary.	Univ Athens, Sch Med, Dept Hyg & Epidemiol, GR-11527 Athens, Greece; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Univ Wales, Coll Med, Dept Child Hlth, Penarth, S Glam, Wales	Petridou, E (corresponding author), Univ Athens, Sch Med, Dept Hyg & Epidemiol, 75 M Asias Str, GR-11527 Athens, Greece.			PETRIDOU, ELENI/0000-0003-3695-3439			Alkon A, 1999, ARCH PEDIAT ADOL MED, V153, P1248, DOI 10.1001/archpedi.153.12.1248; BOND MT, 1993, AM J PUBLIC HEALTH, V83, P731, DOI 10.2105/AJPH.83.5.731; BOYCE WT, 1984, AM J PUBLIC HEALTH, V74, P984, DOI 10.2105/AJPH.74.9.984; BRISS PA, 1995, ARCH PEDIAT ADOL MED, V149, P906, DOI 10.1001/archpedi.1995.02170210080014; BRISS PA, 1994, PEDIATRICS, V93, P364; Chalmers D J, 1996, Inj Prev, V2, P98, DOI 10.1136/ip.2.2.98; CHALMERS DJ, 1990, J PAEDIATR CHILD H, V26, P329, DOI 10.1111/j.1440-1754.1990.tb02446.x; DESSYPRIS N, UNPUB COUNTRYWIDE ES; *EHLASS, 1997, EUR HOM LEIS SURV SY, P1; Hudson S, 1999, J Sch Nurs, V15, P30; ILLINGWORTH C, 1975, BRIT MED J, V4, P332, DOI 10.1136/bmj.4.5992.332; *LAB CTR DIS CONTR, 1990, 1 CHIRPP LAB CTR DIS; Lebart L., 1984, MULTIVARIATE DESCRIP; Lillis KA, 1997, PEDIATR EMERG CARE, V13, P149, DOI 10.1097/00006565-199704000-00016; Macarthur C, 2000, ACCIDENT ANAL PREV, V32, P377, DOI 10.1016/S0001-4575(99)00079-2; MACMAHON B, 1996, EPIDEMIOLOGY PRINCIP; MAEK MG, 1997, INJURY PREV, V3, P100; Mardia K.V., 1979; MAYR J, 1995, ACTA PAEDIATR, V84, P573, DOI 10.1111/j.1651-2227.1995.tb13698.x; MOTT A, 1994, ARCH DIS CHILD, V71, P328, DOI 10.1136/adc.71.4.328; Mott A, 1997, LANCET, V349, P1874, DOI 10.1016/S0140-6736(96)10343-3; SACKS JJ, 1990, AM J PUBLIC HEALTH, V80, P986, DOI 10.2105/AJPH.80.8.986; Waltzman ML, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.5.e58; World Health Organization, 1977, INT CLASS DIS; World Health Organization, 1992, ICD 10 INT STAT CLAS; 1999, MMWR MORB MORTAL WKL, V48, P329	26	25	25	0	4	TAYLOR & FRANCIS AS	OSLO	CORT ADELERSGT 17, PO BOX 2562, SOLLI, 0202 OSLO, NORWAY	0803-5253			ACTA PAEDIATR	Acta Paediatr.		2002	91	6					691	697		10.1080/080352502760069133			7	Pediatrics	Pediatrics	570TQ	WOS:000176674400016	12162604				2021-06-18	
J	Ferrari, R; Constantoyannis, C; Papadakis, N				Ferrari, R; Constantoyannis, C; Papadakis, N			Cross-cultural study of symptom expectation following minor head injury in Canada and Greece	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						minor head injury; mild traumatic brain injury; concussion; symptom expectation	RHEUMATOID-ARTHRITIS; SEQUELAE; WHIPLASH; TRAUMA	Objectives: The purpose of the present study is to compare the frequency and nature of expected symptoms in Greece (a country where the chronic post-concussive syndrome is largely unknown) with that in Canada. Methods: A symptom checklist was administered to two subject groups selected from local companies in Patras, Greece, and Edmonton, Canada, respectively. Subjects were asked to imagine having suffered head trauma with loss of consciousness in a motor vehicle accident and to check off symptoms, they expected might arise from the injury. For symptoms they anticipated, they were asked to select the period of time they expected those symptoms to persist. Results: In both the Greek and Edmontonian groups, the pattern of symptoms anticipated closely resembled the acute symptoms commonly reported by accident victims with minor head injury. Yet, while many Edmontonians also anticipated symptoms to last months or years, very few Greek subjects selected any symptoms as being likely to persist in a chronic manner. Conclusions: In Greece, despite the frequent experience of minor head injury in motor vehicle accidents, there is a very low rate of expectation of any chronic sequelae from such an injury, contrasting greatly with the response shown in Canada, where the prevalence of the chronic post-concussive syndrome is higher. Symptom expectation in some countries may be an important factor in the development of the chronic post-concussive syndrome. (C) 2001 Elsevier Science B.V. All rights reserved.	Univ Hosp Patras, Dept Neurosurg, Patras, Greece	Ferrari, R (corresponding author), 12779-50 St, Edmonton, AB T5A 4L8, Canada.	rferrari@powersurfr.com		Constantoyannis, Constantine/0000-0003-3030-8439			ANDONOPOULOS AP, 1987, RHEUMATOL INT, V7, P101, DOI 10.1007/BF00270461; AUBREY JB, 1989, J NEUROL NEUROSUR PS, V52, P842, DOI 10.1136/jnnp.52.7.842; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Ferrari R, 1999, CLIN EXP RHEUMATOL, V17, P321; FERRARI R, 2001, IN PRESS CLIN NEUROL; FERRRI R, 1999, WHIPLASH ENCY FACTS; Hewlett S, 1995, Arthritis Care Res, V8, P4, DOI 10.1002/art.1790080104; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MADIANOS MG, 1993, PSYCHOTHER PSYCHOSOM, V60, P177, DOI 10.1159/000288691; McMillan TM, 1997, CURR OPIN NEUROL, V10, P479, DOI 10.1097/00019052-199712000-00008; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; PINCUS T, 1983, ARTHRITIS RHEUM-US, V26, P1346, DOI 10.1002/art.1780261107	18	25	25	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	DEC	2001	103	4					254	259		10.1016/S0303-8467(01)00161-5			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	508VK	WOS:000173110300015	11714575				2021-06-18	
J	Fujita, R; Yoshida, A; Mizuno, K; Ueda, H				Fujita, R; Yoshida, A; Mizuno, K; Ueda, H			Cell density-dependent death mode switch of cultured cortical neurons under serum-free starvation stress	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						necrosis; apoptosis; ATP; annexin V; caspase; PARP	TRAUMATIC BRAIN INJURY; POLY(ADP-RIBOSE) POLYMERASE; APOPTOSIS; RAT; ACTIVATION; NECROSIS; CASPASES; STROKE; FATE	1. Cell death mode switch of cortical neurons from E17 rats was studied. Cells rapidly died under the serum-free condition. The time-course of cell death was markedly delayed by increasing cell density for primary culture in the trypan blue exclusion, LDH release, and MTT assays. 2. By analyzing cell death by the use of double staining using PI/TUNEL and PI/Annexin V combinations, the mode in the low density culture was found to be necrosis, while that in the high density culture was apoptosis. 3. The intracellular ATP level after the start of serum-free culture rapidly decline to 25% of 0-time level in the low density culture, but it was 60% in the high density culture. Both oligomycin and zVAD-fmk markedly decreased ATP levels and the population of TUNEL-positive neurons, while 3-aminobenzamide slightly increased these indices. 4. Thus, it is strongly suggested that the cell death mode switch from necrosis to apoptosis is closely related to intracellular ATP levels, and some conditioned medium factors observed in the high density culture may affect both ATP level and cell death mode switch.	Nagasaki Univ, Sch Pharmaceut Sci, Dept Mol Pharmacol & Neurosci, Nagasaki 8528521, Japan	Ueda, H (corresponding author), Nagasaki Univ, Sch Pharmaceut Sci, Dept Mol Pharmacol & Neurosci, 1-14 Bunkyo Machi, Nagasaki 8528521, Japan.						Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Eguchi Y, 1997, CANCER RES, V57, P1835; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; Furlan M, 1996, ANN NEUROL, V40, P216, DOI 10.1002/ana.410400213; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Hamabe W, 2000, MOL BRAIN RES, V78, P186, DOI 10.1016/S0169-328X(00)00074-7; Lam TT, 1997, RES COMMUN MOL PATH, V95, P241; Lee YJ, 2000, FREE RADICAL BIO MED, V29, P684, DOI 10.1016/S0891-5849(00)00366-X; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; MARTIN SJ, 1995, J EXP MED, V182, P1; MUIZELAAR JP, 1994, CAN J NEUROL SCI, V21, P1; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Osuga H, 2000, P NATL ACAD SCI USA, V97, P10254, DOI 10.1073/pnas.170144197; Plaschke K, 2000, NEUROSCI LETT, V284, P109, DOI 10.1016/S0304-3940(00)00988-5; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; RINK A, 1995, AM J PATHOL, V147, P1575; Sasaki Y, 1998, CELL MOL NEUROBIOL, V18, P487, DOI 10.1023/A:1026375225275; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; UEDA H, 1999, P 16 YOK 21 CENT FOR, P83; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16	25	25	27	0	1	KLUWER ACADEMIC/PLENUM PUBL	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340			CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	AUG	2001	21	4					317	324		10.1023/A:1012645920229			8	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	503JV	WOS:000172796100002	11775063				2021-06-18	
J	Shiozaki, T; Akai, H; Taneda, M; Hayakata, T; Aoki, M; Oda, J; Tanaka, H; Hiraide, A; Shimazu, T; Sugimoto, H				Shiozaki, T; Akai, H; Taneda, M; Hayakata, T; Aoki, M; Oda, J; Tanaka, H; Hiraide, A; Shimazu, T; Sugimoto, H			Delayed hemispheric neuronal loss in severely head-injured patients	JOURNAL OF NEUROTRAUMA			English	Article						cerebral atrophy; delayed neuronal loss; head injury	TRAUMATIC BRAIN INJURY; AMYLOID PROTEIN; ISCHEMIA; DEATH; RAT; HYPOTHERMIA; DAMAGE	Recent experimental studies have revealed that traumatic brain injury as well as ischemic brain injury can cause chronic progressive neuronal damage. In the present study, we demonstrate previously unreported delayed cerebral atrophy on computerized tomography (CT) scans in severely head-injured patients. Seventeen severely head-injured patients who required mild hypothermia to control intracranial hypertension after the failure of conventional therapies were retrospectively analyzed. All 17 patients survived more than 1 year. Delayed neuronal loss (DNL) was observed in only eight of the 17 patients. Eight patients with DNL required longer durations of mild hypothermia to control intracranial hypertension than nine patients without DNL. Six of these eight patients with DNL achieved functional recovery despite progressive atrophic changes demonstrated on CT scans. On CT scans, DNL was characterized by (1) the sudden appearance at several months postinjury of a low-density area in the hemisphere ipsilateral to the injury; (2) the preservation of essential cortical structure although related white matter structures showed severe atrophic changes; and (3) no spread of the low-density area to the contiguous territory of the other main cerebral artery. It is concluded that focal primary injury to underlying brain, if severe enough, can result in delayed hemispheric atrophy.	Osaka Univ, Sch Med, Dept Traumatol, Suita, Osaka 565, Japan; Kinki Univ, Sch Med, Dept Neurosurg, Osaka 589, Japan	Shiozaki, T (corresponding author), Osaka Univ, Sch Med, Dept Traumatol, 2-2 Yamadaoka, Suita, Osaka 565, Japan.		Oda, Jun/D-8353-2012	Oda, Jun/0000-0002-8254-3716			Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Evans WA, 1942, ARCH NEURO PSYCHIATR, V47, P931, DOI 10.1001/archneurpsyc.1942.02290060069004; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; JENNETT B, 1975, LANCET, V1, P480; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; NAKANO S, 1990, NEUROSCIENCE, V38, P115, DOI 10.1016/0306-4522(90)90378-H; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; RINK A, 1995, AM J PATHOL, V147, P1575; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH KA, 1984, ANNU REV IMMUNOL, V2, P319, DOI 10.1146/annurev.iy.02.040184.001535; SYNEK V, 1976, NEUROLOGY, V26, P231, DOI 10.1212/WNL.26.3.231; Tomita Hiroki, 1997, Neurologia Medico-Chirurgica, V37, P819, DOI 10.2176/nmc.37.819; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	16	25	25	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2001	18	7					665	674		10.1089/089771501750357618			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	457CK	WOS:000170119400003	11497093				2021-06-18	
J	Bate, AJ; Mathias, JL; Crawford, JR				Bate, AJ; Mathias, JL; Crawford, JR			The covert orienting of visual attention following severe traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; PARKINSONS-DISEASE; ORIENTATION; SYSTEMS	Attentional problems have frequently been identified following traumatic brain injuries (TBIs) using both clinical assessments and self-report measures. Unfortunately, most measures of attention do not enable us to determine the underlying basis of these attentional deficits. One exception is Posner's Covert Orienting of Attention Task (COAT), which is designed to identify some of the fundamental mental operations underlying attention. This study sought to determine whether the COAT task could identify discrete attentional deficits following TBI beyond those caused by reduced speed of information processing. Thirty five patients who had sustained a severe TBI were compared to 35 age-matched controls. Results revealed that, although the reaction times of the patients with TBI were significantly slower than the controls, there were no differences between the two groups in terms of their ability to disengage, move, and engage their attention. The introduction of a secondary (language) task produced no significant difference between the two groups on the COAT task. However, there was a significant difference between the two groups on the language-based task, suggesting a deficit in auditory-verbal attention under dual task conditions.	Julia Farr Serv, Community Rehabil Program, Adelaide, SA, Australia; Univ Adelaide, Dept Psychol, Adelaide, SA 5001, Australia; Univ Aberdeen, Kings Coll, Dept Psychol, Aberdeen, Scotland	Bate, AJ (corresponding author), Julia Farr Serv, Community Rehabil Program, 8 Briar Rd, Felixstow, SA 5070, Australia.	abate@vtown.com.au	Mathias, J L/L-6295-2013; Crawford, John R/A-4165-2008	Crawford, John R/0000-0003-3403-3428; Mathias, Jane/0000-0001-8957-8594			BLUMBERGS PC, 1997, HEAD INJURY; CLARK CR, 1989, NEUROPSYCHOLOGIA, V27, P131, DOI 10.1016/0028-3932(89)90166-8; Crawford J.R., 1992, HDB NEUROPSYCHOLOGIC; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; CREMONAMETEYARD SL, 1992, NEUROPSYCHOLOGIA, V30, P123, DOI 10.1016/0028-3932(92)90022-E; FORRESTER G, 1995, J FARR SERVICES POST; Godefroy O, 1996, BRAIN, V119, P191, DOI 10.1093/brain/119.1.191; GRONWALL D, 1987, NEUROBEHAVIOURAL REC, P354; HARTMAN A, 1992, CLIN REHABIL, V6, P133; JONIDES J, 1984, PSYCHOL BULL, V96, P29, DOI 10.1037/0033-2909.96.1.29; Kucera H, 1967, COMPUTATIONAL ANAL P; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LOKEN WJ, 1995, NEUROPSYCHOLOGY, V9, P592, DOI 10.1037/0894-4105.9.4.592; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; PAVESE A, 2000, UNPUB PATHOLOGIES AT; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Posner M I, 1989, J Cogn Neurosci, V1, P50, DOI 10.1162/jocn.1989.1.1.50; Posner M.I., 1994, IMAGES MIND; POSNER MI, 1988, SCIENCE, V240, P1627, DOI 10.1126/science.3289116; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; POSNER MI, 1984, J NEUROSCI, V4, P1863; POSNER MI, 1982, PHILOS T ROY SOC B, V298, P187, DOI 10.1098/rstb.1982.0081; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; POSNER MI, 1987, PSYCHOBIOLOGY, V15, P107; ROBERTSON IH, 1995, INT NEUR SOC AUSTR S; ROLAND PE, 1985, HUM NEUROBIOL, V4, P155; Sandson J, 1988, COGNITIVE APPROACHES; Schmitter-Edgecombe M, 1998, J INT NEUROPSYCH SOC, V4, P144, DOI 10.1017/S1355617798001441; SchmitterEdgecombe M, 1996, NEUROPSYCHOLOGY, V10, P155; Spreen O., 1991, COMPENDIUM NEUROPSYC; *SPSS INC, 1998, SPSS WIND; Stuss D. T., 1989, CLIN NEUROPSYCHOL, V3, P145, DOI DOI 10.1080/13854048908403287; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; SWANSON JM, 1991, J CHILD NEUROL, V6, pS119, DOI 10.1177/0883073891006001S12; TEASDALE G, 1974, LANCET, V2, P81; Van Zomeren A. H., 1981, REACTION TIME ATTENT; VANZOMEREN AH, 1987, NEUROBEHAVIORAL RECO; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; WRIGHT MJ, 1994, AUST J PSYCHOL, V46, P63, DOI 10.1080/00049539408259475; WRIGHT MJ, 1990, NEUROPSYCHOLOGIA, V28, P151, DOI 10.1016/0028-3932(90)90097-8	42	25	25	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUN	2001	23	3					386	398		10.1076/jcen.23.3.386.1190			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	439JG	WOS:000169112900012	11404815				2021-06-18	
J	Keidel, M; Rieschke, P; Stude, P; Eisentraut, R; van Schayck, R; Diener, HC				Keidel, M; Rieschke, P; Stude, P; Eisentraut, R; van Schayck, R; Diener, HC			Antinociceptive reflex alteration in acute posttraumatic headache following whiplash injury	PAIN			English	Article						posttraumatic headache; whiplash injury; inhibitory temporalis reflex; exteroceptive suppression; antinociceptive brainstem reflex; central pain processing	TEMPORALIS MUSCLE-ACTIVITY; TENSION-TYPE HEADACHE; EXTEROCEPTIVE SUPPRESSION PERIODS; JAW-CLOSING MUSCLES; MENTAL NERVE-STIMULATION; MEDULLARY DORSAL HORN; NUCLEUS RAPHE MAGNUS; ELECTRICAL-STIMULATION; SILENT PERIODS; OPENING REFLEX	Brainstem-mediated antinociceptive inhibitory reflexes of the temporalis muscle were investigated in 82 patients (47 F, 35 M, mean age 28.3 years, SD 9.4) with acute posttraumatic headache (PH) following whiplash injury but without neurological deficits, bone injury of the cervical spine or a combined direct head trauma on average 5 days after the acceleration trauma. Latencies and durations of the early and late exteroceptive suppression (ES1 and ES2) and the interposed EMG burst (IE) of the EMG of the voluntarily contracted right temporalis muscle evoked by ipsilateral stimulation of the second and third branches of the trigeminal nerve were analyzed and compared to a cohort of 82 normal subjects (43 F, 39 M, mean age 27.7 years, SD 7.1). Highly significant reflex alterations were found in patients with PH with a shortening of ES2 duration with delayed onset and premature ending as the primary parameter of this study, a moderate prolongation of ES1 and IE duration and a delayed onset of IE. The latency of ES1 was not significantly changed. These findings indicate that acute PH in whiplash injury is accompanied by abnormal antinociceptive brainstem reflexes. We conclude that the abnormality of the trigeminal inhibitory temporalis reflex is abed on a transient dysfunction of the brainstem-mediated reflex circuit mainly of the late polysynaptic pathways. The reflex abnormalities are considered as a neurophysiological correlate of the posttraumatic (cervico)-cephalic pain syndrome. They point to an altered central pain control in acute PH due to whiplash injury. (C) 2001 International Association for the Study of Pain. Published by Elsevier Science B.V. All rights reserved.	Univ Essen Gesamthsch, Dept Neurol, D-45122 Essen, Germany; Vanderbilt Univ, Med Ctr, Dept Anesthesiol, Nashville, TN USA; Univ Jena, Dept Neurol, D-6900 Jena, Germany	Keidel, M (corresponding author), Univ Essen Gesamthsch, Dept Neurol, Hufelandstr 55, D-45122 Essen, Germany.						AGHAJANIAN GK, 1980, NEUROSCIENCE, V5, P2155, DOI 10.1016/0306-4522(80)90132-3; ANDERSEN RK, 1978, CAN J PHYSIOL PHARM, V56, P157, DOI 10.1139/y78-021; BASBAUM AI, 1978, ANN NEUROL, V4, P451, DOI 10.1002/ana.410040511; Bendtsen L, 1996, CEPHALALGIA, V16, P251, DOI 10.1046/j.1468-2982.1996.1604251.x; BENDTSEN L, 1993, CEPHALALGIA, V13, P184, DOI 10.1046/j.1468-2982.1993.1303184.x; Bendtsen L, 1996, ELECTROMYOGR MOTOR C, V101, P418, DOI 10.1016/S0921-884X(96)96532-7; BOISMARE F, 1985, J AUTONOM NERV SYST, V13, P137, DOI 10.1016/0165-1838(85)90030-X; BOTTIN D, 1989, CEPHALAGIA, V9, P115; Breig A., 1960, BIOMECHANICS CENTRAL; Cadden SW, 1999, J ORAL REHABIL, V26, P952, DOI 10.1046/j.1365-2842.1999.00457.x; CADDEN SW, 1994, ARCH ORAL BIOL, V39, P473, DOI 10.1016/0003-9969(94)90143-0; Connemann BJ, 1997, ELECTROMYOGR MOTOR C, V105, P53, DOI 10.1016/S0924-980X(96)96549-2; Cruccu G, 1998, EXP BRAIN RES, V118, P564, DOI 10.1007/s002210050312; CRUCCU G, 1989, BRAIN, V112, P1333, DOI 10.1093/brain/112.5.1333; CRUCCU G, 1986, BRAIN RES, V371, P298, DOI 10.1016/0006-8993(86)90366-5; DENOORDHOUT AM, 1995, CEPHALALGIA, V15, P301, DOI 10.1046/j.1468-29821995.1504301.x; DESMEDT JE, 1976, BRAIN RES, V106, P21, DOI 10.1016/0006-8993(76)90070-6; DEVISSER BWO, 1990, BRAIN, V113, P781, DOI 10.1093/brain/113.3.781; DOSTROVSKY JO, 1983, J NEUROPHYSIOL, V49, P948; DOSTROVSKY JO, 1982, BRAIN RES, V252, P287, DOI 10.1016/0006-8993(82)90396-1; Ellrich J, 1997, BRAIN RES, V764, P214, DOI 10.1016/S0006-8993(97)00459-9; GOBEL H, 1991, CEPHALALGIA, V11, P65; GOBEL H, 1993, CEPHALALGIA, V13, P15, DOI 10.1046/j.1468-2982.1993.1301015.x; GODAUX E, 1975, BRAIN RES, V85, P447, DOI 10.1016/0006-8993(75)90819-7; Hansen PO, 1999, CLIN NEUROPHYSIOL, V110, P1290, DOI 10.1016/S1388-2457(99)00031-0; Hansen PO, 1998, ACTA NEUROL SCAND, V97, P204; KEIDEL M, 1994, NERVENARZT, V65, P241; KEIDEL M, 1993, ELECTROEN CLIN NEURO, V87, P18; KEIDEL M, 1996, NEUROLOGICAL DISORDE, P65; KEIDEL M, 1993, CEPHALALGIA, V13, P106; KEIDEL M, 2000, HEADACHES, P765; LIGHT AR, 1992, INITIAL PROCESSING P; Lipchik GL, 1997, HEADACHE, V37, P368, DOI 10.1046/j.1526-4610.1997.3706368.x; Lipchik GL, 1996, PAIN, V64, P467, DOI 10.1016/0304-3959(95)00174-3; MASON P, 1985, BRAIN RES REV, V10, P137, DOI 10.1016/0165-0173(85)90003-7; NAKASHIMA K, 1994, HEADACHE, V34, P455, DOI 10.1111/j.1526-4610.1994.hed3408455.x; NAKASHIMA K, 1991, CEPHALALGIA, V11, P23, DOI 10.1046/j.1468-2982.1991.1101023.x; NAKASHIMA K, 1990, ACTA NEUROL SCAND, V81, P407; NAKASHIMA K, 1990, CLIN NEUROL, V30, P133; PAULUS W, 1992, HEADACHE, V32, P41, DOI 10.1111/j.1526-4610.1992.hed3201041.x; PAULUS W, 1991, CEPHALALGIA, V11, P32, DOI 10.1177/0333102491011S1117; Pollmann W, 1997, CEPHALALGIA, V17, P801, DOI 10.1046/j.1468-2982.1997.1708801.x; RAMADAN NM, 2000, HEADACHES, P771; Romaniello A, 2000, EXP BRAIN RES, V132, P306, DOI 10.1007/s002210000353; SCHAFFAR N, 1984, NEUROSCI LETT, V44, P31, DOI 10.1016/0304-3940(84)90216-7; Schepelmann K, 1998, ELECTROEN CLIN NEURO, V107, P196, DOI 10.1016/S0013-4694(98)00059-5; SCHOENEN J, 1994, BRAIN RES, V657, P214, DOI 10.1016/0006-8993(94)90970-9; SCHOENEN J, 1987, NEUROLOGY, V37, P1834, DOI 10.1212/WNL.37.12.1834; SCHOENEN J, 1991, CEPHALALGIA, V11, P16, DOI 10.1177/0333102491011S1109; SCHOENEN J, 1991, CEPHALALGIA, V11, P87, DOI 10.1046/j.1468-2982.1991.1102087.x; SCHOENEN J, 2000, HEADACHES, P579; SCHOPFLIN G, 1992, NEW HUNG QUART, V33, P3; SESSLE BJ, 1986, PAIN, V27, P219, DOI 10.1016/0304-3959(86)90213-7; SPITZER WO, 1995, SPINE, V20, pS2; Strenge H, 1996, FUNCT NEUROL, V11, P17; TURKER KS, 1988, J ORAL REHABIL, V15, P91, DOI 10.1111/j.1365-2842.1988.tb00149.x; WALLASCH TM, 1991, CEPHALALGIA, V11, P109, DOI 10.1046/j.1468-2982.1991.1102109.x; WALLASCH TM, 1991, CEPHALALGIA, V11, P83, DOI 10.1177/0333102491011S1145; WALLASCH TM, 1993, HEADACHE, V33, P121, DOI 10.1111/j.1526-4610.1993.hed3303121.x; WALLASCH TM, 1989, NERVENHEILKUNDE, V9, P58; Wang KL, 1999, PAIN, V82, P253, DOI 10.1016/S0304-3959(99)00058-5; WANG W, 1994, PAIN, V59, P327, DOI 10.1016/0304-3959(94)90018-3; WANG W, 1995, THESIS U LIEGE LIEGE; Welch KMA, 1996, CEPHALALGIA, V16, P216; WILLIS WD, 1982, PROGR SENSORY PHYSL, V3; YU SKJ, 1973, ARCH ORAL BIOL, V18, P861, DOI 10.1016/0003-9969(73)90056-3; ZWART JA, 1995, HEADACHE, V35, P338, DOI 10.1111/j.1526-4610.1995.hed3506338.x	67	25	26	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0304-3959			PAIN	Pain	JUN	2001	92	3					319	326		10.1016/S0304-3959(01)00272-X			8	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	444FR	WOS:000169389900001	11376904				2021-06-18	
J	Watanabe, Y; Shiel, A; McLellan, DL; Kurihara, M; Hayashi, K				Watanabe, Y; Shiel, A; McLellan, DL; Kurihara, M; Hayashi, K			The impact of traumatic brain injury on family members living with patients: a preliminary study in Japan and the UK	DISABILITY AND REHABILITATION			English	Article							BLUNT HEAD-INJURY; SOCIAL SUPPORT; RELATIVES; STRESS	Purpose: To ascertain the views of families living with TBI patients about the nature of the problems experienced as a result of TBI, and to compare the views of Japanese family members (J-FM) and British family members (B-FM) in order to rnd out whether there were cultural differences in family response to TBI. Methods: Family members involved in providing care were identified by the patients. Face to face interviews were conducted with all 18 carers in B-FM and four carers in J-FM. The remaining eight carers in J-FM participated in the postal questionnaire. Questionnaires were developed to explore the nature of problems and the involvement of family such as social embarrassment. Results: Problems arising in families were almost the same reported from both groups. However families in B-FM were likely to know more about how to cope with these problems. Family members in J-FM reported more statistically significant increases in social embarrassment than those in B-FM. Conclusion: The preliminary results showed that family members living with TBI patients in both groups had experienced problems. Appropriate rehabilitation services should be developed to help families as well as TBI patients in Japan.	Saga Med Sch, Dept Orthopaed Surg, Saga, Japan; Univ Southampton, Rehabil Res Unit, Southampton, Hants, England; Juzenkai Hosp, Neurosurg Unit, Nagasaki, Japan	Watanabe, Y (corresponding author), Natl Nagasaki Hosp, Dept Rehabil, 6-41 Sakuragi Cho, Nagasaki 8500835, Japan.	yuriko@zc4.so-net.ne.jp					ABE J, 2000, SOGO RIHABIRITESHON, V28, P141; ASAHARA K, 1995, JAPANESE J NURSING R, V28, P49; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Campbell C H, 1988, Rehabil Nurs, V13, P320; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KAYAMORI R, 1995, SOGO RIHABIRITESHON, V23, P665; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; KOSCIULEK JF, 1994, REHABIL PSYCHOL, V39, P215, DOI 10.1037/0090-5550.39.4.215; Kosciulek JF, 1999, INT J REHABIL RES, V22, P269, DOI 10.1097/00004356-199912000-00003; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; LEAF LE, 1993, BRAIN INJURY, V7, P543, DOI 10.3109/02699059309008182; Leathem J, 1996, BRAIN INJURY, V10, P27; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Matsufuji T, 1999, MICROPOR MESOPOR MAT, V32, P159, DOI 10.1016/S1387-1811(99)00101-8; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; NIINA R, 1992, SHINSHINIGAKU, V32, P324; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Ohta T, 1974, No Shinkei Geka, V2, P623; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Simpson G, 2000, BRAIN INJURY, V14, P125, DOI 10.1080/026990500120790; *SPSS, SPSS BAS 8 0J WIND U; TAKAI Y, 2000, SOGO REHABIRITESHON, V28, P11; TEASDALE G, 1974, LANCET, V2, P81; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; Watanabe Y, 2000, CLIN REHABIL, V14, P172, DOI 10.1191/026921500666833742; WATANABE Y, 1999, JAPANESE J REHABILIT, V36, P180; WATANABE Y, 1998, P 1 AS REH MED ASS C, P80; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183	32	25	29	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.	JUN	2001	23	9					370	378					9	Rehabilitation	Rehabilitation	431UL	WOS:000168650100002	11394587				2021-06-18	
J	Wallen, MA; Mackay, S; Duff, SM; McCartney, LC; O'Flaherty, SJ				Wallen, MA; Mackay, S; Duff, SM; McCartney, LC; O'Flaherty, SJ			Upper-limb function in Australian children with traumatic brain injury: A controlled, prospective study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						arm; brain injuries; disabled children; rehabilitation	CLOSED HEAD-INJURY; MOTOR; RECOVERY; COHORT; PRESCHOOLERS; ADOLESCENTS; PERFORMANCE; SEVERITY; SCALE	Objective: To describe upper-limb function in children with mild and severe traumatic brain injury (TBI), by using both quantitative and qualitative measures. Design: Controlled, prospective cohort study with assessment points initially, at 6 months, and at 2 years after TBI. Setting: A tertiary pediatric trauma center in Australia. Patients: Fifty-one children, ranging in age up to 14 years, who were consecutive admissions with TBI. On the basis of initial and persisting abnormal coma score and persistence of posttraumatic amnesia, they were assigned to either a mild (n = 26) or a severely injured (n = 25) group. Thirty children admitted with non-TBI trauma were recruited as a control group. Main Outcome Measures: Quantitative measures included Bruininks-Oseretsky Test of Motor Proficiency and Peabody Developmental Motor Scales. Qualitative measures included Brunnstrom Recovery Stages (adapted), categoric scales of muscle tone, grasp used when handwriting, quality of writing product, bilateral activity, and splint use. Results: There was little difference between the groups on the standardized assessments for subjects who could complete the tests. Qualitative measures showed the severe TBI group to have more difficulties with gross arm control, hand control, and hand function. Conclusion: Children with severe TBI experience more and persisting difficulties with upper-limb function. It is essential to include both quantitative and qualitative measures in this type of research.	New Childrens Hosp, Occupat Therapy Dept, Parramatta, NSW 2124, Australia; New Childrens Hosp, Rehabil Dept, Parramatta, NSW 2124, Australia	Wallen, MA (corresponding author), New Childrens Hosp, Occupat Therapy Dept, POB 3515, Parramatta, NSW 2124, Australia.			Wallen, Margaret/0000-0002-8040-5053			BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BRUININKS RH, 1978, BRUININKSOSERETSKY T; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; Costeff H, 1985, Scand J Rehabil Med Suppl, V12, P10; COSTER WJ, 1994, AM J OCCUP THER, V48, P211, DOI 10.5014/ajot.48.3.211; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Folio M. R., 1983, PEABODY DEV MOTOR SC; HALEY S M, 1991, Physical and Occupational Therapy in Pediatrics, V11, P1; HEIDEN JS, 1983, PHYS THER, V63, P1946, DOI 10.1093/ptj/63.12.1946; HINDERER K A, 1989, Physical and Occupational Therapy in Pediatrics, V9, P81; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Marosszeky NEV, 1998, PTA PROTOCOL GUIDELI; MAROSSZEKY NEV, 1993, CLIN NEUROPSYCHOL, V7, P86; MASSAGLI TL, 1994, PEDIATR ANN, V23, P29, DOI 10.3928/0090-4481-19940101-08; MAYER T, 1981, CHILD BRAIN, V8, P189; O'Flaherty SJ, 2000, ARCH PHYS MED REHAB, V81, P723, DOI 10.1053/apmr.2000.4428; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; SCOTT AD, 1983, OCCUPATIONAL THERAPY, P97; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; STOKES NA, 1990, AM J OCCUP THER, V44, P334, DOI 10.5014/ajot.44.4.334; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; WESSON DE, 1989, J TRAUMA, V29, P589, DOI 10.1097/00005373-198905000-00008	28	25	25	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2001	82	5					642	649		10.1053/apmr.2001.22620			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	429RR	WOS:000168531200013	11346842				2021-06-18	
J	Ducrocq, F; Vaiva, G; Cottencin, O; Molenda, S; Bailly, D				Ducrocq, F; Vaiva, G; Cottencin, O; Molenda, S; Bailly, D			Post-traumatic stress disorder, post-traumatic depression and major depressive disorder : about literature	ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE			French	Article						comorbidity; epidemiology; major depressive disorder; post-traumatic depression; post-traumatic stress disorder	PSYCHIATRIC-DISORDERS; HOLOCAUST SURVIVORS; VIETNAM VETERANS; COMBAT VETERANS; BRAIN INJURY; CORTISOL; TRAUMA; MOOD; COMORBIDITY; SEVERITY	Although they are likely to add their effects, physical and psychic traumata (or traumas) can provoke in different ways the appearence of depressive symptoms sometimes common. Post-traumatic depression, reactional depression, major depressive disorder and post-traumatic stress disorder represent different clinical and nosographic disorders in despite of their occasionally common symptomatic core. Historically, it is interesting to note during the XXth century the true semantic change of the terms of trauma from the somatic field to the psychic sphere. Physical traumatism is often represented by a material shock for the subject and by its organic consequences. It is defined as an event that leaves its mark which itself inflects and handicaps the vital trajectory of the subject. It primarily comprises brain and rachis injuries, whose evolution is frequently characterized by the occurrence/appearance of a depressive disorder, whose genesis rests on psychological but also neurobiologic and physical arguments. Thus major depressive disorders are often present in the course of various physical traumatisms mainly related to nervous system. In accordance with several studies, the prevalence of major depressive disorders ranges from 25% to 50%. These mood disorders occur in the year which follows the accidental event. Their average time of revelation is estimated at four months and their average duration lies between three and six months. Lastly, although these depressive illnesses present clinical symptoms comparable with those observed in other contexts, some nuances can be raised. Nonetheless, they confine sometimes with true clinical forms depending on the intensity the form, the circumstances or the consequences of the trauma. Psychic traumatism doesn't have the same profile and rests for much dedicated with the reexperiencing. Thus for some authors, depression illness represents a disorder that occurs after a traumatic event whereas others see a differential diagnosis which exludes or which represents a comorbidity with post-traumatic stress disorder. The review of the literature allows us to emphasize the complexity of the links as well as the clinical and epidemiologic differences between stress disorder and major depressive disorder. From the clinical point of view, the major features of PTSD are articulated around a triad of symptoms. They include the reexperiencing symptoms of the traumatic event such as intrusive memories and recurrent nightmares the protective reactions such as avoidance of the stimuli associated with the trauma and emotional numbing and the arousal symptoms such as the startled response and hypervigilance. The complexity of this syndrom is due to the frequent combination of these symptoms with other nonspecific ones. As far as the mood is concerned (the mood symptoms are concerned), the regrouping of some of these symptoms allows the clinician to sometimes releave a depressive symptomatology without being able to assess the DSM diagnosis of major depressive disorder. Epidemiologic studies dealing with the risk of installation of a PTSD after a traumatic event reveal differences in the prevalence depending on the nature of the traumatic events: ranging from 1% in general population to 80% following some situations of extreme and durable psychic suffering. Between both poles, one finds a prevalence ranging between 20 and 50% following other events such as serious accidents, natural disasters or criminal assaults. The clinical features of depressive episodes comorbid or associated with PTSD have some characteristics making it possible to individualize various clinical farms as a function of traumatic event type :asthenic, characterial or with somatic symptoms. According to the majority of authors, the co-occurrence of post-traumatic stress disorder and major depressive disorder is high although differential diagnosis is sometimes difficult However, conceptual differences remain and two conceptions are distinguished. For some authors, like Bleich and Shalev, there would not be true chronological evolution from PTSD to MDD. Moreover the presence of symptoms considered as pertaining to the mood register within the criteria of PTSD would be clearly predictive of the occurrence and the severity of the diagnosis but not of the chronicity. For others, there would be a continuity between post-traumatic stress disorder and major depressive disorder. It is the case in many studies of veterans but also for civilian traumatic events. It is also the case for the American national study of comorbidity in which Kessler concludes that for 78% of the subjects who present a comorbidity PTSD/MDD (comorbidity raised for 48% of the 5 877 subjects included), the mood disorder is secondary to PTSD. In spite of these conceptual differences on the etiology and on the chronology of installation of both disorders, authors agree to affirm and to show a very high level of instantaneous or lifetime comorbidity between them, going until more than 60% in some studies. In conclusion, we have firstly proved that if is possible to individualize a high proportion of depressive syndroms secondary to physical traumatisms. Next we have insisted on the significant frequency of the diagnosis of PTSD in the subjects exposed to a traumatic event in which they experienced or were confronted with actual or threatened death or severe injury. We have then raised the differences of prevalence as a function of the event type. Finally, we have approached the complexity of the links between PTSD and MDD from a psychopathological point of view as well as from an epidemiologic one. A rigorous evaluation of those links remains difficult because of the disparities of clinical forms, of symptomatic combinations and of orders of appearance.	CHRU Lille, Clin Fontan, Ctr Accueil & Crise, F-59037 Lille, France; CHRU Lille, SAMU Reg Lille, F-59037 Lille, France; CHRU Lille, Ctr Informat & Traitement Dependances, F-59037 Lille, France			VAIVA, Guillaume/J-8983-2015; DUCROCQ, Francois/O-7342-2014; /I-4024-2015	VAIVA, Guillaume/0000-0003-2462-008X; DUCROCQ, Francois/0000-0002-0664-761X; BAILLY, Daniel/0000-0002-2809-0525; /0000-0003-3663-1405			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Baker DG, 1999, AM J PSYCHIAT, V156, P585; Barrois C., 1998, NEVROSES TRAUMATIQUE; BASOGLU M, 1994, AM J PSYCHIAT, V151, P76; Beckham JC, 1998, AM J PSYCHIAT, V155, P1565, DOI 10.1176/ajp.155.11.1565; Blanchard EB, 1996, BEHAV RES THER, V34, P1, DOI 10.1016/0005-7967(95)00058-6; Bleich A, 1997, BRIT J PSYCHIAT, V170, P479, DOI 10.1192/bjp.170.5.479; Bremner JD, 1997, AM J PSYCHIAT, V154, P624; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P626, DOI 10.1001/archpsyc.55.7.626; BRIOLE G, 1987, OMICAR, V43, P38; Briole G., 1994, TRAUMATISME PSYCHIQU; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Crocq L, 1994, VICTIMOLOGIE, V1, P25; CROCQ L, 1987, MED CATASTROPHE, P520; CROCQ L, 1998, PSYCHIATRIE; CROCQ L, 1995, THERAPEUTIQUE PSYCHI, P989; Crocq L., 1992, PSYCHOL MED, V24, P395; DAVIDSON J, 1985, AM J PSYCHIAT, V142, P90; Deb S, 1999, AM J PSYCHIAT, V156, P374; DUCROCQ F, 1999, REV FR PSYCHIAT PSYC, V24, P150; Engdahl B, 1998, AM J PSYCHIAT, V155, P1740, DOI 10.1176/ajp.155.12.1740; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Favaro A, 1999, PSYCHOL MED, V29, P87, DOI 10.1017/S0033291798007855; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FERREY G, 1996, DEPRESSION SYNDROMES; FREUD S, 1920, ESSAIS PSYCHANALYSE, P43; FRIEDMAN MJ, 1988, AM J PSYCHIAT, V145, P281; Fukunishi I, 1999, PSYCHOTHER PSYCHOSOM, V68, P82, DOI 10.1159/000012317; Goenjian AK, 1996, AM J PSYCHIAT, V153, P929; GRAFMAN J, 1986, BRAIN, V109, P1127, DOI 10.1093/brain/109.6.1127; GREEN BL, 1992, J NERV MENT DIS, V180, P760, DOI 10.1097/00005053-199212000-00004; GUALTIERI CT, 1998, BR J INJURY, V2, P101, DOI DOI 10.3109/02699058809150936; HOUGEN HP, 1988, FORENSIC SCI INT, V39, P5, DOI 10.1016/0379-0738(88)90113-2; Jenkins MA, 1998, AM J PSYCHIAT, V155, P278; Jensen CF, 1997, AM J PSYCHIAT, V154, P266; JORDAN BK, 1991, ARCH GEN PSYCHIAT, V48, P207, DOI 10.1001/archpsyc.1991.01810270019002; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1993, AM J PSYCHIAT, V150, P916; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; JOSEPHSON PR, 1994, MINERVA, V32, P1, DOI 10.1007/BF01096654; Keane TM, 1997, J ANXIETY DISORD, V11, P317, DOI 10.1016/S0887-6185(97)00013-3; Kellner M, 1998, AM J PSYCHIAT, V155, P1299, DOI 10.1176/ajp.155.9.1299; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; LAUFER RS, 1985, AM J PSYCHIAT, V142, P1304; Lebigot F, 1997, ANN MED-PSYCHOL, V155, P522; LEBIGOT F, 1991, ANN MED-PSYCHOL, V149, P131; LEBIGOT F, 1995, MALADIES DEPRESSIVES, P234; Levin H. S., 1997, SEMINARS CLIN NEUROP, V2, P207; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; MADAKASIRA S, 1987, J NERV MENT DIS, V175, P286, DOI 10.1097/00005053-198705000-00008; MARION EW, 1990, POST TRAUMATIC STRES; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; MCFARLANE AC, 1992, J NERV MENT DIS, V180, P498, DOI 10.1097/00005053-199208000-00004; MELLMAN TA, 1992, AM J PSYCHIAT, V149, P1568; North CS, 1997, AM J PSYCHIAT, V154, P1696, DOI 10.1176/ajp.154.12.1696; NORTH CS, 1994, AM J PSYCHIAT, V151, P82; NORTH CS, 1989, HOSP COMMUNITY PSYCH, V40, P1293; RESNICK HS, 1995, AM J PSYCHIAT, V152, P1675; ROBINSON RG, 1988, AM J PSYCHIAT, V145, P172; ROBINSON RG, 1985, AM J PSYCHIAT, V142, P1424; ROBINSON RG, 1994, NEUROPSYCHIATRY TRAU; ROCA RP, 1992, AM J PSYCHIAT, V149, P1234; Shalev AY, 1996, AM J PSYCHIAT, V153, P219; Shalev AY, 1998, AM J PSYCHIAT, V155, P630, DOI 10.1176/ajp.155.5.630; SIERLES FS, 1983, AM J PSYCHIAT, V140, P1177; SMITH EM, 1990, AM J PSYCHIAT, V147, P202; SOUTHWICK SM, 1991, AM J PSYCHIAT, V148, P179; STARKSTEIN SE, 1987, BRAIN, V110, P1045, DOI 10.1093/brain/110.4.1045; Stolp-Smith KA, 1999, ARCH PHYS MED REHAB, V80, P339, DOI 10.1016/S0003-9993(99)90148-X; SUTKER PB, 1993, AM J PSYCHIAT, V150, P240; THOMAS AP, 1995, CIBA F SYMP, V188, P18; Trappler B, 1996, AM J PSYCHIAT, V153, P705; TYRODE Y, 1996, J EUROP URG, V9, P143; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Vila G, 1999, ENFANT VICTIME AGRES; Wagner D, 1998, AM J PSYCHIAT, V155, P1727, DOI 10.1176/ajp.155.12.1727; WEINE SM, 1995, AM J PSYCHIAT, V152, P536; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; Yehuda R, 1999, CAN J PSYCHIAT, V44, P34, DOI 10.1177/070674379904400104; YEHUDA R, 1991, AM J PSYCHIAT, V148, P499; YEHUDA R, 1995, AM J PSYCHIAT, V152, P1705; YEHUDA R, 1995, AM J PSYCHIAT, V152, P982; YEHUDA R, 1993, AM J PSYCHIAT, V150, P83; Yehuda R, 1998, BIOL PSYCHIAT, V44, P56, DOI 10.1016/S0006-3223(98)80007-3; YEHUDA R, 1994, J TRAUMA STRESS, V7, P699, DOI 10.1002/jts.2490070414	89	25	31	0	24	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0013-7006			ENCEPHALE	Enceph.-Rev. Psychiatr. Clin. Biol. Ther.	MAR-APR	2001	27	2					159	168					10	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	439DE	WOS:000169094900007	11407268				2021-06-18	
J	Abraham, KE; McGinty, JF; Brewer, KL				Abraham, KE; McGinty, JF; Brewer, KL			Spinal and supraspinal changes in opioid mRNA expression are related to the onset of pain behaviors following excitotoxic spinal cord injury	PAIN			English	Article						dynorphin; enkephalin; quisqualic acid; spinal cord injury	MESSENGER-RNA EXPRESSION; DORSAL HORN NEURONS; PERIPHERAL INFLAMMATION; TRAUMATIC INJURY; DYNORPHIN-A; RECEPTOR ANTAGONISTS; RAT MODEL; NMDA; IMMUNOREACTIVITY; HYPERALGESIA	Excitotoxic spinal cord injury (SCI) causes anatomic, physiologic and molecular changes within the spinal cord and brain. Intraspinal injection of quisqualic acid (QUIS) produces an excitotoxic injury that leads to the onset of behavioral syndromes, believed to be related to the clinical condition of chronic pain. The opioid system, classically involved in the suppression of pain transmission, has been associated with the onset of pain-related behaviors and changes in spinal opioid peptide expression have been demonstrated in various models of SCI and chronic pain. Recently, changes in opioid peptide expression have been demonstrated in both spinal and supraspinal areas following excitotoxic SCI. Therefore, the purpose of this study was to examine changes in opioid peptide gene expression as they relate to the onset of pain behaviors following excitotoxic SCI. Male, Long-Evans rats were given an intraspinal injection of 1.2 mul of 125 mM QUIS and allowed to survive for 10 days, a duration sufficient for the development of pain-related behaviors. Animals were assessed daily for the presence of excessive grooming behavior, i.e. self-directed biting and scratching resulting in damage to superficial and deeper layers of the skin. Animals were also tested for thermal hypersensitivity using a cold plate apparatus on days 5, 7, and 10 following QUIS injection. After sacrifice, quantitative in situ hybridization was performed on regions of the spinal cord surrounding the lesion site as well as whole brain sections through various levels of the thalamus and cortex. Spinal preproenkephalin (PPE) and preprodynorphin (PPD) expression was significantly increased in animals that developed excessive grooming behaviors vs. those that did not. For PPE, this difference was seen bilaterally, in areas of cord caudal to the site of injury. For PPD, this difference was seen only ipsilateral to the site of injection, rostral to the site of injury. In addition, PPE expression in the anterior cingulate cortex and PPD expression in the contralateral parietal cortex were significantly higher in grooming vs. non-grooming animals. These results support previous conclusions that both spinal and supraspinal regulation of endogenous opioid peptide expression plays a role in the response to or onset of post-SCI pain. These results also suggest that the opioid peptides are regulated independently and serve different functions in response to SCI. (C) 2001 International Association for the Study of Pain. Published by Elsevier Science B.V. All rights reserved.	E Carolina Univ, Brody Sch Med, Div Res, Dept Emergency Med, Greenville, NC 27858 USA; Med Univ S Carolina, Dept Physiol & Neurosci, Charleston, SC 29425 USA; E Carolina Univ, Sch Med, Dept Anat & Cell Biol, Greenville, NC 27858 USA	Brewer, KL (corresponding author), E Carolina Univ, Brody Sch Med, Div Res, Dept Emergency Med, Physicians Quadrangle,Bldg M, Greenville, NC 27858 USA.	brewerk@mail.ecu.edu			NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA003982] Funding Source: NIH RePORTER; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA 03982] Funding Source: Medline		Abraham KE, 2000, NEUROSCIENCE, V99, P189, DOI 10.1016/S0306-4522(00)00150-0; ATTAL N, 1989, BRAIN RES, V494, P276, DOI 10.1016/0006-8993(89)90596-9; BAKSHI R, 1990, BRAIN RES, V507, P1, DOI 10.1016/0006-8993(90)90512-A; BAKSHI R, 1990, NEUROSCI LETT, V110, P113, DOI 10.1016/0304-3940(90)90797-D; BERIC A, 1988, PAIN, V34, P109, DOI 10.1016/0304-3959(88)90155-8; Beric A, 1997, PAIN, V72, P295, DOI 10.1097/00006396-199709000-00001; Bethea J. R., 1999, Society for Neuroscience Abstracts, V25, P1443; Bian D, 1998, NEUROSCI LETT, V241, P79, DOI 10.1016/S0304-3940(98)00051-2; Bian D, 1999, BRAIN RES, V831, P55, DOI 10.1016/S0006-8993(99)01393-1; Brewer K. L., 1997, Society for Neuroscience Abstracts, V23, P438; BUCHSBAUM MS, 1977, NATURE, V270, P620, DOI 10.1038/270620a0; CAUDLE RM, 1988, J PHARMACOL EXP THER, V246, P508; CAUDLE RM, 1987, BRAIN RES, V435, P1, DOI 10.1016/0006-8993(87)91579-4; COX BM, 1985, NEUROPEPTIDES, V5, P571, DOI 10.1016/0143-4179(85)90082-4; Dancausse H. A., 1995, Society for Neuroscience Abstracts, V21, P231; DAVIDOFF G, 1987, PAIN, V29, P39, DOI 10.1016/0304-3959(87)90176-X; Demirel G, 1998, SPINAL CORD, V36, P25, DOI 10.1038/sj.sc.3100523; DRAISCI G, 1991, BRAIN RES, V560, P186, DOI 10.1016/0006-8993(91)91231-O; EIDE PK, 1995, NEUROSURGERY, V37, P1080, DOI 10.1227/00006123-199512000-00007; ELSOBKY A, 1976, NATURE, V263, P783, DOI 10.1038/263783a0; FADEN AI, 1984, BRIT J PHARMACOL, V81, P271, DOI 10.1111/j.1476-5381.1984.tb10074.x; FADEN AI, 1990, ANN NEUROL, V27, P67, DOI 10.1002/ana.410270111; FADEN AI, 1985, ANN NEUROL, V17, P386, DOI 10.1002/ana.410170414; GRACELY RH, 1983, NATURE, V306, P264, DOI 10.1038/306264a0; GREVERT P, 1983, BIOL PSYCHOL, V18, P1093; Hao JX, 1996, PAIN, V66, P279; Hao JX, 1998, EXP BRAIN RES, V118, P259, DOI 10.1007/s002210050280; HELTON TE, 1993, MOL CELL NEUROSCI, V4, P319, DOI 10.1006/mcne.1993.1042; HYLDEN JLK, 1991, PAIN, V44, P187, DOI 10.1016/0304-3959(91)90136-L; KAYSER V, 1991, BRAIN RES, V567, P197, DOI 10.1016/0006-8993(91)90796-X; Kennedy P, 1997, SPINAL CORD, V35, P814, DOI 10.1038/sj.sc.3100569; KNOX RJ, 1987, BRAIN RES, V415, P21, DOI 10.1016/0006-8993(87)90265-4; KOSTERLITZ HW, 1985, PROC R SOC SER B-BIO, V225, P27, DOI 10.1098/rspb.1985.0048; Laughlin TM, 1997, PAIN, V72, P253, DOI 10.1016/S0304-3959(97)00046-8; Laughlin TM, 1999, PAIN, V80, P37, DOI 10.1016/S0304-3959(98)00191-2; Liu SL, 1997, BRAIN RES, V756, P160, DOI 10.1016/S0006-8993(97)00137-6; LONG JB, 1994, J PHARMACOL EXP THER, V269, P358; MELZACK R, 1978, PAIN, V4, P195, DOI 10.1016/0304-3959(77)90133-6; MILLAN MJ, 1986, PAIN, V27, P303, DOI 10.1016/0304-3959(86)90158-2; Morrow TJ, 2000, EXP NEUROL, V161, P220, DOI 10.1006/exnr.1999.7246; NOGUCHI K, 1992, NEUROSCIENCE, V46, P561, DOI 10.1016/0306-4522(92)90144-Q; NOGUCHI K, 1991, MOL BRAIN RES, V10, P227, DOI 10.1016/0169-328X(91)90065-6; RUDA MA, 1988, P NATL ACAD SCI USA, V85, P622, DOI 10.1073/pnas.85.2.622; Ruda MA, 1995, PROG BRAIN RES, V104, P349; SHARMA HS, 1993, NEUROPHARMACOLOGY, V32, P711, DOI 10.1016/0028-3908(93)90085-H; Siddall PJ, 1997, SPINAL CORD, V35, P69, DOI 10.1038/sj.sc.3100365; SMITH AJW, 1994, MOL BRAIN RES, V21, P359, DOI 10.1016/0169-328X(94)90268-2; STEVENS CW, 1986, J PHARMACOL EXP THER, V238, P833; WANG JQ, 1995, J PHARMACOL EXP THER, V273, P909; Wilson SP, 1999, P NATL ACAD SCI USA, V96, P3211, DOI 10.1073/pnas.96.6.3211; XU XJ, 1992, PAIN, V48, P279, DOI 10.1016/0304-3959(92)90070-R; YAKSH TL, 1987, J NEUROSURG, V67, P157, DOI 10.3171/jns.1987.67.2.0157; YAKSH TL, 1988, PROG BRAIN RES, V77, P371; Yezierski RP, 1998, PAIN, V75, P141, DOI 10.1016/S0304-3959(97)00216-9; Yezierski RP, 1996, J CEREBR BLOOD F MET, V16, P996, DOI 10.1097/00004647-199609000-00025; YEZIERSKI RP, 1993, J NEUROTRAUM, V10, P445, DOI 10.1089/neu.1993.10.445	56	25	25	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	FEB 1	2001	90	1-2					181	190		10.1016/S0304-3959(00)00402-4			10	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	406CY	WOS:000167198400022	11166985				2021-06-18	
J	Corrigan, JD				Corrigan, JD			Conducting statewide needs assessments for persons with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						needs assessment; public policy; traumatic brain injury	UNITED-STATES	The Traumatic Brain Injury Act of 1996 (Public Law 104-166) gave new authority to the Health Resources and Services Administration (HRSA) in the United States Department of Health and Human Services (DHHS) to establish a grant program for states to assist in addressing the needs of persons with traumatic brain injury (TBI). The resulting State Demonstration Grant Program has made available two categories of grants: planning and implementation. Planning grants are awarded to assist states in building infrastructure through the development of four core components. One of the core components is a statewide needs and resource assessment encompassing the full spectrum of services, from initial acute treatment through rehabilitation and long-term community supports. In 1999. assessments completed in 11 states were subjected to a comparative analysis to identify trends across states and to extract salient issues for the State Demonstration Grant Program. This article summarizes the context of the HRSA-funded needs assessments and contrasts the methods of needs assessment utilized. Over-arching issues are discussed, including exemplary qualitative and quantitative methods. and the diversity of theoretical models employed in designing assessments and interpreting findings. Several limitations in approaches were also identified, including shortcomings of convenience samples for conducting mail surveys and the unlikely validity of using a needs and resource discrepancy approach to identify gaps in services.	Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; Traumat Brain Injury Tech Assistance Ctr, Silver Spring, MD USA	Corrigan, JD (corresponding author), Dodd Hall,480 W 9th Ave, Columbus, OH 43210 USA.						Brooks CA, 1997, ARCH PHYS MED REHAB, V78, pS26, DOI 10.1016/S0003-9993(97)90152-0; *CDCP, 1999, TRAUM BRAIN INJ PUBL; Corrigan J D, 1994, NeuroRehabilitation, V4, P109, DOI 10.3233/NRE-1994-4207; DIGRE PG, 1994, J HEAD TRAUMA REHAB, V9, P12; GOODALL P, 1994, J HEAD TRAUMA REHAB, V9, P61; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; ROSEN B, 1994, J HEAT TRAUMA REHABI, V9, P2; Schootman M, 2000, BRAIN INJURY, V14, P373; Sosin DM, 1996, BRAIN INJURY, V10, P47; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; *US GEN ACC OFF, 1998, TRAUM BRAIN INJ PROG; WRIGHT B, 1993, WHAT LEGISLATORS NEE	14	25	25	0	2	ASPEN PUBL INC	GAITHERSBURG	200 ORCHARD RIDGE DR, STE 200, GAITHERSBURG, MD 20878 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	2001	16	1					1	19		10.1097/00001199-200102000-00004			19	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	403ZC	WOS:000167072100006	11277847				2021-06-18	
J	Maryniak, O; Manchanda, R; Velani, A				Maryniak, O; Manchanda, R; Velani, A			Methotrimeprazine in the treatment of agitation in acquired brain injury patients	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; HALOPERIDOL; BEHAVIOR; REHABILITATION; EFFICACY; SCALE	Medical management of the agitation associated with acquired brain injury (ABI) has been problematic. At least 12 distinct drugs are currently recommended in the medical literature. In recent years, on the ABI in-patient rehabilitation unit, methotrimeprazine (MTZ) has come to be the preferred drug and is used routinely for effective treatment of agitation. The objective of this paper is to describe the use and safety of MTZ in the rehabilitation of ABI patients. A retrospective chart review of all patients discharged from the ABI unit over a course of 2 years was conducted. In addition to demographics such a aetiology of ABI, sex, age, length of stay, Glasgow Coma Scale, length of posttraumatic amnesia and others, a detailed analysis was made of the multidisciplinary progress notes to determine the daily agitation status and the daily use of psychotropic medication. All notes on side effects and adverse reactions were carefully documented. 120 first admission recent ABI patients were discharged in the 2-year study period. Of these, 69 (57%) had some level of agitation and 56 (48%) were treated with MTZ, in doses of 2-50 mg up to four times daily. Agitation was controlled in most cases. In only two cases were significant side effects noted. While MTZ has been used as a safe and effective neuroleptic in psychiatry for over 40 years, this is the first report of its use in treating agitation in ABI.	Univ Western Ontario, Dept Phys Med & Rehabil, London, ON, Canada; Univ Western Ontario, Dept Psychiat, London, ON, Canada; St Josephs Hlth Care London, London, England; London Hlth Sci Ctr, London, England	Maryniak, O (corresponding author), Parkwood Hosp, 801 Commiss Rd E, London, ON N6C 5J1, Canada.	olemar.medart@sympatico.ca					AARON H, 1967, MED LETT DRUGS THER, V9, P49; BAKCHINE S, 1989, NEUROLOGY, V39, P777, DOI 10.1212/WNL.39.6.777; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; Bryois C, 1996, Rev Med Suisse Romande, V116, P713; CARDENAS DD, 1992, PHYS MED REH CLIN N, V3, P273; Chandler M C, 1988, Brain Inj, V2, P309; Chater S, 1998, PALLIATIVE MED, V12, P255, DOI 10.1191/026921698671831786; CIFU DX, 1997, P 22 ANN POSTGR COUR, P104; COPE DN, 1996, MED REHABILITATION T, P573; CORRIGAN JD, 1994, J CLIN EXP NEUROPSYC, V16, P386, DOI 10.1080/01688639408402649; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; COURVOISIER S, 1958, COMPTES RENDU SCEANC, V7, P1378; Dombovy Mary L., 1992, Archives of Physical Medicine and Rehabilitation, V73, P975; ELLIOTT FA, 1977, ANN NEUROL, V1, P489, DOI 10.1002/ana.410010516; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FRASER HF, 1963, CLIN PHARMACOL THER, V4, P596; Fugate LP, 1997, ARCH PHYS MED REHAB, V78, P917, DOI 10.1016/S0003-9993(97)90050-2; GERLACH J, 1991, SCHIZOPHRENIA BULL, V17, P289, DOI 10.1093/schbul/17.2.289; GUALTIEREI CT, 1993, BRAIN INJURY REHABIL, P264; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; HIRSCH J, 1993, HEADLINES        MAR, P10; JACKSON RD, 1985, ARCH PHYS MED REHAB, V66, P180; LAMBERT PA, 1964, ENCEPHALE, V1, P262; Levine A M, 1988, Brain Inj, V2, P165, DOI 10.3109/02699058809150940; Mysiw WJ, 1997, ARCH PHYS MED REHAB, V78, P213, DOI 10.1016/S0003-9993(97)90266-5; RAO N, 1985, ARCH PHYS MED REHAB, V66, P30; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; SARWER-FONER G J, 1961, Med Serv J Can, V17, P798; TELATIN I, 1959, JAMA-J AM MED ASSOC, V170, P1349; WILCOCK GK, 1987, LANCET, V1, P929; Wilkinson R, 1999, BRAIN INJURY, V13, P1025; Wroblewski BA, 1997, BRAIN INJURY, V11, P37, DOI 10.1080/026990597123791	32	25	25	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2001	15	2					167	174		10.1080/026990501458399			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	398BG	WOS:000166733800008	11260766				2021-06-18	
J	Karmy-Jones, R; Carter, YM; Nathens, A; Brundage, S; Meissner, MH; Borsa, J; Demirer, S; Jurkovich, G				Karmy-Jones, R; Carter, YM; Nathens, A; Brundage, S; Meissner, MH; Borsa, J; Demirer, S; Jurkovich, G			Impact of presenting physiology and associated injuries on outcome following traumatic rupture of the thoracic aorta	AMERICAN SURGEON			English	Article							LEFT-HEART BYPASS; TREATMENT PRIORITIES; HIGH-RISK; REPAIR; ISTHMUS; EXPERIENCE; MANAGEMENT; PARAPLEGIA; EMERGENCY	We hypothesized that the predominant factor influencing outcome of traumatic rupture of the thoracic aorta (TRA) was the degree of shock on presentation and associated injuries. We reviewed our experience with TRA over a 15-year period. Patients were classified as "unstable" if presenting systolic blood pressure was <90 mm Hg or if it decreased to <90 mm Hg after admission. We determined the presence of closed head injury, cardiac risk factors, a preoperative acute lung injury (ALI). The influence of these factors on mortality, postoperative adult respiratory distress syndrome (ARDS), and paralysis was analyzed. One hundred thirty-six patients were admitted with TRA. One hundred twenty underwent operative repair with a mortality of 31 per cent. Operative mortality was significantly higher in unstable patients (62%) versus stable patients (17%, P = 0.001), in patients with cardiac risk factors (71%) versus those without (24%, P = 0.001), and in patients with preoperative free rupture (83%) with versus those without (19%, P = 0.001). Free rupture was the cause of hypotension in only 10 of 42 unstable patients, with the remainder being due to other causes. Preoperative ALI was associated with a marked increase in postoperative ARDS (47% with vs 9% without, P = 0.001) but not operative mortality. Mechanical circulatory support (MCS) was used in 59 cases, none of whom experienced paralysis, whereas eight of 61 operated on without MCS developed paralysis (P = 0.001). When logistic regression was applied the use of MCS was not determined to be statistically significant. However, preoperative instability was found to be a significant predictor of postoperative paralysis with the risk being increased 5.5 times (confidence interval 3.3-10). The predominant factor influencing mortality, postoperative ARDS, and paralysis was preoperative instability and associated injuries. In patients who are hypotensive, other injuries should take precedence over repair of TRA. Patients who are stable but who have cardiac or pulmonary risk factors may be better managed by a period of nonoperative management until their condition improves.	Univ Washington, Harborview Med Ctr, Dept Surg, Seattle, WA 98104 USA; Univ Washington, Div Cardiothorac Surg, Seattle, WA 98195 USA; Univ Washington, Dept Radiol, Seattle, WA 98195 USA	Karmy-Jones, R (corresponding author), Univ Washington, Harborview Med Ctr, Dept Surg, 325 9th Ave,Box 359796, Seattle, WA 98104 USA.						Attar S, 1999, ANN THORAC SURG, V67, P959, DOI 10.1016/S0003-4975(99)00174-5; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BORMAN KR, 1982, AM J SURG, V144, P728, DOI 10.1016/0002-9610(82)90559-1; Camp PC, 1997, J TRAUMA, V43, P413, DOI 10.1097/00005373-199709000-00004; CLARK DE, 1990, J TRAUMA, V30, P701, DOI 10.1097/00005373-199006000-00008; COWLEY RA, 1990, J THORAC CARDIOV SUR, V100, P652; DEBYDUPONT G, 1999, OXFORD TXB CRITICAL, P54; Fabian TC, 1998, ANN SURG, V227, P666, DOI 10.1097/00000658-199805000-00007; Fabian TC, 1997, J TRAUMA, V42, P374, DOI 10.1097/00005373-199703000-00003; FORBES AD, 1994, ARCH SURG-CHICAGO, V129, P494; FULLERTON DA, 1993, ANN THORAC SURG, V56, P579, DOI 10.1016/0003-4975(93)90908-Z; Hudson H M 2nd, 1991, Ann Vasc Surg, V5, P445; LEE RB, 1992, AM SURGEON, V58, P37; MAGGISANO R, 1995, ANN VASC SURG, V9, P44, DOI 10.1007/BF02015316; MATTOX KL, 1985, ANN THORAC SURG, V40, P456, DOI 10.1016/S0003-4975(10)60100-2; Mattox KL, 1997, J TRAUMA, V42, P353, DOI 10.1097/00005373-199703000-00001; PARMLEY LF, 1958, CIRCULATION, V17, P1086, DOI 10.1161/01.CIR.17.6.1086; Pate JW, 1999, WORLD J SURG, V23, P59, DOI 10.1007/s002689900565; PATE JW, 1995, WORLD J SURG, V19, P119, DOI 10.1007/BF00316994; PATE JW, 1995, ANN THORAC SURG, V59, P90, DOI 10.1016/0003-4975(94)00719-N; PATE JW, 1994, ANN THORAC SURG, V57, P530, DOI 10.1016/0003-4975(94)90540-1; Pezzella AT, 1998, CURR PROB SURG, V35, P652; READ RA, 1993, ARCH SURG-CHICAGO, V128, P746; SACCO WJ, 1988, COMPUT BIOL MED, V18, P419, DOI 10.1016/0010-4825(88)90059-5; Sweeney MS, 1997, ANN THORAC SURG, V64, P384, DOI 10.1016/S0003-4975(97)00561-4; Tatou E, 2000, ANN THORAC SURG, V69, P70, DOI 10.1016/S0003-4975(99)01054-1; VONOPPELL UO, 1994, ANN THORAC SURG, V58, P585, DOI 10.1016/0003-4975(94)92270-5; Wahl WL, 1999, J TRAUMA, V47, P254, DOI 10.1097/00005373-199908000-00006; YOUNG JN, 1989, WESTERN J MED, V150, P662	29	25	30	0	1	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	JAN	2001	67	1					61	66					6	Surgery	Surgery	395RA	WOS:000166594000015	11206899				2021-06-18	
J	Kurtz, MM; Moberg, PJ; Mozley, LH; Swanson, CL; Gur, RC; Gur, RE				Kurtz, MM; Moberg, PJ; Mozley, LH; Swanson, CL; Gur, RC; Gur, RE			Effectiveness of an attention- and memory-training program on neuropsychological deficits in schizophrenia	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						schizophrenia; cognitive; rehabilitation; symptoms; outcome	REMEDIATION; DEFINITION; VALIDATION	The effect of two cognitive remediation procedures developed for closed head injury, Attention Process Training (APT) and Prospective Memory Training (PROMT), on neuropsychological deficits in schizophrenia was investigated. Six patients with schizophrenia, varying in baseline intellectual function and symptoms, were studied; three in a remediation condition and three in a non-remediated control condition. Results were evaluated individually for each of the three treated patients. Two of three remediation, treated subjects showed marked improvement on tests of sustained and divided attention. Untreated patients showed little evidence of change in neuropsychological test performance across a similar time interval, when tested on a subset of the measures administered to remediation-treated patients The results of this study are discussed with a view toward future studies using larger sample sizes with homogeneous subject populations.	Univ Penn, Sch Med, Dept Psychiat, Brain Behav Lab, Philadelphia, PA 19104 USA	Kurtz, MM (corresponding author), Inst Living, Schizophrenia Rehabil Program, 400 Washington St, Hartford, CT 06106 USA.				NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH43880, MH01336, MH19112] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P50MH043880, P30MH043880, T32MH019112] Funding Source: NIH RePORTER		American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ANDREASEN NC, 1982, ARCH GEN PSYCHIAT, V39, P789; ANDREASEN NC, 1982, ARCH GEN PSYCHIAT, V39, P784; BELLACK AS, 1990, AM J PSYCHIAT, V147, P650; BENEDICT RHB, 1989, BRIT J CLIN PSYCHOL, V28, P187, DOI 10.1111/j.2044-8260.1989.tb00832.x; CORNBLATT BA, 1994, SCHIZOPHRENIA BULL, V20, P31, DOI 10.1093/schbul/20.1.31; DILLER L, 1987, NEUROBEHAVIORAL RECO, P146; Golden C., 1978, STROOP COLOR WORD TE; Gordon M., 1983, GORDON DIAGNOSTIC SY; GREEN MF, 1993, AM J PSYCHIAT, V150, P178; Green MF, 1996, AM J PSYCHIAT, V153, P321; GUR RE, 1991, AM J PSYCHIAT, V148, P472; Heinrichs RW, 1998, NEUROPSYCHOLOGY, V12, P426, DOI 10.1037/0894-4105.12.3.426; Medalia A, 1998, SCHIZOPHRENIA BULL, V24, P147, DOI 10.1093/oxfordjournals.schbul.a033306; OVERALL JR, 1980, J OPER PSYCHIATR, V11, P48; Park NW, 1999, NEUROPSYCHOL REHABIL, V9, P135, DOI 10.1080/713755595; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; SOHLBERG M, 1986, PROSPECTIVE MEMORY P; SOHLBERG M M, 1992, Brain Injury, V6, P129, DOI 10.3109/02699059209029651; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; SOHLBERG MM, 1986, ATTENTION PROCESS TR; STUSS D. T., 1988, CLIN NEUROPSYCHOL, V2, P246, DOI DOI 10.1080/13854048808520107; Wechsler, 1981, WAIS R MANUAL; WESULAM MM, 1985, PRINCIPLES BEHAV NEU; WILSON B, 1989, J CLIN EXP NEUROPSYC, V11, P855, DOI 10.1080/01688638908400940; Winograd E., 1988, PRACTICAL ASPECTS ME, V1, P348	27	25	27	0	8	DEMOS MEDICAL PUBLISHING	NEW YORK	386 PARK AVE SOUTH, STE 201, NEW YORK, NY 10016 USA	0888-4390			NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair		2001	15	1					75	80		10.1177/154596830101500110			6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	466BH	WOS:000170624100010	11527282				2021-06-18	
J	Grossman, KJ; Stein, DG				Grossman, KJ; Stein, DG			Does endogenous progesterone promote recovery of chronic sensorimotor deficits following contusion to the forelimb representation of the sensorimotor cortex?	BEHAVIOURAL BRAIN RESEARCH			English	Article						traumatic brain injury; progesterone; pseudopregnant; sex differences; sensorimotor; forelimb use; foot fault; recovery	TRAUMATIC BRAIN INJURY; CORTICAL CONTUSION; NEOCORTICAL DAMAGE; MALE-RATS; PROTECTS; ABLATION; LESIONS; STROKE; AREAS	We studied sensorimotor recovery in male, normal-cycling and pseudopregnant female rats following unilateral FL-SMC contusions. Forelimb use (push off before a rear, support against the walls, and landing after a rear) and the foot fault test (foot misplacements during locomotion on an elevated grid) were analyzed from videotapes taken before surgery, and then again on post-surgical days 2 and 36. High endogenous progesterone levels in females at the time of injury did not affect recovery as there were no differences between males, pseudopregnant females and normal-cycling female rats on these behaviors. None of the brain-injured rats recovered symmetrical forelimb use between 2 and 36 days after injury (P > 0.05) and they also showed foot misplacements (P > 0.05) in the foot fault test. Male and female rats with contusions had fewer mean foot misplacements on day 36 than 2 days after injury (P < 0.001), indicating that there was partial recovery on this task. These results were taken to show that there were no sex differences in motor deficits caused by unilateral FL-SMC injury. In addition, higher endogenous progesterone levels in females did not protect them from the chronic sensorimotor deficits caused by unilateral FL-SMC contusions. (C) 2000 Elsevier Science B.V. All rights reserved.	Emory Univ, Dept Psychol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Brain Res Lab, Dept Neurol, Atlanta, GA 30322 USA	Grossman, KJ (corresponding author), Emory Univ, Dept Psychol, 532 N Kilgo Circle, Atlanta, GA 30322 USA.		Stein, Donald/AAJ-5139-2020				Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P353; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; CASTROALAMANCOS MA, 1995, NEUROSCIENCE, V68, P793, DOI 10.1016/0306-4522(95)00178-L; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; Goldstein LB, 1999, RESTOR NEUROL NEUROS, V15, P39; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; JONES TA, 1994, J NEUROSCI, V14, P2140; JONES TA, 1992, BRAIN RES, V581, P156, DOI 10.1016/0006-8993(92)90356-E; Kolb B, 1996, BEHAV NEUROSCI, V110, P1271, DOI 10.1037/0735-7044.110.6.1271; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; KOZLOWSKI DA, 1996, J NEUROTRAUM, V13, P620; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; ROOF RL, 1993, BEHAV BRAIN RES, V57, P47, DOI 10.1016/0166-4328(93)90060-4; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Stibick D. L., 1996, Society for Neuroscience Abstracts, V22, P1186; Stibick D. L., 1997, Society for Neuroscience Abstracts, V23, P2193; SWANSON LW, 1992, BRAIN MAPS STRUCTURE, P240; Taub E, 1980, BEHAV PSYCHOL REHABI, P371; WOLF SL, 1989, EXP NEUROL, V104, P125, DOI 10.1016/S0014-4886(89)80005-6	25	25	25	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328			BEHAV BRAIN RES	Behav. Brain Res.	DEC 5	2000	116	2					141	148		10.1016/S0166-4328(00)00275-8			8	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	377YA	WOS:000165552800004	11080545				2021-06-18	
J	Craighead, MW; Boutin, H; Middlehurst, KML; Allan, SM; Brooks, N; Kimber, I; Rothwell, NJ				Craighead, MW; Boutin, H; Middlehurst, KML; Allan, SM; Brooks, N; Kimber, I; Rothwell, NJ			Influence of corticotrophin releasing factor on neuronal cell death in vitro and in vivo	BRAIN RESEARCH			English	Article						CRF; neuronal toxicity; cortical neurons; ischaemia; NMDA; AMPA	FOCAL CEREBRAL-ISCHEMIA; MESSENGER-RNA; FACTOR CRF; RAT; RECEPTOR; BRAIN; HORMONE; INJURY; SEIZURES; AMYGDALA	Several studies have demonstrated that antagonists of the corticotrophin releasing factor (CRF) receptor markedly inhibit experimentally induced excitotoxic, ischaemic and traumatic brain injury in the rat, and that CRF expression is elevated in response to experimentally induced stroke or traumatic brain injury. CRF is also induced by the pro-inflammatory cytokine interleukin 1 (IL-1), which participates in various forms of neurodegeneration. The aim of this study was to test the hypothesis that CRF is toxic directly in vivo or in vitro. In primary cultures of rat cortical neurons, exposure to CRF (10 pM-100 nM) for 24 h failed to cause cell death directly, or to modify the neurotoxic effects of N-methyl-D-aspartate (NMDA). Similarly, infusion of CRF (0.3-5 mug) into specific brain regions of the rat did not induce cell death and did not significantly alter the neuronal damage produced by infusion of excitatory amino acids. These data demonstrate that CRF is not directly neurotoxic, and suggest that either CRF mediates neuronal damage by indirect actions (e.g. on the vasculature) and/or that CRF is not the endogenous ligand which contributes to neurodegeneration through activation of CRF receptors. (C) 2000 Elsevier Science B.V. All rights reserved.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Zeneca Cent Toxicol Lab, Macclesfield SK10 4TJ, Cheshire, England	Craighead, MW (corresponding author), Univ Manchester, Sch Biol Sci, 1-124 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	mqbssmwc@man.ac.uk	Allan, Stuart/AAL-1245-2020	Allan, Stuart/0000-0001-9646-4456; Boutin, Herve/0000-0002-0029-5246			ALDENHOFF JB, 1983, SCIENCE, V221, P875, DOI 10.1126/science.6603658; Allan SM, 2000, P NATL ACAD SCI USA, V97, P5580, DOI 10.1073/pnas.090464197; BARAM TZ, 1992, ANN NEUROL, V31, P488, DOI 10.1002/ana.410310505; Casadevall M, 1999, AM J PHYSIOL-GASTR L, V276, pG1016; EHLERS CL, 1983, BRAIN RES, V278, P332, DOI 10.1016/0006-8993(83)90266-4; FISHER LA, 1983, REGUL PEPTIDES, V5, P153, DOI 10.1016/0167-0115(83)90123-4; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Kostich WA, 1998, MOL ENDOCRINOL, V12, P1077, DOI 10.1210/me.12.8.1077; Lawrence CB, 1998, EUR J NEUROSCI, V10, P1188, DOI 10.1046/j.1460-9568.1998.00136.x; LEI S, 1993, BRIT J PHARMACOL, V108, P941, DOI 10.1111/j.1476-5381.1993.tb13490.x; Li H, 1998, INT J BIOCHEM CELL B, V30, P1389, DOI 10.1016/S1357-2725(98)00093-4; Lundkvist J, 1996, EUR J PHARMACOL, V309, P195, DOI 10.1016/0014-2999(96)00337-8; LYONS MK, 1991, BRAIN RES, V545, P339, DOI 10.1016/0006-8993(91)91310-W; Roe SY, 1998, EUR J NEUROSCI, V10, P553, DOI 10.1046/j.1460-9568.1998.00064.x; ROTHWELL NJ, 1989, AM J PHYSIOL, V256, pE111; Schoeffter P, 1999, FUNDAM CLIN PHARM, V13, P484, DOI 10.1111/j.1472-8206.1999.tb00007.x; STRIJBOS PJLM, 1994, BRAIN RES, V656, P405, DOI 10.1016/0006-8993(94)91485-0; Turnbull AV, 1995, BRAIN BEHAV IMMUN, V9, P253, DOI 10.1006/brbi.1995.1026; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; WONG ML, 1995, NEUROREPORT, V6, P1785, DOI 10.1097/00001756-199509000-00019	20	25	27	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 27	2000	881	2					139	143		10.1016/S0006-8993(00)02759-1			5	Neurosciences	Neurosciences & Neurology	368BV	WOS:000090098500005	11036151				2021-06-18	
J	Shohami, E; Mechoulam, R				Shohami, E; Mechoulam, R			Dexanabinol (HU-211): A nonpsychotropic cannabinoid with neuroprotective properties	DRUG DEVELOPMENT RESEARCH			English	Article						dexanabinol; NMDA-antagonist; TNF-inhibitor; brain injury; stroke	CLOSED-HEAD INJURY; TUMOR-NECROSIS-FACTOR; NONCOMPETITIVE NMDA ANTAGONIST; BRAIN-DAMAGE; RECEPTOR ANTAGONIST; SEPTIC SHOCK; OPTIC-NERVE; RAT; ISCHEMIA; MECHANISMS	The synthetic cannabinoid (+)-(6aS,10aS)-11-hydroxy-Delta-8-tetrahydrocannabinol 1',1'dimethylheptyl (dexanabinol, HU-211) is inactive as a cannabimimetic, but exhibits pharmacological properties characteristic of an N-methyl-D-aspartate (NMDA)-receptor antagonist. It blocks NMDA-receptors stereospecifically by interacting with a site close to, but distinct from, that of uncompetitive NMDA-receptor antagonists and from the recognition sites of glutamate, glycine, and polyamines. HU-211 inhibits the synthesis of tumor necrosis factor alpha (TNF alpha) and possesses antioxidant properties. HU-211 blocked NMDA-induced Ca-45 uptake by primary neuronal cultures of rat forebrain and protected the same neuronal cultures against NMDA and glutamate neurotoxicity. Moreover, HU-211 effectively scavenged peroxy radicals in vitro and protected cultured neurons from the toxic effects of reactive oxygen species (ROS). In addition, HU-211 markedly suppressed in vitro TNF alpha production and nitric oxide (NO) generation (by > 90%) by both murine peritoneal macrophages and rat alveolar macrophage cell line exposed to lipopolysaccharide (LPS). Since glutamate, ROS and TNF alpha. are implicated in the pathophysiology of various acute conditions, the promising results showing neuroprotection by HU-211, acting via multiple mechanisms, led to a series of studies in which the drug was given to experimental animals. In the present review we discuss results from experiments describing the potential use of HU-211 as a neuroprotective agent in models of traumatic brain injury, stroke, optic nerve injury, pneumacocal meningitis, sepsis, and soman toxicity. In addition, HU-211 was introduced into clinical trials for traumatic brain injury and the successful results of two phases of clinical trials in head injured patients are also shown. Drug Dev. Res. 50:211-215, 2000. (C) 2000 Wiley-Liss, Inc.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Pharm, Dept Med Chem, IL-91120 Jerusalem, Israel	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.						BARJOSEPH A, 1994, MOL CHEM NEUROPATHOL, V23, P125, DOI 10.1007/BF02815406; Bass R, 1996, J INFECT DIS, V173, P735, DOI 10.1093/infdis/173.3.735; BELAYEV L, 1995, BRAIN RES, V702, P266, DOI 10.1016/0006-8993(95)01127-9; BELAYEV L, 1995, MOL CHEM NEUROPATHOL, V25, P19, DOI 10.1007/BF02815084; BIEGON A, 1995, NEUROL RES, V17, P275, DOI 10.1080/01616412.1995.11740326; Brewster ME, 1997, INT J CLIN PHARM TH, V35, P361; DUVDEVANI R, 1990, RESTOR NEUROL NEUROS, V2, P31, DOI 10.3233/RNN-1990-2104; ESHHAR N, 1995, EUR J PHARMACOL, V283, P19, DOI 10.1016/0014-2999(95)00271-L; ESHHAR N, 1993, NEUROREPORT, V5, P237, DOI 10.1097/00001756-199312000-00013; FEIGENBAUM JJ, 1989, P NATL ACAD SCI USA, V86, P9584, DOI 10.1073/pnas.86.23.9584; Filbert MG, 1999, ANN NY ACAD SCI, V890, P505, DOI 10.1111/j.1749-6632.1999.tb08032.x; Gallily R, 1997, J PHARMACOL EXP THER, V283, P918; KNOLLER N, 1998, C NEUR SURG OCT 7 19; Leker RR, 1999, J NEUROL SCI, V162, P114, DOI 10.1016/S0022-510X(98)00301-3; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LITTLE PJ, 1989, PHARMACOL BIOCHEM BE, V32, P661, DOI 10.1016/0091-3057(89)90014-2; MECHOULAM R, 1990, TETRAHEDRON-ASYMMETR, V1, P315, DOI 10.1016/S0957-4166(00)86322-3; MECHOULAM R, 1988, EXPERIENTIA, V44, P762, DOI 10.1007/BF01959156; MEEHOULAM R, 1992, MARIJUANA CANNABINOI, P1; NADLER V, 1993, NEUROSCI LETT, V162, P43, DOI 10.1016/0304-3940(93)90555-Y; NADLER V, 1993, BRAIN RES, V622, P79, DOI 10.1016/0006-8993(93)90804-V; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; OMMAYA AK, 1994, INT J IMPACT ENG, V15, P535, DOI 10.1016/0734-743X(94)80033-6; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Striem S, 1997, EUR J PHARMACOL, V338, P205, DOI 10.1016/S0014-2999(97)81923-1; Sun AY, 1998, J BIOMED SCI, V5, P401; TRACEY KJ, 1991, CIRC SHOCK, V35, P123; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; Yoles E, 1996, J NEUROTRAUM, V13, P49, DOI 10.1089/neu.1996.13.49	34	25	27	0	4	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0272-4391			DRUG DEVELOP RES	Drug Dev. Res.	JUL-AUG	2000	50	3-4					211	215		10.1002/1098-2299(200007/08)50:3/4<211::AID-DDR3>3.0.CO;2-G			5	Chemistry, Medicinal; Pharmacology & Pharmacy	Pharmacology & Pharmacy	359TK	WOS:000089628000003					2021-06-18	
J	Shimizu, T; Hino, T; Komori, T; Hirai, S				Shimizu, T; Hino, T; Komori, T; Hirai, S			Loss of the muscle silent period evoked by transcranial magnetic stimulation of the motor cortex in patients with cervical cord lesions	NEUROSCIENCE LETTERS			English	Article						transcranial magnetic stimulation; cortical silent period; cervical cord lesion; cortical excitability; cortical reorganization; paired cortical stimulation	BRAIN-STIMULATION; INHIBITION; INJURY; HUMANS; ORIGIN	The silent period following motor evoked potentials in small hand muscles after transcranial magnetic stimulation (TMS) of the human motor cortex is considered to be cortical origin. The authors report three patients with cervical spinal cord lesions who showed loss of the cortical silent period (CSP) after TMS. One patient had traumatic cervical cord injury, and the other two patients had cervical spondylosis. All the patients had cervical cord compression on magnetic resonance imaging. TMS study showed loss of the CSP in both the hand and foot muscles in two patients and only in the foot muscle in one patient. Paired TMS study in one patient with pseudoathetotic hands showed reduced inhibition within the motor cortex. The hand weakness or interrupted sensory afferents might have caused motor cortical reorganization or hyperexcitability, leading to the loss of the CSP. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.	Tokyo Metropolitan Neurol Hosp, Dept Neurol, Tokyo 1830042, Japan	Shimizu, T (corresponding author), Tokyo Metropolitan Neurol Hosp, Dept Neurol, 2-6-1 Musashidai, Tokyo 1830042, Japan.						CANTELLO R, 1992, NEUROLOGY, V42, P1951; Davey NJ, 1998, J NEUROL NEUROSUR PS, V65, P80, DOI 10.1136/jnnp.65.1.80; Hess A, 1999, EXP BRAIN RES, V124, P321, DOI 10.1007/s002210050629; INGHILLERI M, 1993, J PHYSIOL-LONDON, V466, P521; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; LEVY WJ, 1990, BRAIN RES, V510, P130, DOI 10.1016/0006-8993(90)90738-W; ROICK H, 1993, EXP BRAIN RES, V94, P489, DOI 10.1007/BF00230207; Rossini PM, 1996, MUSCLE NERVE, V19, P1302; Schnitzler A, 1996, EXP BRAIN RES, V112, P381; SCHNITZLER A, 1994, NEUROSCI LETT, V180, P41, DOI 10.1016/0304-3940(94)90909-1; Shimizu T, 1999, BRAIN RES, V834, P74, DOI 10.1016/S0006-8993(99)01553-X; TOPKA H, 1991, NEUROLOGY, V41, P1276, DOI 10.1212/WNL.41.8.1276; TRIGGS WJ, 1992, ANN NEUROL, V32, P345, DOI 10.1002/ana.410320307; TRIGGS WJ, 1993, BRAIN RES, V628, P39, DOI 10.1016/0006-8993(93)90935-G; UGAWA Y, 1994, ELECTROEN CLIN NEURO, V93, P225, DOI 10.1016/0168-5597(94)90044-2	15	25	25	0	0	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	JUN 9	2000	286	3					199	202		10.1016/S0304-3940(00)01125-3			4	Neurosciences	Neurosciences & Neurology	321RX	WOS:000087469400012	10832019				2021-06-18	
J	Cascio, C; Guarneri, R; Russo, D; De Leo, G; Guarneri, M; Piccoli, F; Guarneri, P				Cascio, C; Guarneri, R; Russo, D; De Leo, G; Guarneri, M; Piccoli, F; Guarneri, P			Pregnenolone sulfate, a naturally occurring excitotoxin involved in delayed retinal cell death	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; pregnenolone sulfate; NMDA receptors; DNA fragmentation; superoxide dismutase; thiobarbituric acid-reactive substances; progesterone; dehydroepiandrosterone; dehydroepiandrosterone sulfate ester; 17 beta-estradiol	METHYL-D-ASPARTATE; TRAUMATIC BRAIN INJURY; AMYLOID BETA-PEPTIDE; RAT RETINA; HIPPOCAMPAL-NEURONS; LIPID-PEROXIDATION; NERVOUS-SYSTEM; NITRIC-OXIDE; SUPEROXIDE PRODUCTION; NEURAL APOPTOSIS	The present study was designed to investigate the neurosteroid pregnenolone sulfate (PS), known for its ability to modulate NMDA receptors and interfere with acute excitotoxicity, in delayed retinal cell death. Three hours after exposure of the isolated and intact retina to a 30-min PS pulse, DNA fragmentation as assessed by genomic DNA gel electrophoresis and a modified in situ terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling (TUNEL) method appeared concurrently with an increase in superoxide dismutase (SOD) activity and thiobarbituric acid-reactive substances (TBARS) levels. At 7 h, the increased amount of DNA laddering was accompanied by a higher number of TUNEL-positive cells in the inner nuclear and ganglion cell layers. Necrotic signs were characterized by DNA smear migration, lactate dehydrogenase (LDH) release, and damage mainly in the inner nuclear layer. PS-induced delayed cell death was markedly reduced by the NMDA receptor antagonists 4-(3-phosphonopropyl)-2-piperazinecarboxylic acid and 3 alpha-hydroxy-5 beta-pregnan-20-one sulfate but completely blocked after concomitant addition of the non-NMDA receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione. Steroids with antioxidant properties (progesterone, dehydroepiandrosterone and its sulfate ester, and 17 beta-estradiol) differently prevented PS-induced delayed cell death. Cycloheximide treatment protected against DNA fragmentation and LDH release but failed to prevent the rise in SOD activity and TBARS level. We conclude that a brief PS pulse causes delayed cell death in a slowly evolving apoptotic fashion characterized by a cycloheximide-sensitive death program downstream of reactive oxygen species generation and lipid peroxidation, turning into secondary necrosis in a retinal cell subset.	CNR, Ist Biol Sviluppo, I-90100 Palermo, Italy; CNR, Ist Metodol Diagnost Avanzata, Lab Elettromicroscopia, I-90100 Palermo, Italy; Univ Palermo, Dipartimento Biopatol & Metodol Biomed, Sez Biol & Genet, Palermo, Italy; Univ Palermo, Ist Neuropsichiat, Palermo, Italy; Univ Palermo, Fac Med & Chirurg, Palermo, Italy	Guarneri, P (corresponding author), CNR, Ist Biol Sviluppo, Via Ugo La Malfa 153, I-90100 Palermo, Italy.	pguarneri@ibs.pa.cnr.it	cascio, caterina/AAY-2588-2020; Patrizia, Guarneri/AAO-3595-2020	Patrizia, Guarneri/0000-0001-8288-5217; GUARNERI, Marco/0000-0002-0447-6861			Araghiniknam M, 1996, LIFE SCI, V59, pPL147, DOI 10.1016/0024-3205(96)00396-7; ARAGNO M, 1994, FREE RADICAL RES, V21, P427, DOI 10.3109/10715769409056595; Baulieu E.E., 1987, RECEPTOR RECEPTOR IN, P89; Baulieu EE, 1997, RECENT PROG HORM RES, V52, P1; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bindokas VP, 1996, J NEUROSCI, V16, P1324; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Bonne C, 1998, GEN PHARMACOL, V30, P275, DOI 10.1016/S0306-3623(97)00357-1; BOULTON M, 1991, PROG RETIN RES, V11, P125, DOI 10.1016/0278-4327(91)90027-Y; BRAUGHLER JM, 1986, J NEUROTRAUM, V9, P1; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Buege J A, 1978, Methods Enzymol, V52, P302; CHAN PH, 1990, ACT NEUR S, V51, P245; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; DAVID P, 1988, EXP EYE RES, V46, P657, DOI 10.1016/S0014-4835(88)80054-X; DREYER EB, 1995, NEUROREPORT, V6, P942, DOI 10.1097/00001756-199504190-00029; Duarte CB, 1998, GEN PHARMACOL-VASC S, V30, P289, DOI 10.1016/S0306-3623(97)00360-1; Dufort I, 1996, DNA CELL BIOL, V15, P481, DOI 10.1089/dna.1996.15.481; DUGAN LL, 1995, J NEUROSCI, V15, P6377; Fischer AJ, 1998, J COMP NEUROL, V393, P1; FLOOD JF, 1995, P NATL ACAD SCI USA, V92, P10806, DOI 10.1073/pnas.92.23.10806; Fujimura M, 1999, J NEUROSCI, V19, P3414; GEIER A, 1995, J CELL PHYSIOL, V163, P570, DOI 10.1002/jcp.1041630318; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Green PS, 1997, J STEROID BIOCHEM, V63, P229, DOI 10.1016/S0960-0760(97)00124-6; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; GUAMERI P, 1994, J NEUROCHEM, V63, P86; Guarneri P, 1998, EUR J NEUROSCI, V10, P1752, DOI 10.1046/j.1460-9568.1998.00191.x; GUARNERI P, 1995, BRAIN RES, V683, P65, DOI 10.1016/0006-8993(95)00343-O; Guarneri P, 1998, J NEUROSCI RES, V54, P787, DOI 10.1002/(SICI)1097-4547(19981215)54:6<787::AID-JNR6>3.0.CO;2-#; GWAG BJ, 1995, NEUROSCIENCE, V68, P615, DOI 10.1016/0306-4522(95)00232-8; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; IRWIN RP, 1994, J PHARMACOL EXP THER, V271, P677; Joo CK, 1999, INVEST OPHTH VIS SCI, V40, P713; Keller JN, 1998, J NEUROSCI, V18, P687; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Kristal BS, 1996, J BIOL CHEM, V271, P6033, DOI 10.1074/jbc.271.11.6033; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; Lam TT, 1999, INVEST OPHTH VIS SCI, V40, P2391; Leist M, 1997, MOL MED, V3, P750, DOI 10.1007/BF03401713; LI PK, 1995, COGNITIVE BRAIN RES, V2, P251, DOI 10.1016/0926-6410(95)90016-0; Lipton SA, 1998, NEUROSCIENTIST, V4, P345, DOI 10.1177/107385849800400516; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Lu YM, 1996, J NEUROSCI, V16, P5457; MAIONE S, 1992, EUR J PHARMACOL, V219, P477, DOI 10.1016/0014-2999(92)90493-N; MAJEWSKA MD, 1992, PROG NEUROBIOL, V38, P379, DOI 10.1016/0301-0082(92)90025-A; MANEV H, 1989, MOL PHARMACOL, V36, P106; Mark RJ, 1997, J NEUROCHEM, V68, P255; MATHIS C, 1994, PSYCHOPHARMACOLOGY, V116, P201, DOI 10.1007/BF02245063; Mattson MP, 1998, TRENDS NEUROSCI, V21, P53, DOI 10.1016/S0166-2236(97)01188-0; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; Maurice T, 1997, EUR J PHARMACOL, V328, P9, DOI 10.1016/S0014-2999(97)83020-8; Maurice T, 1997, BEHAV BRAIN RES, V83, P159, DOI 10.1016/S0166-4328(97)86061-5; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; Morrison RS, 1998, MENT RETARD DEV D R, V4, P157; MOSINGER JL, 1989, EXP NEUROL, V105, P110, DOI 10.1016/0014-4886(89)90178-7; Nicotera P, 1999, TRENDS PHARMACOL SCI, V20, P46, DOI 10.1016/S0165-6147(99)01304-8; OSTEEN WK, 1977, EXP EYE RES, V25, P361, DOI 10.1016/0014-4835(77)90103-8; Pang Z, 1997, J NEUROSCI, V17, P3064; PAOLETTI F, 1990, METHOD ENZYMOL, V186, P209; Park-Chung M, 1997, MOL PHARMACOL, V52, P1113; PARKCHUNG MJ, 1994, MOL PHARMACOL, V46, P146; Patel M, 1996, NEURON, V16, P345, DOI 10.1016/S0896-6273(00)80052-5; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; REGO AC, 1995, ARCH BIOCHEM BIOPHYS, V321, P127, DOI 10.1006/abbi.1995.1377; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; RINK A, 1995, AM J PATHOL, V147, P1575; Rosenbaum DM, 1998, INVEST OPHTH VIS SCI, V39, P2132; Rosenbaum PS, 1997, CLIN NEUROSCI, V4, P224; Sapolsky, 1996, Stress, V1, P1, DOI 10.3109/10253899609001092; Singer CA, 1996, NEUROSCI LETT, V212, P13, DOI 10.1016/0304-3940(96)12760-9; Vallee M, 1997, P NATL ACAD SCI USA, V94, P14865, DOI 10.1073/pnas.94.26.14865; Weaver CE, 1997, P NATL ACAD SCI USA, V94, P10450, DOI 10.1073/pnas.94.19.10450; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; WROBLEWSKI F, 1955, P SOC EXP BIOL MED, V90, P210; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YOON YH, 1989, ARCH OPHTHALMOL-CHIC, V107, P409, DOI 10.1001/archopht.1989.01070010419037; Zeevalk GD, 1996, J PHARMACOL EXP THER, V279, P332	80	25	25	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUN	2000	74	6					2380	2391		10.1046/j.1471-4159.2000.0742380.x			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	312XG	WOS:000086968800018	10820199				2021-06-18	
J	Frietsch, T; Krafft, P; Piepgras, A; Lenz, C; Kuschinsky, W; Waschke, KF				Frietsch, T; Krafft, P; Piepgras, A; Lenz, C; Kuschinsky, W; Waschke, KF			Relationship between local cerebral blood flow and metabolism during mild and moderate hypothermia in rats	ANESTHESIOLOGY			English	Article						autoradiography; coupling; local cerebral glucose utilization; neuroprotection; pH management; pH-stat	TRAUMATIC BRAIN INJURY; ACID-BASE MANAGEMENT; GLUCOSE-UTILIZATION; CARDIOPULMONARY BYPASS; HIPPOCAMPAL GLUTAMATE; CARBON-DIOXIDE; ALPHA-STAT; PH-STAT; ISCHEMIA; ISOFLURANE	Background: Hypothermia may interfere with the relationship between cerebral blood now (CBF) and metabolism. Because this conclusion was based on the analysis of global values. the question remains whether hypothermic CBF/metabolism uncoupling exists on a local cerebral level. This study investigated the effects of hypothermic anesthesia on local cerebral blood now (LCBF) and local cerebral glucose utilization (LCGU). Methods: Thirty-six rats were anesthetized with isoflurane (1 minimum alveolar concentration) and artificially ventilated to maintain normal arterial carbon dioxide partial pressure (pH-stat). Pericranial temperature was maintained as normothermic (37.5 degrees C, n = 12) or was reduced to 35 degrees C (n = 12) or 32 degrees C (n = 12), Pericranial temperature was maintained constant for 60 min until LCBF or LCGU were measured by autoradiography. Twelve conscious rats served as normothermic controls. Results: Compared with conscious animals, mean CBI: remained unchanged during normothermic anesthesia. Mean CBI: significantly increased during mild hypothermia but was unchanged during moderate hypothermia. During normothermic anesthesia, mean CGU was 45% lower than in conscious controls (P < 0.05), No further CGU reduction was found during mild hypothermia, whereas CGU further decreased during moderate hypothermia (48%; P < 0.05), Local analysis showed a Linear LCBF/LCGU relationship in conscious (r = 0.94) and anesthetized (r = 0.94) normothermic animals, as well as in both hypothermic groups (35 degrees C: r = 0.92; 32 degrees C: r = 0.95; P < 0.05), The LCBF-to-LCGU ratio increased from 1.4 (conscious controls) to 2.4 (normothermic isoflurane) and 3.6 ml/mu mol (mild and moderate hypothermia, P < 0.05), Conclusions: Decrease of mean CGU at unchanged or increased mean CBF during hypothermic anesthesia may not indicate uncoupling. Local analysis shows a maintained linear relationship that is reset to a higher CHF/CGU ratio.	Fac Clin Med Mannheim, Dept Anesthesiol, D-68167 Mannheim, Germany; Fac Clin Med Mannheim, Dept Crit Care Med, D-68167 Mannheim, Germany; Fac Clin Med Mannheim, Dept Neurosurg, D-68167 Mannheim, Germany; Univ Heidelberg, Dept Physiol, Heidelberg, Germany	Waschke, KF (corresponding author), Fac Clin Med Mannheim, Dept Anesthesiol & Crit Care Med, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.						Bacher A, 1998, ANESTHESIOLOGY, V88, P403, DOI 10.1097/00000542-199802000-00019; Brian JE, 1998, ANESTHESIOLOGY, V88, P1365, DOI 10.1097/00000542-199805000-00029; BUSIJA DW, 1987, AM J PHYSIOL, V253, pH869; CALLAGHAN P, 1961, ANN SURG, V154, P903; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Conroy BP, 1998, ANESTHESIOLOGY, V88, P390, DOI 10.1097/00000542-199802000-00018; FORD I, 1991, J CEREBR BLOOD F MET, V11, pA89, DOI 10.1038/jcbfm.1991.43; FRERICHS KU, 1994, J CEREBR BLOOD F MET, V14, P193, DOI 10.1038/jcbfm.1994.26; Gunn AJ, 1997, J CLIN INVEST, V99, P248, DOI 10.1172/JCI119153; HARTUNG J, 1994, J NEUROSURG ANESTH, V6, P1; Hindman BJ, 1998, ANESTHESIOLOGY, V89, P5, DOI 10.1097/00000542-199807000-00004; HINDMAN BJ, 1993, ANESTHESIOLOGY, V79, P580, DOI 10.1097/00000542-199309000-00023; Hoffman WE, 1996, NEUROL RES, V18, P185; ILLIEVICH UM, 1994, ANESTHESIOLOGY, V80, P177, DOI 10.1097/00000542-199401000-00025; ILLIEVICH UM, 1994, ANESTH ANALG, V78, P905; Klementavicius R, 1996, J NEUROSURG, V85, P482, DOI 10.3171/jns.1996.85.3.0482; Kurth CD, 1998, ANESTHESIOLOGY, V89, P110, DOI 10.1097/00000542-199807000-00018; Lenz C, 1998, ANESTHESIOLOGY, V89, P1480, DOI 10.1097/00000542-199812000-00026; MAEKAWA T, 1986, ANESTHESIOLOGY, V65, P144, DOI 10.1097/00000542-198608000-00003; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MCCULLOCH J, 1982, J NEUROCHEM, V39, P255, DOI 10.1111/j.1471-4159.1982.tb04729.x; MCCULLOCH J, 1982, J CEREBR BLOOD F MET, V2, P487, DOI 10.1038/jcbfm.1982.56; MURKIN JM, 1987, ANESTH ANALG, V66, P825; NAKASHIMA K, 1995, ANESTHESIOLOGY, V82, P1199, DOI 10.1097/00000542-199505000-00015; Niwa K, 1998, BRAIN RES, V789, P68, DOI 10.1016/S0006-8993(98)00013-4; PALMER C, 1989, ANESTHESIOLOGY, V71, P730, DOI 10.1097/00000542-198911000-00017; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59; SANO T, 1992, ANESTHESIOLOGY, V76, P221, DOI 10.1097/00000542-199202000-00011; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; STEPHAN H, 1992, BRIT J ANAESTH, V69, P51, DOI 10.1093/bja/69.1.51; Thoresen M, 1997, NEUROREPORT, V8, P3359, DOI 10.1097/00001756-199710200-00033; VERHAEGEN MJJ, 1993, STROKE, V24, P407, DOI 10.1161/01.STR.24.3.407; VITEZ TS, 1974, ANESTHESIOLOGY, V41, P80, DOI 10.1097/00000542-197407000-00020; WASCHKE K, 1993, AM J PHYSIOL, V265, pH1243	36	25	32	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	MAR	2000	92	3					754	763		10.1097/00000542-200003000-00019			10	Anesthesiology	Anesthesiology	289NL	WOS:000085628800017	10719954				2021-06-18	
J	Connolly, B; Turner, C; DeVine, J; Gerlinger, T				Connolly, B; Turner, C; DeVine, J; Gerlinger, T			Jefferson fracture resulting in Collet-Sicard syndrome	SPINE			English	Article						cranial nerve palsy; Collet-Sicard syndrome; Jefferson fracture	CLOSED-HEAD-INJURY; ATLAS	Study Design. A case report and review of the literature. Objective. To increase awareness of and add to the spectrum of injury that can result from Jefferson fractures, to suggest a possible mechanism of injury, and to give a brief review of pertinent facts regarding C1 burst fractures and the Collet-Sicard Syndrome. Summary of Background Data. To the author's knowledge, this is the first reported case of a Jefferson fracture resulting in Collet-Sicard Syndrome. It represents only the second reported case of cranial nerve palsy caused by Jefferson fracture. Methods. A 56-year-old man sustained a C1 burst fracture in a rollover motor vehicle accident. Repeated neurologic examinations over the ensuing days revealed lesions of cranial nerves IX, X, XI, and XII on the left side. Results. Two weeks of traction, 10 weeks in a halo vest, and 2 weeks in a cervical collar resulted in adequate fracture healing and almost complete resolution of the patient's neurologic symptoms; Conclusion. Although this is the first reported case of Collet-Sicard Syndrome caused by Jefferson fracture, the authors' review of the literature suggests that cranial nerve injuries may go unrecognized in some patients with C1 burst fractures. The importance of a thorough neurologic examination, including examination of the cranial nerves, in all cases of cervical spine injury cannot be overemphasized.	Madigan Army Med Ctr, Dept Orthoped Surg, Tacoma, WA 98431 USA; Madigan Army Med Ctr, Dept Gen Surg, Tacoma, WA 98431 USA	Connolly, B (corresponding author), Madigan Army Med Ctr, Dept Orthoped Surg, Tacoma, WA 98431 USA.						Collet FJ, 1915, LYON MED, V124, P121; FERNER H, 1980, PERSKPOF ATLAS TOPOG, P126; FIELDING JW, 1974, J BONE JOINT SURG AM, VA 56, P1683, DOI 10.2106/00004623-197456080-00019; FOWLER JL, 1990, J SPINAL DISORD, V3, P19; FRYMOYER JW, 1997, ADULT SPINE, P1090; HADLEY MN, 1988, NEUROSURGERY, V23, P31, DOI 10.1227/00006123-198807000-00007; HAN SY, 1976, J NEUROSURG, V44, P368, DOI 10.3171/jns.1976.44.3.0368; HASHIMOTO T, 1988, NEUROSURGERY, V23, P367, DOI 10.1227/00006123-198809000-00015; HAVELIUS U, 1982, J NEUROSURG, V56, P850, DOI 10.3171/jns.1982.56.6.0850; Jefferson G, 1920, BRIT J SURG, V7, P407; JUNIOS JL, 1987, BRAIN, V110, P197; Larson WL, 1997, MUSCLE NERVE, V20, P1173, DOI 10.1002/(SICI)1097-4598(199709)20:9<1173::AID-MUS13>3.0.CO;2-U; LEVINE AM, 1986, ORTHOP CLIN N AM, V17, P31; LIPSON SJ, 1977, J BONE JOINT SURG AM, V59, P940, DOI 10.2106/00004623-197759070-00018; MOHANTY SK, 1973, J NEUROSURG, V38, P86, DOI 10.3171/jns.1973.38.1.0086; PACHNER AR, 1985, NEUROLOGY, V35, P47, DOI 10.1212/WNL.35.1.47; ROTHMAN RH, 1982, SPINE, P613; Ruiz J, 1995, Neurologia, V10, P391; SCHLICKE LH, 1981, CLIN ORTHOP RELAT R, P18; SHARMA BS, 1994, CLIN NEUROL NEUROSUR, V96, P197, DOI 10.1016/0303-8467(94)90063-9; SHERK HH, 1970, J BONE JOINT SURG AM, VA 52, P1017, DOI 10.2106/00004623-197052050-00016; Sicard J, 1917, MARSEILLE MED, V53, P383; Silvestrini M, 1991, Riv Neurol, V61, P135; SPENCE KF, 1970, J BONE JOINT SURG AM, VA 52, P543, DOI 10.2106/00004623-197052030-00013; Tappin JA, 1996, J NEUROL NEUROSUR PS, V60, P14, DOI 10.1136/jnnp.60.1.14; VERNET M, 1918, J LARYNGOL OTOL, V33, P354; WANI MA, 1991, J TRAUMA, V31, P1437, DOI 10.1097/00005373-199110000-00025; ZIELINSKI CJ, 1982, J BONE JOINT SURG AM, V63, P1382	28	25	29	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0362-2436			SPINE	SPINE	FEB 1	2000	25	3					395	398		10.1097/00007632-200002010-00023			4	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	283KQ	WOS:000085275100026	10703116				2021-06-18	
J	Furukawa, Y; Okada, M; Akaike, N; Hayashi, T; Nabekura, J				Furukawa, Y; Okada, M; Akaike, N; Hayashi, T; Nabekura, J			Reduction of voltage-dependent magnesium block of N-methyl-D-aspartate receptor-mediated current by in vivo axonal injury	NEUROSCIENCE			English	Article						in vivo; axonal injury; NMDA; voltage-dependent Mg2+ block; motoneuron; time-course	PROTEIN-KINASE-C; NMDA-RECEPTOR; SENSORY NEURONS; GLUTAMATE NEUROTOXICITY; COLCHICINE APPLICATION; APLYSIA NEURONS; BRAIN INJURY; CELL-CULTURE; MG2+ BLOCK; SUBUNIT	The post-traumatic change of the voltage-dependent Mg2+ block of N-methyl-D-aspartate response was investigated using nystatin perforated patch recording mode under the voltage-clamp condition. Motor neurons of the dorsal motor nucleus of vagus nerve were freshly dissociated from rat brain at 2 h to 10 days after receiving axonal crush injuries in vivo at the neck. The reduction of voltage-dependent Mg2+ block of N-methyl-D-aspartate response became evident at more than 12 h after the injury, sustained for at least five days and recovered within 10 days. Other characteristics examined such as reversal potentials, the Hill coefficient and EC50 of N-methyl-D-aspartate-induced current were not affected by axonal injury. The Mg2+ block of N-methyl-D-aspartate response was not affected at all by local application of colchicine onto the vagal axon in in vivo condition, suggesting that axonal injury, but not the blockade of the axonal flow, is responsible for the change of the sensitivity of N-methyl-D-aspartate response to extracellular Mg2+. In addition, the reduction of Mg2+ block by the nerve injury persisted regardless of the presence of protein kinase C modulators, such as 10(-6) M chelerythrine and 10(-7) M calphostin C, Therefore alteration of protein kinase C activity after axonal injury is not responsible for the maintenance of the reduced Mg2+ block. These findings suggest that injured neurons acquire immature characteristics of plasticity with respect to the sensitivity of N-methyl-D-aspartate receptors to extracellular Mg2+ or a long-term increase in the susceptibility to Ca2+ excitotoxicity. (C) 2000 IBRO. Published by Elsevier Science Ltd.	Kyushu Univ, Grad Sch Med Sci, Dept Cellular & Syst Physiol, Fukuoka 8128582, Japan; Univ Tokyo, Fac Med, Brain Res Inst, Dept Neurophysiol, Tokyo 1130033, Japan; St Marys Hosp, Dept Neurosurg, Fukuoka 8308543, Japan	Nabekura, J (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Cellular & Syst Physiol, Fukuoka 8128582, Japan.		Okada, Masayoshi/ABE-9020-2020	Okada, Masayoshi/0000-0001-8515-7143			AKAIKE N, 1994, JPN J PHYSIOL, V44, P433, DOI 10.2170/jjphysiol.44.433; AMBRON RT, 1995, J NEUROSCI, V15, P3440; Ambron RT, 1996, J NEUROSCI, V16, P7469; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; Burne JF, 1997, NEURON, V18, P223, DOI 10.1016/S0896-6273(00)80263-9; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; GUNSTREAM JD, 1995, J NEUROSCI, V15, P439; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; ISHII T, 1993, J BIOL CHEM, V268, P2836; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kuner T, 1996, J NEUROSCI, V16, P3549; Levey MS, 1996, J NEUROSCI, V16, P6878; LUSTIG HS, 1992, NEUROSCI LETT, V143, P229, DOI 10.1016/0304-3940(92)90271-8; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MURPHY TH, 1994, J NEUROSCI, V14, P1320; Nabekura J, 1996, J NEUROPHYSIOL, V76, P2455; NABEKURA J, 1994, BRAIN RES, V648, P152, DOI 10.1016/0006-8993(94)91915-1; PIEHL F, 1995, EUR J NEUROSCI, V7, P2101, DOI 10.1111/j.1460-9568.1995.tb00632.x; PILAR G, 1972, SCIENCE, V177, P1116, DOI 10.1126/science.177.4054.1116; REGAN RF, 1991, NEUROSCIENCE, V43, P585, DOI 10.1016/0306-4522(91)90317-H; Rosenberg M, 1997, J NEUROSCI, V17, P6629; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; SIMAN R, 1989, J NEUROSCI, V9, P1579; Tandon A, 1996, J NEUROCHEM, V66, P1033; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121; WAXMAN SG, 1994, J NEUROPHYSIOL, V72, P466; WU W, 1993, DEV BIOL, V158, P456, DOI 10.1006/dbio.1993.1203; Xu TL, 1996, J PHYSIOL-LONDON, V496, P491, DOI 10.1113/jphysiol.1996.sp021701; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; Yu XM, 1998, NATURE, V396, P469; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	42	25	26	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2000	96	2					385	392		10.1016/S0306-4522(99)00553-9			8	Neurosciences	Neurosciences & Neurology	289JT	WOS:000085618000015	10683578				2021-06-18	
J	Rothoerl, RD; Brawanski, A; Woertgen, C				Rothoerl, RD; Brawanski, A; Woertgen, C			S-100B protein serum levels after controlled cortical impact injury in the rat	ACTA NEUROCHIRURGICA			English	Article						S-100B; traumatic brain injury; rat		S-100B is described to provide information about the severity of brain damage in man. Estimation of serum markers appears to be an easy method of obtaining information regarding severity and outcome after head injury. However less is known about the post traumatic time course of this protein in the serum. The aim of this study was to provide further information about the posttraumatic enzymekinetik. 65 male Wistar rats were subjected to severe cortical impact injury (100 PSI, 2 mm deformation). Blood samples were drawn directly after trauma, then after 1 h, 6 h, 12 h, 24 h, and 48 h. In sham operated animals blood samples were drawn directly after craniotomy, then after 6 h and after 48 h. Also compared were S-100B serum levels at different severities in 20 rats (45 PSI, 75 PSI; 2 mm deformity) after controlled cortical impact to sham operated animals. S-100B serum levels were estimated with a commercially available enzyme immune-assay (DAKO(R)). The mean serum level in the sham group was 0,38 mu g/l. Serum levels at 100 PSI differed statistically significantly directly after trauma up to 24 h. The 48 h S-100B levels showed no significant difference in the sham group. Serum levels at different severities differed significantly from the sham group, but did not differ concerning level of severity. The controlled cortical impact model is able to produce a raised serum level of the S-100B protein for 24 hours. Different trauma severities were not reflected.	Univ Regensburg, Dept Neurosurg, D-93053 Regensburg, Germany	Rothoerl, RD (corresponding author), Univ Regensburg, Dept Neurosurg, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.						Abraha HD, 1997, ANN CLIN BIOCHEM, V34, P546, DOI 10.1177/000456329703400510; Astudillo R, 1996, Eur J Cardiothorac Surg, V10, P1107, DOI 10.1016/S1010-7940(96)80358-7; Blomquist S, 1997, J CARDIOTHOR VASC AN, V11, P699, DOI 10.1016/S1053-0770(97)90160-9; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DIXON CE, 1997, NEUROTRAUMA; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; HARDEMARK HG, 1989, ACTA NEUROCHIR, V99, P135, DOI 10.1007/BF01402322; HARDEMARK HG, 1989, J NEUROSURG, V71, P727, DOI 10.3171/jns.1989.71.5.0727; HIDAKA H, 1983, J BIOL CHEM, V258, P2705; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; ISOBE T, 1984, J NEUROCHEM, V43, P1494, DOI 10.1111/j.1471-4159.1984.tb05415.x; Johnsson P, 1995, J CARDIOTHOR VASC AN, V9, P694, DOI 10.1016/S1053-0770(05)80231-9; Johnsson P, 1996, J CARDIOTHOR VASC AN, V10, P120, DOI 10.1016/S1053-0770(96)80187-X; KATO K, 1985, BIOCHIM BIOPHYS ACTA, V842, P146, DOI 10.1016/0304-4165(85)90196-5; Kim JS, 1996, STROKE, V27, P1553, DOI 10.1161/01.STR.27.9.1553; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MARSHALL LF, 1991, J NEUROSURG, V75, pS15; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Rothoerl RD, 1999, BRAIN INJURY, V13, P387; SEMBA R, 1987, BRAIN RES, V401, P9, DOI 10.1016/0006-8993(87)91156-5; STEFANSSON K, 1982, AM J PATHOL, V106, P261; STEFANSSON K, 1982, NATURE, V295, P63, DOI 10.1038/295063a0; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	31	25	29	0	1	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		2000	142	2					199	203		10.1007/s007010050024			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	288UP	WOS:000085583100022	10795895				2021-06-18	
J	Westergren, H; Farooque, M; Olsson, Y; Holtz, A				Westergren, H; Farooque, M; Olsson, Y; Holtz, A			Motor function changes in the rat following severe spinal cord injury - Does treatment with moderate systemic hypothermia improve functional outcome?	ACTA NEUROCHIRURGICA			English	Article						hypothermia; rat; spinal cord injury; treatment	TRAUMATIC BRAIN INJURY; COMPRESSION INJURY; NEUROLOGICAL RECOVERY; BEHAVIORAL DEFICITS; CORTICAL IMPACT; TEMPERATURE; PROTECTION; IMMUNOHISTOCHEMISTRY; MANAGEMENT; CONTUSION	Systemic hypothermia exerts neuroprotective effects following trauma and ischemia caused by vascular occlusion in the brain. In the spinal cord similar effects have been demonstrated following ischemia after aortic occlusion. We have previously presented protective effects on several morphological parameters in the early period after the injury, using an established spinal cord compression injury model and systemic hypothermia. In the present study we have evaluated the effects on motor function following severe spinal cord compression trauma and treatment with moderate systemic hypothermia. Thirty Sprague Dawley rats were randomized into three groups: In group 1 (n = 4), the animals underwent a hypothermic procedure, including a 2 h hypothermic period with a body temperature of 30 degrees C, following the initial laminectomy. In group 2 (n = 12) a 50 g compression was applied to the spinal cords for 5 min, after which the animals were kept under normothermic anesthesia for 3 h. In group 3 (n = 14), the animals underwent the same trauma procedure as in group 2 and the same hypothermic procedure as in group 1. The animals were allowed to survive for 14 days, during which the motor function was recorded. This degree of trauma results in a non-reversible paraplegia, and the addition of systemic hypothermia as described above did not alter the neurological recovery as measured by two different methods of recording the motor function up to two weeks after injury. All animals survived in group 1. However, the mortality rates in group 2 were 25% and in group 3, 50%, respectively, which mirrors the severity of the trauma. The application of systemic hypothermia and the lack of experimental therapeutic success highlight the difficulties of transferring experimental beneficial neuroprotective effects to a clinically useful treatment method. In this experimental set-up the effects of the severe primary injury may overshadow the effects of the secondary injury mechanisms, which limits the therapeutic possibilities of systemic hypothermic treatment.	Univ Uppsala Hosp, Dept Neurosurg, Neurosurg Sect, S-75185 Uppsala, Sweden; Univ Uppsala Hosp, Res Grp Neuropathol, S-75185 Uppsala, Sweden; Uppsala Univ, Dept Genet & Pathol, Uppsala, Sweden	Westergren, H (corresponding author), Univ Uppsala Hosp, Dept Neurosurg, Neurosurg Sect, S-75185 Uppsala, Sweden.			Westergren, Hans/0000-0002-4052-9692			ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; BERNTMAN L, 1981, ANESTHESIOLOGY, V55, P495, DOI 10.1097/00000542-198111000-00003; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; Farooque M, 1999, ACTA NEUROPATHOL, V98, P22, DOI 10.1007/s004010051047; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; GUTTMANN L, 1973, SPINAL CORD INJURIES, P135; HANSEBOUT RR, 1992, SPINAL CORD DYSFUNCT, P59; HOLTZ A, 1989, SURG NEUROL, V31, P350, DOI 10.1016/0090-3019(89)90066-9; Holtz Anders, 1995, Upsala Journal of Medical Sciences, V100, P93; LEVI R, 1996, THESIS KAROLINSKA I; LI GL, 1995, J NEUROTRAUM, V12, P269, DOI 10.1089/neu.1995.12.269; LI GL, 1997, SPINAL CORD COMPRESS, P683; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARTINEZARIZALA A, 1992, J NEUROTRAUM, V9, pS497; MAUNEY MC, 1995, ANN THORAC SURG, V59, P245, DOI 10.1016/0003-4975(94)00815-O; NYSTROM B, 1988, ACTA NEUROL SCAND, V78, P467, DOI 10.1111/j.1600-0404.1988.tb03689.x; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; SALZMAN S, 1994, NEUROBIOLOGY CENTRAL, P123; TATOR C, 1999, NEUROSURG FOCUS, V6, P1; TATOR CH, 1995, PARAPLEGIA, V33, P254, DOI 10.1038/sc.1995.58; Tator CH, 1998, NEUROSURGERY, V42, P696, DOI 10.1097/00006123-199804000-00007; TATOR CH, 1973, J NEUROSURG, V39, P52, DOI 10.3171/jns.1973.39.1.0052; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; TATOR CH, 1979, NEURAL TRAUMA, P363; TOSCANO J, 1988, PARAPLEGIA, V26, P143, DOI 10.1038/sc.1988.23; Westergren H, 1999, SPINAL CORD, V37, P696, DOI 10.1038/sj.sc.3100920; Westergren H, 1998, J NEUROTRAUM, V15, P943, DOI 10.1089/neu.1998.15.943; Yu WR, 1999, ACTA NEUROPATHOL, V98, P15, DOI 10.1007/s004010051046; Yu WR, 1999, NEUROPATHOLOGY, V19, P172, DOI 10.1046/j.1440-1789.1999.00227.x	37	25	26	0	2	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		2000	142	5					567	573		10.1007/s007010050471			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	338YV	WOS:000088451600020	10898365				2021-06-18	
J	Olby, NJ; Sharp, NJH; Munana, KR; Papich, MG				Olby, NJ; Sharp, NJH; Munana, KR; Papich, MG			Chronic and acute compressive spinal cord lesions in dogs due to intervertebral disc herniation are associated with elevation in lumbar cerebrospinal fluid glutamate concentration	JOURNAL OF NEUROTRAUMA			English	Article						cerebrospinal fluid; dog; excitotoxicity; glutamate; spinal-cord compression; spinal cord injury	EXCITATORY AMINO-ACIDS; TRAUMATIC BRAIN INJURY; BLOOD-FLOW; LIQUID-CHROMATOGRAPHY; CSF GLUTAMATE; CELL-CULTURE; RELEASE; DISEASE; RAT; MICRODIALYSIS	Acute injury to the central nervous system initiates a series of biochemical events that cause secondary tissue damage. The accumulation of excessive concentrations of glutamate in the extracellular space causes excitotoxic damage, and is incriminated as a mediator of this secondary tissue damage, The aim of this study was to measure the concentration of glutamate in cerebrospinal fluid (CSF) obtained from the cerebellomedullary cistern and lumbar subarachnoid space in dogs with acute and chronic compressive injuries of the cervical and thoracolumbar spinal cord, and to correlate the glutamate concentration with injury severity. The results demonstrate that focal injuries of the spinal cord do not affect the glutamate concentration in CSF taken from the cerebellomedullary cistern, However, dogs with severe, acute thoracolumbar disc herniations have two- to 10-fold increases in glutamate concentration in their lumbar CSF at intervals of >12 h after injury, Moreover, the severity of their clinical signs is directly related to the glutamate concentration. Dogs with chronic compressive thoracolumbar lesions have a two-fold elevation of CSF glutamate concentration, suggesting that excitotoxicity may also be a component of chronic spinal cord compression.	N Carolina State Univ, Coll Vet Med, Dept Compan Anim & Special Species, Raleigh, NC 27606 USA; N Carolina State Univ, Coll Vet Med, Dept Anat Physiol Sci & Radiol, Raleigh, NC 27606 USA	Olby, NJ (corresponding author), N Carolina State Univ, Coll Vet Med, Dept Compan Anim & Special Species, 4700 Hillsborough St, Raleigh, NC 27606 USA.			Olby, Natasha/0000-0003-1349-3484; Munana, Karen/0000-0001-9592-6276; Papich, Mark/0000-0002-7591-7898			AUER RN, 1988, ANN NEUROL, V24, P699, DOI 10.1002/ana.410240602; BAILEY CS, 1985, AM J VET RES, V46, P1162; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BONDOLI A, 1981, RESUSCITATION, V9, P119, DOI 10.1016/0300-9572(81)90021-6; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; BUCHAN AM, 1992, BRAIN RES, V574, P171, DOI 10.1016/0006-8993(92)90814-P; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BUNGE RP, 1993, ADV NEUROL, V59, P75; CHAMBERLAIN MC, 1995, J NEURO-ONCOL, V25, P135, DOI 10.1007/BF01057757; CHOI DW, 1987, J NEUROSCI, V7, P357; Davson H., 1967, PHYSL CEREBROSPINAL; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faden AI, 1988, J NEUROTRAUM, V5, P33, DOI 10.1089/neu.1988.5.33; Farooque M, 1996, J NEUROTRAUM, V13, P537, DOI 10.1089/neu.1996.13.537; FERNSTROM MH, 1981, LIFE SCI, V29, P2119, DOI 10.1016/0024-3205(81)90669-X; Fillenz M, 1995, BEHAV BRAIN RES, V71, P51, DOI 10.1016/0166-4328(95)00045-3; GRIFFITHS IR, 1978, NEUROLOGY, V28, P1145, DOI 10.1212/WNL.28.11.1145; HANSEN H J, 1952, Acta Orthop Scand Suppl, V11, P1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; Matsumoto K, 1996, J CEREBR BLOOD F MET, V16, P114, DOI 10.1097/00004647-199601000-00014; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; OLBY NJ, 1994, J SMALL ANIM PRACT, V35, P345, DOI 10.1111/j.1748-5827.1994.tb01713.x; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; PENCALET P, 1993, J NEUROSURG, V78, P603, DOI 10.3171/jns.1993.78.4.0603; Podell M, 1997, AM J VET RES, V58, P451; ROSENBERG PA, 1992, J NEUROSCI, V12, P56; SARWAR G, 1988, J ASSOC OFF ANA CHEM, V71, P1172; SHAW PJ, 1995, NEURODEGENERATION, V4, P209, DOI 10.1006/neur.1995.0026; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; Spranger M, 1996, ARCH NEUROL-CHICAGO, V53, P992, DOI 10.1001/archneur.1996.00550100066016; SUGIYAMA K, 1989, NEUROSCIENCE, V32, P779, DOI 10.1016/0306-4522(89)90298-4; THOMSON CE, 1990, J AM VET MED ASSOC, V196, P1841; THOMSON CE, 1989, J SMALL ANIM PRACT, V30, P685, DOI 10.1111/j.1748-5827.1989.tb01917.x; Wheeler S.J., 1994, SMALL ANIMAL SPINAL; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; Yamamoto K, 1998, NEUROREPORT, V9, P1655, DOI 10.1097/00001756-199805110-00072	41	25	27	0	5	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	1999	16	12					1215	1224		10.1089/neu.1999.16.1215			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	266WC	WOS:000084322400008	10619199				2021-06-18	
J	Zwienenberg, M; Gong, QZ; Lee, LL; Berman, RF; Lyeth, BG				Zwienenberg, M; Gong, QZ; Lee, LL; Berman, RF; Lyeth, BG			ICP monitoring in the rat: Comparison of monitoring in the ventricle, brain parenchyma, and cisterna magna	JOURNAL OF NEUROTRAUMA			English	Article						intracranial pressure monitoring; rat; subdural hematoma	INTRACRANIAL-PRESSURE; LESIONS	Various methods of continuous intracranial pressure (ICP) monitoring during experimental procedures in the rat have been described. However, no systematic comparison of ICP monitoring in the ventricle, brain parenchyma, and cisterna magna has been reported. Since accurate and reliable ICP measurements are important in experimental models of traumatic brain injury, the present study was conducted to compare simultaneous ICP measurements from ventricular, cisterna magna, and intraparenchymal monitors during ICP changes, Subdural hematoma was produced by infusion of 0.3 ml of autologous blood into the subdural space over 6 min, The ventricular and the intraparenchymal fiberoptic catheter produced reliable and comparable pressure recordings, that did not statistically differ (p = 0.4), throughout the one hour monitoring time, In contrast, the cisterna magna catheter was less reliable and produced significantly lower readings throughout the monitoring time (p < 0.001). The intraparenchymal device produced greater cortical damage than the ventricular catheter, In conclusion, ventricular LCP monitoring is the preferred method under these circumstances, since it is accurate and induces least brain damage.	Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA	Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, 1 Shields Ave, Davis, CA 95616 USA.			Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029995] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS-29995] Funding Source: Medline		ANDREWS B T, 1988, Neurological Research, V10, P123; BARTH KNM, 1992, NEUROSURGERY, V30, P138, DOI 10.1227/00006123-199201000-00028; BRAKKEE JH, 1979, LAB ANIM SCI, V29, P78; BULLOCK R, 1990, ACT NEUR S, V51, P274; CRUTCHFIELD JS, 1990, J NEUROSURG, V72, P482, DOI 10.3171/jns.1990.72.3.0482; GAMBARDELLA G, 1992, NEUROSURGERY, V31, P918, DOI 10.1227/00006123-199211000-00014; Giulioni M, 1986, J Neurosurg Sci, V30, P177; Kanter M J, 1991, Neurosurg Clin N Am, V2, P257; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; MANDELL EC, 1980, PHYSIOL BEHAV, V24, P399, DOI 10.1016/0031-9384(80)90105-5; MILLER JD, 1987, ACTA NEUROCHIR, V85, P80, DOI 10.1007/BF01456102; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; NAKAMURA K, 1987, HYPERTENSION, V10, P635, DOI 10.1161/01.HYP.10.6.635; NATH FP, 1986, J NEUROSURG, V65, P697, DOI 10.3171/jns.1986.65.5.0697; SCHICKNER DJ, 1992, SURG NEUROL, V37, P251, DOI 10.1016/0090-3019(92)90147-F; Smyth GE, 1938, J NEUROL PSYCHIATRY, V1, P226, DOI 10.1136/jnnp.1.3.226; WEAVER DD, 1982, J NEUROSURG, V56, P660, DOI 10.3171/jns.1982.56.5.0660; YANO M, 1987, NEUROSURGERY, V21, P688, DOI 10.1227/00006123-198711000-00015	18	25	26	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	1999	16	11					1095	1102		10.1089/neu.1999.16.1095			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	260MM	WOS:000083954500007	10595825				2021-06-18	
J	Gilad, GM; Gilad, VH				Gilad, GM; Gilad, VH			Novel polyamine derivatives as neuroprotective agents	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							ORNITHINE DECARBOXYLASE ACTIVITY; SYMPATHETIC NEURONS; AXONAL INJURY; CEREBRAL-ISCHEMIA; RAT; BRAIN; REGENERATION; FOREBRAIN; SURVIVAL; DAMAGE	The induction of an early increase in polyamine metabolism, termed "the polyamine response," is now recognized to have a critical role in the reaction of neurons to injury. Several studies in experimental animals have demonstrated that treatment with the naturally occurring polyamines spermine, spermidine, and putrescine can protect neurons from dying after the infliction of various types of neurotrauma, including mechanical injuries, neurotoxic insults, and ischemia. These findings led us to synthesize a series of polyamine derivatives of 1-aminoindan and 1-aminotetralin and to determine their effects in several in vitro and in vivo models of neurotrauma. Some of the novel compounds proved to be potent neuroprotective in these models, and one of them, N,N-di-(4-aminobutyl)-1-aminoindan, was superior to the others and to the natural polyamines themselves. We conclude that compounds based on the novel polyamine-based structures we synthesized have therapeutic potential as neuroprotective agents.	Assaf Harofeh Med Ctr, Neurosci Lab, IL-70300 Zerifin, Israel	Gilad, GM (corresponding author), Assaf Harofeh Med Ctr, Neurosci Lab, PO Beer Yaakov, IL-70300 Zerifin, Israel.		Gilad, Gad M/E-7193-2010				Abe K, 1997, BRAIN RES, V766, P281, DOI 10.1016/S0006-8993(97)00750-6; DESIDERIO MA, 1988, J NEUROCHEM, V51, P25, DOI 10.1111/j.1471-4159.1988.tb04830.x; DIETRICH WD, 1991, ACTA NEUROPATHOL, V81, P615, DOI 10.1007/BF00296371; GILAD GM, 1983, EXP NEUROL, V81, P158, DOI 10.1016/0014-4886(83)90165-6; GILAD GM, 1983, BRAIN RES, V273, P191, DOI 10.1016/0006-8993(83)91113-7; GILAD GM, 1988, DEV BRAIN RES, V38, P175, DOI 10.1016/0165-3806(88)90042-9; GILAD GM, 1989, LIFE SCI, V44, P1963, DOI 10.1016/0024-3205(89)90409-8; GILAD GM, 1989, INT J DEV NEUROSCI, V7, P641, DOI 10.1016/0736-5748(89)90023-3; GILAD GM, 1992, BIOCHEM PHARMACOL, V44, P401, DOI 10.1016/0006-2952(92)90428-L; GILAD GM, 1991, EXP NEUROL, V111, P349, DOI 10.1016/0014-4886(91)90102-I; GILAD GM, 1993, MOL CHEM NEUROPATHOL, V18, P197, DOI 10.1007/BF03160034; GILAD GM, 1989, BRAIN RES, V508, P215; GILAD GM, 1995, LIFE SCI, V85, pPL41; GILAD GM, 1997, Patent No. 5646188; GILAD GM, 1983, NERVOUS SYSTEM REGEN, P437; Grafstein B, 1978, NEURONAL PLASTICITY, P155; HALL ED, 1987, CNS TRAUMA, V3, P281; HARA H, 1993, PROG NEUROBIOL, V40, P645, DOI 10.1016/0301-0082(93)90009-H; KANJE M, 1986, BRAIN RES, V381, P24, DOI 10.1016/0006-8993(86)90685-2; Lieberman A R, 1971, Int Rev Neurobiol, V14, P49, DOI 10.1016/S0074-7742(08)60183-X; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; MELDRUM BS, 1985, CALCIUM ENTRY BLOCKE, P183; NORDSTROM CH, 1978, STROKE, V9, P335, DOI 10.1161/01.STR.9.4.335; PASCHEN W, 1988, NEUROCHEM PATHOL, V9, P1; PRESTON E, 1993, NEUROSCI LETT, V149, P75, DOI 10.1016/0304-3940(93)90351-K; SABRI MI, 1988, AM SOC NEUR ABSTR, V19, P89; SEILER N, 1990, INT J BIOCHEM, V22, P211, DOI 10.1016/0020-711X(90)90332-W; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TETZLAFF W, 1985, EXP NEUROL, V89, P679, DOI 10.1016/0014-4886(85)90016-0; TETZLAFF W, 1986, PROCESSES RECOVERY N, P3	30	25	26	1	4	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0022-3565			J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	OCT	1999	291	1					39	43					5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	238QK	WOS:000082721100006	10490884				2021-06-18	
J	Fontani, G; Maffei, D; Cameli, S; Polidori, P				Fontani, G; Maffei, D; Cameli, S; Polidori, P			Reactivity and event-related potentials during attentional tests in athletes	EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY AND OCCUPATIONAL PHYSIOLOGY			English	Article						event-related potentials; CNV; P3; reaction time; athletes	ELICITED P300-COMPLEX PF-P300; CONTINGENT NEGATIVE-VARIATION; CLOSED HEAD-INJURY; MENTAL CHRONOMETRY; EVOKED-POTENTIALS; VISUAL-ATTENTION; BRAIN POTENTIALS; REACTION-TIME; P300; PSYCHOPHYSIOLOGY	A series of attentional tests involving reaction times (RTs) was administered to 12 high-level young (age 17-18 years) volleyball players. During the tests, event-related potentials were recorded by electroencephalogram. In a simple reaction-time test (SRT), the subjects had to respond to a letter that appeared on a white screen. Other tests (attentional shifting tests) consisted of a go/no-go reaction time and a choice reaction time (CRT), divided into a short-latency CRT and a long-latency CRT. In the pre-stimulus period of these tests, there is a shift from broad attention to selective attention, represented by a crowding of black points on the computer screen, followed by the appearance of a letter in the centre of the crowding. The results show that RT increased from SRT to CRT. In the attentional shifting tests, averaged waves of event-related potentials showed a contingent-negative-variation-like wave that was closely related to selective attention (selective attention wave, SAW) before the onset of the stimulus. After the stimulus, a P3 complex was recorded. Correlations were found between the SAW amplitude and P3 latency and amplitude, and between these parameters and RT and its variability. Higher SAW and P3 amplitudes were accompanied by a shorter RT and a lower variability. The characteristics and the correlations that exist between the various parameters are consistent with a possible use of these tests in the analysis of the attentional styles of athletes, and in the evaluation of their progress with training.	Univ Siena, Ist Fisiol Umana, I-53100 Siena, Italy; Catholic Univ Rome, Ctr Med Sport, Rome, Italy; Federaz Italiana Pallavolo, Comitato Olimp Nazl Italiano, Rome, Italy	Fontani, G (corresponding author), Univ Siena, Ist Fisiol Umana, Via A Moro, I-53100 Siena, Italy.						Allport D. A, 1993, ATTENTION PERFORM, P183; ANZENEDER CP, 1997, SDS RIV CULTURA SPOR, V16, P53; ARITO H, 1990, IND HEALTH, V28, P97, DOI 10.2486/indhealth.28.97; BIRBAUMER N, 1990, PHYSIOL REV, V70, P1, DOI 10.1152/physrev.1990.70.1.1; Buckolz E, 1980, Can J Appl Sport Sci, V5, P146; CASTIELLO U, 1992, INT J SPORT PSYCHOL, V23, P301; CEI A, 1991, MOVIMENTO, V7, P154; COLES MGH, 1989, PSYCHOPHYSIOLOGY, V26, P251, DOI 10.1111/j.1469-8986.1989.tb01916.x; CREMONAMETEYARD SL, 1992, NEUROPSYCHOLOGIA, V30, P123, DOI 10.1016/0028-3932(92)90022-E; DEHOUSSE JP, 1986, RECHERCHES PSYCHOL S, P213; Donald M W, 1980, Prog Brain Res, V54, P615, DOI 10.1016/S0079-6123(08)61681-7; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; Donchin E., 1986, PSYCHOPHYSIOLOGY SYS, P702; DUNCANJOHNSON CC, 1981, PSYCHOPHYSIOLOGY, V18, P207; FONTANI G, 1994, FISIOLOGIA PALLAVOLO; GLINER JA, 1979, MED SCI SPORT EXER, V11, P155; HALGREN E, 1980, SCIENCE, V210, P803, DOI 10.1126/science.7434000; HILLYARD SA, 1967, ELECTROEN CLIN NEURO, V22, P297, DOI 10.1016/0013-4694(67)90199-X; HORST RL, 1980, MEM COGNITION, V8, P476, DOI 10.3758/BF03211144; Hull C., 1951, ESSENTIALS BEHAV; Kolev V, 1997, NEUROREPORT, V8, P2061, DOI 10.1097/00001756-199705260-00050; Kugler CFA, 1996, J GERONTOL A-BIOL, V51, pB3, DOI 10.1093/gerona/51A.1.B3; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; LOW MD, 1966, PERCEPT MOTOR SKILL, V22, P443, DOI 10.2466/pms.1966.22.2.443; MCCLELLAND JL, 1979, PSYCHOL REV, V86, P287, DOI 10.1037/0033-295X.86.4.287; NAATANEN R, 1975, BIOL PSYCHOL, V2, P237, DOI 10.1016/0301-0511(75)90038-1; NOUGIER V, 1991, INT J SPORT PSYCHOL, V22, P307; NOUGIER V, 1987, RECHERCHES APS, V2, P209; Picton T.W., 1988, HUMAN EVENT RELATED, VVolume 1, P361; POLICH J, 1995, BIOL PSYCHOL, V41, P103, DOI 10.1016/0301-0511(95)05130-9; POLICH J, 1989, BIOMED PHARMACOTHER, V43, P439; POLICH J, 1989, SPRINGER SERIES BRAI, V2, P331; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; Posner MI., 1978, CHRONOMETRIC EXPLORA; RENAULT B, 1982, SCIENCE, V215, P1413, DOI 10.1126/science.7063853; RIPOLL H, 1988, INT J SPORT PSYCHOL, V19, P9; RITTER W, 1972, ELECTROEN CLIN NEURO, V33, P547, DOI 10.1016/0013-4694(72)90245-3; ROSSI B, 1992, J HUM MOVEMENT STUD, V23, P17; ROSSI B, 1991, INT J SPORT PSYCHOL, V22, P128; RUCHKIN DS, 1975, PSYCHOPHYSIOLOGY, V12, P591, DOI 10.1111/j.1469-8986.1975.tb00052.x; RUGG MD, 1989, BRAIN, V112, P489, DOI 10.1093/brain/112.2.489; SAMAR VJ, 1995, BRAIN COGNITION, V27, P398, DOI 10.1006/brcg.1995.1028; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; SMITH ME, 1990, ELECTROEN CLIN NEURO, V76, P235, DOI 10.1016/0013-4694(90)90018-F; SQUIRES KC, 1976, SCIENCE, V193, P1142, DOI 10.1126/science.959831; STARKES JL, 1983, J SPORT PSYCHOL, V5, P189, DOI 10.1123/jsp.5.2.189; SUTTON S, 1965, SCIENCE, V150, P1187, DOI 10.1126/science.150.3700.1187; TAGHAVY A, 1988, INT J NEUROSCI, V38, P179, DOI 10.3109/00207458809000495; TAGHAVY A, 1988, INT J NEUROSCI, V39, P261, DOI 10.3109/00207458808985713; TECCE JJ, 1972, PSYCHOL BULL, V77, P73, DOI 10.1037/h0032177; TECCE JJ, 1969, SCIENCE, V164, P331, DOI 10.1126/science.164.3877.331; TECCE JJ, 1982, ELECTROENCEPHALOGRAP, P543; TECCE JJ, 1970, ATTENTION CONTEMPORA, P331; TUETING P, 1971, PSYCHOPHYSIOLOGY, V7, P385; Verleger R, 1997, PSYCHOPHYSIOLOGY, V34, P131, DOI 10.1111/j.1469-8986.1997.tb02125.x; WALTER W G, 1965, Br J Physiol Opt, V22, P1; WALTER WG, 1964, NATURE, V203, P380, DOI 10.1038/203380a0; WEI JH, 1990, CHINESE SCI BULL, V35, P227; YINGLING CD, 1984, ELECTROEN CLIN NEURO, V59, P72, DOI 10.1016/0168-5597(84)90022-4; ZANI A, 1991, INT J SPORT PSYCHOL, V22, P376; ZANI A, 1990, AIESEP 88 WORLD C HU, P325	61	25	26	0	4	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0301-5548			EUR J APPL PHYSIOL O	Eur. J. Appl. Physiol. Occup. Physiol.	SEP	1999	80	4					308	317		10.1007/s004210050597			10	Physiology; Sport Sciences	Physiology; Sport Sciences	231FT	WOS:000082298000008	10483800				2021-06-18	
J	Conners, GP; Sacks, WK; Leahey, NF				Conners, GP; Sacks, WK; Leahey, NF			Variations in sedating uncooperative, stable children for post-traumatic head CT	PEDIATRIC EMERGENCY CARE			English	Article						sedation; head injury; CT scan; survey	COMPUTED-TOMOGRAPHY; PEDIATRIC-PATIENTS; HELICAL CT; CRITERIA	Objective: To characterize variations among pediatric emergency physicians and their hospital facilities regarding sedation of the uncooperative, stable child for head CT following closed head injury. Design: Mail survey with two follow-up mailings. Participants: Surveys were sent to all members of the Emergency Medicine Section of the American Academy of Pediatrics (AAP), Results: Of 596 surveys sent, 431 (72%) were returned, with 304 (51%) usable responses. Respondents annually sedate over 17,500 children for post-traumatic head CT. Formal training to sedate children for head CT was noted by 73%, Published guidelines for sedation are followed by 74%; 10% were unaware of the existence of published guidelines for sedation, Twenty-six percent of the respondents were very or somewhat dissatisfied with their sedation-related practices. In response to three clinical scenarios involving sedation of 8-month-old, 3-year-old, and 6-year-old children for head CT, midazolam was the most commonly chosen drug. Over 20 different sedation strategies were selected for each scenario. Conclusions: Sedation practices for post-traumatic pediatric head CT vary widely, among both physicians and individual practitioners. Institutional and individual sedation-relation policies vary widely as well, Variation and dissatisfaction with sedation practices may reflect uncertainty regarding optimal sedation strategies. Further cost-effectiveness research is necessary.	Univ Rochester, Dept Emergency Med, Ctr Med, Rochester, NY 14642 USA	Conners, GP (corresponding author), Univ Rochester, Dept Emergency Med, Ctr Med, 601 Elmwood Ave,Box 4-9200, Rochester, NY 14642 USA.						[Anonymous], 1997, ANN EMERG MED, V29, P834; BLUMENTHAL D, 1994, NEW ENGL J MED, V331, P1017, DOI 10.1056/NEJM199410133311511; COOK BA, 1992, CLIN PEDIATR, V31, P137, DOI 10.1177/000992289203100302; COTE CJ, 1994, PEDIATRICS, V94, P281; COTE CJ, 1994, PEDIATR CLIN N AM, V41, P31; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; Eddy D M, 1984, Health Aff (Millwood), V3, P74, DOI 10.1377/hlthaff.3.2.74; Frush DP, 1996, AM J ROENTGENOL, V167, P1381, DOI 10.2214/ajr.167.6.8956563; Frush DP, 1997, RADIOL CLIN N AM, V35, P789; HAWK W, 1990, Pediatric Emergency Care, V6, P84, DOI 10.1097/00006565-199006000-00003; HUBBARD AM, 1992, J COMPUT ASSIST TOMO, V16, P3, DOI 10.1097/00004728-199201000-00002; Kaste SC, 1997, AM J ROENTGENOL, V168, P1001, DOI 10.2214/ajr.168.4.9124104; KAUFFMAN RE, 1992, PEDIATRICS, V89, P1110; KEETER S, 1990, RADIOLOGY, V175, P745, DOI 10.1148/radiology.175.3.2343126; Parker RI, 1997, PEDIATRICS, V99, P427, DOI 10.1542/peds.99.3.427; PEREIRA JK, 1993, PEDIATR RADIOL, V23, P341, DOI 10.1007/BF02011952; RIVARA F, 1987, PEDIATRICS, V80, P579; ROARK R, 1995, ARCH PEDIAT ADOL MED, V149, P839, DOI 10.1001/archpedi.1995.02170210013002; SACCHETTI A, 1994, ANN EMERG MED, V23, P237, DOI 10.1016/S0196-0644(94)70037-0; SCHUTZMAN SA, 1993, ANN EMERG MED, V22, P535, DOI 10.1016/S0196-0644(05)81938-9; SCHYNOLL W, 1993, AM J EMERG MED, V11, P321, DOI 10.1016/0735-6757(93)90160-D; STEINBERG EP, 1993, MED CARE, V31, pYS86, DOI 10.1097/00005650-199305001-00014; VARNER PD, 1985, ANESTH ANALG, V64, P643; WHITE KS, 1995, PEDIATR RADIOL, V25, P344, DOI 10.1007/BF02021698	24	25	26	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-5161	1535-1815		PEDIATR EMERG CARE	Pediatr. Emerg. Care	AUG	1999	15	4					241	244					4	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	225HN	WOS:000081952500001	10460075				2021-06-18	
J	Wilkinson, AE; Bridges, LR; Sivaloganathan, S				Wilkinson, AE; Bridges, LR; Sivaloganathan, S			Correlation of survival time with size of axonal swellings in diffuse axonal injury	ACTA NEUROPATHOLOGICA			English	Article						diffuse axonal injury; head injury; beta-amyloid precursor protein immunohistochemistry; forensic neuropathology	AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN INJURY; CLOSED-HEAD INJURY; NEUROFILAMENT SUBUNITS; BETA-APP; DAMAGE; MARKER	Widespread damage to axons in the white matter of the brain is a well-recognised consequence of nonmissile head injury. This diffuse axonal injury is characterised by a gradual swelling of the axon associated with an accumulation of cellular organelles and proteins. We have investigated the relationship between the size of the swellings of the damaged axon with survival time in postmortem brain tissue. Sixty-six cases of head injury with known length of post-traumatic survival were selected for study, and immunohistochemistry for beta-amyloid precursor protein (beta APP) was carried out. The minimum diameter of the beta APP-immunolabelled damaged axons was measured in micrometers using the IBAS image analysis system. There was a strong, positive and significant relationship between the mean size of axonal swelling and survival time which plateaued at around 85 h post injury. With longer survival times the situation becomes more complex. beta APP immunolabelling of damaged axons can contribute evidence about trauma and post-injury survival time in the forensic setting but should always be assessed with other evidence.	Univ Leeds, Sch Med, Gen Infirm, Div Clin Sci Pathol Sci, Leeds LS2 9JT, W Yorkshire, England	Wilkinson, AE (corresponding author), Univ Leeds, Sch Med, Gen Infirm, Div Clin Sci Pathol Sci, Algernon Firth Bldg, Leeds LS2 9JT, W Yorkshire, England.						ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAHAM DI, 1987, NEUROPATH APPL NEURO, V13, P209, DOI 10.1111/j.1365-2990.1987.tb00184.x; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; STRICH SJ, 1961, LANCET, V2, P443; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	17	25	28	0	5	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	AUG	1999	98	2					197	202		10.1007/s004010051069			6	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	220DD	WOS:000081648500012	10442560				2021-06-18	
J	Johns, JS; Cifu, DX; Keyser-Marcus, L; Jolles, PR; Fratkin, MJ				Johns, JS; Cifu, DX; Keyser-Marcus, L; Jolles, PR; Fratkin, MJ			Impact of clinically significant heterotopic ossification on functional outcome after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							SEVERE HEAD-INJURY; BONE-FORMATION; LENGTH; STAY	Objective: To assess heterotopic ossification's (HO) impact on functional outcome after TBI. Design: Retrospective with matched control group, single center. Setting: TBI Model System of Care at the Medical College of Virginia of Virginia Commonwealth University, Richmond, VA. Participants: Twenty-six patients with TBI and triple-phase bone scan confirmed HO were matched with 26 patients without clinical evidence of HO. Main outcome measures: Acute and rehabilitation lengths of stay (LOS), Admission and Discharge Functional Independence Measure (FIM) scores, FIM change, FIM efficiency (FIM gains per week), and discharge disposition. Results: The two groups had similar acute care LOS. Patients with HO had significantly longer inpatient rehabilitation LOS and significantly lower FIM mobility and activities of daily living subscale scores on admission and discharge. FIM efficiency was significantly lower for the group with HO. Significantly fewer patients with HO were able to be discharged to home. Conclusions: HO is associated with a poorer functional outcome; however, it is not clear whether HO causes the decreased function or whether it may serve more generally as an indicator Of those patients who will not progress as far or as rapidly during inpatient rehabilitation.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiol, Div Nucl Med, Richmond, VA 23298 USA	Cifu, DX (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, POB 980667, Richmond, VA 23298 USA.			Cifu, David/0000-0003-1600-9387; Keyser-Marcus, Lori/0000-0001-6014-2500			AYERS DC, 1986, J BONE JOINT SURG AM, V68A, P1423, DOI 10.2106/00004623-198668090-00016; BUSCHBACHER R, 1992, AM J PHYS MED REHAB, V71, P86, DOI 10.1097/00002060-199204000-00005; CITTAPIETROLUNGO TJ, 1992, ARCH PHYS MED REHAB, V73, P258; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Crawford C M, 1986, J Burn Care Rehabil, V7, P323, DOI 10.1097/00004630-198607000-00005; Englander JS, 1996, J HEAD TRAUMA REHAB, V11, P15, DOI 10.1097/00001199-199610000-00003; FINERMAN GAM, 1981, METAB BONE DIS RELAT, V4, P337; FREED JH, 1982, PARAPLEGIA, V20, P208, DOI 10.1038/sc.1982.39; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; GARLAND DE, 1991, CLIN ORTHOP RELAT R, P13; Gennarelli T A, 1988, Brain Inj, V2, P175, DOI 10.3109/02699058809150942; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; GRANGER CV, 1994, TOP GERIATR REHABIL, V9, P72; High WM, 1996, J HEAD TRAUMA REHAB, V11, P85, DOI 10.1097/00001199-199610000-00008; Hossack D W, 1967, Med J Aust, V1, P326; JENNETT B, 1976, LANCET, V1, P1031; JENSEN LL, 1988, AM J PHYS MED, V66, P351; Keith R A, 1987, Adv Clin Rehabil, V1, P6; LAL S, 1989, ARCH PHYS MED REHAB, V70, P387; ORZEL JA, 1985, J NUCL MED, V26, P125; Rogers R C, 1988, Brain Inj, V2, P169, DOI 10.3109/02699058809150941; SAZBON L, 1981, J BONE JOINT SURG BR, V63, P120; SINGER BR, 1993, BRIT J HOSP MED, V49, P247; SPIELMAN G, 1983, ARCH PHYS MED REHAB, V64, P539; SUZUKI Y, 1974, RADIOLOGY, V111, P663, DOI 10.1148/111.3.663; VARGHESE G, 1992, PHYS MED REH CLIN N, V3, P407; Warren S B, 1990, Orthop Rev, V19, P603; 1995, GUIDE UNIFORM DATA S	29	25	26	0	0	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1999	14	3					269	276		10.1097/00001199-199906000-00007			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	203XY	WOS:000080734500007	10381979				2021-06-18	
J	Wiegner, S; Donders, J				Wiegner, S; Donders, J			Performance on the Wisconsin Card Sorting Test after traumatic brain injury	ASSESSMENT			English	Article						Wisconsin Card Sorting Test; traumatic brain injury	CLOSED-HEAD-INJURY; CATEGORY TEST; PATHOLOGY; EDUCATION; SUBTYPES; DAMAGE; SAMPLE; AGE	The performance of 100 patients with traumatic brain injury (TBI) on the Wisconsin Card Sorting Test (WCST) was examined to determine the underlying latent structure as well as profile subtypes. Exploratory factor analysis with oblique rotation identified three factors: response accuracy, learning, and failure to maintain set. Marker variables from each factor were then included in a two-stage cluster analysis, which identified two reliable subtypes. Level of performance differences between these subtypes were meaningfully related to both demographic background and length of coma. It is concluded that interpretation of the WCST results of patients with TBI should consider the multifactorial nature of the instrument in combination with injury severity characteristics and demographic variables.	Mary Free Bed Hosp, Grand Rapids, MI 49503 USA	Donders, J (corresponding author), Mary Free Bed Hosp, 235 Wealthy SE, Grand Rapids, MI 49503 USA.						Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; Bernard LC, 1996, ARCH CLIN NEUROPSYCH, V11, P231, DOI 10.1016/0887-6177(95)00025-9; Deshpande SA, 1996, J CLIN EXP NEUROPSYC, V18, P836, DOI 10.1080/01688639608408306; Donders J, 1996, PSYCHOL ASSESSMENT, V8, P312, DOI 10.1037/1040-3590.8.3.312; Donders J, 1995, CHILD NEUROPSYCHOL, V1, P19, DOI 10.1080/09297049508401339; DONDERS J, 1991, CLIN NEUROPSYCHOL, V5, P78, DOI DOI 10.1080/13854049108401844; GOLDMAN GS, 1996, ASSESSMENT, V3, P73; Gorsuch R. L., 1983, FACTOR ANAL; Greve KW, 1998, ARCH CLIN NEUROPSYCH, V13, P597; HATCHER L, 1994, STEP BY STEP APPROAC; Haut M., 1992, NEUROPSYCHOLOGY, V6, P51; Heaton R., 1992, COMPREHENSIVE NORMS; Heaton R., 1993, WISCONSIN CARD SORTI; Heaton R.K., 1991, COMPREHENSIVE NORMS; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; Jones R. D., 1996, P395; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MOUNTAIN MA, 1993, CLIN NEUROPSYCHOL, V7, P108, DOI 10.1080/13854049308401893; PANIAK CE, 1992, J CLIN PSYCHOL, V48, P219, DOI 10.1002/1097-4679(199203)48:2<219::AID-JCLP2270480212>3.0.CO;2-K; PAOLO AM, 1995, ARCH CLIN NEUROPSYCH, V10, P463, DOI 10.1016/0887-6177(95)00052-6; PERRINE K, 1993, J CLIN EXP NEUROPSYC, V15, P461, DOI 10.1080/01688639308402571; Reitan R.M., 1993, HALSTEADREITAN NEURO; REITAN RM, 1995, CLIN NEUROPSYCHOL, V9, P151, DOI 10.1080/13854049508401597; SCHERZER BP, 1993, BRAIN INJURY, V7, P411, DOI 10.3109/02699059309029684; ShuttleworthJordan AB, 1997, CLIN NEUROPSYCHOL, V11, P205, DOI 10.1080/13854049708407053; Stevens J., 1992, APPL MULTIVARIATE ST, V2nd ed.; SULLIVAN EV, 1993, PSYCHIAT RES, V46, P175, DOI 10.1016/0165-1781(93)90019-D; TEASDALE G, 1974, LANCET, V2, P81; Vanderploeg RD, 1997, CLIN NEUROPSYCHOL, V11, P210, DOI 10.1080/13854049708407054; VILKKI J, 1992, NEUROPSYCHOLOGIA, V30, P807, DOI 10.1016/0028-3932(92)90084-Y; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	33	25	25	0	11	PSYCHOLOGICAL ASSESSMENT RESOURCES INC	ODESSA	PO BOX 998, ODESSA, FL 33556 USA	1073-1911			ASSESSMENT	Assessment	JUN	1999	6	2					179	187		10.1177/107319119900600205			9	Psychology, Clinical	Psychology	205CF	WOS:000080803200005	10335020				2021-06-18	
J	Franzen, R; Martin, D; Daloze, A; Moonen, G; Schoenen, J				Franzen, R; Martin, D; Daloze, A; Moonen, G; Schoenen, J			Grafts of meningeal fibroblasts in adult rat spinal cord lesion promote axonal regrowth	NEUROREPORT			English	Article						fibroblasts; neurotrophins; regeneration; spinal cord injury; transplantation	SCHWANN-CELLS; INJURY; RECOVERY; GROWTH; TRANSPLANTATION; DELIVERY; BRAIN; BDNF; SCAR; NGF	WE have studied the morphological consequences of implantation into the injured adult rat spinal cord of fibroblasts derived from the meninges overlying the cerebral cortex. Our initial objective was to reproduce the well known post-traumatic fibroadhesive scar observed in the clinical situation. One month after implantation, instead of having formed a fibroadhesive scar, fibroblasts had promoted the regeneration of peptidergic axons originating from dorsal root afferents and, to a lesser extent, of supraspinal serotonergic fibers at the periphery of the grafts. Using RT-PCR Ne were able to identify in cultures of meningeal-derived fibroblasts mRNAs for beta-NGF, NT3, aFGF and bFGF, which suggests that the promoting effect on axonal regeneration of these cells is at least in part due to their capacity to synthesize neurotrophic factors. NeuroReport 10:1551-1556 (C) 1999 Lippincott Williams & Wilkins.	Univ Liege, Dept Neuroanat, B-4020 Liege, Belgium; Univ Liege, Dept Human Physiol & Pathophysiol, B-4020 Liege, Belgium; Univ Liege, Dept Neurol, B-4020 Liege, Belgium; Univ Liege, Dept Neurosurg, B-4020 Liege, Belgium	Schoenen, J (corresponding author), Univ Liege, Dept Neuroanat, Rue Pitteurs 20, B-4020 Liege, Belgium.						CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Franzen R, 1998, J NEUROSCI RES, V51, P316, DOI 10.1002/(SICI)1097-4547(19980201)51:3<316::AID-JNR5>3.0.CO;2-J; Grill R, 1997, J NEUROSCI, V17, P5560; Kim DH, 1996, NEUROREPORT, V7, P2221, DOI 10.1097/00001756-199609020-00033; KOBAYASHI S, 1995, NEUROSCI LETT, V188, P191, DOI 10.1016/0304-3940(95)11429-Z; KRIKORIAN JG, 1981, EXP NEUROL, V72, P698, DOI 10.1016/0014-4886(81)90018-2; KROMER LF, 1985, P NATL ACAD SCI USA, V82, P6330, DOI 10.1073/pnas.82.18.6330; KRUGER S, 1986, J COMP NEUROL, V249, P103, DOI 10.1002/cne.902490108; MARTIN D, 1991, NEUROSCI LETT, V124, P44, DOI 10.1016/0304-3940(91)90818-E; Martin D, 1996, J NEUROSCI RES, V45, P588; MARTIN D, 1992, J NEUROSCI RES, V32, P539, DOI 10.1002/jnr.490320409; MARTIN D, 1993, BRAIN RES BULL, V30, P507, DOI 10.1016/0361-9230(93)90285-J; MATTHIESSEN HP, 1991, J NEUROCHEM, V56, P759, DOI 10.1111/j.1471-4159.1991.tb01989.x; Menei P, 1998, EUR J NEUROSCI, V10, P607, DOI 10.1046/j.1460-9568.1998.00071.x; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; SENUT MC, 1995, EXP NEUROL, V135, P36, DOI 10.1006/exnr.1995.1064; SIEVERS J, 1994, J NEUROCYTOL, V23, P97, DOI 10.1007/BF01183865; Tuszynski MH, 1996, EXP NEUROL, V137, P157, DOI 10.1006/exnr.1996.0016; Tuszynski MH, 1997, CELL TRANSPLANT, V6, P361, DOI 10.1016/S0963-6897(97)00021-3; TUSZYNSKI MH, 1994, EXP NEUROL, V126, P1, DOI 10.1006/exnr.1994.1037	20	25	25	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	MAY 14	1999	10	7					1551	1556		10.1097/00001756-199905140-00029			6	Neurosciences	Neurosciences & Neurology	202LG	WOS:000080653300030	10380979				2021-06-18	
J	Abrous, DN; Rodriguez, J; le Moal, M; Moser, PC; Barneoud, P				Abrous, DN; Rodriguez, J; le Moal, M; Moser, PC; Barneoud, P			Effects of mild traumatic brain injury on immunoreactivity for the inducible transcription factors c-Fos, c-Jun, JunB, and Krox-24 in cerebral regions associated with conditioned fear responding	BRAIN RESEARCH			English	Article						traumatic brain injury; inducible transcription factor; rat; conditioned freezing response; amygdala; hippocampus	RIGHT PARIETAL CORTEX; POSTTRAUMATIC-STRESS-DISORDER; MEDIAL PREFRONTAL CORTEX; D-ASPARTATE RECEPTORS; NERVOUS-SYSTEM; MESSENGER-RNA; DIFFERENTIAL CONTRIBUTION; BASAL EXPRESSION; FREEZING DEFICIT; CONTEXTUAL CUES	We have previously demonstrated that mild traumatic brain injury (TBI) of the right parietal cortex results in a relatively selective deficit in conditioned fear responding. However, this behavioural deficit is very consistent and unrelated to the extent of the cortical necrotic lesion. We were therefore interested in determining if other brain regions might show a consistent response to mild TBI, and therefore, more reliably relate to the behavioural change. Increased expression of inducible transcription factors (ITFs) has been used to study which brain regions respond to a variety of events. In the present study, we examined the expression patterns of immunoreactivity (IR) for four ITFs (c-Fos, c-Jun, JunB, and Krox-24) at 3 h after mild fluid percussion TBI. Changes in ITF expression were only observed ipsilateral to the side of TBI. The dearest changes were observed in brain regions known to be involved in conditioned fear responding, such as the amygdala complex and hippocampal formation and several cortical regions. In contrast, no changes in IR for any of the ITFs were observed in the striatum, nucleus accumbens, nucleus basalis magnocellularis, septum or periacqueductal grey. Unlike the extent of visible damage to the cortex at the site of impact, the overexpression of ITFs showed a notable consistency between animals subjected to TBI, This consistency in regions known to be involved in conditioned fear responding (i.e,, amygdala complex and hippocampal formation) lead us to suggest that it is these changes, rather than the more variable cortical necrotic lesion, that is responsible for the behavioural deficits we observe following mild TBI. Importantly, our results demonstrate that like the hippocampus, the amygdala is a sub-cortical structure particularly sensitive to the effects of mild brain trauma and underline the fact that cerebral regions distant from the location of the fluid impact can be affected. (C) 1999 Published by Elsevier Science B.V. All rights reserved.	Synthelabo Rech, Cent Nervous Syst Res Dept, F-92500 Rueil Malmaison, France; INSERM, U259, F-33077 Bordeaux, France	Barneoud, P (corresponding author), Synthelabo Rech, Cent Nervous Syst Res Dept, 31 Ave PV Couturier,BP110, F-92225 Bagneux, France.		Abrous, Nora-Djoher/N-6977-2017; LE MOAL, Michel/B-5125-2008	Moser, Paul/0000-0002-6887-3508; abrous, nora/0000-0002-8589-305X			ARMONY JL, 1995, BEHAV NEUROSCI, V109, P246, DOI 10.1037/0735-7044.109.2.246; Armony JL, 1997, TRENDS COGN SCI, V1, P28, DOI 10.1016/S1364-6613(97)01007-3; Beckmann AM, 1997, NEUROCHEM INT, V31, P477, DOI 10.1016/S0197-0186(96)00136-2; BRENNAN PA, 1992, NEUROSCIENCE, V49, P2277; CORODIMAS KP, 1995, BEHAV NEUROSCI, V109, P613, DOI 10.1037/0735-7044.109.4.613; Dave JR, 1997, NEUROREPORT, V8, P395, DOI 10.1097/00001756-199701200-00002; Davis M, 1997, ANN NY ACAD SCI, V821, P305, DOI 10.1111/j.1749-6632.1997.tb48289.x; DAVIS M, 1994, TRENDS NEUROSCI, V17, P208, DOI 10.1016/0166-2236(94)90106-6; DAVIS M, 1994, INT REV NEUROBIOL, V36, P225, DOI 10.1016/S0074-7742(08)60305-0; Desjardins S, 1997, NEUROBIOL AGING, V18, P37, DOI 10.1016/S0197-4580(96)00206-0; DRAGUNOW M, 1995, BRAIN RES REV, V21, P1, DOI 10.1016/0165-0173(95)00003-L; DRAGUNOW M, 1990, BRAIN RES, V527, P41, DOI 10.1016/0006-8993(90)91058-O; DRAGUNOW M, 1990, EXP NEUROL, V107, P236, DOI 10.1016/0014-4886(90)90141-E; DRAGUNOW M, 1987, NATURE, V329, P441, DOI 10.1038/329441a0; DRAGUNOW M, 1993, INT J DEV NEUROSCI, V11, P249, DOI 10.1016/0736-5748(93)90083-P; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; FANSELOW MS, 1994, PSYCHON B REV, V1, P429, DOI 10.3758/BF03210947; Ferrer I, 1997, NEUROREPORT, V8, P2483, DOI 10.1097/00001756-199707280-00014; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Frysztak RJ, 1991, CEREB CORTEX, V1, P418, DOI 10.1093/cercor/1.5.418; GASS P, 1992, NEUROSCIENCE, V48, P315, DOI 10.1016/0306-4522(92)90493-L; Grillon C, 1996, MOL PSYCHIATR, V1, P278; HAMM RJ, 1995, J NEUROTRAUM, V12, P307, DOI 10.1089/neu.1995.12.307; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; HERDEGEN T, 1993, J COMP NEUROL, V333, P271, DOI 10.1002/cne.903330212; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; HERRERA DG, 1990, NEUROSCIENCE, V35, P273, DOI 10.1016/0306-4522(90)90081-E; Hogg S, 1998, BEHAV BRAIN RES, V93, P143, DOI 10.1016/S0166-4328(97)00146-0; Hogg S, 1998, BEHAV BRAIN RES, V93, P157, DOI 10.1016/S0166-4328(97)00145-9; Hogg S, 1998, J NEUROTRAUM, V15, P545, DOI 10.1089/neu.1998.15.545; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; HUGHES P, 1993, NEUROSCIENCE, V57, P319, DOI 10.1016/0306-4522(93)90065-N; HUGHES P, 1995, PHARMACOL REV, V47, P133; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Killcross S, 1997, NATURE, V388, P377, DOI 10.1038/41097; LaBar KS, 1996, BEHAV NEUROSCI, V110, P991, DOI 10.1037/0735-7044.110.5.991; LORENZINI CA, 1991, PHYSIOL BEHAV, V49, P765, DOI 10.1016/0031-9384(91)90316-G; Maren S, 1996, BEHAV NEUROSCI, V110, P718, DOI 10.1037/0735-7044.110.4.718; Matsuoka N, 1996, J PHARMACOL EXP THER, V278, P891; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MICHAEL DB, 1995, J NEUROTRAUM, V12, P991; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MORGAN MA, 1993, NEUROSCI LETT, V163, P109, DOI 10.1016/0304-3940(93)90241-C; MORGAN MA, 1995, BEHAV NEUROSCI, V109, P681, DOI 10.1037/0735-7044.109.4.681; Muller J, 1997, BEHAV NEUROSCI, V111, P683, DOI 10.1037/0735-7044.111.4.683; Paxinos G., 1982, RAT BRAIN STEREOTAXI; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; PHILLIPS RG, 1995, J NEUROSCI, V15, P5308; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; Riedel G, 1997, NEUROREPORT, V8, P2477, DOI 10.1097/00001756-199707280-00013; SELDEN NRW, 1991, NEUROSCIENCE, V42, P335, DOI 10.1016/0306-4522(91)90379-3; Shin LM, 1997, ARCH GEN PSYCHIAT, V54, P233; Tang YP, 1997, J CEREBR BLOOD F MET, V17, P771; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	59	25	29	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAY 1	1999	826	2					181	192		10.1016/S0006-8993(99)01259-7			12	Neurosciences	Neurosciences & Neurology	192BF	WOS:000080057100003	10224295				2021-06-18	
J	Barlow, KM; Minns, RA				Barlow, KM; Minns, RA			The relation between intracranial pressure and outcome in non-accidental head injury	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							NON-TRAUMATIC COMA; CHILDREN; SHAKEN	The aim of this retrospective study was to ascertain whether physiological derangement and potential secondary brain insult from raised intracranial pressure (ICP) or reduced cerebral perfusion pressure (CPP) in non-accidental head injury (NAHI) influences outcome. Any child who had a diagnosis of NARI and had ICP monitoring or measurements during the acute illness was entered in the study. Seventeen children with an average age 5.1 months (range 1 to 20 months) were identified. Details of the acute encephalopathy, lowest mean arterial blood pressure (MAP), mean of maximum ICP measured, lowest CPP, and neurodevelopmental outcome at follow up were obtained from the hospital case notes. Seshia's (1994) outcome classification scale was used. The lowest CPP was very significantly related to outcome (P=0.0047, tau=-0.544). Mean of maximum ICP did not correlate with outcome. The lowest MAP was significantly related to outcome (P=0.039). It was concluded that the degree of secondary brain insult from reduced CPP influences outcome.	Royal Hosp Sick Children, Dept Neurol, Edinburgh EH9 1LF, Midlothian, Scotland; Univ Edinburgh, Dept Child Life & Hlth, Edinburgh, Midlothian, Scotland	Minns, RA (corresponding author), Royal Hosp Sick Children, Dept Neurol, 9 Sciennes Rd, Edinburgh EH9 1LF, Midlothian, Scotland.		Barlow, Karen/I-6492-2019; Barlow, Karen/C-1323-2014	Barlow, Karen/0000-0003-2612-8507			Barlow KM, 1998, SCOT MED J, V43, P112, DOI 10.1177/003693309804300407; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; BROWN JK, 1993, DEV MED CHILD NEUROL, V35, P849; Chesnut R M, 1995, New Horiz, V3, P366; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cho DY, 1995, PEDIATR NEUROSURG, V23, P192, DOI 10.1159/000120958; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; FRANK Y, 1985, DEV MED CHILD NEUROL, V27, P312; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P1328, DOI 10.1097/00003246-199309000-00016; Haviland J, 1997, ARCH DIS CHILD, V77, P504, DOI 10.1136/adc.77.6.504; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; KALFF R, 1989, CHILD NERV SYST, V5, P156, DOI 10.1007/BF00272118; SESHIA SS, 1994, BAILLIERES CLIN PAED, V2, P173; SESHIA SS, 1983, DEV MED CHILD NEUROL, V25, P492; TASKER RC, 1988, ARCH DIS CHILD, V63, P895, DOI 10.1136/adc.63.8.895; TASKER RC, 1988, ARCH DIS CHILD, V63, P888, DOI 10.1136/adc.63.8.888	16	25	25	0	1	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA	0012-1622			DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	APR	1999	41	4					220	225		10.1017/S0012162299000481			6	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	195ZJ	WOS:000080282800002	10355804				2021-06-18	
J	Hermann, DM; Mies, G; Hossmann, KA				Hermann, DM; Mies, G; Hossmann, KA			Expression of c-fos, junB, c-jun, MKP-1 and hsp72 following traumatic neocortical lesions in rats - Relation to spreading depression	NEUROSCIENCE			English	Article						cortical injury; cortical spreading depression; activator protein-1 (AP-1); mitogen-activated protein (MAP) kinase phosphatase; heat shock protein	ACTIVATED PROTEIN-KINASE; IMMEDIATE-EARLY GENE; HEAT-SHOCK PROTEIN; MESSENGER-RNA EXPRESSION; CORTICAL IMPACT INJURY; BRAIN INJURY; TRANSCRIPTION FACTORS; SYNTHESIS INHIBITORS; 3T3 CELLS; INDUCTION	The effects of a traumatic neocortical lesion on c-fos, junB, c-jun, MKP-1 and hsp72 expression were examined by in situ hybridization and immunocytochemistry 1-6 h following transcranial cold injury. The direct current potential was recorded in the injury-remote cortex to evaluate the role of transient direct current shifts, i.e. spreading depressions, in gene expression. In 14 out of 21 injured rats, spreading depression-like depolarizations of the direct current potential were noticed, which were accompanied by a transient decrease in electroencephalographic activity and increase in laser Doppler flow. In seven injured animals, no spontaneous spreading depressions were seen. In animals without spreading depressions, only a short-lasting response of c-fos, junB, c-jun and MKP-1 messenger RNAs as well as c-Fos protein was bilaterally found in the piriform cortex, and-with ipsilateral dominance-the dentate gyrus and hippocampal CA3/4 fields at Ih after lesioning. In injured animals with spreading depressions however, a strong elevation was seen in layers II-TV and VI of the injury-remote ipsilateral cerebral cortex, which persisted over as long as 6 h. Messenger RNA levels for c-Sos, junB and MKP-1 were closely related to the time interval between the last depolarization and the end of experiment. Levels were highest shortly after transient direct current shifts, and decreased thereafter mono-exponentially with half-lives of 48, 75 and 58 min for c-Sos, junB and MKP-1 messenger RNAs, respectively. In 6 h animals with spreading depressions, hsp72 messenger RNA was slightly elevated in layer II of the injury-remote cortex, but heat shock protein 72 was not increased. The present results demonstrate that spreading depression is the most prominent factor influencing the trauma-related gene response in the lesion-remote cortical tissue. (C) 1998 IBRO. Published by Elsevier Science Ltd.	Max Planck Inst Neurol Res, Dept Expt Neurol, D-50931 Cologne, Germany	Hermann, DM (corresponding author), Max Planck Inst Neurol Res, Dept Expt Neurol, Gleueler Str 50, D-50931 Cologne, Germany.		Hermann, Dirk M/AAP-5538-2020				ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; CHARLES CH, 1992, ONCOGENE, V7, P187; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CURRAN T, 1987, ONCOGENE, V2, P79; DIETRICH WD, 1994, J CEREBR BLOOD F MET, V14, P20, DOI 10.1038/jcbfm.1994.4; DRAGUNOW M, 1995, BRAIN RES REV, V21, P1, DOI 10.1016/0165-0173(95)00003-L; DRAGUNOW M, 1990, EXP NEUROL, V107, P236, DOI 10.1016/0014-4886(90)90141-E; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; FIFKOVA E, 1964, PHYSIOL BOHEMOSLOV, V13, P1; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; Gass P, 1996, MOL BRAIN RES, V41, P74, DOI 10.1016/0169-328X(96)00068-X; GASS P, 1993, NEUROSCI LETT, V162, P39, DOI 10.1016/0304-3940(93)90554-X; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; HERMANN DM, 1998, IN PRESS NEUROREPORT, V9; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; HUSZ T, 1992, NEUROREPORT, V3, P51, DOI 10.1097/00001756-199201000-00013; KOBAYASHI S, 1995, J CEREBR BLOOD F MET, V15, P721, DOI 10.1038/jcbfm.1995.92; KOCHER M, 1990, J CEREBR BLOOD F MET, V10, P564, DOI 10.1038/jcbfm.1990.99; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; Lindsberg PJ, 1996, J CEREBR BLOOD F MET, V16, P82, DOI 10.1097/00004647-199601000-00010; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; Mayevsky A, 1996, BRAIN RES, V740, P268, DOI 10.1016/S0006-8993(96)00874-8; MCLACHLAN RS, 1994, BRAIN RES, V666, P133, DOI 10.1016/0006-8993(94)90295-X; MIES G, 1993, NEUROREPORT, V4, P709, DOI 10.1097/00001756-199306000-00027; MIKAWA S, 1995, MOL BRAIN RES, V33, P288, DOI 10.1016/0169-328X(95)00146-J; NEUMANNHAEFELIN T, 1994, J CEREBR BLOOD F MET, V14, P206, DOI 10.1038/jcbfm.1994.27; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Piper RD, 1996, CEPHALALGIA, V16, P87, DOI 10.1046/j.1468-2982.1996.1602087.x; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; Sall J. M., 1997, Society for Neuroscience Abstracts, V23, P1122; SHARP JW, 1990, EXP NEUROL, V109, P323, DOI 10.1016/S0014-4886(05)80023-8; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; WIESSNER C, 1995, NEUROSCIENCE, V64, P959, DOI 10.1016/0306-4522(94)00418-5; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; Yamashita K, 1996, BRAIN RES, V735, P285, DOI 10.1016/0006-8993(96)00578-1; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X	47	25	26	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience	JAN	1999	88	2					599	608		10.1016/S0306-4522(98)00249-8			10	Neurosciences	Neurosciences & Neurology	130EJ	WOS:000076506700023	10197778				2021-06-18	
J	Hermann, DM; Mies, G; Hossmann, KA				Hermann, DM; Mies, G; Hossmann, KA			Biochemical changes and gene expression following traumatic brain injury: Role of spreading depression	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						neocortical trauma; cerebral metabolism; tissue acidosis; immediate-early gene; transient DC depolarization	PROTEIN-SYNTHESIS INHIBITORS; HSP70 MESSENGER-RNA; C-FOS; LACTATE; RATS; METABOLISM; DAMAGE; TRANSCRIPTION; ACTIVATION; ACIDS	The effects of spreading depression-like DC depolarizations on biochemical changes and gene expression were examined following traumatic neocortical lesions, as induced by transcranial cold injury. The surrounding of traumatic cold lesions was characterized by increased glucose and lactate contents, without major disturbances of protein synthesis or energy state. A transient pH decrease by 0.4 units was noticed 1 h post-injury, which shifted towards alkaline values by 3 h. These changes were similar in animals with spontaneous spreading depression-like DC shifts (n = 14) and those without spreading depressions (n = 7), but there was a marked difference in the gene response. In injured animals without SD, only a short-lasting response of c-fos, junB, c-jun and MKP-1 mRNAs as well as c-Fos protein was bilaterally found in the piriform cortex, and - with ipsilateral dominance - the dentate gyrus and hippocampal CA3/4 fields at 1 h after lesioning. In injured animals with spreading depressions, on the contrary, a strong elevation was seen in layers II-IV and VI of the injury-remote ipsilateral cerebral cortex, which persisted over as long as 6 h. The expression of c-Sos, junB and MKP-1 mRNAs was closely related to the time interval between the last spreading depression and the end of the experiments. Levels were highest shortly after transient DC shifts, and decreased thereafter monoexponentially with half-lives of 48, 75 and 58 min for c-fos, junB and MKP-1 mRNAs, respectively. Thus, spreading depression is a prominent factor influencing the trauma-related gene response, but - in contrast to focal ischemia - it does not aggravate the metabolic dysfunction.	Max Planck Inst Neurol Res, Dept Expt Neurol, D-50931 Cologne, Germany	Hermann, DM (corresponding author), Max Planck Inst Neurol Res, Dept Expt Neurol, Gleueler Str 50, D-50931 Cologne, Germany.	hermann@mpin-koeln.mpg.de	Hermann, Dirk M/AAP-5538-2020				Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; Hermann DM, 1998, NEUROREPORT, V9, P1249, DOI 10.1097/00001756-199804200-00053; HERMANN DM, 1998, IN PRESS NEUROSCIENC; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; KAMEZAWA T, 1994, ACTA NEUROCHIR, P499; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Marmarou A, 1993, Acta Neurochir Suppl (Wien), V57, P160; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MIES G, 1993, J NEUROCHEM, V60, P360, DOI 10.1111/j.1471-4159.1993.tb05860.x; MIES G, 1993, NEUROREPORT, V4, P709, DOI 10.1097/00001756-199306000-00027; MIKAWA S, 1995, MOL BRAIN RES, V33, P288, DOI 10.1016/0169-328X(95)00146-J; NEUMANNHAEFELIN T, 1994, J CEREBR BLOOD F MET, V14, P206, DOI 10.1038/jcbfm.1994.27; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; Siesjo BK, 1996, ADV NEUROL, V71, P209; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; WIESSNER C, 1995, NEUROSCIENCE, V64, P959, DOI 10.1016/0306-4522(94)00418-5; WOLF AL, 1993, J NEUROSURG, V78, P54, DOI 10.3171/jns.1993.78.1.0054; Yamashita K, 1996, BRAIN RES, V735, P285, DOI 10.1016/0006-8993(96)00578-1; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X	30	25	26	1	3	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		1999	14	2-3					103	108					6	Neurosciences	Neurosciences & Neurology	183XN	WOS:000079579700004	22387505				2021-06-18	
J	Horowitz, MB; Kopitnik, TA; Landreneau, F; Ramnani, DM; Rushing, EJ; George, E; Purdy, PP; Samson, DS				Horowitz, MB; Kopitnik, TA; Landreneau, F; Ramnani, DM; Rushing, EJ; George, E; Purdy, PP; Samson, DS			Multidisciplinary approach to traumatic intracranial aneurysms secondary to shotgun and handgun wounds	SURGICAL NEUROLOGY			English	Article						aneurysm; traumatic; shotgun; coils; bypass	ARTERY; BRAIN	BACKGROUND Traumatic intracranial aneurysms (TICAs) may develop following gunshot injuries to the head. Management of these lesions often combines various aspects of micro-neurosurgical and endovascular techniques to safely repair or obliterate vessel defects. METHODS We reviewed our experience over the last 18 years and identified five cases of intracranial aneurysms following gunshot and handgun wounds that were treated surgically and/or endovascularly. RESULTS All patients had successful obliteration of their lesions using a variety of therapeutic modalities aimed at preserving neurologic function while at the same time eliminating the aneurysm from the circulation. CONCLUSION Both micro-neurosurgery and endovascular surgery have important roles to play in the management of TICAs. In some cases, both methods can be combined to eliminate lesions and maximize patient recovery in a safe, efficient, and effective fashion. (C) 1999 by Elsevier Science Inc.	Univ Texas, SW Med Ctr, Dept Neurosurg, Dallas, TX 75235 USA	Horowitz, MB (corresponding author), Univ Texas, SW Med Ctr, Dept Neurosurg, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.						AARABI B, 1988, NEUROSURGERY, V22, P1056, DOI 10.1227/00006123-198806010-00014; ACOSTA C, 1972, J NEUROSURG, V36, P531, DOI 10.3171/jns.1972.36.5.0531; BANK WO, 1978, AM J ROENTGENOL, V130, P975, DOI 10.2214/ajr.130.5.975; COURVILLE C B, 1960, Bull Los Angel Neuro Soc, V25, P48; FERRY DJ, 1972, J NEUROSURG, V36, P503, DOI 10.3171/jns.1972.36.4.0503; HADDAD FS, 1991, NEUROSURGERY, V28, P1; HIRSCH JF, 1962, NEURO-CHIR, V8, P189; Jackson F E, 1970, J Trauma, V10, P1158, DOI 10.1097/00005373-197012000-00008; KAUFMAN HH, 1980, NEUROSURGERY, V6, P181, DOI 10.1227/00006123-198002000-00011; Martin E M, 1986, J Neurosci Nurs, V18, P89; MOORE D, 1979, SURG NEUROL, V11, P115; PEERLESS S, 1988, OPERATIVE NEUROSURGI, P973; PETTY J M, 1969, Journal of Neurosurgery, V30, P741, DOI 10.3171/jns.1969.30.6.0741; RAIMONDI AJ, 1960, NEUROCHIRURGIA STUTT, V11, P219; ROBBINS JB, 1976, LARYNGOSCOPE, V86, P893, DOI 10.1288/00005537-197607000-00001; SADAR ES, 1973, SURG GYNECOL OBSTET, V137, P59; SALAR G, 1978, J NEUROSURG, V49, P100, DOI 10.3171/jns.1978.49.1.0100; SARWAR M, 1976, RADIOLOGY, V120, P603, DOI 10.1148/120.3.603; SCHMIDT-VANDERHEYDEN W, 1971, Archiv fuer Psychiatrie und Nervenkrankheiten, V214, P10, DOI 10.1007/BF00344623; SPETZLER RF, 1979, NEUROSURGERY, V4, P334, DOI 10.1227/00006123-197904000-00011	20	25	26	0	0	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA	0090-3019			SURG NEUROL	Surg. Neurol.	JAN	1999	51	1					31	41		10.1016/S0090-3019(98)00029-9			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	160PW	WOS:000078241000014	9952121				2021-06-18	
S	Kelley, KM; Tkachenko, TA; Pliskin, NH; Fink, JW; Lee, RC		Chen, CT; Lee, RC; Shih, JX; Zhong, MH		Kelley, KM; Tkachenko, TA; Pliskin, NH; Fink, JW; Lee, RC			Life after electrical injury - Risk factors for psychiatric sequelae	OCCUPATIONAL ELECTRICAL INJURY: AN INTERNATIONAL SYMPOSIUM	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	3rd International Conference on Electrical Injury and Safety	OCT 26-28, 1998	SHANGHAI, PEOPLES R CHINA	Univ Chicago, Elect Trauma Res Program, Shanghai Elect Power Hosp, China Burn Assoc, China Hydro Elect Power Med Sci Assoc, Cooper Bussmann, Dupont Co, US Electr Power Res Inst, Integra Lifesci, China Med Assoc, Shanghai Branch, Soc Phys Regulat Biol & Med, US Natl Sci Fdn, Univ Chicago, Off Continuing Med Educ, Westaim Biomed Corp			POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN INJURY; AMNESIA; MEMORY; EVENT	Long-term cognitive and emotional deficits have been commonly reported in electrical injury (EI) survivors. However, it remains undetermined what factors may lead to the development of such effects in some patients and not in others. In this study, we hypothesized that certain elements of subjective EI experience may predict specific psychiatric sequelae. A group of 73 postacute EI patients were included in this retrospective study. Statistical associations were examined between major psychiatric diagnoses (posttraumatic stress disorder and major depression) and such EI descriptors as having experienced "no-let-go" or having been knocked away on contact, as well as loss of consciousness or altered states of consciousness at the scene of the accident (including amnesia for the event). The study results will help physicians determine which patients may be at increased risk of developing psychiatric symptoms and address these issues as part of their total rehabilitation plan.	Univ Chicago, Dept Psychiat, Chicago, IL 60637 USA; Univ Chicago, Dept Surg, Chicago, IL 60637 USA	Kelley, KM (corresponding author), Univ Chicago, Dept Psychiat, Chicago, IL 60637 USA.						American Psychiatric Association, 1994, DIAGN STAT MAN MENT; KELLEY KM, 1994, ANN NY ACAD SCI, V720, P213, DOI 10.1111/j.1749-6632.1994.tb30449.x; King NS, 1997, J NEUROL NEUROSUR PS, V62, P82, DOI 10.1136/jnnp.62.1.82; LAYTON BS, 1995, CLIN NEUROPSYCHOL, V9, P2, DOI 10.1080/13854049508402050; LEDOUX J, 1992, NEUROPSYCHOLOGY MEMO, P463; Lee RC, 1997, CURR PROB SURG, V34, P682, DOI 10.1016/S0011-3840(97)80007-X; Mancusi-Ungaro H R Jr, 1986, J Burn Care Rehabil, V7, P521, DOI 10.1097/00004630-198611000-00015; MELLEN PF, 1992, J FORENSIC SCI, V37, P1016; Pliskin NH, 1998, J TRAUMA, V44, P709, DOI 10.1097/00005373-199804000-00027; Premalatha G D, 1994, Med J Malaysia, V49, P292; PRIMEAU M, 1995, SEMIN NEUROL, V15, P279, DOI 10.1055/s-2008-1041033; Saffle Jeffrey R., 1995, Journal of Burn Care and Rehabilitation, V16, P219, DOI 10.1097/00004630-199505000-00002; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SQUIRE LR, 1992, J COGNITIVE NEUROSCI, V4, P232, DOI 10.1162/jocn.1992.4.3.232; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; ZAHARINI MC, 1991, STRUCTURED CLIN INTE	16	25	25	1	3	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-233-9; 1-57331-232-0	ANN NY ACAD SCI	Ann.NY Acad.Sci.		1999	888						356	363		10.1111/j.1749-6632.1999.tb07970.x			8	Emergency Medicine; Public, Environmental & Occupational Health; Multidisciplinary Sciences; Rehabilitation	Emergency Medicine; Public, Environmental & Occupational Health; Science & Technology - Other Topics; Rehabilitation	BP20J	WOS:000084392200036	10842647				2021-06-18	
J	Dritschel, BH; Kogan, L; Burton, A; Burton, E; Goddard, L				Dritschel, BH; Kogan, L; Burton, A; Burton, E; Goddard, L			Everyday planning difficulties following traumatic brain injury: a role for autobiographical memory	BRAIN INJURY			English	Article							DAMAGE	The present study examines the role of autobiographical memory in describing how to perform both open-ended and closed everyday activities in 12 patients suffering traumatic brain injury and 12 aged-matched controls. The frequency thigh versus low) of performing the activities was also manipulated. Patients seemed less well able to benefit from using specific autobiographical memories; they reported using significantly fewer specific autobiographical memories for describing how to perform low-frequency activities and significantly more such memories for high-frequency activities compared with controls. The quality of their descriptions was also significantly poorer for the open-ended activities. Finally, significant correlations were found between the quality of the descriptions and the retrieval of specific autobiographical memories for the controls only. The importance of the retrieval of specific autobiographical memories for everyday problem-solving is discussed.	Univ E London, Dept Psychol, Cognit Neuropsychol Res Unit, London E15 4LZ, England; Inst Psychotherapy Res, Princeton, NJ USA	Dritschel, BH (corresponding author), Univ E London, Dept Psychol, Cognit Neuropsychol Res Unit, Romford Rd, London E15 4LZ, England.		Burton, Mike/A-9491-2008; Goddard, Lorna/R-8635-2016	Burton, Mike/0000-0002-2035-2084; Goddard, Lorna/0000-0001-8884-3253; Dritschel, Barbara/0000-0002-0909-6323			Baddeley A.D., 1986, AUTOBIOGRAPHICAL MEM, P225; BADDELEY AD, 1997, HUMAN MEMORY, P85; BORRINI G, 1989, PSYCHOL MED, V19, P215, DOI 10.1017/S0033291700011181; CONWAY MA, 1996, BASIC APPL MEMORY TH, P295; DELLASALA S, 1993, NEUROPSYCHOLOGIA, V31, P823; DRITSCHEL B, 1991, EUR COGN SOC C CUOM; ELITHORN A, 1955, J NEUROL NEUROSUR PS, V18, P287, DOI 10.1136/jnnp.18.4.287; EVANS J, 1992, PSYCHOL MED, V22, P399, DOI 10.1017/S0033291700030348; Goddard L, 1996, J ABNORM PSYCHOL, V105, P609, DOI 10.1037/0021-843X.105.4.609; HAGEN C, 1979, AM SPEECH LANG HEAR; NEEDHAM DR, 1991, MEM COGNITION, V19, P543, DOI 10.3758/BF03197150; NELSON K, 1991, INT C MEM LANC UK; RYLANDER G, 1939, ACTA PSYCHIAT KBH S, V20, P3; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1988, NEUROPSYCHOLOGY MENT, P328; WILLIAMS JMG, 1996, CONSTRUCTING OUR PAS, P244; Williams WH, 1998, NEUROPSYCHOL REHABIL, V8, P43, DOI 10.1080/713755551; Wilson B. A., 1991, RIVERMEAD BEHAV MEMO	18	25	25	0	8	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	1998	12	10					875	886					12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	121FR	WOS:000076003100006	9783085				2021-06-18	
J	Abu-Judeh, HH; Singh, M; Masdeu, JC; Abdel-Dayem, HM				Abu-Judeh, HH; Singh, M; Masdeu, JC; Abdel-Dayem, HM			Discordance between FDG uptake and technetium-99m-HMPAO brain perfusion in acute traumatic brain injury	JOURNAL OF NUCLEAR MEDICINE			English	Article						fluorine-18-fluorodeoxyglucose; technetium-99m-hexamethyl propyleneamine oxime; traumatic brain injury; coincidence imaging; SPECT brain perfusion	EMISSION COMPUTED-TOMOGRAPHY; HEAD-INJURY; PET; SPECT; METABOLISM; DEFICITS; DISEASE	A 28-yr-old woman who sustained a mild traumatic brain injury had an F-18-fluorodeoxyglucose (FDG) PET brain study using coincidence imaging performed on a dual-head gamma camera (MCD version; ADAC, Milpitas, CA) followed 24 hr later by Tc-99m-hexamethyl propyleneamine oxime SPECT brain perfusion imaging using a triple-head gamma camera (TRIONIX, Twinsburg, OH). The results of the SPECT brain perfusion study demonstrated decreased frontoparietal cortical brain perfusion, whereas F-18-FDG cerebral uptake was normal. Neuropsychological evaluation suggested frontal robe involvement. This case demonstrates the possibility of discordance between brain perfusion and glucose uptake in acute mild traumatic brain injury.	New York Med Coll, St Vincents Hosp & Med Ctr, Dept Radiol, Nucl Med Sect, New York, NY 10011 USA; New York Med Coll, St Vincents Hosp & Med Ctr, Dept Neurol, Nucl Med Sect, New York, NY 10011 USA	Abdel-Dayem, HM (corresponding author), New York Med Coll, St Vincents Hosp & Med Ctr, Dept Radiol, Nucl Med Sect, 53 W 11th St, New York, NY 10011 USA.		Masdeu, Joseph C/B-5052-2010				ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; ADAMS JH, 1975, HDB CLINICAL NEUROLO, V23, P35; Alavi A, 1989, J Neuropsychiatry Clin Neurosci, V1, pS45; ALAVI A, 1991, SEMIN NUCL MED, V21, P58, DOI 10.1016/S0001-2998(05)80079-0; Alavi A, 1996, J NUCL MED, V37, P1170; ALAVI A, 1990, J NUCL MED S, V31, pP741; ALAVI A, 1987, J CEREB BLOOD FLO S1, V7, pS646; BOECKER H, 1994, J COMPUT ASSIST TOMO, V18, P542, DOI 10.1097/00004728-199407000-00005; DAVIS PC, 1994, AM J ROENTGENOL, V162, P1267, DOI 10.2214/ajr.162.6.8191980; GEORGE J K, 1989, Journal of Nuclear Medicine, V30, P802; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; HENKIN R, 1996, NUCL MED ROLE POSITR, P1344; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LOESSNER A, 1995, J NUCL MED, V36, P1141; Masdeu J C, 1994, J Neuroimaging, V4, P177; MESSA C, 1994, J NUCL MED, V35, P210; MIELKE R, 1994, EUR J NUCL MED, V21, P1052; RAO N, 1984, ARCH PHYS MED REHAB, V65, P759; SABRI O, 1995, NUKLEARMED-NUCL MED, V34, P50; SOUDER E, 1990, Journal of Nuclear Medicine, V31, P876; Stuss D. T., 1989, CLIN NEUROPSYCHOL, V3, P145, DOI DOI 10.1080/13854048908403287; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1987, CLIN NEUROPSYCHOLOGI, V5, P139; Yamaki T, 1996, J NUCL MED, V37, P1166	25	25	25	0	0	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA	0161-5505	1535-5667		J NUCL MED	J. Nucl. Med.	AUG	1998	39	8					1357	1359					3	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	108FG	WOS:000075254900012	9708506				2021-06-18	
J	Fitzpatrick, MO; Dewar, D; Teasdale, GM; Graham, DI				Fitzpatrick, MO; Dewar, D; Teasdale, GM; Graham, DI			The neuronal cytoskeleton in acute brain injury	BRITISH JOURNAL OF NEUROSURGERY			English	Article						cytoskeleton; head injury; microtubule; neurofilament	DIFFUSE AXONAL INJURY; MICROTUBULE-ASSOCIATED PROTEIN-2; TRANSIENT CEREBRAL-ISCHEMIA; HEAD-INJURY; RAT; IMMUNOREACTIVITY; HIPPOCAMPUS; GERBIL; VULNERABILITY; PERMEABILITY	The microtubules, neurofilaments and microfilaments of the neuronal cytoskeleton are essential for the normal functioning of the neurone. Recent studies have shown that disruption of the cytoskeleton may represent a final pathway in many types of neuronal cell injury with both the somato-dendritic and axonal cytoskeleton being affected. This review discusses the current evidence on the role of the neuronal cytoskeleton in the pathogenesis of traumatic brain damage.	So Gen Hosp, Inst Neurol Sci, Dept Neurosurg, Glasgow G51 4TF, Lanark, Scotland; So Gen Hosp, Inst Neurol Sci, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland; Univ Glasgow, Wellcome Surg Inst, Glasgow, Lanark, Scotland	Fitzpatrick, MO (corresponding author), So Gen Hosp NHS Trust, Inst Neurol Sci, Dept Neurosurg, Glasgow, Lanark, Scotland.						ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; Adams JH, 1992, GREENFIELDS NEUROPAT; AOKI M, 1995, BRAIN RES, V669, P189, DOI 10.1016/0006-8993(94)01227-9; ARAKI T, 1989, ACTA NEUROL SCAND, V80, P548, DOI 10.1111/j.1600-0404.1989.tb03925.x; BRADY ST, 1992, NEUROREGENERATION, P7; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; DEWAR D, 1995, BRAIN RES, V684, P70, DOI 10.1016/0006-8993(95)00417-O; DEWAR D, 1993, ACTA NEUROPATHOL, V86, P623, DOI 10.1007/BF00294302; Dewar D, 1997, ACTA NEUROPATHOL, V93, P71, DOI 10.1007/s004010050584; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; Fitzpatrick MO, 1996, BRIT J NEUROSURG, V10, P483, DOI 10.1080/02688699647122; GEDDES JW, 1994, J CEREBR BLOOD F MET, V14, P554, DOI 10.1038/jcbfm.1994.69; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HALL GF, 1995, J COMP NEUROL, V353, P38, DOI 10.1002/cne.903530106; HAYES RL, 1995, J NEUROTRAUM, V12, P933, DOI 10.1089/neu.1995.12.933; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; INUZUKA T, 1990, STROKE, V21, P917, DOI 10.1161/01.STR.21.6.917; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Maxwell WL, 1996, MICROSC RES TECHNIQ, V34, P522, DOI 10.1002/(SICI)1097-0029(19960815)34:6<522::AID-JEMT4>3.0.CO;2-L; OGATA N, 1989, J NEUROSURG, V70, P103, DOI 10.3171/jns.1989.70.1.0103; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POSTMANTUR R, 1994, J NEUROTRAUM, V11, P533; POSTMANTUR RM, 1996, J NEUROPATHOL EXP NE, V55, P68; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Vanicky I, 1995, NEUROREPORT, V7, P161, DOI 10.1097/00001756-199512290-00039; WHITSON JS, 1995, BRAIN RES, V694, P213, DOI 10.1016/0006-8993(95)00745-C; YAGHMAI A, 1992, J NEUROPATHOL EXP NE, V23, P63; YAMAMOTO K, 1986, BRAIN RES, V384, P1, DOI 10.1016/0006-8993(86)91212-6; YANAGIHARA T, 1990, ACTA NEUROPATHOL, V80, P499, DOI 10.1007/BF00294610; YOSHIMINE T, 1985, J NEUROSURG, V63, P922, DOI 10.3171/jns.1985.63.6.0922	37	25	26	0	2	CARFAX PUBL CO	ABINGDON	PO BOX 25, ABINGDON, OXFORDSHIRE, ENGLAND OX14 3UE	0268-8697			BRIT J NEUROSURG	Br. J. Neurosurg.	AUG	1998	12	4					313	317					5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	115AC	WOS:000075640500003	10070422				2021-06-18	
J	Zou, LL; Burmeister, LA; Styren, SD; Kochanek, PM; DeKosky, ST				Zou, LL; Burmeister, LA; Styren, SD; Kochanek, PM; DeKosky, ST			Up-regulation of type 2 iodothyronine deiodinase mRNA in reactive astrocytes following traumatic brain injury in the rat	JOURNAL OF NEUROCHEMISTRY			English	Article						astrocytes; in situ hybridization; mRNA; thyroid hormone; 3,5,3 '-triiodothyronine; type 2 5 '-deiodinase; traumatic brain injury	CEREBRAL-CORTEX; AXONAL REGENERATION; INTRACELLULAR 3,5,3'-TRIIODOTHYRONINE; ONSET HYPOTHYROIDISM; THYROXINE TREATMENT; THYROID-HORMONES; PYRAMIDAL CELLS; NERVOUS-SYSTEM; RECOVERY; TISSUES	Type 2 5'-deiodinase (5'-D2), which converts thyroxine to the more active thyroid hormone 3,5,3'-triiodothyronine (T3), is believed to be an important source of intracellular T3 in the brain. The activity of this enzyme is increased in hypothyroidism and decreased in hyperthyroidism, and as such, it serves an important role to protect the brain from wide fluctuations in T3 during changes in thyroidal state. Although it has been hypothesized that T3 may facilitate neuronal regeneration after CNS injury, the 5'-D2 response to brain injury is unknown. To assess the 5'-D2 mRNA response to injury, we performed in situ hybridization following traumatic brain injury. In unlesioned animals, 5'-D2 mRNA was undetectable. At 3 days posttrauma, 5'-D2 mRNA was detected in ipsilateral cortex near the contusion. A significant further increase of 5'-D2 mRNA was noted 7 days posttrauma in both hippocampus and cortex. Similar response was also observed on the contralateral side. Colocalization of 5'-D2 mRNA with glial fibrillary acidic protein indicates that reactive astrocytes were the major cellular source for the trauma-induced 5'-D2 expression. These data demonstrate, for the first time, a trauma-induced, astrocytic up-regulation of 5'-D2 mRNA, suggesting a potential role for T3 action in adult brain's response to injury and recovery.	Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Anesthesiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Neurobiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Neurol, Pittsburgh, PA 15213 USA	DeKosky, ST (corresponding author), Univ Pittsburgh, Med Ctr, Dept Psychiat, 3811 OHara St, Pittsburgh, PA 15213 USA.		Kochanek, Patrick M/D-2371-2015; Burmeister, Lynn/AAA-5434-2020	Kochanek, Patrick M/0000-0002-2627-913X; DeKosky, Steven/0000-0003-3743-2758; Burmeister, Lynn/0000-0003-4795-2546	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG05133] Funding Source: Medline; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK02147-03] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K11DK002147] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P01NS030318, P50NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005133] Funding Source: NIH RePORTER		BERNAL J, 1995, EUR J ENDOCRINOL, V133, P390, DOI 10.1530/eje.0.1330390; Burmeister LA, 1997, ENDOCRINOLOGY, V138, P5231, DOI 10.1210/en.138.12.5231; Clark RSB, 1997, J NEUROSCI, V17, P9172; CRANTZ FR, 1980, J CLIN INVEST, V65, P935, DOI 10.1172/JCI109749; CRANTZ FR, 1982, ENDOCRINOLOGY, V110, P367, DOI 10.1210/endo-110-2-367; Croteau W, 1996, J CLIN INVEST, V98, P405, DOI 10.1172/JCI118806; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DEONA CR, 1988, PEDIATR RES, V24, P588, DOI 10.1203/00006450-198811000-00010; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FARSETTI A, 1991, J BIOL CHEM, V266, P23226; FERTIG A, 1971, EXP NEUROL, V33, P372, DOI 10.1016/0014-4886(71)90029-X; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; GuadanoFerraz A, 1997, P NATL ACAD SCI USA, V94, P10391, DOI 10.1073/pnas.94.19.10391; GUTH L, 1974, EXP NEUROL, V45, P606, DOI 10.1016/0014-4886(74)90165-4; HARVEY JE, 1967, J NEUROPATH EXP NEUR, V26, P661, DOI 10.1097/00005072-196710000-00011; HEINICKE E, 1977, J NEUROL SCI, V31, P293, DOI 10.1016/0022-510X(77)90114-9; KESSLAK JP, 1986, EXP NEUROL, V92, P377, DOI 10.1016/0014-4886(86)90089-0; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; LEONARD JL, 1981, SCIENCE, V214, P571, DOI 10.1126/science.7291997; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Oppenheimer Jack H., 1995, P249; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; POLITIS MJ, 1985, BRAIN RES, V346, P186, DOI 10.1016/0006-8993(85)91114-X; RUDGE JS, 1989, EXP NEUROL, V103, P1, DOI 10.1016/0014-4886(89)90180-5; RUIZDEONA C, 1980, BRAIN RES, V85, P91; RUIZMARCOS A, 1994, J NEUROBIOL, V25, P808, DOI 10.1002/neu.480250706; RUIZMARCOS A, 1988, EXP BRAIN RES, V73, P583, DOI 10.1007/BF00406617; RUIZMARCOS A, 1982, BRAIN RES, V239, P559, DOI 10.1016/0006-8993(82)90530-3; Tu HM, 1997, ENDOCRINOLOGY, V138, P3359, DOI 10.1210/en.138.8.3359; VANDOORN J, 1982, ACTA ENDOCRINOL-COP, V101, P386, DOI 10.1530/acta.0.1010386; VANDOORN J, 1983, J CLIN INVEST, V72, P1778, DOI 10.1172/JCI111138; VANDOORN J, 1984, ENDOCRINOLOGY, V115, P174, DOI 10.1210/endo-115-1-174; ZOU L, 1997, J NEUROTRAUM, V14, P769	33	25	26	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	AUG	1998	71	2					887	890					4	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	102FB	WOS:000074912800050	9681483				2021-06-18	
J	Signorini, DF; Shad, A; Piper, IR; Statham, PFX				Signorini, DF; Shad, A; Piper, IR; Statham, PFX			A clinical evaluation of the Codman MicroSensor for intracranial pressure monitoring	BRITISH JOURNAL OF NEUROSURGERY			English	Article						intracranial pressure; monitoring; traumatic brain injury		The strain-gauge Codman MicroSensor intracranial pressure (ICP) transducer has shown consistently good laboratory performance. To assess the practical performance of the system in patients following acute brain injury, 10 patients were fitted with a MicroSensor and a second ICP monitor. In five cases this was a fibre-optic transducer and in five cases an intraventricular fluid-filled device. Paired ICP values were recorded every 5 min. ICP values ranged from 0 to 31 mmHg. Altman-Bland plots showed that individual readings could differ by as much as 9 mmHg. Further analysis showed that much of this disagreement could be explained try a constant offset on each occasion. Comparison traces of ICP in individual patients show high agreement in timing and size of changes. The unexplained constant offset leads to uncertainty about the true ICP. Treatment decisions are often based upon absolute levels of ICP and patient care may therefore differ depending upon the monitor used.	Univ Edinburgh, Dept Clin Neurosci, Edinburgh, Midlothian, Scotland	Signorini, DF (corresponding author), Univ Edinburgh, Western Gen Hosp, Dept Clin Neurosci, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.						ALTMAN DG, 1983, J ROY STAT SOC D-STA, V32, P307, DOI 10.2307/2987937; BINGHAM K, 1997, J NEUROL NEUROSUR PS, V63, P130; Czosnyka M, 1996, NEUROSURGERY, V38, P219, DOI 10.1097/00006123-199601000-00053; GRAY WP, 1996, NEUROSURGERY, V39, P27; GUILLAUME J, 1951, REV NEUROL, V84, P131; LEGGATE JRS, 1988, INTRACRANIAL PRESSUR, V7, P31; Marmarou A.T., 1994, INTRACRANIAL PRESSUR, P15; MENDELOW AD, 1983, J NEUROSURG, V58, P45, DOI 10.3171/jns.1983.58.1.0045; PIPER IR, 1995, NEUROSURGERY, V36, P1142, DOI 10.1227/00006123-199506000-00012; PIPER IR, 1991, BR J INTENS CARE, V1, P73; Statham P, 1993, INTRACRANIAL PRESSUR, VVIII, P7	11	25	27	0	2	CARFAX PUBL CO	ABINGDON	PO BOX 25, ABINGDON, OXFORDSHIRE, ENGLAND OX14 3UE	0268-8697			BRIT J NEUROSURG	Br. J. Neurosurg.	JUN	1998	12	3					223	227					5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	ZY098	WOS:000074586400005	11013684				2021-06-18	
J	Ebmeyer, U; Safar, P; Radovsky, A; Obrist, W; Alexander, H; Pomeranz, S				Ebmeyer, U; Safar, P; Radovsky, A; Obrist, W; Alexander, H; Pomeranz, S			Moderate hypothermia for 48 hours after temporary epidural brain compression injury in a canine outcome model	JOURNAL OF NEUROTRAUMA			English	Article						brain death; cerebral resuscitation; epidural hematoma; hypothermia; intracranial hypertension; resuscitation; traumatic brain injury	SEVERE HEAD-INJURY; CEREBRAL BLOOD-FLOW; CARDIAC-ARREST; MILD HYPOTHERMIA; POSTISCHEMIC HYPOTHERMIA; INTRACRANIAL HYPERTENSION; GLOBAL-ISCHEMIA; TRAUMATIC COMA; DOGS; DAMAGE	In a previous study with this dog model, post-insult hypothermia of 31 degrees C for 5 h prevented secondary intraventricular pressure (IVP) rise, but during 35 degrees C or 38 degrees C, one-half of the dogs developed delayed IVP rise to brain death. We hypothesized that 31 degrees C extended to 48 h would prevent brain herniation. Using epidural balloon inflation, we increased contralateral IVP to 62 mm Hg for 90 min. Controlled ventilation was to 72 h and intensive care to 96 h. Group 1 dogs (n = 10) were normothermic controls (37.5 degrees C). Group 2 dogs (n = 10) were surface-cooled from 15 to 45 min of balloon inflation and maintained at moderate hypothermia (31 degrees C) to 48 h. Rewarming was from 48 to 72 h. Four additional dogs of hypothermia Group 2 had to be excluded from analysis for pneumonia and/or bleeding diathesis. After balloon deflation, IVP increased to 20 mm Hg or greater at 154 +/- 215 (range 15-720) min following the insult in Group 1 and at 1394 +/- 1191 (range 210-3420) min in Group 2 (p = 0.004), still during 31 degrees C but without further increase during hypothermia. Further IVP rise led to brain death in Group 1 in 6 of 10 dogs at 44 +/- 18 (range 21-72) h (all during controlled ventilation); and in Group 2, in 6 of 10 dogs at 87 +/- 11 (range 72-96) h (p = 0.001), all after rewarming, during spontaneous breathing. Survival to 96 h was achieved by 4 of 10 dogs in Group 1, and by 7 of 10 dogs in Group 2 (NS). Three of the six brain deaths in Group 2 occurred at 96 h. The macroscopically damaged brain volume was only numerically smaller in Group 2. The vermis downward shift was 6.8 +/- 3.5 mm in Group 1, versus 4.7 +/- 2.2 mm in Group 2 (p = 0.05). In an adjunctive study, in 4 additional normothermic dogs, hemispheric cerebral blood flow showed post-insult hypoperfusion bilaterally but no evidence of hyperemia preceding IVP rise to brain death. In conclusion, in this model, moderate hypothermia during and for 48 h after temporary epidural brain compression can maintain a low PVP during hypothermia but cannot prevent lethal brain swelling after rewarming and may cause coagulopathy and pulmonary complications.	Univ Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Med Ctr, Dept Anesthesiol Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA 15260 USA	Safar, P (corresponding author), Univ Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30318] Funding Source: Medline		ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; ASTRUP J, 1980, BRAIN RES, V199, P161, DOI 10.1016/0006-8993(80)90238-3; Baiping Lei, 1994, Stroke, V25, P147; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; BIGELOW WG, 1950, ANN SURG, V132, P849, DOI 10.1097/00000658-195011000-00001; BORISMOLLER F, 1989, NEUROSCI RES COMMUN, V5, P87; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CHEN RYZ, 1978, AM J PHYSIOL, V235, pH136; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHOPP M, 1989, J CEREBR BLOOD F MET, V9, P141, DOI 10.1038/jcbfm.1989.21; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Coimbra C, 1996, STROKE, V27, P1578, DOI 10.1161/01.STR.27.9.1578; DEMPSEY RJ, 1987, NEUROSURGERY, V21, P177, DOI 10.1227/00006123-198708000-00007; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1995, J CEREBR BLOOD F MET, V15, P960, DOI 10.1038/jcbfm.1995.122; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DRIPPS RD, 1956, PHYSL INDUCED HYPOTH; EBMEYER U, 1993, CRIT CARE MED, V21, pS236; EBMEYER U, 1994, RESUSCITATION, V28, pS20; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GISVOLD SE, 1984, STROKE, V15, P803, DOI 10.1161/01.STR.15.5.803; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GREEN EJ, 1995, BRAIN RES, V702, P145, DOI 10.1016/0006-8993(95)01034-1; GRUBB RL, 1975, J NEUROSURG, V43, P385, DOI 10.3171/jns.1975.43.4.0385; HABASH AH, 1982, ACTA NEUROCHIR, V60, P7, DOI 10.1007/BF01401746; JENNETT B, 1975, LANCET, V1, P480; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; KOCHANEK PM, 1997, CRITICAL CARE STATE, P119; KRAMER RS, 1968, J THORAC CARDIOV SUR, V56, P699, DOI 10.1016/S0022-5223(19)42797-9; KUBOYAMA K, 1993, CRIT CARE MED, V21, P1348, DOI 10.1097/00003246-199309000-00019; LEONOV Y, 1990, J CEREBR BLOOD F MET, V10, P57, DOI 10.1038/jcbfm.1990.8; LEONOV Y, 1990, STROKE, V21, P1600, DOI 10.1161/01.STR.21.11.1600; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Marion DW, 1996, CRIT CARE MED, V24, pS81; MARMAROU A, 1996, BRAIN EDEMA 1996, P90; MICHENFELDER JD, 1970, ANESTHESIOLOGY, V33, P430, DOI 10.1097/00000542-197010000-00013; NARAYAN RK, 1995, J NEUROTRAUM, V12, P907, DOI 10.1089/neu.1995.12.907; NEMOTO EM, 1977, STROKE, V8, P558, DOI 10.1161/01.STR.8.5.558; NITTA M, 1990, ACTA NEUROCHIR, V104, P30, DOI 10.1007/BF01842890; OBRIST WD, 1990, CEREBROVAS BRAIN MET, V2, P283; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OUNG CM, 1993, J TRAUMA, V35, P251, DOI 10.1097/00005373-199308000-00013; PATT A, 1988, SURG CLIN N AM, V68, P775; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; POMERANZ S, 1993, J NEUROSURG, V79, P241, DOI 10.3171/jns.1993.79.2.0241; POMERANZ S, 1996, P C NEUR SURG; RADOVSKY A, 1995, STROKE, V26, P2127, DOI 10.1161/01.STR.26.11.2127; ROSOMOFF HL, 1960, SURG GYNECOL OBSTET, V110, P27; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85; Rosomoff HL, 1996, CRIT CARE MED, V24, pS48; ROSOMOFF HL, 1959, ANN NY ACAD SCI, V80, P475, DOI 10.1111/j.1749-6632.1959.tb49225.x; ROSOMOFF HL, 1965, RESP THERAPY, P243; SAFAR P, 1988, CRIT CARE MED, V16, P923, DOI 10.1097/00003246-198810000-00003; Safar P, 1996, STROKE, V27, P105, DOI 10.1161/01.STR.27.1.105; SAFAR P, 1982, PROTECTION TISSUES H, P147; SAFAR P, 1996, TXT NEUROANESTHESIA, P557; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; SNYDER JV, 1975, STROKE, V6, P21, DOI 10.1161/01.STR.6.1.21; STEEN PA, 1980, ANESTHESIOLOGY, V52, P224, DOI 10.1097/00000542-198003000-00007; STERZ F, 1991, CRIT CARE MED, V19, P379, DOI 10.1097/00003246-199103000-00017; STONE HH, 1956, SURG GYNECOL OBSTET, V103, P313; TISHERMAN S, 1991, PREHOSP DISASTER MED, V6, P207; VAAGENES P, 1984, CRIT CARE MED, V12, P846, DOI 10.1097/00003246-198410000-00002; WEINRAUCH V, 1992, STROKE, V23, P1454, DOI 10.1161/01.STR.23.10.1454; Whalen M., 1996, Society for Neuroscience Abstracts, V22, P1904; Xiao F, 1998, AM J EMERG MED, V16, P17, DOI 10.1016/S0735-6757(98)90059-6; XIAO F, 1995, RESUSCITATION, V30, P51, DOI 10.1016/0300-9572(94)00858-D	76	25	26	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	1998	15	5					323	336		10.1089/neu.1998.15.323			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ZL515	WOS:000073441300003	9605347				2021-06-18	
J	McKee, MD; Garay, ME; Schemitsch, EH; Kreder, HJ; Stephen, DJG				McKee, MD; Garay, ME; Schemitsch, EH; Kreder, HJ; Stephen, DJG			Irreducible fracture-dislocation of the hip: A severe injury with a poor prognosis	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						hip fracture-dislocation; irreducible; poor prognosis	TRAUMATIC POSTERIOR DISLOCATION	Objective: To determine the outcome of and prognostic factors associated with irreducible fracture-dislocations of the hip. Design: Retrospective review of a prospectively gathered trauma database. Methods: Using a prospectively gathered trauma database, we identified twenty-five patients with fracture-dislocations of the hip that were irreducible with closed means under a general anaesthetic. All were victims of high-energy trauma with severe injuries (mean Injury Severity Score = 25, range 9 to 54). Eighteen patients had multiple fractures, fifteen had associated systemic injury, and only four sustained the hip injury in an isolated fashion. There were seven associated sciatic nerve injuries (28 percent) and nine associated femoral head or neck fractures (36 percent). The mean time from injury to open reduction was 15.3 hours (range 3 to 58 hours). Results: Twenty-three patients (92 percent) were followed to definitive outcome. Despite accurate reduction, only six patients had satisfactory results (Thompson-Epstein = good or excellent). Poor results were associated with delay in reduction and an associated femoral head or neck fracture. Reasons for the poor results include avascular necrosis, posttraumatic arthritis or chondrolysis, persisting sciatic nerve injury, and heterotopic ossification. Conclusions: An irreducible fracture-dislocation of the hip is a severe injury with a poor prognosis and a high incidence of associated injuries. Outcome is best in patients who do not have an associated femoral head or neck fracture and those whose dislocation is promptly reduced.	St Michaels Hosp, Div Orthopaed, Toronto, ON M5B 1W8, Canada; Univ Toronto, Toronto, ON, Canada; Sunnybrook Hlth Sci Ctr, Div Orthopaed, Toronto, ON M4N 3M5, Canada	McKee, MD (corresponding author), 55 Queen St E,Suite 800, Toronto, ON M5C 1R6, Canada.		Schemitsch, Emil/G-5706-2017	Schemitsch, Emil/0000-0002-6435-9069			BOSSE MJ, 1988, J BONE JOINT SURG AM, V70A, P1231, DOI 10.2106/00004623-198870080-00016; BROOKER AF, 1973, J BONE JOINT SURG AM, VA 55, P1629; Brumback RJ, 1987, P HIP SOC, P181; BUTLER JE, 1981, J BONE JOINT SURG AM, V63, P1292, DOI 10.2106/00004623-198163080-00011; CANALE ST, 1979, J BONE JOINT SURG AM, V61, P7, DOI 10.2106/00004623-197961010-00003; CHAKRABORTI S, 1975, INJURY, V7, P134, DOI 10.1016/0020-1383(75)90011-X; DOWD GSE, 1979, J BONE JOINT SURG AM, V61, P1244, DOI 10.2106/00004623-197961080-00018; DREINHOFER KE, 1994, J BONE JOINT SURG BR, V76B, P6; EPSTEIN HC, 1973, CLIN ORTHOP RELAT R, P116; EPSTEIN HC, 1985, CLIN ORTHOP RELAT R, P9; HEALY WL, 1995, J BONE JOINT SURG AM, V77A, P590, DOI 10.2106/00004623-199504000-00013; HOUGAARD K, 1986, ARCH ORTHOP TRAUM SU, V106, P32, DOI 10.1007/BF00435649; HOUGAARD K, 1988, J BONE JOINT SURG AM, V70A, P233, DOI 10.2106/00004623-198870020-00011; JEFFERY CC, 1957, J BONE JOINT SURG BR, V39, P310; Kaempffe F A, 1991, J Orthop Trauma, V5, P439, DOI 10.1097/00005131-199112000-00009; KARPIK K, 1995, P ORTHOPAEDIC TRAUMA, P116; LEVIN P, 1992, SKELETAL TRAUMA, P1329; MARCHETTI ME, 1995, J ORTHOP TRAUMA, V10, P455; Matta JM, 1996, J BONE JOINT SURG AM, V78A, P1632, DOI 10.2106/00004623-199611000-00002; MOED B, 1989, ORTHOPEDIC T, V13, P759; PIPKIN G, 1957, J BONE JOINT SURG AM, V39, P1027, DOI 10.2106/00004623-195739050-00004; REILLY MC, 1996, P ORTHOPAEDIC TRAUMA, P115; SLATIS P, 1974, INJURY, V5, P188, DOI 10.1016/S0020-1383(74)80003-3; Swiontkowski M F, 1992, J Orthop Trauma, V6, P437, DOI 10.1097/00005131-199212000-00008; THOMPSON VP, 1951, J BONE JOINT SURG AM, V33-A, P746, DOI 10.2106/00004623-195133030-00023; Tornetta 3rd, 1997, J Am Acad Orthop Surg, V5, P27; UPADHYAY SS, 1981, J BONE JOINT SURG BR, V63, P548; Yue JJ, 1996, J ORTHOP TRAUMA, V10, P447, DOI 10.1097/00005131-199610000-00001	28	25	25	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0890-5339			J ORTHOP TRAUMA	J. Orthop. Trauma	MAY	1998	12	4					223	229		10.1097/00005131-199805000-00001			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	ZM882	WOS:000073585800001	9619455				2021-06-18	
J	Alon, G; Dar, A; Katz-Behiri, D; Weingarden, H; Nathan, S				Alon, G; Dar, A; Katz-Behiri, D; Weingarden, H; Nathan, S			Efficacy of a hybrid upper limb neuromuscular electrical stimulation system in lessening selected impairments and dysfunctions consequent to cerebral damage	JOURNAL OF NEUROLOGIC REHABILITATION			English	Article						chronic; stroke; brain injury; electrical stimulation; motor recovery	STROKE PATIENTS; HEMIPLEGIC PATIENTS; FUNCTIONAL STATUS; CONTROLLED TRIAL; LEARNED NONUSE; REHABILITATION; RECOVERY; UNIT; SPASTICITY; DISABILITY	Objective: The purpose of this study was to test the efficacy of a new computerized neuromuscular electric stimulation system (Handmaster(TM)) in improving selected impairments and functional measures of patients who survived stroke and traumatic brain injury (TBI). Methods: Survivors of stroke (n = 13) and TBI (n = 7) with chronic paralysis lasting 6.8 +/- 7.8 years (range 1 to 29 years) participated in a home program of electrical stimulation. The device is a hybrid of a hand-forearm splint that incorporates five surface electrodes and a computerized electrical stimulator. The patterned stimulation elicits finger flexion and extension, lateral pinch, and grasp of the paralyzed hand. Patients practiced daily for 3.4 +/- 0.5 hours over a mean duration of 13.1 +/- 6.6 weeks. Assessment included goniometric measurements of wrist and elbow resting posture, passive and active joints motion, linear distance of fingers to palm, Ashworth scale, and the ability to hold a 1 kg load in the affected hand. The Frenchay arm test represented hand function. Results: ANOVA tests and Wilcoxon signed rank test were employed. There were significant improvements (p = 0.01) in elbow, wrist, and fingers posture; Ashworth scale; volitional active elbow flexion (32.5 +/- 12.7 degrees); wrist extension (12.7 +/- 11.1 degrees) and flexion (9.03 +/- 4.5 degrees). Passive wrist extension improved 13.1 +/- 3.6 degrees. Thirteen patients (65 percent) had active wrist extension post stimulation compared with only three (15 percent) before study commencement. Partial completion of the Frenchay tasks were observed before stimulation in only three patients compared with partial completion of tasks by nine patients at study conclusion. Post stimulation, 16 of 20 patients were able to hold a I kg weight with the NESS system active, compared with only three patients without it. Conclusions: Application of the NESS system for three to four hours daily improves selected impairments and may help to restore partial hand functions of patients with chronic stroke or head injury.	Univ Maryland, Sch Med, Baltimore, MD 21201 USA; NESS Ltd, IL-43654 Raanana, Israel; Chaim Sheba Med Ctr, Dept Neurol Rehabil, IL-52621 Tel Hashomer, Israel; Ben Gurion Univ Negev, Dept Mech Engn, Beer Sheva, Israel		galon@physio.ab.umd.edu					ALFIERI V, 1982, SCAND J REHABIL MED, V14, P177; BACHYRITA P, 1987, J NEURO REHAB, V1, P67; BAKER LL, 1986, PHYS THER, V66, P1930, DOI 10.1093/ptj/66.12.1930; BAKER LL, 1983, PHYS THER, V63, P1967, DOI 10.1093/ptj/63.12.1967; BAKER LL, 1979, PHYS THER, V59, P1495; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BOWMAN BR, 1979, ARCH PHYS MED REHAB, V60, P497; COZAN CD, 1988, ARCH PHYS MED REHAB, V69, P401; DAM M, 1993, STROKE, V24, P1186, DOI 10.1161/01.STR.24.8.1186; DOBKIN B, 1995, NEUROLOGY, V45, pS6; FAGHRI PD, 1994, ARCH PHYS MED REHAB, V75, P73; FIELDS RW, 1987, ARCH PHYS MED REHAB, V68, P407; GOWLAND C, 1992, PHYS THER, V72, P624, DOI 10.1093/ptj/72.9.624; INDREDAVIK B, 1991, STROKE, V22, P1026, DOI 10.1161/01.STR.22.8.1026; Indredavik B, 1997, STROKE, V28, P1861, DOI 10.1161/01.STR.28.10.1861; KALRA L, 1995, STROKE, V26, P990, DOI 10.1161/01.STR.26.6.990; KRAFT GH, 1992, ARCH PHYS MED REHAB, V73, P220; Lincoln NB, 1996, STROKE, V27, P18, DOI 10.1161/01.STR.27.1.18; MCCANN BC, 1976, J AM GERIATR SOC, V24, P211, DOI 10.1111/j.1532-5415.1976.tb06781.x; MERLETTI R, 1978, SCAND J REHABIL MED, V10, P147; NAKAYAMA H, 1994, ARCH PHYS MED REHAB, V75, P394, DOI 10.1016/0003-9993(94)90161-9; OTTENBACHER KJ, 1993, ARCH NEUROL-CHICAGO, V50, P37, DOI 10.1001/archneur.1993.00540010033014; Parker V M, 1986, Int Rehabil Med, V8, P69; REDING MJ, 1988, ARCH NEUROL-CHICAGO, V45, P700; RUSIN MJ, 1990, ARCH PHYS MED REHAB, V71, P914; SCHARFENBERGER JA, 1989, PHYS MED REHABIL STA, V3, P653; SCHULING J, 1993, STROKE, V24, P1173, DOI 10.1161/01.STR.24.8.1173; SMITH ME, 1982, ARCH PHYS MED REHAB, V63, P21; STRAND T, 1985, STROKE, V16, P29, DOI 10.1161/01.STR.16.1.29; SUNDERLAND A, 1992, J NEUROL NEUROSUR PS, V55, P532; TANGEMAN PT, 1990, ARCH PHYS MED REHAB, V71, P876; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; TAUB E, 1994, J EXP ANAL BEHAV, V61, P281, DOI 10.1901/jeab.1994.61-281; TAUB NA, 1994, STROKE, V25, P352, DOI 10.1161/01.STR.25.2.352; Triolo R, 1996, J REHABIL RES DEV, V33, P111; WOLF SL, 1989, EXP NEUROL, V104, P125, DOI 10.1016/S0014-4886(89)80005-6; WOLF SL, 1983, PHYS THER, V63, P1393, DOI 10.1093/ptj/63.9.1393; WOODDAUPHINEE SL, 1990, STROKE, V21, P731, DOI 10.1161/01.STR.21.5.731	38	25	25	0	8	DEMOS MEDICAL PUBLISHING	NEW YORK	386 PARK AVE SOUTH, STE 201, NEW YORK, NY 10016 USA	0888-4390			J NEUROL REHABIL	J. Neurol. Rehabil.		1998	12	2					73	79					7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	123RB	WOS:000076137200005					2021-06-18	
J	Korda, RJ; Douglas, JM				Korda, RJ; Douglas, JM			Attention deficits in stroke patients with aphasia	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							SIMPLE REACTION-TIME; UNILATERAL BRAIN-DAMAGE; CLOSED-HEAD-INJURY; SUSTAINED ATTENTION; RIGHT-HEMISPHERE; MULTIPLE RESOURCES; DIVIDED ATTENTION; PERFORMANCE; VIGILANCE; DISEASE	Attentional capacity and sustained attention were investigated in 21 aphasic stroke patients and 21 non-brain-damaged patients. Attentional capacity was assessed using a series of reaction time (RT) tasks. The aphasic patients demonstrated impaired attentional capacity as shown by slower processing speed than the non-brain-damaged group (p <.01) and greater increases in RT with increased processing load (p <.05). Similar patterns were found for both verbal and spatial material. There was no significant relationship between severity of auditory comprehension deficits and attentional capacity. Sustained attention was assessed using a cognitive vigilance task requiring identification of a target letter presented infrequently over 32 minutes. Both the aphasic and the non-brain-damaged group demonstrated a decline in performance with time on task as shown by a steady increase in RTs (p <.0001), but the decline was equivalent across the groups. Thus, the aphasic group did not show a specific deficit in the ability to sustain attention.	LA TROBE UNIV,FAC HLTH SCI,SCH HUMAN COMMUN SCI,BUNDOORA,VIC 3083,AUSTRALIA; AUSTIN & REPATRIAT MED CTR,DEPT SPEECH PATHOL,HEIDELBERG,VIC,AUSTRALIA			Douglas, Jacinta M/C-2380-2009	Douglas, Jacinta/0000-0003-0940-6624			BLACKBURN H L, 1955, Confin Neurol, V15, P327; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; Bryden M., 1982, LATERALITY FUNCTIONA, P157, DOI [10.1016/B978-0-12-138180-6.50015-8, DOI 10.1016/B978-0-12-138180-6.50015-8]; BUB D, 1990, CORTEX, V26, P227, DOI 10.1016/S0010-9452(13)80352-8; CAMPBELL TF, 1985, J SPEECH HEAR RES, V28, P513, DOI 10.1044/jshr.2804.513; Caplan LR, 1993, STROKE CLIN APPROACH; Carson DH, 1968, CORTEX, V4, P92; Cohen R. A., 1993, NEUROPSYCHOLOGY ATTE; COSLETT HB, 1987, NEUROLOGY, V37, P957, DOI 10.1212/WNL.37.6.957; DEE HL, 1973, ARCH NEUROL-CHICAGO, V28, P163, DOI 10.1001/archneur.1973.00490210043004; DEE HL, 1971, ACTA PSYCHIAT SCAND, V47, P315, DOI 10.1111/j.1600-0447.1971.tb02217.x; DEE HL, 1972, NEUROLOGY, V22, P845, DOI 10.1212/WNL.22.8.845; DERENZI E, 1965, CORTEX, V1, P410; DIMOND SJ, 1979, CORTEX, V15, P43, DOI 10.1016/S0010-9452(79)80005-2; DONNAN GA, 1993, CEREBROVASC DIS, V3, P248, DOI 10.1159/000108710; ELSASS P, 1985, ACTA NEUROL SCAND, V71, P11; FRIEDMAN A, 1981, J EXP PSYCHOL HUMAN, V7, P1031, DOI 10.1037/0096-1523.7.5.1031; FRIEDMAN A, 1982, J EXP PSYCHOL HUMAN, V8, P625, DOI 10.1037/0096-1523.8.5.625; GLOSSER G, 1990, J CLIN EXP NEUROPSYC, V12, P485, DOI 10.1080/01688639008400995; Goodglass H., 1983, ASSESSMENT APHASIA R; Gopher D, 1984, COGNITION MOTOR PROC, P231; GRADY CL, 1989, ARCH NEUROL-CHICAGO, V46, P317, DOI 10.1001/archneur.1989.00520390083021; HAGEMAN CF, 1980, DISS ABSTR INT, V42, P157; HOM J, 1990, J CLIN EXP NEUROPSYC, V12, P644, DOI 10.1080/01688639008401008; HOWES D, 1975, BRAIN, V98, P317, DOI 10.1093/brain/98.2.317; KAIZER F, 1988, STROKE, V19, P335, DOI 10.1161/01.STR.19.3.335; Keppel, 1991, DESIGN ANAL RES HDB; LAPOINTE LL, 1991, APHASIOLOGY, V5, P511, DOI 10.1080/02687039108248556; LILES BZ, 1975, J COMMUN DISORD, V8, P221, DOI 10.1016/0021-9924(75)90015-5; MCDONALD RD, 1964, J NEUROL NEUROSUR PS, V27, P206, DOI 10.1136/jnnp.27.3.206; NEBES RD, 1993, CORTEX, V29, P77, DOI 10.1016/S0010-9452(13)80213-4; NORMAN DA, 1975, COGNITIVE PSYCHOL, V7, P44, DOI 10.1016/0010-0285(75)90004-3; ODONNELL BF, 1993, NEUROPSYCHOLOGY ATTE, P375; Pachella R. G., 1974, HUMAN INFORM PROCESS, P41; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; PEACH RK, 1992, J SPEECH HEAR RES, V35, P810, DOI 10.1044/jshr.3504.810; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; RAMSING S, 1991, APHASIOLOGY, V5, P583, DOI 10.1080/02687039108248567; Salthouse T. A., 1985, THEORY COGNITIVE AGI; Spreen O., 1991, COMPENDIUM NEUROPSYC; Spreen O., 1977, NEUROSENSORY CTR COM; SUNDERLAND A, 1992, NEUROPSYCHOL REHABIL, V2, P137; TARTAGLIONE A, 1991, BRAIN, V114, P1441, DOI 10.1093/brain/114.3.1441; TARTAGLIONE A, 1987, CORTEX, V23, P285, DOI 10.1016/S0010-9452(87)80038-2; TARTAGLIONE A, 1986, NEUROPSYCHOLOGIA, V24, P649, DOI 10.1016/0028-3932(86)90004-7; TATEMICHI TK, 1994, J NEUROL NEUROSUR PS, V57, P202, DOI 10.1136/jnnp.57.2.202; ULRICH R, 1989, BRIT J MATH STAT PSY, V42, P1, DOI 10.1111/j.2044-8317.1989.tb01111.x; VANMOURIK M, 1992, APHASIOLOGY, V6, P491, DOI 10.1080/02687039208249486; Wickens C.D., 1984, VARIETIES ATTENTION, P63, DOI 10.1038/s41598-020-80452-5; WICKENS CD, 1981, HUM FACTORS, V23, P211; WILKINS AJ, 1987, NEUROPSYCHOLOGIA, V25, P359, DOI 10.1016/0028-3932(87)90024-8	51	25	28	0	6	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	AUG	1997	19	4					525	542		10.1080/01688639708403742			18	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	YA413	WOS:A1997YA41300006	9342688				2021-06-18	
J	Parsons, LC; Crosby, LJ; Perlis, M; Britt, T; Jones, P				Parsons, LC; Crosby, LJ; Perlis, M; Britt, T; Jones, P			Longitudinal sleep EEG power spectral analysis studies in adolescents with minor head injury	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	13th Annual Houston Conference on Biomedical Engineering Research	FEB   09, 1996	HOUSTON, TX			electroencephalographic sleep readings; minor brain injury; Delta, Theta & Alpha-1 wave forms; acute and recovery phases; human traumatic brain injury	SEQUELAE; DENSITY	Power spectral analysis (PSA) was used to evaluate the longitudinal overnight electroencephalographic (EEG) sleep recordings of eight subjects, between the ages of 15 and 19 years, who had sustained a minor head injury (MHI). Recordings occurred within 72 h, 6 weeks, and 12 weeks following MHI. A conditioning night preceded the first study night during which EEG electrodes were in place and subjects slept at least 7.5 h with a mean sleep efficiency of 91%. PSA was performed on four channels of EEG data recorded from fronto-temporal (F3-T3, F4-T4), and temporal (T3-T5, T4-T6) electrodes. The three waveforms associated with sleep, Delta, Theta, and Alpha-1 were all significantly elevated within 72 h post-MHI. Over time all wave forms decreased in mean log power. Theta in rapid eye movement (REM) sleep Cycle 1 decreased significantly within 6 weeks postinjury. The greatest number of significant changes, over the 12-week period were recorded during the non-REM (NREM) sleep. Changes included (1) significant decreases in mean log power of Theta and Alpha-1 in Cycle 1 from fronto-temporal leads; (2) significant decreases in Delta, Theta, and Alpha-1 in Cycle 2 from fronto-temporal leads, and (3) significant decreases in Delta and Theta for consistency during Cycle 2 from temporal leads. The intrusion of Theta into the first REM cycle within 6 weeks and its subsequent decrease within 6 weeks suggested the initiation of recovery toward baseline values. This was followed by decreased levels of Theta power during NREM Cycles 1 and 2, and Delta power in Cycle 2, both of which approached their lowest levels within 12 wks. The decrease in Alpha-1 power occurred last. Alpha-1 remained elevated through both Cycles 1 and 2 of the 6th week and then showed a precipitous decrease between the sixth and twelfth week. These findings suggested that following MHI, the brain has a specific sequence of recovery as illustrated by Delta, Theta, and Alpha-1 powers requiring different time frames to reach their lowest levels.	UNIV ARIZONA,COLL MED,TUCSON,AZ 85721; VET AFFAIRS MED CTR,TUCSON,AZ; UNIV ROCHESTER,DEPT PSYCHIAT,ROCHESTER,NY; UNIV ARIZONA,CTR COMP INFORMAT TECHNOL,UNIVERSITY PK,PA; PENN STATE UNIV,UNIVERSITY PK,PA 16802	Parsons, LC (corresponding author), UNIV ARIZONA,COLL NURSING,TUCSON,AZ 85721, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R0 1 NS24169] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS024169] Funding Source: NIH RePORTER		American Sleep Disorders Association, 1990, INT CLASS SLEEP DIS; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BORBELY AA, 1981, ELECTROEN CLIN NEURO, V51, P483, DOI 10.1016/0013-4694(81)90225-X; COOLEY JW, 1965, MATH COMPUT, V19, P297, DOI 10.2307/2003354; DIJK DJ, 1990, SLEEP, V13, P430, DOI 10.1093/sleep/13.5.430; EVANS RW, 1992, NEUROL CLIN, V10, P815; FEINBERG I, 1993, ENCY SLEEP DREAMING, P157; GOTTMAN J, 1990, CURRENT PRACTICE CLI, P51; HUBERTY CJ, 1989, PSYCHOL BULL, V105, P302, DOI 10.1037/0033-2909.105.2.302; JASPER H, 1948, ELECTROEN CLIN NEURO, V10, P371; Kowatch R A, 1989, Psychiatr Med, V7, P37; MACLEAN AW, 1995, SLEEP, V18, P565; MONROE LJ, 1967, J ABNORM PSYCHOL, V72, P255, DOI 10.1037/h0024563; Neter J, 1990, APPLIED LINEAR STATI, p[587, 761]; OHARA C, 1993, ANN C NAT AC NEUR PH; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PARSONS LC, 1981, NEUROSCI LETT, V24, P199, DOI 10.1016/0304-3940(81)90248-2; PARSONS LC, 1982, NURS RES, V31, P260; PARSONS LC, 1993, SLEEP RES, V21, P354; PARSONS LC, 1968, THESIS U TEXAS MED B, V29, P1789; PARSONS LC, 1993, ENCY SLEEP DREAMING, P270; Perlis ML, 1997, PERCEPT MOTOR SKILL, V84, P595, DOI 10.2466/pms.1997.84.2.595; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Rechtschaffen A, 1968, MANUAL STANDARDIZED; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; SAS Institute Inc, 1989, SAS STAT US GUID VER, V2, P846; TEASDALE G, 1974, LANCET, V2, P81; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; WILLIAMS RL, 1988, EEG HUMAN SLEEP CLIN	32	25	26	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	1997	14	8					549	559		10.1089/neu.1997.14.549			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	XU894	WOS:A1997XU89400006	9300565				2021-06-18	
J	Phillips, LL; Lyeth, BG; Hamm, RJ; Jiang, JY; Povlishock, JT; Reeves, TM				Phillips, LL; Lyeth, BG; Hamm, RJ; Jiang, JY; Povlishock, JT; Reeves, TM			Effect of prior receptor antagonism on behavioral morbidity produced by combined fluid percussion injury and entorhinal cortical lesion	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						trauma; deafferentation; scopolamine; MK-801; cognitive function	TRAUMATIC BRAIN INJURY; COGNITIVE IMPAIRMENT; HIPPOCAMPAL FORMATION; NEUROTROPHIC FACTOR; CORTEX LESIONS; MESSENGER-RNA; TIME-COURSE; RAT; RECOVERY; NEURONS	We have used an animal model of traumatic brain injury (TBI) that incorporates both the neurotransmitter toxicity of fluid percussion TBI and deafferentation of bilateral entorhinal cortical (BEC) lesion to explore whether administration of muscarinic cholinergic or N-methyl-D-aspartate glutamatergic antagonists prior to injury ameliorates cognitive morbidity. Fifteen minutes prior to moderate central fluid percussion TBI, rats were given intraperitoneal injections of either scopolamine (1.0 mg/kg) or MK-801 (0.3 mg/kg) and 24 hr later underwent BEC lesion. Body weight was followed for 5 days postinjury, as was beam balance and beam walk performance to assure motor recovery prior to spatial memory testing. Each group was assessed for spatial memory deficits with the Morris water maze at short term (days 11-15) and long-term (60-64 days) postinjury intervals and then compared with untreated combined insult and sham-injured controls. Results showed that each drug significantly elevated body weight relative to untreated injured cases. Both scopolamine and MK-gOl reduced beam balance deficits, whereas neither drug had a significant effect on beam walk deficits. Interestingly, short-term cognitive deficits assessed on days 11-15 were differentially affected by the two drugs: MK-801 pretreatment enhanced the recovery of spatial memory performance, whereas scopolamine pretreatment did not. Long-term (days 60-64) deficits in spatial memory were not altered by pretreatment with either drug. Our results suggest that, unlike fluid percussion TBI alone, behavioral impairment may require more select intervention when deafferentation is part of the head trauma pathology. (C) 1997 Wiley-Liss, Inc.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT ANAT,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHOL,RICHMOND,VA 23298	Phillips, LL (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROSURG,POB 980693 MCV STN,RICHMOND,VA 23298, USA.			Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029995, R01NS020193, P01NS012587, P50NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 29995, NS 20193, NS 12587] Funding Source: Medline		BLACKSTAD TW, 1956, J COMP NEUROL, V105, P417, DOI 10.1002/cne.901050305; BULLOCK R, 1994, INTRACRANIAL PRESSUR, P264; CASTREN E, 1993, EXP NEUROL, V122, P244, DOI 10.1006/exnr.1993.1124; DAI HL, 1995, BRAIN RES BULL, V36, P175, DOI 10.1016/0361-9230(94)00188-7; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faden AI, 1988, J NEUROTRAUM, V5, P33, DOI 10.1089/neu.1988.5.33; FASS B, 1983, BEHAV NEURAL BIOL, V37, P108, DOI 10.1016/S0163-1047(83)91117-2; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HAMM RJ, 1995, EXP NEUROL, V136, P143, DOI 10.1006/exnr.1995.1091; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; HAYES RL, 1988, J NEUROTRAUM, V5, P287; HUGHES P, 1993, NEUROREPORT, V4, P183, DOI 10.1097/00001756-199302000-00017; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LOESCHE J, 1977, BRAIN RES BULL, V2, P31, DOI 10.1016/0361-9230(77)90022-3; LYETH B G, 1989, Society for Neuroscience Abstracts, V15, P1113; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; NITSCH R, 1991, BRAIN RES, V554, P304, DOI 10.1016/0006-8993(91)90205-A; NITSCH R, 1992, P NATL ACAD SCI USA, V89, P5197, DOI 10.1073/pnas.89.11.5197; ODELL DM, 1995, J NEUROSURG, V83, P878, DOI 10.3171/jns.1995.83.5.0878; Paxinos G., 1982, RAT BRAIN STEREOTAXI; Phillips L. L., 1995, Journal of Neurotrauma, V12, P419; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; PHILLIPS LL, 1995, J NEUROTRAUM, V12, P964; Povlishock John T., 1995, P504; REEVES TM, 1987, BEHAV NEUROSCI, V101, P179; Reeves TM, 1997, NEUROSCIENCE, V77, P431, DOI 10.1016/S0306-4522(96)00486-1; SCHACTER GB, 1989, BRAIN RES, V494, P339, DOI 10.1016/0006-8993(89)90602-1; SCHEFF SW, 1977, BEHAV BIOL, V21, P286, DOI 10.1016/S0091-6773(77)90374-1; SCHEFF SW, 1977, BRAIN RES, V150, P45; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; STEWARD O, 1976, J COMP NEUROL, V167, P285, DOI 10.1002/cne.901670303; VARON S, 1989, PHARMACOPSYCHIATRY, V22, P120, DOI 10.1055/s-2007-1014631; ZAFRA F, 1991, P NATL ACAD SCI USA, V88, P10037, DOI 10.1073/pnas.88.22.10037	43	25	25	0	0	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	JUL 15	1997	49	2					197	206					10	Neurosciences	Neurosciences & Neurology	XP112	WOS:A1997XP11200008	9272642				2021-06-18	
J	Furman, JM; Balaban, CD; Pollack, IF				Furman, JM; Balaban, CD; Pollack, IF			Vestibular compensation in a patient with a cerebellar infarction	NEUROLOGY			English	Article							AXIS ROTATIONAL RESPONSES; UNILATERAL LABYRINTHECTOMY; OCULAR REFLEX; FOS EXPRESSION; BRAIN; NYSTAGMUS; FLOCCULUS; NODULUS; RAT; PARAFLOCCULUS	We report the case of a 67-year-old man who suffered a traumatic unilateral peripheral vestibular injury subsequent to an unrelated prior cerebellar infarction that occurred at least 2 years earlier. The patient's clinical course was marked by poor compensation for his peripheral vestibular loss. Four months after his vestibular injury, his symptoms of dizziness had not resolved. He had a spontaneous vestibular nystagmus, and laboratory testing indicated an asymmetric semicircular canal-ocular reflex. The otolith-ocular reflex, tested using off-vertical axis rotation, also was asymmetric but had a preserved modulation component. Visual-vestibular interaction and semicircular canal-otolith interaction were normal. An MRI indicated preservation of the flocculo-nodular lobe but infarction of the pyramis and uvula. Taken together, the findings in this case suggest that despite structural and functional preservation of the flocculo-nodular lobe, an anatomic region often labeled the ''vestibulo-cerebellum,'' a lesion of the cerebellum that can impair CNS compensation for a unilateral peripheral lesion in humans.	UNIV PITTSBURGH,SCH MED,DEPT OTOLARYNGOL,PITTSBURGH,PA; UNIV PITTSBURGH,SCH MED,DEPT NEUROL SURG,PITTSBURGH,PA 15261			Balaban, Carey/I-3467-2017; Balaban, Carey/O-6586-2019	Balaban, Carey/0000-0002-3570-3844; Balaban, Carey/0000-0002-3570-3844	NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [DC00739, DC02556, DC01791] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC002556, R01DC000739, R01DC001791] Funding Source: NIH RePORTER		ANGELAKI DE, 1995, J NEUROPHYSIOL, V73, P1729; BALOH RW, 1986, ADV BIOSCI, V57, P349; CIRELLI C, 1993, ARCH ITAL BIOL, V131, P71; COURJON JH, 1982, BRAIN RES, V239, P251, DOI 10.1016/0006-8993(82)90847-2; Fetter M, 1990, J Vestib Res, V1, P9; Furman JM, 1996, J VESTIBUL RES-EQUIL, V6, P93; FURMAN JMR, 1992, ANN OTO RHINOL LARYN, V101, P643, DOI 10.1177/000348949210100803; FURMAN JMR, 1989, ANN OTO RHINOL LARYN, V98, P551, DOI 10.1177/000348948909800711; FURMAN JMR, 1993, ANN OTO RHINOL LARYN, V102, P137, DOI 10.1177/000348949310200211; GRAFE MR, 1990, AM J NEURORADIOL, V11, P905; HAIN TC, 1988, ACTA OTO-LARYNGOL, V105, P13, DOI 10.3109/00016488809119440; IGARASHI M, 1985, ACTA OTO-LARYNGOL, V99, P452, DOI 10.3109/00016488509108937; Jeannerod M., 1981, LESION INDUCED NEURO, P208; JENKINS HA, 1985, LARYNGOSCOPE, V95, P1224; KAUFMAN GD, 1992, NEUROREPORT, V3, P829, DOI 10.1097/00001756-199210000-00002; Llinas R., 1979, INTEGRATION NERVOUS, P145; LUYTEN WHML, 1986, BRAIN RES, V373, P68, DOI 10.1016/0006-8993(86)90316-1; PATRICKSON JW, 1985, EXP BRAIN RES, V60, P227; PRECHT W, 1966, J NEUROPHYSIOL, V29, P996; SHOTTON JC, 1989, J LARYNGOL OTOL, V103, P263, DOI 10.1017/S0022215100108667; SMITH PF, 1989, BRAIN RES REV, V14, P155, DOI 10.1016/0165-0173(89)90013-1; SOLOMON D, 1994, EXP BRAIN RES, V102, P57; WAESPE W, 1985, SCIENCE, V228, P199, DOI 10.1126/science.3871968; WAESPE W, 1983, EXP BRAIN RES, V50, P9; ZEE DS, 1981, J NEUROPHYSIOL, V46, P878	25	25	25	0	2	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0028-3878			NEUROLOGY	Neurology	APR	1997	48	4					916	920		10.1212/WNL.48.4.916			5	Clinical Neurology	Neurosciences & Neurology	WU327	WOS:A1997WU32700022	9109877				2021-06-18	
J	Giles, GM; Ridley, JE; Dill, A; Frye, S				Giles, GM; Ridley, JE; Dill, A; Frye, S			A consecutive series of adults with brain injury treated with a washing and dressing retraining program	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						activities of daily living; brain injuries; rehabilitation	HEAD-INJURY; TIME-DELAY; SKILLS; ENCEPHALITIS; STRATEGIES; BACKWARD; PATIENT	Objectives. Single-case reports indicate that behavioral method can assist persons with brain injury to redevelop self-care skills. However, the proportion of patients who could benefit from these interventions is unknown. The present study used a specific retraining protocol to treat all patients admitted to a single facility, over a 3-year period who were unable to wash and dress independently. Method. Four patients out of 48 met the study criteria and were treated with the washing and dressing protocol. Three had traumatic brain injury, and one had brain injury after cerebral bleed. The training program involved behavioral observation, task analysis, consistent practice, and cue fading. The Adaptive Behavior Scale was used to measure behavior change. Results. Three subjects achieved rapid independence in washing and dressing (20 days, 37 days, and 11 days of treatment), and one did not show significant clinical Improvement. Conclusion. All patients admitted to the facility during a 3-year period who required washing and dressing retraining were treated with the same protocol. The consecutive series design prevented researchers om selecting patients who they believed were good treatment candidates; therefore, the findings support the general applicability of the training program.	SAMUEL MERRITT COLL,OAKLAND,CA; TRANSIT BERKELEY,BERKELEY,CA; STANFORD SLEEP DISORDERS CTR,STANFORD,CA; GUARDIAN HLTH GRP INC,CORTE MADERA,CA; THERAPY RESOURCES INC,SONOMA,CA	Giles, GM (corresponding author), NEUROBEHAV PROGRAM HIGHVIEW,CLIN SERV,1301 E 31ST ST,OAKLAND,CA 94602, USA.						BLAKE KA, 1969, PSYCHOL REP, V25, P319, DOI 10.2466/pr0.1969.25.1.319; BURKE WH, 1988, INT J REHABIL RES, V11, P235, DOI 10.1097/00004356-198809000-00003; CERMAK LS, 1976, NEUROPSYCHOLOGIA, V14, P311, DOI 10.1016/0028-3932(76)90025-7; COHEN RE, 1986, ARCH PHYSICAL MED RE, V67, P833; DAVIS JR, 1994, BRAIN INJURY REHABIL, P279; EAMES P, 1985, J NEUROL NEUROSUR PS, V48, P613, DOI 10.1136/jnnp.48.7.613; Eames P, 1985, Int Rehabil Med, V7, P130; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; FOX RM, 1989, BEHAV THER, V20, P61; FUSSEY I, 1988, REHABILITATION SEVER; GILES GM, 1989, J CLIN EXP NEUROPSYC, V11, P311, DOI 10.1080/01688638908400891; GILES GM, 1989, ARCH PHYS MED REHAB, V70, P156; GILES GM, 1988, AM J OCCUP THER, V42, P658, DOI 10.5014/ajot.42.10.658; GILES GM, 1993, BRAIN INJURY REHABIL; Heacock L, 1989, Arch Phys Med Rehabil, V70, P720; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Jennett B, 1981, MANAGEMENT HEAD INJU; KATZMANN S, 1994, AM J OCCUP THER, V48, P259, DOI 10.5014/ajot.48.3.259; KAZDIN AE, 1994, BEHAVIOR MODIFICATIO; LEWIS FD, 1988, BEHAV THER, V19, P203, DOI 10.1016/S0005-7894(88)80043-1; MARTIN G, 1981, BEHAV RES SEVERE DEV, V2, P117; MCDONNELL J, 1987, J ASSOC PERS SEVERE, V12, P227; MCDONNELL J, 1989, EDUC TRAIN MENT RET, V24, P230; MCMILLAN T M, 1990, Brain Injury, V4, P399, DOI 10.3109/02699059009026193; NIHARA K, 1975, ADAPTIVE BEHAV SCALE; O'Reilly M. F., 1989, BEHAV RESIDENTIAL TR, V4, P359, DOI 10. 1002/bin. 2360040406; PULASKI KH, 1994, AM J OCCUP THER, V48, P263, DOI 10.5014/ajot.48.3.263; SKINNER BF, 1938, BEHAVIOR ORGANISMS; SPOONER F, 1984, EDUC TRAIN MENT RET, V19, P15; SPOONER F, 1981, DISS ABSTR INT A; TEASDALE G, 1974, LANCET, V2, P81; WALLS RT, 1981, BEHAV MODIF, V5, P61, DOI 10.1177/014544558151005; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; WOLERY M, 1990, EDUC TRAIN MENT RET, V25, P243	34	25	25	1	1	AMER OCCUPATIONAL THERAPY ASSOC	ROCKVILLE	1383 PICCARD DRIVE PO BOX ROCKVILLE, MD 20850-4375	0272-9490			AM J OCCUP THER	Am. J. Occup. Ther.	APR	1997	51	4					256	266		10.5014/ajot.51.4.256			11	Rehabilitation	Rehabilitation	WN496	WOS:A1997WN49600003	9085724				2021-06-18	
J	Iwamoto, Y; Yamaki, T; Murakami, N; Umeda, M; Tanaka, C; Higuchi, T; Aoki, I; Naruse, S; Ueda, S				Iwamoto, Y; Yamaki, T; Murakami, N; Umeda, M; Tanaka, C; Higuchi, T; Aoki, I; Naruse, S; Ueda, S			Investigation of morphological change of lateral and midline fluid percussion injury in rats, using magnetic resonance imaging	NEUROSURGERY			English	Article						brain atrophy; cortical contusion; diffuse axonal injury; fluid percussion; magnetic resonance imaging; rat; traumatic brain injury	DIFFUSE AXONAL INJURY; CLOSED HEAD-INJURY; COMPUTED-TOMOGRAPHY; BRAIN INJURY; TRAUMA; INFARCTION; IMAGES	OBJECTIVE: Investigating the time course of morphological changes in experimental traumatic brain injury (TBI) in vivo helps to clarify the mechanism of TBI and develop new therapeutic modalities. We examined the morphological changes in experimental TBI, using magnetic resonance imaging (MRI) in a rat model. METHODS: We produced lateral fluid percussion injury (LFP) and midline fluid percussion injury (MFP) in rats, using the Yamaki fluid percussion device. The rats were divided into four groups: LFP, MFP, sham LFP, and sham MFP. MRI was performed with a 4.7-T magnetic resonance apparatus 2 days and 90 days after the induction of injury. T1-, T2-, and T2*-weighted images were obtained using a surface coil. RESULTS: Hemorrhage, contusion, and brain edema in LFP models were detected on the 2nd day after injury, and the necrotic tissue was absorbed and replaced by cerebrospinal fluid on the 90th day. In MFP animals, we detected a small hemorrhage in the corpus callosum with minimal brain edema around the hemorrhage on the 2nd day after injury, and on the 90th day, enlarged ventricles and cisterns were observed, indicating brain atrophy. CONCLUSION: MRI, therefore, is useful for plotting morphological changes in experimental TBI in vivo. We report the novel and clinically important finding of brain atrophy after experimental TBI.	KYOTO PREFECTURAL UNIV MED, DEPT NEUROSURG, KAMIGYO KU, KYOTO 602, JAPAN; MEIJI COLL ORIENTAL MED, DEPT NEUROSURG, KYOTO, JAPAN			Aoki, Ichio/G-2529-2011	Aoki, Ichio/0000-0002-4429-5053			Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BUONANNO FS, 1983, STROKE, V14, P178, DOI 10.1161/01.STR.14.2.178; COHEN Y, 1991, MAGNET RESON MED, V17, P225, DOI 10.1002/mrm.1910170125; DUONG DH, 1992, J NEUROSURG, V77, P151, DOI 10.3171/jns.1992.77.1.0151; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; HANSEN G, 1980, RADIOLOGY, V136, P695, DOI 10.1148/radiology.136.3.7403549; HAWKINS TD, 1976, CLIN RADIOL, V27, P279, DOI 10.1016/S0009-9260(76)80069-4; IWAMOTO Y, 1994, LIFE SCI, V55, P1651, DOI 10.1016/0024-3205(94)00332-7; IWAMOTO Y, 1993, ADV NEUROTRAUMA RES, V5, P6; KATO H, 1985, J CEREBR BLOOD F MET, V5, P267, DOI 10.1038/jcbfm.1985.34; LAUTERBUR PC, 1973, NATURE, V242, P190, DOI 10.1038/242190a0; LEVIN HS, 1989, NEUROSURGERY, V24, P223, DOI 10.1227/00006123-198902000-00011; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; MANO I, 1983, INVEST RADIOL, V18, P345, DOI 10.1097/00004424-198307000-00010; MURAKAMI N, 1992, ADV NEUROTRAUMA RES, V4, P7; MURAKAMI N, 1993, ADV NEUROTRAUMA RES, V5, P42; REIDERGROSWASSER I, 1993, AM J ROENTGENOL, V160, P147, DOI 10.2214/ajr.160.1.8416613; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; RUDELLI R, 1982, ARCH NEUROL-CHICAGO, V39, P570, DOI 10.1001/archneur.1982.00510210040009; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; VANDONGEN KJ, 1980, NEUROSURGERY, V7, P14, DOI 10.1227/00006123-198007000-00003; YAMAKI T, 1994, J NEUROTRAUM, V11, P613, DOI 10.1089/neu.1994.11.613; YOKOTA H, 1991, J TRAUMA, V31, P351, DOI 10.1097/00005373-199103000-00007; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	27	25	27	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JAN	1997	40	1					163	167		10.1097/00006123-199701000-00036			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	VY973	WOS:A1997VY97300082	8971838				2021-06-18	
J	Togher, L; Hand, L; Code, C				Togher, L; Hand, L; Code, C			A new perspective on the relationship between communication impairment and disempowerment following head injury in information exchanges	DISABILITY AND REHABILITATION			English	Article						traumatic brain injury; functional communication; empowerment	TRAUMATIC BRAIN INJURY; SOCIAL-INTERACTION; LANGUAGE; MEMORY	Communication disorders following closed head injury (CHI) have been described in terms of the impairments that affect the individual's ability to produce words, sentences and discourse. Rather than focusing on impairments, this paper examines the disability experienced by one CHI subject. Comparison is made between M. R., who has sustained a severe CHI, and his brother, S. R. during four telephone calls to their mother, a therapist, the police and the bus timetable information service, using exchange structure analysis. Results indicated that social distance between communication partners, and the nature of the interaction, affected the language choices made by both subjects. The communication partner was found to have a profound impact on the way each subject was able to negotiate each interaction. Results are discussed in terms of the ways in which therapists and society in general view disability and how this shapes social encounters, which in turn affects the outcomes which are made possible for people with CHI.	UNIV SYDNEY,SCH COMMUN DISORDERS,FAC HLTH SCI,LIDCOMBE,NSW,AUSTRALIA			Togher, Leanne/AAC-7083-2019; Code, Chris/F-4259-2010	Togher, Leanne/0000-0002-4518-6748			Antonak R. F., 1993, J HEAD TRAUMA REHAB, V8, P87, DOI DOI 10.1097/00001199-199312000-00009; Berry M., 1981, STUDIES DISCOURSE AN, P120; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; BURTON LA, 1993, J REHABILITATION OCT, P4; CONGER JA, 1988, ACAD MANAGE REV, V13, P471, DOI 10.2307/258093; CRISP R, 1991, AUSTR DISABILITY REV, V1, P37; FINE M, 1988, J SOC ISSUES, V44, P3, DOI 10.1111/j.1540-4560.1988.tb02045.x; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; Foucault M., 1972, ARCHAEOLOGY KNOWLEDG; FULLAGER S, 1993, AUSTR DISABILITY REV, V4, P36; GODFREY HPD, 1989, PSYCHOL MED, V19, P175, DOI 10.1017/S0033291700011120; GOFFMAN E, 1963, BEHAVIOR PUBLIC PLAC; GROHER M, 1977, J SPEECH HEAR RES, V20, P212, DOI 10.1044/jshr.2002.212; HAGEN C, 1982, COGNITIVE REHABILITA, P131; Hagen C, 1984, LANGUAGE DISORDERS A, P245; HALLIDAY MAK, 1970, NEW HORIZON LINGUIST, P322; Halliday MAK, 1985, LANGUAGE CONTEXT TEX; HALPERN H, 1973, J SPEECH HEAR DISORD, V38, P162, DOI 10.1044/jshd.3802.162; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; Livingston M G, 1985, Int Rehabil Med, V7, P145; LIVINGSTON M G, 1990, Pediatrician, V17, P255; MALKMUS DD, 1989, TOP LANG DISORD, V9, P50, DOI 10.1097/00011363-198903000-00006; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; Martin J. R., 1992, ENGLISH TEXT SYSTEM; MCDONALD S, 1992, Brain Injury, V6, P283, DOI 10.3109/02699059209029670; MILTON SB, 1984, CLIN APHASIOLOGY C P, P114; NEWTON A, 1985, BRIT J CLIN PSYCHOL, V24, P225, DOI 10.1111/j.2044-8260.1985.tb00655.x; ODDY M, 1984, CLOSED HEAD INJURY P, P108; Penn C, 1988, Brain Inj, V2, P3, DOI 10.3109/02699058809150928; Poynton C., 1985, LANGUAGE GENDER MAKI; Prigatano G. P., 1985, LANG SCI, V7, P217, DOI [10.1016/S0388-0001(85)80020-6, DOI 10.1016/S0388-0001(85)80020-6]; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; SOHLBERG MM, 1989, TOP LANG DISORD, V9, P15, DOI 10.1097/00011363-198903000-00004; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THOMSEN IV, 1975, J NEUROL NEUROSUR PS, V38, P713, DOI 10.1136/jnnp.38.7.713; Ventola E., 1987, STRUCTURE SOCIAL INT; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; WRIGHT BA, 1983, PHYSICAL DISABILITY; Ylvisaker Mark, 1992, Seminars in Speech and Language, V13, P308, DOI 10.1055/s-2008-1064205	42	25	28	0	3	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0963-8288			DISABIL REHABIL	Disabil. Rehabil.	NOV	1996	18	11					559	566		10.3109/09638289609166317			8	Rehabilitation	Rehabilitation	VX695	WOS:A1996VX69500004	9233853				2021-06-18	
J	Henley, CM; Muszynski, C; Cherian, L; Robertson, CS				Henley, CM; Muszynski, C; Cherian, L; Robertson, CS			Activation of ornithine decarboxylase and accumulation of putrescine after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; ornithine decarboxylase; polyamines; putrescine; trauma	REVERSIBLE CEREBRAL-ISCHEMIA; CORTICAL IMPACT INJURY; NMDA RECEPTOR; ALPHA-DIFLUOROMETHYLORNITHINE; POLYAMINE METABOLISM; VESTIBULAR NUCLEI; BARRIER BREAKDOWN; RAT; LABYRINTHECTOMY; STIMULATION	Activation of ornithine decarboxylase (ODC), the initial enzyme in polyamine synthesis, and accumulation of putrescine are thought to mediate pathological processes in the ischemic and traumatized brain. Past studies have separately investigated either ODC or polyamines after head injury. The purpose of the present study was to quantify both ODC activity and polyamines in the rat parietal cortex before and after controlled cortical impact injury. Adult, male rats underwent a right craniectomy and were subjected to a 5 m/sec, 2-mm deformation impact injury. Rats were sacrificed 1, 4, 8, and 24 h postimpact and tissues from the injured (right) and contralateral (left) hemisphere were analyzed for ODC and polyamines. ODC activity was determined by measuring the decarboxylation of [C-14]ornithine to putrescine. Putrescine, spermidine, and spermine were determined by high performance liquid chromatography. Cortical impact induced a 10- to 20-fold increase in ODC activity and a 4- to 5-fold increase in putrescine in the ipsilateral cortex. Spermidine and spermine did not significantly increase in the ipsilateral (right) cortex compared to controls (right cortex). In contrast, there was a slight increase in spermidine content in the contralateral (left) cortex after injury. The delayed increase in ODC activity and accumulation of putrescine may mediate pathophysiological changes observed after head injury.	BAYLOR COLL MED,BOBBY R ALFORD DEPT OTORHINOLARYNGOL COMMUNICAT S,DIV NEUROSCI,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT NEUROSURG,HOUSTON,TX 77030	Henley, CM (corresponding author), BAYLOR COLL MED,BOBBY R ALFORD DEPT OTORHINOLARYNGOL COMMUNICAT S,DEPT PHARMACOL,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27616] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS027616, P01NS027616] Funding Source: NIH RePORTER		ANDO M, 1984, J NEUROCHEM, V42, P94, DOI 10.1111/j.1471-4159.1984.tb09703.x; BACKOUS DD, 1994, OTOLARYNG HEAD NECK, V111, P377, DOI 10.1177/019459989411100401; Baskaya MFK, 1996, NEUROSURGERY, V38, P140; Baskaya MK, 1996, J NEUROTRAUM, V13, P85, DOI 10.1089/neu.1996.13.85; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; CARTER C, 1989, EUR J PHARMACOL, V164, P611, DOI 10.1016/0014-2999(89)90275-6; CARTER C, 1988, J PHARMACOL EXP THER, V247, P1222; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; CHOI DW, 1987, J NEUROSCI, V7, P369; COFFINO P, 1991, J CELL BIOCHEM, V45, P54, DOI 10.1002/jcb.240450112; DEMPSEY R J, 1988, Neurological Research, V10, P141; DEVERA N, 1991, J NEUROCHEM, V57, P1; DIENEL GA, 1984, J NEUROCHEM, V42, P1053, DOI 10.1111/j.1471-4159.1984.tb12710.x; DIENEL GA, 1985, J NEUROCHEM, V44, P600, DOI 10.1111/j.1471-4159.1985.tb05454.x; GILAD GM, 1992, BIOCHEM PHARMACOL, V44, P401, DOI 10.1016/0006-2952(92)90428-L; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; GOTTI B, 1990, BRAIN RES, V522, P290, DOI 10.1016/0006-8993(90)91473-T; HENLEY C, 1993, ACTA OTO-LARYNGOL, V113, P235, DOI 10.3109/00016489309135799; HENLEY CM, 1987, BRAIN RES BULL, V19, P695, DOI 10.1016/0361-9230(87)90056-6; HENLEY CM, 1994, OTOLARYNG HEAD NECK, V110, P103, DOI 10.1016/S0194-5998(94)70798-7; KOENIG H, 1983, NATURE, V305, P530, DOI 10.1038/305530a0; KOHSAKA S, 1981, DEV BRAIN RES, V1, P391, DOI 10.1016/0165-3806(81)90076-6; METCALF BW, 1978, J AM CHEM SOC, V100, P2551, DOI 10.1021/ja00476a050; MORRIS DR, 1991, J CELL BIOCHEM, V46, P102, DOI 10.1002/jcb.240460203; MUSZYNSKI CA, 1993, J CEREBR BLOOD F MET, V13, P1033, DOI 10.1038/jcbfm.1993.131; PASCHEN W, 1988, BRAIN RES, V453, P9, DOI 10.1016/0006-8993(88)90138-2; PASCHEN W, 1987, NEUROCHEM PATHOL, V7, P143, DOI 10.1007/BF02834214; PASCHEN W, 1992, CEREBROVAS BRAIN MET, V4, P59; PEGG AE, 1988, BIOCHEMISTRY-US, P11; PERONA BP, 1990, ANN PLAS SURG, V25, P26, DOI 10.1097/00000637-199007000-00006; PORCELLA A, 1991, EUR J PHARMACOL, V199, P267, DOI 10.1016/0014-2999(91)90469-7; REED LJ, 1990, J NEUROCHEM, V55, P780, DOI 10.1111/j.1471-4159.1990.tb04560.x; ROMANO C, 1994, NEUROPHARMAOCLOGY PO; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; RUSSELL DH, 1985, DRUG METAB REV, V16, P1, DOI 10.3109/03602538508991430; RUSSELL DH, 1974, J NEUROBIOL, V5, P349, DOI 10.1002/neu.480050406; SALZER TA, 1994, AM J OTOL, V15, P728; SCATTON B, 1993, FUND CLIN PHARMACOL, V7, P389, DOI 10.1111/j.1472-8206.1993.tb01036.x; SCHMITZ MP, 1993, NEUROSURGERY, V33, P882; SEILER N, 1981, MED BIOL, V59, P334; Seiler N, 1991, Prog Drug Res, V37, P107; Seiler N, 1988, Adv Exp Med Biol, V250, P127; SHOHAMI E, 1992, EXP NEUROL, V117, P189, DOI 10.1016/0014-4886(92)90126-B; TETZLAFF W, 1985, EXP NEUROL, V89, P679, DOI 10.1016/0014-4886(85)90016-0; TROUT JJ, 1986, LAB INVEST, V55, P622; WILLIAMS K, 1991, LIFE SCI, V48, P469, DOI 10.1016/0024-3205(91)90463-L	46	25	25	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	1996	13	9					487	496		10.1089/neu.1996.13.487			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	VP266	WOS:A1996VP26600001	8913965				2021-06-18	
J	Connolly, B; Emery, D; Armstrong, D				Connolly, B; Emery, D; Armstrong, D			The odontoid synchondrotic slip: An injury unique to young children	PEDIATRIC RADIOLOGY			English	Article							FRACTURES	We report seven children (three female, four male) diagnosed with traumatic synchondrotic slip of the odontoid. The clinical records, plain films, and CT scans were evaluated retrospectively. The patients ranged in age between 3 and 5 years. Their injuries resulted from a motor vehicle accident in four cases and from a fall from a height in three. The injury was isolated in five; it was associated with a closed head injury in one and with facial and brachial plexus trauma in another. Radiographs showed anterior angulation with or without displacement in all seven cases. Axial CT with sagittal reformation and 3D reconstructions were performed in six cases. This confirmed the synchondrotic slip and, in addition, identified a rotary component to the injury in three cases, with compromise of the canal in two. Other additional injuries were also noted. All cases were treated conservatively and the injuries healed. Only one child had a neurological deficit attributable to her head injury rather than to her cervical injury (MR of the cervical cord was normal). The presence of the synchondrosis between the dens and the body of C-2 makes this injury unique to children under 7 years of age; by the age of 7 the synchondrosis has fused.		Connolly, B (corresponding author), UNIV TORONTO,HOSP SICK CHILDREN,DEPT DIAGNOST IMAGING,555 UNIV AVE,TORONTO,ON MSG 1X8,CANADA.		Emery, Derek/V-4913-2019	Emery, Derek/0000-0003-2678-3077			ALP MS, 1990, BMJ-BRIT MED J, V300, P319, DOI 10.1136/bmj.300.6720.319; ANDERSON LD, 1974, J BONE JOINT SURG AM, VA 56, P1663, DOI 10.2106/00004623-197456080-00017; APPLE JS, 1987, PEDIATR RADIOL, V17, P45, DOI 10.1007/BF02386594; BAILEY DK, 1952, RADIOLOGY, V59, P712, DOI 10.1148/59.5.712; BLOCKEY NJ, 1956, J BONE JOINT SURG BR, V38, P794; EWALD FC, 1971, J BONE JOINT SURG AM, VA 53, P1636, DOI 10.2106/00004623-197153080-00019; FLOMAN Y, 1991, J BONE JOINT SURG BR, V73, P640; FREIBERGER RH, 1965, J BONE JOINT SURG AM, VA 47, P1231, DOI 10.2106/00004623-196547060-00013; FUJII E, 1988, SPINE, V13, P604; GRIFFITHS SC, 1972, J PEDIATR SURG, V7, P680, DOI 10.1016/0022-3468(72)90279-5; KELLER J, 1990, INJURY, V21, P191, DOI 10.1016/0020-1383(90)90098-F; LEVINE AM, 1986, ORTHOP CLIN N AM, V17, P31; MANDABACH M, 1993, PEDIATR NEUROSURG, V19, P225, DOI 10.1159/000120737; MCGRORY BJ, 1993, J BONE JOINT SURG AM, V75A, P988, DOI 10.2106/00004623-199307000-00004; OGDEN JA, 1984, SKELETAL RADIOL, V12, P169, DOI 10.1007/BF00361083; RIES MD, 1986, SPINE, V11, P1043, DOI 10.1097/00007632-198612000-00018; RUGE JR, 1988, J NEUROSURG, V68, P25, DOI 10.3171/jns.1988.68.1.0025; SEIMON LP, 1977, J BONE JOINT SURG AM, V59, P943, DOI 10.2106/00004623-197759070-00019; SHERK HH, 1978, J BONE JOINT SURG AM, V60, P921, DOI 10.2106/00004623-197860070-00008; VINING DJ, 1992, J NEUROSURG, V77, P795, DOI 10.3171/jns.1992.77.5.0795; Warwick R., 1973, GRAYS ANATOMY, V35th	21	25	25	0	0	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0301-0449			PEDIATR RADIOL	Pediatr. Radiol.	NOV	1995	25			1			S129	S133					5	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	TM948	WOS:A1995TM94800039	8577504				2021-06-18	
J	MIKAWA, S; SHARP, FR; KAMII, H; KINOUCHI, H; EPSTEIN, CJ; CHAN, PH				MIKAWA, S; SHARP, FR; KAMII, H; KINOUCHI, H; EPSTEIN, CJ; CHAN, PH			EXPRESSION OF C-FOS AND HSP70 MESSENGER-RNA AFTER TRAUMATIC BRAIN INJURY IN TRANSGENIC MICE OVEREXPRESSING CUZN-SUPEROXIDE DISMUTASE	MOLECULAR BRAIN RESEARCH			English	Article						C-FOS MESSENGER-RNA; HSP70 MESSENGER-RNA; TRAUMATIC BRAIN INJURY; FREE RADICAL; SUPEROXIDE DISMUTASE; TRANSGENIC MOUSE; SPREADING DEPRESSION	HEAT-SHOCK PROTEIN; FOCAL CEREBRAL-ISCHEMIA; MESSENGER-RNA; CORTICAL INJURY; FREE-RADICALS; NITRIC-OXIDE; RAT-BRAIN; INDUCTION; NEUROTOXICITY; NEURONS	The aim of this study was to determine the role of oxidative stress on c-fos and hsp70 gene expression in transgenic (Tg) mice overexpressing CuZn-superoxide dismutase (SOD-l) following traumatic brain injury (TBI). hsp70 mRNA, as investigated using in situ hybridization, was induced around the lesion at 4 and 24 h, but not at 1 and 48 h, in both Tg and non-transgenic (nTg) mice littermates. The degree of hsp70 induction was somewhat greater in nTg than Tg mice at 4 and 24 h after TBI. c-fos mRNA was induced throughout cortex, hippocampus, caudate putamen and the ventricular wall in Tg and nTg mice. TBI induced c-fos bilaterally in the cortex in both animals. There was a time-dependent difference in cortical c-fos expression between nTg and Tg mice. The induction of c-fos mRNA in the striatum was greater in nTg at 24 h and decreased in both animals by 48 h. Edema of the injured cortex was significantly attenuated in Tg mice at all time points (1-48 h). These data show that the degree of hsp70 induction and the degree, extent, and duration of c-fos induction produced by TBI are affected by levels of superoxide dismutase activity. It is proposed that superoxide radicals affect spreading depression and brain edema produced by TBI and that this effect may either directly or indirectly modulate the expression of the c-fos and hsp70 genes after TBI.	UNIV CALIF SAN FRANCISCO, DEPT NEUROSURG, CNS INJURY & EDEMA RES CTR, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT NEUROL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PEDIAT, SAN FRANCISCO, CA 94143 USA; VET ADM MED CTR, DEPT NEUROL, SAN FRANCISCO, CA 94121 USA; TOHOKU UNIV, SCH MED, DEPT NEUROSURG, SENDAI, MIYAGI 980, JAPAN							AMSTAD PA, 1992, CANCER RES, V52, P3952; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; CHAN PH, 1990, STROKE, V21, P80; CHAN PH, 1989, ANN NY ACAD SCI, V559, P237; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; CHOPP M, 1991, ACTA NEUROPATHOL, V83, P66, DOI 10.1007/BF00294432; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DRAGUNOW M, 1990, EXP NEUROL, V107, P236, DOI 10.1016/0014-4886(90)90141-E; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FLAMM ES, 1978, STROKE, V9, P445, DOI 10.1161/01.STR.9.5.445; FU L, 1992, NEUROSCIENCE, V46, P329, DOI 10.1016/0306-4522(92)90055-7; GONZALEZ MF, 1991, BRAIN RES BULL, V26, P241, DOI 10.1016/0361-9230(91)90234-B; HABY C, 1994, J NEUROCHEM, V62, P496; KAMII H, 1994, BRAIN RES, V662, P240, DOI 10.1016/0006-8993(94)90818-4; KAMII H, 1994, J CEREBR BLOOD F MET, V14, P478, DOI 10.1038/jcbfm.1994.59; KINOUCHI H, 1993, J CEREBR BLOOD F MET, V13, P105, DOI 10.1038/jcbfm.1993.13; KINOUCHI H, 1993, BRAIN RES, V619, P334, DOI 10.1016/0006-8993(93)91630-B; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; KIRINO T, 1991, J CEREBR BLOOD F MET, V11, P299, DOI 10.1038/jcbfm.1991.62; KITAGAWA K, 1991, BRAIN RES, V561, P203, DOI 10.1016/0006-8993(91)91596-S; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KUBOTA M, 1989, BRAIN NERVE, V41, P99; LABANDEIRA-GARCIA JL, 1994, BRAIN RES, V652, P87, DOI 10.1016/0006-8993(94)90321-2; LAURITZEN M, 1982, ANN NEUROL, V12, P469, DOI 10.1002/ana.410120510; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; LOWENSTEIN DH, 1990, BRAIN RES, V531, P173, DOI 10.1016/0006-8993(90)90771-3; MIKAWA S, 1995, IN PRESS 17 INT S CE; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; NOWAK TS, 1991, J CEREBR BLOOD F MET, V11, P432, DOI 10.1038/jcbfm.1991.84; PECHAN PA, 1992, NEUROREPORT, V3, P469, DOI 10.1097/00001756-199206000-00003; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; SHARP JW, 1990, EXP NEUROL, V109, P323, DOI 10.1016/S0014-4886(05)80023-8; SHI YP, 1994, MAMM GENOME, V5, P337, DOI 10.1007/BF00356551; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X	40	25	26	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	NOV	1995	33	2					288	294		10.1016/0169-328X(95)00146-J			7	Neurosciences	Neurosciences & Neurology	TA393	WOS:A1995TA39300013					2021-06-18	
J	SMITH, GA; DIETRICH, AM; GARCIA, CT; SHIELDS, BJ				SMITH, GA; DIETRICH, AM; GARCIA, CT; SHIELDS, BJ			EPIDEMIOLOGY OF SHOPPING CART-RELATED INJURIES TO CHILDREN - AN ANALYSIS OF NATIONAL DATA FOR 1990 TO 1992	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							SAFETY	Objective: To describe the epidemiologic characteristics of shopping cart-related injuries among children in the United States. Design: A retrospective analysis of data from the National Electronic Injury Surveillance System of the US Consumer Product Safety Commission for 1990 to 1992. Results: An estimated 75 200 shopping cart-related injuries occurred in children younger than 15 years treated in US emergency departments during 1990 to 1992 (95% confidence interval, 57 500 to 92 900). Children younger than 5 years were at highest risk, accounting for 63 200 (84%) of the injuries. A 20% increase was observed in the number of injuries among 0- to 4-year-old children from 1990 to 1992. Fifty-three percent of injured children were male. The head and neck region was the most common anatomic site of injury, accounting for 74% of injuries among children younger than 15 years. An estimated 2000 children (2.7%) younger than 15 years required hospital admission (1.2% in 1990 compared with 3.5% in 1992). Children aged 0 to 4 years accounted for 93% of these hospital admissions. Among 0- to 14-year-old children, fractures accounted for 45% of hospital admissions, followed by internal injury (22%) and concussion (17%). Conclusions: Injuries related to shopping carts are an important cause of pediatric morbidity, especially among children younger than 5 years. These injuries can also result in death. Shopping carts should be redesigned to decrease the risk of injury to children, and transportation of children in shopping carts of current design should be prohibited.	OHIO STATE UNIV,COLL MED,DEPT PEDIAT,COLUMBUS,OH 43210							Baker SP, 1992, THE INJURY FACT BOOK; CAMPBELL M, 1990, BRIT MED J, V301, P1370, DOI 10.1136/bmj.301.6765.1370; FERRARI JR, 1989, BEHAV MODIF, V13, P51, DOI 10.1177/01454455890131003; HARRELL WA, 1990, ACCIDENT ANAL PREV, V22, P531, DOI 10.1016/0001-4575(90)90025-G; Robertson LS, 1983, INJURIES CAUSES CONT; SMITH GA, IN PRESS PEDIATRICS; TRINKOFF A, 1993, PUBLIC HEALTH REP, V108, P784; TULLY S, 1993, AM ACADEMY PEDIA JUN; 1986, US CONSUMER PRODUCT; 1992, MMWR-MORBID MORTAL W, V41, P271; 1993, EXPLANATION SHEET NE; 1991, AJDC, V145, P933	12	25	25	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	1072-4710			ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	NOV	1995	149	11					1207	1210		10.1001/archpedi.1995.02170240025003			4	Pediatrics	Pediatrics	TD456	WOS:A1995TD45600003	7581750				2021-06-18	
J	ASGEIRSSON, B; GRANDE, PO; NORDSTROM, CH; MESSETER, K; SJOHOLM, H				ASGEIRSSON, B; GRANDE, PO; NORDSTROM, CH; MESSETER, K; SJOHOLM, H			CEREBRAL HEMODYNAMIC-EFFECTS OF DIHYDROERGOTAMINE IN PATIENTS WITH SEVERE TRAUMATIC BRAIN-LESIONS	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						DIHYDROERGOTAMINE; HYPERVENTILATION; INTRACRANIAL PRESSURE; TRAUMATIC BRAIN INJURY; CEREBRAL HEMODYNAMICS	SEVERE HEAD-INJURY; RAISED INTRACRANIAL-PRESSURE; BLOOD-FLOW; PERFUSION-PRESSURE; HYPERTENSION; MANAGEMENT; THERAPY; VASOREACTIVITY; AUTOREGULATION; CIRCULATION	Dihydroergotamine (DHE) is used in our recently introduced therapy of post-traumatic brain oedema and is suggested to reduce ICP through reduction in both cerebral blood volume and brain water content. This study aims at increasing our knowledge of the mechanisms behind the ICP reducing effect of DHE by analysing cerebrovascular effects of a bolus dose of DHE in severely head injured patients (GCS<8). Mean hemispheric cerebral blood flow (CBF) calculated from the clearance of i.v. (133)Xenon, ICP, and cerebral arterio-venous difference in oxygen content (AVDO(2)); were measured before and after hyperventilation and after a bolus dose of DHE (4 mu g/kg). The patients were divided into two groups, one with preserved and one with impaired cerebrovascular CO2-reactivity to hyperventilation, the latter being predictive of poor outcome. The haemodynamic effects of DHE were compared to those of hyperventilation. Regional CBF and brain volume SPECT measurements were performed in two patients. DHE increased cerebrovascular resistance (CVR) by about 20% and significantly reduced ICP in both groups of patients, resulting in unchanged AVDO(2). Hyperventilation with preserved CO2-reactivity caused a similar decrease in ICP as by DHE but with a much larger increase in CVR (by 70%) and a substantial increase in AVDO(2). Hyperventilation with impaired CO2-reactivity reduced ICP but otherwise had no significant cerebrovascular effects. The study supports the concept that the ICP reducing effect of DHE results more from constriction of the large veins than from arterial vasoconstriction, also implying a relatively smaller risk of ischaemia with DHE than with hyperventilation.	UNIV LUND HOSP,DEPT PHYSIOL & BIOPHYS,S-22185 LUND,SWEDEN; UNIV LUND HOSP,DEPT NEUROSURG,S-22185 LUND,SWEDEN; UNIV LUND HOSP,DEPT CLIN NEUROPHYSIOL,S-22185 LUND,SWEDEN; LUND UNIV,LUND,SWEDEN	ASGEIRSSON, B (corresponding author), UNIV LUND HOSP,DEPT ANAESTHESIA & INTENS CARE,S-22185 LUND,SWEDEN.						ALBRECHT RF, 1987, STROKE, V18, P649, DOI 10.1161/01.STR.18.3.649; ANDERSEN AR, 1987, STROKE, V18, P120, DOI 10.1161/01.STR.18.1.120; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P567, DOI 10.1007/BF01705723; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P347, DOI 10.1111/j.1399-6576.1995.tb04075.x; ASGEIRSSON B, 1991, 8TH INT S INTR PRESS; ASTRUP J, 1991, CURR OPIN ANAESTH, V4, P653; BOREL C, 1990, CHEST, V198, P180; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1992, J NEUROTRAUMA S1, V9, P333; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; COLD GE, 1978, ACTA ANAESTH SCAND, V22, P270, DOI 10.1111/j.1399-6576.1978.tb01301.x; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P359, DOI 10.1111/j.1399-6576.1977.tb01232.x; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; GOSSELIN RE, 1991, J THEOR BIOL, V149, P265, DOI 10.1016/S0022-5193(05)80281-4; GRANDE PO, 1989, INTENS CARE MED, V15, P523, DOI 10.1007/BF00273564; GRANDE PO, 1993, RECENT ADVANCES IN NEUROTRAUMATOLOGY, P319; GUTYON A, 1991, TXB MED PHYSL, P150; HACHINSKI V, 1978, STROKE, V9, P594, DOI 10.1161/01.STR.9.6.594; Jennett B, 1991, J NEUROTRAUMA S1, V8, P15; JENSEN K, 1991, ACTA NEUROCHIR, V108, P116, DOI 10.1007/BF01418518; KAUFMAN AM, 1992, J NEUROSURG, V77, P854; MCCARTHY BG, 1989, HEADACHE, V29, P420, DOI 10.1111/j.1526-4610.1989.hed2907420.x; MELLANDER S, 1970, CLIN SCI, V39, P183, DOI 10.1042/cs0390183; MENDELOW AD, 1979, BRIT MED J, V1, P1240, DOI 10.1136/bmj.1.6173.1240; MESSETER K, 1986, J NEUROSURG, V64, P231, DOI 10.3171/jns.1986.64.2.0231; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MILLER JD, 1992, J NEUROTRAUMA S1, V9, P317; Muizelaar JP, 1991, J NEUROSURG, V64, P81; MULLER H, 1988, PHARMACOLOGY, V37, P248, DOI 10.1159/000138473; MULLERSCHWEINIT.E, 1987, J CARDIOVASC PHARM, V9, P686; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; OBRIST WD, 1985, CEREBRAL BLOOD FLOW, P30; PICKARD JD, 1993, J NEUROL NEUROSUR PS, V56, P845, DOI 10.1136/jnnp.56.8.845; RISBERG J, 1975, STROKE, V6, P142, DOI 10.1161/01.STR.6.2.142; Rosner M., 1987, CEREBRAL BLOOD FLOW, P425; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; SCHALEN W, 1992, ACTA ANAESTH SCAND, V36, P369, DOI 10.1111/j.1399-6576.1992.tb03483.x; SCHALEN W, 1991, ACTA ANAESTH SCAND, V35, P113, DOI 10.1111/j.1399-6576.1991.tb03258.x; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; TEASDALE G, 1974, LANCET, V2, P81; TODD NV, 1990, ACT NEUR S, V51, P296; YADA K, 1973, J NEUROSURG, V39, P723, DOI 10.3171/jns.1973.39.6.0723	46	25	28	0	0	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	OCT	1995	39	7					922	930		10.1111/j.1399-6576.1995.tb04199.x			9	Anesthesiology	Anesthesiology	RX864	WOS:A1995RX86400012	8848893				2021-06-18	
J	PAPERO, PH; PRANZATELLI, MR; MARGOLIS, LJ; TATE, E; WILSON, LA; GLASS, P				PAPERO, PH; PRANZATELLI, MR; MARGOLIS, LJ; TATE, E; WILSON, LA; GLASS, P			NEUROBEHAVIORAL AND PSYCHOSOCIAL FUNCTIONING OF CHILDREN WITH OPSOCLONUS-MYOCLONUS SYNDROME	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							CLOSED HEAD-INJURY; SYDENHAM CHOREA; NEURO-BLASTOMA; ADOLESCENTS; ENCEPHALOPATHY; CHILDHOOD; LEUKEMIA; OUTCOMES	Childhood opsoclonus-myoclonus syndrome (OMS) is a movement disorder which typically strikes children in the early preschool years, seriously affecting intellectual, social-emotional and general adaptive development. This series of 13 cases with well-documented neurological histories, aged 1.7 to 16.3 years, provides an initial systematic evaluation of these children's neuropsychological, psychosocial and adaptive status. As expected, children with OMS had significantly reduced intelligence and severe speech and motor output problems; however, most of them also demonstrated a range of preserved neurocognitive abilities and impressive goal-directedness and communicative effort. Psychosocial problems included mild behavioral impairment on the Achenbach Child Behavior Checklist, and severe adaptive limitations on the Vineland Adaptive Behavior Scales despite relatively strong social skills. Developmental factors and likelihood of subcortical localization are discussed, and practical guidelines are provided for behavioral and educational management of these children.	GEORGE WASHINGTON UNIV,CHILDRENS NATL MED CTR,DEPT NEUROL & PHARMACOL,WASHINGTON,DC 20010; GEORGE WASHINGTON UNIV,CHILDRENS NATL MED CTR,DEPT PEDIAT,WASHINGTON,DC 20010; GEORGE WASHINGTON UNIV,CHILDRENS NATL MED CTR,CHILDRENS RES INST,NATL PEDIAT MYOCLONUS CTR,WASHINGTON,DC 20010	PAPERO, PH (corresponding author), GEORGE WASHINGTON UNIV,CHILDRENS NATL MED CTR,DEPT PSYCHIAT & BEHAV SCI,111 MICHIGAN AVE NW,WASHINGTON,DC 20010, USA.				FDA HHS [FD-R-000746, FD-R-000955] Funding Source: Medline		ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; Annett M, 1985, LEFT RIGHT HAND BRAI; BARON IS, 1993, NEUROPSYCHOL REHABIL, V3, P389, DOI 10.1080/09602019308401448; Bayley N., 1969, BAYLEY SCALES INFANT; BOLTSHAUSER E, 1979, HELV PAEDIATR ACTA, V34, P119; BROUWERS P, 1984, J CLIN NEUROPSYCHOL, V6, P325, DOI 10.1080/01688638408401222; DENNIS M, 1987, J CLIN EXP NEUROPSYC, V9, P593, DOI 10.1080/01688638708410771; Dennis Maureen, 1988, CLIN NEUROPSYCHOLOGY, P89; DYKEN PR, 1986, CHILD NEUROPSYCHOLOG, V1, P175; FANTZ RL, 1979, CAN J PSYCHOL, V33, P277, DOI 10.1037/h0081726; FLETCHER JM, 1991, AM PSYCHOL, V46, P1267, DOI 10.1037/0003-066X.46.12.1267; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1984, EARLY BRAIN DAMAGE, V1, P189; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; GOLDMAN S, 1992, Neurology, V42, P320; HANSON CL, 1987, J CONSULT CLIN PSYCH, V55, P529, DOI 10.1037/0022-006X.55.4.529; HOLMESBERNSTEIN J, 1990, NEUROMETHODS, V17, P311, DOI DOI 10.1385/0896031330; HUBER SJ, 1990, SUBCORTICAL DEMENTIA, P73; Kaufman A.S., 1983, K ABC KAUFMAN ASSESS; KIENZLE GD, 1991, AM J NEURORADIOL, V12, P73; LEVIN HS, 1979, CHILD BRAIN, V5, P281; Luria A. R, 1973, WORKING BRAIN; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; OLEARY DS, 1984, EARLY BRAIN DAMAGE, V1, P215; PAPERO PH, 1993, NEUROPSYCHOL REHABIL, V3, P321, DOI 10.1080/09602019308401445; PHILLIPS S, 1992, Neurology, V42, P288; PRANZATELLI MR, 1994, EXP NEUROL, V125, P142, DOI 10.1006/exnr.1994.1018; PRANZATELLI MR, 1992, CLIN NEUROPHARMACOL, V15, P186, DOI 10.1097/00002826-199206000-00002; ROURKE BP, 1983, NONVERBAL LEARNING D; Rourke BP, 1989, NONVERBAL LEARNING D; Rourke BP, 1983, CHILD NEUROPSYCHOLOG; SENELICK RC, 1973, J PEDIATR SURG, V8, P623, DOI 10.1016/0022-3468(73)90400-4; SHAPIRO EG, 1992, J CLIN EXP NEUROPSYC, V14, P610, DOI 10.1080/01688639208402848; SOLLEE ND, 1987, J ABNORM CHILD PSYCH, V15, P479, DOI 10.1007/BF00917235; Sparrow S., 1984, VINELAND ADAPTIVE BE; SWEDO SE, 1993, PEDIATRICS, V91, P706; SWEDO SE, 1992, INT PEDIAT, V7, P136; TALON P, 1985, PEDIATRIE, V40, P441; TAYLOR HG, 1987, J PEDIATR PSYCHOL, V12, P395, DOI 10.1093/jpepsy/12.3.395; TELANDER RL, 1989, J PEDIATR SURG, V24, P11, DOI 10.1016/S0022-3468(89)80291-X; TUCHMAN RF, 1989, NEURORADIOLOGY, V31, P250, DOI 10.1007/BF00344353; WALLANDER JL, 1988, J PEDIATR PSYCHOL, V13, P197, DOI 10.1093/jpepsy/13.2.197; Wechsler D., 1989, WECHSLER PRESCHOOL P; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1991, WISC 3 WECHSLER INTE	46	25	25	0	2	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211	0012-1622			DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	OCT	1995	37	10					915	932					18	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	TH519	WOS:A1995TH51900008	7493725				2021-06-18	
J	BAVETTA, S; NIMMON, CC; WHITE, J; MCCABE, JM; HUNEIDI, AH; BOMANJI, J; BIRKENFELD, B; CHARLESWORTH, M; BRITTON, KE; GREENWOOD, RJ				BAVETTA, S; NIMMON, CC; WHITE, J; MCCABE, JM; HUNEIDI, AH; BOMANJI, J; BIRKENFELD, B; CHARLESWORTH, M; BRITTON, KE; GREENWOOD, RJ			A PROSPECTIVE-STUDY COMPARING SPET WITH MRI AND CT AS PROGNOSTIC INDICATORS FOLLOWING SEVERE CLOSED-HEAD INJURY	NUCLEAR MEDICINE COMMUNICATIONS			English	Article							CEREBRAL BLOOD-FLOW; COMPUTED-TOMOGRAPHY; TRAUMA; DISABILITY; SCALE	Ten patients were studied prospectively after severe closed head injury to determine the relationship between long-term clinical outcome and abnormalities detected by single photon emission tomography (Tc-99(m)-HMPAO SPET), CT and MRI obtained within 60 days of injury. The ability of SPET to detect abnormalities not visualized by CT or MRI after cerebral trauma is confirmed by the results of this study. Changes detected by SPET [global cerebral Mood flow (gCBF) and number of regional cerebral blood flow (rCBF) deficits] soon after trauma were shown to be more closely correlated with long-term outcome than changes detected by MRI or CT. Templates were used to classify lesions by site and a multivariate analysis was undertaken to establish the importance of defect position in predicting clinical outcome. The results suggest that lesions in the temporal lobes, frontal lobes and basal ganglia are related to poor prognosis, and that SPET yields more useful prognostic data than the other methods.	ST BARTHOLOMEWS HOSP,DEPT NEUROSURG,LONDON,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT NUCL MED,LONDON,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT NEURORADIOL,LONDON,ENGLAND; HOMERTON HOSP,REG REHABIL UNIT,LONDON,ENGLAND			Birkenfeld, Bozena/A-4796-2015	Birkenfeld, Bozena/0000-0003-1174-8199			ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; BRITTON KE, 1985, NUCL MED COMMUN, V6, P251, DOI 10.1097/00006231-198505000-00002; BULLOCK R, 1990, ACT NEUR S, V51, P286; CHOKSEY MS, 1991, J NEUROL NEUROSUR PS, V54, P6, DOI 10.1136/jnnp.54.1.6; ELL PJ, 1985, LANCET, V2, P50; GANDY SE, 1984, ANN NEUROL, V16, P254, DOI 10.1002/ana.410160217; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; HAYS WL, 1963, STATISTICS, P567; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; MAEDER P, 1991, ACTA RADIOL, V32, P271; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; NIMMON CC, 1989, NEUROIMAGING, V2, P43; ODOR W, 1991, INTENS CARE MED, V17, P149; PODREKA I, 1987, J NUCL MED, V28, P1657; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROPER SN, 1991, J NUCL MED, V32, P1684; TENJIN H, 1990, NEUROSURGERY, V26, P971, DOI 10.1227/00006123-199006000-00009; UZZELL BP, 1987, NEUROSURGERY, V20, P396, DOI 10.1227/00006123-198703000-00007; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; Wiedmann KD, 1989, NEUROPSYCHOLOGY, V3, P267, DOI 10.1037//0894-4105.3.4.267; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	24	25	25	0	0	CHAPMAN HALL LTD	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN	0143-3636			NUCL MED COMMUN	Nucl. Med. Commun.	DEC	1994	15	12					961	968		10.1097/00006231-199412000-00007			8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	PU876	WOS:A1994PU87600007	7715895				2021-06-18	
J	JOHNSTON, MV; HALL, KM				JOHNSTON, MV; HALL, KM			OUTCOMES EVALUATION IN TBI REHABILITATION .1. OVERVIEW AND SYSTEM PRINCIPLES	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article								Questions of how to measure outcomes are commonly heard in rehabilitation today. In this supplement we review the current state of the art of outcomes measurement in traumatic brain injury rehabilitation, discuss key issues, and identify steps that need to be taken. The underlying question is not simply that of outcomes measurement but how to infer effective and cost-effective treatment. The validity of such inferences rests on multiple features of the entire clinical information system. Requirements for valid, feasible, outcome-oriented clinical data systems are described. Effectiveness is inferred from variations in outcomes experienced by similar persons who received differing interventions. Outcome data systems need large sample sizes and technically adequate severity adjusters. A nationwide TBI data system is needed to identify reasonably homogeneous subgroups in different programs whose outcomes can be meaningfully compared. In alliance with payors and persons with disabilities, rehabilitation professionals can create outcome data systems that will provide the knowledge necessary to improve the effectiveness and cost-effectiveness of rehabilitation programs.	SANTA CLARA VALLEY MED CTR,SAN JOSE,CA 95128	JOHNSTON, MV (corresponding author), KESSLER INST REHABIL INC,1199 PLEASANT VALLEY WAY,W ORANGE,NJ 07052, USA.							0	25	25	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	1994	75	12			SI		SC2	SC9					8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	PY709	WOS:A1994PY70900002					2021-06-18	
J	STRAUSS, E; SPELLACY, F; HUNTER, M; BERRY, T				STRAUSS, E; SPELLACY, F; HUNTER, M; BERRY, T			ASSESSING BELIEVABLE DEFICITS ON MEASURES OF ATTENTION AND INFORMATION-PROCESSING CAPACITY	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article							HEAD-INJURY; RECOVERY	The vulnerability of tests of sustained attention and speed of processing to faked deficits was evaluated by comparing the performances of normal controls, healthy subjects asked to simulate deficits, and patients with closed head injury on a simple auditory reaction-time task and on the PASAT. The results revealed that persons attempting to feign the effects of brain injury perform more poorly than non-malingerers on a simple reaction-time task and the PASAT. The reaction-time task, however, proved more effective than the PASAT at detecting dissimulation, accurately classifying about 76% of the subjects. This value reflects a respectable hit rate for three-group classification.		STRAUSS, E (corresponding author), UNIV VICTORIA,DEPT PSYCHOL,VICTORIA V8W 3P5,BC,CANADA.						ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Bernard L C, 1991, Arch Clin Neuropsychol, V6, P81, DOI 10.1016/0887-6177(91)90024-4; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; Binder Laurence M, 1990, Clin Neuropsychol, V4, P25, DOI 10.1080/13854049008401494; BINDER LM, 1987, J CLIN EXP NEUROPSYC, V9, P167, DOI 10.1080/01688638708405357; Bradley JV, 1968, DISTRIBUTION FREE ST; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Kolb B., 1990, FUNDAMENTALS HUMAN N; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; PANKRATZ L, 1975, J CONSULT CLIN PSYCH, V43, P421, DOI 10.1037/h0076722; PANKRATZ L, 1979, J CONSULT CLIN PSYCH, V47, P409, DOI 10.1037/0022-006X.47.2.409; Rey A, 1964, EXAMEN CLIN PSYCHOL; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]	16	25	25	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	NOV-DEC	1994	9	6					483	490		10.1016/0887-6177(94)90039-6			8	Psychology, Clinical; Psychology	Psychology	PT254	WOS:A1994PT25400002	14590997				2021-06-18	
J	CREMONAMETEYARD, SL; GEFFEN, GM				CREMONAMETEYARD, SL; GEFFEN, GM			EVENT-RELATED POTENTIAL INDEXES OF VISUAL-ATTENTION FOLLOWING MODERATE TO SEVERE CLOSED-HEAD INJURY	BRAIN INJURY			English	Article							TASK; P300; TIME	Covert orientation of visual attention was studied in eight closed head injury (CHI) subjects who fixated warning cues and pressed a button at peripheral target onset. Directional cues (arrows) indicated the most probable (p=0.8) side of target occurrence while neutral cues (crosses) gave no directional information. A NoGo cue (vertical bar) indicated no response was required. Compared to eight matched controls the CHI subjects displayed slowed processing of all cues (increased P2, N2 and P3 latencies). Also, evidence was found for very early impairment (increased P2 amplitude) in directing attention. Further, the CHI group did not show the normal attenuated CNV after NoGo signals, suggesting perseverative behaviour. Finally, the amplitude and latency of the P3 component (post-cue and post-target) approached normal as time since injury increased.	UNIV QUEENSLAND, DEPT PSYCHOL, COGNIT PYSCHOPHYSIOL LAB, BRISBANE, QLD 4000, AUSTRALIA; UNIV QUEENSLAND, CLIN STUDIES UNIT, BRISBANE, QLD 4000, AUSTRALIA							Brooks N., 1984, CLOSED HEAD INJURY P; CAMPBELL K, 1986, CEREBRAL PSYCHOPHYSI, V38, P486; Clark C. R., 1992, Brain Injury, V6, P509, DOI 10.3109/02699059209008148; CREMONAMETEYARD SL, 1992, NEUROPSYCHOLOGIA, V30, P123, DOI 10.1016/0028-3932(92)90022-E; CURRY SH, 1986, CEREBRAL PSYCH EEG S, V38, P169; CURRY SH, 1980, MOTIVATION MOTOR SEN, P507; DONCHIN E, 1984, COGNITIVE PSYCHOPHYS, V1, P107; GEVINS AS, 1987, HDB ELECTROENCEPHALO, V2, P335; Harter M R, 1989, J Cogn Neurosci, V1, P223, DOI 10.1162/jocn.1989.1.3.223; HARTER MR, 1991, ELECTROEN CLIN NEURO, P183; KEPPEL S, 1982, DESIGN ANAL RES HDB; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; LINDHOLM E, 1985, INT J PSYCHOPHYSIOL, V3, P121, DOI 10.1016/0167-8760(85)90032-7; LOVELESS NE, 1975, BIOL PSYCHOL, V2, P217, DOI 10.1016/0301-0511(75)90021-6; MACAR F, 1985, BIOL PSYCHOL, V21, P293, DOI 10.1016/0301-0511(85)90184-X; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; PFEFFERBAUM A, 1984, ELECTROEN CLIN NEURO, V59, P104, DOI 10.1016/0168-5597(84)90027-3; Posner M.I., 1975, INFORM PROCESSING CO, P55; Posner M. I., 1978, MODES PERCEIVING PRO, P137; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; POSNER MI, 1984, J NEUROSCI, V4, P1863; POSNER MI, 1982, PHILOS T ROY SOC B, V298, P187, DOI 10.1098/rstb.1982.0081; RIZZO PA, 1978, ELECTROEN CLIN NEURO, V45, P281, DOI 10.1016/0013-4694(78)90012-3; Rohrbaugh J W, 1986, Electroencephalogr Clin Neurophysiol Suppl, V38, P189; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1989, BRAIN, V112, P489, DOI 10.1093/brain/112.2.489; SANDMAN CA, 1987, INT J PSYCHOPHYSIOL, V5, P215, DOI 10.1016/0167-8760(87)90008-0; SHUM DHK, 1988, J CLIN EXPT NEUROPSY, V12, P125; Van Zomeren A. H., 1981, REACTION TIME ATTENT; VANVOORHIS S, 1977, PERCEPT PSYCHOPHYS, V22, P54, DOI 10.3758/BF03206080; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; Vogenthaler D R, 1987, Brain Inj, V1, P113; WALTER WG, 1964, NATURE, V203, P380, DOI 10.1038/203380a0; 1983, APSS STATISTICAL PAC	36	25	25	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG-SEP	1994	8	6					541	558		10.3109/02699059409151006			18	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	PE682	WOS:A1994PE68200006	7987290				2021-06-18	
J	KAPLAN, CP; CORRIGAN, JD				KAPLAN, CP; CORRIGAN, JD			THE RELATIONSHIP BETWEEN COGNITION AND FUNCTIONAL INDEPENDENCE IN ADULTS WITH TRAUMATIC BRAIN INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							MEDICAL REHABILITATION; ASSESSMENT SCALES; HEAD-INJURY; ORIENTATION; RECOVERY			KAPLAN, CP (corresponding author), OHIO STATE UNIV,DEPT PHYS MED & REHABIL,DIV REHABIL PSYCHOL,480 W 9TH AVE,COLUMBUS,OH 43210, USA.						BROOKS DN, 1990, REHABILITATION ADULT, P175; COHEN J, 1983, APPLIED MULTIPLE REG, P115; COHEN J, 1988, STATISTICAL POWE ANA, P414; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; CORRIGAN JD, 1985, ARCH PHYS MED REHAB, V66, P626; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; DILLER L, 1987, NEUROBEHAVIORAL RECO, P150; GALBRAITH S, 1987, BRIT MED J, V294, P325, DOI 10.1136/bmj.294.6568.325; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; GRANGER CV, 1976, ARCH PHYS MED REHAB, V57, P103; GRANGER CV, 1992, AM J PHYS MED REHAB, V71, P108, DOI 10.1097/00002060-199204000-00009; GRANGER CV, 1984, FUNCTIONAL ASSESSMEN, P14; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; HAMILTON BB, 1987, ARCH PHYS MED REHAB, V68, P583; HIGH WM, 1990, J CLIN EXP NEUROPSYC, V12, P703, DOI 10.1080/01688639008401013; JACKSON RD, 1989, ARCH PHYS MED REHAB, V70, P33; JENNETT B, 1981, MANAGEMENT HEAD INJU, P295; Keith R, 1987, ADV CLIN REHABILITAT, V1, P10; KOTTKE FJ, 1982, KRUSENS HDB PHYSICAL, pR11; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Mysiw WJ., 1990, J HEAD TRAUMA REHAB, V5, P65; ROSE M, 1981, REHABILITATION MED M, P183; SANEDA D L, 1992, Brain Injury, V6, P167, DOI 10.3109/02699059209029655; SCHERZER BP, 1993, BRAIN INJURY, V7, P411, DOI 10.3109/02699059309029684; SILVERSTEIN B, 1991, ARCH PHYS MED REHAB, V72, P631; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; WILKERSON DL, 1992, ARCH PHYS MED REHAB, V73, P111; Wilson J A, 1987, Brain Inj, V1, P183, DOI 10.3109/02699058709034456; 1980, WHO INT CLASSIFICATI, V14, P27	30	25	25	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	1994	75	6					643	647		10.1016/0003-9993(94)90186-4			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	NP636	WOS:A1994NP63600005	8002762				2021-06-18	
J	CHILDERS, MK; RUPRIGHT, J; SMITH, DW				CHILDERS, MK; RUPRIGHT, J; SMITH, DW			POSTTRAUMATIC HYPERTHERMIA IN ACUTE BRAIN INJURY REHABILITATION	BRAIN INJURY			English	Article							NEUROLEPTIC MALIGNANT SYNDROME; DANTROLENE; DOPAMINE; FEVER; MECHANISM	Fever frequently presents during recovery from traumatic brain injury (TBI). Elevated body temperature may result from ensuing infection, thrombophlebitis, drug reaction, or a defect in the central thermoregulatory system such as seen in post-traumatic hyperthermia (PTH). Typically, the diagnosis of PTH follows only after thorough investigation. Literature supports the theory that the febrile TBI patient, lacking a documented source, has central hyperthermia. The purpose of this study was to determine the incidence of PTH in the acute rehabilitation setting. We reviewed a consecutive series of 84 TBI patients participating in a rehabilitation programme. Four per cent of the patients in this study met our criteria for PTH. We describe a fever protocol that should aid the physician in diagnosis and treatment of the febrile TBI patient. Proposed mechanisms involved in thermoregulation are discussed.		CHILDERS, MK (corresponding author), UNIV HOSP & CLIN,DEPT PHYS MED & REHABIL,COLUMBIA,MO 65212, USA.			Childers, Martin/0000-0003-4754-0883			ACKERMAN D, 1980, J PHYSIOL-LONDON, V307, P59, DOI 10.1113/jphysiol.1980.sp013423; ADAMS RD, 1989, PRINCIPLES NEUROLOGY; BENEDEK G, 1987, CAN J NEUROL SCI, V14, P145; BONTKE CF, 1989, PHYSICAL MED REHABIL, V3, P55; Borison H L, 1967, Adv Pharmacol, V5, P129, DOI 10.1016/S1054-3589(08)60657-2; BULLARD DE, 1977, ANN NEUROL, V21, P138; COX B, 1978, J PHYSIOL-LONDON, V282, P471, DOI 10.1113/jphysiol.1978.sp012476; DAVIES JA, 1973, J PHARM PHARMACOL, V25, P705, DOI 10.1111/j.2042-7158.1973.tb10051.x; DINARELLO CA, 1988, REV INFECT DIS, V10, P168; FUXE K, 1972, J PHARM PHARMACOL, V24, P702, DOI 10.1111/j.2042-7158.1972.tb09093.x; GRANATO JE, 1983, ANN NEUROL, V14, P89, DOI 10.1002/ana.410140117; GRONERT GA, 1976, ANESTHESIOLOGY, V44, P488, DOI 10.1097/00000542-197606000-00005; GUZE BH, 1985, NEW ENGL J MED, V313, P163, DOI 10.1056/NEJM198507183130306; HARRISON GG, 1988, BRIT J ANAESTH, V60, P279, DOI 10.1093/bja/60.3.279; HENDERSON VW, 1981, NEUROLOGY, V31, P132, DOI 10.1212/WNL.31.2.132; HORN LJ, 1988, J HEAD TRAUMA REHAB, V3, P87; JACKSON R D, 1991, Brain Injury, V5, P93, DOI 10.3109/02699059108998518; KALISKY Z, 1985, ARCH PHYS MED REHAB, V66, P25; LIPTON JM, 1986, ANNU REV PHYSIOL, V48, P613; MILTON AS, 1978, PHARM HYPOTHALAMUS, P113; MORGAN KG, 1977, J PHARMACOL EXP THER, V201, P138; Myers R D, 1984, Physiologist, V27, P41; PETERSDORF RG, 1983, HARRISONS PRINCIPLES, P57; QUINLAN JG, 1990, MUSCLE NERVE, V13, P904, DOI 10.1002/mus.880131003; Reid J L, 1975, Adv Neurol, V9, P73; RUDY TA, 1980, FEVER, P165; RUDY TA, J PHYSL, V272, P721; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; SEGATORE M, 1992, J NEUROSCIENCE NURSI, V24, P105; STEWART CR, 1980, NEW ENGL J MED, V302, P1262; STITT JT, 1979, FED PROC, V38, P39; TALMAN WT, 1988, ARCH NEUROL-CHICAGO, V45, P1037, DOI 10.1001/archneur.1988.00520330129022; VANHILTEN JJ, 1991, CLIN NEUROL NEUROSUR, V93, P223, DOI 10.1016/S0303-8467(05)80007-1; YEHUDA S, 1972, NATURE, V240, P477, DOI 10.1038/240477a0	34	25	25	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAY-JUN	1994	8	4					335	343		10.3109/02699059409150984			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	NP445	WOS:A1994NP44500004	8081348				2021-06-18	
J	TANDON, DA; THAKAR, A; MAHAPATRA, AK; GHOSH, P				TANDON, DA; THAKAR, A; MAHAPATRA, AK; GHOSH, P			TRANS-ETHMOIDAL OPTIC-NERVE DECOMPRESSION	CLINICAL OTOLARYNGOLOGY			English	Article						TRANS-ETHMOIDAL; OPTIC NERVE DECOMPRESSION; VISUAL EVOKED POTENTIAL	TRAUMA; FRACTURES; BLINDNESS	Blunt head injury frequently results in visual impairment, the optimal treatment of which is still debated. Over a 5-year-period (1987-1991) 111 patients with indirect optic nerve injury resulting from closed head trauma have been treated. In each case loss of vision was the only neurological deficit. In group A, 66 patients were initially treated with large doses of prednisolone (80 mg/day) for 3 weeks. Twenty-seven patients improved on steroids alone. In the remaining 39 patients in whom either unsatisfactory or no improvement occurred a transethmoidal optic nerve decompression was performed. Twenty-two patients in the latter group improved, thus yielding an overall improvement rate of 74.2% in group A. Group B (control), in which 45 patients were treated with prednisolone only (80 mg/day for 3 weeks), had an overall improvement rate of 51% (23 patients). The study reveals that while nearly half of such patients can improve on steroids alone, optic nerve decompression significantly improves recovery rates in patients where conservative treatment is unsatisfactory (P < 0.05). Total loss of vision not responding to steroids, absence of waveform on visual evoked response, and presence of-an optic canal fracture indicate a poor prognosis.	ALL INDIA INST MED SCI, DEPT NEUROSURG, NEW DELHI 110029, INDIA	TANDON, DA (corresponding author), ALL INDIA INST MED SCI, DEPT OTORHINOLARYNGOL & HEAD & NECK SURG, NEW DELHI 110029, INDIA.		Thakar, Alok/V-7701-2019				Aitken P., 1991, OPHTHALMOL CLIN N AM, V4, P479; ANDERSON RL, 1982, OPHTHALMOLOGY, V89, P445; BRIHAYE J, 1976, ACTA NEUROCHIR, V33, P319, DOI 10.1007/BF01886679; EDMUND J, 1963, ACTA OPHTHALMOL, V41, P693; FUJITANI T, 1986, JPN J OPHTHALMOL, V30, P125; Fukado Y, 1975, Mod Probl Ophthalmol, V14, P474; FUNK GF, 1989, HEAD NECK-J SCI SPEC, V11, P295, DOI 10.1002/hed.2880110403; HUGHES B, 1962, B JOHNS HOPKINS HOSP, V111, P98; KENNERDELL JS, 1976, ARCH OPHTHALMOL-CHIC, V94, P1040; LESSELL S, 1989, ARCH OPHTHALMOL-CHIC, V107, P382, DOI 10.1001/archopht.1989.01070010392031; Lillie WI, 1934, ARCH OPHTHALMOL-CHIC, V12, P500, DOI 10.1001/archopht.1934.00830170038005; MAHAPATRA AK, 1992, NEUROL INDIA, V40, P17; MANFREDI SJ, 1981, PLAST RECONSTR SURG, V68, P479, DOI 10.1097/00006534-198110000-00001; MANISCALCO JE, 1978, J NEUROSURG, V48, P402, DOI 10.3171/jns.1978.48.3.0402; NAU HE, 1987, ACTA NEUROCHIR, V89, P16, DOI 10.1007/BF01406662; NIHO S, 1961, AM J OPHTHALMOL, V51, P659, DOI 10.1016/0002-9394(61)91611-7; NIHO S, 1970, CAN J OPHTHALMOLOGY, V5, P22; OSGUTHORPE JD, 1985, OTOLARYNG CLIN N AM, V18, P125; RAMSAY JH, 1979, BRIT J OPHTHALMOL, V63, P607, DOI 10.1136/bjo.63.9.607; Rodger F C, 1943, Br J Ophthalmol, V27, P23, DOI 10.1136/bjo.27.1.23; SOFFERMAN RA, 1981, LARYNGOSCOPE, V91, P184	21	25	29	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1749-4478	1749-4486		CLIN OTOLARYNGOL	Clin. Otolaryngol.	APR	1994	19	2					98	104		10.1111/j.1365-2273.1994.tb01190.x			7	Otorhinolaryngology	Otorhinolaryngology	NH892	WOS:A1994NH89200003	8026103				2021-06-18	
J	WEISEND, MP; FEENEY, DM				WEISEND, MP; FEENEY, DM			THE RELATIONSHIP BETWEEN TRAUMATIC BRAIN INJURY-INDUCED CHANGES IN BRAIN TEMPERATURE AND BEHAVIORAL AND ANATOMICAL OUTCOME	JOURNAL OF NEUROSURGERY			English	Article						TRAUMATIC BRAIN INJURY; HYPOTHERMIA; HYPERTHERMIA; NEUROPATHOLOGY; BEHAVIORAL RECOVERY	CEREBRAL BLOOD-FLOW; ISCHEMIC NEURONAL INJURY; EXPERIMENTAL HEAD-INJURY; MILD HYPOTHERMIA; MAGNETIC-RESONANCE; INTRACRANIAL-PRESSURE; MODERATE HYPOTHERMIA; FOREBRAIN ISCHEMIA; ENERGY-METABOLISM; ARTERY OCCLUSION	Alteration of brain temperature, experimentally induced or spontaneous, has been shown to affect the symptoms resulting from a variety of cerebral insults. This study examined the effect of traumatic brain injury (TBI) on brain and body temperature in rats and the relationship between TBI-induced temperature changes, neuropathology, and behavioral recovery. Anesthesia, surgery and TBI all caused changes in brain and body temperatures. The level of brain (but not body) temperature at the time of TBI was positively correlated with the severity of hippocampal and thalamic pathology. In contrast, the measured levels of both brain and body temperatures after TBI were not related to behavioral or neuroanatomical outcome. Interestingly, the increase in brain (but not body) temperature from the time of TBI to 5 to 10 minutes after termination of anesthesia was negatively correlated with behavioral and anatomical outcome. Simply stated, the more rapidly brain temperature returned toward normal, the better the rats' behavioral and anatomical outcome. This rate of return toward normal brain temperature is not interpreted as causally related to outcome but rather as an index of the severity of brain injury.	UNIV NEW MEXICO,DEPT PHYSIOL,ALBUQUERQUE,NM	WEISEND, MP (corresponding author), UNIV NEW MEXICO,DEPT PSYCHOL,LOGAN HALL,ROOM 278,ALBUQUERQUE,NM 87131, USA.						ABRAMS R. M., 1965, LIFE SCI, V4, P2399, DOI 10.1016/0024-3205(65)90295-X; AGARDH CD, 1992, ACTA NEUROPATHOL, V83, P379, DOI 10.1007/BF00713529; ANDERSEN BJ, 1989, INTRACRANIAL PRESSUR, V7, P575; BAKER CJ, 1991, SURG NEUROL, V36, P175, DOI 10.1016/0090-3019(91)90109-M; BOYD R J, 1961, Surg Forum, V12, P408; BROWN AW, 1979, ANN NEUROL, V5, P127, DOI 10.1002/ana.410050206; BRUNNER EA, 1971, J NEUROCHEM, V18, P2301, DOI 10.1111/j.1471-4159.1971.tb00186.x; BUCHANAN TA, 1991, METABOLISM, V40, P330, DOI 10.1016/0026-0495(91)90118-G; BUSTO R, 1989, STROKE, V20, P1113, DOI 10.1161/01.STR.20.8.1113; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CAMMERMEYER JAN, 1961, ACTA NEUROPATHOL, V1, P245; CARLSSON C, 1976, ANESTHESIOLOGY, V44, P27, DOI 10.1097/00000542-197601000-00006; CHAN KH, 1992, NEUROSURGERY, V30, P697; CHOPP M, 1989, J CEREBR BLOOD F MET, V9, P141, DOI 10.1038/jcbfm.1989.21; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DAIL WG, 1981, BRAIN RES, V211, P79, DOI 10.1016/0006-8993(81)90068-8; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; DIETRICH WD, 1991, ACTA NEUROPATHOL, V81, P615, DOI 10.1007/BF00296371; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; DUHAIME AC, 1990, BRAIN RES, V512, P169, DOI 10.1016/0006-8993(90)91188-M; FAY T, 1945, RES PUBL ASS NERV ME, V24, P611; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1989, J NEUROTRAUM, V6, P209; FREUND TF, 1990, EXP NEUROL, V108, P251, DOI 10.1016/0014-4886(90)90131-B; GORDON CJ, 1990, PHYSIOL BEHAV, V47, P963, DOI 10.1016/0031-9384(90)90025-Y; GORDON CJ, 1991, AM J PHYSIOL, V260, pR120; GORDON CJ, 1986, ANNU REV PHYSIOL, V48, P595, DOI 10.1146/annurev.ph.48.030186.003115; GORDON CJ, 1988, TOXICOLOGY, V53, P161, DOI 10.1016/0300-483X(88)90211-9; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; HAGERDAL M, 1978, ANESTHESIOLOGY, V49, P165, DOI 10.1097/00000542-197809000-00003; HANSEN TD, 1989, J CEREBR BLOOD F MET, V9, P323, DOI 10.1038/jcbfm.1989.50; HARALDSETH O, 1992, ACTA ANAESTH SCAND, V36, P393, DOI 10.1111/j.1399-6576.1992.tb03487.x; HAYWARD JN, 1969, BRAIN RES, V16, P417, DOI 10.1016/0006-8993(69)90236-4; HORN M, 1991, ACTA NEUROPATHOL, V81, P443, DOI 10.1007/BF00293466; Hynson J M, 1992, J Clin Anesth, V4, P194, DOI 10.1016/0952-8180(92)90064-8; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KONARSKA M, 1990, PSYCHOBIOLOGY, V18, P30; KURAMOTO T, 1979, ANESTHESIOLOGY, V51, P211, DOI 10.1097/00000542-197909000-00006; KUROIWA T, 1990, J CEREBR BLOOD F MET, V10, P550, DOI 10.1038/jcbfm.1990.97; LANDSBERG L, 1984, AM J PHYSIOL, V247, pE181; LAZORTHES G, 1958, J NEUROSURG, V15, P162, DOI 10.3171/jns.1958.15.2.0162; LEONOV Y, 1990, J CEREBR BLOOD F MET, V10, P57, DOI 10.1038/jcbfm.1990.8; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LO EH, 1992, STROKE, V23, P889, DOI 10.1161/01.STR.23.6.889; LONG NC, 1990, PHYSIOL BEHAV, V47, P773, DOI 10.1016/0031-9384(90)90093-J; Maier NRF, 1935, J COMP NEUROL, V61, P395, DOI 10.1002/cne.900610209; MCARTHUR AJ, 1981, J THERM BIOL, V6, P43, DOI 10.1016/0306-4565(81)90042-5; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MICHENFELDER JD, 1984, CLIN NEUROSURG, V32, P105; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; MINAMISAWA H, 1990, STROKE, V21, P758, DOI 10.1161/01.STR.21.5.758; MITANI A, 1991, BRAIN RES, V562, P159, DOI 10.1016/0006-8993(91)91201-B; MIYAZAWA T, 1992, J CEREBR BLOOD F MET, V12, P817, DOI 10.1038/jcbfm.1992.113; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; NAGASAKA T, 1979, JPN J PHYSIOL, V29, P383; NATALE JE, 1989, STROKE, V20, P770, DOI 10.1161/01.STR.20.6.770; NEILL KH, 1990, J NEUROSCI METH, V33, P179, DOI 10.1016/0165-0270(90)90022-8; NEWMAN GC, 1992, BRAIN RES, V575, P159, DOI 10.1016/0006-8993(92)90438-F; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; NILSSON B, 1977, J NEUROSURG, V47, P274, DOI 10.3171/jns.1977.47.2.0274; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Paxinos G, 1986, RAT BRAIN STEREOTAXI; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; RIDENOUR TR, 1992, STROKE, V23, P733, DOI 10.1161/01.STR.23.5.733; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; Schmidt-Nielsen K., 1983, ANIMAL PHYSL ADAPTAT; SESSLER DI, 1987, ANESTHESIOLOGY, V67, P137, DOI 10.1097/00000542-198707000-00032; SHAH KR, 1983, NEUROSCI LETT, V40, P287, DOI 10.1016/0304-3940(83)90053-8; Shima K, 1991, J NEUROTRAUM, V8, P65; SIMPSON RE, 1991, NEUROSCI LETT, V124, P83, DOI 10.1016/0304-3940(91)90827-G; SUTTON R L, 1990, Society for Neuroscience Abstracts, V16, P777; TENJIN H, 1990, NEUROSURGERY, V26, P971, DOI 10.1227/00006123-199006000-00009; TODD MM, 1984, ANESTHESIOLOGY, V60, P276, DOI 10.1097/00000542-198404000-00002; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; VACANTI FX, 1984, STROKE, V15, P695, DOI 10.1161/01.STR.15.4.695; VANDENPOL AN, 1990, J COMP NEUROL, V296, P654, DOI 10.1002/cne.902960410; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; WEISEND M P, 1989, Society for Neuroscience Abstracts, V15, P69; Weisend M. P., 1992, Society for Neuroscience Abstracts, V18, P179; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375	90	25	25	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	JAN	1994	80	1					120	132		10.3171/jns.1994.80.1.0120			13	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	MQ154	WOS:A1994MQ15400017	8270998				2021-06-18	
J	WONG, CW				WONG, CW			THE CT CRITERIA FOR CONSERVATIVE TREATMENT - BUT UNDER CLOSE CLINICAL OBSERVATION - OF POSTERIOR-FOSSA EPIDURAL HEMATOMAS	ACTA NEUROCHIRURGICA			English	Article						HEAD INJURY; EPIDURAL HEMATOMA; POSTERIOR FOSSA; CONSERVATIVE TREATMENT	EXTRADURAL HEMATOMAS; COMPUTED-TOMOGRAPHY; CRANIAL FOSSA; MANAGEMENT; RESOLUTION; CHILDREN	In order to assess whether the indications for conservative treatment of supratentorial epidural haematomas are applicable also to posterior fossa epidural haematomas (PFEDH), the author reviewed the records of 25 patients. With a PFEDH volume of no more than 10 ml, a thickness of no more than 15 mm, a midline shift of no more than 5 mm, and in the absence of a significant intracranial haematoma elsewhere on computed tomography (CT) scans, the patients undergoing conservative treatment achieved the same excellent outcome as those undergoing early surgery. These CT criteria for conservative treatment of PFEDHs are similar to those of supratentorial epidural haematomas except the volume factor, namely, 10 ml in the former against 30 ml in the latter. That means a PFEDH of 10 ml or larger in the small posterior fossa may produce the same degree of midline shift and compression, and be as dangerous as an epidural haematoma of 30 ml or larger in the more capacious supratentorial compartment. But also for epidural haematomas of the posterior fossa, which initially are smaller than 10 ml, the general rule remains valid that they should be under close clinical supervision	CHANG GUNG MED COLL,CHANG GUNG MEM HOSP,DEPT SURG,DIV NEUROSURG,TAIPEI,TAIWAN							AMMIRATI M, 1984, NEUROSURGERY, V14, P541, DOI 10.1227/00006123-198405000-00002; AOKI N, 1988, J NEUROSURG, V68, P149, DOI 10.3171/jns.1988.68.1.0149; ASHKENAZI E, 1990, J TRAUMA, V30, P613, DOI 10.1097/00005373-199005000-00015; BOITEN J, 1989, J NEUROL NEUROSUR PS, V52, P914, DOI 10.1136/jnnp.52.7.914-a; BULLOCK R, 1985, NEUROSURGERY, V16, P602, DOI 10.1227/00006123-198505000-00003; CHEN TY, 1993, NEUROSURGERY, V32, P176, DOI 10.1227/00006123-199302000-00004; ERICSON K, 1981, ACTA RADIOL DIAGN, V22, P513, DOI 10.1177/028418518102200501; GARZAMERCADO R, 1983, J NEUROSURG, V59, P664, DOI 10.3171/jns.1983.59.4.0664; HOOPER RS, 1954, BRIT J SURG, V42, P19, DOI 10.1002/bjs.18004217103; ILLINGWORTH R, 1983, J NEUROL NEUROSUR PS, V46, P558, DOI 10.1136/jnnp.46.6.558; KNUCKEY NW, 1989, J NEUROSURG, V70, P392, DOI 10.3171/jns.1989.70.3.0392; KUSHNER MJ, 1983, NEURORADIOLOGY, V24, P169; MEREDITH JM, 1961, AM J SURG, V102, P524, DOI 10.1016/0002-9610(61)90556-6; MORI K, 1983, CHILD BRAIN, V10, P130; MUNSLOW RA, 1951, J NEUROSURG, V8, P542, DOI 10.3171/jns.1951.8.5.0542; NEUBAUER UJ, 1987, ACTA NEUROCHIR, V87, P105, DOI 10.1007/BF01476060; PANG D, 1983, J NEUROSURG, V59, P958, DOI 10.3171/jns.1983.59.6.0958; PETERSEN OF, 1984, NEURORADIOLOGY, V26, P285; POZZATI E, 1986, NEUROSURGERY, V18, P696, DOI 10.1227/00006123-198606000-00003; POZZATI E, 1989, SURG NEUROL, V32, P300, DOI 10.1016/0090-3019(89)90234-6; RIVANO C, 1992, NEUROCHIRURGIA, V35, P43; SAKAI H, 1988, J NEUROSURG, V68, P566, DOI 10.3171/jns.1988.68.4.0566; SERVADEI F, 1989, ACTA NEUROCHIR, V96, P39, DOI 10.1007/BF01403493; STJOHN JN, 1986, SURG NEUROL, V25, P475; STONE JL, 1979, SURG NEUROL, V11, P419; TSAI FY, 1980, J COMPUT ASSIST TOMO, V4, P291, DOI 10.1097/00004728-198006000-00002; WEAVER D, 1981, J NEUROSURG, V54, P248, DOI 10.3171/jns.1981.54.2.0248; WONG C-W, 1991, Asian Journal of Surgery, V14, P64; WRIGHT RL, 1966, J NEUROSURG, V25, P402, DOI 10.3171/jns.1966.25.4.0402; ZIMMERMAN RA, 1982, RADIOLOGY, V144, P809, DOI 10.1148/radiology.144.4.7111729; ZUCCARELLO M, 1981, NEUROSURGERY, V8, P434, DOI 10.1227/00006123-198104000-00005	31	25	25	0	0	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1994	126	2-4					124	127		10.1007/BF01476421			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	MY920	WOS:A1994MY92000012	8042543				2021-06-18	
J	GARCIALARREA, L; ARTRU, F; BERTRAND, O; PERNIER, J; MAUGUIERE, F				GARCIALARREA, L; ARTRU, F; BERTRAND, O; PERNIER, J; MAUGUIERE, F			THE COMBINED MONITORING OF BRAIN-STEM AUDITORY EVOKED-POTENTIALS AND INTRACRANIAL-PRESSURE IN COMA - A STUDY OF 57 PATIENTS	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							INTENSIVE-CARE UNIT; CLOSED HEAD-INJURY; EEG SPECTRA; RESPONSES; TRAUMA; DAMAGE; DEATH	Continuous monitoring of brainstem auditory evoked potentials (BAEPs) was carried out in 57 comatose patients for periods ranging from 5 hours to 13 days. In 53 cases intracranial pressure (ICP) was also simultaneously monitored. The study of relative changes of evoked potentials over time proved more relevant to prognosis than the mere consideration of "statistical normality" of waveforms; thus progressive degradation of the BAEPs was associated with a bad outcome even if the responses remained within normal limits. Contrary to previous reports, a normal BAEP obtained during the second week of coma did not necessarily indicate a good vital outcome; it could, however, do so in cases with a low probability of secondary insults. The simultaneous study of BAEPs and ICP showed that apparently significant (> 40 mm Hg) acute rises in ICP were not always followed by BAEP changes. The stability of BAEP's despite "significant" ICP rises was associated in our patients with a high probability of survival, while prolongation of central latency of BAEPs in response to ICP modifications was almost invariably followed by brain death. Continuous monitoring of brainstem responses provided a useful physiological counterpart to physical parameters such as ICP. Serial recording of cortical EPs should be added to BAEP monitoring to permit the early detection of rostrocaudal deterioration.	HOP NEUROL,DEPT ANAESTHESIOL,F-69394 LYON 3,FRANCE; INSERM,U280,F-69008 LYON,FRANCE	GARCIALARREA, L (corresponding author), HOP NEUROL,DEPT EEG,CERMEP,59 BVD PINEL,F-69394 LYON 3,FRANCE.		Bertrand, Olivier/B-6165-2008	Bertrand, Olivier/0000-0003-0733-7979; Garcia-Larrea, Luis/0000-0002-9873-789X; MAUGUIERE, Francois/0000-0003-4291-4727			BASTUJI H, 1988, ELECTROEN CLIN NEURO, V70, P9, DOI 10.1016/0013-4694(88)90189-7; BERTRAND O, 1987, ELECTROEN CLIN NEURO, V68, P433, DOI 10.1016/0168-5597(87)90055-4; BERTRAND O, 1985, THESIS LYON FRANCE; BOSTON J R, 1984, International Journal of Clinical Monitoring and Computing, V1, P13, DOI 10.1007/BF01726657; BREWER CC, 1984, EVOKED POTENTIAL, V2, P578; BUCHNER H, 1988, ELECTROEN CLIN NEURO, V69, P14, DOI 10.1016/0013-4694(88)90031-4; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CENZATO M, 1988, EVOKED POTENTIALS IC, P153; CHIAPPA KH, 1983, EVOKED POTENTIALS CL, P145; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; DEWEERD AW, 1985, ACTA NEUROL SCAND, V72, P489; FACCO E, 1985, ELECTROEN CLIN NEURO, V62, P332, DOI 10.1016/0168-5597(85)90041-3; FERBERT A, 1988, ELECTROEN CLIN NEURO, V69, P136, DOI 10.1016/0013-4694(88)90209-X; Fischer C, 1982, Adv Neurol, V32, P177; GARCIALARREA L, 1987, ELECTROEN CLIN NEURO, V68, P446, DOI 10.1016/0168-5597(87)90056-6; GARCIALARREA L, 1988, NEUROLOGY, V38, P1487, DOI 10.1212/WNL.38.9.1487; GARCIALARREA L, 1992, IN PRESS MANUAL CLIN; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; HACKE W, 1985, J NEUROL, V232, P125, DOI 10.1007/BF00313886; HASSLER O, 1967, NEUROLOGY, V17, P368, DOI 10.1212/WNL.17.4.368; JAVEL E, 1982, ARCH OTOLARYNGOL, V108, P71; JOHNSON RT, 1956, ACTA RADIOL, V46, P242, DOI 10.3109/00016925609170833; KAGA K, 1985, LARYNGOSCOPE, V95, P321; KARNAZE DS, 1985, NEUROLOGY, V35, P1122, DOI 10.1212/WNL.35.8.1122; KAWAHARA N, 1989, ACTA NEUROCHIR, V100, P142, DOI 10.1007/BF01403602; KLINTWORTH KG, 1968, AM J PATHOL, V53, P391; LITSCHER G, 1990, J CLIN MONITOR, V6, P10, DOI 10.1007/BF02832177; LUTSCHG J, 1983, AM J DIS CHILD, V137, P421; MARESCH H, 1983, ELECTROEN CLIN NEURO, V56, P531, DOI 10.1016/0013-4694(83)90239-0; MAUGUIERE F, 1988, EVOKED POTENTIALS IN, P153; MAYNARD DE, 1984, ANAESTHESIA, V39, P678, DOI 10.1111/j.1365-2044.1984.tb06477.x; PFURTSCHELLER G, 1987, J CLIN NEUROPHYSIOL, V4, P389, DOI 10.1097/00004691-198710000-00004; PFURTSCHELLER G, 1985, ELECTROEN CLIN NEURO, V61, pS27, DOI 10.1016/0013-4694(85)90138-5; Plum F., 1980, DIAGNOSIS STUPOR COM, V3; PRIOR PF, 1986, MONITORING CEREBRAL; ROSENBERG C, 1989, ADV EVOKED POTENTIAL, P223; ROUGEMONT JD, 1971, NEUROCHIRURGIE, V17, P579; SEALES DM, 1979, J TRAUMA, V19, P347, DOI 10.1097/00005373-197905000-00008; TSUBOKAWA T, 1980, J NEUROL NEUROSUR PS, V43, P1005, DOI 10.1136/jnnp.43.11.1005; Uziel A, 1982, Adv Neurol, V32, P195	41	25	26	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	SEP	1992	55	9					792	798		10.1136/jnnp.55.9.792			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	JN763	WOS:A1992JN76300010	1402970	Green Published, Bronze			2021-06-18	
J	VILKKI, J; HOLST, P; OHMAN, J; SERVO, A; HEISKANEN, O				VILKKI, J; HOLST, P; OHMAN, J; SERVO, A; HEISKANEN, O			COGNITIVE TEST PERFORMANCES RELATED TO EARLY AND LATE COMPUTED-TOMOGRAPHY FINDINGS AFTER CLOSED-HEAD INJURY	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							FRONTAL-LOBE; NEUROPSYCHOLOGICAL DEFICITS; LESIONS; RECOVERY; MEMORY	Computed tomography (CT) findings from early (less than 24 hours) and late scan (6 months) after closed-head injury (CHI) were compared to cognitive test scores obtained on an average of 4 months after injury in a consecutive series of 53 patients. The presence of parenchymal lesion was associated with poor test results, indicating cognitive inflexibility and disinhibition of routine response tendencies in novel tasks. These deficits have previously been found to be related in particular to frontal-lobe dysfunction, but the present study did not support the hypothesis that frontal lesion is the principal cause of this impairment in CHI. Parenchymal lesions in the right and left hemisphere were associated with spatial and verbal deficits, respectively. Ventricular enlargement in the late CT was related to cognitive inefficiency, both being strongly associated with age. The results suggest that parenchymal lesion in the early CT is an indicator of diffuse axonal injury, which results in cognitive inflexibility during recovery.		VILKKI, J (corresponding author), UNIV CENT HOSP HELSINKI,DEPT NEUROSURG,TOPELIUKSENKATU 5,SF-00260 HELSINKI,FINLAND.			Ohman, Juha/0000-0002-6592-1367			ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; BENTON AL, 1963, REVISED VISUAL RETEN; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; FULD PA, 1980, CORTEX, V16, P255, DOI 10.1016/S0010-9452(80)80061-X; GENNARELLI TA, 1982, J NEUROSURG, V56, P25; Goldberg E., 1987, FRONTAL LOBES REVISI, P159; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Milner B, 1964, FRONTAL GRANULAR COR, P313; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1990, J CLIN EXP NEUROPSYC, V12, P34; TEASDALE G, 1984, CLOSED HEAD INJURY P, P5; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630; UZZELL BP, 1987, NEUROSURGERY, V20, P396, DOI 10.1227/00006123-198703000-00007; VILKKI J, 1985, CORTEX, V21, P431, DOI 10.1016/S0010-9452(85)80007-1; VILKKI J, 1989, NEUROPSYCHOLOGIA, V27, P1101, DOI 10.1016/0028-3932(89)90189-9; VILKKI J, 1988, CORTEX, V24, P119, DOI 10.1016/S0010-9452(88)80020-0; Wechsler D., 2008, WECHSLER ADULT INTEL; Whishaw W. H., 1980, FUNDAMENTALS HUMAN N; WILSON J T L, 1990, Brain Injury, V4, P349; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; Zimmerman RA, 1989, NEUROPSYCHOLOGY, V3, P191, DOI 10.1037/h0091791	33	25	26	0	1	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUL	1992	14	4					518	532		10.1080/01688639208402841			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	JK552	WOS:A1992JK55200006	1400915				2021-06-18	
J	DEACON, D; CAMPBELL, KB				DEACON, D; CAMPBELL, KB			EFFECTS OF PERFORMANCE FEEDBACK ON P300 AND REACTION-TIME IN CLOSED HEAD-INJURED OUTPATIENTS	ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY			English	Article						REACTION TIME; P300 LATENCY; CLOSED HEAD INJURY; FEEDBACK	ACCURACY; SPEED; POTENTIALS; LATENCY	In an earlier study, we have demonstrated that the choice reaction times (RTs) of closed head-injured patients may be reduced significantly by instructions which emphasize speed, thus indicating that this portion of the RT delay was not due to a motor deficit. Despite the reduction in patient RTs, however, they remained significantly longer than those of controls. Furthermore, the RTs of patients were 56 msec longer than their P300 latencies, whereas those of controls occurred at about the same time as P300. The delay which remained in patient RTs was thus not entirely due to longer stimulus evaluation times. The goal of the present study was to further reduce patient RTs using feedback (FB) on response speed and time windows within which subjects were required to respond. When FB on speed and a 'narrow' time window were used, patient RTs occurred at about the same time as P300 latency (as was also the case with controls) indicating that the longer RTs of these patients in our earlier study, and in the other conditions of the present study, could not have been exaggerated beyond P300 latency due to a motor deficit. It was suggested that CHI patients may not be able to internally monitor their responses to the same degree as controls. The provision of external cues may have compensated for this deficit.	UNIV OTTAWA,OTTAWA K1N 6N5,ONTARIO,CANADA							BROOKHUIS KA, 1983, BIOL PSYCHOL, V17, P277, DOI 10.1016/0301-0511(83)90004-2; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P794, DOI 10.1136/jnnp.37.7.794; BROUWER WH, 1985, LIMITATION ATTENTION; Campbell K., 1986, ELECTROENCEPHALOGR S, V38, P486; CURRY SH, 1985, INT C ELECTROENCEPHA; DEACON D, UNPUB SPEED DECISION; DENCKER SJ, 1958, ACTA PSYCHIAT NEUROL, V33, P122; DUNCANJOHNSON CC, 1981, SCIENCE, V214, P938, DOI 10.1126/science.7302571; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; FITTS PM, 1966, J EXP PSYCHOL, V71, P849, DOI 10.1037/h0023232; GREEN DM, 1966, SIGNAL DETECTION THE; GREENHOUSE SW, 1959, PSYCHOMETRIKA, V24, P95, DOI 10.1007/BF02289823; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; KINSBOURNE M, 1977, AGING DEMENTIA, P217; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; LINK SW, 1971, PERCEPT PSYCHOPHYS, V9, P284, DOI 10.3758/BF03212649; LURIA AR, 1973, PSYCHOPHYSIOLOGY FRO; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MAGLIERO A, 1984, PSYCHOPHYSIOLOGY, V21, P169; MARTINIUS J, 1977, MONATSSCHR KINDERH, V125, P401; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; Miller E, 1970, Cortex, V6, P121; MULDER G, 1984, PSYCHOL RES-PSYCH FO, V46, P15, DOI 10.1007/BF00308590; NORRMAN B, 1961, ACTA PSYCHIAT SCAND, V37, P236, DOI 10.1111/j.1600-0447.1961.tb07359.x; OMMAYA A, 1961, J NEUROSURG, V35, P236; Otto D., 1978, MULTIDISCIPLINARY PE, P175; Pachella R. G., 1974, HUMAN INFORM PROCESS, P41; PFEFFERBAUM A, 1983, ELECTROEN CLIN NEURO, V55, P188, DOI 10.1016/0013-4694(83)90187-6; RABBITT P, 1979, BRIT J PSYCHOL, V70, P305, DOI 10.1111/j.2044-8295.1979.tb01687.x; RAGOT R, 1981, BIOL PSYCHOL, V13, P289, DOI 10.1016/0301-0511(81)90044-2; Ruesch J, 1944, AM J PSYCHIAT, V100, P480, DOI 10.1176/ajp.100.4.480; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; SCHOUTEN JF, 1967, ACTA PSYCHOL, V27, P143, DOI 10.1016/0001-6918(67)90054-6; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; Stuss D.T., 1986, FRONTAL LOBES; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; Van Zomeren A. H., 1981, REACTION TIME ATTENT; VANZOMEREN AH, 1981, REACTION TIME ATTENT, P23; VANZOMEREN AH, 1981, REACTION TIME ATTENT, P50; VICKERS D, 1981, REACTION TIMES, P25; Welford AT, 1980, REACTION TIMES; WINOGRON HSW, 1986, THESIS CARLETON U OT; WOOD CC, 1976, PERCEPT PSYCHOPHYS, V9, P93	45	25	27	0	0	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0013-4694			ELECTROEN CLIN NEURO	Electroencephalogr. Clin. Neurophysiol.	FEB	1991	78	2					133	141		10.1016/0013-4694(91)90113-I			9	Engineering, Biomedical; Clinical Neurology	Engineering; Neurosciences & Neurology	EY029	WOS:A1991EY02900007	1704836				2021-06-18	
J	KOSTMIKUCKI, SA; OBLINGER, MM				KOSTMIKUCKI, SA; OBLINGER, MM			CHANGES IN GLIAL FIBRILLARY ACIDIC PROTEIN MESSENGER-RNA EXPRESSION AFTER CORTICOSPINAL AXOTOMY IN THE ADULT HAMSTER	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						AXONAL DEGENERATION; INTERMEDIATE FILAMENTS; INSITU HYBRIDIZATION; ASTROCYTES; NEURAL REGENERATION	CENTRAL NERVOUS-SYSTEM; INTERMEDIATE FILAMENTS; SPINAL-CORD; INSITU HYBRIDIZATION; REACTIVE GLIOSIS; RAT-BRAIN; ASTROCYTES; GFAP; INJURY; IMMUNOFLUORESCENCE	We examined changes in the expression of glial fibrillary acidic protein (GFAP) mRNA during Wallerian degeneration in the corticospinal system of the adult Golden hamster following axotomy. GFAP is the product of a type III intermediate filament (IF) gene that is expressed specifically in mature astrocytes. A well-studied component of a complex response termed reactive astrogliosis that occurs after various types of CNS injury is the increased production of astrocytic processes filled with GFAP-containing IFs. While increased expression of GFAP during reactive astrogliosis has been well established at the protein level, little is known about whether or not changes in GFAP mRNA levels occur after CNS injury. In the present study we used in situ hybridization methods to examine this issue. A S-35-labeled mouse GFAP cDNA probe was used for in situ hybridizations of sections of the brain stem obtained 2, 7, and 14 days after unilateral transections of the corticospinal tract in the caudal medulla. Film as well as emulsion autoradiography showed a dramatic increase in GFAP mRNA labeling associated with the degenerating corticospinal tract. GFAP mRNA levels were already dramatically increased in the injured corticospinal tract by 2 days post axotomy and remained elevated at 14 days. Interestingly, in addition to the robust increase in GFAP mRNA levels specifically associated with the degenerating tract, a diffuse increase in GFAP mRNA labeling was observed throughout the grey matter of the brain stem at 2 days post-axotomy, but not after this time. Immunoblotting and immunocytochemical experiments verified that the increased GFAP mRNA levels in the degenerating corticospinal system were accompanied by an increased expression of the protein. These results demonstrate that an increase in GFAP mRNA levels occurs during Wallerian degeneration in the CNS and suggest that increased expression of the GFAP gene is a major contributor to CNS scarring that results after direct traumatic injury.	CHICAGO MED SCH,DEPT CELL BIOL & ANAT,3333 GREEN BAY RD,N CHICAGO,IL 60064					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021571] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21571] Funding Source: Medline		AQUINO DA, 1988, J NEUROCHEM, V51, P1085, DOI 10.1111/j.1471-4159.1988.tb03072.x; AVOLA R, 1988, J NEUROSCI RES, V19, P230, DOI 10.1002/jnr.490190208; BIGNAMI A, 1973, BRAIN RES, V49, P393, DOI 10.1016/0006-8993(73)90430-7; BIGNAMI A, 1976, NEUROPATH APPL NEURO, V2, P99, DOI 10.1111/j.1365-2990.1976.tb00488.x; CHIU FC, 1985, J NEUROIMMUNOL, V8, P283, DOI 10.1016/S0165-5728(85)80067-9; DAHL D, 1986, ASTROCYTES, V3, P1; EISENFELD AJ, 1984, INVEST OPHTH VIS SCI, V25, P1321; ENG LF, 1989, GLIA, V2, P308, DOI 10.1002/glia.440020504; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; FEDOROFF S, 1986, ASTROCYTES, V3, P35; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; GIULIAN D, 1988, J NEUROSCI, V8, P2485; JANECZKO K, 1988, BRAIN RES, V456, P280, DOI 10.1016/0006-8993(88)90229-6; KALIL K, 1982, J COMP NEUROL, V211, P265, DOI 10.1002/cne.902110305; LANDRY CF, 1990, J NEUROSCI RES, V25, P194, DOI 10.1002/jnr.490250207; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; LEWIS SA, 1985, J NEUROCHEM, V45, P913, DOI 10.1111/j.1471-4159.1985.tb04080.x; LEWIS SA, 1984, P NATL ACAD SCI-BIOL, V81, P2743, DOI 10.1073/pnas.81.9.2743; Marangos P. J., 1988, NEURONAL GLIAL PROTE, P339; MILLER RH, 1986, J NEUROSCI, V6, P22; MILLER RH, 1984, J NEUROSCI, V4, P585; MORRISON RS, 1985, J NEUROSCI RES, V14, P167, DOI 10.1002/jnr.490140202; Nathaniel EJ., 1981, ADV CELLULAR NEUROBI, P249, DOI [10.1016/B978-0-12-008302-2.50012-2, DOI 10.1016/B978-0-12-008302-2.50012-2]; NIETOSAMPEDRO M, 1988, CURRENT ISSUES NEURA, P301; OBLINGER M M, 1989, Journal of Cell Biology, V109, p71A; OBLINGER MM, 1987, J NEUROSCI, V7, P2510; PATEL AJ, 1985, BRAIN RES, V331, P1, DOI 10.1016/0006-8993(85)90708-5; PETERS A, 1976, FINE STRUCTURE NERVO, P231; POIRIER J, 1990, P NATL ACAD SCI USA, V87, P303, DOI 10.1073/pnas.87.1.303; PREDY R, 1989, BRAIN RES BULL, V22, P81, DOI 10.1016/0361-9230(89)90131-7; RAFF MC, 1983, J NEUROSCI, V3, P1290; RAJU TR, 1980, BRAIN RES, V200, P225, DOI 10.1016/0006-8993(80)91114-2; RATABOUL P, 1989, BRAIN RES BULL, V22, P155, DOI 10.1016/0361-9230(89)90140-8; RATABOUL P, 1988, J NEUROSCI RES, V20, P165, DOI 10.1002/jnr.490200204; REIER P J, 1989, P183; Schachner M., 1982, NEUROIMMUNOLOGY, P215; SELKOE DJ, 1982, BRAIN RES, V245, P117, DOI 10.1016/0006-8993(82)90344-4; SINGH DNP, 1989, ACTA ANAT, V134, P156; SKOFF RP, 1975, J COMP NEUROL, V161, P595, DOI 10.1002/cne.901610408; SMITH ME, 1983, BRAIN RES, V264, P241, DOI 10.1016/0006-8993(83)90822-3; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; TAKAMIYA M, 1988, J NEUROCHEM, V466, P201; TARDY M, 1989, J NEUROCHEM, V52, P162, DOI 10.1111/j.1471-4159.1989.tb10911.x; TETZLAFF W, 1988, GLIA, V1, P90, DOI 10.1002/glia.440010110; WONG J, 1987, METAB BRAIN DIS, V2, P291, DOI 10.1007/BF00999699	45	25	25	0	0	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	FEB	1991	28	2					182	191		10.1002/jnr.490280205			10	Neurosciences	Neurosciences & Neurology	FA377	WOS:A1991FA37700004	2033647				2021-06-18	
J	MUTTER, SA; HOWARD, DV; HOWARD, JH; WIGGS, CL				MUTTER, SA; HOWARD, DV; HOWARD, JH; WIGGS, CL			PERFORMANCE ON DIRECT AND INDIRECT TESTS OF MEMORY AFTER MILD CLOSED HEAD-INJURY	COGNITIVE NEUROPSYCHOLOGY			English	Article									GEORGETOWN UNIV,WASHINGTON,DC 20057	MUTTER, SA (corresponding author), CATHOLIC UNIV AMER,HUMAN PERFORMANCE LAB,ROOM 100 OBOYLE,WASHINGTON,DC 20064, USA.						BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; Brooks N., 1984, CLOSED HEAD INJURY P; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; DIKMAN S, 1986, NEUROBEHAVIOURAL REC; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P501, DOI 10.1037/0278-7393.11.3.501; GRAF P, 1984, J EXP PSYCHOL LEARN, V10, P164, DOI 10.1037/0278-7393.10.1.164; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; JACOBY LL, 1983, J EXP PSYCHOL LEARN, V9, P21, DOI 10.1037//0278-7393.9.1.21; Kuera M., 1967, COMPUTATIONAL ANAL P; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; MILNER B, 1968, NEUROPSYCHOLOGIA, V6, P215, DOI 10.1016/0028-3932(68)90021-3; RICHARDSONKLAVE.A, 1988, ANN REV PSYCHOL, V39; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROEDIGER HL, 1987, MEMORY LEARNING EBBI; SCHACTER DL, 1986, J EXP PSYCHOL LEARN, V12, P432, DOI 10.1037/0278-7393.12.3.432; SCHACTER DL, 1989, J EXP PSYCHOL LEARN, V15, P3, DOI 10.1037/0278-7393.15.1.3; SCHACTER DL, 1986, J CLIN EXP NEUROPSYC, V8, P727, DOI 10.1080/01688638608405192; SCHACTER DL, 1987, J EXP PSYCHOL LEARN, V13, P501, DOI 10.1037/0278-7393.13.3.501; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SCHACTER DL, 1985, MEMORY SYSTEMS BRAIN; SHIMAMURA AP, 1989, J EXP PSYCHOL LEARN, V15, P721, DOI 10.1037/0278-7393.15.4.721; SHIMAMURA AP, 1986, Q J EXP PSYCHOL-A, V38, P619, DOI 10.1080/14640748608401617; SQUIRE LR, 1978, NEUROPSYCHOLOGIA, V16, P339, DOI 10.1016/0028-3932(78)90027-1; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TULVING E, 1982, J EXP PSYCHOL LEARN, V8, P336, DOI 10.1037/0278-7393.8.4.336; Tulving E, 1983, ELEMENTS EPISODIC ME; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P; WARRINGTON EK, 1968, NATURE, V217, P972, DOI 10.1038/217972a0; WARRINGTON EK, 1970, NATURE, V228, P629; Winer BJ., 1971, STAT PRINCIPLES EXPT	34	25	25	0	0	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE, EAST SUSSEX, ENGLAND BN3 2FA	0264-3294			COGNITIVE NEUROPSYCH	Cogn. Neuropsychol.	AUG	1990	7	4					329	346		10.1080/02643299008253447			18	Psychology; Psychology, Experimental	Psychology	DU364	WOS:A1990DU36400004					2021-06-18	
J	OSHAUGHNESSY, EJ; FOWLER, RS; REID, V				OSHAUGHNESSY, EJ; FOWLER, RS; REID, V			SEQUELAE OF MILD CLOSED HEAD-INJURIES	JOURNAL OF FAMILY PRACTICE			English	Article										OSHAUGHNESSY, EJ (corresponding author), UNIV WASHINGTON,SCH MED,DEPT REHABIL MED,SEATTLE,WA 98195, USA.						ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BOND MR, 1976, SCAND J REHABIL MED, V8, P127; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; DILLER L, 1978, REHABILITATION INDIC; EDWARDS A, 1966, EDWARDS PERSONALITY; EVANS CD, 1976, INJURY, V8, P80, DOI 10.1016/0020-1383(76)90040-1; FLANIGAN C, 1981, THESIS U WASHINGTON; GILCHRIST E, 1979, ARCH NEUROL-CHICAGO, V36, P355, DOI 10.1001/archneur.1979.00500420065008; GRONWALL D, 1974, LANCET, V2, P605; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Kraus J F, 1978, Adv Neurol, V19, P261; Lewin W, 1979, Acta Neurochir Suppl (Wien), V28, P128; LEWIN W, 1970, P ROY SOC MED, V63, P8; LUNDHOLM J, 1975, SCAND J REHABIL MED, V7, P97; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1965, LANCET, V1, P225; NAJENSEN T, 1975, SCAND J REHABIL MED, V8, P101; OVERGAARD J, 1973, LANCET, V2, P631; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; SELZ M, 1979, J CONSULT CLIN PSYCH, V47, P258, DOI 10.1037/0022-006X.47.2.258; Wechsler D., 1955, MANUAL WECHSLER ADUL; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	26	25	25	0	2	APPLETON & LANGE	E NORWALK	25 VAN ZANT ST, E NORWALK, CT 06855	0094-3509			J FAM PRACTICE	J. Fam. Pract.		1984	18	3					391	394					4	Primary Health Care; Medicine, General & Internal	General & Internal Medicine	SF691	WOS:A1984SF69100005	6699578				2021-06-18	
J	PARSONS, LC; SHOGAN, JSO				PARSONS, LC; SHOGAN, JSO			THE EFFECTS OF THE ENDOTRACHEAL-TUBE SUCTIONING MANUAL HYPERVENTILATION PROCEDURE ON PATIENTS WITH SEVERE CLOSED HEAD-INJURIES	HEART & LUNG			English	Article										PARSONS, LC (corresponding author), UNIV VIRGINIA,SCH NURSING,CHARLOTTESVILLE,VA 22903, USA.						BEDFORD RF, 1980, ANESTH ANALG, V59, P435; CAVENESS WF, 1979, ADV NEUROLOGY, V22; Cushing H, 1903, AM J MED SCI, V125, P1017, DOI 10.1097/00000441-190306000-00006; DONEGAN MF, 1980, ANESTHESIOLOGY, V52, P516, DOI 10.1097/00000542-198006000-00014; DOWNES JJ, 1961, ANESTHESIOLOGY, V22, P29, DOI 10.1097/00000542-196101000-00007; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; LUNDBERG N, 1960, ACTA PSYCHIAT S S149, V35, P1; MARSHALL LF, 1977, ACTA NEUROL SCAND, V56, P156; MITCHELL PH, 1978, NURSING RES, V21, P4; Rimel R W, 1981, J Neurosurg Nurs, V13, P132; RODBARD S, 1955, CIRCULATION, V12, P883, DOI 10.1161/01.CIR.12.5.883; SHALIT MN, 1977, ISRAEL J MED SCI, V13, P881; SKELLY BFH, 1981, HEART LUNG, V9, P316; TEASDALE G, 1974, LANCET, V2, P81; URBAN BJ, 1969, ANESTHESIOLOGY, V31, P473, DOI 10.1097/00000542-196911000-00024	15	25	25	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0147-9563			HEART LUNG	Heart Lung		1984	13	4					372	380					9	Cardiac & Cardiovascular Systems; Nursing; Respiratory System	Cardiovascular System & Cardiology; Nursing; Respiratory System	TB345	WOS:A1984TB34500010	6564106				2021-06-18	
J	DENCKER, SJ				DENCKER, SJ			CLOSED HEAD-INJURY IN TWINS - NEUROLOGIC, PSYCHOMETRIC, AND PSYCHIATRIC FOLLOW-UP-STUDY OF CONSECUTIVE CASES, USING CO-TWINS AS CONTROLS	ARCHIVES OF GENERAL PSYCHIATRY			English	Article																ALEXANDER F, 1949, Public Health Rep, V64, P357, DOI 10.2307/4586894; DENCKER SJ, 1958, ACTA PSYCHIAT NEUR S, V122, P33; DENCKER SJ, 1958, ACTA PSYCHIAT NEUR S, V123, P33; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; Dunbar F., 1947, MIND BODY PSYCHOSOMA; ESSENMOLLER E, 1956, ACTA PSYCHIAT NEUR S, V100; PROBST H, 1949, Z Kinderpsychiatr, V15, P186; Ruesch J, 1944, AM J PSYCHIAT, V100, P480, DOI 10.1176/ajp.100.4.480; RUESCH J, 1945, RES PUBL ASS NERV ME, V24, P507; Wolff HG., 1948, HEADACHE OTHER HEAD, V1	10	25	25	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0003-990X	1538-3636		ARCH GEN PSYCHIAT	Arch. Gen. Psychiatry		1960	2	5					569	575					7	Psychiatry	Psychiatry	WF140	WOS:A1960WF14000012	13815890				2021-06-18	
J	Hadfield, G; Christie, RV				Hadfield, G; Christie, RV			A case of pulmonary concussion ("blast") due to high explosive	BRITISH MEDICAL JOURNAL			English	Article																	0	25	25	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN-JUN	1941	1941		1				77	78		10.1136/bmj.1.4176.77			2	Medicine, General & Internal	General & Internal Medicine	V07WL	WOS:000200531500081	20783485	Green Published			2021-06-18	
J	Rowell, SE; Meier, EN; McKnight, B; Kannas, D; May, S; Sheehan, K; Bulger, EM; Idris, AH; Christenson, J; Morrison, LJ; Frascone, RJ; Bosarge, PL; Colella, MR; Johannigman, J; Cotton, BA; Callum, J; McMullan, J; Dries, DJ; Tibbs, B; Richmond, NJ; Weisfeldt, ML; Tallon, JM; Garrett, JS; Zielinski, MD; Aufderheide, TP; Gandhi, RR; Schlamp, R; Robinson, BRH; Jui, J; Klein, L; Rizoli, S; Gamber, M; Fleming, M; Hwang, J; Vincent, LE; Williams, C; Hendrickson, A; Simonson, R; Klotz, P; Sopko, G; Witham, W; Ferrara, M; Schreiber, MA				Rowell, Susan E.; Meier, Eric N.; McKnight, Barbara; Kannas, Delores; May, Susanne; Sheehan, Kellie; Bulger, Eileen M.; Idris, Ahamed H.; Christenson, Jim; Morrison, Laurie J.; Frascone, Ralph J.; Bosarge, Patrick L.; Colella, M. Riccardo; Johannigman, Jay; Cotton, Bryan A.; Callum, Jeannie; McMullan, Jason; Dries, David J.; Tibbs, Brian; Richmond, Neal J.; Weisfeldt, Myron L.; Tallon, John M.; Garrett, John S.; Zielinski, Martin D.; Aufderheide, Tom P.; Gandhi, Rajesh R.; Schlamp, Rob; Robinson, Bryce R. H.; Jui, Jonathan; Klein, Lauren; Rizoli, Sandro; Gamber, Mark; Fleming, Michael; Hwang, Jun; Vincent, Laura E.; Williams, Carolyn; Hendrickson, Audrey; Simonson, Robert; Klotz, Patricia; Sopko, George; Witham, William; Ferrara, Michael; Schreiber, Martin A.			Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	TXA in Trauma Symposium	JUL 05, 2019	Melbourne, AUSTRALIA				SEIZURES	Importance Traumatic brain injury (TBI) is the leading cause of death and disability due to trauma. Early administration of tranexamic acid may benefit patients with TBI. Objective To determine whether tranexamic acid treatment initiated in the out-of-hospital setting within 2 hours of injury improves neurologic outcome in patients with moderate or severe TBI. Design, Setting, and Participants Multicenter, double-blinded, randomized clinical trial at 20 trauma centers and 39 emergency medical services agencies in the US and Canada from May 2015 to November 2017. Eligible participants (N = 1280) included out-of-hospital patients with TBI aged 15 years or older with Glasgow Coma Scale score of 12 or less and systolic blood pressure of 90 mm Hg or higher. Interventions Three interventions were evaluated, with treatment initiated within 2 hours of TBI: out-of-hospital tranexamic acid (1 g) bolus and in-hospital tranexamic acid (1 g) 8-hour infusion (bolus maintenance group; n = 312), out-of-hospital tranexamic acid (2 g) bolus and in-hospital placebo 8-hour infusion (bolus only group; n = 345), and out-of-hospital placebo bolus and in-hospital placebo 8-hour infusion (placebo group; n = 309). Main Outcomes and Measures The primary outcome was favorable neurologic function at 6 months (Glasgow Outcome Scale-Extended score >4 [moderate disability or good recovery]) in the combined tranexamic acid group vs the placebo group. Asymmetric significance thresholds were set at 0.1 for benefit and 0.025 for harm. There were 18 secondary end points, of which 5 are reported in this article: 28-day mortality, 6-month Disability Rating Scale score (range, 0 [no disability] to 30 [death]), progression of intracranial hemorrhage, incidence of seizures, and incidence of thromboembolic events. Results Among 1063 participants, a study drug was not administered to 96 randomized participants and 1 participant was excluded, resulting in 966 participants in the analysis population (mean age, 42 years; 255 [74%] male participants; mean Glasgow Coma Scale score, 8). Of these participants, 819 (84.8%) were available for primary outcome analysis at 6-month follow-up. The primary outcome occurred in 65% of patients in the tranexamic acid groups vs 62% in the placebo group (difference, 3.5%; [90% 1-sided confidence limit for benefit, -0.9%]; P = .16; [97.5% 1-sided confidence limit for harm, 10.2%]; P = .84). There was no statistically significant difference in 28-day mortality between the tranexamic acid groups vs the placebo group (14% vs 17%; difference, -2.9% [95% CI, -7.9% to 2.1%]; P = .26), 6-month Disability Rating Scale score (6.8 vs 7.6; difference, -0.9 [95% CI, -2.5 to 0.7]; P = .29), or progression of intracranial hemorrhage (16% vs 20%; difference, -5.4% [95% CI, -12.8% to 2.1%]; P = .16). Conclusions and Relevance Among patients with moderate to severe TBI, out-of-hospital tranexamic acid administration within 2 hours of injury compared with placebo did not significantly improve 6-month neurologic outcome as measured by the Glasgow Outcome Scale-Extended. This randomized clinical trial compares the effects of an out-of-hospital tranexamic acid bolus vs placebo within 2 hours of traumatic brain injury (TBI) on 6-month functional neurologic outcome (Glasgow Coma Scale-Extended score >4) in patients with moderate or severe TBI. Question Does early administration of tranexamic acid to patients with moderate or severe traumatic brain injury improve neurologic outcome at 6 months? Findings In this randomized multicenter clinical trial that included 966 participants enrolled in the out-of-hospital setting by paramedics, treatment with tranexamic acid as an out-of-hospital bolus with or without in-hospital infusion, compared with placebo as an out-of-hospital bolus and in-hospital infusion, resulted in a favorable neurologic outcome (defined as Glasgow Outcome Scale-Extended score >4) in 65% vs 62% of patients at 6 months, a difference that was not statistically significant. Meaning Among participants suspected of having moderate or severe traumatic brain injury, out-of-hospital administration of tranexamic acid compared with placebo did not significantly improve 6-month neurologic recovery.	[Rowell, Susan E.; Fleming, Michael; Schreiber, Martin A.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA; [Rowell, Susan E.] Duke Univ, Sch Med, Dept Surg, Durham, NC USA; [Meier, Eric N.; McKnight, Barbara; Kannas, Delores; May, Susanne; Sheehan, Kellie; Hwang, Jun] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Bulger, Eileen M.; Robinson, Bryce R. H.; Klotz, Patricia] Univ Washington, Dept Surg, Seattle, WA 98195 USA; [Idris, Ahamed H.] Univ Texas Southwestern Med Ctr Dallas, Dept Emergency Med, Dallas, TX 75390 USA; [Idris, Ahamed H.] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA; [Christenson, Jim; Tallon, John M.] Univ British Columbia, Dept Emergency Med, Vancouver, BC, Canada; [Christenson, Jim] Providence Hlth Care Res Inst, Vancouver, BC, Canada; [Morrison, Laurie J.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Rescu, Toronto, ON, Canada; [Morrison, Laurie J.] Univ Toronto, Div Emergency Med, Dept Med, Toronto, ON, Canada; [Frascone, Ralph J.] Reg Hosp, Dept Emergency Med, St Paul, MN USA; [Bosarge, Patrick L.; Williams, Carolyn] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA; [Bosarge, Patrick L.] Univ Arizona, Dept Surg, Phoenix, AZ USA; [Colella, M. Riccardo; Aufderheide, Tom P.] Med Coll Wisconsin, Dept Emergency Med, Milwaukee, WI 53226 USA; [Johannigman, Jay] Univ Cincinnati, Dept Surg, 231 Bethesda Ave, Cincinnati, OH 45267 USA; [Cotton, Bryan A.; Vincent, Laura E.] Univ Texas Hlth Sci Ctr Houston, Dept Surg, McGovern Med Sch, Houston, TX 77030 USA; [Callum, Jeannie] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [McMullan, Jason] Univ Cincinnati, Dept Emergency Med, Cincinnati, OH USA; [Dries, David J.] Reg Hosp, Dept Surg, St Paul, MN USA; [Tibbs, Brian] Texas Hlth Presbyterian Hosp, Trauma Surg, Dallas, TX USA; [Richmond, Neal J.] John Peter Smith Hlth Network, Dept Emergency Med, Ft Worth, TX USA; [Weisfeldt, Myron L.] Johns Hopkins Sch Med, Baltimore, MD USA; [Tallon, John M.; Schlamp, Rob] British Columbia Emergency Hlth Serv, Vancouver, BC, Canada; [Garrett, John S.; Ferrara, Michael] Baylor Univ, Med Ctr, Dept Emergency Med, Dallas, TX USA; [Zielinski, Martin D.] Mayo Clin, Dept Surg, Rochester, MN USA; [Gandhi, Rajesh R.] John Peter Smith Hlth Network, Dept Surg, Ft Worth, TX USA; [Jui, Jonathan] Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR 97201 USA; [Klein, Lauren; Hendrickson, Audrey] Hennepin Cty Med Ctr, Dept Emergency Med, Minneapolis, MN 55415 USA; [Rizoli, Sandro] St Michaels Hosp, Dept Surg, Toronto, ON, Canada; [Gamber, Mark] Med City Plano, Dept Emergency Med, Plano, TX USA; [Simonson, Robert] Methodist Dallas Med Ctr, Emergency Med, Dallas, TX USA; [Sopko, George] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA; [Witham, William] Texas Hlth Harris Methodist Hosp, Trauma Surg, Ft Worth, TX USA	Rowell, SE (corresponding author), Duke Univ, Sch Med, Dept Surg, Div Trauma & Crit Care Surg, 2301 Erwin Rd, Durham, NC 27707 USA.	susan.rowell@duke.edu	McMullan, Jason/ABB-9691-2020; morrison, laurie J/A-6325-2012	McMullan, Jason/0000-0002-7656-7447; morrison, laurie J/0000-0001-8369-9774	National Heart, Lung and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [W81XWH-13-2-0090, U01 HL077863, U01 HL077866, U01 HL077871, U01 HL077873, U01 HL077881, U01 HL077887]	The Resuscitation Outcomes Consortium institutions participating in the trial were supported by a series of cooperative agreements from the National Heart, Lung and Blood Institute administered by the US Army Medical Research & Material Command (W81XWH-13-2-0090), including U01 HL077863 (University of Washington Data Coordinating Center), U01 HL077866 (Medical College of Wisconsin), U01 HL077871 (University of Pittsburgh), U01 HL077873 (Oregon Health and Science University), U01 HL077881 (University of Alabama at Birmingham), and U01 HL077887 (University of Texas Southwestern Medical Center/Dallas).	Alderson P, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000196.pub2; Boudreau RM, 2019, J SURG RES, V233, P132, DOI 10.1016/j.jss.2018.07.074; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; Feigin VL, 2019, LANCET NEUROL, V18, P459, DOI 10.1016/S1474-4422(18)30499-X; Gausden EB, 2017, J ORTHOP TRAUMA, V31, P513, DOI 10.1097/BOT.0000000000000913; Keyl C, 2011, EUR J CARDIO-THORAC, V39, pE114, DOI 10.1016/j.ejcts.2010.12.030; Kobayashi T, 1966, J Jpn Obstet Gynecol Soc, V13, P158; Lewis SR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001048.pub5; Lin Z, 2016, SEIZURE-EUR J EPILEP, V36, P70, DOI 10.1016/j.seizure.2016.02.011; Ma JP, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008409.pub4; Murkin JM, 2010, ANESTH ANALG, V110, P350, DOI 10.1213/ANE.0b013e3181c92b23; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Pacheco LD, 2017, OBSTET GYNECOL, V130, P765, DOI 10.1097/AOG.0000000000002253; Peterson A.B., 2019, SURVEILLANCE REPORT; Roberts I, 2019, LANCET, V394, P1713, DOI 10.1016/S0140-6736(19)32233-0; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Shukla D, 2011, CLIN NEUROL NEUROSUR, V113, P435, DOI 10.1016/j.clineuro.2011.02.013; van Buuren S, 2007, STAT METHODS MED RES, V16, P219, DOI 10.1177/0962280206074463; Weng ST, 2019, WORLD NEUROSURG, V123, P128, DOI 10.1016/j.wneu.2018.11.214; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; 2011, BMJ-BRIT MED J, V343, DOI DOI 10.1136/BMJ.D3795	21	24	24	3	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	2020	324	10					961	974		10.1001/jama.2020.8958			14	Medicine, General & Internal	General & Internal Medicine	NR9EX	WOS:000571867000019	32897344	Green Published			2021-06-18	
J	Wang, JL; Chu, RL; Ni, N; Nan, GX				Wang, Jiuling; Chu, Ruiliang; Ni, Na; Nan, Guoxin			The effect of Matrigel as scaffold material for neural stem cell transplantation for treating spinal cord injury	SCIENTIFIC REPORTS			English	Article							BASEMENT-MEMBRANE MATRIX; FUNCTIONAL RECOVERY; AXONAL REGENERATION; GROWTH-FACTOR; SURVIVAL; THERAPY	Traumatic injury to the spinal cord causes permanent loss of function and major personal, social, and economic problems. Cell-based delivery strategies is a promising approach for treating spinal cord injury (SCI). However, the inhospitable microenvironment in the injured spinal cord results in poor cell survival and uncontrolled differentiation of the transplanted stem cells. The combination of a scaffold with cells has been developed with a tendency for achieving greater survival and integration with the host tissue. We investigated the effect of Matrigel combined with neural stem cells (NSCs) in vitro and in vivo. We compared the effect of different types of scaffold on the survival and differentiation of brain-derived NSCs in an in vitro culture. Subsequently, NSCs were transplanted subcutaneously into nude mice to detect graft survival and differentiation in vivo. Finally, phosphate-buffered saline (PBS), Matrigel alone, or Matrigel seeded with NSCs was injected into 48 subacute, clinically relevant rat models of SCI (16 rats per group). Matrigel supported cell survival and differentiation efficiently in vitro and in vivo. SCI rats transplanted with NSCs in Matrigel showed improved behavioral recovery and neuronal and reactive astrocyte marker expression levels compared to PBS- or Matrigel-transplanted rats. Functional repair and neuronal and reactive astrocyte marker expression was slightly improved in the Matrigel-alone group relative to the PBS group, but not statistically significantly. These data suggest that Matrigel is a promising scaffold material for cell transplantation to the injured spinal cord.	[Wang, Jiuling; Chu, Ruiliang; Ni, Na; Nan, Guoxin] Chongqing Med Univ, Childrens Hosp, Dept Pediat Res Inst, Minist Educ,Key Lab Child Dev & Disorders, Chongqing 400014, Peoples R China; [Wang, Jiuling; Chu, Ruiliang; Ni, Na; Nan, Guoxin] China Int Sci & Technol Cooperat Base Child Dev &, Chongqing, Peoples R China; [Wang, Jiuling; Chu, Ruiliang; Ni, Na; Nan, Guoxin] Chongqing Engn Res Ctr Stem Cell Therapy, Chongqing, Peoples R China; [Wang, Jiuling; Chu, Ruiliang; Ni, Na; Nan, Guoxin] ChongqingMed Univ, Childrens Hosp, Dept Orthopaed, Chongqing, Peoples R China	Nan, GX (corresponding author), Chongqing Med Univ, Childrens Hosp, Dept Pediat Res Inst, Minist Educ,Key Lab Child Dev & Disorders, Chongqing 400014, Peoples R China.; Nan, GX (corresponding author), China Int Sci & Technol Cooperat Base Child Dev &, Chongqing, Peoples R China.; Nan, GX (corresponding author), Chongqing Engn Res Ctr Stem Cell Therapy, Chongqing, Peoples R China.; Nan, GX (corresponding author), ChongqingMed Univ, Childrens Hosp, Dept Orthopaed, Chongqing, Peoples R China.	ngx1215@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81272172]; National Key Specialty Construction of Clinical Project [2013-544]	This work was supported in part by research grants from the National Natural Science Foundation of China (#81272172 to NAN) and National Key Specialty Construction of Clinical Project (#2013-544).	BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; Bliss TM, 2010, NEUROBIOL DIS, V37, P275, DOI 10.1016/j.nbd.2009.10.003; Deree J, 2007, J SURG RES, V143, P99, DOI 10.1016/j.jss.2007.03.083; Engbring JA, 2003, J PATHOL, V200, P465, DOI 10.1002/path.1396; English D, 2013, J CELL BIOCHEM, V114, P764, DOI 10.1002/jcb.24436; Fujimoto Y, 2012, STEM CELLS, V30, P1163, DOI 10.1002/stem.1083; Garcia-Altes A, 2012, NEUROEPIDEMIOLOGY, V39, P103, DOI 10.1159/000338297; Guo XD, 2012, CELL TRANSPLANT, V21, P1177, DOI 10.3727/096368911X612503; Hall PE, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-71; He B, 2016, SPINE J, V16, P1459, DOI 10.1016/j.spinee.2016.06.020; Iwai H, 2014, CELL TRANSPLANT, V23, P1451, DOI 10.3727/096368913X670967; Jin KL, 2010, J CEREBR BLOOD F MET, V30, P534, DOI 10.1038/jcbfm.2009.219; Jones LL, 2001, MICROSC RES TECHNIQ, V54, P317, DOI 10.1002/jemt.1144; Jurga M, 2011, BIOMATERIALS, V32, P3423, DOI 10.1016/j.biomaterials.2011.01.049; Kaneko A, 2015, BIOMED MATER, V10, DOI 10.1088/1748-6041/10/1/015008; Kim HK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016694; Kleinman HK, 2005, SEMIN CANCER BIOL, V15, P378, DOI 10.1016/j.semcancer.2005.05.004; Meijs MFL, 2004, J NEUROTRAUM, V21, P1415, DOI 10.1089/neu.2004.21.1415; Miller FD, 2009, CELL STEM CELL, V4, P507, DOI 10.1016/j.stem.2009.05.008; Mothe AJ, 2013, BIOMATERIALS, V34, P3775, DOI 10.1016/j.biomaterials.2013.02.002; Mothe AJ, 2012, J CLIN INVEST, V122, P3824, DOI 10.1172/JCI64124; Nomura H, 2006, J NEUROTRAUM, V23, P496, DOI 10.1089/neu.2006.23.496; Novikova LN, 2008, BIOMATERIALS, V29, P1198, DOI 10.1016/j.biomaterials.2007.11.033; Novikova LN, 2003, CURR OPIN NEUROL, V16, P711, DOI 10.1097/00019052-200312000-00011; Ogawa Y, 2002, J NEUROSCI RES, V69, P925, DOI 10.1002/jnr.10341; Okano H, 2003, SEMIN CELL DEV BIOL, V14, P191, DOI 10.1016/S1084-9521(03)00011-9; Ourednik V, 2001, SCIENCE, V293, P1820, DOI 10.1126/science.1060580; Park SS, 2012, CYTOTHERAPY, V14, P584, DOI 10.3109/14653249.2012.658913; Parr AM, 2008, NEUROSCIENCE, V155, P760, DOI 10.1016/j.neuroscience.2008.05.042; Parr AM, 2007, NEUROSURGERY, V60, P926, DOI 10.1227/01.NEU.0000255441.59612.98; Raspa A, 2016, NANOSCALE, V8, P253, DOI 10.1039/c5nr03698d; Sypecka J, 2009, ACTA NEUROBIOL EXP, V69, P37; Teng YD, 2002, P NATL ACAD SCI USA, V99, P3024, DOI 10.1073/pnas.052678899; Tsintou M, 2015, NEURAL REGEN RES, V10, P726, DOI 10.4103/1673-5374.156966; Tysseling-Mattiace VM, 2008, J NEUROSCI, V28, P3814, DOI 10.1523/JNEUROSCI.0143-08.2008; Uemura M, 2010, J NEUROSCI RES, V88, P542, DOI 10.1002/jnr.22223; Wang D, 2013, NEURAL REGEN RES, V8, P677, DOI 10.3969/j.issn.1673-5374.2013.08.001; Willerth SM, 2007, ADV DRUG DELIVER REV, V59, P325, DOI 10.1016/j.addr.2007.03.014; XU XM, 1995, J COMP NEUROL, V351, P145, DOI 10.1002/cne.903510113	40	24	24	7	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	FEB 13	2020	10	1							2576	10.1038/s41598-020-59148-3			11	Multidisciplinary Sciences	Science & Technology - Other Topics	NE8XO	WOS:000562888700010	32054865	DOAJ Gold, Green Published			2021-06-18	
J	Alosco, ML; Stein, TD; Tripodis, Y; Chua, AS; Kowall, NW; Huber, BR; Goldstein, LE; Cantu, RC; Katz, DI; Palmisano, JN; Martin, B; Cherry, JD; Mahar, I; Killiany, RJ; McClean, MD; Au, R; Alvarez, V; Stern, RA; Mez, J; McKee, AC				Alosco, Michael L.; Stein, Thor D.; Tripodis, Yorghos; Chua, Alicia S.; Kowall, Neil W.; Huber, Bertrand Russell; Goldstein, Lee E.; Cantu, Robert C.; Katz, Douglas I.; Palmisano, Joseph N.; Martin, Brett; Cherry, Jonathan D.; Mahar, Ian; Killiany, Ronald J.; McClean, Michael D.; Au, Rhoda; Alvarez, Victor; Stern, Robert A.; Mez, Jesse; McKee, Ann C.			Association of White Matter Rarefaction, Arteriolosclerosis, and Tau With Dementia in Chronic Traumatic Encephalopathy	JAMA NEUROLOGY			English	Article							21ST-CENTURY BRAIN BANKING; FOOTBALL LEAGUE PLAYERS; BODY-MASS INDEX; ALZHEIMERS-DISEASE; CEREBROVASCULAR-DISEASE; MIXED NEUROPATHOLOGIES; COGNITIVE DYSFUNCTION; CLINICAL EXPRESSION; BARRIER DYSFUNCTION; SINGLE SEASON	IMPORTANCE Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease associated with repetitive head impacts, including those from US football, that presents with cognitive and neuropsychiatric disturbances that can progress to dementia. Pathways to dementia in CTE are unclear and likely involve tau and nontau pathologic conditions. OBJECTIVE To investigate the association of white matter rarefaction and cerebrovascular disease with dementia in deceased men older than 40 years who played football and had CTE. DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study involves analyses of data from the ongoing Understanding Neurologic Injury and Traumatic Encephalopathy (UNITE) Study, which is conducted via and included brain donors from the Veterans Affairs-Boston University-Concussion Legacy Foundation brain bank between 2008 and 2017. An original sample of 224 men who had played football and were neuropathologically diagnosed with CTE was reduced after exclusion of those younger than 40 years and those missing data. EXPOSURES The number of years of football play as a proxy for repetitive head impacts. MAIN OUTCOMES AND MEASURES Neuropathological assessment of white matter rarefaction and arteriolosclerosis severity (on a scale of 0-3, where 3 is severe); number of infarcts, microinfarcts, and microbleeds; and phosphorylated tau accumulation determined by CTE stage and semiquantitative rating of dorsolateral frontal cortex (DLFC) neurofibrillary tangles (NFTs) (none or mild vs moderate or severe). Informant-based retrospective clinical interviews determined dementia diagnoses via diagnostic consensus conferences. RESULTS A total of 180 men were included. The mean (SD) age of the sample at death was 67.9 (12.7) years. Of 180, 120 [66.7%]) were found to have had dementia prior to death. Moderate to severe white matter rarefaction (84 of 180 [46.6%]) and arteriolosclerosis (85 of 180 [47.2%]) were common; infarcts, microinfarcts, and microbleeds were not. A simultaneous equations regression model controlling for age and race showed that more years of play was associated with more severe white matter rarefaction (beta, 0.16 [95% CI, 0.02-0.29]; P=.03) and greater phosphorylated tau accumulation (DLFC NFTs: beta, 0.15 [95% CI, 0.004-0.30]; P=.04; CTE stage: beta, 0.27 [95% CI, 0.14-0.41]; P<.001). White matter rarefaction (beta, 0.16 [95% CI, 0.02-0.29]; P=.03) and DLFC NFTs (beta, 0.16 [95% CI, 0.03-0.28]; P=.01) were associated with dementia. Arteriolosclerosis and years of play were not associated, but arteriolosclerosis was independently associated with dementia (beta, 0.21 [95% CI, 0.07-0.35]; P=.003). CONCLUSIONS AND RELEVANCE Among older men who had played football and had CTE, more years of football play were associated with more severe white matter rarefaction and greater DLFC NFT burden. White matter rarefaction, arteriolosclerosis, and DLFC NFTs were independently associated with dementia. Dementia in CTE is likely a result of neuropathologic changes, including white matter rarefaction and phosphorylated tau, associated with repetitive head impact and pathologic changes not associated with head trauma, such as arteriolosclerosis.	[Alosco, Michael L.; Stein, Thor D.; Tripodis, Yorghos; Kowall, Neil W.; Huber, Bertrand Russell; Goldstein, Lee E.; Cantu, Robert C.; Katz, Douglas I.; Palmisano, Joseph N.; Martin, Brett; Cherry, Jonathan D.; Mahar, Ian; Killiany, Ronald J.; Au, Rhoda; Alvarez, Victor; Stern, Robert A.; Mez, Jesse; McKee, Ann C.] Boston Univ, Alzheimers Dis Ctr, 72 E Concord St,B7800, Boston, MA 02118 USA; [Alosco, Michael L.; Stein, Thor D.; Tripodis, Yorghos; Kowall, Neil W.; Huber, Bertrand Russell; Goldstein, Lee E.; Cantu, Robert C.; Katz, Douglas I.; Palmisano, Joseph N.; Martin, Brett; Cherry, Jonathan D.; Mahar, Ian; Killiany, Ronald J.; Au, Rhoda; Alvarez, Victor; Stern, Robert A.; Mez, Jesse; McKee, Ann C.] Boston Univ, CTE Ctr, Dept Neurol, Sch Med, 72 E Concord St,B7800, Boston, MA 02118 USA; [Stein, Thor D.; Kowall, Neil W.; Goldstein, Lee E.; Cherry, Jonathan D.; McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; [Stein, Thor D.; Kowall, Neil W.; Huber, Bertrand Russell; Cherry, Jonathan D.; Alvarez, Victor; McKee, Ann C.] VA Boston Healthcare Syst, Boston, MA USA; [Stein, Thor D.; McKee, Ann C.] Bedford Vet Affairs Med Ctr, Bedford, MA USA; [Tripodis, Yorghos; Chua, Alicia S.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Huber, Bertrand Russell] VA Boston Healthcare, Natl Ctr Posttraumat Stress Disorder, Boston, MA USA; [Goldstein, Lee E.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Goldstein, Lee E.] Boston Univ, Dept Elect & Comp Engn, Coll Engn, Boston, MA 02215 USA; [Goldstein, Lee E.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA; [Goldstein, Lee E.] Boston Univ, Dept Biomed Engn, Coll Engn, Boston, MA 02215 USA; [Cantu, Robert C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Cantu, Robert C.] Concuss Legacy Fdn, Boston, MA USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Katz, Douglas I.] Braintree Rehabil Hosp, Braintree, MA USA; [Palmisano, Joseph N.; Martin, Brett] Boston Univ, Sch Publ Hlth, Biostat & Epidemiol Data Analyt Ctr, Boston, MA USA; [Killiany, Ronald J.; Au, Rhoda; Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Killiany, Ronald J.] Boston Univ, Sch Med, Ctr Biomed Imaging, Boston, MA 02118 USA; [McClean, Michael D.] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Au, Rhoda] NHLBI, Framingham Heart Study, Boston, MA USA; [Au, Rhoda] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA	McKee, AC (corresponding author), Boston Univ, Alzheimers Dis Ctr, 72 E Concord St,B7800, Boston, MA 02118 USA.; McKee, AC (corresponding author), Boston Univ, CTE Ctr, Dept Neurol, Sch Med, 72 E Concord St,B7800, Boston, MA 02118 USA.	amckee@bu.edu	, Bob/ABA-8507-2020		National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG057902, RF1AG054156, R56AG057768, K23AG046377]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS102399]; Department of Veterans Affairs Merit AwardUS Department of Veterans Affairs [I01-CX001038]; Nick and Lynn Buoniconti Foundation; National Center for Advancing Translational Sciences (BU-CTSI) [1UL1TR001430]; Fonds de Recherche du Quebec-SanteFonds de la Recherche en Sante du Quebec; Alzheimer's AssociationAlzheimer's Association [AARF-17-529888]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS102399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG062348, RF1AG054156, RF1AG057902] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX001038] Funding Source: NIH RePORTER	This work was supported by grant funding from the National Institute on Aging (grants AG057902, RF1AG054156, R56AG057768, K23AG046377), National Institute of Neurological Disorders and Stroke (grant K23NS102399), a Department of Veterans Affairs Merit Award (grant I01-CX001038), the Nick and Lynn Buoniconti Foundation, and the National Center for Advancing Translational Sciences (BU-CTSI grant 1UL1TR001430). Dr Mahar is funded by the Fonds de Recherche du Quebec-Sante. Dr Cherry is funded by the Alzheimer's Association (grant AARF-17-529888).	ALOSCO M, 2017, ALZHEIMERS DEMENT, V10, P56, DOI DOI 10.1016/J.DADM.2017.10.003; Alosco ML, 2018, ANN NEUROL, V83, P886, DOI 10.1002/ana.25245; Alosco ML, 2017, J ALZHEIMERS DIS, V57, P953, DOI 10.3233/JAD-161205; Alosco ML, 2017, J NEUROPSYCH CLIN N, V29, P6, DOI 10.1176/appi.neuropsych.16030043; Amen DG, 2016, J ALZHEIMERS DIS, V53, P237, DOI 10.3233/JAD-160207; Arvanitakis Z, 2016, LANCET NEUROL, V15, P934, DOI 10.1016/S1474-4422(16)30029-1; Bahrami N, 2016, RADIOLOGY, V281, P919, DOI 10.1148/radiol.2016160564; Bailey DM, 2013, CLIN SCI, V124, P177, DOI 10.1042/CS20120259; Baron SL, 2012, AM J CARDIOL, V109, P889, DOI 10.1016/j.amjcard.2011.10.050; Beekly DL, 2004, ALZ DIS ASSOC DIS, V18, P270; Bennett DA, 2013, J ALZHEIMERS DIS, V33, pS397, DOI 10.3233/JAD-2012-129007; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Bos D, 2018, ALZHEIMERS DEMENT, V14, P1482, DOI 10.1016/j.jalz.2018.04.007; Bouhrara M, 2018, ALZHEIMERS DEMENT, V14, P998, DOI 10.1016/j.jalz.2018.03.007; Boyle PA, 2018, ANN NEUROL, V83, P74, DOI 10.1002/ana.25123; Brenowitz WD, 2017, NEUROLOGY, V89, P1773, DOI 10.1212/WNL.0000000000004567; Brenowitz WD, 2017, ALZHEIMERS DEMENT, V13, P654, DOI 10.1016/j.jalz.2016.09.015; BUEE L, 1994, ACTA NEUROPATHOL, V87, P469; Cherry JD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185541; Cherry JD, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0382-8; Chui HC, 2006, ANN NEUROL, V60, P677, DOI 10.1002/ana.21009; Clark MD, 2018, RADIOLOGY, V286, P975, DOI 10.1148/radiol.2017170539; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Coughlin JM, 2017, JAMA NEUROL, V74, P67, DOI 10.1001/jamaneurol.2016.3764; Deramecourt V, 2012, NEUROLOGY, V78, P1043, DOI 10.1212/WNL.0b013e31824e8e7f; Doherty CP, 2016, J NEUROPATH EXP NEUR, V75, P656, DOI 10.1093/jnen/nlw036; Filley CM, 2018, J ALZHEIMERS DIS, V65, P345, DOI 10.3233/JAD-180287; Gangolli M, 2019, J NEUROTRAUM, V36, P735, DOI 10.1089/neu.2018.5700; Gardner Raquel C, 2015, Neurol Clin Pract, V5, P285; Haneuse S, 2009, NEUROEPIDEMIOLOGY, V32, P229, DOI 10.1159/000197389; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Holleran L, 2017, ACTA NEUROPATHOL, V133, P367, DOI 10.1007/s00401-017-1686-x; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; James BD, 2016, BRAIN, V139, P2983, DOI 10.1093/brain/aww224; Kalaria RN, 1999, ALZ DIS ASSOC DIS, V13, pS115, DOI 10.1097/00002093-199912003-00017; Kapasi A, 2017, ACTA NEUROPATHOL, V134, P171, DOI 10.1007/s00401-017-1717-7; Kim Julia, 2017, J Alzheimers Dis, V55, P381; Kuzminski SJ, 2018, AM J NEURORADIOL, V39, P245, DOI 10.3174/ajnr.A5489; Lee S, 2016, ANN NEUROL, V79, P929, DOI 10.1002/ana.24647; Ling HL, 2017, ACTA NEUROPATHOL, V133, P337, DOI 10.1007/s00401-017-1680-3; Mahar I, 2017, NEUROSCI BIOBEHAV R, V83, P622, DOI 10.1016/j.neubiorev.2017.08.023; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Mayinger MC, 2018, BRAIN IMAGING BEHAV, V12, P44, DOI 10.1007/s11682-017-9672-4; McAleese KE, 2017, ACTA NEUROPATHOL, V134, P459, DOI 10.1007/s00401-017-1738-2; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Mez J, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0148-8; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Nelson AR, 2016, BBA-MOL BASIS DIS, V1862, P887, DOI 10.1016/j.bbadis.2015.12.016; Nelson PT, 2007, J NEUROPATH EXP NEUR, V66, P1136, DOI 10.1097/nen.0b013e31815c5efb; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Tagge CA, 2018, BRAIN, V141, P422, DOI 10.1093/brain/awx350; Toledo JB, 2013, BRAIN, V136, P2697, DOI 10.1093/brain/awt188; Tucker AM, 2009, JAMA-J AM MED ASSOC, V301, P2111, DOI 10.1001/jama.2009.716; Vonsattel JPG, 2008, CELL TISSUE BANK, V9, P247, DOI 10.1007/s10561-008-9079-y; Vonsattel JPG, 2008, ACTA NEUROPATHOL, V115, P509, DOI 10.1007/s00401-007-0311-9; Weissberg I, 2014, JAMA NEUROL, V71, P1453, DOI 10.1001/jamaneurol.2014.2682; Zlokovic BV, 2011, NAT REV NEUROSCI, V12, P723, DOI 10.1038/nrn3114	63	24	24	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	NOV	2019	76	11					1298	1308		10.1001/jamaneurol.2019.2244			11	Clinical Neurology	Neurosciences & Neurology	JW7ER	WOS:000503211500006	31380975	Green Published			2021-06-18	
J	Kochanek, PM; Tasker, RC; Carney, N; Totten, AM; Adelson, PD; Selden, NR; Davis-O'Reilly, C; Hart, EL; Bell, MJ; Bratton, SL; Grant, GA; Kissoon, N; Reuter-Rice, KE; Vavilala, MS; Wainwright, MS				Kochanek, Patrick M.; Tasker, Robert C.; Carney, Nancy; Totten, Annette M.; Adelson, P. David; Selden, Nathan R.; Davis-O'Reilly, Cynthia; Hart, Erica L.; Bell, Michael J.; Bratton, Susan L.; Grant, Gerald A.; Kissoon, Niranjan; Reuter-Rice, Karin E.; Vavilala, Monica S.; Wainwright, Mark S.			Guidelines for the Management of Pediatric Severe Traumatic Brain Injury, Third Edition: Update of the Brain Trauma Foundation Guidelines, Executive Summary	NEUROSURGERY			English	Article						Critical care; Evidence-based medicine; Head injury; Guidelines; Pediatrics; Systematic review; Traumatic brain injury	EARLY DECOMPRESSIVE CRANIECTOMY; COMMON DATA ELEMENTS; REFRACTORY INTRACRANIAL HYPERTENSION; CEREBRAL PERFUSION-PRESSURE; THERAPEUTIC HYPOTHERMIA; HYPERTONIC SALINE; HEAD-INJURY; CENTER EXPERIENCE; SINGLE-CENTER; CHILDREN	The purpose of this work is to identify and synthesize research produced since the second edition of these Guidelines was published and incorporate new results into revised evidence-based recommendations for the treatment of severe traumatic brain injury in pediatric patients. This document provides an overview of our process, lists the new research added, and includes the revised recommendations. Recommendations are only provided when there is supporting evidence. This update includes 22 recommendations, 9 are new or revised from previous editions. New recommendations on neuroimaging, hyperosmolar therapy, analgesics and sedatives, seizure prophylaxis, temperature control/hypothermia, and nutrition are provided. None are level I, 3 are level II, and 19 are level III. The Clinical Investigators responsible for these Guidelines also created a companion algorithm that supplements the recommendations with expert consensus where evidence is not available and organizes possible interventions into first and second tier utilization. The complete guideline document and supplemental appendices are available electronically (https://doi.org/10.1097/PCC.0000000000001735). The online documents contain summaries and evaluations of all the studies considered, including those from prior editions, and more detailed information on our methodology. New level II and level III evidence-based recommendations and an algorithm provide additional guidance for the development of local protocols to treat pediatric patients with severe traumatic brain injury. Our intention is to identify and institute a sustainable process to update these Guidelines as new evidence becomes available.	[Kochanek, Patrick M.] Univ Pittsburgh, Dept Anesthesiol Pediat Bioengn & Clin & Translat, UPMC Childrens Hosp Pittsburgh, Dept Crit Care Med,Sch Med,Safar Ctr Resuscitat R, Pittsburgh, PA USA; [Tasker, Robert C.] Boston Childrens Hosp, Dept Anesthesiol Crit Care & Pain Med, Dept Neurol, Boston, MA USA; [Tasker, Robert C.] Harvard Med Sch, Boston, MA 02115 USA; [Carney, Nancy; Totten, Annette M.; Davis-O'Reilly, Cynthia; Hart, Erica L.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Pacific Northwest Evidence Based Practice Ctr, Portland, OR 97201 USA; [Adelson, P. David] Childrens Hosp, BARROW Neurol Inst Phoenix, Dept Pediat Neurosurg, Phoenix, AZ USA; [Selden, Nathan R.] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97201 USA; [Bell, Michael J.] Childrens Natl Med Ctr, Dept Crit Care Med, Washington, DC 20010 USA; [Bratton, Susan L.] Univ Utah, Dept Pediat, Salt Lake City, UT USA; [Grant, Gerald A.] Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA; [Kissoon, Niranjan] Univ British Columbia, Child & Family Res Inst, British Columbias Childrens Hosp, Dept Pediat, Vancouver, BC, Canada; [Reuter-Rice, Karin E.] Duke Univ, Sch Nursing, Div Pediat Crit Care Med, Dept Pediat,Sch Med, Durham, NC USA; [Vavilala, Monica S.] Univ Washington, Dept Pediat, Dept Anesthesiol & Pain Med, HIPRC, Seattle, WA 98195 USA; [Wainwright, Mark S.] Univ Washington, Seattle Childrens Hosp, Div Pediat Neurol, Seattle, WA 98195 USA	Kochanek, PM (corresponding author), UPMC Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res, John G Rangos Res Ctr, 6th Floor,4401 Penn Ave, Pittsburgh, PA 15224 USA.	kochanekpm@ccm.upmc.edu	Kissoon, Niranjan/AAC-6140-2021	Kissoon, Niranjan/0000-0001-8847-9973; Reuter-Rice, Karin/0000-0003-1501-8994	U.S. Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division [W911QY-14-C-0086]; Brain Trauma Foundation; Society of Critical Care Medicine; Stanford UniversityStanford University; Robert Wood Johnson FoundationRobert Wood Johnson Foundation (RWJF); Sage Therapeutics	Supported, in part, by the U.S. Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division, through a contract awarded to StanfordUniversity (W911QY-14-C-0086) and a subcontract awarded toOregon Health & Science University. Prior editions were supported, in part, by funding from multiple sources through the Brain Trauma Foundation. Dr Kochanek received funding from the Society of Critical Care Medicine (Editor-in-Chief of Pediatric Critical Care Medicine), from serving as an expert witness on cases in pediatric critical care. DrsCarney and Totten's, MsDavis-O'Reilly's, and MsHart's institutions received funding from Stanford University. Dr Selden disclosed that he has stock options (current $ 0 value) in Cerebrotech for scientific advisory board service (this device is not clinically available and is not referenced in the work). Dr Reuter-Rice received funding from textbook royalties and curriculum content, and she received support for article research from Robert Wood Johnson Foundation funding 2013-2016. Dr Wainwright received funding from Sage Therapeutics. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Adamo MA, 2009, J NEUROSURG-PEDIATR, V3, P334, DOI 10.3171/2008.12.PEDS08310; Adelson PD, 2013, LANCET NEUROL, V12, P546, DOI 10.1016/S1474-4422(13)70077-2; Adelson PD, 2012, J NEUROTRAUM, V29, P639, DOI 10.1089/neu.2011.1952; Alkhoury F, 2014, JAMA SURG, V149, P544, DOI 10.1001/jamasurg.2013.4329; Allen BB, 2014, PEDIATR CRIT CARE ME, V15, P62, DOI 10.1097/PCC.0b013e3182a556ea; Bailey BM, 2012, J TRAUMA ACUTE CARE, V72, P263, DOI 10.1097/TA.0b013e31822a9512; Bar-Joseph G, 2009, J NEUROSURG-PEDIATR, V4, P40, DOI 10.3171/2009.1.PEDS08319; Bata SC, 2014, ANZ J SURG, V84, P438, DOI 10.1111/ans.12582; Beca J, 2015, CRIT CARE MED, V43, P1458, DOI 10.1097/CCM.0000000000000947; Bell MJ, 2017, CHILD NERV SYST, V33, P1663, DOI 10.1007/s00381-017-3530-y; Bell MJ, 2013, PEDIATR CRIT CARE ME, V14, P811, DOI 10.1097/PCC.0b013e3182975e2f; Bennett TD, 2017, JAMA PEDIATR, V171, P965, DOI 10.1001/jamapediatrics.2017.2127; Bennett TD, 2012, ARCH PEDIAT ADOL MED, V166, P641, DOI 10.1001/archpediatrics.2012.322; Berger RP, 2012, J NEUROTRAUM, V29, P672, DOI 10.1089/neu.2011.1861; Bourdages M, 2010, PEDIATR CRIT CARE ME, V11, P408, DOI 10.1097/PCC.0b013e3181c51dea; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chin KH, 2015, PEDIATR CRIT CARE ME, V16, P352, DOI 10.1097/PCC.0000000000000344; Chung MG, 2016, PEDIATR CRIT CARE ME, V17, P150, DOI 10.1097/PCC.0000000000000588; Crompton E, 2017, CRIT CARE MED, V45, pE1091, DOI 10.1097/CCM.0000000000002565; Crompton EM, 2017, CRIT CARE MED, V45, P575, DOI 10.1097/CCM.0000000000002205; Csokay A, 2012, CHILD NERV SYST, V28, P441, DOI 10.1007/s00381-011-1661-0; de Andrade AF, 2011, ARQ NEURO-PSIQUIAT, V69, P79, DOI 10.1590/S0004-282X2011000100016; Desgranges FP, 2014, CHILD NERV SYST, V30, P1393, DOI 10.1007/s00381-014-2417-4; Duhaime AC, 2012, J NEUROTRAUM, V29, P629, DOI 10.1089/neu.2011.1927; Empey PE, 2013, CRIT CARE MED, V41, P2379, DOI 10.1097/CCM.0b013e318292316c; Ferguson NM, 2016, PEDIATR CRIT CARE ME, V17, P444, DOI 10.1097/PCC.0000000000000709; Figaji AA, 2006, SAMJ S AFR MED J, V96, P969; Figaji AA, 2010, NEUROCRIT CARE, V12, P430, DOI 10.1007/s12028-010-9344-3; Gonda DD, 2013, PEDIATR CRIT CARE ME, V14, P610, DOI 10.1097/PCC.0b013e318291772b; Hutchison JS, 2010, DEV NEUROSCI-BASEL, V32, P406, DOI 10.1159/000323260; Jha RM, 2017, LANCET NEUROL, V16, P578, DOI 10.1016/S1474-4422(17)30225-9; Josan VA, 2006, CHILD NERV SYST, V22, P1268, DOI 10.1007/s00381-006-0064-0; Khan SA, 2014, CHILD NERV SYST, V30, P277, DOI 10.1007/s00381-013-2225-2; Kochanek PM, 2019, PEDIATR CRIT CARE ME, V20, pS1, DOI 10.1097/PCC.0000000000001735; Kochanek PM, 2019, PEDIATR CRIT CARE ME, V20, P269, DOI 10.1097/PCC.0000000000001737; Kochanek PM, 2015, CRIT CARE MED, V43, P1544, DOI 10.1097/CCM.0000000000001041; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kurz JE, 2016, PEDIATR CRIT CARE ME, V17, P649, DOI 10.1097/PCC.0000000000000765; Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; Mehta A, 2010, DEV NEUROSCI-BASEL, V32, P413, DOI 10.1159/000316804; Mellion SA, 2013, PEDIATR CRIT CARE ME, V14, P239, DOI 10.1097/PCC.0b013e318271c3b2; Messing-Junger AM, 2003, ZBL NEUROCHIR, V64, P171; Mhanna MJ, 2015, J NEUROSURG-PEDIATR, V16, P508, DOI 10.3171/2014.10.PEDS14117; Oluigbo CO, 2012, J NEUROSURG-PEDIATR, V9, P125, DOI 10.3171/2011.11.PEDS09449; Pearl PL, 2013, EPILEPSIA, V54, pe135, DOI 10.1111/epi.12326; Pechmann A, 2015, NEUROPEDIATRICS, V46, P5, DOI 10.1055/s-0034-1393707; Suarez EP, 2011, J TRAUMA, V71, P133, DOI 10.1097/TA.0b013e318211071f; Piper BJ, 2015, ANAESTH INTENS CARE, V43, P204, DOI 10.1177/0310057X1504300210; Prasad GL, 2015, BRAIN INJURY, V29, P1717, DOI 10.3109/02699052.2015.1075146; Roumeliotis N, 2016, CHILD NERV SYST, V32, P2363, DOI 10.1007/s00381-016-3231-y; Rubiano AM, 2009, ULUS TRAVMA ACIL CER, V15, P28; Shein SL, 2016, PEDIATR CRIT CARE ME, V17, P236, DOI 10.1097/PCC.0000000000000610; Stippler M, 2012, J NEUROSURG-PEDIATR, V10, P383, DOI 10.3171/2012.8.PEDS12165; Su E, 2012, NEUROCRIT CARE, V17, P401, DOI 10.1007/s12028-012-9767-0; Taha AA, 2011, J NEUROSCI NURS, V43, P291, DOI 10.1097/JNN.0b013e318234e9b2; Tasker RC, 2017, CRIT CARE MED, V45, pE1091, DOI 10.1097/CCM.0000000000002526; Tasker RC, 2017, PEDIATR CRIT CARE ME, V18, P355, DOI 10.1097/PCC.0000000000001098; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Thomale UW, 2010, CHILD NERV SYST, V26, P1563, DOI 10.1007/s00381-010-1103-4; Vavilala MS, 2014, CRIT CARE MED, V42, P2258, DOI 10.1097/CCM.0000000000000507; Webster DL, 2015, J CRIT CARE, V30, P1267, DOI 10.1016/j.jcrc.2015.07.022; Welch TP, 2016, CRIT CARE MED, V44, P809, DOI 10.1097/CCM.0000000000001558	63	24	25	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUN	2019	84	6					1169	1178		10.1093/neuros/nyz051			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	IC8QQ	WOS:000471247000028	30822776	Bronze			2021-06-18	
J	Herzog, C; Garcia, LP; Keatinge, M; Greenald, D; Moritz, C; Peri, F; Herrgen, L				Herzog, Chiara; Garcia, Laura Pons; Keatinge, Marcus; Greenald, David; Moritz, Christian; Peri, Francesca; Herrgen, Leah			Rapid clearance of cellular debris by microglia limits secondary neuronal cell death after brain injury in vivo	DEVELOPMENT			English	Article						Brain injury; Secondary cell death; Microglia; Phagocytosis; In vivo imaging; Zebrafish	WILD-TYPE MICROGLIA; SRC FAMILY KINASE; APOPTOTIC CELLS; TRANSGENIC ZEBRAFISH; PHAGOCYTIC CLEARANCE; GENE-EXPRESSION; PHOSPHATIDYLSERINE; RECEPTOR; PROTEIN; REGENERATION	Moderate or severe traumatic brain injury (TBI) causes widespread neuronal cell death. Microglia, the resident macrophages of the brain, react to injury by migrating to the lesion site, where they phagocytose cellular debris. Microglial phagocytosis can have both beneficial (e.g. debris clearance) and detrimental (e.g. respiratory burst, phagoptosis) consequences. Hence, whether the overall effect of microglial phagocytosis after brain injury in vivo is neuroprotective or neurotoxic is not known. Here, we establish a system with which to carry out dynamic real-time analyses of the mechanisms regulating cell death after brain injury in vivo. We show that mechanical injury to the larval zebrafish brain induces distinct phases of primary and secondary cell death. Excitotoxicity contributes to secondary cell death in zebrafish, reflecting findings from mammals. Microglia arrive at the lesion site within minutes of injury, where they rapidly engulf dead cells. Importantly, the rate of secondary cell death is increased when the rapid removal of cellular debris by microglia is reduced pharmacologically or genetically. In summary, our results provide evidence that microglial debris clearance is neuroprotective after brain injury in vivo.	[Herzog, Chiara; Garcia, Laura Pons; Keatinge, Marcus; Greenald, David; Herrgen, Leah] Univ Edinburgh, Ctr Discovery Brain Sci, 49 Little France Crescent, Edinburgh EH16 4SB, Midlothian, Scotland; [Moritz, Christian] EMBL Heidelberg, Meyerhofstr 1, D-69117 Heidelberg, Germany; [Peri, Francesca] Univ Zurich, Inst Mol Life Sci, Winterthurerstr 190, CH-8057 Zurich, Switzerland	Herrgen, L (corresponding author), Univ Edinburgh, Ctr Discovery Brain Sci, 49 Little France Crescent, Edinburgh EH16 4SB, Midlothian, Scotland.	leah.herrgen@ed.ac.uk		Herzog, Chiara/0000-0002-1572-498X; Peri, Francesca/0000-0001-7068-4952	University of Edinburgh Chancellor's Fellowship; Wellcome Trust/The University of Edinburgh Institutional Strategic Support Fund; Carnegie Trust for the Universities of Scotland Research Incentive Grant [70457]; Rosetrees Trust/Stoneygate Trust Seedcorn Award [M602]; Wellcome Trust Seed Award in ScienceWellcome Trust [207701/Z/17/Z]	This work was supported by a University of Edinburgh Chancellor's Fellowship to L.H.; by a Wellcome Trust/The University of Edinburgh Institutional Strategic Support Fund to L.H.; by a Carnegie Trust for the Universities of Scotland Research Incentive Grant (70457 to L.H.); by a Rosetrees Trust/Stoneygate Trust Seedcorn Award (M602 to L.H.); and by a Wellcome Trust Seed Award in Science (207701/Z/17/Z to L.H.). Deposited in PMC for release after 6 months.	Abiega O, 2016, PLOS BIOL, V14, DOI [10.1371/journal.pbio.1002466, 10.1371/journal.pbio.1002554]; Almeida RG, 2011, DEVELOPMENT, V138, P4443, DOI 10.1242/dev.071001; Arundine M, 2003, CELL CALCIUM, V34, P325, DOI 10.1016/S0143-4160(03)00141-6; Avitan L, 2017, CURR BIOL, V27, P2407, DOI 10.1016/j.cub.2017.06.056; Bailey TJ, 2010, EXP EYE RES, V91, P601, DOI 10.1016/j.exer.2010.07.017; Becker T, 2001, J COMP NEUROL, V433, P131, DOI 10.1002/cne.1131; Brouckaert G, 2004, MOL BIOL CELL, V15, P1089, DOI 10.1091/mbc.E03-09-0668; Brown GC, 2014, NAT REV NEUROSCI, V15, P209, DOI 10.1038/nrn3710; Chakraborty S, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-016-0625-x; Chen TW, 2013, NATURE, V499, P295, DOI 10.1038/nature12354; Chia K, 2018, ELIFE, V7, DOI 10.7554/eLife.31918; Claude J, 2013, J NEUROSCI, V33, P18270, DOI 10.1523/JNEUROSCI.2211-13.2013; Czabotar PE, 2015, FEBS J, V282, P4268, DOI 10.1111/febs.13504; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Derecki NC, 2012, NATURE, V484, P105, DOI 10.1038/nature10907; Diaz-Aparicio I, 2016, NEURAL REGEN RES, V11, P1533, DOI 10.4103/1673-5374.193220; Don EK, 2017, ZEBRAFISH, V14, P69, DOI 10.1089/zeb.2016.1321; Dorsett CR, 2017, J NEUROTRAUM, V34, P263, DOI 10.1089/neu.2015.4373; Eilers PHC, 2004, BIOINFORMATICS, V20, P623, DOI 10.1093/bioinformatics/btg454; Ellett F, 2011, BLOOD, V117, pE49, DOI 10.1182/blood-2010-10-314120; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fink SL, 2005, INFECT IMMUN, V73, P1907, DOI 10.1128/IAI.73.4.1907-1916.2005; FOSTER AC, 1988, J NEUROSCI, V8, P4745; Fu RY, 2014, MOL NEUROBIOL, V49, P1422, DOI 10.1007/s12035-013-8620-6; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Harty BL, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1296-8; Hawryluk GWJ, 2016, NEUROSURG CLIN N AM, V27, P375, DOI 10.1016/j.nec.2016.05.002; Herrgen L, 2014, DEV CELL, V31, P599, DOI 10.1016/j.devcel.2014.10.012; Hirt UA, 2003, CELL DEATH DIFFER, V10, P1156, DOI 10.1038/sj.cdd.4401286; James G, 2002, EUR J PHARMACOL, V447, P247, DOI 10.1016/S0014-2999(02)01756-9; Jao LE, 2013, P NATL ACAD SCI USA, V110, P13904, DOI 10.1073/pnas.1308335110; Jin XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041892; Kawabori M, 2015, J NEUROSCI, V35, P3384, DOI 10.1523/JNEUROSCI.2620-14.2015; Knopf F, 2010, P NATL ACAD SCI USA, V107, P19933, DOI 10.1073/pnas.1007799107; Koulen P, 1999, P NATL ACAD SCI USA, V96, P9909, DOI 10.1073/pnas.96.17.9909; Kratz E, 2006, CELL DEATH DIFFER, V13, P1631, DOI 10.1038/sj.cdd.4402016; Kroehne V, 2011, DEVELOPMENT, V138, P4831, DOI 10.1242/dev.072587; Kuscha V, 2012, J COMP NEUROL, V520, P3604, DOI 10.1002/cne.23115; Kwan KM, 2007, DEV DYNAM, V236, P3088, DOI 10.1002/dvdy.21343; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loane David J, 2015, Handb Clin Neurol, V127, P343, DOI 10.1016/B978-0-444-52892-6.00022-2; Lu ZJ, 2011, NAT CELL BIOL, V13, P1076, DOI 10.1038/ncb2299; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Magnus T, 2002, J NEUROPATH EXP NEUR, V61, P760, DOI 10.1093/jnen/61.9.760; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mazaheri F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5046; McCutcheon V, 2016, ZEBRAFISH, V13, P161, DOI 10.1089/zeb.2015.1188; Meijer AH, 2011, CURR DRUG TARGETS, V12, P1000; Minakami R, 2006, INT J HEMATOL, V84, P193, DOI 10.1532/IJH97.06133; Morsch M, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00321; Negoescu A, 1996, J HISTOCHEM CYTOCHEM, V44, P959, DOI 10.1177/44.9.8773561; Neher JJ, 2011, J IMMUNOL, V186, P4973, DOI 10.4049/jimmunol.1003600; Neumann J, 2008, J NEUROSCI, V28, P5965, DOI 10.1523/JNEUROSCI.0060-08.2008; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Noda M, 2011, J BIOL CHEM, V286, P2308, DOI 10.1074/jbc.M110.169839; Ohnmacht J, 2016, DEVELOPMENT, V143, P1464, DOI 10.1242/dev.129155; Pardo-Martin C, 2010, NAT METHODS, V7, P634, DOI [10.1038/NMETH.1481, 10.1038/nmeth.1481]; Park D, 2007, NATURE, V450, P430, DOI 10.1038/nature06329; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Park HC, 2000, DEV BIOL, V227, P279, DOI 10.1006/dbio.2000.9898; Parnaik R, 2000, CURR BIOL, V10, P857, DOI 10.1016/S0960-9822(00)00598-4; Pauls S, 2001, DEV GENES EVOL, V211, P603, DOI 10.1007/s00427-001-0196-x; Peri F, 2008, CELL, V133, P916, DOI 10.1016/j.cell.2008.04.037; Renshaw SA, 2006, BLOOD, V108, P3976, DOI 10.1182/blood-2006-05-024075; RINK A, 1995, AM J PATHOL, V147, P1575; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Sasaki Y, 2003, GLIA, V44, P242, DOI 10.1002/glia.10293; Sieger D, 2012, DEV CELL, V22, P1138, DOI 10.1016/j.devcel.2012.04.012; Sierra A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00006; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Tauzin S, 2014, J CELL BIOL, V207, P589, DOI 10.1083/jcb.201408090; van Ham TJ, 2012, CURR BIOL, V22, P830, DOI 10.1016/j.cub.2012.03.027; van Ham TJ, 2010, FASEB J, V24, P4336, DOI 10.1096/fj.10-161018; Walton EM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138949; Wang JQ, 2015, NATURE, V521, pE1, DOI 10.1038/nature14444; Wang YH, 1997, NEUROREPORT, V8, P3323, DOI 10.1097/00001756-199710200-00026; Westerfield M, 2007, ZEBRAFISH BOOK GUIDE; Wilms H, 2003, FASEB J, V17, P500, DOI 10.1096/fj.02-0314fje; Witting A, 2000, J NEUROCHEM, V75, P1060, DOI 10.1046/j.1471-4159.2000.0751060.x; Wyllie AH, 1997, BRIT MED BULL, V53, P451; Yeo SY, 2007, DEV BIOL, V301, P555, DOI 10.1016/j.ydbio.2006.10.020; Yoo SK, 2012, J CELL BIOL, V199, P225, DOI 10.1083/jcb.201203154; Zhao JS, 2003, CHINESE MED J-PEKING, V116, P1923; 2002, GLIA, V39, P47, DOI DOI 10.1002/GLIA.10088	84	24	24	0	3	COMPANY BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND	0950-1991	1477-9129		DEVELOPMENT	Development	MAY	2019	146	9							dev174698	10.1242/dev.174698			14	Developmental Biology	Developmental Biology	HY2ZL	WOS:000467992500016	31076485	Green Published, Green Accepted, Bronze			2021-06-18	
J	Goetzl, EJ; Elahi, FM; Mustapic, M; Kapogiannis, D; Pryhoda, M; Gilmore, A; Gorgens, KA; Davidson, B; Granholm, AC; Ledreux, A				Goetzl, Edward J.; Elahi, Fanny M.; Mustapic, Maja; Kapogiannis, Dimitrios; Pryhoda, Moira; Gilmore, Anah; Gorgens, Kimberly A.; Davidson, Bradley; Granholm, Anne-Charlotte; Ledreux, Aurelie			Altered levels of plasma neuron-derived exosomes and their cargo proteins characterize acute and chronic mild traumatic brain injury	FASEB JOURNAL			English	Article						biomarkers; exosome immunoabsorption; proteinopathic neurodegeneration	BARRIER DISRUPTION; BIOMARKERS; EPIDEMIOLOGY; PATHOGENESIS; AQUAPORIN-4; ANNEXINS; HYPOXIA; BETA; TAU	Neuron-derived exosomes (NDEs) were enriched by anti-L1CAM antibody immunoabsorption from plasmas of subjects ages 18-26 yr within 1 wk after a sports-related mild traumatic brain injury (acute mTBI) (n = 18), 3 mo or longer after the last of 2-4 mTBIs (chronic mTBI) (n = 14) and with no recent history of TBI (controls) (n = 21). Plasma concentrations of NDEs, assessed by counts and levels of extracted exosome marker CD81, were significantly depressed by a mean of 45% in acute mTBI (P < 0.0001), but not chronic mTBI, compared with controls. Mean CD81-normalized NDE levels of a range of functional brain proteins were significantly abnormal relative to those of controls in acute but not chronic mTBI, including ras-related small GTPase 10, 73% decrease; annexin VII, 8.8-fold increase; ubiquitin C-terminal hydrolase L1, 2.5-fold increase; AII spectrin fragments, 1.9-fold increase; claudin-5, 2.7-fold increase; sodium-potassium-chloride cotransporter-1, 2.8-fold increase; aquaporin 4, 8.9-fold increase (3.6-fold increase in chronic mTBI); and synaptogyrin-3, 3.1-fold increase (1.3-fold increase in chronic mTBI) (all acute mTBI proteins P < 0.0001). In chronic mTBI, there were elevated CD81-normalized NDE levels of usually pathologic beta-amyloid peptide 1-42 (1.6-fold, P < 0.0001), P-T181-tau (2.2-fold, P < 0.0001), P-S396-tau (1.6-fold, P < 0.01), IL-6 (16-fold, P < 0.0001), and prion cellular protein (PRPc) (5.1-fold, P < 0.0001) with lesser or greater (IL-6, PRPc) increases in acute mTBI. Increases in NDE levels of most neurofunctional proteins in acute, but not chronic, mTBI, and elevations of most NDE neuropathological proteins in chronic and acute mTBI delineated phase-specificity. Longitudinal studies of more mTBI subjects may identify biomarkers predictive of and etiologically involved in mTBI-induced neurodegeneration.	[Goetzl, Edward J.] Univ Calif San Francisco, Memory & Aging Ctr, Dept Med, San Francisco, CA 94143 USA; [Elahi, Fanny M.] Univ Calif San Francisco, Memory & Aging Ctr, Dept Neurol, San Francisco, CA 94143 USA; [Mustapic, Maja; Kapogiannis, Dimitrios] NIA, Cellular & Mol Neurosci Sect, Lab Neurosci, Baltimore, MD 21224 USA; [Pryhoda, Moira; Davidson, Bradley] Univ Denver, Dept Mech Engn, Human Dynam Lab, Denver, CO USA; [Gilmore, Anah; Granholm, Anne-Charlotte; Ledreux, Aurelie] Univ Denver, Knoebel Inst Hlth Aging, Denver, CO USA; [Gorgens, Kimberly A.] Univ Denver, Grad Sch Profess Psychol, Denver, CO USA	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Geriatr Res Ctr, 1719 Broderick St, San Francisco, CA 94115 USA.	edward.goetzl@ucsf.edu	Ledreux, Aurelie/M-3967-2018; Kapogiannis, Dimitrios/AAW-4934-2020; Mustapic, Maja/AAV-3212-2020; Pryhoda, Moira/AAQ-1580-2021	Ledreux, Aurelie/0000-0001-6232-7672; Kapogiannis, Dimitrios/0000-0003-2181-3118; 	Knoebel Institute for Healthy Aging; Intramural Program of the U.S. National Institutes of Health, National Institute on Aging; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000975] Funding Source: NIH RePORTER	The authors are grateful to Judith H. Goetzl (Geriatric Research Center, San Francisco, CA, USA) for preparation of the graphic illustrations. This research described was supported by a pilot grant from the Knoebel Institute for Healthy Aging (to A.-C.G.), and by the Intramural Program of the U.S. National Institutes of Health, National Institute on Aging (to M.M. and D.K.). The authors declare no conflicts of interest.	Agoston DV, 2017, BRAIN INJURY, V31, P1195, DOI 10.1080/02699052.2017.1357836; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI [10.1089/neu.2008.0738, 10.1089/neu.2008-0738]; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Bucci C, 2014, MEMBRANES, V4, P642, DOI 10.3390/membranes4040642; Buki A, 2000, J NEUROSCI, V20, P2825; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; Dailey NS, 2018, FRONT BEHAV NEUROSCI, V12, DOI 10.3389/fnbeh.2018.00118; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Galetta K., 2015, CONCUSSION, V1; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hladky SB, 2014, FLUIDS BARRIERS CNS, V11, DOI 10.1186/2045-8118-11-26; Hogue M, 2014, CELL SIGNAL, V26, P1213, DOI 10.1016/j.cellsig.2014.02.012; Hue CD, 2016, J NEUROTRAUM, V33, P1202, DOI 10.1089/neu.2015.4067; Huh GY, 2001, NEUROSCI LETT, V316, P41, DOI 10.1016/S0304-3940(01)02371-0; JACKSON P, 1981, J NEUROL SCI, V49, P429, DOI 10.1016/0022-510X(81)90032-0; Kapogiannis D, 2015, FASEB J, V29, P589, DOI 10.1096/fj.14-262048; Kim HJ, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.97105; Kuriakose M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26813-7; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Larson M, 2012, J NEUROSCI, V32, P16857, DOI 10.1523/JNEUROSCI.1858-12.2012; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McInnes J, 2018, NEURON, V97, P823, DOI 10.1016/j.neuron.2018.01.022; Mettang M, 2018, FASEB J, V32, P1916, DOI 10.1096/fj.201700826R; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Mustapic M, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00278; Nagelhus EA, 2013, PHYSIOL REV, V93, P1543, DOI 10.1152/physrev.00011.2013; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Papa L, 2015, J NEUROTRAUM, V32, P661, DOI 10.1089/neu.2014.3655; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Prince C, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7080105; Quillinan Nidia, 2016, Anesthesiol Clin, V34, P453, DOI 10.1016/j.anclin.2016.04.011; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Roselli F, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00458; Roy D, 2017, J NEUROPSYCH CLIN N, V29, P334, DOI 10.1176/appi.neuropsych.16050088; Rubenstein R, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0435-7; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Shah R, 2018, NEW ENGL J MED, V379, P958, DOI 10.1056/NEJMra1704286; Simon DW, 2017, NAT REV NEUROL, V13, P572, DOI 10.1038/nrneurol.2017.116; Stern RA, 2016, JAMA NEUROL, V73, P1280, DOI 10.1001/jamaneurol.2016.3169; Stern RA, 2016, J ALZHEIMERS DIS, V51, P1099, DOI 10.3233/JAD-151028; Tongaonkar P, 2000, MOL CELL BIOL, V20, P4691, DOI 10.1128/MCB.20.13.4691-4698.2000; Unsain N, 2018, FRONT SYNAPTIC NEURO, V10, DOI 10.3389/fnsyn.2018.00010; Werhane Madeleine L, 2017, Concussion, V2, pCNC30, DOI 10.2217/cnc-2016-0022; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yan EB, 2014, J NEUROTRAUM, V31, P618, DOI 10.1089/neu.2013.3087	49	24	25	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2019	33	4					5082	5088		10.1096/fj.201802319R			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HR1JP	WOS:000462888500037	30605353	Green Published, Bronze			2021-06-18	
J	Li, D; Huang, S; Zhu, JL; Hu, TP; Han, ZL; Zhang, SS; Zhao, L; Chen, FL; Lei, P				Li, Dai; Huang, Shan; Zhu, Jialin; Hu, Tianpeng; Han, Zhaoli; Zhang, Shishuang; Zhao, Ling; Chen, Fanglian; Lei, Ping			Exosomes from MiR-21-5p-Increased Neurons Play a Role in Neuroprotection by Suppressing Rab11a-Mediated Neuronal Autophagy In Vitro After Traumatic Brain Injury	MEDICAL SCIENCE MONITOR			English	Article						Autophagy; Brain Injuries; Exosomes; MicroRNAs	EXTRACELLULAR VESICLES; INHIBITING AUTOPHAGY; MICRORNA EXPRESSION; SIGNALING PATHWAY; DOWN-REGULATION; BLOOD EXOSOMES; PROTEINS; DISEASE; INFLAMMATION; CONTRIBUTES	Background: Traumatic brain injury (TBI) produces a series of pathological processes. Recent studies have indicated that autophagy pathway is persistently activated after TBI, which may lead to deterioration of nerve injury. Our preliminary work found miR-21-5p was upregulated in both in vivo and in vitro TBI models. MicroRNAs (miRNAs) could be loaded into exosomes to perform cell-to-cell interactions. This research aimed to evaluate the therapeutic effect of neuron-derived exosomes enriched with miR-21-5p on the TBI in vitro and to further explore the possible mechanisms. Material/Methods: Brain extracts harvested from an rTBI mouse model were added to cultured HT-22 neurons to imitate the microenvironment of injured brain on in vitro cultured cells. Ultracentrifugation was performed to isolate exosomes. Transmission electron microscopy and Nano sight technology were used to examine exosomes. An in vitro model of TBI was established to study the effect of exosomal miR-21-5p on nerve injury and on neuronal autophagy regulation. Results: The expression of miR-21-5p was increased in exosomes derived from HT-22 neurons after treatment with rTBI mouse brain extracts. Autophagy was activated in HT-22 neurons after scratch injury. Exosomal miR-21-5p produced a protective effect by suppressing autophagy in a TBI model in vitro. MiR-21-5p could directly target the Rab11a 3'UTR region to reduce its translation and further suppressed Rab11a-mediated neuronal autophagy. Conclusions: The levels of miR-21-5p in neuronal exosomes increased from the acute to the chronic phase of TBI. Neuronal exosomes enriched with miR-21-5p can inhibit the activity of neuronal autophagy by targeting Rab11a, thus attenuating trauma-induced, autophagy-mediated nerve injury in vitro.	[Li, Dai; Huang, Shan; Hu, Tianpeng; Han, Zhaoli; Zhang, Shishuang; Zhao, Ling; Lei, Ping] Tianjin Med Univ Gen Hosp, Tianjin Geriatr Inst, Lab Neurotrauma & Neurodegenerat Disorders, Tianjin, Peoples R China; [Li, Dai; Huang, Shan; Hu, Tianpeng; Han, Zhaoli; Zhang, Shishuang; Zhao, Ling; Lei, Ping] Tianjin Med Univ Gen Hosp, Dept Geriatr, Tianjin, Peoples R China; [Zhu, Jialin] Tianjin Med Univ Canc Inst & Hosp, Dept Ultrasound Diag & Treatment, Tianjin, Peoples R China; [Chen, Fanglian] Tianjin Med Univ Gen Hosp, Key Lab Injuries Variat & Regenerat Nervous Syst, Tianjin Neurol Inst, Tianjin, Peoples R China; [Chen, Fanglian] Minist Educ, Key Lab Post Trauma Neurorepair & Regerat Cent Ne, Tianjin, Peoples R China	Lei, P (corresponding author), Tianjin Med Univ Gen Hosp, Tianjin Geriatr Inst, Lab Neurotrauma & Neurodegenerat Disorders, Tianjin, Peoples R China.; Lei, P (corresponding author), Tianjin Med Univ Gen Hosp, Dept Geriatr, Tianjin, Peoples R China.	luke88956@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81772060, 81471252]; Tianjin Science FoundationNatural Science Foundation of Tianjin [16JCYBJC27200, 16JCQNJC11000, 16JCYBJC26900, 18ZXDBSY00090]; Tianjin Medical University General Hospital Youth Cultivation Foundation [ZYYFY2016001]	This research was supported by grants from the National Natural Science Foundation of China (grant no. 81772060, 81471252), Tianjin Science Foundation (grant no. 16JCYBJC27200, 16JCQNJC11000, 16JCYBJC26900, 18ZXDBSY00090), Tianjin Medical University General Hospital Youth Cultivation Foundation (grant no. ZYYFY2016001)	Au AK, 2017, NEUROCRIT CARE, V26, P348, DOI 10.1007/s12028-016-0351-x; Ban BK, 2013, MOL CELL BIOL, V33, P3907, DOI 10.1128/MCB.00627-13; Bianco F, 2009, EMBO J, V28, P1043, DOI 10.1038/emboj.2009.45; Budnik V, 2016, NAT REV NEUROSCI, V17, P160, DOI 10.1038/nrn.2015.29; Coleman BM, 2015, SEMIN CELL DEV BIOL, V40, P89, DOI 10.1016/j.semcdb.2015.02.007; Fader CM, 2008, TRAFFIC, V9, P230, DOI 10.1111/j.1600-0854.2007.00677.x; Faure J, 2006, MOL CELL NEUROSCI, V31, P642, DOI 10.1016/j.mcn.2005.12.003; Fiandaca MS, 2015, ALZHEIMERS DEMENT, V11, P600, DOI 10.1016/j.jalz.2014.06.008; Fineberg SK, 2009, NEURON, V64, P303, DOI 10.1016/j.neuron.2009.10.020; Gamez-Valero A, 2019, NEUROBIOL AGING, V74, P15, DOI 10.1016/j.neurobiolaging.2018.10.006; Gao GY, 2012, J NEUROTRAUMA; Gao HB, 2017, BRAIN RES, V1657, P1, DOI 10.1016/j.brainres.2016.11.028; Gao Y, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00095; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Ge XT, 2016, BRAIN RES, V1650, P31, DOI 10.1016/j.brainres.2016.07.015; Ge XT, 2015, BRAIN RES, V1603, P150, DOI 10.1016/j.brainres.2015.01.009; Goetzl EJ, 2016, FASEB J, V30, P4141, DOI 10.1096/fj.201600816R; Greer JE, 2013, ACTA NEUROPATHOL, V126, P59, DOI 10.1007/s00401-013-1119-4; Han ZL, 2015, DNA CELL BIOL, V34, P703, DOI 10.1089/dna.2015.2800; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Huang S, 2018, FASEB J, V32, P512, DOI 10.1096/fj.201700673R; Jaunmuktane Z, 2015, NATURE, V525, P247, DOI 10.1038/nature15369; Ji W, 2018, NEUROCHEM RES, V43, P1863, DOI 10.1007/s11064-018-2602-z; Jiang JY, 2013, INJURY, V44, P1453, DOI 10.1016/j.injury.2012.08.045; Jiang M, 2018, CELL PHYSIOL BIOCHEM, V47, P864, DOI [10.1159/000490078, 10.1159/000490078and]; Johnson WD, 2017, LANCET NEUROL, V16, P949, DOI 10.1016/S1474-4422(17)30362-9; Kapogiannis D, 2015, FASEB J, V29, P589, DOI 10.1096/fj.14-262048; Klionsky DJ, 2004, NATURE, V431, P31, DOI 10.1038/431031a; Knaevelsrud H, 2013, J CELL BIOL, V202, P331, DOI 10.1083/jcb.201205129; Korkmaz G, 2012, AUTOPHAGY, V8, P165, DOI 10.4161/auto.8.2.18351; Kramer-Albers EM, 2007, PROTEOM CLIN APPL, V1, P1446, DOI 10.1002/prca.200700522; Lamb Christopher A, 2016, Small GTPases, V7, P265; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Levin H, 2013, LANCET NEUROL, V12, P15, DOI 10.1016/S1474-4422(12)70300-9; Levine B, 2008, CELL, V132, P162; Li SP, 2018, EXP THER MED, V16, P2038, DOI 10.3892/etm.2018.6370; Lin CJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.123; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Liu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103948; Longatti A, 2012, J CELL BIOL, V197, P659, DOI 10.1083/jcb.201111079; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Majdan M, 2016, LANCET PUBLIC HEALTH, V1, pE76, DOI 10.1016/S2468-2667(16)30017-2; Martinez B, 2017, NEURAL REGEN RES, V12, P1749, DOI 10.4103/1673-5374.219025; Meissner L, 2016, J NEUROTRAUM, V33, P713, DOI 10.1089/neu.2015.4077; Menghini R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.556; Ngolab J, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0445-5; Osier N, 2018, MOL NEUROBIOL, V55, P9280, DOI 10.1007/s12035-018-1054-4; Potolicchio A, 2005, J IMMUNOL, V175, P2237, DOI 10.4049/jimmunol.175.4.2237; Puri C, 2018, DEV CELL, V45, P114, DOI 10.1016/j.devcel.2018.03.008; Puri C, 2013, CELL, V154, P1285, DOI 10.1016/j.cell.2013.08.044; Rajendran L, 2014, J NEUROSCI, V34, P15482, DOI 10.1523/JNEUROSCI.3258-14.2014; Richards P, 2011, CELL DEATH DIFFER, V18, P191, DOI 10.1038/cdd.2010.127; Rivero-Rios P, 2015, BIOCHEM SOC T, V43, P390, DOI 10.1042/BST20140301; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Seca H, 2013, CURR DRUG TARGETS, V14, P1135, DOI 10.2174/13894501113149990185; Shi M, 2019, PROG NEUROBIOL, V175, P96, DOI 10.1016/j.pneurobio.2019.01.005; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Su CH, 2016, BRAIN RES, V1644, P98, DOI 10.1016/j.brainres.2016.05.011; Sun LQ, 2018, BEHAV BRAIN RES, V340, P126, DOI 10.1016/j.bbr.2016.09.020; Sun LQ, 2017, BIOCHEM BIOPH RES CO, V482, P1141, DOI 10.1016/j.bbrc.2016.12.001; Sun LQ, 2015, BEHAV BRAIN RES, V291, P315, DOI 10.1016/j.bbr.2015.05.049; Szatmari Z, 2014, MOL BIOL CELL, V25, P522, DOI 10.1091/mbc.E13-10-0574; Thompson AG, 2016, NAT REV NEUROL, V12, P346, DOI 10.1038/nrneurol.2016.68; Wang WJ, 2018, BIOMED PHARMACOTHER, V99, P725, DOI 10.1016/j.biopha.2018.01.154; Wu H, 2012, CELL SIGNAL, V24, P2179, DOI 10.1016/j.cellsig.2012.07.001; Xie W, 2018, NEUROCHEM RES, V43, P1641, DOI 10.1007/s11064-018-2580-1; Xin HQ, 2012, STEM CELLS, V30, P1556, DOI 10.1002/stem.1129; Yao XF, 2018, J MOL NEUROSCI, V65, P43, DOI 10.1007/s12031-018-1067-5; Yuan MC, 2018, CURR PHARM DESIGN, V24, P2855, DOI 10.2174/1381612824666180903113136; Yuyama K, 2015, FEBS LETT, V589, P84, DOI 10.1016/j.febslet.2014.11.027; Zhang HY, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00931; Zhang L, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00190; Zhou X, 2010, LAB INVEST, V90, P144, DOI 10.1038/labinvest.2009.126	73	24	28	1	8	INT SCIENTIFIC INFORMATION, INC	MELVILLE	150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA	1643-3750			MED SCI MONITOR	Med. Sci. Monitor	MAR 12	2019	25						1871	1885		10.12659/MSM.915727			15	Medicine, Research & Experimental	Research & Experimental Medicine	HO8JV	WOS:000461197400003	30860987	Green Published			2021-06-18	
J	An, KY; Charles, J; Ali, S; Enache, A; Dhuga, J; Erdodi, LA				An, Kelly Y.; Charles, Jordan; Ali, Sami; Enache, Anca; Dhuga, Jasmine; Erdodi, Laszlo A.			Reexamining performance validity cutoffs within the Complex Ideational Material and the Boston Naming Test-Short Form using an experimental malingering paradigm	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Boston Naming Test; Complex Ideational Material; embedded validity indicators; Erdodi Index; experimental malingering; performance validity	TRAUMATIC BRAIN-INJURY; VERBAL-LEARNING TEST; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; RECOGNITION MEMORY TEST; RELIABLE DIGIT SPAN; CARD SORTING TEST; SYMPTOM VALIDITY; RESPONSE BIAS; NEUROCOGNITIVE DYSFUNCTION; INVALID PERFORMANCE	Objective: This study was designed to cross-validate previously published performance validity cutoffs embedded within the Complex Ideational Material (CIM) and the Boston Naming Test-Short Form (BNT-15).Method: Seventy healthy undergraduate students were randomly assigned to either a control condition (n=40) and instructed to perform to the best of their ability or an experimental malingering (n=30) condition and instructed to feign cognitive impairment while avoiding detection. All participants were administered the same battery of neuropsychological tests.Results: Previously published validity cutoffs within the CIM (raw score 9 or T-score 29) and BNT-15 (12) produced good classification accuracy using both experimental malingering and psychometrically defined invalid responding as criterion variable. However, a BNT-15 completion time 85 s produced a better signal detection profile than BNT-15 accuracy scores.Conclusions: Results support the clinical utility of existing cutoffs. Given the relatively high base rate of failure even in the control group (5-15%), and the perfect specificity of CIM 9 and BNT-1511 to noncredible responding, relabeling this range of performance as Abnormal instead of Impaired would better capture the uncertainty in its clinical interpretation.	[An, Kelly Y.; Charles, Jordan; Ali, Sami; Enache, Anca; Dhuga, Jasmine; Erdodi, Laszlo A.] Univ Windsor, Dept Psychol, Windsor, ON, Canada	Erdodi, LA (corresponding author), 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	lerdodi@gmail.com					Abeare CA, 2018, JAMA NEUROL, V75, P697, DOI 10.1001/jamaneurol.2018.0031; An KY, 2017, CLIN NEUROPSYCHOL, V31, P193, DOI 10.1080/13854046.2016.1217046; An KY, 2012, ARCH CLIN NEUROPSYCH, V27, P849, DOI 10.1093/arclin/acs085; Armistead-Jehle P, 2015, APPL NEUROPSYCH-ADUL, V22, P147, DOI 10.1080/23279095.2014.880842; Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Ashendorf L, 2017, CLIN NEUROPSYCHOL, V31, P857, DOI 10.1080/13854046.2017.1285961; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Axelrod BN, 2014, CLIN NEUROPSYCHOL, V28, P876, DOI 10.1080/13854046.2014.907583; Axelrod BN, 2011, APPL NEUROPSYCHOL, V18, P27, DOI 10.1080/09084282.2010.523369; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Bigler ED, 2015, BRAIN IMAGING BEHAV, V9, P421, DOI 10.1007/s11682-015-9409-1; Bigler ED, 2014, BRAIN INJURY, V28, P1623, DOI 10.3109/02699052.2014.947627; Bigler ED, 2012, J INT NEUROPSYCH SOC, V18, P632, DOI 10.1017/S1355617712000252; Boone K. B., 2013, CLIN PRACTICE FORENS; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bortnik KE, 2010, CLIN NEUROPSYCHOL, V24, P344, DOI 10.1080/13854040903307268; Brennan A, 2009, CLIN NEUROPSYCHOL, V23, P314, DOI 10.1080/13854040802054151; Bush SS, 2014, PSYCHOL INJ LAW, V7, P197, DOI 10.1007/s12207-014-9198-7; Chafetz MD, 2015, CLIN NEUROPSYCHOL, V29, P723, DOI 10.1080/13854046.2015.1099738; Chafetz MD, 2011, ARCH CLIN NEUROPSYCH, V26, P306, DOI 10.1093/arclin/acr030; Coleman RD, 1998, J CLIN EXP NEUROPSYC, V20, P201, DOI 10.1076/jcen.20.2.201.1164; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; DenBoer JW, 2007, CLIN NEUROPSYCHOL, V21, P943, DOI 10.1080/13854040601020783; DeRight J, 2015, CLIN NEUROPSYCHOL, V29, P101, DOI 10.1080/13854046.2014.989267; Donders J, 2011, CLIN NEUROPSYCHOL, V25, P173, DOI 10.1080/13854046.2010.536781; Dunn TM, 2003, ARCH CLIN NEUROPSYCH, V18, P121, DOI 10.1016/S0887-6177(01)00188-3; Erdodi L. A., 2017, PSYCHOL ASSESSMENT; Erdodi L, 2017, APPL NEUROPSYCH-ADUL, V24, P264, DOI 10.1080/23279095.2016.1154856; Erdodi LA, 2019, APPL NEUROPSYCH-ADUL, V26, P155, DOI 10.1080/23279095.2017.1384925; Erdodi LA, 2018, PSYCHOL ASSESSMENT, V30, P755, DOI 10.1037/pas0000525; Erdodi LA, 2018, PSYCHOL INJ LAW, V11, P1, DOI 10.1007/s12207-017-9309-3; Erdodi LA, 2018, APPL NEUROPSYCH-ADUL, V25, P19, DOI 10.1080/23279095.2016.1232262; Erdodi LA, 2017, PSYCHOL INJ LAW, V10, P96, DOI 10.1007/s12207-017-9282-x; Erdodi LA, 2017, J CLIN EXP NEUROPSYC, V39, P369, DOI 10.1080/13803395.2016.1230181; Erdodi LA, 2016, PSYCHOL INJ LAW, V9, P112, DOI 10.1007/s12207-016-9254-6; Erdodi LA, 2017, PSYCHOL ASSESSMENT, V29, P148, DOI 10.1037/pas0000319; Erdodi LA, 2017, CLIN NEUROPSYCHOL, V31, P168, DOI 10.1080/13854046.2016.1224392; Erdodi LA, 2014, ARCH CLIN NEUROPSYCH, V29, P456, DOI 10.1093/arclin/acu026; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Green, 2004, GREENS MED SYMPTOM V; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2009, ASSESSMENT, V16, P237, DOI 10.1177/1073191108326227; Greve K, 2009, CLIN NEUROPSYCHOL, V23, P343, DOI 10.1080/13854040802054169; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; HAYWARD L, 1987, AUST NZ J PSYCHIAT, V21, P87, DOI 10.3109/00048678709160904; Heaton RK, 2004, REVISED COMPREHENSIV; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Jelicic M, 2011, J CLIN PSYCHOL, V67, P850, DOI 10.1002/jclp.20805; Johnson SC, 2012, CLIN NEUROPSYCHOL, V26, P1230, DOI 10.1080/13854046.2012.709886; Jones A, 2013, CLIN NEUROPSYCHOL, V27, P1043, DOI 10.1080/13854046.2013.804949; Kanser RJ, 2019, CLIN NEUROPSYCHOL, V33, P90, DOI 10.1080/13854046.2018.1440006; Kanser RJ, 2017, CLIN NEUROPSYCHOL, V31, P644, DOI 10.1080/13854046.2016.1278040; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Kim N, 2010, ARCH CLIN NEUROPSYCH, V25, P420, DOI 10.1093/arclin/acq040; Kulas JF, 2014, PSYCHOL INJ LAW, V7, P236, DOI 10.1007/s12207-014-9200-4; Lange RT, 2013, PSYCHOL ASSESSMENT, V25, P339, DOI 10.1037/a0030915; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2015, AM PSYCHOL, V70, P779, DOI 10.1037/a0039835; Lau L, 2017, CLIN NEUROPSYCHOL, V31, P1412, DOI 10.1080/13854046.2017.1318954; Leighton A, 2014, J INT NEUROPSYCH SOC, V20, P873, DOI 10.1017/S135561771400085X; Lezak M., 2012, NEUROPSYCHOLOGICAL A, V5th; Lichtenstein JD, 2017, CHILD NEUROPSYCHOL, V23, P284, DOI 10.1080/09297049.2015.1135422; MACK WJ, 1992, J GERONTOL, V47, pP154, DOI 10.1093/geronj/47.3.P154; Marshall P, 2010, CLIN NEUROPSYCHOL, V24, P1204, DOI 10.1080/13854046.2010.514290; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Miele AS, 2012, ARCH CLIN NEUROPSYCH, V27, P10, DOI 10.1093/arclin/acr084; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Nelson NW, 2003, CLIN NEUROPSYCHOL, V17, P263, DOI 10.1076/clin.17.2.263.16511; O'Bryant SE, 2003, CLIN NEUROPSYCHOL, V17, P69, DOI 10.1076/clin.17.1.69.15624; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P380, DOI 10.1080/13803390903066881; Pearson, 2009, ADV CLIN SOL WAIS 4; Persinger V. C., 2017, CLIN NEUROPSYCHOL, P1; Rapport LJ, 1998, J CLIN EXP NEUROPSYC, V20, P89, DOI 10.1076/jcen.20.1.89.1488; Reese CS, 2012, ARCH CLIN NEUROPSYCH, V27, P176, DOI 10.1093/arclin/acr117; Rogers R, 2003, ASSESSMENT, V10, P160, DOI 10.1177/1073191103010002007; Rogers R., 2008, CLIN ASSESSMENT MALI; Roth R.M., 2017, PSYCHOL NEUROSCI, V10, DOI [https//doi.org/10.1037/pne0000103, DOI 10.1037/PNE0000103]; Russeler J, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-37; Santos OA, 2014, ARCH CLIN NEUROPSYCH, V29, P609, DOI 10.1093/arclin/acu039; Shura RD, 2016, APPL NEUROPSYCH-ADUL, V23, P94, DOI 10.1080/23279095.2015.1014556; Silk-Eglit GM, 2014, ARCH CLIN NEUROPSYCH, V29, P415, DOI 10.1093/arclin/acu028; Silverberg ND, 2008, CLIN NEUROPSYCHOL, V22, P140, DOI 10.1080/13854040601160597; Slick DJ, 2000, J CLIN EXP NEUROPSYC, V22, P569, DOI 10.1076/1380-3395(200010)22:5;1-9;FT569; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Smith K, 2014, CLIN NEUROPSYCHOL, V28, P1048, DOI 10.1080/13854046.2014.931465; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Sugarman MA, 2015, APPL NEUROPSYCH-ADUL, V22, P141, DOI 10.1080/23279095.2013.873439; Suhr JA, 2000, ARCH CLIN NEUROPSYCH, V15, P415, DOI 10.1016/S0887-6177(99)00033-5; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Tombaugh TN, 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; Whiteside DM, 2015, J CLIN EXP NEUROPSYC, V37, P220, DOI 10.1080/13803395.2014.1002758; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	97	24	24	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2019	41	1					15	25		10.1080/13803395.2018.1483488			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	HP3MF	WOS:000461580200002	29943654				2021-06-18	
J	Sumislawski, JJ; Kornblith, LZ; Conroy, AS; Callcut, RA; Cohen, MJ				Sumislawski, Joshua J.; Kornblith, Lucy Z.; Conroy, Amanda S.; Callcut, Rachael A.; Cohen, Mitchell Jay			Dynamic coagulability after injury: Is delaying venous thromboembolism chemoprophylaxis worth the wait?	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	48th Annual Meeting of the Western-Trauma-Association (WTA)	FEB 15-MAR 03, 2018	Whistler, CANADA	Western Trauma Assoc		Trauma-induced coagulopathy; hypercoagulability; venous thromboembolism; chemoprophylaxis; thromboelastometry	MOLECULAR-WEIGHT HEPARIN; TRAUMATIC BRAIN-INJURY; RAPID THROMBELASTOGRAPHY; PULMONARY-EMBOLISM; HYPERCOAGULABILITY; PROPHYLAXIS; COAGULATION; ENOXAPARIN; THROMBOSIS; ADMISSION	BACKGROUND Severely injured patients often progress from early hypocoagulable to normal and eventually hypercoagulable states, developing increased risk for venous thromboembolism (VTE). Prophylactic anticoagulation can decrease this risk, but its initiation is frequently delayed for extended periods due to concerns for bleeding. To facilitate timely introduction of VTE chemoprophylaxis, we characterized the transition from hypo- to hypercoagulability and hypothesized that trauma-induced coagulopathy resolves within 24 hours after injury. METHODS Serial blood samples were collected prospectively from critically injured patients for 120 hours after arrival at an urban Level I trauma center. Extrinsic thromboelastometry maximum clot firmness was used to classify patients as hypocoagulable (HYPO, <49 mm), normocoagulable (NORM, 49-71 mm), or hypercoagulable (HYPER, >71 mm) at each time point. Changes in coagulability over hospital course, VTE occurrence, and timing of prophylaxis initiation were analyzed. RESULTS 898 patients (median Injury Severity Score, 13; mortality, 12%; VTE, 8%) were enrolled. Upon arrival, 3% were HYPO (90% NORM, 7% HYPER), which increased to 9% at 6 hours before down-trending. Ninety-seven percent were NORM by 24 hours, and 53% were HYPER at 120 hours. Median maximum clot firmness began in the NORM range, up-trended gradually, and entered the HYPER range at 120 hours. Patients with traumatic brain injury (TBI) followed a similar course and were not more HYPO at any time point than those without TBI. Failure to initiate prophylaxis by 72 hours was predicted by TBI and associated with VTE development (27% vs 16%, p < 0.05). CONCLUSIONS Regardless of injury pattern, trauma-induced coagulopathy largely resolves within 24 hours, after which hypercoagulability becomes increasingly more prevalent. Deferring initiation of chemoprophylaxis, which is often biased toward patients with intracranial injuries, is associated with VTE development. LEVEL OF EVIDENCE Prognostic study, level III; Therapeutic, level IV.	[Sumislawski, Joshua J.; Cohen, Mitchell Jay] Univ Colorado, Dept Surg, Denver Hlth Med Ctr, Denver, CO 80202 USA; [Kornblith, Lucy Z.; Conroy, Amanda S.; Callcut, Rachael A.] Univ Calif San Francisco, Dept Surg, Zuckerberg San Francisco Gen Hosp, San Francisco, CA USA	Sumislawski, JJ (corresponding author), Denver Hlth Med Ctr, Dept Surg, 777 Bannock St,MC 0206, Denver, CO 80204 USA.	joshua.sumislawski@ucdenver.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UM1HL120877, K01ES026834]; United States Department of DefenseUnited States Department of Defense [W911QY-15-C-0044]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K23GM130892] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (grants UM1HL120877 to MJC and K01ES026834 to RAC) and the United States Department of Defense (contract W911QY-15-C-0044 to MJC and RAC).	Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Byrne JP, 2016, J AM COLL SURGEONS, V223, P621, DOI 10.1016/j.jamcollsurg.2016.06.382; Cannon WB, 1914, AM J PHYSIOL, V34, P232; Chapman BC, 2013, AM J SURG, V206, P917, DOI 10.1016/j.amjsurg.2013.07.024; Christie SA, 2017, J TRAUMA ACUTE CARE, V82, P1055, DOI 10.1097/TA.0000000000001423; Cohen MJ, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002359; Coleman JJ, 2015, J AM COLL SURGEONS, V220, P731, DOI 10.1016/j.jamcollsurg.2014.12.032; Connelly CR, 2016, JAMA SURG, V151, DOI 10.1001/jamasurg.2016.2069; Cothren CC, 2007, WORLD J SURG, V31, P98, DOI 10.1007/s00268-006-0304-1; Cotton BA, 2012, J TRAUMA ACUTE CARE, V72, P1470, DOI 10.1097/TA.0b013e31824d56ad; Frank B, 2017, J TRAUMA ACUTE CARE, V83, P1095, DOI 10.1097/TA.0000000000001655; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; Gonzalez E, 2016, ANN SURG, V263, P1051, DOI 10.1097/SLA.0000000000001608; Harr JN, 2013, J TRAUMA ACUTE CARE, V74, P756, DOI 10.1097/TA.0b013e3182826d7e; Hincker A, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0549-2; Joseph B, 2015, AM J SURG, V209, P194, DOI 10.1016/j.amjsurg.2014.03.007; Kashuk JL, 2009, SURGERY, V146, P764, DOI 10.1016/j.surg.2009.06.054; KASHUK JL, 1982, J TRAUMA, V22, P672, DOI 10.1097/00005373-198208000-00004; Knudson MM, 2011, ANN SURG, V254, P625, DOI 10.1097/SLA.0b013e3182300209; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; Koehler DM, 2011, J TRAUMA, V70, P324, DOI 10.1097/TA.0b013e31820b5d22; Kornblith LZ, 2015, J TRAUMA ACUTE CARE, V78, P30, DOI 10.1097/TA.0000000000000490; Kutcher ME, 2013, J TRAUMA ACUTE CARE, V74, P1223, DOI 10.1097/TA.0b013e31828b7fa1; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P13, DOI 10.1097/TA.0b013e318256deab; Kwok AM, 2016, AM J SURG, V212, P1231, DOI 10.1016/j.amjsurg.2016.09.026; Lang T, 2005, BLOOD COAGUL FIBRIN, V16, P301, DOI 10.1097/01.mbc.0000169225.31173.19; Liras IN, 2016, J TRAUMA ACUTE CARE, V80, P778, DOI 10.1097/TA.0000000000000985; Louis SG, 2014, JAMA SURG, V149, P365, DOI 10.1001/jamasurg.2013.3963; Louis SG, 2014, J TRAUMA ACUTE CARE, V76, P937, DOI 10.1097/TA.0000000000000165; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; Menezes AA, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf5045; Moore FA, 1996, J TRAUMA, V40, P501, DOI 10.1097/00005373-199604000-00001; Moore HB, 2017, AM J SURG, V214, P1041, DOI 10.1016/j.amjsurg.2017.08.036; Netto FS, 2012, INJURY, V43, P1502, DOI 10.1016/j.injury.2010.12.028; Park MS, 2009, J TRAUMA, V67, P266, DOI 10.1097/TA.0b013e3181ae6f1c; Pommerening MJ, 2015, SURGERY, V158, P618, DOI 10.1016/j.surg.2015.06.014; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Robles AJ, 2018, J TRAUMA ACUTE CARE, V85, P148, DOI 10.1097/TA.0000000000001926; Saadeh Y, 2012, J TRAUMA ACUTE CARE, V73, P426, DOI 10.1097/TA.0b013e31825a758b; Schreiber MA, 2005, J TRAUMA, V58, P475, DOI 10.1097/01.TA.0000153938.77777.26; Sharpe JP, 2017, J TRAUMA ACUTE CARE, V83, P1108, DOI 10.1097/TA.0000000000001640; Van Gent JM, 2014, J TRAUMA ACUTE CARE, V76, P1270, DOI 10.1097/TA.0000000000000233; Van Haren RM, 2014, J AM COLL SURGEONS, V218, P846, DOI 10.1016/j.jamcollsurg.2013.12.039; Van Haren RM, 2014, J TRAUMA ACUTE CARE, V76, P443, DOI 10.1097/TA.0b013e3182a9d11d; Van PY, 2009, J TRAUMA, V66, P1509, DOI 10.1097/TA.0b013e3181a51e33; Zhan CL, 2003, JAMA-J AM MED ASSOC, V290, P1868, DOI 10.1001/jama.290.14.1868	47	24	24	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	NOV	2018	85	5					907	914		10.1097/TA.0000000000002048			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	GZ0NG	WOS:000449060100012	30124623	Green Accepted			2021-06-18	
J	Jian, WH; Wang, HC; Kuan, CH; Chen, MH; Wu, HC; Sun, JS; Wang, TW				Jian, Wei-Hong; Wang, Huan-Chih; Kuan, Chen-Hsiang; Chen, Ming-Hong; Wu, Hsi-Chin; Sun, Jui-Sheng; Wang, Tzu-Wei			Glycosaminoglycan-based hybrid hydrogel encapsulated with polyelectrolyte complex nanoparticles for endogenous stem cell regulation in central nervous system regeneration	BIOMATERIALS			English	Article						Glycosaminoglycan; Polyelectrolyte complex nanoparticle; Growth factors; Neural stem cell; Hydrogel; Brain	TRAUMATIC BRAIN-INJURY; NUCLEUS PULPOSUS REGENERATION; NEURAL PROGENITOR CELLS; GROWTH-FACTOR DELIVERY; ISCHEMIC-STROKE; HYALURONIC-ACID; MATRIX METALLOPROTEINASES; TISSUE; BLOOD; MIGRATION	The poor regenerative capability of stem cell transplantation in the central nervous system limits their therapeutic efficacy in brain injuries. The sustained inflammatory response, lack of structural support, and trophic factors deficiency restrain the integration and long-term survival of stem cells. Instead of exogenous stem cell therapy, here we described the synthesis of nanohybrid hydrogel containing sulfated glycosaminoglycan-based polyelectrolyte complex nanoparticles (PCN) to mimic the brain extracellular matrix and control the delivery of stromal-derived factor-1 alpha (SDF-1 alpha) and basic fibroblast factor (bFGF) in response to matrix metalloproteinase (MMP) for recruiting endogenous neural stem cells (NSC) and regulating their cellular fate. Bioactive factors are delivered by electrostatic sequestration on PCN to amplify the signaling of SDF-1 alpha and bFGF to regulate NSC in vitro. In in vivo ischemic stroke model, the factors promoted neurological behavior recovery by enhancing neurogenesis and angiogenesis. These combined strategies may be applied for other tissue regenerations by regulating endogenous progenitors through the delivery of different kinds of glycosaminoglycan-binding molecules. (C) 2018 Elsevier Ltd. All rights reserved.	[Jian, Wei-Hong; Wang, Tzu-Wei] Natl Thing Hua Univ, Dept Mat Sci & Engn, 101,Sect 2,Kuang Fu Rd, Hsinchu 30013, Taiwan; [Wang, Huan-Chih] Natl Taiwan Univ Hosp, Dept Surg, Div Neurosurg, Taipei 10002, Taiwan; [Wang, Huan-Chih] Natl Chiao Tung Univ, Coll Biol Sci & Technol, Hsinchu 30010, Taiwan; [Kuan, Chen-Hsiang] Natl Taiwan Univ Hosp, Div Plast Surg, Dept Surg, Taipei 10002, Taiwan; [Kuan, Chen-Hsiang] Natl Taiwan Univ, Grad Inst Clin Med, Coll Med, Taipei 10002, Taiwan; [Chen, Ming-Hong] Cathay Gen Hosp, Div Neurosurg, Dept Surg, Taipei, Taiwan; [Chen, Ming-Hong] Fu Jen Catholic Univ, Sch Med, Coll Med, New Taipei, Taiwan; [Wu, Hsi-Chin] Tatung Univ, Dept Mat Engn, Taipei 10452, Taiwan; [Wu, Hsi-Chin] Tatung Univ, Dept Bioengn, Taipei 10452, Taiwan; [Sun, Jui-Sheng] Natl Taiwan Univ Hosp, Dept Orthoped Surg, Taipei 10002, Taiwan	Wang, TW (corresponding author), Natl Thing Hua Univ, Dept Mat Sci & Engn, 101,Sect 2,Kuang Fu Rd, Hsinchu 30013, Taiwan.	twwang@mx.nthu.edu.tw		SUN, JUI-SHENG/0000-0001-5142-8777; Kuan, Chen-Hsiang/0000-0001-5599-7125; Wang, Huan-Chih/0000-0001-6192-853X	Taiwan Ministry of Science and Technology [MOST-104-2628-E-007 -002 -MY3, MOST-104-2221-E-007 -140 -MY2, MOST -106-2622-E-007-003 -CC2]	We thank for the technical assistance from Magnetic Resonance Imaging Core Lab of Molecular Imaging Center in National Taiwan University (NTU) and IBEN Service in National Health Research Institutes for MR scanning. We are also grateful to the Technology Commons, College of Life Science, NTU for technical assistance with transmission electron microscopy (TEM), and the help of Instrument Center in National Tsing Hua University (NTHU) with NMR analysis. We also acknowledge Zheng-Wei Lu (Department of Chemical Engineering, NTHU) for assistance with the rheology analysis, and Kun-I Chao (Department of Biomedical Engineering and Environmental Sciences, NTHU) for helpful suggestions in MRI analysis. Funding was provided by the Taiwan Ministry of Science and Technology (MOST-104-2628-E-007 -002 -MY3, MOST-104-2221-E-007 -140 -MY2, MOST -106-2622-E-007-003 -CC2).	Addington CP, 2015, BIOMARK INSIGHTS, V10, P43, DOI [10.4137/BMIMI.S20062, 10.4137/BMI.S20062]; Boddohi S, 2010, ADV MATER, V22, P2998, DOI 10.1002/adma.200903790; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Burdick JA, 2011, ADV MATER, V23, pH41, DOI 10.1002/adma.201003963; Chen YC, 2013, ACTA BIOMATER, V9, P5181, DOI 10.1016/j.actbio.2012.09.039; Dibajnia P, 2013, ACTA PHARMACOL SIN, V34, P78, DOI 10.1038/aps.2012.107; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; Fiorini F, 2016, SMALL, V12, P4881, DOI 10.1002/smll.201601017; Freudenberg U, 2016, ADV MATER, V28, P8861, DOI 10.1002/adma.201601908; Ge YQ, 2009, NANOSCALE RES LETT, V4, P287, DOI 10.1007/s11671-008-9239-9; Gregoire CA, 2015, GLIA, V63, P1469, DOI 10.1002/glia.22851; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Hardy JG, 2015, J BIOMAT SCI-POLYM E, V26, P143, DOI 10.1080/09205063.2014.975393; Huang YC, 2012, ACTA BIOMATER, V8, P1048, DOI 10.1016/j.actbio.2011.12.009; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Jin R, 2013, J CARDIOVASC TRANSL, V6, P834, DOI 10.1007/s12265-013-9508-6; Karumbaiah L, 2015, BIOCONJUGATE CHEM, V26, P2336, DOI 10.1021/acs.bioconjchem.5b00397; Khetan S, 2013, NAT MATER, V12, P458, DOI [10.1038/NMAT3586, 10.1038/nmat3586]; Kiprianova I, 2004, EXP NEUROL, V189, P252, DOI 10.1016/j.expneurol.2004.06.004; Kojima T, 2010, STEM CELLS, V28, P545, DOI 10.1002/stem.306; Lee SS, 2017, NAT NANOTECHNOL, V12, P821, DOI [10.1038/nnano.2017.109, 10.1038/NNANO.2017.109]; Li HL, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-58; Li YN, 2014, STROKE, V45, P1822, DOI 10.1161/STROKEAHA.114.005078; Lim TC, 2013, FASEB J, V27, P1023, DOI 10.1096/fj.12-221515; Lin TN, 2002, STROKE, V33, P2985, DOI 10.1161/01.STR.0000037675.97888.9D; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lotz S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056289; Murphy JW, 2007, J BIOL CHEM, V282, P10018, DOI 10.1074/jbc.M608796200; Netelenbos T, 2002, J LEUKOCYTE BIOL, V72, P353; Nih LR, 2016, CURR OPIN BIOTECH, V40, P155, DOI 10.1016/j.copbio.2016.04.021; Oueslati N, 2014, CARBOHYD POLYM, V112, P102, DOI 10.1016/j.carbpol.2014.05.039; Place LW, 2014, BIOMACROMOLECULES, V15, P680, DOI 10.1021/bm401736c; Purcell BP, 2014, NAT MATER, V13, P653, DOI [10.1038/NMAT3922, 10.1038/nmat3922]; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; Sasisekharan R, 2000, CURR OPIN CHEM BIOL, V4, P626, DOI 10.1016/S1367-5931(00)00145-9; Segovia N, 2015, ADV HEALTHC MATER, V4, P271, DOI 10.1002/adhm.201400235; Sifringer M, 2007, NEUROBIOL DIS, V25, P526, DOI 10.1016/j.nbd.2006.10.019; Sirko S, 2010, STEM CELLS, V28, P775, DOI 10.1002/stem.309; Sommer CJ, 2017, ACTA NEUROPATHOL, V133, P245, DOI 10.1007/s00401-017-1667-0; Spencer KC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02107-2; Su EJ, 2008, NAT MED, V14, P731, DOI 10.1038/nm1787; Su WY, 2010, ACTA BIOMATER, V6, P3044, DOI 10.1016/j.actbio.2010.02.037; Sun GJ, 2015, P NATL ACAD SCI USA, V112, P9484, DOI 10.1073/pnas.1508545112; Tam RY, 2014, NEUROPSYCHOPHARMACOL, V39, P169, DOI 10.1038/npp.2013.237; Tuladhar A, 2015, J CONTROL RELEASE, V215, P1, DOI 10.1016/j.jconrel.2015.07.023; Vulic K, 2012, J AM CHEM SOC, V134, P882, DOI 10.1021/ja210638x; Wang YF, 2013, J CONTROL RELEASE, V172, P1, DOI 10.1016/j.jconrel.2013.07.032; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998; Zhong J, 2010, NEUROREHAB NEURAL RE, V24, P636, DOI 10.1177/1545968310361958; Zhu SW, 2015, ADV MATER, V27, P3620, DOI 10.1002/adma.201500417	51	24	25	17	111	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	AUG	2018	174						17	30		10.1016/j.biomaterials.2018.05.009			14	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	GK5OD	WOS:000436223500002	29763775				2021-06-18	
J	Bernick, C; Zetterberg, H; Shan, GG; Banks, S; Blennow, K				Bernick, Charles; Zetterberg, Henrik; Shan, Guogen; Banks, Sarah; Blennow, Kaj			! Longitudinal Performance of Plasma Neurofilament Light and Tau in Professional Fighters: The Professional Fighters Brain Health Study	JOURNAL OF NEUROTRAUMA			English	Article						mild traumatic brain injury; neurofilament light; tau	INJURY; BIOMARKER; CHAIN; PROTEIN	The aim of this study is to evaluate longitudinal change in plasma neurofilament light (NF-L) and tau levels in relationship to clinical and radiological measures in professional fighters. Participants (active and retired professional fighters and control group) underwent annual blood sampling, 3-Tesla magnetic resonance imaging (MRI) brain imaging, computerized cognitive testing, and assessment of exposure to traumatic brain injury. Plasma tau and NF-L concentrations were measured using Simoa assays. Multiple linear regression models were used to compare the difference across groups in regard to baseline measurements, whereas mixed linear models was used for the longitudinal data with multiple measurements for each participant. Plasma samples were available on 471 participants. Baseline NF-L measures differed across groups (F-3,F-393=6.99; p=0.0001), with the active boxers having the highest levels. Higher NF-L levels at baseline were correlated with lower baseline MRI regional volumes and lower cognitive scores. The number of sparring rounds completed by the active fighters was correlated with NF-L (95% confidence interval, 0.0116-0.4053; p=0.0381), but not tau, levels. Among 126 subjects having multiple yearly samples, there was a significant difference in average yearly percentage change in tau across groups (F-3,F-83=3.87; p=0.0121). We conclude that plasma NF-L and tau behave differently in a group of active and retired fighters; NF-L better reflects acute exposure whereas the role of plasma tau levels in signifying chronic change in brain structure over time requires further study.	[Bernick, Charles; Banks, Sarah] Cleveland Clin, Neurol Inst, 888 West Bonneville Ave, Las Vegas, NV 89106 USA; [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, Gothenburg, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden; [Zetterberg, Henrik] UCL Inst Neurol, Dept Mol Neurosci, Queen Sq, London, England; [Zetterberg, Henrik] UCL, UK Dementia Res Inst, London, England; [Shan, Guogen] Univ Nevada, Environm & Occupat Hlth, Las Vegas, NV 89154 USA	Bernick, C (corresponding author), Cleveland Clin, Neurol Inst, 888 West Bonneville Ave, Las Vegas, NV 89106 USA.	bernicc@ccf.org		Banks, Sarah/0000-0001-7536-2370	UFC; Bellator/Spike TV; Haymon Boxing; Top Rank Promotions; UCLA Dream fund	Charles Bernick receives funding support for the Professional Fighters Brain Health Study from UFC, Bellator/Spike TV, Haymon Boxing, Top Rank Promotions, and UCLA Dream fund; he has been a speaker for Allergan pharmaceuticals. Henrik Zetterberg has served at advisory board meetings for Eli Lilly and Roche Diagnostics; has received travel support from TEVA; and is a cofounder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. Kaj Blennow has served as a consultant or at advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Pfizer, and Roche Diagnostics and is a cofounder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg.	Bernick C, 2015, BRIT J SPORT MED, V49, P1007, DOI 10.1136/bjsports-2014-093877; Bernick C, 2013, AM J EPIDEMIOL, V178, P280, DOI 10.1093/aje/kws456; Bishop CA, 2017, NEUROIMAGE-CLIN, V13, P9, DOI 10.1016/j.nicl.2016.11.005; Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Disanto G, 2017, ANN NEUROL, V81, P857, DOI 10.1002/ana.24954; FRIEDE RL, 1970, ANAT REC, V167, P379, DOI 10.1002/ar.1091670402; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Kuhle J, 2016, CLIN CHEM LAB MED, V54, P1655, DOI 10.1515/cclm-2015-1195; Ljungqvist J, 2017, J NEUROTRAUM, V34, P1124, DOI 10.1089/neu.2016.4496; Lu CH, 2015, NEUROLOGY, V84, P2247, DOI 10.1212/WNL.0000000000001642; Mattsson N, 2017, JAMA NEUROL, V74, P557, DOI 10.1001/jamaneurol.2016.6117; Mattsson N, 2016, NEUROLOGY, V87, P1827, DOI 10.1212/WNL.0000000000003246; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mishra VR, 2017, RADIOLOGY, V285, P555, DOI 10.1148/radiol.2017162403; Morris M, 2011, NEURON, V70, P410, DOI 10.1016/j.neuron.2011.04.009; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Oliver JM, 2017, J NEUROTRAUM, V34, P3295, DOI 10.1089/neu.2017.5064; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Rohrer JD, 2016, NEUROLOGY, V87, P1329, DOI 10.1212/WNL.0000000000003154; Rojas JC, 2016, ANN CLIN TRANSL NEUR, V3, P216, DOI 10.1002/acn3.290; Rubenstein R, 2017, JAMA NEUROL, V74, P1063, DOI 10.1001/jamaneurol.2017.0655; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Shahim P, 2016, JAMA NEUROL, V73, P1308, DOI 10.1001/jamaneurol.2016.2038; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shan GG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188709; Skillback T, 2014, NEUROLOGY, V83, P1945, DOI 10.1212/WNL.0000000000001015; Stern RA, 2016, J ALZHEIMERS DIS, V51, P1099, DOI 10.3233/JAD-151028; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; Zetterberg H, 2016, NAT REV NEUROL, V12, P563, DOI 10.1038/nrneurol.2016.127; Zetterberg H, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt163	31	24	25	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2018	35	20					2351	2356		10.1089/neu.2017.5553		JUL 2018	6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GV6DE	WOS:000438238800001	29609512				2021-06-18	
J	Garcia, GGP; Broglio, SP; Lavieri, MS; McCrea, M; McAllister, T				Garcia, Gian-Gabriel P.; Broglio, Steven P.; Lavieri, Mariel S.; McCrea, Michael; McAllister, Thomas		CARE Consortium Investigators	Quantifying the Value of Multidimensional Assessment Models for Acute Concussion: An Analysis of Data from the NCAA-DoD Care Consortium	SPORTS MEDICINE			English	Article							SPORT-RELATED CONCUSSION; HIGH-SCHOOL; RECURRENT CONCUSSION; SEX-DIFFERENCES; NEUROCOGNITIVE PERFORMANCE; COGNITIVE IMPAIRMENT; SIDELINE CONCUSSION; PROLONGED RECOVERY; NORMATIVE DATA; LONG-TERM	Background Many concussion assessment methods exist, but few studies quantify the performance of these methods to determine which can best assess acute concussion alone or in combination. Objectives The objectives of this study were to evaluate: (1) selected concussion assessments for acute concussion assessment; (2) the utility of change scores for acute concussion assessment; and (3) concussion assessment capabilities when constrained to limited clinical data or objective clinical measures. Methods The 'acute concussion' group contained assessments from <6 h post-injury (n = 560) and 24-48 h postinjury (n = 733). The 'normal performance' group contained assessments from baseline testing (n = 842) and unrestricted return to play (n = 707) timepoints. Univariate and multivariate logistic regression models were created separately for <6-and 24-to 48-h timepoints. Models were evaluated on sensitivity, specificity, and area under the receiver operating characteristic curve. Results Within the univariate analysis, Sport Concussion Assessment Tool symptom assessments had the highest combination of sensitivity, specificity, and area under the receiver operating characteristic curve, with values up to 0.93, 0.97, and 0.98, respectively. Full models had a sensitivity, specificity, and area under the receiver operating characteristic curve up to 0.94, 0.97, and 0.99, respectively, and outperformed all univariate models, raw score models, and objective models. Objective models were outperformed by all multivariate models and the univariate models containing only Sport Concussion Assessment Tool symptom assessments. Conclusion Results support the use of multidimensional assessment batteries over single instruments and suggest the importance of self-reported symptoms in acute concussion assessment. Balance assessments, however, may not provide additional benefit when symptom and neurocognitive assessments are available. Additionally, change scores provide some clinical utility over raw scores, but the difference may not be clinically meaningful.	[Garcia, Gian-Gabriel P.; Lavieri, Mariel S.] Univ Michigan, Dept Ind & Operat Engn, 1205 Beal Ave, Ann Arbor, MI 48109 USA; [Broglio, Steven P.] Univ Michigan, Sch Kinesiol, Ann Arbor, MI 48109 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [McAllister, Thomas] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA	Garcia, GGP (corresponding author), Univ Michigan, Dept Ind & Operat Engn, 1205 Beal Ave, Ann Arbor, MI 48109 USA.	garciagg@umich.edu		Master, Christina/0000-0002-6717-4270; Ortega, Justus/0000-0002-9931-5605; Cameron, Kenneth/0000-0002-6276-4482; Clugston, James/0000-0002-2103-1039; Chrisman, Sara/0000-0001-5373-7223; Garcia, Gian-Gabriel/0000-0001-9315-0195	National Science FoundationNational Science Foundation (NSF) [DGE 1256260]; Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium - National Collegiate Athletic Association; Department of DefenseUnited States Department of Defense; Office of the Assistant Secretary of Defense for Health Affairs [W81XWH-14-2-0151]; US Army Medical Research Acquisition Activity, Fort Detrick, MD, USA	This material is based upon work supported by the National Science Foundation Graduate Research Fellowship under Grant No. DGE 1256260. This publication was made possible, in part, with support from the Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium, funded, in part, by the National Collegiate Athletic Association and the Department of Defense. The US Army Medical Research Acquisition Activity, Fort Detrick, MD, USA is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program under Award No. W81XWH-14-2-0151. Opinions, interpretations, conclusions, and recommendations are those of the author(s) and are not necessarily endorsed by the Department of Defense (Defense Health Program funds).	Asken BM, 2016, J ATHL TRAINING, V51, P329, DOI 10.4085/1062-6050-51.5.02; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; BOZDOGAN H, 1987, PSYCHOMETRIKA, V52, P345, DOI 10.1007/BF02294361; Broglio SP, 2008, CLIN J SPORT MED, V18, P148, DOI 10.1097/JSM.0b013e318164f42a; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2017, SPORTS MED, V47, P1437, DOI 10.1007/s40279-017-0707-1; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Bruce JM, 2004, NEUROLOGY, V63, P1516; Carney N, 2014, NEUROSURGERY, V75, pS3, DOI 10.1227/NEU.0000000000000433; Chin EY, 2016, AM J SPORT MED, V44, P2276, DOI 10.1177/0363546516648141; Concussion in Sport Group, 2013, BRIT J SPORT MED, V47, P259; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Davis G.A., 2017, BR J SPORTS MED, V5, P1, DOI DOI 10.1136/BJSPORTS-2017-097506; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Elbin RJ, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0910; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2004, JAMA-J AM MED ASSOC, V290, P2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Moreau M. S., 2014, INT J EXERCISE SCI, V7, P62; Pepe MS, 2009, STATA J, V9, P1; Putukian M, 2015, CLIN J SPORT MED, V25, P36, DOI 10.1097/JSM.0000000000000102; Randolph C, 2013, J INT NEUROPSYCH SOC, V19, P873, DOI 10.1017/S1355617713000805; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Register-Mihalik JK, 2013, J HEAD TRAUMA REHAB, V28, P274, DOI 10.1097/HTR.0b013e3182585d37; Resch JE., 2016, BMJ OPEN SPORT EXERC, V2, P000012, DOI [10.1136/bmjsem-2015-000012, DOI 10.1136/BMJSEM-2015-000012]; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; Sufrinko A, 2017, J ATHL TRAINING, V52, P676, DOI 10.4085/1062-6050-52.4.01; Sufrinko AM, 2017, AM J SPORT MED, V45, P1187, DOI 10.1177/0363546516685061; Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.3.CO;2-I; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	56	24	24	0	6	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0112-1642	1179-2035		SPORTS MED	Sports Med.	JUL	2018	48	7					1739	1749		10.1007/s40279-018-0880-x			11	Sport Sciences	Sport Sciences	GR5HE	WOS:000442657800014	29488165				2021-06-18	
J	Dai, W; Wang, HD; Fang, J; Zhu, YH; Zhou, J; Wang, XL; Zhou, Y; Zhou, ML				Dai, Wei; Wang, Handong; Fang, Jiang; Zhu, Yihao; Zhou, Jian; Wang, Xiaoliang; Zhou, Yuan; Zhou, Mengliang			Curcumin provides neuroprotection in model of traumatic brain injury via the Nrf2-ARE signaling pathway	BRAIN RESEARCH BULLETIN			English	Article						Curcumin; Traumatic brain injury; Nrf2; Neuroprotection	OXIDATIVE STRESS; LIPID-PEROXIDATION; HEAD-INJURY; MICE; ACTIVATION; EXPRESSION; DAMAGE; NANOPARTICLES; INHIBITION; NITRATION	Curcumin has been found to play the protective role in many neurological disorders, however, its roles and the underlying molecular mechanisms in traumatic brain injury (TBI) are not fully understood. The aim of this study was to investigate the potential neuroprotection of curcumin and the possible role of Nrf2-ARE pathway in the weight -drop model of TBI. The administration of curcumin (100 mg/kg, i.p.) significantly ameliorated secondary brain injury induced by TBI, such as brain water content, oxidative stress, neurological severity score, and neuronal apoptosis. Curcumin possessed anti-apoptotic character evidenced by elevating Bcl-2 content and reducing that of cleaved caspase-3. Moreover, curcumin markedly enhanced the translocation of Nrf2 from the cytoplasm to the nucleus, proved by the results of western blot and immunofluorescence, subsequently increased the expression of downstream factors such as heme oxygenase 1 (HO1) and NAD(P)H: quinone oxidoreductase 1 (NQO1) and prevented the decline of antioxidant enzyme activities. In conclusion, curcumin could increase the activities of antioxidant enzymes and attenuate brain injury in the model of TBI, possibly via the activation of the Nrf2-ARE pathway.	[Dai, Wei; Wang, Handong; Zhou, Jian; Zhou, Yuan] Nanjing Med Univ, Jinling Sch Clin Med, Jinling Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China; [Fang, Jiang] Southeast Univ, Med Coll, Jinling Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China; [Zhu, Yihao; Wang, Xiaoliang; Zhou, Mengliang] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China	Wang, HD (corresponding author), Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com		Zhou, Meng-liang/0000-0002-1165-5489	National Natural Science Fund of ChinaNational Natural Science Foundation of China (NSFC) [81371357, 81401026]; PLA medical science and technology youth training project [16QNP042]	This study was supported by the National Natural Science Fund of China (grant Nos. 81371357 and 81401026) and PLA medical science and technology youth training project (No.16QNP042).	Angeloni C, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/370312; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Brooks JC, 2013, ARCH PHYS MED REHAB, V94, P2203, DOI 10.1016/j.apmr.2013.07.005; Butterfield DA, 2016, PROTEOM CLIN APPL, V10, P1191, DOI 10.1002/prca.201600003; Chen GZ, 2011, J LASERS MED SCI, V2, P89; Chopra D, 2016, BIOMATERIALS, V84, P25, DOI 10.1016/j.biomaterials.2016.01.018; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; de Alcantara Glaura Fernandes Teixeira, 2017, J Tradit Complement Med, V7, P14, DOI 10.1016/j.jtcme.2015.10.001; de Vries HE, 2008, FREE RADICAL BIO MED, V45, P1375, DOI 10.1016/j.freeradbiomed.2008.09.001; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hong YA, 2010, ACTA PHARMACOL SIN, V31, P1421, DOI 10.1038/aps.2010.101; Hu YR, 2017, BIOMED PHARMACOTHER, V85, P313, DOI 10.1016/j.biopha.2016.11.031; Jeong YH, 2016, BIOMOL THER, V24, P581, DOI 10.4062/biomolther.2016.141; Jin W, 2011, INJURY, V42, P714, DOI 10.1016/j.injury.2011.03.009; Kakkar V, 2011, FOOD CHEM TOXICOL, V49, P2906, DOI 10.1016/j.fct.2011.08.006; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Maiti P, 2016, HISTOCHEM CELL BIOL, V146, P609, DOI 10.1007/s00418-016-1464-1; Miller TW, 2009, CHEM REV, V109, P3099, DOI 10.1021/cr8005125; Smith JA, 2013, NEUROCHEM INT, V62, P764, DOI 10.1016/j.neuint.2013.02.013; Wang BF, 2015, ACTA PHARMACOL SIN, V36, P939, DOI 10.1038/aps.2015.47; Wang B, 2012, FREE RADICAL BIO MED, V52, P928, DOI 10.1016/j.freeradbiomed.2011.12.006; Wang L, 2017, ONCOTARGET, V8, P65414, DOI 10.18632/oncotarget.18676; Xie YL, 2017, BIOMED PHARMACOTHER, V91, P70, DOI 10.1016/j.biopha.2017.04.070; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Xue F, 2016, BEHAV BRAIN RES, V309, P1, DOI 10.1016/j.bbr.2016.04.045; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Yan W, 2009, J TRAUMA, V66, P1431, DOI 10.1097/TA.0b013e318180f5c7; Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200; Yin Xiao-Ping, 2015, Drug Des Devel Ther, V9, P5973, DOI 10.2147/DDDT.S79399	34	24	25	0	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.	JUN	2018	140						65	71		10.1016/j.brainresbull.2018.03.020			7	Neurosciences	Neurosciences & Neurology	GO0ZR	WOS:000439675700009	29626606				2021-06-18	
J	Tang, R; Lin, YM; Liu, HX; Wang, ES				Tang, Ri; Lin, Yi-Mei; Liu, Hong-Xing; Wang, Er-Song			Neuroprotective effect of docosahexaenoic acid in rat traumatic brain injury model via regulation of TLR4/NF-Kappa B signaling pathway	INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY			English	Article						Traumatic brain injury; TLR-4/NK-Kappa B pathway; Docosahexaenoic acid; Rat model	KAPPA-B; PROMOTES; TLR4; EPIDEMIOLOGY; INFLAMMATION; INHIBITION; ACTIVATION; EXPRESSION; STRESS; IMPACT	Objective: The experiments were conducted to prove that docosahexaenoic acid (DHA) alleviates traumatic brain injury (TBI) through regulating TLR4/NF-Kappa B signaling pathway. Methods: Bioinformatic analysis was performed using published data from Gene Expression Omnibus (GEO) database to investigate differentially expressed genes and signaling pathways. Controlled cortical impact (CCI) injury rat model was built, and DHA (16 mg/kg in DMSO, once each day) was used to treat TBI rats. Neurological severity score (NSS) and beam walking test and rotarod test were used to confirm whether DHA is neuron-protective against TBI. The expression of TLR4, NF-Kappa B p65, (TNF)-alpha and IL-1 beta were examined by qRT-PCR and western blot. The impact of DHA on neurocyte apoptosis was validated by TdT-mediated dUTP Nick-End Labeling (TUNEL) staining. The influence of DHA on CD11b and GFAP expression in the hippocampus was determined through immunohistochemical analysis. Results: TLR4/NF Kappa B pathway was suggested to be closely correlated with TBI by bioinformatic analysis. DHA could improve the neurological function and learning and memory ability of rats after TBI as well as promote neurocytes from apoptosis. TLR4 expression and the expression of inflammatory mediator NF-Kappa B were also repressed by DHA treatment. Conclusions: DHA exerted a neuron-protective influence in a rat model of TBI via repressing TLR4/NF-Kappa B pathway.	[Tang, Ri; Wang, Er-Song] Fudan Univ, Jinshan Hosp, Dept Neurosurg, 1508 Longhang Rd, Shanghai 200540, Peoples R China; [Lin, Yi-Mei] Fuqing City Hosp Fujian Prov, Dept Gastroenterol, Fuqing 350300, Fujian, Peoples R China; [Liu, Hong-Xing] Fujian Med Univ, Affiliated Hosp 1, Dept Neurosurg, Fuzhou 350005, Fujian, Peoples R China	Wang, ES (corresponding author), Fudan Univ, Jinshan Hosp, Dept Neurosurg, 1508 Longhang Rd, Shanghai 200540, Peoples R China.	wersong@aliyun.com					Alfonso-Loeches S, 2016, NEUROCHEM RES, V41, P193, DOI 10.1007/s11064-015-1760-5; Bajo M, 2016, ALCOHOL ALCOHOLISM, V51, P541, DOI 10.1093/alcalc/agw026; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Cao DH, 2009, J NEUROCHEM, V111, P510, DOI 10.1111/j.1471-4159.2009.06335.x; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Desai A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086472; Feng Y, 2016, INT J MOL MED, V37, P921, DOI 10.3892/ijmm.2016.2495; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Hogyes E, 2003, NEUROSCIENCE, V119, P999, DOI 10.1016/S0306-4522(03)00198-2; Homayoun P, 2000, NEUROCHEM RES, V25, P269, DOI 10.1023/A:1007583806138; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; Hwang JK, 2017, ONCOL LETT, V13, P243, DOI 10.3892/ol.2016.5382; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li YJ, 2014, CELL PHYSIOL BIOCHEM, V33, P1527, DOI 10.1159/000358716; Lim SW, 2013, J SURG RES, V184, P1076, DOI 10.1016/j.jss.2013.04.070; Liu YL, 2013, J NUTR, V143, P1331, DOI 10.3945/jn.113.176255; Liu YL, 2012, J NUTR, V142, P2017, DOI 10.3945/jn.112.164947; Meng XE, 2016, MED SCI MONITOR, V22, P284, DOI 10.12659/MSM.894148; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Russell KL, 2014, PROSTAG LEUKOTR ESS, V90, P5, DOI 10.1016/j.plefa.2013.11.003; Stillwell W, 2003, CHEM PHYS LIPIDS, V126, P1, DOI 10.1016/S0009-3084(03)00101-4; Sun G. Y., 2017, FATTY ACIDS; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Tao XG, 2017, CHINESE MED J-PEKING, V130, P187, DOI 10.4103/0366-6999.198001; Wang Y, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/124614; Williams-Bey Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097957; Xing Z, 2015, RNA BIOL, V12, P681, DOI 10.1080/15476286.2015.1053687; Yi Y, 2018, MOL NEUROBIOL, V55, P2454, DOI 10.1007/s12035-017-0504-8; Yu WH, 2012, PHYTOTHER RES, V26, P1838, DOI 10.1002/ptr.4662; Zhu HT, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-59; Zhu W, 2017, EXP THER MED, V14, P4411, DOI 10.3892/etm.2017.5054	35	24	25	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1357-2725	1878-5875		INT J BIOCHEM CELL B	Int. J. Biochem. Cell Biol.	JUN	2018	99						64	71		10.1016/j.biocel.2018.03.017			8	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	GH7SR	WOS:000433654200008	29597004				2021-06-18	
J	Vedantam, A; Yamal, JM; Hwang, H; Robertson, CS; Gopinath, SP				Vedantam, Aditya; Yamal, Jose-Miguel; Hwang, Hyunsoo; Robertson, Claudia S.; Gopinath, Shankar P.			Factors associated with shunt-dependent hydrocephalus after decompressive craniectomy for traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						posttraumatic hydrocephalus; shunt-dependent hydrocephalus; decompressive craniectomy; severe traumatic brain injury	POSTTRAUMATIC HYDROCEPHALUS; SUBDURAL HYGROMA; RISK-FACTORS; INTRACRANIAL HYPERTENSION; INTERHEMISPHERIC HYGROMA; HEAD-INJURY; COMPLICATIONS; DYNAMICS	OBJECTIVE Posttraumatic hydrocephalus (PTH) affects 11.9%-36% of patients undergoing decompressive craniectomy (DC) and is an important cause of morbidity after traumatic brain injury (TBI). Early diagnosis and treatment of PTH can prevent further neurological compromise in patients who are recovering from TBI. There is limited data on predictors of shunting for PTH after DC for TBI. METHODS Prospectively collected data from the erythropoietin severe TBI randomized controlled trial were studied. Demographic, clinical, and imaging data were analyzed for enrolled patients who underwent a DC. All head CT scans during admission were reviewed and assessed for PTH by the Gudeman criteria or the modified Frontal Horn Index >= 33%. The presence of subdural hygromas was categorized as unilateral/bilateral hemispheric or interhemispheric. Using L1-regularized logistic regression to select variables, a multiple logistic regression model was created with ventriculoperitoneal shunting as the binary outcome. Statistical significance was set at p < 0.05. RESULTS A total of 60 patients who underwent DC were studied. Fifteen patients (25%) underwent placement of a ventriculoperitoneal shunt for PTH. The majority of patients underwent unilateral decompressive hemicraniectomy (n = 46, 77%). Seven patients (12%) underwent bifrontal DC. Unilateral and bilateral hemispheric hygromas were noted in 31 (52%) and 7 (11%) patients, respectively. Interhemispheric hygromas were observed in 19 patients (32%). The mean duration from injury to first CT scan showing hemispheric subdural hygroma and interhemispheric hygroma was 7.9 +/- 6.5 days and 14.9 +/- 11.7 days, respectively. The median duration from injury to shunt placement was 43.7 days. Multivariate analysis showed that the presence of interhemispheric hygroma (OR 63.6, p = 0.001) and younger age (OR 0.78, p = 0.009) were significantly associated with the need for a shunt after DC. CONCLUSIONS The presence of interhemispheric subdural hygromas and younger age were associated with shunt-dependent hydrocephalus after DC in patients with severe TBI.	[Vedantam, Aditya; Robertson, Claudia S.; Gopinath, Shankar P.] Baylor Coll Med, Dept Neurosurg, 7200 Cambridge,Ste 9A,MS BCM650, Houston, TX 77030 USA; [Yamal, Jose-Miguel; Hwang, Hyunsoo] Univ Texas Houston, Sch Publ Hlth, Dept Biostat, Houston, TX USA	Gopinath, SP (corresponding author), Baylor Coll Med, Dept Neurosurg, 7200 Cambridge,Ste 9A,MS BCM650, Houston, TX 77030 USA.	shankarg@bcm.tmc.edu			National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS38660]	This study was supported by grant no. P01-NS38660 from the National Institute of Neurological Disorders and Stroke.	Aarabi B, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0947; Choi I, 2008, J KOREAN NEUROSURG S, V43, P227, DOI 10.3340/jkns.2008.43.5.227; De Bonis P, 2013, CLIN NEUROL NEUROSUR, V115, P1308, DOI 10.1016/j.clineuro.2012.12.011; De Bonis P, 2010, J NEUROTRAUM, V27, P1965, DOI 10.1089/neu.2010.1425; GUDEMAN SK, 1981, RADIOLOGY, V141, P397, DOI 10.1148/radiology.141.2.6974874; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Honeybul S, 2012, J NEUROTRAUM, V29, P1872, DOI 10.1089/neu.2012.2356; Huang APH, 2008, J NEUROTRAUM, V25, P1347, DOI 10.1089/neu.2008.0625; Huh PW, 2006, J NEUROSURG, V105, P65, DOI 10.3171/jns.2006.105.1.65; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Jiao Qing-fang, 2007, Chin J Traumatol, V10, P159; Kaen A, 2010, J NEUROSURG, V113, P1287, DOI 10.3171/2010.4.JNS10132; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Ki HJ, 2015, J KOREAN NEUROSURG S, V58, P254, DOI 10.3340/jkns.2015.58.3.254; Kiening KL, 2005, ACT NEUR S, V95, P293; Low CYD, 2013, J CLIN NEUROSCI, V20, P867, DOI 10.1016/j.jocn.2012.06.007; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; Poca MA, 2005, J NEUROTRAUM, V22, P1303, DOI 10.1089/neu.2005.22.1303; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Tian HL, 2008, SURG NEUROL, V69, P241, DOI 10.1016/j.surneu.2007.02.032; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	24	24	28	1	9	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2018	128	5					1547	1552		10.3171/2017.1.JNS162721			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GP2HQ	WOS:000440650000034	28621627				2021-06-18	
J	Xu, KB; Wu, FF; Xu, K; Li, ZM; Wei, XJ; Lu, Q; Jiang, T; Wu, FZ; Xu, XL; Xiao, J; Chen, DQ; Zhang, HY				Xu, Kebin; Wu, Fangfang; Xu, Ke; Li, Zhengmao; Wei, Xiaojie; Lu, Qi; Jiang, Ting; Wu, Fenzan; Xu, Xinlong; Xiao, Jian; Chen, Daqing; Zhang, Hongyu			NaHS restores mitochondrial function and inhibits autophagy by activating the PI3K/Akt/mTOR signalling pathway to improve functional recovery after traumatic brain injury	CHEMICO-BIOLOGICAL INTERACTIONS			English	Article						Hydrogen sulfide; Traumatic brain injury; Blood brain barrier; Autophagy	HYDROGEN-SULFIDE PROTECTS; BARRIER INTEGRITY; CELL-DEATH; AXON REGENERATION; DYSFUNCTION; CARDIOPROTECTION; NEUROPROTECTION; DEGENERATION; CHALLENGES; APOPTOSIS	Traumatic brain injury (TBI) is one of the most serious public health problems in the world. TBI causes neurological deficits by triggering secondary injuries. Hydrogen sulfide (H2S), a gaseous mediator, has been reported to exert neuroprotective effects in central nervous system diseases, such as TBI. However, the molecular mechanisms involved in this effect are still unclear. The present study was designed to explore the ability of NaHS, a H2S donor, to provide neuroprotection in a mouse model of TBI and to discover the associated molecular mechanisms of these protective effects. Here, we found that administration of NaHS not only maintained the integrity of the blood brain barrier (BBB), protected neurons from apoptosis, and promoted remyelination and axonal reparation but also protected mitochondrial function. In addition, we found that autophagy was inhibited after treatment with NaHS following TBI, an effect that was induced by activation of the PI3K/AKT/mTOR signalling pathway. Our study indicated that H2S treatment is beneficial for TBI, pointing to H2S as a potential therapeutic target for treating TBI.	[Xu, Kebin; Li, Zhengmao; Lu, Qi; Jiang, Ting; Xiao, Jian; Zhang, Hongyu] Wenzhou Med Univ, Sch Pharmaceut Sci, Key Lab Biotechnol & Pharmaceut Engn, Wenzhou 325035, Zhejiang, Peoples R China; [Wu, Fangfang; Chen, Daqing] Wenzhou Med Univ, Affiliated Hosp 2, Dept Emergency, Wenzhou 325027, Zhejiang, Peoples R China; [Wu, Fangfang; Chen, Daqing] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou 325027, Zhejiang, Peoples R China; [Xu, Ke] Wenzhou Univ, Inst Life Sci, Wenzhou 325035, Zhejiang, Peoples R China; [Wei, Xiaojie; Xu, Xinlong] Wenzhou Med Univ, Cixi Peoples Hosp, Dept Neurosurg, Ningbo 315300, Zhejiang, Peoples R China; [Wu, Fenzan] Wenzhou Med Univ, Cixi Peoples Hosp, Sci & Educ Div, Ningbo 315300, Zhejiang, Peoples R China; [Zhang, Hongyu] Wenzhou Med Univ, Dongyang Peoples Hosp, Expt Res Ctr, Jinhua 322100, Zhejiang, Peoples R China	Zhang, HY (corresponding author), Wenzhou Med Univ, Sch Pharmaceut Sci, Key Lab Biotechnol & Pharmaceut Engn, Wenzhou 325035, Zhejiang, Peoples R China.; Chen, DQ (corresponding author), Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou 325027, Zhejiang, Peoples R China.; Chen, DQ (corresponding author), Wenzhou Med Univ, Affiliated Hosp 2, Wenzhou 325027, Zhejiang, Peoples R China.	cdq@wzhealth.com; hyzhang@wmu.edu.cn		Wu, Fangfang/0000-0002-1888-4516	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81472165, 81772450, 81572237, 81501953]; National Science Fund for Outstanding Young ScholarsNational Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars [81722028]; Zhejiang Provincial Natural Science Funding [LQ16H090007]; Traditional Chinese Medicine Health Science and Technology Program of Zhejiang Province [2018ZA117]	This work was supported by research grants from the National Natural Science Foundation of China (81472165, 81772450, 81572237, 81501953), The National Science Fund for Outstanding Young Scholars (81722028), Zhejiang Provincial Natural Science Funding (LQ16H090007) and Traditional Chinese Medicine Health Science and Technology Program of Zhejiang Province (2018ZA117).	Armulik A, 2010, NATURE, V468, P557, DOI 10.1038/nature09522; Calvert JW, 2010, CIRCULATION, V122, P11, DOI 10.1161/CIRCULATIONAHA.109.920991; Calvert JW, 2009, CIRC RES, V105, P365, DOI 10.1161/CIRCRESAHA.109.199919; Campolo M, 2013, FASEB J, V27, P4489, DOI 10.1096/fj.13-234716; Chen JT, 2016, INT J CARDIOL, V220, P681, DOI 10.1016/j.ijcard.2016.06.200; Chen Y, 2012, LIFE SCI, V91, P271, DOI 10.1016/j.lfs.2012.07.026; Chen ZQ, 2016, BIOCHEM BIOPH RES CO, V478, P1304, DOI 10.1016/j.bbrc.2016.08.116; Daneman R, 2010, NATURE, V468, P562, DOI 10.1038/nature09513; Fiorucci S, 2006, GASTROENTEROLOGY, V131, P259, DOI 10.1053/j.gastro.2006.02.033; Hadadha M, 2015, J STROKE CEREBROVASC, V24, P2676, DOI 10.1016/j.jstrokecerebrovasdis.2015.07.020; Hellal F, 2011, SCIENCE, V331, P928, DOI 10.1126/science.1201148; Jullienne A, 2016, J NEUROSCI RES, V94, P609, DOI 10.1002/jnr.23732; Jung J, 2014, NEURAL REGEN RES, V9, P2119, DOI 10.4103/1673-5374.147940; Koch JC, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.191; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Li L, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0135-1; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lin CJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.123; Lo Faro ML, 2014, NITRIC OXIDE-BIOL CH, V41, P38, DOI 10.1016/j.niox.2014.05.014; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lu J, 2013, P NATL ACAD SCI USA, V110, P10747, DOI 10.1073/pnas.1308950110; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; Luo YG, 2013, NEUROCHEM INT, V63, P826, DOI 10.1016/j.neuint.2013.06.004; Nakazato R, 2017, J NEUROSCI, V37, P10052, DOI 10.1523/JNEUROSCI.3639-16.2017; Nie J, 2016, PEERJ, V4, DOI 10.7717/peerj.2739; Park BS, 2015, J NEUROCHEM, V132, P230, DOI 10.1111/jnc.12932; Rubiano AM, 2015, NATURE, V527, pS193, DOI 10.1038/nature16035; Ruschel J, 2015, SCIENCE, V348, P347, DOI 10.1126/science.aaa2958; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Shan HY, 2017, MOL MED REP, V16, P5938, DOI 10.3892/mmr.2017.7363; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Wang YL, 2014, J NEUROCHEM, V129, P827, DOI 10.1111/jnc.12695; Xiao J, 2015, CELL PHYSIOL BIOCHEM, V37, P2444, DOI 10.1159/000438597; Xiao L, 2018, J HYPERTENS, V36, P651, DOI 10.1097/HJH.0000000000001605; Xiao T, 2016, MOL MED REP, V13, P1765, DOI 10.3892/mmr.2015.4689; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Yin J, 2013, BRAIN RES, V1491, P188, DOI 10.1016/j.brainres.2012.10.046; Yokobori S, 2014, CNS NEUROL DISORD-DR, V13, P606, DOI 10.2174/187152731304140702112805; Zhao FL, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/8360738	40	24	27	0	10	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0009-2797	1872-7786		CHEM-BIOL INTERACT	Chem.-Biol. Interact.	APR 25	2018	286						96	105		10.1016/j.cbi.2018.02.028			10	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology	GC2DK	WOS:000429592200012	29567101				2021-06-18	
J	Lv, JF; Zeng, Y; Qian, Y; Dong, JF; Zhang, ZX; Zhang, JN				Lv, Jingfang; Zeng, Yong; Qian, Yu; Dong, Jingfei; Zhang, Zhixiang; Zhang, Jianning			MicroRNA let-7c-5p improves neurological outcomes in a murine model of traumatic brain injury by suppressing neuroinflammation and regulating microglial activation	BRAIN RESEARCH			English	Article						MicroRNA let-7c-5p; Traumatic brain injury; Microglia; Neuroinflammation	MICROGLIA/MACROPHAGE POLARIZATION DYNAMICS; KINASE-C-DELTA; NF-KAPPA-B; MACROPHAGE POLARIZATION; CEREBRAL-ISCHEMIA; WHITE-MATTER; INHIBITION; PROMOTES; MICE; PHENOTYPE	MicroRNAs (miRNAs) are a class of non-coding small RNAs that regulate the expression of target genes. They derive from pre-miRNAs that are enzymatically processed by dicer to 22 nucleotide mature miRNAs. Members of the pre-miRNA lethal-7 (let-7) are known to regulate cell proliferation and apoptosis. Here, we showed that the level of let-7c-5p, a key member of the let-7 family, was rapidly reduced in the traumatically injured foci in brains of adult C57BL/6J mice and gradually recovered to the pre-injury level 14 days after traumatic brain injury (TBI) induction. This finding led us to test whether upregulating let-7c-5p in murine cerebral tissue by intracerebroventricular injection (ICV) of let-7c-5p mimic could improve the outcomes of mice subjected to controlled cortical impact (CCI). We found that let-7c-5p overexpression attenuated TBI-induced neurological dysfunction and brain edema. The improvements were attributed to let-7c-5p-mediated inhibiting neuroinflammation and attenuation of microglia/-macrophage activation, both inhibiting M1 polarization and enhancing M2 polarization. In vitro experiments, we observed that let-7c-Sp was decreased in primary microglia activated by LPS treatment or oxygen/glucose deprivation (OGD). Transfection of let-7c-5p mimic suppressed the release of inflammatory mediators in cultured activated primary microglia. In addition, the expressions of caspase-3, a let-7c-5p putative target gene, and the PKC-delta which mediates effect of caspase-3 were inhibited by let-7c-5p in a murine model of TBI. Taken together, these results define the biological activities of cerebral let-7c-5p and delineate its therapeutic potential for improving the neurological outcome of TBI. (C) 2018 Elsevier B.V. All rights reserved.	[Lv, Jingfang; Qian, Yu; Zhang, Jianning] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China; [Lv, Jingfang; Zeng, Yong; Qian, Yu; Zhang, Jianning] Tianjin Neurol Inst, Lab Neurotrauma, Tianjin, Peoples R China; [Lv, Jingfang; Zeng, Yong; Qian, Yu; Zhang, Jianning] Minist Educ, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin, Peoples R China; [Lv, Jingfang; Zeng, Yong; Qian, Yu; Zhang, Jianning] Tianjin Key Lab Injuries Variat & Regenerat Nervo, Tianjin, Peoples R China; [Lv, Jingfang; Zhang, Zhixiang] Tianjin Med Univ, Gen Hosp, Tianjin Gen Surg Inst, Dept Gen Surg, Tianjin, Peoples R China; [Zeng, Yong] Tianjin First Ctr Hosp, Dept Neurosurg, Tianjin, Peoples R China; [Dong, Jingfei] Blood Works Res Inst, Seattle, WA USA; [Dong, Jingfei] Univ Washington, Sch Med, Dept Med, Div Hematol, Seattle, WA 98195 USA	Zhang, JN (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China.	tjjnzhang@163.com			National Natural Science Foundation of China State Key Program [81330029]; National Natural Science Foundation of China researchNational Natural Science Foundation of China (NSFC) [81271361, 81271359]	This work was supported by National Natural Science Foundation of China State Key Program (grant nos. 81330029) and National Natural Science Foundation of China research (grants nos. 81271361 and 81271359).	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Banerjee S, 2013, J IMMUNOL, V190, P6542, DOI 10.4049/jimmunol.1202496; Burguillos MA, 2011, NATURE, V472, P319, DOI 10.1038/nature09788; Cardoso AL, 2016, CURR OPIN PHARMACOL, V26, P1, DOI 10.1016/j.coph.2015.09.001; Chen WW, 2016, MOL MED REP, V13, P3391, DOI 10.3892/mmr.2016.4948; Donat CK, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00208; Dong TT, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0663-y; Essandoh K, 2016, SHOCK, V46, P122, DOI 10.1097/SHK.0000000000000604; Gao HB, 2017, BRAIN RES, V1657, P1, DOI 10.1016/j.brainres.2016.11.028; Hellewell S, 2016, BRAIN RES, V1640, P36, DOI 10.1016/j.brainres.2015.12.024; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Jadhav SP, 2014, J NEUROCHEM, V130, P388, DOI 10.1111/jnc.12731; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kozlowski C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031814; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Li M, 2011, J TRAUMA, V71, P141, DOI [10.1097/TA.0b013e3181f30fc9, 10.1088/1742-5468/2011/12/P12001]; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Ma L., 2017, BRAIN RES, V17, P30366; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Ni JS, 2015, BRAIN BEHAV IMMUN, V49, P75, DOI 10.1016/j.bbi.2015.04.014; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Shen XL, 2016, NAT IMMUNOL, V17, P1282, DOI 10.1038/ni.3545; Storz P, 2004, MOL CELL BIOL, V24, P2614, DOI 10.1128/MCB.24.7.2614-2626.2004; Tan MS, 2014, J ALZHEIMERS DIS, V38, P633, DOI 10.3233/JAD-131148; Truettner JS, 2017, J CEREBR BLOOD F MET, V37, P2952, DOI 10.1177/0271678X16680003; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wu HT, 2012, BRAIN RES, V1486, P121, DOI 10.1016/j.brainres.2012.09.039; Xu X, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0934-2; Xue J, 2014, IMMUNITY, V40, P274, DOI 10.1016/j.immuni.2014.01.006; Yao XL, 2017, J NEUROIMMUNOL, V310, P38, DOI 10.1016/j.jneuroim.2017.06.006; Yuan YM, 2015, BRAIN BEHAV IMMUN, V48, P287, DOI 10.1016/j.bbi.2015.04.008; Zhang JC, 2017, MOL NEUROBIOL, V54, P3652, DOI 10.1007/s12035-016-9924-0; Zhang W, 2015, CELL DEATH DIFFER, V22, P287, DOI 10.1038/cdd.2014.142	37	24	27	0	19	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	APR 15	2018	1685						91	104		10.1016/j.brainres.2018.01.032			14	Neurosciences	Neurosciences & Neurology	GA7AW	WOS:000428488000009	29408500				2021-06-18	
J	Vasterling, JJ; Aslan, M; Lee, LO; Proctor, SP; Ko, J; Jacob, S; Concato, J				Vasterling, Jennifer J.; Aslan, Mihaela; Lee, Lewina O.; Proctor, Susan P.; Ko, John; Jacob, Shawna; Concato, John			Longitudinal Associations among Posttraumatic Stress Disorder Symptoms, Traumatic Brain Injury, and Neurocognitive Functioning in Army Soldiers Deployed to the Iraq War	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Cognitive function; Posttraumatic stress disorders; Military personnel; Veterans; Traumatic brain injury; War exposure	NEUROPSYCHOLOGICAL OUTCOMES; MILITARY DEPLOYMENT; COGNITIVE SEQUELAE; PTSD SYMPTOMS; MENTAL-HEALTH; BLAST; RISK; MEMORY; VETERANS; PERFORMANCE	Objectives: Military deployment is associated with increased risk of adverse emotional and cognitive outcomes. Longitudinal associations involving posttraumatic stress disorder (PTSD), relatively mild traumatic brain injury (TBI), and neurocognitive compromise are poorly understood, especially with regard to long-term outcomes, and rigorous research is necessary to better understand the corresponding relationships. The objective of this study was to examine short-term and long-term (>5 years) longitudinal associations among PTSD, neurocognitive performance, and TBI following military deployment. Methods: In this prospective study, N=315 U.S. Army soldiers were assessed at military installations before (2003-2005) and after (2004-2006) an index deployment to the Iraq War, and again an average of 7.6 years later (2010-2014) as a nationally dispersed cohort of active duty soldiers, reservists, and veterans. Thus, the study design allowed for two measurement intervals over which to examine changes. All assessments included the PTSD Checklist, civilian version, and individually-administered performance-based neurocognitive tests. TBI history was derived from clinical interview. Results: Autoregressive analyses indicated that visual reproduction scores were inversely related to subsequent PTSD symptom severity at subsequent assessments. Conversely, increases in PTSD symptom severity over each measurement interval were associated with poorer verbal and/or visual recall at the end of each interval, and less efficient reaction time at post-deployment. TBI, primarily mild in this sample, was associated with adverse PTSD symptom outcomes at both post-deployment and long-term follow-up. Conclusions: These results suggest longitudinal relationships among PTSD symptoms, TBI, and neurocognitive decrements may contribute to sustained emotional and neurocognitive symptoms over time.	[Vasterling, Jennifer J.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA; [Vasterling, Jennifer J.; Jacob, Shawna] VA Boston Healthcare Syst, Psychol Serv, Boston, MA 02130 USA; [Vasterling, Jennifer J.; Lee, Lewina O.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Aslan, Mihaela; Ko, John; Concato, John] VA Cooperat Studies Program, Clin Epidemiol Res Ctr, West Haven, CT USA; [Aslan, Mihaela; Concato, John] Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA; [Lee, Lewina O.; Proctor, Susan P.] VA Boston Hlth Care Syst, Res Serv, Boston, MA 02130 USA; [Proctor, Susan P.] US Army Res Inst Environm Med, Natick, MA USA; [Proctor, Susan P.] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA	Vasterling, JJ (corresponding author), VA Boston Healthcare Syst, Psychol 116B, 150 S Huntington Ave, Boston, MA 02130 USA.	jennifer.vasterling@va.gov		/0000-0002-1652-8198	Department of Veterans Affairs (VA) Cooperative Studies Program (CSP)US Department of Veterans Affairs [566]; U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [DAMD 17-03-0020]; VA Clinical Sciences Research and Development; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K08AG048221] Funding Source: NIH RePORTER	Funding was provided by the Department of Veterans Affairs (VA) Cooperative Studies Program (CSP#566). Support for previous collection of archived data used in this study's longitudinal analyses was provided by the U.S. Army Medical Research and Materiel Command (DAMD 17-03-0020) and VA Clinical Sciences Research and Development. The funding agency (VA) provided general guidance and policies for conducting human subjects research. The manuscript underwent administrative review at the U.S. Army Research Institute of Environmental Medicine. The views expressed in this article are those of the authors and do not reflect official policy or position of the U.S. Army, Department of Defense, VA, or U.S. government. The authors have no conflicts of interest to declare. We appreciate the support of the Defense Manpower Data Center in obtaining military service status data. We also thank the VACSP#566 team, including Drs. Helen MacDonald and Christopher Harte for their leadership of clinical data collection, Patricia Crutchfield and Joseph Turner for their organizational and administrative support, Drs. Matthew Jakupcak, Brian Marx, and Miles McFall for their roles as site investigators, our dedicated team of study psychologists, Drs. Grant Huang and Theresa Gleason for their support of the study, and the VACSP#566 Executive Committee for their on-going guidance. Finally, we are grateful to the Soldiers and military veterans who comprise the Neurocognition Deployment Health Study cohort for volunteering their time to participate in the study, and also for their military service.	Alosco ML, 2016, J HEAD TRAUMA REHAB, V31, P360, DOI 10.1097/HTR.0000000000000201; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Armistead-Jehle P, 2017, PHYS MED REH CLIN N, V28, P323, DOI 10.1016/j.pmr.2016.12.008; Arnsten AFT, 2015, NEUROBIOL STRESS, V1, P89, DOI 10.1016/j.ynstr.2014.10.002; Aslan M, 2013, J INVEST MED, V61, P569, DOI [10.231/JIM.0b013e31828407ff, 10.2310/JIM.0b013e31828407ff]; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Brewin CR, 2010, PSYCHOL REV, V117, P210, DOI 10.1037/a0018113; Bryant RA, 2015, BRIT J PSYCHIAT, V206, P417, DOI 10.1192/bjp.bp.114.145516; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Clark AL, 2016, BRAIN INJURY, V30, P864, DOI 10.3109/02699052.2016.1144894; Eekhout I, 2016, LANCET PSYCHIAT, V3, P58, DOI 10.1016/S2215-0366(15)00368-5; Gilbertson MW, 2007, BIOL PSYCHIAT, V62, P513, DOI 10.1016/j.biopsych.2006.12.023; Hayes JP, 2015, NEUROIMAGE-CLIN, V8, P148, DOI 10.1016/j.nicl.2015.04.001; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holmes EA, 2005, EMOTION, V5, P489, DOI 10.1037/1528-3542.5.4.489; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Kelley AM, 2012, J PSYCHIATR RES, V46, P582, DOI 10.1016/j.jpsychires.2012.01.017; Letz R, 1996, NEUROTOXICOL TERATOL, V18, P365, DOI 10.1016/0892-0362(96)00041-4; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mac Donald CL, 2017, J NEUROTRAUM, V34, P2206, DOI 10.1089/neu.2016.4434; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; Marx BP, 2009, J INT NEUROPSYCH SOC, V15, P840, DOI 10.1017/S1355617709990488; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; Neipert L, 2014, BRAIN INJURY, V28, P1667, DOI 10.3109/02699052.2014.947623; O'Bryant SE, 2007, CLIN NEUROPSYCHOL, V21, P511, DOI 10.1080/13854040600611368; Parslow RA, 2007, AM J PSYCHIAT, V164, P509, DOI 10.1176/appi.ajp.164.3.509; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Pitman RK, 2012, NAT REV NEUROSCI, V13, P769, DOI 10.1038/nrn3339; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Ramchand R, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-015-0575-z; Reeves D., 2002, ANAM 2001 USERS MANU; Regasa LE, 2016, J HEAD TRAUMA REHAB, V31, pE28, DOI 10.1097/HTR.0000000000000155; Rubin DC, 2003, MEM COGNITION, V31, P877, DOI 10.3758/BF03196442; Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495, DOI 10.1023/A:1025714729117; Scott JC, 2015, PSYCHOL BULL, V141, P105, DOI 10.1037/a0038039; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Stein MB, 2015, AM J PSYCHIAT, V172, P1101, DOI 10.1176/appi.ajp.2015.14121572; Sundin J, 2014, BRIT J PSYCHIAT, V204, P202, DOI 10.1192/bjp.bp.113.129569; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2016, AM J EPIDEMIOL, V184, P796, DOI 10.1093/aje/kww151; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Vasterling JJ, 2006, MIL MED, V171, P253, DOI 10.7205/MILMED.171.3.253; Verfaellie M, 2014, NEUROPSYCHOLOGY, V28, P337, DOI 10.1037/neu0000027; Vogt DS, 2008, ASSESSMENT, V15, P381, DOI 10.1177/1073191108316030; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Wingenfeld K, 2011, CNS NEUROSCI THER, V17, P714, DOI 10.1111/j.1755-5949.2010.00207.x; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080	53	24	24	1	24	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	APR	2018	24	4					311	323		10.1017/S1355617717001059			13	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	GA1JR	WOS:000428072200001	29199924	Green Accepted			2021-06-18	
J	Shi, J; Wang, YY; Chen, TN; Xu, DG; Zhao, HL; Chen, LY; Yan, C; Tang, LH; He, YX; Feng, H; Yao, JQ				Shi, Jia; Wang, Yuye; Chen, Tunan; Xu, Degang; Zhao, Hengli; Chen, Linyu; Yan, Chao; Tang, Longhuang; He, Yixin; Feng, Hua; Yao, Jianquan			Automatic evaluation of traumatic brain injury based on terahertz imaging with machine learning	OPTICS EXPRESS			English	Article							CANCER; TISSUE	The imaging diagnosis and prognostication of different degrees of traumatic brain injury (TBI) is very important for early care and clinical treatment. Especially, the exact recognition of mild TBI is the bottleneck for current label-free imaging technologies in neurosurgery. Here, we report an automatic evaluation method for TBI recognition with terahertz (THz) continuous-wave (CW) transmission imaging based on machine learning (ML). We propose a new feature extraction method for biological THz images combined with the transmittance distribution features in spatial domain and statistical distribution features in normalized gray histogram. Based on the extracted feature database, ML algorithms are performed for the classification of different degrees of TBI by feature selection and parameter optimization. The highest classification accuracy is up to 87.5%. The area under the curve (AUC) scores of the receiver operating characteristics (ROC) curve are all higher than 0.9, which shows this evaluation method has a good generalization ability. Furthermore, the excellent performance of the proposed system in the recognition of mild TBI is analyzed by different methodological parameters and diagnostic criteria. The system can be extensible to various diseases and will be a powerful tool in automatic biomedical diagnostics. (C) 2018 Optical Society of America	[Shi, Jia; Wang, Yuye; Xu, Degang; Chen, Linyu; Yan, Chao; Tang, Longhuang; He, Yixin; Yao, Jianquan] Tianjin Univ, Inst Laser & Optoelect, Sch Precis Instrument & Optoelect Engn, Tianjin 300072, Peoples R China; [Shi, Jia; Wang, Yuye; Xu, Degang; Zhao, Hengli; Chen, Linyu; Yan, Chao; Tang, Longhuang; He, Yixin; Yao, Jianquan] Tianjin Univ, Key Lab Optoelect Informat Sci & Technol, Minist Educ, Tianjin 300072, Peoples R China; [Shi, Jia; Wang, Yuye; Chen, Tunan; Feng, Hua] Army Med Univ, Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing 400038, Peoples R China; [Shi, Jia; Wang, Yuye; Chen, Tunan; Feng, Hua] Army Med Univ, Third Mil Med Univ, Southwest Hosp, Key Lab Neurotrauma, Chongqing 400038, Peoples R China	Wang, YY (corresponding author), Tianjin Univ, Inst Laser & Optoelect, Sch Precis Instrument & Optoelect Engn, Tianjin 300072, Peoples R China.; Wang, YY (corresponding author), Tianjin Univ, Key Lab Optoelect Informat Sci & Technol, Minist Educ, Tianjin 300072, Peoples R China.; Wang, YY (corresponding author), Army Med Univ, Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing 400038, Peoples R China.; Wang, YY (corresponding author), Army Med Univ, Third Mil Med Univ, Southwest Hosp, Key Lab Neurotrauma, Chongqing 400038, Peoples R China.	yuyewang@tju.edu.cn; xudegang@tju.edu.cn; fenghua8888@vip.163.com	Yuye, Wang/AAT-9799-2020; Shi, Jia/T-6002-2017	Shi, Jia/0000-0001-7563-9982	National Basic Research Program of China (973)National Basic Research Program of China [2015CB755403, 2014CB339802]; National Key Research and Development projects [2016YFC0101001]; National Natural Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [61775160, 61771332, 61471257]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2016M602954]; Postdoctoral Science Foundation of Chongqing [Xm2016021]; Joint Incubation Project of Southwest Hospital [SWH2016LHJC04, SWH2016LHJC01]	The National Basic Research Program of China (973) (2015CB755403, 2014CB339802); National Key Research and Development projects (2016YFC0101001); National Natural Science Foundation of China (NSFC) (61775160, 61771332, 61471257); China Postdoctoral Science Foundation (2016M602954); Postdoctoral Science Foundation of Chongqing (Xm2016021); Joint Incubation Project of Southwest Hospital (SWH2016LHJC04, SWH2016LHJC01).	Bajwa N, 2017, BIOMED OPT EXPRESS, V8, P460, DOI 10.1364/BOE.8.000460; Breiman L, 1996, MACH LEARN, V24, P123, DOI 10.1023/A:1018054314350; Chen H, 2011, OPT EXPRESS, V19, P21552, DOI 10.1364/OE.19.021552; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fitzgerald AJ, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.1.016005; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Kan WC, 2010, BIOMED OPT EXPRESS, V1, P967, DOI 10.1364/BOE.1.000967; Kohavi R., 1995, IJCAI-95. Proceedings of the Fourteenth International Joint Conference on Artificial Intelligence, P1137; Kononenko I., 1994, Machine Learning: ECML-94. European Conference on Machine Learning. Proceedings, P171; Loffler T, 2001, OPT EXPRESS, V9, P616, DOI 10.1364/oe.9.000616; Murray CJL., 1996, GLOBAL HLTH STAT COM; Nakajima S, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2433035; Oh SJ, 2014, BIOMED OPT EXPRESS, V5, P2837, DOI 10.1364/BOE.5.002837; Park JY, 2017, BIOMED OPT EXPRESS, V8, P1122, DOI 10.1364/BOE.8.001122; Park JY, 2011, J APPL PHYS, V109, DOI 10.1063/1.3551575; Robnik-Sikonja M, 2003, MACH LEARN, V53, P23, DOI 10.1023/A:1025667309714; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shi J., 2016, 41 INT C INFR MILL T; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Sim YC, 2013, BIOMED OPT EXPRESS, V4, P1413, DOI 10.1364/BOE.4.001413; Taylor ZD, 2008, OPT LETT, V33, P1258, DOI 10.1364/OL.33.001258; Wang YY, 2010, OPT EXPRESS, V18, P15504, DOI 10.1364/OE.18.015504; Wunder A, 2012, EPILEPSIA, V53, P14, DOI 10.1111/j.1528-1167.2012.03698.x; Yang SH, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2749185; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zhang XD, 2016, ADV MATER, V28, P6872, DOI 10.1002/adma.201600706; Zhao H., 2017, 17 INT C BRAIN ED CE	28	24	24	4	36	OPTICAL SOC AMER	WASHINGTON	2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA	1094-4087			OPT EXPRESS	Opt. Express	MAR 5	2018	26	5					6371	6381		10.1364/OE.26.006371			11	Optics	Optics	FY8WW	WOS:000427147200113	29529829	DOAJ Gold			2021-06-18	
J	Cashen, K; Reeder, R; Dalton, HJ; Berg, RA; Shanley, TP; Newth, CJL; Pollack, MM; Wessel, D; Carcillo, J; Harrison, R; Dean, JM; Tamburro, R; Meert, KL				Cashen, Katherine; Reeder, Ron; Dalton, Heidi J.; Berg, Robert A.; Shanley, Thomas P.; Newth, Christopher J. L.; Pollack, Murray M.; Wessel, David; Carcillo, Joseph; Harrison, Rick; Dean, J. Michael; Tamburro, Robert; Meert, Kathleen L.		Eunice Kennedy Shriver Natl Inst	Hyperoxia and Hypocapnia During Pediatric Extracorporeal Membrane Oxygenation: Associations With Complications, Mortality, and Functional Status Among Survivors*	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						child; extracorporeal membrane oxygenation; hyperoxia; hypocapnia; neonate	ARTERIAL CARBON-DIOXIDE; TRAUMATIC BRAIN-INJURY; VASOACTIVE-INOTROPIC SCORE; CARDIAC-ARREST; CARDIOPULMONARY BYPASS; HOSPITAL MORTALITY; CLINICAL-OUTCOMES; LIFE-SUPPORT; RESUSCITATION; CHILDREN	Objectives: To determine the frequency of hyperoxia and hypocapnia during pediatric extracorporeal membrane oxygenation and their relationships to complications, mortality, and functional status among survivors. Design: Secondary analysis of data collected prospectively by the Collaborative Pediatric Critical Care Research Network. Setting: Eight Collaborative Pediatric Critical Care Research Network-affiliated hospitals. Patients: Age less than 19 years and treated with extracorporeal membrane oxygenation. Interventions: Hyperoxia was defined as highest Pao(2) greater than 200 Torr (27 kPa) and hypocapnia as lowest Paco(2) less than 30 Torr (3.9 kPa) during the first 48 hours of extracorporeal membrane oxygenation. Functional status at hospital discharge was evaluated among survivors using the Functional Status Scale. Measurements and Main Results: Of 484 patients, 420 (86.7%) had venoarterial extracorporeal membrane oxygenation and 64 (13.2%) venovenous; 69 (14.2%) had extracorporeal membrane oxygenation initiated during cardiopulmonary resuscitation. Hyperoxia occurred in 331 (68.4%) and hypocapnia in 98 (20.2%). Hyperoxic patients had higher mortality than patients without hyperoxia (167 [50.5%] vs 48 [31.4%]; p < 0.001), but no difference in functional status among survivors. Hypocapnic patients were more likely to have a neurologic event (49 [50.0%] vs 143 (37.0%]; p = 0.021) or hepatic dysfunction (49 [50.0%] vs 121 [31.3%]; p < 0.001) than patients without hypocapnia, but no difference in mortality or functional status among survivors. On multivariable analysis, factors independently associated with increased mortality included highest Pao(2) and highest blood lactate concentration in the first 48 hours of extracorporeal membrane oxygenation, congenital diaphragmatic hernia, and being a preterm neonate. Factors independently associated with lower mortality included meconium aspiration syndrome. Conclusions: Hyperoxia is common during pediatric extracorporeal membrane oxygenation and associated with mortality. Hypocapnia appears to occur less often and although associated with complications, an association with mortality was not observed.	[Cashen, Katherine; Meert, Kathleen L.] Wayne State Univ, Dept Pediat, Childrens Hosp Michigan, Div Crit Care, Detroit, MI 48202 USA; [Reeder, Ron; Dean, J. Michael] Univ Utah, Dept Pediat, Salt Lake City, UT USA; [Dalton, Heidi J.] Inova Fairfax Hosp, Dept Pediat, Falls Church, VA USA; [Berg, Robert A.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Shanley, Thomas P.] Northwestern Univ, Dept Pediat, Ann & Robert H Lurie Childrens Hosp Chicago, Sch Med, Chicago, IL 60611 USA; [Newth, Christopher J. L.] Childrens Hosp Los Angeles, Dept Anesthesiol & Crit Care Med, Los Angeles, CA 90027 USA; [Pollack, Murray M.; Wessel, David] Childrens Natl Med Ctr, Dept Pediat, Washington, DC 20010 USA; [Carcillo, Joseph] Childrens Hosp Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA; [Harrison, Rick] Univ Calif Los Angeles, Dept Pediat, Mattel Childrens Hosp, Los Angeles, CA 90024 USA; [Tamburro, Robert] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediat Trauma & Crit Illness Branch, NIH, Bethesda, MD USA	Meert, KL (corresponding author), Wayne State Univ, Dept Pediat, Childrens Hosp Michigan, Div Crit Care, Detroit, MI 48202 USA.	kmeert@med.wayne.edu		Shanley, Thomas/0000-0001-8936-377X	Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human ServicesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U10HD050096, U10HD049981, U10HD049983, U10HD050012, U10HD063108, U10HD063106, U10HD063114, U01HD049934]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Maquet and Innovative extracorporeal membrane oxygenation (ECMO) Concepts; Springer Publishing; International Pediatric Research Foundation; Raynes McCarty Law Firm; Philips Research North America; Covidien; U.S. Food and Drug Administration Office of Orphan Product Development; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [UG1HD050096, U01HD049934, U10HD063114, U10HD050096, U10HD049983, U10HD050012, U10HD063108, U10HD049981, UG1HD049981, UG1HD063108, U10HD063106] Funding Source: NIH RePORTER	Supported, in part, by the following cooperative agreements from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services: U10HD050096, U10HD049981, U10HD049983, U10HD050012, U10HD063108, U10HD063106, U10HD063114, and U01HD049934.; All authors received support for article research from the National Institutes of Health (NIH). Drs. Reeder's, Berg's, Shanley's, Newth's, Pollack's, and Carcillo's institutions received funding from the National Institute of Child Health and Human Development. Drs. Dalton's, Wessel's, Harrison's, Dean's, and Meert's institutions received funding from the NIH. Dr. Dalton received funding from Maquet and Innovative extracorporeal membrane oxygenation (ECMO) Concepts, and she disclosed off-label product use of ECMO. Dr. Shanley received funding from Springer Publishing, International Pediatric Research Foundation (travel support for biannual meeting), and Raynes McCarty Law Firm. Dr. Newth received funding from Philips Research North America and Covidien. Dr. Tamburro received funding from Springer Publishing; he disclosed government work; and he disclosed receiving grant support from the U.S. Food and Drug Administration Office of Orphan Product Development to study the use of exogenous surfactant in acute lung injury among pediatric hematopoietic cell patients; Ony, Inc. provided the medication free of charge for that trial.	Aufderheide Tom P, 2004, Crit Care Med, V32, pS345, DOI 10.1097/01.CCM.0000134335.46859.09; Bembea Melania M, 2013, J Extra Corpor Technol, V45, P26; Bennett KS, 2013, CRIT CARE MED, V41, P1534, DOI 10.1097/CCM.0b013e318287f54c; Brenner M, 2012, ARCH SURG-CHICAGO, V147, P1042, DOI 10.1001/archsurg.2012.1560; Caputo M, 2009, J THORAC CARDIOV SUR, V138, P206, DOI 10.1016/j.jtcvs.2008.12.028; Dalton HJ, 2017, AM J RESP CRIT CARE, V196, P762, DOI 10.1164/rccm.201609-1945OC; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; del Castillo J, 2012, RESUSCITATION, V83, P1456, DOI 10.1016/j.resuscitation.2012.07.019; Ferguson LP, 2012, CIRCULATION, V126, P335, DOI 10.1161/CIRCULATIONAHA.111.085100; FURNIVAL GM, 1974, TECHNOMETRICS, V16, P499, DOI 10.2307/1267601; Gaies MG, 2014, PEDIATR CRIT CARE ME, V15, P529, DOI 10.1097/PCC.0000000000000153; Gaies MG, 2010, PEDIATR CRIT CARE ME, V11, P234, DOI 10.1097/PCC.0b013e3181b806fc; Guerra-Wallace MM, 2013, PEDIATR CRIT CARE ME, V14, pE143, DOI 10.1097/PCC.0b013e3182720440; Hayes RA, 2013, PERFUSION-UK, V28, P184, DOI 10.1177/0267659112473172; Helmerhorst HJF, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1067-6; Howard TS, 2016, PEDIATR CRIT CARE ME, V17, P1045, DOI 10.1097/PCC.0000000000000943; Kilgannon JH, 2011, CIRCULATION, V123, P2717, DOI 10.1161/CIRCULATIONAHA.110.001016; Kilgannon JH, 2010, JAMA-J AM MED ASSOC, V303, P2165, DOI 10.1001/jama.2010.707; Klinger G, 2005, ARCH DIS CHILD-FETAL, V90, pF49, DOI 10.1136/adc.2003.048785; Man AMES, 2015, ANAESTHESIA, V70, P1307, DOI 10.1111/anae.13218; McDonald CI, 2014, EUR J CARDIO-THORAC, V46, P937, DOI 10.1093/ejcts/ezt637; Munshi L, 2017, CRIT CARE MED, V45, P1997, DOI 10.1097/CCM.0000000000002643; O'Brien NF, 2013, PEDIATR CRIT CARE ME, V14, pE126, DOI 10.1097/PCC.0b013e3182712d62; ORTIZ RM, 1987, PEDIATR CLIN N AM, V34, P39; Pappas A, 2011, J PEDIATR-US, V158, P752, DOI 10.1016/j.jpeds.2010.10.019; Peralta C, 2013, J HEPATOL, V59, P1094, DOI 10.1016/j.jhep.2013.06.017; Pollack MM, 2009, PEDIATRICS, V124, pE18, DOI 10.1542/peds.2008-1987; Quarti A, 2013, PERFUSION-UK, V28, P152, DOI 10.1177/0267659112464382; Ramaiah VK, 2013, CHILD NERV SYST, V29, P629, DOI 10.1007/s00381-012-1984-5; Roberts BW, 2015, RESUSCITATION, V91, P32, DOI 10.1016/j.resuscitation.2015.03.015; Roberts BW, 2013, CIRCULATION, V127, P2107, DOI 10.1161/CIRCULATIONAHA.112.000168; Schneider AG, 2013, RESUSCITATION, V84, P927, DOI 10.1016/j.resuscitation.2013.02.014; SHORT BL, 1993, PEDIATR RES, V33, P289, DOI 10.1203/00006450-199303000-00018; Solaiman O, 2013, J NEUROSURG ANESTH, V25, P254, DOI 10.1097/ANA.0b013e3182806465; Sznycer-Taub NR, 2016, PEDIATR CRIT CARE ME, V17, P350, DOI 10.1097/PCC.0000000000000655; Thiagarajan RR, 2017, ASAIO J, V63, P60, DOI 10.1097/MAT.0000000000000475; Warner KJ, 2007, J TRAUMA, V62, P1330, DOI 10.1097/TA.0b013e31804a8032	37	24	24	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAR	2018	19	3					245	253		10.1097/PCC.0000000000001439			9	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	FY1EK	WOS:000426554400014	29319634	Green Accepted			2021-06-18	
J	Gao, TL; Chen, Z; Chen, H; Yuan, H; Wang, YN; Peng, X; Wei, C; Yang, JX; Xu, CQ				Gao, Tielei; Chen, Zhe; Chen, He; Yuan, Hui; Wang, Yuena; Peng, Xue; Wei, Can; Yang, Jinxia; Xu, Changqing			Inhibition of HMGB1 mediates neuroprotection of traumatic brain injury by modulating the microglia/macrophage polarization	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						Glycyrrhizin; HMGB1; Microglia/macrophage; M1/M2 phenotype; Traumatic brain injury	MACROPHAGE PHENOTYPE; THERAPEUTIC TARGET; GLYCYRRHIZIN; ACTIVATION; INFLAMMATION; EXPRESSION; PROTEIN; REPAIR; CELLS; M1	Microglia/Macrophages have a double-edged role in secondary brain damage after traumatic brain injury (TBI) depending on polarization toward proinflammatory M1 or anti-inflammatory M2 phenotypes. Recently, high-mobility group box 1 (HMGB1) was found to influence the polarization of macrophages. In this study, glycyrrhizin (GL), an inhibitor of HMGB1, was used to investigate whether the inhibition of HMGB1 could modulate microglia/macrophage polarization after TBI. The results showed that treatment with GL improved the neurological function recovery, reduced the lesion volume, and inhibited the release and expression of HMGB1 after TBI. In addition, the administration of GL suppressed M1 phenotype activation and promoted M2 phenotype activation of microglia/macrophages. In conclusion, the results suggested that GL attenuated TBI by inhibiting M1 phenotype while inducing M2 phenotype activation of microglia/macrophages, at least partly through inhibiting HMGB1. Also, targeting HMGB1 to modulate the microglia/macrophage polarization should be one potential therapeutic approach for TBI. (C) 2018 Elsevier Inc. All rights reserved.	[Gao, Tielei; Wei, Can; Yang, Jinxia; Xu, Changqing] Harbin Med Univ, Dept Pathophysiol, 157 Bao Jian Rd, Harbin 150081, Heilongjiang, Peoples R China; [Gao, Tielei; Chen, He; Peng, Xue] Harbin Med Univ, Dept Forens Med, 157 Bao Jian Rd, Harbin 150081, Heilongjiang, Peoples R China; [Chen, Zhe] Gen Hosp, Heilongjiang Land Reclamat Bur, Dept Infect Dis, 235 Ha Shuang Rd, Harbin 150088, Heilongjiang, Peoples R China; [Yuan, Hui] Mudanjiang Med Univ, Dept Med Funct Expt, 3 Tong Xiang Rd, Mudanjiang 157011, Peoples R China; [Wang, Yuena] Harbin Med Univ, Affiliated Hosp 2, Dept Neurosurg, 247 Bao Jian Rd, Harbin 150086, Heilongjiang, Peoples R China	Xu, CQ (corresponding author), Harbin Med Univ, Dept Pathophysiol, 157 Bao Jian Rd, Harbin 150081, Heilongjiang, Peoples R China.	gaotielei8866@126.com; chenzhe810207@sina.com; chenhe_2008@aliyun.com; yuanhui007@163.com; 1004644171@qq.com; flysnow990119@126.com; Canwei528@163.com; Yangjinzia1981@163.com; xucq45@126.com	Wei, Can/AAN-7658-2020	Wei, Can/0000-0003-4291-7653	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81270311]	This research is supported by the National Natural Science Foundation of China (No.81270311).	Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323; Bu W, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00449; Das A, 2015, AM J PATHOL, V185, P2596, DOI 10.1016/j.ajpath.2015.06.001; Fumagalli S, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00081; Gao TL, 2012, J TRAUMA ACUTE CARE, V72, P643, DOI 10.1097/TA.0b013e31823c54a6; Gensel JC, 2015, BRAIN RES, V1619, P1, DOI 10.1016/j.brainres.2014.12.045; Gu XJ, 2014, CHIN J TRAUMATOL, V17, P1, DOI 10.3760/cma.j.issn.1008-1275.2014.01.001; Honda H, 2012, J LEUKOCYTE BIOL, V91, P967, DOI 10.1189/jlb.0112038; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Karuppagounder V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152922; Kim SW, 2012, NEUROBIOL DIS, V46, P147, DOI 10.1016/j.nbd.2011.12.056; Kopitar-Jerala N, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00458; Kumar A, 2016, BRAIN BEHAV IMMUN, V58, P291, DOI 10.1016/j.bbi.2016.07.158; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Mills CD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00212; Mollica L, 2007, CHEM BIOL, V14, P431, DOI 10.1016/j.chembiol.2007.03.007; Okuma Y, 2014, NEUROPHARMACOLOGY, V85, P18, DOI 10.1016/j.neuropharm.2014.05.007; Schaper F, 2016, RHEUMATOLOGY, V55, P2260, DOI 10.1093/rheumatology/kew324; Su ZL, 2016, SCI REP-UK, V6, DOI 10.1038/srep21884; Tian SJ, 2015, AM J PHYSIOL-RENAL, V308, pF69, DOI 10.1152/ajprenal.00484.2014; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Ugrinova I, 2017, ADV PROTEIN CHEM STR, V107, P37, DOI 10.1016/bs.apcsb.2016.10.001; Wang XN, 2015, INT J CLIN EXP MED, V8, P20675; Wu CX, 2015, SHOCK, V43, P412, DOI 10.1097/SHK.0000000000000309; Yang H, 2013, J LEUKOCYTE BIOL, V93, P865, DOI 10.1189/jlb.1212662; Yuan A, 2015, SCI REP-UK, V5, DOI 10.1038/srep14273; ZHAO F, 2017, BIOMED RES INT, V2017, DOI DOI 10.1155/2017/9719647; Zhao Y, 2017, BIOCHEM BIOPH RES CO, V494, P42, DOI 10.1016/j.bbrc.2017.10.088; Zhu LN, 2015, INT REV IMMUNOL, V34, P82, DOI 10.3109/08830185.2014.969421	29	24	26	6	19	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X	1090-2104		BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	FEB 26	2018	497	1					430	436		10.1016/j.bbrc.2018.02.102			7	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	GB5CI	WOS:000429079600064	29448108				2021-06-18	
J	Mayinger, MC; Merchant-Borna, K; Hufschmidt, J; Muehlmann, M; Weir, IR; Rauchmann, BS; Shenton, ME; Koerte, IK; Bazarian, JJ				Mayinger, Michael Christian; Merchant-Borna, Kian; Hufschmidt, Jakob; Muehlmann, Marc; Weir, Isabelle Ruth; Rauchmann, Boris-Stephan; Shenton, Martha Elizabeth; Koerte, Inga Katharina; Bazarian, Jeffrey John			White matter alterations in college football players: a longitudinal diffusion tensor imaging study	BRAIN IMAGING AND BEHAVIOR			English	Article						TBSS; Diffusion tensor imaging; White matter; Longitudinal; High magnitude impact; Sports; Athletics; Subconcussive head trauma; Human studies; Football; Repetitive head impacts; Fractional anisotropy	TRAUMATIC BRAIN-INJURY; PROFESSIONAL SOCCER PLAYERS; SPORTS-RELATED CONCUSSION; HEAD IMPACTS; AXONAL INJURY; DETECTS; DAMAGE; MRI; ENCEPHALOPATHY; EXPOSURE	The aim of this study was to evaluate longitudinal changes in the diffusion characteristics of brain white matter (WM) in collegiate athletes at three time points: prior to the start of the football season (T1), after one season of football (T2), followed by six months of no-contact rest (T3). Fifteen male collegiate football players and 5 male non-athlete student controls underwent diffusion MR imaging and computerized cognitive testing at all three timepoints. Whole-brain tract-based spatial statistics (TBSS) were used to compare fractional anisotropy (FA), radial diffusivity (RD), axial diffusivity (AD), and trace between all timepoints. Average diffusion values were obtained from statistically significant clusters for each individual. No athlete suffered a concussion during the study period. After one season of play (T1 to T2), we observed a significant increase in trace in a cluster located in the brainstem and left temporal lobe, and a significant increase in FA in the left parietal lobe. After six months of no-contact rest (T2 to T3), there was a significant decrease in trace and FA in clusters that were partially overlapping or in close proximity with the initial clusters (T1 to T2), with no significant changes from T1 to T3. Repetitive head impacts (RHI) sustained during a single football season may result in alterations of the brain's WM in collegiate football players. These changes appear to return to baseline after 6 months of no-contact rest, suggesting remission of WM alterations. Our preliminary results suggest that collegiate football players might benefit from periods without exposure to RHI.	[Mayinger, Michael Christian; Koerte, Inga Katharina] Ludwig Maximilians Univ Munchen, Dept Child & Adolescent Psychiat Psychosomat & Ps, Munich, Germany; [Mayinger, Michael Christian; Hufschmidt, Jakob; Muehlmann, Marc; Rauchmann, Boris-Stephan; Shenton, Martha Elizabeth; Koerte, Inga Katharina; Bazarian, Jeffrey John] Harvard Med Sch, Brigham & Womens Hosp, Dept Psychiat, Psychiat Neuroimaging Lab, Boston, MA 02115 USA; [Mayinger, Michael Christian; Hufschmidt, Jakob; Muehlmann, Marc; Rauchmann, Boris-Stephan; Shenton, Martha Elizabeth; Koerte, Inga Katharina; Bazarian, Jeffrey John] Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA; [Merchant-Borna, Kian; Weir, Isabelle Ruth] Univ Rochester, Sch Med & Dent, Emergency Med, Rochester, NY USA; [Hufschmidt, Jakob] Ludwig Maximilians Univ Munchen, Dr von Hauner Childrens Hosp, Dept Pediat Neurol, Munich, Germany; [Muehlmann, Marc; Rauchmann, Boris-Stephan] Ludwig Maximilians Univ Munchen, Inst Clin Radiol, Munich, Germany; [Shenton, Martha Elizabeth] VA Boston Healthcare Syst, Brockton Div, Brockton, MA USA	Koerte, IK (corresponding author), Ludwig Maximilians Univ Munchen, Dept Child & Adolescent Psychiat Psychosomat & Ps, Munich, Germany.; Koerte, IK (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Psychiat, Psychiat Neuroimaging Lab, Boston, MA 02115 USA.; Koerte, IK (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA.	ikoerte@bwh.harvard.edu			National Football League Charities; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM074905] Funding Source: NIH RePORTER	This study was funded in part by the National Football League Charities.	Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bouix S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066205; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Budde MD, 2009, J NEUROSCI, V29, P2805, DOI 10.1523/JNEUROSCI.4605-08.2009; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Darquie A, 2001, P NATL ACAD SCI USA, V98, P9391, DOI 10.1073/pnas.151125698; Davenport E. M., 2016, CONCUSSION 00 CNC19; Dodd AB, 2014, J NEUROTRAUM, V31, P1235, DOI 10.1089/neu.2014.3337; Fedorov A, 2012, MAGN RESON IMAGING, V30, P1323, DOI 10.1016/j.mri.2012.05.001; Fox RJ, 2011, AM J NEURORADIOL, V32, P85, DOI 10.3174/ajnr.A2238; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Grabner G, 2006, LECT NOTES COMPUT SC, V4191, P58; GURDJIAN ES, 1961, SURG GYNECOL OBSTET, V113, P185; Hanggi J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124222; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Iverson GL, 2011, BRAIN INJURY, V25, P1325, DOI 10.3109/02699052.2011.608409; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Koerte IK, 2016, BRAIN IMAGING BEHAV, V10, P792, DOI 10.1007/s11682-015-9442-0; Koerte IK, 2015, J NEUROTRAUM, V32, P1287, DOI 10.1089/neu.2014.3715; Koerte IK, 2015, BRAIN PATHOL, V25, P318, DOI 10.1111/bpa.12249; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kubicki M, 2007, J PSYCHIATR RES, V41, P15, DOI 10.1016/j.jpsychires.2005.05.005; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Li XC, 2013, EUR J RADIOL, V82, pE707, DOI 10.1016/j.ejrad.2013.07.018; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Luker R., 2011, SPORTSBUISNESSDAILY, V14; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matsushita M, 2011, J NEUROSURG, V115, P130, DOI 10.3171/2011.2.JNS101547; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; McGraw KO, 1996, PSYCHOL METHODS, V1, P390, DOI 10.1037//1082-989X.1.4.390; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Ng TSC, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt239; Peled S, 2007, IEEE T MED IMAGING, V26, P1448, DOI 10.1109/TMI.2007.906787; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Reeves AG, 1981, DISORDERS NERVOUS SY; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Sagi Y, 2012, NEURON, V73, P1195, DOI 10.1016/j.neuron.2012.01.025; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shin W, 2014, AM J NEURORADIOL, V35, P285, DOI 10.3174/ajnr.A3676; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; United States Census Bureau, 2009, PART SEL SPORTS ACT; Wang X, 2014, NEUROIMAGE, V88, P32, DOI 10.1016/j.neuroimage.2013.10.066; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	68	24	24	0	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	FEB	2018	12	1					44	53		10.1007/s11682-017-9672-4			10	Neuroimaging	Neurosciences & Neurology	FW4TM	WOS:000425307500005	28092023				2021-06-18	
J	Moszczynski, AJ; Strong, W; Xu, K; McKee, A; Brown, A; Strong, MJ				Moszczynski, Alexander J.; Strong, Wendy; Xu, Kathy; McKee, Ann; Brown, Arthur; Strong, Michael J.			Pathologic Thr(175) tau phosphorylation in CTE and CTE with ALS	NEUROLOGY			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; ALZHEIMER-DISEASE; FIBRIL FORMATION; HYPERPHOSPHORYLATION; INJURY; AGGREGATION; OLIGOMERS; IMPACT	ObjectiveTo investigate whether chronic traumatic encephalopathy (CTE) and CTE with amyotrophic lateral sclerosis (CTE-ALS) exhibit features previously observed in other tauopathies of pathologic phosphorylation of microtubule-associated protein tau at Thr(175) (pThr(175) tau) and Thr(231) (pThr(231) tau), and glycogen synthase kinase-3 (GSK3) activation, and whether these pathologic features are a consequence of traumatic brain injury (TBI).MethodsTau isoform expression was assayed by western blot in 6 stage III CTE cases. We also used immunohistochemistry to analyze 5 cases each of CTE, CTE-ALS, and 5 controls for expression of activated GSK3, pThr(175) tau, pThr(231) tau, and oligomerized tau within spinal cord tissue and hippocampus. Using a rat model of moderate TBI, we assessed tau pathology and phospho-GSK3 expression at 3 months postinjury.ResultsCTE and CTE-ALS are characterized by the presence of all 6 tau isoforms in both soluble and insoluble tau isolates. Activated GSK3, pThr(175) tau, pThr(231) tau, and oligomerized tau protein expression was observed in hippocampal neurons and spinal motor neurons. We observed tau neuronal pathology (fibrillar inclusions and axonal damage) and increased levels of pThr(175) tau and activated GSK3 in moderate TBI rats.ConclusionsPathologic phosphorylation of tau at Thr(175) and Thr(231) and activation of GSK3 are features of the tauopathy of CTE and CTE-ALS. These features can be replicated in an animal model of moderate TBI.	[Moszczynski, Alexander J.; Strong, Wendy; Xu, Kathy; Brown, Arthur; Strong, Michael J.] Western Univ, Schulich Sch Med & Dent, Mol Med Res Grp, Robarts Res Inst, London, ON, Canada; [Strong, Michael J.] Western Univ, Schulich Sch Med & Dent, Dept Clin Neurol Sci, London, ON, Canada; [McKee, Ann] Boston Univ, Sch Med, Alzheimers Dis & CTE Ctr, VA Boston Healthcare Syst, Boston, MA 02215 USA	Strong, MJ (corresponding author), Western Univ, Schulich Sch Med & Dent, Mol Med Res Grp, Robarts Res Inst, London, ON, Canada.; Strong, MJ (corresponding author), Western Univ, Schulich Sch Med & Dent, Dept Clin Neurol Sci, London, ON, Canada.	mstrong@uwo.ca	Strong, Michael/AAU-5699-2020; Strong, Michael J/H-9689-2012; Lang, Steven/AAE-8102-2021; Brown, Arthur/K-8328-2013	Strong, Michael/0000-0003-1988-6262; Lang, Steven/0000-0003-1669-9146; Brown, Arthur/0000-0002-8725-3195	Ontario Neurodegenerative Disease Research Initiative; Windsor-Essex ALS Society; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER	Research supported by an operating grant from the Ontario Neurodegenerative Disease Research Initiative and the Windsor-Essex ALS Society.	Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; BueeScherrer V, 1996, ACTA NEUROPATHOL, V91, P351, DOI 10.1007/s004010050436; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; Delacourte A, 1996, J NEUROPATH EXP NEUR, V55, P159, DOI 10.1097/00005072-199602000-00004; Delacourte A, 1998, ANN NEUROL, V43, P193, DOI 10.1002/ana.410430209; Foote Molly, 2012, Int J Biochem Mol Biol, V3, P152; GARRUTO RM, 1991, NEUROTOXICOLOGY, V12, P347; Gohar M, 2009, J NEUROCHEM, V108, P634, DOI 10.1111/j.1471-4159.2008.05791.x; Hanger DP, 1998, J NEUROCHEM, V71, P2465; HIRANO A, 1961, BRAIN, V84, P662, DOI 10.1093/brain/84.4.662; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lasagna-Reeves CA, 2012, FASEB J, V26, P1946, DOI 10.1096/fj.11-199851; Li DW, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00290; Lin YT, 2007, J NEUROCHEM, V103, P802, DOI 10.1111/j.1471-4159.2007.04792.x; Mattsson N, 2009, JAMA-J AM MED ASSOC, V302, P385, DOI 10.1001/jama.2009.1064; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Moszczynski AJ, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-016-0406-4; Moszczynski AJ, 2015, NEUROBIOL AGING, V36, P1590, DOI 10.1016/j.neurobiolaging.2014.12.001; Nakamura K, 2013, PRION, V7, P117, DOI 10.4161/pri.22849; Perry DC, 2016, J NEUROSURG, V124, P511, DOI 10.3171/2015.2.JNS14503; Planel E, 2004, J NEUROSCI, V24, P2401, DOI 10.1523/JNEUROSCI.5561-03.2004; Schwalbe M, 2015, STRUCTURE, V23, P1448, DOI 10.1016/j.str.2015.06.002; Strong MJ, 2006, NEUROLOGY, V66, P1770, DOI 10.1212/01.wnl.0000218161.15834.db; Tartaglia MC, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00030; Thomsen GM, 2016, J TRAUMA ACUTE CARE, V81, P1070, DOI 10.1097/TA.0000000000001248; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; Ward SM, 2012, BIOCHEM SOC T, V40, P667, DOI 10.1042/BST20120134; Yang WC, 2005, DEV BRAIN RES, V156, P127, DOI 10.1016/j.devbrainres.2005.02.004; Yang WC, 2012, AMYOTROPH LATERAL SC, V13, P178, DOI 10.3109/17482968.2011.622405	34	24	24	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JAN 30	2018	90	5					E380	+		10.1212/WNL.0000000000004899			9	Clinical Neurology	Neurosciences & Neurology	FZ7RQ	WOS:000427799000004	29298849	Green Published, Other Gold			2021-06-18	
J	Mutch, WAC; Ellis, MJ; Ryner, LN; McDonald, PJ; Morissette, MP; Pries, P; Essig, M; Mikulis, DJ; Duffin, J; Fisher, JA				Mutch, W. Alan C.; Ellis, Michael J.; Ryner, Lawrence N.; McDonald, Patrick J.; Morissette, Marc P.; Pries, Philip; Essig, Marco; Mikulis, David J.; Duffin, James; Fisher, Joseph A.			Patient-Specific Alterations in CO2 Cerebrovascular Responsiveness in Acute and Sub-Acute Sports-Related Concussion	FRONTIERS IN NEUROLOGY			English	Article						sports-related concussion; adolescent; magnetic resonance imaging; blood oxygen level dependent imaging; cerebrovascular reactivity	PROSPECTIVE MOTION CORRECTION; TRAUMATIC BRAIN-INJURY; BLOOD-FLOW ALTERATIONS; RECOVERY-TIME; REACTIVITY MEASURES; CLINICAL RECOVERY; CARBON-DIOXIDE; HIGH-SCHOOL; BOLD MRI; MANAGEMENT	Background: Preliminary studies suggest that sports-related concussion (SRC) is associated with alterations in cerebral blood flow (CBF) regulation. Here, we use advanced magnetic resonance imaging (MRI) techniques to measure CBF and cerebrovascular responsiveness (CVR) in individual SRC patients and healthy control subjects. Methods: 15 SRC patients (mean age = 16.3, range 14-20 years) and 27 healthy control subjects (mean age = 17.6, range 13-21 years) underwent anatomical MRI, pseudo-continuous arterial spin labeling (pCASL) MRI and model-based prospective end-tidal targeting (MPET) of CO2 during blood oxygenation level-dependent (BOLD) MRI. Group differences in global mean resting CBF were examined. Voxel-by-voxel group and individual differences in regional CVR were examined using statistical parametric mapping (SPM). Leave-one-out receiver operating characteristic curve analysis was used to evaluate the utility of brain MRI CO2 stress testing biomarkers to correctly discriminate between SRC patients and healthy control subjects. Results: All studies were tolerated with no complications. Traumatic structural findings were identified in one SRC patient. No significant group differences in global mean resting CBF were observed. There were no significant differences in the CO2 stimulus and O-2 targeting during BOLD MRI. Significant group and patient-specific differences in CVR were observed with SRC patients demonstrating a predominant pattern of increased CVR. Leave-one-out ROC analysis for voxels demonstrating a significant increase in CVR was found to reliably discriminate between SRC patients and healthy control subjects (AUC of 0.879, p = 0.0001). The optimal cutoff for increased CVR declarative for SRC was 1,899 voxels resulting in a sensitivity of 0.867 and a specificity of 0.778 for this specific ROC analysis. There was no correlation between abnormal voxel counts and Postconcussion Symptom Scale scores among SRC patients. Conclusion: Acute and subacute SRCs are associated with alterations in CVR that can be reliably detected by brain MRI CO2 stress testing in individual patients.	[Mutch, W. Alan C.] Univ Manitoba, Dept Anesthesia & Perioperat Med, Winnipeg, MB, Canada; [Mutch, W. Alan C.; Ellis, Michael J.; Ryner, Lawrence N.; McDonald, Patrick J.; Essig, Marco] Univ Manitoba, Winnipeg, MB, Canada; [Mutch, W. Alan C.; Ellis, Michael J.; Ryner, Lawrence N.; McDonald, Patrick J.; Essig, Marco] Univ Manitoba, Canada North Concuss Network, Winnipeg, MB, Canada; [Ellis, Michael J.] Univ Manitoba, Dept Surg & Pediat & Child Hlth, Winnipeg, MB, Canada; [Ellis, Michael J.] Univ Manitoba, Sect Neurosurg, Winnipeg, MB, Canada; [Ellis, Michael J.; Essig, Marco] Univ Manitoba, Pan Am Concuss Program, Winnipeg, MB, Canada; [Ellis, Michael J.] Univ Manitoba, Childrens Hosp, Res Inst Manitoba, Winnipeg, MB, Canada; [Ryner, Lawrence N.; Essig, Marco] Univ Manitoba, Dept Radiol Diagnost Imaging, Winnipeg, MB, Canada; [McDonald, Patrick J.] Univ British Columbia, BC Childrens Hosp, Div Neurosurg, Natl Core Neuroeth, Vancouver, BC, Canada; [Morissette, Marc P.] Pan Am Clin Fdn, Winnipeg, MB, Canada; [Pries, Philip] Univ Manitoba, Max Rady Coll Med, Winnipeg, MB, Canada; [Mikulis, David J.] Univ Toronto, Dept Med Imaging, Toronto, ON, Canada; [Mikulis, David J.; Duffin, James; Fisher, Joseph A.] Univ Toronto, Toronto, ON, Canada; [Mikulis, David J.; Duffin, James; Fisher, Joseph A.] Univ Hlth Network, Cerebrovasc React Res Grp, Toronto, ON, Canada; [Duffin, James] Univ Toronto, Dept Physiol, Toronto, ON, Canada; [Duffin, James; Fisher, Joseph A.] Univ Toronto, Dept Anesthesia, Toronto, ON, Canada	Mutch, WAC (corresponding author), Univ Manitoba, Dept Anesthesia & Perioperat Med, Winnipeg, MB, Canada.; Mutch, WAC (corresponding author), Univ Manitoba, Winnipeg, MB, Canada.; Mutch, WAC (corresponding author), Univ Manitoba, Canada North Concuss Network, Winnipeg, MB, Canada.	wacmutch@shaw.ca	Mikulis, David J/H-5167-2019	Morissette, Marc/0000-0002-5342-8938; essig, marco/0000-0002-7964-2297; Mikulis, David/0000-0003-3956-0892	Health Sciences Center Foundation; Manitoba Health Research Council; University of Manitoba Department of Surgery, Winnipeg, MB, Canada	All phases of this study were supported by grants from the Health Sciences Center Foundation, the Manitoba Health Research Council and the University of Manitoba Department of Surgery, Winnipeg, MB, Canada.	Bhogal AA, 2015, NEUROIMAGE, V114, P239, DOI 10.1016/j.neuroimage.2015.04.014; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Davis GA, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097415; Duffin J, 2015, NEUROIMAGE, V114, P207, DOI 10.1016/j.neuroimage.2015.04.029; Ellis MJ, 2017, CAN J NEUROL SCI, V44, P24, DOI 10.1017/cjn.2016.312; Ellis MJ, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00136; Ellis MJ, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00061; Fierstra J, 2013, J PHYSIOL-LONDON, V591, P5809, DOI 10.1113/jphysiol.2013.259150; Fisher JA, 2017, HUM BRAIN MAPP, V38, P3415, DOI 10.1002/hbm.23598; Giza CC, 2001, J ATHL TRAINING, V36, P228; HOSKINS PR, 1990, CLIN PHYS PHYSIOL M, V11, P1, DOI 10.1088/0143-0815/11/1/001; Ito S, 2008, J PHYSIOL-LONDON, V586, P3675, DOI 10.1113/jphysiol.2008.154716; Iverson GL, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097729; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Leddy JJ, 2013, CURR SPORT MED REP, V12, P370, DOI 10.1249/JSR.0000000000000008; Len TK, 2013, BRAIN INJURY, V27, P346, DOI 10.3109/02699052.2012.743185; Len TK, 2011, MED SCI SPORT EXER, V43, P2241, DOI 10.1249/MSS.0b013e3182249539; Leung J, 2016, J MAGN RESON IMAGING, V43, P1191, DOI 10.1002/jmri.25063; Losoi H, 2015, J NEUROTRAUM, V32, P942, DOI 10.1089/neu.2014.3799; Mark CI, 2010, MAGN RESON MED, V64, P749, DOI 10.1002/mrm.22405; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097447; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Militana AR, 2016, BRAIN IMAGING BEHAV, V10, P559, DOI 10.1007/s11682-015-9407-3; Mutch WAC, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00107; Mutch WAC, 2016, J NEUROSURG, V125, P648, DOI 10.3171/2015.6.JNS15972; Mutch WAC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047443; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; Prisman E, 2008, J MAGN RESON IMAGING, V27, P185, DOI 10.1002/jmri.21102; Sobczyk O, 2016, AM J NEURORADIOL, V37, P818, DOI 10.3174/ajnr.A4679; Sobczyk O, 2015, J CEREBR BLOOD F MET, V35, P213, DOI 10.1038/jcbfm.2014.184; Spano VR, 2013, RADIOLOGY, V266, P592, DOI 10.1148/radiol.12112795; Stock M, 2006, MED PHYS, V33, P2868, DOI 10.1118/1.2219775; Tanenbaum AB, 2015, J CEREBR BLOOD F MET, V35, P1697, DOI 10.1038/jcbfm.2015.124; Thomas BP, 2013, NEUROIMAGE, V83, P505, DOI 10.1016/j.neuroimage.2013.07.005; Turner BO, 2015, BRAIN IMAGING BEHAV, V9, P115, DOI 10.1007/s11682-014-9351-7; Wang Y, 2016, J NEUROTRAUM, V33, P1227, DOI 10.1089/neu.2015.4072; Williams RM, 2015, SPORTS MED, V45, P893, DOI 10.1007/s40279-015-0325-8; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; Yuh Esther L, 2014, Neurosurgery, V75 Suppl 4, pS50, DOI 10.1227/NEU.0000000000000491; Zaitsev M, 2017, NEUROIMAGE, V154, P33, DOI 10.1016/j.neuroimage.2016.11.014; Zun ZH, 2014, MAGN RESON MED, V72, P1049, DOI 10.1002/mrm.25024	45	24	24	0	7	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	JAN 24	2018	9								23	10.3389/fneur.2018.00023			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	FT5KH	WOS:000423191900001	29416525	DOAJ Gold, Green Published			2021-06-18	
J	Szarka, N; Pabbidi, MR; Amrein, K; Czeiter, E; Berta, G; Pohoczky, K; Helyes, Z; Ungvari, Z; Koller, A; Buki, A; Toth, P				Szarka, Nikolett; Pabbidi, Mallikarjuna R.; Amrein, Krisztina; Czeiter, Endre; Berta, Gergely; Pohoczky, Krisztina; Helyes, Zsuzsanna; Ungvari, Zoltan; Koller, Akos; Buki, Andras; Toth, Peter			Traumatic Brain Injury Impairs Myogenic Constriction of Cerebral Arteries: Role of Mitochondria-Derived H2O2 and TRPV4-Dependent Activation of BKca Channels	JOURNAL OF NEUROTRAUMA			English	Article						autoregulation; intracranial hypertension; oxidative stress; secondary injury	BLOOD-FLOW; HYDROGEN-PEROXIDE; SMOOTH-MUSCLE; NITRIC-OXIDE; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; AUTO-REGULATION; ANGIOTENSIN-II; AUTOREGULATION; DYSFUNCTION	Traumatic brain injury (TBI) impairs autoregulation of cerebral blood flow, which contributes to the development of secondary brain injury, increasing mortality of patients. Impairment of pressure-induced myogenic constriction of cerebral arteries plays a critical role in autoregulatory dysfunction; however, the underlying cellular and molecular mechanisms are not well understood. To determine the role of mitochondria-derived H2O2 and large-conductance calcium-activated potassium channels (BKCa) in myogenic autoregulatory dysfunction, middle cerebral arteries (MCAs) were isolated from rats with severe weight drop-impact acceleration brain injury. We found that 24 h post-TBI MCAs exhibited impaired myogenic constriction, which was restored by treatment with a mitochondria-targeted antioxidant (mitoTEMPO), by scavenging of H2O2 (polyethylene glycol [PEG]-catalase) and by blocking both BKCa channels (paxilline) and transient receptor potential cation channel subfamily V member 4 (TRPV4) channels (HC 067047). Further, exogenous administration of H2O2 elicited significant dilation of MCAs, which was inhibited by blocking either BKCa or TRPV4 channels. Vasodilation induced by the TRPV4 agonist GSK1016790A was inhibited by paxilline. In cultured vascular smooth muscle cells H2O2 activated BKCa currents, which were inhibited by blockade of TRPV4 channels. Collectively, our results suggest that after TBI, excessive mitochondria-derived H2O2 activates BKCa channels via a TRPV4-dependent pathway in the vascular smooth muscle cells, which impairs pressure-induced constriction of cerebral arteries. Future studies should elucidate the therapeutic potential of pharmacological targeting of this pathway in TBI, to restore autoregulatory function in order to prevent secondary brain damage and decrease mortality.	[Szarka, Nikolett; Amrein, Krisztina; Czeiter, Endre; Koller, Akos; Buki, Andras; Toth, Peter] Univ Pecs, Med Sch, Cerebrovasc Lab, Dept Neurosurg, Pecs, Hungary; [Amrein, Krisztina; Czeiter, Endre; Buki, Andras] Univ Pecs, Med Sch, Janos Szentagothai Res Ctr, Neurotrauma Res Grp, Pecs, Hungary; [Szarka, Nikolett; Toth, Peter] Univ Pecs, Med Sch, Dept Translat Med, Pecs, Hungary; [Berta, Gergely] Univ Pecs, Med Sch, Dept Med Biol, Pecs, Hungary; [Pohoczky, Krisztina; Helyes, Zsuzsanna] Univ Pecs, Med Sch, Dept Pharmacol & Pharmacotherapy, Pecs, Hungary; [Pabbidi, Mallikarjuna R.] Univ Mississippi, Med Ctr, Dept Pharmacol & Toxicol, Jackson, MS 39216 USA; [Czeiter, Endre; Toth, Peter] MTA PTE Clin Neurosci MR Res Grp, Pecs, Hungary; [Pohoczky, Krisztina; Helyes, Zsuzsanna] MTA PTE NAP B Chron Pain Res Grp, Pecs, Hungary; [Ungvari, Zoltan; Toth, Peter] Univ Oklahoma, Hlth Sci Ctr, Donald W Reynolds Dept Geriatr Med, Reynolds Oklahoma Ctr Aging, Oklahoma City, OK USA; [Koller, Akos] Univ Phys Educ, Inst Nat Sci, Budapest, Hungary; [Koller, Akos] New York Med Coll, Dept Physiol, Valhalla, NY 10595 USA	Toth, P (corresponding author), Univ Pecs, Dept Neurosurg, 2 Ret St, H-7624 Pecs, Hungary.	peter-toth@ouhsc.edu	Czeiter, Endre/B-1404-2009; Akos, Koller/Q-4672-2019	Czeiter, Endre/0000-0002-9578-6944	Marie Curie Actions SMARTER 7th Framework Program of the European Union [606998]; Hungarian Academy of Sciences Bolyai Research Scholarship [BO/00634/15]; PTE AOK-KA [3/2016 04.01/F]; National Research, Development and Innovation OfficeNational Research, Development & Innovation Office (NRDIO) - Hungary [NKFI-FK123798, K108444]; UNKP [UNKP-17-4-I-PTE-7]; Hungarian National Brain Research Program [KTIA_13_NAP-A-II/8]; American Heart AssociationAmerican Heart Association [13SDG14000005]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-AT006526, R01-AG047879, R01-AG038747, 3P30AG050911-02S1, R01-NS056218]; Oklahoma Center for the Advancement of Science and Technology;  [GINOP-2.3, 2-15-2016-00048];  [AOK-Post-Doc 3/2012 07.25/C];  [B KTIA_NAP_13-2014-0022];  [888819]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS100782] Funding Source: NIH RePORTER	This work was supported by grants from the Marie Curie Actions SMARTER 7th Framework Program of the European Union 606998 to N.S. and A.K.; the Hungarian Academy of Sciences Bolyai Research Scholarship BO/00634/15 to P.T.; the PTE AOK-KA 3/2016 04.01/F to P.T.; grants from the National Research, Development and Innovation Office to P.T. (NKFI-FK123798) and A.K. (K108444); the UNKP UNKP-17-4-I-PTE-7 Scholarship to P.T.; GINOP-2.3, 2-15-2016-00048 to P.T., E.C., A.B.; AOK-Post-Doc 3/2012 07.25/C to G.B.; the Hungarian National Brain Research Program Grant No. KTIA_13_NAP-A-II/8 to P.T., E.C., and A.B.; Program B KTIA_NAP_13-2014-0022, Research site ID number: 888819 to Z.H.; the American Heart Association to M.R.P. (13SDG14000005), P.T., and Z.U.; the National Institutes of Health R01-AT006526, R01-AG047879, R01-AG038747, 3P30AG050911-02S1, and R01-NS056218 to Z.U.; and the Oklahoma Center for the Advancement of Science and Technology to Z.U. This work is dedicated to the 650th anniversary of the University of Pecs.	Arent AM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/723060; Armstead WM, 2011, J NEUROTRAUM, V28, P105, DOI 10.1089/neu.2010.1581; Bailey-Downs LC, 2012, J GERONTOL A-BIOL, V67, P553, DOI 10.1093/gerona/glr197; Barlow RS, 2000, AM J PHYSIOL-HEART C, V279, pH475; Boveris A, 2000, IUBMB LIFE, V50, P245, DOI 10.1080/15216540051080912; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; Bubolz AH, 2012, AM J PHYSIOL-HEART C, V302, pH634, DOI 10.1152/ajpheart.00717.2011; Budohoski KP, 2012, NEUROSURGERY, V71, P652, DOI 10.1227/NEU.0b013e318260feb1; Budohoski KP, 2012, NEUROCRIT CARE, V17, P211, DOI 10.1007/s12028-011-9572-1; Cao Y, 2016, BMC NEUROSCI, V17, DOI 10.1186/s12868-016-0251-1; Case AJ, 2013, AM J PHYSIOL-HEART C, V305, pH19, DOI 10.1152/ajpheart.00974.2012; Chaplin NL, 2012, CHANNELS, V6, P385, DOI 10.4161/chan.21708; COLD GE, 1978, ACTA ANAESTH SCAND, V22, P270, DOI 10.1111/j.1399-6576.1978.tb01301.x; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; Drose S, 2016, BBA-BIOENERGETICS, V1857, P946, DOI 10.1016/j.bbabio.2015.12.013; Earley S, 2005, CIRC RES, V97, P1270, DOI 10.1161/01.RES.0000194321.60300.d6; Earley S, 2009, AM J PHYSIOL-HEART C, V297, pH1096, DOI 10.1152/ajpheart.00241.2009; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; ENEVOLDSEN EM, 1977, ACTA NEUROL SCAND, V56, P514; Engelborghs K, 2000, J NEUROTRAUM, V17, P667, DOI 10.1089/089771500415418; Gidday JM, 1999, J NEUROTRAUM, V16, P27, DOI 10.1089/neu.1999.16.27; Golding EM, 1998, J NEUROTRAUM, V15, P973, DOI 10.1089/neu.1998.15.973; Greensmith DJ, 2010, CELL CALCIUM, V48, P341, DOI 10.1016/j.ceca.2010.10.007; Guikema BJ, 2005, FREE RADICAL BIO MED, V38, P597, DOI 10.1016/j.freeradbiomed.2004.11.022; Hayabuchi Y, 1998, HEART VESSELS, V13, P9, DOI 10.1007/BF02750638; Iida Y, 2000, STROKE, V31, P2224, DOI 10.1161/01.STR.31.9.2224; Jullienne A, 2016, J NEUROSCI RES, V94, P609, DOI 10.1002/jnr.23732; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kasemsri T, 1997, STROKE, V28, P190, DOI 10.1161/01.STR.28.1.190; Kenney K, 2016, EXP NEUROL, V275, P353, DOI 10.1016/j.expneurol.2015.05.019; Kim JJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163433; Kisler K, 2017, NAT REV NEUROSCI, V18, P419, DOI 10.1038/nrn.2017.48; KNOT HJ, 1995, AM J PHYSIOL-HEART C, V269, pH348; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P187, DOI 10.1097/00001199-200505000-00001; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Liu YP, 2003, CIRC RES, V93, P573, DOI 10.1161/01.RES.0000091261.19387.AE; Lopez-Fabuel I, 2016, P NATL ACAD SCI USA, V113, P13063, DOI 10.1073/pnas.1613701113; Manucha W, 2017, CLIN INVEST ARTERIOS, V29, P92, DOI 10.1016/j.arteri.2016.04.002; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mathew BP, 1999, J NEUROTRAUM, V16, P1177, DOI 10.1089/neu.1999.16.1177; Matoba T, 2000, J CLIN INVEST, V106, P1521, DOI 10.1172/JCI10506; Modrick ML, 2009, J CEREBR BLOOD F MET, V29, P1130, DOI 10.1038/jcbfm.2009.37; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; Newell DW, 1997, ACTA NEUROCHIR, V139, P804, DOI 10.1007/BF01411398; OVERGAARD J, 1974, 1 CEREBRAL BLOOD FLO, V41, P531; Paterno R, 2000, AM J PHYSIOL-HEART C, V278, pH2003; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Price Raymond S, 2014, Handb Clin Neurol, V119, P161, DOI 10.1016/B978-0-7020-4086-3.00012-6; Randhawa PK, 2015, BASIC RES CARDIOL, V110, DOI 10.1007/s00395-015-0512-7; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Salvucci A, 2000, BRAIN RES, V887, P406, DOI 10.1016/S0006-8993(00)03079-1; Springo Z, 2015, J GERONTOL A-BIOL, V70, P1355, DOI 10.1093/gerona/glu244; Suresh K, 2015, AM J PHYSIOL-LUNG C, V309, pL1467, DOI 10.1152/ajplung.00275.2015; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Toth P, 2017, AM J PHYSIOL-HEART C, V312, pH1, DOI 10.1152/ajpheart.00581.2016; Toth P, 2014, J CEREBR BLOOD F MET, V34, P1887, DOI 10.1038/jcbfm.2014.156; Toth P, 2013, J CEREBR BLOOD F MET, V33, P1732, DOI 10.1038/jcbfm.2013.143; Toth P, 2011, J CEREBR BLOOD F MET, V31, P2096, DOI 10.1038/jcbfm.2011.74; Ungvari Z, 1999, STROKE, V30, P1949, DOI 10.1161/01.STR.30.9.1949; Ungvari Z, 2001, J APPL PHYSIOL, V91, P522; Villalba N, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001474; Wang F, 2014, NEUROTOXICOLOGY, V41, P54, DOI 10.1016/j.neuro.2014.01.002; Wang JN, 2012, FREE RADICAL BIO MED, V52, P173, DOI 10.1016/j.freeradbiomed.2011.10.442; Zhang DX, 2012, CIRC RES, V110, P471, DOI 10.1161/CIRCRESAHA.111.258871; Zimmerman MC, 2002, CIRC RES, V91, P1038, DOI 10.1161/01.RES.0000043501.47934.FA	71	24	25	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2018	35	7					930	939		10.1089/neu.2017.5056		JAN 2018	10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GC0NF	WOS:000419902500001	29179622	Green Published			2021-06-18	
J	Aucott, H; Lundberg, J; Salo, H; Klevenvall, L; Damberg, P; Ottosson, L; Andersson, U; Holmin, S; Harris, HE				Aucott, Hannah; Lundberg, Johan; Salo, Henna; Klevenvall, Lena; Damberg, Peter; Ottosson, Lars; Andersson, Ulf; Holmin, Staffan; Harris, Helena Erlandsson			Neuroinflammation in Response to Intracerebral Injections of Different HMGB1 Redox Isoforms	JOURNAL OF INNATE IMMUNITY			English	Article						HMGB1; Brain; Redox; Neuroinflammation; Blood-brain barrier	ISCHEMIC BRAIN-DAMAGE; GROUP BOX-1 HMGB1; PROINFLAMMATORY CYTOKINE; NLRP3 INFLAMMASOME; NERVOUS-SYSTEM; DANGER SIGNALS; ALARMIN HMGB1; RECEPTOR 4; MOBILITY; INJURY	Background: Neuroinflammation triggered by infection or trauma is the cause of central nervous system dysfunction. High-mobility group box 1 protein (HMGB1), released from stressed and dying brain cells, is a potent neuroinflammatory mediator. The proinflammatory functions of HMGB1 are tightly regulated by post-translational redox modifications, and we here investigated detailed neuroinflammatory responses induced by the individual redox isoforms. Methods: Male Dark Agouti rats received a stereotactic injection of saline, lipopolysaccharide, disulfide HMGB1, or fully reduced HMGB1, and were accessed for blood-brain barrier modifications using magnetic resonance imaging (MRI) and inflammatory responses by immunohistochemistry. Results and Conclusions: Significant blood-brain barrier disruption appeared 24 h after injection of lipopolysaccharide, disulfide HMGB1, or fully reduced HMGB1 compared to controls, as assessed in post-gadolinium T1-weighted MRI images and confirmed by increased uptake of FITC-conjugated dextran. Immunohistochemistry revealed that both HMGB1 isoforms also induced a local production of IL-1 beta. Additionally, disulfide HMGB1 increased major histocompatibility complex class II expression and apoptosis. Together, the results demonstrate that extracellular, cerebral HMGB1 causes significant blood-brain barrier disruption in a redox-independent manner and activates several components of neuroinflammation. Blocking HMGB1 might potentially improve clinical outcome in conditions such as stroke and traumatic brain injury. (C) 2018 The Author(s) Published by S. Karger AG, Basel	[Aucott, Hannah; Salo, Henna; Harris, Helena Erlandsson] Karolinska Inst, Ctr Mol Med, Dept Med Solna, Rheumatol Unit, Stockholm, Sweden; [Lundberg, Johan; Damberg, Peter; Holmin, Staffan] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Lundberg, Johan; Holmin, Staffan] Karolinska Univ Hosp, Dept Neuroradiol, Stockholm, Sweden; [Klevenvall, Lena; Ottosson, Lars; Andersson, Ulf] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden	Aucott, H (corresponding author), Karolinska Inst Solna, Karolinska Hosp, Ctr Mol Med L8 04, Rheumatol Unit,Dept Med, SE-17176 Stockholm, Sweden.	hannah.aucott@ki.se		Holmin, Staffan/0000-0002-1628-1615; Andersson, Ulf/0000-0003-0316-3860	Soderberg Foundation; Swedish Heart and Lung AssociationSwedish Heart-Lung Foundation; Linne Center CERIC; Stockholm County Council (SLL)Stockholm County Council; Karolinska InstitutetKarolinska Institutet	The authors would like to thank the staff at the Department of Comparative Medicine, Karolinska Institutet, in particular Kicki Edwardsson, for technique assistance. This work was supported by grants from the Soderberg Foundation, the Swedish Heart and Lung Association, The Linne Center CERIC, Karolinska Institutet, and Stockholm County Council (SLL).	Agalave NM, 2014, PAIN, V155, P1802, DOI 10.1016/j.pain.2014.06.007; Agnello D, 2002, CYTOKINE, V18, P231, DOI 10.1006/cyto.2002.0890; Balosso S, 2014, ANTIOXID REDOX SIGN, V21, P1726, DOI 10.1089/ars.2013.5349; Boutin H, 2001, J NEUROSCI, V21, P5528; Caso JR, 2007, CIRCULATION, V115, P1599, DOI 10.1161/CIRCULATIONAHA.106.603431; Fournier T, 2000, BBA-PROTEIN STRUCT M, V1482, P157, DOI 10.1016/S0167-4838(00)00153-9; Frank MG, 2016, BRAIN BEHAV IMMUN, V55, P215, DOI 10.1016/j.bbi.2015.10.009; GARCIA JH, 1995, AM J PATHOL, V147, P1477; Gelderblom M, 2015, AGEING RES REV, V24, P77, DOI 10.1016/j.arr.2015.07.004; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Hreggvidsdottir HS, 2009, J LEUKOCYTE BIOL, V86, P655, DOI 10.1189/jlb.0908548; Kim JB, 2008, J NEUROSCI RES, V86, P1125, DOI 10.1002/jnr.21555; Kim JB, 2006, J NEUROSCI, V26, P6413, DOI 10.1523/JNEUROSCI.3815-05.2006; Lian YJ, 2017, BRAIN BEHAV IMMUN, V59, P322, DOI 10.1016/j.bbi.2016.09.017; Liesz A, 2015, J NEUROSCI, V35, P583, DOI 10.1523/JNEUROSCI.2439-14.2015; Liu K, 2007, FASEB J, V21, P3904, DOI 10.1096/fj.07-8770com; Muhammad S, 2008, J NEUROSCI, V28, P12023, DOI 10.1523/JNEUROSCI.2435-08.2008; Norden DM, 2015, NEUROPHARMACOLOGY, V96, P29, DOI 10.1016/j.neuropharm.2014.10.028; O'Connor KA, 2003, CYTOKINE, V24, P254, DOI 10.1016/j.cyto.2003.08.001; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467; Rosset A, 2004, J DIGIT IMAGING, V17, P205, DOI 10.1007/s10278-004-1014-6; Sasaki T, 2016, EXP NEUROL, V275, P220, DOI 10.1016/j.expneurol.2015.11.003; Schiraldi M, 2012, J EXP MED, V209, P551, DOI 10.1084/jem.20111739; Singh V, 2016, ANTIOXID REDOX SIGN, V24, P635, DOI 10.1089/ars.2015.6397; Tang YT, 2016, ANTIOXID REDOX SIGN, V24, P620, DOI 10.1089/ars.2015.6409; Terrando N, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00441; Thundyil J, 2015, AGEING RES REV, V24, P17, DOI 10.1016/j.arr.2014.11.003; Venereau E, 2013, MOL IMMUNOL, V55, P76, DOI 10.1016/j.molimm.2012.10.037; Venereau E, 2012, J EXP MED, V209, P1519, DOI 10.1084/jem.20120189; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Weber MD, 2015, J NEUROSCI, V35, P316, DOI 10.1523/JNEUROSCI.3561-14.2015; Yamasoba D, 2016, J PHARMACOL SCI, V130, P139, DOI 10.1016/j.jphs.2016.01.005; Yang H, 2012, MOL MED, V18, P250, DOI 10.2119/molmed.2011.00389; Yang HA, 2010, P NATL ACAD SCI USA, V107, P11942, DOI 10.1073/pnas.1003893107; Yang QW, 2011, J CEREBR BLOOD F MET, V31, P593, DOI 10.1038/jcbfm.2010.129; Zandarashvili L, 2013, J BIOL CHEM, V288, P11621, DOI 10.1074/jbc.M113.449942; Zhang JY, 2011, STROKE, V42, P1420, DOI 10.1161/STROKEAHA.110.598334; Zou JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087915	40	24	24	0	12	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1662-811X	1662-8128		J INNATE IMMUN	J. Innate Immun.		2018	10	3					215	227		10.1159/000487056			13	Immunology	Immunology	GK2KR	WOS:000435959200007	29478057	Green Published, Other Gold			2021-06-18	
J	Erdodi, LA; Pelletier, CL; Roth, RM				Erdodi, Laszlo A.; Pelletier, Chantalle L.; Roth, Robert M.			Elevations on select Conners' CPT-II scales indicate noncredible responding in adults with traumatic brain injury	APPLIED NEUROPSYCHOLOGY-ADULT			English	Article						Conners' CPT-II; embedded validity indicators; performance validity testing; traumatic brain injury	RECOGNITION MEMORY TEST; PERFORMANCE TEST-II; CLOSED-HEAD-INJURY; OFFICIAL POSITION; SYMPTOM VALIDITY; BIAS; CUTOFFS; SCORES; TIME; RECOMMENDATIONS	Elevations on certain Conners' CPT-II scales are known to be associated with invalid responding. However, scales and cutoffs vary across studies. In addition, the methodology behind developing performance validity tests (PVTs) has been challenged for mistaking true impairment for noncredible presentation. Using ability-based tests as a PVT makes clinicians especially vulnerable to this criticism. The present study examined the ability of CPT-II to dissociate effort from impairment in 47 adults clinically referred for neuropsychological assessment. CPT-II scales previously identified as PVTs (Omissions, Commissions, Hit Reaction Time SE, Variability, and Perseverations) produced classification accuracies hovering around .50 sensitivity at .90 specificity. The subsample that failed these PVTs performed within normal range on other tests of working memory, processing speed, visual attention, and executive function. Results suggest that the select CPT-II based PVTs are sensitive to invalid responding, and are associated with depression and anxiety, but are unrelated to cognitive functioning.	[Erdodi, Laszlo A.] Univ Windsor, Neuropsychol Track, Dept Psychol, Windsor, ON, Canada; [Erdodi, Laszlo A.; Pelletier, Chantalle L.; Roth, Robert M.] Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH USA	Erdodi, LA (corresponding author), 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	lerdodi@gmail.com					Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; Bauer L, 2005, APPL NEUROPSYCHOL, V12, P202, DOI 10.1207/s15324826an1204_3; Bigler ED, 2015, BRAIN IMAGING BEHAV, V9, P421, DOI 10.1007/s11682-015-9409-1; Bigler ED, 2012, J INT NEUROPSYCH SOC, V18, P632, DOI 10.1017/S1355617712000252; Boone, 2007, ASSESSMENT FEIGNED C; Boone K. B., 2013, CLIN PRACTICE FORENS; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bortnik KE, 2010, CLIN NEUROPSYCHOL, V24, P344, DOI 10.1080/13854040903307268; Bush SS, 2014, PSYCHOL INJ LAW, V7, P197, DOI 10.1007/s12207-014-9198-7; Chafetz MD, 2015, CLIN NEUROPSYCHOL, V29, P723, DOI 10.1080/13854046.2015.1099738; Conners K. C, 2014, CONNERS CONTINUOUS P; Conners K. C., 2004, CONNERS CONTINUOUS P; Cottingham ME, 2014, CLIN NEUROPSYCHOL, V28, P1030, DOI 10.1080/13854046.2014.951397; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; Erdodi LA, 2017, APPL NEUROPSYCH-CHIL, V6, P355, DOI 10.1080/21622965.2016.1198908; Erdodi LA, 2017, PSYCHOL ASSESSMENT, V29, P148, DOI 10.1037/pas0000319; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Erdodi LA, 2014, ARCH CLIN NEUROPSYCH, V29, P456, DOI 10.1093/arclin/acu026; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Kim N, 2010, ARCH CLIN NEUROPSYCH, V25, P420, DOI 10.1093/arclin/acq040; Lange RT, 2013, PSYCHOL ASSESSMENT, V25, P339, DOI 10.1037/a0030915; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2013, BEHAV SCI LAW, V31, P686, DOI 10.1002/bsl.2087; Lichtenstein JD, 2017, CHILD NEUROPSYCHOL, V23, P284, DOI 10.1080/09297049.2015.1135422; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P380, DOI 10.1080/13803390903066881; Pearson, 2009, ADV CLIN SOL WAIS 4; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Schwartz ES, 2016, J INT NEUROPSYCH SOC, V22, P851, DOI 10.1017/S1355617716000746; SEGALOWITZ SJ, 1992, J CLIN EXP NEUROPSYC, V14, P545, DOI 10.1080/01688639208402844; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Sugarman MA, 2015, APPL NEUROPSYCH-ADUL, V22, P141, DOI 10.1080/23279095.2013.873439	38	24	24	0	3	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	2327-9095	2327-9109		APPL NEUROPSYCH-ADUL	Appl. Neuropsychol.-Adult		2018	25	1					19	28		10.1080/23279095.2016.1232262			10	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	FY7NF	WOS:000427048500004	27662418				2021-06-18	
J	Erdodi, LA; Tyson, BT; Abeare, CA; Zuccato, BG; Rai, JK; Seke, KR; Sagar, S; Roth, RM				Erdodi, Laszlo A.; Tyson, Bradley T.; Abeare, Christopher A.; Zuccato, Brandon G.; Rai, Jaspreet K.; Seke, Kristian R.; Sagar, Sanya; Roth, Robert M.			Utility of critical items within the Recognition Memory Test and Word Choice Test	APPLIED NEUROPSYCHOLOGY-ADULT			English	Article						Critical item analysis; performance validity testing; Recognition Memory Test; Word Choice Test	TRAUMATIC BRAIN-INJURY; VERBAL-LEARNING TEST; COMPLEX FIGURE TEST; MALINGERED NEUROCOGNITIVE DYSFUNCTION; ADVANCED CLINICAL SOLUTIONS; PERFORMANCE TEST-II; CARD SORTING TEST; RESPONSE BIAS; CLASSIFICATION ACCURACY; NEUROPSYCHOLOGICAL ASSESSMENT	This study was designed to examine the clinical utility of critical items within the Recognition Memory Test (RMT) and the Word Choice Test (WCT). Archival data were collected from a mixed clinical sample of 202 patients clinically referred for neuropsychological testing (54.5% male; mean age=45.3 years; mean level of education=13.9 years). The credibility of a given response set was psychometrically defined using three separate composite measures, each of which was based on multiple independent performance validity indicators. Critical items improved the classification accuracy of both tests. They increased sensitivity by correctly identifying an additional 2-17% of the invalid response sets that passed the traditional cutoffs based on total score. They also increased specificity by providing additional evidence of noncredible performance in response sets that failed the total score cutoff. The combination of failing the traditional cutoff, but passing critical items was associated with increased risk of misclassifying the response set as invalid. Critical item analysis enhances the diagnostic power of both the RMT and WCT. Given that critical items require no additional test material or administration time, but help reduce both false positive and false negative errors, they represent a versatile, valuable, and time- and cost-effective supplement to performance validity assessment.	[Erdodi, Laszlo A.; Abeare, Christopher A.; Zuccato, Brandon G.; Rai, Jaspreet K.; Seke, Kristian R.; Sagar, Sanya] Univ Windsor, Dept Psychol, Windsor, ON, Canada; [Erdodi, Laszlo A.; Tyson, Bradley T.; Roth, Robert M.] Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH USA; [Tyson, Bradley T.] Western Washington Med Grp, Everett, WA USA	Erdodi, LA (corresponding author), 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	lerdodi@gmail.com		Abeare, Christopher/0000-0002-7163-7434; Sagar, Sanya/0000-0001-7381-0803			Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Axelrod BN, 2014, CLIN NEUROPSYCHOL, V28, P876, DOI 10.1080/13854046.2014.907583; Barhon LI, 2015, APPL NEUROPSYCH-ADUL, V22, P114, DOI 10.1080/23279095.2013.863775; Bauer L, 2005, APPL NEUROPSYCHOL, V12, P202, DOI 10.1207/s15324826an1204_3; Bauer L, 2007, ASSESSMENT, V14, P215, DOI 10.1177/1073191106297617; Berry DTR, 1996, J PERS ASSESS, V67, P26, DOI 10.1207/s15327752jpa6701_2; Bigler ED, 2015, BRAIN IMAGING BEHAV, V9, P421, DOI 10.1007/s11682-015-9409-1; Bigler ED, 2012, J INT NEUROPSYCH SOC, V18, P632, DOI 10.1017/S1355617712000252; Bilker WB, 2014, ASSESSMENT, V21, P669, DOI 10.1177/1073191114524270; Blaskewitz N, 2009, APPL NEUROPSYCHOL, V16, P54, DOI 10.1080/09084280802644227; Boone, 2007, ASSESSMENT FEIGNED C; Boone K. B., 2013, CLIN PRACTICE FORENS; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bortnik KE, 2010, CLIN NEUROPSYCHOL, V24, P344, DOI 10.1080/13854040903307268; Bush SS, 2014, PSYCHOL INJ LAW, V7, P197, DOI 10.1007/s12207-014-9198-7; Chafetz MD, 2015, CLIN NEUROPSYCHOL, V29, P723, DOI 10.1080/13854046.2015.1099738; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P1278, DOI 10.1080/13854046.2014.975844; Delis DC, 2000, CALIFORNIA VERBAL LE; Denning JH, 2012, ARCH CLIN NEUROPSYCH, V27, P417, DOI 10.1093/arclin/acs044; Embretson SE, 1996, PSYCHOL ASSESSMENT, V8, P341, DOI 10.1037/1040-3590.8.4.341; Erdodi LA, 2017, APPL NEUROPSYCH-CHIL, V6, P355, DOI 10.1080/21622965.2016.1198908; Erdodi LA, 2017, J CLIN EXP NEUROPSYC, V39, P369, DOI 10.1080/13803395.2016.1230181; Erdodi LA, 2016, PSYCHOL INJ LAW, V9, P112, DOI 10.1007/s12207-016-9254-6; Erdodi LA, 2017, PSYCHOL ASSESSMENT, V29, P148, DOI 10.1037/pas0000319; Erdodi LA, 2017, CLIN NEUROPSYCHOL, V31, P168, DOI 10.1080/13854046.2016.1224392; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Erdodi LA, 2014, ARCH CLIN NEUROPSYCH, V29, P456, DOI 10.1093/arclin/acu026; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Fazio RL, 2017, CLIN NEUROPSYCHOL, V31, P251, DOI 10.1080/13854046.2016.1213316; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2009, ASSESSMENT, V16, P237, DOI 10.1177/1073191108326227; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; HAYWARD L, 1987, AUST NZ J PSYCHIAT, V21, P87, DOI 10.3109/00048678709160904; Heaton RK, 2004, REVISED COMPREHENSIV; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Hilsabeck RC, 2011, CLIN NEUROPSYCHOL, V25, P1228, DOI 10.1080/13854046.2011.589409; Horner MD, 2006, INT J NEUROSCI, V116, P1181, DOI 10.1080/00207450500514029; Iverson G.L., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401, DOI 10.1177/107319119400100401]; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; Jones A, 2013, CLIN NEUROPSYCHOL, V27, P1043, DOI 10.1080/13854046.2013.804949; Killgore WDS, 2000, J CLIN EXP NEUROPSYC, V22, P761; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Kim N, 2010, ARCH CLIN NEUROPSYCH, V25, P420, DOI 10.1093/arclin/acq040; Kulas JF, 2014, PSYCHOL INJ LAW, V7, P236, DOI 10.1007/s12207-014-9200-4; Lange RT, 2013, PSYCHOL ASSESSMENT, V25, P339, DOI 10.1037/a0030915; Larrabee G. J., 2012, FORENSIC NEUROPSYCHO, P117; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Lichtenstein JD, 2018, CHILD NEUROPSYCHOL, V24, P247, DOI 10.1080/09297049.2016.1259402; Lichtenstein JD, 2017, CHILD NEUROPSYCHOL, V23, P284, DOI 10.1080/09297049.2015.1135422; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; Miller JB, 2011, CLIN NEUROPSYCHOL, V25, P160, DOI 10.1080/13854046.2010.533197; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; Nelson NW, 2003, CLIN NEUROPSYCHOL, V17, P263, DOI 10.1076/clin.17.2.263.16511; O'Bryant SE, 2007, CLIN NEUROPSYCHOL, V21, P511, DOI 10.1080/13854040600611368; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P380, DOI 10.1080/13803390903066881; Pearson, 2009, ADV CLIN SOLUTIONS W; Randolph C, 1998, REPEATABLE BATTERY A; Reedy SD, 2013, ARCH CLIN NEUROPSYCH, V28, P30, DOI 10.1093/arclin/acs106; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Sugarman MA, 2015, APPL NEUROPSYCH-ADUL, V22, P141, DOI 10.1080/23279095.2013.873439; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Tombaugh TN, 1996, TEST MEMORY MALINGER; Trueblood W., 1994, J CLIN EXPT NEUROPSY, V4, P697, DOI DOI 10.1080/01688639408402671; Warrington EK., 1984, RECOGNITION MEMORY T; Wisdom NM, 2012, ARCH CLIN NEUROPSYCH, V27, P208, DOI 10.1093/arclin/acr107; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	74	24	24	0	0	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	2327-9095	2327-9109		APPL NEUROPSYCH-ADUL	Appl. Neuropsychol.-Adult		2018	25	4			SI		327	339		10.1080/23279095.2017.1298600			13	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	GG4SF	WOS:000432685800007	28306349				2021-06-18	
J	Loftis, KL; Price, J; Gillich, PJ				Loftis, Kathryn L.; Price, Janet; Gillich, Patrick J.			Evolution of the Abbreviated Injury Scale: 1990-2015	TRAFFIC INJURY PREVENTION			English	Article						AIS; injury coding; versions	SEVERITY SCORE	Objective: Although the Abbreviated Injury Scale (AIS) was initially developed in the mid-1960s for tracking injury in automotive and aircraft crashes, it has grown to become an internationally recognized scoring system for a variety of traumatic injuries. This shift in focus and advances in organized medical care, combined with feedback from field use and outcome analysis, have resulted in several AIS updates and revisions. This article demonstrates how AIS codes and severities have changed over the last 25 years and investigates the effects of those changes. Methods: Data from each version and update of the AIS dictionary (AIS 1990, AIS 1998, AIS 2005, AIS 2008, and AIS 2015) were analyzed for changes and shifts in injury descriptions, severities, and code counts. Results: The number of AIS codes has increased to improve coding specificity and reliability for a growing number of injury types. There has also been a shift in severities, mainly within the moderate (AIS 2) to severe (AIS 4) range. AIS 1990 was the first version to utilize the 6-digit predot identifier, to add modifiers for pediatric injury, and to substantially expand brain injury codes. AIS 1998 added coding rules and guidelines throughout the dictionary and integrated the Organ Injury Scale scores. The AIS 2005 dictionary added over 400 codes and made significant changes throughout. Fewer changes were made in the AIS 2008 update. AIS 2015 includes descriptions for tissue injuries with loss of soft tissue that do not qualify as amputations, a need identified in military injury analysis. Conclusions: Each updated version of AIS reflects improving medical care and new advances in understanding, measuring, and documenting injury. AIS changes over time reflect its international and cross-domain utilization for describing injury severity and set the standard for how the world now studies traumatic injury.	[Loftis, Kathryn L.] US RDECOM, Survivabil Lethal Anal Directorate, Bldg 4501,6509 Wayberry Rd, Aberdeen Proving Ground, MD 21005 USA; [Gillich, Patrick J.] US Army Res Lab, Weap & Mat Res Directorate, Aberdeen Proving Ground, MD USA	Loftis, KL (corresponding author), US RDECOM, Survivabil Lethal Anal Directorate, Bldg 4501,6509 Wayberry Rd, Aberdeen Proving Ground, MD 21005 USA.	kathryn.l.loftis2.civ@mail.mil					[Anonymous], 1998, ABBR INJ SCAL 1990 U; Association for the Advancement of Automotive Medicine, 2007, ABBR INJ SCAL 2005 R; Association for the Advancement of Automotive Medicine, 2016, ABBR INJ SCAL 2015 R; Association for the Advancement of Automotive Medicine, 2008, ABBR INJ SCAL 2005 U; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barnes J, 2009, Ann Adv Automot Med, V53, P83; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Loftis KL, 2016, TRAFFIC INJ PREV, V17, P1, DOI 10.1080/15389588.2016.1191069; Loftis KL, 2014, ASS ADV AUT MED ANN; Salottolo K, 2009, INJURY, V40, P999, DOI 10.1016/j.injury.2009.05.013; Skaga NO, 2007, INJURY, V38, P84, DOI 10.1016/j.injury.2006.04.123	13	24	25	2	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1538-9588	1538-957X		TRAFFIC INJ PREV	Traffic Inj. Prev.		2018	19			2			S109	S113		10.1080/15389588.2018.1512747			5	Public, Environmental & Occupational Health; Transportation	Public, Environmental & Occupational Health; Transportation	HQ5UO	WOS:000462478300017	30543458				2021-06-18	
J	Perez-Garcia, G; de Gasperi, R; Sosa, MAG; Perez, GM; Otero-Pagan, A; Tschiffely, A; McCarron, RM; Ahlers, ST; Elder, GA; Gandy, S				Perez-Garcia, Georgina; de Gasperi, Rita; Sosa, Miguel A. Gama; Perez, Gissel M.; Otero-Pagan, Alena; Tschiffely, Anna; McCarron, Richard M.; Ahlers, Stephen T.; Elder, Gregory A.; Gandy, Sam			PTSD-Related Behavioral Traits in a Rat Model of Blast-Induced mTBI Are Reversed by the mGluR2/3 Receptor Antagonist BCI-838	ENEURO			English	Article						BCI-838; blast; metabotropic glutamate receptor; mGluR2/3; posttraumatic stress disorder; traumatic brain injury	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; HIPPOCAMPAL NEUROGENESIS; NADPH OXIDASE; WAR VETERANS; EXPOSURE; MGS0039; DOUBLECORTIN; ACTIVATION; ANXIETY	Battlefield blast exposure related to improvised explosive devices (IEDs) has become the most common cause of traumatic brain injury (TBI) in the recent conflicts in Iraq and Afghanistan. Mental health problems are common after TBI. A striking feature in the most recent veterans has been the frequency with which mild TBI (mTBI) and posttraumatic stress disorder (PTSD) have appeared together, in contrast to the classical situations in which the presence of mTBI has excluded the diagnosis of PTSD. However, treatment of PTSD-related symptoms that follow blast injury has become a significant problem. BCI-838 (MGS0210) is a Group II metabotropic glutamate receptor (mGluR2/3) antagonist prodrug, and its active metabolite BCI-632 (MGS0039) has proneurogenic, procognitive, and antidepressant activities in animal models. In humans, BCI-838 is currently in clinical trials for refractory depression and suicidality. The aim of the current study was to determine whether BCI-838 could modify the anxiety response and reverse PTSD-related behaviors in rats exposed to a series of low-level blast exposures designed to mimic a human mTBI or subclinical blast exposure. BCI-838 treatment reversed PTSD-related behavioral traits improving anxiety and fear-related behaviors as well as long-term recognition memory. Treatment with BCI-838 also increased neurogenesis in the dentate gyrus (DG) of blast-exposed rats. The safety profile of BCI-838 together with the therapeutic activities reported here, make BCI-838 a promising drug for the treatment of former battlefield Warfighters suffering from PTSD-related symptoms following blast-induced mTBI.	[Perez-Garcia, Georgina; de Gasperi, Rita; Sosa, Miguel A. Gama; Perez, Gissel M.; Otero-Pagan, Alena; Elder, Gregory A.; Gandy, Sam] James J Peters Vet Affairs Med Ctr, Res & Dev, Bronx, NY 10468 USA; [Perez-Garcia, Georgina; Elder, Gregory A.; Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [Perez-Garcia, Georgina; Elder, Gregory A.; Gandy, Sam] Icahn Sch Med Mt Sinai, NFL Neurol Care Ctr, New York, NY 10029 USA; [de Gasperi, Rita; Sosa, Miguel A. Gama; Elder, Gregory A.; Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA; [de Gasperi, Rita; Sosa, Miguel A. Gama; Elder, Gregory A.; Gandy, Sam] Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, New York, NY 10029 USA; [Tschiffely, Anna; McCarron, Richard M.; Ahlers, Stephen T.] Naval Med Res Ctr, Operat & Undersea Med Directorate, Dept Neurotrauma, Silver Spring, MD 20910 USA; [McCarron, Richard M.] Uniformed Serv Univ Hlth Sci, Dept Surg, Bethesda, MD 20814 USA	Elder, GA; Gandy, S (corresponding author), James J Peters Vet Affairs Med Ctr, Res & Dev, Bronx, NY 10468 USA.; Elder, GA; Gandy, S (corresponding author), Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA.; Elder, GA; Gandy, S (corresponding author), Icahn Sch Med Mt Sinai, NFL Neurol Care Ctr, New York, NY 10029 USA.; Elder, GA; Gandy, S (corresponding author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.; Elder, GA; Gandy, S (corresponding author), Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, New York, NY 10029 USA.	gregory.elder@mssm.edu; samuel.gandy@mssm.edu		Elder, Gregory/0000-0001-7035-8380	Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development ServiceUS Department of Veterans Affairs [1I01RX000684, 1I01RX000996]; DoDUnited States Department of Defense [0000B999.0000.000.A1503]; Veterans AffairsUS Department of Veterans Affairs [I01RX000996, I01RX002333] Funding Source: NIH RePORTER	This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Awards 1I01RX000684 (to S.G.) 1I01RX000996 (to G.A.E) and by DoD Work Unit Number 0000B999.0000.000.A1503.	Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Jorge MSB, 2014, REV ESC ENFERM USP, V48, P1059, DOI 10.1590/S0080-623420140000700014; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Campo B, 2011, J NEUROGENET, V25, P152, DOI 10.3109/01677063.2011.627485; Celanire S, 2015, EXPERT OPIN THER PAT, V25, P69, DOI 10.1517/13543776.2014.983899; Chaki S, 2017, TRENDS PHARMACOL SCI, V38, P569, DOI 10.1016/j.tips.2017.03.008; Chase Alex, 2015, Nat Rev Neurol, V11, P309, DOI 10.1038/nrneurol.2015.83; Cryan JF, 2011, BRIT J PHARMACOL, V164, P1129, DOI 10.1111/j.1476-5381.2011.01362.x; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Elder GA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00269; Elder GA, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0591-8; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Gandy S, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-37; Gennarelli T. A., 2005, TXB TRAUMATIC BRAIN, P27; Gubata ME, 2014, J HEAD TRAUMA REHAB, V29, P65, DOI 10.1097/HTR.0b013e318295f590; Higgins GA, 2004, NEUROPHARMACOLOGY, V46, P907, DOI 10.1016/j.neuropharm.2004.01.018; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Kabadi SV, 2014, INT J MOL SCI, V15, P1216, DOI 10.3390/ijms15011216; Kempermann G, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a018812; Kim SH, 2014, MOL PSYCHIATR, V19, P1235, DOI 10.1038/mp.2014.87; Kobeissy F, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00186; Li NX, 2011, BIOL PSYCHIAT, V69, P754, DOI 10.1016/j.biopsych.2010.12.015; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Loane DJ, 2009, J BIOL CHEM, V284, P15629, DOI 10.1074/jbc.M806139200; Lu Y, 2014, NEUROSCIENCE, V274, P429, DOI 10.1016/j.neuroscience.2014.05.057; Mahan AL, 2012, TRENDS NEUROSCI, V35, P24, DOI 10.1016/j.tins.2011.06.007; Morgan CA, 1996, AM J PSYCHIAT, V153, P64; ORR SP, 1995, J ABNORM PSYCHOL, V104, P75, DOI 10.1037/0021-843X.104.1.75; Perez-Garcia G, 2018, BEHAV BRAIN RES, V340, P117, DOI 10.1016/j.bbr.2016.09.061; Perez-Garcia G, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00176; Popoli M, 2012, NAT REV NEUROSCI, V13, P22, DOI 10.1038/nrn3138; Rao MS, 2004, EUR J NEUROSCI, V19, P234, DOI 10.1111/j.0953-816X.2003.03123.x; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Shapiro LA, 2017, CELL TRANSPLANT, V26, P1314, DOI 10.1177/0963689717714099; Sherin Jonathan E, 2011, Dialogues Clin Neurosci, V13, P263; Shetty AK, 2014, EPILEPSY BEHAV, V38, P117, DOI 10.1016/j.yebeh.2013.12.001; Shimazaki T, 2004, EUR J PHARMACOL, V501, P121, DOI 10.1016/j.ejphar.2004.08.016; Shively SB, 2016, LANCET NEUROL, V15, P944, DOI 10.1016/S1474-4422(16)30057-6; Tanielian T, 2008, INVISIBLE WOUNDS WAR, P593; Turner PV, 2012, J AM ASSOC LAB ANIM, V51, P25; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Wang XT, 2016, J NEUROTRAUM, V33, P721, DOI 10.1089/neu.2015.4097; Winer JA, 2002, HEARING RES, V168, P181, DOI 10.1016/S0378-5955(02)00489-6; Yoshimizu T, 2004, BIOCHEM BIOPH RES CO, V315, P493, DOI 10.1016/j.bbrc.2004.01.073; Yoshimizu T, 2006, PSYCHOPHARMACOLOGY, V186, P587, DOI 10.1007/s00213-006-0390-7	48	24	24	0	5	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA		2373-2822		ENEURO	eNeuro	JAN-FEB	2018	5	1							UNSP e0357-17.2018	10.1523/ENEURO.0357-17.2018			15	Neurosciences	Neurosciences & Neurology	GB9QW	WOS:000429409900042	29387781	DOAJ Gold, Green Published			2021-06-18	
J	Sollmann, N; Echlin, PS; Schultz, V; Viher, PV; Lyall, AE; Tripodis, Y; Kaufmann, D; Hartl, E; Kinzel, P; Forwell, LA; Johnson, AM; Skopelja, EN; Lepage, C; Bouix, S; Pasternak, O; Lin, AP; Shenton, ME; Koerte, IK				Sollmann, Nico; Echlin, Paul S.; Schultz, Vivian; Viher, Petra V.; Lyall, Amanda E.; Tripodis, Yorghos; Kaufmann, David; Hartl, Elisabeth; Kinzel, Philipp; Forwell, Lorie A.; Johnson, Andrew M.; Skopelja, Elaine N.; Lepage, Christian; Bouix, Sylvain; Pasternak, Ofer; Lin, Alexander P.; Shenton, Martha E.; Koerte, Inga K.			Sex differences in white matter alterations following repetitive subconcussive head impacts in collegiate ice hockey players.	NEUROIMAGE-CLINICAL			English	Article						Diffusion tensor imaging; Ice hockey; Repetitive subconcussive head impacts; Sex difference; Traumatic brain injury; White matter	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; STATES HIGH-SCHOOL; GENDER-DIFFERENCES; NEUROCOGNITIVE PERFORMANCE; DESCRIPTIVE EPIDEMIOLOGY; INTERNATIONAL-CONFERENCE; SURVEILLANCE SYSTEM; CONSENSUS STATEMENT; SOCCER PLAYERS	Objective: Repetitive subconcussive head impacts (RSHI) may lead to structural, functional, and metabolic alterations of the brain. While differences between males and females have already been suggested following a concussion, whether there are sex differences following exposure to RSHI remains unknown. The aim of this study was to identify and to characterize sex differences following exposure to RSHI. Methods: Twenty-five collegiate ice hockey players (14 males and 11 females, 20.6 +/- 2.0 years), all part of the Hockey Concussion Education Project (HCEP), underwent diffusion-weighted magnetic resonance imaging (dMRI) before and after the Canadian Interuniversity Sports (CIS) ice hockey season 2011-2012 and did not experience a concussion during the season. Whole-brain tract-based spatial statistics (TBSS) were used to compare pre-and postseason imaging in both sexes for fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD), and radial diffusivity (RD). Pre-and postseason neurocognitive performance were assessed by the Immediate Post-Concussion Assessment and Cognitive Test (ImPACT). Results: Significant differences between the sexes were primarily located within the superior longitudinal fasciculus (SLF), the internal capsule (IC), and the corona radiata (CR) of the right hemisphere (RH). In significant voxel clusters (p < 0.05), decreases in FA (absolute difference pre-vs. postseason: 0.0268) and increases in MD (0.0002), AD (0.00008), and RD (0.00005) were observed in females whereas males showed no significant changes. There was no significant correlation between the change in diffusion scalar measures over the course of the season and neurocognitive performance as evidenced from postseason ImPACT scores. Conclusions: The results of this study suggest sex differences in structural alterations following exposure to RSHI. Future studies need to investigate further the underlying mechanisms and association with exposure and clinical outcomes.	[Sollmann, Nico; Schultz, Vivian; Viher, Petra V.; Lyall, Amanda E.; Kaufmann, David; Hartl, Elisabeth; Kinzel, Philipp; Lepage, Christian; Bouix, Sylvain; Pasternak, Ofer; Lin, Alexander P.; Shenton, Martha E.; Koerte, Inga K.] Harvard Med Sch, Brigham & Womens Hosp, Psychiat Neuroimaging Lab, 1249 Boylston St, Boston, MA 02215 USA; [Sollmann, Nico] Tech Univ Munich, Klinikum Rechts Isar, Dept Neuroradiol, Munich, Germany; [Sollmann, Nico] Tech Univ Munich, Klinikum Rechts Isar, TUM Neuroimaging Ctr, Munich, Germany; [Sollmann, Nico] Tech Univ Munich, Klinikum Rechts Isar, Dept Neurosurg, Munich, Germany; [Echlin, Paul S.] Elliott Sports Med Clin, Burlington, ON, Canada; [Schultz, Vivian; Kaufmann, David; Kinzel, Philipp; Koerte, Inga K.] Ludwig Maximilians Univ Munchen, Dept Child & Adolescent Psychiat Psychosomat & Ps, Munich, Germany; [Viher, Petra V.] Univ Hosp Psychiat, Translat Res Ctr, Bern, Switzerland; [Lyall, Amanda E.; Koerte, Inga K.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02215 USA; [Tripodis, Yorghos] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Tripodis, Yorghos] Boston Univ, Sch Med, Alzheimers Dis & CTE Ctr, Boston, MA 02118 USA; [Kaufmann, David] Charite, Dept Radiol, Berlin, Germany; [Hartl, Elisabeth] Ludwig Maximilians Univ Munchen, Dept Neurol, Epilepsy Ctr, Munich, Germany; [Forwell, Lorie A.] Univ Western Ontario, Ctr 3M, London, ON, Canada; [Johnson, Andrew M.] Univ Western Ontario, Sch Hlth Studies, London, ON, Canada; [Skopelja, Elaine N.] Indiana Univ, Ruth Lilly Med Lib, Indianapolis, IN 46204 USA; [Lepage, Christian] Univ Ottawa, Sch Psychol, Ottawa, ON, Canada; [Pasternak, Ofer; Lin, Alexander P.; Shenton, Martha E.] Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, Boston, MA 02215 USA; [Lin, Alexander P.; Shenton, Martha E.] Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, Ctr Clin Spect, Boston, MA 02215 USA; [Shenton, Martha E.] VA Boston Healthcare Syst, Brockton Div, Brockton, MA USA	Koerte, IK (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Psychiat Neuroimaging Lab, 1249 Boylston St, Boston, MA 02215 USA.	Nico.Sollmann@tum.de; Psechlin@gmail.com; VivianSchultz@gmx.de; Petra.Viher@puk.unibe.ch; Alyall@bwh.harvard.edu; Yorghos@bu.edu; David.Kaufmann@charite.de; Elisabeth.Hartl@med.uni-muenchen.de; Pkinzel@bwh.harvard.edu; Lforwell@uwo.ca; Ajohnson@uwo.ca; Eskopelj@iu.edu; Clepage@uottawa.ca; Sylvain@bwh.harvard.edu; Ofer@bwh.harvard.edu; Aplin@bwh.harvard.edu; Shenton@bwh.harvard.edu; Ikoerte@bwh.harvard.edu	Shenton, Martha/V-8780-2019; Johnson, Andrew M/B-2048-2012; Lyall, Amanda E./U-8399-2019	Lepage, Chris/0000-0001-5719-0982; Sollmann, Nico/0000-0002-8120-2223; Tripodis, Yorghos/0000-0003-2190-7608; Johnson, Andrew M./0000-0002-7269-3016	Ontario Trillium Foundation; Dave Irwin Foundation for Brain Injury; Ontario Neurotrauma Foundation; Air Canada; Ontario Ministry of Health and Long-Term CareMinistry of Health and Long-Term Care, Ontario; Ontario Ministry of Tourism Culture and Sport; Ontario Ministry of Education; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U01 NS 093334, R01 R01NS100952, R01 HD 090641]; Veterans Affairs (VA Merit Award)US Department of Veterans Affairs [I01 RX00928]; Department of Defense Congressionally Directed Medical Research ProgramsUnited States Department of Defense [W81XWH-08-2-0159]; German Academic Exchange Service PROMOS award; LMU Munich's Institutional Strategy LMU excellent within the German Excellence Initiative; Canadian Institutes of Health Research Frederick Banting and Charles Best Doctoral Award; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD090641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS093334, R01NS100952] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000928] Funding Source: NIH RePORTER	Funding for this work was provided to the HCEP and Dr. Echlin by the Ontario Trillium Foundation, The Dave Irwin Foundation for Brain Injury, the Ontario Neurotrauma Foundation, Air Canada, The Ontario Ministry of Health and Long-Term Care, The Ontario Ministry of Tourism Culture and Sport and The Ontario Ministry of Education. The authors of this study were supported by the NIH (U01 NS 093334: IKK, MES; R01 R01NS100952: IKK; R01 HD 090641: SB), the Veterans Affairs (VA Merit Award I01 RX00928: MES), the Department of Defense Congressionally Directed Medical Research Programs (W81XWH-08-2-0159: MES), the German Academic Exchange Service PROMOS award (VS), the LMU Munich's Institutional Strategy LMU excellent within the framework of the German Excellence Initiative, and by the Canadian Institutes of Health Research Frederick Banting and Charles Best Doctoral Award (CL).	Abrahams S, 2014, BRIT J SPORT MED, V48, P91, DOI 10.1136/bjsports-2013-092734; Agel J, 2007, J ATHL TRAINING, V42, P241; Agel J, 2007, J ATHL TRAINING, V42, P249; ANDREASON PJ, 1994, PSYCHIAT RES, V51, P175, DOI 10.1016/0165-1781(94)90037-X; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Baker JG, 2016, CLIN PEDIATR, V55, P771, DOI 10.1177/0009922815606417; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Black AM, 2017, CLIN J SPORT MED, V27, P52, DOI 10.1097/JSM.0000000000000308; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Caeyenberghs K, 2014, BRAIN STRUCT FUNCT, V219, P193, DOI 10.1007/s00429-012-0494-2; Caeyenberghs K, 2011, J NEUROTRAUM, V28, P897, DOI 10.1089/neu.2010.1721; Caeyenberghs K, 2011, NEUROREHAB NEURAL RE, V25, P492, DOI 10.1177/1545968310394870; Chamard E, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12305; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2013, AM J SPORT MED, V41, P2890, DOI 10.1177/0363546513509962; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Covassin T, 2011, CLIN SPORT MED, V30, P125, DOI 10.1016/j.csm.2010.08.001; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Echemendia RJ, 2016, CLIN NEUROPSYCHOL, V30, P311, DOI 10.1080/13854046.2016.1158320; Echlin PS, 2014, J NEUROSURG, V121, P1331, DOI 10.3171/2014.8.JNS132804; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10210; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10187; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.10.FOCUS10222; Echlin PS, 2012, NEUROSURG FOCUS, V33, P1, DOI DOI 10.3171/2012.10.F0CUS12286; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Esposito G, 1996, J NUCL MED, V37, P559; Fakhran S, 2014, RADIOLOGY, V272, P815, DOI 10.1148/radiol.14132512; Fedorov A, 2012, MAGN RESON IMAGING, V30, P1323, DOI 10.1016/j.mri.2012.05.001; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; Forward KE, 2014, PAED CHILD HEALT-CAN, V19, P418, DOI 10.1093/pch/19.8.418; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Helmer KG, 2014, J NEUROSURG, V120, P864, DOI [10.3171/2013.12.JNS132093, 10.3171/2013.12.JNS132090]; Irick E., 2015, STUDENT ATHLETE PART; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Koerte IK, 2017, J NEUROTRAUM, V34, P2389, DOI 10.1089/neu.2016.4960; Koerte IK, 2015, BRAIN PATHOL, V25, P318, DOI 10.1111/bpa.12249; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Miller JH, 2016, J NEUROSURG-PEDIATR, V17, P491, DOI 10.3171/2015.8.PEDS14332; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Resch JE, 2017, CLIN SPORT MED, V36, P717, DOI 10.1016/j.csm.2017.05.002; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sasaki Takeshi, 2014, J Neurosurg, V120, P882, DOI 10.3171/2013.12.JNS132092; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Westlye LT, 2010, CEREB CORTEX, V20, P2055, DOI 10.1093/cercor/bhp280; Zhang MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057364; Zuckerman SL, 2014, J NEUROSURG-PEDIATR, V13, P72, DOI 10.3171/2013.9.PEDS13257	59	24	24	0	10	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2018	17						642	649		10.1016/j.nicl.2017.11.020			8	Neuroimaging	Neurosciences & Neurology	FX6GA	WOS:000426180300068	29204342	DOAJ Gold, Green Published			2021-06-18	
J	Thomas, DJ; Coxe, K; Li, HM; Pommering, TL; Young, JA; Smith, GA; Yang, JZ				Thomas, Donald J.; Coxe, Kathryn; Li, Hongmei; Pommering, Thomas L.; Young, Julie A.; Smith, Gary A.; Yang, Jingzhen			Length of Recovery From Sports-Related Concussions in Pediatric Patients Treated at Concussion Clinics	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						prolonged recovery; concussion; children; sports	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL PLAYERS; HIGH-SCHOOL; POSTCONCUSSION SYNDROME; RECURRENT CONCUSSION; POSTURAL STABILITY; PROLONGED RECOVERY; SYMPTOM SEVERITY; TEST-PERFORMANCE; EPIDEMIOLOGY	Objectives: We quantified the length of recovery time by week in a cohort of pediatric sports-related concussion patients treated at concussion clinics, and examined patient and injury characteristics associated with prolonged recovery. Design: A retrospective, cohort design. Setting: Seven concussion clinics at a Midwest children's hospital. Patients: Patients aged 10 to 17 years with a diagnosed sports-related concussion presenting to the clinic within 30 days of injury. Main Outcome Measures: Length of recovery by week. Methods: Unadjusted and adjusted multinomial logistic regression analyses were used to model the effect of patient and injury characteristics on length of recovery by week. Results: Median length of recovery was 17 days. Only 16.3% (299/1840) of patients recovered within one week, whereas 26.4% took longer than four weeks to recover. By 2 months postinjury, 6.7% of patients were still experiencing symptoms. Higher symptom scores at injury and initial visit were significantly associated with prolonged symptoms by week. Patients who presented to the clinic more than 2 weeks postinjury or who had 2 or more previous concussions showed increased risk for prolonged recovery. Females were at greater risk for prolonged recovery than males (odds ratio = 2.08, 95% confidence interval = 1.49-2.89). Age was not significantly associated with recovery length. Conclusions: High symptom scores at injury and initial visit, time to initial clinical presentation, presence of 2 or more previous concussions, and female sex are associated with prolonged concussion recovery. Further research should aim to establish objective measures of recovery, accounting for treatment received during the recovery. Clinical Relevance: The median length of recovery is 17 days among pediatric sports-related concussion patients treated at concussion clinics. Only 16.3% of patients recovered within one week, whereas 26.4% took longer than 4 weeks to recover.	[Thomas, Donald J.; Coxe, Kathryn; Li, Hongmei; Smith, Gary A.; Yang, Jingzhen] Nationwide Childrens Hosp, Ctr Injury Res & Policy, Res Inst, Columbus, OH USA; [Thomas, Donald J.; Pommering, Thomas L.; Smith, Gary A.; Yang, Jingzhen] Ohio State Univ, Coll Med, Columbus, OH 43210 USA; [Li, Hongmei] Soochow Univ, Med Coll, Sch Publ Hlth, Dept Epidemiol & Biostat, Suzhou, Jiangsu, Peoples R China; [Pommering, Thomas L.; Young, Julie A.] Nationwide Childrens Hosp, Westerville Sports Med Orthoped Ctr, Concuss Clin, Columbus, OH USA	Yang, JZ (corresponding author), Nationwide Childrens Hosp, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43215 USA.	Ginger.Yang@nationwidechildrens.org	Coxe, Kathryn/AAJ-8041-2021	Coxe, Kathryn/0000-0002-7813-1081	Ohio State University College of Medicine Barnes Research Scholarship	Supported by The Ohio State University College of Medicine Barnes Research Scholarship (D. Thomas). The interpretations and conclusions do not necessarily reflect those of the funding organization.	Adirim TA, 2003, SPORTS MED, V33, P75, DOI 10.2165/00007256-200333010-00006; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bryan MA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4635; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Grubenhoff JA, 2014, PEDIATRICS, V134, P54, DOI 10.1542/peds.2013-2988; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Joyce AS, 2015, MED SCI SPORT EXER, V47, P1119, DOI 10.1249/MSS.0000000000000534; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Khurana VG, 2012, J CLIN NEUROSCI, V19, P1, DOI 10.1016/j.jocn.2011.08.002; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kostyun RO, 2015, SPORTS HEALTH, V7, P52, DOI 10.1177/1941738114555075; Ling H, 2015, MOL CELL NEUROSCI, V66, P114, DOI 10.1016/j.mcn.2015.03.012; MacDonald J, 2015, CLIN J SPORT MED, V25, P367, DOI 10.1097/JSM.0000000000000139; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCarthy MT, 2015, ANN NY ACAD SCI, V1345, P89, DOI 10.1111/nyas.12736; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Meehan WP, 2015, PEDIATRICS, V135, P362, DOI 10.1542/peds.2014-3665; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Murray N, 2014, J ATHL TRAINING, V49, P540, DOI 10.4085/1062-6050-49.3.32; Nelson LD, 2015, AM J SPORT MED, V43, P2018, DOI 10.1177/0363546515587714; Purcell L, 2016, CLIN PEDIATR, V55, P452, DOI 10.1177/0009922815589915; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Ruhe A, 2014, SPORTS HEALTH, V6, P427, DOI 10.1177/1941738114541238; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	45	24	24	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2018	28	1					56	63		10.1097/JSM.0000000000000413			8	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	GB0JM	WOS:000428732000010	28085687				2021-06-18	
J	Zhang, DD; Xiao, YN; Lv, PY; Teng, ZJ; Dong, YH; Qi, QQ; Liu, ZJ				Zhang, Dandan; Xiao, Yining; Lv, Peiyuan; Teng, Zhenjie; Dong, Yanhong; Qi, Qianqian; Liu, Zhijuan			Edaravone attenuates oxidative stress induced by chronic cerebral hypoperfusion injury: role of ERK/Nrf2/HO-1 signaling pathway	NEUROLOGICAL RESEARCH			English	Article						Chronic cerebral hypoperfusion; vascular dementia; edaravone; oxidative stress; cognitive damage; nuclear factor erythroid 2-related factor 2	VASCULAR COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; INTRACEREBROVENTRICULAR STREPTOZOTOCIN; RAT HIPPOCAMPUS; MICE; EXPRESSION; MODEL; NRF2; NEUROPROTECTION; DEMENTIA	Objectives: The potential protective effects and mechanisms of edaravone have not been well elucidated in vascular dementia (VaD) induced by chronic cerebral hypoperfusion (CCH). The aim of this study was to investigate whether edaravone could improve cognitive damage in rats induced by CCH, and whether the effects of edaravone were associated with ERK/Nrf2/HO-1 signaling pathway. Methods: CCH was induced by bilateral common carotid arteries occlusion (BCCAO). Sprague-Dawley (SD) rats were randomly divided into four groups: sham (sham-operated) group, vehicle (BCCAO + normal saline) group, edaravone3.0 group and edaravone6.0 group. The edaravone3.0 and edaravone6.0 group rats were provided 3.0 mg/kg and 6.0 mg/kg of edaravone, respectively, intraperitoneal (i.p.) injection twice daily following the first day after BCCAO. In this experiment, the spatial learning and memory were assessed using the Morris water maze. The malondialdehyde (MDA) contents and superoxide dismutase (SOD) activities in the hippocampus were measured biochemically. And, the levels of total ERK1/2 (t-ERK1/2), Phospho-ERK1/2 (p-ERK1/2), total Nrf2 (t-Nrf2), nuclear Nrf2 (n-Nrf2), and HO-1 were assessed by western blot. Results: The results showed that the treatment with edaravone significantly improved CCH-induced cognitive damage, and boosted endogenous antioxidants SOD activity and HO-1 level, decreased MDA contents in the hippocampus by activating Nrf2 signaling pathway which was related to ERK1/2. We also found that the neuronal morphology of the hippocampal CA1 area significantly improved and the number of Nrf2 positive cells markedly increased in the edaravone treatment groups. Conclusion: Our results demonstrated a neuroprotective effect of edaravone on hippocampus against oxidative stress and cognitive deficit induced by CCH. The mechanism may be related to the enhancement of antioxidant defense system by activating ERK/Nrf2/HO-1 signaling pathway.	[Zhang, Dandan; Lv, Peiyuan; Teng, Zhenjie] Hebei Med Univ, Shijiazhuang, Hebei, Peoples R China; [Zhang, Dandan; Xiao, Yining; Lv, Peiyuan; Teng, Zhenjie; Dong, Yanhong; Qi, Qianqian; Liu, Zhijuan] Hebei Gen Hosp, Dept Neurol, Shijiazhuang, Hebei, Peoples R China	Lv, PY (corresponding author), Hebei Med Univ, Shijiazhuang, Hebei, Peoples R China.; Lv, PY (corresponding author), Hebei Gen Hosp, Dept Neurol, Shijiazhuang, Hebei, Peoples R China.	peiyuanlu@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81241037]; Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [H2013307046]; Provincial Major Medical Scientific Research Projects [zd2013005]	This work was financially supported by the National Natural Science Foundation of China, [grant number 81241037], Natural Science Foundation of China, [grant number H2013307046] and Provincial Major Medical Scientific Research Projects, [grant number zd2013005].	Bhardwaj M, 2016, EUR J PHARMACOL, V772, P43, DOI 10.1016/j.ejphar.2015.12.037; Bordeleau M, 2016, ONCOTARGET, V7, P11864, DOI 10.18632/oncotarget.7689; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Czerska M, 2015, MED PR, V66, P393, DOI 10.13075/mp.5893.00137; Du SQ, 2017, MOL NEUROBIOL, V54, P3670, DOI 10.1007/s12035-016-9915-1; Fan MY, 2015, BEHAV BRAIN RES, V291, P399, DOI 10.1016/j.bbr.2015.05.047; Godman CA, 2010, CELL STRESS CHAPERON, V15, P431, DOI 10.1007/s12192-009-0159-0; Huang TT, 2012, SEMIN CELL DEV BIOL, V23, P738, DOI 10.1016/j.semcdb.2012.04.003; Ihara M, 2014, METHODS MOL BIOL, V1135, P95, DOI 10.1007/978-1-4939-0320-7_8; Jangra A, 2016, EUR J PHARMACOL, V791, P51, DOI 10.1016/j.ejphar.2016.08.003; Jiao L, 2011, NEUROSCIENCE, V182, P177, DOI 10.1016/j.neuroscience.2011.01.017; Jing Z, 2015, J CEREBR BLOOD F MET, V35, P1249, DOI 10.1038/jcbfm.2015.55; Jiwa NS, 2010, J NEUROCHEM, V115, P814, DOI 10.1111/j.1471-4159.2010.06958.x; Kaur C, 2008, CURR MED CHEM, V15, P3068, DOI 10.2174/092986708786848640; Kikuchi K, 2009, BIOCHEM BIOPH RES CO, V390, P1121, DOI 10.1016/j.bbrc.2009.09.015; Kovac S, 2015, BBA-GEN SUBJECTS, V1850, P794, DOI 10.1016/j.bbagen.2014.11.021; Lapchak PA, 2010, EXPERT OPIN PHARMACO, V11, P1753, DOI 10.1517/14656566.2010.493558; Lee BJ, 2010, BRAIN RES, V1307, P22, DOI 10.1016/j.brainres.2009.10.026; Lee KM, 2013, BMC COMPLEM ALTERN M, V13, P246; Li WJ, 2013, NEUROBIOL DIS, V59, P18, DOI 10.1016/j.nbd.2013.06.014; Liu H, 2012, INT J NEUROSCI, V122, P494, DOI 10.3109/00207454.2012.686543; Liu TH, 2016, FOOD FUNCT, V7, P3444, DOI 10.1039/c6fo00223d; Lu XY, 2015, CELL MOL NEUROBIOL, V35, P713, DOI 10.1007/s10571-015-0167-9; Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320; Martin KR, 2002, HUM EXP TOXICOL, V21, P71, DOI 10.1191/0960327102ht213oa; Miyamoto N, 2013, STROKE, V44, P3516, DOI 10.1161/STROKEAHA.113.002813; Nie CJ, 2016, NEUROSCI LETT, V615, P9, DOI 10.1016/j.neulet.2015.11.019; Ozacmak VH, 2009, J PINEAL RES, V47, P156, DOI 10.1111/j.1600-079X.2009.00695.x; Perez-Gonzalez A, 2012, J PHYS CHEM B, V116, P1180, DOI 10.1021/jp209930y; Rong LX, 2015, BEHAV BRAIN FUNCT, V11, DOI 10.1186/s12993-014-0050-8; Saxena AK, 2015, APPL TRANSL GENOM, V5, P30, DOI 10.1016/j.atg.2015.05.004; Ueno Y, 2009, NEUROSCIENCE, V162, P317, DOI 10.1016/j.neuroscience.2009.04.065; Wang C, 2016, CLIN NEUROPHYSIOL, V127, P324, DOI 10.1016/j.clinph.2015.04.063; Wang DY, 2015, J ALZHEIMERS DIS, V43, P519, DOI 10.3233/JAD-140567; Wang GB, 2013, NEUROSCI LETT, V543, P72, DOI 10.1016/j.neulet.2013.02.067; Wang PQ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153708; Wang RM, 2013, HIPPOCAMPUS, V23, P634, DOI 10.1002/hipo.22126; Watanabe T, 2008, CARDIOVASC THER, V26, P101, DOI 10.1111/j.1527-3466.2008.00041.x; Yang Y, 2014, INT J NEUROSCI, V124, P577, DOI 10.3109/00207454.2013.863196; Yoshida H, 2011, NEUROSCI RES, V69, P291, DOI 10.1016/j.neures.2010.12.016; Zhou SS, 2013, NEUROTOXICOLOGY, V38, P136, DOI 10.1016/j.neuro.2013.07.007	41	24	27	1	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.		2018	40	1					1	10		10.1080/01616412.2017.1376457			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	GA2CC	WOS:000428123300001	29125058				2021-06-18	
J	Panahi, S; Aram, Z; Jafari, S; Ma, J; Sprott, JC				Panahi, Shirin; Aram, Zainab; Jafari, Sajad; Ma, Jun; Sprott, J. C.			Modeling of epilepsy based on chaotic artificial neural network	CHAOS SOLITONS & FRACTALS			English	Article						Neural network; Epilepsy; Chaos; Bifurcation	TEMPORAL-LOBE EPILEPSY; TRAUMATIC BRAIN-INJURY; SEIZURES; DYNAMICS; ADULTS; POPULATION; DISORDER; NEURONS; MEMORY; PEOPLE	Epilepsy is a long-term chronic neurological disorder that is characterized by seizures. One type of epilepsy is simple partial seizures that are localized to one area on one side of the brain, especially in the temporal lobe, but some may spread from there. GABA (gamma-aminobutyric acid) is an inhibitory neurotransmitter that is widely distributed in the neurons of the cortex. Scientists recently discovered the basic role of neurotransmitters in epilepsy. Synaptic reorganizations at GABAergic and glutamatergic synapses not only enable seizure occurrence, they also modify the normal information processing performed by these networks. Based on some physiological facts about epilepsy and chaos, a behavioral model is presented in this paper. This model represents the problem of undesired seizure, and also tries to suggest different valuable predictions about possible causes of epilepsy disorder. The proposed model suggests that there is a possible interaction between the role of excitatory and inhibitory neurotransmitters and epilepsy. The result of these studies might be helpful to discern epilepsy in a different way and give some guidance to predict the occurrence of seizures in patients. (C) 2017 Elsevier Ltd. All rights reserved.	[Panahi, Shirin; Aram, Zainab; Jafari, Sajad] Amirkabir Univ Technol, Biomed Engn Dept, Tehran 158754413, Iran; [Ma, Jun] Lanzhou Univ Technol, Dept Phys, Lanzhou 730050, Gansu, Peoples R China; [Sprott, J. C.] Univ Wisconsin, Dept Phys, 1150 Univ Ave, Madison, WI 53706 USA	Ma, J (corresponding author), Lanzhou Univ Technol, Dept Phys, Lanzhou 730050, Gansu, Peoples R China.	hyperchaos@163.com	Ma, Jun/G-2376-2010; Jafari, Sajad/P-7778-2017	Ma, Jun/0000-0002-6127-000X; Jafari, Sajad/0000-0002-6845-7539			Alhawarat M., 2015, ARXIV150102192; Allen AS, 2013, NATURE, V501, P217, DOI 10.1038/nature12439; Baghdadi G, 2015, COMMUN NONLINEAR SCI, V20, P174, DOI 10.1016/j.cnsns.2014.05.015; Baker GA, 2001, EPILEPSIA, V42, P66, DOI 10.1046/j.1528-1157.2001.042suppl.3066.x; Bannai H, 2009, NEURON, V62, P670, DOI 10.1016/j.neuron.2009.04.023; Basar E, 2012, CHAOS BRAIN FUNCTION; Baulac S, 2001, NAT GENET, V28, P46, DOI 10.1038/88254; BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; Berg AT, 2010, EPILEPSIA, V51, P676, DOI 10.1111/j.1528-1167.2010.02522.x; Bernard C, 2010, EPILEPSIA, V51, P42, DOI 10.1111/j.1528-1167.2010.02828.x; Branford D, 1998, SEIZURE-EUR J EPILEP, V7, P473, DOI 10.1016/S1059-1311(98)80005-8; Cossart R, 2001, NAT NEUROSCI, V4, P52; de Boer HM, 2008, EPILEPSY BEHAV, V12, P540, DOI 10.1016/j.yebeh.2007.12.019; de Curtis M, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a022368; Diaz H, 2015, PROCEDIA COMPUT SCI, V55, P1410, DOI 10.1016/j.procs.2015.07.135; Durand E, 2016, BRAIN INJURY, P1; Eid T, 2004, LANCET, V363, P28, DOI 10.1016/S0140-6736(03)15166-5; El Achkar CM, 2015, EPILEPSY BEHAV, V47, P183, DOI 10.1016/j.yebeh.2014.12.022; Engel J, 2012, JAMA-J AM MED ASSOC, V307, P922, DOI 10.1001/jama.2012.220; Englot D, 2015, HDB CLIN NEUROL, V134, P267; Erkaymaz O, 2017, APPL MATH COMPUT, V311, P22, DOI 10.1016/j.amc.2017.05.010; Falahian R, 2015, NONLINEAR DYNAM, V81, P1951, DOI 10.1007/s11071-015-2118-x; Fister I, 2016, NONLINEAR DYNAM, V84, P895, DOI 10.1007/s11071-015-2537-8; Fister I, 2015, APPL MATH COMPUT, V252, P155, DOI 10.1016/j.amc.2014.12.006; Fox CK, 2013, ANN NEUROL, V74, P249, DOI 10.1002/ana.23916; FREEMAN WJ, 1988, IEEE T CIRCUITS SYST, V35, P781, DOI 10.1109/31.1822; FREEMAN WJ, 1987, BIOL CYBERN, V56, P139, DOI 10.1007/BF00317988; Fridley J, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.1.FOCUS11334; Gaiarsa JL, 2002, TRENDS NEUROSCI, V25, P564, DOI 10.1016/S0166-2236(02)02269-5; Groticke I, 2007, EXP NEUROL, V207, P329, DOI 10.1016/j.expneurol.2007.06.021; Guerrini R, 1998, EPILEPSIA, V39, pS2, DOI 10.1111/j.1528-1157.1998.tb05118.x; HANSOTIA P, 1991, NEW ENGL J MED, V324, P22, DOI 10.1056/NEJM199101033240105; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; Heylighen F, 2012, WORKING PAPERS; Hilborn RC, 2000, CHAOS NONLINEAR DYNA; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Huang HL, 2015, CELL BIOCHEM BIOPHYS, V73, P7, DOI 10.1007/s12013-015-0603-y; Iasemidis LD, 1996, NEUROSCIENTIST, V2, P118, DOI 10.1177/107385849600200213; JENSEN I, 1977, ACTA NEUROCHIR, V37, P173, DOI 10.1007/BF01402126; Jouny CC, 2012, CLIN NEUROPHYSIOL, V123, P658, DOI 10.1016/j.clinph.2011.08.003; Karsai M, 2012, SCI REP-UK, V2, DOI 10.1038/srep00397; Kim SY, 2015, THESIS; Knutson AR, 2012, P NATL ACAD SCI USA, V109, P13106, DOI 10.1073/pnas.1208876109; Kwan P, 2011, NEW ENGL J MED, V365, P919, DOI 10.1056/NEJMra1004418; Kwon OY, 2014, J CLIN NEUROL, V10, P175, DOI 10.3988/jcn.2014.10.3.175; Larter R, 1999, CHAOS, V9, P795, DOI 10.1063/1.166453; Leeman-Markowski BA, 2016, NEUROL CLIN, V34, P183, DOI 10.1016/j.ncl.2015.08.008; Lehnertz K, 2000, CHAOS BRAIN WORLD SC; Li XD, 2017, IEEE T AUTOMAT CONTR, V62, P3618, DOI 10.1109/TAC.2017.2669580; Li XD, 2015, ASIAN J CONTROL, V17, P1678, DOI 10.1002/asjc.984; Li XD, 2013, IEEE T NEUR NET LEAR, V24, P868, DOI 10.1109/TNNLS.2012.2236352; Li XD, 2011, COMMUN NONLINEAR SCI, V16, P885, DOI 10.1016/j.cnsns.2010.05.025; Lim SN, 2016, NEUROMODULATION; Loscher W, 2013, NAT REV DRUG DISCOV, V12, P757, DOI 10.1038/nrd4126; Loup F, 2000, J NEUROSCI, V20, P5401, DOI 10.1523/JNEUROSCI.20-14-05401.2000; Ma J, 2017, NONLINEAR DYNAM, V89, P1569, DOI 10.1007/s11071-017-3565-3; Maccotta L, 2013, NEUROIMAGE-CLIN, V2, P862, DOI 10.1016/j.nicl.2013.06.011; MANFORD M, 1992, NEUROLOGY, V42, P1911; Marquez MF, 2015, INT J CARDIOL, V180, P206, DOI 10.1016/j.ijcard.2014.11.157; Maschio M, 2012, CURR NEUROPHARMACOL, V10, P124, DOI 10.2174/157015912800604470; Mathern GW, 1999, NEUROLOGY, V52, P453, DOI 10.1212/WNL.52.3.453; McGrother CW, 2006, SEIZURE-EUR J EPILEP, V15, P376, DOI 10.1016/j.seizure.2006.04.002; Miles R., 2012, CHLORIDE HOMEOSTASIS; MORRIS C, 1981, BIOPHYS J, V35, P193, DOI 10.1016/S0006-3495(81)84782-0; Moshe SL, 2015, LANCET, V385, P884, DOI 10.1016/S0140-6736(14)60456-6; Ngugi AK, 2010, EPILEPSIA, V51, P883, DOI 10.1111/j.1528-1167.2009.02481.x; Olsen R W, 1999, Adv Neurol, V79, P499; Pearl PL, 2016, DEV MED CHILD NEUROL, V58, P330, DOI 10.1111/dmcn.13078; Perrodin C, 2014, J NEUROSCI, V34, P2524, DOI 10.1523/JNEUROSCI.2805-13.2014; Picot MC, 2008, EPILEPSIA, V49, P1230, DOI 10.1111/j.1528-1167.2008.01579.x; Pitkanen A, 2002, LANCET NEUROL, V1, P173, DOI 10.1016/S1474-4422(02)00073-X; Pitkanen A, 2016, LANCET NEUROL, V15, P185, DOI 10.1016/S1474-4422(15)00248-3; Pitkanen A, 2014, NEUROTHERAPEUTICS, V11, P286, DOI 10.1007/s13311-014-0260-7; Purves D, 1985, PRINCIPLES NEURAL DE; Quintas R, 2012, EPILEPSY BEHAV, V25, P60, DOI 10.1016/j.yebeh.2012.05.016; Raiesdana S, 2013, NEUROCOMPUTING, V111, P54, DOI 10.1016/j.neucom.2012.11.033; Rogawski M., 2012, JASPERS BASIC MECH E; Schmidt C, 2013, IEEE T BIO-MED ENG, V60, P1378, DOI 10.1109/TBME.2012.2235835; Schmidt D, 2014, BMJ-BRIT MED J, V348, P1136; Serafini R, 2015, CLIN NEUROPHYSIOL, V126, P1117, DOI 10.1016/j.clinph.2014.08.023; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Singh G, 2008, EPILEPSIA, V49, P1, DOI 10.1111/j.1528-1167.2008.01748.x; Sirven JI, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a022848; Sisodiya SM, 2002, BRAIN, V125, P22, DOI 10.1093/brain/awf002; SKARDA CA, 1987, BEHAV BRAIN SCI, V10, P161, DOI 10.1017/S0140525X00047336; Stamova I, 2014, INT J ADAPT CONTROL, V28, P1227, DOI 10.1002/acs.2440; Takeshita D, 2007, PHYS REV E, V75, DOI 10.1103/PhysRevE.75.051925; Terry Jr RS, 2014, EPILEPSY TOPICS, P139, DOI DOI 10.5772/58332); Timofeev I., 2012, NEURONAL SYNCHRONIZA; Trauner DA, 2015, EPILEPSY BEHAV, V47, P163, DOI 10.1016/j.yebeh.2014.10.020; van Blarikom W, 2006, EPILEPSY BEHAV, V9, P14, DOI 10.1016/j.yebeh.2006.04.001; van Straaten ECW, 2013, EUR NEUROPSYCHOPHARM, V23, P7, DOI 10.1016/j.euroneuro.2012.10.010; Vecht CJ, 2014, ONCOLOGIST, V19, P751, DOI 10.1634/theoncologist.2014-0060; Velazquez JLP, 2003, PHYSICA D, V186, P205, DOI 10.1016/j.physd.2003.07.002; Vezzani A, 2013, EXP NEUROL, V244, P11, DOI 10.1016/j.expneurol.2011.09.033; Viscidi EW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067797; Voltzenlogel V, 2015, EPILEPSY RES, V115, P126, DOI 10.1016/j.eplepsyres.2015.06.006; Wallace RH, 1998, NAT GENET, V19, P366; Wang Y, 2017, INT J BIFURCAT CHAOS, V27, DOI 10.1142/S0218127417500304; Wieser HG, 2004, EPILEPSIA, V45, P32; Wilson HR, 1999, J THEOR BIOL, V200, P375, DOI 10.1006/jtbi.1999.1002; Wisniewski I, 2012, EPILEPSY BEHAV, V23, P254, DOI 10.1016/j.yebeh.2011.12.006; Wu Y, 2015, NEUROSCIENCE, V287, P175, DOI 10.1016/j.neuroscience.2014.06.046; Yeh CC, 2013, J NEUROL NEUROSUR PS, V84, P441, DOI 10.1136/jnnp-2012-302547; Yizhar O, 2012, J MOL NEUROSCI, V48, pS128	105	24	24	3	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-0779	1873-2887		CHAOS SOLITON FRACT	Chaos Solitons Fractals	DEC	2017	105						150	156		10.1016/j.chaos.2017.10.028			7	Mathematics, Interdisciplinary Applications; Physics, Multidisciplinary; Physics, Mathematical	Mathematics; Physics	FO2TK	WOS:000416642100019					2021-06-18	
J	Zhao, Y; Dong, QL; Chen, HB; Iraji, A; Li, YJ; Makkie, M; Kou, ZF; Liu, TM				Zhao, Yu; Dong, Qinglin; Chen, Hanbo; Iraji, Armin; Li, Yujie; Makkie, Milad; Kou, Zhifeng; Liu, Tianming			Constructing fine-granularity functional brain network atlases via deep convolutional autoencoder	MEDICAL IMAGE ANALYSIS			English	Article						fMRI; Functional brain networks; Deep learning	RESTING-STATE FMRI; SPARSE REPRESENTATION; INDEPENDENT COMPONENT; CONNECTIVITY; ARCHITECTURE; SIGNALS; REGIONS; INJURY	State-of-the-art functional brain network reconstruction methods such as independent component analysis (ICA) or sparse coding of whole-brain fMRI data can effectively infer many thousands of volumetric brain network maps from a large number of human brains. However, due to the variability of individual brain networks and the large scale of such networks needed for statistically meaningful group-level analysis, it is still a challenging and open problem to derive group-wise common networks as network atlases. Inspired by the superior spatial pattern description ability of the deep convolutional neural networks (CNNs), a novel deep 3D convolutional autoencoder (CAE) network is designed here to extract spatial brain network features effectively, based on which an Apache Spark enabled computational framework is developed for fast clustering of larger number of network maps into fine-granularity atlases. To evaluate this framework, 10 resting state networks (RSNs) were manually labeled from the sparsely decomposed networks of Human Connectome Project (HCP) fMRI data and 5275 network training samples were obtained, in total. Then the deep CAE models are trained by these functional networks' spatial maps, and the learned features are used to refine the original 10 RSNs into 17 network atlases that possess fine-granularity functional network patterns. Interestingly, it turned out that some manually mislabeled outliers in training networks can be corrected by the deep CAE derived features. More importantly, fine granularities of networks can be identified and they reveal unique network patterns specific to different brain task states. By further applying this method to a dataset of mild traumatic brain injury study, it shows that the technique can effectively identify abnormal small networks in brain injury patients in comparison with controls. In general, our work presents a promising deep learning and big data analysis solution for modeling functional connectomes, with fine granularities, based on fMRI data. (C) 2017 Elsevier B.V. All rights reserved.	[Zhao, Yu; Dong, Qinglin; Chen, Hanbo; Li, Yujie; Makkie, Milad; Liu, Tianming] Univ Georgia, Dept Comp Sci, Cort Architecture Imaging & Discovery Lab, Athens, GA 30602 USA; [Zhao, Yu; Dong, Qinglin; Chen, Hanbo; Li, Yujie; Makkie, Milad; Liu, Tianming] Univ Georgia, Bioimaging Res Ctr, Athens, GA 30602 USA; [Iraji, Armin; Kou, Zhifeng] Wayne State Univ, Dept Biomed Engn, Detroit, MI USA	Liu, TM (corresponding author), Univ Georgia, Dept Comp Sci, Cort Architecture Imaging & Discovery Lab, Athens, GA 30602 USA.; Liu, TM (corresponding author), Univ Georgia, Bioimaging Res Ctr, Athens, GA 30602 USA.	tliu@uga.edu	Dong, Qinglin/V-9204-2019		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA033393, AG042599, R21NS090153]; National Science FoundationNational Science Foundation (NSF) [IIS-1149260, CBET-1302089, BCS-1439051, DBI-1564736]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS090153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG042599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA033393] Funding Source: NIH RePORTER	T. Liu was partially supported by National Institutes of Health (DA033393, AG042599) and National Science Foundation (IIS-1149260, CBET-1302089, BCS-1439051 and DBI-1564736). Z. Kou was partially supported by National Institutes of Health (R21NS090153). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Barch DM, 2013, NEUROIMAGE, V80, P169, DOI 10.1016/j.neuroimage.2013.05.033; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Bengio Y, 2007, GREEDY LAYER WISE TR; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Calhoun VD, 2004, NEUROPSYCHOPHARMACOL, V29, P2097, DOI 10.1038/sj.npp.1300543; Chen HB, 2013, IEEE T MED IMAGING, V32, P1576, DOI [10.1109/TMI.2013.2259248, 10.1007/978-3-642-33454-2_37]; DEVALOIS RL, 1982, VISION RES, V22, P531, DOI 10.1016/0042-6989(82)90112-2; Dosenbach NUF, 2006, NEURON, V50, P799, DOI 10.1016/j.neuron.2006.04.031; Duncan J, 2010, TRENDS COGN SCI, V14, P172, DOI 10.1016/j.tics.2010.01.004; Fedorenko E, 2013, P NATL ACAD SCI USA, V110, P16616, DOI 10.1073/pnas.1315235110; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Ge B, 2016, BRAIN IMAGING BEHAV, V10, P1206, DOI 10.1007/s11682-015-9487-0; Gilmore CS, 2016, BRAIN BEHAV, V6, DOI 10.1002/brb3.454; He K, 2015, DELVING DEEP RECTIFI; Heeger DJ, 2002, NAT REV NEUROSCI, V3, P142, DOI 10.1038/nrn730; Hinton GE, 2006, NEURAL COMPUT, V18, P1527, DOI 10.1162/neco.2006.18.7.1527; Hu XT, 2015, IEEE T AUTON MENT DE, V7, P65, DOI 10.1109/TAMD.2015.2409835; Iraji A, 2015, J NEUROTRAUM, V32, P1031, DOI 10.1089/neu.2014.3610; Jiang X, 2015, HUM BRAIN MAPP, V36, P5301, DOI 10.1002/hbm.23013; Karpathy A, 2014, PROC CVPR IEEE, P1725, DOI 10.1109/CVPR.2014.223; Krizhevsky A, 2017, COMMUN ACM, V60, P84, DOI 10.1145/3065386; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Lecun Y., 1998, P V SVM VIRT SUPP VE; Li X, 2016, KDD'16: PROCEEDINGS OF THE 22ND ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING, P511, DOI 10.1145/2939672.2939730; Liu N, 2015, PROC CVPR IEEE, P362, DOI 10.1109/CVPR.2015.7298633; Lowe D. G., 1999, Proceedings of the Seventh IEEE International Conference on Computer Vision, P1150, DOI 10.1109/ICCV.1999.790410; Lv JL, 2015, LECT NOTES COMPUT SC, V9349, P239, DOI 10.1007/978-3-319-24553-9_30; Lv JL, 2015, PSYCHIAT RES-NEUROIM, V233, P254, DOI 10.1016/j.pscychresns.2015.07.012; Lv JL, 2015, IEEE T BIO-MED ENG, V62, P1120, DOI 10.1109/TBME.2014.2369495; Lv JL, 2015, MED IMAGE ANAL, V20, P112, DOI 10.1016/j.media.2014.10.011; Mairal J, 2010, J MACH LEARN RES, V11, P19; Masci J, 2011, LECT NOTES COMPUT SC, V6791, P52, DOI 10.1007/978-3-642-21735-7_7; McCarthy, 2004, FUNCTIONAL MAGNETIC; Pessoa L, 2012, BEHAV BRAIN SCI, V35, P158, DOI 10.1017/S0140525X11001567; Schairer K., 2012, AM SPEECH LANGUAGE H, V16, P18, DOI DOI 10.1044/HHD16.1.18; Serre T, 2005, PROC CVPR IEEE, P994; Simonyan K, 2014, ABS14091556; Smith SM, 2013, NEUROIMAGE, V80, P144, DOI 10.1016/j.neuroimage.2013.05.039; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Sporns Olaf, 2013, Dialogues Clin Neurosci, V15, P247; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Vander Werff KR, 2012, PERSPECTIVES HEARING, V16, P3, DOI DOI 10.1044/HHD16.13; von Luxburg U, 2007, STAT COMPUT, V17, P395, DOI 10.1007/s11222-007-9033-z; Worsley KJ, 1997, HUM BRAIN MAPP, V5, P254, DOI 10.1002/(SICI)1097-0193(1997)5:4<254::AID-HBM9>3.0.CO;2-2; Xu JS, 2016, NEUROSCI BIOBEHAV R, V71, P83, DOI 10.1016/j.neubiorev.2016.08.035; Zeiler M. D., 2012, ADADELTA ADAPTIVE LE; Zhang S, 2016, BRAIN IMAGING BEHAV, V10, P21, DOI 10.1007/s11682-015-9359-7; Zhao S., 2017, BRAIN IMAGI IN PRESS; Zhao SJ, 2015, IEEE T MED IMAGING, V34, P2036, DOI 10.1109/TMI.2015.2418734; Zhao Y, 2016, NEUROIMAGE-CLIN, V12, P23, DOI 10.1016/j.nicl.2016.06.004	51	24	24	2	38	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1361-8415	1361-8423		MED IMAGE ANAL	Med. Image Anal.	DEC	2017	42						200	211		10.1016/j.media.2017.08.005			12	Computer Science, Artificial Intelligence; Computer Science, Interdisciplinary Applications; Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging	Computer Science; Engineering; Radiology, Nuclear Medicine & Medical Imaging	FN1VA	WOS:000415778100014	28843214	Green Accepted			2021-06-18	
J	Meier, TB; Nelson, LD; Huber, DL; Bazarian, JJ; Hayes, RL; McCrea, MA				Meier, Timothy B.; Nelson, Lindsay D.; Huber, Daniel L.; Bazarian, Jeffrey J.; Hayes, Ronald L.; McCrea, Michael A.			Prospective Assessment of Acute Blood Markers of Brain Injury in Sport-Related Concussion	JOURNAL OF NEUROTRAUMA			English	Article						GFAP; mild traumatic brain injury; S100B; UCH-L1	FIBRILLARY ACIDIC PROTEIN; C-TERMINAL HYDROLASE-L1; HEAD COMPUTED-TOMOGRAPHY; TRAUMATIC INTRACRANIAL LESIONS; FOOTBALL PLAYERS; NEUROSURGICAL INTERVENTION; SERUM BIOMARKERS; MILD; S100B; CHILDREN	There is a pressing need to identify objective biomarkers for the assessment of sport-related concussion (SRC) to reduce the reliance on clinical judgment for the management of these injuries. The goal of the current study was to prospectively establish the acute effects of SRC on serum levels of S100 calcium-binding protein beta (S100B), glial fibrillary acidic protein (GFAP), and ubiquitin C-terminal hydrolase-L1 (UCH-L1). Collegiate and high school football players were enrolled and provided blood at pre-season. Injured athletes participated in follow-up visits at similar to 6 and 24-48 h following documented SRC (n = 32). Uninjured football players participated in similar follow-up visits and served as controls (n = 29). The median time between injury and blood collection was 2 h (6 h visit) and 22.5 h (24-48 h visit) in concussed athletes. Concussed athletes had significantly elevated UCH-L1 levels at the 6 h visit relative to pre-season levels (Z = 2.22, p = 0.03) and levels in control athletes (Z = 3.02, p = 0.003). Concussed athletes also had elevated S100B at 6 h relative to pre-season (Z = 2.07, p = 0.04) and controls (Z = 2.75, p = 0.006). Both markers showed fair discrimination between concussed and control athletes (UCH-L1 area under receiver operating characteristic curve [AUC] [95% CI] = 0.74 [0.61-0.88], S100B AUC=0.72 [0.58-0.87]). Percent-change of UCH-L1 and S100B at 6 h relative to pre-season also showed fair discrimination (AUC = 0.79 [0.66-0.92] and AUC=0.77 [0.64-0.90]). GFAP levels did not differ between groups or in concussed athletes relative to pre-season. This study provides prospective evidence of significant increases in serum levels of UCH-L1 and S100B during the early acute period following SRC, and lays the foundation for future studies examining the clinical potential for blood-based biomarkers in the early detection of concussion.	[Meier, Timothy B.; Nelson, Lindsay D.; Huber, Daniel L.; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Meier, Timothy B.] Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA; [Nelson, Lindsay D.; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Bazarian, Jeffrey J.] Univ Rochester, Sch Med, Dept Emergency Med, Rochester, NY USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Banyan Labs, Alachua, FL USA	Meier, TB (corresponding author), Med Coll Wisconsin, Neurosci Res Ctr, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	tmeier@mcw.edu		Huber, Daniel/0000-0003-2079-0647	Defense Health Program under the Department of Defense Broad Agency Announcement for Extramural Medical Research [W81XWH-14-10561]; National Center for Advancing Translational Sciences, National Institutes of Health (NIH) [8UL1TR000055, 1UL1-RR031973 (-01)]	This work was supported by the Defense Health Program under the Department of Defense Broad Agency Announcement for Extramural Medical Research through Award No. W81XWH-14-10561. This project was also supported by the National Center for Advancing Translational Sciences, National Institutes of Health (NIH), through Grant Number 8UL1TR000055 and 1UL1-RR031973 (-01). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense. The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Dr. Meier had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.	Asadollahi S, 2016, BRAIN INJURY, V30, P172, DOI 10.3109/02699052.2015.1091504; Barth JT, 2002, ENCY HUMAN BRAIN, P81; Bazarian JJ, 2013, J NEUROTRAUM, V30, P1747, DOI 10.1089/neu.2013.2853; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI [10.1089/neu.2008.0738, 10.1089/neu.2008-0738]; Bouvier D, 2017, SPORTS MED, V47, P781, DOI 10.1007/s40279-016-0579-9; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Graham MR, 2015, INT J IMMUNOPATH PH, V28, P539, DOI 10.1177/0394632015577045; Graham MR, 2011, INT J IMMUNOPATH PH, V24, P119, DOI 10.1177/039463201102400114; Holdnack H, 2001, WECHSLER TEST ADULT; Kiechle K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084977; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; Kulbe JR, 2016, EXP NEUROL, V275, P334, DOI 10.1016/j.expneurol.2015.05.004; Mannix R, 2014, J NEUROTRAUM, V31, P1072, DOI 10.1089/neu.2013.3265; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mondello S, 2016, SCI REP-UK, V6, DOI 10.1038/srep28203; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2016, J NEUROTRAUM, V33, P58, DOI 10.1089/neu.2015.3869; Papa L, 2015, ACAD EMERG MED, V22, P1274, DOI 10.1111/acem.12795; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Posti JP, 2017, J NEUROTRAUM, V34, P1427, DOI 10.1089/neu.2016.4442; Posti JP, 2016, NEUROSURGERY, V79, P456, DOI 10.1227/NEU.0000000000001226; Puvenna V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096296; Qu BX, 2016, J NEUROTRAUM, V33, pA19; Schulte S, 2014, J ATHL TRAINING, V49, P830, DOI 10.4085/1062-6050-49.3.33; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Takala RSK, 2016, WORLD NEUROSURG, V87, P8, DOI 10.1016/j.wneu.2015.10.066; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Weissberg I, 2014, JAMA NEUROL, V71, P1453, DOI 10.1001/jamaneurol.2014.2682; Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	40	24	24	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2017	34	22					3134	3142		10.1089/neu.2017.5046			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FL9GC	WOS:000414560000009	28699381	Green Published			2021-06-18	
J	Tan, XG; Przekwas, AJ; Gupta, RK				Tan, X. G.; Przekwas, A. J.; Gupta, R. K.			Computational modeling of blast wave interaction with a human body and assessment of traumatic brain injury	SHOCK WAVES			English	Article						Blast waves; Human body; Coupled modeling; Biomechanics; Traumatic brain injury	DIFFRACTION; SIMULATION; RESPONSES	The modeling of human body biomechanics resulting from blast exposure poses great challenges because of the complex geometry and the substantial material heterogeneity. We developed a detailed human body finite element model representing both the geometry and the materials realistically. The model includes the detailed head (face, skull, brain and spinal cord), the neck, the skeleton, air cavities (lungs) and the tissues. Hence, it can be used to properly model the stress wave propagation in the human body subjected to blast loading. The blast loading on the human was generated from a simulated C4 explosion. We used the highly scalable solvers in the multi-physics code CoBi for both the blast simulation and the human body biomechanics. The meshes generated for these simulations are of good quality so that relatively large time-step sizes can be used without resorting to artificial time scaling treatments. The coupled gas dynamics and biomechanics solutions were validated against the shock tube test data. The human body models were used to conduct parametric simulations to find the biomechanical response and the brain injury mechanism due to blasts impacting the human body. Under the same blast loading condition, we showed the importance of inclusion of the whole body.	[Tan, X. G.; Przekwas, A. J.] CFD Res Corp, Huntsville, AL 35806 USA; [Tan, X. G.] US Naval Res Lab, Washington, DC 20375 USA; [Gupta, R. K.] US Army Med Res & Mat Command, Frederick, MD 21702 USA	Tan, XG (corresponding author), CFD Res Corp, Huntsville, AL 35806 USA.; Tan, XG (corresponding author), US Naval Res Lab, Washington, DC 20375 USA.	Gary.Tan@nrl.navy.mil			DoD Blast Injury Research Program Coordinating Office [W81XWH-14-C-0045]; DoD Congressionally Directed Medical Research Programs [W81XWH-09-2-0168]	This work has resulted from the research project "Physics and Physiology Based Human Body Model of Blast Injury and Protection" (Contract # W81XWH-14-C-0045) managed by the DoD Blast Injury Research Program Coordinating Office. The authors would like to express their appreciation to the DoD Congressionally Directed Medical Research Programs (Contract # W81XWH-09-2-0168) for supporting the initial work. The content included in this work does not necessarily reflect the position or policy of the US government. The authors are very grateful to the reviewers and Amit Bagchi for their careful and meticulous reading of the paper. The reviews were helpful to finalize the manuscript. The authors would like to kindly acknowledge them.	Badia S, 2008, J COMPUT PHYS, V227, P7027, DOI 10.1016/j.jcp.2008.04.006; Baeck K, 2014, COMPUT METHOD BIOMEC, V17, P405, DOI 10.1080/10255842.2012.688106; Belytschko T., 2001, NONLINEAR FINITE ELE; Brands DWA, 2002, THESIS; BRYSON AE, 1961, J FLUID MECH, V10, P1, DOI 10.1017/S0022112061000019; Cotton RT, 2016, COMPUT METHOD BIOMEC, V19, P101, DOI 10.1080/10255842.2014.994118; DAWSON SL, 1980, HUM PATHOL, V11, P155, DOI 10.1016/S0046-8177(80)80136-5; de Lanerolle NC, 2011, J NEUROPATH EXP NEUR, V70, P1046, DOI 10.1097/NEN.0b013e318235bef2; Eskridge SL, 2012, INJURY, V43, P1678, DOI 10.1016/j.injury.2012.05.027; Gayzik FS, 2012, ANN BIOMED ENG, V40, P2019, DOI 10.1007/s10439-012-0546-z; Godunov S.K., 1959, MATEMATICHESKII SBOR, V47, P271; Goeller J, 2012, J NEUROTRAUM, V29, P1970, DOI 10.1089/neu.2011.2224; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gupta R.K., 2015, P ICCM2015 AUCKL NZ; Gupta RK, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00059; Hallquist, 2006, LS DYNA THEORY MANUA; Heltemes KJ, 2012, INJURY, V43, P1990, DOI 10.1016/j.injury.2011.07.021; Horgan T.J., 2008, INT J CRASHWORTHINES, V8, P1, DOI DOI 10.1533/IJCR.2003.0243; Hull J. B, 1995, THESIS; Ji SB, 2014, ANN BIOMED ENG, V42, P11, DOI 10.1007/s10439-013-0907-2; Kannan R, 2014, J PARALLEL DISTR COM, V74, P2808, DOI 10.1016/j.jpdc.2014.05.001; KIEFFER SW, 1977, J GEOPHYS RES, V82, P2895, DOI 10.1029/JB082i020p02895; Kingery C.N., 1984, ARBRLTR02555 US ARM; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; Panzer Matthew B, 2012, Front Neurol, V3, P46, DOI 10.3389/fneur.2012.00046; Przekwas A, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00002; Puso MA, 2012, COMPUT METHOD APPL M, V245, P273, DOI 10.1016/j.cma.2012.07.014; Ripley RC, 2006, COMPUT FLUIDS, V35, P1420, DOI 10.1016/j.compfluid.2005.05.001; Roberts JC, 2007, J BIOMECH, V40, P125, DOI 10.1016/j.jbiomech.2005.11.003; Roberts JC, 2012, J BIOMECH, V45, P2899, DOI 10.1016/j.jbiomech.2012.07.027; SIMO JC, 1991, COMPUT METHOD APPL M, V85, P273, DOI 10.1016/0045-7825(91)90100-K; Sugiyama K, 2011, J COMPUT PHYS, V230, P596, DOI 10.1016/j.jcp.2010.09.032; Takhounts EG, 2008, STAPP CAR C, V52, P1; Tan XG, 2014, PROCEEDINGS OF THE ASME INTERNATIONAL MECHANICAL ENGINEERING CONGRESS AND EXPOSITION, 2013, VOL 3A; Tan X. Gary, 2011, International Journal of Human Factors Modelling and Simulation, V2, P85, DOI 10.1504/IJHFMS.2011.041639; Tan X.G., 2012, P ASME INT MECH ENG; Toro E. F., 1994, Shock Waves, V4, P25, DOI 10.1007/BF01414629; VENKATAKRISHNAN V, 1995, J COMPUT PHYS, V118, P120, DOI 10.1006/jcph.1995.1084; Wallis G. B., 1969, ONE DIMENSIONAL 2 PH; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	41	24	25	0	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0938-1287	1432-2153		SHOCK WAVES	Shock Waves	NOV	2017	27	6					889	904		10.1007/s00193-017-0740-x			16	Mechanics	Mechanics	FN4BE	WOS:000415946600007					2021-06-18	
J	Huang, B; Jiang, XC; Zhang, TY; Hu, YL; Tabata, Y; Chen, Z; Pluchino, S; Gao, JQ				Huang, Bing; Jiang, Xin-Chi; Zhang, Tian-Yuan; Hu, Yu-Lan; Tabata, Yasuhiko; Chen, Zhong; Pluchino, Stefano; Gao, Jian-Qing			Peptide modified mesenchymal stem cells as targeting delivery system transfected with miR-133b for the treatment of cerebral ischemia	INTERNATIONAL JOURNAL OF PHARMACEUTICS			English	Article						Mesenchymal stem cells; Targeting delivery system; Cerebral ischemia; Membrane coating; Peptide-based cell targeting; MiR-133b transfection Stem; cell-based targeting therapy	MARROW STROMAL CELLS; LEUKOTRIENE RECEPTOR-1 ANTAGONIST; HUMAN MYOCARDIAL-INFARCTION; CLOSED-HEAD INJURY; NONVIRAL TRANSFECTION; BEHAVIORAL DEFICITS; FUNCTIONAL RECOVERY; ARTERY OCCLUSION; PROGENITOR CELLS; RAT MODEL	Mesenchymal stem cells (MSCs) have been regarded as potential targeting vehicles and demonstrated to exert therapeutic benefits for brain diseases. Direct homing to diseased tissue is crucial for stem cell-based therapy. In this study, a peptide-based targeting approach was established to enhance cell homing to cerebral ischemic lesion. Palmitic acid-peptide painted onto the cell membrane was able to direct MSCs to ischemic tissues without any observed cell cytotoxicity and influence on differentiation, thus reducing accumulation of cells in peripheral organs and increasing engraftment of cells in the targeted tissues. With enhanced cell homing, MSCs were used to deliver miR-133b to increase the expression level of miR-133b in an ischemic lesion and further improve therapeutic effects. This study is the first to develop MSCs co-modified with targeting peptide and microRNAs as potential targeting therapeutic agents. This targeting delivery system is expected to be applicable to other cell types and other diseases aside from stroke.	[Huang, Bing; Jiang, Xin-Chi; Zhang, Tian-Yuan; Hu, Yu-Lan; Gao, Jian-Qing] Zhejiang Univ, Inst Pharmaceut, Coll Pharmaceut Sci, Hangzhou, Zhejiang, Peoples R China; [Tabata, Yasuhiko] Kyoto Univ, Inst Frontier Med Sci, Dept Biomat, Kyoto, Japan; [Chen, Zhong] Zhejiang Univ, Dept Pharmacol, Coll Pharmaceut Sci, Key Lab Med Neurobiol,Minist Hlth China, Hangzhou, Zhejiang, Peoples R China; [Pluchino, Stefano] Univ Cambridge, Dept Clin Neurosci, Wellcome Trust Med Res Council Stem Cell Inst, Cambridge, Cambs, England; [Gao, Jian-Qing] Zhejiang Univ, Dr Li Dak Sum & Yip Yio Chin Ctr Stem Cell & Rege, Hangzhou, Zhejiang, Peoples R China	Gao, JQ (corresponding author), Zhejiang Univ, Dr Li Dak Sum & Yip Yio Chin Ctr Stem Cell & Rege, Inst Pharmaceut, Coll Pharmaceut Sci, Hangzhou, Zhejiang, Peoples R China.	gaojianqing@zju.edu.cn	Pluchino, Stefano/AAE-9037-2019; Song, Eun Joo/Z-5130-2019	Pluchino, Stefano/0000-0002-6267-9472; 	Zhejiang Provincial Natural Science Foundation of ChinaNatural Science Foundation of Zhejiang Province [LZ14H300001]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81620108028, 81473143, 81273441]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_PC_12009] Funding Source: researchfish	This work was supported by Zhejiang Provincial Natural Science Foundation of China (LZ14H300001) and National Natural Science Foundation of China (81620108028, 81473143, 81273441).	Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Bacigaluppi M, 2008, J NEUROL SCI, V265, P73, DOI 10.1016/j.jns.2007.06.012; Bacigaluppi M, 2009, BRAIN, V132, P2239, DOI 10.1093/brain/awp174; Bao XJ, 2011, BRAIN RES, V1367, P103, DOI 10.1016/j.brainres.2010.10.063; Boado RJ, 1998, J NEUROCHEM, V71, P1761; BORLONGAN CV, 1995, BRAIN RES, V676, P231, DOI 10.1016/0006-8993(95)00150-O; Bostjancic E, 2010, CARDIOLOGY, V115, P163, DOI 10.1159/000268088; Bostjancic E, 2009, DIS MARKERS, V27, P255, DOI 10.3233/DMA-2009-0671; Brenneman M, 2010, J CEREBR BLOOD F MET, V30, P140, DOI 10.1038/jcbfm.2009.198; Celia C, 2011, MED RES REV, V31, P716, DOI 10.1002/med.20201; Chavakis E, 2008, J MOL CELL CARDIOL, V45, P514, DOI 10.1016/j.yjmcc.2008.01.004; Chen AS, 2000, J IMMUNOL, V164, P705, DOI 10.4049/jimmunol.164.2.705; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Dharmasaroja P, 2009, J CLIN NEUROSCI, V16, P12, DOI 10.1016/j.jocn.2008.05.006; Doeppner TR, 2012, STEM CELLS, V30, P1297, DOI 10.1002/stem.1098; Dreyer JL, 2010, GENOME MED, V2, DOI 10.1186/gm213; Garcia-Garcia E, 2005, INT J PHARMACEUT, V298, P274, DOI 10.1016/j.ijpharm.2005.03.031; GERMANO AF, 1994, J NEUROTRAUM, V11, P345, DOI 10.1089/neu.1994.11.345; Gladstone DJ, 2002, STROKE, V33, P2123, DOI 10.1161/01.STR.0000025518.34157.51; Hayase M., 2015, J CEREB BLOOD FLOW M, V149, P1334; He CX, 2012, BIOTECHNOL APPL BIOC, V59, P163, DOI 10.1002/bab.1001; He CX, 2011, PHARM RES-DORDR, V28, P1577, DOI 10.1007/s11095-011-0390-0; Hong HY, 2008, J CONTROL RELEASE, V131, P167, DOI 10.1016/j.jconrel.2008.07.020; Hu YL, 2012, MOL PHARMACEUT, V9, P2698, DOI 10.1021/mp300254s; Hu YL, 2010, J CONTROL RELEASE, V147, P154, DOI 10.1016/j.jconrel.2010.05.015; Huang B, 2012, J CONTROL RELEASE, V162, P464, DOI 10.1016/j.jconrel.2012.07.034; Ikeda N, 2005, STROKE, V36, P2725, DOI 10.1161/01.STR.0000190006.88896.d3; Jo J, 2007, J CONTROL RELEASE, V118, P389, DOI 10.1016/j.jconrel.2007.01.005; Jo J, 2010, J BIOMAT SCI-POLYM E, V21, P185, DOI 10.1163/156856209X415495; Joyce N, 2010, REGEN MED, V5, P933, DOI [10.2217/rme.10.72, 10.2217/RME.10.72]; Kang S. K., 2011, STEM CELLS INT, V2012, P147; Karp JM, 2009, CELL STEM CELL, V4, P206, DOI 10.1016/j.stem.2009.02.001; Kean TJ, 2012, J DRUG TARGET, V20, P23, DOI 10.3109/1061186X.2011.622398; Kim J, 2007, SCIENCE, V317, P1220, DOI 10.1126/science.1140481; Ko IK, 2009, BIOMATERIALS, V30, P3702, DOI 10.1016/j.biomaterials.2009.03.038; Kraitchman DL, 2005, CIRCULATION, V112, P1451, DOI 10.1161/CIRCULATIONAHA.105.537480; Kurozumi K, 2004, MOL THER, V9, P189, DOI 10.1016/j.ymthe.2003.10.012; Li JW, 2011, BIOMATERIALS, V32, P4943, DOI 10.1016/j.biomaterials.2011.03.031; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Sanchez-Simon FM, 2010, MOL PHARMACOL, V78, P935, DOI 10.1124/mol.110.066837; Matsuse D, 2011, TISSUE ENG PT A, V17, P1993, DOI [10.1089/ten.TEA.2010.0585, 10.1089/ten.tea.2010.0585]; Nakamura K, 2004, GENE THER, V11, P1155, DOI 10.1038/sj.gt.3302276; Pardridge W. M., 2003, BLOOD BRAIN BARRIER; Pardridge WM, 2007, PHARM RES, V24, P1733, DOI 10.1007/s11095-007-9324-2; Pardridge WM, 1999, ADV DRUG DELIVER REV, V36, P299, DOI 10.1016/S0169-409X(98)00087-8; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Qin Y, 2012, J DRUG TARGET, V20, P235, DOI 10.3109/1061186X.2011.639022; Rosenblum S, 2012, STROKE, V43, P1624, DOI 10.1161/STROKEAHA.111.637884; Schallert T, 1997, ADV NEUROL, V73, P229; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; van Gijn J., 1998, LANCET S3, V352; Xin H., 2013, STROKE A, V135; Xin HQ, 2012, STEM CELLS, V30, P1556, DOI 10.1002/stem.1129; Yano S, 2005, BRAIN RES, V1065, P60, DOI 10.1016/j.brainres.2005.10.031; Ye YM, 2011, PHYSIOL GENOMICS, V43, P534, DOI 10.1152/physiolgenomics.00130.2010; Yu GL, 2005, BRAIN RES, V1053, P116, DOI 10.1016/j.brainres.2005.06.046; Yu GL, 2005, PHARMACOLOGY, V73, P31, DOI 10.1159/000081072; Yu XL, 2012, J NEUROL SCI, V316, P141, DOI 10.1016/j.jns.2012.01.001; Yu YM, 2011, EUR J NEUROSCI, V33, P1587, DOI 10.1111/j.1460-9568.2011.07643.x; Zhang TY, 2014, NANOMED-NANOTECHNOL, V10, P257, DOI 10.1016/j.nano.2013.06.003; Zhang ZH, 2008, NEUROSCI LETT, V444, P227, DOI 10.1016/j.neulet.2008.08.049	66	24	27	3	32	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0378-5173	1873-3476		INT J PHARMACEUT	Int. J. Pharm.	OCT 5	2017	531	1					90	100		10.1016/j.ijpharm.2017.08.073			11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	FG8AP	WOS:000410648200009	28827201	Green Accepted			2021-06-18	
J	Broglio, SP; Lapointe, A; O'Connor, KL; McCrea, M				Broglio, Steven P.; Lapointe, Andrew; O'Connor, Kathryn L.; McCrea, Michael			Head Impact Density: A Model To Explain the Elusive Concussion Threshold	JOURNAL OF NEUROTRAUMA			English	Article						concussion; head impacts; linear and rotational acceleration	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; HIGH-SCHOOL; FOOTBALL PLAYERS; POSTCONCUSSION SYNDROME; BIOMECHANICS; EXPOSURE; SEVERITY; RECOVERY	Concussion is a heterogeneous injury occurring throughout a range of impact magnitudes. Consequently, research focusing on a single or set of variables at the time of injury to understand concussive biomechanics has been thwarted by low injury prediction sensitivity. The current study examined the role of Impact Density in estimating concussive injury risk. Head impact data were collected across seven high school football seasons with the Head Impact Telemetry System (HIT System). Over the study period, 29 concussions were included for data analysis. The linear acceleration of the concussive impact was matched to a Control athlete, along with impacts in the 24 h before. Linear and rotational acceleration for the 19 impacts leading into the final event and the cumulative accelerations over time were evaluated. Analyses indicated no difference in impact counts within the final 24 h, or impact magnitudes for linear and rotational acceleration among the final 20 impacts (p > 0.05). A novel metric, Impact Density, was calculated from the final 20 impacts by summing the acceleration magnitude divided by time from the previous impact. Analyses indicated the Concussed athletes incurred a significantly higher linear (concussed: 255.4g/sec (standard error of the mean [SEM] = 40.1), controls: 145.4g/sec (SEM = 23.8), p = 0.016), and rotational (Concussed: 10311.3 rad/s/s/s (SEM = 1883.7), Controls: 6083.8 rad/s/s/s (SEM=1115.9), p = 0.029) Impact Density than the Control athletes. Similar to other investigations, there was no difference in individual linear or rotational impact magnitude in the 20 impacts before and including the injury. The measure of Impact Density, however, revealed differences between the Concussed and Control athletes. These data suggest that the biomechanical threshold for concussion fluctuates downwardly with a greater impact magnitude and number with a return to pre-impact levels with time, suggesting physiological vulnerability to repeated head impacts. The current results highlight that time between impacts, not just impact magnitude, influences risk for concussion.	[Broglio, Steven P.; Lapointe, Andrew; O'Connor, Kathryn L.] Univ Michigan, Injury Ctr, Neurotrauma Res Lab, 401 Washtenaw Ave, Ann Arbor, MI 48109 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA	Broglio, SP (corresponding author), Univ Michigan, Injury Ctr, Neurotrauma Res Lab, 401 Washtenaw Ave, Ann Arbor, MI 48109 USA.	broglio@umich.edu	Lapointe, Andrew/L-5698-2019	Lapointe, Andrew/0000-0002-9360-6428; Van Pelt, Kathryn/0000-0002-5494-2357	Skyline High School (Ann Arbor, MI); Father Gabriel Richard High School (Ann Arbor, MI); National Institutes of Health: National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R15NS081691-01]; Unity High School (Tolono, IL)	The authors would like to thank the football players and staff of Unity High School (Tolono, IL), Skyline High School (Ann Arbor, MI), and Father Gabriel Richard High School (Ann Arbor, MI) for their support of this project. In addition, we thank Douglas Martini, PhD, and Richelle Williams, PhD, ATC, for their assistance. The project was supported partly by The National Institutes of Health: National Institute of Neurological Disorders and Stroke (1R15NS081691-01).	Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broglio SP, 2011, J NEUROTRAUM, V28, P2061, DOI 10.1089/neu.2011.1905; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Eckner JT, 2011, J NEUROTRAUM, V28, P2079, DOI 10.1089/neu.2011.1910; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Gordon KE, 2006, BRIT J SPORT MED, V40, P184, DOI 10.1136/bjsm.2005.022251; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Gregory Sean, 2015, TIME; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Iverson GL, 2016, J ATTEN DISORD; King D, 2015, AM J SPORT MED, V43, P614, DOI 10.1177/0363546514560876; Kroshus E, 2015, SOC SCI MED, V134, P66, DOI 10.1016/j.socscimed.2015.04.011; LaRoche AA, 2016, CLIN J SPORT MED, V26, P33, DOI 10.1097/JSM.0000000000000192; Lynall RC, 2016, MED SCI SPORT EXER, V48, P1772, DOI 10.1249/MSS.0000000000000951; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2015, BRAIN INJURY, V29, P276, DOI 10.3109/02699052.2014.965216; McCuen E, 2015, J BIOMECH, V48, P3720, DOI 10.1016/j.jbiomech.2015.08.003; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; O'Connor KL, 2017, J ATHL TRAINING, V52, P206, DOI 10.4085/1062-6050.52.2.05; Patton DA, 2016, APPL BIONICS BIOMECH, V2016, DOI 10.1155/2016/7049743; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Sefton J. M., 2004, J ATHL TRAINING, V39, pS52; Siegmund GP, 2016, ANN BIOMED ENG, V44, P1257, DOI 10.1007/s10439-015-1420-6; Stevens Sean T, 2008, Res Sports Med, V16, P68, DOI 10.1080/15438620701879020; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1042, DOI 10.1093/oxfordjournals.aje.a116398; Wilcox BJ, 2015, J BIOMECH, V48, P2201, DOI 10.1016/j.jbiomech.2015.04.005; Wilcox BJ, 2014, J BIOMECH, V47, P109, DOI 10.1016/j.jbiomech.2013.10.004; Wood RL, 2014, J HEAD TRAUMA REHAB, V29, pE9, DOI 10.1097/HTR.0b013e31827eabba; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	40	24	24	0	24	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2017	34	19					2675	2683		10.1089/neu.2016.4767			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FI1DZ	WOS:000411672700001	28381134	Green Published			2021-06-18	
J	Esnault, P; Nguyen, C; Bordes, J; D'Aranda, E; Montcriol, A; Contargyris, C; Cotte, J; Goutorbe, P; Joubert, C; Dagain, A; Boret, H; Meaudre, E				Esnault, Pierre; Nguyen, Cedric; Bordes, Julien; D'Aranda, Erwan; Montcriol, Ambroise; Contargyris, Claire; Cotte, Jean; Goutorbe, Philippe; Joubert, Christophe; Dagain, Arnaud; Boret, Henry; Meaudre, Eric			Early-Onset Ventilator-Associated Pneumonia in Patients with Severe Traumatic Brain Injury: Incidence, Risk Factors, and Consequences in Cerebral Oxygenation and Outcome	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Ventilator; associated pneumonia; Risk factors; Incidence; Cerebral oxygenation; PbtO(2); Outcome	PULMONARY INFECTION SCORE; SUBARACHNOID HEMORRHAGE; ACQUIRED PNEUMONIA; PRACTICAL SCALE; PREVENTION; MANAGEMENT; DIAGNOSIS; BACTERIA; HYPOXIA; RATS	Early-onset ventilator-associated pneumonia (EOVAP) occurs frequently in severe traumatic brain-injured patients, but potential consequences on cerebral oxygenation and outcome have been poorly studied. The objective of this study was to describe the incidence, risk factors for, and consequences on cerebral oxygenation and outcome of EOVAP after severe traumatic brain injury (TBI). We conducted a retrospective, observational study including all intubated TBI admitted in the trauma center. An EOVAP was defined as a clinical pulmonary infection score > 6, and then confirmed by an invasive method. Patient characteristics, computed tomography (CT) scan results, and outcome were extracted from a prospective register of all intubated TBI admitted in the intensive care unit (ICU). Data concerning the cerebral oxygenation monitoring by PbtO(2) and characteristics of EOVAP were retrieved from patient files. Multivariate logistic regression models were developed to determine the risk factors of EOVAP and to describe the factors independently associated with poor outcome at 1-year follow-up. During 7 years, 175 patients with severe TBI were included. The overall incidence of EOVAP was 60.6% (47.4/1000 days of ventilation). Significant risk factors of EOVAP were: therapeutic hypothermia (OR 3.4; 95% CI [1.2-10.0]), thoracic AIS score ae<yen>3 (OR 2.4; 95% CI [1.1-5.7]), and gastric aspiration (OR 5.2, 95% CI [1.7-15.9]). Prophylactic antibiotics administration was a protective factor against EOVAP (OR 0.3, 95% CI [0.1-0.8]). EOVAP had negative consequences on cerebral oxygenation. The PbtO(2) was lower during EOVAP: 23.5 versus 26.4 mmHg (p < 0.0001), and there were more brain hypoxia episodes: 32 versus 27% (p = 0.03). Finally, after adjusting for confounders, an EOVAP was an independent factor associated with unfavorable neurologic functional outcome at the 1-year follow-up (OR 2.71; 95% CI [1.01-7.25]). EOVAP is frequent after a severe TBI (overall rate: 61%), with therapeutic hypothermia, severe thoracic lesion, and gastric aspiration as main risk factors. EOVAP had a negative impact on cerebral oxygenation measured by PbtO(2) and was independently associated with unfavorable outcome at 1-year follow-up. This suggests that all precautions available should be taken to prevent EOVAP in this population.	[Esnault, Pierre; Nguyen, Cedric; Bordes, Julien; D'Aranda, Erwan; Montcriol, Ambroise; Contargyris, Claire; Cotte, Jean; Goutorbe, Philippe; Boret, Henry; Meaudre, Eric] St Anne Mil Hosp, Intens Care Unit, Toulon, France; [Joubert, Christophe; Dagain, Arnaud] St Anne Mil Hosp, Dept Neurosurg, Toulon, France; [Dagain, Arnaud; Meaudre, Eric] Ecole Val de Grace, French Mil Hlth Serv, Acad Unit, Paris, France	Esnault, P (corresponding author), St Anne Mil Hosp, Intens Care Unit, Toulon, France.	pierre.esnault@gmail.com; ced040@hotmail.fr; bordes.julien@neuf.fr; erwanm3d@gmail.com; ambroise.montcriol@free.fr; contargyris@hotmail.com; jean.cotte@gmail.com; goutorbephil@live.fr; christophe.joubert@neurochirurgie.fr; dr.adagain@gmail.com; henryboret@me.com; eric.meaudre@club-internet.fr	Joubert, Christophe/AAU-4807-2020; Esnault, Pierre/AAN-5792-2020				Acquarolo A, 2005, INTENS CARE MED, V31, P510, DOI 10.1007/s00134-005-2585-5; Alali AS, 2015, VALUE HEALTH, V18, P721, DOI 10.1016/j.jval.2015.04.012; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388; ANTONELLI M, 1994, CHEST, V105, P224, DOI 10.1378/chest.105.1.224; Bao L, 2014, PLOS ONE, V13; Bratton SL, 2008, J NEUROTRAUM, V25, P276; Bronchard G, 2004, ANESTHESIOLOGY, V100, P234, DOI 10.1097/00000542-200402000-00009; Browne E, 2013, BMJ OPEN RESPIR RES, V1, DOI 10.1136/bmjresp-2014-000066; Chang JJJ, 2009, CRIT CARE MED, V37, P283, DOI 10.1097/CCM.0b013e318192fbd7; Cinotti R, 2014, EUR J CLIN MICROBIOL, V33, P823, DOI 10.1007/s10096-013-2020-8; Cotte J, 2013, BURNS, V39, P892, DOI 10.1016/j.burns.2012.12.003; Crossley S, 2014, CRIT CARE, V18, DOI 10.1186/cc13835; Damas P, 2015, CRIT CARE MED, V43, P22, DOI 10.1097/CCM.0000000000000674; de Smet AMGA, 2009, NEW ENGL J MED, V360, P20, DOI 10.1056/NEJMoa0800394; Fartoukh M, 2003, AM J RESP CRIT CARE, V168, P173, DOI 10.1164/rccm.200212-1449OC; Giantsou E, 2005, INTENS CARE MED, V31, P1488, DOI 10.1007/s00134-005-2697-y; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; JENNETT B, 1975, LANCET, V1, P480; Jovanovic B, 2015, INT J INFECT DIS, V38, P46, DOI 10.1016/j.ijid.2015.07.005; Kesinger MR, 2015, J TRAUMA ACUTE CARE, V78, P396, DOI 10.1097/TA.0000000000000526; Kim Y, 1996, STROKE, V27, P2274, DOI 10.1161/01.STR.27.12.2274; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lepelletier D, 2010, J NEUROSURG ANESTH, V22, P32, DOI 10.1097/ANA.0b013e3181bdf52f; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Manoel ALD, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1193-9; Michelet P, 2010, J TRAUMA, V68, P395, DOI 10.1097/TA.0b013e3181a601cb; Monton C, 1999, CRIT CARE MED, V27, P1745, DOI 10.1097/00003246-199909000-00008; Muscedere J, 2008, J CRIT CARE, V23, P138, DOI 10.1016/j.jcrc.2007.12.008; O'Phelan Kristine H, 2015, World J Crit Care Med, V4, P296, DOI 10.5492/wjccm.v4.i4.296; Oddo M, 2011, NEUROSURGERY, V69, P1037, DOI 10.1227/NEU.0b013e3182287ca7; Park David R, 2005, Respir Care, V50, P742; Pelosi P, 2008, CHEST, V134, P101, DOI 10.1378/chest.07-2546; Perbet S, 2011, AM J RESP CRIT CARE, V184, P1048, DOI 10.1164/rccm.201102-0331OC; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Rincon-Ferrari MD, 2004, J TRAUMA, V57, P1234, DOI 10.1097/01.TA.0000119200.70853.23; Shan J, 2011, RESP CARE, V56, P1087, DOI 10.4187/respcare.01097; Sirvent JM, 1997, AM J RESP CRIT CARE, V155, P1729, DOI 10.1164/ajrccm.155.5.9154884; TEASDALE G, 1974, LANCET, V2, P81; Trouillet JL, 1998, AM J RESP CRIT CARE, V157, P531, DOI 10.1164/ajrccm.157.2.9705064; Zygun DA, 2006, NEUROCRIT CARE, V5, P108, DOI 10.1385/NCC:5:2:108	41	24	30	0	9	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	OCT	2017	27	2					187	198		10.1007/s12028-017-0397-4			12	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	FJ4VC	WOS:000412739900006	28432539				2021-06-18	
J	Frassanito, P; Tamburrini, G; Massimi, L; Peraio, S; Caldarelli, M; Di Rocco, C				Frassanito, Paolo; Tamburrini, Gianpiero; Massimi, Luca; Peraio, Simone; Caldarelli, Massimo; Di Rocco, Concezio			Problems of reconstructive cranioplasty after traumatic brain injury in children	CHILDS NERVOUS SYSTEM			English	Article						Reconstructive cranioplasty; Brain injury; Autologous bone; Decompressive craniectomy; Alloplastic material; Biomaterial; Hydroxyapatite	SINGLE-CENTER EXPERIENCE; AUTOLOGOUS BONE FLAP; DECOMPRESSIVE CRANIECTOMY; INTRACRANIAL HYPERTENSION; CRANIAL REPAIR; EARLY OUTCOMES; RISK-FACTORS; SURGERY; COMPLICATIONS; ADOLESCENTS	Cranial repair after traumatic brain injury in children is still burdened by unsolved problems and controversial issues, mainly due to the high rate of resorption of autologous bone as well as the absence of valid alternative material to replace the autologous bone. Indeed, inert biomaterials are associated to satisfactory results in the short period but bear the continuous risk of complications related to the lack of osteointegration capacity. Biomimetic materials claiming osteoconductive properties that could balance their mechanical limits seem to allow good cranial bone reconstruction. However, these results should be confirmed in the long term and in larger series. Further complicating factors that may affect cranial reconstruction after head injury should be identified in the possible associated alterations of CSF dynamics and in difficulties to manage the traumatic skin lesion and the surgical wound, which also might impact on the cranioplasty outcome. All the abovementioned considerations should be taken into account when dealing with the cranial reconstruction after decompressive craniectomy in children.	[Frassanito, Paolo; Tamburrini, Gianpiero; Massimi, Luca; Peraio, Simone; Caldarelli, Massimo] Catholic Univ, Fdn Policlin Univ A Gemelli, Pediat Neurosurg, Sch Med, Largo A Gemelli 8, I-00168 Rome, Italy; [Di Rocco, Concezio] Int Neurosci Inst, Dept Neurosurg, Hannover, Germany	Frassanito, P (corresponding author), Catholic Univ, Fdn Policlin Univ A Gemelli, Pediat Neurosurg, Sch Med, Largo A Gemelli 8, I-00168 Rome, Italy.	paolo.frassanito@gmail.com	FRASSANITO, Paolo/K-4099-2018	FRASSANITO, Paolo/0000-0003-0071-3126			Beuriat PA, 2015, J NEUROSURG SCI, V59, P405; Biskup NI, 2010, J CRANIOFAC SURG, V21, P358, DOI 10.1097/SCS.0b013e3181cf606b; Blum KS, 1997, PEDIATR NEUROSURG, V26, P33, DOI 10.1159/000121158; Bowers CA, 2013, J NEUROSURG-PEDIATR, V11, P526, DOI 10.3171/2013.1.PEDS12483; Breisch E, 2010, FORENSIC SCI MED PAT, V6, P249, DOI 10.1007/s12024-009-9136-2; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Cordaro ER, 2011, J CRANIOFAC SURG, V22, P598, DOI 10.1097/SCS.0b013e3182077dca; De Bonis P, 2012, J NEUROTRAUM, V29, P1071, DOI 10.1089/neu.2011.2116; Duke BJ, 1996, PEDIATR NEUROSURG, V25, P31, DOI 10.1159/000121093; Feroze AH, 2015, J NEUROSURG, V123, P1098, DOI 10.3171/2014.11.JNS14622; Fiaschi P, 2016, J NEUROSURG-PEDIATR, V17, P705, DOI 10.3171/2015.10.PEDS15489; Fong KD, 2003, PLAST RECONSTR SURG, V112, P1312, DOI 10.1097/01.PRS.0000079860.14734.D6; Frassanito P, 2015, ACTA NEUROCHIR, V157, P115, DOI 10.1007/s00701-014-2254-y; Frassanito P, 2014, J NEUROSURG-PEDIATR, V13, P243, DOI 10.3171/2013.6.PEDS13312; Frassanito P, 2012, ACTA NEUROCHIR, V154, P927, DOI 10.1007/s00701-011-1253-5; Goodrich JT, 2012, CHILD NERV SYST, V28, P1577, DOI 10.1007/s00381-012-1776-y; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; Halani SH, 2017, NEUROSURGERY; HASEGAWA M, 1992, NEUROSURGERY, V31, P580, DOI 10.1227/00006123-199209000-00024; Honeybul S, 2012, J NEUROTRAUM, V29, P1872, DOI 10.1089/neu.2012.2356; Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Lee SC, 2009, J CLIN NEUROSCI, V16, P56, DOI 10.1016/j.jocn.2008.04.001; Lemee JM, 2013, NEUROCHIRURGIE, V59, P60, DOI 10.1016/j.neuchi.2012.10.138; Lin AY, 2012, J CRANIOFAC SURG, V23, P67, DOI 10.1097/SCS.0b013e318240c876; Mack J, 2009, PEDIATR RADIOL, V39, P200, DOI 10.1007/s00247-008-1084-6; Martin KD, 2014, ACTA NEUROCHIR, V156, P813, DOI 10.1007/s00701-014-2021-0; Messina G, 2011, ACTA NEUROCHIR, V153, P1717, DOI 10.1007/s00701-011-1014-5; Morice A, 2017, J NEUROSURG-PEDIATR, V19, P51, DOI 10.3171/2016.8.PEDS1653; Ozerdem OR, 2002, ANN PLAS SURG, V49, P127; Payne KFB, 2014, BRIT J ORAL MAX SURG, V52, P7, DOI 10.1016/j.bjoms.2013.03.005; Pechmann A, 2015, NEUROPEDIATRICS, V46, P5, DOI 10.1055/s-0034-1393707; Piitulainen JM, 2015, WORLD NEUROSURG, V83, P708, DOI 10.1016/j.wneu.2015.01.014; Piitulainen JM, 2015, ACTA NEUROCHIR, V157, P681, DOI 10.1007/s00701-015-2363-2; Prasad GL, 2015, BRAIN INJURY, V29, P1717, DOI 10.3109/02699052.2015.1075146; Quah BL, 2016, WORLD NEUROSURG, V94, P13, DOI 10.1016/j.wneu.2016.06.081; RISH BL, 1979, NEUROSURGERY, V4, P381, DOI 10.1227/00006123-197905000-00002; Rocque BG, 2013, J NEUROSURG-PEDIATR, V12, P120, DOI 10.3171/2013.4.PEDS12605; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Servadei F, 2015, WORLD NEUROSURG, V83, P133, DOI 10.1016/j.wneu.2014.08.031; Sgouros S, 1999, J NEUROSURG, V91, P610, DOI 10.3171/jns.1999.91.4.0610; Shah AM, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.2.FOCUS13561; Shido H, 2013, J CRANIOFAC SURG, V24, P946, DOI 10.1097/SCS.0b013e3182868876; Stefini R, 2015, J APPL BIOMATER FUNC, V13, pE136, DOI 10.5301/jabfm.5000211; Stefini Roberto, 2013, Surg Neurol Int, V4, P12, DOI 10.4103/2152-7806.106290; Thesleff T, 2011, NEUROSURGERY, V68, P1535, DOI 10.1227/NEU.0b013e31820ee24e; Tubbs RS, 2011, CHILD NERV SYST, V27, P497, DOI 10.1007/s00381-010-1327-3; Villa MM, 2014, J BIOMED MAT RES B; Wachter D, 2013, CLIN NEUROL NEUROSUR, V115, P1293, DOI 10.1016/j.clineuro.2012.12.002; Williams L, 2016, J CRANIO MAXILL SURG, V44, P789, DOI 10.1016/j.jcms.2016.03.010; Williams PL, 1980, Gray's Anatomy, V36; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470; Zaccaria L, 2017, CHILD NERV SYST, V33, P343, DOI 10.1007/s00381-016-3327-4	54	24	25	2	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	OCT	2017	33	10					1759	1768		10.1007/s00381-017-3541-8			10	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	FG1LZ	WOS:000409558900020	29149388				2021-06-18	
J	Halford, J; Shen, S; Itamura, K; Levine, J; Chong, AC; Czerwieniec, G; Glenn, TC; Hovda, DA; Vespa, P; Bullock, R; Dietrich, WD; Mondello, S; Loo, JA; Wanner, IB				Halford, Julia; Shen, Sean; Itamura, Kyohei; Levine, Jaclynn; Chong, Albert C.; Czerwieniec, Gregg; Glenn, Thomas C.; Hovda, David A.; Vespa, Paul; Bullock, Ross; Dietrich, W. Dalton; Mondello, Stefania; Loo, Joseph A.; Wanner, Ina-Beate			New astroglial injury-defined biomarkers for neurotrauma assessment	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Astrocytes; brain trauma; proteomics; cell culture; cerebrospinal fluid; exploratory factor analysis	TRAUMATIC BRAIN-INJURY; FIBRILLARY ACIDIC PROTEIN; SPINAL-CORD-INJURY; IN-VITRO MODEL; STORAGE CHARACTERISTICS; OXIDATIVE-METABOLISM; CEREBROSPINAL-FLUID; CORTICAL CONTUSION; PROTEOMIC ANALYSIS; CALCIUM INFLUX	Traumatic brain injury (TBI) is an expanding public health epidemic with pathophysiology that is difficult to diagnose and thus treat. TBI biomarkers should assess patients across severities and reveal pathophysiology, but currently, their kinetics and specificity are unclear. No single ideal TBI biomarker exists. We identified new candidates from a TBI CSF proteome by selecting trauma-released, astrocyte-enriched proteins including aldolase C (ALDOC), its 38kD breakdown product (BDP), brain lipid binding protein (BLBP), astrocytic phosphoprotein (PEA15), glutamine synthetase (GS) and new 18-25kD-GFAP-BDPs. Their levels increased over four orders of magnitude in severe TBI CSF. First post-injury week, ALDOC levels were markedly high and stable. Short-lived BLBP and PEA15 related to injury progression. ALDOC, BLBP and PEA15 appeared hyper-acutely and were similarly robust in severe and mild TBI blood; 25kD-GFAP-BDP appeared overnight after TBI and was rarely present after mild TBI. Using a human culture trauma model, we investigated biomarker kinetics. Wounded (mechanoporated) astrocytes released ALDOC, BLBP and PEA15 acutely. Delayed cell death corresponded with GFAP release and proteolysis into small GFAP-BDPs. Associating biomarkers with cellular injury stages produced astroglial injury-defined (AID) biomarkers that facilitate TBI assessment, as neurological deficits are rooted not only in death of CNS cells, but also in their functional compromise.	[Halford, Julia; Itamura, Kyohei; Levine, Jaclynn; Chong, Albert C.; Wanner, Ina-Beate] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, 635 Charles E Young Dr South,NRB 260, Los Angeles, CA 90095 USA; [Shen, Sean; Czerwieniec, Gregg; Loo, Joseph A.] Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; [Glenn, Thomas C.; Hovda, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Injury Res Ctr, Dept Neurosurg,Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Vespa, Paul] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; [Bullock, Ross] Jackson Mem Hosp, Dept Neurol Surg, Miami, FL 33136 USA; [Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Mondello, Stefania] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Messina, Italy; [Loo, Joseph A.] Univ Calif Los Angeles, Inst Mol Biol, Dept Biol Chem, Los Angeles, CA 90095 USA; [Loo, Joseph A.] Univ Calif Los Angeles, UCLA DOE Inst Genom & Prote, Los Angeles, CA 90095 USA	Wanner, IB (corresponding author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, 635 Charles E Young Dr South,NRB 260, Los Angeles, CA 90095 USA.	iwanner@mednet.ucla.edu	Mondello, Stefania/A-1813-2012	Mondello, Stefania/0000-0002-8587-3614; Glenn, Thomas/0000-0003-4273-3408; Chong, Albert/0000-0002-8034-7172			Addona TA, 2011, NAT BIOTECHNOL, V29, P635, DOI 10.1038/nbt.1899; Agoston DV, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00129; [Anonymous], 1979, Fed Regist, V44, P23191; ASAKA M, 1990, AM J MED SCI, V300, P291, DOI 10.1097/00000441-199011000-00004; Barbee KA, 2005, ANN NY ACAD SCI, V1066, P67, DOI 10.1196/annals.1363.006; Bartnik BL, 2007, J NEUROTRAUM, V24, P1079, DOI 10.1089/neu.2006.0210; Bartnik-Olson BL, 2010, J NEUROTRAUM, V27, P2191, DOI 10.1089/neu.2010.1508; Bekar L, 2008, NAT MED, V14, P75, DOI 10.1038/nm1693; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bohac DL, 1997, BRAIN INJURY, V11, P469, DOI 10.1080/713802185; Boutte AM, 2016, J NEUROTRAUM, V33, P147, DOI 10.1089/neu.2014.3672; Boutte AM, 2012, ELECTROPHORESIS, V33, P3693, DOI 10.1002/elps.201200196; Breiman L., 1984, CLASSIFICATION REGRE, px; Brogan ME, 2014, J CRIT CARE, V29, P679, DOI 10.1016/j.jcrc.2014.04.014; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Buki A, 2015, ADV TECH STAND NEURO, V42, P147, DOI 10.1007/978-3-319-09066-5_8; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Buonora JE, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00068; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Carr W, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00049; Chen MH, 2013, ASN NEURO, V5, DOI 10.1042/AN20130032; Chou SHY, 2014, NEUROCRIT CARE, V21, P187, DOI 10.1007/s12028-014-0039-z; Colombo JA, 1997, J NEUROSCI RES, V48, P352, DOI 10.1002/(SICI)1097-4547(19970515)48:4<352::AID-JNR7>3.0.CO;2-A; Colombo JA, 1997, J BRAIN RES, V38, P503; Crowder MJ, 1990, MONOGRAPHS STAT APPL, P1; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; DeJong J, 2009, ASSESSMENT, V16, P328, DOI 10.1177/1073191109336989; Devoto C, 2017, CELL TRANSPLANT, V26, P1169, DOI 10.1177/0963689717714098; Di Pietro V, 2015, NEUROCHEM RES, V40, P991, DOI 10.1007/s11064-015-1554-9; Du S, 1999, EXP NEUROL, V157, P96, DOI 10.1006/exnr.1999.7041; Eckert A, 2008, ONCOGENE, V27, P1155, DOI 10.1038/sj.onc.1210732; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Fabrigar LR, 2012, EXPLORATORY FACTOR A, pviii; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Fujita K, 1998, NEUROCHEM RES, V23, P169, DOI 10.1023/A:1022476724381; Gerstner JR, 2012, J NEUROSCI, V32, P1383, DOI 10.1523/JNEUROSCI.3228-11.2012; HAIMOTO H, 1986, CLIN CHIM ACTA, V154, P203, DOI 10.1016/0009-8981(86)90032-X; Hanrieder J, 2009, J NEUROSCI METH, V177, P469, DOI 10.1016/j.jneumeth.2008.10.038; HARMON HH, 1976, MODERN FACTOR ANAL; Helmick KM, 2015, BRAIN IMAGING BEHAV, V9, P358, DOI 10.1007/s11682-015-9399-z; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; HOPGOOD MF, 1989, BIOCHEM J, V259, P237, DOI 10.1042/bj2590237; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; JONES DG, 1985, RES VET SCI, V38, P301, DOI 10.1016/S0034-5288(18)31799-5; JONES DG, 1985, RES VET SCI, V38, P307, DOI 10.1016/S0034-5288(18)31800-9; Kapushesky M, 2012, NUCLEIC ACIDS RES, V40, pD1077, DOI 10.1093/nar/gkr913; Kirov II, 2013, J NEUROTRAUM, V30, P1200, DOI 10.1089/neu.2012.2696; KLUN B, 1974, J NEUROSURG, V41, P224, DOI 10.3171/jns.1974.41.2.0224; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Kwon BK, 2017, J NEUROTRAUM, V34, P567, DOI 10.1089/neu.2016.4435; Lafrenaye AD, 2012, J CEREBR BLOOD F MET, V32, P1919, DOI 10.1038/jcbfm.2012.95; Latterich M, 2011, NAT BIOTECHNOL, V29, P600, DOI 10.1038/nbt.1917; Lee YB, 2000, BRAIN RES, V864, P220, DOI 10.1016/S0006-8993(00)02180-6; Levine J, 2016, GLIA, V64, P668, DOI 10.1002/glia.22953; Li DR, 2012, LEGAL MED-TOKYO, V14, P84, DOI 10.1016/j.legalmed.2011.12.007; Li DR, 2010, LEGAL MED, V12, P63, DOI 10.1016/j.legalmed.2009.11.005; Lizhnyak PN, 2015, EXPERT REV PROTEOMIC, V12, P75, DOI 10.1586/14789450.2015.1000869; Logsdon AF, 2015, COMPR PHYSIOL, V5, P1147, DOI 10.1002/cphy.c140057; Lovatt D, 2007, J NEUROSCI, V27, P12255, DOI 10.1523/JNEUROSCI.3404-07.2007; Lubieniecka JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019247; Lytle JM, 2007, EUR J NEUROSCI, V25, P1711, DOI 10.1111/j.1460-9568.2007.05390.x; Magistretti PJ, 2011, EXP PHYSIOL, V96, P407, DOI 10.1113/expphysiol.2010.053157; Magistretti PJ, 2006, J EXP BIOL, V209, P2304, DOI 10.1242/jeb.02208; Mamczur P, 2015, GLIA, V63, P328, DOI 10.1002/glia.22753; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Martinez A, 2008, J NEUROPATH EXP NEUR, V67, P1122, DOI 10.1097/NEN.0b013e31818e06f3; Mathiisen TM, 2010, GLIA, V58, P1094, DOI 10.1002/glia.20990; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Mergenthaler P, 2012, P NATL ACAD SCI USA, V109, P1518, DOI 10.1073/pnas.1108225109; Mondello S, 2016, J NEUROTRAUM, V33, P595, DOI 10.1089/neu.2015.4132; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Mouser PE, 2006, AM J PATHOL, V168, P936, DOI 10.2353/ajpath.2006.050798; Muoio V, 2014, ACTA PHYSIOL, V210, P790, DOI 10.1111/apha.12250; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Nuriya M, 2013, CEREB CORTEX, V23, P2118, DOI 10.1093/cercor/bhs198; OFFERMANN MK, 1983, BIOCHEM J, V211, P529, DOI 10.1042/bj2110529; Omenn GS, 2005, PROTEOMICS, V5, P3226, DOI 10.1002/pmic.200500358; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2015, NEUROCRIT CARE, V22, P52, DOI 10.1007/s12028-014-0028-2; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pelsers MMAL, 2004, CLIN CHEM, V50, P1568, DOI 10.1373/clinchem.2003.030361; Pelvig DP, 2008, NEUROBIOL AGING, V29, P1754, DOI 10.1016/j.neurobiolaging.2007.04.013; Plog BA, 2015, EXPERT REV NEUROTHER, V15, P465, DOI 10.1586/14737175.2015.1031112; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; PONTREMOLI S, 1982, P NATL ACAD SCI-BIOL, V79, P2451, DOI 10.1073/pnas.79.8.2451; Poste G, 2012, TRENDS MOL MED, V18, P717, DOI 10.1016/j.molmed.2012.09.003; Posti JP, 2017, J NEUROTRAUM, V34, P1427, DOI 10.1089/neu.2016.4442; Povlishock JT, 1996, ACT NEUR S, V66, P81; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Sakai K, 2013, BRAIN INJURY, V27, P1692, DOI 10.3109/02699052.2013.837198; Schenk S, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-41; Schousboe A, 2014, ADV NEUROBIOL, V11, P13, DOI 10.1007/978-3-319-08894-5_2; Shetty AK, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00232; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Sjodin MOD, 2010, J CHROMATOGR B, V878, P2003, DOI 10.1016/j.jchromb.2010.05.036; Sondej MA, 2011, SAMPLE PREPARATION IN BIOLOGICAL MASS SPECTROMETRY, P829, DOI 10.1007/978-94-007-0828-0_39; Strathmann FG, 2014, CLIN BIOCHEM, V47, P876, DOI 10.1016/j.clinbiochem.2014.01.028; SUTTON RL, 1994, ACTA NEUROCHIR, P446; Sword J, 2013, BRAIN, V136, P1446, DOI 10.1093/brain/awt026; Thelin EP, 2018, BEHAV BRAIN RES, V340, P71, DOI 10.1016/j.bbr.2016.08.058; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Wanner IB, 2008, GLIA, V56, P1691, DOI 10.1002/glia.20721; Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013; Wanner IB, 2012, METHODS MOL BIOL, V814, P189, DOI 10.1007/978-1-61779-452-0_14; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; White RE, 2010, J COMP NEUROL, V518, P1370, DOI 10.1002/cne.22282; Willis CL, 2004, GLIA, V45, P325, DOI 10.1002/glia.10333; WILLSON VJC, 1980, ANN CLIN BIOCHEM, V17, P110, DOI 10.1177/000456328001700302; WILLSON VJC, 1980, ANN CLIN BIOCHEM, V17, P114, DOI 10.1177/000456328001700303; Zetterberg H, 2016, NAT REV NEUROL, V12, P563, DOI 10.1038/nrneurol.2016.127; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; Zoltewicz JS, 2013, J NEUROTRAUM, V30, P1161, DOI 10.1089/neu.2012.2762; Zoltewicz JS, 2012, BIOMARK INSIGHTS, V7, P71, DOI 10.4137/BMI.S9873	120	24	24	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	2017	37	10					3278	3299		10.1177/0271678X17724681			22	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	FI7IV	WOS:000412171300003	28816095	Green Published, Bronze			2021-06-18	
J	Sagarkar, S; Bhamburkar, T; Shelkar, G; Choudhary, A; Kokare, DM; Sakharkar, AJ				Sagarkar, Sneha; Bhamburkar, Tanmayi; Shelkar, Gajanan; Choudhary, Amit; Kokare, Dadasaheb M.; Sakharkar, Amul J.			Minimal traumatic brain injury causes persistent changes in DNA methylation at BDNF gene promoters in rat amygdala: A possible role in anxiety-like behaviors	NEUROBIOLOGY OF DISEASE			English	Article						5-Azacytidine; Amygdala; Anxiety; Brain-derived neurotrophic factor; DNA methylation; Minimal traumatic brain injury	MEDIAL PREFRONTAL CORTEX; DENDRITIC-SPINE FORMATION; NEUROTROPHIC FACTOR; CHRONIC STRESS; EPIGENETIC REGULATION; DEMETHYLATION; EXPRESSION; GADD45B; HIPPOCAMPAL; MODEL	Minimal traumatic brain injury (MTBI) often transforms into chronic neuropsychiatric conditions including anxiety, the underlying mechanisms of which are largely unknown. In the present study, we employed the closed head injury paradigm to induce MTBI in rats and examined whether DNA methylation can explain long-term changes in the expression of the brain-derived neurotrophic factor (BDNF) in the amygdala as well as trauma-induced anxiety-like behaviors. The MTBI caused anxiety-like behaviors and altered the expression of DNA methyltransferase (DNMT) isoforms (DNMT1, DNMT3a, and DNMT3b) and factors involved in DNA demethylation such as the growth arrest and DNA damage 45 (GADD45a and GADD45b). After 30 days of MTBI, the over-expression of DNMT3a and DNMT3b corresponded to heightened DNMT activity, whereas the mRNA levels of GADD45a and GADD45b were declined. The methylated cytosine levels at the BDNF promoters (Ip, IVp and IXp) were increased in the amygdala of the trauma-induced animals; these coincided negatively with the mRNA levels of exon IV and IXa, but not of exon I. Interestingly, treatment with 5-azacytidine, a pan DNMT inhibitor, normalized the MTBI-induced DNMT activity and DNA hypermethylation at exon IVp and IXp. Furthermore, 5-azacytidine also corrected the deficits in the expression of exons IV and IXa and reduced the anxiety-like behaviors. These results suggest that the DNMT-mediated DNA methylation at the BDNF IVp and IXp might be involved in the regulation of BDNF gene expression in the amygdala. Further, it could also be related to MTBI-induced anxiety-like behaviors via the regulation of synaptic plasticity. (C) 2017 Elsevier Inc. All rights reserved.	[Sagarkar, Sneha; Bhamburkar, Tanmayi; Sakharkar, Amul J.] Savitribai Phule Pune Univ, Dept Biotechnol, Pune 411007, Maharashtra, India; [Shelkar, Gajanan; Choudhary, Amit; Kokare, Dadasaheb M.] Rashtrasant Tukadoji Maharaj Nagpur Univ, Dept Pharmaceut Sci, Nagpur 440033, Maharashtra, India	Sakharkar, AJ (corresponding author), Savitribai Phule Pune Univ, Dept Biotechnol, Pune 411007, Maharashtra, India.	amul.sakharkar@unipune.ac.in		SHELKAR, GAJANAN/0000-0001-9351-8375	University Grants Commission, Government of India, New Delhi, IndiaUniversity Grants Commission, India [F.4-5/151-FRP/2014 (BSR)]; Board of Colleges and University Development (BCUD) [AT/UGC/1250]; Savitribai Phule Pune University, Pune; Department Research and Development Program (DRDP) of the Department of Biotechnology, Savitribai Phule Pune University, Pune, India	This work was supported by grants from the University Grants Commission, Government of India, New Delhi, India [F.4-5/151-FRP/2014 (BSR)] and the Board of Colleges and University Development (BCUD) (AT/UGC/1250), Savitribai Phule Pune University, Pune to AJS. AJS and SS also acknowledge funds received from the Department Research and Development Program (DRDP) of the Department of Biotechnology, Savitribai Phule Pune University, Pune, India.	Almeida-Suhett CP, 2015, EXP NEUROL, V273, P11, DOI 10.1016/j.expneurol.2015.07.028; Almeida-Suhett CP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102627; Ashokan A, 2016, PSYCHONEUROENDOCRINO, V69, P189, DOI 10.1016/j.psyneuen.2016.04.009; Autry AE, 2012, PHARMACOL REV, V64, P238, DOI 10.1124/pr.111.005108; Bailey Zachary S, 2015, Biomed Sci Instrum, V51, P423; Barbier E, 2015, J NEUROSCI, V35, P6153, DOI 10.1523/JNEUROSCI.4571-14.2015; Bennett MR, 2014, PROG NEUROBIOL, V112, P80, DOI 10.1016/j.pneurobio.2013.10.005; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Boersma GJ, 2014, EPIGENETICS-US, V9, P437, DOI 10.4161/epi.27558; Boyle Lara M., 2013, Yale Journal of Biology and Medicine, V86, P117; Bu W, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00449; Chou DL, 2014, EXP NEUROL, V255, P19, DOI 10.1016/j.expneurol.2014.02.016; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Elliott E, 2016, J NEUROSCI, V36, P730, DOI 10.1523/JNEUROSCI.0971-15.2016; Feng J, 2010, NAT NEUROSCI, V13, P423, DOI 10.1038/nn.2514; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Gavin DP, 2015, EPIGENOMICS-UK, V7, P567, DOI [10.2217/EPI.15.12, 10.2217/epi.15.12]; Gavin DP, 2013, NEUROPHARMACOLOGY, V75, P233, DOI 10.1016/j.neuropharm.2013.07.036; Govindarajan A, 2006, P NATL ACAD SCI USA, V103, P13208, DOI 10.1073/pnas.0605180103; Green CR, 2013, J DEPRESS ANXIETY, V2013; Haghighi F, 2015, J NEUROTRAUM, V32, P1200, DOI 10.1089/neu.2014.3640; Hohjoh H, 2003, NEUROGENETICS, V4, P151, DOI 10.1007/s10048-002-0141-9; Ji YY, 2005, NAT NEUROSCI, V8, P164, DOI 10.1038/nn1381; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Karpova NN, 2014, NEUROPHARMACOLOGY, V76, P709, DOI 10.1016/j.neuropharm.2013.04.002; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Keeley MB, 2006, LEARN MEMORY, V13, P135, DOI 10.1101/lm.86906; Kigar SL, 2015, BRAIN BEHAV IMMUN, V46, P60, DOI 10.1016/j.bbi.2015.02.018; Klengel T, 2014, NEUROPHARMACOLOGY, V80, P115, DOI 10.1016/j.neuropharm.2014.01.013; Lakshminarasimhan H., 2012, PLOS ONE, V7; Landgrave-Gomez J, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00058; Leach PT, 2012, LEARN MEMORY, V19, P319, DOI 10.1101/lm.024984.111; Lester BM, 2011, ANN NY ACAD SCI, V1226, P14, DOI 10.1111/j.1749-6632.2011.06037.x; Levenson JM, 2006, J BIOL CHEM, V281, P15763, DOI 10.1074/jbc.M511767200; Ling H, 2015, MOL CELL NEUROSCI, V66, P114, DOI 10.1016/j.mcn.2015.03.012; Lubin FD, 2008, J NEUROSCI, V28, P10576, DOI 10.1523/JNEUROSCI.1786-08.2008; Lundberg J, 2009, NEUROSCI LETT, V457, P8, DOI 10.1016/j.neulet.2009.03.105; Ma DK, 2009, SCIENCE, V323, P1074, DOI 10.1126/science.1166859; McGowan PO, 2010, NEUROBIOL DIS, V39, P66, DOI 10.1016/j.nbd.2009.12.026; Meyer DL, 2012, EXP NEUROL, V235, P574, DOI 10.1016/j.expneurol.2012.03.012; Mitchelmore C, 2014, BRAIN RES, V1586, P162, DOI 10.1016/j.brainres.2014.06.037; Moonat S, 2011, ADDICT BIOL, V16, P238, DOI 10.1111/j.1369-1600.2010.00275.x; Mychasiuk R, 2016, NEUROSCIENCE, V322, P489, DOI 10.1016/j.neuroscience.2016.02.053; Mychasiuk R, 2014, JOVE-J VIS EXP, DOI 10.3791/51820; Nestler EJ, 2009, BIOL PSYCHIAT, V65, P189, DOI 10.1016/j.biopsych.2008.10.030; Nieto SJ, 2016, PHARMACOL BIOCHEM BE, V146, P60, DOI 10.1016/j.pbb.2016.05.006; Oliveira AMM, 2012, NAT NEUROSCI, V15, P1111, DOI 10.1038/nn.3151; Pandey SC, 2008, J NEUROSCI, V28, P2589, DOI 10.1523/JNEUROSCI.4752-07.2008; Pandey SC, 2006, J NEUROSCI, V26, P8320, DOI 10.1523/JNEUROSCI.4988-05.2006; Radley JJ, 2004, NEUROSCIENCE, V125, P1, DOI 10.1016/j.neuroscience.2004.01.006; Roth TL, 2011, J PSYCHIATR RES, V45, P919, DOI 10.1016/j.jpsychires.2011.01.013; Roth TL, 2011, HORM BEHAV, V59, P315, DOI 10.1016/j.yhbeh.2010.05.005; Roth TL, 2009, BIOL PSYCHIAT, V65, P760, DOI 10.1016/j.biopsych.2008.11.028; Sakharkar AJ, 2014, INT J NEUROPSYCHOPH, V17, P2057, DOI 10.1017/S1461145714001047; Sales AJ, 2011, BRIT J PHARMACOL, V164, P1711, DOI 10.1111/j.1476-5381.2011.01489.x; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Smith CJ, 2015, FRONT NEUROL, V6, DOI [10.3389/fneur.2015.00240, 10.3389/fneur.2015.00073]; Stankiewicz AM, 2013, BRAIN RES BULL, V98, P76, DOI 10.1016/j.brainresbull.2013.07.003; Sultan FA, 2012, J NEUROSCI, V32, P17059, DOI 10.1523/JNEUROSCI.1747-12.2012; Vyas A, 2002, J NEUROSCI, V22, P6810; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu L, 2014, NEUROCHEM RES, V39, P1193, DOI 10.1007/s11064-014-1296-0; Yang SH, 2013, J SURG RES, V184, P981, DOI 10.1016/j.jss.2013.03.075; You C, 2014, INT J NEUROPSYCHOPH, V17, P313, DOI 10.1017/S1461145713001144; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	68	24	24	0	27	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	OCT	2017	106						101	109		10.1016/j.nbd.2017.06.016			9	Neurosciences	Neurosciences & Neurology	FE5ZW	WOS:000408290800009	28663119				2021-06-18	
J	Cao, JQ; El Gaamouch, F; Meabon, JS; Meeker, KD; Zhu, L; Zhong, MB; Bendik, J; Elder, G; Jing, P; Xia, JH; Luo, WJ; Cook, DG; Cai, DM				Cao, Jiqing; El Gaamouch, Farida; Meabon, James S.; Meeker, Kole D.; Zhu, Li; Zhong, Margaret B.; Bendik, John; Elder, Gregory; Jing, Ping; Xia, Jiahong; Luo, Wenjie; Cook, David G.; Cai, Dongming			ApoE4-associated phospholipid dysregulation contributes to development of Tau hyper-phosphorylation after traumatic brain injury	SCIENTIFIC REPORTS			English	Article							AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN-E; ALZHEIMERS-DISEASE; MOUSE MODEL; HEAD-INJURY; LIPOPROTEIN PARTICLES; BETA-PROTEIN; APOE; HIPPOCAMPAL; REDUCTION	The apolipoprotein E4 (ApoE4) genotype combines with traumatic brain injury (TBI) to increase the risk of developing Alzheimer's Disease (AD). However, the underlying mechanism(s) is not well-understood. We found that after exposure to repetitive blast-induced TBI, phosphoinositol biphosphate (PIP2) levels in hippocampal regions of young ApoE3 mice were elevated and associated with reduction in expression of a PIP2 degrading enzyme, synaptojanin 1 (synj1). In contrast, hippocampal PIP2 levels in ApoE4 mice did not increase after blast TBI. Following blast TBI, phospho-Tau (pTau) levels were unchanged in ApoE3 mice, whereas in ApoE4 mice, levels of pTau were significantly increased. To determine the causal relationship between changes in pTau and PIP2/synj1 levels after TBI, we tested if down-regulation of synj1 prevented blast-induced Tau hyper-phosphorylation. Knockdown of synj1 decreased pTau levels in vitro, and abolished blast-induced elevation of pTau in vivo. Blast TBI increased glycogen synthase kinase (GSK)-3 beta activities in ApoE4 mice, and synj1 knockdown inhibited GSK3 beta phosphorylation of Tau. Together, these data suggest that ApoE proteins regulate brain phospholipid homeostasis in response to TBI and that the ApoE4 isoform is dysfunctional in this process. Downregulation of synj1 rescues blast-induced phospholipid dysregulation and prevents development of Tau hyper-phosphorylation in ApoE4 carriers.	[Cao, Jiqing; El Gaamouch, Farida; Zhu, Li; Elder, Gregory; Cai, Dongming] James J Peters VA Med Ctr, Neurol Serv, Bronx, NY 10468 USA; [Cao, Jiqing; Jing, Ping; Xia, Jiahong; Cai, Dongming] Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Tongji Med Coll, Wuhan 430021, Hubei, Peoples R China; [Cao, Jiqing; El Gaamouch, Farida; Zhu, Li; Zhong, Margaret B.; Bendik, John; Cai, Dongming] Icahn Sch Med Mt Sinai, Dept Neurol, Alzheimer Dis Res Ctr, New York, NY 10029 USA; [Meabon, James S.; Meeker, Kole D.] Mental Illness Res & Educ Clin Ctr, Vet Affairs Med Ctr VAPSHCS, Seattle, WA 98108 USA; [Meabon, James S.; Meeker, Kole D.] Univ Washington, Sch Med, Dept Psychiat, Seattle, WA 98195 USA; [Luo, Wenjie] Weill Cornell Med Coll, Brain & Mind Res Inst, New York, NY 10065 USA; [Cook, David G.] Geriatr Res Educ & Clin Ctr, Vet Affairs Med Ctr VAPSHCS, Seattle, WA 98108 USA; [Cook, David G.] Univ Washington, Sch Med, Dept Med & Pharmacol, Seattle, WA 98195 USA	Cai, DM (corresponding author), James J Peters VA Med Ctr, Neurol Serv, Bronx, NY 10468 USA.; Cai, DM (corresponding author), Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Tongji Med Coll, Wuhan 430021, Hubei, Peoples R China.; Cai, DM (corresponding author), Icahn Sch Med Mt Sinai, Dept Neurol, Alzheimer Dis Res Ctr, New York, NY 10029 USA.; Cook, DG (corresponding author), Geriatr Res Educ & Clin Ctr, Vet Affairs Med Ctr VAPSHCS, Seattle, WA 98108 USA.; Cook, DG (corresponding author), Univ Washington, Sch Med, Dept Med & Pharmacol, Seattle, WA 98195 USA.	dgcook@u.washington.edu; dongming.cai@mssm.edu	Luo, Wenjie/ABF-8451-2020		Alzheimer AssociationAlzheimer's Association [NIRP14-304720]; Department of Veteran Affairs RRD Service SPiRE [1I21RX001558-01A1]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01AG048923-01, 1RF1AG054014]; Department of Veterans Affairs Office of Research and Development Medical Research Service (RDIS)US Department of Veterans Affairs [0005]; University of Washington Friends of Alzheimer's Research; University of Washington Royalty Research FundUniversity of Washington; Northwest Network Mental Illness Research, Education and Clinical Center; James J. Peters VA Medical CenterUS Department of Veterans Affairs; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30DK017047] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG048923, RF1AG054014] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I21RX001558, I01BX003380, I01RX002290] Funding Source: NIH RePORTER	We thank Dr. Pietro De Camilli (Yale School of Medicine) for providing synj1 haploinsufficiency mice. Antibody p369 was generously provided by Dr. Paul Greengard. This work was supported by funding from Alzheimer Association (NIRP14-304720), Department of Veteran Affairs RR&D Service SPiRE (1I21RX001558-01A1), NIH R01 (1R01AG048923-01), NIH RF1 (1RF1AG054014) (DC); and by the Department of Veterans Affairs Office of Research and Development Medical Research Service (RDIS# 0005), the University of Washington Friends of Alzheimer's Research, University of Washington Royalty Research Fund (DGC); and the Northwest Network Mental Illness Research, Education and Clinical Center (JSM). Confocal microscopy studies were supported by James J. Peters VA Medical Center Research Core Facility. We thank Dr. William Netzer and Dr. Christopher Cardozo for critical reading of the manuscript.	Abdullah L, 2014, FASEB J, V28, P5311, DOI 10.1096/fj.14-258228; Anand KS, 2012, ANN INDIAN ACAD NEUR, V15, P239, DOI 10.4103/0972-2327.104323; Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; Baugh CM, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0306-5; Berman DE, 2008, NAT NEUROSCI, V11, P547, DOI 10.1038/nn.2100; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; Castranio EL, 2017, NEUROBIOL DIS, V105, P1, DOI 10.1016/j.nbd.2017.05.006; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Courtney A, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00221; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; Crawford F, 2009, NEUROSCIENCE, V159, P1349, DOI 10.1016/j.neuroscience.2009.01.033; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185; Drelon C, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12751; Emmerich T, 2016, J NEUROTRAUM, V33, P1331, DOI 10.1089/neu.2015.4061; Ezra Y, 2003, NEUROSCIENCE, V121, P315, DOI 10.1016/S0306-4522(03)00436-6; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Fu Y, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0099-y; Girgis F, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00008; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Grootendorst J, 2005, BEHAV BRAIN RES, V159, P1, DOI 10.1016/j.bbr.2004.09.019; Huber BR, 2016, NEUROSCIENCE, V319, P206, DOI 10.1016/j.neuroscience.2016.01.022; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Jiang Q, 2008, NEURON, V58, P681, DOI 10.1016/j.neuron.2008.04.010; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Kay AD, 2003, J NEUROTRAUM, V20, P717, DOI 10.1089/089771503767869953; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Lane RF, 2010, J NEUROSCI, V30, P13110, DOI 10.1523/JNEUROSCI.3872-10.2010; Lawrence DW, 2015, BRAIN INJURY, V29, P1018, DOI 10.3109/02699052.2015.1005131; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Lin LY, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0107-2; Maroon JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117338; MAYEUX R, 1995, AM J PUBLIC HEALTH, V85, P1280, DOI 10.2105/AJPH.85.9.1280; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McIntire LBJ, 2012, J NEUROSCI, V32, P15271, DOI 10.1523/JNEUROSCI.2034-12.2012; Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Meabon JS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaa9585; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Nasuhoglu C, 2002, ANAL BIOCHEM, V301, P243, DOI 10.1006/abio.2001.5489; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Pal R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04528-5; PAYAMI H, 1994, JAMA-J AM MED ASSOC, V271, P1316, DOI 10.1001/jama.271.17.1316; Reitz C, 2011, NAT REV NEUROL, V7, P137, DOI 10.1038/nrneurol.2011.2; Rodriguez GA, 2013, LEARN MEMORY, V20, P256, DOI 10.1101/lm.030031.112; Salzar RS, 2017, J NEUROTRAUM, V34, P1589, DOI 10.1089/neu.2016.4600; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Spolcova A, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-111; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Vandal M, 2014, J NEUROCHEM, V129, P516, DOI 10.1111/jnc.12640; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Wang CS, 2005, NEUROBIOL DIS, V18, P390, DOI 10.1016/j.nbd.2004.10.013; Washington P. M., 2015, EXPT NEUROLOGY; Zhu L, 2015, P NATL ACAD SCI USA, V112, P11965, DOI 10.1073/pnas.1510011112; Zhu L, 2013, J BIOL CHEM, V288, P32050, DOI 10.1074/jbc.M113.504365	67	24	25	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	SEP 12	2017	7								11372	10.1038/s41598-017-11654-7			12	Multidisciplinary Sciences	Science & Technology - Other Topics	FG4ZR	WOS:000410297900086	28900205	DOAJ Gold, Green Published			2021-06-18	
J	Riha, HM; Erdman, MJ; Vandigo, JE; Kimmons, LA; Goyal, N; Davidson, KE; Pandhi, A; Jones, GM				Riha, Heidi M.; Erdman, Michael J.; Vandigo, Joseph E.; Kimmons, Lauren A.; Goyal, Nitin; Davidson, K. Erin; Pandhi, Abhi; Jones, G. Morgan			Impact of Moderate Hyperchloremia on Clinical Outcomes in Intracerebral Hemorrhage Patients Treated With Continuous Infusion Hypertonic Saline: A Pilot Study	CRITICAL CARE MEDICINE			English	Article						hemorrhage; length of stay; mortality; neurology; stroke	TRAUMATIC BRAIN-INJURY; IN-HOSPITAL MORTALITY; CRITICALLY-ILL ADULTS; CEREBRAL EDEMA; KIDNEY INJURY; ASSOCIATION; STROKE; MANAGEMENT; HYPERGLYCEMIA; GUIDELINE	Objectives: Hyperchloremia has been associated with increased morbidity and mortality in critically ill patients. While previous research has demonstrated an association between hypertonic saline and hyperchloremia, limited data exist in neurocritical care patients. The objective of this study is to determine the impact of moderate hyperchloremia (chloride >= 115 mmol/L) on clinical outcomes in intracerebral hemorrhage patients treated with continuous IV infusion 3% hypertonic saline. Design: Multicenter, retrospective, propensity-matched cohort study. Setting: Neurocritical care units at two academic medical centers with dedicated neurocritical care teams and comprehensive stroke center designation. Patients: Intracerebral hemorrhage patients discharged between September 2011 and September 2015 were evaluated and matched 1:1 based on propensity scoring. Interventions: Continuous IV infusion 3% hypertonic saline. Measurements and Main Results: A total of 219 patients were included in the unmatched cohort (143 moderate hyperchloremia and 76 nonhyperchloremia) and 100 patients in the propensity-matched cohort. In-hospital mortality was significantly higher in those who developed moderate hyperchloremia in a propensity-matched cohort (34% vs 14%; p = 0.02). Moderate hyperchloremia independently predicted in-hospital mortality in multivariable logistic regression analysis (odds ratio, 4.4 [95% CI, 1.4-13.5]; p = 0.01). Conclusions: We observed higher rates of in-hospital mortality in patients who developed moderate hyperchloremia during treatment with continuous IV infusion 3% hypertonic saline, with moderate hyperchloremia independently predicting in-hospital mortality. These results suggest that chloride values should be monitored closely during hypertonic saline treatment as moderate elevations may impact outcomes in intracerebral hemorrhage patients.	[Riha, Heidi M.; Kimmons, Lauren A.; Davidson, K. Erin; Jones, G. Morgan] Methodist Univ Hosp, Dept Pharm, Memphis, TN USA; [Erdman, Michael J.] Univ Florida Hlth, Dept Pharm, Jacksonville, FL USA; [Vandigo, Joseph E.] Univ Maryland, Sch Pharm, Dept Pharmaceut Hlth Serv Res, Baltimore, MD 21201 USA; [Kimmons, Lauren A.; Jones, G. Morgan] Univ Tennessee, Hlth Sci Ctr, Dept Clin Pharm, 1265 Union Ave, Memphis, TN 38104 USA; [Goyal, Nitin; Pandhi, Abhi; Jones, G. Morgan] Univ Tennessee, Hlth Sci Ctr, Dept Neurol, 1265 Union Ave, Memphis, TN 38104 USA; [Jones, G. Morgan] Univ Tennessee, Hlth Sci Ctr, Dept Neurosurg, 1265 Union Ave, Memphis, TN 38104 USA	Jones, GM (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Clin Pharm, 1265 Union Ave, Memphis, TN 38104 USA.; Jones, GM (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Neurol, 1265 Union Ave, Memphis, TN 38104 USA.; Jones, GM (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Neurosurg, 1265 Union Ave, Memphis, TN 38104 USA.; Jones, GM (corresponding author), Methodist Univ Hosp, Memphis, TN 38104 USA.	Morgan.Jones@mlh.org	Erdman, Michael/H-5771-2019; Pandhi, Abhi/J-9871-2019; Goyal, Nitin/M-6360-2017	Erdman, Michael/0000-0003-2990-0259; Pandhi, Abhi/0000-0001-5878-6112; Goyal, Nitin/0000-0002-4699-0922			Allen Sara J, 2014, J Extra Corpor Technol, V46, P28; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P399, DOI 10.1080/00273171.2011.568786; AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; Boniatti MM, 2011, J CRIT CARE, V26, P175, DOI 10.1016/j.jcrc.2010.04.013; Erdman MJ, 2017, NEUROHOSPITALIST, V7, P9, DOI 10.1177/1941874416665744; Feasal A, 2015, EGYPT J CRIT CARE ME, V3, P1, DOI 10.1016/j.ejccm.2015.05.001; Feigin VL, 2009, LANCET NEUROL, V8, P355, DOI 10.1016/S1474-4422(09)70025-0; Forsyth LL, 2008, PHARMACOTHERAPY, V28, P469, DOI 10.1592/phco.28.4.469; Frontera JA, 2016, NEUROCRIT CARE, V24, P6, DOI 10.1007/s12028-015-0222-x; Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069; Jones GM, 2017, AM J CRIT CARE, V26, P37, DOI 10.4037/ajcc2017439; Lee JY, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0311-7; Leuven, 2003, PSMATCH2 STATA MODUL; Lord AS, 2014, STROKE, V45, P3535, DOI 10.1161/STROKEAHA.114.006435; Maguigan KL, 2017, J CLIN NEUROSCI, V39, P147, DOI 10.1016/j.jocn.2017.01.025; Mangat HS, 2015, ANN NY ACAD SCI, V1345, P83, DOI 10.1111/nyas.12704; Marttinen M, 2016, ACTA ANAESTH SCAND, V60, P790, DOI 10.1111/aas.12694; McCluskey SA, 2013, ANESTH ANALG, V117, P412, DOI 10.1213/ANE.0b013e318293d81e; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; Middleton S, 2011, LANCET, V378, P1699, DOI 10.1016/S0140-6736(11)61485-2; Neyra JA, 2015, CRIT CARE MED, V43, P1938, DOI 10.1097/CCM.0000000000001161; Qureshi AI, 1999, J TRAUMA, V47, P659, DOI 10.1097/00005373-199910000-00009; Raghunathan K, 2014, CRIT CARE MED, V42, P1585, DOI 10.1097/CCM.0000000000000305; Roquilly A, 2011, CRIT CARE, V15, DOI 10.1186/cc10522; Shaw AD, 2014, INTENS CARE MED, V40, P1897, DOI 10.1007/s00134-014-3505-3; Silva Junior João Manoel, 2009, Rev. Bras. Anestesiol., V59, P304, DOI 10.1590/S0034-70942009000300005; Stuart EA, 2010, STAT SCI, V25, P1, DOI 10.1214/09-STS313; Tani M, 2012, SCI WORLD J, DOI 10.1100/2012/474185; Waters JH, 2001, ANESTH ANALG, V93, P817, DOI 10.1097/00000539-200110000-00004; Yunos NM, 2012, JAMA-J AM MED ASSOC, V308, P1566, DOI 10.1001/jama.2012.13356; Zhao YX, 2017, NEUROL RES, V39, P152, DOI 10.1080/01616412.2016.1270575; Ziai WC, 2007, J NEUROL SCI, V261, P157, DOI 10.1016/j.jns.2007.04.048	32	24	24	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	SEP	2017	45	9					E947	E953		10.1097/CCM.0000000000002522			7	Critical Care Medicine	General & Internal Medicine	FD9LJ	WOS:000407843600006	28538442				2021-06-18	
J	Candefjord, S; Winges, J; Malik, AA; Yu, YN; Rylander, T; McKelvey, T; Fhager, A; Elam, M; Persson, M				Candefjord, Stefan; Winges, Johan; Malik, Ahzaz Ahmad; Yu, Yinan; Rylander, Thomas; McKelvey, Tomas; Fhager, Andreas; Elam, Mikael; Persson, Mikael			Microwave technology for detecting traumatic intracranial bleedings: tests on phantom of subdural hematoma and numerical simulations	MEDICAL & BIOLOGICAL ENGINEERING & COMPUTING			English	Article						Traumatic brain injury; Intracranial bleedings; Microwave technology; Subdural hematoma phantom; Finite element method	MORTALITY; DEVICE; SYSTEM; TIME	Traumatic brain injury is the leading cause of death and severe disability for young people and a major public health problem for elderly. Many patients with intracranial bleeding are treated too late, because they initially show no symptoms of severe injury and are not transported to a trauma center. There is a need for a method to detect intracranial bleedings in the prehospital setting. In this study, we investigate whether broadband microwave technology (MWT) in conjunction with a diagnostic algorithm can detect subdural hematoma (SDH). A human cranium phantom and numerical simulations of SDH are used. Four phantoms with SDH 0, 40, 70 and 110 mL are measured with a MWT instrument. The simulated dataset consists of 1500 observations. Classification accuracy is assessed using fivefold cross-validation, and a validation dataset never used for training. The total accuracy is 100 and 82-96 % for phantom measurements and simulated data, respectively. Sensitivity and specificity for bleeding detection were 100 and 96 %, respectively, for the simulated data. SDH of different sizes is differentiated. The classifier requires training dataset size in order of 150 observations per class to achieve high accuracy. We conclude that the results indicate that MWT can detect and estimate the size of SDH. This is promising for developing MWT to be used for prehospital diagnosis of intracranial bleedings.	[Candefjord, Stefan; Winges, Johan; Malik, Ahzaz Ahmad; Yu, Yinan; Rylander, Thomas; McKelvey, Tomas; Fhager, Andreas; Persson, Mikael] Chalmers Univ Technol, Dept Signals & Syst, S-41296 Gothenburg, Sweden; [Candefjord, Stefan; Yu, Yinan; McKelvey, Tomas; Fhager, Andreas; Elam, Mikael; Persson, Mikael] Sahlgrens Univ Hosp, MedTech West, Roda Straket 10 B, S-41345 Gothenburg, Sweden; [Candefjord, Stefan] SAFER Vehicle & Traff Safety Ctr Chalmers, Gothenburg, Sweden; [Elam, Mikael] Sahlgrens Univ Hosp, Clin Neurophysiol, Bla Straket 5, S-41345 Gothenburg, Sweden	Candefjord, S (corresponding author), Chalmers Univ Technol, Dept Signals & Syst, S-41296 Gothenburg, Sweden.; Candefjord, S (corresponding author), Sahlgrens Univ Hosp, MedTech West, Roda Straket 10 B, S-41345 Gothenburg, Sweden.; Candefjord, S (corresponding author), SAFER Vehicle & Traff Safety Ctr Chalmers, Gothenburg, Sweden.	stefan.candefjord@chalmers.se	McKelvey, Tomas/R-7193-2019; Winges, Johan/A-6770-2016	McKelvey, Tomas/0000-0003-2982-5535; Winges, Johan/0000-0001-8889-7884; /0000-0001-7942-2190	Swedish Research CouncilSwedish Research CouncilEuropean Commission [dnr 2010-4627]	This work was supported in part by the Swedish Research Council (dnr 2010-4627) in the project "Model-based Reconstruction and Classification Based on Near-Field Microwave Measurements." This work has been carried out at SAFER-Vehicle and Traffic Safety Centre at Chalmers, Sweden and CHASE-Chalmers Antenna Systems Excellence Centre. The computations were performed on resources at Chalmers Centre for Computational Science and Engineering (C3SE) provided by the Swedish National Infrastructure for Computing (SNIC). The Department of Anatomy at Sahlgrenska Academy, University of Gothenburg, assisted with development of the hematoma phantom.	Andreuccetti D, 1997, INTERNET RESOURCE CA; BREIMAN L, 1992, INT STAT REV, V60, P291, DOI 10.2307/1403680; Bulters D, 2009, ANAESTHESIA, V64, P277, DOI 10.1111/j.1365-2044.2008.05779.x; Candefjord S, 2013, 35 ANN INT C IEEE EM, P1948; DuBose JJ, 2011, J TRAUMA, V70, P11, DOI 10.1097/TA.0b013e318207c563; Eilers PHC, 2003, ANAL CHEM, V75, P3631, DOI 10.1021/ac034173t; Gabriel C, 1996, PHYS MED BIOL, V41, P2231, DOI 10.1088/0031-9155/41/11/001; Gabriel C., 1996, ALOETR19960037 RAD R; Gean AD, 2010, NEUROIMAG CLIN N AM, V20, P527, DOI 10.1016/j.nic.2010.08.001; Guo L, 2015, IEEE ANTENN WIREL PR, V14, DOI 10.1109/LAWP.2015.2396054; Guo L, 2015, IEEE T ANTENN PROPAG, V63, P3531, DOI 10.1109/TAP.2015.2434394; Haas B, 2010, J AM COLL SURGEONS, V211, P804, DOI 10.1016/j.jamcollsurg.2010.08.014; Ireland D, 2013, IET MICROW ANTENNA P, V7, P909, DOI 10.1049/iet-map.2013.0054; Jin J., 2002, FINITE ELEMENT METHO; Leach P, 2007, BRIT J NEUROSURG, V21, P11, DOI 10.1080/02688690701210562; Leon-Carrion J, 2010, BRAIN INJURY, V24, P1193, DOI 10.3109/02699052.2010.506636; Liu NT, 2014, MED BIOL ENG COMPUT, V52, P193, DOI 10.1007/s11517-013-1130-x; Mahmood Q, 2015, J ELECTROMAG ANAL AP, V7, P152, DOI [DOI 10.4236/jemaa.2015.75017, DOI 10.4236/JEMAA.2015.75017]; Manwaring PK, 2013, ANESTH ANALG, V117, P866, DOI 10.1213/ANE.0b013e318290c7b7; Marion DW, 2006, NEUROSURGERY, V58, P655; Mobashsher AT, 2014, IEEE T MICROW THEORY, V62, P1826, DOI 10.1109/TMTT.2014.2342669; Mohammed BJ, 2014, IEEE T INSTRUM MEAS, V63, P117, DOI 10.1109/TIM.2013.2277562; Nyfors E., 1989, IND MICROWAVE SENSOR; Oh T, 2011, MED BIOL ENG COMPUT, V49, P593, DOI 10.1007/s11517-011-0761-z; Oja E, 1983, ELECT ELECT ENG RES; Persson Mikael, 2009, 2009 3rd European Conference on Antennas and Propagation. EuCAP 2009, P1873; Persson M, 2014, IEEE T BIO-MED ENG, V61, P2806, DOI 10.1109/TBME.2014.2330554; Robertson CS, 2010, J NEUROTRAUM, V27, P1597, DOI 10.1089/neu.2010.1340; ROEBUCK BD, 1975, J FOOD SCI, V40, P899, DOI 10.1111/j.1365-2621.1975.tb02228.x; Salonia R, 2012, J NEUROTRAUM, V29, P1047, DOI 10.1089/neu.2011.1890; Sasser Scott M, 2012, MMWR Recomm Rep, V61, P1; Semenov SY, 2008, INT J ANTENN PROPAG, V2008, DOI 10.1155/2008/254830; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Tien HCN, 2011, ANN SURG, V253, P1178, DOI 10.1097/SLA.0b013e318217e339; Walter S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013758; Zamani A, 2016, IEEE T MICROW THEORY, V64, P653, DOI 10.1109/TMTT.2015.2513398; Zamani A, 2015, IEEE T ANTENN PROPAG, V63, P4921, DOI 10.1109/TAP.2015.2479238; Zeng XZZ, 2011, IEEE T INSTRUM MEAS, V60, P3939, DOI 10.1109/TIM.2011.2141250	38	24	24	0	8	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0140-0118	1741-0444		MED BIOL ENG COMPUT	Med. Biol. Eng. Comput.	AUG	2017	55	8					1177	1188		10.1007/s11517-016-1578-6			12	Computer Science, Interdisciplinary Applications; Engineering, Biomedical; Mathematical & Computational Biology; Medical Informatics	Computer Science; Engineering; Mathematical & Computational Biology; Medical Informatics	FD1PX	WOS:000407310300004	27738858	Green Published, Other Gold			2021-06-18	
J	Holdnack, JA; Tulsky, DS; Brooks, BL; Slotkin, J; Gershon, R; Heinemann, AW; Iverson, GL				Holdnack, James A.; Tulsky, David S.; Brooks, Brian L.; Slotkin, Jerry; Gershon, Richard; Heinemann, Allen W.; Iverson, Grant L.			Interpreting Patterns of Low Scores on the NIH Toolbox Cognition Battery	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Multivariate base rates; Cognition; NIH Toolbox; Traumatic brain injury; Cognitive impairment	TRAUMATIC BRAIN-INJURY; HEALTHY OLDER-ADULTS; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; IQ-ADJUSTED NORMS; BEHAVIORAL FUNCTION; BASE RATES; SCALE-4TH EDITION; MEMORY SCORES; WAIS-IV; WMS-IV	Introduction: The National Institutes of Health Toolbox for Assessment of Neurological and Behavioral Function Cognition Battery is comprised of seven cognitive tests, including two tests measuring crystallized cognitive ability (i.e., vocabulary and reading) and five tests measuring fluid cognitive functioning (i.e., working memory, memory, speed of processing, and executive functioning). This study presents comprehensive base rate tables for the frequency of low scores in adults and older adults from the normative sample. Methods: Participants were 843 adults, ages 20-85, from the NIH Toolbox standardization sample who completed all seven cognition tests. Rates of low scores were derived for standard age-adjusted and fully-demographically-adjusted scores at multiple cut-scores. Base rates were stratified by education, crystallized intellectual ability, and cognitive domain. Results: Using the five demographically-adjusted fluid cognitive test scores, 45.9% of adults obtained one or more scores at or below the 16th percentile, and 16.8% obtained one or more score at or below the 5th percentile, which is consistent with findings from other neurocognitive test batteries. Discussion: Based on the study findings, nearly 50% of adults in the general population would meet psychometric criteria for a diagnosis of the Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) Mild Neurocognitive Disorder (MND). We developed new psychometric criteria for identifying MND using the NIH Toolbox Cognition Battery that reduce the false positive rate. Knowing these multivariate normative base rates will help researchers and clinicians interpret NIH Toolbox scores in people with neurodevelopmental, psychiatric, medical, neurological, and neurodegenerative disorders that affect cognitive functioning.	[Holdnack, James A.; Tulsky, David S.; Slotkin, Jerry] Univ Delaware, Ctr Assessment Res & Translat, Newark, DE 19716 USA; [Tulsky, David S.] Univ Delaware, Dept Phys Therapy, Newark, DE 19716 USA; [Tulsky, David S.] Univ Delaware, Dept Psychol Sci, Newark, DE 19716 USA; [Tulsky, David S.] Univ Delaware, Dept Brain Sci, Newark, DE 19716 USA; [Brooks, Brian L.] Alberta Childrens Prov Gen Hosp, Neurosci Program Brain Injury & Rehabil, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Dept Paediat, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Dept Psychol, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB, Canada; [Gershon, Richard] Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, Evanston, IL 60208 USA; [Gershon, Richard] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Div Biomed Informat, Evanston, IL 60208 USA; [Heinemann, Allen W.] Northwestern Univ, Rehabil Inst Chicago, Feinberg Sch Med, Evanston, IL 60208 USA; [Iverson, Grant L.] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, Boston, MA USA; [Iverson, Grant L.] MassGen Hosp Children, Sports Concuss Program, Cambridge, MA USA; [Iverson, Grant L.] Home Base, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp Program, Boston, MA USA	Holdnack, JA (corresponding author), 5 Rose Hill Dr, Bear, DE 19701 USA.	jhold@udel.edu	Heinemann, Allen W./AAI-2790-2021	Heinemann, Allen W./0000-0003-2782-7326; Tulsky, David/0000-0002-4335-4509; Iverson, Grant/0000-0001-7348-9570	Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health [U54-GM104941]; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); National Institute on Disability, Independent Living, and Rehabilitation ResearchUnited States Department of Health & Human Services [H133B040032]; Mooney-Reed Charitable Foundation	Support for JAH was provided by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number U54-GM104941 (PI: Binder-Macleod). BLB acknowledges support from the Canadian Institutes of Health Research. AWH received funding for the Rehabilitation Research and Training Center on Measuring Rehabilitation Outcomes and Effectiveness (H133B040032) from the National Institute on Disability, Independent Living, and Rehabilitation Research. GLI acknowledges support from the Mooney-Reed Charitable Foundation. GLI notes that this work is related in part to the TBI Endpoints Development Initiative and a grant titled Development and Validation of a Cognition Endpoint for Traumatic Brain Injury Clinical Trials.	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Axelrod BN, 2007, INT J NEUROSCI, V117, P1591, DOI 10.1080/00207450600941189; Beaumont JL, 2013, NEUROLOGY, V80, pS87, DOI 10.1212/WNL.0b013e3182872e70; Binder LM, 2009, ARCH CLIN NEUROPSYCH, V24, P31, DOI 10.1093/arclin/acn001; Brooks BL, 2008, J INT NEUROPSYCH SOC, V14, P463, DOI 10.1017/S1355617708080521; Brooks BL, 2007, J INT NEUROPSYCH SOC, V13, P490, DOI 10.1017/D1355617707070531; Brooks BL, 2013, PRACT RESOUR MENT, P75, DOI 10.1016/B978-0-12-386934-0.00002-X; Brooks BL, 2011, ASSESSMENT, V18, P156, DOI 10.1177/1073191110385316; Brooks BL, 2009, CAN PSYCHOL, V50, P196, DOI 10.1037/a0016066; Brooks BL, 2009, J INT NEUROPSYCH SOC, V15, P613, DOI 10.1017/S1355617709090651; Brooks BL, 2009, DEMENT GERIATR COGN, V27, P439, DOI 10.1159/000215390; Carlozzi NE, 2015, CLIN NEUROPSYCHOL, V29, P21, DOI 10.1080/13854046.2015.1005677; Carlozzi NE, 2013, J CLIN EXP NEUROPSYC, V35, P906, DOI 10.1080/13803395.2013.833178; Casaletto KB, 2015, J INT NEUROPSYCH SOC, V21, P378, DOI 10.1017/S1355617715000351; Crawford JR, 2007, NEUROPSYCHOLOGY, V21, P419, DOI 10.1037/0894-4105.21.4.419; Donders J, 2015, ASSESSMENT, V22, P17, DOI 10.1177/1073191114530776; Gershon RC, 2014, J INT NEUROPSYCH SOC, V20, P642, DOI 10.1017/S1355617714000411; Gershon RC, 2013, NEUROLOGY, V80, pS2, DOI 10.1212/WNL.0b013e3182872e5f; Gershon RC, 2010, LANCET NEUROL, V9, P138, DOI 10.1016/S1474-4422(09)70335-7; Grober E, 1997, PSYCHOL AGING, V12, P183, DOI 10.1037/0882-7974.12.1.183; Heaton R.K., 1991, COMPREHENSIVE NORMS; Heaton RK, 2004, REVISED COMPREHENSIV; Heaton RK, 2014, J INT NEUROPSYCH SOC, V20, P588, DOI 10.1017/S1355617714000241; Heilbronner R.L., 2008, NEUROPSYCHOLOGY COUR, P243; Holdnack J. A., REHABILITAT IN PRESS; Horton AM, 1999, INT J NEUROSCI, V99, P221, DOI 10.3109/00207459908994326; Ingraham LJ, 1996, NEUROPSYCHOLOGY, V10, P120, DOI 10.1037/0894-4105.10.1.120; Iverson G. L., 2008, NEUROPSYCHOLOGY HDB, P279; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Mungas D, 2014, J INT NEUROPSYCH SOC, V20, P579, DOI 10.1017/S1355617714000307; Palmer BW, 1998, ARCH CLIN NEUROPSYCH, V13, P503, DOI 10.1016/S0887-6177(97)00037-1; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Schretlen DJ, 2008, J INT NEUROPSYCH SOC, V14, P436, DOI 10.1017/S1355617708080387; Sinclair KL, 2013, J CLIN EXP NEUROPSYC, V35, P210, DOI 10.1080/13803395.2012.762340; Steinberg BA, 2005, CLIN NEUROPSYCHOL, V19, P464, DOI 10.1080/13854040590945193; Steinberg BA, 2005, CLIN NEUROPSYCHOL, V19, P329, DOI 10.1080/13854040590945210; Tremont G, 1998, CLIN NEUROPSYCHOL, V12, P560, DOI 10.1076/clin.12.4.560.7238; Tulsky D. S., REHABILITATION PSYCH; WARNER MH, 1987, J CLIN EXP NEUROPSYC, V9, P545, DOI 10.1080/01688638708410768; Weintraub S, 2014, J INT NEUROPSYCH SOC, V20, P567, DOI 10.1017/S1355617714000320; Weintraub S, 2013, NEUROLOGY, V80, pS54, DOI 10.1212/WNL.0b013e3182872ded	41	24	24	0	7	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2017	32	5					574	584		10.1093/arclin/acx032			11	Psychology, Clinical; Psychology	Psychology	FC8RL	WOS:000407108500006	28419177	Bronze, Green Published			2021-06-18	
J	McNett, M; Moran, C; Janki, C; Gianakis, A				McNett, Molly; Moran, Cristina; Janki, Clare; Gianakis, Anastasia			Correlations Between Hourly Pupillometer Readings and Intracranial Pressure Values	JOURNAL OF NEUROSCIENCE NURSING			English	Article						neurologic injury; pupil assessment; pupillometer	TRAUMATIC BRAIN-INJURY; GLASGOW COMA SCALE; SEVERE HEAD-INJURY; PREDICTION; IMPACT	Introduction: Automated pupillometry is emerging as a mainstay in neurocritical care primarily because it overcomes limitations of manual pupillary examinations. Although several recent studies show improved assessment accuracy with a pupillometer, few investigate clinical use, specifically how well parameters correlate with multimodality monitoring and outcomes. The primary aim of this study was to examine correlations between serial pupillometer readings and intracranial pressure (ICP) values among neurocritically ill patients. Design: Prospective cohort, repeated measures. Sample: The study sample was composed of adult patients with neurological injury who were admitted to intensive care unit, requiring hourly neurological assessment and pupillary checks within a level I trauma, urban, academic medical center. Procedures: Hourly pupillometer readings and corresponding ICP values were consecutively recorded for 72 hours after intensive care unit admission. Results: Serial assessments resulted in more than 2100 pupillometer readings from 76 subjects. Mean age of the study sample was 55.4 years, with a mean Glasgow Coma Scale score of 8.9. The mean pupillometer values for the enrolled subjects included left constriction velocity of 1.22, left neurological pupil index of 4.21, left pupil size of 2.69, right constriction velocity of 1.18, right neurological pupil index of 4.18, and right pupil size of 2.57. The mean ICP of the study sample was 12, with mean cerebral perfusion pressure of 77. Pupillometer values significantly correlated with ICP values in bivariate (P < .001, r = 0.13-0.23) and multivariate regression models (F(6) = 17.63, P < .001). Conclusions: Automated pupillometry in neurocritical care is a valuable adjunct to traditional invasive monitoring. Integration of routine pupillometer assessments not only improves accuracy of examinations but also correlates with ICP values.	[McNett, Molly] MetroHlth Syst, Nursing Res, Cleveland, OH 44109 USA; [McNett, Molly] MetroHlth Syst, Nursing Educ & Profess Practice, Cleveland, OH 44109 USA; [Moran, Cristina; Janki, Clare; Gianakis, Anastasia] MetroHlth Syst, Surg Intens Care Unit, Cleveland, OH USA	McNett, M (corresponding author), MetroHlth Syst, Nursing Res, Cleveland, OH 44109 USA.; McNett, M (corresponding author), MetroHlth Syst, Nursing Educ & Profess Practice, Cleveland, OH 44109 USA.	mmcnett@metrohealth.org					Adoni Andea, 2007, J Trauma Nurs, V14, P191; Brain Trauma Foundation American Association of Neuro-logical Surgeons, 2000, J NEUROTRAUM, V17, P583; Chen Jeff W, 2011, Surg Neurol Int, V2, P82, DOI 10.4103/2152-7806.82248; Clark A, 2006, EMERG MED J, V23, P440, DOI 10.1136/emj.2005.030247; FISHER CM, 1995, CAN J NEUROL SCI, V22, P83, DOI 10.1017/S0317167100040142; Fountas KN, 2006, NEUROCRIT CARE, V5, P55, DOI 10.1385/NCC:5:1:55; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hoffmann M, 2012, BRIT J SURG, V99, P122, DOI 10.1002/bjs.7707; Hou RHH, 2006, BRIT J CLIN PHARMACO, V61, P752, DOI 10.1111/j.1365-2125.2006.02632.x; Larson MD, 2015, ANESTH ANALG, V120, P1242, DOI 10.1213/ANE.0000000000000314; Litvan I, 2000, NEUROLOGY, V54, P530, DOI 10.1212/WNL.54.2.530; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; McNett Molly, 2007, J Neurosci Nurs, V39, P68; Meeker Michele, 2005, J Neurosci Nurs, V37, P34; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Olson DM, 2016, NEUROCRIT CARE, V24, P251, DOI 10.1007/s12028-015-0182-1; Olson DM, 2016, CRIT CARE NURS CLIN, V28, P101, DOI 10.1016/j.cnc.2015.09.003; Rovlias A, 2004, J NEUROTRAUM, V21, P886, DOI 10.1089/0897715041526249; Shamim MS, 2011, J NEUROSURG, V115, P1007, DOI 10.3171/2011.7.JNS101829; Taylor WR, 2003, J NEUROSURG, V98, P205, DOI 10.3171/jns.2003.98.1.0205	21	24	24	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0888-0395	1945-2810		J NEUROSCI NURS	J. Neurosci. Nurs.	AUG	2017	49	4					229	234		10.1097/JNN.0000000000000290			6	Clinical Neurology; Nursing	Neurosciences & Neurology; Nursing	EZ4CM	WOS:000404658700006	28661946				2021-06-18	
J	Tchekalarova, J; Atanasova, D; Nenchovska, Z; Atanasova, M; Kortenska, L; Gesheva, R; Lazarov, N				Tchekalarova, Jana; Atanasova, Dimitrinka; Nenchovska, Zlatina; Atanasova, Milena; Kortenska, Lidia; Gesheva, Rumyana; Lazarov, Nikolai			Agomelatine protects against neuronal damage without preventing epileptogenesis in the kainate model of temporal lobe epilepsy	NEUROBIOLOGY OF DISEASE			English	Article						Agomelatine; Kainate; Epileptogenesis; Behavior; Neuronal loss	INDUCED STATUS-EPILEPTICUS; TRAUMATIC BRAIN-INJURY; LONG-TERM TREATMENT; OXIDATIVE STRESS; BEHAVIORAL ALTERATIONS; HIPPOCAMPAL-FORMATION; SPATIAL MEMORY; MELATONIN; RECEPTORS; ANTIDEPRESSANT	Recent studies about the novel antidepressant agomelatine, which is a mixed MT1 and MT2 melatonin receptor agonist and 5HT(2c) serotonin receptor antagonist possessing an anticonvulsant and neuroprotective action, suggest that it may have potential to contribute against epileptogenesis and epilepsy-induced memory impairment. In order to ascertain whether protection of some brain structures could suppress epileptogenesis, in the present study, we evaluated the effect of chronic post-status treatment with agomelatine on epileptogenesis, behavioral and neuronal damage induced by kainate acid (KA) status epilepticus (SE). Agomelatine/vehicle treatment (40 mg/kg, i.p.) started one hour after SE and continued up to 10 weeks in Wistar rats. Latency for onset of spontaneous motor seizures (SMS) and their frequency was detected by a 24-h video-recording. Locomotor activity, anxiety and hippocampus-dependent spatial memory in open field (OF), elevated plus maze (EPM), light-dark test (LDT) and radial arm maze (RAM) test, respectively, were evaluated during the last two weeks after SE. Agomelatine significantly decreased the latency for onset of SMS and increased the seizure frequency during the 2nd and the 3rd week of treatment. The MT1 and MT2 receptor agonist and serotonin 5HT2c receptor antagonist exacerbated the KA-induced hyperlocomotion and impulsive behavior and it was unable to prevent spatial memory impairment of epileptic rats. However, agomelatine induced a neuroprotection in the dorsal hippocampus, specifically in the CA1, septal CA2 and partially in the CA3c region, the hilus of the dentate gyrus, piriform cortex and septo-temporal and temporal basolateral amygdala. Our findings suggest that the beneficial impact against SE-induced neuronal loss exerted by agomelatine is not crucial for the suppression of epileptogenesis and its deleterious consequences in MA model of temporal lobe epilepsy. (C) 2017 Elsevier Inc. All rights reserved.	[Tchekalarova, Jana; Atanasova, Dimitrinka; Nenchovska, Zlatina; Kortenska, Lidia; Gesheva, Rumyana; Lazarov, Nikolai] Bulgarian Acad Sci, Inst Neurobiol, Acad G Bonchev Str,Bl 23, Sofia 1113, Bulgaria; [Atanasova, Dimitrinka] Trakia Univ, Dept Anat, Fac Med, Stara Zagora 6003, Bulgaria; [Atanasova, Milena] Med Univ Pleven, Dept Biol, Pleven 5800, Bulgaria; [Lazarov, Nikolai] Med Univ Sofia, Dept Anat & Histol, Sofia 1431, Bulgaria	Tchekalarova, J (corresponding author), Bulgarian Acad Sci, Inst Neurobiol, Acad G Bonchev Str,Bl 23, Sofia 1113, Bulgaria.	janetchekalarova@gmail.com	Atanasova, Dimitrinka/AAK-9242-2020; J, Tchekalarova/H-3826-2014	Atanasova, Dimitrinka/0000-0003-1745-7755	Medical University of Pleven [7/2016]; Medical University of Sofia, Bulgaria [4/2015]; National Science Fund of BulgariaNational Science Fund of Bulgaria [HI 03/10]	This work was supported by the Medical University of Pleven (grant No. 7/2016), the Medical University of Sofia, Bulgaria (grant No. 4/2015) and the National Science Fund of Bulgaria (research grant # NoHI 03/10). The authors would like to thank Sabina Mitova, Faculty of Medicine, Medical University of Sofia for her technical assistance. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.	Akaike K, 2001, BRAIN RES, V900, P65, DOI 10.1016/S0006-8993(01)02252-1; Atanasova M, 2013, PHARMACOL BIOCHEM BE, V111, P44, DOI 10.1016/j.pbb.2013.08.006; Banasr M, 2006, BIOL PSYCHIAT, V59, P1087, DOI 10.1016/j.biopsych.2005.11.025; Barbiero VS, 2007, EUR NEUROPSYCHOPHARM, V17, pS365, DOI 10.1016/S0924-977X(07)70535-7; Bazil CW, 2000, NEUROLOGY, V55, P1746, DOI 10.1212/WNL.55.11.1746; Bertaina-Anglade V, 2011, PHARMACOL BIOCHEM BE, V98, P511, DOI 10.1016/j.pbb.2011.02.015; Borowicz KK, 1999, EUR NEUROPSYCHOPHARM, V9, P185, DOI 10.1016/S0924-977X(98)00022-4; Boulle F, 2016, EUR NEUROPSYCHOPHARM, V26, P65, DOI 10.1016/j.euroneuro.2015.11.003; Brandt C, 2006, NEUROPHARMACOLOGY, V51, P789, DOI 10.1016/j.neuropharm.2006.05.021; Brun VH, 2002, SCIENCE, V296, P2243, DOI 10.1126/science.1071089; Comai S, 2014, J PSYCHIATR NEUROSCI, V39, P6, DOI 10.1503/jpn.130009; Conboy L, 2009, INT J NEUROPSYCHOPH, V12, P329, DOI 10.1017/S1461145708009255; Costa-Lotufo LV, 2002, COMP BIOCHEM PHYS C, V131, P521, DOI 10.1016/S1532-0456(02)00037-6; Dagyte G, 2011, BEHAV BRAIN RES, V218, P121, DOI 10.1016/j.bbr.2010.11.045; Dastgheib M, 2014, EUR J PHARMACOL, V736, P10, DOI 10.1016/j.ejphar.2014.04.039; de Mello AH, 2016, PSYCHIAT CLIN NEUROS, V70, P159, DOI 10.1111/pcn.12371; Delagrange P, 1997, CLIN NEUROPHARMACOL, V20, P482, DOI 10.1097/00002826-199712000-00002; Demirdas A., 2016, METAB BRAIN DIS; Detour J, 2005, EPILEPSIA, V46, P499, DOI 10.1111/j.0013-9580.2005.38704.x; Ding K, 2015, NEUROCHEM INT, V91, P46, DOI 10.1016/j.neuint.2015.10.008; GILBERT M, 1985, BRAIN RES, V361, P389, DOI 10.1016/0006-8993(85)91309-5; Guardiola-Lemaitre B, 2014, BRIT J PHARMACOL, V171, P3604, DOI 10.1111/bph.12720; Gupta M, 2004, EPILEPSIA, V45, P1636, DOI 10.1111/j.0013-9580.2004.17604.x; Isaac M, 2005, CURR TOP MED CHEM, V5, P59, DOI 10.2174/1568026053386980; Isaev D, 2015, NEUROBIOL DIS, V78, P68, DOI 10.1016/j.nbd.2015.03.026; Kennett GA, 1997, NEUROPHARMACOLOGY, V36, P609, DOI 10.1016/S0028-3908(97)00038-5; Kjelstrup KG, 2002, P NATL ACAD SCI USA, V99, P10825, DOI 10.1073/pnas.152112399; Lapin IP, 1998, J PINEAL RES, V24, P215; Lima E, 2011, EPILEPSY BEHAV, V20, P607, DOI 10.1016/j.yebeh.2011.01.018; Mairesse J, 2013, INT J NEUROPSYCHOPH, V16, P323, DOI 10.1017/S1461145711001970; Mallei M, 2009, EUR NEUROPSYCHOPHARM, V19, pS441, DOI 10.1016/S0924-977X(09)70687-X; Markgraf CG, 2014, J PHARMACOL TOX MET, V70, P224, DOI 10.1016/j.vascn.2014.08.005; Mazor A, 2009, WORLD J BIOL PSYCHIA, V10, P856, DOI 10.1080/15622970701561383; Morley-Fletcher S, 2011, PSYCHOPHARMACOLOGY, V217, P301, DOI 10.1007/s00213-011-2280-x; NAGAHARA AH, 1993, HIPPOCAMPUS, V3, P269, DOI 10.1002/hipo.450030304; OLTON DS, 1976, J EXP PSYCHOL-ANIM B, V2, P97, DOI 10.1037/0097-7403.2.2.97; Ozkay UD, 2015, BEHAV PHARMACOL, V26, P469, DOI 10.1097/FBP.0000000000000153; Petkova Z, 2014, EPILEPSY BEHAV, V31, P198, DOI 10.1016/j.yebeh.2013.12.013; Pitkanen A, 2000, ANN NY ACAD SCI, V911, P369; RACINE R, 1977, CAN J NEUROL SCI, V4, P273, DOI 10.1017/S0317167100025117; Rainer Q, 2012, INT J NEUROPSYCHOPH, V15, P321, DOI 10.1017/S1461145711000356; RODGERS RJ, 1995, PHARMACOL BIOCHEM BE, V52, P297, DOI 10.1016/0091-3057(95)00138-M; Rufo-Campos M, 2002, REV NEUROL S, V1, P51; Schwarcz R, 2002, EPILEPSY RES, V50, P161, DOI 10.1016/S0920-1211(02)00077-3; Sejourne J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136494; Shin EJ, 2011, NEUROCHEM INT, V59, P122, DOI 10.1016/j.neuint.2011.03.025; Singh SP, 2015, ENEURO, V2, DOI 10.1523/ENEURO.0087-15.2015; Slominski RM, 2012, MOL CELL ENDOCRINOL, V351, P152, DOI 10.1016/j.mce.2012.01.004; Soumier A, 2008, EUR NEUROPSYCHOPHARM, V18, pS350, DOI 10.1016/S0924-977X(08)70491-7; Srivastava N, 2008, NEUROCHEM RES, V33, P1169, DOI 10.1007/s11064-007-9478-7; STAFSTROM CE, 1993, EPILEPSIA, V34, P420, DOI 10.1111/j.1528-1157.1993.tb02582.x; Stahl SM, 2014, CNS SPECTRUMS, V19, P207, DOI 10.1017/S1092852914000248; Tchekalarova J, 2016, BEHAV BRAIN RES, V302, P11, DOI 10.1016/j.bbr.2015.12.043; Tchekalarova J, 2013, EPILEPSY BEHAV, V27, P174, DOI 10.1016/j.yebeh.2013.01.009; Tchekalarova J, 2011, EPILEPSY BEHAV, V20, P277, DOI 10.1016/j.yebeh.2010.12.021; Tchekalarova J, 2010, EPILEPSY BEHAV, V17, P23, DOI 10.1016/j.yebeh.2009.11.001; Aguiar CCT, 2012, EPILEPSY BEHAV, V24, P324, DOI 10.1016/j.yebeh.2012.04.134; Witt-Enderby PA, 2003, LIFE SCI, V72, P2183, DOI 10.1016/S0024-3205(03)00098-5; Wolden-Hanson T, 2000, ENDOCRINOLOGY, V141, P487, DOI 10.1210/en.141.2.487; Wu HJ, 2016, J PINEAL RES, V61, P241, DOI 10.1111/jpi.12344; Yahyavi-Firouz-Abadi N, 2006, EPILEPSY RES, V68, P103, DOI 10.1016/j.eplepsyres.2005.09.057; Yapca OE, 2014, ADV CLIN EXP MED, V23, P715, DOI 10.17219/acem/37227; YEHUDA S, 1993, PEPTIDES, V14, P203, DOI 10.1016/0196-9781(93)90030-K	63	24	27	0	12	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	AUG	2017	104						1	14		10.1016/j.nbd.2017.04.017			14	Neurosciences	Neurosciences & Neurology	EX6WY	WOS:000403384000001	28438504				2021-06-18	
J	Chen, HZ; Desai, A; Kim, HY				Chen, Huazhen; Desai, Abhishek; Kim, Hee-Yong			Repetitive Closed-Head Impact Model of Engineered Rotational Acceleration Induces Long-Term Cognitive Impairments with Persistent Astrogliosis and Microgliosis in Mice	JOURNAL OF NEUROTRAUMA			English	Article						CHIMERA; learning and memory; neuroinflammation; rmTBI	TRAUMATIC BRAIN-INJURY; MICROGLIA/MACROPHAGE POLARIZATION DYNAMICS; WHITE-MATTER INJURY; PHOSPHORYLATED TAU; DISEASE; ENCEPHALOPATHY; EXPRESSION; PROTEIN; MEMORY; NEUROPATHOLOGY	Repeated mild traumatic brain injury (rmTBI) has been identified by epidemiology as a high-risk factor for dementia at a later stage in life. Animal models to replicate complex features of human rmTBI and/or to evaluate long-term effects on brain function have not been established. In this study, we used a novel closed-head impact model of engineered rotational acceleration (CHIMERA) to investigate the long-term neuropathological and cognitive functional consequences of rmTBI. Adult C57BL/6 male mice were subjected to CHIMERA for 3 consecutive days 24h apart. Functional outcomes were assessed by the beam walk and Morris water maze tests. Neuropathology was evaluated by immunostaining of glial fibrillary acidic protein (GFAP), amyloid precursor protein (APP), and ionizing calcium-binding adaptor molecule-1 (Iba-1), and by quantitative reverse transcription polymerase chain reaction (qRT-PCR) or Western blotting of GFAP, Iba-1, and tumor necrosis factor (TNF)-. Repeated CHIMERA (rCHIMERA) resulted in motor deficits at 3 days, and in learning and memory impairments that were sustained up to 6 months post injury. GFAP and TNF- gene expression was increased within a week, whereas astrogliosis and microgliosis were induced starting from day 1 up to 6.5 months after rCHIMERA with upregulated GFAP and Iba-1 protein levels. rCHIMERA also induced APP deposition from day 1 to day 7, but this diminished by 1 month. In conclusion, rCHIMERA produces long-lasting cognitive impairments with astrogliosis and microgliosis in mice, suggesting that rCHIMERA can be a useful animal model to study the long-term complications, as well as the cellular and molecular mechanisms, of human rmTBI.	[Chen, Huazhen; Desai, Abhishek; Kim, Hee-Yong] NIAAA, Lab Mol Signaling, NIH, Rockville, MD 20852 USA; [Chen, Huazhen] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA	Kim, HY (corresponding author), NIAAA, NIH, 5625 Fishers Lane, Rockville, MD 20852 USA.	hykim@nih.gov			Intramural Program of the NIAAA; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [ZIAAA000501] Funding Source: NIH RePORTER	This study was supported by the Intramural Program of the NIAAA, the NIH, and the Department of Defense in the Center for Neuroscience and Regenerative Medicine. The authors thank the NIAAA animal facility staff for their support.	AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Alexander S, 2007, J NEUROTRAUM, V24, P790, DOI 10.1089/neu.2006.0133; Barrio JR, 2015, P NATL ACAD SCI USA, V112, pE2039, DOI 10.1073/pnas.1409952112; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Beschorner R, 2002, ACTA NEUROPATHOL, V103, P541, DOI 10.1007/s00401-001-0503-7; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Calabrese E, 2014, J NEUROTRAUM, V31, P938, DOI 10.1089/neu.2013.3144; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Chio CC, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-33; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Gerberding J.L., 2003, REPORT C MILD TRAUMA; Goodrich GL, 2014, J REHABIL RES DEV, V51, P547, DOI 10.1682/JRRD.2013.02.0049; Haarbauer-Krupa J, 2017, J NEUROTRAUM, V34, P50, DOI 10.1089/neu.2015.4158; Hennessy E, 2015, J NEUROSCI, V35, P8411, DOI 10.1523/JNEUROSCI.2745-14.2015; Hibbits N, 2012, ASN NEURO, V4, DOI 10.1042/AN20120062; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Itoh T, 2009, NEUROL RES, V31, P103, DOI 10.1179/016164108X323771; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, COGN BEHAV NEUROL, V20, P170, DOI 10.1097/WNN.0b013e318142badb; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Loane David J, 2015, Handb Clin Neurol, V127, P343, DOI 10.1016/B978-0-444-52892-6.00022-2; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Lowing JL, 2014, J NEUROTRAUM, V31, P1700, DOI 10.1089/neu.2013.3286; Lu KP, 2016, JAMA NEUROL, V73, P1356, DOI 10.1001/jamaneurol.2016.2027; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; Marklund N, 2014, J NEUROTRAUM, V31, P42, DOI 10.1089/neu.2013.2964; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McMahon PJ, 2015, J NEUROTRAUM, V32, P527, DOI 10.1089/neu.2014.3635; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Namjoshi DR, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-55; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Paresce DM, 1997, J BIOL CHEM, V272, P29390, DOI 10.1074/jbc.272.46.29390; Ponsford J, 2011, J NEUROTRAUM, V28, P1683, DOI 10.1089/neu.2010.1623; Puvenna V, 2016, BRAIN RES, V1630, P225, DOI 10.1016/j.brainres.2015.11.007; Sajja VSSS, 2016, FRONT INTEGR NEUROSC, V10, DOI [10.3389/fnint.2016.00007, 10.3389/fnint.7016.00007]; Sajja VSSS, 2014, NEUROSCI LETT, V570, P33, DOI 10.1016/j.neulet.2014.03.072; Sajja VSSS, 2014, MOL CELL NEUROSCI, V59, P119, DOI 10.1016/j.mcn.2014.02.004; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stalder M, 2001, NEUROBIOL AGING, V22, P427, DOI 10.1016/S0197-4580(01)00209-3; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Trinchese F, 2004, ANN NEUROL, V55, P801, DOI 10.1002/ana.20101; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu LY, 2016, EXP NEUROL, V275, P436, DOI 10.1016/j.expneurol.2014.11.004; Zetterberg H, 2010, EXP GERONTOL, V45, P23, DOI 10.1016/j.exger.2009.08.002	62	24	24	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 15	2017	34	14					2291	2302		10.1089/neu.2016.4870			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EZ8RQ	WOS:000404995000012	28288551	Green Published			2021-06-18	
J	Clark, RSB; Empey, PE; Bay, H; Rosario, BL; Poloyac, SM; Kochanek, PM; Nolin, TD; Au, AK; Horvat, CM; Wisniewski, SR; Bell, MJ				Clark, Robert S. B.; Empey, Philip E.; Bay, Hulya; Rosario, Bedda L.; Poloyac, Samuel M.; Kochanek, Patrick M.; Nolin, Thomas D.; Au, Alicia K.; Horvat, Christopher M.; Wisniewski, Stephen R.; Bell, Michael J.			Phase I randomized clinical trial of Nacetylcysteine in combination with an adjuvant probenecid for treatment of severe traumatic brain injury in children	PLOS ONE			English	Article							N-ACETYLCYSTEINE; DOUBLE-BLIND; PHARMACOKINETICS; EFFICACY; GLUTATHIONE; SYSTEMS	Background There are no therapies shown to improve outcome after severe traumatic brain injury (TBI) in humans, a leading cause of morbidity and mortality. We sought to verify brain exposure of the systemically administered antioxidant N-acetylcysteine (NAC) and the synergistic adjuvant probenecid, and identify adverse effects of this drug combination after severe TBI in children. Methods IRB-approved, randomized, double- blind, placebo controlled Phase I study in children 2 to 18 years-of-age admitted to a Pediatric Intensive Care Unit after severe TBI (Glasgow Coma Scale [GCS] score <= 8) requiring an externalized ventricular drain for measurement of intracranial pressure (ICP). Patients were recruited from November 2011-August 2013. Fourteen patients (n = 7/group) were randomly assigned after obtaining informed consent to receive probenecid (25 mg/kg load, then 10 mg/kg/dose q6hx11 doses) and NAC (140 mg/kg load, then 70 mg/kg/dose q4hx17 doses), or placebos via naso/orogastric tube. Serum and CSF samples were drawn pre-bolus and 1-96 h after randomization and drug concentrations were measured via UPLC-MS/MS. Glasgow Outcome Scale (GOS) score was assessed at 3 months. Results There were no adverse events attributable to drug treatment. One patient in the placebo group was withdrawn due to adverse effects. In the treatment group, NAC concentrations ranged from 16,977.3 +/- 2,212.3 to 16,786.1 +/- 3,285.3 in serum and from 269.3 +/- 113.0 to 467.9 +/- 262.7 ng/mL in CSF, at 24 to 72 h post-bolus, respectively; and probenecid concentrations ranged from 75.4.3 +/- 10.0 to 52.9 +/- 25.8 in serum and 5.4 +/- 1.0 to 4.6 +/- 2.1 mu g/mL in CSF, at 24 to 72 h post-bolus, respectively (mean +/- SEM). Temperature, mean arterial pressure, ICP, use of ICP-directed therapies, surveillance serum brain injury biomarkers, and GOS at 3 months were not different between groups. Conclusions Treatment resulted in detectable concentrations of NAC and probenecid in CSF and was not associated with undesirable effects after TBI in children.	[Clark, Robert S. B.; Bay, Hulya; Kochanek, Patrick M.; Au, Alicia K.; Horvat, Christopher M.; Bell, Michael J.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Clark, Robert S. B.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; [Clark, Robert S. B.; Bay, Hulya; Kochanek, Patrick M.; Au, Alicia K.; Horvat, Christopher M.; Bell, Michael J.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Clark, Robert S. B.; Bay, Hulya; Kochanek, Patrick M.; Au, Alicia K.; Horvat, Christopher M.; Bell, Michael J.] UPMC, Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; [Clark, Robert S. B.; Empey, Philip E.; Kochanek, Patrick M.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA 15260 USA; [Empey, Philip E.; Poloyac, Samuel M.; Nolin, Thomas D.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Ctr Clin Pharmaceut Sci, Pittsburgh, PA USA; [Bay, Hulya] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA USA; [Rosario, Bedda L.; Wisniewski, Stephen R.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; [Bell, Michael J.] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15261 USA; [Bell, Michael J.] Childrens Natl Hlth Syst, Dept Pediat, Washington, DC USA	Clark, RSB (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA.; Clark, RSB (corresponding author), Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA.; Clark, RSB (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA.; Clark, RSB (corresponding author), UPMC, Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA.; Clark, RSB (corresponding author), Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA 15260 USA.	clarkrs@ccm.upmc.edu	Empey, Philip/L-9604-2019; Nolin, Thomas/AAB-7311-2020	Empey, Philip/0000-0001-7474-2339; Nolin, Thomas/0000-0003-4339-1382	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS069247]; NCATSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR000146, U01NS081041]; Children's Hospital of Pittsburgh of UPMC Scientific Program and Brain Care Institute; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER	This work was supported by NIH grants R01NS069247 (RSBC, PEE, MJB, PMK), NCATS KL2TR000146 (PEE), and U01NS081041 (MJB, SRW, PMK); and the Children's Hospital of Pittsburgh of UPMC Scientific Program and Brain Care Institute. The funding sources had no role in study design, data collection, data analysis, data interpretation, or writing of there port.	Baki SGA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012490; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berk M, 2014, J CLIN PSYCHIAT, V75, P628, DOI 10.4088/JCP.13m08454; BORGSTROM L, 1986, EUR J CLIN PHARMACOL, V31, P217, DOI 10.1007/BF00606662; BURNELL JM, 1951, J CLIN INVEST, V30, P697, DOI 10.1172/JCI102482; Du LN, 2016, J NEUROTRAUM, V33, P1913, DOI 10.1089/neu.2015.4342; Exo J, 2011, PEDIATR CRIT CARE ME, V12, P560, DOI 10.1097/PCC.0b013e3181e8b3ee; Farr SA, 2003, J NEUROCHEM, V84, P1173, DOI 10.1046/j.1471-4159.2003.01580.x; Giustarini D, 2012, BIOCHEM PHARMACOL, V84, P1522, DOI 10.1016/j.bcp.2012.09.010; Hagos FT, 2016, XENOBIOTICA, P1; Hammond CL, 2007, J BIOL CHEM, V282, P14337, DOI 10.1074/jbc.M611019200; Hoffer ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054163; Katz M, 2015, PARKINSONISM RELAT D, V21, P500, DOI 10.1016/j.parkreldis.2015.02.020; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Levin SW, 2014, LANCET NEUROL, V13, P777, DOI 10.1016/S1474-4422(14)70142-5; Maeda K, 2014, EUR J PHARM SCI, V59, P94, DOI 10.1016/j.ejps.2014.04.004; Morris ZS, 2011, J ROY SOC MED, V104, P510, DOI 10.1258/jrsm.2011.110180; Nigam SK, 2015, PHYSIOL REV, V95, P83, DOI 10.1152/physrev.00025.2013; Nikoo M, 2015, CLIN NEUROPHARMACOL, V38, P11, DOI 10.1097/WNF.0000000000000063; NOZAKI K, 1992, J CEREBR BLOOD F MET, V12, P400, DOI 10.1038/jcbfm.1992.57; OLSSON B, 1988, EUR J CLIN PHARMACOL, V34, P77, DOI 10.1007/BF01061422; Papa L, 2016, J NEUROTRAUM, V33, P58, DOI 10.1089/neu.2015.3869; Samuni Y, 2013, BBA-GEN SUBJECTS, V1830, P4117, DOI 10.1016/j.bbagen.2013.04.016; SELEN A, 1982, J PHARM SCI, V71, P1238, DOI 10.1002/jps.2600711114; SMILKSTEIN MJ, 1988, NEW ENGL J MED, V319, P1557, DOI 10.1056/NEJM198812153192401; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Wiest DB, 2014, J PEDIATR-US, V165, P672, DOI 10.1016/j.jpeds.2014.06.044; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304	28	24	25	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2017	12	7							e0180280	10.1371/journal.pone.0180280			16	Multidisciplinary Sciences	Science & Technology - Other Topics	FA5DZ	WOS:000405464100047	28686657	DOAJ Gold, Green Published			2021-06-18	
J	Cusimano, MD; Topolovec-Vranic, J; Zhang, S; Mullen, SJ; Wong, M; Ilie, G				Cusimano, Michael D.; Topolovec-Vranic, Jane; Zhang, Stanley; Mullen, Sarah J.; Wong, Mattew; Ilie, Gabriela			Factors Influencing the Underreporting of Concussion in Sports: A Qualitative Study of Minor Hockey Participants	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; attitude; traumatic brain injury; adolescent; sports	BRAIN-INJURY; ICE HOCKEY; RECURRENT CONCUSSION; FOOTBALL PLAYERS; RETURN; GUIDELINES; EPIDEMIOLOGY; MANAGEMENT; KNOWLEDGE	Objective: The present study is to identify factors contributing to underreporting of concussion in adolescent athletes. Design: Qualitative interviews. Setting: Participants were interviewed in an office environment. Participants: Interviews were conducted with 31 minor hockey players, 10 parents, 6 coaches, 4 trainers, 2 managers, and one game official. Players were 13 to 15 year old. With selective sampling, an inductive approach of analyzing the interviews was undertaken and themes were identified and analyzed. Assessment of Risk Factors: Underreporting is a complex phenomenon. A number of risk factors related to hockey culture, players, reference others, and rules of play were assessed. Main Outcome Measures: Reasons not reporting concussion is accepted in minor hockey. Results: Aspects of hockey culture such as an overemphasis on winning games and upheld misperceptions about the risks associated with concussion were identified as relevant to the underreporting of concussions. Various factors relevant to the underreporting of concussions include player's motivation to win, group membership dynamics such as a player's role as the team's "enforcer," coaches' own motivation to win to further their own opportunities in the sport, and parents' personal financial interest or alternative agenda in terms of time commitments and their child's future career prospects. Conclusions: Our findings indicate that underreporting of concussion among those players interviewed appears to be prevalent and associated with misconceptions about injury risk, and a culture that both reinforces and encourages underreporting with tacit or overt complicity of parents and coaches. Our findings support the need to alter the culture of violence and tough play in hockey by education, rule changes, economic measures, and changes in governance of the sport. Interviewing more stakeholders and policy makers would shed light on such potential interventions.	[Cusimano, Michael D.; Zhang, Stanley; Mullen, Sarah J.; Wong, Mattew; Ilie, Gabriela] Univ Toronto, St Michaels Hosp, Keenan Res Ctr, Injury Prevent Res Off,Dept Surg,Div Neurosurg, Toronto, ON, Canada; [Cusimano, Michael D.] Canadian Brain Injury & Violence Res Team, Toronto, ON, Canada; [Cusimano, Michael D.; Topolovec-Vranic, Jane] St Michaels Hosp, Li KaShing Knowledge Inst, Trauma & Neurosurg Program, Keenan Res Ctr, Toronto, ON, Canada; [Cusimano, Michael D.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada	Cusimano, MD (corresponding author), Univ Toronto, St Michaels Hosp, Div Neurosurg, Educ & Publ Hlth, 30 Bond St, Toronto, ON M5B 1W8, Canada.	injuryprevention@smh.ca	Cusimano, Michael/X-4059-2019; Ilie, Gabriela/AAM-9122-2021; Topolovec-Vranic, Jane/A-5293-2013	Topolovec-Vranic, Jane/0000-0001-7695-4212	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [TIR-103946]; Ontario Neurotrauma Foundation	M. D. Cusimano is currently receiving a grant (#TIR-103946) from the Canadian Institutes of Health Research and Ontario Neurotrauma Foundation.	Ackery A, 2009, CAN J NEUROL SCI, V36, P207, DOI 10.1017/S0317167100120281; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Bauman J, 2005, CLIN J SPORT MED, V15, P432, DOI 10.1097/01.jsm.0000186682.21040.82; Canadian Broadcasting Corporation, 2003, HOCK NIGHT CAN COACH; CANTU RV, 1994, J NEUROSURG, V80, P592; Charmaz K, 2006, CONSTRUCTING GROUNDE; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Cusimano MD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061865; Cusimano Michael D, 2011, Open Med, V5, pe57; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; DeMatteo CA, 2010, PEDIATRICS, V125, P327, DOI 10.1542/peds.2008-2720; Denzin N. K., 2011, SAGE HDB QUALITATIVE, V4th; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10210; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; FICK DS, 1995, POSTGRAD MED, V97, P53; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; Fuld GL, 2009, PEDIATRICS, V124, P1495, DOI 10.1542/peds.2009-2146; Greenwald RM, 2012, CLIN J SPORT MED, V22, P83, DOI 10.1097/JSM.0b013e31824cc5d3; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Ilie G, 2015, J NEUROTRAUM, V32, P1130, DOI 10.1089/neu.2014.3619; Ilie G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094936; Ilie G, 2013, JAMA-J AM MED ASSOC, V309, P2550, DOI 10.1001/jama.2013.6750; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lear AM, 2012, J FAM PRACTICE, V61, P323; Macpherson A, 2006, PEDIATRICS, V117, pE143, DOI 10.1542/peds.2005-1163; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; Mrazik M, 2011, CLIN J SPORT MED, V21, P315, DOI 10.1097/JSM.0b013e31821e2b78; Murphy A, 2012, PM&R, V4, P419, DOI 10.1016/j.pmrj.2012.03.013; Nolin P, 2006, BRAIN INJURY, V20, P1147, DOI 10.1080/02699050601049247; Prichep LS, 2013, J HEAD TRAUMA REHAB, V28, P266, DOI 10.1097/HTR.0b013e318247b54e; Shenouda C, 2012, PM&R, V4, P427, DOI 10.1016/j.pmrj.2012.02.016; Smith M D, 1979, Can J Appl Sport Sci, V4, P76; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171	40	24	24	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2017	27	4					375	380		10.1097/JSM.0000000000000372			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	EZ4EA	WOS:000404663800012	28653965				2021-06-18	
J	Kawwass, JF; Sanders, KM; Loucks, TL; Rohan, LC; Berga, SL				Kawwass, Jennifer F.; Sanders, Kristen M.; Loucks, Tammy L.; Rohan, Lisa Cencia; Berga, Sarah L.			Increased cerebrospinal fluid levels of GABA, testosterone and estradiol in women with polycystic ovary syndrome	HUMAN REPRODUCTION			English	Article						polycystic ovary syndrome; GABA; estradiol; testosterone; CSF	HORMONE PULSE-GENERATOR; FUNCTIONAL HYPOTHALAMIC AMENORRHEA; FOLLICLE-STIMULATING-HORMONE; ALPHA-SUBUNIT SECRETION; TRAUMATIC BRAIN-INJURY; LUTEINIZING-HORMONE; GONADOTROPIN-SECRETION; HYPERANDROGENIC ANOVULATION; GENE-EXPRESSION; NEURONS	Do cerebrospinal fluid (CSF) concentrations of gamma-aminobutyric acid (GABA), testosterone (T) and estradiol (E2) differ in women with polycystic ovary syndrome (PCOS) as compared to eumenorrheic, ovulatory women (EW)? Women with PCOS displayed higher CSF levels of GABA and E2, and possibly T, than EW. The chronic anovulation characteristic of PCOS has been attributed to increased central GnRH drive and resulting gonadotropin aberrations. Androgens are thought to regulate GABA, which in turn regulates the neural cascade that modulates GnRH drive. This cross-sectional observational study included 15 EW and 12 non-obese women with PCOS who consented to a lumbar puncture in addition to 24 h of serum blood collection at 15-min intervals. In total, 27 women were studied at a the General Clinical Research Center (GCRC) at the University of Pittsburgh. Serum analytes included T, E2 and androstenedione. CSF analytes included GABA, glutamate, glucose, T and E2. Women with PCOS had higher CSF GABA as compared to EW (9.04 versus 7.04 mu mol/L, P < 0.05). CSF glucose and glutamate concentrations were similar between the two groups. CSF T was 52% higher (P = 0.1) and CSF E2 was 30% higher (P < 0.01) in women with PCOS compared to EW. Circulating T was 122% higher (P < 0.01) and circulating E2 was 75% higher (P < 0.01) in women with PCOS than in EW. The study is limited by its small sample size and the technical limitations of measuring CSF analytes that are pulsatile and have short half-lives. Women with PCOS displayed significantly higher circulating levels of T and E2, significantly higher CSF levels of E2, and higher levels of CSF testosterone, although the latter was not statistically significant. A better understanding of the central milieu informs our understanding of the mechanisms mediating increased the GnRH drive in PCOS and lends a new perspective for understanding the presentation, pathogenesis and potential health consequences of PCOS, including gender identity issues.	[Kawwass, Jennifer F.] Emory Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Endocrinol & Infertil, Atlanta, GA USA; [Sanders, Kristen M.] Temple Univ, Lewis Katz Sch Med, Dept Anat & Cell Biol, Philadelphia, PA 19122 USA; [Loucks, Tammy L.] Emory Univ, Dept Gynecol & Obstet, Div Res, Atlanta, GA 30322 USA; [Rohan, Lisa Cencia] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA; [Rohan, Lisa Cencia] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA; [Berga, Sarah L.] Wake Forest Sch Med, Sect Reprod Endocrinol & Infertil, Dept Obstet & Gynecol, Med Ctr Blvd, Winston Salem, NC 27157 USA	Berga, SL (corresponding author), Wake Forest Sch Med, Sect Reprod Endocrinol & Infertil, Dept Obstet & Gynecol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	sberga@wakehealth.edu	Loucks, Tammy/N-8223-2019	Loucks, Tammy/0000-0001-7651-7602; Kawwass, Jennifer/0000-0001-7345-735X; Sanders, Kristen/0000-0002-9326-427X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-MH50748, RR-00056]; NICHD/NIH as part of the Specialized Cooperative Centers Program in Reproduction Research [U54 HD08610]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54HD008610] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH045074] Funding Source: NIH RePORTER	This work was supported in part by grants to SLB from NIH R01-MH50748, from NICHD/NIH as part of the Specialized Cooperative Centers Program in Reproduction Research through cooperative agreement U54 HD08610 (Project I-PI SLB, Program Director Tony Plant), and by grant NIH RR-00056 to the General Clinical Research Center of the University of Pittsburgh.	ARCHER DF, 1988, FERTIL STERIL, V50, P555; Berga SL, 2009, J CLIN ENDOCR METAB, V94, P2250, DOI 10.1210/jc.2009-0959; BERGA SL, 1993, J CLIN ENDOCR METAB, V77, P895, DOI 10.1210/jc.77.4.895; Berga SL, 1997, FERTIL STERIL, V67, P1024, DOI 10.1016/S0015-0282(97)81434-3; Berga SL, 2000, AM J OBSTET GYNECOL, V182, P776, DOI 10.1016/S0002-9378(00)70326-7; Cesta CE, 2016, PSYCHONEUROENDOCRINO, V73, P196, DOI 10.1016/j.psyneuen.2016.08.005; Chan YM, 2013, ADV EXP MED BIOL, V784, P89, DOI 10.1007/978-1-4614-6199-9_5; Chapman IM, 1997, CLIN ENDOCRINOL, V46, P175, DOI 10.1046/j.1365-2265.1997.1200936.x; Chiapponi C, 2016, FRONT PSYCHIATRY, V7, DOI 10.3389/fpsyt.2016.00061; Daniels TL, 1997, J CLIN ENDOCR METAB, V82, P4179, DOI 10.1210/jc.82.12.4179; De Bond JAP, 2014, REPRODUCTION, V147, pR53, DOI 10.1530/REP-13-0509; DeFazio RA, 2002, MOL ENDOCRINOL, V16, P2872, DOI 10.1210/me.2002-0163; Deligiannidis KM, 2016, PSYCHONEUROENDOCRINO, V70, P98, DOI 10.1016/j.psyneuen.2016.05.010; Eagleson CA, 2000, J CLIN ENDOCR METAB, V85, P4047, DOI 10.1210/jc.85.11.4047; Franks S, 2012, FERTIL STERIL, V97, P2, DOI 10.1016/j.fertnstert.2011.11.029; Herbison AE, 2011, J NEUROENDOCRINOL, V23, P557, DOI 10.1111/j.1365-2826.2011.02145.x; Huang W, 2008, ENDOCRINOLOGY, V149, P2423, DOI 10.1210/en.2007-0830; Kalro BN, 2001, OBSTET GYN CLIN N AM, V28, P35, DOI 10.1016/S0889-8545(05)70184-4; KAZER RR, 1987, J CLIN ENDOCR METAB, V65, P233, DOI 10.1210/jcem-65-2-233; Kerr ME, 2003, CRIT CARE MED, V31, P2371, DOI 10.1097/01.CCM.0000080484.72004.C4; Kowalczyk R, 2012, ACTA OBSTET GYN SCAN, V91, P710, DOI 10.1111/j.1600-0412.2012.01408.x; LEONHARDT S, 1995, NEUROENDOCRINOLOGY, V61, P655, DOI 10.1159/000126892; Loscher W, 1999, PROG NEUROBIOL, V58, P31, DOI 10.1016/S0301-0082(98)00075-6; Manlove HA, 2008, ANN HUM BIOL, V35, P584, DOI 10.1080/03014460802337067; Marsh CA, 2013, FERTIL STERIL, V100, P200, DOI 10.1016/j.fertnstert.2013.02.054; Martin C, 2014, J NEUROSCI, V34, P6047, DOI 10.1523/JNEUROSCI.3003-13.2014; MATSUMOTO AM, 1984, J CLIN ENDOCR METAB, V58, P609, DOI 10.1210/jcem-58-4-609; McCartney CR, 2016, NEW ENGL J MED, V375, P54, DOI 10.1056/NEJMcp1514916; McCartney CR, 2002, SEMIN REPROD MED, V20, P317, DOI 10.1055/s-2002-36706; Michopoulos V, 2013, NEUROSCIENCE, V250, P300, DOI 10.1016/j.neuroscience.2013.07.002; Moore AM, 2016, J STEROID BIOCHEM, V160, P106, DOI 10.1016/j.jsbmb.2015.10.002; Morales AJ, 1996, J CLIN ENDOCR METAB, V81, P2854, DOI 10.1210/jc.81.8.2854; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Pastor CL, 1998, J CLIN ENDOCR METAB, V83, P582, DOI 10.1210/jc.83.2.582; Perrot-Sinal TS, 2001, ENDOCRINOLOGY, V142, P2238, DOI 10.1210/en.142.6.2238; Pielecka J, 2006, ENDOCRINOLOGY, V147, P1474, DOI 10.1210/en.2005-1029; Pielecka-Fortuna J, 2008, ENDOCRINOLOGY, V149, P1979, DOI 10.1210/en.2007-1365; Pielecka-Fortuna J, 2010, ENDOCRINOLOGY, V151, P291, DOI 10.1210/en.2009-0692; PLANT TM, 1986, ENDOCRINOLOGY, V119, P539, DOI 10.1210/endo-119-2-539; Ratnasabapathy R, 2013, CURR DRUG TARGETS, V14, P365; Rees DA, 2016, J CLIN ENDOCR METAB, V101, P313, DOI 10.1210/jc.2015-2318; Rickenlund A, 2003, FERTIL STERIL, V79, P947, DOI 10.1016/S0015-0282(02)04850-1; Smith JT, 2013, ADV EXP MED BIOL, V784, P275, DOI 10.1007/978-1-4614-6199-9_13; SPRATT DI, 1986, J CLIN ENDOCR METAB, V62, P102, DOI 10.1210/jcem-62-1-102; Sullivan SD, 2005, BIOL REPROD, V72, P33, DOI 10.1095/biolreprod.104.033126; Sullivan SD, 2004, P NATL ACAD SCI USA, V101, P7129, DOI 10.1073/pnas.0308058101; Taylor AE, 1997, J CLIN ENDOCR METAB, V82, P2248, DOI 10.1210/jc.82.7.2248; Terasawa E, 1998, GEN COMP ENDOCR, V112, P283, DOI 10.1006/gcen.1998.7155; Van der Meer M, 1998, J CLIN ENDOCR METAB, V83, P423, DOI 10.1210/jc.83.2.423; VELDHUIS JD, 1986, AM J PHYSIOL, V250, pE486; Wagner AK, 2005, CRIT CARE MED, V33, P407, DOI 10.1097/01.CCM.0000153931.23488.DD; WALDSTREICHER J, 1988, J CLIN ENDOCR METAB, V66, P165, DOI 10.1210/jcem-66-1-165; Yan XN, 2014, J ENDOCRINOL, V222, P73, DOI 10.1530/JOE-14-0021; YEN SSC, 1970, J CLIN ENDOCR METAB, V30, P435, DOI 10.1210/jcem-30-4-435; Zawadzki JK, 1992, POLYCYSTIC OVARY SYN; Zhang C, 2007, J NEUROSCI, V27, P10153, DOI 10.1523/JNEUROSCI.1657-07.2007	56	24	24	0	11	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0268-1161	1460-2350		HUM REPROD	Hum. Reprod.	JUL	2017	32	7					1450	1456		10.1093/humrep/dex086			7	Obstetrics & Gynecology; Reproductive Biology	Obstetrics & Gynecology; Reproductive Biology	EZ7GC	WOS:000404889000012	28453773	Green Published, Bronze			2021-06-18	
J	Kowalski, RG; Haarbauer-Krupa, JK; Bell, JM; Corrigan, JD; Hammond, FM; Torbey, MT; Hofmann, MC; Dams-O'Connor, K; Miller, AC; Whiteneck, GG				Kowalski, Robert G.; Haarbauer-Krupa, Juliet K.; Bell, Jeneita M.; Corrigan, John D.; Hammond, Flora M.; Torbey, Michel T.; Hofmann, Melissa C.; Dams-O'Connor, Kristen; Miller, A. Cate; Whiteneck, Gale G.			Acute Ischemic Stroke After Moderate to Severe Traumatic Brain Injury Incidence and Impact on Outcome	STROKE			English	Article						acute ischemic stroke; cognition; outcome; stroke; traumatic brain injury	TISSUE-PLASMINOGEN ACTIVATOR; HEALTH-CARE PROFESSIONALS; ENDOVASCULAR TREATMENT; YOUNG-ADULTS; RISK; EPIDEMIOLOGY; REHABILITATION; MULTICENTER; ORIENTATION; RELIABILITY	Background and Purpose-Traumatic brain injury (TBI) leads to nearly 300 000 annual US hospitalizations and increased lifetime risk of acute ischemic stroke (AIS). Occurrence of AIS immediately after TBI has not been well characterized. We evaluated AIS acutely after TBI and its impact on outcome. Methods-A prospective database of moderate to severe TBI survivors, admitted to inpatient rehabilitation at 22 Traumatic Brain Injury Model Systems centers and their referring acute-care hospitals, was analyzed. Outcome measures were AIS incidence, duration of posttraumatic amnesia, Functional Independence Measure, and Disability Rating Scale, at rehabilitation discharge. Results-Between October 1, 2007, and March 31, 2015, 6488 patients with TBI were enrolled in the Traumatic Brain Injury Model Systems National Database. One hundred and fifty-nine (2.5%) patients had a concurrent AIS, and among these, median age was 40 years. AIS was associated with intracranial mass effect and carotid or vertebral artery dissection. High-velocity events more commonly caused TBI with dissection. AIS predicted poorer outcome by all measures, accounting for a 13.3-point reduction in Functional Independence Measure total score (95% confidence interval, -16.8 to -9.7; P<0.001), a 1.9-point increase in Disability Rating Scale (95% confidence interval, 1.3-2.5; P<0.001), and an 18.3-day increase in posttraumatic amnesia duration (95% confidence interval, 13.1-23.4; P<0.001). Conclusions-Ischemic stroke is observed acutely in 2.5% of moderate to severe TBI survivors and predicts worse functional and cognitive outcome. Half of TBI patients with AIS were aged <= 40 years, and AIS patients more often had cervical dissection. Vigilance for AIS is warranted acutely after TBI, particularly after high-velocity events.	[Kowalski, Robert G.; Hofmann, Melissa C.; Whiteneck, Gale G.] Craig Hosp, Res Dept, 3425 S Clarkson St, Englewood, CO 80113 USA; [Haarbauer-Krupa, Juliet K.; Bell, Jeneita M.] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Atlanta, GA USA; [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Wexner Med Ctr, Columbus, OH 43210 USA; [Torbey, Michel T.] Ohio State Univ, Dept Neurosci, Wexner Med Ctr, Columbus, OH 43210 USA; [Torbey, Michel T.] Ohio State Univ, Dept Neurol, Wexner Med Ctr, Columbus, OH 43210 USA; [Torbey, Michel T.] Ohio State Univ, Dept Neurol Surg, Div Cerebrovasc Dis & Neurocrit Care, Wexner Med Ctr, Columbus, OH 43210 USA; [Hammond, Flora M.] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN 46202 USA; [Dams-O'Connor, Kristen] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Miller, A. Cate] NIDILRR, Adm Community Living, US Dept HHS, Detroit, MI USA	Kowalski, RG (corresponding author), Craig Hosp, 3425 S Clarkson St, Englewood, CO 80113 USA.	rkowalski@craighospital.org	Corrigan, John D./E-2921-2011		Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; US Department of Education, National Institute on Disability and Rehabilitation Research (NIDRR)US Department of Education [H133A110006]; US Department of Health and Human Services (HHS)	This research was supported by an interagency agreement between the US Department of Health and Human Services (HHS), Centers for Disease Control and Prevention (CDC), and the US Department of Education, National Institute on Disability and Rehabilitation Research (NIDRR) with supplemental funding to the NIDRR-funded Traumatic Brain Injury Model Systems National Data and Statistical Center (grant no. H133A110006; online-only Data Supplement).	Aarnio K, 2016, NEUROLOGY, V86, P1872, DOI 10.1212/WNL.0000000000002689; Burke JF, 2013, NEUROLOGY, V81, P33, DOI 10.1212/WNL.0b013e318297eecf; Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792; Centers for Disease Control and Prevention, TBI GET FACTS; Centers for Disease Control and Prevention, TRAUM BRAIN INJ CONC; Chen GS, 2016, J NEUROTRAUM, V33, P1263, DOI 10.1089/neu.2015.4063; Chen YH, 2011, STROKE, V42, P2733, DOI 10.1161/STROKEAHA.111.620112; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cuthbert JP, 2015, J HEAD TRAUMA REHAB, V30, P122, DOI 10.1097/HTR.0000000000000012; del Zoppo GJ, 2009, STROKE, V40, P2945, DOI 10.1161/STROKEAHA.109.192535; Demaerschalk BM, 2016, STROKE, V47, P581, DOI 10.1161/STR.0000000000000086; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; Kernan WN, 2014, STROKE, V45, P2160, DOI 10.1161/STR.0000000000000024; Kwon HS, 2016, J STROKE CEREBROVASC, V25, P1503, DOI 10.1016/j.jstrokecerebrovasdis.2016.02.034; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Liao CC, 2014, MAYO CLIN PROC, V89, P163, DOI 10.1016/j.mayocp.2013.09.019; Mandalenakis Z, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.003071; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mozaffarian D, 2016, CIRCULATION, V133, pE38, DOI 10.1161/CIR.0000000000000350; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Ramirez L, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003233; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rutten-Jacobs LCA, 2013, ANN NEUROL, V74, P592, DOI 10.1002/ana.23953; Saver JL, 2015, INT J STROKE, V10, P439, DOI 10.1111/ijs.12459; Smajlovic D, 2015, VASC HEALTH RISK MAN, V11, P157, DOI 10.2147/VHRM.S53203; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tibaek M, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.003158; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Zivin JA, 2009, ANN NEUROL, V66, P6, DOI 10.1002/ana.21750	35	24	25	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	JUL	2017	48	7					1802	+		10.1161/STROKEAHA.117.017327			17	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	EY5TX	WOS:000404044100033	28611087	Green Accepted, Bronze, Green Published			2021-06-18	
J	Russell, K; Selci, E; Chu, S; Fineblit, S; Ritchie, L; Ellis, MJ				Russell, Kelly; Selci, Erin; Chu, Stephanie; Fineblit, Samuel; Ritchie, Lesley; Ellis, Michael J.			Longitudinal Assessment of Health-Related Quality of Life following Adolescent Sports-Related Concussion	JOURNAL OF NEUROTRAUMA			English	Article						concussion; health-related quality of life; patient-reported outcomes; pediatric; post-concussion syndrome	MILD TRAUMATIC BRAIN; GENERIC CORE SCALES; POSTCONCUSSIVE SYMPTOMS; HIGH-SCHOOL; 1ST YEAR; CHILDREN; RELIABILITY; INJURY; PEDSQL(TM)-4.0; PREDICTORS	To examine initial and longitudinal health-related quality of life (HRQOL) in adolescent sports-related concussion (SRC) patients, a prospective observational case-series study was conducted among adolescent SRC patients who were evaluated at a multi-disciplinary pediatric concussion program. Health-related quality of life was measured using the child selfreport Pediatric Quality of Life Inventory (PedsQL) generic score scale (age 13-18 version) and the PedsQL Cognitive Functioning scale. Initial and longitudinal HRQOL outcomes were compared between patients who did and did not develop post-concussion syndrome (PCS). A total of 63 patients met the inclusion criteria during the study period. The mean age of the cohort was 14.57 years (standard deviation, 1.17) and 61.9% were male. The median time from injury to initial consultation was 6.5 days (interquartile range, 5, 11). At initial consultation, impairments in physical and cognitive HRQOL but not social or emotional HRQOL were observed. Initial symptom burden and length of recovery were associated with greater impairment in physical and cognitive HRQOL. Patients who went on to develop PCS had significantly worse physical and cognitive HRQOL at initial consultation and demonstrated a slower rate of recovery in these domains, compared with those who recovered in less than 30 days. Adolescent SRC was associated with HRQOL impairments that correlated with clinical outcomes. No persistent impairments in HRQOL were detected among patients who achieved physician-documented clinical recovery. Future studies are needed to evaluate the clinical utility of HRQOL measurement in the longitudinal management of adolescent SRC and PCS patients.	[Ellis, Michael J.] Pan Am Concuss Program, Winnipeg, MB, Canada; [Russell, Kelly; Selci, Erin; Chu, Stephanie; Fineblit, Samuel; Ritchie, Lesley; Ellis, Michael J.] Canada North Concuss Network, Winnipeg, MB, Canada; [Ritchie, Lesley] Univ Manitoba, Dept Clin Hlth Psychol, Winnipeg, MB, Canada; [Ellis, Michael J.] Univ Manitoba, Dept Surg, Winnipeg, MB, Canada; [Russell, Kelly; Selci, Erin; Chu, Stephanie; Fineblit, Samuel] Univ Manitoba, Dept Pediat & Child Hlth, 656-715 McDermot Ave, Winnipeg, MB R3E 3P4, Canada; [Ellis, Michael J.] Univ Manitoba, Sect Neurosurg, Winnipeg, MB, Canada; [Russell, Kelly; Selci, Erin; Chu, Stephanie; Fineblit, Samuel; Ellis, Michael J.] Childrens Hosp Res Inst Manitoba, Winnipeg, MB, Canada	Russell, K (corresponding author), Univ Manitoba, Dept Pediat & Child Hlth, 656-715 McDermot Ave, Winnipeg, MB R3E 3P4, Canada.	krussell@chrim.ca		Russell, Kelly/0000-0002-9159-9201	University Research Grants Program from the University of Manitoba	All phases of this study were supported by a grant from University Research Grants Program from the University of Manitoba.	Anderson V, 2013, J INT NEUROPSYCH SOC, V19, P539, DOI 10.1017/S1355617712001543; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Cordingley D, 2016, J NEUROSURG-PEDIATR, V18, P693, DOI 10.3171/2016.5.PEDS16139; Di Battista A, 2012, J NEUROTRAUM, V29, P1717, DOI 10.1089/neu.2011.2157; Eiser C, 2001, QUAL LIFE RES, V10, P347, DOI 10.1023/A:1012253723272; Ellis MJ, 2017, CAN J NEUROL SCI, V44, P24, DOI 10.1017/cjn.2016.312; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P709, DOI 10.3171/2015.5.PEDS15220; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P248, DOI 10.3171/2015.1.PEDS14524; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Ferracini GN, 2014, HEADACHE, V54, P325, DOI 10.1111/head.12251; Fineblit S, 2016, J NEUROTRAUM, V33, P1561, DOI 10.1089/neu.2015.4292; Grubenhoff JA, 2014, PEDIATRICS, V134, P54, DOI 10.1542/peds.2013-2988; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Houston MN, 2016, BRAIN INJURY, V30, P891, DOI 10.3109/02699052.2016.1146960; Iadevaia C, 2015, J ATHL TRAINING, V50, P1182, DOI 10.4085/1062-6050-50.11.02; Iverson GL, 2015, JAMA PEDIATR, V169, P1132, DOI 10.1001/jamapediatrics.2015.2374; Kuehl MD, 2010, CLIN J SPORT MED, V20, P86, DOI 10.1097/JSM.0b013e3181cf4534; Leddy J, 2016, PM&R, V8, pS91, DOI 10.1016/j.pmrj.2015.10.017; Leddy JJ, 2016, PHYS MED REH CLIN N, V27, P437, DOI 10.1016/j.pmr.2015.12.003; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Moran LM, 2012, J PEDIATR PSYCHOL, V37, P736, DOI 10.1093/jpepsy/jsr087; Novak Z, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2016.2900; Petersen C, 2008, BRAIN INJURY, V22, P215, DOI 10.1080/02699050801935245; Pieper P, 2015, J PEDIATR HEALTH CAR, V29, P343, DOI 10.1016/j.pedhc.2015.01.008; Pieper P, 2014, BRAIN INJURY, V28, P105, DOI 10.3109/02699052.2013.847208; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Uzark K, 2013, CONGENIT HEART DIS, V8, P211, DOI 10.1111/chd.12002; Varni JW, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-43; Varni JW, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-26; Varni JW, 2007, J PEDIATR PSYCHOL, V32, P1151, DOI 10.1093/jpepsy/jsm008; Varni JW, 2011, QUAL LIFE RES, V20, P913, DOI 10.1007/s11136-010-9823-1; Varni JW, 2003, AMBUL PEDIATR, V3, P329, DOI 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Varni JW, 2002, J BEHAV MED, V25, P175, DOI 10.1023/A:1014836921812; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	40	24	24	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2017	34	13					2147	2153		10.1089/neu.2016.4704			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EZ2HM	WOS:000404530400453	28077006				2021-06-18	
J	Masoudi, A; Dargahi, L; Abbaszadeh, F; Pourgholami, MH; Asgari, A; Manoochehri, M; Jorjani, M				Masoudi, Alireza; Dargahi, Leila; Abbaszadeh, Fatemeh; Pourgholami, Mohammad Hosein; Asgari, Alireza; Manoochehri, Mehdi; Jorjani, Masoumeh			Neuroprotective effects of astaxanthin in a rat model of spinal cord injury	BEHAVIOURAL BRAIN RESEARCH			English	Article						Astaxanthin; Neuroprotection; Spinal cord injury; Apoptosis	EARLY BRAIN-INJURY; OXIDATIVE STRESS; FUNCTIONAL RECOVERY; TRAUMATIC BRAIN; SUBARACHNOID HEMORRHAGE; ELECTROLYTIC LESION; SPINOTHALAMIC TRACT; CEREBRAL-ISCHEMIA; IN-VITRO; APOPTOSIS	Spinal cord injury (SCI) often leads to constant neurological deficits and long-term unalterable disability. Apoptosis plays an important role in the initiation of the secondary injury cascades leading to progressive tissue damage and severely functional deficits after SCI. Although the primary mechanical destructive events cannot be reversed, a therapeutic intervention could be carried out in order to moderate the secondary injury damage several hours to weeks after injury. Astaxanthin (AST) is a strong antioxidant and anti-inflammatory agents with the potential to render anti-apoptotic and neuroprotective effects. In the current study, we examined the therapeutic potential of AST on adult rats after severe SCI contusion. Results of BBB scores showed that AST improved motor function after SCI compared to control groups. Westem blot analysis showed reduced expression of Box and Cleaved-caspase-3 proteins and increased expression of the Bcl-2 protein in response to AST treatment (p < 0.05). The histology results also showed that AST considerably preserved myelinated white matter and the number of motor neurons. This study is the first to report that AST reduces neuronal apoptosis, diminishes pathological tissue damage and improves functional recovery after SCI. The observed prominent neuroprotective effects, introduces AST as a promising therapy for SCI.	[Masoudi, Alireza; Jorjani, Masoumeh] Shahid Beheshti Univ Med Sci, Sch Med, Dept Pharmacol, Tehran, Iran; [Dargahi, Leila; Abbaszadeh, Fatemeh; Jorjani, Masoumeh] Shahid Beheshti Univ Med Sci, Neurobiol Res Ctr, Tehran, Iran; [Pourgholami, Mohammad Hosein] Shahid Beheshti Univ Med Sci, Neurosci Res Ctr, Tehran, Iran; [Asgari, Alireza] Baqiyatallah Univ Med Sci, Sport Physiol Res Ctr, Tehran, Iran; [Asgari, Alireza] AJA Med Sci Univ, Aerosp Med Res Ctr, Tehran, Iran; [Manoochehri, Mehdi] Shahroud Univ Med Sci, Sch Med, Shahroud, Iran	Jorjani, M (corresponding author), Shahid Beheshti Univ Med Sci, Sch Med, Tehran, Iran.	msjorjani@sbmu.ac.ir	Dargahi, Leila/K-4693-2017	Dargahi, Leila/0000-0001-7777-5435; masoudi, alireza/0000-0002-5598-9384	School of Medicine and Neurobiology Research Center of Shahid Beheshti University of Medical Sciences [B-N-28-1394]	This study was performed as part of a Ph.D. thesis project funded by School of Medicine and Neurobiology Research Center (Grant No. B-N-28-1394) of Shahid Beheshti University of Medical Sciences.	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Al-Amin MM, 2015, BEHAV BRAIN RES, V286, P112, DOI 10.1016/j.bbr.2015.02.041; Ambati RR, 2014, MAR DRUGS, V12, P128, DOI 10.3390/md12010128; Aydemir S., 2015, SPIN CORD; Bai WS, 2012, AFR J PHARM PHARMACO, V6, P2559, DOI 10.5897/AJPP12.855; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bastani NE, 2012, ARCH PHYS MED REHAB, V93, P2223, DOI 10.1016/j.apmr.2012.06.021; Cemil B, 2010, ACTA NEUROCHIR, V152, P1583, DOI 10.1007/s00701-010-0702-x; Chan KC, 2009, J FOOD SCI, V74, pH225, DOI 10.1111/j.1750-3841.2009.01274.x; Chang CH, 2010, J MED FOOD, V13, P548, DOI 10.1089/jmf.2009.1291; Chen HC, 2014, SPINAL CORD, V52, P24, DOI 10.1038/sc.2013.140; Chen WP, 2014, INT IMMUNOPHARMACOL, V19, P174, DOI 10.1016/j.intimp.2013.12.007; Chen WF, 2015, CNS NEUROSCI THER, V21, P698, DOI 10.1111/cns.12429; Choi HD, 2011, BRIT J NUTR, V105, P220, DOI 10.1017/S0007114510003454; Chu W., 2015, NEUROCHEM RES, V40; Ciftci U, 2016, ULUS TRAVMA ACIL CER, V22, P423, DOI 10.5505/tjtes.2016.44575; Costa P, 2014, SPINAL CORD, V52, P749, DOI 10.1038/sc.2014.138; Cruz CD, 2015, ADV DRUG DELIVER REV, V82-83, P153, DOI 10.1016/j.addr.2014.11.007; Dong LY, 2013, MAR DRUGS, V11, P960, DOI 10.3390/md11030960; Du F., 2016, ACTA BIOCH POL, V63; Faden AI, 2016, BRIT J PHARMACOL, V173, P681, DOI 10.1111/bph.13179; Fassett RG, 2009, FUTUR CARDIOL, V5, P333, DOI 10.2217/FCA.09.19; Fatima G, 2015, SPINAL CORD, V53, P3, DOI 10.1038/sc.2014.178; Ghanbari A, 2014, EXP BRAIN RES, V232, P415, DOI 10.1007/s00221-013-3749-0; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Guerin M, 2003, TRENDS BIOTECHNOL, V21, P210, DOI 10.1016/S0167-7799(03)00078-7; Hall ED, 2016, J NEUROTRAUM, V33, P972, DOI 10.1089/neu.2016.4473; Hall ED, 2016, J BIOENERG BIOMEMBR, V48, P169, DOI 10.1007/s10863-015-9600-5; Ikeda Y, 2008, J NEUROCHEM, V107, P1730, DOI 10.1111/j.1471-4159.2008.05743.x; Jongen P. J., 2016, J NEUROL, P1; Kidd P, 2011, ALTERN MED REV, V16, P355; Kim JH, 2009, J MICROBIOL BIOTECHN, V19, P1355, DOI 10.4014/jmb.0906.06003; Kupcinskas L, 2008, PHYTOMEDICINE, V15, P391, DOI 10.1016/j.phymed.2008.04.004; Lee DH, 2011, FOOD CHEM TOXICOL, V49, P271, DOI 10.1016/j.fct.2010.10.029; Lee DH, 2010, J CLIN BIOCHEM NUTR, V47, P121, DOI 10.3164/jcbn.10-29; Lee J. Y., 2016, NEUROPHARMACOLOGY; Li ZR, 2013, MOL VIS, V19, P1656; Lin TY, 2010, J AGR FOOD CHEM, V58, P8271, DOI 10.1021/jf101689t; Liu CJ, 2011, BRAIN RES, V1374, P100, DOI 10.1016/j.brainres.2010.11.061; Liu X., 2009, FORUM NUTR; Liu XB, 2009, BRAIN RES, V1254, P18, DOI 10.1016/j.brainres.2008.11.076; Lu YP, 2010, BRAIN RES, V1360, P40, DOI 10.1016/j.brainres.2010.09.016; Lu Y, 2015, NEUROSCI LETT, V597, P49, DOI 10.1016/j.neulet.2015.04.018; Luo Y, 2015, MOL MED REP, V12, P7132, DOI 10.3892/mmr.2015.4274; MESTRE C, 1994, J PHARMACOL TOX MET, V32, P197, DOI 10.1016/1056-8719(94)90087-6; Mosquera L, 2014, BRAIN RES, V1561, P11, DOI 10.1016/j.brainres.2014.03.002; Nagai J., 2015, SCI REP, V5; Nakae A., 2011, BIOMED RES INT; Naseri K, 2013, J MOL NEUROSCI, V49, P470, DOI 10.1007/s12031-012-9840-3; Ormond DR, 2012, J NEUROSURG-SPINE, V16, P497, DOI 10.3171/2012.1.SPINE11769; OZDEMIR US, 2015, MOL NEUROBIOL, V23, P1; Park JS, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-18; Robert AA, 2012, NEUROL SCI, V33, P785, DOI 10.1007/s10072-011-0829-4; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Sakurai M, 2003, J THORAC CARDIOV SUR, V125, P370, DOI 10.1067/mtc.2003.112; Samantaray S, 2008, J PINEAL RES, V44, P348, DOI 10.1111/j.1600-079X.2007.00534.x; Sharif-Alhoseini M., 2014, TOPICS PARAPLEGIA IN; Shen H, 2009, FASEB J, V23, P1958, DOI 10.1096/fj.08-123281; Shul'ga A E, 2014, Ross Fiziol Zh Im I M Sechenova, V100, P145; Silva NA, 2014, PROG NEUROBIOL, V114, P25, DOI 10.1016/j.pneurobio.2013.11.002; Song XD, 2014, J CELL MOL MED, V18, P2198, DOI 10.1111/jcmm.12347; Su ZD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4338; Tang PF, 2014, MOL NEUROBIOL, V49, P276, DOI 10.1007/s12035-013-8518-3; Tsuchida M, 2014, J MOL NEUROSCI, V54, P380, DOI 10.1007/s12031-014-0338-z; Visavadiya NP, 2016, REDOX BIOL, V8, P59, DOI 10.1016/j.redox.2015.12.011; Wang HQ, 2010, BRAIN RES, V1360, P159, DOI 10.1016/j.brainres.2010.08.100; Wang WG, 2015, NEUROL SCI, V36, P521, DOI 10.1007/s10072-014-1965-4; Wu HJ, 2015, CELL MOL NEUROBIOL, V35, P85, DOI 10.1007/s10571-014-0116-z; Wu Q, 2014, MAR DRUGS, V12, P6125, DOI 10.3390/md12126125; Wu WQ, 2014, FOOD FUNCT, V5, P158, DOI 10.1039/c3fo60400d; Wu YC, 2013, J NEUROTRAUM, V30, P441, DOI 10.1089/neu.2012.2622; Yamagishi R., 2014, MOL VIS; Yan M, 2014, SPINAL CORD, V52, P803, DOI 10.1038/sc.2014.135; Yao M, 2015, J NEUROTRAUM, V32, P381, DOI 10.1089/neu.2014.3520; Yu H.J., 2016, J SPINE, V5, P1, DOI [10. 4172/2165-7939. 1000322, DOI 10.4172/2165-7939.1000322]; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang N, 2012, INDIAN J MED RES, V135, P287; Zhang XS, 2014, MAR DRUGS, V12, P4291, DOI 10.3390/md12084291; Zhang XS, 2014, J NEUROSURG, V121, P42, DOI 10.3171/2014.2.JNS13730; Zheng D, 2014, NEUROPHARMACOLOGY, V84, P13, DOI 10.1016/j.neuropharm.2014.04.013; Zhou LP, 2015, J SURG RES, V195, P559, DOI 10.1016/j.jss.2015.02.026	81	24	24	1	17	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	JUN 30	2017	329						104	110		10.1016/j.bbr.2017.04.026			7	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	EY4YV	WOS:000403985100014	28442361				2021-06-18	
J	Vink, R; Gabrielian, L; Thornton, E				Vink, Robert; Gabrielian, Levon; Thornton, Emma			The Role of Substance P in Secondary Pathophysiology after Traumatic Brain injury	FRONTIERS IN NEUROLOGY			English	Article						substance P; traumatic brain injury; edema; intracranial pressure; brain oxygenation; sheep model	GENE-RELATED PEPTIDE; ANGIOTENSIN-CONVERTING ENZYME; PRIMARY SENSORY NEURONS; CENTRAL-NERVOUS-SYSTEM; ACUTE ISCHEMIC-STROKE; SPINAL-CORD-INJURY; NEUROGENIC INFLAMMATION; EDEMA FORMATION; BARRIER BREAKDOWN; NEUROKININ-1 RECEPTOR	It has recently been shown that substance P (SP) plays a major role in the secondary injury process following traumatic brain injury (TBI), particularly with respect to neuroinflammation, increased blood-brain barrier (BBB) permeability, and edema formation. Edema formation is associated with the development of increased intracranial pressure (ICP) that has been widely associated with increased mortality and morbidity after neurotrauma. However, a pharmacological intervention to specifically reduce ICP is yet to be developed, with current interventions limited to osmotic therapy rather than addressing the cause of increased ICP. Given that previous publications have shown that SP, NK1 receptor antagonists reduce edema after TBI, more recent studies have examined whether these compounds might also reduce ICP and improve brain oxygenation after TBI. We discuss the results of these studies, which demonstrate that NK1 antagonists reduce posttraumatic ICP to near normal levels within 4 h of drug administration, as well as restoring brain oxygenation to near normal levels in the same time frame. The improvements in these parameters occurred in association with an improvement in BBB integrity to serum proteins, suggesting that SP-mediated increases in vascular permeability significantly contribute to the development of increased ICP after acute brain injury. NK1 antagonists may therefore provide a novel, mechanistically targeted approach to the management of increased ICP.	[Vink, Robert] Univ South Australia, Sansom Inst Hlth Res, Adelaide, SA, Australia; [Gabrielian, Levon; Thornton, Emma] Univ Adelaide, Adelaide Med Sch, Discipline Anat & Pathol, Adelaide, SA, Australia	Vink, R (corresponding author), Univ South Australia, Sansom Inst Hlth Res, Adelaide, SA, Australia.	robert.vink@unisa.edu.au	AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667	National Health and Medical Research Council, AustraliaNational Health and Medical Research Council of Australia	This study was supported by grants to RV from the National Health and Medical Research Council, Australia.	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; AZARYAN AV, 1988, J NEUROSCI RES, V19, P268, DOI 10.1002/jnr.490190213; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Bergner AJ, 2000, NEUROSCIENCE, V96, P611, DOI 10.1016/S0306-4522(99)00576-X; Black PH, 2002, BRAIN BEHAV IMMUN, V16, P622, DOI 10.1016/S0889-1591(02)00021-1; BLUMBERG S, 1980, BRAIN RES, V192, P477, DOI 10.1016/0006-8993(80)90898-7; Bohman LE, 2011, NEUROCRIT CARE, V14, P361, DOI 10.1007/s12028-011-9526-7; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P14, DOI DOI 10.1089/NEU.2007.9994; Byard RW, 2012, J FORENSIC SCI, V57, P973, DOI 10.1111/j.1556-4029.2012.02109.x; Byard Roger W, 2009, Leg Med (Tokyo), V11 Suppl 1, pS128, DOI 10.1016/j.legalmed.2009.02.001; Cabella B, 2017, NEUROCRIT CARE, V27, P103, DOI 10.1007/s12028-016-0319-x; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Cook NL, 2009, J NEUROSCI RES, V87, P34, DOI 10.1002/jnr.21846; Corrigan F, 2016, BRIT J PHARMACOL, V173, P703, DOI 10.1111/bph.13155; Corrigan F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0738-9; Corrigan F, 2012, CNS NEUROSCI THER, V18, P513, DOI 10.1111/j.1755-5949.2012.00332.x; Cyrino LAR, 2002, PHYTOTHER RES, V16, P545, DOI 10.1002/ptr.987; Czosnyka M, 2017, HAND CLINIC, V140, P67, DOI 10.1016/B978-0-444-63600-3.00005-2; Di Maria GU, 1998, EUR RESPIR J, V12, P1454, DOI 10.1183/09031936.98.12061454; Donkin JJ, 2007, PROG BRAIN RES, V161, P97, DOI 10.1016/S0079-6123(06)61007-8; Donkin JJ, 2011, J NEUROTRAUM, V28, P217, DOI 10.1089/neu.2010.1632; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Donkin JJ, 2009, J CEREBR BLOOD F MET, V29, P1388, DOI 10.1038/jcbfm.2009.63; DUN NJ, 1981, J PHYSIOL-LONDON, V321, P259, DOI 10.1113/jphysiol.1981.sp013982; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; Gabrielian L, 2013, THESIS; Gabrielian Levon, 2013, Acta Neurochir Suppl, V118, P201, DOI 10.1007/978-3-7091-1434-6_37; Gabrielian L, 2011, J NEUROTRAUM, V28, P2103, DOI 10.1089/neu.2011.1785; GIBBINS IL, 1987, CELL TISSUE RES, V248, P417; Harford-Wright E, 2010, NEUROSCI LETT, V481, P26, DOI 10.1016/j.neulet.2010.06.044; Harrison JE, 2008, HOSP SEPARATIONS DUE; Harrison S, 2001, INT J BIOCHEM CELL B, V33, P555, DOI 10.1016/S1357-2725(01)00031-0; HELKE CJ, 1982, PEPTIDES, V3, P479, DOI 10.1016/0196-9781(82)90111-5; HELKE CJ, 1982, BRAIN RES, V243, P147, DOI 10.1016/0006-8993(82)91128-3; HEYMANN E, 1978, FEBS LETT, V91, P360, DOI 10.1016/0014-5793(78)81210-1; HOKFELT T, 1975, SCIENCE, V190, P889, DOI 10.1126/science.242075; HOKFELT T, 1994, TRENDS NEUROSCI, V17, P22, DOI 10.1016/0166-2236(94)90031-0; Hokfelt T, 2001, J INTERN MED, V249, P27, DOI 10.1046/j.0954-6820.2000.00773.x; HOOPER NM, 1987, BIOCHEM J, V241, P625, DOI 10.1042/bj2410625; Hu DE, 2005, BRIT J PHARMACOL, V146, P576, DOI 10.1038/sj.bjp.0706350; KAGEYAMA T, 1993, EUR J BIOCHEM, V216, P717, DOI 10.1111/j.1432-1033.1993.tb18191.x; KLINTWORTH GK, 1968, ANAT RECORD, V160, P635, DOI 10.1002/ar.1091600312; KOTANI H, 1986, P NATL ACAD SCI USA, V83, P7074, DOI 10.1073/pnas.83.18.7074; KRAUSE JE, 1987, P NATL ACAD SCI USA, V84, P881, DOI 10.1073/pnas.84.3.881; Kubale V, 2007, CELL TISSUE RES, V330, P231, DOI 10.1007/s00441-007-0462-y; LEE Y, 1985, BRAIN RES, V330, P194, DOI 10.1016/0006-8993(85)90027-7; Leeman SE, 2000, NEUROPEPTIDES, V34, P249, DOI 10.1054/npep.2000.0826; Leonard AV, 2014, SPINAL CORD, V52, P17, DOI 10.1038/sc.2013.136; Leonard AV, 2013, J NEUROTRAUM, V30, P1812, DOI 10.1089/neu.2013.2993; Li W, 2015, J CRANIOFAC SURG, V26, P393, DOI 10.1097/SCS.0000000000001339; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lorente L, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0911-z; Ma JP, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008409.pub4; MAGGI CA, 1995, GEN PHARMACOL-VASC S, V26, P911, DOI 10.1016/0306-3623(94)00292-U; MARKOWITZ S, 1987, J NEUROSCI, V7, P4129, DOI 10.1523/jneurosci.07-12-04129.1987; MARLIER L, 1991, EXP BRAIN RES, V85, P482; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; MATSAS R, 1984, BIOCHEM J, V223, P433, DOI 10.1042/bj2230433; McCarson KE, 1999, NEUROSCIENCE, V93, P361, DOI 10.1016/S0306-4522(99)00102-5; Meyer BH, 2006, P NATL ACAD SCI USA, V103, P2138, DOI 10.1073/pnas.0507686103; Meyer MJ, 2010, BRAIN INJURY, V24, P706, DOI 10.3109/02699051003692126; Monastyrskaya K, 2005, J BIOL CHEM, V280, P7135, DOI 10.1074/jbc.M405806200; NADEL JA, 1991, EUR RESPIR J, V4, P745; Nag S, 2007, ACTA NEUROPATHOL, V114, P459, DOI 10.1007/s00401-007-0274-x; Nag S, 2009, ACTA NEUROPATHOL, V118, P197, DOI 10.1007/s00401-009-0541-0; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; Node Y, 1990, Adv Neurol, V52, P359; NOGUCHI K, 1988, MOL BRAIN RES, V4, P31, DOI 10.1016/0169-328X(88)90015-0; O'Connor CA, 2006, ACTA NEUROCHIR SUPPL, V96, P121; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; Prakash R, 2015, CURR OPIN NEUROL, V28, P556, DOI 10.1097/WCO.0000000000000248; PROBERT L, 1987, NEUROSCI LETT, V78, P132, DOI 10.1016/0304-3940(87)90621-5; Rowlands HE, 2007, PAEDIAT CHILD HLTH, V17, P82, DOI DOI 10.1016/J.PAED.2007.01.011; Saadoun S, 2010, NEUROSCIENCE, V168, P1036, DOI 10.1016/j.neuroscience.2009.08.019; Saffroy M, 2003, NEUROSCIENCE, V116, P761, DOI 10.1016/S0306-4522(02)00748-0; SAKURADA T, 1990, PHARMACOL TOXICOL, V66, P75, DOI 10.1111/j.1600-0773.1990.tb00708.x; SCHAIBLE HG, 1990, BRAIN RES, V529, P214, DOI 10.1016/0006-8993(90)90830-5; Seybold VS, 2003, J NEUROSCI, V23, P1816; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; SHULTS CW, 1984, PEPTIDES, V5, P1097, DOI 10.1016/0196-9781(84)90177-3; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Skidgel R A, 1987, Agents Actions Suppl, V22, P289; Stein DG, 1998, NEUROSCIENTIST, V4, P435, DOI 10.1177/107385849800400615; STERNINI C, 1995, J COMP NEUROL, V358, P531, DOI 10.1002/cne.903580406; Stumm RK, 2001, J NEUROSCI, V21, P798; Turner RJ, 2006, ACTA NEUROCHIR SUPPL, V96, P263; Turner RJ, 2012, NEUROSCIENCE, V220, P1, DOI 10.1016/j.neuroscience.2012.06.047; Turner RJ, 2014, NEUROPEPTIDES, V48, P267, DOI 10.1016/j.npep.2014.07.002; Turner RJ, 2011, BRAIN RES, V1393, P84, DOI 10.1016/j.brainres.2011.03.066; Vennekens R, 2012, REV PHYSIOL BIOCH P, V163, P27, DOI 10.1007/112_2012_8; Vink R, 2003, ACT NEUR S, V86, P257; Vink R, 2010, NEUROTHERAPEUTICS, V7, P74, DOI 10.1016/j.nurt.2009.10.018; Vink R, 2008, ACTA NEUROCHIR SUPPL, V102, P189, DOI 10.1007/978-3-211-85578-2_37; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; WANG LH, 1991, PEPTIDES, V12, P1357, DOI 10.1016/0196-9781(91)90220-J; Zacest AC, 2010, ACTA NEUROCHIR SUPPL, V106, P211, DOI 10.1007/978-3-211-98811-4_39	97	24	25	0	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	JUN 28	2017	8								304	10.3389/fneur.2017.00304			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	EY9PU	WOS:000404331300001	28701994	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Dall'Acqua, P; Johannes, S; Mica, L; Simmen, HP; Glaab, R; Fandino, J; Schwendinger, M; Meier, C; Ulbrich, EJ; Muller, A; Baetschmann, H; Jancke, L; Hanggi, J				Dall'Acqua, Patrizia; Johannes, Sonke; Mica, Ladislav; Simmen, Hans-Peter; Glaab, Richard; Fandino, Javier; Schwendinger, Markus; Meier, Christoph; Ulbrich, Erika J.; Mueller, Andreas; Baetschmann, Hansruedi; Jancke, Lutz; Hanggi, Jurgen			Functional and Structural Network Recovery after Mild Traumatic Brain Injury: A 1-Year Longitudinal Study	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						mild traumatic brain injury; longitudinal; network recovery; functional connectivity; structural connectivity; graph theoretical analysis; plasticity	RESTING-STATE NETWORKS; DEFAULT-MODE NETWORK; GRAPH-THEORETICAL ANALYSIS; POST-CONCUSSION SYMPTOMS; DIFFUSION MRI; HEAD-INJURY; CONNECTIVITY; MATTER; WHITE; TRACTOGRAPHY	Brain connectivity after mild traumatic brain injury (mTBI) has not been investigated longitudinally with respect to both functional and structural networks together within the same patients, crucial to capture the multifaceted neuropathology of the injury and to comprehensively monitor the course of recovery and compensatory reorganizations at macro-level. We performed a prospective study with 49 mTBI patients at an average of 5 days and 1 year post-injury and 49 healthy controls. Neuropsychological assessments as well as resting-state functional and diffusion-weighted magnetic resonance imaging were obtained. Functional and structural connectome analyses were performed using network-based statistics. They included a cross-sectional group comparison and a longitudinal analysis with the factors group and time. The latter tracked the subnetworks altered at the early phase and, in addition, included a whole-brain group x time interaction analysis. Finally, we explored associations between the evolution of connectivity and changes in cognitive performance. The early phase of mTBI was characterized by a functional hypoconnectivity in a subnetwork with a large overlap of regions involved within the classical default mode network. In addition, structural hyperconnectivity in a subnetwork including central hub areas such as the cingulate cortex was found. The impaired functional and structural subnetworks were strongly correlated and revealed a large anatomical overlap. One year after trauma and compared to healthy controls we observed a partial normalization of both subnetworks along with a considerable compensation of functional and structural connectivity subsequent to the acute phase. Connectivity changes over time were correlated with improvements in working memory, divided attention, and verbal recall. Neuroplasticity-induced recovery or compensatory processes following mTBI differ between brain regions with respect to their time course and are not fully completed 1 year after trauma.	[Dall'Acqua, Patrizia; Johannes, Sonke] Bellikon Rehabil Clin, Bellikon, Switzerland; [Dall'Acqua, Patrizia; Baetschmann, Hansruedi; Jancke, Lutz; Hanggi, Jurgen] Univ Zurich, Dept Psychol, Div Neuropsychol, Zurich, Switzerland; [Mica, Ladislav; Simmen, Hans-Peter] Univ Hosp Zurich, Div Trauma Surg, Zurich, Switzerland; [Glaab, Richard] Kantonsspital Aarau, Div Traumatol, Dept Surg, Aarau, Switzerland; [Fandino, Javier] Kantonsspital Aarau, Dept Neurosurg, Aarau, Switzerland; [Schwendinger, Markus] Baden Cantonal Hosp, Interdisciplinary Emergency Ctr, Baden, Switzerland; [Meier, Christoph] Waid Hosp Zurich, Dept Surg, Zurich, Switzerland; [Ulbrich, Erika J.] Univ Hosp Zurich, Inst Diagnost & Intervent Radiol, Zurich, Switzerland; [Mueller, Andreas] Brain & Trauma Fdn Grison, Chur, Switzerland; [Jancke, Lutz] Univ Zurich, Int Normal Aging & Plast Imaging Ctr, Zurich, Switzerland; [Jancke, Lutz] Univ Zurich, Dynam Hlth Aging, Univ Res Prior Program, Zurich, Switzerland	Dall'Acqua, P (corresponding author), Bellikon Rehabil Clin, Bellikon, Switzerland.; Dall'Acqua, P (corresponding author), Univ Zurich, Dept Psychol, Div Neuropsychol, Zurich, Switzerland.	patrizia.dallacqua@rehabellikon.ch		Simmen, Hans-Peter/0000-0002-5201-4549; Hanggi, Jurgen/0000-0001-8124-6018	research fund of Swiss Accident Insurance (SUVA)	This study was supported by research fund of Swiss Accident Insurance (SUVA).	Amyot F, 2015, J NEUROTRAUM, V32, P1693, DOI 10.1089/neu.2013.3306; Andersson JLR, 2016, NEUROIMAGE, V125, P1063, DOI 10.1016/j.neuroimage.2015.10.019; Andrews-Hanna JR, 2010, NEURON, V65, P550, DOI 10.1016/j.neuron.2010.02.005; Baker STE, 2015, J NEUROSCI, V35, P9078, DOI 10.1523/JNEUROSCI.5043-14.2015; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Bharath RD, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00513; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Croall ID, 2014, NEUROLOGY, V83, P494, DOI 10.1212/WNL.0000000000000666; Dall'Acqua P, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00127; Dean PJA, 2015, BRAIN INJURY, V29, P1211, DOI 10.3109/02699052.2015.1035334; Dennis EL, 2013, NEUROIMAGE, V64, P671, DOI 10.1016/j.neuroimage.2012.09.004; Dodd AB, 2014, J NEUROTRAUM, V31, P1235, DOI 10.1089/neu.2014.3337; Du HX, 2015, CNS NEUROSCI THER, V21, P802, DOI 10.1111/cns.12431; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Farquharson S, 2013, J NEUROSURG, V118, P1367, DOI 10.3171/2013.2.JNS121294; Franco AR, 2013, BRAIN CONNECT, V3, P363, DOI 10.1089/brain.2012.0134; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Harrison BJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001794; Hillary FG, 2011, INT J PSYCHOPHYSIOL, V82, P115, DOI 10.1016/j.ijpsycho.2011.03.011; Honey CJ, 2009, P NATL ACAD SCI USA, V106, P2035, DOI 10.1073/pnas.0811168106; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Iraji A, 2015, J NEUROTRAUM, V32, P1031, DOI 10.1089/neu.2014.3610; Jeurissen B, 2013, HUM BRAIN MAPP, V34, P2747, DOI 10.1002/hbm.22099; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Jones DK, 2013, NEUROIMAGE, V73, P239, DOI 10.1016/j.neuroimage.2012.06.081; Jones DK, 2010, NMR BIOMED, V23, P803, DOI 10.1002/nbm.1543; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Laird AR, 2011, J COGNITIVE NEUROSCI, V23, P4022, DOI 10.1162/jocn_a_00077; Leech R, 2014, BRAIN, V137, P12, DOI 10.1093/brain/awt162; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2015, NEUROSCI BIOBEHAV R, V49, P8, DOI 10.1016/j.neubiorev.2014.11.016; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Mayer JS, 2010, HUM BRAIN MAPP, V31, P126, DOI 10.1002/hbm.20850; Messe A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065470; Messe A, 2012, BRAIN IMAGING BEHAV, V6, P283, DOI 10.1007/s11682-012-9159-2; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Newton AT, 2007, HUM BRAIN MAPP, V28, P663, DOI 10.1002/hbm.20294; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Power JD, 2015, NEUROIMAGE, V105, P536, DOI 10.1016/j.neuroimage.2014.10.044; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Sours C, 2015, BRAIN CONNECT, V5, P442, DOI 10.1089/brain.2014.0333; Sours C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134019; Stam CJ, 2009, BRAIN, V132, P213, DOI 10.1093/brain/awn262; Stam CJ, 2014, NAT REV NEUROSCI, V15, P683, DOI 10.1038/nrn3801; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Sun Y, 2016, SCHIZOPHR RES, V171, P149, DOI 10.1016/j.schres.2016.01.025; Tamnes CK, 2011, NEUROPSYCHOLOGIA, V49, P3605, DOI 10.1016/j.neuropsychologia.2011.09.012; Tournier JD, 2007, NEUROIMAGE, V35, P1459, DOI 10.1016/j.neuroimage.2007.02.016; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; van den Heuvel MP, 2011, J NEUROSCI, V31, P15775, DOI 10.1523/JNEUROSCI.3539-11.2011; van den Heuvel MP, 2009, HUM BRAIN MAPP, V30, P3127, DOI 10.1002/hbm.20737; van den Heuvel MP, 2009, J NEUROSCI, V29, P7619, DOI 10.1523/JNEUROSCI.1443-09.2009; van der Horn HJ, 2016, BRAIN IMAGING BEHAV, V10, P1243, DOI 10.1007/s11682-015-9489-y; Vos PE, 2012, EUR J NEUROL, V19, P191, DOI 10.1111/j.1468-1331.2011.03581.x; Waites AB, 2005, HUM BRAIN MAPP, V24, P59, DOI 10.1002/hbm.20069; Wang JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021976; Wang JY, 2012, NEUROIMAGE, V60, P1127, DOI 10.1016/j.neuroimage.2011.12.062; Weissman DH, 2006, NAT NEUROSCI, V9, P971, DOI 10.1038/nn1727; Xia MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068910; Yamada H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112411; Yendiki A, 2014, NEUROIMAGE, V88, P79, DOI 10.1016/j.neuroimage.2013.11.027; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413; Zumstein MA, 2011, J TRAUMA, V71, P120, DOI 10.1097/TA.0b013e3181f2d670	79	24	24	0	12	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	MAY 30	2017	11								280	10.3389/fnhum.2017.00280			16	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	EW5SQ	WOS:000402567200002	28611614	DOAJ Gold, Green Accepted, Green Published			2021-06-18	
J	Khalili, H; Derakhshan, N; Niakan, A; Ghaffarpasand, F; Salehi, M; Eshraghian, H; Shakibafard, A; Zahabi, B				Khalili, Hosseinali; Derakhshan, Nima; Niakan, Amin; Ghaffarpasand, Fariborz; Salehi, Mohammad; Eshraghian, Hamed; Shakibafard, Alireza; Zahabi, Bita			Effects of Oral Glibenclamide on Brain Contusion Volume and Functional Outcome of Patients with Moderate and Severe Traumatic Brain Injuries: A Randomized Double-Blind Placebo-Controlled Clinical Trial	WORLD NEUROSURGERY			English	Article						Contusion; Functional outcome; Glibenclamide; Traumatic brain injury	RAT MODEL; UNITED-STATES; EDEMA; NEUROINFLAMMATION; PATHOPHYSIOLOGY; INHIBITION; HEMORRHAGE; GLYBURIDE	OBJECTIVE: This study investigated effects of oral glibenclamide on brain contusion volume and functional outcome of patients with moderate and severe traumatic brain injuries. METHODS: A randomized clinical trial including 66 patients with moderate (Glasgow Coma Scale score 9-12) to severe (Glasgow Coma Scale score 5-8) traumatic brain injury and brain contusions of <30 mL volume was conducted from May 2015 to August 2016 in a Level I trauma center in southern Iran. Patients who required surgical intervention were excluded. Patients were randomly assigned to receive 10 mg oral glibenclamide daily for 10 days (n = 29) or placebo in the same dosage (n = 23). Brain contusion volumetry was performed on days 0, 3, and 7 using spiral thin-cut brain computed tomography scan (1-mm thickness). Outcome measures including modified Rankin Scale, Glasgow Outcome Scale, and Disability Rating Scale were evaluated 3 months after injury. RESULTS: There was no significant difference between the 2 study groups in baseline, day 3, and day 7 contusion volumes. Patients receiving glibenclamide had a significantly lower expansion ratio from first to second volumetry (P < 0.001). Similarly, the first to third expansion ratio was significantly lower in the glibenclamide group compared with placebo (P = 0.003). There was no significant difference between the 2 groups regarding functional outcome measured by Glasgow Outcome Scale, modified Rankin Scale, and Disability Rating Scale. CONCLUSIONS: Oral glibenclamide is associated with decreased contusion expansion rate in patients with moderate and severe traumatic brain injuries sustaining cerebral contusions.	[Khalili, Hosseinali; Niakan, Amin] Shiraz Univ Med Sci, Trauma Res Ctr, Shiraz, Iran; [Derakhshan, Nima; Ghaffarpasand, Fariborz] Shiraz Univ Med Sci, Student Res Comm, Shiraz, Iran; [Khalili, Hosseinali; Derakhshan, Nima; Niakan, Amin; Ghaffarpasand, Fariborz; Salehi, Mohammad; Eshraghian, Hamed] Shiraz Univ Med Sci, Dept Neurosurg, Shiraz, Iran; [Shakibafard, Alireza; Zahabi, Bita] Shiraz Univ Med Sci, Dept Radiol, Shiraz, Iran; [Zahabi, Bita] Chamran Hosp, Radiol Dept, Shiraz, Iran	Derakhshan, N (corresponding author), Shiraz Univ Med Sci, Student Res Comm, Shiraz, Iran.; Derakhshan, N (corresponding author), Shiraz Univ Med Sci, Dept Neurosurg, Shiraz, Iran.	nima_med83@yahoo.com	niakan, amin/A-6818-2019; Derakhshan, Nima/Q-2454-2019; Ghaffarpasand, Fariborz/I-4204-2019; Khalili, Hosseinali/I-1087-2016	niakan, amin/0000-0003-2644-8543; Derakhshan, Nima/0000-0001-7142-3404; Ghaffarpasand, Fariborz/0000-0002-1721-9987; Khalili, Hosseinali/0000-0002-3390-4212			Boggs DH, 2014, EXPERT REV NEUROTHER, V14, P379, DOI 10.1586/14737175.2014.890891; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Ding J, 2013, CLIN NEUROL NEUROSUR, V115, P2166, DOI 10.1016/j.clineuro.2013.08.010; Fiez JA, 2000, HUM BRAIN MAPP, V9, P192, DOI 10.1002/(SICI)1097-0193(200004)9:4<192::AID-HBM2>3.0.CO;2-Y; Gerzanich V, 2009, NAT MED, V15, P185, DOI 10.1038/nm.1899; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Heydari ST, 2013, PUBLIC HEALTH, V127, P704, DOI 10.1016/j.puhe.2013.05.003; Hosier H, 2015, J NEUROTRAUM, V32, P1633, DOI 10.1089/neu.2015.3892; Khalili H, 2017, CLIN NEUROL NEUROSUR, V152, P34, DOI 10.1016/j.clineuro.2016.11.011; Khalili H, 2016, WORLD NEUROSURG, V94, P120, DOI 10.1016/j.wneu.2016.06.122; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Kunte H, 2007, STROKE, V38, P2526, DOI 10.1161/STROKEAHA.107.482216; Kunte H, 2012, ANN NEUROL, V72, P799, DOI 10.1002/ana.23680; Kurland DB, 2013, PHARMACEUTICALS, V6, P1287, DOI 10.3390/ph6101287; Lu J, 2005, ACT NEUR S, V95, P281; Mandell JG, 2015, J NEUROSURG-PEDIATR, V15, P133, DOI 10.3171/2014.9.PEDS12428; Michinaga S, 2015, INT J MOL SCI, V16, P9949, DOI 10.3390/ijms16059949; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Rahmanian Abdolkarim, 2014, Bull Emerg Trauma, V2, P151; Rambiritch V, 2016, CLIN PHARMACOL-ADV A, V8, P83, DOI 10.2147/CPAA.S102676; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Sheth KN, 2014, STROKE, V45, P281, DOI 10.1161/STROKEAHA.113.003352; Simard JM, 2013, SPINAL CORD, V51, P823, DOI 10.1038/sc.2013.99; Simard JM, 2007, J CLIN INVEST, V117, P2105, DOI 10.1172/JCI32041; Simard JM, 2012, J CEREBR BLOOD F MET, V32, P1699, DOI 10.1038/jcbfm.2012.91; Simard JM, 2012, EXP NEUROL, V233, P829, DOI 10.1016/j.expneurol.2011.11.048; Simard JM, 2012, EXP NEUROL, V233, P566, DOI 10.1016/j.expneurol.2011.11.044; Simard JM, 2010, STROKE, V41, P531, DOI 10.1161/STROKEAHA.109.572644; Simard JM, 2009, J NEUROTRAUM, V26, P2257, DOI 10.1089/neu.2009.1021; Simard JM, 2009, J CEREBR BLOOD F MET, V29, P317, DOI 10.1038/jcbfm.2008.120; Simard JM, 2009, STROKE, V40, P604, DOI 10.1161/STROKEAHA.108.522409; Simard JM, 2013, J SPINE S4; Stokum JA, 2016, J CEREBR BLOOD F MET, V36, P513, DOI 10.1177/0271678X15617172; Taghipour M, 2006, J RES MED SCI, V11, P248; Thompson EM, 2013, NEOPLASIA, V15, P535, DOI 10.1593/neo.13164; Tosun C, 2013, STROKE, V44, P3522, DOI 10.1161/STROKEAHA.113.002904; Welling LC, 2016, WORLD NEUROSURG, V87, P475, DOI 10.1016/j.wneu.2016.01.044; Xu ZM, 2016, J NEUROTRAUMA; Zacko JC, 2011, YOUMANS NEUROLOGICAL, P3424; Zafardoost P, 2016, TRAUMA MON, V21, DOI 10.5812/traumamon.25113; Zweckberger K, 2014, NEUROSCIENCE, V272, P199, DOI 10.1016/j.neuroscience.2014.04.040	44	24	24	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	MAY	2017	101						130	136		10.1016/j.wneu.2017.01.103			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	EV7CR	WOS:000401932500016	28185976				2021-06-18	
J	Liu, ZW; Wang, HD; Shi, XF; Li, LW; Zhou, ML; Ding, H; Yang, YQ; Li, X; Ding, K				Liu, Zhengwei; Wang, Handong; Shi, Xiaofeng; Li, Liwen; Zhou, Mengliang; Ding, Hui; Yang, Youqing; Li, Xiang; Ding, Ke			DL-3-n-Butylphthalide (NBP) Provides Neuroprotection in the Mice Models After Traumatic Brain Injury via Nrf2-ARE Signaling Pathway	NEUROCHEMICAL RESEARCH			English	Article						DL-3-n-Butylphthalide; Neuroprotection; Traumatic brain injury; Nrf2-ARE signaling pathway; Mice model	FOCAL CEREBRAL-ISCHEMIA; CLOSED-HEAD INJURY; OXIDATIVE STRESS; CHIRAL 3-N-BUTYLPHTHALIDE; ANTIOXIDANT ENZYMES; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; UP-REGULATION; MOUSE MODEL; CELL-DEATH	The present study was aimed to evaluate the neuroprotective effects of NBP in the mice models of TBI, as well as the possible role of Nrf2-ARE pathways in the assumptive neuroprotection. In mice,a modified Marmarou's weight-drop model was employed to induce TBI. ICR mice were randomly assigned to four experimental groups: sham, TBI, TBI+vehicle(V) and TBI+NBP. NBP (100 mg/kg) was administered via an intraperitoneal (i.p.) injection at 1 h following TBI. The administration of NBP significantly ameliorated the effects of the brain injury, including neurological deficits, brain water content, and cortical neuronal apoptosis. Furthermore, the level of malondialdehyde and the activity of superoxide dismutase (SOD) paired with glutathione peroxidase (GPx) were restored in the NBP treatment group. NBP promoted the translocation of Nrf2 protein from the cytoplasm to the nucleus markedly, increased the expressions of Nrf2-ARE pathway-related downstream factors, including hemeoxygenase-1(HO-1) and NAD(P)H: quinone oxidoreductase 1 (NQO1), and prevented the decline of antioxidant enzyme activities, including SOD and GPx. NBP enhanced the translocation of Nrf2 to the nucleus from the cytoplasm,verified by a western blot, immunofluorescence. Additionally, it upregulated the expression of the Nrf2 downstream factors such as HO-1 and NQO1 were also confirmed via a western blot and real-time quantitative polymerase chain reaction. In conclusion, NBP administration may increase the activities of antioxidant enzymes and attenuate brain injury in a TBI model, potentially via the mediation of the Nrf2-ARE pathway.	[Liu, Zhengwei; Wang, Handong; Ding, Hui; Yang, Youqing] Southern Med Univ Guangzhou, Sch Med, Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China; [Liu, Zhengwei; Shi, Xiaofeng] Shenzhen Longgang Cent Hosp, Dept Neurosurg, 6082 Longgangdadao Rd, Shenzhen 518116, Guangdong, Peoples R China; [Li, Liwen; Zhou, Mengliang; Li, Xiang; Ding, Ke] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China	Wang, HD (corresponding author), Southern Med Univ Guangzhou, Sch Med, Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com		Zhou, Meng-liang/0000-0002-1165-5489	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371357, 81571162]	This work was supported by Grants from the National Natural Science Foundation of China (No. 81371357) and National Natural Science Foundation of China (No. 81571162).	Chang Q, 2003, ACTA PHARMACOL SIN, V24, P796; Chong ZZ, 2000, CHINESE MED J-PEKING, V113, P613; Chong ZZ, 1999, ACTA PHARMACOL SIN, V20, P696; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Deng W, 1997, Chin Med Sci J, V12, P102; Ding K, 2015, NEUROCHEM INT, V91, P46, DOI 10.1016/j.neuint.2015.10.008; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Feng XH, 2012, NEUROPHARMACOLOGY, V62, P1004, DOI 10.1016/j.neuropharm.2011.10.009; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Hong YA, 2010, ACTA PHARMACOL SIN, V31, P1421, DOI 10.1038/aps.2010.101; Huang JZ, 2010, NEUROSCI LETT, V475, P89, DOI 10.1016/j.neulet.2010.03.053; Jin W, 2008, CYTOKINE, V44, P135, DOI 10.1016/j.cyto.2008.07.005; Jin W, 2014, INFLAMM RES, V63, P381, DOI 10.1007/s00011-014-0710-z; Jin W, 2011, INJURY, V42, P714, DOI 10.1016/j.injury.2011.03.009; Kobayashi M, 2005, ANTIOXID REDOX SIGN, V7, P385, DOI 10.1089/ars.2005.7.385; Kobayashi M, 2006, ADV ENZYME REGUL, V46, P113, DOI 10.1016/j.advenzreg.2006.01.007; Li JM, 2010, BRAIN RES, V1359, P216, DOI 10.1016/j.brainres.2010.08.061; Li L, 2009, BRAIN RES, V1290, P91, DOI 10.1016/j.brainres.2009.07.020; Li LR, 2014, CHEM-BIOL INTERACT, V209, P56, DOI 10.1016/j.cbi.2013.12.005; Liang L, 2013, J AGR FOOD CHEM, V61, P2755, DOI 10.1021/jf304768p; Liu X. G., 1995, Yaoxue Xuebao, V30, P896; Peng Y, 2010, J NEUROSCI, V30, P8180, DOI 10.1523/JNEUROSCI.0340-10.2010; Sun B, 2012, NEUROSCI LETT, V516, P247, DOI 10.1016/j.neulet.2012.04.003; Vriend J, 2015, MOL CELL ENDOCRINOL, V401, P213, DOI 10.1016/j.mce.2014.12.013; Wang CY, 2016, NEUROBIOL AGING, V38, P32, DOI 10.1016/j.neurobiolaging.2015.10.024; Wang FX, 2016, SCI REP-UK, V6, DOI 10.1038/srep19396; Wang HC, 2016, WORLD NEUROSURG, V87, P463, DOI 10.1016/j.wneu.2015.10.010; Wang YG, 2014, ACTA PHYSIOL, V210, P524, DOI 10.1111/apha.12186; Wei WT, 2015, NEUROCHEM INT, V87, P85, DOI 10.1016/j.neuint.2015.06.003; Xiong NA, 2012, NEUROBIOL AGING, V33, P1777, DOI 10.1016/j.neurobiolaging.2011.03.007; Xu HL, 2000, ACTA PHARMACOL SIN, V21, P433; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Yan CH, 1998, ACTA PHARMACOL SIN, V19, P117; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Zhang LH, 2012, CURR NEUROVASC RES, V9, P167, DOI 10.2174/156720212801618956; Zhang MJ, 2013, PROG NEUROBIOL, V100, P30, DOI 10.1016/j.pneurobio.2012.09.003; Zhang T, 2014, NEUROSCIENCE, V263, P130, DOI 10.1016/j.neuroscience.2014.01.012; Zhang T, 2010, NEUROL RES, V32, P390, DOI 10.1179/016164110X12670144526264; Zhuang Z, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-47	39	24	28	1	9	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	MAY	2017	42	5					1375	1386		10.1007/s11064-017-2186-z			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	ES9UD	WOS:000399906000011	28214984				2021-06-18	
J	Dennis, EL; Rashid, F; Ellis, MU; Babikian, T; Vlasova, RM; Villalon-Reina, JE; Jin, Y; Olsen, A; Mink, R; Babbitt, C; Johnson, J; Giza, CC; Thompson, PM; Asarnow, RF				Dennis, Emily L.; Rashid, Faisal; Ellis, Monica U.; Babikian, Talin; Vlasova, Roza M.; Villalon-Reina, Julio E.; Jin, Yan; Olsen, Alexander; Mink, Richard; Babbitt, Christopher; Johnson, Jeffrey; Giza, Christopher C.; Thompson, Paul M.; Asarnow, Robert F.			Diverging white matter trajectories in children after traumatic brain injury The RAPBI study	NEUROLOGY			English	Article							MODERATE; INFLAMMATION; OUTCOMES; REVEALS; TRACTS; UCLA	Objective: To examine longitudinal trajectories of white matter organization in pediatric moderate/severe traumatic brain injury (msTBI) over a 12-month period. Methods: We studied 21 children (16 M/5 F) with msTBI, assessed 2-5 months postinjury and again 13-19 months postinjury, as well as 20 well-matched healthy control children. We assessed corpus callosum function through interhemispheric transfer time (IHTT), measured using event-related potentials, and related this to diffusion-weighted MRI measures of white matter (WM) microstructure. At the first time point, half of the patients with TBI had significantly slower IHTT (TBI-slow-IHTT, n = 11) and half were in the normal range (TBI-normal-IHTT, n = 10). Results: The TBI-normal-IHTT group did not differ significantly from healthy controls, either inWM organization in the chronic phase or in the longitudinal trajectory of WM organization between the 2 evaluations. In contrast, the WM organization of the TBI-slow-IHTT group was significantly lower than in healthy controls across a large portion of the WM. Longitudinal analyses showed that the TBI-slow-IHTT group experienced a progressive decline between the 2 evaluations in WM organization throughout the brain. Conclusions: We present preliminary evidence suggesting a potential biomarker that identifies a subset of patients with impaired callosal organization in the first months postinjury who subsequently experience widespread continuing and progressive degeneration in the first year postinjury.	[Dennis, Emily L.; Rashid, Faisal; Villalon-Reina, Julio E.; Jin, Yan; Thompson, Paul M.] Univ Southern Calif, Keck Sch Med, Imaging Genet Ctr, Mary & Mark Stevens Inst Neuroimaging & Informat, Los Angeles, CA 90033 USA; [Ellis, Monica U.; Babikian, Talin; Olsen, Alexander; Asarnow, Robert F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA; [Asarnow, Robert F.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA; [Asarnow, Robert F.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA; [Ellis, Monica U.] Fuller Theol Seminary Sch Psychol, Pasadena, CA USA; [Vlasova, Roza M.] Childrens Hosp Los Angeles, Dept Radiol, CIBORG Lab, Los Angeles, CA 90027 USA; [Olsen, Alexander] Norwegian Univ Sci & Technol, Dept Psychol, Trondheim, Norway; [Olsen, Alexander] Univ Trondheim Hosp, St Olavs Hosp, Dept Phys Med & Rehabil, Trondheim, Norway; [Mink, Richard] Harbor UCLA Med Ctr, Dept Pediat, Torrance, CA USA; [Mink, Richard] Los Angeles BioMed Res Inst, Dept Pediat, Torrance, CA USA; [Babbitt, Christopher] Miller Childrens Hosp, Long Beach, CA USA; [Johnson, Jeffrey] LAC USC Med Ctr, Dept Pediat, Los Angeles, CA USA; [Giza, Christopher C.] Mattel Childrens Hosp, UCLA Brain Injury Res Ctr, Dept Neurosurg & Div Pediat Neurol, Los Angeles, CA USA; [Thompson, Paul M.] USC, Dept Neurol, Los Angeles, CA USA; [Thompson, Paul M.] USC, Dept Pediat, Los Angeles, CA USA; [Thompson, Paul M.] USC, Dept Psychiat, Los Angeles, CA USA; [Thompson, Paul M.] USC, Dept Radiol Engn & Ophthalmol, Los Angeles, CA USA	Dennis, EL (corresponding author), Univ Southern Calif, Keck Sch Med, Imaging Genet Ctr, Mary & Mark Stevens Inst Neuroimaging & Informat, Los Angeles, CA 90033 USA.	emily.dennis@ini.usc.edu	Thompson, Paul M/C-4194-2018; Olsen, Alexander/P-5235-2019; Dennis, Emily/AAD-5223-2021	Thompson, Paul M/0000-0002-4720-8867; Olsen, Alexander/0000-0001-8691-3860; 	NICHDS [R01 HD061504]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K99 NS096116]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD061504, K99 NS096116, U54 EB020403, R01 EB008432, R01 AG040060, R01 NS080655, NS027544, NS05489]; UCLA BIRC [NS027544, NS05489]; UCLA Steve Tisch BrainSPORT Program; Easton Foundation; Staglin IMHRO Center for Cognitive Neuroscience; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [U54EB020403, P41EB015922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K99NS096116] Funding Source: NIH RePORTER	This study was supported by the NICHDS (R01 HD061504). E.L.D. is supported by a grant from the NINDS (K99 NS096116). E.L.D., F.R., Y.J., J.V., and P.T. are also supported by NIH grants to P.T.: U54 EB020403, R01 EB008432, R01 AG040060, and R01 NS080655. C.C.G. is supported by the UCLA BIRC, NS027544, NS05489, UCLA Steve Tisch BrainSPORT Program, and Easton Foundation. Scanning was supported by the Staglin IMHRO Center for Cognitive Neuroscience. The Recovery After Pediatric Brain Injury Study (RAPBI) was supported by NIH (R01 HD061504, K99 NS096116, U54 EB020403, R01 EB008432, R01 AG040060, R01 NS080655, NS027544, NS05489), the UCLA BIRC, the UCLA Steve Tisch BrainSPORT Program, the Easton Foundation, and the Staglin IMHRO Center for Cognitive Neuroscience.	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Babikian T, 2015, J NEUROTRAUM, V32, P1849, DOI 10.1089/neu.2015.3971; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bartzokis G, 2010, NEUROBIOL AGING, V31, P1554, DOI 10.1016/j.neurobiolaging.2008.08.015; Carrera E, 2014, BRAIN, V137, P2408, DOI 10.1093/brain/awu101; Catani M, 2007, P NATL ACAD SCI USA, V104, P17163, DOI 10.1073/pnas.0702116104; Daianu M, 2016, BRAIN IMAGING BEHAV, V10, P1038, DOI 10.1007/s11682-015-9458-5; Dennis EL, 2015, P 12 IEEE INT S BIOM; Dennis EL, 2016, J NEUROTRAUM, V33, P840, DOI 10.1089/neu.2015.4012; Dennis EL, 2015, PROC SPIE, V9681, DOI 10.1117/12.2207574; Dennis EL, 2015, I S BIOMED IMAGING, P930, DOI 10.1109/ISBI.2015.7164023; Dennis EL, 2015, J NEUROSCI, V35, P10202, DOI 10.1523/JNEUROSCI.1595-15.2015; Dennis EL, 2015, NEUROIMAGE-CLIN, V7, P493, DOI 10.1016/j.nicl.2015.02.002; Ellis MU, 2016, J NEUROTRAUM, V33, P990, DOI 10.1089/neu.2015.4023; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Jin Y, 2014, NEUROIMAGE, V100, P75, DOI 10.1016/j.neuroimage.2014.04.048; Jin Y, 2013, I S BIOMED IMAGING, P512, DOI 10.1109/isbi.2013.6556524; Jin Yan, 2012, Multimodal Brain Image Anal (2012), V7509, P147, DOI 10.1007/978-3-642-33530-3_12; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kochunov P, 2012, NEUROBIOL AGING, V33, P9, DOI 10.1016/j.neurobiolaging.2010.01.014; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Mathias JL, 2004, APPL NEUROPSYCHOL, V11, P134, DOI 10.1207/s15324826an1103_2; Moran LM, 2016, J INT NEUROPSYCH SOC, V22, P512, DOI 10.1017/S1355617716000175; Nagy Z, 2004, J COGNITIVE NEUROSCI, V16, P1227, DOI 10.1162/0898929041920441; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; Pasternak O, 2012, J NEUROSCI, V32, P17365, DOI 10.1523/JNEUROSCI.2904-12.2012; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P404, DOI 10.1007/s11682-012-9150-y; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Zhang YJ, 2010, NEUROIMAGE, V52, P1289, DOI 10.1016/j.neuroimage.2010.05.049	33	24	24	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	APR 11	2017	88	15					1392	1399		10.1212/WNL.0000000000003808			8	Clinical Neurology	Neurosciences & Neurology	ER3CW	WOS:000398674100007	28298549	Green Published			2021-06-18	
J	Archbold, HAP; Rankin, AT; Webb, M; Nicholas, R; Eames, NWA; Wilson, RK; Henderson, LA; Heyes, GJ; Bleakley, CM				Archbold, H. A. P.; Rankin, A. T.; Webb, M.; Nicholas, R.; Eames, N. W. A.; Wilson, R. K.; Henderson, L. A.; Heyes, G. J.; Bleakley, C. M.			RISUS study: Rugby Injury Surveillance in Ulster Schools	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							UNION PLAYERS; WORLD-CUP; CONSENSUS STATEMENT; CONCUSSION; TERM; FOOTBALL; OUTCOMES; SPORTS; AGE	Objective To examine injury patterns in adolescent rugby players and determine factors associated with injury risk. Design Prospective injury surveillance study. Setting N=28 Grammar Schools in Ulster, Ireland (2014-2015 playing season). Participants 825 adolescent rugby players, across in 28 school first XV rugby squads; mean age 16.9 years. Main outcome measures Injuries were classified by body part and diagnosis, and injury incidence using injuries per 1000 match hours of exposure. HRs for injury were calculated through Cox proportional hazard regression after correction for influential covariates. Results A total of n=426 injuries were reported across the playing season. Over 50% of injuries occurred in the tackle situation or during collisions (270/426), with few reported during set plays. The 3 most common injury sites were head/face (n=102, 23.9%), clavicle/shoulder (n=65, 15.3%) and the knee (n=56, 13.1%). Sprain (n=133, 31.2%), concussion (n=81, 19%) and muscle injury (n=65, 15.3%) were the most common diagnoses. Injury incidence is calculated at 29.06 injuries per 1000 match hours. There were no catastrophic injuries. A large percentage of injuries (208/424) resulted in absence from play for more than 28 days. Concussion carried the most significant time out from play (n=33; 15.9%), followed by dislocations of the shoulder (n=22; 10.6%), knee sprains (n=19, 9.1%), ankle sprains (n=14, 6.7%), hand/finger/thumb (n=11; 5.3%). 36.8% of participants in the study (304/825) suffered at least one injury during the playing season. Multivariate models found higher risk of injury (adjusted HR (AHR); 95% CI) with: higher age (AHR 1.45; 1.14 to 1.83), heavier weight (AHR 1.32; 1.04 to 1.69), playing representative rugby (AHR 1.42; 1.06 to 1.90) and undertaking regular strength training (AHR 1.65; 1.11 to 2.46). Playing for a lower ranked team (AHR 0.67; 0.49 to 0.90) and wearing a mouthguard (AHR 0.70; 0.54 to 0.92) were associated with lower risk of injury. Conclusions There was a high incidence of severe injuries, with concussion, ankle and knee ligament injuries and upper limb fractures/dislocations causing greatest time loss. Players were compliant with current graduated return-to-play regulations following concussion. Physical stature and levels of competition were important risk factors and there was limited evidence for protective equipment.	[Archbold, H. A. P.; Nicholas, R.; Eames, N. W. A.; Henderson, L. A.; Heyes, G. J.] Royal Victoria Hosp, Belfast, Antrim, North Ireland; [Rankin, A. T.] Bupa Hlth Clin, Belfast, Antrim, North Ireland; [Webb, M.] Kingspan Stadium, Ulster Rugby, Belfast, Antrim, North Ireland; [Wilson, R. K.] Musgrave Pk Hosp, Belfast, Antrim, North Ireland; [Bleakley, C. M.] Univ Ulster, Sport & Exercise Sci Res Inst, Newtownabbey BT37 0QB, North Ireland	Bleakley, CM (corresponding author), Univ Ulster, Sport & Exercise Sci Res Inst, Newtownabbey BT37 0QB, North Ireland.	c.bleakley@ulster.ac.uk		Bleakley, Chris/0000-0001-9032-9691	Irish Rugby Football Union; MITRE Trust; Ulster Rugby	Financial support was received by the following institutions: Irish Rugby Football Union, MITRE Trust and Ulster Rugby.	Alexander DG, 2015, BRAIN INJURY, V29, P1113, DOI 10.3109/02699052.2015.1031699; Bahr R, 2014, BRIT J SPORT MED, V48, P1265, DOI 10.1136/bjsports-2014-093832; Bathgate A, 2002, BRIT J SPORT MED, V36, P265, DOI 10.1136/bjsm.36.4.265; Best JP, 2005, BRIT J SPORT MED, V39, P812, DOI 10.1136/bjsm.2004.016402; Bleakley C, 2011, J ATHL TRAINING, V46, P555; Carman AJ, 2015, NAT REV NEUROL, V11, P230, DOI 10.1038/nrneurol.2015.30; Corwin DJ, 2015, J PEDIATR-US, V166, P1221, DOI 10.1016/j.jpeds.2015.01.039; Delahunt E, 2013, J STRENGTH COND RES, V27, P3252, DOI 10.1519/JSC.0b013e3182915ea6; Delahunty SE, 2015, J SCHOOL HEALTH, V85, P17, DOI 10.1111/josh.12219; Freitag A, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1587; Freitag A, 2015, BRIT J SPORT MED, V49, P511, DOI 10.1136/bjsports-2014-093684; Fuller CW, 2008, BRIT J SPORT MED, V42, P452, DOI 10.1136/bjsm.2008.047035; Fuller CW, 2007, CLIN J SPORT MED, V17, P177, DOI 10.1097/JSM.0b013e31803220b3; Fuller CW, 2007, BRIT J SPORT MED, V41, P862, DOI 10.1136/bjsm.2007.037499; Fuller CW, 2010, BRIT J SPORT MED, V44, P159, DOI 10.1136/bjsm.2008.050864; Fuller CW, 2010, J SCI MED SPORT, V13, P36, DOI 10.1016/j.jsams.2008.09.008; Hollis SJ, 2012, BRIT J SPORT MED, V46, P735, DOI 10.1136/bjsm.2011.085332; Kirkwood G, 2015, BRIT J SPORT MED, V49, P506, DOI 10.1136/bjsports-2014-093774; Krause LM, 2015, J SCI MED SPORT, V18, P358, DOI 10.1016/j.jsams.2014.05.012; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McIntosh AS, 2009, MED SCI SPORT EXER, V41, P306, DOI 10.1249/MSS.0b013e3181864bee; Quarrie KL, 2008, AM J SPORT MED, V36, P1705, DOI 10.1177/0363546508316768; Quarrie KL, 2005, BRIT J SPORT MED, V39, P650, DOI 10.1136/bjsm.2004.016022; Schwebel DC, 2014, J ATHL TRAINING, V49, P780, DOI 10.4085/1062-6050-49.3.41; Sedeaud A, 2012, BRIT J SPORT MED, V46, P580, DOI 10.1136/bjsports-2011-090506; Smith AR, 2013, HORM BEHAV, V64, P323, DOI 10.1016/j.yhbeh.2013.03.006; Solomon GS, 2011, CLIN SPORT MED, V30, P165, DOI 10.1016/j.csm.2010.09.002; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Watson AWS, 1988, J SPORT SCI, V6, P131, DOI 10.1080/02640418808729803	29	24	25	0	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	APR	2017	51	7					600	606		10.1136/bjsports-2015-095491			7	Sport Sciences	Sport Sciences	EQ1GC	WOS:000397816800012	26701931				2021-06-18	
J	Krasny-Pacini, A; Chevignard, M; Lancien, S; Escolano, S; Laurent-Vannier, A; De Agostini, M; Meyer, P				Krasny-Pacini, Agata; Chevignard, Mathilde; Lancien, Sabine; Escolano, Sylvie; Laurent-Vannier, Anne; De Agostini, Maria; Meyer, Philippe			Executive function after severe childhood traumatic brain injury - Age-at-injury vulnerability periods: The TGE prospective longitudinal study	ANNALS OF PHYSICAL AND REHABILITATION MEDICINE			English	Article						Traumatic brain injury; Executive functions; Child; Cohort; Longitudinal prospective study; Outcome; Vulnerability periods; Follow-up	PERFORMANCE-BASED MEASURES; BEHAVIOR RATING INVENTORY; YOUNG-CHILDREN; ECOLOGICAL ASSESSMENT; COGNITIVE PREDICTORS; OUTCOMES; PLASTICITY; TBI; RECOVERY; DEFICITS	Background: Executive function (EF) impairment is a major predictor of overall outcome after traumatic brain injury (TBI). TBI severity is a factor of poor outcome, but most studies include a majority of children with mild and moderate TBI. The aims of this study were to estimate EF impairment after severe childhood TBI and to explore factors predicting EF outcome. The secondary aim was to compare recovery trajectories by age-at-injury groups. Methods: This was a prospective longitudinal study of children with severe TBI who were tested for EFs by performance-based tests and questionnaires at 3, 12 and 24 months. Results: Children with TBI (n = 65) showed significant impairment in working memory, inhibition, attention and global EF, with little or no recovery at 24 months. For flexibility and performance-based EF score, children were impaired at 3 months only and showed normal scores by 12 months. No impairment was found in planning. At 3 and 24 months, Glasgow Coma Scale score and parental education predicted global EF. Coma length was not a significant predictor of outcome. Age at injury predicted progress in EF, but the relationship was not linear; children 10-12 years old at injury showed better outcome than older and younger children. Conclusions: EFs are impaired after severe TBI in childhood. The relationship between age at injury and outcome is not linear. Relying on only performance-based EF tests can underestimate EF impairment. (C) 2016 Elsevier Masson SAS. All rights reserved.	[Krasny-Pacini, Agata] Univ Rehabil Inst Clemenceau Strasbourg, Outreach Dept Patients Acquired Brain Injury, Strasbourg, France; [Krasny-Pacini, Agata] Strasbourg Univ Hosp, Hautepierre Hosp, Pediat Orthoped Dept, Strasbourg, France; [Krasny-Pacini, Agata; Chevignard, Mathilde] UPMC Univ Paris 06, LIB, Sorbonne Univ, CNRS,INSERM, Paris, France; [Chevignard, Mathilde; Laurent-Vannier, Anne] Hop St Maurice, Rehabil Dept Children Acquired Brain Injury, F-7013 St Maurice, France; [Krasny-Pacini, Agata; Chevignard, Mathilde] UPMC Paris 6, Grp Rech Clin Handicap Cognitif & Readaptat, Paris, France; [Lancien, Sabine] AP HP, Dept Rech Clin & Dev DRCC, Paris, France; [Escolano, Sylvie] INSERM, UMR 1181, Equipe Biostat & Pharmacoepidemiol, Biostat Biomath Pharmacoepidemiol & Malad Infect, Villejuif, France; [Laurent-Vannier, Anne] St Maurice Hosp, Outreach Team Children & Adolescents Acquired Bra, St Maurice, France; [De Agostini, Maria] INSERM, Epidemiol & Biostat Sorbonne Paris Cite Ctr CRESS, UMR1153, Dev Origins Hlth & Dis ORCHAD Team, F-94807 Villejuif, France; [Meyer, Philippe] Univ Descartes Paris5, Hop Univ Necker, Anesthesiol Dept, Pediat Neuro Crit Care Unit, F-75015 Paris, France	Krasny-Pacini, A (corresponding author), Inst Univ Readaptat Clemenceau, Serv EMOI TC Illkirch, 10 Ave Achille Baumann,BP 80096, F-67402 Illkirch Graffenstaden, France.	agatakrasny@yahoo.com	Meyer, Philippe/ABE-4242-2020	Meyer, Philippe/0000-0002-3829-6631; escolano, sylvie/0000-0003-0864-4321	Departement de la recherche clinique et du developpement, AP-HP (Paris) [PHRC 2003, AOM 03018]	This study was funded by the Departement de la recherche clinique et du developpement, AP-HP (Paris, No. PHRC 2003; AOM 03018). We thank Drs. Dominique Brugel and Hanna Toure for help in data collection and Laurence Watier for help with data management.	Achenbach T., 2001, VOL ADAPTATION FRANC; Anderson P, 2002, CHILD NEUROPSYCHOL, V8, P71, DOI 10.1076/chin.8.2.71.8724; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V, 2001, Pediatr Rehabil, V4, P119, DOI 10.1080/13638490110091347; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Anderson V, 2012, PEDIATRICS, V129, pE254, DOI 10.1542/peds.2011-0311; Anderson V, 2011, BRAIN, V134, P2197, DOI 10.1093/brain/awr103; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Arnett AB, 2013, J INT NEUROPSYCH SOC, V19, P881, DOI 10.1017/S1355617713000635; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Baddeley A. D., 1994, Neuropsychology, V8, P485, DOI [10.1037/0894-4105.8.4.485., 10.1037/0894-4105.8.4.485]; Bagiella E, 2010, J HEAD TRAUMA REHAB, V25, P375, DOI 10.1097/HTR.0b013e3181d27fe3; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Beauchamp M, 2011, DEV NEUROPSYCHOL, V36, P578, DOI 10.1080/87565641.2011.555572; Beck DM, 2011, J COGN DEV, V12, P169, DOI 10.1080/15248372.2011.563485; Burgess PW., 2005, EFFECTIVENESS REHABI; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; Chevignard MP, 2012, BRAIN INJURY, V26, P1033, DOI 10.3109/02699052.2012.666366; Chevignard MP, 2010, BRAIN IMPAIR, V11, P125, DOI 10.1375/brim.11.2.125; Cowan N, 2011, DEVELOPMENTAL SCI, V14, P1066, DOI 10.1111/j.1467-7687.2011.01060.x; Crowe LM, 2012, J PEDIATR PSYCHOL, V37, P745, DOI 10.1093/jpepsy/jss070; Davidson MC, 2006, NEUROPSYCHOLOGIA, V44, P2037, DOI 10.1016/j.neuropsychologia.2006.02.006; Denckla M.B., 1994, FRAMES REFERENCE ASS, P117; Diamond A, 2013, ANNU REV PSYCHOL, V64, P135, DOI 10.1146/annurev-psych-113011-143750; Donders J, 2004, ASSESSMENT, V11, P275, DOI 10.1177/1073191104268914; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Duncan J, 1997, COGNITIVE NEUROPSYCH, V14, P713, DOI 10.1080/026432997381420; DUNCAN J, 1986, COGNITIVE NEUROPSYCH, V3, P271, DOI 10.1080/02643298608253360; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Fulton JB, 2012, NEUROPSYCHOLOGY, V26, P314, DOI 10.1037/a0027973; Gerrard-Morris A, 2010, J INT NEUROPSYCH SOC, V16, P157, DOI 10.1017/S1355617709991135; Gioia G.A., 2000, BEHAV RATING INVENTO; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Jonsson CA, 2013, BRAIN INJURY, V27, P831, DOI 10.3109/02699052.2013.775493; Klingberg T, 1999, NEUROREPORT, V10, P2817, DOI 10.1097/00001756-199909090-00022; Kolb B, 2004, BRAIN COGNITION, V55, P104, DOI 10.1016/s0278-2626(03)00278-1; Korkman M, 2003, TEST NEPSY BILAN NEU; Krasny-Pacini A, 2015, DEV NEUROREHABIL, P1; Kurowski BG, 2013, ARCH PHYS MED REHAB, V94, P543, DOI 10.1016/j.apmr.2012.10.029; Kurowski BG, 2011, PM&R, V3, P836, DOI 10.1016/j.pmrj.2011.05.016; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Longaud-Vales A, 2015, NEUROPSYCHOL REHABIL, P1; Luna B, 2004, CHILD DEV, V75, P1357, DOI 10.1111/j.1467-8624.2004.00745.x; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P223, DOI 10.1016/S0003-9993(96)90102-1; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Nybo T, 2004, J INT NEUROPSYCH SOC, V10, P719, DOI 10.1017/S1355617704105109; Rabbitt P., 1997, METHODOLOGY FRONTAL; Recla M, 2013, BRAIN INJURY, V27, P862, DOI 10.3109/02699052.2013.775499; Roy A, 2012, BEHAV RATING INVENTO; Schmitt AJ, 2004, ARCH CLIN NEUROPSYCH, V19, P1077, DOI 10.1016/j.acn.2004.02.002; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; SHALLICE T, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P125; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; Stinnett TA, 2002, J PSYCHOEDUC ASSESS, V20, P66, DOI 10.1177/073428290202000105; Thurman D. J., 2014, J CHILD NEUROL; Toplak ME, 2013, J CHILD PSYCHOL PSYC, V54, P131, DOI 10.1111/jcpp.12001; Toplak ME, 2009, CHILD NEUROPSYCHOL, V15, P53, DOI 10.1080/09297040802070929; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	68	24	24	0	3	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	1877-0657	1877-0665		ANN PHYS REHABIL MED	Ann. Phys. Rehabil. Med.	APR	2017	60	2					74	82		10.1016/j.rehab.2016.06.001			9	Rehabilitation	Rehabilitation	FO5VL	WOS:000416929400003	27566925	Bronze			2021-06-18	
J	Trifan, G; Gattu, R; Haacke, EM; Kou, ZF; Benson, RR				Trifan, Gabriela; Gattu, Ramtilak; Haacke, Ewart Mark; Kou, Zhifeng; Benson, Randall R.			MR imaging findings in mild traumatic brain injury with persistent neurological impairment	MAGNETIC RESONANCE IMAGING			English	Article						Traumatic brain injury; Mild TBI; Litigation; Subcortical; Deep; Microhemorrhage; Post concussive symptoms; White matter; Hyperintensities; Fluid-attenuated inversion recovery; Flair; Susceptibility-weighted imaging; SWI; MRI; Sensitivity; Detection; Agerelated	WHITE-MATTER HYPERINTENSITIES; SUSCEPTIBILITY-WEIGHTED MRI; DIFFUSE AXONAL INJURY; MAGNETIC-RESONANCE; CEREBRAL MICROBLEEDS; RISK-FACTORS; LESIONS; PREVALENCE; MIGRAINE; SPECTRUM	Traumatic brain injury (TBI) is a widespread cause of neurologic disability, with >70% of cases being mild in severity. Magnetic resonance imaging provides objective biomarlcers in the diagnosis of brain injury by detecting brain lesions resulting from trauma. This paper reports on the detection rates of presumed trauma related pathology using fluid-attenuated inversion recovery (FLAIR) and susceptibility-weighted imaging (SWI) in TBI patients with chronic, persistent symptoms. Methods: 180 subjects with persistent neurobehavioral symptoms following head trauma referred by personal injury attorneys and 94 asymptomatic, age-matched volunteers were included in the study. 83% of TBI subjects were classified as mild. Results: TBI subjects had a significantly greater number of lesions detected by FLAIR than controls (42% vs. 22%) and more lesions detected by SWI than controls (28% vs. 3%). To reduce the confounding effects of aging, we examined mild TBI subjects <45 years of age, which reduced the rate of lesions detected by FLAIR (26% vs. 2%) and SWI (15% vs. 0%). This younger group, which contained few age-related lesions, also demonstrated that subcortical lesions on FLAIR are more specific for TBI than deeper lesions. Conclusions: While the presence of litigation in mild TBI cases with incomplete recovery has been associated with greater expression of symptomatology and, by extension, poorer outcomes, this study shows that mild TBI patients in litigation with chronic, persistent symptoms may have associated brain injury underlying their symptoms detectable by MRI biomarkers. (C) 2016 Elsevier Inc. All rights reserved.	[Trifan, Gabriela; Benson, Randall R.] Ctr Neurol Studies, 23400 Michigan Ave,Suite 210, Dearborn, MI 48124 USA; [Gattu, Ramtilak; Haacke, Ewart Mark; Kou, Zhifeng] Wayne State Univ, MR Res Ctr, Sch Med, Dept Radiol, 3990 John R St,HUH Harper Suite 4J, Detroit, MI 48201 USA; [Haacke, Ewart Mark; Kou, Zhifeng] Wayne State Univ, Dept Biomed Engn, Detroit, MI 48201 USA	Benson, RR (corresponding author), Ctr Neurol Studies, Dearborn, MI 48375 USA.	gabby@neurologicstudies.com; ramtilak.gattu@wayne.edu; nmrimaging@aol.com; zhifeng_kou@wayne.edu; drbenson@neurologicstudies.com		Trifan, Gabriela/0000-0003-3427-2605	NIH grantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R37 AG011230]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R37AG011230] Funding Source: NIH RePORTER	The authors thank Dr. Naftali Raz, who shared data on 50 control participants (acquired under NIH grant R37 AG011230), and Dr. Darren Fuerst for assistance with statistical analysis. Portions of this paper were presented at the WSU 75th Anniversary Symposium, August 2014, and at the International Society for Magnetic Resonance in Medicine, May 2014.	Alaee A, 2014, IRAN J RADIOL, V11, DOI 10.5812/iranjradiol.14275; [Anonymous], 2014, NAT DIAB STAT REP; Aradi M, 2013, HEADACHE, V53, P752, DOI 10.1111/head.12013; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Ashikaga Ryuichiro, 1996, Nippon Acta Radiologica, V56, P1045; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; BROWN FW, 1992, AM J PSYCHIAT, V149, P620; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chowdhury MH, 2011, J STROKE CEREBROVASC, V20, P302, DOI 10.1016/j.jstrokecerebrovasdis.2009.12.010; Chutinet Aurauma, 2014, Curr Treat Options Cardiovasc Med, V16, P292, DOI 10.1007/s11936-013-0292-z; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Datta SGS, 2009, NEUROL INDIA, V57, P594, DOI 10.4103/0028-3886.57810; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; DeCuypere M, 2012, SURG CLIN N AM, V92, P939, DOI 10.1016/j.suc.2012.04.005; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; El Sayed T, 2008, COMPUT METHOD APPL M, V197, P4692, DOI 10.1016/j.cma.2008.06.006; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Fazekas F, 1998, J NEURAL TRANSM-SUPP, P31; Feinstein A, 2001, MED SCI LAW, V41, P116, DOI 10.1177/002580240104100206; Figiel G S, 1991, J Neuropsychiatry Clin Neurosci, V3, P18; Geurts BHJ, 2012, BRAIN INJURY, V26, P1439, DOI 10.3109/02699052.2012.694563; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Gunde E, 2011, J PSYCHIATR RES, V45, P76, DOI 10.1016/j.jpsychires.2010.04.019; Hamedani AG, 2013, NEUROLOGY, V81, P1308, DOI 10.1212/WNL.0b013e3182a8235b; Hopkins RO, 2006, J NEUROIMAGING, V16, P243, DOI 10.1111/j.1552-6569.2006.00047.x; Huang YL, 2015, NEUROLOGY, V84, P580, DOI 10.1212/WNL.0000000000001237; Imaizumi T, 2011, J NEUROIMAGING, V21, P359, DOI 10.1111/j.1552-6569.2011.00593.x; Jarrett M, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00011; Kanekar S, 2014, RADIOL CLIN N AM, V52, P241, DOI 10.1016/j.rcl.2013.11.010; Kennedy KM, 2009, BRAIN RES, V1297, P41, DOI 10.1016/j.brainres.2009.08.058; Kennedy KM, 2009, NEUROPSYCHOLOGIA, V47, P916, DOI 10.1016/j.neuropsychologia.2009.01.001; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Liu G, 2014, ACTA RADIOL; Liu W, 2016, RADIOLOGY, V278, P536, DOI 10.1148/radiol.2015150160; Loitfelder M, 2012, PANMINERVA MED, V54, P149; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Mantyla R, 1999, STROKE, V30, P2053, DOI 10.1161/01.STR.30.10.2053; McMahon PJ, 2013, J NEUROTRAUMA; Mooney G, 1997, NEUROREHABILITATION, V8, P223, DOI 10.3233/NRE-1997-8308; Morais DF, 2008, ARQ NEURO-PSIQUIAT, V66, P53, DOI 10.1590/S0004-282X2008000100013; MOZAFFARIAN D, 2015, CIRCULATION, V131, pE29, DOI [DOI 10.1161/CIR.0000000000000152, 10.1161/CIR.0000000000000152]; Neema M, 2009, AM J NEURORADIOL, V30, P911, DOI 10.3174/ajnr.A1514; Pape TLB, 2013, PM&R, V5, P856, DOI 10.1016/j.pmrj.2013.06.007; Pearson WS, 2012, PREHOSP EMERG CARE, V16, P323, DOI 10.3109/10903127.2012.682701; Poels MMF, 2010, STROKE, V41, pS103, DOI 10.1161/STROKEAHA.110.595181; Raz N., 2009, IMAGING AGING BRAIN, P151; Raz N, 2012, BBA-MOL BASIS DIS, V1822, P361, DOI 10.1016/j.bbadis.2011.08.007; Riedy G, 2016, RADIOLOGY, V279, P207, DOI 10.1148/radiol.2015150438; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Salat D.H., 2013, NEUROSCIENCE; Sassi RB, 2003, J AFFECT DISORDERS, V77, P237, DOI 10.1016/S0165-0327(02)00170-2; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; SCHMIDT R, 1991, ARCH NEUROL-CHICAGO, V48, P417, DOI 10.1001/archneur.1991.00530160087019; Seneviratne U, 2013, CLIN NEUROL NEUROSUR, V115, P1040, DOI 10.1016/j.clineuro.2012.10.033; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Shukla D, 2010, J NEUROSCI RURAL PRA, V1, P82, DOI 10.4103/0976-3147.71723; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Spitz G, 2013, J NEUROTRAUMA; Stehling C, 2008, ACAD RADIOL, V15, P895, DOI 10.1016/j.acra.2008.01.013; Tsurushima H, 1996, NEUROL SURG TOKYO, V24, P891; Wang X, 2014, NEUROL SCI; Wang X, 2014, NEUROL SCI, V35, P1533, DOI 10.1007/s10072-014-1788-3; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Wen W, 2004, NEUROIMAGE, V22, P144, DOI 10.1016/j.neuroimage.2003.12.027; Wen W, 2009, HUM BRAIN MAPP, V30, P1155, DOI 10.1002/hbm.20586; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Young VG, 2008, NEUROLOGY, V71, P804, DOI 10.1212/01.wnl.0000319691.50117.54	71	24	24	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0730-725X	1873-5894		MAGN RESON IMAGING	Magn. Reson. Imaging	APR	2017	37						243	251		10.1016/j.mri.2016.12.009			9	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	EO0IT	WOS:000396382200033	27939436				2021-06-18	
J	Fountain, DM; Kolias, AG; Lecky, FE; Bouamra, O; Lawrence, T; Adams, H; Bond, SJ; Hutchinson, PJ				Fountain, Daniel M.; Kolias, Angelos G.; Lecky, Fiona E.; Bouamra, Omar; Lawrence, Thomas; Adams, Hadie; Bond, Simon J.; Hutchinson, Peter J.			Survival Trends After Surgery for Acute Subdural Hematoma in Adults Over a 20-year Period	ANNALS OF SURGERY			English	Article						craniotomy; neurosurgery; trauma; traumatic brain injury	MULTIPLE IMPUTATION; HEAD-INJURY; TRAUMA CARE; MORTALITY; ENGLAND; TIME; REDUCTION; OUTCOMES; WALES	Objective: We sought to determine 30-day survival trends and prognostic factors following surgery for acute subdural hematomas (ASDHs) in England and Wales over a 20-year period. Summary of Background Data: ASDHs are still considered the most lethal type of traumatic brain injury. It remains unclear whether the adjusted odds of survival have improved significantly over time. Methods: Using the Trauma Audit and Research Network (TARN) database, we analyzed ASDH cases in the adult population (> 16 yrs) treated surgically between 1994 and 2013. Two thousand four hundred ninety-eight eligible cases were identified. Univariable and multiple logistic regression analyses were performed, using multiple imputation for missing data. Results: The cohort was 74% male with a median age of 48.9 years. Over half of patients were comatose at presentation (53%). Mechanism of injury was due to a fall (<2 m 34%, > 2 m 24%), road traffic collision (25%), and other (17%). Thirty-six per cent of patients presented with polytrauma. Gross survival increased from 59% in 1994 to 1998 to 73% in 2009 to 2013. Under multivariable analysis, variables independently associated with survival were year of injury, Glasgow Coma Scale, Injury Severity Score, age, and pupil reactivity. The time interval from injury to craniotomy and direct admission to a neurosurgical unit were not found to be significant prognostic factors. Conclusions: A significant improvement in survival over the last 20 years was observed after controlling for multiple prognostic factors. Prospective trials and cohort studies are expected to elucidate the distribution of functional outcome in survivors.	[Fountain, Daniel M.; Kolias, Angelos G.; Adams, Hadie; Hutchinson, Peter J.] Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge, England; [Fountain, Daniel M.; Kolias, Angelos G.; Adams, Hadie; Hutchinson, Peter J.] Univ Cambridge, Cambridge, England; [Lecky, Fiona E.; Bouamra, Omar; Lawrence, Thomas] Univ Manchester, Trauma Audit & Res Network, Salford, Lancs, England; [Bond, Simon J.] Cambridge Univ Hosp NHS Fdn Trust, Cambridge Clin Trials Unit, Cambridge, England; [Bond, Simon J.] Univ Cambridge, Inst Publ Hlth, MRC, Biostat Unit, Cambridge, England; [Lecky, Fiona E.] Univ Sheffield, Sch Hlth & Related Res, Hlth Serv Res, Emergency Med Res Sheffield EMRiS, Sheffield, S Yorkshire, England	Kolias, AG (corresponding author), Univ Cambridge, Div Neurosurg, Box 167,Cambridge Biomed Campus, Cambridge CB2 0QQ, England.	angeloskolias@gmail.com	Bond, Simon/AAB-9077-2020	Bond, Simon/0000-0003-2528-1040; Kolias, Angelos/0000-0003-3992-0587; Fountain, Daniel/0000-0001-6227-9930; bouamra, omar/0000-0002-3155-4634; Lawrence, Thomas/0000-0003-3648-7634	Royal College of Surgeons of England Research Fellowship; National Institute for Health Research (NIHR) Academic Clinical FellowshipNational Institute for Health Research (NIHR); Raymond and Beverly Sackler Studentship; NIHR Research Professorship; NIHR Cambridge Biomedical Research CentreNational Institute for Health Research (NIHR); National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-R3-12-013, 12/35/57, 13/15/02] Funding Source: researchfish	AGK is supported by a Royal College of Surgeons of England Research Fellowship, a National Institute for Health Research (NIHR) Academic Clinical Fellowship, and a Raymond and Beverly Sackler Studentship. PJH is supported by a NIHR Research Professorship and the NIHR Cambridge Biomedical Research Centre.	Altman DG, 2014, BMJ-BRIT MED J, V332, P16; Arifin MZ, 2013, J NEUROSURG SCI, V57, P277; Bullock AR, 2006, NEUROSURGERY, V58, pVI; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; DENT DL, 1995, J TRAUMA, V39, P36, DOI 10.1097/00005373-199507000-00005; Fuller G, 2011, BRIT J NEUROSURG, V25, P414, DOI 10.3109/02688697.2011.570882; Harrell Frank E., 2001, REGRESSION MODELING; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; Heraud-Bousquet V, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-73; Hutchinson PJ, 2014, BIOMED CENTRAL; Kalanithi P, 2011, J NEUROSURG, V115, P1013, DOI 10.3171/2011.6.JNS101989; Kolias AG, 2013, NAT REV NEUROL, V9, P405, DOI 10.1038/nrneurol.2013.106; KOTWICA Z, 1993, ACTA NEUROCHIR, V121, P95, DOI 10.1007/BF01809257; Lecky F, 2000, LANCET, V355, P1771, DOI 10.1016/S0140-6736(00)02264-9; Lecky FE, 2002, EMERG MED J, V19, P520, DOI 10.1136/emj.19.6.520; National Institute for Health and Care Excellence, 2014, HEAD INJ TRIAG ASS I; PHUENPATHOM N, 1993, SURG NEUROL, V40, P22, DOI 10.1016/0090-3019(93)90164-V; R Development Core Team, 2008, R LANGUAGE ENV STAT; Raj R, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-67; *ROYAL COLL SURG E, 1999, REP WORK PART MAN PA; Rubin DB., 1987, MULTIPLE IMPUTATION; Ruff LM, 2013, BRIT J NEUROSURG, V27, P19, DOI 10.3109/02688697.2012.709555; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Sergides IG, 2006, BRIT J NEUROSURG, V20, P301, DOI 10.1080/02688690600999976; TARN, 2006, TRAUM AUD RES NETW O; Tien HCN, 2011, ANN SURG, V253, P1178, DOI 10.1097/SLA.0b013e318217e339; Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.3.CO;2-I; Walcott BP, 2014, J CLIN NEUROSCI, V21, P2107, DOI 10.1016/j.jocn.2014.05.016; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Wilson MH, 2014, INT J CLIN PRACT, V68, P5, DOI 10.1111/ijcp.12246; YATES DW, 1990, BRIT MED J, V301, P1090, DOI 10.1136/bmj.301.6760.1090	34	24	24	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	MAR	2017	265	3					590	596		10.1097/SLA.0000000000001682			7	Surgery	Surgery	EL1ON	WOS:000394389800026	27172128	Green Accepted, Green Published			2021-06-18	
J	Lu, KT; Huang, TC; Tsai, YH; Yang, YL				Lu, Kwok-Tung; Huang, Tai-Chun; Tsai, Ya-Hsin; Yang, Yi-Ling			Transient receptor potential vanilloid type 4 channels mediate Na-K-Cl-co-transporter-induced brain edema after traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						brain edema; mitogen-activated protein kinases cascade; NKCC1; traumatic brain injury; TRPV4	CORTICAL IMPACT INJURY; PROTEIN-KINASE-C; CATION CHANNEL; ACTIVATE TRPV4; EXPRESSION; RATS; NEURONS; CYCLOOXYGENASE-2; DAMAGE; MODEL	Na+-K+-2Cl(-) co-transporter (NKCC1) plays an important role in traumatic brain injury (TBI)-induced brain edema via the MAPK cascade. The transient receptor potential vanilloid type 4 (TRPV4) channel participates in neurogenic inflammation, pain transmission, and edema. In this study, we investigated the relationship between NKCC1 and TRPV4 and the related signaling pathways in TBI-induced brain edema and neuronal damage. TBI was induced by the calibrated weight-drop device. Adult male Wistar rats were randomly assigned into sham and experimental groups for time-course studies of TRPV4 expression after TBI. Hippocampal TRPV4, NKCC1, MAPK, and PI-3K cascades were analyzed by western blot, and brain edema was also evaluated among the different groups. Expression of hippocampal TRPV4 peaked at 8h after TBI, and phosphorylation of the MAPK cascade and Akt was significantly elevated. Administration of either the TRPV4 antagonist, RN1734, or NKCC1 antagonist, bumetanide, significantly attenuated TBI-induced brain edema through decreasing the phosphorylation of MEK, ERK, and Akt proteins. Bumetanide injection inhibited TRPV4 expression, which suggests NKCC1 activation is critical to TRPV4 activation. Our results showed that hippocampal NKCC1 activation increased TRPV4 expression after TBI and then induced severe brain edema and neuronal damage through activation of the MAPK cascade and Akt-related signaling pathway.	[Lu, Kwok-Tung; Huang, Tai-Chun; Tsai, Ya-Hsin] Natl Taiwan Normal Univ, Dept Life Sci, Taipei, Taiwan; [Yang, Yi-Ling] Natl Chiayi Univ, Inst Biochem Sci & Technol, Chiayi, Taiwan	Yang, YL (corresponding author), Natl Chiayi Univ, Inst Biochem Sci & Technol, Chiayi, Taiwan.	ylyang@mail.ncyu.edu.tw			Ministry of Science and Technology (MOST), Taiwan	This study was supported by the Ministry of Science and Technology (MOST), Taiwan. There is no conflict of interest to declare.	Alessandri-Haber N, 2006, J NEUROSCI, V26, P3864, DOI 10.1523/JNEUROSCI.5385-05.2006; Alessandri-Haber N, 2003, NEURON, V39, P497, DOI 10.1016/S0896-6273(03)00462-8; Alexander R, 2013, BRIT J PHARMACOL, V168, P761, DOI 10.1111/j.1476-5381.2012.02186.x; AMANN R, 1990, EUR J PHARMACOL, V186, P169, DOI 10.1016/0014-2999(90)90430-E; Anderova M, 2011, J CEREBR BLOOD F MET, V31, P894, DOI 10.1038/jcbfm.2010.168; Bai JZ, 2010, NEUROTOXICOLOGY, V31, P204, DOI 10.1016/j.neuro.2010.01.001; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Benfenati V, 2007, NEUROSCIENCE, V148, P876, DOI 10.1016/j.neuroscience.2007.06.039; Benfenati V, 2011, P NATL ACAD SCI USA, V108, P2563, DOI 10.1073/pnas.1012867108; BULLOCK R, 1990, ACT NEUR S, V51, P286; Butenko O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039959; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Chao PK, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-121; Chung MK, 2003, J BIOL CHEM, V278, P32037, DOI 10.1074/jbc.M303251200; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429; Everaerts W, 2010, P NATL ACAD SCI USA, V107, P19084, DOI 10.1073/pnas.1005333107; Fichna J, 2012, NEUROGASTROENT MOTIL, V24, pe557, DOI 10.1111/j.1365-2982.2012.01999.x; Fu Y, 2006, AM J PHYSIOL-RENAL, V290, pF1305, DOI 10.1152/ajprenal.00391.2005; Gradilone SA, 2010, GASTROENTEROLOGY, V139, P304, DOI 10.1053/j.gastro.2010.04.010; Grunnet M, 2005, BBA-BIOMEMBRANES, V1714, P114, DOI 10.1016/j.bbamem.2005.05.012; Guilak F, 2010, ANN NY ACAD SCI, V1192, P404, DOI 10.1111/j.1749-6632.2010.05389.x; Kraus JF, 1996, OCCUP MED, V11, P201; Kunz T, 2002, J NEUROTRAUM, V19, P1051, DOI 10.1089/089771502760341965; Li L, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00017; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Lipski J, 2006, BRAIN RES, V1077, P187, DOI 10.1016/j.brainres.2006.01.016; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Lu KT, 2008, CRIT CARE MED, V36, P917, DOI 10.1097/CCM.0B013E31816590C4; Lu KT, 2007, NEUROL RES, V29, P404, DOI 10.1179/016164107X204738; Lu KT, 2015, PFLUG ARCH EUR J PHY, V467, P1651, DOI 10.1007/s00424-014-1588-x; Ma YY, 2008, BIOL PHARM BULL, V31, P426, DOI 10.1248/bpb.31.426; Mackrell PJ, 2001, SURGERY, V130, P826, DOI 10.1067/msy.2001.116669; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Murphy MP, 2012, NEUROREHABILITATION, V31, P85, DOI 10.3233/NRE-2012-0777; O'Donnell ME, 2006, J CEREBR BLOOD F MET, V26, P1234, DOI 10.1038/sj.jcbfm.9600278; Panet R, 2006, J CELL PHYSIOL, V206, P578, DOI 10.1002/jcp.20506; Payne JA, 2003, TRENDS NEUROSCI, V26, P199, DOI 10.1016/S0166-2236(03)00068-7; Reiter B, 2006, FASEB J, V20, P1802, DOI 10.1096/fj.06-5772com; Shibasaki K, 2007, J NEUROSCI, V27, P1566, DOI 10.1523/JNEUROSCI.4284-06.2007; Stroop R, 1998, ACT NEUR S, V71, P303; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Strotmann R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010580; Tian W, 2004, AM J PHYSIOL-RENAL, V287, pF17, DOI 10.1152/ajprenal.00397.2003; Unterberg AW, 1997, ACT NEUR S, V70, P106; Vriens J, 2004, P NATL ACAD SCI USA, V101, P396, DOI 10.1073/pnas.0303329101; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Weiss B, 1997, NEUROCHEM INT, V31, P321, DOI 10.1016/S0197-0186(96)00105-2; Yan ZP, 2004, CELL IMMUNOL, V232, P116, DOI 10.1016/j.cellimm.2005.03.001	49	24	24	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAR	2017	140	5					718	727		10.1111/jnc.13920			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	EM8OX	WOS:000395571900004	27926982	Bronze			2021-06-18	
J	Abdallah, CG; Wrocklage, KM; Averill, CL; Akiki, T; Schweinsburg, B; Roy, A; Martini, B; Southwick, SM; Krystal, JH; Scott, JC				Abdallah, C. G.; Wrocklage, K. M.; Averill, C. L.; Akiki, T.; Schweinsburg, B.; Roy, A.; Martini, B.; Southwick, S. M.; Krystal, J. H.; Scott, J. C.			Anterior hippocampal dysconnectivity in posttraumatic stress disorder: a dimensional and multimodal approach	TRANSLATIONAL PSYCHIATRY			English	Article							ADMINISTERED PTSD SCALE; FUNCTIONAL CONNECTIVITY; BRAIN NETWORKS; PREFRONTAL CORTEX; SCHIZOPHRENIA; MODEL; NEUROBIOLOGY; METAANALYSIS; KETAMINE; ANXIETY	The anterior hippocampus (aHPC) has a central role in the regulation of anxiety-related behavior, stress response, emotional memory and fear. However, little is known about the presence and extent of aHPC abnormalities in posttraumatic stress disorder (PTSD). In this study, we used a multimodal approach, along with graph-based measures of global brain connectivity (GBC) termed functional GBC with global signal regression (f-GBCr) and diffusion GBC (d-GBC), in combat-exposed US Veterans with and without PTSD. Seed-based aHPC anatomical connectivity analyses were also performed. A whole-brain voxel-wise data-driven investigation revealed a significant association between elevated PTSD symptoms and reduced medial temporal f-GBCr, particularly in the aHPC. Similarly, aHPC d-GBC negatively correlated with PTSD severity. Both functional and anatomical aHPC dysconnectivity measures remained significant after controlling for hippocampal volume, age, gender, intelligence, education, combat severity, depression, anxiety, medication status, traumatic brain injury and alcohol/substance comorbidities. Depression-like PTSD dimensions were associated with reduced connectivity in the ventromedial and dorsolateral prefrontal cortex. In contrast, hyperarousal symptoms were positively correlated with ventromedial and dorsolateral prefrontal connectivity. We believe the findings provide first evidence of functional and anatomical dysconnectivity in the aHPC of veterans with high PTSD symptomatology. The data support the putative utility of aHPC connectivity as a measure of overall PTSD severity. Moreover, prefrontal global connectivity may be of clinical value as a brain biomarker to potentially distinguish between PTSD subgroups.	[Abdallah, C. G.; Wrocklage, K. M.; Averill, C. L.; Akiki, T.; Schweinsburg, B.; Roy, A.; Martini, B.; Southwick, S. M.; Krystal, J. H.] US Dept Vet Affairs, Clin Neurosci Div, VA Natl Ctr PTSD, West Haven, CT 06516 USA; [Abdallah, C. G.; Wrocklage, K. M.; Averill, C. L.; Akiki, T.; Schweinsburg, B.; Roy, A.; Martini, B.; Southwick, S. M.; Krystal, J. H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; [Scott, J. C.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA; [Scott, J. C.] Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN4, Philadelphia, PA USA	Abdallah, CG (corresponding author), US Dept Vet Affairs, Clin Neurosci Div, VA Natl Ctr PTSD, West Haven, CT 06516 USA.; Abdallah, CG (corresponding author), Yale Univ, Sch Med, Dept Psychiat, 950 Campbell Ave,151E, West Haven, CT 06516 USA.	chadi.abdallah@yale.edu	Averill, Christopher L./R-4036-2019; Akiki, Teddy J./D-4502-2019; Abdallah, Chadi/M-9969-2017	Averill, Christopher L./0000-0001-7575-6142; Akiki, Teddy J./0000-0003-1988-9201; Abdallah, Chadi/0000-0001-5783-6181; Scott, J. Cobb/0000-0001-6538-9043	U.S. Department of Veterans Affairs National Center for PTSD and NIH [MH-101498]; Department of Veterans Affairs Career Development AwardUS Department of Veterans Affairs [IK2CX000772]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH101498] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [IK2CX000772] Funding Source: NIH RePORTER	The authors thank the Veterans who participated in this study for their invaluable contribution. Funding support was provided by the U.S. Department of Veterans Affairs National Center for PTSD and NIH (MH-101498). Dr. Scott's participation was supported by a Department of Veterans Affairs Career Development Award (IK2CX000772). The content is solely the responsibility of the authors and does not necessarily represent the official views of the sponsors. The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.	Abdallah CG, 2017, NEUROPSYCHOPHARMACOL, V42, P1210, DOI 10.1038/npp.2016.186; Abdallah CG, 2015, ANNU REV MED, V66, P509, DOI 10.1146/annurev-med-053013-062946; Abdallah CG, 2012, NEUROSCI LETT, V530, P103, DOI 10.1016/j.neulet.2012.09.054; Admon R, 2013, TRENDS COGN SCI, V17, P337, DOI 10.1016/j.tics.2013.05.005; Anticevic A, 2015, BIOL PSYCHIAT, V77, P569, DOI 10.1016/j.biopsych.2014.07.022; Anticevic A, 2014, BIOL PSYCHIAT, V75, P595, DOI 10.1016/j.biopsych.2013.10.021; Anticevic A, 2013, BIOL PSYCHIAT, V73, P565, DOI 10.1016/j.biopsych.2012.07.031; Beck A.T., 1990, MANUAL BECK ANXIETY; Beck AT, 1996, MANUAL BECK DEPRESSI, V1, P82; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bonne O, 2008, J CLIN PSYCHIAT, V69, P1087, DOI 10.4088/JCP.v69n0707; Brown VM, 2014, NEUROPSYCHOPHARMACOL, V39, P351, DOI 10.1038/npp.2013.197; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Chen AC, 2013, NEUROPSYCHOPHARMACOL, V38, P1889, DOI 10.1038/npp.2013.122; Chowdhury GMI, 2017, MOL PSYCHIATR, V22, P120, DOI 10.1038/mp.2016.34; Cole MW, 2012, J NEUROSCI, V32, P8988, DOI 10.1523/JNEUROSCI.0536-12.2012; Cole MW, 2011, BIOL PSYCHIAT, V70, P43, DOI 10.1016/j.biopsych.2011.02.010; Coplan JD, 2016, J AFFECT DISORDERS, V192, P167, DOI 10.1016/j.jad.2015.11.049; Driesen NR, 2013, MOL PSYCHIATR, V18, P1199, DOI 10.1038/mp.2012.194; Driesen NR, 2013, NEUROPSYCHOPHARMACOL, V38, P2613, DOI 10.1038/npp.2013.170; Eklund A, 2016, P NATL ACAD SCI USA, V113, P7900, DOI 10.1073/pnas.1602413113; Fanselow MS, 2010, NEURON, V65, P7, DOI 10.1016/j.neuron.2009.11.031; First MB., 2002, STRUCTURED CLIN INTE; Gilbertson MW, 2002, NAT NEUROSCI, V5, P1242, DOI 10.1038/nn958; Hirshhorn M, 2012, NEUROPSYCHOLOGIA, V50, P3094, DOI 10.1016/j.neuropsychologia.2012.08.008; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Keane T.M., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI DOI 10.1037/1040-3590.1.1.53; Kennis M, 2015, HUM BRAIN MAPP, V36, P99, DOI 10.1002/hbm.22615; Kheirbek MA, 2013, NEURON, V77, P955, DOI 10.1016/j.neuron.2012.12.038; King DW, 1998, PSYCHOL ASSESSMENT, V10, P90, DOI 10.1037/1040-3590.10.2.90; Koch SBJ, 2016, DEPRESS ANXIETY, V33, P592, DOI 10.1002/da.22478; Kuhn S, 2013, BIOL PSYCHIAT, V73, P70, DOI 10.1016/j.biopsych.2012.06.029; Lanius RA, 2015, EUR J PSYCHOTRAUMATO, V6, DOI 10.3402/ejpt.v6.27313; Liang X, 2013, P NATL ACAD SCI USA, V110, P1929, DOI 10.1073/pnas.1214900110; Liberzon I, 2016, NEURON, V92, P14, DOI 10.1016/j.neuron.2016.09.039; Liberzon I, 2007, PROG BRAIN RES, V167, P151, DOI 10.1016/S0079-6123(07)67011-3; McEwen BS, 2015, NAT NEUROSCI, V18, P1353, DOI 10.1038/nn.4086; Milad MR, 2012, ANNU REV PSYCHOL, V63, P129, DOI 10.1146/annurev.psych.121208.131631; Moser MB, 1998, HIPPOCAMPUS, V8, P608, DOI 10.1002/(SICI)1098-1063(1998)8:6<608::AID-HIPO3>3.0.CO;2-7; Murphy K, 2009, NEUROIMAGE, V44, P893, DOI 10.1016/j.neuroimage.2008.09.036; Murrough JW, 2016, HUM BRAIN MAPP, V37, P3214, DOI 10.1002/hbm.23235; O'Doherty DCM, 2015, PSYCHIAT RES-NEUROIM, V232, P1, DOI 10.1016/j.pscychresns.2015.01.002; Pitman RK, 2012, NAT REV NEUROSCI, V13, P769, DOI 10.1038/nrn3339; Popoli M, 2012, NAT REV NEUROSCI, V13, P22, DOI 10.1038/nrn3138; Sripada RK, 2012, PSYCHOSOM MED, V74, P904, DOI 10.1097/PSY.0b013e318273bf33; Sripada RK, 2012, J PSYCHIATR NEUROSCI, V37, P241, DOI 10.1503/jpn.110069; Strange BA, 2014, NAT REV NEUROSCI, V15, P655, DOI 10.1038/nrn3785; Thomaes K, 2014, J PSYCHIATR RES, V50, P1, DOI 10.1016/j.jpsychires.2013.11.002; Vythilingam M, 2005, PSYCHIAT RES-NEUROIM, V139, P89, DOI 10.1016/j.pscychresns.2005.04.003; Wechsler D., 2001, WECHSLER TEST ADULT; Yendiki Anastasia, 2011, Front Neuroinform, V5, P23, DOI 10.3389/fninf.2011.00023	52	24	24	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	2158-3188			TRANSL PSYCHIAT	Transl. Psychiatr.	FEB 28	2017	7								e1045	10.1038/tp.2017.12			7	Psychiatry	Psychiatry	EP2LT	WOS:000397215300002	28244983	DOAJ Gold, Green Published			2021-06-18	
J	Cen, LP; Liang, JJ; Chen, JH; Harvey, AR; Ng, TK; Zhang, MZ; Pang, CP; Cui, Q; Fan, YM				Cen, Ling-Ping; Liang, Jia-Jian; Chen, Jian-Huan; Harvey, Alan R.; Ng, Tsz Kin; Zhang, Mingzhi; Pang, Chi Pui; Cui, Qi; Fan, You-Ming			AAV-MEDIATED TRANSFER OF RhoA shRNA AND CNTF PROMOTES RETINAL GANGLION CELL SURVIVAL AND AXON REGENERATION	NEUROSCIENCE			English	Article						CNTF; retina; ganglion cell; RhoA; RNAi; nerve; regeneration	CILIARY NEUROTROPHIC FACTOR; OPTIC-NERVE REGENERATION; MYELIN-ASSOCIATED GLYCOPROTEIN; ADENOASSOCIATED VIRAL VECTORS; ADULT-RATS; IN-VIVO; NEURITE GROWTH; NOGO RECEPTOR; GENE-THERAPY; CYCLIC-AMP	The aim of the present study was to determine whether adeno-associated viral vector (AAV) mediated transfer of ciliary neurotrophic factor (CNTF) and RhoA shRNA has additive effects on promoting the survival and axon regeneration of retinal ganglion cells (RGCs) after optic nerve crush (ONC). Silencing effects of AAV-RhoA shRNA were confirmed by examining neurite outgrowth in PC12 cells, and by quantifying RhoA expression levels with western blotting. Young adult Fischer rats received an intravitreal injection of (i) saline, (ii) AAV green fluorescent protein (GFP), (iii) AAV-CNTF, (iv) AAV-RhoA shRNA, or (v) a combination of both AAV-CNTF and AAV-RhoA shRNA. Two weeks later, the ON was completely crushed. Three weeks after ONC, RGC survival was estimated by counting beta III-tubulin-positive neurons in retinal whole mounts. Axon regeneration was evaluated by counting GAP-43-positive axons in the crushed ON. It was found that AAV-RhoA shRNA decreased RhoA expression levels and promoted neurite outgrowth in vitro. In the ONC model, AAV-RhoA shRNA by itself had only weak beneficial effects on RGC axon regeneration. However, when combined with AAV-CNTF, AAV-RhoA shRNA significantly improved the therapeutic effect of AAV-CNTF on axon regeneration by nearly two fold, even though there was no significant change in RGC viability. In sum, this combination of vectors increases the regenerative response and can lead to more successful therapeutic outcomes following neurotrauma. (C) 2016 IBRO. Published by Elsevier Ltd. All rights reserved.	[Cen, Ling-Ping; Liang, Jia-Jian; Chen, Jian-Huan; Zhang, Mingzhi; Pang, Chi Pui; Cui, Qi; Fan, You-Ming] Shantou Univ, Joint Shantou Int Eye Ctr, Shantou, Peoples R China; [Cen, Ling-Ping; Liang, Jia-Jian; Chen, Jian-Huan; Zhang, Mingzhi; Pang, Chi Pui; Cui, Qi; Fan, You-Ming] Chinese Univ Hong Kong, Shantou, Peoples R China; [Ng, Tsz Kin; Pang, Chi Pui; Cui, Qi] Chinese Univ Hong Kong, Fac Med, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China; [Harvey, Alan R.] Univ Western Australia, Sch Anat Physiol & Human Biol, Crawley, WA, Australia; [Fan, You-Ming] Hubei Univ Nationalities, Dept Neurol, Affiliated Hosp, Enshi, Peoples R China	Cen, LP (corresponding author), Shantou Univ, Joint Shantou Int Eye Ctr, Shantou, Peoples R China.; Cen, LP (corresponding author), Chinese Univ Hong Kong, Shantou, Peoples R China.	cenlp@hotmail.com; youmingf@aliyun.com	Ng, Tsz Kin/I-8061-2014; Cen Ling-Ping, Cen Lingping/O-4216-2015	Ng, Tsz Kin/0000-0001-7863-7229; Cen Ling-Ping, Cen Lingping/0000-0003-3876-0606; , Alan/0000-0002-2590-831X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81570849, 30672038]; Research Fund for Doctoral Program of Higher Education of ChinaResearch Fund for the Doctoral Program of Higher Education of China (RFDP) [20114402120007]; Natural Science Foundation of Guangdong Province, ChinaNational Natural Science Foundation of Guangdong Province [2015A030313446]; Joint Shantou International Eye Center of The Shantou University; Chinese University of Hong KongChinese University of Hong Kong [09-017]	This work is supported by the National Natural Science Foundation of China (81570849, 30672038), Research Fund for Doctoral Program of Higher Education of China (20114402120007), Natural Science Foundation of Guangdong Province, China (2015A030313446), and an internal grant from the Joint Shantou International Eye Center of The Shantou University and The Chinese University of Hong Kong (09-017).	Asher R A, 2001, Prog Brain Res, V132, P611; Atwal JK, 2008, SCIENCE, V322, P967, DOI 10.1126/science.1161151; BENOWITZ LI, 1988, J NEUROSCI, V8, P339; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Bertrand J, 2005, J NEUROSCI, V25, P1113, DOI 10.1523/JNEUROSCI.3931-04.2005; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Cheng L, 2002, J NEUROSCI, V22, P3977, DOI 10.1523/JNEUROSCI.22-10-03977.2002; Cui Q, 2003, MOL CELL NEUROSCI, V22, P49, DOI 10.1016/S1044-7431(02)00037-4; Cui Q, 1999, INVEST OPHTH VIS SCI, V40, P760; Cui Qi, 2004, Anatomical Science International, V79, P209, DOI 10.1111/j.1447-073x.2004.00089.x; de Lima S, 2012, INT REV NEUROBIOL, V106, P153, DOI 10.1016/B978-0-12-407178-0.00007-7; Dergham P, 2002, J NEUROSCI, V22, P6570; Drummond ES, 2014, RESTOR NEUROL NEUROS, V32, P391, DOI 10.3233/RNN-130360; Fan YM, 2008, NEUROSCI LETT, V440, P170, DOI 10.1016/j.neulet.2008.05.045; Fischer D, 2000, INVEST OPHTH VIS SCI, V41, P3943; Fischer D, 2004, J NEUROSCI, V24, P1646, DOI 10.1523/JNEUROSCI.5119-03.2004; Fischer D, 2004, J NEUROSCI, V24, P8726, DOI 10.1523/JNEUROSCI.2774-04.2004; Fischer D, 2001, EXP NEUROL, V172, P257, DOI 10.1006/exnr.2001.7822; Fournier AE, 2003, J NEUROSCI, V23, P1416; Fujita Y, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.85; Fujita Y, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00338; Fujita Y, 2011, EMBO J, V30, P1389, DOI 10.1038/emboj.2011.55; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Guo X, 2016, ELIFE, V5; Harvey AR, 2006, PROG RETIN EYE RES, V25, P449, DOI 10.1016/j.preteyeres.2006.07.002; Harvey AR, 2012, INT REV NEUROBIOL, V106, P1, DOI 10.1016/B978-0-12-407178-0.00002-8; Harvey AR, 2002, MOL CELL NEUROSCI, V21, P141, DOI 10.1006/mcne.2002.1168; Hellstrom M, 2011, MOL CELL NEUROSCI, V46, P507, DOI 10.1016/j.mcn.2010.12.003; Hellstrom M, 2014, INT J BIOCHEM CELL B, V56, P66, DOI 10.1016/j.biocel.2014.04.018; Hellstrom M, 2011, J NEUROTRAUM, V28, P2475, DOI 10.1089/neu.2011.1928; Hellstrom M, 2011, CURR GENE THER, V11, P116, DOI 10.2174/156652311794940746; Hermens WTJMC, 1998, PROG NEUROBIOL, V55, P399, DOI 10.1016/S0301-0082(98)00007-0; Heskamp A, 2013, NEUROBIOL DIS, V55, P76, DOI 10.1016/j.nbd.2013.04.001; Hoffmann A, 2008, GLIA, V56, P1162, DOI 10.1002/glia.20687; Hu Y, 2005, MOL THER, V11, P906, DOI 10.1016/j.ymthe.2005.01.016; Hu Y, 2007, MOL CELL NEUROSCI, V34, P88, DOI 10.1016/j.mcn.2006.10.005; Israelsson C, 2014, RESTOR NEUROL NEUROS, V32, P717, DOI 10.3233/RNN-140419; Just I, 2011, N-S ARCH PHARMACOL, V383, P247, DOI 10.1007/s00210-010-0589-3; Koch JC, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00273; Leaver SG, 2006, GENE THER, V13, P1328, DOI 10.1038/sj.gt.3302791; Leaver SG, 2006, EUR J NEUROSCI, V24, P3323, DOI 10.1111/j.1460-9568.2006.05230.x; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Leon S, 2000, J NEUROSCI, V20, P4615, DOI 10.1523/JNEUROSCI.20-12-04615.2000; Lingor P, 2008, BRAIN, V131, P250, DOI 10.1093/brain/awm284; Loucks FA, 2006, J NEUROCHEM, V97, P957, DOI 10.1111/j.1471-4159.2006.03802.x; MALORNI W, 1991, TOXICON, V29, P417, DOI 10.1016/0041-0101(91)90016-K; Martin KRG, 2002, METHODS, V28, P267, DOI 10.1016/S1046-2023(02)00232-3; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; MEY J, 1993, BRAIN RES, V602, P304, DOI 10.1016/0006-8993(93)90695-J; Muller A, 2009, MOL CELL NEUROSCI, V41, P233, DOI 10.1016/j.mcn.2009.03.002; Niederost B, 2002, J NEUROSCI, V22, P10368; Park K, 2004, J NEUROSCI, V24, P10806, DOI 10.1523/JNEUROSCI.3532-04.2004; Park KK, 2009, MOL CELL NEUROSCI, V41, P313, DOI 10.1016/j.mcn.2009.04.002; PeinadoRamon P, 1996, INVEST OPHTH VIS SCI, V37, P489; Sharma A, 2012, INVEST OPHTH VIS SCI, V53, P8367, DOI 10.1167/iovs.12-10799; Sharma B, 2014, INT OPHTHALMOL, V34, P893, DOI 10.1007/s10792-014-9898-8; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Xu R, 2001, GENE THER, V8, P1323, DOI 10.1038/sj.gt.3301529; Yavas GF, 2007, EUR J OPHTHALMOL, V17, P812; Yin YQ, 2003, J NEUROSCI, V23, P2284; Yin YQ, 2006, NAT NEUROSCI, V9, P843, DOI 10.1038/nn1701; You SW, 2016, EXP NEUROL, V279, P197, DOI 10.1016/j.expneurol.2016.03.006; Yungher BJ, 2015, GENE THER, V22, P811, DOI 10.1038/gt.2015.51; Zheng BH, 2005, P NATL ACAD SCI USA, V102, P1205, DOI 10.1073/pnas.0409026102; Zheng BH, 2003, NEURON, V38, P213, DOI 10.1016/S0896-6273(03)00225-3	66	24	26	0	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	FEB 20	2017	343						472	482		10.1016/j.neuroscience.2016.12.027			11	Neurosciences	Neurosciences & Neurology	EJ5PB	WOS:000393269100044	28017835				2021-06-18	
J	Krolikowski, MP; Black, AM; Palacios-Derflingher, L; Blake, TA; Schneider, KJ; Emery, CA				Krolikowski, Maciej P.; Black, Amanda M.; Palacios-Derflingher, Luz; Blake, Tracy A.; Schneider, Kathryn J.; Emery, Carolyn A.			The Effect of the "Zero Tolerance for Head Contact" Rule Change on the Risk of Concussions in Youth Ice Hockey Players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; child and adolescent; ice hockey; injury prevention	SPORT-RELATED CONCUSSION; BODY-CHECKING; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; RATES; INJURIES; EPIDEMIOLOGY; MANAGEMENT; EMERGENCY; FOOTBALL	Background: Ice hockey is a popular winter sport in Canada. Concussions account for the greatest proportion of all injuries in youth ice hockey. In 2011, a policy change enforcing zero tolerance for head contact was implemented in all leagues in Canada. Purpose: To determine if the risk of game-related concussions and more severe concussions (ie, resulting in >10 days of time loss) and the mechanisms of a concussion differed for Pee Wee class (ages 11-12 years) and Bantam class (ages 13-14 years) players after the 2011 zero tolerance for head contact policy change compared with players in similar divisions before the policy change. Study Design: Cohort study; Level of evidence, 3. Methods: The retrospective cohort included Pee Wee (most elite 70%, 2007-2008; n = 891) and Bantam (most elite 30%, 2008-2009; n = 378) players before the rule change and Pee Wee (2011-2012; n = 588) and Bantam (2011-2012; n = 242) players in the same levels of play after the policy change. Suspected concussions were identified by a team designate and referred to a sport medicine physician for diagnosis. Incidence rate ratios (IRRs) were estimated based on multiple Poisson regression analysis, controlling for clustering by team and other important covariates and offset by game-exposure hours. Incidence rates based on the mechanisms of a concussion were estimated based on univariate Poisson regression analysis. Results: The risk of game-related concussions increased after the head contact rule in Pee Wee (IRR, 1.85; 95% CI, 1.20-2.86) and Bantam (IRR, 2.48; 95% CI, 1.17-5.24) players. The risk of more severe concussions increased after the head contact rule in Pee Wee (IRR, 4.12; 95% CI, 2.00-8.50) and Bantam (IRR, 7.91; 95% CI, 3.13-19.94) players. The rates of concussions due to body checking and direct head contact increased after the rule change. Conclusion: The zero tolerance for head contact policy change did not reduce the risk of game-related concussions in Pee Wee or Bantam class ice hockey players. Increased concussion awareness and education after the policy change may have contributed to the increased risk of concussions found after the policy change.	[Krolikowski, Maciej P.; Black, Amanda M.; Palacios-Derflingher, Luz; Blake, Tracy A.; Schneider, Kathryn J.; Emery, Carolyn A.] Univ Calgary, Calgary, AB, Canada; [Krolikowski, Maciej P.; Black, Amanda M.; Palacios-Derflingher, Luz; Blake, Tracy A.; Schneider, Kathryn J.; Emery, Carolyn A.] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada; [Black, Amanda M.; Schneider, Kathryn J.] Alberta Childrens Prov Gen Hosp, Res Inst, Calgary, AB, Canada; [Black, Amanda M.; Schneider, Kathryn J.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada; [Palacios-Derflingher, Luz; Emery, Carolyn A.] Univ Calgary, Cumming Sch Med, Community Hlth Sci, Calgary, AB, Canada; [Emery, Carolyn A.] Univ Calgary, Dept Paediat, Calgary, AB, Canada	Krolikowski, MP (corresponding author), Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	mkrolikowski9@gmail.com	Emery, Carolyn/AAI-2761-2020; Black, Amanda/O-7675-2017	Black, Amanda/0000-0001-5668-9706; Schneider, Kathryn/0000-0002-5951-5899	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Alberta Children's Hospital Research Institute (ACHRI) for Child and Maternal Health; Max Bell Foundation; Undergraduate Student Research Program; Alberta Innovates: Health Solutions Summer Studentship; ACHRI's Scholars Training Program and Talisman Energy Fund in Support of Healthy Living and Injury Prevention; CIHR's Frederick Banting and Charles Best Canada Graduate Scholarship; Hotchkiss Brain Institute's Dr. T. Chen Fong Doctoral Scholarship in Neuroscience; Alberta Children's Hospital Foundation; Canadian Foundation for Innovation's John R. Evans Leaders Fund; Alberta Children's Hospital Foundation Chair in Pediatric Rehabilitation; Alberta Innovates [201201160] Funding Source: researchfish	This study was funded by the Canadian Institutes of Health Research (CIHR), the Alberta Children's Hospital Research Institute (ACHRI) for Child and Maternal Health, and the Max Bell Foundation. M.P.K. is supported by the Undergraduate Student Research Program, an Alberta Innovates: Health Solutions Summer Studentship, the ACHRI's Scholars Training Program and Talisman Energy Fund in Support of Healthy Living and Injury Prevention, and a CIHR's Frederick Banting and Charles Best Canada Graduate Scholarship. A.M.B. is supported by a Hotchkiss Brain Institute's Dr. T. Chen Fong Doctoral Scholarship in Neuroscience. K.J.S. is supported by the Alberta Children's Hospital Foundation and the Canadian Foundation for Innovation's John R. Evans Leaders Fund. C.A.E. is supported by an Alberta Children's Hospital Foundation Chair in Pediatric Rehabilitation.	Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Bjorneboe J, 2013, BRIT J SPORT MED, V47, P508, DOI 10.1136/bjsports-2012-091522; Black AM, 2016, BRIT J SPORT MED, V50, P55, DOI 10.1136/bjsports-2015-095103; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Cusimano Michael D, 2011, Open Med, V5, pe57; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Donaldson L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069122; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Emery C, 2011, CAN MED ASSOC J, V183, P1249, DOI 10.1503/cmaj.101540; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Fuller CW, 2004, AM J SPORT MED, V32, p17S, DOI 10.1177/0363546503261249; Gordon KE, 2014, BRAIN INJURY, V28, P311, DOI 10.3109/02699052.2013.862740; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Hockey Canada, 2013, HOCK CAN ANN REP; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Macpherson A, 2006, PEDIATRICS, V117, pE143, DOI 10.1542/peds.2005-1163; Malenfant S, 2012, J SCI MED SPORT, V15, P463, DOI 10.1016/j.jsams.2012.03.003; Marchie A, 2003, CAN MED ASSOC J, V169, P124; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Mihalik JP, 2010, MED SCI SPORT EXER, V42, P1431, DOI 10.1249/MSS.0b013e3181d2521a; Pleacher MD, 2006, BRIT J SPORT MED, V40, DOI 10.1136/bjsm.2005.019067; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Roberts WO, 1999, MED SCI SPORT EXER, V31, P46, DOI 10.1097/00005768-199901000-00009; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091	29	24	24	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	FEB	2017	45	2					468	473		10.1177/0363546516669701			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	EL7BU	WOS:000394776900027	27789471				2021-06-18	
J	Roberts, SP; Trewartha, G; England, M; Goodison, W; Stokes, KA				Roberts, Simon P.; Trewartha, Grant; England, Michael; Goodison, William; Stokes, Keith A.			Concussions and Head Injuries in English Community Rugby Union Match Play	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						rugby union; concussion; injury; epidemiology	PERFORMANCE PROJECT; CONSENSUS STATEMENT; EPIDEMIOLOGY; METAANALYSIS; COHORT; RISK	Background: Previous research has described general injury patterns in community-level rugby union, but specific information on time-loss head injuries has not been reported. Purpose: To establish the incidence and nature of significant time-loss head injuries in English community rugby match play, and to identify the injury risk for specific contact events. Study Design: Descriptive epidemiology study. Methods: Over 6 seasons, injury information was collected from 46 (2009-2010), 67 (2010-2011), 76 (2011-2012), 50 (2012-2013), 67 (2013-2014), and 58 (2014-2015) English community rugby clubs (Rugby Football Union levels 3-9) over a total of 175,940 hours of player match exposure. Club injury management staff reported information for all head injuries sustained during match play whereby the player was absent for 8 days or greater. Clubs were subdivided into semiprofessional (mean player age, 24.6 4.7 years), amateur (24.9 5.1 years), and recreational (25.6 +/- 6.1 years) playing levels. Contact events from a sample of 30 matches filmed over seasons 2009-2010, 2010-2011, and 2011-2012 provided mean values for the frequency of contact events. Results: The overall incidence for time-loss head injuries was 2.43 injuries per 1000 player match hours, with a higher incidence for the amateur (2.78; 95% CI, 2.37-3.20) compared with recreational (2.20; 95% CI, 1.86-2.53) (P = .032) playing level but not different to the semiprofessional (2.31; 95% CI, 1.83-2.79) playing level. Concussion was the most common time-loss head injury, with 1.46 per 1000 player match hours. The tackle event was associated with 64% of all head injuries and 74% of all concussions. There was also a higher risk of injuries per tackle (0.33 per 1000 events; 95% CI, 0.30-0.37) compared with all other contact events. Conclusion: Concussion was the most common head injury diagnosis, although it is likely that this injury was underreported. Continuing education programs for medical staff and players are essential for the improved identification and management of these injuries. With the majority of head injuries occurring during a tackle, an improved technique in this contact event through coach and player education may be effective in reducing these injuries.	[Roberts, Simon P.; Trewartha, Grant; England, Michael; Goodison, William; Stokes, Keith A.] Univ Bath, Bath, Avon, England; [Roberts, Simon P.; Trewartha, Grant; Stokes, Keith A.] Univ Bath, Dept Hlth, 1 West 4-112, Bath BA2 7AY, Avon, England; [England, Michael] Rugby Football Union, Twickenham, England; [Goodison, William] Royal Natl Orthopaed Hosp, Stanmore, Middx, England	Roberts, SP (corresponding author), Univ Bath, Dept Hlth, 1 West 4-112, Bath BA2 7AY, Avon, England.	s.p.roberts@bath.ac.uk	Stokes, Keith/C-2605-2009	Stokes, Keith/0000-0002-5049-2838	RFU Injured Players Foundation	The study was funded by a grant from the RFU Injured Players Foundation in which S.P.R., G.T., and K.A.S. are investigators.	Bathgate A, 2002, BRIT J SPORT MED, V36, P265, DOI 10.1136/bjsm.36.4.265; Best JP, 2005, BRIT J SPORT MED, V39, P812, DOI 10.1136/bjsm.2004.016402; Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Cross M, 2016, BRIT J SPORT MED, V50, P926, DOI 10.1136/bjsports-2015-094982; Fraas MR, 2014, PHYS THER SPORT, V15, P136, DOI 10.1016/j.ptsp.2013.08.002; Fuller CW, 2008, BRIT J SPORT MED, V42, P452, DOI 10.1136/bjsm.2008.047035; Fuller CW, 2007, CLIN J SPORT MED, V17, P177, DOI 10.1097/JSM.0b013e31803220b3; Fuller CW, 2007, BRIT J SPORT MED, V41, P862, DOI 10.1136/bjsm.2007.037499; Fuller CW, 2010, BRIT J SPORT MED, V44, P159, DOI 10.1136/bjsm.2008.050864; Gardner AJ, 2014, SPORTS MED, V44, P1717, DOI 10.1007/s40279-014-0233-3; Hollis SJ, 2012, BRIT J SPORT MED, V46, P735, DOI 10.1136/bjsm.2011.085332; Hollis SJ, 2009, AM J SPORT MED, V37, P2328, DOI 10.1177/0363546509341032; Holtzhausen LJ, 2006, SAMJ S AFR MED J, V96, P1260; Kemp S, ENGLAND PROFESSIONAL; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; Kerr HA, 2008, BRIT J SPORT MED, V42, P595, DOI 10.1136/bjsm.2007.035881; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; Mcintosh AS, 2010, MED SCI SPORT EXER, V42, P977, DOI 10.1249/MSS.0b013e3181c07b5b; McIntosh AS, 2008, RUGBY UNION INJURY S; Quarrie KL, 2001, BRIT J SPORT MED, V35, P157, DOI 10.1136/bjsm.35.3.157; Rae K, 2007, CLIN J SPORT MED, V17, P201, DOI 10.1097/JSM.0b013e318059b536; Roberts SP, 2008, J SPORT SCI, V26, P825, DOI 10.1080/02640410801942122; Roberts SP, 2014, ORTHOP J SPORTS MED, V2, DOI 10.1177/2325967114562781; Roberts SP, 2015, BRIT J SPORT MED, V49, P536, DOI 10.1136/bjsports-2013-092988; Roberts SP, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003998; Rugby Football Union, CONC HEADC; Schneiders AG, 2009, PHYS THER SPORT, V10, P85, DOI 10.1016/j.ptsp.2009.05.001; Williams S, 2013, SPORTS MED, V43, P1043, DOI 10.1007/s40279-013-0078-1; World Rugby, CONC GUID	30	24	24	0	11	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	FEB	2017	45	2					480	487		10.1177/0363546516668296			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	EL7BU	WOS:000394776900029	28146395	Green Accepted			2021-06-18	
J	Duclos, C; Dumont, M; Arbour, C; Paquet, J; Blais, H; Menon, DK; De Beaumont, L; Bernard, F; Gosselin, N				Duclos, Catherine; Dumont, Marie; Arbour, Caroline; Paquet, Jean; Blais, Helene; Menon, David K.; De Beaumont, Louis; Bernard, Francis; Gosselin, Nadia			Parallel recovery of consciousness and sleep in acute traumatic brain injury	NEUROLOGY			English	Article							WAKE DISTURBANCES; ACTIGRAPHY; PLASTICITY; COMA; POLYSOMNOGRAPHY; CLASSIFICATION; WAKEFULNESS; DEFINITION; DISRUPTION; MEMORY	Objective: To investigate whether the progressive recuperation of consciousness was associated with the reconsolidation of sleep and wake states in hospitalized patients with acute traumatic brain injury (TBI). Methods: This study comprised 30 hospitalized patients (age 29.1 +/- 6 13.5 years) in the acute phase of moderate or severe TBI. Testing started 21.0 +/- 6 13.7 days postinjury. Consciousness level and cognitive functioning were assessed daily with the Rancho Los Amigos scale of cognitive functioning (RLA). Sleep and wake cycle characteristics were estimated with continuous wrist actigraphy. Mixed model analyses were performed on 233 days with the RLA (fixed effect) and sleep-wake variables (random effects). Linear contrast analyses were performed in order to verify if consolidation of the sleep and wake states improved linearly with increasing RLA score. Results: Associations were found between scores on the consciousness/cognitive functioning scale and measures of sleep-wake cycle consolidation (p < 0.001), nighttime sleep duration (p = 0.018), and nighttime fragmentation index (p < 0.001). These associations showed strong linear relationships (p, 0.01 for all), revealing that consciousness and cognition improved in parallel with sleep-wake quality. Consolidated 24-hour sleep-wake cycle occurred when patients were able to give context-appropriate, goal-directed responses. Conclusions: Our results showed that when the brain has not sufficiently recovered a certain level of consciousness, it is also unable to generate a 24-hour sleep-wake cycle and consolidated nighttime sleep. This study contributes to elucidating the pathophysiology of severe sleepwake cycle alterations in the acute phase of moderate to severe TBI.	[Duclos, Catherine; Dumont, Marie; Arbour, Caroline; Paquet, Jean; Blais, Helene; De Beaumont, Louis; Gosselin, Nadia] Hop Sacre Coeur, Ctr Adv Res Sleep Med, Montreal, PQ, Canada; [Bernard, Francis] Hop Sacre Coeur, Traumatol Program, Montreal, PQ, Canada; [Duclos, Catherine; Dumont, Marie] Univ Montreal, Dept Psychiat, Montreal, PQ, Canada; [Arbour, Caroline; Gosselin, Nadia] Univ Montreal, Dept Psychol, Montreal, PQ, Canada; [Bernard, Francis] Univ Montreal, Dept Med, Montreal, PQ, Canada; [Menon, David K.] Univ Cambridge, Div Anaesthesia, Cambridge, England; [De Beaumont, Louis] Univ Quebec Trois Rivieres, Dept Psychol, Trois Rivieres, PQ GA9 5H7, Canada	Gosselin, N (corresponding author), Hop Sacre Coeur, Ctr Adv Res Sleep Med, Montreal, PQ, Canada.	nadia.gosselin@umontreal.ca			Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [115172]; Fonds pour la Recherche du Quebec-Sante [24742]; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish	This study was supported by the Canadian Institutes of Health Research (grant no. 115172) and by the Fonds pour la Recherche du Quebec-Sante (grant no. 24742).	Bagnato S, 2010, CLIN NEUROPHYSIOL, V121, P274, DOI 10.1016/j.clinph.2009.11.008; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; BERGAMASCO B, 1968, ELECTROEN CLIN NEURO, V24, P374, DOI 10.1016/0013-4694(68)90198-3; Blume C, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00105; Chiu HY, 2013, J FORMOS MED ASSOC, V112, P545, DOI 10.1016/j.jfma.2013.06.007; Cruse D, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-18; de Biase S, 2014, SLEEP MED, V15, P393, DOI 10.1016/j.sleep.2013.09.026; Dowling G A, 1985, J Neurosurg Nurs, V17, P129; Duclos C, 2014, PATHOL BIOL, V62, P252, DOI 10.1016/j.patbio.2014.05.014; Duclos C, 2014, NEUROREHAB NEURAL RE, V28, P472, DOI 10.1177/1545968313517756; Gabor JY, 2003, AM J RESP CRIT CARE, V167, P708, DOI 10.1164/rccm.2201090; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Hagen C, 1972, RANCHO LOS AMIGOS LE; Han HJ, 2003, J KOREAN NEUROL ASS, V21, P156; Holcomb EM, 2016, J HEAD TRAUMA REHAB, V31, P108, DOI 10.1097/HTR.0000000000000206; Imbach LL, 2015, BRAIN, V138, P726, DOI 10.1093/brain/awu391; Kamper JE, 2016, J HEAD TRAUMA REHAB, V31, P117, DOI 10.1097/HTR.0000000000000215; Kreutzmann JC, 2015, NEUROSCIENCE, V309, P173, DOI 10.1016/j.neuroscience.2015.04.053; Littell RC, 2000, STAT MED, V19, P1793, DOI 10.1002/1097-0258(20000715)19:13<1793::AID-SIM482>3.3.CO;2-H; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Makley MJ, 2009, NEUROREHAB NEURAL RE, V23, P320, DOI 10.1177/1545968308325268; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Martin JL, 2011, CHEST, V139, P1514, DOI 10.1378/chest.10-1872; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Olden JD, 2001, MAR BIOL, V138, P1063, DOI 10.1007/s002270000517; Olson E, 2016, J NEUROTRAUM, V33, P734, DOI 10.1089/neu.2015.4085; Ouellet MC, 2015, LANCET NEUROL, V14, P746, DOI 10.1016/S1474-4422(15)00068-X; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RON S, 1980, ELECTROEN CLIN NEURO, V48, P432, DOI 10.1016/0013-4694(80)90135-2; Sabir M, 2015, BRAIN BEHAV IMMUN, V47, P118, DOI 10.1016/j.bbi.2014.12.023; Skopin MD, 2015, J NEUROTRAUM, V32, P289, DOI 10.1089/neu.2014.3664; Sommerauer M, 2013, J SLEEP RES, V22, P634, DOI 10.1111/jsr.12068; TEASDALE G, 1974, LANCET, V2, P81; Tononi G, 2014, NEURON, V81, P12, DOI 10.1016/j.neuron.2013.12.025; Walker MP, 2006, ANNU REV PSYCHOL, V57, P139, DOI 10.1146/annurev.psych.56.091103.070307; Wang D, 2008, J CLIN SLEEP MED, V4, P450	36	24	24	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JAN 17	2017	88	3					268	275		10.1212/WNL.0000000000003508			8	Clinical Neurology	Neurosciences & Neurology	EO2YS	WOS:000396562600012	28003503	Green Published			2021-06-18	
J	Wojtowicz, M; Iverson, GL; Silverberg, ND; Mannix, R; Zafonte, R; Maxwell, B; Berkner, PD				Wojtowicz, Magdalena; Iverson, Grant L.; Silverberg, Noah D.; Mannix, Rebekah; Zafonte, Ross; Maxwell, Bruce; Berkner, Paul D.			Consistency of Self-Reported Concussion History in Adolescent Athletes	JOURNAL OF NEUROTRAUMA			English	Article						assessment tools; head trauma; pediatric brain injury	SPORT-RELATED CONCUSSIONS; STATES HIGH-SCHOOL; YOUTH ICE HOCKEY; FOOTBALL PLAYERS; NEUROCOGNITIVE PERFORMANCE; SYMPTOMS; MANAGEMENT; EPIDEMIOLOGY; DIAGNOSIS; CHILDREN	Relying on self-reported concussion injury history is common in both clinical care and research. However, young athletes may not provide consistent medical information. To date, little is known about the reliability of self-reported concussion history in high school students. This study examined whether student athletes reported their lifetime history of concussions consistently over time. Self-reported concussion history was examined in 4792 student athletes (ages 13-18) from Maine who completed a preseason health survey on two occasions (median re-test interval = 23.7 months; standard deviation = 7.3; interquartile range = 12.4-24.5). Consistency of self-reported concussion history was determined by differences in the number of concussions reported during the second survey. Inconsistent concussion history was defined primarily by a decrease in the number of lifetime concussions reported at the second testing, compared with at the first testing. The majority of the sample (80.3%) reported no change in the number of concussions between the two baseline assessments. A minority (15.9%; n = 763) reported more concussions during the second assessment. Only 3.8% (n = 181) of student athletes provided inconsistent concussion histories, defined as fewer concussions at the second assessment. Boys provided inconsistent concussion histories a little more frequently, compared with girls (5.3% and 2.0%, respectively; p < 0.001). Similarly, athletes with self-reported attention-deficit hyperactivity disorder (ADHD) provided inconsistent concussion histories somewhat more frequently, compared with those without ADHD (7.8% and 3.5%, respectively; p < 0.001). Of the athletes with inconsistent concussion histories, greater degree of inconsistency was associated with a greater number of concussions initially reported at baseline (r(s) = 0.54; p < 0.001). Only a small proportion of student athletes provided inconsistent concussion histories. Male gender, ADHD, and greater number of baseline concussions were significantly associated with inconsistency in reporting. Overall, these findings suggest that student athletes are quite consistent when reporting their concussion history when surveyed twice during high school.	[Wojtowicz, Magdalena] Harvard Med Sch, Dept Psychiat, Boston, MA USA; [Wojtowicz, Magdalena; Iverson, Grant L.; Zafonte, Ross] Harvard Med Sch, Dept Phys Med & Rehabil, 101 Merrimac 250, Boston, MA 02124 USA; [Wojtowicz, Magdalena; Iverson, Grant L.; Zafonte, Ross] MassGeneral Hosp Children Sports Concuss Program, Boston, MA USA; [Wojtowicz, Magdalena; Iverson, Grant L.; Silverberg, Noah D.; Zafonte, Ross] Red Sox Fdn, Boston, MA USA; [Wojtowicz, Magdalena; Iverson, Grant L.; Silverberg, Noah D.; Zafonte, Ross] Massachusetts Gen Hosp Home Base Program, Boston, MA USA; [Iverson, Grant L.; Silverberg, Noah D.; Zafonte, Ross] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA; [Silverberg, Noah D.] Univ British Columbia, Div Phys Med & Rehabil, Vancouver, BC, Canada; [Silverberg, Noah D.] GF Strong Rehabil Ctr, Vancouver, BC, Canada; [Mannix, Rebekah] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Zafonte, Ross] Massachusetts Gen Hosp, Dept Phys Med & Rehabil, Boston, MA 02114 USA; [Zafonte, Ross] Brigham & Womens Hosp, Dept Phys Med & Rehabil, 75 Francis St, Boston, MA 02115 USA; [Maxwell, Bruce] Colby Coll, Dept Comp Sci, Waterville, ME 04901 USA; [Berkner, Paul D.] Colby Coll, Hlth Serv, Waterville, ME 04901 USA; [Berkner, Paul D.] Colby Coll, Dept Biol, Waterville, ME 04901 USA	Wojtowicz, M (corresponding author), Harvard Med Sch, Dept Phys Med & Rehabil, 101 Merrimac 250, Boston, MA 02124 USA.	mwojtowicz@mgh.harvard.edu	Mannix, Rebekah/AAD-8702-2020	Iverson, Grant/0000-0001-7348-9570	Goldfarb Center for Public Policy and Civic Engagement/Colby College; Bill and Joan Alfond Foundation; NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD40128-11A1]; Harvard Integrated Program to Protect and Improve the Health of National Football League Players Association Members; Mooney-Reed Charitable Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025758] Funding Source: NIH RePORTER	Funding source: Goldfarb Center for Public Policy and Civic Engagement/Colby College and the Bill and Joan Alfond Foundation. RM is funded by NICHD T32 HD40128-11A1. RZ was supported in part by the Harvard Integrated Program to Protect and Improve the Health of National Football League Players Association Members. The research program at MassGeneral Hospital for Children Sport Concussion Program acknowledges funding support from the Mooney-Reed Charitable Foundation.	Alla S, 2009, BRIT J SPORT MED, V43, pI3, DOI 10.1136/bjsm.2009.058339; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Belanger H. G, 2005, NEUROPSYCHOLOGICAL I, P345; Brener ND, 2003, J ADOLESCENT HEALTH, V33, P436, DOI 10.1016/S1054-139X(03)00052-1; Clay MB, 2013, J CHIROPR MED, V12, P230, DOI 10.1016/j.jcm.2012.11.005; Covassin T, 2013, AM J SPORT MED, V41, P2885, DOI 10.1177/0363546513499230; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Frommer L. J., J ATHL TRAIN, V46, P76; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; HAREL Y, 1994, AM J PUBLIC HEALTH, V84, P599, DOI 10.2105/AJPH.84.4.599; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; IVERSON GL, 2012, REHABIL RES PRACT, V2012, DOI DOI 10.1155/2012/316575; Kerr ZY, 2016, AM J SPORT MED, V44, P220, DOI 10.1177/0363546515612082; Kerr ZY, 2015, AM J SPORT MED, V43, P606, DOI 10.1177/0363546514562180; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Krol AL, 2011, BRAIN INJURY, V25, P1300, DOI 10.3109/02699052.2011.624571; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Mckay CD, 2014, J ORTHOP SPORT PHYS, V44, P329, DOI 10.2519/jospt.2014.5053; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Noble JM, 2013, NEUROPSYCHOL REV, V23, P273, DOI 10.1007/s11065-013-9239-0; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Sullivan L, 2016, INT J ADOLESC MED HL; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; McLeod TCV, 2008, CLIN J SPORT MED, V18, P235, DOI 10.1097/JSM.0b013e3181705756; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	30	24	24	0	27	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2017	34	2					322	327		10.1089/neu.2016.4412			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EH4QD	WOS:000391754800007	27349296	Green Published			2021-06-18	
J	Abrahamson, V; Jensen, J; Springett, K; Sakel, M				Abrahamson, Vanessa; Jensen, Jan; Springett, Kate; Sakel, Mohamed			Experiences of patients with traumatic brain injury and their carers during transition from in-patient rehabilitation to the community: a qualitative study	DISABILITY AND REHABILITATION			English	Article						Community rehabilitation; integrated care; traumatic brain injury	SENTINEL EVENTS; LIFE; INDIVIDUALS; HOME; EPIDEMIOLOGY; INTEGRATION; CONTINUITY; CAREGIVERS; PEOPLE	Purpose: To explore the experiences of individuals who have had a severe traumatic brain injury (TBI) and their carers in the first month post-discharge from in-patient rehabilitation into living in the community.Method: Using a qualitative approach underpinned by critical realism, we explored the narratives of 10 patients and nine carers using semi-structured interviews approximately one month post-discharge. Thematic analysis was carried out independently by two researchers.Results: Firstly, perceptions of support were mixed but many patients and carers felt unsupported in the inpatient phase, during transitions between units and when preparing for discharge. Secondly, they struggled to accept a new reality of changed abilities, loss of roles and loss of autonomy. Thirdly, early experiences post-discharge exacerbated fears for the future.Conclusions: Most patients and carers struggled to identify a cohesive plan that supported their transition to living in the community. Access to services required much persistence on the part of carers and tended to be short-term, and therefore did not meet their long-term needs. We propose the need for a case manager to be involved at an early stage of their rehabilitation and act as a key point for information and access to on-going rehabilitation and other support services.Implications for RehabilitationTraumatic Brain Injury (TBI) is a major cause of long-term disability. It can affect all areas of daily life and significantly reduce quality of life for both patient and carer.Professionals appear to underestimate the change in abilities and impact on daily life once patients return home. Community services maintain a short-term focus, whereas patients and carers want to look further ahead - this dissonance adds to anxiety.The study's findings on service fragmentation indicate an urgent need for better integration within health services and across health, social care and voluntary sectors.A link person/case manager who oversees the patient journey from admission onwards would help improve integrated care and ensure the patient, and carer, are at the center of service provision.	[Abrahamson, Vanessa] Canterbury Christ Church Univ, Canterbury, Kent, England; [Jensen, Jan; Springett, Kate] Canterbury Christ Church Univ, Sch Allied Hlth Profess, Canterbury, Kent, England; [Sakel, Mohamed] East Kent Hosp Univ NHS Fdn Trust, Kent & Canterbury Hosp, Canterbury, Kent, England	Abrahamson, V (corresponding author), Univ Kent, George Allen Wing, CHSS, Canterbury CT2 7NZ, Kent, England.	va63@kent.ac.uk		Abrahamson, Vanessa/0000-0002-1169-9457			[Anonymous], 2013, COUNTING COST REHABI; [Anonymous], 2010, MED REHABILITATION 2; [Anonymous], 2014, OPTIMIZINGS COPES PR; [Anonymous], 2014, MANDATE GOVT NHS ENG; [Anonymous], 2012, LIFE BRAIN INJURY WA; [Anonymous], 2015, INVISIBLE PATIENTS R; [Anonymous], 2013, COORDINATED CARE PEO; [Anonymous], 2005, NATL SERVICE FRAMEWO; [Anonymous], 2015, TRANSITION INPATIENT; [Anonymous], 2008, HIGH QUALITY CARE AL; [Anonymous], 2011, WHAT IS INTEGRATED C; [Anonymous], 2015, ACQUIRED BRAIN INJUR; Aspinal F, 2012, J ADV NURS, V68, P2309, DOI 10.1111/j.1365-2648.2011.05928.x; Baker A, 2017, CLIN REHABIL, V31, P45, DOI 10.1177/0269215516639357; Bhaskar R., 1978, REALIST THEORY SCI; Brands I, 2015, CLIN REHABIL, V29, P611, DOI 10.1177/0269215514549484; Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706qp063oa]; Carlozzi NE, 2015, ARCH PHYS MED REHAB, V96, P105, DOI 10.1016/j.apmr.2014.08.021; Clark Alexander M, 2008, ANS Adv Nurs Sci, V31, pE67, DOI 10.1097/01.ANS.0000341421.34457.2a; Conneeley AL, 2012, BRAIN IMPAIR, V13, P72, DOI 10.1017/BrImp.2012.3; Emerson R.M., 2011, WRITING ETHNOGRAPHIC; Gray J, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0573-6; Haggerty JL, 2013, ANN FAM MED, V11, P262, DOI 10.1370/afm.1499; Hesse-Biber S.N., 2011, PRACTICE QUALITATIVE; Kneebone II, 2012, NEUROREHAB NEURAL RE, V26, P834, DOI 10.1177/1545968311431962; Kodner Dennis L, 2009, Healthc Q, V13 Spec No, P6; Laver K, 2014, BMC HEALTH SERV RES, V14, P1; Levack WMM, 2010, DISABIL REHABIL, V32, P986, DOI 10.3109/09638281003775394; Maxwell J., 2012, REALIST APPROACH QUA; Morse JM, 2015, QUAL HEALTH RES, V25, P1212, DOI 10.1177/1049732315588501; Nalder E, 2016, ARCH PHYS MED REHAB, V97, pS46, DOI 10.1016/j.apmr.2014.07.428; Nalder E, 2013, BRAIN INJURY, V27, P1294, DOI 10.3109/02699052.2013.823560; Nalder E, 2012, J REHABIL MED, V44, P837, DOI 10.2340/16501977-1033; Nalder E, 2012, BRAIN IMPAIR, V13, P108, DOI 10.1017/BrImp.2012.4; Paterson B, 2001, Rehabil Nurs, V26, P48; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Piccenna L, 2016, BRAIN INJURY, V30, P241, DOI 10.3109/02699052.2015.1113569; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sander AM, 2010, J HEAD TRAUMA REHAB, V25, P121, DOI 10.1097/HTR.0b013e3181cd1635; Sayer, 1992, METHOD SOCIAL SCI RE; SAYER R.A., 2000, REALISM SOCIAL SCI; Schonberger M, 2014, NEUROPSYCHOL REHABIL, V24, P202, DOI 10.1080/09602011.2013.878252; Sherer M, 2015, REHABIL PSYCHOL, V60, P138, DOI 10.1037/rep0000030; Tennant A., 2005, 0300067 U LEEDS; Turner BJ, 2011, DISABIL REHABIL, V33, P818, DOI 10.3109/09638288.2010.513422; Tverdov AH, 2016, BRAIN INJURY, V30, P324, DOI 10.3109/02699052.2015.1113566; Whiffin CJ, 2015, J ADV NURS, V71, P849, DOI 10.1111/jan.12551; Williams MW, 2014, REHABIL PSYCHOL, V59, P298, DOI 10.1037/a0037164; Yin RK, 2014, CASE STUDY RES DESIG, V5	49	24	24	2	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2017	39	17					1683	1694		10.1080/09638288.2016.1211755			12	Rehabilitation	Rehabilitation	EV4CM	WOS:000401705900001	27557977	Green Accepted			2021-06-18	
J	Formisano, R; Azicnuda, E; Sefid, MK; Zampolini, M; Scarponi, F; Avesani, R				Formisano, Rita; Azicnuda, Eva; Sefid, Maryam Khan; Zampolini, Mauro; Scarponi, Federico; Avesani, Renato			Early rehabilitation: benefits in patients with severe acquired brain injury	NEUROLOGICAL SCIENCES			English	Article						Early rehabilitation; Outcome; Severe acquired brain injury	SEVERE HEAD-INJURY	Establish the best time to start rehabilitation by means of scientific evidence. Observational study in patients with a diagnosis of Severe Brain Injury who received intensive inpatient rehabilitation after acute care. 1470 subjects enrolled: 651 with Traumatic Brain Injury (TBI) and 819 with Non-TBI. Male gender was prevalent in the population study, but sex distribution was not different among groups, with a prevalence of male gender in both populations. This project involved 29 rehabilitation facilities for Severe ABI. The registry was an electronic database, remained active only during the period of data collection. The patients were divided into three different categories according to the time interval from brain injury to inpatient rehabilitation admission and demographic and clinical data were collected. Etiology, time interval from injury to inpatient rehabilitation, disability severity, the presence of tracheostomy at admission to the rehabilitation facility, rehabilitation length of stay and transfer back to acute care wards because of medical, surgical or neurosurgical complications. The interval from brain injury to rehabilitation facilities admission increases along with age, brain injury severity according to DRS scores, the presence of a tracheal tube and the percentage of transfers back to acute care wards from rehabilitation facilities, because of medical, surgical or neurosurgical complications. The better recovery and more positive outcomes, reported as resulting from early rehabilitation, may be due more to less severity of brain injury and fewer complications in the acute and post-acute phase than to when the rehabilitation starts.	[Formisano, Rita; Azicnuda, Eva] IRCCS Santa Lucia Fdn, Postcoma Unit, Via Ardeatina 306, I-00179 Rome, Italy; [Sefid, Maryam Khan; Avesani, Renato] Sacro Cuore Don Calabria Hosp, Rehabil Dept, Negrar, Italy; [Zampolini, Mauro; Scarponi, Federico] ASL 3, Dept Rehabil, Perugia, Italy	Formisano, R (corresponding author), IRCCS Santa Lucia Fdn, Postcoma Unit, Via Ardeatina 306, I-00179 Rome, Italy.	r.formisano@hsantalucia.it	Azicnuda, Eva/K-9010-2016; mandala, giorgio/AAC-1842-2019; Scarponi, Federico/K-5714-2018	mandala, giorgio/0000-0002-4384-8672; Scarponi, Federico/0000-0001-9683-8104			Actis MV, 2001, G ITAL MED RIABIL, V15, P49; Avesani R, 2013, EUR J PHYS REHAB MED, V49, P611; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; Derrikson JG, 1989, APTA NEUROL REP, V13, P10; Hu MH, 2010, DISABIL REHABIL, V32, P1251, DOI 10.3109/09638280903464448; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Morgan AS, 1988, 1 ANN C E ASS SURG T; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118	9	24	25	0	7	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1590-1874	1590-3478		NEUROL SCI	Neurol. Sci.	JAN	2017	38	1					181	184		10.1007/s10072-016-2724-5			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	EK9AZ	WOS:000394217500024	27696274				2021-06-18	
J	Gouttebarge, V; Aoki, H; Lambert, M; Stewart, W; Kerkhoffs, G				Gouttebarge, Vincent; Aoki, Haruhito; Lambert, Michael; Stewart, William; Kerkhoffs, Gino			A history of concussions is associated with symptoms of common mental disorders in former male professional athletes across a range of sports	PHYSICIAN AND SPORTSMEDICINE			English	Article						Concussions; sports; mental disorders; epidemiology; athletes	CHRONIC TRAUMATIC ENCEPHALOPATHY; REPORTED OUTCOME MEASURES; FOOTBALL PLAYERS; SLEEP DISTURBANCE; RUGBY UNION; RISK; DETERMINANTS; DEPRESSION; PREVALENCE; DIAGNOSIS	Objective: Recent reports suggest that exposure to repetitive concussions in sports is associated with an increased risk of symptoms of distress, anxiety and depression, sleep disturbance or substance abuse/dependence (typically referred as symptoms of common mental disorders[CMD]) and of later development of neurodegenerative disease, in particular chronic traumatic encephalopathy (CTE). The primary aim of this study was to explore the relationship between sports career-related concussions and the subsequent occurrence of symptoms of CMD among former male professional athletes retired from football (soccer), ice hockey and rugby (union).Methods: Cross-sectional analyses were performed on baseline electronic questionnaires from three prospective cohort studies among former male professional athletes retired from football (soccer), ice hockey and rugby (union). The number of confirmed concussions was examined through a single question, while symptoms of distress, anxiety and depression, sleep disturbance and adverse alcohol use were assessed using validated questionnaires.Results: From 1,957 former professional athletes contacted, a total of 576 (29%) completed the questionnaire. Of these, 23% had not incurred a concussion during their career, 34% had two or three, 18% four or five, and 11% six or more concussions. The number of sports career-related concussions was a predictor for all outcome measures (=0.072-0.109; P0.040). Specifically, former professional athletes who reported a history of four or five concussions were approximately 1.5 times more likely to report symptoms of CMD, rising to a two- to five-fold increase in those reporting a history of six or more sports career-related concussions.Conclusions: These data demonstrate an association between exposure to sports concussion and subsequent risk of symptoms of CMD in former professional athletes across a range of contact sports. Further work to explore the association between sports concussion and symptoms of CMD is required; in the meanwhile, strategies for effective risk reduction and improved management appear indicated.	[Gouttebarge, Vincent; Kerkhoffs, Gino] Acad Med Ctr, Acad Ctr Evidence Based Sports Med ACES, Amsterdam, Netherlands; [Gouttebarge, Vincent] World Players Union FIFPro, Hoofddorp, Netherlands; [Gouttebarge, Vincent; Lambert, Michael] Univ Cape Town, Div Exercise Sci & Sports Med ESSM, Cape Town, South Africa; [Aoki, Haruhito] St Marianna Univ, Sch Med, Kawazaki, Japan; [Stewart, William] Queen Elizabeth Hosp, Dept Neuropathol, Glasgow, Lanark, Scotland; [Kerkhoffs, Gino] Vrije Univ Amsterdam, Med Ctr, Acad Med Ctr, ACHSS, Amsterdam, Netherlands	Gouttebarge, V (corresponding author), Acad Med Ctr, Acad Ctr Evidence Based Sports Med ACES, Amsterdam, Netherlands.	v.gouttebarge@amc.nl		Stewart, William/0000-0003-2199-2582; Lambert, Michael/0000-0001-8979-1504			Araujo CGS, 2016, SCAND J MED SCI SPOR, V26, P4, DOI 10.1111/sms.12632; Blake C., 2014, BRIT J SPORT MED, V48, P569, DOI [10.1136/bjsports-2014-093494.25, DOI 10.1136/BJSPORTS-2014-093494.25]; Braam C, 2009, J OCCUP REHABIL, V19, P231, DOI 10.1007/s10926-009-9178-z; Burger N, 2016, BRIT J SPORT MED, V50, P932, DOI 10.1136/bjsports-2015-095295; Buysse DJ, 2010, SLEEP, V33, P781, DOI 10.1093/sleep/33.6.781; Davis JC, 2015, BRIT J SPORT MED, V49, P1545, DOI 10.1136/bjsports-2014-093707; Dawson DA, 2005, ALCOHOL CLIN EXP RES, V29, P844, DOI 10.1097/01.ALC.0000164374.32229.A2; Decq P, 2016, ACTA NEUROCHIR, V158, P289, DOI 10.1007/s00701-015-2681-4; England Professional Rugby Injury Surveillance Project Steering Group, 2016, RUGB PLAYERS ENGL PR; Goldberg DP, 1997, PSYCHOL MED, V27, P191, DOI 10.1017/S0033291796004242; Gouttebarge V, 2016, J SPORT MED PHYS FIT, V56, P648; Gouttebarge V, 2016, EUR J SPORT SCI, V16, P595, DOI 10.1080/17461391.2015.1086819; Green Sb, 1991, MULTIVARIATE BEHAV R; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Hay J, 2016, ANNU REV PATHOL-MECH, V11, P21, DOI 10.1146/annurev-pathol-012615-044116; JACOBSON E, 1957, J AM PSYCHOANAL ASS, V5, P61, DOI 10.1177/000306515700500102; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Martland H, 1991, JAMA-J AM MED ASSOC, V91, P1103; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; Meneses-Gaya Carolina de, 2009, Psychol. Neurosci., V2, P83, DOI 10.3922/j.psns.2009.1.12; Ruhe A, 2014, BRIT J SPORT MED, V48, P102, DOI 10.1136/bjsports-2012-091609; Salama-Younes M, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477-7525-7-22; Schuring N, 2017, KNEE SURG SPORT TR A, V25, P3179, DOI 10.1007/s00167-016-4255-2; Slobounov SM, 2017, NEUROIMAGE-CLIN, V14, P708, DOI 10.1016/j.nicl.2017.03.006; Smith AM, 2016, BMJ OPEN SPORT EXERC, V2, DOI 10.1136/bmjsem-2015-000074; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stewart W, 2016, QJM-INT J MED, V109, P11, DOI 10.1093/qjmed/hcv070; Terluin B, 2006, BMC PSYCHIATRY, V6, DOI 10.1186/1471-244X-6-34; Walden M, 2013, SCAND J MED SCI SPOR, V23, P424, DOI 10.1111/j.1600-0838.2011.01409.x; Woodward M., 2013, EPIDEMIOLOGY STUDY D; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Yu L, 2012, BEHAV SLEEP MED, V10, P6, DOI 10.1080/15402002.2012.636266	34	24	25	1	21	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0091-3847	2326-3660		PHYSICIAN SPORTSMED	Physician Sportsmed.		2017	45	4					443	449		10.1080/00913847.2017.1376572			7	Primary Health Care; Orthopedics; Sport Sciences	General & Internal Medicine; Orthopedics; Sport Sciences	FN4HT	WOS:000415966600013	28870119	Green Accepted, Other Gold			2021-06-18	
J	Sennik, S; Schweizer, TA; Fischer, CE; Munoz, DG				Sennik, Simrin; Schweizer, Tom A.; Fischer, Corinne E.; Munoz, David G.			Risk Factors and Pathological Substrates Associated with Agitation/Aggression in Alzheimer's Disease: A Preliminary Study using NACC Data	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Alzheimer's disease; agitation; aggression; neuropathology; (p)-TDP-43; traumatic brain injury; vascular lesions; vascular risk factors	DEMENTIA; SEVERITY; SYMPTOMS; ONSET	Background: Neuropsychiatric symptoms are common manifestations of Alzheimer's disease (AD). A number of studies have targeted psychosis, i.e., hallucinations and delusions in AD, but few have assessed agitation/aggression in AD. Objective: To investigate the risk factors and pathological substrates associated with presence [A(+)] and absence [A(-)] of agitation/aggression (A) in autopsy-confirmed AD. Methods: Data was collected from the UDS data as of 2015 on the NACC database. Patients were stratified as intermediate (IAD) or high (HAD) pathological load of AD. Clinical diagnoses were not considered; additional pathological diagnoses were treated as variables. Analysis of data did not include a control group or corrections for multiple comparisons. Results: 1,716 patients met the eligibility criteria; 34.6% of the IAD and 49.6% of the HAD patients were A(+), indicating an association with severity of pathology (p = 0.001). Risk factors for A(+) included: age at initial visit, age at death, years of education, smoking (in females), recent cardiac events (in males), and clinical history of traumatic brain injury (TBI) (in males). A history of hypertension was not related to A(+). In terms of comorbidity, clinical diagnosis of Lewy body dementia syndrome was associated with A(+) but the association was not confirmed when pathological diagnosis based on demonstration of Lewy bodies was used as the criterion. The additional presence of phosphorylated TDP-43, but not tau pathologies, was associated with A(+) HAD. Vascular lesions, including lacunes, large arterial infarcts, and severity of atherosclerosis were negatively associated with A(+). Associated symptoms included delusions, hallucinations, and depression, but not irritability, aberrant motor behavior, sleep and night time behavioral changes, or changes in appetite and eating habits. Conclusions: Smoking, TBI, and phosphorylated TDP-43 are associated with A(+) AD in specific groups, respectively. A(+) is directly associated with AD pathology load and inversely with vascular lesions.	[Sennik, Simrin; Schweizer, Tom A.; Fischer, Corinne E.; Munoz, David G.] St Michaels Hosp, Keenan Biomed Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Schweizer, Tom A.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Schweizer, Tom A.] Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada; [Schweizer, Tom A.] Univ Toronto, Dept Surg, Div Neurosurg, Fac Med, Toronto, ON, Canada; [Schweizer, Tom A.] St Michaels Hosp, Div Neurosurg, Toronto, ON, Canada; [Fischer, Corinne E.] Univ Toronto, Fac Med, Dept Psychiat, Toronto, ON, Canada; [Munoz, David G.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Munoz, David G.] St Michaels Hosp, Dept Lab Med, Room 2-097 CC Wing,30 Bond St, Toronto, ON M5B 1W8, Canada	Munoz, DG (corresponding author), St Michaels Hosp, Dept Lab Med, Room 2-097 CC Wing,30 Bond St, Toronto, ON M5B 1W8, Canada.	MunozD@smh.ca	Munoz, David G./AAQ-8003-2020	Munoz, David G./0000-0003-0957-6244	NIA/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01 AG016976, U01 AG032984]; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG019610, P30 AG013846, P50 AG008702, P50 AG025688, P50 AG047266, P30 AG010133, P50 AG005146, P50AG005134, P50 AG016574];  [P50 AG047366];  [P30 AG010129];  [P50AG016573];  [P50 AG016570];  [P50 AG005131];  [P50 AG023501];  [P30 AG035982];  [P30AG028383];  [P30 AG010124];  [P50 AG005138];  [P30 AG008051];  [P30 AG013854];  [P30 AG008017];  [P30 AG010161];  [P50 AG005133];  [P50 AG005142];  [P30 AG012300];  [P50 AG005136];  [P50 AG033514];  [P50AG005681];  [P50 AG047270]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005142, P30AG008017, U01AG032984, P50AG005133, P50AG023501, P30AG008051, P50AG008702, P50AG005131, P50AG033514, P50AG047366, P30AG013846, P50AG047266, P30AG010129, P30AG010161, P50AG047270, P50AG005136, P30AG028383, P50AG016574, P50AG005146, P50AG005134, P50AG005681, P50AG016573, P30AG012300, P30AG035982, P30AG010133, P50AG025688, P50AG016570, P30AG010124, P50AG005138, U01AG016976, P30AG019610, P30AG013854] Funding Source: NIH RePORTER	The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by the NIA funded ADCs: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P50 AG047266 (PI Todd Golde, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P50AG005134(PI Bradley Hyman, MD, PhD), P50 AG016574 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Steven Ferris, PhD), P30 AG013854 (PI M. Marsel Mesulam, MD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P50 AG047366 (PI Victor Henderson, MD, MS), P30 AG010129(PI Charles DeCarli, MD), P50AG016573 (PI Frank LaFerla, PhD), P50 AG016570 (PI Marie-Francoise Chesselet, MD, PhD), P50 AG005131 (PI Douglas Galasko, MD), P50 AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD), P30AG028383 (PI LindaVan Eldik, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P50 AG005136 (PI Thomas Montine, MD, PhD), P50 AG033514 (PI Sanjay Asthana, MD, FRCP), P50AG005681 (PI John Morris, MD), and P50 AG047270 (PI Stephen Strittmatter, MD, PhD) [1].; Alzheimer's Disease Genetic Consortium (ADGC) (NIA/NIH Grant U01 AG032984).	Aarsland D, 1996, AM J PSYCHIAT, V153, P243; Abner EL, 2016, ALZHEIMERS DEMENT, V12, P882, DOI 10.1016/j.jalz.2015.12.006; Beekly DL, 2007, ALZ DIS ASSOC DIS, V21, P249, DOI 10.1097/WAD.0b013e318142774e; BERG L, 1988, PSYCHOPHARMACOL BULL, V24, P637; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gavett BE, 2016, J ALZHEIMERS DIS, V49, P531, DOI 10.3233/JAD-150252; Holmes C, 1998, HUM MOL GENET, V7, P1507, DOI 10.1093/hmg/7.9.1507; Lopez OL, 2003, J NEUROPSYCH CLIN N, V15, P346, DOI 10.1176/appi.neuropsych.15.3.346; Luchsinger Jose A, 2004, Curr Atheroscler Rep, V6, P261, DOI 10.1007/s11883-004-0056-z; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Ortiz CA, 2007, ANN NEUROL, V61, P435; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; Tekin S, 2001, ANN NEUROL, V49, P355, DOI 10.1002/ana.72.abs	13	24	24	0	11	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2017	55	4					1519	1528		10.3233/JAD-160780			10	Neurosciences	Neurosciences & Neurology	EH1JQ	WOS:000391523200023	27911311	Green Accepted			2021-06-18	
J	Wu, FZ; Chen, ZF; Tang, CH; Zhang, JJ; Cheng, L; Zuo, HX; Zhang, HY; Chen, DQ; Xiang, LP; Xiao, J; Li, XK; Xu, XL; Wei, XJ				Wu, Fenzan; Chen, Zaifeng; Tang, Chonghui; Zhang, Jinjing; Cheng, Li; Zuo, Hongxia; Zhang, Hongyu; Chen, Daqing; Xiang, Liping; Xiao, Jian; Li, Xiaokun; Xu, Xinlong; Wei, Xiaojie			Acid fibroblast growth factor preserves blood-brain barrier integrity by activating the PI3K-Akt-Rac1 pathway and inhibiting RhoA following traumatic brain injury	AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH			English	Article						Traumatic brain injury; blood-brain barrier; acid fibroblast growth factor; junction protein; RhoA	MICROVASCULAR ENDOTHELIAL-CELLS; CEREBRAL-ISCHEMIA; PERMEABILITY; PROTECTS; EDEMA; DISRUPTION; MECHANISMS; CLAUDIN-5; OCCLUDIN; DELIVERY	The blood-brain barrier (BBB) plays important roles in the recovery of traumatic brain injury (TBI) which is a major factor contributing to cerebral edema. Acid fibroblast growth factor (aFGF) contributes to maintain vascular integrity and restores nerve function. However, whether aFGF protects BBB following TBI remains unknown. The purpose of this study was to determine whether exogenous aFGF preserves BBB integrity by activating the PI3K-Akt-Rac1 pathway and inhibiting RhoA after TBI. BBB permeability was assessed using evans blue dye and fluorescein isothiocyanate dextran fluorescence. Neurofunctional tests, such as the garcia test, were conducted in a blinded fashion, and protein expression was evaluated via western blotting and immunofluorescence staining. Our results showed that aFGF improved neurofunctional deficits, preserved BBB integrity, and up-regulated tight junction proteins and adherens junction proteins 24 h after experimental TBI. However, the PI3K/Akt inhibitor LY294002 reversed the protective effects of aFGF on neurofunctional deficits and junction protein expression and significantly suppressed p-Akt and GTP-Rac1 activity. Furthermore, aFGF administration significantly decreased GTP-RhoA expression in the treated group compared with the vehicle group, while PI3K/Akt inhibition increased GTP-RhoA expression. Similar results were observed in vitro, as aFGF exerted protective effects on endothelial cell integrity by up-regulating junction proteins and PI3K-Akt-Rac1 pathway and down-regulating RhoA expression under oxygen-glucose deprivation/reoxygenation (OGD) conditions. These data suggest that exogenous aFGF reduces RhoA activity in part by activating the PI3K-Akt-Rac1 signaling pathway, thus improving neurofunctional deficits and preserving BBB integrity after TBI.	[Wu, Fenzan; Chen, Zaifeng; Tang, Chonghui; Zhang, Jinjing; Cheng, Li; Zuo, Hongxia; Xu, Xinlong; Wei, Xiaojie] Wenzhou Med Univ, Cixi Peoples Hosp, Dept Neurosurg, Ningbo 315300, Zhejiang, Peoples R China; [Zhang, Hongyu; Xiao, Jian; Li, Xiaokun] Wenzhou Med Univ, Sch Pharm, Mol Pharmacol Res Ctr, Key Lab Biotechnol & Pharmaceut Engn, Wenzhou 325035, Zhejiang, Peoples R China; [Chen, Daqing] Wenzhou Med Univ, Affiliated Hosp 2, Dept Emergency, Wenzhou 325035, Zhejiang, Peoples R China; [Xiang, Liping] Cangnan Peoples Hosp, Dept Nursing, Wenzhou 325800, Zhejiang, Peoples R China	Xu, XL; Wei, XJ (corresponding author), Wenzhou Med Univ, Cixi Peoples Hosp, Dept Neurosurg, Ningbo 315300, Zhejiang, Peoples R China.	cry9020@126.com; weixj5100@126.com			Nature Science Foundation of Zhejiang ProvinceNatural Science Foundation of Zhejiang Province [LY14H09-0013, LQ16H090007, LY14H150010]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81501953]; Nature Science Foundation of Ningbo City [2015A610192, 2015A610213]	This work was supported by the Nature Science Foundation of Zhejiang Province (LY14H09-0013, LQ16H090007, LY14H150010), the National Natural Science Foundation of China (81501953) and Nature Science Foundation of Ningbo City (2015A610192, 2015A610213).	Alvarez JI, 2011, SCIENCE, V334, P1727, DOI 10.1126/science.1206936; Balda MS, 2000, J CELL BIOCHEM, V78, P85, DOI 10.1002/(SICI)1097-4644(20000701)78:1<85::AID-JCB8>3.3.CO;2-6; Bao HJ, 2012, NEUROCHEM RES, V37, P2856, DOI 10.1007/s11064-012-0880-4; Beaumont A, 2006, ACTA NEUROCHIR SUPPL, V96, P171; Camire RB, 2014, J PHARMACOL EXP THER, V351, P654, DOI 10.1124/jpet.114.218339; Citi Sandra, 2014, Small GTPases, V5, P1, DOI 10.4161/21541248.2014.973760; Courtney A, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00221; Crosby CV, 2005, BLOOD, V105, P2771, DOI 10.1182/blood-2004-06-2244; Cuevas P, 1998, SURG NEUROL, V49, P77, DOI 10.1016/S0090-3019(97)00193-6; Daniels BP, 2014, MBIO, V5, DOI 10.1128/mBio.01476-14; Dejana E, 2013, J CELL SCI, V126, P2545, DOI 10.1242/jcs.124529; Goddard LM, 2013, THROMB HAEMOSTASIS, V109, P407, DOI 10.1160/TH12-09-0678; Gonzalez-Mariscal L, 2008, BBA-BIOMEMBRANES, V1778, P729, DOI 10.1016/j.bbamem.2007.08.018; Gunduz D, 2010, ARTERIOSCL THROM VAS, V30, P1237, DOI 10.1161/ATVBAHA.110.203901; Haseloff RF, 2015, SEMIN CELL DEV BIOL, V38, P16, DOI 10.1016/j.semcdb.2014.11.004; Hemmings B.A., 2015, COLD SPRING HARB PER, V7; Herbert C, 2014, PHARM PAT ANAL, V3, P585, DOI [10.4155/PPA.14.45, 10.4155/ppa.14.45]; Huang B, 2012, NEUROBIOL DIS, V46, P204, DOI 10.1016/j.nbd.2012.01.008; Huang XT, 2013, J NEUROTRAUM, V30, P2080, DOI 10.1089/neu.2013.2996; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Israeli D, 2011, INT J BIOL SCI, V7, P1; Lee HS, 2004, MICROVASC RES, V68, P231, DOI 10.1016/j.mvr.2004.07.005; Li Z, 2016, J MOL NEUROSCI, V59, P193, DOI 10.1007/s12031-015-0668-5; Liu N, 2015, INT J CLIN EXP PATHO, V8, P4204; Lucke-Wold BP, 2015, MOL NEUROBIOL, V52, P1119, DOI 10.1007/s12035-014-8902-7; Lv QS, 2013, BRAIN RES, V1493, P80, DOI 10.1016/j.brainres.2012.11.028; Murillo CA, 2004, SURGERY, V136, P143, DOI 10.1016/j.surg.2004.04.006; Reyes R, 2009, J NEUROSURG, V110, P1218, DOI 10.3171/2008.8.JNS08382; Shimizu F, 2011, J CELL PHYSIOL, V226, P255, DOI 10.1002/jcp.22337; Spindler V, 2010, CARDIOVASC RES, V87, P243, DOI 10.1093/cvr/cvq086; Stenman JM, 2008, SCIENCE, V322, P1247, DOI 10.1126/science.1164594; Strbian D, 2008, NEUROSCIENCE, V153, P175, DOI 10.1016/j.neuroscience.2008.02.012; Suzuki Y, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00002; Thurman D. J., 2016, J CHILD NEUROL, V31, P20, DOI DOI 10.1177/0883073814544363; Tran KA, 2016, CIRCULATION, V133, P177, DOI 10.1161/CIRCULATIONAHA.115.015982; Wang ZG, 2016, MOL NEUROBIOL, V53, P7298, DOI 10.1007/s12035-015-9583-6; Wu S, 2010, MOL CELL BIOCHEM, V343, P223, DOI 10.1007/s11010-010-0517-3; Xue Q, 2013, INT J BIOL SCI, V9, P174, DOI 10.7150/ijbs.5115; Yamamoto M, 2008, AM J PATHOL, V172, P521, DOI 10.2353/ajpath.2008.070076; Zhao J, 2012, J NEUROTRAUM, V29, P1209, DOI 10.1089/neu.2011.1858; Zheng BB, 2016, J CELL MOL MED, V20, P1062, DOI 10.1111/jcmm.12761	41	24	27	0	6	E-CENTURY PUBLISHING CORP	MADISON	40 WHITE OAKS LN, MADISON, WI 53711 USA	1943-8141			AM J TRANSL RES	Am. J. Transl. Res.		2017	9	3					910	+					18	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	ER7XK	WOS:000399028800007	28386321				2021-06-18	
J	Gutierrez, PM; Pease, J; Matarazzo, BB; Monteith, LL; Hernandez, T; Osman, A				Gutierrez, Peter M.; Pease, James; Matarazzo, Bridget B.; Monteith, Lindsey L.; Hernandez, Theresa; Osman, Augustine			Evaluating the Psychometric Properties of the Interpersonal Needs Questionnaire and the Acquired Capability for Suicide Scale in Military Veterans	PSYCHOLOGICAL ASSESSMENT			English	Article						Interpersonal Needs Questionnaire; Acquired Capability for Suicide Scale; veterans; psychometrics	TRAUMATIC BRAIN-INJURY; PSYCHOLOGICAL THEORY; CONSTRUCT-VALIDITY; PERCEIVED BURDENSOMENESS; SCREENING-TEST; 2 SAMPLES; RISK; IDEATION; BEHAVIOR; TESTS	Joiner's (2005) interpersonal-psychological theory of suicide (IPTS) has become one of the most frequently studied in the field. Currently there are 2 primary measures designed to assess the 3 main constructs of the theory-the Interpersonal Needs Questionnaire (INQ; Van Orden, Witte, Gordon, Bender, & Joiner, 2008) and the Acquired Capability for Suicide Scale (ACSS; Van Orden et al., 2008). The psychometric properties of these 2 measures were evaluated in a sample of 477 U.S. military veterans. It was determined that the factor structure for both measures is consistent with the underlying theory and that all internal consistency reliability estimates are good. Acceptable convergent validity was found for the INQ, but not for the ACSS. Recommendations for refining the ACSS based on the results of the current analyses are provided. Comparisons of scale performance were made with data from participants with and without a history of 1 or more suicide attempts. Burdensomeness alone and the interaction between thwarted belongingness and burdensomeness were associated with prior suicide attempts. In conclusion, although some refinement may improve performance of the ACSS, both measures are appropriate and psychometrically sound for use in research and clinical applications with veterans of the U.S. military.	[Gutierrez, Peter M.; Pease, James; Matarazzo, Bridget B.; Monteith, Lindsey L.; Hernandez, Theresa] Denver Vet Affairs Med Ctr, Rocky Mt Mental Illness Res Educ & Clin Ctr, Denver, CO USA; [Gutierrez, Peter M.; Pease, James; Matarazzo, Bridget B.; Monteith, Lindsey L.] Univ Colorado, Sch Med, Dept Psychiat, Boulder, CO 80309 USA; [Hernandez, Theresa] Univ Colorado, Dept Psychol & Neurosci, Boulder, CO 80309 USA; [Osman, Augustine] Univ Texas San Antonio, Dept Psychol, San Antonio, TX USA	Gutierrez, PM (corresponding author), Denver Vet Affairs Med Ctr, Rocky Mt Mental Illness Res Educ & Clin Ctr, MIRECC, 1055 Clermont St, Denver, CO 80220 USA.	peter.gutierrez@va.gov	Gutierrez, Peter/K-8905-2019; Monteith, Lindsey L./X-3658-2019	Gutierrez, Peter/0000-0001-8981-8404; Monteith, Lindsey L./0000-0002-8104-5280; Osman, Augustine/0000-0002-3306-3249			Asparouhov T, 2009, STRUCT EQU MODELING, V16, P397, DOI 10.1080/10705510903008204; Baglin J, 2014, PRACTICAL ASSESSMENT, V19, P2; Bahraini NH, 2013, J CONTEXTUAL BEHAV S, V2, P31, DOI 10.1016/j.jcbs.2013.03.001; Beck A.T., 1991, MANUAL BECK SCALE SU; BECK AT, 1988, J CLIN PSYCHOL, V44, P499, DOI 10.1002/1097-4679(198807)44:4<499::AID-JCLP2270440404>3.0.CO;2-6; Bender T. W., 2007, IMPULSIVEITY S UNPUB; Bezdjian S, 2015, MIL PSYCHOL, V27, P325, DOI 10.1037/mil0000090; BONNER RL, 1991, J NERV MENT DIS, V179, P29, DOI 10.1097/00005053-199101000-00006; Bradley KA, 2003, ARCH INTERN MED, V163, P821, DOI 10.1001/archinte.163.7.821; Brenner L.A., 2008, J MENT HLTH COUNS, V30, P211; Brenner LA, 2013, J HEAD TRAUMA REHAB, V28, P21, DOI 10.1097/HTR.0b013e31827df0b5; Brenner LA, 2009, REHABIL PSYCHOL, V54, P390, DOI 10.1037/a0017802; Brown GK, REV SUICIDE ASSESSME; Browne M. W., 1992, SOCIOL METHOD RES, V21, P136; Bryan CJ, 2013, J CLIN PSYCHOL, V69, P64, DOI 10.1002/jclp.21932; Bryan CJ, 2010, PERS INDIV DIFFER, V48, P347, DOI 10.1016/j.paid.2009.10.023; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Ciarrochi J., 2008, CBT PRACTITIONERS GU; Clark LA, 1995, PSYCHOL ASSESSMENT, V7, P309, DOI 10.1037/1040-3590.7.3.309; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; CRONBACH LJ, 1951, PSYCHOMETRIKA, V16, P297; Enders CK, 2001, STRUCT EQU MODELING, V8, P128, DOI 10.1207/S15328007SEM0801_7; Fabrigar LR, 1999, PSYCHOL METHODS, V4, P272, DOI 10.1037/1082-989X.4.3.272; Floyd FJ, 1995, PSYCHOL ASSESSMENT, V7, P286, DOI 10.1037/1040-3590.7.3.286; Frearson J., 2008, LINKING LIFE P UNPUB; Freedenthal S, 2011, J CLIN PSYCHOL, V67, P609, DOI 10.1002/jclp.20782; GAVIN DR, 1989, BRIT J ADDICT, V84, P301; Gutierrez PM, 2013, J CLIN PSYCHOL, V69, P923, DOI 10.1002/jclp.21997; Haney E.M., 2012, 05225 VAESP; HORN JL, 1965, PSYCHOMETRIKA, V30, P179, DOI 10.1007/BF02289447; IBM Corp, 2012, IBM SPSS WIND 21 0 S; Jobes D.A., 2006, MANAGING SUICIDAL RI; Joiner T. E., 2005, WHY PEOPLE DIE SUICI; Joiner TE, 2000, J CONSULT CLIN PSYCH, V68, P909, DOI 10.1037/0022-006X.68.5.909; Joiner TE, 2002, J SOC CLIN PSYCHOL, V21, P531, DOI 10.1521/jscp.21.5.531.22624; Joiner TE, 2009, J ABNORM PSYCHOL, V118, P634, DOI 10.1037/a0016500; KAISER HF, 1970, PSYCHOMETRIKA, V35, P401, DOI 10.1007/BF02291817; Lance CE, 2006, ORGAN RES METHODS, V9, P202, DOI 10.1177/1094428105284919; LINEHAN MM, 1983, J CONSULT CLIN PSYCH, V51, P276, DOI 10.1037/0022-006X.51.2.276; Lorenzo-Seva U, 2006, BEHAV RES METHODS, V38, P88, DOI 10.3758/BF03192753; MacCallum RC, 1999, PSYCHOL METHODS, V4, P84, DOI 10.1037/1082-989x.4.1.84; MARDIA KV, 1970, BIOMETRIKA, V57, P519, DOI 10.2307/2334770; Marsh HW, 2013, PSYCHOL ASSESSMENT, V25, P796, DOI 10.1037/a0032573; Marty MA, 2012, J CLIN PSYCHOL, V68, P1008, DOI 10.1002/jclp.21877; McDonald R. P., 1999, TEST THEORY UNIFIED; Monteith LL, 2013, SUICIDE LIFE-THREAT, V43, P418, DOI 10.1111/sltb.12027; Muthen L. K., 1998, MPLUS 7 3 COMPUTER S; Nademin E, 2008, ARCH SUICIDE RES, V12, P309, DOI 10.1080/13811110802324847; Nock MK, 2014, JAMA PSYCHIAT, V71, P514, DOI 10.1001/jamapsychiatry.2014.30; Osman A, 1993, PSYCHOL ASSESSMENT, V5, P154, DOI DOI 10.1037/1040-3590.5.2.154; Osman A., 2010, MSRI28 U TEX SAN AN; Pfeiffer PN, 2014, J AFFECT DISORDERS, V152, P277, DOI 10.1016/j.jad.2013.09.025; Ribeiro JD, 2013, J PSYCHOTHER INTEGR, V23, P207, DOI 10.1037/a0031416; Ribeiro JD, 2014, PSYCHOL ASSESSMENT, V26, P115, DOI 10.1037/a0034858; Rogers J. R., 2001, SUICIDE RESOURCES NE, P31; Schwartz SH, 2004, J RES PERS, V38, P230, DOI 10.1016/S0092-6566(03)00069-2; Selby EA, 2010, CLIN PSYCHOL REV, V30, P298, DOI 10.1016/j.cpr.2009.12.004; Stefanic N., 2008, LINKING LIFE P UNPUB; STROSAHL K, 1992, COMPR PSYCHIAT, V33, P366, DOI 10.1016/0010-440X(92)90057-W; TUCKER LR, 1973, PSYCHOMETRIKA, V38, P1, DOI 10.1007/bf02291170; Tucker RP, 2015, SUICIDE LIFE-THREAT, V45, P679, DOI 10.1111/sltb.12161; Van Orden KA, 2008, J CONSULT CLIN PSYCH, V76, P72, DOI 10.1037/0022-006X.76.1.72; Van Orden KA, 2012, PSYCHOL ASSESSMENT, V24, P197, DOI 10.1037/a0025358; Yuan KH, 2000, SOCIOL METHODOL, V30, P165, DOI 10.1111/0081-1750.00078; Zinbarg RE, 2005, PSYCHOMETRIKA, V70, P123, DOI 10.1007/s11336-003-0974-7	65	24	24	1	10	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1040-3590	1939-134X		PSYCHOL ASSESSMENT	Psychol. Assess.	DEC	2016	28	12					1684	1694		10.1037/pas0000310			11	Psychology, Clinical	Psychology	EE0ZE	WOS:000389308700015	26998894				2021-06-18	
J	Isaev, NK; Stelmashook, EV; Genrikhs, EE; Korshunova, GA; Sumbatyan, NV; Kapkaeva, MR; Skulachev, VP				Isaev, Nickolay K.; Stelmashook, Elena V.; Genrikhs, Elisaveta E.; Korshunova, Galina A.; Sumbatyan, Natalya V.; Kapkaeva, Marina R.; Skulachev, Vladimir P.			Neuroprotective properties of mitochondria-targeted antioxidants of the SkQ-type	REVIEWS IN THE NEUROSCIENCES			English	Article						Alzheimer's disease; brain stroke; mitochondria-targeted antioxidant; neuroprotection; traumatic brain injury	TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; INDUCED NEUROLOGICAL DEFICIT; BETA-INDUCED IMPAIRMENT; AMYLOID-BETA; ALZHEIMERS-DISEASE; PLASTOQUINONE DERIVATIVES; INTERRUPT EXECUTION; CEREBRAL-ISCHEMIA; RAT	In 2008, using a model of compression brain ischemia, we presented the first evidence that mitochondria-targeted antioxidants of the SkQ family, i.e. SkQR1 [10-(6'-plastoquinonyl)decylrhodamine], have a neuroprotective action. It was shown that intraperitoneal injections of SkQR1 (0.5-1 mu mol/kg) 1 day before ischemia significantly decreased the damaged brain area. Later, we studied in more detail the anti-ischemic action of this antioxidant in a model of experimental focal ischemia provoked by unilateral intravascular occlusion of the middle cerebral artery. The neuroprotective action of SkQ family compounds (SkQR1, SkQ1, SkQTR1, SkQT1) was manifested through the decrease in trauma-induced neurological deficit in animals and prevention of amyloid-beta-induced impairment of long-term potentiation in rat hippocampal slices. At present, most neurophysiologists suppose that long-term potentiation underlies cellular mechanisms of memory and learning. They consider inhibition of this process by amyloid-beta(1-42) as an in vitro model of memory disturbance in Alzheimer's disease. Further development of the above studies revealed that mitochondria- targeted antioxidants could retard accumulation of hyperphosphorylated tau-protein, as well as amyloid-beta(1-42), and its precursor APP in the brain, which are involved in developing neurodegenerative processes in Alzheimer's disease.	[Isaev, Nickolay K.; Korshunova, Galina A.; Sumbatyan, Natalya V.; Skulachev, Vladimir P.] Lomonosov Moscow State Univ, Belozersky Res Inst Physicochem Biol, Dept Bioenerget, Leninsky Gory,1,B 40, Moscow 119992, Russia; [Isaev, Nickolay K.; Stelmashook, Elena V.; Genrikhs, Elisaveta E.; Kapkaeva, Marina R.] Res Ctr Neurol, Brain Res Dept, Moscow 125367, Russia	Isaev, NK (corresponding author), Lomonosov Moscow State Univ, Belozersky Res Inst Physicochem Biol, Dept Bioenerget, Leninsky Gory,1,B 40, Moscow 119992, Russia.; Isaev, NK (corresponding author), Res Ctr Neurol, Brain Res Dept, Moscow 125367, Russia.	isaev@genebee.msu.ru	Sumbatyan, Nataliya V./B-2902-2015; Isaev, Nikolay K/B-4194-2012; Kapkaeva, Marina/AAO-1646-2020; Sumbatyan, Natalia/AAI-4474-2021; Genrikhs, Elizaveta E/C-3854-2012; Stelmashook, Elena V/B-4442-2012	Sumbatyan, Natalia/0000-0001-9361-7314; Skulachev, Vladimir/0000-0001-5141-7517	Russian Science FoundationRussian Science Foundation (RSF) [16-15-10108, 14-24-00107]	This work was done with financial support from the Russian Science Foundation (Project no. 16-15-10108, section 'SkQs decrease brain damage after traumatic brain injury', and no. 14-24-00107, section 'SkQs decrease brain damage after ischemia' and 'SkQ in models of Alzheimer's disease').	Antonenko YN, 2008, J MEMBRANE BIOL, V222, P141, DOI 10.1007/s00232-008-9108-6; Antonenko YN, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1273, DOI 10.1134/S0006297908120018; Bakeeva LE, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1288, DOI 10.1134/S000629790812002X; Burits M, 2000, PHYTOTHER RES, V14, P323, DOI 10.1002/1099-1573(200008)14:5&lt;323::AID-PTR621&gt;3.0.CO;2-Q; Calkins MJ, 2012, PHARMACEUTICALS, V5, P1103, DOI 10.3390/ph5101103; Chatagner A, 2010, ARCH PEDIATRIE, V17, pS78, DOI 10.1016/S0929-693X(10)70905-2; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; DERYCK M, 1989, STROKE, V20, P1383, DOI 10.1161/01.STR.20.10.1383; Di Domenico F, 2015, EXPERT REV NEUROTHER, V15, P19, DOI 10.1586/14737175.2015.955853; Egea J, 2014, NEUROSCIENCE, V267, P11, DOI 10.1016/j.neuroscience.2014.02.025; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fernandez-Gajardo R, 2014, CNS DRUGS, V28, P229, DOI 10.1007/s40263-013-0138-y; Genrikhs EE, 2015, J DRUG TARGET, V23, P347, DOI 10.3109/1061186X.2014.997736; GREEN DE, 1974, BIOCHIM BIOPHYS ACTA, V346, P27, DOI 10.1016/0304-4173(74)90011-1; Gupta R, 2016, REV NEUROSCIENCE, V27, P93, DOI 10.1515/revneuro-2015-0017; Hobbs CE, 2008, PEDIATR INT, V50, P481, DOI 10.1111/j.1442-200X.2008.02705.x; Isaev NK, 2015, BIOCHEMISTRY-MOSCOW+, V80, P1578, DOI 10.1134/S0006297915120056; Isaev NK, 2012, BIOCHEMISTRY-MOSCOW+, V77, P996, DOI 10.1134/S0006297912090052; Ji J, 2015, J CEREBR BLOOD F MET, V35, P319, DOI 10.1038/jcbfm.2014.204; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Jolkkonen J, 2000, EUR J PHARMACOL, V400, P211, DOI 10.1016/S0014-2999(00)00409-X; Kapay NA, 2011, BIOCHEMISTRY-MOSCOW+, V76, P1367, DOI 10.1134/S0006297911120108; Kapay NA, 2013, J ALZHEIMERS DIS, V36, P377, DOI 10.3233/JAD-122428; Kapinya KJ, 2002, STROKE, V33, P1889, DOI 10.1161/01.STR.0000020092.41820.58; Kirpatovsky VI, 2013, BIOCHEMISTRY-MOSCOW+, V78, P542, DOI 10.1134/S0006297913050131; Lloret A, 2011, J ALZHEIMERS DIS, V27, P701, DOI 10.3233/JAD-2011-110890; Loshchenova PS, 2015, BIOCHEMISTRY-MOSCOW+, V80, P596, DOI 10.1134/S0006297915050120; Ma T, 2011, J NEUROSCI, V31, P5589, DOI 10.1523/JNEUROSCI.6566-10.2011; Manczak M, 2010, J ALZHEIMERS DIS, V20, pS609, DOI 10.3233/JAD-2010-100564; McManus MJ, 2011, J NEUROSCI, V31, P15703, DOI 10.1523/JNEUROSCI.0552-11.2011; Persson T, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/427318; Plotnikov EY, 2010, BIOCHEMISTRY-MOSCOW+, V75, P145, DOI 10.1134/S0006297910020045; Severina II, 2013, FEBS LETT, V587, P2018, DOI 10.1016/j.febslet.2013.04.043; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Silachev DN, 2015, MOLECULES, V20, P14487, DOI 10.3390/molecules200814487; Silachev DN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051553; Skulachev MV, 2011, CURR DRUG TARGETS, V12, P800; Skulachev VP, 2007, BIOCHEMISTRY-MOSCOW+, V72, P1385, DOI 10.1134/S0006297907120139; Skulachev V. P., 2014, MITOCHONDRIA TARGETE, P195, DOI 10.1016/B978-0-12-405933-7.00019-6; Skulachev VP, 2012, J ALZHEIMERS DIS, V28, P283, DOI 10.3233/JAD-2011-111391; Skulachev VP, 2009, BBA-BIOENERGETICS, V1787, P437, DOI 10.1016/j.bbabio.2008.12.008; Stefanova NA, 2014, J ALZHEIMERS DIS, V38, P681, DOI 10.3233/JAD-131034; Stelmashook EV, 2015, BIOCHEMISTRY-MOSCOW+, V80, P592, DOI 10.1134/S0006297915050119; Ulamek-Koziol M, 2016, PHARMACOL REP, V68, P582, DOI 10.1016/j.pharep.2016.01.006; Vermeer SE, 2003, NEW ENGL J MED, V348, P1215, DOI 10.1056/NEJMoa022066; Walker KR, 2012, J NEUROSCI, V32, P10423, DOI 10.1523/JNEUROSCI.5491-11.2012; Watanabe S, 2001, STROKE, V32, P2615, DOI 10.1161/hs1101.097384; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang ST, 2015, J NEUROL SCI, V349, P99, DOI 10.1016/j.jns.2014.12.032; Yani EV, 2012, PRACTICHESKAYA MED, V59, P134	51	24	29	0	13	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0334-1763	1607-8470		REV NEUROSCIENCE	Rev. Neurosci.	DEC	2016	27	8					849	855		10.1515/revneuro-2016-0036			7	Neurosciences	Neurosciences & Neurology	ED9SU	WOS:000389213900006	27559690				2021-06-18	
J	Makdissi, M; Davis, G				Makdissi, Michael; Davis, Gavin			Using video analysis for concussion surveillance in Australian football	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Brain concussion; Football; Video analysis; Epidemiology	SPORT-RELATED CONCUSSION; HOCKEY LEAGUE NHL; KNOWLEDGE; INJURIES; EPIDEMIOLOGY; MECHANISMS; RISK	Objectives: The objectives of the study were to assess the relationship between various player and game factors and risk of concussion; and to assess the reliability of video analysis for mechanistic assessment of concussion in Australian football. Design: Prospective cohort study. Methods: All impacts and collisions resulting in concussion were identified during the 2011 Australian Football League season. An extensive list of factors for assessment was created based upon previous analysis of concussion in Australian Football League and expert opinions. The authors independently reviewed the video clips and correlation for each factor was examined. Results: A total of 82 concussions were reported in 194 games (rate: 8.7 concussions per 1000 match hours; 95% confidence interval: 6.9-10.5). Player demographics and game variables such as venue, timing of the game (day, night or twilight), quarter, travel status (home or interstate) or score margin did not demonstrate a significant relationship with risk of concussion; although a higher percentage of concussions occurred in the first 5 min of game time of the quarter (36.6%), when compared to the last 5 min (20.7%). Variables with good inter-rater agreement included position on the ground, circumstances of the injury and cause of the impact. The remainder of the variables assessed had fair-poor inter-rater agreement. Common problems included insufficient or poor quality video and interpretation issues related to the definitions used. Conclusions: Clear definitions and good quality video from multiple camera angles are required to improve the utility of video analysis for concussion surveillance in Australian football. (C) 2016 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Makdissi, Michael; Davis, Gavin] Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Austin Campus, Melbourne, Vic, Australia; [Makdissi, Michael] Federat Univ, Australian Ctr Res Injury Sport & Its Prevent ACR, Ballarat, Vic, Australia; [Makdissi, Michael] La Trobe Univ, Sch Allied Hlth, Bundoora, Vic 3086, Australia; [Davis, Gavin] Austin Hosp, Dept Neurosurg, Heidelberg, Vic, Australia; [Davis, Gavin] Cabrini Hlth, Dept Neurosurg, Malvern, Vic, Australia	Makdissi, M (corresponding author), Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Austin Campus, Melbourne, Vic, Australia.; Makdissi, M (corresponding author), Federat Univ, Australian Ctr Res Injury Sport & Its Prevent ACR, Ballarat, Vic, Australia.; Makdissi, M (corresponding author), La Trobe Univ, Sch Allied Hlth, Bundoora, Vic 3086, Australia.	makdissi@unimelb.edu.au					Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Bahr R, 2005, BRIT J SPORT MED, V39, P324, DOI 10.1136/bjsm.2005.018341; Benson BW, 2013, BRIT J SPORT MED, V47, P321, DOI 10.1136/bjsports-2013-092216; Bjorneboe J, 2014, BRIT J SPORT MED, V48, P774, DOI 10.1136/bjsports-2012-091856; Bjorneboe J, 2013, BRIT J SPORT MED, V47, P508, DOI 10.1136/bjsports-2012-091522; Finch CF, 2013, MED J AUSTRALIA, V198, P427, DOI 10.5694/mja12.11217; Gardner AJ, 2015, BRAIN INJURY, V17, P1; Hutchison MG, 2015, BRIT J SPORT MED, V49, P547, DOI 10.1136/bjsports-2013-092234; Hutchison MG, 2014, BRIT J SPORT MED, V48, P125, DOI 10.1136/bjsports-2012-092059; King D, 2014, SPORTS MED, V44, P449, DOI 10.1007/s40279-013-0134-x; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Makdissi M, 2009, AM J SPORT MED, V37, P877, DOI 10.1177/0363546508328118; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Orchard J, 2002, BRIT J SPORT MED, V36, P39, DOI 10.1136/bjsm.36.1.39; Provvidenza C, 2013, BRIT J SPORT MED, V47, P332, DOI 10.1136/bjsports-2012-092099; White PE, 2014, BRIT J SPORT MED, V48, P119, DOI 10.1136/bjsports-2013-092785	17	24	24	0	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	DEC	2016	19	12					958	963		10.1016/j.jsams.2016.02.014			6	Sport Sciences	Sport Sciences	EG3VO	WOS:000390973000002	27006067				2021-06-18	
J	Seiger, R; Hahn, A; Hummer, A; Kranz, GS; Ganger, S; Woletz, M; Kraus, C; Sladky, R; Kautzky, A; Kasper, S; Windischberger, C; Lanzenberger, R				Seiger, Rene; Hahn, Andreas; Hummer, Allan; Kranz, Georg S.; Ganger, Sebastian; Woletz, Michael; Kraus, Christoph; Sladky, Ronald; Kautzky, Alexander; Kasper, Siegfried; Windischberger, Christian; Lanzenberger, Rupert			Subcortical gray matter changes in transgender subjects after long-term cross-sex hormone administration	PSYCHONEUROENDOCRINOLOGY			English	Article						Hormone therapy; Transgender; Transsexuals; Hormones; Gray matter volume	ESTROGEN-RECEPTOR-ALPHA; TRAUMATIC BRAIN-INJURY; MESSENGER-RNA EXPRESSION; SURFACE-BASED ANALYSIS; HUMAN CEREBRAL-CORTEX; HIPPOCAMPAL NEUROGENESIS; PROGESTERONE TREATMENT; ANDROGEN RECEPTORS; HUMAN HYPOTHALAMUS; PREFRONTAL CORTEX	Sex-steroid hormones are primarily involved in sexual differentiation and development and are thought to underlie processes related to cognition and emotion. However, divergent results have been reported concerning the effects of hormone administration on brain structure including side effects like brain atrophy and dementia. Cross-sex hormone therapy in transgender subjects offers a unique model for studying the effects of sex hormones on the living human brain. In this study, 25 Female-to-Male (FtM) and 14 Male-to-Female (MtF) subjects underwent MRI examinations at baseline and after a period of at least 4-months of continuous cross-sex hormone administration. While MtFs received estradiol and anti-androgens, FtM subjects underwent high-dose testosterone treatment. The longitudinal processing stream of the FreeSurfer software suite was used for the automated assessment and delineation of brain volumes to assess the structural changes over the treatment period of cross-sex hormone administration. Most prominent results were found for MtFs receiving estradiol and anti-androgens in the form of significant decreases in the hippocampal region. Further analysis revealed that these decreases were reflected by increases in the ventricles. Additionally, changes in progesterone levels correlated with changes in gray matter structures in MtF subjects. In line with prior studies, our results indicate hormonal influences on subcortical structures related to memory and emotional processing. Additionally, this study adds valuable knowledge that progesterone may play an important role in this process. (C) 2016 Elsevier Ltd. All rights reserved.	[Seiger, Rene; Hahn, Andreas; Kranz, Georg S.; Ganger, Sebastian; Kraus, Christoph; Kautzky, Alexander; Kasper, Siegfried; Lanzenberger, Rupert] Med Univ Vienna, Dept Psychiat & Psychotherapy, A-1090 Vienna, Austria; [Hummer, Allan; Woletz, Michael; Sladky, Ronald; Windischberger, Christian] Med Univ Vienna, MR Ctr Excellence, Ctr Med Phys & Biomed Engn, A-1090 Vienna, Austria	Lanzenberger, R (corresponding author), Med Univ Vienna, NEUROIMAGING LABs NIL, PET & MRI & EEG & Chem Lab, Dept Psychiat & Psychotherapy, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	rupert.lanzenberger@meduniwien.ac.at	Kranz, Georg S./T-8981-2019; Lanzenberger, Rupert/I-5438-2019	Hummer, Allan/0000-0002-9819-0433; Hahn, Andreas/0000-0001-9727-7580; Lanzenberger, Rupert/0000-0003-4641-9539; Kasper, Siegfried/0000-0001-8278-191X; Woletz, Michael/0000-0002-9200-4468; Windischberger, Christian/0000-0002-9944-0190; Kautzky, Alexander/0000-0001-9251-8285; Kranz, Georg/0000-0002-3892-1804; Kraus, Christoph/0000-0002-7144-2282; Sladky, Ronald/0000-0002-5986-1572; Seiger, Rene/0000-0003-1556-4346			Anderson GD, 2011, J NEUROTRAUM, V28, P1827, DOI 10.1089/neu.2011.1911; Bao AM, 2011, FRONT NEUROENDOCRIN, V32, P214, DOI 10.1016/j.yfrne.2011.02.007; BAULIEU EE, 1990, J STEROID BIOCHEM, V37, P395, DOI 10.1016/0960-0760(90)90490-C; Beyenburg S, 2000, NEUROSCI LETT, V294, P25, DOI 10.1016/S0304-3940(00)01542-1; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; BROWN TJ, 1995, STEROIDS, V60, P726, DOI 10.1016/0039-128X(95)00107-2; Buckwalter JG, 1999, PSYCHONEUROENDOCRINO, V24, P69; Cooke B, 1998, FRONT NEUROENDOCRIN, V19, P323, DOI 10.1006/frne.1998.0171; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; De Nicola AF, 2006, J MOL NEUROSCI, V28, P3, DOI 10.1385/JMN:28:1:3; Derntl B., 2008, PSYCHONEUROENDOCRINO; Drew PD, 2000, J NEUROIMMUNOL, V111, P77, DOI 10.1016/S0165-5728(00)00386-6; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fernandez-Guasti A, 2000, J COMP NEUROL, V425, P422, DOI 10.1002/1096-9861(20000925)425:3<422::AID-CNE7>3.0.CO;2-H; Finley SK, 1999, J NEUROBIOL, V40, P446; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Follesa P, 2000, MOL PHARMACOL, V57, P1262; Galea LAM, 2006, HIPPOCAMPUS, V16, P225, DOI 10.1002/hipo.20154; Gonzalez M, 2007, J COMP NEUROL, V503, P790, DOI 10.1002/cne.21419; Gould E, 2000, BIOL PSYCHIAT, V48, P715, DOI 10.1016/S0006-3223(00)01021-0; GOULD E, 1990, J NEUROSCI, V10, P1286; Griksiene R., 2011, PSYCHONEUROENDOCRINO; Hagler DJ, 2006, NEUROIMAGE, V33, P1093, DOI 10.1016/j.neuroimage.2006.07.036; Hahn A, 2015, CEREB CORTEX, V25, P3527, DOI 10.1093/cercor/bhu194; Hazell GGJ, 2009, J ENDOCRINOL, V202, P223, DOI 10.1677/JOE-09-0066; Hofer P, 2013, EUR NEUROPSYCHOPHARM, V23, P79, DOI 10.1016/j.euroneuro.2012.04.013; Pol HEH, 2006, EUR J ENDOCRINOL, V155, pS107, DOI 10.1530/eje.1.02248; KATO J, 1994, HORM BEHAV, V28, P454, DOI 10.1006/hbeh.1994.1043; Kranz GS, 2014, J NEUROSCI, V34, P15466, DOI 10.1523/JNEUROSCI.2488-14.2014; Kruijver FPM, 2000, J CLIN ENDOCR METAB, V85, P2034, DOI 10.1210/jc.85.5.2034; Kruijver FPM, 2002, J COMP NEUROL, V454, P115, DOI 10.1002/cne.10416; Leranth C, 2003, J NEUROSCI, V23, P1588; MacLusky NJ, 2006, NEUROSCIENCE, V138, P957, DOI 10.1016/j.neuroscience.2005.12.054; Montague D, 2008, J NEUROENDOCRINOL, V20, P893, DOI 10.1111/j.1365-2826.2008.01743.x; Neufang S, 2009, CEREB CORTEX, V19, P464, DOI 10.1093/cercor/bhn100; Osterlund MK, 2000, NEUROSCIENCE, V95, P333; Osterlund MK, 2000, J CLIN ENDOCR METAB, V85, P3840, DOI 10.1210/jc.85.10.3840; Paus T, 2010, HORM BEHAV, V57, P63, DOI 10.1016/j.yhbeh.2009.08.004; Peper JS, 2009, PSYCHONEUROENDOCRINO, V34, P332, DOI 10.1016/j.psyneuen.2008.09.012; PUY L, 1995, J STEROID BIOCHEM, V55, P197, DOI 10.1016/0960-0760(95)00165-V; Rametti G, 2012, PSYCHONEUROENDOCRINO, V37, P1261, DOI 10.1016/j.psyneuen.2011.12.019; Resnick SM, 2009, NEUROLOGY, V72, P135, DOI 10.1212/01.wnl.0000339037.76336.cf; Reuter M, 2012, NEUROIMAGE, V61, P1402, DOI 10.1016/j.neuroimage.2012.02.084; Reuter M, 2011, NEUROIMAGE, V57, P19, DOI 10.1016/j.neuroimage.2011.02.076; Reuter M, 2010, NEUROIMAGE, V53, P1181, DOI 10.1016/j.neuroimage.2010.07.020; Rupprecht R, 1999, TRENDS NEUROSCI, V22, P410, DOI 10.1016/S0166-2236(99)01399-5; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Schulz KM, 2009, HORM BEHAV, V55, P597, DOI 10.1016/j.yhbeh.2009.03.010; Schumacher M, 1996, DEV NEUROSCI-BASEL, V18, P6, DOI 10.1159/000111391; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; SIMERLY RB, 1990, J COMP NEUROL, V294, P76, DOI 10.1002/cne.902940107; Sisk CL, 2005, FRONT NEUROENDOCRIN, V26, P163, DOI 10.1016/j.yfrne.2005.10.003; Stein DG, 2013, HORM BEHAV, V63, P291, DOI 10.1016/j.yhbeh.2012.05.004; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; Steiner M, 2003, J AFFECT DISORDERS, V74, P67, DOI 10.1016/S0165-0327(02)00432-9; Talairach J., 1988, COPLANAR STEREOTAXIC; Toffoletto S, 2014, PSYCHONEUROENDOCRINO, V50, P28, DOI 10.1016/j.psyneuen.2014.07.025; van Wingen GA, 2009, NEUROPSYCHOPHARMACOL, V34, P539, DOI [10.1038/sj.npp.2008.2, 10.1038/npp.2008.2]; Wharton W, 2012, CURR PSYCHIATRY REV, V8, P247, DOI 10.2174/157340012800792957; Witte AV, 2010, NEUROIMAGE, V49, P1205, DOI 10.1016/j.neuroimage.2009.09.046; WOOLLEY CS, 1992, J NEUROSCI, V12, P2549; Yankova M, 2001, P NATL ACAD SCI USA, V98, P3525, DOI 10.1073/pnas.051624598; ZHOU JN, 1995, NATURE, V378, P68, DOI 10.1038/378068a0; Zubiaurre-Elorza L, 2014, J SEX MED, V11, P1248, DOI 10.1111/jsm.12491	67	24	24	1	39	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4530			PSYCHONEUROENDOCRINO	Psychoneuroendocrinology	DEC	2016	74						371	379		10.1016/j.psyneuen.2016.09.028			9	Endocrinology & Metabolism; Neurosciences; Psychiatry	Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry	EB6VW	WOS:000387524700043	27744092				2021-06-18	
J	Haar, CV; Lam, FCW; Adams, WK; Riparip, LK; Kaur, S; Muthukrishna, M; Rosi, S; Winstanley, CA				Haar, Cole Vonder; Lam, Frederick C. W.; Adams, Wendy K.; Riparip, Lara-Kirstie; Kaur, Sukhbir; Muthukrishna, Michael; Rosi, Susanna; Winstanley, Catharine A.			Frontal Traumatic Brain Injury in Rats Causes Long-Lasting Impairments in Impulse Control That Are Differentially Sensitive to Pharmacotherapeutics and Associated with Chronic Neuroinflammation	ACS CHEMICAL NEUROSCIENCE			English	Article						Controlled cortical impact; impulsivity; amphetamine; prelimbic; cytokine	CONTROLLED CORTICAL IMPACT; REACTION-TIME-TASK; COGNITIVE DYSFUNCTION; METHYLPHENIDATE TREATMENT; INFLAMMATORY RESPONSE; ORBITOFRONTAL CORTEX; HEAD-INJURY; ATTENTION; MODERATE; DEFICITS	Traumatic brain injury (TBI) affects millions yearly, and is increasingly associated with chronic neuropsychiatric symptoms. We assessed the long-term effects of different bilateral frontal controlled cortical impact injury severities (mild, moderate, and severe) on the five-choice serial reaction time task, a paradigm with relatively independent measurements of attention, motor impulsivity, and motivation. Moderately-and severely injured animals exhibited impairments across all cognitive domains that were still evident 14 weeks postinjury, while mild-injured animals only demonstrated persistent deficits in impulse control. However, recovery of function varied considerably between subjects such that some showed no impairment ("TBI-resilient"), some demonstrated initial deficits that recovered ("TBI-vulnerable"), and some never recovered ("chronically-impaired"). Three clinically relevant treatments for impulse-control or TBI, amphetamine, atomoxetine, and amantadine, were assessed for efficacy in treating injury-induced deficits. Susceptibility to TBI affected the response to pharmacological challenge with amphetamine. Whereas sham and TBI-resilient animals showed characteristic impairments in impulse control at higher doses, amphetamine had the opposite effect in chronically impaired rats, improving task performance. In contrast, atomoxetine and amantadine reduced premature responding but increased omissions, suggesting psychomotor slowing. Analysis of brain tissue revealed that generalized neuroinflammation was associated with impulsivity even when accounting for the degree of brain damage. This is one of the first studies to characterize psychiatric-like symptoms in experimental TBI. Our data highlight the importance of testing pharmacotherapies in TBI models in order to predict efficacy, and suggest that neuroinflammation may represent a treatment target for impulse control problems following injury.	[Haar, Cole Vonder; Lam, Frederick C. W.; Adams, Wendy K.; Kaur, Sukhbir; Winstanley, Catharine A.] Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, 2215 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada; [Haar, Cole Vonder; Lam, Frederick C. W.; Adams, Wendy K.; Muthukrishna, Michael; Winstanley, Catharine A.] Univ British Columbia, Dept Psychol, Vancouver, BC V6T 1Z3, Canada; [Riparip, Lara-Kirstie; Rosi, Susanna] Univ Calif San Francisco, Dept Phys Therapy Rehabil Sci, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA; [Riparip, Lara-Kirstie; Rosi, Susanna] Univ Calif San Francisco, Dept Neurol Surg, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA; [Haar, Cole Vonder] West Virginia Univ, Injury & Recovery Lab, Dept Psychol, Morgantown, WV USA	Winstanley, CA (corresponding author), Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, 2215 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.; Haar, CV (corresponding author), Dept Psychol, 53 Campus Dr, Morgantown, WV 26506 USA.	cole.vonderhaar@mail.wvu.edu; cwinstanley@psych.ubc.ca	Muthukrishna, Michael/Z-1655-2019	Muthukrishna, Michael/0000-0002-7079-5166; Vonder Haar, Cole/0000-0001-7949-2068	Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for Health ResearchMichael Smith Foundation for Health Research; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS087458]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS087458] Funding Source: NIH RePORTER	This work was supported by the Canadian Institutes for Health Research, the Michael Smith Foundation for Health Research, and the National Institute of Neurological Disorders and Stroke (R21NS087458).	Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; CARLI M, 1983, BEHAV BRAIN RES, V9, P361, DOI 10.1016/0166-4328(83)90138-9; Coccaro EF, 2014, JAMA PSYCHIAT, V71, P158, DOI 10.1001/jamapsychiatry.2013.3297; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Comeau WL, 2014, EUR J NEUROSCI, V40, P3078, DOI 10.1111/ejn.12671; Courtet P., 2016, WORLD J BIOL PSYCHIA, P1; Davidson J, 2015, NEUROSCIENTIST, V21, P424, DOI 10.1177/1073858414543150; Diaz-Arrastia R., 2014, TRAUMATIC BRAIN INJU, P183; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Donegan JJ, 2014, J NEUROSCI, V34, P953, DOI 10.1523/JNEUROSCI.3968-13.2014; Gatson JW, 2013, J TRAUMA ACUTE CARE, V74, P470, DOI 10.1097/TA.0b013e31827e1f51; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Greve KW, 2001, BRAIN INJURY, V15, P255; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Kasturi BS, 2009, J NEUROTRAUM, V26, P1315, DOI [10.1089/neu.2008.0751, 10.1089/neu.2008-0751]; Leeds PR, 2014, ACS CHEM NEUROSCI, V5, P422, DOI 10.1021/cn500040g; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Martens KM, 2012, J NEUROTRAUM, V29, P2505, DOI 10.1089/neu.2012.2388; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Najjar S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-43; Navarra R, 2008, PROG NEURO-PSYCHOPH, V32, P34, DOI 10.1016/j.pnpbp.2007.06.017; Piao CS, 2013, NEUROBIOL DIS, V54, P252, DOI 10.1016/j.nbd.2012.12.017; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Reeves RR, 2011, J PSYCHOSOC NURS MEN, V49, P42, DOI 10.3928/02793695-20110201-03; Robbins TW, 2002, PSYCHOPHARMACOLOGY, V163, P362, DOI 10.1007/s00213-002-1154-7; Rochat L, 2010, NEUROPSYCHOL REHABIL, V20, P778, DOI 10.1080/09602011.2010.495245; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Rosenblat JD, 2015, J AFFECT DISORDERS, V188, P149, DOI 10.1016/j.jad.2015.08.058; SEMCHUK KM, 1993, NEUROLOGY, V43, P1173, DOI 10.1212/WNL.43.6.1173; Shear DA, 2010, J NEUROTRAUM, V27, P1911, DOI 10.1089/neu.2010.1399; Shim SS, 2016, J NEUROTRAUM, V33, P2065, DOI 10.1089/neu.2015.4177; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; Sun HS, 2012, PSYCHOPHARMACOLOGY, V219, P285, DOI 10.1007/s00213-011-2419-9; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vaishnavi S, 2009, PSYCHOSOMATICS, V50, P198, DOI 10.1176/appi.psy.50.3.198; van der Staay FJ, 2006, BRAIN RES REV, V52, P131, DOI 10.1016/j.brainresrev.2006.01.006; Vonder Haar C, 2016, J NEUROTRAUM, V33, P1892, DOI 10.1089/neu.2015.4276; Vonder Haar C, 2014, J NEUROTRAUM, V31, P1711, DOI 10.1089/neu.2014.3459; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wang T, 2014, J NEUROTRAUM, V31, P370, DOI 10.1089/neu.2013.2917; Winstanley CA, 2010, BEHAV BRAIN RES, V210, P263, DOI 10.1016/j.bbr.2010.02.044; Yan H, 2012, CHINESE MED J-PEKING, V125, P1618, DOI 10.3760/cma.j.issn.0366-6999.2012.09.018; Yu G, 2016, J CHILD ADOL PSYCHOP, V26, P314, DOI 10.1089/cap.2015.0137; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang Y, 2014, J NEUROSCI, V34, P11929, DOI [10.11772/j.issn.1001-9081.2014.07.1929, 10.1523/JNEUROSCI.1860-14.2014]; Zou HC, 2013, NEUROREHAB NEURAL RE, V27, P878, DOI 10.1177/1545968313491007	54	24	24	0	9	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1948-7193			ACS CHEM NEUROSCI	ACS Chem. Neurosci.	NOV	2016	7	11					1531	1542		10.1021/acschemneuro.6b00166			12	Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology	EC9AA	WOS:000388433000009	27525447	Green Accepted			2021-06-18	
J	Govindarajan, KA; Narayana, PA; Hasan, KM; Wilde, EA; Levin, HS; Hunter, JV; Miller, ER; Patel, VKS; Robertson, CS; McCarthy, JJ				Govindarajan, Koushik A.; Narayana, Ponnada A.; Hasan, Khader M.; Wilde, Elisabeth A.; Levin, Harvey S.; Hunter, Jill V.; Miller, Emmy R.; Patel, Vipul Kumar S.; Robertson, Claudia S.; McCarthy, James J.			Cortical Thickness in Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cortical thickness; FreeSurfer; longitudinal analysis; mTBI; orthopedic injury	HUMAN CEREBRAL-CORTEX; COORDINATE SYSTEM; HEAD-INJURY; VETERANS; ACCURATE; SURFACE; MODELS; MRI	Magnetic resonance imaging data were acquired at approximate to 24h and approximate to 3 months post-injury on mild traumatic brain injury (mTBI; n=75) and orthopedic injury (n=60) cohorts. The mTBI subjects were randomly assigned to a treatment group with atorvastatin or a non-treatment mTBI group. The treatment group was further divided into drug and placebo subgroups. FreeSurfer software package was used to compute cortical thickness based on the three dimensional T1-weighted images at both time-points. Cross-sectional analysis was carried out to compare cortical thickness between the mTBI and control groups. Longitudinal unbiased templates were generated for all subjects and cortical thickness measurements were compared between baseline and follow-up scans in the mTBI group. At baseline, significant reduction in cortical thickness was observed in the left middle temporal and the right superior parietal regions in the mTBI group, relative to the control group (p=0.01). At follow-up, significant cortical thinning was again observed in the left middle temporal cortex in the mTBI group. Further analysis revealed significant cortical thinning only in the non-treatment group relative to the control group. In the follow-up, small regions with significant but subtle cortical thinning and thickening were seen in the frontal, temporal, and parietal lobes in the left hemisphere in the non-treatment group only. Our results indicate that cortical thickness could serve as a useful measure in identifying subtle changes in mTBI patients.	[Govindarajan, Koushik A.; Narayana, Ponnada A.; Hasan, Khader M.; Patel, Vipul Kumar S.] Univ Texas Hlth Sci Ctr Houston, Dept Diagnost & Intervent Imaging, Houston, TX 77030 USA; [McCarthy, James J.] Univ Texas Hlth Sci Ctr Houston, Dept Emergency Med, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Miller, Emmy R.] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA	Narayana, PA (corresponding author), Univ Texas Med Sch Houston, Dept Diagnost & Intervent Imaging, 6431 Fannin St, Houston, TX 77030 USA.	ponnada.a.narayana@uth.tmc.edu	Govindarajan, Koushik Athreya/L-9758-2019; Hasan, Khader M./ABB-5767-2020	Govindarajan, Koushik/0000-0001-8397-1360			Assistant Secretary of Defense for Health Affairs, 2007, HLTH AFF MEM TRAUM B; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Corbo V, 2014, PSYCHIAT RES-NEUROIM, V223, P53, DOI 10.1016/j.pscychresns.2014.04.013; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Hasan KM, 2014, J NEUROTRAUM, V31, P466, DOI [10.1089/NEU.2013.3085, 10.1089/neu.2013.3085]; Iscan Z, 2015, HUM BRAIN MAPP, V36, P3472, DOI 10.1002/hbm.22856; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Keightley M., 2014, ARCH PHYS MED REHAB, V95, pe68; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lindemer ER, 2013, NEUROIMAGE-CLIN, V2, P601, DOI 10.1016/j.nicl.2013.04.009; Narayana PA, 2013, NEUROIMAGE-CLIN, V2, P120, DOI 10.1016/j.nicl.2012.11.009; Reuter M., 2012, LONGITUDINAL FREESUR; Reuter M, 2012, NEUROIMAGE, V61, P1402, DOI 10.1016/j.neuroimage.2012.02.084; Reuter M, 2010, NEUROIMAGE, V53, P1181, DOI 10.1016/j.neuroimage.2010.07.020; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; Tate DF, 2014, BRAIN IMAGING BEHAV, V8, P102, DOI 10.1007/s11682-013-9257-9; Wang X, 2015, J NEUROTRAUM, V32, P455, DOI 10.1089/neu.2014.3492; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763	27	24	24	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2016	33	20					1809	1817		10.1089/neu.2015.4253			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EA6YO	WOS:000386775300001	26959810	Green Published			2021-06-18	
J	Armstead, WM; Riley, J; Vavilala, MS				Armstead, William M.; Riley, John; Vavilala, Monica S.			Norepinephrine Protects Cerebral Autoregulation and Reduces Hippocampal Necrosis after Traumatic Brain Injury via Blockade of ERK MAPK and IL-6 in Juvenile Pigs	JOURNAL OF NEUROTRAUMA			English	Article						age; brain injury; cerebral autoregulation; histopathology; sex; signal transduction; vasopressor	TRANSIENT HYPEREMIC RESPONSE; NITROUS-OXIDE; UP-REGULATION; CHILDREN; HYPOTENSION; IMPAIRMENT; PREDICTORS; NEWBORN; PHENYLEPHRINE; INTERLEUKIN-6	Traumatic brain injury (TBI) contributes to morbidity in children, and boys are disproportionately represented. Cerebral autoregulation is impaired after TBI, contributing to poor outcome. Cerebral perfusion pressure (CPP) is often normalized by use of vasoactive agents to increase mean arterial pressure (MAP). In prior studies of 1-to 5-day-old newborn piglets, we observed that norepinephrine (NE) preferentially protected cerebral autoregulation and prevented hippocampal necrosis in females but not males after fluid percussion injury (FPI). The ERK isoform of mitogen activated protein kinase (MAPK) produces hemodynamic impairment after FPI, but less is known about the role of the cytokine interleukin-6 (IL-6). We investigated whether NE protects autoregulation and limits histopathology after FPI in older juvenile (4-week-old) pigs and the role of ERK and IL-6 in that outcome by sex. Results show that NE significantly protects autoregulation and prevents reduction in cerebral blood flow (CBF) in both male and female juvenile pigs after FPI; co-administration of the ERK antagonist U 0126 with NE fully protects both indices of outcome. Papaverine induced dilation was unchanged by FPI and NE. NE blunted ERK MAPK and IL-6 upregulation in both males and females after FPI. NE attenuated loss of neurons in CA1 and CA3 hippocampus of males and females after FPI. These data indicate that NE protects autoregulation and limits hippocampal neuronal cell necrosis via blockade of ERK and IL-6 after FPI in both male and female juvenile pigs. These data suggest that use of NE to improve outcome after TBI is both sex and age dependent.	[Armstead, William M.; Riley, John] Univ Penn, Dept Anesthesiol & Crit Care, 3620 Hamilton Walk,JM3, Philadelphia, PA 19104 USA; [Armstead, William M.] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol Pediat & Neurol Surg, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA	Armstead, WM (corresponding author), Univ Penn, Dept Anesthesiol & Crit Care, 3620 Hamilton Walk,JM3, Philadelphia, PA 19104 USA.	armsteaw@uphs.upenn.edu		Riley, John/0000-0002-7932-8935	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS090998] Funding Source: NIH RePORTER		Armstead WM, 2007, J CEREBR BLOOD F MET, V27, P1702, DOI 10.1038/sj.jcbfm.9600473; Armstead WM, 2016, PEDIATR CRIT CARE ME, V17, pe130, DOI 10.1097/PCC.0000000000000603; Armstead WM, 2013, PEDIATR CRIT CARE ME, V14, pE103, DOI 10.1097/PCC.0b013e3182712b44; Armstead WM, 2012, J NEUROTRAUM, V29, P1794, DOI 10.1089/neu.2012.2328; Armstead WM, 2010, CRIT CARE MED, V38, P1868, DOI 10.1097/CCM.0b013e3181e8ac1a; Armstead WM, 2010, J NEUROTRAUM, V27, P391, DOI 10.1089/neu.2009.1094; Armstead William M., 2016, ANESTHESIOLOGY CLIN, V34, P465; Armstead WM, 2000, MICROCIRCULATION, V7, P225, DOI 10.1038/sj.mn.7300110; Bedford NM, 1999, ANESTH ANALG, V89, P170; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Carter BG, 2008, CHILD NERV SYST, V24, P245, DOI 10.1007/s00381-007-0461-z; Catala-Temprano A, 2007, J NEUROSURG, V106, P463, DOI 10.3171/ped.2007.106.6.463; Chaiwat O, 2009, J NEUROTRAUM, V26, P657, DOI 10.1089/neu.2008.0770; Di Gennaro JL, 2010, DEV NEUROSCI-BASEL, V32, P420, DOI 10.1159/000322083; Dobbing J, 1981, SCI F PAEDIATRICS, P744; Freeman SS, 2008, ANESTHESIOLOGY, V108, P588, DOI 10.1097/ALN.0b013e31816725d7; Girling KJ, 1999, ANESTH ANALG, V89, P175, DOI 10.1097/00000539-199907000-00031; Ishikawa S, 2009, ANESTH ANALG, V108, P1631, DOI 10.1213/ane.0b013e31819d94e3; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Newacheck PW, 2004, PEDIATRICS, V114, P79, DOI 10.1542/peds.114.1.79; Oto J, 2008, J ANESTH, V22, P207, DOI 10.1007/s00540-008-0639-x; Sharma D, 2010, J NEUROSURG ANESTH, V22, P132, DOI 10.1097/ANA.0b013e3181c9fbf1; Sookplung P, 2011, NEUROCRIT CARE, V15, P46, DOI 10.1007/s12028-010-9448-9; Steiner LA, 2004, CRIT CARE MED, V32, P1049, DOI 10.1097/01.CCM.0000120054.32845.A6; Tibble RK, 2001, ANESTH ANALG, V93, P171; Yang SH, 2013, SHOCK, V40, P471, DOI 10.1097/SHK.0000000000000037	27	24	26	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2016	33	19					1761	+		10.1089/neu.2015.4290			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DY8KP	WOS:000385379100004	26597684	Green Published			2021-06-18	
J	Honeybul, S; Ho, KM				Honeybul, Stephen; Ho, Kwok M.			Cranioplasty: morbidity and failure	BRITISH JOURNAL OF NEUROSURGERY			English	Article						Complications; cranioplasty; decompressive craniectomy; outcome	MIDDLE CEREBRAL-ARTERY; DEATH FOLLOWING CRANIOPLASTY; TRAUMATIC BRAIN-INJURY; DECOMPRESSIVE CRANIECTOMY; HEAD-INJURY; AUTOLOGOUS BONE; RISK-FACTORS; COMPLICATION; HEMICRANIECTOMY; RESORPTION	Objective: Cranioplasty is a technically straightforward procedure; however, it is becoming increasingly apparent that it is associated with relatively high morbidity and a significant failure rate due to either infection or autologous bone flap resorption. The aim of this study was to determine which factors influenced the incidence of cranioplasty complications and failure. Methods: A retrospective analysis was undertaken of all patients who had a cranioplasty at the two major trauma hospitals in Western Australia between the start of 2004 and the middle of 2015. Results: Five hundred and twelve had a cranioplasty after craniectomy for a variety of different indications. Sixty-three patients developed a postoperative intracranial collection following cranioplasty (12.3%, 95% confidence interval [Cl] 9.7-15.4), however only 19 required surgical evacuation. One hundred and twenty-one patients had seizures following cranioplasty (23.6%, 95% Cl 20.2-27.5) Nine patients died within six months following cranioplasty. Forty-two patients (8.2%, 95% Cl 6.1-10.9) developed cranioplasty infection that necessitated removal of the implant. However a change in clinical management of these patients had led to no infections for the past three years. Amongst 330 patients who had autologous cranioplasty, clinically significant bone resorption occurred in 69 patients (20.9%, 95% Cl 16.9-25.6). Conclusion: One key finding in this study is the reduction in infection rate that can occur when a single senior clinician performs the procedure and there is strict adherence to aseptic technique. This may result in a significant reduction in morbidity.	[Honeybul, Stephen] Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA, Australia; [Honeybul, Stephen] Royal Perth Hosp, Perth, WA, Australia; [Ho, Kwok M.] Royal Perth Hosp, Dept Intens Care, Perth, WA, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat Hlth, Perth, WA, Australia; [Ho, Kwok M.] Murdoch Univ, Sch Vet & Life Sci, Murdoch, WA 6150, Australia	Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA, Australia.; Honeybul, S (corresponding author), Royal Perth Hosp, Perth, WA, Australia.	stephen.honeybul@health.wa.gov.au	Ho, Kwok M./E-3546-2010	Ho, Kwok M./0000-0002-6705-6004	WA Health and Raine Medical Research Foundation through the Raine Clinical Research Fellowship	K.M.H. is funded by WA Health and Raine Medical Research Foundation through the Raine Clinical Research Fellowship.	Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Agrawal D, 2005, EUR J CLIN MICROBIOL, V24, P772, DOI 10.1007/s10096-005-0017-7; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Coulter IC, 2014, ACTA NEUROCHIR, V156, P1361, DOI 10.1007/s00701-014-2081-1; Day RE, 2012, BRIT J ORAL MAX SURG, V50, P376, DOI 10.1016/j.bjoms.2011.05.001; Di Rienzo A, 2008, ACTA NEUROCHIR, V150, P1057, DOI 10.1007/s00701-008-0019-1; Dunisch P, 2013, J NEUROSURG, V118, P1141, DOI 10.3171/2013.1.JNS12860; Ferro JM, 2011, STROKE, V42, P2825, DOI 10.1161/STROKEAHA.111.615393; FISHER CM, 1994, SURG NEUROL, V41, P65, DOI 10.1016/0090-3019(94)90210-0; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grant FC, 1939, ANN SURG, V110, P488, DOI 10.1097/00000658-193910000-00002; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Honeybul S, 2013, BRAIN INJURY, V27, P979, DOI 10.3109/02699052.2013.794974; Honeybul S, 2010, J CLIN NEUROSCI, V17, P430, DOI 10.1016/j.jocn.2009.09.007; Honeybul S, 2009, J CLIN NEUROSCI, V16, P727, DOI 10.1016/j.jocn.2008.06.015; Honeybul S, 2016, J NEUROSURG, V18, P1; Honeybul S, 2016, J NEUROSURG-PEDIATR, V17, P701, DOI 10.3171/2015.11.PEDS15556; Honeybul S, 2013, BRIT J NEUROSURG, V27, P636, DOI 10.3109/02688697.2013.817532; Honeybul S, 2012, PLAST RECONSTR SURG, V130, P1110, DOI 10.1097/PRS.0b013e318267d4de; Honeybul S, 2011, BRIT J NEUROSURG, V25, P343, DOI 10.3109/02688697.2011.568643; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Kelly AG, 2010, NEUROLOGY, V75, P682, DOI 10.1212/WNL.0b013e3181eee273; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Prolo DJ, 1996, NEUROSURGERY, V2, P2783; Puetz V, 2007, LANCET NEUROL, V6, P580, DOI 10.1016/S1474-4422(07)70160-6; Schuss P, 2013, J NEUROTRAUM, V30, P91, DOI 10.1089/neu.2012.2542; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; Stieglitz LH, 2015, ACTA NEUROCHIR, V157, P275, DOI 10.1007/s00701-014-2310-7; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Sultan SM, 2011, PLAST RECONSTR SURG, V127, P1855, DOI 10.1097/PRS.0b013e31820e89a5; Sviri GE, 2015, J NEUROSURG, V123, P1188, DOI 10.3171/2014.11.JNS141152; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9; Zebian B, 2011, BRIT J NEUROSURG, V25, P785, DOI 10.3109/02688697.2011.623801	40	24	25	1	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	OCT	2016	30	5					523	528		10.1080/02688697.2016.1187259			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DW7IX	WOS:000383825500005	27215939				2021-06-18	
J	van der Ploeg, T; Nieboer, D; Steyerberg, EW				van der Ploeg, Tjeerd; Nieboer, Daan; Steyerberg, Ewout W.			Modern modeling techniques had limited external validity in predicting mortality from traumatic brain injury	JOURNAL OF CLINICAL EPIDEMIOLOGY			English	Article						Prediction models; Modeling techniques; Internal validation; External validation; Discrimination; Calibration	LOGISTIC-REGRESSION; VALIDATION; RISK; PERFORMANCE; SIMULATION; PROGNOSIS; DESIGN	Background and Objective: Prediction of medical outcomes may potentially benefit from using modern statistical modeling techniques. We aimed to externally validate modeling strategies for prediction of 6 -month mortality of patients suffering from traumatic brain injury (TBI) with predictor sets of increasing complexity. Methods: We analyzed individual patient data from 15 different studies including 11,026 TBI patients. We consecutively considered a core set of predictors (age, motor score, and pupillary reactivity), an extended set with computed tomography scan characteristics, and a further extension with two laboratory measurements (glucose and hemoglobin). With each of these sets, we predicted 6-month mortality using default settings with five statistical modeling techniques: logistic regression (LR), classification and regression trees, random forests (RFs), support vector machines (SVM) and neural nets. For external validation, a model developed on one of the 15 data sets was applied to each of the 14 remaining sets. This process was repeated 15 times for a total of 630 validations. The area under the receiver operating characteristic curve (AUC) was used to assess the discriminative ability of the models. Results: For the most complex predictor set, the LR models performed best (median validated AUC value, 0.757), followed by RF and support vector machine models (median validated AUC value, 0.735 and 0.732, respectively). With each predictor set, the classification and regression trees models showed poor performance (median validated AUC value, <0.7). The variability in performance across the studies was smallest for the RF-and LR-based models (inter quartile range for validated AUC values from 0.07 to 0.10). Conclusion: In the area of predicting mortality from TBI, nonlinear and nonadditive effects are not pronounced enough to make modern prediction methods beneficial. (C) 2016 Elsevier Inc. All rights reserved.	[van der Ploeg, Tjeerd] Med Ctr Alkmaar, Dept Sci, Wilhelminalaan 12, NL-1815 JD Alkmaar, Netherlands; [van der Ploeg, Tjeerd] Inholland Univ, Dept Sci, Bergerweg 200, NL-1817 MN Alkmaar, Netherlands; [van der Ploeg, Tjeerd; Nieboer, Daan; Steyerberg, Ewout W.] Erasmus MC Univ Med Ctr Rotterdam, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands	van der Ploeg, T (corresponding author), Med Ctr Alkmaar, Dept Sci, Wilhelminalaan 12, NL-1815 JD Alkmaar, Netherlands.; van der Ploeg, T (corresponding author), Inholland Univ, Dept Sci, Bergerweg 200, NL-1817 MN Alkmaar, Netherlands.; van der Ploeg, T (corresponding author), Erasmus MC Univ Med Ctr Rotterdam, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands.	tvdploeg@quicknet.nl					Austin PC, 2013, STAT MED, V32, P661, DOI 10.1002/sim.5598; Bleeker SE, 2003, J CLIN EPIDEMIOL, V56, P826, DOI 10.1016/S0895-4356(03)00207-5; Breiman L., 1984, CLASSIFICATION REGRE, V19; Collins GS, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-40; Colombet I, 2000, J AM MED INFORM ASSN, P156; CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1023/A:1022627411411; COX DR, 1958, BIOMETRIKA, V45, P562, DOI 10.1093/biomet/45.3-4.562; Ecke TH, 2012, ISRN UROL, V2012; Eftekhar Behzad, 2005, BMC Med Inform Decis Mak, V5, P3; Ennis M, 1998, STAT MED, V17, P2501; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Harrell Frank E., 2001, REGRESSION MODELING; Hastie T., 2009, ELEMENTS STAT LEARNI, V2; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; JENNETT B, 1976, LANCET, V1, P1031; Justice AC, 1999, ANN INTERN MED, V130, P515, DOI 10.7326/0003-4819-130-6-199903160-00016; Konig IR, 2007, STAT MED, V26, P5499, DOI 10.1002/sim.3069; Lang EW, 1997, NEUROL RES, V19, P274, DOI 10.1080/01616412.1997.11740813; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; Maroco Joao, 2011, BMC Res Notes, V4, P299, DOI 10.1186/1756-0500-4-299; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; R Core Development Team,, 2015, R LANG ENV STAT COMP, DOI [10.1007/978-3-540-74686-7, DOI 10.1007/978-3-540-74686-7]; Roozenbeek B, 2012, J NEUROTRAUM, V29, P1306, DOI 10.1089/neu.2011.1988; Siontis GCM, 2015, J CLIN EPIDEMIOL, V68, P25, DOI 10.1016/j.jclinepi.2014.09.007; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; Steyerberg EW, 2000, STAT MED, V19, P1059, DOI 10.1002/(SICI)1097-0258(20000430)19:8<1059::AID-SIM412>3.0.CO;2-0; Steyerberg EW, 2009, CLIN PREDICTION MODE, V19; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Terrin N, 2003, J CLIN EPIDEMIOL, V56, P721, DOI 10.1016/S0895-4356(03)00120-3; Tuffery S., 2011, DATA MINING STAT DEC; van der Ploeg T, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-137; van der Ploeg T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100234; VANHOUWELINGEN JC, 1990, STAT MED, V9, P1303, DOI 10.1002/sim.4780091109; Vergouwe Y, 2010, AM J EPIDEMIOL, V172, P971, DOI 10.1093/aje/kwq223; Young NH, 2008, PLOS MED, V5, P1186, DOI 10.1371/journal.pmed.0050168	38	24	24	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0895-4356	1878-5921		J CLIN EPIDEMIOL	J. Clin. Epidemiol.	OCT	2016	78						83	89		10.1016/j.jclinepi.2016.03.002			7	Health Care Sciences & Services; Public, Environmental & Occupational Health	Health Care Sciences & Services; Public, Environmental & Occupational Health	EE4ZV	WOS:000389615400011	26987507				2021-06-18	
J	Zhou, HL; Zhang, XJ; Zhang, MY; Yan, ZJ; Xu, ZM; Xu, RX				Zhou, Hong-Long; Zhang, Xue-Jun; Zhang, Mao-Ying; Yan, Zhong-Jie; Xu, Zhi-Min; Xu, Ru-Xiang			Transplantation of Human Amniotic Mesenchymal Stem Cells Promotes Functional Recovery in a Rat Model of Traumatic Spinal Cord Injury	NEUROCHEMICAL RESEARCH			English	Article						Human amnion; Mesenchymal stem cells; Spinal cord injury; Transplantation; Functional recovery	MARROW STROMAL CELLS; TISSUE; DIFFERENTIATION; ANGIOGENESIS; MEMBRANE; ISCHEMIA; BLOOD; VEGF	Human amniotic membrane mesenchymal stem cells (hAMSCs) are considered ideal candidate stem cells for cell-based therapy. In this study, we assessed whether hAMSCs transplantation promotes neurological functional recovery in rats after traumatic spinal cord injury (SCI). In addition, the potential mechanisms underlying the possible benefits of this therapy were investigated. Female Sprague-Dawley rats were subjected to SCI using a weight drop device and then hAMSCs, or phosphate-buffered saline (PBS) were immediately injected into the contused dorsal spinal cord at 2 mm rostral and 2 mm caudal to the injury site. Our results indicated that transplanted hAMSCs migrated in the host spinal cord without differentiating into neuronal or glial cells. Compared with the control group, hAMSCs transplantation significantly decreased the numbers of ED1(+) macrophages/microglia and caspase-3(+) cells. In addition, hAMSCs transplantation significantly increased the levels of brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF) in the injured spinal cord, and promoted both angiogenesis and axonal regeneration. These effects were associated with significantly improved neurobehavioral recovery in the hAMSCs transplantation group. These results show that transplantation of hAMSCs provides neuroprotective effects in rats after SCI, and could be candidate stem cells for the treatment of SCI.	[Zhou, Hong-Long; Zhang, Mao-Ying; Xu, Ru-Xiang] Southern Med Univ, Affiliated Bayi Brain Hosp, Bayi Clin Coll, Beijing, Peoples R China; [Zhou, Hong-Long; Zhang, Mao-Ying; Xu, Zhi-Min; Xu, Ru-Xiang] PLA, Beijing Mil Reg, Gen Hosp, Affiliated Bayi Brain Hosp, 5 Nanmen Cang, Beijing 100700, Peoples R China; [Zhou, Hong-Long; Zhang, Mao-Ying; Xu, Zhi-Min; Xu, Ru-Xiang] Beijing Mil Reg, Inst Neurosurg, Beijing, Peoples R China; [Zhang, Xue-Jun] Beijing Mil Reg, Gen Hosp, Dept Gynecol & Obstet, Beijing, Peoples R China; [Yan, Zhong-Jie] Hebei Med Univ, Hosp 2, Dept Neurosurg, Shijiazhuang, Peoples R China	Xu, RX (corresponding author), Southern Med Univ, Affiliated Bayi Brain Hosp, Bayi Clin Coll, Beijing, Peoples R China.; Xu, RX (corresponding author), PLA, Beijing Mil Reg, Gen Hosp, Affiliated Bayi Brain Hosp, 5 Nanmen Cang, Beijing 100700, Peoples R China.; Xu, RX (corresponding author), Beijing Mil Reg, Inst Neurosurg, Beijing, Peoples R China.	jzxuruxiang@163.com			Military Twelfth Five-Year Key Sci-Tech Research Projects [BWS11J002, BWS12J010]; Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81401032]	This work was supported by funding from the Military Twelfth Five-Year Key Sci-Tech Research Projects (Grants Nos. BWS11J002 and BWS12J010) and the Natural Science Foundation of China (81401032).	Abrams MB, 2009, RESTOR NEUROL NEUROS, V27, P307, DOI 10.3233/RNN-2009-0480; Bottai D, 2010, EXP NEUROL, V223, P452, DOI 10.1016/j.expneurol.2010.01.010; Chang YJ, 2010, CELLS TISSUES ORGANS, V192, P93, DOI 10.1159/000295774; Dasari VR, 2007, NEUROCHEM RES, V32, P2080, DOI 10.1007/s11064-007-9368-z; De Coppi P, 2007, NAT BIOTECHNOL, V25, P100, DOI 10.1038/nbt1274; Diaz-Prado S, 2011, DIFFERENTIATION, V81, P162, DOI 10.1016/j.diff.2011.01.005; Hagg T, 2006, J NEUROTRAUM, V23, P264, DOI 10.1089/neu.2006.23.263; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; Hermann A, 2004, J CELL SCI, V117, P4411, DOI 10.1242/jcs.01307; Hu SL, 2010, CRIT CARE MED, V38, P2181, DOI 10.1097/CCM.0b013e3181f17c0e; Kang JW, 2012, J VET SCI, V13, P23, DOI 10.4142/jvs.2012.13.1.23; Kawabe J, 2011, J NEUROSURG-SPINE, V15, P414, DOI 10.3171/2011.5.SPINE10421; Kim HM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004987; Kim KS, 2013, NEUROBIOL AGING, V34, P2408, DOI 10.1016/j.neurobiolaging.2013.03.029; Kim SW, 2013, INT J CARDIOL, V168, P1062, DOI 10.1016/j.ijcard.2012.11.003; Kim SW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041105; Kim SW, 2012, CARDIOVASC RES, V93, P525, DOI 10.1093/cvr/cvr328; Kishino A, 1997, EXP NEUROL, V144, P273, DOI 10.1006/exnr.1996.6367; Lee KH, 2007, ACTA NEUROBIOL EXP, V67, P13; Lee OK, 2004, BLOOD, V103, P1669, DOI 10.1182/blood-2003-05-1670; Liu XZ, 1997, J NEUROSCI, V17, P5395; Lu P, 2005, EXP NEUROL, V191, P344, DOI 10.1016/j.expneurol.2004.09.018; Magatti M, 2009, CELL TRANSPLANT, V18, P899, DOI 10.3727/096368909X471314; McMahon SS, 2010, CYTOTHERAPY, V12, P313, DOI 10.3109/14653241003695018; Novikova L, 1996, NEUROSCI LETT, V220, P203, DOI 10.1016/S0304-3940(96)13267-5; Oudega M, 2012, CELL TISSUE RES, V349, P269, DOI 10.1007/s00441-012-1440-6; Pierdomenico L, 2005, TRANSPLANTATION, V80, P836, DOI 10.1097/01.tp.0000173794.72151.88; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Rodriguez AM, 2005, BIOCHIMIE, V87, P125, DOI 10.1016/j.biochi.2004.11.007; Sasaki M, 2009, J NEUROSCI, V29, P14932, DOI 10.1523/JNEUROSCI.2769-09.2009; Stenderup K, 2003, BONE, V33, P919, DOI 10.1016/j.bone.2003.07.005; Stolzing A, 2006, AGING CELL, V5, P213, DOI 10.1111/j.1474-9726.2006.00213.x; Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092; Sundberg LM, 2011, J NEUROTRAUM, V28, P565, DOI 10.1089/neu.2010.1533; Tao J, 2012, BRAIN RES, V1448, P1, DOI 10.1016/j.brainres.2012.01.069; Tian DS, 2007, BRAIN RES, V1135, P177, DOI 10.1016/j.brainres.2006.11.085; Zhang DY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021397	37	24	26	0	5	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	OCT	2016	41	10					2708	2718		10.1007/s11064-016-1987-9			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	EA1TY	WOS:000386376000021	27351200				2021-06-18	
J	Ebenezer, PJ; Wilson, CB; Wilson, LD; Nair, AR; Francis, J				Ebenezer, Philip J.; Wilson, C. Brad; Wilson, Leslie D.; Nair, Anand R.; Francis, J.			The Anti-Inflammatory Effects of Blueberries in an Animal Model of Post-Traumatic Stress Disorder (PTSD)	PLOS ONE			English	Article							OXIDATIVE STRESS; PROTECTIVE ROLE; BRAIN-INJURY; INFLAMMATION; MICE; ACTIVATION; ANXIETY; ACID; HIPPOCAMPUS; VACCINATION	Post-traumatic stress disorder (PTSD) is a trauma and stressor-related disorder that results in a prolonged stress response. It is associated with increased oxidative stress and inflammation in the prefrontal cortex (PFC) and hippocampus (HC). The only approved therapy for PTSD is selective serotonin re-uptake inhibitors (SSRIs), but their efficacy ismarginal. Recently, we demonstrated that over-production of norepinephrine (NE) as the possible reason for the lack of efficacy of SSRIs. Hence, there is a need for novel therapeutic approaches for the treatment of PTSD. In this study, we investigated the anti-inflammatory role of blueberries in modulating inflammatory markers and neurotransmitter levels in PTSD. Rats were fed either a blueberry enriched (2%) or a control diet. Rats were exposed to cats for one hour on days 1 and 11 of a 31-day schedule to simulate traumatic conditions. The rats were also subjected to psychosocial stress via daily cage cohort changes. At the end of the study, the rats were euthanized and the PFC and HC were isolated. Monoamines were measured by high-performance liquid chromatography. Reactive oxygen species (ROS), gene and protein expression levels of inflammatory cytokines were alsomeasured. In our PTSD-model, NE levels were increased and 5-HT levels were decreased when compared to control. In contrast, a blueberry enriched diet increased 5-HT without affecting NE levels. The rate limiting enzymes tyrosine hydroxylase and tryptophan hydroxylase were also studied and they confirmed our findings. The enhanced levels free radicals, gene and protein expression of inflammatory cytokines seen in the PTSD group were normalized with a blueberry enriched diet. Decreased anxiety in this group was shown by improved performance on the elevated plus-maze. These findings indicate blueberries can attenuate oxidative stress and inflammation and restore neurotransmitter imbalances in a ratmodel of PTSD.	[Ebenezer, Philip J.; Wilson, C. Brad; Nair, Anand R.; Francis, J.] Louisiana State Univ, Sch Vet Med, Comparat Biomed Sci, Baton Rouge, LA 70803 USA; [Wilson, Leslie D.] Louisiana State Univ, Sch Vet Med, Pathobiol Sci, Baton Rouge, LA 70803 USA	Francis, J (corresponding author), Louisiana State Univ, Sch Vet Med, Comparat Biomed Sci, Baton Rouge, LA 70803 USA.	jfrancis@lsu.edu			Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Research Program [W81XWH-15-1-0061]; United States Highbush Blueberry Council	This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Research Program 2014 under Award No. W81XWH-15-1-0061 and United States Highbush Blueberry Council for JF. The opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense or United States Highbush Blueberry Council. There was no additional external funding received for this study.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081585; Alam Q., 2015, CURR PHARM DES; Baker DG, 2001, NEUROIMMUNOMODULAT, V9, P209, DOI 10.1159/000049028; Bollinger JL, 2016, BRAIN BEHAV IMMUN, V52, P88, DOI 10.1016/j.bbi.2015.10.003; Brewin CR, 2000, J TRAUMA STRESS, V13, P499, DOI 10.1023/A:1007741526169; Chaki S, 2003, EUR J PHARMACOL, V464, P49, DOI 10.1016/S0014-2999(03)01368-2; Chaki S, 2003, J PHARMACOL EXP THER, V304, P818, DOI 10.1124/jpet.102.044826; Chang CH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011971; Chuang CY, 2014, FREE RADICAL RES, V48, P970, DOI 10.3109/10715762.2014.920087; Cusack K, 2016, CLIN PSYCHOL REV, V43, P128, DOI 10.1016/j.cpr.2015.10.003; Denev P, 2014, FOOD CHEM, V157, P37, DOI 10.1016/j.foodchem.2014.02.022; Diamond DM, 2016, J NEUROSCI RES, V94, P437, DOI 10.1002/jnr.23684; Diamond David M., 2007, Neural Plasticity, V2007, P1, DOI 10.1155/2007/60803; Elks CM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024028; Eyre H, 2012, BRAIN BEHAV IMMUN, V26, P251, DOI 10.1016/j.bbi.2011.09.015; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Garate I, 2013, BIOL PSYCHIAT, V73, P32, DOI 10.1016/j.biopsych.2012.07.005; Hohne C, 2013, BRAIN, V136, P1746, DOI 10.1093/brain/awt064; Hoogland ICM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0332-6; Huang M, 2012, J ETHNOPHARMACOL, V143, P228, DOI 10.1016/j.jep.2012.06.028; Jesudason EP, 2007, MOL CELL BIOCHEM, V298, P69, DOI 10.1007/s11010-006-9353-x; Jesudason EP, 2005, BRAIN RES BULL, V65, P361, DOI 10.1016/j.brainresbull.2005.01.010; Jiang W, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152371; Johnson SA, 2015, J ACAD NUTR DIET, V115, P369, DOI 10.1016/j.jand.2014.11.001; Joseph SV, 2014, J AGR FOOD CHEM, V62, P3886, DOI 10.1021/jf4044056; Lemieux A, 2008, BRAIN BEHAV IMMUN, V22, P994, DOI 10.1016/j.bbi.2008.02.005; Liu YN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127813; Loganovsky KN, 2013, CNS SPECTRUMS, V18, P95, DOI 10.1017/S109285291200096X; Maddox SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054463; Masilamoni JG, 2005, BBA-MOL BASIS DIS, V1740, P411, DOI 10.1016/j.bbadis.2004.11.002; McEwen BS, 2000, BRAIN RES, V886, P172, DOI 10.1016/S0006-8993(00)02950-4; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Nair AR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111976; Nair AR, 2014, FREE RADICAL BIO MED, V71, P16, DOI 10.1016/j.freeradbiomed.2014.03.012; Naviaux RK, 2014, MITOCHONDRION, V16, P7, DOI 10.1016/j.mito.2013.08.006; Nawaz MI, 2015, J RECEPT SIG TRANSD, V35, P340, DOI 10.3109/10799893.2014.984309; Nie H, 2014, PROG NEURO-PSYCHOPH, V51, P16, DOI 10.1016/j.pnpbp.2014.01.002; Oosthuizen Frasia, 2005, Neuropsychiatr Dis Treat, V1, P109, DOI 10.2147/nedt.1.2.109.61049; Potter KA, 2014, ACTA BIOMATER, V10, P2209, DOI 10.1016/j.actbio.2014.01.018; Poulose SM, 2014, BRAIN RES, V1593, P9, DOI 10.1016/j.brainres.2014.10.028; Redlich S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-71; Sasaki T, 2016, EXP NEUROL, V275, P220, DOI 10.1016/j.expneurol.2015.11.003; Schneider BL, 2016, J NEUROTRAUM, V33, P1614, DOI 10.1089/neu.2015.4190; Shukitt-Hale B, 2012, GERONTOLOGY, V58, P518, DOI 10.1159/000341101; Tataranno ML, 2015, CLIN PERINATOL, V42, P529, DOI 10.1016/j.clp.2015.04.011; Taverniti V, 2014, J AGR FOOD CHEM, V62, P8346, DOI 10.1021/jf502180j; Varman DR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127945; Vida C, 2014, CURR PHARM DESIGN, V20, P4656; Viggiano Davide, 2004, Neural Plasticity, V11, P97, DOI 10.1155/NP.2004.97; Weston CSE, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00037; Wilson CB, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00256; Wilson CB, 2014, BEHAV BRAIN RES, V268, P72, DOI 10.1016/j.bbr.2014.03.029; Wilson CB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089104; Wilson CB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076146; Wolf EG, 2015, UNDERSEA HYPERBAR M, V42, P313; Zhao MY, 2015, J FOOD SCI, V80, pH869, DOI 10.1111/1750-3841.12815; Zoladz PR, 2012, PSYCHONEUROENDOCRINO, V37, P1531, DOI 10.1016/j.psyneuen.2012.02.007; Zoladz PR, 2013, NEUROSCI BIOBEHAV R, V37, P860, DOI 10.1016/j.neubiorev.2013.03.024	58	24	24	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2016	11	9							e0160923	10.1371/journal.pone.0160923			17	Multidisciplinary Sciences	Science & Technology - Other Topics	DV9IX	WOS:000383255200009	27603014	DOAJ Gold, Green Published			2021-06-18	
J	Beamer, M; Tummala, SR; Gullotti, D; Kopil, C; Gorka, S; Abel, T; Bass, CR; Morrison, B; Cohen, AS; Meaney, DF				Beamer, Matthew; Tummala, Shanti R.; Gullotti, David; Kopil, Catherine; Gorka, Samuel; Abel, Ted; Bass, Cameron R. Dale; Morrison, Barclay, III; Cohen, Akiva S.; Meaney, David F.			Primary blast injury causes cognitive impairments and hippocampal circuit alterations	EXPERIMENTAL NEUROLOGY			English	Article						Blast induced traumatic brain injury; Concussion; Blood-brain barrier	TRAUMATIC BRAIN-INJURY; INTRACRANIAL-PRESSURE RESPONSE; RISK-ASSESSMENT; BARRIER DYSFUNCTION; EXPLOSIVE BLAST; DENTATE GYRUS; SHOCK-WAVES; IN-VITRO; MODEL; RAT	Blast-induced traumatic brain injury (bTBI) and its long term consequences are a major health concern among veterans. Despite recent work enhancing our knowledge about bTBI, very little is known about the contribution of the blast wave alone to the observed sequelae. Herein, we isolated its contribution in a mouse model by constraining the animals' heads during exposure to a shockwave (primary blast). Our results show that exposure to primary blast alone results in changes in hippocampus-dependent behaviors that correspond with electro-physiological changes in area CA1 and are accompanied by reactive gliosis. Specifically, five days after exposure, behavior in an open field and performance in a spatial object recognition (SOR) task were significantly different from sham. Network electrophysiology, also performed five days after injury, demonstrated a significant decrease in excitability and increase in inhibitory tone. Immunohistochemistry for GFAP and Iba1 performed ten days after injury showed a significant increase in staining. Interestingly, a threefold increase in the impulse of the primary blast wave did not exacerbate these measures. However, we observed a significant reduction in the contribution of the NMDA receptors to the field EPSP at the highest blast exposure level. Our results emphasize the need to account for the effects of primary blast loading when studying the sequelae of bTBI. (C) 2016 Published by Elsevier Inc.	[Beamer, Matthew; Tummala, Shanti R.; Gullotti, David; Kopil, Catherine; Gorka, Samuel; Meaney, David F.] Univ Penn, Dept Bioengn, 240 Skirkanich Hall,210 South 33rd St, Philadelphia, PA 19104 USA; [Abel, Ted] Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; [Meaney, David F.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Cohen, Akiva S.] Univ Penn, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Cohen, Akiva S.] Childrens Hosp Philadelphia, Div Crit Care Med, Philadelphia, PA 19104 USA; [Bass, Cameron R. Dale] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA; [Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, New York, NY USA	Meaney, DF (corresponding author), Univ Penn, Dept Bioengn, 240 Skirkanich Hall,210 South 33rd St, Philadelphia, PA 19104 USA.	dmeaney@seas.upenn.edu	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864; Abel, Ted/0000-0003-2423-4592; Meaney, David/0000-0002-0954-4122	Army Research Office [W911NF-10-1-0526]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R37HD059288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS088176, R01NS069629, R01NS045975] Funding Source: NIH RePORTER	The authors thank Dr. Brian N. Johnson for his help and assistance over the course of this study. Funding was provided by the Army Research Office through W911NF-10-1-0526.	Alphonse Vanessa D, 2014, Biomed Sci Instrum, V50, P248; Baalman KL, 2013, J NEUROTRAUM, V30, P741, DOI 10.1089/neu.2012.2478; Bandak F A, 2015, Handb Clin Neurol, V127, P89, DOI 10.1016/B978-0-444-52892-6.00006-4; Bass CR, 2008, J TRAUMA, V65, P604, DOI 10.1097/TA.0b013e3181454ab4; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; BOWEN IG, 1968, ANN NY ACAD SCI, V152, P122, DOI 10.1111/j.1749-6632.1968.tb11971.x; Budde MD, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00154; Center D.a.V.B.1., 2012, DOD WORLDW NUMB TBI; Cole JT, 2010, P NATL ACAD SCI USA, V107, P366, DOI 10.1073/pnas.0910280107; de Lanerolle NC, 2014, ANN CLIN TRANSL NEUR, V1, P692, DOI 10.1002/acn3.98; de Lanerolle NC, 2011, J NEUROPATH EXP NEUR, V70, P1046, DOI 10.1097/NEN.0b013e318235bef2; De Palma RG., 2015, BRAIN NEUROTRAUMA MO; del Mar N, 2015, EXP NEUROL, V271, P53, DOI 10.1016/j.expneurol.2015.04.023; Ding MC, 2011, J NEUROSCI, V31, P14085, DOI 10.1523/JNEUROSCI.3572-11.2011; Effgen G. B., 2015, J NEUROTRAUMA; Effgen GB, 2014, J NEUROTRAUM, V31, P1202, DOI 10.1089/neu.2013.3227; Elder GA, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00048; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gullotti DM, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4027873; Heldt SA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00002; Heltemes KJ, 2012, INJURY, V43, P1990, DOI 10.1016/j.injury.2011.07.021; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howard AL, 2007, J NEUROPHYSIOL, V97, P2394, DOI 10.1152/jn.00509.2006; Huang MX, 2014, NEUROIMAGE-CLIN, V5, P109, DOI 10.1016/j.nicl.2014.06.004; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Hue CD, 2015, J NEUROTRAUMA; Hue CD, 2014, J NEUROTRAUM, V31, P951, DOI 10.1089/neu.2013.3149; Hue CD, 2013, J NEUROTRAUM, V30, P1652, DOI 10.1089/neu.2012.2773; Hunt RF, 2011, J NEUROSCI, V31, P6880, DOI 10.1523/JNEUROSCI.0032-11.2011; Jean A, 2014, P NATL ACAD SCI USA, V111, P15310, DOI 10.1073/pnas.1415743111; Johnson BN, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00435; Johnstone VPA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063454; Kabu S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127971; Kovacs SK, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00047; Leonardi AD, 2013, ANN BIOMED ENG, V41, P2488, DOI 10.1007/s10439-013-0850-2; Leonardi AD, 2012, J BIOMECH, V45, P2595, DOI 10.1016/j.jbiomech.2012.08.024; Meaney DF, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4026364; Nakagawa A, 2008, ACTA NEUROCHIR SUPPL, V102, P421, DOI 10.1007/978-3-211-85578-2_82; Ning YL, 2013, J CEREBR BLOOD F MET, V33, P1789, DOI 10.1038/jcbfm.2013.127; Ortinski PI, 2010, NAT NEUROSCI, V13, P584, DOI 10.1038/nn.2535; Panzer MB, 2014, EXP NEUROL, V261, P120, DOI 10.1016/j.expneurol.2014.07.002; Panzer Matthew B, 2012, Front Neurol, V3, P46, DOI 10.3389/fneur.2012.00046; Patel TP, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00349; Patel TP, 2014, J NEUROSCI, V34, P4200, DOI 10.1523/JNEUROSCI.4172-13.2014; Rafaels K, 2011, J NEUROTRAUM, V28, P2319, DOI 10.1089/neu.2009.1207; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Sajja VSSS, 2015, SCI REP-UK, V5, DOI 10.1038/srep15075; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Shetty AK, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00232; Smith DH, 2015, J NEUROTRAUM, V32, P1725, DOI 10.1089/neu.2014.3861; Sundaramurthy A, 2012, J NEUROTRAUM, V29, P2352, DOI 10.1089/neu.2012.2413; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Tate CM, 2013, J NEUROTRAUM, V30, P1620, DOI 10.1089/neu.2012.2683; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tompkins P, 2013, J NEUROTRAUM, V30, P1888, DOI 10.1089/neu.2012.2674; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Vogel E. W., 2015, J NEUROTRAUMA; Wall PLH, 2012, J AM PSYCHIAT NURSES, V18, P278, DOI 10.1177/1078390312460578; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Xie K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064907; Yang L, 2007, J NEUROPHYSIOL, V97, P178, DOI 10.1152/jn.01374.2005; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7; Yin TC, 2014, CELL REP, V8, P1731, DOI 10.1016/j.celrep.2014.08.030	70	24	25	0	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	SEP	2016	283		A				16	28		10.1016/j.expneurol.2016.05.025			13	Neurosciences	Neurosciences & Neurology	DW0EU	WOS:000383314500002	27246999	Green Accepted			2021-06-18	
J	Li, W; Watts, L; Long, J; Zhou, W; Shen, Q; Jiang, Z; Li, YX; Duong, TQ				Li, Wei; Watts, Lora; Long, Justin; Zhou, Wei; Shen, Qiang; Jiang, Zhao; Li, Yunxia; Duong, Timothy Q.			Spatiotemporal changes in blood-brain barrier permeability, cerebral blood flow, T-2 and diffusion following mild traumatic brain injury	BRAIN RESEARCH			English	Article						Traumatic brain injury; BBB permeability; Edema; Diffusion MRI; Dynamic contrast enhanced MRI	QUANTITATIVE PERFUSION; REPERFUSION INJURY; BOLD; GENERATION; RESPONSES; BREAKDOWN; ISCHEMIA; HYPOXIA; MRI; CBF	The blood-brain barrier (BBB) can be impaired following traumatic brain injury (TBI), however the spatiotemporal dynamics of BBB leakage remain incompletely understood. In this study, we evaluated the spatiotemporal evolution of BBB permeability using dynamic contrast-enhanced MRI and measured the volume transfer coefficient, (Kt(rans)), a quantitative measure of contrast agent leakage across the blood and extravascular compartment. Measurements were made in a controlled cortical impact (CCI) model of mild TBI in rats from 1 h to 7 days following TBI. The results were compared with cerebral blood flow, T-2 and diffusion MRI from the same animal. Spatially, K-trans changes were localized to superficial cortical layers within a 1 mm thickness, which was dramatically different from the changes in cerebral blood flow, T-2 and diffusion, which were localized to not only the superficial layers but also to brain regions up to 2.2 mm from the cortical surface. Temporally, K-trans changes peaked at day 3, similar to CBF and ADC changes, but differed from T-2 and FA, whose changes peaked on day 2. The pattern of superficial cortical layer localization of K-trans was consistent with patterns revealed by Evans Blue extravasation. Collectively, these results suggest that BBB disruption, edema formation, blood flow disturbance and diffusion changes are related to different components of the mechanical impact, and may play different roles in determining injury progression and tissue fate processes following TBI. (C) 2016 Elsevier B.V. All rights reserved.	[Li, Wei; Watts, Lora; Long, Justin; Zhou, Wei; Shen, Qiang; Jiang, Zhao; Li, Yunxia; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA; [Li, Wei; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA; [Watts, Lora] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; [Watts, Lora] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA	Duong, TQ (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.	duongt@uthscsa.edu	Shen, Qiang/B-8784-2008; Zhou, Wei/AAJ-8509-2020; Duong, Tim/AAL-8357-2021	Shen, Qiang/0000-0002-4287-3403; Zhou, Wei/0000-0003-2130-1913; Duong, Tim/0000-0001-6403-2827; jiang, zhao/0000-0002-8192-9908	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS45879]; TL1 grant; Clinical Translational Science Awards (CTSA) [KL2 TR001118, 8UL1TR000149, TL1TR001119]; Clinical Translational Science Awards [UL1 TR001119]; William & Ella Owens Medical Research Foundation; American Heart AssociationAmerican Heart Association [15SDG26020003]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [TL1TR001119, KL2TR001118, UL1TR000149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045879] Funding Source: NIH RePORTER	This research was funded in part by NIH/NINDS R01 NS45879 (TQD), a TL1 grant (JAL) and KL2 TR001118 (LTW) via the Clinical Translational Science Awards (CTSA, parent grant 8UL1TR000149 and TL1TR001119). This study was supported in part by UL1 TR001119 via the Clinical Translational Science Awards (WL), and a research grant from William & Ella Owens Medical Research Foundation (WL), and a Scientist Development Grant 15SDG26020003 from American Heart Association (WL).	Adelson PD, 1998, ACT NEUR S, V71, P104; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bilston LE, 2011, STUD MECHANOBIOL TIS, V3, P1, DOI 10.1007/978-3-642-13890-4; Chen Y, 2010, ACTA MECH, V213, P155, DOI 10.1007/s00707-009-0274-0; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Danker JF, 2007, BRAIN RES, V1150, P217, DOI 10.1016/j.brainres.2007.02.082; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; Duong TQ, 2007, BRAIN RES, V1135, P186, DOI 10.1016/j.brainres.2006.11.097; Gursoy-Ozdemir Y, 2000, STROKE, V31, P1974, DOI 10.1161/01.STR.31.8.1974; Jiang Z, 2014, NEUROSCI LETT, V566, P298, DOI 10.1016/j.neulet.2014.02.066; Leach MO, 2005, BRIT J CANCER, V92, P1599, DOI 10.1038/sj.bjc.6602550; Li W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114173; Long J. A., 2014, J NEUROTRAUMA; Long JA, 2015, J NEUROTRAUM, V32, P598, DOI 10.1089/neu.2014.3563; Nagaraja TN, 2008, STROKE, V39, P427, DOI 10.1161/STROKEAHA.107.496059; Shen Q, 2005, J CEREBR BLOOD F MET, V25, P1265, DOI 10.1038/sj.jcbfm.9600132; Shen Q, 2004, J CEREBR BLOOD F MET, V24, P280, DOI 10.1097/01.WCB.0000110048.43905.E5; Shen Q, 2003, J CEREBR BLOOD F MET, V23, P1479, DOI 10.1097/01.WCB.0000100064.36077.03; Shen Q, 2004, J CEREBR BLOOD F MET, V24, P887, DOI 10.1097/01.WCB.0000124321.60992.87; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Sicard K, 2003, J CEREBR BLOOD F MET, V23, P472, DOI 10.1097/01.WCB.0000054755.93668.20; Sicard KM, 2005, NEUROIMAGE, V25, P850, DOI 10.1016/j.neuroimage.2004.12.010; Lawrence KS, 2012, MAGN RESON MED, V67, P1275, DOI 10.1002/mrm.23104; Takhounts EG, 2008, STAPP CAR C, V52, P1; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Tofts PS, 2010, SIGNAL, V500, P400; UENO K, 1995, J NEUROTRAUM, V12, P695, DOI 10.1089/neu.1995.12.695; Watts LT, 2014, J NEUROTRAUM, V31, P1063, DOI 10.1089/neu.2013.3193; Wei XE, 2012, J NEUROTRAUM, V29, P2413, DOI 10.1089/neu.2010.1510; Wei XE, 2011, J TRAUMA, V71, P1645, DOI 10.1097/TA.0b013e31823498eb	30	24	25	0	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 1	2016	1646						53	61		10.1016/j.brainres.2016.05.036			9	Neurosciences	Neurosciences & Neurology	DT9TH	WOS:000381844700006	27208495				2021-06-18	
J	McDonald, T; Burghart, MA; Nazir, N				McDonald, Tracy; Burghart, Mark A.; Nazir, Niaman			Underreporting of Concussions and Concussion-Like Symptoms in Female High School Athletes	JOURNAL OF TRAUMA NURSING			English	Article						Adolescents; Concussion education; Female athletes; Mild traumatic brain injury; Sport-related concussion	SPORTS-RELATED CONCUSSION; HEAD-INJURY; MANAGEMENT; KNOWLEDGE; PLAYERS; HISTORY	Underreporting of concussions and concussion-like symptoms in athletes continues to be a serious medical concern and research focus. Despite mounting worry, little evidence exists examining incidence of underreporting and documenting characteristics of head injury in female athletes participating in high school sports. This study examined the self-reporting behaviors of female high school athletes. Seventy-seven athletes participated, representing 14 high school sports. Nearly half of the athletes (31 participants) reported a suspected concussion, with 10 of the 31 athletes refraining from reporting symptoms to training staff after injury. Only 66% reported receiving concussion education. Concussion education appeared to have no relationship with diagnosed concussion rates in athletes, removing athletes from play, or follow-up medical care after injury. In conclusion, female high school athletes underreport signs and symptoms of concussions. Concussion education should occur at higher rates among female athletes to influence reporting behaviors.	[McDonald, Tracy] Univ Kansas Hosp, Trauma Acute Care Surg Burn & Concuss Adm, Kansas City, KS USA; [Burghart, Mark A.] Univ Kansas, Med Ctr, Occupat Therapy Educ, Sch Hlth Profess, Kansas City, KS 66103 USA; [Nazir, Niaman] Univ Kansas, Med Ctr, Sch Med, Prevent Med & Publ Hlth, Kansas City, KS 66103 USA	McDonald, T (corresponding author), Univ Kansas Hosp, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	trogers@kumc.edu					Bramley H, 2012, CLIN PEDIATR, V51, P332, DOI 10.1177/0009922811425233; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guthrie RM, 2015, PHYSICIAN SPORTSMED, V43, P333, DOI 10.1080/00913847.2015.1081552; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kirschen MP, 2014, NEUROLOGY, V83, P352, DOI 10.1212/WNL.0000000000000613; Kostyun RO, 2015, SPORTS HEALTH, V7, P52, DOI 10.1177/1941738114555075; LaBotz M, 2005, CLIN J SPORT MED, V15, P73, DOI 10.1097/01.jsm.0000157649.99867.fc; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Moreno MA, 2012, ARCH PEDIAT ADOL MED, V166, P296, DOI [10.1001/archpediatrics.2012.8, 10.1001/archpediatrics.2012.79]; Moreno MA, 2011, ARCH PEDIAT ADOL MED, V165, P376, DOI 10.1001/archpediatrics.2011.31; Patel Dilip R, 2002, Adolesc Med, V13, P569; Patel DR, 2005, SPORTS MED, V35, P671, DOI 10.2165/00007256-200535080-00002; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Tomei KL, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12280; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	24	24	24	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1078-7496	1932-3883		J TRAUMA NURS	J. Trauma Nurs.	SEP-OCT	2016	23	5					241	246		10.1097/JTN.0000000000000227			6	Critical Care Medicine; Nursing	General & Internal Medicine; Nursing	DX1FY	WOS:000384112700003	27618372				2021-06-18	
J	Radulovic, M; Yoon, H; Wu, JM; Mustafa, K; Scarisbrick, IA				Radulovic, Maja; Yoon, Hyesook; Wu, Jianmin; Mustafa, Karim; Scarisbrick, Isobel A.			Targeting the thrombin receptor modulates inflammation and astrogliosis to improve recovery after spinal cord injury	NEUROBIOLOGY OF DISEASE			English	Article						Traumatic spinal cord injury; Astrogliosis; Inflammation; Cytokine; GPCR; Serine protease; Astrocyte; Microglia; Interleukin 6	PROTEASE-ACTIVATED RECEPTOR-1; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FIBRILLARY ACIDIC PROTEIN; INDUCED MICROGLIAL ACTIVATION; PROTHROMBIN-MESSENGER-RNA; MODEL MOTOR-NEURONS; BLOOD-BRAIN-BARRIER; REACTIVE ASTROCYTES; NERVOUS-SYSTEM; FUNCTIONAL RECOVERY	The deregulation of serine protease activity is a common feature of neurological injury, but little is known regarding their mechanisms of action or whether they can be targeted to facilitate repair. In this study we demonstrate that the thrombin receptor (Protease Activated Receptor 1, (PAR1)) serves as a critical translator of the spinal cord injury (SCI) proteolytic microenvironment into a cascade of pro-inflammatory events that contribute to astrogliosis and functional decline. PAR1 knockout mice displayed improved locomotor recovery after SCI and reduced signatures of inflammation and astrogliosis, including expression of glial fibrillary acidic protein (GFAP), vimentin, and STAT3 signaling. SCI-associated elevations in pro-inflammatory cytokines such as IL-1 beta and IL-6 were also reduced in PAR1-/- mice and co-ordinate improvements in tissue sparing and preservation of NeuN-positive ventral horn neurons, and PKC gamma corticospinal axons, were observed. PAR1 and its agonist's thrombin and neurosin were expressed by perilesional astrocytes and each agonist increased the production of IL-6 and STAT3 signaling in primary astrocyte cultures in a PAR1-dependent manner. In turn, IL-6-stimulated astrocytes increased expression of PAR1, thrombin, and neurosin, pointing to a model in which PAR1 activation contributes to increased astrogliosis by feedforward- and feedback-signaling dynamics. Collectively, these findings identify the thrombin receptor as a key mediator of inflammation and astrogliosis in the aftermath of SCI that can be targeted to reduce neurodegeneration and improve neurobehavioral recovery. (C) 2016 Elsevier Inc. All rights reserved.	[Radulovic, Maja; Mustafa, Karim; Scarisbrick, Isobel A.] Mayo Med & Grad Sch, Rehabil Med Res Ctr, Neurobiol Dis Program, Rochester, MN 55905 USA; [Yoon, Hyesook; Wu, Jianmin; Scarisbrick, Isobel A.] Mayo Med & Grad Sch, Rehabil Med Res Ctr, Dept Phys Med & Rehabil, Rochester, MN 55905 USA; [Yoon, Hyesook; Scarisbrick, Isobel A.] Mayo Med & Grad Sch, Rehabil Med Res Ctr, Dept Physiol & Biomed Engn, Rochester, MN 55905 USA	Scarisbrick, IA (corresponding author), Mayo Clin Rochester, Neurobiol Dis Program, 642B Guggenheim Bldg,200 First St SW, Rochester, MN 55905 USA.	Scarisbrick.Isobel@mayo.edu		Mustafa, Karim/0000-0003-2567-635X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R01NS052741]; Pilot Project [PP2009, RG4958]; National Multiple Sclerosis SocietyNational Multiple Sclerosis Society [CA1060A11]; Mayo Clinic Center for Regenerative Medicine; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052741] Funding Source: NIH RePORTER	Studies were supported by the National Institutes of Health 5R01NS052741, Pilot Project PP2009, RG4958 and a Collaborative MS Research Center Award CA1060A11 from the National Multiple Sclerosis Society, and an Accelerated Regenerative Medicine Award from the Mayo Clinic Center for Regenerative Medicine. The authors declare no competing financial interests.	Acharjee S, 2011, BRAIN, V134, P3209, DOI 10.1093/brain/awr242; Adams MN, 2011, PHARMACOL THERAPEUT, V130, P248, DOI 10.1016/j.pharmthera.2011.01.003; Arai T, 2006, J NEUROPATH EXP NEUR, V65, P19, DOI 10.1097/01.jnen.0000196133.74087.cb; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Blaber SI, 2004, FASEB J, V18, P920, DOI 10.1096/fj.03-1212fje; Boven LA, 2003, J IMMUNOL, V170, P2638, DOI 10.4049/jimmunol.170.5.2638; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Burda JE, 2013, GLIA, V61, P1456, DOI 10.1002/glia.22534; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Chen B, 2012, J NEUROSCI, V32, P7622, DOI 10.1523/JNEUROSCI.0369-12.2012; Chen B, 2010, STROKE, V41, P2348, DOI 10.1161/STROKEAHA.110.584920; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Citron BA, 2000, J NEUROTRAUM, V17, P1191, DOI 10.1089/neu.2000.17.1191; CUNNINGHAM DD, 1993, THROMB HAEMOSTASIS, V70, P168; Dibaj P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043963; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; Dominguez E, 2010, J NEUROSCI, V30, P5754, DOI 10.1523/JNEUROSCI.5007-09.2010; Donnelly DJ, 2011, J NEUROSCI, V31, P9910, DOI 10.1523/JNEUROSCI.2114-11.2011; Drucker KL, 2013, NEURO-ONCOLOGY, V15, P305, DOI 10.1093/neuonc/nos313; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Festoff BM, 2000, MOL MED, V6, P410, DOI 10.1007/BF03401784; Festoff BW, 2004, J NEUROTRAUM, V21, P907, DOI 10.1089/0897715041526168; French SL, 2015, BLOOD REV, V29, P179, DOI 10.1016/j.blre.2014.10.006; Gingrich MB, 2000, TRENDS NEUROSCI, V23, P399, DOI 10.1016/S0166-2236(00)01617-9; Hamill Cecily E, 2005, Clin Neurosurg, V52, P29; Hamill CE, 2009, EXP NEUROL, V217, P136, DOI 10.1016/j.expneurol.2009.01.023; Han KS, 2011, MOL BRAIN, V4, DOI 10.1186/1756-6606-4-32; HARIRI RJ, 1994, BRAIN RES, V636, P139, DOI 10.1016/0006-8993(94)90188-0; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Itsekson-Hayosh Z, 2015, J NEUROTRAUMA; Joshi M, 2002, J NEUROTRAUM, V19, P191, DOI 10.1089/08977150252806956; Junge CE, 2004, EXP NEUROL, V188, P94, DOI 10.1016/j.expneurol.2004.02.018; Junge CE, 2003, P NATL ACAD SCI USA, V100, P13019, DOI 10.1073/pnas.2235594100; Kendziorski C, 2005, P NATL ACAD SCI USA, V102, P4252, DOI 10.1073/pnas.0500607102; Kim HN, 2015, J NEUROCHEM, V135, P577, DOI 10.1111/jnc.13285; Kim OS, 2002, J BIOL CHEM, V277, P40594, DOI 10.1074/jbc.M203885200; Kraft AW, 2013, FASEB J, V27, P187, DOI 10.1096/fj.12-208660; Laabs TL, 2007, J NEUROSCI, V27, P14494, DOI 10.1523/JNEUROSCI.2807-07.2007; Lepekhin EA, 2001, J NEUROCHEM, V79, P617, DOI 10.1046/j.1471-4159.2001.00595.x; Li LZ, 2008, J CEREBR BLOOD F MET, V28, P468, DOI 10.1038/sj.jcbfm.9600546; Liberto CM, 2004, J NEUROCHEM, V89, P1092, DOI 10.1111/j.1471-4159.2004.02420.x; Liedtke W, 1998, AM J PATHOL, V152, P251; Lieu A, 2013, J NEUROIMMUNOL, V256, P43, DOI 10.1016/j.jneuroim.2013.01.003; Liu DZ, 2010, ANN NEUROL, V67, P526, DOI 10.1002/ana.21924; Liu ZW, 2014, GLIA, V62, P2022, DOI 10.1002/glia.22723; Lyden P, 2014, STROKE, V45, P896, DOI 10.1161/STROKEAHA.113.004488; Macauley SL, 2011, J NEUROSCI, V31, P15575, DOI 10.1523/JNEUROSCI.3579-11.2011; Menet V, 2003, P NATL ACAD SCI USA, V100, P8999, DOI 10.1073/pnas.1533187100; Middeldorp J, 2011, PROG NEUROBIOL, V93, P421, DOI 10.1016/j.pneurobio.2011.01.005; MORI M, 1990, J COMP NEUROL, V299, P167, DOI 10.1002/cne.902990204; NICLOU S, 1994, CELL MOL BIOL, V40, P421; Niclou SP, 1998, EUR J NEUROSCI, V10, P1590, DOI 10.1046/j.1460-9568.1998.00183.x; Nicole O, 2005, J NEUROSCI, V25, P4319, DOI 10.1523/JNEUROSCI.5200-04.2005; NISHINO A, 1993, J NEUROTRAUM, V10, P167, DOI 10.1089/neu.1993.10.167; Okada S, 2004, J NEUROSCI RES, V76, P265, DOI 10.1002/jnr.20044; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Olson EE, 2004, J CEREBR BLOOD F MET, V24, P964, DOI 10.1097/01.WCB.0000128266.87474.BF; Panos M, 2014, BIOL CHEM, V395, P1063, DOI 10.1515/hsz-2014-0141; Pekny M, 2004, J PATHOL, V204, P428, DOI 10.1002/path.1645; Radulovic M, 2015, NEUROBIOL DIS, V83, P75, DOI 10.1016/j.nbd.2015.08.021; Radulovic Maja, 2013, J Neuropathol Exp Neurol, V72, P1072, DOI 10.1097/NEN.0000000000000007; Rajput PS, 2014, NEUROSCIENCE, V281, P229, DOI 10.1016/j.neuroscience.2014.09.038; Riek-Burchardt M, 2002, NEUROSCI LETT, V329, P181, DOI 10.1016/S0304-3940(02)00645-6; Scarisbrick IA, 2008, CURR TOP MICROBIOL, V318, P133; Scarisbrick IA, 2006, EUR J NEUROSCI, V24, P1457, DOI 10.1111/j.1460-9568.2006.05021.x; Scarisbrick I.A, 2012, HDB PROTEOLYTIC ENZY, P2780; Scarisbrick IA, 1999, J NEUROSCI, V19, P7757; Scarisbrick IA, 2002, BRAIN, V125, P1283, DOI 10.1093/brain/awf142; Scarisbrick IA, 1997, J NEUROSCI, V17, P8156; Scarisbrick IA, 2012, BRAIN PATHOL, V22, P709, DOI 10.1111/j.1750-3639.2012.00577.x; Scarisbrick IA, 2012, BIOL CHEM, V393, P355, DOI 10.1515/hsz-2011-0241; Scarisbrick IA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018376; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Shao W, 2013, NATURE, V494, P90, DOI 10.1038/nature11748; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Smirnova IV, 1998, J NEUROBIOL, V36, P64, DOI 10.1002/(SICI)1097-4695(199807)36:1<64::AID-NEU6>3.0.CO;2-8; Smirnova IV, 2001, J NEUROBIOL, V48, P87, DOI 10.1002/neu.1044.abs; SMITHSWINTOSKY VL, 1995, J NEUROSCI, V15, P5840; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Sorensen SD, 2003, MOL PHARMACOL, V64, P1199, DOI 10.1124/mol.64.5.1199; Striggow F, 2001, EUR J NEUROSCI, V14, P595, DOI 10.1046/j.0953-816x.2001.01676.x; Striggow F, 2000, P NATL ACAD SCI USA, V97, P2264, DOI 10.1073/pnas.040552897; Suo ZM, 2003, J BIOL CHEM, V278, P37681, DOI 10.1074/jbc.M301406200; Suo ZM, 2003, J BIOL CHEM, V278, P31177, DOI 10.1074/jbc.M302137200; Suo ZM, 2002, J NEUROCHEM, V80, P655, DOI 10.1046/j.0022-3042.2001.00745.x; Taoka Y, 2000, THROMB HAEMOSTASIS, V83, P462; Toft-Hansen H, 2011, GLIA, V59, P166, DOI 10.1002/glia.21088; Turgeon VL, 1998, J NEUROSCI, V18, P6882; Vandell AG, 2008, J NEUROCHEM, V107, P855, DOI 10.1111/j.1471-4159.2008.05658.x; Voskuhl RR, 2009, J NEUROSCI, V29, P11511, DOI 10.1523/JNEUROSCI.1514-09.2009; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; Wang H, 2002, AM J PHYSIOL-CELL PH, V283, pC1351, DOI 10.1152/ajpcell.00001.2002; Wang H, 2002, GLIA, V37, P53, DOI 10.1002/glia.10012; Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Xue MZ, 2001, STROKE, V32, P2164, DOI 10.1161/hs0901.095408; Yamauchi K, 2006, J NEUROCHEM, V96, P1060, DOI 10.1111/j.1471-4159.2005.03559.x; Yoon H, 2015, GLIA, V63, P846, DOI 10.1002/glia.22788; Yoon H, 2013, J NEUROCHEM, V127, P283, DOI 10.1111/jnc.12293; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zhang J, 2012, J NEUROL SCI, V320, P6, DOI 10.1016/j.jns.2012.05.040	101	24	25	0	21	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	SEP	2016	93						226	242		10.1016/j.nbd.2016.04.010			17	Neurosciences	Neurosciences & Neurology	DQ8IE	WOS:000379452600021	27145117	Green Accepted			2021-06-18	
J	Ibanez, I; Diez-Guerra, FJ; Gimenez, C; Zafra, F				Ibanez, Ignacio; Javier Diez-Guerra, F.; Gimenez, Cecilio; Zafra, Francisco			Activity dependent internalization of the glutamate transporter GLT-1 mediated by beta-arrestin 1 and ubiquitination	NEUROPHARMACOLOGY			English	Article						Intracellular trafficking; Endocytosis; Glutamate; Ubiquitination; Transport	SYNAPTIC-TRANSMISSION; MICE LACKING; ENDOCYTOSIS; PHOSPHORYLATION; UBIQUITYLATION; DEGRADATION; ASTROCYTES; ISCHEMIA; EPILEPSY; CORTEX	GLT-1 is the main glutamate transporter in the brain and undergoes trafficking processes that control its concentration on the cell surface thereby shaping glutamatergic neurotransmission. We have investigated how the traffic of GLT-1 is regulated by transporter activity. We report that internalization of GLT-1 from the cell surface is accelerated by transportable substrates like glutamate or aspartate, as well as by the transportable inhibitor L-trans-2,4-PDC, but not by the non-substrate inhibitor WAY 213613 in primary mixed cultures and in transiently transfected HEK293 cells. Analysis of the mechanism of endocytosis in HEK293 cells revealed that glutamate promoted the association with the transporter of the adaptor protein beta-arrestin and the ubiquitin ligase Nedd4-2. The addition of glutamate is accompanied by an increase in the transporter ubiquitination, and the internalization is suppressed by an ubiquitination inhibitor (PYR41), and in a mutant defective in C-terminal lysines. The glutamate triggered endocytosis was also suppressed by siRNA for beta-arrestin. This regulatory mechanism might be relevant in controlling the amount of transporter on the cell surface in conditions such as ischemia or traumatic brain injury, where extracellular concentrations of glutamate are persistently elevated. (C) 2016 Elsevier Ltd. All rights reserved.	[Ibanez, Ignacio; Javier Diez-Guerra, F.; Gimenez, Cecilio; Zafra, Francisco] Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Fac Ciencias, Consejo Super Invest Cient, C Nicolas Cabrera 1, E-28049 Madrid, Spain; [Ibanez, Ignacio; Gimenez, Cecilio; Zafra, Francisco] Ctr Invest Biomed Red Enfermedades Raras, Barcelona, Spain; [Ibanez, Ignacio; Gimenez, Cecilio; Zafra, Francisco] Inst Salud Carlos III, IdiPAZ, Madrid, Spain	Zafra, F (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, C Nicolas Cabrera 1, E-28049 Madrid, Spain.	fzafra@cbm.csic.es	Diez-Guerra, Fco. Javier/K-9063-2014; Gimenez, Cecilio/K-8027-2014; Zafra, Francisco/A-6121-2008	Diez-Guerra, Fco. Javier/0000-0003-1707-4519; Gimenez, Cecilio/0000-0001-6726-8405; Zafra, Francisco/0000-0003-3801-3109	Spanish MINECO [SAF2011-29961, SAF2014-55686-R]; Fundacion Ramon Areces	We would like to thank E. Nunez for expert technical help. This work was supported by grants from the Spanish MINECO (SAF2011-29961 and SAF2014-55686-R), and by an institutional grant from the "Fundacion Ramon Areces". The group is member of the Network for Rare Disease Research (CIBERER).	Abe K, 2001, J NEUROCHEM, V76, P217, DOI 10.1046/j.1471-4159.2001.00062.x; Becuwe M, 2012, BIOCHEM RES INT, V2012, DOI 10.1155/2012/242764; Benediktsson AM, 2012, GLIA, V60, P175, DOI 10.1002/glia.21249; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; Cremona ML, 2011, NAT NEUROSCI, V14, P469, DOI 10.1038/nn.2781; Fontana AC, 2015, J NEUROTRAUMA; Garcia-Tardon N, 2012, J BIOL CHEM, V287, P19177, DOI 10.1074/jbc.M112.355909; Ghaddar K, 2014, MOL CELL BIOL, V34, P4447, DOI 10.1128/MCB.00699-14; Gonzalez MI, 2004, CURR OPIN PHARMACOL, V4, P30, DOI 10.1016/j.coph.2003.09.004; Gonzalez-Gonzalez IM, 2008, GLIA, V56, P963, DOI 10.1002/glia.20670; Gurevich VV, 2014, CURR PROTOC PHARM, V67; Jimenez E, 2011, J BIOL CHEM, V286, P10712, DOI 10.1074/jbc.M110.167056; Kendall RT, 2014, J BIOL CHEM, V289, P26155, DOI 10.1074/jbc.M114.595728; Kommaddi RP, 2013, PROG MOL BIOL TRANSL, V118, P175, DOI 10.1016/B978-0-12-394440-5.00007-3; Lai TW, 2014, PROG NEUROBIOL, V115, P157, DOI 10.1016/j.pneurobio.2013.11.006; Leon S, 2009, EXP CELL RES, V315, P1574, DOI 10.1016/j.yexcr.2008.11.014; Lopez-Colome AM, 2012, ASN NEURO, V4, P331, DOI 10.1042/AN20120022; Mitani A, 2003, J NEUROSCI, V23, P7176, DOI 10.1523/JNEUROSCI.23-18-07176.2003; Munir M, 2000, NEUROCHEM INT, V37, P147, DOI 10.1016/S0197-0186(00)00018-8; Murphy-Royal C, 2015, NAT NEUROSCI, V18, P219, DOI 10.1038/nn.3901; Nishizawa Y, 2001, LIFE SCI, V69, P369, DOI 10.1016/S0024-3205(01)01142-0; Otis TS, 2004, NEUROCHEM INT, V45, P537, DOI 10.1016/j.neuint.2003.11.007; Petr GT, 2015, J NEUROSCI, V35, P5187, DOI 10.1523/JNEUROSCI.4255-14.2015; Polo S, 2008, CELL, V135, P590, DOI 10.1016/j.cell.2008.10.032; Puca L, 2013, J CELL SCI, V126, P4457, DOI 10.1242/jcs.130500; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; Robinson MB, 2006, HANDB EXP PHARM, V175, P251; Sattler R, 2006, HANDB EXP PHARM, V175, P277; Saunders C, 2000, P NATL ACAD SCI USA, V97, P6850, DOI 10.1073/pnas.110035297; Shea FF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050557; Sheldon AL, 2008, NEUROCHEM INT, V53, P296, DOI 10.1016/j.neuint.2008.07.010; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Tzingounis AV, 2007, NAT REV NEUROSCI, V8, P935, DOI 10.1038/nrn2274; Underhill SM, 2015, J NEUROSCI, V35, P5260, DOI 10.1523/JNEUROSCI.4365-14.2015	35	24	24	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	AUG	2016	107						376	386		10.1016/j.neuropharm.2016.03.042			11	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	DQ1HZ	WOS:000378953400035	27044663				2021-06-18	
J	Sirajuddin, S; Valdez, C; DePalma, L; Maluso, P; Singhal, R; Schroeder, M; Sarani, B				Sirajuddin, Sarah; Valdez, Carrie; DePalma, Louis; Maluso, Patrick; Singhal, Rishi; Schroeder, Mary; Sarani, Babak			Inhibition of platelet function is common following even minor injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Thrombocytopathy; platelet dysfunction; coagulopathy; trauma; platelet inhibition	TRAUMA PATIENTS; COAGULOPATHY; DYSFUNCTION; THROMBOELASTOGRAPHY; EPIDEMIOLOGY; TRANSFUSION; COAGULATION; PLASMA; IMPACT	BACKGROUND: Hemorrhage remains the leading cause of preventable death following injury. Whereas significant attention has been paid to the coagulation cascade, there are fewer studies evaluating platelet dysfunction following injury. Thrombelastogram platelet mapping (TEG-PM) allows for the measurement of maximal potential clot strength and clot strength selectively caused by arachidonic acid and adenosine disphosphate receptors on the platelet. The purpose of this study was to determine the incidence and magnitude of receptor-specific platelet dysfunction following injury in patients who are not otherwise pharmacologically anticoagulated. METHODS: A retrospective study of adult trauma patients evaluated at a Level I trauma center from August 2013 to September 2014 was conducted. Platelet function was assessed using TEG-PM. Patients on any anticoagulant or antiplatelet medication were excluded. Patients were divided into those with and without radiographically evident traumatic brain injury (TBI). Demographic variables, Injury Severity Score (ISS), injury pattern, laboratory test results, and mortality were abstracted. Statistical comparisons were made using the Student's t test or Mann-Whitney U-test. RESULTS: The study includes 459 patients, 92% following blunt injury. Median ISS was 5. Patients with TBI (n = 102) were significantly older (median age, 54 years vs. 35 years), weremore severely injured (median ISS, 10 vs. 4), had a longer stay and higher mortality (9% vs. 0.3%). Maximal potential clot strength was normal in all cohorts, but the arachidonic acid and adenosine diphosphate pathways were significantly inhibited (30% +/- 26% and 58% +/- 27%, respectively). There was no correlation between TEG-PM values and ISS, length of stay, or mortality. There was no difference in the TBI cohort. There were no significant differences in TEG-PM parameters in those with an ISS greater than 14. There was no significant change in TEG-PM following platelet transfusion. CONCLUSION: Marked platelet inhibition is common following minor injury. Whereas the clinical significance of this finding remains unknown, the results of this study should be factored in the overall resuscitative strategy. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.	[Sirajuddin, Sarah; Valdez, Carrie; Maluso, Patrick; Singhal, Rishi; Schroeder, Mary; Sarani, Babak] George Washington Univ, Ctr Trauma & Crit Care, Washington, DC USA; [DePalma, Louis] George Washington Univ, Dept Surg, Washington, DC USA; [DePalma, Louis] George Washington Univ, Dept Pathol, Washington, DC USA	Sarani, B (corresponding author), 2150 Penn Ave NW,Suite 6B, Washington, DC 20037 USA.	bsarani@mfa.gwu.edu					Basila D, 2005, THROMB RES, V117, P49, DOI 10.1016/j.thromres.2005.04.017; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Castellino FJ, 2014, J TRAUMA ACUTE CARE, V76, P1169, DOI 10.1097/TA.0000000000000216; Davis PK, 2013, NEUROCRIT CARE, V18, P201, DOI 10.1007/s12028-012-9745-6; Gonzalez E, 2010, SEMIN THROMB HEMOST, V36, P723, DOI 10.1055/s-0030-1265289; Gonzalez E, 2010, J SURG RES, V163, P96, DOI 10.1016/j.jss.2010.03.058; Harrison P, 2005, BLOOD REV, V19, P111, DOI 10.1016/j.blre.2004.05.002; Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad; Holcomb JB, 2007, J TRAUMA, V62, P307, DOI 10.1097/TA.0b013e3180324124; Inaba K, 2010, J AM COLL SURGEONS, V211, P573, DOI 10.1016/j.jamcollsurg.2010.06.392; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P13, DOI 10.1097/TA.0b013e318256deab; Lindemann S, 2001, J CELL BIOL, V154, P485, DOI 10.1083/jcb.200105058; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; PARETI FI, 1980, AM J MED, V69, P235, DOI 10.1016/0002-9343(80)90383-6; Solomon C, 2011, THROMB HAEMOSTASIS, V106, P322, DOI 10.1160/TH11-03-0175; Swallow RA, 2006, PLATELETS, V17, P385, DOI 10.1080/09537100600757521; Wohlauer MV, 2012, J AM COLL SURGEONS, V214, P739, DOI 10.1016/j.jamcollsurg.2012.01.050; Zink KA, 2009, AM J SURG, V197, P70; Zink KA, 2009, AM J SURG, V197, P565, DOI 10.1016/j.amjsurg.2008.12.014	21	24	24	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	AUG	2016	81	2					328	332		10.1097/TA.0000000000001057			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	DS5CE	WOS:000380797300017	27027558				2021-06-18	
J	Di Battista, AP; Rhind, SG; Richards, D; Churchill, N; Baker, AJ; Hutchison, MG				Di Battista, Alex P.; Rhind, Shawn G.; Richards, Doug; Churchill, Nathan; Baker, Andrew J.; Hutchison, Michael G.			Altered Blood Biomarker Profiles in Athletes with a History of Repetitive Head Impacts	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; INCLUSION-BODY MYOSITIS; COATED-PLATELET LEVELS; NECROSIS-FACTOR-ALPHA; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; BASE-LINE; TAU; PLASMA	The long-term health effects of concussion and sub-concussive impacts in sport are unknown. Growing evidence suggests both inflammation and neurodegeneration are pivotal to secondary injury processes and the etiology of neurodegenerative diseases. In the present study we characterized circulating brain injury and inflammatory mediators in healthy male and female athletes according to concussion history and collision sport participation. Eighty-seven university level athletes (male, n = 60; female, n = 27) were recruited before the start of the competitive season. Athletes were healthy at the time of the study (no medications, illness, concussion or musculoskeletal injuries). Dependent variables included 29 inflammatory and 10 neurological injury analytes assessed in the peripheral blood by immunoassay. Biomarkers were statistically evaluated using partial least squares multivariate analysis to identify possible relationships to self-reported previous concussion history, number of previous concussions and collision sport participation in male and female athletes. Multiple concussions were associated with increases in peripheral MCP-1 in females, and MCP-4 in males. Collision sport participation was associated with increases in tau levels in males. These results are consistent with previous experimental and clinical findings that suggest ongoing inflammatory and cerebral injury processes after repetitive mild head trauma. However, further validation is needed to correlate systemic biomarkers to repetitive brain impacts, as opposed to the extracranial effects common to an athletic population such as exercise and muscle damage.	[Di Battista, Alex P.; Baker, Andrew J.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Di Battista, Alex P.; Rhind, Shawn G.] Def Res & Dev Canada, Toronto Res Ctr, Toronto, ON, Canada; [Rhind, Shawn G.; Richards, Doug; Hutchison, Michael G.] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Churchill, Nathan; Hutchison, Michael G.] St Michaels Hosp, Keenan Res Ctr Biomed Sci, Toronto, ON, Canada; [Baker, Andrew J.] Univ Toronto, St Michaels Hosp, Dept Crit Care Anesthesia & Surg, Toronto, ON, Canada; [Baker, Andrew J.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON, Canada	Hutchison, MG (corresponding author), Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada.; Hutchison, MG (corresponding author), St Michaels Hosp, Keenan Res Ctr Biomed Sci, Toronto, ON, Canada.	michael.hutchison@utoronto.ca		Rhind, Shawn/0000-0003-2300-0620; Di Battista, Alex/0000-0002-3325-6833	CIMVHR	The work was supported by CIMVHR Task 7.	Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Anthony DC, 2014, EXP NEUROL, V258, P105, DOI 10.1016/j.expneurol.2014.03.013; Avila J, 2014, J ALZHEIMERS DIS, V40, pS7, DOI 10.3233/JAD-131832; Baker JG, 2015, CLIN PEDIAT PHILA; Ballabio D, 2013, PLS DA ANAL METHODS, DOI [10.1002/elps.201500352, DOI 10.1002/ELPS.201500352]; Balu R, 2014, CURR NEUROL NEUROSCI, V14, DOI 10.1007/s11910-014-0484-2; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; Barrio JR, 2015, P NATL ACAD SCI USA, V112, pE2039, DOI 10.1073/pnas.1409952112; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Blennow K, 2010, NAT REV NEUROL, V6, P131, DOI 10.1038/nrneurol.2010.4; Bouman A, 2005, HUM REPROD UPDATE, V11, P411, DOI 10.1093/humupd/dmi008; Ferreira LCB, 2014, BRAIN INJURY, V28, P1311, DOI 10.3109/02699052.2014.916818; Breland UM, 2010, CARDIOVASC RES, V86, P265, DOI 10.1093/cvr/cvq044; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Brown DA, 2015, SPORTS MED, V45, P1027, DOI 10.1007/s40279-015-0335-6; Bulut M, 2006, ADV THER, V23, P12, DOI 10.1007/BF02850342; Buonora JE, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00068; Cahill L, 2006, NAT REV NEUROSCI, V7, P477, DOI 10.1038/nrn1909; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Comper P, 2010, BRAIN INJURY, V24, P1257, DOI 10.3109/02699052.2010.506854; Debad J, 2016, KEYST S AX CELLL BIO; Deyhle MR, 2016, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00424; Di Battista AP, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0500-3; Di Battista AP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00044; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Erlanger DM, 2015, BRAIN INJURY, V29, P171, DOI 10.3109/02699052.2014.965211; Fakhran S, 2013, RADIOLOGY, V269, P249, DOI 10.1148/radiol.13122343; Fish EN, 2008, NAT REV IMMUNOL, V8, P737, DOI 10.1038/nri2394; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Gosselin N, 2010, PHYSICIAN SPORTSMED, V38, P27, DOI 10.3810/psm.2010.10.1805; Armitage EG, 2015, ELECTROPHORESIS, V36, P3050, DOI 10.1002/elps.201500352; Gu YJ, 1996, J NEUROCHEM, V67, P1235; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Jaerve A, 2012, CELL TISSUE RES, V349, P229, DOI 10.1007/s00441-012-1427-3; Jaerve A, 2011, EXP NEUROL, V231, P284, DOI 10.1016/j.expneurol.2011.07.002; Jin SJ, 2009, TOHOKU J EXP MED, V217, P87; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kumar RG, 2015, J HEAD TRAUMA REHAB, V30, P369, DOI 10.1097/HTR.0000000000000067; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Maurage CA, 2004, NEUROPATH APPL NEURO, V30, P624, DOI 10.1111/j.1365-2990.2004.00577.x; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Meehan WP, 2016, J NEUROTRAUM, V33, P254, DOI 10.1089/neu.2015.3930; Mendez MF, 2015, J ALZHEIMERS DIS, V47, P985, DOI 10.3233/JAD-143207; Muccigrosso MM, 2016, BRAIN BEHAV IMMUN, V54, P95, DOI 10.1016/j.bbi.2016.01.009; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Neselius S, 2013, BRAIN INJURY, V27, P425, DOI 10.3109/02699052.2012.750752; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Nogalska A, 2011, NEUROSCI LETT, V503, P229, DOI 10.1016/j.neulet.2011.08.042; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Peake JM, 2005, EUR J APPL PHYSIOL, V95, P514, DOI 10.1007/s00421-005-0035-2; Perry HV, 2014, MICROGLIAL PRIMING N, V10, P217; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Prodan CI, 2016, J NEUROTRAUM, V33, P818, DOI 10.1089/neu.2014.3846; Prodan CI, 2014, J HEAD TRAUMA REHAB, V29, P522, DOI 10.1097/HTR.0000000000000010; Ramien C., 2016, NEUROSCI BIOBEHAV RE; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Soares FMS, 2012, NEUROIMMUNOMODULAT, V19, P377, DOI 10.1159/000342141; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Stellwagen D, 2005, J NEUROSCI, V25, P3219, DOI 10.1523/JNEUROSCI.4486-04.2005; Stern RA, 2016, J ALZHEIMERS DIS, V51, P1099, DOI 10.3233/JAD-151028; Su SH, 2014, BRAIN BEHAV IMMUN, V38, P111, DOI 10.1016/j.bbi.2014.01.009; Takeuchi H, 2006, J BIOL CHEM, V281, P21362, DOI 10.1074/jbc.M600504200; Tasci A, 2003, NEUROL RES, V25, P871, DOI 10.1179/016164103771953998; Webster KM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0457-7; Wold S, 2001, CHEMOMETR INTELL LAB, V58, P109, DOI 10.1016/S0169-7439(01)00155-1; Yawata I, 2008, LIFE SCI, V82, P1111, DOI 10.1016/j.lfs.2008.03.010; Yuh Esther L, 2014, Neurosurgery, V75 Suppl 4, pS50, DOI 10.1227/NEU.0000000000000491; Zetterberg H, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt163; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	82	24	24	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 26	2016	11	7							e0159929	10.1371/journal.pone.0159929			14	Multidisciplinary Sciences	Science & Technology - Other Topics	DT5IH	WOS:000381515600065	27458972	DOAJ Gold, Green Published			2021-06-18	
J	Newsome, MR; Li, XQ; Lin, XD; Wilde, EA; Ott, S; Biekman, B; Hunter, JV; Dash, PK; Taylor, BA; Levin, HS				Newsome, Mary R.; Li, Xiaoqi; Lin, Xiaodi; Wilde, Elisabeth A.; Ott, Summer; Biekman, Brian; Hunter, Jill V.; Dash, Pramod K.; Taylor, Brian A.; Levin, Harvey S.			Functional Connectivity Is Altered in Concussed Adolescent Athletes Despite Medical Clearance to Return to Play: A Preliminary Report	FRONTIERS IN NEUROLOGY			English	Article						sports concussion; functional connectivity; adolescent; memory; athletic injuries; traumatic brain injury	SPORTS-RELATED CONCUSSION; DEFAULT NETWORK; SAMPLE-SIZE; BRAIN; INJURY; RELIABILITY; IMPACT	Recovery following sports-related concussion (SRC) is slower and often more complicated in young adolescent athletes than in collegiate players. Further, the clinical decision to return to play is currently based on symptoms and cognitive performance without direct knowledge of brain function. We tested the hypothesis that brain functional connectivity (FC) would be aberrant in recently concussed, asymptomatic athletes who had been cleared to return to play. A seed-based FC analysis measured the FC of the default mode network (DMN) (seeds = anterior cingulate cortex, posterior cingulate cortex (PCC), right lateral parietal cortex, and left lateral parietal cortex) 30 days after SRC in asymptomatic high school athletes cleared to return to play (n = 13) and was compared to the FC of high school athletes with orthopedic injury (OI) ( n = 13). The SRC group demonstrated greater FC than the OI group between the PCC and the ventral lateral prefrontal cortex, as well as between the right lateral parietal cortex and lateral temporal cortex (with regions both outside of and within the DMN). Additionally, the OI group demonstrated greater FC than the SRC group between right lateral parietal cortex and supramarginal gyrus. When relating the FC results to verbal memory performance approximately 1 week and 1 month after injury, significantly different between-group relations were found for the posterior cingulate and right lateral parietal cortex seeds. However, the groups did not differ in verbal memory at 1 month. We suggest that changes in FC are apparent 1-month post-SRC despite resolution of post-concussion symptoms and recovery of cognitive performance in adolescent athletes cleared to return to play.	[Newsome, Mary R.; Li, Xiaoqi; Lin, Xiaodi; Wilde, Elisabeth A.; Biekman, Brian; Taylor, Brian A.; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Taylor, Brian A.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Ott, Summer] UTHlth McGovern Med Sch, Dept Orthoped Surg, Houston, TX USA; [Hunter, Jill V.] Texas Childrens Hosp, Dept Radiol, Houston, TX 77030 USA; [Dash, Pramod K.] UTHlth McGovern Med Sch, Dept Neurobiol & Anat, Houston, TX USA	Newsome, MR (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA.	mnewsome@bcm.edu		Taylor, Brian/0000-0001-9745-1075	National Institutes of Health: National Institutes of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R21NS086714-01]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS086714] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I21RX001608] Funding Source: NIH RePORTER	This study was supported by National Institutes of Health: National Institutes of Neurological Disorders and Stroke, #1R21NS086714-01 (HL, SO, PD). The South Central Mental Illness Research, Education, and Clinical Center (SCMIRECC) at the Michael E. DeBakey VA Medical Center provided facilities that allowed analyses of the fMRI data. We also gratefully acknowledge Coy VanValkenburgh, Marlene Diaz, and Qisheng Liu; David Ress, Ph.D. and the Center for Advanced Magnetic Resonance Imaging at Baylor College of Medicine; Memorial Hermann Ironman Sports Medicine Institute; and the computing resources provided by the CIBR Center for Computational and Integrative Biomedical Research of Baylor College of Medicine. We are grateful to the athletes for taking part in this research. The content is solely the responsibility of the authors and does not necessarily represent the official views of Baylor College of Medicine or University of Texas Health Science Center at Houston. There are no potential conflicts of interest, including financial, between any of the authors and the work presented in this manuscript.	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Ashby F. G., 2011, PROCESSING STAT ANAL; *ASS ADV AUT MED, 1998, ABBR INJ SCAL 1990 R; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Borich M, 2015, J NEUROTRAUM, V32, P265, DOI 10.1089/neu.2013.3269; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475; Covassin T, 2016, J ATHL TRAINING, V51, P189, DOI 10.4085/1062-6050-51.3.05; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Friston KJ, 2013, NEUROIMAGE, V81, P503, DOI 10.1016/j.neuroimage.2013.02.057; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Iraji A, 2015, J NEUROTRAUM, V32, P1031, DOI 10.1089/neu.2014.3610; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Lindquist MA, 2013, NEUROIMAGE, V81, P499, DOI 10.1016/j.neuroimage.2013.02.056; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P287; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Risen SR, 2015, J PEDIATR REHAB MED, V8, P309, DOI 10.3233/PRM-150349; Slobounov S, 2014, BRIT J SPORT MED, V48, P75, DOI 10.1136/bjsports-2013-092362; Snedecor G.W., 1980, STAT METHODS, V7th; Spreng RN, 2009, J COGNITIVE NEUROSCI, V21, P489, DOI 10.1162/jocn.2008.21029; TEASDALE G, 1974, LANCET, V2, P81; Whitfield-Gabrieli S, 2012, BRAIN CONNECT, V2, P125, DOI 10.1089/brain.2012.0073; Wiech K, 2014, PAIN, V155, P2047, DOI 10.1016/j.pain.2014.07.009; Wilde EA, 2016, J NEUROTRAUMA	28	24	24	0	7	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	JUL 25	2016	7								116	10.3389/fneur.2016.00116			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DS1FI	WOS:000380340800001	27504104	DOAJ Gold, Green Published			2021-06-18	
J	Emmerich, T; Abdullah, L; Crynen, G; Dretsch, M; Evans, J; Ait-Ghezala, G; Reed, J; Montague, H; Chaytow, H; Mathura, V; Martin, J; Pelot, R; Ferguson, S; Bishop, A; Phillips, J; Mullan, M; Crawford, F				Emmerich, Tanja; Abdullah, Laila; Crynen, Gogce; Dretsch, Michael; Evans, James; Ait-Ghezala, Ghania; Reed, Jon; Montague, Hannah; Chaytow, Helena; Mathura, Venkatarajan; Martin, Justin; Pelot, Robert; Ferguson, Scott; Bishop, Alex; Phillips, John; Mullan, Michael; Crawford, Fiona			Plasma Lipidomic Profiling in a Military Population of Mild Traumatic Brain Injury and Post-Traumatic Stress Disorder with Apolipoprotein E epsilon 4-Dependent Effect	JOURNAL OF NEUROTRAUMA			English	Article						apolipoprotein E; human studies; lipidomics; phospholipids; post-traumatic stress disorder; traumatic brain injury	NEURON-SPECIFIC ENOLASE; SEVERE HEAD-INJURY; N-3 FATTY-ACIDS; ALZHEIMERS-DISEASE; COGNITIVE DECLINE; ANIMAL-MODELS; APOE GENOTYPE; E ISOFORMS; FOLLOW-UP; SERUM	In the military population, there is high comorbidity between mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD) due to the inherent risk of psychological trauma associated with combat. These disorders present with long-term neurological dysfunction and remain difficult to diagnose due to their comorbidity and overlapping clinical presentation. Therefore, we performed cross-sectional analysis of blood samples from demographically matched soldiers (total, n = 120) with mTBI, PTSD, and mTBI+PTSD and those who were considered cognitively and psychologically normal. Soldiers were genotyped for apolipoprotein E (APOE) epsilon 4, and phospholipids (PL) were examined using liquid chromatography/mass spectrometry analysis. We observed significantly lower levels of several major PL classes in TBI, PTSD, and TBI+PTSD, compared with controls. PTSD severity analysis revealed that significant PL decreases were primarily restricted to the moderate-to-severe PTSD group. An examination of the degree of unsaturation showed that monounsaturated fatty acid-containing phosphatidylcholine (PC) and phosphatidylinositol (PI) species were lower in the TBI and TBI+PTSD groups. However, these PLs were unaltered among PTSD subjects, compared with controls. Similarly, ether PC (ePC) levels were lower in PTSD and TBI+PTSD subjects, relative to controls. Ratios of arachidonic acid (AA) to docosahexaenoic acid (DHA)-containing species were significantly decreased within PC and phosphatidylethanolamine (PE) classes. APOE epsilon 4 (+) subjects exhibited higher PL levels than their APOE epsilon 4 (-) counterparts within the same diagnostic groups. These findings suggest that PL profiles, together with APOE genotyping, could potentially aid to differentiate diagnosis of mTBI and PTSD and warrant further validation. In conclusion, PL profiling may facilitate clinical diagnosis of mTBI and PTSD currently hindered by comorbid pathology and overlapping symptomology of these two conditions.	[Emmerich, Tanja; Abdullah, Laila; Crynen, Gogce; Evans, James; Ait-Ghezala, Ghania; Reed, Jon; Montague, Hannah; Chaytow, Helena; Mathura, Venkatarajan; Martin, Justin; Pelot, Robert; Ferguson, Scott; Bishop, Alex; Phillips, John; Mullan, Michael; Crawford, Fiona] Roskamp Inst, 2040 Whitfield Ave, Sarasota, FL 34243 USA; [Emmerich, Tanja; Abdullah, Laila; Crynen, Gogce; Ait-Ghezala, Ghania; Mathura, Venkatarajan; Pelot, Robert; Ferguson, Scott; Mullan, Michael; Crawford, Fiona] Open Univ, Milton Keynes, Bucks, England; [Emmerich, Tanja; Abdullah, Laila; Ait-Ghezala, Ghania; Reed, Jon; Mathura, Venkatarajan; Pelot, Robert; Ferguson, Scott; Crawford, Fiona] James A Haley Vet Hosp, Tampa, FL 33612 USA; [Dretsch, Michael] Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence, Bethesda, MD USA; [Dretsch, Michael] US Army, Aeromed Res Lab, Rucker, AL USA	Emmerich, T (corresponding author), Roskamp Inst, 2040 Whitfield Ave, Sarasota, FL 34243 USA.	temmerich@roskampinstitute.net		Ait-Ghezala, Ghania/0000-0002-9836-8617; Chaytow, Helena/0000-0003-2257-7620; Emmerich, Tanja/0000-0001-5064-7150			Abdullah L, 2014, FASEB J, V28, P5311, DOI 10.1096/fj.14-258228; Abdullah L, 2012, NEUROMOL MED, V14, P349, DOI 10.1007/s12017-012-8192-z; Baker DG, 2012, NEUROPHARMACOLOGY, V62, P663, DOI 10.1016/j.neuropharm.2011.02.027; Barberger-Gateau P, 2007, NEUROLOGY, V69, P1921, DOI 10.1212/01.wnl.0000278116.37320.52; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; Bazinet RP, 2014, NAT REV NEUROSCI, V15, P771, DOI 10.1038/nrn3820; Beydoun MA, 2007, AM J CLIN NUTR, V85, P1103; Binder EB, 2009, PSYCHONEUROENDOCRINO, V34, P99, DOI [10.1016/j.psyneuen.2008.08.018, 10.1016/j.psyneuen.2009.05.021]; Binder EB, 2004, NAT GENET, V36, P1319, DOI 10.1038/ng1479; Brenner Lisa A, 2011, Dialogues Clin Neurosci, V13, P311; Breslau N, 2002, PSYCHOL MED, V32, P573, DOI 10.1017/S0033291701004998; Conquer JA, 2000, LIPIDS, V35, P1305, DOI 10.1007/s11745-000-0646-3; Copeland WE, 2012, BIOL PSYCHIAT, V71, P15, DOI 10.1016/j.biopsych.2011.09.023; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Cunningham RT, 1996, EUR J CLIN INVEST, V26, P298, DOI 10.1046/j.1365-2362.1996.129282.x; Department of Defense, 2014, DOD WORLDW NUMB TBI; EMI M, 1988, GENOMICS, V3, P373, DOI 10.1016/0888-7543(88)90130-9; FADEN AI, 1992, AM J PHYSIOL, V263, pR909; Fisher H, 2014, GUIDE US MILITARY CA; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fredman G, 2011, BIOCHEM J, V437, P185, DOI 10.1042/BJ20110327; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Glenn TC, 2015, J NEUROTRAUM, V32, P820, DOI 10.1089/neu.2014.3483; Hamilton JA, 2007, J MOL NEUROSCI, V33, P2, DOI 10.1007/s12031-007-0060-1; Heude B, 2003, AM J CLIN NUTR, V77, P803; HORN M, 1995, STROKE, V26, P290, DOI 10.1161/01.STR.26.2.290; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; Huang TL, 2005, NEUROLOGY, V65, P1409, DOI 10.1212/01.wnl.0000183148.34197.2e; Jacobs A, 1996, J NUCL MED, V37, P1605; Kagan BL, 1999, BIOL PSYCHIAT, V45, P374, DOI 10.1016/S0006-3223(98)00059-6; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Karlovic D, 2004, J KOREAN MED SCI, V19, P431, DOI 10.3346/jkms.2004.19.3.431; Kay AD, 2003, J NEUROTRAUM, V20, P717, DOI 10.1089/089771503767869953; Kennelly S, 2012, INT J GERIATR PSYCH, V27, P415, DOI 10.1002/gps.2735; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Langeland W, 2008, NEUROSCI BIOBEHAV R, V32, P161, DOI 10.1016/j.neubiorev.2007.07.002; Lehrner A, 2014, EUR J PSYCHOTRAUMATO, V5, DOI 10.3402/ejpt.v5.23797; Lekman M, 2008, BIOL PSYCHIAT, V63, P1103, DOI 10.1016/j.biopsych.2007.10.026; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Liu MC, 2006, BIOCHEM J, V394, P715, DOI 10.1042/BJ20050905; Lyons MJ, 2013, AM J MED GENET B, V162, P762, DOI 10.1002/ajmg.b.32154; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MAHLEY RW, 1983, KLIN WOCHENSCHR, V61, P225, DOI 10.1007/BF01496128; McKeen HD, 2011, BIOCHEM SOC T, V39, P663, DOI 10.1042/BST0390663; Mitchell RW, 2011, PROSTAG LEUKOTR ESS, V85, P293, DOI 10.1016/j.plefa.2011.04.007; Mitchener A, 1997, J NEUROL NEUROSUR PS, V62, P633, DOI 10.1136/jnnp.62.6.633; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Pasvogel AE, 2010, BIOL RES NURS, V11, P325, DOI 10.1177/1099800409346056; Polozova A, 2007, J MOL NEUROSCI, V33, P56, DOI 10.1007/s12031-007-0039-y; Raabe A, 1998, J NEUROL NEUROSUR PS, V65, P930, DOI 10.1136/jnnp.65.6.930; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schaefer EJ, 2006, ARCH NEUROL-CHICAGO, V63, P1545, DOI 10.1001/archneur.63.11.1545; Schwab KA, 2006, NEUROLOGY, V66, pA235; Serhan CN, 2008, ANNU REV PATHOL-MECH, V3, P279, DOI 10.1146/annurev.pathmechdis.3.121806.151409; Shannon R. J., 2015, J NEUROTRAUMA; Solter V, 2002, CROAT MED J, V43, P685; Spector AA, 2001, J MOL NEUROSCI, V16, P159, DOI 10.1385/JMN:16:2-3:159; Stanimirovic D, 2000, BRAIN PATHOL, V10, P113; Tanielian T, 2008, INVISIBLE WOUNDS WAR; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; VA National Center for PTSD, 2014, PTSD CHECKL DSM 4; Vandal M, 2014, J NEUROCHEM, V129, P516, DOI 10.1111/jnc.12640; Weathers F. W., 1991, PCL M FOR DSM 4; WEISGRABER KH, 1981, J BIOL CHEM, V256, P9077; Whalley LJ, 2008, AM J CLIN NUTR, V87, P449; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	73	24	24	1	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 15	2016	33	14					1331	1348		10.1089/neu.2015.4061			18	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DQ5CX	WOS:000379223100005	26714394				2021-06-18	
J	Karpman, S; Reid, P; Phillips, L; Qin, ZL; Gross, DP				Karpman, Shelby; Reid, Patrick; Phillips, Leah; Qin, Ziling; Gross, Douglas P.			Combative Sports Injuries: An Edmonton Retrospective	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						case series; injury; incidence; concussion; mixed martial arts; boxing	MIXED MARTIAL ARTS; COMPETITION	Objective: Mixed martial arts (MMA) is an increasingly popular combative sport involving aggressive techniques that present substantial injury risk. We examined the incidence and types of injuries sustained in MMA fights and compared this with injuries sustained in boxing matches. Design: Consecutive Case Series. Setting: We used data from post-fight medical examinations on all bouts in Edmonton, Canada, between 2000 and 2013. Participants: The participants were 1181 MMA competitors and 550 boxers. Main Outcome Measures: The attending physician conducted a mandatory post-fight examination of all fighters and documented the nature of injuries sustained. Results: Boxers were significantly more likely not to experience injury (49.8% vs 59.4%, P < 0.001), whereas MMA fighters were significantly more likely to experience 1 injury (typically contusion/bruising, P < 0.001). Boxers were more likely to experience loss of consciousness (7.1% vs 4.2%, P = 0.01) and serious eye injury (1.1% vs 0.3%, P = 0.02). Conclusions: The overall injury incidence in MMA competitors appears slightly higher than for boxers, but MMA fighters experience more minor contusion/bruising injuries. Boxers are more likely to experience serious injury such as concussion/head trauma involving loss of consciousness or eye injury such as retinal detachment.	[Karpman, Shelby; Gross, Douglas P.] Univ Alberta, Glen Sather Sports Med Clin, Edmonton, AB, Canada; [Reid, Patrick] Univ Alberta, Fac Phys Educ, Edmonton, AB, Canada; [Reid, Patrick] Edmonton Combat Sports Commiss, Edmonton, AB, Canada; [Phillips, Leah] Alberta Hlth Serv, Edmonton, AB, Canada; [Qin, Ziling; Gross, Douglas P.] Univ Alberta, Fac Rehabil Med, Rehabil Res Ctr, Edmonton, AB, Canada; [Gross, Douglas P.] Univ Alberta, Dept Phys Therapy, Edmonton, AB, Canada	Gross, DP (corresponding author), Univ Alberta, 2-50 Corbett Hall, Edmonton, AB T6G 2G4, Canada.	dgross@ualberta.ca	Gross, Douglas P./AAF-6997-2020	Gross, Douglas P./0000-0002-2427-6277	Glen Sather University of Alberta Sports Medicine Clinic in Edmonton, Alberta, Canada	The Glen Sather University of Alberta Sports Medicine Clinic in Edmonton, Alberta, Canada, provided resources and funding for this research. The Edmonton Combative Sports Commission facilitated data collection.	Bledsoe GH, 2006, J SPORT SCI MED, V5, P136; Buse GJ, 2006, BRIT J SPORT MED, V40, P169, DOI 10.1136/bjsm.2005.021295; Kochhar T, 2005, BRIT J SPORT MED, V39, P444, DOI 10.1136/bjsm.2004.011270; Ngai KM, 2008, BRIT J SPORT MED, V42, P686, DOI 10.1136/bjsm.2007.044891; Pappas E, 2007, J SPORT SCI MED, V6, P58; Rainey Charles E, 2009, N Am J Sports Phys Ther, V4, P190; Scoggin James F 3rd, 2010, Am J Orthop (Belle Mead NJ), V39, P247; Walrod B, 2011, CURR SPORT MED REP, V10, P288, DOI 10.1249/JSR.0b013e31822dc2c2; Woodward Thomas W, 2009, WMJ, V108, P40; Zazryn TR, 2003, BRIT J SPORT MED, V37, P321, DOI 10.1136/bjsm.37.4.321	10	24	24	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2016	26	4					332	334		10.1097/JSM.0000000000000235			3	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	DQ8DC	WOS:000379438300012	26327287				2021-06-18	
J	Walker, MS; Kaimal, G; Koffman, R; DeGraba, TJ				Walker, Melissa S.; Kaimal, Girija; Koffman, Robert; DeGraba, Thomas J.			Art therapy for PTSD and TBI: A senior active duty military service member's therapeutic journey	ARTS IN PSYCHOTHERAPY			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS; SYMPTOM PROVOCATION; ARMY	Art therapy is increasingly being accepted as a form of complementary and integrative care for military veterans affected by trauma and injuries in the line of duty. Less is known, however, about the applications of art therapy for co-morbid traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD). In addition, most studies to date have focused on art therapy with veterans (former military service members) rather than with active duty service members; furthermore, there are no studies that have examined the unique context of PTSD in senior military personnel. This case study presents the therapeutic process through art therapy in the case of a senior active duty military service member (with chronic PTSD and TBI), in the context of an integrated model of care that included medical and complementary therapies. (C) 2016 The Authors. Published by Elsevier Ltd.	[Walker, Melissa S.; Koffman, Robert; DeGraba, Thomas J.] Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence, Bldg 51,4860 S Palmer Rd, Bethesda, MD 20889 USA; [Kaimal, Girija] Drexel Univ, Coll Nursing & Hlth Profess, 1601 Cherry St, Philadelphia, PA 19102 USA	Walker, MS (corresponding author), Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence, Bldg 51,4860 S Palmer Rd, Bethesda, MD 20889 USA.	Melissa.s.walker12.civ@mail.mil; Gk27@drexel.edu; Rlkoffman@gmail.com; Thomas.j.degraba.civ@mail.mil		Walker, Melissa/0000-0001-9375-567X	National Endowment for the Arts (NEA) Military Healing Arts Partnership	The authors would like to thank the National Endowment for the Arts (NEA) Military Healing Arts Partnership for funding support. We would also like to thank Drs. Anda and Mihai Popescu for the magnetoencephalography analysis. In addition we would like to acknowledge COL Geoffrey Grammer, Ms. Katherine Myers Coffman, Ms. Adele Gonzaga, and Ms. Barbara Granger for their help with various stages of the manuscript.	Balfour M, 2015, ARTS HEALTH, V7, P87, DOI 10.1080/17533015.2014.999247; Barker V.L., 1991, MUSIC THERAPY PERSPE, V9, P26; Burnam MA, 2008, INVISIBLE WOUNDS WAR, P245; Collie K, 2006, ART THER, V23, P157, DOI 10.1080/07421656.2006.10129335; Creswell J.W., 2000, DESIGNING CONDUCTING; Dodd F., 1975, J ART THERAPY, V14, P83; Gantt L, 2009, ART PSYCHOTHER, V36, P148, DOI 10.1016/j.aip.2008.12.005; GOLUB D, 1985, ART PSYCHOTHER, V12, P285, DOI 10.1016/0197-4556(85)90041-3; Greece M, 2003, ART PSYCHOTHER, V30, P229, DOI 10.1016/S0197-4556(03)00057-1; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Howie P., 2002, ART THERAPY J AM ART, V19, P100; Lamonthe D., 2015, WASHINGTON POST; Lazarus-Leff B., 2013, J AM ART THERAPY ASS, V15, P120; Lehrner A, 2016, POSTTRAUMATIC STRESS DISORDER: FROM NEUROBIOLOGY TO TREATMENT, P265; Malchiodi CA, 2012, HDB ART THERAPY, P320; Peres JFP, 2008, AUST NZ J PSYCHIAT, V42, P478, DOI 10.1080/00048670802050561; Rauch SL, 1997, BIOL PSYCHIAT, V42, P446, DOI 10.1016/S0006-3223(97)00145-5; Shenton A. K., 2004, EDUC INFORM, V22, P63, DOI [10.3233/EFI-2004, 10.3233/EFI-2004-22201, DOI 10.3233/EFI-2004-22201]; Shin LM, 1997, ANN NY ACAD SCI, V821, P521, DOI 10.1111/j.1749-6632.1997.tb48320.x; Stein MB, 2015, AM J PSYCHIAT, V172, P1101, DOI 10.1176/appi.ajp.2015.14121572; Van Der Kolk Bessel, 1996, P303; Yin RK, 2014, CASE STUDY RES DESIG, V5; Zinzow HM, 2013, MIL PSYCHOL, V25, P514, DOI 10.1037/mil0000015	23	24	24	0	18	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-4556	1873-5878		ART PSYCHOTHER	Arts Psychother.	JUL	2016	49						10	18		10.1016/j.aip.2016.05.015			9	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	DP3CH	WOS:000378369500004		Other Gold			2021-06-18	
J	Douglas, JM; Bracy, CA; Snow, PC				Douglas, Jacinta M.; Bracy, Christine A.; Snow, Pamela C.			Return to Work and Social Communication Ability Following Severe Traumatic Brain Injury	JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH			English	Article							CLOSED HEAD-INJURY; VOCATIONAL-REHABILITATION; SUPPORTED EMPLOYMENT; DISCOURSE ABILITIES; ADULTS; TBI; QUESTIONNAIRE; OUTCOMES; PREDICTION; SKILLS	Purpose: Return to competitive employment presents a major challenge to adults who survive traumatic brain injury (TBI). This study was undertaken to better understand factors that shape employment outcome by comparing the communication profiles and self-awareness of communication deficits of adults who return to and maintain employment with those who do not. Method: Forty-six dyads (46 adults with TBI, 46 relatives) were recruited into 2 groups based on the current employment status (employed or unemployed) of participants with TBI. Groups did not differ in regard to sex, age, education, preinjury employment, injury severity, or time postinjury. The La Trobe Communication Questionnaire (Douglas, O'Flaherty, & Snow, 2000) was used to measure communication. Group comparisons on La Trobe Communication Questionnaire scores were analyzed by using mixed 2 x 2 analysis of variance (between factor: employment status; within factor: source of perception). Results: Analysis yielded a significant group main effect (p = .002) and a significant interaction (p = .004). The employed group reported less frequent difficulties (self and relatives). Consistent with the interaction, unemployed participants perceived themselves to have less frequent difficulties than their relatives perceived, whereas employed participants reported more frequent difficulties than their relatives. Conclusion: Communication outcome and awareness of communication deficits play an important role in reintegration to the workplace following TBI.	[Douglas, Jacinta M.; Bracy, Christine A.] La Trobe Univ, Bundoora, Vic, Australia; [Douglas, Jacinta M.] Summer Fdn, Box Hill, Vic, Australia; [Snow, Pamela C.] La Trobe Univ, Bendigo, Vic, Australia	Douglas, JM (corresponding author), La Trobe Univ, Bundoora, Vic, Australia.; Douglas, JM (corresponding author), Summer Fdn, Box Hill, Vic, Australia.	J.Douglas@latrobe.edu.au		Douglas, Jacinta/0000-0003-0940-6624; Snow, Pamela/0000-0002-2426-8349			Athanasou J., 2008, INT J DISABIL MANAG, V3, P54; Bootes K, 2010, WORK, V36, P207, DOI [10.3233/WOR-2010-1021, 10.3233/WOR-2010-01021]; Bracy C. A., 2005, BRAIN IMPAIR, V6, P1, DOI [10.1375/brim.6.1.1.65476., DOI 10.1375/BRIM.6.1.1.65476, DOI 10.1375/brim.6.1.1.65476]; Braden C, 2010, BRAIN INJURY, V24, P1298, DOI 10.3109/02699052.2010.506859; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Channon Shelley, 2003, Cogn Neuropsychiatry, V8, P243, DOI 10.1080/135468000344000002; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; Douglas JM, 2007, APHASIOLOGY, V21, P1181, DOI 10.1080/02687030600980950; Douglas JM, 2007, J HEAD TRAUMA REHAB, V22, P31, DOI 10.1097/00001199-200701000-00004; Douglas JM, 2014, BRAIN IMPAIR, V15, P190, DOI 10.1017/BrImp.2014.25; Douglas JM, 2010, BRAIN IMPAIR, V11, P171, DOI 10.1375/brim.11.2.171; Douglas JM, 2010, J SPEECH LANG HEAR R, V53, P365, DOI 10.1044/1092-4388(2009/08-0205); Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS51, DOI 10.1016/j.apmr.2008.09.552; Grice P, 1975, SYNTAX SEMANTICS, VIII, P41; Groswasser Z, 1999, NEUROPSYCHOL REHABIL, V9, P493, DOI 10.1080/096020199389545; Hofgren C, 2010, WORK, V36, P431, DOI 10.3233/WOR-2010-1039; Hoofien D, 2001, BRAIN INJURY, V15, P189; Isaki E, 2000, BRAIN INJURY, V14, P441; Kertesz A., 1982, W APHASIA BATTERY; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Larkins BM, 2004, BRAIN INJURY, V18, P691, DOI 10.1080/02699050310001617389; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; Macdonald S., 2005, FUNCTIONAL ASSESSMEN; Marosszeky NEV, 1997, PTA PROTOCOL GUIDELI; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; Murphy L, 2006, BRAIN INJURY, V20, P1119, DOI 10.1080/02699050600664335; Nightingale EJ, 2007, BRAIN IMPAIR, V8, P101, DOI [10.1375/brim.8.2.101, DOI 10.1375/BRIM.8.2.101]; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; OFlaherty CA, 1997, APHASIOLOGY, V11, P889, DOI 10.1080/02687039708250463; Ownsworth T, 2006, REHABIL PSYCHOL, V51, P50, DOI 10.1037/0090-5550.51.1.50; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P567, DOI 10.1080/13803390500434466; Rietdijk R, 2013, BRAIN INJURY, V27, P812, DOI 10.3109/02699052.2013.775491; Ryan NP, 2013, INT J DEV NEUROSCI, V31, P811, DOI 10.1016/j.ijdevneu.2013.10.002; Sale P., 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [DOI 10.1097/00001199-199109000-00004, 10.1097/00001199-199109000-00004.]; Sander AM, 1997, J HEAD TRAUMA REHAB, V12, P28, DOI 10.1097/00001199-199710000-00004; Sander AM, 2010, J HEAD TRAUMA REHAB, V25, P121, DOI 10.1097/HTR.0b013e3181cd1635; Schonberger M, 2011, J NEUROL NEUROSUR PS, V82, P936, DOI 10.1136/jnnp.2010.210021; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Sherer M, 2008, ARCH PHYS MED REHAB, V89, P42, DOI 10.1016/j.apmr.2007.08.128; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow P, 1997, BRAIN INJURY, V11, P409; Snow PC, 1999, APHASIOLOGY, V13, P529, DOI 10.1080/026870399401993; Snow PC, 2000, BRAIN INJURY, V14, P397; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; STRATTON MC, 1994, BRAIN INJURY, V8, P631, DOI 10.3109/02699059409151016; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; Tate R., 2005, BRAIN IMPAIR, V6, P75, DOI DOI 10.1375/BRIM.2005.6.2.75; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Trewin D., 2006, AUSTR NZ STANDARD CL; Tu LV, 2011, BRAIN INJURY, V25, P560, DOI 10.3109/02699052.2011.571655; Turkstra L., 1995, BRAIN INJURY, V10, P319; van Velzen JM, 2009, BRAIN INJURY, V23, P473, DOI 10.1080/02699050902970737; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; WEST MD, 1995, BRAIN INJURY, V9, P301, DOI 10.3109/02699059509008200; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271	73	24	24	1	14	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1092-4388	1558-9102		J SPEECH LANG HEAR R	J. Speech Lang. Hear. Res.	JUN	2016	59	3					511	520		10.1044/2015_JSLHR-L-15-0025			10	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	EA7AW	WOS:000386781500009	27124205				2021-06-18	
J	Iyyathurai, J; Decuypere, JP; Leybaert, L; D'hondt, C; Bultynck, G				Iyyathurai, Jegan; Decuypere, Jean-Paul; Leybaert, Luc; D'hondt, Catheleyne; Bultynck, Geert			Connexins: substrates and regulators of autophagy	BMC CELL BIOLOGY			English	Article; Proceedings Paper	International Gap Junction Conference	MAR 28-APR 02, 2015	Valparaiso, CHILE			Autophagy; Connexins; Degradation; Regulation	JUNCTION PROTEIN CONNEXIN43; INOSITOL TRISPHOSPHATE RECEPTOR; ISCHEMIA-REPERFUSION INJURY; TRAUMATIC BRAIN-INJURY; GAP-JUNCTIONS; CELL-DEATH; ENDOPLASMIC-RETICULUM; DOWN-REGULATION; CONNEXIN43-INTERACTING PROTEIN; INTERCELLULAR COMMUNICATION	Connexins mediate intercellular communication by assembling into hexameric channel complexes that act as hemichannels and gap junction channels. Most connexins are characterized by a very rapid turn-over in a variety of cell systems. The regulation of connexin turn-over by phosphorylation and ubiquitination events has been well documented. Moreover, different pathways have been implicated in connexin degradation, including proteasomal and lysosomal-based pathways. Only recently, autophagy emerged as an important connexin-degradation pathway for different connexin isoforms. As such, conditions well known to induce autophagy have an immediate impact on the connexin-expression levels. This is not only limited to experimental conditions but also several pathophysiological conditions associated with autophagy (dys) function affect connexin levels and their presence at the cell surface as gap junctions. Finally, connexins are not only substrates of autophagy but also emerge as regulators of the autophagy process. In particular, several connexin isoforms appear to recruit pre-autophagosomal autophagy-related proteins, including Atg16 and PI3K-complex components, to the plasma membrane, thereby limiting their availability and capacity for regulating autophagy.	[Iyyathurai, Jegan; D'hondt, Catheleyne; Bultynck, Geert] Katholieke Univ Leuven, Lab Mol & Cellular Signaling, Dept Cellular & Mol Med, Campus Gasthuisberg O-N-I Bus 802,Herestr 49, B-3000 Leuven, Belgium; [Decuypere, Jean-Paul] Katholieke Univ Leuven, Lab Membrane Trafficking, Dept Human Genet, Campus Gasthuisberg,O-N-4,7-159,Herestr 49, B-3000 Leuven, Belgium; [Decuypere, Jean-Paul] VIB Ctr Biol Dis, Campus Gasthuisberg,O-N-4,7-159,Herestr 49, B-3000 Leuven, Belgium; [Leybaert, Luc] Univ Ghent, Physiol Grp, Dept Basic Med Sci, B-9000 Ghent, Belgium	Bultynck, G (corresponding author), Katholieke Univ Leuven, Lab Mol & Cellular Signaling, Dept Cellular & Mol Med, Campus Gasthuisberg O-N-I Bus 802,Herestr 49, B-3000 Leuven, Belgium.	geert.bultynck@med.kuleuven.be	Leybaert, Luc/F-4079-2015	Leybaert, Luc/0000-0001-6452-6982; Bultynck, Geert/0000-0002-5968-4828			Axe EL, 2008, J CELL BIOL, V182, P685, DOI 10.1083/jcb.200803137; Barsoum IB, 2014, CANCER RES, V74, P7185, DOI 10.1158/0008-5472.CAN-14-2598; Bejarano E, 2014, NAT CELL BIOL, V16, P401, DOI 10.1038/ncb2934; Bejarano E, 2012, MOL BIOL CELL, V23, P2156, DOI 10.1091/mbc.E11-10-0844; Berthoud VA, 2004, CARDIOVASC RES, V62, P256, DOI 10.1016/j.cardiores.2003.12.021; Bray K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041831; Brisset AC, 2009, ANTIOXID REDOX SIGN, V11, P267, DOI 10.1089/ars.2008.2115; Carette D, 2015, BIOL CELL, V107, P218, DOI 10.1111/boc.201400048; Cochrane K, 2013, CELL COMMUN ADHES, V20, P53, DOI 10.3109/15419061.2013.784745; Criollo A, 2007, CELL DEATH DIFFER, V14, P1029, DOI 10.1038/sj.cdd.4402099; Criollo A, 2007, AUTOPHAGY, V3, P350, DOI 10.4161/auto.4077; Czaja MJ, 2013, AUTOPHAGY, V9, P1131, DOI 10.4161/auto.25063; Czyz J, 2012, NAT REV UROL, V9, P274, DOI 10.1038/nrurol.2012.14; D'hondt C, 2009, BIOESSAYS, V31, P953, DOI 10.1002/bies.200800236; Decrock E, 2012, CELL DEATH DIFFER, V19, P947, DOI 10.1038/cdd.2011.176; Decrock E, 2009, CELL DEATH DIFFER, V16, P524, DOI 10.1038/cdd.2008.196; Decrock E, 2013, BBA-MOL CELL RES, V1833, P1772, DOI 10.1016/j.bbamcr.2012.12.016; Decrock E, 2011, CELL CALCIUM, V50, P310, DOI 10.1016/j.ceca.2011.05.007; Decuypere JP, 2014, AM J TRANSPLANT, V14, P1464, DOI 10.1111/ajt.12717; Decuypere JP, 2015, AM J KIDNEY DIS, V66, P699, DOI 10.1053/j.ajkd.2015.05.021; Decuypere JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061020; Decuypere Jean-Paul, 2012, Cells, V1, P284, DOI 10.3390/cells1030284; Decuypere JP, 2011, AUTOPHAGY, V7, P1472, DOI 10.4161/auto.7.12.17909; Decuypere JP, 2011, CELL CALCIUM, V50, P242, DOI 10.1016/j.ceca.2011.04.001; Driscoll JJ, 2012, CANCER LETT, V325, P147, DOI 10.1016/j.canlet.2012.06.016; Dumit VI, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00043; EK JF, 1994, CIRC RES, V74, P1058, DOI 10.1161/01.RES.74.6.1058; Elias LAB, 2007, NATURE, V448, P901, DOI 10.1038/nature06063; Falk MM, 2014, FEBS LETT, V588, P1221, DOI 10.1016/j.febslet.2014.01.031; Falk MM, 2012, J MEMBRANE BIOL, V245, P465, DOI 10.1007/s00232-012-9464-0; Falk MM, 2009, MOL BIOL CELL, V20, P3342, DOI 10.1091/mbc.E09-04-0288; Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168; Fong JT, 2012, AUTOPHAGY, V8, P794, DOI 10.4161/auto.19390; Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784; Garcia-Dorado D, 2002, CARDIOVASC RES, V55, P456, DOI 10.1016/S0008-6363(02)00441-8; Gilleron J, 2012, CRIT REV BIOCHEM MOL, V47, P407, DOI 10.3109/10409238.2012.683482; Girao H, 2009, EXP CELL RES, V315, P3587, DOI 10.1016/j.yexcr.2009.10.003; Green DR, 2015, EMBO REP, V16, P674, DOI 10.15252/embr.201540470; Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049; Gump JM, 2014, NAT CELL BIOL, V16, P47, DOI 10.1038/ncb2886; Gumpert AM, 2008, FEBS LETT, V582, P2887, DOI 10.1016/j.febslet.2008.07.024; Hayashi-Nishino M, 2009, NAT CELL BIOL, V11, P1433, DOI 10.1038/ncb1991; Hesketh GG, 2010, CIRC RES, V106, P1153, DOI 10.1161/CIRCRESAHA.108.182147; Hou W, 2010, AUTOPHAGY, V6, P891, DOI 10.4161/auto.6.7.13038; Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191; Kar R, 2013, J BONE MINER RES, V28, P1611, DOI 10.1002/jbmr.1917; Kelly JJ, 2015, CELL TISSUE RES, V360, P701, DOI 10.1007/s00441-014-2024-4; Kelly SM, 2007, MOL BIOL CELL, V18, P4279, DOI 10.1091/mbc.E07-05-0487; Kheloufi M, 2015, HEPATOLOGY, V62, P657, DOI 10.1002/hep.27597; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Klionsky DJ, 2011, AUTOPHAGY, V7, P1273, DOI 10.4161/auto.7.11.17661; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Kopanic JL, 2015, BIOCHEM J, V466, P571, DOI 10.1042/BJ20141042; Kroemer G, 2015, J CLIN INVEST, V125, P1, DOI 10.1172/JCI78652; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; LAING JG, 1995, J BIOL CHEM, V270, P26399, DOI 10.1074/jbc.270.44.26399; Laing JG, 1997, EXP CELL RES, V236, P482, DOI 10.1006/excr.1997.3747; Laing JG, 1998, CARDIOVASC RES, V38, P711, DOI 10.1016/S0008-6363(98)00060-1; Laird DW, 2014, FEBS LETT, V588, P1339, DOI 10.1016/j.febslet.2013.12.022; Laird DW, 2005, BBA-BIOMEMBRANES, V1711, P172, DOI 10.1016/j.bbamem.2004.09.009; Lamb CA, 2013, BIOESSAYS, V35, P34, DOI 10.1002/bies.201200130; Lan Z, 2005, BIOCHEMISTRY-US, V44, P2385, DOI 10.1021/bi048306w; Leithe E, 2004, J BIOL CHEM, V279, P50089, DOI 10.1074/jbc.M402006200; Leithe E, 2007, J MEMBRANE BIOL, V217, P43, DOI 10.1007/s00232-007-9050-z; Leithe Edward, 2006, Critical Reviews in Oncogenesis, V12, P225; Leithe E, 2009, J CELL SCI, V122, P3883, DOI 10.1242/jcs.053801; Leybaert L, 2012, PHYSIOL REV, V92, P1359, DOI 10.1152/physrev.00029.2011; Leykauf K, 2006, J CELL SCI, V119, P3634, DOI 10.1242/jcs.03149; Li XL, 2008, J BIOL CHEM, V283, P5748, DOI 10.1074/jbc.M709288200; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liaw NY, 2013, AM J PHYSIOL-REG I, V305, pR1171, DOI 10.1152/ajpregu.00198.2013; Lichtenstein A, 2011, J CELL SCI, V124, P910, DOI 10.1242/jcs.073072; Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143; Liu Y, 2013, P NATL ACAD SCI USA, V110, P20364, DOI 10.1073/pnas.1319661110; Ma S, 2015, BBA-MOL BASIS DIS, V1852, P271, DOI 10.1016/j.bbadis.2014.05.010; Maes M, 2015, TRANSL RES, V166, P332, DOI 10.1016/j.trsl.2015.05.005; Mancuso M, 2011, ONCOGENE, V30, P4601, DOI 10.1038/onc.2011.176; Mari Muriel, 2011, F1000 Biol Rep, V3, P25, DOI 10.3410/B3-25; Martins-Marques T, 2015, BIOCHEM J, V467, P231, DOI 10.1042/BJ20141370; Minogue PJ, 2013, J BIOL CHEM, V288, P20427, DOI 10.1074/jbc.M113.452847; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Mizushima N, 2007, AUTOPHAGY, V3, P542; Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005; Molica F, 2014, BIOL CELL, V106, P269, DOI 10.1111/boc.201400038; Nikoletopoulou V, 2013, BBA-MOL CELL RES, V1833, P3448, DOI 10.1016/j.bbamcr.2013.06.001; Nishida Y, 2009, NATURE, V461, P654, DOI 10.1038/nature08455; Orellana JA, 2012, REV NEUROSCIENCE, V23, P163, DOI 10.1515/revneuro-2011-0065; Orellana JA, 2011, J NEUROSCI, V31, P4962, DOI 10.1523/JNEUROSCI.6417-10.2011; Orellana JA, 2011, J NEUROCHEM, V118, P826, DOI 10.1111/j.1471-4159.2011.07210.x; Parys JB, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-17; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Piehl M, 2007, MOL BIOL CELL, V18, P337, DOI 10.1091/mbc.E06-06-0487; Polson HEJ, 2010, AUTOPHAGY, V6, P506, DOI 10.4161/auto.6.4.11863; Reed AM, 2014, AM J PHYSIOL-GASTR L, V307, pG24, DOI 10.1152/ajpgi.00010.2014; Retamal MA, 2007, J NEUROSCI, V27, P13781, DOI 10.1523/JNEUROSCI.2042-07.2007; Rubinsztein DC, 2015, J EXP MED, V212, P979, DOI 10.1084/jem.20150956; Russell RC, 2013, NAT CELL BIOL, V15, P741, DOI 10.1038/ncb2757; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Siebert AP, 2013, J BIOL CHEM, V288, P6140, DOI 10.1074/jbc.M112.409789; Sin WC, 2012, BBA-BIOMEMBRANES, V1818, P2058, DOI 10.1016/j.bbamem.2011.10.022; Solan JL, 2014, FEBS LETT, V588, P1423, DOI 10.1016/j.febslet.2014.01.049; Stehberg J, 2012, FASEB J, V26, P3649, DOI 10.1096/fj.11-198416; Su V, 2014, FEBS LETT, V588, P1212, DOI 10.1016/j.febslet.2014.01.013; Su V, 2014, BIOCHEM J, V458, P57, DOI 10.1042/BJ20131247; Su V, 2012, J MEMBRANE BIOL, V245, P389, DOI 10.1007/s00232-012-9461-3; Su V, 2010, J BIOL CHEM, V285, P40979, DOI 10.1074/jbc.M110.170753; Su V, 2009, CELL MOL LIFE SCI, V66, P2819, DOI 10.1007/s00018-009-0048-9; Sun LQ, 2014, MOL MED REP, V9, P77, DOI 10.3892/mmr.2013.1787; Sun LQ, 2015, BEHAV BRAIN RES, V291, P315, DOI 10.1016/j.bbr.2015.05.049; Tittarelli A, 2015, J BIOL CHEM, V290, P23670, DOI 10.1074/jbc.M115.651547; VanSlyke JK, 2005, MOL BIOL CELL, V16, P5247, DOI 10.1091/mbc.E05-05-0415; VanSlyke JK, 2002, J CELL BIOL, V157, P381, DOI 10.1083/jcb.200111045; Vanslyke JK, 2000, MOL BIOL CELL, V11, P1933, DOI 10.1091/mbc.11.6.1933; Vicencio JM, 2009, CELL DEATH DIFFER, V16, P1006, DOI 10.1038/cdd.2009.34; Vinken M, 2012, BBA-BIOMEMBRANES, V1818, P2002, DOI 10.1016/j.bbamem.2011.06.011; Wang N, 2013, BBA-BIOMEMBRANES, V1828, P35, DOI 10.1016/j.bbamem.2012.07.002; Wei CJ, 2004, ANNU REV CELL DEV BI, V20, P811, DOI 10.1146/annurev.cellbio.19.111301.144309; White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941; Xu HY, 2015, J BONE MINER RES, V30, P550, DOI 10.1002/jbmr.2374; Yamamoto H, 2012, J CELL BIOL, V198, P219, DOI 10.1083/jcb.201202061; Yonekawa T, 2015, EMBO REP, V16, P700, DOI 10.15252/embr.201439496; Zhong WQ, 2015, HISTOPATHOLOGY, V66, P798, DOI 10.1111/his.12569; Zhou JZ, 2016, ONCOGENE, V35, P5597, DOI 10.1038/onc.2016.101	125	24	24	0	10	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2121			BMC CELL BIOL	BMC Cell Biol.	MAY 24	2016	17			1					20	10.1186/s12860-016-0093-9			16	Cell Biology	Cell Biology	DT4GC	WOS:000381437200011	27229147	DOAJ Gold, Green Published			2021-06-18	
J	Bryant, RA; McFarlane, AC; Silove, D; O'Donnell, ML; Forbes, D; Creamer, M				Bryant, Richard A.; McFarlane, Alexander C.; Silove, Derrick; O'Donnell, Meaghan L.; Forbes, David; Creamer, Mark			The Lingering Impact of Resolved PTSD on Subsequent Functioning	CLINICAL PSYCHOLOGICAL SCIENCE			English	Article						posttraumatic stress disorder; trauma; life satisfaction	POSTTRAUMATIC-STRESS-DISORDER; QUALITY-OF-LIFE; TRAUMATIC-BRAIN-INJURY; MALE VIETNAM VETERANS; RISK-FACTORS; SYMPTOMS; METAANALYSIS; MILITARY; HEALTH; ADULTS	This study investigated whether impairment persists after posttraumatic stress disorder (PTSD) has resolved. Traumatically injured patients (N = 1,035) were assessed during hospital admission and at 3 (85%) and 12 months (73%). Quality of life prior to traumatic injury was measured with the World Health Organization Quality of Life-BREF during hospitalization and at each subsequent assessment. PTSD was assessed using the Clinician-Administered PTSD Scale at 3 and 12 months. After controlling for preinjury functioning, current pain, and comorbid depression, patients whose PTSD symptoms had resolved by 12 months were more likely to have poorer quality of life in psychological (OR = 3.51), physical (OR = 10.17), social (OR = 4.54), and environmental (OR = 8.83) domains than those who never developed PTSD. These data provide initial evidence that PTSD can result in lingering effects on functional capacity even after remission of symptoms.	[Bryant, Richard A.] Univ New South Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Bryant, Richard A.] Westmead Millennium Inst, Brain Dynam Ctr, Westmead, NSW, Australia; [McFarlane, Alexander C.] Univ Adelaide, Ctr Mil & Vet Hlth, Adelaide, SA, Australia; [Silove, Derrick] Univ New South Wales, Sch Psychiat, Sydney, NSW, Australia; [O'Donnell, Meaghan L.; Forbes, David; Creamer, Mark] Univ Melbourne, Dept Psychiat, Ctr Posttraumat Mental Hlth, Phoenix Australia, Melbourne, Vic, Australia	Bryant, RA (corresponding author), Univ New South Wales, Sch Psychol, Sydney, NSW 2052, Australia.	r.bryant@unsw.edu.au	Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [568970]; Victorian Trauma Foundation [V-11]; National Health and Medical Research Council Australian Clinical Research FellowshipNational Health and Medical Research Council of Australia [359284]	This research was supported by National Health and Medical Research Council Program Grant 568970, Victorian Trauma Foundation Grant #V-11, and National Health and Medical Research Council Australian Clinical Research Fellowship 359284. The study sponsors had no role in the design or conduct of the study, or in the collection, analysis, or interpretation of the data. R.A.B. had full access to all the data and had final responsibility for the decision to submit for publication.	Aziz Mohamed A, 2004, J Psychiatr Pract, V10, P307, DOI 10.1097/00131746-200409000-00004; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bolton D, 2004, J CHILD PSYCHOL PSYC, V45, P1007, DOI 10.1111/j.1469-7610.2004.t01-1-00292.x; Breslau N, 1998, REV PSYCHIAT SER, V17, P1; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Bryant RA, 2007, J ABNORM PSYCHOL, V116, P837, DOI 10.1037/0021-843X.116.4.837; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Connell MJO, 2008, PSYCHIAT SERV, V59, P268, DOI 10.1176/appi.ps.59.3.268; Cornelis MC, 2010, CURR PSYCHIAT REP, V12, P313, DOI 10.1007/s11920-010-0126-6; Cotella EM, 2013, STRESS, V16, P477, DOI 10.3109/10253890.2013.775241; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; Foa E. B., 2009, EFFECTIVE TREATMENTS; Gadermann AM, 2012, DEPRESS ANXIETY, V29, P797, DOI 10.1002/da.21924; Gladis MM, 1999, J CONSULT CLIN PSYCH, V67, P320, DOI 10.1037/0022-006X.67.3.320; Guthrie RM, 2006, PSYCHOSOM MED, V68, P307, DOI 10.1097/01.psy.0000208629.67653.cc; Hawthorne G, 2006, SOC INDIC RES, V77, P37, DOI 10.1007/s11205-005-5552-1; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Lanius RA, 2006, J PSYCHIATR RES, V40, P709, DOI 10.1016/j.jpsychires.2005.07.007; LeardMann CA, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1273; Li B, 2011, AM J EPIDEMIOL, V174, P761, DOI 10.1093/aje/kwr154; Lunney CA, 2007, J TRAUMA STRESS, V20, P955, DOI 10.1002/jts.20269; Mikulincer M., J SOCIAL CLIN PSYCHO; Morina N, 2014, CLIN PSYCHOL REV, V34, P249, DOI 10.1016/j.cpr.2014.03.002; Riggs DS, 1998, J TRAUMA STRESS, V11, P87, DOI 10.1023/A:1024409200155; Rona RJ, 2009, J PSYCHIATR RES, V43, P649, DOI 10.1016/j.jpsychires.2008.09.006; Samper RE, 2004, J TRAUMA STRESS, V17, P311, DOI 10.1023/B:JOTS.0000038479.30903.ed; Sayers SL, 2009, J CLIN PSYCHIAT, V70, P163, DOI 10.4088/JCP.07m03863; Schnurr PP, 2006, J CONSULT CLIN PSYCH, V74, P707, DOI 10.1037/0022-006X.74.4.707; Shalev AY, 1998, AM J PSYCHIAT, V155, P630, DOI 10.1176/ajp.155.5.630; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Stein MB, 2002, INT J METH PSYCH RES, V11, P143, DOI 10.1002/mpr.132; Stein MB, 1997, AM J PSYCHIAT, V154, P1114; The WHOQOL Group, 1996, WHOQOL BREF INTR ADM; Yehuda R, 2003, PSYCHIAT ANN, V33, P30, DOI 10.3928/0048-5713-20030101-06; Yehuda R, 2007, PROG BRAIN RES, V167, P121, DOI 10.1016/S0079-6123(07)67009-5; Zlotnick C, 2002, COMPR PSYCHIAT, V43, P413, DOI 10.1053/comp.2002.35900	36	24	24	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2167-7026	2167-7034		CLIN PSYCHOL SCI	Clin. Psychol. Sci.	MAY	2016	4	3					493	498		10.1177/2167702615598756			6	Psychology, Clinical; Psychiatry; Psychology	Psychology; Psychiatry	FE9OW	WOS:000408534000010					2021-06-18	
J	Jagannatha, AT; Sriganesh, K; Devi, BI; Rao, GSU				Jagannatha, Aniruddha Tekkatte; Sriganesh, Kamath; Devi, Bhagavatula Indira; Rao, Ganne Sesha Umamaheswara			An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						Brain Trauma Foundation; Hypertonic saline; Intracranial hypertension; Mannitol; Outcome; Traumatic brain injury	20-PERCENT MANNITOL; SODIUM-CHLORIDE; WATER-CONTENT; PRESSURE; FUROSEMIDE; TRIAL	The impact of hypertonic saline (HTS) on long term control of intracranial hypertension (ICH) is yet to be established. The current prospective randomized controlled study was carried out in 38 patients with severe traumatic brain injury (TBI). Over 450 episodes of refractory ICH were treated with equiosmolar boluses of 20% mannitol in 20 patients and 3.0% HTS in 18 subjects. Intracranial pressure (ICP) was monitored for 6 days. ICP and cerebral perfusion pressure (CPP) were comparable between the groups. The mannitol group had a progressive increase in the ICP over the study period (p = 0.01). A similar increase was not seen in the HTS group (p = 0.1). The percentage time for which the ICP remained below a threshold of 20 mmHg on day 6 was higher in the HTS group (63% versus 49%; p = 0.3). The duration of inotrope requirement in the HTS group was less compared to the mannitol group (p = 0.06). The slope of fall in ICP in response to a bolus dose at a given baseline value of ICP was higher with HTS compared to mannitol (p = 0.0001). In-hospital mortality tended to be lower in the HTS group (3 versus 10; p = 0.07) while mortality at 6 months was not different between the groups (6 versus 10; p = 0.41). Dichotomized Glasgow Outcome Scale scores at 6 months were comparable between the groups (p = 0.21). To conclude, immediate physiological advantages seen with HTS over mannitol did not translate into long term benefit on ICP/CPP control or mortality of patients with TBI. (C) 2015 Elsevier Ltd. All rights reserved.	[Devi, Bhagavatula Indira] Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Neurosurg, Bangalore, Karnataka, India; [Sriganesh, Kamath; Rao, Ganne Sesha Umamaheswara] Natl Inst Mental Hlth & Neurosci NIMHANS, Neuroctr, Dept Neuroanaesthesia, 3rd Floor,Fac Block,Hosur Rd, Bangalore 560029, Karnataka, India; [Jagannatha, Aniruddha Tekkatte] MS Ramaiah Med Coll, Dept Neurosurg, Bangalore, Karnataka, India	Rao, GSU (corresponding author), Natl Inst Mental Hlth & Neurosci NIMHANS, Neuroctr, Dept Neuroanaesthesia, 3rd Floor,Fac Block,Hosur Rd, Bangalore 560029, Karnataka, India.	gsuma123@yahoo.com					Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; BERGER S, 1994, ACT NEUR S, V60, P494; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS55; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Celli P, 1997, Minerva Chir, V52, P1467; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; Himmelseher S, 2007, CURR OPIN ANESTHESIO, V20, P414, DOI 10.1097/ACO.0b013e3282eff9ea; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Ichai C, 2009, INTENS CARE MED, V35, P471, DOI 10.1007/s00134-008-1283-5; Kalita J, 2003, NEUROL INDIA, V51, P104; Kamel H, 2011, CRIT CARE MED, V39, P554, DOI 10.1097/CCM.0b013e318206b9be; Mayzler O, 2006, J NEUROSURG ANESTH, V18, P24, DOI 10.1097/01.ana.0000188358.41284.cb; Mortazavi MM, 2012, J NEUROSURG, V116, P210, DOI 10.3171/2011.7.JNS102142; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; Ogden AT, 2005, NEUROSURGERY, V57, P207, DOI 10.1227/01.NEU.0000166533.79031.D8; Sakellaridis N, 2011, J NEUROSURG, V114, P545, DOI 10.3171/2010.5.JNS091685; Strandvik GF, 2009, ANAESTHESIA, V64, P990, DOI 10.1111/j.1365-2044.2009.05986.x; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Wang LC, 2013, ANESTHESIOLOGY, V118, P903, DOI 10.1097/ALN.0b013e31828156ff; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; Ziai WC, 2007, J NEUROL SCI, V261, P157, DOI 10.1016/j.jns.2007.04.048	23	24	27	0	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	MAY	2016	27						68	73		10.1016/j.jocn.2015.08.035			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DK0LZ	WOS:000374605600013	26924183				2021-06-18	
J	Levine, J; Kwon, E; Paez, P; Yan, WH; Czerwieniec, G; Loo, JA; Sofroniew, MV; Wanner, IB				Levine, Jaclynn; Kwon, Eunice; Paez, Pablo; Yan, Weihong; Czerwieniec, Gregg; Loo, Joseph A.; Sofroniew, Michael V.; Wanner, Ina-Beate			Traumatically injured astrocytes release a proteomic signature modulated by STAT3-dependent cell survival	GLIA			English	Article						trauma; proteome; astrocyte; mechanoporation; biomarker	FIBRILLARY ACIDIC PROTEIN; SPINAL-CORD-INJURY; ALPHA-B-CRYSTALLIN; STRETCH-INDUCED INJURY; IN-VITRO TRAUMA; BRAIN-INJURY; WHITE-MATTER; CULTURED ASTROCYTES; CEREBROSPINAL-FLUID; CEREBRAL CONTUSION	Molecular markers associated with CNS injury are of diagnostic interest. Mechanical trauma generates cellular deformation associated with membrane permeability with unknown molecular consequences. We used an in vitro model of stretch-injury and proteomic analyses to determine protein changes in murine astrocytes and their surrounding fluids. Abrupt pressure-pulse stretching resulted in the rapid release of 59 astrocytic proteins with profiles reflecting cell injury and cell death, i.e., mechanoporation and cell lysis. This acute trauma-release proteome was overrepresented with metabolic proteins compared with the uninjured cellular proteome, bearing relevance for post-traumatic metabolic depression. Astrocyte-specific deletion of signal transducer and activator of transcription 3 (STAT3-CKO) resulted in reduced stretch-injury tolerance, elevated necrosis and increased protein release. Consistent with more lysed cells, more protein complexes, nuclear and transport proteins were released from STAT3-CKO versus nontransgenic astrocytes. STAT3-CKO astrocytes had reduced basal expression of GFAP, lactate dehydrogenase B (LDHB), aldolase C (ALDOC), and astrocytic phosphoprotein 15 (PEA15), and elevated levels of tropomyosin (TPM4) and actinin 4 (ACTN4). Stretching caused STAT3-dependent cellular depletion of PEA15 and GFAP, and its filament disassembly in subpopulations of injured astrocytes. PEA15 and ALDOC signals were low in injured astrocytes acutely after mouse spinal cord crush injury and were robustly expressed in reactive astrocytes 1 day postinjury. In contrast, crystallin (CRYAB) was present in acutely injured astrocytes, and absent from uninjured and reactive astrocytes, demonstrating novel marker differences among postinjury astrocytes. These findings reveal a proteomic signature of traumatically-injured astrocytes reflecting STAT3-dependent cellular survival with potential diagnostic value. GLIA 2016;64:668-694	[Levine, Jaclynn; Kwon, Eunice; Wanner, Ina-Beate] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Paez, Pablo] SUNY Buffalo, Dept Pharmacol & Toxicol, Hunter James Kelly Res Inst, Sch Med & Biomed Sci,NYS Ctr Excellence, Buffalo, NY 14260 USA; [Yan, Weihong; Czerwieniec, Gregg; Loo, Joseph A.] Univ Calif Los Angeles, Dept Chem & Biochem, 405 Hilgard Ave, Los Angeles, CA 90024 USA; [Loo, Joseph A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; [Loo, Joseph A.] Univ Calif Los Angeles, UCLA DOE Inst Genom & Proteom, Los Angeles, CA USA; [Sofroniew, Michael V.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA	Wanner, IB (corresponding author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, 635 Charles E Young Dr South,NRB 260, Los Angeles, CA 90095 USA.	iwanner@mednet.ucla.edu	Paez, Pablo Martin/ABI-7783-2020; Sofroniew, Michael/ABE-8857-2020	Paez, Pablo Martin/0000-0001-9362-9454; 	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R21NS072606, R01NS057624, R01GM104610]; Craig H. Neilsen Foundation [82776]; Dr. Miriam and Sheldon Adelson Medical Research Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM104610] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057624, R21NS072606] Funding Source: NIH RePORTER	Grant sponsor: NIH; Grant number: 1R21NS072606 to IBW; R01NS057624 to MVS; and R01GM104610 to JAL; Grant sponsor: Craig H. Neilsen Foundation (82776 to IBW).; Grant sponsor: Dr. Miriam and Sheldon Adelson Medical Research Foundation (to MVS).	Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Barbee KA, 2005, ANN NY ACAD SCI, V1066, P67, DOI 10.1196/annals.1363.006; Bartnik BL, 2007, J NEUROTRAUM, V24, P1079, DOI 10.1089/neu.2006.0210; BIANCHI R, 1994, BBA-MOL CELL RES, V1223, P354, DOI 10.1016/0167-4889(94)90095-7; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Burda JE, 2014, NEURON, V81, P229, DOI 10.1016/j.neuron.2013.12.034; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; CANONNEHERGAUX F, 1994, NEUROCHEM INT, V25, P545, DOI 10.1016/0197-0186(94)90153-8; Cao X, 2010, NEUROSCI LETT, V479, P118, DOI 10.1016/j.neulet.2010.05.040; CHIU FC, 1981, J NEUROCHEM, V37, P147, DOI 10.1111/j.1471-4159.1981.tb05302.x; Choi JS, 2003, GLIA, V41, P237, DOI 10.1002/glia.10186; Choo AM, 2007, J NEUROSURG-SPINE, V6, P255, DOI 10.3171/spi.2007.6.3.255; CIESIELSKITRESKA J, 1984, EUR J BIOCHEM, V138, P465, DOI 10.1111/j.1432-1033.1984.tb07939.x; Colombo JA, 1997, J BRAIN RES, V38, P503; DEARMOND SJ, 1983, BRAIN RES, V262, P275, DOI 10.1016/0006-8993(83)91018-1; desVellis J, 2009, PROTOCOLS NEURAL CEL, P193; DisDomenico F, 2010, BRAIN RES, V1362, P1; Dziennis S, 2007, J NEUROSCI, V27, P7268, DOI 10.1523/JNEUROSCI.1558-07.2007; EFRON B, 1991, SCIENCE, V253, P390, DOI 10.1126/science.253.5018.390; Ellis EF, 2007, J NEUROCHEM, V101, P1463, DOI 10.1111/j.1471-4159.2007.04515.x; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Estelles A, 1996, J BIOL CHEM, V271, P14800, DOI 10.1074/jbc.271.25.14800; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Fern RF, 2014, GLIA, V62, P1780, DOI 10.1002/glia.22722; FERRIER R, 1994, CELL MOTIL CYTOSKEL, V28, P303, DOI 10.1002/cm.970280404; Floyd CL, 2001, GLIA, V33, P12, DOI 10.1002/1098-1136(20010101)33:1<12::AID-GLIA1002>3.0.CO;2-V; FRANKE WW, 1982, CELL, V30, P103, DOI 10.1016/0092-8674(82)90016-2; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Godell CM, 1997, P NATL ACAD SCI USA, V94, P4751, DOI 10.1073/pnas.94.9.4751; Greco TM, 2010, J PROTEOME RES, V9, P2764, DOI 10.1021/pr100134n; Hagemann TL, 2006, J NEUROSCI, V26, P11162, DOI 10.1523/JNEUROSCI.3260-06.2006; Hagemann TL, 2009, HUM MOL GENET, V18, P1190, DOI 10.1093/hmg/ddp013; Hanrieder J, 2009, J NEUROSCI METH, V177, P469, DOI 10.1016/j.jneumeth.2008.10.038; Harrington MG, 2009, FLUIDS BARRIERS CNS, V6, DOI 10.1186/1743-8454-6-10; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Hertz L, 2008, NEUROPHARMACOLOGY, V55, P289, DOI 10.1016/j.neuropharm.2008.05.023; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Ito U, 2009, STROKE, V40, P2173, DOI 10.1161/STROKEAHA.108.534990; Justicia C, 2000, GLIA, V30, P253, DOI 10.1002/(SICI)1098-1136(200005)30:3<253::AID-GLIA5>3.0.CO;2-O; Karl J, 2000, BRAIN RES, V853, P32, DOI 10.1016/S0006-8993(99)02224-6; Kazanis I, 2005, BRAIN RES REV, V50, P377, DOI 10.1016/j.brainresrev.2005.09.003; Kilinc D, 2009, EXP NEUROL, V219, P553, DOI 10.1016/j.expneurol.2009.07.014; Klopstein A, 2012, J NEUROSCI, V32, P14478, DOI 10.1523/JNEUROSCI.0923-12.2012; Koyama Y, 1999, AM J PATHOL, V154, P1563, DOI 10.1016/S0002-9440(10)65409-0; Kwon BK, 2011, CLIN CHEM LAB MED, V49, P425, DOI 10.1515/CCLM.2011.068; Lafrenaye AD, 2012, J CEREBR BLOOD F MET, V32, P1919, DOI 10.1038/jcbfm.2012.95; Lee YB, 2000, BRAIN RES, V864, P220, DOI 10.1016/S0006-8993(00)02180-6; Li DR, 2012, LEGAL MED-TOKYO, V14, P84, DOI 10.1016/j.legalmed.2011.12.007; Li HH, 2006, J CELL SCI, V119, P4452, DOI 10.1242/jcs.03219; Lubieniecka JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019247; Lukaszevicz AC, 2002, J CEREBR BLOOD F MET, V22, P289, DOI 10.1097/00004647-200203000-00006; Lusardi TA, 2003, BIORHEOLOGY, V40, P401; Lytle JM, 2007, EUR J NEUROSCI, V25, P1711, DOI 10.1111/j.1460-9568.2007.05390.x; Martinez A, 2008, J NEUROPATH EXP NEUR, V67, P1122, DOI 10.1097/NEN.0b013e31818e06f3; Mellgren RL, 2007, J BIOL CHEM, V282, P2567, DOI 10.1074/jbc.M604560200; Mills LR, 2004, NEUROIMAGE, V21, P1069, DOI 10.1016/j.neuroimage.2003.10.041; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Nam S, 2005, P NATL ACAD SCI USA, V102, P5998, DOI 10.1073/pnas.0409467102; NEWCOMBE J, 1986, J NEUROCHEM, V47, P1713, DOI 10.1111/j.1471-4159.1986.tb13079.x; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Reich NC, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.290pe61; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Salter MG, 2008, J CEREBR BLOOD F MET, V28, P588, DOI 10.1038/sj.jcbfm.9600555; Sandoval M, 2013, BRAIN RES, V1520, P1, DOI 10.1016/j.brainres.2013.04.049; Sarafian TA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009532; Scafidi S, 2009, J NEUROCHEM, V109, P189, DOI 10.1111/j.1471-4159.2009.05896.x; Shen S, 2014, CLIN PROTEOM, V11, DOI 10.1186/1559-0275-11-11; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; Sjodin MOD, 2010, J CHROMATOGR B, V878, P2003, DOI 10.1016/j.jchromb.2010.05.036; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Sondej MA, 2011, SAMPLE PREPARATION IN BIOLOGICAL MASS SPECTROMETRY, P829, DOI 10.1007/978-94-007-0828-0_39; Sriram K, 2004, J BIOL CHEM, V279, P19936, DOI 10.1074/jbc.M309304200; Takeda K, 1998, J IMMUNOL, V161, P4652; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; TOPP KS, 1989, GLIA, V2, P201, DOI 10.1002/glia.440020309; Wanner IB, 2008, GLIA, V56, P1691, DOI 10.1002/glia.20721; Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013; Wanner IB, 2012, METHODS MOL BIOL, V814, P189, DOI 10.1007/978-1-61779-452-0_14; Wegrzyn J, 2009, SCIENCE, V323, P793, DOI 10.1126/science.1164551; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283	91	24	25	0	11	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	MAY	2016	64	5					668	694		10.1002/glia.22953			27	Neurosciences	Neurosciences & Neurology	DI0OR	WOS:000373197000002	26683444	Green Accepted			2021-06-18	
J	Powell, JM; Fraser, R; Brockway, JA; Temkin, N; Bell, KR				Powell, Janet M.; Fraser, Robert; Brockway, Jo Ann; Temkin, Nancy; Bell, Kathleen R.			A Telehealth Approach to Caregiver Self-Management Following Traumatic Brain Injury: A Randomized Controlled Trial	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injuries; caregivers; problem solving; randomized controlled trial; telehealth; telemedicine	PROBLEM-SOLVING ABILITIES; FAMILY-MEMBER ADJUSTMENT; SEVERE HEAD-INJURY; PARTICIPATION ASSESSMENT; STROKE SURVIVORS; INTERVENTION; REHABILITATION; OUTCOMES; CARE; APPRAISAL	Objective: To determine whether a telephone-based, individualized education and mentored problem-solving intervention would improve outcomes for caregivers of persons with traumatic brain injury (TBI). Design: Parallel group, randomized controlled trial with blinded outcome assessment. Setting: General community. Participants: A total of 153 caregivers (mean age = 49.7 years; 82% female; 54% spouses/partners, 35% parents) of persons with moderate to severe TBI who received acute and/or rehabilitation care at a level I trauma center. Eighty-two percent of participants were evaluated at 6-month follow-up. Intervention: Individualized education and mentored problem-solving intervention focused on caregivers' primary concerns delivered via up to 10 telephone calls at 2-week intervals. Main Outcome Measures: Composite of Bakas Caregiving Outcomes Scale (BCOS) and Brief Symptom Inventory (BSI-18) at 6 months post-TBI survivor discharge. Secondary measures included the Brief COPE. Results: Caregivers in the treatment arm scored higher on the BCOS-BSI composite (P = .032), with more active coping (P = .020) and less emotional venting (P = .028) as measured by the Brief COPE. Conclusions: An individualized education and mentored problem-solving approach delivered via telephone in the first few months following community discharge of the TBI survivor resulted in better caregiver outcomes than usual care. Consideration should be given to using this approach to augment the limited support typically offered to caregivers.	[Powell, Janet M.; Fraser, Robert] Univ Washington, Dept Rehabil Med, Div Occupat Therapy, Box 356490, Seattle, WA 98195 USA; [Fraser, Robert] Univ Washington, Dept Neurol, Seattle, WA 98195 USA; [Fraser, Robert; Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Brockway, Jo Ann] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Bell, Kathleen R.] Univ Texas Southwestern, Dept Phys Med & Rehabil, Dallas, TX USA	Powell, JM (corresponding author), Univ Washington, Dept Rehabil Med, Div Occupat Therapy, Box 356490, Seattle, WA 98195 USA.	jmpowell@uw.edu		Bell, Kathleen/0000-0002-0928-2046	Department of Education, National Institute on Disability and Rehabilitation Research, TBI Model Systems: University of Washington Traumatic Brain Injury Model System [H133A070032]	This study was funded by the Department of Education, National Institute on Disability and Rehabilitation Research, TBI Model Systems: University of Washington Traumatic Brain Injury Model System (H133A070032). The authors thank Kimberly Glorieux for her contributions as the study coordinator; Jason Barber for his assistance with data analysis; Heather Porter, MSW, for her work as the study interventionist; and Melissa Mayes for assistance with data collection.	Bakas T, 1999, NURS RES, V48, P250, DOI 10.1097/00006199-199909000-00005; Bakas T, 2006, NURS RES, V55, P346, DOI 10.1097/00006199-200609000-00007; Berry JW, 2012, REHABIL PSYCHOL, V57, P98, DOI 10.1037/a0028229; Bogner JA, 2011, ARCH PHYS MED REHAB, V92, P552, DOI 10.1016/j.apmr.2010.11.014; Boschen K, 2007, NEUROREHABILITATION, V22, P19; Broadstock MJ, 1997, PATIENT EDUC COUNS, V32, P141, DOI 10.1016/S0738-3991(97)00036-0; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Campbell C H, 1988, Rehabil Nurs, V13, P320; Carver CS, 1997, INT J BEHAV MED, V4, P92, DOI 10.1207/s15327558ijbm0401_6; Corbin J, 1988, UNENDING WORK CARE M; D'Zurilla TJ, 2010, HDB COGNITIVE BEHAV, V3, P197; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Elliott TR, 2008, BEHAV RES THER, V46, P1220, DOI 10.1016/j.brat.2008.08.004; Elliott TR, 1999, REHABIL PSYCHOL, V44, P104, DOI 10.1037/0090-5550.44.1.104; Elliott TR, 2001, J COUNS PSYCHOL, V48, P223, DOI 10.1037//0022-0167.48.2.223; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fleig L, 2013, REHABIL PSYCHOL, V58, P323, DOI 10.1037/a0033885; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Grant JS, 2002, STROKE, V33, P2060, DOI 10.1161/01.STR.0000020711.38824.E3; Grant JS, 2001, REHABIL PSYCHOL, V46, P44, DOI 10.1037/0090-5550.46.1.44; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Holland D, 1998, BRAIN INJURY, V12, P993, DOI 10.1080/026990598121918; Holman H, 2004, PUBLIC HEALTH REP, V119, P239, DOI 10.1016/j.phr.2004.04.002; Jordan JE, 2007, MED J AUSTRALIA, V186, P84, DOI 10.5694/j.1326-5377.2007.tb00807.x; Karlik B A, 1990, J Cardiovasc Nurs, V4, P70; Katz S, 2005, BRAIN INJURY, V19, P59, DOI 10.1080/02699050410001719970; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Kreutzer JS, 2001, BRAIN INJURY, V15, P763, DOI 10.1080/02699050010025786; Kurylo M, 2004, J CLIN PSYCHOL MED S, V11, P151, DOI 10.1023/B:JOCS.0000037609.23007.24; LAWTON MP, 1991, J GERONTOL, V46, pP181, DOI 10.1093/geronj/46.4.P181; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LORIG K, 1986, J RHEUMATOL, V13, P763; Lorig KR, 2003, ANN BEHAV MED, V26, P1, DOI 10.1207/S15324796ABM2601_01; Machamer J, 2002, J CLIN EXP NEUROPSYC, V24, P420, DOI 10.1076/jcen.24.4.420.1040; Machamer J, 2013, J NEUROTRAUM, V30, P1845, DOI 10.1089/neu.2013.2920; Newton KM, 1998, PROG CARDIOVASC NURS, V3, P62; Nezu A. M., 2007, SOLVING LIFES PROBLE; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; Paterson B, 2001, Rehabil Nurs, V26, P48; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rivera P, 2007, NEUROREHABILITATION, V22, P3; Rivera PA, 2008, ARCH PHYS MED REHAB, V89, P931, DOI 10.1016/j.apmr.2007.12.032; Schulz R, 2002, GERONTOLOGIST, V42, P589, DOI 10.1093/geront/42.5.589; Struchen MA, 2002, J HEAD TRAUMA REHAB, V17, P132, DOI 10.1097/00001199-200204000-00005; TEASDALE G, 1974, LANCET, V2, P81; Teri L, 1997, J GERONTOL B-PSYCHOL, V52, pP159, DOI 10.1093/geronb/52B.4.P159; Tremont Geoffrey, 2008, Dementia (London), V7, P503, DOI 10.1177/1471301208096632; vanVeenendaal H, 1996, PATIENT EDUC COUNS, V28, P265, DOI 10.1016/0738-3991(95)00853-5; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P542, DOI 10.1016/j.apmr.2010.08.002	56	24	25	1	29	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2016	31	3					180	190		10.1097/HTR.0000000000000167			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DR3FK	WOS:000379787800010	26394294				2021-06-18	
J	Purcell, L; Harvey, J; Seabrook, JA				Purcell, Laura; Harvey, Janice; Seabrook, Jamie A.			Patterns of Recovery Following Sport-Related Concussion in Children and Adolescents	CLINICAL PEDIATRICS			English	Article						sport concussion; children; adolescents; youth; recovery	HIGH-SCHOOL; PROLONGED RECOVERY; NEUROCOGNITIVE PERFORMANCE; INTERNATIONAL-CONFERENCE; EMERGENCY-DEPARTMENTS; CONSENSUS STATEMENT; HEAD-INJURY; SYMPTOMS; EPIDEMIOLOGY; MANAGEMENT	Time to symptom resolution, return to school, and return to play after a sport-related concussion in children and adolescents (8-17 years of age) was examined using a retrospective cohort design. A total of 198 patients aged 8 to 17 years were included, with a mean age of 13.5 years (SD = 2.2). Patients aged 8 to 12 years were symptom-free in a median of 12.0 (range 1-60) days whereas 13- to 17-year olds were symptom-free in a median of 14.0 (range 1-300) days (P = .04). Patients aged 8 to 12 years returned to learn in a median of 4.0 (range 0-30) days compared with 2.5 (range 0-55.0) days in 13- to 17-year-olds (P = .86). Patients aged 8 to 12 years returned to play in a median of 14.0 (range 4-75) days compared with a median of 19.5 (range 5-75) days in 13- to 17-year-olds (P = .06). These results indicate that children and adolescents generally take 2 to 4 weeks to recover from a sport-related concussion.	[Purcell, Laura; Harvey, Janice] McMaster Univ, Hamilton, ON, Canada; [Seabrook, Jamie A.] Brescia Univ Coll, London, ON, Canada; [Seabrook, Jamie A.] London Hlth Sci Ctr, London, ON, Canada	Purcell, L (corresponding author), McMaster Univ, Hamilton, ON, Canada.	lpurcell1015@rogers.com					Alla S, 2009, BRIT J SPORT MED, V43, pI3, DOI 10.1136/bjsm.2009.058339; [Anonymous], 2009, BR J SPORTS MED S1, V43, pi85; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Browne GJ, 2006, BRIT J SPORT MED, V40, P163, DOI 10.1136/bjsm.2005.021220; Covassin T, 2010, PHYSICIAN SPORTSMED, V38, P87, DOI 10.3810/psm.2010.12.1830; Davis GA, 2014, BRIT J SPORT MED, V48, P98, DOI 10.1136/bjsports-2012-092132; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Emery CA, 2006, CLIN J SPORT MED, V16, P20, DOI 10.1097/01.jsm.0000184638.72075.b7; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fridman L, 2013, BMC SPORTS SCI MED R, V5, DOI 10.1186/2052-1847-5-30; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harris AW, 2012, J SCI MED SPORT, V15, P298, DOI 10.1016/j.jsams.2011.12.005; Institute of Medicine, 2014, SPORTS REL CONC YOUT; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Meehan WP, 2011, CLIN SPORT MED, V30, P133, DOI 10.1016/j.csm.2010.08.004; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Purcell L, 2009, BRIT J SPORT MED, V43, pI51, DOI 10.1136/bjsm.2009.058214; Purcell LK, 2012, PAED CHILD HEALT-CAN, V17, P36; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Stoller J, 2014, CAN FAM PHYSICIAN, V60, P548; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003; Zemek R, 2014, PAED CHILD HEALT-CAN, V19, P474, DOI 10.1093/pch/19.9.475	38	24	24	0	11	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0009-9228	1938-2707		CLIN PEDIATR	Clin. Pediatr.	MAY	2016	55	5					452	458		10.1177/0009922815589915			7	Pediatrics	Pediatrics	DJ5FM	WOS:000374232200008	26063756				2021-06-18	
J	Turkstra, LS; Norman, R; Whyte, J; Dijkers, MP; Hart, T				Turkstra, Lyn S.; Norman, Rocio; Whyte, John; Dijkers, Marcel P.; Hart, Tessa			Knowing What We're Doing: Why Specification of Treatment Methods Is Critical for Evidence-Based Practice in Speech-Language Pathology	AMERICAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; TREATMENT TAXONOMY; SOCIAL-SKILLS; REHABILITATION TREATMENTS; THERAPY; DISORDERS; CHILDREN; SERIES; TRIAL	Purpose: The purpose of this clinical focus article is to describe the conceptual framework of the multidisciplinary rehabilitation treatment taxonomy (RTT) and illustrate its potential use in speech-language pathology (SLP) clinical practice and research. Method: The method used was a critical discussion. Results: Current methods of defining and classifying SLP and other rehabilitation interventions maintain the "black box" of rehabilitation by referring to hours or days of therapy or using problem-oriented labels (e.g., naming treatment) to describe treatments, none of which reveal what is actually done to effect desired changes in patient functioning. The RTT framework uses treatment targets, ingredients, and mechanisms of action defined by treatment theory to specify SLP and other rehabilitation interventions with greater precision than current methods of treatment labeling and classification. It also makes a distinction between the target of treatment at which ingredients are directed and broader aims of treatment, which may be downstream effects explained instead by enablement/disablement theory. Conclusion: Future application of the RTT conceptual scheme to SLP intervention may enhance clinical practice, research, and knowledge translation as well as training and program evaluation efforts.	[Turkstra, Lyn S.; Norman, Rocio] Univ Wisconsin, Madison, WI 53706 USA; [Whyte, John; Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA USA; [Dijkers, Marcel P.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA	Turkstra, LS (corresponding author), Univ Wisconsin, Madison, WI 53706 USA.	lyn.turkstra@wisc.edu		Whyte, John/0000-0002-4381-1474	Patient-Centered Outcomes Research Institute AwardPatient-Centered Outcomes Research Institute - PCORI [ME-1403-14083]; National Institute on Disability, Independent Living, and Rehabilitation ResearchUnited States Department of Health & Human Services [H133A080053]; National Institute on Child Health and Human Development, National Center for Medical Rehabilitation Research [R01 HD071089]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD071089] Funding Source: NIH RePORTER	This work was partially supported through a Patient-Centered Outcomes Research Institute Award (ME-1403-14083) and National Institute on Disability and Rehabilitation Research (now National Institute on Disability, Independent Living, and Rehabilitation Research) Cooperative Agreement H133A080053 and a Diversity Supplement to Grant R01 HD071089 from the National Institute on Child Health and Human Development, National Center for Medical Rehabilitation Research, to Rocio Norman. All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the National Institute on Disability and Rehabilitation Research, National Institute on Child Health and Human Development, and the Patient-Centered Outcomes Research Institute or its Board of Governors or Methodology Committee.	Beaulieu CL, 2015, ARCH PHYS MED REHAB, V96, pS222, DOI 10.1016/j.apmr.2014.10.028; Boyle M., 1995, AM J SPEECH-LANG PAT, V4, P94, DOI DOI 10.1044/1058-0360.0404.94; Dijkers MP, 2014, ARCH PHYS MED REHAB, V95, pS1, DOI 10.1016/j.apmr.2013.09.023; Dijkers MP, 2014, ARCH PHYS MED REHAB, V95, pS6, DOI 10.1016/j.apmr.2013.03.032; Dijkers MP, 2014, ARCH PHYS MED REHAB, V95, pS45, DOI 10.1016/j.apmr.2013.05.033; Edmonds LA, 2014, AM J SPEECH-LANG PAT, V23, P312, DOI 10.1044/2014_AJSLP-13-0098; Fletcher-Watson S, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008785.pub2; Gordan W, 2009, J SPINAL CORD MED, V32, P307, DOI 10.1080/10790268.2009.11760784; Granholm E, 2014, J CONSULT CLIN PSYCH, V82, P1173, DOI 10.1037/a0037098; Hart T, 2014, ARCH PHYS MED REHAB, V95, pS33, DOI 10.1016/j.apmr.2013.05.032; Hatfield B, 2005, ARCH PHYS MED REHAB, V86, pS61, DOI 10.1016/j.apmr.2005.08.111; Johnson ML, 2014, AM J SPEECH-LANG PAT, V23, P60, DOI 10.1044/1058-0360(2013/12-0168); Kasari C, 2012, J CHILD PSYCHOL PSYC, V53, P431, DOI 10.1111/j.1469-7610.2011.02493.x; KEITH RA, 1993, IMPROVING ASSESSMENT IN REHABILITATION AND HEALTH, P33; Llorens R, 2015, J NEUROENG REHABIL, V12, DOI 10.1186/s12984-015-0029-1; Meulenbroek P, 2016, J VOCAT REHABIL, V44, P15, DOI 10.3233/JVR-150777; Naeini TS, 2013, IRAN RED CRESCENT ME, V15, DOI 10.5812/ircmj.5426; Sohlberg M. M., 2011, OPTIMIZING INSTRUCTI; Van Stan JH, 2015, AM J SPEECH-LANG PAT, V24, P101, DOI 10.1044/2015_AJSLP-14-0030; Wambaugh JL, 2013, AM J SPEECH-LANG PAT, V22, pS334, DOI 10.1044/1058-0360(2013/12-0070); Whyte J, 2014, ARCH PHYS MED REHAB, V95, pS24, DOI 10.1016/j.apmr.2013.05.034; Whyte J, 2012, ARCH PHYS MED REHAB, V93, pS101, DOI 10.1016/j.apmr.2011.11.040; Wong C, 2015, J AUTISM DEV DISORD, V45, P1951, DOI 10.1007/s10803-014-2351-z; World Health Organization, 2001, INT CLASS FUNCT DIS	24	24	24	0	8	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1058-0360	1558-9110		AM J SPEECH-LANG PAT	Am. J. Speech-Lang. Pathol.	MAY	2016	25	2								10.1044/2015_AJSLP-15-0060			8	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	DO6AE	WOS:000377863600006	27145191	Green Published			2021-06-18	
J	Pakkanen, T; Virkkunen, I; Kamarainen, A; Huhtala, H; Silfvast, T; Virta, J; Randell, T; Yli-Hankala, A				Pakkanen, Toni; Virkkunen, Ilkka; Kamarainen, Antti; Huhtala, Heini; Silfvast, Tom; Virta, Janne; Randell, Tarja; Yli-Hankala, Arvi			Pre-hospital severe traumatic brain injury - comparison of outcome in paramedic versus physician staffed emergency medical services	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article						Pre-hospital Emergency Care (MeSH); Emergency Medical Services (MeSH); Critical Care (MeSH); Traumatic Brain Injury (MeSH); Airway Management (MeSH); Endotracheal Intubation (MeSH); Patient Outcome Assessment (MeSH); Glasgow Outcome Scale (MeSH)	RAPID-SEQUENCE INTUBATION; SEVERE HEAD-INJURY; PRACTICAL SCALE; CARE; IMPACT; TRIAL	Background: Traumatic brain injury (TBI) is one of the leading causes of death and permanent disability. Emergency Medical Services (EMS) personnel are often the first healthcare providers attending patients with TBI. The level of available care varies, which may have an impact on the patient's outcome. The aim of this study was to evaluate mortality and neurological outcome of TBI patients in two regions with differently structured EMS systems. Methods: A 6-year period (2005 - 2010) observational data on pre-hospital TBI management in paramedic-staffed EMS and physician-staffed EMS systems were retrospectively analysed. Inclusion criteria for the study were severe isolated TBI presenting with unconsciousness defined as Glasgow coma scale (GCS) score <= 8 occurring either on-scene, during transportation or verified by an on-call neurosurgeon at admission to the hospital. For assessment of one-year neurological outcome, a modified Glasgow Outcome Score (GOS) was used. Results: During the 6-year study period a total of 458 patients met the inclusion criteria. One-year mortality was higher in the paramedic-staffed EMS group: 57 % vs. 42 %. Also good neurological outcome was less common in patients treated in the paramedic-staffed EMS group. Discussion: We found no significant difference between the study groups when considering the secondary brain injury associated vital signs on-scene. Also on arrival to ED, the proportion of hypotensive patients was similar in both groups. However, hypoxia was common in the patients treated by the paramedic-staffed EMS on arrival to the ED, while in the physician-staffed EMS almost none of the patients were hypoxic. Prehospital intubation by EMS physicians probably explains this finding. Conclusion: The results suggest to an outcome benefit from physician-staffed EMS treating TBI patients.	[Pakkanen, Toni; Virkkunen, Ilkka] FinnHEMS Ltd, Res & Dev Unit, Vantaa, Finland; [Pakkanen, Toni; Yli-Hankala, Arvi] Tampere Univ Hosp, Dept Anaesthesia, Tampere, Finland; [Kamarainen, Antti; Virta, Janne] Tampere Univ Hosp, FinnHEMS 30, Tays Emergency Med Serv, Tampere, Finland; [Huhtala, Heini] Univ Tampere, Sch Hlth Sci, FIN-33101 Tampere, Finland; [Silfvast, Tom; Randell, Tarja] Univ Helsinki, Helsinki Univ Hosp, Dept Anaesthesia & Intens Care, Helsinki, Finland; [Yli-Hankala, Arvi] Univ Tampere, Sch Med, FIN-33101 Tampere, Finland	Pakkanen, T (corresponding author), FinnHEMS Ltd, Res & Dev Unit, Vantaa, Finland.; Pakkanen, T (corresponding author), Tampere Univ Hosp, Dept Anaesthesia, Tampere, Finland.	toni.pakkanen@fimnet.fi		Kamarainen, Antti/0000-0002-2299-3918	VTR Study Grant from Special State Allocation via Tampere University Hospital [9N088]; FinnHEMS ltd, Research and development unit	This study was supported by a VTR Study Grant #9N088 from Special State Allocation via Tampere University Hospital and FinnHEMS ltd, Research and development unit.	Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; BAXT WG, 1987, J TRAUMA, V27, P365, DOI 10.1097/00005373-198704000-00004; Bernard SA, 2010, ANN SURG, V252, P959, DOI 10.1097/SLA.0b013e3181efc15f; Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Davis DF, 2008, CURR OPIN CRIT CARE, V14, P142, DOI 10.1097/MCC.0b013e3282f63c40; Davis DP, 2008, RESUSCITATION, V76, P333, DOI 10.1016/j.resuscitation.2007.08.004; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Garner A, 2001, INJURY, V32, P455, DOI 10.1016/S0020-1383(01)00013-4; JENNETT B, 1975, LANCET, V1, P480; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2001, Eur J Emerg Med, V8, P215, DOI 10.1097/00063110-200109000-00009; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; TEASDALE G, 1974, LANCET, V2, P81; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008	20	24	25	0	12	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	APR 29	2016	24								62	10.1186/s13049-016-0256-x			7	Emergency Medicine	Emergency Medicine	DM1AK	WOS:000376077200001	27130216	DOAJ Gold, Green Published			2021-06-18	
J	Bogdanov, VB; Middleton, NA; Theriot, JJ; Parker, PD; Abdullah, OM; Ju, YS; Hartings, JA; Brennan, KC				Bogdanov, Volodymyr B.; Middleton, Natalie A.; Theriot, Jeremy J.; Parker, Patrick D.; Abdullah, Osama M.; Ju, Y. Sungtaek; Hartings, Jed A.; Brennan, K. C.			Susceptibility of Primary Sensory Cortex to Spreading Depolarizations	JOURNAL OF NEUROSCIENCE			English	Article						anoxic depolarization; cortical spreading depression; migraine; sensory cortex; traumatic brain injury	MOUSE BARREL CORTEX; CYTOCHROME-OXIDASE; CEREBRAL-CORTEX; VISUAL-CORTEX; MIGRAINE AURA; BRAIN TRAUMA; RAT-BRAIN; DEPRESSION; NEOCORTEX; SLICES	Spreading depolarizations (SDs) are recognized as actors in neurological disorders as diverse as migraine and traumatic brain injury (TBI). Migraine aura involves sensory percepts, suggesting that sensory cortices might be intrinsically susceptible to SDs. We used optical imaging, MRI, and field potential and potassium electrode recordings in mice and electrocorticographic recordings in humans to determine the susceptibility of different brain regions to SDs. Optical imaging experiments in mice under isoflurane anesthesia showed that both cortical spreading depression and terminal anoxic depolarization arose preferentially in the whisker barrel region of parietal sensory cortex. MRI recordings under isoflurane, ketamine/xylazine, ketamine/isoflurane, and urethane anesthesia demonstrated that the depolarizations did not propagate from a subcortical source. Potassium concentrations showed larger increases in sensory cortex, suggesting a mechanism of susceptibility. Sensory stimulation biased the timing but not the location of depolarization onset. In humans with TBI, there was a trend toward increased incidence of SDs in parietal/temporal sensory cortex compared with other regions. In conclusion, SDs are inducible preferentially in primary sensory cortex in mice and most likely in humans. This tropism can explain the predominant sensory phenomenology of migraine aura. It also demonstrates that sensory cortices are vulnerable in brain injury.	[Bogdanov, Volodymyr B.; Middleton, Natalie A.; Theriot, Jeremy J.; Parker, Patrick D.; Brennan, K. C.] Univ Utah, Dept Neurol, 383 Colorow Dr,Room 364, Salt Lake City, UT 84108 USA; [Abdullah, Osama M.] Univ Utah, Dept Bioengn & Small Anim Imaging, Salt Lake City, UT 84108 USA; [Parker, Patrick D.] Univ Utah, Interdept Program Neurosci, Salt Lake City, UT 84108 USA; [Ju, Y. Sungtaek] Univ Calif Los Angeles, Dept Mech & Aerosp Engn, Los Angeles, CA 90095 USA; [Hartings, Jed A.] Univ Cincinnati, Dept Neurosurg, Cincinnati, OH 45220 USA	Brennan, KC (corresponding author), Univ Utah, Dept Neurol, 383 Colorow Dr,Room 364, Salt Lake City, UT 84108 USA.	k.c.brennan@hsc.utah.edu	Bogdanov, Volodymyr/AAN-6209-2020	Ju, Y. Sungtaek/0000-0003-1238-8674; Brennan, K.C./0000-0003-4193-5841; Bogdanov, Volodymyr/0000-0002-7107-1426; Parker, Patrick/0000-0001-5217-107X; Hartings, Jed/0000-0001-8583-3471	International Headache Society; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 085413]; US Army Congressionally Directed Medical Research Programs (CDMRP) Peer Reviewed Medical Research Program [PR100060, PR130373]; US Army Congressionally Directed Medical Research Programs (CDMRP) Peer Reviewed Medical Research Program (Psychological Health/Traumatic Brain Injury Research Program); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS085413] Funding Source: NIH RePORTER	This work was supported by the International Headache Society (Research Fellowship to V.B.B.), the National Institutes of Health (Grant NS 085413), US Army Congressionally Directed Medical Research Programs (CDMRP) Peer Reviewed Medical Research Program (Grants PR100060 and PR130373 to K.C.B. and Psychological Health/Traumatic Brain Injury Research Program Grant to J.A.H.). We thank David O. Okonkwo, Clemens Pahl, M. Ross Bullock, Bruce Mathern, and Norberto Andaluz (Co-Operative Study on Brain Injury Depolarizations) for contributing clinical data, and we thank the members of the Headache Physiology Laboratory for helpful discussions on experimental design, analysis, and review of the manuscript.	Ayata C, 2006, ANN NEUROL, V59, P652, DOI 10.1002/ana.20778; Basarsky TA, 1998, J NEUROSCI, V18, P7189; Bere Z, 2014, NEUROSCIENCE, V260, P217, DOI 10.1016/j.neuroscience.2013.12.032; Bergman TL, 2011, FUNDAMENTALS HEAT MA; Cetas JS, 2009, NEUROSCIENCE, V163, P719, DOI 10.1016/j.neuroscience.2009.06.031; Charles A, 2009, CEPHALALGIA, V29, P1115, DOI 10.1111/j.1468-2982.2009.01983.x; Collins CE, 2010, P NATL ACAD SCI USA, V107, P15927, DOI 10.1073/pnas.1010356107; Constantinople CM, 2011, NEURON, V69, P1061, DOI 10.1016/j.neuron.2011.02.040; de Crespigny A, 1998, J CEREBR BLOOD F MET, V18, P1008; Dreier JP, 2015, NEURON, V86, P902, DOI 10.1016/j.neuron.2015.04.004; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Eikermann-Haerter K, 2011, J NEUROSCI, V31, P5755, DOI 10.1523/JNEUROSCI.5346-10.2011; Farkas E, 2010, NEUROIMAGE, V51, P734, DOI 10.1016/j.neuroimage.2010.02.055; Fujita S, 2016, CEREB CORTEX, V26, P1580, DOI 10.1093/cercor/bhu336; HARLEY CA, 1992, J COMP NEUROL, V322, P377, DOI 10.1002/cne.903220307; Hartings JA, 2014, ANN NEUROL, V76, P681, DOI 10.1002/ana.24256; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; HEINEMANN U, 1977, BRAIN RES, V120, P231, DOI 10.1016/0006-8993(77)90903-9; Helmchen F, 2005, NAT METHODS, V2, P932, DOI 10.1038/NMETH818; Herculano-Houzel S, 2013, FRONT NEUROANAT, V7, DOI 10.3389/fnana.2013.00035; Hertle DN, 2012, BRAIN, V135, P2390, DOI 10.1093/brain/aws152; HEVNER RF, 1995, NEUROSCIENCE, V65, P313, DOI 10.1016/0306-4522(94)00514-6; HORTON JC, 1981, NATURE, V292, P762, DOI 10.1038/292762a0; Houades V, 2008, J NEUROSCI, V28, P5207, DOI 10.1523/JNEUROSCI.5100-07.2008; HUBEL DH, 1969, NATURE, V221, P747, DOI 10.1038/221747a0; Kaas JH, 2012, P NATL ACAD SCI USA, V109, P10655, DOI 10.1073/pnas.1201892109; Kelman L, 2004, CEPHALALGIA, V24, P728, DOI 10.1111/j.1468-2982.2004.00748.x; Lashley KS, 1941, ARCH NEURO PSYCHIATR, V46, P331, DOI 10.1001/archneurpsyc.1941.02280200137007; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; Lopez-Valdes HE, 2014, STROKE, V45, P2093, DOI 10.1161/STROKEAHA.113.004476; LOTHMAN E, 1975, BRAIN RES, V88, P15, DOI 10.1016/0006-8993(75)90943-9; MATSUURA T, 1971, EXP BRAIN RES, V12, P238, DOI 10.1007/BF00237916; Mayevsky A, 1996, BRAIN RES, V740, P268, DOI 10.1016/S0006-8993(96)00874-8; MODY I, 1987, J NEUROPHYSIOL, V57, P869; Nimmerjahn A, 2004, NAT METHODS, V1, P31, DOI 10.1038/nmeth706; Periasamy N, 1998, BIOPHYS J, V75, P557, DOI 10.1016/S0006-3495(98)77545-9; Petzold GC, 2008, STROKE, V39, P1292, DOI 10.1161/STROKEAHA.107.500710; Pietrobon D, 2014, NAT REV NEUROSCI, V15, P379, DOI 10.1038/nrn3770; Pietrobon D, 2013, ANNU REV PHYSIOL, V75, P365, DOI 10.1146/annurev-physiol-030212-183717; Polack PO, 2013, NAT NEUROSCI, V16, P1331, DOI 10.1038/nn.3464; Rorden C, 2007, J COGNITIVE NEUROSCI, V19, P1081, DOI 10.1162/jocn.2007.19.7.1081; Russell MB, 1996, BRAIN, V119, P355, DOI 10.1093/brain/119.2.355; Schott GD, 2007, BRAIN, V130, P1690, DOI 10.1093/brain/awl348; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; SUR M, 1981, SCIENCE, V212, P1059, DOI 10.1126/science.7233199; Tang YT, 2014, J NEUROPHYSIOL, V112, P2572, DOI 10.1152/jn.00205.2014; TOOTELL RBH, 1985, J NEUROSCI, V5, P2786; von Bornstadt D, 2015, NEURON, V85, P1117, DOI 10.1016/j.neuron.2015.02.007; Wang FS, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002334; Wu JP, 2016, CEREB CORTEX, V26, P23, DOI 10.1093/cercor/bhu166; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407	52	24	24	0	7	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	APR 27	2016	36	17					4733	4743		10.1523/JNEUROSCI.3694-15.2016			11	Neurosciences	Neurosciences & Neurology	DK7UF	WOS:000375130500009	27122032	Green Published, Bronze			2021-06-18	
J	Tsushima, WT; Geling, O; Arnold, M; Oshiro, R				Tsushima, William T.; Geling, Olga; Arnold, Monica; Oshiro, Ross			Are There Subconcussive Neuropsychological Effects in Youth Sports? An Exploratory Study of High- and Low-Contact Sports	APPLIED NEUROPSYCHOLOGY-CHILD			English	Article						contact; subconcussive neuropsychological effects; youth sports	CHRONIC TRAUMATIC ENCEPHALOPATHY; HIGH-SCHOOL; CONCUSSION INCIDENCE; WHITE-MATTER; IMPACT; RECOVERY; PLAY	This exploratory study was designed to examine the neuropsychological effects of sports-related head traumaspecifically, repetitive subconcussive impacts or head blows that do not result in a diagnosable concussion. The researchers compared the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) neurocognitive test scores of 2 groups of nonconcussed youth athletes (n=282), grouped according to the frequency of concussions in their respective sports, with the assumption that more subconcussive impacts occur in sports in which there are more reported concussions. The results indicated that high-contact-sport (football) athletes had significantly poorer performance in processing speed and reaction time compared with athletes in low-contact sports (wrestling, soccer, baseball, judo, and basketball). This study into the effects of repetitive subconcussive head trauma tentatively raises concern that participation in high-contact sports, even without evidence of a diagnosable concussion, could result in lowered neuropsychological functioning among high school athletes. Limitations of this exploratory research effort are discussed.	[Tsushima, William T.] Straub Clin & Hosp, Dept Psychiat & Psychol, 888 South King St, Honolulu, HI 96813 USA; [Geling, Olga] PPE Solut, Honolulu, HI USA; [Arnold, Monica] Syntactx, New York, NY USA; [Oshiro, Ross] Queens Ctr Sports Med, Honolulu, HI USA	Tsushima, WT (corresponding author), Straub Clin & Hosp, Dept Psychiat & Psychol, 888 South King St, Honolulu, HI 96813 USA.	wtsushima@straub.net	Meijer, Anna/K-5118-2016		Hawaii Pacific Health (HPH)	This work was supported in part by funding from Hawaii Pacific Health (HPH) to Monica Arnold as a participant in the HPH Summer Scholar Research Program.	Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2012, EXERC SPORT SCI REV, V40, P138, DOI 10.1097/JES.0b013e3182524273; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Chamard E, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12305; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Datalys Center for Sports Injury Research and Prevention, 2013, NATA NATION PREL CON; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Eckner JT, 2011, J NEUROTRAUM, V28, P2079, DOI 10.1089/neu.2011.1910; Fainaru-Wada M., 2013, LEAGUE DENIAL NFL CO; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gardner A, 2015, BRIT J SPORT MED, V49, P495, DOI 10.1136/bjsports-2013-093102; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Giza CC, 2004, STUD NEUROPSYCHOL DE, P45; Graham R., 2014, SPORTS RELATED CONCU; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Lovell M.R., 2006, SPORTS NEUROPSYCHOLO, P193; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P236, DOI 10.1093/arclin/act009; Shuttleworth-Edwards Ann B, 2009, Phys Sportsmed, V37, P45, DOI 10.3810/psm.2009.12.1741; Stephens R, 2010, J NEUROPSYCH CLIN N, V22, P295, DOI 10.1176/appi.neuropsych.22.3.295; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; WEBBE FM, 2006, SPORTS NEUROPSYCHOLO, P45; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8	43	24	24	0	27	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	2162-2965	2162-2973		APPL NEUROPSYCH-CHIL	Appl. Neuropsychol.-Child	APR 2	2016	5	2					149	155		10.1080/21622965.2015.1052813			7	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	DJ1BG	WOS:000373937500008	26979930				2021-06-18	
J	Brooks, BL; Daya, H; Khan, S; Carlson, HL; Mikrogianakis, A; Barlow, KM				Brooks, Brian L.; Daya, Hussain; Khan, Samna; Carlson, Helen L.; Mikrogianakis, Angelo; Barlow, Karen M.			Cognition in the Emergency Department as a Predictor of Recovery after Pediatric Mild Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Brain injuries; Traumatic; Concussion; Mild; Cognition; Outcomes research; Child; Post-concussion syndrome	POSTCONCUSSION SYNDROME; CONCUSSION; SYMPTOMS; ADOLESCENTS; CHILDREN; OUTCOMES; SEVERITY	Cognitive abilities can be acutely disrupted in children and adolescents who sustain a mild traumatic brain injury (mTBI), with the potential that these disruptions may be predictive of recovery. The objective of this study was to determine if cognitive abilities in the emergency department (ED) can differentiate and predict poor symptom recovery following a pediatric mTBI. Participants included 77 male and female youth with a mTBI (mean age = 13.6; SD = 2.6). All participants completed computerized cognitive testing (four subtests from the CNS Vital Signs) when they presented to the ED. Symptom measurement occurred in the ED (for pre-injury), at 7-10 days, 1 month, 2 months, and 3 months post-mTBI using the post-concussion symptom inventory (PCSI). Recovery was determined using reliable change scores for symptom ratings from 28 orthopedic injury controls (mean age = 13.9 years; SD = 2.1). Significantly worse Reaction Time scores (i.e., rapid information processing) in the ED were found in those who remained symptomatic at 1 month. Performances on the Reaction Time and Cognitive Flexibility domain scores were predictive of symptom outcome at 1 month for youth (above and beyond sex and baseline symptom burden). Youth with low scores on Reaction Time and/or Cognitive Flexibility were nearly 15 times (95%CI = 1.8-323.5) more likely to remain symptomatic at 1 month post-mTBI. No significant group differences were found at 7-10 days, 2 months, or 3 months post-injury. Rapid computerized cognitive testing in the ED following a mTBI may help clinicians predict which youth may or may not remain symptomatic at follow-up.	[Brooks, Brian L.; Carlson, Helen L.; Barlow, Karen M.] Alberta Childrens Prov Gen Hosp, Neurosci Brain Injury & Vi Riddell Rehabil Progra, Calgary, AB T3B 6A8, Canada; [Brooks, Brian L.; Mikrogianakis, Angelo; Barlow, Karen M.] Univ Calgary, Dept Paediat, Cumming Sch Med, Calgary, AB T2N 1N4, Canada; [Brooks, Brian L.; Mikrogianakis, Angelo; Barlow, Karen M.] Univ Calgary, Dept Clin Neurosci, Cumming Sch Med, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Dept Psychol, Fac Arts, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada; [Brooks, Brian L.; Carlson, Helen L.; Mikrogianakis, Angelo; Barlow, Karen M.] Univ Calgary, Alberta Childrens Hosp, Res Inst Child & Maternal Hlth, Calgary, AB, Canada; [Daya, Hussain] Univ Lethbridge, Dept Psychol, Lethbridge, AB T1K 3M4, Canada; [Khan, Samna] McMaster Univ, Michael G DeGroote Sch Med, Hamilton, ON, Canada; [Mikrogianakis, Angelo] Alberta Childrens Prov Gen Hosp, Sect Emergency Med, Calgary, AB T3B 6A8, Canada	Brooks, BL (corresponding author), Alberta Childrens Prov Gen Hosp, Neurosci Program, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.	brian.brooks@albertahealthservices.ca	Barlow, Karen/I-6492-2019; Meijer, Anna/K-5118-2016; Barlow, Karen/C-1323-2014	Barlow, Karen/0000-0003-2612-8507; Carlson, Helen/0000-0002-5788-0542	Pediatric Brain Injury Research Program; Canadian Institutes of Health Research training programCanadian Institutes of Health Research (CIHR); McCarthy Tetrault Award	Funding for this study was provided by: the Pediatric Brain Injury Research Program (administered by the Alberta Children's Hospital Research Institute) awarded to Drs. Barlow and Brooks; summer studentships from the Canadian Institutes of Health Research training program (administered by the Alberta Children's Hospital Research Institute; the McCarthy Tetrault Award (administered by the Alberta Children's Hospital Research Institute) awarded to Dr. Brooks; in-kind test credits from the computerized test publisher (CNS Vital Signs); and in-kind support from the neurosciences program at Alberta Children's Hospital (Conny Betuzzi). None of the funding sources were involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.	*AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Barlow KM, 2015, PEDIATR NEUROL, V53, P491, DOI 10.1016/j.pediatrneurol.2015.04.011; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324; Brooks BL, 2014, J NEUROTRAUM, V31, P1744, DOI 10.1089/neu.2014.3356; Brooks BL, 2014, J HEAD TRAUMA REHAB, V29, P257, DOI 10.1097/HTR.0000000000000016; Brooks BL, 2014, ARCH CLIN NEUROPSYCH, V29, P186, DOI 10.1093/arclin/act083; Brooks BL, 2013, J NEUROTRAUM, V30, P1469, DOI 10.1089/neu.2012.2720; Brooks BL, 2012, J CHILD NEUROL, V27, P982, DOI 10.1177/0883073811430863; Brooks BL, 2011, J CHILD NEUROL, V26, P786, DOI 10.1177/0883073810391532; Brooks BL, 2010, APPL NEUROPSYCHOL, V17, P37, DOI 10.1080/09084280903526083; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Centers for Disease Control and Prevention, 2011, NONF TRAUM BRAIN INJ; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Grubenhoff JA, 2014, PEDIATRICS, V134, P54, DOI 10.1542/peds.2013-2988; Grubenhoff JA, 2010, PEDIATRICS, V126, P688, DOI 10.1542/peds.2009-2804; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Haring RS, 2015, BRAIN INJURY, V29, P989, DOI 10.3109/02699052.2015.1033014; IBM Corp, 2010, IBM SPSS STAT WIND V; Iverson G, 2007, CLIN J SPORT MED, V17, P31; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Khetani A, 2014, BRAIN INJURY, V28, P844; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lemon SC, 2003, ANN BEHAV MED, V26, P172, DOI 10.1207/S15324796ABM2603_02; Macpherson A, 2014, PAED CHILD HEALT-CAN, V19, P543, DOI 10.1093/pch/19.10.543; Mannix R, 2014, ANN CLIN TRANSL NEUR, V1, P433, DOI 10.1002/acn3.70; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Nance ML, 2009, ANN SURG, V249, P859, DOI 10.1097/SLA.0b013e3181a41ae5; Olshen RA, 1984, CLASSIFICATION REGRE; R Core Team, 2012, R LANG ENV STAT COMP; Rieger BP, 2013, BRAIN INJURY, V27, P169, DOI 10.3109/02699052.2012.729290; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Scopaz KA, 2013, SPORTS HEALTH, V5, P537, DOI 10.1177/1941738112473059; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Sheedy J, 2009, J HEAD TRAUMA REHAB, V24, P333, DOI 10.1097/HTR.0b013e3181aea51f; Strobl C, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-307; Therneau T.M., 2014, INTRO RECURSIVE PART; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	47	24	24	0	15	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	APR	2016	22	4					379	387		10.1017/S1355617715001368			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	DI1ZK	WOS:000373295300001	26786357				2021-06-18	
J	Mollayeva, T; Pratt, B; Mollayeva, S; Shapiro, CM; Cassidy, JD; Colantonio, A				Mollayeva, Tatyana; Pratt, Brandy; Mollayeva, Shirin; Shapiro, Colin M.; Cassidy, J. David; Colantonio, Angela			The relationship between insomnia and disability in workers with mild traumatic brain injury/concussion Insomnia and disability in chronic mild traumatic brain injury	SLEEP MEDICINE			English	Article						Insomnia; Mild traumatic brain injury; Concussion; Work disability; Social disability; Family life disability	QUALITY-OF-LIFE; ASSESSING DEPRESSION; SLEEP DYSFUNCTION; SEX-DIFFERENCES; PANIC DISORDER; CHRONIC PAIN; FOLLOW-UP; HEALTH; POPULATION; SYMPTOMS	Aim/Background: The principal aim of this study was to, for the first time, examine the relationship between insomnia and perceived disability among workers with mild traumatic brain injury (mTBI)/concussion. Patients/Methods: A cross-sectional study was conducted at the Workplace Safety and Insurance Board Clinic of the largest rehabilitation teaching hospital in Canada. Data from questionnaires, insurer records and clinical investigations were analysed. The Insomnia Severity Index measured the primary independent variable, and the Sheehan Disability Scale measured disability outcomes, classified as 'mild/moderate' or 'marked/extreme'. Two-sided t-tests and Chi-squared tests were used for bivariate associations. A binomial logistic regression model was fit using previously identified variables. Results: The sample comprised 92 workers (45.1 +/- 9.9 years old, 61% male) with mTBI/concussion at median time 196 days after injury. When compared with workers reporting lower disability, workers with higher disability were found with more severe insomnia, depression, anxiety and pain. In the multivariable analysis, the odds of reporting higher global disability increased with increasing insomnia and pain [adjusted odds ratio (OR) 1.16 (95% CI 1.03-1.31) and 1.117 (95% CI 1.01-1.24), respectively]. Insomnia was the only significant covariate in a fully adjusted work disability model. None of the variables studied were statistically significant in the social and family life disability models. Conclusions: Greater attention should be given to the diagnosis and management of insomnia in persons with mTBI/concussion. (C) 2015 Elsevier B.V. All rights reserved.	[Mollayeva, Tatyana; Colantonio, Angela] Univ Toronto, Fac Med, Grad Dept Rehabil Sci, Toronto, ON, Canada; [Mollayeva, Tatyana] Univ Toronto, Collaborat Program Neurosci, Toronto, ON, Canada; [Mollayeva, Tatyana; Colantonio, Angela] Toronto Rehab Univ Hlth Network, Toronto, ON, Canada; [Pratt, Brandy; Cassidy, J. David] Univ Toronto, Dalla Lana Sch Publ Hlth, Div Epidemiol, Toronto, ON, Canada; [Mollayeva, Shirin; Shapiro, Colin M.] Univ Toronto, Fac Arts & Sci, Toronto, ON, Canada; [Mollayeva, Shirin; Colantonio, Angela] Univ Toronto, Aquired Brain Injury Res Lab, Toronto, ON, Canada; [Mollayeva, Shirin; Shapiro, Colin M.] Univ Hlth Network, Toronto Western Hosp, Toronto, ON, Canada; [Shapiro, Colin M.] Youthdale Child & Adolescent Sleep Clin, Toronto, ON, Canada; [Cassidy, J. David] Univ Hlth Network, Div Hlth Care & Outcomes Res, Toronto Western Res Inst, Toronto, ON, Canada; [Colantonio, Angela] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada	Mollayeva, T (corresponding author), Toronto Rehabil Inst, 550 Univ Ave,Rm 11207, Toronto, ON M5G 2A2, Canada.	tatyana.mollayeva@utoronto.ca	, Mollayeva/A-4522-2018	Mollayeva, Tatyana/0000-0002-2787-1848; Colantonio, Angela/0000-0003-2094-4765	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Work Disability Prevention CIHR Strategic Training Program; CIHR Travel AwardsCanadian Institutes of Health Research (CIHR) [142525]; Canadian Institutes for Health Research Grant - Institute for Gender and HealthCanadian Institutes of Health Research (CIHR) [CGW-126580]	This study had no external funding source. The first author was supported by 2010/2011 Toronto Rehabilitation Institute Scholarship, the Ontario Graduate Scholarship 2012/2013 and the 2013/2015 Frederick Banting and Charles Best Doctoral Research Award from the Canadian Institutes of Health Research (CIHR), the 2014/2015 Work Disability Prevention CIHR Strategic Training Program and the CIHR Travel Awards (#142525). Angela Colantonio was supported by the Canadian Institutes for Health Research Grant - Institute for Gender and Health (#CGW-126580).	American Psychiatric Association, 2000, AM PSYCH ASS DIAGN S, VFourth; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Brain Injury Association of America, BRAIN INJ; Burke W H, 1988, Brain Inj, V2, P313, DOI 10.3109/02699058809150902; Cancelliere C, 2012, SYST REV-LONDON, V1, DOI 10.1186/2046-4053-1-17; Cantor JB, 2012, J HEAD TRAUMA REHAB, V27, pE1, DOI 10.1097/HTR.0b013e318270f91e; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS278, DOI 10.1016/j.apmr.2013.08.295; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cochiarella L, 2001, GUIDES EVALUATION PE, V5; Collins GS, 2015, J CLIN EPIDEMIOL, V68, P112, DOI [10.1016/j.jclinepi.2014.11.010, 10.1186/s12916-014-0241-z]; Crain TL, 2014, J OCCUP HEALTH PSYCH, V19, P155, DOI 10.1037/a0036010; Crocker TF, 2015, J CLIN EPIDEMIOL, V68, P584, DOI 10.1016/j.jclinepi.2014.12.007; Dahm J, 2013, J AFFECT DISORDERS, V151, P392, DOI 10.1016/j.jad.2013.06.011; Davis CG, 2013, J FORENSIC LEG MED, V20, P74, DOI 10.1016/j.jflm.2012.05.004; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Fortier-Brochu E, 2012, SLEEP MED REV, V16, P83, DOI 10.1016/j.smrv.2011.03.008; Fuller-Iglesias HR, 2016, RES AGING, V38, P3, DOI 10.1177/0164027514568324; Gagnon C, 2013, J AM BOARD FAM MED, V26, P701, DOI 10.3122/jabfm.2013.06.130064; Gamboa AM, 2006, NEUROREHABILITATION, V21, P327; Gutierrez-Rojas L, 2011, PSYCHIAT RES, V186, P254, DOI 10.1016/j.psychres.2010.06.020; He Yuxin, 2014, Glob Adv Health Med, V3, P35, DOI 10.7453/gahmj.2014.034; Himanen L, 2011, BRAIN INJURY, V25, P443, DOI 10.3109/02699052.2011.556580; Hoffman SW, 2009, CLIN NEUROPSYCHOL, V23, P1400, DOI 10.1080/13854040903369433; Hou LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076087; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; Jain A, 2014, ASIAN J PSYCHIATR, V8, P99, DOI 10.1016/j.ajp.2013.12.017; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kucharczyk Erica R, 2012, Sleep Med Rev, V16, P547, DOI 10.1016/j.smrv.2012.01.005; Lentino Cynthia V, 2013, US Army Med Dep J, P98; LEON AC, 1992, SOC PSYCH PSYCH EPID, V27, P78, DOI 10.1007/BF00788510; Li Y, 2013, J AM STAT ASS, V108; LILLISTON BA, 1985, SOC WORK HEALTH CARE, V10, P1, DOI 10.1300/J010v10n04_01; Macera CA, 2013, SLEEP, V36, P83, DOI 10.5665/sleep.2306; Malfliet A, 2015, PAIN PRACT, V15, P757, DOI 10.1111/papr.12244; Maroon JC, 2014, PROG NEUROL SURG, V28, P1, DOI 10.1159/000358746; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McDougall J, 2014, DISABIL REHABIL, V36, P2143, DOI 10.3109/09638288.2014.892642; Mollayeva T, 2016, SLEEP MED, V19, P153, DOI 10.1016/j.sleep.2015.05.014; Mollayeva T, 2013, SLEEP MED, V14, P1235, DOI 10.1016/j.sleep.2013.07.009; Mollayeya T, 2013, SLEEP MED REV, V17, P411, DOI 10.1016/j.smrv.2013.02.001; Motor Accident Authority NSW (MAA), 2008, GUID MILD TRAUM BRAI; O'Neill J, 2014, J CLIN EPIDEMIOL, V67, P56, DOI 10.1016/j.jclinepi.2013.08.005; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Paul P, 2013, STAT MED, V32, P67, DOI 10.1002/sim.5525; Paunio T, 2015, J AFFECT DISORDERS, V172, P381, DOI 10.1016/j.jad.2014.10.002; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Quatrano LA, 2011, ARCH PHYS MED REHAB, V92, pS7, DOI 10.1016/j.apmr.2010.08.032; Rubin HC, 2000, J AFFECT DISORDERS, V57, P217, DOI 10.1016/S0165-0327(99)00030-0; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Scalo J, 2015, QUAL LIFE RES, V24, P1223, DOI 10.1007/s11136-014-0842-1; Sendroy-Terrill M, 2010, ARCH PHYS MED REHAB, V91, P489, DOI 10.1016/j.apmr.2009.11.011; Sheehan DV, 1996, INT CLIN PSYCHOPHARM, V11, P89, DOI 10.1097/00004850-199606003-00015; Shekleton JA, 2014, SLEEP, V37, P107, DOI 10.5665/sleep.3318; Sherer M, 2014, ARCH PHYS MED REHAB, V95, P1162, DOI [10.1016/j.apmr.2014.02.006, 10.1016/j.apmr.2013.06.004]; Sivertsen B, 2014, J SLEEP RES, V23, P124, DOI 10.1111/jsr.12102; Statistics Canada, OCC CLASS; Statistics Canada, LAB FORC SURV EST LF; Styrke J, 2013, J REHABIL MED, V45, P749, DOI 10.2340/16501977-1215; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Vellante F, 2013, CLIN TER, V164, P429, DOI 10.7417/CT.2013.1609; Waljas M, 2014, J HEAD TRAUMA REHAB, V29, P443, DOI 10.1097/HTR.0000000000000002; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	74	24	24	0	12	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1389-9457	1878-5506		SLEEP MED	Sleep Med.	APR	2016	20						157	166		10.1016/j.sleep.2015.09.008			10	Clinical Neurology	Neurosciences & Neurology	DO8RO	WOS:000378051400028	26790723				2021-06-18	
J	Kamper, JE; Garofano, J; Schwartz, DJ; Silva, MA; Zeitzer, J; Modarres, M; Barnett, SD; Nakase-Richardson, R				Kamper, Joel E.; Garofano, Jeffrey; Schwartz, Daniel J.; Silva, Marc A.; Zeitzer, Jamie; Modarres, Mo; Barnett, Scott D.; Nakase-Richardson, Risa			Concordance of Actigraphy With Polysomnography in Traumatic Brain Injury Neurorehabilitation Admissions	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						rehabilitation; head injury; traumatic brain injury; actigraphy; polysomnography; sleep	MODIFIED ASHWORTH SCALE; SLEEP-APNEA; RELIABILITY; DISORDERS; REHABILITATION; CONSCIOUSNESS; PREVALENCE; SPASTICITY; VETERANS; COMA	Objective: To examine concordance of accelerometer-based actigraphy (ACG) with polysomnography (PSG) in the determination of sleep states in inpatients with traumatic brain injury (TBI), and examine the impact of injury severity and comorbid conditions (spasticity, apnea) on concordance. Participants: This was a convenience sample of 50 participants with primarily severe TBI. Design: This was a retrospective chart review of concurrent administration of PSG with ACG in nonconsecutive rehabilitation admissions with TBI. Main Measures: Total sleep time and sleep efficiency were measured by PSG and ACG. Results: Moderate to strong correlations between ACG and PSG were observed for total sleep time (r = 0.78, P < .01) and sleep efficiency (r = 0.66, P < .01). PSG and ACG estimates of total sleep time (316 minutes vs 325 minutes, respectively) and sleep efficiency (78% vs 77%, respectively) were statistically indistinguishable. Conclusions: Actigraphy is a valid proxy for monitoring of sleep in this population across injury severity and common comorbidity groups. However, further research with larger sample sizes to examine concordance in patients with TBI with disorder of consciousness and spasticity is recommended.	[Kamper, Joel E.; Silva, Marc A.; Nakase-Richardson, Risa] James A Haley Vet Hosp, MHBS, Tampa, FL 33612 USA; [Schwartz, Daniel J.] James A Haley Vet Hosp, Med, Tampa, FL 33612 USA; [Barnett, Scott D.] James A Haley Vet Hosp, Res, Tampa, FL 33612 USA; [Garofano, Jeffrey] Univ S Florida, Dept Psychol & Social Fdn, Tampa, FL USA; [Schwartz, Daniel J.; Nakase-Richardson, Risa] Univ S Florida, Dept Med, Tampa, FL USA; [Zeitzer, Jamie] Stanford Univ, Stanford Ctr Sleep Sci & Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA; [Zeitzer, Jamie] VA Palo Alto Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Palo Alto, CA USA; [Modarres, Mo] North Florida South Georgia Vet Hlth Syst, Brain Rehabil Res Ctr, Gainesville, FL USA; [Nakase-Richardson, Risa] HSR&D Ctr Innovat Disabil Rehabil & Res, Tampa, FL USA; [Silva, Marc A.; Nakase-Richardson, Risa] Def & Vet Brain Injury Ctr, Silver Spring, MD USA	Nakase-Richardson, R (corresponding author), James A Haley Vet Hosp, Polytrauma Mail Code 117,13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	Risa.Richardson@va.gov	Zeitzer, Jamie M/A-1168-2007; Zeitzer, Jamie/AAO-2103-2020; Kamper, Joel/V-2450-2019; Silva, Marc A./J-1874-2019	Zeitzer, Jamie M/0000-0001-6174-5282; Zeitzer, Jamie/0000-0001-6174-5282; Kamper, Joel/0000-0001-5098-5176; Silva, Marc A./0000-0002-3879-6054	Department of Veterans AffairsUS Department of Veterans Affairs; Department of Education, National Institute on Disability, Independent Living, and Rehabilitation Research; VHA Central Office VA TBI Model System Program of Research; General Dynamics Health Solutions from the Defense and Veterans Brain Injury Center, US Army Medical Research and Material Command (USAMRMC), U.S. Department of Veterans Affairs [W91YTZ-13-C-0015, I50 HX001233-01, W81XWH-13-2-0095]; General Dynamics Health Solutions from U.S. Department of Defense Congressionally Directed Medical Research Programs	The Polytrauma Rehabilitation Center Traumatic Brain Injury (TBI) Model System collaboration is funded through an Interagency Agreement between the Department of Veterans Affairs and the Department of Education, National Institute on Disability, Independent Living, and Rehabilitation Research. This research is sponsored by VHA Central Office VA TBI Model System Program of Research, and Subcontract from General Dynamics Health Solutions (W91YTZ-13-C-0015) from the Defense and Veterans Brain Injury Center, US Army Medical Research and Material Command (USAMRMC), U.S. Department of Veterans Affairs grants (1 I50 HX001233-01, W81XWH-13-2-0095), and U.S. Department of Defense Congressionally Directed Medical Research Programs.	Allison SC, 1996, INT J REHABIL RES, V19, P67, DOI 10.1097/00004356-199603000-00007; ALLISON SC, 1995, J NEUROL, V242, P699, DOI 10.1007/BF00866923; Ancoli-Israel S, 2003, SLEEP, V26, P342, DOI 10.1093/sleep/26.3.342; Baker FC, 1999, J PSYCHOSOM RES, V47, P335, DOI 10.1016/S0022-3999(99)00017-3; Berry RB, 2020, AASM MANUAL SCORING; Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1191/096228099673819272; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Chesnut Randall M., 1997, Emergency Medicine Clinics of North America, V15, P581, DOI 10.1016/S0733-8627(05)70319-9; Chiu HY, 2013, J FORMOS MED ASSOC, V112, P545, DOI 10.1016/j.jfma.2013.06.007; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Cologan V, 2013, J NEUROTRAUM, V30, P339, DOI 10.1089/neu.2012.2654; Cruse D, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-18; Duclos C, 2014, NEUROREHAB NEURAL RE, V28, P472, DOI 10.1177/1545968313517756; EDINGER JD, 1995, SLEEP, V18, P232, DOI 10.1093/sleep/18.4.232; Fischer J, 1997, RESPIRATION, V64, P39; Fogelberg DJ, 2012, ARCH PHYS MED REHAB, V93, P1313, DOI 10.1016/j.apmr.2012.04.031; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Hagen C, 1979, REHABILITATION HEAD, P87; Holcomb E, 2016, EFFECTS SLEEP WAKE C, V31, P108; Holcomb E, 2015, J HEAD TRAU IN PRESS; IOM, 2006, SLEEP DISORDERS SLEE; Kushida CA, 2005, SLEEP, V28, P499, DOI 10.1093/sleep/28.4.499; Lamberty GJ, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0b013e31829a64d1; Madsen MT, 2013, J CLIN SLEEP MED, V9, P387, DOI 10.5664/jcsm.2598; Maglione JE, 2013, SLEEP, V36, P1209, DOI 10.5665/sleep.2888; Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598; Makley MJ, 2009, NEUROREHAB NEURAL RE, V23, P320, DOI 10.1177/1545968308325268; Martin JL, 2011, CHEST, V139, P1514, DOI 10.1378/chest.10-1872; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Mccall C, 2012, J SLEEP RES, V21, P122, DOI 10.1111/j.1365-2869.2011.00917.x; Mehrholz J, 2005, CLIN REHABIL, V19, P751, DOI 10.1191/0269215505cr889oa; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Nakase-Richardson R, 2007, J NEUROL NEUROSUR PS, V78, P872, DOI 10.1136/jnnp.2006.104190; Nakase-Richardson R, 2013, ARCH PHYS MED REHAB, V94, P1861, DOI 10.1016/j.apmr.2013.05.027; Nakase-Richardson R, 2013, ARCH PHYS MED REHAB, V94, P875, DOI 10.1016/j.apmr.2013.01.001; Nakase-Thompson R, 2004, BRAIN INJURY, V18, P131, DOI 10.1080/0269905031000149542; Okifuji A, 2011, CLIN J PAIN, V27, P289, DOI 10.1097/AJP.0b013e31820485db; Rechtschaffen A, 1968, MANUAL STANDARDIZED; Richardson A, 2007, J CLIN NURS, V16, P1660, DOI 10.1111/j.1365-2702.2005.01546.x; SADEH A, 1995, SLEEP, V18, P288, DOI 10.1093/sleep/18.4.288; Sassani A, 2004, SLEEP, V27, P453, DOI 10.1093/sleep/27.3.453; Seel RT, 2013, ARCH PHYS MED REHAB, V94, P1908, DOI 10.1016/j.apmr.2012.11.052; Silva MA, 2012, AM J PHYS MED REHAB, V91, P890, DOI 10.1097/PHM.0b013e31825a1648; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; Vallieres A, 2003, SLEEP, V26, P902, DOI 10.1093/sleep/26.7.902; van de Water ATM, 2011, J SLEEP RES, V20, P183, DOI 10.1111/j.1365-2869.2009.00814.x; Webster JB, 2001, ARCH PHYS MED REHAB, V82, P316, DOI 10.1053/apmr.2001.20840; Whyte J, 2013, ARCH PHYS MED REHAB, V94, P1877, DOI 10.1016/j.apmr.2012.12.027; Zollman FS, 2010, BRAIN INJURY, V24, P748, DOI 10.3109/02699051003692167	50	24	24	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2016	31	2			SI		117	125		10.1097/HTR.0000000000000215			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DH7NO	WOS:000372981100005	26959665				2021-06-18	
J	MacManus, DB; Pierrat, B; Murphy, JG; Gilchrist, MD				MacManus, David B.; Pierrat, Baptiste; Murphy, Jeremiah G.; Gilchrist, Michael D.			Mechanical characterization of the P56 mouse brain under large-deformation dynamic indentation	SCIENTIFIC REPORTS			English	Article							VISCOELASTIC PROPERTIES; IN-VIVO; TISSUE; HEAD; EPIDEMIOLOGY; VALIDATION; CELLS; SITU	The brain is a complex organ made up of many different functional and structural regions consisting of different types of cells such as neurons and glia, as well as complex anatomical geometries. It is hypothesized that the different regions of the brain exhibit significantly different mechanical properties, which may be attributed to the diversity of cells and anisotropy of neuronal fibers within individual brain regions. The regional dynamic mechanical properties of P56 mouse brain tissue in vitro and in situ at velocities of 0.71-4.28 mm/s, up to a deformation of 70 mu m are presented and discussed in the context of traumatic brain injury. The experimental data obtained from micro-indentation measurements were fit to three hyperelastic material models using the inverse Finite Element method. The cerebral cortex elicited a stiffer response than the cerebellum, thalamus, and medulla oblongata regions for all velocities. The thalamus was found to be the least sensitive to changes in velocity, and the medulla oblongata was most compliant. The results show that different regions of the mouse brain possess significantly different mechanical properties, and a significant difference also exists between the in vitro and in situ brain.	[MacManus, David B.; Pierrat, Baptiste; Gilchrist, Michael D.] Univ Coll Dublin, Sch Mech & Mat Engn, Dublin 2, Ireland; [Murphy, Jeremiah G.] Dublin City Univ, Dept Mech & Mfg Engn, Dublin 9, Ireland	Gilchrist, MD (corresponding author), Univ Coll Dublin, Sch Mech & Mat Engn, Dublin 2, Ireland.	michael.gilchrist@ucd.ie		MacManus, David/0000-0003-2959-698X; Pierrat, Baptiste/0000-0001-8064-8496	Science Foundation IrelandScience Foundation IrelandEuropean Commission [12/IP/1732]	This work was supported by Science Foundation Ireland (Grant No. 12/IP/1732).	Atkin R. J., 2005, INTRO THEORY ELASTIC, P79; Azevedo FAC, 2009, J COMP NEUROL, V513, P532, DOI 10.1002/cne.21974; Efremov YM, 2011, ACTA NATURAE, V3, P93, DOI 10.32607/20758251-2011-3-3-93-99; El Sayed T, 2008, COMPUT METHOD APPL M, V197, P4692, DOI 10.1016/j.cma.2008.06.006; Elkin BS, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025386; Elkin BS, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4004494; Elkin BS, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000164; England M. A., 1996, COLOUR ATLAS BRAIN S, P10; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Ferrer I, 2007, J NEUROPATH EXP NEUR, V66, P35, DOI 10.1097/nen.0b013e31802c3e7d; Finan JD, 2012, ANN BIOMED ENG, V40, P70, DOI 10.1007/s10439-011-0394-2; Fountoulakis M, 2001, EXP NEUROL, V167, P86, DOI 10.1006/exnr.2000.7529; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Giordano C, 2014, J BIOMECH, V47, P1052, DOI 10.1016/j.jbiomech.2013.12.036; Ho J, 2007, J BIOMECH, V40, P3006, DOI 10.1016/j.jbiomech.2007.02.011; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hrapko M, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2907746; Iivarinen J. T., 2013, SKIN RES TECHNOL, P1; Jin X, 2013, J BIOMECH, V46, P2795, DOI 10.1016/j.jbiomech.2013.09.001; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Lin DC, 2009, BIOMECH MODEL MECHAN, V8, P345, DOI 10.1007/s10237-008-0139-9; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; MacManus DB, 2015, J BIOMECH, V48, P3213, DOI 10.1016/j.jbiomech.2015.06.028; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; Mihai LA, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2015.0486; Moerman KM, 2009, J BIOMECH, V42, P1150, DOI 10.1016/j.jbiomech.2009.02.016; Mooney M, 1940, J APPL PHYS, V11, P582, DOI 10.1063/1.1712836; OGDEN RW, 1972, PROC R SOC LON SER-A, V326, P565, DOI 10.1098/rspa.1972.0026; Pervin F, 2011, NEUROIMAGE, V54, pS98, DOI 10.1016/j.neuroimage.2010.03.077; Prevost TP, 2011, ACTA BIOMATER, V7, P4090, DOI 10.1016/j.actbio.2011.06.032; Rashid B, 2013, J MECH BEHAV BIOMED, V28, P71, DOI 10.1016/j.jmbbm.2013.07.017; Rashid B, 2014, J MECH BEHAV BIOMED, V33, P43, DOI 10.1016/j.jmbbm.2012.07.015; Rashid B, 2012, J MECH BEHAV BIOMED, V10, P23, DOI 10.1016/j.jmbbm.2012.01.022; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sharp AA, 2009, IEEE T BIO-MED ENG, V56, P45, DOI 10.1109/TBME.2008.2003261; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; van Dommelen JAW, 2010, J MECH BEHAV BIOMED, V3, P158, DOI 10.1016/j.jmbbm.2009.09.001; Weissenberger C. A., 2010, EXPT TRANSLATIONAL M, V2; Willinger R, 1999, CR ACAD SCI II B, V327, P125, DOI 10.1016/S1287-4620(99)80021-0; Xu G, 2009, BIOMECH MODEL MECHAN, V8, P253, DOI 10.1007/s10237-008-0131-4; Zhang J, 2011, J BIOMECH, V44, P1909, DOI 10.1016/j.jbiomech.2011.04.034	43	24	24	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	FEB 22	2016	6								21569	10.1038/srep21569			9	Multidisciplinary Sciences	Science & Technology - Other Topics	DE3BJ	WOS:000370501500001	26898475	DOAJ Gold, Green Published			2021-06-18	
J	Colantonio, A				Colantonio, Angela			Sex, Gender, and Traumatic Brain Injury: A Commentary	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain concussion; Brain injuries; Gender identity; Rehabilitation; Sex; Women	HEALTH; WOMEN; TRANSITION; OUTCOMES; ADULTS; WORK	The goal of this supplemental issue is to address major knowledge, research, and clinical practice gaps regarding the limited focus on brain injury in girls and women as well as limited analysis of the effect of sex and gender in research on acquired brain injury. Integrating sex and gender in research is recognized as leading to better science and, ultimately, to better clinical practice. A sex and gender analytical approach to rehabilitation research is crucial to understanding traumatic brain injury and improving quality of life outcomes for survivors. Put another way, the lack of focus on sex and gender reduces the rigor of research design, the generalizability of study findings, and the effectiveness of clinical implementation and knowledge dissemination practices. The articles in this supplement examine sex and gender using a variety of methodological approaches and research contexts. Recommendations for future research on acquired brain injury that consciously incorporates sex and gender are made throughout this issue. This supplement is a product of the Girls and Women with ABI Task Force of the American Congress of Rehabilitation Medicine. (C) 2016 by the American Congress of Rehabilitation Medicine	[Colantonio, Angela] Univ Toronto, Rehabil Sci Inst, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada; [Colantonio, Angela] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON M5G 1V7, Canada; [Colantonio, Angela] Univ Hlth Network, Toronto Rehabil Inst, Toronto, ON, Canada	Colantonio, A (corresponding author), Univ Toronto, Rehabil Sci Inst, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	angela.colantonio@utoronto.ca		Colantonio, Angela/0000-0003-2094-4765	Ontario Neurotrauma Foundation; Toronto Rehabilitation Institute University Health Network; Canadian Institutes of Health Research Research Chair in Gender, Work and Health [CGW-126580]; Saunderson Family Chair in Acquired Brain Injury Research at the Toronto Rehabilitation Institute	Supported by the Ontario Neurotrauma Foundation and the Toronto Rehabilitation Institute University Health Network as well as through a Canadian Institutes of Health Research Research Chair in Gender, Work and Health (#CGW-126580) and the Saunderson Family Chair in Acquired Brain Injury Research at the Toronto Rehabilitation Institute.	Albrecht J.S., 2015, J HEAD TRAUMA REHABI; Canadian Institutes of Health Research -Institute of Gender and Health, ONL TRAIN MOD INT SE; Canadian Institutes of Health Research -Institute of Gender and Health, DEF SEX GEND; Cancelliere C, 2016, ARCH PHYS MED REHAB, V97, pS5, DOI 10.1016/j.apmr.2014.11.028; Chang VC, 2015, AM J IND MED, V58, P353, DOI 10.1002/ajim.22418; Chang VC, 2014, OCCUP ENVIRON MED, V71, P695, DOI 10.1136/oemed-2014-102097; Clayton JA, 2014, NATURE, V509, P282, DOI 10.1038/509282a; Cohen PN, 2013, SOCIOL COMPASS, V7, P889, DOI 10.1111/soc4.12083; Corrigan John D., 2003, American Journal of Obstetrics and Gynecology, V188, pS71, DOI 10.1067/mob.2003.404; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; Despins EH, 2016, ARCH PHYS MED REHAB, V97, pS26, DOI 10.1016/j.apmr.2014.06.023; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gahagan J, 2015, INT J EQUITY HEALTH, V14, DOI 10.1186/s12939-015-0144-4; Government of Canada, GEND BAS AN PLUS; Haag HL, 2016, ARCH PHYS MED REHAB, V97, pS64, DOI 10.1016/j.apmr.2014.12.018; Harris JE, 2012, BRAIN INJURY, V26, P177, DOI 10.3109/02699052.2011.635361; Iverson KM, 2011, WOMEN HEALTH ISS, V21, pS210, DOI 10.1016/j.whi.2011.04.019; Johnson JL, 2009, INT J EQUITY HEALTH, V8, DOI 10.1186/1475-9276-8-14; Krieger N, 2003, INT J EPIDEMIOL, V32, P652, DOI 10.1093/ije/dyg156; Kwako LE, 2011, TRAUMA VIOLENCE ABUS, V12, P115, DOI 10.1177/1524838011404251; Lindsay S, 2016, ARCH PHYS MED REHAB, V97, pS33, DOI 10.1016/j.apmr.2014.04.032; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; Nalder E, 2016, ARCH PHYS MED REHAB, V97, pS46, DOI 10.1016/j.apmr.2014.07.428; National Institutes of Health -Office of Research on Women's Health, WHATS DIFF SEX GEND; National Institutes of Health -Office of Research on Women's Health, SCI SEX GEND HUM HLT; Oliffe JL, 2008, J MENS HEALTH, V5, P194, DOI 10.1016/j.jomh.2008.03.016; Raukar NP, 2014, ACAD EMERG MED, V21, P1370, DOI 10.1111/acem.12535; Saverino C, 2015, ARCH PHYS MED REHABI; Sharman Z, 2012, SOC SCI MED, V74, P1812, DOI 10.1016/j.socscimed.2011.08.039; Stergiou-Kita M, 2016, ARCH PHYS MED REHAB, V97, pS40, DOI 10.1016/j.apmr.2015.04.008; The Cochrane Collaboration -Sex and Gender Methods Group, WHY SEX GEND MATT SY; Toor GK, 2016, ARCH PHYS MED REHAB, V97, pS54, DOI 10.1016/j.apmr.2015.02.010; World Health Organization, SOC DET HLTH WOM GEN; Wright DW, 2014, ACAD EMERG MED, V21, P1414, DOI 10.1111/acem.12532	34	24	24	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2016	97	2		1			S1	S4		10.1016/j.apmr.2015.12.002			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	DC4RI	WOS:000369207600001	26804988	Bronze			2021-06-18	
J	Hackenberg, K; Unterberg, A				Hackenberg, K.; Unterberg, A.			Traumatic brain injury	NERVENARZT			German	Article						Traumatic brain injury; Glasgow coma score; Pathophysiology; Brain edema; Intracranial pressure	CEREBRAL PERFUSION-PRESSURE; HEAD-INJURY; SPREADING DEPRESSION; INTRACEREBRAL MICRODIALYSIS; COMPUTED-TOMOGRAPHY; HYPERTONIC SALINE; BLOOD-FLOW; RESUSCITATION; IMPACT; EPIDEMIOLOGY	Since traumatic brain injury is the most common cause of long-term disability and death among young adults, it represents an enormous socio-economic and healthcare burden. As a consequence of the primary lesion, a perifocal brain edema develops causing an elevation of the intracranial pressure due to the limited intracranial space. This entails a reduction of the cerebral perfusion pressure and the cerebral blood flow. A cerebral perfusion deficit below the threshold for ischemia leads to further ischemic lesions and to a progression of the contusion. As the irreversible primary lesion can only be inhibited by primary prevention, the therapy of traumatic brain injury focuses on the secondary injuries. The treatment consists of surgical therapy evacuating the space-occupying intracranial lesion and conservative intensive medical care. Due to the complex pathophysiology the therapy of traumatic brain injury should be rapidly performed in a neurosurgical unit.	[Hackenberg, K.; Unterberg, A.] Univ Klinikum Heidelberg, Neurochirurg Klin, Neuenheimer Feld 400, D-69120 Heidelberg, Germany	Hackenberg, K (corresponding author), Univ Klinikum Heidelberg, Neurochirurg Klin, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	katharina.hackenberg@gmail.com					Andrews PJD, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-8; Bauer H, 2005, NEUROGLIA, P325; Bostrom K, 1986, Acta Neurochir Suppl (Wien), V36, P51; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOURKE RS, 1972, J NEUROCHEM, V19, P663, DOI 10.1111/j.1471-4159.1972.tb01383.x; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS87; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS65; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bullock M Ross, 2006, Neurosurgery, V58, pS7; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1987, J NEUROSCI, V7, P369; Cooper DJ, 2013, J NEUROTRAUM, V30, P512, DOI 10.1089/neu.2012.2573; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Engstrom M, 2005, J NEUROSURG, V102, P460, DOI 10.3171/jns.2005.102.3.0460; Greenberg MS, 2010, HDB NEUROSURGERY, V7, P850; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Heo JH, 2005, FREE RADICAL BIO MED, V39, P51, DOI 10.1016/j.freeradbiomed.2005.03.035; Herold G, 2012, INN MED, P700; JENNETT B, 1976, LANCET, V1, P1031; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; Krantz K P, 1986, Acta Neurochir Suppl (Wien), V36, P47; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; KUROIWA T, 1985, ACTA NEUROPATHOL, V66, P3, DOI 10.1007/BF00698288; Kuschinsky W, 2005, PHYSIOLOGIE, P50; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; Lee JM, 2000, J CLIN INVEST, V106, P723, DOI 10.1172/JCI11003; Marion DW, 2006, NEUROSURGERY, V58, P655; Mortazavi MM, 2012, J NEUROSURG, V116, P210, DOI 10.3171/2011.7.JNS102142; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Myburgh JA, 2012, NEW ENGL J MED, V367, P1901, DOI 10.1056/NEJMoa1209759; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Piek J, 2010, EUR MAN MED, P249, DOI 10.1007/978-3-540-79565-0_8; Polderman KH, 2009, CRIT CARE MED, V37, P1101, DOI 10.1097/CCM.0b013e3181962ad5; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; Rickels E, 2010, BRAIN INJURY, V24, P1491, DOI 10.3109/02699052.2010.498006; Roberts I, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000033.pub2; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Samandouras G., 2010, NEUROSURGEONS HDB, P207; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Somjen GG, 2001, PHYSIOL REV, V81, P1065; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Steudel WI, 2005, ACTA NEUROCHIR, V147, P231, DOI 10.1007/s00701-004-0441-y; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TEASDALE G, 1974, LANCET, V2, P81; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vespa P, 2002, ACTA NEUROCHIR SUPPL, V81, P355; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Watts DD, 1998, J TRAUMA, V44, P846, DOI 10.1097/00005373-199805000-00017; YOUNG W, 1987, STROKE, V18, P751, DOI 10.1161/01.STR.18.4.751; Zhang MY, 2012, J MOL NEUROSCI, V46, P631, DOI 10.1007/s12031-011-9651-y	62	24	27	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0028-2804	1433-0407		NERVENARZT	Nervenarzt	FEB	2016	87	2					203	214		10.1007/s00115-015-0051-3			12	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	DD9PD	WOS:000370257100012	26810405				2021-06-18	
J	Kasamatsu, T; Cleary, M; Bennett, J; Howard, K; McLeod, TV				Kasamatsu, Tricia; Cleary, Michelle; Bennett, Jason; Howard, Keith; McLeod, Tamara Valovich			Examining Academic Support After Concussion for the Adolescent Student-Athlete: Perspectives of the Athletic Trainer	JOURNAL OF ATHLETIC TRAINING			English	Article						sport-related concussion; academic accommodations; return to learn	COGNITIVE REST; RETURN; RECOMMENDATIONS; MANAGEMENT; KNOWLEDGE; LEARN	Context: Student-athletes may require cognitive rest and academic support after concussion. Athletic trainers (ATs) in secondary schools are uniquely positioned to provide medical care and to collaborate with school professionals while managing concussions. However, little is known regarding return-to-learn policies and their implementation in secondary schools. Objective: To examine ATs' perspectives on return to learn, cognitive rest, and communication with school professionals after concussion. Design: Cross-sectional study. Setting: Web-based survey. Patients or Other Participants: A total of 1124 secondary school ATs completed the survey (28.5% response rate). The majority of participants were employed full time (752/1114 [67.5%]) in public schools (911/1117 [81.6%]). Main Outcome Measure(s): School and AT employment characteristics, demographics, number of concussions evaluated annually, and perceptions of school professionals' familiarity with ATs' responsibilities were independent variables. Results: Of the ATs, 44% reported having an existing return-to-learn policy. The strongest predictor of a return-to-learn policy was frequent communication with teachers after concussion (odds ratio = 1.5; 95% confidence interval = 1.2, 1.7). Most ATs recommended complete cognitive rest (eg, no reading, television; 492/1087 [45.3%]) or limited cognitive activity based upon symptoms (391/1087 [36.0%]). Common academic accommodations were postponed due dates (789/954 [82.7%]), rest breaks (765/954 [80.2%]), and partial attendance (740/954 [77.6%]). Athletic trainers self-reported as primary monitors of health (764/1037 [73.7%]) and academic progression (359/1011 [35.5%]). The strongest predictor of ATs' communication with school professionals was their perception of school professionals' understanding of ATs' roles. Conclusions: Overall, ATs followed best practices for cognitive rest and return to learn after concussion. Although ATs are central to the management of student-athletes' physical health after concussion, school professionals may be better suited to monitor academic progress. Increased communication between the AT and school professionals is recommended to monitor recovery and facilitate academic support for symptomatic student-athletes.	[Kasamatsu, Tricia] Calif State Univ Fullerton, 800 North State Coll Blvd, Fullerton, CA 92831 USA; [Cleary, Michelle; Bennett, Jason; Howard, Keith] Chapman Univ, Orange, CA USA; [McLeod, Tamara Valovich] AT Still Univ, Mesa, AZ USA	Kasamatsu, T (corresponding author), Calif State Univ Fullerton, 800 North State Coll Blvd, Fullerton, CA 92831 USA.	tkasamatsu@fullerton.edu	McLeod, Tamara/AAU-9435-2020	Kasamatsu, Tricia M./0000-0002-6911-6955			Adams WM, 2014, J ATHL TRAINING, V49, P469, DOI 10.4085/1062-6050-49.3.01; [Anonymous], 2013, REAP BEN GOOD CONC M; [Anonymous], 2012, HEADS SCH KNOW YOUR; Arbogast KB, 2013, CLIN PEDIATR, V52, P397, DOI 10.1177/0009922813478160; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Carson JD, 2014, CAN FAM PHYSICIAN, V60, pE310; Covassin T, 2013, BRAIN INJURY, V27, P1589, DOI 10.3109/02699052.2013.823656; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Heyer GL, 2015, J PEDIATR-US, V166, P594, DOI 10.1016/j.jpeds.2014.09.038; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; Mensch J, 2005, J ATHL TRAINING, V40, P333; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Olympia RP, 2016, CLIN J SPORT MED, V26, P115, DOI 10.1097/JSM.0000000000000208; Popoli DM, 2014, CLIN PEDIATR, V53, P217, DOI 10.1177/0009922813499070; Ransom DM, 2015, PEDIATRICS, V135, P1043, DOI 10.1542/peds.2014-3434; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Williams RM, 2015, J ATHL TRAINING, V50, P262, DOI 10.4085/1062-6050-49.3.81; Williams RM, 2014, SPORTS HEALTH, V6, P434, DOI 10.1177/1941738114545612; Wing R, 2016, CLIN PEDIATR, V55, P228, DOI 10.1177/0009922815592879; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	25	24	24	0	8	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	FEB	2016	51	2					153	161		10.4085/1062-6050-51.4.02			9	Sport Sciences	Sport Sciences	DK2OW	WOS:000374755300007	26942658	Bronze, Green Published			2021-06-18	
J	Elkahloun, AG; Hafko, R; Saavedra, JM				Elkahloun, Abdel G.; Hafko, Roman; Saavedra, Juan M.			An integrative genome-wide transcriptome reveals that candesartan is neuroprotective and a candidate therapeutic for Alzheimer's disease	ALZHEIMERS RESEARCH & THERAPY			English	Article						Alzheimer's disease; Neurodegenerative disorders; Glutamate excitotoxicity; Neuroprotection; Angiotensin II receptor blockers; IPA analysis; GEO database; GSEA	AT(1) RECEPTOR BLOCKADE; APOLIPOPROTEIN-E PROTECTS; INNATE IMMUNE-RESPONSE; TRAUMATIC BRAIN-INJURY; METHYL-D-ASPARTATE; FACTOR-KAPPA-B; AMYLOID-BETA; INFLAMMATORY RESPONSE; OXIDATIVE STRESS; AT(1)-RECEPTOR BLOCKER	Background: Alzheimer's disease is the most frequent age-related dementia, and is currently without treatment. To identify possible targets for early therapeutic intervention we focused on glutamate excitotoxicity, a major early pathogenic factor, and the effects of candesartan, an angiotensin receptor blocker of neuroprotective efficacy in cell cultures and rodent models of Alzheimer's disease. The overall goal of the study was to determine whether gene analysis of drug effects in a primary neuronal culture correlate with alterations in gene expression in Alzheimer's disease, thus providing further preclinical evidence of beneficial therapeutic effects. Methods: Primary neuronal cultures were treated with candesartan at neuroprotective concentrations followed by excitotoxic glutamate amounts. We performed genome-wide expression profile analysis and data evaluation by ingenuity pathway analysis and gene set enrichment analysis, compared with alterations in gene expression from two independent published datasets identified by microarray analysis of postmortem hippocampus from Alzheimer's disease patients. Preferential expression in cerebrovascular endothelial cells or neurons was analyzed by comparison to published gene expression in these cells isolated from human cortex by laser capture microdissection. Results: Candesartan prevented glutamate upregulation or downregulation of several hundred genes in our cultures. Ingenuity pathway analysis and gene set enrichment analysis revealed that inflammation, cardiovascular disease and diabetes signal transduction pathways and amyloid beta metabolism were major components of the neuronal response to glutamate excitotoxicity. Further analysis showed associations of glutamate-induced changes in the expression of several hundred genes, normalized by candesartan, with similar alterations observed in hippocampus from Alzheimer's disease patients. Gene analysis of neurons and cerebrovascular endothelial cells obtained by laser capture microdissection revealed that genes up- and downregulated by glutamate were preferentially expressed in endothelial cells and neurons, respectively. Conclusions: Our data may be interpreted as evidence of direct candesartan neuroprotection beyond its effects on blood pressure, revealing common and novel disease mechanisms that may underlie the in vitro gene alterations reported here and glutamate-induced cell injury in Alzheimer's disease. Our observations provide novel evidence for candesartan neuroprotection through early molecular mechanisms of injury in Alzheimer's disease, supporting testing this compound in controlled clinical studies in the early stages of the illness.	[Elkahloun, Abdel G.] NHGRI, Comparat Genom & Canc Genet Branch, NIH, Bethesda, MD 20892 USA; [Hafko, Roman; Saavedra, Juan M.] NIMH, Sect Pharmacol, NIH, Bethesda, MD 20892 USA; [Saavedra, Juan M.] Georgetown Univ, Med Ctr, Dept Pharmacol & Physiol, Med Dent SE402, 3900 Reservoir Rd, Washington, DC 20057 USA	Saavedra, JM (corresponding author), NIMH, Sect Pharmacol, NIH, Bethesda, MD 20892 USA.; Saavedra, JM (corresponding author), Georgetown Univ, Med Ctr, Dept Pharmacol & Physiol, Med Dent SE402, 3900 Reservoir Rd, Washington, DC 20057 USA.	jms522@georgetown.edu	Saavedra, Juan/AAO-7149-2020		National Human Genome Research Institute, National Institutes of Health, Bethesda [MD 20892]; National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, USA [MH 002762-16]; Division of Intramural Research ProgramsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL HUMAN GENOME RESEARCH INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI) [ZICHG200365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [Z01MH002762] Funding Source: NIH RePORTER	AGE was supported by the National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892. RH and JMS were supported by the Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, USA (MH 002762-16).	AbdAlla S, 2013, INT J MOL SCI, V14, P16917, DOI 10.3390/ijms140816917; Abel S, 2004, J IMMUNOL, V172, P6362, DOI 10.4049/jimmunol.172.10.6362; Anderson C, 2010, J HYPERTENS, V28, P429, DOI 10.1097/HJH.0b013e3283371355; Ando H, 2004, STROKE, V35, P1726, DOI 10.1161/01.STR.0000129788.26346.18; Asai M, 2003, BIOCHEM BIOPH RES CO, V301, P231, DOI 10.1016/S0006-291X(02)02999-6; Ashabi G, 2013, BASIC CLIN PHARMACOL, V112, P145, DOI 10.1111/bcpt.12000; Ashby EL, 2013, EXPERT OPIN INV DRUG, V22, P1229, DOI 10.1517/13543784.2013.812631; Ben Menachem-Zidon O, 2014, NEUROPSYCHOPHARMACOL, V39, P401, DOI 10.1038/npp.2013.208; Benicky J, 2011, NEUROPSYCHOPHARMACOL, V36, P857, DOI 10.1038/npp.2010.225; Bian C, 2014, J MOL NEUROSCI, V54, P271, DOI 10.1007/s12031-014-0285-8; Blair LJ, 2013, J CLIN INVEST, V123, P4158, DOI 10.1172/JCI69003; Blalock EM, 2004, P NATL ACAD SCI USA, V101, P2173, DOI 10.1073/pnas.0308512100; Bobba A, 2014, BBA-BIOENERGETICS, V1837, P1338, DOI 10.1016/j.bbabio.2014.03.016; CHANG MS, 1994, J BIOL CHEM, V269, P25277; Chen CC, 2014, ONCOGENE, V33, P3648, DOI 10.1038/onc.2013.345; Chrysant SG, 2010, CURR CLIN PHARMACOL, V5, P89, DOI 10.2174/157488410791110742; Contestabile Antonio, 2002, Cerebellum, V1, P41, DOI 10.1080/147342202753203087; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Cuenda A, 2007, BBA-MOL CELL RES, V1773, P1358, DOI 10.1016/j.bbamcr.2007.03.010; Dandona P, 2003, J CLIN ENDOCR METAB, V88, P4496, DOI 10.1210/jc.2002-021836; Danielyan L, 2010, REJUV RES, V13, P195, DOI 10.1089/rej.2009.0944; Danysz W, 2012, BRIT J PHARMACOL, V167, P324, DOI 10.1111/j.1476-5381.2012.02057.x; Davies NM, 2011, J ALZHEIMERS DIS, V26, P699, DOI 10.3233/JAD-2011-110347; DELACRETAZ E, 1995, HYPERTENSION, V25, P14, DOI 10.1161/01.HYP.25.1.14; Deuss M, 2008, CURR ALZHEIMER RES, V5, P187, DOI 10.2174/156720508783954686; Esposito Z, 2013, CNS NEUROSCI THER, V19, P549, DOI 10.1111/cns.12095; Ewers M, 2010, EXP GERONTOL, V45, P75, DOI 10.1016/j.exger.2009.09.005; Fleegal-DeMotta MA, 2009, J CEREBR BLOOD F MET, V29, P640, DOI 10.1038/jcbfm.2008.158; Fogari R, 2004, EUR J CLIN PHARMACOL, V59, P863, DOI 10.1007/s00228-003-0717-9; Frankfurt M, 2015, HORM BEHAV, V74, P28, DOI 10.1016/j.yhbeh.2015.05.004; Gao XM, 1995, BRAIN RES, V703, P63, DOI 10.1016/0006-8993(95)01066-1; Giger T, 2010, GENOME BIOL EVOL, V2, P284, DOI 10.1093/gbe/evq018; Goruppi S, 2010, J BIOL CHEM, V285, P1577, DOI 10.1074/jbc.R109.080887; Ha JS, 2012, NEUROSCI LETT, V526, P112, DOI 10.1016/j.neulet.2012.08.023; Hajjar Ihab, 2009, BMC Geriatr, V9, P48, DOI 10.1186/1471-2318-9-48; Harris LW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003964; Hoe HS, 2005, J NEUROCHEM, V93, P145, DOI 10.1111/j.1471-4159.2004.03007.x; Hokama M, 2014, CEREB CORTEX, V24, P2476, DOI 10.1093/cercor/bht101; Iadecola C, 2013, NEURON, V80, P844, DOI 10.1016/j.neuron.2013.10.008; Igase M, 2012, INT J HYPERTENS, V2012, DOI 10.1155/2012/320648; Israelsson C, 2010, EUR J NEUROSCI, V31, P852, DOI 10.1111/j.1460-9568.2010.07105.x; Ito T, 2002, STROKE, V33, P2297, DOI 10.1161/01.STR.0000027274.03779.F3; Jin P, 2012, CLIN EXP PHARMACOL P, V39, P852, DOI 10.1111/j.1440-1681.2012.12000.x; Kelleher RJ, 2013, AM J CARDIOVASC DIS, V3, P197; Klohs J, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00032; Konstam MA, 2009, LANCET, V374, P1840, DOI 10.1016/S0140-6736(09)61913-9; Kramer D, 2010, METHODS MOL BIOL, V633, P233, DOI 10.1007/978-1-59745-019-5_17; Lane RM, 2005, J LIPID RES, V46, P949, DOI 10.1194/jlr.M400486-JLR200; Larrayoz IM, 2009, J HYPERTENS, V27, P2365, DOI 10.1097/HJH.0b013e3283314bc7; Latta CH, 2015, NEUROSCIENCE, V302, P103, DOI 10.1016/j.neuroscience.2014.09.061; Lau A, 2010, PFLUG ARCH EUR J PHY, V460, P525, DOI 10.1007/s00424-010-0809-1; Lee CW, 2014, CURR ALZHEIMER RES, V11, P4, DOI 10.2174/1567205010666131119234308; Lee Hae Young, 2009, J Vis Exp, DOI 10.3791/990; Lee HP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028033; Lee Y, 2004, NEUROCHEM INT, V44, P107, DOI 10.1016/S0197-0186(03)00112-8; Lehmann SM, 2012, NAT NEUROSCI, V15, P827, DOI 10.1038/nn.3113; Li NC, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b5465; Liu L, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-175; Lyros E, 2014, CURR ALZHEIMER RES, V11, P18, DOI 10.2174/1567205010666131119235254; McArthur S, 2010, J IMMUNOL, V185, P6317, DOI 10.4049/jimmunol.1001095; Medeiros R, 2010, BEHAV BRAIN RES, V209, P165, DOI 10.1016/j.bbr.2010.01.040; Meng PF, 2013, NEUROSCI RES, V75, P94, DOI 10.1016/j.neures.2012.11.007; Michel MC, 2013, PHARMACOL REV, V65, P809, DOI 10.1124/pr.112.007278; Miners JS, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00238; Miyoshi M, 2008, EUR J NEUROSCI, V27, P343, DOI 10.1111/j.1460-9568.2007.06014.x; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Morkuniene R, 2015, J NEUROSCI RES, V93, P475, DOI 10.1002/jnr.23510; Mota SI, 2015, BBA-MOL BASIS DIS, V1852, P1428, DOI 10.1016/j.bbadis.2015.03.015; Mullane K, 2013, BIOCHEM PHARMACOL, V85, P289, DOI 10.1016/j.bcp.2012.11.014; Muresanu DF, 2014, CURR NEUROVASC RES, V11, P168, DOI 10.2174/1567202611666140408105333; Nelson L, 2014, J ALZHEIMERS DIS, V41, P331, DOI 10.3233/JAD-140024; Nishimura Y, 2000, STROKE, V31, P2478, DOI 10.1161/01.STR.31.10.2478; Oh J, 2014, EXP GERONTOL, V60, P87, DOI 10.1016/j.exger.2014.10.004; Palmer JC, 2012, J ALZHEIMERS DIS, V29, P853, DOI 10.3233/JAD-2012-111760; Pang T, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-102; Pang T, 2012, J HYPERTENS, V30, P87, DOI 10.1097/HJH.0b013e32834dde5f; Perez-Palma E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095413; Perry VH, 2014, NAT REV NEUROL, V10, P217, DOI 10.1038/nrneurol.2014.38; Petrone AB, 2014, MOL CELL ENDOCRINOL, V389, P40, DOI 10.1016/j.mce.2013.12.017; Phillips MI, 2008, J MOL MED, V86, P715, DOI 10.1007/s00109-008-0331-5; Piantadosi CA, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.207738; Quintanilla RA, 2004, EXP CELL RES, V295, P245, DOI 10.1016/j.yexcr.2004.01.002; Rincon F, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00024; Rouch L, 2015, CNS DRUGS, V29, P113, DOI 10.1007/s40263-015-0230-6; SAAVEDRA JM, 1992, ENDOCR REV, V13, P329, DOI 10.1210/er.13.2.329; Saavedra JM, 2012, CLIN SCI, V123, P567, DOI 10.1042/CS20120078; Saavedra JM, 2011, PSYCHONEUROENDOCRINO, V36, P1, DOI 10.1016/j.psyneuen.2010.10.001; Savoia C, 2007, CLIN SCI, V112, P375, DOI 10.1042/CS20060247; Shindo T, 2012, BIOL PHARM BULL, V35, P2141, DOI 10.1248/bpb.b12-00387; Sintes J, 2010, J LEUKOCYTE BIOL, V88, P687, DOI 10.1189/jlb.1109756; Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takeda S, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00171; Talantova M, 2013, P NATL ACAD SCI USA, V110, pE2518, DOI 10.1073/pnas.1306832110; Thies W, 2013, ALZHEIMERS DEMENT, V9, P208, DOI 10.1016/j.jalz.2013.02.003; Tian MJ, 2013, FEBS LETT, V587, P818, DOI 10.1016/j.febslet.2013.01.060; Tian MJ, 2012, FEBS LETT, V586, P3737, DOI 10.1016/j.febslet.2012.09.004; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; Trenkwalder P, 2002, J HUM HYPERTENS, V16, pS71, DOI 10.1038/sj.jhh.1001443; Tsukuda K, 2009, HYPERTENSION, V54, P782, DOI 10.1161/HYPERTENSIONAHA.109.136879; de la Torre AV, 2013, PHARMACOL RES, V70, P116, DOI 10.1016/j.phrs.2013.01.007; Villapol S, 2015, AM J HYPERTENS, V28, P289, DOI 10.1093/ajh/hpu197; Villapol S, 2012, NEUROPSYCHOPHARMACOL, V37, P2817, DOI 10.1038/npp.2012.152; Wang F, 2015, NEUROBIOL AGING, V36, P111, DOI 10.1016/j.neurobiolaging.2014.06.029; Wang J, 2014, NEUROPHARMACOLOGY, V79, P249, DOI 10.1016/j.neuropharm.2013.11.022; Wang J, 2007, J CLIN INVEST, V117, P3393, DOI 10.1172/JCI31547; Wiesmann M, 2013, J CEREBR BLOOD F MET, V33, P1696, DOI 10.1038/jcbfm.2013.159; Wu X, 2010, BRIT J PHARMACOL, V161, P33, DOI 10.1111/j.1476-5381.2010.00840.x; Wyss-Coray T, 2000, AM J PATHOL, V156, P139, DOI 10.1016/S0002-9440(10)64713-X; Yu X, 2012, BEHAV BRAIN RES, V235, P200, DOI 10.1016/j.bbr.2012.07.045; Zhao W, 2009, J ALZHEIMERS DIS, V16, P49, DOI 10.3233/JAD-2009-0925; Zhou J, 2005, J CEREBR BLOOD F MET, V25, P878, DOI 10.1038/sj.jcbfm.9600082; Zhou Q, 2015, ANN NEUROL, V77, P637, DOI 10.1002/ana.24361; Zhou S, 2013, FEBS LETT, V587, P254, DOI 10.1016/j.febslet.2012.12.003; Zhu DL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016037	115	24	26	0	17	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1758-9193		ALZHEIMERS RES THER	Alzheimers Res. Ther.	JAN 28	2016	8								5	10.1186/s13195-015-0167-5			18	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DB8HV	WOS:000368758700001	26822027	DOAJ Gold, Green Published			2021-06-18	
J	Meng, XE; Zhang, Y; Li, N; Fan, DF; Yang, C; Li, H; Guo, DZ; Pan, SY				Meng, Xiang-En; Zhang, Yu; Li, Na; Fan, Dan-Feng; Yang, Chen; Li, Hang; Guo, Da-Zhi; Pan, Shu-Yi			Hyperbaric Oxygen Alleviates Secondary Brain Injury After Trauma Through Inhibition of TLR4/NF-kappa B Signaling Pathway	MEDICAL SCIENCE MONITOR			English	Article						Brain Injuries; Hyperbaric Oxygenation; Toll-Like Receptor 4	MICROGLIAL ACTIVATION; INFLAMMATION; TLR4; RAT	Background: The aim of this study was to investigate the efficacy of hyperbaric oxygen in secondary brain injury after trauma and its mechanism in a rat model. Material/Methods: A rat model of TBI was constructed using the modified Feeney's free-fall method, and 60 SD rats were randomly divided into three groups - the sham group, the untreated traumatic brain injury (TBI) group, and the hyperbaric oxygen-treated TBI group. The neurological function of the rats was evaluated 12 and 24 hours after TBI modeling; the expression levels of TLR4, I kappa B, p65, and cleaved caspase-3 in the peri-trauma cortex were determined by Western blot; levels of TNF-alpha, IL-6, and IL-1 beta were determined by ELISA; and apoptosis of the neurons was evaluated by TUNEL assay 24 hours after TBI modeling. Results: Hyperbaric oxygen therapy significantly inhibited the activation of the TLR4/NF-kappa B signaling pathway, reduced the expression of cleaved caspase-3, TNF-alpha, IL-6 and IL-1 beta (P<0.05), reduced apoptosis of the neurons and improved the neurological function of the rats (P<0.05). Conclusions: Hyperbaric oxygen therapy protects the neurons after traumatic injury, possibly through inhibition of the TLR4/NF-kappa B signaling pathway.	[Meng, Xiang-En; Zhang, Yu; Li, Na; Fan, Dan-Feng; Yang, Chen; Li, Hang; Guo, Da-Zhi; Pan, Shu-Yi] Navy Gen Hosp, Dept Hyperbar Oxygen, Beijing, Peoples R China	Pan, SY (corresponding author), Navy Gen Hosp, Dept Hyperbar Oxygen, Beijing, Peoples R China.	shuyipan_oooo@126.com					Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Boussi-Gross R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079995; Fang H, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-27; Lim SW, 2013, J SURG RES, V184, P1076, DOI 10.1016/j.jss.2013.04.070; Liu Y, 2014, CLIN REV ALLERG IMMU, V47, P136, DOI 10.1007/s12016-013-8402-y; Mattson MP, J CLIN INVEST, V107, P247; Si DW, 2014, EXP THER MED, V8, P1010, DOI 10.3892/etm.2014.1840; Wang GH, 2010, J NEUROTRAUM, V27, P1733, DOI 10.1089/neu.2009.1175; Wang Y, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/124614; Yao LL, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-23; Zhang DD, 2014, NEUROCHEM INT, V75, P11, DOI 10.1016/j.neuint.2014.05.003; Zhu BF, 2010, CLIN EMERGENCY, V11, P204	13	24	27	0	3	INT SCIENTIFIC LITERATURE, INC	SMITHTOWN	361 FOREST LANE, SMITHTOWN, NY 11787 USA	1643-3750			MED SCI MONITOR	Med. Sci. Monitor	JAN 26	2016	22						284	288		10.12659/MSM.894148			5	Medicine, Research & Experimental	Research & Experimental Medicine	DC0EY	WOS:000368891200002	26812205	Green Published			2021-06-18	
J	Meehan, WP; Taylor, AM; Berkner, P; Sandstrom, NJ; Peluso, MW; Kurtz, MM; Pascual-Leone, A; Mannix, R				Meehan, William P., III; Taylor, Alex M.; Berkner, Paul; Sandstrom, Noah J.; Peluso, Mark W.; Kurtz, Matthew M.; Pascual-Leone, Alvaro; Mannix, Rebekah			Division III Collision Sports Are Not Associated with Neurobehavioral Quality of Life	JOURNAL OF NEUROTRAUMA			English	Article						athletics; chronic traumatic encephalopathy; concussions; head injury	CHRONIC TRAUMATIC ENCEPHALOPATHY; COLLEGIATE FOOTBALL PLAYERS; SUBCONCUSSIVE HEAD TRAUMA; LEAGUE PLAYER; IMPACTS; CONCUSSION; BRAIN; INJURY; COHORT	We sought to determine whether the exposure to the sub-concussive blows that occur during division III collegiate collision sports affect later life neurobehavioral quality-of-life measures. We conducted a cross-sectional study of alumni from four division III colleges, targeting those between the ages of 40-70 years, using several well-validated quality-of-life measures for executive function, general concerns, anxiety, depression, emotional and behavior dyscontrol, fatigue, positive affect, sleep disturbance, and negative consequences of alcohol use. We used multivariable linear regression to assess for associations between collision sport participation and quality-of-life measures while adjusting for covariates including age, gender, race, annual income, highest educational degree, college grades, exercise frequency, and common medical conditions. We obtained data from 3702 alumni, more than half of whom (2132) had participated in collegiate sports, 23% in collision sports, 23% in non-contact sports. Respondents with a history of concussion had worse self-reported health on several measures. When subjects with a history of concussion were removed from the analyses in order to assess for any potential effect of sub-concussive blows alone, negative consequences of alcohol use remained higher among collision sport athletes (-coefficient 1.957, 95% CI 0.827-3.086). There were, however, no other significant associations between exposure to collision sports during college and any other quality-of-life measures. Our results suggest that, in the absence of a history of concussions, participation in collision sports at the Division III collegiate level is not a risk factor for worse long-term neurobehavioral outcomes, despite exposure to repeated sub-concussive blows.	[Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA 02453 USA; [Meehan, William P., III; Taylor, Alex M.; Mannix, Rebekah] Boston Childrens Hosp, Brain Injury Ctr, Boston, MA USA; [Meehan, William P., III; Taylor, Alex M.] Boston Childrens Hosp, Sports Concuss Clin, Boston, MA USA; [Meehan, William P., III; Mannix, Rebekah] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Taylor, Alex M.] Boston Childrens Hosp, Dept Neurol, Boston, MA USA; [Berkner, Paul] Colby Coll, Hlth Serv, Waterville, ME 04901 USA; [Sandstrom, Noah J.] Williams Coll, Dept Psychol, Williamstown, MA 01267 USA; [Peluso, Mark W.] Middlebury Coll, Middlebury, VT 05753 USA; [Kurtz, Matthew M.] Wesleyan Univ, Dept Psychol, Middletown, CT USA; [Pascual-Leone, Alvaro] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA	Meehan, WP (corresponding author), Micheli Ctr Sports Injury Prevent, 9 Hope Ave,Suite 100, Waltham, MA 02453 USA.	william.meehan@childrens.harvard.edu	Pascual-Leone, Alvaro/AAC-5101-2019; Mannix, Rebekah/AAD-8702-2020	Pascual-Leone, Alvaro/0000-0001-8975-0382; 	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR025758] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD040128, R01HD069776, R21HD07616] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21 MH099196] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS085491, R01NS073601, R21 NS082870] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069776, T32HD040128] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD007616] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH099196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS082870, R01NS073601, R21NS085491] Funding Source: NIH RePORTER		Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Brenner J, 2007, J AM COLL HEALTH, V56, P267, DOI 10.3200/JACH.56.3.267-272; Broglio SP, 2012, EXERC SPORT SCI REV, V40, P138, DOI 10.1097/JES.0b013e3182524273; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gershon Richard C, 2010, J Appl Meas, V11, P304; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Harris D., 2012, ABC NEWS; Hinton PS, 2011, PHYSICIAN SPORTSMED, V39, P11, DOI 10.3810/psm.2011.09.1916; Johnson B, 2014, J NEUROTRAUM, V31, P1907, DOI 10.1089/neu.2014.3415; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Lorente FO, 2003, ALCOHOL ALCOHOLISM, V38, P427, DOI 10.1093/alcalc/agg105; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Robbins L., 2012, REAL CLEAR SPOR 1206; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Singh-Manoux A, 2012, BRIT MED J, V344, DOI 10.1136/bmj.d7622; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512	25	24	24	1	40	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2016	33	2					254	259		10.1089/neu.2015.3930			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DA7PH	WOS:000367995800011	26193380	Green Published			2021-06-18	
J	Yu, M; Zhang, Y; Chen, XY; Zhang, T				Yu, Mei; Zhang, Yuan; Chen, Xiaoyu; Zhang, Tao			Antidepressant-like effects and possible mechanisms of amantadine on cognitive and synaptic deficits in a rat model of chronic stress	STRESS-THE INTERNATIONAL JOURNAL ON THE BIOLOGY OF STRESS			English	Article						Amantadine; chronic stress; cognition; synaptic plasticity; NR2B; PSD-95	CHRONIC MILD STRESS; LONG-TERM POTENTIATION; TRAUMATIC BRAIN-INJURY; NMDA RECEPTOR; GLUTAMATE RELEASE; DENTATE GYRUS; WATER MAZE; DEPRESSION; PLASTICITY; HIPPOCAMPUS	The aim of this study was to examine whether amantadine (AMA), as a low-affinity noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, is able to improve cognitive deficits caused by chronic stress in rats. Male Wistar rats were divided into four groups: control, control + AMA, stress and stress + AMA groups. The chronic stress model combined chronic unpredictable stress (CUS) with isolated feeding. Animals were exposed to CUS continued for 21 days. AMA (25 mg/kg) was administrated p.o. for 20 days from the 4th day of CUS to the 23rd. Weight and sucrose consumption were measured during model establishing period. Spatial memory was evaluated using the Morris water maze (MWM) test. Following MWM testing, both long-term potentiation (LTP) and depotentiation were recorded in the hippocampal CA1 region. NR2B and postsynaptic density protein 95 (PSD-95) proteins were measured by Western-blot analysis. AMA increased weight and sucrose consumption of stressed rats. Spatial memory and reversal learning in stressed rats were impaired relative to controls, whereas AMA significantly attenuated cognitive impairment. AMA also mitigated the chronic stress-induced impairment of hippocampal synaptic plasticity, in which both the LTP and depotentiation were significantly inhibited in stressed rats. Moreover, AMA enhanced the expression of hippocampal NR2B and PSD-95 in stressed rats. The data suggest that AMA may be an effective therapeutic agent for depression-like symptoms and associated cognitive disturbances.	[Zhang, Tao] Nankai Univ, Coll Life Sci, Tianjin 300071, Peoples R China; [Zhang, Tao] Nankai Univ, Minist Educ, Key Lab Bioact Mat, Tianjin 300071, Peoples R China	Zhang, T (corresponding author), Nankai Univ, Coll Life Sci, Tianjin 300071, Peoples R China.; Zhang, T (corresponding author), Nankai Univ, Minist Educ, Key Lab Bioact Mat, Tianjin 300071, Peoples R China.	zhangtao@nankai.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31171053, 11232005]; Funds for National Basic Science Personnel Training [J1103503]; 111 ProjectMinistry of Education, China - 111 Project [B08011]	This work was supported by grants from the National Natural Science Foundation of China (31171053, 11232005), Funds for National Basic Science Personnel Training (J1103503) and 111 Project (B08011). The authors have no conflict of interest to declare.	Airaksinen E, 2004, PSYCHOL MED, V34, P83, DOI 10.1017/S0033291703008559; Alfarez DN, 2003, EUR J NEUROSCI, V17, P1928, DOI 10.1046/j.1460-9568.2003.02622.x; An L, 2013, ALCOHOL CLIN EXP RES, V37, P763, DOI 10.1111/acer.12040; An L, 2013, NEUROBIOL LEARN MEM, V100, P18, DOI 10.1016/j.nlm.2012.12.003; BALDESSARINI RJ, 1972, BIOCHEM PHARMACOL, V21, P77, DOI 10.1016/0006-2952(72)90252-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Casarotto PC, 2007, EUR NEUROPSYCHOPHARM, V17, P735, DOI 10.1016/j.euroneuro.2007.03.001; Cera N, 2014, NEUROPSYCH DIS TREAT, V10, P1093, DOI 10.2147/NDT.S54423; Collingridge GL, 2013, NEUROPHARMACOLOGY, V64, P13, DOI 10.1016/j.neuropharm.2012.06.051; Conrad CD, 2010, PROG NEURO-PSYCHOPH, V34, P742, DOI 10.1016/j.pnpbp.2009.11.003; Cousins SL, 2012, J BIOL CHEM, V287, P13465, DOI 10.1074/jbc.M111.292862; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Ehrlich I, 2007, P NATL ACAD SCI USA, V104, P4176, DOI 10.1073/pnas.0609307104; Fox CJ, 2006, HIPPOCAMPUS, V16, P907, DOI 10.1002/hipo.20230; Henningsen K, 2009, BEHAV BRAIN RES, V198, P136, DOI 10.1016/j.bbr.2008.10.039; Hosenbocus S, 2013, J CAN ACAD CHILD ADO, V22, P55; Huber TJ, 1999, PHARMACOPSYCHIATRY, V32, P47, DOI 10.1055/s-2007-979191; Jun D, 2010, J ECT, V26, P126, DOI 10.1097/YCT.0b013e3181a9947a; Kaefer V, 2010, J APPL TOXICOL, V30, P745, DOI 10.1002/jat.1550; Kim JJ, 2002, NAT REV NEUROSCI, V3, P453, DOI 10.1038/nrn849; Li B, 2003, J NEUROSCI, V23, P11244; Lou JS, 2010, PHARM BIOL, V48, P1328, DOI 10.3109/13880201003789440; Marsden WN, 2013, PROG NEURO-PSYCHOPH, V43, P168, DOI 10.1016/j.pnpbp.2012.12.012; McEwen BS, 2001, HUM PSYCHOPHARM CLIN, V16, pS7, DOI 10.1002/hup.266; Mizoguchi K, 2000, J NEUROSCI, V20, P1568; MORYL E, 1993, PHARMACOL TOXICOL, V72, P394, DOI 10.1111/j.1600-0773.1993.tb01351.x; Neves G, 2008, NAT REV NEUROSCI, V9, P65, DOI 10.1038/nrn2303; Nishikawa N, 2009, PARKINSONISM RELAT D, V15, P351, DOI 10.1016/j.parkreldis.2008.08.005; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Qi YJ, 2013, CEREB CORTEX, V23, P932, DOI 10.1093/cercor/bhs086; Quan MN, 2011, NEUROSCIENCE, V182, P88, DOI 10.1016/j.neuroscience.2011.03.026; Quan MN, 2011, BRAIN RES BULL, V85, P109, DOI 10.1016/j.brainresbull.2011.03.002; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Richter-Levin G, 1998, LEARN MEMORY, V4, P445, DOI 10.1101/lm.4.6.445; RICHTER-LEVIN G, 1995, BEHAV BRAIN RES, V66, P37, DOI 10.1016/0166-4328(94)00121-U; Rogoz Z, 2007, PHARMACOL REP, V59, P778; Rogoz Z, 2008, PHARMACOL REP, V60, P817; Sapolsky RM, 2000, ARCH GEN PSYCHIAT, V57, P925, DOI 10.1001/archpsyc.57.10.925; Stryjer R, 2003, INT CLIN PSYCHOPHARM, V18, P93, DOI 10.1097/00004850-200303000-00005; Szakacs Reka, 2012, Neuropsychopharmacol Hung, V14, P29; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Wang T, 2014, J NEUROTRAUM, V31, P370, DOI 10.1089/neu.2013.2917; Willner P, 2005, NEUROPSYCHOBIOLOGY, V52, P90, DOI 10.1159/000087097; Willner P, 1997, PSYCHOPHARMACOLOGY, V134, P319, DOI 10.1007/s002130050456; Xu P, 2012, PLOS ONE, V7; Zarate Carlos A, 2002, Psychopharmacol Bull, V36, P35	46	24	25	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1025-3890	1607-8888		STRESS	Stress	JAN 2	2016	19	1					104	113		10.3109/10253890.2015.1108302			10	Behavioral Sciences; Endocrinology & Metabolism; Neurosciences	Behavioral Sciences; Endocrinology & Metabolism; Neurosciences & Neurology	DB7JS	WOS:000368691800013	26466744				2021-06-18	
J	Heyer, GL; Fischer, A; Wilson, J; MacDonald, J; Cribbs, S; Ravindran, R; Pommering, TL; Cuff, S				Heyer, Geoffrey L.; Fischer, Anastasia; Wilson, Julie; MacDonald, James; Cribbs, Sarah; Ravindran, Reno; Pommering, Thomas L.; Cuff, Steven			Orthostatic Intolerance and Autonomic Dysfunction in Youth With Persistent Postconcussion Symptoms: A Head-Upright Tilt Table Study	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						orthostatic; autonomic; tilt table; concussion; TBI; pediatric; adolescent; postconcussion; dizziness; POTS	TRAUMATIC BRAIN-INJURY; POSTURAL TACHYCARDIA SYNDROME; CONCUSSION SYMPTOMS; RATE-VARIABILITY; UNITED-STATES; CHILDREN; EPIDEMIOLOGY; PREDICTORS; RECOVERY; SEX	Objective:To explore head-upright tilt table (HUT) signs of autonomic dysfunction in a cohort of youth with persistent postconcussion symptoms (PCSs) that include light-headedness and to correlate repeat tilt table results with symptom improvements for those patients found to have postural tachycardia syndrome (POTS) on initial testing.Design:Prospective cohort design.Setting:Nationwide Children's Hospital, Neurology Clinic.Participants:Thirty-four patients (13-18 years of age) with persistent PCSs.Main Outcome Measures:All patients underwent at least 1 tilt table test. The PCS Interview (PCS-I) and patient ratings of light-headedness and vertigo were used to measure symptom burden. Patients found to have POTS were asked to repeat tilt table testing when PCSs improved or 3 to 6 months after the initial test if symptoms persisted.Results:Twenty-four of the 34 (70.6%) patients had abnormal tilt table results with patients categorized as normal (n = 10), isolated syncope (n = 10), and POTS (n = 14). Patients with POTS had higher PCS-I scores than normal patients (P < 0.001) and higher ratings of light-headedness than both normal patients (P = 0.015) and syncope patients (P = 0.04). Twelve POTS patients underwent repeat tilt table testing, and 9 of 12 (75%) no longer met POTS diagnostic criteria. All patients with resolution of POTS had corresponding improvements in PCSs, including light-headedness and vertigo.Conclusions:Our study demonstrates a high rate of tilt table abnormalities among youth with persistent PCSs. Several patients with POTS had normalization of tilt table testing when PCSs improved. These findings warrant further research of autonomic dysfunction related to concussion.	[Heyer, Geoffrey L.] Nationwide Childrens Hosp, Div Pediat Neurol, Columbus, OH 43205 USA; [Heyer, Geoffrey L.] Ohio State Univ, Dept Neurol, Columbus, OH 43210 USA; [Fischer, Anastasia; MacDonald, James; Ravindran, Reno; Pommering, Thomas L.; Cuff, Steven] Nationwide Childrens Hosp, Div Sports Med, Columbus, OH 43205 USA; [Wilson, Julie] Childrens Hosp Colorado, Dept Orthoped, Aurora, CO USA; [Cribbs, Sarah] Childrens Alabama, Dept Pediat, Birmingham, AL USA; [Cribbs, Sarah] Childrens Alabama, Dept Orthoped, Birmingham, AL USA	Heyer, GL (corresponding author), Nationwide Childrens Hosp, Dept Pediat, 700 Childrens Dr,ED-5, Columbus, OH 43205 USA.	geoffrey.heyer@nationwidechildrens.org		MacDonald, James/0000-0002-0432-0808; Heyer, Geoffrey/0000-0001-9334-3739			Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Berz K, 2013, PHYSICIAN SPORTSMED, V41, P58, DOI 10.3810/psm.2013.05.2015; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Chrisman SP, 2013, BRAIN INJURY, V27, P1, DOI 10.3109/02699052.2012.722251; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Hajek CA, 2011, CHILD NEUROPSYCHOL, V17, P17, DOI 10.1080/09297049.2010.495058; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kanjwal K, 2010, CARDIOL J, V17, P482; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; Kimpinski K, 2012, MAYO CLIN PROC, V87, P746, DOI 10.1016/j.mayocp.2012.02.020; La Fountaine MF, 2009, AUTON NEUROSCI-BASIC, V148, P101, DOI 10.1016/j.autneu.2009.03.001; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Low PA, 2009, J CARDIOVASC ELECTR, V20, P352, DOI 10.1111/j.1540-8167.2008.01407.x; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8; Yang CC, 2009, BRAIN INJURY, V23, P299, DOI 10.1080/02699050902788543; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	29	24	24	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2016	26	1					40	45		10.1097/JSM.0000000000000183			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	DA2JB	WOS:000367620000006	25706664				2021-06-18	
J	Hong, Y; Sarntinoranont, M; Subhash, G; Canchi, S; King, MA				Hong, Y.; Sarntinoranont, M.; Subhash, G.; Canchi, S.; King, M. A.			Localized Tissue Surrogate Deformation due to Controlled Single Bubble Cavitation	EXPERIMENTAL MECHANICS			English	Article						Cavitation collapse; Traumatic brain injury; Agarose hydrogel; Shockwave; Brain tissue	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; STRAIN-RATE; MECHANICAL STRETCH; BLAST OVERPRESSURE; SOLID BOUNDARY; SLICE CULTURES; RAT-BRAIN; COLLAPSE; MODEL	Cavitation-induced shock wave, as might occur in the head during exposure to blast waves, was investigated as a possible damage mechanism for soft brain tissues. A novel experimental technique was developed to visualize and control single bubble cavitation and its collapse, and the influence of this process on a nearby tissue surrogate was investigated. The experiment utilized a Hopkinson pressure bar system which transmits a simulated blast pressure wave (with over-pressure and under-pressure components) to a fluid-filled test chamber implanted with a seed gas bubble. Growth and collapse of this bubble was recorded during passage of the blast wave with a high speed camera. To investigate the potential for cavitation damage to a tissue surrogate, local changes in strain were measured in hydrogel slices placed in various configurations next to the bubble. The strain measurements were made using digital image correlation (DIC) technique by monitoring the motion of material points on the tissue surrogate. In one configuration, bubble contact dynamics resulted in compression contact (> 60 mu s) followed by inertially-driven tension (> 140 mu s). In another configuration, the influence of local shock waves emanating from collapsed bubbles was captured. Large compressive strains (0.25 to 0.5) that were highly localized (0.18 mm(2)) were measured over a short time period (< 24 mu s) after bubble collapse. High bubble collapse pressures 29 to 125 times that of peak blast overpressure are predicted to be the source of these large strains. Consistent with theoretical predictions, these cavitation-based strains are far larger than the strains imposed by passage of the simulated blast wave alone. Finally, the value of this experimental platform to investigate the single bubble cavitation-induced damage in a biological tissue is illustrated with an example test on rat brain slices.	[Hong, Y.; Sarntinoranont, M.; Subhash, G.; Canchi, S.] Univ Florida, Dept Mech & Aerosp Engn, Gainesville, FL 32611 USA; [King, M. A.] Univ Florida, Dept Pharmacol & Therapeut, Gainesville, FL 32611 USA	Subhash, G (corresponding author), Univ Florida, Dept Mech & Aerosp Engn, Gainesville, FL 32611 USA.	subhash@ufl.edu	Subhash, Ghatu/J-4851-2017	Subhash, Ghatu/0000-0002-5996-0909	Army Research Office [W911NF-10-1-0276]	This research was funded by the Army Research Office award number W911NF-10-1-0276.	APFEL RE, 1991, ULTRASOUND MED BIOL, V17, P179, DOI 10.1016/0301-5629(91)90125-G; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; BENJAMIN TB, 1966, PHILOS TR R SOC S-A, V260, P221, DOI 10.1098/rsta.1966.0046; Blatteau JE, 2006, ANN FR ANESTH, V25, P874, DOI 10.1016/j.annfar.2006.04.007; Brennen C.E, 1995, CAVITATION BUBBLE DY; Cullen DK, 2007, BRAIN RES, V1158, P103, DOI 10.1016/j.brainres.2007.04.070; Cullen DK, 2006, J NEUROTRAUM, V23, P1304, DOI 10.1089/neu.2006.23.1304; Delius M, 2002, EUR SURG RES, V34, P30, DOI 10.1159/000048884; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Gateau J, 2013, ULTRASOUND MED BIOL, V39, P1812, DOI 10.1016/j.ultrasmedbio.2013.04.011; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Goeller J, 2012, J NEUROTRAUM, V29, P1970, DOI 10.1089/neu.2011.2224; Goldsmith W, 2001, CRIT REV BIOMED ENG, V29, P441, DOI 10.1615/CritRevBiomedEng.v29.i56.10; GROSS AG, 1958, J NEUROSURG, V15, P548, DOI 10.3171/jns.1958.15.5.0548; HARRISON M, 1952, J ACOUST SOC AM, V24, P454, DOI 10.1121/1.1917513; HARVEY EN, 1945, B NEW YORK ACAD MED, V21, P505; JONES IR, 1960, J FLUID MECH, V7, P596, DOI 10.1017/S0022112060000311; Kato K, 2007, J NEUROSURG, V106, P667, DOI 10.3171/jns.2007.106.4.667; KENNER VH, 1973, J BIOMECH, V6, P1, DOI 10.1016/0021-9290(73)90032-8; Kornfeld M, 1944, J APPL PHYS, V15, P495, DOI 10.1063/1.1707461; Kurosawa Y, 2009, IEEE ENG MED BIO, P7224, DOI 10.1109/IEMBS.2009.5335260; Lee SJ, 2011, J BIOMED MATER RES B, V97B, P84, DOI 10.1002/jbm.b.31789; Liu QL, 2006, MECH MATER, V38, P1105, DOI 10.1016/j.mechmat.2006.01.001; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; LUBOCK P, 1980, J BIOMECH, V13, P1041, DOI 10.1016/0021-9290(80)90048-2; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison B, 2000, J BIOMECH ENG-T ASME, V122, P224, DOI 10.1115/1.429650; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Nakase-Richardson R, 2013, ARCH PHYS MED REHAB, V94, P1861, DOI 10.1016/j.apmr.2013.05.027; Nyein MK, 2010, P NATL ACAD SCI USA, V107, P20703, DOI 10.1073/pnas.1014786107; Ohl CD, 2006, BIOPHYS J, V91, P4285, DOI [10.1529/biophysj.105.075366, 10.1529/biophysj.106.075366]; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pan B, 2007, OPT ENG, V46, DOI 10.1117/1.2714926; Pan B, 2009, MEAS SCI TECHNOL, V20, DOI 10.1088/0957-0233/20/6/062001; PLESSET MS, 1971, J FLUID MECH, V47, P283, DOI 10.1017/S0022112071001058; RAVICHANDRAN G, 1994, J AM CERAM SOC, V77, P263, DOI 10.1111/j.1151-2916.1994.tb06987.x; Rayleigh, 1917, PHILOS MAG, V34, P94, DOI 10.1080/14786440808635681; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Sarntinoranont M, 2012, J NEUROTRAUM, V29, P418, DOI 10.1089/neu.2011.1772; SHIMA A, 1981, J FLUID ENG-T ASME, V103, P370; Shridharani Jay K, 2012, Front Neurol, V3, P70, DOI 10.3389/fneur.2012.00070; Subhash G, 2006, INT J IMPACT ENG, V32, P1113, DOI 10.1016/j.ijimpeng.2004.11.006; Subhash G, 2011, EXP MECH, V51, P255, DOI 10.1007/s11340-010-9354-2; Subhash G., 2000, MECH TESTING EVALUAT, V8, P497, DOI DOI 10.1361/ASMHBA0003299; TOMITA Y, 1986, J FLUID MECH, V169, P535, DOI 10.1017/S0022112086000745; van Dommelen JAW, 2010, J MECH BEHAV BIOMED, V3, P158, DOI 10.1016/j.jmbbm.2009.09.001; VOGEL A, 1989, J FLUID MECH, V206, P299, DOI 10.1017/S0022112089002314; Wang YC, 2006, EXP FLUIDS, V41, P365, DOI 10.1007/s00348-006-0135-8	50	24	24	2	21	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0014-4851	1741-2765		EXP MECH	Exp. Mech.	JAN	2016	56	1			SI		97	109		10.1007/s11340-015-0024-2			13	Materials Science, Multidisciplinary; Mechanics; Materials Science, Characterization & Testing	Materials Science; Mechanics	DC6JN	WOS:000369326200008					2021-06-18	
J	Rodriguez-Rodriguez, A; Egea-Guerrero, JJ; Gordillo-Escobar, E; Enamorado-Enamorado, J; Hernandez-Garcia, C; de Azua-Lopez, ZR; Vilches-Arenas, A; Guerrero, JM; Murillo-Cabezas, F				Rodriguez-Rodriguez, Ana; Jose Egea-Guerrero, Juan; Gordillo-Escobar, Elena; Enamorado-Enamorado, Judy; Hernandez-Garcia, Conary; Ruiz de Azua-Lopez, Zaida; Vilches-Arenas, Angel; Miguel Guerrero, Juan; Murillo-Cabezas, Francisco			S100B and Neuron-Specific Enolase as mortality predictors in patients with severe traumatic brain injury	NEUROLOGICAL RESEARCH			English	Article						Traumatic brain injury; S100B; Neuron-Specific Enolase; Mortality; Biomarkers	SERUM BIOMARKERS; S100-BETA PROTEIN; PROGNOSTIC VALUE; NSE; ASSOCIATION; MARKER; S-100B; DAMAGE; MODEL	Objective: To determine temporal profile and prognostic ability of S100B protein and neuron-specific enolase (NSE) for prediction of short/long-term mortality in patients suffering from severe traumatic brain injury (sTBI). Methods: Ninety-nine patients with sTBI were included in the study. Blood samples were drawn on admission and on subsequent 24, 48, 72, and 96 h. Results: 15.2% of patients died in NeuroCritical Care Unit, and 19.2% died within 6 months of the accident. S100B concentrations were significantly higher in patients who died compared to survivors. NSE levels were different between groups just at 48 h. In the survival group, S100B levels decreased from 1st to 5th sample (p < 0.001); NSE just from 1st to 3rd (p < 0.001) and then stabilized. Values of S100B and NSE in non-survival patients did not significantly vary over the four days post sTBI. ROC-analysis showed that all S100B samples were useful tools for predicting mortality, the best the 72 h sample (AUC 0.848 for discharge mortality, 0.855 for six-month mortality). NSE ROC-analysis indicated that just the 48-h sample predicted mortality (AUC 0.733 for discharge mortality, 0.720 for six-month mortality). Conclusion: S100B protein showed higher prognostic capacity than NSE to predict short/long-term mortality in sTBI patients.	[Rodriguez-Rodriguez, Ana; Jose Egea-Guerrero, Juan; Gordillo-Escobar, Elena; Enamorado-Enamorado, Judy; Ruiz de Azua-Lopez, Zaida; Murillo-Cabezas, Francisco] Univ Seville, Virgen del Rocio Univ Hosp, NeuroCrit Care Unit, IBIS,CSIC, Avda Manuel Siurot S-N, Seville 41013, Spain; [Hernandez-Garcia, Conary; Miguel Guerrero, Juan] Univ Seville, Virgen del Rocio Univ Hosp, Dept Clin Biochem, IBIS,CSIC, Seville 41013, Spain; [Vilches-Arenas, Angel] Univ Seville, Dept Stat, Seville 41013, Spain	Egea-Guerrero, JJ (corresponding author), Univ Seville, Virgen del Rocio Univ Hosp, NeuroCrit Care Unit, IBIS,CSIC, Avda Manuel Siurot S-N, Seville 41013, Spain.	juanj.egea.sspa@juntadeandalucia.es	Vilches-Arenas, Angel/C-1167-2015; IBIS, NEUROINMUNO/O-9306-2015; Murillo-Cabezas, Francisco/AAO-3348-2021; Guerrero, Josep M./Y-2929-2019; IBIS, NEUROCRITICOS/C-1805-2016; Egea-Guerrero, Juan Jose/P-5080-2014	Vilches-Arenas, Angel/0000-0003-2197-3760; Guerrero, Josep M./0000-0001-5236-4592; Egea-Guerrero, Juan Jose/0000-0002-4166-313X; Ruiz de Azua Lopez, Zaida/0000-0002-9157-600X; Guerrero, Juan Miguel/0000-0001-7553-0119			Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Buonora JE, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00068; Chabok SY, 2012, J TRAUMA ACUTE CARE, V72, P1654, DOI 10.1097/TA.0b013e318246887e; COPES WS, 1990, J TRAUMA, V30, P1200, DOI 10.1097/00005373-199010000-00003; Di Battista AP, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00110; Egea-Guerrero JJ, 2012, BRAIN INJURY, V26, P76, DOI 10.3109/02699052.2011.635360; Egea-Guerrero JJ, 2013, J NEUROTRAUM, V30, P1762, DOI 10.1089/neu.2012.2606; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Gonzalez-Mao MC, 2011, CLIN LAB, V57, P587; Gradisek P, 2012, BRAIN INJURY, V26, P1472, DOI 10.3109/02699052.2012.694567; Haddad SH, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-12; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Jauch EC, 2006, STROKE, V37, P2508, DOI 10.1161/01.STR.0000242290.01174.9e; Kleine TO, 2003, BRAIN RES BULL, V61, P265, DOI 10.1016/S0361-9230(03)00090-X; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Krohn M, 2015, J NEUROTRAUM, V32, P430, DOI 10.1089/neu.2014.3524; Leon-Carrion Jose, 2005, Pituitary, V8, P197, DOI 10.1007/s11102-006-6041-5; Lesko MM, 2014, BRAIN INJURY, V28, P987, DOI 10.3109/02699052.2014.890743; MARANGOS PJ, 1980, J NEUROCHEM, V34, P1254, DOI 10.1111/j.1471-4159.1980.tb09967.x; Morrison Gavin, 2013, Pathophysiology, V20, P49, DOI 10.1016/j.pathophys.2012.02.006; Murillo-Cabezas F, 2010, BRAIN INJURY, V24, P609, DOI 10.3109/02699051003652823; Olivecrona Z, 2015, BRAIN INJURY, V29, P446, DOI 10.3109/02699052.2014.989403; Petrova DT, 2013, CLIN BIOCHEM, V46, P1298, DOI 10.1016/j.clinbiochem.2013.06.018; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Rainey T, 2009, RESUSCITATION, V80, P341, DOI 10.1016/j.resuscitation.2008.11.021; Rodriguez-Rodriguez A, 2012, CLIN CHIM ACTA, V414, P228, DOI 10.1016/j.cca.2012.09.025; Schultke E, 2009, CAN J NEUROL SCI, V36, P612, DOI 10.1017/S031716710000812X; Shimamura M, 2005, NEUROSCIENCE, V131, P87, DOI 10.1016/j.neuroscience.2004.10.041; Soto-Hernandez Jose L, 2008, Neurosurgery, V62, pE1384, DOI 10.1227/01.neu.0000333328.42706.db; Stein DM, 2012, SHOCK, V37, P563, DOI 10.1097/SHK.0b013e3182534f93; Stein DM, 2012, J NEUROTRAUM, V29, P1140, DOI 10.1089/neu.2011.2149; Streitburger DP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043284; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wolf H, 2013, J NEUROSURG, V118, P1298, DOI 10.3171/2013.1.JNS121181	37	24	30	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.		2016	38	2					130	137		10.1080/01616412.2016.1144410			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DK8BQ	WOS:000375152400007	27078699				2021-06-18	
J	Thompson, WH; Thelin, EP; Lilja, A; Bellander, BM; Fransson, P				Thompson, William Hedley; Thelin, Eric Peter; Lilja, Anders; Bellander, Bo-Michael; Fransson, Peter			Functional resting-state fMRI connectivity correlates with serum levels of the S100B protein in the acute phase of traumatic brain injury	NEUROIMAGE-CLINICAL			English	Article						Traumatic brain injury; Resting-state; Brain connectivity; fMRI; S100B	DEFAULT-MODE NETWORK; PROPOFOL-INDUCED LOSS; GLASGOW COMA SCALE; PROGNOSTIC VALUE; S-100B PROTEIN; AXONAL INJURY; HEAD-INJURY; CONNECTOMICS; BIOMARKERS; COMPONENT	The S100B protein is an intra-cellular calcium-binding protein that mainly resides in astrocytes in the central nervous system. The serum level of S100B is used as biomarker for the severity of brain damage in traumatic brain injury (TBI) patients. In this study we investigated the relationship between intrinsic resting-state brain connectivity, measured 1-22 days (mean 8 days) after trauma, and serum levels of S100B in a patient cohort with mild-to-severe TBI in need of neuro-intensive care in the acute phase. In line with previous investigations, our results show that the peak level of S100B acquired during the acute phase of TBI was negatively correlated with behavioral measures (Glasgow Outcome Score, GOS) of functional outcome assessed 6 to 12 months post injury. Using a multi-variate pattern analysis-informed seed-based correlation analysis, we show that the strength of resting-state brain connectivity in multiple resting-state networks was negatively correlated with the peak of serum levels of S100B. A negative correspondence between S100B peak levels recorded 12-36 h after trauma and intrinsic connectivity was found for brain regions located in the default mode, fronto-parietal, visual and motor resting-state networks. Our results suggest that resting-state brain connectivity measures acquired during the acute phase of TBI is concordant with results obtained from molecular biomarkers and that it may hold a capacity to predict long-term cognitive outcome in TBI patients. (C) 2016 The Authors. Published by Elsevier Inc.	[Thompson, William Hedley; Thelin, Eric Peter; Bellander, Bo-Michael; Fransson, Peter] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Bellander, Bo-Michael] Karolinska Univ Hosp, Dept Neurosurg, Stockholm, Sweden; [Lilja, Anders] Karolinska Inst, Dept Clin Neurosci, Neuroradiol Sect, Stockholm, Sweden	Fransson, P (corresponding author), Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.	Peter.Fransson@ki.se	Thelin, Eric Peter/K-2144-2012; Thompson, William Hedley/I-1347-2019; Fransson, Peter/M-5679-2014	Thelin, Eric Peter/0000-0002-2338-4364; Thompson, William Hedley/0000-0002-0533-6035; Bellander, Bo-Michael/0000-0002-0648-2501; Fransson, Peter/0000-0002-1305-9875	Swedish Research Agency (Vetenskapstradet) [621-202-4911]	Peter Fransson was funded by the Swedish Research Agency (Vetenskapstradet), 621-202-4911.	Achard S, 2012, P NATL ACAD SCI USA, V109, P20608, DOI 10.1073/pnas.1208933109; ACS, 2012, ADV TRAUM LIF SUPP P; Astrand Ramona, 2013, Methods Mol Biol, V963, P373, DOI 10.1007/978-1-62703-230-8_23; Beaty RE, 2015, SCI REP-UK, V5, DOI 10.1038/srep10964; Bledsoe BE, 2015, PREHOSP DISASTER MED, V30, P46, DOI 10.1017/S1049023X14001289; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Boveroux P, 2010, ANESTHESIOLOGY, V113, P1038, DOI 10.1097/ALN.0b013e3181f697f5; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chabok SY, 2012, J TRAUMA ACUTE CARE, V72, P1654, DOI 10.1097/TA.0b013e318246887e; COOK S, 1989, Journal of Drug Development, V2, P65; DIKMEN S, 1978, EPILEPSIA, V19, P177, DOI 10.1111/j.1528-1157.1978.tb05028.x; Donato R, 2009, BBA-MOL CELL RES, V1793, P1008, DOI 10.1016/j.bbamcr.2008.11.009; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Fagerholm ED, 2015, BRAIN, V138, P1696, DOI 10.1093/brain/awv075; Fornito A, 2015, NAT REV NEUROSCI, V16, P159, DOI 10.1038/nrn3901; Fox MD, 2010, FRONT SYST NEUROSCI, V4, DOI [10.3389/fnsys.2010.00019, 10.3389/fnsys.2010.0001]; Fransson P, 2008, NEUROIMAGE, V42, P1178, DOI 10.1016/j.neuroimage.2008.05.059; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Greenacre M., 1983, THEORY APPL CORRES A; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Greicius MD, 2008, HUM BRAIN MAPP, V29, P839, DOI 10.1002/hbm.20537; Ham TE, 2012, CURR OPIN NEUROL, V25, P662, DOI 10.1097/WCO.0b013e328359488f; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Hillary FG, 2011, INT J PSYCHOPHYSIOL, V82, P115, DOI 10.1016/j.ijpsycho.2011.03.011; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Husson EC, 2010, J REHABIL MED, V42, P425, DOI 10.2340/16501977-0566; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Iraji A, 2015, J NEUROTRAUM, V32, P1031, DOI 10.1089/neu.2014.3610; Irimia A, 2012, NEUROIMAGE-CLIN, V1, P1, DOI 10.1016/j.nicl.2012.08.002; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1975, LANCET, V1, P480; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Lorenzo-Seva U, 2009, J STAT SOFTW, V31, P1; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Martins ET, 2009, J TRAUMA, V67, P85, DOI 10.1097/TA.0b013e318187acee; Mayer AR, 2015, J NEUROTRAUM, V32, P1046, DOI 10.1089/neu.2014.3542; Mercier E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1757; MILLER H, 1966, P ROY SOC MED, V59, P257, DOI 10.1177/003591576605900327; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Miller KJ, 2005, J NEUROSURG, V103, P239, DOI 10.3171/jns.2005.103.2.0239; Moen KG, 2014, J NEUROTRAUM, V31, P1486, DOI 10.1089/neu.2013.3258; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Raabe A, 2004, NEUROL RES, V26, P440, DOI 10.1179/016164104225015958; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schrouff J, 2011, NEUROIMAGE, V57, P198, DOI 10.1016/j.neuroimage.2011.04.020; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Tate RL, 2013, NEUROREHABILITATION, V32, P729, DOI 10.3233/NRE-130898; Teasdale G., 1976, LANCET, V13, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; Thelin E. P., 2015, EUR J TRAUMA EMERG S; Thelin EP, 2014, NEUROCRIT CARE, V20, P217, DOI 10.1007/s12028-013-9916-0; Thelin EP, 2013, J NEUROTRAUM, V30, P519, DOI 10.1089/neu.2012.2553; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Whitfield- Gabrieli S., 2015, MOL PSYCHIATR, P1; Whitfield-Gabrieli S, 2012, BRAIN CONNECT, V2, P125, DOI 10.1089/brain.2012.0073; Wintermark Max, 2015, J Am Coll Radiol, V12, pe1, DOI 10.1016/j.jacr.2014.10.014; Yarkoni T, 2011, NAT METHODS, V8, P665, DOI [10.1038/NMETH.1635, 10.1038/nmeth.1635]; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127	78	24	24	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2016	12						1004	1012		10.1016/j.nicl.2016.05.005			9	Neuroimaging	Neurosciences & Neurology	EF3AI	WOS:000390196400113	27995066	DOAJ Gold, Green Published			2021-06-18	
J	Winkler, EA; Yue, JK; McAllister, TW; Temkin, NR; Oh, SS; Burchard, EG; Hu, DL; Ferguson, AR; Lingsma, HF; Burke, JF; Sorani, MD; Rosand, J; Yuh, EL; Barber, J; Tarapore, PE; Gardner, RC; Sharma, S; Satris, GG; Eng, C; Puccio, AM; Wang, KKW; Mukherjee, P; Valadka, AB; Okonkwo, DO; Diaz-Arrastia, R; Manley, GT				Winkler, Ethan A.; Yue, John K.; McAllister, Thomas W.; Temkin, Nancy R.; Oh, Sam S.; Burchard, Esteban G.; Hu, Donglei; Ferguson, Adam R.; Lingsma, Hester F.; Burke, John F.; Sorani, Marco D.; Rosand, Jonathan; Yuh, Esther L.; Barber, Jason; Tarapore, Phiroz E.; Gardner, Raquel C.; Sharma, Sourabh; Satris, Gabriela G.; Eng, Celeste; Puccio, Ava M.; Wang, Kevin K. W.; Mukherjee, Pratik; Valadka, Alex B.; Okonkwo, David O.; Diaz-Arrastia, Ramon; Manley, Geoffrey T.		TRACK-TBI Investigators	COMT Val (158) Met polymorphism is associated with nonverbal cognition following mild traumatic brain injury	NEUROGENETICS			English	Article						Traumatic brain injury; Genetic factors; Cognitive function; Outcome measures; Human studies	COMMON DATA ELEMENTS; CATECHOL-O-METHYLTRANSFERASE; VERBAL-LEARNING TEST; WORKING-MEMORY; GENE POLYMORPHISMS; PREFRONTAL CORTEX; PERFORMANCE; GENOTYPE; RECOMMENDATIONS; RESILIENCE	Mild traumatic brain injury (mTBI) results in variable clinical outcomes, which may be influenced by genetic variation. A single-nucleotide polymorphism in catechol-o-methyltransferase (COMT), an enzyme which degrades catecholamine neurotransmitters, may influence cognitive deficits following moderate and/or severe head trauma. However, this has been disputed, and its role in mTBI has not been studied. Here, we utilize the Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot (TRACK-TBI Pilot) study to investigate whether the COMT Val (158) Met polymorphism influences outcome on a cognitive battery 6 months following mTBI-Wechsler Adult Intelligence Test Processing Speed Index Composite Score (WAIS-PSI), Trail Making Test (TMT) Trail B minus Trail A time, and California Verbal Learning Test, Second Edition Trial 1-5 Standard Score (CVLT-II). All patients had an emergency department Glasgow Coma Scale (GCS) of 13-15, no acute intracranial pathology on head CT, and no polytrauma as defined by an Abbreviated Injury Scale (AIS) score of a parts per thousand yen3 in any extracranial region. Results in 100 subjects aged 40.9 (SD 15.2) years (COMT Met (158) /Met (158) 29 %, Met (158) /Val (158) 47 %, Val (158) /Val (158) 24 %) show that the COMT Met (158) allele (mean 101.6 +/- SE 2.1) associates with higher nonverbal processing speed on the WAIS-PSI when compared to Val (158) /Val (158) homozygotes (93.8 +/- SE 3.0) after controlling for demographics and injury severity (mean increase 7.9 points, 95 % CI [1.4 to 14.3], p = 0.017). The COMT Val (158) Met polymorphism did not associate with mental flexibility on the TMT or with verbal learning on the CVLT-II. Hence, COMT Val (158) Met may preferentially modulate nonverbal cognition following uncomplicated mTBI. Registry: ClinicalTrials.gov Identifier NCT01565551.	Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA; [Winkler, Ethan A.; Yue, John K.; Ferguson, Adam R.; Burke, John F.; Sorani, Marco D.; Yuh, Esther L.; Tarapore, Phiroz E.; Sharma, Sourabh; Satris, Gabriela G.; Mukherjee, Pratik; Manley, Geoffrey T.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [McAllister, Thomas W.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [Temkin, Nancy R.; Barber, Jason] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, Nancy R.; Barber, Jason; Eng, Celeste] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Oh, Sam S.; Burchard, Esteban G.; Hu, Donglei; Eng, Celeste] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94110 USA; [Lingsma, Hester F.] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Rosand, Jonathan; Gardner, Raquel C.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; [Rosand, Jonathan] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA USA; [Yuh, Esther L.; Mukherjee, Pratik] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94110 USA; [Gardner, Raquel C.] San Francisco Vet Adm Med Ctr, Dept Neurol, San Francisco, CA USA; [Puccio, Ava M.; Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Ctr Neuroprote & Biomarkers Res, Gainesville, FL 32611 USA; [Wang, Kevin K. W.] Univ Florida, Dept Neurosci, Ctr Neuroprote & Biomarkers Res, Gainesville, FL 32610 USA; [Valadka, Alex B.] Seton Brain & Spine Inst, Austin, TX USA; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA; [Diaz-Arrastia, Ramon] Ctr Neurosci & Regenerat Med, Bethesda, MD USA	Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.	manleyg@neurosurg.ucsf.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722; Gardner, Raquel C./0000-0003-4028-440X; Diaz-Arrastia, Ramon/0000-0001-6051-3594; Burke, John/0000-0002-6190-5116; Wang, Kevin/0000-0002-9343-6473; Ferguson, Adam/0000-0001-7102-1608	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RC2 NS069409, RC2 NS069409-02S1, U01 NS086090-01]; DODUnited States Department of Defense [USAMRAAW81XWH-13-1-0441, W81XWH-14-2-0176]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS095755, U01NS086090, RC2NS069409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG044281] Funding Source: NIH RePORTER	This work was supported by the following grants: NIH RC2 NS069409, NIH RC2 NS069409-02S1, NIH U01 NS086090-01, DOD USAMRAAW81XWH-13-1-0441, DOD W81XWH-14-2-0176	Agren T, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.5; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Buckner RL, 2004, NEURON, V44, P195, DOI 10.1016/j.neuron.2004.09.006; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chen CW, 2011, ACCIDENT ANAL PREV, V43, P823, DOI 10.1016/j.aap.2010.11.001; Chen JS, 2004, AM J HUM GENET, V75, P807, DOI 10.1086/425589; Christidi F, 2015, AGING NEUROPSYCHOL C, V22, P667, DOI 10.1080/13825585.2015.1027650; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; Davidson J, 2015, NEUROSCIENTIST, V21, P424, DOI 10.1177/1073858414543150; Delis DC, 2000, CALIFORNIA VERBAL LE; Dias R, 1996, NATURE, V380, P69, DOI 10.1038/380069a0; Diaz-Arrastia R, 2006, J HEAD TRAUMA REHAB, V21, P361, DOI 10.1097/00001199-200607000-00007; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Flashman L.A., 2004, J NEUROPSYCHIATRY CL, V16, P238; Floresco SB, 2006, PSYCHOPHARMACOLOGY, V188, P567, DOI 10.1007/s00213-006-0404-5; Frenette AJ, 2012, J NEUROTRAUM, V29, P1, DOI 10.1089/neu.2011.1812; Graham DP, 2013, J PSYCHIATR RES, V47, P835, DOI 10.1016/j.jpsychires.2013.02.006; Greer SE, 2010, PERCEPT MOTOR SKILL, V111, P3, DOI 10.2466/03.22.27.PMS.111.4.3-18; Hanninen T, 1997, NEUROLOGY, V48, P148, DOI 10.1212/WNL.48.1.148; Hildebrand F, 2005, INJURY, V36, P293, DOI 10.1016/j.injury.2004.08.012; Hill Shirley Y, 2013, Adv J Mol Imaging, V3, P43; Hong SB, 2015, HUM BRAIN MAPP, V36, P367, DOI 10.1002/hbm.22634; Kang JI, 2013, NEUROPSYCHOBIOLOGY, V68, P174, DOI 10.1159/000353257; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Kennedy JE, 2003, CLIN NEUROPSYCHOL, V17, P303, DOI 10.1076/clin.17.3.303.18091; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipsky RH, 2005, J NEUROPSYCH CLIN N, V17, P465, DOI 10.1176/appi.neuropsych.17.4.465; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Malhotra AK, 2002, AM J PSYCHIAT, V159, P652, DOI 10.1176/appi.ajp.159.4.652; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; McAllister TW, 2009, J HEAD TRAUMA REHAB, V24, P65, DOI 10.1097/HTR.0b013e3181996e6b; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Monchi O, 2001, J NEUROSCI, V21, P7733; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Sanchez-Cubillo I, 2009, J INT NEUROPSYCH SOC, V15, P438, DOI 10.1017/S1355617709090626; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Slick DJ, 2000, J CLIN EXP NEUROPSYC, V22, P569, DOI 10.1076/1380-3395(200010)22:5;1-9;FT569; Slifstein M, 2008, MOL PSYCHIATR, V13, P821, DOI 10.1038/mp.2008.19; STALLINGS G, 1995, J CLIN EXP NEUROPSYC, V17, P706, DOI 10.1080/01688639508405160; Stein DJ, 2006, CNS SPECTRUMS, V11, P745, DOI 10.1017/S1092852900014863; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Tunbridge EM, 2006, BIOL PSYCHIAT, V60, P141, DOI 10.1016/j.biopsych.2005.10.024; Tunbridge EM, 2004, J NEUROSCI, V24, P5331, DOI 10.1523/JNEUROSCI.1124-04.2004; van der Heijden P, 2003, ASSESSMENT, V10, P115, DOI 10.1177/1073191103010002001; Wang YJ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/293687; Waters RJ, 2013, J NEUROTRAUM, V30, P1710, DOI 10.1089/neu.2012.2792; Weaver SM, 2012, NEUROSCIENTIST, V18, P631, DOI 10.1177/1073858411435706; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Willmott C, 2014, J NEUROTRAUM, V31, P1507, DOI 10.1089/neu.2013.3308; Willmott C, 2013, BRAIN INJURY, V27, P1281, DOI 10.3109/02699052.2013.809553; Witte AV, 2012, BRAIN RES BULL, V88, P418, DOI 10.1016/j.brainresbull.2011.11.012; Yue JK, 2015, NEUROGENETICS, V16, P169, DOI 10.1007/s10048-015-0437-1; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970	68	24	25	0	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1364-6745	1364-6753		NEUROGENETICS	Neurogenetics	JAN	2016	17	1					31	41		10.1007/s10048-015-0467-8			11	Genetics & Heredity; Clinical Neurology	Genetics & Heredity; Neurosciences & Neurology	DA3KJ	WOS:000367695300005	26576546	Green Accepted			2021-06-18	
J	dela Pena, I; Borlongan, CV				dela Pena, Ike; Borlongan, Cesar V.			Translating G-CSF as an Adjunct Therapy to Stem Cell Transplantation for Stroke	TRANSLATIONAL STROKE RESEARCH			English	Article						G-CSF; hUCB cells; Stroke; Combination therapy	COLONY-STIMULATING FACTOR; UMBILICAL-CORD BLOOD; ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; FUNCTIONAL RECOVERY; PROGENITOR CELLS; HEMORRHAGIC TRANSFORMATION; ENDOTHELIAL-CELLS	Among recently investigated stroke therapies, stem cell treatment holds great promise by virtue of their putative ability to replace lost cells, promote endogenous neurogenesis, and produce behavioral and functional improvement through their "bystander effects." Translating stem cell in the clinic, however, presents a number of technical difficulties. A strategy suggested to enhance therapeutic utility of stem cells is combination therapy, i.e., co-transplantation of stem cells or adjunct treatment with pharmacological agents and substrates, which is assumed to produce more profound therapeutic benefits by circumventing limitations of individual treatments and facilitating complementary brain repair processes. We previously demonstrated enhanced functional effects of co-treatment with granulocyte-colony stimulating factor (G-CSF) and human umbilical cord blood cell (hUCB) transplantation in animal models of traumatic brain injury (TBI). Here, we suggest that the aforementioned combination therapy may also produce synergistic effects in stroke. Accordingly, G-CSF treatment may reduce expression of pro-inflammatory cytokines and enhance neurogenesis rendering a receptive microenvironment for hUCB engraftment. Adjunct treatment of G-CSF with hUCB may facilitate stemness maintenance and guide neural lineage commitment of hUCB cells. Moreover, regenerative mechanisms afforded by G-CSF-mobilized endogenous stem cells, secretion of growth factors by hUCB grafts and G-CSF-recruited endothelial progenitor cells (EPCs), as well as the potential graft-host integration that may promote synaptic circuitry re-establishment could altogether produce more pronounced functional improvement in stroked rats subjected to a combination G-CSF treatment and hUCB transplantation. Nevertheless, differences in pathology and repair processes underlying TBI and stroke deserve consideration when testing the effects of combinatorial G-CSF and hUCB cell transplantation for stroke treatment. Further studies are also required to determine the safety and efficacy of this intervention in both preclinical and clinical stroke studies.	[dela Pena, Ike] Loma Linda Univ, Dept Pharmaceut & Adm Sci, Loma Linda, CA 92350 USA; [Borlongan, Cesar V.] Univ S Florida, Morsani Coll Med, Ctr Excellence Aging & Brain Repair, Dept Neurosurg & Brain Repair, Tampa, FL 33612 USA	dela Pena, I (corresponding author), Loma Linda Univ, Dept Pharmaceut & Adm Sci, Loma Linda, CA 92350 USA.	idelapena@llu.edu		dela Pena, Ike/0000-0003-2046-522X	National Institutes of Health National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS071956-01A1, 1R21NS089851-01]; James and Esther King Biomedical Research Foundation [1KG01-33966]; Loma Linda University School of Pharmacy; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS089851, R01NS071956] Funding Source: NIH RePORTER	This study was supported, in part, by the National Institutes of Health National Institute of Neurological Disorders and Stroke 1R01NS071956-01A1, 1R21NS089851-01, James and Esther King Biomedical Research Foundation 1KG01-33966, and Loma Linda University School of Pharmacy.	Acosta S. A., 2013, J STEM CELL RES T S4, V1, pS004; Acosta SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090953; An CR, 2014, PROG NEUROBIOL, V115, P6, DOI 10.1016/j.pneurobio.2013.12.002; Balseanu AT, 2014, FRONT AGING NEUROSCI, V6, DOI [10.3389/fnagi.2014.00130, 10.3389/fnagi.2014.00044]; Boltze J, 2012, CELL TRANSPLANT, V21, P723, DOI 10.3727/096368911X586783; Borlongan CV, 2011, LEUKEMIA, V25, P1674, DOI 10.1038/leu.2011.167; Borlongan CV, 1997, NEUROSCI BIOBEHAV R, V21, P79, DOI 10.1016/0149-7634(95)00063-1; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Broderick J, 2007, CIRCULATION, V116, pE391, DOI 10.1161/CIRCULATIONAHA.107.183689; Chung DJ, 2009, J NEUROSCI RES, V87, P3554, DOI 10.1002/jnr.22162; Copeland N, 2009, CLIN MED, V9, P342, DOI 10.7861/clinmedicine.9-4-342; Cui X, 2012, CELL TRANSPLANT, V21, P845, DOI 10.3727/096368911X627417; Dailey T, 2013, J CLIN MED, V2, P220, DOI 10.3390/jcm2040220; De La Pena I, 2015, CELL TRANSPLANT, V24, P447, DOI 10.3727/096368915X686913; de la Pena I, 2014, REGEN MED, V9, P409, DOI [10.2217/rme.14.32, 10.2217/RME.14.32]; Dela Pena I, 2014, J NEUROSURG SCI, V58, P145; dela Pena IC, 2015, J CEREBR BLOOD F MET, V35, P338, DOI 10.1038/jcbfm.2014.208; Diederich K, 2009, J NEUROSCI, V29, P11572, DOI 10.1523/JNEUROSCI.0453-09.2009; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; England TJ, 2012, STROKE, V43, P405, DOI 10.1161/STROKEAHA.111.636449; Fan CG, 2005, NEUROSCI LETT, V380, P322, DOI 10.1016/j.neulet.2005.01.070; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; Graham GD, 2003, STROKE, V34, P2847, DOI 10.1161/01.STR.0000101752.23813.C3; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Hafez S, 2014, TRANSL STROKE RES, V5, P442, DOI 10.1007/s12975-014-0336-z; Han JL, 2008, NEUROSCI LETT, V432, P167, DOI 10.1016/j.neulet.2007.07.056; Hayakawa K, 2013, J NEUROCHEM, V125, P273, DOI 10.1111/jnc.12120; Henning RJ, 2008, STEM CELLS DEV, V17, P1207, DOI 10.1089/scd.2008.0023; Ilic D, 2012, BRIT MED BULL, V102, P43, DOI 10.1093/bmb/lds008; Ishikawa H, 2013, STROKE, V44, P3473, DOI 10.1161/STROKEAHA.113.001943; Iskander A, 2013, STEM CELL TRANSL MED, V2, P703, DOI 10.5966/sctm.2013-0066; Jin KL, 2010, J CEREBR BLOOD F MET, V30, P534, DOI 10.1038/jcbfm.2009.219; Kaneko Y, 2012, CURR PHARM DESIGN, V18, P3731, DOI 10.2174/138161212802002733; Komine-Kobayashi M, 2006, J CEREBR BLOOD F MET, V26, P402, DOI 10.1038/sj.jcbfm.9600195; Koton S, 2014, JAMA-J AM MED ASSOC, V312, P259, DOI 10.1001/jama.2014.7692; Lapchak PA, 2013, TRANSL STROKE RES, V4, P279, DOI 10.1007/s12975-012-0209-2; Li L, 2015, EXP NEUROL, VS0014-4886, P00005; Liu XF, 2014, PROG NEUROBIOL, V115, P92, DOI 10.1016/j.pneurobio.2013.11.007; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Ma JH, 2015, NEUROL RES, V37, P50, DOI 10.1179/1743132814Y.0000000399; Matsuda R, 2009, CELL TRANSPLANT, V18, P39, DOI 10.3727/096368909788237122; Metcalf D, 2010, NAT REV CANCER, V10, P425, DOI 10.1038/nrc2843; Minnerup Jens, 2009, Exp Transl Stroke Med, V1, P2, DOI 10.1186/2040-7378-1-2; Nakagomi N, 2009, STEM CELLS, V27, P2185, DOI 10.1002/stem.161; Newman MB, 2006, EXP NEUROL, V199, P201, DOI 10.1016/j.expneurol.2006.04.001; Nishino H, 2000, Prog Brain Res, V127, P461; Pimentel-Coelho PM, 2012, PEDIATR RES, V71, P464, DOI 10.1038/pr.2011.59; PLATZER E, 1985, J EXP MED, V162, P1788, DOI 10.1084/jem.162.6.1788; Popa-Wagner A, 2010, STROKE, V41, P1027, DOI 10.1161/STROKEAHA.109.575621; Ringelstein EB, 2013, STROKE, V44, P2681, DOI 10.1161/STROKEAHA.113.001531; Sanberg PR, 2012, PROG BRAIN RES, V201, P99, DOI 10.1016/B978-0-444-59544-7.00006-8; Sanberg PR, 2012, BRIT MED BULL, V101, P163, DOI 10.1093/bmb/lds001; Sanberg PR, 2005, ANN NY ACAD SCI, V1049, P67, DOI 10.1196/annals.1334.008; Sanchez-Ramos J, 2009, NEUROSCIENCE, V163, P55, DOI 10.1016/j.neuroscience.2009.05.071; Schabitz WR, 2003, STROKE, V34, P745, DOI 10.1161/01.STR.0000057814.70180.17; Schabitz WR, 2010, STROKE, V41, P2545, DOI 10.1161/STROKEAHA.110.579508; Schneider A, 2005, CELL CYCLE, V4, P1753, DOI 10.4161/cc.4.12.2213; Schneider A, 2005, J CLIN INVEST, V115, P2083, DOI 10.1172/JCI23559; Shahaduzzaman M, 2013, AGE, V35, P2071, DOI 10.1007/s11357-012-9496-5; Shinozuka K, 2013, BRAIN SCI, V3, P239, DOI 10.3390/brainsci3010239; Shyu WC, 2006, CAN MED ASSOC J, V174, P927, DOI 10.1503/cmaj.051322; Shyu WC, 2004, CIRCULATION, V110, P1847, DOI 10.1161/01.CIR.0000142616.07367.66; Sinden JD, 2012, INT J STROKE, V7, P426, DOI 10.1111/j.1747-4949.2012.00840.x; Sobrino T, 2010, J THROMB HAEMOST, V8, P1567, DOI 10.1111/j.1538-7836.2010.03897.x; Solaroglu I, 2006, NEUROSCIENCE, V143, P965, DOI 10.1016/j.neuroscience.2006.09.014; Solaroglu I, 2009, NEUROL RES, V31, P167, DOI 10.1179/174313209X393582; Sprigg N, 2006, STROKE, V37, P2979, DOI 10.1161/01.STR.0000248763.49831.c3; Stachura DL, 2013, BLOOD, V122, P3918, DOI 10.1182/blood-2012-12-475392; Stone LL, 2013, BRAIN SCI, V3, P599, DOI 10.3390/brainsci3020599; Sullivan R, 2015, EXPERT OPIN BIOL TH, V15, P949, DOI 10.1517/14712598.2015.1043264; The NINDS rt-PA Stroke Study Group, 1997, STROKE, V28, P2109; Toth ZE, 2008, BLOOD, V111, P5544, DOI 10.1182/blood-2007-10-119073; Tsuji T, 1999, GROWTH FACTORS, V16, P225, DOI 10.3109/08977199909002132; Vendrame M, 2004, STROKE, V35, P2390, DOI 10.1161/01.STR.0000141681.06735.9b; Wang XY, 2004, STROKE, V35, P2726, DOI 10.1161/01.STR.0000143219.16695.af; Welte K., 2012, 20 YEARS G CSF MILES, P15; Willing AE, 2003, J NEUROSCI RES, V73, P296, DOI 10.1002/jnr.10659; Willing AE, 2003, CELL TRANSPLANT, V12, P449, DOI 10.3727/000000003108746885; World Health Organization, 2004, WORLD HLTH REPORT 20; Xiao BG, 2007, J CELL MOL MED, V11, P1272, DOI 10.1111/j.1582-4934.2007.00101.x; Xiao J, 2005, STEM CELLS DEV, V14, P722, DOI 10.1089/scd.2005.14.722; Yang DY, 2010, NEUROL RES, V32, P1041, DOI 10.1179/016164110X12807570510013; Yang M, 2010, CELL TRANSPLANT, V19, P1073, DOI 10.3727/096368910X503415; Yip TR, 2007, STROKE, V38, P1952, DOI 10.1161/STROKEAHA.106.479477; Zhang W, 2010, BRAIN RES, V1359, P256, DOI 10.1016/j.brainres.2010.08.072; Zhang XM, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-61; Zhao Li R, 2013, Recent Pat CNS Drug Discov, V8, P2	88	24	25	0	12	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	DEC	2015	6	6					421	429		10.1007/s12975-015-0430-x			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CV3JE	WOS:000364154700003	26482176	Green Accepted			2021-06-18	
J	Di Leva, A; Lam, T; Alcaide-Leon, P; Bharatha, A; Montanera, W; Cusimano, MD				Di Leva, Antonio; Lam, Timothy; Alcaide-Leon, Paula; Bharatha, Aditya; Montanera, Walter; Cusimano, Michael D.			Magnetic resonance susceptibility weighted imaging in neurosurgery: current applications and future perspectives	JOURNAL OF NEUROSURGERY			English	Article						brain tumors; vascular neurosurgery; neurotrauma; functional neurosurgery; MRI; neuroradiology; SWI; susceptibility weighted imaging; diagnostic and operative techniques	TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; CEREBRAL CAVERNOUS MALFORMATIONS; CHARACTERIZING IRON DEPOSITION; SUBTHALAMIC NUCLEUS; NECROTIC GLIOBLASTOMAS; RADIATION-THERAPY; HIGH-FIELD; IN-VIVO; MRI	Susceptibility weighted imaging (SWI) is a relatively new imaging technique. Its high sensitivity to hemorrhagic components and ability to depict microvasculature by means of susceptibility effects within the veins allow for the accurate detection, grading, and monitoring of brain tumors. This imaging modality can also detect changes in blood flow to monitor stroke recovery and reveal specific subtypes of vascular malformations. In addition, small punctate lesions can be demonstrated with SWI, suggesting diffuse axonal injury, and the location of these lesions can help predict neurological outcome in patients. This imaging technique is also beneficial for applications in functional neurosurgery given its ability to clearly depict and differentiate deep midbrain nuclei and close submillimeter veins, both of which are necessary for presurgical planning of deep brain stimulation. By exploiting the magnetic susceptibilities of substances within the body, such as deoxyhemoglobin, calcium, and iron, SWI can clearly visualize the vasculature and hemorrhagic components even without the use of contrast agents. The high sensitivity of SWI relative to other imaging techniques in showing tumor vasculature and microhemorrhages suggests that it is an effective imaging modality that provides additional information not shown using conventional MRI. Despite SWI's clinical advantages, its implementation in MRI protocols is still far from consistent in clinical usage. To develop a deeper appreciation for SWI, the authors here review the clinical applications in 4 major fields of neurosurgery: neurooncology, vascular neurosurgery, neurotraumatology, and functional neurosurgery. Finally, they address the limitations of and future perspectives on SWI in neurosurgery.	[Di Leva, Antonio; Lam, Timothy; Cusimano, Michael D.] Univ Toronto, St Michaels Hosp, Div Neurosurg, Dept Surg, Toronto, ON M5B 1W8, Canada; [Alcaide-Leon, Paula; Bharatha, Aditya; Montanera, Walter] Univ Toronto, St Michaels Hosp, Dept Radiol, Div Neuroradiol, Toronto, ON M5B 1W8, Canada	Di Leva, A (corresponding author), Univ Toronto, St Michaels Hosp, Div Neurosurg, 30 Bond St, Toronto, ON M5B 1W8, Canada.	diieva@hotmail.com	Cusimano, Michael/X-4059-2019	Cusimano, Michael/0000-0002-9989-0650; Di Ieva, Antonio/0000-0002-5341-5416			Abosch A, 2010, NEUROSURGERY, V67, P1745, DOI 10.1227/NEU.0b013e3181f74105; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Akiyama Y, 2009, NEUROL MED-CHIR, V49, P97, DOI 10.2176/nmc.49.97; Ashwal S, 2010, DEV NEUROSCI-BASEL, V32, P343, DOI 10.1159/000316801; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Bai QK, 2013, NEUROL RES, V35, P586, DOI 10.1179/1743132813Y.0000000179; Baik SK, 2012, CEREBROVASC DIS, V34, P206, DOI 10.1159/000342148; Bauer S, 2013, PHYS MED BIOL, V58, pR97, DOI 10.1088/0031-9155/58/13/R97; Beauchamp MH, 2013, CORTEX, V49, P591, DOI 10.1016/j.cortex.2012.08.015; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; Beggs CB, 2012, NEUROL RES, V34, P793, DOI 10.1179/1743132812Y.0000000048; Bian W, 2014, NEURORADIOLOGY, V56, P91, DOI 10.1007/s00234-013-1297-8; Butcher KS, 2003, STROKE, V34, pE215, DOI 10.1161/01.STR.0000099066.23627.24; Cai M, 2015, NEURORADIOLOGY, V57, P163, DOI 10.1007/s00234-014-1450-z; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Chavhan GB, 2009, RADIOGRAPHICS, V29, P1433, DOI 10.1148/rg.295095034; Choi JI, 2014, CHILD NERV SYST, V30, P1011, DOI 10.1007/s00381-013-2349-4; Colbert CA, 2010, RADIOLOGY, V256, P898, DOI 10.1148/radiol.10091842; CRAELIUS W, 1982, ARCH PATHOL LAB MED, V106, P397; de Champfleur NM, 2011, NEUROSURGERY, V68, P641, DOI 10.1227/NEU.0b013e31820773cf; de Souza JM, 2008, AM J NEURORADIOL, V29, P154, DOI 10.3174/ajnr.A0748; Deistung A, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00710; Deistung A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057924; Di Ieva A, 2015, NEUROSCIENTIST, V21, P30, DOI 10.1177/1073858413513928; Di Ieva A, 2013, NEURORADIOLOGY, V55, P35, DOI 10.1007/s00234-012-1081-1; Di Ieva A, 2012, WORLD NEUROSURG, V77, DOI 10.1016/j.wneu.2011.09.006; Di Ieva A, 2011, NEUROIMAGE, V54, P74, DOI 10.1016/j.neuroimage.2010.07.045; El-Koussy M, 2012, AM J NEURORADIOL, V33, P715, DOI 10.3174/ajnr.A2893; Frischer JM, 2012, NEUROIMAGE-CLIN, V1, P116, DOI 10.1016/j.nicl.2012.09.005; Fu JH, 2015, EUR RADIOL, V25, P1413, DOI 10.1007/s00330-014-3518-x; Fujima N, 2010, RADIOLOGY, V254, P891, DOI 10.1148/radiol.09090286; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Geurts BHJ, 2012, BRAIN INJURY, V26, P1439, DOI 10.3109/02699052.2012.694563; Go JL, 1998, NEUROIMAG CLIN N AM, V8, P541; Grabner G, 2014, J MAGN RESON IMAGING, V40, P655, DOI 10.1002/jmri.24393; Grabner G, 2012, MAGN RESON IMAGING, V30, P139, DOI 10.1016/j.mri.2011.08.004; Grabner G, 2011, J MAGN RESON IMAGING, V33, P543, DOI 10.1002/jmri.22452; Gramsch C, 2013, EUR RADIOL, V23, P2622, DOI 10.1007/s00330-013-2857-3; Gupta D, 2010, NEURORADIOLOGY, V52, P1087, DOI 10.1007/s00234-010-0677-6; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Haacke EM, 2009, J MAGN RESON IMAGING, V29, P537, DOI 10.1002/jmri.21676; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Haller S, 2013, EUR RADIOL, V23, P12, DOI 10.1007/s00330-012-2579-y; Han YH, 2013, J NEUROL SCI, V325, P29, DOI 10.1016/j.jns.2012.11.009; Hasiloglu ZI, 2011, AM J NEURORADIOL, V32, P99, DOI 10.3174/ajnr.A2250; Helmer KG, 2014, J NEUROSURG, V120, P864, DOI [10.3171/2013.12.JNS132093, 10.3171/2013.12.JNS132090]; Hori M, 2010, MAGN RESON IMAGING, V28, P594, DOI 10.1016/j.mri.2010.01.002; Hu J, 2008, J MAGN RESON IMAGING, V28, P300, DOI 10.1002/jmri.21435; Huang PY, 2012, J NEUROL, V259, P1426, DOI 10.1007/s00415-011-6369-2; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Iwamura A, 2012, NEURORADIOLOGY, V54, P335, DOI 10.1007/s00234-011-0892-9; Jagadeesan BD, 2012, AM J NEURORADIOL, V33, P1747, DOI 10.3174/ajnr.A3058; Jagadeesan BD, 2011, STROKE, V42, P87, DOI 10.1161/STROKEAHA.110.584862; Jenkinson MD, 2006, BRAIN, V129, P1884, DOI 10.1093/brain/awl108; Jin L, 2012, EUR J NEUROL, V19, P969, DOI 10.1111/j.1468-1331.2011.03658.x; Kao HW, 2012, EUR RADIOL, V22, P1397, DOI 10.1007/s00330-012-2387-4; Kawabori M, 2009, NEUROL MED-CHIR, V49, P248, DOI 10.2176/nmc.49.248; Keightley ML, 2012, CURR OPIN PEDIATR, V24, P709, DOI 10.1097/MOP.0b013e3283599a55; Kesavadas C, 2010, NEURORADIOLOGY, V52, P1047, DOI 10.1007/s00234-010-0733-2; Kim HS, 2009, AM J NEURORADIOL, V30, P1574, DOI 10.3174/ajnr.A1635; Kumar R, 1998, MOVEMENT DISORD, V13, P73; Letourneau-Guillon L, 2012, AM J NEURORADIOL, V33, P301, DOI 10.3174/ajnr.A2777; Li CT, 2010, EUR J RADIOL, V75, pE81, DOI 10.1016/j.ejrad.2009.08.003; Li M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063013; Lobel U, 2010, NEURORADIOLOGY, V52, P1167, DOI 10.1007/s00234-010-0771-9; Lotfipour AK, 2012, J MAGN RESON IMAGING, V35, P48, DOI 10.1002/jmri.22752; Lou X, 2009, AM J NEURORADIOL, V30, P1694, DOI 10.3174/ajnr.A1696; Lou X, 2012, J MAGN RESON IMAGING, V36, P92, DOI 10.1002/jmri.23624; Luo S, 2014, J NEURORADIOL; Lupo JM, 2013, NEURO-ONCOLOGY, V15, P480, DOI 10.1093/neuonc/nos325; Lupo JM, 2012, INT J RADIAT ONCOL, V82, pE493, DOI 10.1016/j.ijrobp.2011.05.046; Lupo JM, 2009, MAGN RESON IMAGING, V27, P480, DOI 10.1016/j.mri.2008.08.003; Maderwald S, 2012, NEUROIMAGE, V63, P1421, DOI 10.1016/j.neuroimage.2012.07.063; Mahvash M, 2014, CLIN NEUROL NEUROSUR, V124, P151, DOI 10.1016/j.clineuro.2014.06.041; MARTIN F, 1952, AM J PATHOL, V28, P1107; Mittal S, 2009, AM J NEURORADIOL, V30, P232, DOI 10.3174/ajnr.A1461; Moenninghoff C, 2010, KOREAN J RADIOL, V11, P244, DOI 10.3348/kjr.2010.11.2.244; MORK SJ, 1985, J NEUROSURG, V63, P881, DOI 10.3171/jns.1985.63.6.0881; Nishiguchi T, 2013, EUR RADIOL, V23, P551, DOI 10.1007/s00330-012-2618-8; O'Gorman RL, 2011, EUR RADIOL, V21, P130, DOI 10.1007/s00330-010-1885-5; Ohmoto Y, 2002, NEUROL MED-CHIR, V42, P264, DOI 10.2176/nmc.42.264; Park JH, 2009, J KOREAN NEUROSURG S, V46, P365, DOI 10.3340/jkns.2009.46.4.365; Park MJ, 2009, AM J NEURORADIOL, V30, P1402, DOI 10.3174/ajnr.A1593; Park SM, 2010, BRIT J RADIOL, V83, P466, DOI 10.1259/bjr/34304111; Patel NK, 2008, STEREOT FUNCT NEUROS, V86, P153, DOI 10.1159/000120427; Peters S, 2013, NEURORADIOLOGY, V55, P853, DOI 10.1007/s00234-013-1185-2; Peters S, 2012, ROFO-FORTSCHR RONTG, V184, P713, DOI 10.1055/s-0032-1312862; Pinker K, 2007, INVEST RADIOL, V42, P346, DOI 10.1097/01.rli.0000262744.85397.fc; Radbruch A, 2012, EUR J RADIOL, V81, P4064, DOI 10.1016/j.ejrad.2012.06.016; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Rossi M, 2010, INVEST RADIOL, V45, P795, DOI 10.1097/RLI.0b013e3181ec9c96; Sehgal V, 2006, J MAGN RESON IMAGING, V24, P41, DOI 10.1002/jmri.20598; Shimoda Y, 2011, MAGN RESON MED SCI, V10, P49, DOI 10.2463/mrms.10.49; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Spitz G, 2013, J NEUROTRAUM, V30, P2038, DOI 10.1089/neu.2013.3021; Starr PA, 2002, STEREOT FUNCT NEUROS, V79, P118, DOI 10.1159/000070828; Sun W, 2013, CEREBROVASC DIS, V35, P469, DOI 10.1159/000350203; Toh CH, 2012, AM J NEURORADIOL, V33, P1534, DOI 10.3174/ajnr.A2986; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Toth A, 2013, J NEUROTRAUM, V30, P2, DOI 10.1089/neu.2012.2486; Tuleasca C, 2014, NEUROCHIRURGIE, V60, P347; Vossough A, 2012, PEDIATR RADIOL, V42, P481, DOI 10.1007/s00247-011-2330-x; WALTON JC, 1984, ARCH PATHOL LAB MED, V108, P755; Wang MY, 2011, MAGN RESON IMAGING, V29, P365, DOI 10.1016/j.mri.2010.10.016; Wang Y, 2012, AM J NEURORADIOL, V33, P266, DOI 10.3174/ajnr.A2765; Whitehead KJ, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a006635; Wieczorek-Pastusiak J, 2013, POL J RADIOL, V78, P50, DOI 10.12659/PJR.883767; Willats L, 2013, NMR BIOMED, V26, P913, DOI 10.1002/nbm.2833; Wu JL, 2011, J MAGN RESON IMAGING, V34, P791, DOI 10.1002/jmri.22687; Wu Z, 2010, AM J NEURORADIOL, V31, P1302, DOI 10.3174/ajnr.A2022; Wu Z, 2009, J MAGN RESON IMAGING, V29, P177, DOI 10.1002/jmri.21617; Yamada N, 1996, RADIOLOGY, V198, P171, DOI 10.1148/radiology.198.1.8539373; ZABRAMSKI JM, 1994, J NEUROSURG, V80, P422, DOI 10.3171/jns.1994.80.3.0422; Zeng QS, 2011, ACTA RADIOL, V52, P115, DOI 10.1258/ar.2010.100220; Zhang JQ, 2010, BRAIN RES, V1330, P124, DOI 10.1016/j.brainres.2010.03.036; Zhang W, 2009, J INT MED RES, V37, P1139, DOI 10.1177/147323000903700418; Zulfiqar M, 2012, AM J NEURORADIOL, V33, P858, DOI 10.3174/ajnr.A2862	118	24	25	1	23	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2015	123	6					1463	1475		10.3171/2015.1.JNS142349			13	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CX0FK	WOS:000365372100015	26207600	Bronze			2021-06-18	
J	Kroshus, E; Garnett, BR; Baugh, CM; Calzo, JP				Kroshus, Emily; Garnett, Bernice R.; Baugh, Christine M.; Calzo, Jerel P.			Social norms theory and concussion education	HEALTH EDUCATION RESEARCH			English	Article							SPORT-RELATED CONCUSSION; HIGH-SCHOOL; ICE HOCKEY; EPIDEMIOLOGY; INTERVENTION; COLLEGIATE; KNOWLEDGE; SYMPTOMS; DRINKING; RISK	Secondary prevention of harm from sport-related concussion is contingent on immediate removal from play post-injury. To-date, educational efforts to reduce the prevalent risk behavior of continued play while symptomatic have been largely ineffective. Social norms theory may hold promise as a foundation for more effective concussion education aimed at increasing concussion reporting. The primary objective of this study was to assess whether perceived team concussion reporting norms would be less supportive of an individual's safe concussion symptom reporting behavior than objective team norms. Participants were 328 male and female US collegiate athletes. Written surveys were completed in person during the spring of 2014. Among both male and female athletes, team concussion reporting norms were significantly misperceived, with athletes tending to think that they themselves have safer attitudes about concussion reporting than their teammates. Perceived norms were associated with symptom reporting intention, independent of the team's objective reporting norm. A social norms approach to concussion education, in which misperceived group norms are corrected and shifted in the direction of safety, is an important avenue for program development and evaluation research aimed at the secondary prevention of harm from concussion. Implications for the design of this type of educational programming are discussed.	[Kroshus, Emily] Univ Washington, Dept Pediat, Ctr Child Hlth Behav & Dev, Seattle Childrens Res Inst, Seattle, WA 98195 USA; [Kroshus, Emily] Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Garnett, Bernice R.] Univ Vermont, Dept Educ, Coll Educ & Social Serv, Burlington, VT USA; [Baugh, Christine M.] Harvard Univ, Interfac Initiat Hlth Policy, Cambridge, MA 02138 USA; [Baugh, Christine M.] Boston Childrens Hosp, Div Sports Med, Cambridge, MA USA; [Calzo, Jerel P.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Calzo, Jerel P.] Boston Childrens Hosp, Div Adolescent & Young Adult Med, Boston, MA USA	Kroshus, E (corresponding author), Univ Washington, Dept Pediat, Ctr Child Hlth Behav & Dev, Seattle Childrens Res Inst, Seattle, WA 98195 USA.	ekroshus@u.washington.edu	Baugh, Christine/AAG-2324-2020	Baugh, Christine/0000-0002-9340-6338; Calzo, Jerel/0000-0002-4656-1052	National Institute of Mental Health of National Institutes of Health [T32MH019733]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [K01DA034753] Funding Source: NIH RePORTER	Christine M. Baugh was supported by the National Institute of Mental Health of theNational Institutes of Health under Award Number T32MH019733. The content is solely theresponsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Anderson E, 2009, ROUTL RES GEND SOC, P1; Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; Baugh CM, 2014, J LAW MED ETHICS, V42, P314, DOI 10.1111/jlme.12148; Berkowitz A.D., 2003, SOCIAL NORMS APPROAC, P259; Borsari B, 2003, J STUD ALCOHOL, V64, P331, DOI 10.15288/jsa.2003.64.331; Carey KB, 2007, ADDICT BEHAV, V32, P2469, DOI 10.1016/j.addbeh.2007.05.004; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; *CDCP, HEADS CONC HIGH SCH; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Covassin T, 2013, AM J SPORT MED, V41, P2885, DOI 10.1177/0363546513499230; Cusimano MD, 2014, BRIT J SPORT MED, V48, P141, DOI 10.1136/bjsports-2012-091660; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Delaney JS, 2015, CLIN J SPORT MED, V25, P113, DOI 10.1097/JSM.0000000000000112; Eagley A., 1987, SEX DIFFERENCES SOCI; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10210; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10187; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Festinger L, 1954, HUM RELAT, V7, P117, DOI 10.1177/001872675400700202; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Gidycz CA, 2011, VIOLENCE AGAINST WOM, V17, P720, DOI 10.1177/1077801211409727; Giza CC, 2011, SPORTS HEALTH, V3, P46, DOI 10.1177/1941738110391732; Graham R., 2014, SPORTS RELATED CONCU; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hardy J, 2005, SMALL GR RES, V36, P166, DOI 10.1177/1046496404266715; HECKATHORN DD, 1988, AM J SOCIOL, V94, P535, DOI 10.1086/229029; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Horne C, 2001, SOC PSYCHOL QUART, V64, P253, DOI 10.2307/3090115; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kerr ZY, 2014, INT EPIDEMIOL, V1, P1; Kitts JA, 2006, AM SOCIOL REV, V71, P235, DOI 10.1177/000312240607100204; Kitts JA, 2003, SOC PSYCHOL QUART, V66, P222, DOI 10.2307/1519823; Kroshus E, 2015, SOC SCI MED, V134, P66, DOI 10.1016/j.socscimed.2015.04.011; Kroshus E, 2015, CLIN J SPORT MED, V25, P243, DOI 10.1097/JSM.0000000000000137; Kroshus E, 2015, HEALTH EDUC BEHAV, V42, P153, DOI 10.1177/1090198114543011; Kroshus E, 2015, ANN BEHAV MED, V49, P95, DOI 10.1007/s12160-014-9636-5; Kroshus E, 2014, EAT DISORD, V22, P136, DOI 10.1080/10640266.2013.867744; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; LaBrie JW, 2010, ADDICT BEHAV, V35, P1094, DOI 10.1016/j.addbeh.2010.08.003; Lewis MA, 2006, J AM COLL HEALTH, V54, P213, DOI 10.3200/JACH.54.4.213-218; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Manasse-Cohick NJ, 2014, COMMUN DISORD Q, V35, P182, DOI 10.1177/1525740113506605; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; MILLER DT, 1994, PERS SOC PSYCHOL B, V20, P541, DOI 10.1177/0146167294205011; Miyashita TL, 2013, CLIN J SPORT MED, V23, P349, DOI 10.1097/JSM.0b013e318289c321; Moreira MT, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006748.pub2; National Collegiate Athletic Association, 1981 82 2012 13 NCAA; National Federation of High School Sports, 2014, HIGH SCH SPORT PART; NOELLENE.E, 1974, J COMMUN, V24, P43, DOI 10.1111/j.1460-2466.1974.tb00367.x; Perkins HW, 2011, GROUP PROCESS INTERG, V14, P703, DOI 10.1177/1368430210398004; Popoli DM, 2014, CLIN PEDIATR, V53, P217, DOI 10.1177/0009922813499070; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Sandstrom MJ, 2010, BASIC APPL SOC PSYCH, V32, P217, DOI 10.1080/01973533.2010.495645; Thomas M, 2011, PEDIATRICS, V128, pE1, DOI 10.1542/peds.2010-2743; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Wiebe DJ, 2011, INJURY PREV, V17, P69, DOI 10.1136/ip.2010.031211; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	64	24	24	0	24	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0268-1153	1465-3648		HEALTH EDUC RES	Health Educ. Res.	DEC	2015	30	6					1004	1013		10.1093/her/cyv047			10	Education & Educational Research; Public, Environmental & Occupational Health	Education & Educational Research; Public, Environmental & Occupational Health	CZ5UG	WOS:000367166900015	26471918	Bronze, Green Published			2021-06-18	
J	Morgan, CD; Zuckerman, SL; King, LE; Beaird, SE; Sills, AK; Solomon, GS				Morgan, Clinton D.; Zuckerman, Scott L.; King, Lauren E.; Beaird, Susan E.; Sills, Allen K.; Solomon, Gary S.			Post-concussion syndrome (PCS) in a youth population: defining the diagnostic value and cost-utility of brain imaging	CHILDS NERVOUS SYSTEM			English	Article						Brain injury; Concussion; Magnetic resonance imaging (MRI); Computed tomography (CT) neuroimaging; Mild traumatic brain injury; Decision making; Post-concussion syndrome; Sports	HIGH-SCHOOL; RECOVERY; SYMPTOMS; INJURY	Purpose Approximately 90% of concussions are transient, with symptoms resolving within 10-14 days. However, a minority of patients remain symptomatic several months post-injury, a condition known as post-concussion syndrome (PCS). The treatment of these patients can be challenging. The goal of our study was to assess the utility and cost-effectiveness of neurologic imaging two or more weeks post-injury in a cohort of youth with PCS. We conducted a retrospective study of 52 pediatric patients with persistent post-concussion symptoms after 3 months. We collected demographics and neuroimaging results obtained greater than 2 weeks post-concussion. Neuroimaging ordered in the first 2 weeks post-concussion was excluded, except to determine the rate of re-imaging. Descriptive statistics and corresponding cost data were collected. Of 52 patients with PCS, 23/52 (44 %) had neuroimaging at least 2 weeks after the initial injury, for a total of 32 diagnostic studies. In summary, 1/19 MRIs (5.3 %), 1/8 CTs (13 %), and 0/5 x-rays (0 %) yielded significant positive findings, none of which altered clinical management. Chronic phase neuroimaging estimated costs from these 52 pediatric patients totaled $129,025. We estimate the cost to identify a single positive finding was $21,000 for head CT and $104,500 for brain MRI. In this cohort of pediatric PCS patients, brain imaging in the chronic phase (defined as more than 2 weeks after concussion) was pursued in almost half the study sample, had low diagnostic yield, and had poor cost-effectiveness. Based on these results, outpatient management of pediatric patients with long-term post-concussive symptoms should rarely include repeat neuroimaging beyond the acute phase.	[Morgan, Clinton D.; Zuckerman, Scott L.; Sills, Allen K.; Solomon, Gary S.] Vanderbilt Univ, Sch Med, Dept Neurol Surg, Vanderbilt Sports Concuss Ctr, Nashville, TN 37212 USA; [King, Lauren E.; Beaird, Susan E.] Vanderbilt Univ, Sch Med, Div Pediat Neurol, Nashville, TN 37212 USA	Zuckerman, SL (corresponding author), Vanderbilt Univ, Sch Med, Dept Neurol Surg, Vanderbilt Sports Concuss Ctr, Med Ctr North T-4224, Nashville, TN 37212 USA.	scott.zuckerman@vanderbilt.edu	Solomon, Gary/K-9011-2019	Morgan, Clinton/0000-0002-7511-0488	Rawlings	Support for this study came from an unrestricted educational grant from Rawlings. Dr. Solomon is a consultant for ImPACT, Nashville Predators, and Tennessee Titans. Otherwise, the study authors have no conflicts of interest or financial interests to report.	American Psychiatric A American Psychiatric A, 2000, DIAGN STAT MAN MENT; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; Forbes JA, 2013, PEDIATR NEUROSURG, V49, P43, DOI 10.1159/000355121; Gonzalez PG, 2011, PM&R, V3, pS413, DOI 10.1016/j.pmrj.2011.08.536; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Packard RC, 2000, HEADACHE, V40, P736, DOI 10.1046/j.1526-4610.2000.00128.x; Parizel PM, 2005, EUR RADIOL, V15, P569, DOI 10.1007/s00330-004-2558-z; Parsch CS, 1997, NEUROSURGERY, V40, P483, DOI 10.1097/00006123-199703000-00010; Peterlin BL, 2008, HEADACHE, V48, P517, DOI 10.1111/j.1526-4610.2008.00917.x; Pulsipher DT, 2011, CURR SPORT MED REP, V10, P14, DOI 10.1249/JSR.0b013e31820711b8; Reddy CC, 2013, J HEAD TRAUMA REHAB, V28, P260, DOI 10.1097/HTR.0b013e318257fbc6; Riley Debra, 2014, Nurse Pract, V39, P50, DOI 10.1097/01.NPR.0000446871.69156.a3; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Schrader Harald, 2009, BMC Med Imaging, V9, P11, DOI 10.1186/1471-2342-9-11; Sener RN, 1997, COMPUT MED IMAG GRAP, V21, P341; Solomon Gary S, 2013, J Surg Orthop Adv, V22, P193; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x; Yuh Esther L, 2014, Neurosurgery, V75 Suppl 4, pS50, DOI 10.1227/NEU.0000000000000491; Zamosky L., 2013, HEALTHCARE INSURANCE, P75; Zuckerman SL, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12279; Zuckerman SL, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12257	30	24	24	1	19	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	DEC	2015	31	12					2305	2309		10.1007/s00381-015-2916-y			5	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	CW6AM	WOS:000365079000015	26419243				2021-06-18	
J	Soltani, Z; Khaksari, M; Jafari, E; Iranpour, M; Shahrokhi, N				Soltani, Zahra; Khaksari, Mohammad; Jafari, Elham; Iranpour, Maryam; Shahrokhi, Nader			Is genistein neuroprotective in traumatic brain injury?	PHYSIOLOGY & BEHAVIOR			English	Article						Brain injury; Intracranial pressure; Blood-brain barrier; Brain edema	KINASE INHIBITOR GENISTEIN; ESTROGEN-RECEPTOR-ALPHA; SEX STEROID-HORMONES; INTRACRANIAL-PRESSURE; OXIDATIVE STRESS; NEUROLOGIC OUTCOMES; EXPERIMENTAL STROKE; SOY PHYTOESTROGENS; CEREBRAL-ISCHEMIA; NEURONAL DAMAGE	The concerns about negative consequences of estrogen therapy have led to introduce other strategies to obtain estrogen's benefits in the brain. The present study tests the hypothesis that a major isoflavone of soy; genistein with estrogen-like activity can be neuroprotective in traumatic brain injury (TBI). The male Wistar rats were randomly divided to four groups: sham, TB!, vehicle and genistein. The TBI was induced by Marmarou method. The brain edema and the disruption of blood-brain-barrier (BBB) were evaluated 48 h post-TBI. Genistein (15 mg/kg) or dimethyl sulfoxide (DMSO) was injected i.p., twice after TBI. The intracranial pressure (ICP), the motor performance, and the beam-walk task (WB) were determined before trauma, on trauma day (DO), and first (D1) and second (D2) days post-TBI, Genistein inhibited a development of brain edema and a BBB permeability in TB! animals. An increase of ICP and a defect in motor and WB performance were showed following TB!, in all times evaluated. An increase of ICP induced by TBI was suppressed by genistein on D1 and D2 times. Genistein improved a motor disorder induced by TB!, on D1 and D2 times. Also an increase of traversal time in WB task was suppressed by genistein in TBI animals, on D1 and D2 times. The results of this study demonstrated that genistein can be neuroprotective in TB!. Genistein inhibited the disruption of BBB, the brain edema and the increase of ICP, and the disturbance of neurobehavioral performance in TBI. (C) 2015 Elsevier Inc All rights reserved.	[Soltani, Zahra] Kerman Univ Med Sci, Physiol Res Ctr, Inst Neuropharmacol, Kerman, Iran; [Khaksari, Mohammad] Kerman Univ Med Sci, Neurosci Res Ctr, Inst Neuropharmacol, Kerman, Iran; [Jafari, Elham; Iranpour, Maryam] Kerman Univ Med Sci, Dept Pathol, Aftalipour Coll Med Sci, Kerman, Iran; [Shahrokhi, Nader] Kerman Univ Med Sci, Endocrinol & Metab Res Ctr, Inst Basic & Clin Physiol Sci, Kerman, Iran	Khaksari, M (corresponding author), Kerman Univ Med Sci, Neurosci Res Ctr, Inst Neuropharmacol, Kerman, Iran.	mkhaksari@kmu.ac.ir	jafari, elham/AAA-1028-2020; Jafari, Elham/AAC-2580-2019; IRANPOUR, MARYAM/AAH-7467-2019; Haddad, Mohammad Khaksari/AAB-9025-2019; Soltani, Zahra/AAC-1350-2019; Shahrokhi, Nader/AAV-3747-2020	Haddad, Mohammad Khaksari/0000-0003-0770-4281; Soltani, Zahra/0000-0002-8423-6189; Shahrokhi, Nader/0000-0002-0149-7819			AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Aras A.B., 2015, INFLAMMATION; Azcoitia I, 2006, GYNECOL ENDOCRINOL, V22, P63, DOI 10.1080/09513590500519161; Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; Bang OY, 2004, NEUROBIOL DIS, V16, P21, DOI 10.1016/j.nbd.2003.12.017; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Biddle KR, 1996, J COMMUN DISORD, V29, P447, DOI 10.1016/0021-9924(95)00038-0; Choi EJ, 2004, LIFE SCI, V75, P499, DOI 10.1016/j.lfs.2004.01.010; Cornwell T, 2004, PHYTOCHEMISTRY, V65, P995, DOI 10.1016/j.phytochem.2004.03.005; Dehghan F, 2013, ARCH MED RES, V44, P251, DOI 10.1016/j.arcmed.2013.04.002; Dixon RA, 2004, ANNU REV PLANT BIOL, V55, P225, DOI 10.1146/annurev.arplant.55.031903.141729; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.041483198; Duckles S.P., 2007, CLIN EXP PHARM PHYSL, V34, P801; Fazel MR, 2012, ARCH TRAUMA RES, V1, P63, DOI 10.5812/atr.6770; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Felton M, 2001, DISCOURSE PROCESS, V32, P135; Gasche Y, 2001, J CEREBR BLOOD F MET, V21, P1393, DOI 10.1097/00004647-200112000-00003; Hall JM, 2002, J BIOL CHEM, V277, P44455, DOI 10.1074/jbc.M200849200; Hart SA, 2001, J COMP NEUROL, V440, P144, DOI 10.1002/cne.1376; HERTOG MGL, 1993, J AGR FOOD CHEM, V41, P1242, DOI 10.1021/jf00032a015; Huang RQ, 1999, MOL BRAIN RES, V67, P177, DOI 10.1016/S0169-328X(99)00061-3; Khaksari M, 2013, IRAN J BASIC MED SCI, V16, P858; Khaksari M, 2011, CAN J PHYSIOL PHARM, V89, P31, DOI 10.1139/y10-103; Kim H, 1998, AM J CLIN NUTR, V68, p1418S, DOI 10.1093/ajcn/68.6.1418S; KINDY MS, 1993, J CEREBR BLOOD F MET, V13, P372, DOI 10.1038/jcbfm.1993.50; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; Lee YW, 2008, J NUTR BIOCHEM, V19, P819, DOI 10.1016/j.jnutbio.2007.10.006; Liang HW, 2008, NEUROSCI LETT, V438, P116, DOI 10.1016/j.neulet.2008.04.058; Linford NJ, 2001, J PHARMACOL EXP THER, V299, P67; Lovekamp-Swan T, 2007, NEUROSCIENCE, V148, P644, DOI 10.1016/j.neuroscience.2007.06.046; Ma YL, 2013, ENDOCRINOLOGY, V154, P1589, DOI 10.1210/en.2012-2120; Ma YL, 2010, AM J PHYSIOL-REG I, V299, pR871, DOI 10.1152/ajpregu.00031.2010; Maghool F, 2013, BRAIN RES, V1497, P61, DOI 10.1016/j.brainres.2012.12.014; MARKOVITS J, 1989, CANCER RES, V49, P5111; Marmarou Anthony, 2004, Cleve Clin J Med, V71 Suppl 1, pS6; MILDE LN, 1985, ANESTHESIOLOGY, V63, P371, DOI 10.1097/00000542-198510000-00005; Neal CJ, 2007, J NEUROTRAUM, V24, P1609, DOI 10.1089/neu.2007.0301; Oddo M, 2011, NEUROSURGERY, V69, P1037, DOI 10.1227/NEU.0b013e3182287ca7; Osborne CK, 2000, J CLIN ONCOL, V18, P3172, DOI 10.1200/JCO.2000.18.17.3172; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Patel RP, 2001, FREE RADICAL BIO MED, V31, P1570, DOI 10.1016/S0891-5849(01)00737-7; Patisaul HB, 2002, ENDOCRINOLOGY, V143, P2189, DOI 10.1210/en.143.6.2189; Prongay KD, 2010, LAB ANIM-UK, V44, P238, DOI 10.1258/la.2009.009031; Sarkaki AR, 2013, J NEUROTRAUM, V30, P47, DOI 10.1089/neu.2010.1686; Schreihofer DA, 2009, NEUROSCIENCE, V158, P602, DOI 10.1016/j.neuroscience.2008.10.003; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Shakeril M, 2013, ARCH TRAUMA RES, V2, P76, DOI 10.5812/atr.8549; Shambayati M, 2014, BRAIN RES, V1593, P76, DOI 10.1016/j.brainres.2014.09.042; Shenaq M, 2012, J NEUROL SCI, V323, P134, DOI 10.1016/j.jns.2012.08.036; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; Sirotkin AV, 2014, EUR J PHARMACOL, V741, P230, DOI 10.1016/j.ejphar.2014.07.057; Soltani Z., 2014, J NEUROL NEUROPHYSIO; Sonee M, 2004, NEUROTOXICOLOGY, V25, P885, DOI 10.1016/j.neuro.2003.11.001; Soustiel JF, 2010, NEUROTHERAPEUTICS, V7, P13, DOI 10.1016/j.nurt.2009.11.001; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Trieu VN, 1999, RADIAT RES, V152, P508, DOI 10.2307/3580147; Wang SQ, 2014, INT J BIOL SCI, V10, P457, DOI 10.7150/ijbs.7562; Wei M, 2014, BRAIN RES, V1585, P150, DOI 10.1016/j.brainres.2014.06.018; Yakovlev Alexander G, 2004, NeuroRx, V1, P5, DOI 10.1007/BF03206563; Yan EB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-147; Zeng HY, 2004, FREE RADICAL BIO MED, V36, P180, DOI 10.1016/j.freeradbiomed.2003.10.018; Zhao LX, 2002, EXP BIOL MED, V227, P509	63	24	24	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0031-9384			PHYSIOL BEHAV	Physiol. Behav.	DEC 1	2015	152		A				26	31		10.1016/j.physbeh.2015.08.037			6	Psychology, Biological; Behavioral Sciences	Psychology; Behavioral Sciences	CZ2RZ	WOS:000366953600004	26367454	Green Accepted			2021-06-18	
J	Kanninen, KM; Pomeshchik, Y; Leinonen, H; Malm, T; Koistinaho, J; Levonen, AL				Kanninen, Katja M.; Pomeshchik, Yuriy; Leinonen, Hanna; Malm, Tarja; Koistinaho, Jari; Levonen, Anna-Liisa			Applications of the Keap1-Nrf2 system for gene and cell therapy	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						Nrf2; Transcription factor; Gene therapy; Stem cell therapy; Cancer; Spinal cord injury; Neurodegenerative diseases	SPINAL-CORD-INJURY; NEURAL STEM-CELLS; IMPROVE MEMORY DYSFUNCTION; TRAUMATIC BRAIN-INJURY; NF-KAPPA-B; OXIDATIVE STRESS; ALZHEIMERS-DISEASE; MOUSE MODEL; ISCHEMIC-STROKE; LENTIVIRAL VECTORS	Oxidative stress has been implicated to play a role in a number of acute and chronic diseases including acute injuries of the central nervous system, neurodegenerative and cardiovascular diseases, and cancer. The redox-activated transcription factor Nrf2 has been shown to protect many different cell types and organs from a variety of toxic insults, whereas in many cancers, unchecked Nrf2 activity increases the expression of cytoprotective genes and, consequently, provides growth advantage to cancerous cells. Herein, we discuss current preclinical gene therapy approaches to either increase or decrease Nrf2 activity with a special reference to neurological diseases and cancer. In addition, we discuss the role of Nrf2 in stem cell therapy for neurological disorders. (C) 2015 Elsevier Inc. All rights reserved.	[Kanninen, Katja M.; Pomeshchik, Yuriy; Malm, Tarja; Koistinaho, Jari] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, Joensuu, Finland; [Leinonen, Hanna; Levonen, Anna-Liisa] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Biotechnol & Mol Med, Joensuu, Finland	Koistinaho, J (corresponding author), Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, Joensuu, Finland.	jari.koistinaho@uef.fi; anna-liisa.levonen@uef.fi		Pomeshchik, Yuriy/0000-0002-1412-7403; Levonen, Anna-Liisa/0000-0002-6575-2137; Malm, Tarja/0000-0002-9530-7472			Akhter H, 2011, J ALZHEIMERS DIS, V26, P767, DOI 10.3233/JAD-2011-110512; Al Yacoub N, 2007, J GENE MED, V9, P579, DOI 10.1002/jgm.1052; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Barber SC, 2010, FREE RADICAL BIO MED, V48, P629, DOI 10.1016/j.freeradbiomed.2009.11.018; Barnabe-Heider F, 2010, CELL STEM CELL, V7, P470, DOI 10.1016/j.stem.2010.07.014; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Bastani NE, 2012, ARCH PHYS MED REHAB, V93, P2223, DOI 10.1016/j.apmr.2012.06.021; Ben Menachem-Zidon O, 2014, NEUROPSYCHOPHARMACOL, V39, P401, DOI 10.1038/npp.2013.208; Benedict AL, 2012, J NEUROTRAUM, V29, P2576, DOI 10.1089/neu.2012.2474; Benraiss A, 2011, NEUROTHERAPEUTICS, V8, P577, DOI 10.1007/s13311-011-0075-8; Blurton-Jones M., 2009, P NATL ACAD SCI US; Bobkova NV, 2013, B EXP BIOL MED+, V156, P119, DOI 10.1007/s10517-013-2293-z; Bourdenx M, 2014, FRONT MOL NEUROSCI, V7, DOI 10.3389/fnmol.2014.00050; Burger C, 2005, HUM GENE THER, V16, P781, DOI 10.1089/hum.2005.16.781; Cai G, 2006, J GENE MED, V8, P1369, DOI 10.1002/jgm.983; Calkins MJ, 2010, TOXICOL SCI, V115, P557, DOI 10.1093/toxsci/kfq072; Capasso C, 2014, VIRUSES-BASEL, V6, P832, DOI 10.3390/v6020832; Chang KA, 2014, J PHARMACOL SCI, V126, P293, DOI 10.1254/jphs.14R10CP; Chang KA, 2014, NEURODEGENER DIS, V13, P99, DOI 10.1159/000355261; Chen LJ, 2008, J NEUROCHEM, V107, P197, DOI 10.1111/j.1471-4159.2008.05603.x; Chen M, 2007, J NEUROCHEM, V103, P2015, DOI 10.1111/j.1471-4159.2007.04885.x; Chen SD, 2010, J BIOENERG BIOMEMBR, V42, P461, DOI 10.1007/s10863-010-9321-8; Chen Yuying, 2013, Top Spinal Cord Inj Rehabil, V19, P1, DOI 10.1310/sci1901-1; Chen ZC, 2014, NEUROSCI BULL, V30, P271, DOI 10.1007/s12264-013-1423-y; Choi BH, 2007, NEUROSCI LETT, V412, P118, DOI 10.1016/j.neulet.2006.11.015; Choi Sung S, 2014, Exp Neurobiol, V23, P45, DOI 10.5607/en.2014.23.1.45; Choudhry F, 2012, NEUROBIOL AGING, V33, P960, DOI 10.1016/j.neurobiolaging.2010.07.008; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Cyranoski D, 2013, NATURE, V494, P413, DOI 10.1038/494413a; D'Amico E, 2013, FREE RADICAL BIO MED, V65, P509, DOI 10.1016/j.freeradbiomed.2013.06.029; Dachs GU, 1997, NAT MED, V3, P515, DOI 10.1038/nm0597-515; Danet GH, 2003, J CLIN INVEST, V112, P126, DOI 10.1172/JCI200317669; Darlington D, 2013, STEM CELLS DEV, V22, P412, DOI 10.1089/scd.2012.0345; Dasari Venkata Ramesh, 2014, World J Stem Cells, V6, P120, DOI 10.4252/wjsc.v6.i2.120; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Drechsel DA, 2008, FREE RADICAL BIO MED, V44, P1873, DOI 10.1016/j.freeradbiomed.2008.02.008; Emerit J, 2004, BIOMED PHARMACOTHER, V58, P39, DOI 10.1016/j.biopha.2003.11.004; Ezashi T, 2005, P NATL ACAD SCI USA, V102, P4783, DOI 10.1073/pnas.0501283102; Fehlings MG, 2011, NEUROTHERAPEUTICS, V8, P704, DOI 10.1007/s13311-011-0076-7; Feron F, 2005, BRAIN, V128, P2951, DOI 10.1093/brain/awh657; Ferreira M.E., 2015, CELL MOL NEUROBIOL; Follenzi Antonia, 2002, Methods Mol Med, V69, P259; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Fujimoto Y, 2012, STEM CELLS, V30, P1163, DOI 10.1002/stem.1083; Gaki GS, 2014, NEUROMOL MED, V16, P217, DOI 10.1007/s12017-014-8294-x; Gamblin TC, 2000, BIOCHEMISTRY-US, V39, P14203, DOI 10.1021/bi001876l; Genovese T, 2008, SHOCK, V29, P32, DOI 10.1097/shk.0b013e318059053a; Genovese T, 2009, J NEUROCHEM, V108, P1360, DOI 10.1111/j.1471-4159.2009.05899.x; Gu G, 2015, NEUROSCIENCE, V291, P81, DOI 10.1016/j.neuroscience.2015.01.073; Hall E.D., 2015, J BIOENERG BIOMEMBR; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; Hall ED, 2011, NEUROTHERAPEUTICS, V8, P152, DOI 10.1007/s13311-011-0026-4; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hao L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/468748; Harvey TJ, 2011, CANCER GENE THER, V18, P773, DOI 10.1038/cgt.2011.43; Hast BE, 2013, CANCER RES, V73, P2199, DOI 10.1158/0008-5472.CAN-12-4400; Hermann DM, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00291; Hisahara S, 1997, J NEUROCHEM, V69, P10; Hitoshi S, 2002, GENE DEV, V16, P846, DOI 10.1101/gad.975202; Hong YA, 2010, ACTA PHARMACOL SIN, V31, P1421, DOI 10.1038/aps.2010.101; Hurttila H, 2008, GENE THER, V15, P1271, DOI 10.1038/gt.2008.75; Hwang DH, 2011, EXPERT OPIN BIOL TH, V11, P1599, DOI 10.1517/14712598.2011.631908; Imayoshi I, 2010, J NEUROSCI, V30, P3489, DOI 10.1523/JNEUROSCI.4987-09.2010; Jia Z, 2012, SPINAL CORD, V50, P264, DOI 10.1038/sc.2011.111; Jiang T, 2010, CANCER RES, V70, P5486, DOI 10.1158/0008-5472.CAN-10-0713; Jin W, 2014, ANN CLIN LAB SCI, V44, P151; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Johnson DA, 2010, TOXICOL SCI, V114, P237, DOI 10.1093/toxsci/kfp274; Joshi G, 2015, NEUROBIOL AGING, V36, P664, DOI 10.1016/j.neurobiolaging.2014.09.004; Kalladka D, 2014, STEM CELLS CLONING, V7, P31, DOI 10.2147/SCCAA.S38003; Kanamaru T, 2015, NEUROSCI LETT, V587, P126, DOI 10.1016/j.neulet.2014.12.033; Kanninen K, 2008, MOL CELL NEUROSCI, V39, P302, DOI 10.1016/j.mcn.2008.07.010; Kanninen K, 2009, P NATL ACAD SCI USA, V106, P16505, DOI 10.1073/pnas.0908397106; Karkkainen V, 2014, STEM CELLS, V32, P1904, DOI 10.1002/stem.1666; Kazmerova Z, 2013, J ALZHEIMERS DIS, V37, P251, DOI 10.3233/JAD-130572; Kefalopoulou Z, 2014, JAMA NEUROL, V71, P83, DOI 10.1001/jamaneurol.2013.4749; Kensler TW, 2010, CARCINOGENESIS, V31, P90, DOI 10.1093/carcin/bgp231; Kim HV, 2013, AMYLOID, V20, P7, DOI 10.3109/13506129.2012.751367; Kim SU, 2013, NEUROPATHOLOGY, V33, P491, DOI 10.1111/neup.12020; Kobayashi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052787; Kotterman MA, 2014, NAT REV GENET, V15, P445, DOI 10.1038/nrg3742; L'Episcopo F, 2013, J NEUROSCI, V33, P1462, DOI 10.1523/JNEUROSCI.3206-12.2013; Lacroix S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085916; Lazarov O, 2010, TRENDS NEUROSCI, V33, P569, DOI 10.1016/j.tins.2010.09.003; Lebkowski Jane, 2011, Regen Med, V6, P11, DOI 10.2217/rme.11.77; Lee JM, 2005, FASEB J, V19, P1061, DOI 10.1096/fj.04-2591hyp; Lee RJ, 2000, CIRCULATION, V102, P898; Leinonen HM, 2014, ADV CANCER RES, V122, P281, DOI 10.1016/B978-0-12-420117-0.00008-6; Leinonen HM, 2012, CANCER RES, V72, P6227, DOI 10.1158/0008-5472.CAN-12-1166; Leiser SF, 2010, MOL CELL BIOL, V30, P871, DOI 10.1128/MCB.01145-09; Lentz TB, 2012, NEUROBIOL DIS, V48, P179, DOI 10.1016/j.nbd.2011.09.014; Levonen AL, 2014, FREE RADICAL BIO MED, V71, P196, DOI 10.1016/j.freeradbiomed.2014.03.025; Lewis TB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012672; Leyva FJ, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-13; Li J, 2005, TOXICOL SCI, V83, P313, DOI 10.1093/toxsci/kfi027; Li T, 2014, BRAIN RES, V1558, P90, DOI 10.1016/j.brainres.2014.02.036; Lindvall O, 2012, NAT BIOTECHNOL, V30, P56, DOI 10.1038/nbt.2077; Liu XF, 2014, PROG NEUROBIOL, V115, P92, DOI 10.1016/j.pneurobio.2013.11.007; Lu P, 2014, NEURON, V83, P789, DOI 10.1016/j.neuron.2014.07.014; Ma T, 2013, CELL TRANSPLANT, V22, pS113, DOI 10.3727/096368913X672181; Mackay-Sim A, 2008, BRAIN, V131, P2376, DOI 10.1093/brain/awn173; Malik YS, 2013, BIOCHEM BIOPH RES CO, V432, P355, DOI 10.1016/j.bbrc.2013.01.097; Mallanna SK, 2010, DEV BIOL, V344, P16, DOI 10.1016/j.ydbio.2010.05.014; Manzanero S, 2013, NEUROCHEM INT, V62, P712, DOI 10.1016/j.neuint.2012.11.009; Mao L, 2012, J TRAUMA ACUTE CARE, V72, P189, DOI 10.1097/TA.0b013e31821bf541; Mao L, 2011, J SURG RES, V170, pE105, DOI 10.1016/j.jss.2011.05.049; Mao L, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/238321; Marei HES, 2015, J CELL PHYSIOL, V230, P116, DOI 10.1002/jcp.24688; Marignol L, 2009, J GENE MED, V11, P169, DOI 10.1002/jgm.1281; Mattis VB, 2011, LANCET NEUROL, V10, P383, DOI 10.1016/S1474-4422(11)70022-9; Meletis K, 2008, PLOS BIOL, V6, P1494, DOI 10.1371/journal.pbio.0060182; Melov S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000536; Mendell JT, 2012, CELL, V148, P1172, DOI 10.1016/j.cell.2012.02.005; Mendez-Armenta M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/293689; Merson TD, 2014, INT J BIOCHEM CELL B, V56, P4, DOI 10.1016/j.biocel.2014.08.003; Mielke MM, 2014, CLIN EPIDEMIOL, V6, P37, DOI 10.2147/CLEP.S37929; Mittal D, 2014, DRUG DELIV, V21, P75, DOI 10.3109/10717544.2013.838713; Mohamad O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064160; Morroni F, 2013, NEUROTOXICOLOGY, V36, P63, DOI 10.1016/j.neuro.2013.03.004; Mothe AJ, 2013, INT J DEV NEUROSCI, V31, P701, DOI 10.1016/j.ijdevneu.2013.07.004; Mu YL, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-85; Namani A, 2014, BBA-MOL CELL RES, V1843, P1875, DOI 10.1016/j.bbamcr.2014.05.003; Negi G, 2011, CURR NEUROVASC RES, V8, P294, DOI 10.2174/156720211798120972; Nori S, 2011, P NATL ACAD SCI USA, V108, P16825, DOI 10.1073/pnas.1108077108; Nowakowski A, 2013, ACTA NEUROBIOL EXP, V73, P1; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; Olanow CW, 2003, ANN NEUROL, V54, P403, DOI 10.1002/ana.10720; Oyinbo CA, 2011, ACTA NEUROBIOL EXP, V71, P281; Pachori AS, 2004, P NATL ACAD SCI USA, V101, P12282, DOI 10.1073/pnas.0404616101; Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013; Pan H, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/217580; Park D, 2012, EXP NEUROL, V234, P521, DOI 10.1016/j.expneurol.2011.12.040; Pecot CV, 2011, NAT REV CANCER, V11, P59, DOI 10.1038/nrc2966; Persson A, 2006, J NEURO-ONCOL, V78, P1, DOI 10.1007/s11060-005-9055-3; Persson T, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/427318; Petit GH, 2014, NEUROPATH APPL NEURO, V40, P60, DOI 10.1111/nan.12110; Pineau I, 2007, J COMP NEUROL, V500, P267, DOI 10.1002/cne.21149; Polentes J, 2012, CELL TRANSPLANT, V21, P2587, DOI 10.3727/096368912X653228; Policastro LL, 2009, MOL THER, V17, P1355, DOI 10.1038/mt.2009.103; Pollari E, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00131; Pomeshchik Y, 2014, ANTIOXID REDOX SIGN, V20, P1313, DOI 10.1089/ars.2013.5453; Pratico D, 2008, ANN NY ACAD SCI, V1147, P70, DOI 10.1196/annals.1427.010; Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142; Ramsey CP, 2007, J NEUROPATH EXP NEUR, V66, P75, DOI 10.1097/nen.0b013e31802d6da9; Reddy SA, 2015, INT IMMUNOPHARMACOL, V24, P440, DOI 10.1016/j.intimp.2014.12.037; Reeh M, 2013, BRIT J CANCER, V109, P1848, DOI 10.1038/bjc.2013.509; Reitz C, 2014, BIOCHEM PHARMACOL, V88, P640, DOI 10.1016/j.bcp.2013.12.024; Ren DM, 2011, P NATL ACAD SCI USA, V108, P1433, DOI 10.1073/pnas.1014275108; Rinsch C, 1997, HUM GENE THER, V8, P1881, DOI 10.1089/hum.1997.8.16-1881; Roet KCD, 2014, EXP NEUROL, V261, P594, DOI 10.1016/j.expneurol.2014.05.007; Romanyuk N, 2014, CELL TRANSPLANT; Rooney GE, 2009, TISSUE ENG PT A, V15, P3049, DOI [10.1089/ten.tea.2009.0045, 10.1089/ten.TEA.2009.0045]; Rowland JW, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E2; Rowley S, 2013, FREE RADICAL BIO MED, V62, P121, DOI 10.1016/j.freeradbiomed.2013.02.002; Ruggieri S, 2014, THER CLIN RISK MANAG, V10, P229, DOI 10.2147/TCRM.S53285; Ruszkiewicz J., 2015, NEUROCHEM INT; Sabelstrom H, 2014, EXP NEUROL, V260, P44, DOI 10.1016/j.expneurol.2013.01.026; Saberi H, 2008, NEUROSCI LETT, V443, P46, DOI 10.1016/j.neulet.2008.07.041; Sakata H, 2012, J NEUROSCI, V32, P3462, DOI 10.1523/JNEUROSCI.5686-11.2012; Selkoe DJ, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004457; Semenza GL, 2014, ANNU REV PHYSIOL, V76, P39, DOI 10.1146/annurev-physiol-021113-170322; Shah ZA, 2007, NEUROSCIENCE, V147, P53, DOI 10.1016/j.neuroscience.2007.02.066; Shi QD, 2009, NEUROSCI LETT, V465, P220, DOI 10.1016/j.neulet.2009.08.049; Shibata T, 2002, NEOPLASIA, V4, P40, DOI 10.1038/sj.neo.7900189; Shih AY, 2005, J BIOL CHEM, V280, P22925, DOI 10.1074/jbc.M414635200; Silva NA, 2014, PROG NEUROBIOL, V114, P25, DOI 10.1016/j.pneurobio.2013.11.002; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Singh A, 2010, ANTIOXID REDOX SIGN, V13, P1627, DOI 10.1089/ars.2010.3219; Smith JG, 2010, CURR TOP MICROBIOL, V343, P195, DOI 10.1007/82_2010_16; Springer ML, 1998, MOL CELL, V2, P549, DOI 10.1016/S1097-2765(00)80154-9; Su H, 2004, P NATL ACAD SCI USA, V101, P16280, DOI 10.1073/pnas.0407449101; Suh H, 2009, ANNU REV CELL DEV BI, V25, P253, DOI 10.1146/annurev.cellbio.042308.113256; Tabakow P, 2013, CELL TRANSPLANT, V22, P1591, DOI 10.3727/096368912X663532; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tanaka N, 2011, BRAIN RES, V1370, P246, DOI 10.1016/j.brainres.2010.11.010; Tang J, 2008, NEUROSCI RES, V62, P86, DOI 10.1016/j.neures.2008.06.005; Tatarishvili J, 2014, RESTOR NEUROL NEUROS, V32, P547, DOI 10.3233/RNN-140404; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Tobin MK, 2014, J CEREBR BLOOD F MET, V34, P1573, DOI 10.1038/jcbfm.2014.130; Tong LM, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.124; Tong LM, 2014, J NEUROSCI, V34, P9506, DOI 10.1523/JNEUROSCI.0693-14.2014; Tornero D, 2013, BRAIN, V136, P3561, DOI 10.1093/brain/awt278; Trono D, 2000, GENE THER, V7, P20, DOI 10.1038/sj.gt.3301105; Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Vannucci L, 2013, NEW MICROBIOL, V36, P1; Vawda R, 2013, CURR STEM CELL RES T, V8, P25, DOI 10.2174/1574888X11308010005; Vehvilaainen P, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00126; Wakabayashi N, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000762; Wang CY, 2014, ANTIOXID REDOX SIGN, V21, P2208, DOI 10.1089/ars.2014.5845; Wang W, 2014, BRAIN RES, V1544, P54, DOI 10.1016/j.brainres.2013.12.004; Wang XL, 2012, J NEUROTRAUM, V29, P936, DOI 10.1089/neu.2011.1922; Wang Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097685; Weinreb O, 2013, FREE RADICAL BIO MED, V62, P52, DOI 10.1016/j.freeradbiomed.2013.01.017; Xiong WJ, 2015, J CLIN INVEST, V125, P1433, DOI 10.1172/JCI79735; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Yan W, 2009, J TRAUMA, V66, P1431, DOI 10.1097/TA.0b013e318180f5c7; Yang H, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt227; Yla-Herttuala S, 2012, MOL THER, V20, P1831, DOI 10.1038/mt.2012.194; Yuan SH, 2013, AGEING RES REV, V12, P739, DOI 10.1016/j.arr.2013.04.002; Yuan X, 2011, STEM CELLS, V29, P549, DOI 10.1002/stem.594; Yun HM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.490; Zavattari P., 2015, HEPATOLOGY; Zhang MJ, 2013, PROG NEUROBIOL, V100, P30, DOI 10.1016/j.pneurobio.2012.09.003; Zhang P, 2010, MOL CANCER THER, V9, P336, DOI 10.1158/1535-7163.MCT-09-0589; Zhang W, 2014, J NEUROSCI RES, V92, P185, DOI 10.1002/jnr.23299; Zhang YS, 2013, NEURON, V78, P785, DOI 10.1016/j.neuron.2013.05.029; Zhao F, 2009, FREE RADICAL BIO MED, V47, P867, DOI 10.1016/j.freeradbiomed.2009.06.029; Zhao J, 2006, NEUROSCI LETT, V393, P108, DOI 10.1016/j.neulet.2005.09.065; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007; Zhao Y, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/316523	211	24	24	0	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	NOV	2015	88		B				350	361		10.1016/j.freeradbiomed.2015.06.037			12	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	CV0TN	WOS:000363966300023	26164630				2021-06-18	
J	Kelly, KM; Miller, ER; Lepsveridze, E; Kharlamov, EA; Mchedlishvili, Z				Kelly, Kevin M.; Miller, Eric R.; Lepsveridze, Eka; Kharlamov, Elena A.; Mchedlishvili, Zakaria			Posttraumatic seizures and epilepsy in adult rats after controlled cortical impact	EPILEPSY RESEARCH			English	Article						Traumatic brain injury; Video-EEG monitoring; Mossy fiber sprouting	TRAUMATIC BRAIN-INJURY; STATUS EPILEPTICUS; DENTATE GYRUS; SYNAPTIC REORGANIZATION; FUNCTIONAL-CHANGES; MODEL; HIPPOCAMPUS; EPILEPTOGENESIS; POPULATION; PATTERNS	Posttraumatic epilepsy (PTE) has been modeled with different techniques of experimental traumatic brain injury (TBI) using mice and rats at various ages. We hypothesized that the technique of controlled cortical impact (CCI) could be used to establish a model of PTE in young adult rats. A total of 156 male Sprague-Dawley rats of 2-3 months of age (128 CCI-injured and 28 controls) was used for monitoring and/or anatomical studies. Provoked class 3-5 seizures were recorded by video monitoring in 7/57 (12.3%) animals in the week immediately following CCI of the right parietal cortex; none of the 7 animals demonstrated subsequent spontaneous convulsive seizures. Monitoring with video and/or video-EEG was performed on 128 animals at various time points 8-619 days beyond one week following CCI during which 26 (20.3%) demonstrated nonconvulsive or convulsive epileptic seizures. Nonconvulsive epileptic seizures of >10 s were demonstrated in 7/40 (17.5%) animals implanted with 2 or 3 depth electrodes and usually characterized by an initial change in behavior (head raising or animal alerting) followed by motor arrest during an ictal discharge that consisted of high-amplitude spikes or spike-waves with frequencies ranging between 1 and 2 Hz. Class 3-5 epileptic seizures were recorded by video monitoring in 17/88 (19%) and by video-EEG in 2/40 (5%) CCI-injured animals. Ninety of 156 (58%) animals (79 CCI-injured, 13 controls) underwent transcardial perfusion for gross and microscopic studies. CCI caused severe brain tissue loss and cavitation of the ipsilateral cerebral hemisphere associated with cell loss in the hippocampal CA1 and CA3 regions, hilus, and dentate granule cells, and thalamus. All Timm-stained CCI-injured brains demonstrated ipsilateral hippocampal mossy fiber sprouting in the inner molecular layer. These results indicate that the CCI model of TBI in adult rats can be used to study the structure-function relationships that underlie epileptogenesis and PTE. (C) 2015 Elsevier B.V. All rights reserved.	[Kelly, Kevin M.; Miller, Eric R.; Kharlamov, Elena A.; Mchedlishvili, Zakaria] Allegheny Hlth Network Res Inst, Ctr Neurosci Res, Pittsburgh, PA USA; [Kelly, Kevin M.; Kharlamov, Elena A.; Mchedlishvili, Zakaria] Allegheny Gen Hosp, Dept Neurol, Pittsburgh, PA 15212 USA; [Kelly, Kevin M.; Kharlamov, Elena A.; Mchedlishvili, Zakaria] Dept Neurol, Philadelphia, PA USA; [Kelly, Kevin M.] Drexel Univ, Dept Neurobiol & Anat, Coll Med, Philadelphia, PA 19104 USA; [Lepsveridze, Eka] Ilia State Univ, Fac Nat Sci & Engn, Tbilisi, Georgia	Kelly, KM (corresponding author), Allegheny Gen Hosp, 940 South Tower,320 E North Ave, Pittsburgh, PA 15212 USA.	kelly@wpahs.org; emiller@wpahs.org; eka_lepsveridze@iliauni.edu.ge; zmchedlishvili@sentientmedical.com			Health Research Formula Fund [RFA 01-07-26]; Pennsylvania Department of Health; Epilepsy Foundation	The authors would like to thank Bo Lu, M.D., who provided technical support for the animal studies, and to Teresa Hentosz for clerical support in the preparation of the manuscript. The study was supported by Health Research Formula Fund RFA 01-07-26, Pennsylvania Department of Health, and a Research Grant from the Epilepsy Foundation to ZM.	BABB TL, 1991, NEUROSCIENCE, V42, P351, DOI 10.1016/0306-4522(91)90380-7; Belousov AB, 2012, NEUROSCI LETT, V524, P16, DOI 10.1016/j.neulet.2012.06.065; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Buckmaster PS, 2009, J NEUROSCI, V29, P8259, DOI 10.1523/JNEUROSCI.4179-08.2009; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; BUZSAKI G, 1990, NEUROSCIENCE, V38, P323, DOI 10.1016/0306-4522(90)90031-X; COENEN AML, 1992, EPILEPSY RES, V12, P75, DOI 10.1016/0920-1211(92)90029-S; Curia G, 2011, CEREB CORTEX, V21, P1574, DOI 10.1093/cercor/bhq218; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 2013, EXPERT REV NEUROTHER, V13, P615, DOI [10.1586/ERN.13.54, 10.1586/ern.13.54]; D'Ambrosio R, 2013, ANN NEUROL, V73, P199, DOI 10.1002/ana.23764; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Faul M., 2010, TRAUMATIC BRAIN INJU, P1; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; Fisher RS, 2005, EPILEPSIA, V46, P470, DOI 10.1111/j.0013-9580.2005.66104.x; Golarai G, 2001, J NEUROSCI, V21, P8523; Gorter JA, 2001, EUR J NEUROSCI, V13, P657, DOI 10.1046/j.1460-9568.2001.01428.x; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hunt RF, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00089; Hunt RF, 2012, EPILEPSY RES, V99, P167, DOI 10.1016/j.eplepsyres.2011.10.011; Hunt RF, 2011, J NEUROSCI, V31, P6880, DOI 10.1523/JNEUROSCI.0032-11.2011; Hunt RF, 2010, J NEUROPHYSIOL, V103, P1490, DOI 10.1152/jn.00957.2009; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Jiao YQ, 2007, EXP NEUROL, V205, P569, DOI 10.1016/j.expneurol.2007.03.025; JUCKER M, 1994, NEUROSCIENCE, V60, P875, DOI 10.1016/0306-4522(94)90269-0; Kelly Kevin M, 2004, Epilepsy Curr, V4, P176, DOI 10.1111/j.1535-7597.2004.04503.x; Kelly KM, 2001, EPILEPSY RES, V47, P189, DOI 10.1016/S0920-1211(01)00294-7; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2010, EPILEPSY RES, V90, P47, DOI 10.1016/j.eplepsyres.2010.03.007; Kharatishvili I, 2010, CURR OPIN NEUROL, V23, P183, DOI 10.1097/WCO.0b013e32833749e4; Kharlamov EA, 2003, EPILEPSY RES, V56, P185, DOI 10.1016/j.eplepsyres.2003.09.005; Kharlamov EA, 2011, EPILEPSY RES, V95, P20, DOI 10.1016/j.eplepsyres.2011.02.008; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Mtchedlishvili Z, 2010, NEUROBIOL DIS, V38, P464, DOI 10.1016/j.nbd.2010.03.012; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Nissinen J, 2001, HIPPOCAMPUS, V11, P299, DOI 10.1002/hipo.1044; Norris CM, 2009, J NEUROTRAUM, V26, P2269, DOI 10.1089/neu.2009.1029; Patrylo PR, 1998, J NEUROPHYSIOL, V79, P418; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Pitkanen A, 2011, NEUROSCI LETT, V497, P163, DOI 10.1016/j.neulet.2011.02.033; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; SEMBA K, 1980, BRAIN RES, V195, P281, DOI 10.1016/0006-8993(80)90065-7; Shibley H, 2002, EPILEPSY RES, V49, P109, DOI 10.1016/S0920-1211(02)00012-8; SLOVITER RS, 1982, BRAIN RES BULL, V8, P771, DOI 10.1016/0361-9230(82)90104-6; Statler KD, 2009, EPILEPSY RES, V86, P221, DOI 10.1016/j.eplepsyres.2009.05.006; TAUCK DL, 1985, J NEUROSCI, V5, P1016; VANLUIJTELAAR ELJM, 1986, NEUROSCI LETT, V70, P393, DOI 10.1016/0304-3940(86)90586-0; VERGNES M, 1982, NEUROSCI LETT, V33, P97, DOI 10.1016/0304-3940(82)90136-7; Wenzel HJ, 1997, P NATL ACAD SCI USA, V94, P12676, DOI 10.1073/pnas.94.23.12676; Williams PA, 2007, NEUROSCIENCE, V149, P943, DOI 10.1016/j.neuroscience.2007.07.067; Willmore LJ, 2009, NEUROCHEM RES, V34, P688, DOI 10.1007/s11064-008-9841-3; Willoughby J.O., 1992, LAB ANIM SCI, V12, P75; Yang L, 2010, J NEUROTRAUM, V27, P1541, DOI 10.1089/neu.2009.1244; Yu WH, 2002, NEUROBIOL AGING, V23, P105, DOI 10.1016/S0197-4580(01)00258-5; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	65	24	24	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0920-1211	1872-6844		EPILEPSY RES	Epilepsy Res.	NOV	2015	117						104	116		10.1016/j.eplepsyres.2015.09.009			13	Clinical Neurology	Neurosciences & Neurology	CY2ID	WOS:000366231100018	26432760				2021-06-18	
J	Ya, JC; Zheng, KB; Zhang, X				Ya, Junchao; Zheng, Kebin; Zhang, Xiang			Rosiglitazone exerts neuroprotective effects via the suppression of neuronal autophagy and apoptosis in the cortex following traumatic brain injury	MOLECULAR MEDICINE REPORTS			English	Article						rosiglitazone; neuroprotection; traumatic brain injury; inflammatory; autophagy; apoptosis; rats	GAMMA AGONIST ROSIGLITAZONE; CONTROLLED CORTICAL IMPACT; SECONDARY INJURY; CELL-DEATH; RAT MODEL; MECHANISMS; MICE; PPAR; PROTECTS; DISEASE	Traumatic brain injury (TBI) is one of the leading causes of mortality and morbidity in adults and children worldwide. Recent studies have demonstrated that both apoptosis and autophagy participate in TBI-induced neuronal cell death and functional loss. The peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist rosiglitazone (RSG) is a well-known anti-inflammatory, which carries out its effects via the activation of PPAR-gamma. Previous studies have suggested that RSG may exert neuroprotective effects in animal models of both chronic and acute brain injury; however, whether RSG is involved in autophagic neuronal death following TBI remains to be elucidated. The present study aimed to determine whether RSG carries out its neuroprotective properties via the attenuation of neuronal apoptosis and autophagy, following TBI in a rat model. Furthermore, the role of RSG was investigated with regards to the modulation of inflammation and glutamate excitotoxicity, and the impact of RSG on functional recovery following TBI was determined The rats were subjected to controlled cortical impact injury, prior to being randomly divided into three groups: A sham-operated group, a TBI group, and an RSG treatment group. The RSG treatment group was intraperitoneally treated with 2 mg/kg RSG immediately after TBI. The results of the present study demonstrated that RSG treatment following TBI significantly reduced neuronal apoptosis and autophagy, and increased functional recovery. These effects were correlated with a decrease in the protein expression levels of tumor necrosis factor alpha and interleukin-6. However, no significant changes were observed in the protein expression levels of glutamate transporter-1 in the brain cortex. The results of the present study provide in vivo evidence that RSG may exert neuroprotective effects via the inhibition of neuronal apoptosis and autophagy following experimental TBI in rats, and the mechanism underlying these effects may be associated with the anti-inflammatory action of RSG. The present study offers a novel insight into the potential use of RSG as a neuroprotective agent for the treatment of cerebral injuries.	[Ya, Junchao; Zhang, Xiang] Cent Hosp Cangzhou, Dept Neurosurg, Cangzhou 061000, Hebei, Peoples R China; [Zheng, Kebin] Hebei Univ, Affiliated Hosp, Dept Neurosurg, Baoding 071000, Hebei, Peoples R China	Ya, JC (corresponding author), Cent Hosp Cangzhou, Dept Neurosurg, Cangzhou 061000, Hebei, Peoples R China.	junchaoyao24k@163.com			Natural Science Foundation of Hebei ProvinceNatural Science Foundation of Hebei Province [H2013201283]	The present study was supported by a grant from the Natural Science Foundation of Hebei Province (grant no. H2013201283)	Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78; Chaturvedi RK, 2008, J NEUROCHEM, V106, P506, DOI 10.1111/j.1471-4159.2008.05388.x; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Cui CM, 2014, NEUROL SCI, V35, P695, DOI 10.1007/s10072-013-1585-4; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Liu Y, 2014, MOL MED REP, V9, P333, DOI 10.3892/mmr.2013.1803; Luo YM, 2006, J NEUROCHEM, V97, P435, DOI 10.1111/j.1471-4159.2006.03758.x; Mohanty P, 2004, J CLIN ENDOCR METAB, V89, P2728, DOI 10.1210/jc.2003-032103; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Rao VLR, 1998, J NEUROCHEM, V70, P2020; RINK A, 1995, AM J PATHOL, V147, P1575; Risner ME, 2006, PHARMACOGENOMICS J, V6, P246, DOI 10.1038/sj.tpj.6500369; Schutz B, 2005, J NEUROSCI, V25, P7805, DOI 10.1523/JNEUROSCI.2038-05.2005; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Wang YQ, 2012, NEUROCHEM RES, V37, P1849, DOI 10.1007/s11064-012-0791-4; Xu M, 2011, ACTA PHARMACOL SIN, V32, P1089, DOI 10.1038/aps.2011.50; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zhang Q, 2010, NEUROL RES, V32, P852, DOI 10.1179/016164110X12556180206112	28	24	26	0	9	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	NOV	2015	12	5	A				6591	6597		10.3892/mmr.2015.4292			7	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	CW3JP	WOS:000364888900025	26351751	Green Published, Other Gold			2021-06-18	
J	Zhang, B; Wang, B; Cao, SH; Wang, YQ				Zhang, Bo; Wang, Bing; Cao, Shuhua; Wang, Yongqiang			Epigallocatechin-3-Gallate (EGCG) Attenuates Traumatic Brain Injury by Inhibition of Edema Formation and Oxidative Stress	KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY			English	Article						Anti-oxidant; Edema; EGCG; NADPH; Traumatic brain injury	GREEN TEA POLYPHENOL; CEREBRAL-ISCHEMIA; DOWN-REGULATION; GALLATE; DAMAGE; ACTIVATION; EXPRESSION; PATHOPHYSIOLOGY; INVOLVEMENT; MECHANISMS	Traumatic brain injury (TBI) is a major cause of mortality and long-term disability, which can decrease quality of life. In spite of numerous studies suggesting that Epigallocatechin-3- gallate (EGCG) has been used as a therapeutic agent for a broad range of disorders, the effect of EGCG on TBI remains unknown. In this study, a weight drop model was established to evaluate the therapeutic potential of EGCG on TBI. Rats were administered with 100 mg/kg EGCG or PBS intraperitoneally. At different times following trauma, rats were sacrificed for analysis. It was found that EGCG (100 mg/kg, i.p.) treatment significantly reduced brain water content and vascular permeability at 12, 24, 48, 72 hour after TBI. Real-time PCR results revealed that EGCG inhibited TBI-induced IL-1 beta and TNF-alpha mRNA expression. Importantly, CD68 mRNA expression decreasing in the brain suggested that EGCG inhibited microglia activation. Western blotting and immunohistochemistry results showed that administering of EGCG significantly inhibited the levels of aquaporin-4 (AQP4) and glial fibrillary acidic protein (GFAP) expression. TBI-induced oxidative stress was remarkably impaired by EGCG treatment, which elevated the activities of SOD and GSH-PX. Conversely, EGCG significantly reduced the contents of MDA after TBI. In addition, EGCG decreased TBI-induced NADPH oxidase activation through inhibition of p47(phox) translocation from cytoplasm to plasma membrane. These data demonstrate that EGCG treatment may be an effective therapeutic strategy for TBI and the underlying mechanism involves inhibition of oxidative stress.	[Zhang, Bo] Tianjin Huanhu Hosp, Intens Care Unit, Tianjin Key Lab Cerebral Vasc & Neurodegenerat Di, Tianjin 300060, Peoples R China; [Zhang, Bo; Wang, Bing; Cao, Shuhua; Wang, Yongqiang] Tianjin First Ctr Hosp, Tianjin Inst Emergency Med, Intens Care Unit, Tianjin 300192, Peoples R China	Wang, YQ (corresponding author), Tianjin First Ctr Hosp, Tianjin Inst Emergency Med, Intens Care Unit, 24 Fukang Rd, Tianjin 300192, Peoples R China.	yongqiangwangdr@163.com			National Clinical Key Specialty Construction Project [2011873]	This work was supported by National Clinical Key Specialty Construction Project (2011873).	Adachi N, 2006, EUR J PHARMACOL, V531, P171, DOI 10.1016/j.ejphar.2005.12.024; Ahn HY, 2010, KOREAN J PHYSIOL PHA, V14, P325, DOI 10.4196/kjpp.2010.14.5.325; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Donkin JJ, 2009, J CEREBR BLOOD F MET, V29, P1388, DOI 10.1038/jcbfm.2009.63; Fang MZ, 2003, CANCER RES, V63, P7563; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Ge R, 2013, BRAIN RES, V1527, P40, DOI 10.1016/j.brainres.2013.06.009; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Huang J, 2013, BRAIN RES, V1539, P61, DOI 10.1016/j.brainres.2013.09.022; Kim KC, 2014, KOREAN J PHYSIOL PHA, V18, P61, DOI 10.4196/kjpp.2014.18.1.61; Kou ZF, 2014, GLIA, V62, P1831, DOI 10.1002/glia.22690; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lee H, 2004, J NEUROSCI RES, V77, P892, DOI 10.1002/jnr.20193; Lehmann GL, 2004, CURR NEUROVASC RES, V1, P293, DOI 10.2174/1567202043362081; Levites Y, 2002, J BIOL CHEM, V277, P30574, DOI 10.1074/jbc.M202832200; Li GX, 2015, KOREAN J PHYSIOL PHA, V19, P1, DOI 10.4196/kjpp.2015.19.1.1; Liu XB, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-187; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Rezai-Zadeh K, 2005, J NEUROSCI, V25, P8807, DOI 10.1523/JNEUROSCI.1521-05.2005; Schroeder EK, 2009, ANTIOXID REDOX SIGN, V11, P469, DOI [10.1089/ars.2008.2215, 10.1089/ARS.2008.2215]; Shaftel SS, 2007, J NEUROSCI, V27, P9301, DOI 10.1523/JNEUROSCI.1418-07.2007; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Singh BN, 2011, BIOCHEM PHARMACOL, V82, P1807, DOI 10.1016/j.bcp.2011.07.093; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; Steinmann J, 2013, BRIT J PHARMACOL, V168, P1059, DOI 10.1111/bph.12009; Suganuma M, 1998, CARCINOGENESIS, V19, P1771, DOI 10.1093/carcin/19.10.1771; Surh YJ, 2001, MUTAT RES-FUND MOL M, V480, P243, DOI 10.1016/S0027-5107(01)00183-X; Tobi SE, 2002, INT J CANCER, V102, P439, DOI 10.1002/ijc.10730; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Yu JX, 2010, FEBS LETT, V584, P2921, DOI 10.1016/j.febslet.2010.05.011; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	38	24	26	1	19	KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY	SEOUL	C/O EDITORIAL OFFICE, 448-13 SEOKYO-DONG, SEOUL, SOUTH KOREA	1226-4512	2093-3827		KOREAN J PHYSIOL PHA	KOREAN J. PHYSIOL. PHARMACOL.	NOV	2015	19	6					491	497		10.4196/kjpp.2015.19.6.491			7	Pharmacology & Pharmacy; Physiology	Pharmacology & Pharmacy; Physiology	CU2LW	WOS:000363356000003	26557015	Green Published			2021-06-18	
J	Sandhaug, M; Andelic, N; Langhammer, B; Mygland, A				Sandhaug, Maria; Andelic, Nada; Langhammer, Birgitta; Mygland, Aase			Functional level during the first 2 years after moderate and severe traumatic brain injury	BRAIN INJURY			English	Article						Level of function; rehabilitation; traumatic brain injury	EMPLOYMENT OUTCOME 2; INDEPENDENCE MEASURE; HEAD-INJURY; FOLLOW-UP; REHABILITATION; PREDICTORS; DISABILITY; SCALE; MULTICENTER; INTEGRATION	Background: Long-term outcomes after TBI are examined to a large extent, but longitudinal studies with more than 1-year follow-up time after injury have been fewer in number. The course of recovery may vary due to a number of factors and it is still somewhat unclear which factors are contributing.Aim: The aim of this study was to describe the functional level at four time points up to 24 months after traumatic brain injury (TBI) and to evaluate the predictive impact of pre-injury and injury-related factors.Design: A cohort study.Setting: Outpatient.Population: Sixty-five patients with moderate (n=21) or severe (n = 44) TBI.Methods: The patients with TBI were examined with Functional Independence Measure (FIM) and Glasgow Outcome Scale Extended (GOSE) at 3 months, 12 months and 24 months after injury. Possible predictors were analysed in a regression model using FIM total score at 24 months as the outcome measure.Results: FIM scores improved significantly from rehabilitation unit discharge to 24 months after injury, with peak levels at 3 and 24 months after injury (p<0.001), for the whole TBI group and the group with severe TBI. The moderate TBI group did not show significant FIM score improvement during this time period. GOSE scores for the whole group and the moderate group improved significantly over time, but the severe group did not. FIM at admission to the rehabilitation unit and GCS score at admission to the rehabilitation unit were closest to being significant predictors of FIM total scores 24 months after injury (B=0.265 and 2.883, R-2=0.39, p=0.073, p=0.081).Conclusion: FIM levels improved during the period from rehabilitation unit discharge to 3 months follow-up; thereafter, there was a plateauing' of recovery. In contrast, GOSE plateauing' of recovery was at 12 months.Clinical rehabilitation impact: The study results may indicate that two of the most used outcome measures in TBI research are more relevant for assessment of the functional recovery in a sub-acute phase than in later stages of TBI recovery.	[Sandhaug, Maria; Langhammer, Birgitta] Oslo & Akershus Univ Coll, Inst Physiotherapy, Oslo, Norway; [Sandhaug, Maria] Statped, Head Off, Oslo, Norway; [Sandhaug, Maria] Statped, Dept Acquired Brain Injury, Oslo, Norway; [Andelic, Nada] Oslo Univ Hosp, Dept Phys Med & Rehabil, Ulleval, Norway; [Andelic, Nada] Univ Oslo, Inst Hlth & Soc, Res Ctr Habilitat & Rehabil Models & Serv CHARM, Oslo, Norway; [Langhammer, Birgitta] Sunnaas Rehabil Hosp, Nesoddtangen, Norway; [Mygland, Aase] Sorlandet Hosp, Dept Habilitat, Kristiansand, Norway; [Mygland, Aase] Sorlandet Hosp, Dept Neurol, Kristiansand, Norway; [Mygland, Aase] Univ Bergen, Dept Clin Med, Bergen, Norway	Sandhaug, M (corresponding author), Statped Head Off, Acquired Brain Injury, Postbox 2814, N-0204 Oslo, Norway.	maria.sandhaug@statped.no	Langhammer, Birgitta/P-1765-2019	Langhammer, Birgitta/0000-0002-9639-0570; Andelic, Nada/0000-0002-3719-4406	Norwegian Foundation for Health and Rehabilitation	The authors report no conflicts of interest. This study has been financed with the aid of EXTRA funds from the Norwegian Foundation for Health and Rehabilitation.	Bilbao A, 2003, NEUROREHABILITATION, V18, P239; Borg J, 2011, AM J PHYS MED REHAB, V90, P65, DOI 10.1097/PHM.0b013e3181fc80e7; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Bulletin of the World Health Organization, 2001, B WHO, P79; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Deutsch A, 2006, STROKE, V37, P1477, DOI 10.1161/01.STR.0000221172.99375.5a; Dijikers M., 1997, J HEAD TRAUMA REHAB, V12, P74; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dunn LT, 2000, BRIT J NEUROSURG, V14, P219; Forslund MV, 2013, ACTA NEUROL SCAND, V128, P220, DOI 10.1111/ane.12130; Forslund MV, 2013, J REHABIL MED, V45, P801, DOI 10.2340/16501977-1168; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Grimby G, 1996, SCAND J REHABIL MED, V28, P51; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Kunik CL, 2008, ARCH PHYS MED REHAB, V89, pS3; Langhammer Birgitta, 2009, Physiotherapy Theory and Practice, V25, P55, DOI 10.1080/09593980802686938; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Ma YW, 2013, INT J MOL SCI, V14, P8570, DOI 10.3390/ijms14048570; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Sandhaug M, 2011, J NEUROLOGICAL RES, V1, P48; Sandhaug M, 2010, BRAIN INJURY, V24, P740, DOI 10.3109/02699051003652849; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Silver JM, 2005, TXB TRAUMATIC BRAIN; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Sveen U, 2008, CLIN REHABIL, V22, P45, DOI 10.1177/0269215507080768; Tennant KA, 2012, NEUROBIOL LEARN MEM, V98, P291, DOI 10.1016/j.nlm.2012.09.004; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Walker WC, 2010, J NEUROL NEUROSUR PS, V81, P87, DOI 10.1136/jnnp.2008.161570; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; World Health Organization, 2001, INT CLASS FUNCT DIS	42	24	24	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT 15	2015	29	12					1431	1438		10.3109/02699052.2015.1063692			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CV7CO	WOS:000364430200006	26361939				2021-06-18	
J	Seidman, DH; Burlingame, J; Yousif, LR; Donahue, XP; Krier, J; Rayes, LJ; Young, R; Lilla, M; Mazurek, R; Hittle, K; McCloskey, C; Misra, S; Shaw, MK				Seidman, Daniel H.; Burlingame, Jennifer; Yousif, Lina R.; Donahue, Xinh P.; Krier, Joshua; Rayes, Lydia J.; Young, Rachel; Lilla, Muareen; Mazurek, Rochelle; Hittle, Kristie; McCloskey, Charles; Misra, Saroj; Shaw, Michael K.			Evaluation of the King-Devick test as a concussion screening tool in high school football players	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Traumatic brain injury; Diffuse axonal injury; Neuropsychological tests; Post-concussion syndrome; Visual motor coordination; Football	CHRONIC TRAUMATIC ENCEPHALOPATHY; SPORT; VULNERABILITY; STATEMENT; POSITION	Objective: Concussion is the most common type of traumatic brain injury, and results from impact or impulsive forces to the head, neck or face. Due to the variability and subtlety of symptoms, concussions may go unrecognized or be ignored, especially with the pressure placed on athletes to return to competition. The King-Devick (KID) test, an oculomotor test originally designed for reading evaluation, was recently validated as a concussion screening tool in collegiate athletes. A prospective study was performed using high school football players in an attempt to study the KD as a concussion screening tool in this younger population. Methods: 343 athletes from four local high school football teams were recruited to participate. These athletes were given baseline KD tests prior to competition. Individual demographic information was collected on the subjects. Standard team protocol was employed to determine if a concussion had occurred during competition. Immediately after diagnosis, the MD test was re-administered to the concussed athlete for comparison to baseline. Post-season testing was also performed in non-concussed individuals. Results: Of the 343 athletes, nine were diagnosed with concussions. In all concussed players, cumulative read times for the KD test were significantly increased (p < 0.001). Post-season testing of non-concussed athletes revealed minimal change in read times relative to baseline. Univariate analysis revealed that history of concussion was the only demographic factor predictive of concussion in this cohort. Conclusion: The MD test is an accurate and easily administered sideline screening tool for concussion in adolescent football players. (C) 2015 Elsevier B.V. All rights reserved.	[Seidman, Daniel H.; Burlingame, Jennifer; Yousif, Lina R.; Donahue, Xinh P.; Krier, Joshua; Rayes, Lydia J.; Young, Rachel; McCloskey, Charles; Misra, Saroj] St John Providence Hlth Syst, St John Macomb Oakland Hosp, Dept Family Med, Detroit, MI USA; [Lilla, Muareen; Mazurek, Rochelle; Hittle, Kristie] St John Providence Hlth Syst, St John Macomb Oakland Hosp, Dept Phys Rehabil, Detroit, MI USA; [Shaw, Michael K.] St John Providence Hlth Syst, St John Macomb Oakland Hosp, Dept Med Educ & Res, Detroit, MI USA	Shaw, MK (corresponding author), St John Macomb Oakland Hosp, 12001 E Twelve Mile Rd, Warren, MI 48093 USA.	michael.shaw@stjohn.org			Medical Executive Committee at St. John Macomb-Oakland Hospital	The authors would like to thank the following individuals for their contributions: Allison Blumenthal BS, Scott Mueller BS, Collin Blattner BS, Logan McCool BS, Jacqueline Dufour BS, and Mary Predko BS. We would like to acknowledge the Medical Executive Committee at St. John Macomb-Oakland Hospital for their financial support of these research efforts. We would also like to acknowledge all of the high school football coaches and administrators who allowed us access to the athletes throughout the football season. Finally, we would like to acknowledge the athletes and their parents for their participation in this study.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Baugh CM, 2015, J NEUROTRAUM, V32, P314, DOI 10.1089/neu.2014.3582; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS210, DOI 10.1016/j.apmr.2013.06.035; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Donovan J, 2014, CHIROPR MAN THER, V22, DOI 10.1186/s12998-014-0038-3; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta K.M., 2015, J NEURO-OPHTHALMOL, P1; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; King D, 2013, J NEUROL SCI, V326, P59, DOI 10.1016/j.jns.2013.01.012; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Kroshus E, 2015, SOC SCI MED, V134, P66, DOI 10.1016/j.socscimed.2015.04.011; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Leong DF, 2014, J SPORT MED PHYS FIT, V54, P70; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Luoto T.M., 2003, IMMEDIATE POSTCONCUS; Luoto TM, 2014, J NEUROTRAUM, V31, P728, DOI 10.1089/neu.2013.3174; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Tjarks BJ, 2013, J NEUROL SCI, V334, P148, DOI 10.1016/j.jns.2013.08.015; Wetjen NM, 2010, J AM COLL SURGEONS, V211, P553, DOI 10.1016/j.jamcollsurg.2010.05.020	26	24	24	1	29	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	SEP 15	2015	356	1-2					97	101		10.1016/j.jns.2015.06.021			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CQ9QU	WOS:000360950800017	26094155				2021-06-18	
J	Babaee, A; Eftekhar-Vaghefi, SH; Asadi-shekaari, M; Shahrokhi, N; Soltani, SD; Malekpour-Afshar, R; Basiri, M				Babaee, Abdolreza; Eftekhar-Vaghefi, Seyed Hassan; Asadi-shekaari, Majid; Shahrokhi, Nader; Soltani, Samereh Dehghani; Malekpour-Afshar, Reza; Basiri, Mohsen			Melatonin treatment reduces astrogliosis and apoptosis in rats with traumatic brain injury	IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES			English	Article						Apoptosis; Astrogliosis; GFAP; Melatonin; Traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; WHITE-MATTER; PATHOPHYSIOLOGY; INFLAMMATION; DAMAGE; EDEMA; NEUROPROTECTION; DEGENERATION; HIPPOCAMPUS	Objective(s): Melatonin is known as an anti-inflammatory agent, and it has been proven to exert neuroprotection through inhibition of cell death (apoptosis) in several models of brain injury. Secondary injury following the primary traumatic brain injury (TBI) results in glial cells activation, especially astrocytes. In fact, astrocyte activation causes the production of pro-inflammatory cytokines that may lead to secondary injury. Since most TBI research studies have focused on injured neurons and paid little attention to glial cells, the aim of current study was to investigate the effects of melatonin against astrocytes activation (astrogliosis), as well as inhibition of apoptosis in brain tissue of male rats after TBI. Materials and Methods: The animals were randomly allocated into five groups: sham group, TBI+ vehicle group (1% ethanol in saline) and TBI+ melatonin groups (5 mg/kg, 10 mg/kg and 20 mg/kg). All rats were intubated and then exposed to diffuse TBI, except for the sham group. Immunohistochemical methods were conducted using glial fibrillary acidic protein (GFAP) marker and TUNEL assay to evaluate astrocyte reactivity and cell death, respectively. Results: The results showed that based on the number of GFAP positive astrocytes in brain cortex, astrogliosis was reduced significantly (P<0.05) in melatonin-treated groups (no dose dependent) compared to the vehicle group. Furthermore, based on TUNEL results, melatonin treatment considerably reduced the number of apoptotic cells (P<0.05). Conclusion: In total, the present findings suggest that melatonin treatment following TBI diminishes astrocyte reactivity and neuronal cells apoptosis in brain cortex in the rat model.	[Babaee, Abdolreza; Eftekhar-Vaghefi, Seyed Hassan; Soltani, Samereh Dehghani] Kerman Univ Med Sci, Afzalipour Sch Med, Dept Anat Sci, Kerman, Iran; [Asadi-shekaari, Majid; Basiri, Mohsen] Kerman Univ Med Sci, Inst Neuropharmacol, Neurosci Res Ctr, Kerman, Iran; [Shahrokhi, Nader] Kerman Univ Med Sci, Afzalipour Sch Med, Dept Physiol, Kerman, Iran; [Malekpour-Afshar, Reza] Kerman Univ Med Sci, Afzalipour Sch Med, Dept Pathol, Kerman, Iran	Basiri, M (corresponding author), Kerman Univ Med Sci, Inst Neuropharmacol, Neurosci Res Ctr, Kerman, Iran.	m_basiri@kmu.ac.ir	Babaee, Abdolreza/AAB-1310-2021; Dehghani-Soltani, Samereh/AAR-7297-2021; Basiri, Mohsen/AAH-2438-2021; Dehghani, Samereh/ABC-1351-2020; Vaghefi, Seyed Hassan Eftekhar/AAW-9916-2020; Shahrokhi, Nader/AAV-3747-2020	Babaee, Abdolreza/0000-0002-9848-5442; Dehghani-Soltani, Samereh/0000-0003-1074-3345; Basiri, Mohsen/0000-0002-8372-3655; Vaghefi, Seyed Hassan Eftekhar/0000-0002-5083-9563; Shahrokhi, Nader/0000-0002-0149-7819	Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran	The present study was financially supported by Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran. This work was part of MSc thesis of Mr Babaee at the Department of Anatomical Sciences. The authors have no conflicts of interest to declare.	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Aghakhani N, 2013, IRAN RED CRESCENT ME, V15, P173, DOI 10.5812/ircmj.2090; Ahmad molai Gh, 2008, KERMAN U MED SCI, V15, P47; Ahmadiasl N, 2013, IRAN J BASIC MED SCI, V16, P1209; Ananth C, 2003, HIPPOCAMPUS, V13, P375, DOI 10.1002/hipo.10090; Babaei-Balderlou F, 2010, IRAN J BASIC MED SCI, V13, P1; Barreto GE, 2011, NEUROSCI RES, V71, P107, DOI 10.1016/j.neures.2011.06.004; Baydas G, 2003, FREE RADICAL BIO MED, V35, P797, DOI 10.1016/S0891-5849(03)00408-8; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Cameron B, 2010, NEUROBIOL DIS, V37, P503, DOI 10.1016/j.nbd.2009.10.006; Candace LF, 2007, PROG BRAIN RES, P161; Chern CM, 2012, FREE RADICAL BIO MED, V52, P1634, DOI 10.1016/j.freeradbiomed.2012.01.030; Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31; Claustrat B, 2005, SLEEP MED REV, V9, P11, DOI 10.1016/j.smrv.2004.08.001; Dehghan F, 2013, ARCH MED RES, V44, P251, DOI 10.1016/j.arcmed.2013.04.002; Ding K, 2014, NEUROCHEM INT, V76, P23, DOI 10.1016/j.neuint.2014.06.015; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Domowicz MS, 2011, BRAIN RES, V1389, P35, DOI 10.1016/j.brainres.2011.03.006; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kabadi SV, 2010, ANN NY ACAD SCI, V1199, P105, DOI 10.1111/j.1749-6632.2009.05352.x; Keshavarzi Z, 2014, IRAN J BASIC MED SCI, V17, P406; Keskin I, 2015, INT J DEV NEUROSCI, V41, P1, DOI 10.1016/j.ijdevneu.2014.12.002; Khorasani-Zavareh D, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-486; Koizumi S, 2007, NATURE, V446, P1091, DOI 10.1038/nature05704; Kunz A, 2010, BEST PRACT RES-CLIN, V24, P495, DOI 10.1016/j.bpa.2010.10.001; Lee MY, 2007, J PINEAL RES, V42, P297, DOI 10.1111/j.1600-079X.2007.00420.x; LI Y, 1995, STROKE, V26, P1252, DOI 10.1161/01.STR.26.7.1252; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marmarou CR, 2014, BRAIN RES, V1581, P89, DOI 10.1016/j.brainres.2014.06.005; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Pineau I, 2010, BRAIN BEHAV IMMUN, V24, P540, DOI 10.1016/j.bbi.2009.11.007; REITER RJ, 1991, MOL CELL ENDOCRINOL, V79, pC153, DOI 10.1016/0303-7207(91)90087-9; Seifman MA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00237; Skaper SD, 1999, ANN NY ACAD SCI, V890, P107, DOI 10.1111/j.1749-6632.1999.tb07985.x; Tsai MC, 2011, J PINEAL RES, V51, P233, DOI 10.1111/j.1600-079X.2011.00885.x; Welin AK, 2007, PEDIATR RES, V61, P153, DOI 10.1203/01.pdr.0000252546.20451.1a; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	39	24	27	0	3	MASHHAD UNIV MED SCIENCES	MASHHAD	VICE-CHANCELLOR FOR RES CTR OFF IJBMS, DANESHGAH ST, PO BOX 9138813944 - 445, MASHHAD, 00000, IRAN	2008-3866	2008-3874		IRAN J BASIC MED SCI	Iran. J. Basic Med. Sci.	SEP	2015	18	9					867	872					6	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	CV4DY	WOS:000364217400004	26523219	DOAJ Gold			2021-06-18	
J	Beynon, C; Potzy, A; Sakowitz, OW; Unterberg, AW				Beynon, Christopher; Potzy, Anna; Sakowitz, Oliver W.; Unterberg, Andreas W.			Rivaroxaban and intracranial haemorrhage after mild traumatic brain injury: A dangerous combination?	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Anticoagulants; Factor Xa inhibitors; Haemostasis; Intracerebral haemorrhage; Head injury	PROTHROMBIN COMPLEX CONCENTRATE; DABIGATRAN; MANAGEMENT; REVERSAL; ANTICOAGULANTS; PATIENT; COMPLICATIONS; EVENTS	Objectives: Despite several advantages of the novel anticoagulant rivaroxaban compared with vitamin K antagonists (VKA), its lack of specific antidotes to reverse anticoagulant effects may increase the risk profile of patients with bleeding complications. The purpose of this study was to analyze the effects of pre-injury treatment with rivaroxaban on patients with mild traumatic brain injury (TBI) and traumatic intracranial haemorrhage (tICH). Methods: A total of 70 patients with tICH after mild TBI were included in this retrospective analysis and were categorized into three groups: group A (no antithrombotics n = 37), group B (antiplatelet medication n = 22, VKA = 5), and group C (rivaroxaban n = 6). Medical charts were reviewed for baseline characteristics, laboratory values, intracranial haemorrhage, repeated computed tomography (CT) scans, re-haemorrhage, Glasgow Coma Scale (GCS) scores and in-hospital mortality. Results: No significant differences were observed for baseline characteristics. The rate of re-haemorrhage was significantly higher in group C (50%) than in group A (11%) (p < 0.05). Two patients died and both had been treated with rivaroxaban which resulted in a significantly higher mortality rate of 33% in group C compared with groups A (0%) and B (0%). No significant differences were observed for GCS at discharge and length of hospital stay between survivors of groups A-C. Conclusions: Despite major limitations of retrospective design and small patient numbers, our results suggest that rivaroxaban may exacerbate intracranial haemorrhage in patients with mild TBI. Further studies are needed to characterize the risk profile of this drug in patients with tICH. (C) 2015 Elsevier B.V. All rights reserved.	[Beynon, Christopher; Potzy, Anna; Sakowitz, Oliver W.; Unterberg, Andreas W.] Univ Heidelberg Hosp, Dept Neurosurg, D-69120 Heidelberg, Germany	Beynon, C (corresponding author), Univ Heidelberg Hosp, Dept Neurosurg, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	christopher.beynon@med.uni-heidelberg.de			CSL Behring	C.B. has received speaker honoraria from CSL Behring and Advisory Board fees from Boehringer Ingelheim. O.W.S. has received speaker honoraria from CSL Behring.	Akwaa Frank, 2013, Curr Treat Options Cardiovasc Med, V15, P288, DOI 10.1007/s11936-013-0238-5; Berger R, 2013, ANN EMERG MED, V61, P475, DOI 10.1016/j.annemergmed.2013.02.008; Beyer-Westendorf J, 2014, BLOOD, V124, P955, DOI 10.1182/blood-2014-03-563577; Bowry R, 2014, STROKE, V45, P880, DOI 10.1161/STROKEAHA.113.004016; Edavettal M, 2014, AM SURGEON, V80, P372; Fawole A, 2013, CLEV CLIN J MED, V80, P443, DOI 10.3949/ccjm.80a.13025; Garber ST, 2012, J NEUROSURG, V116, P1093, DOI 10.3171/2012.2.JNS112132; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Kalina M, 2008, AM SURGEON, V74, P858; Karni A, 2001, AM SURGEON, V67, P1098; Lee FMH, 2014, THROMB RES, V133, P705, DOI 10.1016/j.thromres.2014.01.031; Lu GM, 2013, NAT MED, V19, P446, DOI 10.1038/nm.3102; Marlu R, 2012, THROMB HAEMOSTASIS, V108, P217, DOI 10.1160/TH12-03-0179; Maurice-Szamburski A, 2014, J NEUROSURG ANESTH, V26, P183, DOI 10.1097/ANA.0000000000000030; Mega JL, 2013, J AM COLL CARDIOL, V61, P1853, DOI 10.1016/j.jacc.2013.01.066; Melnikova I, 2009, NAT REV DRUG DISCOV, V8, P353, DOI 10.1038/nrd2851; Molina M, 2014, HEMATOL REP, V6, P14, DOI 10.4081/hr.2014.5283; Parra MW, 2013, J NEUROSURG, V119, P760, DOI 10.3171/2013.3.JNS12503; Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638; Pfeilschifter W, 2013, CEREBROVASC DIS, V36, P115, DOI 10.1159/000352062; Piccini JP, 2014, EUR HEART J, V35, P1873, DOI 10.1093/eurheartj/ehu083; Purrucker JC, 2014, AM J EMERG MED, V32, DOI 10.1016/j.ajem.2014.01.042; Samama MM, 2013, THROMB J, V11, DOI 10.1186/1477-9560-11-11; Spahn DR, 2013, CRIT CARE, V17, DOI 10.1186/cc12685; Stangier J, 2010, CLIN PHARMACOKINET, V49, P259, DOI 10.2165/11318170-000000000-00000; Wassef SN, 2013, NEUROSURGERY, V73, pE368, DOI 10.1227/01.neu.0000430763.95349.5f; Woo CH, 2014, WORLD NEUROSURG, V81, P110, DOI 10.1016/j.wneu.2012.12.002	27	24	24	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	SEP	2015	136						73	78		10.1016/j.clineuro.2015.05.035			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CP4XV	WOS:000359886800015	26070116				2021-06-18	
J	Dorminy, M; Hoogeveen, A; Tierney, RT; Higgins, M; McDevitt, JK; Kretzschmar, J				Dorminy, Millie; Hoogeveen, Ashley; Tierney, Ryan T.; Higgins, Michael; McDevitt, Jane K.; Kretzschmar, Jan			Effect of soccer heading ball speed on S100B, sideline concussion assessments and head impact kinematics	BRAIN INJURY			English	Article						Brain injury; brain injury biomarker; head impact acceleration; subconcussion; sub-concussive head impacts	NEURON-SPECIFIC ENOLASE; SERUM S-100B PROTEIN; BIOCHEMICAL MARKERS; POSTURAL CONTROL; BRAIN-INJURY; POSITION STATEMENT; DAMAGE S-100B; PLAYERS; ACCELERATION; SYMPTOMS	Objective: To examine the effect of soccer heading ball speed on S-100B serum concentration, concussion sideline assessments and linear head impact acceleration. Methods: Sixteen division I soccer players participated in this pre-test post-test design study. Athletes performed five standing headers over a 10 minute period at 30 (n=5), 40 (n=5) or 50 (n=6) miles per hour (mph) (randomized). S-100B serum concentration (ng mL(-1)) and sideline concussion assessments were measured prior to and post-heading. Peak resultant linear head acceleration (gravitational units; g) was measured during soccer heading. Results: No statistically significant interaction effects were identified between ball velocity groups over time on S100B (effect sizes ranged from 0.03-0.23) or concussion assessments tests. There was a non-significant increase (p=0.06) in head impact acceleration from the 30 (30.6; SD = 6.2 g) to 50 mph (50.7; SD = 7.7 g) ball speed. Conclusions: In this controlled setting, an acute bout of soccer heading across various ball velocities did not affect S100B or concussion assessment test scores. These findings are preliminary, as the small sample size in each group may have played a role in the lack of significant findings.	[Dorminy, Millie; Hoogeveen, Ashley; Tierney, Ryan T.; McDevitt, Jane K.; Kretzschmar, Jan] Temple Univ, Dept Kinesiol, Philadelphia, PA 19122 USA; [Higgins, Michael] Towson Univ, Dept Kinesiol, Towson, MD USA	Tierney, RT (corresponding author), 259 Pearson Hall,1800 North Broad St, Philadelphia, PA 19122 USA.	rtierney@temple.edu			Mid-Atlantic Athletic Trainers' Association	The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. This research was funded in part with a grant from the Mid-Atlantic Athletic Trainers' Association.	Biberthaler P, 2002, EUR J MED RES, V7, P164; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Broglio SP, 2004, BRIT J SPORT MED, V38, P561, DOI 10.1136/bjsm.2003.004887; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; de boussard CN, 2004, BRAIN INJURY, V18, P671, DOI 10.1080/02699050310001646215; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Eckner JT, 2011, J NEUROTRAUM, V28, P2079, DOI 10.1089/neu.2011.1910; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Haran FJ, 2013, INT J SPORTS MED, V34, P350, DOI 10.1055/s-0032-1304647; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Higgins MJ, 2009, P I MECH ENG P-J SPO, V223, P117, DOI 10.1243/17543371JSET15; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kaminski TW, 2008, RES Q EXERCISE SPORT, V79, P235; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Korfias S, 2009, MINI-REV MED CHEM, V9, P227, DOI 10.2174/138955709787315994; Mangus Brent C, 2004, Sports Biomech, V3, P209, DOI 10.1080/14763140408522841; Mansell JL, 2010, BRAIN INJURY, V24, P1070, DOI 10.3109/02699052.2010.494589; Matek J, 2012, Rozhl Chir, V91, P545; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Mussack T, 2003, EUR J MED RES, V8, P457; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; Portney L., 2015, FDN CLIN RES APPL PR, V3rd ed.; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Schmitt DM, 2004, INT J SPORTS MED, V25, P326, DOI 10.1055/s-2004-819941; Stalnacke BM, 2006, BRIT J SPORT MED, V40, P313, DOI 10.1136/bjsm.2005.021584; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; Straume-Naesheim TM, 2008, NEUROSURGERY, V62, P1297, DOI 10.1227/01.neu.0000333301.34189.3d; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Zetterberg H, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.037143; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	44	24	24	0	14	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2015	29	10					1158	1164		10.3109/02699052.2015.1035324			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CR3UK	WOS:000361258400003	26004753				2021-06-18	
J	Giatti, S; Garcia-Segura, LM; Melcangi, RC				Giatti, Silvia; Miguel Garcia-Segura, Luis; Melcangi, Roberto Cosimo			New steps forward in the neuroactive steroid field	JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY			English	Article						Synthesis; Metabolism; Levels; Sex difference; Protection; Detrimental effects	ACUTE REGULATORY PROTEIN; PERIPHERAL NERVOUS-SYSTEM; NEURAL ANDROGEN RECEPTOR; TRAUMATIC BRAIN-INJURY; SEX-DIMORPHIC CHANGES; GENDER-DIFFERENCES; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; MULTIPLE-SCLEROSIS; BENZODIAZEPINE-RECEPTOR	Evidence accumulated in recent years suggests that the systemic treatment with neuroactive steroids, or the pharmacological modulation of its production by brain cells, represent therapeutic options to promote neuroprotection. However, new findings, which are reviewed in this paper, suggest that the factors to be considered for the design of possible therapies based on neuroactive steroids are more complex than previously thought. Thus, although as recently reported, the nervous system regulates neuroactive steroid synthesis and metabolism in adaptation to modifications in peripheral steroidogenesis, the neuroactive steroid levels in the brain do not fully reflect its levels in plasma. Even, in some cases, neuroactive steroid level modifications occurring in the nervous tissues, under physiological and pathological conditions, are in the opposite direction than in the periphery. This suggests that the systemic treatment with these molecules may have unexpected outcomes on neural steroid levels. In addition, the multiple metabolic pathways and signaling mechanisms of neuroactive steroids, which may change from one brain region to another, together with the existence of regional and sex differences in its neural levels are additional sources of complexity that should be clarified. This complexity in the levels and actions of these molecules may explain why in some cases these molecules have detrimental rather than beneficial actions for the nervous system. This article is part of a Special Issue entitled 'Steroid Perspectives'. (C) 2015 Elsevier Ltd. All rights reserved.	[Giatti, Silvia; Melcangi, Roberto Cosimo] Univ Milan, Dept Pharmacol & Biomol Sci, I-20133 Milan, Italy; [Miguel Garcia-Segura, Luis] CSIC, Inst Cajal, E-28002 Madrid, Spain	Melcangi, RC (corresponding author), Univ Milan, Ctr Excellence Neurodegenerat Dis, Sect Biomed & Endocrinol, Dept Pharmacol & Biomol Sci, Via Balzaretti 9, I-20133 Milan, Italy.	roberto.melcangi@unimi.it	Giatti, Silvia/G-9334-2016; Garcia-Segura, Luis M/U-3711-2017	Giatti, Silvia/0000-0001-7741-826X; Garcia-Segura, Luis M/0000-0002-2450-2916; MELCANGI, COSIMO ROBERTO/0000-0003-0861-8967	Fondazione CariploFondazione Cariplo [2012-0547]; Ministerio de Economia y Competitividad, Spain [BFU2011-30217-C03-01]	We acknowledge financial support from the Fondazione Cariplo to R.C.M. (Grant number 2012-0547) and the Ministerio de Economia y Competitividad, Spain to L.M.G.S. (BFU2011-30217-C03-01).	Aaberg ML, 2008, J DIABETES COMPLICAT, V22, P83, DOI 10.1016/j.jdiacomp.2007.06.009; Aguirre C, 2010, J NEUROCHEM, V115, P1277, DOI 10.1111/j.1471-4159.2010.07038.x; Aguirre CC, 2009, EUR J NEUROSCI, V29, P447, DOI 10.1111/j.1460-9568.2008.06591.x; Almey A, 2014, ENDOCRINOLOGY, V155, P4422, DOI 10.1210/en.2014-1463; Andersen K, 1999, NEUROLOGY, V53, P1992, DOI 10.1212/WNL.53.9.1992; Arevalo MA, 2011, J MOL ENDOCRINOL, V46, pR1, DOI 10.1677/JME-10-0122; Backstrom T, 2014, PROG NEUROBIOL, V113, P88, DOI 10.1016/j.pneurobio.2013.07.005; Barros LA, 2015, NEUROSCI BIOBEHAV R, V49, P193, DOI 10.1016/j.neubiorev.2014.11.015; Basit Abdul, 2004, J Coll Physicians Surg Pak, V14, P79; Bauman ML, 2005, INT J DEV NEUROSCI, V23, P183, DOI 10.1016/j.ijdevneu.2004.09.006; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; Bengtsson SK, 2013, CURR ALZHEIMER RES, V10, P38; Biamonte F, 2009, NEUROBIOL DIS, V36, P103, DOI 10.1016/j.nbd.2009.07.001; Booya F, 2005, BMC NEUROL, V5, DOI 10.1186/1471-2377-5-24; Brinton RD, 2013, NAT REV ENDOCRINOL, V9, P241, DOI 10.1038/nrendo.2013.31; Brinton Roberta Diaz, 2006, Current Alzheimer Research, V3, P185; Brunton J.A., 2013, PROG NEUROBIOL; Buletko AB, 2012, NEUROTOXICOL TERATOL, V34, P336, DOI 10.1016/j.ntt.2012.03.003; Bychowski ME, 2012, HORM BEHAV, V61, P598, DOI 10.1016/j.yhbeh.2012.02.009; Carroll JC, 2008, NEUROSCI LETT, V445, P229, DOI 10.1016/j.neulet.2008.09.010; Caruso A, 2004, J NEUROCHEM, V88, P1179, DOI 10.1046/j.1471-4159.2004.02284.x; Caruso D, 2010, J NEUROENDOCRINOL, V22, P1137, DOI 10.1111/j.1365-2826.2010.02064.x; Caruso D, 2008, NEUROCHEM INT, V52, P560, DOI 10.1016/j.neuint.2007.06.004; Caruso D, 2008, J MOL NEUROSCI, V34, P249, DOI 10.1007/s12031-007-9029-3; Caruso D, 2015, J STEROID BIOCHEM, V146, P74, DOI 10.1016/j.jsbmb.2014.03.012; Caruso D, 2014, J NEUROCHEM, V130, P591, DOI 10.1111/jnc.12745; Caruso D, 2013, PSYCHONEUROENDOCRINO, V38, P2278, DOI 10.1016/j.psyneuen.2013.04.016; Caruso D, 2013, NEUROBIOL AGING, V34, P1080, DOI 10.1016/j.neurobiolaging.2012.10.007; Caruso D, 2010, J NEUROCHEM, V114, P921, DOI 10.1111/j.1471-4159.2010.06825.x; Cermenati G, 2010, J NEUROSCI, V30, P11896, DOI 10.1523/JNEUROSCI.1898-10.2010; Chen C, 2014, ENDOCRINOLOGY, V155, P2976, DOI 10.1210/en.2013-1844; Cheng J, 2007, J CEREBR BLOOD F MET, V27, P1553, DOI 10.1038/sj.jcbfm.9600457; Ciriza I, 2006, J NEUROBIOL, V66, P916, DOI 10.1002/neu.20293; Coirini H, 2002, NEUROSCIENCE, V113, P883, DOI 10.1016/S0306-4522(02)00224-5; Confavreux C, 2003, BRAIN, V126, P770, DOI 10.1093/brain/awg081; CORPECHOT C, 1993, ENDOCRINOLOGY, V133, P1003, DOI 10.1210/en.133.3.1003; Cummins CL, 2006, BIOCHEM SOC T, V34, P1110, DOI 10.1042/BST0341110; Darbra S, 2014, PROG NEUROBIOL, V113, P95, DOI 10.1016/j.pneurobio.2013.07.007; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; de Michele F, 2003, NEUROL SCI, V24, P172, DOI 10.1007/s10072-003-0115-1; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Fombonne E, 1999, PSYCHOL MED, V29, P769, DOI 10.1017/S0033291799008508; Fombonne E, 2003, J AUTISM DEV DISORD, V33, P365, DOI 10.1023/A:1025054610557; Fratiglioni L, 1997, NEUROLOGY, V48, P132, DOI 10.1212/WNL.48.1.132; Garcia-Segura LM, 2009, FRONT NEUROENDOCRIN, V30, pV, DOI 10.1016/j.yfrne.2009.04.006; Gemignani F, 2006, MOVEMENT DISORD, V21, P1254, DOI 10.1002/mds.20928; Giatti S, 2009, NEUROSCIENCE, V164, P520, DOI 10.1016/j.neuroscience.2009.08.005; Giatti S, 2013, J NEUROIMMUNE PHARM, V8, P238, DOI 10.1007/s11481-012-9385-9; Giatti S, 2012, J MOL ENDOCRINOL, V49, pR125, DOI 10.1530/JME-12-0127; Giatti S, 2010, NEUROCHEM INT, V56, P118, DOI 10.1016/j.neuint.2009.09.009; Gonzales RJ, 2013, PFLUG ARCH EUR J PHY, V465, P627, DOI 10.1007/s00424-013-1267-3; Handa RJ, 2008, HORM BEHAV, V53, P741, DOI 10.1016/j.yhbeh.2007.09.012; Hirst JJ, 2014, J STEROID BIOCHEM, V139, P144, DOI 10.1016/j.jsbmb.2013.04.002; Hoffman GE, 2001, EXP NEUROL, V171, P272, DOI 10.1006/exnr.2001.7783; Hojo Y, 2009, ENDOCRINOLOGY, V150, P5106, DOI 10.1210/en.2009-0305; Holmes S, 2013, ENDOCRINOLOGY, V154, P4281, DOI 10.1210/en.2013-1242; Irwin RW, 2014, PROG NEUROBIOL, V113, P40, DOI 10.1016/j.pneurobio.2013.08.004; JO D-H, 1989, Steroids, V54, P287, DOI 10.1016/0039-128X(89)90003-2; Kaye W, 2008, PHYSIOL BEHAV, V94, P121, DOI 10.1016/j.physbeh.2007.11.037; Khasnavis S, 2013, J BIOL CHEM, V288, P20843, DOI 10.1074/jbc.M112.443556; Kim HJ, 2003, MOL BRAIN RES, V115, P39, DOI 10.1016/S0169-328X(03)00177-3; Kipp M, 2009, FRONT NEUROENDOCRIN, V30, P188, DOI 10.1016/j.yfrne.2009.04.004; Kiziltan ME, 2007, J NEUROL SCI, V258, P75, DOI 10.1016/j.jns.2007.02.028; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Lacapere JJ, 2003, STEROIDS, V68, P569, DOI 10.1016/S0039-128X(03)00101-6; Lambert Jeremy J, 2009, Psychoneuroendocrinology, V34 Suppl 1, pS48, DOI 10.1016/j.psyneuen.2009.08.009; Lambert JJ, 2003, PROG NEUROBIOL, V71, P67, DOI 10.1016/j.pneurobio.2003.09.001; Lavaque E, 2006, NEUROSCIENCE, V138, P741, DOI 10.1016/j.neuroscience.2005.05.060; Lavaque E, 2006, J NEUROBIOL, V66, P308, DOI 10.1002/neu.20221; Lewis C, 2008, NEUROSCI LETT, V448, P130, DOI 10.1016/j.neulet.2008.10.011; Lu SF, 2003, J NEUROBIOL, V57, P163, DOI 10.1002/neu.10260; Luchetti S, 2011, NEUROSCIENCE, V191, P6, DOI 10.1016/j.neuroscience.2011.04.010; Luchetti S, 2014, J NEUROPATH EXP NEUR, V73, P123, DOI 10.1097/NEN.0000000000000037; Luchetti S, 2011, NEUROBIOL AGING, V32, P1964, DOI 10.1016/j.neurobiolaging.2009.12.014; Luchetti S, 2010, BRAIN PATHOL, V20, P945, DOI 10.1111/j.1750-3639.2010.00396.x; Madigan JE, 2012, EQUINE VET J, V44, P109, DOI 10.1111/j.2042-3306.2011.00504.x; Maninger N, 2009, FRONT NEUROENDOCRIN, V30, P65, DOI 10.1016/j.yfrne.2008.11.002; Marcus SM, 2008, COMPR PSYCHIAT, V49, P238, DOI 10.1016/j.comppsych.2007.06.012; Marx CE, 2011, NEUROSCIENCE, V191, P78, DOI 10.1016/j.neuroscience.2011.06.076; Marx CE, 2006, BIOL PSYCHIAT, V60, P1287, DOI 10.1016/j.biopsych.2006.06.017; Marx CE, 2009, NEUROPSYCHOPHARMACOL, V34, P1885, DOI 10.1038/npp.2009.26; Meffre D, 2007, ENDOCRINOLOGY, V148, P2505, DOI 10.1210/en.2006-1678; Meffre D, 2007, J STEROID BIOCHEM, V104, P293, DOI 10.1016/j.jsbmb.2007.03.003; Melcangi RC, 2008, CELL MOL LIFE SCI, V65, P777, DOI 10.1007/s00018-007-7403-5; Melcangi RC, 2013, J NEUROENDOCRINOL, V25, P957, DOI 10.1111/jne.12110; Melcangi RC, 2014, PROG NEUROBIOL, V113, P56, DOI 10.1016/j.pneurobio.2013.07.006; Melcangi RC, 2014, PROG NEUROBIOL, V113, P1, DOI 10.1016/j.pneurobio.2013.09.005; Melcangi RC, 2013, J SEX MED, V10, P2598, DOI 10.1111/jsm.12269; Melcangi Roberto Cosimo, 2011, Front Endocrinol (Lausanne), V2, P104, DOI 10.3389/fendo.2011.00104; Melcangi RC, 2012, J MOL NEUROSCI, V46, P177, DOI 10.1007/s12031-011-9570-y; Melcangi RC, 2010, HORM BEHAV, V57, P2, DOI 10.1016/j.yhbeh.2009.06.001; Mensah-Nyagan AG, 2008, NEUROCHEM INT, V52, P554, DOI 10.1016/j.neuint.2007.06.010; Mitro N, 2012, NEUROCHEM INT, V60, P616, DOI 10.1016/j.neuint.2012.02.025; Mo QX, 2006, J STEROID BIOCHEM, V99, P50, DOI 10.1016/j.jsbmb.2005.11.011; Mo QX, 2009, J STEROID BIOCHEM, V114, P135, DOI 10.1016/j.jsbmb.2009.01.015; Mo QM, 2004, MOL BRAIN RES, V126, P165, DOI 10.1016/j.molbrainres.2004.05.001; Morohaku K, 2014, ENDOCRINOLOGY, V155, P89, DOI 10.1210/en.2013-1556; Murray HE, 2003, NEUROSCIENCE, V116, P213, DOI 10.1016/S0306-4522(02)00578-X; Nag S, 2014, NEUROSCIENCE, V267, P122, DOI 10.1016/j.neuroscience.2014.02.040; Nakano T, 2010, BRAIN RES, V1357, P124, DOI 10.1016/j.brainres.2010.08.013; Niemeier JP, 2007, NEUROPSYCHOL REHABIL, V17, P293, DOI 10.1080/09602010600814729; Noonan CW, 2002, NEUROLOGY, V58, P136, DOI 10.1212/WNL.58.1.136; Noorbakhsh F, 2011, BRAIN, V134, P2703, DOI 10.1093/brain/awr200; Gomes FGN, 2014, PSYCHONEUROENDOCRINO, V50, P106, DOI 10.1016/j.psyneuen.2014.08.009; Orlando R, 2007, BRAIN RES, V1165, P21, DOI 10.1016/j.brainres.2007.06.047; Orton SM, 2006, LANCET NEUROL, V5, P932, DOI 10.1016/S1474-4422(06)70581-6; Padua L, 2006, NEUROL SCI, V27, P417, DOI 10.1007/s10072-006-0722-8; Palmen SJMC, 2004, BRAIN, V127, P2572, DOI 10.1093/brain/awh287; Panzica GC, 2012, J NEUROENDOCRINOL, V24, P1, DOI 10.1111/j.1365-2826.2011.02265.x; Papadopoulos V, 1997, J BIOL CHEM, V272, P32129, DOI 10.1074/jbc.272.51.32129; Parodi S, 2011, FRONT NEUROENDOCRIN, V32, P416, DOI 10.1016/j.yfrne.2011.06.003; Patte-Mensah C, 2014, PROG NEUROBIOL, V113, P70, DOI 10.1016/j.pneurobio.2013.07.004; PAUL SM, 1992, FASEB J, V6, P2311; Pediaditakis I, 2015, ENDOCRINOLOGY, V156, P16, DOI 10.1210/en.2014-1596; Pesaresi M, 2010, HORM BEHAV, V57, P46, DOI 10.1016/j.yhbeh.2009.04.008; PURDY RH, 1991, P NATL ACAD SCI USA, V88, P4553, DOI 10.1073/pnas.88.10.4553; Qin Y., 2015, J STEROID BIOCH MOL; Roglio I, 2008, NEUROSCIENCE, V155, P673, DOI 10.1016/j.neuroscience.2008.06.034; Romeo E, 1998, AM J PSYCHIAT, V155, P910, DOI 10.1176/ajp.155.7.910; Rosario ER, 2006, BRAIN RES, V1099, P206, DOI 10.1016/j.brainres.2006.03.127; Rosario ER, 2011, NEUROBIOL AGING, V32, P604, DOI 10.1016/j.neurobiolaging.2009.04.008; Rose KA, 1997, P NATL ACAD SCI USA, V94, P4925, DOI 10.1073/pnas.94.10.4925; Rupprecht R, 2010, NAT REV DRUG DISCOV, V9, P971, DOI 10.1038/nrd3295; Safarinejad MR, 2008, J NEUROENDOCRINOL, V20, P1368, DOI 10.1111/j.1365-2826.2008.01791.x; Schule C, 2014, PROG NEUROBIOL, V113, P79, DOI 10.1016/j.pneurobio.2013.09.003; Schumacher M, 2014, PROG NEUROBIOL, V113, P6, DOI 10.1016/j.pneurobio.2013.09.004; Schwendimann RN, 2007, INT REV NEUROBIOL, V79, P377, DOI 10.1016/S0074-7742(07)79017-7; Simonds VA, 2003, J AFFECT DISORDERS, V77, P197, DOI 10.1016/S0165-0327(02)00113-1; Smith CC, 2014, MOL PHARMACOL, V86, P390, DOI 10.1124/mol.114.094128; Tsuji M, 2012, EXP NEUROL, V233, P214, DOI 10.1016/j.expneurol.2011.10.004; Tsutsui K, 2012, CEREBELLUM, V11, P414, DOI 10.1007/s12311-011-0341-7; Uzunova V, 1998, P NATL ACAD SCI USA, V95, P3239, DOI 10.1073/pnas.95.6.3239; VOLKMAR FR, 1993, J AUTISM DEV DISORD, V23, P579, DOI 10.1007/BF01046103; Wei T, 1997, BRAIN, V120, P1067, DOI 10.1093/brain/120.6.1067; Weill-Engerer S, 2002, J CLIN ENDOCR METAB, V87, P5138, DOI 10.1210/jc.2002-020878; Wicher G, 2015, J STEROID BIOCHEM, V145, P21, DOI 10.1016/j.jsbmb.2014.09.022; Yang SH, 2002, J APPL PHYSIOL, V92, P195; Yang SY, 2014, J STEROID BIOCHEM, V143, P460, DOI 10.1016/j.jsbmb.2014.07.001; Yao J, 2011, BRAIN RES, V1379, P2, DOI 10.1016/j.brainres.2010.11.090; Yue X, 2005, P NATL ACAD SCI USA, V102, P19198, DOI 10.1073/pnas.0505203102; Zorumski CF, 2013, NEUROSCI BIOBEHAV R, V37, P109, DOI 10.1016/j.neubiorev.2012.10.005	141	24	24	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-0760			J STEROID BIOCHEM	J. Steroid Biochem. Mol. Biol.	SEP	2015	153				SI		127	134		10.1016/j.jsbmb.2015.03.002			8	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	CS9AY	WOS:000362382700015	25797031				2021-06-18	
J	Hsu, HL; Chen, DYT; Tseng, YC; Kuo, YS; Huang, YL; Chiu, WT; Yan, FX; Wang, WS; Chen, CJ				Hsu, Hui-Ling; Chen, David Yen-Ting; Tseng, Ying-Chi; Kuo, Ying-Sheng; Huang, Yen-Lin; Chiu, Wen-Ta; Yan, Feng-Xian; Wang, Wei-Shuan; Chen, Chi-Jen			Sex Differences in Working Memory after Mild Traumatic Brain Injury: A Functional MR Imaging Study	RADIOLOGY			English	Article							GENDER-DIFFERENCES; ABNORMALITIES; METAANALYSIS; CONCUSSION; SYMPTOMS; MODERATE; FMRI	Purpose: To evaluate sex differences in mild traumatic brain injury (MTBI) with working memory functional magnetic resonance (MR) imaging. Materials and Methods: Research ethics committee approval and patient written informed consent were obtained. Working memory brain activation patterns were assessed with functional MR imaging in 30 patients (15 consecutive men and 15 consecutive women) with MTBI and 30 control subjects (15 consecutive men and 15 consecutive women). Two imaging studies were performed in patients: the initial study, which was performed within 1 month after the injury, and a follow-up study, which was performed 6 weeks after the first study. For each participant, digit span and continuous performance testing were performed before functional MR imaging. Clinical data were analyzed by using Kruskal-Wallis, Mann-Whitney U, Wilcoxon signed rank, and Fisher exact tests. Within-and between-group differences of functional MR imaging data were analyzed with one-and two-sample t tests, respectively. Results: Among female participants, the total digit span score was lower in the MTBI group than in the control group (P = .044). In initial working memory functional MR imaging studies, hyperactivation was found in the male MTBI group and hypoactivation was found in the female MTBI group compared with control male and female groups, respectively. At the 6-week follow-up study, the female MTBI group showed persistent hypoactivation, whereas the male MTBI group showed a regression of hyperactivation at visual comparison of activation maps. The male MTBI group was also found to have a higher initial ss value than the male control group (P = .040), and there was no significant difference between the male MTBI group and the male control group (P = .221) at follow-up evaluation, which was comparable to findings on activation maps. In the female MTBI group, average ss values at both initial and follow-up studies were lower compared with those in the female control group but were not statistically significant (P = .663 and P = .191, respectively). Conclusion: Female patients with MTBI had lower digit span scores than did female control subjects, and functional MR imaging depicted sex differences in working memory functional activation; hypoactivation with nonrecovery of activation change at follow-up studies may suggest a worse working memory outcome in female patients with MTBI. (C) RSNA, 2015	[Chen, Chi-Jen] Taipei Med Univ, Shuang Ho Hosp, Dept Diagnost Radiol, New Taipei, Taiwan; Taipei Med Univ, Shuang Ho Hosp, Brain & Consciousness Res Ctr, New Taipei, Taiwan	Chen, CJ (corresponding author), Taipei Med Univ, Shuang Ho Hosp, Dept Diagnost Radiol, 291 Jhong Jheng Rd,235 Jhonghe Dist, New Taipei, Taiwan.	ed100975@yahoo.com			National Science Council, TaiwanMinistry of Science and Technology, Taiwan [NSC 101-2314-B-038-035-MY3]; Taipei Medical University, Taiwan [102TMU-SHH-20]	Supported by the National Science Council, Taiwan (grant NSC 101-2314-B-038-035-MY3), and Taipei Medical University, Taiwan (grant 102TMU-SHH-20).	American Congress of Rehabilitation Medicine (ACRM), 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Bryer EJ, 2013, J INT NEUROPSYCH SOC, V19, P751, DOI 10.1017/S1355617713000490; Cantu RC, 2010, PM&R, V2, P1088, DOI 10.1016/j.pmrj.2010.07.483; Chen CJ, 2012, RADIOLOGY, V264, P844, DOI 10.1148/radiol.12112154; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Covassin T, 2012, J NEUROSCI NURS, V44, P124, DOI 10.1097/JNN.0b013e318252737d; D'Esposito M, 1998, COGNITIVE BRAIN RES, V7, P1, DOI 10.1016/S0926-6410(98)00004-4; D'Esposito M, 2000, EXP BRAIN RES, V133, P3, DOI 10.1007/s002210000395; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Farace E, 2000, Neurosurg Focus, V8, pe6; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Goldstein JM, 2005, NEUROPSYCHOLOGY, V19, P509, DOI 10.1037/0894-4105.19.4.509; Hill AC, 2014, BIOL PSYCHOL, V102, P18, DOI 10.1016/j.biopsycho.2014.06.008; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Mayer AR, 2015, NEUROSCI BIOBEHAV R, V49, P8, DOI 10.1016/j.neubiorev.2014.11.016; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Speck O, 2000, NEUROREPORT, V11, P2581, DOI 10.1097/00001756-200008030-00046; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027	31	24	24	0	14	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	SEP	2015	276	3					828	835		10.1148/radiol.2015142549			8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CV6EM	WOS:000364363500022	25919663	Bronze			2021-06-18	
J	Huang, KB; Gu, Y; Hu, YF; Ji, Z; Wang, SN; Lin, ZZ; Li, X; Xie, ZS; Pan, SY				Huang, Kaibin; Gu, Yong; Hu, Yafang; Ji, Zhong; Wang, Shengnan; Lin, Zhenzhou; Li, Xing; Xie, Zuoshan; Pan, Suyue			Glibenclamide Improves Survival and Neurologic Outcome After Cardiac Arrest in Rats	CRITICAL CARE MEDICINE			English	Article						apoptosis; cardiac arrest; cytokines; glibenclamide; necrosis	EMERGENCY CARDIOVASCULAR CARE; AMERICAN-HEART-ASSOCIATION; TRAUMATIC BRAIN-INJURY; POTENTIAL MELASTATIN 4; NON-SHOCKABLE RHYTHMS; SPINAL-CORD-INJURY; ISCHEMIC-STROKE; CARDIOPULMONARY-RESUSCITATION; THERAPEUTIC HYPOTHERMIA; SUBARACHNOID HEMORRHAGE	Objectives: Glibenclamide confers neuroprotection in animal models as well as in retrospective clinical studies. This study determines whether glibenclamide improves outcome after cardiac arrest in rats. Design: Prospective randomized laboratory study. Setting: University research laboratory. Subjects: Male Sprague-Dawley rats (n = 126). Interventions: Rats successfully resuscitated from 8-minute asphyxial cardiac arrest were randomized to glibenclamide or vehicle group. Rats in the glibenclamide group were intraperitoneally administered glibenclamide with a loading dose of 10 mu g/kg at 10 minutes and a maintenance dose of 1.2 mu g at 6, 12, 18, and 24 hours after return of spontaneous circulation, whereas rats in the vehicle group received equivalent volume of vehicle solution. Measurements and Main Results: Survival was recorded every day, and neurologic deficit scores were assessed at 24, 48, and 72 hours and 7 days after return of spontaneous circulation (n = 22 in each group). Results showed that glibenclamide treatment increased 7-day survival rate, reduced neurologic deficit scores, and prevented neuronal loss in the hippocampal cornu ammonis 1 region. To investigate the neuroprotective effects of glibenclamide in acute phase, we observed neuronal injury at 24 hours after return of spontaneous circulation and found that glibenclamide significantly decreased the rate of neuronal necrosis and apoptosis. In addition, glibenclamide reduced the messenger RNA expression of tumor necrosis factor-a and monocyte chemoattractant protein-1 in the cortex after return of spontaneous circulation. Furthermore, the sulfonylurea receptor 1 and transient receptor potential M4 heteromers, the putative therapeutic targets of glibenclamide, were up-regulated after cardiac arrest and cardiopulmonary resuscitation, indicating that they might be involved in neuroprotective effect of glibenclamide. Conclusions: Glibenclamide treatment substantially improved survival and neurologic outcome throughout a 7-day period after return of spontaneous circulation. The salutary effects of glibenclamide were associated with suppression of neuronal necrosis and apoptosis, as well as inflammation in the brain.	[Huang, Kaibin; Gu, Yong; Hu, Yafang; Ji, Zhong; Wang, Shengnan; Lin, Zhenzhou; Li, Xing; Xie, Zuoshan; Pan, Suyue] Southern Med Univ, Nanfang Hosp, Dept Neurol, Guangzhou, Guangdong, Peoples R China	Pan, SY (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Neurol, Guangzhou, Guangdong, Peoples R China.	pansuyue82@126.com	Huang, Kaibin/AAC-6346-2019		National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271521, 81471339]; Science and Technology Planning Project of Guangdong Province of China [2012A030400011]; Ministry of Education of ChinaMinistry of Education, China [20124433110017]	This work is supported, in part, by the National Natural Science Foundation of China (grant No. 81271521, 81471339), the Science and Technology Planning Project of Guangdong Province of China (grant No. 2012A030400011), and the Doctoral Fund of Ministry of Education of China (grant No. 20124433110017).	Aittoniemi J, 2009, PHILOS T R SOC B, V364, P257, DOI 10.1098/rstb.2008.0142; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Callaway CW, 2008, CRIT CARE MED, V36, P2607, DOI 10.1097/CCM.0b013e318184443b; Ebmeyer U, 2014, RESUSCITATION, V85, P276, DOI 10.1016/j.resuscitation.2013.10.009; Field JM, 2010, CIRCULATION, V122, pS640, DOI 10.1161/CIRCULATIONAHA.110.970889; Gao CJ, 2010, NEUROSCIENCE, V168, P531, DOI 10.1016/j.neuroscience.2010.02.025; Gao CJ, 2012, NEUROSCIENCE, V202, P352, DOI 10.1016/j.neuroscience.2011.11.060; Gerzanich V, 2009, NAT MED, V15, P185, DOI 10.1038/nm.1899; Hickey RW, 2000, CRIT CARE MED, V28, P3511, DOI 10.1097/00003246-200010000-00027; Holzer M, 2002, NEW ENGL J MED, V346, P549; Huo TT, 2014, ANESTH ANALG, V119, P368, DOI 10.1213/ANE.0000000000000303; KATZ L, 1995, J CEREBR BLOOD F MET, V15, P1032, DOI 10.1038/jcbfm.1995.129; Katz LM, 2004, CRIT CARE MED, V32, P806, DOI 10.1097/01.CCM.0000114998.00860.FD; Kunte H, 2012, ANN NEUROL, V72, P799, DOI 10.1002/ana.23680; Lundbye JB, 2012, RESUSCITATION, V83, P202, DOI 10.1016/j.resuscitation.2011.08.005; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; Ortega FJ, 2013, J CEREBR BLOOD F MET, V33, P356, DOI 10.1038/jcbfm.2012.166; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Sheth KN, 2014, STROKE, V45, P281, DOI 10.1161/STROKEAHA.113.003352; Simard JM, 2013, SPINAL CORD, V51, P823, DOI 10.1038/sc.2013.99; Simard JM, 2012, PFLUG ARCH EUR J PHY, V464, P573, DOI 10.1007/s00424-012-1166-z; Simard JM, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000522; Simard JM, 2010, STROKE, V41, P531, DOI 10.1161/STROKEAHA.109.572644; Simard JM, 2009, J CEREBR BLOOD F MET, V29, P317, DOI 10.1038/jcbfm.2008.120; Simard JM, 2009, STROKE, V40, P604, DOI 10.1161/STROKEAHA.108.522409; Simard JM, 2006, NAT MED, V12, P433, DOI 10.1038/nm1390; Testori C, 2011, RESUSCITATION, V82, P1162, DOI 10.1016/j.resuscitation.2011.05.022; Tosun C, 2013, STROKE, V44, P3522, DOI 10.1161/STROKEAHA.113.002904; Tosun C, 2013, BRAIN SCI, V3, P215, DOI 10.3390/brainsci3010215; Vennekens R., 2007, V179, P269; Wang JM, 2013, J CEREBR BLOOD F MET, V33, P1574, DOI 10.1038/jcbfm.2013.111; Woo SK, 2013, J BIOL CHEM, V288, P3655, DOI 10.1074/jbc.M112.428219; Xiao F, 2004, RESUSCITATION, V61, P209, DOI 10.1016/j.resuscitation.2003.12.022; Yang L, 2014, RESUSCITATION, V85, P299, DOI 10.1016/j.resuscitation.2013.10.022; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Zhou YL, 2009, BRAIN RES, V1270, P131, DOI 10.1016/j.brainres.2009.03.010; Zweckberger K, 2014, NEUROSCIENCE, V272, P199, DOI 10.1016/j.neuroscience.2014.04.040	37	24	24	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	SEP	2015	43	9					E341	E349		10.1097/CCM.0000000000001093			9	Critical Care Medicine	General & Internal Medicine	DC5JH	WOS:000369256800002	26010685				2021-06-18	
J	Shelhamer, MC; Rowan, MP; Cancio, LC; Aden, JK; Rhie, RY; Merrill, GA; Wolf, SE; Renz, EM; Chung, KK				Shelhamer, Mehdi C.; Rowan, Matthew P.; Cancio, Leopoldo C.; Aden, James K.; Rhie, Ryan Y.; Merrill, Gerald A.; Wolf, Steven E.; Renz, Evan M.; Chung, Kevin K.			Recent trends in hospitalization and in-hospital mortality associated with traumatic brain injury in Canada: A nationwide, population-based study	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article							ACUTE RESPIRATORY-DISTRESS; FREQUENCY PERCUSSIVE VENTILATION; INHALATION INJURY; PREDICTIVE-VALUE; TIDAL VOLUMES; PATIENT; TIME; BIOMARKERS; PNEUMONIA; IMPROVES		[Shelhamer, Mehdi C.] Univ Cincinnati, Med Ctr, US Air Force, Ctr Sustainment Trauma & Readiness Skills, Cincinnati, OH 45267 USA; [Rowan, Matthew P.; Cancio, Leopoldo C.; Aden, James K.; Rhie, Ryan Y.; Merrill, Gerald A.; Renz, Evan M.; Chung, Kevin K.] US Army, Inst Surg Res, Jbsa Ft Sam Houston, TX USA; [Cancio, Leopoldo C.; Chung, Kevin K.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA; [Wolf, Steven E.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Renz, Evan M.; Chung, Kevin K.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA	Rowan, MP (corresponding author), 3698 Chambers Pass, San Antonio, TX 78234 USA.	matthew.p.rowan.vol@mail.mil		Rasmussen, Todd/0000-0003-1120-4116; Wolf, Steven/0000-0003-2972-3440; Cannon, Jeremy/0000-0002-2969-9316	Percussionaire, Inc.	This research was supported in part by an appointment (M.P.R.) to the Postgraduate Research Participation Program and an appointment (L.C.C.) to the Knowledge Preservation Program at the US Army Institute of Surgical Research administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and USAMRMC. L.C.C. received funding for travel expenses from Percussionaire, Inc., to speak at the Bird Institute, Sandpoint, Idaho, in 2013. The authors have no other conflicts of interest to declare.	Allan PF, 2010, J BURN CARE RES, V31, P510, DOI 10.1097/BCR.0b013e3181e4d605; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Belenkiy SM, 2014, J TRAUMA ACUTE CARE, V76, P821, DOI 10.1097/TA.0b013e3182aa2d21; BERNARD GR, 1994, INTENS CARE MED, V20, P225, DOI 10.1007/BF01704707; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Cancio LC, 2009, CLIN PLAST SURG, V36, P555, DOI 10.1016/j.cps.2009.05.013; Chung KK, 2010, CRIT CARE MED, V38, P1970, DOI 10.1097/CCM.0b013e3181eb9d0b; Csontos C, 2010, BURNS, V36, P483, DOI 10.1016/j.burns.2009.10.009; Davis Kimberly A, 2006, J Intensive Care Med, V21, P211, DOI 10.1177/0885066606288837; Determann RM, 2010, CRIT CARE, V14, DOI 10.1186/cc8230; Dries DJ, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-31; DROST AC, 1993, J TRAUMA, V35, P335, DOI 10.1097/00005373-199309000-00001; Eastman A, 2006, AM J SURG, V192, P191, DOI 10.1016/j.amjsurg.2006.01.021; Finnerty CC, 2008, MOL MED, V14, P553, DOI 10.2119/2007-00132.Finnerty; Finnerty CC, 2006, SHOCK, V26, P13, DOI 10.1097/01.shk.0000223120.26394.7d; Finnerty CC, 2013, CRIT CARE MED, V41, P1421, DOI 10.1097/CCM.0b013e31827c072e; Finnerty CC, 2012, CTS-CLIN TRANSL SCI, V5, P243, DOI 10.1111/j.1752-8062.2012.00412.x; Forde CT, 2014, BRIT J NEUROSURG, V28, P8, DOI 10.3109/02688697.2013.815317; Gauglitz GG, 2008, CRIT CARE, V12, DOI 10.1186/cc6932; Gomez R, 2009, J AM COLL SURGEONS, V208, P348, DOI 10.1016/j.jamcollsurg.2008.11.012; Guo R, 2014, CLIN CHEST MED, V35, P729, DOI 10.1016/j.ccm.2014.08.010; Hellyer TP, 2015, THORAX, V70, P41, DOI 10.1136/thoraxjnl-2014-205766; Jeschke MG, 2014, ANN SURG, V259, P814, DOI 10.1097/SLA.0b013e31828dfbf1; Kacmarek RM, 2010, CRIT CARE MED, V38, P2069, DOI 10.1097/CCM.0b013e3181f178cb; Kraft R, 2015, SHOCK, V43, P222, DOI 10.1097/SHK.0000000000000294; Luh Shi-Ping, 2007, Journal of Zhejiang University-Science B, V8, P60, DOI 10.1631/jzus.2007.B0060; Morris AC, 2010, THORAX, V65, P201, DOI 10.1136/thx.2009.122291; Peck MD, 2009, J BURN CARE RES, V30, P172, DOI 10.1097/BCR.0b013e3181923c32; Pham TN, 2008, J BURN CARE RES, V29, P257, DOI 10.1097/BCR.0b013e31815f3876; Ramirez P, 2009, CRIT CARE MED, V37, P1691, DOI 10.1097/CCM.0b013e31819fec5f; SHIRANI KZ, 1987, ANN SURG, V205, P82, DOI 10.1097/00000658-198701000-00015; Terpstra ML, 2014, CRIT CARE MED, V42, P691, DOI 10.1097/01.ccm.0000435669.60811.24; Tousoulis D, 2012, CURR MED CHEM, V19, P2534, DOI 10.2174/092986712800492968; Tousoulis D, 2015, CURR MED CHEM; Wang Y, 2010, BURNS, V36, P57, DOI 10.1016/j.burns.2009.04.014; Zambon M, 2008, CHEST, V133, P1120, DOI 10.1378/chest.07-2134	36	24	25	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	SEP	2015	79	3					431	436		10.1097/TA.0000000000000786			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	CQ4JV	WOS:000360571900018	26307877				2021-06-18	
J	Weersink, CSA; Aries, MJH; Dias, C; Liu, MX; Kolias, AG; Donnelly, J; Czosnyka, M; van Dijk, JMC; Regtien, J; Menon, DK; Hutchinson, PJ; Smielewski, P				Weersink, Corien S. A.; Aries, Marcel J. H.; Dias, Celeste; Liu, Mary X.; Kolias, Angelos G.; Donnelly, Joseph; Czosnyka, Marek; van Dijk, J. Marc C.; Regtien, Joost; Menon, David K.; Hutchinson, Peter J.; Smielewski, Peter			Clinical and Physiological Events That Contribute to the Success Rate of Finding "Optimal" Cerebral Perfusion Pressure in Severe Brain Trauma Patients	CRITICAL CARE MEDICINE			English	Article						cerebral autoregulation; optimal cerebral perfusion pressure; pressure reactivity index; therapy; traumatic brain injury	INTRACRANIAL-PRESSURE; DECOMPRESSIVE CRANIECTOMY; VASCULAR REACTIVITY; WAVE-FORM; AUTOREGULATION; NOREPINEPHRINE; HYPERTENSION; OXYGENATION; PROPOFOL	Objective: Recently, a concept of an individually targeted level of cerebral perfusion pressure that aims to restore impaired cerebral vasoreactivity has been advocated after traumatic brain injury. The relationship between cerebral perfusion pressure and pressure reactivity index normally is supposed to have a U-shape with its minimum interpreted as the value of "optimal" cerebral perfusion pressure. The aim of this study is to investigate the relation between the absence of the optimal cerebral perfusion pressure curve and physiological variables, clinical factors, and interventions. Design: Retrospective analysis of prospectively collected data. Setting: Neurocritical care units in two university centers. Patients: Between May 2012 and December 2013, a total of 48 traumatic brain injury patients were studied with real-time annotation of predefined clinical events. Interventions: None. Measurements and Main Results: All patients had continuous monitoring of arterial blood pressure, intracranial pressure, and cerebral perfusion pressure, with real-time calculations of pressure reactivity index and optimal cerebral perfusion pressure using ICM+ software (Cambridge Enterprise, University of Cambridge, Cambridge, UK). Selected clinical events were inserted on a daily basis, including changes in physiological variables, sedativeanalgesic drugs, vasoactive drugs, and medical/surgical therapies for intracranial hypertension. The collected data were divided into 4-hour periods, with the primary outcome being absence of the optimal cerebral perfusion pressure curve. For every period, mean values (+/- sds) of arterial blood pressure, intracranial pressure, pressure reactivity index, and other physiological variables were calculated; clinical events were organized using predefined scales. In 28% of all 1,561 periods, an optimal cerebral perfusion pressure curve was absent. A generalized linear mixed model with binary logistic regression was fitted. Absence of slow arterial blood pressure waves (odds ratio, 2.7; p < 0.001), higher pressure reactivity index values (odds ratio, 2.9; p < 0.001), lower amount of sedative-analgesic drugs (odds ratio, 1.9; p = 0.03), higher vasoactive medication dose (odds ratio, 3.2; p = 0.02), no administration of maintenance neuromuscular blockers (odds ratio, 1.7; p < 0.01), and following decompressive craniectomy (odds ratio, 1.8; p < 0.01) were independently associated with optimal cerebral perfusion pressure curve absence. Conclusions: This study identified six factors that were independently associated with absence of optimal cerebral perfusion pressure curves.	[Weersink, Corien S. A.; Aries, Marcel J. H.; Liu, Mary X.; Kolias, Angelos G.; Donnelly, Joseph; Czosnyka, Marek; Menon, David K.; Hutchinson, Peter J.; Smielewski, Peter] Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Cambridge CB2 2QQ, England; [Weersink, Corien S. A.; van Dijk, J. Marc C.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurosurg, Groningen, Netherlands; [Aries, Marcel J. H.; Regtien, Joost] Univ Groningen, Univ Med Ctr Groningen, Dept Crit Care, Groningen, Netherlands; [Dias, Celeste] Hosp Sao Joao, Neurocrit Care Unit, Dept Intens Care, Oporto, Portugal	Aries, MJH (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Cambridge CB2 2QQ, England.	m.j.h.aries@umcg.nl	Donnelly, Joseph/N-6803-2019; Donnelly, Joseph/E-9235-2018; Dias, Celeste/AAV-3820-2020; van Dijk, J. Marc C./C-1078-2013; Dias, Celeste/AAD-8711-2019	Donnelly, Joseph/0000-0002-6502-8069; Donnelly, Joseph/0000-0002-6502-8069; Dias, Celeste/0000-0003-0340-9808; van Dijk, J. Marc C./0000-0002-0814-5680; Smielewski, Peter/0000-0001-5096-3938; czosnyka, marek/0000-0003-2446-8006; Hutchinson, Peter/0000-0002-2796-1835; Kolias, Angelos/0000-0003-3992-0587	Marco Polo Fund, Groningen University Fund; Jan Kornelis de Cock Fund; Freemason Lodge "L' Union Provinciale" Groningen; Gates Scholarship; Royal College of Surgeons of England Research Fellowship; NIHR Academic Clinical Fellowship; Sackler Studentship; University of CambridgeUniversity of Cambridge; CenterTBI; Speaker fee BrainLab; National Institute for Health Research (NIHR), United KingdomNational Institute for Health Research (NIHR); NIHR Cambridge Biomedical Centre; NIHR Senior Investigator award; NIHR, United Kingdom; Framework Program 7 of the European Union; Medical Research Council (MRC), United KingdomUK Research & Innovation (UKRI)Medical Research Council UK (MRC); MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC); NIHRNational Institute for Health Research (NIHR); NIHR Cambridge Biomedical Research Centre grant; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390, G1002277] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-R3-12-013, NF-SI-0512-10090] Funding Source: researchfish	Dr. Weersink received grant support from the Marco Polo Fund, Groningen University Fund, and Jan Kornelis de Cock Fund (subsidizing study-related stay abroad) and is employed by HagaZiekenhuis Den Haag (from April 2014). Dr. Aries received grant support from Freemason Lodge "L' Union Provinciale" Groningen. Dr. Dias is employed by University Hospital Sao Joao, Porto. Dr. Liu received grant support and received support for travel from the Gates Scholarship. Dr. Kolias is supported by a Royal College of Surgeons of England Research Fellowship, an NIHR Academic Clinical Fellowship, and a Sackler Studentship. Dr. Czosnyka lectured for Inegra Life Science, consulted for Johnson and Johnson and Carag-Switzerland, and received support for article research from the University of Cambridge. Dr. Czosnyka and his institution received other support: licensing fee for ICM+ software. His institution received grant support from CenterTBI. Dr. van Dijk received support for travel from Speaker fee BrainLab (invited educational lecture at RT User meeting Copenhagen [March 2012]). Dr. Menon served as board member (he holds the following directorships on academic/charitable organizations: Co-Chair, European Brain Injury Consortium and Member, Board of Management, Intensive Care National Audit and Research Centre [London], but receives no financial benefit from these). He served as a paid consultant or member of the Data Monitoring Committee for Solvay, GlaxoSmithKline, Brainscope, Ornim Medical, Shire Medical, and Neurovive (not all are current-but all relevant associations for last 5 yr are listed). His contract of employment is with the University of Cambridge and with Addenbrooke's Hospital, Cambridge. He has a patent filed for PET ligand for mitochondrial function (no financial rewards so far); received royalties as Editor of the Textbook of Neuro-anaesthesia and Critical Care; and received support for article research from the National Institute for Health Research (NIHR), United Kingdom; the NIHR Cambridge Biomedical Centre; and an NIHR Senior Investigator award. His institution received grant support from the NIHR, United Kingdom; Framework Program 7 of the European Union; and Medical Research Council (MRC), United Kingdom (Project and Program Grant support); and has pending grants with MRC and NIHR, United Kingdom. Dr. Hutchinson received support for article research from the NIHR, the NIHR Cambridge Biomedical Research Centre grant, and the MRC; provided expert testimony for Medico-Legal; and lectured for J&J. His institution is employed by the NIHR. Dr. Smielewski and his institution received royalties from ICM+ software licensing fees (the author receives part of ICM+ [the software used to collect and partially analyzed data] licensing fees). The remaining authors have disclosed that they do not have any potential conflicts of interest.	Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Aries MJH, 2012, NEUROCRIT CARE, V17, P67, DOI 10.1007/s12028-012-9687-z; Balestreri M, 2004, ACTA NEUROCHIR, V146, P131, DOI 10.1007/s00701-003-0187-y; Brady KM, 2012, J APPL PHYSIOL, V113, P1362, DOI 10.1152/japplphysiol.00853.2012; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Coles JP, 2004, BRAIN, V127, P2479, DOI 10.1093/brain/awh268; Czosnyka M, 1997, J NEUROL NEUROSUR PS, V63, P721, DOI 10.1136/jnnp.63.6.721; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Depreitere B, 2014, J NEUROSURG, V120, P1451, DOI 10.3171/2014.3.JNS131500; Dias C., 2015, NEUROCRIT CARE; Feyen BFE, 2012, MINERVA ANESTESIOL, V78, P949; Harrison JM, 1999, BRIT J ANAESTH, V83, P839, DOI 10.1093/bja/83.6.839; Ho CL, 2008, J NEUROSURG, V108, P943, DOI 10.3171/JNS/2008/108/5/0943; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Howells T, 2015, J CLIN MONIT COMPUT, V29, P97, DOI 10.1007/s10877-014-9573-7; HSIANG JK, 1994, CRIT CARE MED, V22, P1471, DOI 10.1097/00003246-199409000-00019; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Le Roux P, 2014, INTENS CARE MED, V40, P1189, DOI 10.1007/s00134-014-3369-6; Maas AIR, 2012, LANCET NEUROL, V11, P12, DOI 10.1016/S1474-4422(11)70267-8; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Moppett IK, 2008, BRIT J ANAESTH, V100, P240, DOI 10.1093/bja/aem374; Panerai RB, 2010, J APPL PHYSIOL, V109, P1860, DOI 10.1152/japplphysiol.00857.2010; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Sanchez-Porras R, 2012, ACTA NEUROCHIR, V154, P1575, DOI 10.1007/s00701-012-1423-0; Smielewski P, 2008, ACTA NEUROCHIR SUPPL, V102, P145, DOI 10.1007/978-3-211-85578-2_30; Steiner LA, 2004, CRIT CARE MED, V32, P1049, DOI 10.1097/01.CCM.0000120054.32845.A6; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2003, ANESTH ANALG, V97, P572, DOI 10.1213/01.ANE.0000070234.17226.B0; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Stocchetti N, 2014, NEW ENGL J MED, V370, P2121, DOI 10.1056/NEJMra1208708; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066	33	24	25	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	SEP	2015	43	9					1952	1963		10.1097/CCM.0000000000001165			12	Critical Care Medicine	General & Internal Medicine	DC5JH	WOS:000369256800042	26154931				2021-06-18	
J	Zhang, Z; Saraswati, M; Koehler, RC; Robertson, C; Kannan, S				Zhang, Zhi; Saraswati, Manda; Koehler, Raymond C.; Robertson, Courtney; Kannan, Sujatha			A New Rabbit Model of Pediatric Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						microglia; pediatric traumatic brain injury; motor; rabbit; cognition	CONTROLLED CORTICAL IMPACT; CENTRAL-NERVOUS-SYSTEM; PROTEIN 18 KDA; WHITE-MATTER; HEAD-INJURY; CEREBRAL-PALSY; POSTNATAL-DEVELOPMENT; COGNITIVE DEFICITS; MOTOR DEFICITS; AXONAL INJURY	Traumatic brain injury (TBI) is a common cause of disability in childhood, resulting in numerous physical, behavioral, and cognitive sequelae, which can influence development through the lifespan. The mechanisms by which TBI influences normal development and maturation remain largely unknown. Pediatric rodent models of TBI often do not demonstrate the spectrum of motor and cognitive deficits seen in patients. To address this problem, we developed a New Zealand white rabbit model of pediatric TBI that better mimics the neurological injury seen after TBI in children. On postnatal Day 5-7 (P5-7), rabbits were injured by a controlled cortical impact (6-mm impactor tip; 5.5 m/sec, 2-mm depth, 50-msec duration). Rabbits from the same litter served as naive (no injury) and sham (craniotomy alone) controls. Functional abilities and activity levels were measured 1 and 5 d after injury. Maturation level was monitored daily. We performed cognitive tests during P14-24 and sacrificed the animals at 1, 3, 7, and 21 d after injury to evaluate lesion volume and microglia. TBI kits exhibited delayed achievement of normal developmental milestones. They also demonstrated significant cognitive deficits, with lower percentage of correct alternation rate in the T-maze (n=9-15/group; p<0.001) and less discrimination between novel and old objects (p<0.001). Lesion volume increased from 16% at Day 3 to 30% at Day 7 after injury, indicating ongoing secondary injury. Activated microglia were noted at the injury site and also in white matter regions of the ipsilateral and contralateral hemispheres. The neurologic and histologic changes in this model are comparable to those reported clinically. Thus, this rabbit model provides a novel platform for evaluating neuroprotective therapies in pediatric TBI.	[Zhang, Zhi; Saraswati, Manda; Koehler, Raymond C.; Robertson, Courtney; Kannan, Sujatha] Johns Hopkins Sch Med, Dept Anesthesiol & Crit Care, Baltimore, MD USA	Kannan, S (corresponding author), Dept Anesthesiol & Crit Care Med, Bloomberg Childrens Bldg 6318D-C4,1800 Orleans St, Baltimore, MD 21287 USA.	skannan3@jhmi.edu		Zhang, Zhi/0000-0001-6256-9516; Kannan, Sujatha/0000-0002-9497-5786	NICHD, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069562]; Department of Anesthesiology and Critical Care Medicine; Brain Science Institute, Johns Hopkins University School of Medicine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069562] Funding Source: NIH RePORTER	This work was funded in part by R01HD069562, NICHD, NIH; by the Department of Anesthesiology and Critical Care Medicine, and the Brain Science Institute, Johns Hopkins University School of Medicine.	Adelson PD, 2013, CHILD NERV SYST, V29, P43, DOI 10.1007/s00381-012-1932-4; Amick Jonathan E., 2001, Pediatr Crit Care Med, V2, P260, DOI 10.1097/00130478-200107000-00013; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Bass WT, 1998, HISTOCHEM J, V30, P657, DOI 10.1023/A:1003597010707; Bauman Johnson WL, 2010, ARCH CLIN NEUROPSYCH, V25, P601, DOI 10.1093/arclin/acq049; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Bigler ED, 2013, NEUROPSYCHOLOGY, V27, P438, DOI 10.1037/a0032837; Billiards SS, 2006, J COMP NEUROL, V497, P199, DOI 10.1002/cne.20991; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; BRODY BA, 1987, J NEUROPATH EXP NEUR, V46, P283, DOI 10.1097/00005072-198705000-00005; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Casey PA, 2008, J NEUROTRAUM, V25, P603, DOI 10.1089/neu.2007.0481; Chen CY, 2013, DEV NEUROSCI-BASEL, V35, P474, DOI 10.1159/000355874; Chen MK, 2008, PHARMACOL THERAPEUT, V118, P1, DOI 10.1016/j.pharmthera.2007.12.004; Clancy B, 2007, NEUROTOXICOLOGY, V28, P931, DOI 10.1016/j.neuro.2007.01.014; Conley YP, 2014, J NEUROTRAUM, V31, P34, DOI 10.1089/neu.2013.2855; Dapul HR, 2013, J NEUROTRAUM, V30, P382, DOI 10.1089/neu.2012.2536; de Graaf-Peters VB, 2006, EARLY HUM DEV, V82, P257, DOI 10.1016/j.earlhumdev.2005.10.013; Deacon RMJ, 2006, NAT PROTOC, V1, P7, DOI 10.1038/nprot.2006.2; DEGROOT D, 1978, BRAIN RES, V147, P362, DOI 10.1016/0006-8993(78)90846-6; DELHAYE-BOUCHAUD N, 1971, Developmental Psychobiology, V4, P375, DOI 10.1002/dev.420040410; Derrick M, 2004, J NEUROSCI, V24, P24, DOI 10.1523/JNEUROSCI.2816-03.2004; Derrick M, 2007, STROKE, V38, P731, DOI 10.1161/01.STR.0000251445.94697.64; Di Battista A, 2012, J NEUROTRAUM, V29, P1717, DOI 10.1089/neu.2011.2157; DIRESTA GR, 1990, ACT NEUR S, V51, P34; DOBBING J, 1973, ARCH DIS CHILD, V48, P757, DOI 10.1136/adc.48.10.757; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; Drobyshevsky A, 2005, J NEUROSCI, V25, P5988, DOI 10.1523/JNEUROSCI.4983-04.2005; Drobyshevsky A, 2014, EXP NEUROL, V261, P76, DOI 10.1016/j.expneurol.2014.06.021; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Durafourt BA, 2012, GLIA, V60, P717, DOI 10.1002/glia.22298; Eixarch E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031497; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Garringer JA, 2013, J NEUROTRAUM, V30, P1415, DOI 10.1089/neu.2012.2565; Georgiadis P, 2008, STROKE, V39, P3378, DOI 10.1161/STROKEAHA.107.510883; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; Hagberg H, 2012, ANN NEUROL, V71, P444, DOI 10.1002/ana.22620; HAREL S, 1972, BIOL NEONATE, V21, P381; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; Huh JW, 2007, J NEUROTRAUM, V24, P1460, DOI 10.1089/neu.2006.3787; Hutchison JS, 2001, J NEUROTRAUM, V18, P1333, DOI 10.1089/08977150152725632; Kannan S, 2007, J NUCL MED, V48, P946, DOI 10.2967/jnumed.106.038539; Kannan S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003162; Kannan S, 2011, DEV NEUROSCI-BASEL, V33, P231, DOI 10.1159/000328125; Kannan S, 2009, J CHILD NEUROL, V24, P1190, DOI 10.1177/0883073809338063; Kenk M., 2014, SCHIZOPHR B, V41, P85; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kilbaugh TJ, 2011, J NEUROTRAUM, V28, P763, DOI 10.1089/neu.2010.1635; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; MATHERS LH, 1979, BRAIN RES, V168, P21, DOI 10.1016/0006-8993(79)90125-2; Matsushima K, 2012, J CRIT CARE, V27, P125, DOI 10.1016/j.jcrc.2011.08.012; MCMULLEN NT, 1988, J COMP NEUROL, V278, P139, DOI 10.1002/cne.902780109; Mendez DR, 2004, J TRAUMA, V56, P1235, DOI 10.1097/01.TA.0000130759.62286.0E; Missios S, 2009, J NEUROTRAUM, V26, P1943, DOI [10.1089/neu.2009.0956, 10.1089/neu.2009-0956]; Mitchell RL, 2003, CLEFT PALATE-CRAN J, V40, P486, DOI 10.1597/1545-1569(2003)040<0486:ENBICR>2.0.CO;2; Morrison Gavin, 2013, Pathophysiology, V20, P49, DOI 10.1016/j.pathophys.2012.02.006; Pinto PS, 2012, J NEUROIMAGING, V22, pe1, DOI 10.1111/j.1552-6569.2011.00688.x; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Prinz M, 2014, NAT REV NEUROSCI, V15, P300, DOI 10.1038/nrn3722; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; RICE FL, 1985, J COMP NEUROL, V236, P477, DOI 10.1002/cne.902360405; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Robertson CL, 2013, J NEUROTRAUM, V30, P2066, DOI 10.1089/neu.2013.3007; Saadani-Makki F, 2009, J CHILD NEUROL, V24, P1179, DOI 10.1177/0883073809338213; Saadani-Makki F, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.06.090; Semple BD, 2012, J NEUROTRAUM, V29, P2672, DOI 10.1089/neu.2012.2595; Tan S, 2005, J CHILD NEUROL, V20, P972, DOI 10.1177/08830738050200120801; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Melo JRT, 2010, NEUROSURGERY, V67, P1542, DOI 10.1227/NEU.0b013e3181fa7049; Venneti S, 2006, PROG NEUROBIOL, V80, P308, DOI 10.1016/j.pneurobio.2006.10.002; Wang Y, 2014, EUR J NUCL MED MOL I, V41, P1440, DOI 10.1007/s00259-014-2727-5; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333	76	24	26	0	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP 1	2015	32	17					1369	1379		10.1089/neu.2014.3701			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CP0KP	WOS:000359564500010	25758339	Green Published			2021-06-18	
J	Carlozzi, NE; Beaumont, JL; Tulsky, DS; Gershon, RC				Carlozzi, Noelle E.; Beaumont, Jennifer L.; Tulsky, David S.; Gershon, Richard C.			The NIH Toolbox Pattern Comparison Processing Speed Test: Normative Data	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						NIH Toolbox; Processing speed; Pattern Comparison Processing Speed Test; Cognition; Neuropsychological assessment	TRAUMATIC BRAIN-INJURY; MILD COGNITIVE IMPAIRMENT; ADULT AGE-DIFFERENCES; ADDITION TASK PASAT; MULTIPLE-SCLEROSIS; ALZHEIMERS-DISEASE; WORKING-MEMORY; BEHAVIORAL FUNCTION; EXECUTIVE FUNCTION; VASCULAR DEMENTIA	The NIH Toolbox Pattern Comparison Processing Speed Test was developed to assess processing speed. While initial validation work provides preliminary support for this test in both children and adults, more work is needed to ensure dependability and generalizability. Thus, this replication study examines descriptive data (including age effects), test-retest reliability, and construct validity in n = 4,859 participants ages 3-85 years (matched to 2010 census data). Although the Pattern Comparison was not appropriate for all 3 and 4 years old, by ages 5 and 6, more meaningful scores were apparent. There was evidence for convergent and discriminant validity. There was also a moderate practice effect (i.e., increase of 5.5 points) over a 1-week time frame. Pattern Comparison exhibits a number of strengths: it is appropriate for use across the lifespan (ages 5-85), it is short and easy to administer, and there is support for construct validity.	[Carlozzi, Noelle E.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI USA; [Beaumont, Jennifer L.; Gershon, Richard C.] Northwestern Univ, Dept Med Social Sci, Chicago, IL 60611 USA; [Tulsky, David S.] Univ Delaware Hlth Sci, Dept Phys Therapy, Newark, DE USA; [Tulsky, David S.] Kessler Fdn, Neuropsychol & Neurosci Lab, Spinal Cord Injury Lab, West Orange, NJ USA	Carlozzi, NE (corresponding author), Ctr Clin Outcomes Dev & Applicat, Dept Phys Med & Rehabil, North Campus Res Complex,Bldg 14,2800 Plymouth Rd, Ann Arbor, MI 48109 USA.	carlozzi@med.umich.edu	Beaumont, Jennifer/AAA-2825-2020	Tulsky, David/0000-0002-4335-4509; Beaumont, Jennifer/0000-0002-1484-260X	National Institute of Health; NIH Toolbox for Assessment of Neurological and Behavioral Function [N01AG60007]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [N44AA002006] Funding Source: NIH RePORTER	This work was supported by the National Institute of Health; NIH Toolbox for Assessment of Neurological and Behavioral Function (contract number: N01AG60007).	Baudouin A, 2009, BRAIN COGNITION, V71, P240, DOI 10.1016/j.bandc.2009.08.007; Beaumont JL, 2013, NEUROLOGY, V80, pS87, DOI 10.1212/WNL.0b013e3182872e70; Bell NL, 2001, J CLIN PSYCHOL, V57, P417, DOI 10.1002/jclp.1024; Boone KB, 2007, ARCH CLIN NEUROPSYCH, V22, P355, DOI 10.1016/j.acn.2007.01.010; Breed S, 2008, J HEAD TRAUMA REHAB, V23, P149, DOI 10.1097/01.HTR.0000319931.76966.ff; Carlozzi NE, 2014, J INT NEUROPSYCH SOC, V20, P630, DOI 10.1017/S1355617714000319; Carlozzi NE, 2013, MONOGR SOC RES CHILD, V78, P88, DOI 10.1111/mono.12036; Casaletto K. B., J INT NEURO IN PRESS; Chiaravalloti ND, 2003, J CLIN EXP NEUROPSYC, V25, P489, DOI 10.1076/jcen.25.4.489.13878; Clay OJ, 2009, J AGING HEALTH, V21, P547, DOI 10.1177/0898264309333326; Coyle TR, 2011, PSYCHOL SCI, V22, P1265, DOI 10.1177/0956797611418243; de Jager CA, 2004, NEUROL RES, V26, P481, DOI 10.1179/016164104225016209; de Jager CA, 2003, PSYCHOL MED, V33, P1039, DOI 10.1017/S0033291703008031; De Monte VE, 2010, J CLIN EXP NEUROPSYC, V32, P28, DOI 10.1080/13803390902806519; DeLuca J, 2004, J CLIN EXP NEUROPSYC, V26, P550, DOI 10.1080/13803390490496641; Demaree HA, 1999, J NEUROL NEUROSUR PS, V67, P661, DOI 10.1136/jnnp.67.5.661; Denney DR, 2011, ARCH CLIN NEUROPSYCH, V26, P110, DOI 10.1093/arclin/acq104; Diehr MC, 1998, ASSESSMENT, V5, P375, DOI 10.1177/107319119800500407; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Duff K, 2007, ARCH CLIN NEUROPSYCH, V22, P15, DOI 10.1016/j.acn.2006.08.013; Earles JL, 1999, EXP AGING RES, V25, P243, DOI 10.1080/036107399244011; Forn C, 2008, J CLIN EXP NEUROPSYC, V30, P789, DOI 10.1080/13803390701779560; Funder DC, 2014, PERS SOC PSYCHOL REV, V18, P3, DOI 10.1177/1088868313507536; Gerritsen MJJ, 2003, J CLIN EXP NEUROPSYC, V25, P1, DOI 10.1076/jcen.25.1.1.13622; Gershon RC, 2014, J INT NEUROPSYCH SOC, V20, P642, DOI 10.1017/S1355617714000411; Gershon RC, 2013, MONOGR SOC RES CHILD, V78, P49, DOI 10.1111/mono.12034; Gershon RC, 2013, NEUROLOGY, V80, pS2, DOI 10.1212/WNL.0b013e3182872e5f; Gershon RC, 2010, LANCET NEUROL, V9, P138, DOI 10.1016/S1474-4422(09)70335-7; Gontkovsky ST, 2006, INT J NEUROSCI, V116, P1317, DOI 10.1080/00207450500516537; Gonzalez R, 2006, CLIN NEUROPSYCHOL, V20, P396, DOI 10.1080/13854040590967559; Gonzalez-Blanch C, 2010, SCHIZOPHR RES, V119, P18, DOI 10.1016/j.schres.2010.02.1072; Heaton R. K., 2003, CLIN INTERPRETATION, P181, DOI [DOI 10.1016/B978-012703570-3/50010-9, 10.1016/B978-012703570-3/50010-9]; Heyanka DJ, 2010, INT J NEUROSCI, V120, P409, DOI 10.3109/00207451003597177; KAIL R, 1994, ACTA PSYCHOL, V86, P199, DOI 10.1016/0001-6918(94)90003-5; Kail R, 1998, J CLIN EXP NEUROPSYC, V20, P98, DOI 10.1076/jcen.20.1.98.1483; KLINTEBERG B. A., 1987, PERCEPT MOTOR SKILL, V65, P683; Leskela M, 1999, EUR J NEUROL, V6, P653, DOI 10.1046/j.1468-1331.1999.660653.x; LINDENBERGER U, 1993, PSYCHOL AGING, V8, P207, DOI 10.1037/0882-7974.8.2.207; Llorente AM, 2004, APPL NEUROPSYCHOL, V11, P47, DOI 10.1207/s15324826an1101_6; Loranger M, 2000, PSYCHOL REP, V87, P893, DOI 10.2466/PR0.87.7.893-900; Machulda MM, 2013, CLIN NEUROPSYCHOL, V27, P1247, DOI 10.1080/13854046.2013.836567; Majeres RL, 1999, MEM COGNITION, V27, P246, DOI 10.3758/BF03211409; Majeres RL, 1997, PERCEPT MOTOR SKILL, V85, P1243, DOI 10.2466/pms.1997.85.3f.1243; Makel MC, 2014, PSYCHOL AESTHET CREA, V8, P27, DOI 10.1037/a0035811; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Mayes SD, 2007, CHILD NEUROPSYCHOL, V13, P469, DOI 10.1080/09297040601112773; McCaffrey R.J., 2000, PRACTITIONERS GUIDE; Mendez MF, 1997, BRAIN COGNITION, V34, P301, DOI 10.1006/brcg.1997.0923; Morrens M, 2008, Cogn Neuropsychiatry, V13, P457, DOI 10.1080/13546800802439312; Norman MA, 2011, J CLIN EXP NEUROPSYC, V33, P793, DOI 10.1080/13803395.2011.559157; Ojeda N, 2008, SCHIZOPHR RES, V101, P225, DOI 10.1016/j.schres.2007.12.483; Perbal S, 2003, NEUROPSYCHOLOGIA, V41, P1599, DOI 10.1016/S0028-3932(03)00110-6; Peters M, 1997, J MOTOR BEHAV, V29, P290, DOI 10.1080/00222899709600016; RAO SM, 1989, J CLIN EXP NEUROPSYC, V11, P471, DOI 10.1080/01688638908400907; ROIG M, 1992, PERCEPT MOTOR SKILL, V74, P1143, DOI 10.2466/PMS.74.4.1143-1148; SALTHOUSE TA, 1993, DEV PSYCHOL, V29, P722, DOI 10.1037/0012-1649.29.4.722; SALTHOUSE TA, 1983, LIFE-SPAN DEV BEHAV, V5, P89; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; SALTHOUSE TA, 1993, J GERONTOL, V48, pP245, DOI 10.1093/geronj/48.5.P245; Schmidt S, 2009, REV GEN PSYCHOL, V13, P90, DOI 10.1037/a0015108; Schwartz BS, 2004, ENVIRON HEALTH PERSP, V112, P314, DOI 10.1289/ehp.6727; Sliwinski M, 1999, PSYCHOL AGING, V14, P18, DOI 10.1037/0882-7974.14.1.18; Taylor MJ, 2001, J INT NEUROPSYCH SOC, V7, P867, DOI 10.1017/S1355617701777107; Tombaugh TN, 2007, ARCH CLIN NEUROPSYCH, V22, P25, DOI 10.1016/j.acn.2006.06.013; Tulsky DS, 2014, J INT NEUROPSYCH SOC, V20, P599, DOI 10.1017/S135561771400040X; Tulsky DS, 2013, MONOGR SOC RES CHILD, V78, P70, DOI 10.1111/mono.12035; Weintraub S, 2013, NEUROLOGY, V80, pS54, DOI 10.1212/WNL.0b013e3182872ded; Zelazo PD, 2014, J INT NEUROPSYCH SOC, V20, P620, DOI 10.1017/S1355617714000472; Zelazo PD, 2013, MONOGR SOC RES CHILD, V78, P16, DOI 10.1111/mono.12032	69	24	24	0	16	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2015	30	5					359	368		10.1093/arclin/acv031			10	Psychology, Clinical; Psychology	Psychology	CO3PS	WOS:000359071300001	26025230	Bronze, Green Published			2021-06-18	
J	Goiaei, A; Adhikari, U; Berkowitz, ML				Goiaei, Ardeshir; Adhikari, Upendra; Berkowitz, Max L.			Opening of the Blood-Brain Barrier Tight Junction Due to Shock Wave Induced Bubble Collapse: A Molecular Dynamics Simulation Study	ACS CHEMICAL NEUROSCIENCE			English	Article						Blood-brain barrier; shock wave; cavitation effect; traumatic brain injury; claudin protein; tight junction	DRUG-DELIVERY; FOCUSED ULTRASOUND; FORCE-FIELD; INJURY; INFLAMMATION; DISRUPTION; MELITTIN; MODEL; MICROBUBBLES; DYSFUNCTION	Passage of a shock wave across living organisms may produce bubbles in the blood vessels and capillaries. It was suggested that collapse of these bubbles imposed by an impinging shock wave can be responsible for the damage or even destruction of the blood-brain barrier. To check this possibility, we performed molecular dynamics computer simulations on systems that contained a model of tight junction from the blood-brain barrier. In our model, we represent the tight junction by two pairs of interacting proteins, claudin-15. Some of the simulations were done in the absence of a nanobubble, some in its presence. Our simulations show that when no bubble is present in the system, no damage to tight junction is observed when the shock wave propagates across it. In the presence of a nanobubble, even when the impulse of the shock wave is relatively low, the implosion of the bubble causes serious damage to our model tight junction.	[Goiaei, Ardeshir] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; [Goiaei, Ardeshir] Univ N Carolina, Program Mol & Cellular Biophys, Chapel Hill, NC 27599 USA; [Adhikari, Upendra; Berkowitz, Max L.] Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA	Berkowitz, ML (corresponding author), Univ N Carolina, Dept Chem, CB 3290, Chapel Hill, NC 27599 USA.	maxb@unc.edu		Berkowitz, Max/0000-0002-9116-0362	Office of Naval ResearchOffice of Naval Research [N00014-14-1-0241]	The support by Grant N00014-14-1-0241 from the Office of Naval Research is gratefully acknowledged.	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Adcock SA, 2006, CHEM REV, V106, P1589, DOI 10.1021/cr040426m; Adhikari U, 2015, J PHYS CHEM B, V119, P6225, DOI 10.1021/acs.jpcb.5b02218; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Choubey A, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3518472; de Jong DH, 2013, J CHEM THEORY COMPUT, V9, P687, DOI 10.1021/ct300646g; Del Razo M. J., 2015, ARXIV150309157; Dodson GG, 2008, EMBO REP, V9, P144, DOI 10.1038/sj.embor.7401160; Goliaei A, 2014, J PHYS CHEM B, V118, P12673, DOI 10.1021/jp507919p; Haseloff RF, 2015, SEMIN CELL DEV BIOL, V38, P16, DOI 10.1016/j.semcdb.2014.11.004; Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q; Hue CD, 2013, J NEUROTRAUM, V30, P1652, DOI 10.1089/neu.2012.2773; Husseini GA, 2014, COLLOID SURFACE B, V123, P364, DOI 10.1016/j.colsurfb.2014.07.051; Karplus M, 2005, P NATL ACAD SCI USA, V102, P6679, DOI 10.1073/pnas.0408930102; Kodama T, 2000, BIOPHYS J, V79, P1821, DOI 10.1016/S0006-3495(00)76432-0; Krause G, 2008, BBA-BIOMEMBRANES, V1778, P631, DOI 10.1016/j.bbamem.2007.10.018; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Liu HL, 2014, THERANOSTICS, V4, P432, DOI 10.7150/thno.8074; Liu HL, 2010, RADIOLOGY, V255, P415, DOI 10.1148/radiol.10090699; Marrink SJ, 2007, J PHYS CHEM B, V111, P7812, DOI 10.1021/jp071097f; Marrink SJ, 2013, CHEM SOC REV, V42, P6801, DOI 10.1039/c3cs60093a; McDannold N, 2012, CANCER RES, V72, P3652, DOI 10.1158/0008-5472.CAN-12-0128; Monticelli L, 2008, J CHEM THEORY COMPUT, V4, P819, DOI 10.1021/ct700324x; Nomura KI, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.148303; Ollila OHS, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.078101; Santo KP, 2015, J PHYS CHEM B, V119, P8879, DOI 10.1021/jp505720d; Santo KP, 2014, J CHEM PHYS, V140, DOI 10.1063/1.4862987; Santo KP, 2013, J PHYS CHEM B, V117, P5031, DOI 10.1021/jp312328n; Santo KP, 2012, J PHYS CHEM B, V116, P3021, DOI 10.1021/jp212018f; Sheikov N, 2004, ULTRASOUND MED BIOL, V30, P979, DOI 10.1016/j.ultrasmedbio.2004.04.010; Shetty AK, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00232; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Suzuki H, 2014, SCIENCE, V344, P304, DOI 10.1126/science.1248571; Tompkins P, 2013, J NEUROTRAUM, V30, P1888, DOI 10.1089/neu.2012.2674; Tribello GA, 2014, COMPUT PHYS COMMUN, V185, P604, DOI 10.1016/j.cpc.2013.09.018; Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291; Vedadi M, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.014503; Vykhodtseva N, 2008, ULTRASONICS, V48, P279, DOI 10.1016/j.ultras.2008.04.004; Warshel A, 2002, ACCOUNTS CHEM RES, V35, P385, DOI 10.1021/ar010033z; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7; Yesylevskyy SO, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000810; Zhao YZ, 2013, INT J NANOMED, V8, P1621, DOI 10.2147/IJN.S43589	44	24	24	2	43	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1948-7193			ACS CHEM NEUROSCI	ACS Chem. Neurosci.	AUG	2015	6	8					1296	1301		10.1021/acschemneuro.5b00116			6	Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology	CP6AS	WOS:000359967300005	26075566				2021-06-18	
J	Horn, SD; Corrigan, JD; Beaulieu, CL; Bogner, J; Barrett, RS; Giuffrida, CG; Ryser, DK; Cooper, K; Carroll, DM; Deutscher, D				Horn, Susan D.; Corrigan, John D.; Beaulieu, Cynthia L.; Bogner, Jennifer; Barrett, Ryan S.; Giuffrida, Clare G.; Ryser, David K.; Cooper, Kelli; Carroll, Deborah M.; Deutscher, Daniel			Traumatic Brain Injury Patient, Injury, Therapy, and Ancillary Treatments Associated With Outcomes at Discharge and 9 Months Postdischarge	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Craniocerebral trauma; Outcome assessment (health care); Rehabilitation	LENGTH-OF-STAY; FUNCTIONAL INDEPENDENCE MEASURE; COGNITIVE REHABILITATION; INPATIENT REHABILITATION; STROKE REHABILITATION; THE-LITERATURE; RECOVERY; INTENSITY; HALOPERIDOL; IMPAIRMENT	Objective: To examine associations of patient and injury characteristics, inpatient rehabilitation therapy activities, and neurotropic medications with outcomes at discharge and 9 months postdischarge for patients with traumatic brain injury (TBI). Design: Prospective, longitudinal observational study. Setting: Inpatient rehabilitation centers. Participants: Consecutive patients (N=2130) enrolled between 2008 and 2011, admitted for inpatient rehabilitation after an index TBI injury. Interventions: Not applicable. Main Outcome Measures: Rehabilitation length of stay, discharge to home, and FIM at discharge and 9 months postdischarge. Results: The admission F114 cognitive score was used to create 5 relatively homogeneous subgroups for subsequent analysis of treatment outcomes. Within each subgroup, significant associations were found between outcomes and patient and injury characteristics, time spent in therapy activities, and medications used. Patient and injury characteristics explained on average 35.7% of the variation in discharge outcomes and 22.3% in 9-month outcomes. Adding time spent and level of effort in therapy activities and percentage of stay using specific medications explained approximately 20% more variation for discharge outcomes and 12.9% for 9-month outcomes. After patient, injury, and treatment characteristics were used to predict outcomes, center differences added only approximately 1.9% additional variance explained. Conclusions: At discharge, greater effort during therapy sessions, time spent in more complex therapy activities, and use of specific medications were associated with better outcomes for patients in all admission FIM cognitive subgroups. At 9 months postdischarge, similar but less pervasive associations were observed for therapy activities, but not classes of medications. Further research is warranted to examine more specific combinations of therapy activities and medications that are associated with better outcomes. (C) 2015 by the American Congress of Rehabilitation Medicine	[Horn, Susan D.; Barrett, Ryan S.] Int Sever Informat Syst, Inst Clin Outcomes Res, Salt Lake City, UT USA; [Corrigan, John D.; Bogner, Jennifer] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Beaulieu, Cynthia L.] Brooks Rehabil Hosp, Jacksonville, FL USA; [Giuffrida, Clare G.] Rush Univ, Med Ctr, Chicago, IL 60612 USA; [Ryser, David K.; Cooper, Kelli; Carroll, Deborah M.] Intermt Med Ctr, Neuro Specialty Rehabil Unit, Salt Lake City, UT USA; [Deutscher, Daniel] Maccabi Healthcare Serv, Tel Aviv, Israel	Horn, SD (corresponding author), Univ Utah, Sch Med, Dept Populat Hlth Sci, Hlth Syst Innovat & Res Program, Williams Bdg,Rm 1N461,295 Chipeta Way, Salt Lake City, UT 84108 USA.	susan.horn@hsc.utah.edu			National Institutes of Health, National Center for Medical Rehabilitation ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01HD050439-01]; National Institute on Disability and Rehabilitation Research [H133A080023]; Ontario Neurotrauma Foundation [2007-ABI-ISIS-525]; American Congress of Rehabilitation Medicine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD050439] Funding Source: NIH RePORTER	Supported by the National Institutes of Health, National Center for Medical Rehabilitation Research (grant no. 1R01HD050439-01); National Institute on Disability and Rehabilitation Research (grant no. H133A080023); and Ontario Neurotrauma Foundation (grant no. 2007-ABI-ISIS-525).; Publication of this article was supported by the American Congress of Rehabilitation Medicine.	Baker E, 2012, INT J SPEECH-LANG PA, V14, P478, DOI 10.3109/17549507.2012.717967; Beaulieu CL, 2015, ARCH PHYS MED REHAB, V96, pS222, DOI 10.1016/j.apmr.2014.10.028; Blicher JU, 2008, NEUROREHABILITATION, V23, P175; Bode RK, 2004, ARCH PHYS MED REHAB, V85, P1901, DOI 10.1016/j.apmr.2004.02.023; Breceda EY, 2013, CURR OPIN NEUROL, V26, P595, DOI 10.1097/WCO.0000000000000024; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cifu DX, 2003, ARCH PHYS MED REHAB, V84, P1441, DOI 10.1016/S0003-9993(03)00272-7; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 2015, ARCH PHYS MED REHAB, V96, pS209, DOI 10.1016/j.apmr.2015.03.026; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; Dumas Helene M, 2004, Pediatr Phys Ther, V16, P157, DOI 10.1097/01.PEP.0000136004.69289.01; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Hammond FM, 2015, ARCH PHYS MED REHAB, V96, pS256, DOI 10.1016/j.apmr.2015.01.025; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; Horn SD, 2005, ARCH PHYS MED REHAB, V86, pS101, DOI 10.1016/j.apmr.2005.09.016; Horn SD, 2015, ARCH PHYS MED REHAB, V96, pS178, DOI 10.1016/j.apmr.2014.09.042; Horn SD, 2012, ARCH PHYS MED REHAB, V93, pS127, DOI 10.1016/j.apmr.2011.10.031; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Koehler R, 2011, COGNITIVE REHABILITATION THERAPY FOR TRAUMATIC BRAIN INJURY: EVALUATING THE EVIDENCE, P1; Kortte KB, 2007, ARCH PHYS MED REHAB, V88, P877, DOI 10.1016/j.apmr.2007.03.030; Kunik CL, 2006, ARCH PHYS MED REHAB, V87, P1590, DOI 10.1016/j.apmr.2006.09.001; Leon-Carrion J, 2013, BRAIN INJURY, V27, P1119, DOI 10.3109/02699052.2013.804204; Lequerica AH, 2007, J HEAD TRAUMA REHAB, V22, P177, DOI 10.1097/01.HTR.0000271118.96780.bc; Lequerica AH, 2010, AM J PHYS MED REHAB, V89, P415, DOI 10.1097/PHM.0b013e3181d8ceb2; Madeira G, 2007, LARYNGOL OTOL RHINOL, V128, P145; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; MASSAGLI TL, 1991, ARCH PHYS MED REHAB, V72, P219; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Rice SA, 2005, ARCH PHYS MED REHAB, V86, P834, DOI 10.1016/j.apmr.2004.11.006; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Seel RT, 2015, ARCH PHYS MED REHAB, V96, pS235, DOI 10.1016/j.apmr.2014.10.027; Seel RT, 2015, ARCH PHYS MED REHAB, V96, pS197, DOI 10.1016/j.apmr.2015.02.034; Tepas JJ, 2009, J PEDIATR SURG, V44, P368, DOI 10.1016/j.jpedsurg.2008.10.089; Togher L, 2012, INT J SPEECH-LANG PA, V14, P438, DOI 10.3109/17549507.2012.689334; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; Wagner AK, 2003, AM J PHYS MED REHAB, V82, P526, DOI 10.1097/00002060-200307000-00006; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; Whyte J, 2009, PROG BRAIN RES, V177, P63, DOI 10.1016/S0079-6123(09)17706-3	44	24	24	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2015	96	8		3			S304	S329		10.1016/j.apmr.2014.11.030			26	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	CO3CV	WOS:000359035100012	26212406	Green Accepted			2021-06-18	
J	Madden, LK; DeVon, HA				Madden, Lori Kennedy; DeVon, Holli A.			A Systematic Review of the Effects of Body Temperature on Outcome After Adult Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE NURSING			English	Article						body temperature; body temperature changes; brain injuries; craniocerebral trauma; emergency treatment; fever; hypothermia; normothermia; outcome	MILD HYPOTHERMIA THERAPY; SEVERE HEAD-INJURY; INTRACRANIAL HYPERTENSION; MODERATE HYPOTHERMIA; INTENSIVE-CARE; SECONDARY INSULTS; CARDIAC-ARREST; PHASE-II; HYPERTHERMIA; MANAGEMENT	Objective: This systematic review describes effects of body temperature alterations defined as fever, controlled normothermia, and spontaneous or induced hypothermia on outcome after traumatic brain injury (TBI) in adults. Data Sources: A search was conducted using PubMed, Cochrane Library database, Cumulative Index to Nursing and Allied Health Literature, EMBASE, and ISI Web of Science in July 2013 with no back date restriction except for induced hypothermia (2009). Study Selection: Of 1366 titles identified, 712 were reviewed. Sixteen articles met inclusion criteria: randomized controlled trials in hypothermia since 2009 (last Cochrane review) or cohort studies of temperature in TBI, measure core and/or brain temperature, neurologic outcome reporting, primarily adult patients, and English language publications. Exclusion criteria were as follows: most patients with non-TBI diagnosis, primarily pediatric patients, case reports, or laboratory/animal studies. Data Synthesis: Most studies found that fever avoidance resulted in positive outcomes including decreased length of stay in the intensive care unit; mortality; and incidence of hypertension, elevated intracranial pressure, and tachycardia. Hypothermia on admission correlated with poor outcomes. Controlled normothermia improved surrogate outcomes. Prophylactic induced hypothermia is not supported by the available evidence from randomized controlled trial. Conclusion: Setting a goal of normothermia, avoiding fever, and aggressively treating fever may be most important after TBI. Further research is needed to characterize the magnitude and duration of temperature alteration after TBI, determine if temperature alteration influences or predicts neurologic outcome, determine if rate of temperature change influences or predicts neurologic outcome, and compare controlled normothermia versus standard practice or hypothermia.	[Madden, Lori Kennedy] Univ Calif Davis, Dept Neurol Surg, Sacramento, CA 95817 USA; [DeVon, Holli A.] Univ Illinois, Coll Nursing, Dept Biobehav Hlth Sci, Chicago, IL USA	Madden, LK (corresponding author), Univ Calif Davis, Dept Neurol Surg, Sacramento, CA 95817 USA.	lkmadden@ucdavis.edu	Madden, Lori K/K-3749-2012	Madden, Lori K/0000-0001-9179-4202; DeVon, Holli/0000-0002-4526-9631	National Institute of Nursing Research of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [F31NR013813]; Gordon and Betty Moore FoundationGordon and Betty Moore Foundation; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR012012, F31NR013813] Funding Source: NIH RePORTER	Research reported in this publication was supported by the National Institute of Nursing Research of the National Institutes of Health (F31NR013813) and the Gordon and Betty Moore Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Adelson PD, 2009, J NEUROTRAUM, V26, P429, DOI 10.1089/neu.2008.0571; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Barker-Collo SL, 2009, NEUROEPIDEMIOLOGY, V32, P1, DOI 10.1159/000170084; Bayir H, 2009, CRIT CARE MED, V37, P689, DOI 10.1097/CCM.0b013e318194abf2; Bratton S.L., 2007, J NEUROTRAUMA S1, V24; Bukur M, 2012, J SURG RES, V175, P24, DOI 10.1016/j.jss.2011.07.003; BURCH JM, 1992, ANN SURG, V215, P476, DOI 10.1097/00000658-199205000-00010; Childs C, 2006, NEUROCRIT CARE, V5, P10, DOI 10.1385/NCC:5:1:10; Childs Charmaine, 2010, Front Neurol, V1, P146, DOI 10.3389/fneur.2010.00146; Clifton G L, 1995, New Horiz, V3, P474; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1995, J NEUROTRAUM, V12, P923, DOI 10.1089/neu.1995.12.923; Clifton GL, 2012, J NEUROSURG, V117, P714, DOI 10.3171/2012.6.JNS111690; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; Elf K, 2008, NEUROL RES, V30, P1097, DOI 10.1179/174313208X319125; Faul M. D., 2010, NATL CTR INJURY PREV, V2, P1; Fox JL, 2010, CAN J EMERG MED, V12, P355; Geffroy A, 2004, INTENS CARE MED, V30, P785, DOI 10.1007/s00134-004-2280-y; Inamasu J, 2006, J CLIN NEUROSCI, V13, P733, DOI 10.1016/j.jocn.2005.03.018; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Jiang JY, 2009, J NEUROTRAUM, V26, P399, DOI 10.1089/neu.2008.0525; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; JURKOVICH GJ, 1987, J TRAUMA, V27, P1019, DOI 10.1097/00005373-198709000-00011; Konstantinidis A, 2011, J TRAUMA, V71, P1627, DOI 10.1097/TA.0b013e3182159e31; Krieger DW, 2001, STROKE, V32, P1847, DOI 10.1161/01.STR.32.8.1847; Li J, 2012, J NEUROTRAUM, V29, P96, DOI 10.1089/neu.2011.1753; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Polderman KH, 2009, CRIT CARE MED, V37, P1101, DOI 10.1097/CCM.0b013e3181962ad5; Povlishock JT, 2009, J NEUROTRAUM, V26, P333, DOI 10.1089/neu.2008.0604; Puccio AM, 2009, NEUROCRIT CARE, V11, P82, DOI 10.1007/s12028-009-9213-0; Rittenberger JC, 2013, NEW ENGL J MED, V369, P2262, DOI 10.1056/NEJMe1312700; Sacho RH, 2010, J NEUROTRAUM, V27, P2157, DOI 10.1089/neu.2010.1384; Sadaka F, 2012, BRAIN INJURY, V26, P899, DOI 10.3109/02699052.2012.661120; Schroder ML, 1996, J NEUROTRAUM, V13, P17, DOI 10.1089/neu.1996.13.17; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shann F, 2003, LANCET, V362, P1950, DOI 10.1016/S0140-6736(03)15083-0; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Spiotta AM, 2008, NEUROSURGERY, V62, P864, DOI 10.1227/01.neu.0000316900.63124.ce; STEINEMANN S, 1990, J TRAUMA, V30, P200, DOI 10.1097/00005373-199002000-00011; Stocchetti N, 2002, INTENS CARE MED, V28, P1555, DOI 10.1007/s00134-002-1513-1; Sydenham E, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001048.pub4; Thompson Hilaire J, 2010, J Trauma Nurs, V17, P173, DOI 10.1097/JTN.0b013e3181ff272e; Thompson Hilaire J, 2007, Intensive Crit Care Nurs, V23, P91, DOI 10.1016/j.iccn.2006.11.005; Thompson HJ, 2003, J NEUROL NEUROSUR PS, V74, P614, DOI 10.1136/jnnp.74.5.614; Tokutomi T, 2009, J TRAUMA, V66, P166, DOI 10.1097/TA.0b013e318157dbec; Wong F W, 2000, Crit Care Nurse, V20, P18; Yamamoto T, 2002, NEUROL RES, V24, P789, DOI 10.1179/016164102101200906; Zhao QJ, 2011, J CRIT CARE, V26, P311, DOI 10.1016/j.jcrc.2010.08.014	53	24	24	0	31	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0888-0395	1945-2810		J NEUROSCI NURS	J. Neurosci. Nurs.	AUG	2015	47	4					190	203		10.1097/JNN.0000000000000142			14	Clinical Neurology; Nursing	Neurosciences & Neurology; Nursing	CM8KC	WOS:000357948100002	25951311	Green Accepted			2021-06-18	
J	Jin, YC; Lin, YY; Feng, JF; Jia, F; Gao, GY; Jiang, JY				Jin, Yichao; Lin, Yingying; Feng, Jun-feng; Jia, Feng; Gao, Guo-yi; Jiang, Ji-yao			Moderate Hypothermia Significantly Decreases Hippocampal Cell Death Involving Autophagy Pathway after Moderate Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						autophagy; cell death; hippocampus; moderate hypothermia; traumatic brain injury	BCL-X-L; FLUID-PERCUSSION MODEL; CLOSED-HEAD INJURY; BECLIN 1; THERAPEUTIC HYPOTHERMIA; REGULATES AUTOPHAGY; BEHAVIORAL DEFICITS; MILD HYPOTHERMIA; RAT MODEL; APOPTOSIS	Here, we evaluated changes in autophagy after post-traumatic brain injury (TBI) followed by moderate hypothermia in rats. Adult male Sprague-Dawley rats were randomly divided into four groups: sham injury with normothermia group (37 degrees C); sham injury with hypothermia group (32 degrees C); TBI with normothermia group (TNG; 37 degrees C); and TBI with hypothermia group (THG; 32 degrees C). Injury was induced by a fluid percussion TBI device. Moderate hypothermia (32 degrees C) was achieved by partial immersion in a water bath (0 degrees C) under general anesthesia for 4h. All rats were killed at 24h after fluid percussion TBI. The ipsilateral hippocampus in all rats was analyzed with hematoxylin and eosin staining; terminal deoxynucleoitidyl transferase-mediated nick end labeling staining was used to determine cell death in ipsilateral hippocampus. Immunohistochemistry and western blotting of microtubule-associated protein light chain 3 (LC3), Beclin-1, as well as transmission electron microscopy performed to assess changes in autophagy. At 24h after TBI, the cell death index was 27.90 +/- 2.36% in TNG and 14.90 +/- 1.52% in THG. Expression level of LC3 and Beclin-1 were significantly increased after TBI and were further up-regulated after post-TBI hypothermia. Further, ultrastructural observations showed that there was a marked increase of autophagosomes and autolysosomes in ipsilateral hippocampus after post-TBI hypothermia. Our data demonstrated that moderate hypothermia significantly attenuated cell death and increased autophagy in ipsilateral hippocampus after fluid percussion TBI. In conclusion, autophagy pathway may participate in the neuroprotective effect of post-TBI hypothermia.	[Jin, Yichao; Lin, Yingying; Feng, Jun-feng; Jia, Feng; Gao, Guo-yi; Jiang, Ji-yao] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Neurosurg, Shanghai 200127, Peoples R China	Jiang, JY (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Renji Hosp, Dept Neurosurg, 1630 Dongfang Rd, Shanghai 200127, Peoples R China.	jiyaojiang@126.com			National Science and Nature grant [81271381]; National Key project [2012CB518100]	This work was supported by grants from a National Science and Nature grant (no. 81271381) and the National Key project (no. 2012CB518100).	Balduini W, 2012, J MATERN-FETAL NEO M, V25, P30, DOI 10.3109/14767058.2012.663176; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Celik SE, 2006, J NEUROTRAUM, V23, P1355, DOI 10.1089/neu.2006.23.1355; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Gordy C, 2012, PROTEIN CELL, V3, P17, DOI 10.1007/s13238-011-1127-x; He Y, 2008, J CEREBR BLOOD F MET, V28, P897, DOI 10.1038/sj.jcbfm.9600578; Jia F, 2009, J NEUROTRAUM, V26, P243, DOI 10.1089/neu.2008.0670; Jiang JY, 2009, J NEUROTRAUM, V26, P399, DOI 10.1089/neu.2008.0525; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Jing CH, 2012, NEUROSCIENCE, V213, P144, DOI 10.1016/j.neuroscience.2012.03.055; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191; Kang R, 2010, AUTOPHAGY, V6, P1209, DOI 10.4161/auto.6.8.13651; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Lu J, 2000, NEUROSCI LETT, V290, P89, DOI 10.1016/S0304-3940(00)01307-0; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo S, 2007, CELL DEATH DIFFER, V14, P1247, DOI 10.1038/sj.cdd.4402149; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002; Moore EM, 2011, INJURY, V42, P843, DOI 10.1016/j.injury.2011.03.027; Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Sadasivan S, 2008, BIOCHEM BIOPH RES CO, V373, P478, DOI 10.1016/j.bbrc.2008.05.031; Slemmer JE, 2008, AM J PATHOL, V173, P1795, DOI 10.2353/ajpath.2008.080168; Son JH, 2012, EXP MOL MED, V44, P89, DOI 10.3858/emm.2012.44.2.031; Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Uchiyama Y, 2008, HISTOCHEM CELL BIOL, V129, P407, DOI 10.1007/s00418-008-0406-y; Urbano LA, 2012, CURR NEUROL NEUROSCI, V12, P580, DOI 10.1007/s11910-012-0304-5; Viscomi MT, 2012, AUTOPHAGY, V8, P222, DOI 10.4161/auto.8.2.18599; Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001; Zalckvar E, 2009, AUTOPHAGY, V5, P720, DOI 10.4161/auto.5.5.8625; Zalckvar E, 2009, EMBO REP, V10, P285, DOI 10.1038/embor.2008.246; Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0	43	24	28	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 15	2015	32	14					1090	1100		10.1089/neu.2014.3649			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV0TB	WOS:000363965000008	25942484	Green Published			2021-06-18	
J	Amen, DG; Raji, CA; Willeumier, K; Taylor, D; Tarzwell, R; Newberg, A; Henderson, TA				Amen, Daniel G.; Raji, Cyrus A.; Willeumier, Kristen; Taylor, Derek; Tarzwell, Robert; Newberg, Andrew; Henderson, Theodore A.			Functional Neuroimaging Distinguishes Posttraumatic Stress Disorder from Traumatic Brain Injury in Focused and Large Community Datasets	PLOS ONE			English	Article							CEREBRAL-BLOOD-FLOW; TRANSCRANIAL MAGNETIC STIMULATION; EMISSION COMPUTED-TOMOGRAPHY; MENTAL-HEALTH PROBLEMS; PSYCHIATRIC-DISORDERS; PREFRONTAL CORTEX; POLICE OFFICERS; PTSD SYMPTOMS; PERFUSION; SPECT	Background Traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD) are highly heterogeneous and often present with overlapping symptomology, providing challenges in reliable classification and treatment. Single photon emission computed tomography (SPECT) may be advantageous in the diagnostic separation of these disorders when comorbid or clinically indistinct. Methods Subjects were selected from a multisite database, where rest and on-task SPECT scans were obtained on a large group of neuropsychiatric patients. Two groups were analyzed: Group 1 with TBI (n=104), PTSD (n=104) or both (n=73) closely matched for demographics and comorbidity, compared to each other and healthy controls (N=116); Group 2 with TBI (n=7,505), PTSD (n=1,077) or both (n=1,017) compared to n=11,147 without either. ROIs and visual readings (VRs) were analyzed using a binary logistic regression model with predicted probabilities inputted into a Receiver Operating Characteristic analysis to identify sensitivity, specificity, and accuracy. One-way ANOVA identified the most diagnostically significant regions of increased perfusion in PTSD compared to TBI. Analysis included a 10-fold cross validation of the protocol in the larger community sample (Group 2). Results For Group 1, baseline and on-task ROIs and VRs showed a high level of accuracy in differentiating PTSD, TBI and PTSD+TBI conditions. This carefully matched group separated with 100% sensitivity, specificity and accuracy for the ROI analysis and at 89% or above for VRs. Group 2 had lower sensitivity, specificity and accuracy, but still in a clinically relevant range. Compared to subjects with TBI, PTSD showed increases in the limbic regions, cingulum, basal ganglia, insula, thalamus, prefrontal cortex and temporal lobes. Conclusions This study demonstrates the ability to separate PTSD and TBI from healthy controls, from each other, and detect their co-occurrence, even in highly comorbid samples, using SPECT. This modality may offer a clinical option for aiding diagnosis and treatment of these conditions.	[Amen, Daniel G.; Willeumier, Kristen; Taylor, Derek] Amen Clin Inc, Dept Res, Costa Mesa, CA 92626 USA; [Raji, Cyrus A.] Univ Calif Los Angeles, Dept Radiol, Los Angeles, CA USA; [Tarzwell, Robert] Univ British Columbia, Lions Gate Hosp, Fac Med, Dept Psychiat, N Vancouver, BC, Canada; [Newberg, Andrew] Thomas Jefferson Univ, Dept Radiol, Philadelphia, PA 19107 USA; [Henderson, Theodore A.] Synapt Space, Denver, CO USA; [Henderson, Theodore A.] Int Soc Appl Neuroimaging, Denver, CO USA	Amen, DG (corresponding author), Amen Clin Inc, Dept Res, Costa Mesa, CA 92626 USA.	docamen@amenclinics.com					Amen DG, 2008, J PSYCHOACTIVE DRUGS, V40, P139, DOI 10.1080/02791072.2008.10400623; Amen DG, 2008, J PSYCHOACTIVE DRUGS, V40, P131, DOI 10.1080/02791072.2008.10400622; Anderson RJ, 2008, MOL INTERV, V8, P204, DOI 10.1124/mi.8.5.2; [Anonymous], 2009, GULF AND WAR HEALTH; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Berlim MT, 2014, CAN J PSYCHIAT, V59, P487, DOI 10.1177/070674371405900905; Bigler ED, 2003, ARCH CLIN NEUROPSYCH, V18, P595; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bonne O, 2003, BIOL PSYCHIAT, V54, P1077, DOI 10.1016/S0006-3223(03)00525-0; Bremner J D, 1999, Semin Clin Neuropsychiatry, V4, P249; Bremner JD, 1997, ARCH GEN PSYCHIAT, V54, P246; Bremner JD, 2003, AM J PSYCHIAT, V160, P924, DOI 10.1176/appi.ajp.160.5.924; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Byrnes Kimberly R, 2014, Front Neuroenergetics, V5, P13, DOI 10.3389/fnene.2013.00013; Casson IR, 2011, SPORTS HEALTH, V3, P11, DOI 10.1177/1941738110391413; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; Castel-Lacanal E, 2014, ANN FR ANESTH, V33, P83, DOI 10.1016/j.annfar.2013.11.006; Centers for Disease Control and Prevention, INJURY PREVENTION AN; Centers for Disease Control and Prevention, EB BASED INJURY STAT; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; CHANG W, 1984, J NUCL MED, V25, P788; Chung YA, 2006, CLIN NEUROPHYSIOL, V117, P637, DOI 10.1016/j.clinph.2005.10.020; Davenport ND, 2015, HUM BRAIN MAPP, V36, P1053, DOI 10.1002/hbm.22685; Defense and Veterans Brain Injury Center, DOD WORLDWIDE NUMBER; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fischer BL, 2014, J NEUROTRAUM, V31, P169, DOI 10.1089/neu.2013.2877; Fischer H, 2014, U S MILITARY CASUALT; Francati V, 2007, DEPRESS ANXIETY, V24, P202, DOI 10.1002/da.20208; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; Hastie TT, 2001, THE ELEMENTS OF STAT, DOI [10.1016/j.neunet.2009.04.005, DOI 10.1016/J.NEUNET.2009.04.005]; Hayes JP, 2012, BIOL MOOD ANXIETY DI, V2, DOI 10.1186/2045-5380-2-9; Hermes E, 2014, EPIDEMIOL PSYCH SCI, V23, P281, DOI 10.1017/S2045796013000449; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Huang MX, 2016, PSYCHONEUROENDOCRINO, V63, P398, DOI 10.1016/j.psyneuen.2015.02.008; Jacobs A, 1996, J NUCL MED, V37, P1605; Jain S, 2012, PSYCHIAT SERV, V63, P154, DOI 10.1176/appi.ps.201100199; Jeyaraj JA, 2013, BRAIN INJURY, V27, P1338, DOI 10.3109/02699052.2013.823650; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kasai K, 2008, BIOL PSYCHIAT, V63, P550, DOI 10.1016/j.biopsych.2007.06.022; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kim J, 2012, NEUROREHAB NEURAL RE, V26, P870, DOI 10.1177/1545968311434553; Kim SY, 2012, PSYCHIAT RES-NEUROIM, V201, P214, DOI 10.1016/j.pscychresns.2011.08.007; Kinuya K, 2004, NUCL MED COMMUN, V25, P333, DOI 10.1097/00006231-200404000-00004; Kitayama N, 2006, J AFFECT DISORDERS, V90, P171, DOI 10.1016/j.jad.2005.11.006; Kline AE, 2008, NEUROSCI LETT, V448, P263, DOI 10.1016/j.neulet.2008.10.076; Krystal JH, 2014, CELL, V157, P201, DOI 10.1016/j.cell.2014.02.042; Krystal JH, 2011, JAMA-J AM MED ASSOC, V306, P493, DOI 10.1001/jama.2011.1080; Lanius RA, 2010, ACTA PSYCHIAT SCAND, V121, P33, DOI 10.1111/j.1600-0447.2009.01391.x; Lee Bruce, 2005, NeuroRx, V2, P372; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; Lindauer RJL, 2008, PSYCHOL MED, V38, P543, DOI 10.1017/S0033291707001432; Lindauer RJL, 2004, BIOL PSYCHIAT, V56, P853, DOI 10.1016/j.biopsych.2004.08.003; Lindauer RJL, 2004, BIOL PSYCHIAT, V56, P356, DOI 10.1016/j.biopsych.2004.05.021; Lucey JV, 1997, BRIT J PSYCHIAT, V171, P346, DOI 10.1192/bjp.171.4.346; Macera CA, 2012, J REHABIL RES DEV, V49, P1197, DOI 10.1682/JRRD.2011.07.0131; Mai JK, 1997, ATLAS OF THE HUMAN B; Maroon JC, 2012, PHYSICIAN SPORTSMED, V40, P73, DOI 10.3810/psm.2012.11.1990; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Morgan M, 2012, PSYCHIAT SERV, V63, P182, DOI 10.1176/appi.ps.201000531; National Institute of Mental Health, POST TRAUMATIC STRES; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pavel D, 2006, BRAIN COGNITION, V60, P211; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Peterson A, 2014, CAN J PSYCHIAT, V59, P294; Phelps TI, 2015, J NEUROTRAUM, V32, P590, DOI 10.1089/neu.2014.3711; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Raji CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091088; Rauch SL, 2000, BIOL PSYCHIAT, V47, P769, DOI 10.1016/S0006-3223(00)00828-3; Rigg JL, 2011, PM&R, V3, pS380, DOI 10.1016/j.pmrj.2011.08.005; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Ruffolo LF, 2000, CLIN NEUROPSYCHOL, V14, P223, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT223; Sachinvala N, 2000, MIL MED, V165, P473; Sartory G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058150; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Seedat S, 2004, J AFFECT DISORDERS, V80, P45, DOI 10.1016/S0165-0327(03)00047-8; Selassie AW, 2013, ANN EPIDEMIOL, V23, P750, DOI 10.1016/j.annepidem.2013.07.022; Shin LM, 2004, ARCH GEN PSYCHIAT, V61, P168, DOI 10.1001/archpsyc.61.2.168; Silver JM, 2011, TEXTBOOK OF TRAUMATI, P609; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Stamatakis EA, 1999, BEHAV NEUROL, V12, P29, DOI 10.1155/2000/681916; Stamatakis EA, 2002, J NUCL MED, V43, P476; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Tanielan T, 2008, INVISIBLE WOUNDS OF; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; TEASDALE G, 1974, LANCET, V2, P81; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; The American College of Radiology, 2014, ACR SPR PRACTICE PAR; Thomas JT, 1964, J AM STAT ASSOC, V61, P852; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Vaishnavi S, 2009, PSYCHOSOMATICS, V50, P198, DOI 10.1176/appi.psy.50.3.198; Van Boven RW, 2009, J REHABIL RES DEV, V46, P717, DOI 10.1682/JRRD.2008.12.0161; Van Laere KJ, 2002, J NUCL MED, V43, P458; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Villarreal G, 2004, PSYCHIAT RES-NEUROIM, V131, P227, DOI 10.1016/j.pscychresns.2004.05.002; Wang HR, 2013, CLIN NEUROPHARMACOL, V36, P216, DOI 10.1097/WNF.0b013e3182aa365f; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Watts BV, 2013, J CLIN PSYCHIAT, V74, pE541, DOI 10.4088/JCP.12r08225; Weniger G, 2008, ACTA PSYCHIAT SCAND, V118, P281, DOI 10.1111/j.1600-0447.2008.01246.x; Whipple E, 2014, ARCH CLIN NEUROPSYCH, V29; Woodward SH, 2006, BIOL PSYCHIAT, V59, P582, DOI 10.1016/j.biopsych.2005.07.033; Yamasue H, 2003, P NATL ACAD SCI USA, V100, P9039, DOI 10.1073/pnas.1530467100; Yeh PH, 2014, HUM BRAIN MAPP, V35, P2652, DOI 10.1002/hbm.22358; Zaroya G., 2005, US TODAY; Zubieta JK, 1999, J PSYCHIAT RES, V33, P259, DOI 10.1016/S0022-3956(98)00060-0	114	24	24	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 1	2015	10	7							e0129659	10.1371/journal.pone.0129659			22	Multidisciplinary Sciences	Science & Technology - Other Topics	CN1CG	WOS:000358153000031	26132293	DOAJ Gold, Green Published			2021-06-18	
J	Anke, A; Andelic, N; Skandsen, T; Knoph, R; Ader, T; Manskow, U; Sigurdardottir, S; Roe, C				Anke, Audny; Andelic, Nada; Skandsen, Toril; Knoph, Rein; Ader, Tiina; Manskow, Unn; Sigurdardottir, Solrun; Roe, Cecilie			Functional Recovery and Life Satisfaction in the First Year After Severe Traumatic Brain Injury: A Prospective Multicenter Study of a Norwegian National Cohort	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							GLASGOW OUTCOME SCALE; INTENSIVE-CARE-UNIT; SEVERE HEAD-INJURY; COGNITIVE FUNCTION; DEPRESSION SCALE; HOSPITAL ANXIETY; REHABILITATION; POPULATION; SYMPTOMS; IMPACT	Objectives: (1) To examine the impact of demographic and acute injury-related variables on functional recovery and life satisfaction after severe traumatic brain injury (sTBI) and (2) to test whether postinjury functioning, postconcussive symptoms, emotional state, and functional improvement are related to life satisfaction. Design: Prospective national multicenter study. Setting: Level 1 trauma centers in Norway. Participants: 163 adults with sTBI. Main Measures: Functional recovery between 3 and 12 months postinjury measured with Glasgow Outcome Scale Extended, Rivermead Postconcussion Symptoms Questionnaire, Hospital Anxiety and Depression Scale, and satisfaction with life situation. Results: 60% of cases experienced functional improvement from 3 to 12 months postinjury. Multivariate logistic regression analysis revealed that discharge to a rehabilitation department from acute care (odds ratio [OR] = 2.14; P < .05) and fewer days with artificial ventilation (OR = 1.04; P < .05) were significantly related to improvement. At 12 months postinjury, 85% were independent in daily activities. Most participants (63%) were satisfied with their life situation. Regression analysis revealed that older age (>65 years), low education, better functional outcome, and the absence of depressive and postconcussion symptoms were significant (P < .05) predictors of life satisfaction. Functional improvement was significantly associated with emotional state but not to life satisfaction. Conclusion: Following sTBI, approximately two-thirds of survivors improve between 3 and 12 months postinjury and are satisfied with their life. Direct discharge from acute care to specialized rehabilitation appears to increase functional recovery.	[Anke, Audny; Manskow, Unn] Univ Hosp North Norway, Dept Rehabil, N-9016 Tromso, Troms, Norway; [Anke, Audny] Univ Tromso, Fac Hlth Sci, Dept Clin Med, N-9001 Tromso, Norway; [Andelic, Nada; Roe, Cecilie] Oslo Univ Hosp, Dept Phys Med & Rehabil, Oslo, Norway; [Skandsen, Toril] Norwegian Univ Sci & Technol NTNU, Dept Neurosci, Fac Med, Trondheim, Norway; [Skandsen, Toril] St Olavs Hosp, Dept Phys Med & Rehabil, Trondheim, Norway; [Knoph, Rein] Sorlandet Hosp, Dept Phys Med & Rehabil, Kristiansand, Norway; [Ader, Tiina] Haukeland Hosp, Dept Phys Med & Rehabil, N-5021 Bergen, Norway; [Manskow, Unn] Univ Tromso, Fac Hlth Sci, Dept Hlth & Care Sci, N-9001 Tromso, Norway; [Sigurdardottir, Solrun] Sunnaas Rehabil Hosp, Dept Res, Nesoddtangen, Norway; [Roe, Cecilie] Univ Oslo, Fac Med, Oslo, Norway	Anke, A (corresponding author), Univ Hosp North Norway, Dept Rehabil, Sykehusveien 1, N-9016 Tromso, Troms, Norway.	audny.anke@uit.no		Andelic, Nada/0000-0002-3719-4406; Anke, Audny/0000-0002-2491-2560	Norwegian Research CouncilResearch Council of NorwayEuropean Commission [185267]	This study was conducted with grants from the Norwegian Research Council, grant number 185267.	Andelic N, 2012, NEUROEPIDEMIOLOGY, V38, P259, DOI 10.1159/000338032; Andelic N, 2008, NEUROEPIDEMIOLOGY, V30, P120, DOI 10.1159/000120025; Andelic N, 2012, J NEUROTRAUM, V29, P66, DOI 10.1089/neu.2011.1811; Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Anke AGW, 2003, CLIN REHABIL, V17, P431, DOI 10.1191/0269215503cr629oa; Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Brown AW, 2010, BRAIN INJURY, V24, P472, DOI 10.3109/02699051003610466; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Corral L, 2007, BRAIN INJURY, V21, P1225, DOI 10.1080/02699050701727460; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Dahm J, 2013, J AFFECT DISORDERS, V151, P392, DOI 10.1016/j.jad.2013.06.011; Davis LC, 2012, ARCH PHYS MED REHAB, V93, P1324, DOI 10.1016/j.apmr.2012.02.036; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Fugl-Meyer AR, 2002, J REHABIL MED, V34, P239, DOI 10.1080/165019702760279242; Fujita F, 2005, J PERS SOC PSYCHOL, V88, P158, DOI 10.1037/0022-3514.88.1.158; Hudak AM, 2012, J HEAD TRAUMA REHAB, V27, P87, DOI 10.1097/HTR.0b013e3182114efd; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jacobsson LJ, 2011, NEUROPSYCHOL REHABIL, V21, P383, DOI 10.1080/09602011.2011.566711; Ketchum JM, 2012, NEUROREHABILITATION, V30, P23, DOI 10.3233/NRE-2012-0724; King JT, 2005, J NEUROTRAUM, V22, P947, DOI 10.1089/neu.2005.22.947; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Leon-Carrion J, 2012, J REHABIL MED, V44, P505, DOI 10.2340/16501977-0982; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Livingston DH, 2009, J TRAUMA, V67, P341, DOI 10.1097/TA.0b013e3181a5cc34; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Novack TA, 2000, BRAIN INJURY, V14, P987; Shukla D, 2011, CLIN NEUROL NEUROSUR, V113, P435, DOI 10.1016/j.clineuro.2011.02.013; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Skandsen T, 2013, J REHABIL MED, V45, P734; Skandsen T, 2008, CLIN REHABIL, V22, P653, DOI 10.1177/0269215508089067; Soberg HL, 2013, J REHABIL MED, V45, P785, DOI 10.2340/16501977-1158; Styrke J, 2013, J REHABIL MED, V45, P749, DOI 10.2340/16501977-1215; Sundstrom T, 2007, J NEUROTRAUM, V24, P147, DOI 10.1089/neu.2006.0099; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; Till C, 2008, ARCH PHYS MED REHAB, V89, pS25, DOI 10.1016/j.apmr.2008.07.004; Toien K, 2010, J TRAUMA, V69, P1552, DOI 10.1097/TA.0b013e3181e125f3; Tsanadis J, 2008, CLIN NEUROPSYCHOL, V22, P1080, DOI 10.1080/13854040701796928; Utomo WK, 2009, INJURY, V40, P973, DOI 10.1016/j.injury.2009.05.034; van der Horn HJ, 2013, ARCH PHYS MED REHAB, V94, P867, DOI 10.1016/j.apmr.2012.11.039; von Wild KRH, 2008, ACT NEUR S, V101, P55; Weir J, 2012, J NEUROTRAUM, V29, P53, DOI 10.1089/neu.2011.2137; Wertheimer JC, 2008, ARCH PHYS MED REHAB, V89, P1983, DOI 10.1016/j.apmr.2008.04.010; Williamson OD, 2011, J TRAUMA, V71, P63, DOI 10.1097/TA.0b013e31820e898d; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zampolini M, 2012, BRAIN INJURY, V26, P27, DOI 10.3109/02699052.2011.635358; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	57	24	24	1	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2015	30	4					E38	E49		10.1097/HTR.0000000000000080			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CM8JB	WOS:000357944800005	25033035				2021-06-18	
J	Biscotti, M; Gannon, WD; Abrams, D; Agerstrand, C; Claassen, J; Brodie, D; Bacchetta, M				Biscotti, M.; Gannon, W. D.; Abrams, D.; Agerstrand, C.; Claassen, J.; Brodie, D.; Bacchetta, M.			Extracorporeal membrane oxygenation use in patients with traumatic brain injury	PERFUSION-UK			English	Article						Extracorporeal membrane oxygenation; ECMO; traumatic brain injury; TBI; acute respiratory distress syndrome; ARDS		Venovenous extracorporeal membrane oxygenation (ECMO) is used for patients with severe, potentially reversible, respiratory failure unresponsive to conventional management. It is relatively contraindicated in patients with traumatic brain injury (TBI) due to bleeding complications and use of anticoagulation. We report two cases of TBI patients treated with ECMO.	[Biscotti, M.] Columbia Univ, Med Ctr, Dept Gen Surg, New York, NY 10032 USA; [Gannon, W. D.; Abrams, D.; Agerstrand, C.; Brodie, D.] Columbia Univ, Med Ctr, Dept Pulm Allergy & Crit Care Med, New York, NY 10032 USA; [Claassen, J.] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA; [Bacchetta, M.] Columbia Univ, Med Ctr, Dept Cardiothorac Surg, New York, NY 10032 USA	Bacchetta, M (corresponding author), Columbia Univ, Med Ctr, Surg, Herbert Irving Pavil, 3rd Floor 161 Ft Washington Ave, New York, NY 10032 USA.	mb781@columbia.edu	Claassen, Jan/AAA-5451-2020				Arlt M, 2010, RESUSCITATION, V81, P804, DOI 10.1016/j.resuscitation.2010.02.020; Brodie D, 2011, NEW ENGL J MED, V365, P1905, DOI 10.1056/NEJMct1103720; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Hwang GJ, 2013, J KOREAN MED SCI, V28, P962, DOI 10.3346/jkms.2013.28.6.962; Messing JA, 2014, ASAIO J, V60, P597, DOI 10.1097/MAT.0000000000000103; Yen TS, 2008, CLIN NEUROL NEUROSUR, V110, P295, DOI 10.1016/j.clineuro.2007.10.017	6	24	24	0	3	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0267-6591	1477-111X		PERFUSION-UK	Perfusion-UK	JUL	2015	30	5					407	409		10.1177/0267659114554327			3	Cardiac & Cardiovascular Systems; Peripheral Vascular Disease	Cardiovascular System & Cardiology	CK2AJ	WOS:000356011400009	25313096				2021-06-18	
J	Cohen, AR; Caruso, P; Duhaime, AC; Klig, JE				Cohen, Ari R.; Caruso, Paul; Duhaime, Ann-Christine; Klig, Jean E.			Feasibility of "rapid" magnetic resonance imaging in pediatric acute head injury	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							EMERGENCY-DEPARTMENT; COMPUTED-TOMOGRAPHY; RADIATION-EXPOSURE; HYDROCEPHALUS; CT	Objective: The objective was to determine the feasibility of "rapid" magnetic resonance imaging (rMRI) versus noncontrast computed tomography (NCCT) for pediatric patients with possible traumatic brain injury and to compare the populations receiving imaging in an urban tertiary care emergency department ED. Methods: We retrospectively reviewed the electronic medical records of ED patients younger than 19 years with possible traumatic brain injury over 4 years who received an rMRI and then age-matched with NCCT patients. Data collection and analysis included demographic and clinical variables, ED length of stay (LOS), and follow-up outcomes. Results: The final cohort had 45 rMRIs and 45 NCCTs. The mean age was 2.7 years, 63% were male, and 65% sustained a fall. Age, sex, and injury mechanism were similar. Time parameters were longer for rMRI patients: ED arrival to completion of imaging (172 vs 93 minutes, P < .001) and ED LOS (266 vs 225 minutes, P = .008). The NCCT group had higher-acuity patients with higher pediatric intensive care unit admission rates (33% vs 7%, P = .002). No patients returned to the ED within 72 hours. Follow-up was available on 78% patients. No clinically significant intracranial injuries were missed. Conclusions: Rapid MRI may be a viable imaging modality for moderate-risk pediatric head injury. Although rMRI took longer to obtain during this pilot study, scan time was only 3 to 4 minutes; and LOS was only 41 minutes longer. Further integration of rMRI in patient care should decrease time variation. Future study of rMRI reliability and satisfaction is needed. (C) 2015 Elsevier Inc. All rights reserved.	[Cohen, Ari R.; Klig, Jean E.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Caruso, Paul] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Duhaime, Ann-Christine] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA	Cohen, AR (corresponding author), Massachusetts Gen Hosp, Dept Emergency Med, Zero Emerson Pl,Suite 3B, Boston, MA 02114 USA.	Acohen7@partners.org	Klig, Jean/N-8505-2019				Ashley WW, 2005, J NEUROSURG, V103, P124, DOI 10.3171/ped.2005.103.2.0124; Bleyer A, 2002, PEDIATR RADIOL, V32, P242, DOI 10.1007/s00247-002-0674-y; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Iskandar BJ, 2004, J NEUROSURG, V101, P147, DOI 10.3171/ped.2004.101.2.0147; Kocher KE, 2011, ANN EMERG MED, V58, P452, DOI 10.1016/j.annemergmed.2011.05.020; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Missios S, 2008, J NEUROS-PEDIATR, V2, P438, DOI 10.3171/PED.2008.2.12.438; Patel DM, 2014, J NEUROSURG-PEDIATR, V13, P440, DOI 10.3171/2014.1.PEDS13447; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Radiology M.G.H.D.o., FACTS RAD IM EX; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Wylie MC, 2014, PEDIATR EMERG CARE, V30, P680, DOI 10.1097/PEC.0000000000000227	13	24	24	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	JUL	2015	33	7					887	890		10.1016/j.ajem.2015.03.052			4	Emergency Medicine	Emergency Medicine	CL0BG	WOS:000356602900005	25912791				2021-06-18	
J	Glaviano, NR; Benson, S; Goodkin, HP; Broshek, DK; Saliba, S				Glaviano, Neal R.; Benson, Shari; Goodkin, Howard P.; Broshek, Donna K.; Saliba, Susan			Baseline SCAT2 Assessment of Healthy Youth Student-Athletes: Preliminary Evidence for the Use of the Child-SCAT3 in Children Younger Than 13 Years	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						neurocognitive testing; neuropsychological testing; SCAT3; Child-SCAT3	HIGH-SCHOOL; NEUROCOGNITIVE PERFORMANCE; CONCUSSION ASSESSMENT; SPORT CONCUSSION; INTERNATIONAL-CONFERENCE; STANDARDIZED ASSESSMENT; CONSENSUS STATEMENT; POSTURAL STABILITY; SEX-DIFFERENCES; NORMATIVE DATA	Objective:To compare baseline scores of middle and high school students on the Sport Concussion Assessment Tool 2 (SCAT2) by sex and age.Design:Cross-sectional study.Setting:Single private school athletic program.Participants:Three hundred sixty-one middle and high school student-athletes.Intervention:Preseason SCAT2 was administered to student-athletes before athletic participation.Main Outcome Measures:Total SCAT2 score, symptoms, symptom severity, Glasgow coma scale, modified Balance Error Scoring System (BESS), coordination, and Standardized Assessment of Concussion (SAC) with subsections: Orientation, Immediate Memory, Concentration, and Delayed Recall.Results:No differences were found in total SCAT2 scores between sex (P = 0.463) or age (P = 0.21). Differences were found in subcomponents of the SCAT2. Twelve year olds had significantly lower concentration scores (3.3 1.2) than 15 and 18 year olds (3.9 1.0 and 4.2 +/- 1.0, respectively). The 12 year olds also had the lowest percentage of correct responses for the SAC's concentration 5-digit (46%), 6-digit (21%), and months' backward (67%) tasks. Females presented with more symptoms (20.0 +/- 2.2 vs 20.6 +/- 2.1 P = 0.007) better immediate memory (14.6 +/- 0.9 vs 14.3 +/- 1.0, P = 0.022) and better BESS scores (27.2 +/- 2.3 vs 26.6 +/- 2.6, P = 0.043) than their male counterparts.Conclusions:Normative values for total SCAT2 and subscale scores show differences in concentration between ages, whereas symptoms, BESS, and immediate memory differed between sexes. We also found that 12 year olds have increased difficultly with the advanced concentration tasks, which lends support to the development of a separate instrument, such as the Child-SCAT3. The presence of developmental differences in the younger age groups suggests the need for annual baseline testing.Clinical Relevance:Subtle differences between age and sex have been identified in many components of the SCAT2 assessment. These differences may support the current evolution of concussion assessment tools to provide the most appropriate test. Baseline testing should be used when available, and clinicians should be aware of potential differences when using normalized values.	[Glaviano, Neal R.] Univ Virginia, Dept Kinesiol, Exercise & Sport Injury Lab, Charlottesville, VA USA; [Benson, Shari] St Annes Belfield Sch, Charlottesville, VA USA; [Goodkin, Howard P.] Univ Virginia, Dept Neurol, Charlottesville, VA 22903 USA; [Broshek, Donna K.] Univ Virginia, Dept Psychiat & Neurobehav Sci, Charlottesville, VA 22903 USA; [Saliba, Susan] Univ Virginia, Curry Sch Educ, Dept Human Serv Kinesiol Program Area, Charlottesville, VA 22903 USA	Glaviano, NR (corresponding author), Univ Virginia, Exercise & Sport Injury Lab, Mem Gymnasium, POB 400267, Charlottesville, VA 22903 USA.	ng2w@virginia.edu	Glaviano, Neal/AAW-1648-2020	Glaviano, Neal/0000-0003-4515-8015; Goodkin, Howard/0000-0003-0528-4949; Saliba, Susan/0000-0001-7179-8310			[Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Capitani E, 1997, NEUROPSYCHOL REHABIL, V7, P295, DOI 10.1080/713755543; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Erdal K, 2012, ARCH CLIN NEUROPSYCH, V27, P473, DOI 10.1093/arclin/acs050; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Hopkins WG, 2009, MED SCI SPORT EXER, V41, P3, DOI 10.1249/MSS.0b013e31818cb278; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; Jinguji TM, 2012, BRIT J SPORT MED, V46, P365, DOI 10.1136/bjsports-2011-090526; Kendall PC, 1999, J CONSULT CLIN PSYCH, V67, P285, DOI 10.1037/0022-006X.67.3.285; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee AJY, 2007, J APPL BIOMECH, V23, P173, DOI 10.1123/jab.23.3.173; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Register-Mihalik JK, 2013, J HEAD TRAUMA REHAB, V28, P274, DOI 10.1097/HTR.0b013e3182585d37; Schatz P, 2012, J ATHL TRAINING, V47, P289, DOI 10.4085/1062-6050-47.3.14; Schatz P, 2011, CLIN NEUROPSYCHOL, V25, P1042, DOI 10.1080/13854046.2011.556669; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Schneider KJ, 2010, BRIT J SPORT MED, V44, P1112, DOI 10.1136/bjsm.2009.071266; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832	39	24	24	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2015	25	4					373	379		10.1097/JSM.0000000000000154			7	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	CM2EK	WOS:000357492400011	25318531				2021-06-18	
J	Pape, TLB; Rosenow, JM; Steiner, M; Parrish, T; Guernon, A; Harton, B; Patil, V; Bhaumik, DK; McNamee, S; Walker, M; Froehlich, K; Burress, C; Odle, C; Wang, X; Herrold, AA; Zhao, WH; Reda, D; Mallinson, T; Conneely, M; Nemeth, AJ				Pape, Theresa Louise-Bender; Rosenow, Joshua M.; Steiner, Monica; Parrish, Todd; Guernon, Ann; Harton, Brett; Patil, Vijaya; Bhaumik, Dulal K.; McNamee, Shane; Walker, Matthew; Froehlich, Kathleen; Burress, Catherine; Odle, Cheryl; Wang, Xue; Herrold, Amy A.; Zhao, Weihan; Reda, Domenic; Mallinson, Trudy; Conneely, Mark; Nemeth, Alexander J.			Placebo-Controlled Trial of Familiar Auditory Sensory Training for Acute Severe Traumatic Brain Injury: A Preliminary Report	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury; neurorehabilitation; sensory stimulation; disordered consciousness; treatment; auditory plasticity	MINIMALLY CONSCIOUS STATE; VEGETATIVE STATE; DISORDERS; COMA; STIMULATION; REHABILITATION; SCALES	Background. Sensory stimulation is often provided to persons incurring severe traumatic brain injury (TBI), but therapeutic effects are unclear. Objective. This preliminary study investigated neurobehavioral and neurophysiological effects related to sensory stimulation on global neurobehavioral functioning, arousal, and awareness. Methods. A double-blind randomized placebo-controlled trial where 15 participants in states of disordered consciousness (DOC), an average of 70 days after TBI, were provided either the Familiar Auditory Sensory Training (FAST) or Placebo of silence. Global neurobehavioral functioning was measured with the Disorders of Consciousness Scale (DOCS). Arousal and awareness were measured with the Coma-Near-Coma (CNC) scale. Neurophysiological effect was measured using functional magnetic resonance imaging (fMRI). Results. FAST (n = 8) and Placebo (n = 7) groups each showed neurobehavioral improvement. Mean DOCS change (FAST = 13.5, SD = 8.2; Placebo = 18.9, SD = 15.6) was not different, but FAST patients had significantly (P = .049; 95% confidence interval [CI] = -1.51, -.005) more CNC gains (FAST = 1.01, SD = 0.60; Placebo = 0.25, SD = 0.70). Mixed-effects models confirm CNC findings (P = .002). Treatment effect, based on CNC, is large (d = 1.88, 95% CI = 0.77, 3.00). Number needed to treat is 2. FAST patients had more fMRI activation in language regions and whole brain (P values <.05) resembling healthy controls' activation. Conclusions. For persons with DOC 29 to 170 days after TBI, FAST resulted in CNC gains and increased neural responsivity to vocal stimuli in language regions. Clinicians should consider providing the FAST to support patient engagement in neurorehabilitation.	[Pape, Theresa Louise-Bender; Steiner, Monica; Guernon, Ann; Harton, Brett; Patil, Vijaya; Bhaumik, Dulal K.; Odle, Cheryl; Herrold, Amy A.; Reda, Domenic] Edward Hines Jr VA Hosp, Hines, IL 60141 USA; [Pape, Theresa Louise-Bender; Rosenow, Joshua M.; Parrish, Todd; Wang, Xue; Nemeth, Alexander J.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Rosenow, Joshua M.] Northwestern Mem Hosp, Chicago, IL USA; [Steiner, Monica; Patil, Vijaya] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA; [Guernon, Ann] Marianjoy Rehabil Hosp, Wheaton, IL USA; [Bhaumik, Dulal K.; Zhao, Weihan] Univ Illinois, Chicago, IL USA; [McNamee, Shane] Hunter Holmes McGuire VA Med Ctr, Richmond, VA USA; [Walker, Matthew] Northshore Univ Hlth Syst, Evanston, IL USA; [Froehlich, Kathleen; Burress, Catherine] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Mallinson, Trudy] George Washington Univ, Washington, DC USA; [Conneely, Mark] Rosalind Franklin Univ Med & Sci, N Chicago, IL USA	Pape, TLB (corresponding author), Edward Hines Jr VA Hosp, Ctr Innovat Complex Chron Healthcare & Res Serv, Dept Vet Affairs VA, PO 5000 S 5th Ave,Bldg 1 M-C 151H, Hines, IL 60141 USA.	Theresa.Pape@va.gov	Nemeth, Alexander J./AAI-2481-2020; Mallinson, Trudy/S-7381-2019	Nemeth, Alexander J./0000-0003-0579-3866; Mallinson, Trudy/0000-0002-4888-5579; Parrish, Todd/0000-0002-1184-1572; Bender Pape, Theresa/0000-0001-7738-5963	Department of Veterans Affairs, Office of Research and DevelopmentUS Department of Veterans Affairs; Rehabilitation Research and Development Merit Grant [B4591R]; career development transition award [B4949N]; National Center for Research Resources, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025741]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025741] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development Merit Grant # B4591R and career development transition award # B4949N. Northwestern University's Clinical and Translation Sciences Institute, which is supported by the National Center for Research Resources, National Institutes of Health (Grant UL1RR025741). The Nick Kot Charity for traumatic brain injury (www.nkc4tbi.com).	Adamovich B. B., 1992, SCALES COGNITIVE ABI; American Academy of Neurology, 1995, PRACT PAR ASS MAN PA; ANSELL BJ, 1991, J SPEECH HEAR RES, V34, P1017, DOI 10.1044/jshr.3405.1017; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Chleboun S, 2009, BRAIN INJURY, V23, P101, DOI 10.1080/02699050802649639; Citrome L, 2013, INT J CLIN PRACT, V67, P407, DOI 10.1111/ijcp.12142; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Di Stefano C, 2012, BRAIN INJURY, V26, P1250, DOI 10.3109/02699052.2012.667588; Eton DT, 2004, J CLIN EPIDEMIOL, V57, P898, DOI 10.1016/j.jclinepi.2004.01.012; Ganesh S, 2013, ARCH PHYS MED REHAB, V94, P1899, DOI 10.1016/j.apmr.2012.12.026; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Giacino JT, 1996, NEUROREHABILITATION, V6, P69, DOI 10.3233/NRE-1996-6108; Gibbons R, 2009, STAT METHODS GROUND, V2; GIBBONS RD, 2000, SANKHYA SERIES B, V62, P70; Gruner ML, 2000, BRAIN INJURY, V14, P585; Hedeker D., 2006, LONGITUDINAL DATA AN; Imaizumi S, 1997, NEUROREPORT, V8, P2809, DOI 10.1097/00001756-199708180-00031; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Kraemer HC, 2006, BIOL PSYCHIAT, V59, P990, DOI 10.1016/j.biopsych.2005.09.014; KURTZ D, 1977, REV EEG NEUROPHYSIOL, V7, P62, DOI 10.1016/S0370-4475(77)80036-1; Lancioni GE, 2010, RES DEV DISABIL, V31, P1121, DOI 10.1016/j.ridd.2010.06.019; Laureys S, 2006, CURR OPIN NEUROL, V19, P520, DOI 10.1097/WCO.0b013e3280106ba9; Linacre M., 1994, MANY FACETS RASCH ME; Lombardi F, 2002, CLIN REHABIL, V16, P464, DOI 10.1191/0269215502cr519oa; Megha M, 2013, BRAIN INJURY, V27, P570, DOI 10.3109/02699052.2013.767937; Menon DK, 1998, LANCET, V352, P200, DOI 10.1016/S0140-6736(05)77805-3; Meyer MJ, 2010, BRAIN INJURY, V24, P722, DOI 10.3109/02699051003692134; MORAY N, 1959, Q J EXP PSYCHOL, V11, P56, DOI 10.1080/17470215908416289; Moritz CH, 2001, MAGN RESON IMAGING, V19, P1129, DOI 10.1016/S0730-725X(01)00432-5; Pape TLB, 2014, ARCH PHYS MED REHAB, V95, P1672, DOI 10.1016/j.apmr.2014.04.015; Pape TLB, 2013, REHABIL PSYCHOL, V58, P253, DOI 10.1037/a0032610; Pape TLB, 2012, J REHABIL RES DEV, V49, P1137, DOI 10.1682/JRRD.2011.08.0154; Pape TLB, 2009, PM&R, V1, P152, DOI 10.1016/j.pmrj.2008.11.002; Pape TLB, 2005, J REHABIL RES DEV, V42, P1, DOI 10.1682/JRRD.2004.03.0032; Perrin F, 2006, ARCH NEUROL-CHICAGO, V63, P562, DOI 10.1001/archneur.63.4.562; Plum F., 1980, DIAGNOSIS STUPOR COM, V3; Proverbio AM, 2001, NEUROPSYCHOLOGIA, V39, P815, DOI 10.1016/S0028-3932(01)00003-3; Rappaport M, 2005, NEUROPSYCHOL REHABIL, V15, P442, DOI 10.1080/09602010443000335; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; RAPPAPORT M, 1981, CLIN ELECTROENCEPHAL, V12, P154, DOI 10.1177/155005948101200402; Rappaport M, 1996, MED REHABILITATION T, P271; RAPPAPORT M, 1986, J HEAD TRAUMA REHABI, P00015, DOI DOI 10.1097/00001199-198603000-00005; Rasch G., 1980, PROBABILISTIC MODELS; Schnakers C, 2008, NEUROLOGY, V71, P1614, DOI 10.1212/01.wnl.0000334754.15330.69; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; SIGNORINO M, 1995, LANCET, V345, P255, DOI 10.1016/S0140-6736(95)90252-X; Tempini MLG, 1998, BRAIN, V121, P2103, DOI 10.1093/brain/121.11.2103; Weiss N, 2007, CRIT CARE, V11, DOI 10.1186/cc6107; Whyte J, 2003, AM J PHYS MED REHAB, V82, pS16, DOI 10.1097/01.PHM.0000086992.95121.C2; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; Yasuda K, 2000, APHASIOLOGY, V14, P1067, DOI 10.1080/02687030050174638	53	24	24	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	JUL	2015	29	6					537	547		10.1177/1545968314554626			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CN3GM	WOS:000358313600005	25613986				2021-06-18	
J	Wade, SL; Taylor, HG; Cassedy, A; Zhang, NH; Kirkwood, MW; Brown, TM; Stancin, T				Wade, Shari L.; Taylor, H. Gerry; Cassedy, Amy; Zhang, Nanhua; Kirkwood, Michael W.; Brown, Tanya M.; Stancin, Terry			Long-Term Behavioral Outcomes after a Randomized, Clinical Trial of Counselor-Assisted Problem Solving for Adolescents with Complicated Mild-to-Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						adolescent; behavior; brain injury; child; online; therapy	PSYCHIATRIC-DISORDERS; CHILD-BEHAVIOR; INTERVENTION; PREVALENCE; DEPRESSION; DEFICITS	Family problem-solving therapy (FPST) has been shown to reduce behavior problems after pediatric traumatic brain injury (TBI). It is unclear whether treatment gains are maintained. We sought to evaluate the maintenance of improvements in behavior problems after a Web-based counselor-assisted FPST (CAPS) intervention compared to an Internet resource comparison (IRC) intervention provided to adolescents within the initial year post-TBI. We hypothesized that family socioeconomic status, child educational status, and baseline levels of symptoms would moderate the efficacy of the treatment over time. Participants included 132 adolescents ages 12-17 years who sustained a complicated mild-to-severe TBI 1-6 months before study enrollment. Primary outcomes were the Child Behavior Checklist Internalizing and Externalizing Totals. Mixed-models analyses, using random intercepts and slopes, were conducted to examine group differences over time. There was a significant groupxtimexgrade interaction (F-(1,F-304)=4.42; p=0.03) for internalizing problems, with high school-age participants in CAPS reporting significantly lower symptoms at 18 months postbaseline than those in the IRC. Post-hoc analyses to elucidate the nature of effects on internalizing problems revealed significant groupxtimexgrade interactions for the anxious/depressed (p=0.03) and somatic complaints subscales (p=0.04). Results also indicated significant improvement over time for CAPS participants who reported elevated externalizing behavior problems at baseline (F-(1,F- 310)=7.17; p=0.008). Findings suggest that CAPS may lead to long-term improvements in behavior problems among older adolescents and those with pretreatment symptoms.	[Wade, Shari L.; Cassedy, Amy; Zhang, Nanhua] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Phys Med & Rehabil, Cincinnati, OH 45229 USA; [Wade, Shari L.; Cassedy, Amy; Zhang, Nanhua] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Div Dev & Behav Pediat & Psychol, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Rainbow Babies & Childrens Hosp, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA; [Kirkwood, Michael W.] Childrens Hosp Colorado, Dept Phys Med & Rehabil, Aurora, CO USA; [Kirkwood, Michael W.] Univ Colorado, Sch Med, Aurora, CO USA; [Brown, Tanya M.] Mayo Clin, Coll Med, Dept Psychiat & Psychol, Rochester, MN USA; [Stancin, Terry] MetroHlth Med Ctr, Dept Pediat, Div Pediat Psychol, Cleveland, OH USA; [Stancin, Terry] Case Western Reserve Univ, Cleveland, OH 44106 USA	Wade, SL (corresponding author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave,MLC 4009, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org	Stancin, Terry/L-7993-2019; Zhang, Nanhua/L-7606-2015	Zhang, Nanhua/0000-0001-5796-3404	National Institutes of Health from the National Institute of Mental Health [R01-MH073764]; Colorado Traumatic Brain Injury Trust Fund Research Program, Colorado Department of Human Services, Division of Vocational Rehabilitation, Traumatic Brain Injury Program; Department of Education's National Institute on Disability and Rehabilitation Research (Center on Interventions for Children and Youth with Traumatic Brain Injury) [H133B090010-10]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH073764] Funding Source: NIH RePORTER	This work was supported, in part, by National Institutes of Health grant R01-MH073764 from the National Institute of Mental Health; a grant from the Colorado Traumatic Brain Injury Trust Fund Research Program, Colorado Department of Human Services, Division of Vocational Rehabilitation, Traumatic Brain Injury Program; and the Department of Education's National Institute on Disability and Rehabilitation Research (Center on Interventions for Children and Youth with Traumatic Brain Injury; grant no.: H133B090010-10). This material does not necessarily represent the policy of these agencies, nor is the material necessarily endorsed by the federal government. Clinical Trial Registration: NCT00409448.	Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Antonini TN, 2014, BEHAV THER, V45, P455, DOI 10.1016/j.beth.2014.02.003; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Brown FL, 2013, J HEAD TRAUMA REHAB, V28, P349, DOI 10.1097/HTR.0b013e318245fed5; Cole WR, 2008, BRAIN INJURY, V22, P932, DOI 10.1080/02699050802454808; D'Zurilla TJN A. M., 2010, HDB COGNITIVE BEHAV, P197; Di Battista A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101842; Gan C, 2010, BRAIN INJURY, V24, P651, DOI 10.3109/02699051003692142; Hofer TP, 1998, HEALTH SERV RES, V33, P243; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Krieger N, 2003, J EPIDEMIOL COMMUN H, V57, P186, DOI 10.1136/jech.57.3.186; Li L, 2013, DEV MED CHILD NEUROL, V55, P37, DOI 10.1111/j.1469-8749.2012.04414.x; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 2012, INT J DEV NEUROSCI, V30, P239, DOI 10.1016/j.ijdevneu.2011.12.005; O'Connor SS, 2012, J TRAUMA STRESS, V25, P264, DOI 10.1002/jts.21704; Rath JF, 2011, REHABIL PSYCHOL, V56, P320, DOI 10.1037/a0025817; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wade SL, 2015, PEDIATRICS, V135, pE487, DOI 10.1542/peds.2014-1386; Wade SL, 2014, J HEAD TRAUMA REHAB, V29, P198, DOI 10.1097/HTR.0b013e31828f9fe8; Wade SL, 2011, PEDIATRICS, V128, pE947, DOI 10.1542/peds.2010-3721; Wade SL, 2010, J HEAD TRAUMA REHAB, V25, P409, DOI 10.1097/HTR.0b013e3181fb900d; Woods D, 2015, SOCIAL CARE NEURODIS, V5, P70, DOI [DOI 10.1108/SCN-01-2014-0001, 10.1108/SCN-01-2014-0001]	24	24	24	0	18	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2015	32	13					967	975		10.1089/neu.2014.3684			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV0SU	WOS:000363964200005	25738891	Green Published			2021-06-18	
J	Jiang, Z; Watts, LT; Huang, SL; Shen, Q; Rodriguez, P; Chen, CH; Zhou, CM; Duong, TQ				Jiang, Zhao; Watts, Lora Talley; Huang, Shiliang; Shen, Qiang; Rodriguez, Pavel; Chen, Chunhua; Zhou, Changman; Duong, Timothy Q.			The Effects of Methylene Blue on Autophagy and Apoptosis in MRI-Defined Normal Tissue, Ischemic Penumbra and Ischemic Core	PLOS ONE			English	Article							QUANTITATIVE PERFUSION; CARDIAC-ARREST; STROKE; OXYGEN; REPERFUSION; DIFFUSION; NEUROPROTECTION; BRAIN; RESPONSES; RELEASE	Methylene blue (MB) USP, which has energy-enhancing and antioxidant properties, is currently used to treat methemoglobinemia and cyanide poisoning in humans. We recently showed that MB administration reduces infarct volume and behavioral deficits in rat models of ischemic stroke and traumatic brain injury. This study reports the underlying molecular mechanisms of MB neuroprotection following transient ischemic stroke in rats. Rats were subjected to transient (60-mins) ischemic stroke. Multimodal MRI during the acute phase and at 24hrs were used to define three regions of interest (ROIs): i) the perfusion-diffusion mismatch salvaged by reperfusion, ii) the perfusion-diffusion mismatch not salvaged by reperfusion, and iii) the ischemic core. The tissues from these ROIs were extracted for western blot analyses of autophagic and apoptotic markers. The major findings were: 1) MB treatment reduced infarct volume and behavioral deficits, 2) MB improved cerebral blood flow to the perfusion-diffusion mismatch tissue after reperfusion and minimized harmful hyperperfusion 24hrs after stroke, 3) MB inhibited apoptosis and enhanced autophagy in the perfusion-diffusion mismatch, 4) MB inhibited apoptotic signaling cascades (p53-Bax-Bcl2- Caspase3), and 5) MB enhanced autophagic signaling cascades (p53-AMPK-TSC2-mTOR). MB induced neuroprotection, at least in part, by enhancing autophagy and reducing apoptosis in the perfusion-diffusion mismatch tissue following ischemic stroke.	[Jiang, Zhao; Chen, Chunhua; Zhou, Changman] Peking Univ, Hlth Sci Ctr, Dept Anat & Embryol, Beijing 100871, Peoples R China; [Jiang, Zhao; Watts, Lora Talley; Huang, Shiliang; Shen, Qiang; Rodriguez, Pavel; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA; [Chen, Chunhua] Univ Penn, Dept Anesthesiol & Crit Care, Perelman Sch Med, Philadelphia, PA 19104 USA	Duong, TQ (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.	DuongT@uthscsa.edu	Shen, Qiang/B-8784-2008; Duong, Tim/AAL-8357-2021	Shen, Qiang/0000-0002-4287-3403; Duong, Tim/0000-0001-6403-2827	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS45879]; American Heart AssociationAmerican Heart Association [EIA 0940104N, 12BGIA 9300047]; Translational Technology Resource grant [UL1TR000149]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31271280]; Clinical Translational Science Award Pilot Grant; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000149, KL2TR001118, UL1TR001120] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045879] Funding Source: NIH RePORTER	This work was supported by the NIH (R01-NS45879), the American Heart Association (EIA 0940104N and 12BGIA 9300047), a Clinical Translational Science Award Pilot Grant and a Translational Technology Resource grant (parent grant UL1TR000149) to TQD. This work was also supported in part by the National Natural Science Foundation of China (31271280) to CZ. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ashwal S, 1998, STROKE, V29, P1037, DOI 10.1161/01.STR.29.5.1037; Barbier EL, 2001, J MAGN RESON IMAGING, V13, P496, DOI 10.1002/jmri.1073; Bonova P, 2013, NEUROCHEM INT, V62, P8, DOI 10.1016/j.neuint.2012.10.015; Calamante F, 1999, J CEREBR BLOOD F MET, V19, P701, DOI 10.1097/00004647-199907000-00001; Chen CH, 2013, CNS NEUROSCI THER, V19, P566, DOI 10.1111/cns.12114; Congdon EE, 2012, AUTOPHAGY, V8, P609, DOI 10.4161/auto.19048; Dani KA, 2011, ANN NEUROL, V70, P384, DOI 10.1002/ana.22500; Davis SM, 2008, LANCET NEUROL, V7, P299, DOI 10.1016/S1474-4422(08)70044-9; Duong TQ, 2012, TRANSL STROKE RES, V3, P8, DOI 10.1007/s12975-011-0140-y; Feng X, 2011, EMBO J, V30, P3397, DOI 10.1038/emboj.2011.248; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Geisler BS, 2006, STROKE, V37, P1778, DOI 10.1161/01.STR.0000226738.97426.6f; Gomes B, 2012, ANN ONCOL, V23, P2006, DOI 10.1093/annonc/mdr602; Hacke W, 2005, STROKE, V36, P66, DOI 10.1161/01.STR.0000149938.08731.2c; Hacke W, 2009, LANCET NEUROL, V8, P141, DOI 10.1016/S1474-4422(08)70267-9; HOSSMANN KA, 1994, ANN NEUROL, V36, P557, DOI 10.1002/ana.410360404; Huang SL, 2013, NEUROIMAGE, V72, P237, DOI 10.1016/j.neuroimage.2013.01.027; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kidwell CS, 2000, ANN NEUROL, V47, P462, DOI 10.1002/1531-8249(200004)47:4<462::AID-ANA9>3.3.CO;2-P; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Kubli DA, 2012, CIRC RES, V111, P1208, DOI 10.1161/CIRCRESAHA.112.265819; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li PA, 2001, BRAIN RES, V896, P69, DOI 10.1016/S0006-8993(01)01997-7; Lin AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046585; Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001; Martijn C, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-27; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI [10.1161/01.cir.0000441139.02102.80, 10.1161/CIR.0000000000000152, 10.1161/CIR.0b013e31828124ad]; Peter C, 2000, EUR J CLIN PHARMACOL, V56, P247, DOI 10.1007/s002280000124; Poteet E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048279; Rojas JC, 2012, PROG NEUROBIOL, V96, P32, DOI 10.1016/j.pneurobio.2011.10.007; Rosse T, 1998, NATURE, V391, P496; SALARIS SC, 1991, BIOCHEM PHARMACOL, V42, P499, DOI 10.1016/0006-2952(91)90311-R; Santosh C, 2008, J CEREBR BLOOD F MET, V28, P1742, DOI 10.1038/jcbfm.2008.56; Sharma HS, 2011, J NEURAL TRANSM, V118, P87, DOI 10.1007/s00702-010-0486-4; Shen Q, 2004, J CEREBR BLOOD F MET, V24, P280, DOI 10.1097/01.WCB.0000110048.43905.E5; Shen Q, 2003, J CEREBR BLOOD F MET, V23, P1479, DOI 10.1097/01.WCB.0000100064.36077.03; Shen Q, 2004, J CEREBR BLOOD F MET, V24, P887, DOI 10.1097/01.WCB.0000124321.60992.87; Shen Q, 2014, J CEREBR BLOOD F MET, V34, P169, DOI 10.1038/jcbfm.2013.179; Shen Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079833; Shen Q, 2011, BRAIN RES, V1425, P132, DOI 10.1016/j.brainres.2011.09.052; Shen Q, 2011, J CEREBR BLOOD F MET, V31, P2076, DOI 10.1038/jcbfm.2011.64; Sun PZ, 2007, J CEREBR BLOOD F MET, V27, P1129, DOI 10.1038/sj.jcbfm.9600424; Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; van der Plaat L W, 2012, Eur Spine J, V21 Suppl 4, pS445, DOI 10.1007/s00586-011-2053-6; Wang P, 2012, AUTOPHAGY, V8, P77, DOI 10.4161/auto.8.1.18274; Watts LT, 2014, J NEUROTRAUMA; Wei K, 2012, CNS NEUROSCI THER, V18, P879, DOI 10.1111/cns.12005; Xie LK, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00056; Yoo AJ, 2012, J STROKE CEREBROVASC; Yuan JY, 2009, APOPTOSIS, V14, P469, DOI 10.1007/s10495-008-0304-8	53	24	31	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2015	10	6							e0131929	10.1371/journal.pone.0131929			16	Multidisciplinary Sciences	Science & Technology - Other Topics	CN1BL	WOS:000358150400181	26121129	DOAJ Gold, Green Published			2021-06-18	
J	Albrecht, JS; Kiptanui, Z; Tsang, Y; Khokhar, B; Liu, XG; Simoni-Wastila, L; Zuckerman, IH				Albrecht, Jennifer S.; Kiptanui, Zippora; Tsang, Yuen; Khokhar, Bilal; Liu, Xinggang; Simoni-Wastila, Linda; Zuckerman, Ilene H.			Depression Among Older Adults After Traumatic Brain Injury: A National Analysis	AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY			English	Article						Depression; older adults; traumatic brain injury	MAJOR DEPRESSION; EPIDEMIOLOGY; COMORBIDITY; ASSOCIATION; DISORDERS; OUTCOMES; ALCOHOL; HEALTH; LIFE	Objective: Sequelae of traumatic brain injury (TBI) include depression, which could exacerbate the poorer cognitive and functional recovery experienced by older adults. The objective of this study was to estimate incidence rates of depression after hospital discharge for TBI among Medicare beneficiaries aged at least 65 years, quantify the increase in risk of depression after TBI, and evaluate risk factors for incident depression post-TBI. Methods: Using a retrospective analysis, the authors studied Medicare beneficiaries at least 65 years old hospitalized for TBI during 2006 to 2010 who survived to hospital discharge and had no documented diagnosis of depression before the study period (N = 67,347). Results: The annualized incidence rate of depression per 1,000 beneficiaries was 62.8 (95% confidence interval [CI]: 61.6, 64.1) pre-TBI and 123.9 (95% CI: 121.6, 126.2) post-TBI. Annualized incidence rates were highest immediately after hospital discharge and declined over the 12 months post-TBI. TBI increased the risk of incident depression in men (hazard ratio: 1.95; 95% CI: 1.84, 2.06; Wald chi(2) = 511.4, df = 1, p < 0.001) and in women (hazard ratio: 1.69; 95% CI: 1.62, 1.77; Wald chi(2) = 589.3, df = 1, p < 0.001). The strongest predictor of depression post-TBI for both men and women was discharge to a skilled nursing facility (men: odds ratio, 1.91; 95% CI, 1.77, 2.06; Wald chi(2) = 277.1, df = 1, p < 0.001; women: odds ratio, 1.72; 95% CI, 1.63, 1.83; Wald chi(2) = 324.2, df = 1, p < 0.001). Conclusion: TBI significantly increased the risk of depression among older adults, especially among men and those discharged to a skilled nursing facility. Results from this study will help increase awareness of the risk of depression post-TBI among older adults.	[Albrecht, Jennifer S.; Kiptanui, Zippora; Tsang, Yuen; Khokhar, Bilal; Liu, Xinggang; Simoni-Wastila, Linda; Zuckerman, Ilene H.] Univ Maryland, Sch Pharm, Dept Pharmaceut Hlth Serv Res, Baltimore, MD 21201 USA; [Liu, Xinggang] Philips Healthcare, Baltimore, MD USA; [Zuckerman, Ilene H.] IMPAQ Int LLC, Columbia, MD USA	Albrecht, JS (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Hlth Serv Res, 220 Arch St,12th Floor, Baltimore, MD 21201 USA.	jalbrecht@rx.umaryland.edu		Albrecht, Jennifer/0000-0003-4838-2274	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 AG042768-01, T32AG000262-14]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000262, R21AG042768] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grant R21 AG042768-01 (Zuckerman, PI). Dr. Albrecht and Mr. Khokhar are supported by National Institutes of Health grant T32AG000262-14 (Magaziner, PI). The funding agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript or decision to submit the manuscript for publication.	Allison P.D., 1995, SURVIVAL ANAL USING; [Anonymous], MED BEN PREV CHRON C; Bay E, 2009, J NEUROSCI NURS, V41, P298, DOI 10.1097/JNN.0b013e3181b6be81; Beekman ATF, 1997, J AFFECT DISORDERS, V46, P219, DOI 10.1016/S0165-0327(97)00145-6; BLAZER D, 1991, J GERONTOL, V46, pM210, DOI 10.1093/geronj/46.6.M210; Blazer DG, 2003, J GERONTOL A-BIOL, V58, P249; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Centers for Disease Control and Prevention, 2001, RAT TBI REL HOSP AG; Chronic condition warehouse categories, CHRON COND WAR CAT; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Demakis GJ, 2010, APPL NEUROPSYCHOL, V17, P183, DOI 10.1080/09084282.2010.499752; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Faul M, TRAUMATIC BRAIN INJU; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Fiske A, 2009, ANNU REV CLIN PSYCHO, V5, P363, DOI 10.1146/annurev.clinpsy.032408.153621; GRANT BF, 1995, DRUG ALCOHOL DEPEN, V39, P197, DOI 10.1016/0376-8716(95)01160-4; Hasin DS, 2005, ARCH GEN PSYCHIAT, V62, P1097, DOI 10.1001/archpsyc.62.10.1097; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Menzel JC, 2008, BRAIN INJURY, V22, P375, DOI 10.1080/02699050802001492; Rapoport MJ, 2006, J AFFECT DISORDERS, V92, P273, DOI 10.1016/j.jad.2005.05.022; Rapoport MJ, 2012, CNS DRUGS, V26, P111, DOI 10.2165/11599560-000000000-00000; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Utomo WK, 2009, INJURY, V40, P973, DOI 10.1016/j.injury.2009.05.034	32	24	25	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1064-7481	1545-7214		AM J GERIAT PSYCHIAT	Am. J. Geriatr. Psychiatr.	JUN	2015	23	6					607	614		10.1016/j.jagp.2014.07.006			8	Geriatrics & Gerontology; Gerontology; Psychiatry	Geriatrics & Gerontology; Psychiatry	CH9EF	WOS:000354338100008	25154547	Green Accepted			2021-06-18	
J	Ravindra, VM; Riva-Cambrin, J; Sivakumar, W; Metzger, RR; Bollo, RJ				Ravindra, Vijay M.; Riva-Cambrin, Jay; Sivakumar, Walavan; Metzger, Ryan R.; Bollo, Robert J.			Risk factors for traumatic blunt cerebrovascular injury diagnosed by computed tomography angiography in the pediatric population: a retrospective cohort study	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						cerebrovascular injury; computed tomography angiography; pediatrics; traumatic brain injury; trauma; technique	CLINICAL-PREDICTION RULES; RADIATION-EXPOSURE; BRAIN-INJURY; CHILDREN; CT	OBJECT Computed tomography angiography (CTA) is frequently used to examine patients for blunt cerebrovascular injury (BCVI) after cranial trauma, but the pediatric population at risk for BCVI is poorly defined. Although CTA is effective for BCVI screening in adults, the increased lifetime risk for malignant tumors associated with this screening modality warrants efforts to reduce its use in children. The authors' objective was to evaluate the incidence of BCVI diagnosed by CTA in a pediatric patient cohort and to create a prediction model to identify children at high risk for BCVI. METHODS Demographic, clinical, and radiographic data were collected retrospectively for pediatric patients who underwent CTA during examination for traumatic cranial injury from 2003 through 2013. The primary outcome was injury to the carotid or vertebral artery diagnosed by CTA. RESULTS The authors identified 234 patients (mean age 8.3 years, range 0.04-17 years, 150 [64%] boys) who underwent CTA screening for BCVI. Of these, 24 (10.3%) had a focal neurological deficit, and 153 (65.4%) had intracranial hemorrhage on a head CTA. Thirty-seven BCVls were observed in 36 patients (15.4%), and 16 patients (6.8%) died. Multivariate regression analysis identified fracture through the carotid canal, petrous temporal bone fracture, Glasgow Coma Scale (GCS) score of < 8, focal neurological deficit, and stroke on initial CT scan as independent risk factors for BCVI. A prediction model for identifying children at high risk for BCVI was created. A score of <= 2 yielded a 7.9% probability of BCVI and a score of >= 3 a risk of 39.3% for BCVI. CONCLUSIONS For cranial trauma in children, fracture of the petrous temporal bone or through the carotid canal, focal neurological deficit, stroke, and a GCS score of < 8 are independent risk factors for BCVI.	[Ravindra, Vijay M.; Riva-Cambrin, Jay; Sivakumar, Walavan; Bollo, Robert J.] Univ Utah, Sch Med, Dept Neurosurg, Div Pediat Neurosurg, Salt Lake City, UT USA; [Metzger, Ryan R.] Univ Utah, Sch Med, Dept Surg, Salt Lake City, UT USA; [Metzger, Ryan R.] Primary Childrens Med Ctr, Div Pediat Surg, Salt Lake City, UT 84113 USA	Bollo, RJ (corresponding author), Primary Childrens Med Ctr, Div Pediat Neurosurg, 100 N Mario Capecchi Dr,Ste 1475, Salt Lake City, UT 84113 USA.	robert.bollo@hsc.utah.edu					Azarakhsh N, 2013, J TRAUMA ACUTE CARE, V75, P1006, DOI 10.1097/TA.0b013e31829d3526; Biffl WL, 2006, J TRAUMA, V60, P745, DOI 10.1097/01.ta.0000204034.94034.c4; Biffl WL, 1999, J TRAUMA, V47, P845, DOI 10.1097/00005373-199911000-00004; Biffl WL, 1999, AM J SURG, V178, P517, DOI 10.1016/S0002-9610(99)00245-7; Bok APL, 1996, J TRAUMA, V40, P968, DOI 10.1097/00005373-199606000-00017; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Bromberg WJ, 2010, J TRAUMA, V68, P471, DOI 10.1097/TA.0b013e3181cb43da; Carrillo EH, 1999, J TRAUMA, V46, P1120, DOI 10.1097/00005373-199906000-00030; Chamoun RB, 2008, J NEUROS-PEDIATR, V2, P101, DOI 10.3171/PED/2008/2/8/101; Donnelly LF, 2005, AM J ROENTGENOL, V184, P655, DOI 10.2214/ajr.184.2.01840655; Eastman AL, 2006, J TRAUMA, V60, P925, DOI 10.1097/01.ta.0000197479.28714.62; Jones TS, 2012, AM J SURG, V204, P7, DOI 10.1016/j.amjsurg.2011.07.015; Kaye D, 2011, J TRAUMA, V70, P1051, DOI 10.1097/TA.0b013e318211857d; Kopelman TR, 2011, J TRAUMA, V71, P559, DOI 10.1097/TA.0b013e318226eadd; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; Lew SM, 1999, PEDIATR NEUROSURG, V30, P239, DOI 10.1159/000028804; Liesemer K, 2014, PEDIATR CRIT CARE ME, V15, P554, DOI 10.1097/PCC.0000000000000150; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; Miller PR, 2002, ANN SURG, V236, P386, DOI 10.1097/00000658-200209000-00015; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Redberg R F, 2014, NY TIMES; Sarkar K, 2014, J NEUROSURG-PEDIATR, V13, P307, DOI 10.3171/2013.12.PEDS13223; Schonfeld D, 2014, ARCH DIS CHILD, V99, P427, DOI 10.1136/archdischild-2013-305004; Slovis TL, 2003, PEDIATRICS, V112, P971, DOI 10.1542/peds.112.4.971; Tu JV, 1997, J CLIN EPIDEMIOL, V50, P743, DOI 10.1016/S0895-4356(97)89028-2; Wang AC, 2012, J TRAUMA ACUTE CARE, V72, P1599, DOI 10.1097/TA.0b013e318246ead4; WEINSTEIN MC, 1980, CLIN DECISION ANAL, P84	29	24	25	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	JUN	2015	15	6					599	606		10.3171/2014.11.PEDS14397			8	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	CI8OL	WOS:000355031500008	25745952	Bronze			2021-06-18	
J	Sours, C; Rosenberg, J; Kane, R; Roys, S; Zhuo, JC; Shanmuganathan, K; Gullapalli, RP				Sours, Chandler; Rosenberg, Joseph; Kane, Robert; Roys, Steve; Zhuo, Jiachen; Shanmuganathan, Kathirkamanthan; Gullapalli, Rao P.			Associations between interhemispheric functional connectivity and the Automated Neuropsychological Assessment Metrics (ANAM) in civilian mild TBI	BRAIN IMAGING AND BEHAVIOR			English	Article						Resting state fMRI; Mild TBI; Automated Neuropsychological Assessment Metrics; Functional connectivity	TRAUMATIC BRAIN-INJURY; COGNITIVE DEFICITS; HEAD-INJURY; PERFORMANCE; NETWORK; CONCUSSION; STATE; RELIABILITY; DISRUPTION; BATTERY	This study investigates cognitive deficits and alterations in resting state functional connectivity in civilian mild traumatic brain injury (mTBI) participants with high and low symptoms. Forty-one mTBI participants completed a resting state fMRI scan and the Automated Neuropsychological Assessment Metrics (ANAM) during initial testing (< 10 days of injury) and a 1 month follow up. Data were compared to 30 healthy control subjects. Results from the ANAM demonstrate that mTBI participants performed significantly worse than controls on the code substitution delayed subtest (p = 0.032) and weighted throughput score (p = 0.001). Among the mTBI patients, high symptom mTBI participants performed worse than those with low symptoms on the code substitution delayed (p = 0.017), code substitution (p = 0.012), repeated simple reaction time (p = 0.031), and weighted throughput score (p = 0.009). Imaging results reveal that during the initial visit, low symptom mTBI participants had reduced interhemispheric functional connectivity (IH-FC) within the lateral parietal lobe (p = 0.020); however, during follow up, high symptom mTBI participants showed reduced IH-FC compared to the control group within the dorsolateral prefrontal cortex (DLPFC) (p = 0.013). Reduced IH-FC within the DLPFC during the follow-up was associated with reduced cognitive performance. Together, these findings suggest that reduced rs-FC may contribute to the subtle cognitive deficits noted in high symptom mTBI participants compared to control subjects and low symptom mTBI participants.	[Sours, Chandler; Rosenberg, Joseph; Roys, Steve; Zhuo, Jiachen; Gullapalli, Rao P.] Univ Maryland, Sch Med, Magnet Resonance Res Ctr, Baltimore, MD 21201 USA; [Sours, Chandler; Rosenberg, Joseph; Roys, Steve; Zhuo, Jiachen; Shanmuganathan, Kathirkamanthan; Gullapalli, Rao P.] Univ Maryland, Sch Med, Dept Diagnost Radiol & Nucl Med, Baltimore, MD 21201 USA; [Sours, Chandler; Gullapalli, Rao P.] Univ Maryland, Sch Med, Program Neurosci, Baltimore, MD 21201 USA; [Kane, Robert] Georgetown Univ, Sch Med, Washington, DC 20057 USA	Gullapalli, RP (corresponding author), Univ Maryland, Sch Med, Dept Diagnost Radiol & Nucl Med, 22 South Greene St, Baltimore, MD 21201 USA.	csour001@umaryland.edu; jrosenberg2@umm.edu; kaner@georgetown.edu; sroys@umm.edu; jzhuo@umm.edu; kshanmuganathan@umm.edu; rgullapalli@umm.edu			DODUnited States Department of Defense [W81XWH-08-1-0725, W81XWH- 12-1-0098]; NRSA Grant from the National Institute of Neurological Disorders and Stroke [1F31NS081984]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR019214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS081984, R03NS088014] Funding Source: NIH RePORTER	The authors would like to thank Joshua Betz, Jacqueline Janowich and Teodora Stoica for their help with participant recruitment and George Makris for his help with acquiring and processing the data. This study was supported by DOD award W81XWH-08-1-0725 and W81XWH- 12-1-0098. Chandler Sours was partly supported by an NRSA Grant from the National Institute of Neurological Disorders and Stroke (1F31NS081984).	Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Brown CN, 2007, J ATHL TRAINING, V42, P515; Centers for Disease Control and Prevention, 2003, C MILD TRAUM BRAIN I; Coldren RL, 2012, MIL MED, V177, P179, DOI 10.7205/MILMED-D-11-00278; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Hampson M, 2006, J NEUROSCI, V26, P13338, DOI 10.1523/JNEUROSCI.3408-06.2006; Hawkins KA, 2012, PARKINSONISM RELAT D, V18, P864, DOI 10.1016/j.parkreldis.2012.04.021; Hillary FG, 2010, BRAIN IMAGING BEHAV, V4, P141, DOI 10.1007/s11682-010-9094-z; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Johnson B, 2012, NEUROSCI LETT, V509, P5, DOI 10.1016/j.neulet.2011.11.013; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kabat MH, 2001, CLIN NEUROPSYCHOL, V15, P498, DOI 10.1076/clin.15.4.498.1882; Kane RL, 2007, ARCH CLIN NEUROPSYCH, V22, pS115, DOI 10.1016/j.acn.2006.10.006; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Levinson D, 2005, ARCH CLIN NEUROPSYCH, V20, P403, DOI 10.1016/j.acn.2004.09.001; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McCrea M., 2000, STAND ASSESSMENT CON; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Miotto EC, 2010, ARQ NEURO-PSIQUIAT, V68, P862, DOI 10.1590/S0004-282X2010000600006; Pellicano C, 2013, J NEUROIMAGING, V23, P445, DOI 10.1111/j.1552-6569.2011.00687.x; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Reeves DL, 2007, ARCH CLIN NEUROPSYCH, V22, pS15, DOI 10.1016/j.acn.2006.10.013; Reeves DL, 2006, MIL MED, V171, P982, DOI 10.7205/MILMED.171.10.982; Reich S, 2005, VALIDATION ANAM TEST; Roebuck-Spencer TM, 2012, CLIN NEUROPSYCHOL, V26, P473, DOI 10.1080/13854046.2011.650214; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Thorne DR, 2006, BEHAV RES METHODS, V38, P569; van den Heuvel MP, 2010, EUR NEUROPSYCHOPHARM, V20, P519, DOI 10.1016/j.euroneuro.2010.03.008; Vincent AS, 2008, MIL MED, V173, P836, DOI 10.7205/MILMED.173.9.836; Vincent AS, 2012, MIL MED, V177, P256, DOI 10.7205/MILMED-D-11-00289; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Whitfield-Gabrieli S, 2012, BRAIN CONNECT, V2, P125, DOI 10.1089/brain.2012.0073; World Health Organization, 2010, INT CLASS DIS; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	56	24	25	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2015	9	2					190	203		10.1007/s11682-014-9295-y			14	Neuroimaging	Neurosciences & Neurology	CI7TB	WOS:000354966600005	24557591	Green Accepted			2021-06-18	
J	Urban, KJ; Barlow, KM; Jimenez, JJ; Goodyear, BG; Dunn, JF				Urban, Karolina J.; Barlow, Karen M.; Jimenez, Jon J.; Goodyear, Bradley G.; Dunn, Jeff F.			Functional Near-Infrared Spectroscopy Reveals Reduced Interhemispheric Cortical Communication after Pediatric Concussion	JOURNAL OF NEUROTRAUMA			English	Article						coherence; concussion; fNIRS; mild traumatic brain injury; near infrared spectroscopy	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; 4TH INTERNATIONAL-CONFERENCE; PROTON MR SPECTROSCOPY; DIFFUSE AXONAL INJURY; RESTING HUMAN BRAIN; WORKING-MEMORY; CONSENSUS STATEMENT; NOVEMBER 2012; MOTOR CORTEX	Concussion, or mild traumatic brain injury (mTBI), is a growing concern, especially among the pediatric population. By age 25, as many as 30% of the population are likely to have had a concussion. Many result in long-term disability, with some evolving to postconcussion syndrome. Treatments are being developed, but are difficult to assess given the lack of measures to quantitatively monitor concussion. There is no accepted quantitative imaging metric for monitoring concussion. We hypothesized that because cognitive function and fiber tracks are often impacted in concussion, interhemispheric brain communication may be impaired. We used functional near-infrared spectroscopy (fNIRS) to quantify functional coherence between the left and right motor cortex as a marker of interhemispheric communication. Studies were undertaken during the resting state and with a finger-tapping task to activate the motor cortex. Pediatric patients (ages 12-18) had symptoms for 31-473 days, compared to controls, who have not had reported a previous concussion. We detected differences between patients and controls in coherence between the contralateral motor cortices using measurements of total hemoglobin and oxy-hemoglobin with a p<0.01 (n=8, control; n=12mTBI). Given the critical need for a quantitative biomarker for recovery after a concussion, we present these data to highlight the potential of fNIRS coupled with interhemispheric coherence analysis as a biomarker of concussion injury.	[Urban, Karolina J.; Goodyear, Bradley G.; Dunn, Jeff F.] Univ Calgary, Dept Radiol, Calgary, AB T2N 4N1, Canada; [Urban, Karolina J.; Goodyear, Bradley G.; Dunn, Jeff F.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB T2N 4N1, Canada; [Urban, Karolina J.; Jimenez, Jon J.; Dunn, Jeff F.] Univ Calgary, Expt Imaging Ctr, Calgary, AB T2N 4N1, Canada; [Barlow, Karen M.] Univ Calgary, Dept Pediat & Clin Neurosci, Calgary, AB T2N 4N1, Canada; [Barlow, Karen M.] Univ Calgary, Alberta Childrens Hosp Res Inst, Calgary, AB T2N 4N1, Canada	Dunn, JF (corresponding author), Univ Calgary, Dept Radiol, Fac Med, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	dunnj@ucalgary.ca	Barlow, Karen/I-6492-2019; Meijer, Anna/K-5118-2016; Barlow, Karen/C-1323-2014	Barlow, Karen/0000-0003-2612-8507; Urban, Karolina/0000-0003-1301-7891			Arfanakis K, 2000, MAGN RESON IMAGING, V18, P921, DOI 10.1016/S0730-725X(00)00190-9; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Boas DA, 2004, NEUROIMAGE, V23, pS275, DOI 10.1016/j.neuroimage.2004.07.011; Bryer EJ, 2013, J INT NEUROPSYCH SOC, V19, P751, DOI 10.1017/S1355617713000490; Buxton RB, 1997, J CEREBR BLOOD F MET, V17, P64, DOI 10.1097/00004647-199701000-00009; Chamard E, 2014, J NEUROTRAUM, V31, P339, DOI 10.1089/neu.2013.3083; Chamard E, 2013, BRAIN INJURY, V27, P1038, DOI 10.3109/02699052.2013.794968; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Ciuciu P, 2014, NEUROIMAGE, V95, P248, DOI 10.1016/j.neuroimage.2014.03.047; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; De Guio F, 2012, PEDIATR NEUROL, V46, P94, DOI 10.1016/j.pediatrneurol.2011.11.019; Emanuelson I, 2003, INT J REHABIL RES, V26, P257, DOI 10.1097/00004356-200312000-00002; Franceschini MA, 2003, PSYCHOPHYSIOLOGY, V40, P548, DOI 10.1111/1469-8986.00057; Gagnon I, 2005, J HEAD TRAUMA REHAB, V20, P436, DOI 10.1097/00001199-200509000-00005; Giza CC, 2001, J ATHL TRAINING, V36, P228; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Hammeke TA, 2013, J INT NEUROPSYCH SOC, V19, P863, DOI 10.1017/S1355617713000702; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Huppert TJ, 2009, APPL OPTICS, V48, pD280, DOI 10.1364/AO.48.00D280; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Jimenez JJ, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.7.076008; Johnson B, 2012, NEUROSCI LETT, V509, P5, DOI 10.1016/j.neulet.2011.11.013; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kasahara K, 2012, MAGN RESON IMAGING, V30, P496, DOI 10.1016/j.mri.2011.12.018; Keightley ML, 2012, CURR OPIN PEDIATR, V24, P709, DOI 10.1097/MOP.0b013e3283599a55; Keightley ML, 2014, J NEUROTRAUM, V31, P437, DOI [10.1089/NEU.2013.3052, 10.1089/neu.2013.3052]; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kirov II, 2013, J NEUROTRAUM, V30, P1200, DOI 10.1089/neu.2012.2696; Kirov II, 2013, J NEUROL, V260, P242, DOI 10.1007/s00415-012-6626-z; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Kontos AP, 2014, BRAIN IMAGING BEHAV, V8, P621, DOI 10.1007/s11682-014-9289-9; Krivitzky LS, 2011, J INT NEUROPSYCH SOC, V17, P1143, DOI 10.1017/S1355617711001226; Kumar S, 2009, J NEUROTRAUM, V26, P665, DOI [10.1089/neu.2008.0644, 10.1089/neu.2008-0644]; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McCrory P, 2013, J AM COLL SURGEONS, V216, pE55, DOI 10.1016/j.jamcollsurg.2013.02.020; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mesquita RC, 2010, BIOMED OPT EXPRESS, V1, P324, DOI 10.1364/BOE.1.000324; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Newton AT, 2007, HUM BRAIN MAPP, V28, P663, DOI 10.1002/hbm.20294; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; OGAWA S, 1993, BIOPHYS J, V64, P803, DOI 10.1016/S0006-3495(93)81441-3; Pieper P, 2014, BRAIN INJURY, V28, P105, DOI 10.3109/02699052.2013.847208; Riedl V, 2014, J NEUROSCI, V34, P6260, DOI 10.1523/JNEUROSCI.0492-14.2014; Sasai S, 2011, NEUROIMAGE, V56, P252, DOI 10.1016/j.neuroimage.2010.12.075; Shrey DW, 2011, PHYS MED REH CLIN N, V22, P577, DOI 10.1016/j.pmr.2011.08.002; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Strangman G, 2002, NEUROIMAGE, V17, P719, DOI 10.1006/nimg.2002.1227; Strangman G, 2002, BIOL PSYCHIAT, V52, P679, DOI 10.1016/S0006-3223(02)01550-0; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tallus J, 2013, J NEUROTRAUM, V30, P1270, DOI 10.1089/neu.2012.2760; Varshney VP, 2012, J EUR OPT SOC-RAPID, V7, DOI 10.2971/jeos.2012.12047; Wilde EA, 2011, INT J PSYCHOPHYSIOL, V82, P86, DOI 10.1016/j.ijpsycho.2011.04.006; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhou YX, 2014, J MAGN RESON IMAGING, V39, P1558, DOI 10.1002/jmri.24310; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542	68	24	24	1	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2015	32	11					833	840		10.1089/neu.2014.3577			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV0YU	WOS:000363980700008	25387354	Green Published			2021-06-18	
J	Wylie, GR; Freeman, K; Thomas, A; Shpaner, M; OKeefe, M; Watts, R; Naylor, MR				Wylie, Glenn R.; Freeman, Kalev; Thomas, Alex; Shpaner, Marina; OKeefe, Michael; Watts, Richard; Naylor, Magdalena R.			Cognitive Improvement after Mild Traumatic Brain Injury Measured with Functional Neuroimaging during the Acute Period	PLOS ONE			English	Article							WORKING-MEMORY LOAD; HEAD-INJURY; NETWORK; CONNECTIVITY; SYMPTOMS; RECOVERY; RETURN; TBI; ABNORMALITIES; RECRUITMENT	Functional neuroimaging studies in mild traumatic brain injury (mTBI) have been largely limited to patients with persistent post-concussive symptoms, utilizing images obtained months to years after the actual head trauma. We sought to distinguish acute and delayed effects of mild traumatic brain injury on working memory functional brain activation patterns < 72 hours after mild traumatic brain injury (mTBI) and again one-week later. We hypothesized that clinical and fMRI measures of working memory would be abnormal in symptomatic mTBI patients assessed < 72 hours after injury, with most patients showing clinical recovery (i.e., improvement in these measures) within 1 week after the initial assessment. We also hypothesized that increased memory workload at 1 week following injury would expose different cortical activation patterns in mTBI patients with persistent post-concussive symptoms, compared to those with full clinical recovery. We performed a prospective, cohort study of working memory in emergency department patients with isolated head injury and clinical diagnosis of concussion, compared to control subjects (both uninjured volunteers and emergency department patients with extremity injuries and no head trauma). The primary outcome of cognitive recovery was defined as resolution of reported cognitive impairment and quantified by scoring the subject's reported cognitive post-concussive symptoms at 1 week. Secondary outcomes included additional post-concussive symptoms and neurocognitive testing results. We enrolled 46 subjects: 27 with mild TBI and 19 controls. The time of initial neuroimaging was 48 (22 S.D.) hours after injury (time 1). At follow up (8.7, + 1.2 S.D., days after injury, time 2), 18 of mTBI subjects (64%) reported moderate to complete cognitive recovery, 8 of whom fully recovered between initial and follow-up imaging. fMRI changes from time 1 to time 2 showed an increase in posterior cingulate activation in the mTBI subjects compared to controls. Increases in activation were greater in those mTBI subjects without cognitive recovery. As workload increased in mTBI subjects, activation increased in cortical regions in the right hemisphere. In summary, we found neuroimaging evidence for working memory deficits during the first week following mild	[Wylie, Glenn R.] Kessler Fdn, Rocco Ortenzio Neuroimaging Ctr, W Orange, NJ USA; [Wylie, Glenn R.] Rutgers State Univ, Sch Med, Dept Phys Med & Rehabil, Newark, NJ 07102 USA; [Wylie, Glenn R.] War Related Illness & Injury Study Ctr, Dept Vet Affairs, E Orange, NJ USA; [Freeman, Kalev; Thomas, Alex; Shpaner, Marina; OKeefe, Michael; Watts, Richard; Naylor, Magdalena R.] Univ Vermont, Dept Psychiat, Burlington, VT 05405 USA	Naylor, MR (corresponding author), Univ Vermont, Dept Psychiat, Burlington, VT 05405 USA.	magdalena.naylor@uvm.edu			Department of Surgery at UVM; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K08GM098795] Funding Source: NIH RePORTER	This work was supported by an internal grant from the Department of Surgery at UVM to Dr. Freeman.	Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Bryer EJ, 2013, J INT NEUROPSYCH SOC, V19, P751, DOI 10.1017/S1355617713000490; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Das A, 2012, NEUROLOGY, V79, P2146, DOI 10.1212/WNL.0b013e3182752cdb; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gosselin N, 2011, J NEUROTRAUM, V28, P329, DOI 10.1089/neu.2010.1493; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hillary FG, 2011, BRAIN, V134, P1555, DOI 10.1093/brain/awr043; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Kasahara M, 2011, BRAIN INJURY, V25, P1170, DOI 10.3109/02699052.2011.608210; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; Palacios EM, 2012, NEUROLOGY, V78, P852, DOI 10.1212/WNL.0b013e31824c465a; Pardini JE, 2010, NEUROSURGERY, V67, P1020, DOI 10.1227/NEU.0b013e3181ee33e2; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Ricker JH, 2001, J HEAD TRAUMA REHAB, V16, P191, DOI 10.1097/00001199-200104000-00007; Sanchez-Carrion R, 2008, NEUROIMAGE, V43, P421, DOI 10.1016/j.neuroimage.2008.08.003; Singh KD, 2008, NEUROIMAGE, V41, P100, DOI 10.1016/j.neuroimage.2008.01.051; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Turner GR, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00009; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wilde EA, 2011, INT J PSYCHOPHYSIOL, V82, P86, DOI 10.1016/j.ijpsycho.2011.04.006	38	24	26	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2015	10	5							e0126110	10.1371/journal.pone.0126110			18	Multidisciplinary Sciences	Science & Technology - Other Topics	CI1YY	WOS:000354542500063	25962067	DOAJ Gold, Green Published			2021-06-18	
J	Sherer, M; Sander, AM; Nick, TG; Melguizo, MS; Tulsky, DS; Kisala, P; Hanks, R; Novack, TA				Sherer, Mark; Sander, Angelle M.; Nick, Todd G.; Melguizo, Maria S.; Tulsky, David S.; Kisala, Pamela; Hanks, Robin; Novack, Thomas A.			Key Dimensions of Impairment, Self-Report, and Environmental Supports in Persons With Traumatic Brain Injury	REHABILITATION PSYCHOLOGY			English	Article						traumatic brain injury; cognitive function; self-report; environmental facilitators; outcome	FAMILY ASSESSMENT DEVICE; PARTICIPATION ASSESSMENT; SYMPTOMS; DISORDER; OUTCOMES	Purpose/Objectives: To determine key dimensions relevant to recovery in the postacute period for persons with traumatic brain injury (TBI) and to determine the ability of scores on these dimensions to predict participation outcomes for persons with TBI. Research Method/Design: This was a prospective cohort, observational study of 504 persons with medically documented TBI. Participants completed a comprehensive battery of measures including cognitive tests; questionnaires assessing self-report of physical, cognitive, and emotional symptoms and strengths; environmental supports; and a measure of participation outcome. Results: Participants were a predominantly male, ethnically/racially diverse sample of persons with complicated mild, moderate, and severe TBI. Variable cluster analysis identified 12 key dimensions of cognitive function, neurobehavioral complaints, personal strengths, physical symptoms and function, environmental supports, and performance validity. In unadjusted analyses, all 12 dimensions were predictive of participation outcome. In multivariable regression analysis with adjustment of all predictors for all other predictors, dimensions measuring memory, independence and self-esteem, resilience, emotional distress, physical functioning, and economic and family support made unique contributions to predicting participation outcome. Conclusions/Implications: Findings add to our understanding of key aspects of functioning and self-perception for persons with TBI. Knowledge of the profile of an individual patient on these 12 dimensions may assist with development of a treatment approach for the person with TBI.	[Sherer, Mark] TIRR Mem Hermann, Dept Res, Houston, TX 77030 USA; [Sander, Angelle M.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Sander, Angelle M.] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX 77030 USA; [Sander, Angelle M.] Harris Hlth Syst, Ctr Trauma Rehabil, Dept Phys Med & Rehabil, Houston, TX USA; [Nick, Todd G.; Melguizo, Maria S.] Univ Arkansas Med Sci, Dept Pediat & Biostat, Little Rock, AR 72205 USA; [Tulsky, David S.; Kisala, Pamela] Univ Delaware, Coll Hlth Sci, Dept Phys Therapy, Newark, DE 19716 USA; [Hanks, Robin] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Wayne, NJ USA; [Novack, Thomas A.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA	Sherer, M (corresponding author), TIRR Mem Hermann, 1333 Moursund, Houston, TX 77030 USA.	mark.sherer@memorialhermann.org		Tulsky, David/0000-0002-4335-4509; Sherer, Mark/0000-0003-1784-7008	U.S. Department of Education National Institute on Disability and Rehabilitation ResearchUS Department of Education [H133B090023, H133A120020]	This research was supported by U.S. Department of Education National Institute on Disability and Rehabilitation Research Grants H133B090023 and H133A120020. This article was presented as the Leonard Diller Lecture at Rehabilitation Psychology's 16th Annual Conference, San Antonio, Texas, February-March, 2014.	Bertisch H, 2014, NEUROREHABILITATION, V34, P573, DOI 10.3233/NRE-141059; Bogner JA, 2011, ARCH PHYS MED REHAB, V92, P552, DOI 10.1016/j.apmr.2010.11.014; Cella D, 2011, ARCH PHYS MED REHAB, V92, pS28, DOI 10.1016/j.apmr.2011.01.025; Cella D, 2010, J CLIN EPIDEMIOL, V63, P1179, DOI 10.1016/j.jclinepi.2010.04.011; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cook KF, 2011, ARCH PHYS MED REHAB, V92, P818, DOI 10.1016/j.apmr.2010.12.008; D'Agostino R. B., 1992, P 5 ANN C NE SAS US; Dams-O'Connor K, 2013, BRAIN IMPAIR, V14, P51, DOI 10.1017/BrImp.2013.9; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Forslund MV, 2013, ACTA NEUROL SCAND, V128, P220, DOI 10.1111/ane.12130; Gladsjo JA, 1999, ASSESSMENT, V6, P147, DOI 10.1177/107319119900600204; Green P., 1996, WORD MEMORY TEST USE; Green Paul, 2007, Phys Med Rehabil Clin N Am, V18, P43, DOI 10.1016/j.pmr.2006.11.002; Harch PG, 2012, J NEUROTRAUM, V29, P168, DOI 10.1089/neu.2011.1895; Harrell F. E., 2009, RMS S FUNCTIONS BIOS; Kim YJ, 2011, J CLIN NURS, V20, P1518, DOI 10.1111/j.1365-2702.2010.03618.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; Nightingale EJ, 2007, BRAIN IMPAIR, V8, P101, DOI [10.1375/brim.8.2.101, DOI 10.1375/BRIM.8.2.101]; Reistetter Timothy A, 2005, Occup Ther Int, V12, P196; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rey A, 1958, EXAMIN CLINIQUE PSYC; Ridenour TA, 1999, FAM PROCESS, V38, P497, DOI 10.1111/j.1545-5300.1999.00497.x; Saltychev M, 2013, BRAIN INJURY, V27, P1516, DOI 10.3109/02699052.2013.831131; SAS Institute Inc, 2008, SAS STAQT 9 2 US GUI; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Sherer M, 2014, ARCH PHYS MED REHAB, V95, P1162, DOI [10.1016/j.apmr.2014.02.006, 10.1016/j.apmr.2013.06.004]; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Trexler LE, 2010, J HEAD TRAUMA REHAB, V25, P440, DOI 10.1097/HTR.0b013e3181d41139; Tulsky D. S., J HEAD TRAUMA REHABI; Tulsky D. S., 2014, ARCH PHYS MED REHABI; Vickery CD, 2008, REHABIL PSYCHOL, V53, P101, DOI 10.1037/0090-5550.53.1.101; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P542, DOI 10.1016/j.apmr.2010.08.002; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033	37	24	24	0	12	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	MAY	2015	60	2					138	146		10.1037/rep0000030			9	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	CL5CG	WOS:000356976800005	26120740	Bronze			2021-06-18	
J	Taylor, CA; Greenspan, AI; Xu, LK; Kresnow, MJ				Taylor, Christopher A.; Greenspan, Arlene I.; Xu, Likang; Kresnow, Marcie-jo			Comparability of National Estimates for Traumatic Brain Injury-Related Medical Encounters	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						emergency department visits; epidemiology; hospitalizations; traumatic brain injury		Objective: To describe similarities and differences in the number of civilian traumatic brain injury (TBI)-related hospitalizations and emergency department visits between national databases that capture US hospital data. Participants: TBI-related hospitalizations included in the National Hospital Discharge Survey (NHDS) and Healthcare Cost and Utilization Project Nationwide Inpatient Sample (HCUP-NIS) and emergency department visits in the National Hospital Ambulatory Medical Care Survey (NHAMCS) and HCUP Nationwide Emergency Department Sample (HCUP-NEDS) for 2006-2010. Design: Cross-sectional design. Main Measures: Nationwide counts of TBI-related medical encounters. Results: Overall, the frequency of TBI is comparable when comparing NHDS with HCUP-NIS and NHAMCS with HCUP-NEDS. However, annual counts in both NHDS and NHAMCS are consistently unstable when examined in smaller subgroups, such as by age group and injury mechanism. Injury mechanism is consistently missing from many more records in NHDS compared with HCUP-NIS. Conclusion: Given the large sample size of HCUP-NIS and HCUP-NEDS, these data can offer a valuable resource for examining TBI-related hospitalization and emergency department visits, especially by subgroup. These data hold promise for future examinations of annual TBI counts, but ongoing comparisons with national probability samples will be necessary to ensure that HCUP continues to track with estimates from these data.	[Taylor, Christopher A.; Greenspan, Arlene I.; Xu, Likang; Kresnow, Marcie-jo] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA	Taylor, CA (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy,MS F-62, Atlanta, GA 30341 USA.	CATaylor1@cdc.gov	Taylor, Christopher A/D-2067-2013	Taylor, Christopher A/0000-0002-0937-5461	Intramural CDC HHS [CC999999] Funding Source: Medline		Agency for Healthcare Research and Quality, 2012, INTR 2010 HCUP NAT I; Agency for Healthcare Research and Quality, 2012, INTR 2010 HCUP NAT E; Barrett M, 2014, 201401 HCUP; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; Centers for Disease Control and Prevention, 2010, PUBL US DAT FIL DOC; Centers for Disease Control and Prevention, HOSP CAR SURV; Centers for Disease Control and Prevention, EST PROC; Centers for Medicare & Medicaid Services Statistics NCfH, 2011, STAT NCFH ICD 9 CM O; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Dennison C, 2000, Vital Health Stat 1, P1; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Johnson R. L., 2010, STATE INJURY INDICAT; Kish L., 1965, SURVEY SAMPLING, P182; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Levit K., 2007, HCUP FACTS FIGURES S; Marr AL., 2004, CENTRAL NERVOUS SYST; Pfuntner AW, 2012, OVERVIEW HOSP STAYS	17	24	24	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2015	30	3					150	159		10.1097/HTR.0000000000000105			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CH8PJ	WOS:000354298100128	25955702	Green Accepted			2021-06-18	
J	Joseph, B; Pandit, V; Zangbar, B; Kulvatunyou, N; Khalil, M; Tang, A; O'Keeffe, T; Gries, L; Vercruysse, G; Friese, RS; Rhee, P				Joseph, Bellal; Pandit, Viraj; Zangbar, Bardiya; Kulvatunyou, Narong; Khalil, Mazhar; Tang, Andrew; O'Keeffe, Terence; Gries, Lynn; Vercruysse, Gary; Friese, Randall S.; Rhee, Peter			Secondary brain injury in trauma patients: The effects of remote ischemic conditioning	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	73rd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma / Clinical Congress of Acute Care Surgery	SEP 09-13, 2014	Philadelphia, PA	Amer Assoc Surg Trauma		Remote ischemic conditioning; traumatic brain injury; S-100B; neuron-specific enolase	NEURON-SPECIFIC ENOLASE; CHANNEL-DEPENDENT MECHANISM; ACUTE MYOCARDIAL-INFARCTION; REPERFUSION INJURY; INTRACRANIAL HYPERTENSION; POSTCONDITIONING PROTECTS; GENE-EXPRESSION; HUMANS; HEART; SERUM	BACKGROUND: Management of traumatic brain injury (TBI) is focused on preventing secondary brain injury. Remote ischemic conditioning (RIC) is an established treatment modality that has been shown to improve patient outcomes secondary to inflammatory insults. The aim of our study was to assess whether RIC in trauma patients with severe TBI could reduce secondary brain injury. METHODS: This prospective consented interventional trial included all TBI patients admitted to our Level 1 trauma center with an intracranial hemorrhage and a Glasgow Coma Scale (GCS) score of 8 or lower on admission. In each patient, four cycles of RIC were performed within 1 hour of admission. Each cycle consisted of 5 minutes of controlled upper limb (arm) ischemia followed by 5 minutes of reperfusion using a blood pressure cuff. Serum biomarkers of acute brain injury, S-100B, and neuron-specific enolase (NSE) were measured at 0, 6, and 24 hours. Outcome measure was reduction in the level of serum biomarkers after RIC. RESULTS: A total of 40 patients (RIC, 20; control, 20) were enrolled. The mean (SD) age was 46.15 (18.64) years, the median GCS score was 8 (interquartile range, 3-8), and the median head Abbreviated Injury Scale (AIS) score was 3 (interquartile range, 3-5), and there was no difference between the RIC and control groups in any of the baseline demographics or injury characteristics including the type and size of intracranial bleed or skull fracture patterns. There was no difference in the 0-hour S-100B (p = 0.9) and NSE (p = 0.72) level between the RIC and the control group. There was a significant reduction in the mean levels of S-100B (p = 0.01) and NSE (p = 0.04) at 6 hours and 24 hours in comparison with the 0-hour level in the RIC group. CONCLUSION: This study showed that RIC significantly decreased the standard biomarkers of acute brain injury in patients with severe TBI. Our study highlights the novel therapeutic role of RIC for preventing secondary brain insults in TBI patients. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.	[Joseph, Bellal; Pandit, Viraj; Zangbar, Bardiya; Kulvatunyou, Narong; Khalil, Mazhar; Tang, Andrew; O'Keeffe, Terence; Gries, Lynn; Vercruysse, Gary; Friese, Randall S.; Rhee, Peter] Univ Arizona, Dept Surg, Div Trauma Crit Care Burns & Emergency Surg, Med Ctr, Tucson, AZ 85724 USA	Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Crit Care Burns & Emergency Surg, 1501 N Campbell Ave,Room 5411,POB 245063, Tucson, AZ 85724 USA.	bjoseph@surgery.arizona.edu	Zangbar, Bardiya/K-7147-2014	Zangbar, Bardiya/0000-0003-1215-1693			Ali ZA, 2007, CIRCULATION, V116, pI98, DOI 10.1161/circulationaha.106.679167; Andreka G, 2007, HEART, V93, P749, DOI 10.1136/hrt.2006.114504; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Botker HE, 2010, LANCET, V375, P727, DOI 10.1016/S0140-6736(09)62001-8; Candilio L, 2013, J CARDIOVASC MED, V14, P193, DOI 10.2459/JCM.0b013e328359dd7b; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Cooper DJ, 2013, J NEUROTRAUM, V30, P512, DOI 10.1089/neu.2012.2573; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Darnous LL, 2008, TRANSPL P, V40, P861, DOI 10.1016/j.transproceed.2008.02.065; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Farahvar A, 2011, J NEUROSURG, V114, P1471, DOI 10.3171/2010.11.JNS101116; Hausenloy DJ, 2011, NAT REV CARDIOL, V8, P619, DOI 10.1038/nrcardio.2011.85; Hu S, 2010, J NEUROSURG ANESTH, V22, P46, DOI 10.1097/ANA.0b013e3181c572bd; Kanoria S, 2007, TRANSPLANTATION, V84, P445, DOI 10.1097/01.tp.0000228235.55419.e8; Kharbanda RK, 2006, HEART, V92, P1506, DOI 10.1136/hrt.2004.042366; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Konstantinov IE, 2005, J THORAC CARDIOV SUR, V130, P1326, DOI 10.1016/j.jtcvs.2005.03.050; Konstantinov IE, 2005, TRANSPLANTATION, V79, P1691, DOI 10.1097/01.TP.0000159137.76400.5D; Konstantinov IE, 2004, PHYSIOL GENOMICS, V19, P143, DOI 10.1152/physiolgenomics.00046.2004; Kuntscher MV, 2003, ANN PLAS SURG, V51, P84; Lim SY, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00027; Loukogeorgakis SP, 2005, J AM COLL CARDIOL, V46, P450, DOI 10.1016/j.jacc.2005.04.044; Loukogeorgakis SP, 2007, CIRCULATION, V116, P1386, DOI 10.1161/CIRCULATIONAHA.106.653782; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; McKeating EG, 1998, ACT NEUR S, V71, P117; Munk K, 2010, CIRC-CARDIOVASC IMAG, V3, P656, DOI 10.1161/CIRCIMAGING.110.957340; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Sahebally SM, 2014, INT J SURG, V12, P16, DOI 10.1016/j.ijsu.2013.11.004; Saxena P, 2010, J CARDIAC SURG, V25, P127, DOI 10.1111/j.1540-8191.2009.00820.x; Steiger HJ, 2007, ACTA NEUROCHIR, V149, P1, DOI 10.1007/s00701-006-1057-1; Stein DM, 2012, J NEUROTRAUM, V29, P1140, DOI 10.1089/neu.2011.2149; Stein DM, 2011, NEUROCRIT CARE, V14, P200, DOI 10.1007/s12028-010-9496-1; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Wei M, 2011, CIRC RES, V108, P1220, DOI 10.1161/CIRCRESAHA.110.236190; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131	38	24	29	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	APR	2015	78	4					698	703		10.1097/TA.0000000000000584			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	CE8EJ	WOS:000352074000005	25742251				2021-06-18	
J	Miao, XY; Wu, XY; Shi, W				Miao, Xingyu; Wu, Xiaoying; Shi, Wei			Umbilical cord mesenchymal stem cells in neurological disorders: A clinical study	INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSICS			English	Article						Neurological diseases; Umbilical cord mesenchymal stem cells; Stem cell; Intrathecal administration; Lumbar puncture	AMYOTROPHIC-LATERAL-SCLEROSIS; BRAIN-INJURY; TRANSPLANTATION; THERAPY; IMMUNOASSAY; INHIBITION; TISSUE; BLOOD; TRIAL; RATS	We investigated the intrathecally administrated unbilical cord mesenchymal stem cells (UC-MSCs) by lumbar puncture and assessed the technical difficulties and effects in various neurological conditions. One hundred patients underwent subarachnoid placement of UC-MSCs between December 2006 and May 2010 in the Affiliated Hospital of Medicine. Technical difficulties in patients in the form of localization of subarachnoid space, number of attempts, and post-procedural complications were evaluated. Functional evaluation was done using Hauser Ambulation Index (HAT) by the stem cell transplant team on a regular basis. All patients were followed-up for more than 1 yr after the treatment. Clinical symptoms, related biochemical index and photographic examinations were observed regularly. We encountered technical difficulties in 31 patients (31%) in the form of general anesthesia supplementation and difficulty localizing the lumbar space. Side effects (headache, low-grade fever, low back pain and lower limb pain) were observed in 22 (22%) patients, which were treated with symptomatic therapy within 48 h. One year after the treatment, functional indices improved in 47 patients (47%): 12 patients with spinal cord injury, 11 patients with cerebral palsy, 9 patients with post-traumatic brain syndroine, 9 patients with post-brain infarction syndrome, 3 patients with spinocerebellar ataxias, and 3 patients with motor nenton-disease. In conclusion, intrathecal administration of UC-MSCs is a safe and effective way to treat neurological disorders. Our encouraging results of intrathecal administration of UC-MSCs indicate the potential of restoration of lost tissue and improvement of function in patients with profound neurological defects and inefficient conventional cure. These data support expanded double-blind, placebo-controlled studies for this treatment modality.	[Miao, Xingyu] Xi An Jiao Tong Univ, Affiliated Hosp 3, Dept Neurosurg, Xian 710068, Shanxi Province, Peoples R China; [Miao, Xingyu; Shi, Wei] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Neurosurg, Xian 710004, Shanxi Province, Peoples R China; [Wu, Xiaoying] Xi An Jiao Tong Univ, Affiliated Hosp 3, Dept Orthoped, Xian 710068, Shanxi Province, Peoples R China	Shi, W (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Neurosurg, 157 West Fifth Rd, Xian 710004, Shanxi Province, Peoples R China.	sweins@126.com					Carrion FA, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt64; Chen Jieli, 2006, NeuroRx, V3, P466, DOI 10.1016/j.nurx.2006.07.007; Chen YC, 2011, MYCOSES, V54, pE248, DOI 10.1111/j.1439-0507.2009.01847.x; Cui XY, 2015, MOL MED REP, V11, P3269, DOI 10.3892/mmr.2015.3198; Cursio R, 1999, FASEB J, V13, P253; Dotsikas Y, 2007, TALANTA, V71, P906, DOI 10.1016/j.talanta.2006.05.068; Glass JD, 2012, STEM CELLS, V30, P1144, DOI 10.1002/stem.1079; Gu Z, 2010, LUPUS, V19, P1502, DOI 10.1177/0961203310373782; HAUSER SL, 1983, NEW ENGL J MED, V308, P173, DOI 10.1056/NEJM198301273080401; Kang EJ, 2013, J TISSUE ENG REGEN M, V7, P169, DOI 10.1002/term.504; Kawai T, 2015, CYTOTHERAPY, V17, P369, DOI 10.1016/j.jcyt.2014.11.009; Kim DW, 2013, INT J MOL SCI, V14, P11692, DOI 10.3390/ijms140611692; Lepore AC, 2011, JOVE-J VIS EXP, V55, P3069; Li JF, 2014, CELL TRANSPLANT, V23, pS113, DOI 10.3727/096368914X685005; Lim JY, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt79; Liu J, 2013, CYTOTHERAPY, V15, P185, DOI 10.1016/j.jcyt.2012.09.005; Lundberg J, 2012, CELL TRANSPLANT, V21, P333, DOI 10.3727/096368911X576036; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Marquez ME, 2015, BRIT J HAEMATOL, V169, P211, DOI 10.1111/bjh.13286; Mehta T, 2008, TRANSPL P, V40, P1145, DOI 10.1016/j.transproceed.2008.03.026; Messerli M, 2013, REPROD SCI, V20, P1455, DOI 10.1177/1933719113488443; Questroy M, 1995, SOINS PEDIAT PUERIC, V166, P28; Riley J, 2012, NEUROSURGERY, V71, P405, DOI 10.1227/NEU.0b013e31825ca05f; Titomanlio L, 2011, ANN NEUROL, V70, P698, DOI 10.1002/ana.22518; Trivanovic D, 2013, SRP ARK CELOK LEK, V141, P178, DOI 10.2298/SARH1304178T; Wang HS, 2004, STEM CELLS, V22, P1330, DOI 10.1634/stemcells.2004-0013; Wang Liming, 2013, Case Rep Transplant, V2013, P146347, DOI 10.1155/2013/146347; Wang WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066599; Wang ZP, 2011, LUMINESCENCE, V26, P136, DOI 10.1002/bio.1196; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; WILEY CA, 1994, ANN NEUROL, V36, P673, DOI 10.1002/ana.410360422; Xinaris C, 2013, CELL TRANSPLANT, V22, P423, DOI 10.3727/096368912X653246; Zacharek A, 2007, J CEREBR BLOOD F MET, V27, P1684, DOI 10.1038/sj.jcbfm.9600475; Zhang RY, 2015, MOL MED REP, V11, P1807, DOI 10.3892/mmr.2014.2985	34	24	27	0	17	NATL INST SCIENCE COMMUNICATION-NISCAIR	NEW DELHI	DR K S KRISHNAN MARG, PUSA CAMPUS, NEW DELHI 110 012, INDIA	0301-1208	0975-0959		INDIAN J BIOCHEM BIO	Indian J. Biochem. Biophys.	APR	2015	52	2					140	146					7	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	CO0EF	WOS:000358822200004	26118125	DOAJ Gold			2021-06-18	
J	Solga, AC; Pong, WW; Walker, J; Wylie, T; Magrini, V; Apicelli, AJ; Griffith, M; Griffith, OL; Kohsaka, S; Wu, GF; Brody, DL; Mardis, ER; Gutmann, DH				Solga, Anne C.; Pong, Winnie W.; Walker, Jason; Wylie, Todd; Magrini, Vincent; Apicelli, Anthony J.; Griffith, Malachi; Griffith, Obi L.; Kohsaka, Shinichi; Wu, Gregory F.; Brody, David L.; Mardis, Elaine R.; Gutmann, David H.			RNA-Sequencing Reveals Oligodendrocyte and Neuronal Transcripts in Microglia Relevant to Central Nervous System Disease	GLIA			English	Article						laser-capture microdissection; fluorescence-activated cell sorting; macrophage	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TRANSLATIONAL PROFILING APPROACH; CONTROLLED CORTICAL IMPACT; AMYLOID-BETA-PROTEIN; PERITONEAL-MACROPHAGES; ALVEOLAR MACROPHAGES; ACTIVATION; EXPRESSION; SUBPOPULATIONS; FRACTIONATION	Expression profiling of distinct central nervous system (CNS) cell populations has been employed to facilitate disease classification and to provide insights into the molecular basis of brain pathology. One important cell type implicated in a wide variety of CNS disease states is the resident brain macrophage (microglia). In these studies, microglia are often isolated from dissociated brain tissue by flow sorting procedures [fluorescence-activated cell sorting (FACS)] or from postnatal glial cultures by mechanic isolation. Given the highly dynamic and state-dependent functions of these cells, the use of FACS or short-term culture methods may not accurately capture the biology of brain microglia. In the current study, we performed RNA-sequencing using Cx3cr1(+/GFP) labeled microglia isolated from the brainstem of 6-week-old mice to compare the transcriptomes of FACS-sorted versus laser capture microdissection (LCM). While both isolation techniques resulted in a large number of shared (common) transcripts, we identified transcripts unique to FACS-isolated and LCM-captured microglia. In particular, approximate to 50% of these LCM-isolated microglial transcripts represented genes typically associated with neurons and glia. While these transcripts clearly localized to microglia using complementary methods, they were not translated into protein. Following the induction of murine experimental autoimmune encephalomyelitis, increased oligodendrocyte and neuronal transcripts were detected in microglia, while only the myelin basic protein oligodendrocyte transcript was increased in microglia after traumatic brain injury. Collectively, these findings have implications for the design and interpretation of microglia transcriptome-based investigations. GLIA 2015;63:531-548	[Solga, Anne C.; Pong, Winnie W.; Apicelli, Anthony J.; Wu, Gregory F.; Brody, David L.; Gutmann, David H.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Walker, Jason; Wylie, Todd; Magrini, Vincent; Griffith, Malachi; Griffith, Obi L.; Mardis, Elaine R.] Washington Univ, Sch Med, Genome Inst, St Louis, MO USA; [Kohsaka, Shinichi] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neurochem, Kodaira, Tokyo 1870031, Japan	Gutmann, DH (corresponding author), Dept Neurol, Box 8111,660 South Euclid Ave, St Louis, MO 63110 USA.	gutmannd@neuro.wustl.edu	Apicelli, Anthony/AAB-8879-2021; Magrini, Vincent/AAT-5830-2020; Mardis, Elaine/W-2202-2019; Griffith, Malachi/P-1285-2014; Griffith, Obi/P-1286-2014	Apicelli, Anthony/0000-0001-6791-8113; Magrini, Vincent/0000-0002-2019-4872; Griffith, Malachi/0000-0002-6388-446X; Pong, Winnie/0000-0001-8254-3305; Gutmann, David/0000-0002-3127-5045; Griffith, Obi/0000-0002-0843-4271	NCI Cancer Center Support GrantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA91842]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RC4 NS072916]; W.M. Keck FoundationW.M. Keck Foundation; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA091842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC4NS072916] Funding Source: NIH RePORTER	Grant sponsor: NCI Cancer Center Support Grant (to The Siteman Cancer Center); Grant number: #P30 CA91842; Grant sponsor: National Institutes of Health; Grant number: RC4 NS072916 (to DHG); Grant sponsor: W.M. Keck Foundation (to WWP).	Boddeke EWGH, 1999, EUR J PHARMACOL, V374, P309, DOI 10.1016/S0014-2999(99)00307-6; Cabanski CR, 2014, J MOL DIAGN, V16, P440, DOI 10.1016/j.jmoldx.2014.03.004; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Casha S, 2012, BRAIN, V135, P1224, DOI 10.1093/brain/aws072; CHANDLER DB, 1986, J LEUKOCYTE BIOL, V39, P371; Davalos D, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2230; DAVIS JB, 1992, BIOCHEM BIOPH RES CO, V189, P1096, DOI 10.1016/0006-291X(92)92317-Q; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; Doyle JP, 2008, CELL, V135, P749, DOI 10.1016/j.cell.2008.10.029; Fitzner D, 2011, J CELL SCI, V124, P447, DOI 10.1242/jcs.074088; Gitik M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-24; Govindan R, 2012, CELL, V150, P1121, DOI 10.1016/j.cell.2012.08.024; Graeber MB, 2002, GLIA, V40, P252, DOI 10.1002/glia.10147; HASSAN NF, 1991, J LEUKOCYTE BIOL, V50, P86; Heiman M, 2008, CELL, V135, P738, DOI 10.1016/j.cell.2008.10.028; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Hirasawa T, 2005, J NEUROSCI RES, V81, P357, DOI 10.1002/jnr.20480; Hurley SD, 1999, GLIA, V25, P304, DOI 10.1002/(SICI)1098-1136(19990201)25:3<304::AID-GLIA10>3.0.CO;2-W; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; Izzo A, 2008, BIOL CHEM, V389, P333, DOI 10.1515/BC.2008.037; Jack C, 2005, J NEUROSCI RES, V81, P363, DOI 10.1002/jnr.20482; Jiang Y, 2012, J NEUROTRAUM, V29, P2332, DOI 10.1089/neu.2012.2362; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kaindl AM, 2012, ANN NEUROL, V72, P536, DOI 10.1002/ana.23626; Kettenmann H, 2013, NEURON, V77, P10, DOI 10.1016/j.neuron.2012.12.023; Khodosevich K, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001151; Klein RS, 2004, J CELL BIOCHEM, V92, P213, DOI 10.1002/jcb.20052; Lemarchant S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-133; Lewis CA, 2012, NEUROL RES INT, V2012, DOI 10.1155/2012/803701; Liang KJ, 2009, INVEST OPHTH VIS SCI, V50, P4444, DOI 10.1167/iovs.08-3357; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; MATSUMOTO Y, 1992, J NEUROIMMUNOL, V37, P23, DOI 10.1016/0165-5728(92)90152-B; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Miranda KC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096094; MORIMURA T, 1990, ACTA NEUROPATHOL, V80, P287, DOI 10.1007/BF00294647; OHMANN HB, 1986, J LEUKOCYTE BIOL, V39, P167; Ohtaki Hirokazu, 2013, Acta Neurochir Suppl, V118, P49, DOI 10.1007/978-3-7091-1434-6_8; ONEILL SJ, 1984, INFECT IMMUN, V46, P282, DOI 10.1128/IAI.46.1.282-284.1984; Oram JF, 2000, CURR OPIN LIPIDOL, V11, P253, DOI 10.1097/00041433-200006000-00005; Ozsolak F, 2011, NAT REV GENET, V12, P87, DOI 10.1038/nrg2934; Parkhurst CN, 2010, CURR OPIN NEUROBIOL, V20, P595, DOI 10.1016/j.conb.2010.07.002; PENFOLD PL, 1991, VISUAL NEUROSCI, V7, P383, DOI 10.1017/S0952523800004879; PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5; Petersohn D, 1996, EUR J BIOCHEM, V239, P827, DOI 10.1111/j.1432-1033.1996.0827u.x; PLASMAN N, 1993, RES IMMUNOL, V144, P151, DOI 10.1016/0923-2494(93)80070-F; Pong WW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077571; Pong WW, 2013, ANN NEUROL, V73, P303, DOI 10.1002/ana.23813; Racke M.K., 2001, CURR PROTOC NEUROSCI, DOI 10.1002/0471142301.ns0907s14; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; RASMUSSEN SE, 1983, ACTA PATH MICRO IM C, V91, P299; RINNER WA, 1995, GLIA, V14, P257, DOI 10.1002/glia.440140403; Roberts A, 2011, BIOINFORMATICS, V27, P2325, DOI 10.1093/bioinformatics/btr355; Roberts A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-3-r22; Roggendorf W, 1996, ACTA NEUROPATHOL, V92, P288, DOI 10.1007/s004010050520; Sanz E, 2009, P NATL ACAD SCI USA, V106, P13939, DOI 10.1073/pnas.0907143106; Sasaki A, 1997, ACTA NEUROPATHOL, V94, P316, DOI 10.1007/s004010050713; Simmons GW, 2011, J NEUROPATH EXP NEUR, V70, P51, DOI 10.1097/NEN.0b013e3182032d37; Szabo M, 2013, NEUROSCIENCE, V241, P280, DOI 10.1016/j.neuroscience.2013.03.033; Tariq MA, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr547; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Veillette A, 2007, IMMUNITY, V27, P698, DOI 10.1016/j.immuni.2007.11.005; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Waller R, 2012, J NEUROSCI METH, V208, P108, DOI 10.1016/j.jneumeth.2012.04.014; Wang LH, 1996, J NEUROSCI, V16, P6197; Windak R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073294	67	24	24	1	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	APR	2015	63	4					531	548		10.1002/glia.22754			18	Neurosciences	Neurosciences & Neurology	CB9SX	WOS:000349973900002	25258010	Green Accepted			2021-06-18	
J	Buonora, JE; Yarnell, AM; Lazarus, RC; Mousseau, M; Latour, LL; Rizoli, SB; Baker, AJ; Rhind, SG; Diaz-Arrastia, R; Mueller, GP				Buonora, John E.; Yarnell, Angela M.; Lazarus, Rachel C.; Mousseau, Michael; Latour, Lawrence L.; Rizoli, Sandro B.; Baker, Andrew J.; Rhind, Shawn G.; Diaz-Arrastia, Ramon; Mueller, Gregory P.			Multivariate analysis of traumatic brain injury: development of an assessment score	FRONTIERS IN NEUROLOGY			English	Article						biomarkers; assessment score; human; mild traumatic brain injury; multivariate analysis	NEURON-SPECIFIC ENOLASE; C-TERMINAL HYDROLASE; CREATINE-KINASE-BB; MILD HEAD-INJURY; SERUM-LEVELS; CEREBROSPINAL-FLUID; NEUROTROPHIC FACTOR; OXIDATIVE STRESS; SYSTEMS BIOLOGY; ICE HOCKEY	Important challenges for the diagnosis and monitoring of mild traumatic brain injury (mTBI) include the development of plasma biomarkers for assessing neurologic injury, monitoring pathogenesis, and predicting vulnerability for the development of untoward neurologic outcomes. While several biomarker proteins have shown promise in this regard, used individually, these candidates lack adequate sensitivity and/or specificity for making a definitive diagnosis or identifying those at risk of subsequent pathology. The objective for this study was to evaluate a panel of six recognized and novel biomarker candidates for the assessment of TB I in adult patients. The biomarkers studied were selected on the basis of their relative brain-specificities and potentials to reflect distinct features of TBI mechanisms including (1) neuronal damage assessed by neuron-specific enolase (NSE) and brain derived neurotrophic factor (BDNF); (2) oxidative stress assessed by peroxiredoxin 6 (PRDX6); (3) glial damage and gliosis assessed by glial fibrillary acidic protein and S100 calcium binding protein beta (S100b); (4) immune activation assessed by monocyte chemoattractant protein 1/chemokine (C-C motif) ligand 2 (MCP1/CCL2); and (5) disruption of the intercellular adhesion apparatus assessed by intercellular adhesion protein-5 (ICAM-5). The combined fold-changes in plasma levels of PRDX6, S100b, MCP1, NSE, and BDNF resulted in the formulation of a TBI assessment score that identified mTBI with a receiver operating characteristic (ROC) area under the curve of 0.97, when compared to healthy controls. This research demonstrates that a profile of biomarker responses can be used to formulate a diagnostic score that is sensitive for the detection of mTBI. Ideally, this multivariate assessment strategy will be refined with additional biomarkers that can effectively assess the spectrum of TBI and identify those at particular risk for developing neuropathologies as consequence of a mTBI event.	[Buonora, John E.; Lazarus, Rachel C.; Mousseau, Michael; Mueller, Gregory P.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Buonora, John E.] US Army, Grad Program Anesthesia Nursing, Acad Hlth Sci, Ft Sam Houston, TX USA; [Yarnell, Angela M.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci Res, Behav Biol Branch, Silver Spring, MD USA; [Latour, Lawrence L.] NINDS, Stroke Branch, Bethesda, MD 20892 USA; [Latour, Lawrence L.; Rhind, Shawn G.] Toronto Res Ctr, Def Res & Dev Canada, Toronto, ON, Canada; [Rizoli, Sandro B.; Baker, Andrew J.] Univ Toronto, St Michaels Hosp, Dept Anesthesia, Keenan Res Ctr,Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Rizoli, Sandro B.; Baker, Andrew J.] Univ Toronto, St Michaels Hosp, Dept Surg, Keenan Res Ctr,Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Rizoli, Sandro B.; Baker, Andrew J.] Univ Toronto, St Michaels Hosp, Dept Crit Care Med, Keenan Res Ctr,Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Baker, Andrew J.] Univ Toronto, Cara Phelan Ctr Trauma Res, Brain Injury Lab, Keenan Res Ctr,Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA	Mueller, GP (corresponding author), Uniformed Serv Univ Hlth Sci USU, Dept Anat Physiol & Genet, Room C2117,4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	gregory.mueller@usuhs.edu	Latour, Larry/AAH-5663-2021	Latour, Larry/0000-0001-6160-5263; Diaz-Arrastia, Ramon/0000-0001-6051-3594; Rhind, Shawn/0000-0003-2300-0620	Defense Medical Research and Development; Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; TriService Nursing Research Program Grant [HT9404-12-1-TS13]; Department of National Defense of Canada (DND) through the Technology Investment Fund (TIF) program; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS003120] Funding Source: NIH RePORTER	Principle source of funding was provided by a grant from the Defense Medical Research and Development, the Center for Neuroscience and Regenerative Medicine and the TriService Nursing Research Program Grant # HT9404-12-1-TS13. The authors also gratefully acknowledge the support of the Department of National Defense of Canada (DND) through the Technology Investment Fund (TIF) program. We also would like to acknowledge Mr. James Freedy for his contribution to the development of the single and multiplex assay platforms; Ms. Maria Shiu and Mr. Alex Di Battista for their technical assistance with sample collection and processing. The opinions expressed here are those of the author(s), and are not necessarily representative of those of the Uniformed Services University of the Health Sciences (USUHS), the United States Army and/or the Department of Defense, USA.	Agoston Denes V, 2012, Front Neurol, V3, P107, DOI 10.3389/fneur.2012.00107; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Bazarian JJ, 2006, RESTOR NEUROL NEUROS, V24, P163; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Blyth BJ, 2010, EMERG MED CLIN N AM, V28, P571, DOI 10.1016/j.emc.2010.03.003; Bruce J, 2014, CLIN NEUROPSYCHOL, V28, P14, DOI 10.1080/13854046.2013.866272; Carr ME, 2009, MIL MED, V174, P622, DOI 10.7205/MILMED-D-02-4708; Chase Alex, 2014, Nat Rev Neurol, V10, P240, DOI 10.1038/nrneurol.2014.65; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Chhunchha B, 2013, AM J PHYSIOL-CELL PH, V304, pC636, DOI 10.1152/ajpcell.00345.2012; Cirillo C, 2011, WORLD J GASTROENTERO, V17, P1261, DOI 10.3748/wjg.v17.i10.1261; Conductier G, 2010, J NEUROIMMUNOL, V224, P93, DOI 10.1016/j.jneuroim.2010.05.010; Cook GA, 2014, MIL MED, V179, P1083, DOI 10.7205/MILMED-D-13-00435; DAY INM, 1984, CLIN CHIM ACTA, V136, P219, DOI 10.1016/0009-8981(84)90295-X; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Di Battista AP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00044; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Doppenberg EMR, 1997, ANN NY ACAD SCI, V825, P305, DOI 10.1111/j.1749-6632.1997.tb48441.x; El-Maraghi S, 2013, EGYPT J CRIT CARE ME, V1, P25, DOI 10.1016/j.ejccm.2012.12.002; Fatma N, 2009, FREE RADICAL RES, V43, P783, DOI 10.1080/10715760903062887; Feala JD, 2013, J NEUROTRAUM, V30, P1101, DOI 10.1089/neu.2012.2631; Fujimura H, 2002, THROMB HAEMOSTASIS, V87, P728; Goemaere J, 2012, J COMP NEUROL, V520, P258, DOI 10.1002/cne.22689; Graham MR, 2011, INT J IMMUNOPATH PH, V24, P119, DOI 10.1177/039463201102400114; Guingab-Cagmat JD, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00061; Guo H, 2000, ANN NEUROL, V48, P590, DOI 10.1002/1531-8249(200010)48:4<590::AID-ANA5>3.3.CO;2-Z; Guzel A, 2008, NEUROSURG REV, V31, P439, DOI 10.1007/s10143-008-0148-2; Gyorgy A, 2011, J NEUROTRAUM, V28, P1121, DOI 10.1089/neu.2010.1561; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Kabadi SV, 2014, INT J MOL SCI, V15, P1216, DOI 10.3390/ijms15011216; KATZ RT, 1992, AM FAM PHYSICIAN, V46, P1491; KENT C, 1992, DEV BRAIN RES, V68, P241, DOI 10.1016/0165-3806(92)90066-6; Kim RY, 2014, J NEUROIMMUNOL, V274, P53, DOI 10.1016/j.jneuroim.2014.06.009; Kleindienst A, 2007, PROG BRAIN RES, V161, P317, DOI 10.1016/S0079-6123(06)61022-4; Manevich Y, 2014, FREE RADICAL BIO MED, V72, P210, DOI 10.1016/j.freeradbiomed.2014.04.002; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mondello S, 2014, MED RES REV, V34, P503, DOI 10.1002/med.21295; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Newman TA, 2013, HUM REPROD, V28, P2502, DOI 10.1093/humrep/det274; Ning L, 2013, J CELL SCI, V126, P77, DOI 10.1242/jcs.106674; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Ploughman M, 2009, STROKE, V40, P1490, DOI 10.1161/STROKEAHA.108.531806; Romner B, 2001, NEUROSURGERY, V49, P1490, DOI 10.1097/00006123-200112000-00053; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Rostami Elham, 2012, Front Neurol, V3, P115, DOI 10.3389/fneur.2012.00115; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Sedaghat F, 2008, HIPPOKRATIA, V12, P198; Selenica MLB, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-86; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Shetty AK, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00232; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; Tait RJ, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-171; Tator CH, 2002, INJURY PREV, V8, pIV33, DOI 10.1136/ip.8.suppl_4.iv33; Tolonen A, 2007, J REHABIL MED, V39, P622, DOI 10.2340/16501977-0101; Topolovec-Vranic J, 2011, J TRAUMA, V71, pS478, DOI 10.1097/TA.0b013e318232fa70; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xu Y, 2014, EXP ANIM TOKYO, V63, P247, DOI 10.1538/expanim.63.247; Yang HP, 2012, COMP FUNCT GENOM, DOI 10.1155/2012/368938; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	67	24	25	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	MAR 30	2015	6								68	10.3389/fneur.2015.00068			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CU8EV	WOS:000363775100001	25870583	DOAJ Gold, Green Published			2021-06-18	
J	Merritt, VC; Rabinowitz, AR; Arnett, PA				Merritt, Victoria C.; Rabinowitz, Amanda R.; Arnett, Peter A.			Injury-related predictors of symptom severity following sports-related concussion	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Mild traumatic brain injury; Headache; Sports injuries; Concussion; Symptom reporting	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC MIGRAINE CHARACTERISTICS; HIGH-SCHOOL; POSTCONCUSSIVE SYMPTOMS; PROLONGED RECOVERY; SEX-DIFFERENCES; PERFORMANCE; COLLEGIATE	Introduction: Decisions regarding return to play after sports-related concussion partially revolve around athletes' self-reported symptoms. Given this emphasis on symptoms, it would be beneficial to be able to identify characteristics that could predict which athletes may be susceptible to developing an increase in postconcussion symptoms following head injury. The purpose of this study was to describe the symptoms that athletes endorse immediately following concussion and to determine what impact injury-related characteristics have on the development of postconcussion symptoms within the first week following concussion. Method: Participants included 54 collegiate athletes who sustained concussions and were referred to our concussion management program for postconcussion testing. The main outcome measures included the Post-Concussion Symptom Scale and an interview querying athletes' retrospective symptoms over time, starting immediately postinjury. Results: Descriptive statistics revealed that the most common immediate symptoms following concussion include dizziness (endorsed by 83.6% of the sample), headache (65.5%), feeling in a fog (61.8%), and visual disturbance (60.0%). Logistic regression analyses indicated that retrograde and anterograde amnesia, as well as loss of consciousness, were not significantly predictive of postconcussion symptoms within one week following concussion (p > .05). However, the total symptom score assessed immediately postinjury, in addition to endorsing immediate headache symptoms following concussion, reliably predicted a higher level of symptom reporting in the first week following concussion (p < .05). Finally, receiver-operating characteristic (ROC) curve analysis, using 80% sensitivity to predict the high postconcussion symptom group, established cutoff scores of 7.5 for the immediate total symptom score and 0.5 for immediate headache. Conclusions: These findings demonstrate the importance of evaluating symptoms immediately following concussion. Athletes who endorse more immediate postconcussion symptoms, especially headache symptoms, may be at risk for greater and more severe postconcussion symptoms within the first week following concussion. The present findings have implications for the management and treatment of sports-related concussions.	[Merritt, Victoria C.; Arnett, Peter A.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA; [Rabinowitz, Amanda R.] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA	Merritt, VC (corresponding author), Penn State Univ, Dept Psychol, 372 Moore Bldg, University Pk, PA 16802 USA.	vca106@psu.edu		Merritt, Victoria/0000-0001-5683-4168	Penn State Sports Medicine	We would like to thank Dr. Wayne Sebastianelli and Penn State Sports Medicine for their generous support of our research. Also, the authors would like to thank Gray Vargas, Fiona Barwick, Aaron Rosenbaum, and Chris Bailey for their help as project coordinators of the program over the years. Finally, a special thanks to the following individuals for their help with running participants and data entry for this project: Karissa Arthur, Dan Brynien, Saima Farooq, Caitlin Gaffney, Alex Garrison, Briana Hauser, Mark Petusky, Matt Phillips, Jordyn Sessel, Julie Turco, and Steven Yacovelli.	Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; King J. E, 2008, BINARY LOGISTIC REGR; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR., 2000, IMPACT IMMEDIATE POS; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Mihalik JP, 2013, AM J SPORT MED, V41, P1490, DOI 10.1177/0363546513487982; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Peng CYJ, 2002, J EDUC RES, V96, P3, DOI 10.1080/00220670209598786; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056	32	24	24	1	16	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	MAR 16	2015	37	3					265	275		10.1080/13803395.2015.1004303			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	CI7FV	WOS:000354929200004	25685959				2021-06-18	
J	Cobb, BR; MacAlister, A; Young, TJ; Kemper, AR; Rowson, S; Duma, SM				Cobb, Bryan R.; MacAlister, Anna; Young, Tyler J.; Kemper, Andrew R.; Rowson, Steven; Duma, Stefan M.			Quantitative comparison of Hybrid III and National Operating Committee on Standards for Athletic Equipment headform shape characteristics and implications on football helmet fit	PROCEEDINGS OF THE INSTITUTION OF MECHANICAL ENGINEERS PART P-JOURNAL OF SPORTS ENGINEERING AND TECHNOLOGY			English	Article						Impact biomechanics; concussion; mild traumatic brain injury; dummy head laboratory testing; sports injury	ICE HOCKEY HELMETS; DYNAMIC IMPACT RESPONSE; TRAUMATIC BRAIN-INJURY; AMERICAN FOOTBALL; PROFESSIONAL FOOTBALL; PERFORMANCE; ACCELERATION; RECONSTRUCTION; CONCUSSION; KINEMATICS	Laboratory tests in which dummy headforms are used to evaluate helmet performance must be representative of real-world conditions to ensure helmets perform well in the field. The objective of this study was to quantify shape differences that may affect helmet fit between two dummy headforms commonly used for football helmet testing. Point-cloud models of a 50th percentile male Hybrid III headform and a medium NOCSAE headform were generated using a coordinate measuring machine. The headforms were optimally aligned and shape comparisons were made in the mid-sagittal plane, three coronal planes, and 3D. Planar and 3D differences were quantified by comparing maximum (MRD) and root-mean-square (RMSD) radial deviations. Minor differences were observed in the upper skull contours of all planar cross-sections, where MRDs were less than 3.5 mm and RMSDs were less than 1.7 mm. Larger deviations were observed in other regions including the jaw in the anterior coronal plane, where the MRD was 6.6 mm and the RMSD deviation was 4.5 mm. Substantial differences were noted between the Hybrid III and NOCSAE at the base of the skull, cheeks, jaw and chin. The headforms were also compared to a head model based on medical imaging of a human subject, which the NOCSAE matched more closely than the Hybrid III. The data presented in this study show that the Hybrid III and NOCSAE headforms have substantial shape differences in several regions that are important for helmet fit, possibly making the NOCSAE a better option for realistic helmet fit.	[Cobb, Bryan R.; MacAlister, Anna; Young, Tyler J.; Kemper, Andrew R.; Rowson, Steven; Duma, Stefan M.] Virginia Tech Wake Forest Univ, Sch Biomed Engn & Sci, Blacksburg, VA 24061 USA	Cobb, BR (corresponding author), Virginia Tech Wake Forest Univ, Sch Biomed Engn & Sci, 440 Kelly Hall,325 Stanger St, Blacksburg, VA 24061 USA.	cobb84@vt.edu	Duma, Stefan/A-8368-2012; Kemper, Andrew/B-4353-2012; Rowson, Steven/B-1270-2012	Kemper, Andrew/0000-0002-5177-1820; Rowson, Steven/0000-0002-3227-0596			Bartsch A, 2012, J NEUROSURG, V116, P222, DOI 10.3171/2011.9.JNS111059; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Blanco DH, 2014, P I MECH ENG P-J SPO, V228, P95, DOI 10.1177/1754337113518748; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Cormier J, 2010, SAE INT J PASSEN CAR, V3, P842, DOI 10.4271/2010-01-1317; Foster J.K., 1977, P 21 STAPP CAR CRASH; Gayzik FS., 2012, 12 INT LS DYNA US C; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Gwin JT, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000249; Hanlon E, 2010, J APPL BIOMECH, V26, P424, DOI 10.1123/jab.26.4.424; Hertzberg H, 1953, ANTHROPOMETRY FLYING; HODGSON VR, 1975, MED SCI SPORT EXER, V7, P225; Hoshizaki TB, 2012, P I MECH ENG P-J SPO, V226, P226, DOI 10.1177/1754337112448765; Hubbard RP, 1973, HUMAN IMPACT RESPONS, P129; HUBBARD RP, 1974, P 18 STAPP CAR CRASH; Kendall M, 2012, P I MECH ENG P-J SPO, V226, P260, DOI 10.1177/1754337112436901; Kroon DJ, 2011, WAVEFRONT OBJ TOOLBO; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; McIntosh AS, 2012, P I MECH ENG P-J SPO, V226, P237, DOI 10.1177/1754337112436628; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; Mihalik JP, 2008, P I MECH ENG P-J SPO, V222, P45, DOI 10.1243/17543371JSET4; National Operating Committee on Standards for Athletic Equipment (NOCSAE), 2006, STAND LIN IMP TEST M; National Operating Committee on Standards for Athletic Equipment (NOCSAE), 2011, STAND PERF SPEC NEWL; National Operating Committee on Standards for Athletic Equipment (NOCSAE), 2009, STAND PROJ IMP TEST; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; NOCSAE (National Operating Committee on Standards for Athletic Equipment), 2011, STAND TEST METH EQ U; Ouckama R, 2012, P I MECH ENG P-J SPO, V226, P185, DOI 10.1177/1754337111435625; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Post A, 2012, P I MECH ENG P-J SPO, V226, P290, DOI 10.1177/1754337112436629; Riddell, FITT INSTR HELM CAR; Rousseau P, 2009, P I MECH ENG P-J SPO, V223, P159, DOI 10.1243/17543371JSET36; Rowson S, 2013, P I MECH ENG P-J SPO, V227, P12, DOI 10.1177/1754337112442620; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Walsh ES, 2011, SPORTS ENG, V13, P135, DOI 10.1007/s12283-011-0060-9; Walsh ES, 2012, P I MECH ENG P-J SPO, V226, P220, DOI 10.1177/1754337112442299	37	24	24	0	10	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1754-3371	1754-338X		P I MECH ENG P-J SPO	Proc. Inst. Mech. Eng. Part P-J. Sport. Eng. Technol.	MAR	2015	229	1					39	46		10.1177/1754337114548245			8	Engineering, Mechanical; Sport Sciences	Engineering; Sport Sciences	CC4HA	WOS:000350311900005					2021-06-18	
J	Ryan, NP; Catroppa, C; Beare, R; Coleman, L; Ditchfield, M; Crossley, L; Beauchamp, MH; Anderson, VA				Ryan, Nicholas P.; Catroppa, Cathy; Beare, Richard; Coleman, Lee; Ditchfield, Michael; Crossley, Louise; Beauchamp, Miriam H.; Anderson, Vicki A.			Predictors of longitudinal outcome and recovery of pragmatic language and its relation to externalizing behaviour after pediatric traumatic brain injury	BRAIN AND LANGUAGE			English	Article						Child; Brain injuries; Magnetic resonance imaging; Pragmatic language; Neurobiology	CLOSED-HEAD-INJURY; CORPUS-CALLOSUM; SOCIAL BRAIN; COGNITIVE-DEVELOPMENT; EXECUTIVE FUNCTION; CHILDHOOD; CHILDREN; LESIONS; TERM; DISCOURSE	The purpose of the present investigation was to evaluate the contribution of age-at-insult and brain pathology on longitudinal outcome and recovery of pragmatic language in a sample of children and adolescents with traumatic brain injury (TBI). Children and adolescents with mild to severe TBI (n = 112) were categorized according to timing of brain insult: (i) Middle Childhood (5-9 years; n = 41); (ii) Late Childhood (10-11 years; n = 39); and (iii) Adolescence (12-15 years; n = 32) and group-matched for age, gender and socio-economic status (SES) to a typically developing (TD) control group (n = 43). Participants underwent magnetic resonance imaging (MRI) including a susceptibility weighted imaging (SWI) sequence 2-8 weeks after injury and were assessed on measures of pragmatic language and behavioural functioning at 6- and 24-months after injury. Children and adolescents with TBI of all severity levels demonstrated impairments in these domains at 6-months injury before returning to age-expected levels at 2-years post-TBI. However, while adolescent TBI was associated with post-acute disruption to skills that preceded recovery to age-expected levels by 2-years post injury, the middle childhood TBI group demonstrated impairments at 6-months post-injury that we're maintained at 2-year follow up. Reduced pragmatic communication was associated with frontal, temporal and corpus callosum lesions, as well as more frequent externalizing behaviour at 24-months post injury. Findings show that persisting pragmatic language impairment after pediatric TBI is related to younger age at brain insult, as well as microhemorrhagic pathology in brain regions that contribute to the anatomically distributed social brain network. Relationships between reduced pragmatic communication and more frequent externalizing behavior underscore the need for context-sensitive rehabilitation programs that aim to increase interpersonal effectiveness and reduce risk for maladaptive behavior trajectories into the long-term post injury. (C) 2015 Elsevier Inc. All rights reserved.	[Ryan, Nicholas P.; Catroppa, Cathy; Ditchfield, Michael; Crossley, Louise; Anderson, Vicki A.] Murdoch Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Melbourne, Vic, Australia; [Catroppa, Cathy; Anderson, Vicki A.] Royal Childrens Hosp, Dept Psychol, Melbourne, Vic, Australia; [Ryan, Nicholas P.; Catroppa, Cathy; Anderson, Vicki A.] Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic, Australia; [Beare, Richard] Murdoch Childrens Res Inst, Dev Imaging, Melbourne, Vic, Australia; [Coleman, Lee] Royal Childrens Hosp, Dept Radiol, Melbourne, Vic, Australia; [Catroppa, Cathy; Anderson, Vicki A.] Univ Melbourne, Dept Pediat, Melbourne, Vic, Australia; [Beauchamp, Miriam H.] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Beauchamp, Miriam H.] Ste Justine Res Ctr, Montreal, PQ, Canada	Ryan, NP (corresponding author), Murdoch Childrens Res Inst, Child Neuropsychol, Flemington Rd, Parkville, Vic 3052, Australia.	nicholas.ryan@mcri.edu.au; cathy.catroppa@mcri.edu.au; richard.beare@mcri.edu.au; lee.coleman@rch.org.au; michael.ditchfield@southernhealth.org.au; louise.crossley@mcri.edu.au; Miriam.beauchamp@umontreal.ca; vicki.anderson@rch.org.au	Ryan, Nicholas/K-5445-2019	Ryan, Nicholas/0000-0002-0878-8889; Beare, Richard/0000-0002-7530-5664			Achenbach T. M., 2001, ASEBA SCH AGE FORMS; Alderman N, 2003, NEUROPSYCHOL REHABIL, V13, P211, DOI 10.1080/09602010244000327; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V., 2011, BRAIN; Anderson V, 2013, J INT NEUROPSYCH SOC, V19, P539, DOI 10.1017/S1355617712001543; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Badre D, 2006, P NATL ACAD SCI USA, V103, P7186, DOI 10.1073/pnas.0509550103; Barbey A. K., 2012, BRAIN; Barbey A. K., 2013, BRAIN; Barnes MA, 2001, BRAIN LANG, V76, P253, DOI 10.1006/brln.2000.2385; Bates E, 1997, DEV NEUROPSYCHOL, V13, P275, DOI 10.1080/87565649709540682; Beauchamp MH, 2013, CORTEX, V49, P591, DOI 10.1016/j.cortex.2012.08.015; Beauchamp MH, 2011, BRAIN INJURY, V25, P950, DOI 10.3109/02699052.2011.589791; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Beauchamp MH, 2009, J NEUROTRAUM, V26, P1645, DOI [10.1089/neu.2009.0916, 10.1089/neu.2009-0916]; Blakemore SJ, 2008, NAT REV NEUROSCI, V9, P267, DOI 10.1038/nrn2353; Catroppa C, 2004, BRAIN LANG, V88, P68, DOI 10.1016/S0093-934X(03)00159-7; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; Choudhury S, 2006, SOC COGN AFFECT NEUR, V1, P165, DOI 10.1093/scan/nsl024; Coffey C., 1991, Psychopathology and the Brain, V3, P243; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Colbert CA, 2010, RADIOLOGY, V256, P898, DOI 10.1148/radiol.10091842; Crowe LM, 2012, J PEDIATR PSYCHOL, V37, P745, DOI 10.1093/jpepsy/jss070; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; DENNIS M, 1988, LANGUAGE YOUNG DAMAG; Dennis M., 2014, NEUROPSYCHOL REV, P1; Dennis M, 1989, CLIN NEUROPSYCHOLOGY, P85; Didus E, 1999, Pediatr Rehabil, V3, P177; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Dumontheil I, 2010, DEVELOPMENTAL SCI, V13, P331, DOI 10.1111/j.1467-7687.2009.00888.x; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 2012, INT J DEV NEUROSCI, V30, P247, DOI 10.1016/j.ijdevneu.2011.07.004; Factor P. I., 2013, J ATTENTION DISORDER; Farina E., 2007, PSYCHOL LANGUAGE COM, V11, P3; Ferstl EC, 2008, HUM BRAIN MAPP, V29, P581, DOI 10.1002/hbm.20422; Geraci A, 2010, BRAIN INJURY, V24, P978, DOI 10.3109/02699052.2010.487477; Gerrard-Morris A, 2010, J INT NEUROPSYCH SOC, V16, P157, DOI 10.1017/S1355617709991135; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Giedd JN, 1996, DEV BRAIN RES, V91, P274; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Glascher J, 2010, P NATL ACAD SCI USA, V107, P4705, DOI 10.1073/pnas.0910397107; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Hallett T L, 1997, Pediatr Rehabil, V1, P219; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P161, DOI 10.1080/09602010802188393; Hattier MA, 2011, DEV NEUROREHABIL, V14, P221, DOI 10.3109/17518423.2011.573836; HEBB D. O., 1942, PROC AMER PHIL SOC, V85, P275; Jacobs R, 2007, CORTEX, V43, P792, DOI 10.1016/S0010-9452(08)70507-0; Johnson MH, 2005, DEV PSYCHOPATHOL, V17, P599, DOI 10.1017/S0954579405050297; Kennedy DP, 2012, TRENDS COGN SCI, V16, P559, DOI 10.1016/j.tics.2012.09.006; Kolb B, 2004, BRAIN COGNITION, V55, P104, DOI 10.1016/s0278-2626(03)00278-1; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Li L, 2013, DEV MED CHILD NEUROL, V55, P37, DOI 10.1111/j.1469-8749.2012.04414.x; Luders E, 2010, J NEUROSCI, V30, P10985, DOI 10.1523/JNEUROSCI.5122-09.2010; Manly T., 1999, TEA CH TEST EVERYDAY; Masten AS, 2010, DEV PSYCHOPATHOL, V22, P491, DOI 10.1017/S0954579410000222; McMillan J, 2009, J SOCIOL, V45, P123, DOI 10.1177/1440783309103342; Muller F, 2010, CORTEX, V46, P1088, DOI 10.1016/j.cortex.2009.08.014; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Rosema S, 2012, J NEUROTRAUM, V29, P1277, DOI 10.1089/neu.2011.2144; Ryan NP, 2015, NEUROPSYCHOLOGIA, V66, P32, DOI 10.1016/j.neuropsychologia.2014.10.040; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; Ryan NP, 2013, INT J DEV NEUROSCI, V31, P811, DOI 10.1016/j.ijdevneu.2013.10.002; SATZ P, 1981, SEX DIFFERENCES DYSL; Saxe R, 2006, CURR OPIN NEUROBIOL, V16, P235, DOI 10.1016/j.conb.2006.03.001; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; Shaw P, 2008, J NEUROSCI, V28, P3586, DOI 10.1523/JNEUROSCI.5309-07.2008; Spitz G, 2013, J NEUROTRAUM, V30, P2038, DOI 10.1089/neu.2013.3021; Stowe LA, 1998, NEUROREPORT, V9, P2995, DOI 10.1097/00001756-199809140-00014; Sullivan JR, 2010, APPL NEUROPSYCHOL, V17, P93, DOI 10.1080/09084281003708852; Tabachnick B., 2001, USING MULTIVARIATE S; Tasker RC, 2006, DEV NEUROSCI-BASEL, V28, P302, DOI 10.1159/000094156; Taylor MJ, 2014, AM J MED GENET B, V165, P587, DOI 10.1002/ajmg.b.32262; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; Wechsler D., 2003, WECHSLER INTELLIGENC; Wechsler D, 1999, WASI WECHSLER ABBREV; Wigg E. H., 1989, TEST LANGUAGE COMPET; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Ylvisaker M., 2005, SEM SPEECH LANG; Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015	89	24	24	2	36	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X	1090-2155		BRAIN LANG	Brain Lang.	MAR	2015	142						86	95		10.1016/j.bandl.2015.01.007			10	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	CD0QU	WOS:000350779800010	25677376				2021-06-18	
J	Tsai, MC; Chang, CP; Peng, SW; Jhuang, KS; Fang, YH; Lin, MT; Tsao, TCY				Tsai, Ming-Che; Chang, Ching-Ping; Peng, Syue-Wei; Jhuang, Kai-Sheng; Fang, Yi-Hsien; Lin, Mao-Tsun; Tsao, Thomas Chang-Yao			Therapeutic Efficacy of Neuro AiD (TM) (MLC 601), a Traditional Chinese Medicine, in Experimental Traumatic Brain Injury	JOURNAL OF NEUROIMMUNE PHARMACOLOGY			English	Article						Astragalosides; Traumatic brain injury; Microglia; Tumor necrosis factor-alpha	MOTOR-ACTIVITY; ADULT-RAT; STROKE; MICROGLIA; EXPRESSION; SYNAPTOGENESIS; ANGIOGENESIS; ETANERCEPT; INHIBITION; ACTIVATION	Traumatic brain injury (TBI) causes increased release of several mediators from injured and dead cells and elicits microglial activation. Activated microglia change their morphology, migrate to injury sites, and release tumor necrosis factor-alpha (TNF-alpha) and others. In this study we used a controlled fluid percussion injury model of TBI in the rat to determine whether early (4 h post-injury) or late (4 days post-injury) treatment with MLC 601, a Traditional Chinese Medicine, would affect microglial activation and improve recovery. MLC 601 was chosen for this study because its herbal component MLC 901 was beneficial in treating TBI in rats. Herein, rats with induced TBI were treated with MLC 601 (0.2-0.8 mg/kg) 1 h (early treatment) or 4 day post-injury (late treatment) and then injected once daily for consecutive 2 days. Acute neurological and motor deficits were assessed in all rats the day before and 4 days after early MLC 601 treatment. An immunofluorescence microscopy method was used to count the numbers of the cells colocalized with neuron- and apoptosis-specific markers, and the cells colocalized with microglia- and TNF-alpha-specific markers, in the contused brain regions 4 days post-injury. An immunohistochemistry method was used to evaluate both the number and the morphological transformation of microglia in the injured areas. It was found that early treatment with MLC 601 had better effects in reducing TBI-induced cerebral contusion than did the late therapy with MLC 601. Cerebral contusion caused by TBI was associated with neurological motor deficits, brain apoptosis, and activated microglia (e.g., microgliosis, amoeboid microglia, and microglial overexpression of TNF-alpha), which all were significantly attenuated by MLC 601 therapy. Our data suggest that MLC 601 is a promising agent for treatment of TBI in rats.	[Tsai, Ming-Che] Chung Shan Med Univ, Inst Med, Taichung, Taiwan; [Tsai, Ming-Che] Chung Shan Med Univ, Sch Med, Taichung, Taiwan; [Tsai, Ming-Che] Chung Shan Med Univ Hosp, Dept Emergency Med, Taichung 40201, Taiwan; [Chang, Ching-Ping; Peng, Syue-Wei; Jhuang, Kai-Sheng; Fang, Yi-Hsien; Lin, Mao-Tsun] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan; [Peng, Syue-Wei] Taipei Med Univ, Grad Inst Med Sci, Coll Med, Taipei, Taiwan; [Jhuang, Kai-Sheng] Natl Chung Cheng Univ, Inst Biomed Sci, Inst Mol Biol, Dept Life Sci, Chiayi, Taiwan; [Chang, Ching-Ping; Lin, Mao-Tsun] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan; [Tsao, Thomas Chang-Yao] Chung Shan Med Univ Hosp, Div Thorac Med, Taichung 40201, Taiwan; [Tsao, Thomas Chang-Yao] Chung Shan Med Univ, Taichung, Taiwan	Lin, MT (corresponding author), Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan.	891201@mail.chimei.org.tw; tcyt@csmu.edu.tw			Taiwan National Science and Technology Department [NSC 101-2314-B-218-001-MY3]	This work was supported by research grant NSC 101-2314-B-218-001-MY3 from the Taiwan National Science and Technology Department.	Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Batchelor PE, 1999, J NEUROSCI, V19, P1708; BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568; Chang CP, 2013, CLIN SCI, V124, P165, DOI 10.1042/CS20120226; Chen C, 2009, STROKE, V40, P859, DOI 10.1161/STROKEAHA.108.531616; Chen CLH, 2013, STROKE, V44, P3580, DOI 10.1161/STROKEAHA.113.003226; Chen CLH, 2013, STROKE, V44, P2093, DOI 10.1161/STROKEAHA.113.002055; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Cheong CU, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/620837; Chio CC, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-33; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; Ding Y, 2004, NEUROSCIENCE, V123, P667, DOI 10.1016/j.neuroscience.2003.08.031; Ding YC, 2002, J NEUROSURG, V96, P310, DOI 10.3171/jns.2002.96.2.0310; Ding YC, 2002, BEHAV BRAIN RES, V132, P29, DOI 10.1016/S0166-4328(01)00405-3; Ding YC, 2001, NEUROL RES, V23, P193, DOI 10.1179/016164101101198334; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gan R, 2008, CEREBROVASC DIS, V25, P450, DOI 10.1159/000126919; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Heurteaux C, 2010, NEUROPHARMACOLOGY, V58, P987, DOI 10.1016/j.neuropharm.2010.01.001; Iosif RE, 2008, J CEREBR BLOOD F MET, V28, P1574, DOI 10.1038/jcbfm.2008.47; ISAACS KR, 1992, J CEREBR BLOOD F MET, V12, P110, DOI 10.1038/jcbfm.1992.14; Kleim JA, 1996, J NEUROSCI, V16, P4529; Klintsova AY, 1998, BRAIN RES, V800, P48, DOI 10.1016/S0006-8993(98)00495-8; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maati HMO, 2012, NEUROPHARMACOLOGY, V63, P692, DOI 10.1016/j.neuropharm.2012.05.035; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Navarro JC, 2014, 23 EUR STROK C NIC; Oshima T, 2009, BRAIN RES, V1290, P102, DOI 10.1016/j.brainres.2009.07.022; Quintard H, 2014, NEUROSCIENCE, V277, P72, DOI 10.1016/j.neuroscience.2014.06.047; Quintard H, 2011, NEUROPHARMACOLOGY, V61, P622, DOI 10.1016/j.neuropharm.2011.05.003; Rimaniol AC, 1995, NEUROREPORT, V7, P133, DOI 10.1097/00001756-199512290-00032; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Scherbel U., 1997, J NEUROTRAUM, V14, P781; Shahripour RB, 2011, EUR J INTERN MED, V22, P509, DOI 10.1016/j.ejim.2011.01.002; Wang Y, 1997, J NEUROSCI, V17, P4341; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Young SHY, 2010, CEREBROVASC DIS, V30, P1, DOI 10.1159/000313398	46	24	24	0	10	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1557-1890	1557-1904		J NEUROIMMUNE PHARM	J. Neuroimmune Pharm.	MAR	2015	10	1					45	54		10.1007/s11481-014-9570-0			10	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	CC4PK	WOS:000350335100005	25331680				2021-06-18	
J	Robinson, ME; Shenk, TE; Breedlove, EL; Leverenz, LJ; Nauman, EA; Talavage, TM				Robinson, Meghan E.; Shenk, Trey E.; Breedlove, Evan L.; Leverenz, Larry J.; Nauman, Eric A.; Talavage, Thomas M.			The Role of Location of Subconcussive Head Impacts in fMRI Brain Activation Change	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	2nd Annual Meeting of the CIC/Big Ten/Ivy League Traumatic Brain Injury Summit	JUL 16-17, 2014	Philadelphia, PA				HIGH-SCHOOL FOOTBALL; BIOMECHANICS; CONCUSSION	Monte-Carlo permutation analysis was used to identify sets of head impacts most predictive of functional magnetic resonance imaging (fMRI) changes in football players. The relative distribution of impact location was found to be more predictive of brain activation changes than the number of impacts, suggesting that fMRI changes are related to systematic playing style.	[Robinson, Meghan E.; Shenk, Trey E.; Nauman, Eric A.; Talavage, Thomas M.] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA; [Robinson, Meghan E.] VA Boston Healthcare Syst, Translat Res Ctr TBI & Stress Disorders TRACTS, Neuroimaging Res Vet NeRVe Ctr, Boston, MA 02132 USA; [Shenk, Trey E.; Talavage, Thomas M.] Purdue Univ, Sch Elect & Comp Engn, W Lafayette, IN 47907 USA; [Breedlove, Evan L.; Nauman, Eric A.] Purdue Univ, Sch Mech Engn, W Lafayette, IN 47907 USA; [Leverenz, Larry J.] Purdue Univ, Dept Hlth & Kinesiol, W Lafayette, IN 47907 USA; [Nauman, Eric A.] Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA	Robinson, ME (corresponding author), VA Boston Healthcare Syst, TRACTS 182, 150 South Huntington Ave, Boston, MA 02132 USA.	meghan.robinson@va.gov			Indiana Spinal Cord and Brain Injury Research Fund, a part of the Indiana State Department of Health; National Science FoundationNational Science Foundation (NSF); NDSEG Graduate Research Fellowship Programs	This work was supported by the Indiana Spinal Cord and Brain Injury Research Fund, a part of the Indiana State Department of Health. This work was also partially supported through the National Science Foundation and NDSEG Graduate Research Fellowship Programs.	Allison MA, 2014, MED SCI SPORT EXER, V46, P115, DOI 10.1249/MSS.0b013e3182a32d0d; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Breedlove KM., 2014, ATHLETIC TRAIN SPORT, V6, P119, DOI [10.3928/19425864-20140507-02, DOI 10.3928/19425864-20140507-02]; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Martini D, 2013, MED SCI SPORT EXER, V45, P755, DOI 10.1249/MSS.0b013e3182798758; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512	11	24	24	0	9	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.	FEB 17	2015	40	2			SI		74	79		10.1080/87565641.2015.1012204			6	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	CH6UW	WOS:000354172800005	25961589				2021-06-18	
J	Goodus, MT; Guzman, AM; Calderon, F; Jiang, YH; Levison, SW				Goodus, Matthew T.; Guzman, Alanna M.; Calderon, Frances; Jiang, Yuhui; Levison, Steven W.			Neural Stem Cells in the Immature, but Not the Mature, Subventricular Zone Respond Robustly to Traumatic Brain Injury	DEVELOPMENTAL NEUROSCIENCE			English	Article						Subventricular zone; Neurogenesis; Stem cells; Progenitor; Cell proliferation	LEUKEMIA INHIBITORY FACTOR; CONTROLLED CORTICAL IMPACT; HYPOXIC-ISCHEMIC INJURY; RAT-BRAIN; PERINATAL HYPOXIA/ISCHEMIA; CELLULAR PROLIFERATION; REACTIVE ASTROCYTES; CEREBRAL-CORTEX; MOUSE-BRAIN; ADULT RATS	Pediatric traumatic brain injury is a significant problem that affects many children each year. Progress is being made in developing neuroprotective strategies to combat these injuries. However, investigators are a long way from therapies to fully preserve injured neurons and glia. To restore neurological function, regenerative strategies will be required. Given the importance of stem cells in repairing damaged tissues and the known persistence of neural precursors in the subventricular zone (SVZ), we evaluated regenerative responses of the SVZ to a focal brain lesion. As tissues repair more slowly with aging, injury responses of male Sprague Dawley rats at 6, 11, 17, and 60 days of age and C57BI/6 mice at 14 days of age were compared. In the injured immature animals, cell proliferation in the dorsolateral SVZ more than doubled by 48 h. By contrast, the proliferative response was almost undetectable in the adult brain. Three approaches were used to assess the relative numbers of bona fide neural stem cells, as follows: the neurosphere assay (on rats injured at postnatal day 11, P11), flow cytometry using a novel 4-marker panel (on mice injured at P14) and staining for stem/progenitor cell markers in the niche (on rats injured at P17). Precursors from the injured immature SVZ formed almost twice as many spheres as precursors from uninjured age-matched brains. Furthermore, spheres formed from the injured brain were larger, indicating that the neural precursors that formed these spheres divided more rapidly. Flow cytometry revealed a 2-fold increase in the percentage of stem cells, a 4-fold increase in multipotential progenitor-3 cells and a 2.5-fold increase in glial-restricted progenitor-2/multipotential-3 cells. Analogously, there was a 2-fold increase in the mitotic index of nestin+/Mash1-immunoreactive cells within the immediately subependymal region. As the early postnatal SVZ is predominantly generating glial cells, an expansion of precursors might not necessarily lead to the production of many new neurons. On the contrary, many BrdU+/doublecortin+ cells were observed streaming out of the SVZ into the neocortex 2 weeks after injuries to P11 rats. However, very few new mature neurons were seen adjacent to the lesion 28 days after injury. Altogether, these data indicate that immature SVZ cells mount a more robust proliferative response to a focal brain injury than adult cells, which includes an expansion of stem cells, primitive progenitors and neuroblasts. Nonetheless, this regenerative response does not result in significant neuronal replacement, indicating that new strategies need to be implemented to retain the regenerated neurons and glia that are being produced. (C) 2014 S. Karger AG, Basel	[Goodus, Matthew T.; Guzman, Alanna M.; Calderon, Frances; Jiang, Yuhui; Levison, Steven W.] Rutgers State Univ, New Jersey Med Sch, Dept Neurol & Neurosci, Newark, NJ 07103 USA; [Goodus, Matthew T.; Guzman, Alanna M.; Calderon, Frances; Jiang, Yuhui; Levison, Steven W.] Rutgers State Univ, New Jersey Med Sch, Grad Sch Biomed Sci, Newark, NJ 07103 USA	Levison, SW (corresponding author), Rutgers State Univ, New Jersey Med Sch, Dept Neurol & Neurosci, Lab Regenerat Neurobiol, 205 South Orange Ave, Newark, NJ 07103 USA.	steve.levison@rutgers.edu	Levison, Steven W./Q-6903-2019; Goodus, Matthew T/O-4986-2016	Levison, Steven W./0000-0002-1264-7309; Goodus, Matthew T/0000-0001-5022-8562	New Jersey Commission on Brain Injury Research [09-3207-BIR-E-2]	This research was supported by grant 09-3207-BIR-E-2 from the New Jersey Commission on Brain Injury Research awarded to S.W.L.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Aguirre A, 2005, J NEUROSCI, V25, P11092, DOI 10.1523/JNEUROSCI.2981-05.2005; Alagappan D, 2013, ASN NEURO, V5, DOI 10.1042/AN20120032; Alagappan D, 2009, ASN NEURO, V1, DOI 10.1042/AN20090002; Amankulor NM, 2009, J NEUROSCI, V29, P10299, DOI 10.1523/JNEUROSCI.2500-09.2009; Banner LR, 1997, EXP NEUROL, V147, P1, DOI 10.1006/exnr.1997.6536; Bessis A, 2007, GLIA, V55, P233, DOI 10.1002/glia.20459; Brazel CY, 2005, NEUROSCIENCE, V131, P55, DOI 10.1016/j.neuroscience.2004.10.038; Buono KD, 2011, THESIS U MED DENT NE, P1; Buono KD, 2012, DEV NEUROSCI-BASEL, V34, P449, DOI 10.1159/000345155; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Clancy B, 2007, NEUROTOXICOLOGY, V28, P931, DOI 10.1016/j.neuro.2007.01.014; Covey MV, 2011, ANN NEUROL, V70, P616, DOI 10.1002/ana.22473; Covey MV, 2010, DEV NEUROSCI-BASEL, V32, P488, DOI 10.1159/000321607; Craig CG, 1996, J NEUROSCI, V16, P2649; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Faiz M, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-26; Felling RJ, 2006, J NEUROSCI, V26, P4359, DOI 10.1523/JNEUROSCI.1898-05.2006; Florio P, 2007, ADV CLIN CHEM, V43, P117, DOI 10.1016/S0065-2423(06)43004-3; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Goings GE, 2004, BRAIN RES, V996, P213, DOI 10.1016/j.brainres.2003.10.034; Jones KS, 2012, AM J STEM CELLS, V1, P48; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kennard MA, 1936, AM J PHYSIOL, V115, P138; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kim WR, 2011, EUR J NEUROSCI, V33, P599, DOI 10.1111/j.1460-9568.2010.07557.x; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Levison SW, 1997, J NEUROSCI RES, V48, P83, DOI 10.1002/(SICI)1097-4547(19970415)48:2<83::AID-JNR1>3.3.CO;2-4; Liberto CM, 2004, J NEUROCHEM, V89, P1092, DOI 10.1111/j.1471-4159.2004.02420.x; Macas J, 2006, J NEUROSCI, V26, P13114, DOI 10.1523/JNEUROSCI.4667-06.2006; Mattson MP, 2008, ANN NY ACAD SCI, V1144, P97, DOI 10.1196/annals.1418.005; Mignone JL, 2004, J COMP NEUROL, V469, P311, DOI 10.1002/cne.10964; Miller JT, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-63; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Popa-Wagner A, 2011, AGEING RES REV, V10, P71, DOI 10.1016/j.arr.2009.10.008; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Romanko MJ, 2004, J CEREBR BLOOD F MET, V24, P814, DOI 10.1097/01.WCB.0000123906.17746.00; ROMIJN HJ, 1991, EARLY HUM DEV, V26, P61, DOI 10.1016/0378-3782(91)90044-4; Rothstein RP, 2002, DEV NEUROSCI-BASEL, V24, P426, DOI 10.1159/000069052; Sanai N, 2011, NATURE, V478, P382, DOI 10.1038/nature10487; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Shi J, 2007, EUR J NEUROSCI, V25, P3499, DOI 10.1111/j.1460-9568.2007.05624.x; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Smith KS, 2007, BEHAV NEUROSCI, V121, P449, DOI 10.1037/0735-7044.121.3.449; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; Szele FG, 1996, J COMP NEUROL, V368, P439, DOI 10.1002/(SICI)1096-9861(19960506)368:3<439::AID-CNE9>3.0.CO;2-6; Tanaka N, 1999, BRAIN RES, V827, P130, DOI 10.1016/S0006-8993(99)01319-0; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Xu G, 2005, DEV NEUROSCI-BASEL, V27, P228, DOI 10.1159/000085996; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131	54	24	25	0	10	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2015	37	1					29	42		10.1159/000367784			14	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	CB5IK	WOS:000349660500003	25377490				2021-06-18	
J	Lillie, EM; Urban, JE; Weaver, AA; Powers, AK; Stitzel, JD				Lillie, Elizabeth M.; Urban, Jillian E.; Weaver, Ashley A.; Powers, Alexander K.; Stitzel, Joel D.			Estimation of skull table thickness with clinical CT and validation with microCT	JOURNAL OF ANATOMY			English	Article						computed tomography; cortex; skull; thickness	MECHANICAL-PROPERTIES; THIN STRUCTURES; DENSITY; ACCURACY; FLEXURE	Brain injuries resulting from motor vehicle crashes (MVC) are extremely common yet the details of the mechanism of injury remain to be well characterized. Skull deformation is believed to be a contributing factor to some types of traumatic brain injury (TBI). Understanding biomechanical contributors to skull deformation would provide further insight into the mechanism of head injury resulting from blunt trauma. In particular, skull thickness is thought be a very important factor governing deformation of the skull and its propensity for fracture. Current computed tomography (CT) technology is limited in its ability to accurately measure cortical thickness using standard techniques. A method to evaluate cortical thickness using cortical density measured from CT data has been developed previously. This effort validates this technique for measurement of skull table thickness in clinical head CT scans using two postmortem human specimens. Bone samples were harvested from the skulls of two cadavers and scanned with microCT to evaluate the accuracy of the estimated cortical thickness measured from clinical CT. Clinical scans were collected at 0.488 and 0.625mm in plane resolution with 0.625mm thickness. The overall cortical thickness error was determined to be 0.078 +/- 0.58mm for cortical samples thinner than 4mm. It was determined that 91.3% of these differences fell within the scanner resolution. Color maps of clinical CT thickness estimations are comparable to color maps of microCT thickness measurements, indicating good quantitative agreement. These data confirm that the cortical density algorithm successfully estimates skull table thickness from clinical CT scans. The application of this technique to clinical CT scans enables evaluation of cortical thickness in population-based studies.	[Lillie, Elizabeth M.; Urban, Jillian E.; Weaver, Ashley A.; Stitzel, Joel D.] Wake Forest Univ, Virginia Tech, Ctr Injury Biomech, Winston Salem, NC 27157 USA; [Lillie, Elizabeth M.; Urban, Jillian E.; Weaver, Ashley A.; Powers, Alexander K.; Stitzel, Joel D.] Wake Forest Univ, Sch Med, Winston Salem, NC 27157 USA; [Powers, Alexander K.] Wake Forest Univ, Dept Neurosurg, Winston Salem, NC 27157 USA	Stitzel, JD (corresponding author), Wake Forest Univ, Virginia Tech, Ctr Injury Biomech, Med Ctr Blvd, Winston Salem, NC 27157 USA.	jdstitzel@gmail.com	Stitzel, Joel/B-4045-2012	Stitzel, Joel/0000-0001-9762-3033; Weaver, Ashley/0000-0002-4383-0106	National Highway Traffic Safety Administration [DTN22-09-H-00242]	The authors would like to thank the Wake Forest School of Medicine Department of Neurobiology & Anatomy, especially Robert Bowden, for assistance in obtaining the cadaveric skulls. Funding was provided by the National Highway Traffic Safety Administration under Cooperative Agreement Number DTN22-09-H-00242. Views expressed are those of the authors and do not represent the views of NHTSA. Additionally the authors would like to thank Debra Fuller for her aid in collecting CT scans as well as Kevin Guley at the University of North Carolina Chapel Hill for his help with microCT imaging.	Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Dougherty G, 1999, MED PHYS, V26, P1341, DOI 10.1118/1.598629; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Hodgson V., 1970, P 14 STAPP CAR CRASH, P341; HUBBARD RP, 1971, J BIOMECH, V4, P251, DOI 10.1016/0021-9290(71)90031-5; HUBBARD RP, 1971, J BIOMECH, V4, P491, DOI 10.1016/0021-9290(71)90039-X; JASLOW CR, 1990, J BIOMECH, V23, P313, DOI 10.1016/0021-9290(90)90059-C; Licata A, 2009, CLEV CLIN J MED, V76, P331, DOI 10.3949/ccjm.76a.08041; MCELHANEY JH, 1970, J BIOMECH, V3, P495, DOI 10.1016/0021-9290(70)90059-X; More J. J., 1978, Proceedings of the Biennial Conference on numerical analysis, P105; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Newman DL, 1998, PHYS MED BIOL, V43, P619, DOI 10.1088/0031-9155/43/3/013; Nusholtz G.S., 1984, 841657 SAE, P41; Peterson J, 2003, ANAT REC PART A, V274A, P785, DOI 10.1002/ar.a.10096; Peterson J, 2002, ANAT REC, V268, P7, DOI 10.1002/ar.10131; Poole KES, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038466; Prevrhal S, 2003, MED PHYS, V30, P1, DOI 10.1118/1.1521940; Prevrhal S, 1999, PHYS MED BIOL, V44, P751, DOI 10.1088/0031-9155/44/3/017; Ruan J, 2001, Stapp Car Crash J, V45, P395; Saladin K., 2007, ANATOMY PHYSL UNITY; Shatsky SA, 1974, P STAPP CAR CRASH C, P351; Treece GM, 2012, MED IMAGE ANAL, V16, P952, DOI 10.1016/j.media.2012.02.008; Treece GM, 2010, MED IMAGE ANAL, V14, P276, DOI 10.1016/j.media.2010.01.003; Urban JE, 2012, J NEUROTRAUM, V29, P2774, DOI 10.1089/neu.2012.2373; WOOD JL, 1971, J BIOMECH, V4, P1, DOI 10.1016/0021-9290(71)90010-8; Yoganandan N, 2007, J TRAUMA, V66, P7; Yoganandan N, 2010, ACCIDENT ANAL PREV, V42, P1370, DOI 10.1016/j.aap.2010.02.017	27	24	26	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-8782	1469-7580		J ANAT	J. Anat.	JAN	2015	226	1					73	80		10.1111/joa.12259			8	Anatomy & Morphology	Anatomy & Morphology	AW9NF	WOS:000346583500007	25441171	Bronze, Green Published			2021-06-18	
J	Pokorna, P; Wildschut, ED; Vobruba, V; van den Anker, JN; Tibboel, D				Pokorna, P.; Wildschut, E. D.; Vobruba, V.; van den Anker, John N.; Tibboel, D.			The Impact of Hypothermia on the Pharmacokinetics of Drugs Used in Neonates and Young Infants	CURRENT PHARMACEUTICAL DESIGN			English	Article						Hypothermia; pharmacokinetics; pharmacodynamics; pharmacogenomics; developmental pharmacology; absorption; distribution; metabolism; and excretion; neonates; infants; covariates; asphyxia; sepsis; multiorgan dysfunction syndrome; cardiac arrest	HYPOXIC-ISCHEMIC ENCEPHALOPATHY; WHOLE-BODY HYPOTHERMIA; TRAUMATIC BRAIN-INJURY; REGIONAL BLOOD-FLOW; MILD THERAPEUTIC HYPOTHERMIA; CEREBRAL ENERGY-METABOLISM; HOSPITAL CARDIAC-ARREST; CARDIOPULMONARY BYPASS; GENTAMICIN PHARMACOKINETICS; RENAL-FUNCTION	Therapeutic hypothermia (HT) is frequently used in neonates with hypoxic-ischemic encephalopathy and young infants during cardiopulmonary bypass (CPB). Hypothermia and CPB result in physiological changes contributing to pharmacokinetic (PK) and pharmacodynamic (PD) changes. Changes in the absorption, the volume of distribution (Vd) and the total body clearance (CL) of drugs used during hypothermia and CPB might lead to the interindividual PK variability resulting in either insufficient or toxic plasma concentrations and have an impact on the biodisposition and action of drugs. Both under-or overdosing of medicines in these critically ill patients may contribute to a worse overall outcome. Overall, hypothermia decreases CL but may decrease or increase Vd by changing intravascular blood volume, organ perfusion and enzymatic metabolic processes. In addition, maturational as well as organ specific changes may occur during hypothermia superimposed on the underlying disease and/or procedures such as extracorporeal membrane oxygenation (ECMO) or CPB. This paper will provide an overview of variables and potential covariates (e.g., asphyxia, sepsis, multiorgan dysfunction syndrome, cardiac arrest) determining the PK of frequently used drugs. In addition, the effects of hypothermia on individual drugs are described as well as alternative ways for future study designs such as the use of population PK-PD and opportunistic sampling. Ultimately, these investigations are warranted to obtain specific dosing nomograms of medicines for use in clinical practice and to improve the treatment results of this vulnerable group of pediatric patients.	[Pokorna, P.; Vobruba, V.; Tibboel, D.] Charles Univ Prague, Intens Care Unit, Dept Pediat, Gen Fac Hosp,Fac Med 1, Prague, Czech Republic; [Pokorna, P.; Wildschut, E. D.; van den Anker, John N.; Tibboel, D.] Erasmus MC Sophia Childrens Hosp, Intens Care, NL-3015 GJ Rotterdam, Netherlands; [Pokorna, P.; Wildschut, E. D.; van den Anker, John N.; Tibboel, D.] Erasmus MC Sophia Childrens Hosp, Dept Pediat Surg, NL-3015 GJ Rotterdam, Netherlands; [Pokorna, P.; Vobruba, V.] Charles Univ Prague, Dept Pharmacol, Gen Univ Hosp, Fac Med 1, Prague 12800 2, Czech Republic; [van den Anker, John N.] Childrens Natl Med Ctr, Div Pediat Clin Pharmacol, Washington, DC 20010 USA; [van den Anker, John N.] George Washington Univ, Sch Med & Hlth Sci, Dept Pediat, Washington, DC 20052 USA; [van den Anker, John N.] George Washington Univ, Sch Med & Hlth Sci, Dept Integrat Syst Biol, Washington, DC 20052 USA; [van den Anker, John N.] George Washington Univ, Sch Med & Hlth Sci, Dept Pharmacol, Washington, DC 20052 USA; [van den Anker, John N.] George Washington Univ, Sch Med & Hlth Sci, Dept Physiol, Washington, DC 20052 USA; [van den Anker, John N.] Univ Childrens Hosp Basel, Dept Paediat Pharmacol, Basel, Switzerland	Tibboel, D (corresponding author), Erasmus MC Sophia Childrens Hosp, Intens Care, Dr Molewaterplein 60, NL-3015 GJ Rotterdam, Netherlands.	d.tibboel@erasmusmc.nl	Pokorna, Pavla/N-3785-2017; Vobruba, Vaclav/N-6378-2017	Pokorna, Pavla/0000-0001-6803-7350; Vobruba, Vaclav/0000-0001-9476-0614; Vobruba, Vaclav/0000-0001-9148-8467	Erasmus Medical Center, Rotterdam the NetherlandsNetherlands Government	Dr. P. Pokorna is supported by an unrestricted research grant of Erasmus Medical Center, Rotterdam the Netherlands.	Abend NS, 2012, PEDIATR CRIT CARE ME, V13, P32, DOI 10.1097/PCC.0b013e3182196a7b; AKINBI H, 1994, J PEDIATR-US, V125, P625, DOI 10.1016/S0022-3476(94)70024-9; ALCARAZ C, 1989, CLIN EXP PHARMACOL P, V16, P367, DOI 10.1111/j.1440-1681.1989.tb01573.x; ALCARAZ C, 1989, ARCH INT PHARMACOD T, V297, P133; Allegaert K, 2007, BRIT J ANAESTH, V99, P864, DOI 10.1093/bja/aem294; Allegaert K, 2006, ARCH DIS CHILD, V91, P451; Allegaert K, 2004, BIOL NEONATE, V86, P207, DOI 10.1159/000079618; Allegaert K, 2010, NEONATAL PEDIAT PHAR, P194; Allegaert K, 2013, EUR J PEDIATR, V172, P429, DOI 10.1007/s00431-012-1734-4; Allegaert K, 2012, J MATERN-FETAL NEO M, V25, P1678, DOI 10.3109/14767058.2012.657277; Allegaert K, 2011, PEDIATR ANESTH, V21, P266, DOI 10.1111/j.1460-9592.2010.03389.x; Allegaert K, 2007, CURR CLIN PHARMACOL, V2, P23, DOI 10.2174/157488407779422294; Alonso-Spilsbury M, 2005, ANIM REPROD SCI, V90, P1, DOI 10.1016/j.anireprosci.2005.01.007; Alonso-Spilsbury M, 2004, ANIM REPROD SCI, V84, P157, DOI 10.1016/j.anireprosci.2003.11.002; Amaker RD, 1996, ANTIMICROB AGENTS CH, V40, P1139, DOI 10.1128/AAC.40.5.1139; Anand KJS, 2008, BRIT J ANAESTH, V101, P680, DOI 10.1093/bja/aen248; Anderson BJ, 2002, ANESTHESIOLOGY, V96, P1336, DOI 10.1097/00000542-200206000-00012; ARANDA JV, 1979, SCIENCE, V206, P1319, DOI 10.1126/science.515734; Arpino PA, 2008, PHARMACOTHERAPY, V28, P102, DOI 10.1592/phco.28.1.102; Askenazi DJ, 2012, J PEDIATR-US, V161, P270, DOI 10.1016/j.jpeds.2012.02.007; Atkins DL, 2009, CIRCULATION, V119, P1484, DOI 10.1161/CIRCULATIONAHA.108.802678; Atkins DL, 2006, PEDIATRICS, V117, pE1005, DOI 10.1542/peds.2006-0346; Azzopardi D, 2008, BMC PEDIATR, V8, DOI 10.1186/1471-2431-8-17; Baltagi S, 2011, PEDIATR CRIT CARE ME, V12, P370, DOI 10.1097/PCC.0b013e3181e8b7ef; BANSINATH M, 1988, J CLIN PHARMACOL, V28, P860, DOI 10.1002/j.1552-4604.1988.tb03229.x; Barks JD, 2010, PEDIATR RES, V67, P532, DOI 10.1203/PDR.0b013e3181d4ff4d; Bartelink IH, 2006, CLIN PHARMACOKINET, V45, P1077, DOI 10.2165/00003088-200645110-00003; BEAUFORT AM, 1995, EUR J ANAESTH, V12, P95; Bell SG, 2012, NEONATAL NETW, V31, P48, DOI 10.1891/0730-0832.31.1.48; Berger R, 1999, BRAIN RES REV, V30, P107, DOI 10.1016/S0165-0173(99)00009-0; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bhagat H, 2006, J CLIN NEUROSCI, V13, P953, DOI 10.1016/j.jocn.2005.09.018; Bhalla T, 2012, PEDIATR ANESTH, V22, P627, DOI 10.1111/j.1460-9592.2012.03842.x; BHAT R, 1990, J PEDIATR-US, V117, P477, DOI 10.1016/S0022-3476(05)81102-3; Bisschops LLA, 2012, CRIT CARE MED, V40, P1136, DOI 10.1097/CCM.0b013e3182377050; Bjelland TW, 2013, DRUG METAB DISPOS, V41, P214, DOI 10.1124/dmd.112.045567; Blake MJ, 2005, SEMIN FETAL NEONAT M, V10, P123, DOI 10.1016/j.siny.2004.11.001; Bourdages M, 2010, PEDIATR CRIT CARE ME, V11, P408, DOI 10.1097/PCC.0b013e3181c51dea; Bouwmeester NJ, 2004, BRIT J ANAESTH, V92, P208, DOI 10.1093/bja/aeh042; Bouwmeester NJ, 2003, BRIT J ANAESTH, V90, P642, DOI 10.1093/bja/aeg121; Buck ML, 1998, PHARMACOTHERAPY, V18, P1082; Buonocore G, 2012, CURR PHARM DESIGN, V18, P3086, DOI 10.2174/1381612811209023086; Caldwell JE, 2000, ANESTHESIOLOGY, V92, P84, DOI 10.1097/00000542-200001000-00018; Capparelli E., 2010, NEONATAL PEDIAT PHAR, P819; Capparelli EV, 2001, J CLIN PHARMACOL, V41, P927, DOI 10.1177/00912700122010898; Ceelie I, 2013, JAMA-J AM MED ASSOC, V309, P149, DOI 10.1001/jama.2012.148050; Chambers D W, 2000, J Am Coll Dent, V67, P2; CHAY PCW, 1992, CLIN PHARMACOL THER, V51, P334, DOI 10.1038/clpt.1992.30; COHN HE, 1974, AM J OBSTET GYNECOL, V120, P817, DOI 10.1016/0002-9378(74)90587-0; COOMBS RC, 1990, ARCH DIS CHILD-FETAL, V65, P1067, DOI 10.1136/adc.65.10_Spec_No.1067; Corneli HM, 2012, PEDIATR EMERG CARE, V28, P475, DOI 10.1097/PEC.0b013e3182539098; Coskun KO, 2010, ARTIF ORGANS, V34, P1026, DOI 10.1111/j.1525-1594.2010.01156.x; DANZL DF, 1994, NEW ENGL J MED, V331, P1756, DOI 10.1056/NEJM199412293312607; De Cock RFW, 2011, EUR J CLIN PHARMACOL, V67, pS5, DOI 10.1007/s00228-009-0782-9; de Haan TR, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-45; De Paepe P, 2002, CLIN PHARMACOKINET, V41, P1135, DOI 10.2165/00003088-200241140-00002; de Toledo JS, 2010, PEDIATR CRIT CARE ME, V11, P439, DOI 10.1097/PCC.0b013e3181c510e9; de Wildt SN, 2001, CLIN PHARMACOL THER, V70, P525, DOI 10.1067/mcp.2001.120683; de Wildt SN, 1999, CLIN PHARMACOKINET, V37, P485, DOI 10.2165/00003088-199937060-00004; DELIN NA, 1965, J THORAC CARDIOV SUR, V49, P511, DOI 10.1016/S0022-5223(19)33287-8; Donoghue A, 2009, PEDIATRICS, V124, P1541, DOI 10.1542/peds.2009-0727; DRISCOLL DJ, 1987, CLIN PERINATOL, V14, P931; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; Empey PE, 2012, CRIT CARE MED, V40, P1221, DOI 10.1097/CCM.0b013e31823779f9; Faura CC, 1998, PAIN, V74, P43, DOI 10.1016/S0304-3959(97)00142-5; Field DJ, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-24; Filippi L, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-144; Filippi L, 2011, EPILEPSIA, V52, P794, DOI 10.1111/j.1528-1167.2011.02978.x; Filippi L, 2010, J PEDIATR-US, V157, P361, DOI 10.1016/j.jpeds.2010.04.019; Filippi L, 2009, EPILEPSIA, V50, P2355, DOI 10.1111/j.1528-1167.2009.02302.x; Fink EL, 2010, PEDIATR CRIT CARE ME, V11, P66, DOI 10.1097/PCC.0b013e3181c58237; Fox JL, 2010, CAN J EMERG MED, V12, P355; FRANK SM, 1995, ANESTHESIOLOGY, V82, P83, DOI 10.1097/00000542-199501000-00012; FRIEDMAN WF, 1985, J PEDIATR-US, V106, P697, DOI 10.1016/S0022-3476(85)80339-5; Fries M, 2012, CRIT CARE MED, V40, P1297, DOI 10.1097/CCM.0b013e31823c8ce7; Fritz HG, 2005, ANESTH ANALG, V100, P996, DOI 10.1213/01.ANE.0000146517.17910.54; Frymoyer A, 2013, J PERINATOL, V33, P778, DOI 10.1038/jp.2013.59; Frymoyer A, 2013, PHARMACOTHERAPY, V33, P718, DOI 10.1002/phar.1263; Fukuoka N, 2004, RESUSCITATION, V60, P225, DOI 10.1016/j.resuscitation.2003.09.017; Gebauer CM, 2006, PEDIATRICS, V117, P843, DOI 10.1542/peds.2004-1587; Geiduschek JM, 1997, CRIT CARE MED, V25, P360, DOI 10.1097/00003246-199702000-00027; Gluckman P D, 2001, Semin Neonatol, V6, P109, DOI 10.1053/siny.2001.0042; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Godambe S V, 1997, Indian Pediatr, V34, P927; Goldstein Brahm, 2005, Pediatr Crit Care Med, V6, P2; GORODISCHER R, 1976, CLIN PHARMACOL THER, V19, P256; GUIGNARD JP, 1982, PEDIATR CLIN N AM, V29, P777; Guignard JP, 1997, ACTA PAEDIATR, V86, P1040, DOI 10.1111/j.1651-2227.1997.tb14802.x; Gupta BD, 2005, INDIAN PEDIATR, V42, P928; HAM J, 1978, ANESTHESIOLOGY, V49, P324, DOI 10.1097/00000542-197811000-00005; Hammerman C, 1998, CLIN PERINATOL, V25, P757; Hartling L, 2011, CLIN PHARMACOL THER, V90, P727, DOI 10.1038/clpt.2011.212; Hofer N, 2012, J PERINAT MED, V0, P1; HOIE EB, 1990, CLIN PHARMACY, V9, P711; Holzer M, 2002, NEW ENGL J MED, V346, P549; Horan MR, 2004, J PEDIATR-US, V144, P301, DOI 10.1016/j.jpeds.2003.11.034; HORROW JC, 1983, ANESTHESIOLOGY, V58, P357, DOI 10.1097/00000542-198304000-00010; Hostler D, 2010, DRUG METAB DISPOS, V38, P781, DOI 10.1124/dmd.109.031377; Ichiba S, 2003, ARCH DIS CHILD-FETAL, V88, pF128, DOI 10.1136/fn.88.2.F128; Inder T E, 2000, Semin Neonatol, V5, P3, DOI 10.1053/siny.1999.0112; Jalan R, 1999, LANCET, V354, P1164, DOI 10.1016/S0140-6736(98)12440-6; JONES JH, 1962, J PATHOL BACTERIOL, V84, P428, DOI 10.1002/path.1700840218; KADAR D, 1982, CAN ANAESTH SOC J, V29, P16, DOI 10.1007/BF03007942; KALSER SC, 1969, J PHARMACOL EXP THER, V170, P145; Kart T, 1997, PAEDIATR ANAESTH, V7, P5, DOI 10.1046/j.1460-9592.1997.d01-30.x; Kaufmann R., 2010, NEONATAL PEDIAT PHAR, P20; Kearns GL, 2003, NEW ENGL J MED, V349, P1157, DOI 10.1056/NEJMra035092; KERN FH, 1991, ANESTH ANALG, V72, P487; Kirkham F, 2011, EUR J PAEDIATR NEURO, V15, P379, DOI 10.1016/j.ejpn.2011.04.009; Kleinman ME, 2010, CIRCULATION, V122, P8466, DOI 10.1161/CIRCULATIONAHA.110.971093; Knibbe CAJ, 2011, EXPERT OPIN DRUG MET, V7, P1, DOI 10.1517/17425255.2011.539201; Koren G, 1997, CLIN CHEM, V43, P222; KOREN G, 1985, CRIT CARE MED, V13, P844, DOI 10.1097/00003246-198510000-00014; KOREN G, 1987, EUR J CLIN PHARMACOL, V32, P373, DOI 10.1007/BF00543972; KOSKA AJ, 1981, CLIN PHARMACOL THER, V29, P100, DOI 10.1038/clpt.1981.16; Kramer C, 2012, NEUROLOGIST, V18, P173, DOI 10.1097/NRL.0b013e318253f8ef; Krekels EHJ, 2011, CLIN PHARMACOKINET, V50, P51, DOI 10.2165/11536750-000000000-00000; Kuppens M, 2012, J MATERN-FETAL NEO M, V25, P978, DOI 10.3109/14767058.2011.602144; Kussman BD, 2005, J CARDIOTHOR VASC AN, V19, P316, DOI 10.1053/j.jvca.2005.03.008; Lavinio A, 2007, BRIT J ANAESTH, V99, P237, DOI 10.1093/bja/aem118; LAZENBY WD, 1992, ANN THORAC SURG, V53, P957, DOI 10.1016/0003-4975(92)90367-D; Lee CR, 2002, CLIN PHARMACOL THER, V72, P562, DOI 10.1067/mcp.2002.127913; Leeder J., 2010, NEONATAL PEDIAT PHAR, P46; LESLIE K, 1995, ANESTH ANALG, V80, P1007, DOI 10.1097/00000539-199505000-00027; Lingvall M, 2005, BRIT J CLIN PHARMACO, V59, P54, DOI 10.1111/j.1365-2125.2005.02260.x; Liu MZ, 2001, ANESTHESIOLOGY, V94, P429, DOI 10.1097/00000542-200103000-00011; Liu X, 2009, PEDIATRICS, V124, P310, DOI 10.1542/peds.2008-2942; Liu YQ, 2012, PEDIATR RES, V71, P559, DOI 10.1038/pr.2012.7; Lynn A, 1998, ANESTH ANALG, V86, P958, DOI 10.1097/00000539-199805000-00008; Madadi P, 2007, CAN FAM PHYSICIAN, V53, P33; Mallet ML, 2002, QJM-INT J MED, V95, P775, DOI 10.1093/qjmed/95.12.775; Mark LF, 2013, THER DRUG MONIT, V35, P872, DOI 10.1097/FTD.0b013e318299f660; Mark LF, 2013, THER DRUG MONIT, V35, P217, DOI 10.1097/FTD.0b013e3182834335; Martin RS, 2005, SHOCK, V24, P114, DOI 10.1097/01.shk.0000169726.25189.b1; MARTINANCEL A, 1995, J PEDIATR-US, V127, P786, DOI 10.1016/S0022-3476(95)70174-5; Martinkova J, 2010, CLIN THER, V32, P2400, DOI 10.1016/j.clinthera.2011.01.013; Massaro A, 2010, J PEDIAT, V157; Massaro A, 2010, J PEDIATR-US, V157, P499, DOI 10.1016/j.jpeds.2010.04.011; Mathew PJ, 2009, PERFUSION-UK, V24, P27, DOI 10.1177/0267659109106071; Mathur N. B., 2006, Indian Journal of Pediatrics, V73, P499, DOI 10.1007/BF02759894; MCCANCE RA, 1954, COLD SPRING HARB SYM, V19, P161, DOI 10.1101/SQB.1954.019.01.022; MCCRACKEN GH, 1978, PEDIATRICS, V62, P738; Mercer JM, 2010, PHARMACOTHERAPY, V30, P654, DOI 10.1592/phco.30.7.654; MERETOJA OA, 1989, BRIT J ANAESTH, V62, P184, DOI 10.1093/bja/62.2.184; MERETOJA OA, 1989, ANESTH ANALG, V68, P20; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MILLER RD, 1978, J PHARMACOL EXP THER, V207, P532; Mommsen P, 2013, INJURY, V44, P86, DOI 10.1016/j.injury.2011.10.013; MOORE RD, 1984, J INFECT DIS, V149, P443, DOI 10.1093/infdis/149.3.443; Mulla H, 2005, BRIT J CLIN PHARMACO, V60, P265, DOI 10.1111/j.1365-2125.2005.02432.x; Newland M C, 1989, J Cardiothorac Anesth, V3, P407, DOI 10.1016/S0888-6296(89)97315-8; Ohri SK, 1997, ANN THORAC SURG, V64, P163, DOI 10.1016/S0003-4975(97)00290-7; OLSEN GD, 1975, CLIN PHARMACOL THER, V17, P31; Orozco-Gregorio H, 2010, AM J VET RES, V71, P1214, DOI 10.2460/ajvr.71.10.1214; Pacifici G, 2009, EUR J CLIN PHARMACOL, V65, P191, DOI 10.1007/s00228-008-0562-y; Pacifici GM, 2012, CLINICS, V67, P831, DOI 10.6061/clinics/2012(07)21; Pacifici G, 2009, EUR J CLIN PHARMACOL, V65, P419, DOI 10.1007/s00228-008-0599-y; PALMER CM, 1993, ANESTH ANALG, V76, P457; Perlman JM, 2006, CLIN PERINATOL, V33, P335, DOI 10.1016/j.clp.2006.03.004; Perrone S, 2012, J MATERN-FETAL NEO M, V25, P83, DOI 10.3109/14767058.2012.663168; PETITTI DB, 1985, J CHRON DIS, V38, P581, DOI 10.1016/0021-9681(85)90047-5; PETROS A, 1995, ANESTH ANALG, V81, P458, DOI 10.1097/00000539-199509000-00005; Pettifer GR, 2004, VET ANAESTH ANALG, V31, P109, DOI 10.1111/j.1467-2987.2004.00158.x; Pietrini D, 2012, CURR DRUG TARGETS, V13, P925, DOI 10.2174/138945012800675641; Poloyac SM, 2013, PEDIATR CRIT CARE ME, V14, P228, DOI 10.1097/PCC.0b013e31826775cd; Powell RW, 1999, J PEDIATR SURG, V34, P193, DOI 10.1016/S0022-3468(99)90255-5; PUIG MM, 1987, BRIT J ANAESTH, V59, P1459, DOI 10.1093/bja/59.11.1459; Quaedackers JS, 2004, J PHYSIOL-LONDON, V557, P1033, DOI 10.1113/jphysiol.2004.062554; Quaedackers JS, 2004, AM J PHYSIOL-REG I, V286, pR576, DOI 10.1152/ajpregu.00592.2003; Rajska-Neumann Agnieszka, 2004, Przegl Lek, V61, P401; Rakhmanina NY, 2006, ADV DRUG DELIVER REV, V58, P4, DOI 10.1016/j.addr.2005.12.001; Rane A., 2010, NEONATAL PEDIAT PHAR, P31; Reed MD, 2002, PEDIAT INFECT DIS PR, P147; Rocha Milagros, 2012, Infectious Disorders - Drug Targets, V12, P161; Roka A, 2008, PEDIATRICS, V121, pE844, DOI 10.1542/peds.2007-1987; Saarenmaa E, 2000, CLIN PHARMACOL THER, V68, P160, DOI 10.1067/mcp.2000.108947; Samiee S, 2013, THER DRUG MONIT, V35, P872, DOI 10.1097/FTD.0b013e318296bcfe; Sando Mitsuru, 2004, Journal of Infection and Chemotherapy, V10, P280, DOI 10.1007/s10156-004-0339-x; Sarkar S, 2012, J PERINATOL, V32, P15, DOI 10.1038/jp.2011.41; Satas S, 2000, BIOL NEONATE, V77, P50; SCHAIBLE DH, 1982, J PEDIATR-US, V100, P655, DOI 10.1016/S0022-3476(82)80780-4; Shah P, 2004, ARCH DIS CHILD-FETAL, V89, P152, DOI 10.1136/adc.2002.023093; Shah PS, 2010, SEMIN FETAL NEONAT M, V15, P238, DOI 10.1016/j.siny.2010.02.003; Shah Sachin, 2004, J Perinatol, V24, P16, DOI 10.1038/sj.jp.7211023; Shank RP, 2000, EPILEPSIA, V41, pS3, DOI 10.1111/j.1528-1157.2000.tb06045.x; Shankaran S, 2008, PEDIATRICS, V122, pE791, DOI 10.1542/peds.2008-0456; Shankaran S, 2012, NEW ENGL J MED, V366, P2085, DOI 10.1056/NEJMoa1112066; Shellhaas RA, 2013, PEDIATR CRIT CARE ME, V14, P194, DOI 10.1097/PCC.0b013e31825bbbc2; SIMANTOV R, 1976, MOL PHARMACOL, V12, P977; Simbruner G, 2010, PEDIATRICS, V126, pE771, DOI 10.1542/peds.2009-2441; Smits A, 2012, CURR PHARM DESIGN, V18, P3119, DOI 10.2174/1381612811209023119; Statler KD, 2010, PEDIATR CRIT CARE ME, V11, P151, DOI 10.1097/PCC.0b013e3181c0115a; Stravitz RT, 2009, CRIT CARE MED, V37, pS258, DOI 10.1097/CCM.0b013e3181aa5fb8; Thoresen M, 2000, PEDIATRICS, V106, P92, DOI 10.1542/peds.106.1.92; Thoresen M, 2008, CLIN PERINATOL, V35, P749, DOI 10.1016/j.clp.2008.07.018; THORNBERG E, 1995, ACTA PAEDIATR, V84, P927, DOI 10.1111/j.1651-2227.1995.tb13794.x; Ting JY, 2015, INDIAN J PEDIATR, V82, P119, DOI 10.1007/s12098-014-1527-z; Topjian A, 2011, PEDIATR CRIT CARE ME, V12, pE127, DOI 10.1097/PCC.0b013e3181e28717; Tortorici MA, 2007, CRIT CARE MED, V35, P2196, DOI 10.1097/01.CCM.0000281517.97507.6E; Touw DJ, 2009, CLIN PHARMACOKINET, V48, P71, DOI [10.2165/00003088-200948020-00001, 10.2165/0003088-200948020-00001]; Trentzsch H, 2012, SHOCK, V37, P131, DOI 10.1097/SHK.0b013e318245f6b2; UTLEY JR, 1982, ANN THORAC SURG, V33, P250, DOI 10.1016/S0003-4975(10)61920-0; van den Anker JN, 2012, CURR PHARM DESIGN, V18, P3114; van den Anker Johannes N, 2011, Handb Exp Pharmacol, V205, P51, DOI 10.1007/978-3-642-20195-0_2; van den Broek MPH, 2012, CLIN PHARMACOKINET, V51, P671, DOI 10.1007/s40262-012-0004-y; van den Broek MPH, 2015, NEONATOLOGY, V107, P150, DOI 10.1159/000368180; van den Broek MPH, 2013, ARCH DIS CHILD-FETAL, V98, pF341, DOI 10.1136/archdischild-2012-302678; van den Broek MPH, 2010, CLIN PHARMACOKINET, V49, P277, DOI 10.2165/11319360-000000000-00000; van Saet A, 2013, CURR CLIN PHARMACOL, V8, P297, DOI 10.2174/15748847113089990067; VANDENANKER JN, 1995, PEDIATR RES, V38, P808, DOI 10.1203/00006450-199511000-00028; VANDENANKER JN, 1995, BRIT J CLIN PHARMACO, V40, P439; VandenAnker JN, 1997, CRIT CARE MED, V25, P1933, DOI 10.1097/00003246-199711000-00039; vandenAnker JN, 1996, ACTA PAEDIATR, V85, P1393, DOI 10.1111/j.1651-2227.1996.tb13942.x; Vargha R, 2012, INDIAN PEDIATR, V49, P60; Vergnano S, 2005, ARCH DIS CHILD-FETAL, V90, P220, DOI 10.1136/adc.2002.022863; Vet NJ, 2011, DRUG DISCOV TODAY, V16, P435, DOI 10.1016/j.drudis.2011.02.014; VOLPE JJ, 1976, PEDIATR CLIN N AM, V23, P383; Volpe JJ, 2001, MENT RETARD DEV D R, V7, P56, DOI 10.1002/1098-2779(200102)7:1<56::AID-MRDD1008>3.0.CO;2-A; von Tavel L, 2005, DEUT TIERARZTL WOCH, V112, P443; Wang CG, 2012, PHARM RES-DORDR, V29, P1570, DOI 10.1007/s11095-012-0668-x; Whitelaw A, 2001, LANCET, V358, P36, DOI 10.1016/S0140-6736(00)05269-7; Wildschut ED, 2010, INTENS CARE MED, V36, P2109, DOI 10.1007/s00134-010-2041-z; Wildschut ED, 2012, PEDIATR CLIN N AM, V59, P1183, DOI 10.1016/j.pcl.2012.07.013; WILLIAMS CE, 1993, CLIN PERINATOL, V20, P305; Williams GD, 1997, PEDIATR RES, V42, P700, DOI 10.1203/00006450-199711000-00024; Withington D, 2000, CAN J ANAESTH, V47, P1188, DOI 10.1007/BF03019867; Withington D, 2011, PEDIATR ANESTH, V21, P341, DOI 10.1111/j.1460-9592.2010.03514.x; Yager JY, 1996, STROKE, V27, P919, DOI 10.1161/01.STR.27.5.919; Yoshitani K, 2003, BRIT J ANAESTH, V90, P122, DOI 10.1093/bja/aeg010; Yu RG, 2001, BRIT J ANAESTH, V86, P338, DOI 10.1093/bja/86.3.338; Zalzstein E., 2010, NEONATAL PEDIAT PHAR, P610; Zanelli S, 2011, J PERINATOL, V31, P377, DOI 10.1038/jp.2010.146; Zhao W, 2013, BRIT J CLIN PHARMACO, V75, P1068, DOI 10.1111/j.1365-2125.2012.04406.x; Zhou JQ, 2011, DRUG METAB DISPOS, V39, P2209, DOI 10.1124/dmd.111.040642; Zhou JQ, 2011, EXPERT OPIN DRUG MET, V7, P803, DOI 10.1517/17425255.2011.574127; Zhou JX, 2002, CHINESE MED J-PEKING, V115, P1014; Zhou JX, 2001, ANESTH ANALG, V93, P234	237	24	25	1	8	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1381-6128	1873-4286		CURR PHARM DESIGN	Curr. Pharm. Design		2015	21	39					5705	5724		10.2174/1381612821666150901110929			20	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CW5OF	WOS:000365044900012	26323408				2021-06-18	
J	Pugh, MJV; Orman, JA; Jaramillo, CA; Salinsky, MC; Eapen, BC; Towne, AR; Amuan, ME; Roman, G; McNamee, SD; Kent, TA; McMillan, KK; Hamid, H; Grafman, JH				Pugh, Mary Jo V.; Orman, Jean A.; Jaramillo, Carlos A.; Salinsky, Martin C.; Eapen, Blessen C.; Towne, Alan R.; Amuan, Megan E.; Roman, Gustavo; McNamee, Shane D.; Kent, Thomas A.; McMillan, Katharine K.; Hamid, Hamada; Grafman, Jordan H.			The Prevalence of Epilepsy and Association With Traumatic Brain Injury in Veterans of the Afghanistan and Iraq Wars	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						epidemiology; epilepsy; traumatic brain injury; Veterans	NEW-ONSET EPILEPSY; POSTTRAUMATIC EPILEPSY; BIDIRECTIONAL RELATION; SEIZURE DISORDERS; CHRONIC PAIN; COMORBIDITY; HYPERTENSION; DEPRESSION; MINNESOTA; ROCHESTER	Objective: To examine the association of epilepsy with traumatic brain injury (TBI) in Afghanistan and Iraq (Operation Enduring Freedom [OEF]/Operation Iraqi Freedom [OIF]) Veterans. Design: Cross-sectional observational study. Participants: A total 256 284 OEF/OIF Veterans who received inpatient and outpatient care in the Veterans Health Administration in fiscal years 2009-2010. Main Outcome Measures: We used algorithms developed for use with International Classification of Diseases, Ninth Revision, Clinical Modification, codes to identify epilepsy, TBI (penetrating TBI [pTBI]/other TBI), and other risk factors for epilepsy (eg, stroke). TBI and other risk factors were identified prior to the index date (first date of seizure or October 1, 2009) for primary analyses. Results: Epilepsy prevalence was 10.6 per 1000 (N = 2719) in fiscal year 2010; age-adjusted prevalence was 6.1. Of 37 718 individuals with a diagnosis of TBI, 29 297 Veterans had a diagnosis of TBI prior to the index date. Statistically significant associations were found between epilepsy and prior TBI diagnosis (pTBI: adjusted odds ratio = 18.77 [95% confidence interval, 9.21-38.23]; other TBI: adjusted odds ratio = 1.64 [1.43-1.89]). Conclusions: Among OEF/OIF Veterans, epilepsy was associated with previous TBI diagnosis, with pTBI having the strongest association. Because war-related epilepsy in Vietnam War Veterans with TBI continued 35 years postwar, a detailed, prospective study is needed to understand the relationship between epilepsy and TBI severity in OEF/OIF Veterans.	[Pugh, Mary Jo V.; McMillan, Katharine K.] South Texas Vet Hlth Care Syst VERDICT, San Antonio, TX USA; [Pugh, Mary Jo V.; Orman, Jean A.; McMillan, Katharine K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA; [Pugh, Mary Jo V.] Texas A&M Univ, Dept Med, Sch Med, College Stn, TX 77843 USA; [Orman, Jean A.] US Army Inst Surg Res, Houston, TX USA; [Orman, Jean A.] Univ Texas San Antonio, Sch Publ Hlth, San Antonio, TX USA; [Jaramillo, Carlos A.; Eapen, Blessen C.] UT Hlth Sci Ctr San Antonio, Dept Rehabil Med, Polytrauma Rehabil Ctr South Texas Vet Hlth Care, San Antonio, TX USA; [Salinsky, Martin C.] Portland VA Med Ctr, Portland, OR USA; [Salinsky, Martin C.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Towne, Alan R.] Virginia Commonwealth Univ, Richmond, VA 23284 USA; [Towne, Alan R.] McGuire Vet Adm Hosp, Epilepsy Ctr Excellence, Richmond, VA USA; [Amuan, Megan E.] Edith Nourse Rogers Mem Hosp, CHQOER, Bedford, MA USA; [Roman, Gustavo] Methodist Neurol Inst, Nantz Natl Alzheimer Ctr, Houston, TX USA; [McNamee, Shane D.] Hunter Holmes McGuire Vet Adm Hosp, Phys Med & Rehabil Serv, Richmond, VA USA; [Kent, Thomas A.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Kent, Thomas A.] Baylor Coll Med, Houston, TX 77030 USA; [Hamid, Hamada] West Haven VA Med Ctr, West Haven, CT USA; [Grafman, Jordan H.] Rehabil Inst Chicago, Chicago, IL 60611 USA	Pugh, MJV (corresponding author), South Texas Vet Hlth Care Syst ALMD, 7400 Merton Minter Blvd 11C6, San Antonio, TX 78229 USA.	pughm@uthscsa.edu	Altalib, Hamada/B-9656-2018; Pugh, Mary Jo/K-5336-2019	Altalib, Hamada/0000-0001-7154-1400; Pugh, Mary Jo/0000-0003-4196-7763; Kent, Thomas/0000-0002-9877-7584; Grafman, Jordan H./0000-0001-8645-4457	VA Health Services Research and DevelopmentUS Department of Veterans Affairs [DHI 09-237]	The study was funded by VA Health Services Research and Development (DHI 09-237). Administrative, technical, or material support was provided by Kathleen Franklin, South Texas Veterans Healthcare System. Data analysis was conducted by Ms Amuan.	Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Armed Forces Health Surveillance Center (AFHSC), 2013, MSMR, V20, P19; Banerjee PN, 2009, EPILEPSY RES, V85, P31, DOI 10.1016/j.eplepsyres.2009.03.003; Borzecki AM, 2004, AM J MED QUAL, V19, P201, DOI 10.1177/106286060401900504; CAVENESS WF, 1962, J NEUROSURG, V19, P122, DOI 10.3171/jns.1962.19.2.0122; CAVENESS WF, 1976, EPILEPSIA, V17, P207, DOI 10.1111/j.1528-1157.1976.tb03398.x; Chang YT, 2011, EPILEPSIA, V52, P2036, DOI 10.1111/j.1528-1167.2011.03268.x; Chen JWY, 2009, J REHABIL RES DEV, V46, P685, DOI 10.1682/JRRD.2008.09.0130; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; De Simone R, 2007, NEUROL SCI, V28, pS150, DOI 10.1007/s10072-007-0769-1; Defense and Veterans Brain Injury Center, DOD WORLDW NUMB TBI; Department of Defense, 2004, DOD INSTR 6130 4 CRI; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Ettinger AB, 2009, EPILEPSY BEHAV, V15, pS60, DOI 10.1016/j.yebeh.2009.03.010; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; HAUSER WA, 1992, EPILEPSIA, V33, pS6; Hebert P L, 1999, Am J Med Qual, V14, P270, DOI 10.1177/106286069901400607; Hesdorffer DC, 2012, ANN NEUROL, V72, P184, DOI 10.1002/ana.23601; Hesdorffer DC, 1996, NEUROLOGY, V46, P727, DOI 10.1212/WNL.46.3.727; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hope OA, 2009, EPILEPSIA, V50, P1085, DOI 10.1111/j.1528-1167.2008.01892.x; Kanner AM, 2012, EPILEPSY BEHAV, V24, P156, DOI 10.1016/j.yebeh.2012.01.007; Kanner AM, 2011, EPILEPSIA, V52, P21, DOI 10.1111/j.1528-1167.2010.02907.x; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Li XH, 1997, EPILEPSIA, V38, P1216, DOI 10.1111/j.1528-1157.1997.tb01219.x; Mazza M, 2007, NEUROSCIENTIST, V13, P392, DOI 10.1177/10738584070130041101; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; NG SKC, 1993, NEUROLOGY, V43, P425, DOI 10.1212/WNL.43.2.425; Pugh MJV, 2008, NEUROLOGY, V70, P2171, DOI 10.1212/01.wnl.0000313157.15089.e6; Pugh MJV, 2009, J AM GERIATR SOC, V57, P237, DOI 10.1111/j.1532-5415.2008.02124.x; Pugh MJV, 2005, J AM GERIATR SOC, V53, P1282, DOI 10.1111/j.1532-5415.2005.53402.x; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Rieger R, 2012, EPILEPSY CTR EXCELLE; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Salinsky M, 2012, EPILEPSY BEHAV, V25, P345, DOI 10.1016/j.yebeh.2012.07.013; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Selim A, 2002, MEASURING MANAGING H, V4, P91; Selim Alfredo J, 2004, J Ambul Care Manage, V27, P281; So EL, 1996, NEUROLOGY, V46, P350, DOI 10.1212/WNL.46.2.350; Tanielian TL, 2008, INVISIBLE WOUNDS WAR, V720; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; US Department of Veterans Affairs, COMPR TBI EV VHA SUM; WALKER AE, 1989, SURG NEUROL, V32, P235, DOI 10.1016/0090-3019(89)90185-7; WALKER AE, 1961, FOLLOW UP STUDY HEAD; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WEISS GH, 1986, ARCH NEUROL-CHICAGO, V43, P771, DOI 10.1001/archneur.1986.00520080019013; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	51	24	25	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2015	30	1					29	37		10.1097/HTR.0000000000000045			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AY8BW	WOS:000347780400012	24695268				2021-06-18	
J	Sharma, VK; Rango, J; Connaughton, AJ; Lombardo, DJ; Sabesan, VJ				Sharma, Vinay K.; Rango, Juan; Connaughton, Alexander J.; Lombardo, Daniel J.; Sabesan, Vani J.			The Current State of Head and Neck Injuries in Extreme Sports	ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE			English	Article						extreme sports; head and neck injuries; concussions; epidemiology	HEALTH; EPIDEMIOLOGY; CHILDREN; RISK	Background: Since their conception during the mid-1970s, international participation in extreme sports has grown rapidly. The recent death of extreme snowmobiler Caleb Moore at the 2013 Winter X Games has demonstrated the serious risks associated with these sports. Purpose: To examine the incidence and prevalence of head and neck injuries (HNIs) in extreme sports. Study Design: Descriptive epidemiological study. Methods: The National Electronic Injury Surveillance System (NEISS) was used to acquire data from 7 sports (2000-2011) that were included in the Winter and Summer X Games. Data from the NEISS database were collected for each individual sport per year and type of HNI. Cumulative data for overall incidence and injuries over the entire 11-year period were calculated. National estimates were determined using NEISS-weighted calculations. Incidence rates were calculated for extreme sports using data from Outdoor Foundation Participation Reports. Results: Over 4 million injuries were reported between 2000 and 2011, of which 11.3% were HNIs. Of all HNIs, 83% were head injuries and 17% neck injuries. The 4 sports with the highest total incidence of HNI were skateboarding (129,600), snowboarding (97,527), skiing (83,313), and motocross (78,236). Severe HNI (cervical or skull fracture) accounted for 2.5% of extreme sports HNIs. Of these, skateboarding had the highest percentage of severe HNIs. Conclusion: The number of serious injuries suffered in extreme sports has increased as participation in the sports continues to grow. A greater awareness of the dangers associated with these sports offers an opportunity for sports medicine and orthopaedic physicians to advocate for safer equipment, improved on-site medical care, and further research regarding extreme sports injuries.	[Sharma, Vinay K.; Rango, Juan; Connaughton, Alexander J.; Lombardo, Daniel J.; Sabesan, Vani J.] Western Michigan Univ, Homer Stryker MD Sch Med, Kalamazoo, MI 49008 USA	Sabesan, VJ (corresponding author), Wayne State Univ, Sch Med, Dept Orthopaed Surg, Suite 305,18100 Oakwood Blvd, Detroit, MI 48124 USA.	vsabesan@med.wayne.edu					Ackery A, 2007, INJURY PREV, V13, P368, DOI 10.1136/ip.2007.017285; Balthrop PM, 2009, J EMERG MED, V36, P121, DOI 10.1016/j.jemermed.2007.05.013; Bergeron MF, 2012, BRIT J SPORT MED, V46, DOI 10.1136/bjsports-2012-091457; Brymer E, 2013, J HEALTH PSYCHOL, V18, P477, DOI 10.1177/1359105312446770; Caine DJ, 2012, MED SPORT SCI, V58, P1, DOI 10.1159/000338558; (CPSC) USCPSC, NEISS NAT EL INJ SUR; de Jong P, 2012, RISK ANAL, V32, P782, DOI 10.1111/j.1539-6924.2011.01785.x; Goulet C, 2010, J SCI MED SPORT, V13, P39, DOI 10.1016/j.jsams.2008.10.002; Graves JM, 2013, INJURY PREV, V19, P399, DOI 10.1136/injuryprev-2012-040727; Jennum P, 2013, SPINE, V38, P449, DOI 10.1097/BRS.0b013e3182819203; Larson AN, 2009, J PEDIATR ORTHOPED, V29, P847, DOI 10.1097/BPO.0b013e3181c1e2fa; Ma R, 2012, J BONE JOINT SURG AM, V94A, P1618, DOI 10.2106/JBJS.K.01127; Ogawa H, 2010, AM J SPORT MED, V38, P532, DOI 10.1177/0363546509348763; Osberg JS, 1998, ARCH PEDIAT ADOL MED, V152, P985; Pikora TJ, 2012, MED SPORT SCI, V58, P80, DOI 10.1159/000338583; Rice MR, 2000, PEDIATRICS, V105, P615, DOI 10.1542/peds.105.3.615; Schroeder T., NEISS SAMPLE DESIGN; Sulheim S, 2006, JAMA-J AM MED ASSOC, V295, P919, DOI 10.1001/jama.295.8.919; TATOR CH, 1993, PARAPLEGIA, V31, P700, DOI 10.1038/sc.1993.112; The Outdoor Foundation, 2013, 2013 OUTD RECR PART; Wedcliffe T, 2001, S Afr J Commun Disord, V48, P77; Willig C, 2008, J HEALTH PSYCHOL, V13, P690, DOI 10.1177/1359105307082459	22	24	24	0	15	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA		2325-9671		ORTHOP J SPORTS MED	Orthop. J. Sports Med.	JAN	2015	3	1							2325967114564358	10.1177/2325967114564358			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	DA7II	WOS:000367977400006	26535369	DOAJ Gold, Green Published			2021-06-18	
J	Xiong, KL; Zhu, YS; Zhang, L; Yin, ZY; Zhang, JN; Qiu, MG; Zhang, WG				Xiong, Kunlin; Zhu, Yongshan; Zhang, Long; Yin, Zhiyong; Zhang, Jingna; Qiu, Mingguo; Zhang, Weiguo			White matter integrity and cognition in mild traumatic brain injury following motor vehicle accident	BRAIN RESEARCH			English	Article						Mild traumatic brain injury; Diffuse axonal injury; Cognitive impairment; Diffusion tensor imaging; Tract-based spatial statistics; Fractional anisotropy; Mean diffusivity	DIFFUSE AXONAL INJURY; MULTIPLE-SCLEROSIS; HEAD-INJURY; TENSOR; ADULTS; MEMORY; DAMAGE	The aim of this study is to explore the white matter structure integrity in patients with mild traumatic brain injury (mTBI) using diffusion tensor imaging (DTI), and to analyze the relationship between the white matter structure integrity and cognitive impairment of patients with mTBI. Twenty-five patients with mTBI and 25 healthy control subjects were studied with conventional MR imaging and diffusion tensor imaging. Fractional anisotropy (FA) and mean diffusivity (MD) maps of patients with mTBI were calculated and compared, with these control maps using tract-based spatial statistics (TBSS). Significantly lower fractional anisotropy was found in patients in the uncinate fasciculus, superior longitudinal fasciculus, inferior longitudinal fasciculus, and internal capsule. Mean diffusivity was significantly elevated in the body of corpus callosum, uncinate fasciculus, superior longitudinal fasciculus, and internal capsule in the mTBI group compared with the control group (P<0.05). The mTBI group showed a significant negative correlation between the elevated mean diffusivity of the uncinate fasciculus and the working memory index (WMI) (R-2=0.51, P<0.05), and the internal capsule of MD values was significantly negatively related to processing speed index (PSI) (R-2=0.45, P<0.05). There was a positive correlation between the FA value of the uncinate fasciculus and Mini Mental State Examination (MMSE) in the mTBI patient group (R-2=0.36, P<0.05). TBSS analysis of DTI suggests that patients with mTBI have focal axonal injury, and the pathophysiology is significantly related to the MMSE and IQ of mTBI patients. Diffusion tensor imaging can be a powerful technique for in vivo detection of mTBI, and can help in the diagnosis of patients with mTBI. (C) 2014 Elsevier B.V. All rights reserved.	[Xiong, Kunlin; Zhu, Yongshan; Zhang, Long; Zhang, Weiguo] Third Mil Med Univ, Daping Hosp, Dept Radiol, Chongqing 400042, Peoples R China; [Yin, Zhiyong] Third Mil Med Univ, Inst Surg Res, Dept 4, Chongqing 400042, Peoples R China; [Zhang, Jingna; Qiu, Mingguo] Third Mil Med Univ, Coll Biomed Engn, Dept Med Image, Chongqing 400038, Peoples R China	Qiu, MG (corresponding author), Third Mil Med Univ, Coll Biomed Engn, Dept Med Image, Chongqing 400038, Peoples R China.	jellyhuangsci2@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81171866, 30870696]; Chongqing research [cstc2012gg-yyjs10059]	This study was sponsored by the National Natural Science Foundation of China (Grant numbers 81171866, 30870696), and supported in part by Chongqing research grant no. cstc2012gg-yyjs10059.	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Basser PJ, 1998, MAGNET RESON MED, V39, P928, DOI 10.1002/mrm.1910390610; Ceccarelli A, 2009, HUM BRAIN MAPP, V30, P3009, DOI 10.1002/hbm.20725; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Dineen RA, 2009, BRAIN, V132, P239, DOI 10.1093/brain/awn275; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gu L, 2013, J TRAUMA ACUTE CARE, V74, P242, DOI 10.1097/TA.0b013e3182684fe8; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lowenstein Daniel H, 2009, Ann Neurol, V66, pA7, DOI 10.1002/ana.21876; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Seo JP, 2012, NEUROREHABILITATION, V30, P323, DOI 10.3233/NRE-2012-0762; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055	24	24	28	0	19	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 3	2014	1591						86	92		10.1016/j.brainres.2014.10.030			7	Neurosciences	Neurosciences & Neurology	AU6QZ	WOS:000345728300008	25451093				2021-06-18	
J	Anderova, M; Benesova, J; Mikesova, M; Dzamba, D; Honsa, P; Kriska, J; Butenko, O; Novosadova, V; Valihrach, L; Kubista, M; Dmytrenko, L; Cicanic, M; Vargova, L				Anderova, Miroslava; Benesova, Jana; Mikesova, Michaela; Dzamba, David; Honsa, Pavel; Kriska, Jan; Butenko, Olena; Novosadova, Vendula; Valihrach, Lukas; Kubista, Mikael; Dmytrenko, Lesia; Cicanic, Michal; Vargova, Lydia			Altered Astrocytic Swelling in the Cortex of alpha-Syntrophin-Negative GFAP/EGFP Mice	PLOS ONE			English	Article							3-DIMENSIONAL CONFOCAL MORPHOMETRY; BLOOD-BRAIN-BARRIER; DIFFUSION PARAMETERS; VOLUME REGULATION; GLIAL-CELLS; AQUAPORIN-4; EXPRESSION; K+; MORPHOLOGY; ISCHEMIA	Brain edema accompanying ischemic or traumatic brain injuries, originates from a disruption of ionic/neurotransmitter homeostasis that leads to accumulation of K+ and glutamate in the extracellular space. Their increased uptake, predominantly provided by astrocytes, is associated with water influx via aquaporin-4 (AQP4). As the removal of perivascular AQP4 via the deletion of alpha-syntrophin was shown to delay edema formation and K+ clearance, we aimed to elucidate the impact of alpha-syntrophin knockout on volume changes in individual astrocytes in situ evoked by pathological stimuli using three dimensional confocal morphometry and changes in the extracellular space volume fraction (alpha) in situ and in vivo in the mouse cortex employing the real-time iontophoretic method. RT-qPCR profiling was used to reveal possible differences in the expression of ion channels/transporters that participate in maintaining ionic/neurotransmitter homeostasis. To visualize individual astrocytes in mice lacking alpha-syntrophin we crossbred GFAP/EGFP mice, in which the astrocytes are labeled by the enhanced green fluorescent protein under the human glial fibrillary acidic protein promoter, with alpha-syntrophin knockout mice. Three-dimensional confocal morphometry revealed that alpha-syntrophin deletion results in significantly smaller astrocyte swelling when induced by severe hypoosmotic stress, oxygen glucose deprivation (OGD) or 50 mM K+. As for the mild stimuli, such as mild hypoosmotic or hyperosmotic stress or 10 mM K+, alpha-syntrophin deletion had no effect on astrocyte swelling. Similarly, evaluation of relative alpha changes showed a significantly smaller decrease in alpha-syntrophin knockout mice only during severe pathological conditions, but not during mild stimuli. In summary, the deletion of alpha-syntrophin markedly alters astrocyte swelling during severe hypoosmotic stress, OGD or high K+.	[Anderova, Miroslava; Benesova, Jana; Mikesova, Michaela; Dzamba, David; Honsa, Pavel; Kriska, Jan; Butenko, Olena] Acad Sci Czech Republ, Inst Expt Med, Dept Cellular Neurophysiol, Prague, Czech Republic; [Novosadova, Vendula; Valihrach, Lukas; Kubista, Mikael] Acad Sci Czech Republ, Gene Express Lab, Inst Biotechnol, Prague, Czech Republic; [Anderova, Miroslava; Dmytrenko, Lesia; Cicanic, Michal; Vargova, Lydia] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic	Anderova, M (corresponding author), Acad Sci Czech Republ, Inst Expt Med, Dept Cellular Neurophysiol, Prague, Czech Republic.	anderova@biomed.cas.cz	Butenko, Olena/AAL-3766-2021; Valihrach, Lukas/H-4368-2014; Novosadova, Vendula/AAJ-1449-2021; Anderova, Miroslava/H-2249-2014; Valihrach, Lukas/AAL-6651-2020; Kriska, Jan/D-4889-2019	Butenko, Olena/0000-0003-2959-559X; Valihrach, Lukas/0000-0002-6704-4337; Anderova, Miroslava/0000-0002-9030-4571; Valihrach, Lukas/0000-0002-6704-4337; Kriska, Jan/0000-0001-5684-5828	Grant Agency of the Czech RepublicGrant Agency of the Czech Republic [GA CR 13-02154S, P304/12/G069]; European Regional Development FundEuropean Commission [BIOCEV CZ.1.05/1.1.00/02.0109]; Operational Programme Education for Competitiveness from the European Social Fund [CZ.1.07/2.3.00/30.0045]; state budget of the Czech Republic	This study was supported by the grants GA CR 13-02154S, and P304/12/G069 from the Grant Agency of the Czech Republic, by the project BIOCEV CZ.1.05/1.1.00/02.0109 from the European Regional Development Fund and by the Operational Programme Education for Competitiveness CZ.1.07/2.3.00/30.0045 from the European Social Fund and the state budget of the Czech Republic. The authors state that the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams ME, 2000, J CELL BIOL, V150, P1385, DOI 10.1083/jcb.150.6.1385; Alvestad S, 2013, EPILEPSY RES, V105, P30, DOI 10.1016/j.eplepsyres.2013.01.006; Amiry-Moghaddam M, 2004, FASEB J, V18, P542, DOI 10.1096/fj.03-0869fje; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P13615, DOI 10.1073/pnas.2336064100; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; Amiry-Moghaddam M, 2004, NEUROSCIENCE, V129, P999, DOI 10.1016/j.neuroscience.2004.08.049; Anderova M, 2011, J CEREBR BLOOD F MET, V31, P894, DOI 10.1038/jcbfm.2010.168; Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496; Benesova J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029725; Benesova J, 2009, J NEUROSCI RES, V87, P96, DOI 10.1002/jnr.21828; Binder DK, 2012, GLIA, V60, P1203, DOI 10.1002/glia.22317; Binder DK, 2006, GLIA, V53, P631, DOI 10.1002/glia.20318; Bragg AD, 2006, GLIA, V53, P879, DOI 10.1002/glia.20347; Chvatal A, 2007, J ANAT, V210, P671, DOI 10.1111/j.1469-7580.2007.00724.x; Chvatal A, 2007, J NEUROSCI RES, V85, P260, DOI 10.1002/jnr.21113; Connors NC, 2004, J BIOL CHEM, V279, P28387, DOI 10.1074/jbc.M402604200; Dmytrenko L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068044; Florence CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051124; Fryclenlund DS, 2006, P NATL ACAD SCI USA, V103, P13532, DOI 10.1073/pnas.0605796103; HEINEMANN U, 1977, BRAIN RES, V120, P231, DOI 10.1016/0006-8993(77)90903-9; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; Lindinger MI, 2011, J PHYSIOL-LONDON, V589, P2887, DOI 10.1113/jphysiol.2011.206730; Macaulay N, 2004, NEUROSCIENCE, V129, P1031, DOI 10.1016/j.neuroscience.2004.06.045; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Matthias K, 2003, J NEUROSCI, V23, P1750; McManus ML, 1998, ANESTHESIOLOGY, V88, P1586, DOI 10.1097/00000542-199806000-00023; MOODY WJ, 1974, EXP NEUROL, V42, P248, DOI 10.1016/0014-4886(74)90023-5; Neely JD, 2001, P NATL ACAD SCI USA, V98, P14108, DOI 10.1073/pnas.241508198; NICHOLSON C, 1981, J PHYSIOL-LONDON, V321, P225, DOI 10.1113/jphysiol.1981.sp013981; Nolte C, 2001, GLIA, V33, P72; PasantesMorales H, 1996, METAB BRAIN DIS, V11, P187, DOI 10.1007/BF02237957; Pivonkova H, 2010, NEUROCHEM INT, V57, P783, DOI 10.1016/j.neuint.2010.08.016; Potokar M, 2013, GLIA, V61, P917, DOI 10.1002/glia.22485; Ransom CB, 2000, J PHYSIOL-LONDON, V522, P427, DOI 10.1111/j.1469-7793.2000.00427.x; Ross SB, 2007, AM J PHYSIOL-CELL PH, V293, pC1181, DOI 10.1152/ajpcell.00066.2007; Rusnakova V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069734; Saadoun S, 2010, NEUROSCIENCE, V168, P1036, DOI 10.1016/j.neuroscience.2009.08.019; Solenov E, 2004, AM J PHYSIOL-CELL PH, V286, pC426, DOI 10.1152/ajpcell.00298.2003; Song D, 2014, J NEUROSCI RES; Sykova E., 1992, MONITORING NEURONAL, P261; Tait MJ, 2008, TRENDS NEUROSCI, V31, P37, DOI 10.1016/j.tins.2007.11.003; Takano T, 2014, GLIA, V62, P78, DOI 10.1002/glia.22588; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vargova L, 2001, J NEUROSCI RES, V65, P129, DOI 10.1002/jnr.1136.abs; Vorisek I, 1997, J CEREBR BLOOD F MET, V17, P191; Walz W, 2000, NEUROCHEM INT, V36, P291, DOI 10.1016/S0197-0186(99)00137-0; Zeynalov E, 2008, CRIT CARE MED, V36, P2634, DOI 10.1097/CCM.0b013e3181847853; Zoremba N, 2008, J CEREBR BLOOD F MET, V28, P1665, DOI 10.1038/jcbfm.2008.58	48	24	24	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 26	2014	9	11							e113444	10.1371/journal.pone.0113444			34	Multidisciplinary Sciences	Science & Technology - Other Topics	CA8CZ	WOS:000349145400053	25426721	DOAJ Gold, Green Published			2021-06-18	
J	Doig, RLO; Bartlett, CA; Maghzal, GJ; Lam, M; Archer, M; Stocker, R; Fitzgerald, M				Doig, Ryan L. O'Hare; Bartlett, Carole A.; Maghzal, Ghassan J.; Lam, Magdalena; Archer, Michael; Stocker, Roland; Fitzgerald, Melinda			Reactive species and oxidative stress in optic nerve vulnerable to secondary degeneration	EXPERIMENTAL NEUROLOGY			English	Article						Neurotrauma; Secondary degeneration; Oxidative stress; Reactive species; Antioxidant enzymes; Oxidative damage; Mitophagy	SPINAL-CORD-INJURY; CELL-DEATH; IN-VIVO; LIPID-PEROXIDATION; WHITE-MATTER; CALCIUM; DAMAGE; BRAIN; PEROXYNITRITE; OXYGEN	Secondary degeneration contributes substantially to structural and functional deficits following traumatic injury to the CNS. While it has been proposed that oxidative stress is a feature of secondary degeneration, contributing reactive species and resultant oxidized products have not been clearly identified in vivo. The study is designed to identify contributors to, and consequences of, oxidative stress in a white matter tract vulnerable to secondary degeneration. Partial dorsal transection of the optic nerve (ON) was used to model secondary degeneration in ventral nerve unaffected by the primary injury. Reactive species were assessed using fluorescent labelling and liquid chromatography/tandem mass spectroscopy (LC/MS/MS). Antioxidant enzymes and oxidized products were semi-quantified immunohistochemically. Mitophagy was assessed by electron microscopy. Fluorescent indicators of reactive oxygen and/or nitrogen species increased at 1, 3 and 7 days after injury, in ventral ON. LC/MS/MS confirmed increases in reactive species linked to infiltrating microglia/macrophages in dorsal ON. Similarly, immunoreactivity for glutathione peroxidase and haem oxygenase-1 increased in ventral ON at 3 and 7 days after injury, respectively. Despite increased antioxidant immunoreactivity, DNA oxidation was evident from 1 day, lipid oxidation at 3 days, and protein nitration at 7 days after injury. Nitrosative and oxidative damage was particularly evident in CC1-positive oligodendrocytes, at times after injury at which structural abnormalities of the Node of Ranvier/paranode complex have been reported. The incidence of mitochondrial autophagic profiles was also significantly increased from 3 days. Despite modest increases in antioxidant enzymes, increased reactive species are accompanied by oxidative and nitrosative damage to DNA, lipid and protein, associated with increasing abnormal mitochondria, which together may contribute to the deficits of secondary degeneration. (C) 2014 Elsevier Inc. All rights reserved.	[Doig, Ryan L. O'Hare; Bartlett, Carole A.; Archer, Michael; Fitzgerald, Melinda] Univ Western Australia, Sch Anim Biol, Crawley, WA 6009, Australia; [Maghzal, Ghassan J.; Lam, Magdalena; Stocker, Roland] Victor Chang Cardiac Res Inst, Vasc Biol Div, Darlinghurst, NSW, Australia; [Maghzal, Ghassan J.; Stocker, Roland] Univ New S Wales, Sydney, NSW 2052, Australia	Fitzgerald, M (corresponding author), Univ Western Australia, Sch Anim Biol, Crawley, WA 6009, Australia.	lindy.fitzgerald@uwa.edu.au	maghzal, ghassan/A-9692-2015; Doig, Ryan O'Hare/AAG-7585-2019; Fitzgerald, Melinda/C-4235-2011	Fitzgerald, Melinda/0000-0002-4823-8179; Lam, Magdalena/0000-0002-5350-8006	Neurotrauma Research Program of Western Australia; Road Safety Council of Western Australia; Road Trauma Trust Account, Western Australia; Australian Research Council Discovery ProjectAustralian Research Council [DP 110102135]; National Health & Medical Research Council of Australia (NHMRC) ProjectNational Health and Medical Research Council of Australia [1037879]; NHMRC Senior Principal Research FellowshipNational Health and Medical Research Council of Australia	We are grateful to Elora Bartlett and Conor McCarthy for technical assistance with mitochondrial quantification and Ivan Lozic for the schematic diagram. We acknowledge financial support from the Neurotrauma Research Program of Western Australia, an initiative of the Road Safety Council of Western Australia. This project is funded through the Road Trauma Trust Account, Western Australia, but does not reflect views or recommendations of the Road Safety Council. This work was partly supported by an Australian Research Council Discovery Project Grant DP 110102135 (to G.J.M.) and a National Health & Medical Research Council of Australia (NHMRC) Project Grant 1037879 (to R.S.). R.S. is supported by a NHMRC Senior Principal Research Fellowship.	Aldini G, 2006, CHEMMEDCHEM, V1, P1045, DOI 10.1002/cmdc.200600075; Back SA, 2005, ANN NEUROL, V58, P108, DOI 10.1002/ana.20530; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Bodeutsch N, 1999, J NEUROBIOL, V38, P116, DOI 10.1002/(SICI)1097-4695(199901)38:1<116::AID-NEU9>3.0.CO;2-F; BONGARZONE ER, 1995, J NEUROSCI RES, V41, P213, DOI 10.1002/jnr.490410209; Camello-Almaraz MC, 2006, J CELL PHYSIOL, V206, P487, DOI 10.1002/jcp.20498; Carrico KM, 2009, J NEUROTRAUM, V26, P1369, DOI [10.1089/neu.2008.0870, 10.1089/neu.2008-0870]; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Crow JP, 1997, J NEUROCHEM, V69, P1945; Cummins N, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-98; DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140; Dasgupta A, 2013, ASN NEURO, V5, P99, DOI 10.1042/AN20120088; Denicola A, 2005, TOXICOLOGY, V208, P273, DOI 10.1016/j.tox.2004.11.023; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Ferguson AR, 2008, J NEUROSCI, V28, P11391, DOI 10.1523/JNEUROSCI.3708-08.2008; Fitzgerald M, 2010, J NEUROTRAUM, V27, P439, DOI 10.1089/neu.2009.1112; Fitzgerald M, 2009, INVEST OPHTH VIS SCI, V50, P5456, DOI 10.1167/iovs.09-3717; Fitzgerald M, 2009, EXP NEUROL, V216, P219, DOI 10.1016/j.expneurol.2008.11.026; French HM, 2009, J NEUROSCI RES, V87, P3076, DOI 10.1002/jnr.22139; Fuss B, 2000, DEV BIOL, V218, P259, DOI 10.1006/dbio.1999.9574; Gaut JP, 2002, J CLIN INVEST, V109, P1311, DOI 10.1172/JCI200215021; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Goldberg JA, 2012, NAT NEUROSCI, V15, P1414, DOI 10.1038/nn.3209; GRIOT C, 1990, FREE RADICAL RES COM, V11, P181, DOI 10.3109/10715769009088915; Haider L, 2011, BRAIN, V134, P1914, DOI 10.1093/brain/awr128; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x; Higgins GC, 2009, CELL MOL LIFE SCI, V66, P2773, DOI 10.1007/s00018-009-0079-2; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; Izzotti A, 2006, MUTAT RES-REV MUTAT, V612, P105, DOI 10.1016/j.mrrev.2005.11.001; Jeney V, 2002, BLOOD, V100, P879, DOI 10.1182/blood.V100.3.879; Kalyanaraman B, 2012, FREE RADICAL BIO MED, V52, P1, DOI 10.1016/j.freeradbiomed.2011.09.030; Knoferle J, 2010, P NATL ACAD SCI USA, V107, P6064, DOI 10.1073/pnas.0909794107; Kowaltowski AJ, 2009, FREE RADICAL BIO MED, V47, P333, DOI 10.1016/j.freeradbiomed.2009.05.004; Levkovitch-Verbin H, 2003, INVEST OPHTH VIS SCI, V44, P3388, DOI 10.1167/iovs.02-0646; Li ZS, 2010, FEBS LETT, V584, P2291, DOI 10.1016/j.febslet.2010.03.040; Lu JK, 2000, SPINE, V25, P1859, DOI 10.1097/00007632-200007150-00022; Ma F, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-31; Maghzal GJ, 2014, J BIOL CHEM, V289, P5580, DOI 10.1074/jbc.M113.539486; Matute C, 2007, J ANAT, V210, P693, DOI 10.1111/j.1469-7580.2007.00733.x; Min KJ, 2006, J NEUROSCI, V26, P1880, DOI 10.1523/JNEUROSCI.3696-05.2006; Moreira PI, 2005, ANN NY ACAD SCI, V1043, P545, DOI 10.1196/annals.1333.062; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Pamplona R, 2005, J BIOL CHEM, V280, P21522, DOI 10.1074/jbc.M502255200; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Payne SC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065710; Payne SC, 2012, INVEST OPHTH VIS SCI, V53, P6093, DOI 10.1167/iovs.12-10080; Peng TI, 2010, ANN NY ACAD SCI, V1201, P183, DOI 10.1111/j.1749-6632.2010.05634.x; Pryde KR, 2011, J BIOL CHEM, V286, P18056, DOI 10.1074/jbc.M110.186841; Reynolds MR, 2005, BIOCHEMISTRY-US, V44, P1690, DOI 10.1021/bi047982v; Schlieve CR, 2006, INVEST OPHTH VIS SCI, V47, P3878, DOI 10.1167/iovs.05-1010; Schneider C, 2008, J BIOL CHEM, V283, P15539, DOI 10.1074/jbc.R800001200; STOCKER R, 1990, FREE RADICAL RES COM, V9, P101, DOI 10.3109/10715769009148577; Sultana R, 2006, ANTIOXID REDOX SIGN, V8, P2021, DOI 10.1089/ars.2006.8.2021; Szymanski CR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066448; Tang EHC, 2008, J PHARMACOL EXP THER, V327, P148, DOI 10.1124/jpet.108.140046; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Tezel G, 2006, PROG RETIN EYE RES, V25, P490, DOI 10.1016/j.preteyeres.2006.07.003; Tretter L, 2007, J NEUROSCI RES, V85, P3471, DOI 10.1002/jnr.21405; URSINI F, 1987, CHEM PHYS LIPIDS, V44, P255, DOI 10.1016/0009-3084(87)90053-3; Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823; VACA CE, 1988, MUTAT RES, V195, P137, DOI 10.1016/0165-1110(88)90022-X; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Wells J, 2012, J NEUROSCI RES, V90, P606, DOI 10.1002/jnr.22784; Xiong YQ, 2009, EXP NEUROL, V216, P105, DOI 10.1016/j.expneurol.2008.11.025; Yu HB, 2005, CHEM RES TOXICOL, V18, P1849, DOI 10.1021/tx050146h; Zielonka J, 2008, FREE RADICAL BIO MED, V44, P835, DOI 10.1016/j.freeradbiomed.2007.11.013; Zielonka J, 2008, NAT PROTOC, V3, P8, DOI 10.1038/nprot.2007.473; Zielonka J, 2010, FREE RADICAL BIO MED, V48, P983, DOI 10.1016/j.freeradbiomed.2010.01.028	69	24	24	0	12	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	NOV	2014	261						136	146		10.1016/j.expneurol.2014.06.007			11	Neurosciences	Neurosciences & Neurology	AR4AX	WOS:000343531500014	24931225				2021-06-18	
J	McMillan, TM; Weir, CJ; Wainman-Lefley, J				McMillan, T. M.; Weir, C. J.; Wainman-Lefley, J.			Mortality and morbidity 15 years after hospital admission with mild head injury: a prospective case-controlled population study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; LIFE-STYLE INTERVENTIONS; YOUNG-PEOPLE; EPIDEMIOLOGY; DYSFUNCTION; DISABILITY; DEMENTIA; SINGLE; ADULTS; WORSE	Objective To investigate mortality rate in a population of adults admitted to hospital with mild head injury (MHI) 15 years later. Design A prospective case control, record linkage study. Participants 2428 adults with MHI and an equal number of community controls (CC) were case-matched for age, gender and social deprivation. A further control group admitted with a non-head injury was in addition matched for duration of hospital admission. Controls with a history of head injury prior to study entry were excluded. Main outcome measures Death or survival 15 years poststudy entry. Results Mortality per 1000 per year after MHI (24.49; 95% CI 23.21 to 25.79) was higher than in CC (13.34; 95% CI 12.29 to 14.44; p<0.0001) or 'other injury' controls (OIC) (19.63; 95% CI 18.43 to 20.87; p<0.0001). Age at injury was important: younger adults (15-54 years) with MHI had a 4.2-fold greater risk of death than CC; in adults aged over 54, the risk was 1.4 times higher. Gender and social deprivation showed a similar association with death in the MHI and control groups. Repeated head injury was a risk factor for death in the MHI group. The frequency of hospital admission with systemic disease preinjury and postinjury was higher in both injury groups than in CC and higher in MHI than OIC. Prospective data in the MHI group suggest an association between preinjury lifestyle and mortality. Causes of death after MHI were similar to those of the control groups. Conclusions Adults hospitalised with MHI had greater risk of death in the following 15 years than matched controls. The extent to which lifestyle and potential chronic changes in neuropathology explain these findings is unclear. Lifestyle factors do contribute to risk of death after MHI and this finding has implications for lifestyle management interventions.	[McMillan, T. M.; Wainman-Lefley, J.] Univ Glasgow, Inst Hlth & Wellbeing, MVLS, Glasgow G12 0XH, Lanark, Scotland; [Weir, C. J.] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland; [Weir, C. J.] Edinburgh Hlth Serv Res Unit, Edinburgh, Midlothian, Scotland	McMillan, TM (corresponding author), Univ Glasgow, Inst Hlth & Wellbeing, Gartnavel Royal Hosp, 1055 Great Western Rd, Glasgow G12 0XH, Lanark, Scotland.	thomas.mcmillan@glasgow.ac.uk		Weir, Christopher/0000-0002-6494-4903	Chief Scientist Office for Scotland [CZH/4/674]; NHS Lothian via the Edinburgh Health Services Research Unit; Chief Scientist Office [CZH/4/674] Funding Source: researchfish	The study was funded by the Chief Scientist Office for Scotland; grant number CZH/4/674. CJW was supported in this work by NHS Lothian via the Edinburgh Health Services Research Unit.	[Anonymous], 2009, SCOTT INT GUID NETW; Baguley IJ, 2012, MED J AUSTRALIA, V196, P40, DOI 10.5694/mja11.10090; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Chacon F, 2011, ANN GEN PSYCHIATR, V10, DOI 10.1186/1744-859X-10-22; Cole JA, 2011, CARDIOL RES PRACT, V2011, DOI 10.4061/2011/232351; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE69, DOI 10.1097/HTR.0b013e3182738010; Hilz MJ, 2011, J NEUROTRAUM, V28, P1727, DOI 10.1089/neu.2010.1497; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Lawrence M, 2012, INT J STROKE, V7, P243, DOI 10.1111/j.1747-4949.2012.00771.x; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McCartney G, 2012, PUBLIC HEALTH, V126, P459, DOI 10.1016/j.puhe.2012.03.007; McMillan TM, 2007, BRAIN, V130, P2520, DOI 10.1093/brain/awm185; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; McMillan TM, 2012, J NEUROL NEUROSUR PS, V83, P1086, DOI 10.1136/jnnp-2012-302746; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; ROWORTH MA, 1988, COMMUNITY MED, V10, P327; Scottish Exec, 2006, SCOTT IND MULT DEPR; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Starkstein SE, 2005, INT PSYCHOGERIATR, V17, pS93, DOI 10.1017/S1041610205001973; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Taulbut M, 2013, PUBLIC HEALTH, V127, P153, DOI 10.1016/j.puhe.2012.11.007; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	33	24	24	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	NOV	2014	85	11					1214	1220		10.1136/jnnp-2013-307279			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	AS2ER	WOS:000344093100009	24623794				2021-06-18	
J	Lowing, JL; Susick, LL; Caruso, JP; Provenzano, AM; Raghupathi, R; Conti, AC				Lowing, Jennifer L.; Susick, Laura L.; Caruso, James P.; Provenzano, Anthony M.; Raghupathi, Ramesh; Conti, Alana C.			Experimental Traumatic Brain Injury Alters Ethanol Consumption and Sensitivity	JOURNAL OF NEUROTRAUMA			English	Article						alcohol; DARPP-32; loss of righting reflex; nucleus accumbens; traumatic brain injury	CONTROLLED CORTICAL IMPACT; SPINAL-CORD-INJURY; SUBSTANCE-ABUSE; SYNAPTIC PLASTICITY; NUCLEUS-ACCUMBENS; PSYCHIATRIC-DISORDERS; ADENYLYL CYCLASES; OXIDATIVE STRESS; AXONAL INJURY; RAT STRIATUM	Altered alcohol consumption patterns after traumatic brain injury (TBI) can lead to significant impairments in TBI recovery. Few preclinical models have been used to examine alcohol use across distinct phases of the post-injury period, leaving mechanistic questions unanswered. To address this, the aim of this study was to describe the histological and behavioral outcomes of a noncontusive closed-head TBI in the mouse, after which sensitivity to and consumption of alcohol were quantified, in addition to dopaminergic signaling markers. We hypothesized that TBI would alter alcohol consumption patterns and related signal transduction pathways that were congruent to clinical observations. After midline impact to the skull, latency to right after injury, motor deficits, traumatic axonal injury, and reactive astrogliosis were evaluated in C57BL/6J mice. Amyloid precursor protein (APP) accumulation was observed in white matter tracts at 6, 24, and 72 h post-TBI. Increased intensity of glial fibrillary acidic protein (GFAP) immunoreactivity was observed by 24 h, primarily under the impact site and in the nucleus accumbens, a striatal subregion, as early as 72 h, persisting to 7 days, after TBI. At 14 days post-TBI, when mice were tested for ethanol sensitivity after acute high-dose ethanol (4 g/kg, intraperitoneally), brain-injured mice exhibited increased sedation time compared with uninjured mice, which was accompanied by deficits in striatal dopamine-and cAMP-regulated neuronal phosphoprotein, 32 kDa (DARPP-32) phosphorylation. At 17 days post-TBI, ethanol intake was assessed using the Drinking-in-the-Dark paradigm. Intake across 7 days of consumption was significantly reduced in TBI mice compared with sham controls, paralleling the reduction in alcohol consumption observed clinically in the initial post-injury period. These data demonstrate that TBI increases sensitivity to ethanol-induced sedation and affects downstream signaling mediators of striatal dopaminergic neurotransmission while altering ethanol consumption. Examining TBI effects on ethanol responsitivity will improve our understanding of alcohol use post-TBI in humans.	[Lowing, Jennifer L.; Susick, Laura L.; Caruso, James P.; Provenzano, Anthony M.; Conti, Alana C.] Wayne State Univ, Sch Med, John D Dingell VA Med Ctr, Detroit, MI 48201 USA; [Lowing, Jennifer L.; Susick, Laura L.; Caruso, James P.; Provenzano, Anthony M.; Conti, Alana C.] Wayne State Univ, Sch Med, Dept Neurosurg, Detroit, MI 48201 USA; [Raghupathi, Ramesh] Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19104 USA	Conti, AC (corresponding author), Wayne State Univ, Sch Med, John D Dingell VA Med Ctr, Dept Neurosurg, 4646 John R St 11R, Detroit, MI 48201 USA.	aconti@med.wayne.edu		Susick, Laura/0000-0002-1389-837X	Wayne State University (WSU) Department of Neurosurgery; Children's Hospital of Michigan Foundation; WSU Office of the Vice President for Research (ACC)	This material is the result of work supported with resources and the use of facilities at the John D. Dingell VA Medical Center, Detroit, MI, and by funds from Wayne State University (WSU) Department of Neurosurgery, Children's Hospital of Michigan Foundation, and WSU Office of the Vice President for Research (ACC).	Adams RS, 2012, J SOC WORK PRACT ADD, V12, P28, DOI 10.1080/1533256X.2012.647580; Adams RS, 2012, J HEAD TRAUMA REHAB, V27, P349, DOI 10.1097/HTR.0b013e318268db94; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Baldo BA, 2007, PSYCHOPHARMACOLOGY, V191, P439, DOI 10.1007/s00213-007-0741-z; Bales JW, 2011, EXP NEUROL, V229, P300, DOI 10.1016/j.expneurol.2011.02.013; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Calabresi P, 2000, J NEUROSCI, V20, P8443, DOI 10.1523/JNEUROSCI.20-22-08443.2000; Calabresi P, 2007, TRENDS NEUROSCI, V30, P211, DOI 10.1016/j.tins.2007.03.001; Chen G, 2011, ALCOHOL CLIN EXP RES, V35, P1739, DOI 10.1111/j.1530-0277.2011.01520.x; Conti AC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005697; CORRIGAN JD, 1995, BRAIN INJURY, V9, P221, DOI 10.3109/02699059509008195; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Ding YC, 2001, NEUROL RES, V23, P193, DOI 10.1179/016164101101198334; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; ELLERD DA, 1992, J APPL REHABILITATIO, V23, P48; Greengard P, 1999, NEURON, V23, P435, DOI 10.1016/S0896-6273(00)80798-9; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hinzman JM, 2012, J NEUROTRAUM, V29, P1197, DOI 10.1089/neu.2011.2261; Jones TA, 2012, J NEUROTRAUM, V29, P1455, DOI 10.1089/neu.2011.2207; KAKIHANA R, 1966, SCIENCE, V154, P1574, DOI 10.1126/science.154.3756.1574; KEIR WJ, 1990, J PHARMACOL EXP THER, V254, P831; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Lyons AM, 2008, ALCOHOL CLIN EXP RES, V32, P1962, DOI 10.1111/j.1530-0277.2008.00784.x; Maas JW, 2005, J NEUROSCI, V25, P4118, DOI 10.1523/JNEUROSCI.4273-04.2005; Maldve RE, 2002, NAT NEUROSCI, V5, P641, DOI 10.1038/nn877; Margulies S, 2000, J CLIN NEUROSCI, V7, P400, DOI 10.1054/jocn.1999.0681; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Ommaya AK, 1996, J TRAUMA, V41, P972, DOI 10.1097/00005373-199612000-00005; Papa M, 2014, NEUROSCI BIOBEHAV R, V42, P35, DOI 10.1016/j.neubiorev.2014.01.010; PENNARTZ CMA, 1991, J NEUROSCI, V11, P2838; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; Ponomarev I, 2002, GENES BRAIN BEHAV, V1, P82, DOI 10.1034/j.1601-183X.2002.10203.x; Rhodes JS, 2007, GENES BRAIN BEHAV, V6, P1, DOI 10.1111/j.1601-183X.2006.00210.x; Rhodes JS, 2005, PHYSIOL BEHAV, V84, P53, DOI 10.1016/j.physbeh.2004.10.007; Ridley RM, 2006, BEHAV BRAIN RES, V166, P253, DOI 10.1016/j.bbr.2005.08.007; Risinger FO, 2001, J NEUROSCI, V21, P340, DOI 10.1523/JNEUROSCI.21-01-00340.2001; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Ron D, 2004, NEUROSCIENTIST, V10, P325, DOI 10.1177/1073858404263516; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Shah S, 2012, BRAIN INJURY, V26, P201, DOI 10.3109/02699052.2012.654591; Shin SS, 2011, BRAIN RES, V1369, P208, DOI 10.1016/j.brainres.2010.10.096; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; TABAKOFF B, 1979, DRUG ALCOHOL DEPEN, V4, P87, DOI 10.1016/0376-8716(79)90043-7; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wagner AK, 2009, J NEUROCHEM, V108, P986, DOI 10.1111/j.1471-4159.2008.05840.x; Wallsten S., 2005, AEI BROOKINGS JOINT, P5; Wilcox MV, 2014, NEUROPSYCHOPHARMACOL, V39, P579, DOI 10.1038/npp.2013.230; Yan HQ, 2007, BRAIN RES, V1134, P171, DOI 10.1016/j.brainres.2006.11.087	67	24	24	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2014	31	20					1700	1710		10.1089/neu.2013.3286			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AP8BF	WOS:000342302200003	24934382	Green Published			2021-06-18	
J	Phelan, HA; Richter, AA; Scott, WW; Pruitt, JH; Madden, CJ; Rickert, KL; Wolf, SE				Phelan, Herb A.; Richter, Adam A.; Scott, William W.; Pruitt, Jeffrey H.; Madden, Christopher J.; Rickert, Kim L.; Wolf, Steven E.			Does Isolated Traumatic Subarachnoid Hemorrhage Merit a Lower Intensity Level of Observation Than Other Traumatic Brain Injury?	JOURNAL OF NEUROTRAUMA			English	Article						isolated; progression; sequelae; subarachnoid; traumatic	RISK	Evidence is emerging that isolated traumatic subarachnoid hemorrhage (ITSAH) may be a milder form of traumatic brain injury (TBI). If true, ITSAH may not benefit from intensive care unit (ICU) admission, which would, in turn, decrease resource utilization. We conducted a retrospective review of all TBI admissions to our institution between February 2010 and November 2012 to compare the presentation and clinical course of subjects with ITSAH to all other TBI. We then performed descriptive statistics on the subset of ITSAH subjects presenting with a Glasgow Coma Score (GCS) of 13-15. Of 698 subjects, 102 had ITSAH and 596 had any other intracranial hemorrhage pattern. Compared to all other TBI, ITSAH had significantly lower injury severity scores (p < 0.0001), lower head abbreviated injury scores (p < 0.0001), higher emergency department GCS (p < 0.0001), shorter ICU stays (p = 0.007), higher discharge GCS (p = 0.005), lower mortality (p = 0.003), and significantly fewer head computed tomography scans (p < 0.0001). Of those ITSAH subjects presenting with a GCS of 13-15 (n = 77), none underwent placement of an intracranial monitor or craniotomy. One subject (1.3%) demonstrated a change in exam (worsened headache and dizziness) concomitant with a progression of his intracranial injury. His symptoms resolved with readmission to the ICU and continued observation. Our results suggest that ITSAH are less-severe brain injuries than other TBI. ITSAH patients with GCS scores of 13-15 demonstrate low rates of clinical progression, and when progression occurs, it resolves without further intervention. This subset of TBI patients does not appear to benefit from ICU admission.	[Phelan, Herb A.; Wolf, Steven E.] Univ Texas SW Med Ctr Dallas, Dept Surg, Div Burns Trauma Crit Care, Parkland Mem Hosp, Dallas, TX 75390 USA; [Richter, Adam A.] Vanderbilt Univ Sch Med, Dept Surg, Div Vasc Surg, Nashville, TN USA; [Scott, William W.; Madden, Christopher J.; Rickert, Kim L.] Univ Texas SW Med Ctr Dallas, Dept Neurol Surg, Parkland Mem Hosp, Dallas, TX 75390 USA; [Pruitt, Jeffrey H.] Univ Texas SW Med Ctr Dallas, Dept Radiol, Parkland Mem Hosp, Dallas, TX 75390 USA	Phelan, HA (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Surg, Div Burns Trauma Crit Care, Parkland Mem Hosp, 5323 Harry Hines Blvd,E5-508A, Dallas, TX 75390 USA.	herb.phelan@utsouthwestern.edu		Wolf, Steven/0000-0003-2972-3440	UT Southwestern Clinical Translational Science Initiative - NIH [1 KL2 RR024983-01]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR001103] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR024983] Funding Source: NIH RePORTER	This work was supported by a pilot grant awarded by the UT Southwestern Clinical Translational Science Initiative, which is itself funded by NIH grant no. 1 KL2 RR024983-01 titled, "North and Central Texas Clinical and Translational Science Initiative" (Robert Toto MD, PI). This work was presented as a poster at the October 2013 Annual Meeting of the Neurocritical Care Society in Philadelphia, Pennsylvania.	AbdelFattah KR, 2012, J TRAUMA ACUTE CARE, V73, P685, DOI 10.1097/TA.0b013e318265ccd9; Borczuk P, 2013, J TRAUMA ACUTE CARE, V74, P1504, DOI 10.1097/TA.0b013e31829215cf; Levy AS, 2011, J TRAUMA, V71, P1199, DOI 10.1097/TA.0b013e31822067fc; Lin TK, 2012, J TRAUMA ACUTE CARE, V73, P131, DOI 10.1097/TA.0b013e31824aff74; Phelan HA, 2012, J TRAUMA ACUTE CARE, V73, pS122, DOI 10.1097/TA.0b013e3182606327; Quigley MR, 2013, J TRAUMA ACUTE CARE, V74, P581, DOI 10.1097/TA.0b013e31827d6088; Sander S., 1993, J NEUROL SCI, V119, P1	7	24	25	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2014	31	20					1733	1736		10.1089/neu.2014.3377			4	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AP8BF	WOS:000342302200006	24926612	Green Published			2021-06-18	
J	Donaldson, L; Li, B; Cusimano, MD				Donaldson, Laura; Li, Bing; Cusimano, Michael D.			Economic burden of time lost due to injury in NHL hockey players	INJURY PREVENTION			English	Article							LEAGUE PLAYERS; CONCUSSIONS; VIOLENCE	Objective To determine the economic burden of salary costs lost due to injury in the National Hockey League (NHL). Methods All NHL players who engaged in at least one regular season game during the 2009-2010 to 2011-2012 seasons comprised the study population. We performed a retrospective cross-sectional analysis of publically available media sources to collect injury and salary data. Outcome measurements were games missed during regular season play due to hockey-related injury and lost salary. Results A total of 50.9% of all NHL players missed at least one game within a season of play, and injuries represented a total salary cost of approximately US$ 218 million per year. Concussions alone amounted to a salary loss of US$ 42.8 million a year. Head/neck injuries and leg/foot injuries were the most expensive in terms of overall cost, while head/neck and shoulder injuries had the highest mean cost. Conclusions NHL players commonly miss time due to injury, which creates a substantial burden in lost salary costs.	[Donaldson, Laura; Cusimano, Michael D.] Univ Toronto, St Michaels Hosp, Div Neurosurg, Toronto, ON M5B 1W8, Canada; [Donaldson, Laura; Cusimano, Michael D.] Univ Toronto, St Michaels Hosp, Injury Prevent Res Off, Toronto, ON M5B 1W8, Canada; [Donaldson, Laura; Cusimano, Michael D.] Canadian Brain Injury & Violence Res Team, Toronto, ON, Canada; [Li, Bing] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON M5B 1W8, Canada	Cusimano, MD (corresponding author), Univ Toronto, St Michaels Hosp, Div Neurosurg, 30 Bond St, Toronto, ON M5B 1W8, Canada.	injuryprevention@smh.ca	Cusimano, Michael/X-4059-2019	Cusimano, Michael/0000-0002-9989-0650	Canadian Institutes of Health Research Strategic Team Grant in Applied Injury ResearchCanadian Institutes of Health Research (CIHR) [TIR-103946]; Ontario Neurotrauma Foundation; University of Toronto Faculty of Medicine CREMS funding	This research was supported by the Canadian Institutes of Health Research Strategic Team Grant in Applied Injury Research no. TIR-103946, the Ontario Neurotrauma Foundation, as well as University of Toronto Faculty of Medicine CREMS funding.	[Anonymous], 2011, THN COM; [Anonymous], 2012, NHL CONCUSSIONS PUT; [Anonymous], 2011, CANADIANS HOCKEY FAN; [Anonymous], 2010, NATIONAL HOCKEY LEAG; [Anonymous], 2011, NATIONAL HOCKEY LEAG; Caron JG, 2013, J SPORT EXERCISE PSY, V35, P168, DOI 10.1123/jsep.35.2.168; Daly B, 2012, CONCUSSION CLAIMS WO; Donaldson L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069122; Haisken-DeNew JP, 2008, RUHR ECONOMIC PAPERS, V47, P1; Hutchison MG, 2015, BRIT J SPORT MED, V49, P552, DOI 10.1136/bjsports-2013-092235; Jones JCH, 1996, AM J ECON SOCIOL, V55, P231, DOI 10.1111/j.1536-7150.1996.tb03203.x; Kennan HT, 1999, ARCH SURG-CHICAGO, V134, P14, DOI 10.1001/archsurg.134.1.14; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; Monette M, 2012, CAN MED ASSOC J, V184, pE641, DOI 10.1503/cmaj.109-4244; Orchard J., 2001, INT SPORTMED J, V2, P1; Pappachan B, 2006, J ORAL MAXIL SURG, V64, P1023, DOI 10.1016/j.joms.2006.03.021; Paul RJ, 2003, AM J ECON SOCIOL, V62, P345, DOI 10.1111/1536-7150.t01-2-00003; Schoalts D, 2011, NHL WONT EVEN CONSID; Stuart MJ, 2000, AM SOC TEST MATER, V1341, P19, DOI 10.1520/STP15224S; Wennberg RA, 2008, CAN J NEUROL SCI, V35, P647, DOI 10.1017/S031716710000946X	21	24	24	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	OCT	2014	20	5								10.1136/injuryprev-2013-041016			3	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	AQ0SL	WOS:000342492900012	24446078	Green Accepted			2021-06-18	
J	Prichep, LS; Dastidar, SG; Jacquin, A; Koppes, W; Miller, J; Radman, T; O'Neil, B; Naunheim, R; Huff, JS				Prichep, Leslie S.; Dastidar, Samanwoy Ghosh; Jacquin, Arnaud; Koppes, William; Miller, Jonathan; Radman, Thomas; O'Neil, Brian; Naunheim, Rosanne; Huff, J. Stephen			Classification algorithms for the identification of structural injury in TBI using brain electrical activity	COMPUTERS IN BIOLOGY AND MEDICINE			English	Article						TBI; Acute traumatic brain injury; Classifier algorithms; Genetic algorithms; Quantitative brain activity; Electrophysiology of TBI; TBI triage; Structural brain injury; CT plus TBI	NEW-ORLEANS CRITERIA; CT HEAD RULE; GENETIC ALGORITHMS; SEVERITY; SCALE; CONCUSSION; REDUCTION; RECOVERY	Background: There is an urgent need for objective criteria adjunctive to standard clinical assessment of acute Traumatic Brain Injury (TBI). Details of the development of a quantitative index to identify structural brain injury based on brain electrical activity will be described. Methods: Acute closed head injured and normal patients (n=1470) were recruited from 16 US Emergency Departments and evaluated using brain electrical activity (EEG) recorded from forehead electrodes. Patients had high GCS (median=15), and most presented with low suspicion of brain injury. Patients were divided into a CT positive (CT+) group and a group with CT negative findings or where CT scans were not ordered according to standard assessment (CT-/CT_NR). Three different classifier methodologies, Ensemble Harmony, Least Absolute Shrinkage and Selection Operator (LASSO), and Genetic Algorithm (GA), were utilized. Results: Similar performance accuracy was obtained for all three methodologies with an average sensitivity/specificity of 97.5%/59.5%, area under the curves (AUC) of 0.90 and average Negative Predictive Validity (NPV) > 99%. Sensitivity was highest for CT+ cases with potentially life threatening hematomas, where two of three classifiers were 100%. Conclusion: Similar performance of these classifiers suggests that the optimal separation of the populations was obtained given the overlap of the underlying distributions of features of brain activity. High sensitivity to CT+ injuries (highest in hematomas) and specificity significantly higher than that obtained using ED guidelines for imaging, supports the enhanced clinical utility of this technology and suggests the potential role in the objective, rapid and more optimal triage of TB! patients. Published by Elsevier Ltd.	[Prichep, Leslie S.] NYU, Sch Med, Dept Psychiat, Brain Res Labs, New York, NY USA; [Dastidar, Samanwoy Ghosh; Jacquin, Arnaud; Koppes, William; Miller, Jonathan; Radman, Thomas] BrainScope Co Inc, Algorithm Dev Dept, Bethesda, MD USA; [O'Neil, Brian] Wayne State Univ, Sch Med, Dept Emergency Med, Detroit, MI USA; [Naunheim, Rosanne; Huff, J. Stephen] Washington Univ, Sch Med, Div Emergency Med, St Louis, MO USA; [Huff, J. Stephen] Univ Virginia, Dept Emergency Med, Charlottesville, VA USA; [Huff, J. Stephen] Univ Virginia, Dept Neurol, Charlottesville, VA USA	Prichep, LS (corresponding author), Brain Res Labs, Old Bellevue Admin Bldg,8th Floor,462 First Ave, New York, NY 10016 USA.	Leslie.Prichep@nyumc.org			BrainScope Co., Inc., Bethesda Maryland	The authors acknowledge the contributions of those who made this research possible, including the primary investigators and research technicians at all the clinical sites and the patients who volunteered. The authors also acknowledge the contributions of Greg Mahowald and Julie Filipenko in support of the project. This research was supported by BrainScope Co., Inc., Bethesda Maryland who granted expenses related to data acquisition.	Baranauskas JA, 2003, KNOWL-BASED SYST, V16, P129, DOI 10.1016/S0950-7051(02)00021-7; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Duda O.R., 2001, PATTERN CLASSIFICATI; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fawcett T, 2006, PATTERN RECOGN LETT, V27, P861, DOI 10.1016/j.patrec.2005.10.010; Giza CC, 2001, J ATHL TRAINING, V36, P228; Hanley D.F., 2013, J NEUROTRAUMA; He BYJ, 2010, NEURON, V66, P353, DOI 10.1016/j.neuron.2010.04.020; Ibanez J, 2004, J NEUROSURG, V100, P825, DOI 10.3171/jns.2004.100.5.0825; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; JOHN ER, 1988, SCIENCE, V239, P162, DOI 10.1126/science.3336779; Laalo JP, 2009, J NEUROTRAUM, V26, P2169, DOI 10.1089/neu.2009.1011; Langlois J.A., 2006, J HEAD TRAUMA REHABI, V21; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Mitchell M., 1996, INTRO GENETIC ALGORI; Molina DK, 2007, J TRAUMA, V63, P625, DOI 10.1097/01.ta.0000236055.33085.77; Naunheim RS, 2011, AM J EMERG MED, V29, P845, DOI 10.1016/j.ajem.2010.03.010; Naunheim RS, 2010, BRAIN INJURY, V24, P1324, DOI 10.3109/02699052.2010.506862; O'Neil B, 2012, WEST J EMERG MED, V13, P394, DOI 10.5811/westjem.2011.12.6815; Oh IS, 2004, IEEE T PATTERN ANAL, V26, P1424, DOI 10.1109/TPAMI.2004.105; Opitz D., 1999, JAIR, V11, P169, DOI [DOI 10.1613/jair.614, DOI 10.1613/JAIR.614]; Polikar R., 2006, IEEE Circuits and Systems Magazine, V6, P21, DOI 10.1109/MCAS.2006.1688199; Prichep L., 1987, HDB ELECTROENCEPHALO, P449; Prichep LS, 2005, CLIN EEG NEUROSCI, V36, P82, DOI 10.1177/155005940503600207; Prichep LS, 2012, IEEE T NEUR SYS REH, V20, P806, DOI 10.1109/TNSRE.2012.2206609; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Raymer ML, 2000, IEEE T EVOLUT COMPUT, V4, P164, DOI 10.1109/4235.850656; Rokach L, 2010, ARTIF INTELL REV, V33, P1, DOI 10.1007/s10462-009-9124-7; Sakkalis V, 2011, COMPUT BIOL MED, V41, P1110, DOI 10.1016/j.compbiomed.2011.06.020; SIEDLECKI W, 1989, PATTERN RECOGN LETT, V10, P335, DOI 10.1016/0167-8655(89)90037-8; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Stiell I.G., 2000, ACAD EMERG MED, V7, P572; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Syswerda G., 1991, P 4 INT C GEN ALG, P502; TEASDALE G, 1974, LANCET, V2, P81; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; Thakor NV, 2004, ANNU REV BIOMED ENG, V6, P453, DOI 10.1146/annurev.bioeng.5.040202.121601; Thatcher RW, 1998, NEUROIMAGE, V7, P352, DOI 10.1006/nimg.1998.0330; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Tomassini M., 1999, EVOLUTIONARY ALGORIT; Turner K., 1996, P 13 INT C PATT REC, P25; Yang JH, 1998, IEEE INTELL SYST APP, V13, P44, DOI 10.1109/5254.671091	47	24	24	0	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0010-4825	1879-0534		COMPUT BIOL MED	Comput. Biol. Med.	OCT 1	2014	53						125	133		10.1016/j.compbiomed.2014.07.011			9	Biology; Computer Science, Interdisciplinary Applications; Engineering, Biomedical; Mathematical & Computational Biology	Life Sciences & Biomedicine - Other Topics; Computer Science; Engineering; Mathematical & Computational Biology	AR5HY	WOS:000343617000014	25137412				2021-06-18	
J	Chen, JW; Vakil-Gilani, K; Williamson, KL; Cecil, S				Chen, Jefferson William; Vakil-Gilani, Kiana; Williamson, Kay Lyn; Cecil, Sandy			Infrared pupillometry, the Neurological Pupil index and unilateral pupillary dilation after traumatic brain injury: implications for treatment paradigms	SPRINGERPLUS			English	Article						Infrared pupillometry; Neurological Pupil index; Traumatic third nerve palsy; Pupillometer; Oculomotor nerve palsy; Traumatic brain injury; Pupillary outcome	OCULOMOTOR NERVE PALSY; MILD HEAD-INJURY; QUANTITATIVE PUPILLOMETRY; CEREBRAL-ARTERY; NORMATIVE DATA; LIGHT REFLEX; 3RD; PUPILLOGRAPHY; RECOVERY; SEDATION	Pupillary dysfunction, a concerning finding in the neurologic examination of the patient with an acute traumatic brain injury often dictates the subsequent treatment paradigm. Patients were monitored closely with an infrared pupillometer, with NPi technology, for acute changes in pupillary function. NPi technology applies a scalar value to pupillary function. A retrospective chart review was performed of traumatic brain injury patients with acute unilateral pupillary dilation, admitted to Legacy Emanuel Medical Center's NeuroTrauma Unit, Portland, OR, and followed as outpatients, between January 2012 and December 2013. Clinical exam findings of pupillary size, NPi scores, and brain Magnetic Resonance Imaging and Computed Tomography images were analyzed. Five traumatic brain injury patients were identified with unilateral pupillary dysfunction with long-term follow-up after the initial injury. Each patient was monitored closely in the trauma bay for neurological deterioration with a pupillometer and the clinical exam. Two patients underwent subsequent intracranial pressure monitoring based on a deteriorating clinical scenario, including consistent abnormal unilateral NPi scores. One patient with consistent abnormal NPi scores and an improved clinical exam did not undergo invasive interventions. Two patients showed early improvement in NPi scores correlating with the normalization of their pupillary reactivity. Anisocoria improved in all patients despite concurrent abnormal NPi scores. Magnetic Resonance Imaging and Computed Tomography imaging studies, with a focus on the third nerve, revealed focal abnormalities consistent with the clinical findings. A unilateral blown pupil and abnormal NPi score in a traumatic brain injury patient are not necessarily indicative of intracranial pressure issues, and must be correlated with the entire clinical scenario, to determine the etiology of the third nerve injury and direct potential therapeutic interventions. Early NPi score normalization suggests pupillary function may improve. We found that NPi scores, as a component of the clinical exam, provide a sensitive, noninvasive and quantitative means of following pupillary function acutely and chronically after a traumatic brain injury.	[Chen, Jefferson William; Vakil-Gilani, Kiana; Williamson, Kay Lyn; Cecil, Sandy] Legacy Emanuel Med Ctr, Dept Neurol Surg, Portland, OR 97227 USA; [Chen, Jefferson William] Univ Calif Irvine, Dept Neurol Surg, Orange, CA 92868 USA	Chen, JW (corresponding author), Legacy Emanuel Med Ctr, Dept Neurol Surg, 2801 N Gantenbein Ave, Portland, OR 97227 USA.	jeffewc1@uci.edu	chen, jeff/AAR-7375-2020	chen, jeff/0000-0003-0624-6864			[Anonymous], 2010, TRAUMATIC BRAIN INJU; Behrends M, 2012, RESUSCITATION, V83, P1223, DOI 10.1016/j.resuscitation.2012.05.013; BELANI KG, 1993, ANESTHESIOLOGY, V79, P23, DOI 10.1097/00000542-199307000-00006; Bhatti MT, 2006, ARCH NEUROL-CHICAGO, V63, P771, DOI 10.1001/archneur.63.5.771; Boev AN, 2005, J NEUROSURG, V103, P496, DOI 10.3171/ped.2005.103.6.0496; Brazis PW, 2009, SEMIN NEUROL, V29, P14, DOI 10.1055/s-0028-1124019; Chaudhary N, 2009, J NEURO-OPHTHALMOL, V29, P238, DOI 10.1097/WNO.0b013e3181b415f4; Chen CC, 2005, BRIT J SPORT MED, V39, DOI 10.1136/bjsm.2004.016311; Chen Jeff W, 2011, Surg Neurol Int, V2, P82, DOI 10.4103/2152-7806.82248; CHESNUT RM, 1994, NEUROSURGERY, V34, P840, DOI 10.1227/00006123-199405000-00008; Du R, 2005, NEUROSURGERY, V57, P198, DOI 10.1227/01.NEU.0000163425.79170.CB; Fotiou F, 2000, CLIN PHYSIOL, V20, P336, DOI 10.1046/j.1365-2281.2000.00259.x; Fountas KN, 2006, NEUROCRIT CARE, V5, P55, DOI 10.1385/NCC:5:1:55; Garcia-Rivera CA, 2001, NEUROLOGY, V57, P1755, DOI 10.1212/WNL.57.10.1755; Guresir E, 2012, J NEUROSURG, V117, P904, DOI 10.3171/2012.8.JNS111239; Hallman MR., 2013, CURR ANESTHESIOL REP, V3, P89; HELLER PH, 1990, INVEST OPHTH VIS SCI, V31, P156; Hou RH, 2007, PSYCHOPHARMACOLOGY, V195, P41, DOI 10.1007/s00213-007-0884-y; Hults Kathryn N, 2006, J Neurosci Nurs, V38, P447; Kau HC, 2007, AM J OPHTHALMOL, V143, P280, DOI 10.1016/j.ajo.2006.10.035; Kim SC, 2009, J KOREAN NEUROSURG S, V45, P240, DOI 10.3340/jkns.2009.45.4.240; Kuo JR, 2011, J FORMOS MED ASSOC, V110, P258, DOI 10.1016/S0929-6646(11)60038-7; Kwon HG, 2013, J NEUROL NEUROSUR PS, V84, P1073, DOI 10.1136/jnnp-2013-305111; Larson MD, 1997, ANESTHESIOLOGY, V87, P849, DOI 10.1097/00000542-199710000-00019; LARSON MD, 1995, ARCH NEUROL-CHICAGO, V52, P369, DOI 10.1001/archneur.1995.00540280051018; Lee AG, 2009, CLIN EXP OPHTHALMOL, V37, P30, DOI 10.1111/j.1442-9071.2008.01822.x; Lieberman JD, 2003, J TRAUMA, V55, P437, DOI 10.1097/01.TA.0000081882.79587.17; Lin C, 2013, J NEUROSURG, V118, P364, DOI 10.3171/2012.9.JNS12702; Litvan I, 2000, NEUROLOGY, V54, P530, DOI 10.1212/WNL.54.2.530; LOWENSTEIN O, 1958, ARCH OPHTHALMOL-CHIC, V59, P352, DOI 10.1001/archopht.1958.00940040058007; Manley GT, 2002, J NEUROSURG ANESTH, V14, P223, DOI 10.1097/00008506-200207000-00009; Martinez-Ricarte F, 2013, NEUROLOGIA, V28, P41, DOI 10.1016/j.nrl.2010.07.028; Meeker Michele, 2005, J Neurosci Nurs, V37, P34; Motoyama Y, 2012, NEUROL MED-CHIR, V52, P202, DOI 10.2176/nmc.52.202; Murchison AP, 2011, ARCH OPHTHALMOL-CHIC, V129, P301, DOI 10.1001/archophthalmol.2011.25; Muthu P, 2001, EMERG MED J, V18, P310, DOI 10.1136/emj.18.4.310; Najafi MR, 2012, ARCH IRAN MED, V15, P583, DOI 012159/AIM.0015; Nistri M, 2007, J NEUROL NEUROSUR PS, V78, P197, DOI 10.1136/jnnp.2006.098129; Ortube MC, 2013, INVEST OPHTH VIS SCI, V54, P9, DOI 10.1167/iovs.12-10241; Prasad S, 2010, NEUROL CLIN, V28, P803, DOI 10.1016/j.ncl.2010.04.001; Pula JH, 2011, CURR OPIN OPHTHALMOL, V22, P451, DOI 10.1097/ICU.0b013e32834c46aa; Quisling SV, 2006, J NEURO-OPHTHALMOL, V26, P47, DOI 10.1097/01.wno.0000204660.41183.1b; Rebolleda G, 2013, ARCH SOC ESP OFTALMO, V88, P125, DOI [10.1016/j.oftal.2013.02.014, DOI 10.1016/J.0FTAL.2013.02.014]; Ritter AM, 1999, NEUROSURGERY, V44, P941, DOI 10.1097/00006123-199905000-00005; Rollins MD, 2014, ANESTHESIOLOGY, V121, P1037, DOI 10.1097/ALN.0000000000000384; Rosenberg JB, 2011, NEUROCRIT CARE, V15, P599, DOI 10.1007/s12028-011-9545-4; Rouche O, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-5; Sadagopan KA, 2013, CURR OPIN OPHTHALMOL, V24, P438, DOI 10.1097/ICU.0b013e3283645a9b; Saremi F, 2005, AM J ROENTGENOL, V185, P1487, DOI 10.2214/AJR.04.1518; Taylor WR, 2003, J NEUROSURG, V98, P205, DOI 10.3171/jns.2003.98.1.0205; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P583; Volpe NJ, 2000, OPHTHALMOLOGY, V107, P1913, DOI 10.1016/S0161-6420(00)00354-7; Wachler BSB, 1999, OPHTHALMOLOGY, V106, P319; Yanovitch T, 2007, CURR OPIN OPHTHALMOL, V18, P373, DOI 10.1097/ICU.0b013e328270b8db	54	24	24	0	5	SPRINGER INTERNATIONAL PUBLISHING AG	CHAM	GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND	2193-1801			SPRINGERPLUS	SpringerPlus	SEP 23	2014	3								548	10.1186/2193-1801-3-548			10	Multidisciplinary Sciences	Science & Technology - Other Topics	CO3WS	WOS:000359092500001	25332854	Other Gold, Green Published			2021-06-18	
J	Hosseini, B; Flora, DB; Banwell, BL; Till, C				Hosseini, Banafsheh; Flora, David B.; Banwell, Brenda L.; Till, Christine			Age of Onset as a Moderator of Cognitive Decline in Pediatric-Onset Multiple Sclerosis	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Pediatric multiple sclerosis; Longitudinal analysis; Processing speed; Working memory; Cognitive reserve; Age of onset	INFORMATION-PROCESSING SPEED; TRAUMATIC BRAIN-INJURY; PSYCHOSOCIAL FEATURES; WORKING-MEMORY; JUVENILE MS; CHILDREN; RESERVE; CHILDHOOD; EFFICIENCY; ADOLESCENTS	Cognitive impairment is often reported in pediatric-onset multiple sclerosis (MS). Using serial cognitive data from 35 individuals with pediatric-onset MS, this study examined how age at disease-onset and proxies of cognitive reserve may impact cognitive maturation over the course of childhood and adolescence. Neuropsychological evaluations were conducted at baseline and up to four more assessments. Of the 35 participants, 7 completed only one assessment, 5 completed two assessments, 13 completed three assessments, 10 completed four or more assessments. Growth curve modeling was used to assess longitudinal trajectories on the Trail Making Test-Part B (TMT-B) and the Symbol Digit Modalities (SDMT; oral version) and to examine how age at disease onset, baseline Full Scale IQ, and social status may moderate rate of change on these measures. Mean number of evaluations completed per patient was 2.8. Younger age at disease onset was associated with a greater likelihood of cognitive decline on both the TMT-B (p = .001) and SDMT (p = .005). Baseline IQ and parental social status did not moderate any of the cognitive trajectories. Findings suggest that younger age at disease-onset increases the vulnerability for disrupted performance on measures of information processing, visual scanning, perceptual/motor speed, and working memory. Proxies of cognitive reserve did not protect against the progression of decline on these measures. Young patients with MS should be advised to seek follow-up cognitive evaluation to assess cognitive maturation and to screen for the potential late emergence of cognitive deficits. (JINS, 2014, 20, 796-804)	[Hosseini, Banafsheh; Flora, David B.; Till, Christine] York Univ, Dept Psychol, Toronto, ON M3J 1P3, Canada; [Banwell, Brenda L.; Till, Christine] Hosp Sick Children, Neurosci & Mental Hlth Program, Toronto, ON M5G 1X8, Canada; [Banwell, Brenda L.] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA	Till, C (corresponding author), York Univ, Dept Psychol, 4700 Keele St, Toronto, ON M3J 1P3, Canada.	ctill@yorku.ca		Till, Christine/0000-0001-5030-3155	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Multiple Sclerosis Society of Canada; Scottish Rite Charitable Foundation	This study was supported in part by the Canadian Institutes of Health Research, the Multiple Sclerosis Society of Canada, and the Scottish Rite Charitable Foundation. We thank Emily Ursell, Courtney Fair-brother, Julie Coleman and Austin Sye for assistance with recruitment and testing of research participants. We also thank the children and families who generously contributed their time to this research. The authors of this study declare no conflicts of interest.	Amato MP, 2008, NEUROLOGY, V70, P1891, DOI 10.1212/01.wnl.0000312276.23177.fa; Amato MP, 2010, NEUROLOGY, V75, P1134, DOI 10.1212/WNL.0b013e3181f4d821; Anderson V, 2010, J PEDIATR PSYCHOL, V35, P716, DOI 10.1093/jpepsy/jsp100; Archibald CJ, 2000, J CLIN EXP NEUROPSYC, V22, P686, DOI 10.1076/1380-3395(200010)22:5;1-9;FT686; Banwell BL, 2005, NEUROLOGY, V64, P891, DOI 10.1212/01.WNL.0000152896.35341.51; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Barratt W., 2006, BARRATT SIMPLI UNPUB; Benedict RHB, 2008, MULT SCLER J, V14, P940, DOI 10.1177/1352458508090923; Benedict RHB, 2010, J INT NEUROPSYCH SOC, V16, P829, DOI 10.1017/S1355617710000688; Boiko A, 2002, NEUROLOGY, V59, P1006, DOI 10.1212/WNL.59.7.1006; DeLuca J, 2004, J CLIN EXP NEUROPSYC, V26, P550, DOI 10.1080/13803390490496641; Demaree HA, 1999, J NEUROL NEUROSUR PS, V67, P661, DOI 10.1136/jnnp.67.5.661; Dennis M., 2006, COGNITIVE RESERVE TH, P53; Drew MA, 2009, ARCH CLIN NEUROPSYCH, V24, P47, DOI 10.1093/arclin/acp007; Farmer JE, 2002, DEV NEUROPSYCHOL, V22, P455, DOI 10.1207/S15326942DN2202_2; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Ghezzi A, 1997, MULT SCLER, V3, P43, DOI 10.1177/135245859700300105; Hart SA, 2007, INTELLIGENCE, V35, P233, DOI 10.1016/j.intell.2006.08.004; Holland AA, 2014, CHILD NEUROPSYCHOL, V20, P71, DOI 10.1080/09297049.2012.748888; Kesler SR, 2010, BRAIN IMAGING BEHAV, V4, P256, DOI 10.1007/s11682-010-9104-1; Krupp LB, 2007, NEUROLOGY, V68, pS7, DOI 10.1212/01.wnl.0000259422.44235.a8; Leavitt VM, 2011, J CLIN EXP NEUROPSYC, V33, P580, DOI 10.1080/13803395.2010.541427; MacAllister WS, 2007, DEV NEUROPSYCHOL, V32, P625, DOI 10.1080/87565640701375872; MacAllister WS, 2005, NEUROLOGY, V64, P1422, DOI 10.1212/01.WNL.0000158474.24191.BC; Marin SE, 2013, J CHILD NEUROL, V28, P1577, DOI 10.1177/0883073812465010; Marrie RA, 2008, MULT SCLER J, V14, P1091, DOI 10.1177/1352458508092263; Portaccio E, 2009, MULT SCLER J, V15, P620, DOI 10.1177/1352458508101950; Reitan R, 1959, MANUAL ADM SCORING T; Sanchez-Cubillo I, 2009, J INT NEUROPSYCH SOC, V15, P438, DOI 10.1017/S1355617709090626; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Singer J.D., 2003, APPL LONGITUDINAL DA; Smith A., 2002, SYMBOL DIGIT MODALIT; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Sumowski JF, 2010, BRAIN, V133, P362, DOI 10.1093/brain/awp307; Sumowski JF, 2009, J INT NEUROPSYCH SOC, V15, P606, DOI 10.1017/S1355617709090912; Till C, 2012, ARCH CLIN NEUROPSYCH, V27, P495, DOI 10.1093/arclin/acs058; Till C, 2011, NEUROPSYCHOLOGY, V25, P319, DOI 10.1037/a0022051; Till C, 2013, NEUROPSYCHOLOGY, V27, P210, DOI 10.1037/a0031665; Wechsler D., 1991, WISC 3 WECHSLER INTE; Wechsler D, 1997, WAIS 3 ADM SCORING M; WEISS LG, 1999, CANADIAN J SCH PSYCH, V14, P1, DOI DOI 10.1177/082957359901400202	42	24	25	0	7	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2014	20	8					796	804		10.1017/S1355617714000642			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	AT4ZB	WOS:000344951500003	25033163				2021-06-18	
J	Maestas, KL; Sander, AM; Clark, AN; van Veldhoven, LM; Struchen, MA; Sherer, M; Hannay, HJ				Maestas, Kacey Little; Sander, Angelle M.; Clark, Allison N.; van Veldhoven, Laura M.; Struchen, Margaret A.; Sherer, Mark; Hannay, H. Julia			Preinjury Coping, Emotional Functioning, and Quality of Life Following Uncomplicated and Complicated Mild Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						anxiety; cluster analysis; coping behavior; coping skills; depression; emotional disturbances; quality of life; rehabilitation; traumatic brain injury	CLUSTER-ANALYTIC APPROACH; SPINAL-CORD-INJURY; BREAST-CANCER; HEAD-INJURY; STRESS-DISORDER; SOCIAL SUPPORT; RISK-FACTORS; MONTE-CARLO; DEPRESSION; ADJUSTMENT	Objective: To identify preinjury coping profiles among adults with uncomplicated mild traumatic brain injury (mTBI) and complicated mTBI and to determine whether preinjury coping profiles contribute to the prediction of emotional functioning and quality of life (QOL) 3 months post-mTBI. Participants: One hundred eighty-seven persons with medically documented mTBI (uncomplicated mTBI, n = 89; complicated mTBI, n = 98) were recruited from the emergency center of a level I trauma center and followed in community 3 months post-mTBI. Measures: The Ways of Coping Questionnaire was administered within 2 weeks of injury. Cluster analysis was used to group participants on basis of their preinjury use of problem-focused and avoidant coping strategies. The Brief Symptom Inventory and the 36-item Short-Form Health Survey were administered 3 months postinjury. Results: Cluster analysis distinguished 3 distinct preinjury coping profiles that were differentially associated with outcomes. Participants who used avoidant coping showed the worse emotional functioning and QOL outcomes, although this cluster also reported high usage of problem-focused strategies. Preinjury coping profiles explained a significant proportion of the variance in depression, anxiety, and mental health QOL at 3 months postinjury beyond that accounted for by demographic characteristics andmTBI severity. Conclusions: Cluster analysis holds practical value in illustrating the pattern of coping strategies used by person with uncomplicated and complicated mTBI. It appears worthwhile to address coping in future trials of interventions that are aimed at improving emotional functioning after mTBI.	[Maestas, Kacey Little; Clark, Allison N.; van Veldhoven, Laura M.; Struchen, Margaret A.; Sherer, Mark] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77019 USA; [Maestas, Kacey Little; Sander, Angelle M.; Clark, Allison N.; van Veldhoven, Laura M.; Struchen, Margaret A.; Sherer, Mark] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX USA; [Sander, Angelle M.] Univ Houston, Dept Phys Med & Rehabil, Houston, TX USA; [Hannay, H. Julia] Univ Houston, Dept Neurosurg, Houston, TX USA; [Hannay, H. Julia] Univ Houston, Baylor Coll Med Harris Hlth Syst, Houston, TX USA; [Hannay, H. Julia] Univ Houston, Dept Psychol, Houston, TX USA	Maestas, KL (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 2323 S Shepherd Dr,Ste 907, Houston, TX 77019 USA.	kacey.maestas@memorialhermann.org		Hannay, H. Julia/0000-0001-7023-912X	National Institute on Disability and Rehabilitation Research, US Department of EducationUS Department of Education [H133P080007, H133B990014, H133B090023, H133A070043]	This work was supported in part by grants from the National Institute on Disability and Rehabilitation Research, US Department of Education (grant nos. H133P080007, H133B990014, H133B090023, and H133A070043).	Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Backhaus SL, 2010, ARCH PHYS MED REHAB, V91, P840, DOI 10.1016/j.apmr.2010.03.015; BOMBARDIER CH, 1990, BEHAV RES THER, V28, P297, DOI 10.1016/0005-7967(90)90081-S; Broomhall LGJ, 2009, J NERV MENT DIS, V197, P178, DOI 10.1097/NMD.0b013e318199fe7f; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Centers for Disease Control and Prevention, 2003, NAT CTR INJ PREV CON; Clatworthy J, 2005, BRIT J HEALTH PSYCH, V10, P329, DOI 10.1348/135910705X25697; Clatworthy J, 2007, PSYCHOL HEALTH, V22, P123, DOI 10.1080/14768320600774496; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; Dawson DR, 2006, BRAIN COGNITION, V60, P214; Derogatis L, 1993, BRIEF SYMPTOM INVENT; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Finset A, 2000, BRAIN INJURY, V14, P887; FOLKMAN S, 1980, J HEALTH SOC BEHAV, V21, P219, DOI 10.2307/2136617; Folkman S., 1988, MANUAL WAYS COPING Q; FRANK RG, 1987, J CONSULT CLIN PSYCH, V55, P727; Hack TF, 1999, BREAST CANCER RES TR, V54, P185, DOI 10.1023/A:1006145504850; Hack TF, 2004, PSYCHO-ONCOL, V13, P235, DOI 10.1002/pon.739; Hamilton JB, 2011, J PAIN SYMPTOM MANAG, V41, P79, DOI 10.1016/j.jpainsymman.2010.04.013; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Hsieh MY, 2012, NEUROPSYCHOL REHABIL, V22, P585, DOI 10.1080/09602011.2012.678860; Krpan KM, 2007, J CLIN EXP NEUROPSYC, V29, P36, DOI 10.1080/13803390500376816; Krpan KM, 2011, BRAIN INJURY, V25, P989, DOI 10.3109/02699052.2011.597045; Krpan KM, 2011, J INT NEUROPSYCH SOC, V17, P248, DOI 10.1017/S1355617710001499; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Lazarus R.S., 1984, STRESS APPRAISAL COP; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrea M, 2008, MILD TRAUMATIC BRAIN; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; MILLIGAN GW, 1981, MULTIVAR BEHAV RES, V16, P379, DOI 10.1207/s15327906mbr1603_7; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Moore A D, 1989, Brain Inj, V3, P171, DOI 10.3109/02699058909004549; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018; Panayiotou A, 2010, J CLIN EXP NEUROPSYC, V32, P463, DOI 10.1080/13803390903164371; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Rutskij R, 2010, PSYCHOL HEALTH MED, V15, P146, DOI 10.1080/13548501003623955; Shapiro DE, 1997, J PSYCHOSOM RES, V43, P143, DOI 10.1016/S0022-3999(97)80001-3; SHAPIRO DE, 1994, J PSYCHOSOM RES, V38, P151, DOI 10.1016/0022-3999(94)90088-4; Snell DL, 2011, BRAIN INJURY, V25, P1126, DOI 10.3109/02699052.2011.607786; Strom TQ, 2007, BRAIN INJURY, V21, P1137, DOI 10.1080/02699050701687334; Tomberg T, 2007, BRAIN INJURY, V21, P479, DOI 10.1080/02699050701311737; Trask PC, 2004, J PSYCHOSOM RES, V57, P287, DOI 10.1016/j.jpsychores.2004.01.005; van Leeuwen CMC, 2012, SPINAL CORD, V50, P174, DOI 10.1038/sc.2011.120; van Veldhoven LM, 2011, J NEUROL NEUROSUR PS, V82, P782, DOI 10.1136/jnnp.2010.228254; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE., 1994, SF 36 PHYS MENTAL HL, V1st; Willebrand M, 2002, BURNS, V28, P549, DOI 10.1016/S0305-4179(02)00064-5; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wolters G, 2011, J HEAD TRAUMA REHAB, V26, P150, DOI 10.1097/HTR.0b013e3181e421dc; Zasler N, 2007, BRAIN INJURY MED PRI	64	24	24	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2014	29	5					407	417		10.1097/HTR.0b013e31828654b4			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AP2GW	WOS:000341891700009	23535388				2021-06-18	
J	Ohnishi, M; Monda, A; Takemoto, R; Fujimoto, Y; Sugitani, M; Iwamura, T; Hiroyasu, T; Inoue, A				Ohnishi, Masatoshi; Monda, Ayaka; Takemoto, Ryoko; Fujimoto, Yukina; Sugitani, Mitsumasa; Iwamura, Takahiro; Hiroyasu, Takashi; Inoue, Atsuko			High-mobility group box 1 up-regulates aquaporin 4 expression via microglia-astrocyte interaction	NEUROCHEMISTRY INTERNATIONAL			English	Article						Aquaporin 4; Astrocyte; High-mobility group box 1; Interleukin-1 beta; Microglia; Nuclear factor-kappa B	TRAUMATIC BRAIN-INJURY; C-DEPENDENT PATHWAY; INTRACEREBRAL HEMORRHAGE; CHROMATIN PROTEIN; WATER CHANNELS; IN-VITRO; EDEMA; RAT; HMGB1; MICE	To clarify the mechanism of high-mobility group box (HMGB) 1-induced brain edema formation, this study focused on the effect of HMGB1 on aquaporin (AQP) 4, a water channel, in rat brain. Treatments for 6 h with 100-1000 ng/ml HMGB1, not showing self-toxicity, of primary-cultured rat astrocytes didnot increase AQP4 mRNA, unexpectedly. In contrast, intracerebroventricular (i.c.v.) injection of 300 ng of HMGB1 significantly increased AQP4 protein after 8 h and formed edema after 24 h in vivo. Thus, we investigated the roles of microglia as well as astrocytes. HMGB1 (1000 ng/ml) drastically increased interleukin (IL)-1 beta in the primary-cultured rat microglia after 2 h. The exposure of microglia to conditioned medium with HMGB1 and 3 mM adenosine 5'-triphosphate for 6 h significantly increased AQP4 mRNA in astrocytes after 6 h. Although 1000 ng/ml HMGB1 didnot induce transfer of nuclear factor (NF)-kappa B into the nucleus in astrocytes after 1 h, the conditioned medium containing IL-1 beta led to its nuclear import. As factors likely to be involved in the nuclear import of NF-kappa B besides IL-1 beta, nitric oxide and tumor necrosis factor-alpha didnot contribute under these conditions. Finally, i.c.v. injection of 30 nmol parthenolide, an NF-kappa B inhibitor, reversed 300 ng of HMGB1 injection-induced AQP4 protein increase after 8 h in vivo. The effect of parthenolide and the outcomes obtained so far suggest that HMGB1 indirectly up-regulates AQP4 expression through diffusible factor(s) such as IL-1 beta from microglia since HMGB1 by itself didnot affect NF-kappa B intracellular localization in astrocytes. (C) 2014 Elsevier Ltd. All rights reserved.	[Ohnishi, Masatoshi; Monda, Ayaka; Takemoto, Ryoko; Fujimoto, Yukina; Sugitani, Mitsumasa; Iwamura, Takahiro; Hiroyasu, Takashi; Inoue, Atsuko] Fukuyama Univ, Fac Pharm & Pharmaceut Sci, Dept Pharmacotherapeut, Fukuyama, Hiroshima 7290292, Japan	Ohnishi, M (corresponding author), Fukuyama Univ, Fac Pharm & Pharmaceut Sci, Dept Pharmacotherapeut, 985-1 Sanzo,Higashimura Cho, Fukuyama, Hiroshima 7290292, Japan.	ohnishi@fupharm.fukuyama-u.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)	This work was supported by the Strategic Support Project of Research Infrastructure Formation for Private Universities from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; Bianchi ME, 2005, CURR OPIN GENET DEV, V15, P496, DOI 10.1016/j.gde.2005.08.007; Castaneyra-Ruiz L, 2013, FLUIDS BARRIERS CNS, V10, DOI 10.1186/2045-8118-10-18; Fazzina G, 2010, J NEUROTRAUM, V27, P453, DOI 10.1089/neu.2008.0782; Gea-Sorli S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041933; Hu HC, 2011, J SURG RES, V168, pE181, DOI 10.1016/j.jss.2011.02.019; Inoue A, 2012, J MOL NEUROSCI, V48, P541, DOI 10.1007/s12031-012-9747-z; Ishibashi K, 2009, CLIN EXP NEPHROL, V13, P107, DOI 10.1007/s10157-008-0118-6; Ito H, 2006, J NEUROCHEM, V99, P107, DOI 10.1111/j.1471-4159.2006.04036.x; Laird MD, 2013, GLIA; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Leclerc P, 2013, SCAND J IMMUNOL, V77, P350, DOI 10.1111/sji.12041; Lo Pizzo M, 2013, NEUROL SCI, V34, P1309, DOI 10.1007/s10072-012-1233-4; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Muller S, 2001, EMBO J, V20, P4337, DOI 10.1093/emboj/20.16.4337; Ohnishi M, 2013, NEUROSCIENCE, V232, P45, DOI 10.1016/j.neuroscience.2012.11.057; Ohnishi M, 2007, EXP NEUROL, V206, P43, DOI 10.1016/j.expneurol.2007.03.030; Ohnishi M, 2011, NEUROPHARMACOLOGY, V61, P975, DOI 10.1016/j.neuropharm.2011.06.026; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; Papadopoulos MC, 2013, NAT REV NEUROSCI, V14, P265, DOI 10.1038/nrn3468; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; Rash JE, 1998, P NATL ACAD SCI USA, V95, P11981, DOI 10.1073/pnas.95.20.11981; Sanchez JF, 2003, MOL CELL BIOL, V23, P4649, DOI 10.1128/MCB.23.13.4649-4662.2003; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Spooren A, 2011, BIOCHEM PHARMACOL, V81, P1004, DOI 10.1016/j.bcp.2011.01.019; Taguchi T, 2006, J ENDOCRINOL, V188, P321, DOI 10.1677/joe.1.06418; Tang YP, 2007, J MOL NEUROSCI, V31, P83, DOI 10.1007/BF02686120; Tourdias T, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-143; Unemura K, 2012, J PHARMACOL SCI, V119, P30, DOI 10.1254/jphs.12047FP; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Zhou Y, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/142458; Zhu SM, 2009, ANESTH ANALG, V109, P1493, DOI 10.1213/ANE.0b013e3181b893f3	33	24	24	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	SEP	2014	75						32	38		10.1016/j.neuint.2014.05.007			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	AN8JZ	WOS:000340851800005	24893328				2021-06-18	
J	Zhang, DD; Li, H; Li, T; Zhou, ML; Hao, SY; Yan, HY; Yu, Z; Li, W; Li, KY; Hang, CH				Zhang, Dingding; Li, Hua; Li, Tao; Zhou, Mengliang; Hao, Shuangying; Yan, Huiying; Yu, Zhuang; Li, Wei; Li, Kuanyu; Hang, Chunhua			TLR4 inhibitor resatorvid provides neuroprotection in experimental traumatic brain injury: Implication in the treatment of human brain injury	NEUROCHEMISTRY INTERNATIONAL			English	Article						Traumatic brain injury; Toll-like receptor 4; Resatorvid; Apoptosis	NEURONAL DEATH; RECEPTOR 4; TAK-242; TAK1; RATS; PATHWAY; ACTIVATION; MICE	Toll-like receptor 4 (TLR4) is considered to play an important role in neuronal death in animal models and could be an important therapeutic target following traumatic brain injury (TBI). Resatorvid is a small molecule, commonly accepted to inhibit TLR4-mediated pathway. The purpose of this study was to investigate the neuroprotective effect of resatorvid after TBI. Our data revealed that inhibition of TLR4 by resatorvid attenuated the development of TBI in mouse model. And we found that resatorvid administration dramatically reduced neuronal apoptosis. To investigate the cellular mechanism, we evaluated the expression of transforming growth factor-beta-activated kinase 1 (TAK1), which plays a crucial role in TLR4 signal transduction pathway and is activated by phosphorylation in response to TBI. In addition, enzyme-linked immunosorbent assay was used to determine the expression of tumor necrosis factor-alpha (TNF-alpha) and interlukin-1 beta (IL-1 beta) at 24 h after injury. Our results showed that resatorvid treatment significantly reduced the protein levels of TAK1, p-TAK1, TNF-alpha, and IL-1 beta compared with vehicle treatment. Importantly, the delayed therapy (4 h post injury) once daily consecutively for 5 days ameliorated brain damage and improved neurological recovery, suggesting that this drug has a wide therapeutic time window. Clinically, we observed that TLR4 and TAK1 expression was significantly increased in human contusion specimens after TBI. These data provide an experimental rationale for the evaluation of TLR4 as a clinical target and therapeutic implication of resatorvid in human traumatic brain injury. (C) 2014 Elsevier Ltd. All rights reserved.	[Zhang, Dingding; Li, Hua; Li, Tao; Zhou, Mengliang; Yan, Huiying; Yu, Zhuang; Li, Wei; Hang, Chunhua] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China; [Hao, Shuangying; Li, Kuanyu] Nanjing Univ, Sch Med, Jiangsu Key Lab Mol Med, Nanjing 210093, Jiangsu, Peoples R China	Li, KY (corresponding author), Nanjing Univ, Sch Med, Jiangsu Key Lab Mol Med, 22 Hankou Rd, Nanjing 210093, Jiangsu, Peoples R China.	likuanyu@nju.edu.cn; hang_neurosurgery@163.com	Li, Kuanyu/AAL-2051-2020	Li, Hua/0000-0001-5893-535X; Zhou, Meng-liang/0000-0002-1165-5489	National Natural Science Foundation, ChinaNational Natural Science Foundation of China (NSFC) [81171170, 31071085, 31371060]; Nature Science Foundation of the Jiangsu Province, China [BK2010459]	This study was supported by the National Natural Science Foundation, China (Nos. 81171170, 31071085, 31371060) and the Nature Science Foundation of the Jiangsu Province, China (BK2010459).	Adeleye A, 2010, EUR J PHARMACOL, V629, P25, DOI 10.1016/j.ejphar.2009.11.066; Adhikari A, 2007, ONCOGENE, V26, P3214, DOI 10.1038/sj.onc.1210413; Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Chen CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030294; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Goldmann T, 2013, NAT NEUROSCI, V16, P1618, DOI 10.1038/nn.3531; Ii M, 2006, MOL PHARMACOL, V69, P1288, DOI 10.1124/mol.105.019695; Kabadi SV, 2012, NEUROTHERAPEUTICS, V9, P405, DOI 10.1007/s13311-011-0095-4; Kawamoto T, 2008, EUR J PHARMACOL, V584, P40, DOI 10.1016/j.ejphar.2008.01.026; Klatt AR, 2006, BIOMED PHARMACOTHER, V60, P55, DOI 10.1016/j.biopha.2005.08.007; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Li W, 2014, MOL NEUROBIOL, V49, P187, DOI 10.1007/s12035-013-8509-4; Maas AIR, 2004, ACT NEUR S, V89, P113; Mao SS, 2012, J NEUROTRAUM, V29, P1941, DOI 10.1089/neu.2011.2244; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Matsunaga N, 2011, MOL PHARMACOL, V79, P34, DOI 10.1124/mol.110.068064; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Rice TW, 2010, CRIT CARE MED, V38, P1685, DOI 10.1097/CCM.0b013e3181e7c5c9; Sakurai H, 2012, TRENDS PHARMACOL SCI, V33, P522, DOI 10.1016/j.tips.2012.06.007; Sha T, 2007, EUR J PHARMACOL, V571, P231, DOI 10.1016/j.ejphar.2007.06.027; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Suzuki Y, 2012, SCI REP-UK, V2, DOI 10.1038/srep00896; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Vassar M. J., 2013, J NEUROTRAUMA; Wang YC, 2013, STROKE, V44, P2545, DOI 10.1161/STROKEAHA.113.001038; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Zhang D, 2013, NEUROSCIENCE, V238, P209, DOI 10.1016/j.neuroscience.2013.02.022; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511	30	24	30	1	21	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	SEP	2014	75						11	18		10.1016/j.neuint.2014.05.003			8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	AN8JZ	WOS:000340851800002	24858944				2021-06-18	
J	Kirschen, MP; Tsou, A; Nelson, SB; Russell, JA; Larriviere, D				Kirschen, Matthew P.; Tsou, Amy; Nelson, Sarah Bird; Russell, James A.; Larriviere, Daniel		Ethics Law Humanities Comm	Legal and ethical implications in the evaluation and management of sports-related concussion	NEUROLOGY			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; HIGH-SCHOOL; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; POSITION STATEMENT; BRAIN-INJURY; RISK; CARE; EPIDEMIOLOGY; CHILDREN	Objective: To examine the ethical and legal issues physicians face when evaluating and managing athletes with sports-related concussions, and to offer guidance to physicians as they navigate these situations. Results: This position paper reviews and compares the components of sports-related concussion laws, including education, removal from play, and clearance for return to play. It highlights the challenges privacy laws present relevant to providing care to concussed athletes and suggests ways to help physicians overcome these obstacles. The report also explores the ethical considerations physicians should bear in mind as they evaluate and manage concussed athletes, addressing them through a framework that includes considerations of professionalism, informed decision-making, patient autonomy, beneficence, nonmaleficence, conflicts of interest, and distributive justice. Conclusions: Physicians caring for concussed athletes have an ethical obligation to ensure that their primary responsibility is to safeguard the current and future physical and mental health of their patients. Physicians have a duty to provide athletes and their parents with information about concussion risk factors, symptoms, and the risks for postconcussion neurologic impairments. Physicians should facilitate informed and shared decision-making among athletes, parents, and medical teams while protecting athletes from potential harm. Additionally, including concussion evaluation and management training in neurology residency programs, as well as developing a national concussion registry, will benefit patients by the development of policies and clinical guidelines that optimize prevention and treatment of concussive head injury.	[Kirschen, Matthew P.] Univ Penn, Perelman Sch Med, Dept Pediat, Div Neurol, Philadelphia, PA 19104 USA; [Kirschen, Matthew P.] Univ Penn, Perelman Sch Med, Dept Anesthesia & Crit Care Med, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Tsou, Amy] Emergency Care Res Inst, Plymouth, PA USA; [Tsou, Amy] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA; [Nelson, Sarah Bird] Amer Acad Neurol, Minneapolis, MN USA; [Russell, James A.] Tufts Univ, Sch Med, Lahey Clin, Dept Neurol, Boston, MA 02111 USA; [Larriviere, Daniel] Ochsner Med Ctr, Ochner Neurosci Inst, New Orleans, LA USA	Kirschen, MP (corresponding author), Univ Penn, Perelman Sch Med, Dept Pediat, Div Neurol, Philadelphia, PA 19104 USA.	kirschenm@chop.edu	Larriviere, Daniel G/N-7786-2013	Tsou, Amy/0000-0002-5544-3090			American Academy of Neurology, 2012, SPORTS NEUR SURV FIN; Arora S, 2011, NEW ENGL J MED, V364, P2199, DOI 10.1056/NEJMoa1009370; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Beauchamp TL., 2009, PRINCIPLES BIOMEDICA, V7; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Dahodwala N, 2009, ANN NEUROL, V66, P142, DOI 10.1002/ana.21774; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gavett BE, 2011, CURR OPIN NEUROL, V24, P525, DOI 10.1097/WCO.0b013e32834cd477; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hollis SJ, 2009, AM J SPORT MED, V37, P2328, DOI 10.1177/0363546509341032; Institute of Medicine, 2013, SPORTS REL CONC YOUT; Joynt KE, 2011, JAMA-J AM MED ASSOC, V306, P45, DOI 10.1001/jama.2011.902; Judd T, 2009, ARCH CLIN NEUROPSYCH, V24, P127, DOI 10.1093/arclin/acp016; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; Kimball MM, 2014, J STROKE CEREBROVASC, V23, P17, DOI 10.1016/j.jstrokecerebrovasdis.2012.06.004; KOHRMAN A, 1995, PEDIATRICS, V95, P314; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pennington B., 2008, NEW YORK TIMES; Shuttleworth-Rdwards AB, 2008, ARCH CLIN NEUROPSYCH, V23, P511, DOI 10.1016/j.acn.2008.05.002; Talavage TM, 2013, J NEUROTRAUM, V30, P1; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Watanabe T, 2010, PM&R, V2, P671, DOI 10.1016/j.pmrj.2010.06.002; WEITHORN LA, 1982, CHILD DEV, V53, P1589, DOI 10.2307/1130087	38	24	24	0	38	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JUL 22	2014	83	4					352	358		10.1212/WNL.0000000000000613			7	Clinical Neurology	Neurosciences & Neurology	AM9YH	WOS:000340236500017	25008394	Bronze			2021-06-18	
J	Zupan, B; Neumann, D				Zupan, Barbra; Neumann, Dawn			Affect Recognition in Traumatic Brain Injury: Responses to Unimodal and Multimodal Media	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						affect recognition; media; multimodal; traumatic brain injury; unimodal	FACIAL AFFECT RECOGNITION; EMOTION RECOGNITION; HEAD-INJURY; PERCEPTION; EXPRESSION; COMMUNICATION; DEFICITS; FACES; COMPREHENSION; IMPAIRMENTS	Objectives: To compare affect recognition by people with and without traumatic brain injury (TBI) for (1) unimodal and context-enriched multimodal media; (2) positive (happy) and negative emotions; and (3) neutral multimodal stimuli. Participants: A total of 60 people with moderate to severe TBI and 60 matched controls. Measures: (1) facial affect, (2) vocal affect, and (3) multimodal affect. Results: Compared with controls, people with TBI scored significantly lower on both unimodal measures but not on the multimodal measure. Within-group comparisons for people with TBI revealed that they were better at recognizing affect from multimodal than unimodal stimuli. As a group, participants with TBI who were categorized as having impaired facial/vocal affect recognition were less accurate at recognizing all emotions, including happy, than unimpaired participants. Neutral stimuli were more poorly identified by participants with TBI than by those with controls. Conclusion: Context-enriched multimodal stimuli may enhance affect recognition for people with TBI. People with TBI who have impaired affect recognition may have problems identifying both positive (happy) and negative expressions. Furthermore, people with TBI may perceive affect when there is none.	[Zupan, Barbra] Brock Univ, Dept Appl Linguist, St Catharines, ON L2S 3A1, Canada; [Neumann, Dawn] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indiana, PA USA; [Neumann, Dawn] Rehabil Hosp Indiana, Indiana, PA USA	Zupan, B (corresponding author), Brock Univ, Dept Appl Linguist, 500 Glenridge Ave, St Catharines, ON L2S 3A1, Canada.	bzupan@brocku.ca		Barbra, Zupan/0000-0002-4603-333X	Humanities Research Institute at Brock University in St. Catharines, Ontario; Cannon Research Center at Carolinas Rehabilitation in Charlotte, North Carolina	This work was funded through the Humanities Research Institute at Brock University in St. Catharines, Ontario, and by the Cannon Research Center at Carolinas Rehabilitation in Charlotte, North Carolina.	Babbage DR, 2011, NEUROPSYCHOLOGY, V25, P277, DOI 10.1037/a0021908; Biele C, 2006, EXP BRAIN RES, V171, P1, DOI 10.1007/s00221-005-0254-0; Busselle R, 2008, COMMUN THEOR, V18, P255, DOI 10.1111/j.1468-2885.2008.00322.x; CARRERALEVILLAIN P, 1994, J NONVERBAL BEHAV, V18, P281, DOI 10.1007/BF02172290; Collignon O, 2008, BRAIN RES, V1242, P126, DOI 10.1016/j.brainres.2008.04.023; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Cunningham DW, 2009, J VISION, V9, DOI 10.1167/9.13.7; Dimoska A, 2010, J INT NEUROPSYCH SOC, V16, P369, DOI 10.1017/S1355617709991445; Dobel C, 2008, PSYCHOL RES-PSYCH FO, V72, P580, DOI 10.1007/s00426-007-0132-4; Ekman P., 1976, PICTURES FACIAL AFFE; Frank MG, 2001, J PERS SOC PSYCHOL, V80, P75, DOI 10.1037/0022-3514.80.1.75; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; GROSS JJ, 1995, COGNITION EMOTION, V9, P87, DOI 10.1080/02699939508408966; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Ietswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148, DOI 10.1016/j.neuropsychologia.2007.08.002; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Koelsch S, 2006, HUM BRAIN MAPP, V27, P239, DOI 10.1002/hbm.20180; Kucharska-Pietura K, 2003, NEUROPSYCHOLOGIA, V41, P1082, DOI 10.1016/S0028-3932(02)00294-4; LaBar KS, 2003, CEREB CORTEX, V13, P1023, DOI 10.1093/cercor/13.10.1023; Marquardt TP, 2001, APHASIOLOGY, V15, P1091, DOI 10.1080/02687040143000429; Mayes AK, 2009, BRAIN TOPOGR, V22, P145, DOI 10.1007/s10548-009-0106-5; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S., 2002, AWARENESS SOCIAL INF; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; Neumann D, 2013, J HEAD TRAUMA REHABI; Nowicki S., 2008, MANUAL RECEPTIVE TES; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; Pell MD, 2006, BRAIN LANG, V96, P221, DOI 10.1016/j.bandl.2005.04.007; Radice-Neumann D, 2007, BRAIN INJURY, V21, P807, DOI 10.1080/02699050701504281; Radice-Neumann D, 2009, J HEAD TRAUMA REHAB, V24, P313, DOI 10.1097/HTR.0b013e3181b09160; Rottenberg J., 2007, HDB EMOTION ELICITAT; RUSSELL JA, 1994, PSYCHOL BULL, V115, P102, DOI 10.1037/0033-2909.115.1.102; Scherer KR, 2003, SPEECH COMMUN, V40, P227, DOI 10.1016/S0167-6393(02)00084-5; Schultz J, 2009, EXP BRAIN RES, V194, P465, DOI 10.1007/s00221-009-1721-9; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Walbott HG, 1986, J PERS SOC PSYCHOL, V51, P690; WIERZBICKA A, 1992, COGNITIVE SCI, V16, P539, DOI 10.1207/s15516709cog1604_4; Wild-Wall N, 2008, BIOL PSYCHOL, V77, P138, DOI 10.1016/j.biopsycho.2007.10.001; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P113, DOI 10.1080/13803390902806543; Zagalo N., 2004, P ACM WORKSH STOR RE; Zupan B, 2009, J COMMUN DISORD, V42, P1, DOI 10.1016/j.jcomdis.2008.06.001	44	24	24	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2014	29	4					E1	E12		10.1097/HTR.0b013e31829dded6			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AM2AK	WOS:000339650300001	23982789				2021-06-18	
J	Brown, EA; Kenardy, JA; Dow, BL				Brown, Erin A.; Kenardy, Justin A.; Dow, Belinda L.			PTSD Perpetuates Pain in Children With Traumatic Brain Injury	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						children; mutual maintenance; pain; perpetual avoidance; posttraumatic stress; PTSD; TBI; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; HEALTH QUESTIONNAIRE; MUTUAL MAINTENANCE; RISK-FACTORS; BURNS; ADOLESCENTS; PREVALENCE; SYMPTOMS; RELIABILITY; DISABILITY	Objective This study tested theoretical models of the relationship between pain and posttraumatic stress disorder (PTSD) in children with traumatic brain injury (TBI). Methods Participants consisted of 195 children aged 6-15 years presenting to 1 of 3 Australian hospitals following a mild-severe TBI. Children were assessed at 3, 6, and 18 months after their accident for PTSD (via the Clinician-Administered PTSD Scale for Children and Adolescents [CAPS-CA] clinical interview) as well as physical pain (via the Child Health Questionnaire, 50-item version [CHQ-PF50]). Trained clinicians administered the CAPS-CA at home visits, and the CHQ-PF50 was collected through questionnaires. Results Structural equation modeling found the data supported the mutual maintenance model and also the nested perpetual avoidance model. Conclusions Both models indicate PTSD is driving the presence of pain, and not vice versa. A fourth model stating this was proposed. Therefore, it may be useful to address PTSD symptoms in treating child pain for expediting recovery.	[Brown, Erin A.; Kenardy, Justin A.; Dow, Belinda L.] Univ Queensland, Sch Med, Ctr Natl Res Disabil & Rehabil Med CONROD, Brisbane, Qld, Australia	Brown, EA (corresponding author), Univ Queensland, Royal Brisbane & Womens Hosp, CONROD, Level 1 Edith Cavell Bldg, Herston, Qld 4029, Australia.	e.brown5@uq.edu.au	Dow, Belinda/G-8402-2011; Kenardy, Justin/F-2085-2010; Kenardy, Justin A/H-6603-2014	Dow, Belinda/0000-0003-3645-9414; Kenardy, Justin A/0000-0001-9475-8450; Brown, Erin A./0000-0001-9963-1192			Aaron J, 1999, J PEDIATR PSYCHOL, V24, P335, DOI 10.1093/jpepsy/24.4.335; Anderson V, 2012, DISABIL REHABIL, V34, P1639, DOI 10.3109/09638288.2012.656789; Australian Bureau of Statistics, 2006, YB AUSTR 2006; Blume HK, 2012, PEDIATRICS, V129, pE31, DOI 10.1542/peds.2011-1742; Daviss WB, 2000, J AM ACAD CHILD PSY, V39, P576, DOI 10.1097/00004583-200005000-00011; de Leeuw R, 2005, HEADACHE, V45, P1365, DOI 10.1111/j.1526-4610.2005.00269.x; De Young A. C., 2014, J TRAUMATIC ST UNPUB; De Young AC, 2014, J CHILD ADOL PSYCHOP, V24, P9, DOI 10.1089/cap.2013.0066; Dirkzwager AJE, 2007, PSYCHOSOM MED, V69, P435, DOI 10.1097/PSY.0b013e318052e20a; Dunne R. L., 2010, THESIS U QUEENSLAND; Dunne RL, 2012, CLIN J PAIN, V28, P755, DOI 10.1097/AJP.0b013e318243e16b; Iselin G, 2010, J ANXIETY DISORD, V24, P774, DOI 10.1016/j.janxdis.2010.05.011; Kenardy J, 2012, J CLIN CHILD ADOLESC, V41, P5, DOI 10.1080/15374416.2012.632348; King S, 2011, PAIN, V152, P2729, DOI 10.1016/j.pain.2011.07.016; Kline R.B., 2005, PRINCIPLES PRACTICE, V2nd; Kline R.B., 2012, HDB STRUCTURAL EQUAT, P111; Landgraf JM, 1996, CHILD HLTH QUESTIONN, V1st; Liedl A, 2010, PSYCHOL MED, V40, P1215, DOI 10.1017/S0033291709991310; Liedl Alexandra, 2008, Torture, V18, P69; McGrath PJ, 2008, J PAIN, V9, P771, DOI 10.1016/j.jpain.2008.04.007; Nader K., 1996, CLIN ADM PTSD SCALE; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Norman SB, 2008, PSYCHOL MED, V38, P533, DOI 10.1017/S0033291707001389; O'Donnell ML, 2013, J CLIN PSYCHIAT, V74, pE137, DOI 10.4088/JCP.12m08011; Ofek H, 2007, PAIN, V131, P330, DOI 10.1016/j.pain.2007.06.015; Otis JD, 2003, J REHABIL RES DEV, V40, P397, DOI 10.1682/JRRD.2003.09.0397; Otis JD, 2006, PSYCHOLOGICAL KNOWLEDGE IN COURT: PTSD, PAIN, AND TBI, P242, DOI 10.1007/0-387-25610-5_14; Raat H, 2005, J EPIDEMIOL COMMUN H, V59, P75, DOI 10.1136/jech.2003.012914; Ritchie C, 2013, PAIN, V154, P2198, DOI 10.1016/j.pain.2013.07.001; Saxe G, 2001, J AM ACAD CHILD PSY, V40, P915, DOI 10.1097/00004583-200108000-00013; Saxe GN, 2005, AM J PSYCHIAT, V162, P1299; Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147; Scheeringa MS, 2011, DEPRESS ANXIETY, V28, P770, DOI 10.1002/da.20736; Scheeringa MS, 2006, AM J PSYCHIAT, V163, P644, DOI 10.1176/appi.ajp.163.4.644; Sharp TJ, 2001, CLIN PSYCHOL REV, V21, P857, DOI 10.1016/S0272-7358(00)00071-4; Stoddard FJ, 2006, J AM ACAD CHILD PSY, V45, P87, DOI 10.1097/01.chi.0000184934.71917.3a; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Trickey D, 2012, CLIN PSYCHOL REV, V32, P122, DOI 10.1016/j.cpr.2011.12.001; Villano CL, 2007, J REHABIL RES DEV, V44, P167, DOI 10.1682/JRRD.2006.05.0052; Waters E, 2000, J PEDIATR PSYCHOL, V25, P381, DOI 10.1093/jpepsy/25.6.381	40	24	24	0	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693	1465-735X		J PEDIATR PSYCHOL	J. Pediatr. Psychol.	JUN	2014	39	5					512	520		10.1093/jpepsy/jsu014			9	Psychology, Developmental	Psychology	AI7JN	WOS:000337065100003	24727749				2021-06-18	
J	Honzel, N; Justus, T; Swick, D				Honzel, Nikki; Justus, Timothy; Swick, Diane			Posttraumatic stress disorder is associated with limited executive resources in a working memory task	COGNITIVE AFFECTIVE & BEHAVIORAL NEUROSCIENCE			English	Article						Working memory; PTSD; ERP; Dual task; Executive function; Sternberg memory task	EVENT-RELATED POTENTIALS; TRAUMATIC BRAIN-INJURY; SHORT-TERM-MEMORY; RECOGNITION MEMORY; INTERFERENCE RESOLUTION; RESPONSE-INHIBITION; PREFRONTAL CORTEX; PERFORMANCE; ATTENTION; ANXIETY	Patients with posttraumatic stress disorder (PTSD) can show declines in working memory. A dual-task design was used to determine whether these impairments are linked to executive control limitations. Participants performed a Sternberg memory task with either one or four letters. In the dual-task condition, the maintenance period was filled with an arrow flanker task. PTSD patients were less accurate on the working memory task than were controls, especially in the dual-task condition. In the single-task condition, both groups showed similar patterns of brain potentials from 300 to 500 ms when discriminating old and new probes. However, when taxed with an additional task, the event-related potentials (ERPs) of the PTSD group no longer differentiated old and new probes. In contrast, interference resolution processes in both the single- and dual-task conditions of the flanker task were intact. The lack of differentiation in the ERPs reflects impaired working memory performance under more difficult, dual-task conditions. Exacerbated difficulty in performing a working memory task with concurrent task demands suggests a specific limitation in executive control resources in PTSD.	[Honzel, Nikki; Swick, Diane] VA Northern Calif Hlth Care Syst, Med Res Serv, Martinez, CA 94553 USA; [Justus, Timothy] Pitzer Coll, Psychol Field Grp, Claremont, CA 91711 USA; [Swick, Diane] Univ Calif Davis, Dept Neurol, Davis, CA 95616 USA	Honzel, N (corresponding author), VA Northern Calif Hlth Care Syst, Med Res Serv, 150 Muir Rd,Ste 151-1, Martinez, CA 94553 USA.	nhonzel@gmail.com			U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-08-2-0086]; VA Merit Review grant from the Clinical Science Research and Development Service; Veterans AffairsUS Department of Veterans Affairs [I01CX000566] Funding Source: NIH RePORTER	We thank Jary Larsen and Victoria Ashley for their assistance in recruiting our veteran population. In addition, we thank Devin Adair and Julien Cayton for their assistance with scheduling and running participants, and Adrian Willoughby for task design. This work was supported by the U.S. Army Medical Research and Materiel Command under Grant No. W81XWH-08-2-0086 and by a VA Merit Review grant from the Clinical Science Research and Development Service. The authors declare that they have no conflicts of interest. The information in this article and the article itself have never been published, either electronically or in print. The contents do not represent the views of the Department of Veterans Affairs or the United States Government.	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Andres P, 2002, NEUROPSYCHOLOGIA, V40, P835, DOI 10.1016/S0028-3932(01)00182-8; Aupperle RL, 2012, ARCH GEN PSYCHIAT, V69, P360, DOI 10.1001/archgenpsychiatry.2011.1539; Aupperle RL, 2012, NEUROPHARMACOLOGY, V62, P686, DOI 10.1016/j.neuropharm.2011.02.008; BADDELEY A, 1986, Q J EXP PSYCHOL-A, V38, P603, DOI 10.1080/14640748608401616; Baddeley A, 1996, P NATL ACAD SCI USA, V93, P13468, DOI 10.1073/pnas.93.24.13468; Baddeley A, 2000, TRENDS COGN SCI, V4, P417, DOI 10.1016/S1364-6613(00)01538-2; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bledowski C, 2004, NEUROIMAGE, V22, P530, DOI 10.1016/j.neuroimage.2003.12.034; BREMNER JD, 1993, AM J PSYCHIAT, V150, P1015; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Chao LL, 1998, J COGNITIVE NEUROSCI, V10, P167, DOI 10.1162/089892998562636; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Cowey CM, 1996, MEMORY, V4, P19, DOI 10.1080/741940668; Danckwerts A, 2003, NEUROPSYCHOL REV, V13, P221, DOI 10.1023/B:NERV.0000009485.76839.b7; Danker JF, 2008, PSYCHOPHYSIOLOGY, V45, P784, DOI 10.1111/j.1469-8986.2008.00672.x; de Fockert JW, 2001, SCIENCE, V291, P1803, DOI 10.1126/science.1056496; Downing PE, 2000, PSYCHOL SCI, V11, P467, DOI 10.1111/1467-9280.00290; Drag LL, 2012, J INT NEUROPSYCH SOC, V18, P576, DOI 10.1017/S1355617712000203; Dreher JC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003227; Elzinga BM, 2002, J AFFECT DISORDERS, V70, P1, DOI 10.1016/S0165-0327(01)00351-2; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Etkin A, 2007, AM J PSYCHIAT, V164, P1476, DOI 10.1176/appi.ajp.2007.07030504; Eysenck MW, 2007, EMOTION, V7, P336, DOI 10.1037/1528-3542.7.2.336; EYSENCK MW, 1992, COGNITION EMOTION, V6, P409, DOI 10.1080/02699939208409696; Fales CL, 2008, COGN AFFECT BEHAV NE, V8, P239, DOI 10.3758/CABN.8.3.239; Folstein JR, 2011, PSYCHOPHYSIOLOGY, V48, P825, DOI 10.1111/j.1469-8986.2010.01146.x; FRIEDMAN D, 1990, BIOL PSYCHOL, V30, P61, DOI 10.1016/0301-0511(90)90091-A; Garcia-Larrea L, 1998, EVOKED POTENTIAL, V108, P260, DOI 10.1016/S0168-5597(97)00085-3; Gazzaley A, 2011, NEUROPSYCHOLOGIA, V49, P1410, DOI 10.1016/j.neuropsychologia.2010.12.022; Henry Julie D, 2006, Cogn Neuropsychiatry, V11, P156, DOI 10.1080/13546800444000227; Hopf JM, 2000, CLIN NEUROPHYSIOL, V111, P1241, DOI 10.1016/S1388-2457(00)00313-8; Johnsen GE, 2008, J AFFECT DISORDERS, V111, P74, DOI 10.1016/j.jad.2008.02.007; Johnsen GE, 2009, PSYCHIAT RES, V165, P68, DOI 10.1016/j.psychres.2008.01.001; Koso M, 2006, EUR PSYCHIAT, V21, P167, DOI 10.1016/j.eurpsy.2005.06.004; Lavie N, 2005, PSYCHON B REV, V12, P669, DOI 10.3758/BF03196756; Lavie N, 2004, J EXP PSYCHOL GEN, V133, P339, DOI 10.1037/0096-3445.133.3.339; Leskin LP, 2007, NEUROPSYCHOLOGY, V21, P275, DOI 10.1037/0894-4105.21.3.275; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Miyake A, 2012, CURR DIR PSYCHOL SCI, V21, P8, DOI 10.1177/0963721411429458; Nee DE, 2007, COGN AFFECT BEHAV NE, V7, P1, DOI 10.3758/CABN.7.1.1; Nee DE, 2013, CEREB CORTEX, V23, P264, DOI 10.1093/cercor/bhs007; Neylan TC, 2003, BIOL PSYCHIAT, V53, P216, DOI 10.1016/S0006-3223(02)01450-6; Nielsen-Bohlman L, 1999, COGNITIVE BRAIN RES, V8, P299, DOI 10.1016/S0926-6410(99)00035-X; Pantelis C, 2002, J PSYCHOSOM RES, V53, P655, DOI 10.1016/S0022-3999(02)00434-8; Polak AR, 2012, J AFFECT DISORDERS, V141, P11, DOI 10.1016/j.jad.2012.01.001; Pratt N, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00057; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Roussel M, 2012, BRAIN, V135, P2192, DOI 10.1093/brain/aws132; RUGG MD, 1992, J COGNITIVE NEUROSCI, V4, P69, DOI 10.1162/jocn.1992.4.1.69; Rugg MD, 2007, TRENDS COGN SCI, V11, P251, DOI 10.1016/j.tics.2007.04.004; Seal KH, 2008, AM J PUBLIC HEALTH, V98, P714, DOI 10.2105/AJPH.2007.115519; Sebastian A, 2013, NEUROIMAGE, V64, P601, DOI 10.1016/j.neuroimage.2012.09.020; SMITH ME, 1993, J COGNITIVE NEUROSCI, V5, P1, DOI 10.1162/jocn.1993.5.1.1; Soto D, 2005, J EXP PSYCHOL HUMAN, V31, P248, DOI 10.1037/0096-1523.31.2.248; Stuss DT, 2011, J INT NEUROPSYCH SOC, V17, P759, DOI 10.1017/S1355617711000695; Swick D, 1997, J EXP PSYCHOL LEARN, V23, P123, DOI 10.1037/0278-7393.23.1.123; Swick D, 2012, J INT NEUROPSYCH SOC, V18, P917, DOI 10.1017/S1355617712000458; Swick D, 2011, NEUROIMAGE, V56, P1655, DOI 10.1016/j.neuroimage.2011.02.070; Tays WJ, 2008, J COGNITIVE NEUROSCI, V20, P2250, DOI 10.1162/jocn.2008.20158; Tays WJ, 2011, BRAIN RES, V1393, P62, DOI 10.1016/j.brainres.2011.04.006; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Vasterling JJ, 2009, J INT NEUROPSYCH SOC, V15, P826, DOI 10.1017/S1355617709990683; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; Vilkki J, 1996, NEUROPSYCHOLOGIA, V34, P1051, DOI 10.1016/0028-3932(96)00028-0; Wager TD, 2005, NEUROIMAGE, V27, P323, DOI 10.1016/j.neuroimage.2005.01.054; Wager TD, 2003, COGN AFFECT BEHAV NE, V3, P255, DOI 10.3758/CABN.3.4.255; Weathers F.W., 1994, PTSD CHECKLIST MILIT; Weber DL, 2005, PSYCHIAT RES-NEUROIM, V140, P27, DOI 10.1016/j.pscychresns.2005.07.003; Wilding EL, 2006, CLIN EEG NEUROSCI, V37, P315, DOI 10.1177/155005940603700409	73	24	24	0	31	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1530-7026	1531-135X		COGN AFFECT BEHAV NE	Cogn. Affect. Behav. Neurosci.	JUN	2014	14	2					792	804		10.3758/s13415-013-0219-x			13	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	AK6CY	WOS:000338516800024	24165904	Green Accepted			2021-06-18	
J	Kolias, AG; Bulters, DO; Cowie, CJ; Wilson, MH; Afshari, FT; Helmy, A; Broughton, E; Joannides, AJ; Zebian, B; Harrisson, SE; Hill, CS; Ahmed, AI; Barone, DG; Thakur, B; McMahon, CJ; Adlam, DM; Bentley, RP; Tolias, CM; Mitchell, PM; Whitfield, PC; Critchley, GR; Belli, A; Brennan, PM; Hutchinson, PJ				Kolias, Angelos G.; Bulters, Diederik O.; Cowie, Christopher J.; Wilson, Mark H.; Afshari, Fardad T.; Helmy, Adel; Broughton, Ellie; Joannides, Alexis J.; Zebian, Bassel; Harrisson, Stuart E.; Hill, Ciaran S.; Ahmed, Animul I.; Barone, Damiano G.; Thakur, Bhaskar; McMahon, Catherine J.; Adlam, David M.; Bentley, Robert P.; Tolias, Christos M.; Mitchell, Patrick M.; Whitfield, Peter C.; Critchley, Giles R.; Belli, Antonio; Brennan, Paul M.; Hutchinson, Peter J.		British Neurosurgical Trainee Res; British Neurotrauma Grp; UKCRR Collaborative Grp	Proposal for establishment of the UK Cranial Reconstruction Registry (UKCRR)	BRITISH JOURNAL OF NEUROSURGERY			English	Article						cranioplasty; decompressive craniectomy; stroke; surveillance; traumatic brain injury	DEATH FOLLOWING CRANIOPLASTY; TRAUMATIC BRAIN-INJURY; DECOMPRESSIVE CRANIECTOMY; TITANIUM CRANIOPLASTY; CLINICAL ARTICLE; HEAD-INJURY; COMPLICATIONS; HEMICRANIECTOMY; STROKE; SCALE	Background. The increasing utilisation of decompressive craniectomy for traumatic brain injury and stroke has led to an increase in the number of cranioplasties undertaken. Cranioplasty is also undertaken following excision of tumours originating from or invading the skull vault, removal of bone flaps due to post-operative infection, and decompressive craniectomy for the management of rarer causes of brain oedema and/or refractory intracranial hypertension. The existing literature which mainly consists of single-centre, retrospective studies, shows a significant variation in practice patterns and a wide range of morbidity. There also exists a need to measure the outcome as perceived by the patients themselves with patient reported outcome measures (PROMs; functional outcome, quality of life, satisfaction with cosmesis). In the UK, the concept of long-term surveillance of neurosurgical implants is well established with the UK shunt registry. Based on this background, we propose to establish the UK Cranial Reconstruction Registry (UKCRR). Aim. The overarching aim of the UKCRR is to collect high-quality data about cranioplasties undertaken across the UK and Ireland in order to improve outcomes for patients. Methods. Any patient undergoing reconstruction of the skull vault with autologous bone, titanium, or synthetic material in participating units will be eligible for inclusion. Data will be submitted directly by participating units to the Outcome Registry Intervention and Operation Network secure platform. A Steering Committee will be responsible for overseeing the strategic direction and running of the UKCRR. Outcome measures. These will include re-operation due to a cranioplasty-related issue, surgical site infection, re-admission due to a cranioplasty-related issue, unplanned post-operative escalation of care, adverse events, length of stay in admitting unit, destination at discharge from admitting unit, mortality at discharge from admitting unit, neurological status and PROMs during routine follow-up. Conclusion. The UKCRR will be an important pillar in the ongoing efforts to optimise the outcomes of patients undergoing cranioplasty.	[Kolias, Angelos G.; Helmy, Adel; Joannides, Alexis J.; Hutchinson, Peter J.] Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge CB2 0QQ, England; [Kolias, Angelos G.; Helmy, Adel; Joannides, Alexis J.; Hutchinson, Peter J.] Univ Cambridge, Cambridge CB2 0QQ, England; [Bulters, Diederik O.; Ahmed, Animul I.] Southampton Univ Hosp, Div Neurosurg, Southampton, Hants, England; [Bulters, Diederik O.; Ahmed, Animul I.] Univ Southampton, Southampton, Hants, England; [Cowie, Christopher J.; Mitchell, Patrick M.] Royal Victoria Infirm, Dept Neurosurg, Newcastle Upon Tyne, Tyne & Wear, England; [Cowie, Christopher J.; Mitchell, Patrick M.] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England; [Wilson, Mark H.] St Marys Hosp, Div Neurosurg, London, England; [Wilson, Mark H.] Univ London Imperial Coll Sci Technol & Med, London, England; [Afshari, Fardad T.] Frenchay Hosp, Dept Neurosurg, Bristol BS16 1LE, Avon, England; [Broughton, Ellie; Whitfield, Peter C.] Derriford Hosp, South West Neurosurg Ctr, Plymouth PL6 8DH, Devon, England; [Zebian, Bassel; Thakur, Bhaskar; Tolias, Christos M.] Kings Coll Hosp London, Dept Neurosurg, London, England; [Harrisson, Stuart E.; Belli, Antonio] Queen Elizabeth Hosp, Dept Neurosurg, Birmingham, AL USA; [Hill, Ciaran S.] Royal London Hosp, Dept Neurosurg, London E1 1BB, England; [Barone, Damiano G.; McMahon, Catherine J.] Walton Ctr, Dept Neurosurg, Liverpool, Merseyside, England; [Adlam, David M.] Addenbrookes Hosp, Dept Oral & Maxillofacial Surg, Cambridge CB2 0QQ, England; [Bentley, Robert P.] Kings Coll Hosp London, Dept Oral & Craniofacial Surg, London, England; [Critchley, Giles R.] Hurstwood Pk Neurol Ctr, Dept Neurosurg, Haywards Heath, England; [Belli, Antonio] Queen Elizabeth Hosp, NIHR Ctr Surg Reconstruct & Microbiol, Birmingham B15 2TH, W Midlands, England; [Belli, Antonio] Univ Birmingham, Birmingham, W Midlands, England; [Brennan, Paul M.] Western Gen Hosp, Dept Clin Neurosci, Div Neurosurg, Edinburgh EH4 2XU, Midlothian, Scotland; [Brennan, Paul M.] Univ Edinburgh, Edinburgh, Midlothian, Scotland	Hutchinson, PJ (corresponding author), Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Box 167, Cambridge CB2 0QQ, England.	pjah2@cam.ac.uk	Belli, Antonio/I-3799-2015; Barone, Damiano Giuseppe/O-5728-2018; Whitfield, Peter/ABA-4471-2020; Bulters, Diederik/ABH-3573-2020; Helmy, Adel/AAS-3084-2020	Belli, Antonio/0000-0002-3211-9933; Barone, Damiano Giuseppe/0000-0002-0091-385X; Helmy, Adel/0000-0002-0531-0556; Hill, Ciaran/0000-0002-4488-4034; Ahmed, Aminul/0000-0001-6670-0438; Kolias, Angelos/0000-0003-3992-0587; Bulters, Diederik/0000-0001-9884-9050; Wilson, Mark/0000-0002-2346-4911; Cowie, Christopher/0000-0003-0439-2278; Whitfield, Peter/0000-0003-0566-1820; Harrisson, Stuart/0000-0003-4995-4270	Royal College of Surgeons of England Research Fellowship - Freemasons and the Rosetrees Trust; National Institute of Health Research (NIHR)National Institute for Health Research (NIHR); Raymond and Beverly Sackler Studentship; NIHR Cambridge Biomedical Research CentreNational Institute for Health Research (NIHR); Codman UK; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0601025] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [12/35/57, NIHR-RP-R3-12-013] Funding Source: researchfish	Angelos Kolias is supported by a Royal College of Surgeons of England Research Fellowship (funded by the Freemasons and the Rosetrees Trust), a National Institute of Health Research (NIHR) Academic Clinical Fellowship, and a Raymond and Beverly Sackler Studentship. Antonio Belli is supported by the NIHR and heads the neurotrauma research theme of the NIHR Surgical Reconstruction and Micro biology Research Centre. Paul Brennan holds a Clinical Lectureship, Edinburgh Clinical Academic Training Programme. Peter Hutchinson is supported by an NIHR Research Professorship, the NIHR Cambridge Biomedical Research Centre and has been appointed as the Surgical Specialty Lead for Neurosurgery, Royal College of Surgeons of England Clinical Research Initiative.; Mark Wilson and Peter Hutchinson have delivered lectures sponsored by Codman. Mark Wilson has co-ordinated London Neurotrauma Group meetings sponsored by Codman. The launch meeting of the British Neurosurgical Trainee Research Collaborative was supported by an educational grant from Codman UK.	Al-Tamimi YZ, 2012, BRIT J NEUROSURG, V26, P510, DOI 10.3109/02688697.2011.633640; Archavlis E, 2012, ACTA NEUROCHIR, V154, P1055, DOI 10.1007/s00701-012-1333-1; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Broughton E, 2011, BRIT J NEUROSURG, V25, P544; Broughton E, 2014, BRIT J NEUROSURG, V28, P34, DOI 10.3109/02688697.2013.815319; Bruno A, 2011, STROKE, V42, P2276, DOI 10.1161/STROKEAHA.111.613273; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Coulter IC, 2014, BRIT J NEUROSURG, V28, P199, DOI 10.3109/02688697.2013.835378; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Hill CS, 2012, BRIT J NEUROSURG, V26, P832, DOI 10.3109/02688697.2012.692839; Honeybul S, 2011, BRIT J NEUROSURG, V25, P343, DOI 10.3109/02688697.2011.568643; Kolias AG, 2013, NAT REV NEUROL, V9, P405, DOI 10.1038/nrneurol.2013.106; Kolias AG, 2013, BRIT J NEUROSURG, V27, P307, DOI 10.3109/02688697.2013.781122; Mohan A, 2013, INT J SURG, V11, P4, DOI 10.1016/j.ijsu.2012.11.016; Richards HK, 2009, J NEUROSURG-PEDIATR, V4, P389, DOI 10.3171/2009.4.PEDS09210; Sarov M, 2010, STROKE, V41, P560, DOI 10.1161/STROKEAHA.109.568543; Saver JL, 2012, STROKE, V43, P967, DOI 10.1161/STROKEAHA.111.634352; Schuss P, 2012, J NEUROTRAUM, V29, P1090, DOI 10.1089/neu.2011.2176; Stiver SI, 2008, J NEUROSURG, V109, P245, DOI 10.3171/JNS/2008/109/8/0245; Surgical Site Infection Surveillance Service, 2013, PROT SURV SURG SIT I; Walcott BP, 2013, J NEUROSURG, V118, P757, DOI 10.3171/2013.1.JNS121626; Wiggins A, 2013, NEUROSURGERY, V72, P248, DOI 10.1227/NEU.0b013e31827b98f3; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zebian B, 2011, BRIT J NEUROSURG, V25, P785, DOI 10.3109/02688697.2011.623801	25	24	24	0	9	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	JUN	2014	28	3					310	314		10.3109/02688697.2013.859657			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AI6LT	WOS:000336986900005	24237069				2021-06-18	
J	Wilson, SM; Yeon, SK; Yang, XF; Park, KD; Khanna, R				Wilson, Sarah M.; Yeon, Seul Ki; Yang, Xiao-Fang; Park, Ki Duk; Khanna, Rajesh			Differential regulation of collapsin response mediator protein 2 (CRMP2) phosphorylation by GSK3 beta and CDK5 following traumatic brain injury	FRONTIERS IN CELLULAR NEUROSCIENCE			English	Article						CRMP2; GSK3 beta; CDK5; phosphorylation; mossy fiber sprouting; TIMM staining; epileptogenesis; (S)-Lacosamide	TEMPORAL-LOBE EPILEPSY; GLYCOGEN-SYNTHASE KINASE-3; NATIONAL GENERAL-PRACTICE; ANTICONVULSANT LACOSAMIDE; EPILEPTIFORM ACTIVITY; HIPPOCAMPAL-NEURONS; THERAPEUTIC TARGET; SIGNALING PATHWAY; RHO-KINASE; ACTIVATION	Aberrant ion channel function has been heralded as a main underlying mechanism driving epilepsy and its symptoms. However, it has become increasingly clear that treatment strategies targeting voltage-gated sodium or calcium channels merely mask the symptoms of epilepsy without providing disease-modifying benefits. Ion channel function is likely only one important cog in a highly complex machine. Gross morphological changes, such as reactive sprouting and outgrowth, may also play a role in epileptogenesis. Mechanisms responsible for these changes are not well-understood. Here we investigate the potential involvement of the neurite outgrowth-promoting molecule collapsin response mediator protein 2 (CRMP2). CRMP2 activity, in this respect, is regulated by phosphorylation state, where phosphorylation by a variety of kinases, including glycogen synthase kinase 3 (GSK3 beta) renders it inactive. Phosphorylation (inactivation) of CRMP2 was decreased at two distinct phases following traumatic brain injury (TBI). While reduced CRMP2 phosphorylation during the early phase was attributed to the inactivation of GSK3 beta, the sustained decrease in CRMP2 phosphorylation in the late phase appeared to be independent of GSK3 beta activity. Instead, the reduction in GSK3 beta-phosphorylated CRMP2 was attributed to a loss of priming by cyclin-dependent kinase 5 (CDK5), which allows for subsequent phosphorylation by GSK3 beta. Based on the observation that the proportion of active CRMP2 is increased for up to 4 weeks following TBI, it was hypothesized that it may drive neurite outgrowth, and therefore, circuit reorganization during this time. Therefore, a novel small-molecule tool was used to target CRMP2 in an attempt to determine its importance in mossy fiber sprouting following TBI. In this report, we demonstrate novel differential regulation of CRMP2 phosphorylation by GSK3 beta and CDK5 following TB I.	[Wilson, Sarah M.; Khanna, Rajesh] Indiana Univ, Sch Med, Paul & Carole Stark Neurosci Res Inst, Indianapolis, IN USA; [Yeon, Seul Ki; Park, Ki Duk] Korea Inst Sci & Technol, Brain Sci Inst, Ctr Neuromed, Seoul, South Korea; [Yang, Xiao-Fang; Khanna, Rajesh] Univ Arizona, Dept Pharmacol, Coll Med, Tucson, AZ 85724 USA	Khanna, R (corresponding author), Univ Arizona, Dept Pharmacol, Coll Med, Rm 650,POB 245050,1501 North Campbell Dr, Tucson, AZ 85724 USA.	rkhanna@email.arizona.edu		Khanna, Rajesh/0000-0002-9066-2969	National Scientist Development from the American Heart AssociationAmerican Heart Association [5DG5280023]; Showalter foundation; Stark Fellowship and a Larry Kays Medical Neuroscience award	We thank Dr. Weina Ju for help with some of the immunoblots, and members of the Stark Neurosciences Research Institute for helpful comments and discussions. We express many thanks to Dr. Fletcher White and Matthew Ripsch for their generous guidance in experimental design, as well as, the use of their equipment. This work was supported, in part, by a grant a National Scientist Development from the American Heart Association (5DG5280023 to Rajesh Khanna) and a grant from the Showalter foundation (to Rajesh Khanna). Sarah M. Wilson was partially funded by a Stark Fellowship and a Larry Kays Medical Neuroscience award.	Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ANDERSEN P, 1969, ACTA PHYSIOL SCAND, V76, pA4; Andurkar SV, 1999, BIOORGAN MED CHEM, V7, P2381, DOI 10.1016/S0968-0896(99)00186-8; Arimura N, 2000, J BIOL CHEM, V275, P23973, DOI 10.1074/jbc.M001032200; Arimura N, 2005, MOL CELL BIOL, V25, P9973, DOI 10.1128/MCB.25.22.9973-9984.2005; Beyreuther BK, 2007, CNS DRUG REV, V13, P21, DOI 10.1111/j.1527-3458.2007.00001.x; Bhave SV, 1999, J NEUROSCI, V19, P3277, DOI 10.1523/jneurosci.19-09-03277.1999; Blaabjerg M, 2007, PROG BRAIN RES, V163, P85, DOI 10.1016/S0079-6123(07)63005-2; Brittain JM, 2012, FEBS LETT, V586, P3813, DOI 10.1016/j.febslet.2012.09.022; Brittain JM, 2012, CHANNELS, V6, P52, DOI 10.4161/chan.18919; Brittain JM, 2011, J BIOL CHEM, V286, P37778, DOI 10.1074/jbc.M111.255455; Brittain JM, 2011, NAT MED, V17, P822, DOI 10.1038/nm.2345; Brittain JM, 2009, J BIOL CHEM, V284, P31375, DOI 10.1074/jbc.M109.009951; Brown M, 2004, J NEUROSCI, V24, P8994, DOI 10.1523/JNEUROSCI.3184-04.2004; CAVAZOS JE, 1991, J NEUROSCI, V11, P2795; Chae YC, 2009, CELL SIGNAL, V21, P1818, DOI 10.1016/j.cellsig.2009.07.017; Chen YC, 2008, J NEUROSCI METH, V171, P239, DOI 10.1016/j.jneumeth.2008.03.013; Cole AR, 2006, J BIOL CHEM, V281, P16591, DOI 10.1074/jbc.M513344200; Cole AR, 2004, J BIOL CHEM, V279, P50176, DOI 10.1074/jbc.C400412200; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dash PK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024648; de Lanerolle NC, 2003, EPILEPSIA, V44, P677, DOI 10.1046/j.1528-1157.2003.32701.x; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; Dustrude ET, 2013, J BIOL CHEM, V288, P24316, DOI 10.1074/jbc.M113.474924; Endo H, 2006, J CEREBR BLOOD F MET, V26, P1479, DOI 10.1038/sj.jcbfm.9600303; England MJ, 2012, EPILEPSY BEHAV, V25, P266, DOI 10.1016/j.yebeh.2012.06.016; Errington AC, 2008, MOL PHARMACOL, V73, P157, DOI 10.1124/mol.107.039867; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; Ghasemi M, 2011, EPILEPSY BEHAV, V22, P617, DOI 10.1016/j.yebeh.2011.07.024; GODDARD GV, 1969, EXP NEUROL, V25, P295, DOI 10.1016/0014-4886(69)90128-9; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; GOSLIN K, 1989, J CELL BIOL, V108, P1507, DOI 10.1083/jcb.108.4.1507; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3; Hou ST, 2009, J NEUROCHEM, V111, P870, DOI 10.1111/j.1471-4159.2009.06375.x; Ju WN, 2013, CHANNELS, V7, P153, DOI 10.4161/chan.24224; Kharatishvili I, 2010, CURR OPIN NEUROL, V23, P183, DOI 10.1097/WCO.0b013e32833749e4; Kimura T, 2005, J NEUROCHEM, V93, P1371, DOI 10.1111/j.1471-4159.2005.03063.x; Kobau Rosemarie, 2012, Morbidity and Mortality Weekly Report, V61, P909; Koyama R, 2004, CURR NEUROVASC RES, V1, P3, DOI 10.2174/1567202043480242; LARNER AJ, 1995, SEIZURE, V4, P249, DOI 10.1016/S1059-1311(95)80001-8; Lee CY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038789; Lees G, 2006, NEUROPHARMACOLOGY, V50, P98, DOI 10.1016/j.neuropharm.2005.08.016; LeTiran A, 2001, BIOORGAN MED CHEM, V9, P2693, DOI 10.1016/S0968-0896(01)00204-8; Licko T, 2013, EPILEPSIA, V54, P1176, DOI 10.1111/epi.12196; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MANFORD M, 1992, ARCH NEUROL-CHICAGO, V49, P801, DOI 10.1001/archneur.1992.00530320025008; MANFORD M, 1992, NEUROLOGY, V42, P1911; O'Dell CM, 2012, J NEUROSCI RES, V90, P913, DOI 10.1002/jnr.22829; Oliva M, 2012, EPILEPSIA, V53, P1849, DOI 10.1111/j.1528-1167.2012.03631.x; Panayiotopoulos C., 2005, EPILEPSIES SEIZURES; Park KD, 2009, J MED CHEM, V52, P6897, DOI 10.1021/jm9012054; Pitkanen A, 2009, EPILEPSY BEHAV, V14, P16, DOI 10.1016/j.yebeh.2008.09.023; Pitkanen A, 2014, EPILEPSY RES, V108, P653, DOI 10.1016/j.eplepsyres.2014.02.001; Sasaki C, 2001, NEUROL RES, V23, P588, DOI 10.1179/016164101101199054; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; Sharma AK, 2007, TOXICOL PATHOL, V35, P984, DOI 10.1080/01926230701748305; Siwek M, 2012, ADV EXP MED BIOL, V740, P1219, DOI 10.1007/978-94-007-2888-2_55; Sutula TP, 2004, EPILEPSY RES, V60, P161, DOI 10.1016/j.eplepsyres.2004.07.001; TIMM F, 1958, Dtsch Z Gesamte Gerichtl Med, V46, P706, DOI 10.1007/BF00665092; Uchida Y, 2005, GENES CELLS, V10, P165, DOI 10.1111/j.1365-2443.2005.00827.x; Uchida Y, 2009, J BIOL CHEM, V284, P27393, DOI 10.1074/jbc.M109.000240; Wang YY, 2011, TRANSL NEUROSCI, V2, P13, DOI 10.2478/s13380-011-0002-9; Wang YY, 2010, J BIOL CHEM, V285, P25296, DOI 10.1074/jbc.M110.128801; Wilson SM, 2012, NEUROSCIENCE, V210, P451, DOI 10.1016/j.neuroscience.2012.02.038; Wilson SM, 2012, J BIOL CHEM, V287, P35065, DOI 10.1074/jbc.M112.378695; Xiong T, 2012, NEUROSCIENCE, V216, P123, DOI 10.1016/j.neuroscience.2012.04.052; Yang L, 2010, J NEUROTRAUM, V27, P1541, DOI 10.1089/neu.2009.1244; Yang TH, 2010, J NEUROL SCI, V296, P1, DOI 10.1016/j.jns.2010.06.002; Yoshimura T, 2005, CELL, V120, P137, DOI 10.1016/j.cell.2004.11.012; Zhang XP, 2006, J CEREBR BLOOD F MET, V26, P915, DOI 10.1038/sj.jcbfm.9600238; Zhao SF, 2012, NEUROL RES, V34, P400, DOI 10.1179/1743132812Y.0000000025; ZIMMER J, 1973, BRAIN RES, V64, P313, DOI 10.1016/0006-8993(73)90186-8	76	24	25	0	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		1662-5102		FRONT CELL NEUROSCI	Front. Cell. Neurosci.	MAY 28	2014	8								135	10.3389/fncel.2014.00135			14	Neurosciences	Neurosciences & Neurology	AI1XM	WOS:000336648500001	24904280	DOAJ Gold, Green Published			2021-06-18	
J	Liang, JM; Luan, YX; Lu, B; Zhang, HB; Luo, YN; Ge, PF				Liang, Jianmin; Luan, Yongxin; Lu, Bin; Zhang, Hongbo; Luo, Yi-nan; Ge, Pengfei			Protection of Ischemic Postconditioning against Neuronal Apoptosis Induced by Transient Focal Ischemia Is Associated with Attenuation of NF-kappa B/p65 Activation	PLOS ONE			English	Article							NF-KAPPA-B; CEREBRAL ISCHEMIA/REPERFUSION INJURY; SIGNALING PATHWAY CONTRIBUTES; TRAUMATIC BRAIN-INJURY; CELL-DEATH; REPERFUSION INJURY; STATUS EPILEPTICUS; INFARCT SIZE; RATS; INHIBITION	Background and Purpose: Accumulating evidences have demonstrated that nuclear factor kappa B/p65 plays a protective role in the protection of ischemic preconditioning and detrimental role in lethal ischemia-induced programmed cell death including apoptosis and autophagic death. However, its role in the protection of ischemic postconditioning is still unclear. Methods: Rat MCAO model was used to produce transient focal ischemia. The procedure of ischemic postconditioning consisted of three cycles of 30 seconds reperfusion/reocclusion of MCA. The volume of cerebral infarction was measured by TTC staining and neuronal apoptosis was detected by TUNEL staining. Western blotting was used to analyze the changes in protein levels of Caspase-3, NF-kappa B/p65, phosphor-NF-kappa B/p65, IkB alpha, phosphor-IkB alpha, Noxa, Bim and Bax between rats treated with and without ischemic postconditioning. Laser scanning confocal microscopy was used to examine the distribution of NF-kappa B/p65 and Noxa. Results: Ischemic postconditioning made transient focal ischemia-induced infarct volume decrease obviously from 38.6% +/- 65.8% to 23.5% +/- 64.3%, and apoptosis rate reduce significantly from 46.5% +/- 66.2 to 29.6% +/- 65.3% at reperfusion 24 h following 2 h focal cerebral ischemia. Western blotting analysis showed that ischemic postconditioning suppressed markedly the reduction of NF-kappa B/p65 in cytoplasm, but elevated its content in nucleus either at reperfusion 6 h or 24 h. Moreover, the decrease of IkBa and the increase of phosphorylated IkB alpha and phosphorylated NF-kappa B/p65 at indicated reperfusion time were reversed by ischemic postconditioning. Correspondingly, proapoptotic proteins Caspase-3, cleaved Caspase-3, Noxa, Bim and Bax were all mitigated significantly by ischemic postconditioning. Confocal microscopy revealed that ischemic postconditioning not only attenuated ischemia-induced translocation of NF-kappa B/p65 from neuronal cytoplasm to nucleus, but also inhibited the abnormal expression of proapoptotic protein Noxa within neurons. Conclusions: We demonstrated in this study that the protection of ischemic postconditioning on neuronal apoptosis caused by transient focal ischemia is associated with attenuation of the activation of NF-kappa B/p65 in neurons.	[Liang, Jianmin; Zhang, Hongbo] Jilin Univ, Hosp 1, Dept Pediat, Changchun 130023, Peoples R China; [Luan, Yongxin; Lu, Bin; Luo, Yi-nan; Ge, Pengfei] Jilin Univ, Hosp 1, Dept Neurosurg, Changchun 130023, Peoples R China; [Liang, Jianmin; Luo, Yi-nan; Ge, Pengfei] Jilin Univ, Hosp 1, Neurosci Res Ctr, Changchun 130023, Peoples R China	Ge, PF (corresponding author), Jilin Univ, Hosp 1, Dept Neurosurg, Changchun 130023, Peoples R China.	pengfeige@gmail.com			National Nature and Science FoundationNational Natural Science Foundation of China (NSFC) [30973110, 81171234]; Science and Technology Department of Jilin Province [20080139]	This work was supported by National Nature and Science Foundation (30973110) and (81171234), the Outstanding Youth Grant (20080139) from the Science and Technology Department of Jilin Province. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albers GW, 2002, NEW ENGL J MED, V347, P1713, DOI 10.1056/NEJMsb020987; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Blondeau N, 2001, J NEUROSCI, V21, P4668, DOI 10.1523/JNEUROSCI.21-13-04668.2001; Chu WH, 2013, J TRAUMA ACUTE CARE, V74, P1446, DOI 10.1097/TA.0b013e31829246ad; Chuang YC, 2010, J NEUROSCI RES, V88, P1898, DOI 10.1002/jnr.22369; Clemens JA, 1997, MOL BRAIN RES, V48, P187, DOI 10.1016/S0169-328X(97)00092-2; Danielisova V, 2006, CELL MOL NEUROBIOL, V26, P1181, DOI 10.1007/s10571-006-9034-z; Darling CE, 2005, AM J PHYSIOL-HEART C, V289, pH1618, DOI 10.1152/ajpheart.00055.2005; Ding ZM, 2012, INT J MOL SCI, V13, P6089, DOI 10.3390/ijms13056089; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Engel T, 2011, J CEREBR BLOOD F MET, V31, P1196, DOI 10.1038/jcbfm.2011.26; Feng XD, 2013, MOL MED REP, V7, P1516, DOI 10.3892/mmr.2013.1392; Fischer Uwe M, 2006, Interact Cardiovasc Thorac Surg, V5, P531, DOI 10.1510/icvts.2006.130765; Gao XW, 2008, J NEUROCHEM, V105, P943, DOI 10.1111/j.1471-4159.2008.05218.x; Guo JY, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-79; Han HS, 2003, J CEREBR BLOOD F MET, V23, P589, DOI 10.1097/01.WCB.0000059566.39780.8D; Hu J, 2005, MOL CARCINOGEN, V44, P274, DOI 10.1002/mc.20142; Hu J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050764; Inta I, 2006, J NEUROSCI, V26, P12896, DOI 10.1523/JNEUROSCI.3670-06.2006; Ishihara Y, 2012, J PHARMACOL SCI, V119, P251, DOI 10.1254/jphs.12079FP; Jang ER, 2011, NEUROCHEM INT, V58, P52, DOI 10.1016/j.neuint.2010.10.012; Kim EJ, 2010, TRANSL STROKE RES, V1, P40, DOI 10.1007/s12975-009-0006-8; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Kin H, 2008, SHOCK, V29, P761, DOI 10.1097/SHK.0b013e31815cfd5a; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Kong YH, 2013, NEUROCHEM RES, V38, P815, DOI 10.1007/s11064-013-0984-5; Li L, 2013, INFLAMM RES, V62, P387, DOI 10.1007/s00011-013-0590-7; Li WL, 2013, NEUROSCIENCE, V244, P16, DOI 10.1016/j.neuroscience.2013.03.045; Li ZY, 2012, J INT MED RES, V40, P954, DOI 10.1177/147323001204000314; Liang JM, 2013, J INT MED RES, V41, P618, DOI 10.1177/0300060513476587; Liang JM, 2012, INT J MED SCI, V9, P923, DOI 10.7150/ijms.4878; Liu KX, 2009, INTENS CARE MED, V35, P933, DOI 10.1007/s00134-009-1428-1; Loukogeorgakis SP, 2006, CIRCULATION, V113, P1015, DOI 10.1161/CIRCULATIONAHA.105.590398; Nakai M, 2000, J NEUROCHEM, V74, P647, DOI 10.1046/j.1471-4159.2000.740647.x; Pignataro Giuseppe, 2011, Int J Physiol Pathophysiol Pharmacol, V3, P1; Pizzi M, 2009, FEBS J, V276, P27, DOI 10.1111/j.1742-4658.2008.06767.x; Qian YS, 2012, NEUROCHEM INT, V60, P759, DOI 10.1016/j.neuint.2012.03.011; Ren CC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003851; Ryu HJ, 2011, NEUROSCIENCE, V187, P93, DOI 10.1016/j.neuroscience.2011.04.048; Sasaki CY, 2005, J BIOL CHEM, V280, P34538, DOI 10.1074/jbc.M504943200; Schneider A, 1999, NAT MED, V5, P554; Shen WH, 2003, ACTA PHARMACOL SIN, V24, P1125; Song YS, 2010, J CEREBR BLOOD F MET, V30, P1265, DOI 10.1038/jcbfm.2010.6; Wang JY, 2008, STROKE, V39, P983, DOI 10.1161/STROKEAHA.107.499079; Wang Y, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/124614; Xing BZ, 2008, STROKE, V39, P2362, DOI 10.1161/STROKEAHA.107.507939; Xiong J, 2011, INFLAMM RES, V60, P547, DOI 10.1007/s00011-010-0303-4; Xu L, 2002, BIOCHEM BIOPH RES CO, V299, P14, DOI 10.1016/S0006-291X(02)02573-1; Xu M, 2012, BRAIN RES, V1454, P48, DOI 10.1016/j.brainres.2012.03.020; Yin LL, 2012, INT J NEUROSCI, V122, P748, DOI 10.3109/00207454.2012.721827; You WC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060290; Yuan YJ, 2011, BRAIN RES, V1367, P85, DOI 10.1016/j.brainres.2010.10.017; Zeng M, 2013, BIOCHEM BIOPH RES CO, V436, P180, DOI 10.1016/j.bbrc.2013.05.070; Zhang W, 2005, J CEREBR BLOOD F MET, V25, P30, DOI 10.1038/sj.jcbfm.9600004; Zhao H, 2006, J CEREBR BLOOD F MET, V26, P1114, DOI 10.1038/sj.jcbfm.9600348; Zhou XL, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-251	57	24	25	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 6	2014	9	5							e96734	10.1371/journal.pone.0096734			9	Multidisciplinary Sciences	Science & Technology - Other Topics	AJ9KS	WOS:000338029800116	24800741	DOAJ Gold, Green Published			2021-06-18	
J	Hubel, N; Scholl, E; Dahlem, MA				Huebel, Niklas; Schoell, Eckehard; Dahlem, Markus A.			Bistable Dynamics Underlying Excitability of Ion Homeostasis in Neuron Models	PLOS COMPUTATIONAL BIOLOGY			English	Article							CORTICAL SPREADING DEPRESSION; POTASSIUM DYNAMICS; MIGRAINE GENETICS; WAVE PATTERNS; DEPOLARIZATION; STATES; SIMULATIONS; SEIZURES; SODIUM; TISSUE	When neurons fire action potentials, dissipation of free energy is usually not directly considered, because the change in free energy is often negligible compared to the immense reservoir stored in neural transmembrane ion gradients and the long-term energy requirements are met through chemical energy, i.e., metabolism. However, these gradients can temporarily nearly vanish in neurological diseases, such as migraine and stroke, and in traumatic brain injury from concussions to severe injuries. We study biophysical neuron models based on the Hodgkin-Huxley (HH) formalism extended to include time-dependent ion concentrations inside and outside the cell and metabolic energy-driven pumps. We reveal the basic mechanism of a state of free energy-starvation (FES) with bifurcation analyses showing that ion dynamics is for a large range of pump rates bistable without contact to an ion bath. This is interpreted as a threshold reduction of a new fundamental mechanism of ionic excitability that causes a long-lasting but transient FES as observed in pathological states. We can in particular conclude that a coupling of extracellular ion concentrations to a large glial-vascular bath can take a role as an inhibitory mechanism crucial in ion homeostasis, while the Na+/K+ pumps alone are insufficient to recover from FES. Our results provide the missing link between the HH formalism and activator-inhibitor models that have been successfully used for modeling migraine phenotypes, and therefore will allow us to validate the hypothesis that migraine symptoms are explained by disturbed function in ion channel subunits, Na+/K+ pumps, and other proteins that regulate ion homeostasis.	[Huebel, Niklas; Schoell, Eckehard] Tech Univ Berlin, Dept Theoret Phys, Berlin, Germany; [Dahlem, Markus A.] Humboldt Univ, Dept Phys, D-10099 Berlin, Germany	Hubel, N (corresponding author), Tech Univ Berlin, Dept Theoret Phys, Berlin, Germany.	dahlem@physik.hu-berlin.de			Bundesministerium fur Bildung und Forschung within the Bernstein Center of Computational Neuroscience BerlinFederal Ministry of Education & Research (BMBF) [BMBF 01GQ1001B, 01GQ1109]	This work was supported by the Bundesministerium fur Bildung und Forschung (BMBF 01GQ1001B, 01GQ1109) within the Bernstein Center of Computational Neuroscience Berlin. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AIHARA K, 1983, BIOPHYS J, V41, P87, DOI 10.1016/S0006-3495(83)84408-7; Arce H, 2000, CHAOS, V10, P411, DOI 10.1063/1.166508; Atwater I, 1980, HORM METAB RES S, V10, P100; Barreto E, 2011, J BIOL PHYS, V37, P361, DOI 10.1007/s10867-010-9212-6; Bazhenov M, 2004, J NEUROPHYSIOL, V92, P1116, DOI 10.1152/jn.00529.2003; BEILBY MJ, 1979, AUST J PLANT PHYSIOL, V6, P337; Boucher PA, 2012, J COMPUT NEUROSCI, P1; Cha CY, 2011, J GEN PHYSIOL, V138, P21, DOI 10.1085/jgp.201110611; Cha CY, 2009, BIOPHYS J, V97, P3086, DOI 10.1016/j.bpj.2009.08.060; Chang JC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070469; Charles AC, 2013, NAT REV NEUROL, V9, P637, DOI 10.1038/nrneurol.2013.192; CHAY TR, 1983, BIOPHYS J, V42, P181, DOI 10.1016/S0006-3495(83)84384-7; Cressman JR, 2009, J COMPUT NEUROSCI, V26, P159, DOI 10.1007/s10827-008-0132-4; Dahlem MA, 2008, J THEOR BIOL, V251, P202, DOI 10.1016/j.jtbi.2007.11.019; Dahlem MA, 2004, ANN PHYS-BERLIN, V13, P442, DOI 10.1002/andp.200410087; Dahlem MA, 2013, CHAOS, V23, DOI 10.1063/1.4813815; Dahlem MA, 2013, TRANSL NEUROSCI, V4, P282, DOI 10.2478/s13380-013-0127-0; Dahlem MA, 2013, J MATH NEUROSCI, V3, DOI 10.1186/2190-8567-3-7; Dahlem MA, 2010, PHYSICA D, V239, P889, DOI 10.1016/j.physd.2009.08.009; Dahlem MA, 2008, CHAOS, V18, DOI 10.1063/1.2937120; Dahlem MA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005007; DIFRANCESCO D, 1985, PHILOS T ROY SOC B, V307, P353, DOI 10.1098/rstb.1985.0001; DOKOS S, 1993, ANN BIOMED ENG, V21, P321, DOI 10.1007/BF02368625; Dreier JP, 2013, NEUROSCIENTIST, V19, P25, DOI 10.1177/1073858412453340; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; EBIHARA L, 1980, BIOPHYS J, V32, P779, DOI 10.1016/S0006-3495(80)85016-8; Endresen LP, 2000, EUR BIOPHYS J BIOPHY, V29, P90, DOI 10.1007/s002490050254; Ermentrout B, 1998, REP PROG PHYS, V61, P353, DOI 10.1088/0034-4885/61/4/002; Ermentrout G. B., 2010, MATH FDN NEUROSCIENC; FITZHUGH R, 1961, BIOPHYS J, V1, P445, DOI 10.1016/S0006-3495(61)86902-6; Florence G, 2009, J THEOR BIOL, V258, P219, DOI 10.1016/j.jtbi.2009.01.032; Frohlich F, 2008, NEUROSCIENTIST, V14, P422, DOI 10.1177/1073858408317955; Frohlich F, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.031922; Hahn PJ, 2001, J COMPUT NEUROSCI, V11, P5, DOI 10.1023/A:1011250329341; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Kager H, 2000, J NEUROPHYSIOL, V84, P495; Kuznetsov Y.A., 1995, ELEMENTS APPL BIFURC; May RM, 2004, SCIENCE, V303, P790, DOI 10.1126/science.1094442; Miura RM, 2007, EUR PHYS J-SPEC TOP, V147, P287, DOI 10.1140/epjst/e2007-00214-8; Muller M, 1998, BRAIN RES, V812, P1, DOI 10.1016/S0006-8993(98)00812-9; NAGUMO J, 1962, P IRE, V50, P2061, DOI 10.1109/JRPROC.1962.288235; Noble D, 2001, PHILOS T ROY SOC A, V359, P1127, DOI 10.1098/rsta.2001.0820; Oldeman B.E, 2009, AUTO 07P CONTINUATIO; Postnov DE, 2012, BRAIN RES, V1434, P200, DOI 10.1016/j.brainres.2011.10.001; Postnov DE, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.031921; Rinzel J., 1989, METHODS NEURONAL MOD, P251; Schneider FM, 2009, CHAOS, V19, DOI 10.1063/1.3096411; Shapiro BE, 2001, J COMPUT NEUROSCI, V10, P99, DOI 10.1023/A:1008924227961; Silberstein SD, 2013, HEADACHE, V53, P1207, DOI 10.1111/head.12156; Silberstein SD, 2013, HEADACHE, V53, P1218, DOI 10.1111/head.12169; Somjen GG, 2008, J COMPUT NEUROSCI, V25, P349, DOI 10.1007/s10827-008-0083-9; Varghese A, 1997, J THEOR BIOL, V189, P33, DOI 10.1006/jtbi.1997.0487; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224; Yao W, 2011, B MATH BIOL, V73, P2773, DOI 10.1007/s11538-011-9647-3; Yu N, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002664; Zamecnik J, 2012, EUR J NEUROSCI, V36, P2017, DOI 10.1111/j.1460-9568.2012.08107.x; Zandt BJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022127	57	24	24	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA		1553-7358		PLOS COMPUT BIOL	PLoS Comput. Biol.	MAY	2014	10	5							e1003551	10.1371/journal.pcbi.1003551			15	Biochemical Research Methods; Mathematical & Computational Biology	Biochemistry & Molecular Biology; Mathematical & Computational Biology	AI9VB	WOS:000337288000002	24784149	DOAJ Gold, Green Published			2021-06-18	
J	Eramudugolla, R; Bielak, AAM; Bunce, D; Easteal, S; Cherbuin, N; Anstey, KJ				Eramudugolla, Ranmalee; Bielak, Allison A. M.; Bunce, David; Easteal, Simon; Cherbuin, Nicolas; Anstey, Kaarin J.			Long-Term Cognitive Correlates of Traumatic Brain Injury across Adulthood and Interactions with APOE Genotype, Sex, and Age Cohorts	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Cognitive decline; Dementia; Prospective study; Head injury; Epidemiology	APOLIPOPROTEIN-E POLYMORPHISM; ALZHEIMERS-DISEASE; HEAD-INJURY; RISK-FACTOR; GENDER-DIFFERENCES; AMYLOID-BETA; EPSILON-4; ASSOCIATION; POPULATION; METAANALYSIS	There is continuing debate about long-term effects of brain injury. We examined a range of traumatic brain injury (TBI) variables (TBI history, severity, frequency, and age of injury) as predictors of cognitive outcome over 8 years in an adult population, and interactions with apolipoprotein E (APOE) genotype, sex, and age cohorts. Three randomly sampled age cohorts (20-24, 40-44, 60-64 years at baseline; N = 6333) were each evaluated three times over 8 years. TBI variables, based on self-report, were separately modeled as predictors of cognitive performance using linear mixed effects models. TBI predicted longitudinal cognitive decline in all three age groups. APOE epsilon 4 ( + ) genotypes in the young and middle-aged groups predicted lower baseline cognitive performance in the context of TBI. Baseline cognitive performance was better for young females than males but this pattern reversed in middle age and old age. The findings suggest TBI history is associated with long-term cognitive impairment and decline across the adult lifespan. A role for APOE genotype was apparent in the younger cohorts but there was no evidence that it is associated with impairment in early old age. The effect of sex and TBI on cognition varied with age cohort, consistent with a proposed neuroprotective role for estrogen. (JINS, 2014, 20, 444-454)	[Eramudugolla, Ranmalee; Cherbuin, Nicolas; Anstey, Kaarin J.] Australian Natl Univ, Ctr Res Aging Hlth & Wellbeing, Canberra, ACT 0200, Australia; [Bielak, Allison A. M.] Colorado State Univ, Dept Human Dev & Family Studies, Ft Collins, CO 80523 USA; [Bunce, David] Univ Leeds, Inst Psychol Sci, Fac Med & Hlth, Leeds, W Yorkshire, England; [Easteal, Simon] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 0200, Australia	Eramudugolla, R (corresponding author), Australian Natl Univ, Ctr Res Aging Hlth & Wellbeing, GPO Box 4, Canberra, ACT 0200, Australia.	ranmalee.eramudugolla@anu.edu.au	Bielak, Allison A. M./H-2388-2012; Anstey, Kaarin J/A-3852-2008; Anstey, Kaarin/AAB-4870-2020; Eramudugolla, Ranmalee/AAL-7661-2021; Cherbuin, Nicolas/A-8515-2008	Bielak, Allison A. M./0000-0003-2925-0372; Cherbuin, Nicolas/0000-0001-6481-0748; Anstey, Kaarin/0000-0002-9706-9316; Easteal, Simon/0000-0002-0462-502X; Eramudugolla, Ranmalee/0000-0001-5097-8267; Bunce, David/0000-0003-3265-2700	National Health and Medical Research Council (NHMRC) of Australia Unit GrantNational Health and Medical Research Council of Australia [973302, 179805]; NHMRC project grantNational Health and Medical Research Council of Australia [157125]; Australian Rotary Health Research Fund; Australian Brewers Foundation; NHMRCNational Health and Medical Research Council of Australia [1002560]; Dr. Cherbuin by ARC FellowshipAustralian Research Council [120100227]; Leverhulme Trust, UKLeverhulme Trust	The authors are grateful to the PATH Chief Investigators, Chantal Meslin, Patricia Jacomb, Karen Maxwell, and the PATH interviewers. Susan Tan and Karen Nunweek provided technical assistance with the APOE genotyping. The study was supported by the National Health and Medical Research Council (NHMRC) of Australia Unit Grant No. 973302, Program Grant No. 179805, NHMRC project grant No. 157125, grants from the Australian Rotary Health Research Fund, and the Australian Brewers Foundation. Prof Anstey was funded by NHMRC Fellowships No. 1002560, and Dr. Cherbuin by ARC Fellowship 120100227. Dr. Bunce was funded by the Leverhulme Trust, UK. The authors declare there are no financial or other relationships that could be interpreted as a conflict of interest affecting this manuscript. The authors have no conflicts of interest to declare.	Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Anstey KJ, 2012, INT J EPIDEMIOL, V41, P951, DOI 10.1093/ije/dyr025; Ardelt AA, 2012, BRAIN RES, V1461, P76, DOI 10.1016/j.brainres.2012.04.024; BADDELEY A, 1993, BRIT J CLIN PSYCHOL, V32, P55, DOI 10.1111/j.2044-8260.1993.tb01027.x; Blackman JA, 2005, DEV MED CHILD NEUROL, V47, P64, DOI 10.1017/S0012162205000113; Bunce D., 2013, J GERONTOLOGY A; Bunce D, 2011, NEUROPSYCHOLOGIA, V49, P1693, DOI 10.1016/j.neuropsychologia.2011.02.042; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Dardiotis E, 2012, CURR OPIN PSYCHIATR, V25, P231, DOI 10.1097/YCO.0b013e3283523c0e; Delis DC, 1987, CALIFORNIA VERBAL LE; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Han SD, 2008, ALZHEIMERS DEMENT, V4, P251, DOI 10.1016/j.jalz.2008.02.006; Han SD, 2007, J NEUROL NEUROSUR PS, V78, P1103, DOI 10.1136/jnnp.2006.108183; Hartman RE, 2002, J NEUROSCI, V22, P10083; Ihle A, 2012, NEUROPSYCHOLOGY, V26, P267, DOI 10.1037/a0026769; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Jorm AF, 2007, NEUROPSYCHOLOGY, V21, P1, DOI 10.1037/0894-4105.21.1.1; Katzman R, 1996, NEUROLOGY, V46, P889; Kokjohn TA, 2012, ALZHEIMERS DEMENT, V8, P574, DOI 10.1016/j.jalz.2011.05.2429; Liu CC, 2013, NAT REV NEUROL, V9, P106, DOI 10.1038/nrneurol.2012.263; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Mondadori CRA, 2007, CEREB CORTEX, V17, P1934, DOI 10.1093/cercor/bhl103; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Ost M, 2008, ACTA ANAESTH SCAND, V52, P1364, DOI 10.1111/j.1399-6576.2008.01675.x; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ponsford J, 2011, J NEUROTRAUM, V28, P1683, DOI 10.1089/neu.2010.1623; Rapoport M, 2008, J NEUROPSYCH CLIN N, V20, P68, DOI 10.1176/jnp.2008.20.1.68; Renner C, 2012, BRAIN INJURY, V26, P1360, DOI 10.3109/02699052.2012.667592; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Smith A., 1982, SYMBOL DIGIT MODALIT; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Sundstrom A, 2007, INT PSYCHOGERIATR, V19, P159, DOI 10.1017/S1041610206003498; Tang MX, 1996, ANN NY ACAD SCI, V802, P6, DOI 10.1111/j.1749-6632.1996.tb32593.x; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Wechsler D., 1955, MANUAL WECHSLER ADUL; Willemse-Van Son AHP, 2008, J NEUROL NEUROSUR PS, V79, P426, DOI 10.1136/jnnp.2007.129460; Zhong N, 2008, ALZHEIMERS DEMENT, V4, P179, DOI 10.1016/j.jalz.2008.01.006	49	24	25	0	19	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	APR	2014	20	4					444	454		10.1017/S1355617714000174			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	AD9CI	WOS:000333561900010	24670469	Green Accepted			2021-06-18	
J	Monea, AG; Baeck, K; Verbeken, E; Verpoest, I; Sloten, JV; Goffin, J; Depreitere, B				Monea, Aida Georgeta; Baeck, Katrien; Verbeken, Eric; Verpoest, Ignaas; Vander Sloten, Jos; Goffin, Jan; Depreitere, Bart			The biomechanical behaviour of the bridging vein-superior sagittal sinus complex with implications for the mechanopathology of acute subdural haematoma	JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS			English	Article						Acute subdural haematoma; Parasagittal bridging veins; Superior sagittal sinus; Strain rate; Uniaxial tensile test; Longitudinal stretch	CEREBRAL BLOOD-VESSELS; MECHANICAL-PROPERTIES; STRAIN TOLERANCE; MORTALITY; CADAVERS; RUPTURE; FRESH; TESTS; AGE	Background: Traumatic brain injury is expected to become the major cause of death and disability for children and young adults by the year 2020. One of the most frequent and most morbid pathologies resulted from a head trauma is acute subdural haematoma (ASDH). For nearly one third of the ASDH cases the etiopathology directly relates to a bridging vein (BV) rupture. Methods: In the current study the bridging vein-superior sagittal sinus (BV-SSS) units were axially stretched until failure for strain rates ranging from 2.66 s(-1) to 185.61 s(-1), in order to investigate any strain rate dependency in their mechanical behaviour. Findings: Results showed that up to 200 s(-1), the effect of the strain rate on veins' mechanical behaviour is outweighed by the large morphological intra- and inter-individual variations. Gender had a strong influence on the BVs geometrical description, but exerted no direct influence on the BV biomechanical parameters. Veins' dimensions had the strongest influence on the BV mechanical behaviour and on the failure mechanism. Interpretation: The present study brings important contribution to the ASDH research, emphasising the importance of considering the BV-SSS complex as a whole when trying to describe the ASDH mechanopathology. (c) 2013 Elsevier Ltd. All rights reserved.	[Monea, Aida Georgeta] Katholieke Univ Leuven, Div Expt Neurosurg & Neuroanat, B-3000 Louvain, Belgium; [Monea, Aida Georgeta; Baeck, Katrien; Vander Sloten, Jos] Katholieke Univ Leuven, Biomech Sect, B-3001 Heverlee, Belgium; [Verbeken, Eric] Katholieke Univ Leuven, Translat Cell & Tissue Res, B-3000 Louvain, Belgium; [Verpoest, Ignaas] Katholieke Univ Leuven, Dept Met & Mat Engn MTM, B-3001 Heverlee, Belgium	Monea, AG (corresponding author), Biomech Sect, Celestijnenlaan 300 Box 2419, B-3001 Heverlee, Belgium.	moneaaida@yahoo.com; katrien.baeck@mech.kuleuven.be; erik.verbeken@med.kuleuven.be; ignaas.verpoest@mtm.kuleuven.be; jos.vandersloten@mech.kuleuven.be; jan.goffin@med.kuleuven.be; bart.depreitere@med.kuleuven.be	Depreitere, Bart/AAA-9846-2020	Depreitere, Bart/0000-0002-7458-0648			BOUISSOU H, 1991, RETURN CIRCULATION AND NOREPINEPHRINE : AN UPDATE, P139; Brossollet LJ, 1997, J BIOMECH ENG-T ASME, V119, P1, DOI 10.1115/1.2796059; BROSSOLLET LJ, 1995, J BIOMECH, V28, P679, DOI 10.1016/0021-9290(94)00119-O; Delye Hans, 2006, Stapp Car Crash J, V50, P625; Depreitere B, 2006, J NEUROSURG, V104, P950, DOI 10.3171/jns.2006.104.6.950; Depreitere B, 2004, ACCIDENT ANAL PREV, V36, P561, DOI 10.1016/S0001-4575(03)00062-9; Depreitere B., 2004, THESIS KU LEUVEN BEL; FRUIN AH, 1984, J NEUROSURG, V60, P1300, DOI 10.3171/jns.1984.60.6.1300; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; Gentner JM, 1998, CELL MOL BIOL, V44, P251; Graham DI, 1996, NEUROTRAUMA, P43; Greaney JL, 2011, J APPL PHYSIOL, V110, P11, DOI 10.1152/japplphysiol.01273.2010; GUR RC, 1991, P NATL ACAD SCI USA, V88, P2845, DOI 10.1073/pnas.88.7.2845; Han H., 2008, J NEURORADIOLOGY, V49, P169; Han H, 2007, NEURORADIOLOGY, V49, P169, DOI 10.1007/s00234-006-0175-z; LEE MC, 1989, J BIOMECH, V22, P537, DOI 10.1016/0021-9290(89)90005-5; LOWENHIELM P, 1978, J BIOENG, V2, P509; LOWENHIELM P, 1974, Z RECHTSMED, V75, P131, DOI 10.1007/BF02114709; LOWENHIELM P, 1974, Z RECHTSMED, V74, P55, DOI 10.1007/BF01869185; Maxeiner H, 1997, FORENSIC SCI INT, V89, P103, DOI 10.1016/S0379-0738(97)00124-2; Meaney DF, 1991, THESIS U PENNSYLVANI; Monea AG, 2012, J NEUROTRAUM, V29, P2305, DOI 10.1089/neu.2011.2271; Monson K. L., 2001, THESIS U CALIFORNIA; Monson KL, 2005, J BIOMECH, V38, P737, DOI 10.1016/j.jbiomech.2004.05.004; Monson KL, 2003, J BIOMECH ENG-T ASME, V125, P288, DOI 10.1115/1.1554412; OKA K, 1985, NEUROSURGERY, V17, P711, DOI 10.1227/00006123-198511000-00003; OLSON CL, 1974, J AM STAT ASSOC, V69, P894, DOI 10.2307/2286159; Pang Q, 2001, J VASC RES, V38, P83, DOI 10.1159/000051033; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Stemper BD, 2007, J BIOMECH, V40, P1806, DOI 10.1016/j.jbiomech.2006.07.005; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; WILLIAMS PL, 1995, GRAYS ANATOMY, P1580; YAMASHIMA T, 1984, J NEUROL NEUROSUR PS, V47, P121, DOI 10.1136/jnnp.47.2.121; Young RJ, 2002, NEUROIMAG CLIN N AM, V12, P189, DOI 10.1016/S1052-5149(02)00003-5	34	24	25	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1751-6161	1878-0180		J MECH BEHAV BIOMED	J. Mech. Behav. Biomed. Mater.	APR	2014	32						155	165		10.1016/j.jmbbm.2013.12.007			11	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	AD8AG	WOS:000333488300016	24463477				2021-06-18	
J	Suppiej, A; Cainelli, E; Casara, G; Cappellari, A; Nosadini, M; Sartori, S				Suppiej, Agnese; Cainelli, Elisa; Casara, Giulia; Cappellari, Ambra; Nosadini, Margherita; Sartori, Stefano			Long-Term Neurocognitive Outcome and Quality of Life in Pediatric Acute Disseminated Encephalomyelitis	PEDIATRIC NEUROLOGY			English	Article						ADEM; neuropsychological; cognitive; sequelae; follow-up; impairments; multiple sclerosis	TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; BACTERIAL-MENINGITIS; FOLLOW-UP; CHILDREN; AGE; PERFORMANCE; ATTENTION; DEFICITS; ONSET	BACKGROUND: Acute disseminated encephalomyelitis is an inflammatory-demyelinating disorder of the central nervous system usually with a monophasic course and a favorable neurological outcome. Long-term neurocognitive sequelae and quality of life have not yet been fully investigated. AIM: To examine neurocognitive outcome and quality of life in pediatric monophasic acute disseminated encephalomyelitis. METHODS: Of the 36 patients diagnosed with acute disseminated encephalomyelitis at our institution, six were lost to follow-up and eight relapsed (two with multiphasic forms and six with multiple sclerosis). The outcome of the 22 remaining patients was evaluated using four subscales of the Wechsler Intelligence Scales for estimation of IQ a battery of neuropsychological tests, and semistructured and PedsQL questionnaires for quality of life. The effect of age at onset, neuroradiological recovery, and time elapsed from the acute event on outcome was also investigated. RESULTS: Estimated IQ neuropsychological mean group scores, and quality of life at follow-up were within the normal range, but 23% of the patients had pathological scores in various neuropsychological functions, among which attention was the most clearly affected. The neuroradiological recovery was not correlated with the result of the neuropsychological tests. Age at onset correlated with linguistic skills, whereas the time elapsed from the acute event had a significant effect on attention tasks: scores were worse in the group of patients with a follow-up shorter than 7 years. CONCLUSION: Our results suggest that pediatric monophasic acute disseminated encephalomyelitis has a favorable neurocognitive outcome. Patients with longer follow-up had a better outcome, suggesting a neurocognitive course that is different from that of multiple sclerosis and a potential for long-term recovery of affected functions.	[Suppiej, Agnese; Cainelli, Elisa; Casara, Giulia; Cappellari, Ambra; Nosadini, Margherita; Sartori, Stefano] Univ Padua, Paediat Univ Hosp, I-35128 Padua, Italy; [Cainelli, Elisa] Univ Padua, Dept Gen Psychol, Lifespan Cognit Neurosci Lab, I-35128 Padua, Italy	Suppiej, A (corresponding author), Univ Padua, Paediat Univ Hosp, Via Giustiniani 3, I-35128 Padua, Italy.	suppiej@pediatria.unipd.it	Sartori, Stefano/K-9498-2016; Nosadini, Margherita/AAW-4843-2020; Cainelli, Elisa/AAD-1651-2020; Suppiej, Agnese/K-3424-2016	Sartori, Stefano/0000-0002-0012-6848; Suppiej, Agnese/0000-0001-5130-1450			Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P319, DOI 10.1080/713755568; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V, 2004, J PEDIATR PSYCHOL, V29, P67, DOI 10.1093/jpepsy/jsh011; Bisiacchi P., 2005, BATTERIA VALUTAZIONE; Cohen J, 1998, STAT POWER ANAL BEHA; Dale RC, 2000, BRAIN, V123, P2407, DOI 10.1093/brain/123.12.2407; Deery B, 2010, DEV NEUROPSYCHOL, V35, P506, DOI 10.1080/87565641.2010.494921; Grimwood K, 2000, ARCH DIS CHILD, V83, P111, DOI 10.1136/adc.83.2.111; Hahn CD, 2003, PEDIATR NEUROL, V29, P117, DOI 10.1016/S0887-8994(03)00143-7; Holland BA, 1986, AM SOC NEURORADIOL, V7, P20; HUDSPETH WJ, 1990, J EDUC PSYCHOL, V82, P881, DOI 10.1037/0022-0663.82.4.881; Jacobs RK, 2004, PEDIATR NEUROL, V31, P191, DOI 10.1016/j.pediatrneurol.2004.03.008; Jayakrishnan MP, 2010, J PEDIATR NEUROSCI, V5, P111, DOI 10.4103/1817-1745.76098; Krupp LB, 2013, MULT SCLER J, V19, P1261, DOI 10.1177/1352458513484547; Kuni BJ, 2012, DEV NEUROPSYCHOL, V37, P682, DOI 10.1080/87565641.2012.690799; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; Mar S, 2010, J CHILD NEUROL, V25, P681, DOI 10.1177/0883073809343320; MCKAY KE, 1994, DEV NEUROPSYCHOL, V10, P121, DOI 10.1080/87565649409540572; Mulhern RK, 2001, J CLIN ONCOL, V19, P472, DOI 10.1200/JCO.2001.19.2.472; Orsini A., 2006, WISC 3 CONTRIBUTO TA; Panepinto JA, 2008, J PEDIAT HEMATOL ONC, V30, P666, DOI 10.1097/MPH.0b013e31817e4a44; Reddick WE, 2006, CANCER-AM CANCER SOC, V106, P941, DOI 10.1002/cncr.21679; Rostasy K, 2009, NEUROPEDIATRICS, V40, P211, DOI 10.1055/s-0030-1247518; Ruff HA, 1996, ATTENTION EARLY DEV; Sannio Facello G, 2006, TOL TORRE LONDRA TES; Sattler J. M., 1992, ASSESSMENT CHILDREN; Stoppa E, 1997, PSICH INF ADOLESC, V64, P73; Suppiej A, 2008, PEDIATR NEUROL, V39, P12, DOI 10.1016/j.pediatrneurol.2008.03.009; Tenembaum S, 2002, NEUROLOGY, V59, P1224, DOI 10.1212/WNL.59.8.1224; Tenembaum S, 2007, NEUROLOGY, V68, pS23, DOI 10.1212/01.wnl.0000259404.51352.7f; THATCHER R, 1997, DEV PREFRONTAL CORTE; Thatcher RW, 1991, DEV NEUROPSYSCHOL, V7, P783; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yakovlev PI, 1967, REGIONAL DEV BRAIN E; Young NP, 2008, SEMIN NEUROL, V28, P84, DOI 10.1055/s-2007-1019130; Zarei M, 2003, J NEUROL NEUROSUR PS, V74, P872, DOI 10.1136/jnnp.74.7.872	36	24	25	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	APR	2014	50	4					363	367		10.1016/j.pediatrneurol.2013.12.006			5	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	AE3GY	WOS:000333866200018	24630282				2021-06-18	
J	Mtaweh, H; Smith, R; Kochanek, PM; Wisniewski, SR; Fabio, A; Vavilala, MS; Adelson, PD; Toney, NA; Bell, MJ				Mtaweh, Haifa; Smith, Rebecca; Kochanek, Patrick M.; Wisniewski, Stephen R.; Fabio, Anthony; Vavilala, Monica S.; Adelson, P. David; Toney, Nicole A.; Bell, Michael J.			Energy Expenditure in Children After Severe Traumatic Brain Injury	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						energy expenditure; metabolism; nutritional support; pediatric neurocritical care; traumatic brain injury	SEVERE HEAD-INJURY; INTENSIVE-CARE-UNIT; NEUROMUSCULAR BLOCKADE; INDIRECT CALORIMETRY; NUTRITION; TEMPERATURE; HYPOTHERMIA; METABOLISM; SEDATION; SUPPORT	Objective: To evaluate energy expenditure in a cohort of children with severe traumatic brain injury. Design: A prospective observational study. Setting: A pediatric neurotrauma center within a tertiary care institution. Patients: Mechanically ventilated children admitted with severe traumatic brain injury (Glasgow Coma Scale < 9) with a weight more than 10 kg were eligible for study. A subset of children was co-enrolled in a phase 3 study of early therapeutic hypothermia. All children were treated with a comprehensive neurotrauma protocol that included sedation, neuromuscular blockade, temperature control, antiseizure prophylaxis, and a tiered-based system for treating intracranial hypertension. Interventions: Within the first week after injury, indirect calorimetry measurements were performed daily when the patient's condition permitted. Measurements and Main Results: Data from 13 children were analyzed (with a total of 32 assessments). Measured energy expenditure obtained from indirect calorimetry was compared with predicted resting energy expenditure calculated from Harris-Benedict equation. Overall, measured energy expenditure/predicted resting energy expenditure averaged 70.2% 3.8%. Seven measurements obtained while children were hypothermic did not differ from normothermic values (75% +/- 4.5% vs 68.9% +/- 4.7%, respectively, p = 0.273). Furthermore, children with favorable neurologic outcome at 6 months did not differ from children with unfavorable outcome (76.4% +/- 6% vs 64.7% +/- 4.7% for the unfavorable outcome, p = 0.13). Conclusions: Contrary to previous work from several decades ago that suggested severe pediatric traumatic brain injury is associated with a hypermetabolic response (measured energy expenditure/predicted resting energy expenditure > 110%), our data suggest that contemporary neurocritical care practices may blunt such a response. Understanding the metabolic requirements of children with severe traumatic brain injury is the first step in development of rational nutritional support goals that might lead to improvements in outcome.	[Mtaweh, Haifa; Smith, Rebecca; Kochanek, Patrick M.; Toney, Nicole A.; Bell, Michael J.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Mtaweh, Haifa; Smith, Rebecca; Kochanek, Patrick M.; Toney, Nicole A.; Bell, Michael J.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Wisniewski, Stephen R.; Fabio, Anthony] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA; [Adelson, P. David] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ USA; [Bell, Michael J.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA	Bell, MJ (corresponding author), Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA.	bellmj4@upmc.edu	Kochanek, Patrick M/D-2371-2015; Smith, Rebecca L/N-5911-2014; Adelson, David/W-2083-2019	Kochanek, Patrick M/0000-0002-2627-913X; Fabio, Anthony/0000-0002-6808-4939; Wisniewski, Stephen/0000-0002-3877-9860	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS070003]; US ArmyUnited States Department of Defense; DARPAUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA); Laerdal Foundation; AHAAmerican Heart Association; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS070003] Funding Source: NIH RePORTER	Dr. Bell received support for article research from the National Institutes of Health. His institution received grant support from NIH. Dr. Smith received support for travel from the University of Pittsburgh Medical Center and Safar Center for Resuscitation Research, is employed as PICU fellow and attending at the University of Pittsburgh Medical Center, and received support for article research from NIH. Her institution received grant support from NIH (T32 Grant). Dr. Kochanek disclosed United States provisional patents (Method of Inducing EPR Following Cardiopulmonary Arrest 6/22/05, CMU Invention Disclosure 2012-081: Validation of a Multiplex Biomarker Panel for Detection of Abusive Head Trauma in Well-Appearing Children 1/10/2012, and United States Invention Disclosure: Small Molecule Inhibitors of RNA Binding MOTIF (RBM) Proteins for the Treatment of Acute Cellular Injury). He received support for article research from NIH. His institution received grant support from NIH (NS070003), US Army, DARPA, Laerdal Foundation, and AHA (Dr. Kochanek has numerous grants under consideration from these entities, including grants for trainees). Dr. Wisniewski's institution received grant support from NIH. Dr. Adelson receives royalties from Thieme Publishing and consulted for Tramatec. His institution received grant support from NIH, Integra Life Sciences, and Codman. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS68; Adelson PD, 2013, LANCET NEUROL, V12, P546, DOI 10.1016/S1474-4422(13)70077-2; Bell MJ, 2013, PEDIATR CRIT CARE ME, V14, P811, DOI 10.1097/PCC.0b013e3182975e2f; BENOTTI PN, 1989, CRIT CARE MED, V17, P181, DOI 10.1097/00003246-198902000-00017; BORZOTTA AP, 1994, J TRAUMA, V37, P459, DOI 10.1097/00005373-199409000-00022; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS77; Briassoulis G, 2005, INTENS CARE MED, V31, P851, DOI 10.1007/s00134-005-2631-3; Bruder N, 1998, CRIT CARE MED, V26, P568, DOI 10.1097/00003246-199803000-00033; BRUDER N, 1994, CRIT CARE MED, V22, P1114, DOI 10.1097/00003246-199407000-00011; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CARLSON GL, 1994, AM J PHYSIOL, V266, pE845; CLIFTON GL, 1986, J NEUROSURG, V64, P895, DOI 10.3171/jns.1986.64.6.0895; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; Coss-Bu JA, 1998, AM J CLIN NUTR, V67, P74; COVELLI HD, 1981, ANN INTERN MED, V95, P579, DOI 10.7326/0003-4819-95-5-579; DEMPSEY DT, 1985, SURG GYNECOL OBSTET, V160, P128; Exo J, 2009, Ped Health, V3, P533, DOI 10.2217/phe.09.54; Faul MD, 2010, TRAMAUTIC BRAIN INJU; Foley N, 2008, J NEUROTRAUM, V25, P1415, DOI 10.1089/neu.2008.0628; FRASER IM, 1986, CLIN CHEST MED, V7, P131; HADFIELD JM, 1992, INJURY, V23, P177, DOI 10.1016/S0020-1383(05)80040-3; Harris JA, 1918, P NATL ACAD SCI USA, V4, P370, DOI 10.1073/pnas.4.12.370; Havalad Suresh, 2006, Nutr Clin Pract, V21, P175, DOI 10.1177/0115426506021002175; Heyland DK, 2003, JPEN-PARENTER ENTER, V27, P74, DOI 10.1177/014860710302700174; HEYMSFIELD SB, 1987, AM J CLIN NUTR, V45, P526; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Malakouti A, 2012, PEDIATR CRIT CARE ME, V13, pE18, DOI 10.1097/PCC.0b013e31820aba1f; MATTHEWS DSF, 1995, PEDIATR RES, V37, P409, DOI 10.1203/00006450-199504000-00005; McCall M, 2003, JPEN-PARENTER ENTER, V27, P27, DOI 10.1177/014860710302700127; MOORE R, 1989, J TRAUMA, V29, P1633, DOI 10.1097/00005373-198912000-00007; Naumann RB, 2010, TRAFFIC INJ PREV, V11, P353, DOI 10.1080/15389588.2010.486429; Osuka A, 2013, J CRIT CARE, V28, DOI 10.1016/j.jcrc.2012.05.012; PHILLIPS R, 1987, J NEUROSURG, V67, P846, DOI 10.3171/jns.1987.67.6.0846; ROBERTSON CS, 1984, NEUROSURGERY, V15, P307, DOI 10.1227/00006123-198409000-00003; ROBERTSON CS, 1985, J NEUROSURG, V63, P714, DOI 10.3171/jns.1985.63.5.0714; Rubinson L, 2004, CRIT CARE MED, V32, P350, DOI 10.1097/01.CCM.0000089641.06306.68; Saadat SMS, 2012, CHILD NERV SYST, V28, P1773, DOI 10.1007/s00381-012-1753-5; Smith RL, 2012, PEDIATR CRIT CARE ME, V13, P85, DOI 10.1097/PCC.0b013e3182192c30; Stanley RM, 2012, PEDIATRICS, V129, pE24, DOI 10.1542/peds.2011-2074; Suman OE, 2006, BURNS, V32, P335, DOI 10.1016/j.burns.2005.10.023; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013; Vernon DD, 2000, CRIT CARE MED, V28, P1569, DOI 10.1097/00003246-200005000-00051; Weekes Elizabeth, 1996, Journal of Parenteral and Enteral Nutrition, V20, P31, DOI 10.1177/014860719602000131; YOUNG B, 1985, NEUROSURGERY, V17, P784, DOI 10.1227/00006123-198511000-00010	44	24	27	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAR	2014	15	3					242	249		10.1097/PCC.0000000000000041			8	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	AG3PL	WOS:000335331700011	24394999	Green Accepted			2021-06-18	
J	Rau, TF; Kothiwal, AS; Rova, AR; Brooks, DM; Rhoderick, JF; Poulsen, AJ; Hutchinson, J; Poulsen, DJ				Rau, Thomas F.; Kothiwal, Aakriti S.; Rova, Annela R.; Brooks, Diane M.; Rhoderick, Joseph F.; Poulsen, Austin J.; Hutchinson, Jim; Poulsen, David J.			Administration of low dose methamphetamine 12 h after a severe traumatic brain injury prevents neurological dysfunction and cognitive impairment in rats	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Neuroprotection; Methamphetamine	PROTEIN 88 MYD88; CORTICOTROPIN-RELEASING HORMONE; MOTOR CORTEX INJURY; EXPRESSION; MODEL; AMPHETAMINE; HIPPOCAMPUS; RECOVERY; NEUROPROTECTION; PHARMACOLOGY	We recently published data that showed low dose of methamphetamine is neuroprotective when delivered 3 h after a severe traumatic brain injury (TBI). In the current study, we further characterized the neuroprotective potential of methamphetamine by determining the lowest effective dose, maximum therapeutic window, pharmacokinetic profile and gene expression changes associated with treatment. Graded doses of methamphetamine were administered to rats beginning 8 h after severe TBI. We assessed neuroprotection based on neurological severity scores, foot fault assessments, cognitive performance in the Morris water maze, and histopathology. We defined 0250 mg/kg/h as the lowest effective dose and treatment at 12 has the therapeutic window following severe TBI. We examined gene expression changes following TBI and methamphetamine treatment to further define the potential molecular mechanisms of neuroprotection and determined that methamphetamine significantly reduced the expression of key pro-inflammatory signals. Pharmacokinetic analysis revealed that a 24-hour intravenous infusion of methamphetamine at a dose of 0.500 mg/kg/h produced a plasma C-max value of 25.9 ng/ml and a total exposure of 544 ng/ml over a 32 hour time frame. This represents almost half the 24-hour total exposure predicted for a daily oral dose of 25 mg in a 70 kg adult human. Thus, we have demonstrated that methamphetamine is neuroprotective when delivered up to 12 h after injury at doses that are compatible with current FDA approved levels. (C) 2013 The Authors. Published by Elsevier Inc. All rights reserved.	[Rau, Thomas F.; Kothiwal, Aakriti S.; Rova, Annela R.; Brooks, Diane M.; Rhoderick, Joseph F.; Poulsen, Austin J.; Poulsen, David J.] Univ Montana, Dept Biomed & Pharmaceut Sci, Missoula, MT 59812 USA; [Hutchinson, Jim] Montana Dept Justice, Forens Sci Div, Missoula, MT 59808 USA	Poulsen, DJ (corresponding author), Univ Montana, Dept Biomed & Pharmaceut Sci, 32 Campus Dr, Missoula, MT 59812 USA.	david.poulsen@umontana.edu					Administration F.a.D, 2007, DES PROD INF; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Brown GC, 2010, MOL NEUROBIOL, V41, P242, DOI 10.1007/s12035-010-8105-9; Cadet JL, 2009, INT REV NEUROBIOL, V88, P101, DOI 10.1016/S0074-7742(09)88005-7; Charron C, 2008, BEHAV BRAIN RES, V188, P125, DOI 10.1016/j.bbr.2007.10.027; Chen WM, 2009, MOL CELL, V34, P663, DOI 10.1016/j.molcel.2009.04.029; Coffeen U, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-75; Cravey B., 1982, INTRO FORENSIC TOXIC, P90; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Dempsey Kenneth E, 2009, J Trauma Nurs, V16, P6, DOI 10.1097/01.JTN.0000348063.41099.a7; Ding GL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061241; Dolan S, 2012, NEUROPSYCHOL REV, V22, P21, DOI 10.1007/s11065-012-9190-5; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1981, P W PHARMACOL SOC, V24, P15; FEENEY DM, 1983, PSYCHOPHARMACOLOGY, V79, P67, DOI 10.1007/BF00433018; Gheysen F, 2010, EXP BRAIN RES, V202, P795, DOI 10.1007/s00221-010-2186-6; Gorchetchnikov A, 2007, NEURAL NETWORKS, V20, P182, DOI 10.1016/j.neunet.2006.11.007; Grossberg S, 1996, J COGNITIVE NEUROSCI, V8, P257, DOI 10.1162/jocn.1996.8.3.257; Grossberg S, 2006, PSYCHOL REV, V113, P483, DOI 10.1037/0033-295X.113.3.483; Gupta SC, 2012, ANTIOXID REDOX SIGN, V16, P1295, DOI 10.1089/ars.2011.4414; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Jin W, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/725174; Koutmani Y, 2013, MOL PSYCHIATR, V18, P300, DOI 10.1038/mp.2012.198; Krasnova IN, 2009, BRAIN RES REV, V60, P379, DOI 10.1016/j.brainresrev.2009.03.002; Lee LL, 2004, EXP NEUROL, V190, P70, DOI 10.1016/j.expneurol.2004.07.003; Li GZ, 2011, BRAIN RES, V1396, P96, DOI 10.1016/j.brainres.2011.04.014; Li W, 2013, J SURG RES, V180, P133, DOI 10.1016/j.jss.2012.10.928; Ling HP, 2013, J SURG RES, V179, pE227, DOI 10.1016/j.jss.2012.03.030; Lippert-Gruener M, 2007, EXP NEUROL, V203, P82, DOI 10.1016/j.expneurol.2006.07.025; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Luo T, 2013, ANESTHESIOLOGY, V119, P1370, DOI 10.1097/ALN.0000000000000020; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Martin E.M, 2008, J TRAUMA NURS, V15, P100; Martin Elisabeth Moy, 2008, J Trauma Nurs, V15, P94, DOI 10.1097/01.JTN.0000337149.29549.28; Mendelson J, 2006, CLIN PHARMACOL THER, V80, P403, DOI 10.1016/j.clpt.2006.06.013; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Ooigawa H, 2006, ACTA NEUROPATHOL, V112, P471, DOI 10.1007/s00401-006-0108-2; Otani N, 2007, J CLIN NEUROSCI, V14, P42, DOI 10.1016/j.jocn.2005.11.044; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; Prevention C.f.D.C.a, 2006, TRAUMATIC BRAIN INJU; Rau T.K., 2012, J TRAUMA ACUTE CARE, V73; Rau TF, 2011, NEUROPHARMACOLOGY, V61, P677, DOI 10.1016/j.neuropharm.2011.05.010; Reeves RR, 2011, J PSYCHOSOC NURS MEN, V49, P42, DOI 10.3928/02793695-20110201-03; Saulle M, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/816069; Schober ME, 2012, METAB BRAIN DIS, V27, P167, DOI 10.1007/s11011-012-9309-7; Semple BD, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-67; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shao W, 2013, NATURE, V494, P90, DOI 10.1038/nature11748; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; SOZZANI S, 1994, J IMMUNOL, V152, P3615; SOZZANI S, 1994, BIOCHEM BIOPH RES CO, V199, P761, DOI 10.1006/bbrc.1994.1294; Stevens SL, 2003, J CEREBR BLOOD F MET, V23, P1151, DOI 10.1097/01.WCB.0000086957.72078.D4; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Vaarmann A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.194; Wittenberg GM, 2002, HIPPOCAMPUS, V12, P637, DOI 10.1002/hipo.10102; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhang ZR, 2012, NEUROIMMUNOMODULAT, V19, P10, DOI 10.1159/000326771; 1996, MERCK INDEX ENCY CHE	63	24	25	0	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2014	253						31	40		10.1016/j.expneurol.2013.12.001			10	Neurosciences	Neurosciences & Neurology	AB8QS	WOS:000332055700004	24333768	Other Gold			2021-06-18	
J	Andruszkow, H; Deniz, E; Urner, J; Probst, C; Grun, O; Lohse, R; Frink, M; Krettek, C; Zeckey, C; Hildebrand, F				Andruszkow, Hagen; Deniz, Ezin; Urner, Julia; Probst, Christian; Gruen, Orna; Lohse, Ralf; Frink, Michael; Krettek, Christian; Zeckey, Christian; Hildebrand, Frank			Physical and psychological long-term outcome after traumatic brain injury in children and adult patients	HEALTH AND QUALITY OF LIFE OUTCOMES			English	Article						Traumatic brain injury; Long-term outcome; Morbidity; Children	RECOVERY 10 YEARS; QUALITY-OF-LIFE; YOUNG-CHILDREN; PRACTICAL SCALE; HEAD-INJURIES; HEALTH SURVEY; EVENT SCALE; PREDICTORS; ADOLESCENTS; POLYTRAUMA	Background: Several studies have indicated that younger age is associated with worse recovery after pediatric traumatic brain injury (TBI) compared to elder children. In order to verify this association between long-term outcome after moderate to severe TBI and patient's age, direct comparison between different pediatric age groups as well as an adult population was performed. Methods: This investigation represents a retrospective cohort study at a level I trauma center including patients with moderate to severe, isolated TBI with a minimum follow-up of 10 years. According to their age at time of injury, patients were divided in pre-school (0-7 years), school (8-17 years) and adult (18-65 years) patients. Physical examination and standardized questionnaire on physical and psychological aspects (Glasgow Outcome Scale, Barthel Index, Impact of Event Scale, Hospital Anxiety and Depression Scale, short form 12) were performed. Results: 135 traumatized patients were included. Physical and psychological long-term outcome was associated with injury severity but not with patients' age at time of injury. Outcome recovery measured by Glasgow Outcome Scale was demonstrated with best results for pre-school aged children (p = 0.009). According to the Hospital Anxiety and Depression Scale an increased incidence of anxiety (p = 0.010) and depression (p = 0.026) was evaluated in older patients. Conclusion: Long-term outcome perceptions after moderate to severe TBI presented in this study question current views of deteriorated recovery for the immature brain. The sustained TBI impact seemed not to reduce the child's ability to overcome the suffered impairment measured by questionnaire based psychological, physical and health related outcome scores. These results distinguish the relevance of rehabilitation and family support in the long term.	[Andruszkow, Hagen; Hildebrand, Frank] Univ Aachen, Dept Orthopaed Trauma, D-52074 Aachen, Germany; [Probst, Christian] Univ Witten Herdecke, Sch Med, Cologne Merheim Med Ctr, Dept Trauma & Orthopaed Surg,Fac Hlth, D-51109 Cologne, Germany; [Gruen, Orna; Lohse, Ralf] Hannover Re Insurance, D-30625 Hannover, Germany; [Frink, Michael] Univ Med Ctr Marburg, Dept Trauma Hand & Reconstruct Surg, D-35043 Marburg, Germany; [Andruszkow, Hagen; Deniz, Ezin; Urner, Julia; Frink, Michael; Krettek, Christian; Zeckey, Christian] Hannover Med Sch, Trauma Dept, D-30625 Hannover, Germany	Andruszkow, H (corresponding author), Univ Aachen, Dept Orthopaed Trauma, Pauwelsstr 30, D-52074 Aachen, Germany.	handruszkow@ukaachen.de	Hildebrand, Frank/J-3176-2017	Krettek, Christian/0000-0001-9807-0020	Hannover Life Re-Insurance, Hannover, Germany	Industrial support was provided by Hannover Life Re-Insurance, Hannover, Germany. Nicola Alexander Sittaro, MD and Ralf Lohse, PhD gave advice. The Trauma Department, Hannover Medical School, Hannover, Germany, has received funding from Hannover Life Re-Insurance, Hannover, Germany, during the study period. No direct or indirect financial support or other assets were transferred to the authors of this study.	Ahmadi SA, 2010, BRAIN INJURY, V24, P1539, DOI 10.3109/02699052.2010.523049; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Anderson V, 2012, PEDIATRICS, V129, pE254, DOI 10.1542/peds.2011-0311; Anderson V, 2009, PEDIATRICS, V124, pE1064, DOI 10.1542/peds.2009-0365; Andruszkow H, 2013, PATIENT SAF SURG, V7, DOI 10.1186/1754-9493-7-32; Bailey BM, 2012, J TRAUMA ACUTE CARE, V72, P263, DOI 10.1097/TA.0b013e31822a9512; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; BULLINGER M, 1995, SOC SCI MED, V41, P1359, DOI 10.1016/0277-9536(95)00115-N; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Catroppa C, 2012, J NEUROTRAUM, V29, P2539, DOI 10.1089/neu.2012.2403; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Crowe L, 2009, J PAEDIATR CHILD H, V45, P346, DOI 10.1111/j.1440-1754.2009.01499.x; Crowe LM, 2012, PEDIATRICS, V129, pE262, DOI 10.1542/peds.2011-0438; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Greenspan AI, 2006, BRAIN INJURY, V20, P733, DOI 10.1080/02699050600773276; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; HAHN YS, 1988, CHILD NERV SYST, V4, P34; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Hawley CA, 2012, NEUROREHABILITATION, V30, P173, DOI 10.3233/NRE-2012-0742; Hung MC, 2014, MED CARE, V52, P63, DOI 10.1097/MLR.0000000000000010; Jacobsson LJ, 2010, BRAIN INJURY, V24, P1075, DOI 10.3109/02699052.2010.494590; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JENNETT B, 1975, LANCET, V1, P480; Kramer ME, 2013, J HEAD TRAUMA REHAB, V28, P361, DOI 10.1097/HTR.0b013e31824da031; Lippert-Gruner M, 2007, BRAIN INJURY, V21, P451, DOI 10.1080/02699050701343961; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MAHONEY F I, 1965, Md State Med J, V14, P61; Max JE, 2012, J NEUROPSYCH CLIN N, V24, P427, DOI 10.1176/appi.neuropsych.12060149; Pape HC, 2006, INJURY, V37, P1197, DOI 10.1016/j.injury.2006.07.032; Probst C, 2010, J TRAUMA, V68, P706, DOI 10.1097/TA.0b013e3181a8b21c; REILLY PL, 1988, CHILD NERV SYST, V4, P30; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Sundin EC, 2003, PSYCHOSOM MED, V65, P870, DOI 10.1097/01.PSY.0000084835.46074.F0; Suskauer SJ, 2009, DEV DISABIL RES REV, V15, P117, DOI 10.1002/ddrr.62; TEASDALE G, 1974, LANCET, V2, P81; TOMPKINS CA, 1990, BRAIN COGNITION, V13, P86, DOI 10.1016/0278-2626(90)90042-M; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Zigmond AS, 1983, PSYCHIAT SCAND, V76, P361, DOI DOI 10.1111/J.1600-0447.1983.TB09716.X; ZILBERG NJ, 1982, J CONSULT CLIN PSYCH, V50, P407, DOI 10.1037/0022-006X.50.3.407; Zumstein MA, 2011, J TRAUMA, V71, P120, DOI 10.1097/TA.0b013e3181f2d670	43	24	24	1	19	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1477-7525			HEALTH QUAL LIFE OUT	Health Qual. Life Outcomes	FEB 26	2014	12								26	10.1186/1477-7525-12-26			8	Health Care Sciences & Services; Health Policy & Services	Health Care Sciences & Services	AF8IQ	WOS:000334959600001	24571742	DOAJ Gold, Green Published			2021-06-18	
J	Schober, ME; Requena, DF; Block, B; Davis, LJ; Rodesch, C; Casper, TC; Juul, SE; Kesner, RP; Lane, RH				Schober, Michelle E.; Requena, Daniela F.; Block, Benjamin; Davis, Lizeth J.; Rodesch, Christopher; Casper, T. Charles; Juul, Sandra E.; Kesner, Raymond P.; Lane, Robert H.			Erythropoietin Improved Cognitive Function and Decreased Hippocampal Caspase Activity in Rat Pups after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; controlled cortical impect; developmental; EPO; memory	RECOMBINANT ERYTHROPOIETIN; CEREBROSPINAL-FLUID; NERVOUS-SYSTEM; PROTECTS; MODEL; PHARMACOKINETICS; RECEPTOR; NEUROPROTECTION; LOCALIZATION; APOPTOSIS	Traumatic brain injury (TBI) is a leading cause of acquired neurologic disability in children. Erythropoietin (EPO), an anti-apoptotic cytokine, improved cognitive outcome in adult rats after TBI. To our knowledge, EPO has not been studied in a developmental TBI model. Hypothesis: We hypothesized that EPO would improve cognitive outcome and increase neuron fraction in the hippocampus in 17-day-old (P17) rat pups after controlled cortical impact (CCI). Methods: EPO or vehicle was given at 1, 24, and 48h after CCI and at post injury day (PID) 7. Cognitive outcome at PID14 was assessed using Novel Object Recognition (NOR). Hippocampal EPO levels, caspase activity, and mRNA levels of the apoptosis factors Bcl2, Bax, Bcl-xL, and Bad were measured during the first 14 days after injury. Neuron fraction and caspase activation in CA1, CA3, and DG were studied at PID2. Results: EPO normalized recognition memory after CCI. EPO blunted the increased hippocampal caspase activity induced by CCI at PID1, but not at PID2. EPO increased neuron fraction in CA3 at PID2. Brain levels of exogenous EPO appeared low relative to endogenous. Timing of EPO administration was associated with temporal changes in hippocampal mRNA levels of EPO and pro-apoptotic factors. Conclusion/Speculation: EPO improved recognition memory, increased regional hippocampal neuron fraction, and decreased caspase activity in P17 rats after CCI. We speculate that EPO improved cognitive outcome in rat pups after CCI as a result of improved neuronal survival via inhibition of caspase-dependent apoptosis early after injury.	[Schober, Michelle E.; Casper, T. Charles] Univ Utah, Dept Pediat, Div Crit Care, Salt Lake City, UT 84158 USA; [Requena, Daniela F.; Block, Benjamin; Davis, Lizeth J.; Lane, Robert H.] Univ Utah, Dept Pediat, Div Neonatol, Salt Lake City, UT 84158 USA; [Rodesch, Christopher] Univ Utah, Dept Pediat, Div Hlth Sci Res Core Facil, Salt Lake City, UT 84158 USA; [Kesner, Raymond P.] Univ Utah, Dept Psychol, Salt Lake City, UT 84158 USA; [Juul, Sandra E.] Univ Washington, Sch Med, Div Neonatol, Seattle, WA USA	Schober, ME (corresponding author), Univ Utah, Sch Med, Dept Pediat, Div Crit Care, POB 581289, Salt Lake City, UT 84158 USA.	michelle.schober@hsc.utah.edu			CHRCDA [NIH K12HD001410]; Divisions of Neonatology and Pediatric Critical Care Medicine, Department of Pediatrics, University of Utah, Salt Lake City, Utah; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001410] Funding Source: NIH RePORTER	Statement of Financial Support: funding for this study was provided by the CHRCDA (NIH K12HD001410) and from the Divisions of Neonatology and Pediatric Critical Care Medicine, Department of Pediatrics, University of Utah, Salt Lake City, Utah. Input on histology from Scott Rogers, PhD<SUP>1</SUP> is greatly appreciated.	Agarwal MK, 2004, CELL CYCLE, V3, P205; Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Ammar HI, 2011, AM J PHYSIOL-HEART C, V301, pH2413, DOI 10.1152/ajpheart.01096.2010; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson V, 2012, INT J DEV NEUROSCI, V30, P217, DOI 10.1016/j.ijdevneu.2011.09.008; Antunes M, 2012, COGN PROCESS, V13, P93, DOI 10.1007/s10339-011-0430-z; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Bittigau P, 2004, EXP TOXICOL PATHOL, V56, P83, DOI 10.1016/j.etp.2004.04.006; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Broadbent NJ, 2010, LEARN MEMORY, V17, P794, DOI 10.1101/lm.1650110; Catroppa C, 2007, CHILD NEUROPSYCHOL, V13, P240, DOI 10.1080/09297040600837362; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; Chong ZZ, 2003, BRIT J PHARMACOL, V138, P1107, DOI 10.1038/sj.bjp.0705161; D'Amelio M, 2010, CELL DEATH DIFFER, V17, P1104, DOI 10.1038/cdd.2009.180; Dame C, 2001, BIOL NEONATE, V79, P228; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; Dzietko M, 2004, NEUROBIOL DIS, V15, P177, DOI 10.1016/j.nbd.2003.10.006; Gonzalez FF, 2007, DEV NEUROSCI-BASEL, V29, P321, DOI 10.1159/000105473; Gonzalez FF, 2009, DEV NEUROSCI-BASEL, V31, P403, DOI 10.1159/000232558; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; Hagemeyer N, 2012, MOL MED, V18, P628, DOI 10.2119/molmed.2011.00457; Juul SE, 2008, PEDIATRICS, V122, P383, DOI 10.1542/peds.2007-2711; Juul SE, 1999, PEDIATR DEVEL PATHOL, V2, P148, DOI 10.1007/s100249900103; Juul SE, 2004, BIOL NEONATE, V85, P138, DOI 10.1159/000074970; Kim SS, 2008, J KOREAN MED SCI, V23, P484, DOI 10.3346/jkms.2008.23.3.484; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li Y, 2008, ACTA NEUROCHIR SUPPL, V105, P105; Li Yun-Xia, 2008, Neurosci Bull, V24, P89, DOI 10.1007/s12264-008-0089-3; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; Liao ZB, 2009, NEUROL INDIA, V57, P722, DOI 10.4103/0028-3886.59466; Lieutaud T, 2008, J NEUROTRAUM, V25, P1179, DOI 10.1089/neu.2008.0591; Liu J, 2006, GLIA, V53, P360, DOI 10.1002/glia.20289; Lowthert L, 2012, BIOL MOOD ANXIETY DI, V2, DOI 10.1186/2045-5380-2-15; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; Maiese K, 2004, TRENDS PHARMACOL SCI, V25, P577, DOI 10.1016/j.tips.2004.09.006; Mammis A, 2009, SURG NEUROL, V71, P527, DOI 10.1016/j.surneu.2008.02.040; Mandalis A, 2007, DEV NEUROPSYCHOL, V32, P683, DOI 10.1080/87565640701376045; Marvizon JCG, 2007, NEUROSCIENCE, V148, P250, DOI 10.1016/j.neuroscience.2007.05.036; McBride J, 2013, IEEE T BIO-MED ENG, V60, P90, DOI 10.1109/TBME.2012.2223698; Noguchi CT, 2007, CRIT REV ONCOL HEMAT, V64, P159, DOI 10.1016/j.critrevonc.2007.03.001; Pavlica S, 2012, BRAIN RES, V1452, P18, DOI 10.1016/j.brainres.2012.02.043; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Pierce DR, 2011, BRAIN RES, V1378, P54, DOI 10.1016/j.brainres.2011.01.028; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Polster BM, 2003, CELL DEATH DIFFER, V10, P365, DOI 10.1038/sj.cdd.4401158; Ponce LL, 2012, PATHOPHYSIOLOGY, V20, P31; Rakusan K, 2001, AM J PHYSIOL-HEART C, V281, pH2425; Reger ML, 2009, DEV PSYCHOBIOL, V51, P672, DOI 10.1002/dev.20402; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.2307/3454543; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Sargin D, 2009, GLIA, V57, P693, DOI 10.1002/glia.20797; Scafidi S, 2010, DEV NEUROSCI-BASEL, V32, P480, DOI 10.1159/000323178; Schober ME, 2010, J NEUROTRAUM, V27, P2011, DOI 10.1089/neu.2009.1226; Scott HL, 2012, EUR J NEUROSCI, V36, P2941, DOI 10.1111/j.1460-9568.2012.08220.x; Shein NA, 2008, J NEUROTRAUM, V25, P112, DOI 10.1089/neu.2007.0358; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Sola A, 2005, PEDIATR RES, V57, p110R, DOI 10.1203/01.PDR.0000159571.50758.39; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Statler PA, 2007, PEDIATR RES, V61, P671, DOI 10.1203/pdr.0b013e31805341dc; SWIGART RH, 1965, CIRC RES, V17, P30, DOI 10.1161/01.RES.17.1.30; Tang ZH, 2013, NEUROPHARMACOLOGY, V67, P8, DOI 10.1016/j.neuropharm.2012.10.017; Vairano M, 2002, EUR J NEUROSCI, V16, P584, DOI 10.1046/j.1460-9568.2002.02125.x; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443; Wang Y, 2007, BRIT J PHARMACOL, V151, P1377, DOI 10.1038/sj.bjp.0707285; Wu YW, 2012, PEDIATRICS, V130, P683, DOI 10.1542/peds.2012-0498; Xenocostas A, 2005, EUR J CLIN PHARMACOL, V61, P189, DOI 10.1007/s00228-005-0896-7; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2010, J NEUROTRAUM, V27, P205, DOI 10.1089/neu.2009.1001; Yamada M, 2011, J PATHOL, V224, P101, DOI 10.1002/path.2862; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Zhang YL, 2012, EXP NEUROL, V235, P336, DOI 10.1016/j.expneurol.2012.02.015; Zhu L, 2009, BRAIN RES, V1289, P96, DOI 10.1016/j.brainres.2009.07.015	76	24	25	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2014	31	4					358	369		10.1089/neu.2013.2922			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AA7PY	WOS:000331290600008	23972011	Green Published			2021-06-18	
J	Cuthbert, JP; Staniszewski, K; Hays, K; Gerber, D; Natale, A; O'Dell, D				Cuthbert, Jeffrey P.; Staniszewski, Kristi; Hays, Kaitlin; Gerber, Don; Natale, Audrey; O'Dell, Denise			Virtual reality-based therapy for the treatment of balance deficits in patients receiving inpatient rehabilitation for traumatic brain injury	BRAIN INJURY			English	Article						Balance; BBS; brain injuries; FGA; virtual reality; Wii	EXERCISE PROGRAMS; MOTOR IMPAIRMENT; OUTCOME MEASURES; STROKE; RELIABILITY; VALIDITY; SYSTEM; SCALE; GAIT	Objective: To evaluate the feasibility and safety of utilizing a commercially available virtual reality gaming system as a treatment intervention for balance training. Design: A randomized controlled trial in which assessment and analysis were blinded. Setting: An inpatient rehabilitation facility. Intervention: Interventions included balance-based physical therapy using a Nintendo Wii, as monitored by a physical therapist, and receipt of one-on-one balance-based physical therapy using standard physical therapy modalities available for use in the therapy gym. Results: Participants in the standard physical therapy group were found to have slightly higher enjoyment at mid-intervention, while those receiving the virtual reality-based balance intervention were found to have higher enjoyment at study completion. Both groups demonstrated improved static and dynamic balance over the course of the study, with no significant differences between groups. Correlational analyses suggest a relationship exists between Wii balance board game scores and BBS scores for measures taken beyond the baseline assessment. Conclusions: This study provides a modest level of evidence to support using commercially available VR gaming systems for the treatment of balance deficits in patients with a primary diagnosis of TBI receiving inpatient rehabilitation. Additional research of these types of interventions for the treatment of balance deficits is warranted.	[Cuthbert, Jeffrey P.; Staniszewski, Kristi; Hays, Kaitlin; Gerber, Don; Natale, Audrey; O'Dell, Denise] Craig Hosp, Res Dept, Englewood, CO USA	Cuthbert, JP (corresponding author), 3425 S Clarkson St, Englewood, CO 80113 USA.	jcuthbert@Craighospital.org			Craig Hospital Foundation	This work was funded by the Craig Hospital Foundation. We certify that no party having a direct interest in the results of the research supporting this article has or will confer a benefit on us or on any organization with which we are associated and we certify that all financial and material support for this research are clearly identified in the title page of the manuscript.	Adamovich SV, 2009, NEUROREHABILITATION, V25, P29, DOI 10.3233/NRE-2009-0497; BERG K, 1989, Physiotherapy Canada, V41, P304; BERG KO, 1992, CAN J PUBLIC HEALTH, V83, pS7; BERG KO, 1992, ARCH PHYS MED REHAB, V73, P1073; Black K, 2000, BRAIN INJURY, V14, P141, DOI 10.1080/026990500120808; Bland DC, 2011, BRAIN INJURY, V25, P664, DOI 10.3109/02699052.2011.576306; Blum L, 2008, PHYS THER, V88, P559, DOI 10.2522/ptj.20070205; Cameirao MS, 2010, J NEUROENG REHABIL, V7, DOI 10.1186/1743-0003-7-48; Campbell M, 2005, BRAIN INJURY, V19, P1095, DOI 10.1080/02699050500188898; Cikajlo I, 2012, DISABIL REHABIL, V34, P13, DOI 10.3109/09638288.2011.583308; English CK, 2006, CLIN REHABIL, V20, P52, DOI 10.1191/0269215506cr877oa; Feld JA, 2001, NEUROREHAB NEURAL RE, V15, P239, DOI 10.1177/154596830101500312; Flynn Sheryl, 2007, J Neurol Phys Ther, V31, P180, DOI 10.1097/NPT.0b013e31815d00d5; Granger CV, 2010, AM J PHYS MED REHAB, V89, P265, DOI 10.1097/PHM.0b013e3181d3eb20; Greenwald BD, 2001, J HEAD TRAUMA REHAB, V16, P238, DOI 10.1097/00001199-200106000-00003; Hayes KW, 2003, ARTHRITIS CARE RES H, V49, pS28, DOI DOI 10.1002/ART.11411; Hellweg S, 2008, BRAIN INJURY, V22, P365, DOI 10.1080/02699050801998250; Holden MK, 2005, CYBERPSYCHOL BEHAV, V8, P187, DOI 10.1089/cpb.2005.8.187; Ivers R, 2008, INJURY PREV, V14, P209, DOI 10.1136/ip.2008.019133; KENDZIERSKI D, 1991, J SPORT EXERCISE PSY, V13, P50, DOI 10.1123/jsep.13.1.50; Kim JH, 2009, AM J PHYS MED REHAB, V88, P693, DOI 10.1097/PHM.0b013e3181b33350; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Laver KE, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008349.pub2; Liston RAL, 1996, ARCH PHYS MED REHAB, V77, P425, DOI 10.1016/S0003-9993(96)90028-3; Marshall S, 2007, BRAIN INJURY, V21, P133, DOI 10.1080/02699050701201383; Moore JB, 2009, J APPL SPORT PSYCHOL, V21, pS116, DOI 10.1080/10413200802593612; Mumford N, 2010, BRAIN INJURY, V24, P780, DOI 10.3109/02699051003652807; Raedeke T, 2003, J SPORT EXERCISE PSY, V25, pS109; Rizzo AA, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199712000-00002; Saposnik G, 2011, STROKE, V42, P1380, DOI 10.1161/STROKEAHA.110.605451; Suarez H, 2011, BRAZ J OTORHINOLAR, V77, P651, DOI 10.1590/S1808-86942011000500019; Sveistrup H, 2003, CYBERPSYCHOL BEHAV, V6, P245, DOI 10.1089/109493103322011524; Thornton M, 2005, BRAIN INJURY, V19, P989, DOI 10.1080/02699050500109944; Ustinova KI, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-61; Vos-Vromans Desiree C. W. M., 2005, Physiotherapy Theory and Practice, V21, P173, DOI 10.1080/09593980500212920; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Wang CY, 2011, ARCH PHYS MED REHAB, V92, P1238, DOI 10.1016/j.apmr.2011.03.014; WATSON MJ, 2001, PHYS THER REV, V6, P233; Wood-Dauphinee SL, 2002, CANADIAN J REHABILIT, V10, P35; Wrisley DM, 2004, PHYS THER, V84, P906, DOI 10.1093/ptj/84.10.906; Yang YR, 2008, GAIT POSTURE, V28, P201, DOI 10.1016/j.gaitpost.2007.11.007; Zhang L, 2001, AM J PHYS MED REHAB, V80, P597, DOI 10.1097/00002060-200108000-00010	43	24	27	1	44	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2014	28	2					181	188		10.3109/02699052.2013.860475			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	302XR	WOS:000330638900007	24456057				2021-06-18	
J	Goverover, Y; Chiaravalloti, N				Goverover, Yael; Chiaravalloti, Nancy			The impact of self-awareness and depression on subjective reports of memory, quality-of-life and satisfaction with life following TBI	BRAIN INJURY			English	Article						Awareness; brain injury; community integration; outcome; rehabilitation	TRAUMATIC BRAIN-INJURY; HEALTH SURVEY; DEFICITS; ASSOCIATION; VALIDATION; SYMPTOMS; RETURN; TESTS	Objective: To determine the relationship between self-awareness and depressive symptomatology with self-reports of memory, Quality-of-Life (QoL) and satisfaction with life in individuals with traumatic brain injury (TBI). Methods: Cross-sectional survey of 30 community dwelling adults, who sustained a TBI at least 1 year prior to study enrolment. Participants completed questionnaires to assess the constructs of depression, self-awareness, QoL, satisfaction with life and memory. Results: Symptoms of depression were significantly associated with self-reports of poor memory abilities, lower QoL and lower satisfaction with life. Additionally, higher levels of self-awareness were associated with lower ratings of QoL and reduced memory abilities and better strategy use regarding memory. However, when examining the contribution of each construct individually, depressive symptomatology, and not self-awareness, was significantly associated with subjective self-reports of memory, QoL and satisfaction with life. Conclusions: This pattern of relationships illustrates that, when a person has a low level of depressive symptoms, his/her reports of QoL, memory and satisfaction with life will be more positive; however, he/she will demonstrate more difficulty with self-awareness. Thus, psychological aspects of recovery must, therefore, be taken into account when using self-reported measures in the evaluation of persons who have sustained TBI.	[Goverover, Yael] NYU, Dept Occupat Therapy, New York, NY 10012 USA; [Goverover, Yael; Chiaravalloti, Nancy] Kessler Fdn Res Ctr, W Orange, NJ USA; [Chiaravalloti, Nancy] Rutgers State Univ, Dept Phys Med & Rehabil, New Jersey Med Sch, Newark, NJ 07102 USA	Goverover, Y (corresponding author), NYU, Steinhardt Sch Culture Educ & Human Dev, Dept Occupat Therapy, 35 West 4th St,11th Floor, New York, NY 10012 USA.	yg243@nyu.edu		Chiaravalloti, Nancy/0000-0003-2943-7567	Department of EducationUS Department of Education; NIDRR [H133A070037]	The authors report no conflicts of interest. The contents of this article were developed under a grant from the Department of Education, NIDRR grant number H133A070037. However, those contents do not necessarily represent the policy of the Department of Education and you should not assume endorsement by the Federal Government. This study was presented in part at the 3rd Federal Interagency Conference on TBI in Washington DC, 13-15 June 2011.	Bay E, 2008, BRAIN INJURY, V22, P233, DOI 10.1080/02699050801953073; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Chang CH, 2003, MULT SCLER J, V9, P160, DOI 10.1191/1352458503ms885oa; Corrigan J., 2000, SATISFACTION LIFE SC; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; Diaz AP, 2012, J NEUROTRAUM, V29, P1029, DOI 10.1089/neu.2011.2089; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dowds MM, 2011, J HEAD TRAUMA REHAB, V26, P339, DOI 10.1097/HTR.0b013e3181f2bf1d; Draper K, 2009, NEUROPSYCHOL REHABIL, V19, P645, DOI 10.1080/17405620802613935; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fischer S, 2004, BRAIN INJURY, V18, P547, DOI 10.1080/02699050310001645793; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; Fleming J., 1995, BRIT J OCCUP THER, V58, P55, DOI DOI 10.1177/030802269505800204; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Gandek B, 1998, J CLIN EPIDEMIOL, V51, P1171, DOI 10.1016/S0895-4356(98)00109-7; Gasquoine PG, 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187]; GILEWSKI MJ, 1990, PSYCHOL AGING, V5, P482, DOI 10.1037/0882-7974.5.4.482; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; Goverover Y, 2004, J CLIN EXP NEUROPSYC, V26, P737, DOI 10.1080/13803390490509321; Goverover Y, 2007, BRAIN INJURY, V21, P913, DOI 10.1080/02699050701553205; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P161, DOI 10.1080/09602010802188393; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; Kraus J. F., 1999, REHABILITATION ADULT, P3; Lewis L., 1991, AWARENESS DEFICIT BR, P223; Lundqvist A, 2010, BRAIN INJURY, V24, P823, DOI 10.3109/02699051003724986; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; McCrimmon S, 2006, BRAIN INJURY, V20, P1037, DOI 10.1080/02699050600909656; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Nyenhuis DL, 1998, J PERS ASSESS, V70, P386, DOI 10.1207/s15327752jpa7002_14; Ownsworth T, 2006, CLIN PSYCHOL REV, V26, P783, DOI 10.1016/j.cpr.2006.05.003; Ownsworth T, 2011, J INT NEUROPSYCH SOC, V17, P112, DOI 10.1017/S1355617710001311; Prigatano GP, 2005, ACT NEUR S, V93, P39; Sandhaug M, 2012, DISABIL REHABIL, V34, P904, DOI 10.3109/09638288.2011.626484; Schiehser DM, 2011, J CLIN EXP NEUROPSYC, V33, P704, DOI 10.1080/13803395.2011.553587; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; ZELINSKI EM, 1990, PSYCHOL AGING, V5, P388, DOI 10.1037/0882-7974.5.3.388	43	24	24	0	20	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2014	28	2					174	180		10.3109/02699052.2013.860474			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	302XR	WOS:000330638900006	24304140				2021-06-18	
J	Lapp, DW; Zhang, SS; Barnstable, CJ				Lapp, Daniel W.; Zhang, Samuel S.; Barnstable, Colin J.			Stat3 Mediates LIF-Induced Protection of Astrocytes Against Toxic ROS by Upregulating the UPC2 mRNA Pool	GLIA			English	Article						glia; oxidative stress; uncoupling protein 2	MITOCHONDRIAL UNCOUPLING PROTEIN-2; LEUKEMIA INHIBITORY FACTOR; FOCAL CEREBRAL-ISCHEMIA; RETINAL GANGLION-CELLS; TRAUMATIC BRAIN-INJURY; EMBRYONIC STEM-CELLS; REACTIVE OXYGEN; IN-VITRO; OXIDATIVE STRESS; NERVOUS-SYSTEM	Reactive oxygen species (ROS) have been implicated in various types of CNS damage, including stroke. We used a cultured astrocyte model to explore mechanisms of survival of CNS cells following ROS damage. We found that pretreatment with leukemia inhibitory factor (LIF) preserves astrocytes exposed to toxic levels of t-BHP by inhibiting an increase in intracellular ROS following t-BHP treatment. Astrocytes lacking functional Stat3 did not benefit from the pro-survival or antioxidant effects of LIF. Inhibition of mitochondrial uncoupling protein 2 (UCP2) using a chemical inhibitor or siRNA abrogates the prosurvival effects of LIF, indicating a critical role for UCP2 in modulation of mitochondrial ROS production in survival following ROS exposure. LIF treatment of astrocytes results in increased UCP2 mRNA that is accompanied by an increase in Stat3 binding to the UCP2 promoter region. Although treatment with LIF alone did not increase UCP2 protein, a combination of LIF treatment and ROS stress led to increased UCP2 protein levels. We conclude that LIF protects astrocytes from ROS-induced death by increasing UCP2 mRNA, allowing cells to respond to ROS stress by rapidly producing UCP2 protein that ultimately decreases endogenous mitochondrial ROS production. GLIA 2014;62:159-170	[Lapp, Daniel W.; Zhang, Samuel S.; Barnstable, Colin J.] Penn State Coll Med, Dept Neural & Behav Sci, Hershey, PA USA; [Zhang, Samuel S.; Barnstable, Colin J.] Penn State Coll Med, Penn State Hershey Eye Ctr, Hershey, PA USA	Barnstable, CJ (corresponding author), Penn State Milton S Hershey Med Ctr, Dept Neural & Behav Sci, 500 Univ Dr, Hershey, PA 17033 USA.	cjb30@psu.edu		Barnstable, Colin/0000-0002-7011-4068			Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Adam-Vizi V, 2006, TRENDS PHARMACOL SCI, V27, P639, DOI 10.1016/j.tips.2006.10.005; Azzu V, 2010, BBA-BIOENERGETICS, V1797, P785, DOI 10.1016/j.bbabio.2010.02.035; Banner LR, 1997, EXP NEUROL, V147, P1, DOI 10.1006/exnr.1997.6536; Barreto GE, 2011, NEUROSCI RES, V71, P107, DOI 10.1016/j.neures.2011.06.004; Boeuf H, 1997, J CELL BIOL, V138, P1207, DOI 10.1083/jcb.138.6.1207; CHAN PH, 1994, BRAIN PATHOL, V4, P59; Chan SHH, 2009, CIRC RES, V105, P886, DOI 10.1161/CIRCRESAHA.109.199018; Choi JS, 2003, GLIA, V41, P237, DOI 10.1002/glia.10186; Craig R, 2001, J BIOL CHEM, V276, P37621, DOI 10.1074/jbc.M103276200; Cui Y, 2006, EXP EYE RES, V83, P807, DOI 10.1016/j.exer.2006.03.024; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Desagher S, 1996, J NEUROSCI, V16, P2553; Dienel GA, 2005, GLIA, V50, P362, DOI 10.1002/glia.20157; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; Fang XX, 2013, CELL MOL NEUROBIOL, V33, P241, DOI 10.1007/s10571-012-9891-6; Giardina TM, 2008, BBA-BIOENERGETICS, V1777, P118, DOI 10.1016/j.bbabio.2007.11.006; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Horvath TL, 2003, BIOCHEM PHARMACOL, V65, P1917, DOI 10.1016/S0006-2952(03)00143-6; Hurtaud C, 2006, CELL MOL LIFE SCI, V63, P1780, DOI 10.1007/s00018-006-6129-0; Ibarretxe G, 2006, GLIA, V53, P201, DOI 10.1002/glia.20267; Jacoby JJ, 2003, P NATL ACAD SCI USA, V100, P12929, DOI 10.1073/pnas.2134694100; Ji JZ, 2004, EUR J NEUROSCI, V19, P265, DOI 10.1111/j.0953-816X.2003.03107.x; Jung JE, 2009, J NEUROSCI, V29, P7003, DOI 10.1523/JNEUROSCI.1110-09.2009; Kondrikov D, 2011, FREE RADICAL BIO MED, V50, P1689, DOI 10.1016/j.freeradbiomed.2011.03.020; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Liang QH, 2005, BIOCHEM PHARMACOL, V70, P1371, DOI 10.1016/j.bcp.2005.04.011; Lucius R, 1996, BRAIN RES, V743, P56, DOI 10.1016/S0006-8993(96)01029-3; Macauley SL, 2011, J NEUROSCI, V31, P15575, DOI 10.1523/JNEUROSCI.3579-11.2011; Mronga T, 2004, GLIA, V46, P446, DOI 10.1002/glia.20022; Naha PC, 2010, TOXICOL APPL PHARM, V246, P91, DOI 10.1016/j.taap.2010.04.014; NegreSalvayre A, 1997, FASEB J, V11, P809; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; OTERO GC, 1994, GLIA, V11, P117, DOI 10.1002/glia.440110207; Panickar KS, 2005, GLIA, V50, P287, DOI 10.1002/glia.20181; PARK CK, 1994, BRAIN RES, V645, P157; Pecqueur C, 2001, J MOL MED, V79, P48, DOI 10.1007/s001090000150; Peterson WM, 2000, J NEUROSCI, V20, P4081; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rousset S, 2007, FEBS LETT, V581, P479, DOI 10.1016/j.febslet.2007.01.010; Sarafian TA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009532; Schulz R., CURR PHARM IN PRESS; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; Sofroniew MV, 2000, MOL PSYCHIATR, V5, P230, DOI 10.1038/sj.mp.4000753; Spence RD, 2011, P NATL ACAD SCI USA, V108, P8867, DOI 10.1073/pnas.1103833108; Tanaka J, 1999, GLIA, V28, P85, DOI 10.1002/(SICI)1098-1136(199911)28:2<85::AID-GLIA1>3.0.CO;2-Y; Trendelenburg G, 2005, GLIA, V50, P307, DOI 10.1002/glia.20204; Wang DT, 2010, J IMMUNOL, V184, P582, DOI 10.4049/jimmunol.0902352; Zhang SSM, 2004, INVEST OPHTH VIS SCI, V45, P2407, DOI 10.1167/iovs.04-0003; Zheng Z, 2010, INVEST OPHTH VIS SCI, V51, P64, DOI 10.1167/iovs.09-3511; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	52	24	28	3	13	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	FEB	2014	62	2					159	170		10.1002/glia.22594			12	Neurosciences	Neurosciences & Neurology	268ZL	WOS:000328209300001	24307565				2021-06-18	
J	Nwachuku, EL; Puccio, AM; Fetzick, A; Scruggs, B; Chang, YF; Shutter, LA; Okonkwo, DO				Nwachuku, Enyinna L.; Puccio, Ava M.; Fetzick, Anita; Scruggs, Bobby; Chang, Yue-Fang; Shutter, Lori A.; Okonkwo, David O.			Intermittent Versus Continuous Cerebrospinal Fluid Drainage Management in Adult Severe Traumatic Brain Injury: Assessment of Intracranial Pressure Burden	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; External ventricular drain; Intracranial pressure; Neuromonitoring; Adults	SUBARACHNOID HEMORRHAGE; PEDIATRIC-PATIENTS; CHILDREN	There is clinical equipoise regarding whether neurointensive care unit management of external ventricular drains (EVD) in severe traumatic brain injury (TBI) should involve an open EVD, with continuous drainage of cerebrospinal fluid (CSF), versus a closed EVD, with intermittent opening as necessary to drain CSF. In a matched cohort design, we assessed the relative impact of continuous versus intermittent CSF drainage on intracranial pressure in the management of adult severe TBI. Sixty-two severe TBI patients were assessed. Thirty-one patients managed by open EVD drainage were matched by age, sex, and injury severity (initial Glasgow Coma Scale (GCS) score) to 31 patients treated with a closed EVD drainage. Patients in the open EVD group also had a parenchymal intracranial pressure (ICP) monitor placed through an adjacent burr hole, allowing real-time recording of ICP. Hourly ICP and other pertinent data, such as length of stay in intensive care unit (LOS-ICU), Injury Severity Score, and survival status, were extracted from our prospective database. With age, injury severity (initial GCS score), and neurosurgical intervention adjusted for, there was a statistically significant difference of 5.66 mmHg in mean ICP (p < 0.0001) between the open and the closed EVD groups, with the closed EVD group exhibiting greater mean ICP. ICP burden (ICP a parts per thousand yen 20 mmHg) was shown to be significantly higher in the intermittent EVD group (p = 0.0002) in comparison with the continuous EVD group. Continuous CSF drainage via an open EVD seemed to be associated with more effective ICP control in the management of adult severe TBI.	[Nwachuku, Enyinna L.; Puccio, Ava M.; Fetzick, Anita; Scruggs, Bobby; Chang, Yue-Fang; Shutter, Lori A.; Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA 15260 USA; [Shutter, Lori A.] Univ Pittsburgh, Med Ctr, Dept Crit Care Med, Pittsburgh, PA USA; [Shutter, Lori A.] Univ Pittsburgh, Dept Neurol, Med Ctr, Pittsburgh, PA 15260 USA	Okonkwo, DO (corresponding author), Univ Pittsburgh, Med Ctr, Dept Neurosurg, 200 Lothrop St,Suite B-400, Pittsburgh, PA 15260 USA.	okonkwodo@upmc.edu	Shutter, Lori A/G-2957-2013	Shutter, Lori/0000-0002-1390-0628	National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [2R25MH054318]; Brain Trauma Research Center; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS030318]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R25MH054318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318] Funding Source: NIH RePORTER	Mr. Nwachuku was supported by the National Institute of Mental Health (2R25MH054318) and the Brain Trauma Research Center was supported by the National Institute of Neurological Disorders and Stroke (P01 NS030318).	Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Exo J, 2011, PEDIATR CRIT CARE ME, V12, P560, DOI 10.1097/PCC.0b013e3181e8b3ee; Gigante P, 2010, BRIT J NEUROSURG, V24, P625, DOI 10.3109/02688697.2010.505989; Jagannathan J, 2008, J NEUROSURG-PEDIATR, V2, P240, DOI 10.3171/PED.2008.2.10.240; Kahraman S, 2010, J TRAUMA, V69, P110, DOI 10.1097/TA.0b013e3181c99853; Kim GS, 2011, NEUROCRIT CARE, V14, P68, DOI 10.1007/s12028-010-9401-y; Mehta A, 2010, DEV NEUROSCI-BASEL, V32, P413, DOI 10.1159/000316804; Ngo QN, 2009, PEDIATR CRIT CARE ME, V10, P346, DOI 10.1097/PCC.0b013e3181a320cd; Shore PM, 2004, NEUROSURGERY, V54, P605, DOI 10.1227/01.NEU.0000108642.88724.DB; Shore PM, 2004, J NEUROTRAUM, V21, P1113; Vender J, 2011, J CLIN MONIT COMPUT, V25, P231, DOI 10.1007/s10877-011-9300-6	11	24	25	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	FEB	2014	20	1					49	53		10.1007/s12028-013-9885-3			5	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	AB2RI	WOS:000331639400007	23943318				2021-06-18	
J	Post, A; Hoshizaki, TB; Gilchrist, MD; Brien, S; Cusimano, MD; Marshall, S				Post, Andrew; Hoshizaki, T. Blaine; Gilchrist, Michael D.; Brien, Susan; Cusimano, Michael D.; Marshall, Shawn			The influence of dynamic response and brain deformation metrics on the occurrence of subdural hematoma in different regions of the brain Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; subdural hematoma; falling injuries; injury reconstruction	HUMAN HEAD; INJURY; FALLS; RECONSTRUCTION; ACCELERATION; BIOMECHANICS; TISSUE; MODEL	Object. The purpose of this study was to examine how the dynamic response and brain deformation of the head and brain-representing a series of injury reconstructions of which subdural hematoma (SDH) was the Outcome influence the location of the lesion in the lobes of the brain. Methods. Sixteen cases of falls in which SDH was the outcome were reconstructed using a monorail drop rig and Hybrid III headform. The location of the SDH in 1 of the 4 lobes of the brain (frontal, parietal, temporal, and occipital) was confirmed by CT/MR scan examined by a neurosurgeon. Results. The results indicated that there were minimal differences between locations of the SDH for linear acceleration. The peak resultant rotational acceleration and x-axis component were larger for the parietal lobe than for other lobes. There were also some differences between the parietal lobe and the other lobes in the z-axis component. Maximum principal strain, von Mises stress, shear strain, and product of strain and strain rate all had differences in magnitude depending on the lobe in which SDH was present. The parietal lobe consistently had the largest-magnitude response, followed by the frontal lobe and the occipital lobe. Conclusions. The results indicated that there are differences in magnitude for rotational acceleration and brain deformation metrics that may identify the location of SDH in the brain.	[Post, Andrew; Hoshizaki, T. Blaine; Gilchrist, Michael D.; Brien, Susan] Univ Ottawa, Fac Hlth Sci, Sch Human Kinet, Ottawa, ON, Canada; [Gilchrist, Michael D.] Univ Coll Dublin, Sch Mech & Mat Engn, Dublin, Ireland; [Brien, Susan] Hull Hosp, Gatineau, PQ, Canada; [Cusimano, Michael D.] St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Marshall, Shawn] Ottawa Hosp, Res Inst, Ottawa, ON, Canada; [Marshall, Shawn] Univ Ottawa, Dept Med, Ottawa, ON, Canada	Post, A (corresponding author), Univ Ottawa, 200 Lees Ave,Rm A106, Ottawa, ON K1N 6N5, Canada.	apost@uottawa.ca	Lang, Steven/AAE-8102-2021; Cusimano, Michael/X-4059-2019	Lang, Steven/0000-0003-1669-9146; Cusimano, Michael/0000-0002-9989-0650; Post, Andrew/0000-0002-5960-5552	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR)	Funding for this work was received from the Canadian Institutes of Health Research (to T.B.H.). The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.	Adamec J, 2010, J FORENSIC SCI, V55, P1615, DOI 10.1111/j.1556-4029.2010.01445.x; Auer C, 2001, INT SOC BIOM 18 C JU; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Doorly M. C., 2006, Computer Methods in Biomechanics and Biomedical Engineering, V9, P371, DOI 10.1080/10255840601003551; Doorly MC, 2009, INT J CRASHWORTHINES, V14, P503, DOI 10.1080/13588260902826554; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; Gennarelli TA, 1979, STAPP CAR CRASH C, P563; Gennarelli Thomas A, 1987, P 31 STAPP CAR CRASH, DOI [10.4271/872197, DOI 10.4271/872197]; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hodgson VR, 1983, P 27 STAPP CAR CRASH, P225; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Huang HM, 1999, J TRAUMA, V47, P538, DOI 10.1097/00005373-199909000-00019; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Kraft RH, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002619; LEE MC, 1989, J BIOMECH, V22, P537, DOI 10.1016/0021-9290(89)90005-5; LOWENHIELM P, 1974, Z RECHTSMED, V74, P55, DOI 10.1007/BF01869185; Miller R.T., 1998, STAPP CAR CRASH J, P155; Monson KL, 2003, J BIOMECH ENG-T ASME, V125, P288, DOI 10.1115/1.1554412; Nahum AM., 1977, P 21 STAPP CAR CRASH, P339, DOI [10.4271/770922., DOI 10.4271/770922]; O'Riordain K, 2003, CLIN BIOMECH, V18, P590, DOI 10.1016/S0268-0033(03)00111-6; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Post A, 2012, P I MECH ENG P-J SPO, V226, P290, DOI 10.1177/1754337112436629; Prange MT, 2002, P 44 STAPP CAR CRASH, P205; Rueda MAF, 2009, FORENSIC SCI INT, V191, P52, DOI 10.1016/j.forsciint.2009.06.007; Shreiber D.I., 1997, STAPP CAR CRASH J, V41, P277; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; UENO K, 1995, J BIOMECH ENG-T ASME, V117, P319, DOI 10.1115/1.2794187; Ward C. C., 1980, P 24 STAPP CAR CRASH, P347; Willinger R, 2003, INT J CRASHWORTHINES, V8, P605, DOI 10.1533/cras.8.6.605.19261; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhou C, 1995, P 39 STAPP CAR CRASH, V39, P121, DOI DOI 10.4271/952714	33	24	24	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	FEB	2014	120	2					453	461		10.3171/2013.10.JNS131101			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	301UA	WOS:000330556400029	24313604				2021-06-18	
J	Marquine, MJ; Iudicello, JE; Morgan, EE; Brown, GG; Letendre, SL; Ellis, RJ; Deutsch, R; Woods, SP; Grant, I; Heaton, RK				Marquine, Maria J.; Iudicello, Jennifer E.; Morgan, Erin E.; Brown, Gregory G.; Letendre, Scott L.; Ellis, Ronald J.; Deutsch, Reena; Woods, Steven Paul; Grant, Igor; Heaton, Robert K.		TMARC Grp	"Frontal systems" behaviors in comorbid human immunodeficiency virus infection and methamphetamine dependency	PSYCHIATRY RESEARCH			English	Article						Substance abuse; HIV; Apathy; Impulsive behavior; Sensation	DIAGNOSTIC INTERVIEW CIDI; HUMAN PREFRONTAL CORTEX; TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; HIV-INFECTION; SENSATION SEEKING; NEUROPSYCHOLOGICAL IMPAIRMENT; RISK BEHAVIOR; SUBSTANCE USE; IMPULSIVITY	Human immunodeficiency virus (HIV) infection and methamphetamine (MA) dependence are associated with neural injury preferentially involving frontostriatal circuits. Little is known, however, about how these commonly comorbid conditions impact behavioral presentations typically associated with frontal systems dysfunction. Our sample comprised 47 HIV-uninfected/MA-nondependent; 25 HIV-uninfected/MA-dependent; 36 HIV-infected/MA-nondependent; and 28 HIV-infected/MA-dependent subjects. Participants completed self-report measures of "frontal systems" behaviors, including impulsivity/disinhibition, sensation-seeking, and apathy. They also underwent comprehensive neurocognitive and neuropsychiatric assessments that allowed for detailed characterization of neurocognitive deficits and comorbid/premorbid conditions, including lifetime Mood and Substance Use Disorders, Attention-Deficit/Hyperactivity Disorder, and Antisocial Personality Disorder. Multivariable regression models adjusting for potential confounds (i.e., demographics and comorbid/premorbid conditions) showed that MA dependence was independently associated with increased impulsivity/disinhibition, sensation-seeking and apathy, and HIV infection with greater apathy. However, we did not see synergistic/additive effects of HIV and MA on frontal systems behaviors. Global neurocognitive impairment was relatively independent of the frontal systems behaviors, which is consistent with the view that these constructs may have relatively separable biopsychosocial underpinnings. Future research should explore whether both neurocognitive impairment and frontal systems behaviors may independently contribute to everyday functioning outcomes relevant to HIV and MA. (C) 2013 Elsevier Ireland Ltd. All rights reserved.	[Marquine, Maria J.; Iudicello, Jennifer E.; Morgan, Erin E.; Brown, Gregory G.; Deutsch, Reena; Woods, Steven Paul; Grant, Igor; Heaton, Robert K.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Brown, Gregory G.] Vet Adm San Diego Healthcare Syst, San Diego, CA USA; [Letendre, Scott L.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; [Ellis, Ronald J.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA	Heaton, RK (corresponding author), Univ Calif San Diego, HIV Neurobehav Res Program, 220 Dickinson St,Suite B MC 8231, San Diego, CA 92103 USA.	rheaton@ucsd.edu	Ellis, Ronald/K-3543-2015	Ellis, Ronald/0000-0003-4931-752X; Woods, Steven Paul/0000-0003-0776-4233	National Institute on Drug Abuse (NIDA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [P50DA026306]; NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [NIDA-funded Institutional Training Grant award T32DA031098]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019934, P30MH062512, R25MH080663] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS083415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA031098, K23DA037793, P50DA026306] Funding Source: NIH RePORTER	The Translational Methamphetamine AIDS Research Center (TMARC) is supported by Center award P50DA026306 from the National Institute on Drug Abuse (NIDA) and is affiliated with the University of California, San Diego (UCSD) and the Sanford-Burnham Medical Research Institute (SBMRI).; Additional support for this research was provided by the NIDA-funded Institutional Training Grant award T32DA031098, Training in Research on Addictions in Interdisciplinary NeuroAIDS (TRAIN).	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anderson SW, 1999, NAT NEUROSCI, V2, P1032; Archibald SL, 2012, PSYCHIAT RES-NEUROIM, V202, P46, DOI 10.1016/j.pscychresns.2012.03.006; Barclay TR, 2007, HEALTH PSYCHOL, V26, P40, DOI 10.1037/0278-6133.26.1.40; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A., 2007, IOWA GAMBLING TASK P; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Blackstone K, 2013, J ADDICT MED, V7, P255, DOI 10.1097/ADM.0b013e318293653d; Bonelli Raphael M, 2007, Dialogues Clin Neurosci, V9, P141; Boyle PA, 2003, AM J GERIAT PSYCHIAT, V11, P214, DOI 10.1176/appi.ajgp.11.2.214; Boyle Patricia A, 2004, Curr Psychiatry Rep, V6, P20, DOI 10.1007/s11920-004-0033-9; Brecht ML, 2004, ADDICT BEHAV, V29, P89, DOI 10.1016/S0306-4603(03)00082-0; Cadet JL, 2007, NEUROTOX RES, V12, P181, DOI 10.1007/BF03033915; Carey CL, 2006, AIDS BEHAV, V10, P185, DOI 10.1007/s10461-005-9056-4; Carey CL, 2004, J CLIN EXP NEUROPSYC, V26, P307, DOI 10.1080/13803390490510031; Castellon SA, 2006, J CLIN EXP NEUROPSYC, V28, P420, DOI 10.1080/13803390590935444; Castellon SA, 1998, J NEUROPSYCH CLIN N, V10, P320, DOI 10.1176/jnp.10.3.320; Cattie JE, 2012, J NEUROPSYCH CLIN N, V24, P331, DOI 10.1176/appi.neuropsych.11080192; Chang L, 2005, AM J PSYCHIAT, V162, P361, DOI 10.1176/appi.ajp.162.2.361; Cherner M, 2005, NEUROLOGY, V64, P1343, DOI 10.1212/01.WNL.0000158328.26897.0D; Clarke D, 2006, PERS INDIV DIFFER, V40, P5, DOI 10.1016/j.paid.2005.05.008; Freeman HD, 2010, J PERS, V78, P1497, DOI 10.1111/j.1467-6494.2010.00659.x; Gonzalez R, 2005, J INT NEUROPSYCH SOC, V11, P121, DOI 10.1017/S1355617705050186; Grace J, 1999, ASSESSMENT, V6, P269, DOI 10.1177/107319119900600307; Heaton R K, 1995, J Int Neuropsychol Soc, V1, P231; Heaton RK, 2010, NEUROLOGY, V75, P2087, DOI 10.1212/WNL.0b013e318200d727; Heaton RK, 2004, J INT NEUROPSYCH SOC, V10, P317, DOI 10.1017/S1355617704102130; HEATON RK, 1994, PSYCHOSOM MED, V56, P8, DOI 10.1097/00006842-199401000-00001; Heaton RK, 2002, DEMOGRAPHIC EFFECTS; Heaton RK, 2004, REVISED COMPREHENSIV; Henry BL, 2010, ADDICT BEHAV, V35, P593, DOI 10.1016/j.addbeh.2010.01.013; Horn NR, 2003, NEUROPSYCHOLOGIA, V41, P1959, DOI 10.1016/S0028-3932(03)00077-0; Jernigan TL, 2005, AM J PSYCHIAT, V162, P1461, DOI 10.1176/appi.ajp.162.8.1461; KALICHMAN SC, 1994, J PERS ASSESS, V62, P385, DOI 10.1207/s15327752jpa6203_1; KALICHMAN SC, 1995, J PERS ASSESS, V65, P586, DOI 10.1207/s15327752jpa6503_16; Kalichman SC, 1996, ARCH SEX BEHAV, V25, P141, DOI 10.1007/BF02437933; Kamat R, 2012, ARCH CLIN NEUROPSYCH, V27, P520, DOI 10.1093/arclin/acs055; Kessler RC, 2004, INT J METH PSYCH RES, V13, P93, DOI 10.1002/mpr.168; Lee B, 2009, J NEUROSCI, V29, P14734, DOI 10.1523/JNEUROSCI.3765-09.2009; Leroi I, 2011, AGE AGEING, V40, P614, DOI 10.1093/ageing/afr078; Looby A, 2007, HUM PSYCHOPHARM CLIN, V22, P167, DOI 10.1002/hup.831; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; Marin RS, 1997, PSYCHIAT ANN, V27, P30, DOI 10.3928/0048-5713-19970101-08; Martin EM, 2004, J INT NEUROPSYCH SOC, V10, P931, DOI 10.1017/S1355617704107054; Martin SB, 2007, NEUROPSYCHOLOGIA, V45, P2874, DOI 10.1016/j.neuropsychologia.2007.05.009; MCNAIR DM, 1980, MANUAL PROFILE MOOD; Mikami K, 2013, AM J GERIAT PSYCHIAT, V21, P848, DOI 10.1016/j.jagp.2013.03.012; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; Plankey MW, 2007, JAIDS-J ACQ IMM DEF, V45, P85, DOI 10.1097/QAI.0b013e3180417c99; Purcell DW, 2005, AIDS, V19, pS37, DOI 10.1097/01.aids.0000167350.00503.db; Rabkin JG, 2000, J NEUROPSYCH CLIN N, V12, P451, DOI 10.1176/appi.neuropsych.12.4.451; Reid-Arndt SA, 2007, BRAIN INJURY, V21, P1361, DOI 10.1080/02699050701785062; Rippeth JD, 2004, J INT NEUROPSYCH SOC, V10, P1, DOI 10.1017/S1355617704101021; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; Salo R, 2013, PSYCHIAT RES-NEUROIM, V211, P234, DOI 10.1016/j.pscychresns.2012.10.003; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Scott JC, 2007, NEUROPSYCHOL REV, V17, P275, DOI 10.1007/s11065-007-9031-0; Semple SJ, 2005, J SUBST ABUSE TREAT, V29, P85, DOI 10.1016/j.jsat.2005.05.001; Tate D, 2003, AIDS PATIENT CARE ST, V17, P115, DOI 10.1089/108729103763807936; Tekin S, 2001, AM J GERIAT PSYCHIAT, V9, P81, DOI 10.1176/appi.ajgp.9.1.81; Velligan DI, 2002, PSYCHIAT RES, V113, P227, DOI 10.1016/S0165-1781(02)00264-0; Weber E, 2012, DRUG ALCOHOL DEPEN, V125, P146, DOI 10.1016/j.drugalcdep.2012.04.002; Whiteside SP, 2003, EXP CLIN PSYCHOPHARM, V11, P210, DOI 10.1037/1064-1297.11.3.210; Whiteside SP, 2001, PERS INDIV DIFFER, V30, P669, DOI 10.1016/S0191-8869(00)00064-7; Wilkinson GS, 2006, WIDE RANGE ACHIEVEME, V4th; Winhusen TM, 2013, DRUG ALCOHOL DEPEN, V127, P94, DOI 10.1016/j.drugalcdep.2012.06.017; WITTCHEN HU, 1994, J PSYCHIAT RES, V28, P57, DOI 10.1016/0022-3956(94)90036-1; Zawacki TM, 2002, J NEUROPSYCH CLIN N, V14, P296, DOI 10.1176/appi.neuropsych.14.3.296; Zuckerman M, 1964, J CONSULT PSYCHOL, V28, P477, DOI DOI 10.1037/H0040995	69	24	24	1	13	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-1781			PSYCHIAT RES	Psychiatry Res.	JAN 30	2014	215	1					208	216		10.1016/j.psychres.2013.11.004			9	Psychiatry	Psychiatry	AA9LF	WOS:000331414300032	24290100	Green Accepted			2021-06-18	
J	Baker, DA; Connery, AK; Kirk, JW; Kirkwood, MW				Baker, David A.; Connery, Amy K.; Kirk, John W.; Kirkwood, Michael W.			Embedded Performance Validity Indicators Within the California Verbal Learning Test, Children's Version	CLINICAL NEUROPSYCHOLOGIST			English	Article						California Verbal Learning Test; Children's Version (CVLT-C); Embedded validity indicators; Performance validity testing; Noncredible effort; Suboptimal performance; Postconcussion; Mild Traumatic Brain Injury	DISABILITY CONSULTATIVE EXAM; TRAUMATIC BRAIN-INJURY; SYMPTOM VALIDITY; DIGIT SPAN; NEUROPSYCHOLOGICAL EVALUATION; SUBOPTIMAL EFFORT; INCOMPLETE EFFORT; TEST-II; TOMM; ADOLESCENTS	To date, few studies have examined the use of embedded performance validity indicators in pediatric populations. The present study examined the utility of variables within the California Verbal Learning Test, Children's Version (CVLT-C) in detecting noncredible effort among a pediatric mild traumatic brain injury sample. The sample consisted of 411 clinically referred patients aged 8-16 years. A total of 13% of the participants failed both the Medical Symptom Validity Test and at least one other performance validity measure. No demographic or injury-related variables differentiated the noncredible and adequate effort groups. The noncredible group performed significantly worse than the adequate effort group across a majority of CVLT-C variables. Logistic regression analysis revealed that the Recognition Discriminability (RD) score was the most robust in predicting noncredible effort. Among this relatively high-functioning sample, an RD cutoff z-score of -0.5 resulted in sensitivity of 55% and specificity of 91%. A more conservative RD cutoff z-score of -1.0 resulted in sensitivity of 41% and specificity of 97%. These findings are comparable to the classification statistics found for many embedded indicators in the adult literature. Although only moderately sensitive, the RD score on the CVLT-C appears to have good utility in identifying noncredible effort in a relatively high-functioning pediatric mTBI population.	Univ Colorado Denver, Sch Med, Dept Phys Med & Rehabil, Aurora, CO USA; Childrens Hosp Colorado, Aurora, CO 80045 USA	Baker, DA (corresponding author), Childrens Hosp Colorado, Concuss Program, 13123 E 16th Ave,285, Aurora, CO 80045 USA.	david.baker@childrenscolorado.org					Bauer L, 2005, APPL NEUROPSYCHOL, V12, P202, DOI 10.1207/s15324826an1204_3; Belsley D, 1980, REGRESSION DIAGNOSTI; Belsley D, 2004, REGRESSION DIAGNOSTI; Blaskewitz N, 2008, ARCH CLIN NEUROPSYCH, V23, P379, DOI 10.1016/j.acn.2008.01.008; Boone, 2007, ASSESSMENT FEIGNED C; Boone K. B., 2008, CLIN NEUROPSYCHOL, V23, P729; Brooks BL, 2012, ARCH CLIN NEUROPSYCH, V27, P858, DOI 10.1093/arclin/acs087; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Chafetz MD, 2008, CLIN NEUROPSYCHOL, V22, P529, DOI 10.1080/13854040701346104; Chafetz MD, 2007, ARCH CLIN NEUROPSYCH, V22, P1, DOI 10.1016/j.acn.2006.10.003; Constantinou M, 2003, CHILD NEUROPSYCHOL, V9, P81, DOI 10.1076/chin.9.2.81.14505; Courtney JC, 2003, CHILD NEUROPSYCHOL, V9, P109, DOI 10.1076/chin.9.2.109.14507; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; Delis D, 1994, CALIFORNIA VERBAL LE; Delis DC, 2000, CALIFORNIA VERBAL LE; Donders J, 2005, CHILD NEUROPSYCHOL, V11, P221, DOI 10.1080/09297040490917298; Donders J, 2011, CLIN NEUROPSYCHOL, V25, P173, DOI 10.1080/13854046.2010.536781; Flaro L., 2009, NEUROPSYCHOLOGY MALI, P369; Green, 2004, GREENS MED SYMPTOM V; Green CM, 2011, CLIN NEUROPSYCHOL, V25, P585; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2005, MANUAL WORD MEMORY T; Henry G. K., 2005, FORENSIC NEUROPSYCHO, P205; Kirk JW, 2011, CHILD NEUROPSYCHOL, V17, P242, DOI 10.1080/09297049.2010.533166; Kirkwood M. W., 2013, CHILD NEUROPSYCOLOGY, DOI 10.1080/09297049.2012.759553; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Kirkwood MW, 2012, PSYCHOL ASSESSMENT, V24, P36, DOI 10.1037/a0024628; Kirkwood MW, 2011, ARCH CLIN NEUROPSYCH, V26, P377, DOI 10.1093/arclin/acr040; Kirkwood MW, 2010, CHILD NEUROPSYCHOL, V16, P604, DOI 10.1080/09297049.2010.495059; Kirkwood MW, 2010, CLIN NEUROPSYCHOL, V24, P860, DOI 10.1080/13854040903527287; Lange RT, 2010, J CLIN EXP NEUROPSYC, V32, P961, DOI 10.1080/13803391003645657; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Loughan AR, 2012, ARCH CLIN NEUROPSYCH, V27, P716, DOI 10.1093/arclin/acs072; Lu PH, 2002, CLIN NEUROPSYCHOL, V16, P90, DOI 10.1076/clin.16.1.90.8328; MacAllister WS, 2009, CHILD NEUROPSYCHOL, V15, P521, DOI 10.1080/09297040902748226; McCaffrey R. J., 2009, NEUROPSYCHOLOGY MALI, P377; McKinzey RK, 2003, BRIT J CLIN PSYCHOL, V42, P95, DOI 10.1348/014466503762842048; Miele AS, 2012, ARCH CLIN NEUROPSYCH, V27, P10, DOI 10.1093/arclin/acr084; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Slick DJ, 2000, J CLIN EXP NEUROPSYC, V22, P569, DOI 10.1076/1380-3395(200010)22:5;1-9;FT569; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Welsh AJ, 2012, ARCH CLIN NEUROPSYCH, V27, P735, DOI 10.1093/arclin/acs063; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	48	24	24	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	JAN 2	2014	28	1					116	127		10.1080/13854046.2013.858184			12	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	AA0AF	WOS:000330756800008	24229006				2021-06-18	
J	Escribano, BM; Colin-Gonzalez, AL; Santamaria, A; Tunez, I				Escribano, Begona M.; Colin-Gonzalez, Ana L.; Santamaria, Abel; Tunez, Isaac			The Role of Melatonin in Multiple Sclerosis, Huntington's Disease and Cerebral Ischemia	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Huntington's disease; melatonin; multiple sclerosis; neurodegeneration; neuroprotection; oxidative stress; stroke	NITRIC-OXIDE SYNTHASE; ERYTHROID 2-RELATED FACTOR-2; CONCUSSIVE BRAIN-INJURY; TRANSCRANIAL MAGNETIC STIMULATION; FREQUENCY ELECTROMAGNETIC-FIELDS; ACID-INDUCED NEUROTOXICITY; COLLAGEN-INDUCED ARTHRITIS; MESSENGER-RNA EXPRESSION; PINEAL HORMONE MELATONIN; TRANSGENIC MOUSE MODEL	Melatonin is produced and released by the pineal gland in a circadian rhythm. This neurohormone has proven to be an antioxidant and anti-inflammatory molecule able to reduce or mitigate cell damage associated with oxidative stress and inflammation, and this phenomenon underlies neurodegenerative disorders. These facts have drawn attention to this indole, triggering interest in evaluating its changes and in its relationship to the processes indicated, and analyzing its role in the mechanisms involved at the onset and development of neurodegenerative diseases, as well as its therapeutic potential. Multiple sclerosis, the most common cause of non-traumatic disability in young adults, is a chronic neuroinflammatory disease, characterized by demyelination, inflammation, and neuronal and oxidative damage. In its early diagnosis, it often requires a differential screening with other neurodegenerative diseases with similar symptoms, such as Huntington's disease, an autosomal dominant disorder. The onset of both diseases occurs in the second or third decade of life. On the other hand, cerebral ischemia is a major cause of human disability all over the world. Although a cerebral stroke can occur as the result of different damaging insults, severe ischemia produces the death of neuronal cells within minutes. Changes in melatonin levels have been observed in these processes (Huntington's disease, multiple sclerosis and cerebral ischemia) as part of their pathogenic features. This review aims to update and discuss the role played by melatonin during neurodegenerative processes, specifically in multiple sclerosis, Huntington's disease, and cerebral ischemia, and its possible therapeutic use. We also provide readers with an update on the many neuroprotective mechanisms exerted by this neurohormone in the Central Nervous System.	[Escribano, Begona M.] Univ Cordoba, Fac Vet Med, Dept Cell Biol Physiol & Immunol, E-14071 Cordoba, Spain; [Colin-Gonzalez, Ana L.; Santamaria, Abel] Natl Inst Neurol & Neurosurg Manuel Velasco Suare, Excitatory Aminoacids Lab, Mexico City, DF, Mexico; [Tunez, Isaac] Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Inst Res Biomed Cordoba IMIBIC, Dept Biochem & Mol Biol,Fac Med, Cordoba 14004, Spain	Tunez, I (corresponding author), Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Inst Res Biomed Cordoba IMIBIC, Dept Biochem & Mol Biol,Fac Med, Ave Menendez Pidal S-N, Cordoba 14004, Spain.	fm2tufii@uco.es					Acuna-Castroviejo D, 2003, ADV EXP MED BIOL, V527, P549; Ahmad A, 2011, BIOL TRACE ELEM RES, V139, P81, DOI 10.1007/s12011-010-8643-z; Akpmar Z, 2008, PSYCHIAT RES, V161, P253, DOI 10.1016/j.psychres.2007.11.022; Al-Ghoul WM, 1998, NEUROREPORT, V9, P4063, DOI 10.1097/00001756-199812210-00011; Alders J, 2009, J NEUROPSYCH CLIN N, V21, P226, DOI 10.1176/appi.neuropsych.21.2.226; Alexiuk NAM, 2007, J NEURAL TRANSM, V114, P549, DOI 10.1007/s00702-006-0582-7; Alonso-Alconada D, 2012, HISTOL HISTOPATHOL, V27, P771, DOI 10.14670/HH-27.771; Anderson G, 2011, EUR J NEUROL, V18, P680, DOI 10.1111/j.1468-1331.2010.03257.x; Arendt J, 1995, MELATONIN MAMMALIAN; Arnulf I, 2008, ARCH NEUROL-CHICAGO, V65, P482, DOI 10.1001/archneur.65.4.482; Asayama Kentaro, 2003, Journal of Nippon Medical School, V70, P334; Aziz NA, 2009, J NEUROL, V256, P1961, DOI 10.1007/s00415-009-5196-1; Back T, 1998, CELL MOL NEUROBIOL, V18, P621, DOI 10.1023/A:1020265701407; Bahamonde C, 2014, EUR J PHARMACOL, V730, P26, DOI 10.1016/j.ejphar.2014.02.020; Balduini W, 2012, J MATERN-FETAL NEO M, V25, P119, DOI 10.3109/14767058.2012.663232; BARLOWWALDEN LR, 1995, NEUROCHEM INT, V26, P497, DOI 10.1016/0197-0186(94)00154-M; Beal MF, 2011, AMINO ACIDS, V40, P1305, DOI 10.1007/s00726-011-0851-0; BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; Behan WMH, 1999, BRIT J PHARMACOL, V128, P1754, DOI 10.1038/sj.bjp.0702940; Benitez-King G, 2006, J PINEAL RES, V40, P1, DOI 10.1111/j.1600-079X.2005.00282.x; Benitez-King G, 2010, EUR J PHARMACOL, V644, P24, DOI 10.1016/j.ejphar.2010.06.057; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bettahi I, 1996, J PINEAL RES, V20, P205, DOI 10.1111/j.1600-079X.1996.tb00260.x; Bilici D, 2002, PHARMACOL RES, V46, P133, DOI 10.1016/S1043-6618(02)00089-0; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brown EN, 1997, AM J PHYSIOL-ENDOC M, V272, pE506; Browne SE, 1997, ANN NEUROL, V41, P646, DOI 10.1002/ana.410410514; CAGNOLI CM, 1995, J PINEAL RES, V18, P222, DOI 10.1111/j.1600-079X.1995.tb00163.x; CAINE ED, 1986, ARCH NEUROL-CHICAGO, V43, P249, DOI 10.1001/archneur.1986.00520030039009; Calabresi PA, 2004, AM FAM PHYSICIAN, V70, P1935; Carampin P, 2003, J PINEAL RES, V34, P134, DOI 10.1034/j.1600-079X.2003.00020.x; Cardinali DP, 2013, HORM BEHAV, V63, P322, DOI 10.1016/j.yhbeh.2012.02.020; Cardinali DP, 2002, NEUROENDOCRINOL LETT, V23, P20; Carpentieri A, 2012, PHARMACOL RES, V65, P437, DOI 10.1016/j.phrs.2012.01.003; Carrillo-Vico A, 2005, J PINEAL RES, V39, P400, DOI 10.1111/j.1600-079X.2005.00265.x; Carrillo-Vico A, 2005, J CLIN ENDOCR METAB, V90, P992, DOI 10.1210/jc.2004-1429; Carrillo-Vico A, 2005, ENDOCRINE, V27, P189, DOI 10.1385/ENDO:27:2:189; Chahbouni M, 2010, J PINEAL RES, V48, P282, DOI 10.1111/j.1600-079X.2010.00752.x; Chang CF, 2012, J PINEAL RES, V52, P312, DOI 10.1111/j.1600-079X.2011.00945.x; Chen HY, 2009, J PINEAL RES, V47, P260, DOI 10.1111/j.1600-079X.2009.00709.x; Chern CM, 2012, FREE RADICAL BIO MED, V52, P1634, DOI 10.1016/j.freeradbiomed.2012.01.030; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; CHOI DW, 1987, J NEUROSCI, V7, P357; Comai S, 2013, J PSYCHIATR NEUROSCI, V38; Constantinescu CS, 1997, PATHOBIOLOGY, V65, P190, DOI 10.1159/000164122; CONSTANTINESCU CS, 1995, MED HYPOTHESES, V45, P455, DOI 10.1016/0306-9877(95)90220-1; Costa EJX, 1997, FEBS LETT, V416, P103, DOI 10.1016/S0014-5793(97)01178-2; Costantino G, 1998, EUR J PHARMACOL, V363, P57, DOI 10.1016/S0014-2999(98)00673-6; Coto-Montes A, 2012, MOL CELL ENDOCRINOL, V361, P12, DOI 10.1016/j.mce.2012.04.009; Cree BAC, 2007, CURRENT DIAGNOSIS TR; Crespo E, 1999, FASEB J, V13, P1537; Crespo I, 2010, J PINEAL RES, V49, P193, DOI 10.1111/j.1600-079X.2010.00787.x; Cuesta M, 2014, NEUROBIOL DIS, V63, P85, DOI 10.1016/j.nbd.2013.11.008; Cuzzocrea S, 1997, J PINEAL RES, V23, P106, DOI 10.1111/j.1600-079X.1997.tb00342.x; Dai J, 2002, J PINEAL RES, V32, P112, DOI 10.1034/j.1600-079x.2002.1844.x; Dardiotis E, 2013, NEUROSCI LETT, V548, P170, DOI 10.1016/j.neulet.2013.05.058; Das A, 2013, J PINEAL RES, V54, P58, DOI 10.1111/j.1600-079X.2012.01022.x; de Lago E, 2006, EUR NEUROPSYCHOPHARM, V16, P7, DOI 10.1016/j.euroneuro.2005.06.001; Deigner HP, 2000, EXPERT OPIN INV DRUG, V9, P747, DOI 10.1517/13543784.9.4.747; DELGOBBO V, 1989, INT J IMMUNOPHARMACO, V11, P567, DOI 10.1016/0192-0561(89)90187-2; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dominguez-Rodriguez A, 2007, CONTEMP CLIN TRIALS, V28, P532, DOI 10.1016/j.cct.2006.10.007; Dong WG, 2010, J PINEAL RES, V48, P117, DOI 10.1111/j.1600-079X.2009.00734.x; Dringen R, 2005, ANTIOXID REDOX SIGN, V7, P1223, DOI 10.1089/ars.2005.7.1223; Dubocovich ML, 2000, IUPHAR COMPENDIUM RE, P270; Dwivedi S, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/294501; Ekmekcioglu C, 2006, BIOMED PHARMACOTHER, V60, P97, DOI 10.1016/j.biopha.2006.01.002; El-Shenawy SM, 2002, PHARMACOL RES, V46, P235, DOI 10.1016/S1043-6618(02)00094-4; Escames G, 2006, J PINEAL RES, V40, P71, DOI 10.1111/j.1600-079X.2005.00281.x; Escames G, 2003, FASEB J, V17, P932, DOI 10.1096/fj.02-0692fje; Esposito E, 2010, CURR NEUROPHARMACOL, V8, P228, DOI 10.2174/157015910792246155; Feng YM, 2013, AUTOPHAGY, V9, P1395, DOI 10.4161/auto.25468; Fu JL, 2013, J PINEAL RES, V55, P364, DOI 10.1111/jpi.12079; Galano A, 2011, J PINEAL RES, V51, P1, DOI 10.1111/j.1600-079X.2011.00916.x; Garcia-Navarro A, 2007, J PINEAL RES, V43, P195, DOI 10.1111/j.1600-079X.2007.00463.x; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Girish KS, 2013, BIOCHEM BIOPH RES CO, V438, P198, DOI 10.1016/j.bbrc.2013.07.053; Godson C, 1997, ENDOCRINOLOGY, V138, P397, DOI 10.1210/en.138.1.397; Goffredo D, 2005, PHARMACOL RES, V52, P140, DOI 10.1016/j.phrs.2005.01.006; Goldenberg Marvin M, 2012, P T, V37, P175; Gong XM, 2008, MED HYPOTHESES, V71, P580, DOI 10.1016/j.mehy.2008.04.026; Goodman AOG, 2011, CURR NEUROL NEUROSCI, V11, P211, DOI 10.1007/s11910-010-0163-x; Gupta M, 2004, EPILEPSY BEHAV, V5, P316, DOI 10.1016/j.yebeh.2004.01.012; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Hamdi A, 1998, LIFE SCI, V63, P2115, DOI 10.1016/S0024-3205(99)80008-3; Han F, 2011, J PINEAL RES, V50, P281, DOI 10.1111/j.1600-079X.2010.00838.x; HANSSON I, 1990, J NEUROIMMUNOL, V27, P79, DOI 10.1016/0165-5728(90)90139-E; HANSSON I, 1992, J NEUROIMMUNOL, V39, P23, DOI 10.1016/0165-5728(92)90171-G; Hardeland R, 2003, J PINEAL RES, V34, P233, DOI 10.1034/j.1600-079X.2003.00040.x; Hardeland Rudiger, 2005, Nutr Metab (Lond), V2, P22, DOI 10.1186/1743-7075-2-22; Hardeland R, 2010, CURR NEUROPHARMACOL, V8, P168, DOI 10.2174/157015910792246244; Hauser S.L., 2008, HARRISONS PRINCIPLES, P2611; He HW, 2010, CURR NEUROPHARMACOL, V8, P211, DOI 10.2174/157015910792246137; Heiser V, 2000, P NATL ACAD SCI USA, V97, P6739, DOI 10.1073/pnas.110138997; Hersch SM, 2006, NEUROLOGY, V66, P250, DOI 10.1212/01.wnl.0000194318.74946.b6; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Hutter CDD, 1996, MED HYPOTHESES, V46, P67; Hyson HC, 2010, MOVEMENT DISORD, V25, P1924, DOI 10.1002/mds.22408; Jacob S, 2002, J PINEAL RES, V33, P186, DOI 10.1034/j.1600-079X.2002.02943.x; Jang JW, 2012, J NEUROL SCI, V323, P221, DOI 10.1016/j.jns.2012.09.021; Jarzynka MJ, 2009, J PINEAL RES, V46, P161, DOI 10.1111/j.1600-079X.2008.00644.x; Jiang HK, 1998, J FORMOS MED ASSOC, V97, P830; Jimenez-Rubio G, 2012, NEUROSCI LETT, V511, P47, DOI 10.1016/j.neulet.2012.01.040; Johri A, 2012, BBA-MOL BASIS DIS, V1822, P664, DOI 10.1016/j.bbadis.2011.11.014; Jung KH, 2010, J PINEAL RES, V48, P239, DOI 10.1111/j.1600-079X.2010.00748.x; Jung KH, 2009, J PINEAL RES, V47, P173, DOI 10.1111/j.1600-079X.2009.00698.x; Kang J C, 2001, J Vet Sci, V2, P85; Karasek M, 2003, J PINEAL RES, V34, P294, DOI 10.1034/j.1600-079X.2003.00046.x; Karasek M, 2006, FRONTIERS CHRONOBIOL, P1; Karasek M, 1999, NEUROENDOCRINOL LETT, V20, P179; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kaur C, 2008, CURR MED CHEM, V15, P3068, DOI 10.2174/092986708786848640; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kieseier BC, 2009, PHARMACOL RES, V60, P207, DOI 10.1016/j.phrs.2009.03.016; Kilic E, 2005, J PINEAL RES, V39, P151, DOI 10.1111/j.1600-079X.2005.00228.x; Kilic E, 2004, J PINEAL RES, V36, P171, DOI 10.1046/j.1600-079X.2003.00115.x; Kilic E, 1999, J CEREBR BLOOD F MET, V19, P511, DOI 10.1097/00004647-199905000-00005; Kilic U, 2013, NEUROSCIENCE, V237, P268, DOI 10.1016/j.neuroscience.2013.01.059; Kilic U, 2012, J PINEAL RES, V52, P228, DOI 10.1111/j.1600-079X.2011.00932.x; Kitkhuandee A, 2013, J STROKE CEREBROVASC, VS1052-3057, P00015; Koh PO, 2008, J PINEAL RES, V44, P101, DOI 10.1111/j.1600-079X.2007.00495.x; Koh PO, 2012, J PINEAL RES, V53, P358, DOI 10.1111/j.1600-079X.2012.01005.x; Korkmaz A, 2008, J PINEAL RES, V44, P41, DOI 10.1111/j.1600-079X.2007.00509.x; Korkmaz A, 2012, GENE, V503, P1, DOI 10.1016/j.gene.2012.04.040; Kotini A, 2007, Eura Medicophys, V43, P345; Krokosz A, 2013, ADV MED SCI-POLAND, V58, P134, DOI 10.2478/v10039-012-0067-x; Lahiri DK, 2004, J PINEAL RES, V36, P217, DOI 10.1111/j.1600-079X.2004.00120.x; Lahiri DK, 2004, J PINEAL RES, V36, P224, DOI 10.1111/j.1600-079X.2004.00121.x; LANE EA, 1985, J CLIN ENDOCR METAB, V61, P1214, DOI 10.1210/jcem-61-6-1214; Laothong U, 2010, J PINEAL RES, V49, P271, DOI 10.1111/j.1600-079X.2010.00792.x; Lassmann H, 2007, BRAIN PATHOL, V17, P210, DOI 10.1111/j.1750-3639.2007.00064.x; Lassmann H, 2012, NAT REV NEUROL, V8, P647, DOI 10.1038/nrneurol.2012.168; Lee CH, 2010, J NEUROSCI RES, V88, P2630, DOI 10.1002/jnr.22430; Lee EJ, 2004, J PINEAL RES, V36, P33, DOI 10.1046/j.1600-079X.2003.00093.x; Lee MY, 2007, J PINEAL RES, V42, P297, DOI 10.1111/j.1600-079X.2007.00420.x; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Leon J, 2004, LIFE SCI, V75, P765, DOI 10.1016/j.lfs.2004.03.003; LERNER AB, 1959, J AM CHEM SOC, V81, P6084, DOI 10.1021/ja01531a060; LERNER AB, 1958, J AM CHEM SOC, V80, P2587, DOI 10.1021/ja01543a060; Letechipia-Vallejo G, 2007, J PINEAL RES, V42, P139, DOI 10.1111/j.1600-079X.2006.00395.x; Li XJ, 1997, ACTA PHARMACOL SIN, V18, P394; Lin CH, 2008, J PINEAL RES, V44, P205, DOI 10.1111/j.1600-079X.2007.00510.x; Lin HW, 2009, NEUROPSYCH DIS TREAT, V5, P157; Liu Y, 2012, J PINEAL RES, V52, P47, DOI 10.1111/j.1600-079X.2011.00917.x; Luchetti F, 2010, FASEB J, V24, P3603, DOI 10.1096/fj.10-154450; Ma YX, 2013, J HISTOCHEM CYTOCHEM, V61, P591, DOI 10.1369/0022155413492159; MAESTRONI GJM, 1986, J NEUROIMMUNOL, V13, P19, DOI 10.1016/0165-5728(86)90047-0; Maharaj DS, 2005, J PHARM PHARMACOL, V57, P877, DOI 10.1211/0022357056424; Mahlberg R, 2006, PSYCHONEUROENDOCRINO, V31, P634, DOI 10.1016/j.psyneuen.2006.01.009; Maldonado MD, 2010, PHARMACOL RES, V62, P282, DOI 10.1016/j.phrs.2009.11.014; Maldonado MD, 2006, NEUROENDOCRINOL LETT, V27, P601; Marshall KA, 1996, FREE RADICAL BIO MED, V21, P307, DOI 10.1016/0891-5849(96)00046-9; Martin M, 2000, FASEB J, V14, P1677; Matuszak Z, 1997, FREE RADICAL BIO MED, V23, P367, DOI 10.1016/S0891-5849(96)00614-4; Mayo JC, 2005, J NEUROIMMUNOL, V165, P139, DOI 10.1016/j.jneuroim.2005.05.002; Mazzucchelli C, 1996, MOL BRAIN RES, V39, P117, DOI 10.1016/0169-328X(96)00017-4; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; Medina FJ, 2010, CURR MED CHEM, V17, P2482, DOI 10.2174/092986710791556078; Melamud L, 2012, J NEUROL SCI, V314, P37, DOI 10.1016/j.jns.2011.11.003; Melen-Mucha G, 1998, ANTICANCER RES, V18, P3615; Medeiros CAM, 2007, J NEUROL, V254, P459, DOI 10.1007/s00415-006-0390-x; MENENDEZPELAEZ A, 1993, J PINEAL RES, V15, P59, DOI 10.1111/j.1600-079X.1993.tb00511.x; Micale V, 2007, PHARMACOL RES, V56, P382, DOI 10.1016/j.phrs.2007.09.008; Miller Elzbieta, 2011, Pol Merkur Lekarski, V31, P150; Miller E, 2013, J NEUROIMMUNOL, V257, P97, DOI 10.1016/j.jneuroim.2013.02.012; MISHIMA K, 1994, ACTA PSYCHIAT SCAND, V89, P1, DOI 10.1111/j.1600-0447.1994.tb01477.x; Montilla P, 2003, J PHYSIOL BIOCHEM, V59, P263, DOI 10.1007/BF03179883; Montilla P, 1997, J PHYSIOL BIOCHEM, V53, P301; Morandi B, 2008, PHARMACOL RES, V57, P1, DOI 10.1016/j.phrs.2007.11.003; Mrowicka Malgorzata, 2010, Wiad Lek, V63, P3; Mu SH, 2011, NEUROCHEM INT, V59, P224, DOI 10.1016/j.neuint.2011.05.009; Musshoff U, 2002, HIPPOCAMPUS, V12, P165, DOI 10.1002/hipo.1105; Nair SM, 2011, J PINEAL RES, V51, P313, DOI 10.1111/j.1600-079X.2011.00891.x; Nam E, 2005, BRAIN RES, V1046, P90, DOI 10.1016/j.brainres.2005.03.053; Natarajan R, 2012, J NEUROIMMUNOL, V250, P106, DOI 10.1016/j.jneuroim.2012.05.014; National Pediatric MS Center, GUID NURS; Negi G, 2011, J PINEAL RES, V50, P124, DOI 10.1111/j.1600-079X.2010.00821.x; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Onuki J, 2005, J PINEAL RES, V38, P107, DOI 10.1111/j.1600-079X.2004.00180.x; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Ozyener F, 2012, RESTOR NEUROL NEUROS, V30, P435, DOI 10.3233/RNN-2012-120217; Padillo FJ, 2010, J PINEAL RES, V49, P264, DOI 10.1111/j.1600-079X.2010.00791.x; Pajovic SB, 2003, PHYSIOL RES, V52, P189; Pandi-Perumal SR, 2006, FEBS J, V273, P2813, DOI 10.1111/j.1742-4658.2006.05322.x; Pandi-Perumal SR, 2012, PHYS CHEM B, V116, P7291; Paparrigopoulos T, 2001, J AFFECT DISORDERS, V65, P307, DOI 10.1016/S0165-0327(00)00270-6; Paradies G, 2010, J PINEAL RES, V48, P297, DOI 10.1111/j.1600-079X.2010.00759.x; Park OK, 2010, J NEUROL SCI, V294, P7, DOI 10.1016/j.jns.2010.04.013; Passineau MJ, 2000, AM J PHYSIOL-HEART C, V279, pH924; Persinger MA, 2006, MED HYPOTHESES, V66, P811, DOI 10.1016/j.mehy.2005.09.044; Petit L, 1999, BIOCHEM PHARMACOL, V58, P633, DOI 10.1016/S0006-2952(99)00134-3; Petrosillo G, 2008, REJUV RES, V11, P935, DOI 10.1089/rej.2008.0772; Petrosillo G, 2009, FREE RADICAL BIO MED, V47, P969, DOI 10.1016/j.freeradbiomed.2009.06.032; PEYSER CE, 1995, AM J PSYCHIAT, V152, P1771; PIOLI C, 1993, INT J IMMUNOPHARMACO, V15, P463, DOI 10.1016/0192-0561(93)90060-C; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; Poluektov M G, 2012, Zh Nevrol Psikhiatr Im S S Korsakova, V112, P26; Pozo D, 2004, J PINEAL RES, V37, P48, DOI 10.1111/j.1600-079X.2004.00135.x; Pozo D, 1997, J CELL BIOCHEM, V65, P430, DOI 10.1002/(SICI)1097-4644(19970601)65:3<430::AID-JCB12>3.0.CO;2-J; POZO D, 1994, LIFE SCI, V55, pPL455, DOI 10.1016/0024-3205(94)00532-X; Prieto-Gomez B, 2008, NEUROSCI LETT, V448, P56, DOI 10.1016/j.neulet.2008.10.041; Provinciali M, 1996, MECH AGEING DEV, V90, P1, DOI 10.1016/0047-6374(96)01746-0; Ramaswamy S, 2007, ILAR J, V48, P356, DOI 10.1093/ilar.48.4.356; Ramaswamy S, 2007, CELL TRANSPLANT, V16, P301, DOI 10.3727/000000007783464687; Ramirez-Rodriguez G, 2011, J PINEAL RES, V50, P29, DOI 10.1111/j.1600-079X.2010.00802.x; Ranen NG, 1996, MOVEMENT DISORD, V11, P549, DOI 10.1002/mds.870110510; Reiter RJ, 1999, ANN NY ACAD SCI, V890, P471, DOI 10.1111/j.1749-6632.1999.tb08028.x; Reiter RJ, 2000, BIOL SIGNAL RECEPT, V9, P160; REITER RJ, 1993, BRAZ J MED BIOL RES, V26, P1141; Reiter RJ, 2003, BEST PRACT RES CL EN, V17, P273, DOI 10.1016/S1521-690X(03)00016-2; Reiter RJ, 2002, MECH AGEING DEV, V123, P1007, DOI 10.1016/S0047-6374(01)00384-0; REITER RJ, 1991, MOL CELL ENDOCRINOL, V79, pC153, DOI 10.1016/0303-7207(91)90087-9; Reiter RJ, 2007, MELATONIN PRESENT FU, P261; Reiter RJ, 2007, ACTA BIOCHIM POL, V54, P1; REPPERT SM, 1995, P NATL ACAD SCI USA, V92, P8734, DOI 10.1073/pnas.92.19.8734; Ressmeyer AR, 2003, REDOX REP, V8, P205, DOI 10.1179/135100003225002709; Ritzenthaler T, 2009, J PINEAL RES, V46, P349, DOI 10.1111/j.1600-079X.2009.00670.x; Rodriguez C, 2013, INT J MOL SCI, V14, P6597, DOI 10.3390/ijms14046597; Rodriguez-Martinez E, 2000, BRAIN RES, V858, P436, DOI 10.1016/S0006-8993(99)02474-9; Roos RAC, 2010, ORPHANET J RARE DIS, V5, DOI 10.1186/1750-1172-5-40; Rostami A, 2013, J NEUROL SCI, V333, P76, DOI 10.1016/j.jns.2013.03.002; Sainz RM, 2003, CELL MOL LIFE SCI, V60, P1407, DOI 10.1007/s00018-003-2319-1; Sanchez-Barcelo EJ, 2005, J PINEAL RES, V38, P217, DOI 10.1111/j.1600-079X.2004.00207.x; Sanchez-Hidalgo M, 2007, AM J PHYSIOL-REG I, V292, pR2208, DOI 10.1152/ajpregu.00013.2007; Sanchez-Lopez F, 2012, NEUROL RES, V34, P721, DOI 10.1179/1743132812Y.0000000073; Sandyk R, 1993, Int J Neurosci, V72, P141; SANDYK R, 1993, INT J NEUROSCI, V72, P95, DOI 10.3109/00207459308991626; SANDYK R, 1992, INT J NEUROSCI, V67, P173, DOI 10.3109/00207459208994783; SANDYK R, 1993, INT J NEUROSCI, V71, P173, DOI 10.3109/00207459309000602; SANDYK R, 1992, INT J NEUROSCI, V62, P65; Sandyk R, 1994, Int J Neurosci, V74, P95; Sandyk R, 1995, INT J NEUROSCI, V83, P1; SANDYK R, 1993, INT J NEUROSCI, V68, P227, DOI 10.3109/00207459308994278; SANDYK R, 1994, INT J NEUROSCI, V75, P213, DOI 10.3109/00207459408986305; SANDYK R, 1991, INT J NEUROSCI, V61, P61, DOI 10.3109/00207459108986271; Sariahmetoglu M, 2003, PHARMACOL RES, V48, P361, DOI 10.1016/S1043-6618(03)00177-4; Sarlak G, 2013, J PHARMACOL SCI, V123, P9, DOI 10.1254/jphs.13R01SR; Savina TA, 2006, B EXP BIOL MED+, V142, P601, DOI 10.1007/s10517-006-0429-0; Shamir E, 2001, ARCH GEN PSYCHIAT, V58, P1049, DOI 10.1001/archpsyc.58.11.1049; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; Silva SO, 2004, J NEUROIMMUNOL, V156, P146, DOI 10.1016/j.jneuroim.2004.07.015; Silva SO, 2005, J PINEAL RES, V39, P302, DOI 10.1111/j.1600-079X.2005.00247.x; SLAUGENHAUPT SA, 1995, GENOMICS, V27, P355, DOI 10.1006/geno.1995.1056; Slominski A, 2002, FASEB J, V16, P896, DOI 10.1096/fj.01-0952fje; Sofic E, 2005, J NEURAL TRANSM, V112, P349, DOI 10.1007/s00702-004-0270-4; Spiro DB, 2012, J PEDIATR HEALTH CAR, V26, P399, DOI 10.1016/j.pedhc.2011.02.006; Spokoini R, 2010, MOL ENDOCRINOL, V24, P1136, DOI 10.1210/me.2009-0466; Srinivasan V, 2006, Behav Brain Funct, V2, P15, DOI 10.1186/1744-9081-2-15; Srinivasan V, 2005, NEUROTOX RES, V7, P293, DOI 10.1007/BF03033887; Stefulj J, 2001, J PINEAL RES, V30, P243, DOI 10.1034/j.1600-079X.2001.300408.x; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; SUGDEN D, 1989, EXPERIENTIA, V45, P922, DOI 10.1007/BF01953049; Sunami E, 2012, INTERNAL MED, V51, P1187, DOI 10.2169/internalmedicine.51.6699; Tai SH, 2010, J PINEAL RES, V49, P332, DOI 10.1111/j.1600-079X.2010.00797.x; Tan DX, 2007, J PINEAL RES, V42, P28, DOI 10.1111/j.1600-079X.2006.00407.x; Tan Dun-Xian, 2002, Current Topics in Medicinal Chemistry, V2, P181, DOI 10.2174/1568026023394443; Tan DX, 2001, FASEB J, V15, P2294; Tan DX, 2003, J PINEAL RES, V34, P75, DOI 10.1034/j.1600-079X.2003.02111.x; Tan DX, 2005, J PINEAL RES, V39, P185, DOI 10.1111/j.1600-079X.2005.00234.x; Tan DX, 2000, FREE RADICAL BIO MED, V29, P1177, DOI 10.1016/S0891-5849(00)00435-4; Tan DX, 2003, EXPERT OPIN THER PAT, V13, P593; Tang Y, 2014, CELL TRANSPLANT; Tapias V, 2010, J NEUROSCI RES, V88, P420, DOI 10.1002/jnr.22201; Tapias V, 2009, J NEUROSCI RES, V87, P3002, DOI 10.1002/jnr.22123; Tardito D, 2012, EUR NEUROPSYCHOPHARM, V22, pS482, DOI 10.1016/j.euroneuro.2012.06.016; Tasset I, 2012, NEUROSCIENCE, V209, P54, DOI 10.1016/j.neuroscience.2012.02.034; Tasset I, 2011, NUTR NEUROSCI, V14, P106, DOI 10.1179/1476830511Y.0000000005; Tasset I, 2009, J PHYSIOL BIOCHEM, V65, P291, DOI 10.1007/BF03180581; Tasset I, 2009, REV NEUROLOGIA, V49, P424, DOI 10.33588/rn.4908.2009192; Tasset I, 2013, BRAIN STIMUL, V6, P84, DOI 10.1016/j.brs.2012.03.015; Tasset I, 2012, REV NEUROLOGIA, V54, P449, DOI 10.33588/rn.5408.2011672; Tasset I, 2012, CLIN BIOCHEM, V45, P440, DOI 10.1016/j.clinbiochem.2012.01.023; Tasset I, 2012, J NEUROL SCI, V315, P133, DOI 10.1016/j.jns.2011.12.014; Tasset I, 2011, PROG NEURO-PSYCHOPH, V35, P1944, DOI 10.1016/j.pnpbp.2011.09.005; Tasset I, 2010, NEUROSIGNALS, V18, P24, DOI 10.1159/000243650; Taylor N, 1997, BRIT J PSYCHIAT, V171, P393; Tripathi DN, 2010, J PINEAL RES, V48, P324, DOI 10.1111/j.1600-079X.2010.00756.x; Tunez I, 2006, J NEUROCHEM, V97, P619, DOI 10.1111/j.1471-4159.2006.03724.x; Tunez I, 2004, J PINEAL RES, V37, P252, DOI 10.1111/j.1600-079X.2004.00163.x; Tunez I, 2009, REV NEUROLOGIA, V48, P430, DOI 10.33588/rn.4808.2008678; Tunez I, 2007, MELATONIN PRESENT FU, P315; Tunez I, 2006, NEUROSCI RES, V56, P91, DOI 10.1016/j.neures.2006.05.012; Tunez I, 2011, J MED CHEM, V54, P5602, DOI 10.1021/jm200605a; Tunez I, 2010, MOLECULES, V15, P878, DOI 10.3390/molecules15020878; van Horssen J, 2011, BBA-MOL BASIS DIS, V1812, P141, DOI 10.1016/j.bbadis.2010.06.011; van Wamelen DJ, 2013, SLEEP, V36, P117, DOI 10.5665/sleep.2314; Venero JL, 2002, J PINEAL RES, V32, P6, DOI 10.1034/j.1600-079x.2002.10813.x; Videnovic A, 2009, PARKINSONISM RELAT D, V15, P471, DOI 10.1016/j.parkreldis.2008.10.002; Vijayalaxmi, 2002, J CLIN ONCOL, V20, P2575, DOI 10.1200/JCO.2002.11.004; Villapol S, 2011, PEDIATR RES, V69, P51, DOI 10.1203/PDR.0b013e3181fcb40b; VOORDOUW BCG, 1992, J CLIN ENDOCR METAB, V74, P108, DOI 10.1210/jc.74.1.108; WALDHAUSER F, 1984, NEUROENDOCRINOLOGY, V39, P307, DOI 10.1159/000123997; Wang X, 2011, J NEUROSCI, V31, P14496, DOI 10.1523/JNEUROSCI.3059-11.2011; Wang X, 2009, CNS NEUROSCI THER, V15, P345, DOI 10.1111/j.1755-5949.2009.00105.x; Wang Z, 2012, J PINEAL RES, V53, P129, DOI 10.1111/j.1600-079X.2012.00978.x; Weil ZM, 2009, NEUROBIOL DIS, V36, P352, DOI 10.1016/j.nbd.2009.07.032; Weishaupt JH, 2006, J PINEAL RES, V41, P313, DOI 10.1111/j.1600-079X.2006.00377.x; Wilhelm EA, 2013, EUR J PHARMACOL, V701, P65, DOI 10.1016/j.ejphar.2013.01.007; Winczyk K, 2002, TUMOR BIOL, V23, P298, DOI 10.1159/000068569; Winczyk K, 2001, J PINEAL RES, V31, P179, DOI 10.1034/j.1600-079x.2001.310213.x; Witherick J, 2011, AUTOIMMUN DIS, V2011, DOI 10.4061/2011/164608; Wu YH, 2005, J PINEAL RES, V38, P145, DOI 10.1111/j.1600-079X.2004.00196.x; Yang SH, 2011, CURR TOP BEHAV NEURO, V7, P61, DOI 10.1007/7854_2010_105; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhang HW, 1999, CHEM RES TOXICOL, V12, P526, DOI 10.1021/tx980243t; Zhang L, 2013, BEHAV BRAIN RES, V256, P72, DOI 10.1016/j.bbr.2013.07.051; Zhang YC, 2004, ACTA PHARMACOL SIN, V25, P447; Zhou JN, 2003, J PINEAL RES, V34, P11, DOI 10.1034/j.1600-079X.2003.01897.x; ZIMMERMAN RA, 1982, RADIOLOGY, V142, P659, DOI 10.1148/radiology.142.3.7063680; Zipp F, 2006, TRENDS NEUROSCI, V29, P518, DOI 10.1016/j.tins.2006.07.006; Zuccato C, 2005, PHARMACOL RES, V52, P133, DOI 10.1016/j.phrs.2005.01.001	315	24	26	0	9	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets		2014	13	6					1096	1119		10.2174/1871527313666140806160400			24	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	AP1YW	WOS:000341869400023	25106623				2021-06-18	
J	Habib, P; Dang, J; Slowik, A; Victor, M; Beyer, C				Habib, Pardes; Dang, Jon; Slowik, Alexander; Victor, Marion; Beyer, Cordian			Hypoxia-Induced Gene Expression of Aquaporin-4, Cyclooxygenase-2 and Hypoxia-Inducible Factor 1 alpha in Rat Cortical Astroglia Is Inhibited by 17 beta-Estradiol and Progesterone	NEUROENDOCRINOLOGY			English	Article						Hypoxia; Astroglia; Estrogen; Progesterone; Aquaporin;4; Cyclooxygenase-2	ESTROGEN-RECEPTOR-ALPHA; GONADAL-STEROID HORMONES; TRAUMATIC BRAIN-INJURY; NEUROINFLAMMATORY PROCESSES; INFLAMMATORY RESPONSES; CEREBRAL-ISCHEMIA; GLT-1 EXPRESSION; SEX STEROIDS; ASTROCYTES; CELLS	17 beta-Estradiol (E-2) and progesterone (P) are neuroprotective in acute brain injury by attenuating neuropathophysiological processes and regulating local glial function. Besides controlling brain-intrinsic immune responses, astrocytes are cellular targets for sex steroids in health and disease and typically resist to hypoxic damage. In this in vitro study, we aimed at uncovering astroglia-specific reactions to sublethal hypoxic conditions and astroglia-specific effects of both sex steroid hormones on these parameters. Short-term hypoxia for 3 h increased reactive oxygen species production, but had no influence on cell viability of cerebral cortical rat astroglia. Astrocytes expressed classical estrogen receptors (ER), progesterone receptor (PR), and a set of nonclassical steroid hormone receptors. Hypoxia specifically induced ERa and PR isoform A gene expression. Oxygen deprivation increased gene expression of aquaporin-4 (AQP4), hypoxiainducible factor la (Hifi a), and cyclooxygenase-2 (COX2). The application of E2 and P selectively prevented this induction. Effects on protein levels of these genes appeared to be delayed. These data show that astrocytes change their receptivity for sex steroid hormones by switching steroid hormone receptor expression and that E2 and P modify or antagonize proinflannmatory COX2 synthesis, edema-promoting AQP4 expression, and the Hif1 a increase. In vivo studies have to address whether these cell responses contribute to steroid-mediated neuroprotection in stroke. (C) 2014 S. Ka rger AG, Basel	[Habib, Pardes; Dang, Jon; Slowik, Alexander; Victor, Marion; Beyer, Cordian] Rhein Westfal TH Aachen, Inst Neuroanat, DE-52074 Aachen, Germany	Beyer, C (corresponding author), Rhein Westfal TH Aachen, Inst Neuroanat, DE-52074 Aachen, Germany.	cbeyer@ukaachen.de		Dr. Slowik, Alexander/0000-0001-9907-2263			Arevalo MA, 2013, HORM BEHAV, V63, P216, DOI 10.1016/j.yhbeh.2012.02.021; Arevalo MA, 2010, BBA-GEN SUBJECTS, V1800, P1106, DOI 10.1016/j.bbagen.2009.10.002; Arnold S, 2009, J NEUROCHEM, V110, P1, DOI 10.1111/j.1471-4159.2009.06133.x; Bajramovic JJ, 2011, CNS NEUROL DISORD-DR, V10, P4; Baker AE, 2004, ENDOCRINOLOGY, V145, P5021, DOI 10.1210/en.2004-0619; Barreto George, 2011, Central Nervous System Agents in Medicinal Chemistry, V11, P164; Bustin SA, 2005, J MOL ENDOCRINOL, V34, P597, DOI 10.1677/jme.1.01755; Charlier TD, 2005, REV NEUROSCIENCE, V16, P339; Coomber B, 2010, BRAIN RES, V1361, P124, DOI 10.1016/j.brainres.2010.09.037; Dang J, 2011, BRAIN BEHAV IMMUN, V25, P715, DOI 10.1016/j.bbi.2011.01.013; Dhandapani KM, 2007, EXP GERONTOL, V42, P70, DOI 10.1016/j.exger.2006.06.032; Freeman RS, 2005, CNS NEUROL DISORD-DR, V4, P85, DOI 10.2174/1568007053005154; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gunnarson E, 2009, P NATL ACAD SCI USA, V106, P1602, DOI 10.1073/pnas.0812708106; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Habib P, 2014, J MOL NEUROSCI, V52, P277, DOI 10.1007/s12031-013-0137-y; Habib P, 2013, J STEROID BIOCHEM, V138, P195, DOI 10.1016/j.jsbmb.2013.06.003; Han EH, 2010, TOXICOL LETT, V198, P331, DOI 10.1016/j.toxlet.2010.07.015; Hara K, 1998, NEUROSCI LETT, V256, P53, DOI 10.1016/S0304-3940(98)00755-1; Hardy DB, 2008, MOL ENDOCRINOL, V22, P1812, DOI 10.1210/me.2007-0443; Johann S, 2008, J MOL NEUROSCI, V34, P177, DOI 10.1007/s12031-007-9028-4; Johann S, 2013, J STEROID BIOCHEM, V137, P71, DOI 10.1016/j.jsbmb.2012.11.006; Jung-Testas I, 1998, J STEROID BIOCHEM, V65, P243, DOI 10.1016/S0960-0760(97)00191-X; Kaur C, 2006, GLIA, V54, P826, DOI 10.1002/glia.20420; Kipp M, 2007, J NEUROENDOCRINOL, V19, P819, DOI 10.1111/j.1365-2826.2007.01588.x; Kipp M, 2012, J NEUROENDOCRINOL, V24, P62, DOI 10.1111/j.1365-2826.2011.02163.x; Kipp M, 2009, FRONT NEUROENDOCRIN, V30, P188, DOI 10.1016/j.yfrne.2009.04.004; Lakhan SE, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-97; Lee E, 2012, J BIOL CHEM, V287, P26817, DOI 10.1074/jbc.M112.341867; Leung YK, 2006, P NATL ACAD SCI USA, V103, P13162, DOI 10.1073/pnas.0605676103; Liu W, 2011, LIFE SCI, V89, P141, DOI 10.1016/j.lfs.2011.05.011; Loram LC, 2012, PSYCHONEUROENDOCRINO, V37, P1688, DOI 10.1016/j.psyneuen.2012.02.018; Maier O, 2013, NEUROCHEM INT, V62, P1029, DOI 10.1016/j.neuint.2013.03.008; Meffre D, 2013, NEUROSCIENCE, V231, P111, DOI 10.1016/j.neuroscience.2012.11.039; Mor G, 1999, J NEUROBIOL, V40, P484, DOI 10.1002/(SICI)1097-4695(19990915)40:4<484::AID-NEU6>3.0.CO;2-C; Mu DZ, 2003, NEUROBIOL DIS, V14, P524, DOI 10.1016/j.nbd.2003.08.020; Neumann J, 2006, FASEB J, V20, P714, DOI 10.1096/fj.05-4882fje; Patani N, 2014, MOL CELL ENDOCRINOL, V382, P683, DOI 10.1016/j.mce.2013.09.038; Pawlak J, 2005, MOL BRAIN RES, V138, P1, DOI 10.1016/j.molbrainres.2004.10.043; Pawlak J, 2005, GLIA, V50, P270, DOI 10.1002/glia.20162; Rutkowsky JM, 2011, AM J PHYSIOL-CELL PH, V301, pC204, DOI 10.1152/ajpcell.00399.2010; Shenaq M, 2012, J NEUROL SCI, V323, P134, DOI 10.1016/j.jns.2012.08.036; Shin JA, 2011, BBA-MOL BASIS DIS, V1812, P1154, DOI 10.1016/j.bbadis.2011.05.004; Sierra A, 2008, GLIA, V56, P659, DOI 10.1002/glia.20644; Sohrabji F, 2013, NEUROCHEM INT, V63, P291, DOI 10.1016/j.neuint.2013.06.013; Spence RD, 2011, P NATL ACAD SCI USA, V108, P8867, DOI 10.1073/pnas.1103833108; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stirone C, 2003, AM J PHYSIOL-ENDOC M, V284, pE184, DOI 10.1152/ajpendo.00165.2002; Strauss KI, 2010, CRIT CARE MED, V38, P723, DOI 10.1097/CCM.0b013e3181bc80b9; Su C, 2012, ENDOCRINOLOGY, V153, P4389, DOI 10.1210/en.2011-2177; Suzuki S, 2009, FRONT NEUROENDOCRIN, V30, P201, DOI 10.1016/j.yfrne.2009.04.007; Thomas P, 2008, FRONT NEUROENDOCRIN, V29, P292, DOI 10.1016/j.yfrne.2008.01.001; Tichauer J, 2007, NEUROIMMUNOMODULAT, V14, P168, DOI 10.1159/000110642; Ulbrich C, 2012, J STEROID BIOCHEM, V131, P10, DOI 10.1016/j.jsbmb.2012.01.007; Wagner DC, 2013, ACTA NEUROBIOL EXP, V73, P79; Yang M, 2009, BRAIN RES, V1290, P121, DOI 10.1016/j.brainres.2009.07.018; Yeh SH, 2011, BRAIN PATHOL, V21, P249, DOI 10.1111/j.1750-3639.2010.00443.x; Zhang QG, 2009, J NEUROSCI, V29, P13823, DOI 10.1523/JNEUROSCI.3574-09.2009; Zuloaga KL, 2012, STEROIDS, V77, P835, DOI 10.1016/j.steroids.2012.04.013	59	24	25	0	8	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0028-3835	1423-0194		NEUROENDOCRINOLOGY	Neuroendocrinology		2014	99	3-4					156	167		10.1159/000362279			12	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	AR5RB	WOS:000343640100002	24685982				2021-06-18	
J	Kraus, JF; Hsu, P; Schafer, K; Afifi, AA				Kraus, Jess F.; Hsu, Paul; Schafer, Kathryn; Afifi, A. A.			Sustained outcomes following mild traumatic brain injury: Results of a five-emergency department longitudinal study	BRAIN INJURY			English	Article						Cohort study; comparison cohort; emergency department; inverse probability weighting; outcomes; persistent symptoms; post-concussion; Rivermead Post-Concussion Symptoms Questionnaire	MINOR HEAD-INJURY; POST-CONCUSSION SYMPTOMS; EMERGENCY-DEPARTMENT; POSTCONCUSSIVE SYNDROME; EARLY PREDICTORS; QUESTIONNAIRE; RECOVERY; CONSCIOUSNESS; RELIABILITY; POPULATION	Objective: To report on the occurrence of sustained outcomes including post-concussion symptoms, health services used and indicators of social disruption following a mild traumatic brain injury (MTBI). Research design: A dual cohort comparing MTBI Emergency Department (ED) patients and a comparison group of non-head injured ED patients. Methods and procedures: The outcomes measures employed were the Rivermead Post-Concussion Symptoms Questionnaire (RPQ) and indicators of health services used and social disruption all recorded at the ED and at 3 and 6 months post-ED discharge. 'Sustained' meant a positive response to these measures at 3 and 6 months. Main outcomes and results: Reasonable follow-up success was achieved at 3 and 6 months and the cohorts were alike on all demographic descriptors. RPQ average score and symptom occurrence were far more frequent among MTBI patients than for the comparison cohort from 3 to 6 months. The use of health services and indicators of social disruption were also more frequent among MTBI post-discharge patients. Conclusions: These findings argue that some with an MTBI suffer real complaints and they are sustained from 3 to at least 6 months. More effort should be given toward specificity of these symptoms from those reported by members of the comparison group.	[Kraus, Jess F.] Univ Calif Los Angeles, Dept Epidemiol, San Marcos, CA 92089 USA; [Hsu, Paul] Univ Calif Los Angeles, Dept Epidemiol, Los Angeles, CA USA; [Schafer, Kathryn] Scripps Mem Hosp, Trauma Serv, La Jolla, CA USA; [Afifi, A. A.] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90024 USA	Kraus, JF (corresponding author), Univ Calif Los Angeles, Dept Epidemiol, 1173 San Marino Dr 4202, San Marcos, CA 92089 USA.	jkraus3637@roadrunner.com	Schafer, Katrin/P-4728-2015	Hsu, Paul/0000-0002-6153-364X			Afifi AA, 2007, ANNU REV PUBL HEALTH, V28, P95, DOI 10.1146/annurev.publhealth.28.082206.094100; American Psychiatric Association, 1994, DIAGN STAT MAN MEN D; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bazarian J, 2000, BRAIN INJURY, V14, P285; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABILITATION MED, V43, P4; Chan RCK, 2003, BRAIN INJURY, V17, P131, DOI 10.1080/0269905021000010168; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Dean PJA, 2012, BRAIN INJURY, V26, P14, DOI 10.3109/02699052.2011.635354; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Faux S, 2011, BRAIN INJURY, V25, P14, DOI 10.3109/02699052.2010.531686; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Gravel J, 2013, SYST REV, V2, DOI 10.1186/2046-4053-2-63; Hanna-Pladdy B, 2001, CLIN NEUROPSYCHOL, V15, P289, DOI 10.1076/clin.15.3.289.10272; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; ICD-9-CM, 1989, INT CLASS DIS 9 REV; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Kraus J, 2009, J HEAD TRAUMA REHAB, V24, P344, DOI 10.1097/HTR.0b013e3181ae35fd; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P1084, DOI 10.1136/jnnp.46.12.1084; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Paniak C, 2000, J MUSCULOSKELET PAIN, V8, P193, DOI 10.1300/J094v08n01_16; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rienmann BL, 2002, J ATHL TRAINING, V35, P19; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; TEASDALE G, 1974, LANCET, V2, P81; World Health Organization, 1992, ICD 10 CLASS MENT BE	52	24	24	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2014	28	10					1248	1256		10.3109/02699052.2014.916420			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AN2ZZ	WOS:000340455900003	24841806				2021-06-18	
J	Reljic, T; Mahony, H; Djulbegovic, B; Etchason, J; Paxton, H; Flores, M; Kumar, A				Reljic, Tea; Mahony, Helen; Djulbegovic, Benjamin; Etchason, Jeff; Paxton, Hannah; Flores, Michelle; Kumar, Ambuj			Value of Repeat Head Computed Tomography after Traumatic Brain Injury: Systematic Review and Meta-Analysis	JOURNAL OF NEUROTRAUMA			English	Article						computed tomography; meta-analysis; systematic review; traumatic brain injury	CLINICAL-EFFICACY; FOLLOW-UP; INFLUENCE MANAGEMENT; CT-SCAN; UTILITY; HEMORRHAGE; CHILDREN; MODERATE; PROGRESSION; DIAGNOSIS	Diagnosis and management of traumatic brain injury (TBI) is crucial to improve patient outcomes. While initial head computed tomography (CT) scan is the optimum tool for quick and accurate detection of intracranial hemorrhage, the guidelines on use of repeat CT differ among institutions. Three systematic reviews have been conducted on a similar topic; none have performed a comprehensive meta-analysis of all studies. Search of Medline, the Cochrane Library database, and Clinicaltrials.gov, and a hand search of conference abstracts and references for all completed studies reporting data on change in management following repeat CT was conducted. Two authors reviewed all studies and extracted data using a standardized form. A proportional meta-analysis was conducted using the random-effects model for outcomes related to any change in management following repeat CT. Any change in management included intracranial intervention, change in intracranial pressure monitoring, and/or administration of drug therapy. Search results yielded 6982 references. In all, 41 studies enrolling 10,501 patients were included. Change in management following repeat CT was reported in 13 prospective and 28 retrospective studies and yielded a pooled proportion of 11.4% (95% confidence interval [CI] 5.9-18.4) and 9.6% (95% CI 6.5-13.2), respectively. In a subgroup analysis of mild TBI patients (Glasgow Coma Scale score 13 to 15), five prospective and nine retrospective studies reported on change in management following repeat CT with the pooled proportion across prospective studies at 2.3% (95% CI 0.3-6.3) and across retrospective studies at 3.9% (95% CI 2.3-5.7), respectively. The evidence suggests that repeat CT in patients with TBI results in a change in management for only a minority of patients. Better designed studies are needed to address the issue of the value of repeat CT in the management of TBI.	[Reljic, Tea; Mahony, Helen; Djulbegovic, Benjamin; Kumar, Ambuj] Univ S Florida, Ctr Evidence Based Med & Hlth Outcomes Res, Tampa, FL 33612 USA; [Etchason, Jeff] Univ S Florida, Dept Internal Med, Morsani Coll Med, Tampa, FL 33612 USA; [Djulbegovic, Benjamin; Kumar, Ambuj] H Lee Moffitt Canc Ctr & Res Inst, Dept Hlth Outcomes & Behav, Tampa, FL USA; [Djulbegovic, Benjamin] H Lee Moffitt Canc Ctr & Res Inst, Dept Hematol Malignancies, Tampa, FL USA; [Etchason, Jeff; Paxton, Hannah; Flores, Michelle] Lehigh Valley Hlth Network, Allentown, PA USA	Kumar, A (corresponding author), Univ S Florida, Ctr Evidence Based Med, 3515 East Fletcher Ave,MDT 1202, Tampa, FL 33612 USA.	akumar1@health.usf.edu	Reljic, Tea/I-7578-2013; Kumar, Ambuj/I-4940-2012	Reljic, Tea/0000-0003-2029-6753; 	Dorothy Rider Pool Health Care Trust	This study was funded by the Dorothy Rider Pool Health Care Trust. No competing financial interests exist.	Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; Almenawer S., 2012, NEUROSURGERY; Bee TK, 2009, J TRAUMA, V66, P1015, DOI 10.1097/TA.0b013e31819adbc8; Brown CVR, 2007, J TRAUMA, V62, P1339, DOI 10.1097/TA.0b013e318054e25a; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; Connon FF, 2011, ANN SURG, V254, P1028, DOI 10.1097/SLA.0b013e318219727f; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; Dekkers OM, 2012, ANN INTERN MED, V156, P37, DOI 10.7326/0003-4819-156-1-201201030-00006; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dharap SB, 2005, INJURY, V36, P412, DOI 10.1016/j.injury.2004.06.020; DURHAM RM, 1992, AM J SURG, V164, P477, DOI 10.1016/S0002-9610(05)81184-5; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Figg RE, 2006, PEDIATR SURG INT, V22, P215, DOI 10.1007/s00383-005-1560-0; Figg RE, 2003, J TRAUMA, V55, P1061, DOI 10.1097/01.TA.0000096712.90133.5C; FRENCH BN, 1977, SURG NEUROL, V7, P171; Giannetti AV, 2005, SURG NEUROL, V64, pS22, DOI 10.1016/j.surneu.2004.11.008; Givner A, 2002, J PEDIATR SURG, V37, P381, DOI 10.1053/jpsu.2002.30825; Haynes RB, 2004, BMJ-BRIT MED J, V328, P1040, DOI 10.1136/bmj.38068.557998.EE; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Hollingworth W, 2007, PEDIATR CRIT CARE ME, V8, P348, DOI 10.1097/01.PCC.0000270837.66217.3B; Huynh T, 2006, AM SURGEON, V72, P1162; IBM, 2012, SPSS STAT; Kaen A, 2010, J TRAUMA, V68, P895, DOI 10.1097/TA.0b013e3181b28a76; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Kim JJ, 2011, NEUROTHERAPEUTICS, V8, P39, DOI 10.1007/s13311-010-0003-3; Lobato RD, 2005, NEUROCIRUGIA, V16, P217; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; da Silva PSL, 2008, J TRAUMA, V65, P1293, DOI 10.1097/TA.0b013e318156866c; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MACPHERSON P, 1990, CLIN RADIOL, V42, P85, DOI 10.1016/S0009-9260(05)82072-0; Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007]; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Park HK, 2009, BRIT J NEUROSURG, V23, P617, DOI 10.3109/02688690902999302; Roka Y B, 2008, Nepal Med Coll J, V10, P225; Ron E, 2003, HEALTH PHYS, V85, P47, DOI 10.1097/00004032-200307000-00011; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schnellinger MG, 2010, CLIN PEDIATR, V49, P569, DOI 10.1177/0009922809352375; Schunemann HJ, 2008, BMJ-BRIT MED J, V336, P1106, DOI 10.1136/bmj.39500.677199.AE; Schuster R, 2005, AM SURGEON, V71, P701; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; Sifri ZC, 2006, J TRAUMA, V61, P862, DOI 10.1097/01.ta.0000224225.54982.90; Sifri ZC, 2011, J TRAUMA, V71, P1605, DOI 10.1097/TA.0b013e31822b3728; Smith JS, 2007, J TRAUMA, V63, P75, DOI 10.1097/01.ta.0000245991.42871.87; StataCorp, 2009, STAT STAT SOFTW; StatsDirectLtd, 2011, STATSDIRECT STAT SOF; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Stippler M, 2012, EMERG MED J, V29, P528, DOI 10.1136/emermed-2011-200162; Stuart A., 1994, KENDALLS ADV THEORY, P173; Sullivan TP, 1999, AM J NEURORADIOL, V20, P107; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; Thomas BW, 2010, J AM COLL SURGEONS, V210, P824, DOI 10.1016/j.jamcollsurg.2009.12.039; Turedi S, 2008, J EMERG MED, V34, P253, DOI 10.1016/j.jemermed.2007.05.055; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89; Washington CW, 2012, J NEUROSURG, V116, P549, DOI 10.3171/2011.11.JNS111092; Zahari M., 1996, Singapore Medical Journal, V37, P285	62	24	24	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2014	31	1					78	98		10.1089/neu.2013.2873			21	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	302WJ	WOS:000330635500008	23914924				2021-06-18	
J	Silverberg, ND; Luoto, TM; Ohman, J; Iverson, GL				Silverberg, Noah D.; Luoto, Teemu M.; Ohman, Juha; Iverson, Grant L.			Assessment of mild traumatic brain injury with the King-Devick Test (R) in an emergency department sample	BRAIN INJURY			English	Article						All neuropsychology/behavior; assessment of cognitive disorders/dementia; brain trauma; diagnostic test assessment; MRI	VISUAL SCREENING TOOL; SPORT CONCUSSION; SYMPTOMS	Objective: The King-Devick Test (R) (K-D) is a brief measure of cognitive processing speed and rapid gaze shifting that appears sensitive to the effects of sport-related concussion. This study evaluated its diagnostic and incremental validity in civilian patients with mild traumatic brain injury (MTBI). Methods: Participants with MTBI (n = 26) and controls with non-head injuries (n = 33) were prospectively recruited from an Emergency Department (ED). They underwent a clinical evaluation including the K-D test and the Sport Concussion Assessment Tool 2 (SCAT2). Magnetic resonance imaging (MRI) was conducted within 10 days post-injury. Results: The patients with MTBI differed from those without MTBI on components of the SCAT2, including the Symptom Scale (Cohen's d = 1.02-1.15, p<0.001) and Standardized Assessment of Concussion (d = 0.81, p = 0.004), but not the K-D test (d = 0.40, p = 0.148). In a logistic regression analysis, the K-D Test did not contribute over and above these two measures in predicting group membership (MTBI vs. control), p = 0.191. Low K-D Test scores in the MTBI group (<1 SD below controls) were not associated with poor SCAT2 performance, loss of consciousness or traumatic abnormalities on MRI, suggesting these cases may have been false positives. Conclusions: The present findings do not support the K-D Test for the assessment of civilian MTBI in an ED setting.	[Silverberg, Noah D.] Univ British Columbia, Dept Med, Div Phys Med & Rehabil, Vancouver, BC, Canada; [Silverberg, Noah D.] GF Strong Rehab Ctr, Vancouver, BC, Canada; [Luoto, Teemu M.; Ohman, Juha] Tampere Univ Hosp, Dept Neurosci & Rehabil, FI-33521 Tampere, Finland; [Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA	Luoto, TM (corresponding author), Tampere Univ Hosp, Dept Neurosci & Rehabil, POB 2000, FI-33521 Tampere, Finland.	teemu.luoto@pshp.fi	Luoto, Teemu/W-6468-2018	Luoto, Teemu/0000-0002-7329-3284; Ohman, Juha/0000-0002-6592-1367; Iverson, Grant/0000-0001-7348-9570	Medical Research Fund of Tampere University Hospital; Maire Taponen Foundation; Emil Aaltonen Foundation	The authors report no conflicts of interest. This study has been supported by the Medical Research Fund of Tampere University Hospital, the Maire Taponen Foundation and the Emil Aaltonen Foundation.	Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Davies EC, 2012, NEUROLOGY, V78, pE103, DOI 10.1212/WNL.0b013e318251833d; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Grubenhoff JA, 2010, PEDIATRICS, V126, P688, DOI 10.1542/peds.2009-2804; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; King D, 2013, J NEUROL SCI, V326, P59, DOI 10.1016/j.jns.2013.01.012; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Larrabee GJ, 2013, CLIN NEUROPSYCHOL, V27, P215, DOI 10.1080/13854046.2013.769634; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Luoto TM, 2014, J NEUROTRAUM, V31, P728, DOI 10.1089/neu.2013.3174; McCrea M, 2013, BRIT J SPORT MED, V47, P272, DOI 10.1136/bjsports-2013-092145; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McLean SA, 2009, AM J EMERG MED, V27, P182, DOI 10.1016/j.ajem.2008.01.054; Naunheim RS, 2008, J HEAD TRAUMA REHAB, V23, P116, DOI 10.1097/01.HTR.0000314530.30401.70; ORIDE MKH, 1986, AM J OPTOM PHYS OPT, V63, P419; Preece MHW, 2010, NEUROPSYCHOLOGY, V24, P493, DOI 10.1037/a0018903; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x	24	24	24	1	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2014	28	12					1590	1593		10.3109/02699052.2014.943287			4	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AR6UD	WOS:000343717700010	25093537				2021-06-18	
J	Wang, KW; Wang, HK; Chen, HJ; Liliang, PC; Liang, CL; Tsai, YD; Cho, CL; Lu, K				Wang, Kuo-Wei; Wang, Hao-Kuang; Chen, Han-Jung; Liliang, Po-Chou; Liang, Cheng-Loong; Tsai, Yu-Duan; Cho, Chung-Lung; Lu, Kang			Simvastatin Combined with Antioxidant Attenuates the Cerebral Vascular Endothelial Inflammatory Response in a Rat Traumatic Brain Injury	BIOMED RESEARCH INTERNATIONAL			English	Article							L-ASCORBIC-ACID; VITAMIN-C; NITRIC-OXIDE; ATORVASTATIN; DYSFUNCTION; ISCHEMIA; STATINS; MARKERS; STRESS	Traumatic brain injury (TBI) leads to important and deleterious neuroinflammation, as evidenced by indicators such as edema, cytokine production, induction of nitric oxide synthase, and leukocyte infiltration. After TBI, cerebral vascular endothelial cells play a crucial role in the pathogenesis of inflammation. In our previous study, we proved that simvastatin could attenuate cerebral vascular endothelial inflammatory response in a rat traumatic brain injury. This purpose of this study was to determine whether simvastatin combined with an antioxidant could produce the same effect or greater and to examine affected surrogate biomarkers for the neuroinflammation after traumatic brain injury in rat. In our study, cortical contusions were induced, and the effect of acute and continuous treatment of simvastatin and vitamin C on behavior and inflammation in adult rats following experimental TBI was evaluated. The results demonstrated that simvastatin combined with an antioxidant could provide neuroprotection and it may be attributed to a dampening of cerebral vascular endothelial inflammatory response.	[Wang, Kuo-Wei; Wang, Hao-Kuang; Chen, Han-Jung; Liliang, Po-Chou; Liang, Cheng-Loong; Tsai, Yu-Duan; Lu, Kang] I Shou Univ, E Da Hosp, Dept Neurosurg, Kaohsiung 824, Taiwan; [Cho, Chung-Lung] Natl Sun Yat Sen Univ, Dept Biol Sci, Kaohsiung, Taiwan	Lu, K (corresponding author), I Shou Univ, E Da Hosp, Dept Neurosurg, Kaohsiung 824, Taiwan.	kanglu.1002@gmail.com			Research Program of E-DA hospital [EDAHP 101013]	This study was supported by a Research Program of E-DA hospital (EDAHP 101013).	Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Beckman JA, 2001, CIRCULATION, V103, P1618, DOI 10.1161/01.CIR.103.12.1618; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brown AA, 2001, AM J CLIN NUTR, V73, P673; Burk RF, 2006, J NUTR, V136, P1576; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Duffy SJ, 2001, AM J PHYSIOL-HEART C, V280, pH528; Engler MM, 2003, CIRCULATION, V108, P1059, DOI 10.1161/01.CIR.0000086345.09861.A0; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Greenwood J, 2007, TRENDS IMMUNOL, V28, P88, DOI 10.1016/j.it.2006.12.003; Gupta Amrita Das, 2006, J Basic Clin Physiol Pharmacol, V17, P87; HALL RD, 1974, BRAIN RES, V66, P23, DOI 10.1016/0006-8993(74)90076-6; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Han XG, 2011, NEUROSCI LETT, V487, P255, DOI 10.1016/j.neulet.2010.09.007; Hattiwale SH, 2013, BIOMETALS, V26, P329, DOI 10.1007/s10534-013-9617-3; Heller R, 2001, J BIOL CHEM, V276, P40, DOI 10.1074/jbc.M004392200; Huang A, 2000, J BIOL CHEM, V275, P17399, DOI 10.1074/jbc.M002248200; Jackson TS, 1998, CIRC RES, V83, P916; Jawa Randeep S, 2006, J Intensive Care Med, V21, P63, DOI 10.1177/0885066605284325; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Pirat A, 2006, ANESTH ANALG, V102, P225, DOI 10.1213/01.ane.0000189554.41095.98; Qu CS, 2005, J NEUROSURG, V103, P695, DOI 10.3171/jns.2005.103.4.0695; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Sanchez-Moreno C, 2004, STROKE, V35, P163, DOI 10.1161/01.STR.0000105391.62306.2E; Shao HT, 2007, ANN THORAC SURG, V84, P2011, DOI 10.1016/j.athoracsur.2007.07.022; Sheu JR, 2008, YB CHINESE MED PHARM, V26, P161; Vita JA, 1998, J CLIN INVEST, V101, P1408, DOI 10.1172/JCI1155; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wang KW, 2014, ANN CLIN LAB SCI, V44, P145; Wannamethee SG, 2006, AM J CLIN NUTR, V83, P567	31	24	24	0	5	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2314-6133	2314-6141		BIOMED RES INT	Biomed Res. Int.		2014	2014								910260	10.1155/2014/910260			6	Biotechnology & Applied Microbiology; Medicine, Research & Experimental	Biotechnology & Applied Microbiology; Research & Experimental Medicine	AJ6ZJ	WOS:000337845100001	25013810	DOAJ Gold, Green Published			2021-06-18	
J	Franzblau, M; Gonzales-Portillo, C; Gonzales-Portillo, GS; Diamandis, T; Borlongan, MC; Tajiri, N; Borlongan, CV				Franzblau, Max; Gonzales-Portillo, Chiara; Gonzales-Portillo, Gabriel S.; Diamandis, Theo; Borlongan, Mia C.; Tajiri, Naoki; Borlongan, Cesar V.			Vascular damage: A persisting pathology common to Alzheimer's disease and traumatic brain injury	MEDICAL HYPOTHESES			English	Article							BARRIER BREAKDOWN; EXPRESSION; TARGET; PATHOPHYSIOLOGY; INFLAMMATION; HYPOTHESIS; CAVEOLIN-1; MECHANISM; GENES; MODEL	Alzheimer's disease (AD) and traumatic brain injury (TBI) are both significant clinical problems characterized by debilitating symptoms with limited available treatments. Interestingly, both neurological diseases are characterized by neurovascular damage. This impaired brain vasculature correlates with the onset of dementia, a symptom associated with hippocampal degeneration seen in both diseases. We posit that vascular damage is a major pathological link between TBI and AD, in that TBI victims are predisposed to AD symptoms due to altered brain vasculature; vice versa, the progression of AD pathology may be accelerated by TBI especially when the brain insult worsens hippocampal degeneration. Our hypothesis is supported by recent data reporting expedited AD pathology in presymptomatic transgenic AD mice subjected to TBI. If our hypothesis is correct, treatments targeted at repairing the vasculature may prove effective at treating both diseases and preventing the evolution of AD symptoms in TBI victims. (C) 2013 Elsevier Ltd. All rights reserved.	[Franzblau, Max; Gonzales-Portillo, Chiara; Gonzales-Portillo, Gabriel S.; Diamandis, Theo; Borlongan, Mia C.; Tajiri, Naoki; Borlongan, Cesar V.] Univ S Florida, Morsani Coll Med, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain Repair, Tampa, FL 33613 USA	Tajiri, N (corresponding author), 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.	cborlong@health.usf.edu	Borlongan, Cesar/I-5696-2012	Borlongan, Cesar/0000-0002-2966-9782; Borlongan, Mia/0000-0003-3223-8374	Department of Neurosurgery and Brain Repair; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS071956-01]; Department of DefenseUnited States Department of Defense [W81XWH-11-1-0634]; James and Esther King Foundation for Biomedical Research Program; SanBio Inc.; KMPHC; NeuralStem Inc.; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071956] Funding Source: NIH RePORTER	This research was supported by the Department of Neurosurgery and Brain Repair funds. CVB is supported by National Institutes of Health, National Institute of Neurological Disorders and Stroke 1R01NS071956-01, Department of Defense W81XWH-11-1-0634, James and Esther King Foundation for Biomedical Research Program, SanBio Inc., KMPHC and NeuralStem Inc.	Aliev G, 2003, NEUROL RES, V25, P665, DOI 10.1179/016164103101201977; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Arendash GW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035751; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Borlongan CV, 2012, EXP NEUROL, V237, P142, DOI 10.1016/j.expneurol.2012.06.024; Borroni B, 2002, J NEUROL SCI, V203, P189, DOI 10.1016/S0022-510X(02)00289-7; Cirrito JR, 2008, NEURON, V58, P42, DOI 10.1016/j.neuron.2008.02.003; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; Davies TA, 2000, AMYLOID, V7, P153, DOI 10.3109/13506120009146830; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Duckworth JL, 2012, PATHOPHYSIOLOGY; Goeller J, 2012, J NEUROTRAUM, V29, P1970, DOI 10.1089/neu.2011.2224; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Iadecola C, 2010, STROKE, V41, pS127, DOI 10.1161/STROKEAHA.110.595488; Infante-Duarte C, 2008, J MOL MED, V86, P975, DOI 10.1007/s00109-007-0292-0; Jantaratnotai N, 2011, INT J ALZHEIMERS DIS; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; Kellogg SL, 2011, SOC NEUR ABSTR, V561, P20; McKeating EG, 1998, ACT NEUR S, V71, P200; Meyer-Luehmann M, 2008, NATURE, V451, P720, DOI 10.1038/nature06616; Miller G, 2011, SCIENCE, V333, P517, DOI 10.1126/science.333.6042.517; Mlekusch R, 2009, NEUROSCI LETT, V466, P135, DOI 10.1016/j.neulet.2009.09.043; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Nag S, 2011, NEUROPATH APPL NEURO, V37, P3, DOI 10.1111/j.1365-2990.2010.01138.x; Nag S, 2009, NEUROPATH APPL NEURO, V35, P417, DOI 10.1111/j.1365-2990.2008.01009.x; Nag S, 2007, ACTA NEUROPATHOL, V114, P459, DOI 10.1007/s00401-007-0274-x; Oby E, 2006, EPILEPSIA, V47, P1761, DOI 10.1111/j.1528-1167.2006.00817.x; Palmer JC, 2010, NEUROPATH APPL NEURO, V36, P487, DOI 10.1111/j.1365-2990.2010.01084.x; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; Skaper SD, 2007, ANN NY ACAD SCI, V1122, P23, DOI 10.1196/annals.1403.002; Stanimirovic DB, 2012, J CEREBR BLOOD F MET, V32, P1207, DOI 10.1038/jcbfm.2012.25; Tajiri N, 2011, INT C ALZH DRUG DISC, V12, P12; Tomkins O, 2008, J NEUROL NEUROSUR PS, V79, P774, DOI 10.1136/jnnp.2007.126425; Tompkins P, 2013, J NEUROTRAUMA; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Verdile G, 2004, PHARMACOL RES, V50, P397, DOI 10.1016/j.phrs.2003.12.028; Walker DG, 2008, MICROVASC RES, V75, P411, DOI 10.1016/j.mvr.2007.10.004; WHITEHOUSE PJ, 1981, ANN NEUROL, V10, P122, DOI 10.1002/ana.410100203; Yesil Y, 2012, ARCH GERONTOL GERIAT, V55, P257, DOI 10.1016/j.archger.2011.09.016; Yeung D, 2008, ACTA NEUROPATHOL, V115, P635, DOI 10.1007/s00401-008-0364-4; You ZR, 2007, J CEREBR BLOOD F MET, V27, P1954, DOI 10.1038/sj.jcbfm.9600497; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007; Zlokovic BV, 2010, NAT MED, V16, P1370, DOI 10.1038/nm1210-1370	51	24	24	0	9	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0306-9877	1532-2777		MED HYPOTHESES	Med. Hypotheses	NOV	2013	81	5					842	845		10.1016/j.mehy.2013.09.012			4	Medicine, Research & Experimental	Research & Experimental Medicine	257DI	WOS:000327363400023	24074832	Green Accepted			2021-06-18	
J	Hill, BD; Rohling, ML; Boettcher, AC; Meyers, JE				Hill, Benjamin D.; Rohling, Martin L.; Boettcher, Anneliese C.; Meyers, John E.			Cognitive Intra-Individual Variability Has a Positive Association with Traumatic Brain Injury Severity and Suboptimal Effort	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Intra-individual variability; Traumatic brain injury; Dispersion; Performance validity	REACTION-TIME; PERFORMANCE; CONSISTENCY; ATTENTION; INCONSISTENCY; VALIDATION; DISPERSION; FATIGUE; SCORES	This study examined intra-individual variability in a large sample (n 629) of individuals with a history of mild traumatic brain injury (mTBI) or TBI referred for neuropsychological evaluation. Variability was assessed using the overall test battery mean standard deviation (OTBM SD). We found a negative linear relation between OTBM and OTBM SD (r .672) in this sample with a history of neurologic pathology, indicating that the variability is inversely related to cognitive performance and contrary to what is observed in most normative data. Analyses revealed main effects for OTBM and OTBM SD across three TBI severity groups: loss of consciousness (LOC) 1 h, LOC 1 h6 days, and LOC 6 days. These effects were found for both a valid performance group (no failed embedded validity measures; n 504) and an invalid performance group (failed one or more embedded validity measures; n 125). These findings support that cognitive intra-individual variability is increased uniquely by both neuropathology and suboptimal effort, there is a doseresponse relationship between neuropathology and cognitive variability, and intra-individual variability may have utility as a clinical index of both.	[Hill, Benjamin D.; Rohling, Martin L.; Boettcher, Anneliese C.] Univ S Alabama, Dept Psychol, Mobile, AL 36688 USA; [Meyers, John E.] Meyers Neuropsychol Serv, Mililani, HI USA	Hill, BD (corresponding author), Univ S Alabama, Dept Psychol, Mobile, AL 36688 USA.	bdhill@southalabama.edu		Hill, Benjamin/0000-0002-5797-5082			Benton A, 1989, MULTILINGUAL APHASIA; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Bielak AAM, 2010, NEUROPSYCHOLOGY, V24, P731, DOI 10.1037/a0019802; Bielak AAM, 2010, PSYCHOL AGING, V25, P575, DOI 10.1037/a0019503; Binder LM, 2009, ARCH CLIN NEUROPSYCH, V24, P31, DOI 10.1093/arclin/acn001; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; BRANDT J, 1985, ANN NY ACAD SCI, V444, P502, DOI 10.1111/j.1749-6632.1985.tb37625.x; Brooks BL, 2009, CAN PSYCHOL, V50, P196, DOI 10.1037/a0016066; Castellanos FX, 2008, BIOL PSYCHIAT, V63, P332, DOI 10.1016/j.biopsych.2007.06.025; Demakis GJ, 1999, ARCH CLIN NEUROPSYCH, V14, P401, DOI 10.1016/S0887-6177(98)00039-0; Duchek JM, 2009, NEUROPSYCHOLOGY, V23, P746, DOI 10.1037/a0016583; Fuentes K, 2001, CLIN NEUROPSYCHOL, V15, P210, DOI 10.1076/clin.15.2.210.1896; Green P., 2003, GREENS WORD MEMORY T; Gunner JH, 2012, ARCH CLIN NEUROPSYCH, V27, P1, DOI 10.1093/arclin/acr089; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; HERTZOG C, 1992, BRAIN LANG, V42, P248, DOI 10.1016/0093-934X(92)90100-S; Hetherington CR, 1996, BRAIN INJURY, V10, P473, DOI 10.1080/026990596124197; Hilborn JV, 2009, J CLIN EXP NEUROPSYC, V31, P412, DOI 10.1080/13803390802232659; Hultsch DF, 2002, J GERONTOL B-PSYCHOL, V57, pP101, DOI 10.1093/geronb/57.2.P101; Kozel JJ, 1998, ARCH CLIN NEUROPSYCH, V13, P327, DOI 10.1016/S0887-6177(97)00036-X; MacDonald SWS, 2008, PSYCHOL AGING, V23, P595, DOI 10.1037/0882-7974.23.3.595; MacDonald SWS, 2003, PSYCHOL AGING, V18, P510, DOI 10.1037/0882-7974.18.3.510; Meyers J, 2000, TELEPHONY, V239, P7; Meyers J., 1995, REY COMPLEX FIGURE T; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P79, DOI 10.1016/S0887-6177(00)00105-0; Miller LS, 2001, NEUROPSYCHOL REV, V11, P143, DOI 10.1023/A:1016602708066; Morgan EE, 2011, NEUROPSYCHOLOGY, V25, P645, DOI 10.1037/a0023792; Nesselroade JR, 2001, EUR PSYCHOL, V6, P187, DOI 10.1027//1016-9040.6.3.187; Pilgrim B M, 1999, Appl Neuropsychol, V6, P243, DOI 10.1207/s15324826an0604_7; Ram N, 2005, PSYCHOL AGING, V20, P623, DOI 10.1037/0882-7974.20.4.623; Reitan RM, 1997, CLIN NEUROPSYCHOL, V11, P69, DOI 10.1080/13854049708407031; Reitan RM., 1985, HALSTEAD REITAN NEUR; Roberts M A, 1994, Appl Neuropsychol, V1, P45, DOI 10.1207/s15324826an0101&2_9; SCHINKA JA, 1994, PSYCHOL ASSESSMENT, V6, P364; Schretlen DJ, 2003, J INT NEUROPSYCH SOC, V9, P864, DOI 10.1017/S1355617703960061; Sosnoff JJ, 2007, NEUROPSYCHOLOGY, V21, P796, DOI 10.1037/0894-4105.21.6.796; Spreen O., 1998, COMPENDIUM NEUROPSYC, P2; Strauss E, 2002, ARCH CLIN NEUROPSYCH, V17, P423, DOI 10.1016/S0887-6177(01)00126-3; Strauss E, 1999, CLIN NEUROPSYCHOL, V13, P420, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT420; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Tombaugh TN, 1996, TEST MEMORY MALINGER; WARD LC, 1990, J CLIN PSYCHOL, V46, P436, DOI 10.1002/1097-4679(199007)46:4<436::AID-JCLP2270460411>3.0.CO;2-M	45	24	25	0	8	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	NOV	2013	28	7					640	648		10.1093/arclin/act045			9	Psychology, Clinical; Psychology	Psychology	243AS	WOS:000326289300002	23832096	Bronze, Green Published			2021-06-18	
J	Wortzel, HS; Brenner, LA; Arciniegas, DB				Wortzel, Hal S.; Brenner, Lisa A.; Arciniegas, David B.			Traumatic Brain Injury and Chronic Traumatic Encephalopathy: A Forensic Neuropsychiatric Perspective	BEHAVIORAL SCIENCES & THE LAW			English	Article							COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; FOOTBALL; DISEASE; RISK; NEUROPATHOLOGY; SYMPTOMS; DEMENTIA; RECOVERY; HISTORY	Recent scientific reports and popular press describing chronic traumatic encephalopathy (CTE) collectively link this condition to a broad array of neuropsychiatric symptoms, including extremely rare and multi-determined behaviors such as murder-suicide. These reports are difficult to reconcile with several decades of research on the science of traumatic brain injury (TBI) and its consequences, especially the natural history and prognosis of mild TBI. This article attempts to reconcile these sources by reviewing the state of the science on CTE, with particular attention to case definitions and neuropathological criteria for this diagnosis. The evidence for links between TBI, CTE, and catastrophic clinical events is explored, and the complexity of attributing rare frequency behavioral events to CTE is highlighted. The clinical and medicolegal implications of the best available evidence are discussed, concluding with a cautionary note against prematurely generalizing current findings on CTE to entire populations of persons with, or at risk for, concussion exposures. Copyright (c) 2013 John Wiley & Sons, Ltd.	[Wortzel, Hal S.; Brenner, Lisa A.; Arciniegas, David B.] Univ Colorado, Sch Med, Dept Psychiat, Neuropsychiat Serv, Aurora, CO 80045 USA; [Wortzel, Hal S.] Univ Colorado, Sch Med, Dept Psychiat, Div Forens Psychiat, Aurora, CO 80045 USA; [Wortzel, Hal S.; Brenner, Lisa A.; Arciniegas, David B.] Univ Colorado, Sch Med, Dept Neurol, Behav Neurol Sect, Aurora, CO 80045 USA; [Brenner, Lisa A.] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Aurora, CO 80045 USA; [Wortzel, Hal S.; Arciniegas, David B.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Beth K & Stuart C Yudofsky Div Neuropsychiat, Houston, TX 77030 USA; [Arciniegas, David B.] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX USA	Wortzel, HS (corresponding author), Univ Colorado, Sch Med, Dept Psychiat, Anschutz Med Campus,Bldg 500,Mail Stop F546,13001, Aurora, CO 80045 USA.	hal.wortzel@ucdenver.edu	Brenner, Lisa A./AAG-2442-2019				[Anonymous], 1969, Lancet, V2, P1114; Arciniegas David B, 2011, Dialogues Clin Neurosci, V13, P325; Baron SL, 2012, AM J CARDIOL, V109, P889, DOI 10.1016/j.amjcard.2011.10.050; Bedi S., 2012, FORBES          0505; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Bennett DA, 2006, NEUROLOGY, V66, P1837, DOI 10.1212/01.wnl.0000219668.47116.e6; Bianchini KJ, 2006, CLIN NEUROPSYCHOL, V20, P831, DOI 10.1080/13854040600875203; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cearnal L, 2012, ANN EMERG MED, V60, p17A, DOI 10.1016/j.annemergmed.2012.08.013; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Goldstein L E, 2012, SCI TRANSLATIONAL ME, V4; Granier J. P., 2011, AJOB NEUROSCIENCE, V2, P60; Greenemeier L., 2012, SCI AM; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hohler B., 2013, BOSTON GLOBE; Institute of Medicine Committee on Gulf War and Health, 2008, GULF WAR HLTH, V7; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Kristof N.D., 2012, NY TIMES; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ., 1997, SEMIN CLIN NEUROPSYC, V2, P196, DOI [10.1053/SCNP00200196, DOI 10.1053/SCNP00200196]; Larrabee GJ, 2013, CLIN NEUROPSYCHOL, V27, P215, DOI 10.1080/13854046.2013.769634; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Martin J., 2012, US TODAY; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; Mihoces G., 2013, US TODAY; MILLER H, 1966, P ROY SOC MED, V59, P257, DOI 10.1177/003591576605900327; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; O'Neil ME, 2012, COMPLICATIONS MILD T; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; PEARCE JMS, 1984, BRIT MED J, V288, P933, DOI 10.1136/bmj.288.6421.933-a; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Savica R, 2012, MAYO CLIN PROC, V87, P335, DOI 10.1016/j.mayocp.2011.12.016; Sayed N, 2013, J NEUROTRAUM, V30, P1117, DOI 10.1089/neu.2012.2638; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schwarz A, 2011, NY TIMES; Silver JM, 2012, J NEUROL NEUROSUR PS, V83, P836, DOI 10.1136/jnnp-2011-302078; STRUB RL, 1988, NEUROBEHAVIORAL DISO; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilner B., 2013, HUFFINGTON POST; Wortzel HS, 2008, J AM ACAD PSYCHIATRY, V36, P310; Wortzel HS, 2013, J AM ACAD PSYCHIATRY, V41, P274; Wortzel HS, 2011, J AM ACAD PSYCHIATRY, V39, P511	70	24	24	1	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0735-3936	1099-0798		BEHAV SCI LAW	Behav. Sci. Law	NOV	2013	31	6			SI		721	738		10.1002/bsl.2079			18	Psychology, Applied; Law	Psychology; Government & Law	262KI	WOS:000327733400004	24019038				2021-06-18	
J	Borlongan, CV; Burns, J; Tajiri, N; Stahl, CE; Weinbren, NL; Shojo, H; Sanberg, PR; Emerich, DF; Kaneko, Y; van Loveren, HR				Borlongan, Cesar V.; Burns, Jack; Tajiri, Naoki; Stahl, Christine E.; Weinbren, Nathan L.; Shojo, Hideki; Sanberg, Paul R.; Emerich, Dwaine F.; Kaneko, Yuji; van Loveren, Harry R.			Epidemiological Survey-Based Formulae to Approximate Incidence and Prevalence of Neurological Disorders in the United States: a Meta-Analysis	PLOS ONE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; TRAUMATIC BRAIN-INJURY; HUNTINGTONS-DISEASE; POPULATION; DURATION; DEMENTIA; COUNTY; AGE	Background: This study aims to create a convenient reference for both clinicians and researchers so that vis-a-vis comparisons between brain disorders can be made quickly and accurately. We report here the incidence and prevalence of the major adult-onset brain disorders in the United States using a meta-analysis approach. Material and Methods: Epidemiological figures were collected from the most recent, reliable data available in the research literature. Population statistics were based on the most recent census from the US Census Bureau. Extrapolations were made only when necessary. The most current epidemiological studies for each disorder were chosen. All effort was made to use studies based on national cohorts. Studies reviewed were conducted between 1950 and 2009. The data of the leading studies for several neurological studies was compiled in order to obtain the most accurate extrapolations. Results were compared to commonly accepted values in order to evaluate validity. Results: It was found that 6.75% of the American adult population is afflicted with brain disorders. This number was eclipsed by the 8.02% of Floridians with brain disorders, which is due to the large aged population residing in the state. Conclusions: There was a noticeable lack of epidemiological data concerning adult-onset brain disorders. Since approximately 1 out of every 7 households is affected by brain disorders, increased research into this arena is warranted.	[Borlongan, Cesar V.; Burns, Jack; Tajiri, Naoki; Stahl, Christine E.; Weinbren, Nathan L.; Shojo, Hideki; Sanberg, Paul R.; Emerich, Dwaine F.; Kaneko, Yuji; van Loveren, Harry R.] Univ S Florida, Dept Neurosurg & Brain Repair, Tampa, FL 33620 USA	Borlongan, CV (corresponding author), Univ S Florida, Dept Neurosurg & Brain Repair, Tampa, FL 33620 USA.	cborlong@health.usf.edu	Kaneko, Yuji/J-6447-2012; Borlongan, Cesar/I-5696-2012	Borlongan, Cesar/0000-0002-2966-9782	University of South Florida Department of Neurosurgery and Brain Repair; James and Esther King Biomedical Research Foundation [1KG01-33966]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5U01NS055914-04, 1R01NS071956-01A1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071956, U01NS055914] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [24659336] Funding Source: KAKEN	Financial support for this study was through the University of South Florida Department of Neurosurgery and Brain Repair funds. CVB is funded by the James and Esther King Biomedical Research Foundation 1KG01-33966, NIH 5U01NS055914-04 and NIH 1R01NS071956-01A1. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANNEGERS JF, 1991, ARCH NEUROL-CHICAGO, V48, P589, DOI 10.1001/archneur.1991.00530180041015; Brain Central Tumor Registry of the United States, 2009, CENTR BRAIN TUM REG; Campsmith M. L., 2008, Morbidity and Mortality Weekly Report, V57, P1073; Centers for Disease Control (CDC), 2008, MMWR-MORBID MORTAL W, V56, P469; Cronin S, 2007, NEUROLOGY, V68, P1002, DOI 10.1212/01.wnl.0000258551.96893.6f; Day JC, 1996, CURRENT POPULATION R; de Lau LML, 2006, LANCET NEUROL, V5, P525, DOI 10.1016/S1474-4422(06)70471-9; EISEN A, 1993, MUSCLE NERVE, V16, P27, DOI 10.1002/mus.880160107; Ferri CP, 2005, LANCET, V366, P2112, DOI 10.1016/S0140-6736(05)67889-0; FOLSTEIN SE, 1987, AM J HUM GENET, V41, P168; Hall HI, 2008, JAMA-J AM MED ASSOC, V300, P520, DOI 10.1001/jama.300.5.520; Hebert LE, 2004, NEUROLOGY, V62, P1645, DOI 10.1212/01.WNL.0000123018.01306.10; Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3; KOKMEN E, 1994, ARCH NEUROL-CHICAGO, V51, P696, DOI 10.1001/archneur.1994.00540190076018; KURLAND L T, 1958, J Chronic Dis, V8, P378, DOI 10.1016/0021-9681(58)90002-X; Kurtzke JF, 1983, CLIN NEUROLOGY, V3, P1; Lobo A, 2000, NEUROLOGY, V54, pS4; Myrianthopoulos N., 1973, ADV NEUROL, V1, P150; PEARSON JS, 1955, P STAFF M MAYO CLIN, V30, P349; Population Estimates Program, 2009, SCEST200801 US CENS; Population Estimates Program, 2009, NSTEST200901 US CENS; Population Estimates Program, 2009, NCEST200902 US CENS; ROOS RAC, 1993, J NEUROL NEUROSUR PS, V56, P98, DOI 10.1136/jnnp.56.1.98; Sacktor N, 2002, J NEUROVIROL, V8, P136, DOI 10.1080/13550280290049615; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; U.S. Census Bureau Population Division, 2009, STAT COUNT QUICKFACT; Williams G R, 2001, BMC Neurol, V1, P2, DOI 10.1186/1471-2377-1-2; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	29	24	24	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 24	2013	8	10							e78490	10.1371/journal.pone.0078490			9	Multidisciplinary Sciences	Science & Technology - Other Topics	241FR	WOS:000326152300063	24205243	DOAJ Gold, Green Published			2021-06-18	
J	Si, DW; Wang, HT; Wang, Q; Zhang, CY; Sun, JY; Wang, ZG; Zhang, ZF; Zhang, YX				Si, Daowen; Wang, Haitao; Wang, Qian; Zhang, Chengyun; Sun, Jingyu; Wang, Zhigang; Zhang, Zuofeng; Zhang, Yuxin			Progesterone treatment improves cognitive outcome following experimental traumatic brain injury in rats	NEUROSCIENCE LETTERS			English	Article						Progesterone; Traumatic brain injury; Cognitive function; Inflammation; Apoptosis	SEX STEROID-HORMONES; HEAD-INJURY; CNS INJURY; ALLOPREGNANOLONE; NEUROPROTECTION; EXPRESSION; MODEL	Progesterone (FROG) has recently been shown to have a neuroprotective effect and improve cognitive outcome in animal models of traumatic brain injury (TBI). However, the precise mechanisms remain unclear. This study was aimed to investigate the inhibitory effects of PROG on inflammation and apoptosis in the hippocampus after TBI and its influence on the cognitive outcome. In this study, the model of TBI was established by modified Feeney's weight-dropping method. The PROG was given in a dose of 16 mg/kg by intraperitoneal injection 1 h post injury and subsequent injections subcutaneously at 6 h and 12 h after TBI. Brain samples were extracted at 24h after trauma. The expression of COX-2 and caspase-3 was measured by immunohistochemistry and western blot technique. The cognitive outcome was assessed by Morris water maze test (MWM). The results revealed that the expression of COX-2 and caspase-3 in TBI-PROG group was distinctly less than those of the TB! group (p < 0.05). In addition, the performance of Morris water maze showed that progesterone treatment exhibited shorter latencies, more platform crossings and more time swimming in the quadrant area in the TBI + PROG rats compared to the TBI rats. In conclusion, post-TBI PROG administration may attenuate inflammation and apoptosis in the hippocampus, and this may be one of the mechanisms by which PROG improves cognitive outcome following TBI. (C) 2013 Elsevier Ireland Ltd. All rights reserved.	[Si, Daowen; Wang, Haitao; Wang, Qian; Zhang, Chengyun; Zhang, Zuofeng; Zhang, Yuxin] Hebei United Univ, Sch Basic Med Sci, Tangshan 063000, Hebei Province, Peoples R China; [Sun, Jingyu] Tangshan Fengrun Peoples Hosp, Dept Osteol, Tangshan 063000, Hebei Province, Peoples R China; [Wang, Zhigang] Tangshan Fengrun Second Peoples Hosp, Dept Clin Lab, Tangshan 063000, Hebei Province, Peoples R China	Zhang, YX (corresponding author), Hebei United Univ, Sch Basic Med Sci, Tangshan 063000, Hebei Province, Peoples R China.	sidaowen@yahoo.com.cn; jpzyx@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81201048]; Natural Science Foundation of Hebei ProvinceNatural Science Foundation of Hebei Province [H2012401009]; Tangshan Science and Technology Research and Development Program [12140209a-55]; Higher School Science Research Project of Education Department of Hebei Province, China [Z2011168]	This work was supported by National Natural Science Foundation of China (81201048); Natural Science Foundation of Hebei Province (H2012401009); Tangshan Science and Technology Research and Development Program (12140209a-55); Higher School Science Research Project of Education Department of Hebei Province (Z2011168), China.	Barha C.K., EXPT NEUROLOGY, V231; Berry C, 2011, AM J SURG, V201, P429, DOI 10.1016/j.amjsurg.2010.10.008; Cooke PS, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00108; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Garay LI, 2012, NEUROSCIENCE, V226, P40, DOI 10.1016/j.neuroscience.2012.09.032; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Hu ZY, 2009, CURR MED CHEM, V16, P1418, DOI 10.2174/092986709787846523; Ishrat T, 2010, EXP NEUROL, V226, P183, DOI 10.1016/j.expneurol.2010.08.023; Labombarda F, 2010, NEUROIMMUNOMODULAT, V17, P146, DOI 10.1159/000258709; Li ZY, 2012, J NEUROTRAUM, V29, P343, DOI 10.1089/neu.2011.1807; Luoma JI, 2012, J STEROID BIOCHEM, V131, P30, DOI 10.1016/j.jsbmb.2011.11.002; Orr PI, 2009, PHARMACOL BIOCHEM BE, V93, P177, DOI 10.1016/j.pbb.2009.05.012; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Shahrokhi N, 2012, PAK J PHARM SCI, V25, P219; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Stein Donald G, 2011, Dialogues Clin Neurosci, V13, P352; Vagnerova K, 2008, ANESTH ANALG, V107, P201, DOI 10.1213/ane.0b013e31817326a5; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wali B, 2011, RESTOR NEUROL NEUROS, V29, P61, DOI 10.3233/RNN-2011-0579; Wang YS, 2009, J NEUROL SCI, V285, P172, DOI 10.1016/j.jns.2009.06.034; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Zink Brian J., 1996, Emergency Medicine Clinics of North America, V14, P115	30	24	27	0	18	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	OCT 11	2013	553						18	23		10.1016/j.neulet.2013.07.052			6	Neurosciences	Neurosciences & Neurology	239FT	WOS:000326008700004	23954829				2021-06-18	
J	Aziz, H; Rhee, P; Pandit, V; Ibrahim-Zada, I; Kulvatunyou, N; Wynne, J; Zangbar, B; O'Keeffe, T; Tang, A; Friese, RS; Joseph, B				Aziz, Hassan; Rhee, Peter; Pandit, Viraj; Ibrahim-Zada, Irada; Kulvatunyou, Narong; Wynne, Julie; Zangbar, Bardiya; O'Keeffe, Terence; Tang, Andrew; Friese, Randall S.; Joseph, Bellal			Mild and moderate pediatric traumatic brain injury: Replace routine repeat head computed tomography with neurologic examination	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Pediatric traumatic brain injury; repeat head CT; neurological examination; progression on repeat head CT; neurosurgical intervention	CT; UTILITY; CHILDREN	BACKGROUND: Opinion is divided on the role of routine repeat head computed tomography (RHCT) for guiding clinical management in pediatric patients with blunt head trauma. We hypothesize that routine RHCT does not lead to change in management in mild and moderate traumatic brain injury (TBI). METHODS: This is a 3-year retrospective study of all patients of age 2 years to 18 years with blunt TBI admitted to our Level 1 trauma center with an abnormal head CT. Indications for RHCT (routine vs. neurologic deterioration) and their findings (progression or improvement) were recorded. Neurosurgical intervention was defined as extraventricular drain placement, craniectomy, or craniotomy. Primary outcome was a change in management after RHCT. RESULTS: A total of 291 pediatric patients were identified; of which 191 patients received an RHCT. Routine RHCT did not lead to neurosurgical intervention in the mild and moderate TBI group. In patients who received RHCT due to neurologic decline (n = 7), radiographic progression was seen on 85% of the patients (n = 6), with subsequent neurosurgical interventions in three patients. Two of these patients had a Glasgow Coma Scale (GCS) score of less than 8 at admission. CONCLUSION: Our study showed that the neurologic examination can be trusted and is reliable in pediatric blunt TBI patients in determining when an RHCT scan is necessary. We recommend that RHCT is required routinely in patients with intracranial hemorrhage with GCS score of 8 or less and in patients with GCS greater than 8 and that RHCT be performed only when there are clinical indications. Copyright (C) 2013 by Lippincott Williams & Wilkins	[Aziz, Hassan; Rhee, Peter; Pandit, Viraj; Ibrahim-Zada, Irada; Kulvatunyou, Narong; Wynne, Julie; Zangbar, Bardiya; O'Keeffe, Terence; Tang, Andrew; Friese, Randall S.; Joseph, Bellal] Univ Arizona, Dept Surg, Div Trauma, Tucson, AZ 85727 USA	Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Crit Care & Emergency Surg, 1501 N Campbell Ave,Room 5411,POB 245063, Tucson, AZ 85727 USA.	bjoseph@surgery.arizona.edu	Zangbar, Bardiya/K-7147-2014	Zangbar, Bardiya/0000-0003-1215-1693			Brenner DJ, AJR AM J ROENTGENOL, V176, P289; Brown CVR, 2007, J TRAUMA, V62, P1339, DOI 10.1097/TA.0b013e318054e25a; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; Figg RE, 2006, PEDIATR SURG INT, V22, P215, DOI 10.1007/s00383-005-1560-0; Hollingworth W, 2007, PEDIATR CRIT CARE ME, V8, P348, DOI 10.1097/01.PCC.0000270837.66217.3B; Holmes JF, 2005, ACAD EMERG MED, V12, P814, DOI 10.1197/j.aem.2005.04.019; Joseph B, 2013, AM SURG; Joseph B, 2013, J TRAUMA ACUTE CARE, V75, P102, DOI 10.1097/TA.0b013e3182946667; KOBAYASHI S, 1983, SURG NEUROL, V20, P25, DOI 10.1016/0090-3019(83)90101-5; LEVI L, 1991, BRIT J NEUROSURG, V5, P617, DOI 10.3109/02688699109002885; da Silva PSL, 2008, J TRAUMA, V65, P1293, DOI 10.1097/TA.0b013e318156866c; Mattox K, 2012, TRAUMA; Ngo QN, 2009, PEDIATR CRIT CARE ME, V10, P346, DOI 10.1097/PCC.0b013e3181a320cd; Slovis TL, 2002, RADIOLOGY, V223, P5, DOI 10.1148/radiol.2231012100; Stippler M, 2012, EMERG MED J, V29, P528, DOI 10.1136/emermed-2011-200162; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89	19	24	25	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	OCT	2013	75	4					550	554		10.1097/TA.0b013e3182a53a77			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	300IK	WOS:000330457400002	24064865				2021-06-18	
J	Zemek, R; Clarkin, C; Farion, KJ; Vassilyadi, M; Anderson, P; Irish, B; Goulet, K; Barrowman, N; Osmond, MH				Zemek, Roger; Clarkin, Chantalle; Farion, Ken J.; Vassilyadi, Michael; Anderson, Peter; Irish, Brendan; Goulet, Kristian; Barrowman, Nick; Osmond, Martin H.			Parental Anxiety at Initial Acute Presentation Is Not Associated With Prolonged Symptoms Following Pediatric Concussion	ACADEMIC EMERGENCY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; MINOR HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; EMERGENCY-DEPARTMENT; ABDOMINAL-PAIN; CHILDREN; IMPACT; INTERVENTION; EPIDEMIOLOGY	ObjectivesAnxiety modulates symptom perception in adults following concussion, prolonging the time to full recovery. The authors sought to determine whether parental anxiety was associated with persistent postconcussive symptoms (PCS) in their children following concussion. MethodsA prospective observational cohort with 98 children aged 5 to 17years following concussion participated from a tertiary pediatric emergency department (ED). The main exposure was parental anxiety at the time of acute presentation following pediatric concussion, measured using the self-administered, validated Spielberger State-Trait Anxiety Inventory-State Anxiety Scale (STAI-S). The primary outcome measured was presence of PCS in the child at 1month, per the validated Post-Concussive Symptom Inventory (PCSI). Secondary outcome measures included parental anxiety score over time, school absenteeism, and return to sports. Data were collected during the initial ED visit and at 3-day, 7-day, 2-week, 1-month, and 3-month follow-ups. ResultsOf 98 children enrolled, 27% (95% confidence interval [CI]=19% to 36%) developed PCS at 1month. No significant associations were detected between parental anxiety at the index visits and the number of previous pediatric concussions (p=0.73), sex (p=0.61), loss of consciousness (p=0.43), history of migraines (p=0.31), or history of anxiety diagnosed in the patients (p=0.09). A significant association was noted between patient diagnosis of attention deficit hyperactivity disorder (ADHD) and parental anxiety at the index visits (p=0.001). Parental anxiety at acute presentation was not associated with children's prolonged symptoms at 1month (p=0.63). Parental anxiety remained elevated in parents whose children had prolonged symptoms compared to those parents whose children's symptoms resolved (median=30, interquartile range [IQR]=22 to 44; and median=21, IQR=20 to 25, respectively; p<0.001). Initial parental anxiety presentation was not associated with school absenteeism (p=0.23) or not returning to sport or gym class (p=0.89). There were no significant effects involving ADHD alone (p=0.44) or together with baseline parental anxiety (p=0.36 for ADHD and p=0.55 for anxiety) using logistic regression analysis to examine potential predictive effects of child's ADHD combined with parental anxiety at the index visit on persistent symptoms at 1month. ConclusionsParental anxiety at time of acute presentation does not appear to be associated with prolongation of postconcussive symptoms in their children. However, parents of persistently symptomatic children remain significantly more anxious than those whose children's symptoms have resolved. Future research should attempt to reduce the familial burden of concussion through expectation management strategies.	[Zemek, Roger; Farion, Ken J.; Barrowman, Nick; Osmond, Martin H.] Childrens Hosp Eastern Ontario, Div Pediat Emergency Med, Toronto, ON, Canada; [Vassilyadi, Michael] Childrens Hosp Eastern Ontario, Div Neurosurg, Toronto, ON, Canada; [Anderson, Peter] Childrens Hosp Eastern Ontario, Div Neuropsychol, Toronto, ON, Canada; [Zemek, Roger; Farion, Ken J.; Barrowman, Nick; Osmond, Martin H.] Univ Ottawa, Dept Pediat, Ottawa, ON K1N 6N5, Canada; [Vassilyadi, Michael] Univ Ottawa, Dept Surg, Ottawa, ON K1N 6N5, Canada; [Anderson, Peter] Univ Ottawa, Dept Psychol, Ottawa, ON K1N 6N5, Canada; [Irish, Brendan] Univ Ottawa, Fac Med, Ottawa, ON K1N 6N5, Canada; [Zemek, Roger; Clarkin, Chantalle; Farion, Ken J.; Barrowman, Nick; Osmond, Martin H.] Childrens Hosp Eastern Ontario, Res Inst, Toronto, ON, Canada; [Goulet, Kristian] Eastern Ontario Concuss Clin, Ottawa, ON, Canada	Zemek, R (corresponding author), Childrens Hosp Eastern Ontario, Div Pediat Emergency Med, Toronto, ON, Canada.	rzemek@cheo.on.ca	Barrowman, Nick/AAL-3166-2020; Zemek, Roger/H-1039-2018; Meijer, Anna/K-5118-2016	Barrowman, Nick/0000-0002-4704-9595; Osmond, Martin/0000-0001-8275-8381	Academic Health Science Innovation Fund, Ontario, Canada	This study was funded by a grant from the Academic Health Science Innovation Fund, Ontario, Canada. The authors have no conflicts of interest or financial relationships relevant to this article to disclose.	Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Barnes LLB, 2002, EDUC PSYCHOL MEAS, V62, P603, DOI 10.1177/0013164402062004005; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Burton LJ, 1997, PEDIATR EMERG CARE, V13, P1, DOI 10.1097/00006565-199702000-00001; Campo JV, 2007, ARCH PEDIAT ADOL MED, V161, P131, DOI 10.1001/archpedi.161.2.131; Carroll L J, 2011, CONCUSSION CRISIS AN; CASEY R, 1987, PEDIATRICS, V80, P159; Edmed S, 2012, PSYCHIAT RES, V200, P41, DOI 10.1016/j.psychres.2012.05.022; Emery C, 2011, CAN MED ASSOC J, V183, P1249, DOI 10.1503/cmaj.101540; Emiroglu FNI, 2004, J CHILD NEUROL, V19, P332; Feldman JM, 2010, J NERV MENT DIS, V198, P272, DOI 10.1097/NMD.0b013e3181d61271; Ganesalingam K, 2008, J PEDIATR PSYCHOL, V33, P621, DOI 10.1093/jpepsy/jsm133; GARBER J, 1990, J AM ACAD CHILD PSY, V29, P648, DOI 10.1097/00004583-199007000-00021; GAUTHIER J, 1993, CAN J BEHAV SCI, V25, P559, DOI 10.1037/h0078881; Gennaro S, 1986, J Obstet Gynecol Neonatal Nurs, V15, P160; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia GA, 2008, J INT NEUROPSYCH SOC, V14, P204; Gioia GA, 2009, TOP LANG DISORD, V29, P266, DOI 10.1097/TLD.0b013e3181b5322b; Grubenhoff JA, 2010, PEDIATRICS, V126, P688, DOI 10.1542/peds.2009-2804; HATCHER JW, 1989, J PEDIATR PSYCHOL, V14, P335, DOI 10.1093/jpepsy/14.3.335; Korinthenberg R, 2004, BRAIN DEV-JPN, V26, P113, DOI 10.1016/S0387-7604(03)00110-4; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; National Center for Injury Prevention and Control, 2010, TRAUMATIC BRAIN INJU; Ontario Injury Prevention Resource Centre, ONT INJ SPOTL; Parkinson GW, 1999, CLIN PEDIATR, V38, P219, DOI 10.1177/000992289903800403; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Rivara FP, 2012, ARCH PEDIAT ADOL MED, V166, P666, DOI 10.1001/archpediatrics.2011.1602; Scorza KA, 2012, AM FAM PHYSICIAN, V85, P123; SESTI A, 2000, QUAL LIFE NEWSL, V25, P15; Spielberger CD, 1983, STATE TRAIT ANXIETY; Wood RL, 2011, BRAIN INJURY, V25, P1296, DOI 10.3109/02699052.2011.624569; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003; Youngblut JM, 2006, J PEDIATR PSYCHOL, V31, P608, DOI 10.1093/jpepsy/jsj066; Zafonte R, 2011, JAMA-J AM MED ASSOC, V306, P79, DOI 10.1001/jama.2011.819; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	46	24	24	0	20	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	OCT	2013	20	10					1041	1049		10.1111/acem.12220			9	Emergency Medicine	Emergency Medicine	239KX	WOS:000326023700010	24127708	Bronze			2021-06-18	
J	Holmes, AK; Rauch, PK; Cozza, SJ				Holmes, Allison K.; Rauch, Paula K.; Cozza, Stephen J.			When a Parent Is Injured or Killed in Combat	FUTURE OF CHILDREN			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; BEREAVED CHILDREN; PROVIDER PERSPECTIVES; VIETNAM VETERANS; SERVICE MEMBERS; WAR VETERANS; ADJUSTMENT; SOLDIERS	When a service member is injured or dies in a combat zone, the consequences for his or her family can be profound and long-lasting. Visible, physical battlefield injuries often require families to adapt to long and stressful rounds of treatment and rehabilitation, and they can leave the service member with permanent disabilities that mean new roles for everyone in the family. Invisible injuries, both physical and psychological, including traumatic brain injury and combat-related stress disorders, are often not diagnosed until many months after a service member returns from war (if they are diagnosed at all-many sufferers never seek treatment). They can alter a service member's behavior and personality in ways that make parenting difficult and reverberate throughout the family. And a parent's death in combat not only brings immediate grief but can also mean that survivors lose their very identity as a military family when they must move away from their supportive military community. Sifting through the evidence on both military and civilian families, Allison Holmes, Paula Rauch, and Stephen Cozza analyze, in turn, how visible injuries, traumatic brain injuries, stress disorders, and death affect parents' mental health, parenting capacity, and family organization; they also discuss the community resources that can help families in each situation. They note that most current services focus on the needs of injured service members rather than those of their families. Through seven concrete recommendations, they call for a greater emphasis on family-focused care that supports resilience and positive adaptation for all members of military families who are struggling with a service member's injury or death.	[Holmes, Allison K.; Cozza, Stephen J.] Uniformed Serv Univ Hlth Sci, Ctr Study Traumat Stress, Bethesda, MD 20814 USA; [Rauch, Paula K.] Massachusetts Gen Hosp Home Base Team, Boston, MA USA; [Rauch, Paula K.] Harvard Univ, Med School, Cambridge, MA 02138 USA; [Cozza, Stephen J.] US Army, Adelphi, MD USA	Holmes, AK (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Study Traumat Stress, Bethesda, MD 20814 USA.						ARMISTEAD L, 1995, CLIN PSYCHOL REV, V15, P409, DOI 10.1016/0272-7358(95)00023-I; Bachar E, 1997, J NERV MENT DIS, V185, P402, DOI 10.1097/00005053-199706000-00007; Ben Arzi N, 2000, BRAIN INJURY, V14, P725; Brown J, 1998, CHILD ABUSE NEGLECT, V22, P1065, DOI 10.1016/S0145-2134(98)00087-8; Butera-Prinzi F, 2004, BRAIN INJURY, V18, P83, DOI 10.1080/0269905031000118500; Charles N, 2007, NEUROREHABILITATION, V22, P61; Chwastiak LA, 2010, PSYCHOSOM MED, V72, P817, DOI 10.1097/PSY.0b013e3181eb33e9; Cohen J, 2002, TRAUMA VIOLENCE ABUS, V3, P307, DOI DOI 10.1177/1524838002237332; Cozza S., 2011, CLIN WORK TRAUMATIZE, P139; Cozza S. J., 2011, ANN M INT SOC TRAUM; Cozza SJ, 2011, RISK AND RESILIENCE IN U S MILITARY FAMILIES, P259, DOI 10.1007/978-1-4419-7064-0_13; Cozza SJ, 2010, J TRAUMA STRESS, V23, P112, DOI 10.1002/jts.20488; Cozza Stephen J., 2009, P WORKGROUP INTERVEN; Cozza Stephen J., 2011, CARING VETERANS DEPL, V172, P171; Davidson AC, 2001, AUST NZ J PSYCHIAT, V35, P345, DOI 10.1046/j.1440-1614.2001.00897.x; Defense and Veterans Brain Injury Center, DOD WORLDW TBI; Dekel R, 2005, ANXIETY STRESS COPIN, V18, P71, DOI 10.1080/10615800412336427; del Valle L E, 1996, P R Health Sci J, V15, P101; Department of Defense, 2010, REP IMP DEPL MEMB AR; Diareme S, 2006, EUR CHILD ADOLES PSY, V15, P309, DOI 10.1007/s00787-006-0534-7; Fischer, CASUALTY STAT; Friedemann-Sanchez G, 2008, ARCH PHYS MED REHAB, V89, P171, DOI 10.1016/j.apmr.2007.10.017; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Gewirtz AH, 2010, J CONSULT CLIN PSYCH, V78, P599, DOI 10.1037/a0020571; Gorman LA, 2010, PSYCHIAT QUART, V81, P1, DOI 10.1007/s11126-009-9116-4; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Hakman M, 2009, CHILD ABUSE NEGLECT, V33, P461, DOI 10.1016/j.chiabu.2008.08.003; Halcomb Elizabeth, 2005, Contemp Nurse, V19, P232; Harrington-LaMorie Jill, GRIEF BEREAVEMENT CO; Herzog JR, 2011, CHILD ADOLESC SOC WO, V28, P459, DOI 10.1007/s10560-011-0243-z; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Iraq Coalition Casualty Count, IR COAL CAS COUNT; Jaycox Lisa H., 2008, INVISIBLE WOUNDS WAR, pxxi; Johnson JG, 2009, DEATH STUD, V33, P691, DOI 10.1080/07481180903070392; Jones KD, 2010, J COUNS DEV, V88, P372, DOI 10.1002/j.1556-6678.2010.tb00036.x; Kalter N, 2002, OMEGA-J DEATH DYING, V46, P15; Keeley D, 2000, BRIT MED J, V321, P462, DOI 10.1136/bmj.321.7259.462; Kelley AM, 2012, J PSYCHIATR RES, V46, P582, DOI 10.1016/j.jpsychires.2012.01.017; Kieffer-Kristensen R, 2011, BRAIN INJURY, V25, P752, DOI 10.3109/02699052.2011.579933; Koren D, 2005, AM J PSYCHIAT, V162, P276, DOI 10.1176/appi.ajp.162.2.276; Kotchick BA, 1997, BEHAV MODIF, V21, P409, DOI 10.1177/01454455970214002; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; Lehman Douglas H., COMBAT OPERATIONAL B, P543; Lin KK, 2004, J CLIN CHILD ADOLESC, V33, P673, DOI 10.1207/s15374424jccp3304_3; MacDermid Shelley M., 2008, UNDERSTANDIG PROMOTI; MacDonald C, 1999, J TRAUMA STRESS, V12, P701, DOI 10.1023/A:1024729520686; Masten A.S, 2009, EDUC CAN, V49, P28, DOI DOI 10.1037/0003-066X.56.3.227; Monson CM, 2009, CLIN PSYCHOL REV, V29, P707, DOI 10.1016/j.cpr.2009.09.002; Muriel Anna C, 2003, J Support Oncol, V1, P143; PESSAR LF, 1993, BRAIN INJURY, V7, P231, DOI 10.3109/02699059309029675; Pine DS, 2002, BIOL PSYCHIAT, V51, P519, DOI 10.1016/S0006-3223(01)01352-X; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; President's Commission on Care for America's Returning Wounded Warriors, 2007, SERV SUPP SIMPL REP; Pynoos R., 1992, BEREAVEMENT CARE, V11, P2, DOI DOI 10.1080/02682629208657280; RAND Center for Military Health Policy Research, 2008, INV WOUNDS MENT HLTH; Raveis VH, 1999, J YOUTH ADOLESCENCE, V28, P165, DOI 10.1023/A:1021697230387; Regehr C, 2005, FAM RELAT, V54, P423, DOI 10.1111/j.1741-3729.2005.00328.x; Renshaw KD, 2011, J FAM PSYCHOL, V25, P461, DOI 10.1037/a0023994; Resnik LJ, 2007, J REHABIL RES DEV, V44, P991, DOI 10.1682/JRRD.2007.05.0071; Riggs DS, 1998, J TRAUMA STRESS, V11, P87, DOI 10.1023/A:1024409200155; Ruscio AM, 2002, J TRAUMA STRESS, V15, P351, DOI 10.1023/A:1020125006371; Sandler I, 2001, AM J COMMUN PSYCHOL, V29, P19, DOI 10.1023/A:1005237110505; Sayers SL, 2009, J CLIN PSYCHIAT, V70, P163, DOI 10.4088/JCP.07m03863; Schaeffer CM, 2005, J FAM VIOLENCE, V20, P123, DOI 10.1007/s10896-005-3175-6; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Silverman PR, 2002, OMEGA-J DEATH DYING, V46, P335, DOI 10.2190/AC8P-7CAY-LF55-YXKR; Tanielian, INVISIBLE WOUNDS, pxxii; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Tremblay GC, 1998, CLIN PSYCHOL-SCI PR, V5, P424, DOI 10.1111/j.1468-2850.1998.tb00165.x; URBACH JR, 1991, PSYCHOSOMATICS, V32, P24, DOI 10.1016/S0033-3182(91)72108-7; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Visser-Meily A, 2005, STROKE, V36, P2436, DOI 10.1161/01.STR.0000185681.33790.0a; Visser-Meily A, 2005, J REHABIL MED, V37, P236, DOI 10.1080/16501970510025990; Wadsworth SM, 2011, ANN AM ACAD POLIT SS, V638, P163, DOI 10.1177/0002716211416445; Weaver FM, 2009, ARCH PHYS MED REHAB, V90, P517, DOI 10.1016/j.apmr.2008.09.560; Weinstein Edwin A., 1995, WAR PSYCHIAT, P353; Willerton E, 2011, J FAM PSYCHOL, V25, P521, DOI 10.1037/a0024511; Wolchik SA, 2006, J ABNORM CHILD PSYCH, V34, P221, DOI 10.1007/s10802-005-9016-5; Worden J. William, 2009, GRIEF COUNSELING GRI, P231; Worden JW, 1996, OMEGA-J DEATH DYING, V33, P91, DOI 10.2190/P77L-F6F6-5W06-NHBX; Zeber John E, 2010, Ment Health Fam Med, V7, P135	82	24	24	0	15	PRINCETON UNIV	PRINCETON	277 WALLACE HALL, PRINCETON, NJ 08544 USA	1054-8289	1550-1558		FUTURE CHILD	Future Child.	FAL	2013	23	2					143	162		10.1353/foc.2013.0017			20	Family Studies; Health Policy & Services; Social Sciences, Interdisciplinary	Family Studies; Health Care Sciences & Services; Social Sciences - Other Topics	230FR	WOS:000325322600008	25518696				2021-06-18	
J	Siponkoski, ST; Wilson, L; von Steinbuchel, N; Sarajuuri, J; Koskinen, S				Siponkoski, Sini-Tuuli; Wilson, Lindsay; von Steinbuechel, Nicole; Sarajuuri, Jaana; Koskinen, Sanna			QUALITY OF LIFE AFTER TRAUMATIC BRAIN INJURY: FINNISH EXPERIENCE OF THE QOLIBRI IN RESIDENTIAL REHABILITATION	JOURNAL OF REHABILITATION MEDICINE			English	Article						health-related quality of life; traumatic brain injury; rehabilitation; outcome assessment; psychometrics	SATISFACTION; HEALTH; OUTCOMES; DISABILITY; DEPRESSION; VALIDITY; ADULTS; SCALE; SF-36	Objective: To evaluate health-related quality of life of traumatic brain injury patients who have received intensive multidisciplinary residential rehabilitation. To examine the psychometric characteristics of the Finnish Quality of Life after Brain Injury (QOLIBRI) questionnaire. Subjects: A total of 157 adults with TBI, up to 15 years post-injury, who had been treated in the Kapyla Rehabilitation Centre, Helsinki, Finland. Methods: Functional status was assessed using the Extended Glasgow Outcome Scale. Emotional state was evaluated using the Hospital Anxiety and Depression Scale. Health-related quality of life was measured using a generic measure (Short Form-36) and the QOLIBRI. Results: Quality of life was related to depression, amount of help needed, anxiety, education level and age at injury. Quality of life was not associated with time since injury, but a paradoxical relationship was found with injury severity. Internal consistency (alpha = 0.79-0.95) and test-retest reliability (rtt = 0.75-0.87) of the Finnish QOLIBRI met standard psychometric criteria. Conclusion: Quality of life remained relatively stable in the long term. Milder injuries were associated with lower life satisfaction, and careful follow-up is recommended to target patients in special need. This study confirms the reliability and validity of the Finnish QOLIBRI.	[Siponkoski, Sini-Tuuli; Sarajuuri, Jaana; Koskinen, Sanna] Kapyla Rehabil Ctr, FIN-00251 Helsinki, Finland; [Wilson, Lindsay] Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland; [von Steinbuechel, Nicole] Univ Gottingen, Dept Med Psychol & Med Sociol, Gottingen, Germany	Siponkoski, ST (corresponding author), Kapyla Rehabil Ctr, Nordenskioldinkatu 18 B,Box 103, FIN-00251 Helsinki, Finland.	stsipo@gmail.com	Wilson, Lindsay/A-3659-2009; Wilson, Lindsay/O-8883-2019; Sarajuuri, Jaana/AAD-8665-2019	Wilson, Lindsay/0000-0003-4113-2328; Wilson, Lindsay/0000-0003-4113-2328; Sarajuuri, Jaana/0000-0002-6432-0295; Koskinen, Sanna/0000-0002-3453-5084; Siponkoski, Sini-Tuuli/0000-0001-8078-3620			Anagnostopoulos F, 2009, QUAL LIFE RES, V18, P53, DOI 10.1007/s11136-008-9423-5; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Branca B, 2004, J HEAD TRAUMA REHAB, V19, P40, DOI 10.1097/00001199-200401000-00005; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P93; Cicerone KD, 2007, J HEAD TRAUMA REHAB, V22, P257, DOI 10.1097/01.HTR.0000290970.56130.81; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P445, DOI 10.1097/00001199-200411000-00003; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jacobsson LJ, 2011, NEUROPSYCHOL REHABIL, V21, P383, DOI 10.1080/09602011.2011.566711; Jones JM, 2011, PSYCHOL HEALTH, V26, P353, DOI 10.1080/08870440903440699; Kalpakjian CZ, 2004, AM J PHYS MED REHAB, V83, P255, DOI 10.1097/01.PHM.0000118033.07952.8C; Kim YJ, 2011, J CLIN NURS, V20, P1518, DOI 10.1111/j.1365-2702.2010.03618.x; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kozlowski O., 2002, Annales de Readaptation et de Medecine Physique, V45, P466, DOI 10.1016/S0168-6054(02)00297-0; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; Neugebauer E, 2002, RESTOR NEUROL NEUROS, V20, P161; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Power M, 2005, QUAL LIFE RES, V14, P2197, DOI 10.1007/s11136-005-7380-9; Power M, 1998, SOC SCI MED, V46, P1569, DOI 10.1016/s0277-9536(98)00009-4; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; Sasse N, 2012, J HEAD TRAUMA REHABI; Shukla D, 2010, J NEUROSCI RURAL PRA, V1, P82, DOI 10.4103/0976-3147.71723; Truelle JL, 2010, BRAIN INJURY, V24, P1272, DOI 10.3109/02699052.2010.506865; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; von Steinbuechel N, 2005, CURR OPIN NEUROL, V18, P681, DOI 10.1097/01.wco.0000194140.56429.75; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1157, DOI 10.1089/neu.2009.1077; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	39	24	24	0	7	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	SEP	2013	45	8					835	842		10.2340/16501977-1189			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	243ZS	WOS:000326357500021	24002322	DOAJ Gold, Green Published			2021-06-18	
J	Van Wie, EY; Fosgate, GT; Mankin, JM; Jeffery, ND; Kerwin, SC; Levine, GJ; Greatting, HH; Chen, AV; Barker, AK; Levine, JM				Van Wie, E. Y.; Fosgate, G. T.; Mankin, J. M.; Jeffery, N. D.; Kerwin, S. C.; Levine, G. J.; Greatting, H. H.; Chen, A. V.; Barker, A. K.; Levine, J. M.			Prospectively Recorded versus Medical Record-Derived Spinal Cord Injury Scores in Dogs with Intervertebral Disk Herniation	JOURNAL OF VETERINARY INTERNAL MEDICINE			English	Article						Gait scores; Texas spinal cord injury score; Neurotrauma; Canine; Modified Frankel score	INTERRATER RELIABILITY	Background Validated spinal cord injury (SCI) scores have been established for veterinary species but are not uniformly used in practice. Hypothesis/objectives To determine the level of agreement of SCI scores at the time of admission versus those assigned from reconstructed medical records in a population of dogs with intervertebral disk herniation (IVDH). Animals Eighty-six client-owned dogs with confirmed IVDH. Methods Retrospective study. Medical records were reviewed for history, physical examination, neurologic examination, and recorded Modified Frankel score (MFS) and Texas spinal cord injury score (TSCIS) at the time of admission. Three raters, all board-certified neurologists, assigned MFS and TSCIS based on digitized abstracted medical records to each patient. These scores were then compared to the recorded score at the time of admission. Results Actual agreement for MFS and TSCIS derived from medical records by the 3 raters compared to prospectively derived MFS and TSCIS was 77.9 and 51.2%, respectively. A kappa value of 0.572 (95% CI 0.450, 0.694; P < .001) and an ICC of 0.533 (95% CI 0.410, 0.646; P < .001) were calculated for MFS scores. A kappa value of 0.100 (95% CI 0.000, 0.222; P = .107), and an ICC of 0.503 (95% CI 0.377, 0.620; P < .001) were calculated for TSCIS scores. Conclusions and Clinical Importance Results showed that SCI scores recorded at the time of admission often do not agree with those retrospectively abstracted from medical records. Agreement was less when using the more complex TSCIS scale and therefore the MFS scale might be more appropriate for use in retrospective studies.	[Van Wie, E. Y.; Mankin, J. M.; Kerwin, S. C.; Levine, G. J.; Greatting, H. H.] Texas A&M Univ, Dept Small Anim Clin Sci, Coll Vet Med & Biomed Sci, College Stn, TX 77843 USA; [Fosgate, G. T.] Univ Pretoria, Dept Prod Anim Studies, Onderstepoort, South Africa; [Jeffery, N. D.; Barker, A. K.] Iowa State Univ, Dept Small Anim Clin Sci, Coll Vet Med, Ames, IA USA; [Levine, G. J.] Texas A&M Univ, Dept Vet Pathobiol, Coll Vet Med & Biomed Sci, College Stn, TX 77843 USA; [Chen, A. V.] Washington State Univ, Coll Vet Med & Biomed Sci, Dept Small Anim Clin Sci, Pullman, WA 99164 USA; Texas A&M Univ, College Stn, TX 77843 USA	Levine, JM (corresponding author), Texas A&M Univ, Dept Small Anim Clin Sci, 4474 TAMU, College Stn, TX 77843 USA.	jlevine@cvm.tamu.edu	Fosgate, Geoffrey T/N-8700-2014	Fosgate, Geoffrey T/0000-0002-9432-0042; Jeffery, Nick/0000-0002-9812-1788			Brisson BA, 2010, VET CLIN N AM-SMALL, V40, P829, DOI 10.1016/j.cvsm.2010.06.001; Frankel H L, 1969, Paraplegia, V7, P179; Ishida K, 2013, STROKE, V44, P803, DOI 10.1161/STROKEAHA.112.675611; Jonsson M, 2000, SPINAL CORD, V38, P675, DOI 10.1038/sj.sc.3101067; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Levine GJ, 2009, PREV VET MED, V89, P121, DOI 10.1016/j.prevetmed.2009.02.016; Levine JM, 2009, J SMALL ANIM PRACT, V50, P507, DOI 10.1111/j.1748-5827.2009.00834.x; Marino RJ, 2002, J SPINAL CORD MED S1, V26, pS50; Olby NJ, 2001, AM J VET RES, V62, P1624, DOI 10.2460/ajvr.2001.62.1624; Yavuz N, 1998, SPINAL CORD, V36, P832, DOI 10.1038/sj.sc.3100726	10	24	24	0	7	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0891-6640	1939-1676		J VET INTERN MED	J. Vet. Intern. Med.	SEP	2013	27	5					1273	1277		10.1111/jvim.12149			5	Veterinary Sciences	Veterinary Sciences	217VR	WOS:000324391000040	23888873				2021-06-18	
J	Williams, GP; Schache, AG; Morris, ME				Williams, Gavin P.; Schache, Anthony G.; Morris, Meg E.			Mobility After Traumatic Brain Injury: Relationships With Ankle Joint Power Generation and Motor Skill Level	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injuries; mobility limitation; motor skills; muscle spasticity; muscle strength; outcome assessment; postural balance; rehabilitation	ASSESSMENT-TOOL; CEREBRAL-PALSY; TARDIEU SCALE; GAIT ANALYSIS; DEFICITS; CHILDREN; RECOVERY; RELIABILITY; MANAGEMENT; SPASTICITY	Background: Reduced balance, spasticity, contractures, muscle weakness, and motor skill levels may all contribute to mobility limitations after traumatic brain injury (TBI), yet the key physical impairments that contribute to mobility limitations remain unclear. Objective: The aim of this study was to determine which physical impairments best predict mobility performance after a period of 6 months of rehabilitation. Participants: Participants with TBI were selected if they were receiving therapy for mobility limitations but were able to walk without physical assistance. Outcome Measures: The clinical assessment included measures of balance, spasticity, and contracture, and 3-dimensional quantitative gait analysis was used to quantify joint power generation and motor skill level on 31 adults with severe TBI. Mobility outcome was quantified with the high-level mobility assessment tool. Results: Two variables, ankle joint power generation during the push-off phase of gait and motor skill level, explained 66.5% of the variability in mobility outcome. Balance, strength, and mobility performance, all improved significantly over the 6 months of rehabilitation. Only 2 participants had contractures, which affected mobility. Balance disorders were prevalent and improved with rehabilitation, yet they contributed to only a limited extent to the level of recovery in mobility. Conclusion: Ankle joint power generation at push-off was the strongest predictor of mobility outcome after 6 months of rehabilitation in ambulant people with TBI.	[Williams, Gavin P.] Epworth Med Fdn, Physiotherapy Dept, Melbourne, Vic 3121, Australia; [Williams, Gavin P.; Morris, Meg E.] Univ Melbourne, Sch Physiotherapy, Melbourne, Vic, Australia; [Schache, Anthony G.] Univ Melbourne, Dept Mech Engn, Melbourne, Vic, Australia	Williams, GP (corresponding author), Epworth Med Fdn, Physiotherapy Dept, Melbourne, Vic 3121, Australia.	gavin.williams@epworth.org.au	Schache, Anthony G/F-4482-2016	Schache, Anthony G/0000-0002-1041-5213; Morris, Meg/0000-0002-0114-4175; Williams, Gavin/0000-0003-2758-7473	Victorian Neurotrauma Initiative	This project was funded by the Victorian Neurotrauma Initiative.	Baker R, 2009, GAIT POSTURE, V30, P265, DOI 10.1016/j.gaitpost.2009.05.020; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; BERG K, 1989, Physiotherapy Canada, V41, P304; Beynon S, 2010, GAIT POSTURE, V32, P129, DOI 10.1016/j.gaitpost.2010.01.010; Bode RK, 2002, ARCH PHYS MED REHAB, V83, P100, DOI 10.1053/apmr.2002.26073; Boyd RN, 1999, EUR J NEUROL, V6, pS23, DOI 10.1111/j.1468-1331.1999.tb00031.x; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Dumas Helene M., 2002, Physical & Occupational Therapy in Pediatrics, V22, P73, DOI 10.1300/J006v22n03_06; Dumas HM, 2004, PHYS THER, V84, P232, DOI 10.1093/ptj/84.3.232; Duong TT, 2004, ARCH PHYS MED REHAB, V85, P1291, DOI 10.1016/j.apmr.2003.11.032; Dvir Z, 1997, CLIN REHABIL, V11, P36, DOI 10.1177/026921559701100106; Englander JS, 1996, J HEAD TRAUMA REHAB, V11, P15, DOI 10.1097/00001199-199610000-00003; Esquenazi A, 2004, J HEAD TRAUMA REHAB, V19, P109, DOI 10.1097/00001199-200403000-00004; Fock J, 2004, BRAIN INJURY, V18, P57, DOI 10.1080/0269905031000149498; Gracies JM, 2010, ARCH PHYS MED REHAB, V91, P421, DOI 10.1016/j.apmr.2009.11.017; Harrington ME, 2007, J BIOMECH, V40, P595, DOI 10.1016/j.jbiomech.2006.02.003; Haugh AB, 2006, DISABIL REHABIL, V28, P899, DOI 10.1080/09638280500404305; Hillier SL, 1997, BRAIN INJURY, V11, P661; Katz DI, 2004, ARCH PHYS MED REHAB, V85, P865, DOI 10.1016/j.apmr.2003.11.020; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; Keenan M A, 1988, Orthop Rev, V17, P1185; Keenan MA, 1999, NEUROREHABILITATION, V12, P119; KEENAN MAE, 1988, CLIN ORTHOP RELAT R, P221; Kisner C., 2007, THERAPEUTIC EXERCISE; MacAvoy MC, 2007, J HAND SURG-AM, V32A, P149, DOI 10.1016/j.jhsa.2006.10.020; MANN RA, 1980, AM J SPORT MED, V8, P345, DOI 10.1177/036354658000800510; McCulloch KL, 2010, J HEAD TRAUMA REHAB, V25, P153, DOI 10.1097/HTR.0b013e3181e773cf; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; McFadyen BJ, 2009, ARCH PHYS MED REHAB, V90, P1596, DOI 10.1016/j.apmr.2009.03.010; McGinley JL, 2003, PHYS THER, V83, P146, DOI 10.1093/ptj/83.2.146; Mulroy SJ, 1997, J ORTHOP SPORT PHYS, V26, P192, DOI 10.2519/jospt.1997.26.4.192; Novacheck TF, 1998, GAIT POSTURE, V7, P77, DOI 10.1016/S0966-6362(97)00038-6; Nussbaumer S, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-194; Nuttin B, 1999, NEUROMODULATION, V2, P120, DOI 10.1046/j.1525-1403.1999.00120.x; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Paulis WD, 2011, GAIT POSTURE, V33, P185, DOI 10.1016/j.gaitpost.2010.10.094; Perry J, 1999, J HEAD TRAUMA REHAB, V14, P116, DOI 10.1097/00001199-199904000-00003; Pohl M, 2002, ARCH PHYS MED REHAB, V83, P784, DOI 10.1053/apmr.2002.32821; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Reavenall S, 2010, INT J THER REHABIL, V17, P360, DOI 10.12968/ijtr.2010.17.7.48893; Rinne MB, 2006, J REHABIL MED, V38, P224, DOI 10.1080/16501970600582989; Schache AG, 2007, GAIT POSTURE, V25, P440, DOI 10.1016/j.gaitpost.2006.05.018; Sullivan P., 2007, 15 INT C WORLD CONF; Swaine BR, 1996, BRAIN INJURY, V10, P347, DOI 10.1080/026990596124368; Thurman DJ, 1999, TRAUMATIC BRAIN INJU; Toro B, 2003, ARCH PHYS MED REHAB, V84, P1878, DOI 10.1016/S0003-9993(03)00482-9; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Williams G, 2006, ARCH PHYS MED REHAB, V87, P437, DOI 10.1016/j.apmr.2005.10.028; Williams G, 2010, J HEAD TRAUMA REHAB, V25, P366, DOI 10.1097/HTR.0b013e3181cd3600; Williams G, 2010, NEUROREHAB NEURAL RE, V24, P550, DOI 10.1177/1545968309357925; Williams GP, 2011, PHYSIOTHER CAN, V63, P58, DOI 10.3138/ptc.2009-53; Williams GP, 2009, BRAIN INJURY, V23, P307, DOI 10.1080/02699050902774170; Williams GP, 2005, BRAIN INJURY, V19, P833, DOI 10.1080/02699050500058711; Winter DA., 1991, BIOMECHANICS MOTOR C	55	24	24	0	23	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2013	28	5					371	378		10.1097/HTR.0b013e31824a1d40			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	298ZU	WOS:000330364600083	22613943				2021-06-18	
J	Ibrahim, GM; Fallah, A; Macdonald, RL				Ibrahim, George M.; Fallah, Aria; Macdonald, R. Loch			Clinical, laboratory, and radiographic predictors of the occurrence of seizures following aneurysmal subarachnoid hemorrhage Clinical article	JOURNAL OF NEUROSURGERY			English	Article						subarachnoid hemorrhage; seizure; traumatic brain injury	ONSET SEIZURES; INTRAVENTRICULAR HEMORRHAGE; ANTICONVULSANT PROPHYLAXIS; INTRACRANIAL ANEURYSMS; CEREBRAL ANEURYSMS; COIL EMBOLIZATION; EPILEPSY; TRIAL; RISK; STROKE	Object. At present, the administration of prophylactic antiepileptic medication following aneurysmal subarachnoid hemorrhage (SAH) is controversial, and the practice is heterogeneous. Here, the authors sought to inform clinical decision making by identifying factors associated with the occurrence of seizures following aneurysm rupture. Methods. Exploratory analysis was performed on 413 patients enrolled in CONSCIOUS-1 (Clazosentan to Overcome Neurological Ischemia and Infarction Occurring after Subarachnoid Hemorrhage), a prospective randomized trial of clazosentan for the prevention of angiographic vasospasm. The association among clinical, laboratory, and radiographic covariates and the occurrence of seizures following SAH were determined. Covariates with a significance level of p < 0.20 on univariate analysis were entered into a multivariate logistic regression model. Receiver operating characteristic (ROC) curve analysis was used to define optimal predictive thresholds. Results. Of the 413 patients enrolled in the study, 57 (13.8%) had at least 1 seizure following SAH. On univariate analysis, a World Federation of Neurosurgical Societies grade of IV-V, a greater subarachnoid clot burden, and the presence of midline shift and subdural hematomas were associated with seizure activity. On multivariate analysis, only a subarachnoid clot burden (OR 2.76, 95% CI 1.39-5.49) and subdural hematoma (OR 5.67, 95% CI 1.56-20.57) were associated with seizures following SAH. Using ROC curve analysis, the optimal predictive cutoff for subarachnoid clot burden was determined to be 21 (of a possible 30) on the Hijdra scale (area under the curve 0.63). Conclusions. A greater subarachnoid clot burden and subdural hematoma are associated with the occurrence of seizures after aneurysm rupture. These findings may help to identify patients at greatest risk for seizures and guide informed decisions regarding the prescription of prophylactic anticonvulsive therapy. Clinical trial registration no.: NCT00111085 (ClinicalTrials.gov).	Univ Toronto, Labatt Family Ctr Excellence Brain Injury & Traum, Li Ka Shing Knowledge Inst, Div Neurosurg,St Michaels Hosp,Keenan Res Ctr, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Surg, Toronto, ON M5S 1A1, Canada	Macdonald, RL (corresponding author), St Michaels Hosp, 30 Bond St, Toronto, ON M5B 1W8, Canada.	MacdonaldLo@smh.ca		Fallah, Aria/0000-0002-9703-0964	Actelion Pharmaceuticals, Ltd.; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR)	Actelion Pharmaceuticals, Ltd., was the sponsor of the CON-SCIOUS-1 trial; the company provided the authors with the trial data set but had no role in this exploratory analysis nor in the development of the article. The data analysis and writing are the work of the authors. R. Loch Macdonald has ownership in and is the chief scientific officer for Edge Therapeutics, Inc.; is a consultant for Actelion Pharmaceuticals; and receives support from the Canadian Institutes of Health Research for non study related clinical or research effort.	Adelow C, 2011, EPILEPSIA, V52, P301, DOI 10.1111/j.1528-1167.2010.02757.x; Arboix A, 1999, CLIN NEUROL NEUROSUR, V101, P100, DOI 10.1016/S0303-8467(99)00026-8; BAKER CJ, 1995, NEUROSURGERY, V37, P863, DOI 10.1227/00006123-199511000-00003; Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; BERGER AR, 1988, NEUROLOGY, V38, P1363, DOI 10.1212/WNL.38.9.1363; BRAWLEY BW, 1968, J NEUROSURG, V28, P1, DOI 10.3171/jns.1968.28.1.0001; Butzkueven H, 2000, NEUROLOGY, V55, P1315, DOI 10.1212/WNL.55.9.1315; Byrne JV, 2003, NEUROSURGERY, V52, P545, DOI 10.1227/01.NEU.0000047672.25068.4A; CABRAL RJ, 1976, J NEUROL NEUROSUR PS, V39, P1052, DOI 10.1136/jnnp.39.11.1052; Choi KS, 2009, J KOREAN NEUROSURG S, V46, P93, DOI 10.3340/jkns.2009.46.2.93; Claassen J, 2003, NEUROLOGY, V60, P208, DOI 10.1212/01.WNL.0000038906.71394.DE; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; De Reuck J, 2005, EUR NEUROL, V54, P68, DOI 10.1159/000087715; Dreier JP, 2012, BRAIN, V135, P259, DOI 10.1093/brain/awr303; ECHLIN F, 1971, J NEUROSURG, V35, P646, DOI 10.3171/jns.1971.35.6.0646; GRAEB DA, 1982, RADIOLOGY, V143, P91, DOI 10.1148/radiology.143.1.6977795; HART RG, 1981, NEUROSURGERY, V8, P417, DOI 10.1227/00006123-198104000-00002; Hart Y, 2011, J NEUROSURG, V115, P1159, DOI 10.3171/2011.6.JNS101836; HASAN D, 1993, ANN NEUROL, V33, P286; HIJDRA A, 1990, STROKE, V21, P1156, DOI 10.1161/01.STR.21.8.1156; Hoh BL, 2011, NEUROSURGERY, V69, P644, DOI 10.1227/NEU.0b013e31821bc46d; Huff JS, 2001, NEUROLOGY, V56, P1423, DOI 10.1212/WNL.56.10.1423; Ibrahim GM, 2011, J NEUROSURG, V115, P1191, DOI 10.3171/2011.7.JNS11725; KOTILA M, 1992, EPILEPSIA, V33, P495, DOI 10.1111/j.1528-1157.1992.tb01698.x; KVAM DA, 1983, NEUROSURGERY, V12, P14, DOI 10.1227/00006123-198301000-00003; Lanzino G, 2011, NEUROCRIT CARE, V15, P247, DOI 10.1007/s12028-011-9584-x; LEROUX PD, 1992, NEUROSURGERY, V31, P678, DOI 10.1227/00006123-199210000-00010; Lin CL, 2003, J NEUROSURG, V99, P978, DOI 10.3171/jns.2003.99.6.0978; Macdonald RL, 2008, STROKE, V39, P3015, DOI 10.1161/STROKEAHA.108.519942; Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5; Naidech AM, 2005, STROKE, V36, P583, DOI 10.1161/01.STR.0000141936.36596.1e; OHMAN J, 1990, NEUROSURGERY, V27, P578; Pinto AN, 1996, J NEUROL, V243, P161, DOI 10.1007/BF02444009; Rhoney DH, 2000, NEUROLOGY, V55, P258, DOI 10.1212/WNL.55.2.258; ROSE FC, 1965, BRIT MED J, V1, P18, DOI 10.1136/bmj.1.5426.18; Rosengart AJ, 2007, J NEUROSURG, V107, P253, DOI 10.3171/JNS-07/08/0253; Shah D, 2009, SEIZURE-EUR J EPILEP, V18, P676, DOI 10.1016/j.seizure.2009.09.003; SUNDARAM MBM, 1986, CAN J NEUROL SCI, V13, P229, DOI 10.1017/S0317167100036325; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; TEASDALE GM, 1988, J NEUROL NEUROSUR PS, V51, P1457, DOI 10.1136/jnnp.51.11.1457; UKKOLA V, 1990, ACTA NEUROCHIR, V106, P115, DOI 10.1007/BF01809452; Zubkov Alexander Y, 2008, Rev Neurol Dis, V5, P178	42	24	24	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2013	119	2					347	352		10.3171/2013.3.JNS122097			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	187CL	WOS:000322094400014	23581590				2021-06-18	
J	Lapitskaya, N; Gosseries, O; De Pasqua, V; Pedersen, AR; Nielsen, JF; de Noordhout, AM; Laureys, S				Lapitskaya, Natallia; Gosseries, Olivia; De Pasqua, Victor; Pedersen, Asger Roer; Nielsen, Joergen Feldbaek; de Noordhout, Alain Maertens; Laureys, Steven			Abnormal Corticospinal Excitability in Patients with Disorders of Consciousness	BRAIN STIMULATION			English	Article						Vegetative state; Unresponsive wakefulness syndrome; Minimally conscious state; Brain injury; Transcranial magnetic stimulation; Motor evoked potentials; Somatosensory evoked potentials; Short latency afferent inhibition	TRANSCRANIAL MAGNETIC STIMULATION; TRAUMATIC BRAIN-INJURY; CENTRAL CHOLINERGIC CIRCUITS; LATENCY AFFERENT INHIBITION; VIVO FUNCTIONAL-EVALUATION; MOTOR EVOKED-POTENTIALS; VEGETATIVE STATE; CORTEX; RECOVERY; STROKE	Background: Transcranial magnetic stimulation (TMS) has been frequently used to explore changes in the human motor cortex in different conditions, while the extent of motor cortex reorganization in patients in vegetative state (VS) (now known as unresponsive wakefulness syndrome, UWS) and minimally conscious (MCS) states due to severe brain damage remains largely unknown. Objective/hypothesis: It was hypothesized that cortical motor excitability would be decreased and would correlate to the level of consciousness in patients with disorders of consciousness. Methods: Corticospinal excitability was assessed in 47 patients (24 VS/UWS and 23 MCS) and 14 healthy controls. The test parameters included maximal peak-to-peak M-wave (Mm a x), F-wave persistence, peripheral and central motor conduction times, sensory (SEP) and motor evoked (MEP) potential latencies and amplitudes, resting motor threshold (RMT), stimulus/response curves, and short latency afferent inhibition (SAI). TMS measurements were correlated to the level of consciousness (assessed using the Coma Recovery Scale-Revised). Results: On average, the patient group had lower M-max, lower MEP and SEP amplitudes, higher RMTs, narrower stimulus/response curves, and reduced SAI compared to the healthy controls (P < 0.05). The SAI alterations were correlated to the level of consciousness (P < 0.05). Conclusions: The findings demonstrated the impairment of the cortical inhibitory circuits in patients with disorders of consciousness. Moreover, the significant relationship was found between cortical inhibition and clinical consciousness dysfunction. (C) 2013 Elsevier Inc. All rights reserved.	[Lapitskaya, Natallia; Pedersen, Asger Roer; Nielsen, Joergen Feldbaek] Hammel Neurorehabil & Res Ctr, Res Dept, DK-8450 Hammel, Denmark; [Lapitskaya, Natallia; Gosseries, Olivia; Laureys, Steven] Univ Liege, Cyclotron Res Ctr, Coma Sci Grp, B-4000 Liege, Belgium; [Lapitskaya, Natallia; De Pasqua, Victor; de Noordhout, Alain Maertens; Laureys, Steven] Univ Liege, Dept Neurol, B-4000 Liege, Belgium; [De Pasqua, Victor; de Noordhout, Alain Maertens] Ctr Hosp Reg Citadelle, B-4000 Liege, Belgium	Lapitskaya, N (corresponding author), Hammel Neurorehabil & Res Ctr, Res Dept, Voldbyvej 15, DK-8450 Hammel, Denmark.	natlap@rm.dk	Laureys, Steven/A-3349-2011; Laureys, Steven/AAN-2097-2021; Gosseries, Olivia/AAB-6469-2020; Nielsen, Jorgen Feldbak/AAR-6384-2021	Laureys, Steven/0000-0002-3096-3807; Nielsen, Jorgen Feldbak/0000-0001-5339-171X; Gosseries, Olivia/0000-0001-9011-7496	European Neurological Society Fellowship; Danish Medical Research CouncilDanish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Belgian National Funds for Scientific Research (FNRS)Fonds de la Recherche Scientifique - FNRS; European Commission (DISCOS); French Speaking Community Concerted Research Action; James McDonnell Foundation; Mind Science Foundation; University of LiegeUniversity of Liege; European Commission (Mindbridge)European Commission; European Commission (DECODER); European Commission (COST)	NL was supported by the European Neurological Society Fellowship and Danish Medical Research Council. This research was funded by the Belgian National Funds for Scientific Research (FNRS), the European Commission (DISCOS, Mindbridge, DECODER & COST), the French Speaking Community Concerted Research Action, the James McDonnell Foundation, the Mind Science Foundation and the University of Liege.	Abbruzzese G, 2002, J CLIN NEUROPHYSIOL, V19, P307, DOI 10.1097/00004691-200208000-00005; [Anonymous], 2003, Clin Med (Lond), V3, P249; Babiloni C, 2009, HUM BRAIN MAPP, V30, P1431, DOI 10.1002/hbm.20612; Bagnato S, 2012, CLIN NEUROPHYSIOL, V123, P1937, DOI 10.1016/j.clinph.2012.03.014; Bagnato S, 2011, J PERIPHER NERV SYST, V16, P315, DOI 10.1111/j.1529-8027.2011.00363.x; Bernabeu M, 2009, J NEUROTRAUM, V26, P2185, DOI 10.1089/neu.2008.0859; Boly M, 2011, SCIENCE, V332, P858, DOI 10.1126/science.1202043; Chen R, 2008, CLIN NEUROPHYSIOL, V119, P504, DOI 10.1016/j.clinph.2007.10.014; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; Chistyakov AV, 1998, ACTA NEUROCHIR, V140, P467, DOI 10.1007/s007010050126; Chistyakov AV, 1999, CLIN NEUROPHYSIOL, V110, P1080, DOI 10.1016/S1388-2457(99)00029-2; De Jonghe B, 2002, JAMA-J AM MED ASSOC, V288, P2859, DOI 10.1001/jama.288.22.2859; Delvaux V, 2003, CLIN NEUROPHYSIOL, V114, P1217, DOI 10.1016/S1388-2457(03)00070-1; Di Lazzaro V, 2004, CLIN NEUROPHYSIOL, V115, P255, DOI 10.1016/j.clinph.2003.10.009; Di Lazzaro V, 2006, NEUROLOGY, V66, P1111, DOI 10.1212/01.wnl.0000204183.26231.23; Di Lazzaro V, 2005, J PHYSIOL-LONDON, V564, P661, DOI 10.1113/jphysiol.2004.061747; Di Lazzaro V, 2003, NEUROL RES, V25, P143, DOI 10.1179/016164103101201292; Di Lazzaro V, 2002, NEUROLOGY, V59, P392, DOI 10.1212/WNL.59.3.392; Di Lazzaro V, 2008, CLIN NEUROPHYSIOL, V119, P2494, DOI 10.1016/j.clinph.2008.08.010; Di Lazzaro V, 1999, CLIN NEUROPHYSIOL, V110, P1297, DOI 10.1016/S1388-2457(99)00060-7; Di Lazzaro V, 2012, STROKE, V43, P250, DOI 10.1161/STROKEAHA.111.631085; DOMANN R, 1993, NEUROSCI LETT, V155, P69, DOI 10.1016/0304-3940(93)90675-B; Fernandez-Espejo D, 2011, NEUROIMAGE, V54, P103, DOI 10.1016/j.neuroimage.2010.08.035; Fujiki M, 2006, NEUROSCI LETT, V405, P226, DOI 10.1016/j.neulet.2006.07.005; Giacino JT, 2004, NEUROREHABILITATION, V19, P293; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; HOMBERG V, 1991, ELECTROEN CLIN NEURO, V81, P377, DOI 10.1016/0168-5597(91)90027-U; Kloppel S, 2008, NEUROIMAGE, V40, P1782, DOI 10.1016/j.neuroimage.2008.01.019; Lapitskaya N, 2013, BRAIN STIMUL, V6, P130, DOI 10.1016/j.brs.2012.03.010; Lapitskaya N, 2009, PROG BRAIN RES, V177, P191, DOI 10.1016/S0079-6123(09)17713-0; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Magistris MR, 1999, BRAIN, V122, P265, DOI 10.1093/brain/122.2.265; Manganelli F, 2008, CLIN NEUROPHYSIOL, V119, P351, DOI 10.1016/j.clinph.2007.10.011; Masanic CA, 2001, ARCH PHYS MED REHAB, V82, P896, DOI 10.1053/apmr.2001.23833; MITTMANN T, 1994, NEUROSCIENCE, V60, P891, DOI 10.1016/0306-4522(94)90270-4; Moosavi SH, 1999, J NEUROL SCI, V164, P179, DOI 10.1016/S0022-510X(99)00065-9; Nardone R, 2008, J NEURAL TRANSM, V115, P737, DOI 10.1007/s00702-007-0003-6; Nardone R, 2011, DEMENT GERIATR COGN, V32, P18, DOI 10.1159/000330016; Nardone R, 2011, J NEURAL TRANSM, V118, P1349, DOI 10.1007/s00702-011-0650-5; Neumann-Haefelin T, 2000, J CEREBR BLOOD F MET, V20, P45, DOI 10.1097/00004647-200001000-00008; Oliviero A, 2005, CLIN NEUROPHYSIOL, V116, P2592, DOI 10.1016/j.clinph.2005.07.015; Paulus W, 2008, BRAIN STIMUL, V1, P151, DOI 10.1016/j.brs.2008.06.002; Pennisi G, 1999, STROKE, V30, P2666, DOI 10.1161/01.STR.30.12.2666; Puksa L, 2003, CLIN NEUROPHYSIOL, V114, P1079, DOI 10.1016/S1388-2457(03)00028-2; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Rossini PM, 1999, ELECTROENCEPHALOGR S, V52, P171; Samii A, 1998, MUSCLE NERVE, V21, P1445, DOI 10.1002/(SICI)1097-4598(199811)21:11<1445::AID-MUS12>3.0.CO;2-#; Schiene K, 1996, J CEREBR BLOOD F MET, V16, P906, DOI 10.1097/00004647-199609000-00014; Selden NR, 1998, BRAIN, V121, P2249, DOI 10.1093/brain/121.12.2249; Siebner HR, 2003, EXP BRAIN RES, V148, P1, DOI 10.1007/s00221-002-1234-2; Takeuchi N, 2006, BRAIN INJURY, V20, P991, DOI 10.1080/02699050600909771; Talelli P, 2006, CLIN NEUROPHYSIOL, V117, P1641, DOI 10.1016/j.clinph.2006.01.016; Taverni JP, 1998, BRAIN INJURY, V12, P77; Tokimura H, 2000, J PHYSIOL-LONDON, V523, P503, DOI 10.1111/j.1469-7793.2000.t01-1-00503.x; VALLSSOLE J, 1994, NEUROLOGY, V44, P735, DOI 10.1212/WNL.44.4.735	59	24	24	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1935-861X	1876-4754		BRAIN STIMUL	Brain Stimul.	JUL	2013	6	4					590	597		10.1016/j.brs.2013.01.002			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	189UA	WOS:000322292600018	23403267	Green Published			2021-06-18	
J	Nilsson, M; Hagglund, M; Ekstrand, J; Walden, M				Nilsson, Michael; Hagglund, Martin; Ekstrand, Jan; Walden, Markus			Head and Neck Injuries in Professional Soccer	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; football; injury incidence; risk factor	FOOTBALL PLAYERS; ELITE FOOTBALL; CONCUSSION; DEFINITIONS; STATEMENT; RETURN	Objective: To investigate the rate of and risk factors for head and neck injury in male soccer. Design: Prospective cohort study. Setting: Professional soccer. Participants: Twenty-six European teams between 2001/2002 and 2009/2010. Assessment of Risk Factors: Simple and multiple risk factor analyses were evaluated using Cox regression for player-related variables and logistic regression for match-related variables. Main Outcome Measures: Injury rate (number of time loss injuries per 1000 hours). Results: A total of 136 head and neck injuries were recorded (2.2% of all injuries). The head and neck injury rate was 0.17 (0.06 concussions) per 1000 hours. There was a 20-fold higher rate of head and neck injury during match play compared with training (rate ratio [RR], 20.2; 95% confidence interval [CI], 13.3-30.6) and a 78-fold higher rate of concussions (RR, 78.5; 95% CI, 24.4-252.5). Mean layoff for concussion was 10.5 days, but 27% of the concussed players returned to play within 5 days. Defender was the only significant player-related risk factor for head and neck injuries in the multiple analysis (RR, 1.8; 95% CI, 1.0-3.1), whereas no significant variables were identified for concussions. Conclusions: Head and neck injuries were relatively uncommon in professional soccer. Defender was the playing position most at risk. More than one-quarter of the concussed players returned to play before what is recommended in the consensus statements by the major sports governing bodies.	[Nilsson, Michael; Hagglund, Martin; Ekstrand, Jan; Walden, Markus] Football Res Grp, Linkoping, Sweden; [Nilsson, Michael] Angelholm Hosp, Dept Rehabil Ctr, S-26281 Angelholm, Sweden; [Hagglund, Martin] Linkoping Univ, Div Physiotherapy, Dept Med & Hlth Sci, Linkoping, Sweden; [Ekstrand, Jan; Walden, Markus] Linkoping Univ, Div Community Med, Dept Med & Hlth Sci, Linkoping, Sweden	Nilsson, M (corresponding author), Angelholm Hosp, Dept Rehabil Ctr, S-26281 Angelholm, Sweden.	michael.nilsson@skane.se	NILSSON, MICHAEL/ABE-7821-2020	NILSSON, MICHAEL/0000-0002-8826-1621	Union of European Football Associations; Swedish National Centre for Research in Sports; Praktikertjanst AB	Grants were obtained from the Union of European Football Associations, Swedish National Centre for Research in Sports, and Praktikertjanst AB.	Al-Kashmiri A, 2006, TRAUMA, V8, P189, DOI 10.1177/1460408606071144; Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Benson BW, 2011, CAN MED ASSOC J, V183, P905, DOI 10.1503/cmaj.092190; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Broglio SP, 2010, J SPORT SCI MED, V9, P418; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Dvorak J, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2006.034579; Ekstrand J, 2011, BRIT J SPORT MED, V45, P553, DOI 10.1136/bjsm.2009.060582; Fuller CW, 2006, BRIT J SPORT MED, V40, P193, DOI 10.1136/bjsm.2005.025270; Fuller CW, 2005, BRIT J SPORT MED, V39, pI3, DOI 10.1136/bjsm.2005.018937; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hagglund M, 2005, BRIT J SPORT MED, V39, P340, DOI 10.1136/bjsm.2005.018267; Hagglund M, 2009, SCAND J MED SCI SPOR, V19, P819, DOI 10.1111/j.1600-0838.2008.00861.x; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; LINDENFELD TN, 1994, AM J SPORT MED, V22, P364, DOI 10.1177/036354659402200312; Makdissi M, 2009, AM J SPORT MED, V37, P877, DOI 10.1177/0363546508328118; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, P76; ORCHARD J, 1993, SPORT HLTH, V11, P39; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; Price J, 2012, BRIT J SPORT MED, V46, P1000, DOI 10.1136/bjsports-2011-090687; Walden M, 2005, SCAND J MED SCI SPOR, V15, P118, DOI 10.1111/j.1600-0838.2004.00393.x; Walden M, 2011, KNEE SURG SPORT TR A, V19, P11, DOI 10.1007/s00167-010-1170-9	26	24	24	1	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2013	23	4					255	260		10.1097/JSM.0b013e31827ee6f8			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	299AM	WOS:000330366700002	23348605				2021-06-18	
J	Arya, SK; Pui, TS; Wong, CC; Kumar, S; Rahman, ARA				Arya, Sunil K.; Pui, Tze Sian; Wong, Chee Chung; Kumar, Sai; Rahman, Abdur Rub Abdur			Effects of the Electrode Size and Modification Protocol on a Label-Free Electrochemical Biosensor	LANGMUIR			English	Article							TRAUMATIC BRAIN-INJURY; FIBRILLARY ACIDIC PROTEIN; SELF-ASSEMBLED MONOLAYERS; IMPEDANCE SPECTROSCOPY; SERUM; IMMUNOSENSOR; BIOMARKER; GFAP; APTASENSOR; HUMANS	In the present work, the effect of a surface modification protocol along with the electrode size has been investigated for developing an efficient, label-free electrochemical biosensing method for diagnosis of traumatic brain injury (TBI) biomarkers. A microdisk electrode array (MDEA) and a macroelectrode with a comb structure (MECS) were modified with an anti-GFAP (GFAP = glial fibrillary acidic protein) antibody using two protocols for optimum and label-free detection of GEAP, a promising acute-phase TBI biomarker. For the MDEA, an array of six microdisks with a 100 mu m diameter and, for the MECS, a 3.2 mm x 5.5 mm electrode 5 mu m wide With 10 mu m spaced Comb fingers were modified using an optimized protocol for dithiobis(succinimidyl propionate) (DSP) self-assembled monolayer formation. Anti-GFAP was covalently bound, and the remaining free DSP, groups were blocked using ethanol amine (Ea). Sensors, were exposed to solutions with different GFAP concentrations, and a label-free electrochemical,1:impedance spectroscopy (EIS) technique was used to determine the concentration. EIS results confirmed that both types of Ea/anti-GFAP/DSP/Au electrodes modified with an optimized DSP-based protocol can accurately detect GFAP in the range of 1 pg mL(-1) to 100 ng mL(-1) with a detection limit of 1 pg mL(-1) However, the cross-use of the MDEA protocol on the MECS and vice versa resulted in very low sensitivity or poor signal resolution, underscoring the importance of proper Matching oldie electrode size and type and the surface modification protocol.	[Arya, Sunil K.; Pui, Tze Sian; Wong, Chee Chung; Rahman, Abdur Rub Abdur] ASTAR, Inst Microelect, Bioelect Programme, Singapore 117685, Singapore; [Kumar, Sai] SFC Fluid LLC, Enterprise Ctr, Fayetteville, AR 72701 USA	Arya, SK (corresponding author), ASTAR, Inst Microelect, Bioelect Programme, 11 Sci Pk Rd,Singapore Sci Pk 2, Singapore 117685, Singapore.	sunilarya333@gmail.com		Pui, Tze Sian/0000-0003-1056-9826	A*STAR (Agency for Science, Technology and Research), SingaporeAgency for Science Technology & Research (ASTAR) [IME/12-330041]	This work was supported by the A*STAR (Agency for Science, Technology and Research), Singapore, Grant IME/12-330041.	Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Arya SK, 2007, ANAL BIOCHEM, V363, P210, DOI 10.1016/j.ab.2007.01.029; Arya SK, 2013, BIOSENS BIOELECTRON, V41, P446, DOI 10.1016/j.bios.2012.09.006; Arya SK, 2012, ANAL CHIM ACTA, V737, P1, DOI 10.1016/j.aca.2012.05.048; Arya SK, 2012, LAB CHIP, V12, P2362, DOI 10.1039/c2lc21174b; Arya SK, 2010, BIOSENS BIOELECTRON, V25, P2296, DOI 10.1016/j.bios.2010.03.016; Arya SK, 2009, BIOSENS BIOELECTRON, V24, P2810, DOI 10.1016/j.bios.2009.02.008; Bai HY, 2013, BIOSENS BIOELECTRON, V42, P17, DOI 10.1016/j.bios.2012.10.063; Ennen CS, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.06.025; Fan LF, 2013, BIOSENS BIOELECTRON, V43, P12, DOI 10.1016/j.bios.2012.11.033; Fraser DD, 2011, PEDIATR CRIT CARE ME, V12, P319, DOI 10.1097/PCC.0b013e3181e8b32d; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Mendes RK, 2008, J ELECTROANAL CHEM, V612, P164, DOI 10.1016/j.jelechem.2007.09.033; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Niu LM, 2013, SENSOR ACTUAT B-CHEM, V178, P10, DOI 10.1016/j.snb.2012.12.015; North SH, 2012, ANNU REV ANAL CHEM, V5, P35, DOI 10.1146/annurev-anchem-062011-143105; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Pandey CM, 2011, SENSOR ACTUAT B-CHEM, V151, P333, DOI 10.1016/j.snb.2010.07.046; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Park MK, 2012, SENSOR ACTUAT B-CHEM, V171, P323, DOI 10.1016/j.snb.2012.04.017; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pui TS, 2013, SENSOR ACTUAT B-CHEM, V181, P494, DOI 10.1016/j.snb.2013.02.019; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Singh A, 2010, BIOSENS BIOELECTRON, V26, P131, DOI 10.1016/j.bios.2010.05.024; Solanki PR, 2007, SENSOR ACTUAT B-CHEM, V123, P829, DOI 10.1016/j.snb.2006.10.046; Szymanska I, 2007, BIOSENS BIOELECTRON, V22, P1955, DOI 10.1016/j.bios.2006.08.025; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Vasudev A, 2013, BIOSENS BIOELECTRON, V39, P300, DOI 10.1016/j.bios.2012.06.012; Venkatasubbarao S, 2011, PROC SPIE, V8029, DOI 10.1117/12.886661; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Zoltewicz JS, 2012, BIOMARK INSIGHTS, V7, P71, DOI 10.4137/BMI.S9873; Zurek J, 2012, ACTA NEUROCHIR, V154, P93, DOI 10.1007/s00701-011-1175-2	37	24	24	0	54	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0743-7463			LANGMUIR	Langmuir	JUN 4	2013	29	22					6770	6777		10.1021/la401109r			8	Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science, Multidisciplinary	Chemistry; Materials Science	160DK	WOS:000320097000032	23651210				2021-06-18	
J	Max, JE; Schachar, RJ; Landis, J; Bigler, ED; Wilde, EA; Saunders, AE; Ewing-Cobbs, L; Chapman, SB; Dennis, M; Hanten, G; Levin, HS				Max, Jeffrey E.; Schachar, Russell J.; Landis, Julie; Bigler, Erin D.; Wilde, Elisabeth A.; Saunders, Ann E.; Ewing-Cobbs, Linda; Chapman, Sandra B.; Dennis, Maureen; Hanten, Gerri; Levin, Harvey S.			Psychiatric Disorders in Children and Adolescents in the First Six Months After Mild Traumatic Brain Injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							POST-CONCUSSIVE SYMPTOMS; HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; RELIABILITY; VALIDITY; IMPAIRMENT; CHILDHOOD; SCHEDULE; OUTCOMES	The objective was to assess the nature, rate, predictive factors, and neurocognitive correlates of novel psychiatric disorders (NPD) after mild traumatic brain injury (MTBI). Children age 5-14 years with MTBI (N=87) from consecutive admissions to five trauma centers were enrolled and studied with semistructured psychiatric interviews soon after injury (baseline), and 70 of these children were assessed again 6 months post-injury. Injury severity; lesion characteristics; pre-injury variables, including psychiatric disorder, family psychiatric history, family functioning, socioeconomic status, psychosocial adversity, and adaptive functioning; and post-injury neurocognitive and adaptive functioning measures were assessed with standardized instruments. NPD occurred in 25 of 70 participants (36%) in the first 6 months after injury. NPD at 6 months was predicted by the presence of frontal white-matter lesions on MRI at 3 months post-injury, and was associated with concurrent decrements on neurocognitive indices of processing speed, expressive language, and intellectual functioning. NPD was not predicted by other indices of severity, pre-injury psychosocial variables, estimated pre-injury academic functioning, or adaptive and executive function decrements 6 months post-injury. These findings suggest that short-term psychiatric morbidity associated with MTBI in children and adolescents may be more common than previously thought and may have readily identifiable neuroimaging and neurocognitive correlates.	[Max, Jeffrey E.] Rady Childrens Hosp, Dept Psychiat, San Diego, CA USA; [Max, Jeffrey E.] Univ Calif San Diego, San Diego, CA 92103 USA; [Schachar, Russell J.] Hosp Sick Children, Dept Psychiat, Toronto, ON M5G 1X8, Canada; [Dennis, Maureen] Hosp Sick Children, Dept Psychol, Toronto, ON M5G 1X8, Canada; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Wilde, Elisabeth A.; Hanten, Gerri; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Saunders, Ann E.] Univ Texas Hlth Sci Ctr Houston, Dept Psychiat, Houston, TX 77030 USA; [Ewing-Cobbs, Linda] Univ Texas Hlth Sci Ctr Houston, Dept Pediat, Houston, TX 77030 USA; [Chapman, Sandra B.] Univ Texas Dallas, Ctr BrainHlth, Dallas, TX 75230 USA	Max, JE (corresponding author), Rady Childrens Hosp, San Diego, CA USA.	jmax@ucsd.edu		Schachar, Russell/0000-0002-2015-4395	National institute of Mental health (NIMH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K-08 MH01800]; National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This study was supported by National institute of Mental health (NIMH) Grant K-08 MH01800 (Dr. Max) and National Institute of Neurological Disorders and Stroke (NINDS) Grant NS-21889 (Dr. Levin).	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Boyle MH, 1996, J AM ACAD CHILD PSY, V35, P1440, DOI 10.1097/00004583-199611000-00012; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Costello EJ, 1996, ARCH GEN PSYCHIAT, V53, P1137; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Hajek CA, 2010, BRAIN INJURY, V24, P100, DOI 10.3109/02699050903508226; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Leblanc N, 2005, DEV NEUROPSYCHOL, V28, P829, DOI 10.1207/s15326942dn2803_5; LECKMAN JF, 1982, ARCH GEN PSYCHIAT, V39, P879; Logan Gordon D., 1994, P189; Maillard-Wermelinger A, 2009, DEV NEUROREHABIL, V12, P330, DOI 10.3109/17518420903087251; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Semel E. M., 1995, CLIN EVALUATION LANG; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Sparrow S., 1984, VINELAND ADAPTIVE BE; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Wechsler D, 1991, WISC 3 MANUAL; Wechsler D., 1991, WECHSLER INTELLIGENC; Wechsler D., 1999, WESCHLER ABBREVIATED; Woodcock R.W., 1989, WOODCOCK JOHNSON TES; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	44	24	24	0	12	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SUM	2013	25	3					187	197		10.1176/appi.neuropsych.12010011			11	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	215XC	WOS:000324243300036	24026712				2021-06-18	
J	Ortuzar, N; Rico-Barrio, I; Bengoetxea, H; Argandona, EG; Lafuente, JV				Ortuzar, N.; Rico-Barrio, I.; Bengoetxea, H.; Argandona, E. G.; Lafuente, J. V.			VEGF reverts the cognitive impairment induced by a focal traumatic brain injury during the development of rats raised under environmental enrichment	BEHAVIOURAL BRAIN RESEARCH			English	Article						VEGF; Enriched environment; Neurogliovascular unit; Vascularization; Learning and memory	EXPERIENCE-DEPENDENT PLASTICITY; GROWTH-FACTOR EXPRESSION; PRIMARY VISUAL-CORTEX; HIPPOCAMPAL NEUROGENESIS; POSTNATAL-DEVELOPMENT; SYNAPTIC PLASTICITY; NEURONAL PLASTICITY; CEREBRAL-ISCHEMIA; OCCIPITAL CORTEX; ARTERY OCCLUSION	The role of VEGF in the nervous system is extensive; apart from its angiogenic effect, VEGF has been described as a neuroprotective, neurotrophic and neurogenic molecule. Similar effects have been described for enriched environment (EE). Moreover, both VEGF and EE have been related to improved spatial memory. Our aim was to investigate the neurovascular and cognitive effects of intracerebrally-administered VEGF and enriched environment during the critical period of the rat visual cortex development. Results showed that VEGF infusion as well as enriched environment induced neurovascular and cognitive effects in developing rats. VEGF administration produced an enhancement during the learning process of enriched animals and acted as an angiogenic factor both in primary visual cortex (V1) and dentate gyrus (DG) in order to counteract minipump implantation-induced damage. This fact revealed that DG vascularization is critical for normal learning. In contrast to this enriched environment acted on the neuronal density of the DG and V1 cortex, and results showed learning enhancement only in non-operated rats. In conclusion, VEGF administration only has effects if damage is observed due to injury:Once control values were reached, no further effects appeared, showing a ceiling effect. Our results strongly support that in addition to neurogenesis, vascularization plays a pivotal role for learning and memory. (C) 2013 Elsevier B.V. All rights reserved.	[Ortuzar, N.; Rico-Barrio, I.; Bengoetxea, H.; Lafuente, J. V.] Univ Basque Country UPV EHU, Lab Clin & Expt Neurosci LaNCE, Dept Neurosci, Fac Med & Odontol, E-48940 Leioa, Spain; [Argandona, E. G.] Univ Fribourg, Dept Med, Unit Anat, CH-1700 Fribourg, Switzerland	Ortuzar, N (corresponding author), Univ Basque Country UPV EHU, Lab Clin & Expt Neurosci LaNCE, Dept Neurosci, Fac Med & Odontol, Barrio Sarriena S-N, E-48940 Leioa, Spain.	naiara.ortuzar@ehu.es	Rico Barrio, Irantzu/H-6757-2015; Bengoetxea, Harkaitz/AAD-5751-2021; Lafuente, Jose-Vicente/O-6395-2014	Rico Barrio, Irantzu/0000-0003-4908-1182; Lafuente, Jose-Vicente/0000-0001-7246-0987	SAIOTEK (Industry Dept., Government of the Basque Country); Basque GovernmentBasque Government [IT/491/10]; UPV/EHU [UFI 11/32]; (FPU) from the Spanish Ministry of Education; University of the Basque Country (UPV/EHU)	This study has been supported by SAIOTEK (Industry Dept., Government of the Basque Country), IT/491/10 (Basque Government) and UFI 11/32 (UPV/EHU). N. Ortuzar is supported by a predoctoral grant (FPU) from the Spanish Ministry of Education and a post-doctoral grant of the University of the Basque Country (UPV/EHU). Confocal microscopy analysis was performed at the "Servicio de Microscopia Analitica y de Alta Resolucion en Biomedicina" (High Resolution Analytical Microscopy Services for Biomedicine) at the University of the Basque Country (UPV/EHU).	Anderson V, 2011, BRAIN, V134, P2197, DOI 10.1093/brain/awr103; Argandona EG, 2012, BRAIN RES, V1473, P141, DOI 10.1016/j.brainres.2012.07.008; Argandona EG, 2012, CURR NEUROVASC RES, V9, P72; Ballantyne AO, 2008, BRAIN, V131, P2975, DOI 10.1093/brain/awn176; Bengoetxea H, 2008, CEREB CORTEX, V18, P1630, DOI 10.1093/cercor/bhm190; BENNETT EL, 1969, SCIENCE, V163, P825, DOI 10.1126/science.163.3869.825; Brown MW, 2001, NAT REV NEUROSCI, V2, P51, DOI 10.1038/35049064; Burwell RD, 1998, J COMP NEUROL, V398, P179, DOI 10.1002/(SICI)1096-9861(19980824)398:2<179::AID-CNE3>3.0.CO;2-Y; Cancedda L, 2004, J NEUROSCI, V24, P4840, DOI 10.1523/JNEUROSCI.0845-04.2004; Cao L, 2004, NAT GENET, V36, P827, DOI 10.1038/ng1395; Dahlqvist P, 1999, NEUROSCIENCE, V93, P527, DOI 10.1016/S0306-4522(99)00183-9; DIAMOND MC, 1976, J NEUROBIOL, V7, P75, DOI 10.1002/neu.480070108; During Matthew J., 2006, Current Alzheimer Research, V3, P29, DOI 10.2174/156720506775697133; FAGIOLINI M, 1994, VISION RES, V34, P709, DOI 10.1016/0042-6989(94)90210-0; Fagiolini M, 2000, NATURE, V404, P183, DOI 10.1038/35004582; Faherty CJ, 2003, DEV BRAIN RES, V141, P55, DOI 10.1016/S0165-3806(02)00642-9; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Frenkel MY, 2006, NEURON, V51, P339, DOI 10.1016/j.neuron.2006.06.026; Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481; GREENOUGH WT, 1973, EXP NEUROL, V40, P491, DOI 10.1016/0014-4886(73)90090-3; Heynen AJ, 2001, J NEUROSCI, V21, P9801, DOI 10.1523/JNEUROSCI.21-24-09801.2001; Hooks BM, 2007, NEURON, V56, P312, DOI 10.1016/j.neuron.2007.10.003; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Johansson BB, 2002, J CEREBR BLOOD F MET, V22, P89, DOI 10.1097/00004647-200201000-00011; Jones TA, 2011, DEV PSYCHOBIOL, V53, P466, DOI 10.1002/dev.20557; Karmarkar UR, 2006, NEURON, V52, P577, DOI 10.1016/j.neuron.2006.11.001; Kaya D, 2005, J CEREBR BLOOD F MET, V25, P1111, DOI 10.1038/sj.jcbfm.9600109; Kee N, 2007, NAT NEUROSCI, V10, P355, DOI 10.1038/nn1847; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kerr AL, 2010, NEUROSCIENCE, V171, P214, DOI 10.1016/j.neuroscience.2010.08.008; Kim BW, 2008, CELL SIGNAL, V20, P714, DOI 10.1016/j.cellsig.2007.12.009; Kolb B, 1999, CAN J EXP PSYCHOL, V53, P62, DOI 10.1037/h0087300; Licht T, 2011, P NATL ACAD SCI USA, V108, P5081, DOI 10.1073/pnas.1007640108; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; Marti HH, 2000, AM J PATHOL, V156, P965, DOI 10.1016/S0002-9440(10)64964-4; Martinez-Cue C, 2005, BEHAV BRAIN RES, V163, P174, DOI 10.1016/j.bbr.2005.04.016; Meshi D, 2006, NAT NEUROSCI, V9, P729, DOI 10.1038/nn1696; Nithianantharajah J, 2006, NAT REV NEUROSCI, V7, P697, DOI 10.1038/nrn1970; Nithianantharajah J, 2009, PROG NEUROBIOL, V89, P369, DOI 10.1016/j.pneurobio.2009.10.001; Ogunshola OO, 2000, DEV BRAIN RES, V119, P139, DOI 10.1016/S0165-3806(99)00125-X; Ortuzar N, 2011, J NEURAL TRANSM, V118, P135, DOI 10.1007/s00702-010-0496-2; Overstreet LS, 2004, J NEUROSCI, V24, P3251, DOI 10.1523/JNEUROSCI.5173-03.2004; Paban V, 2011, NEUROBIOL AGING, V32, P470, DOI 10.1016/j.neurobiolaging.2009.03.010; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Pati S, 2009, BRAIN RES, V1256, P85, DOI 10.1016/j.brainres.2008.11.086; Pham TM, 2002, PHARMACOL BIOCHEM BE, V73, P167, DOI 10.1016/S0091-3057(02)00783-9; Pizzorusso T, 2007, NEURON, V54, P508, DOI 10.1016/j.neuron.2007.05.003; Plaschke K, 2008, EXP NEUROL, V214, P285, DOI 10.1016/j.expneurol.2008.08.014; Rampon C, 2000, NAT NEUROSCI, V3, P238; Rosenstein JM, 2004, EXP NEUROL, V187, P246, DOI 10.1016/j.expneurol.2004.01.022; ROSENZWEIG MR, 1969, BRAIN RES, V14, P427, DOI 10.1016/0006-8993(69)90120-6; ROSENZWEIG MR, 1978, BRAIN RES, V153, P563, DOI 10.1016/0006-8993(78)90340-2; Sale A, 2007, NAT NEUROSCI, V10, P679, DOI 10.1038/nn1899; Shors TJ, 2002, HIPPOCAMPUS, V12, P578, DOI 10.1002/hipo.10103; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092; Sun YJ, 2006, DEV BIOL, V289, P329, DOI 10.1016/j.ydbio.2005.10.016; Thau-Zuchman O, 2012, J MOL NEUROSCI, V47, P166, DOI 10.1007/s12031-012-9706-8; Tsanov M, 2008, NEUROSCIENTIST, V14, P584, DOI 10.1177/1073858408315655; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Vann SD, 2009, NAT REV NEUROSCI, V10, P792, DOI 10.1038/nrn2733; Wang YM, 2006, BRAIN RES, V1115, P186, DOI 10.1016/j.brainres.2006.07.060; Zacchigna S, 2008, NAT REV NEUROSCI, V9, P169, DOI 10.1038/nrn2336	64	24	24	0	18	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	JUN 1	2013	246	1					36	46		10.1016/j.bbr.2013.02.036			11	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	140PT	WOS:000318668100006	23470903				2021-06-18	
J	Xie, K; Kuang, H; Tsien, JZ				Xie, Kun; Kuang, Hui; Tsien, Joe Z.			Mild Blast Events Alter Anxiety, Memory, and Neural Activity Patterns in the Anterior Cingulate Cortex	PLOS ONE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; BRAIN-INJURY; ENHANCEMENT; SURVIVORS; DEFICITS; COMBAT; TRAUMA; IMPACT; MODEL	There is a general interest in understanding of whether and how exposure to emotionally traumatizing events can alter memory function and anxiety behaviors. Here we have developed a novel laboratory-version of mild blast exposure comprised of high decibel bomb explosion sound coupled with strong air blast to mice. This model allows us to isolate the effects of emotionally fearful components from those of traumatic brain injury or bodily injury typical associated with bomb blasts. We demonstrate that this mild blast exposure is capable of impairing object recognition memory, increasing anxiety in elevated O-maze test, and resulting contextual generalization. Our in vivo neural ensemble recording reveal that such mild blast exposures produced diverse firing changes in the anterior cingulate cortex, a region processing emotional memory and inhibitory control. Moreover, we show that these real-time neural ensemble patterns underwent post-event reverberations, indicating rapid consolidation of those fearful experiences. Identification of blast-induced neural activity changes in the frontal brain may allow us to better understand how mild blast experiences result in abnormal changes in memory functions and excessive fear generalization related to post-traumatic stress disorder.	[Xie, Kun; Kuang, Hui; Tsien, Joe Z.] Georgia Regents Univ, Med Coll Georgia, Brain & Behav Discovery Inst, Augusta, GA USA; [Xie, Kun; Kuang, Hui; Tsien, Joe Z.] Georgia Regents Univ, Med Coll Georgia, Dept Neurol, Augusta, GA USA	Tsien, JZ (corresponding author), Georgia Regents Univ, Med Coll Georgia, Brain & Behav Discovery Inst, Augusta, GA USA.	jtsien@gru.edu	Kuang, Hui/I-1006-2013; Kilic, Cengiz/I-9145-2013; Xie, Kun/L-9926-2013	Kuang, Hui/0000-0002-7806-2864; 	US Army Research Office [W911NF-09-1-0112]; Yunnan Province Department of Science and Technology [2012BA009]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS079774-01A1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS079774] Funding Source: NIH RePORTER	This work was supported by grants from US Army Research Office (W911NF-09-1-0112), Yunnan Province Department of Science and Technology (Grant # 2012BA009), and National Institutes of Health (NS079774-01A1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Cao XH, 2008, NEURON, V60, P353, DOI 10.1016/j.neuron.2008.08.027; Cesur R, 2013, J HEALTH ECON, V32, P51, DOI 10.1016/j.jhealeco.2012.09.001; Chen GF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008256; Eren-Kocak E, 2009, ACTA PSYCHIAT SCAND, V119, P35, DOI 10.1111/j.1600-0447.2008.01281.x; Fani N, 2012, BIOL PSYCHOL, V90, P134, DOI 10.1016/j.biopsycho.2012.03.001; Golub Y, 2009, BEHAV BRAIN RES, V205, P544, DOI 10.1016/j.bbr.2009.08.019; Jovanovic N, 2010, CROAT MED J, V51, P131, DOI 10.3325/cmj.2010.51.131; Jovanovic T, 2012, NEUROPHARMACOLOGY, V62, P695, DOI 10.1016/j.neuropharm.2011.02.023; Jovanovic T, 2010, DEPRESS ANXIETY, V27, P244, DOI 10.1002/da.20663; Lin LN, 2006, TRENDS NEUROSCI, V29, P48, DOI 10.1016/j.tins.2005.11.004; Lin LN, 2005, P NATL ACAD SCI USA, V102, P6125, DOI 10.1073/pnas.0408233102; Lin LN, 2006, J NEUROSCI METH, V155, P28, DOI 10.1016/j.jneumeth.2005.12.032; MACGREGOR AJ, 2012, INJURY; Miller MM, 2006, ANN NY ACAD SCI, V1071, P294, DOI 10.1196/annals.1364.023; Mumby DG, 1996, BEHAV NEUROSCI, V110, P266, DOI 10.1037/0735-7044.110.2.266; Osan R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000404; Quinn JJ, 2008, LEARN MEMORY, V15, P368, DOI 10.1101/lm.813608; Rampon C, 2000, NAT NEUROSCI, V3, P238; Rau V, 2005, NEUROSCI BIOBEHAV R, V29, P1207, DOI 10.1016/j.neubiorev.2005.04.010; Shalev AY, 2000, AM J PSYCHIAT, V157, P255, DOI 10.1176/appi.ajp.157.2.255; Shively SB, 2012, J HEAD TRAUMA REHAB, V27, P234, DOI 10.1097/HTR.0b013e318250e9dd; Siegmund A, 2007, J PSYCHIATR RES, V41, P848, DOI 10.1016/j.jpsychires.2006.07.017; Solomon Z, 2001, J CLIN PSYCHIAT, V62, P11; SQUIRE LR, 1987, MEMORY BRAIN, pR12; Tang YP, 1999, NATURE, V401, P63; van Wingen GA, 2012, P NATL ACAD SCI USA, V109, P15508, DOI 10.1073/pnas.1206330109; Wang DV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017047; Yehuda R, 2004, J CLIN PSYCHIAT, V65, P29	29	24	24	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 31	2013	8	5							e64907	10.1371/journal.pone.0064907			13	Multidisciplinary Sciences	Science & Technology - Other Topics	156DC	WOS:000319799900129	23741416	DOAJ Gold, Green Published			2021-06-18	
J	Guyenet, SJ; Nguyen, HT; Hwang, BH; Schwartz, MW; Baskin, DG; Thaler, JP				Guyenet, Stephan J.; Nguyen, Hong T.; Hwang, Bang H.; Schwartz, Michael W.; Baskin, Denis G.; Thaler, Joshua P.			High-fat diet feeding causes rapid, non-apoptotic cleavage of caspase-3 in astrocytes	BRAIN RESEARCH			English	Article						Glia; Astrocytes; Apoptosis; Obesity; Neuron injury; Hypothalamus	POSTNATAL EXCITOTOXIC DAMAGE; FIBRILLARY ACIDIC PROTEIN; TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; REACTIVE ASTROCYTES; CELL-DEATH; KAPPA-B; ACTIVATION; OBESITY; MICE	Astrocytes respond to multiple forms of central nervous system (CNS) injury by entering a reactive state characterized by morphological changes and a specific pattern of altered protein expression. Termed astrogliosis, this response has been shown to strongly influence the injury response and functional recovery of CNS tissues. This pattern of CNS inflammation and injury associated with astrogliosis has recently been found to occur in the energy homeostasis centers of the hypothalamus during diet-induced obesity (DIO) in rodent models, but the characterization of the astrocyte response remains incomplete. Here, we report that astrocytes in the mediobasal hypothalamus respond robustly and rapidly to purified high-fat diet (HFD) feeding by cleaving caspase-3, a protease whose cleavage is often associated with apoptosis. Although obesity develops in HFD-fed rats by day 14, caspase-3 cleavage occurs by day 3, prior to the development of obesity, suggesting the possibility that it could play a causal role in the hypothalamic neuropathology and fat gain observed in DIO. Caspase-3 cleavage is not associated with an increase in the rate of apoptosis, as determined by TUNEL staining, suggesting it plays a non-apoptotic role analogous to the response to excitotoxic neuron injury. Our results indicate that astrocytes in the mediobasal hypothalamus respond rapidly and robustly to HFD feeding, activating caspase-3 in the absence of apoptosis, a process that has the potential to influence the course of DIO. (C) 2013 Elsevier B.V. All rights reserved.	[Guyenet, Stephan J.; Nguyen, Hong T.; Hwang, Bang H.; Schwartz, Michael W.; Baskin, Denis G.; Thaler, Joshua P.] Univ Washington, Diabet & Obes Ctr Excellence, Div Metab Endocrinol & Nutr, UW Med South Lake Union,Dept Med, Seattle, WA 98109 USA; [Hwang, Bang H.; Baskin, Denis G.] VA Puget Sound Hlth Care Syst, Dept Vet Affairs Puget Sound Hlth Care Syst, Off Res & Dev, Seattle, WA 98108 USA	Thaler, JP (corresponding author), Univ Washington, Diabet & Obes Ctr Excellence, Div Metab Endocrinol & Nutr, UW Med South Lake Union,Dept Med, 850 Republican St,Box 358055, Seattle, WA 98109 USA.	guyenet@uw.edu; hongtng@uw.edu; bhhwang@uw.edu; mschwart@uw.edu; baskindg@uw.edu; jpthaler@uw.edu			National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32DK007247, F32DK091989, DK088872, DK017047, P30DK017047, DK068384, DK083042, DK052989]; Department of Veterans Affairs Senior Research Career Scientist Award at the Veterans Affairs Puget Sound Health Care System; Biomedical Research Core Programs Cellular and Molecular Imaging Core of the University of Washington NIH/NIDDK Diabetes Research Center; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007028] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30DK017047, F32DK091989, T32DK007247, R01DK083042, R01DK052989, K08DK088872, P30DK035816, P01DK068384, R01DK090320] Funding Source: NIH RePORTER	This work was supported by a National Institutes of Health (NIH) Fellowship Training Program Award (T32DK007247), an NIH National Research Service Award (F32DK091989) to S.G., an NIH Career Development Award (DK088872), an NIH-funded Diabetes Research Center Pilot and Feasibility award (DK017047) to J.T., the NIH-funded University of Washington Nutrition Obesity Research Center and Diabetes Research Center (Grant P30DK017047 to D.B.), and NIH Grants DK068384, DK083042, and DK052989 to M.S.; This work was also supported by resources from the Office of Research and Development, Medical Research Service, Department of Veterans Affairs, including the Merit Review Research Program and the Research Enhancement Award Program. D.B. is the recipient of a Department of Veterans Affairs Senior Research Career Scientist Award at the Veterans Affairs Puget Sound Health Care System. Additional support came from the Biomedical Research Core Programs Cellular and Molecular Imaging Core of the University of Washington NIH/NIDDK Diabetes Research Center.	Acarin L, 2005, J NEUROTRAUM, V22, P189, DOI 10.1089/neu.2005.22.189; Acarin L, 2007, GLIA, V55, P954, DOI 10.1002/glia.20518; Aras R, 2012, BRAIN RES, V1450, P102, DOI 10.1016/j.brainres.2012.02.056; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; De Souza CT, 2005, ENDOCRINOLOGY, V146, P4192, DOI 10.1210/en.2004-1520; EAMSHAW WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI DOI 10.1146/ANNUREV.BI0CHEM.68.1383; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Horvath TL, 2010, P NATL ACAD SCI USA, V107, P14875, DOI 10.1073/pnas.1004282107; Jeon BT, 2012, DIABETES, V61, P1444, DOI 10.2337/db11-1498; Kleinridders A, 2009, CELL METAB, V10, P249, DOI 10.1016/j.cmet.2009.08.013; Lamkanfi M, 2006, J CELL BIOL, V173, P165, DOI 10.1083/jcb.200509092; Larsson A, 2004, NEUROCHEM RES, V29, P2069, DOI 10.1007/s11064-004-6880-2; Li LZ, 2008, J CEREBR BLOOD F MET, V28, P468, DOI 10.1038/sj.jcbfm.9600546; McNay DEG, 2012, J CLIN INVEST, V122, P142, DOI 10.1172/JCI43134; Menet V, 2003, P NATL ACAD SCI USA, V100, P8999, DOI 10.1073/pnas.1533187100; Moraes JC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005045; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Narkilahti S, 2003, EUR J NEUROSCI, V18, P1486, DOI 10.1046/j.1460-9568.2003.02874.x; Oomman S, 2006, BRAIN RES, V1078, P19, DOI 10.1016/j.brainres.2006.01.041; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Petrilli V, 2004, J CLIN INVEST, V114, P1072, DOI 10.1172/JCI200421854; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rohn TT, 2004, EXP CELL RES, V295, P215, DOI 10.1016/j.yexcr.2003.12.029; Schwerk C, 2003, BIOCHEM PHARMACOL, V66, P1453, DOI 10.1016/S0006-2952(03)00497-0; Shu IW, 2003, BRAIN RES, V985, P1, DOI 10.1016/S0006-8993(03)02806-3; Su JH, 2001, BRAIN RES, V898, P350, DOI 10.1016/S0006-8993(01)02018-2; Thaler JP, 2012, J CLIN INVEST, V122, P153, DOI 10.1172/JCI59660; Villapol S, 2008, NEUROSCIENCE, V153, P108, DOI 10.1016/j.neuroscience.2008.01.054; Wang DD, 2008, PROG NEUROBIOL, V86, P342, DOI 10.1016/j.pneurobio.2008.09.015; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082; Zhang XC, 2005, EXP NEUROL, V191, P318, DOI 10.1016/j.expneurol.2004.10.011; Zhang XQ, 2008, CELL, V135, P61, DOI 10.1016/j.cell.2008.07.043; Zhao XX, 2006, J BIOL CHEM, V281, P29357, DOI 10.1074/jbc.M513105200	36	24	25	0	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAY 28	2013	1512						97	105		10.1016/j.brainres.2013.03.033			9	Neurosciences	Neurosciences & Neurology	160AG	WOS:000320087800010	23548599	Green Accepted			2021-06-18	
J	Booth-Kewley, S; Schmied, EA; Highfill-McRoy, RM; Larson, GE; Garland, CF; Ziajko, LA				Booth-Kewley, Stephanie; Schmied, Emily A.; Highfill-McRoy, Robyn M.; Larson, Gerald E.; Garland, Cedric F.; Ziajko, Lauretta A.			Predictors of psychiatric disorders in combat veterans	BMC PSYCHIATRY			English	Article						Psychiatric disorders; Military populations; Marines; Iraq/Afghanistan wars; Veterans; Combat	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH DIAGNOSES; WAR ZONE STRESSORS; UK ARMED-FORCES; RISK-FACTORS; VIETNAM VETERANS; US SOLDIERS; GULF-WAR; ORGANIZATIONAL COMMITMENT	Background: Most previous research that has examined mental health among Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF) combatants has relied on self-report measures to assess mental health outcomes; few studies have examined predictors of actual mental health diagnoses. The objective of this longitudinal investigation was to identify predictors of psychiatric disorders among Marines who deployed to combat in Iraq and Afghanistan. Methods: The study sample consisted of 1113 Marines who had deployed to Iraq or Afghanistan. Demographic and psychosocial predictor variables from a survey that all Marines in the sample had completed were studied in relation to subsequent psychiatric diagnoses. Univariate and multivariate logistic regression were used to determine the influence of the predictors on the occurrence of psychiatric disorders. Results: In a sample of Marines with no previous psychiatric disorder diagnoses, 18% were diagnosed with a new-onset psychiatric disorder. Adjusting for other variables, the strongest predictors of overall psychiatric disorders were female gender, mild traumatic brain injury symptoms, and satisfaction with leadership. Service members who expressed greater satisfaction with leadership were about half as likely to develop a mental disorder as those who were not satisfied. Unique predictors of specific types of mental disorders were also identified. Conclusions: Overall, the study's most relevant result was that two potentially modifiable factors, low satisfaction with leadership and low organizational commitment, predicted mental disorder diagnoses in a military sample. Additional research should aim to clarify the nature and impact of these factors on combatant mental health.	[Booth-Kewley, Stephanie; Schmied, Emily A.; Highfill-McRoy, Robyn M.; Larson, Gerald E.; Garland, Cedric F.] USN, Hlth Res Ctr, Behav Sci & Epidemiol Dept, San Diego, CA 92106 USA; [Garland, Cedric F.] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA; [Garland, Cedric F.] Univ Calif San Diego, Moores UCSD Canc Ctr, La Jolla, CA 92093 USA; [Ziajko, Lauretta A.] USN, Med Ctr, San Diego, CA 92134 USA	Booth-Kewley, S (corresponding author), USN, Hlth Res Ctr, Behav Sci & Epidemiol Dept, 140 Sylvester Rd, San Diego, CA 92106 USA.	stephanie.kewley@med.navy.mi			U.S. Navy Bureau of Medicine and Surgery, Washington, DC [61111]	This research was supported by the U.S. Navy Bureau of Medicine and Surgery, Washington, DC, under Work Unit No. 61111. The views and opinions expressed herein are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, or the U.S. Government. Approved for public release; distribution is unlimited. This research has been conducted in compliance with all applicable federal regulations governing the protection of human subjects in research (protocol NHRC.2007.0003).	Adler AB, 1996, MIL PSYCHOL, V8, P1, DOI 10.1207/s15327876mp0801_1; Allen NJ, 2003, MIL PSYCHOL, V15, P237, DOI 10.1207/S15327876MP1503_06; ALLEN NJ, 1990, J OCCUP PSYCHOL, V63, P1, DOI 10.1111/j.2044-8325.1990.tb00506.x; Bartone PT, 2002, MIL PSYCHOL, V14, P321, DOI 10.1207/S15327876MP1404_6; Bartone PT, 1998, MIL MED, V163, P587; Booth-Kewley S, 2005, MIL MED, V170, P87, DOI 10.7205/MILMED.170.1.87; Booth-Kewley S, 2010, J TRAUMA STRESS, V23, P69, DOI 10.1002/jts.20485; Brailey K, 2007, J TRAUMA STRESS, V20, P495, DOI 10.1002/jts.20234; Britt TW, 2004, MIL MED, V169, P541, DOI 10.7205/MILMED.169.7.541; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Castro CA, 2007, TRAUMATOLOGY, V13, P6, DOI [DOI 10.1177/1534765607309950, 10.1177/1534765607309950]; Cwikel J, 2008, SOC PSYCH PSYCH EPID, V43, P184, DOI 10.1007/s00127-007-0286-9; Dohrenwend BP, 2007, J TRAUMA STRESS, V20, P449, DOI 10.1002/jts.20296; Engelhard IM, 2007, CAN J PSYCHIAT, V52, P505, DOI 10.1177/070674370705200808; Fontana A, 1999, J TRAUMA STRESS, V12, P111, DOI 10.1023/A:1024750417154; Fredrickson BL, 2001, AM PSYCHOL, V56, P218, DOI 10.1037/0003-066X.56.3.218; Gade PA, 2003, MIL PSYCHOL, V15, P191, DOI 10.1207/S15327876MP1503_03; Goodman GP, 2011, GEN HOSP PSYCHIAT, V33, P51, DOI 10.1016/j.genhosppsych.2010.10.007; GRIFFITH J, 1988, BASIC APPL SOC PSYCH, V9, P149, DOI 10.1207/s15324834basp0902_6; Gunderson EKE, 2005, MIL MED, V170, P172; Helmus HT, 2005, STEELING MIND COMBAT; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Iversen AC, 2008, PSYCHOL MED, V38, P511, DOI 10.1017/S0033291708002778; JORDAN BK, 1992, J CONSULT CLIN PSYCH, V60, P916, DOI 10.1037/0022-006X.60.6.916; Kehle SM, 2011, J PSYCHIATR RES, V45, P126, DOI 10.1016/j.jpsychires.2010.05.013; KESSLER RC, 1995, AM J PSYCHIAT, V152, P1026; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KING DW, 1995, J ABNORM PSYCHOL, V104, P184, DOI 10.1037/0021-843X.104.1.184; Koenen KC, 2003, J CONSULT CLIN PSYCH, V71, P980, DOI 10.1037/0022-006X.71.6.980; Lapierre CB, 2007, J TRAUMA STRESS, V20, P933, DOI 10.1002/jts.20278; Litz BT, 1997, J CONSULT CLIN PSYCH, V65, P1001, DOI 10.1037/0022-006X.65.6.1001; Lyubomirsky S, 2005, PSYCHOL BULL, V131, P803, DOI 10.1037/0033-2909.131.6.803; Macklin ML, 1998, J CONSULT CLIN PSYCH, V66, P323, DOI 10.1037/0022-006X.66.2.323; Maguen S, 2006, J APPL SOC PSYCHOL, V36, P820, DOI 10.1111/j.0021-9029.2006.00045.x; Maguen S, 2010, AM J PUBLIC HEALTH, V100, P2450, DOI 10.2105/AJPH.2009.166165; Mental Health Advisory Team VI, 2009, MENT HLTH ADV TEAM M; Oliver LW, 1999, MIL PSYCHOL, V11, P57, DOI 10.1207/s15327876mp1101_4; Richardson JD, 2007, CAN J PSYCHIAT, V52, P510, DOI 10.1177/070674370705200809; Riddle JR, 2007, J CLIN EPIDEMIOL, V60, P192, DOI 10.1016/j.jclinepi.2006.04.008; Rona RJ, 2007, INT J EPIDEMIOL, V36, P319, DOI 10.1093/ije/dyl273; Rona RJ, 2009, J TRAUMA STRESS, V22, P11, DOI 10.1002/jts.20383; Rundell JR, 2006, GEN HOSP PSYCHIAT, V28, P352, DOI 10.1016/j.genhosppsych.2006.04.006; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; SOUTHWICK SM, 1995, AM J PSYCHIAT, V152, P1150; Street AE, 2009, CLIN PSYCHOL REV, V29, P685, DOI 10.1016/j.cpr.2009.08.007; Turner JB, 2007, J TRAUMA STRESS, V20, P643, DOI 10.1002/jts.20245; Vasterling JJ, 2000, J TRAUMA STRESS, V13, P441, DOI 10.1023/A:1007781107513; Vogt DS, 2005, J TRAUMA STRESS, V18, P115, DOI 10.1002/jts.20018; WOLFE J, 1993, J SOC ISSUES, V49, P15, DOI 10.1111/j.1540-4560.1993.tb01179.x; Zinzow HM, 2008, PSYCHIAT RES, V159, P226, DOI 10.1016/j.psychres.2007.04.008	55	24	24	0	20	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-244X			BMC PSYCHIATRY	BMC Psychiatry	MAY 7	2013	13								130	10.1186/1471-244X-13-130			11	Psychiatry	Psychiatry	145TW	WOS:000319041800003	23651663	DOAJ Gold, Green Published			2021-06-18	
J	Birnie, M; Morrison, R; Camara, R; Strauss, KI				Birnie, Matthew; Morrison, Ryan; Camara, Ramatoulie; Strauss, Kenneth I.			Temporal changes of cytochrome P450 (Cyp) and eicosanoid-related gene expression in the rat brain after traumatic brain injury	BMC GENOMICS			English	Article						Cytochrome P450 genes; Arachidonic acid metabolic genes; Hippocampus; Parietal cortex; qPCR low density array; In situ hybridization	EPOXIDE HYDROLASE INHIBITION; ARACHIDONIC-ACID METABOLISM; TRANSIENT CEREBRAL-ISCHEMIA; EPOXYEICOSATRIENOIC ACIDS; RETINOIC ACID; PROSTAGLANDIN E-2; CEREBROSPINAL-FLUID; CATALYTIC-ACTIVITY; LEUKOTRIENE C-4; BLOOD-PRESSURE	Background: Traumatic brain injury (TBI) induces arachidonic acid (ArA) release from cell membranes. ArA metabolites form a class of over 50 bioactive eicosanoids that can induce both adaptive and/or maladaptive brain responses. The dynamic metabolism of ArA to eicosanoids, and how they affect the injured brain, is poorly understood due to their diverse activities, trace levels, and short half-lives. The eicosanoids produced in the brain postinjury depend upon the enzymes present locally at any given time. Eicosanoids are synthesized by heme-containing enzymes, including cyclooxygenases, lipoxygenases, and arachidonate monoxygenases. The latter comprise a subset of the cytochrome P450 "Cyp" gene family that metabolize fatty acids, steroids, as well as endogenous and exogenous toxicants. However, for many of these genes neither baseline neuroanatomical nor injury-related temporal expression have been studied in the brain. In a rat model of parietal cortex TBI, Cyp and eicosanoid-related mRNA levels were determined at 6 h, 24 h, 3d, and 7d postinjury in parietal cortex and hippocampus, where dynamic changes in eicosanoids have been observed. Quantitative real-time polymerase chain reaction with low density arrays were used to assay 62 rat Cyps, 37 of which metabolize ArA or other unsaturated fatty acids; 16 eicosanoid-related enzymes that metabolize ArA or its metabolites; 8 eicosanoid receptors; 5 other inflammatory- and recovery-related genes, plus 2 mouse Cyps as negative controls and 3 highly expressed "housekeeping" genes. Results: Sixteen arachidonate monoxygenases, 17 eicosanoid-related genes, and 12 other Cyps were regulated in the brain postinjury (p < 0.05, Tukey HSD). Discrete tissue levels and distinct postinjury temporal patterns of gene expression were observed in hippocampus and parietal cortex. Conclusions: The results suggest complex regulation of ArA and other lipid metabolism after TBI. Due to the temporal nature of brain injury-induced Cyp gene induction, manipulation of each gene (or its products) at a given time after TBI will be required to assess their contributions to secondary injury and/or recovery. Moreover, a better understanding of brain region localization and cell type-specific expression may be necessary to deduce the role of these eicosanoid-related genes in the healthy and injured brain.	[Birnie, Matthew; Morrison, Ryan; Camara, Ramatoulie; Strauss, Kenneth I.] Univ Cincinnati, Coll Med, Cincinnati, OH 45267 USA	Strauss, KI (corresponding author), Michigan State Univ, Coll Human Med, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA.	kenneth.strauss@hc.msu.edu		Birnie, Matthew/0000-0003-3964-5247	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS054890]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS054890] Funding Source: NIH RePORTER	This work was supported by NINDS R01-NS054890. The authors express their appreciation for excellent technical assistance from Nathan Kuhn, Jason Dudley, Andrew Barnikow, and Allyson Cole-Strauss.	Abdu E, 2011, J NEUROCHEM, V117, P632, DOI 10.1111/j.1471-4159.2010.07139.x; ADESUYI SA, 1985, J NEUROCHEM, V45, P770, DOI 10.1111/j.1471-4159.1985.tb04059.x; Ashkar S, 2004, J OCUL PHARMACOL TH, V20, P65, DOI 10.1089/108076804772745473; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; Bolbrinker J, 2011, J HYPERTENS, V29, P56, DOI 10.1097/HJH.0b013e32833f5de5; Bowles J, 2006, SCIENCE, V312, P596, DOI 10.1126/science.1125691; Brenneis C, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-78; Bromek E, 2011, J NEUROCHEM, V118, P806, DOI 10.1111/j.1471-4159.2011.07339.x; Bromek E, 2010, EUR J PHARMACOL, V626, P171, DOI 10.1016/j.ejphar.2009.09.062; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Bylund J, 2002, BIOCHEM BIOPH RES CO, V296, P677, DOI 10.1016/S0006-291X(02)00918-X; Bylund J, 1998, J PHARMACOL EXP THER, V284, P51; Camara NOS, 2009, CURR OPIN NEPHROL HY, V18, P21, DOI 10.1097/MNH.0b013e32831a9df7; Campbell WB, 2000, TRENDS PHARMACOL SCI, V21, P125, DOI 10.1016/S0165-6147(00)01472-3; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; Canals S, 2003, J BIOL CHEM, V278, P21542, DOI 10.1074/jbc.M213174200; Candelario-Jalil E, 2002, BRAIN RES, V927, P212, DOI 10.1016/S0006-8993(01)03358-3; Candelario-Jalil E, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-3; Capidevila JH, 2007, CURR OPIN NEPHROL HY, V16, P465; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Chen JK, 2001, MOL CELL BIOL, V21, P6322, DOI 10.1128/MCB.21.18.6322-6331.2001; Chiba Y, 2006, NEUROSCIENCE, V141, P917, DOI 10.1016/j.neuroscience.2006.04.012; Christmas P, 2006, J BIOL CHEM, V281, P7189, DOI 10.1074/jbc.M513101200; Chuang SS, 2004, J BIOL CHEM, V279, P6305, DOI 10.1074/jbc.M311830200; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Conti AC, 1998, J NEUROSCI, V18, P5663; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; Dhillon HS, 1996, J NEUROTRAUM, V13, P781, DOI 10.1089/neu.1996.13.781; Dunn KM, 2008, AM J PHYSIOL-HEART C, V295, pH2455, DOI 10.1152/ajpheart.00512.2008; ELLIS E F, 1989, Journal of Neurotrauma, V6, P31, DOI 10.1089/neu.1989.6.31; ELLIS EF, 1991, ADV PROSTAG THROMB L, V21, P201; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; Ermert L, 2000, AM J PHYSIOL-LUNG C, V278, pL744; Fathali N, 2009, CRIT CARE M IN PRESS; Fathali N, 2010, CRIT CARE MED, V38, P572, DOI 10.1097/CCM.0b013e3181cb1158; Ferroni S, 2003, J NEUROSCI RES, V72, P363, DOI 10.1002/jnr.10580; FITZPATRICK FA, 1988, PHARMACOL REV, V40, P229; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; Garcia-Segura LM, 1999, J NEUROBIOL, V40, P574, DOI 10.1002/(SICI)1097-4695(19990915)40:4<574::AID-NEU12>3.0.CO;2-8; Gebremedhin D, 2000, CIRC RES, V87, P60, DOI 10.1161/01.RES.87.1.60; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; Gilep AA, 2011, BBA-PROTEINS PROTEOM, V1814, P200, DOI 10.1016/j.bbapap.2010.06.021; Gonzalez-Quevedo R, 2010, DEV CELL, V18, P136, DOI 10.1016/j.devcel.2009.11.010; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Hagglund M, 2006, J NEUROSCI, V26, P3281, DOI 10.1523/JNEUROSCI.4955-05.2006; Hampson AJ, 2002, J NEUROSCI, V22, P257, DOI 10.1523/JNEUROSCI.22-01-00257.2002; Hansen HS, 2010, EXP NEUROL, V224, P48, DOI 10.1016/j.expneurol.2010.03.022; HARDER DR, 1994, AM J PHYSIOL, V266, pH2098; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hernandez RE, 2007, DEVELOPMENT, V134, P177, DOI 10.1242/dev.02706; Higashimori H, 2010, AM J PHYSIOL-CELL PH, V299, pC1068, DOI 10.1152/ajpcell.00225.2010; Hoch U, 2000, ARCH BIOCHEM BIOPHYS, V373, P63, DOI 10.1006/abbi.1999.1504; Hoffman SW, 2003, J NEUROTRAUM, V20, P859, DOI 10.1089/089771503322385791; Hojo Y, 2004, P NATL ACAD SCI USA, V101, P865, DOI 10.1073/pnas.2630225100; Holla VR, 1999, J CLIN INVEST, V104, P751, DOI 10.1172/JCI7013; Homayoun P, 1997, J NEUROCHEM, V69, P199; Iliff JJ, 2007, EXP PHYSIOL, V92, P653, DOI 10.1113/expphysiol.2006/036889; Iliff JJ, 2010, J NEUROCHEM, V115, P1530, DOI 10.1111/j.1471-4159.2010.07059.x; Iliff JJ, 2009, AM J PHYSIOL-HEART C, V296, pH1352, DOI 10.1152/ajpheart.00950.2008; IMAOKA S, 1993, J PHARMACOL EXP THER, V267, P1012; Imaoka Susumu, 2005, Drug Metab Pharmacokinet, V20, P478, DOI 10.2133/dmpk.20.478; Imig JD, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411001773; Inceoglu B, 2007, PROSTAG OTH LIPID M, V82, P42, DOI 10.1016/j.prostaglandins.2006.05.004; Inceoglu B, 2011, P NATL ACAD SCI USA, V108, P5093, DOI 10.1073/pnas.1101073108; Kawashima H, 1997, ARCH BIOCHEM BIOPHYS, V347, P148, DOI 10.1006/abbi.1997.0342; Kelso ML, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-108; Kibaly C, 2005, J NEUROCHEM, V93, P1220, DOI 10.1111/j.1471-4159.2005.03113.x; Kimoto T, 2010, ENDOCRINOLOGY, V151, P5795, DOI 10.1210/en.2010-0581; KONTOS HA, 1981, FED PROC, V40, P2326; Kozak W, 2000, AM J PHYSIOL-REG I, V279, pR455; Kroetz DL, 2002, CURR OPIN LIPIDOL, V13, P273, DOI 10.1097/00041433-200206000-00007; Kunz T, 2002, J NEUROTRAUM, V19, P1051, DOI 10.1089/089771502760341965; Ladecola C, 2001, P NATL ACAD SCI USA, V98, P1294, DOI 10.1073/pnas.98.3.1294; LAETHEM RM, 1993, J BIOL CHEM, V268, P12912; Lammers CH, 1996, J NEUROCHEM, V66, P147; Leffler CW, 1997, AM J PHYSIOL-HEART C, V273, pH333; LESLIE JB, 1985, J NEUROSURG, V63, P659, DOI 10.3171/jns.1985.63.5.0659; Levi G, 1998, BIOCHIMIE, V80, P899, DOI 10.1016/S0300-9084(00)88886-0; Li J, 2011, J CEREBR BLOOD F MET, V31, P413, DOI 10.1038/jcbfm.2010.181; Li Z, 2009, J CEREBR BLOOD F MET, V29, P287, DOI 10.1038/jcbfm.2008.118; Liu M, 2005, J CEREBR BLOOD F MET, V25, P939, DOI 10.1038/sj.jcbfm.9600085; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Makita K, 1996, FASEB J, V10, P1456; Malik AS, 2003, J NEUROTRAUM, V20, P463, DOI 10.1089/089771503765355531; Mastyugin V, 1999, J PHARMACOL EXP THER, V289, P1611; Mateos L, 2011, J BIOL CHEM, V286, P25574, DOI 10.1074/jbc.M111.236877; McCullough L, 2004, J NEUROSCI, V24, P257, DOI 10.1523/JNEUROSCI.4485-03.2004; McCullough LD, 2003, J NEUROSCI, V23, P8701; McDonough W, 1998, J NEUROPATH EXP NEUR, V57, P449, DOI 10.1097/00005072-199805000-00008; MCGIFF JC, 1991, ADV PROSTAG THROMB L, V21, P675; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Mezentsev A, 2005, J PHARMACOL EXP THER, V315, P42, DOI 10.1124/jpet.105.088211; Michaelis UR, 2005, J CELL SCI; Nagayama M, 1999, J CEREBR BLOOD F MET, V19, P1213, DOI 10.1097/00004647-199911000-00005; Nelson DR, 2004, PHARMACOGENETICS, V14, P1, DOI 10.1097/00008571-200401000-00001; Nguyen TV, 2010, J NEUROENDOCRINOL, V22, P1013, DOI 10.1111/j.1365-2826.2010.02044.x; Nissbrandt H, 2001, SYNAPSE, V40, P294, DOI 10.1002/syn.1052; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; OHTSUKI T, 1995, AM J PHYSIOL-HEART C, V268, pH1249; Peng XQ, 2002, AM J PHYSIOL-HEART C, V283, pH2029, DOI 10.1152/ajpheart.01130.2000; Phillis JW, 2006, BRAIN RES REV, V52, P201, DOI 10.1016/j.brainresrev.2006.02.002; Phillis JW, 2004, BRAIN RES REV, V44, P13, DOI 10.1016/j.brainresrev.2003.10.002; Pilitsis JG, 2003, NEUROSCI LETT, V349, P136, DOI 10.1016/S0304-3940(03)00803-6; Poloyac SM, 2006, J CEREBR BLOOD F MET, V26, P1551, DOI 10.1038/sj.jcbfm.9600309; Poloyac SM, 2005, J NEUROSCI METH, V144, P257, DOI 10.1016/j.jneumeth.2004.11.015; Qian LX, 2010, J LIPID RES, V51, P1781, DOI 10.1194/jlr.M002840; Qu W, 2001, J BIOL CHEM, V276, P25467, DOI 10.1074/jbc.M100545200; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Ramamurthy S, 2006, J NEUROSCI RES, V84, P1402, DOI 10.1002/jnr.21061; RIFKIND AB, 1995, ARCH BIOCHEM BIOPHYS, V320, P380, DOI 10.1016/0003-9861(95)90023-3; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Ruparel S, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-73; Ruparel S, 2012, PAIN, V153, P2031, DOI 10.1016/j.pain.2012.04.027; Sarkar P, 2011, NEUROSCIENCE, V194, P241, DOI 10.1016/j.neuroscience.2011.07.058; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; SHAW PM, 1993, MOL PHARMACOL, V44, P775; Shi J, 2010, J IMMUNOL, V184, P7207, DOI 10.4049/jimmunol.0903487; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; Shohami E, 2011, BRIT J PHARMACOL, V163, P1402, DOI 10.1111/j.1476-5381.2011.01343.x; Simpson AECM, 1997, GEN PHARMACOL-VASC S, V28, P351, DOI 10.1016/S0306-3623(96)00246-7; Sisignano M, 2012, J NEUROSCI, V32, P6364, DOI 10.1523/JNEUROSCI.5793-11.2012; Snider NT, 2010, PHARMACOL REV, V62, P136, DOI 10.1124/pr.109.001081; Stark K, 2008, FEBS J, V275, P3706, DOI 10.1111/j.1742-4658.2008.06518.x; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; STRAUSS KI, 1993, MOL BRAIN RES, V20, P229, DOI 10.1016/0169-328X(93)90045-Q; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Strauss KI, 2000, RESTOR NEUROL NEUROS, V16, P263; Strauss KI, 2012, PROSTAGLAND IN PRESS; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Takemiya T, 2007, NEUROCHEM INT, V51, P112, DOI 10.1016/j.neuint.2007.05.009; Tehranipour M, 2010, J MOTOR BEHAV, V42, P151, DOI 10.1080/00222891003697921; Terashvili M, 2008, J PHARMACOL EXP THER, V326, P614, DOI 10.1124/jpet.108.136739; Tindberg N, 1996, J NEUROCHEM, V67, P2066, DOI 10.1046/j.1471-4159.1996.67052066.x; Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666; Wagner K, 2011, PROSTAG OTH LIPID M, V96, P76, DOI 10.1016/j.prostaglandins.2011.08.001; Wang C, 2011, J BIOL CHEM, V286, P6542, DOI 10.1074/jbc.M110.198382; Wang MH, 1999, AM J PHYSIOL-RENAL, V276, pF246; Wang Y, 2008, J NEUROTRAUM, V25, P1187, DOI 10.1089/neu.2008.0542; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WESTCOTT JY, 1987, PROSTAGLANDINS, V34, P877, DOI 10.1016/0090-6980(87)90068-2; Wu SN, 2000, BIOCHEM PHARMACOL, V60, P251, DOI 10.1016/S0006-2952(00)00317-8; Xu FY, 2004, J PHARMACOL EXP THER, V308, P887, DOI 10.1124/jpet.103.059626; Xu XZ, 2011, ADV DRUG DELIVER REV, V63, P597, DOI 10.1016/j.addr.2011.03.006; YERGEY JA, 1990, J CEREBR BLOOD F MET, V10, P143, DOI 10.1038/jcbfm.1990.20; Ying CJ, 2008, HYPERTENS RES, V31, P1821, DOI 10.1291/hypres.31.1821; Yu M, 2004, EUR J PHARMACOL, V486, P297, DOI 10.1016/j.ejphar.2004.01.009; Yu ZG, 2000, MOL PHARMACOL, V57, P1011; Yuan JS, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-85; Zhang F, 2005, CELL RES, V15, P717, DOI 10.1038/sj.cr.7290341; Zhang F, 2002, ACTA PHARMACOL SIN, V23, P497; Zhang J, 1999, EUR J NEUROSCI, V11, P2651, DOI 10.1046/j.1460-9568.1999.00682.x; Zhang QY, 1997, ARCH BIOCHEM BIOPHYS, V340, P270, DOI 10.1006/abbi.1997.9922; Zhang WR, 2008, STROKE, V39, P2073, DOI 10.1161/STROKEAHA.107.508325; Zou AP, 1996, AM J PHYSIOL-REG I, V270, pR228	156	24	24	0	9	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2164			BMC GENOMICS	BMC Genomics	MAY 4	2013	14								303	10.1186/1471-2164-14-303			14	Biotechnology & Applied Microbiology; Genetics & Heredity	Biotechnology & Applied Microbiology; Genetics & Heredity	148DU	WOS:000319223900001	23642095	DOAJ Gold, Green Published			2021-06-18	
J	McDonald, S; English, T; Randall, R; Longman, T; Togher, L; Tate, RL				McDonald, Skye; English, Therese; Randall, Rebekah; Longman, Thea; Togher, Leanne; Tate, Robyn L.			Assessing Social Cognition and Pragmatic Language in Adolescents with Traumatic Brain Injuries	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Emotion; Theory of mind; Pragmatics; Sarcasm; Brain injury; Adolescence	HEAD-INJURY; FRONTOTEMPORAL DEMENTIA; EMOTION RECOGNITION; ASPERGER-SYNDROME; RIGHT-HEMISPHERE; CHILDREN; MIND; SARCASM; PERCEPTION; CHILDHOOD	Traumatic brain injuries (TBI) in children and adolescents can impair social cognition and communication skills but there are few assessment tools suitable for adolescents. The Awareness of Social Inference Test (TASIT) uses professionally enacted audiovisual vignettes of everyday conversational exchanges and is a valid measure of social perception disorders in adults. This study examined its utility for assessing impairments in social cognition in a group of 16 adolescents with TBI, compared to a group of 16 typically developing (TD) adolescents. Adolescents with TBI were, on average, no different to their TD peers on TASIT 1 (emotion recognition) and TASIT 3 (recognizing lies and sarcasm when provided with additional cues) but performed more poorly on TASIT 2 which required them to interpret sarcastic and sincere conversational exchanges with few cues other than the demeanor of the speakers. Within the TBI group, poor performance on TASIT correlated to both relative and self-reported communication difficulties at home. It also correlated with IQ, face recognition and severity of injury as indexed by duration of post-traumatic amnesia. Overall, this study suggests TASIT is a valid measure for adolescents although it raised questions as to how effective normative data is for comparing performance in social cognition during childhood and adolescence.	[McDonald, Skye; English, Therese; Randall, Rebekah; Longman, Thea; Togher, Leanne; Tate, Robyn L.] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia	McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	s.mcdonald@unsw.edu.au	McDonald, Skye/G-4118-2014; Togher, Leanne/AAC-7083-2019	McDonald, Skye/0000-0003-0723-6094; Togher, Leanne/0000-0002-4518-6748	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC)	This research was funded by the National Health and Medical Research Council of Australia. We are grateful to the Prince of Wales Children's Hospital, Brain Injury Unit and the John Hunter Pediatric Brain Injury Service for their assistance with recruitment. We are especially indebted to the young people and their families who participated in this research. The Awareness of Social Inference Test (TASIT) is sold commercially by Pearson Assessment and the first author receives royalties for this. Other than this there are no conflicts of interest.	Adolphs R, 2009, ANNU REV PSYCHOL, V60, P693, DOI 10.1146/annurev.psych.60.110707.163514; Asher S. R., 1986, SOCIAL WORK ED, V8, P205, DOI [10.1093/cs/8.4.205, DOI 10.1093/CS/8.4.205]; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; Baron-Cohen S, 1999, J AUTISM DEV DISORD, V29, P407, DOI 10.1023/A:1023035012436; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; BERNDT DJ, 1983, J CONSULT CLIN PSYCH, V51, P627, DOI 10.1037/0022-006X.51.4.627; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Blake ML, 2009, J SPEECH LANG HEAR R, V52, P359, DOI 10.1044/1092-4388(2009/07-0012); Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; Channon S, 2005, BRAIN LANG, V93, P123, DOI 10.1016/j.bandl.2004.09.002; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; DeGroot T, 1999, J APPL PSYCHOL, V84, P986, DOI 10.1037/0021-9010.84.6.986; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2001, J HEAD TRAUMA REHAB, V16, P456, DOI 10.1097/00001199-200110000-00005; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fournier NM, 2008, EPILEPSY BEHAV, V12, P460, DOI 10.1016/j.yebeh.2007.12.009; Gamino JF, 2009, TOP LANG DISORD, V29, P224, DOI 10.1097/TLD.0b013e3181b531da; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; Kern RS, 2009, PSYCHOL MED, V39, P645, DOI 10.1017/S0033291708003966; Kipps CM, 2009, BRAIN, V132, P592, DOI 10.1093/brain/awn314; KOLB B, 1992, BRAIN COGNITION, V20, P74, DOI 10.1016/0278-2626(92)90062-Q; Kosmidis MH, 2008, BEHAV NEUROL, V19, P65, DOI 10.1155/2008/157356; Kovacs M., 1992, CHILDRENS DEPRESSION; LEVIN HS, 1975, J PSYCHOL, V91, P223, DOI 10.1080/00223980.1975.9923946; Lovibond S.H., 1995, MANUAL DEPRESSION AN; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2004, NEUROPSYCHOL REHABIL, V14, P285, DOI 10.1080/09602010343000237; McDonald S., 2011, AWARENESS SOCIAL INF; Morse S, 1999, Pediatr Rehabil, V3, P139; PERNER J, 1985, J EXP CHILD PSYCHOL, V39, P437, DOI 10.1016/0022-0965(85)90051-7; PLACE KS, 1991, DISCOURSE PROCESS, V14, P227, DOI 10.1080/01638539109544783; Rankin KP, 2009, NEUROIMAGE, V47, P2005, DOI 10.1016/j.neuroimage.2009.05.077; REYNOLDS CR, 1978, J ABNORM CHILD PSYCH, V6, P271, DOI 10.1007/BF00919131; Shamay-Tsoory SG, 2005, NEUROPSYCHOLOGY, V19, P288, DOI 10.1037/0894-4105.19.3.288; Sparks A, 2010, SCHIZOPHR RES, V122, P172, DOI 10.1016/j.schres.2010.06.011; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; Tlustos SJ, 2011, J INT NEUROPSYCH SOC, V17, P1132, DOI 10.1017/S1355617711001202; Tonks J, 2007, BRAIN INJURY, V21, P623, DOI 10.1080/02699050701426865; Tonks J, 2007, BRAIN INJURY, V21, P731, DOI 10.1080/02699050701426899; TOWNE RL, 1993, LANG SPEECH HEAR SER, V24, P100; Turkstra LS, 2004, NEUROREHABILITATION, V19, P245; Turkstra LS, 1996, BRAIN INJURY, V10, P329, DOI 10.1080/026990596124359; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Turkstra LS, 2000, APHASIOLOGY, V14, P349, DOI 10.1080/026870300401405; Turkstra LS, 2008, BRAIN INJURY, V22, P397, DOI 10.1080/02699050802027059; Turkstra LS, 2008, NEUROREHABILITATION, V23, P501; Vicari S, 2000, CORTEX, V36, P31, DOI 10.1016/S0010-9452(08)70834-7; Walz NC, 2010, J NEUROPSYCHOL, V4, P181, DOI 10.1348/174866410X488788; Wechsler D., 2011, WECHLSER ABBREVIATED; Williamson D. J. G., 1996, NEUROPSYCHOLOGY CLIN, P9, DOI [10.1037/10198-001, DOI 10.1037/10198-001]; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	57	24	24	0	45	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2013	19	5					528	538		10.1017/S1355617713000039			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	136OB	WOS:000318370100005	23442218				2021-06-18	
J	Gao, HL; Li, C; Nabeka, H; Shimokawa, T; Saito, S; Wang, ZY; Cao, YM; Matsuda, S				Gao, H. L.; Li, C.; Nabeka, H.; Shimokawa, T.; Saito, S.; Wang, Z. Y.; Cao, Y. M.; Matsuda, S.			ATTENUATION OF MPTP/MPP+ TOXICITY IN VIVO AND IN VITRO BY AN 18-MER PEPTIDE DERIVED FROM PROSAPOSIN	NEUROSCIENCE			English	Article						prosaposin-derived 18-mer peptide; dopaminergic neurons; 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-methyl-4-phenylpyridinium ion; SH-SY5Y; Parkinson's disease	CEREBELLAR GRANULE NEURONS; INDUCED PARKINSONS-DISEASE; ACTIVATED PROTEIN-KINASE; TRAUMATIC BRAIN-INJURY; CELL-DEATH PREVENTION; C-JUN; DOPAMINERGIC-NEURONS; GLIAL-CELLS; SIGNAL-TRANSDUCTION; NEUROTROPHIC FACTOR	Parkinson's disease (PD) is a chronic progressive neurological disorder with an increasing incidence in the aging population. Neuroprotective and/or neuroregenerative strategies remain critical in the treatment of this increasingly prevalent disease. Prosaposin is a neurotrophic factor whose neurotrophic activity is attributed to a stretch of 12 amino acids located at the N-terminal region of saposin C. The present study was performed to investigate the protective effect and mechanism of action of a prosaposin-derived 18-mer peptide (PS18: LSELIINNATEELLIKGL) in Parkinson's disease models. We used 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or 1-methyl-4-phenylpyridinium ion (MPP+)-induced dopaminergic neurotoxicity in C57BL/6J mice or SH-SY5Y cells and explored the protective effect and mechanisms of action of PS18 on dopaminergic neurons. Treatment with 2.0 mg/kg PS18 significantly improved behavioral deficits, enhanced the survival of tyrosine hydroxylase-positive neurons, and decreased the activity of astrocytes in the substantia nigra and striatum in MPTP-induced PD model mice. In vitro, a Cell Counting Kit-8 assay and Hoechst 33258 staining revealed that co-treatment with 300 ng/mL PS18 and 5 mM MPP+ protected against MPP+-induced nuclear morphological changes and attenuated cell death induced by MPP+. We also found that PS18-FAM entered the cells, and the retention time of PS18-FAM in the cytoplasm of MPP+-treated cells was shorter than that of untreated cells. In addition, PS18 showed protection from MPP+/MPTP-induced apoptosis in the SH-SY5Y cells and dopaminergic neurons in the PD model mice via suppression of the c-Jun N-terminal kinase/c-Jun pathway; upregulation of Bcl-2; downregulation of BAX, attenuating mitochondrial damage; and inhibition of caspase-3. These findings suggest that PS18 may provide a valuable therapeutic strategy for the treatment of progressive neurodegenerative diseases such as PD. (C) 2013 IBRO. Published by Elsevier Ltd. All rights reserved.	[Gao, H. L.; Li, C.; Nabeka, H.; Shimokawa, T.; Matsuda, S.] Ehime Univ, Grad Sch Med, Dept Anat & Embryol, Toon, Ehime 7910295, Japan; [Saito, S.] Gifu Univ, Fac Appl Biol Sci, Lab Vet Anat, Gifu, Japan; [Gao, H. L.; Wang, Z. Y.] Northeastern Univ, Coll Life & Hlth Sci, Shenyang, Peoples R China; [Li, C.; Cao, Y. M.] China Med Univ, Dept Immunol, Shenyang, Peoples R China	Nabeka, H (corresponding author), Ehime Univ, Grad Sch Med, Dept Anat & Embryol, Toon, Ehime 7910295, Japan.	nabeka@m.ehime-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [14370466, 22591637, 19659380]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [22591637] Funding Source: KAKEN	This study was supported in part by Grants to SM (Nos. 14370466, 22591637, 19659380) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: http://www.textcheck.com/certificate/AOHNpL.	Beal M F, 1992, Curr Opin Neurobiol, V2, P657, DOI 10.1016/0959-4388(92)90035-J; Bjorklund A, 2007, TRENDS NEUROSCI, V30, P194, DOI 10.1016/j.tins.2007.03.006; Blum D, 2001, PROG NEUROBIOL, V65, P135, DOI 10.1016/S0301-0082(01)00003-X; Borsello T, 2007, CURR PHARM DESIGN, V13, P1875; Cabral ALB, 2001, MOL CELL ENDOCRINOL, V175, P67, DOI 10.1016/S0303-7207(01)00396-3; Campana WM, 1998, FASEB J, V12, P307; Cheng BH, 2007, AUTON NEUROSCI-BASIC, V134, P38, DOI 10.1016/j.autneu.2007.02.002; Choi WS, 1999, J NEUROSCI RES, V57, P86, DOI 10.1002/(SICI)1097-4547(19990701)57:1<86::AID-JNR9>3.3.CO;2-5; Chun HS, 2001, J NEUROCHEM, V76, P1010, DOI 10.1046/j.1471-4159.2001.00096.x; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Crompton M, 2000, CURR OPIN CELL BIOL, V12, P414, DOI 10.1016/S0955-0674(00)00110-1; Czlonkowska A, 1996, NEURODEGENERATION, V5, P137, DOI 10.1006/neur.1996.0020; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dodel RC, 1998, NEUROSCIENCE, V86, P701, DOI 10.1016/S0306-4522(98)00154-7; FURST W, 1988, BIOL CHEM H-S, V369, P317, DOI 10.1515/bchm3.1988.369.1.317; Gao HL, 2009, NEUROTOX RES, V16, P416, DOI 10.1007/s12640-009-9072-7; Gearan T, 2001, PARKINSONISM RELAT D, V8, P19, DOI 10.1016/S1353-8020(00)00078-X; GIULIAN D, 1988, J NEUROSCI, V8, P2485; Hartmann A, 2000, P NATL ACAD SCI USA, V97, P2875, DOI 10.1073/pnas.040556597; Hartmann A, 2001, J NEUROCHEM, V76, P1785, DOI 10.1046/j.1471-4159.2001.00160.x; Hausmann R, 2000, INT J LEGAL MED, V113, P70, DOI 10.1007/PL00007711; HEIKKILA RE, 1984, SCIENCE, V224, P1451, DOI 10.1126/science.6610213; Hiesberger T, 1998, EMBO J, V17, P4617, DOI 10.1093/emboj/17.16.4617; Himeda T, 2006, J NEURAL TRANSM, V113, P1887, DOI 10.1007/s00702-006-0482-x; HINENO T, 1991, BIOCHEM BIOPH RES CO, V176, P668, DOI 10.1016/S0006-291X(05)80236-0; Hiraiwa M, 1997, P NATL ACAD SCI USA, V94, P4778, DOI 10.1073/pnas.94.9.4778; HIRAIWA M, 1992, P NATL ACAD SCI USA, V89, P11254, DOI 10.1073/pnas.89.23.11254; HIRAIWA M, 1993, J BIOCHEM-TOKYO, V114, P901, DOI 10.1093/oxfordjournals.jbchem.a124274; Hiraiwa M, 1997, BIOCHEM BIOPH RES CO, V240, P415, DOI 10.1006/bbrc.1997.7673; Hirsch EC, 1998, ANN NEUROL, V44, pS115, DOI 10.1002/ana.410440717; Hozumi I, 1999, NEUROSCI LETT, V267, P73, DOI 10.1016/S0304-3940(99)00325-0; Igase K, 1999, J CEREBR BLOOD F MET, V19, P298, DOI 10.1097/00004647-199903000-00008; Joel D, 2000, NEUROSCIENCE, V96, P451, DOI 10.1016/S0306-4522(99)00575-8; Junn E, 2001, J NEUROCHEM, V78, P374, DOI 10.1046/j.1471-4159.2001.00425.x; Kanthasamy AG, 2006, FREE RADICAL BIO MED, V41, P1578, DOI 10.1016/j.freeradbiomed.2006.08.016; Kim HE, 2001, BIOCHEM BIOPH RES CO, V286, P659, DOI 10.1006/bbrc.2001.5446; Kim IS, 2011, EUR J PHARMACOL, V650, P48, DOI 10.1016/j.ejphar.2010.09.063; Kohutnicka M, 1998, IMMUNOPHARMACOLOGY, V39, P167, DOI 10.1016/S0162-3109(98)00022-8; Kotani Y, 1996, J NEUROCHEM, V66, P2197; Kotani Y, 1996, J NEUROCHEM, V66, P2019; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kuwana T, 2003, CURR OPIN CELL BIOL, V15, P691, DOI 10.1016/j.ceb.2003.10.004; Lee DH, 2008, BIOCHEM PHARMACOL, V75, P2345, DOI 10.1016/j.bcp.2008.03.013; Liberatore GT, 1999, NAT MED, V5, P1403; Matsuda W, 2009, J NEUROSCI, V29, P444, DOI 10.1523/JNEUROSCI.4029-08.2009; Mazumder Suparna, 2008, V414, P13; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Misasi R, 2001, FASEB J, V15, P467, DOI 10.1096/fj.00-0217com; Misasi R, 2004, EXP CELL RES, V298, P38, DOI 10.1016/j.yexcr.2004.04.011; Mizuno Y, 1998, INTERNAL MED, V37, P192, DOI 10.2169/internalmedicine.37.192; Morita F, 2001, J CEREBR BLOOD F MET, V21, P1295, DOI 10.1097/00004647-200111000-00005; Morris MA, 2001, FASEB J, V15, pA1026, DOI 10.1096/fj.00-0603fje; Newman M, 2009, J ALZHEIMERS DIS, V16, P133, DOI 10.3233/JAD-2009-0945; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; OBRIEN JS, 1995, FASEB J, V9, P681; OBRIEN JS, 1994, P NATL ACAD SCI USA, V91, P9593, DOI 10.1073/pnas.91.20.9593; OBRIEN JS, 1991, FASEB J, V5, P301; OYARCE AM, 1991, ARCH BIOCHEM BIOPHYS, V290, P503, DOI 10.1016/0003-9861(91)90573-2; Pan J, 2007, NEUROSCI LETT, V428, P82, DOI 10.1016/j.neulet.2007.09.032; Pan J, 2010, LAB INVEST, V90, P156, DOI 10.1038/labinvest.2009.124; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Przedborski S, 2000, RESTOR NEUROL NEUROS, V16, P135; Qi XY, 1996, J BIOL CHEM, V271, P6874, DOI 10.1074/jbc.271.12.6874; Rawal N, 2007, CELL DEATH DIFFER, V14, P381, DOI 10.1038/sj.cdd.4402010; Riedout HJ, 2001, HISTOL HISTOPATHOL, V16, P895, DOI 10.14670/HH-16.895; RORMAN EG, 1989, GENOMICS, V5, P486, DOI 10.1016/0888-7543(89)90014-1; Samii A, 2004, LANCET, V363, P1783, DOI 10.1016/S0140-6736(04)16305-8; SANO A, 1994, BIOCHEM BIOPH RES CO, V204, P994, DOI 10.1006/bbrc.1994.2558; Saporito MS, 2000, J NEUROCHEM, V75, P1200, DOI 10.1046/j.1471-4159.2000.0751200.x; Saporito MS, 1999, J PHARMACOL EXP THER, V288, P421; Sikora J, 2007, ACTA NEUROPATHOL, V113, P163, DOI 10.1007/s00401-006-0148-7; Song B, 2011, NEUROSCI LETT, V505, P76, DOI 10.1016/j.neulet.2011.09.060; Sortwell CE, 2000, J COMP NEUROL, V426, P143; Sun YN, 2005, WORLD J GASTROENTERO, V11, P4827, DOI 10.3748/wjg.v11.i31.4827; TAKAHASHI T, 1994, J NEURAL TRANSM-GEN, V98, P107, DOI 10.1007/BF01277014; Tatton WG, 2003, ANN NEUROL, V53, pS61, DOI 10.1002/ana.10489; Taylor EM, 2000, J PHARMACOL EXP THER, V293, P403; Teismann P, 2003, MOVEMENT DISORD, V18, P121, DOI 10.1002/mds.10332; Teng XC, 2006, J NEUROCHEM, V97, P1126, DOI 10.1111/j.1471-4159.2006.03833.x; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsuboi K, 1998, DEV BRAIN RES, V110, P249, DOI 10.1016/S0165-3806(98)00109-6; UNGERSTEDT U, 1971, ACTA PHYSIOL SCAND, P49; VANELDIK LJ, 1984, P NATL ACAD SCI-BIOL, V81, P6034; Vila M, 2001, CURR OPIN NEUROL, V14, P483, DOI 10.1097/00019052-200108000-00009; Viswanath V, 2001, J NEUROSCI, V21, P9519, DOI 10.1523/JNEUROSCI.21-24-09519.2001; Yamada M, 2010, BIOCHEM BIOPH RES CO, V402, P312, DOI 10.1016/j.bbrc.2010.10.023; Yokoyama H, 2011, NEUROL SCI, V32, P1, DOI 10.1007/s10072-010-0424-0	88	24	24	0	21	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	APR 16	2013	236						373	393		10.1016/j.neuroscience.2013.01.007			21	Neurosciences	Neurosciences & Neurology	115QT	WOS:000316827700032	23321539				2021-06-18	
J	McDonald, S; Togher, L; Tate, R; Randall, R; English, T; Gowland, A				McDonald, S.; Togher, L.; Tate, R.; Randall, R.; English, T.; Gowland, A.			A randomised controlled trial evaluating a brief intervention for deficits in recognising emotional prosody following severe ABI	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Emotion; Brain injury; Remediation	TRAUMATIC BRAIN-INJURY; FACIAL EXPRESSION; RIGHT-HEMISPHERE; RECOGNITION; PEOPLE; REHABILITATION; COMMUNICATION; COMPREHENSION; PERCEPTION; APROSODIA	Many adults with acquired brain injuries, including traumatic brain injuries (TBI) have impaired emotion perception. Impaired perception of emotion in voice can occur independently to facial expression and represents a specific target for remediation. No research to date has addressed this. The current study used a randomised controlled trial to examine the efficacy of a short treatment (three x two-hour sessions) for improving the ability to recognise emotional prosody for people with acquired brain injury, mostly TBI. Ten participants were allocated to treatment and 10 to waitlist. All participants remained involved for the duration of the study in the groups to which they were allocated. There were no significant treatment effects for group, but analyses of individual performances indicated that six of the treated participants made demonstrable improvements on objective measures of prosody recognition. The reasons why some participants showed improvements while others did not, was not obvious. Improvements on objective lab-based measures did not generalise to relative reports of improvements in everyday communicative ability. Nor was there clear evidence of long-term effects. In conclusion, treatment of emotional prosody was effective in the short-term for half of the participants. Further research is required to determine what conditions are required to optimise generalisability and longer-term gains.	[McDonald, S.; Randall, R.; English, T.; Gowland, A.] Univ New S Wales, Sydney, NSW 2052, Australia; [Togher, L.; Tate, R.] Univ Sydney, Sydney, NSW 2006, Australia	McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	s.mcdonald@unsw.edu.au	Togher, Leanne/AAC-7083-2019; McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094; Togher, Leanne/0000-0002-4518-6748; Gowland, Alison/0000-0002-6578-4112	Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia	This study was funded by the Australian National Health and Medical Research Council. The authors wish to express their gratitude to staff at the Royal Rehabilitation Centre, Ryde, the Westmead Brain Injury Unit and the Liverpool Brain Injury Unit for their assistance with recruitment. We are especially grateful to the many people with brain injuries and their families who willingly gave of their time to assist this project.	Adolphs R, 2002, EMOTION, V2, P23, DOI 10.1037/1528-3542.2.1.23; Babbage DR, 2011, NEUROPSYCHOLOGY, V25, P277, DOI 10.1037/a0021908; Baum SR, 1999, APHASIOLOGY, V13, P581, DOI 10.1080/026870399401957; Bornhofen C, 2008, J HEAD TRAUMA REHAB, V23, P103, DOI 10.1097/01.HTR.0000314529.22777.43; Bornhofen C, 2008, NEUROPSYCHOL REHABIL, V18, P22, DOI 10.1080/09602010601061213; BOWERS D, 1987, NEUROPSYCHOLOGIA, V25, P317, DOI 10.1016/0028-3932(87)90021-2; Buchanan TW, 2000, COGNITIVE BRAIN RES, V9, P227, DOI 10.1016/S0926-6410(99)00060-9; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; Dimoska A, 2010, J INT NEUROPSYCH SOC, V16, P369, DOI 10.1017/S1355617709991445; Hargrove P., 2009, INT J SPEECH-LANG PA, V11, P298, DOI [10.1080/17549500902969477, DOI 10.1080/17549500902969477]; HEILMAN KM, 1984, NEUROLOGY, V34, P917, DOI 10.1212/WNL.34.7.917; Hornak J, 2003, BRAIN, V126, P1691, DOI 10.1093/brain/awg168; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Knox L, 2009, BRAIN COGNITION, V69, P442, DOI 10.1016/j.bandc.2008.09.009; Leon SA, 2005, J REHABIL RES DEV, V42, P93, DOI 10.1682/JRRD.2003.12.0182; Ley P., 1972, QUANTITATIVE ASPECTS; Lovibond P, 1995, DEPRESSION ANXIETY S; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2004, NEUROPSYCHOL REHABIL, V14, P285, DOI 10.1080/09602010343000237; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; McDonald S., 2011, AWARENESS SOCIAL INF; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Pell MD, 2009, J PHONETICS, V37, P417, DOI 10.1016/j.wocn.2009.07.005; Pell MD, 1997, BRAIN LANG, V57, P195, DOI 10.1006/brln.1997.1736; Pell MD, 2006, BRAIN LANG, V96, P221, DOI 10.1016/j.bandl.2005.04.007; Radice-Neumann D, 2009, J HEAD TRAUMA REHAB, V24, P313, DOI 10.1097/HTR.0b013e3181b09160; REITAN RM, 1992, TRIAL MAKING TEST; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; Rosenbek JC, 2004, J INT NEUROPSYCH SOC, V10, P786, DOI 10.1017/S135561770410502X; Ross ED, 2008, BRAIN LANG, V104, P51, DOI 10.1016/j.bandl.2007.04.007; Ruff RM, 1996, ARCH CLIN NEUROPSYCH, V11, P329, DOI 10.1016/0887-6177(95)00033-X; Shallice, 1997, HAYLING BRIXTON TEST; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Stringer AY, 1996, BRAIN INJURY, V10, P583, DOI 10.1080/026990596124151; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002; Ylvisaker M, 2003, J HEAD TRAUMA REHAB, V18, P7, DOI 10.1097/00001199-200301000-00005	45	24	25	0	20	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	APR 1	2013	23	2					267	286		10.1080/09602011.2012.751340			20	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	105KU	WOS:000316068800007	23215966				2021-06-18	
J	Shaw, KE; Bondi, CO; Light, SH; Massimino, LA; McAloon, RL; Monaco, CM; Kline, AE				Shaw, Kaitlyn E.; Bondi, Corina O.; Light, Samuel H.; Massimino, Lire A.; McAloon, Rose L.; Monaco, Christina M.; Kline, Anthony E.			Donepezil Is Ineffective in Promoting Motor and Cognitive Benefits after Controlled Cortical Impact Injury in Male Rats	JOURNAL OF NEUROTRAUMA			English	Article						AChE inhibitor; behavior; CCI; functional recovery; learning and memory; Morris water maze; TBI	TRAUMATIC BRAIN-INJURY; RECEPTOR AGONIST 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; VESICULAR ACETYLCHOLINE TRANSPORTER; REDUCED EVOKED RELEASE; ENVIRONMENTAL ENRICHMENT; CHOLINESTERASE INHIBITOR; NEUROBEHAVIORAL BENEFIT; CHOLINERGIC MARKERS; CLINICAL-TRIALS; UNITED-STATES	The acetylcholinesterase (AChE) inhibitor donepezil is used as a therapy for Alzheimer's disease and has been recommended as a treatment for enhancing attention and memory after traumatic brain injury (TBI). Although select clinical case studies support the use of donepezil for enhancing cognition, there is a paucity of experimental TBI studies assessing the potential efficacy of this pharmacotherapy. Hence, the aim of this pre-clinical study was to evaluate several doses of donepezil to determine its effect on functional outcome after TBI. Ninety anesthetized adult male rats received a controlled cortical impact (CCI; 2.8mm cortical depth at 4 m/sec) or sham injury, and then were randomly assigned to six TBI and six sham groups (donepezil 0.25, 0.5, 1.0, 2.0, or 3.0 mg/kg, and saline vehicle 1.0 mL/kg). Treatments began 24 h after surgery and were administered i.p. once daily for 19 days. Function was assessed by motor (beam balance/walk) and cognitive (Morris water maze) tests on days 1-5 and 14-19, respectively. No significant differences were observed among the sham control groups in any evaluation, regardless of dose, and therefore the data were pooled. Furthermore, no significant differences were revealed among the TBI groups in acute neurological assessments (e. g., righting reflex), suggesting that all groups received the same level of injury severity. None of the five doses of donepezil improved motor or cognitive function relative to vehicle-treated controls. Moreover, the two highest doses significantly impaired beam-balance (3.0 mg/kg), beam-walk (2.0 mg/kg and 3.0 mg/kg), and cognitive performance (3.0 mg/kg) versus vehicle. These data indicate that chronic administration of donepezil is not only ineffective in promoting functional improvement after moderate CCI injury, but depending on the dose is actually detrimental to the recovery process. Further work is necessary to determine if other AChE inhibitors exert similar effects after TBI.	[Shaw, Kaitlyn E.; Bondi, Corina O.; Light, Samuel H.; Massimino, Lire A.; McAloon, Rose L.; Monaco, Christina M.; Kline, Anthony E.] Univ Pittsburgh, Pittsburgh, PA 15213 USA; [Shaw, Kaitlyn E.; Bondi, Corina O.; Light, Samuel H.; Massimino, Lire A.; McAloon, Rose L.; Monaco, Christina M.; Kline, Anthony E.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Bondi, Corina O.; Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA	Kline, AE (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu		Light, Sam/0000-0002-8074-1348; Bondi, Corina/0000-0002-5733-4912	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS060005, HD069620]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER	This work was supported, in part, by National Institutes of Health (NIH) grants NS060005 and HD069620 (to Dr. Kline)	ALBIN RL, 1988, NEUROSCI LETT, V88, P303, DOI 10.1016/0304-3940(88)90228-5; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Bentham P, 2004, LANCET, V363, P2105; Besheer J, 2004, NEUROSCI INTELL UNIT, P113; Bontempi B, 2003, NEUROPSYCHOPHARMACOL, V28, P1235, DOI 10.1038/sj.npp.1300150; BORNSTEIN MB, 1946, J NEUROPHYSIOL, V9, P349; CARDENAS DD, 1994, BRAIN INJURY, V8, P579, DOI 10.3109/02699059409151010; CDC, 2003, REP C MILD TRAUM BRA; CDC, 1999, TRAUM BRAIN INJ US R; Chen Z, 2002, ACTA PHARMACOL SIN, V23, P355; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Cheng JP, 2007, NEUROSCI LETT, V416, P165, DOI 10.1016/j.neulet.2007.02.006; Cheng JP, 2012, J NEUROTRAUM, V29, P2684, DOI 10.1089/neu.2012.2560; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Creeley CE, 2008, NEUROBIOL AGING, V29, P153, DOI 10.1016/j.neurobiolaging.2006.10.020; DEANGELIS MM, 1994, BRAIN RES, V653, P39, DOI 10.1016/0006-8993(94)90369-7; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; Dixon CE, 1997, BRAIN RES, V749, P127, DOI 10.1016/S0006-8993(96)01310-8; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Flanagan Steven R, 2008, Neuropsychiatr Dis Treat, V4, P877; Garcia AN, 2011, PM&R, V3, pS18, DOI 10.1016/j.pmrj.2011.03.017; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; Griffin SL, 2003, J NEUROPSYCH CLIN N, V15, P17, DOI 10.1176/appi.neuropsych.15.1.17; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1994, J NEUROSURG, V81, P267, DOI 10.3171/jns.1994.81.2.0267; Haug KH, 2005, NEUROCHEM RES, V30, P1511, DOI 10.1007/s11064-005-8828-6; Hernandez CM, 2006, J PHARMACOL EXP THER, V316, P679, DOI 10.1124/jpet.105.093047; Holschneider DP, 2011, J NEUROTRAUM, V28, P1909, DOI 10.1089/neu.2011.1978; Horneman G, 2009, BRAIN INJURY, V23, P907, DOI 10.1080/02699050903283239; Khateb A, 2005, EUR NEUROL, V54, P39, DOI 10.1159/000087718; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2012, J NEUROTRAUM, V29, P1960, DOI 10.1089/neu.2012.2385; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; Li DQ, 2012, INT J MED SCI, V9, P248, DOI 10.7150/ijms.4363; Liang YQ, 2004, NEUROSCI LETT, V361, P56, DOI 10.1016/j.neulet.2003.12.071; Lindner MD, 2006, PSYCHOPHARMACOLOGY, V188, P629, DOI 10.1007/s00213-006-0556-3; Maurice T, 2006, J PHARMACOL EXP THER, V317, P606, DOI 10.1124/jpet.105.097394; McCarthy AD, 2011, PHARMACOL BIOCHEM BE, V98, P76, DOI 10.1016/j.pbb.2010.11.019; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Morey CE, 2003, BRAIN INJURY, V17, P809, DOI 10.1080/0269905031000088586; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Murdoch I, 2002, J NEUROTRAUM, V19, P279, DOI 10.1089/08977150252807018; Olsen AS, 2012, J NEUROTRAUM, V29, P1898, DOI 10.1089/neu.2012.2358; Pike BR, 1997, J NEUROTRAUM, V14, P897, DOI 10.1089/neu.1997.14.897; Pike BR, 1997, EXP NEUROL, V147, P55, DOI 10.1006/exnr.1997.6582; PIKE BR, 1995, BRAIN RES, V686, P37, DOI 10.1016/0006-8993(95)00448-Y; Rezvani AH, 2012, PSYCHOPHARMACOLOGY, V223, P251, DOI 10.1007/s00213-012-2712-2; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Sarter M, 2005, BRAIN RES REV, V48, P98, DOI 10.1016/j.brainresrev.2004.08.006; Scremin OU, 2012, J NEUROTRAUM, V29, P2457, DOI 10.1089/neu.2012.2465; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Seltzer Ben, 2005, Expert Opin Drug Metab Toxicol, V1, P527, DOI 10.1517/17425255.1.3.527; Shao LF, 1999, J NEUROTRAUM, V16, P555, DOI 10.1089/neu.1999.16.555; SHAW KP, 1985, MOL PHARMACOL, V28, P527; Su DS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027632; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Taverni JP, 1998, BRAIN INJURY, V12, P77; Tenovuo O, 2005, PROG NEURO-PSYCHOPH, V29, P61, DOI 10.1016/j.pnpbp.2004.10.006; Tenovuo OS, 2006, CURR DRUG THER, V1, P187, DOI 10.2174/157488506776930932; Walker W, 2004, BRAIN INJURY, V18, P739, DOI 10.1080/02699050310001646224; Wise LE, 2007, NEUROPSYCHOPHARMACOL, V32, P1805, DOI 10.1038/sj.npp.1301297; Yelleswarapu NK, 2012, NEUROSCI LETT, V515, P153, DOI 10.1016/j.neulet.2012.03.033; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014	73	24	24	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2013	30	7					557	564		10.1089/neu.2012.2782			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	133PD	WOS:000318150300007	23227953	Green Published			2021-06-18	
J	Wong, GKC; Ngai, K; Lam, SW; Wong, A; Mok, V; Poon, WS				Wong, George Kwok Chu; Ngai, Karine; Lam, Sandy Wai; Wong, Adrian; Mok, Vincent; Poon, Wai Sang			Validity of the Montreal Cognitive Assessment for traumatic brain injury patients with intracranial haemorrhage	BRAIN INJURY			English	Article						Cognitive assessment; mini-mental state examination; Montreal cognitive assessment; traumatic brain injury; intracranial haemorrhage	SCALE; IMPAIRMENT; PREVALENCE; VALIDATION; DEFICITS; DISEASE; UTILITY; MOCA	Background and primary objective: In recent years, the Montreal Cognitive Assessment (MoCA) has been developed to assess patients with ischemic stroke. However, it has not been validated for use on traumatic brain injury patients with intracranial haemorrhage (tICH). The aim was to evaluate the psychometric properties of the MoCA (MoCA) in such patients. Research design and method: A cross-sectional observational study was carried out on 40 controls and 48 tICH patients recruited in Hong Kong. Concurrent validity was assessed by a comprehensive battery of neuropsychological tests and the Mini-Mental State Examination (MMSE). Criterion validity was assessed by the differentiation of tICH patients from controls. Main outcome and results: In tICH patients, cognitive z-scores (beta = 0.579; p < 0.001) and MMSE (beta = 0.366, p = 0.012) significantly correlated with performance in the MoCA after adjustment for age, gender and total score for the Geriatric Depressive Scale. For the differentiation of tICH patients from controls, analysis of receiver operating characteristics curves in the MoCA revealed an optimal balance of sensitivity and specificity at 25/26 with an area under the curve of 0.704 (p = 0.001). MoCA is applicable to and significantly correlated with excellent neurological outcomes in tICH patients. Conclusions: MoCA is a useful and psychometrically valid tool for the assessment of gross cognitive function in tICH patients.	[Wong, George Kwok Chu; Ngai, Karine; Lam, Sandy Wai; Poon, Wai Sang] Chinese Univ Hong Kong, Prince Wales Hosp, Div Neurosurg, Hong Kong, Hong Kong, Peoples R China; [Wong, Adrian; Mok, Vincent] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China	Wong, GKC (corresponding author), Prince Wales Hosp, Dept Surg, 4-F Clin Sci Bldg,1 Ngan Shing St, Shatin, Hong Kong, Peoples R China.	georgewong@surgery.cuhk.edu.hk	Mok, Vincent/N-6421-2015; Wong, Adrian/K-4859-2014; Poon, Wai Sang/F-1558-2011; Wong, George KC/A-6378-2011; Wong, George Kwok Chu/L-4344-2016	Mok, Vincent/0000-0002-8102-8835; Wong, Adrian/0000-0002-7859-3956; Wong, George KC/0000-0002-6078-2548; 	Chinese University of Hong KongChinese University of Hong Kong	This study was supported by the Neurosurgery Research and Training Fund of the Chinese University of Hong Kong. The funding source had no role in the study design, collection, analysis or interpretation of data, manuscript preparation or decision for submission. The authors report no conflicts of interest.	Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; Bagiella E, 2010, J HEAD TRAUMA REHAB, V25, P375, DOI 10.1097/HTR.0b013e3181d27fe3; Brink TL., 1982, CLIN GERONTOLOGIST, V1, P37, DOI [10.1300/J018v01n01_06, DOI 10.1300/J018V01N01_06]; Chiu H.F., 1994, HONG KONG J PSYCHIAT, V4, P25; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Lee JY, 2008, J GERIATR PSYCH NEUR, V21, P104, DOI 10.1177/0891988708316855; Lim PPJ, 2000, INT J GERIATR PSYCH, V15, P824, DOI 10.1002/1099-1166(200009)15:9<824::AID-GPS207>3.0.CO;2-C; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Pallant J., 2013, SPSS SURVIVAL MANUAL; Pendlebury ST, 2010, STROKE, V41, P1290, DOI 10.1161/STROKEAHA.110.579888; Smith T, 2007, CAN J PSYCHIAT, V52, P329, DOI 10.1177/070674370705200508; Tang WK, 2005, J GERIATR PSYCH NEUR, V18, P3, DOI 10.1177/0891988704269814; Wen Hong-Bo, 2008, Zhonghua Nei Ke Za Zhi, V47, P36; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wong A, 2009, DEMENT GERIATR COGN, V28, P81, DOI 10.1159/000232589; Wong GKC, 2012, ACTA NEUROCHIR, V154, P105, DOI 10.1007/s00701-011-1198-8; Wong GKC, 2011, HONG KONG J OCCUP TH, V21, P27, DOI 10.1016/j.hkjot.2011.05.004; Zadikoff C, 2008, MOVEMENT DISORD, V23, P297, DOI 10.1002/mds.21837; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	20	24	28	0	12	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2013	27	4					394	398		10.3109/02699052.2012.750746			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	117LG	WOS:000316954300003	23473067				2021-06-18	
J	Li, J; Zhao, L; He, X; Zeng, YJ; Dai, SS				Li, Jun; Zhao, Li; He, Xie; Zeng, Yi-Jun; Dai, Shuang-Shuang			Sinomenine Protects against Lipopolysaccharide-Induced Acute Lung Injury in Mice via Adenosine A(2A) Receptor Signaling	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; ISCHEMIA-REPERFUSION INJURY; NF-KAPPA-B; ALKALOID SINOMENINE; CYTOKINE EXPRESSION; MAST-CELLS; IN-VIVO; ACTIVATION; INFLAMMATION; NEUTROPHILS	Sinomenine (SIN) is a bioactive alkaloid extracted from the Chinese medicinal plant Sinomenium acutum, which is widely used in the clinical treatment of rheumatoid arthritis (RA). However, its role in acute lung injury (ALI) is unclear. In this study, we investigate the role of SIN in lipopolysaccharide (LPS)-induced ALI in mice. After ALI, lung water content and histological signs of pulmonary injury were attenuated, whereas the PaO2/FIO2 (P/F) ratios were elevated significantly in the mice pretreated with SIN. Additionally, SIN markedly inhibited inflammatory cytokine TNF-alpha and IL-1 beta expression levels as well as neutrophil infiltration in the lung tissues of the mice. Microarray analysis and real-time PCR showed that SIN treatment upregulated adenosine A(2A) receptor (A(2A)R) expression, and the protective effect of SIN was abolished in A(2A)R knockout mice. Further investigation in isolated mouse neutrophils confirmed the upregulation of A(2A)R by SIN and showed that A(2A)R-cAMP-PKA signaling was involved in the anti-inflammatory effect of SIN. Taken together, these findings demonstrate an A(2A)R-associated anti-inflammatory effect and the protective role of SIN in ALI, which suggests a potential novel approach to treat ALI.	[Li, Jun] Third Mil Med Univ, Southwest Hosp, Dept Cardiothorac Surg, Chongqing, Peoples R China; [Zhao, Li; He, Xie; Zeng, Yi-Jun; Dai, Shuang-Shuang] Third Mil Med Univ, Dept Biochem & Mol Biol, Chongqing, Peoples R China	Dai, SS (corresponding author), Third Mil Med Univ, Dept Biochem & Mol Biol, Chongqing, Peoples R China.	tmmubiodss@yahoo.com.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81172817]; Natural Science Foundation of Chongqing, ChinaNatural Science Foundation of Chongqing [CSTC2009BB5317]	This work is supported by National Natural Science Foundation of China (81172817), Natural Science Foundation of Chongqing, China (CSTC2009BB5317). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham E, 2000, AM J PHYSIOL-LUNG C, V279, pL1137; Allen-Gipson DS, 2006, AM J PHYSIOL-LUNG C, V290, pL849, DOI 10.1152/ajplung.00373.2005; Belperio JA, 2002, J CLIN INVEST, V110, P1703, DOI 10.1172/JCI200215849; Bonneau O, 2006, AM J PHYSIOL-LUNG C, V290, pL1036, DOI 10.1152/ajplung.00422.2005; Bshesh K, 2002, J LEUKOCYTE BIOL, V72, P1027; Candinas D, 1996, TRANSPLANTATION, V62, P1855, DOI 10.1097/00007890-199612270-00030; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Cheng Y, 2009, INT IMMUNOPHARMACOL, V9, P894, DOI 10.1016/j.intimp.2009.03.014; Dai SS, 2010, J NEUROCHEM, V113, P1536, DOI 10.1111/j.1471-4159.2010.06716.x; Dai SS, 2010, J NEUROSCI, V30, P5802, DOI 10.1523/JNEUROSCI.0268-10.2010; Eckle T, 2008, J CLIN INVEST, V118, P3301, DOI 10.1172/JCI34203; Eckle T, 2009, PHYSIOLOGY, V24, P298, DOI 10.1152/physiol.00022.2009; Ellman PI, 2008, J SURG RES, V149, P3, DOI 10.1016/j.jss.2007.08.008; Ernens I, 2006, CIRC RES, V99, P590, DOI 10.1161/01.RES.0000241428.82502.d4; Folkesson HG, 2012, AM J PHYSIOL-LUNG C, V303, pL259, DOI 10.1152/ajplung.00395.2011; Gazoni LM, 2008, J THORAC CARDIOV SUR, V135, P156, DOI 10.1016/j.jtcvs.2007.08.041; Graham DB, 2007, J CLIN INVEST, V117, P3445, DOI 10.1172/JCI32729; Hasko G, 2008, J LEUKOCYTE BIOL, V83, P447, DOI 10.1189/jlb.0607359; Heyn J, 2012, SHOCK, V37, P156, DOI 10.1097/SHK.0b013e31823f16bc; HOJO H, 1985, J IMMUNOPHARMACOL, V7, P33, DOI 10.3109/08923978509026467; Huang J, 2007, J ETHNOPHARMACOL, V114, P180, DOI 10.1016/j.jep.2007.07.036; Kim HM, 2000, J ETHNOPHARMACOL, V70, P135, DOI 10.1016/S0378-8741(99)00160-9; Kok T. W., 2005, Angiogenesis, V8, P3, DOI 10.1007/s10456-005-2892-z; KONDO Y, 1994, BIOCHEM PHARMACOL, V48, P1050, DOI 10.1016/0006-2952(94)90378-6; Li W, 2008, NEUROSCIENCE, V151, P1198, DOI 10.1016/j.neuroscience.2007.11.020; Lin MC, 1997, J CLIN INVEST, V99, P737, DOI 10.1172/JCI119219; LIU L, 1994, ARZNEIMITTEL-FORSCH, V44-2, P1223; LIU L, 1994, INT J IMMUNOPHARMACO, V16, P685, DOI 10.1016/0192-0561(94)90142-2; Liu LA, 1996, INT J IMMUNOPHARMACO, V18, P529, DOI 10.1016/S0192-0561(96)00025-2; Lukashev D, 2004, J IMMUNOL, V173, P21, DOI 10.4049/jimmunol.173.1.21; Malcolm KC, 2003, AM J PHYSIOL-LUNG C, V284, pL663, DOI 10.1152/ajplung.00094.2002; Mark W, 2003, TRANSPLANTATION, V75, P940, DOI 10.1097/01.TP.0000056610.22062.03; Martin TR, 2002, J CLIN INVEST, V110, P1603, DOI 10.1172/JCI200217302; Murphree LJ, 2005, BIOCHEM J, V391, P575, DOI 10.1042/BJ20050888; Nadeem A, 2007, AM J PHYSIOL-LUNG C, V292, pL1335, DOI 10.1152/ajplung.00416.2006; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Reece TB, 2005, J THORAC CARDIOV SUR, V129, P1137, DOI 10.1016/j.jtcvs.2004.11.042; Reutershan J, 2007, J IMMUNOL, V179, P1254, DOI 10.4049/jimmunol.179.2.1254; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Sharma AK, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-58; Spicuzza L, 2006, EUR J PHARMACOL, V533, P77, DOI 10.1016/j.ejphar.2005.12.056; Thiel M, 2005, PLOS BIOL, V3, P1088, DOI 10.1371/journal.pbio.0030174; Vieregge B, 1999, PLANTA MED, V65, P80, DOI 10.1055/s-2006-960446; Wang QX, 2011, INT IMMUNOPHARMACOL, V11, P373, DOI 10.1016/j.intimp.2010.11.018; Wang Y, 2005, J ETHNOPHARMACOL, V98, P37, DOI 10.1016/j.jep.2004.12.022; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Wu RQ, 2006, CRIT CARE MED, V34, P1273, DOI 10.1097/01.CCM.0000208437.93725.18; YAMASAKI H, 1976, ACTA MED OKAYAMA, V30, P1; Zhao Y, 2007, INT IMMUNOPHARMACOL, V7, P637, DOI 10.1016/j.intimp.2007.01.007; Zhong H, 2003, J IMMUNOL, V171, P338, DOI 10.4049/jimmunol.171.1.338	50	24	32	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 15	2013	8	3							e59257	10.1371/journal.pone.0059257			11	Multidisciplinary Sciences	Science & Technology - Other Topics	109ZC	WOS:000316409800076	23555007	DOAJ Gold, Green Published			2021-06-18	
J	Figley, SA; Chen, YH; Maeda, A; Conroy, L; McMullen, JD; Silver, JI; Stapleton, S; Vitkin, A; Lindsay, P; Burrell, K; Zadeh, G; Fehlings, MG; DaCosta, RS				Figley, Sarah A.; Chen, Yonghong; Maeda, Azusa; Conroy, Leigh; McMullen, Jesse D.; Silver, Jason I.; Stapleton, Shawn; Vitkin, Alex; Lindsay, Patricia; Burrell, Kelly; Zadeh, Gelareh; Fehlings, Michael G.; DaCosta, Ralph S.			A Spinal Cord Window Chamber Model for In Vivo Longitudinal Multimodal Optical and Acoustic Imaging in a Murine Model	PLOS ONE			English	Article							MULTIPLE-SCLEROSIS; NERVOUS-SYSTEM; INJURY; TOMOGRAPHY; MICROSCOPY; REGENERATION; INFLAMMATION; PATHOLOGY; PROTEIN; BRAIN	In vivo and direct imaging of the murine spinal cord and its vasculature using multimodal (optical and acoustic) imaging techniques could significantly advance preclinical studies of the spinal cord. Such intrinsically high resolution and complementary imaging technologies could provide a powerful means of quantitatively monitoring changes in anatomy, structure, physiology and function of the living cord over time after traumatic injury, onset of disease, or therapeutic intervention. However, longitudinal in vivo imaging of the intact spinal cord in rodent models has been challenging, requiring repeated surgeries to expose the cord for imaging or sacrifice of animals at various time points for ex vivo tissue analysis. To address these limitations, we have developed an implantable spinal cord window chamber (SCWC) device and procedures in mice for repeated multimodal intravital microscopic imaging of the cord and its vasculature in situ. We present methodology for using our SCWC to achieve spatially co-registered optical-acoustic imaging performed serially for up to four weeks, without damaging the cord or induction of locomotor deficits in implanted animals. To demonstrate the feasibility, we used the SCWC model to study the response of the normal spinal cord vasculature to ionizing radiation over time using white light and fluorescence microscopy combined with optical coherence tomography (OCT) in vivo. In vivo power Doppler ultrasound and photoacoustics were used to directly visualize the cord and vascular structures and to measure hemoglobin oxygen saturation through the complete spinal cord, respectively. The model was also used for intravital imaging of spinal micrometastases resulting from primary brain tumor using fluorescence and bioluminescence imaging. Our SCWC model overcomes previous in vivo imaging challenges, and our data provide evidence of the broader utility of hybridized optical-acoustic imaging methods for obtaining multiparametric and rich imaging data sets, including over extended periods, for preclinical in vivo spinal cord research.	[Figley, Sarah A.; Fehlings, Michael G.] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada; [Figley, Sarah A.; Burrell, Kelly; Zadeh, Gelareh; Fehlings, Michael G.] Univ Hlth Network, Toronto Western Res Inst, Krembil Neurosci Program, Toronto, ON, Canada; [Chen, Yonghong; McMullen, Jesse D.; Silver, Jason I.; Vitkin, Alex; DaCosta, Ralph S.] Princess Margaret Hosp, Ontario Canc Inst, Univ Hlth Network, Toronto, ON M4X 1K9, Canada; [Maeda, Azusa; Conroy, Leigh; Stapleton, Shawn; Vitkin, Alex; DaCosta, Ralph S.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Vitkin, Alex; Lindsay, Patricia; DaCosta, Ralph S.] Princess Margaret Hosp, Dept Radiat Oncol, Univ Hlth Network, Toronto, ON M4X 1K9, Canada	DaCosta, RS (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, Univ Hlth Network, Toronto, ON M4X 1K9, Canada.	rdacosta@uhnres.utoronto.ca	Vitkin, Alex/C-8123-2016; Vitkin, Alex/I-8166-2012	Vitkin, Alex/0000-0001-5495-8888; Conroy, Leigh/0000-0003-0055-3660; Fehlings, Michael/0000-0002-5722-6364	Cancer Care Ontario; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [93578]; Ontario Ministry of Health and Long Term careMinistry of Health and Long-Term Care, Ontario	This research was funded in part by Cancer Care Ontario (DaCosta holds a CCO Research Chair in Cancer Imaging; https://www.cancercare.on.ca/), the Canadian Institutes of Health Research (awarded to Dr. DaCosta, reference number 93578; http://www.cihr-irsc.gc.ca/e/193.html) and the Ontario Ministry of Health and Long Term Care (http://www.health.gov.on.ca/en/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson CR, 2009, SPINAL CORD: A CHRISTOPHER AND DANA REEVE FOUNDATION TEXT AND ATLAS, P115; Bhavna Y, 2009, CURR BIOL, V19, P930; Bilgen M., 2006, NEUROANATOMY, V5, P12; BRAUN IF, 1983, RADIOLOGY, V147, P459, DOI 10.1148/radiology.147.2.6340159; Byrnes KR, 2010, J MAGN RESON IMAGING, V32, P836, DOI 10.1002/jmri.22323; Cadotte DW, 2012, BIOMED OPT EXPRESS, V3, P911, DOI 10.1364/BOE.3.000911; Clarkson R, 2011, MED PHYS, V38, P845, DOI 10.1118/1.3533947; Davalos D, 2008, J NEUROSCI METH, V169, P1, DOI 10.1016/j.jneumeth.2007.11.011; Dibaj P, 2010, GLIA, V58, P1133, DOI 10.1002/glia.20993; DOMMISSE GF, 1974, J BONE JOINT SURG BR, VB 56, P225; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Dray C, 2009, P NATL ACAD SCI USA, V106, P9459, DOI 10.1073/pnas.0900222106; Farrar MJ, 2012, NATURE METHODS ADV; Fehlings MG, 2011, NEUROTHERAPEUTICS, V8, P704, DOI 10.1007/s13311-011-0076-7; Fenrich KK, 2012, J PHYSIOL-LONDON, V590, P3665, DOI 10.1113/jphysiol.2012.230532; HORNSEY S, 1990, INT J RADIAT ONCOL, V18, P1437, DOI 10.1016/0360-3016(90)90319-F; Hsu W, 2012, NEUROSURGERY, DOI [10.1227/NEU.1220-b1013e3182532e3182571, DOI 10.1227/NEU.1220-B1013E3182532E3182571]; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; Johannssen HC, 2010, J PHYSIOL-LONDON, V588, P3397, DOI 10.1113/jphysiol.2010.191833; Kerschensteiner M, 2005, NAT MED, V11, P572, DOI 10.1038/nm1229; Kim JV, 2010, J IMMUNOL METHODS, V352, P89, DOI 10.1016/j.jim.2009.09.007; Kirkpatrick JP, 2010, INT J RADIAT ONCOL, V76, pS42, DOI 10.1016/j.ijrobp.2009.04.095; Lassmann H, 2005, BRAIN PATHOL, V15, P217; Liu TW, 2011, BIOCONJUGATE CHEM, V22, P1021, DOI 10.1021/bc200169x; Madi S, 2001, AM J NEURORADIOL, V22, P1768; MARCUS ML, 1977, CIRC RES, V41, P128, DOI 10.1161/01.RES.41.1.128; MCAFEE PC, 1986, SPINE, V11, P295, DOI 10.1097/00007632-198605000-00001; Misgeld T, 2006, NAT REV NEUROSCI, V7, P449, DOI 10.1038/nrn1905; MOSELEY ME, 1990, RADIOLOGY, V176, P439, DOI 10.1148/radiology.176.2.2367658; NIX W, 1976, STROKE, V7, P560, DOI 10.1161/01.STR.7.6.560; Ntziachristos V, 2010, NAT METHODS, V7, P603, DOI [10.1038/NMETH.1483, 10.1038/nmeth.1483]; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; POWERS BE, 1992, INT J RADIAT ONCOL, V23, P539, DOI 10.1016/0360-3016(92)90009-7; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; Sahgal A, 2011, J NEUROSURG-SPINE, V14, P151, DOI 10.3171/2010.9.SPINE091005; Sasaki Y, 2001, BIOCHEM BIOPH RES CO, V286, P292, DOI 10.1006/bbrc.2001.5388; Shtoyerman E, 2000, J NEUROSCI, V20, P8111; SIEGAL T, 1995, INT J RADIAT ONCOL, V31, P57, DOI 10.1016/0360-3016(94)E0305-4; Sinescu Crina, 2010, J Med Life, V3, P254; Stroman PW, 2005, CLIN MED RES, V3, P146, DOI 10.3121/cmr.3.3.146; Tench CR, 2005, J NEUROIMAGING, V15, p94S, DOI 10.1177/1051228405283292; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; VANDERKOGEL AJ, 1993, RADIOTHER ONCOL, V29, P105, DOI 10.1016/0167-8140(93)90234-Y; Wang XD, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2192804; Xu MH, 2006, REV SCI INSTRUM, V77, DOI 10.1063/1.2195024; Yu WR, 2011, ACTA NEUROPATHOL, V122, P747, DOI 10.1007/s00401-011-0882-3	46	24	25	1	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2013	8	3							e58081	10.1371/journal.pone.0058081			14	Multidisciplinary Sciences	Science & Technology - Other Topics	109YM	WOS:000316407400015	23516432	DOAJ Gold, Green Published			2021-06-18	
J	Lamy, M; Baumgartner, D; Yoganandan, N; Stemper, BD; Willinger, R				Lamy, Michael; Baumgartner, Daniel; Yoganandan, Narayan; Stemper, Brian D.; Willinger, Remy			Experimentally validated three-dimensional finite element model of the rat for mild traumatic brain injury	MEDICAL & BIOLOGICAL ENGINEERING & COMPUTING			English	Article						Biomechanics; Finite element model; Stress-strain analysis; Traumatic brain injuries	CONTROLLED CORTICAL IMPACT; PRESSURE CHANGES; AXONAL INJURY; HEAD; TISSUE; ACCELERATION; CONTUSION	The aim of our work was to expand on the knowledge concerning mild Traumatic Brain Injuries (TBI), by combining numerical modeling and animal experiments within a joint approach. A three-dimensional finite element model of the rat brain and braincase was developed, and experimental acceleration pulses were applied. Pulse data were obtained from tests conducted using anesthetized rats, subjected to coronal plane rotational acceleration loadings of varying amplitudes and durations, aimed to generate mild TBI. Times of loss of consciousness were obtained. Biomechanical response parameters generally associated with TBI (stresses and strains) in the three anatomical regions, i.e., hypothalamus, thalamus and parietal cortex were analyzed. While the parameters correlated well with changes in injury severity linked to peak rotational acceleration, they were relatively insensitive to the pulse duration or times of loss of consciousness. As a consequence, new stress-time and strain-time metrics were computed, and these metrics were more efficient in predicting changes in injury severity associated both with acceleration characteristics and loss of consciousness outcomes in all three anatomical regions controlling the aforementioned behavior. Results of our analysis tend to show that time-related metrics may be more suited for the explanation of mild TBI than commonly used peak metrics in the three anatomical regions of the brain.	[Lamy, Michael; Baumgartner, Daniel; Willinger, Remy] Univ Strasbourg, Dept Fluid & Solid Mech, IMFS, F-67000 Strasbourg, France; [Yoganandan, Narayan; Stemper, Brian D.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA	Baumgartner, D (corresponding author), Univ Strasbourg, Dept Fluid & Solid Mech, IMFS, 2 Rue Boussingault, F-67000 Strasbourg, France.	daniel.baumgartner@unistra.fr	Stemper, Brian/AAX-7611-2020				AIS, 1990, ABBR INJ SCAL, P74; Anderson RWG, 2003, J NEUROTRAUM, V20, P961, DOI 10.1089/089771503770195812; Anderson RWG, 1999, P INT IRCOBI C BIOM, P107; Baumgartner D, 2004, REV EUROPEENNE ELEME, V14, P421; Davidsson J, 2009, NEW MODEL INJURY THR, P73; Deck C, 2008, INT J CRASHWORTHINES, V13, P667, DOI 10.1080/13588260802411523; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; Fijalkowski RJ, 2009, STAPP CAR CRASH JO, V53, P193; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1996, MECH PRIMARY HEAD IN, P2611; Greenberg MS., 2010, HDB NEUROSURGERY, V7th; Guan FJ, 2011, ANN BIOMED ENG, V39, P85, DOI 10.1007/s10439-010-0125-0; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Kandel E.R., 2000, PRINCIPLES NEURAL SC; King A.I., 2003, IRCOBI C LISB PORT, P1; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Levchakov A, 2006, J NEUROTRAUM, V23, P1570, DOI 10.1089/neu.2006.23.1570; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LINDGREN S, 1969, ACTA PHYSIOL SCAND, V76, P340, DOI 10.1111/j.1748-1716.1969.tb04477.x; LISSNER HR, 1960, SURG GYNECOL OBSTET, V111, P329; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; MacGregor AJ, 2011, J HEAD TRAUMA REHAB, V26, P312, DOI 10.1097/HTR.0b013e3181e94404; Mao HJ, 2013, COMPUT METHOD BIOMEC, V16, P271, DOI 10.1080/10255842.2011.617005; Mao HJ, 2011, J MECH MED BIOL, V11, P1199, DOI 10.1142/S021951941100423X; Mao Haojie, 2006, Stapp Car Crash J, V50, P583; MARGULIES SS, 1985, STUDY SCALING HEAD I; Marion DW, 2011, J NEUROTRAUM, V28, P517, DOI 10.1089/neu.2010.1638; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Ommaya AK, 1967, 11 STAPP CAR CRASH C, P73; Pena A, 2005, ACT NEUR S, V95, P333; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Shreiber D.I., 1997, STAPP CAR CRASH J, V41, P277; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Vappou J, 2008, J BIOMECH, V41, P2954, DOI 10.1016/j.jbiomech.2008.07.034; Winn R, 2004, NEUROLOGICAL SURG; YOGANANDAN N, 1998, FRONTIERS HEAD NECK; Yoganandan N, 2008, J BIOMECH, V41, P2253, DOI 10.1016/j.jbiomech.2008.04.019; Zhang Jiangyue, 2006, Annu Proc Assoc Adv Automot Med, V50, P1; Zhu Feng, 2010, Stapp Car Crash J, V54, P211	47	24	24	0	11	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0140-0118	1741-0444		MED BIOL ENG COMPUT	Med. Biol. Eng. Comput.	MAR	2013	51	3					353	365		10.1007/s11517-012-1004-7			13	Computer Science, Interdisciplinary Applications; Engineering, Biomedical; Mathematical & Computational Biology; Medical Informatics	Computer Science; Engineering; Mathematical & Computational Biology; Medical Informatics	098WN	WOS:000315579900011	23192366				2021-06-18	
J	Maruta, J; Heaton, KJ; Kryskow, EM; Maule, AL; Ghajar, J				Maruta, Jun; Heaton, Kristin J.; Kryskow, Elisabeth M.; Maule, Alexis L.; Ghajar, Jamshid			Dynamic visuomotor synchronization: Quantification of predictive timing	BEHAVIOR RESEARCH METHODS			English	Article						Attention; Smooth pursuit; Test-retest reliability; Concussion; Traumatic brain injury	PURSUIT EYE-MOVEMENTS; TRAUMATIC BRAIN-INJURY; SMOOTH-PURSUIT; PARKINSONS-DISEASE; COGNITIVE CONTROL; CEREBRAL CONTROL; TARGET MOTIONS; ATTENTION; TRACKING; DEFICITS	When a moving target is tracked visually, spatial and temporal predictions are used to circumvent the neural delay required for the visuomotor processing. In particular, the internally generated predictions must be synchronized with the external stimulus during continuous tracking. We examined the utility of a circular visual-tracking paradigm for assessment of predictive timing, using normal human subjects. Disruptions of gaze-target synchronization were associated with anticipatory saccades that caused the gaze to be temporarily ahead of the target along the circular trajectory. These anticipatory saccades indicated preserved spatial prediction but suggested impaired predictive timing. We quantified gaze-target synchronization with several indices, whose distributions across subjects were such that instances of extremely poor performance were identifiable outside the margin of error determined by test-retest measures. Because predictive timing is an important element of attention functioning, the visual-tracking paradigm and dynamic synchronization indices described here may be useful for attention assessment.	[Maruta, Jun; Ghajar, Jamshid] Brain Trauma Fdn, New York, NY 10007 USA; [Heaton, Kristin J.; Kryskow, Elisabeth M.; Maule, Alexis L.] USA, Environm Med Res Inst, Natick, MA 01760 USA; [Heaton, Kristin J.; Maule, Alexis L.] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Ghajar, Jamshid] Weill Cornell Med Coll, Dept Neurol Surg, New York, NY USA	Maruta, J (corresponding author), Brain Trauma Fdn, 7 World Trade Ctr,34th Floor,250 Greenwich St, New York, NY 10007 USA.	jmaruta@braintrauma.org	Heaton, Kristin J/E-3660-2013; Maruta, Jun/I-3790-2019	Maruta, Jun/0000-0002-5054-6605			Angelaki DE, 2003, J NEUROSCI, V23, P2971; BAHILL AT, 1983, VISION RES, V23, P1573; Barnes GR, 2008, BRAIN COGNITION, V68, P309, DOI 10.1016/j.bandc.2008.08.020; BARTKO JJ, 1966, PSYCHOL REP, V19, P3, DOI 10.2466/pr0.1966.19.1.3; BARTKO JJ, 1991, SCHIZOPHRENIA BULL, V17, P483, DOI 10.1093/schbul/17.3.483; Baumann O, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007110; Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1191/096228099673819272; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Blekher T, 1997, INVEST OPHTH VIS SCI, V38, P1768; Boeder P, 1962, Br J Ophthalmol, V46, P397, DOI 10.1136/bjo.46.7.397; BRONSTEIN AM, 1985, BRAIN, V108, P925, DOI 10.1093/brain/108.4.925; Chen Y, 2002, PROG BRAIN RES, V140, P255; COLLEWIJN H, 1984, J PHYSIOL-LONDON, V351, P217, DOI 10.1113/jphysiol.1984.sp015242; Corbetta M, 1998, NEURON, V21, P761, DOI 10.1016/S0896-6273(00)80593-0; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Diefendorf AR, 1908, BRAIN, V31, P451, DOI 10.1093/brain/31.3.451; Ettinger U, 2008, CEREB CORTEX, V18, P1148, DOI 10.1093/cercor/bhm147; Ghajar J, 2008, NEUROREHAB NEURAL RE, V22, P217, DOI 10.1177/1545968308315600; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Gronqvist H, 2006, VISION RES, V46, P1754, DOI 10.1016/j.visres.2005.11.007; Heide W, 1996, BRAIN, V119, P1951, DOI 10.1093/brain/119.6.1951; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; HOLZMAN PS, 1976, ARCH GEN PSYCHIAT, V33, P1415; Hwang K, 2010, J NEUROSCI, V30, P15535, DOI 10.1523/JNEUROSCI.2825-10.2010; IACONO WG, 1979, ARCH GEN PSYCHIAT, V36, P1361; KEATING EG, 1991, EXP BRAIN RES, V86, P311; Khan AZ, 2010, J VISION, V10, DOI 10.1167/10.13.7; Kowler E, 2011, VISION RES, V51, P1457, DOI 10.1016/j.visres.2010.12.014; Krauzlis RJ, 2005, NEUROSCIENTIST, V11, P124, DOI 10.1177/1073858404271196; Lekwuwa GU, 1996, BRAIN, V119, P473, DOI 10.1093/brain/119.2.473; Lekwuwa GU, 1996, BRAIN, V119, P491, DOI 10.1093/brain/119.2.491; LIPTON RB, 1980, PSYCHIAT RES, V3, P193, DOI 10.1016/0165-1781(80)90036-0; Lisberger SG, 2010, NEURON, V66, P477, DOI 10.1016/j.neuron.2010.03.027; Lovejoy LP, 2009, VISION RES, V49, P1275, DOI 10.1016/j.visres.2009.01.011; Maruta J, 2010, ANN NY ACAD SCI, V1208, P58, DOI 10.1111/j.1749-6632.2010.05695.x; Maruta J, 2010, J HEAD TRAUMA REHAB, V25, P293, DOI 10.1097/HTR.0b013e3181e67936; MORROW MJ, 1995, ANN NEUROL, V37, P443, DOI 10.1002/ana.410370406; Munoz DP, 2004, NAT REV NEUROSCI, V5, P218, DOI 10.1038/nrn1345; Orban de Xivry J. J., 2009, ENCY NEUROSCIENCE, P421; Osborne LC, 2005, NATURE, V437, P412, DOI 10.1038/nature03961; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RASHBASS C, 1961, J PHYSIOL-LONDON, V159, P326, DOI 10.1113/jphysiol.1961.sp006811; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; ROTHENBERG SJ, 1981, PSYCHOPHARMACOLOGY, V74, P237, DOI 10.1007/BF00427101; Rottach KG, 1996, VISION RES, V36, P2189, DOI 10.1016/0042-6989(95)00302-9; SHAGASS C, 1976, ARCH GEN PSYCHIAT, V33, P121; SIMPSON JI, 1981, ANN NY ACAD SCI, V374, P20, DOI 10.1111/j.1749-6632.1981.tb30856.x; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; UMEDA Y, 1975, ORL J OTO-RHINO-LARY, V37, P290, DOI 10.1159/000275237; Van Donkelaar P, 2002, PROG BRAIN RES, V140, P267; VANDERSTEEN J, 1983, VISION RES, V23, P1655, DOI 10.1016/0042-6989(83)90180-3; VANGELDER P, 1995, VISION RES, V35, P667, DOI 10.1016/0042-6989(94)00161-E; Wang P, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00085; WESTHEIMER G, 1954, AMA ARCH OPHTHALMOL, V52, P710; WHITE OB, 1983, BRAIN, V106, P571, DOI 10.1093/brain/106.3.571	55	24	24	0	12	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1554-351X			BEHAV RES METHODS	Behav. Res. Methods	MAR	2013	45	1					289	300		10.3758/s13428-012-0248-3			12	Psychology, Mathematical; Psychology, Experimental	Psychology	156DK	WOS:000319800900027	22956395	Green Published			2021-06-18	
J	Mellion, SA; Bennett, KS; Ellsworth, GL; Moore, K; Riva-Cambrin, J; Metzger, RR; Bratton, SL				Mellion, Sarah A.; Bennett, Kimberly Statler; Ellsworth, German L.; Moore, Kevin; Riva-Cambrin, Jay; Metzger, Ryan R.; Bratton, Susan L.			High-Dose Barbiturates for Refractory Intracranial Hypertension in Children With Severe Traumatic Brain Injury	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						barbiturates; cerebral perfusion pressure; intracranial hypertension; pediatric traumatic brain injury	HYPOTHERMIA THERAPY; HYPOTENSION; PRESSURE; OUTCOMES; COMA	Objectives: To evaluate high-dose barbiturates as a second-tier therapy for pediatric refractory intracranial hypertension complicating severe traumatic brain injury. Design: This is a retrospective cohort study of children with refractory intracranial hypertension treated with high-dose barbiturates. Setting: A single center level I pediatric trauma from 2001 to 2010. Patients: Thirty-six children with refractory intracranial hypertension defined as intracranial pressure greater than 20 mm Hg despite standard management treated with high-dose barbiturates after severe traumatic brain injury. Interventions: High-dose barbiturates were administered for refractory intracranial hypertension for a minimum duration of 6 hours and monitored by continuous electroencephalography. Measurements and Main Results: Exposure was control of -refractory intracranial hypertension defined as > 20 mm Hg -within 6 hours after starting barbiturates. Pediatric cerebral performance category scores at hospital discharge and at 3 months (or longer) follow-up were the primary outcomes. Ten of 36 patients (28%) had control of refractory intracranial hypertension. Neither demographic nor injury characteristics were associated with refractory intracranial hypertension con-trol. Children who responded received barbiturates significantly later after injury (76 vs. 29 median hours). Overall, 14 children died, 13 without control of intracranial pressure. Survival was more common in those who responded compared with those who did not respond to high-dose barbiturates, although this did not reach statistical significance (relative risk of death 0.2; 95% confidence interval; [0.03-1.3]). Of the 22 survivors, 19 had an acceptable survival (pediatric cerebral performance category less than 3) at 3 months or longer after injury; however, only three returned to normal function. Among survivors, control of refractory intracranial hypertension was associated with significantly better pediatric cerebral performance category scores and over two-fold likelihood of acceptable long-term outcome (relative risk 2.3; 95% confidence interval [1.4-4.0]) compared with uncontrolled refractory intracranial hypertension despite high-dose barbiturates. Conclusions: Addition of high-dose barbiturates achieved control of refractory intracranial hypertension in almost 30% of treated children. Control of refractory intracranial hypertension was associated with increased likelihood of an acceptable long-term outcome. (Pediatr Crit Care Med 2013; 14:239-247)	[Mellion, Sarah A.; Bennett, Kimberly Statler; Bratton, Susan L.] Univ Utah, Dept Pediat, Salt Lake City, UT 84112 USA; [Ellsworth, German L.] Univ Utah, Sch Med, Salt Lake City, UT USA; [Moore, Kevin] Primary Childrens Med Ctr, Salt Lake City, UT 84103 USA; [Riva-Cambrin, Jay] Univ Utah, Dept Neurosurg, Salt Lake City, UT USA; [Metzger, Ryan R.] Univ Utah, Div Pediat Surg, Salt Lake City, UT USA	Bratton, SL (corresponding author), Univ Utah, Dept Pediat, Salt Lake City, UT 84112 USA.	Susan.Bratton@hsc.utah.edu		Bratton, Susan/0000-0002-4605-8078	Office of Vice President for Health Sciences Center; Department of Pediatrics	Supported, in part, by the Office of Vice President for Health Sciences Center and the Department of Pediatrics.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS65; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Farahvar A, 2011, J NEUROSURG, V114, P1471, DOI 10.3171/2010.11.JNS101116; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Guerra SD, 2010, J PEDIAT-BRAZIL, V86, P73, DOI [10.1590/S0021-75572010000100013, 10.2223/JPED.1960]; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Hutchison JS, 2010, DEV NEUROSCI-BASEL, V32, P406, DOI 10.1159/000323260; KASOFF SS, 1988, PEDIATR NEUROSCI, V14, P241, DOI 10.1159/000120397; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Marshall GT, 2010, J TRAUMA, V69, P275, DOI 10.1097/TA.0b013e3181de74c7; Nadkarni VM, 2006, JAMA-J AM MED ASSOC, V295, P50, DOI 10.1001/jama.295.1.50; Pittman T, 1998, PEDIAT NEUROSCI, V15, P13; Roberts I, 2008, COCHRANE DB SYST REV; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; Zebrack M, 2009, PEDIATRICS, V124, P56, DOI 10.1542/peds.2008-1006	20	24	24	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAR	2013	14	3					239	247		10.1097/PCC.0b013e318271c3b2			9	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	103WG	WOS:000315949600007	23392360				2021-06-18	
J	Sears, JM; Blanar, L; Bowman, SM; Adams, D; Silverstein, BA				Sears, Jeanne M.; Blanar, Laura; Bowman, Stephen M.; Adams, Darrin; Silverstein, Barbara A.			Predicting Work-Related Disability and Medical Cost Outcomes: Estimating Injury Severity Scores from Workers' Compensation Data	JOURNAL OF OCCUPATIONAL REHABILITATION			English	Article						Injury severity; Trauma severity indices; ICDPIC; Occupational injuries; Workers' compensation; Work disability	REGISTRY INTERNATIONAL CLASSIFICATION; STATE TRAUMA REGISTRY; SYSTEM ICD-9 CODES; 9TH REVISION ICD-9; OCCUPATIONAL INJURY; UNITED-STATES; IMPROVES ACCURACY; DISJOINTED NATURE; WASHINGTON-STATE; SCORING SYSTEM	Purpose Acute work-related trauma is a leading cause of death and disability among US workers. The research objectives were to assess: (1) the feasibility of estimating Abbreviated Injury Scale-based injury severity scores (ISS) from ICD-9-CM codes available in workers' compensation (WC) medical billing data, (2) whether ISS predicts work-related disability and medical cost outcomes, (3) whether ISS adds value over other injury severity proxies, and (4) whether the utility of ISS differs for an all-injury sample compared with three specific injury samples (amputations, extremity fractures, traumatic brain injury). Methods ISS was estimated from ICD-9-CM codes using Stata's user-written -icdpic- program for 208,522 compensable nonfatal WC claims for workers injured in Washington State from 1998 to 2008. The Akaike Information Criterion and R-2 were used to compare severity measures. Competing risks survival analysis was used to evaluate work disability outcomes. Adjusted total medical costs were modeled using linear regression. Results Work disability and medical costs increased monotonically with injury severity. For a subset of 4,301 claims linked to the Washington State Trauma Registry (WTR), there was moderate agreement between WC-based ISS and WTR-based ISS. Including ISS together with an early hospitalization indicator resulted in the most informative models; however, early hospitalization is a more downstream measure. Conclusions ISS was significantly associated with work disability and medical cost outcomes for work-related injuries. Injury severity should be considered as a potential confounder for occupational injury intervention, program evaluation, or outcome studies, and can be estimated using existing software when ICD-9-CM codes are available.	[Sears, Jeanne M.; Blanar, Laura] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA; [Bowman, Stephen M.] Johns Hopkins Univ, Dept Hlth Policy & Management, Bloomberg Sch Publ Hlth, Ctr Injury Res & Policy, Baltimore, MD 21218 USA; [Adams, Darrin; Silverstein, Barbara A.] Washington State Dept Labor & Ind, Olympia, WA 98504 USA; [Silverstein, Barbara A.] Univ Washington, Sch Publ Hlth, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA	Sears, JM (corresponding author), Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Box 354809, Seattle, WA 98195 USA.	jeannes@u.washington.edu	Bowman, Stephen/AAF-2154-2019		NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTHUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH) [R03OH009883] Funding Source: NIH RePORTER; NIOSH CDC HHS [R03 OH009883, 1R03OH009883] Funding Source: Medline		Alexander BH, 1999, AM J IND MED, V36, P317, DOI 10.1002/(SICI)1097-0274(199908)36:2<317::AID-AJIM11>3.3.CO;2-I; [Anonymous], STAT SE UI WIND; *ASS ADV AUT MED, 1990, ABBR INJ SCAL; Augenstein JS, 1997, J TRAUMA, V43, P256; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barth P, 2008, 0825 UPJ I DEP LAB I; Burnham KP, 2004, SOCIOL METHOD RES, V33, P261, DOI 10.1177/0049124104268644; Butterfield PG, 1998, AM J IND MED, V34, P559, DOI 10.1002/(SICI)1097-0274(199812)34:6<559::AID-AJIM3>3.3.CO;2-V; Campbell DA, 1996, J HAND SURG-BRIT EUR, V21B, P295, DOI 10.1016/S0266-7681(05)80187-1; Campbell Kevin M, 2008, Health Informatics J, V14, P5, DOI 10.1177/1460458208088855; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CHEADLE A, 1994, AM J PUBLIC HEALTH, V84, P190, DOI 10.2105/AJPH.84.2.190; Clark DE., 2010, ICDPIC STATA MODULE; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; Cryer C, 2010, INJURY PREV, V16, P254, DOI 10.1136/ip.2009.023903; Dasinger LK, 1999, AM J IND MED, V35, P619, DOI 10.1002/(SICI)1097-0274(199906)35:6<619::AID-AJIM9>3.0.CO;2-I; Di Bartolomeo S, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-17; DiRusso SCM, 2004, J TRAUMA, V57, P486; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Forst LS, 1999, J OCCUP ENVIRON MED, V41, P514, DOI 10.1097/00043764-199906000-00019; Friedman LS, 2008, J OCCUP ENVIRON MED, V50, P350, DOI 10.1097/JOM.0b013e3181617324; Gillen M, 1999, AAOHN J, V47, P65; GLANCY KE, 1992, J TRAUMA, V33, P602, DOI 10.1097/00005373-199210000-00017; Harwood PJ, 2006, J TRAUMA, V60, P334, DOI 10.1097/01.ta.0000197148.86271.13; Hepp U, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-53; Husberg BJ, 1998, AM J IND MED, V34, P493, DOI 10.1002/(SICI)1097-0274(199811)34:5&lt;493::AID-AJIM10&gt;3.0.CO;2-X; Kilgo PD, 2004, J TRAUMA, V57, P479, DOI 10.1097/01.TA.0000141024.96440.7C; Krause N, 2001, AM J IND MED, V40, P464, DOI 10.1002/ajim.1116; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Leigh JP, 2011, MILBANK Q, V89, P728, DOI 10.1111/j.1468-0009.2011.00648.x; Leigh JP, 1997, ARCH INTERN MED, V157, P1557, DOI 10.1001/archinte.157.14.1557; Lin MR, 2009, ARCH PHYS MED REHAB, V90, P1716, DOI 10.1016/j.apmr.2009.04.006; Lumley T, 2002, ANNU REV PUBL HEALTH, V23, P151, DOI 10.1146/annurev.publhealth.23.100901.140546; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; Mann NC, 2006, ACAD EMERG MED, V13, P946, DOI 10.1197/j.aem.2006.04.019; Marchenko YV., 2010, INTRO SURVIVAL ANAL; Miller TR, 1995, ACCIDENT ANAL PREV, V27, P741, DOI 10.1016/0001-4575(95)00022-4; MITCHELL CS, 1993, ACCIDENT ANAL PREV, V25, P453, DOI 10.1016/0001-4575(93)90074-7; National Center for Health Statistics (NCHS) Expert Group on Injury Severity Measurement, 2004, DISC DOC INJ SEV MEA; National Institute for Occupational Safety and Health, WORKPL SAF HLTH TOP; National Trauma Data Bank, 2011, NAT TRAUM DAT STAND; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Osler TM, 1997, J TRAUMA, V43, P253, DOI 10.1097/00005373-199708000-00008; Pintilie M, 2006, STAT PRACTICE; Pransky G, 2001, AM J IND MED, V40, P295, DOI 10.1002/ajim.1104; Schnyder U, 2003, AM J PSYCHIAT, V160, P2025, DOI 10.1176/appi.ajp.160.11.2025; Sears JM, 2012, J OCCUP ENVIRON MED, V54, P356, DOI 10.1097/JOM.0b013e3182444fe7; Sears JM, 2011, J OCCUP ENVIRON MED, V53, P1243, DOI 10.1097/JOM.0b013e31822cff63; Shaw WS, 2001, DISABIL REHABIL, V23, P815; Soberg HL, 2011, J TRAUMA, V71, P425, DOI 10.1097/TA.0b013e3181eff54f; Soderstrom CA, 1997, J TRAUMA, V43, P925; State of Washington, EMPL OCC COV; State of Washington Office of Financial Management, COUNT POP DENS LESS; Stevenson M, 2001, Inj Prev, V7, P10, DOI 10.1136/ip.7.1.10; STIPDA: Injury Surveillance Workgroup 5, 2007, STIPDA INJ SURV WORK; Tiesman HM, 2011, AM J PREV MED, V41, P61, DOI 10.1016/j.amepre.2011.03.007; TOBIASEN J, 1982, ANN EMERG MED, V11, P260, DOI 10.1016/S0196-0644(82)80096-6; Toien K, 2011, INJURY	59	24	24	0	14	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1053-0487			J OCCUP REHABIL	J. Occup. Rehabil.	MAR	2013	23	1					19	31		10.1007/s10926-012-9377-x			13	Rehabilitation; Social Issues	Rehabilitation; Social Issues	083ZI	WOS:000314505200003	22736281				2021-06-18	
J	Timofeev, I; Nortje, J; Al-Rawi, PG; Hutchinson, PJA; Gupta, AK				Timofeev, Ivan; Nortje, Jurgens; Al-Rawi, Pippa G.; Hutchinson, Peter J. A.; Gupta, Arun K.			Extracellular brain pH with or without hypoxia is a marker of profound metabolic derangement and increased mortality after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain ischemia; brain trauma; energy metabolism; microdialysis; neurocritial care; pH	SEVERE HEAD-INJURY; IN-VITRO; ACIDOSIS; BASE; RAT; PATHOPHYSIOLOGY; HYPERGLYCEMIA; TROMETHAMINE; ISCHEMIA; SENSOR	Cerebral hypoxia and acidosis can follow traumatic brain injury (TBI) and are associated with increased mortality. This study aimed to evaluate a relationship between reduced pH(bt) and disturbances of cerebral metabolism. Prospective data from 56 patients with TBI, receiving microdialysis and Neurotrend monitoring, were analyzed. Four tissue states were defined based on pH(bt) and PbtO2: 1-low PbtO2/pH(bt), 2-low pH(bt)/normal PbtO2, 3-normal pH(bt)/low PbtO2, and 4-normal pH(bt)/PbtO2). Microdialysis values were compared between the groups. The relationship between PbtO2 and lactate/pyruvate (LP) ratio was evaluated at different pH(bt) levels. Proportional contribution of each state was evaluated against mortality. As compared with the state 4, the state 3 was not different, the state 2 exhibited higher levels of lactate, LP, and glucose and the state 1-higher LP and reduced glucose (P<0.001). A significant negative correlation between LP and PbtO2 (rho=-0.159, P<0.001) was stronger at low pHbt (rho=-0.201, P<0.001) and nonsignificant at normal pH(bt) (P=0.993). The state 2 was a significant discriminator of mortality categories (P=0.031). Decreased pH(bt) is associated with impaired metabolism. Measuring pH(bt) with PbtO2 is a more robust way of detecting metabolic derangements. Journal of Cerebral Blood Flow & Metabolism (2013) 33, 422-427; doi: 10.1038/jcbfm.2012.186; published online 12 December 2012	[Timofeev, Ivan; Al-Rawi, Pippa G.; Hutchinson, Peter J. A.] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Acad Neurosurg Unit, Cambridge CB2 0QQ, England; [Nortje, Jurgens; Gupta, Arun K.] Univ Cambridge, Addenbrookes Hosp, Dept Med, Div Anaesthesia, Cambridge CB2 0QQ, England	Timofeev, I (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Acad Neurosurg Unit, Box 167,Hills Rd, Cambridge CB2 0QQ, England.	it227@cam.ac.uk	Timofeev, Ivan/AAE-7019-2019	Timofeev, Ivan/0000-0002-1168-0393	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1002277] Funding Source: Medline		BROOKE NSR, 1994, P NATL ACAD SCI USA, V91, P1903, DOI 10.1073/pnas.91.5.1903; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Clausen T, 2005, J NEUROSURG, V103, P597, DOI 10.3171/jns.2005.103.4.0597; Grant SA, 2001, SENSOR ACTUAT B-CHEM, V72, P174, DOI 10.1016/S0925-4005(00)00650-X; Gupta AK, 2004, J NEUROTRAUM, V21, P678, DOI 10.1089/0897715041269722; Hoelper BM, 2005, ACTA NEUROCHIR, V147, P767, DOI 10.1007/s00701-005-0512-8; HOFFMAN TL, 1994, J NEUROSURG, V81, P567, DOI 10.3171/jns.1994.81.4.0567; Hoffman W E, 1997, Neurosurg Focus, V2, pE2; Holbein M, 2009, CRIT CARE, V13, DOI 10.1186/cc7711; Huang YZ, 2004, CELL, V118, P665, DOI 10.1016/j.cell.2004.09.004; Jaeger M, 2005, ACTA NEUROCHIR SUPPL, V95, P79; Korostynska O, 2008, IEEE SENS J, V8, P20, DOI 10.1109/JSEN.2007.912522; Kristian T, 2001, J NEUROTRAUM, V18, P1059, DOI 10.1089/08977150152693755; Li PA, 1997, ACTA PHYSIOL SCAND, V161, P567, DOI 10.1046/j.1365-201X.1997.00264.x; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Marmarou A, 1993, Acta Neurochir Suppl (Wien), V57, P160; McDonald JW, 1998, J NEUROSCI, V18, P6290; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MELLERGARD P, 1994, ACTA NEUROCHIR, P34; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; NAGY Z, 1985, ACTA NEUROPATHOL, V68, P160, DOI 10.1007/BF00688639; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; ROSNER MJ, 1984, J NEUROSURG, V60, P961, DOI 10.3171/jns.1984.60.5.0961; Shiogai T, 1999, ACT NEUR S, V75, P49; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; Smielewski P, 2008, ACTA NEUROCHIR SUPPL, V102, P145, DOI 10.1007/978-3-211-85578-2_30; Swanson RA, 1996, DEV NEUROSCI-BASEL, V18, P515, DOI 10.1159/000111448; SWANSON RA, 1995, J CEREBR BLOOD F MET, V15, P417, DOI 10.1038/jcbfm.1995.52; Velisek L, 1998, HIPPOCAMPUS, V8, P24, DOI 10.1002/(SICI)1098-1063(1998)8:1<24::AID-HIPO3>3.3.CO;2-2; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; WOLF AL, 1993, J NEUROSURG, V78, P54, DOI 10.3171/jns.1993.78.1.0054; Wu SZ, 2010, SENSOR ACTUAT B-CHEM, V144, P255, DOI 10.1016/j.snb.2009.10.058; Yermolaieva O, 2004, P NATL ACAD SCI USA, V101, P6752, DOI 10.1073/pnas.0308636100; Ying WH, 1999, J NEUROCHEM, V73, P1549, DOI 10.1046/j.1471-4159.1999.0731549.x; Yokota H, 2000, CRIT CARE MED, V28, P3275, DOI 10.1097/00003246-200009000-00025; YOSHIDA K, 1990, ACT NEUR S, V51, P317; YOSHIDA K, 1991, J NEUROSURG, V74, P87, DOI 10.3171/jns.1991.74.1.0087; Zauner A, 2002, J NEUROSURG, V97, P643, DOI 10.3171/jns.2002.97.3.0643; Zygun DA, 2004, NEUROSURGERY, V55, P877, DOI 10.1227/01.NEU.0000137658.14906.E4	41	24	24	0	17	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	2013	33	3					422	427		10.1038/jcbfm.2012.186			6	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	099AG	WOS:000315590200015	23232949	Bronze, Green Published			2021-06-18	
J	Wood, RL; Doughty, C				Wood, Rodger Ll.; Doughty, Caitriona			Alexithymia and Avoidance Coping Following Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						alexithymia; avoidant behavior; coping styles; psychological distress; traumatic brain injury	DEPRESSION INVENTORY-II; SOCIAL SUPPORT; STRATEGIES; STRESS; SCALE; RELIABILITY; SENSITIVITY; RESPONSES; VALIDITY; AMNESIA	Background: Individuals who develop maladaptive coping styles after traumatic brain injury (TBI) usually experience difficulty expressing their emotional state, increasing the risk of psychological distress. Difficulties expressing emotion and identifying feelings are features of alexithymia, which is prevalent following TBI. Objective: To examine the relations among coping styles, alexithymia, and psychological distress following TBI. Participants: Seventy-one patients with TBI drawn from a head injury clinic population and 54 demographically matched healthy controls. Main Measures: Toronto Alexithymia Scale-20, Estonian COPE-D Inventory, Beck Depression Inventory-II, and Beck Anxiety Inventory. Results: The participants with TBI exhibited significantly higher rates of alexithymia and psychological distress and lower levels of task-oriented coping than healthy controls. Levels of avoidance coping and psychological distress were significantly higher in a subgroup of TBI patients with alexithymia than in a nonalexithymic TBI subsample. There were significant relations among alexithymia, avoidance coping, and levels of psychological distress. Regression analysis revealed that difficulty identifying feelings was a significant predictor for psychological distress. Conclusion: Early screening for alexithymia following TBI might identify those most at risk of developing maladaptive coping mechanisms. This could assist in developing early rehabilitation interventions to reduce vulnerability to later psychological distress.	[Wood, Rodger Ll.; Doughty, Caitriona] Swansea Univ, Dept Psychol, Sch Human & Hlth Sci, Brain Injury Res Grp, Swansea SA2 8PP, W Glam, Wales	Wood, RL (corresponding author), Swansea Univ, Dept Psychol, Sch Human & Hlth Sci, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.	r.l.wood@swansea.ac.uk					American Psychiatric Association, 2000, HDB PSYCHIAT MEASURE; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Bagby RM, 2007, J PERS ASSESS, V89, P258, DOI 10.1080/00223890701629771; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Beck AT., 1996, BECK DEPRESSION INVE, V2; Besharat MA, 2010, PROCD SOC BEHV, V5, P614, DOI 10.1016/j.sbspro.2010.07.152; BONANNO GA, 1995, J PERS SOC PSYCHOL, V69, P975, DOI 10.1037/0022-3514.69.5.975; Bouteyre E, 2007, STRESS HEALTH, V9, P3, DOI 10.3109/02699052.2014.919538; BRYANT RA, 1995, BEHAV RES THER, V33, P631, DOI 10.1016/0005-7967(94)00093-Y; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; COMPAS BE, 1988, J CONSULT CLIN PSYCH, V56, P405, DOI 10.1037/0022-006X.56.3.405; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dawson DR, 2006, BRAIN COGNITION, V60, P214; de Ayala RJ, 2005, EDUC PSYCHOL MEAS, V65, P742, DOI DOI 10.1177/0013164405278557; De Berardis D, 2008, PROG NEURO-PSYCHOPH, V32, P1982, DOI 10.1016/j.pnpbp.2008.09.022; Di Schiena R, 2011, PERS INDIV DIFFER, V50, P10, DOI 10.1016/j.paid.2010.07.037; Finset A, 2000, BRAIN INJURY, V14, P887; FUKUNISHI I, 1995, PSYCHOL REP, V76, P1299, DOI 10.2466/pr0.1995.76.3c.1299; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P62, DOI 10.1016/j.neuropsychologia.2005.04.011; HIGGINS JE, 1995, EUR J PERSONALITY, V9, P253, DOI 10.1002/per.2410090403; Homaifar BY, 2009, ARCH PHYS MED REHAB, V90, P652, DOI 10.1016/j.apmr.2008.10.028; Kallasmaa T, 2000, PERS INDIV DIFFER, V29, P881, DOI 10.1016/S0191-8869(99)00240-8; KIRSCHBAUM C, 1993, NEUROPSYCHOBIOLOGY, V28, P76, DOI 10.1159/000119004; Kooiman CG, 2002, J PSYCHOSOM RES, V53, P1083, DOI 10.1016/S0022-3999(02)00348-3; Krpan KM, 2007, J CLIN EXP NEUROPSYC, V29, P36, DOI 10.1080/13803390500376816; Krpan KM, 2011, J INT NEUROPSYCH SOC, V17, P248, DOI 10.1017/S1355617710001499; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Motan I, 2007, TURK PSIKIYATR DERG, V18, P333; Mueller J, 2006, COMPR PSYCHIAT, V47, P489, DOI 10.1016/j.comppsych.2006.03.001; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Ownsworth T, 2007, NEUROPSYCHOL REHABIL, V17, P129, DOI 10.1080/09602010600615506; Parker JDA, 1998, COMPR PSYCHIAT, V39, P91, DOI 10.1016/S0010-440X(98)90084-0; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Sprinkle SD, 2002, J COUNS PSYCHOL, V49, P381, DOI 10.1037//0022-0167.49.3.381; Taylor G. J., 1997, DISORDERS AFFECT REG; TAYLOR GJ, 1992, PSYCHOTHER PSYCHOSOM, V57, P34, DOI 10.1159/000288571; TEASDALE G, 1974, LANCET, V2, P81; Tomberg T, 2007, BRAIN INJURY, V21, P479, DOI 10.1080/02699050701311737; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; VINGERHOETS AJJM, 1995, PSYCHOTHER PSYCHOSOM, V64, P32, DOI 10.1159/000288988; Wechsler D., 2001, WECHSLER TEST ADULT; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P259, DOI 10.1080/13803390902976940; Windle M, 1996, J ABNORM PSYCHOL, V105, P551, DOI 10.1037/0021-843X.105.4.551; Wolters G, 2010, NEUROPSYCHOL REHABIL, V20, P587, DOI 10.1080/09602011003683836; Wood RLL, 2010, J INT NEUROPSYCH SOC, V16, P1108, DOI 10.1017/S1355617710001013; Wood RLL, 2009, BRAIN INJURY, V23, P649, DOI 10.1080/02699050902970786; Wood RL, 2007, J INT NEUROPSYCH SOC, V13, P471, DOI 10.1017/S1355617707070518	51	24	24	0	26	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2013	28	2					98	105		10.1097/HTR.0b013e3182426029			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	105HU	WOS:000316058300003	22495103				2021-06-18	
J	Boonstra, AM; Reneman, MF; Stewart, RE; Post, MW; Preuper, HRS				Boonstra, Anne M.; Reneman, Michiel F.; Stewart, Roy E.; Post, Marcel W.; Preuper, Henrica R. Schiphorst			Life satisfaction in patients with chronic musculoskeletal pain and its predictors	QUALITY OF LIFE RESEARCH			English	Article						Life satisfaction; Musculoskeletal pain; Quality of life	SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; FOLLOW-UP; DETERMINANTS; IMPACT; COHORT	Purpose To determine the life satisfaction of patients with chronic non-malignant musculoskeletal pain (CMP) compared to the general population (GP) and to identify predictors of life satisfaction. Methods Subjects were patients with CMP (n = 1,082) admitted to multidisciplinary rehabilitation and a general population sample (n = 506). Lisat-9 measures satisfaction with life as a whole and eight life domains. Physical, emotional and social functioning and pain intensity were assessed using the SF-36. Ordinal logistic regression was used to analyse differences between patients with CMP and the GP, and predictors of life satisfaction in patients with CMP. Results Compared to the general population, patients with CMP reported lower satisfaction with 'life as a whole', and with six life domains: self-care, leisure, vocational and financial situation, sex life and contacts with friends. In the CMP group, pain was associated with satisfaction with self-care, vocational situation, partnership, family life and contacts with friends. Marital status, age and mental health were associated with most satisfaction scores. Conclusions Compared to the general population, patients with CMP reported lower satisfaction with 'life as a whole' and most life domains. The most consistent predictors of life satisfaction were marital status, mental health, vitality and pain.	[Boonstra, Anne M.] Revalidatie Friesland, Ctr Rehabil, NL-9244 ZN Beetsterzwaag, Netherlands; [Reneman, Michiel F.; Preuper, Henrica R. Schiphorst] Univ Groningen, Univ Med Ctr Groningen, Dept Rehabil, Ctr Rehabil, Groningen, Netherlands; [Stewart, Roy E.] Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci Community & Occupat Med, Groningen, Netherlands; [Post, Marcel W.] Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, Utrecht, Netherlands; [Post, Marcel W.] Univ Med Ctr Utrecht, Ctr Excellence Rehabil Med, Utrecht, Netherlands	Boonstra, AM (corresponding author), Revalidatie Friesland, Ctr Rehabil, POB 2, NL-9244 ZN Beetsterzwaag, Netherlands.	a.m.boonstra@revalidatie-friesland.nl					Anke AGW, 2003, CLIN REHABIL, V17, P431, DOI 10.1191/0269215503cr629oa; Berges IM, 2007, ARCH PHYS MED REHAB, V88, P413, DOI 10.1016/j.apmr.2006.12.022; Boonstra AM, 2008, INT J REHABIL RES, V31, P181, DOI 10.1097/MRR.0b013e3282fc0fdf; Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009; Brox JI, 2005, J REHABIL MED, V37, P95, DOI 10.1080/16501970410017738; Budh CN, 2007, CLIN REHABIL, V21, P89, DOI 10.1177/0269215506070313; Chen YY, 2008, ARCH PHYS MED REHAB, V89, P2285, DOI 10.1016/j.apmr.2008.06.008; Cummins RA, 1998, SOC INDIC RES, V43, P307, DOI 10.1023/A:1006831107052; DIENER E, 1984, PSYCHOL BULL, V95, P542, DOI 10.1037/0033-2909.95.3.542; Fugl-Meyer A. R., 1991, CLIN REHABIL, V5, DOI [10.1177/026921559100500105, DOI 10.1177/026921559100500105, 10.1177/026921559100500105.]; Fugl-Meyer AR, 2002, J REHABIL MED, V34, P239, DOI 10.1080/165019702760279242; Heikkila H, 1998, CLIN REHABIL, V12, P487, DOI 10.1191/026921598670569564; Hicken BL, 2002, J REHABIL RES DEV, V39, P359; Leonard MT, 2006, J PAIN, V7, P377, DOI 10.1016/j.jpain.2006.01.442; Lund ML, 2007, DISABIL REHABIL, V29, P1417, DOI 10.1080/09638280601029068; NEAR JP, 1993, SOC INDIC RES, V29, P109, DOI 10.1007/BF01136199; PETRIE K, 1994, AUST NZ J SURG, V64, P115, DOI 10.1111/j.1445-2197.1994.tb02155.x; Post Marcel, 2005, J Neurol Phys Ther, V29, P139; Post MWM, 1998, SCAND J REHABIL MED, V30, P23; Post MWM, 1998, ARCH PHYS MED REHAB, V79, P395, DOI 10.1016/S0003-9993(98)90139-3; POST MWM, 1996, TIJDSCHR SOC GEZONDH, V74, P204; Putzke JD, 2002, ARCH PHYS MED REHAB, V83, P555, DOI 10.1053/apmr.2002.31173; Silvemark AJ, 2008, DISABIL REHABIL, V30, P1929, DOI 10.1080/09638280701748773; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; TENNANT A, 1995, BRIT J RHEUMATOL, V34, P899; Tonack M, 2008, SPINAL CORD, V46, P380, DOI 10.1038/sj.sc.3102088; van Koppenhagen CF, 2008, ARCH PHYS MED REHAB, V89, P1733, DOI 10.1016/j.apmr.2007.12.042; Veenhoven R., WORLD DATABASE HAPPI; Ware JE, 2000, SPINE, V25, P3130, DOI 10.1097/00007632-200012150-00008; World Health Organization, 1958, 1 10 YEARS WHO; World Health Organization, 1997, PROGR MENT HLTH MEAS; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	32	24	25	0	11	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0962-9343			QUAL LIFE RES	Qual. Life Res.	FEB	2013	22	1					93	101		10.1007/s11136-012-0132-8			9	Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health	Health Care Sciences & Services; Public, Environmental & Occupational Health	094QQ	WOS:000315279300010	22350589				2021-06-18	
J	Elliott, JT; Milej, D; Gerega, A; Weigl, W; Diop, M; Morrison, LB; Lee, TY; Liebert, A; Lawrence, KS				Elliott, Jonathan T.; Milej, Daniel; Gerega, Anna; Weigl, Wojciech; Diop, Mamadou; Morrison, Laura B.; Lee, Ting-Yim; Liebert, Adam; Lawrence, Keith St.			Variance of time-of-flight distribution is sensitive to cerebral blood flow as demonstrated by ICG bolus-tracking measurements in adult pigs	BIOMEDICAL OPTICS EXPRESS			English	Article							NEAR-INFRARED SPECTROSCOPY; INDOCYANINE GREEN; NONINVASIVE MEASUREMENT; TRANSIT TIME; PHOTONS; MOMENTS; VOLUME; BRAIN; MEDIA; MODEL	Variance of time-of-flight distributions have been shown to be more sensitive to cerebral blood flow (CBF) during dynamic-contrast enhanced monitoring of neurotrauma patients than attenuation. What is unknown is the degree to which variance is affected by changes in extracerebral blood flow. Furthermore, the importance of acquiring the arterial input function (AIF) on quantitative analysis of the data is not yet clear. This animal study confirms that variance is both sensitive and specific to changes occurring in the brain when measurements are acquired on the surface of the scalp. Furthermore, when the variance data along with the measured AIF is analyzed using a nonparametric deconvolution method, the recovered change in CBF is in good agreement with CT perfusion values. (c) 2013 Optical Society of America	[Elliott, Jonathan T.; Lee, Ting-Yim; Lawrence, Keith St.] Univ Western Ontario, Dept Med Biophys, London, ON N6A 3K7, Canada; [Elliott, Jonathan T.; Diop, Mamadou; Morrison, Laura B.; Lee, Ting-Yim; Lawrence, Keith St.] St Josephs Hosp, Lawson Hlth Res Inst, Imaging Div, London, ON N6A 4V2, Canada; [Milej, Daniel; Gerega, Anna; Liebert, Adam] Polish Acad Sci, Nalecz Inst Biocybernet & Biomed Engn, PL-02109 Warsaw, Poland; [Weigl, Wojciech] Med Univ Warsaw, Dept Anesthesiol & Intens Care, PL-02005 Warsaw, Poland	Elliott, JT (corresponding author), Univ Western Ontario, Dept Med Biophys, 1151 Richmond St, London, ON N6A 3K7, Canada.	jellio@uwo.ca	Liebert, Adam/D-7654-2011; Lee, Ting-Yim/M-1721-2013; Weigl, Wojciech/B-4294-2015; Diop, Mamadou/B-6487-2015; Gerega, Anna/AAR-1496-2021; St. Lawrence, Keith/B-5726-2015; Milej, Daniel/B-6729-2014	Weigl, Wojciech/0000-0001-5184-6602; Gerega, Anna/0000-0002-9809-6041; Milej, Daniel/0000-0003-3173-0834; St Lawrence, Keith/0000-0001-8022-8205; Liebert, Adam/0000-0003-1643-7568	European Community's Seventh Framework Programme (FP7) [201076]; Canadian Health Institutes of Research; Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada	This research project was supported by funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under Grant agreement No. 201076, the Canadian Health Institutes of Research, and the Heart and Stroke Foundation of Canada. The authors gratefully acknowledge Jennifer Hadway who provided consultation regarding the animal experiments.	Brown DW, 2002, PEDIATR RES, V51, P564, DOI 10.1203/00006450-200205000-00004; Cenic A, 1999, AM J NEURORADIOL, V20, P63; Diop M, 2012, OPT LETT, V37, P2358, DOI 10.1364/OL.37.002358; Diop M, 2010, PROC SPIE, V7555, DOI 10.1117/12.842521; Diop M, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3488626; Elliott JK, 2010, TLS-TIMES LIT SUPPL, P15; Elliott JT, 2012, OPT LETT, V37, P2571, DOI 10.1364/OL.37.002571; Elliott JT, 2011, PROC SPIE, V7896, DOI 10.1117/12.875361; Fantini S, 1999, PHYS MED BIOL, V44, P1543, DOI 10.1088/0031-9155/44/6/308; FRIBERG L, 1986, SCAND J CLIN LAB INV, V46, P375, DOI 10.3109/00365518609083685; Gora F, 2002, J NEUROSURG ANESTH, V14, P218, DOI 10.1097/00008506-200207000-00008; GRUBB RL, 1977, J NEUROSURG, V46, P446, DOI 10.3171/jns.1977.46.4.0446; GRUBB RL, 1974, STROKE, V5, P630, DOI 10.1161/01.STR.5.5.630; Jaynes ET, 2003, PROBABILITY THEORY L, DOI DOI 10.1017/CBO9780511790423; Jelzow A, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.5.057003; Kacprzak M, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2743964; Kuebler WM, 1998, J CEREBR BLOOD F MET, V18, P445, DOI 10.1097/00004647-199804000-00013; LANDSMAN MLJ, 1976, J APPL PHYSIOL, V40, P575; Liebert A, 2006, NEUROIMAGE, V31, P600, DOI 10.1016/j.neuroimage.2005.12.046; Liebert A, 2005, NEUROIMAGE, V24, P426, DOI 10.1016/j.neuroimage.2004.08.046; Liebert A, 2004, APPL OPTICS, V43, P3037, DOI 10.1364/AO.43.003037; Liebert A, 2003, APPL OPTICS, V42, P5785, DOI 10.1364/AO.42.005785; Liebert A., 2012, BIOMEDICAL OPTICS; MEIER P, 1954, J APPL PHYSIOL, V6, P731; Steinbrink J, 2001, PHYS MED BIOL, V46, P879, DOI 10.1088/0031-9155/46/3/320; Steinkellner O, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3505009; Terborg C, 2003, CEREBROVASC DIS, V16, P36, DOI 10.1159/000070113; THOMPSON HK, 1964, CIRC RES, V14, P502, DOI 10.1161/01.RES.14.6.502; U.S. Food and Drug Administration, 2012, APPR DRUG PROD THER; ZACCANTI G, 1995, P SOC PHOTO-OPT INS, V2359, P755	30	24	24	0	10	OPTICAL SOC AMER	WASHINGTON	2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA	2156-7085			BIOMED OPT EXPRESS	Biomed. Opt. Express	FEB 1	2013	4	2					206	218		10.1364/BOE.4.000206			13	Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging	Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging	088AQ	WOS:000314806600003	23413183	DOAJ Gold, Green Published			2021-06-18	
J	Aligene, K; Lin, E				Aligene, Kathy; Lin, Emerald			Vestibular and balance treatment of the concussed athlete	NEUROREHABILITATION			English	Article						Vestibular and balance dysfunction; concussion; concussed athlete and treatment; vestibular rehabilitation therapy	TRAUMATIC BRAIN-INJURY; REHABILITATION; MANAGEMENT; COLLEGIATE; DIZZINESS; STATEMENT; THERAPY; SPORT; MRI	OBJECTIVES: The purpose of this chapter is to provide an update on the clinical management of vestibular and balance dysfunction in a concussed athlete with a focus on diagnosis, initial work-up, and initial and continuing management. Although much is still unknown about the etiology of vestibular and balance dysfunction in a concussed athlete, we briefly review current theories about neural pathophysiology to help link proposed treatment methodologies. INTRODUCTION: The treatment and management of vestibular and balance dysfunction in concussed athletes requires a multidisciplinary approach and is based on continuous reassessment of the presenting symptoms. The clinical challenge toward managing persistent symptoms of the post-concussive athlete is discerning whether a set of symptoms match diagnostic testing and whether further neurological work up is necessary. Because there are no discrete time boundaries to make such judgment calls, we offer a guide to help with the difficult clinical decisions necessary to treat the post-concussive athlete. METHODS: Literature search was performed using the following keywords: Vestibular and balance dysfunction, concussion, concussed athlete and treatment, vestibular rehabilitation therapy. Original research studies, literature reviews, and clinical guidelines were reviewed between 1997 and 2012, with the majority of articles dating beyond 2004. Although we acknowledge that post-concussive states lie within a continuum, we decided to divide treatment and management into three stages: time after initial impact, recovery, and prolonged recovery. RESULTS: In post-concussive athletes, impairments in balance may exist as a result of transmitted force to peripheral and central neural substrates that integrate sensory information and coordinate motor function. Corroborative information, clinical examination, neuropsychological testing, and continual reassessment are means to determine severity of dysfunction and track clinical course and resolution of symptoms. Persistence of symptoms beyond initial impact may require medication trials or adjustments that are tailored to the patient's medical history and/or neurocognitive rehabilitative techniques such as vestibular rehabilitation therapy to prevent progression of neurologic sequelae. Prolonged recovery of more than six months may require neurological consultation. CONCLUSION: Concussion management and treatment of vestibular and balance impairments in athletes should be assessed in a stepwise manner, from initial impact to resolution of symptoms. If symptoms are prolonged, impaired neuronal mechanisms or irreversible cerebral damage may underlie persistent symptoms and cognitive deficits seen in neurocognitive testing. Management protocols are currently focused on individualized assessment of neurocognitive assessment and comprehensive symptomatic evaluation (Reddy et al., 2008). It is widely accepted that neurocognitive and resolution of concussion-induced symptoms must be resolved prior to returning to sport or play and therefore, the athlete should be reassessed and treated until symptoms resolved.	[Aligene, Kathy] Mt Sinai Sch Med, Dept Rehabil Med, Box 1240,1425 Madison Ave, New York, NY 10029 USA; [Lin, Emerald] Kessler Inst, W Orange, NJ USA	Aligene, K (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, Box 1240,1425 Madison Ave, New York, NY 10029 USA.	kathy_a@yahoo.com					Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Benson RR, 2012, NEUROREHABILITATION, V31, P261, DOI 10.3233/NRE-2012-0795; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Black FO, 2000, AM J OTOL, V21, P543; Blume HK, 2011, PHYS MED REH CLIN N, V22, P665, DOI 10.1016/j.pmr.2011.08.007; Brown KE, 2006, ARCH PHYS MED REHAB, V87, P76, DOI 10.1016/j.apmr.2005.08.003; Crooks C. Y., 2007, TRAUMATIC BRAIN INJU; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Ernst A, 2005, OTOLARYNG HEAD NECK, V132, P554, DOI 10.1016/j.otohns.2004.09.034; Friedman Jules M, 2004, Med Health R I, V87, P296; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hall CD, 2009, OTOLARYNG CLIN N AM, V42, P161, DOI 10.1016/j.otc.2008.09.006; Han BI, 2011, J CLIN NEUROL, V7, P184, DOI 10.3988/jcn.2011.7.4.184; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Levin H., 2012, J NEUROTRAUMA; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell M, 2009, CLIN SPORT MED, V28, P95, DOI 10.1016/j.csm.2008.08.008; Ma R, 2012, J BONE JOINT SURG AM, V94A, P1618, DOI 10.2106/JBJS.K.01127; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Maskell F, 2006, BRAIN INJURY, V20, P293, DOI 10.1080/02699050500488041; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P., 2009, PM&R, V1, P406; Moen KG, 2012, J NEUROL NEUROSUR PS, V83, P1193, DOI 10.1136/jnnp-2012-302644; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Reddy CC, 2011, PM&R, V3, pS396, DOI 10.1016/j.pmrj.2011.07.012; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; Sabini RC, 2010, PHYSICIAN SPORTSMED, V38, P139, DOI 10.3810/psm.2010.04.1771; Sahler CS, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/659652; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Saulle M, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/816069; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Shrier I, 2012, CLIN J SPORT MED, V22, P211, DOI 10.1097/JSM.0b013e31824cc5f9; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Yeo SS, 2012, NEUROREHABILITATION, V31, P143, DOI 10.3233/NRE-2012-0783	40	24	25	0	20	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2013	32	3					543	553		10.3233/NRE-130876			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	135DM	WOS:000318266200012	23648608				2021-06-18	
J	Bigler, ED; Yeates, KO; Dennis, M; Gerhardt, CA; Rubin, KH; Stancin, T; Taylor, HG; Vannatta, K				Bigler, Erin D.; Yeates, Keith Owen; Dennis, Maureen; Gerhardt, Cynthia A.; Rubin, Kenneth H.; Stancin, Terry; Taylor, H. Gerry; Vannatta, Kathryn			Neuroimaging and social behavior in children after traumatic brain injury: Findings from the Social Outcomes of Brain Injury in Kids (SOBIK) study	NEUROREHABILITATION			English	Article						Traumatic brain injury; social brain; neuroimaging; theory of mind; frontotemporolimbic damage	MIND; NEUROSCIENCE; ADOLESCENTS; COGNITION; AMYGDALA; BELIEFS; EMOTION; TRUTH; TBI	BACKGROUND: Neuroimaging studies identified either focal and/or non-specific frontotemporolimbic damage resulting from mild-complicated to severe traumatic brain injury (TBI) in a subset of 12 children 8-12 years of age who were part of the Social Outcomes of Brain Injury in Kids (SOBIK) study. The influence of identifiable damage on social behavior was examined. METHODS: Magnetic resonance imaging was obtained on average 2.5 years post injury wherein cases with distinct abnormalities were selected. Various direct, performance-based measures of cognitive-social-emotional functioning were obtained along with data regarding peer relations and friendships in the classroom. RESULTS: Overall, children with TBI were impaired on tasks of social-emotional processing compared to children with orthopedic injury (OI). Ten of the 12 children with TBI had multiple areas of impaired social-emotional functioning in comparison to OI controls. With regards to friendships, four of the nine children with TBI who had classroom data had no mutual friends, four also received low peer acceptance ratings, and two were perceived by peers as having high levels of rejection/victimization in the classroom. CONCLUSIONS: Children with frontotemporolimbic or diffuse damage demonstrated variable social outcomes from their TBI. Results are discussed in terms of the heterogeneity of TBI-related abnormalities and their relationship to social behavior.	[Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Sch Med, Dept Psychiat, Salt Lake City, UT 84112 USA; [Yeates, Keith Owen; Gerhardt, Cynthia A.; Vannatta, Kathryn] Nationwide Childrens Hosp, Res Inst, Dept Pediat, Columbus, OH USA; [Yeates, Keith Owen; Gerhardt, Cynthia A.; Vannatta, Kathryn] Ohio State Univ, Columbus, OH 43210 USA; [Dennis, Maureen] Hosp Sick Children, Toronto, ON M5G 1X8, Canada; [Dennis, Maureen] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Dennis, Maureen] Univ Toronto, Dept Surg, Toronto, ON M5S 1A1, Canada; [Rubin, Kenneth H.] Univ Maryland, Dept Human Dev, College Pk, MD 20742 USA; [Stancin, Terry; Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, MetroHlth Med Ctr, Cleveland, OH 44106 USA	Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol Sci, 1001 SWKT, Provo, UT 84602 USA.	erin_bigler@byu.edu	Vannatta, Kathryn/E-4237-2011; Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020; Gerhardt, Cynthia/E-3109-2011; Rubin, Kenneth H/M-5276-2018	Rubin, Kenneth H/0000-0002-2608-2484; Yeates, Keith/0000-0001-7680-2892	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5 R01 HD048946]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048946] Funding Source: NIH RePORTER	The preparation of this paper was supported in part by grant 5 R01 HD048946 from the National Institute of Child Health and Human Development. The assitance in manuscript preparation of Jo ANN Petrie, Ph.D. and Tracy J. Abildskov is gratefully acknowledged.	Adolphs R, 2010, ANN NY ACAD SCI, V1191, P42, DOI 10.1111/j.1749-6632.2010.05445.x; Adolphs R, 2009, ANNU REV PSYCHOL, V60, P693, DOI 10.1146/annurev.psych.60.110707.163514; Anderson V., 2012, DISABIL REHABIL; Arnett JJ, 2000, AM PSYCHOL, V55, P469, DOI 10.1037/0003-066X.55.5.469; ASHER SR, 1979, DEV PSYCHOL, V15, P443, DOI 10.1037/0012-1649.15.4.443; Bava S, 2010, NEUROPSYCHOL REV, V20, P398, DOI 10.1007/s11065-010-9146-6; Beauchamp MH, 2009, J NEUROTRAUM, V26, P1645, DOI [10.1089/neu.2009.0916, 10.1089/neu.2009-0916]; Bukowski W., 1989, PEER RELATIONSHIPS C; Burnett S, 2011, NEUROSCI BIOBEHAV R, V35, P1654, DOI 10.1016/j.neubiorev.2010.10.011; Cacioppo JT, 2011, ANN NY ACAD SCI, V1224, P162, DOI 10.1111/j.1749-6632.2010.05858.x; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2001, J HEAD TRAUMA REHAB, V16, P456, DOI 10.1097/00001199-200110000-00005; Dennis M., J INT NEUROPSYCHOL S, V19, P338; Dennis M, 2013, DEV COGN NEUROS-NETH, V5, P25, DOI 10.1016/j.dcn.2012.11.006; Dennis M, 2012, J INT NEUROPSYCH SOC, V18, P908, DOI 10.1017/S1355617712000756; Ewing-Cobbs L., 2011, INT J DEV NEUROSCI; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Martin-Rodriguez JF, 2010, NEUROPSYCHOLOGIA, V48, P1181, DOI 10.1016/j.neuropsychologia.2010.02.009; Gale SD, 2010, J HEAD TRAUMA REHAB, V25, P15, DOI 10.1097/HTR.0b013e3181c39960; Gerhardt CA, 2012, J PEDIATR PSYCHOL, V37, P209, DOI 10.1093/jpepsy/jsr082; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Hanten G, 2011, NEUROPSYCHOLOGIA, V49, P486, DOI 10.1016/j.neuropsychologia.2010.12.007; Heatherton TF, 2011, ANNU REV PSYCHOL, V62, P363, DOI 10.1146/annurev.psych.121208.131616; Hein G, 2008, CURR OPIN NEUROBIOL, V18, P153, DOI 10.1016/j.conb.2008.07.012; Jakobson R., 1960, STYLE LANGUAGE; Jernigan TL, 2011, PROG BRAIN RES, V189, P77, DOI 10.1016/B978-0-444-53884-0.00019-1; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; Mars RB, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00189; MASTEN AS, 1985, DEV PSYCHOL, V21, P523, DOI 10.1037/0012-1649.21.3.523; Max JE, 2012, INT J DEV NEUROSCI, V30, P239, DOI 10.1016/j.ijdevneu.2011.12.005; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Ochsner KN, 2008, BIOL PSYCHIAT, V64, P48, DOI 10.1016/j.biopsych.2008.04.024; Oitzl MS, 2010, NEUROSCI BIOBEHAV R, V34, P853, DOI 10.1016/j.neubiorev.2009.07.006; Prigatano GP, 2006, J HEAD TRAUMA REHAB, V21, P505, DOI 10.1097/00001199-200611000-00005; Rosema S., 2012, J NEUROTRAUMA; Ross KA, 2011, BRAIN INJURY, V25, P1206, DOI 10.3109/02699052.2011.609519; Shamay-Tsoory SG, 2007, NEUROPSYCHOLOGIA, V45, P3054, DOI 10.1016/j.neuropsychologia.2007.05.021; Shaw P, 2005, J COGNITIVE NEUROSCI, V17, P1410, DOI 10.1162/0898929054985491; Stiles J, 2010, NEUROPSYCHOL REV, V20, P327, DOI 10.1007/s11065-010-9148-4; Turkstra LS, 2004, NEUROREHABILITATION, V19, P245; Turkstra LS, 2008, NEUROREHABILITATION, V23, P501; Wellman HM, 2001, CHILD DEV, V72, P655, DOI 10.1111/1467-8624.00304; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5; Yeates K. O., J INT NEUROPSYCHOL S, V19, P518; Yeates K. O., 2013, J INT NEURO IN PRESS; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Ziv I, 2011, COGN NEUROPSYCHIATRY, V16, P71, DOI 10.1080/13546805.2010.492693	49	24	24	0	26	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2013	32	4					707	720		10.3233/NRE-130896			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	184QF	WOS:000321907100003	23867398				2021-06-18	
J	Hamel, A; Llari, M; Piercecchi-Marti, MD; Adalian, P; Leonetti, G; Thollon, L				Hamel, Anissa; Llari, Maxime; Piercecchi-Marti, Marie-Dominique; Adalian, Pascal; Leonetti, Georges; Thollon, Lionel			Effects of fall conditions and biological variability on the mechanism of skull fractures caused by falls	INTERNATIONAL JOURNAL OF LEGAL MEDICINE			English	Article						Skull fractures; Falls; Multibody dynamics; Finite element modeling; Forensic investigations	MULTIBODY DYNAMICS ANALYSIS; TRAUMATIC BRAIN-INJURY; FINITE-ELEMENT MODELS; HUMAN HEAD; TOLERANCE LIMITS; IMPACT; BIOMECHANICS; RECONSTRUCTION	In a forensic investigation, there is considerable difficulty in distinguishing between different mechanisms that could explain the head injury sustained. The key question is often whether the injury was the consequence of a fall, a blow, or a fall caused by a blow. Better understanding of the parameters influencing the mechanism of skull fracture could be of use when attempting to distinguish between different causes of injury. Numerous parameters concerning fall conditions and biological variability are reported in the literature to influence the mechanism of skull fracture. At the current time, there are no studies that investigate both the effect of a fall and biological parameters. The aim of this paper is to study the influence of these parameters on the mechanism of skull fracture using a numerical approach. We focused on accidental falls from a standing height. A multibody model was used to estimate head impact velocities and a finite element model was used to investigate the effect of the fall conditions and of biological variability on skull fracture. The results show that the mechanism of skull fractures is influenced by a combination of at least four parameters: impact velocity, impact surface, cortical thickness and cortical density.	[Hamel, Anissa; Llari, Maxime; Thollon, Lionel] Fac Med Sect No, Lab Biomecan Appl, F-13916 Marseille 20, France; [Piercecchi-Marti, Marie-Dominique; Adalian, Pascal; Leonetti, Georges] CHU Timone Fac Med, Serv Med Legale & Droit Sante, F-13385 Marseille 5, France; [Hamel, Anissa; Piercecchi-Marti, Marie-Dominique; Adalian, Pascal; Leonetti, Georges] Fac Med Sect No, Lab Anthropol, UMR 6578, F-13385 Marseille 5, France	Thollon, L (corresponding author), Fac Med Sect No, Lab Biomecan Appl, Blvd Pierre Dramard, F-13916 Marseille 20, France.	lionel.thollon@ifsttar.fr	ADALIAN, Pascal/F-4126-2010	ADALIAN, Pascal/0000-0002-5101-9508			BANDAK FA, 1995, J NEUROTRAUM, V12, P679, DOI 10.1089/neu.1995.12.679; Baumgartner D, 2005, SOLID MECH APPL, V124, P195; Behr M., 2003, Computer Methods in Biomechanics and Biomedical Engineering, V6, P263, DOI 10.1080/10255840310001606080; Bertocci GE, 2004, INJURY, V35, P417, DOI 10.1016/S0020-1383(03)00062-7; Chalmers D J, 1996, Inj Prev, V2, P98, DOI 10.1136/ip.2.2.98; Cory CZ, 2001, FORENSIC SCI INT, V123, P89, DOI 10.1016/S0379-0738(01)00523-0; Doorly M. C., 2006, Computer Methods in Biomechanics and Biomedical Engineering, V9, P371, DOI 10.1080/10255840601003551; Doorly MC, 2009, INT J CRASHWORTHINES, V14, P503, DOI 10.1080/13588260902826554; Glasson E, 2000, IMECHE CONF TRANS, V2000, P79; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Kang HS, 1997, P 41 STAPP CAR CRASH, P329; Laforest S, 2001, Inj Prev, V7, P35, DOI 10.1136/ip.7.1.35; Macarthur C, 2000, ACCIDENT ANAL PREV, V32, P377, DOI 10.1016/S0001-4575(99)00079-2; Motherway J, 2009, Leg Med (Tokyo), V11 Suppl 1, pS220, DOI 10.1016/j.legalmed.2009.01.072; North JB, 1991, P INT RES COUNC BIOK, P77; O'Riordain K, 2003, CLIN BIOMECH, V18, P590, DOI 10.1016/S0268-0033(03)00111-6; Ramet M, 1983, P PED IMP INJ ASS DE, P225; Raul JS, 2008, INT J LEGAL MED, V122, P359, DOI 10.1007/s00414-008-0248-0; Raul JS, 2006, INT J LEGAL MED, V120, P212, DOI 10.1007/s00414-005-0018-1; Ruan J, 2001, Stapp Car Crash J, V45, P395; Rueda MAF, 2009, FORENSIC SCI INT, V191, P52, DOI 10.1016/j.forsciint.2009.06.007; Turquier F, 1996, P 40 STAPP CAR CRASH, P1912; Voo L, 1996, MED BIOL ENG COMPUT, V34, P375, DOI 10.1007/BF02520009; Willinger R, 2003, INT J CRASHWORTHINES, V8, P605, DOI 10.1533/cras.8.6.605.19261; WILLINGER R, 1995, J NEUROTRAUM, V12, P743, DOI 10.1089/neu.1995.12.743; Willinger R, 1999, ANN BIOMED ENG, V27, P403, DOI 10.1114/1.165; Yang JK., 2000, J CRASH PREV INJ CON, V2, P131, DOI DOI 10.1080/10286580008902559; YOGANANDAN N, 1995, J NEUROTRAUM, V12, P659, DOI 10.1089/neu.1995.12.659; Yoganandan N, 2004, CLIN BIOMECH, V19, P225, DOI 10.1016/j.clinbiomech.2003.12.014	30	24	26	2	31	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0937-9827	1437-1596		INT J LEGAL MED	Int. J. Legal Med.	JAN	2013	127	1					111	118		10.1007/s00414-011-0627-9			8	Medicine, Legal	Legal Medicine	065QR	WOS:000313164100016	21984166				2021-06-18	
J	Huang, YH; Lee, TC; Yang, KY; Liao, CC				Huang, Yu-Hua; Lee, Tao-Chen; Yang, Ka-Yen; Liao, Chen-Chieh			Is timing of cranioplasty following posttraumatic craniectomy related to neurological outcome?	INTERNATIONAL JOURNAL OF SURGERY			English	Article						Cranioplasty; Decompressive craniectomy; Timing; Outcomes; Complications	TRAUMATIC BRAIN-INJURY; DECOMPRESSIVE CRANIECTOMY; SITE INFECTIONS; RECOVERY; MULTICENTER; EFFICACY; SURGERY; AGE	Background: With the use of decompressive craniectomy for traumatic brain injury (TBI) come a corresponding number of cranioplasties. TBI causes dynamic processes to commence or change during the period from injury to recovery; hence, the role of the timing of surgical intervention should be emphasized. Aims: We attempt to identify the relationship between the timing of cranioplasty and neurological outcomes following posttraumatic craniectomy. Methods: In this 3-year retrospective study, 105 patients undergoing decompressive craniectomies and subsequent cranioplasties for TBI were enrolled. We documented the patients' demographic information, including Glasgow Coma Scale (GCS) at admission for trauma. The follow-up period was terminated by death or a minimum of 6 months after TBI. Glasgow Outcome Scale (GOS) at the end of follow-up was used as an outcome measure. Unfavorable outcome was defined as a GOS score of 1-3. Results: The 105 patients included 71 male and 34 female subjects. The mean age was 41.94 +/- 19.73 years. Neurological assessment showed that admission GCS was 8.50 +/- 3.15, on average. The mean time interval between cranioplasty and craniectomy was 78.84 +/- 49.04 days (range, 13-245 days). Univariate logistic regression analysis showed that the association between the timing of cranioplasty and unfavorable outcomes was not statistically significant (odds ratio = 1.005, confidence interval 0.997-1.013; p = 0.195). Conclusion: The timing of cranioplasty following posttraumatic craniectomy was not related to the neurological outcomes of TBI. Despite the limitations of the retrospective design, the analyses provide preliminary information to elucidate the question. (C) 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.	[Huang, Yu-Hua; Lee, Tao-Chen; Yang, Ka-Yen; Liao, Chen-Chieh] Kaohsiung Chang Gung Mem Hosp, Dept Neurosurg, Kaohsiung, Taiwan; [Huang, Yu-Hua; Lee, Tao-Chen; Yang, Ka-Yen; Liao, Chen-Chieh] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan; [Huang, Yu-Hua] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung, Taiwan	Huang, YH (corresponding author), Kaohsiung Chang Gung Mem Hosp, Dept Neurosurg, 123 Ta Pei Rd, Kaohsiung, Taiwan.	newlupin2001@yahoo.com.tw					Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Cheng YK, 2008, J CLIN NEUROSCI, V15, P1115, DOI 10.1016/j.jocn.2007.09.022; Chun HJ, 2011, J CRANIOFAC SURG, V22, P203, DOI 10.1097/SCS.0b013e3181f753bd; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Ho KM, 2011, CRIT CARE MED, V39, P2495, DOI 10.1097/CCM.0b013e318225764e; HORAN TC, 1992, INFECT CONT HOSP EP, V13, P606; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Korinek AM, 1997, NEUROSURGERY, V41, P1073, DOI 10.1097/00006123-199711000-00010; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Pompucci A, 2007, J NEUROTRAUM, V24, P1182, DOI 10.1089/neu.2006.0244; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Sancisi E, 2009, BRAIN INJURY, V23, P163, DOI 10.1080/02699050802660446; SEGAL DH, 1994, NEUROSURGERY, V34, P729, DOI 10.1227/00006123-199404000-00024; Sobani Zain A, 2011, Surg Neurol Int, V2, P123, DOI 10.4103/2152-7806.85055; Stelling H, 2011, BRIT J NEUROSURG, V25, P407, DOI 10.3109/02688697.2011.566385; Stiver SI, 2008, J NEUROSURG, V109, P245, DOI 10.3171/JNS/2008/109/8/0245; Tahir MZ, 2013, BRIT J NEUROSURG; Tokutomi T, 2008, J NEUROTRAUM, V25, P1407, DOI 10.1089/neu.2008.0577; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470	25	24	29	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1743-9191	1743-9159		INT J SURG	Int. J. Surg.		2013	11	9					886	890		10.1016/j.ijsu.2013.07.013			5	Surgery	Surgery	252AS	WOS:000326977200029	23933129	Bronze			2021-06-18	
J	Stroupe, KT; Smith, BM; Hogan, TP; Andre, JRS; Pape, T; Steiner, ML; Proescher, E; Huo, ZP; Evans, CT				Stroupe, Kevin T.; Smith, Bridget M.; Hogan, Timothy P.; Andre, Justin R. St.; Pape, Theresa; Steiner, Monica L.; Proescher, Eric; Huo, Zhiping; Evans, Charlesnika T.			Healthcare utilization and costs of Veterans screened and assessed for traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						cost analysis; Department of Veterans Affairs; evaluation; head injury; healthcare costs; healthcare utilization; Operation Enduring Freedom; Operation Iraqi Freedom; traumatic brain injury; Veterans	POSTTRAUMATIC-STRESS-DISORDER; SERVICE MEMBERS; US VETERANS; AFGHANISTAN; IRAQ; PAIN; POLYTRAUMA; DIAGNOSES; NETWORKS; TAXONOMY	Approximately 15% of casualties in the Afghanistan (Operation Enduring Freedom [OEF]) and Iraq (Operation Iraqi Freedom [OIF]) conflicts received mild traumatic brain injury (TBI). To identify Veterans who may benefit from treatment, the Department of Veterans Affairs (VA) implemented a national clinical reminder in 2007 to screen for TBI. Veterans who screen positive are referred for a comprehensive TBI evaluation. We conducted a national retrospective study of OIF/OEF Veterans receiving care at VA facilities between 2007 and 2008. We examined the association of the TBI screen with healthcare costs over a 12 mo period following the initial evaluation. Of the Veterans, 164,438 met inclusion criteria: 31,627 screened positive, 118,545 screened negative, and 14,266 received no TBI screening. Total healthcare costs of Veterans who screened positive, screened negative, or had no TBI screening were $9,610, $5,184, and $3,399, respectively (p < 0.001). Understanding these healthcare utilization and cost patterns will assist policy-makers to address the ongoing and future healthcare needs of these returning Veterans.	[Stroupe, Kevin T.; Smith, Bridget M.; Pape, Theresa; Huo, Zhiping; Evans, Charlesnika T.] Edward Hines Jr Dept Vet Affairs VA Hosp, Ctr Management Complex Chron Care, Hines, IL USA; [Stroupe, Kevin T.] Loyola Univ Chicago, Stritch Sch Med, Program Hlth Serv Res, Maywood, IL USA; [Smith, Bridget M.; Evans, Charlesnika T.] Edward Hines Jr VA Hosp, Spinal Cord Injury Qual Enhancement Res Initiat Q, Hines, IL USA; [Hogan, Timothy P.] Edith Nourse Rogers Mem Vet Hosp, Natl eHealth QUERI Coordinating Ctr, Ctr Hlth Qual Outcomes & Econ Res & eHealth QUERI, Bedford, MA USA; [Hogan, Timothy P.] Univ Massachusetts, Sch Med, Div Hlth Informat & Implementat Sci, Worcester, MA USA; [Andre, Justin R. St.] Hlth Res & Educ Trust, Chicago, IL USA; [Pape, Theresa; Steiner, Monica L.] Edward Hines Jr VA Hosp, Hines, IL USA; [Pape, Theresa] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Proescher, Eric] Jesse Brown VA Med Ctr, Chicago, IL USA; [Evans, Charlesnika T.] Northwestern Univ, Feinberg Sch Med, Ctr Healthcare Studies, Chicago, IL 60611 USA	Stroupe, KT (corresponding author), Edward Hines Jr VA Hosp, Ctr Management Complex Chron Care, 5000 South 5th Ave,151H,Bldg 1B260, Hines, IL 60141 USA.	kevin.stroupe@va.gov		Bender Pape, Theresa/0000-0001-7738-5963	VA Office of Research and Development, Health Services Research and Development ServiceUS Department of Veterans Affairs	This material was based on work supported by the VA Office of Research and Development, Health Services Research and Development Service.	Andersen J, 2010, PSYCHOSOM MED, V72, P498, DOI 10.1097/PSY.0b013e3181d969a1; [Anonymous], 2013, CAR FAC; Barber Julie, 2004, J Health Serv Res Policy, V9, P197, DOI 10.1258/1355819042250249; Bass E., 2012, VETERANS HLTH ADM TR; Bazzoli GJ, 1999, HEALTH SERV RES, V33, P1683; Carlson K, 2009, ASSESSMENT TREATMENT; Dubbs NL, 2004, HEALTH SERV RES, V39, P207, DOI 10.1111/j.1475-6773.2004.00222.x; Dunn AS, 2011, J REHABIL RES DEV, V48, P493, DOI 10.1682/JRRD.2010.05.0104; Frayne SM, 2011, J GEN INTERN MED, V26, P33, DOI 10.1007/s11606-010-1497-4; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; Goldberg M. S., 2007, PROJECTING COSTS CAR; Hagedorn HJ, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-46; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Homaifar BY, 2009, J REHABIL RES DEV, V46, P1003, DOI 10.1682/JRRD.2008.12.0166; Iverson KM, 2011, WOMEN HEALTH ISS, V21, pS210, DOI 10.1016/j.whi.2011.04.019; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Manning WG, 2001, J HEALTH ECON, V20, P461, DOI 10.1016/S0167-6296(01)00086-8; McCullagh P., 1989, GEN LINEAR MODELS; Otis JD, 2011, J CLIN PSYCHOL MED S, V18, P145, DOI 10.1007/s10880-011-9239-2; Phibbs C, 2008, RES GUIDE DECISION S; Ruff RL, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000312; Sayer NA, 2009, PM&R, V1, P23, DOI 10.1016/j.pmrj.2008.10.003; Scholten JD, 2012, BRAIN INJURY, V26, P1177, DOI 10.3109/02699052.2012.661914; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Smith M.W., 2010, FEE BASIS DATA GUIDE; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; [VA Information Resource Center (VIReC). US Department of Veterans Affairs Health Services Research and Development Service.], 2008, VIREC RES US GUID VH; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; *VIREC, 2003, VIREC RES US GUID FY; Wilk JE, 2010, DRUG ALCOHOL DEPEN, V108, P115, DOI 10.1016/j.drugalcdep.2009.12.003	32	24	24	0	3	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2013	50	8					1047	1068		10.1682/JRRD.2012.06.0107			22	Rehabilitation	Rehabilitation	270GX	WOS:000328308000005	24458891	Bronze			2021-06-18	
J	Wang, T; Van, KC; Gavitt, BJ; Grayson, JK; Lu, YC; Lyeth, BG; Pichakron, KO				Wang, Tao; Van, Ken C.; Gavitt, Brian J.; Grayson, J. Kevin; Lu, Yi-Cheng; Lyeth, Bruce G.; Pichakron, Kullada O.			Effect of fish oil supplementation in a rat model of multiple mild traumatic brain injuries	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						Mild traumatic brain injury; omega-3 fatty acids; dietary supplementation; hippocampus; morris water maze	POLYUNSATURATED FATTY-ACIDS; FLUID-PERCUSSION MODEL; DIETARY SUPPLEMENTATION; DOCOSAHEXAENOIC ACID; HEAD TRAUMA; US SOLDIERS; HIPPOCAMPUS; IMPAIRMENT; CONCUSSION; COGNITION	Purpose: Repetitive mild traumatic brain injury (TBI) is a major military and sports health concern. The purpose of this study was to determine if a diet rich in omega-3 fatty acids would reduce cognitive deficits and neuronal cell death in a novel fluid percussion rat model of repetitive mild TBIs. Methods: Thirty-two Sprague-Dawley rats were assigned to either an experimental rat chow enhanced with 6% fish oil (source of omega-3 fatty acids) or a control rat chow. Both rat chows contained equivalent quantities of calories, oil, and nutrients. After four weeks, both groups received mild repetitive bilateral fluid percussion TBIs on two sequential days. Pre-injury diets were resumed, and the animals were monitored for two weeks. On post-injury days 10-14, Morris Water Maze testing was performed to assess spatial learning and cognitive function. Animals were euthanized at 14 days post-injury to obtain specimens for neurohistopathology. Results: There was no difference in pre-injury weight gain between groups. Post-injury, animals on the fish oil diet lost less weight and recovered their weight significantly faster. By 14 days, the fish oil diet group performed significantly better in the Morris Water Maze. Neurohistopathology identified a non-significant trend toward a higher density of hippocampal neurons in the fish oil diet group. Conclusions: Pre-injury dietary supplementation with fish oil improves recovery of body weight and provides a small improvement in cognitive performance in a rat model of multiple mild TBIs.	[Wang, Tao] 306th Hosp PLA, Dept Neurosurg, Beijing, Peoples R China; [Wang, Tao; Van, Ken C.; Lyeth, Bruce G.] Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA; [Gavitt, Brian J.; Pichakron, Kullada O.] David Grant Med Ctr, Dept Surg, Travis AFB, CA USA; [Gavitt, Brian J.; Pichakron, Kullada O.] Univ Calif Davis, Dept Surg, Sacramento, CA 95817 USA; [Gavitt, Brian J.; Grayson, J. Kevin; Pichakron, Kullada O.] David Grant Med Ctr, Clin Invest Facil, Travis AFB, CA USA; [Lu, Yi-Cheng] Second Mil Med Univ, Changzheng Hosp, Dept Neurosurg, Shanghai, Peoples R China	Pichakron, KO (corresponding author), USAF, MC, Dept Surg, David Grant USAF Med Ctr,Lieutenant Colonel, 60 MSGS SGCQ,101 Bodin Circle, Travis Air Force Base, CA 94535 USA.	kullada.pichakron@us.af.mil		Lyeth, Bruce/0000-0003-4811-1474	Henry M. Jackson Foundation [050611]	This research was supported by a grant from the Henry M. Jackson Foundation (050611).	Babcock TA, 2002, J SURG RES, V107, P135, DOI 10.1006/jsre.2002.6498; Bhatia HS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028451; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Doughman SD, 2007, CURR DIABETES REV, V3, P198, DOI 10.2174/157339907781368968; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fedorova I, 2006, PROSTAG LEUKOTR ESS, V75, P271, DOI 10.1016/j.plefa.2006.07.006; Feng J. F., 2011, BRAIN RES; Fontani G, 2005, EUR J CLIN INVEST, V35, P691, DOI 10.1111/j.1365-2362.2005.01570.x; Gomez-Pinilla F, 2008, NAT REV NEUROSCI, V9, P568, DOI 10.1038/nrn2421; Grossman Elan J, 2010, Top Magn Reson Imaging, V21, P379, DOI 10.1097/RMR.0b013e31823e65b8; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jacka FN, 2011, PSYCHOSOM MED, V73, P483, DOI 10.1097/PSY.0b013e318222831a; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lauritzen I, 2000, EMBO J, V19, P1784, DOI 10.1093/emboj/19.8.1784; Li HB, 1999, BRAIN RES BULL, V48, P113, DOI 10.1016/S0361-9230(98)00157-9; Lonergan PE, 2004, J NEUROCHEM, V91, P20, DOI 10.1111/j.1471-4159.2004.02689.x; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mills JD, 2011, J NEUROSURG, V114, P77, DOI 10.3171/2010.5.JNS08914; Mills JD, 2011, NEUROSURGERY, V68, P474, DOI 10.1227/NEU.0b013e3181ff692b; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Shahrokhi N, 2012, PAK J PHARM SCI, V25, P219; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wang X, 2003, NEUROREPORT, V14, P2457, DOI 10.1097/00001756-200312190-00033; Weber J. T., 2007, PROG BRAIN RES; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wu A, 2008, NEUROSCIENCE, V155, P751, DOI 10.1016/j.neuroscience.2008.05.061; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu AG, 2011, J NEUROTRAUM, V28, P2113, DOI 10.1089/neu.2011.1872; Yaman M, 2007, ARCH MED RES, V38, P489, DOI 10.1016/j.arcmed.2007.01.008; Yang CC, 2009, BRAIN INJURY, V23, P299, DOI 10.1080/02699050902788543; Yehuda S, 2002, NEUROBIOL AGING, V23, P843, DOI 10.1016/S0197-4580(02)00074-X; Yimit D, 2012, NUTRITION, V28, P154, DOI 10.1016/j.nut.2011.05.008; Zlotnik A, 2012, INTENS CARE MED, V38, P137, DOI 10.1007/s00134-011-2401-3	42	24	24	1	13	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2013	31	5					647	659		10.3233/RNN-130316			13	Neurosciences	Neurosciences & Neurology	216DQ	WOS:000324262100010	23835930				2021-06-18	
J	Zonfrillo, MR; Durbin, DR; Winston, FK; Zhao, HQ; Stineman, MG				Zonfrillo, Mark R.; Durbin, Dennis R.; Winston, Flaura K.; Zhao, Huaqing; Stineman, Margaret G.			Physical Disability After Injury-Related Inpatient Rehabilitation in Children	PEDIATRICS			English	Article						disability; injury; rehabilitation; trauma; functional outcomes	TRAUMATIC BRAIN-INJURY; UNIFORM DATA SYSTEM; QUALITY-OF-LIFE; FUNCTIONAL OUTCOMES; INDEPENDENCE; ADOLESCENTS; ASSOCIATION; MECHANISM; PROGRAMS; IMPACT	OBJECTIVE: To determine the residual physical disability after inpatient rehabilitation for children 7 to 18 years old with traumatic injuries. METHODS: This was a retrospective cohort study of patients aged 7 to 18 years who underwent inpatient rehabilitation for traumatic injuries from 2002 to 2011. Patients were identified from the Uniform Data System for Medical Rehabilitation. Injuries were captured by using standardized Medicare Inpatient Rehabilitation Facility Patient Assessment Instrument codes. Functional outcome was measured with the Functional Independence Measure (FIM) instrument. A validated, categorical grading system of the FIM motor items was used, consisting of clinically relevant levels of physical achievement from grade 1 (need for total assistance) to grade 7 (completely independent for self-care and mobility). RESULTS: A total of 13 798 injured children underwent inpatient rehabilitation across 523 facilities during the 10-year period. After a mean 3-week length of stay, functional limitations were reduced, but children still tended to have residual physical disabilities (median admission grade: 1; median discharge grade: 4). Children with spinal cord injuries, either alone or in combination with other injuries, had lower functional grade at discharge, longer lengths of stay, and more comorbidities at discharge than those with traumatic brain injuries, burns, and multiple injuries (P < .0001 for all comparisons). CONCLUSIONS: Children had very severe physical disability on admission to inpatient rehabilitation for traumatic injuries, and those with spinal cord injuries had persistent disability at discharge. These traumatic events during critical stages of development may result in a substantial care burden over the child's lifespan. Pediatrics 2013;131:e206-e213	[Zonfrillo, Mark R.] Childrens Hosp Philadelphia, Div Emergency Med, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Biostat & Data Management Core, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.; Durbin, Dennis R.; Winston, Flaura K.] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.; Durbin, Dennis R.; Zhao, Huaqing; Stineman, Margaret G.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Stineman, Margaret G.] Univ Penn, Dept Phys Med & Rehabil, Perelman Sch Med, Philadelphia, PA 19104 USA; [Winston, Flaura K.; Stineman, Margaret G.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA	Zonfrillo, MR (corresponding author), Childrens Hosp Philadelphia, Div Emergency Med, Ctr Injury Res & Prevent, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	zonfrillo@email.chop.edu	Zonfrillo, Mark R./H-9403-2017	Zonfrillo, Mark R./0000-0002-0610-9563	Academic Pediatric Association Young Investigators Award; University of Pennsylvania; National Science Foundation Center for Child Injury Prevention Studies at The Children's Hospital of Philadelphia; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD073241] Funding Source: NIH RePORTER	Supported by the Academic Pediatric Association Young Investigators Award, the Thomas B. and Jeannette E. Laws McCabe Pilot Fund Award at the University of Pennsylvania, and the National Science Foundation Center for Child Injury Prevention Studies at The Children's Hospital of Philadelphia.	Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Aitken ME, 1999, ARCH PHYS MED REHAB, V80, P889, DOI 10.1016/S0003-9993(99)90079-5; Alexander MS, 2009, SPINAL CORD, V47, P582, DOI 10.1038/sc.2009.18; Allen DD, 2009, SPINAL CORD, V47, P213, DOI 10.1038/sc.2008.94; Anderson CJ, 2009, DEV MED CHILD NEUROL, V51, P826, DOI 10.1111/j.1469-8749.2009.03268.x; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Barnett SD, 2012, J REHABIL RES DEV, V49, P175, DOI 10.1682/JRRD.2010.12.0242; Blume HK, 2012, PEDIATRICS, V129, pE31, DOI 10.1542/peds.2011-1742; Burd RS, 2007, J TRAUMA, V62, P1004, DOI 10.1097/01.ta.0000221555.01704.c9; Burd RS, 2009, ACAD EMERG MED, V16, P639, DOI 10.1111/j.1553-2712.2009.00446.x; Centers for Disease Control and Prevention, 10 LEAD CAUS DEATH I; Centers for Medicare & Medicaid Services, INP REH FAC IRF PAT; Chevignard M, 2010, CHILD CARE HLTH DEV, V36, P31, DOI 10.1111/j.1365-2214.2009.00949.x; Dasarathi M, 2011, CHILD CARE HLTH DEV, V37, P418, DOI 10.1111/j.1365-2214.2010.01199.x; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; Dumas HM, 2008, INT J REHABIL RES, V31, P257, DOI 10.1097/MRR.0b013e3282fb7d03; Forsyth RJ, 2010, ARCH DIS CHILD, V95, P554, DOI 10.1136/adc.2009.161083; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Garma SI, 2011, J PEDIATR PSYCHOL, V36, P226, DOI 10.1093/jpepsy/jsq037; Granger CV, 2012, AM J PHYS MED REHAB, V91, P289, DOI 10.1097/PHM.0b013e31824ad2fd; Granger CV, 2010, AM J PHYS MED REHAB, V89, P265, DOI 10.1097/PHM.0b013e3181d3eb20; Groeschel S, 2010, INT J DEV NEUROSCI, V28, P481, DOI 10.1016/j.ijdevneu.2010.06.004; Haider AH, 2007, J TRAUMA, V62, P1259, DOI 10.1097/TA.0b013e31803c760e; Haider AH, 2011, J PEDIATR SURG, V46, P1557, DOI 10.1016/j.jpedsurg.2011.04.055; Hakmeh W, 2010, ACAD EMERG MED, V17, P809, DOI 10.1111/j.1553-2712.2010.00819.x; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Jaffe KM, 2008, J TRAUMA, V64, P819, DOI 10.1097/TA.0b013e318165f177; Jette DU, 2005, ARCH PHYS MED REHAB, V86, P373, DOI 10.1016/j.apmr.2004.10.018; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kokoska ER, 2001, J PEDIATR SURG, V36, P100, DOI 10.1053/jpsu.2001.20022; Long C E, 2005, Pediatr Rehabil, V8, P156; Majnemer A, 2009, PHYS OCCUP THER PEDI, V29, P219, DOI 10.1080/01942630903032392; Massagli T L, 2000, Phys Med Rehabil Clin N Am, V11, P169; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; Miller AC, 2012, J NEUROTRAUM, V29, P634, DOI 10.1089/neu.2011.1932; Niewczyk PM, 2010, PEDIATR PHYS THER, V22, P42, DOI 10.1097/PEP.0b013e3181cd17e8; Rice SA, 2005, ARCH PHYS MED REHAB, V86, P834, DOI 10.1016/j.apmr.2004.11.006; Rivara FP, 2012, ARCH PHYS MED REHAB, V93, P381, DOI 10.1016/j.apmr.2011.08.015; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; Stallion A, 2007, J TRAUMA, V62, P1262; Stineman MG, 2009, ARCH SURG-CHICAGO, V144, P543, DOI 10.1001/archsurg.2009.37; Stineman MG, 2003, ARCH PHYS MED REHAB, V84, P1647, DOI 10.1053/S0003-9993(03)00317-4; Tepas Joseph J 3rd, 2004, Semin Pediatr Surg, V13, P126, DOI 10.1053/j.sempedsurg.2004.01.009; Tham SW, 2012, J NEUROTRAUM, V29, P154, DOI 10.1089/neu.2011.2126; Upperman JS, 2010, J TRAUMA, V69, P1304, DOI 10.1097/TA.0b013e3181fa4858; Vogel LC, 2003, J SPINAL CORD MED, V26, P193, DOI 10.1080/10790268.2003.11753682; Wechsler B, 2005, J TRAUMA, V58, P940, DOI 10.1097/01.TA.0000162630.78386.98; Willis CD, 2006, INJURY, V37, P1185, DOI 10.1016/j.injury.2006.07.011; Winthrop AL, 2010, CURR OPIN PEDIATR, V22, P346, DOI 10.1097/MOP.0b013e3283394351; Zatzick DF, 2008, ARCH PEDIAT ADOL MED, V162, P642, DOI 10.1001/archpedi.162.7.642; Zatzick DF, 2011, PSYCHIAT SERV, V62, P264, DOI 10.1176/ps.62.3.pss6203_0264; Zidek Kathryn, 2003, Semin Pediatr Neurol, V10, P140, DOI 10.1016/S1071-9091(03)00022-6	53	24	24	0	15	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JAN	2013	131	1					E206	E213		10.1542/peds.2012-1418			8	Pediatrics	Pediatrics	063PO	WOS:000313012400025	23248228	Green Published			2021-06-18	
J	Waid-Ebbs, JK; Wen, PS; Heaton, SC; Donovan, NJ; Velozo, C				Waid-Ebbs, J. Kay; Wen, Pey-Shan; Heaton, Shelley C.; Donovan, Neila J.; Velozo, Craig			The item level psychometrics of the behaviour rating inventory of executive function-adult (BRIEF-A) in a TBI sample	BRAIN INJURY			English	Article						Measurement; Rasch analysis; traumatic brain injury; executive function; BRIEF-A	TRAUMATIC BRAIN-INJURY; CONFIRMATORY FACTOR-ANALYSIS; SELF-REPORT; DYSEXECUTIVE SYMPTOMS; ECOLOGICAL VALIDITY; COMMUNITY SAMPLE; SCALE FRSBE; OUTCOMES; REHABILITATION; CHILDREN	Primary objective: To determine whether the psychometrics of the BRIEF-A are adequate for individuals diagnosed with TBI. Research design: A prospective observational study in which the BRIEF-A was collected as part of a larger study. Methods and procedures: Informant ratings of the 75-item BRIEF-A on 89 individuals diagnosed with TBI were examined to determine items level psychometrics for each of the two BRIEF-A indexes: Behaviour Rating Index (BRI) and Metacognitive Index (MI). Patients were either outpatients or at least 1 year post-injury. Main outcomes and results: Each index measured a latent trait, separating individuals into five-to-six ability levels and demonstrated good reliability (0.94 and 0.96). Four items were identified that did not meet the infit criteria. Conclusions: The results provide support for the use of the BRIEF-A as a supplemental assessment of executive function in TBI populations. However, further validation is needed with other measures of executive function. Recommendations include use of the index scores over the Global Executive Composite score and use of the difficulty hierarchy for setting therapy goals.	[Waid-Ebbs, J. Kay; Velozo, Craig] N Florida S Georgia Vet Hlth Syst, Brain Rehabil Res Ctr Excellence, Gainesville, FL USA; [Wen, Pey-Shan] Univ Florida, Dept Hlth Outcomes & Policy, Gainesville, FL USA; [Heaton, Shelley C.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA; [Donovan, Neila J.] Louisiana State Univ, Dept Commun Sci & Disorders, Baton Rouge, LA 70803 USA; [Velozo, Craig] N Florida S Georgia Vet Hlth Syst, Rehabil Outcome Res Ctr, Res Enhancement Award Program, Gainesville, FL USA; [Velozo, Craig] Univ Florida, Occupat Therapy Dept, Gainesville, FL USA	Waid-Ebbs, JK (corresponding author), 2314 SW 95th Terrace, Gainesville, FL 32607 USA.	julia.waid-ebbs@va.gov		Wen, Pey-Shan/0000-0002-8921-8801	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21HD045869-03]; VA RR&D Pre-Doctoral Fellowship Award; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development ServiceUS Department of Veterans Affairs; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD045869] Funding Source: NIH RePORTER	This study was conducted using existing data from an NIH funded study entitled 'Developing a Computer Adaptive TBI Cognitive Measure' (NIH R-21: #5R21HD045869-03) and from a VA RR&D Pre-Doctoral Fellowship Award. The study was approved by the Institutional Review Board of the University of Florida and the Research and Development Committee at the North Florida/South Georgia VA Medical Center.; This material is based on work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service. The contents do not represent the views of the Department of Veterans Affairs or the United States Government.	Amieva H, 2003, BRAIN COGNITION, V53, P129, DOI 10.1016/S0278-2626(03)00094-0; ARRINDELL WA, 1985, APPL PSYCH MEAS, V9, P165, DOI 10.1177/014662168500900205; Barrett P.T., 1981, PERSONAL STUDY GROUP, V1, P23; Bond T.G., 2001, APPL RASCH MODEL FUN; Brown T.A, 2006, CONFIRMATORY FACTOR, V3rd; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW., 2005, EFFECTIVENESS REHABI; Chan RCK, 2008, ARCH CLIN NEUROPSYCH, V23, P201, DOI 10.1016/j.acn.2007.08.010; Chan RCK, 2001, BRIT J PSYCHOL, V92, P551, DOI 10.1348/000712601162338; Chaytor N, 2006, ARCH CLIN NEUROPSYCH, V21, P217, DOI 10.1016/j.acn.2005.12.002; Crocker L., 1986, INTRO CLASSICAL MODE; Cummings JL, 2007, HUMAN FRONTAL LOBES; Donders J, 2010, J NEUROPSYCHOL, V4, P197, DOI 10.1348/174866409X478970; Donovan NJ, 2011, BRAIN INJURY, V25, P348, DOI 10.3109/02699052.2011.556105; Egeland J, 2010, CHILD NEUROPSYCHOL, V16, P326, DOI 10.1080/09297041003601462; Fuster JM, 2000, EXP BRAIN RES, V133, P66, DOI 10.1007/s002210000401; Garlinghouse MA, 2010, SCHIZOPHR RES, V120, P71, DOI 10.1016/j.schres.2010.02.1067; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P249, DOI 10.1076/chin.8.4.249.13513; GRAHAM DI, 1999, REHABILITATION ADULT, P19; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jette AM, 2005, J REHABIL MED, V37, P339, DOI 10.1080/16501970500302793; Johnston MV, 2006, BRAIN INJURY, V20, P391, DOI 10.1080/02699050500487795; JOHNSTON MV, 1992, ARCH PHYS MED REHAB, V73, pS3; Lane-Brown AT, 2009, BRAIN INJURY, V23, P999, DOI 10.3109/02699050903379347; LeJeune B, 2010, CHILD NEUROPSYCHOL, V16, P182, DOI 10.1080/09297040903352556; Levin B, 2008, COGNITIVE NEUROREHAB; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Linacre J.M., 1994, RASCH MEASUREMENT T, V7, P328; Linacre J.M., 2002, RASCH MEASUREMENT T, V16, P878; Linacre John M, 2002, J Appl Meas, V3, P85; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; MARSH HW, 1988, PSYCHOL BULL, V103, P391, DOI 10.1037/0033-2909.103.3.391; Massof Robert W, 2010, J Appl Meas, V11, P253; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McMahon Brian T, 2005, Work, V25, P67; Muthen B, 2006, MPLUS USERS GUIDE; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Rabin LA, 2006, ARCH CLIN NEUROPSYCH, V21, P721, DOI 10.1016/j.acn.2006.08.004; Reid RC, 2010, INT J NEUROSCI, V120, P120, DOI 10.3109/00207450903165577; Reid-Arndt SA, 2007, BRAIN INJURY, V21, P1361, DOI 10.1080/02699050701785062; Roth R.M., 2005, BEHAV RATING INVENTO; Sbordone RJ, 2001, NEUROREHABILITATION, V16, P199; Slick DJ, 2006, CHILD NEUROPSYCHOL, V12, P181, DOI 10.1080/09297040600611320; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Spinella M, 2005, BIOL PSYCHOL, V70, P175, DOI 10.1016/j.biopsycho.2004.01.005; Stone MH., 1979, BEST TEST DESIGN; Stout JC, 2003, ASSESSMENT, V10, P79, DOI 10.1177/1073191102250339; Stuss D. T., 2002, PR FRONTAL LOBE FUNC, P392, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0025; TEASDALE G, 1974, LANCET, V2, P81; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Toglia J, 2010, BRAIN INJURY, V24, P664, DOI 10.3109/02699051003610474; Velozo CA, 2006, J OCCUP REHABIL, V16, P109, DOI 10.1007/s10926-005-9014-z; Velozo CA, 2011, J REHABIL RES DEV, V48, P1211, DOI 10.1682/JRRD.2010.10.0203; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wright B.D., 1982, RATING SCALE ANAL; Wright BD., 1994, RASCH MEASUREMENT T, V8, P370, DOI DOI 10.1177/01461672012710004	58	24	24	0	19	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	2012	26	13-14					1646	1657		10.3109/02699052.2012.700087			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	041RU	WOS:000311419700011	22876936				2021-06-18	
J	Koz, ST; Etem, EO; Baydas, G; Yuce, H; Ozercan, HI; Kuloglu, T; Koz, S; Etem, A; Demir, N				Koz, Sema Tulay; Etem, Ebru Onalan; Baydas, Gyasettin; Yuce, Huseyin; Ozercan, Halil Ibrahim; Kuloglu, Tuncay; Koz, Suleyman; Etem, Arzu; Demir, Nevgul			Effects of resveratrol on blood homocysteine level, on homocysteine induced oxidative stress, apoptosis and cognitive dysfunctions in rats	BRAIN RESEARCH			English	Article						Resveratrol; Homocysteine; Oxidative stress; Apoptosis; TUNEL; Cognitive function	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; RED WINE; IN-VITRO; ENDOTHELIAL FUNCTION; PLATELET ACTIVATION; CELL PROLIFERATION; ALZHEIMERS-DISEASE; CEREBRAL-ISCHEMIA; HYPERHOMOCYSTEINEMIA	We aimed to examine the protective effects of resveratrol against homocysteine induced oxidative stress, apoptosis and cognitive impairment. Rats were randomly divided into three groups. Control group received standard rat food; homocysteine group (I-Icy group) received daily methionine at a dose of 1 g/kg-body weight dissolved in drinking water for thirty days; third group (Hcy+Res group) received same amount of methionine plus 20 mg/kg/day resveratrol intraperitoneally for thirty days. Cognitive performances of the animals were tested by Morris water maze test. Then all animals were sacrificed to study lipid peroxidation (LPO), DNA fragmentation and p53 mRNA expression in the rat brain. The aortas of the sacrificed rats were processed for histopathological examination. Apoptosis in the aortas was assessed by TUNEL staining. Resveratrol significantly decreased serum levels of homocysteine, reversed Hcy induced LPO increase, decreased DNA fragmentation and p53 mRNA expression in the rat brains, and improved homocysteine induced impairment of long term spatial memory. Resveratrol could inhibit homocysteine induced apoptosis and histopathological deterioration in the rat aortic sections. In conclusion, resveratrol is effective in preventing homocysteine induced vascular and neural defects. In hyperhomocysteinemic rat model, our findings consequently warrant in future studies to reveal the true improvement mechanism of resveratrol. (C) 2012 Elsevier B.V. All rights reserved.	[Koz, Sema Tulay] Malatya State Hosp, Dept Lab, TR-44000 Malatya, Turkey; [Etem, Ebru Onalan; Yuce, Huseyin] Firat Univ, Fac Med, Dept Med Biol & Genet, TR-23119 Elazig, Turkey; [Baydas, Gyasettin] Bingol Univ, TR-12000 Bingol, Turkey; [Ozercan, Halil Ibrahim] Firat Univ, Fac Med, Dept Pathol, TR-23119 Elazig, Turkey; [Kuloglu, Tuncay] Firat Univ, Fac Med, Dept Histol & Embryol, TR-23119 Elazig, Turkey; [Koz, Suleyman] Inonu Univ, Turgut Ozal Med Ctr, Dept Nephrol, TR-44300 Malatya, Turkey; [Demir, Nevgul] Okmeydani Res Hosp, Dept Biochim, Istanbul, Turkey; Kecioren Res Hosp, Dept Family Med, TR-06380 Ankara, Turkey	Koz, ST (corresponding author), Malatya State Hosp, Dept Lab, TR-44000 Malatya, Turkey.	kozsema@hotmail.com	kuloglu, tuncay/W-2310-2018; onalan, ebru/C-6463-2016; BAYDAS, GIYASETTIN/AAI-4266-2021	onalan, ebru/0000-0001-9968-8201; Baydas, Giyasettin/0000-0002-9206-3177			Akar F, 2011, CARDIOVASC DRUG THER, V25, P119, DOI 10.1007/s10557-010-6255-7; Al-Obaidi MK, 2000, CIRCULATION, V101, P372, DOI 10.1161/01.CIR.101.4.372; Aman M, 2010, J VASC RES, V47, P494, DOI 10.1159/000313877; Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Bagi Z, 2003, AM J PHYSIOL-HEART C, V285, pH2277, DOI 10.1152/ajpheart.00448.2003; Baydas G, 2005, NEUROSCIENCE, V135, P879, DOI 10.1016/j.neuroscience.2005.05.048; Baydas G, 2005, BRAIN RES, V1046, P187, DOI 10.1016/j.brainres.2005.04.011; Baydas G, 2007, INT J DEV NEUROSCI, V25, P133, DOI 10.1016/j.ijdevneu.2007.03.001; Berrougui H, 2009, ATHEROSCLEROSIS, V207, P420, DOI 10.1016/j.atherosclerosis.2009.05.017; Binienda ZK, 2010, NEUROSCI LETT, V480, P117, DOI 10.1016/j.neulet.2010.06.020; Dasgupta B, 2007, P NATL ACAD SCI USA, V104, P7217, DOI 10.1073/pnas.0610068104; Dayal S, 2008, ARTERIOSCL THROM VAS, V28, P1596, DOI 10.1161/ATVBAHA.108.166421; Deng WG, 2004, WORLD J GASTROENTERO, V10, P46; Dong ZG, 2003, MUTAT RES-FUND MOL M, V523, P145, DOI 10.1016/S0027-5107(02)00330-5; Gatz SA, 2008, CARCINOGENESIS, V29, P321, DOI 10.1093/carcin/bgm276; Ghribi O, 2003, J NEUROSCI RES, V71, P853, DOI 10.1002/jnr.10511; Henning SM, 1997, FREE RADICAL BIO MED, V23, P936, DOI 10.1016/S0891-5849(97)00097-X; Hsieh TC, 1999, CANCER RES, V59, P2596; Hsieh TC, 2010, INT J MOL MED, V26, P741, DOI 10.3892/ijmm_00000521; Huang RFS, 2001, J NUTR, V131, P33; Janicke RU, 2008, CELL DEATH DIFFER, V15, P959, DOI 10.1038/cdd.2008.33; Kaneider NC, 2004, THROMB RES, V114, P185, DOI 10.1016/j.thromres.2004.06.020; Karuppagounder SS, 2009, NEUROCHEM INT, V54, P111, DOI 10.1016/j.neuint.2008.10.008; Khan MM, 2010, BRAIN RES, V1328, P139, DOI 10.1016/j.brainres.2010.02.031; Kim D, 2007, EMBO J, V26, P3169, DOI 10.1038/sj.emboj.7601758; Kim DH, 2011, AM J PHYSIOL-RENAL, V301, pF427, DOI 10.1152/ajprenal.00258.2010; Koz S.T., 2011, PHYTOTHER RES; Koz ST, 2010, INT J DEV NEUROSCI, V28, P325, DOI 10.1016/j.ijdevneu.2010.02.006; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; Kumar A, 2010, BIOCHEM BIOPH RES CO, V394, P360, DOI 10.1016/j.bbrc.2010.03.014; Lee SJ, 2005, J BIOL CHEM, V280, P5781, DOI 10.1074/jbc.M411224200; Lipton SA, 1997, P NATL ACAD SCI USA, V94, P5923, DOI 10.1073/pnas.94.11.5923; Lu KT, 2008, J AGR FOOD CHEM, V56, P6910, DOI 10.1021/jf8007212; Malinowska J, 2011, PLATELETS, V22, P277, DOI 10.3109/09537104.2010.550349; Martinez-Cruz F, 2006, NEUROSCI LETT, V392, P1, DOI 10.1016/j.neulet.2005.02.073; McCall MA, 1996, P NATL ACAD SCI USA, V93, P6361, DOI 10.1073/pnas.93.13.6361; Mokni M, 2007, NEUROCHEM RES, V32, P981, DOI 10.1007/s11064-006-9255-z; Mokni M, 2007, ARCH BIOCHEM BIOPHYS, V457, P1, DOI 10.1016/j.abb.2006.10.015; Moriya J, 2011, BIOL PHARM BULL, V34, P354, DOI 10.1248/bpb.34.354; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Murray-Zmijewski F, 2008, NAT REV MOL CELL BIO, V9, P702, DOI 10.1038/nrm2451; Nicholson SK, 2010, BRIT J NUTR, V103, P1398, DOI 10.1017/S0007114509993485; Noll C, 2009, FOOD CHEM TOXICOL, V47, P230, DOI 10.1016/j.fct.2008.11.005; Okawara M, 2007, BIOCHEM PHARMACOL, V73, P550, DOI 10.1016/j.bcp.2006.11.003; Poussier B, 2005, J VASC SURG, V42, P1190, DOI 10.1016/j.jvs.2005.08.014; Ranney A, 2009, BEHAV PHARMACOL, V20, P330, DOI 10.1097/FBP.0b013e32832f0193; Ridker P.M., 2011, BONOW BRAUNWALDS HEA, P927; Rivera L, 2009, BIOCHEM PHARMACOL, V77, P1053, DOI 10.1016/j.bcp.2008.11.027; Robb EL, 2008, BIOCHEM BIOPH RES CO, V372, P254, DOI 10.1016/j.bbrc.2008.05.028; Ruef J, 2001, CARDIOVASC PATHOL, V10, P311, DOI 10.1016/S1054-8807(01)00095-3; Sakata Y, 2010, EXP NEUROL, V224, P325, DOI 10.1016/j.expneurol.2010.03.032; Schmatz R, 2009, EUR J PHARMACOL, V610, P42, DOI 10.1016/j.ejphar.2009.03.032; Schroecksnadel K, 2005, CLIN CHEM LAB MED, V43, P1084, DOI 10.1515/CCLM.2005.189; Shen MY, 2007, BRIT J HAEMATOL, V139, P475, DOI 10.1111/j.1365-2141.2007.06788.x; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; Sinha K, 2002, LIFE SCI, V71, P655, DOI 10.1016/S0024-3205(02)01691-0; Smith AD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012244; Soh UJK, 2010, BRIT J PHARMACOL, V160, P191, DOI 10.1111/j.1476-5381.2010.00705.x; Soleas GJ, 1997, CLIN BIOCHEM, V30, P91, DOI 10.1016/S0009-9120(96)00155-5; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Streck EL, 2004, BEHAV BRAIN RES, V153, P377, DOI 10.1016/j.bbr.2003.12.013; Streck EL, 2003, METAB BRAIN DIS, V18, P147, DOI 10.1023/A:1023815119931; Tsai SK, 2007, J VASC SURG, V46, P346, DOI 10.1016/j.jvs.2007.04.044; Tyagi N, 2005, AM J PHYSIOL-HEART C, V289, pH2649, DOI 10.1152/ajpheart.00548.2005; Upchurch GR, 1997, J BIOL CHEM, V272, P17012, DOI 10.1074/jbc.272.27.17012; Wallerath T, 2002, CIRCULATION, V106, P1652, DOI 10.1161/01.CIR.0000029925.18593.5C; Wang JY, 2003, J NEUROSCI RES, V72, P508, DOI 10.1002/jnr.10597; Wang Q, 2004, NEUROCHEM RES, V29, P2105, DOI 10.1007/s11064-004-6883-z; Win W, 2002, MUTAT RES-GEN TOX EN, V513, P113, DOI 10.1016/S1383-5718(01)00303-5; Yang YM, 2008, EUR J PHARMACOL, V583, P148, DOI 10.1016/j.ejphar.2008.01.009; Yousuf S, 2009, BRAIN RES, V1250, P242, DOI 10.1016/j.brainres.2008.10.068; Zhang C, 2011, CARDIOVASC RES, V90, P538, DOI 10.1093/cvr/cvr022; Zhang HR, 2009, ARTERIOSCL THROM VAS, V29, P1164, DOI 10.1161/ATVBAHA.109.187146; Zhang J, 2011, INT J FOOD SCI NUTR, V62, P814, DOI 10.3109/09637486.2011.581651; Zou JG, 2000, LIFE SCI, V68, P153, DOI 10.1016/S0024-3205(00)00925-5; Zou JG, 2003, INT J MOL MED, V11, P317	76	24	24	0	36	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	NOV 12	2012	1484						29	38		10.1016/j.brainres.2012.09.026			10	Neurosciences	Neurosciences & Neurology	038LB	WOS:000311175100003	22995369				2021-06-18	
J	Brady, KM; Easley, RB; Kibler, K; Kaczka, DW; Andropoulos, D; Fraser, CD; Smielewski, P; Czosnyka, M; Adams, GJ; Rhee, CJ; Rusin, CG				Brady, Ken M.; Easley, R. Blaine; Kibler, Kathleen; Kaczka, David W.; Andropoulos, Dean; Fraser, Charles D., III; Smielewski, Peter; Czosnyka, Marek; Adams, Gerald J.; Rhee, Christopher J.; Rusin, Craig G.			Positive end-expiratory pressure oscillation facilitates brain vascular reactivity monitoring	JOURNAL OF APPLIED PHYSIOLOGY			English	Article						cerebrovascular autoregulation; pressure reactivity; positive end-expiratory pressure; neonatal	CEREBRAL PERFUSION-PRESSURE; NEAR-INFRARED SPECTROSCOPY; BLOOD-FLOW VELOCITY; CEREBROVASCULAR REACTIVITY; INTRACRANIAL-PRESSURE; PHASE RELATIONSHIP; AUTOREGULATION; INJURY; HUMANS	Brady KM, Easley RB, Kibler K, Kaczka DW, Andropoulos D, Fraser CD 3rd, Smielewski P, Czosnyka M, Adams GJ, Rhee CJ, Rusin CG. Positive end-expiratory pressure oscillation facilitates brain vascular reactivity monitoring. J Appl Physiol 113: 1362-1368, 2012. First published September 13, 2012; doi:10.1152/japplphysiol.00853.2012.-The pressure reactivity index (PRx) identifies optimal cerebral perfusion pressure after traumatic brain injury. We describe a method to improve PRx precision by induced variations in arterial blood pressure (ABP) using positive end-expiratory pressure (PEEP) modulation (iPRx). Neonatal swine (n = 10) were ventilated with static PEEP and then with PEEP oscillated between 5 and 10 cmH(2)O at a frequency of 1/min. PRx was recorded as a moving correlation coefficient between ABP and intracranial pressure (ICP) from spontaneous ABP activity (0.05-0.003 Hz) during static PEEP. iPRx was similarly recorded with PEEP oscillation-induced ABP waves. The lower limit of autoregulation (LLA) was delineated with continuous cortical laser Doppler flux monitoring. PEEP oscillation increased autoregulation-monitoring precision. The ratios of median absolute deviations to range of possible values for the PRx and iPRx were 9.5% (8.3-13.7%) and 6.2% (4.2-8.7%), respectively (P = 0.006; median, interquartile range). The phase-angle difference between ABP and ICP above LLA was 161 degrees (150 degrees-166 degrees) and below LLA, -31 degrees (-42 degrees to 12 degrees, P < 0.0001). iPRx above LLA was -0.42 (-0.67 to -0.29) and below LLA, 0.32 (0.22-0.43, P = 0.0004). A positive iPRx was 97% specific and 91% sensitive for perfusion pressure below LLA. PEEP oscillation caused stable, low-frequency ABP oscillations that reduced noise in the PRx. Safe translation of these findings to clinical settings is expected to yield more accurate and rapid delineation of individualized optimal perfusion-pressure goals for patients.	[Brady, Ken M.; Easley, R. Blaine; Kibler, Kathleen; Andropoulos, Dean; Adams, Gerald J.; Rhee, Christopher J.; Rusin, Craig G.] Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA; [Kaczka, David W.] Harvard Univ, Sch Med, Boston, MA USA; [Fraser, Charles D., III] Univ Texas Houston, Sch Med, Houston, TX USA; [Smielewski, Peter; Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Neurosurg Unit, Cambridge CB2 2QQ, England	Brady, KM (corresponding author), Texas Childrens Hosp, Baylor Coll Med, 6621 Fannin,WT 17-417B, Houston, TX 77030 USA.	kbrady@texaschildrens.org	Kaczka, David W./U-2580-2018	Kaczka, David W./0000-0003-4378-5242; Rusin, Craig/0000-0003-3812-8133; Smielewski, Peter/0000-0001-5096-3938			AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Brady KM, 2008, STROKE, V39, P2531, DOI 10.1161/STROKEAHA.108.514877; Brady KM, 2007, STROKE, V38, P2818, DOI 10.1161/STROKEAHA.107.485706; Brady KM, 2010, ANESTH ANALG, V111, P191, DOI 10.1213/ANE.0b013e3181e054ba; Brady KM, 2009, PEDIATRICS, V124, pE1205, DOI 10.1542/peds.2009-0550; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; Diedler J, 2011, ANESTH ANALG, V113, P849, DOI 10.1213/ANE.0b013e3182285dc0; DIEHL RR, 1995, STROKE, V26, P1801, DOI 10.1161/01.STR.26.10.1801; Lang EW, 2001, CRIT CARE MED, V29, P158, DOI 10.1097/00003246-200101000-00031; Lee JK, 2009, STROKE, V40, P1820, DOI 10.1161/STROKEAHA.108.536094; Lewis PM, 2008, ACTA NEUROCHIR, V150, P139, DOI 10.1007/s00701-007-1447-z; Pedersen TF, 2003, AM J PHYSIOL-HEART C, V285, pH1097, DOI 10.1152/ajpheart.00098.2003; Ragauskas A, 2005, ACTA NEUROCHIR SUPPL, V95, P367; RangeL-Castilla L, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E7; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steinmeier R, 1996, STROKE, V27, P2236, DOI 10.1161/01.STR.27.12.2236	19	24	24	0	3	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	8750-7587			J APPL PHYSIOL	J. Appl. Physiol.	NOV	2012	113	9					1362	1368		10.1152/japplphysiol.00853.2012			7	Physiology; Sport Sciences	Physiology; Sport Sciences	031NQ	WOS:000310649200003	22984248				2021-06-18	
J	Tsuchikawa, D; Nakamachi, T; Tsuchida, M; Wada, Y; Hori, M; Farkas, J; Yoshikawa, A; Kagami, N; Imai, N; Shintani, N; Hashimoto, H; Atsumi, T; Shioda, S				Tsuchikawa, Daisuke; Nakamachi, Tomoya; Tsuchida, Masashi; Wada, Yoshihiro; Hori, Motohide; Farkas, Jozsef; Yoshikawa, Akira; Kagami, Nobuyuki; Imai, Nori; Shintani, Norihito; Hashimoto, Hitoshi; Atsumi, Takashi; Shioda, Seiji			Neuroprotective Effect of Endogenous Pituitary Adenylate Cyclase-Activating Polypeptide on Spinal Cord Injury	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						PACAP; Spinal cord injury; Neuroprotective effect; Knockout mouse	TRAUMATIC BRAIN-INJURY; NEURONAL CELL-DEATH; REACTIVE ASTROCYTES; MESSENGER-RNA; PACAP; PEPTIDE; RATS; EXPRESSION; APOPTOSIS; RECEPTOR	Pituitary adenylate cyclase-activating polypeptide (PACAP) is a neuroprotective peptide expressed in the central nervous system. To date, changes in the expression and effect of endogenous PACAP have not been clarified with respect to spinal cord injury (SCI). The aim of this study was to elucidate the expression pattern and function of endogenous PACAP on the contusion model of SCI using heterozygous PACAP knockout (PACAP(+/-)) and wild-type mice. Real-time polymerase chain reaction methods revealed that the level of PACAP mRNA increased gradually for 14 days after SCI and that PAC1R mRNA levels also increased for 7 days compared with intact control mice. PACAP and PAC1R immunoreactivities colabeled with a neuronal marker in the intact spinal cord. Seven days after SCI, PAC1R immunoreactivity was additionally co-expressed with an astrocyte marker. Wild-type mice gradually recovered motor function after 14 days, but PACAP(+/-) mice showed significantly impaired recovery from 3 days compared with wild-type mice. The injury volume at day 7 in PACAP(+/-) mice, and the number of single-stranded DNA-immunopositive cells as a marker of neuronal cell death at day 3 were significantly higher than values measured in wild-type mice. These data suggest that endogenous PACAP is upregulated by SCI and has a neuroprotective effect on the damaged spinal cord.	[Tsuchikawa, Daisuke; Nakamachi, Tomoya; Tsuchida, Masashi; Wada, Yoshihiro; Hori, Motohide; Farkas, Jozsef; Yoshikawa, Akira; Kagami, Nobuyuki; Imai, Nori; Shioda, Seiji] Showa Univ, Sch Med, Dept Anat, Shinagawa Ku, Tokyo 1428555, Japan; [Tsuchikawa, Daisuke; Tsuchida, Masashi; Atsumi, Takashi] Showa Univ, Fujigaoka Hosp, Dept Orthoped Surg, Tokyo, Kanagawa, Japan; [Nakamachi, Tomoya] Showa Univ, Ctr Biotechnol, Shinagawa Ku, Tokyo 1428555, Japan; [Shintani, Norihito; Hashimoto, Hitoshi] Osaka Univ, Lab Mol Neuropharmacol, Grad Sch Pharmaceut Sci, Suita, Osaka 5650871, Japan; [Hashimoto, Hitoshi] Kanazawa Univ, Osaka Univ, Ctr Child Mental Dev, United Grad Sch Child Dev, Suita, Osaka 5650871, Japan; [Hashimoto, Hitoshi] Hamamatsu Univ Sch Med, Suita, Osaka 5650871, Japan	Shioda, S (corresponding author), Showa Univ, Sch Med, Dept Anat, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	shioda@med.showa-u.ac.jp	Shintani, Norihito/D-5860-2014; Shintani, Norihito/N-1600-2019; Hashimoto, Hitoshi/D-1209-2010	Shintani, Norihito/0000-0002-7850-9064; Shintani, Norihito/0000-0002-7850-9064; Hashimoto, Hitoshi/0000-0001-6548-4016	Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [24592680] Funding Source: KAKEN		Alexanian AR, 2011, NEUROREHAB NEURAL RE, V25, P873, DOI 10.1177/1545968311416823; ARIMURA A, 1991, ENDOCRINOLOGY, V129, P2787, DOI 10.1210/endo-129-5-2787; ARIMURA A, 1995, FRONT NEUROENDOCRIN, V16, P53, DOI 10.1006/frne.1995.1003; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bracken M. B., 2012, COCHRANE DB SYST REV, V18; Chen WH, 2005, NEUROSCI LETT, V384, P117, DOI 10.1016/j.neulet.2005.04.070; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Das AK, 2011, CURR STEM CELL RES T, V6, P93; Dohi K, 2002, REGUL PEPTIDES, V109, P83, DOI 10.1016/S0167-0115(02)00190-8; Endo K, 2011, J MOL NEUROSCI, V43, P22, DOI 10.1007/s12031-010-9434-x; Fang KM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015299; Farkas O, 2004, REGUL PEPTIDES, V123, P69, DOI 10.1016/j.regpep.2004.05.014; GHATEI MA, 1993, J ENDOCRINOL, V136, P159, DOI 10.1677/joe.0.1360159; Hashimoto H, 2001, P NATL ACAD SCI USA, V98, P13355, DOI 10.1073/pnas.231094498; Hashimoto H, 2011, CURR PHARM DESIGN, V17, P985, DOI 10.2174/138161211795589382; Jongsma H, 2000, BRAIN RES, V853, P186, DOI 10.1016/S0006-8993(99)02233-7; Kim WK, 2000, J NEUROSCI, V20, P3622; Kovesdi E, 2008, NEUROTOX RES, V13, P71, DOI 10.1007/BF03033558; Ma MH, 2001, EXP NEUROL, V169, P239, DOI 10.1006/exnr.2001.7679; Masmoudi-Kouki O, 2011, J NEUROCHEM, V117, P403, DOI 10.1111/j.1471-4159.2011.07185.x; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MOLLER K, 1993, NEUROSCIENCE, V57, P725, DOI 10.1016/0306-4522(93)90018-B; Morino T, 2003, NEUROSCI RES, V46, P309, DOI 10.1016/S0168-0102(03)00095-6; Nakamachi T, 2006, PEPTIDES, V27, P1859, DOI 10.1016/j.peptides.2006.01.007; Nakamachi T, 2011, CURR PHARM DESIGN, V17, P973, DOI 10.2174/138161211795589346; Nakamachi T, 2011, J MOL NEUROSCI, V43, P16, DOI 10.1007/s12031-010-9404-3; Nakamachi T, 2010, ACTA NEUROCHIR SUPPL, V106, P43, DOI 10.1007/978-3-211-98811-4_6; Ohtaki H, 2006, P NATL ACAD SCI USA, V103, P7488, DOI 10.1073/pnas.0600375103; Ohtaki H, 2008, J MOL NEUROSCI, V36, P16, DOI 10.1007/s12031-008-9077-3; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Pettersson LME, 2004, J COMP NEUROL, V471, P85, DOI 10.1002/cne.20015; Seaborn T, 2011, CURR PHARM DESIGN, V17, P204, DOI 10.2174/138161211795049679; Sherwood NM, 2000, ENDOCR REV, V21, P619, DOI 10.1210/er.21.6.619; Shioda S, 2006, ANN NY ACAD SCI, V1070, P550, DOI 10.1196/annals.1317.080; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; Somogyvari-Vigh A, 2004, CURR PHARM DESIGN, V10, P2861, DOI 10.2174/1381612043383548; Stumm R, 2007, J NEUROCHEM, V103, P1666, DOI 10.1111/j.1471-4159.2007.04895.x; Suarez V, 2006, EUR J NEUROSCI, V24, P1555, DOI 10.1111/j.1460-9568.2006.05029.x; Suzuki R, 2003, MOL BRAIN RES, V115, P10, DOI 10.1016/S0169-328X(03)00172-4; Szabadfi K, 2012, NEUROTOX RES, V21, P41, DOI 10.1007/s12640-011-9254-y; Tamas A, 2006, J NEUROTRAUM, V23, P686, DOI 10.1089/neu.2006.23.686; van Landeghem FKH, 2007, ACTA NEUROPATHOL, V113, P683, DOI 10.1007/s00401-007-0208-7; Vaudry D, 2005, PEPTIDES, V26, P2518, DOI 10.1016/j.peptides.2005.05.015; Vaudry D, 2009, PHARMACOL REV, V61, P283, DOI 10.1124/pr.109.001370; Zhang Q, 1995, BRAIN RES, V705, P149, DOI 10.1016/0006-8993(95)01150-1	47	24	24	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696			J MOL NEUROSCI	J. Mol. Neurosci.	NOV	2012	48	3					508	517		10.1007/s12031-012-9817-2			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	008LS	WOS:000308959100005	22674051				2021-06-18	
J	Uthaikhup, S; Jull, G; Sungkarat, S; Treleaven, J				Uthaikhup, Sureeporn; Jull, Gwendolen; Sungkarat, Somporn; Treleaven, Julia			The influence of neck pain on sensorimotor function in the elderly	ARCHIVES OF GERONTOLOGY AND GERIATRICS			English	Article						Neck pain; Elderly; Sensorimotor; Postural control	CERVICOCEPHALIC KINESTHETIC SENSIBILITY; POSTURAL STABILITY; OLDER-ADULTS; WHIPLASH INJURY; VERTICALITY PERCEPTION; PERSISTENT WHIPLASH; BALANCE CONFIDENCE; STANDING BALANCE; GAIT PARAMETERS; CERVICAL-SPINE	Greater disturbances in sensorimotor control have been demonstrated in younger to middle aged groups. However, it is unknown whether or not the impairments documented in these populations can be extrapolated to elders with neck pain. The aim of this study was to investigate the influence of neck pain on sensorimotor function in elders. Twenty elders with neck pain (12 women and 8 men) and 20 healthy elder controls (14 women and 6 men) aged 65 years and over were recruited from the general community. Tests for sensorimotor function included; cervical joint position sense (JPS); computerised rod-and-frame test (RFT); smooth pursuit neck torsion test (SPNT); standing balance (under conditions of eyes open, eyes closed on firm and soft surfaces in comfortable stance); step test and ten-meter walk test with and without head movement. Elders with neck pain had greater deficits in the majority of sensorimotor function tests after controlling for effects of age and comorbidities. Significant differences were found in the SPNT (p < 0.01), error in the RFT (frame angled at 10 degrees and 15 degrees anticlockwise) (p < 0.05), standing balance (amplitude of sway) - eyes open on a firm surface in the medio-lateral (ML) direction (p = 0.03), and total number of steps on the step test, both left and right sides (p < 0.01). Elders with neck pain have greater sensorimotor disturbances than elders without neck pain, supporting a contribution of altered afferent information originating from the cervical spine to such disturbances. The findings may inform falls prevention and management programs. (C) 2012 Elsevier Ireland Ltd. All rights reserved.	[Uthaikhup, Sureeporn; Sungkarat, Somporn] Chiang Mai Univ, Dept Phys Therapy, Fac Associated Med Sci, Chiang Mai 50200, Thailand; [Jull, Gwendolen; Treleaven, Julia] Univ Queensland, Sch Hlth & Rehabil Sci, Div Physiotherapy, Brisbane, Qld 4072, Australia; [Jull, Gwendolen; Treleaven, Julia] Univ Queensland, NHMRC Ctr Clin Res Excellence Spinal Pain Injury, Brisbane, Qld 4072, Australia	Uthaikhup, S (corresponding author), Chiang Mai Univ, Dept Phys Therapy, Fac Associated Med Sci, Chiang Mai 50200, Thailand.	sureeporn.uthaikhup@cmu.ac.th	Jull, Gwendolen/F-4233-2010; Treleaven, Julia M/F-8734-2010; Treleaven, Julia/N-1379-2019; SUNGKARAT, SOMPORN/AAU-3448-2020	Jull, Gwendolen/0000-0003-2670-1318; Treleaven, Julia M/0000-0002-6258-3972; Treleaven, Julia/0000-0002-6258-3972; SUNGKARAT, SOMPORN/0000-0003-4283-7469	Chiang Mai University	This work has been funded by Chiang Mai University.	Ahmed Mohamed S, 2005, Phys Med Rehabil Clin N Am, V16, P19, DOI 10.1016/j.pmr.2004.06.017; Akdal G, 2009, HEADACHE, V49, P419, DOI 10.1111/j.1526-4610.2008.01256.x; Bagust J, 2005, ARCH PHYS MED REHAB, V86, P1062, DOI 10.1016/j.apmr.2004.05.022; Bohannon RW, 1997, AGE AGEING, V26, P15, DOI 10.1093/ageing/26.1.15; Bolton PS, 1998, J MANIP PHYSIOL THER, V21, P553; Bove M, 2002, J NEUROPHYSIOL, V88, P2232, DOI 10.1152/jn.00198.2002; Boyd-Clark LC, 2002, SPINE, V27, P694, DOI 10.1097/00007632-200204010-00005; Cesari M, 2005, J AM GERIATR SOC, V53, P1675, DOI 10.1111/j.1532-5415.2005.53501.x; Chamberlin ME, 2005, J GERONTOL A-BIOL, V60, P1163, DOI 10.1093/gerona/60.9.1163; Choy NL, 2003, J GERONTOL A-BIOL, V58, P525; Courtine G, 2003, NEUROREPORT, V14, P2365, DOI 10.1097/00001756-200312190-00015; CRESS ME, 1995, J AM GERIATR SOC, V43, P93, DOI 10.1111/j.1532-5415.1995.tb06372.x; della Volpe R, 2006, GAIT POSTURE, V24, P349, DOI 10.1016/j.gaitpost.2005.10.009; Field S, 2008, MANUAL THER, V13, P183, DOI 10.1016/j.math.2006.12.005; Gill J, 2001, J GERONTOL A-BIOL, V56, pM438, DOI 10.1093/gerona/56.7.M438; Grod JP, 2002, ARCH PHYS MED REHAB, V83, P412, DOI 10.1053/apmr.2002.29660; Hatch J, 2003, PHYS THER, V83, P1072, DOI 10.1093/ptj/83.12.1072; Hawk Cheryl, 2006, Chiropr Osteopat, V14, P3, DOI 10.1186/1746-1340-14-3; Hill KD., 1996, PHYSIOTHER CAN, V48, P257, DOI DOI 10.3138/PTC.48.4.257; Humphreys BK, 2008, J MANIP PHYSIOL THER, V31, P540, DOI 10.1016/j.jmpt.2008.08.007; Jacobson GP, 2008, J AM ACAD AUDIOL, V19, P799, DOI 10.3766/jaaa.19.10.7; Jull G., 2008, WHIPLASH HEADACHE NE; Kelders WPA, 2003, J PHYSIOL-LONDON, V553, P311, DOI 10.1113/jphysiol.2003.049338; Kogler A, 2000, ACTA OTO-LARYNGOL, V120, P151; Kristjansson E, 2009, J ORTHOP SPORT PHYS, V39, P364, DOI 10.2519/jospt.2009.2834; Liaw Mei-Yun, 2009, Chang Gung Med J, V32, P297; Maki BE, 1997, J AM GERIATR SOC, V45, P313, DOI 10.1111/j.1532-5415.1997.tb00946.x; March LM, 1998, MED J AUSTRALIA, V168, P439, DOI 10.5694/j.1326-5377.1998.tb139023.x; Montfoort I, 2008, J NEUROTRAUM, V25, P687, DOI 10.1089/neu.2007.0314; Pajala S, 2008, J GERONTOL A-BIOL, V63, P171, DOI 10.1093/gerona/63.2.171; Poole E, 2008, MANUAL THER, V13, P317, DOI 10.1016/j.math.2007.02.002; POWELL LE, 1995, J GERONTOL A-BIOL, V50, pM28, DOI 10.1093/gerona/50A.1.M28; REVEL M, 1991, ARCH PHYS MED REHAB, V72, P288; Rix GD, 2001, ARCH PHYS MED REHAB, V82, P911, DOI 10.1053/apmr.2001.23300; Salzman B, 2010, AM FAM PHYSICIAN, V82, P61; Schrager MA, 2008, GAIT POSTURE, V28, P466, DOI 10.1016/j.gaitpost.2008.02.009; Shumway-Cook A, 2000, PHYS THER, V80, P896, DOI 10.1093/ptj/80.9.896; Storaci R, 2006, EUR SPINE J, V15, P1811, DOI 10.1007/s00586-006-0085-0; Tjell C, 1998, AM J OTOL, V19, P76; Tjell C., 2002, J WHIPLASH RELAT DIS, V1, P9, DOI [10.3109/J180v01n02_02, DOI 10.3109/J180V01N02_02]; Treleaven J, 2005, J REHABIL MED, V37, P219, DOI 10.1080/16501970410024299; Treleaven J, 2005, GAIT POSTURE, V21, P395, DOI 10.1016/j.gaitpost.2004.04.008; Treleaven J, 2003, J REHABIL MED, V35, P36, DOI 10.1080/16501970306109; Treleaven J, 2008, ARCH PHYS MED REHAB, V89, P522, DOI 10.1016/j.apmr.2007.11.002; Treleaven J, 2008, MANUAL THER, V13, P2, DOI 10.1016/j.math.2007.06.003; VERNON H, 1991, J MANIP PHYSIOL THER, V14, P409; Vuillerme N, 2008, AGING CLIN EXP RES, V20, P355; Vuillerme N, 2009, EXP BRAIN RES, V192, P723, DOI 10.1007/s00221-008-1639-7; Woollacott MH, 1997, PHYS THER, V77, P646, DOI 10.1093/ptj/77.6.646	49	24	25	0	21	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0167-4943			ARCH GERONTOL GERIAT	Arch. Gerontol. Geriatr.	NOV-DEC	2012	55	3					667	672		10.1016/j.archger.2012.01.013			6	Geriatrics & Gerontology	Geriatrics & Gerontology	004GC	WOS:000308667900023	22349008				2021-06-18	
J	Krisanova, N; Sivko, R; Kasatkina, L; Borisova, T				Krisanova, N.; Sivko, R.; Kasatkina, L.; Borisova, T.			Neuroprotection by lowering cholesterol: A decrease in membrane cholesterol content reduces transporter-mediated glutamate release from brain nerve terminals	BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE			English	Article						Neuroprotection; Cholesterol; Methyl-beta-cyclodextrin; Ambient glutamate; Transporter-mediated glutamate release; Synaptosomes	PLASMA-MEMBRANE; NMDA RECEPTORS; INDUCED EXCITOTOXICITY; BETA-CYCLODEXTRIN; CORTICAL-NEURONS; RAT-BRAIN; IN-VITRO; STATINS; STROKE; SIMVASTATIN	Background: In our earlier work, a reduction of cholesterol content increased the extracellular glutamate level in rat brain nerve terminals (synaptosomes) that was a result of the lack of transporter-mediated glutamate uptake. The aim of this study was to assess transporter-mediated release of glutamate from cholesterol-deficient synaptosomes. In stroke, cerebral hypoxia/ischemia, and traumatic brain injury, the development of neurotoxicity is provoked by enhanced extracellular glutamate, which is released from nerve cells mainly by glutamate transporter reversal - a distinctive feature of these pathological states. Methods: Laser scanning confocal microscopy, spectrofluorimetry, radiolabeled assay, and glutamate dehydrogenase assay. Results: Cholesterol acceptor methyl-beta-cyclodextrin (15 mM) reduced the cholesterol content in the synaptosomes by one quarter. Transporter-mediated glutamate release from synaptosomes: 1) stimulated by depolarization of the plasma membrane; 2) by means of heteroexchange with competitive transportable inhibitor of glutamate transporters DL-threo-beta-hydroxyaspartate; 3) in low [Na+] medium; and 4) during dissipation of the proton gradient of synaptic vesicles by the protonophore cyanide-p-trifluoromethoxyphenyl-hydrazon (FCCP); was decreased under conditions of cholesterol deficiency by similar to 24, 28, 40, and 17%, respectively. Conclusions: A decrease in the level of membrane cholesterol attenuated transporter-mediated glutamate release from nerve terminals. Therefore, lowering cholesterol may be used in neuroprotection in stroke, ischemia, and traumatic brain injury which are associated with an increase in glutamate uptake reversal. This data may explain the neuroprotective effects of statins in these pathological states and provide one of the mechanisms of their neuroprotective action. However, beside these disorders, lowering cholesterol may cause harmful consequences by decreasing glutamate uptake in nerve terminals. (C) 2012 Elsevier B.V. All rights reserved.	[Krisanova, N.; Sivko, R.; Kasatkina, L.; Borisova, T.] NAS Ukraine, Palladin Inst Biochem, Dept Neurochem, UA-01601 Kiev, Ukraine	Borisova, T (corresponding author), NAS Ukraine, Palladin Inst Biochem, Dept Neurochem, 9 Leontovicha St, UA-01601 Kiev, Ukraine.	tborisov@biochem.kiev.ua	Kasatkina, Ludmila/O-3953-2017	Kasatkina, Ludmila/0000-0003-3935-5389; Borisova, Tatiana/0000-0002-6533-1420	National program "Nanotechnology and nanomaterials" [5.18.5.27]	This work was supported by Grant #5.18.5.27 (National program "Nanotechnology and nanomaterials"). We would like to thank Dr. V. Gorchev and Dr. S. Karakhim for the excellent technical assistance and help in confocal microscopy studies. We appreciate Dr. I. Trikash, N. Kanivetz and V. Gumenuk for help in fluorimetry.	Abulrob A, 2005, J NEUROCHEM, V92, P1477, DOI 10.1111/j.1471-4159.2005.03001.x; Berger C, 2008, BRAIN RES REV, V58, P48, DOI 10.1016/j.brainresrev.2007.10.010; Bezzi P, 1998, NATURE, V391, P281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Borisova T, 2011, NEUROCHEM INT, V59, P965, DOI 10.1016/j.neuint.2011.07.007; Borisova T, 2010, CELL MOL NEUROBIOL, V30, P1013, DOI 10.1007/s10571-010-9532-x; Borisova T, 2010, NEUROCHEM INT, V56, P466, DOI 10.1016/j.neuint.2009.12.006; Borlsova TA, 2008, ADV SPACE RES, V42, P1971, DOI 10.1016/j.asr.2008.04.012; Bosel J, 2005, J NEUROCHEM, V92, P1386, DOI 10.1111/j.1471-4159.2004.02980.x; Butchbach MER, 2004, J BIOL CHEM, V279, P34388, DOI 10.1074/jbc.M403938200; Camargo F, 2001, LIFE SCI, V70, P131, DOI 10.1016/S0024-3205(01)01384-4; Cavelier P, 2005, J PHYSIOL-LONDON, V564, P397, DOI 10.1113/jphysiol.2004.082131; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; CIDON S, 1989, J BIOL CHEM, V264, P8281; Cotman C W, 1974, Methods Enzymol, V31, P445; Dalby NO, 2003, J NEUROPHYSIOL, V90, P786, DOI 10.1152/jn.00118.2003; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; Funck VR, 2011, EPILEPSIA, V52, P2094, DOI 10.1111/j.1528-1167.2011.03261.x; Gonzalez MI, 2007, J NEUROCHEM, V103, P1917, DOI 10.1111/j.1471-4159.2007.04881.x; Grewer C, 2008, IUBMB LIFE, V60, P609, DOI 10.1002/iub.98; Hess DC, 2000, NEUROLOGY, V54, P790, DOI 10.1212/WNL.54.4.790; Jabaudon D, 2000, P NATL ACAD SCI USA, V97, P5610, DOI 10.1073/pnas.97.10.5610; Jadot M, 2001, EUR J BIOCHEM, V268, P1392, DOI 10.1046/j.1432-1327.2001.02006.x; Jennings LJ, 1999, AM J PHYSIOL-GASTR L, V277, pG1017, DOI 10.1152/ajpgi.1999.277.5.G1017; Kirsch C, 2003, BIOCHEM PHARMACOL, V65, P843, DOI 10.1016/S0006-2952(02)01654-4; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; KRUTH HS, 1980, J LIPID RES, V21, P123; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; LARSON E, 1986, ANAL BIOCHEM, V155, P243, DOI 10.1016/0003-2697(86)90432-X; Monnaert V, 2004, J PHARMACOL EXP THER, V310, P745, DOI 10.1124/jpet.104.067512; Nagaraja TN, 2006, NEUROL RES, V28, P826, DOI 10.1179/174313206X153914; NICHOLLS DG, 1986, NATURE, V321, P772, DOI 10.1038/321772a0; Nishida A, 2004, BIOL PHARM BULL, V27, P813, DOI 10.1248/bpb.27.813; O'Kane RL, 1999, J BIOL CHEM, V274, P31891, DOI 10.1074/jbc.274.45.31891; Phillis JW, 2000, BRAIN RES, V868, P105, DOI 10.1016/S0006-8993(00)02303-9; Ponce J, 2008, STROKE, V39, P1269, DOI 10.1161/STROKEAHA.107.498923; Ramirez C, 2011, J ALZHEIMERS DIS, V24, P161, DOI 10.3233/JAD-2010-101653; Robinson MB, 2006, HANDB EXP PHARM, V175, P251; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; SAH P, 1989, SCIENCE, V246, P815, DOI 10.1126/science.2573153; Sierra S, 2011, J ALZHEIMERS DIS, V23, P307, DOI 10.3233/JAD-2010-101179; Sironi L, 2003, ARTERIOSCL THROM VAS, V23, P322, DOI 10.1161/01.ATV.0000044458.23905.3B; Sugiura S, 2007, BRAIN RES, V1181, P125, DOI 10.1016/j.brainres.2007.08.069; Tretter L, 1998, MOL PHARMACOL, V53, P734; Trikash I, 2010, CHEM PHYS LIPIDS, V163, P778, DOI 10.1016/j.chemphyslip.2010.09.003; Tsai HI, 2006, BRAIN RES, V1104, P27, DOI 10.1016/j.brainres.2006.05.081; Wang Q, 2011, EXP NEUROL, V230, P27, DOI 10.1016/j.expneurol.2010.04.006; Wang Q, 2009, EXP NEUROL, V216, P132, DOI 10.1016/j.expneurol.2008.11.016; Wood WG, 2010, ANN NY ACAD SCI, V1199, P69, DOI 10.1111/j.1749-6632.2009.05359.x; Xu YQ, 2012, PROG NEUROBIOL, V97, P1, DOI 10.1016/j.pneurobio.2012.02.002; Yan JQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020945; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zacco A, 2003, J NEUROSCI, V23, P11104; Zhang L, 2005, CIRCULATION, V112, P3486, DOI 10.1161/CIRCULATIONAHA.104.516757; ZLATKIS A, 1953, J LAB CLIN MED, V41, P486; Zoccarato F, 1999, J NEUROCHEM, V72, P625, DOI 10.1046/j.1471-4159.1999.0720625.x	57	24	25	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-4439	0006-3002		BBA-MOL BASIS DIS	Biochim. Biophys. Acta-Mol. Basis Dis.	OCT	2012	1822	10					1553	1561		10.1016/j.bbadis.2012.06.005			9	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Biochemistry & Molecular Biology; Biophysics; Cell Biology	996AM	WOS:000308056400006	22713486	Bronze			2021-06-18	
J	Lauridsen, E; Hermann, NV; Gerds, TA; Ahrensburg, SS; Kreiborg, S; Andreasen, JO				Lauridsen, Eva; Hermann, Nuno Vibe; Gerds, Thomas Alexander; Ahrensburg, Soren Steno; Kreiborg, Sven; Andreasen, Jens Ove			Combination injuries 1. The risk of pulp necrosis in permanent teeth with concussion injuries and concomitant crown fractures	DENTAL TRAUMATOLOGY			English	Article						dental trauma; concussion; crown fracture; pulp necrosis; permanent teeth	RESTORATIVE DENTISTRY; DENTINAL TUBULES; INCISORS; ENAMEL; BIOLOGY; INVASION	Background: The reported risk of pulp necrosis (PN) is low in teeth with concussion injuries. A concomitant crown fracture may affect the risk of PN. Aim: To analyze the influence of a crown fracture (with and without pulp exposure) on the risk of PN in teeth with concussion injury. Material: The study included 469 permanent incisors with concussion from 358 patients (226 male, 132 female). Among these, 292 had a concomitant crown fracture (70 with and 222 without pulp exposure). All teeth were examined and treated according to standardized protocol. Statistical analysis: The risk of PN was analyzed by the KaplanMeier method and Cox regression. Risk factors included in the analysis: gender, age, stage of root development, type of crown fracture, and response to electric pulp test (EPT) at the initial examination. The level of significance was set at 5%. Results: The risk of PN was low in teeth with immature root development [1.1%, 95% confidence intervals (CI): 03.4]. The following factors significantly increased the risk of PN in teeth with mature root development: crown fracture without pulp exposure [hazard ratio 4.1 (95% CI: 1.411.9), P = 0.01] and no response to EPT at the initial examination [hazard ratio 30.7 (95% CI: 7.7121), P < 0.0001]. The overall risk of PN increased from 3.5% (95% CI: 0.26.8) to 11.0% (95% CI: 5.216.7) when a concomitant crown fracture without pulp exposure was present. If the tooth had both a crown fracture and gave no response to EPT, the risk further increased to 55.0% (95% CI: 34.375.8). Conclusion: No response to EPT at the initial examination or a concomitant crown fracture significantly increased the risk of PN in teeth with concussion injury and mature root development. If both risk factors were present there was a synergetic effect.	[Lauridsen, Eva; Hermann, Nuno Vibe; Kreiborg, Sven] Univ Copenhagen, Sch Dent, Fac Hlth Sci, Dept Pediat Dent & Clin Genet, DK-2200 Copenhagen N, Denmark; [Gerds, Thomas Alexander] Univ Copenhagen, Fac Hlth Sci, Dept Biostat, DK-2200 Copenhagen N, Denmark; [Ahrensburg, Soren Steno; Andreasen, Jens Ove] Copenhagen Univ Hosp, Rigshosp, Ctr Rare Oral Dis, Dept Oral & Maxillofacial Surg, Copenhagen, Denmark	Lauridsen, E (corresponding author), Univ Copenhagen, Sch Dent, Fac Hlth Sci, Dept Pediat Dent & Clin Genet, DK-2200 Copenhagen N, Denmark.	ela@sund.ku.dk		Hermann, Nuno Vibe/0000-0002-8079-8571; Gerds, Thomas Alexander/0000-0002-5955-816X			ANDREASEN F M, 1985, Endodontics and Dental Traumatology, V1, P160; ANDREASEN F M, 1985, Endodontics and Dental Traumatology, V1, P207; Andreasen JO, 2010, ENDOD TOPICS, V14, P80; [Anonymous], 2010, R LANG ENV STAT COMP; Cavalleri G, 1995, ENDOD DENT TRAUMATOL, V11, P294; Chuang SK, 2001, J DENT RES, V80, P2016, DOI 10.1177/00220345010800111301; CVEK M, 1990, ENDOD DENT TRAUMATOL, V6, P157; Cvek Miomir, 1993, Acta Stomatologica Croatica, V27, P167; Day PF, 2006, DENT TRAUMATOL, V22, P258, DOI 10.1111/j.1600-9657.2006.00439.x; Fouad A, 2008, INGLES ENDODONTICS, P343; Fuks A B, 1982, Pediatr Dent, V4, P240; Gerds T., 2009, STAT METHODOLOGICAL, P259; Glendor U., 2007, TXB COLOR ATLAS TRAU, P217; Gopikrishna V, 2009, INT J PAEDIATR DENT, V19, P3, DOI 10.1111/j.1365-263X.2008.00955.x; Heyeraas KJ, 2001, QUINTESSENCE INT, V32, P611; Jafarzadeh H, 2010, INT ENDOD J, V43, P945, DOI 10.1111/j.1365-2591.2010.01760.x; Love R M, 1997, Pract Periodontics Aesthet Dent, V9, P427; Love RM, 2002, CRIT REV ORAL BIOL M, V13, P171, DOI 10.1177/154411130201300207; Mjor IA, 2001, QUINTESSENCE INT, V32, P427; Mjor IA, 2001, QUINTESSENCE INT, V32, P771; NAGAOKA S, 1995, J ENDODONT, V21, P70, DOI 10.1016/S0099-2399(06)81098-8; Olsburgh S, 2002, DENT TRAUMATOL, V18, P103, DOI 10.1034/j.1600-9657.2002.00004.x; RAVN JJ, 1981, SCAND J DENT RES, V89, P117; RAVN JJ, 1981, SCAND J DENT RES, V89, P355; RAVN JJ, 1981, SCAND J DENT RES, V89, P213; Robertson A, 1998, ENDOD DENT TRAUMATOL, V14, P245; Robertson A, 2000, Int J Paediatr Dent, V10, P191, DOI 10.1046/j.1365-263x.2000.00191.x; ZADIK D, 1979, ORAL SURG ORAL MED O, V47, P173, DOI 10.1016/0030-4220(79)90175-0	28	24	25	2	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1600-4469	1600-9657		DENT TRAUMATOL	Dent. Traumatol.	OCT	2012	28	5					364	370		10.1111/j.1600-9657.2011.01102.x			7	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	009ZC	WOS:000309063100006	22221538				2021-06-18	
J	Grady, MF; Master, CL; Gioia, GA				Grady, Matthew F.; Master, Christina L.; Gioia, Gerard A.			Concussion Pathophysiology: Rationale for Physical and Cognitive Rest	PEDIATRIC ANNALS			English	Article							TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; SPORT-RELATED CONCUSSION; FLUID PERCUSSION INJURY; EXERCISE; MANAGEMENT; CHILDREN; RECOVERY	Matthew F. Grady, MD, is the Director of the Primary Care Sports Medicine fellowship program at The Children's Hospital of Philadelphia; and Assistant Professor of Clinical Pediatrics, Departments of Surgery and Pediatrics, Division of Pediatric Orthopedics and Sports Medicine, Perelman School of Medicine at the University of Pennsylvania. Christina L. Master, MD, is the Associate Director of the Primary Care Sports Medicine fellowship program at The Children's Hospital of Philadelphia; and Associate Professor of Clinical Pediatrics, Departments of Surgery and Pediatrics, Division of Pediatric Orthopedics and Sports Medicine, Perelman School of Medicine at the University of Pennsylvania. Gerard A. Gioia, PhD, is the Chief, Division of Pediatric Neuropsychology, and Director, Safe Concussion Outcome, Recovery & Education (SCORE) Program, Children's National Medical Center; and Associate Professor, Departments of Pediatrics and Psychiatry & Behavioral Sciences; The George Washington University School of Medicine, Division of Pediatric Neuropsychology. Address correspondence to: Matthew F. Grady, MD, Center for Performance and Sports Medicine, The Children's Hospital of Philadelphia, 210 Mall Blvd., King of Prussia, PA 19406; email: gradym@email.chop.edu. Disclosure: The authors have no relevant financial relationships to disclose. doi: 10.3928/00904481-20120827-12	[Grady, Matthew F.; Master, Christina L.] Childrens Hosp Philadelphia, Primary Care Sports Med Fellowship Program, King Of Prussia, PA 19406 USA; [Grady, Matthew F.; Master, Christina L.] Univ Penn, Perelman Sch Med, Div Pediat Orthoped & Sports Med, Dept Surg, Philadelphia, PA 19104 USA; [Grady, Matthew F.; Master, Christina L.] Univ Penn, Perelman Sch Med, Div Pediat Orthoped & Sports Med, Dept Pediat, Philadelphia, PA 19104 USA; [Gioia, Gerard A.] George Washington Univ, Sch Med, Div Pediat Neuropsychol, Washington, DC 20052 USA; [Gioia, Gerard A.] George Washington Univ, Sch Med, Div Pediat Neuropsychol, SCORE Program,Childrens Natl Med Ctr, Washington, DC 20052 USA; [Gioia, Gerard A.] George Washington Univ, Sch Med, Div Pediat Neuropsychol, Dept Pediat, Washington, DC 20052 USA; [Gioia, Gerard A.] George Washington Univ, Sch Med, Div Pediat Neuropsychol, Dept Psychiat & Behav Sci, Washington, DC 20052 USA	Grady, MF (corresponding author), Childrens Hosp Philadelphia, Ctr Performance & Sports Med, 210 Mall Blvd, King Of Prussia, PA 19406 USA.	gradym@email.chop.edu		Master, Christina/0000-0002-6717-4270			Bergschneider M, 2003, J NEUROSURG, V86, P241; Centers for Disease Control and Prevention (CDC), 2007, HEADS BRAIN INJ YOUR; Crane AT, 2012, RESTOR NEUROL NEUROS, V30, P325, DOI 10.3233/RNN-2012-120232; Donat CK, 2010, INT J DEV NEUROSCI, V28, P31, DOI 10.1016/j.ijdevneu.2009.10.001; FOX PT, 1986, P NATL ACAD SCI USA, V83, P1140, DOI 10.1073/pnas.83.4.1140; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Gioia GA, 2006, HEADS BRAIN INJURY Y; Gioia GA, 2010, J INT NEUROPSYCH SOC, V16, P178; Gioia GA, 2012, PEDIATR ANN, V41, P198, DOI 10.3928/00904481-20120426-10; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2011, PM&R, V3, pS64, DOI 10.1016/j.pmrj.2011.02.008; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lovell M, 2008, NEUROL CLIN, V26, P45, DOI 10.1016/j.ncl.2007.12.001; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McLeod TCV, 2010, ATHLET THER TODAY, V15, P1, DOI 10.1123/att.15.2.1; Mintun MA, 2001, P NATL ACAD SCI USA, V98, P6859, DOI 10.1073/pnas.111164398; Moser RS, 2012, J PEDIAT; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Tang-Schomer MD, 2009, FASEB J; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Udomphorn Y, 2008, PEDIATR NEUROL, V38, P225, DOI 10.1016/j.pediatrneurol.2007.09.012; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P319, DOI 10.1007/s11682-012-9174-3; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161	32	24	24	0	23	SLACK INC	THOROFARE	6900 GROVE RD, THOROFARE, NJ 08086 USA	0090-4481	1938-2359		PEDIATR ANN	Pediatr. Ann.	SEP	2012	41	9					377	382		10.3928/00904481-20120827-12			5	Pediatrics	Pediatrics	082NM	WOS:000314398700012	22953984				2021-06-18	
J	Holmes, MW; Goodacre, S; Stevenson, MD; Pandor, A; Pickering, A				Holmes, M. W.; Goodacre, S.; Stevenson, M. D.; Pandor, A.; Pickering, A.			The cost-effectiveness of diagnostic management strategies for adults with minor head injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Minor head injuries; Cost-effectiveness; Diagnostic management strategies; Quality adjusted life-years; Economic modelling	TRAUMATIC BRAIN-INJURY; COMPUTED-TOMOGRAPHY; MILD	Study objective: To estimate the cost-effectiveness of diagnostic management strategies for adults with minor head injury. Methods: A mathematical model was constructed to evaluate the incremental costs and effectiveness (Quality Adjusted Life years Gained, QALYs) of ten diagnostic management strategies for adults with minor head injuries. Secondary analyses were undertaken to determine the cost-effectiveness of hospital admission compared to discharge home and to explore the cost-effectiveness of strategies when no responsible adult was available to observe the patient after discharge. Results: The apparent optimal strategy was based on the high and medium risk Canadian CT Head Rule (CCHRhm), although the costs and outcomes associated with each strategy were broadly similar. Hospital admission for patients with non-neurosurgical injury on CT dominated discharge home, whilst hospital admission for clinically normal patients with a normal CT was not cost-effective compared to discharge home with or without a responsible adult at 39 pound and 2.5 pound million per QALY, respectively. A selective CT strategy with discharge home if the CT scan was normal remained optimal compared to not investigating or CT scanning all patients when there was no responsible adult available to observe them after discharge. Conclusion: Our economic analysis confirms that the recent extension of access to CT scanning for minor head injury is appropriate. Liberal use of CT scanning based on a high sensitivity decision rule is not only effective but also cost-saving. The cost of CT scanning is very small compared to the estimated cost of caring for patients with brain injury worsened by delayed treatment. It is recommended therefore that all hospitals receiving patients with minor head injury should have unrestricted access to CT scanning for use in conjunction with evidence based guidelines. Provisionally the CCHRhm decision rule appears to be the best strategy although there is considerable uncertainty around the optimal decision rule. However, the CCHRhm rule appears to be the most widely validated and it therefore seems appropriate to conclude that the CCHRhm rule has the best evidence to support its use. (C) 2011 Elsevier Ltd. All rights reserved.	[Holmes, M. W.; Goodacre, S.; Stevenson, M. D.; Pandor, A.; Pickering, A.] Univ Sheffield, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England	Holmes, MW (corresponding author), Univ Sheffield, Sch Hlth & Related Res, 30 Regent St, Sheffield S1 4DA, S Yorkshire, England.	m.w.holmes@shef.ac.uk	Pandor, Abdullah/E-4643-2010	Pandor, Abdullah/0000-0003-2552-5260	Department of HealthEuropean Commission [HTA/07/37/08, 07/37/08] Funding Source: Medline; National Institute for Health ResearchNational Institute for Health Research (NIHR) [07/37/08] Funding Source: researchfish		af Geijerstam JL, 2005, EMERG MED J, V22, P103, DOI 10.1136/emj.2004.015396; Aoki N, 1998, MED DECIS MAKING, V18, P357, DOI 10.1177/0272989X9801800401; Beecham J, 2009, BRAIN INJURY, V23, P30, DOI 10.1080/02699050802590338; CANTOR SB, 1994, MED DECIS MAKING, V14, P259, DOI 10.1177/0272989X9401400308; Claxton K, 2005, HEALTH ECON, V14, P339, DOI 10.1002/hec.985; Curtis L. A., 2009, UNIT COSTS HLTH SOCI; Department of Health, 2010, NAT SCHED REF COSTS; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P1180, DOI 10.1136/jnnp.2007.135178; Fenwick E, 2001, HEALTH ECON, V10, P779, DOI 10.1002/hec.635; Garside R, 2007, HEALTH TECHNOL ASSES, V11, P1; Goodacre S, 2008, EMERG MED J, V25, P556, DOI 10.1136/emj.2007.055723; Harnan SE, 2011, J TRAUMA, V71, P245, DOI 10.1097/TA.0b013e31820d090f; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Mower WR, 2005, J TRAUMA, V59, P954, DOI 10.1097/01.ta.0000187813.79047.42; National Health Service, HLTH RES GROUP VERS; National Institute for Health and Clinical Excellence (NICE), 2007, HEAD INJ TRIAG ASS I; National Radiological Protection Board (NRPB), 2001, XRAYS SAF AR THEY; NICE, 2008, GUID METH TECHN APPR; Office for National Statistics (ONS), 2008, UK INT LIF TABL 1980; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Smits M, 2010, RADIOLOGY, V254, P532, DOI 10.1148/radiol.2541081672; Stein SC, 2006, J TRAUMA, V61, P558, DOI 10.1097/01.ta.0000233766.60315.5e; Stein SC, 2009, ANN EMERG MED, V53, P180, DOI 10.1016/j.annemergmed.2008.01.002; Stein SC, 2008, PEDIATR NEUROSURG, V44, P448, DOI 10.1159/000172967; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Swann I, 1999, TRAUMA, V1, P143; The Multi-Society Task Force on PVS, 1995, NEW ENGL J MED, V333, P130	30	24	25	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	SEP	2012	43	9					1423	1431		10.1016/j.injury.2011.07.017			9	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	977MK	WOS:000306666100016	21835403				2021-06-18	
J	Rose, SR; Auble, BA				Rose, Susan R.; Auble, Bethany A.			Endocrine changes after pediatric traumatic brain injury	PITUITARY			English	Article						Traumatic brain injury; Hypopituitarism; Precocious puberty; Hypogonadotropic hypogonadism; Central hypothyroidism; Growth hormone deficiency; Adrenal insufficiency; Hyperprolactinemia; Adult; Pediatric	ANTERIOR-PITUITARY FUNCTION; GROWTH-HORMONE DEFICIENCY; CENTRAL HYPOTHYROIDISM; CRANIAL IRRADIATION; SHORT STATURE; CHILDREN; HYPOPITUITARISM; DYSFUNCTION; TBI; INSUFFICIENCY	Traumatic brain injury (TBI) is a very common occurrence in childhood, and can lead to devastating long term consequences. Recent research has focused on the potential endocrine consequences of TBI in adults. The research in children is less robust. This paper reviews current literature regarding TBI and possible hypothalamic and pituitary deficiencies in childhood. Acute endocrine changes are commonly found after TBI in pediatric patients, which can include changes in hypothalamic-pituitary-adrenal axis and antidiuretic hormone production and release. In the long term, both temporary and permanent alterations in pituitary function have been found. About 30% of children have hypopituitarism up to 5 years after injury. Growth hormone deficiency and disturbances in puberty are the most common, but children can also experience ACTH deficiency, diabetes insipidus, central hypothyroidism, and elevated prolactin. Every hormonal axis can be affected after TBI in children, although growth hormone deficiency and alterations in puberty are the most common. Because transient and permanent hypopituitarism is common after TBI, survivors should be screened serially for possible endocrine disturbances. These children should undergo routine surveillance at least 1 year after injury to ensure early detection of deficiencies in hormonal production in order to permit normal growth and development.	[Rose, Susan R.; Auble, Bethany A.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA	Rose, SR (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave,MLC 7012, Cincinnati, OH 45229 USA.	susan.rose@cchmc.org					Acerini CL, 2008, J PEDIATR ENDOCR MET, V21, P611; Acerini CL, 2007, HORM RES, V68, P14, DOI 10.1159/000110465; Agha Amar, 2005, Pituitary, V8, P245, DOI 10.1007/s11102-005-3463-4; Agha A, 2007, BRIT J NEUROSURG, V21, P210, DOI 10.1080/02688690701253331; Aimaretti G, 2005, J ENDOCRINOL INVEST, V28, P984, DOI 10.1007/BF03345336; Aleksijevic D, 2011, ENDOCRINE DYSFUNCTIO; BARTON RN, 1987, J TRAUMA, V27, P384, DOI 10.1097/00005373-198704000-00007; BARZILAY Z, 1988, J MED, V19, P47; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Behan LA, 2008, J NEUROL NEUROSUR PS, V79, P753, DOI 10.1136/jnnp.2007.132837; Behan LA, 2007, HORM RES, V68, P18, DOI 10.1159/000110466; Berg C, 2010, EXP CLIN ENDOCR DIAB, V118, P139, DOI 10.1055/s-0029-1225611; BLATT J, 1984, J PEDIATR-US, V104, P182, DOI 10.1016/S0022-3476(84)80989-0; Bolado G. G., 2011, ASSESSMENT PITUITARY; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Bourguignon JP, 1997, J NEUROENDOCRINOL, V9, P193, DOI 10.1046/j.1365-2826.1997.00568.x; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; Casanueva FF, 2005, ARCH PHYS MED REHAB, V86, P463, DOI 10.1016/j.apmr.2004.05.018; CHIOLERO RL, 1988, ACTA ENDOCRINOL-COP, V117, P80, DOI 10.1530/acta.0.1170080; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Einaudi S, 2006, J PEDIATR ENDOCR MET, V19, P691; FAGLIA G, 1979, J CLIN ENDOCR METAB, V48, P989, DOI 10.1210/jcem-48-6-989; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Grumbach MM, 2002, HORM RES, V57, P2, DOI 10.1159/000058094; Hewitt J, 2011, ENDOCRINE SEQUELAE T; Kaulfers AMD, 2010, J PEDIATR-US, V157, P894, DOI 10.1016/j.jpeds.2010.07.004; Kazlauskaite R, 2008, J CLIN ENDOCR METAB, V93, P4245, DOI 10.1210/jc.2008-0710; Keenan HT, 2006, PEDIATRICS, V117, P1291, DOI 10.1542/peds.2005-1883; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Kokshoorn NE, 2010, EUR J ENDOCRINOL, V162, P11, DOI 10.1530/EJE-09-0601; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; Medic-Stoianoska M, 2007, ENDOCRINE, V31, P268, DOI 10.1007/s12020-007-0037-4; Moraes RB, 2011, ARQ BRAS ENDOCRINOL, V55, P295, DOI 10.1590/S0004-27302011000500001; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; Norwood KW, 2010, CLIN PEDIATR, V49, P1044, DOI 10.1177/0009922810376234; Pavlovic D, 2010, EUR J NEUROL, V17, P696, DOI 10.1111/j.1468-1331.2009.02910.x; Poomthavorn P, 2008, ARCH DIS CHILD, V93, P133, DOI 10.1136/adc.2007.121137; Popii V, 2004, CLIN CHIM ACTA, V350, P1, DOI 10.1016/j.cccn.2004.06.007; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; ROMSHE CA, 1984, J PEDIATR-US, V104, P177, DOI 10.1016/S0022-3476(84)80988-9; ROSE SR, 1995, PEDIATR RES, V38, P967, DOI 10.1203/00006450-199512000-00023; Rose SR, 1999, J PEDIATR ENDOCR MET, V12, P167; ROSE SR, 1989, J CLIN ENDOCR METAB, V68, P1086, DOI 10.1210/jcem-68-6-1086; Rose SR, 2001, TRENDS ENDOCRIN MET, V12, P97, DOI 10.1016/S1043-2760(00)00359-3; Rose SR, 2010, J PEDIATR-US, V157, P662, DOI 10.1016/j.jpeds.2010.04.047; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Srinivas R, 2010, CHILD NERV SYST, V26, P647, DOI 10.1007/s00381-009-1038-9; Tanriverdi F, 2008, EUR J ENDOCRINOL, V159, P7, DOI 10.1530/EJE-08-0050; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x	54	24	26	0	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1386-341X	1573-7403		PITUITARY	Pituitary	SEP	2012	15	3					267	275		10.1007/s11102-011-0360-x			9	Endocrinology & Metabolism	Endocrinology & Metabolism	006KB	WOS:000308817000001	22057966				2021-06-18	
J	Sun, S; Lee, D; Lee, NP; Pu, JKS; Wong, STS; Lui, WM; Fung, CF; Leung, GKK				Sun, Stella; Lee, Derek; Lee, Nikki P.; Pu, Jenny K. S.; Wong, Stanley T. S.; Lui, W. M.; Fung, C. F.; Leung, Gilberto K. K.			Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide	JOURNAL OF NEURO-ONCOLOGY			English	Article						Glioma; Temozolomide; Chemoresistance; Hypoxia; Apoptosis; MAPK	TRAUMATIC BRAIN-INJURY; HYPERBARIC-OXYGEN; IN-VIVO; CHEMOTHERAPY ADJUVANT; NORMOBARIC HYPEROXIA; MALIGNANT GLIOMAS; EPITHELIAL-CELLS; GENE-EXPRESSION; MAMMARY-TUMORS; LUNG INJURY	Temozolomide (TMZ) is standard chemotherapy for glioblastoma multiforme (GBM). Intratumoral hypoxia is common in GBM and may be associated with the development of TMZ resistance. Oxygen therapy has previously been reported to potentiate the effect of chemotherapy in cancer. In this study, we investigated whether hyperoxia can enhance the TMZ-induced cytotoxicity of human GBM cells, and whether and how it would resensitize TMZ-resistant GBM cells to TMZ. TMZ-sensitive human GBM cells (D54-S and U87-S) were treated with TMZ to develop isogenic subclones of TMZ-resistant cells (D54-R and U87-R). All cell lines were then exposed to different oxygen levels (1, 21, 40, or 80 %), with or without concomitant TMZ treatment, before assessment of cell cytotoxicity and morphology. Cell death and survival pathways elicited by TMZ and/or hyperoxia were elucidated by western blotting. Our results showed that TMZ sensitivity of both chemo-sensitive and resistant cells was enhanced significantly under hyperoxia. At the cell line-specific optimum oxygen concentration (D54-R, 80 %; U87-R, 40 %), resistant cells had the same response to TMZ as the parent chemosensitive cells under normoxia via the caspase-dependent pathway. Both TMZ and hyperoxia were associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and TMZ-mediated cell death. Overall, hyperoxia enhanced TMZ toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. Induced hyperoxia is a potentially promising approach for treatment of TMZ-resistant GBM.	[Sun, Stella; Lee, Derek; Lee, Nikki P.; Pu, Jenny K. S.; Wong, Stanley T. S.; Lui, W. M.; Fung, C. F.; Leung, Gilberto K. K.] Univ Hong Kong, Queen Mary Hosp, Li Ka Shing Fac Med, Div Neurosurg,Dept Surg, Hong Kong, Hong Kong, Peoples R China	Leung, GKK (corresponding author), Univ Hong Kong, Queen Mary Hosp, Li Ka Shing Fac Med, Div Neurosurg,Dept Surg, 102 Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	gilberto@hkucc.hku.hk	Leung, Gilberto Ka Kit/C-4337-2009	Leung, Gilberto Ka Kit/0000-0003-3147-3057; Wong, Thian Sze/0000-0002-8245-4019	University of Hong KongUniversity of Hong Kong [201007176020]	This work was supported by small project grant from the University of Hong Kong (project code: 201007176020).	Al-Waili NS, 2007, MED HYPOTHESES, V68, P528, DOI 10.1016/j.mehy.2005.12.054; ALAGOZ T, 1995, CANCER, V75, P2313, DOI 10.1002/1097-0142(19950501)75:9<2313::AID-CNCR2820750921>3.0.CO;2-6; Amberger-Murphy V, 2009, CURR CANCER DRUG TAR, V9, P381, DOI 10.2174/156800909788166637; Auger N, 2006, MOL CANCER THER, V5, P2182, DOI 10.1158/1535-7163.MCT-05-0428; Bar EE, 2010, AM J PATHOL, V177, P1491, DOI 10.2353/ajpath.2010.091021; Beppu T, 2002, J NEURO-ONCOL, V58, P47, DOI 10.1023/A:1015832726054; Beppu T, 2003, J NEURO-ONCOL, V61, P161, DOI 10.1023/A:1022169107872; Bocangel DB, 2002, CLIN CANCER RES, V8, P2725; Brat DJ, 2003, ANN INTERN MED, V138, P659, DOI 10.7326/0003-4819-138-8-200304150-00014; Buckley S, 1999, AM J PHYSIOL-LUNG C, V277, pL159; Chakravarti Arnab, 2008, P173; Chinot OL, 2011, ADV THER, V28, P334, DOI 10.1007/s12325-011-0007-3; D'agostino DP, 2009, NEUROSCIENCE, V159, P1011, DOI 10.1016/j.neuroscience.2009.01.062; Fischer JDD, 2011, J PROTEOME RES, V10, P153, DOI 10.1021/pr100677g; Esteller M, 1999, CANCER RES, V59, P793; Granowitz EV, 2005, ANTICANCER RES, V25, P3833; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Kalns J, 1998, ANTICANCER RES, V18, P363; Kawasoe Y, 2009, ONCOL REP, V22, P1045, DOI 10.3892/or_00000534; Konsavage WM, 2012, AM J PHYSIOL-LUNG C, V302, pL27, DOI 10.1152/ajplung.00174.2011; Kumaria A, 2009, BRIT J NEUROSURG, V23, P576, DOI 10.3109/02688690903050352; Le Calve B, 2010, NEOPLASIA, V12, P727, DOI 10.1593/neo.10526; Li LM, 2006, CLIN CANCER RES, V12, P4747, DOI 10.1158/1078-0432.CCR-05-2842; Li LM, 2005, CANCER RES, V65, P7249, DOI 10.1158/0008-5472.CAN-04-4426; Lu Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015823; Moen I, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-446; Moen I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006381; Norden AD, 2006, NEUROLOGIST, V12, P279, DOI 10.1097/01.nrl.0000250928.26044.47; O'Reilly MA, 2000, LAB INVEST, V80, P1845, DOI 10.1038/labinvest.3780195; Oliva CR, 2010, J BIOL CHEM, V285, P39759, DOI 10.1074/jbc.M110.147504; Perez-Espejo MA, 2009, NEUROCIRUGIA, V20, P449; Petrache I, 1999, AM J PHYSIOL-LUNG C, V277, pL589; Petre PM, 2003, J THORAC CARDIOV SUR, V125, P85, DOI 10.1067/mtc.2003.90; Pistollato F, 2010, STEM CELLS, V28, P851, DOI 10.1002/stem.415; Pourgholami MH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-143; Quinn JA, 2009, J CLIN ONCOL, V27, P1262, DOI 10.1200/JCO.2008.18.8417; Romashko J, 2003, FREE RADICAL BIO MED, V35, P978, DOI 10.1016/S0891-5849(03)00494-5; SEGER R, 1995, FASEB J, V9, P726; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Singhal AB, 2007, NEUROL RES, V29, P173, DOI 10.1179/016164107X181815; Stuhr LEB, 2004, CANCER LETT, V210, P35, DOI 10.1016/j.canlet.2004.02.012; Stuhr LEB, 2007, J NEURO-ONCOL, V85, P191, DOI 10.1007/s11060-007-9407-2; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Sun S, 2012, J NEURO-ONCOL, V107, P89, DOI 10.1007/s11060-011-0729-8; Takiguchi N, 2001, CANCER CHEMOTH PHARM, V47, P11, DOI 10.1007/s002800000190; Tatarkova Z, 2011, NEUROCHEM RES, V36, P1475, DOI 10.1007/s11064-011-0473-7; Tateda K, 2003, J IMMUNOL, V170, P4209, DOI 10.4049/jimmunol.170.8.4209; Tolias CM, 2009, J NEUROSURG, V110, P607, DOI 10.3171/JNS.2009.110.3.0607a; Zaher TE, 2007, FREE RADICAL BIO MED, V42, P897, DOI 10.1016/j.freeradbiomed.2007.01.021; Zhang Xiang-feng, 2004, Zhonghua Jiehe He Huxi Zazhi, V27, P465	50	24	27	1	15	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0167-594X	1573-7373		J NEURO-ONCOL	J. Neuro-Oncol.	SEP	2012	109	3					467	475		10.1007/s11060-012-0923-3			9	Oncology; Clinical Neurology	Oncology; Neurosciences & Neurology	001DZ	WOS:000308441700004	22763762	Green Published, Other Gold			2021-06-18	
J	Tu, Y; Chen, C; Sun, HT; Cheng, SX; Liu, XZ; Qu, Y; Li, XH; Zhang, S				Tu, Yue; Chen, Chong; Sun, Hong-Tao; Cheng, Shi-Xiang; Liu, Xiao-Zhi; Qu, Yang; Li, Xiao-hong; Zhang, Sai			Combination of Temperature-Sensitive Stem Cells and Mild Hypothermia: A New Potential Therapy for Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						mild hypothermia; stem cell; temperature-sensitive; transplantation; traumatic brain injury	LARGE-T-ANTIGEN; MARROW STROMAL CELLS; IN-VITRO MODEL; NONPERMISSIVE TEMPERATURE; NEURONAL DIFFERENTIATION; TRANSPLANTATION; LINES; GENE; TRANSFORMATION; EXPRESSION	Stem cell transplantation holds great potential for the treatment of traumatic brain injury (TBI). However, the micro-environment of reduced oxygen and accumulated toxins leads to low survival rates of grafted cells, which dramatically limits their clinical application. Mild hypothermia has been demonstrated to improve the micro-environment after severe TBI. Thus, we speculate that combinational therapy of mild hypothermia may promote survival of grafted cells, especially temperature-sensitive stem cells, which show the most activity in mild temperatures. In this study, we first isolated mesenchymal stem cells from umbilical cord (UCSMCs) and generated the temperature-sensitive UCSMCs (tsUCSMCs) by infection with a retrovirus carrying the temperature-sensitive tsA58 SV40 LT antigen gene. We demonstrated that tsUCSMCs grew and proliferated with more activity at 33 degrees C than at 37 degrees C by counting cell numbers with a hematocytometer, measuring the cell cycle with flow cytometry, and detecting proliferating cell nuclear antigen (PCNA) with immunofluorescence staining. Thereafter, we established the rat severe TBI model by fluid percussion, and injected PBS, UCSMCs, or tsUCSMCs into the injured region, and subject the animals to normothermia or mild hypothermia (33 degrees C). We found that, compared with UCSMC or tsUCSMC treatment alone, their combination with hypothermia could significantly improve motor and cognitive function with more survival of the grafted cells. Furthermore, we observed that combined therapy with hypothermia and tsUCSMCs exerted the most protective effect on the recovery of neurological function of all the tested treatments, with the highest survival and proliferation rates, and the lowest apoptosis rate. Thus this may represent a new therapeutic strategy for the treatment of severe TBI.	[Tu, Yue; Chen, Chong; Sun, Hong-Tao; Cheng, Shi-Xiang; Liu, Xiao-Zhi; Qu, Yang; Li, Xiao-hong; Zhang, Sai] Chinese Peoples Armed Police Forces, Logist Coll, Pingjin Hosp, Inst Traumat Brain Injury & Neurol, Tianjin 300162, Peoples R China	Zhang, S (corresponding author), Chinese Peoples Armed Police Forces, Logist Coll, Pingjin Hosp, Inst Traumat Brain Injury & Neurol, Tianjin 300162, Peoples R China.	Zhangsai718@yahoo.com			National Nature Scientific Fund of China [30872668]	This work was supported by the National Nature Scientific Fund of China (grant no. 30872668).	Bacher A, 1998, ANESTHESIOLOGY, V88, P403, DOI 10.1097/00000542-199802000-00019; Brinkkoetter PT, 2008, CELL PHYSIOL BIOCHEM, V22, P195, DOI 10.1159/000149797; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Chen LM, 2012, J NEUROCHEM, V120, P157, DOI 10.1111/j.1471-4159.2011.07275.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Dietrich WD, 2009, J NEUROTRAUM, V26, P301, DOI 10.1089/neu.2008.0806; Ebihara S, 2004, J BIOCHEM, V136, P321, DOI 10.1093/jb/mvh120; Fu YS, 2004, J BIOMED SCI, V11, P652, DOI 10.1159/000079678; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GLOBUS MYT, 1987, NEUROLOGY, V37, P1712, DOI 10.1212/WNL.37.11.1712; Hasan SM, 2010, CELL TRANSPLANT, V19, P1291, DOI 10.3727/096368910X505477; Hernandez TD, 2006, J NEUROTRAUM, V23, P1211, DOI 10.1089/neu.2006.23.1211; Hsieh JK, 2000, ARTERIOSCL THROM VAS, V20, P973, DOI 10.1161/01.ATV.20.4.973; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; Kanehira M, 2006, J BIOCHEM, V140, P211, DOI 10.1093/jb/mvj140; Karlsson J, 2005, CELL TRANSPLANT, V14, P301, DOI 10.3727/000000005783983089; Karlsson J, 2000, NEUROREPORT, V11, P1665, DOI 10.1097/00001756-200006050-00014; Kawai N, 2000, J NEUROTRAUM, V17, P193, DOI 10.1089/neu.2000.17.193; Kohno S, 2011, CELL BIOL INT, V35, P325, DOI 10.1042/CBI20090344; Koizumi M, 2004, BIOCHEM BIOPH RES CO, V319, P612, DOI 10.1016/j.bbrc.2004.04.196; Larsson O, 2004, CANCER RES, V64, P482, DOI 10.1158/0008-5472.CAN-03-1872; Li XH, 2012, NEUROBIOL AGING, V33, P1400, DOI 10.1016/j.neurobiolaging.2011.02.003; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maier CM, 2002, NEUROBIOL DIS, V11, P28, DOI 10.1006/nbdi.2002.0513; Marion D, 2009, J NEUROTRAUM, V26, P455, DOI 10.1089/neu.2008.0582; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Mitchell KE, 2003, STEM CELLS, V21, P50, DOI 10.1634/stemcells.21-1-50; Munoz-Elias G, 2003, STEM CELLS, V21, P437, DOI 10.1634/stemcells.21-4-437; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Obinata M, 1997, GENES CELLS, V2, P235, DOI 10.1046/j.1365-2443.1997.1160314.x; Oostendorp RAJ, 2002, J CELL SCI, V115, P2099; Riess P, 2007, J NEUROTRAUM, V24, P216, DOI 10.1089/neu.2006.0141; Salem HK, 2010, STEM CELLS, V28, P585, DOI 10.1002/stem.269; Shindo T, 2006, J MED INVESTIG, V53, P42, DOI 10.2152/jmi.53.42; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Tabuchi Y, 2005, BIOCHEM BIOPH RES CO, V329, P947, DOI 10.1016/j.bbrc.2005.02.065; TEGTMEYER P, 1975, J VIROL, V15, P613, DOI 10.1128/JVI.15.3.613-618.1975; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Valle-Prieto A, 2010, STEM CELLS DEV, V19, P1885, DOI 10.1089/scd.2010.0093; Wang HS, 2004, STEM CELLS, V22, P1330, DOI 10.1634/stemcells.2004-0013; Weiss ML, 2006, STEM CELLS, V24, P781, DOI 10.1634/stemcells.2005-0330; Yan Y, 2010, J CLIN NEUROSCI, V17, P196, DOI 10.1016/j.jocn.2009.05.022; YANAI N, 1994, EXP CELL RES, V211, P296, DOI 10.1006/excr.1994.1090; Yano S, 2005, BRAIN RES, V1065, P60, DOI 10.1016/j.brainres.2005.10.031; Zanier ER, 2011, CRIT CARE MED, V39, P2501, DOI 10.1097/CCM.0b013e31822629ba; Zhang F, 2009, J CEREBR BLOOD F MET, V29, P1022, DOI 10.1038/jcbfm.2009.28	52	24	32	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2012	29	14					2393	2403		10.1089/neu.2012.2374			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	004SM	WOS:000308701400003	22655683	Green Published			2021-06-18	
J	Klein, P; Herr, D; Pearl, PL; Natale, J; Levine, Z; Nogay, C; Sandoval, F; Trzcinsky, S; Atabaki, SM; Tsuchida, T; van den Anker, J; Soldin, SJ; He, JP; McCarter, R				Klein, Pavel; Herr, Daniel; Pearl, Phillip L.; Natale, JoAnne; Levine, Zachary; Nogay, Claude; Sandoval, Fabian; Trzcinsky, Stacey; Atabaki, Shireen M.; Tsuchida, Tammy; van den Anker, John; Soldin, Steven J.; He, Jianping; McCarter, Robert			Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy	EPILEPSY & BEHAVIOR			English	Article						Epilepsy; Seizures; Post-traumatic epilepsy; Traumatic brain injury; Head injury; Levetiracetam; Pharmacokinetics; Epilepsy prevention; Saliva	INTRAVENOUS-INFUSION; SEIZURES; PLACEBO; EPILEPTOGENESIS; CHILDREN	Levetiracetam (LEV) has antiepileptogenic effects in animals and is a candidate for prevention of epilepsy after traumatic brain injury. Pharmacokinetics of LEV in TBI patients was unknown. We report pharmacokinetics of TBI subjects >= 6 years with high PTE risk treated with LEV 55 mg/kg/day orally, nasogastrically or intravenously for 30 days starting <= 8 h after injury in a phase II safety and pharmacokinetic study. Forty-one subjects (26 adults and 15 children) were randomized to PK studies on treatment days 3 and 30. Thirty-six out of forty-one randomized subjects underwent PK study on treatment day 3, and 24/41 subjects underwent PK study on day 30. On day 3, mean T-max was 2.2 h, C-max was 60.2 mu g/ml and AUC was 403.7 mu g/h/ml. T-max was longer in the elderly than in children and non-elderly adults (5.96 h vs. 1.5 h and 1.8 h; p=0.0001). AUC was non-significantly lower in children compared with adults and the elderly (317.4 mu g/h/ml vs. 461.4 mu g/h/ml and 450.2 mu g/h/ml; p=0.08). C-max trended higher in i.v.-versus tablet-or n.g.-treated subjects (78.4 mu g/ml vs. 59 mu g/ml and 48.2 mu g/ml; p=0.07). AUC of n.g. and i.v. administrations was 79% and 88% of AUC of oral administration. There were no significant PK differences between days 3 and 30. Treatment of TBI patients with high PTE risk with 55 mg/kg/day LEV, a dose with antiepileptogenic effect in animals, results in plasma LEV levels comparable to those in animal studies. (C) 2012 Elsevier Inc. All rights reserved.	[Klein, Pavel] Mid Atlantic Epilepsy & Sleep Ctr, Bethesda, MD 20817 USA; [Klein, Pavel; Herr, Daniel; Levine, Zachary; Nogay, Claude; Sandoval, Fabian] MedStar Res Inst, Dept Neurol, Washington, DC 20010 USA; [Pearl, Phillip L.; Natale, JoAnne; Trzcinsky, Stacey; Tsuchida, Tammy; van den Anker, John; Soldin, Steven J.; He, Jianping; McCarter, Robert] Childrens Natl Med Ctr, Dept Neurol, Washington, DC 20010 USA; [Atabaki, Shireen M.] Childrens Natl Med Ctr, Dept Emergency Med, Washington, DC 20010 USA	Klein, P (corresponding author), Mid Atlantic Epilepsy & Sleep Ctr, 6410 Rockledge Dr,Suite 410, Bethesda, MD 20817 USA.	kleinp@epilepsydc.com	Herr, Daniel/X-4215-2019	Herr, Daniel/0000-0001-8533-9000	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1 R01 NS45656]; NIH National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR031988, M01RR020359]; Intellectual and Developmental Disabilities Research Center of the NIH National Center for Child Health and Human Development [P30HD040677]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD040677] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000101] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR031987, M01RR020359, UL1RR031988] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045656] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL010355] Funding Source: NIH RePORTER	The study was supported by the NIH, grant 1 R01 NS45656, and by Award Numbers UL1RR031988 and M01RR020359 from the NIH National Center for Research Resources, as well as Award Number P30HD040677 from the Intellectual and Developmental Disabilities Research Center of the NIH National Center for Child Health and Human Development. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. The investigators would like to thank Michelle Mendoza, MD, Be Tadzong, MD, Jennifer Scarito, RN, Nazli Bolouri, MD and Said Goudarzi for assistance with the study.	Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS83; Fountain NB, 2007, EPILEPSY RES, V74, P60, DOI 10.1016/j.eplepsyres.2006.12.005; Glauser TA, 2006, NEUROLOGY, V66, P1654, DOI 10.1212/01.wnl.0000217916.00225.3a; Guo TD, 2007, CLIN CHIM ACTA, V375, P115, DOI 10.1016/j.cca.2006.06.022; Klein P, ARCH NEUROL IN PRESS; Loscher W, 2010, PHARMACOL REV, V62, P668, DOI 10.1124/pr.110.003046; Patsalos PN, 2000, PHARMACOL THERAPEUT, V85, P77, DOI 10.1016/S0163-7258(99)00052-2; Pellock JM, 2001, EPILEPSIA, V42, P1574, DOI 10.1046/j.1528-1157.2001.41300.x; Ramael S, 2006, CLIN THER, V28, P734, DOI 10.1016/j.clinthera.2006.05.004; Ramael S, 2006, EPILEPSIA, V47, P1128, DOI 10.1111/j.1528-1167.2006.00586.x; SILVER JM, 1991, ANN NEUROL, V29, P356, DOI 10.1002/ana.410290404; Statler KD, 2006, DEV NEUROSCI-BASEL, V28, P354, DOI 10.1159/000094162; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; *UCB PHARM INC, 1999, DAT FIL	15	24	24	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050			EPILEPSY BEHAV	Epilepsy Behav.	AUG	2012	24	4					457	461		10.1016/j.yebeh.2012.05.011			5	Behavioral Sciences; Clinical Neurology; Psychiatry	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	980NO	WOS:000306900300013	22771222	Green Accepted			2021-06-18	
J	Plantman, S				Plantman, Stefan			Osteopontin is upregulated after mechanical brain injury and stimulates neurite growth from hippocampal neurons through beta 1 integrin and CD44	NEUROREPORT			English	Article						brain injury; cell cultures; central nervous system; extracellular matrix; neurite growth	DORSAL-ROOT GANGLION; SPINAL-CORD-INJURY; EXPRESSION; ADULT; OUTGROWTH; MICROGLIA; STROKE; TISSUE; CELLS; GENE	Brain trauma induces a multitude of reactions at molecular, cellular, and tissue levels, some of which are beneficial to recovery, whereas others are detrimental. Osteopontin (OPN), a glycosylated phosphoprotein, can be found in both the soluble form and as an extracellular matrix constituent in several tissues in the vertebrate body, but its function after brain injury is largely unknown. In this study, the expression of OPN after an experimental traumatic brain injury in rats was examined and its effects on hippocampal neurons and cortical astrocytes were studied using cell-culture techniques. OPN had no influence astrocyte behavior in a scratch assay. However, hippocampal neurons grew well on an OPN substrate with growth comparable to that seen on laminin, but showed a higher degree of primary neurites. Finally, growth on OPN was mediated through beta 1 intregrins and CD44. These findings indicate that injury-induced OPN may support neurite sprouting, suggesting a role for this molecule in recovery from central nervous system trauma. NeuroReport 23:647-652 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.	Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden	Plantman, S (corresponding author), Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden.	stefan.plantman@ki.se		plantman, stefan/0000-0003-2236-4238	Swedish Brain Foundation (Hjarnfonden); Karolinska Institutet (KI fonder)	S.P. is supported by a grant from the Swedish Brain Foundation (Hjarnfonden). This study was financed by grants from Karolinska Institutet (KI fonder) to S.P.	Busch SA, 2010, J NEUROSCI, V30, P255, DOI 10.1523/JNEUROSCI.3705-09.2010; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Carmichael ST, 2002, J NEUROSCI, V22, P6062; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Christopherson KS, 2005, CELL, V120, P421, DOI 10.1016/j.cell.2004.12.020; DAGERLIND A, 1992, HISTOCHEMISTRY, V98, P39, DOI 10.1007/BF00716936; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Hashimoto M, 2003, J NEUROTRAUM, V20, P287, DOI 10.1089/089771503321532879; Hashimoto M, 2007, J NEUROSCI, V27, P3603, DOI 10.1523/JNEUROSCI.4805-06.2007; Hikita ST, 2003, MOL CELL NEUROSCI, V23, P427, DOI 10.1016/S1044-7431(03)00065-4; Hynds DL, 2004, GLIA, V46, P218, DOI 10.1002/glia.10353; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Jander S, 2002, J NEUROSCI RES, V67, P156, DOI 10.1002/jnr.10099; Jones LL, 2000, J COMP NEUROL, V426, P468, DOI 10.1002/1096-9861(20001023)426:3<468::AID-CNE9>3.0.CO;2-I; Kury P, 2004, FASEB J, V18, P398, DOI 10.1096/fj.04-1777fje; Marsh BCL, 2007, NEUROREPORT, V18, P153, DOI 10.1097/WNR.0b013e328010d4fa; Meller R, 2005, J CEREBR BLOOD F MET, V25, P217, DOI 10.1038/sj.jcbfm.9600022; Pinkstaff JK, 1999, J NEUROSCI, V19, P1541; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; Ries A, 2007, J NEUROCHEM, V103, P1491, DOI 10.1111/j.1471-4159.2007.04858.x; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Stylli SS, 2000, J CLIN NEUROSCI, V7, P137, DOI 10.1054/jocn.1999.0187; Tom VJ, 2004, J NEUROSCI, V24, P9282, DOI 10.1523/JNEUROSCI.2120-04.2004; Wang XK, 1998, J NEUROSCI, V18, P2075; Zhang D, 2010, MOL NEUROBIOL, V41, P232, DOI 10.1007/s12035-010-8098-4	25	24	24	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	AUG 1	2012	23	11					647	652		10.1097/WNR.0b013e328355380e			6	Neurosciences	Neurosciences & Neurology	972AQ	WOS:000306249300003	22692550				2021-06-18	
J	Rattka, M; Brandt, C; Loscher, W				Rattka, Marta; Brandt, Claudia; Loescher, Wolfgang			Do proconvulsants modify or halt epileptogenesis? Pentylenetetrazole is ineffective in two rat models of temporal lobe epilepsy	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						antiepileptogenesis; epileptogenesis; GABA; glutamate; pilocarpine; seizures; status epilepticus	TRAUMATIC BRAIN-INJURY; ACUTE SYMPTOMATIC SEIZURE; STATUS EPILEPTICUS; GABAERGIC INHIBITION; POSTTRAUMATIC EPILEPSY; RECEPTOR ANTAGONIST; PILOCARPINE MODEL; MULTIPLE FACETS; P-GLYCOPROTEIN; ANIMAL-MODELS	In patients at risk of developing epilepsy after an initial precipitating injury to the brain, the epileptogenic latent period may offer a window of opportunity for initiating potential antiepileptogenic therapy in an attempt to prevent epilepsy from developing. One potential target for antiepileptogenesis is the development of neuronal hyperexcitability during the latent period. Surprisingly, some recent studies in models of temporal lobe epilepsy (TLE) have suggested that proconvulsant drugs could have favourable effects on epileptogenesis, resulting in the proposal of pursuing proconvulsant prophylaxis for epileptogenesis. In the present study, we evaluated this provocative hypothesis by experiments with the GABAA receptor antagonist pentylenetetrazole (PTZ) in two TLE models, the intrahippocampal kainate model and the lithiumpilocarpine model in rats. First, we repeatedly determined the PTZ seizure threshold by i.v. infusion of the convulsant during the latent period following intrahippocampal kainate. In line with recent experiments in the lithiumpilocarpine model, the PTZ seizure threshold was significantly decreased over several days following status epilepticus. We then studied whether prolonged infusion of a proconvulsant dose of PTZ at different times after kainate or pilocarpine affected the development of epilepsy. PTZ did not prevent the development of spontaneous recurrent seizures and did not decrease their frequency or severity, but exerted only a moderate disease-modifying effect in that spontaneous seizures in the kainate model were significantly shortened. These data indicate that administration of proconvulsant drugs such as PTZ during the latent period following SE is not a promising strategy for preventing epilepsy.	[Rattka, Marta; Brandt, Claudia; Loescher, Wolfgang] Univ Vet Med, Dept Pharmacol Toxicol & Pharm, D-30559 Hannover, Germany; [Rattka, Marta; Brandt, Claudia; Loescher, Wolfgang] Ctr Syst Neurosci, Hannover, Germany	Loscher, W (corresponding author), Univ Vet Med, Dept Pharmacol Toxicol & Pharm, Bunteweg 17, D-30559 Hannover, Germany.	wolfgang.loescher@tiho-hannover.de	Loscher, Wolfgang/G-9824-2016	Loscher, Wolfgang/0000-0002-9648-8973	Deutsche Forschungsgemeinschaft (Bonn, Germany)German Research Foundation (DFG) [Lo 274/10]; Friedrich-Ebert-Stiftung (Bonn, Germany)	We thank Dr Robert S. Sloviter for constructive discussion of our manuscript, Nicole Ernst, Philip Demmer, Julia Hinz and Stefan Obili for skilful technical assistance, and Dr Kathrin Tollner for providing data on SE controls from the pilocarpine models. The study was supported by a grant (Lo 274/10) from the Deutsche Forschungsgemeinschaft (Bonn, Germany). Marta Rattka receives a scholarship from the Friedrich-Ebert-Stiftung (Bonn, Germany).	Armstrong C, 2009, EPILEPSIA, V50, P1657, DOI 10.1111/j.1528-1167.2009.02173.x; Atkins CM, 2010, EUR J NEUROSCI, V32, P1912, DOI 10.1111/j.1460-9568.2010.07467.x; Bankstahl JP, 2008, EPILEPSY RES, V82, P70, DOI 10.1016/j.eplepsyres.2008.07.007; Beghi E, 2010, EPILEPSIA, V51, P671, DOI 10.1111/j.1528-1167.2009.02285.x; Ben-Ari Y, 2005, CURR OPIN NEUROL, V18, P141, DOI 10.1097/01.wco.0000162855.75391.6a; Blaesse P, 2009, NEURON, V61, P820, DOI 10.1016/j.neuron.2009.03.003; Bragin A, 2005, EPILEPSIA, V46, P1592, DOI 10.1111/j.1528-1167.2005.00268.x; Bragin A, 2004, EPILEPSIA, V45, P1017, DOI 10.1111/j.0013-9580.2004.17004.x; Bragin A, 2009, J NEUROSCI, V29, P3660, DOI 10.1523/JNEUROSCI.5309-08.2009; Brandt C, 2010, J NEUROSCI, V30, P8602, DOI 10.1523/JNEUROSCI.0633-10.2010; Chang BS, 2003, NEW ENGL J MED, V349, P1257, DOI 10.1056/NEJMra022308; Chen K, 2007, J NEUROSCI, V27, P46, DOI 10.1523/JNEUROSCI.3966-06.2007; Cossart R, 2005, TRENDS NEUROSCI, V28, P108, DOI 10.1016/j.tins.2004.11.011; Coulter DA, 2002, BRAIN PATHOL, V12, P240; Coulter DA, 2001, INT REV NEUROBIOL, V45, P237; Dichter MA, 2009, EPILEPSIA, V50, P41, DOI 10.1111/j.1528-1167.2008.02009.x; Dudek FE, 2010, EPILEPSIA, V51, P126, DOI 10.1111/j.1528-1167.2010.02626.x; Dudek FE, 2009, NEUROTHERAPEUTICS, V6, P319, DOI 10.1016/j.nurt.2009.01.020; Echegoyen J, 2009, EPILEPSY RES, V85, P123, DOI 10.1016/j.eplepsyres.2009.02.019; ESPLIN DW, 1956, J PHARMACOL EXP THER, V118, P129; Everett J W, 1989, Monogr Endocrinol, V32, P1; FINN DA, 1994, J PHARMACOL EXP THER, V271, P164; Friedman A, 2011, EPILEPSIA, V52, P19, DOI 10.1111/j.1528-1167.2011.03227.x; Gernert M, 2001, EUR J PHARMACOL, V432, P35, DOI 10.1016/S0014-2999(01)01458-3; Glien M, 2001, EPILEPSY RES, V46, P111, DOI 10.1016/S0920-1211(01)00272-8; Golarai G, 2001, J NEUROSCI, V21, P8523; HALONEN T, 1995, BRAIN RES, V693, P217, DOI 10.1016/0006-8993(95)00744-B; Hesdorffer DC, 2009, EPILEPSIA, V50, P1102, DOI 10.1111/j.1528-1167.2008.01945.x; Jacobs MP, 2009, EPILEPSY BEHAV, V14, P438, DOI 10.1016/j.yebeh.2009.02.036; Khalilov I, 2002, J NEUROPHYSIOL, V88, P523, DOI 10.1152/jn.2002.88.1.523; Khazipov R, 2003, J NEUROSCI, V23, P5337; Klaassen A, 2006, P NATL ACAD SCI USA, V103, P19152, DOI 10.1073/pnas.0608215103; Kohling R, 1998, BRAIN, V121, P1073, DOI 10.1093/brain/121.6.1073; Kohling R, 2002, SCIENCE, V298, P1350; Kohling R, 2000, J NEUROSCI, V20, P6820, DOI 10.1523/JNEUROSCI.20-18-06820.2000; Kucker S, 2010, NEUROBIOL DIS, V37, P661, DOI 10.1016/j.nbd.2009.12.002; Loscher W, 2010, PHARMACOL REV, V62, P668, DOI 10.1124/pr.110.003046; Loscher W, 2009, EUR J PHARMACOL, V610, P1, DOI 10.1016/j.ejphar.2009.03.025; LOSCHER W, 1995, EPILEPSIA, V36, P929, DOI 10.1111/j.1528-1157.1995.tb01637.x; Mann EO, 2008, CURR OPIN NEUROL, V21, P155, DOI 10.1097/WCO.0b013e3282f52f5f; NEHLIG A, 1992, BRAIN RES REV, V17, P139, DOI 10.1016/0165-0173(92)90012-B; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Payne JA, 2003, TRENDS NEUROSCI, V26, P199, DOI 10.1016/S0166-2236(03)00068-7; Pitkanen A, 2009, EPILEPSY BEHAV, V14, P16, DOI 10.1016/j.yebeh.2008.09.023; Pitkanen A, 2004, EPILEPSY RES, V61, P119, DOI 10.1016/j.eplepsyres.2004.07.005; Pitkanen A, 2007, EPILEPSIA, V48, P13, DOI 10.1111/j.1528-1167.2007.01063.x; Pitkanen A, 2011, LANCET NEUROL, V10, P173, DOI 10.1016/S1474-4422(10)70310-0; Pitkanen A, 2010, EPILEPSIA, V51, P2, DOI 10.1111/j.1528-1167.2010.02602.x; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; Potschka H, 2001, EPILEPSIA, V42, P1231, DOI 10.1046/j.1528-1157.2001.01901.x; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Raedt R, 2009, ACTA NEUROL SCAND, V119, P293, DOI 10.1111/j.1600-0404.2008.01108.x; RAMZAN IM, 1985, J PHARMACOL EXP THER, V234, P624; Rattka M, 2011, NEUROPHARMACOLOGY, V60, P505, DOI 10.1016/j.neuropharm.2010.11.005; Rigoulot MA, 2003, EPILEPSIA, V44, P529, DOI 10.1046/j.1528-1157.2003.50502.x; SHORR EPHRAIM, 1941, SCIENCE, V94, P545, DOI 10.1126/science.94.2449.545-a; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; Sloviter RS, 2003, J COMP NEUROL, V459, P44, DOI 10.1002/cne.10630; Statler KD, 2008, EPILEPSY RES, V80, P163, DOI 10.1016/j.eplepsyres.2008.04.001; Stefan H, 2006, ACTA NEUROL SCAND, V113, P139, DOI 10.1111/j.1600-0404.2005.00561.x; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; VOHLAND HW, 1976, N-S ARCH PHARMACOL, V293, P277, DOI 10.1007/BF00507350; Wallace MJ, 2003, J PHARMACOL EXP THER, V307, P129, DOI 10.1124/jpet.103.051920; Wallace MJ, 2002, EUR J PHARMACOL, V452, P295, DOI 10.1016/S0014-2999(02)02331-2; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496	65	24	24	0	14	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	AUG	2012	36	4					2505	2520		10.1111/j.1460-9568.2012.08143.x			16	Neurosciences	Neurosciences & Neurology	993XO	WOS:000307893500012	22672239				2021-06-18	
J	Kang, GH; Yan, BC; Cho, GS; Kim, WK; Lee, CH; Cho, JH; Kim, M; Kang, IJ; Won, MH; Lee, JC				Kang, Gu Hyun; Yan, Bing Chun; Cho, Geum-Sil; Kim, Won-Ki; Lee, Choong Hyun; Cho, Jun Hwi; Kim, Missok; Kang, Il-Jun; Won, Moo-Ho; Lee, Jae-Chul			Neuroprotective effect of fucoidin on lipopolysaccharide accelerated cerebral ischemic injury through inhibition of cytokine expression and neutrophil infiltration	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Sulfated polysaccharide; Corpus callosum; Neuroprotection; Cytokines/chemokines; Neutrophil recruitment	INFLAMMATORY CELL INFILTRATION; TRAUMATIC BRAIN-INJURY; POLYSACCHARIDE FUCOIDIN; LEUKOCYTE INFILTRATION; REPERFUSION INJURY; BLOOD-FLOW; IN-VIVO; PNEUMOCOCCAL MENINGITIS; CEREBROSPINAL-FLUID; ARTERY OCCLUSION	In our previous study, we reported that lipopolysaccharide (LPS) activated microglia and accelerated cerebral ischemic injury in the rat brain through the overexpression of cytokines in microglia. In the present study, we investigated the effect of the intraperitoneal administration of fucoidin, a potent inhibitor of leukocyte rolling and anti-inflammatory agent, against accelerated cerebral ischemic injury by LPS pretreatment using rats. We found that fucoidin treatment inhibited the expressions of some brain cytokine or chemokine mRNA such as IL-8, TNF-alpha and iNOS in the brain of the rats treated only with LPS. We also observed that fucoidin treatment dramatically decreased the infarct size in accelerated cerebral ischemic injury induced by LPS treatment at an early time after ischemic injury. In addition, the immunoreactivity of myleoperoxidase (MPO), a marker for quantifying neutrophil accumulation, was distinctively decreased in the ischemic brain of the fucoidin-treated rat. In brief, our results indicate that fucoidin showed a neuroprotective effect on LPS accelerated cerebral ischemic injury through inhibiting the expression of some cytokine/chemokine and neutrophil recruitments. (C) 2012 Elsevier B.V. All rights reserved.	[Yan, Bing Chun; Won, Moo-Ho] Kangwon Natl Univ, Dept Neurobiol, Sch Med, Chunchon 200701, South Korea; [Kang, Gu Hyun] Hallym Univ, Dept Emergency Med, Kangnam Sacred Heart Hosp, Coll Med, Seoul 150950, South Korea; [Yan, Bing Chun; Won, Moo-Ho] Kangwon Natl Univ, Inst Med Sci, Sch Med, Chunchon 200701, South Korea; [Cho, Geum-Sil; Kim, Won-Ki] Korea Univ, Coll Med, Dept Neurosci, Seoul 136705, South Korea; [Lee, Choong Hyun] Dankook Univ, Dept Anat & Physiol, Coll Pharm, Cheonan 330714, South Korea; [Cho, Jun Hwi] Kangwon Natl Univ, Dept Emergency Med, Kangwon Natl Univ Hosp, Sch Med, Chunchon 200701, South Korea; [Cho, Jun Hwi] Kangwon Natl Univ, Inst Med Sci, Kangwon Natl Univ Hosp, Sch Med, Chunchon 200701, South Korea; [Kim, Missok] Dankook Univ, Dept Food Sci & Nutr, Yongin 448701, South Korea; [Kang, Il-Jun] Hallym Univ, Dept Food Sci & Nutr, Chunchon 200702, South Korea; [Lee, Jae-Chul] Seoul Natl Univ Hosp, Biomed Res Inst, Seoul 110744, South Korea	Won, MH (corresponding author), Kangwon Natl Univ, Dept Neurobiol, Sch Med, Chunchon 200701, South Korea.	mhwon@kangwon.ac.kr; anajclee@hanmail.net			Brain Research Center of the 21st Century Frontier Research ProgramMinistry of Education, Science and Technology, Republic of Korea [2010K000823]; Ministry of Education, Science and Technology, the Republic of KoreaMinistry of Education, Science and Technology, Republic of Korea; National Research Foundation of Korea (NRF)National Research Foundation of Korea; Ministry of Education, Science and TechnologyMinistry of Education, Science and Technology, Republic of Korea [2011-0007307]	This work was supported by a grant (2010K000823) from the Brain Research Center of the 21st Century Frontier Research Program funded by the Ministry of Education, Science and Technology, the Republic of Korea, and by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2011-0007307).	Ahmed SH, 2000, STROKE, V31, P193, DOI 10.1161/01.STR.31.1.193; Antonicelli F, 2004, AM J PHYSIOL-LUNG C, V286, pL1319, DOI 10.1152/ajplung.00329.2003; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; BELAYEV L, 1996, STROKE, V27, P1623; Chamorro A, 2006, STROKE, V37, P291, DOI 10.1161/01.STR.0000200561.69611.f8; Chi OZ, 2011, J NEUROL SCI, V301, P66, DOI 10.1016/j.jns.2010.10.024; Danielisova V, 2007, J NEUROL SCI, V253, P61, DOI 10.1016/j.jns.2006.12.001; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; Davies CA, 1998, EXP NEUROL, V154, P199, DOI 10.1006/exnr.1998.6891; De Lema GP, 2001, J AM SOC NEPHROL, V12, P1369, DOI 10.1681/ASN.V1271369; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Durmaz R, 2008, NEUROSCIENCES, V13, P217; Emerich DF, 2002, EXP NEUROL, V173, P168, DOI 10.1006/exnr.2001.7835; Granert C, 1998, CLIN DIAGN LAB IMMUN, V5, P322, DOI 10.1128/CDLI.5.3.322-324.1998; Granert C, 1999, INFECT IMMUN, V67, P2071, DOI 10.1128/IAI.67.5.2071-2074.1999; HALLENBECK JM, 1986, STROKE, V17, P246, DOI 10.1161/01.STR.17.2.246; Haqqani AS, 2000, NEOPLASIA, V2, P561, DOI 10.1038/sj.neo.7900110; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; KOCHANEK PM, 1987, STROKE, V18, P634, DOI 10.1161/01.STR.18.3.634; Lakhan SE, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-97; Lee JC, 2005, GLIA, V50, P168, DOI 10.1002/glia.20164; Li CM, 2011, FOOD CHEM TOXICOL, V49, P2090, DOI 10.1016/j.fct.2011.05.022; Mirabelli-Badenier M, 2011, THROMB HAEMOSTASIS, V105, P409, DOI 10.1160/TH10-10-0662; Omata M, 1997, J CARDIOVASC PHARM, V30, P717, DOI 10.1097/00005344-199712000-00003; Pochechueva TV, 2003, BIOORG MED CHEM LETT, V13, P1709, DOI 10.1016/S0960-894X(03)00234-8; Raza SS, 2011, J NEUROL SCI, V309, P45, DOI 10.1016/j.jns.2011.07.035; Rhodes J, 2011, CURR OPIN CRIT CARE, V17, P122, DOI 10.1097/MCC.0b013e3283447948; Samson Y, 2005, REV NEUROL-FRANCE, V161, P1177; Shimaoka M, 1996, AM J RESP CRIT CARE, V153, P307, DOI 10.1164/ajrccm.153.1.8542135; Spencer SJ, 2007, STROKE, V38, P1570, DOI 10.1161/STROKEAHA.106.476507; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; Teixeira MM, 1997, BRIT J PHARMACOL, V120, P1059, DOI 10.1038/sj.bjp.0701024; Tuttolomondo A, 2008, CURR PHARM DESIGN, V14, P3574, DOI 10.2174/138161208786848739; WANG PY, 1993, STROKE, V24, P236, DOI 10.1161/01.STR.24.2.236; Wang YP, 2008, J NEUROL SCI, V267, P107, DOI 10.1016/j.jns.2007.10.004; Weston RM, 2007, J CEREBR BLOOD F MET, V27, P100, DOI 10.1038/sj.jcbfm.9600324; Witko-Sarsat V, 2000, LAB INVEST, V80, P617, DOI 10.1038/labinvest.3780067; Zhou H, 2006, J IMMUNOL, V177, P8103, DOI 10.4049/jimmunol.177.11.8103	40	24	27	2	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	JUL 15	2012	318	1-2					25	30		10.1016/j.jns.2012.04.013			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	964BK	WOS:000305668500003	22560605				2021-06-18	
J	Nalder, E; Fleming, J; Cornwell, P; Foster, M				Nalder, Emily; Fleming, Jennifer; Cornwell, Petrea; Foster, Michele			Linked Lives: The Experiences of Family Caregivers During the Transition from Hospital to Home Following Traumatic Brain Injury	BRAIN IMPAIRMENT			English	Article						transition; family caregiver; community integration; lived experience	LIFE SATISFACTION; SOCIAL SUPPORT; STROKE; NEEDS; IMPACT; HOPE; INDIVIDUALS; PREDICTORS; DISCHARGE; SYMPTOMS	The transition from hospital to home following traumatic brain injury (TBI) has been identified as the point where responsibility for care shifts from rehabilitation services to informal family caregivers. There has, however, been little research examining the experiences of family members during this important transition that involves adopting or, in some cases, resuming a caring role (e.g., a parent caring for an adult child). The aim of this qualitative investigation was to understand the experiences of family caregivers during the transition from hospital to home, defined as the first six months postdischarge. The sample included 10 family caregivers, of which all were female and either a mother, spouse or ex-partner of an individual with TBI. Semistructured interviews were conducted on average nine months following community reentry and data were analysed thematically using a framework approach. The overarching theme was that caregivers wished to move past the injury. This desire to move forward stemmed from a realisation of how their life had changed and the weight of the care responsibility. Caregivers were also aware of how the life of the individual with a TBI had changed and hoped for a return to normality (by regaining independence, engaging in meaningful occupation and having meaningful relationships). Implications of the findings for research and clinical practice are discussed. There is a need for services to support family caregivers during the transition from hospital to home.	[Nalder, Emily; Fleming, Jennifer] Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia; [Fleming, Jennifer] Queensland Hlth, Ctr Functioning & Hlth Res, Brisbane, Qld, Australia; [Fleming, Jennifer] Princess Alexandra Hosp, Queensland Hlth, Occupat Therapy Dept, Brisbane, Qld, Australia; [Cornwell, Petrea] Griffith Univ, Griffith Hlth Inst, Brisbane, Qld 4111, Australia; [Foster, Michele] Univ Queensland, Sch Social Work & Human Serv, Brisbane, Qld 4072, Australia	Nalder, E (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia.	e.nalder@uq.edu.au	Cornwell, Petrea/AAE-5547-2019		Australian Research CouncilAustralian Research Council [LP0776294]; Queensland Government Department of Communities (Disability Services); Acquired Brain Injury Outreach Service	The authors wish to acknowledge the funding support provided by way of an Australian Research Council Linkage Grant (LP0776294) and from partner organisations Queensland Government Department of Communities (Disability Services) and the Acquired Brain Injury Outreach Service. Our sincere appreciation goes also to Professor Linda Worrall, Dr Terry Haines, Dr Tamara Ownsworth, Dr Melissa Kendall and Professor Lesley Chenoweth for their contribution to the design and development of this project. The authors are also grateful to Mrs Cassandra Shields for her assistance in the peer-checking process.	Arnaert Antonia, 2006, Holist Nurs Pract, V20, P137; Australian Bureau of Statistics, 1993, DIS AG CAR BRAIN INJ; Backstrom B, 2007, NURS INQ, V14, P243, DOI 10.1111/j.1440-1800.2007.00373.x; Bluvol A, 2004, J ADV NURS, V48, P322, DOI 10.1111/j.1365-2648.2004.03004.x; Borneman T., 2002, J HOSPICE PALLIATIVE, V4, P21, DOI DOI 10.1097/00129191-200201000-00012; Chwalisz K, 1996, Appl Neuropsychol, V3, P28, DOI 10.1207/s15324826an0301_5; Creswell J. W., 2017, DESIGNING CONDUCTING; Cross A, 2010, TOP STROKE REHABIL, V17, P484, DOI 10.1310/tsr1706-484; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Elder G.H., 2009, CRAFT LIFE COURSE RE; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Fraser C, 1999, J Neurosci Nurs, V31, P9; Gebhardt MC, 2011, REHABIL NURS, V36, P3, DOI 10.1002/j.2048-7940.2011.tb00059.x; Gum A, 2006, PSYCHOL HEALTH, V21, P319, DOI 10.1080/14768320500422907; Johnson B P, 1995, J Neurosci Nurs, V27, P113; Jumisko E, 2007, J FAM NURS, V13, P353, DOI 10.1177/1074840707303842; Keenan Alanna, 2010, Can J Neurosci Nurs, V32, P25; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; Kreutzer JS, 2009, BRAIN INJURY, V23, P535, DOI 10.1080/02699050902926291; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Leathem J, 1996, BRAIN INJURY, V10, P27; Livingston LA, 2010, NEUROREHABILITATION, V27, P73, DOI 10.3233/NRE-2010-0582; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Michels N, 1988, Home Health Care Serv Q, V9, P29, DOI 10.1300/J027v09n01_03; Minichiello V., 1995, IN DEPTH INTERVIEWIN; Murray HM, 2006, BRAIN INJURY, V20, P575, DOI 10.1080/02699050600664590; Nalder E., 2011, REFLECTIONS LI UNPUB; Nalder E, 2012, J HEAD TRAUMA REHAB, V27, P143, DOI 10.1097/HTR.0b013e3182168fb1; O'Callaghan AM, 2011, INT J SPEECH-LANG PA, V13, P218, DOI 10.3109/17549507.2011.549240; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; Patton MQ., 1990, QUALITATIVE EVALUATI; Peleg G, 2009, BRAIN INJURY, V23, P800, DOI 10.1080/02699050903196696; Penna S, 2010, J HEAD TRAUMA REHAB, V25, P52, DOI 10.1097/HTR.0b013e3181c29952; QSR International, 2010, NVIVO QUAL DAT AN SO; Ritchie J., 2003, QUALITATIVE RES PRAC; Rotondi AJ, 2007, J HEAD TRAUMA REHAB, V22, P14, DOI 10.1097/00001199-200701000-00002; TATE RL, 2003, 26 ANN BRAIN IMP C S; Tooth L, 2001, BRAIN INJURY, V15, P613, DOI 10.1080/02699050010013923; Turner B, 2010, BRAIN IMPAIR, V11, P281, DOI 10.1375/brim.11.3.281; Turner B, 2007, BRAIN INJURY, V21, P1119, DOI 10.1080/02699050701651678; Turner BJ, 2008, DISABIL REHABIL, V30, P1153, DOI 10.1080/09638280701532854; Turner BJ, 2011, DISABIL REHABIL, V33, P818, DOI 10.3109/09638288.2010.513422; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Willis J.W., 2007, FDN QUALITATIVE RES; World Health Organization, 2001, INT CLASS FUNCT DIS	47	24	24	0	30	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1443-9646	1839-5252		BRAIN IMPAIR	Brain Impair.	JUL	2012	13	1			SI		108	122		10.1017/BrImp.2012.4			15	Clinical Neurology; Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	964VQ	WOS:000305725200010		Green Published			2021-06-18	
J	Yang, H; Feng, GD; Liang, Z; Vitale, A; Jiao, XY; Ju, G; You, SW				Yang, Hao; Feng, Guo-Dong; Liang, Zhe; Vitale, Angela; Jiao, Xi-Ying; Ju, Gong; You, Si-Wei			In vitro beneficial activation of microglial cells by mechanically-injured astrocytes enhances the synthesis and secretion of BDNF through p38MAPK	NEUROCHEMISTRY INTERNATIONAL			English	Article						Astrocyte; Mechanical injury; Microglial cell; BDNF; p38MAPK; Rat	TUMOR-NECROSIS-FACTOR; NERVE GROWTH-FACTOR; SPINAL-CORD-INJURY; NEUROTROPHIC FACTOR; PROTEIN-KINASE; NEURITE OUTGROWTH; MESSENGER-RNAS; ACUTE NEURODEGENERATION; OXIDATIVE STRESS; INTERFERON-GAMMA	It has long been promulgated that microglial cells serve beneficial roles in the central nervous system (CNS). The beneficial role of microglial cells is considered to be linked with microglial activation and consequent up-regulation of various trophic factors. However, what triggers microglial activation and consequent elevated level of trophic factors, especially brain-derived neurotrophic factor (BDNF), following traumatic CNS injury has become a crucial but elusive issue. Furthermore, an effort still remains in understanding of the cellular and molecular mechanisms underlying the endogenous neuroprotection of activated microglial cells. In this study, we demonstrated that mechanically-injured astrocyte conditioned medium (ACM) could provoke beneficial activation of microglial cells and thus promote the transcription, synthesis and release of BDNF in cultured microglial cells. The microglia-derived BDNF can exerted a demonstrable biological role in promoting neurite outgrowth and intimate terminal contacts of dorsal root ganglion (DRG) neurons co-cultured with microglial cells. Moreover, ACM induced remarkable p38MAPK phosphorylation in cultured microglial cells that preceded the burst of BDNF. Activating p38-MAPK by anisomycin resulted in salutary effects similar to those seen with ACM, whereas specific inhibition of the p38MAPK by SB203580 abrogated all the positive effects of ACM, including BDNF promotion and subsequent neurite outgrowth of DRG neurite outgrowth of DRG neurons and their intimate terminal contacts with microglial cells. Together, our results indicated that the neuroprotection of the microglial source is mainly caused by micro-environmental soluble molecules released from injured astrocytes, and ACM-induced BDNF production and release from microglial cells may be mediated through p38-MAPK signaling pathway. Therefore, these findings may lay a foundation to further investigations on the microglial beneficial activation role in the repair of traumatic CNS injury and neurodegenerative diseases. (c) 2012 Elsevier Ltd. All rights reserved.	[Yang, Hao; Jiao, Xi-Ying; Ju, Gong; You, Si-Wei] Fourth Mil Med Univ, Inst Neurosci, Xian 710032, Peoples R China; [Feng, Guo-Dong] Fourth Mil Med Univ, Xijing Hosp, Dept Neurol, Xian 710032, Peoples R China; [Liang, Zhe] Emory Univ, Sch Med, Dept Surg & Lab Med, Atlanta, GA 30322 USA; [Vitale, Angela] Emory Univ, Dept Human Genet, Atlanta, GA 30322 USA	Yang, H (corresponding author), Fourth Mil Med Univ, Inst Neurosci, Xian 710032, Peoples R China.	yanghao71_99@yahoo.com; yousiwei@fmmu.edu.cn			Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30973088, 30901649]; National Key Basic Research and Development Project (the 973 Project)National Basic Research Program of China [2011CB504402]; 11th Five-special-purpose Program for PLA [O8Z028]	We are grateful to Dr. Kavita Bhat from Emory University School of medicine, USA, for her kind help in the preparation of this manuscript. This work was supported by Natural Science Foundation of China (Nos. 30973088 and 30901649), National Key Basic Research and Development Project (the 973 Project, 2011CB504402) and the 11th Five-special-purpose Program for PLA (O8Z028).	Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Balschun D, 2004, FASEB J, V18, P1788, DOI 10.1096/fj.04-1625fje; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Batchelor PE, 2002, MOL CELL NEUROSCI, V21, P436, DOI 10.1006/mcne.2002.1185; Batchelor PE, 1999, J NEUROSCI, V19, P1708; Bilsland J, 1999, J NEUROSCI METH, V92, P75, DOI 10.1016/S0165-0270(99)00099-0; Buisson A, 2003, CELL MOL NEUROBIOL, V23, P539, DOI 10.1023/A:1025072013107; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Crown ED, 2006, EXP NEUROL, V199, P397, DOI 10.1016/j.expneurol.2006.01.003; David S, 2003, ANNU REV NEUROSCI, V26, P411, DOI 10.1146/annurev.neuro.26.043002.094946; De Groot CJA, 1999, J NEUROPATH EXP NEUR, V58, P174, DOI 10.1097/00005072-199902000-00007; Elkabes S, 1998, J NEUROSCI RES, V54, P117, DOI 10.1002/(SICI)1097-4547(19981001)54:1<117::AID-JNR12>3.3.CO;2-8; Gingras J, 1999, J COMP NEUROL, V414, P551; Gomez-Pinilla F, 1990, Neuroreport, V1, P211; Gras G, 2003, BRAIN PATHOL, V13, P211; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Heese K, 1997, NEUROSCI LETT, V231, P83, DOI 10.1016/S0304-3940(97)00545-4; Heese K, 1998, J NEUROCHEM, V70, P699; HEUMANN R, 1987, P NATL ACAD SCI USA, V84, P8735, DOI 10.1073/pnas.84.23.8735; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Ji RR, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-33; Katoh-Semba R, 2009, NEUROSCIENCE, V163, P352, DOI 10.1016/j.neuroscience.2009.06.011; KIEFER R, 1993, EUR J NEUROSCI, V5, P775, DOI 10.1111/j.1460-9568.1993.tb00929.x; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Lambertsen KL, 2009, J NEUROSCI, V29, P1319, DOI 10.1523/JNEUROSCI.5505-08.2009; Largo C, 1996, J NEUROSCI, V16, P1219; Lehrmann E, 1998, GLIA, V24, P437, DOI 10.1002/(SICI)1098-1136(199812)24:4<437::AID-GLIA9>3.0.CO;2-X; Liberto CM, 2004, J NEUROCHEM, V89, P1092, DOI 10.1111/j.1471-4159.2004.02420.x; Luo XG, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-12; Miwa T, 1997, J NEUROSCI RES, V50, P1023; Murer MG, 2001, PROG NEUROBIOL, V63, P71, DOI 10.1016/S0301-0082(00)00014-9; Nakajima K, 2001, J NEUROSCI RES, V65, P322, DOI 10.1002/jnr.1157; Neumann H, 2002, J NEUROSCI, V22, P854, DOI 10.1523/JNEUROSCI.22-03-00854.2002; Patel HC, 2003, ANN NY ACAD SCI, V992, P39, DOI 10.1111/j.1749-6632.2003.tb03136.x; Pavelko KD, 2003, J NEUROSCI, V23, P481; Pearson LL, 2001, INT IMMUNOL, V13, P273, DOI 10.1093/intimm/13.3.273; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Riley CP, 2004, J MOL HISTOL, V35, P771, DOI 10.1007/s10735-004-0778-9; Rimaniol AC, 2000, J IMMUNOL, V164, P5430, DOI 10.4049/jimmunol.164.10.5430; Shah A, 2004, J NEUROSCI METH, V136, P123, DOI 10.1016/j.jneumeth.2004.01.010; Shaked I, 2005, J NEUROCHEM, V92, P997, DOI 10.1111/j.1471-4159.2004.02954.x; Shibuya S, 2009, CELL ADHES MIGR, V3, P99, DOI 10.4161/cam.3.1.7372; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; Streit WJ, 2008, FRONT BIOSCI-LANDMRK, V13, P3423; Suzuki H, 2001, NEUROSCI LETT, V312, P95, DOI 10.1016/S0304-3940(01)02198-X; Svensson CI, 2005, J NEUROCHEM, V92, P1508, DOI 10.1111/j.1471-4159.2004.02996.x; Trang T, 2009, J NEUROSCI, V29, P3518, DOI 10.1523/JNEUROSCI.5714-08.2009; Tuttolomondo A, 2008, CURR PHARM DESIGN, V14, P3547, DOI 10.2174/138161208786848829; Tyler WJ, 2002, LEARN MEMORY, V9, P224, DOI 10.1101/lm.51202; Ulmann L, 2008, J NEUROSCI, V28, P11263, DOI 10.1523/JNEUROSCI.2308-08.2008; Wong G, 2004, EXP NEUROL, V187, P171, DOI 10.1016/j.expneurol.2004.01.009; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Yang H, 2006, CYTOTECHNOLOGY, V52, P87, DOI 10.1007/s10616-006-9033-4; Yang H, 2011, NEUROCHEM INT, V59, P1010, DOI 10.1016/j.neuint.2011.08.021; Yang H, 2009, CELL MOL NEUROBIOL, V29, P455, DOI 10.1007/s10571-008-9337-3; Yang Hao, 2003, Shi Yan Sheng Wu Xue Bao, V36, P5; Zadran S, 2010, J NEUROSCI, V30, P1086, DOI 10.1523/JNEUROSCI.5120-09.2010; Zhang SE, 2012, J LEUKOCYTE BIOL, V91, P137, DOI 10.1189/jlb.0511268; Zheng Z, 2004, NEUROL RES, V26, P884, DOI 10.1179/016164104X2357	61	24	26	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	JUL	2012	61	2					175	186		10.1016/j.neuint.2012.04.020			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	991HH	WOS:000307691600006	22561407				2021-06-18	
J	Purins, K; Enblad, P; Wiklund, L; Lewen, A				Purins, Karlis; Enblad, Per; Wiklund, Lars; Lewen, Anders			Brain Tissue Oxygenation and Cerebral Perfusion Pressure Thresholds of Ischemia in a Standardized Pig Brain Death Model	NEUROCRITICAL CARE			English	Article						Brain tissue oxygenation; Cerebral perfusion pressure; Microdialysis; Threshold levels; Traumatic brain injury	SEVERE HEAD-INJURY; POSITRON-EMISSION-TOMOGRAPHY; INTRACEREBRAL MICRODIALYSIS; SUBARACHNOID HEMORRHAGE; MODERATE HYPOTHERMIA; ENERGY-METABOLISM; CARBON-DIOXIDE; BLOOD-FLOW; TENSION; RESUSCITATION	Neurointensive care of traumatic brain injury (TBI) patients is currently based on intracranial pressure (ICP) and cerebral perfusion pressure (CPP) targeted protocols. Monitoring brain tissue oxygenation (B(ti)pO(2)) is of considerable clinical interest, but the exact threshold level of ischemia has been difficult to establish due to the complexity of the clinical situation. The objective of this study was to use the Neurovent-PTO (NV) probe, and to define critical cerebral oxygenation- and CPP threshold levels of cerebral ischemia in a standardized brain death model caused by increasing the ICP in pig. Ischemia was defined by a severe increase of cerebral microdialysis (MD) lactate/pyruvate ratio (L/P ratio > 30). B(ti)pO(2), L/P ratio, Glucose, Glutamate, Glycerol and CPP were recorded using NV and MD probes during gradual increase of ICP by inflation of an epidural balloon catheter with saline until brain death was achieved. Baseline level of B(ti)pO(2) was 22.9 +/- A 6.2 mmHg, the L/P ratio 17.7 +/- A 6.1 and CPP 73 +/- A 17 mmHg. B(ti)pO(2) and CPP decreased when intracranial volume was added. The L/P ratio increased above its ischemic levels, (> 30) when CPP decreased below 30 mmHg and B(ti)pO(2) to < 10 mmHg. A severe increase of ICP leading to CPP below 30 mmHg and B(ti)pO(2) below 10 mmHg is associated with an increase of the L/P ratio, thus seems to be critical thresholds for cerebral ischemia under these conditions.	[Purins, Karlis; Enblad, Per; Lewen, Anders] Uppsala Univ, Neurosurg Sect, Dept Neurosci, S-75185 Uppsala, Sweden; [Wiklund, Lars] Uppsala Univ, Sect Anaesthesia & Intens Care, Dept Surg Sci, S-75185 Uppsala, Sweden	Purins, K (corresponding author), Uppsala Univ, Neurosurg Sect, Dept Neurosci, S-75185 Uppsala, Sweden.	Karlis.Purins@neuro.uu.se	Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348	Swedish Research CouncilSwedish Research CouncilEuropean Commission	The study was supported by The Swedish Research Council. Lars Berglund, Ph.D., Uppsala Clinical Research Center, Uppsala University is acknowledged for statistical analysis. We thank Anders Nordgren, Monica Hall, and Inger Stahl Myllyaho for their excellent laboratory assistance.	Bardt TF, 1998, ACT NEUR S, V71, P153; Baron JC, 2001, CEREBROVASC DIS, V11, P2, DOI 10.1159/000049119; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Cavus E, 2006, RESUSCITATION, V71, P97, DOI 10.1016/j.resuscitation.2006.03.007; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Dings J, 1998, NEUROL RES, V20, pS71; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Hoffman WE, 1996, ANESTH ANALG, V82, P582, DOI 10.1097/00000539-199603000-00027; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MAAS AIR, 1993, ACTA NEUROCHIR, P50; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Manley GT, 1999, J TRAUMA, V46, P261, DOI 10.1097/00005373-199902000-00011; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Meixensberger J, 2001, NEUROL RES, V23, P801, DOI 10.1179/016164101101199379; Nielsen TH, 2011, NEUROCRIT CARE, V15, P585, DOI 10.1007/s12028-011-9563-2; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Orakcioglu B, 2010, NEUROSURGERY, V67, P1716, DOI 10.1227/NEU.0b013e3181f9bb5b; Pennings FA, 2008, J NEUROTRAUM, V25, P1173, DOI 10.1089/neu.2007.0402; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; Purins K, 2011, CRIT CARE MED, V39, P512, DOI 10.1097/CCM.0b013e318206b824; Purins K, 2010, ACTA NEUROCHIR, V152, P681, DOI 10.1007/s00701-009-0532-x; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Valadka AB, 2002, ACT NEUR S, V81, P299; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Zoremba N, 2007, ANESTH ANALG, V105, P744, DOI 10.1213/01.ane.0000278160.66389.1c	41	24	25	1	8	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	JUN	2012	16	3					462	469		10.1007/s12028-012-9675-3			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	949ZX	WOS:000304619000019	22302179				2021-06-18	
J	Spaethling, J; Le, L; Meaney, DF				Spaethling, Jennifer; Le, Linda; Meaney, David F.			NMDA receptor mediated phosphorylation of GluR1 subunits contributes to the appearance of calcium-permeable AMPA receptors after mechanical stretch injury	NEUROBIOLOGY OF DISEASE			English	Article						Calcium permeable AMPA receptor; Traumatic brain injury; Glutamate receptor phosphorylation; Intracellular signaling; Synaptic NMDAR; Extrasynaptic NDMAR	GLUTAMATE RECEPTORS; EXCITATORY SYNAPSES; SYNAPTIC PLASTICITY; TRAUMATIC INJURY; NITRIC-OXIDE; IN-VITRO; BRAIN; HIPPOCAMPUS; ACTIVATION; NEURONS	Alterations in neuronal cytosolic calcium is a key mediator of the traumatic brain injury (TBI) pathobiology, but less is known of the role and source of calcium in shaping early changes in synaptic receptors and neural circuits after TBI. In this study, we examined the calcium source and potential phosphorylation events leading to insertion of calcium-permeable AMPARs (CP-AMPARs) after in vitro traumatic brain injury, a receptor subtype that influences neural circuit dynamics for hours to days following injury. We found that both synaptic and NR2B-containing NMDARs contribute significantly to the calcium influx following stretch injury. Moreover, an early and sustained phosphorylation of the S-831 site of the GluR1 subunit appeared after mechanical injury, and this phosphorylation was blocked with the inhibition of either synaptic NMDARs or NR2B-containing NMDARs. In comparison, mechanical injury led to no significant change in the S-845 phosphorylation of the GluR1 subunit. Although no change in S-845 phosphorylation appeared in injured cultures, we observed that inhibition of NR2B-containing NMDARs significantly increased S-845 phosphorylation 1 h after injury while blockade of synaptic NMDARs did not change S-845 phosphorylation at any time point following injury. These findings show that a broad class of NMDARs are activated in parallel and that targeting either subpopulation will reverse some of the consequences of mechanical injury, providing distinct paths to treat the effects of mechanical injury on neural circuits after TBI. (C) 2012 Elsevier Inc. All rights reserved.	[Spaethling, Jennifer; Meaney, David F.] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; [Le, Linda] Univ Penn, Dept Chem & Biomol Engn, Philadelphia, PA 19104 USA; [Meaney, David F.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA	Meaney, DF (corresponding author), Univ Penn, Dept Pharmacol, 240 Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA.	dmeaney@seas.upenn.edu		Meaney, David/0000-0002-0954-4122	NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [41699]; Commonwealth of Pennsylvania; NS [35712]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD041699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035712] Funding Source: NIH RePORTER	Funding was provided by: NICHD 41699, NS 35712, and from the Commonwealth of Pennsylvania.	Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; Barria A, 2005, NEURON, V48, P289, DOI 10.1016/j.neuron.2005.08.034; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; Bayir H, 2007, J NEUROCHEM, V101, P168, DOI 10.1111/j.1471-4159.2006.04353.x; Bell JD, 2009, CELL DEATH DIFFER, V16, P1665, DOI 10.1038/cdd.2009.106; Bengtson CP, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-11; Boehm J, 2006, NEURON, V51, P213, DOI 10.1016/j.neuron.2006.06.013; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Cheriyan J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016495; CHETKOVICH DM, 1993, J NEUROCHEM, V61, P1933, DOI 10.1111/j.1471-4159.1993.tb09836.x; Christopherson KS, 1999, J BIOL CHEM, V274, P27467, DOI 10.1074/jbc.274.39.27467; DeRidder MN, 2006, NEUROBIOL DIS, V22, P165, DOI 10.1016/j.nbd.2005.10.011; Derkach V, 1999, P NATL ACAD SCI USA, V96, P3269, DOI 10.1073/pnas.96.6.3269; Derkach VA, 2007, NAT REV NEUROSCI, V8, P101, DOI 10.1038/nrn2055; Folkerts MM, 2007, J NEUROTRAUM, V24, P638, DOI 10.1089/neu.2006.0188; Fu XZ, 2004, NEUROSCI RES, V48, P85, DOI 10.1016/j.neures.2003.09.009; Geddes-Klein DM, 2006, J NEUROCHEM, V97, P462, DOI 10.1111/j.1471-4159.2006.03761.x; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; GLAUM SR, 1990, P NATL ACAD SCI USA, V87, P3454, DOI 10.1073/pnas.87.9.3454; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Goforth PB, 2004, J NEUROTRAUM, V21, P719, DOI 10.1089/0897715041269704; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Hall BJ, 2007, J NEUROSCI, V27, P13446, DOI 10.1523/JNEUROSCI.3793-07.2007; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; He KW, 2009, P NATL ACAD SCI USA, V106, P20033, DOI 10.1073/pnas.0910338106; Hudmon A, 2002, BIOCHEM J, V364, P593, DOI 10.1042/BJ20020228; Jin SX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011732; Kumar SS, 2002, J NEUROSCI, V22, P3005, DOI 10.1523/JNEUROSCI.22-08-03005.2002; Lee HK, 2006, PHARMACOL THERAPEUT, V112, P810, DOI 10.1016/j.pharmthera.2006.06.003; Lin YC, 2002, J NEUROSCI RES, V67, P484, DOI 10.1002/jnr.10077; Lisman JE, 2001, NEURON, V31, P191, DOI 10.1016/S0896-6273(01)00364-6; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; Mauceri D, 2004, J BIOL CHEM, V279, P23813, DOI 10.1074/jbc.M402796200; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Nikandrova YA, 2010, J BIOL CHEM, V285, P923, DOI 10.1074/jbc.M109.033985; Oh MC, 2006, J BIOL CHEM, V281, P752, DOI 10.1074/jbc.M509677200; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; Papadia S, 2007, NEUROSCIENTIST, V13, P572, DOI 10.1177/1073858407305833; PELLEGRINIGIAMPIETRO DE, 1991, P NATL ACAD SCI USA, V88, P4157, DOI 10.1073/pnas.88.10.4157; Rakhade SN, 2008, J NEUROSCI, V28, P7979, DOI 10.1523/JNEUROSCI.1734-08.2008; Rameau GA, 2007, J NEUROSCI, V27, P3445, DOI 10.1523/JNEUROSCI.4799-06.2007; Serulle Y, 2007, NEURON, V56, P670, DOI 10.1016/j.neuron.2007.09.016; Sheng M, 2007, ANNU REV BIOCHEM, V76, P823, DOI 10.1146/annurev.biochem.76.060805.160029; Spaethling JM, 2008, J NEUROTRAUM, V25, P1207, DOI 10.1089/neu.2008.0532; Wang HS, 2007, J BIOL CHEM, V282, P1507, DOI 10.1074/jbc.M607291200; Wang HG, 2005, NEURON, V45, P389, DOI 10.1016/j.neuron.2005.01.011; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Willoughby D, 2007, PHYSIOL REV, V87, P965, DOI 10.1152/physrev.00049.2006; Wojda U, 2008, IUBMB LIFE, V60, P575, DOI 10.1002/iub.91; Xu J, 2009, J NEUROSCI, V29, P9330, DOI 10.1523/JNEUROSCI.2212-09.2009; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	54	24	27	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	JUN	2012	46	3					646	654		10.1016/j.nbd.2012.03.003			9	Neurosciences	Neurosciences & Neurology	950DK	WOS:000304629300014	22426393	Green Accepted			2021-06-18	
J	Maxwell, WL				Maxwell, William L.			Traumatic brain injury in the neonate, child and adolescent human: An overview of pathology	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						TBI; Hematoma; Immature or unmyelinated axons; Myelination; Neuronal injury; Oligodendrocytes; Macrophages and microglia; Inflammatory response; The neurovascular unit	NONDISRUPTIVE AXONAL INJURY; WHITE-MATTER DEVELOPMENT; SITU DNA FRAGMENTATION; INFLICTED HEAD-INJURY; RAT OPTIC-NERVE; YOUNG-CHILDREN; HUMAN FETAL; AXOLEMMAL PERMEABILITY; CYTOSKELETAL CHANGES; CEREBRAL-CORTEX	In the middle of the last century it had been thought that a good recovery of function and behavior would occur after traumatic brain injury (TBI) in very young human beings. A recent major change in thinking states that early childhood TBI may result in a severe compromise of normal brain growth and development such that TBI, rather, may compromise later normal development resulting in a need for very long term patient care and management. The mechanisms of injury and pathology within the injured brain are reviewed and compared between when injury occurs at or close to the time of birth, in an infant, in a young child, in a child between ages 5 and 10, in young and older adolescents and in young adulthood. Our understanding of pathophysiological responses by cells of the human central nervous system has recently greatly increased but has really only served to illustrate the great complexity of interactions between different types of cell within the growing and developing CNS. The hypothesis is developed that the outcome for a very young patient differs with the relative state of development of injured cells at the locus of injury. And that the potential for either repair, re-instatement of normal cellular and organ function or for continued normal development is much reduced after an early brain insult (EBI) compared with TBI in a slightly older child or young adult patient. The advent of increasingly sophisticated non-invasive imaging technology has allowed assessment of the influence and time course of brain pathology both early and late after TBI. This has generated greater confidence on the part of clinicians in forecasting outcomes for an injured patient. But our increased understanding has still not allowed development of therapeutic strategies that might ameliorate the effect of an injury. It is suggested that an improved integration of major clinical and scientific effort needs to be made to appreciate the import of multiple interactions between cells forming the neurovascular unit in order to improve any potential for post-traumatic recovery after TBI in neonates and young children. (C) 2011 ISDN. Published by Elsevier Ltd. All rights reserved.	Univ Glasgow, Sch Med Vet Med & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	Maxwell, WL (corresponding author), Univ Glasgow, Sch Med Vet Med & Life Sci, Thomson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	William.Maxwell@Glasgow.ac.uk					ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Anderson V, 2011, BRAIN, V134, P2197, DOI 10.1093/brain/awr103; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Asato MR, 2010, CEREB CORTEX, V20, P2122, DOI 10.1093/cercor/bhp282; Ball G, 2012, CEREB CORTEX, V22, P1016, DOI 10.1093/cercor/bhr176; BALLESTEROS MC, 1993, RADIOGRAPHICS, V13, P611, DOI 10.1148/radiographics.13.3.8316668; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Barnea-Goraly N, 2005, CEREB CORTEX, V15, P1848, DOI 10.1093/cercor/bhi062; Barrientos SA, 2011, J NEUROSCI, V31, P966, DOI 10.1523/JNEUROSCI.4065-10.2011; Beirowski B, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-6; Bell JE, 2005, BRAIN, V128, P1070, DOI 10.1093/brain/awh436; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Bigler ED, 2011, NEUROREHABILITATION, V28, P63, DOI 10.3233/NRE-2011-0633; Bittigau P, 2003, NEUROTOX RES, V5, P475, DOI 10.1007/BF03033158; Blakemore SJ, 2008, NAT REV NEUROSCI, V9, P267, DOI 10.1038/nrn2353; Bonnier C, 2007, J CHILD NEUROL, V22, P519, DOI 10.1177/0883073807302604; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Cagin A., 2001, BRAIN, V124, P2014; Case ME, 2008, BRAIN PATHOL, V18, P571, DOI 10.1111/j.1750-3639.2008.00204.x; Case ME, 2008, BRAIN PATHOL, V18, P583, DOI 10.1111/j.1750-3639.2008.00203.x; Case Mary E., 2007, Legal Medicine, V9, P83, DOI 10.1016/j.legalmed.2006.11.017; Christian CW, 2009, PEDIATRICS, V123, P1409, DOI 10.1542/peds.2009-0408; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Ding XQ, 2008, AM J NEURORADIOL, V29, P1261, DOI 10.3174/ajnr.A1097; DOBBING J, 1973, ARCH DIS CHILD, V48, P757, DOI 10.1136/adc.48.10.757; Dratviman-Storobinsky O, 2008, MOL VIS, V14, P2171; DUHAIME AC, 1992, PEDIATRICS, V90, P179; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Emery B, 2010, SCIENCE, V330, P779, DOI 10.1126/science.1190927; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Fitzgerald M, 2010, J NEUROTRAUM, V27, P439, DOI 10.1089/neu.2009.1112; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Gerlach R, 2009, PEDIATR EMERG CARE, V25, P164, DOI 10.1097/PEC.0b013e31819a8966; Giedd JN, 2004, ANN NY ACAD SCI, V1021, P77, DOI 10.1196/annals.1308.009; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gilmore JH, 2007, J NEUROSCI, V27, P1255, DOI 10.1523/JNEUROSCI.3339-06.2007; Giza CC, 2006, INDIAN J NEUROTRAUM, V3, P19; Gorrie C, 2001, J NEUROTRAUM, V18, P849, DOI 10.1089/089771501750451776; Gorrie C, 2002, J NEUROTRAUM, V19, P1171, DOI 10.1089/08977150260337976; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Groeschel S, 2010, INT J DEV NEUROSCI, V28, P481, DOI 10.1016/j.ijdevneu.2010.06.004; Hafiz M Z Mohd, 2011, Med J Malaysia, V66, P95; Hagmann P, 2010, P NATL ACAD SCI USA, V107, P19067, DOI 10.1073/pnas.1009073107; Hamilton N, 2008, GLIA, V56, P734, DOI 10.1002/glia.20649; Hausmann R, 2004, INT J LEGAL MED, V118, P32, DOI 10.1007/s00414-003-0413-4; Hobbs C, 2005, ARCH DIS CHILD, V90, P952, DOI 10.1136/adc.2003.037739; Horneman G, 2009, BRAIN INJURY, V23, P907, DOI 10.1080/02699050903283239; Huang H, 2006, NEUROIMAGE, V33, P27, DOI 10.1016/j.neuroimage.2006.06.009; Inglese M, 2005, AM J NEURORADIOL, V26, P719; Iwata S, 2010, INT J DEV NEUROSCI, V28, P573, DOI 10.1016/j.ijdevneu.2010.07.233; Jafari SS, 1998, J NEUROTRAUM, V15, P955, DOI 10.1089/neu.1998.15.955; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Jakovcevski I, 2005, GLIA, V49, P480, DOI 10.1002/glia.20134; Jakovcevski I, 2009, FRONT NEUROANAT, V3, DOI 10.3389/neuro.05.005.2009; Jette N, 2006, J CEREBR BLOOD F MET, V26, P777, DOI 10.1038/sj.jcbfm.9600226; Johnson MW, 2011, J FORENSIC SCI, V56, P1198, DOI 10.1111/j.1556-4029.2011.01814.x; Kennard MA, 1940, ARCH NEURO PSYCHIATR, V44, P377, DOI 10.1001/archneurpsyc.1940.02280080137008; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Knickmeyer RC, 2008, J NEUROSCI, V28, P12176, DOI 10.1523/JNEUROSCI.3479-08.2008; Koehler RC, 2006, J APPL PHYSIOL, V100, P307, DOI 10.1152/japplphysiol.00938.2005; Kumar S, 2002, BIOPHYS J, V82, P2360, DOI 10.1016/S0006-3495(02)75581-1; LaPlaca MC, 2010, J BIOMECH, V43, P71, DOI 10.1016/j.jbiomech.2009.09.011; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Looney CB, 2007, RADIOLOGY, V242, P535, DOI 10.1148/radiol.2422060133; Lotocki G, 2011, THER HYPOTHERMIA TEM, V1, DOI 10.1089/ther.2010.0011; Mahad DJ, 2009, BRAIN, V132, P1161, DOI 10.1093/brain/awp046; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; MAXWELL WL, 1992, ACTA NEUROPATHOL, V84, P289; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Minambres E, 2008, J NEUROTRAUM, V25, P581, DOI 10.1089/neu.2007.0398; Mori I, 2005, BRAIN RES, V1057, P186, DOI 10.1016/j.brainres.2005.07.037; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Namas R, 2009, LIBYAN J MED, V4, P97, DOI 10.4176/090325; Nimmerjahn A, 2009, J PHYSIOL-LONDON, V587, P1639, DOI 10.1113/jphysiol.2008.167171; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Raja F, 1997, ACTA NEUROPATHOL, V93, P184, DOI 10.1007/s004010050601; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; REIBER GD, 1993, AM J FOREN MED PATH, V14, P201, DOI 10.1097/00000433-199309000-00005; Rezaie Payam, 2002, Neuroembryology, V1, P91, DOI 10.1159/000054268; Robinson RJ, 2011, J NEUROIMAGING, V21, pE189, DOI 10.1111/j.1552-6569.2010.00516.x; ROESSMANN U, 1986, ACTA NEUROPATHOL, V70, P302, DOI 10.1007/BF00686088; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Sarnat HB, 1998, BRAIN DEV-JPN, V20, P88, DOI 10.1016/S0387-7604(97)00111-3; Shaw P, 2008, J NEUROSCI, V28, P3586, DOI 10.1523/JNEUROSCI.5309-07.2008; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Staal JA, 2011, J NEUROTRAUM, V28, P841, DOI 10.1089/neu.2010.1658; Staal JA, 2010, J NEUROCHEM, V112, P1147, DOI 10.1111/j.1471-4159.2009.06531.x; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Stys PK, 2005, J NEUROL SCI, V233, P3, DOI 10.1016/j.jns.2005.03.031; Sulaiman AM, 2011, J NEUROTRAUM, V28, P383, DOI 10.1089/neu.2010.1707; Supekar K, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000157; Susuki K, 2008, EXP BIOL MED, V233, P394, DOI 10.3181/0709-MR-243; Tamnes CK, 2010, CEREB CORTEX, V20, P534, DOI 10.1093/cercor/bhp118; Toro K, 2011, J FORENSIC SCI, V56, P617, DOI 10.1111/j.1556-4029.2010.01674.x; TOMEI G, 1990, ACTA NEUROPATHOL, V80, P506, DOI 10.1007/BF00294611; Tong K.A., 2008, AJNR, V29, P1; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Verderio C, 2001, J IMMUNOL, V166, P6383, DOI 10.4049/jimmunol.166.10.6383; Vezina G, 2009, PEDIATR RADIOL, V39, P586, DOI 10.1007/s00247-009-1212-y; von Reyn CR, 2009, J NEUROSCI, V29, P10350, DOI 10.1523/JNEUROSCI.2339-09.2009; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; WAXMAN SG, 1992, BRAIN RES, V574, P105, DOI 10.1016/0006-8993(92)90806-K; White RE, 2010, J COMP NEUROL, V518, P1370, DOI 10.1002/cne.22282; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001	131	24	25	0	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0736-5748	1873-474X		INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	MAY	2012	30	3			SI		167	183		10.1016/j.ijdevneu.2011.12.008			17	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	936XH	WOS:000303622800002	22212603				2021-06-18	
J	Thau-Zuchman, O; Shohami, E; Alexandrovich, AG; Leker, RR				Thau-Zuchman, Orli; Shohami, Esther; Alexandrovich, Alexander G.; Leker, Ronen R.			Combination of Vascular Endothelial and Fibroblast Growth Factor 2 for Induction of Neurogenesis and Angiogenesis after Traumatic Brain Injury	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						Traumatic brain injury; Angiogenesis; Neurogenesis; Vascular endothelial growth factor; Fibroblast growth factor 2; Neuroprotection	CLOSED-HEAD INJURY; UP-REGULATION; VEGF; EXPRESSION; MICE; PERMEABILITY; REGENERATION; HIPPOCAMPUS; ASTROCYTES; CONTUSION	Fibroblast growth factor 2 (FGF2) and vascular endothelial growth factor (VEGF) are potent mitogens for endogenous neural stem cells (eNSC) and also induce angiogenesis. We infused the individual factors or their combination into the lateral ventricles of mice for 7 days after traumatic brain injury (TBI) in order to evaluate the effects on functional outcome and on eNSC proliferation and differentiation. The results show that VEGF induced a significant increment in the number of proliferating eNSC in the subventricular zone and in the perilesion cortex and that combination of FGF2 and VEGF did not augment the effects of VEGF alone. Fate analysis showed that most newborn cells differentiated into astrocytes and oligodendroglia while only a few cells differentiated into neurons. Functional outcome was significantly better in mice treated with VEGF, FGF2, or their combination as compared to vehicle. Injury size was significantly reduced only in mice treated with VEGF suggesting additional neuroprotective effects for VEGF. Combination therapy did not have an additive effect on outcome or neuronal differentiation. In conclusion, FGF2-VEGF combination does not augment neurogenesis and angiogenesis or reduce lesion volumes after TBI compared with individual factors. This may suggest the existence of a ceiling effect for brain regeneration.	[Leker, Ronen R.] Hadassah Univ Hosp, Dept Neurol, IL-91120 Jerusalem, Israel; [Thau-Zuchman, Orli; Shohami, Esther; Alexandrovich, Alexander G.] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; [Thau-Zuchman, Orli; Leker, Ronen R.] Hadassah Hebrew Univ Med Ctr, Peritz & Chantal Scheinberg Cerebrovasc Res Lab, Jerusalem, Israel; [Thau-Zuchman, Orli; Leker, Ronen R.] Hadassah Hebrew Univ Med Ctr, Dept Neurol, Jerusalem, Israel	Leker, RR (corresponding author), Hadassah Univ Hosp, Dept Neurol, POB 12000, IL-91120 Jerusalem, Israel.	leker@cc.huji.ac.il	Leker, Ronen/ABC-6096-2020	Leker, Ronen/0000-0003-4794-0334; Thau-Zuchman, Orli/0000-0003-0403-7962	Sol Irwin Juni Trust; Peritz and Chantal Scheinberg Cerebrovascular Research Fund	This study was supported by the Sol Irwin Juni Trust Fund and by the Peritz and Chantal Scheinberg Cerebrovascular Research Fund	Androutsellis-Theotokis A, 2006, NATURE, V442, P823, DOI 10.1038/nature04940; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Dore-Duffy P, 2007, NEUROL RES, V29, P395, DOI 10.1179/016164107X204729; Fabel K, 2003, EUR J NEUROSCI, V18, P2803, DOI 10.1111/j.1460-9568.2003.03041.x; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Horner PJ, 2003, TRENDS NEUROSCI, V26, P597, DOI 10.1016/j.tins.2003.09.010; Jin KL, 2006, J NEUROBIOL, V66, P236, DOI 10.1002/neu.20215; Kilic E, 2006, FASEB J, V20, P1185, DOI 10.1096/fj.05-4829fje; Kim JH, 2004, J KOREAN MED SCI, V19, P879, DOI 10.3346/jkms.2004.19.6.879; Krum JM, 1998, EXP NEUROL, V154, P57, DOI 10.1006/exnr.1998.6930; Lafuente JV, 2006, J NEURAL TRANSM, V113, P487, DOI 10.1007/s00702-005-0407-0; Leker RR, 2007, STROKE, V38, P153, DOI 10.1161/01.STR.0000252156.65953.a9; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Nieto M, 2001, NEURON, V29, P401, DOI 10.1016/S0896-6273(01)00214-8; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Papavassiliou E, 1997, J NEUROSCI RES, V49, P451, DOI 10.1002/(SICI)1097-4547(19970815)49:4<451::AID-JNR6>3.0.CO;2-7; Parcellier A, 2008, CELL SIGNAL, V20, P21, DOI 10.1016/j.cellsig.2007.07.010; Shein NA, 2007, J NEUROCHEM, V103, P1523, DOI 10.1111/j.1471-4159.2007.04862.x; Shetty AK, 2004, J NEUROSCI RES, V78, P520, DOI 10.1002/jnr.20302; Shore PM, 2004, NEUROSURGERY, V54, P605, DOI 10.1227/01.NEU.0000108642.88724.DB; Skold MK, 2006, EUR J NEUROSCI, V23, P21, DOI 10.1111/j.1460-9568.2005.04527.x; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Thored P, 2007, STROKE, V38, P3032, DOI 10.1161/STROKEAHA.107.488445; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Wang WY, 2005, NEUROSCIENCE, V134, P1167, DOI 10.1016/j.neuroscience.2005.04.064; Wang YM, 2007, J NEUROSCI RES, V85, P740, DOI 10.1002/jnr.21169; Widenfalk J, 2003, NEUROSCIENCE, V120, P951, DOI 10.1016/S0306-4522(03)00399-3; Xiao ZF, 2007, CELL RES, V17, P73, DOI 10.1038/sj.cr.7310126; Yun YR, 2010, J TISSUE ENG, V1, DOI 10.4061/2010/218142	36	24	28	0	11	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.	MAY	2012	47	1					166	172		10.1007/s12031-012-9706-8			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	924NQ	WOS:000302699000019	22246995				2021-06-18	
J	Cherry, S; Judd, L; Muniz, JC; Elzawahry, H; LaRoche, S				Cherry, Sunil; Judd, Lilith; Muniz, Juan Carlos; Elzawahry, Hoda; LaRoche, Suzette			Safety and Efficacy of Lacosamide in the Intensive Care Unit	NEUROCRITICAL CARE			English	Article						Lacosamide; Non-convulsive status epilepticus; Refractory status epilepticus; Seizures; Hypotension	TRAUMATIC BRAIN-INJURY; NONCONVULSIVE STATUS EPILEPTICUS; ELECTROGRAPHIC SEIZURES; INTRACEREBRAL HEMORRHAGE; INTRAVENOUS LACOSAMIDE; ORAL LACOSAMIDE	Background Seizures are common in critically ill patients and can impact morbidity and mortality. Traditional anti-epileptic drugs (AEDs) in this setting are not always effective and are associated with adverse events and drug interactions. Lacosamide (LCM) is a new AED which is available in parental form although few studies have evaluated the safety and efficacy of LCM in critically ill patients. Methods Critically ill patients at Emory University Hospital who received LCM from April 1, 2009 to February 1, 2010 were retrospectively reviewed. Primary outcome measure was incidence and time to seizure cessation. Adverse effects were also recorded. Results LCM was administered in 24 patients including 13 episodes of refractory status epilepticus (RSE) occurring in 10 patients and for treatment of isolated seizures or following resolution of RSE in an additional 14 patients. Seizure cessation was achieved in 5/13 (38%) episodes of RSE (mean 11.2 h) while there was at least a 50% decrease in seizure frequency in 7/13 (54%). 11/14 patients (76%) who received LCM for treatment of isolated seizures or prevention of seizure recurrence remained seizure free. Three patients experienced a decline in systolic blood pressure (> 20 mmHg) while one patient experienced unexplained fever and one patient had elevation of liver function tests. Conclusions This preliminary data suggests that LCM may be a safe and effective alternative for treatment of seizures in critically ill patients. Further prospective, randomized controlled trials are needed to confirm these findings and further explore the incidence of adverse effects.	[Cherry, Sunil; Judd, Lilith; Muniz, Juan Carlos; Elzawahry, Hoda; LaRoche, Suzette] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA	LaRoche, S (corresponding author), Emory Univ, Sch Med, Dept Neurol, 1365 Clifton Rd,NE Clin A, Atlanta, GA 30322 USA.	Slaroch@emory.edu					Albers JM, 2011, SEIZURE-EUR J EPILEP, V20, P428, DOI 10.1016/j.seizure.2011.01.017; Ben-Menachem E, 2007, EPILEPSIA, V48, P1308, DOI 10.1111/j.1528-1167.2007.01188.x; Beyreuther BK, 2007, CNS DRUG REV, V13, P21, DOI 10.1111/j.1527-3458.2007.00001.x; Biton V, 2008, EPILEPSIA, V49, P418, DOI 10.1111/j.1528-1167.2007.01317.x; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; Goodwin H, 2011, NEUROCRIT CARE, V14, P348, DOI 10.1007/s12028-010-9501-8; JORDAN KG, 1995, NEUROL CLIN, V13, P579, DOI 10.1016/S0733-8619(18)30035-5; Kellinghaus C, 2010, ACTA NEUROL SCAND, V123, P137; Koubeissi MZ, 2011, ACTA NEUROL SCAND, V123, P142, DOI 10.1111/j.1600-0404.2010.01430.x; Pandian JD, 2004, ARCH NEUROL-CHICAGO, V61, P1090, DOI 10.1001/archneur.61.7.1090; Parkerson KA, 2011, EPILEPSY BEHAV, V20, P48, DOI 10.1016/j.yebeh.2010.10.012; PRIVITERA M, 1994, EPILEPSY RES, V18, P155, DOI 10.1016/0920-1211(94)90008-6; Rantsch K, 2011, SEIZURE-EUR J EPILEP, V20, P529, DOI 10.1016/j.seizure.2011.03.010; Tilz C, 2010, EPILEPSIA, V51, P316, DOI 10.1111/j.1528-1167.2009.02256.x; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; Vespa P, 2005, J CLIN NEUROPHYSIOL, V22, P99, DOI 10.1097/01.WNP.0000154919.54202.E0; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Young GB, 1996, NEUROLOGY, V47, P83	22	24	24	0	0	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2012	16	2					294	298		10.1007/s12028-011-9662-0			5	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	949ZS	WOS:000304618500014	22203547				2021-06-18	
J	Sauter, E; Buckwalter, JA; McKinley, TO; Martin, JA				Sauter, Ellen; Buckwalter, Joseph A.; McKinley, Todd O.; Martin, James A.			Cytoskeletal dissolution blocks oxidant release and cell death in injured cartilage	JOURNAL OF ORTHOPAEDIC RESEARCH			English	Article						cartilage injury; cytoskeleton; chondrocyte death; mitochondria; oxidants	TRAUMATIC BRAIN-INJURY; MITOCHONDRIAL DYSFUNCTION; ACTIN CYTOSKELETON; HUMAN CHONDROCYTES; CHONDRAL EXPLANTS; NITRIC-OXIDE; COMPRESSION; MECHANOTRANSDUCTION; ORGANIZATION; APOPTOSIS	The mechanisms by which articular surface impact causes post-traumatic osteoarthritis are not well understood, but studies of cartilage explants implicate the mitochondrial electron transport chain as a source of oxidants that cause chondrocyte death from mechanical injury. The linkage of mitochondria to the cytoskeleton suggests that they might release oxidants in response to mechanical strain, an effect that disrupting the cytoskeleton would prevent. To test this we investigated the effects of agents that promote the dissolution of microfilaments (cytochalasin B) or microtubules (nocodazole) on oxidant production and chondrocyte death following impact injury. Osteochondral explants treated with cytochalasin B or nocodazole for 4h were impacted (7J/cm2) and stained for oxidant production directly after impact and for cell viability 24h after impact. Surfaces within and outside impact sites were then imaged by confocal microscopy. Both agents significantly reduced impact-induced oxidant release (p<0.05); however, cytochalasin B was more effective than nocodazole (>60% reduction vs. 40% reduction, respectively). Both agents also prevented impact induced cell death. Dissolution of the cytoskeleton by both drugs was confirmed by phalloidin staining and confocal microscopy. These findings show that chondrocyte mortality from impact injury depends substantially on mitochondrialcytoskeletal linkage, suggesting new approaches to stem mechanically induced cartilage degeneration. (C) 2011 Orthopaedic Research Society. (C) 2011 Orthopaedic Research Society Published by Wiley Periodicals, Inc. J Orthop Res 30:593598, 2012	[Sauter, Ellen; Buckwalter, Joseph A.; McKinley, Todd O.; Martin, James A.] Univ Iowa, Iowa City, IA 52242 USA; [Buckwalter, Joseph A.] Vet Affairs Med Ctr, Iowa City, IA 52242 USA	Martin, JA (corresponding author), Univ Iowa, Iowa City, IA 52242 USA.	james-martin@uiowa.edu		Buckwalter, Joseph/0000-0003-4308-7583; Martin, James/0000-0001-5085-0108	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [CORT NIH P50 AR055533]; Department of Veterans Affaires; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR025439] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [P50AR055533, P50AR048939] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (CORT NIH P50 AR055533), and by a Merit Review Award from the Department of Veterans Affaires.	Ali MH, 2004, AM J PHYSIOL-LUNG C, V287, pL486, DOI 10.1152/ajplung.00389.2003; Baars DC, 2006, BIOMECH MODEL MECHAN, V5, P133, DOI 10.1007/s10237-006-0024-3; Boldogh IR, 2003, MOL BIOL CELL, V14, P4618, DOI 10.1091/mbc.E03-04-0225; Borrelli J, 2009, J ORTHOP RES, V27, P347, DOI 10.1002/jor.20760; Clements KM, 2004, OSTEOARTHR CARTILAGE, V12, P577, DOI 10.1016/j.joca.2004.04.006; D'Lima DD, 2001, OSTEOARTHR CARTILAGE, V9, P712, DOI 10.1053/joca.2001.0468; Durrant LA, 1999, J ANAT, V194, P343, DOI 10.1046/j.1469-7580.1999.19430343.x; Garrido CP, 2009, OSTEOARTHR CARTILAGE, V17, P1244, DOI 10.1016/j.joca.2009.03.007; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Goodwin W, 2010, J ORTHOP RES, V28, P1057, DOI 10.1002/jor.21091; Grishko V, 2009, J BIOL CHEM, V284, P9132, DOI 10.1074/jbc.M804178200; Guilak F, 1995, J BIOMECH, V28, P1529, DOI 10.1016/0021-9290(95)00100-X; Haudenschild DR, 2008, BIORHEOLOGY, V45, P219, DOI 10.3233/BIR-2008-0499; Hurtig M, 2009, J ORTHOP RES, V27, P602, DOI 10.1002/jor.20787; Knight MM, 2006, J BIOMECH, V39, P1547, DOI 10.1016/j.jbiomech.2005.04.006; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Lee I, 2001, BIOL CHEM, V382, P1629, DOI 10.1515/BC.2001.198; Lewis JL, 2003, J ORTHOP RES, V21, P881, DOI 10.1016/S0736-0266(03)00039-1; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; Martin JA, 2009, J BONE JOINT SURG AM, V91A, P1890, DOI 10.2106/JBJS.H.00545; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; Milentijevic D, 2003, J BIOMECH ENG-T ASME, V125, P594, DOI 10.1115/1.1610021; Ohashi T, 2006, BIORHEOLOGY, V43, P201; Phillips DM, 2004, J ORTHOP RES, V22, P1135, DOI 10.1016/j.orthres.2004.02.002; Suelmann R, 2000, CELL MOTIL CYTOSKEL, V45, P42, DOI 10.1002/(SICI)1097-0169(200001)45:1<42::AID-CM4>3.0.CO;2-C; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Trickey WR, 2004, J ORTHOPAED RES, V22, P131, DOI 10.1016/S0736-0266(03)00150-5; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Wu GJ, 2007, J CELL BIOCHEM, V101, P1520, DOI 10.1002/jcb.21268; Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780	30	24	25	1	14	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0736-0266			J ORTHOP RES	J. Orthop. Res.	APR	2012	30	4					593	598		10.1002/jor.21552			6	Orthopedics	Orthopedics	887NW	WOS:000299935900014	21928429	Green Accepted, Bronze			2021-06-18	
J	Bitto, A; Polito, F; Irrera, N; Calo, M; Spaccapelo, L; Marini, HR; Giuliani, D; Ottani, A; Rinaldi, M; Minutoli, L; Guarini, S; Squadrito, F; Altavilla, D				Bitto, Alessandra; Polito, Francesca; Irrera, Natasha; Calo, Margherita; Spaccapelo, Luca; Marini, Herbert R.; Giuliani, Daniela; Ottani, Alessandra; Rinaldi, Mariagrazia; Minutoli, Letteria; Guarini, Salvatore; Squadrito, Francesco; Altavilla, Domenica			Protective effects of melanocortins on short-term changes in a rat model of traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						apoptosis; functional recovery; inflammation; melanocortins; neuroprotection; traumatic brain injury	SYSTEMIC INFLAMMATORY RESPONSE; CEREBRAL-ISCHEMIA; HEMORRHAGIC-SHOCK; DELAYED TREATMENT; NEUROPROTECTION; ACTIVATION; RECEPTORS; PEPTIDES; HORMONE; WEIGHT	Objective: Treatment for traumatic brain injury remains elusive despite compelling evidence from animal models for a variety of therapeutic targets. Melanocortins have established neuroprotective effects against experimental ischemic stroke. We investigated whether melanocortin treatment of traumatic brain injury induces neuroprotection and promotes functional recovery. Design: Randomized experiment. Setting: Research laboratory at a university hospital. Subjects: Male Sprague-Dawley rats (n = 215). Interventions: Experimental rat model of diffuse traumatic brain injury, the impact-acceleration model. Measurement and Main Results: Brain tissue nitrites, phosphorylation level of extracellular signal-regulated kinases, and c-jun N-terminal kinases; and expression of active caspase-3, tumor necrosis factor-alpha, BAX, and Bcl-2 as well as serum levels of interleukin-6, high mobility group box-1, interleukin-10, and brain histologic damage were evaluated 24 or 48 hrs after the insult. Sensorimotor orientation and limb use were evaluated at day 7 and learning and memory at days 23-30 after injury. Posttraumatic treatment every 12 hrs with the melanocortin analog [Nle(4), D-Phe(7)]-alpha-melanocyte-stimulating hormone (starting 3 or 6 hrs after injury) inhibited traumatic brain injury-induced upregulation of nitric oxide synthesis, phosphorylation level of extracellular signal-regulated kinases, phosphorylation level of c-jun N-terminal kinases, and active caspase-3; reduced expressions/levels of tumor necrosis factor-alpha, BAX, interleukin-6, and high mobility group box-1; and increased those of Bcl-2 and interleukin-10. These molecular changes were associated with a reduction in brain tissue damage, as highlighted by histopathological findings and improved functional recovery. Pretreatment with the melanocortin MC4 receptor antagonist HS024abated the positive effects of [Nle(4), D-Phe(7)]-alpha-melanocyte-stimulating hormone. Conclusions: Our data indicate that melanocortins protect against traumatic brain injury, in a broad time window and through activation of MC4 receptors, by counteracting the main traumatic brain injury-related mechanisms of damage. These findings could have major clinical implications. (Grit Care Med 2012; 40:945-951)	[Bitto, Alessandra; Irrera, Natasha; Rinaldi, Mariagrazia; Minutoli, Letteria; Squadrito, Francesco; Altavilla, Domenica] Univ Messina, Pharmacol Sect, Dept Clin & Expt Med & Pharmacol, Messina, Italy; [Calo, Margherita] Univ Messina, Dept Expt Sci & Appl Biotechnol, Messina, Italy; [Polito, Francesca; Marini, Herbert R.] Dept Biochem Physiol & Nutr Sci, Sect Physiol & Human Nutr, Messina, Italy; [Spaccapelo, Luca; Giuliani, Daniela; Ottani, Alessandra; Guarini, Salvatore] Univ Modena & Reggio Emilia, Pharmacol Sect, Dept Biomed Sci, Modena, Italy	Squadrito, F (corresponding author), Univ Messina, Pharmacol Sect, Dept Clin & Expt Med & Pharmacol, Messina, Italy.	Francesco.Squadrito@unime.it	Bitto, Alessandra/K-8942-2016; Irrera, Natasha/K-5411-2018; Giuliani, Daniela/B-2968-2016; Ottani, Alessandra/G-7316-2016; GUARINI, SALVATORE/O-3139-2013; Marini, Herbert Ryan/U-6004-2019	Bitto, Alessandra/0000-0001-9300-7532; Giuliani, Daniela/0000-0001-6061-5662; Ottani, Alessandra/0000-0002-1676-051X; GUARINI, SALVATORE/0000-0002-1164-1706; Marini, Herbert Ryan/0000-0002-8254-177X	Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR), Rome, ItalyMinistry of Education, Universities and Research (MIUR); Italian Ministry of ResearchMinistry of Education, Universities and Research (MIUR)	This work was supported by grants from Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR; project PRIN 2007), Rome, Italy. All authors received funding from the Italian Ministry of Research.	BANKS WA, 1995, PEPTIDES, V16, P1157, DOI 10.1016/0196-9781(95)00043-J; Bazzani C, 2001, J PHARMACOL EXP THER, V297, P1082; Borovikova LV, 2000, NATURE, V405, P458; Catania A, 2004, PHARMACOL REV, V56, P1, DOI 10.1124/pr.56.1.1; Catania A, 2008, TRENDS NEUROSCI, V31, P353, DOI 10.1016/j.tins.2008.04.002; Chlu WT, 2007, J CLIN NEUROSCI, V14, P930, DOI 10.1016/j.jocn.2006.08.004; Corander MP, 2009, CIRCULATION, V120, P2260, DOI 10.1161/CIRCULATIONAHA.109.854612; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Giuliani D, 2006, ENDOCRINOLOGY, V147, P1126, DOI 10.1210/en.2005-0692; Giuliani D, 2007, EUR J PHARMACOL, V570, P57, DOI 10.1016/j.ejphar.2007.05.025; Giuliani D, 2006, EUR J PHARMACOL, V538, P48, DOI 10.1016/j.ejphar.2006.03.038; Giuliani D, 2010, ADV EXP MED BIOL, V681, P71, DOI 10.1007/978-1-4419-6354-3_6; Giuliani D, 2009, BRAIN BEHAV IMMUN, V23, P844, DOI 10.1016/j.bbi.2009.03.009; GUARINI S, 1990, CRIT CARE MED, V18, P862, DOI 10.1097/00003246-199008000-00014; Guarini S, 2004, CARDIOVASC RES, V63, P357, DOI 10.1016/j.cardiores.2004.03.029; Guarini S, 2003, CIRCULATION, V107, P1189, DOI 10.1161/01.CIR.0000050627.90734.ED; Guarini S, 1997, BRIT J PHARMACOL, V121, P1454, DOI 10.1038/sj.bjp.0701264; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Maas AIR, 2001, EXPERT OPIN INV DRUG, V10, P753, DOI 10.1517/13543784.10.4.753; Maegele M, 2007, EUR SURG RES, V39, P372, DOI 10.1159/000107097; Magnoni S, 2003, J NEUROTRAUM, V20, P251, DOI 10.1089/089771503321532833; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARSHALL JF, 1974, J COMP PHYSIOL PSYCH, V86, P375, DOI 10.1037/h0035941; Martins ET, 2009, J TRAUMA, V67, P85, DOI 10.1097/TA.0b013e318187acee; Mock C, 2005, J TRAUMA, V59, P1243, DOI 10.1097/01.ta.0000197290.02807.de; Ottani A, 2009, J CEREBR BLOOD F MET, V29, P512, DOI 10.1038/jcbfm.2008.140; Schioth HB, 2001, VITAM HORM, V63, P195, DOI 10.1016/S0083-6729(01)63007-3; Schneider CP, 2004, BBA-MOL BASIS DIS, V1689, P22, DOI 10.1016/j.bbadis.2004.01.003; Tatro JB, 2006, ENDOCRINOLOGY, V147, P1122, DOI 10.1210/en.2005-1573; Tracey KJ, 2007, J CLIN INVEST, V117, P289, DOI 10.1172/JCI30555; U. S. Department of Health and Human Services Centers for Disease Control and Prevention, 2010, TRAUM BRAIN INJ US E; Vila N, 2003, STROKE, V34, P671, DOI 10.1161/01.STR.0000057976.53301.69; Wikberg JES, 2008, NAT REV DRUG DISCOV, V7, P307, DOI 10.1038/nrd2331; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Yattoo Gh, 2008, J Trauma Manag Outcomes, V2, P5, DOI 10.1186/1752-2897-2-5	38	24	26	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	2012	40	3					945	951		10.1097/CCM.0b013e318236efde			7	Critical Care Medicine	General & Internal Medicine	895YO	WOS:000300532800031	22036855				2021-06-18	
J	Choi, GS; Kim, OL; Kim, SH; Ahn, SH; Cho, YW; Son, SM; Jang, SH				Choi, Gyu Sik; Kim, Oh Lyong; Kim, Seong Ho; Ahn, Sang Ho; Cho, Yoon Woo; Son, Su Min; Jang, Sung Ho			Classification of Cause of Motor Weakness in Traumatic Brain Injury Using Diffusion Tensor Imaging	ARCHIVES OF NEUROLOGY			English	Article							AXONAL INJURY; CORTICOSPINAL TRACT; BASAL GANGLIA; TRANSTENTORIAL HERNIATION; PYRAMIDAL TRACT; RED NUCLEUS; HEAD-INJURY; RECOVERY; IMPAIRMENT; LESIONS	Background: Many studies have attempted to elucidate the causes of motor weakness in patients with traumatic brain injury (TBI). Most of these studies have focused on the specific cause of motor weakness. However, little is known about the classification and elucidation of the causes of motor weakness in consecutive patients with TBI. Objective: To attempt to classify with diffusion tensor imaging the causes of motor weakness in patients with TBI by conducting an analysis of the injury mechanism of the corticospinal tract (CST). Design: Retrospective study. Setting: Rehabilitation department of a university hospital. Patients: We recruited 41 consecutive patients who showed motor weakness among patients with TBI admitted for rehabilitation. Main Outcome Measures: We classified the causes of weakness according to the injury mechanism of the CST on diffusion tensor imaging. Results: Injury mechanisms of the CST were classified as follows, in order: diffuse axonal injury, 24 patients (58.5%); traumatic intracerebral hemorrhage, 9 patients (21.9%); transtentorial herniation, 6 patients (14.6%); and focal cortical contusion, 4 patients (9.8%). In patients with diffuse axonal injury, the mean number of lesions composing CST injury was 3.6 (range, 2-6) and CST injury locations were as follows: the pons (61%), the cerebral peduncle (50%), the medulla (40%), the posterior limb of the internal capsule (17%), and the corona radiata (13%). Conclusion: We found that diffusion tensor imaging was useful in elucidation and classification of the causes of motor weakness resulting from CST injury in patients with TBI.	[Choi, Gyu Sik; Ahn, Sang Ho; Cho, Yoon Woo; Son, Su Min; Jang, Sung Ho] Yeungnam Univ, Dept Phys Med & Rehabil, Coll Med, Taegu 705717, South Korea; [Kim, Oh Lyong; Kim, Seong Ho] Yeungnam Univ, Dept Neurosurg, Coll Med, Taegu 705717, South Korea	Jang, SH (corresponding author), Yeungnam Univ, Dept Phys Med & Rehabil, Coll Med, 317-1 Daemyungdong, Taegu 705717, South Korea.	strokerehab@hanmail.net			National Research Foundation of KoreaNational Research Foundation of Korea; Korean GovernmentKorean Government [KRF-2008-314-E00173]	This work was supported by National Research Foundation of Korea Grant funded by the Korean Government (KRF-2008-314-E00173).	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Ahn YH, 2006, NEUROREHABILITATION, V21, P239; ANDREWS BT, 1991, NEUROSURGERY, V29, P227, DOI 10.1227/00006123-199108000-00010; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Belhaj-Saif A, 2000, J NEUROPHYSIOL, V83, P3147; Binder DK, 2004, NEUROSURGERY, V54, P999, DOI 10.1227/01.NEU.0000115674.15497.09; Binder DK, 2004, NEUROSURGERY, V54, P1002; Binkofski F, 1996, ANN NEUROL, V39, P460, DOI 10.1002/ana.410390408; Black K, 2000, BRAIN INJURY, V14, P141, DOI 10.1080/026990500120808; Boto GR, 2001, J NEUROSURG, V94, P224, DOI 10.3171/jns.2001.94.2.0224; Brown AW, 2007, BRAIN INJURY, V21, P673, DOI 10.1080/02699050701468925; DeLisa JA, 1998, REHABILITATION PATIE, P1191; DEMEURISSE G, 1980, EUR NEUROL, V19, P382, DOI 10.1159/000115178; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; Han BS, 2007, NEUROREHABILITATION, V22, P151; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hillier SL, 1997, BRAIN INJURY, V11, P661; Jang SH, 2005, RESTOR NEUROL NEUROS, V23, P51; Jang SH, 2010, INT J REHABIL RES, V33, P285, DOI 10.1097/MRR.0b013e32833f0500; Jang SH, 2009, NEUROREHABILITATION, V25, P229, DOI 10.3233/NRE-2009-0519; Jang SH, 2009, NEUROREHABILITATION, V24, P349, DOI 10.3233/NRE-2009-0489; Jang SH, 2009, NEUROREHABILITATION, V24, P273, DOI 10.3233/NRE-2009-0478; JAYAKUMAR PN, 1989, ACTA NEUROCHIR, V97, P114, DOI 10.1007/BF01772820; Katz DI, 1998, ARCH PHYS MED REHAB, V79, P488, DOI 10.1016/S0003-9993(98)90060-0; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KATZ DI, 1989, NEUROLOGY, V39, P897, DOI 10.1212/WNL.39.7.897; KENNEDY PR, 1990, TRENDS NEUROSCI, V13, P474, DOI 10.1016/0166-2236(90)90079-P; Kunimatsu Akira, 2004, Magn Reson Med Sci, V3, P11, DOI 10.2463/mrms.3.11; Lee JW, 2006, J HEAD TRAUMA REHAB, V21, P272, DOI 10.1097/00001199-200605000-00007; Lotze M, 2006, NEUROREHAB NEURAL RE, V20, P14, DOI 10.1177/1545968305282919; MACPHERSON P, 1986, J NEUROL NEUROSUR PS, V49, P29, DOI 10.1136/jnnp.49.1.29; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Neil JJ, 2008, J MAGN RESON IMAGING, V27, P1, DOI 10.1002/jmri.21087; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Pettersson LG, 2000, NEUROSCI RES, V38, P109, DOI 10.1016/S0168-0102(00)00143-7; Skoglund TS, 2005, ACTA ANAESTH SCAND, V49, P337, DOI 10.1111/j.1399-6576.2005.00624.x; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Ward NS, 2006, BRAIN, V129, P809, DOI 10.1093/brain/awl002; Yasokawa YT, 2007, J NEUROTRAUM, V24, P163, DOI 10.1089/neu.2006.0073; Yeo SS, 2010, NEUROREHABILITATION, V27, P373, DOI 10.3233/NRE-2010-0622; YORK DH, 1987, NEUROSURGERY, V20, P70	44	24	24	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	MAR	2012	69	3					363	367		10.1001/archneurol.2011.1930			5	Clinical Neurology	Neurosciences & Neurology	906VQ	WOS:000301377300010	22083801	Bronze			2021-06-18	
J	Steinbaugh, LA; Lindsell, CJ; Shutter, LA; Szaflarski, JP				Steinbaugh, Linda A.; Lindsell, Christopher J.; Shutter, Lori A.; Szaflarski, Jerzy P.			Initial EEG predicts outcomes in a trial of levetiracetam vs. fosphenytoin for seizure prevention	EPILEPSY & BEHAVIOR			English	Article						Levetiracetam; Fosphenytoin; Electroencephalogram; Traumatic brain injury; Subarachnoid hemorrhage; Outcomes	TRAUMATIC BRAIN-INJURY; ELECTROGRAPHIC SEIZURES; STATUS EPILEPTICUS; PHENYTOIN; SUBCOMMITTEE; PROPHYLAXIS	Continuous electroencephalography (cEEG) is increasingly used to detect both clinical and subclinical seizures in patients with traumatic brain injury (TBI) or subarachnoid hemorrhage (SAH). We assess whether EEG findings predict outcomes in TBI/SAH patients enrolled in a levetiracetam (LEV) vs. fosphenytoin (fos-PHT) seizure prevention trial (NCT00618436). This prospective, single-blinded, comparative trial randomized 52 patients with TBI or SAH to receive prophylactic LEV or fos-PHT. Continuous video EEG monitoring was conducted for the initial 72 h of medication administration. The association between EEG findings (degree of generalized and focal slowing, presence and frequency of epileptiform discharges and seizures) and outcomes (Glasgow Outcomes Scale-Extended (GOS-E) and Disability Rating Scale (DRS)) at discharge, 3 and 6 months was assessed using a generalized linear model. Severity of generalized slowing tended to be associated with outcomes in both treatment groups (discharge DRS, p=0.042; discharge GOS-E, p=0.026; 3 month DRS, p=0.051). The presence of focal slowing, the presence and frequency of epileptiform discharges and the presence of seizures were not predictive of outcome in either treatment group (all p > 0.15). While it has been shown that LEV is associated with better outcome than fos-PHT when used as seizure prophylaxis in brain injury, aside from severity of generalized slowing, electrographic findings of focal slowing, epileptiform discharges, and seizures were not themselves associated with outcomes in patients with TBI or SAH enrolled in a randomized clinical trial. (C) 2011 Elsevier Inc. All rights reserved.	[Steinbaugh, Linda A.; Shutter, Lori A.; Szaflarski, Jerzy P.] Univ Cincinnati, Acad Hlth Ctr, Dept Neurol, Cincinnati, OH 45267 USA; [Lindsell, Christopher J.] Univ Cincinnati, Acad Hlth Ctr, Dept Emergency Med, Cincinnati, OH 45267 USA; [Shutter, Lori A.] Univ Cincinnati, Acad Hlth Ctr, Dept Neurosurg, Cincinnati, OH 45267 USA; [Shutter, Lori A.; Szaflarski, Jerzy P.] Univ Cincinnati, Acad Hlth Ctr, Inst Neurosci, Cincinnati, OH 45267 USA; [Szaflarski, Jerzy P.] Univ Cincinnati, Acad Hlth Ctr, Dept Neurosci, Cincinnati, OH 45267 USA; [Szaflarski, Jerzy P.] Univ Cincinnati, Acad Hlth Ctr, Cincinnati Epilepsy Ctr, Cincinnati, OH 45267 USA	Szaflarski, JP (corresponding author), Univ Cincinnati, Acad Hlth Ctr, Dept Neurol, 260 Stetson St, Cincinnati, OH 45267 USA.	Jerzy.Szaflarski@uc.edu	Shutter, Lori A/G-2957-2013	Shutter, Lori/0000-0002-1390-0628; Lindsell, Christopher/0000-0002-3297-2811	UCB Pharma, Inc. (PI)UCB Pharma SA; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000077] Funding Source: NIH RePORTER	This study was supported by UCB Pharma, Inc. (PI: Lori A. Shutter, MD, PT). Dr. Szaflarski has received compensation for educational activities with UCB Pharma, Inc. This study was presented, in part, at the 63rd Annual Meeting of the American Academy of Neurology.	Abend NS, 2011, NEUROCRIT CARE, V15, P70, DOI 10.1007/s12028-010-9380-z; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Bonett DG, 2002, PSYCHOL METHODS, V7, P370, DOI 10.1037//1082-989X.7.3.370; Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Claassen J, 2006, NEUROCRIT CARE, V4, P103, DOI 10.1385/NCC:4:2:103; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; Friedman D, 2009, ANESTH ANALG, V109, P506, DOI 10.1213/ane.0b013e3181a9d8b5; Hesdorffer D, 2007, EPILEPSY COMPREHENSI, V57-63; Hirsch LJ, 2005, J CLIN NEUROPHYSIOL, V22, P128, DOI 10.1097/01.WNP.0000158701.89576.4C; Jirsch J, 2007, CLIN NEUROPHYSIOL, V118, P1660, DOI 10.1016/j.clinph.2006.11.312; Jones KE, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E3; Kilbride RD, 2009, ARCH NEUROL-CHICAGO, V66, P723, DOI 10.1001/archneurol.2009.100; Kurtz P, 2009, CURR OPIN CRIT CARE, V15, P99, DOI 10.1097/MCC.0b013e3283294947; Orta DS, 2009, ARCH NEUROL-CHICAGO, V66, P985, DOI 10.1001/archneurol.2009.137; PRIVITERA M, 1994, EPILEPSY RES, V18, P155, DOI 10.1016/0920-1211(94)90008-6; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Szaflarski JP, 2008, EPILEPSIA, V49, P974, DOI 10.1111/j.1528-1167.2007.01513.x; Szaflarski JP, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-264; Szaflarski JP, 2010, EPILEPSY BEHAV, V17, P525, DOI 10.1016/j.yebeh.2010.02.005; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 1999, J CLIN NEUROPHYSIOL, V16, P1, DOI 10.1097/00004691-199901000-00001	28	24	24	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050	1525-5069		EPILEPSY BEHAV	Epilepsy Behav.	MAR	2012	23	3					280	284		10.1016/j.yebeh.2011.12.005			5	Behavioral Sciences; Clinical Neurology; Psychiatry	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	910RC	WOS:000301657900017	22342434				2021-06-18	
J	Haines, B; Li, PA				Haines, Bryan; Li, P. Andy			Overexpression of Mitochondrial Uncoupling Protein 2 Inhibits Inflammatory Cytokines and Activates Cell Survival Factors after Cerebral Ischemia	PLOS ONE			English	Article							OXYGEN-GLUCOSE DEPRIVATION; NECROSIS-FACTOR-ALPHA; BROWN ADIPOSE-TISSUE; BRAIN-INJURY; OXIDATIVE STRESS; ARTERY OCCLUSION; TRANSGENIC MICE; FOCAL ISCHEMIA; RAT-BRAIN; STROKE	Mitochondria play a critical role in cell survival and death after cerebral ischemia. Uncoupling proteins (UCPs) are inner mitochondrial membrane proteins that disperse the mitochondrial proton gradient by translocating H+ across the inner membrane in order to stabilize the inner mitochondrial membrane potential (Delta psi(m)) and reduce the formation of reactive oxygen species. Previous studies have demonstrated that mice transgenically overexpressing UCP2 (UCP2 Tg) in the brain are protected from cerebral ischemia, traumatic brain injury and epileptic challenges. This study seeks to clarify the mechanisms responsible for neuroprotection after transient focal ischemia. Our hypothesis is that UCP2 is neuroprotective by suppressing innate inflammation and regulating cell cycle mediators. PCR gene arrays and protein arrays were used to determine mechanisms of damage and protection after transient focal ischemia. Our results showed that ischemia increased the expression of inflammatory genes and suppressed the expression of anti-apoptotic and cell cycle genes. Overexpression of UCP2 blunted the ischemia-induced increase in IL-6 and decrease in Bcl2. Further, UCP2 increased the expression of cell cycle genes and protein levels of phospho-AKT, PKC and MEK after ischemia. It is concluded that the neuroprotective effects of UCP2 against ischemic brain injury are associated with inhibition of pro-inflammatory cytokines and activation of cell survival factors.	[Haines, Bryan] Buck Inst Res Aging, Novato, CA 94945 USA; [Li, P. Andy] N Carolina Cent Univ, Dept Pharmaceut Sci, BRITE, Durham, NC USA	Haines, B (corresponding author), Buck Inst Res Aging, Novato, CA 94945 USA.	pli@nccu.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01DK075476-06]; Golden Leaf Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK075476] Funding Source: NIH RePORTER	Work was funded by the National Institutes of Health R01DK075476-06. The BRITE program is partially funded by the Golden Leaf Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acalovschi D, 2003, STROKE, V34, P1864, DOI 10.1161/01.STR.0000079815.38626.44; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bechmann I, 2002, BIOCHEM PHARMACOL, V64, P363, DOI 10.1016/S0006-2952(02)01166-8; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Bernardi R, 2000, ONCOGENE, V19, P2447, DOI 10.1038/sj.onc.1203564; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; Choi K, 2009, CURR NEUROVASC RES, V6, P213, DOI 10.2174/156720209789630375; Chung H, 2007, ENDOCRINOLOGY, V148, P148, DOI 10.1210/en.2006-0991; Clark CB, 2009, FREE RADICAL BIO MED, V47, P1440, DOI 10.1016/j.freeradbiomed.2009.08.012; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Dang S, 2011, NEUROL RES, V33, P520, DOI 10.1179/016164111X13007856084287; Dhodda VK, 2004, J NEUROCHEM, V89, P73, DOI 10.1111/j.1471-4159.2004.02316.x; Ding XL, 2000, AM J PATHOL, V157, P1983, DOI 10.1016/S0002-9440(10)64837-7; Elzer JG, J CEREB BLOOD FLOW M, V30, P935; Fiskum G, 2004, J BIOENERG BIOMEMBR, V36, P347, DOI 10.1023/B:JOBB.0000041766.71376.81; Gao QL, 2006, MOL THER, V13, P928, DOI 10.1016/j.ymthe.2005.12.009; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; Horvath TL, 2003, INT J OBESITY, V27, P433, DOI 10.1038/sj.ijo.0802257; Iijima T, 2003, BRAIN RES, V993, P140, DOI 10.1016/j.brainres.2003.09.041; Ishibashi N, 2002, J IMMUNOL, V168, P1926, DOI 10.4049/jimmunol.168.4.1926; Jezek P, 2002, INT J BIOCHEM CELL B, V34, P1190, DOI 10.1016/S1357-2725(02)00061-4; Kaya D, 2005, J CEREBR BLOOD F MET, V25, P1111, DOI 10.1038/sj.jcbfm.9600109; Kim HS, 2007, DIABETES RES CLIN PR, V77, pS46, DOI 10.1016/j.diabres.2007.01.032; Lengacher S, 2004, J CEREBR BLOOD F MET, V24, P780, DOI 10.1097/01.WCB.0000122743.72175.52; Li PA, 1998, BRAIN RES, V804, P36, DOI 10.1016/S0006-8993(98)00651-9; Li Y, 1997, J CEREBR BLOOD F MET, V17, P846, DOI 10.1097/00004647-199708000-00003; Liu XQ, 2009, ACTA PHARMACOL SIN, V30, P1071, DOI 10.1038/aps.2009.105; Liu Yajun, 2009, BMC Physiology, V9, P17, DOI 10.1186/1472-6793-9-17; Lu D, 1997, Zhongguo Ying Yong Sheng Li Xue Za Zhi, V13, P224; Macdonald K, 1999, CIRC RES, V84, P820; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; Mehta SL, 2009, J CEREBR BLOOD F MET, V29, P1069, DOI 10.1038/jcbfm.2009.4; Minami M, 2006, J PHARMACOL SCI, V100, P461, DOI 10.1254/jphs.CRJ06005X; Mori M, 2004, CELL DEATH DIFFER, V11, P1223, DOI 10.1038/sj.cdd.4401483; Nakagomi T, 1996, NEUROL RES, V18, P559; Nakase T, 2007, NEUROPATHOLOGY, V27, P442, DOI 10.1111/j.1440-1789.2007.00815.x; NICHOLLS DG, 1977, EUR J BIOCHEM, V75, P601, DOI 10.1111/j.1432-1033.1977.tb11560.x; Ouyang YB, 2004, CELL CALCIUM, V36, P303, DOI 10.1016/j.ceca.2004.02.015; Ouyang YB, 2006, CELL STRESS CHAPERON, V11, P180, DOI 10.1379/CSC-182R.1; Palgrave CJ, 2011, J VIROL, V85, P6008, DOI 10.1128/JVI.00331-11; Pignataro G, 2008, J CEREBR BLOOD F MET, V28, P232, DOI 10.1038/sj.jcbfm.9600559; Rousset S, 2006, CYTOKINE, V35, P135, DOI 10.1016/j.cyto.2006.07.012; Sawe N, 2008, J NEUROSCI RES, V86, P1659, DOI 10.1002/jnr.21604; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Sriram K, 2007, J NEUROIMMUNE PHARM, V2, P140, DOI 10.1007/s11481-007-9070-6; Teshima Y, 2003, CIRC RES, V93, P192, DOI 10.1161/01.RES.0000085581.60197.4D; Tuttolomondo A, 2008, CURR PHARM DESIGN, V14, P3574, DOI 10.2174/138161208786848739; Yano S, 2001, J CEREBR BLOOD F MET, V21, P351, DOI 10.1097/00004647-200104000-00004; Yoshitomi H, 1999, BIOCHEM J, V340, P397, DOI 10.1042/0264-6021:3400397; Zhao H, 2005, J NEUROSCI, V25, P9794, DOI 10.1523/JNEUROSCI.3163-05.2005; Zhao H, 2009, J CEREBR BLOOD F MET, V29, P873, DOI 10.1038/jcbfm.2009.13	52	24	28	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2012	7	2							e31739	10.1371/journal.pone.0031739			6	Multidisciplinary Sciences	Science & Technology - Other Topics	925CF	WOS:000302737400046	22348126	DOAJ Gold, Green Published			2021-06-18	
J	Saraiva, ALL; Ferreira, APO; Silva, LFA; Hoffmann, MS; Dutra, FD; Furian, AF; Oliveira, MS; Fighera, MR; Royes, LFF				Lopes Saraiva, Andre Luis; Oliveira Ferreira, Ana Paula; Almeida Silva, Luiz Fernando; Hoffmann, Mauricio Scopel; Dutra, Fabricio Diniz; Furian, Ana Flavia; Oliveira, Mauro Schneider; Fighera, Michele Rechia; Freire Royes, Luiz Fernando			Creatine reduces oxidative stress markers but does not protect against seizure susceptibility after severe traumatic brain injury	BRAIN RESEARCH BULLETIN			English	Article						Creatine; Traumatic brain injury; Post-traumatic epilepsy; TBARS; Carbonyl; Na+,K+-ATPase	PENTYLENETETRAZOL-INDUCED SEIZURES; POSTTRAUMATIC EPILEPSY; NA+,K+-ATPASE ACTIVITY; TIME-COURSE; K+-ATPASE; RAT; HYPEREXCITABILITY; SUPPLEMENTATION; EPILEPTOGENESIS; CONVULSIONS	Achievements made over the last years have highlighted the important role of creatine in health and disease. However, its effects on hyperexcitable circuit and oxidative damage induced by traumatic brain injury (TBI) are not well understood. In the present study we revealed that severe TBI elicited by fluid percussion brain injury induced oxidative damage characterized by protein carbonylation, thiobarbituric acid reactive species (TBARS) increase and Na+,K+-ATPase activity inhibition 4 and 8 days after neuronal injury. Statistical analysis showed that after TBI creatine supplementation (300 mg/kg, p.o.) decreased the levels of protein carbonyl and TBARS but did not protect against TBI-induced Na+,K+-ATPase activity inhibition. Electroencephalography (EEG) analysis revealed that the injection of a subconvulsant dose of PTZ (35 mg/kg, i.p.), 4 but not 8 days after neuronal injury, decreased latency for the first clonic seizures and increased the time of spent generalized tonic-clonic seizures compared with the sham group. In addition, creatine supplementation had no effect on convulsive parameters induced by a subconvulsant dose of PTZ. Current experiments provide evidence that lipid and protein oxidation represents a separate pathway in the early post-traumatic seizures susceptibility. Furthermore, the lack of consistent anticonvulsant effect exerted by creatine in this early phase suggests that its apparent antioxidant effect does not protect against excitatory input generation induced by TBI. (C) 2011 Elsevier Inc. All rights reserved.	[Freire Royes, Luiz Fernando] Univ Fed Santa Maria, Dept Metodos & Tecnicas Desport, Ctr Educ Fis & Desportos, BR-97119900 Santa Maria, RS, Brazil; [Lopes Saraiva, Andre Luis; Oliveira Ferreira, Ana Paula; Almeida Silva, Luiz Fernando; Furian, Ana Flavia; Oliveira, Mauro Schneider; Fighera, Michele Rechia; Freire Royes, Luiz Fernando] Univ Fed Santa Maria, Programa Posgrad Ciencias Biol Bioquim Toxicologi, Ctr Ciencias Nat & Exatas, BR-97119900 Santa Maria, RS, Brazil; [Lopes Saraiva, Andre Luis; Oliveira Ferreira, Ana Paula; Almeida Silva, Luiz Fernando; Hoffmann, Mauricio Scopel; Dutra, Fabricio Diniz; Furian, Ana Flavia; Fighera, Michele Rechia; Freire Royes, Luiz Fernando] Univ Fed Santa Maria, Lab Bioquim Exercicio, Ctr Educ Fis & Desportos, BR-97119900 Santa Maria, RS, Brazil; [Oliveira, Mauro Schneider] Univ Fed Santa Maria, Dept Fisiol & Farmacol, Ctr Ciencias Saude, BR-97119900 Santa Maria, RS, Brazil	Royes, LFF (corresponding author), Univ Fed Santa Maria, Dept Metodos & Tecnicas Desport, Ctr Educ Fis & Desportos, BR-97105900 Anta Maria, RS, Brazil.	nandoroyes@yahoo.com.br	Oliveira, Mauro Schneider/G-3437-2012; Hoffmann, Mauricio/AAM-9899-2020; Fighera, Michele R/J-9576-2014; royes, luiz/T-3581-2019	Oliveira, Mauro Schneider/0000-0002-5381-1208; Hoffmann, Mauricio/0000-0003-4232-3169; Saraiva, Andre Lopes/0000-0001-9612-3846; Almeida Silva, Luiz Fernando/0000-0002-7621-4836; royes, luiz/0000-0003-4045-4827			Adhihetty PJ, 2008, NEUROMOL MED, V10, P275, DOI 10.1007/s12017-008-8053-y; Silva LFA, 2011, J NEUROL SCI, V308, P35, DOI 10.1016/j.jns.2011.06.030; Andres RH, 2008, BRAIN RES BULL, V76, P329, DOI 10.1016/j.brainresbull.2008.02.035; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Bertorello AM, 2003, MOL BIOL CELL, V14, P1149, DOI 10.1091/mbc.E02-06-0367; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cheng SXJ, 1999, J PHYSIOL-LONDON, V518, P37, DOI 10.1111/j.1469-7793.1999.0037r.x; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Ferraro TN, 1999, J NEUROSCI, V19, P6733, DOI 10.1523/JNEUROSCI.19-16-06733.1999; Fiske CH, 1925, J BIOL CHEM, V66, P375; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Furian AF, 2007, NEUROCHEM INT, V50, P164, DOI 10.1016/j.neuint.2006.07.012; Garga Nina, 2006, Epilepsy Curr, V6, P1, DOI 10.1111/j.1535-7511.2005.00083.x; Glaser V, 2010, NEUROTOXICOLOGY, V31, P454, DOI 10.1016/j.neuro.2010.05.012; Golarai G, 2001, J NEUROSCI, V21, P8523; Graber KD, 2004, ANN NEUROL, V55, P860, DOI 10.1002/ana.20124; Gurkoff GG, 2009, NEUROSCIENCE, V164, P862, DOI 10.1016/j.neuroscience.2009.08.021; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Kharatishvili I, 2010, CURR OPIN NEUROL, V23, P183, DOI 10.1097/WCO.0b013e32833749e4; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; Lima FD, 2008, BEHAV BRAIN RES, V193, P306, DOI 10.1016/j.bbr.2008.05.013; Lima FD, 2009, BRAIN RES, V1279, P147, DOI 10.1016/j.brainres.2009.04.052; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; LOSCHER W, 1991, EPILEPSY RES, V8, P171, DOI 10.1016/0920-1211(91)90062-K; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Maciejak P, 2010, BRAIN RES, V1342, P150, DOI 10.1016/j.brainres.2010.04.045; Magni DV, 2007, BRAIN RES, V1185, P336, DOI 10.1016/j.brainres.2007.09.023; McColl CD, 2003, NEUROPHARMACOLOGY, V44, P234, DOI 10.1016/S0028-3908(02)00369-6; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; Morel P, 1998, NEUROCHEM INT, V33, P531, DOI 10.1016/S0197-0186(98)00062-X; Mujika I, 1997, INT J SPORTS MED, V18, P491, DOI 10.1055/s-2007-972670; Nishi A, 1999, J NEUROCHEM, V73, P1492, DOI 10.1046/j.1471-4159.1999.0731492.x; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Oliveira MS, 2004, NEUROSCIENCE, V128, P721, DOI 10.1016/j.neuroscience.2004.07.012; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Pitkanen A, 2009, EPILEPSY BEHAV, V14, P16, DOI 10.1016/j.yebeh.2008.09.023; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Rambo LM, 2009, NEUROCHEM INT, V55, P333, DOI 10.1016/j.neuint.2009.04.007; Sakellaris G, 2006, J TRAUMA, V61, P322, DOI 10.1097/01.ta.0000230269.46108.d5; Scheff SW, 2004, NEUROCHEM RES, V29, P469, DOI 10.1023/B:NERE.0000013753.22615.59; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Wallimann T, 2011, AMINO ACIDS, V40, P1271, DOI 10.1007/s00726-011-0877-3; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wyse ATS, 2000, NEUROREPORT, V11, P2331, DOI 10.1097/00001756-200007140-00052; YAN LJ, 1995, ANAL BIOCHEM, V228, P349, DOI 10.1006/abio.1995.1362	46	24	24	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230			BRAIN RES BULL	Brain Res. Bull.	FEB 10	2012	87	2-3					180	186		10.1016/j.brainresbull.2011.10.010			7	Neurosciences	Neurosciences & Neurology	909FP	WOS:000301548300005	22051612				2021-06-18	
J	Thau-Zuchman, O; Shohami, E; Alexandrovich, AG; Leker, RR				Thau-Zuchman, O.; Shohami, E.; Alexandrovich, A. G.; Leker, R. R.			SUBACUTE TREATMENT WITH VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER TRAUMATIC BRAIN INJURY INCREASES ANGIOGENESIS AND GLIOGENESIS	NEUROSCIENCE			English	Article						angiogenesis; growth factor; neurogenesis; neuroprotection; traumatic brain injury; vascular endothelial	CLOSED-HEAD INJURY; IMPROVES FUNCTIONAL RECOVERY; CELL-PROLIFERATION; CEREBRAL-ISCHEMIA; INFARCT VOLUME; UP-REGULATION; STEM-CELLS; RAT-BRAIN; VEGF; MODEL	Vascular endothelial growth factor (VEGF) is neuroprotective and induces neurogenesis and angiogenesis when given early after traumatic brain injury (TBI). However, the effects of VEGF administration in the subacute phase after TBI remain unknown. Mice were subjected to TBI and treated with vehicle or VEGF beginning 7 days later for an additional 7 days. The animals were injected with BrdU to label proliferating cells and examined with a motor-sensory scale at pre-determined time points. Mice were killed 90 days post injury and immunohistochemistry was used to study cell fates. Our results demonstrate that lesion volumes did not differ between the groups confirming the lack of neuroprotective effects in this paradigm. VEGF treatment led to significant increments in cell proliferation (1.9 fold increase vs. vehicle, P<0.0001) and angiogenesis in the lesioned cortex (1.7 fold increase vs. vehicle, P=0.0001) but most of the proliferating cells differentiated into glia and no mature newly-generated neurons were detected. In conclusion, VEGF induces gliogenesis and angiogenesis when given 7 days post TBI. However, treated mice had only insignificant motor improvements in this paradigm, suggesting that the bulk of the beneficial effects observed when VEGF is given early after TBI results from the neuroprotective effects. (C) 2011 IBRO. Published by Elsevier Ltd. All rights reserved.	[Thau-Zuchman, O.; Leker, R. R.] Hadassah Hebrew Univ Med Ctr, Dept Neurol, Jerusalem, Israel; [Thau-Zuchman, O.; Leker, R. R.] Hadassah Hebrew Univ Med Ctr, Peritz & Chantal Scheinberg Cerebrovasc Res Lab, Jerusalem, Israel; [Thau-Zuchman, O.; Shohami, E.; Alexandrovich, A. G.] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel	Leker, RR (corresponding author), Hadassah Hebrew Univ Med Ctr, Dept Neurol, Jerusalem, Israel.	leker@cc.huji.ac.il	Leker, Ronen/ABC-6096-2020	Leker, Ronen/0000-0003-4794-0334; Thau-Zuchman, Orli/0000-0003-0403-7962	Pertiz and Chantal Scheinberg Cerebrovascular Research Fund; Sol Irwin Juni Trust Fund	This study was supported in part by the Pertiz and Chantal Scheinberg Cerebrovascular Research Fund and by the Sol Irwin Juni Trust Fund. E.S. is the incumbent of the Dr. Leon and Mina Deutch Chair in Psychopharmacology at the Hebrew University.	Ben-Hur T, 2008, J NEUROL SCI, V265, P102, DOI 10.1016/j.jns.2007.05.007; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Biegon A, 2004, CURR PHARM DESIGN, V10, P2177, DOI 10.2174/1381612043384196; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Cirulli V, 2007, NAT REV MOL CELL BIO, V8, P296, DOI 10.1038/nrm2142; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dore-Duffy P, 2007, NEUROL RES, V29, P395, DOI 10.1179/016164107X204729; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Forsberg-Nilsson K, 1998, J NEUROSCI RES, V53, P521, DOI 10.1002/(SICI)1097-4547(19980901)53:5<521::AID-JNR2>3.0.CO;2-B; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Gotts JE, 2005, EXP NEUROL, V194, P139, DOI 10.1016/j.expneurol.2005.02.001; Jin KL, 2006, J NEUROBIOL, V66, P236, DOI 10.1002/neu.20215; Kim JH, 2004, J KOREAN MED SCI, V19, P879, DOI 10.3346/jkms.2004.19.6.879; Lafuente JV, 2006, J NEURAL TRANSM, V113, P487, DOI 10.1007/s00702-005-0407-0; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lee C, 2009, EXP NEUROL, V220, P400, DOI 10.1016/j.expneurol.2009.08.019; Leker RR, 2007, STROKE, V38, P153, DOI 10.1161/01.STR.0000252156.65953.a9; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; Lu KT, 2011, J NEUROTRAUM, V28, P441, DOI 10.1089/neu.2010.1473; Manwani B, 2011, BRAIN BEHAV IMMUN, V25, P1689, DOI 10.1016/j.bbi.2011.06.015; McTigue DM, 2008, J NEUROCHEM, V107, P1, DOI 10.1111/j.1471-4159.2008.05570.x; Morgan R, 2007, NEUROL RES, V29, P375, DOI 10.1179/016164107X204693; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; Nieto M, 2001, NEURON, V29, P401, DOI 10.1016/S0896-6273(01)00214-8; Ogunshola OO, 2000, DEV BRAIN RES, V119, P139, DOI 10.1016/S0165-3806(99)00125-X; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Shetty AK, 2005, GLIA, V51, P173, DOI 10.1002/glia.20187; Shetty AK, 2004, J NEUROSCI RES, V78, P520, DOI 10.1002/jnr.20302; Skold MK, 2006, EUR J NEUROSCI, V23, P21, DOI 10.1111/j.1460-9568.2005.04527.x; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Thored P, 2007, STROKE, V38, P3032, DOI 10.1161/STROKEAHA.107.488445; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Wang WY, 2005, NEUROSCIENCE, V134, P1167, DOI 10.1016/j.neuroscience.2005.04.064; Wang YM, 2007, J NEUROSCI RES, V85, P740, DOI 10.1002/jnr.21169; Widenfalk J, 2003, NEUROSCIENCE, V120, P951, DOI 10.1016/S0306-4522(03)00399-3; Xiao ZF, 2007, CELL RES, V17, P73, DOI 10.1038/sj.cr.7310126; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Zhao XH, 2007, MOL CELL NEUROSCI, V36, P260, DOI 10.1016/j.mcn.2007.07.008	43	24	26	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience	JAN 27	2012	202						334	341		10.1016/j.neuroscience.2011.11.071			8	Neurosciences	Neurosciences & Neurology	887DV	WOS:000299908000032	22173016				2021-06-18	
J	Brittain, JM; Pan, R; You, HT; Brustovetsky, T; Brustovetsky, N; Zamponi, GW; Lee, WH; Khanna, R				Brittain, Joel M.; Pan, Rui; You, Haitao; Brustovetsky, Tatiana; Brustovetsky, Nickolay; Zamponi, Gerald W.; Lee, Wei-Hua; Khanna, Rajesh			Disruption of NMDAR-CRMP-2 signaling protects against focal cerebral ischemic damage in the rat middle cerebral artery occlusion model	CHANNELS			English	Article						N-methylD-aspartate receptor; CRMP-2; peptide; focal cerebral ischemia; MCAO model	TRAUMATIC BRAIN-INJURY; RESPONSE MEDIATOR PROTEIN-2; CALCIUM-CHANNEL ANTAGONIST; NMDA RECEPTOR SUBUNITS; GENE-EXPRESSION; NEUROPROTECTION; GLUTAMATE; TRANSIENT; STROKE; HIPPOCAMPUS	Collapsin response mediator protein 2 (CRMP-2), traditionally viewed as an axon/dendrite specification and axonal growth protein, has emerged as nidus in regulation of both pre- and post-synaptic Ca2+ channels. Building on our discovery of the interaction and regulation of Ca2+ channels by CRMP-2, we recently identified a short sequence in CRMP-2 which, when appended to the transduction domain of HIV TAT protein, suppressed acute, inflammatory and neuropathic pain in vivo by functionally uncoupling CRMP-2 from the Ca2+ channel. Remarkably, we also found that this region attenuated Ca2+ influx via N-methylD-Aspartate receptors (NMDARs) and reduced neuronal death in a moderate controlled cortical impact model of traumatic brain injury (TBI). Here, we sought to extend these findings by examining additional neuroprotective effects of this peptide (TAT-CBD3) and exploring the biochemical mechanisms by which TAT-CBD3 targets NMDARs. We observed that an intraperitoneal injection of TAT-CBD3 peptide significantly reduced infarct volume in an animal model of focal cerebral ischemia. Neuroprotection was observed when TAT-CBD3 peptide was given either prior to or after occlusion but just prior to reperfusion. Surprisingly, a direct biochemical complex was not resolvable between the NMDAR subunit NR2B and CRMP-2. Intracellular application of TAT-CBD3 failed to inhibit NMDAR current. NR2B interactions with the post synaptic density protein 95 (PSD-95) remained intact and were not disrupted by TAT-CBD3. Peptide tiling of intracellular regions of NR2B revealed two 15-mer sequences, in the carboxyl-terminus of NR2B, that may confer binding between NR2B and CRMP-2 which supports CRMP-2's role in excitotoxicity and neuroprotection.	[Brittain, Joel M.; Brustovetsky, Nickolay; Lee, Wei-Hua; Khanna, Rajesh] Indiana Univ, Sch Med, Paul & Carole Stark Neurosci Res Inst, Indianapolis, IN 46204 USA; [Pan, Rui] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Pediat, Wuhan 430074, Hubei, Peoples R China; [You, Haitao; Zamponi, Gerald W.] Univ Calgary, Hotchkiss Brain Inst, Dept Physiol & Pharmacol, Calgary, AB, Canada; [Brustovetsky, Tatiana; Brustovetsky, Nickolay; Khanna, Rajesh] Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; [Brustovetsky, Tatiana; Brustovetsky, Nickolay; Khanna, Rajesh] Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; [Lee, Wei-Hua] Indiana Univ, Sch Med, Indiana Spinal Cord & Brain Injury Res Grp, Indianapolis, IN USA; [Khanna, Rajesh] Sophia Therapeut LLC, Indianapolis, IN USA	Khanna, R (corresponding author), Indiana Univ, Sch Med, Paul & Carole Stark Neurosci Res Inst, Indianapolis, IN 46204 USA.	khanna5@iupui.edu		Zamponi, Gerald/0000-0002-0644-9066; Khanna, Rajesh/0000-0002-9066-2969	Indiana Clinical and Translational Sciences Institute; National Institutes of Health, National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR025761]; Indiana State Department of Health [A70-9-079138]; Indiana University Biomedical Committee [2286501]; National Scientist Development from the American Heart AssociationAmerican Heart Association [SDG5280023]; Elwert Award in Medicine; Larry Kays Medical Neuroscience fellowship; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078008] Funding Source: NIH RePORTER	The authors would like to acknowledge Sarah Wilson, Dr May Khanna and colleagues at the Stark Neurosciences Research Institute (SNRI) for comments on the manuscript. The peptide blot was synthesized at the SNRI core facility by Dr Andy Hudmon with assistance from Nicole Ashpole. This work was supported, in part, by grants from the Indiana Clinical and Translational Sciences Institute funded, in part by a Project Development Team Grant Number (RR025761) from the National Institutes of Health, National Center for Research Resources, Clinical and Translational Sciences Award, the Indiana State Department of Health-Spinal Cord and Brain Injury Fund (A70-9-079138 to R. K.), the Indiana University Biomedical Committee-Research Support Funds (2286501 to R. K.), a National Scientist Development from the American Heart Association (SDG5280023 to R. K.), and the Elwert Award in Medicine to R.K. J. M. B. is the recipient of a Larry Kays Medical Neuroscience fellowship. R. K. is a majority shareholder of Sophia Therapeutics L.L.C.	Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; Al-Hallaq RA, 2007, J NEUROSCI, V27, P8334, DOI 10.1523/JNEUROSCI.2155-07.2007; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bordet T, 2009, NEUROTHERAPEUTICS, V6, P648, DOI 10.1016/j.nurt.2009.07.001; Bordi F, 1997, EXP NEUROL, V145, P425, DOI 10.1006/exnr.1997.6442; Bowersox SS, 1997, BRAIN RES, V747, P343; Bretin S, 2006, J NEUROCHEM, V98, P1252, DOI 10.1111/j.1471-4159.2006.03969.x; Brittain JM, 2011, J BIOL CHEM, V286, P37778, DOI 10.1074/jbc.M111.255455; Brittain JM, 2011, NAT MED, V17, P822, DOI 10.1038/nm.2345; Brittain JM, 2009, J BIOL CHEM, V284, P31375, DOI 10.1074/jbc.M109.009951; Brustovetsky T, 2009, CELL CALCIUM, V46, P18, DOI 10.1016/j.ceca.2009.03.017; Bu XN, 2011, J NEUROCHEM, V117, P346, DOI 10.1111/j.1471-4159.2011.07209.x; Chi XX, 2009, J CELL SCI, V122, P4351, DOI 10.1242/jcs.053280; Chung MA, 2005, NEUROREPORT, V16, P1647, DOI 10.1097/01.wnr.0000176520.49841.e6; DAWSON DA, 1994, BRIT J PHARMACOL, V113, P247, DOI 10.1111/j.1476-5381.1994.tb16201.x; Derugin N, 1998, NEUROSCI RES, V32, P349, DOI 10.1016/S0168-0102(98)00096-0; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gonzalez FF, 2007, DEV NEUROSCI-BASEL, V29, P321, DOI 10.1159/000105473; Hensley K, 2011, MOL NEUROBIOL, V43, P180, DOI 10.1007/s12035-011-8166-4; Hou ST, 2009, J NEUROCHEM, V111, P870, DOI 10.1111/j.1471-4159.2009.06375.x; Husi H, 2000, NAT NEUROSCI, V3, P661; Indraswari F, 2009, NEUROCHEM INT, V55, P235, DOI 10.1016/j.neuint.2009.03.005; Kloda A, 2007, CHANNELS, V1, P334, DOI 10.4161/chan.5044; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lee LL, 2004, EXP NEUROL, V190, P70, DOI 10.1016/j.expneurol.2004.07.003; Martel MA, 2009, CHANNELS, V3, P12, DOI 10.4161/chan.3.1.7864; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; Niethammer M, 1996, J NEUROSCI, V16, P2157; Orgogozo JM, 2002, STROKE, V33, P1834, DOI 10.1161/01.STR.0000020094.08790.49; PARK CK, 1988, ANN NEUROL, V24, P543, DOI 10.1002/ana.410240411; Perez-Pinzon MA, 1997, J NEUROL SCI, V153, P25, DOI 10.1016/S0022-510X(97)00196-2; Reisberg B, 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128; Ryan TJ, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-6; SAUTER A, 1995, J PHARMACOL EXP THER, V274, P1008; Schmidt EF, 2007, ADV EXP MED BIOL, V600, P1; Takahara A, 2004, BIOL PHARM BULL, V27, P1388, DOI 10.1248/bpb.27.1388; Touma E, 2007, EUR J NEUROSCI, V26, P3368, DOI 10.1111/j.1460-9568.2007.05943.x; VALENTINO K, 1993, P NATL ACAD SCI USA, V90, P7894, DOI 10.1073/pnas.90.16.7894; Villmann C, 2007, NEUROSCIENTIST, V13, P594, DOI 10.1177/1073858406296259; Wang Yuying, 2010, Commun Integr Biol, V3, P172; Wilson SM, 2011, CHANNELS, V5, P447, DOI 10.4161/chan.5.5.17363; Zhang ZQ, 2007, J NEUROTRAUM, V24, P460, DOI 10.1089/neu.2006.0078	42	24	25	1	10	LANDES BIOSCIENCE	AUSTIN	1806 RIO GRANDE ST, AUSTIN, TX 78702 USA	1933-6950			CHANNELS	Channels	JAN-FEB	2012	6	1					52	59		10.4161/chan.18919			8	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	953XG	WOS:000304906500007	22373559	Green Published, Bronze			2021-06-18	
J	Hockel, K; Scholler, K; Trabold, R; Nussberger, J; Plesnila, N				Hockel, Konstantin; Schoeller, Karsten; Trabold, Raimund; Nussberger, Juerg; Plesnila, Nikolaus			Vasopressin V-1a Receptors Mediate Posthemorrhagic Systemic Hypertension Thereby Determining Rebleeding Rate and Outcome After Experimental Subarachnoid Hemorrhage	STROKE			English	Article						antidiuretic hormone (ADH); arginine vasopressin (AVP); brain edema; Cushing response; experimental; rat; subarachnoid hemorrhage; V1(a) receptors	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; ARGININE-VASOPRESSIN; V-2 RECEPTORS; PLASMA; EDEMA; MODEL; MECHANISMS; ISCHEMIA; HORMONE	Background and Purpose-Arginine vasopressin V-1 receptors have been suggested to be involved in the pathophysiology of acute brain injury. Therefore, we aimed to determine the role of arginine vasopressin V-1 receptors after experimental subarachnoid hemorrhage (SAH). Methods-Sprague-Dawley rats subjected to SAH by endovascular puncture received either vehicle or a V1 receptor antagonist intravenously from 1 minute before until 3 hours after SAH. Intracranial pressure, cerebral blood flow, and mean arterial blood pressure were monitored until 60 minutes after SAH. Brain water content was quantified 24 hours after SAH and neurological function and mortality were assessed daily for 7 days after hemorrhage. Results-In control rats, SAH induced high intracranial pressure, a brief increase in plasma arginine vasopressin, a subsequent increase in systemic blood pressure (Cushing response), a high rebleeding rate (30%), severe neurological deficits, and a 7-day mortality rate of 50%. V1 receptor antagonist-treated animals exhibited a far less pronounced Cushing response, a less severe increase of intracranial pressure, did not exhibit rebleedings, had less severe brain edema formation and neurological deficits, and a mortality rate of only 20% (all P<0.05 versus vehicle). Conclusions-Inhibition of arginine vasopressin V-1a receptors reduces the severity of SAH and prevents rebleedings by blunting the posthemorrhagic hypertonic response (Cushing reflex), thereby reducing mortality and secondary brain damage after experimental SAH. Because the severity of the initial bleeding and rebleedings are major factors contributing to an unfavorable outcome after SAH, inhibition of V-1a receptors may represent a novel strategy to treat SAH. (Stroke. 2012;43:227-232.)	[Plesnila, Nikolaus] Univ Munich, Inst Stroke & Dementia Res, Med Ctr, Munich, Germany; [Schoeller, Karsten; Trabold, Raimund] Univ Munich, Med Ctr Grosshadern, Dept Neurosurg, Munich, Germany; [Hockel, Konstantin; Schoeller, Karsten; Trabold, Raimund; Plesnila, Nikolaus] Univ Munich, Med Ctr Grosshadern, Inst Surg Res, Munich, Germany; [Nussberger, Juerg] CHU Vaudois, Div Angiol & Hypertens, CH-1011 Lausanne, Switzerland; Univ Lausanne, Lausanne, Switzerland; [Plesnila, Nikolaus] Royal Coll Surgeons Ireland, Dublin 2, Ireland	Plesnila, N (corresponding author), Univ Munich, Inst Stroke & Dementia Res, Med Ctr, Munich, Germany.	plesnila@med.uni-muenchen.de	Plesnila, Nikolaus/T-7522-2019		Friedrich Baur Foundation	The current study was partly funded by a grant from the Friedrich Baur Foundation.	BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; BRODERICK JP, 1994, STROKE, V25, P1342, DOI 10.1161/01.STR.25.7.1342; Chen EP, 1996, CRIT CARE MED, V24, P1352, DOI 10.1097/00003246-199608000-00014; Claassen J, 2004, CRIT CARE MED, V32, P832, DOI 10.1097/01.CCM.0000114830.48833.8A; Claassen J, 2002, STROKE, V33, P1225, DOI 10.1161/01.STR.0000015624.29071.1F; ISOTANI E, 1994, STROKE, V25, P2198, DOI 10.1161/01.STR.25.11.2198; JOYNT RJ, 1981, ANN NEUROL, V9, P182, DOI 10.1002/ana.410090212; Kleindienst A, 2006, ACTA NEUROCHIR SUPPL, V96, P303; Kleindienst A, 2004, ACTA NEUROL SCAND, V109, P361, DOI 10.1046/j.1600-0404.2003.00245.x; Kozniewska E, 2006, J PHYSIOL PHARMACOL, V57, P145; LIU XF, 1991, CHINESE MED J-PEKING, V104, P480; MANNING M, 1987, NATURE, V329, P839, DOI 10.1038/329839a0; MATHER HM, 1981, J NEUROL NEUROSUR PS, V44, P216, DOI 10.1136/jnnp.44.3.216; Niermann H, 2001, J NEUROSCI, V21, P3045, DOI 10.1523/JNEUROSCI.21-09-03045.2001; Ostrowski RP, 2006, NEUROL RES, V28, P399, DOI 10.1179/016164106X115008; SCHALLER MD, 1987, AM J CARDIOL, V60, P1178, DOI 10.1016/0002-9149(87)90416-4; Scholler K, 2004, BRAIN RES, V1023, P272, DOI 10.1016/j.brainres.2004.01.094; Szmydynger-Chodobska J, 2004, J NEUROTRAUM, V21, P1090, DOI 10.1089/0897715041651033; Thal SC, 2007, J NEUROSCI METH, V159, P261, DOI 10.1016/j.jneumeth.2006.07.016; Trabold R, 2008, J NEUROTRAUM, V25, P1459, DOI 10.1089/neu.2008.0597; Tribollet E, 1998, PROG BRAIN RES, V119, P45; Vakili A, 2005, J CEREBR BLOOD F MET, V25, P1012, DOI 10.1038/sj.jcbfm.9600097; van Gijn J, 2001, BRAIN, V124, P249, DOI 10.1093/brain/124.2.249; Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35; Xu M, 2007, CHIN J TRAUMATOL, V10, P90; Zausinger S, 2000, BRAIN RES, V863, P94, DOI 10.1016/S0006-8993(00)02100-4	26	24	24	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	JAN	2012	43	1					227	U432		10.1161/STROKEAHA.111.626168			10	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	866LY	WOS:000298383600056	21998059	Bronze			2021-06-18	
J	Janzen, C; Kruger, K; Honeybul, S				Janzen, Courtney; Kruger, Kate; Honeybul, Stephen			Syndrome of the trephined following bifrontal decompressive craniectomy: Implications for rehabilitation	BRAIN INJURY			English	Article						Decompressive craniectomy; syndrome of trephined; traumatic brain injury; rehabilitation	TRAUMATIC BRAIN-INJURY; SINKING SKIN FLAP; NEUROLOGICAL IMPROVEMENT; SURGICAL DECOMPRESSION; BLOOD-FLOW; CRANIOPLASTY; RECOVERY	Objective: The syndrome of the trephined is a rare complication observed following a unilateral decompressive craniectomy for traumatic brain injury. What has not been previously reported is the occurrence of this complication following a bifrontal procedure. The objective of this study was to present two clinical cases that serve to highlight this condition. Design: A case study of two patients who had had a bifrontal decompressive craniectomy for severe traumatic brain injury Method: A review was undertaken detailing the clinical course of the two patients. Results: Both cases were young males. They had initially made significant improvement in their functional and cognitive performance whilst undergoing rehabilitation. However, after some months they demonstrated marked deterioration. Immediately following cranioplasty they showed considerable clinical improvement. Conclusion: If the use of bifrontal decompressive craniectomies continues to increase it is important that those involved in the rehabilitation process are familiar with this rare condition. Early recognition is important so that patients can receive timely intervention and it also avoids valuable health resources being allocated to patients who cannot receive maximal benefit.	[Honeybul, Stephen] Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA, Australia; [Honeybul, Stephen] Royal Perth Hosp, Perth, WA, Australia; [Janzen, Courtney; Kruger, Kate] Sir Charles Gairdner Hosp, Dept Occupat Therapy, Perth, WA, Australia	Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA, Australia.	stephen.honeybul@health.wa.gov.au					Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; Giuffrida CG, 2009, AM J OCCUP THER, V63, P398, DOI 10.5014/ajot.63.4.398; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Grant FC, 1939, ANN SURG, V110, P488, DOI 10.1097/00000658-193910000-00002; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Helps Y., 2008, INJURY RES STAT SERI, V45; Ho KM, 2011, CRIT CARE MED, V39, P2495, DOI 10.1097/CCM.0b013e318225764e; Honeybul S, 2010, J CLIN NEUROSCI, V17, P430, DOI 10.1016/j.jocn.2009.09.007; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Isago T, 2004, ANN PLAS SURG, V53, P288, DOI 10.1097/01.sap.0000106433.89983.72; Joseph V, 2009, J NEUROSURG, V111, P650, DOI 10.3171/2009.3.JNS0984; Kuo JR, 2004, J CLIN NEUROSCI, V11, P486, DOI 10.1016/j.jocn.2003.06.005; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Sakamoto S, 2006, CLIN NEUROL NEUROSUR, V108, P583, DOI 10.1016/j.clineuro.2005.03.012; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Sorbo A, 2005, BRAIN INJURY, V19, P493, DOI 10.1080/02699050400013709; Stiver SI, 2008, J NEUROSURG, V109, P245, DOI 10.3171/JNS/2008/109/8/0245; SUZUKI N, 1993, ACTA NEUROCHIR, V122, P49, DOI 10.1007/BF01446986; Timofeev I, 2006, INJURY, V37, P1125, DOI 10.1016/j.injury.2006.07.031; Voss HU, 2011, CLIN IMAG, V35, P253, DOI 10.1016/j.clinimag.2010.07.008; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	28	24	24	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2012	26	1					101	105		10.3109/02699052.2011.635357			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	858HY	WOS:000297787900011	22149449				2021-06-18	
J	Lau, D; El-Sayed, AM; Ziewacz, JE; Jayachandran, P; Huq, FS; Zamora-Berridi, GJ; Davis, MC; Sullivan, SE				Lau, Darryl; El-Sayed, Abdulrahman M.; Ziewacz, John E.; Jayachandran, Priya; Huq, Farhan S.; Zamora-Berridi, Grettel J.; Davis, Matthew C.; Sullivan, Stephen E.			Postoperative outcomes following closed head injury and craniotomy for evacuation of hematoma in patients older than 80 years Clinical article	JOURNAL OF NEUROSURGERY			English	Article						age; craniotomy; hematoma; intracranial hemorrhage; morbidity; trauma; traumatic brain injury	CHRONIC SUBDURAL-HEMATOMA; INTRACEREBRAL HEMORRHAGE; ELDERLY-PATIENTS; SURGERY; MORTALITY; RISK; AGE; COMPLICATIONS; EXPERIENCE; SURVIVAL	Object. Advances in the management of trauma-induced intracranial hematomas and hemorrhage (epidural, subdural, and intraparenchymal hemorrhage) have improved survival in these conditions over the last several decades. However, there is a paucity of research investigating the relation between patient age and outcomes of surgical treatment for these conditions. In this study, the authors examined the relation between patient age over 80 years and postoperative outcomes following closed head injury and craniotomy for intracranial hemorrhage. Methods. A consecutive population of patients undergoing emergent craniotomy for evacuation of intracranial hematoma following closed head trauma between 2006 and 2009 was identified. Using multivariable logistic regression models, the authors assessed the relation between age (> 80 vs <= 80 years) and postoperative complications, intensive care unit stay, hospital stay, morbidity, and mortality. Results. Of 103 patients, 27 were older than 80 years and 76 patients were 80 years of age or younger. Older age was associated with longer length of hospital stay (p = 0.014), a higher rate of complications (OR 5.74, 95% CI 1.29-25.34), and a higher likelihood of requiring rehabilitation (OR 3.28, 95% CI 1.13-9.74). However, there were no statistically significant differences between the age groups in 30-day mortality or ability to recover to functional baseline status. Conclusions. The findings suggest that in comparison with younger patients, patients over 80 years of age may be similarly able to return to preinjury functional baselines but may require increased postoperative medical attention in the forms of rehabilitation and longer hospital stays. Prospective studies concerned with the relation between older age, perioperative parameters, and postoperative outcomes following craniotomy for intracranial hemorrhage are needed. Nonetheless, the findings of this study may allow for more informed decisions with respect to the care of elderly patients with intracranial hemorrhage. (DOI: 10.3171/2011.7.JNS11396)	[El-Sayed, Abdulrahman M.] Columbia Univ, Dept Epidemiol, New York, NY 10031 USA; [Lau, Darryl; Jayachandran, Priya; Huq, Farhan S.; Zamora-Berridi, Grettel J.; Davis, Matthew C.] Univ Michigan, Sch Med, Ann Arbor, MI USA; [Ziewacz, John E.; Sullivan, Stephen E.] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA; [El-Sayed, Abdulrahman M.] Univ Oxford, Dept Publ Hlth, Oxford, England; [El-Sayed, Abdulrahman M.] Columbia Univ, Coll Phys & Surg, New York, NY 10031 USA; [Ziewacz, John E.] Harvard Univ, Sch Publ Hlth, Ctr Surg & Publ Hlth, Boston, MA 02115 USA; [Ziewacz, John E.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA	El-Sayed, AM (corresponding author), Columbia Univ, Dept Epidemiol, 722 W 168th St,15th Floor, New York, NY 10031 USA.	ame2145@columbia.edu	El-Sayed, Abdulrahman/F-7427-2013	El-Sayed, Abdulrahman/0000-0002-4809-5630	Rhodes Trust; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HSO 18537-01]	This study was funded in part by grants from the Rhodes Trust (to A. M. E.-S.) and the NIH (HSO 18537-01 to J.E.Z.). The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.	Adhiyaman V, 2002, POSTGRAD MED J, V78, P71, DOI 10.1136/pmj.78.916.71; ANDREWS BT, 1988, J NEUROSURG, V69, P518, DOI 10.3171/jns.1988.69.4.0518; Asghar M, 2002, J ROY SOC MED, V95, P290, DOI 10.1258/jrsm.95.6.290; Awe OO, 2011, NEUROSURGERY, V68, P753, DOI 10.1227/NEU.0b013e318207a9fb; Baechli H, 2004, NEUROSURG REV, V27, P263, DOI 10.1007/s10143-004-0337-6; Biagi E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010667; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; BRODERICK JP, 1994, HDB NEUROEPIDEMIOLOG, P141; Brott T, 1997, STROKE, V28, P1, DOI 10.1161/01.STR.28.1.1; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; Ghaferi AA, 2009, NEW ENGL J MED, V361, P1368, DOI 10.1056/NEJMsa0903048; Hanif S, 2009, Ir Med J, V102, P255; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; Iantosca MR, 2000, NEUROSURG CLIN N AM, V11, P447, DOI 10.1016/S1042-3680(18)30107-4; JANNY P, 1982, ACTA NEUROCHIR, V61, P181, DOI 10.1007/BF01740083; KASE CS, 1994, INTRACEREBRAL HEMORR, P467; Kim KH, 2009, J KOREAN NEUROSURG S, V45, P143, DOI 10.3340/jkns.2009.45.3.143; Kovacs EJ, 2009, TRENDS IMMUNOL, V30, P319, DOI 10.1016/j.it.2009.03.012; Lawrence VA, 1995, J GEN INTERN MED, V10, P671, DOI 10.1007/BF02602761; LISK DR, 1994, NEUROLOGY, V44, P133, DOI 10.1212/WNL.44.1.133; Long DM, 2003, NEUROSURGERY, V52, P1056, DOI 10.1227/01.NEU.0000057745.48813.93; Petridis AK, 2009, CENT EUR NEUROSURG, V70, P73, DOI 10.1055/s-0029-1224096; Polanczyk CA, 2001, ANN INTERN MED, V134, P637, DOI 10.7326/0003-4819-134-8-200104170-00008; Qureshi Adnan I, 2005, J Intensive Care Med, V20, P34, DOI 10.1177/0885066604271619; Qureshi AI, 2001, NEW ENGL J MED, V344, P1450, DOI 10.1056/NEJM200105103441907; Rathlev NK, 2006, ACAD EMERG MED, V13, P302, DOI 10.1197/j.aem.2005.10.015; Sahni R, 2007, VASC HEALTH RISK MAN, V3, P701; Sawada T, 2008, HEPATO-GASTROENTEROL, V55, P1971; Shaw AC, 2010, CURR OPIN IMMUNOL, V22, P507, DOI 10.1016/j.coi.2010.05.003; Stachniak JB, 1996, STROKE, V27, P276, DOI 10.1161/01.STR.27.2.276; Stieg PE, 1998, NEUROL CLIN, V16, P373, DOI 10.1016/S0733-8619(05)70069-4; Sundermann S, 2011, EUR J CARDIO-THORAC, V39, P33, DOI 10.1016/j.ejcts.2010.04.013; Taussky P, 2008, SWISS MED WKLY, V138, P281, DOI 2008/19/smw-12056; Tian HL, 2008, CHINESE MED J-PEKING, V121, P1080, DOI 10.1097/00029330-200806020-00007; TUHRIM S, 1995, CRIT CARE MED, V23, P950, DOI 10.1097/00003246-199505000-00026; Vyas NA, 2007, SURG NEUROL, V67, P314, DOI 10.1016/j.surneu.2006.03.039; White M, 2010, BRIT J NEUROSURG, V24, P257, DOI 10.3109/02688691003675218; Wright James D, 2005, Care Manag J, V6, P178, DOI 10.1891/cmaj.6.4.178; YANG GY, 1994, J NEUROSURG, V81, P93, DOI 10.3171/jns.1994.81.1.0093	39	24	24	1	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2012	116	1					234	245		10.3171/2011.7.JNS11396			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	869XJ	WOS:000298632500038	21888477				2021-06-18	
J	Pavawalla, SP; Schmitter-Edgecombe, M; Smith, RE				Pavawalla, Shital P.; Schmitter-Edgecombe, Maureen; Smith, Rebekah E.			Prospective Memory After Moderate-to-Severe Traumatic Brain Injury: A Multinomial Modeling Approach	NEUROPSYCHOLOGY			English	Article						traumatic brain injury; prospective memory; retrospective memory; multinomial modeling	CLOSED-HEAD-INJURY; PROCESSING TREE MODELS; POWER ANALYSIS PROGRAM; RETROSPECTIVE-MEMORY; COMPUTER-PROGRAM; TASK COMPLEXITY; PERFORMANCE; EVENT; RETRIEVAL; ADULTS	Objective: Prospective memory (PM), which can be understood as the processes involved in realizing a delayed intention, is consistently found to be impaired after a traumatic brain injury (TBI). Although PM can be empirically dissociated from retrospective memory, it inherently involves both a prospective component (i.e., remembering that an action needs to be carried out) and retrospective components (i.e., remembering what action needs to be executed and when). This study utilized a multinomial processing tree model to disentangle the prospective (that) and retrospective recognition (when) components underlying PM after moderate-to-severe TBI. Method: Seventeen participants with moderate to severe TBI and 17 age-and education-matched control participants completed an event-based PM task that was embedded within an ongoing computer-based color-matching task. Results: The multinomial processing tree modeling approach revealed a significant group difference in the prospective component, indicating that the control participants allocated greater preparatory attentional resources to the PM task compared to the TBI participants. Participants in the TBI group were also found to be significantly more impaired than controls in the when aspect of the retrospective component. Conclusions: These findings indicated that the TBI participants had greater difficulty allocating the necessary preparatory attentional resources to the PM task and greater difficulty discriminating between PM targets and nontargets during task execution, despite demonstrating intact posttest recall and/or recognition of the PM tasks and targets.	[Pavawalla, Shital P.] James A Haley Vet Hosp, Tampa, FL 33612 USA; [Schmitter-Edgecombe, Maureen] Washington State Univ, Dept Psychol, Pullman, WA 99164 USA; [Smith, Rebekah E.] Univ Texas San Antonio, Dept Psychol, San Antonio, TX USA	Pavawalla, SP (corresponding author), James A Haley Vet Hosp, 13000 Bruce B Downs Blvd,MH&BS 116B, Tampa, FL 33612 USA.	shitalpavawalla@yahoo.com	Smith, Rebekah E/A-6128-2013	Smith, Rebekah/0000-0002-9297-9177	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS47690]; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG034965]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [SC1AG034965] Funding Source: NIH RePORTER	We thank the TBI participants and the members of the Head Injury Research Team for their help in collecting and scoring the data and Laura Randol for assistance with manuscript preparation. This study was partially supported by Grant R01 NS47690 from NINDS to MSE and was completed as partial fulfillment of the first author's dissertation requirements at the Department of Psychology, Washington State University. Additional support was provided by Grant AG034965 from the National Institute on Aging to R. E. Smith.	Altgassen M, 2008, J CLIN EXP NEUROPSYC, V30, P777, DOI 10.1080/13803390701779552; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; BROOKS DN, 1972, CORTEX, V11, P329; Carlesimo GA, 2004, J INT NEUROPSYCH SOC, V10, P679, DOI 10.1017/S1355617704105079; Cockburn J, 1996, J CLIN EXP NEUROPSYC, V18, P304, DOI 10.1080/01688639608408284; Cohen AL, 2008, MEM COGNITION, V36, P149, DOI 10.3758/MC.36.1.149; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; Delis DC, 2001, DELISKAPLAN EXECUTIV; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; EINSTEIN GO, 1992, PSYCHOL AGING, V7, P471, DOI 10.1037/0882-7974.7.3.471; Einstein GO, 2005, J EXP PSYCHOL GEN, V134, P327, DOI 10.1037/0096-3445.134.3.327; Ellis JA., 1996, PROSPECTIVE MEMORY T, P1; Erdfelder E, 1996, BEHAV RES METH INS C, V28, P1, DOI 10.3758/BF03203630; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Henry JD, 2007, J CLIN EXP NEUROPSYC, V29, P457, DOI 10.1080/13803390600762717; Horn S. S., EXPT PSYCHO IN PRESS; Jager T, 2008, J GEN PSYCHOL, V135, P4, DOI 10.3200/GENP.135.1.4-22; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kliegel M, 2004, BRAIN COGNITION, V56, P43, DOI 10.1016/j.bandc.2004.05.005; Knight RG, 2006, J INT NEUROPSYCH SOC, V12, P8, DOI 10.1017/S1355617706060048; Knight RG, 2005, BRAIN INJURY, V19, P19, DOI 10.1080/02699050410001720022; Kucera H, 1967, COMPUTATIONAL ANAL P; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, P23; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; Maylor EA, 2002, MEM COGNITION, V30, P871, DOI 10.3758/BF03195773; McDaniel MA, 2004, J EXP PSYCHOL LEARN, V30, P605, DOI 10.1037/0278-7393.30.3.605; McDaniel MA, 2000, APPL COGNITIVE PSYCH, V14, pS127, DOI 10.1002/acp.775; Moshagen M, 2010, BEHAV RES METHODS, V42, P42, DOI 10.3758/BRM.42.1.42; Palmer HM, 2000, BRAIN COGNITION, V44, P103; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; Reitan R. M., 1992, TRAIL MAKING TEST MA; Roche NL, 2007, NEUROPSYCHOL REHABIL, V17, P314, DOI 10.1080/09602010600831004; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P353, DOI 10.1037/0894-4105.18.2.353; Schmitter-Edgecombe M, 2001, J INT NEUROPSYCH SOC, V7, P615, DOI 10.1017/S1355617701755099; Schmitter-Edgecombe M., 1993, NEUROPSYCHOLOGY, V7, P136, DOI DOI 10.1037/0894-4105.7.2.136; SchmitterEdgecombe M, 1997, NEUROPSYCHOLOGY, V11, P296, DOI 10.1037/0894-4105.11.2.296; Schneider W., 2002, E PRIME USERS GUIDE; Shipley WC, 1940, J PSYCHOL, V9, P371, DOI 10.1080/00223980.1940.9917704; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Smith G, 2000, MEMORY, V8, P311, DOI 10.1080/09658210050117735; Smith R. E., 2008, PROSPECTIVE MEMORY C, P29; Smith RE, 2005, EXP PSYCHOL, V52, P243, DOI 10.1027/1618-3169.52.4.243; Smith RE, 2004, J EXP PSYCHOL LEARN, V30, P756, DOI 10.1037/0278-7393.30.4.756; Smith RE, 2003, J EXP PSYCHOL LEARN, V29, P347, DOI 10.1037/0278-7393.29.3.347; Smith RE, 2006, J EXP PSYCHOL LEARN, V32, P623, DOI 10.1037/0278-7393.32.3.623; Smith RE, 2010, J EXP PSYCHOL LEARN, V36, P1089, DOI 10.1037/a0019183; Smith RE, 2010, DEV PSYCHOL, V46, P230, DOI 10.1037/a0017100; Stahl C, 2007, BEHAV RES METHODS, V39, P267, DOI 10.3758/BF03193157; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; TULVING E, 1973, PSYCHOL REV, V80, P352, DOI 10.1037/h0020071; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; VAKIL E, 1991, J CLIN EXP NEUROPSYC, V13, P291, DOI 10.1080/01688639108401044; West R, 2001, PSYCHOL AGING, V16, P682, DOI 10.1037//0882-7974.16.4.682; West R, 2005, NEUROPSYCHOLOGIA, V43, P418, DOI 10.1016/j.neuropsychologia.2004.06.012; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson B. A., 1996, BEHAV ASSESSMET DYSE	65	24	28	0	5	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JAN	2012	26	1					91	101		10.1037/a0025866			11	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	867XI	WOS:000298487700008	21988127	Green Accepted			2021-06-18	
J	Slovarp, L; Azuma, T; Lapointe, L				Slovarp, Laurie; Azuma, Tamiko; Lapointe, Leonard			The effect of traumatic brain injury on sustained attention and working memory	BRAIN INJURY			English	Article						Vigilance; 2-back task	CLOSED-HEAD-INJURY; DEFICITS; SYSTEM; TASK; IMPAIRMENT; LOAD	Primary objective: The aim of the study was to evaluate working memory (WM) and sustained attention (SA) following severe traumatic brain injury (TBI). Research design: The study was a quasi-experimental design with two dependent measures. Methods and procedures: Nine individuals with severe TBI and nine non-injured controls completed two visual tasks containing alphabetic stimuli: a WM task (2-back task) and a 10-minute SA task. Main outcomes and results: Participants with TBI had lower hit rates and higher false alarm rates than controls on the WM task. Quantitative analysis of the group data did not reveal a differential deficit in SA; however, post-hoc qualitative visual analysis of individual data revealed considerable variability in four participants with TBI, indicating evidence of impaired SA in select individuals. The hit rates for both tasks were positively correlated, supporting the contention that WM and SA are inter-related. Conclusions: This study provides further evidence of WM deficits following TBI as well as possible SA deficits in some individuals. The results also suggest that WM and SA are inter-related processes. Future studies are needed to replicate the results with larger sample sizes. Based on these findings, patients with TBI may present with WM and SA deficits.	[Slovarp, Laurie] Univ Montana, Dept Communicat Sci & Disorders, Missoula, MT 59812 USA; [Azuma, Tamiko] Arizona State Univ, Dept Speech & Hearing Sci, Tempe, AZ 85287 USA; [Lapointe, Leonard] Florida State Univ, Dept Commun Sci & Disorders, Tallahassee, FL 32306 USA	Slovarp, L (corresponding author), Univ Montana, Dept Communicat Sci & Disorders, 32 Campus Dr, Missoula, MT 59812 USA.	laurie.slovarp@umontana.edu					AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; Awh E, 1996, PSYCHOL SCI, V7, P25, DOI 10.1111/j.1467-9280.1996.tb00662.x; BADDELEY A, 1987, NEUROBEHAVIORAL RECO, P295; Baddeley A. D., 1986, WORKING MEMORY; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; BENNETT T, 1998, J COGN REHABIL, V16, P8; BENYISHAY Y, 1980, REHABILITATION MONOG, V16, P71; Bloomfield ILM, 2010, J INT NEUROPSYCH SOC, V16, P17, DOI 10.1017/S1355617709990798; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; BURG JS, 1995, BRAIN INJURY, V9, P395, DOI 10.3109/02699059509005779; Caggiano DM, 2004, PSYCHON B REV, V11, P932, DOI 10.3758/BF03196724; Chan RCK, 2003, BRAIN INJURY, V17, P131, DOI 10.1080/0269905021000010168; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; COHEN J, 1993, BEHAV RES METH INSTR, V25, P257, DOI 10.3758/BF03204507; D'Esposito M, 2000, EXP BRAIN RES, V133, P3, DOI 10.1007/s002210000395; GILES GM, 1993, BRAIN INJURY REHABIL; Hartley L. L., 1995, COGNITIVE COMMUNICAT; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Manly T, 2003, NEUROCASE, V9, P340, DOI 10.1076/neur.9.4.340.15553; MATEER C, 1992, SEMINARS SPEECH LANG, V13, P281; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Robertson I H, 1996, J Int Neuropsychol Soc, V2, P525; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Schumacher EH, 1996, NEUROIMAGE, V3, P79, DOI 10.1006/nimg.1996.0009; Serino A, 2006, BRAIN INJURY, V20, P23, DOI 10.1080/02699050500309627; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; Smith EE, 1998, P NATL ACAD SCI USA, V95, P12061, DOI 10.1073/pnas.95.20.12061; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Sturm W, 2001, NEUROIMAGE, V14, pS76, DOI 10.1006/nimg.2001.0839; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012; Zoccolotti P, 2000, CORTEX, V36, P93, DOI 10.1016/S0010-9452(08)70839-6	42	24	25	0	19	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2012	26	1					48	57		10.3109/02699052.2011.635355			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	858HY	WOS:000297787900005	22149444				2021-06-18	
J	Krol, AL; Mrazik, M; Naidu, D; Brooks, BL; Iverson, GL				Krol, Andrea L.; Mrazik, Martin; Naidu, Dhiren; Brooks, Brian L.; Iverson, Grant L.			Assessment of symptoms in a concussion management programme: Method influences outcome	BRAIN INJURY			English	Article						Head injuries; mild traumatic brain injury; concussions; self-report symptoms	TRAUMATIC BRAIN-INJURY; INTERNATIONAL-CONFERENCE; INTERVIEWER GENDER; STATEMENT; SPORT	Context: Monitoring of subjective symptoms is the foundation of all sport concussion management programmes. The purpose of this study is to examine methodological variables that impact symptom reporting during baseline testing. Objective: To investigate how the administration method of a concussion assessment tool (self-report vs interview) affects the report of symptoms. Design, setting and participants: This was a cross-sectional, semi-randomized study of 117 athletes. Main outcome measurements: Subjects completed the Post-Concussion Scale during pre-season evaluations. Results: A two-factor ANOVA revealed a significant difference in total symptom scores (p=0.02) and number of endorsed symptoms (p=0.02) across administration modes. Athletes had a greater total symptom score and reported a greater number of symptoms in the self-administration condition than in the interview condition. Furthermore, there was a significant difference in symptom reporting across interviewer gender. Athletes endorsed more symptoms when the interviewer was a woman. Conclusions: Because the method of collecting symptoms, as well as interviewer gender, can impact test results, self-report measures may be a better way of obtaining consistent results. Clinicians and researchers should be aware that both the nature and extent of symptom reporting is greater when using questionnaires than when athletes are interviewed.	[Krol, Andrea L.; Mrazik, Martin; Naidu, Dhiren; Brooks, Brian L.] Univ Alberta, Calgary, AB T2W 3E7, Canada; [Brooks, Brian L.] Alberta Childrens Prov Gen Hosp, Calgary, AB, Canada; [Iverson, Grant L.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Iverson, Grant L.] Copeman Neurosci Ctr, Vancouver, BC, Canada	Krol, AL (corresponding author), Univ Alberta, 37 10401 19 St SW, Calgary, AB T2W 3E7, Canada.	alkrol@ualberta.ca		Iverson, Grant/0000-0001-7348-9570			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bowling A, 2005, J PUBLIC HEALTH-UK, V27, P281, DOI 10.1093/pubmed/fdi031; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; Holtgraves T, 2004, PERS SOC PSYCHOL B, V30, P161, DOI 10.1177/0146167203259930; Hyman H. H., 1954, INTERVIEWING SOCIAL; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; JOHNSON TP, 1993, SEX ROLES, V28, P243, DOI 10.1007/BF00289884; KANE EW, 1993, PUBLIC OPIN QUART, V57, P1, DOI 10.1086/269352; LOCANDER W, 1976, J AM STAT ASSOC, V71, P269, DOI 10.2307/2285297; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Nolin P, 2006, BRAIN INJURY, V20, P1147, DOI 10.1080/02699050601049247; Pollner M, 1998, J NERV MENT DIS, V186, P369, DOI 10.1097/00005053-199806000-00008; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Tourangeau R, 1996, PUBLIC OPIN QUART, V60, P275, DOI 10.1086/297751; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Wesner ML, 2007, CLIN J SPORT MED, V17, P143, DOI 10.1097/JSM.0b013e31802b4fa6	25	24	24	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2011	25	13-14					1300	1305		10.3109/02699052.2011.624571			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	847MI	WOS:000296976600005	22077535				2021-06-18	
J	Goldfine, AM; Schiff, ND				Goldfine, Andrew M.; Schiff, Nicholas D.			Consciousness: Its Neurobiology and the Major Classes of Impairment	NEUROLOGIC CLINICS			English	Article						Consciousness; Vegetative state; Minimally conscious state; Traumatic brain injury; Arousal	TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; VEGETATIVE STATE; GLUCOSE-UTILIZATION; CEREBRAL METABOLISM; RETICULAR-FORMATION; AKINETIC MUTISM; CARDIAC-ARREST; LATE RECOVERY; BLOOD-FLOW	Human consciousness requires brainstem, basal forebrain, and diencephalic areas to support generalized arousal, and functioning thalamocortical networks to respond to environmental and internal stimuli. Disconnection of these interconnected systems, typically from cardiac arrest and traumatic brain injury, can result in disorders of consciousness. Brain injuries can also result in loss of motor output out of proportion to consciousness, resulting in misdiagnoses. The authors review pathology and imaging studies and derive mechanistic models for each of these conditions. Such models may guide the development of target-based treatment algorithms to enhance recovery of consciousness in many of these patients.	[Goldfine, Andrew M.] Weill Cornell Med Coll, Burke Med Res Inst, White Plains, NY 10605 USA; [Goldfine, Andrew M.; Schiff, Nicholas D.] Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY 10065 USA	Goldfine, AM (corresponding author), Weill Cornell Med Coll, Burke Med Res Inst, 785 Mamaroneck Ave, White Plains, NY 10605 USA.	andygoldfine@gmail.com		Goldfine, Andrew/0000-0003-1962-5564	NIH-NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [51912]; James S McDonnell Foundation; Clinical & Translational Science Center at Weill Cornell Medical College [KL2RR024997]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD051912] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR024997] Funding Source: NIH RePORTER	This work was supported by NIH-NICHD 51912, the James S McDonnell Foundation. AMG is supported by grant KL2RR024997 of the Clinical & Translational Science Center at Weill Cornell Medical College.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; ALKIRE MT, 1995, ANESTHESIOLOGY, V82, P393, DOI 10.1097/00000542-199502000-00010; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bardin JC, 2011, BRAIN, V134, P769, DOI 10.1093/brain/awr005; Bekinschtein T, 2004, J NEUROL NEUROSUR PS, V75, P788, DOI 10.1136/jnnp.2003.034876; Bekinschtein T, 2009, PROG BRAIN RES, V177, P171, DOI 10.1016/S0079-6123(09)17712-9; Bekinschtein TA, 2009, P NATL ACAD SCI USA, V106, P1672, DOI 10.1073/pnas.0809667106; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BHATIA KP, 1994, BRAIN, V117, P859, DOI 10.1093/brain/117.4.859; BLACKLOCK JB, 1987, J NEUROSURG, V67, P71, DOI 10.3171/jns.1987.67.1.0071; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; Brefel-Courbon C, 2007, ANN NEUROL, V62, P102, DOI 10.1002/ana.21110; Brentano F., 1995, PSYCHOL EMPIRICAL ST; Broadbent DE, 1958, PERCEPTION COMMUNICA; Cairns H, 1941, BRAIN, V64, P273, DOI 10.1093/brain/64.4.273; CASTAIGNE P, 1981, ANN NEUROL, V10, P127, DOI 10.1002/ana.410100204; Chollet F, 2011, LANCET NEUROL, V10, P123, DOI 10.1016/S1474-4422(10)70314-8; Clauss P, 2001, SAMJ S AFR MED J, V91, P788; Cruse D, 2010, CURR OPIN NEUROL, V23, P656, DOI 10.1097/WCO.0b013e32833fd4e7; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Eidelberg D, 1997, BRAIN, V120, P1315, DOI 10.1093/brain/120.8.1315; Elliott L, 2005, J NEUROL NEUROSUR PS, V76, P298, DOI 10.1136/jnnp.2004.047357; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; Fins JJ, 2003, NAT REV NEUROSCI, V4, P323, DOI 10.1038/nrn1079; Fisher C M, 1983, Clin Neurosurg, V31, P9; FRITH CD, 1991, P ROY SOC B-BIOL SCI, V244, P241, DOI 10.1098/rspb.1991.0077; Garey J, 2003, P NATL ACAD SCI USA, V100, P11019, DOI 10.1073/pnas.1633773100; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Goldfine A.M., 2011, CLIN NEUROPHYSIOL; GOLDSTEIN LB, 1995, NEUROLOGY, V45, P865, DOI 10.1212/WNL.45.5.865; Hart T, 2006, ARCH PHYS MED REHAB, V87, P647, DOI 10.1016/j.apmr.2006.01.016; Holzer M, 2002, NEW ENGL J MED, V346, P549; INGVAR DH, 1970, ARCH NEUROL-CHICAGO, V23, P1; JENNETT B, 1972, LANCET, V1, P734; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Jennett B., 2002, VEGETATIVE STATE MED; Jones EG, 2002, PHILOS T R SOC B, V357, P1659, DOI 10.1098/rstb.2002.1168; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; KATZ DI, 1987, ARCH NEUROL-CHICAGO, V44, P1127, DOI 10.1001/archneur.1987.00520230017007; Kinomura S, 1996, SCIENCE, V271, P512, DOI 10.1126/science.271.5248.512; Kobylarz EJ, 2005, NEUROPSYCHOL REHABIL, V15, P323, DOI 10.1080/09602010443000605; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S, 1999, J NEUROL NEUROSUR PS, V67, P121, DOI 10.1136/jnnp.67.1.121; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; Laureys S, 2000, BRAIN, V123, P1589, DOI 10.1093/brain/123.8.1589; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; LEVY DE, 1987, ANN NEUROL, V22, P673, DOI 10.1002/ana.410220602; Llinas R, 1998, PHILOS T ROY SOC B, V353, P1841, DOI 10.1098/rstb.1998.0336; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; MAGOUN HW, 1958, WAKING BRAIN; MAQUET P, 1990, BRAIN RES, V513, P136, DOI 10.1016/0006-8993(90)91099-3; Maquet P, 1997, J NEUROSCI, V17, P2807; Maya-Vetencourt JF, 2008, SCIENCE, V320, P385, DOI 10.1126/science.1150516; McCarthy Michelle M, 2008, J Neurosci, V28, P13488, DOI 10.1523/JNEUROSCI.3536-08.2008; Mega MS, 1997, NEUROPSY NEUROPSY BE, V10, P254; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Mignot E, 2002, NAT NEUROSCI, V5, P1071, DOI 10.1038/nn944; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90219-9; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Panksepp J, 2004, AFFECTIVE NEUROSCIEN; Parvizi J, 2001, COGNITION, V79, P135, DOI 10.1016/S0010-0277(00)00127-X; Paus T, 1997, J COGNITIVE NEUROSCI, V9, P392, DOI 10.1162/jocn.1997.9.3.392; Paus T, 1998, NEUROREPORT, V9, pR37, DOI 10.1097/00001756-199806220-00001; PFAFF DW, 2005, BRAIN AROUSAL INFORM; Posner J., 2007, PLUM POSNERS DIAGNOS, V4; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rossetti AO, 2010, ANN NEUROL, V67, P301, DOI 10.1002/ana.21984; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2000, J CLIN NEUROPHYSIOL, V17, P438, DOI 10.1097/00004691-200009000-00002; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Schiff ND, 2007, ANN NEUROL, V62, P5, DOI 10.1002/ana.21158; Schiff ND, 2010, TRENDS NEUROSCI, V33, P1, DOI 10.1016/j.tins.2009.11.002; Schiff ND, 2009, ANN NY ACAD SCI, V1157, P101, DOI 10.1111/j.1749-6632.2008.04123.x; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Searle John, 1983, INTENTIONALITY ESSAY; SEGARRA JM, 1970, ARCH NEUROL-CHICAGO, V22, P408, DOI 10.1001/archneur.1970.00480230026003; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smart CM, 2008, NAT CLIN PRACT NEURO, V4, P448, DOI 10.1038/ncpneuro0823; STERIADE M, 1982, J NEUROPHYSIOL, V48, P352; Steriade M., 2005, BRAIN CONTROL WAKEFU; Stuss DT, 2007, PHILOS T R SOC B, V362, P901, DOI 10.1098/rstb.2007.2096; Tononi G, 1998, SCIENCE, V282, P1846, DOI 10.1126/science.282.5395.1846; Vanhaudenhuyse A, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.121624; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Whyte J, 2009, AM J PHYS MED REHAB, V88, P410, DOI 10.1097/PHM.0b013e3181a0e3a0	92	24	24	1	18	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0733-8619	1557-9875		NEUROL CLIN	Neurol. Clin.	NOV	2011	29	4					723	+		10.1016/j.ncl.2011.08.001			16	Clinical Neurology; Neurosciences	Neurosciences & Neurology	853BN	WOS:000297401300002	22032656	Green Accepted			2021-06-18	
J	Tsaousides, T; Matsuzawa, Y; Lebowitz, M				Tsaousides, Theodore; Matsuzawa, Yuka; Lebowitz, Matthew			Familiarity and prevalence of Facebook use for social networking among individuals with traumatic brain injury	BRAIN INJURY			English	Article						Traumatic brain injury; community integration; head injury; support system; technology	ONLINE SUPPORT; INTERNET USE; SITES; COMMUNICATION; IMPAIRMENT; RECOVERY; MAIL	Objective: To examine use of Facebook among individuals with traumatic brain injury (TBI) and to identify barriers preventing Facebook use. Method: An online survey was developed assessing frequency and barriers to use of Facebook. The survey was distributed electronically to individuals with TBI through four state brain injury associations. Ninety-six individuals with TBI completed the survey (60%% female, age range: 23-70). Results: The relative majority of respondents (60%%) reported using Facebook on a regular basis. Among those who reported not using Facebook, the most commonly reported barriers were security concerns and cognitive deficits. Approximately half of non-users indicated interest in learning to use the site, with 70%% reporting that they would use it more if they were more knowledgeable about it. Both users and non-users indicated that they would be interested in receiving training to learn how to use Facebook better. Conclusions: Social networking sites are increasingly important in creating and maintaining social networks. A significant number of survey respondents expressed interest in further training on Facebook use. Increased use of social networking may have important implications for social integration among individuals with TBI.	[Tsaousides, Theodore; Matsuzawa, Yuka; Lebowitz, Matthew] Mt Sinai Sch Med, New York, NY 10029 USA	Tsaousides, T (corresponding author), Mt Sinai Sch Med, 1 Gustave L Levy Pl,Box 1240, New York, NY 10029 USA.	theodore.tsaousides@mssm.edu			Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [1R49CE001171-01]; National Institute on Disability and Rehabilitation Services, Office of Special Education and Rehabilitation Services, United States Department of EducationUS Department of Education [H133P050004]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001171] Funding Source: NIH RePORTER	This study was supported by grant 1R49CE001171-01 from the Centers for Disease Control and Prevention and H133P050004 from the National Institute on Disability and Rehabilitation Services, Office of Special Education and Rehabilitation Services, United States Department of Education. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.	Ahmed OH, 2010, DISABIL REHABIL, V32, P1877, DOI 10.3109/09638281003734409; Boyd DM, 2007, J COMPUT-MEDIAT COMM, V13, P210, DOI 10.1111/j.1083-6101.2007.00393.x; Carey JC, 2008, CYBERPSYCHOL BEHAV, V11, P188, DOI 10.1089/cpb.2007.0025; Coulson NS, 2007, PATIENT EDUC COUNS, V68, P173, DOI 10.1016/j.pec.2007.06.002; Ehlhardt LA, 2005, BRAIN INJURY, V19, P569, DOI 10.1080/002699050400013550; Ellison NB, 2007, J COMPUT-MEDIAT COMM, V12, P1143, DOI 10.1111/j.1083-6101.2007.00367.x; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; Fogel J, 2009, COMPUT HUM BEHAV, V25, P153, DOI 10.1016/j.chb.2008.08.006; Fraas M, 2008, J PSYCHOLINGUIST RES, V37, P115, DOI 10.1007/s10936-007-9062-y; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Hill WG, 2004, CIN-COMPUT INFORM NU, V22, P282, DOI 10.1097/00024665-200409000-00008; Hoofien D, 2001, BRAIN INJURY, V15, P189; Horner MD, 2008, J HEAD TRAUMA REHAB, V23, P74, DOI 10.1097/01.HTR.0000314526.01006.c8; Idriss SZ, 2009, ARCH DERMATOL, V145, P46, DOI 10.1001/archdermatol.2008.529; Kilov AM, 2010, BRAIN INJURY, V24, P1135, DOI 10.3109/02699052.2010.490511; Lewis K, 2008, SOC NETWORKS, V30, P330, DOI 10.1016/j.socnet.2008.07.002; Miller SM, 2008, REHABIL COUNS BULL, V51, P148, DOI 10.1177/0034355207311315; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Polomano Rosemary C, 2007, J Pain Palliat Care Pharmacother, V21, P49, DOI 10.1300/J354v21n03_09; Ricker JH, 2002, J HEAD TRAUMA REHAB, V17, P242, DOI 10.1097/00001199-200206000-00005; Sheldon P, 2008, J MEDIA PSYCHOL, V20, P67, DOI DOI 10.1027/1864-1105.20.2.67; Sohlberg MM, 2003, BRAIN INJURY, V17, P609, DOI 10.1080/0269905031000070189; Steinfield C, 2008, J APPL DEV PSYCHOL, V29, P434, DOI 10.1016/j.appdev.2008.07.002; Subrahmanyam K, 2008, J APPL DEV PSYCHOL, V29, P420, DOI 10.1016/j.appdev.2008.07.003; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; Todis B, 2005, BRAIN INJURY, V19, P389, DOI 10.1080/02699050400003957; Vaccaro M, 2007, DISABIL REHABIL-ASSI, V2, P85, DOI 10.1080/17483100601167586; Verburg G, 2003, NEUROREHABILITATION, V18, P113; Wade SL, 2008, J HEAD TRAUMA REHAB, V23, P369, DOI 10.1097/01.HTR.0000341432.67251.48; Weiss Jacob B, 2007, AMIA Annu Symp Proc, P1151	32	24	24	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2011	25	12					1155	1162		10.3109/02699052.2011.613086			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	829WF	WOS:000295615200002	21961574				2021-06-18	
J	Severino, PC; Muller, GDS; Vandresen, S; Tasca, CI				Severino, Patricia Cardoso; Silva Muller, Gabriele do Amaral; Vandresen-Filho, Samuel; Tasca, Carla Ines			Cell signaling in NMDA preconditioning and neuroprotection in convulsions induced by quinolinic acid	LIFE SCIENCES			English	Article; Proceedings Paper	International Symposium on Cell Signaling	OCT 28-31, 2010	Florianopolis, BRAZIL			Preconditioning; N-methyl-D-aspartate; Neuroprotection; Glutamatergic excitotoxicity; Quinolinic acid; NMDA receptor	INHIBITS GLUTAMATE UPTAKE; CEREBELLAR GRANULE CELLS; TRAUMATIC BRAIN-INJURY; D-ASPARTATE; ISCHEMIC TOLERANCE; APOPTOTIC NEURODEGENERATION; INDUCED SEIZURES; RECEPTORS; PHOSPHORYLATION; PROTECTS	The search for novel, less invasive therapeutic strategies to treat neurodegenerative diseases has stimulated scientists to investigate the mechanisms involved in preconditioning. Preconditioning has been report to occur in many organs and tissues. In the brain, the modulation of glutamatergic transmission is an important and promising target to the use of effective neuroprotective agents. The glutamatergic excitotoxicity is a factor common to neurodegenerative diseases and acute events such as cerebral ischemia, traumatic brain injury and epilepsy. In this review we focus on the neuroprotection and preconditioning by chemical agents. Specially, chemical preconditioning models using N-methyl-D-aspartate (NMDA) pre-treatment, which has demonstrated to lead to neuroprotection against seizures and damage to neuronal tissue induced by quinolinic acid (QA). Here we attempted to gather important results obtained in the study of cellular and molecular mechanisms involved in NMDA preconditioning and neuroprotection. (C) 2011 Elsevier Inc. All rights reserved.	[Severino, Patricia Cardoso; Silva Muller, Gabriele do Amaral] Univ Fed Santa Catarina, Dept Bioquim CCB, Ctr Biol Mol & Estrutural, BR-88040900 Florianopolis, SC, Brazil; [Vandresen-Filho, Samuel; Tasca, Carla Ines] Univ Fed Santa Catarina, Dept Bioquim CCB, Lab Neuroquim 4, BR-88040900 Florianopolis, SC, Brazil	Severino, PC (corresponding author), Univ Fed Santa Catarina, Dept Bioquim CCB, Ctr Biol Mol & Estrutural, BR-88040900 Florianopolis, SC, Brazil.	patsics@gmail.com	Vandresen-Filho, Samuel/A-1239-2013; Tasca, Carla Ines/AAB-8287-2019	Vandresen-Filho, Samuel/0000-0002-4718-2900; Tasca, Carla Ines/0000-0002-3414-6150	CAPES/PRODOCCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); REUNI Program scholarship; INCT; CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)	We want to thank CAPES/PRODOC and Biochemistry Post Graduation program for Patricia Cardoso Severino fellowship. Samuel Vandresen-Filho and Gabriele Muller for REUNI Program scholarship. Carla Tasca is thankful for INCT research funding. And we also thank CNPq for financial support.	Adams SM, 2004, J NEUROSCI, V24, P9441, DOI 10.1523/JNEUROSCI.3290-04.2004; Ahmadian G, 2004, EMBO J, V23, P1040, DOI 10.1038/sj.emboj.7600126; Ahn J, 2008, NEUROSCI LETT, V433, P11, DOI 10.1016/j.neulet.2007.12.045; Arundine M, 2003, CELL CALCIUM, V34, P325, DOI 10.1016/S0143-4160(03)00141-6; Barria A, 2002, NEURON, V35, P345, DOI 10.1016/S0896-6273(02)00776-6; Beas-Zarate C, 2001, NEUROCHEM INT, V39, P1, DOI 10.1016/S0197-0186(01)00008-0; Bengtson CP, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-11; Boeck CR, 2007, AMINO ACIDS, V33, P439, DOI 10.1007/s00726-006-0455-2; Boeck CR, 2005, J NEUROCHEM, V94, P48; Boeck CR, 2005, NEUROPHARMACOLOGY, V49, P17, DOI 10.1016/j.neuropharm.2005.01.024; Boeck CR, 2004, EPILEPSIA, V45, P745, DOI 10.1111/j.0013-9580.2004.65203.x; Bond A, 1999, EUR J PHARMACOL, V380, P91, DOI 10.1016/S0014-2999(99)00523-3; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Burnstock G, 2007, CELL MOL LIFE SCI, V64, P1471, DOI 10.1007/s00018-007-6497-0; CHUANG DM, 1992, MOL PHARMACOL, V42, P210; Corasaniti MT, 2007, BRIT J PHARMACOL, V151, P518, DOI 10.1038/sj.bjp.0707237; Costa T, 2010, J NEUROSCI RES, V88, P1329, DOI 10.1002/jnr.22300; Cunha Rodrigo A, 2005, Purinergic Signal, V1, P111, DOI 10.1007/s11302-005-0649-1; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; de Oliveira DL, 2004, BRAIN RES, V1018, P48, DOI 10.1016/j.brainres.2004.05.033; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; Emerson MR, 1999, BRAIN RES, V825, P189, DOI 10.1016/S0006-8993(99)01195-6; Featherstone DE, 2010, ACS CHEM NEUROSCI, V1, P4, DOI 10.1021/cn900006n; Gielen M, 2009, NATURE, V459, P703, DOI 10.1038/nature07993; Grazioso G, 2005, J MED CHEM, V48, P5489, DOI 10.1021/jm050174x; Hardingham GE, 2003, TRENDS NEUROSCI, V26, P81, DOI 10.1016/S0166-2236(02)00040-1; Hardingham GE, 2010, NAT REV NEUROSCI, V11, P682, DOI 10.1038/nrn2911; Herculano BD, 2011, BEHAV BRAIN RES, V219, P92, DOI 10.1016/j.bbr.2010.12.025; Hynd MR, 2004, NEUROCHEM INT, V45, P583, DOI 10.1016/j.neuint.2004.03.007; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Kanai Y, 2003, EUR J PHARMACOL, V479, P237, DOI 10.1016/j.ejphar.2003.08.073; Kelly PJ, 2004, STROKE, V35, P12, DOI 10.1161/01.STR.0000106481.59944.2F; Khaspekov L, 1998, NEUROREPORT, V9, P1273, DOI 10.1097/00001756-199805110-00003; KITAGAWA K, 1991, BRAIN RES, V561, P203, DOI 10.1016/0006-8993(91)91596-S; Kolb B, 2002, NEUROCIENCIA COMPORT, P664; LAPIN IP, 1978, J NEURAL TRANSM, V42, P37, DOI 10.1007/BF01262727; Lee B, 2005, J NEUROSCI, V25, P1137, DOI 10.1523/JNEUROSCI.4288-04.2005; Lin JHC, 2008, J NEUROSCI, V28, P681, DOI 10.1523/JNEUROSCI.3827-07.2008; Loveridge R, 2010, BJA EDUC, V10, P38, DOI 10.1093/bjaceaccp/mkq005; Ma DQ, 2006, J CEREBR BLOOD F MET, V26, P199, DOI 10.1038/sj.jcbfm.9600184; Madden DR, 2002, NAT REV NEUROSCI, V3, P91, DOI 10.1038/nrn725; MARINI AM, 1992, P NATL ACAD SCI USA, V89, P6555, DOI 10.1073/pnas.89.14.6555; Mark LP, 2001, AM J NEURORADIOL, V22, P1813; Mergenthaler P, 2004, METAB BRAIN DIS, V19, P151, DOI 10.1023/B:MEBR.0000043966.46964.e6; Miao H, 2005, J VASC RES, V42, P77, DOI 10.1159/000083094; Molz S, 2003, THESIS U FEDERAL SAN; Monti B, 2000, EUR J NEUROSCI, V12, P3117, DOI 10.1046/j.1460-9568.2000.00189.x; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; Moroni F, 1999, EUR J PHARMACOL, V375, P87, DOI 10.1016/S0014-2999(99)00196-X; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Noh J, 2009, J NEUROCHEM, V109, P1261, DOI 10.1111/j.1471-4159.2009.06044.x; Olney JW, 2002, BRAIN PATHOL, V12, P488, DOI 10.1111/j.1750-3639.2002.tb00467.x; Papadia S, 2005, J NEUROSCI, V25, P4279, DOI 10.1523/JNEUROSCI.5019-04.2005; PERKINS MN, 1983, BRAIN RES, V259, P172, DOI 10.1016/0006-8993(83)91084-3; Puisieux F, 2004, BRAIN RES, V1027, P30, DOI 10.1016/j.brainres.2004.08.067; Rahman A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006344; Ralevic V, 1998, PHARMACOL REV, V50, P413; Ravati A, 2001, J NEUROCHEM, V78, P909, DOI 10.1046/j.1471-4159.2001.00463.x; Rebola N, 2005, NEUROCHEM INT, V47, P317, DOI 10.1016/j.neuint.2005.05.009; Rebola N, 2005, NEUROSCIENCE, V133, P79, DOI 10.1016/j.neuroscience.2005.01.054; Rejdak R, 2001, POL J PHARMACOL, V53, P73; Riva MA, 1997, MOL BRAIN RES, V50, P136, DOI 10.1016/S0169-328X(97)00175-7; Rivera-Cervantes MC, 2009, INT J DEV NEUROSCI, V27, P197, DOI 10.1016/j.ijdevneu.2008.09.006; Saleh A, 2007, STROKE, V38, P2733, DOI 10.1161/STROKEAHA.107.481788; Saleh MC, 2009, BRAIN RES, V1247, P212, DOI 10.1016/j.brainres.2008.10.014; Samoilov M O, 2003, Neurosci Behav Physiol, V33, P1, DOI 10.1023/A:1021119112927; Schaller B, 2002, J NEUROL, V249, P1503, DOI 10.1007/s00415-002-0933-8; Schmidt AP, 2010, OPEN NEUROSCI J, V4, P102, DOI DOI 10.2174/1874082001004010113; Schorge S, 2003, J NEUROSCI, V23, P1151; Schumann J, 2008, J NEUROTRAUM, V25, P945, DOI 10.1089/neu.2008.0521; SCHURR A, 1986, BRAIN RES, V374, P244, DOI 10.1016/0006-8993(86)90418-X; Schwarcz R, 2002, J PHARMACOL EXP THER, V303, P1, DOI 10.1124/jpet.102.034439; Scott DB, 2003, NEUROPHARMACOLOGY, V45, P755, DOI 10.1016/S0028-3908(03)00250-8; Siegel GJ, 2006, BASIC NEUROCHEMISTRY; Sokka AL, 2007, J NEUROSCI, V27, P901, DOI 10.1523/JNEUROSCI.4289-06.2007; Soriano FX, 2006, J NEUROSCI, V26, P4509, DOI 10.1523/JNEUROSCI.0455-06.2006; Stone TW, 2001, PROG NEUROBIOL, V64, P185, DOI 10.1016/S0301-0082(00)00032-0; Stone TW, 2002, EUR J PHARMACOL, V447, P285, DOI 10.1016/S0014-2999(02)01851-4; Tasca CI, 1999, NEUROCHEM RES, V24, P1067, DOI 10.1023/A:1021017112717; Tasca CI, 2000, NEUROCHEM RES, V25, P181, DOI 10.1023/A:1007557600687; Tavares RG, 2000, NEUROREPORT, V11, P249, DOI 10.1097/00001756-200002070-00005; Tavares RG, 2005, NEUROCHEM RES, V30, P439, DOI 10.1007/s11064-005-2678-0; Tavares RG, 2002, NEUROCHEM INT, V40, P621, DOI 10.1016/S0197-0186(01)00133-4; Vandresen S, 2007, BRAIN RES, V1184, P38, DOI 10.1016/j.brainres.2007.09.091; Vega-Naredo I, 2005, J PINEAL RES, V39, P266, DOI 10.1111/j.1600-079X.2005.00243.x; Vianna EPM, 2005, EPILEPSIA, V46, P166, DOI 10.1111/j.1528-1167.2005.01027.x; Waring P, 2005, ARCH BIOCHEM BIOPHYS, V434, P33, DOI 10.1016/j.abb.2004.08.001; Waxman EA, 2005, NEUROSCIENTIST, V11, P37, DOI 10.1177/1073858404269012; Wollmuth LP, 1998, J PHYSIOL-LONDON, V506, P33, DOI 10.1111/j.1469-7793.1998.00033.x; Youssef FF, 2001, BRAIN RES, V907, P144, DOI 10.1016/S0006-8993(01)02594-X; Zhang MJ, 2010, AM J PHYSIOL-HEART C, V299, pH713, DOI 10.1152/ajpheart.00273.2010	93	24	25	0	10	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205	1879-0631		LIFE SCI	Life Sci.	OCT 10	2011	89	15-16			SI		570	576		10.1016/j.lfs.2011.05.014			7	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	827KW	WOS:000295428400010	21683718				2021-06-18	
J	Bie, XD; Chen, YQ; Zheng, XS; Dai, HB				Bie, Xiaodong; Chen, Yueqing; Zheng, Xuesheng; Dai, Haibin			The role of crocetin in protection following cerebral contusion and in the enhancement of angiogenesis in rats	FITOTERAPIA			English	Article						Crocetin; Cerebral contusion; Cell apoptosis; Angiogenesis	TRAUMATIC BRAIN-INJURY; GENE-EXPRESSION; BCL-2; EPIDEMIOLOGY	The protective role of crocetin following cerebral contusion and its effects on the enhancement of angiogenesis in rats was investigated. A total of 60 Sprague-Dawley rats were divided into three groups (n = 20 each): crocetin therapy group (cerebral contusion treated with crocetin), cerebral trauma control group (without treatment), sham operation control group. The effect of crocetin was examined by modified Neurological Severity Scores (mNSS), electron microscopy, terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL) procedure, western blotting analysis of Bcl-2 protein expression, microvessel count (MVC), endothelial cell culture and immunocyto-chemistry. The mNSS results indicated that neurological function of therapy group was significantly recovered seven days and fifteen days after the trauma. The TUNEL staining and electron microscopy revealed that crocetin treatment led to an inhibition of neuronal apoptosis 72 h following treatment; this finding was confirmed by western blot analysis of B cell lymphoma/leukemia-2 (Bcl-2) protein expression. Expression levels of vascular endothelial growth factor receptor-2 (VEGFR-2) and serum response factor (SRF) were higher in the crocetin therapy group in comparison to the two other experimental groups. Our results demonstrate that the protective effects of crocetin upon brain injury may be related to its ability to inhibit apoptosis at early stages of the injury and its ability to promote angiogenesis at the sub-acute stage. (C) 2011 Published by Elsevier B.V.	[Chen, Yueqing] Zhejiang Acad Med Sci, Hangzhou, Zhejiang, Peoples R China; [Bie, Xiaodong] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Tradit Chinese Med, Hangzhou 310003, Zhejiang, Peoples R China; [Zheng, Xuesheng] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China; [Dai, Haibin] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Pharm, Hangzhou 310003, Zhejiang, Peoples R China	Chen, YQ (corresponding author), Zhejiang Acad Med Sci, Hangzhou, Zhejiang, Peoples R China.	bie@hzcnc.com		Dai, Haibin/0000-0002-5768-2714	Zhejiang Science and Technology Projects [2008c33061]; Natural Science Foundation of ZhejiangNatural Science Foundation of Zhejiang Province [Y207256]	This work was supported by the Zhejiang Science and Technology Projects (2008c33061 to XD Bie) and by the Natural Science Foundation of Zhejiang (Y207256 to XD Bie).	Ahmad AS, 2005, PHARMACOL BIOCHEM BE, V81, P805, DOI 10.1016/j.pbb.2005.06.007; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Chai JY, 2004, FASEB J, V18, P1264, DOI 10.1096/fj.03-1232fje; CONSTANTINO RSS, 2007, EXP CELL RES, V313, P1561; Dong GX, 2001, BRAIN RES, V903, P45, DOI 10.1016/S0006-8993(01)02379-4; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; [皋聪 GAO Cong], 2009, [中国临床药理学与治疗学, Chinese Journal of Clinical Pharmacology and Therapeutics], V14, P421; Giaccio M, 2004, CRIT REV FOOD SCI, V44, P155, DOI 10.1080/10408690490441433; JIANG JR, 2004, MODERN CRANIOCEREBRA, P1; Jin XY, 2008, J ETHNOPHARMACOL, V117, P473, DOI 10.1016/j.jep.2008.02.033; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; LIU HJ, 2005, CHIN J CLIN REHABIL, V9, P213; MAO WF, 2005, ANAT CLIN, V10, P30; Ochiai T, 2007, BBA-GEN SUBJECTS, V1770, P578, DOI 10.1016/j.bbagen.2006.11.012; Papandreou MA, 2006, J AGR FOOD CHEM, V54, P8762, DOI 10.1021/jf061932a; Schofield PW, 1997, NEUROLOGY, V49, P30, DOI 10.1212/WNL.49.1.30; Shimamura M, 2005, NEUROSCIENCE, V131, P87, DOI 10.1016/j.neuroscience.2004.10.041; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Strauss KI, 2004, NEUROTOX RES, V6, P333, DOI 10.1007/BF03033444; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Yang Shu-Yuan, 2004, Chin J Traumatol, V7, P159; [余卫平 YU Weiping], 2006, [中国病理生理杂志, Chinese Journal of Pathophysiology], V22, P54; ZHANG R, 2009, CHIN J NAT MED, V15, P200; ZHAO MG, 2005, CHIN J CLIN REHABIL, V9, P211; Zheng SG, 2007, J CARDIOVASC PHARM, V50, P519, DOI 10.1097/FJC.0b013e31813c114e; 别晓东, 2003, [中国中西医结合杂志, Chinese Journal of Integrated Traditional and Western Medicine], V23, P296; 刘东博, 2007, [中草药, Chinese Traditional and Herbal Drugs], V38, P1915; 潘德生, 2006, [中华神经外科杂志, Chinese Journal of Neurosurgery], V22, P186	32	24	26	0	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0367-326X	1873-6971		FITOTERAPIA	Fitoterapia	OCT	2011	82	7					997	1002		10.1016/j.fitote.2011.06.001			6	Chemistry, Medicinal; Pharmacology & Pharmacy	Pharmacology & Pharmacy	827QK	WOS:000295442800011	21741458				2021-06-18	
J	de Souza, A; Nalini, A; Kovoor, JME; Yeshraj, G; Siddalingaiah, HS; Thennarasu, K				de Souza, Aaron; Nalini, Atchayaram; Kovoor, Jerry M. E.; Yeshraj, Gangappa; Siddalingaiah, Hanumanthaiah S.; Thennarasu, Kandavel			Perilesional gliosis around solitary cerebral parenchymal cysticerci and long-term seizure outcome: A prospective study using serial magnetization transfer imaging	EPILEPSIA			English	Article						Solitary cerebral cysticercal lesion; Neurocysticercosis; Perilesional gliosis; Magnetic resonance imaging; Magnetization transfer imaging	TRAUMATIC BRAIN-INJURY; RISK-FACTORS; DIAGNOSTIC-CRITERIA; AXONAL INJURY; NEUROCYSTICERCOSIS; EPILEPSY; GRANULOMA; QUANTITATION; PROPOSAL; MATTER	Purpose: Epilepsy following solitary cerebral cysticercosis (SCC) is possibly caused by perilesional gliosis, best visualized on magnetization transfer imaging (MTI). This study aims to describe development of gliosis around SCC by prospective serial MTI and to correlate this gliosis with long-term seizure outcome. Methods: We randomized 123 patients with SCC and new-onset seizures to treatment with albendazole plus antiepileptics (treatment), or antiepileptics only (control), and performed magnetic resonance imaging (MRI) scans at 0, 3, 6, 12, and 24 months. Prospective follow-up data regarding seizure outcome up to 5 years later were collected. MRI studies were analyzed for lesion characteristics and perilesional magnetization transfer (MT) hyperintensity. Key Findings: Clinical and radiologic data of 77 patients were analyzed. Demographic and seizure characteristics were similar in treatment and control groups. Clinical data were available up to 64 months after enrollment. At 12 months, 89.5% patients were seizure-free. MTI is more sensitive than routine imaging for detection of perilesional gliosis. Albendazole treatment did not affect imaging or clinical outcome, including development of gliosis. Independent of duration of follow-up, gliosis was associated with more seizures, and with seizure recurrence at 12 months; duration of seizures and antiepileptic therapy was longer. Gliosis was not dependent on seizure type or stage of degeneration at enrollment or persistence/calcification of the lesion. Significance: Perilesional gliosis around SCC helps prognosticate seizure outcome. Poorer outcome in patients with persistent lesions is likely to be related to mechanisms other than gliosis. The lack of effect of albendazole on seizure outcome may be due to its inability to decrease formation of gliosis.	[de Souza, Aaron; Nalini, Atchayaram; Yeshraj, Gangappa; Siddalingaiah, Hanumanthaiah S.] Natl Inst Mental Hlth & Neurosci, Dept Neurol, Bangalore 560029, Karnataka, India; [Kovoor, Jerry M. E.] Natl Inst Mental Hlth & Neurosci, Dept Neuroimaging & Intervent Radiol, Bangalore 560029, Karnataka, India; [Thennarasu, Kandavel] Natl Inst Mental Hlth & Neurosci, Dept Biostat, Bangalore 560029, Karnataka, India	Nalini, A (corresponding author), Natl Inst Mental Hlth & Neurosci, Dept Neurol, Neurosci Fac Block, Bangalore 560029, Karnataka, India.	nalini@nimhans.kar.nic.in	H.S., Siddalingaiah/U-4322-2017	H.S., Siddalingaiah/0000-0002-4771-8285; de Souza, Aaron/0000-0001-6941-5683	Indian Council of Medical Research (ICMR)Indian Council of Medical Research (ICMR) [SWG/Neuro/7/2001-NCD-I]	We are grateful to the Indian Council of Medical Research (ICMR) for funding this study (ICMR grant no. SWG/Neuro/7/2001-NCD-I). We thank all the participants of the study and in particular the radiographers of the department of Neuroimaging and Interventional Radiology, NIMHANS for their constant support.	Agarwal A, 2004, NEUROL INDIA, V52, P197; Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; Carpio A, 1998, EPILEPSIA, V39, P1025, DOI 10.1111/j.1528-1157.1998.tb01287.x; Chatterjee KD, 1973, PARASITOLOGY PROTOZO; Chawla S, 2004, J MAGN RESON IMAGING, V20, P208, DOI 10.1002/jmri.20105; Chung C K, 1998, J Korean Med Sci, V13, P445; De Souza A, 2010, NEURORADIOL J, V23, P574, DOI 10.1177/197140091002300506; de Souza A, 2010, J NEUROL SCI, V288, P135, DOI 10.1016/j.jns.2009.09.018; de Souza A, 2009, J NEUROL SCI, V276, P108, DOI 10.1016/j.jns.2008.09.010; deBittencourt PRM, 1996, EPILEPSIA, V37, P1121, DOI 10.1111/j.1528-1157.1996.tb01035.x; DELBRUTTO OH, 1992, NEUROLOGY, V42, P389; DELBRUTTO OH, 1994, NEUROLOGY, V44, P1706, DOI 10.1212/WNL.44.9.1706; DelBrutto OH, 1996, J NEUROL SCI, V142, P1, DOI 10.1016/0022-510X(96)00130-X; Fazekas F, 2005, BRAIN, V128, P2926, DOI 10.1093/brain/awh567; Ferreira LS, 2001, EPILEPSIA, V42, P1438, DOI 10.1046/j.1528-1157.2001.11101.x; Filippi M, 2004, J NEUROIMAGING, V14, P303, DOI 10.1177/1051228404265708; Filippi M, 2007, NEUROTHERAPEUTICS, V4, P401, DOI 10.1016/j.nurt.2007.03.002; GARCIA HH, 1993, LANCET, V341, P197, DOI 10.1016/0140-6736(93)90064-N; Gemmell M, 1983, GUIDELINES SURVEILLA; Gupta R. K., 2000, MAGNETIZATION TRANSF; Gupta RK, 1999, LANCET, V354, P44, DOI 10.1016/S0140-6736(99)00881-8; Kathuria MK, 1998, JMRI-J MAGN RESON IM, V8, P473, DOI 10.1002/jmri.1880080231; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; KRAMER LD, 1989, RADIOLOGY, V171, P459, DOI 10.1148/radiology.171.2.2704811; Kumar CSS, 2004, NEUROL INDIA, V52, P265; Kumar R, 2003, MAGN RESON IMAGING, V21, P893, DOI 10.1016/S0730-725X(03)00189-9; Kumar R, 2002, NEUROIMAGE, V15, P1015, DOI 10.1006/nimg.2001.1036; Kuruvilla A., 2001, SMJ Singapore Medical Journal, V42, P297; Lino RD, 2007, ARQ NEURO-PSIQUIAT, V65, P87, DOI 10.1590/S0004-282X2007000100019; McGowan JC, 1999, NEUROLOGY, V53, pS3; Murthy JMK, 1998, SEIZURE-EUR J EPILEP, V7, P153, DOI 10.1016/S1059-1311(98)80072-1; Pradhan S, 2000, ANN NEUROL, V48, P181, DOI 10.1002/1531-8249(200008)48:2&lt;181::AID-ANA7&gt;3.0.CO;2-C; Pradhan S, 2003, ACTA NEUROL SCAND, V107, P260, DOI 10.1034/j.1600-0404.2003.01380.x; Proano JV, 2001, NEW ENGL J MED, V345, P879, DOI 10.1056/NEJMoa010212; Rajshekhar V, 1997, ACTA NEUROL SCAND, V96, P76; RAJSHEKHAR V, 1993, J NEUROSURG, V78, P402, DOI 10.3171/jns.1993.78.3.0402; Rajshekhar V, 2004, NEUROLOGY, V62, P2236, DOI 10.1212/01.WNL.0000130471.19171.D8; Roman G, 2000, B WORLD HEALTH ORGAN, V78, P399; SARTI E, 1992, AM J TROP MED HYG, V46, P677, DOI 10.4269/ajtmh.1992.46.677; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Udani Vrajesh, 2005, Indian Journal of Pediatrics, V72, P309, DOI 10.1007/BF02724012; Wallin MT, 2004, NEUROLOGY, V63, P1559, DOI 10.1212/01.WNL.0000142979.98182.FF	42	24	24	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	OCT	2011	52	10					1918	1927		10.1111/j.1528-1167.2011.03189.x			10	Clinical Neurology	Neurosciences & Neurology	835WH	WOS:000296067000029	21777233	Other Gold			2021-06-18	
J	Kelley, BG; Mermelstein, PG				Kelley, Brooke G.; Mermelstein, Paul G.			Progesterone blocks multiple routes of ion flux	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article						Traumatic brain injury; Neuroprotection; Steroid; Striatum; Side effects	TRAUMATIC BRAIN-INJURY; RANDOMIZED CONTROLLED-TRIAL; CALCIUM-CHANNEL BLOCKERS; POTASSIUM CHANNELS; PARKINSONS-DISEASE; NIFEDIPINE; INHIBITION; PHARMACOKINETICS; PHARMACODYNAMICS; NEUROPROTECTION	The administration of progesterone as a neuroprotective agent following traumatic brain injury has recently entered phase III clinical trials. Previous work has demonstrated that therapeutic concentrations of progesterone decrease excitotoxicity through direct inhibition of voltage-gated calcium channels, an action independent of the nuclear progesterone receptor. Here we report using cultured rat striatal neurons that these same concentrations of progesterone also block voltage-gated potassium channels, sodium channels and GABA(A) currents. The actions of progesterone act at the surface membrane of neurons in a steroid specific, voltage-independent, concentration-dependent manner. Notably, these broad actions of progesterone on ion channel and neurotransmitter receptor function mirror those of dihydropyridines, and indicate potential shared mechanisms of action, the prospective of additional therapeutic applications, and possibly, untoward effects. (C) 2011 Elsevier Inc. All rights reserved.	[Kelley, Brooke G.; Mermelstein, Paul G.] Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA	Mermelstein, PG (corresponding author), Univ Minnesota, Dept Neurosci, 6-145 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	pmerm@umn.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS41302, NS062158]; IRACDA [GM074628]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K12GM074628] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS062158, R01NS041302] Funding Source: NIH RePORTER	This research was supported by the National Institutes of Health NS41302 (PGM), Core Funding NS062158, and an IRACDA Post-Doctoral Fellowship GM074628 (BGK). We thank Dr. John Meitzen for his comments on this manuscript.	Ahmad M, 2009, TROP J PHARM RES, V8, P385; ALLEN GS, 1983, NEW ENGL J MED, V308, P619, DOI 10.1056/NEJM198303173081103; Anderson L, 2009, REPROD SCI, V16, P1052, DOI 10.1177/1933719109340926; Atif F, 2009, MOL MED, V15, P328, DOI 10.2119/molmed.2009.00016; Becker C, 2008, NEUROLOGY, V70, P1438, DOI 10.1212/01.wnl.0000303818.38960.44; *BHR PHARM, 2010, LLC EFF SAF STUD INT; BIELEFELDT K, 1996, AM J PHYSIOL, V271, P370; Borna S, 2008, AUST NZ J OBSTET GYN, V48, P58, DOI 10.1111/j.1479-828X.2007.00803.x; Chien SC, 2004, BIOPHARM DRUG DISPOS, V25, P77, DOI 10.1002/bdd.386; Das P, 2004, NEUROSCIENCE, V124, P195, DOI 10.1016/j.neuroscience.2003.12.005; Ehring GR, 1998, J EXP MED, V188, P1593, DOI 10.1084/jem.188.9.1593; Gellersen B, 2009, HUM REPROD UPDATE, V15, P119, DOI 10.1093/humupd/dmn044; GELMERS HJ, 1985, AM J CARDIOL, V55, P139; Ginsberg MD, 2008, NEUROPHARMACOLOGY, V55, P363, DOI 10.1016/j.neuropharm.2007.12.007; Goodnick PJ, 2000, BIPOLAR DISORD, V2, P165, DOI 10.1034/j.1399-5618.2000.020303.x; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; HOFFMAN SW, 2008, Patent No. 7915244; HURD C, 1988, BIOCHEMISTRY-US, V27, P3618, DOI 10.1021/bi00410a014; Ilijic E, 2011, NEUROBIOL DIS, V43, P364, DOI 10.1016/j.nbd.2011.04.007; Judge SIV, 2006, J REHABIL RES DEV, V43, P111, DOI 10.1682/JRRD.2004.09.0116; KHAN A, 1991, BRIT J CLIN PHARMACO, V32, P519, DOI 10.1111/j.1365-2125.1991.tb03943.x; King JF, 2003, COCHRANE DB SYST REV, V1; Kittaka M, 1997, J NEUROSURG, V87, P731, DOI 10.3171/jns.1997.87.5.0731; LANCEL M, 1996, AM J PHYSIOL, V271, P763; Luoma JI, 2011, STEROIDS, V76, P845, DOI 10.1016/j.steroids.2011.02.013; Lyell DJ, 2008, OBSTET GYNECOL, V112, P1221, DOI 10.1097/AOG.0b013e31818d8386; Mermelstein PG, 2000, J NEUROSCI, V20, P266, DOI 10.1523/JNEUROSCI.20-01-00266.2000; MYERS MG, 1994, J HYPERTENS, V12, pS73; Pedrinelli R, 2001, J HUM HYPERTENS, V15, P455, DOI 10.1038/sj.jhh.1001201; PUTNAM CD, 1991, BIOL REPROD, V45, P266, DOI 10.1095/biolreprod45.2.266; RENWICK AG, 1988, BRIT J CLIN PHARMACO, V25, P701, DOI 10.1111/j.1365-2125.1988.tb05256.x; Ritz B, 2010, ANN NEUROL, V67, P600, DOI 10.1002/ana.21937; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; ROBERTSON DRC, 1988, BRIT J CLIN PHARMACO, V25, P297, DOI 10.1111/j.1365-2125.1988.tb03307.x; Rosendorff Clive, 2007, J Clin Hypertens (Greenwich), V9, P790; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Selye H, 1942, ENDOCRINOLOGY, V30, P437, DOI 10.1210/endo-30-3-437; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Wang Y, 2008, MED HYPOTHESES, V71, P546, DOI 10.1016/j.mehy.2008.05.021; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; WRIGHT DW, 2005, J CLIN PHARMACOL, V45, P460; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; YATANI A, 1985, CIRC RES, V56, P868, DOI 10.1161/01.RES.56.6.868; Zhang ML, 2002, J PHARM PHARMACOL, V54, P1667, DOI 10.1211/002235702405; Zhang X, 1997, J PHARMACOL EXP THER, V281, P1247; Zhang XL, 2009, NEUROSCIENCE, V161, P184, DOI 10.1016/j.neuroscience.2009.03.012	47	24	26	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431			MOL CELL NEUROSCI	Mol. Cell. Neurosci.	OCT	2011	48	2					137	141		10.1016/j.mcn.2011.07.002			5	Neurosciences	Neurosciences & Neurology	822CF	WOS:000295020600003	21782024	Green Accepted			2021-06-18	
J	Hoane, MR; Swan, AA; Heck, SE				Hoane, Michael R.; Swan, Alicia A.; Heck, Sarah E.			The effects of a high-fat sucrose diet on functional outcome following cortical contusion injury in the rat	BEHAVIOURAL BRAIN RESEARCH			English	Article						American diet; Brain injury; Recovery of function; Nutrition; Behavior; TBI	TRAUMATIC BRAIN-INJURY; NICOTINAMIDE TREATMENT; NEUROTROPHIC FACTOR; SATURATED-FAT; COGNITIVE FUNCTION; RECOVERY; PLASTICITY; SENSORIMOTOR; MEMORY	Traumatic brain injury (TBI) is a major public health issue affecting 1.7 million Americans each year, of which approximately 50,000 are fatal. High-fat sucrose (HFS) diets are another public health issue which can lead to obesity, hypertension, and many other debilitating disorders. These two disorders combined can lead to more complicated issues. It has recently been shown that HFS diets can reduce levels of brain-derived neurotrophic factor (BDNF) leading to reductions in neuronal and behavioral plasticity. This reduction in BDNF is suspected of increasing the susceptibility of the brain to injury. To test the effects of a HFS diet on recovery of function post-TBI, male Sprague-Dawley rats were used in this study. Eight weeks prior to TBI, rats were placed on a special HFS diet (n = 14) or a standard rodent diet (n =14). Following this eight-week period, rats were prepared with bilateral frontal cortical contusion injuries (CCI) or sham procedures. Beginning two days post-TBI, animals were tested on a battery of behavioral tests to assess somatosensory dysfunction and spatial memory in the Morris water maze, with a reference memory and a working memory task. Following testing, animals were sacrificed and their brains processed for lesion analysis. The HFS diet worsened performance on the bilateral tactile adhesive removal test in sham animals. Injured animals on the Standard diet had a greater improvement in somatosensory performance in the adhesive removal test and had better performance on the working memory task compared to animals on the HFS diet. The HFS diet also resulted in significantly greater loss of cortical tissue post-CC than in the Standard diet group. This study may aid in determining how nutritional characteristics or habits interact with damage to the brain. (C) 2011 Elsevier B.V. All rights reserved.	[Hoane, Michael R.; Swan, Alicia A.; Heck, Sarah E.] So Illinois Univ Carbondale, Restorat Neurosci Lab, Ctr Integrat Res Cognit & Neural Sci, Dept Psychol, Carbondale, IL 62901 USA	Hoane, MR (corresponding author), So Illinois Univ Carbondale, Restorat Neurosci Lab, Ctr Integrat Res Cognit & Neural Sci, Dept Psychol, Carbondale, IL 62901 USA.	mhoane@siu.edu	Swan, Alicia A/O-3536-2018	Swan, Alicia A/0000-0003-2412-0499; Hoane, Michael/0000-0001-7779-2657	SIU-C; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS045647]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647] Funding Source: NIH RePORTER	Research support provided by an SIU-C REACH award and the NIH, NS045647. The authors would like to thank Nick Kaufman for his assistance on the project.	Castren E, 1998, PROG BRAIN RES, V117, P57; Centers for Disease Control, 2010, INJ PREV CONTR TRAUM; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Gao X, 2009, J NEUROTRAUM, V26, P1325, DOI 10.1089/neu.2008-0744; Goffus AM, 2010, OXID MED CELL LONGEV, V3, P145, DOI 10.4161/oxim.3.2.11315; Gomez-Pinilla F, 2008, NAT REV NEUROSCI, V9, P568, DOI 10.1038/nrn2421; Granholm AC, 2008, J ALZHEIMERS DIS, V14, P133; Hartl R, 2008, J NEUROSURG, V109, P50, DOI 10.3171/JNS/2008/109/7/0050; Hoane MR, 2008, NEUROSCIENCE, V154, P861, DOI 10.1016/j.neuroscience.2008.04.044; Hoane MR, 2007, MAGNESIUM RES, V20, P229; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Hoane MR, 2006, NEUROSCI LETT, V408, P35, DOI 10.1016/j.neulet.2006.07.011; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoane MR, 2008, OXID MED CELL LONGEV, V1, P46, DOI 10.4161/oxim.1.1.6694; Hoane MR, 2009, J NEUROTRAUM, V26, P121, DOI 10.1089/neu.2008.0565; Hoane MR, 2005, J NEUROTRAUM, V22, P1112, DOI 10.1089/neu.2005.22.1112; Hoane MR, 2005, RESTOR NEUROL NEUROS, V23, P67; Hoane MR, 2004, BEHAV BRAIN RES, V153, P189, DOI 10.1016/j.bbr.2003.11.012; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Holland MA, 2008, J NEUROTRAUM, V25, P140, DOI 10.1089/neu.2007.0312; Kuypers NJ, 2010, J NEUROTRAUM, V27, P1275, DOI 10.1089/neu.2010.1327; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; MORRIS LK, 2010, AM J PHYSIOL-REG I, V299, P1082; OGDEN C, 2002, JAMA-J AM MED ASSOC, P288; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Quigley A, 2009, BRAIN RES, V1304, P138, DOI 10.1016/j.brainres.2009.09.062; RUTLANDBROWN W, 2003, J HEAD TRAUMA REHAB, V2006, P456; Tan AA, 2009, J NEUROTRAUM, V26, P539, DOI 10.1089/neu.2008.0611; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2004, EUR J NEUROSCI, V19, P1699, DOI 10.1111/j.1460-9568.2004.03246.x	33	24	24	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	SEP 30	2011	223	1					119	124		10.1016/j.bbr.2011.04.028			6	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	790KU	WOS:000292587700017	21549156	Green Accepted			2021-06-18	
J	Carlomagno, S; Giannotti, S; Vorano, L; Marini, A				Carlomagno, Sergio; Giannotti, Sara; Vorano, Lorenzo; Marini, Andrea			Discourse information content in non-aphasic adults with brain injury: A pilot study	BRAIN INJURY			English	Article						Traumatic brain injury; discourse analysis; pragmatic errors; information content	CONNECTED SPEECH SAMPLES; LANGUAGE; IMPROVEMENT; COHESION; SYSTEM	Background: The functional evaluation of discourse informativeness is widely used in both clinical practice and research, and impoverished and confused discourse has been described in individuals with traumatic brain injury (TBI). These symptoms have been related to language processing deficits at the macrolinguistic level. However, the functional counterpart of these deficits, i.e. poor informativeness in standardized analysis of elicited speech samples, has been less explored. Methods and procedures: In this pilot study, samples of narrative discourse from 10 non-aphasic TBI adults and 28 healthy adults were examined to study the relationship between standardized measures of informativeness (i.e. Correct Information Unit analysis) and language processing errors at the macrolinguistic level and to compare performance of the two groups. Main outcomes and results: The participants with TBI did not produce relevant within-sentence errors and information content of their narratives was not different from that of the healthy participants. However, their production of errors of cohesion, local coherence and global coherence was significantly greater. These macrolinguistic errors corresponded to reduced levels of information efficiency (% CIUs score). Conclusions: Functional measures of speech informativeness such as the CIU scores may be useful for the clinical assessment of discourse processing deficits in TBI individuals without aphasic symptoms.	[Carlomagno, Sergio; Giannotti, Sara] Univ Trieste, Dipartimento Psicol, I-34134 Trieste, Italy; [Vorano, Lorenzo] IMFR Gervasutta, Udine, Italy; [Marini, Andrea] Univ Udine, I-33100 Udine, Italy; [Marini, Andrea] IRCCS E Medea, S Vito Al Tagliamento, Pn, Italy	Carlomagno, S (corresponding author), Univ Trieste, Dipartimento Psicol, Via St Anastasio 12, I-34134 Trieste, Italy.	scarlomagno@units.it		Marini, Andrea/0000-0002-6058-3864			BROOKSHIRE RH, 1994, J SPEECH HEAR RES, V37, P399, DOI 10.1044/jshr.3702.399; BROOKSHIRE RH, 1995, AM J SPEECH-LANG PAT, V4, P118, DOI DOI 10.1044/1058-0360.0404.118; Brookshire RH, 1993, DISCOURSE COMPREHENS; CRAIG HK, 1993, APHASIOLOGY, V7, P155, DOI 10.1080/02687039308249503; Davis GA, 2004, BRAIN LANG, V89, P508, DOI 10.1016/j.bandl.2004.01.003; Doyle P.J., 1995, AM J SPEECH-LANG PAT, V4, P130, DOI [10.1044/1058-0360.0404.130, DOI 10.1044/1058-0360.0404.130]; EHRLICH JS, 1988, J COMMUN DISORD, V21, P1, DOI 10.1016/0021-9924(88)90006-8; Giles E, 1996, APHASIOLOGY, V10, P395, DOI 10.1080/02687039608248419; GLOSSER G, 1991, BRAIN LANG, V40, P67, DOI 10.1016/0093-934X(91)90117-J; Goodglass H., 1972, BOSTON DIAGNOSTIC AP; HARAVON A, 1994, STUDIES ADULT CLIN P, P47; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; HUBER W, 1982, BRAIN LANG, V16, P1, DOI 10.1016/0093-934X(82)90069-4; Jacobs BJ, 2001, BRAIN LANG, V78, P115, DOI 10.1006/brln.2001.2452; Kertesz A., 1982, W APHASIA BATTERY; Luzzatti C., 1991, AACHENER APHASIE TES; Marini A, 2005, J PSYCHOLINGUIST RES, V34, P439, DOI 10.1007/s10936-005-6203-z; Marini A, 2008, SCHIZOPHR RES, V105, P144, DOI 10.1016/j.schres.2008.07.011; Marini A, 2007, APHASIOLOGY, V21, P164, DOI 10.1080/02687030600633799; MENN L, 1994, APHASIOLOGY, V8, P343, DOI 10.1080/02687039408248664; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; NICHOLAS LE, 1993, J SPEECH HEAR RES, V36, P338, DOI 10.1044/jshr.3602.338; Oelschlaeger ML, 1999, J SPEECH LANG HEAR R, V42, P636, DOI 10.1044/jslhr.4203.636; Ross KB, 1999, APHASIOLOGY, V13, P113, DOI 10.1080/026870399402235; Schuell H., 1972, MINNESOTA TEST DIFFE; SHEWAN CM, 1988, J COMMUN DISORD, V21, P103, DOI 10.1016/0021-9924(88)90001-9; Snow PC, 2000, BRAIN INJURY, V14, P397; Stout CE, 2000, J MED SPEECH-LANG PA, V8, P15; YORKSTON KM, 1980, J SPEECH HEAR DISORD, V45, P27, DOI 10.1044/jshd.4501.27	30	24	24	0	31	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2011	25	10					1010	1018		10.3109/02699052.2011.605097			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	801TZ	WOS:000293464800012	21812587				2021-06-18	
J	Lv, LQ; Hou, LJ; Yu, MK; Qi, XQ; Chen, HR; Chen, JX; Hu, GH; Luo, C; Lu, YC				Lv, Li-Quan; Hou, Li-Jun; Yu, Ming-Kun; Qi, Xiang-Qian; Chen, Huai-Rui; Chen, Ju-Xiang; Hu, Guo-Han; Luo, Chun; Lu, Yi-Cheng			Risk Factors Related to Dysautonomia After Severe Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Dysautonomia; Traumatic brain injury; Incidence; Risk factors	SEVERE HEAD-INJURY; DIENCEPHALIC SEIZURES; SYMPATHETIC STORMS	Background: Dysautonomia after severe traumatic brain injury (TBI) is a clinical syndrome affecting a subgroup of survivors and is characterized by episodes of autonomic dysregulation and muscle overactivity. The purpose of this study was to determine the incidence of dysautonomia after severe TBI in an intensive care unit setting and analyze the risk factors for developing dysautonomia. Methods: A consecutive series of 101 patients with severe TBI admitted in a major trauma hospital during a 2-year period were prospectively observed to determine the effects of age, sex, mode of injury, hypertension history, admission systolic blood pressure, fracture, lung injury, admission Glasgow Coma Scale (GCS) score, injury severity score, emergency craniotomy, sedation or analgesia, diffuse axonal injury (DAI), magnetic resonance imaging (MRI) scales, and hydrocephalus on the development of dysautonomia. Risk factors for dysautonomia were evaluated by using logistic regression analysis. Results: Seventy-nine of the 101 patients met inclusion criteria, and dysautonomia was observed in 16 (20.3%) of these patients. Univariate analysis revealed significant correlations between the occurrence of dysautonomia and patient age, admission GCS score, DAI, MRI scales, and hydrocephalus. Sex, mode of injury, hypertension history, admission systolic blood pressure, fracture, lung injury, injury severity score, sedation or analgesia, and emergency craniotomy did not influence the development of dysautonomia. Multivariate logistic regression revealed that patient age and DAI were two independent predictors of dysautonomia. There was no independent association between dysautonomia and admission GCS score, MRI scales, or hydrocephalus. Conclusions: Dysautonomia frequently occurs in patients with severe TBI. A younger age and DAI could be risk factors for facilitating the development of dysautonomia.	[Lv, Li-Quan; Hou, Li-Jun; Yu, Ming-Kun; Qi, Xiang-Qian; Chen, Huai-Rui; Chen, Ju-Xiang; Hu, Guo-Han; Luo, Chun; Lu, Yi-Cheng] Second Mil Med Univ, Dept Neurosurg, Shanghai Inst Neurosurg, Shanghai Changzheng Hosp, Shanghai 200003, Peoples R China	Hou, LJ (corresponding author), Second Mil Med Univ, Dept Neurosurg, Shanghai Inst Neurosurg, Shanghai Changzheng Hosp, 415 Feng Yang Rd, Shanghai 200003, Peoples R China.	neuro_hlj@yahoo.com.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30600635]	Supported by the National Natural Science Foundation of China (30600635).	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Baguley IJ, 2008, MED HYPOTHESES, V70, P26, DOI 10.1016/j.mehy.2007.04.037; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 2004, BRAIN INJURY, V18, P409, DOI 10.1080/02699050310001645775; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; Dolce G, 2021, J NEUROTRAUM, V38, P1441, DOI 10.1089/neu.2008.0536; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Goh KYC, 1999, PEDIATR NEUROL, V21, P742, DOI 10.1016/S0887-8994(99)00069-7; Hendricks HT, 2010, EUR J NEUROL, V17, P1172, DOI 10.1111/j.1468-1331.2010.02989.x; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; KISHNER S, POSTHEAD INJURY AUTO; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; MEYTHALER JM, 1994, ARCH PHYS MED REHAB, V75, P816; Ogawa T, 1992, Acta Neurochir Suppl (Wien), V55, P8; PRANZATELLI MR, 1991, J CHILD NEUROL, V6, P115, DOI 10.1177/088307389100600204; Rabinstein AA, 2007, NEUROL RES, V29, P680, DOI 10.1179/016164107X240071; Rossitch E Jr, 1988, Br J Neurosurg, V2, P471, DOI 10.3109/02688698809029601; TALMAN WT, 1988, ARCH NEUROL-CHICAGO, V45, P1037, DOI 10.1001/archneur.1988.00520330129022	25	24	27	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2011	71	3					538	542		10.1097/TA.0b013e31820ebee1			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	818MX	WOS:000294756900008	21427610				2021-06-18	
J	Shahlaie, K; Keachie, K; Hutchins, IM; Rudisill, N; Madden, LK; Smith, KA; Ko, KA; Latchaw, RE; Muizelaar, JP				Shahlaie, Kiarash; Keachie, Krista; Hutchins, Irene M.; Rudisill, Nancy; Madden, Lori K.; Smith, Karen A.; Ko, Karen A.; Latchaw, Richard E.; Muizelaar, J. Paul			Risk factors for posttraumatic vasospasm Clinical article	JOURNAL OF NEUROSURGERY			English	Article						fever; inflammation; intracranial hemorrhage; traumatic brain injury; vasospasm; vascular disorders	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; CEREBRAL BLOOD-FLOW; INTRACRANIAL ARTERIAL SPASM; SUBARACHNOID HEMORRHAGE; TIME-COURSE; CT-SCAN; TEMPERATURE; VELOCITIES; FEVER	Object. Posttraumatic vasospasm (PTV) is an underrecognized cause of ischemic damage after severe traumatic brain injury (TBI) that independently predicts poor outcome. There are, however, no guidelines for PTV screening and management, partly due to limited understanding of its pathogenesis and risk factors. Methods. A database review of 46 consecutive cases of severe TBI in pediatric and adult patients was conducted to identify risk factors for the development of PTV. Univariate analysis was performed to identify potential risk factors for PTV, which were subsequently analyzed using a multivariate logistic regression model to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Results. Fever on admission was an independent risk factor for development of PTV (OR 22.2, 95% CI 1.9-256.8), and patients with hypothermia on admission did not develop clinically significant vasospasm during their hospital stay. The presence of small parenchymal contusions was also an independent risk factor for PTV (OR 7.8, 95% CI 0.9-69.5), whereas the presence of subarachnoid hemorrhage or other patterns of intracranial injury were not. Other variables, such as age, sex, ethnicity, degree of TBI severity, or admission laboratory values, were not independent predictors for the development of clinically significant PTV. Conclusions. Independent risk factors for PTV include parenchymal contusions and fever. These results suggest that diffuse mechanical injury and activation of inflammatory pathways may be underlying mechanisms for the development of PTV, and that a subset of patients with these risk factors may be an appropriate population for aggressive screening. Further studies are needed to determine if treatments targeting fever and inflammation may be effective in reducing the incidence of vasospasm following severe TBI. (DOI: 10.3171/2011.5.JNS101667)	[Shahlaie, Kiarash; Keachie, Krista; Hutchins, Irene M.; Rudisill, Nancy; Madden, Lori K.; Smith, Karen A.; Ko, Karen A.; Muizelaar, J. Paul] Univ Calif Davis, Dept Neurol Surg, Sch Med, Sacramento, CA 95817 USA; [Latchaw, Richard E.] Univ Calif Davis, Dept Radiol, Sch Med, Sacramento, CA 95817 USA	Shahlaie, K (corresponding author), Univ Calif Davis, Dept Neurol Surg, Sch Med, 4860 Y St,Suite 3740, Sacramento, CA 95817 USA.	kiarash.shahlaie@ucdmc.ucdavis.edu	Madden, Lori K/K-3749-2012	Madden, Lori K/0000-0001-9179-4202			Armin SS, 2008, ACTA NEUROCHIR SUPPL, V104, P421; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; ARSENI C, 1971, ACTA NEUROCHIR, V24, P25, DOI 10.1007/BF01403138; ARUTIUNOV AI, 1974, J NEUROSURG, V40, P459, DOI 10.3171/jns.1974.40.4.0459; Bakshi A, 1998, NATL MED J INDIA, V11, P220; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CHAN KH, 1992, NEUROSURGERY, V30, P697; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; Compton J S, 1987, Br J Neurosurg, V1, P435, DOI 10.3109/02688698708999633; CORK RC, 1983, ANESTH ANALG, V62, P211; Dhar R, 2008, NEUROCRIT CARE, V8, P253, DOI 10.1007/s12028-007-9020-4; Echlin FA, 1942, ARCH NEURO PSYCHIATR, V47, P77, DOI 10.1001/archneurpsyc.1942.02290010087007; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Fergusen S, 2007, NEUROSURGERY, V60, P658, DOI 10.1227/01.NEU.0000255396.23280.31; Ferrara-Love R, 1991, J Post Anesth Nurs, V6, P161; Fountas KN, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.2.FOCUS08311; FULBROOK P, 1993, J ADV NURS, V18, P1451, DOI 10.1046/j.1365-2648.1993.18091451.x; Geffroy A, 2004, INTENS CARE MED, V30, P785, DOI 10.1007/s00134-004-2280-y; GROLIMUND P, 1988, LANCET, V1, P1173; Hadani M, 1997, J NEUROTRAUM, V14, P629, DOI 10.1089/neu.1997.14.629; HAMER J, 1976, NEUROCHIRURGIA, V19, P185; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; KAKARIEKA A, 1994, ACTA NEUROCHIR, V129, P1, DOI 10.1007/BF01400864; Kim GH, 2008, J NEUROSURG, V109, P38, DOI 10.3171/JNS/2008/109/7/0038; KISTLER JP, 1983, NEUROLOGY, V33, P424, DOI 10.1212/WNL.33.4.424; KORDESTANI RK, 1995, NEUROSURG CLIN N AM, V6, P657; Lee DJ, 2008, NEUROSURGERY, V63, P1004, DOI 10.1227/01.NEU.0000327685.90800.F7; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; LEWIN W, 1968, BRIT J SURG, V55, P321, DOI 10.1002/bjs.1800550502; Lynch JR, 2005, STROKE, V36, P2024, DOI 10.1161/01.STR.0000177879.11607.10; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MARSHALL LF, 1978, J NEUROSURG, V48, P560, DOI 10.3171/jns.1978.48.4.0560; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MARTIN NA, 1995, J NEUROTRAUM, V12, P897, DOI 10.1089/neu.1995.12.897; Mattioli C, 2003, J NEUROSURG, V98, P37, DOI 10.3171/jns.2003.98.1.0037; McGirt MJ, 2006, J NEUROSURG, V105, P671, DOI 10.3171/jns.2006.105.5.671; McGirt MJ, 2003, J NEUROSURG, V98, P1222, DOI 10.3171/jns.2003.98.6.1222; Meixensberger J, 2003, NEUROL RES, V25, P445, DOI 10.1179/016164103101201823; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; PASQUALIN A, 1984, NEUROSURGERY, V15, P855, DOI 10.1227/00006123-198412000-00015; Povlishock JT, 2009, J NEUROTRAUM, V26, P333, DOI 10.1089/neu.2008.0604; Rabinstein AA, 2007, J NEUROL NEUROSUR PS, V78, P1278, DOI 10.1136/jnnp.2006.112730; Romner B, 1996, J NEUROSURG, V85, P90, DOI 10.3171/jns.1996.85.1.0090; ROUSSEAUX P, 1980, SURG NEUROL, V14, P459; Rozsa L, 1989, Radiol Diagn (Berl), V30, P151; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; SANDER D, 1993, J NEUROL SCI, V119, P1, DOI 10.1016/0022-510X(93)90185-2; Schoch B, 2007, NEUROSURGERY, V60, P828, DOI 10.1227/01.NEU.0000255440.21495.80; Seo W, 2009, WORLDV EVID-BASED NU, V6, P36, DOI 10.1111/j.1741-6787.2008.00139.x; Shahlaie K, 2009, NEUROCRIT CARE, V10, P61, DOI 10.1007/s12028-008-9138-z; Shahlaie K, 2009, J NEUROTRAUM, V26, pA91; Soustiel JF, 2004, SURG NEUROL, V62, P201, DOI 10.1016/j.surneu.2003.10.037; Soustiel JF, 2002, ACTA NEUROCHIR, V144, P137, DOI 10.1007/s007010200016; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; SYMON L, 1967, J NEUROL NEUROSUR PS, V30, P497, DOI 10.1136/jnnp.30.6.497; Taneda M, 1996, J NEUROSURG, V84, P762, DOI 10.3171/jns.1996.84.5.0762; Tseng Ming-Yuan, 2006, Neurosurg Focus, V21, pE10; Tseng MY, 2005, STROKE, V36, P1627, DOI 10.1161/01.STR.0000176743.67564.5d; Vajramani GV, 1999, BRIT J NEUROSURG, V13, P468, DOI 10.1080/02688699908540620; Vath A, 2002, ACT NEUR S, V81, P307; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; WEIR B, 1989, NEUROSURGERY, V25, P161, DOI 10.1227/00006123-198908000-00002; WILKINS RH, 1970, J NEUROSURG, V32, P626, DOI 10.3171/jns.1970.32.6.0626; Zubkov AY, 1999, J NEUROTRAUM, V16, P763, DOI 10.1089/neu.1999.16.763; Zubkov ZY, 2000, SURG NEUROL, V53, P126	71	24	29	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2011	115	3					602	611		10.3171/2011.5.JNS101667			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	816FG	WOS:000294583500025	21663415				2021-06-18	
J	van Kampen, PJ; Martina, JD; Vos, PE; Hoedemaekers, CWE; Hendricks, HT				van Kampen, P. J.; Martina, J. D.; Vos, P. E.; Hoedemaekers, C. W. E.; Hendricks, H. T.			Potential Risk Factors for Developing Heterotopic Ossification in Patients With Severe Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						autonomic dysregulation; bone fractures; heterotopic ossification; immobilization; risk factors; spasticity; traumatic brain injury	BONE-FORMATION	Background: Heterotopic ossification (HO) is a frequent complication after traumatic brain injury (TBI). The current preliminary study is intended to provide additional data on the potential roles that brain injury severity, concomitant orthopaedic trauma, and specific intensive care complicating events may play in the prediction of HO in patients who have sustained severe TBI. Methods: A prospective cohort study in patients with severe TBI. Results: Ninety-seven of the 176 patients were eligible for follow-up; 13 patients (13%) developed 19 clinically relevant HOs at 1 or more sites. Univariate analysis indicated that patients with HO remained in coma longer (P<.001) and were ventilated during a longer period (P=.002). Autonomic dysregulation (relative risk = 6.11, 95% confidence interval: 2.53-14.76) and surgically treated extremity fractures (relative risk = 5.02, 95% confidence interval: 1.68-15.04) also showed significant associations with the development of HO. Conclusion: Prolonged coma duration and mechanical ventilation, coexistent surgically treated bone fractures and clinical signs of autonomic dysregulation should be given further consideration as potential risk factors for developing clinically relevant HO. Larger-scale studies are needed to develop a valid risk profile that takes into account the interrelationships between variables.	[Hendricks, H. T.] Radboud Univ Nijmegen, Med Ctr, Dept Rehabil Med, NL-6500 HB Nijmegen, Netherlands; [van Kampen, P. J.; Martina, J. D.] Rehabil Ctr Groot Klimmendaal, Arnhem, Netherlands; [Vos, P. E.] Radboud Univ Nijmegen, Med Ctr, Inst Neurol, NL-6500 HB Nijmegen, Netherlands; [Hoedemaekers, C. W. E.] Radboud Univ Nijmegen, Med Ctr, Dept Intens Care Med, NL-6500 HB Nijmegen, Netherlands	Hendricks, HT (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Rehabil Med, Post Box 9011, NL-6500 HB Nijmegen, Netherlands.	h.hendricks@reval.umcn.nl	Hoedemaekers, C.W.E./L-4375-2015; Vos, Pieter/A-6043-2012		Ever Neuro Pharma	Conflict of Interest: Dr Vos serves on a scientific advisory board and received funding for travel and speaker honoraria from Ever Neuro Pharma, serves as a member of the editorial advisory board of The European Journal of Neurology, and has received honoraria for lectures or educational activities not funded by the industry.	*AM COL SURG, 2008, ATLS ADV TRAUM LIF S; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; *BRAIN TRAUM FDN, 2007, J NEUROTRAUM S1, V24; Chauveau C, 2008, J RECEPT SIG TRANSD, V28, P347, DOI 10.1080/10799890802239762 ; Cipriano CA, 2009, J AM ACAD ORTHOP SUR, V17, P689, DOI 10.5435/00124635-200911000-00003; CITTAPIETROLUNGO TJ, 1992, ARCH PHYS MED REHAB, V73, P258; CLEMENTS NC, 1993, CHEST, V104, P1526, DOI 10.1378/chest.104.5.1526; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Ebinger T, 2000, J TRAUMA, V48, P1058, DOI 10.1097/00005373-200006000-00010; Flin C., 2002, Annales de Readaptation et de Medecine Physique, V45, P517, DOI 10.1016/S0168-6054(02)00305-7; Fransen M, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001160.PUB2; GARLAND DE, 1983, PHYS THER, V63, P2004, DOI 10.1093/ptj/63.12.2004; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; Gautschi OP, 2009, ANZ J SURG, V79, P449, DOI 10.1111/j.1445-2197.2008.04803.x; Hendricks HT, 2007, CLIN REHABIL, V21, P545, DOI 10.1177/0269215507075260; Hunt JL, 2006, J BURN CARE RES, V27, P535, DOI 10.1097/01.BCR.0000226023.58438.14; HURVITZ EA, 1992, ARCH PHYS MED REHAB, V73, P459; Ippolito E, 1999, CLIN ORTHOP RELAT R, P130, DOI 10.1097/00003086-199908000-00018; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARTINA JD, 2006, NEUROREHAB NEURAL RE, V20, P236; MIELANTS H, 1975, ACTA ORTHOP SCAND, V46, P190, DOI 10.3109/17453677508989207; Pape HC, 2000, J ORTHOP TRAUMA, V14, P238, DOI 10.1097/00005131-200005000-00003; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521; ROBERTS P H, 1968, Journal of Bone and Joint Surgery British Volume, V50B, P70; Sebastiani GD, 2002, CLIN RHEUMATOL, V21, P173, DOI 10.1007/PL00011219; Simonsen LL, 2007, INJURY, V38, P1146, DOI 10.1016/j.injury.2007.03.019; Trentz OA, 2005, CRIT CARE MED, V33, P399, DOI 10.1097/01.CCM.0000152221.87477.21; Tsur A, 1996, BRAIN INJURY, V10, P259, DOI 10.1080/026990596124430; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Warren S B, 1990, Orthop Rev, V19, P603	31	24	24	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2011	26	5					384	391		10.1097/HTR.0b013e3181f78a59			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	814VO	WOS:000294485500007	21321512				2021-06-18	
J	Johnson, CP; Juranek, J; Kramer, LA; Prasad, MR; Swank, PR; Ewing-Cobbs, L				Johnson, Chad P.; Juranek, Jenifer; Kramer, Larry A.; Prasad, Mary R.; Swank, Paul R.; Ewing-Cobbs, Linda			Predicting Behavioral Deficits in Pediatric Traumatic Brain Injury Through Uncinate Fasciculus Integrity	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Diffusion tensor imaging; Executive function; Neuropsychology; Child; Anisotropy; Behavior	CLOSED-HEAD INJURY; TEMPORAL-LOBE EPILEPSY; HUMAN CEREBRAL-CORTEX; DIFFUSION-TENSOR; WHITE-MATTER; EXECUTIVE FUNCTION; COGNITIVE CONTROL; CORPUS-CALLOSUM; SELF-REGULATION; CHILDREN	Behavioral dysregulation is a common and detrimental consequence of traumatic brain injury (TBI) in children that contributes to poor academic achievement and deficits in social development. Unfortunately, behavioral dysregulation is difficult to predict from either injury severity or early neuropsychological evaluation. The uncinate fasciculus (UF) connects orbitofrontal and anterior temporal lobes, which are commonly implicated in emotional and behavioral regulation. Using probabilistic diffusion tensor tractography (DTT), we examined the relationship between the integrity of the UF 3 months post-injury and ratings of executive functions 12 months post-injury in children with moderate to severe TBI and a comparison group with orthopedic injuries. As expected, fractional anisotropy of the UF was lower in the TBI group relative to the orthopedic injury group. DTT metrics from the UF served as a biomarker and predicted ratings of emotional and behavior regulation, but not metacognition. In contrast, the Glasgow Coma Scale score was not related to either UF integrity or to executive function outcomes. Neuroanatomical biomarkers like the uncinate fasciculus may allow for early identification of behavioral problems and allow for investigation into the relationship of frontotemporal networks to brain-behavior relationships. (JINS, 2011, 17, 663-673)	[Ewing-Cobbs, Linda] Univ Texas Hlth Sci Ctr Houston, Dan L Duncan Childrens Neurodev Clin, Childrens Learning Inst, Dept Pediat, Houston, TX 77030 USA; [Johnson, Chad P.] Univ Houston, Dept Psychol, Houston, TX USA; [Kramer, Larry A.] Univ Texas Hlth Sci Ctr Houston, Dept Radiol, Houston, TX 77030 USA; [Ewing-Cobbs, Linda] Univ Texas Hlth Sci Ctr Houston, Dept Psychiat & Behav Sci, Houston, TX 77030 USA	Ewing-Cobbs, L (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dan L Duncan Childrens Neurodev Clin, Childrens Learning Inst, Dept Pediat, 7000 Fannin,Suite 2401, Houston, TX 77030 USA.	linda.ewing-cobbs@uth.tmc.edu			Phillip M. Rennick award;  [NIH-NINDS-R01-NS046308]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046308] Funding Source: NIH RePORTER	This work was funded by NIH-NINDS-R01-NS046308 awarded to LEC. Portions of this study were awarded the Phillip M. Rennick award when presented as a poster at the 38th Annual Meeting of the International Neuropsychological Society in Acapulco. No conflicts of interest exist.	Allen JS, 2008, NEUROIMAGE, V42, P535, DOI 10.1016/j.neuroimage.2008.05.047; Amodio DM, 2006, NAT REV NEUROSCI, V7, P268, DOI 10.1038/nrn1884; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Bachevalier J, 2006, NEUROSCI BIOBEHAV R, V30, P97, DOI 10.1016/j.neubiorev.2005.07.002; Barkovich AJ, 2005, PEDIAT NEUROIMAGING; Barnea-Goraly N, 2004, BIOL PSYCHIAT, V55, P323, DOI 10.1016/j.biopsych.2003.10.022; Basser PJ, 1997, ANN NY ACAD SCI, V820, P123, DOI 10.1111/j.1749-6632.1997.tb46192.x; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Bunge SA, 2007, CURR OPIN NEUROBIOL, V17, P243, DOI 10.1016/j.conb.2007.02.005; Castellanos FX, 2006, TRENDS COGN SCI, V10, P117, DOI 10.1016/j.tics.2006.01.011; Chao YP, 2008, MED ENG PHYS, V30, P989, DOI 10.1016/j.medengphy.2008.01.010; Cook PA, 2005, LECT NOTES COMPUT SC, V3749, P164; Croxson PL, 2005, J NEUROSCI, V25, P8854, DOI 10.1523/JNEUROSCI.1311-05.2005; Damasio A., 1994, DESCARTESERROR EMOTI; DENNIS M, 1991, DEV NEUROPSYCHOL, V7, P327, DOI 10.1080/87565649109540497; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; Diehl B, 2008, EPILEPSIA, V49, P1409, DOI 10.1111/j.1528-1167.2008.01596.x; Eluvathingal TJ, 2007, CEREB CORTEX, V17, P2760, DOI 10.1093/cercor/bhm003; Eluvathingal TJ, 2006, PEDIATRICS, V117, P2093, DOI 10.1542/peds.2005-1727; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Ewing-Cobbs L, 2006, AM J NEURORADIOL, V27, P879; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; FUSTER JM, 1991, PROG BRAIN RES, V87, P201, DOI DOI 10.1016/S0079-6123(08)63053-8; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; Gerring J, 2000, BRAIN INJURY, V14, P205; Gioia G.A., 2000, BEHAV RATING INVENTO; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Goldman PS, 1974, PLASTICITY RECOVERY; GOLDMANRAKIC PS, 1988, ANNU REV NEUROSCI, V11, P137, DOI 10.1146/annurev.neuro.11.1.137; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Hasan KM, 2006, RADIOLOGY, V239, P611, DOI 10.1148/radiol.2392051172; HASAN KM, 2003, MEDICAMUNDI, V49, P30; Herskovits EH, 2002, RADIOLOGY, V224, P345, DOI 10.1148/radiol.2242011439; Highley JR, 2002, CEREB CORTEX, V12, P1218, DOI 10.1093/cercor/12.11.1218; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Johansen-Berg H, 2006, CURR OPIN NEUROL, V19, P379, DOI 10.1097/01.wco.0000236618.82086.01; Kober H, 2008, NEUROIMAGE, V42, P998, DOI 10.1016/j.neuroimage.2008.03.059; Kubicki M, 2002, HARVARD REV PSYCHIAT, V10, P324, DOI 10.1093/hrp/10.6.324; Le Bihan D, 2003, NAT REV NEUROSCI, V4, P469, DOI 10.1038/nrn1119; Lee JE, 2007, NEUROSCI LETT, V424, P127, DOI 10.1016/j.neulet.2007.07.042; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; LEVIN HS, 1993, CURR OPIN NEUROL, V6, P841, DOI 10.1097/00019052-199312000-00003; Lin JJ, 2008, EPILEPSY RES, V82, P162, DOI 10.1016/j.eplepsyres.2008.07.020; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1032, DOI 10.1097/01.chi.0000173293.05817.b1; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Moseley M, 2002, BRAIN COGNITION, V50, P396, DOI 10.1016/S0278-2626(02)00524-9; Ochsner KN, 2009, PSYCHOL SCI, V20, P1322, DOI 10.1111/j.1467-9280.2009.02459.x; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Pugliese L, 2009, NEUROIMAGE, V47, P427, DOI 10.1016/j.neuroimage.2009.05.014; Rubia K, 2006, HUM BRAIN MAPP, V27, P973, DOI 10.1002/hbm.20237; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Somerville LH, 2010, CURR OPIN NEUROBIOL, V20, P236, DOI 10.1016/j.conb.2010.01.006; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tasker RC, 2006, DEV NEUROSCI-BASEL, V28, P302, DOI 10.1159/000094156; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wager TD, 2008, NEURON, V59, P1037, DOI 10.1016/j.neuron.2008.09.006; Wallis LI, 2006, ACTA RADIOL, V47, P1094, DOI 10.1080/02841850600979048; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940	75	24	24	0	8	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2011	17	4					663	673		10.1017/S1355617711000464			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	781NL	WOS:000291939900010	21492497	Green Accepted			2021-06-18	
J	Pappadis, MR; Sander, AM; Struchen, MA; Leung, P; Smith, DW				Pappadis, Monique R.; Sander, Angelle M.; Struchen, Margaret A.; Leung, Patrick; Smith, Dennis W.			Common Misconceptions About Traumatic Brain Injury Among Ethnic Minorities With TBI	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						minorities; misconceptions; recovery; traumatic brain injury	COMMUNITY INTEGRATION; HEAD-INJURY; RECOVERY; REPLICATION; DEPRESSION; AWARENESS; OUTCOMES; IMPACT; RETURN; WORK	Objective: To investigate common TBI misconceptions among ethnic minorities with TBI. Design: Cross-sectional study. Setting: Level I trauma center. Participants: Fifty-eight persons with TBI (28 black and 30 Hispanic) discharged from the neurosurgery unit and living in the community. Main Measure: Forty-item Common Misconceptions about Traumatic Brain Injury Questionnaire (CM-TBI). Results: Participants displayed misconceptions about approximately one-third of the 40 items, most regarding amnesia and recovery. Fewer misconceptions were found in the brain damage/injury and sequelae categories. A greater percentage of TBI misconceptions was associated with having lower education, actively practicing religion, being Spanish-speaking and non-US born. After controlling for education and actively practicing religion, Spanish-speaking Hispanics reported a greater percentage of misconceptions than English-speaking Hispanics and blacks. Conclusions and Implications: Understanding common TBI misconceptions can assist rehabilitation staff in tailoring education programs for racial/ethnic minorities including those who are Spanish-speaking. Educational attainment and cultural factors should be considered when developing educational interventions for persons with TBI from diverse backgrounds. Inaccurate information regarding TBI, especially the recovery process, may hinder treatment planning by rehabilitation professionals and may result in disappointment and the setting of unrealistic goals for persons with injury and their families.	[Pappadis, Monique R.; Sander, Angelle M.; Struchen, Margaret A.] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX 77019 USA; [Pappadis, Monique R.; Leung, Patrick] Univ Houston, Grad Coll Social Work, Houston, TX USA; [Smith, Dennis W.] Univ Houston, Dept Hlth & Human Performance, Houston, TX USA; [Sander, Angelle M.; Struchen, Margaret A.] Harris Cty Hosp Dist, Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX USA	Pappadis, MR (corresponding author), TIRR Mem Hermann, Brain Injury Res Ctr, 2323 S Shepherd,Ste 907, Houston, TX 77019 USA.	monique.pappadis@memorialhermann.org	Pappadis, Monique/Q-8639-2016	Pappadis, Monique/0000-0003-4742-4380	National Institute on Disability and Rehabilitation Research; US Department of EducationUS Department of Education [H133B031117]	This work was supported by a grant from the National Institute on Disability and Rehabilitation Research, US Department of Education ( grant H133B031117, Rehabilitation Research and Training Center on Community Integration in Persons with Traumatic Brain Injury). Special thanks to the patients and staff of Harris County Hospital District, including Drs Shankar Gopinath and Claudia Robertson.	Arango-Lasprilla JC, 2009, PM&R, V1, P41, DOI 10.1016/j.pmrj.2008.07.001; Bier N, 2009, J HEAD TRAUMA REHAB, V24, P187, DOI 10.1097/HTR.0b013e3181a0b15a; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Capella ME, 2002, REHABIL COUNS BULL, V45, P143, DOI 10.1177/003435520204500303; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Dowswell G, 2000, J CLIN NURS, V9, P507, DOI 10.1046/j.1365-2702.2000.00411.x; Ernst WJ, 2009, J HEAD TRAUMA REHAB, V24, P213, DOI 10.1097/HTR.0b013e3181a7ecd8; Farmer JE, 1997, REHABIL PSYCHOL, V42, P273; Glover NM, 2007, J REHABIL, V73, P41; GORDON WA, 1999, REHABILITATION ADULT, P312; Gouvier W. D., 1988, ARCH CLIN NEUROPSYCH, V3, P331; Guilmette TJ, 2004, ARCH CLIN NEUROPSYCH, V19, P183, DOI 10.1016/S0887-6177(03)00025-8; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P161, DOI 10.1080/09602010802188393; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hux K, 2006, BRAIN INJURY, V20, P547, DOI 10.1080/02699050600676784; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; McGrane SA, 2000, BRAIN INJURY, V14, P975; McKinlay W, 1999, REHABILITATION ADULT, V3, P74; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Nunnally J. C., 1994, PSYCHOMETRIC THEORY; O'Jile J. R., 1997, INT J REHABILITATION, V3, P61, DOI DOI 10.1007/BF02766798; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; Rapport L, 2006, J HEAD TRAUMA REHAB, V21, P34, DOI 10.1097/00001199-200601000-00004; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Sander AM, 2009, NEUROREHABILITATION, V24, P15, DOI 10.3233/NRE-2009-0450; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Springer JA, 1997, J HEAD TRAUMA REHAB, V12, P41, DOI 10.1097/00001199-199706000-00005; Staudenmayer KL, 2007, J TRAUMA, V63, P1364, DOI 10.1097/TA.0b013e31815b897b; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; Uysal S, 1998, J HEAD TRAUMA REHAB, V13, P57, DOI 10.1097/00001199-199812000-00007; WILLER B, 1993, ARCH CLIN NEUROPSYCH, V8, P461, DOI 10.1016/0887-6177(93)90009-P	45	24	24	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2011	26	4					301	311		10.1097/HTR.0b013e3181e7832b			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	789FZ	WOS:000292501700007	20808242				2021-06-18	
J	Barber, L; Barrett, R; Lichtwark, G				Barber, Lee; Barrett, Rod; Lichtwark, Glen			Validity and reliability of a simple ultrasound approach to measure medial gastrocnemius muscle length	JOURNAL OF ANATOMY			English	Article						acquired brain injury; cerebral palsy; muscle contracture; muscle length; spasticity; spinal injury; stroke; traumatic brain injury; ultrasound	CHILDREN; MORPHOLOGY; PROGRESSION; VALIDATION; SUPPORT; VOLUME	Fixed shortening of a muscle, or contracture, often develops in individuals with an upper motor neuron disorder. A clinical measure of muscle length would therefore be useful for identifying the presence of muscle contracture, tracking changes over time and evaluating the effect of interventions. This study compared a novel ultrasound-tape length method with a previously validated freehand 3D ultrasound method for measuring muscle length. The ultrasound-tape method intra-session reliability was also assessed. Resting medial gastrocnemius muscle length was measured at three ankle joint angles in 15 typically developed (TD) adults and nine adults with cerebral palsy (CP) using the two methods. The ultrasound-tape method on average overestimated the muscle length in the TD group by < 0.1% (95% CI, 6%) and underestimated in the muscle length in the CP group by 0.1% (95% CI, 6%) compared with the 3D ultrasound method. Intra-session reliability of the ultrasound-tape method was high, with intra-class correlation coefficients > 0.99. The ultrasound-tape method has sufficient accuracy to detect clinically relevant differences and changes in medial gastrocnemius muscle length and may therefore be a useful clinical tool for assessing muscle length changes associated with contracture.	[Barber, Lee; Barrett, Rod] Griffith Univ, Sch Physiotherapy & Exercise Sci, Gold Coast, Qld 4222, Australia; [Lichtwark, Glen] Univ Queensland, Sch Human Movement Studies, Brisbane, Qld, Australia	Barber, L (corresponding author), Griffith Univ, Sch Physiotherapy & Exercise Sci, Gold Coast Campus, Gold Coast, Qld 4222, Australia.	l.barber@griffith.edu.au	Barber, Lee/V-6900-2019; Barrett, Rod/B-4419-2009; Barber, Lee/G-3575-2011; Lichtwark, Glen A/B-6002-2008	Barber, Lee/0000-0002-3220-3078; Barber, Lee/0000-0002-3220-3078; Lichtwark, Glen A/0000-0001-7366-3348; Barrett, Rod/0000-0002-1784-1629	National Health and Medical Research Council, AustraliaNational Health and Medical Research Council of Australia [481953]	This work was supported by funding from the National Health and Medical Research Council, Australia (Biomedical Postgraduate Scholarship Grant ID: 481953).	Bache CE, 2003, CURR ORTHOPAED, V17, P88, DOI 10.1054/cuor.2003.0328; Barber L, 2009, J BIOMECH, V42, P1313, DOI 10.1016/j.jbiomech.2009.03.005; Barrett RS, 2010, DEV MED CHILD NEUROL, V52, P794, DOI 10.1111/j.1469-8749.2010.03686.x; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; CAMPBELL RSD, 2002, IMAGING, V14, P229; Fry NR, 2007, J PEDIATR ORTHOPED, V27, P769, DOI 10.1097/BPO.0b013e3181558943; Fry NR, 2004, GAIT POSTURE, V20, P177, DOI 10.1016/j.gaitpost.2003.08.010; Fry NR, 2003, GAIT POSTURE, V17, P119, DOI 10.1016/S0966-6362(02)00059-0; Gao F, 2008, J APPL PHYSIOL, V105, P1802, DOI 10.1152/japplphysiol.90930.2008; Liu MQ, 2008, J BIOMECH, V41, P3243, DOI 10.1016/j.jbiomech.2008.07.031; Maganaris CN, 2003, CLIN ANAT, V16, P215, DOI 10.1002/ca.10064; Malaiya R, 2007, J ELECTROMYOGR KINES, V17, P657, DOI 10.1016/j.jelekin.2007.02.009; McDowell BC, 2000, GAIT POSTURE, V12, P114, DOI 10.1016/S0966-6362(00)00068-0; Mitsiopoulos N, 1998, J APPL PHYSIOL, V85, P115; Oberhofer K, 2010, CLIN BIOMECH, V25, P88, DOI 10.1016/j.clinbiomech.2009.09.007; Ohata K, 2008, DEV MED CHILD NEUROL, V50, P152, DOI 10.1111/j.1469-8749.2007.02018.x; Palisano RJ, 2008, DEV MED CHILD NEUROL, V50, P744, DOI 10.1111/j.1469-8749.2008.03089.x; Sheean G, 2002, EUR J NEUROL, V9, P3, DOI 10.1046/j.1468-1331.2002.0090s1003.x; Steele KM, 2010, J BIOMECH, V43, P2099, DOI 10.1016/j.jbiomech.2010.04.003; Weller R, 2007, ULTRASOUND MED BIOL, V33, P402, DOI 10.1016/j.ultrasmedbio.2006.08.007; Whittaker JL, 2007, J ORTHOP SPORT PHYS, V37, P434, DOI 10.2519/jospt.2007.2350	21	24	25	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-8782	1469-7580		J ANAT	J. Anat.	JUN	2011	218	6					637	642		10.1111/j.1469-7580.2011.01365.x			6	Anatomy & Morphology	Anatomy & Morphology	758PE	WOS:000290176400006	21450014	Green Published, Bronze			2021-06-18	
J	Garcia, AN; Shah, MA; Dixon, CE; Wagner, AK; Kline, AE				Garcia, Alexandra N.; Shah, Mansi A.; Dixon, C. Edward; Wagner, Amy K.; Kline, Anthony E.			Biologic and Plastic Effects of Experimental Traumatic Brain Injury Treatment Paradigms and Their Relevance to Clinical Rehabilitation	PM&R			English	Article							CONTROLLED CORTICAL IMPACT; FACTOR MESSENGER-RNA; RECEPTOR AGONIST 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; BAY X 3702; ENVIRONMENTAL ENRICHMENT; COGNITIVE DEFICITS; HEAD-INJURY; CHOLINE-ACETYLTRANSFERASE; NEUROBEHAVIORAL RECOVERY; CEREBRAL METABOLISM	Neuroplastic changes, whether induced by traumatic brain injury (TBI) or therapeutic interventions, alter neurobehavioral outcome. Here we present several treatment strategies that have been evaluated by using experimental TBI models and discuss potential mechanisms of action (ie, plasticity) and how such changes affect function. PM R 2011;3:S18-S27	[Kline, Anthony E.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Ctr Neural Basis Cognit, Dept Phys Med & Rehabil,Ctr Neurosci,Dept Psychol, Pittsburgh, PA 15213 USA; [Garcia, Alexandra N.] Arizona State Univ, Dept Psychol, Tempe, AZ 85287 USA; [Dixon, C. Edward] Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Neurol Surg, Dept Phys Med & Rehabil,Ctr Neurosci, Pittsburgh, PA 15213 USA	Kline, AE (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Ctr Neural Basis Cognit, Dept Phys Med & Rehabil,Ctr Neurosci,Dept Psychol, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD046700, R01 HD046700-04, R01 HD069620] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS060005, R01 NS060005-04, R01 NS060005-03] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD046700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER		Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Arciniegas D, 2000, J NEUROPSYCH CLIN N, V12, P77, DOI 10.1176/jnp.12.1.77; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6; Baxter MG, 1999, CURR OPIN NEUROBIOL, V9, P178, DOI 10.1016/S0959-4388(99)80024-5; Berchtold NC, 2001, EUR J NEUROSCI, V14, P1992, DOI 10.1046/j.0953-816x.2001.01825.x; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BLACKERBY W F, 1990, Brain Injury, V4, P167, DOI 10.3109/02699059009026162; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Buytaert KA, 2001, BRAIN RES, V894, P121, DOI 10.1016/S0006-8993(01)01987-4; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Chandler M C, 1988, Brain Inj, V2, P309; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Chen X, 2005, NEUROSCIENCE, V135, P11, DOI 10.1016/j.neuroscience.2005.05.041; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Cheng JP, 2007, NEUROSCI LETT, V416, P165, DOI 10.1016/j.neulet.2007.02.006; Clark WM, 1997, NEUROLOGY, V49, P671, DOI 10.1212/WNL.49.3.671; CRISMON ML, 1988, CLIN NEUROPHARMACOL, V11, P462, DOI 10.1097/00002826-198810000-00007; Darrah SH, 2011, J NEUROTRAUM, V28, P43, DOI 10.1089/neu.2010.1521; De Vry J, 1998, J PHARMACOL EXP THER, V284, P1082; De Vry J, 1998, EUR J PHARMACOL, V357, P1, DOI 10.1016/S0014-2999(98)00503-2; De Vry Jean, 1997, Drugs of the Future, V22, P341; de Witt BW, 2011, NEUROREHAB NEURAL RE, V25, P343, DOI 10.1177/1545968310390520; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Donat CK, 2008, BRAIN RES, V1246, P167, DOI 10.1016/j.brainres.2008.09.059; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Dossett LA, 2008, J TRAUMA, V64, P580, DOI 10.1097/TA.0b013e31816543dd; Dossett LA, 2008, SURG INFECT, V9, P41, DOI 10.1089/sur.2007.037; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; Duffau H, 2006, J CLIN NEUROSCI, V13, P885, DOI 10.1016/j.jocn.2005.11.045; Everitt BJ, 1997, ANNU REV PSYCHOL, V48, P649, DOI 10.1146/annurev.psych.48.1.649; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; Finger S, 2004, ARCH NEUROL-CHICAGO, V61, P283, DOI 10.1001/archneur.61.2.283; Gibbs RB, 2010, ENDOCR REV, V31, P224, DOI 10.1210/er.2009-0036; Gillespie LN, 2003, CLIN EXP PHARMACOL P, V30, P724, DOI 10.1046/j.1440-1681.2003.03909.x; Goldstein LB, 2002, NEUROREHAB NEURAL RE, V16, P321, DOI 10.1177/154596830201600402; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hernandez TD, 2006, J NEUROTRAUM, V23, P1211, DOI 10.1089/neu.2006.23.1211; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Hovda DA, 1996, J CEREBR BLOOD F MET, V16, P134, DOI 10.1097/00004647-199601000-00016; HOVDA DA, 1985, P W PHARMACOL SOC, V28, P209; Hughes S, 2005, BRAIN INJURY, V19, P1197, DOI 10.1080/02699050500309296; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; Karli DC, 1999, BRAIN INJURY, V13, P63, DOI 10.1080/026990599121908; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kleim JA, 2002, NEUROBIOL LEARN MEM, V77, P63, DOI 10.1006/nlme.2000.4004; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2007, CRIT CARE MED, V35, P919, DOI 10.1097/01.CCM.0000256722.88854.C0; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; Kline AE, 2008, NEUROSCI LETT, V448, P263, DOI 10.1016/j.neulet.2008.10.076; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; Kraus MF, 2005, BRAIN INJURY, V19, P471, DOI 10.1080/02699050400025059; KumeKick J, 1996, BRAIN RES, V738, P8, DOI 10.1016/0006-8993(96)00744-5; Lanari A, 2006, MECH AGEING DEV, V127, P158, DOI 10.1016/j.mad.2005.09.016; Leggio MG, 2005, BEHAV BRAIN RES, V163, P78, DOI 10.1016/j.bbr.2005.04.009; Leon-Carrion J, 2000, NEUROREHABILITATION, V14, P33; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Lu B, 1997, REV NEUROSCIENCE, V8, P1; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Matter AM, 2011, NEUROREHABIL NEURAL; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; McEwen BS, 2010, ANN NY ACAD SCI, V1204, pE38, DOI 10.1111/j.1749-6632.2010.05568.x; Mendelowitsch A, 2001, BRAIN RES, V901, P230, DOI 10.1016/S0006-8993(01)02359-9; Meneses A, 1999, NEUROSCI BIOBEHAV R, V23, P1111, DOI 10.1016/S0149-7634(99)00067-6; MEYER JS, 1993, NEUROL RES, V15, P362; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Montanez S, 2000, BRAIN RES, V860, P29, DOI 10.1016/S0006-8993(00)01951-X; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mufson Elliott J, 2008, Expert Rev Neurother, V8, P1703, DOI 10.1586/14737175.8.11.1703; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Murdoch I, 2002, J NEUROTRAUM, V19, P279, DOI 10.1089/08977150252807018; Nishibe M, 2010, J NEUROTRAUM, V27, P2221, DOI 10.1089/neu.2010.1456; O'Dell DM, 2000, BRAIN RES, V861, P325, DOI 10.1016/S0006-8993(00)02055-2; Olson AK, 2006, HIPPOCAMPUS, V16, P250, DOI 10.1002/hipo.20157; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; Powell JH, 1996, J NEUROL NEUROSUR PS, V60, P416, DOI 10.1136/jnnp.60.4.416; PULASKI KH, 1994, AM J OCCUP THER, V48, P263, DOI 10.5014/ajot.48.3.263; Queen SA, 1997, BRAIN RES, V777, P42, DOI 10.1016/S0006-8993(97)00717-8; Rampon C, 2000, P NATL ACAD SCI USA, V97, P12880, DOI 10.1073/pnas.97.23.12880; Roloff EV, 1999, CELL MOL LIFE SCI, V55, P601, DOI 10.1007/s000180050318; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sawyer E, 2008, ANN PHARMACOTHER, V42, P247, DOI 10.1345/aph.1K284; SCHALLERT T, 1986, BRAIN RES, V379, P104, DOI 10.1016/0006-8993(86)90261-1; Schmidt RH, 2000, J NEUROTRAUM, V17, P1129, DOI 10.1089/neu.2000.17.1129; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; Schneider WN, 1999, BRAIN INJURY, V13, P863; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shiel A, 2001, CLIN REHABIL, V15, P501, DOI 10.1191/026921501680425225; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DE, 1999, P NATL ACAD SCI USA, V96, P10893, DOI 10.1073/pnas.96.19.10893; Sozda CN, 2010, J NEUROTRAUM, V27, P1047, DOI 10.1089/neu.2010.1313; Spencer JL, 2008, FRONT NEUROENDOCRIN, V29, P219, DOI 10.1016/j.yfrne.2007.08.006; Spratt DI, 2008, AM J PHYSIOL-ENDOC M, V295, pE63, DOI 10.1152/ajpendo.00472.2007; Spratt DI, 2006, AM J PHYSIOL-ENDOC M, V291, pE631, DOI 10.1152/ajpendo.00467.2005; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Torasdotter M, 1998, BEHAV BRAIN RES, V93, P83, DOI 10.1016/S0166-4328(97)00142-3; Turner CA, 2003, PHYSIOL BEHAV, V80, P259, DOI 10.1016/j.physbeh.2003.07.008; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Vanderploeg RD, 2008, ARCH PHYS MED REHAB, V89, P2227, DOI 10.1016/j.apmr.2008.06.015; Verbois SL, 2003, NEUROSCIENCE, V119, P1199, DOI 10.1016/S0306-4522(03)00206-9; VONMONAKOW C, 1969, MOODS STATES MIND, P27; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; Wagner AK, 2007, J NEUROSURG, V106, P538, DOI 10.3171/jns.2007.106.4.538; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Wagner AK, 2009, J NEUROCHEM, V108, P986, DOI 10.1111/j.1471-4159.2008.05840.x; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Weaver CE, 1997, BRAIN RES, V761, P338, DOI 10.1016/S0006-8993(97)00449-6; Whyte J, 2008, AM J PHYS MED REHAB, V87, P85, DOI 10.1097/PHM.0b013e3181619609; Widenfalk J, 1999, NEUROSCI RES, V34, P125, DOI 10.1016/S0168-0102(99)00051-6; Wilson MS, 2003, AM J PHYS MED REHAB, V82, P871, DOI 10.1097/01.PHM.0000091982.33232.CB; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wu TS, 2005, J EMERG MED, V28, P289, DOI 10.1016/j.jemermed.2004.11.016; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; Yan HQ, 2007, BRAIN RES, V1134, P171, DOI 10.1016/j.brainres.2006.11.087; Zafonte RD, 1998, BRAIN INJURY, V12, P617; Zhang YQ, 1998, BRAIN RES, V784, P321, DOI 10.1016/S0006-8993(97)00502-7; Zhao CS, 2005, BEHAV BRAIN RES, V158, P211, DOI 10.1016/j.bbr.2004.09.001; Zhao LR, 2000, NEUROSCIENCE, V97, P177, DOI 10.1016/S0306-4522(00)00023-3; Zhu XL, 2007, BRAIN INJURY, V21, P681, DOI 10.1080/02699050701468941; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	150	24	24	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	JUN	2011	3	6		S			S18	S27		10.1016/j.pmrj.2011.03.017			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	961BB	WOS:000305437800004	21703575	Green Accepted			2021-06-18	
J	Kobeissy, FH; Guingab-Cagmat, JD; Razafsha, M; O'Steen, L; Zhang, ZQ; Hayes, RL; Chiu, WT; Wang, KKW				Kobeissy, Firas H.; Guingab-Cagmat, Joy D.; Razafsha, Mandi; O'Steen, Laura; Zhang, Zhiqun; Hayes, Ronald L.; Chiu, Wen-Ta; Wang, Kevin K. W.			Leveraging Biomarker Platforms and Systems Biology for Rehabilomics and Biologics Effectiveness Research	PM&R			English	Article							TRAUMATIC BRAIN-INJURY; NEURON-SPECIFIC ENOLASE; MINOR HEAD-INJURY; S-100 PROTEIN MEASUREMENTS; POST-CONCUSSION SYMPTOMS; LONG-TERM DISABILITY; OXIDATIVE LIPIDOMICS; CEREBROSPINAL-FLUID; UNITED-STATES; OUTCOME PREDICTION	Although traumatic brain injury (TBI) remains a major health problem, with approximately 2 million incidents occurring annually in the United States, no therapeutic agents to treat TBI have been approved by the Food and Drug Administration despite several clinical trials. It is estimated that 3.5 million Americans now have a lifelong condition that might be termed "chronic traumatic brain, injury disease." Some health care providers categorize TBI as an "event" for which patients require brief periods of rehabilitation with no further treatment. On the contrary, TBI should be seen as a chronic disease process that fits the World Health Organization definition as being a non-reversible pathologic condition requiring special rehabilitation training. Among the major obstacles that contribute to this type of misconception is the absence of brain injury specific diagnostic biomarker(s) that can indicate and monitor the long-term health status of patients with TBI after use of conventional therapeutics and a rehabilitation process. It is of interest that recent advances in genomics, proteomics, and systems biology have enabled us to use these high throughput based approaches in developing biomarkers and therapeutic targets in the area of TBI. One aim of this article is to provide an overview that evaluates the current status of TBI biomarker discovery using neuroproteomics/systems biology techniques, along with their clinical utilization. In addition, we discuss the need for strengthening the role of biomarker-based neuroproteomics/systems biology and its potential utility in the field of rehabilitation, which would lead to the establishment of rehabilomics studies, where biomarkers would indicate and predict the long-term efficacy and health status of patients with chronic TBI conditions. PM R 201,1;3:S139-S147	[Kobeissy, Firas H.; Guingab-Cagmat, Joy D.; Razafsha, Mandi; O'Steen, Laura; Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Ctr Neuroprote & Biomarkers Res, McKnight Brain Inst, Gainesville, FL 32611 USA; [Kobeissy, Firas H.; Guingab-Cagmat, Joy D.; Zhang, Zhiqun; Hayes, Ronald L.; Wang, Kevin K. W.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL 32615 USA; [Hayes, Ronald L.; Chiu, Wen-Ta; Wang, Kevin K. W.] Taipei Med Univ, Taipei, Taiwan	Wang, KKW (corresponding author), Univ Florida, Dept Psychiat, Ctr Neuroprote & Biomarkers Res, McKnight Brain Inst, Gainesville, FL 32611 USA.	kwang@banyanbio.com	Kobeissy, Firas/E-7042-2017	Kobeissy, Firas/0000-0002-5008-6944; Wang, Kevin/0000-0002-9343-6473			Adams JE, 1999, CLIN CHIM ACTA, V284, P127, DOI 10.1016/S0009-8981(99)00074-1; Adibhatla RM, 2007, FUTURE LIPIDOL, V2, P403, DOI 10.2217/17460875.2.4.403; [Anonymous], 2010, TRAUM BRAIN INJ MOD; Armstrong JD, 2006, PROTEOMICS, V6, P4724, DOI 10.1002/pmic.200500895; Assmus HE, 2006, EXPERT REV MOL DIAGN, V6, P891, DOI 10.1586/14737159.6.6.891; Bard J, 2007, MAMM GENOME, V18, P402, DOI 10.1007/s00335-007-9027-3; Barrett CL, 2006, CURR OPIN BIOTECH, V17, P488, DOI 10.1016/j.copbio.2006.08.001; Bayir H, 2007, ANN NEUROL, V62, P154, DOI 10.1002/ana.21168; Beltrao P, 2007, CURR OPIN STRUC BIOL, V17, P378, DOI 10.1016/j.sbi.2007.05.005; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Boettler T, 2007, DEUT MED WOCHENSCHR, V132, P2702, DOI 10.1055/s-2007-993122; Burgess JA, 2006, J PROTEOME RES, V5, P1674, DOI 10.1021/pr060160v; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Celis JE, 2004, MOL CELL PROTEOMICS, V3, P327, DOI 10.1074/mcp.M400009-MCP200; Chen S. S., 2007, DATA MINING BIOMEDIC, P1; Cockerham GC, 2009, J REHABIL RES DEV, V46, P811, DOI 10.1682/JRRD.2008.08.0109; Davidov EJ, 2003, DRUG DISCOV TODAY, V8, P175, DOI 10.1016/S1359-6446(03)02600-X; Davidsson P, 2005, DIS MARKERS, V21, P81, DOI 10.1155/2005/848676; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Drake AI, 2010, NEUROREHABILITATION, V26, P183, DOI 10.3233/NRE-2010-0554; Dumont D, 2004, PROTEOMICS, V4, P2117, DOI 10.1002/pmic.200300715; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; Guan ZQ, 2009, J CHROMATOGR B, V877, P2814, DOI 10.1016/j.jchromb.2009.03.002; Guingab JD, ESSENTIALS IN PRESS; Guzel A, 2008, NEUROSURG REV, V31, P439, DOI 10.1007/s10143-008-0148-2; Hammack BN, 2004, MULT SCLER, V10, P245, DOI 10.1191/1352458504ms1023oa; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Hucka M, 2003, BIOINFORMATICS, V19, P524, DOI 10.1093/bioinformatics/btg015; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; JENNETT B, 1975, LANCET, V1, P480; Kagan VE, 2006, CHEM-BIOL INTERACT, V163, P15, DOI 10.1016/j.cbi.2006.04.019; Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727; Kagan VE, 2004, ANTIOXID REDOX SIGN, V6, P199, DOI 10.1089/152308604322899260; Kagan VE, 2004, FREE RADICAL BIO MED, V37, P1963, DOI 10.1016/j.freeradbiomed.2004.08.016; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; Kitano H, 2002, SCIENCE, V295, P1662, DOI 10.1126/science.1069492; Kitano H, 2002, NATURE, V420, P206, DOI 10.1038/nature01254; Kobeissy FH, 2008, PROTEOM CLIN APPL, V2, P1467, DOI 10.1002/prca.200800011; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Koizumi S, 2010, NEUROSCIENCE, V168, P219, DOI 10.1016/j.neuroscience.2010.03.056; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McFadyen BJ, 2009, ARCH PHYS MED REHAB, V90, P1596, DOI 10.1016/j.apmr.2009.03.010; Meric E, 2010, J EMERG MED, V38, P297, DOI 10.1016/j.jemermed.2007.11.032; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Niemoller TD, 2010, PROSTAG OTH LIPID M, V91, P85, DOI 10.1016/j.prostaglandins.2009.09.005; Ogawa T, 1992, Acta Neurochir Suppl (Wien), V55, P8; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RIEDERER BM, 1986, J CELL BIOL, V102, P2088, DOI 10.1083/jcb.102.6.2088; Romeo MJ, 2005, EXPERT REV PROTEOMIC, V2, P57, DOI 10.1586/14789450.2.1.57; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Servadei F, 2000, NEUROSURGERY, V46, P70; Shin BK, 2002, J MAMMARY GLAND BIOL, V7, P407, DOI 10.1023/A:1024038132381; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; Sinclair AJ, 2010, NMR BIOMED, V23, P123, DOI 10.1002/nbm.1428; SINDIC CJM, 1982, J NEUROL NEUROSUR PS, V45, P1130, DOI 10.1136/jnnp.45.12.1130; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Stapert S, 2005, EUR NEUROL, V53, P22, DOI 10.1159/000083678; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; Svetlov SI, 2006, BIOMARKERS, V11, P355, DOI 10.1080/13547500600775110; Tanaka Hiroki, 2009, Tanpakushitsu Kakusan Koso, V54, P224; Tanaka K, 1988, RAPID COMMUN MASS SP, V2, P3; Tepe V, SCREENING DIAGNOSIS; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Townend W, 2006, INJURY, V37, P1098, DOI 10.1016/j.injury.2006.07.014; Turner-Stokes L., 2005, MULTIDISCIPLINARY RE; Tyurin VA, 2008, METHOD ENZYMOL, V442, P375, DOI [10.1016/S0076-6879(08)01419-5, 10.1017/S0076-6879(08)01419-5]; Tyurin VA, 2010, METHODS MOL BIOL, V610, P353, DOI 10.1007/978-1-60327-029-8_21; Vance DE, 2008, N COMP BIOC, P1; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Viant MR, 2005, NMR BIOMED, V18, P507, DOI 10.1002/nbm.980; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; Wasserman L, 2008, BRAIN INJURY, V22, P811, DOI 10.1080/02699050802372166; Waybright T, 2010, J PROTEOMICS, V73, P1156, DOI 10.1016/j.jprot.2010.02.004; Wenk MR, 2005, NAT REV DRUG DISCOV, V4, P594, DOI 10.1038/nrd1776; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; Wiesmann M, 2010, ACTA NEUROL SCAND, V121, P178, DOI 10.1111/j.1600-0404.2009.01196.x; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	93	24	24	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	JUN	2011	3	6		S			S139	S147		10.1016/j.pmrj.2011.02.012			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	961BB	WOS:000305437800023	21703572				2021-06-18	
J	Namiki, J; Yamazaki, M; Funabiki, T; Hori, S				Namiki, Jun; Yamazaki, Motoyasu; Funabiki, Tomohiro; Hori, Shingo			Inaccuracy and misjudged factors of Glasgow Coma Scale scores when assessed by inexperienced physicians	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Brain injury; Glasgow Coma Scale; Triage; Emergency department; Simulation; Consciousness level	LINEAR-REGRESSION PREDICTION; INTERRATER RELIABILITY; IMPAIRED CONSCIOUSNESS; EMERGENCY-DEPARTMENT; OBSERVER VARIABILITY; INTUBATED PATIENTS; VERBAL SCORE; INJURY; ADULTS; EYE	Objectives: Appropriate triage of a large number of patients with head injury is crucial in the emergency department (ED) as well as in the field. Traumatic brain injury (TBI) is primarily assessed using the Glasgow Coma Scale (GCS) to evaluate consciousness. However, GCS score assignment is far from sufficiently reliable for correct assessment, especially with inexperienced users. The purpose of this study was to reveal what factors are misjudged when assessed by inexperienced medical personnel. Methods: We analyzed GCS eye, verbal, and motor response (EVM) scoring profiles conducted by postgraduate year 1 junior residents (n = 94) before they began residency in specific departments. GCS assessment was tested using a video simulation that portrayed mock patients with eight different levels of consciousness that are frequently encountered in trauma patients. Results: On average, 26 +/- 18% of examinees failed to provide the correct EVM profiles for the eight selected consciousness levels. Primary misjudged GCS factors belonged to two categories: the assessment of "confused conversation (V4)", and the assessment of "withdrawal motor response (M4)". Conclusion: Additional instruction regarding the specific misjudged factors identified in this study may help inexperienced medical personnel improve the reliability of GCS score assignment to casualties with TBI. (C) 2011 Elsevier B.V. All rights reserved.	[Namiki, Jun; Yamazaki, Motoyasu; Funabiki, Tomohiro; Hori, Shingo] Keio Univ Sch Med, Dept Emergency & Crit Care Med, Shinjuku Ku, Tokyo 1608582, Japan	Namiki, J (corresponding author), Keio Univ Sch Med, Dept Emergency & Crit Care Med, Shinjuku Ku, Shinanomachi 35, Tokyo 1608582, Japan.	namiki@sc.itc.keio.ac.jp			General Insurance Association of Japan	The authors thank Mr. Kiyotaka Yasui, Department of Medical Education Center, Keio University School of Medicine, and the medical students at Keio University who are members of the Keio ACLS Popularizing and Promoting Association, for the production of the video simulation. This work was partly supported by the General Insurance Association of Japan.	BRAIN TRAUM FD, 2000, J NEUROTRAUM, V17, P563; Buechler CM, 1998, J TRAUMA, V45, P429, DOI 10.1097/00005373-199809000-00001; Crossman J, 1998, INJURY, V29, P435, DOI 10.1016/S0020-1383(98)00079-5; Dunning J, 2004, J NEUROTRAUM, V21, P877, DOI 10.1089/0897715041526122; Elliott M, 1996, J Neurosci Nurs, V28, P213; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P1180, DOI 10.1136/jnnp.2007.135178; Gill M, 2007, ANN EMERG MED, V49, P403, DOI 10.1016/j.annemergmed.2006.03.031; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Heard K, 2004, HUM EXP TOXICOL, V23, P197, DOI 10.1191/0960327104ht436oa; Holdgate Anna, 2006, Emerg Med Australas, V18, P379, DOI 10.1111/j.1742-6723.2006.00867.x; JENNETT B, 1977, LANCET, V1, P878; Juarez V J, 1995, J Neurosci Nurs, V27, P283; LINDSAY KW, 1983, J NEUROSURG, V58, P57, DOI 10.3171/jns.1983.58.1.0057; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MENEGAZZI JJ, 1993, J TRAUMA, V34, P46, DOI 10.1097/00005373-199301000-00008; Meredith W, 1998, J TRAUMA, V44, P839, DOI 10.1097/00005373-199805000-00016; *NICE CLIN GUID DE, 2007, NICE CLIN GUID 56 HE, P14; *NICE CLIN GUID DE, 2007, NICE CLIN GUID 56 HE, P22; Riechers RG, 2005, J NEUROTRAUM, V22, P1327, DOI 10.1089/neu.2005.22.1327; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; Rutledge R, 1996, J TRAUMA, V41, P514, DOI 10.1097/00005373-199609000-00022; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; TEASDALE G, 1978, J NEUROL NEUROSUR PS, V41, P603, DOI 10.1136/jnnp.41.7.603; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; TESSERIS J, 1991, ACTA NEUROCHIR, V110, P65, DOI 10.1007/BF01402050	26	24	24	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	JUN	2011	113	5					393	398		10.1016/j.clineuro.2011.01.001			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	775HG	WOS:000291449000009	21295908				2021-06-18	
J	Tu, LV; Togher, L; Power, E				Tu, Lan Vy; Togher, Leanne; Power, Emma			The impact of communication partner and discourse task on a person with traumatic brain injury: The use of multiple perspectives	BRAIN INJURY			English	Article						Traumatic brain injury; communication partner; conversation; communication skills; rehabilitation	QUALITY-OF-LIFE; REHABILITATION; PEOPLE; IMPAIRMENT; MANAGEMENT; CHILDREN; DEFICITS; ABILITY; INTERVENTION; COMPETENCE	Primary objective: This study investigated whether varying the communication partner (i.e. mother vs paid caregiver) and discourse task (i.e. casual conversation vs purposeful conversation vs problem-solving task) affected the nature of information exchange for a person with traumatic brain injury (TBI). Methods: Three discourse tasks were recorded involving a TBI participant with his mother and, on a separate occasion, with his paid caregiver. Texts were analysed using multiple perspectives, comprising exchange structure analysis, ratings by independent observers and self and others' perceptions of communication. Results: The TBI participant was more likely to give information when interacting with his mother than with the paid caregiver, as shown by exchange structure analysis. The participants also varied the way they exchanged information according to the discourse tasks. Results from exchange structure analysis were corroborated by the ratings by independent observers. Additionally, the mother was found to perceive that the TBI participant 'usually' had communication difficulty, while the caregiver perceived that he 'rarely' had communication difficulty. Conclusion: The nature of information exchange for a person with TBI varied with the communication partner and discourse task. The multiple perspectives used in this study appeared promising for the examination of discourse ability following TBI.	[Tu, Lan Vy] Univ Sydney, Fac Hlth Sci, Discipline Speech Pathol, Lidcombe, NSW 1825, Australia	Tu, LV (corresponding author), Univ Sydney, Fac Hlth Sci, Discipline Speech Pathol, 75 E St,POB 170, Lidcombe, NSW 1825, Australia.	latu5513@uni.sydney.edu.au	Togher, Leanne/AAC-7083-2019; Power, Emma/A-9263-2015	Power, Emma/0000-0002-2638-0406; Togher, Leanne/0000-0002-4518-6748	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia	This research was funded by a National Health and Medical Research Council Project Grant. The granting body did not have any input into the research study design, implementation and outcomes. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.	Adamovich B. B., 1992, SCALES COGNITIVE ABI; Berry M., 1981, STUDIES DISCOURSE AN, P120; BODY R, 1999, BRAIN DAM B, P147; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Carnevale GJ, 2006, ARCH PHYS MED REHAB, V87, P1289, DOI 10.1016/j.apmr.2006.06.010; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Coelho C. A., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; Coelho CA, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; Coelho Carl A., 2007, Seminars in Speech and Language, V28, P122, DOI 10.1055/s-2007-970570; Douglas JM, 2007, APHASIOLOGY, V21, P1181, DOI 10.1080/02687030600980950; Douglas JM, 2007, J HEAD TRAUMA REHAB, V22, P31, DOI 10.1097/00001199-200701000-00004; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Eggins S., 1997, ANAL CASUAL CONVERSA; EHRLICH JS, 1988, J COMMUN DISORD, V21, P1, DOI 10.1016/0021-9924(88)90006-8; Fasotti L, 2000, NEUROPSYCHOL REHABIL, V10, P47, DOI 10.1080/096020100389291; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Godfrey HPD, 2000, APHASIOLOGY, V14, P433, DOI 10.1080/026870300401441; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Halliday M., 1994, INTRO FUNCTIONAL GRA, V3rd; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; HUNT KW, 1970, MONOGR SOC RES CHILD, V35, P1; Kagan Aura, 2004, Top Stroke Rehabil, V11, P67; Kalpakjian CZ, 2004, AM J PHYS MED REHAB, V83, P255, DOI 10.1097/01.PHM.0000118033.07952.8C; Kendall E, 1997, J HEAD TRAUMA REHAB, V12, P68, DOI 10.1097/00001199-199706000-00007; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Kennedy Mary R. T, 2005, Seminars in Speech and Language, V26, P242, DOI 10.1055/s-2005-922103; Kennedy MRT, 2004, AM J SPEECH-LANG PAT, V13, P142, DOI 10.1044/1058-0360(2004/015); Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kilov AM, 2009, APHASIOLOGY, V23, P584, DOI 10.1080/02687030701855382; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Larkins B, 1999, ASIA PACIFIC J SPEEC, V4, P183; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Linscott RJ, 1996, BRAIN INJURY, V10, P397, DOI 10.1080/026990596124269; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; Marshall RC, 2003, BRAIN INJURY, V17, P589, DOI 10.1080/0269905031000088496; Martin J. R., 1992, ENGLISH TEXT SYSTEM; McCluskey AE, 2000, BRAIN INJURY, V14, P943, DOI 10.1080/02699050050191896; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Rosenthal M., 1999, REHABILITATION ADULT; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; SPENCER EL, 2005, THESIS U SYDNEY SYDN; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 1997, APHASIOLOGY, V11, P491, DOI 10.1080/02687039708248486; Togher L, 1996, DISABIL REHABIL, V18, P559, DOI 10.3109/09638289609166317; Togher L, 2004, APHASIOLOGY, V18, P313, DOI 10.1080/02687030344000535; TOGHER L, 1998, THESIS NSW U SYDNEY; TOGHER L, 2006, BRAIN IMPAIR, V7, P190, DOI DOI 10.1375/brim.7.3.190; Togher L., 1998, ANAL INTERPERSONAL M; TOGHER L, 2002, INT APH RES C BRISB; Togher L, 2010, APHASIOLOGY, V24, P914, DOI 10.1080/02687030903422478; Ventola E., 1987, STRUCTURE SOCIAL INT; Wade SL, 2006, J HEAD TRAUMA REHAB, V21, P57, DOI 10.1097/00001199-200601000-00006; Ylvisaker M., 1993, STAFF DEV CLIN INTER, P57	59	24	24	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2011	25	6					560	580		10.3109/02699052.2011.571655			21	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	758FF	WOS:000290146300003	21534734				2021-06-18	
J	Nelson, NW; Hoelzle, JB; McGuire, KA; Ferrier-Auerbach, AG; Charlesworth, MJ; Sponheim, SR				Nelson, Nathaniel W.; Hoelzle, James B.; McGuire, Kathryn A.; Ferrier-Auerbach, Amanda G.; Charlesworth, Molly J.; Sponheim, Scott R.			Neuropsychological evaluation of blast-related concussion: Illustrating the challenges and complexities through OEF/OIF case studies	BRAIN INJURY			English	Article						Traumatic brain injury; blast injury; neuropsychological injury	TRAUMATIC BRAIN-INJURY; POSTCONCUSSIVE SYMPTOMS; POSTTRAUMATIC-STRESS; MILITARY TBI; VETERANS; IRAQ; PERFORMANCE; DEPLOYMENT; CONTEXT; METAANALYSIS	Background/objective: Soldiers of Operations Enduring Freedom (OEF) and Iraqi Freedom (OIF) sustain blast-related mild traumatic brain injury (concussion) with alarming regularity. This study discusses factors in addition to concussion, such as co-morbid psychological difficulty (e. g. post-traumatic stress) and symptom validity concerns that may complicate neuropsychological evaluation in the late stage of concussive injury. Case report: The study presents the complexities that accompany neuropsychological evaluation of blast concussion through discussion of three case reports of OEF/OIF personnel. Discussion: The authors emphasize uniform assessment of blast concussion, the importance of determining concussion severity according to acute-injury characteristics and elaborate upon non-concussion-related factors that may impact course of cognitive limitation. The authors conclude with a discussion of the need for future research examining the impact of blast concussion (particularly recurrent concussion) and neuropsychological performance.	[Nelson, Nathaniel W.] Univ St Thomas, GSPP, MOH 217, Minneapolis, MN 55403 USA; [Nelson, Nathaniel W.; McGuire, Kathryn A.; Ferrier-Auerbach, Amanda G.; Charlesworth, Molly J.; Sponheim, Scott R.] Minneapolis VA Med Ctr, Minneapolis, MN USA; [Hoelzle, James B.] Marquette Univ, Dept Psychol, Milwaukee, WI 53233 USA; [McGuire, Kathryn A.; Ferrier-Auerbach, Amanda G.; Sponheim, Scott R.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA	Nelson, NW (corresponding author), Univ St Thomas, GSPP, MOH 217, LaSalle Ave, Minneapolis, MN 55403 USA.	nels0600@stthomas.edu	Sponheim, Scott/J-3857-2017	Sponheim, Scott/0000-0002-2782-0856	Congressionally Directed Medical Research ProgramsUnited States Department of Defense [PT074550, W81XWH-08-2-0038]; Minnesota Veterans Research Institute (MVRI)	This study was supported in part by Grants funded by the Congressionally Directed Medical Research Programs (number PT074550, contract W81XWH-08-2-0038) to Scott R. Sponheim, PhD, and the Minnesota Veterans Research Institute (MVRI) to Nathaniel W. Nelson, PhD.	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benedict R., 1997, BRIEF VISUOSPATIAL M; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Blake D. D., 1990, BEHAV THER, V13, P187; Boone KB, 2003, CLIN NEUROPSYCHOL, V17, P244, DOI 10.1076/clin.17.2.244.16497; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Butcher JN, 1989, MANUAL ADM SCORING M; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Delis DC, 2000, CALIFORNIA VERBAL LE; Diehr MC, 1998, ASSESSMENT, V5, P375, DOI 10.1177/107319119800500407; FIRST MB, 2007, STRUCTURED CLIN INTW; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; General Accounting Office, 2008, VA HLTH CAR MILD TRA; Gladsjo JA, 1999, ASSESSMENT, V6, P147, DOI 10.1177/107319119900600204; Golden C., 1978, STROOP COLOR WORD TE; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Heaton R., 1993, WISCONSIN CARD SORTI; Heaton R.K., 1991, COMPREHENSIVE NORMS; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Kaplan E., 1983, BOSTON NAMING TEST; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; King JH, 2002, CLIN NEUROPSYCHOL, V16, P506, DOI 10.1076/clin.16.4.506.13912; KROENKE K, 1993, ARCH INTERN MED, V153, P2474, DOI 10.1001/archinte.153.21.2474; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2008, MILD TRAUMATIC BRAIN; McCrea M, 2008, CLIN NEUROPSYCHOL, V22, P10, DOI 10.1080/13854040701760981; Meyers J., 1995, MEYERS SCORING SYSTE; Murray CK, 2005, MIL MED, V170, P516, DOI 10.7205/MILMED.170.6.516; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; *PSYCH CORP, 1994, VIG W CONT PERF TEST; Psychological Corporation, 2001, WECHSL TEST AD READ; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; Ruff RM, 1999, STUD NEUROPSYCHOL DE, P315; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Tanielian T, 2008, INVISIBLE WOUNDS WAR; TEASDALE G, 1974, LANCET, V2, P81; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tombaugh TN, 1996, TEST MEMORY MALINGER; VANDERPLOEG RD, 2009, NEUROPSYCHOLOGY MALI, P41; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M	57	24	24	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2011	25	5					511	525		10.3109/02699052.2011.558040			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	745KQ	WOS:000289164700009	21405948	Green Published			2021-06-18	
J	Sher, L				Sher, L.			Brain-derived neurotrophic factor and suicidal behavior	QJM-AN INTERNATIONAL JOURNAL OF MEDICINE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; NEURODEGENERATIVE DISORDERS; GENE-EXPRESSION; BDNF; DEPRESSION; PATHOGENESIS; INJURY; 5-HT; AREA	Studies of the neurobiology of suicidal behavior have become an important and integral part of psychiatric research. Over the past several years, studies of the role of brain-derived neurotrophic factor (BDNF) in the pathophysiology of suicidality have attracted significant interest of researchers. Multiple lines of evidence including studies of levels of BDNF in blood cells and plasma of suicidal patients, postmortem brain studies in suicidal subjects with or without depression, and genetic association studies linking BDNF to suicide suggest that suicidal behavior may be associated with a decrease in BDNF functioning. Studies of the BDNF function are important for suicide research and prevention because of the multiple reasons including the following: (i) BDNF plays a role in the pathophysiology of depression, post-traumatic stress disorder, substance use disorders and other conditions associated with suicidal behavior. Treatment-induced enhancements of BDNF can facilitate neural integrity and recovery of function in psychiatric disorders, and consequently prevent suicidal behavior; (ii) abnormal BDNF function may be associated with elevated suicidality independently of psychiatric diagnoses. It is possible that treatment-induced improvement in the BDNF function prevents suicidal behavior independently of improvement in psychiatric disorders; (iii) BDNF may be a biological marker of suicidal behavior in certain patient populations. It is to be hoped that the studies of the neurobiology of suicidal behavior will lead to the development of new methods of suicide prevention.	James J Peters Vet Adm Med Ctr, Mt Sinai Sch Med, Dept Psychiat, New York, NY 10468 USA	Sher, L (corresponding author), James J Peters Vet Adm Med Ctr, Mt Sinai Sch Med, Dept Psychiat, 130 W Kingsbridge Rd, New York, NY 10468 USA.	drleosher@gmail.com					*AM FDN SUIC PREV, FACT FIG INT STAT; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; Carballo Juan J, 2006, Int J Adolesc Med Health, V18, P15; Castren E, 2010, CNS DRUGS, V24, P1, DOI 10.2165/11530010-000000000-00000; Dell'Osso L, 2009, PROG NEURO-PSYCHOPH, V33, P899, DOI 10.1016/j.pnpbp.2009.04.018; Dwivedi Y, 2003, ARCH GEN PSYCHIAT, V60, P804, DOI 10.1001/archpsyc.60.8.804; Dwivedi Y, 2009, NEUROPSYCH DIS TREAT, V5, P433; Dwivedi Y, 2010, ANN MED, V42, P87, DOI 10.3109/07853890903485730; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Hashimoto K, 2010, PSYCHIAT CLIN NEUROS, V64, P341, DOI 10.1111/j.1440-1819.2010.02113.x; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Karege F, 2005, MOL BRAIN RES, V136, P29, DOI 10.1016/j.molbrainres.2004.12.020; Keller S, 2010, ARCH GEN PSYCHIAT, V67, P258, DOI 10.1001/archgenpsychiatry.2010.9; Kim YK, 2007, PROG NEURO-PSYCHOPH, V31, P78, DOI 10.1016/j.pnpbp.2006.06.024; Lee BH, 2010, J AFFECT DISORDERS, V125, P369, DOI 10.1016/j.jad.2010.01.074; Logrip ML, 2009, J NEUROCHEM, V109, P1459, DOI 10.1111/j.1471-4159.2009.06073.x; Mann JJ, 2003, NAT REV NEUROSCI, V4, P819, DOI 10.1038/nrn1220; Mattson MP, 2004, TRENDS NEUROSCI, V27, P589, DOI 10.1016/j.tins.2004.08.001; McEwen BS, 2000, BIOL PSYCHIAT, V48, P721, DOI 10.1016/S0006-3223(00)00964-1; *NAT I MENT HLTH, SUIC US STAT PREV; *OFF NAT STAT, SUIC UK SUIC INCR 20; Pardon MC, 2010, VITAM HORM, V82, P185, DOI 10.1016/S0083-6729(10)82010-2; Pizarro JM, 2004, BRAIN RES, V1025, P10, DOI 10.1016/j.brainres.2004.06.085; PREGELJ P, J AFFECT DI IN PRESS; Reichardt LF, 2006, PHILOS T R SOC B, V361, P1545, DOI 10.1098/rstb.2006.1894; Sen S, 2008, BIOL PSYCHIAT, V64, P527, DOI 10.1016/j.biopsych.2008.05.005; Sher L, 2004, QJM-INT J MED, V97, P677, DOI 10.1093/qjmed/hch106; Shirayama Y, 2002, J NEUROSCI, V22, P3251, DOI 10.1523/JNEUROSCI.22-08-03251.2002; SMITH MA, 1995, J NEUROSCI, V15, P1768; TADIC A, PROG NEUROP IN PRESS; Thomas MJ, 2008, BRIT J PHARMACOL, V154, P327, DOI 10.1038/bjp.2008.77; Vargas-Perez H, 2009, SCIENCE, V324, P1732, DOI 10.1126/science.1168501; Zetterstrom TSC, 1999, NEUROPHARMACOLOGY, V38, P1063, DOI 10.1016/S0028-3908(99)00022-2	33	24	26	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1460-2725	1460-2393		QJM-INT J MED	QJM-An Int. J. Med.	MAY	2011	104	5					455	458		10.1093/qjmed/hcq207			4	Medicine, General & Internal	General & Internal Medicine	754EY	WOS:000289838200017	21051476	Bronze			2021-06-18	
J	Blennow, K; Jonsson, M; Andreasen, N; Rosengren, L; Wallin, A; Hellstrom, PA; Zetterberg, H				Blennow, K.; Jonsson, M.; Andreasen, N.; Rosengren, L.; Wallin, A.; Hellstrom, P. A.; Zetterberg, H.			No neurochemical evidence of brain injury after blast overpressure by repeated explosions or firing heavy weapons	ACTA NEUROLOGICA SCANDINAVICA			English	Article						biomarkers; blast injury; cerebrospinal fluid; neurofilament protein; tau protein; traumatic brain injury; war injury	FIBRILLARY ACIDIC PROTEIN; CEREBROSPINAL-FLUID; NEUROFILAMENT PROTEIN; TAU-PROTEIN; RAT-BRAIN; CSF; MARKER; IRAQ; DEMENTIA; EXPOSURE	Background - Psychiatric and neurological symptoms are common among soldiers exposed to blast without suffering a direct head injury. It is not known whether such symptoms are direct consequences of blast overpressure. Objective - To examine if repeated detonating explosions or firing if of heavy weapons is associated with neurochemical evidence of brain damage. Materials and methods - Three controlled experimental studies. In the first, army officers were exposed to repeated firing of a FH77B howitzer or a bazooka. Cerebrospinal fluid (CSF) was taken post-exposure to measure biomarkers for brain damage. In the second, officers were exposed for up to 150 blasts by firing a bazooka, and in the third to 100 charges of detonating explosives of 180 dB. Serial serum samples were taken after exposure. Results were compared with a control group consisting of 19 unexposed age-matched healthy volunteers. Results - The CSF biomarkers for neuronal/axonal damage (tau and neurofilament protein), glial cell injury (GFAP and S-100b), blood-brain barrier damage (CSF/serum albumin ratio) and hemorrhages (hemoglobin and bilirubin) and the serum GFAP and S-100b showed normal and stable levels in all exposed officers. Discussion - Repeated exposure to high-impact blast does not result in any neurochemical evidence of brain damage. These findings are of importance for soldiers regularly exposed to high-impact blast when firing artillery shells or other types of heavy weapons.	[Blennow, K.; Zetterberg, H.] Univ Gothenburg, Clin Neurochem Lab, Inst Neurosci & Physiol, Dept Psychiat & Neurochem,Sahlgrenska Acad, Gothenburg, Sweden; [Jonsson, M.; Wallin, A.] Univ Gothenburg, Dept Neuropsychiat, Inst Neurosci & Physiol, Dept Psychiat & Neurochem,Sahlgrenska Acad, Gothenburg, Sweden; [Andreasen, N.] Karolinska Univ Hosp, Dept Geriatr Med, Huddinge, Sweden; [Rosengren, L.] Univ Gothenburg, Dept Neurol, Gothenburg, Sweden; [Hellstrom, P. A.] Swedish Armed Forces, Mil Headquarters, Stockholm, Sweden	Blennow, K (corresponding author), Univ Gothenburg, Sahlgrenska Univ Hosp Molndal, Clin Neurochem Lab, SE-43180 Molndal, Sweden.	kaj.blennow@neuro.gu.se		Rosengren, Lars/0000-0003-0505-8896	Swedish Armed Forces; Sahlgrenska University Hospital; University of Gothenburg	Dr Hellstrom is an employee of the Swedish Armed Forces, Military Headquarters, Stockholm. Funded by the Swedish Armed Forces, The Sahlgrenska University Hospital, and University of Gothenburg. We thank Monica Christiansson, Asa Kallen, Christina Sjodin, Steinar Syversen, Ewa Styrud, Christina Holmberg, and Ingela Isblad, for technical assistance.	Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Blennow K, 1995, MOL CHEM NEUROPATHOL, V26, P231, DOI 10.1007/BF02815140; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Goncalves CA, 2008, CLIN BIOCHEM, V41, P755, DOI 10.1016/j.clinbiochem.2008.04.003; HAYAKAWA T, 1979, STROKE, V10, P685, DOI 10.1161/01.STR.10.6.685; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Hesse Camilla, 2000, Journal of Alzheimer's Disease, V2, P199; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hotopf M, 2006, LANCET, V367, P1731, DOI 10.1016/S0140-6736(06)68662-5; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Lidstrom AM, 2001, J ALZHEIMERS DIS, V3, P435, DOI 10.3233/JAD-2001-3501; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Nylen K, 2006, NEUROSCI LETT, V404, P132, DOI 10.1016/j.neulet.2006.05.029; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Otto M, 1997, NEUROSCI LETT, V225, P210, DOI 10.1016/S0304-3940(97)00215-2; Petzold A, 2007, NEURODEGENER DIS, V4, P185, DOI 10.1159/000101843; Petzold A, 2006, NEUROCRIT CARE, V4, P153, DOI 10.1385/NCC:4:2:153; ROSENGREN LE, 1994, J NEUROSCI METH, V51, P197, DOI 10.1016/0165-0270(94)90011-6; Rosengren LE, 1996, J NEUROCHEM, V67, P2013, DOI 10.1046/j.1471-4159.1996.67052013.x; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo Annette, 2001, Pathophysiology, V8, P105, DOI 10.1016/S0928-4680(01)00067-0; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Sjogren M, 2000, NEUROLOGY, V54, P1960, DOI 10.1212/WNL.54.10.1960; Sjogren M, 2001, J NEUROSCI RES, V66, P510, DOI 10.1002/jnr.1242; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; TIBBLING G, 1977, SCAND J CLIN LAB INV, V37, P385, DOI 10.3109/00365517709091496; Zachrisson OCG, 2000, PSYCHIAT RES, V96, P157, DOI 10.1016/S0165-1781(00)00202-X; Zetterberg H, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.037143; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277	31	24	24	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6314	1600-0404		ACTA NEUROL SCAND	Acta Neurol. Scand.	APR	2011	123	4					245	251		10.1111/j.1600-0404.2010.01408.x			7	Clinical Neurology	Neurosciences & Neurology	728GR	WOS:000287863100003	20637009				2021-06-18	
J	Helmes, E; Ostbye, T; Steenhuis, RE				Helmes, Edward; Ostbye, Truls; Steenhuis, Runa E.			Incremental contribution of reported previous head injury to the prediction of diagnosis and cognitive functioning in older adults	BRAIN INJURY			English	Article						Dementia; risk factors; head injury; older adults; longitudinal study	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; RISK-FACTORS; NEUROPSYCHOLOGICAL FUNCTION; HEALTH; RECOVERY; PERFORMANCE; DEMENTIA; MILD; METAANALYSIS	Background: Severe brain injuries may be a risk factor for the development of dementia in later life. Less severe incidents with relatively short or even no loss of consciousness may not carry the same prognosis. Objectives: This study used data from the first two waves of the Canadian Study of Health and Ageing (CSHA-1 and CSHA-2) to investigate two questions. (1) Does a history of head injury improve the prediction of the diagnosis of dementia? This analysis was based on the 921 elderly individuals who underwent a clinical assessment in CSHA-2 and, 5 years earlier, had reported whether or not they had had a head injury. (2) Does adding information about a history of head injury improve the prediction of neuropsychological test scores? This second analysis included 585 elderly people who underwent neuropsychological assessment in both waves and who also reported whether or not they had had a history of mild or moderate-to-severe head injury. Results: Results showed that the inclusion of head injury information did not improve the prediction of diagnostic outcome of dementia. Age and overall cognitive status were associated with most neuropsychological test scores, more so than the more limited influence of chronic health problems, which was associated with about half of the neuropsychological measures.	[Helmes, Edward] James Cook Univ, Dept Psychol, Townsville, Qld 4811, Australia; [Ostbye, Truls] Duke Univ, Dept Family & Community Med, Chapel Hill, NC USA	Helmes, E (corresponding author), James Cook Univ, Dept Psychol, Townsville, Qld 4811, Australia.	edward.helmes@jcu.edu.au			Health Canada's National Health Research Development Program (NHRDP); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission; Pfizer Canada Inc. through MRC/PMACUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Pfizer Canada Inc. through NHRDP; Bayer Inc.Bayer AG; B.C. Health Research Foundation; Canadian Institute for Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Merck-Frosst; Jansen-Ortho	Core funding for Phases 1 & 2 of the CSHA was provided by the Seniors' Independence Research Program through Health Canada's National Health Research Development Program (NHRDP). Funding for analysis of the caregiver component was provided by the Medical Research Council. Additional funding was provided by Pfizer Canada Inc. through the MRC/PMAC, NHRDP, by Bayer Inc., and by the B.C. Health Research Foundation. Core funding for Phase 3 was provided by the Canadian Institute for Health Research (CIHR). Supplementary funding for the caregiver component was obtained from CIHR. Additional funding was provided by Merck-Frosst and by Jansen-Ortho. CSHA was coordinated through the University of Ottawa and Health Canada.	American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3rd; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1996, AM J PSYCHIAT, V153, P7; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; CHANDRA V, 1989, NEUROLOGY, V39, P1576, DOI 10.1212/WNL.39.12.1576; CONWELL Y, 1993, J AM GERIATR SOC, V41, P38, DOI 10.1111/j.1532-5415.1993.tb05945.x; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; FIELDS RB, 1997, HDB NEUROPSYCHOLOGY, P280; Goldstein FC, 2001, J CLIN EXP NEUROPSYC, V23, P739, DOI 10.1076/jcen.23.6.739.1028; Graham JE, 1996, NEUROEPIDEMIOLOGY, V15, P246, DOI 10.1159/000109914; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; HENDERSON AS, 1988, ACTA PSYCHIAT SCAND, V78, P257, DOI 10.1111/j.1600-0447.1988.tb06336.x; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hessen E, 2006, SCAND J PSYCHOL, V47, P245, DOI 10.1111/j.1467-9450.2006.00514.x; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Jellinger KA, 2004, J NEUROL NEUROSUR PS, V75, P511; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; McCrea M, 2008, MILD TRAUMATIC BRAIN; McDowell I, 2004, AGING NEUROPSYCHOL C, V11, P149, DOI 10.1080/13825580490511044; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1994, DEMENTIA NORMAL AGIN, P208; Nilsson L.-G., 2001, PERSPECTIVES HUMAN M, P253; Patterson C, 2007, ALZHEIMERS DEMENT, V3, P341, DOI 10.1016/j.jalz.2007.07.001; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; RICHARDSON JTE, 1990, CLIN NEUROPSYCHOLOGI; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Rosnick CB, 2004, AGING NEUROPSYCHOL C, V11, P89, DOI 10.1076/anec.11.1.89.29367; Roth M., 1988, CAMDEX CAMBRIDGE EXA; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Senathi-Raja D, 2010, NEUROPSYCHOLOGY, V24, P336, DOI 10.1037/a0018239; STEENHUIS RE, 1995, J CLIN EXP NEUROPSYC, V17, P773, DOI 10.1080/01688639508405166; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; TUOKKO H, 1995, J CLIN EXP NEUROPSYC, V17, P352, DOI 10.1080/01688639508405129; VANBOXTEL MPJ, 1997, PHYS HLTH VASCULAR R; VANDUIJN CM, 1991, INT J EPIDEMIOL, V20, pS4, DOI 10.1093/ije/20.Supplement_2.S4; Wechsler, 1981, WAIS R MANUAL; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; 1994, NEUROLOGY, V44, P2073	48	24	26	0	3	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	2011	25	4					338	347		10.3109/02699052.2011.556104			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	739RL	WOS:000288735600003	21314278				2021-06-18	
J	Oliveira, L; Fregni, F				Oliveira, Lais; Fregni, Felipe			Pharmacological and electrical stimulation in chronic disorders of consciousness: New insights and future directions	BRAIN INJURY			English	Article						Vegetative state; minimally conscious state; anoxia; traumatic brain injury; therapy; outcome	PERSISTENT VEGETATIVE STATE; TRAUMATIC BRAIN-INJURY; RECOVERY; PREDICTORS; AMANTADINE; ZOLPIDEM; THERAPY; COMA	Background: Chronic disorders of consciousness are costly and challenging conditions to treat. Although recent studies that have tested pharmacological and electrical stimulation for these conditions are promising, the optimal intervention, mechanisms of action and side effects of these experimental therapies are unclear. Objective: To systematically review the clinical results of treatments for vegetative state (VS) and minimally conscious state (MCS) from the last 10 years. Methods: MEDLINE, LILACS and SCOPUS were searched as data sources. Because the potential bias when search is limited to databases of peer-reviewed journals, reference lists were examined and experts in the field were contacted for other relevant or unpublished articles (i.e. negative studies). No negative unpublished studies were found. Studies were included related to therapeutic interventions in adult MCS or VS patients at least 3 and 12 months after non-traumatic and traumatic injuries, respectively. Eight studies met the inclusion criteria. The following interventions were reviewed: levodopa, amantadine, zolpidem, baclofen, dorsal column stimulation and deep brain stimulation. Conclusions: The adverse effects that were associated with these treatments were typically mild. Most of the studies demonstrated considerable improvements with the interventions, but their low strength of evidence limit the generalizability of the findings.	[Oliveira, Lais; Fregni, Felipe] Harvard Univ, Sch Med, Lab Neuromodulat, Phys Med & Rehabil Dept,Spaulding Rehabil Hosp, Boston, MA USA; [Oliveira, Lais; Fregni, Felipe] Harvard Univ, Beth Israel Deaconess Med Ctr, Berenson Allen Ctr Noninvas Brain Stimulat, Sch Med,Neurol Dept, Boston, MA 02215 USA	Fregni, F (corresponding author), 125 Nashua St,Room 725, Boston, MA 02114 USA.	ffregni@bidmc.harvard.edu		Fregni, Felipe/0000-0001-9359-8643; Oliveira, Lais/0000-0002-1980-6755			ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bates D, 2003, CLIN MED, V3, P249; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; Clauss R, 2006, NEUROREHABILITATION, V21, P23; Di HB, 2008, CLIN MED, V8, P502, DOI 10.7861/clinmedicine.8-5-502; Fridman EA, 2009, BRAIN INJURY, V23, P172, DOI 10.1080/02699050802649662; Giacino JT, 2005, PROG BRAIN RES, V150, P381, DOI 10.1016/S0079-6123(05)50027-X; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; JENNETT B, 1972, LANCET, V1, P734; Kalmar K, 2005, NEUROPSYCHOL REHABIL, V15, P454, DOI 10.1080/09602010443000425; Kanno T, 2009, NEUROMODULATION, V12, P33, DOI 10.1111/j.1525-1403.2009.00185.x; Kobylarz EJ, 2005, NEUROPSYCHOL REHABIL, V15, P323, DOI 10.1080/09602010443000605; Krimchansky BZ, 2004, BRAIN INJURY, V18, P1099, DOI 10.1080/02699050310001646206; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Laureys S, 2006, CURR OPIN NEUROL, V19, P520, DOI 10.1097/WCO.0b013e3280106ba9; Matsuda W, 2003, J NEUROL NEUROSUR PS, V74, P1571, DOI 10.1136/jnnp.74.11.1571; Monti MM, 2009, ANN NY ACAD SCI, V1157, P81, DOI 10.1111/j.1749-6632.2008.04121.x; Moseley AM, 2002, AUST J PHYSIOTHER, V48, P43, DOI 10.1016/S0004-9514(14)60281-6; Noda R, 2003, ACTA NEUROCHIR SUPPL, V87, P23; Oxford Centre for Evidence-based Medicine, 2009, LEV EV; PORTNEY LG, 2008, FDN CLIN RES APPL PR, P357; Sara M, 2009, ARCH PHYS MED REHAB, V90, P1245, DOI 10.1016/j.apmr.2009.01.012; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2006, J NEUROTRAUM, V23, P1436, DOI 10.1089/neu.2006.23.1436; Schnakers C, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.124099; Shames JL, 2008, ARCH PHYS MED REHAB, V89, P386, DOI 10.1016/j.apmr.2007.08.137; Singh R, 2008, BRAIN INJURY, V22, P103, DOI 10.1080/02699050701829704; Strauss DJ, 2000, PEDIATR NEUROL, V23, P312, DOI 10.1016/S0887-8994(00)00194-6; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; Wu TS, 2005, J EMERG MED, V28, P289, DOI 10.1016/j.jemermed.2004.11.016; Yamamoto T, 2005, NEUROPSYCHOL REHABIL, V15, P406, DOI 10.1080/09602010443000353	32	24	24	1	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2011	25	4					315	327		10.3109/02699052.2011.556103			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	739RL	WOS:000288735600001	21314279				2021-06-18	
J	Wauters, S; Verleden, GM; Belmans, A; Coosemans, W; De Leyn, P; Nafteux, P; Lerut, T; Van Raemdonck, D				Wauters, Shana; Verleden, Geert M.; Belmans, Ann; Coosemans, Willy; De Leyn, Paul; Nafteux, Philippe; Lerut, Toni; Van Raemdonck, Dirk			Donor cause of brain death and related time intervals: does it affect outcome after lung transplantation?	EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY			English	Article						Brain death; Lung donors; Lung transplantation	BRONCHIOLITIS OBLITERANS; HEART-TRANSPLANTATION; SURVIVAL; INJURY; DURATION; DYSFUNCTION; REGISTRY; IMPACT; MODEL	Objective: It remains uncertain whether donor cause of brain death (DCBD) affects survival and freedom from bronchiolitis obliterans syndrome (BOS) after lung transplantation (LTx). In addition, it is unknown whether the length of time interval from brain insult to brain death [BI-BD] and from brain death to cold preservation [BD-CP] has an impact on outcome. Methods: Medical charts of isolated lung transplant recipients from 400 consecutive donors were reviewed and classified according to DCBD: 190 vascular [V], 185 traumatic [T], 25 others [0]. Demographics were compared between donor groups. Hospital outcome, survival, and freedom from BUS in recipients were analyzed in relation to DCBD and related time intervals. Results: Donor age, gender, and weight differed between donor groups ( p < 0.001, p < 0.001, p < 0.05; respectively). No differences in recipient hospital outcome, survival, and freedom from BUS were found between groups. [BD-CP] longer than 10 h resulted in a survival advantage (69% vs 58% and 51% vs 42% at 5 and 10 years, respectively; p < 0.05) and a reduced hazard risk (0.952) of dying after LTx; (p < 0.05). Multivariable analysis failed to show a significant correlation between DCBD and [BI-BD] versus survival and BUS. Conclusion: DCBD and [BI-BD] do not affect survival and freedom from BUS after LTx. Lung recipients from donors certified brain dead with a time interval longer than 10 h prior to organ preservation showed improved survival unrelated to BUS. This may result from longer and better donor management with reduced lung injury. (C) 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.	[Wauters, Shana; Van Raemdonck, Dirk] Catholic Univ Louvain, Lab Expt Thorac Surg, B-3000 Louvain, Belgium; [Verleden, Geert M.] Univ Hosp Leuven, Dept Pneumol, Louvain, Belgium; [Belmans, Ann] Catholic Univ Louvain, Biostat & Stat Bioinformat Ctr, B-3000 Louvain, Belgium; [Coosemans, Willy; De Leyn, Paul; Nafteux, Philippe; Lerut, Toni; Van Raemdonck, Dirk] Univ Hosp Leuven, Dept Thorac Surg, Louvain, Belgium	Van Raemdonck, D (corresponding author), Univ Hosp Gasthuisberg, Dept Thorac Surg, Herestr 49, B-3000 Louvain, Belgium.	dirk.vanraemdonck@uzleuven.be	Van Raemdonck, Dirk/AAL-4147-2020	Van Raemdonck, Dirk/0000-0003-1261-0992	Fund for Research-Flanders [G.0282.07, G.3C04.99]	The work was supported by grant G.0282.07 from the Fund for Research-Flanders. Dirk Van Raemdonck is a senior clinical investigator supported by the Fund for Research-Flanders (G.3C04.99).	Avlonitis VS, 2007, AM J TRANSPLANT, V7, P83, DOI 10.1111/j.1600-6143.2006.01593.x; Avlonitis VS, 2003, TRANSPLANTATION, V75, P1928, DOI 10.1097/01.TP.0000066351.87480.9E; Chen EP, 1996, CRIT CARE MED, V24, P1352, DOI 10.1097/00003246-199608000-00014; Christie JD, 2010, J HEART LUNG TRANSPL, V29, P1104, DOI 10.1016/j.healun.2010.08.004; Ciccone AM, 2002, J THORAC CARDIOV SUR, V123, P429, DOI 10.1067/mtc.2002.120732; Estenne M, 2002, AM J RESP CRIT CARE, V166, P440, DOI 10.1164/rccm.200201-003PP; European Ombudsman, 2008, ANN REP 2008 EUR INT, P29; Ganesh JS, 2005, J HEART LUNG TRANSPL, V24, P1544, DOI 10.1016/j.healun.2004.11.316; Ganesh JS, 2005, J THORAC CARDIOV SUR, V129, P1153, DOI 10.1016/j.jtcvs.2004.09.029; Hadjiliadis D, 2006, AM J TRANSPLANT, V6, P183, DOI 10.1111/j.1600-6143.2005.01159.x; Kaneda H, 2006, AM J TRANSPLANT, V6, P544, DOI 10.1111/j.1600-6143.2005.01204.x; Kunzendorf U, 2002, AM J TRANSPLANT, V2, P292, DOI 10.1034/j.1600-6143.2002.20316.x; LIN DY, 1993, BIOMETRIKA, V80, P557, DOI 10.2307/2337177; Meers C, 2009, TRANSPL P, V41, P572, DOI 10.1016/j.transproceed.2008.12.029; Neyrinck AR, 2006, EUR J CARDIO-THORAC, V30, P628, DOI 10.1016/j.ejcts.2006.06.027; Novitzky D, 1997, TRANSPLANT P, V29, P3770, DOI 10.1016/S0041-1345(97)01149-4; Odim J, 2005, J THORAC CARDIOV SUR, V130, P187, DOI 10.1016/j.jtcvs.2005.02.038; Pessione F, 2003, TRANSPLANTATION, V75, P361, DOI 10.1097/01.TP.0000044171.97375.61; Singhal AK, 2009, TRANSPL P, V41, P3539, DOI 10.1016/j.transproceed.2009.06.192; van der Hoeven JAB, 2003, KIDNEY INT, V64, P1874, DOI 10.1046/j.1523-1755.2003.00272.x; Van Raemdonck Dirk, 2009, Proc Am Thorac Soc, V6, P28, DOI 10.1513/pats.200808-098GO; VANRAEMDONCK DEM, 2009, EUR RESP MON, V45, P1; Verleden GM, 2009, TRANSPL INT, V22, P771, DOI 10.1111/j.1432-2277.2009.00872.x; WALLER DA, 1995, J HEART LUNG TRANSPL, V14, P318; Zweers N, 2004, TRANSPLANTATION, V78, P1251, DOI 10.1097/01.TP.0000142679.45418.96	25	24	25	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1010-7940	1873-734X		EUR J CARDIO-THORAC	Eur. J. Cardio-Thorac. Surg.	APR	2011	39	4					E68	E76		10.1016/j.ejcts.2010.11.049			9	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Cardiovascular System & Cardiology; Respiratory System; Surgery	747SX	WOS:000289341100051	21232966	Bronze			2021-06-18	
J	Chen, JA; Wu, XJ; Shao, B; Zhao, W; Shi, W; Zhang, SW; Ni, LC; Shen, AG				Chen, Jian; Wu, Xiujie; Shao, Bai; Zhao, Wei; Shi, Wei; Zhang, Shuangwei; Ni, Lanchun; Shen, Aiguo			Increased Expression of TNF Receptor-Associated Factor 6 After Rat Traumatic Brain Injury	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Traumatic brain injury; TRAF6; Glial proliferation; Apoptosis; Rat	NF-KAPPA-B; ACTIVATION; TRAF6; LIPOPOLYSACCHARIDE; MECHANISMS; INTERLEUKIN-1; APOPTOSIS; REQUIRES; FAMILY; ENZYME	TRAF6 (TNF receptor-associated factor 6), a member of tumor necrosis factor receptor-associated factors family was identified as a molecule that binds to the cytoplasmic domain of CD40. TRAF6 functions as an adaptor, positively regulating the NF-kappa B, JNK pathway. Additionally, some studies have reported that TRAF6 is required for apoptosis within the developing CNS and regulates cell fate decisions by inducing caspase 8-dependent apoptosis. However, its distribution and function in the central nervous system (CNS) lesion are not well understood. In this study, we performed an acute traumatic brain injury model in adult rats. And we mainly examined protein expression and cellular localization of TRAF6 during rat traumatic brain injury (TBI). Western blot analysis showed TRAF6 level significantly improved at 7 days after injury, and then declined during the following days. The protein expression of TRAF6 was further analysed by immunohistochemistry. In comparison to contralateral cerebral cortex, we observed a highly significant accumulation of TRAF6 at the ipsilateral brain. Immunofluorescence double-labeling showed that TRAF6 was co-expressed with NeuN and GFAP. Besides, co-localization of TRAF6/active caspase 3 and TRAF6/proliferating cell nuclear antigen (PCNA) were detected in NeuN and GFAP, respectively. We also examined the expression profiles of proliferating cell nuclear antigen (PCNA) and active caspase 3 whose changes were correlated with the expression profiles of TRAF6. In conclusion, this is the first description of TRAF6 expression in traumatic brains. Our data suggested that TRAF6 might play important roles in CNS pathophysiology after TBI.	[Chen, Jian; Wu, Xiujie; Zhao, Wei; Shi, Wei; Zhang, Shuangwei; Ni, Lanchun; Shen, Aiguo] Nantong Univ, Dept Neurosurg, Affiliated Hosp, Nantong 226001, Jiangsu, Peoples R China; [Chen, Jian; Wu, Xiujie; Zhao, Wei; Shi, Wei; Zhang, Shuangwei; Ni, Lanchun; Shen, Aiguo] Nantong Univ, Jiangsu Prov Key Lab Neuroregenerat, Nantong 226001, Jiangsu, Peoples R China; [Shao, Bai] Nantong Univ, Affiliated Dongtai Hosp, Dept Neurosurg, Yancheng 224200, Jiangsu, Peoples R China	Chen, JA (corresponding author), Nantong Univ, Dept Neurosurg, Affiliated Hosp, Nantong 226001, Jiangsu, Peoples R China.	chenjian9079@163.com; shen_aiguo@yahoo.com			Chinese 973 programNational Basic Research Program of China [2011CS910600]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30770488, 30870320, 31070723, 81070275]; Natural Science Foundation of Jiangsu provinceNatural Science Foundation of Jiangsu Province [BK2009156, BK2009157, BK2009161]; Natural science Foundation of Jiangsu Colleges and Universities [09KJB320011]	This study was supported by the Chinese 973 program (2011CS910600); the National Natural Science Foundation of China (No. 30770488, No. 30870320, No. 31070723, and No. 81070275); Natural Science Foundation of Jiangsu province (No. BK2009156, No. BK2009157, and No. BK2009161); Natural science Foundation of Jiangsu Colleges and Universities Grant (09KJB320011).	Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chung JY, 2002, J CELL SCI, V115, P679; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Ea CK, 2004, P NATL ACAD SCI USA, V101, P15318, DOI 10.1073/pnas.0404132101; Erhardt L, 1996, EUR HEART J, V17, P1781; Fawcett JW, 1997, CELL TISSUE RES, V290, P371, DOI 10.1007/s004410050943; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; He LS, 2006, J BIOL CHEM, V281, P11235, DOI 10.1074/jbc.M508779200; Lamothe B, 2007, J BIOL CHEM, V282, P4102, DOI 10.1074/jbc.M609503200; Lamothe B, 2008, J BIOL CHEM, V283, P24871, DOI 10.1074/jbc.M802749200; LOGAN A, 1992, J NEUROSCI, V12, P3828; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Lomaga MA, 2000, J NEUROSCI, V20, P7384; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Morlon A, 2005, HUM MOL GENET, V14, P3751, DOI 10.1093/hmg/ddi405; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; Muroi M, 2008, J LEUKOCYTE BIOL, V83, P702, DOI 10.1189/jlb.0907629; Pollet I, 2003, BLOOD, V102, P1740, DOI 10.1182/blood-2003-01-0288; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Wong F, 2004, BLOOD, V103, P4520, DOI 10.1182/blood-2003-06-2118; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008	26	24	28	0	4	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	MAR	2011	31	2					269	275		10.1007/s10571-010-9617-6			7	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	726VC	WOS:000287753500010	21072581				2021-06-18	
J	Wu, CT; Wen, LL; Wong, CS; Tsai, SY; Chan, SM; Yeh, CC; Borel, CO; Cherng, CH				Wu, Ching-Tang; Wen, Li-Li; Wong, Chih-Shung; Tsai, Shih-Ying; Chan, Shun-Ming; Yeh, Chun-Chang; Borel, Cecil O.; Cherng, Chen-Hwan			Temporal Changes in Glutamate, Glutamate Transporters, Basilar Arteries Wall Thickness, and Neuronal Variability in an Experimental Rat Model of Subarachnoid Hemorrhage	ANESTHESIA AND ANALGESIA			English	Article							TRAUMATIC BRAIN-INJURY; CEREBRAL VASOSPASM; DOWN-REGULATION; ISCHEMIA; RELEASE; GLT-1; GLAST; HIPPOCAMPUS; MECHANISMS; EXPRESSION	BACKGROUND: Glutamate and glutamate transporters (GTs) (including glutamate/aspartate transporter, glutamate transporter-1, and excitatory amino acid carrier 1) have important roles in the pathogenesis of ischemic neurological injury. The changes in glutamate, GTs, and neuronal injury after subarachnoid hemorrhage (SAH) have not been widely investigated. In this study, we examined the changes in extracellular glutamate concentration, GTs, wall thickness of basilar arteries (BAs), and neuronal degeneration in experimental SAH rats. METHODS: An intrathecal microdialysis probe was inserted into male Sprague Dawley rats. SAH was induced using a double-hemorrhage model. To measure glutamate concentrations, extracellular dialysates were collected for 30 minutes before, and daily for 7 days after SAH. Changes in neurological scores, body weight, and BA wall thickness were measured. The neuron degeneration in the hippocampus and the changes of GTs in the cerebral cortex and hippocampus were measured. RESULTS: Glutamate concentrations were significantly higher in SAH rats from day (D) 1 to D7 after SAH compared with the sham rats, especially at D1. A significant body weight reduction and neurological defects were observed at D3 after SAH. The walls of BAs in SAH rats were significantly thicker compared with those of sham rats; the maximum change was observed at D7. Hippocampal neuronal degeneration was observed after SAH and the highest severity was at D7. The expression of GTs was downregulated after SAH and persisted for 7 days. CONCLUSIONS: SAH induced in the double-hemorrhage rat model may produce an excessive and prolonged increase of extracellular glutamate concentrations and downregulation of GTs, which are accompanied by BA wall thickness, and hippocampal neuronal degeneration. (Anesth Analg 2011;112:666-73)	[Wu, Ching-Tang; Chan, Shun-Ming; Yeh, Chun-Chang; Cherng, Chen-Hwan] Tri Serv Gen Hosp, Natl Def Med Ctr, Dept Anesthesiol, Taipei, Taiwan; [Wen, Li-Li] En Chu Kong Hosp, Dept Clin Lab, Taipei, Taiwan; [Wong, Chih-Shung] Cathay Gen Hosp, Dept Anesthesiol, Taipei, Taiwan; [Tsai, Shih-Ying] Taipei Med Univ, Grad Inst Med Sci, Sch Med, Taipei, Taiwan; [Tsai, Shih-Ying] Taipei Med Univ, Dept Physiol, Sch Med, Taipei, Taiwan; [Borel, Cecil O.] Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA	Cherng, CH (corresponding author), Tri Serv Gen Hosp, Natl Def Med Ctr, Dept Anesthesiol, Taipei, Taiwan.	cherng1018@yahoo.com.tw	Wu, Zhi-Fu/ABE-6379-2020		National Science Council, Taiwan, Republic of ChinaMinistry of Science and Technology, Taiwan [NSC 95-2314-B-016-049]	Supported by the National Science Council (NSC 95-2314-B-016-049), Taiwan, Republic of China.	Chen JC, 2005, NEUROPHARMACOLOGY, V49, P703, DOI 10.1016/j.neuropharm.2005.05.002; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; Davalos A, 1997, STROKE, V28, P708, DOI 10.1161/01.STR.28.4.708; Fergusen S, 2007, NEUROSURGERY, V60, P658, DOI 10.1227/01.NEU.0000255396.23280.31; Germano A, 2007, J NEUROTRAUM, V24, P732, DOI 10.1089/neu.2006.0181; Han F, 2008, NEUROSCI LETT, V430, P275, DOI 10.1016/j.neulet.2007.11.021; Jeon H, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-103; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Macdonald RL, 2007, NAT CLIN PRACT NEURO, V3, P256, DOI 10.1038/ncpneuro0490; MITANI A, 1992, NEUROSCIENCE, V48, P307, DOI 10.1016/0306-4522(92)90492-K; Nishizawa Y, 2001, LIFE SCI, V69, P369, DOI 10.1016/S0024-3205(01)01142-0; Park S, 2004, STROKE, V35, P2412, DOI 10.1161/01.STR.0000141162.29864.e9; Prunell GF, 2003, NEUROSURGERY, V52, P165, DOI 10.1097/00006123-200301000-00022; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2000, NEUROCHEM INT, V36, P531, DOI 10.1016/S0197-0186(99)00153-9; Rosengart AJ, 2007, J NEUROSURG, V107, P253, DOI 10.3171/JNS-07/08/0253; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Sabri M, 2008, BRAIN RES, V1238, P163, DOI 10.1016/j.brainres.2008.08.031; Schmitt A, 1997, J NEUROSCI, V17, P1, DOI 10.1523/jneurosci.17-01-00001.1997; Seckin H, 2008, SURG NEUROL, V70, P344, DOI 10.1016/j.surneu.2007.07.052; Suarez JI, 2006, NEW ENGL J MED, V354, P387, DOI 10.1056/NEJMra052732; Sung CS, 2004, BRAIN RES, V1015, P145, DOI 10.1016/j.brainres.2004.04.068; Susarla BTS, 2004, J NEUROCHEM, V91, P1151, DOI 10.1111/j.1471-4159.2004.02791.x; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; VelazFaircloth M, 1996, AM J PHYSIOL-CELL PH, V270, pC67; Yeh TH, 2005, NEUROBIOL DIS, V18, P476, DOI 10.1016/j.nbd.2004.12.011; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zemke D, 2007, VASC MED, V12, P243, DOI 10.1177/1358863x07081316; Zhou CM, 2004, J CEREBR BLOOD F MET, V24, P419, DOI 10.1097/00004647-200404000-00007	30	24	25	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	MAR	2011	112	3					666	673		10.1213/ANE.0b013e318207c51f			8	Anesthesiology	Anesthesiology	726DG	WOS:000287698400032	21233495				2021-06-18	
J	Yoshioka, N; Kimura-Kuroda, J; Saito, T; Kawamura, K; Hisanaga, S; Kawano, H				Yoshioka, Nozomu; Kimura-Kuroda, Junko; Saito, Taro; Kawamura, Koki; Hisanaga, Shin-ichi; Kawano, Hitoshi			Small Molecule Inhibitor of Type I Transforming Growth Factor-beta Receptor Kinase Ameliorates the Inhibitory Milieu in Injured Brain and Promotes Regeneration of Nigrostriatal Dopaminergic Axons	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						traumatic brain injury; fibrotic scar; glial scar; chondroitin sulfate proteoglycans; axonal regeneration	SPINAL-CORD-INJURY; CHONDROITIN SULFATE PROTEOGLYCANS; FIBROTIC SCAR FORMATION; CENTRAL-NERVOUS-SYSTEM; ADULT-RAT BRAIN; REACTIVE ASTROCYTES; GENE-EXPRESSION; TGF-BETA; EXTRACELLULAR-MATRIX; CORTICOSPINAL TRACT	Transforming growth factor-beta (TGF-beta), a multifunctional cytokine, plays a crucial role in wound healing in the damaged central nervous system. To examine effects of the TGF-beta signaling inhibition on formation of scar tissue and axonal regeneration, the small molecule inhibitor of type I TGF-beta receptor kinase LY-364947 was continuously infused in the lesion site of mouse brain after a unilateral transection of the nigrostriatal dopaminergic pathway. At 2 weeks after injury, the fibrotic scar comprising extracellular matrix molecules including fibronectin, type IV collagen, and chondroitin sulfate proteoglycans was formed in the lesion center, and reactive astrocytes were increased around the fibrotic scar. In the brain injured and infused with LY-364947, fibrotic scar formation was suppressed and decreased numbers of reactive astrocytes occupied the lesion site. Although leukocytes and serum IgG were observed within the fibrotic scar in the injured brain, they were almost absent in the injured and LY-364947-treated brain. At 2 weeks after injury, tyrosine hydroxylase (TH)-immunoreactive fibers barely extended beyond the fibrotic scar in the injured brain, but numerous TH-immunoreactive fibers regenerated over the lesion site in the LY-364947-treated brain. These results indicate that inhibition of TGF-beta signaling suppresses formation of the fibrotic scar and creates a permissive environment for axonal regeneration. (C) 2010 Wiley-Liss, Inc.	[Yoshioka, Nozomu; Saito, Taro; Hisanaga, Shin-ichi] Tokyo Metropolitan Univ, Dept Biol Sci, Tokyo 158, Japan; [Yoshioka, Nozomu; Kimura-Kuroda, Junko; Kawamura, Koki; Kawano, Hitoshi] Tokyo Metropolitan Inst Neurosci, Dept Dev Morphol, Tokyo, Japan	Kawano, H (corresponding author), Tokyo Metropolitan Inst Neurosci, Dept Dev Morphol, Tokyo, Japan.	kawano-ht@igakuken.or.jp			Ministry of Education, Science, Sports and Culture of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [20500318]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [11J04608, 23500422] Funding Source: KAKEN	Contract grant sponsor: Ministry of Education, Science, Sports and Culture of Japan; Contract grant number: 20500318.	Ashcroft GS, 1999, NAT CELL BIOL, V1, P260; Asher RA, 2000, J NEUROSCI, V20, P2427; BAGHDASSARIAN D, 1993, GLIA, V7, P193, DOI 10.1002/glia.440070302; Berry M, 1983, Acta Neurochir Suppl (Wien), V32, P31; Boche D, 2003, J CEREBR BLOOD F MET, V23, P1174, DOI 10.1097/01.WCB.0000090080.64176.44; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Brazda N, 2009, PROG BRAIN RES, V175, P269, DOI 10.1016/S0079-6123(09)17518-0; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Cafferty WBJ, 2007, J NEUROSCI, V27, P2176, DOI 10.1523/JNEUROSCI.5176-06.2007; Correale J, 2004, J NEUROL, V251, P1304, DOI 10.1007/s00415-004-0649-z; Davies JE, 2004, EUR J NEUROSCI, V19, P1226, DOI 10.1111/j.1460-9568.2004.03184.x; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Gris P, 2007, GLIA, V55, P1145, DOI 10.1002/glia.20537; Hamada Y, 1996, NEUROSCI LETT, V203, P97, DOI 10.1016/0304-3940(95)12271-0; Homma A, 2006, J COMP NEUROL, V499, P120, DOI 10.1002/cne.21097; Kano MR, 2007, P NATL ACAD SCI USA, V104, P3460, DOI 10.1073/pnas.0611660104; Kawano H, 2005, J NEUROSCI RES, V80, P191, DOI 10.1002/jnr.20441; KAWANO H, 1995, DEV BRAIN RES, V86, P101, DOI 10.1016/0165-3806(95)00018-9; Kimura-Kuroda J, 2010, MOL CELL NEUROSCI, V43, P177, DOI 10.1016/j.mcn.2009.10.008; King VR, 2004, NEUROSCIENCE, V126, P173, DOI 10.1016/j.neuroscience.2004.03.035; Klapka N, 2005, EUR J NEUROSCI, V22, P3047, DOI 10.1111/j.1460-9568.2005.04495.x; Kohta M, 2009, NEUROSCI RES, V65, P393, DOI 10.1016/j.neures.2009.08.017; Komuta Y, 2010, CELL MOL NEUROBIOL, V30, P101, DOI 10.1007/s10571-009-9435-x; Laabs TL, 2007, J NEUROSCI, V27, P14494, DOI 10.1523/JNEUROSCI.2807-07.2007; Lagord C, 2002, MOL CELL NEUROSCI, V20, P69, DOI 10.1006/mcne.2002.1121; Li HP, 2007, J NEUROSCI RES, V85, P536, DOI 10.1002/jnr.21141; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; Liesi P, 2002, EXP NEUROL, V173, P31, DOI 10.1006/exnr.2001.7800; LOGAN A, 1994, EUR J NEUROSCI, V6, P355, DOI 10.1111/j.1460-9568.1994.tb00278.x; Logan A, 1999, EXP NEUROL, V159, P504, DOI 10.1006/exnr.1999.7180; Logan A, 1999, EUR J NEUROSCI, V11, P2367, DOI 10.1046/j.1460-9568.1999.00654.x; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; Makwana M, 2007, J NEUROSCI, V27, P11201, DOI 10.1523/JNEUROSCI.2255-07.2007; McAuliffe JJ, 2008, BRAIN RES, V1190, P175, DOI 10.1016/j.brainres.2007.11.038; McTigue DM, 2000, EXP NEUROL, V163, P220, DOI 10.1006/exnr.2000.7372; Moon LDF, 2001, EUR J NEUROSCI, V14, P1667, DOI 10.1046/j.0953-816x.2001.01795.x; Moon LDF, 2001, NAT NEUROSCI, V4, P465; Nakamura M, 2003, EXP NEUROL, V184, P313, DOI 10.1016/S0014-4886(03)00361-3; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; PASINETTI GM, 1993, NEUROSCIENCE, V54, P893, DOI 10.1016/0306-4522(93)90583-2; Rhodes KE, 2006, NEUROSCIENCE, V140, P87, DOI 10.1016/j.neuroscience.2006.01.055; Rhodes KE, 2004, J ANAT, V204, P33, DOI 10.1111/j.1469-7580.2004.00261.x; Roberts AB, 2003, ANN NY ACAD SCI, V995, P1, DOI 10.1111/j.1749-6632.2003.tb03205.x; Sandvig A, 2004, GLIA, V46, P225, DOI 10.1002/glia.10315; Sawyer JS, 2003, J MED CHEM, V46, P3953, DOI 10.1021/jm0205705; Schachtrup C, 2010, J NEUROSCI, V30, P5843, DOI 10.1523/JNEUROSCI.0137-10.2010; Schiwy N, 2009, EUR J NEUROSCI, V30, P1544, DOI 10.1111/j.1460-9568.2009.06929.x; SempleRowland SL, 1995, J NEUROTRAUM, V12, P1003, DOI 10.1089/neu.1995.12.1003; Shearer MC, 2001, CELL TISSUE RES, V305, P267, DOI 10.1007/s004410100384; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Smith GM, 2005, GLIA, V52, P209, DOI 10.1002/glia.20236; Stichel CC, 1999, EUR J NEUROSCI, V11, P632, DOI 10.1046/j.1460-9568.1999.00466.x; Stichel CC, 1999, NEUROSCIENCE, V93, P321, DOI 10.1016/S0306-4522(99)00112-8; Teng X, 2008, J NEUROSCI RES, V86, P3140, DOI 10.1002/jnr.21767; Uemura K, 1996, J BIOL CHEM, V271, P4581; Wang Y, 2007, EXP NEUROL, V203, P168, DOI 10.1016/j.expneurol.2006.08.006; Wu MH, 2009, AM J PATHOL, V174, P519, DOI 10.2353/ajpath.2009.080574; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; Yoshioka N, 2010, J COMP NEUROL, V518, P3867, DOI 10.1002/cne.22431	61	24	26	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	MAR	2011	89	3					381	393		10.1002/jnr.22552			13	Neurosciences	Neurosciences & Neurology	717RG	WOS:000287064500011	21259325				2021-06-18	
J	Potvin, MJ; Rouleau, I; Audy, J; Charbonneau, S; Giguere, JF				Potvin, Marie-Julie; Rouleau, Isabelle; Audy, Julie; Charbonneau, Simon; Giguere, Jean-Francois			Ecological prospective memory assessment in patients with traumatic brain injury	BRAIN INJURY			English	Article						Prospective memory; traumatic brain injury; assessment; neuropsychology	CLOSED-HEAD INJURY; COMPLEX INTENTIONS; PERFORMANCE; EVENT; REALIZATION; IMPAIRMENT; DAMAGE; AGE	Primary objective: Prospective memory (PM) impairments are often observed after traumatic brain injury (TBI). Although PM is crucial for daily functioning, few sensitive, valid and ecological clinical tests are available. To address these concerns, the authors developed a PM task, the TEMP, using naturalistic stimuli, in which each PM phase and component is evaluated independently in time- and event-based conditions. Main outcomes and results: The results show that moderate and severe TBI patients (n = 30), evaluated after spontaneous neurological recovery, experienced problems in learning the delayed intentions content and retrieving these intentions in the right context (prospective component), especially in the time-based condition. They also recalled fewer associated actions (retrospective component), but only in the time-based condition. Correlations revealed that the retrospective component was mainly supported by episodic retrospective memory processes, while the prospective component was supported by episodic retrospective memory processes, along with attentional and executive functions. Moreover, there was a significant correlation between performance on the TEMP and results on a questionnaire assessing PM functioning in daily living completed by participants' relatives. Conclusions: The TEMP therefore appears to be a sensitive tool for assessing PM problems that combines internal and ecological validity.	[Rouleau, Isabelle] Univ Quebec, Dept Psychol, Inst Cognit Sci, Montreal, PQ H3C 3P8, Canada; [Potvin, Marie-Julie; Giguere, Jean-Francois] Hop Sacre Coeur Montreal, Neurotraumatol Programme, Montreal, PQ, Canada	Rouleau, I (corresponding author), Univ Quebec, Dept Psychol, Inst Cognit Sci, CP 8888,Succursale Ctr Ville, Montreal, PQ H3C 3P8, Canada.	rouleau.isabelle@uqam.ca		Potvin, Marie-Julie/0000-0001-5503-8063	NSERCNatural Sciences and Engineering Research Council of Canada (NSERC); FRSQFonds de la Recherche en Sante du Quebec	This research was supported by NSERC and FRSQ scholarships (M.-J. Potvin). The authors report no conflicts of interest.	Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Beck A.T., 1993; Brandt J., 2001, BRIEF VISUOSPATIAL M; Brooks BM, 2004, BRAIN INJURY, V18, P391, DOI 10.1080/02699050310001619855; Burgess PW, 2003, NEUROPSYCHOLOGIA, V41, P906, DOI 10.1016/S0028-3932(02)00327-5; Carlesimo GA, 2004, J INT NEUROPSYCH SOC, V10, P679, DOI 10.1017/S1355617704105079; COCKBURN J, 1995, CORTEX, V31, P87, DOI 10.1016/S0010-9452(13)80107-4; Delis DC, 2001, DELISKAPLAN EXECUTIV; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Elliott J, 2008, POPULAR FEMINIST FICTION AS AMERICAN ALLEGORY: REPRESENTING NATIONAL TIME, P1, DOI 10.1057/9780230612808; Ellis J, 2000, APPL COGNITIVE PSYCH, V14, pS1, DOI 10.1002/acp.767; Ellis JA., 1996, PROSPECTIVE MEMORY T, P1; Fayol P., 2004, Annales de Readaptation et de Medecine Physique, V47, P142, DOI 10.1016/j.annrmp.2004.01.004; Graf P, 2001, CONSCIOUS COGN, V10, P437, DOI 10.1006/ccog.2001.0504; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Huppert FA, 2000, APPL COGNITIVE PSYCH, V14, pS63, DOI 10.1002/acp.771; Kinch J., 2001, BRAIN IMPAIR, V2, P119, DOI [10.1375/brim.2.2.119, DOI 10.1375/BRIM.2.2.119]; Kliegel M, 2005, J NEUROL NEUROSUR PS, V76, P1501, DOI 10.1136/jnnp.2004.051268; Kliegel M, 2004, BRAIN COGNITION, V56, P43, DOI 10.1016/j.bandc.2004.05.005; Kliegel M., 2008, PROSPECTIVE MEMORY C, P283; Knight RG, 2006, J INT NEUROPSYCH SOC, V12, P8, DOI 10.1017/S1355617706060048; Knight RG, 2005, BRAIN INJURY, V19, P19, DOI 10.1080/02699050410001720022; Kopp UA, 2003, INT J PSYCHOL, V38, P229, DOI 10.1080/00207590344000150; KVAVILASHVILI L, 1987, BRIT J PSYCHOL, V78, P507, DOI 10.1111/j.2044-8295.1987.tb02265.x; Mackinnon A, 1999, INT J METHODS PSYCHI, V8, P27, DOI [10.1002/mpr.54., DOI 10.1002/MPR.54]; Madjan A., 1996, J CLIN EXP NEUROPSYC, V18, P416; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; Maujean A., 2003, BRAIN IMPAIR, V4, P135, DOI DOI 10.1375/BRIM.4.2.135.27024; McDaniel M. A., 2007, PROSPECTIVE MEMORY O; McDaniel MA, 2000, APPL COGNITIVE PSYCH, V14, pS127, DOI 10.1002/acp.775; MCDANIEL MA, 1992, ADV LEARNING BEHAVIO, V7, P87; Mesulam M., 1985, CONT NEUROLOGY SERIE, V26; Okuda J, 1998, NEUROSCI LETT, V253, P127, DOI 10.1016/S0304-3940(98)00628-4; Palmer HM, 2000, BRAIN COGNITION, V44, P103; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Rendell PG, 2000, APPL COGNITIVE PSYCH, V14, pS43, DOI 10.1002/acp.770; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P353, DOI 10.1037/0894-4105.18.2.353; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Smith RE, 2003, J EXP PSYCHOL LEARN, V29, P347, DOI 10.1037/0278-7393.29.3.347; Sullivan K, 2005, ARCH CLIN NEUROPSYCH, V20, P745, DOI 10.1016/j.acn.2005.04.006; Titov N, 2000, BRAIN INJURY, V14, P877; VANDERLINDEN M, 1992, COGNITIVE NEUROPSYCH, V9, P301, DOI 10.1080/02643299208252063; Waugh N., 1999, THESIS GRIFFITH U BR; Wechsler D., 1991, WECHSLER INTELLIGENC; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilson B., 2005, CAMBRIDGE PROSPECTIV; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO	50	24	26	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2011	25	2					192	205		10.3109/02699052.2010.541896			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	731JJ	WOS:000288101800006	21219091				2021-06-18	
J	Armstead, WM; Kiessling, JW; Riley, J; Kofke, WA; Vavilala, MS				Armstead, William M.; Kiessling, J. Willis; Riley, John; Kofke, W. Andrew; Vavilala, Monica S.			Phenylephrine Infusion Prevents Impairment of ATP- and Calcium-Sensitive Potassium Channel-Mediated Cerebrovasodilation after Brain Injury in Female, but Aggravates Impairment in Male, Piglets through Modulation of ERK MAPK Upregulation	JOURNAL OF NEUROTRAUMA			English	Article						cerebral circulation; newborn; potassium channels; signal transduction	CEREBRAL-BLOOD-FLOW; K-ATP; ARTERY OCCLUSION; ISCHEMIC BRAIN; PIAL-ARTERIES; ADRENOMEDULLIN; HYPOTENSION; NEWBORN; FLUID; AUTOREGULATION	Traumatic brain injury (TBI) contributes to morbidity in children and boys, and hypotension worsens outcome. Extracellular signal-related kinase (ERK) mitogen-activated protein kinase (MAPK) is upregulated more in males and reduces cerebral blood flow (CBF) after fluid percussion injury (FPI). Increased cerebral perfusion pressure (CPP) via phenylephrine (Phe) sex-dependently improves impairment of the cerebral autoregulation seen after FPI through modulation of ERK MAPK upregulation, which is aggravated in males, but is blocked in females. Activation of ATP- and calcium-sensitive (Katp and Kca) channels produces cerebrovasodilation and contributes to autoregulation, both of which are impaired after FPI. Using piglets equipped with a closed cranial window, we hypothesized that potassium channel functional impairment after FPI is prevented by Phe in a sex-dependent manner through modulation of ERK MAPK upregulation. The Katp and Kca agonists cromakalim and NS 1619 produced vasodilation that was impaired after FPI more in males than in females. Phe prevented reductions in cerebrovasodilation after cromakalim and NS 1619 in females, but reduced dilation after these potassium channel agonists were given to males after FPI. Co-administration of U 0126, an ERK antagonist, and Phe fully restored dilation to cromakalim, calcitonin gene-related peptide (CGRP), and NS 1619, in males after FPI. These data indicate that Phe sex-dependently prevents impairment of Katp and Kca channel-mediated cerebrovasodilation after FPI in females, but aggravates impairment in males, through modulation of ERK MAPK upregulation. Since autoregulation of CBF is dependent on intact functioning of potassium channels, these data suggest a role for sex-dependent mechanisms in the treatment of cerebral autoregulation impairment after pediatric TBI.	[Armstead, William M.; Kiessling, J. Willis; Kofke, W. Andrew] Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Armstead, William M.] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; [Kofke, W. Andrew] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol Pediat & Neurol Surg, Seattle, WA 98195 USA	Armstead, WM (corresponding author), Univ Penn, Dept Anesthesiol & Crit Care, 3620 Hamilton Walk,JM3, Philadelphia, PA 19104 USA.	armsteaw@uphs.upenn.edu		Riley, John/0000-0002-7932-8935	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD57355]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD057355] Funding Source: NIH RePORTER	This research was supported by grant HD57355 from the National Institutes of Health.	Armstead WM, 2007, J CEREBR BLOOD F MET, V27, P1702, DOI 10.1038/sj.jcbfm.9600473; Armstead WM, 2010, CRIT CARE MED, V38, P1868, DOI 10.1097/CCM.0b013e3181e8ac1a; Armstead WM, 2010, J NEUROTRAUM, V27, P391, DOI 10.1089/neu.2009.1094; Armstead WM, 2009, J CEREBR BLOOD F MET, V29, P524, DOI 10.1038/jcbfm.2008.142; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 1999, BRAIN RES, V816, P158, DOI 10.1016/S0006-8993(98)01146-9; Armstead WM, 1997, STROKE, V28, P2273, DOI 10.1161/01.STR.28.11.2273; Armstead WM, 2000, MICROCIRCULATION, V7, P225, DOI 10.1038/sj.mn.7300110; BASKAYA MK, 1995, J CEREBR BLOOD F MET, V15, P827, DOI 10.1038/jcbfm.1995.103; Chaiwat O, 2009, J NEUROTRAUM, V26, P657, DOI 10.1089/neu.2008.0770; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; DOBBING J, 1974, PEDIATRICS, V53, P2; Dogan A, 1997, J CEREBR BLOOD F MET, V17, P19, DOI 10.1097/00004647-199701000-00004; Faraci FM, 1998, PHYSIOL REV, V78, P53; Ishikawa S, 2009, ANESTH ANALG, V108, P1631, DOI 10.1213/ane.0b013e31819d94e3; Juhl L, 2006, EUR J PHARMACOL, V538, P101, DOI 10.1016/j.ejphar.2006.03.005; Laher I, 2001, J CEREBR BLOOD F MET, V21, P887, DOI 10.1097/00004647-200108000-00001; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Miyashita K, 2006, ENDOCRINOLOGY, V147, P1642, DOI 10.1210/en.2005-1038; Robertson CL, 2001, J NEUROTRAUM, V18, P861, DOI 10.1089/089771501750451785; Ross J, 2003, AM J PHYSIOL-REG I, V285, pR149, DOI 10.1152/ajpregu.00003.2003; Salvucci A, 2000, BRAIN RES, V887, P406, DOI 10.1016/S0006-8993(00)03079-1; WANG XK, 1995, P NATL ACAD SCI USA, V92, P11480, DOI 10.1073/pnas.92.25.11480; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37	24	24	26	0	2	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2011	28	1					105	111		10.1089/neu.2010.1581			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	710DT	WOS:000286491800010	20964536	Green Published			2021-06-18	
J	Morali, G; Montes, P; Hernandez-Morales, L; Monfil, T; Espinosa-Garcia, C; Cervantes, M				Morali, Gabriela; Montes, Pedro; Hernandez-Morales, Lucia; Monfil, Tomas; Espinosa-Garcia, Claudia; Cervantes, Miguel			Neuroprotective effects of progesterone and allopregnanolone on long-term cognitive outcome after global cerebral ischemia	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						Neuroprotection; global cerebral ischemia; progesterone; allopregnanolone; long-term cognitive performance; hippocampal pyramidal neurons loss	TRAUMATIC BRAIN-INJURY; MORRIS WATER MAZE; RADIAL-ARM MAZE; PREFRONTAL CORTEX; ARTERY OCCLUSION; CELL-DEATH; NEURONAL DAMAGE; WORKING-MEMORY; INFLAMMATORY RESPONSE; FUNCTIONAL DEFICITS	Purpose: To assess the long-term neuroprotective effects of progesterone (P-4) and allopregnanolone (ALLO) on functional and morphological parameters of the integrity of the hippocampus, after global cerebral ischemia. Methods: Adult male Sprague-Dawley rats were subjected to a transient severe (20 min) forebrain ischemia (Isch) episode and treated with P-4 or ALLO (8 mg/kg i.v.) or its vehicle, at 20 min, 2, 6, 24, 48 and 72 h after ischemia. Rats subjected to Sham procedures, and intact rats were included as non-ischemic controls. Three months after ischemia, both the functional (spatial learning and memory, and reference and working memory), and the morphological integrity (dimensions of the hippocampal formation, thickness of the CA1 subfield, and pyramidal neuron population) of the hippocampus and the medial prefrontal cortex (mPFC) were determined. Results: Treatment with P-4 or ALLO significantly reduced the impairment in spatial learning and memory, as well as in reference and working memory, and prevented the narrowing of the hippocampus, otherwise induced by ischemia. This better performance of P-4-and ALLO-treated rats than vehicle (Veh) -treated rats, occurred in spite of a loss of pyramidal neurons in the CA1, CA2, CA3 and hilus subfields of the Ammon's horn (remaining neurons: Isch+Veh: 21.0, 35.6, 44.1, and 40.3%; Isch+P-4: 19.9, 32.2, 41.1, and 32.5%; Isch+ALLO: 25.5, 62.0, 73.7, and 56.7%), and non-significant changes in the mPFC, as compared to the Intact group (100%). Conclusions: Performance of P-4-or ALLO-treated rats in learning and memory tests suggests that these steroids promoted neural conditions accounting for adequate functioning long after ischemia, in spite of the loss of hippocampal pyramidal neurons.	[Morali, Gabriela; Montes, Pedro; Hernandez-Morales, Lucia; Monfil, Tomas; Espinosa-Garcia, Claudia] IMSS, Ctr Med Nacl Siglo 21, Unidad Invest Med Farmacol, Mexico City 03100, DF, Mexico; [Cervantes, Miguel] Univ Michoacana, Neurosci Lab, Div Estudios Posgrad, Fac Ciencias Med & Biol Dr Ignacio Chavez, Morelia, Michoacan, Mexico	Morali, G (corresponding author), IMSS, Ctr Med Nacl Siglo 21, Unidad Invest Med Farmacol, Eugenia 626 Girasol 302, Mexico City 03100, DF, Mexico.	gmorali@hotmail.com	Morali, Gabriela/AAH-8014-2020	Montes, Pedro/0000-0003-1630-5047; Espinosa-Garcia, Claudia/0000-0002-9909-9092	Consejo Nacional de Ciencia y Tecnologia (CONACYT)Consejo Nacional de Ciencia y Tecnologia (CONACyT) [31073-M]; Instituto Mexicano del Seguro Social [FP-2003/035, FP-2003/451]	Partially supported by Consejo Nacional de Ciencia y Tecnologia (CONACYT, 31073-M), and by Instituto Mexicano del Seguro Social (FP-2003/035 and FP-2003/451). Laboratory expenses including a system for image analysis under the microscope, steroid hormones, reagents, and maintenance of laboratory rats, were the main aspects in which the work was funded.	Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; Block F, 1999, PROG NEUROBIOL, V58, P279, DOI 10.1016/S0301-0082(98)00085-9; Cai WY, 2008, NEUROPHARMACOLOGY, V55, P127, DOI 10.1016/j.neuropharm.2008.04.023; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Ciriza I, 2006, J NEUROBIOL, V66, P916, DOI 10.1002/neu.20293; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; Crepel V, 2003, J CELL MOL MED, V7, P401, DOI 10.1111/j.1582-4934.2003.tb00242.x; Cutler SM, 2006, EXP NEUROL, V200, P378, DOI 10.1016/j.expneurol.2006.02.137; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; DAVIS HP, 1986, PHYSIOL BEHAV, V37, P387, DOI 10.1016/0031-9384(86)90195-2; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; DOWNIE MM, 1983, BASIC STAT METHODS; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Floresco SB, 1997, J NEUROSCI, V17, P1880; Frye CA, 2000, PSYCHONEUROENDOCRINO, V25, P407, DOI 10.1016/S0306-4530(99)00068-2; Fujioka M, 2000, CEREBROVASC DIS, V10, P2, DOI 10.1159/000016018; Fuster JM, 1999, ACTA PSYCHIAT SCAND, V99, P51, DOI 10.1111/j.1600-0447.1999.tb05983.x; Garcia-Chavez D, 2008, NEUROSCI LETT, V448, P148, DOI 10.1016/j.neulet.2008.10.043; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Gibson CL, 2009, NEUROSCIENTIST, V15, P324, DOI 10.1177/1073858409333069; Gobbo OL, 2004, BEHAV BRAIN RES, V152, P231, DOI 10.1016/j.bbr.2003.10.017; Gonzalez-Burgos I, 2007, NEUROSCI LETT, V423, P162, DOI 10.1016/j.neulet.2007.06.050; Gonzalez-Vidal MD, 1998, ARCH MED RES, V29, P117; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; GWAG BJ, 2002, METH NE FRO NEUROSCI, P79; HARA H, 1993, PROG NEUROBIOL, V40, P645, DOI 10.1016/0301-0082(93)90009-H; Hartman RE, 2005, BRAIN RES, V1043, P48, DOI 10.1016/j.brainres.2005.02.030; Herson PS, 2009, SEMIN REPROD MED, V27, P229, DOI 10.1055/s-0029-1216276; Hoffman GE, 2003, EXP NEUROL, V182, P124, DOI 10.1016/S0014-4886(03)00104-3; Hoffman GE, 2006, ENDOCRINE, V29, P217, DOI 10.1385/ENDO:29:2:217; HORI N, 1994, EXP NEUROL, V129, P279, DOI 10.1006/exnr.1994.1170; Hu ZY, 2009, CURR MED CHEM, V16, P1418, DOI 10.2174/092986709787846523; Ishrat T, 2009, BRAIN RES, V1257, P94, DOI 10.1016/j.brainres.2008.12.048; Ito U, 2006, STROKE, V37, P2134, DOI 10.1161/01.STR.0000231875.96714.b1; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Jung MW, 1998, CEREB CORTEX, V8, P437, DOI 10.1093/cercor/8.5.437; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; Langdon KD, 2008, EUR J NEUROSCI, V28, P2310, DOI 10.1111/j.1460-9568.2008.06513.x; Laroche S, 2000, HIPPOCAMPUS, V10, P438; Lee I, 2003, J NEUROSCI, V23, P1517; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Letechipia-Vallejo G, 2007, J PINEAL RES, V42, P139, DOI 10.1111/j.1600-079X.2006.00395.x; Lim C, 2004, NEUROLOGY, V63, P1774, DOI 10.1212/01.WNL.0000144189.83077.8E; Lipton P, 1999, PHYSIOL REV, V79, P1431; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; MCDONALD RJ, 1994, BEHAV NEURAL BIOL, V61, P260, DOI 10.1016/S0163-1047(05)80009-3; MCDONALD RJ, 1995, BEHAV NEUROSCI, V109, P579, DOI 10.1037/0735-7044.109.4.579; Mehta SL, 2007, BRAIN RES REV, V54, P34, DOI 10.1016/j.brainresrev.2006.11.003; Morali G, 2005, NEUROSCI LETT, V382, P286, DOI 10.1016/j.neulet.2005.03.066; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181; NAKANO S, 1990, NEUROSCIENCE, V38, P115, DOI 10.1016/0306-4522(90)90378-H; Nilsen J, 2002, ENDOCRINOLOGY, V143, P205, DOI 10.1210/en.143.1.205; NUNN JA, 1994, BEHAV BRAIN RES, V62, P41, DOI 10.1016/0166-4328(94)90036-1; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Oliveira MGM, 1997, NEUROBIOL LEARN MEM, V68, P32, DOI 10.1006/nlme.1996.3761; OLSEN GM, 1994, BEHAV NEUROSCI, V108, P681, DOI 10.1037/0735-7044.108.4.681; OLTON DS, 1987, PHYSIOL BEHAV, V40, P793, DOI 10.1016/0031-9384(87)90286-1; Olvera-Cortes E, 2004, BRAIN RES BULL, V62, P379, DOI 10.1016/j.brainresbull.2003.10.003; Olvera-Cortes E, 2002, BRAIN RES BULL, V58, P261, DOI 10.1016/S0361-9230(02)00769-4; Ozacmak VH, 2009, PHYSIOL RES, V58, P909, DOI 10.33549/physiolres.931647; Packard MG, 1996, NEUROBIOL LEARN MEM, V65, P65, DOI 10.1006/nlme.1996.0007; Papadopoulos CM, 2006, CEREB CORTEX, V16, P529, DOI 10.1093/cercor/bhi132; PAXINOS G, 1986, RAT BRAIN STEREOTAXI, pR8; Plamondon H, 2008, PHYSIOL BEHAV, V95, P492, DOI 10.1016/j.physbeh.2008.07.020; PULSINELLI WA, 1988, STROKE, V19, P913, DOI 10.1161/01.STR.19.7.913; PULSINELLI WA, 1979, STROKE, V10, P267, DOI 10.1161/01.STR.10.3.267; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Roberge MC, 2008, BEHAV BRAIN RES, V187, P123, DOI 10.1016/j.bbr.2007.09.002; ROD MR, 1990, CAN J PSYCHOL, V44, P196, DOI 10.1037/h0084242; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Rupprecht R, 1999, TRENDS NEUROSCI, V22, P410, DOI 10.1016/S0166-2236(99)01399-5; Sarraf-Yazdi S, 1999, NEUROL DIS, V48, P243; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Sayeed I, 2009, BRAIN RES, V1263, P165, DOI 10.1016/j.brainres.2009.01.045; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Siegel S., 1956, NONPARAMETRIC STAT B; SMITH SS, 1991, NEUROSCIENCE, V42, P309, DOI 10.1016/0306-4522(91)90377-Z; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; Vagnerova K, 2008, ANESTH ANALG, V107, P201, DOI 10.1213/ane.0b013e31817326a5; VanLandingham JW, 2007, NEUROSCI LETT, V425, P94, DOI 10.1016/j.neulet.2007.08.045; VanLandingham JW, 2006, NEUROPHARMACOLOGY, V51, P1078, DOI 10.1016/j.neuropharm.2006.07.015; VOLPE BT, 1984, STROKE, V15, P558, DOI 10.1161/01.STR.15.3.558; Wang JP, 2009, BRAIN RES BULL, V79, P426, DOI 10.1016/j.brainresbull.2009.05.018; White NM, 2002, NEUROBIOL LEARN MEM, V77, P125, DOI 10.1006/nlme.2001.4008; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; Zheng P, 2009, PROG NEUROBIOL, V89, P134, DOI 10.1016/j.pneurobio.2009.07.001; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	104	24	25	1	5	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2011	29	1					1	15		10.3233/RNN-2011-0571			15	Neurosciences	Neurosciences & Neurology	722ZZ	WOS:000287476200001	21335664				2021-06-18	
J	Smerbeck, AM; Parrish, J; Yeh, EA; Hoogs, M; Krupp, LB; Weinstock-Guttman, B; Benedict, RHB				Smerbeck, A. M.; Parrish, J.; Yeh, E. A.; Hoogs, M.; Krupp, Lauren B.; Weinstock-Guttman, B.; Benedict, R. H. B.			Regression-Based Pediatric Norms for the Brief Visuospatial Memory Test - Revised and the Symbol Digit Modalities Test	CLINICAL NEUROPSYCHOLOGIST			English	Article						Brief Visuospatial Memory Test - Revised; BVMTR; Symbol Digit Modalities Test; SDMT; Multiple sclerosis; Psychometrics; Multiple regression; Normative data	TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; COGNITIVE FUNCTION; MINIMAL ASSESSMENT; ALCOHOL; VALIDITY; CHILDREN	The Brief Visuospatial Memory Test - Revised (BVMTR) and the Symbol Digit Modalities Test (SDMT) oral-only administration are known to be sensitive to cerebral disease in adult samples, but pediatric norms are not available. A demographically balanced sample of healthy control children (N = 92) ages 6-17 was tested with the BVMTR and SDMT. Multiple regression analysis (MRA) was used to develop demographically controlled normative equations. This analysis provided equations that were then used to construct demographically adjusted z-scores for the BVMTR Trial 1, Trial 2, Trial 3, Total Learning, and Delayed Recall indices, as well as the SDMT total correct score. To demonstrate the utility of this approach, a comparison group of children with acute disseminated encephalomyelitis (ADEM) or multiple sclerosis (MS) were also assessed. We find that these visual processing tests discriminate neurological patients from controls. As the tests are validated in adult multiple sclerosis, they are likely to be useful in monitoring pediatric onset multiple sclerosis patients as they transition into adulthood.	[Smerbeck, A. M.; Parrish, J.; Yeh, E. A.; Hoogs, M.; Weinstock-Guttman, B.; Benedict, R. H. B.] SUNY Buffalo, Dept Neurol, Buffalo, NY 14260 USA; [Smerbeck, A. M.; Parrish, J.; Yeh, E. A.; Hoogs, M.; Weinstock-Guttman, B.; Benedict, R. H. B.] Buffalo Gen Hosp, Jacobs Neurol Inst, Buffalo, NY 14203 USA; [Krupp, Lauren B.] SUNY Stony Brook, Med Ctr, Natl Pediat MS Ctr, Stony Brook, NY 11794 USA	Benedict, RHB (corresponding author), Buffalo Gen Hosp, Jacobs Neurol Inst, 100 High St, Buffalo, NY 14203 USA.	benedict@buffalo.edu		krupp, lauren/0000-0001-7003-807X			Benedict R., 1997, BRIEF VISUOSPATIAL M; Benedict RHB, 2008, MULT SCLER J, V14, P940, DOI 10.1177/1352458508090923; Benedict RHB, 2006, J INT NEUROPSYCH SOC, V12, P549, DOI 10.1017/S1355617706060723; Benedict RHB, 2005, J INT NEUROPSYCH SOC, V11, P727, DOI 10.1017/S1355617705050782; Benedict RHB, 2002, CLIN NEUROPSYCHOL, V16, P381, DOI 10.1076/clin.16.3.381.13859; Burden MJ, 2005, ALCOHOL CLIN EXP RES, V29, P1473, DOI 10.1097/01.alc.0000175036.34076.a0; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd, pXXI; Dalen K, 2009, NEUROPEDIATRICS, V40, P162, DOI 10.1055/s-0029-1243176; Delis DC, 2000, CALIFORNIA VERBAL LE; Deloire MSA, 2006, MULT SCLER J, V12, P445, DOI 10.1191/1352458506ms1289oa; Donders J, 2008, J INT NEUROPSYCH SOC, V14, P651, DOI 10.1017/S1355617708080752; Drake AS, 2010, MULT SCLER J, V16, P228, DOI 10.1177/1352458509354552; Lajiness-O'Neill R, 2010, APPL NEUROPSYCHOL, V17, P83, DOI 10.1080/09084281003708837; Manji S, 2009, DEV NEUROREHABIL, V12, P239, DOI 10.1080/17518420902980118; Parmenter BA, 2007, MULT SCLER J, V13, P52, DOI 10.1177/1352458506070750; Parmenter BA, 2010, J INT NEUROPSYCH SOC, V16, P6, DOI 10.1017/S1355617709990750; Rao SM, 1991, MANUAL BRIEF REPEATA; Smith A., 1982, SYMBOL DIGIT MODALIT	18	24	24	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2011	25	3					402	412	PII 934543196	10.1080/13854046.2011.554445			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	751RU	WOS:000289636100005	21391150				2021-06-18	
B	Soekadar, SR; Birbaumer, N; Cohen, LG		Kansaku, K; Cohen, LG		Soekadar, Surjo R.; Birbaumer, Niels; Cohen, Leonardo G.			Brain-Computer Interfaces in the Rehabilitation of Stroke and Neurotrauma	SYSTEMS NEUROSCIENCE AND REHABILITATION			English	Article; Book Chapter							TRANSCRANIAL MAGNETIC STIMULATION; EVENT-RELATED DESYNCHRONIZATION; PRIMARY MOTOR CORTEX; NONINVASIVE CORTICAL STIMULATION; CONTROLLED-TRIAL; ELECTROCORTICOGRAPHIC SIGNALS; MACHINE INTERFACES; SKILL ACQUISITION; MOVEMENT; HAND	Paralysis after stroke or neurotrauma is among the leading causes of long term disability in adults. The development of brain-computer interface (BCI) systems that allow online classification of electric or metabolic brain activity and their translation into control signals of external devices or computers have led to two major approaches in tackling the problem of paralysis. While assistive Bel systems strive for continuous high-dimensional control of robotic devices or functional electric stimulation (FES) of paralyzed muscles to substitute for lost motor functions in a 'daily life environment (e.g. Velliste et al. 2008 [1]; Hochberg et al. 2006 [2]; Pfurtscheller et al. 2000 [3]), restorative BCI systems aim at normalization of neurophysiologic activity that might facilitate motor recovery (e.g. Birbaumer et al. 2007, 2009 [4, 5]; Daly et al. 2008 [6]). In order to make assistive BCI systems work in daily life, high BCI communication speed is necessary, an issue that by now can only be achieved by invasive recordings of brain activity (e.g. via multi-unit arrays, MUA, or electrocorticogram, ECoG). Restorative BCI systems, in contrast, were developed as training tools based on non-invasive methods such as electro- or magnetoencephalography (EEG/MEG). More recently developed approaches use real-time functional magnetic resonance imaging (rtfMRI) or near-infrared spectroscopy (NIRS). Here, we provide an overview of the current state in the development and application of assistive and restorative BCI and introduce novel approaches to improve BCI control with brain stimulation such as transcranial direct current stimulation (tDCS). The outlook of using BCI in rehabilitation of stroke and neurotrauma is discussed.	[Soekadar, Surjo R.; Cohen, Leonardo G.] NINDS, Human Cort Physiol & Stroke Neurorehabil Sect, NIH, Bethesda, MD 20892 USA; [Soekadar, Surjo R.; Birbaumer, Niels] Univ Tubingen, Inst Med Psychol & Behav Neurobiol, Tubingen, Germany; [Birbaumer, Niels] Osped san Camillo, IRCCS, Venice, Italy	Cohen, LG (corresponding author), NINDS, Human Cort Physiol & Stroke Neurorehabil Sect, NIH, 10 Ctr Dr, Bethesda, MD 20892 USA.	cohenl@ninds.nih.gov	Soekadar, Surjo/AAA-3801-2020	Soekadar, Surjo/0000-0003-1280-5538			Ang KK, 2010, IEEE ENG MED BIO, P5549, DOI 10.1109/IEMBS.2010.5626782; Antal A, 2004, EUR J NEUROSCI, V19, P2888, DOI 10.1111/j.1460-9568.2004.03367.x; Ball T, 2009, NEUROIMAGE, V46, P708, DOI 10.1016/j.neuroimage.2009.02.028; Berger H, 1929, ARCH PSYCHIAT NERVEN, V87, P527, DOI 10.1007/BF01797193; Birbaumer N, 2003, IEEE T NEUR SYS REH, V11, P120, DOI 10.1109/TNSRE.2003.814439; Birbaumer N, 1999, NATURE, V398, P297, DOI 10.1038/18581; BIRBAUMER N, 1986, CEREBRAL PSYCHOPHYSI; Birbaumer N, 2007, J PHYSIOL-LONDON, V579, P621, DOI 10.1113/jphysiol.2006.125633; Birbaumer N, 2006, PSYCHOPHYSIOLOGY, V43, P517, DOI 10.1111/j.1469-8986.2006.00456.x; Birbaumer N, 2009, INT REV NEUROBIOL, V86, P107, DOI 10.1016/S0074-7742(09)86008-X; Blankertz B, 2007, NEUROIMAGE, V37, P539, DOI 10.1016/j.neuroimage.2007.01.051; Boggio PS, 2007, RESTOR NEUROL NEUROS, V25, P123; Bradberry TJ, 2010, J NEUROSCI, V30, P3432, DOI 10.1523/JNEUROSCI.6107-09.2010; Broetz D, 2010, NEUROREHAB NEURAL RE, V24, P674, DOI 10.1177/1545968310368683; BUCH ER, 2010, ANATOMICAL PARIETO F; Buch E, 2008, STROKE, V39, P910, DOI 10.1161/STROKEAHA.107.505313; Calautti C, 2007, NEUROIMAGE, V34, P322, DOI 10.1016/j.neuroimage.2006.08.026; Caria A, 2007, NEUROIMAGE, V35, P1238, DOI 10.1016/j.neuroimage.2007.01.018; Caria A, 2011, PSYCHOPHYSIOLOGY, V48, P578, DOI 10.1111/j.1469-8986.2010.01117.x; Carmena JM, 2003, PLOS BIOL, V1, P193, DOI 10.1371/journal.pbio.0000042; Chao Zenas C, 2010, Front Neuroeng, V3, P3, DOI 10.3389/fneng.2010.00003; Chklovskii DB, 2004, NATURE, V431, P782, DOI 10.1038/nature03012; Conforto AB, 2002, ANN NEUROL, V51, P122, DOI 10.1002/ana.10070; Daly JJ, 2008, LANCET NEUROL, V7, P1032, DOI 10.1016/S1474-4422(08)70223-0; Daly JJ, 2009, J NEUROL PHYS THER, V33, P203, DOI 10.1097/NPT.0b013e3181c1fc0b; deCharms RC, 2005, P NATL ACAD SCI USA, V102, P18626, DOI 10.1073/pnas.0505210102; Dickey AS, 2009, J NEUROPHYSIOL, V102, P1331, DOI 10.1152/jn.90920.2008; Diwakar M, 2011, NEUROIMAGE, V54, P253, DOI 10.1016/j.neuroimage.2010.07.023; Donoghue JP, 2007, J PHYSIOL-LONDON, V579, P603, DOI 10.1113/jphysiol.2006.127209; DUM RP, 1991, J NEUROSCI, V11, P667; Duque J, 2005, NEUROIMAGE, V28, P940, DOI 10.1016/j.neuroimage.2005.06.033; Elbert T., 1984, SELF REGULATION BRAI; FARWELL LA, 1988, ELECTROEN CLIN NEURO, V70, P510, DOI 10.1016/0013-4694(88)90149-6; FETZ EE, 1969, SCIENCE, V163, P955, DOI 10.1126/science.163.3870.955; Floel A, 2004, ANN NEUROL, V56, P206, DOI 10.1002/ana.20170; Fountas KN, 2007, STEREOT FUNCT NEUROS, V85, P264, DOI 10.1159/000107358; Freeman WJ, 2000, J NEUROSCI METH, V95, P111, DOI 10.1016/S0165-0270(99)00160-0; Fregni F, 2006, STROKE, V37, P2115, DOI 10.1161/01.STR.0000231390.58967.6b; Frost SB, 2003, J NEUROPHYSIOL, V89, P3205, DOI 10.1152/jn.01143.2002; Fuchs T, 2003, APPL PSYCHOPHYS BIOF, V28, P1, DOI 10.1023/A:1022353731579; Fulton JF, 1935, BRAIN, V58, P311, DOI 10.1093/brain/58.2.311; GASTAUT H, 1952, Mars Med, V89, P296; GEORGOPOULOS AP, 1989, SCIENCE, V243, P234, DOI 10.1126/science.2911737; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; Grefkes C, 2008, ANN NEUROL, V63, P236, DOI 10.1002/ana.21228; Harris-Love ML, 2007, J NEUROPHYSIOL, V97, P2511, DOI 10.1152/jn.01331.2006; Hesse S, 2007, RESTOR NEUROL NEUROS, V25, P9; Hinterberger T, 2005, EUR J NEUROSCI, V21, P3169, DOI 10.1111/j.1460-9568.2005.04092.x; Hochberg LR, 2006, NATURE, V442, P164, DOI 10.1038/nature04970; HOWE RC, 1972, ELECTROEN CLIN NEURO, V32, P681, DOI 10.1016/0013-4694(72)90104-6; Hummel F, 2005, BRAIN, V128, P490, DOI 10.1093/brain/awh369; Kennard MA, 1934, BRAIN, V57, P69, DOI 10.1093/brain/57.1.69; Khedr EM, 2005, NEUROLOGY, V65, P466, DOI 10.1212/01.wnl.0000173067.84247.36; Kim YH, 2006, STROKE, V37, P1471, DOI 10.1161/01.STR.0000221233.55497.51; Kotchoubey B, 2001, EPILEPSIA, V42, P406, DOI 10.1046/j.1528-1157.2001.22200.x; Kubler A, 2005, NEUROLOGY, V64, P1775, DOI 10.1212/01.WNL.0000158616.43002.6D; Kubler A, 2001, PSYCHOL BULL, V127, P358, DOI 10.1037//0033-2909.127.3.358; Kwakkel G, 2003, STROKE, V34, P2181, DOI 10.1161/01.STR.0000087172.16305.CD; Lebedev MA, 2006, TRENDS NEUROSCI, V29, P536, DOI 10.1016/j.tins.2006.07.004; Lefaucheur Jean-Pascal, 2004, Suppl Clin Neurophysiol, V57, P737; Lenhardt A, 2008, IEEE T NEUR SYS REH, V16, P121, DOI 10.1109/TNSRE.2007.912816; Leocani L, 2001, CLIN NEUROPHYSIOL, V112, P923, DOI 10.1016/S1388-2457(01)00530-2; Leuthardt EC, 2004, J NEURAL ENG, V1, P63, DOI 10.1088/1741-2560/1/2/001; Liu KPY, 2009, STROKE, V40, P2222, DOI 10.1161/STROKEAHA.108.540997; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Lotze M, 1999, NAT NEUROSCI, V2, P501, DOI 10.1038/9145; Luft AR, 2004, JAMA-J AM MED ASSOC, V292, P1853, DOI 10.1001/jama.292.15.1853; Malouin F, 2004, NEUROREHAB NEURAL RE, V18, P66, DOI 10.1177/0888439004266304; Mansur CG, 2005, NEUROLOGY, V64, P1802, DOI 10.1212/01.WNL.0000161839.38079.92; McFarland DJ, 2008, J NEURAL ENG, V5, P101, DOI 10.1088/1741-2560/5/2/001; Mellinger J, 2007, NEUROIMAGE, V36, P581, DOI 10.1016/j.neuroimage.2007.03.019; Miniussi C, 2005, CLIN NEUROPHYSIOL, V116, P1062, DOI 10.1016/j.clinph.2005.01.002; Murase N, 2004, ANN NEUROL, V55, P400, DOI 10.1002/ana.10848; Nagaoka T, 2010, ADV EXP MED BIOL, V662, P497, DOI 10.1007/978-1-4419-1241-1_72; Nicolelis MAL, 2003, NAT REV NEUROSCI, V4, P417, DOI 10.1038/nrn1105; Nitsche MA, 2003, J COGNITIVE NEUROSCI, V15, P619, DOI 10.1162/089892903321662994; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Page SJ, 2007, STROKE, V38, P1293, DOI 10.1161/01.STR.0000260205.67348.2b; PENFIELD W, 1951, AMA ARCH NEUROL PSY, V66, P289, DOI 10.1001/archneurpsyc.1951.02320090038004; Perelmouter J, 2000, IEEE T REHABIL ENG, V8, P227, DOI 10.1109/86.847824; Pfurtscheller G, 2000, NEUROSCI LETT, V292, P211, DOI 10.1016/S0304-3940(00)01471-3; Pfurtscheller G, 2003, NEUROSCI LETT, V351, P33, DOI 10.1016/S0304-3940(03)00947-9; PFURTSCHELLER G, 1992, J CLIN NEUROPHYSIOL, V9, P120, DOI 10.1097/00004691-199201000-00013; Pfurtscheller G, 1996, INT J PSYCHOPHYSIOL, V24, P39, DOI 10.1016/S0167-8760(96)00066-9; PFURTSCHELLER G, 1979, ELECTROEN CLIN NEURO, V46, P138, DOI 10.1016/0013-4694(79)90063-4; PFURTSCHELLER G, 2004, CLIN NEUROPHYSIOL, V57, P583; Platz T, 2002, RESTOR NEUROL NEUROS, V20, P21; Reis J, 2009, P NATL ACAD SCI USA, V106, P1590, DOI 10.1073/pnas.0805413106; Rosamond W, 2008, CIRCULATION, V117, pE25, DOI 10.1161/CIRCULATIONAHA.107.187998; Rousche PJ, 1998, J NEUROSCI METH, V82, P1, DOI 10.1016/S0165-0270(98)00031-4; Schalk G, 2008, J NEURAL ENG, V5, P75, DOI 10.1088/1741-2560/5/1/008; Scheidtmann K, 2004, RESTOR NEUROL NEUROS, V22, P393; Scherberger H, 2005, NEURON, V46, P347, DOI 10.1016/j.neuron.2005.03.004; SEIFERT AR, 1975, BIOL PSYCHOL, V3, P157, DOI 10.1016/0301-0511(75)90033-2; Serruya MD, 2002, NATURE, V416, P141, DOI 10.1038/416141a; Sitaram R, 2009, NEURAL NETWORKS, V22, P1320, DOI 10.1016/j.neunet.2009.05.009; Skinner F, 1953, SCI HUMAN BEHAV; Staba RJ, 2002, J NEUROPHYSIOL, V88, P1743, DOI 10.1152/jn.2002.88.4.1743; Strehl U, 2006, PEDIATRICS, V118, pE1530, DOI 10.1542/peds.2005-2478; Takeuchi N, 2005, STROKE, V36, P2681, DOI 10.1161/01.STR.0000189658.51972.34; Takeuchi N, 2008, J REHABIL MED, V40, P298, DOI 10.2340/16501977-0181; Taub E, 2006, Eura Medicophys, V42, P241; Taylor DM, 2002, SCIENCE, V296, P1829, DOI 10.1126/science.1070291; Theodore William H., 2003, Epilepsy Curr, V3, P191, DOI 10.1046/j.1535-7597.2003.03607.x; Vargas-Irwin CE, 2010, J NEUROSCI, V30, P9659, DOI 10.1523/JNEUROSCI.5443-09.2010; Velliste M, 2008, NATURE, V453, P1098, DOI 10.1038/nature06996; Waldert S, 2008, J NEUROSCI, V28, P1000, DOI 10.1523/JNEUROSCI.5171-07.2008; Ward NS, 2004, ARCH NEUROL-CHICAGO, V61, P1844, DOI 10.1001/archneur.61.12.1844; Weiskopf N, 2003, NEUROIMAGE, V19, P577, DOI 10.1016/S1053-8119(03)00145-9; Wilhelm B, 2006, NEUROLOGY, V67, P534, DOI 10.1212/01.wnl.0000228226.86382.5f; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095; Wolpaw JR, 2007, J PHYSIOL-LONDON, V579, P613, DOI 10.1113/jphysiol.2006.125948; Wolpaw JR, 2000, IEEE T REHABIL ENG, V8, P164, DOI 10.1109/TRE.2000.847807; Wolpaw JR, 2004, P NATL ACAD SCI USA, V101, P17849, DOI 10.1073/pnas.0403504101; Wolpaw JR, 2002, CLIN NEUROPHYSIOL, V113, P767, DOI 10.1016/S1388-2457(02)00057-3; World Health Organization, 2003, WORLD HLTH REP SHAP; Yoo SS, 2004, NEUROREPORT, V15, P1591, DOI 10.1097/01.wnr.0000133296.39160.fe	117	24	24	0	5	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES			978-4-431-53998-8				2011							3	18		10.1007/978-4-431-54008-3_1	10.1007/978-4-431-54008-3		16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	BWO16	WOS:000294371300001					2021-06-18	
S	Tachtsidis, I; Tisdall, MM; Pritchard, C; Leung, TS; Ghosh, A; Elwell, CE; Smith, M		LaManna, JC; Puchowicz, MA; Xu, K; Harrison, DK; Bruley, DF		Tachtsidis, Ilias; Tisdall, Martin M.; Pritchard, Caroline; Leung, Terence S.; Ghosh, Arnab; Elwell, Clare E.; Smith, Martin			Analysis of the Changes in the Oxidation of Brain Tissue Cytochrome-c-Oxidase in Traumatic Brain Injury Patients during Hypercapnoea A Broadband NIRS Study	OXYGEN TRANSPORT TO TISSUE XXXII	Advances in Experimental Medicine and Biology		English	Article; Proceedings Paper	37th Annual Meeting of the International-Society-on-Oxygen-Transport-to-Tissue	JUL 05-09, 2009	Cleveland, OH	Rockland Technimed Ltd, Seahorse Bioscience, Sherwin Williams, Int Soc Cerebral Blood Flow & Metabolism, Case Western Reserve Univ, Perimed, STARR Life Sci Corp, Univ Akron, HypOxygen			CARBON-DIOXIDE; BLOOD-FLOW; METABOLISM; MICRODIALYSIS; SPECTROSCOPY; TOMOGRAPHY; HYPEROXIA	Using broadband near-infrared spectroscopy (NIRS) and cerebral micro-dialysis (MD), we investigated cerebral cellular metabolism and mitochondrial redox states, following hypercapnoea in 6 patients with traumatic brain injury (TBI). In all patients hypercapnoea increased intracranial pressure and cerebral blood flow velocity measured with transcranial Doppler. Despite the likely increase in cerebral oxygen delivery, we did not see an increase in the oxidation status of cytochrome-c-oxidase [oxCCO] in every patient. Analysis of the NIRS data demonstrated two patterns of the changes; Group A (n = 4) showed an increase in [oxCCO] of 0.34(+/-0.34)mu M and Group B (n = 2) a decrease of 0.40(+/- 0.41)mu M. Although no obvious association was seen between the Delta[oxCCO] and the MD, measured changes in lactate and pyruvate concentrations. Further work using model informed data interpretation may be helpful in understanding the multimodal signals acquired in this heterogeneous patient group.	[Tachtsidis, Ilias; Leung, Terence S.; Elwell, Clare E.; Smith, Martin] UCL, Biomed Opt Res Lab, Dept Med Phys & Bioengn, London WC1E 6BT, England; [Tisdall, Martin M.; Pritchard, Caroline; Ghosh, Arnab; Smith, Martin] Univ Coll London Hosp, Natl Hosp Neurol & Neurosurg, Neurocrit Care Unit, London, England	Tachtsidis, I (corresponding author), UCL, Biomed Opt Res Lab, Dept Med Phys & Bioengn, Gower St, London WC1E 6BT, England.	iliastac@medphys.ucl.ac.uk	Ghosh, Arnab/C-9513-2013; Tachtsidis, Ilias/N-2747-2018	Ghosh, Arnab/0000-0002-6498-258X; Tachtsidis, Ilias/0000-0002-8125-0313; Tisdall, Martin/0000-0001-8880-8386; Elwell, Clare/0000-0002-7281-7234	EPSRCUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/D060982/1]; Department of Health's National Institute for Health Research CentresNational Institute for Health Research (NIHR); Engineering and Physical Sciences Research CouncilUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/D060982/1] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1000292, G0701458] Funding Source: researchfish	The authors would like to thank the EPSRC (EP/D060982/1) for the financial support of this work. This work was undertaken at University College London Hospitals and partially funded by the Department of Health's National Institute for Health Research Centres funding scheme.	Banaji M, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000212; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Brian JE, 1998, ANESTHESIOLOGY, V88, P1365, DOI 10.1097/00000542-199805000-00029; MATCHER SJ, 1994, PHYS MED BIOL, V39, P177, DOI 10.1088/0031-9155/39/1/011; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; Tachtsidis I, 2009, ADV EXP MED BIOL, V645, P315, DOI 10.1007/978-0-387-85998-9_47; Tisdall MM, 2008, J NEUROSURG, V109, P424, DOI 10.3171/JNS/2008/109/9/0424; Tisdall MM, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2718541; Valdueza JM, 1997, AM J NEURORADIOL, V18, P1929; Vannucci RC, 1997, PEDIATR RES, V42, P24, DOI 10.1203/00006450-199707000-00005; Vespa P, 2004, BRAIN PATHOL, V14, P210, DOI 10.1111/j.1750-3639.2004.tb00055.x	11	24	24	0	7	SPRINGER-VERLAG BERLIN	BERLIN	HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY	0065-2598		978-1-4419-7755-7	ADV EXP MED BIOL	Adv.Exp.Med.Biol.		2011	701						9	14					6	Biology; Medicine, Research & Experimental; Physiology	Life Sciences & Biomedicine - Other Topics; Research & Experimental Medicine; Physiology	BVG71	WOS:000291499500002	21445763	Green Published			2021-06-18	
J	Cocchi, MN; Lucas, JM; Salciccioli, J; Carney, E; Herman, S; Zimetbaum, P; Donnino, MW				Cocchi, Michael N.; Lucas, Jason M.; Salciccioli, Justin; Carney, Erin; Herman, Susan; Zimetbaum, Peter; Donnino, Michael W.			The role of cranial computed tomography in the immediate post-cardiac arrest period	INTERNAL AND EMERGENCY MEDICINE			English	Article						Cardiac arrest; Neuroimaging; Intracranial hemorrhage; Cerebral edema	AMERICAN-HEART-ASSOCIATION; SUBARACHNOID HEMORRHAGE; RECOMMENDED GUIDELINES; UTSTEIN STYLE; WHITE-MATTER; RESUSCITATION; DENSITY	Patients who initially survive cardiac arrest are often admitted to an intensive care unit comatose and on mechanical ventilation. It is not clear whether or not a screening cranial computed tomography (CT scan) is necessary in the immediate post-arrest period. We hypothesized that there may be clinically relevant information gleaned from head CT scans obtained early in the post-arrest period that could affect immediate management of these patients, even when non-neurologic causes of cardiac arrest are suspected. A retrospective data analysis was conducted of all survivors (age > 18 years) of non-traumatic out-of-hospital cardiac arrest (OHCA) who underwent non-contrast head CT (NCHCT) within the first 24 h of admission. A total of 84 patients were identified and 51 (60.7%) met the inclusion criteria. As much as 45 (88.2%) patients in the total cohort had an NCHCT negative for ICH or herniation; of this group, 39 (76.5%) had a normal NCHCT, while six (11.8%, 95% CI: 5.1-23.8%) demonstrated varying degrees of cerebral edema or loss of gray-white matter distinction consistent with anoxic brain injury, but without herniation. Six patients (11.8%, 95% CI: 5.1-23.8%) exhibited findings consistent with either an ICH (with or without herniation) or herniation without an ICH. Four (7.8%) of these patients had an ICH without herniation, one had an acute SAH with edema and herniation, and one had frank herniation due to massive cerebral edema. The overall incidence of any kind of intracranial hemorrhage in our cohort was 9.8% (95% CI: 3.8-21.4%). In this cohort of post-cardiac arrest patients who underwent cranial computed tomography, 11.8% of patients had clinically significant abnormalities identified. The exact role of neuroimaging in this population is still in evolution, and further prospective evaluation is warranted.	[Cocchi, Michael N.; Lucas, Jason M.; Salciccioli, Justin; Carney, Erin; Donnino, Michael W.] Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA; [Herman, Susan] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA; [Zimetbaum, Peter] Beth Israel Deaconess Med Ctr, Div Cardiol, Dept Med, Boston, MA 02215 USA; [Donnino, Michael W.] Beth Israel Deaconess Med Ctr, Div Pulm Crit Care Med, Dept Med, Boston, MA 02215 USA	Cocchi, MN (corresponding author), Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA.	mcocchi@bidmc.harvard.edu		Herman, Susan/0000-0002-6556-083X	American Heart AssociationAmerican Heart Association [0735533T]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30DK040561] Funding Source: NIH RePORTER	This study was funded in part by a grant from the American Heart Association (grant number 0735533T).	Berek K, 1997, J NEUROL, V244, P556, DOI 10.1007/s004150050143; Choi SP, 2008, EMERG MED J, V25, P666, DOI 10.1136/emj.2007.053306; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; Inamasu J, 2009, RESUSCITATION, V80, P977, DOI 10.1016/j.resuscitation.2009.05.010; Inamasu J, 2009, J HEADACHE PAIN, V10, P357, DOI 10.1007/s10194-009-0138-y; Kitahara Takao, 1993, Neurological Surgery, V21, P781; Kuisma M, 1997, EUR HEART J, V18, P1122; Kurkciyan I, 2001, RESUSCITATION, V51, P27, DOI 10.1016/S0300-9572(01)00381-1; Langhelle A, 2005, RESUSCITATION, V66, P271, DOI 10.1016/j.resuscitation.2005.06.005; MORIMOTO Y, 1993, CRIT CARE MED, V21, P104, DOI 10.1097/00003246-199301000-00020; Naples R, 2009, AM J EMERG MED, V27, P63, DOI 10.1016/j.ajem.2008.01.014; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; Puettgen HA, 2007, J NEUROL SCI, V261, P108, DOI 10.1016/j.jns.2007.04.041; Rosamond W, 2008, CIRCULATION, V117, pE25, DOI 10.1161/CIRCULATIONAHA.107.187998; Sasson C, 2008, JAMA-J AM MED ASSOC, V300, P1432, DOI 10.1001/jama.300.12.1432; Torbey MT, 2004, RESUSCITATION, V63, P55, DOI 10.1016/j.resuscitation.2004.03.021; Torbey MT, 2000, STROKE, V31, P2163, DOI 10.1161/01.STR.31.9.2163; Yanagawa Y, 2005, RESUSCITATION, V64, P97, DOI 10.1016/j.resuscitation.2004.06.015	18	24	24	0	3	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1828-0447	1970-9366		INTERN EMERG MED	Intern. Emerg. Med.	DEC	2010	5	6					533	538		10.1007/s11739-010-0403-8			6	Medicine, General & Internal	General & Internal Medicine	684LN	WOS:000284551500011	20454869				2021-06-18	
J	Yang, DY; Chen, YJ; Wang, MF; Pan, HC; Chen, SY; Cheng, FC				Yang, Dar-Yu; Chen, Ying-Ju; Wang, Ming-Fu; Pan, Hung-Chuan; Chen, Shen-Ying; Cheng, Fu-Chou			Granulocyte colony-stimulating factor enhances cellular proliferation and motor function recovery on rats subjected to traumatic brain injury	NEUROLOGICAL RESEARCH			English	Article						G-CSF; TBI; Osmotic pump; Neurogenesis; Neuroprotection	CONTROLLED CORTICAL IMPACT; FOCAL CEREBRAL-ISCHEMIA; G-CSF; GROWTH-FACTOR; NEUROGENESIS; MICE; CELLS; MIGRATION; PROTECTS; CHILDREN	Objective: Traumatic brain injury (TBI) results in neurological dysfunction and death through primary or secondary mechanisms. Here, we evaluated the effect of osmotic pump delivery of granulocyte colony-stimulating factor (G-CSF) on the histopathology and motor function recovery of rats after experimental TBI. Methods: Sprague-Dawley rats were used as experimental model by fluid percussion device to cause brain injury on the motor cortex area. The rats were simultaneously subjected to TBI and were implanted of min-osmotic pump containing recombinant human G-CSF (300 mu g/700 mu l) via intraperitoneal injection. Motor function was assessed by rotarod test. 5-bromo-2'-deoxyuridine (BrdU) was used to label the proliferating cells and their differentiation was evaluated by histology and immunohistochemistry. Results: The G-CSF group showed significantly better motor function recovery than the control group, and the effect lasted up to 14 days after TBI. Moreover, the G-CSF group exhibited a greater increase in the number of BrdU-positive cells compared with the control group. The G-CSF group also had a significantly higher number of DCX-positive cells in the ipsilateral subventricular zone (SVZ) than the control group. Conclusions: These data suggest that the beneficial effect of delivering G-CSF via an osmotic pump may improve the motor function and enhance neurogenesis in the SVZ of the injured brain.	[Chen, Ying-Ju; Chen, Shen-Ying; Cheng, Fu-Chou] Taichung Vet Gen Hosp, Dept Med Res, Stem Cell Ctr, Taichung 407, Taiwan; [Yang, Dar-Yu] Chang Bing Chwan Mem Hosp, Dept Neurosurg, Changhua, Taiwan; [Chen, Ying-Ju; Wang, Ming-Fu; Chen, Shen-Ying] Providence Univ, Dept Food & Nutr, Taichung, Taiwan; [Pan, Hung-Chuan] Taichung Vet Gen Hosp, Dept Neurosurg, Taichung 407, Taiwan	Cheng, FC (corresponding author), Taichung Vet Gen Hosp, Dept Med Res, Stem Cell Ctr, 160,Sec 3,Taichung Port Rd, Taichung 407, Taiwan.	fucheng@vghtc.gov.tw			Taichung Veterans General Hospital and Providence University [TCVGH-PU-978107]	This study was supported by a grant from Taichung Veterans General Hospital and Providence University (TCVGH-PU-978107). We also thank the Biostatistics Task Force of TCVGH for their assistance with the statistical analyses.	Baron R, 2008, FASEB J, V22, P2843, DOI 10.1096/fj.08-105866; Cao XQ, 2006, J NEUROCHEM, V99, P861, DOI 10.1111/j.1471-4159.2006.04125.x; Chiaretti A, 2009, NEUROLOGY, V72, P609, DOI 10.1212/01.wnl.0000342462.51073.06; Chiaretti A, 2008, J TRAUMA, V65, P80, DOI 10.1097/TA.0b013e31805f7036; Conley R, 2006, CURR MED RES OPIN, V22, P1879, DOI 10.1185/030079906X132613; Cooper JD, 2007, J NEUROSCI METH, V160, P269, DOI 10.1016/j.jneumeth.2006.09.014; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Huang HY, 2007, NEUROBIOL AGING, V28, P1258, DOI 10.1016/j.neurobiolaging.2006.05.037; Jung KH, 2006, BRAIN RES, V1073, P190, DOI 10.1016/j.brainres.2005.12.037; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Lee ST, 2008, BRAIN RES, V1194, P130, DOI 10.1016/j.brainres.2007.11.058; Lee ST, 2005, BRAIN RES, V1058, P120, DOI 10.1016/j.brainres.2005.07.076; Lu CZ, 2006, BIOCHEM SOC T, V34, P1327, DOI 10.1042/BST0341327; Nygren J, 2006, STROKE, V37, P2824, DOI 10.1161/01.STR.0000244769.39952.90; Paredes J, 2000, BRAIN RES, V887, P157, DOI 10.1016/S0006-8993(00)02972-3; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Ren JM, 2005, CNS NEUROL DISORD-DR, V4, P121, DOI 10.2174/1568007053544101; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Sakowitz OW, 2006, ACTA NEUROCHIR SUPPL, V96, P139; Schneider A, 2005, CELL CYCLE, V4, P1753, DOI 10.4161/cc.4.12.2213; Schneider A, 2005, J CLIN INVEST, V115, P2083, DOI 10.1172/JCI23559; Sehara Y, 2007, BRAIN RES, V1151, P142, DOI 10.1016/j.brainres.2007.01.149; Sheibani N, 2004, CRIT CARE MED, V32, P2274, DOI 10.1097/01.CCM.0000145998.11686.ED; Shyu WC, 2004, CIRCULATION, V110, P1847, DOI 10.1161/01.CIR.0000142616.07367.66; Solaroglu I, 2006, STROKE, V37, P1123, DOI 10.1161/01.STR.0000208205.26253.96; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Vink R, 2003, NEUROSCI LETT, V336, P41, DOI 10.1016/S0304-3940(02)01244-2; Volmar CH, 2008, CYTOKINE, V42, P336, DOI 10.1016/j.cyto.2008.03.007; Whittlesey KJ, 2004, EXP NEUROL, V190, P1, DOI 10.1016/j.expneurol.2004.06.020; Yang SX, 2008, STROKE, V39, P2079, DOI 10.1161/STROKEAHA.107.508911	33	24	24	0	4	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0161-6412			NEUROL RES	Neurol. Res.	DEC	2010	32	10					1041	1049		10.1179/016164110X12807570510013			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	670LD	WOS:000283422300005	20810026				2021-06-18	
J	Chauhan, NB; Gatto, R				Chauhan, Neelima B.; Gatto, Roclolfo			Synergistic benefits of erythropoietin and simvastatin after traumatic brain injury	BRAIN RESEARCH			English	Article						Axonal injury; Cell proliferation; Spatial learning; Memory; Cortex; Dentate gyrus	CONTROLLED CORTICAL IMPACT; RECOMBINANT-HUMAN-ERYTHROPOIETIN; AMYLOID PRECURSOR PROTEIN; RECOVERY TRIAL NEUSTART; NITRIC-OXIDE SYNTHASE; ACUTE ISCHEMIC-STROKE; HIGH-DOSE LOVASTATIN; AGED GARLIC EXTRACT; NERVE GROWTH-FACTOR; MORRIS WATER MAZE	Simvastatin and recombinant human erythropoietin (rhEpo) are implicated as potential therapeutic candidates for traumatic brain injury (TBI). Prominent effects of simvastatin include its anti-inflammatory, neurotrophic and neuroregenerative actions studied in various models of neuronal injury. On the other hand, rhEpo has been shown to promote cell survival mechanisms by producing anti-apoptotic and cell proliferative actions. Beneficial effects of rhEpo and statin monotherapies have been well studied. However, there are no reports showing combined use of rhEpo and statins after TBI. This investigation examined if combined efficacy of cell proliferative ability of rhEpo along with the neuroregenerative ability of simvastatin will render maximum recovery in a controlled cortical impact (CCI) mouse model of TBI. Results showed that compared to baseline TBI, rhEpo was more effective than simvastatin in promoting cell proliferation while simvastatin was more effective than rhEpo in restoring axonal damage following TBI. Combined treatment with simvastatin and rhEpo maximally restored axonal integrity while simultaneously inducing greater proliferation of newly formed cells resulting in better functional recovery after TBI than either alone. This is the first study showing the efficacy of erythropoietin simvastatin combinational therapeutic approach in achieving greater structural and cognitive recovery after TBI. Published by Elsevier B.V.	[Chauhan, Neelima B.; Gatto, Roclolfo] Univ Illinois, Jesse Brown VA Med Ctr, Chicago, IL USA; [Chauhan, Neelima B.; Gatto, Roclolfo] Univ Illinois, Westside Inst Sci & Educ, Chicago, IL USA; [Chauhan, Neelima B.] Univ Illinois, Dept Pediat, Chicago, IL USA; [Chauhan, Neelima B.] Univ Illinois, Dept Anat & Cell Biol, Chicago, IL USA; [Gatto, Roclolfo] Univ Illinois, Dept Bioengn, Chicago, IL USA	Chauhan, NB (corresponding author), Jesse Brown VA Med Ctr Chicago, 820 S Damen Ave, Chicago, IL 60612 USA.	nchauhan@uic.edu	Gatto, Rodolfo Gabriel/R-7155-2018	Gatto, Rodolfo Gabriel/0000-0003-2170-6662	Department of Veterans AffairsUS Department of Veterans Affairs [B6285R]; Westside Institute for Science and Education Chicago; Department of Pediatrics, University of Illinois at Chicago; Department of Anatomy & Cell Biology, University of Illinois at Chicago; Department of BioEngineering, University of Illinois at Chicago; Veterans AffairsUS Department of Veterans Affairs [I01RX000880] Funding Source: NIH RePORTER	This work was supported by the Department of Veterans Affairs (VA MERIT Grant #B6285R, Chauhan NB). Authors are thankful for the support provided by the Westside Institute for Science and Education Chicago; and by the Departments of Pediatrics, Anatomy & Cell Biology, and BioEngineering, University of Illinois at Chicago.	Abrahamson EE, 2009, ANN NEUROL, V66, P407, DOI 10.1002/ana.21731; Adembri C, 2004, J NEUROTRAUM, V21, P1103, DOI 10.1089/0897715041651079; Balduini W, 2001, STROKE, V32, P2185, DOI 10.1161/hs0901.094287; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Blanco M, 2007, NEUROLOGY, V69, P904, DOI 10.1212/01.wnl.0000269789.09277.47; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Byts Nadiya, 2009, Exp Transl Stroke Med, V1, P4, DOI 10.1186/2040-7378-1-4; Carloni S, 2006, NEUROBIOL DIS, V21, P119, DOI 10.1016/j.nbd.2005.06.014; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chauhan NB, 2005, NEUROSCI LETT, V375, P143, DOI 10.1016/j.neulet.2004.10.090; Chauhan NB, 2005, NEUROPHARMACOLOGY, V48, P93, DOI 10.1016/j.neuropharm.2004.09.014; Chauhan NB, 2004, NEUROCHEM RES, V29, P1897, DOI 10.1023/B:NERE.0000042217.90204.8d; Chauhan NB, 2003, NEUROCHEM INT, V43, P225, DOI 10.1016/S0197-0186(03)00006-8; Chauhan NB, 2001, J CHEM NEUROANAT, V21, P277, DOI 10.1016/S0891-0618(01)00115-6; Chauhan NB, 2006, J ETHNOPHARMACOL, V108, P385, DOI 10.1016/j.jep.2006.05.030; Chauhan NB, 2007, PHYTOTHER RES, V21, P629, DOI 10.1002/ptr.2122; Chauhan NB, 2007, J NEUROSCI RES, V85, P451, DOI 10.1002/jnr.21110; Chauhan NB, 2010, J NEUROSCI METH, V190, P1, DOI 10.1016/j.jneumeth.2010.04.004; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Chen XR, 2008, J PHARMACOL EXP THER, V326, P966, DOI 10.1124/jpet.108.140368; Cheng Y, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-156; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Christian E, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E9; Chung RS, 2003, J NEUROSCI, V23, P3336; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; DeKosky ST, 2004, J NEUROTRAUM, V21, P491, DOI 10.1089/089771504774129838; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Drake AI, 2010, NEUROREHABILITATION, V26, P183, DOI 10.3233/NRE-2010-0554; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Elkind MSV, 2008, INT J STROKE, V3, P210, DOI 10.1111/j.1747-4949.2008.00200.x; Elkind MSV, 2009, CEREBROVASC DIS, V28, P266, DOI 10.1159/000228709; Emir M, 2004, TRANSPLANT P, V36, P2935, DOI 10.1016/j.transproceed.2004.11.101; Fenjves ES, 2003, TRANSPLANTATION, V75, P1356, DOI 10.1097/01.TP.0000062862.88375.BD; Fisher JW, 2003, EXP BIOL MED, V228, P1; Fonseca ACRG, 2010, EXP NEUROL, V223, P282, DOI 10.1016/j.expneurol.2009.09.013; FRANKLIN KBJ, 1998, MOUSE BRAIN STEREOTA; Giles GM, 2009, ARCH PHYS MED REHAB, V90, P530, DOI 10.1016/j.apmr.2009.01.004; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; Grasso G, 2002, P NATL ACAD SCI USA, V99, P5627, DOI 10.1073/pnas.082097299; Hartley CE, 2008, J NEUROSURG, V109, P708, DOI 10.3171/JNS/2008/109/10/0708; Hoffman SW, 2010, NEUROREHABILITATION, V26, P257, DOI 10.3233/NRE-2010-0561; Hoffman SW, 2009, CLIN NEUROPSYCHOL, V23, P1400, DOI 10.1080/13854040903369433; Hoglund K, 2007, CNS DRUGS, V21, P449; Itoh T, 2009, NEUROL RES, V31, P103, DOI 10.1179/016164108X323771; Jaffee CMS, 2009, CLIN NEUROPSYCHOL, V23, P1291, DOI 10.1080/13854040903307250; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Johnson VE, 2009, J NEUROTRAUM, V26, P1197, DOI [10.1089/neu.2008.0843, 10.1089/neu.2008-0843]; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Knowlton BJ, 1998, CURR OPIN NEUROBIOL, V8, P293, DOI 10.1016/S0959-4388(98)80154-2; Lahiri DK, 2009, MOL PSYCHIATR, V14, P992, DOI 10.1038/mp.2009.82; Laufs U, 2000, STROKE, V31, P2442, DOI 10.1161/01.STR.31.10.2442; Laufs U, 2002, BRAIN RES, V942, P23, DOI 10.1016/S0006-8993(02)02649-5; Lee ST, 2006, J NEUROCHEM, V96, P1728, DOI 10.1111/j.1471-4159.2006.03697.x; Lee S, 2008, ACTA NEUROCHIR SUPPL, V102, P405, DOI 10.1007/978-3-211-85578-2_79; Li BY, 2009, ACTA CRYSTALLOGR E, V65, pM1, DOI 10.1107/S1600536808039846; Liao ZB, 2009, NEUROL INDIA, V57, P722, DOI 10.4103/0028-3886.59466; Lieutaud T, 2008, J NEUROTRAUM, V25, P1179, DOI 10.1089/neu.2008.0591; Liu P, 1998, BEHAV NEUROSCI, V112, P304, DOI 10.1037/0735-7044.112.2.304; Liu XB, 2008, CNS NEUROL DISORD-DR, V7, P227, DOI 10.2174/187152708784936617; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; Mahmood A, 2009, NEUROSURGERY, V65, P187, DOI 10.1227/01.NEU.0000343540.24780.D6; Mammis A, 2009, SURG NEUROL, V71, P527, DOI 10.1016/j.surneu.2008.02.040; Mans RA, 2010, NEUROSCIENCE, V166, P435, DOI 10.1016/j.neuroscience.2009.12.062; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Martin E.M, 2008, J TRAUMA NURS, V15, P100; Martin Elisabeth Moy, 2008, J Trauma Nurs, V15, P94, DOI 10.1097/01.JTN.0000337149.29549.28; Matchett G, 2006, J NEUROSCI METH, V158, P234, DOI 10.1016/j.jneumeth.2006.06.003; Michikawa Makoto, 2004, Current Alzheimer Research, V1, P271, DOI 10.2174/1567205043331983; Moore DF, 2010, NEUROREHABILITATION, V26, P179, DOI 10.3233/NRE-2010-0553; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Nichol AD, 2009, INJURY, V40, P471, DOI 10.1016/j.injury.2009.01.002; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Ozisik PA, 2007, SURG NEUROL, V68, P547, DOI 10.1016/j.surneu.2007.01.030; Ozturk E, 2008, PROG NEURO-PSYCHOPH, V32, P81, DOI 10.1016/j.pnpbp.2007.07.016; Poucet B, 2000, REV NEUROSCIENCE, V11, P95; Qu CS, 2005, J NEUROSURG, V103, P695, DOI 10.3171/jns.2005.103.4.0695; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P166, DOI 10.1176/appi.neuropsych.22.2.166; Richardson RM, 2010, J NEUROSURG, V112, P1125, DOI 10.3171/2009.4.JNS081087; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sandhir R, 2010, NEUROCHEM INT, V56, P188, DOI 10.1016/j.neuint.2009.10.002; Savage LM, 1997, BEHAV BRAIN RES, V82, P133, DOI 10.1016/S0166-4328(97)80983-7; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Schmeer C, 2006, RESTOR NEUROL NEUROS, V24, P79; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Siren AL, 2009, NEUROTHERAPEUTICS, V6, P108, DOI 10.1016/j.nurt.2008.10.041; Sironi L, 2003, ARTERIOSCL THROM VAS, V23, P322, DOI 10.1161/01.ATV.0000044458.23905.3B; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Snell FI, 2010, J PSYCHOSOC NURS MEN, V48, P22, DOI [10.3928/02793695-20100108-02, 10.3928/02793695-20100107-01]; Szczepanska-Szerej A, 2007, PHARMACOL REP, V59, P94; Tanaka K, 2009, NEUROSCI LETT, V462, P235, DOI 10.1016/j.neulet.2009.07.024; Tapia-Perez JH, 2008, J NEUROTRAUM, V25, P1011, DOI 10.1089/neu.2008.0554; Turkoglu OF, 2009, SURG NEUROL, V72, P146, DOI 10.1016/j.surneu.2008.07.004; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Vaishnavi S, 2009, PSYCHOSOMATICS, V50, P198, DOI 10.1176/appi.psy.50.3.198; Valable S, 2010, J CEREBR BLOOD F MET, V30, P361, DOI 10.1038/jcbfm.2009.222; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wang LN, 2010, NEUROSCI LETT, V471, P152, DOI 10.1016/j.neulet.2010.01.030; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wheaton P, 2009, J CLIN PSYCHOPHARM, V29, P468, DOI 10.1097/JCP.0b013e3181b66f04; Whishaw IQ, 1997, CURR OPIN NEUROBIOL, V7, P228, DOI 10.1016/S0959-4388(97)80011-6; Wible EF, 2010, NEUROTHERAPEUTICS, V7, P62, DOI 10.1016/j.nurt.2009.11.003; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Xiong Y, 2010, J NEUROTRAUM, V27, P205, DOI 10.1089/neu.2009.1001; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Zhang YL, 2009, BRAIN RES, V1294, P153, DOI 10.1016/j.brainres.2009.07.077	115	24	26	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	NOV 11	2010	1360						177	192		10.1016/j.brainres.2010.09.010			16	Neurosciences	Neurosciences & Neurology	680RR	WOS:000284252600017	20833152				2021-06-18	
J	Keenan, HT; Leventhal, JM				Keenan, Heather T.; Leventhal, John M.			A Case-Control Study to Evaluate Utah's Shaken Baby Prevention Program	ACADEMIC PEDIATRICS			English	Article						abusive head trauma; child abuse; prevention	TRAUMATIC BRAIN-INJURY; YOUNG-CHILDREN; INFANTS	OBJECTIVE: Educational programs designed to inform mothers and other child caretakers about the dangers of infant shaking have been widely adopted; however, only one has been evaluated to ascertain its effect on abusive head trauma (AHT). This project's goal was to evaluate whether an educational video delivered on the postpartum ward decreased AHT occurrence. METHODS: A case-control study was conducted in which 77 Utah resident mothers of children aged under 2 years who had AT-IT were drawn from the only pediatric level-one trauma center in Utah and the Medical Examiner's Office from 2001 to 2007. Five control mothers per case matched by birth year were identified through the state's birth certificate registry. Conditional logistic regression was used to calculate the adjusted odds of AHT given maternal exposure to the educational video. An alternate injury and alternate educational exposures were assessed to examine potential confounding. RESULTS: The educational video was associated with nonstatistically significant reductions of both AHT (odds ratio [OR] 0.7, 95% confidence interval [CI], 0.5-1.2) and the alternate injury mechanism, child injury from motor vehicle crash (OR 0.9, 95% Cl, 0.6-1.4). Alternate education about car seat use (OR 0.4, 95% CI, 0.2-0.8), back to sleep (OR 0.3, 95% CI, 0.2-0.5), and setting hot water temperature (OR 0.2, 95% CI, 0.1-0.4) were associated with significant reductions in AHT. CONCLUSIONS: AHT occurrence was not significantly associated with the educational video but was associated with alternate postpartum education provided to mothers. These results suggest that the shaken baby prevention video is not causal at reducing AHT.	[Keenan, Heather T.] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT 84158 USA; [Leventhal, John M.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA	Keenan, HT (corresponding author), Univ Utah, Sch Med, Dept Pediat, POB 581289, Salt Lake City, UT 84158 USA.	heather.keenan@hsc.utah.edu			Primary Children's Medical Center Foundation	This study was funded by a Primary Children's Medical Center Foundation grant, awarded to Heather Keenan. Partial support for all datasets within the Utah Population Database was provided by the University of Utah's Huntsman Cancer Institute.	Blair PS, 2006, LANCET, V367, P314, DOI 10.1016/S0140-6736(06)67968-3; Colson ER, 2006, PEDIATRICS, V118, pE243, DOI 10.1542/peds.2005-2517; Dias MS, 2005, PEDIATRICS, V115, DOI 10.1542/peds.2004-1896; Ellingson KD, 2008, AM J PREV MED, V34, pS157, DOI 10.1016/j.amepre.2007.12.021; Joint Commission, 2006, SOURCE, V4, P3; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; Midwest Childrens' Resource Center & Junior League of Saint Paul, 1995, PORTR PROM PREV SHAK; *NAT CTR SHAK BAB, 2000, EL STOR; Shapiro ED, 2004, PEDIATR INFECT DIS J, V23, P127, DOI 10.1097/01.inf.0000109248.32907.1d; Shapiro ED, 2008, AM J PREV MED, V34, pS153, DOI 10.1016/j.amepre.2008.01.022; Vazquez M, 2001, NEW ENGL J MED, V344, P955, DOI 10.1056/NEJM200103293441302	12	24	25	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1876-2859			ACAD PEDIATR	Acad. Pediatr.	NOV-DEC	2010	10	6					389	394		10.1016/j.acap.2010.08.005			6	Pediatrics	Pediatrics	680SD	WOS:000284253800006	21075319				2021-06-18	
J	Shain, KS; Madigan, ML; Rowson, S; Bisplinghoff, J; Duma, SM				Shain, Kellen S.; Madigan, Michael L.; Rowson, Steven; Bisplinghoff, Jill; Duma, Stefan M.			Analysis of the Ability of Catcher's Masks to Attenuate Head Accelerations on Impact With a Baseball	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						catcher's masks; head accelerations; concussions; baseball impacts	TRAUMATIC BRAIN-INJURY; UNITED-STATES; MILD; FOOTBALL; CONCUSSION; SEVERITY; RISK	Objective: The goals of this study were to measure the ability of catcher's masks to attenuate head accelerations on impact with a baseball and to compare these head accelerations to established injury thresholds for mild traumatic brain injury. Design: Testing involved using a pneumatic cannon to shoot baseballs at an instrumented Hybrid III headform (a 50th percentile male head and neck) with and without a catcher's mask on the head. The ball speed was controlled from approximately 26.8 to 35.8 m/s (60-80 mph), and the regulation National Collegiate Athletic Association baseballs were used. Setting: Research laboratory. Patients: None. Independent Variables: Catcher's masks and impact velocity. Main Outcome Measures: The linear and angular head accelerations of the Hybrid III headform. Results: Peak linear resultant acceleration was 140 to 180 g without a mask and 16 to 30 g with a mask over the range of ball's speed investigated. Peak angular resultant acceleration was 19 500 to 25 700 rad/s(2) without a mask and 2250 to 3230 rad/s(2) with a mask. The Head Injury Criterion was 93 to 181 without a mask and 3 to 13 with a mask, and the Severity Index was 110 to 210 without a mask and 3 to 15 with a mask. Conclusions: Catcher's masks reduced head acceleration metrics by approximately 85%. Head acceleration metrics with a catcher's mask were significantly lower than contemporary injury thresholds, yet reports in the mass media clearly indicate that baseball impacts to the mask still occasionally result in mild traumatic brain injuries. Further research is needed to address this apparent contradiction.	[Shain, Kellen S.; Madigan, Michael L.; Rowson, Steven; Bisplinghoff, Jill; Duma, Stefan M.] Virginia Tech, Dept Engn Sci & Mech, Blacksburg, VA 24061 USA	Madigan, ML (corresponding author), Virginia Tech, Dept Engn Sci & Mech, 326 Norris Hall, Blacksburg, VA 24061 USA.	mlm@vt.edu	Rowson, Steven/B-1270-2012; Duma, Stefan/A-8368-2012	Rowson, Steven/0000-0002-3227-0596; Madigan, Michael/0000-0002-4299-3851			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BRAINARD LL, 2009, ANN M AM SOC BIOM SL; *CDCP, HEADS UP FACTS PHYS; Collins CL, 2008, PEDIATRICS, V121, P1181, DOI 10.1542/peds.2007-2572; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; DRAPER R, CONCUSSIONS END MATH; *ESPN, UMP SUST CONC; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; HEALD JH, 1994, AM SOC TEST MATER, V1229, P223, DOI 10.1520/STP12816S; HIBBARD D, FOUL TIP TRAUMA; Hodgson VR, 1970, P 14 STAPP CAR CRASH; Jones I. S., 1984, HEAD IMPACT TOLERANC; King A.I., 2003, P INT RES C BIOM IMP; KING WF, 1973, GEN MOTORS S SERIES; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; MELVIN JW, 1984, UMTRI8436; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Ommaya A.K., 1985, BIOMECHANICS TRAUMA, P245; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rowson S, 2008, CLIN J SPORT MED, V18, P316, DOI 10.1097/JSM.0b013e31817f016a; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Sosin DM, 1996, BRAIN INJURY, V10, P47; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; WHITE P, USA TODAY; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	30	24	24	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	NOV	2010	20	6					422	427		10.1097/JSM.0b013e3181f7db25			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	682DC	WOS:000284379100007	21079437				2021-06-18	
J	Llompart-Pou, JA; Perez, G; Raurich, JM; Riesco, M; Brell, M; Ibanez, J; Perez-Barcena, J; Abadal, JM; Homar, J; Burguera, B				Antonio Llompart-Pou, Juan; Perez, Gerardo; Maria Raurich, Joan; Riesco, Maria; Brell, Marta; Ibanez, Javier; Perez-Barcena, Jon; Maria Abadal, Josep; Homar, Javier; Burguera, Bartolome			Loss of Cortisol Circadian Rhythm in Patients with Traumatic Brain Injury: A Microdialysis Evaluation	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Cortisol; Brain interstitial cortisol; Microdialysis; Circadian rhythm		Traumatic brain injury (TBI) is commonly associated with disturbances of the hypothalamic-pituitary-adrenal axis secretion. Cerebral microdialysis techniques have been recently applied to measure brain interstitial cortisol levels. We evaluated for the first time the circadian rhythm of cortisol secretion at 08:00, 16:00, and 24:00 h in the acute phase of TBI by determination of total serum and brain interstitial cortisol levels (microdialysis samples) in 10 patients with TBI. Non-parametric Friedman's two way analysis of variance test was used. Mean age was 29.8 +/- A 13.6 years. Median Glasgow Coma Scale score after resuscitation was 5 (range 3-10). No differences were found in total serum (P = 0.26) and brain interstitial cortisol (P = 0.77) in the whole sample. Intraindividual analysis showed that circadian variability was lost in all patients, both in serum and brain interstitial cortisol samples in the acute phase after TBI. In our series, circadian variability of cortisol evaluated by serum and cerebral microdialysis samples seems to be lost in TBI patients.	[Antonio Llompart-Pou, Juan; Maria Raurich, Joan; Perez-Barcena, Jon; Maria Abadal, Josep; Homar, Javier] Hosp Univ Son Dureta, Serv Med Intens, Palma De Mallorca 07014, Illes Balears, Spain; [Perez, Gerardo; Riesco, Maria] Hosp Univ Son Dureta, Anal Clin, Palma De Mallorca 07014, Illes Balears, Spain; [Burguera, Bartolome] Hosp Univ Son Dureta, Endocrinol IUNICS CAIBER, Palma De Mallorca 07014, Illes Balears, Spain	Llompart-Pou, JA (corresponding author), Hosp Univ Son Dureta, Serv Med Intens, Andrea Doria 55, Palma De Mallorca 07014, Illes Balears, Spain.	juanantonio.llompart@ssib.es		Ibanez, Javier/0000-0003-3735-8332	Spanish government: Fondo de Investigacion Sanitaria [FIS PI070307]	This research was supported by a public grant from the Spanish government: Fondo de Investigacion Sanitaria (FIS PI070307) awarded to Dr J. Perez Barcena. This public institution will not gain or lose financially from the publication of this manuscript in any way.	*AM ASS NEUR SURG, 2007, J NEUROTRAUMA S1, V24, pS71; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Cohen J, 2009, CRIT CARE RESUSC, V11, P287; Cohen J, 2009, CRIT CARE, V13, DOI 10.1186/cc8184; JENNETT B, 1975, LANCET, V7905, P480; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Llompart-Pou JA, 2010, J ENDOCRINOL INVEST, V33, P368, DOI 10.1007/BF03346605; Llompart-Pou JA, 2008, NEUROCRIT CARE, V9, P230, DOI 10.1007/s12028-008-9115-6; Maiya B, 2008, INTENS CARE MED, V34, P468, DOI 10.1007/s00134-007-0902-x; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Paul T, 2007, CHRONOBIOL INT, V24, P45, DOI 10.1080/07420520601142569; Savaridas T, 2004, INTENS CARE MED, V30, P1479, DOI 10.1007/s00134-004-2306-5; Schwarz S, 2003, J NEUROL NEUROSUR PS, V74, P725, DOI 10.1136/jnnp.74.6.725; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x	15	24	26	0	8	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933			NEUROCRIT CARE	Neurocrit. Care	OCT	2010	13	2					211	216		10.1007/s12028-010-9399-1			6	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	653LS	WOS:000282093500008	20593248				2021-06-18	
J	Lee, SY; Choi, YC; Kim, JH; Kim, WJ				Lee, Seung-Yeob; Choi, Young-Chul; Kim, Jeong-Ho; Kim, Won-Joo			Serum neuron-specific enolase level as a biomarker in differential diagnosis of seizure and syncope	JOURNAL OF NEUROLOGY			English	Article						Neuron-specific enolase; Seizure; Syncope	CREUTZFELDT-JAKOB-DISEASE; TRAUMATIC BRAIN-INJURY; TONIC-CLONIC SEIZURES; CEREBROSPINAL-FLUID; NONEPILEPTIC SEIZURES; EPILEPTIC SEIZURES; AMERICAN ACADEMY; ISCHEMIC-STROKE; S-100 PROTEIN; RAT-BRAIN	Patients who experience a single generalized tonic-clonic seizure or syncope may have similar clinical symptoms, which can cause difficulty in the differential diagnosis. The aim of this study was to examine whether serum neuron-specific enolase (NSE) has diagnostic relevance as a biochemical marker for these disorders. Serum NSE levels were analyzed following a loss of consciousness in patients who were diagnosed with a seizure (n = 52) and syncope (n = 42) compared with normal controls (n = 91). NSE was 14.97 +/- A 7.57 ng/dl for the seizure group, 10.15 +/- A 3.22 ng/dl for the syncope group, and 10.03 +/- A 1.28 ng/dl for the control group. The seizure group showed a significantly increased serum NSE (p < 0.05) compared to the syncope and control groups. By receiver operating characteristic (ROC) curve analysis, the cut-off value with the highest diagnostic accuracy was defined as 11.5 ng/ml with a sensitivity of 0.58 and specificity of 0.91. The NSE values of the syncope and control groups showed no significant differences. Syncope may not influence diffuse brain damage. Serum NSE measurement may be a helpful test for the identification and diagnosis of a seizure rather than syncope.	[Lee, Seung-Yeob; Choi, Young-Chul; Kim, Won-Joo] Yonsei Univ Coll Med, Gangnam Severance Hosp, Dept Neurol, Seoul 135720, South Korea; [Kim, Jeong-Ho] Yonsei Univ Coll Med, Gangnam Severance Hosp, Dept Clin Pathol, Seoul 135720, South Korea	Kim, WJ (corresponding author), Yonsei Univ Coll Med, Gangnam Severance Hosp, Dept Neurol, 146-92 Dogok Dong, Seoul 135720, South Korea.	kzoo@yuhs.ac		Choi, Young-Chul/0000-0001-5525-6861; Kim, Won-Joo/0000-0002-5850-010X; Kim, Jeong-Ho/0000-0003-2479-0548			Aksamit AJ, 2001, NEUROLOGY, V57, P728, DOI 10.1212/WNL.57.4.728; Anand N, 2005, CEREBROVASC DIS, V20, P213, DOI 10.1159/000087701; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bergfeldt L, 2003, HEART, V89, P353, DOI 10.1136/heart.89.3.353; Britton JW, 2006, CLIN AUTON RES, V16, P18, DOI 10.1007/s10286-006-0277-z; Britton JW, 2004, CLIN AUTON RES, V14, P148, DOI 10.1007/s10286-004-0184-0; Buttner T, 1999, J NEUROL, V246, P459, DOI 10.1007/s004150050383; Chen DK, 2005, NEUROLOGY, V65, P668, DOI 10.1212/01.wnl.0000178391.96957.d0; Cuthill FM, 2005, SEIZURE-EUR J EPILEP, V14, P293, DOI 10.1016/j.seizure.2005.04.006; DeGiorgio CM, 1999, NEUROLOGY, V52, P746, DOI 10.1212/WNL.52.4.746; FRANCIS A, 1983, BRAIN RES, V263, P89, DOI 10.1016/0006-8993(83)91203-9; HARDEMARK HG, 1989, J NEUROSURG, V71, P727, DOI 10.3171/jns.1989.71.5.0727; HARDEMARK HG, 1988, STROKE, V19, P1140, DOI 10.1161/01.STR.19.9.1140; Kohira I, 2000, ACTA NEUROL SCAND, V102, P385, DOI 10.1034/j.1600-0404.2000.102006385.x; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Massabki PS, 2003, J RHEUMATOL, V30, P2606; McKeon A, 2006, LANCET NEUROL, V5, P171, DOI 10.1016/S1474-4422(06)70350-7; Oh SH, 2003, ARCH NEUROL-CHICAGO, V60, P37, DOI 10.1001/archneur.60.1.37; PAHLMAN S, 1984, TUMOUR BIOL, V5, P127; Petramfar P, 2009, EPILEPSY BEHAV, V15, P330, DOI 10.1016/j.yebeh.2009.04.016; PRINZ RA, 1982, SURGERY, V92, P887; Rabinowicz AL, 1996, EPILEPSIA, V37, P122, DOI 10.1111/j.1528-1157.1996.tb00002.x; Schreiber SS, 1999, EXP NEUROL, V159, P329, DOI 10.1006/exnr.1999.7147; Sheldon R, 2002, J AM COLL CARDIOL, V40, P142, DOI 10.1016/S0735-1097(02)01940-X; Sulter G, 1998, NEUROSCI LETT, V253, P71, DOI 10.1016/S0304-3940(98)00595-3; Tumani H, 1999, EPILEPSIA, V40, P713, DOI 10.1111/j.1528-1157.1999.tb00768.x; Wijdicks EFM, 2006, NEUROLOGY, V67, P203, DOI 10.1212/01.wnl.0000227183.21314.cd	28	24	27	0	3	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5354			J NEUROL	J. Neurol.	OCT	2010	257	10					1708	1712		10.1007/s00415-010-5608-2			5	Clinical Neurology	Neurosciences & Neurology	661CJ	WOS:000282700300017	20532546				2021-06-18	
J	Wigginton, JG; Pepe, PE; Idris, AH				Wigginton, Jane G.; Pepe, Paul E.; Idris, Ahamed H.			Rationale for routine and immediate administration of intravenous estrogen for all critically ill and injured patients	CRITICAL CARE MEDICINE			English	Article; Proceedings Paper	Conference on Thinking Outside the Box	MAR, 2010	Brussels, BELGIUM			resuscitation; cardiopulmonary resuscitation; cardiac arrest; hemorrhagic shock; trauma; traumatic brain injury; burns; estrogen; progesterone; antiapoptotic; anti-inflammatory	TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; ISCHEMIA-REPERFUSION INJURY; ACUTE MYOCARDIAL-INFARCTION; CEREBRAL-ARTERY OCCLUSION; RECEPTOR-BETA AGONIST; HEAT-SHOCK PROTEINS; GENDER-DIFFERENCES; CEREBROSPINAL-FLUID; HEMORRHAGIC-SHOCK	In addition to a number of very compelling clinical observations, an extensive body of extremely supportive experimental data has generated a very persuasive argument that intravenous estrogen should be routinely administered, as soon as possible, to all persons identified as having a critical illness or injury. Although, to date, definitive gold-standard clinical trials are lacking, what has made this provocative argument even more convincing is the longstanding, documented safety of intravenous estrogen for various illnesses and conditions as well as the relative ease and inexpensive cost of treatment. As such, even routine prehospital administration becomes extremely feasible for a myriad of conditions. More importantly, the worldwide magnitude of potential patients who could benefit is profound. Even if estrogen only changes the outcome in a relatively small percentage of applicable cases, the potential impact may still be of dramatic proportions in terms of the absolute number of lives saved and the resources spared worldwide. Resources may be spared not only in terms of diminishing the economic impact of death and long-term disability, but also in terms of preventing extended intensive care unit stays and treatment of preventable complications that result in longer recovery. (Crit Care Med 2010; 38[Suppl.]: S620-S629)	[Pepe, Paul E.; Idris, Ahamed H.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA; [Wigginton, Jane G.; Pepe, Paul E.; Idris, Ahamed H.] Univ Texas SW Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA; [Pepe, Paul E.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Pepe, Paul E.] Univ Texas SW Med Ctr Dallas, Sch Publ Hlth, Dallas, TX 75390 USA; Parkland Hlth & Hosp Syst, Dallas, TX USA; [Wigginton, Jane G.; Pepe, Paul E.; Idris, Ahamed H.] Dallas Ft Worth Ctr Resuscitat Res, Dallas, TX USA	Pepe, PE (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA.	Paul.Pepe@UTSW.edu		Wigginton, Jane/0000-0002-8561-3492; Idris, Ahamed/0000-0001-7113-6499	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024982] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [5 UL1 RR024982-04] Funding Source: Medline		Allen DB, 2009, PEDIATRICS, V123, P1556, DOI 10.1542/peds.2008-2951; *AM HEART ASS, MISS LIF LIN ST EL M; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Angele Martin K., 2006, Clinics, V61, P479, DOI 10.1590/S1807-59322006000500017; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Berkley KJ, 2006, AM J PHYSIOL-REG I, V291, pR241, DOI 10.1152/ajpregu.00287.2006; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Cekic M, 2010, FUTUR NEUROL, V5, P37, DOI 10.2217/FNL.09.72; Chae SU, 2007, ARCH PHARM RES, V30, P1225, DOI 10.1007/BF02980263; Choudhry MA, 2007, INJURY, V38, P1382, DOI 10.1016/j.injury.2007.09.027; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Elhendy A, 1999, AM J CARDIOL, V84, P865, DOI 10.1016/S0002-9149(99)00456-7; Ely JW, 2006, J AM BOARD FAM MED, V19, P590, DOI 10.3122/jabfm.19.6.590; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Gan SC, 2000, NEW ENGL J MED, V343, P8, DOI 10.1056/NEJM200007063430102; Gannon CJ, 2002, J AM COLL SURGEONS, V195, P11, DOI 10.1016/S1072-7515(02)01187-0; Gatson JW, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-30; GREGOR RD, 1994, CLIN INVEST MED, V17, P551; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Hawk T, 1998, BRAIN RES, V796, P296, DOI 10.1016/S0006-8993(98)00327-8; Hsieh YC, 2007, AM J PHYSIOL-LUNG C, V292, pL1227, DOI 10.1152/ajplung.00479.2006; Hsu JT, 2008, AM J PHYSIOL-REG I, V294, pR1825, DOI 10.1152/ajpregu.00112.2008; Idris AH, 2005, CRIT CARE MED, V33, P2043, DOI 10.1097/01.CCM.0000174104.50799.BD; JARVIS J, 2009, FORT WORTH STAR 0709, pA1; Knoferl MW, 2000, ARCH SURG-CHICAGO, V135, P425, DOI 10.1001/archsurg.135.4.425; Lu AG, 2002, J CEREBR BLOOD F MET, V22, P183, DOI 10.1097/00004647-200202000-00006; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; McCullough LD, 2001, STROKE, V32, P796, DOI 10.1161/01.STR.32.3.796; Meldrum DR, 2007, AM J PATHOL, V170, P1148, DOI 10.2353/ajpath.2007.070025; Merchant RM, 2009, CIRC-CARDIOVASC QUAL, V2, P421, DOI 10.1161/CIRCOUTCOMES.108.839605; Messingham KAN, 2001, J LEUKOCYTE BIOL, V70, P887; Mizushima Y, 2000, ANN SURG, V232, P673, DOI 10.1097/00000658-200011000-00009; MURRAY CJC, 1996, GLOBAL BURDEN DIS IN, P373; Nakamura T, 2005, J NEUROSURG, V103, P97, DOI 10.3171/jns.2005.103.1.0097; *NAT HEART LUNG BL, 2008, WHAT HEART ATT; *NIH, 1998, NIH, P1; Nohria Anju, 1998, Cardiology Clinics, V16, P45, DOI 10.1016/S0733-8651(05)70383-0; Norman G, 2008, BRIT J CANCER, V98, P697, DOI 10.1038/sj.bjc.6604230; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Oberholzer A, 2000, J TRAUMA, V48, P932, DOI 10.1097/00005373-200005000-00019; Ozveri ES, 2001, INFLAMM RES, V50, P585, DOI 10.1007/PL00000238; Palacios B, 1998, J CARDIOVASC PHARM, V31, P479, DOI 10.1097/00005344-199804000-00001; Pepe PE, 2009, CRIT CARE MED, V37, pS91, DOI 10.1097/CCM.0b013e318192154d; PEPE PE, 2003, EX SUMM NAT I NEUR D, pR5; Petitti DB, 1998, JAMA-J AM MED ASSOC, V280, P650, DOI 10.1001/jama.280.7.650; Phelan HA, 2007, J TRAUMA, V63, P1127, DOI 10.1097/TA.0b013e318154c1b8; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; ROBERTS I, 1999, COCHRANE DB SYST REV; ROBERTS LJ, 1994, ANN NY ACAD SCI, V744, P237, DOI 10.1111/j.1749-6632.1994.tb52741.x; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Roppolo LP, 2004, 2004 YB INTENSIVE CA, P139; SALAHUDEEN A, 1995, J AM SOC NEPHROL, V6, P1300; Sener G, 2005, J SURG RES, V128, P70, DOI 10.1016/j.jss.2005.02.019; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Simpkins JW, 2005, CNS NEUROL DISORD-DR, V4, P69, DOI 10.2174/1568007053005073; Simpkins JW, 1997, J NEUROSURG, V87, P724, DOI 10.3171/jns.1997.87.5.0724; SKELLY LM, 2009, EMORY ANNOUNCES PHAS; Sonke GS, 1996, BRIT MED J, V313, P853; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; Sribnick E.A., 2003, ANN NY ACAD SCI, V993, P159; Sribnick EA, 2005, J NEUROSCI RES, V82, P283, DOI 10.1002/jnr.20622; Sribnick EA, 2003, ANN NY ACAD SCI, V993, P125, DOI 10.1111/j.1749-6632.2003.tb07521.x; Sudlow CLM, 1997, STROKE, V28, P491, DOI 10.1161/01.STR.28.3.491; Suzuki T, 2008, CYTOKINE, V42, P32, DOI 10.1016/j.cyto.2008.02.002; Szalay L, 2005, AM J PHYSIOL-HEART C, V289, pH92, DOI 10.1152/ajpheart.01247.2004; Topjian AA, 2010, CRIT CARE MED, V38, P1254, DOI 10.1097/CCM.0b013e3181d8ca43; TunstallPedoe H, 1996, CIRCULATION, V93, P1981, DOI 10.1161/01.CIR.93.11.1981; Vaccarino V, 2005, NEW ENGL J MED, V353, P671, DOI 10.1056/NEJMsa032214; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wichmann MW, 1996, CYTOKINE, V8, P853, DOI 10.1006/cyto.1996.0114; Wigginton J, 2010, INFLAMM RES, V59, pS138; Wigginton J, 2009, CRIT CARE MED, V37, pA409; Wigginton J, 2009, CIRCULATION, V120, pS1441; Wigginton JG, 2002, CRIT CARE MED, V30, pS131, DOI 10.1097/00003246-200204001-00002; WIGGINTON JG, 2007, 2007 YB INTENSIVE CA, P880; WIGGINTON JG, 2006, ACAD EMERG MED S1, V13, P17; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Yang SH, 2003, ANN NY ACAD SCI, V1007, P101, DOI 10.1196/annals.1286.010; Yang SH, 2000, STROKE, V31, P745, DOI 10.1161/01.STR.31.3.745; Yang SH, 2002, J APPL PHYSIOL, V92, P195; Yu HP, 2006, AM J PHYSIOL-LUNG C, V290, pL1004, DOI 10.1152/ajplung.00504.2005; Yu HP, 2006, J MOL CELL CARDIOL, V40, P185, DOI 10.1016/j.yjmcc.2005.10.001; Yune TY, 2004, J NEUROTRAUM, V21, P293, DOI 10.1089/089771504322972086; ZDENKO H, 1999, MOL CELL BIOL, V19, P5124; Zellweger Rene, 1995, Surgical Forum, V46, P65; Zhang YQ, 1998, BRAIN RES, V784, P321, DOI 10.1016/S0006-8993(97)00502-7; Zheng ZJ, 2001, CIRCULATION, V104, P2158, DOI 10.1161/hc4301.098254; Zuckerbraun BS, 2009, CRIT CARE MED, V37, P2471, DOI 10.1097/CCM.0b013e3181a9f62c	89	24	24	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	OCT	2010	38			S			S620	S629		10.1097/CCM.0b013e3181f243a9			10	Critical Care Medicine	General & Internal Medicine	745EP	WOS:000289148900018	21164406				2021-06-18	
J	Spentzas, T; Henricksen, J; Patters, AB; Chaum, E				Spentzas, Thomas; Henricksen, Jared; Patters, Andrea B.; Chaum, Edward			Correlation of intraocular pressure with intracranial pressure in children with severe head injuries	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						tonometry; intraocular pressure; intracranial pressure; traumatic brain injury	CEREBROSPINAL-FLUID PRESSURE; NERVE SHEATH DIAMETER; GLAUCOMA; PATIENT	Objective: To determine whether there was a correlation between tonometric measurements of the intraocular pressure and transducer measurements of the intracranial pressure in the acute setting, and whether intraocular pressure can be used as a surrogate measure of intracranial pressure. Children with traumatic brain injuries commonly develop increased intracranial pressure requiring surgical placement of a pressure transducer to measure the intracranial pressure during the acute recovery period. The increased intracranial pressure may cause engorgement of the orbital compartments via dilation of the episcleral veins and manifest as increased intraocular pressure. Design: Prospective study. Setting: Tertiary academic pediatric intensive care unit. Patients: Children admitted with severe traumatic brain injury. Interventions: Tonometric intraocular pressure measurements. Measurements and Main Results: We performed an Institutional Review Board-approved, prospective study on 36 children (age range, 2.9-15.1 yrs) with traumatic brain injuries, requiring intracranial pressure monitoring. A total of 274 intraocular pressure measurements were made after placement of the pressure transducer, and concordance between the sites of injury and measurement was documented. The average age of the patients was 8.3 yrs. The mean intraocular pressure, intracranial pressure difference was -0.5 +/- 0.68 cm H2O, and the variance was 29.88 (SD, 5.47). The 95% confidence interval was between -11.22 and 10.22. With concordance between the sites of measurement and injury, the mean IOP, intracranial pressure difference was -0.02 +/- 0.61 cm H2O (variance, 23.28; SD, 4.82; 95% confidence interval, -9.47 to 9.42). Concordance reduced the variance of the intraocular pressure, intracranial pressure discrepancy by 20.3%. The Pearson intraocular pressure-intracranial pressure regression coefficient and the Krippendorff's alpha reliability estimate analyses indicated good agreement. The patient's age or PaCO2 did not influence the intraocular pressure, intracranial pressure difference. Using 20 cm H2O as a normal intracranial pressure cutoff, the intraocular pressure had a specificity of 0.7 and sensitivity of 0.97; with concordance, the values improved to 0.78 and 0.96, respectively. Conclusions: Tonometry is a useful screening surrogate measure of intracranial pressure in children with traumatic brain injuries, but seems to lack the accuracy necessary for close management of intracranial pressure in the acute posttraumatic period. (Pediatr Crit Care Med 2010; 11:593-598)	[Spentzas, Thomas; Henricksen, Jared; Patters, Andrea B.; Chaum, Edward] Univ Tennessee, Hlth Sci Ctr, Dept Pediat, Memphis, TN USA; [Chaum, Edward] Univ Tennessee, Hlth Sci Ctr, Dept Biomed Engn, Memphis, TN USA; [Chaum, Edward] Univ Tennessee, Hlth Sci Ctr, Dept Ophthalmol, Memphis, TN USA	Spentzas, T (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Pediat, Memphis, TN USA.	Tom.Spentzas@gmail.com	Chaum, Edward/AAR-1512-2021	Chaum, Edward/0000-0003-3542-8376			Abegg M, 2008, KLIN MONATSBL AUGENH, V225, P441, DOI 10.1055/s-2008-1027307; ALTMAN DG, 1983, J ROY STAT SOC D-STA, V32, P307, DOI 10.2307/2987937; Ballantyne J, 1999, CLIN RADIOL, V54, P740, DOI 10.1016/S0009-9260(99)91176-5; Berdahl JP, 2008, OPHTHALMOLOGY, V115, P763, DOI 10.1016/j.ophtha.2008.01.013; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Ceruti P, 2008, J GLAUCOMA, V17, P62, DOI 10.1097/IJG.0b013e318133a82e; Chen WT, 2003, NEUROLOGY, V61, P1265, DOI 10.1212/01.WNL.0000092022.95447.93; Czarnik T, 2009, INJURY, V40, P33, DOI 10.1016/j.injury.2008.10.010; Dickerman RD, 1999, NEUROL RES, V21, P243, DOI 10.1080/01616412.1999.11740925; DRUMMOND SR, 2009, INT OPHTHALMOL 0408; Firsching R, 2000, J NEUROSURG, V93, P33, DOI 10.3171/jns.2000.93.1.0033; GOLDMANN H, 1957, Ophthalmologica, V134, P221; Han Y, 2008, ANN NEUROL, V64, P221, DOI 10.1002/ana.21416; Hanneman SK, 2008, AACN ADV CRIT CARE, V19, P223, DOI 10.1097/01.AACN.0000318125.41512.a3; Hayes AF, 2007, COMMUN METHODS MEAS, V1, P77, DOI 10.1080/19312450709336664; Korber F, 2005, ROFO-FORTSCHR RONTG, V177, P229, DOI 10.1055/s-2004-813936; Krippendorff K., 2013, CONTENT ANAL INTRO I, V3rd; Lashutka MK, 2004, ANN EMERG MED, V43, P585, DOI 10.1016/j.annemergmed.2003.12.006; Le A, 2009, ANN EMERG MED, V53, P785, DOI 10.1016/j.annemergmed.2008.11.025; Lee LA, 2004, CAN J ANAESTH, V51, P388, DOI 10.1007/BF03018245; Lirng JF, 2003, AM J NEURORADIOL, V24, P700; Morgan WH, 2008, J GLAUCOMA, V17, P408, DOI 10.1097/IJG.0b013e31815c5f7c; Neuendorf K.A., 2002, DEFINING CONTENT ANA; Newman WD, 2002, BRIT J OPHTHALMOL, V86, P1109, DOI 10.1136/bjo.86.10.1109; Nowroozzadeh MH, 2009, AM J OPHTHALMOL, V147, P945, DOI 10.1016/j.ajo.2009.01.002; Patel DK, 2008, ANN OPHTHALMOL, V40, P177; Sajjadi SA, 2006, ANN NEUROL, V59, P867, DOI 10.1002/ana.20856; Sheeran P, 2000, LANCET, V355, P899, DOI 10.1016/S0140-6736(99)02768-3; Wostyn P, 2008, CLIN NEUROL NEUROSUR, V110, P101, DOI 10.1016/j.clineuro.2007.10.011	29	24	27	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	SEP	2010	11	5					593	598		10.1097/PCC.0b013e3181ce755c			6	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	647PA	WOS:000281629300007	20081553				2021-06-18	
J	Moriyama, M; Jayakumar, AR; Tong, XY; Norenberg, MD				Moriyama, M.; Jayakumar, A. R.; Tong, X. Y.; Norenberg, M. D.			Role of Mitogen-Activated Protein Kinases in the Mechanism of Oxidant-Induced Cell Swelling in Cultured Astrocytes	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						astrocytes; cell signalling; cell volume regulation; edema; oxidative stress	SUPEROXIDE-DISMUTASE ACTIVITY; OXIDATIVE STRESS; CEREBRAL EDEMA; SIGNAL-TRANSDUCTION; GLIOMA-CELLS; NITRIC-OXIDE; BRAIN-INJURY; GLIAL-CELLS; IN-VITRO; MITOCHONDRIAL INTEGRITY	Cytotoxic brain edema, usually a consequence of astrocyte swelling, is an important complication of stroke, traumatic brain injury, hepatic encephalopathy, and other neurological disorders. Although mechanisms underlying astrocyte swelling are not fully understood, oxidative stress (OS) has generally been considered an important factor in its pathogenesis. To better understand the mechanism(s) by which OS causes cell swelling, we examined the potential involvement of mitogen-activated protein kinases (MAPKs) in this process. Cultures exposed to the oxidant H2O2 (10, 25, 50 mu M) for different time periods (1-24 hr) significantly increased cell swelling in a triphasic manner. Swelling was initially observed at 10 min (peaking at 30 min), which was followed by cell shrinkage at 1 hr. A subsequent increase in cell volume occurred at approximately 6 hr, and the rise lasted for at least 24 hr. Cultures exposed to H2O2 caused the activation of MAPKs (ERK1/2, JNK and p38-MAPK), whereas inhibition of MAPKs diminished cell swelling induced by 10 and 25 mu M H2O2. These findings suggest that activation of MAPKs is an important factor in the mediation of astrocyte swelling following oxidative stress. (C) 2010 Wiley-Liss, Inc.	[Moriyama, M.; Jayakumar, A. R.; Tong, X. Y.; Norenberg, M. D.] Univ Miami, Sch Med, Dept Pathol, Miami, FL 33101 USA; [Moriyama, M.] Osaka Prefecture Univ, Lab Integrat Physiol Vet Sci, Osaka, Japan; [Jayakumar, A. R.; Norenberg, M. D.] Vet Affairs Med Ctr, Miami, FL 33125 USA; [Norenberg, M. D.] Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	Norenberg, MD (corresponding author), Univ Miami, Sch Med, Dept Pathol D 33, POB 016960, Miami, FL 33101 USA.	mnorenbe@med.miami.edu		Moriyama, Mitsuaki/0000-0001-8123-8835	Department of Veterans AffairsUS Department of Veterans Affairs; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DK063311]; American Association for the Study of Liver Disease/American Liver Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK063311] Funding Source: NIH RePORTER	Contract grant sponsor: Merit Review from the Department of Veterans Affairs; Contract grant sponsor: National Institutes of Health; Contract grant number: DK063311; Contract grant sponsor: American Association for the Study of Liver Disease/American Liver Foundation (to A.R.J.).	Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Andersen GO, 2004, AM J PHYSIOL-HEART C, V286, pH1354, DOI 10.1152/ajpheart.00549.2003; Bender AS, 1998, J NEUROSCI RES, V54, P673, DOI 10.1002/(SICI)1097-4547(19981201)54:5<673::AID-JNR12>3.3.CO;2-G; Blei AT, 1999, J HEPATOL, V31, P771, DOI 10.1016/S0168-8278(99)80361-4; Bouaboula M, 1999, FEBS LETT, V449, P61, DOI 10.1016/S0014-5793(99)00395-6; Brahma B, 2000, J NEUROCHEM, V74, P1263; Buege J A, 1978, Methods Enzymol, V52, P302; CHAN PH, 1989, ANN NY ACAD SCI, V559, P237; CHAN PH, 1982, J NEUROCHEM, V38, P525, DOI 10.1111/j.1471-4159.1982.tb08659.x; Chen CJ, 2000, J NEUROCHEM, V75, P1557, DOI 10.1046/j.1471-4159.2000.0751557.x; Chen SH, 2001, EUR J PHARMACOL, V414, P177, DOI 10.1016/S0014-2999(01)00792-0; CUBELLS JF, 1994, J NEUROSCI, V14, P2260, DOI 10.1523/jneurosci.14-04-02260.1994; Czaja MJ, 2003, HEPATOLOGY, V37, P1405, DOI 10.1053/jhep.2003.50233; DUCIS I, 1989, BRAIN RES, V493, P362, DOI 10.1016/0006-8993(89)91171-2; Faraci FM, 2006, J APPL PHYSIOL, V100, P739, DOI 10.1152/japplphysiol.01044.2005; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; HALLBRUCKER C, 1993, EUR J BIOCHEM, V211, P449, DOI 10.1111/j.1432-1033.1993.tb17570.x; Hazell AS, 1997, NEUROCHEM RES, V22, P1443, DOI 10.1023/A:1021994126329; Herlaar E, 1999, MOL MED TODAY, V5, P439, DOI 10.1016/S1357-4310(99)01544-0; HYSLOP PA, 1988, J BIOL CHEM, V263, P1665; JAKUBOVICZ DE, 1989, BRAIN RES, V485, P215, DOI 10.1016/0006-8993(89)90564-7; Javadov S, 2006, J PHARMACOL EXP THER, V317, P1036, DOI 10.1124/jpet.105.100107; Jayakumar AR, 2008, J NEUROCHEM, V104, P135; Jayakumar AR, 2006, J NEUROSCI, V26, P4774, DOI 10.1523/JNEUROSCI.0120-06.2006; Jayakumar AR, 2008, J BIOL CHEM, V283, P33874, DOI 10.1074/jbc.M804016200; JUURLINK BHJ, 1985, DEV NEUROSCI-BASEL, V7, P263, DOI 10.1159/000112295; Kahle KT, 2009, PHYSIOLOGY, V24, P257, DOI 10.1152/physiol.00015.2009; Karageuzyan KG, 1998, BIOCHEMISTRY-MOSCOW+, V63, P1226; Kim SO, 2004, EUR J PHARMACOL, V487, P81, DOI 10.1016/j.ejphar.2003.12.037; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KIMELBERG HK, 1987, J PHYSIOL-PARIS, V82, P294; KLETZIEN RF, 1975, ANAL BIOCHEM, V68, P537, DOI 10.1016/0003-2697(75)90649-1; Kondo T, 1997, J NEUROSCI, V17, P4180; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lennon AM, 2002, BIOCHEM PHARMACOL, V63, P163, DOI 10.1016/S0006-2952(01)00826-7; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; Liang Danny, 2007, Neurosurg Focus, V22, pE2, DOI 10.3171/foc.2007.22.5.3; Ligtenberg JJM, 1998, INTENS CARE MED, V24, P644, DOI 10.1007/s001340050634; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Luo YQ, 2000, ANTIOXID REDOX SIGN, V2, P449, DOI 10.1089/15230860050192224; MacGregor DG, 2003, J NEUROCHEM, V85, P1402, DOI 10.1046/j.1471-4159.2003.01772.x; Markos F, 2005, NEPHRON PHYSIOL, V99, P1, DOI DOI 10.1159/000081796); Marmarou A, 2003, ACT NEUR S, V86, P7; Mazzio EA, 2004, J APPL TOXICOL, V24, P99, DOI 10.1002/jat.954; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Mielke K, 2000, MOL BRAIN RES, V75, P128, DOI 10.1016/S0169-328X(99)00308-3; Mizuhashi S, 2000, JPN J PHARMACOL, V84, P339, DOI 10.1254/jjp.84.339; Morbidelli L, 2003, CURR PHARM DESIGN, V9, P521, DOI 10.2174/1381612033391405; Murthy CRK, 2001, J NEUROSCI RES, V66, P282, DOI 10.1002/jnr.1222; Norenberg MD, 2007, METAB BRAIN DIS, V22, P219, DOI 10.1007/s11011-007-9062-5; Norenberg MD, 2009, METAB BRAIN DIS, V24, P103, DOI 10.1007/s11011-008-9113-6; Norenberg MD, 2005, METAB BRAIN DIS, V20, P303, DOI 10.1007/s11011-005-7911-7; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Panickar KS, 2009, NEUROCHEM INT, V55, P98, DOI 10.1016/j.neuint.2008.12.022; Papadopoulos MC, 2004, NEUROSCIENCE, V129, P1011, DOI 10.1016/j.neuroscience.2004.05.044; Paucard A, 2005, FUND CLIN PHARMACOL, V19, P57, DOI 10.1111/j.1472-8206.2004.00297.x; Petty MA, 1996, EUR J PHARMACOL, V307, P149, DOI 10.1016/0014-2999(96)00235-X; Rao KVR, 2003, METAB BRAIN DIS, V18, P113, DOI 10.1023/A:1023858902184; REMACLE J, 1995, MUTAT RES-DNAGING G, V316, P103, DOI 10.1016/0921-8734(95)90004-7; Ringel F, 2006, J NEUROTRAUM, V23, P1693, DOI 10.1089/neu.2006.23.1693; Robb SJ, 1999, J NEUROSCI RES, V56, P166, DOI 10.1002/(SICI)1097-4547(19990415)56:2<166::AID-JNR6>3.3.CO;2-J; Rosenblum WI, 2007, J NEUROPATH EXP NEUR, V66, P771, DOI 10.1097/nen.0b013e3181461965; SAHA N, 1993, BIOCHEM J, V296, P701, DOI 10.1042/bj2960701; Santandreu FM, 2008, CELL PHYSIOL BIOCHEM, V22, P757, DOI 10.1159/000185559; Sarrafzadeh AS, 2000, ACTA NEUROCHIR, V142, P1293, DOI 10.1007/s007010070028; Schlenker T, 2000, GASTROENTEROLOGY, V118, P395, DOI 10.1016/S0016-5085(00)70222-8; Sharma HS, 1996, NEUROSCI RES, V24, P373, DOI 10.1016/0168-0102(95)01015-7; Sinke AP, 2008, J NEUROCHEM, V106, P2302, DOI 10.1111/j.1471-4159.2008.05549.x; SLATER AFG, 1995, BBA-MOL BASIS DIS, V1271, P59, DOI 10.1016/0925-4439(95)00010-2; Smith-Pearson PS, 2008, FREE RADICAL BIO MED, V45, P1178, DOI 10.1016/j.freeradbiomed.2008.07.015; Snabaitis AK, 2000, CIRC RES, V86, P214, DOI 10.1161/01.RES.86.2.214; STAUB F, 1994, J CEREBR BLOOD F MET, V14, P1030, DOI 10.1038/jcbfm.1994.135; Suffredini AF, 1998, SCHWEIZ MED WSCHR, V128, P1444; Suzuki Y, 2002, BRAIN RES, V945, P242, DOI 10.1016/S0006-8993(02)02806-8; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Tan S, 1999, J NEUROPATH EXP NEUR, V58, P972, DOI 10.1097/00005072-199909000-00007; Tang HW, 1996, J APPL TOXICOL, V16, P187, DOI 10.1002/(SICI)1099-1263(199605)16:3<187::AID-JAT329>3.0.CO;2-Y; Thorburne SK, 1996, J NEUROCHEM, V67, P1014; Trackey JL, 2001, J NEUROCHEM, V79, P445, DOI 10.1046/j.1471-4159.2001.00584.x; Tsai KL, 1997, J PHYSIOL-LONDON, V502, P161, DOI 10.1111/j.1469-7793.1997.161bl.x; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; VANDERMEULEN JA, 1987, LANCET, V2, P306; Wegrzynowicz M, 2007, NEUROCHEM INT, V50, P883, DOI 10.1016/j.neuint.2006.12.003; Westman J, 2000, AMINO ACIDS, V19, P339, DOI 10.1007/s007260070065; Widmer R, 2007, ARCH BIOCHEM BIOPHYS, V464, P1, DOI 10.1016/j.abb.2007.03.027; Wong JA, 2001, AM J PHYSIOL-REG I, V281, pR561; WROBLEWSKI F, 1955, P SOC EXP BIOL MED, V90, P210; Zhao HY, 2004, J PHYSIOL-LONDON, V560, P123, DOI 10.1113/jphysiol.2004.066423; Zwingmann C, 2000, DEV NEUROSCI-BASEL, V22, P463, DOI 10.1159/000017476	90	24	26	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	AUG 15	2010	88	11					2450	2458		10.1002/jnr.22400			9	Neurosciences	Neurosciences & Neurology	632PL	WOS:000280436600014	20623534				2021-06-18	
J	Al-Qattan, MM				Al-Qattan, M. M.			Nonunion and Avascular Necrosis Following Phalangeal Neck Fractures in Children	JOURNAL OF HAND SURGERY-AMERICAN VOLUME			English	Article						Children; complications; phalangeal neck fractures	PROXIMAL PHALANX; MALUNION	Purpose To investigate the characteristics of nonunion and avascular necrosis following phalangeal neck fracture in children. Methods A cohort of all pediatric phalangeal neck fractures complicated by nonunion, with or without avascular necrosis of the phalangeal head, over the last 10 years was reviewed retrospectively. The following data were documented: age, gender, fracture site, mechanism of injury, fracture type, presence of digital ischemia, initial management, and outcome. Results Our database of phalangeal neck fractures in children over the last 10 years included 215 fractured digits. Of these, 4 developed nonunion (group A) and 8 developed nonunion with avascular necrosis (group B). All patients in group A were young children (mean age, 2.5 y) with fractured thumbs, initially managed by closed reduction and splinting. The fractures redisplaced and failed to unite, resulting in instability that was later treated by bone grafting and stabilization with a K-wire. Patients in group B were older children (mean age, 5.6 y) and 7 of 8 had finger fractures. All 8 patients presented with stiffness of the affected joint, and no further surgery was performed. Conclusions When nonunion occurs following pediatric phalangeal neck fractures, it usually affects the thumb and presents with thumb instability, and bone grafting is often required to achieve union. In contrast, avascular necrosis following phalangeal neck fractures usually affects the little finger and presents with stiffness, and hence, further surgery is not often required short term, although the long-term result after skeletal maturity is unknown. (J Hand Surg 2010;35A:1269-1274. (C) 2010 Published by Elsevier Inc. on behalf of the American Society for Surgery of the Hand.)	[Al-Qattan, M. M.] King Saud Univ, Dept Surg, Riyadh, Saudi Arabia	Al-Qattan, MM (corresponding author), POB 18097, Riyadh 11415, Saudi Arabia.	moqattan@hotmail.com					Al-Qattan MM, 2006, J HAND SURG-BRIT EUR, V31B, P484, DOI 10.1016/j.jhsb.2006.06.005; Al-Qattan MM, 2009, J HAND SURG-EUR VOL, V34E, P104, DOI 10.1177/1753193408091430; Al-Qattan MM, 2001, J HAND SURG-BRIT EUR, V26, P112, DOI 10.1054/jhsb.2000.0506; Al-Qattan MM, 2004, INJURY, V35, P1207, DOI 10.1016/j.injury.2003.09.042; Al-Qattan MM, 2004, INJURY, V35, P1185, DOI 10.1016/j.injury.2003.09.043; Al-Qattan MM, 1999, J HAND SURG-BRIT EUR, V24B, P693, DOI 10.1054/jhsb.1999.0260; Al-Qattan MM, 2000, HAND CLIN, V16, P535; BARTNIKAS R, 1979, ENG DIELECTRICS, V1, P134; BARTON NJ, 1984, J BONE JOINT SURG BR, V66, P159; Cornwall R, 2004, J HAND SURG-AM, V29A, P458, DOI 10.1016/j.jhsa.2004.01.008; DIXON GL, 1972, CLIN ORTHOP RELAT R, P151; Hennrikus WL, 2003, J BONE JOINT SURG BR, V85B, P273, DOI 10.1302/0301-620X.85B2.13167; LEONARD MH, 1970, CLIN ORTHOP RELAT R, P160; MINTZER CM, 1994, J HAND SURG-BRIT EUR, V19B, P594, DOI 10.1016/0266-7681(94)90122-8; NEWINGTON DP, 1995, J HAND SURG-BRIT EUR, V20B, P353, DOI 10.1016/S0266-7681(05)80093-2; SIMMONS BP, 1987, J HAND SURG-AM, V12A, P1079, DOI 10.1016/S0363-5023(87)80117-X; Waters PM, 2004, J HAND SURG-AM, V29A, P707, DOI 10.1016/j.jhsa.2004.03.007	17	24	24	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0363-5023			J HAND SURG-AM	J. Hand Surg.-Am. Vol.	AUG	2010	35A	8					1269	1274		10.1016/j.jhsa.2010.03.038			6	Orthopedics; Surgery	Orthopedics; Surgery	637MS	WOS:000280822800007	20684927				2021-06-18	
J	Brown, JB; Stassen, NA; Cheng, JD; Sangosanya, AT; Bankey, PE; Gestring, ML				Brown, Joshua B.; Stassen, Nicole A.; Cheng, Julius D.; Sangosanya, Ayodele T.; Bankey, Paul E.; Gestring, Mark L.			Trauma Center Designation Correlates With Functional Independence After Severe But Not Moderate Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	68th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma (AAST)	OCT 01-03, 2009	Pittsburgh, PA	Amer Assoc Surg Trauma (AAST)		Traumatic brain injury; Trauma center designation; Functional outcome; National Trauma Databank	GLASGOW COMA SCALE; AMERICAN-COLLEGE; LEVEL-I; UNITED-STATES; CENTER VOLUME; MORTALITY; SURGEONS; IMPACT; VERIFICATION; OUTCOMES	Background: The mortality of traumatic brain injury (TBI) continues to decline, emphasizing functional outcomes. Trauma center designation has been linked to survival after TBI, but the impact on functional outcomes is unclear. The objective was to determine whether trauma center designation influenced functional outcomes after moderate and severe TBI. Methods: Trauma subjects presenting to an American College of Surgeons (ACS) Level I or II trauma center with a Glasgow Coma Score (GCS) <= 12 who survived to discharge were identified using the National Trauma Databank (2002-2006). Outcomes were functional independence (FI) defined as a modified functional independence measure (FIM) of 12, and independent expression (IE) defined as a FIM component of 4. These were compared between Level I and Level II centers in subjects with both moderate (GCS 9-12) and severe (GCS <= 8) TBI using stepwise logistic regression to adjust for demographics, injuries, and comorbidities. Results: Analysis identified 25,170 subjects (72% severe TBI). After adjusting for covariates, ACS Level I designation was associated with FI (odds ratio: 1.16; confidence interval: 1.07-1.24, p < 0.01) and IE (1.10; 1.03-1.17, p < 0.01) after severe TBI. Trauma center designation was not associated with FI or IE after moderate TBI. Conclusions: ACS trauma center designation is significantly associated with FI and IE after severe, but not moderate TBI. Prospective study is warranted to verify and explore factors contributing to this discrepancy.	[Brown, Joshua B.; Stassen, Nicole A.; Cheng, Julius D.; Sangosanya, Ayodele T.; Bankey, Paul E.; Gestring, Mark L.] Univ Rochester, Sch Med, Dept Surg, Rochester, NY 14642 USA	Gestring, ML (corresponding author), Univ Rochester, Sch Med, Dept Surg, 601 Elmwood Ave,Box SURG, Rochester, NY 14642 USA.	mark_gestring@urmc.rochester.edu		Brown, Joshua/0000-0002-6936-035X			*AD HOC TRAUM REG, 2007, NAT TRAUM DAT REF MA; American College of : Surgeons Committee on Trauma, 2007, RES OPT CAR INJ PAT; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cooper A, 2000, J TRAUMA, V48, P16, DOI 10.1097/00005373-200001000-00004; Cornwell EE, 2003, ARCH SURG-CHICAGO, V138, P838, DOI 10.1001/archsurg.138.8.838; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; Cudnik MT, 2009, J TRAUMA, V66, P1321, DOI 10.1097/TA.0b013e3181929e2b; Demetriades D, 2006, J AM COLL SURGEONS, V202, P212, DOI 10.1016/j.jamcollsurg.2005.09.027; Demetriades D, 2005, ANN SURG, V242, P512, DOI 10.1097/01.sla.0000184169.73614.09; DiRusso S, 2001, J TRAUMA, V51, P294, DOI 10.1097/00005373-200108000-00011; DuBose JJ, 2008, ARCH SURG-CHICAGO, V143, P1213, DOI 10.1001/archsurg.143.12.1213; Ehrlich PF, 2002, J TRAUMA, V53, P811, DOI 10.1097/00005373-200211000-00001; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Greenwald BND, 2009, MT SINAI J MED, V76, P182, DOI 10.1002/msj.20103; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; London JA, 2003, J TRAUMA, V54, P16, DOI 10.1097/00005373-200301000-00003; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Marcin JP, 2004, CRIT CARE MED, V32, P1477, DOI 10.1097/01.CCM.0000127781.08985.03; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Mullins RJ, 1998, J TRAUMA, V44, P609, DOI 10.1097/00005373-199804000-00009; Mullins RJ, 1996, J TRAUMA, V40, P536, DOI 10.1097/00005373-199604000-00004; Nathens AB, 2001, JAMA-J AM MED ASSOC, V285, P1164, DOI 10.1001/jama.285.9.1164; Nirula R, 2006, J TRAUMA, V61, P268, DOI 10.1097/01.ta.0000230305.36456.4e; Piontek FA, 2003, J TRAUMA, V54, P1041, DOI 10.1097/01.TA.0000061107.55798.31; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; Williams RF, 2009, J TRAUMA, V66, P1570, DOI 10.1097/TA.0b013e3181a594c4; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	32	24	24	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2010	69	2					263	269		10.1097/TA.0b013e3181e5d72e			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	638JN	WOS:000280890800004	20699734				2021-06-18	
J	Sjodin, MOD; Bergquist, J; Wetterhall, M				Sjodin, Marcus O. D.; Bergquist, Jonas; Wetterhall, Magnus			Mining ventricular cerebrospinal fluid from patients with traumatic brain injury using hexapeptide ligand libraries to search for trauma biomarkers	JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES			English	Article						Cerebrospinal fluid; Hexapeptide ligand library; Traumatic brain injury; Proteomics; Mass spectrometry	SEVERE HEAD-INJURY; PROTEOMIC ANALYSIS; PROTEIN; SERUM; CSF; DISCOVERY; MARKERS; INTERLEUKIN-6; NEUROTRAUMA; MECHANISMS	Traumatic brain injury (TBI) is an acute event resulting from external force to the brain and is a majorcause of death and disability associated with high health care costs in the western world. Additional injuries, originating from the secondary molecular events after the initial intensive care, may be limited by the use of objective biomarkers to provide the best treatment and patient prediction outcome. In this study, hexapeptide ligand libraries (HLL) have been used for the enrichment of suggested protein biomarkers for TBI in cerebrospinal fluid (CSF). HLL have the potential to enrich low abundant proteins and simultaneously reduce the high abundant proteins, rendering a sample with significantly reduced dynamic range. The CSF proteome from two TBI inflicted patients have been extensively mapped using a large initial sample volume obtained by extraventricular drainage. Shotgun proteomics, in combination with isoelectric focusing (IEF) and nano-LC-MS/MS, identified 339 unique proteins (MudPIT scoring p <= 0.05) with a protein overlap of 130 between the patients. As much as 45% of the proteins reported in the literature to be associated with degenerative/regenerative processes occurring after a trauma to the head were identified. Out of the most prominent potential protein biomarkers, such as neuron specific enolase, glial fibrillary acidic protein, myelin basic protein, creatine kinase B-type and S-100 beta, all except myelin basic protein were detected in the study. This study shows the possibility of using HLL as a tool for screening of low abundant protein biomarkers in human CSF. (C) 2010 Elsevier B.V. All rights reserved.	[Sjodin, Marcus O. D.; Bergquist, Jonas; Wetterhall, Magnus] Uppsala Univ, Dept Phys & Analyt Chem, SE-75124 Uppsala, Sweden	Sjodin, MOD (corresponding author), Uppsala Univ, Dept Phys & Analyt Chem, Husargatan 3,POB 599, SE-75124 Uppsala, Sweden.	marcus.sjodin@kemi.uu.se	Bergquist, Jonas/C-5894-2015	Bergquist, Jonas/0000-0002-4597-041X	Uppsala Berzelii Technology Center for Neurodiagnostics; Swedish Governmental Agency for Innovation SystemsVinnova [P29797-1]; Swedish Research CouncilSwedish Research CouncilEuropean Commission [P29797-1, VR 621-2008-3562]	This research was supported by Uppsala Berzelii Technology Center for Neurodiagnostics, with financing from the Swedish Governmental Agency for Innovation Systems and the Swedish Research Council, both with grant number P29797-1. The Swedish Research Council (VR 621-2008-3562) are also greatly acknowledged for financial support.	Ahn SM, 2007, PROTEOM CLIN APPL, V1, P1004, DOI 10.1002/prca.200700217; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Boschetti E, 2009, PROTEOMICS, V9, P1492, DOI 10.1002/pmic.200800389; Castagna A, 2005, J PROTEOME RES, V4, P1917, DOI 10.1021/pr050153r; Chiaretti A, 2008, EUR J PAEDIATR NEURO, V12, P195, DOI 10.1016/j.ejpn.2007.07.016; Conti A, 2004, J NEUROTRAUM, V21, P854, DOI 10.1089/0897715041526212; D'Ambrosio C, 2008, J PROTEOME RES, V7, P3461, DOI 10.1021/pr800193y; Gao WM, 2007, J NEUROTRAUM, V24, P43, DOI 10.1089/neu.2006.0061; Govorukhina NI, 2003, J CHROMATOGR A, V1009, P171, DOI 10.1016/S0021-9673(03)00921-X; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Guerrier L, 2007, J CHROMATOGR A, V1176, P192, DOI 10.1016/j.chroma.2007.11.007; Guerrier L, 2008, NAT PROTOC, V3, P883, DOI 10.1038/nprot.2008.59; Han YY, 2000, PEDIATR RES, V47, p57A; Hanrieder J, 2009, J NEUROSCI METH, V177, P469, DOI 10.1016/j.jneumeth.2008.10.038; Hausmann R, 2000, INT J LEGAL MED, V113, P70, DOI 10.1007/PL00007711; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Huhmer AF, 2006, DIS MARKERS, V22, P3; Ichibangase T, 2009, BIOMED CHROMATOGR, V23, P480, DOI 10.1002/bmc.1139; Is M, 2007, J CLIN NEUROSCI, V14, P1163, DOI 10.1016/j.jocn.2006.05.020; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Ottens AK, 2006, MASS SPECTROM REV, V25, P380, DOI 10.1002/mas.20073; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Roche S, 2008, PROTEOM CLIN APPL, V2, P428, DOI 10.1002/prca.200780040; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Sennels L, 2007, J PROTEOME RES, V6, P4055, DOI 10.1021/pr070339l; Shore PM, 2007, J NEUROTRAUM, V24, P75, DOI 10.1089/neu.2006.0062; Shores KS, 2007, J PROTEOME RES, V6, P3739, DOI 10.1021/pr070293w; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; STEPHANE R, 2008, PROTEOM CLIN APPL, V2, P428; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Thulasiraman V, 2005, ELECTROPHORESIS, V26, P3561, DOI 10.1002/elps.200500147; Uzan M, 2006, ACTA NEUROCHIR, V148, P1157, DOI 10.1007/s00701-006-0887-1; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777	38	24	25	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1570-0232	1873-376X		J CHROMATOGR B	J. Chromatogr. B	JUL 15	2010	878	22					2003	2012		10.1016/j.jchromb.2010.05.036			10	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	629OU	WOS:000280210300014	20542479				2021-06-18	
J	Chauhan, NB; Gatto, R; Chauhan, MB				Chauhan, Neelima B.; Gatto, Rodolfo; Chauhan, Mihirsinh B.			Neuroanatomical correlation of behavioral deficits in the CCI model of TBI	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Traumatic brain injury; Controlled cortical impact injury; DeOlmos Silver Stain; Diffuse axonal injury; Morris water maze	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; AGED GARLIC EXTRACT; COGNITIVE DEFICITS; SILVER TECHNIQUE; MOTOR; RATS; BLOOD; MICE; DEXAMETHASONE	Traumatic brain injury (TBI) is the leading cause of death and disability both in combat and civilian situations with limited treatment options including surgical removal of hematoma, ventricular drainage and use of hyperosmotic agents that restrict secondary injury following TBI. Availability of appropriate model system with full-range characterization of anatomical and behavioral components correlative with brain injury provides a pre-clinical platform to test candidate therapies for clinical translation. Modeling of TBI using controlled cortical impact injury (CCI) is largely considered to be close to clinical TBI and hence CCI models have been widely used in pre-clinical TBI research. Most studies reported so far using CCI models were presented with a limited behavioral characterization and lacked its correlation with the signature histopathology of TBI. Current investigation validated a detailed sensomotor and cognitive behavioral characterization correlative with diffuse axonal injury-the signature histopathology of TBI, in the CCI mouse model of TBI. Present study offers a comprehensively characterized model of TBI that can be used to investigate cellular and molecular mechanisms underlying TBI and to test candidate therapies in developing novel and effective treatments for TBI. Published by Elsevier B.V.	[Chauhan, Neelima B.; Gatto, Rodolfo] Jesse Brown VA Med Ctr, Chicago, IL 60612 USA; [Chauhan, Neelima B.] Univ Illinois, Dept Pediat, Chicago, IL 60680 USA; [Chauhan, Neelima B.] Univ Illinois, Dept Anat & Cell Biol, Chicago, IL 60680 USA; [Chauhan, Mihirsinh B.] Med Univ Lublin, PL-20059 Lublin, Poland	Chauhan, NB (corresponding author), Jesse Brown VA Med Ctr, R&D 151,820 S Damen Ave, Chicago, IL 60612 USA.	Neelima.Chauhan2@va.gov; Rodolfo.Gatto@va.gov; mchauhan99@gmail.com	Gatto, Rodolfo Gabriel/R-7155-2018	Gatto, Rodolfo Gabriel/0000-0003-2170-6662	Department of Veterans Affairs (VA, Chauhan NB)US Department of Veterans Affairs [B6285R]; Westside Institute for Science and Education; Department of Pediatrics; Department of Anatomy & Cell Biology, University of Illinois at Chicago; Veterans AffairsUS Department of Veterans Affairs [I01RX000880] Funding Source: NIH RePORTER	This work has been supported by the Department of Veterans Affairs (VA MERIT grant #B6285R, Chauhan NB). Authors wish to thank support provided by the Westside Institute for Science and Education, and by the Department of Pediatrics, Department of Anatomy & Cell Biology, University of Illinois at Chicago.	Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chauhan NB, 1999, INT J DEV NEUROSCI, V17, P255, DOI 10.1016/S0736-5748(99)00003-9; Chauhan NB, 2006, J ETHNOPHARMACOL, V108, P385, DOI 10.1016/j.jep.2006.05.030; Chauhan NB, 2007, PHYTOTHER RES, V21, P629, DOI 10.1002/ptr.2122; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; Clark RSB, 2007, J NEUROTRAUM, V24, P1399, DOI 10.1089/neu.2007.0305; Conti AC, 1998, J NEUROSCI, V18, P5663; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Donat CK, 2007, BRAIN INJURY, V21, P1031, DOI 10.1080/02699050701630359; Faden AI, 1999, AM J PHYSIOL-REG I, V277, pR1196; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P355, DOI 10.1097/01.WCB.0000046144.31247.33; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gibson JB, 2002, SHOCK, V17, P234, DOI 10.1097/00024382-200203000-00013; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hartl R, 1997, ACT NEUR S, V70, P240; Imaki J, 2009, NEUROSCI LETT, V454, P143, DOI 10.1016/j.neulet.2009.03.001; King JT, 2005, J NEUROTRAUM, V22, P947, DOI 10.1089/neu.2005.22.947; Lema PP, 2004, J VET PHARMACOL THER, V27, P321, DOI 10.1111/j.1365-2885.2004.00597.x; Mammis A, 2009, SURG NEUROL, V71, P527, DOI 10.1016/j.surneu.2008.02.040; Matthews MA, 1998, BRAIN RES, V794, P1, DOI 10.1016/S0006-8993(98)00107-3; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; MILLEN JE, 1985, J NEUROSURG, V62, P587, DOI 10.3171/jns.1985.62.4.0587; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Pedersen MO, 2009, PROG HISTOCHEM CYTO, V44, P1, DOI 10.1016/j.proghi.2008.10.002; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; Petit-Demouliere B, 2009, BEHAV BRAIN RES, V204, P200, DOI 10.1016/j.bbr.2009.06.006; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; Piot-Grosjean O, 2001, NEUROBIOL DIS, V8, P1082, DOI 10.1006/nbdi.2001.0450; RICHARDSON RM, 2009, J NEUROSURG, V110, P1; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; Tanaka K, 2009, NEUROSCI LETT, V462, P235, DOI 10.1016/j.neulet.2009.07.024; Tenkova Tatyana I., 2007, V399, P31, DOI 10.1007/978-1-59745-504-6_3; Vachon P, 2003, CAN J VET RES, V67, P157; Wagner AK, 2007, J NEUROTRAUM, V24, P1308, DOI 10.1089/neu.2007.0274; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Yakhnitsa V, 2006, NEUROSCIENCE, V143, P615, DOI 10.1016/j.neuroscience.2006.08.006; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; You ZR, 2007, J CEREBR BLOOD F MET, V27, P1954, DOI 10.1038/sj.jcbfm.9600497; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zauner A, 2002, J NEUROSURG, V97, P643, DOI 10.3171/jns.2002.97.3.0643	56	24	25	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	JUN 30	2010	190	1					1	9		10.1016/j.jneumeth.2010.04.004			9	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	625IN	WOS:000279888800001	20385166				2021-06-18	
J	Zeng, LH; McDaniel, S; Rensing, NR; Wong, M				Zeng, Ling-Hui; McDaniel, Sharon; Rensing, Nicholas R.; Wong, Michael			Regulation of cell death and epileptogenesis by the mammalian target of rapamycin (mTOR) A double-edged sword?	CELL CYCLE			English	Article						kainate; apoptosis; epilepsy; seizure; rat	TUBEROUS SCLEROSIS COMPLEX; TEMPORAL-LOBE EPILEPSY; TRAUMATIC BRAIN-INJURY; SIGNALING PATHWAY; ANTIEPILEPTIC DRUGS; MOUSE MODEL; KINASE; INHIBITION; GROWTH; HYPERTROPHY	Identification of cell signaling mechanisms mediating seizure-related neuronal death and epileptogenesis is important for developing more effective therapies for epilepsy. The mammalian target of rapamycin (mTOR) pathway has recently been implicated in regulating neuronal death and epileptogenesis in rodent models of epilepsy. In particular, kainate-induced status epilepticus causes abnormal activation of the mTOR pathway, and the mTOR inhibitor, rapamycin, can decrease the development of neuronal death and chronic seizures in the kainate model. Here, we discuss the significance of these findings and extend them further by identifying upstream signaling pathways through which kainate status epilepticus activates the mTOR pathway and by demonstrating limited situations where rapamycin may paradoxically increase mTOR activation and worsen neuronal death in the kainate model. Thus, the regulation of seizure-induced neuronal death and epileptogenesis by mTOR is complex and may have dual, opposing effects depending on the physiological and pathological context. Overall, these findings have important implications for designing potential neuroprotective and antiepileptogenic therapies that modulate the mTOR pathway.	[McDaniel, Sharon; Rensing, Nicholas R.; Wong, Michael] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [McDaniel, Sharon; Rensing, Nicholas R.; Wong, Michael] Washington Univ, Sch Med, Hope Ctr Neurol Disorders, St Louis, MO USA; [Zeng, Ling-Hui] Zhejiang Univ City Coll, Dept Pharm, Hangzhou 310027, Zhejiang, Peoples R China	Wong, M (corresponding author), Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.	wong_m@wustl.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K02 NS045583, R01 NS056872]; Tuberous Sclerosis Alliance, and Citizens United for Research in Epilepsy; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056872, K02NS045583] Funding Source: NIH RePORTER	Work from the authors has been supported by the National Institutes of Health (K02 NS045583, R01 NS056872), the Tuberous Sclerosis Alliance, and Citizens United for Research in Epilepsy.	Asnaghi L, 2004, PHARMACOL RES, V50, P545, DOI 10.1016/j.phrs.2004.03.007; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; Buckmaster PS, 2009, J NEUROSCI, V29, P8259, DOI 10.1523/JNEUROSCI.4179-08.2009; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Castedo M, 2002, CELL DEATH DIFFER, V9, P99, DOI 10.1038/sj/cdd/4400978; Chen SY, 2007, J CEREBR BLOOD F MET, V27, P939, DOI 10.1038/sj.jcbfm.9600393; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Daniel C, 2004, LAB INVEST, V84, P588, DOI 10.1038/labinvest.3700078; Dichter MA, 2006, EPILEPSY RES, V68, P31, DOI 10.1016/j.eplepsyres.2005.09.014; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Kawamata S, 1998, BLOOD, V91, P561, DOI 10.1182/blood.V91.2.561.561_561_569; Kimura N, 2003, GENES CELLS, V8, P65, DOI 10.1046/j.1365-2443.2003.00615.x; Kwon CH, 2003, P NATL ACAD SCI USA, V100, P12923, DOI 10.1073/pnas.2132711100; Ljungberg MC, 2009, DIS MODEL MECH, V2, P389, DOI 10.1242/dmm.002386; Loscher W, 2006, EPILEPSY RES, V69, P183, DOI 10.1016/j.eplepsyres.2006.03.014; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Meikle L, 2008, J NEUROSCI, V28, P5422, DOI 10.1523/JNEUROSCI.0955-08.2008; Sandsmark DK, 2007, HISTOL HISTOPATHOL, V22, P895, DOI 10.14670/HH-22.895; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Stefan H, 2006, ACTA NEUROL SCAND, V113, P139, DOI 10.1111/j.1600-0404.2005.00561.x; Sutton G, 2002, J NEUROCHEM, V82, P1097, DOI 10.1046/j.1471-4159.2002.01031.x; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Tsang CK, 2007, DRUG DISCOV TODAY, V12, P112, DOI 10.1016/j.drudis.2006.12.008; Wong M, 2010, EPILEPSIA, V51, P27, DOI 10.1111/j.1528-1167.2009.02341.x; Zeng LH, 2008, ANN NEUROL, V63, P444, DOI 10.1002/ana.21331; Zeng LH, 2009, J NEUROSCI, V29, P6964, DOI 10.1523/JNEUROSCI.0066-09.2009; Zhou J, 2009, J NEUROSCI, V29, P1773, DOI 10.1523/JNEUROSCI.5685-08.2009; Zhu D, 2002, AMINO ACIDS, V23, P11, DOI 10.1007/s00726-001-0103-9	32	24	26	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1538-4101	1551-4005		CELL CYCLE	Cell Cycle	JUN 15	2010	9	12					2281	2285		10.4161/cc.9.12.11866			5	Cell Biology	Cell Biology	615QC	WOS:000279149000015	20603607	Green Accepted, Green Published, Bronze			2021-06-18	
J	Gandia-Martinez, F; Martinez-Gil, I; Andaluz-Ojeda, D; de Lamo, FB; Parra-Morais, L; Diez-Gutierrez, F				Gandia-Martinez, F.; Martinez-Gil, I.; Andaluz-Ojeda, D.; Bobillo de Lamo, F.; Parra-Morais, L.; Diez-Gutierrez, F.			Analysis of early tracheostomy and its impact on development of pneumonia, use of resources and mortality in neurocritically ill patients	NEUROCIRUGIA			Spanish	Article						Tracheostomy; Early tracheostomy; Neurocritically ill patients; Ventilator-associated pneumonia	CRITICALLY-ILL; PERCUTANEOUS TRACHEOSTOMY; SURGICAL TRACHEOSTOMY; TRAUMA PATIENTS; TRACHEOTOMY; METAANALYSIS; INTUBATION; DURATION; OUTCOMES; COHORT	Objective. We analyze the most suitable time to perform tracheostomy in neurocritically ill patients. We compare morbimortality and use of resources between those patients in which tracheostomy was done early (<= 9 days) and those in which it was perform later (>9 days), in a selected group of patients. Material and methods. We made an observational prospective study involving a group of patients diagnosed as traumatic brain injury (TBI) or stroke, whose tracheostomy was performed during their stay at the Intensive Care Unit. We compared two groups: a) early tracheostomy (during first 9 days of ICU stay); b) late tracheostomy (made on 10th day or later). As variables, we studied: demographic data, severity of illness at admission, admittance department, diagnosis, length of intubation, length of mechanical ventilation (LMV), sedation and antibiotic treatment needs, ventilator-associated pneumonia (VAP) events, ICU length of stay and mortality. We calculated relative risk of suffering from pneumonia and made a multivariate logistic regression to establish which factors were associated with an increased risk of developing pneumonia. Statistical signification p < 0.05. Results. We analyzed 118 patients, 60% with TBI. Mean length of intubation before tracheostomy was 12 days and mean LMV was 20 days. 94 VAP events were diagnosed in 81 patients (68.6%). Early tracheostomy group showed lower length of mechanical ventilation and ICU stay, lower length of sedation and antibiotic treatment, and less pneumonia events (p<0,001). The precocity of tracheostomy didn't have any influence either on hospital length of stay (p=0.844), ICU mortality (p=0.924) or in-hospital mortality (p=0.754). At the TBI group mean age was lower (p<0.001), tracheostomy was made later (p=0.026), and patients needed a longer sedation (p=0.001) and a longer antibiotic treatment (p=0.002). Length of intubation (p=0.034, OR 1.177) and ICU length of stay (p=0.003, OR 1.100) were factors independently associated with development of pneumonia. Relative risk of suffering from pneumonia when tracheostomy was made after 9 days of ICU stay was 1.55 (IC 95%: 1.10-2.16). The number needed to treat (NNT) for early tracheostomy avoiding one pneumonia event was 3.13. VAP was not associated with a higher ICU (p=0.558) or in-hospital mortality (p=0.370). Conclusions. Early tracheostomy (<= 9 days) provides significant advantages in neurocritically ill patients: it shortens length of mechanical ventilation and ICU stay and decreases antibiotic and sedatives requirements. Although later tracheostomy is not directly related with mortality, it increases considerably the risk of suffering from pneumonia, particularly in patients with TBI. These clinical circumstances should be evaluated individually in each patient, so the best time to perform tracheostomy in neurocritically ill patients could be established.	[Gandia-Martinez, F.; Martinez-Gil, I.; Andaluz-Ojeda, D.; Bobillo de Lamo, F.; Parra-Morais, L.; Diez-Gutierrez, F.] Hosp Clin Univ Valladolid, Serv Med Intens, Valladolid, Spain	Gandia-Martinez, F (corresponding author), Hosp Clin Univ, Serv Med Intens, Ave Ramon & Cajal 3, Valladolid 47005, Spain.	fgandia@saludcastillayleon.es					Ahmed Nasim, 2007, Surg Infect (Larchmt), V8, P343, DOI 10.1089/sur.2006.065; Arabi Y, 2004, CRIT CARE, V8, pR347, DOI 10.1186/cc2924; Armstrong PA, 1998, SURGERY, V124, P763, DOI 10.1067/msy.1998.91224; Barquist ES, 2006, J TRAUMA, V60, P91, DOI 10.1097/01.ta.0000196743.37261.3f; Bouderka MA, 2004, J TRAUMA, V57, P251, DOI 10.1097/01.TA.0000087646.68382.9A; Boynton JH, 2004, CRIT CARE, V8, pR261, DOI 10.1186/cc2885; Brook A D, 2000, Am J Crit Care, V9, P352; Browd SR, 2005, NEUROCRIT CARE, V2, P268, DOI 10.1385/NCC:2:3:268; CHIALIN H, 2005, CRITICAL CARE, V9, pR46, DOI DOI 10.1186/CC3018; Diaz-Reganon G, 2008, ANAESTHESIA, V63, P1198, DOI 10.1111/j.1365-2044.2008.05606.x; Freeman BD, 2005, CRIT CARE MED, V33, P2513, DOI 10.1097/01.CCM.0000186369.91799.44; Freeman BD, 2000, CHEST, V118, P1412, DOI 10.1378/chest.118.5.1412; Frutos-Vivar F, 2005, CRIT CARE MED, V33, P290, DOI 10.1097/01.CCM.0000150026.85210.13; Goettler CE, 2006, J TRAUMA, V60, P991, DOI 10.1097/01.ta.0000217270.16860.32; Griffiths J, 2005, BMJ-BRIT MED J, V330, P1243, DOI 10.1136/bmj.38467.485671.E0; Groves DS, 2007, CURR OPIN CRIT CARE, V13, P90, DOI 10.1097/MCC.0b013e328011721e; Gurkin MA, 2002, AM SURGEON, V68, P324; HEFFNER JE, 1989, CHEST, V96, P186, DOI 10.1378/chest.96.1.186; Heffner JE, 2001, CHEST, V120, p477S, DOI 10.1378/chest.120.6_suppl.477S; HEFFNER JE, 1993, AM REV RESPIR DIS, V147, P768, DOI 10.1164/ajrccm/147.3.768; Huttner HB, 2006, CEREBROVASC DIS, V21, P159, DOI 10.1159/000090527; Koh WY, 1997, ANAESTH INTENS CARE, V25, P365, DOI 10.1177/0310057X9702500407; Kollef MH, 1999, CRIT CARE MED, V27, P1714, DOI 10.1097/00003246-199909000-00003; Lee JC, 2005, CRIT CARE, V9, DOI 10.1186/cc3759; Major KM, 2003, AM J SURG, V186, P615, DOI 10.1016/j.amjsurg.2003.08.012; Milanchi S, 2008, J TRAUMA, V65, P73, DOI 10.1097/TA.0b013e31814693f2; Moller MG, 2005, AM J SURG, V189, P293, DOI 10.1016/j.amjsurg.2005.01.002; Qureshi AI, 2000, CRIT CARE MED, V28, P1383, DOI 10.1097/00003246-200005000-00020; Rello J, 2003, CHEST, V124, P2239, DOI 10.1378/chest.124.6.2239; RODRIGUEZ JL, 1990, SURGERY, V108, P655; Rumbak MJ, 2004, CRIT CARE MED, V32, P1689, DOI 10.1097/01.CCM.0000134835.05161.B6; Scales DC, 2008, CRIT CARE MED, V36, P2547, DOI 10.1097/CCM.0b013e31818444a5; Schauer JM, 2009, J TRAUMA, V66, P220, DOI 10.1097/TA.0b013e31816073e3; Silvester W, 2006, CRIT CARE MED, V34, P2145, DOI 10.1097/01.CCM.0000229882.09677.FD; Sugerman HJ, 1997, J TRAUMA, V43, P741, DOI 10.1097/00005373-199711000-00002; Zygun DA, 2006, NEUROCRIT CARE, V5, P108, DOI 10.1385/NCC:5:2:108	36	24	28	0	1	ELSEVIER ESPANA SLU	BARCELONA	AV JOSEP TARRADELLAS, 20-30, 1ERA PLANTA, BARCELONA, CP-08029, SPAIN	1130-1473	2340-6305		NEUROCIRUGIA	Neurocirugia	JUN	2010	21	3					211	221					11	Neurosciences; Surgery	Neurosciences & Neurology; Surgery	623OT	WOS:000279752400003	20571724				2021-06-18	
J	Elliott, JT; Diop, M; Tichauer, KM; Lee, TY; St Lawrence, K				Elliott, Jonathan T.; Diop, Mamadou; Tichauer, Kenneth M.; Lee, Ting-Yim; St. Lawrence, Keith			Quantitative measurement of cerebral blood flow in a juvenile porcine model by depth-resolved near-infrared spectroscopy	JOURNAL OF BIOMEDICAL OPTICS			English	Article						near-infrared spectroscopy; traumatic brain injury; cerebral blood flow; indocyanine green; depth resolved; Monte Carlo	TRAUMATIC BRAIN-INJURY; ACUTE ISCHEMIC-STROKE; INDOCYANINE GREEN; TECHNICAL IMPLEMENTATIONS; OPTICAL SPECTROSCOPY; ABSORPTION CHANGES; NEWBORN PIGLETS; THEORETIC BASIS; CT PERFUSION; HUMAN HEAD	Nearly half a million children and young adults are affected by traumatic brain injury each year in the United States. Although adequate cerebral blood flow (CBF) is essential to recovery, complications that disrupt blood flow to the brain and exacerbate neurological injury often go undetected because no adequate bedside measure of CBF exists. In this study we validate a depth-resolved, near-infrared spectroscopy (NIRS) technique that provides quantitative CBF measurement despite significant signal contamination from skull and scalp tissue. The respiration rates of eight anesthetized pigs (weight: 16.2 +/- 0.5 kg, age: 1 to 2 months old) are modulated to achieve a range of CBF levels. Concomitant CBF measurements are performed with NIRS and CT perfusion. A significant correlation between CBF measurements from the two techniques is demonstrated (r(2)=0.714, slope=0.92, p<0.001), and the bias between the two techniques is -2.83 mL . min(-1) . 100 g(-1) (Cl(0.95): -19.63 mL . min(-1) . 100 g(-1) -13.9 mL . min(-1) . 100 g(-1)). This study demonstrates that accurate measurements of CBF can be achieved with depth-resolved NIRS despite significant signal contamination from scalp and skull. The ability to measure CBF at the bedside provides a means of detecting, and thereby preventing, secondary ischemia during neurointensive care. (C) 2010 Society of Photo-Optical Instrumentation Engineers. [DOI:10.1117/1.3449579]	[Elliott, Jonathan T.; Diop, Mamadou; Tichauer, Kenneth M.; Lee, Ting-Yim; St. Lawrence, Keith] Lawson Hlth Res Inst, Imaging Program, London, ON N6A 4V2, Canada; [Elliott, Jonathan T.; Diop, Mamadou; Lee, Ting-Yim; St. Lawrence, Keith] Univ Western Ontario, Dept Med Biophys, London, ON N6A 3K7, Canada; [Lee, Ting-Yim] Robarts Res Inst, Imaging Res Labs, London, ON N6A 5K8, Canada	Elliott, JT (corresponding author), Lawson Hlth Res Inst, Imaging Program, 268 Grosvenor St, London, ON N6A 4V2, Canada.	jelliott@lawsonimaging.ca	St. Lawrence, Keith/B-5726-2015; Lee, Ting-Yim/M-1721-2013; Diop, Mamadou/B-6487-2015	St Lawrence, Keith/0000-0001-8022-8205; Tichauer, Kenneth/0000-0003-1667-3026	Lawson Health Research Institute; Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada	This study was supported through grants from the Lawson Health Research Institute and the Heart and Stroke Foundation of Canada. This work was made possible by the facilities of the Shared Hierarchical Academic Research Computing Network (SHARCNET, see http://www.sharcnet.ca) and Compute/Calcul Canada. The authors would also like to thank Jennifer Hadway and Lise Desjardins for their help in conducting the animal experiments, and Chris d'Esterre for his assistance in the CT perfusion measurements.	Brown DW, 2002, PEDIATR RES, V51, P564, DOI 10.1203/00006450-200205000-00004; Cenic A, 1999, AM J NEURORADIOL, V20, P63; Chaiwat O, 2009, J NEUROTRAUM, V26, P657, DOI 10.1089/neu.2008.0770; COPE M, 1991, THESIS U COLL LONDON, P290; Diop M, 2009, REV SCI INSTRUM, V80, DOI 10.1063/1.3123347; Fabbri F, 2004, PHYS MED BIOL, V49, P1183, DOI 10.1088/0031-9155/49/7/007; Gora F, 2002, J NEUROSURG ANESTH, V14, P218, DOI 10.1097/00008506-200207000-00008; HIRAOKA M, 1993, PHYS MED BIOL, V38, P1859, DOI 10.1088/0031-9155/38/12/011; HONGO K, 1995, NEUROL RES, V17, P89, DOI 10.1080/01616412.1995.11740293; Jantzen JPAH, 2007, BEST PRACT RES-CLIN, V21, P517, DOI 10.1016/j.bpa.2007.09.001; Kohl-Bareis M, 2002, J BIOMED OPT, V7, P464, DOI 10.1117/1.1482719; Kohno S, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2814249; Konstas AA, 2009, AM J NEURORADIOL, V30, P885, DOI 10.3174/ajnr.A1492; Konstas AA, 2009, AM J NEURORADIOL, V30, P662, DOI 10.3174/ajnr.A1487; Langlois JA, 2000, TRAUMATIC BRAIN INJU; Leung TS, 2007, APPL OPTICS, V46, P1604, DOI 10.1364/AO.46.001604; Liebert A, 2006, NEUROIMAGE, V31, P600, DOI 10.1016/j.neuroimage.2005.12.046; Liebert A, 2005, NEUROIMAGE, V24, P426, DOI 10.1016/j.neuroimage.2004.08.046; Liebert A, 2004, APPL OPTICS, V43, P3037, DOI 10.1364/AO.43.003037; MATCHER SJ, 1994, PHYS MED BIOL, V39, P177, DOI 10.1088/0031-9155/39/1/011; MCCORMICK PW, 1991, CRIT CARE MED, V19, P89, DOI 10.1097/00003246-199101000-00020; Muehlschlegel S, 2006, J CARDIOTHOR VASC AN, V20, P613, DOI 10.1053/j.jvca.2006.05.015; OwenReece H, 1996, BRIT J ANAESTH, V76, P43; Patel J, 1998, PEDIATR RES, V43, P34, DOI 10.1203/00006450-199801000-00006; Rothoerl RD, 2003, NEUROL RES, V25, P528, DOI 10.1179/016164103101201779; Saager RB, 2005, J OPT SOC AM A, V22, P1874, DOI 10.1364/JOSAA.22.001874; Schytz HW, 2009, EUR J NEUROL, V16, P461, DOI 10.1111/j.1468-1331.2008.02398.x; Singhi SC, 2009, INDIAN J PEDIATR, V76, P519, DOI 10.1007/s12098-009-0137-7; Springett R, 2001, PHYS MED BIOL, V46, P2209, DOI 10.1088/0031-9155/46/8/312; Steinbrink J, 2001, PHYS MED BIOL, V46, P879, DOI 10.1088/0031-9155/46/3/320; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Strangman G, 2003, NEUROIMAGE, V18, P865, DOI 10.1016/S1053-8119(03)00021-1; Tachtsidis I, 2009, ADV EXP MED BIOL, V645, P315, DOI 10.1007/978-0-387-85998-9_47; Themelis G, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2710250; Tichauer KM, 2006, J CEREBR BLOOD F MET, V26, P722, DOI 10.1038/sj.jcbfm.9600230; VANDERZEE P, 1992, ADV EXP MED BIOL, V316, P143; Wang R. S., 1995, J MATH SCI-U TOKYO, V2, P131; Wright TM, 2007, J ADDICT MED, V1, P15, DOI 10.1097/ADM.0b013e318044ce4f; Yamada T, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3275469; Zhang Q, 2009, NEUROIMAGE, V45, P788, DOI 10.1016/j.neuroimage.2008.12.048	40	24	24	0	1	SPIE-SOC PHOTOPTICAL INSTRUMENTATION ENGINEERS	BELLINGHAM	1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA	1083-3668			J BIOMED OPT	J. Biomed. Opt.	MAY-JUN	2010	15	3							037014	10.1117/1.3449579			9	Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging	Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging	635GF	WOS:000280642900056	20615043	Bronze			2021-06-18	
